{"meta":{"query_hash":"dd57b2333e5f","filters":{"topic":"Chronic Lymphocytic Leukemia Research"},"cohort_total":1742,"direct_labels_cover":5,"predictions_cover":1742,"exported":1742,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/dd57b2333e5f","api":"https://metacan.xera.ac/api/v1/cohort?topic=Chronic+Lymphocytic+Leukemia+Research"},"results":[{"id":"W1003723336","doi":"10.1007/978-1-4614-4741-2_7","title":"DNA-PK in CLL Chemotherapy","year":2012,"lang":"en","type":"book-chapter","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"DNA; Chronic lymphocytic leukemia; DNA damage; Cancer research; DNA repair; Leukemia; Biology; Chemistry; Genetics","score_opus":0.03356526591689779,"score_gpt":0.305273392271577,"score_spread":0.2717081263546792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1003723336","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008205525,0.002287196,0.000014706371,0.0006647995,0.00012982752,0.0006839054,0.0000046736245,0.00007999416,0.99531436],"genre_scores_gemma":[0.0092165405,0.0019194677,0.00031731307,0.0014590622,0.00081023294,0.000015472542,0.000052553398,0.00013941765,0.9860699],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981019,0.000008705934,0.00036588815,0.00037888173,0.00062049384,0.0005241559],"domain_scores_gemma":[0.99876785,0.00009654296,0.00006724308,0.0007265106,0.000072322255,0.0002695042],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028850272,0.0003227216,0.00061646645,0.000289823,0.000016212913,0.000011866975,0.00017027254,0.00061005994,0.02481548],"category_scores_gemma":[0.00002689228,0.00025878387,0.00017404604,0.0000404988,0.00013238608,0.000044875476,0.00008884106,0.0006130092,0.0032267305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002348998,0.0006258682,0.00040508594,0.0024932784,0.0011619842,0.0027800766,0.0013357814,0.0000014326425,0.0014885971,0.37180296,0.23833661,0.37721935],"study_design_scores_gemma":[0.015457172,0.00012836762,0.00011133658,0.0004237739,0.000047687296,0.0002874901,0.0000099911085,0.00012768708,0.0008198533,0.0020387887,0.98021346,0.00033438634],"about_ca_topic_score_codex":0.00029776542,"about_ca_topic_score_gemma":0.000108597254,"teacher_disagreement_score":0.74187684,"about_ca_system_score_codex":0.01448977,"about_ca_system_score_gemma":0.004593052,"threshold_uncertainty_score":0.9999864},"labels":[],"label_agreement":null},{"id":"W144797469","doi":"10.1182/blood.v122.21.1810.1810","title":"Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Refractory (planetary science); Toxicity; Phases of clinical research; Gastroenterology; Oncology","score_opus":0.02333358448421981,"score_gpt":0.3469080447660509,"score_spread":0.3235744602818311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W144797469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396557,0.00020636964,0.000003645536,0.00037455617,0.000044317436,0.0051714075,0.000015775788,0.00005889345,0.00015946548],"genre_scores_gemma":[0.99530697,0.00011311973,0.002451346,0.00018201518,0.000069080634,0.0005570101,0.000015201596,0.000057598794,0.0012476479],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99634033,0.000566695,0.00096011354,0.0008084999,0.0006832188,0.0006411244],"domain_scores_gemma":[0.9974113,0.0011532771,0.00013973375,0.00066752,0.00020274604,0.00042544169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017557933,0.00029673142,0.0008464825,0.00036715783,0.00006113449,0.000028578386,0.00020874175,0.00017546375,0.00025765324],"category_scores_gemma":[0.0019634701,0.00020848855,0.000052339787,0.0006686355,0.00017858452,0.00018893443,0.00019320592,0.00056183944,0.000083595274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60345,0.09703947,0.16900648,0.001161891,0.00047806776,0.01858774,0.022258397,0.000010614001,0.07339534,0.00000798765,0.0011408621,0.013463145],"study_design_scores_gemma":[0.66986066,0.022088047,0.2964875,0.0013929704,0.00012492936,0.00023039742,0.0049997997,0.00091981277,0.0030327146,0.000004422742,0.00041927918,0.0004394748],"about_ca_topic_score_codex":0.00090797583,"about_ca_topic_score_gemma":0.0012442421,"teacher_disagreement_score":0.12748103,"about_ca_system_score_codex":0.0014399706,"about_ca_system_score_gemma":0.0047947927,"threshold_uncertainty_score":0.8505757},"labels":[],"label_agreement":null},{"id":"W1482977728","doi":"10.4049/jimmunol.188.supp.159.5","title":"Interaction of TAPP adapter proteins with phosphatidylinositol (3,4)-bisphosphate regulates B cell activation and autoantibody production (159.5)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Cell biology; Signal transducing adaptor protein; Autoimmunity; Antibody; Autoantibody; Phosphatidylinositol; B cell; Signal transduction; Chemistry; PI3K/AKT/mTOR pathway; Biology; Immunology","score_opus":0.013796952073463287,"score_gpt":0.270287918684701,"score_spread":0.2564909666112377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1482977728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485594,0.002758518,0.00041413517,0.0010700604,0.0002750381,0.00044395184,4.0693942e-7,0.000009161458,0.00017278476],"genre_scores_gemma":[0.99801093,0.00056713243,0.00074295484,0.000024031684,0.00019942281,0.000004555857,0.0000019657223,0.000018140896,0.00043088043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988503,0.00013495192,0.0003996517,0.00008593078,0.0002839418,0.00024522922],"domain_scores_gemma":[0.9986331,0.000116470306,0.0005893912,0.00024747002,0.000357085,0.00005648119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007352566,0.00012037767,0.00029445675,0.00014049532,0.00006769195,0.0000070307237,0.00010335376,0.00008612365,0.000047179306],"category_scores_gemma":[0.00012695098,0.00006766146,0.000042090218,0.00017001007,0.00024703797,0.00040370307,0.000048435963,0.00038653883,0.000005167461],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009614959,0.0004095103,0.002957451,0.0001924268,0.00043264212,0.0000069318344,0.004620598,0.00009072695,0.9733555,0.00009955378,0.0002523514,0.0079673575],"study_design_scores_gemma":[0.004480948,0.0015231952,0.02329243,0.00032918854,0.00017575394,0.0026581862,0.001227599,0.00022277403,0.9651296,0.000032618358,0.0008575588,0.00007010514],"about_ca_topic_score_codex":0.00016652569,"about_ca_topic_score_gemma":0.000002761223,"teacher_disagreement_score":0.02033498,"about_ca_system_score_codex":0.0009091113,"about_ca_system_score_gemma":0.00064620806,"threshold_uncertainty_score":0.2759154},"labels":[],"label_agreement":null},{"id":"W1486606013","doi":"10.1002/9781444300857.ch51","title":"Management of Waldenstrom's Macroglobulinemia","year":2008,"lang":"en","type":"other","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Fludarabine; Plasmapheresis; Macroglobulinemia; Waldenstrom macroglobulinemia; Medicine; Pediatrics; Intensive care medicine; Surgery; Internal medicine; Chemotherapy; Multiple myeloma; Immunology; Cyclophosphamide; Lymphoma","score_opus":0.016161477486021127,"score_gpt":0.3007477028364345,"score_spread":0.28458622535041334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1486606013","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016038115,0.0016321677,0.00009483026,0.000082542305,0.00011383593,0.00063840527,0.000016102327,0.00016799041,0.99709374],"genre_scores_gemma":[0.0010184078,0.0048574326,0.009444826,0.00006475436,0.0002180372,0.000017487435,0.000057225458,0.0003679574,0.9839539],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845487,0.000011909305,0.00025480302,0.00031574685,0.00065402087,0.00030865273],"domain_scores_gemma":[0.9989811,0.000013933961,0.000097258344,0.00073052145,0.000037743917,0.00013942368],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000053536805,0.00021413255,0.00050096633,0.00021981308,0.000009884548,0.0000028317372,0.00017613547,0.00026038106,0.019428136],"category_scores_gemma":[0.000006227408,0.00016858478,0.00014939914,0.00017685593,0.00016674274,0.0000058522874,0.00015226305,0.00016780554,0.0009022729],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052332285,0.00008590208,0.000019807403,0.0016801219,0.0005037073,0.002520961,0.000008545024,2.9081673e-7,0.000014302018,0.0005116645,0.9883178,0.00628456],"study_design_scores_gemma":[0.009568907,0.000098770186,0.000044260807,0.0012366129,0.00015398722,0.00061640993,0.000030541636,0.00011251042,0.0004436221,0.0000071621257,0.9875232,0.00016399758],"about_ca_topic_score_codex":0.00094720785,"about_ca_topic_score_gemma":0.000017846374,"teacher_disagreement_score":0.018525863,"about_ca_system_score_codex":0.0028251114,"about_ca_system_score_gemma":0.0015181227,"threshold_uncertainty_score":0.99987566},"labels":[],"label_agreement":null},{"id":"W1499370228","doi":"10.4049/jimmunol.0902324","title":"Lysine Acetylation Regulates Bruton’s Tyrosine Kinase in B Cell Activation","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"RIKEN; Science and Technology Commission of Shanghai Municipality; Institute of Genetics and Developmental Biology, Chinese Academy of Sciences; Chinese Academy of Sciences; Institute of Genetics; National Natural Science Foundation of China","keywords":"Bruton's tyrosine kinase; Acetylation; Histone; Phosphorylation; Lysine; Histone acetyltransferase; Histone H3; Tyrosine phosphorylation; breakpoint cluster region; Molecular biology; Signal transduction; Tyrosine kinase; Biology; Cancer research; Cell biology; Chemistry; Biochemistry; Gene","score_opus":0.014302149656600524,"score_gpt":0.2822660243852541,"score_spread":0.2679638747286536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1499370228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889498,0.0019913784,0.00016492167,0.008024074,0.00007902239,0.00014467436,2.2106633e-7,0.000008066657,0.00063785067],"genre_scores_gemma":[0.99808085,0.0006664386,0.00023271586,0.00027449543,0.00013564872,5.577713e-7,0.0000033497754,0.000008976139,0.0005969491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988794,0.00015920872,0.00042745325,0.000070876085,0.000241455,0.00022160757],"domain_scores_gemma":[0.99902433,0.00020436336,0.0002697272,0.00025612634,0.00020903874,0.000036426787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079145,0.00009242896,0.00026653803,0.00026449483,0.000041365267,0.0000071790396,0.0001669981,0.00010646968,0.00008526799],"category_scores_gemma":[0.0002723165,0.000058328354,0.00005937421,0.0003366288,0.00009198614,0.00013535513,0.000027690321,0.00041712337,0.000017622502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027963626,0.00023520137,0.00014396025,0.000014662156,0.00004468356,0.00006123795,0.00071453355,0.00040711468,0.98354983,0.00014452403,0.0005876991,0.011300186],"study_design_scores_gemma":[0.024031697,0.0023454821,0.11048248,0.00027211622,0.0000956223,0.0021355718,0.00040606313,0.0025466718,0.8548984,0.001424333,0.0012437986,0.00011776277],"about_ca_topic_score_codex":0.00009981284,"about_ca_topic_score_gemma":0.000004963382,"teacher_disagreement_score":0.12865143,"about_ca_system_score_codex":0.003200945,"about_ca_system_score_gemma":0.0011676665,"threshold_uncertainty_score":0.83703595},"labels":[],"label_agreement":null},{"id":"W1506715112","doi":"10.1002/ijc.27989","title":"The phosphatidylinositol‐3 kinase I inhibitor BKM120 induces cell death in B‐chronic lymphocytic leukemia cells <i>in vitro</i>","year":2012,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Cytotoxic T cell; PI3K/AKT/mTOR pathway; In vitro; Leukemia; Immunology; Biology; Apoptosis; In vivo; Cancer research; Biochemistry","score_opus":0.017432964266000384,"score_gpt":0.3261096123349818,"score_spread":0.30867664806898143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1506715112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97407466,0.021400768,0.000018672115,0.0005692767,0.0025596255,0.00023591763,0.000011003005,0.00000797154,0.0011220908],"genre_scores_gemma":[0.991992,0.004150899,0.0001558469,0.00043768762,0.0025834094,0.000027744898,0.0000031995,0.00003252053,0.0006166892],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969712,0.000095287665,0.00083497306,0.00017383115,0.0013373084,0.0005874333],"domain_scores_gemma":[0.9983237,0.00041433336,0.00038252337,0.00020691387,0.00041392265,0.0002586534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008736741,0.00020150481,0.00035219383,0.0003293547,0.000047000667,0.000072515984,0.00055955723,0.00013078019,0.00011281592],"category_scores_gemma":[0.00012106573,0.00014092021,0.00017328843,0.0002695535,0.000109665554,0.00038336104,0.00012098764,0.00060256955,0.000039977367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0097678155,0.0005172399,0.016887426,0.00027048614,0.0006973862,0.00275871,0.0024585163,0.01038435,0.9035837,0.00035894604,0.0080596525,0.044255782],"study_design_scores_gemma":[0.024943313,0.00015696771,0.00469351,0.0006757165,0.00006630175,0.00034225904,0.00018935296,0.005090839,0.9406684,0.000079977915,0.022891257,0.00020210465],"about_ca_topic_score_codex":0.002149644,"about_ca_topic_score_gemma":0.00020152208,"teacher_disagreement_score":0.12072258,"about_ca_system_score_codex":0.15088081,"about_ca_system_score_gemma":0.03015824,"threshold_uncertainty_score":0.9753399},"labels":[],"label_agreement":null},{"id":"W1522676959","doi":"10.1111/bcp.12662","title":"Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia","year":2015,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Rituximab; Medicine; Fludarabine; Cyclophosphamide; Pharmacokinetics; Internal medicine; Urology; Pharmacology; Gastroenterology; Chemotherapy; Lymphoma","score_opus":0.03402879915857482,"score_gpt":0.3734540108024317,"score_spread":0.33942521164385686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1522676959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871656,0.010286826,0.00024251426,0.0002837597,0.00087202375,0.00094424776,0.000057648984,0.000013098144,0.00013430657],"genre_scores_gemma":[0.986251,0.010009987,0.0019365489,0.0005898429,0.0009908217,0.0000113863025,0.000015737294,0.000050546823,0.00014412322],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965209,0.00023022816,0.0017885197,0.00035218897,0.0006166507,0.0004915173],"domain_scores_gemma":[0.995225,0.0015671673,0.00079306297,0.00013704483,0.0013843604,0.0008933436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016379796,0.00022233899,0.0014765325,0.000117678814,0.00006422444,0.000022416649,0.00020649379,0.00022717548,0.0000765547],"category_scores_gemma":[0.0012509245,0.00020302649,0.00017180854,0.00016942846,0.00092937244,0.00013267066,0.0001433563,0.0006295891,0.0000024862893],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.32787704,0.0056256973,0.046787538,0.0048220605,0.0056774043,0.024356117,0.0004682351,0.002984737,0.0015763828,0.00006786302,0.09168472,0.4880722],"study_design_scores_gemma":[0.8292654,0.029823488,0.02210739,0.0012385541,0.002835851,0.05006898,0.00006712227,0.026613884,0.0014827234,0.00027506385,0.03562845,0.0005930899],"about_ca_topic_score_codex":0.00010913154,"about_ca_topic_score_gemma":0.000018330244,"teacher_disagreement_score":0.5013884,"about_ca_system_score_codex":0.005055271,"about_ca_system_score_gemma":0.015843878,"threshold_uncertainty_score":0.99876416},"labels":[],"label_agreement":null},{"id":"W1535133783","doi":"","title":"Caractérisation du site commun d'intégration KIS2 : implication de MIR-106-363 dans les leucémies de type T","year":2007,"lang":"fr","type":"article","venue":"Archipelago (Université du Québec à Montréal)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Molecular biology; Biology; Philosophy","score_opus":0.010983723632141283,"score_gpt":0.2294244091625718,"score_spread":0.21844068553043053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1535133783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9357631,0.011899759,0.038694166,0.009503736,0.00035508996,0.0007246128,0.000036937876,0.00018237538,0.0028401976],"genre_scores_gemma":[0.9896276,0.004249234,0.0022209028,0.00035873387,0.0008573378,0.000010063022,0.00023053419,0.000094537034,0.002351063],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9964004,0.00045619925,0.0005465533,0.0005893906,0.00067781634,0.0013296003],"domain_scores_gemma":[0.99619937,0.0013591181,0.00030714128,0.0010024377,0.0004439042,0.0006880051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016089178,0.00045695913,0.00048761375,0.00046229947,0.0009453452,0.000074901174,0.0005693936,0.00045805686,0.000354725],"category_scores_gemma":[0.0006309317,0.0005298255,0.00025698304,0.00078545103,0.0006569239,0.0005179757,0.00035896513,0.0008383377,0.000494565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003154924,0.00091374456,0.11887432,0.00067965,0.0006356434,0.0016294633,0.5115829,0.0018681935,0.11060543,0.010139777,0.008855047,0.23106086],"study_design_scores_gemma":[0.015931776,0.0012730586,0.64354545,0.000755376,0.0011900737,0.0025514916,0.11826674,0.12639444,0.011954132,0.0009914589,0.07599307,0.0011529163],"about_ca_topic_score_codex":0.7961181,"about_ca_topic_score_gemma":0.75859183,"teacher_disagreement_score":0.52467114,"about_ca_system_score_codex":0.045939043,"about_ca_system_score_gemma":0.010867467,"threshold_uncertainty_score":0.9997153},"labels":[],"label_agreement":null},{"id":"W1558809176","doi":"","title":"Correlation of MicroRNA Expressions with mutated and unmutated IgVH gene groups in chronic lymphocytic leukemia","year":2005,"lang":"en","type":"article","venue":"University Library - University of Saskatchewan (University of Saskatchewan)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; microRNA; Correlation; Gene; Genetics; Biology; Mutation; Leukemia; Cancer research; Mathematics","score_opus":0.006766516050374427,"score_gpt":0.18645684952313532,"score_spread":0.1796903334727609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1558809176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593073,0.00026945086,0.0015559308,0.00035335193,0.000028632756,0.0007033684,0.00020928514,0.00014352967,0.0008057241],"genre_scores_gemma":[0.98119766,0.0004551458,0.010147287,0.0000260105,0.000027531954,3.462637e-8,0.00024520553,0.000042656276,0.007858472],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9974103,0.00021072968,0.00035439397,0.00077451445,0.0006350319,0.000615032],"domain_scores_gemma":[0.9977537,0.00025135704,0.00056260685,0.0006920055,0.00025562997,0.0004847076],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020213114,0.00042337176,0.0010636224,0.0011575139,0.00027835203,0.000010174727,0.0007168037,0.00046830546,0.0006941558],"category_scores_gemma":[0.000012639997,0.0005446192,0.00026099465,0.0016232763,0.00180317,0.0016987327,0.0006678905,0.00052323454,0.00002107382],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03986286,0.0015391331,0.034662947,0.0043083057,0.0029268644,0.008917788,0.6450546,0.052307915,0.19762269,0.00016132329,0.0012665393,0.011369077],"study_design_scores_gemma":[0.0630057,0.0016253232,0.019923804,0.0018889408,0.0009799728,0.0002962327,0.83889484,0.046201207,0.024440177,0.00006634565,0.0016743852,0.0010030796],"about_ca_topic_score_codex":0.04121479,"about_ca_topic_score_gemma":0.011910233,"teacher_disagreement_score":0.19384027,"about_ca_system_score_codex":0.013292885,"about_ca_system_score_gemma":0.022094771,"threshold_uncertainty_score":0.99970055},"labels":[],"label_agreement":null},{"id":"W1559664759","doi":"10.4049/jimmunol.180.3.1954","title":"Successful Treatment of Animal Models of Rheumatoid Arthritis with Small-Molecule Cyclin-Dependent Kinase Inhibitors","year":2008,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics","keywords":"Cyclin-dependent kinase; Arthritis; Rheumatoid arthritis; Medicine; Immunology; Pharmacology; Cancer research; Kinase; Cell cycle; Chemistry; Internal medicine; Cancer; Biochemistry","score_opus":0.027407166243528146,"score_gpt":0.26758159226989886,"score_spread":0.2401744260263707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559664759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816759,0.017006978,0.00023054788,0.00037629448,0.0000746333,0.00024845626,0.0000045683064,0.0000066343646,0.0003759647],"genre_scores_gemma":[0.9646218,0.034857247,0.00034888243,0.000017875813,0.00005144653,0.000003725801,0.0000016165286,0.000024787863,0.000072647585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981144,0.00020086927,0.000801406,0.00011526301,0.00045695048,0.00031107565],"domain_scores_gemma":[0.99819493,0.00024075674,0.00062041724,0.00041391648,0.00044183602,0.000088126864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035847898,0.00017384661,0.000738647,0.00022097777,0.00006513742,0.0000028479715,0.00025309966,0.000110772446,0.00006118646],"category_scores_gemma":[0.000066458124,0.00009859489,0.00016286563,0.00019117685,0.00070435804,0.000078680794,0.000067299145,0.00025483107,0.000004817366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050159432,0.0039534466,0.0036685898,0.00014809526,0.003930665,0.005614299,0.0103714485,0.0015700368,0.90506065,0.0004061468,0.0002377354,0.014879452],"study_design_scores_gemma":[0.04573045,0.02466951,0.0017328196,0.00061753107,0.00013532187,0.04218637,0.0016820378,0.0008371822,0.8819884,0.000116258125,0.00014570385,0.0001583896],"about_ca_topic_score_codex":0.0011846349,"about_ca_topic_score_gemma":0.00006224048,"teacher_disagreement_score":0.03657207,"about_ca_system_score_codex":0.0017057214,"about_ca_system_score_gemma":0.0036647483,"threshold_uncertainty_score":0.6501106},"labels":[],"label_agreement":null},{"id":"W1581048908","doi":"10.1080/15384047.2015.1026482","title":"PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53","year":2015,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital; University of Toronto","funders":"","keywords":"Bortezomib; Apoptosis; Waldenstrom macroglobulinemia; Downregulation and upregulation; Dexamethasone; Cancer research; Macroglobulinemia; Gene silencing; Gene knockdown; Cell culture; Chemistry; Medicine; Multiple myeloma; Internal medicine; Biology; Lymphoma","score_opus":0.0664349728768754,"score_gpt":0.37062730283990963,"score_spread":0.30419232996303425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1581048908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043554,0.0067091263,0.00001516577,0.0008148198,0.00045164392,0.0005574342,0.000029044935,0.000031446478,0.00095576665],"genre_scores_gemma":[0.9938235,0.004307964,0.0003175804,0.000755477,0.00026052207,0.00011078651,0.000026852253,0.000028637876,0.000368654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823415,0.00013820089,0.00042862468,0.0004176082,0.0002886738,0.00049274834],"domain_scores_gemma":[0.9988747,0.00009678655,0.00013877003,0.00045098687,0.00021987791,0.0002188426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049621373,0.00020865745,0.00057092746,0.00021100724,0.000019668785,0.000007120285,0.00029470754,0.00034963322,0.00032733154],"category_scores_gemma":[0.00005174684,0.00015960923,0.0000930238,0.000385182,0.00034459992,0.00004359066,0.000092886105,0.00035306186,0.000033465705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033764977,0.0004983733,0.041828733,0.00011679461,0.00042842847,0.00007100455,0.0023803802,0.00007313642,0.8286347,0.00017103026,0.004234138,0.11818678],"study_design_scores_gemma":[0.03164489,0.0010774209,0.003869886,0.00013978238,0.000032253723,0.00005089411,0.00043550576,0.00017991036,0.94530565,0.00041367894,0.016583016,0.00026709778],"about_ca_topic_score_codex":0.0034272296,"about_ca_topic_score_gemma":0.00012229719,"teacher_disagreement_score":0.117919676,"about_ca_system_score_codex":0.005105273,"about_ca_system_score_gemma":0.0064640087,"threshold_uncertainty_score":0.9991684},"labels":[],"label_agreement":null},{"id":"W1582839313","doi":"10.1038/sj.leu.2403740","title":"Reply to ‘Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4’ by Chow et al","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Apoptosis; Imatinib; Haematopoiesis; Cancer research; Leukemia; Hematology; Medicine; Immunology; Internal medicine; Biology; Cell biology; Genetics; Stem cell","score_opus":0.01520192161925808,"score_gpt":0.29503351891131174,"score_spread":0.27983159729205365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1582839313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898964,0.00023012079,0.000060331284,0.0065132673,0.000044869295,0.0006348413,0.000018675757,0.00007236421,0.0025291343],"genre_scores_gemma":[0.9795805,0.00010443168,0.007590777,0.011528663,0.00009055731,0.00012684119,0.00005689021,0.000059484046,0.00086181634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99728787,0.00010315152,0.000549964,0.0005818701,0.00089368486,0.0005834781],"domain_scores_gemma":[0.9983788,0.000265363,0.00015460956,0.0007603778,0.0001290817,0.0003117749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005067046,0.00027669314,0.0005747685,0.00025733668,0.00004550736,0.00002836982,0.00028982694,0.00014871306,0.00021094525],"category_scores_gemma":[0.00031188517,0.00021080827,0.00006684332,0.00059655774,0.00013058803,0.00021623612,0.00016763862,0.00034082937,0.00008721492],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0039463975,0.0005349017,0.004440415,0.0004127849,0.00010210939,0.00008697724,0.0039264765,0.0014664086,0.5999187,0.00012871987,0.3692831,0.015752975],"study_design_scores_gemma":[0.019941136,0.0005835966,0.0024918225,0.0009764431,0.000024949599,0.0000648977,0.00023975396,0.00092604564,0.93859226,0.000017804536,0.03586862,0.0002726657],"about_ca_topic_score_codex":0.0048591397,"about_ca_topic_score_gemma":0.00011510614,"teacher_disagreement_score":0.33867353,"about_ca_system_score_codex":0.015096026,"about_ca_system_score_gemma":0.006077327,"threshold_uncertainty_score":0.9995573},"labels":[],"label_agreement":null},{"id":"W1583810038","doi":"10.1002/9783527633470.ch10","title":"Cellular Protein Kinases as Antiviral Targets","year":2011,"lang":"en","type":"other","venue":"Methods and principles in medicinal chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Kinase; Cyclin-dependent kinase; Cell biology; Biology; Chemistry; Biochemistry; Cell; Cell cycle","score_opus":0.04331068953418269,"score_gpt":0.37797030227742645,"score_spread":0.33465961274324374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1583810038","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012748091,0.02166711,0.00071483775,0.000096149786,0.00013736071,0.0009097806,0.000018042025,0.0001328444,0.9635758],"genre_scores_gemma":[0.008025949,0.0019025487,0.0798364,0.00014462972,0.0013174401,0.0001692829,0.00011892408,0.0005366191,0.9079482],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972711,0.00022412968,0.00048676733,0.0007925951,0.00060269167,0.00062267244],"domain_scores_gemma":[0.99848807,0.00015556716,0.00021827716,0.0007507264,0.00004613657,0.00034119716],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015743834,0.0004957683,0.0010157744,0.00018910813,0.000039005005,0.000015876209,0.0002897815,0.00076127646,0.0065085446],"category_scores_gemma":[0.0011175275,0.00040618493,0.00011852318,0.000218583,0.00058837887,0.000021772747,0.00029643622,0.0010322887,0.000048401813],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002878335,0.0014386188,0.0019606613,0.056093212,0.0012829193,0.024726383,0.001908353,5.095924e-7,0.6293334,0.001485382,0.080741756,0.19815052],"study_design_scores_gemma":[0.0057989922,0.00019554602,0.000042943982,0.0040152646,0.00014082059,0.00044460665,0.00016230848,0.0001706154,0.34214774,0.000369666,0.646043,0.00046845258],"about_ca_topic_score_codex":0.001858035,"about_ca_topic_score_gemma":0.000021591495,"teacher_disagreement_score":0.5653013,"about_ca_system_score_codex":0.0012887263,"about_ca_system_score_gemma":0.0026863774,"threshold_uncertainty_score":0.999839},"labels":[],"label_agreement":null},{"id":"W1587113887","doi":"10.1002/eji.201242371","title":"Interaction of <scp>TAPP</scp> adapter proteins with phosphatidylinositol (3,4)‐bisphosphate regulates <scp>B</scp>‐cell activation and autoantibody production","year":2012,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Phosphatidylinositol; Biology; Molecular biology; B cell; Phosphorylation; Autoantibody; Antibody; Cell biology; Immunology","score_opus":0.01477246421281489,"score_gpt":0.252941109989424,"score_spread":0.2381686457766091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1587113887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913981,0.0035736084,0.0008444087,0.0001868347,0.0005187207,0.00056412816,0.0000013897019,0.00003257463,0.002880263],"genre_scores_gemma":[0.9941424,0.00064575154,0.0021490061,0.000043057706,0.00045299702,0.0000046890323,0.000010055797,0.00007316073,0.0024788508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975436,0.0004403037,0.0007971912,0.00026318931,0.00045231092,0.0005034595],"domain_scores_gemma":[0.9973623,0.00033507223,0.001120569,0.0003834704,0.0006204587,0.00017812927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012495959,0.00026569207,0.0005178746,0.0003538645,0.000099908626,0.000030695825,0.00019192106,0.00009370519,0.000020450954],"category_scores_gemma":[0.001067529,0.00019885098,0.00010224491,0.00029817593,0.00031600508,0.00073490065,0.00011416838,0.00068982266,0.000036518435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011136406,0.0009913953,0.008579169,0.0004503086,0.0009156397,0.00019073146,0.007582505,0.00014179059,0.96446884,0.00011074073,0.002662731,0.01279252],"study_design_scores_gemma":[0.008252038,0.002795362,0.07860349,0.00077141804,0.00018982565,0.003940143,0.0021728422,0.00019430152,0.88833725,0.00001011378,0.014675882,0.000057324134],"about_ca_topic_score_codex":0.000039161965,"about_ca_topic_score_gemma":9.86509e-7,"teacher_disagreement_score":0.07613157,"about_ca_system_score_codex":0.0009823296,"about_ca_system_score_gemma":0.00070317974,"threshold_uncertainty_score":0.81089073},"labels":[],"label_agreement":null},{"id":"W1588091866","doi":"10.1158/1538-7445.am2014-1881","title":"Abstract 1881: New therapeutic options for CLL treatment: Src/c-abl-directed molecular re-engineering of chlorambucil and bendamustine","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Concordia University; Royal Victoria Regional Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Chlorambucil; Chronic lymphocytic leukemia; Fludarabine; Cancer research; Dasatinib; Nitrogen mustard; Bendamustine; Medicine; Pharmacology; Imatinib; Leukemia; Chemistry; Immunology; Chemotherapy; Cyclophosphamide; Internal medicine; Myeloid leukemia","score_opus":0.09612360987829247,"score_gpt":0.41265592706558135,"score_spread":0.3165323171872889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1588091866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847417,0.0088904,0.0011010646,0.0019645856,0.000094684736,0.0017635411,0.0000507236,0.00012150694,0.0012718351],"genre_scores_gemma":[0.9939852,0.0014394799,0.0013588854,0.00004095228,0.00031843208,0.00030100453,0.000037497288,0.000069211725,0.0024493427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790215,0.00005447162,0.0002925043,0.0004256594,0.00063643145,0.00068878836],"domain_scores_gemma":[0.99794775,0.0006238848,0.00004682904,0.00052573386,0.0004627024,0.00039312404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007340708,0.00018530722,0.0003977205,0.0003177795,0.0001034715,0.000040408504,0.00016173613,0.00013534074,0.00024147677],"category_scores_gemma":[0.0005732666,0.00015482574,0.00010254812,0.0005201206,0.00017940674,0.00006587366,0.00006843995,0.0003007187,0.000010820529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022307194,0.0004215775,0.00031672086,0.0023982099,0.00087419676,0.000074969816,0.0011185823,0.0023790172,0.84783244,0.0035000506,0.0042625056,0.13459098],"study_design_scores_gemma":[0.0676507,0.004419051,0.009217077,0.0019070214,0.00042460978,0.00011254227,0.00036367038,0.17018,0.5814462,0.0012276645,0.16225189,0.00079961395],"about_ca_topic_score_codex":0.0030384788,"about_ca_topic_score_gemma":0.0001180935,"teacher_disagreement_score":0.2663863,"about_ca_system_score_codex":0.0042623905,"about_ca_system_score_gemma":0.0042033973,"threshold_uncertainty_score":0.99956006},"labels":[],"label_agreement":null},{"id":"W1589118013","doi":"10.71781/27107","title":"Caractérisation cytogénétique et clinique des gènes de fusion impliquant MLL dans les leucémies","year":2010,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology","score_opus":0.07898050679174548,"score_gpt":0.42504023719462797,"score_spread":0.3460597304028825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1589118013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95482385,0.0012063157,0.0010014767,0.0004929443,0.0009717249,0.0026334724,0.00014882076,0.000011923017,0.03870946],"genre_scores_gemma":[0.94576365,0.003788631,0.0135264825,0.000102734826,0.00095634715,0.0003295835,0.0032898576,0.00018519949,0.032057513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99467266,0.0008298182,0.001236721,0.0011771581,0.0008489644,0.0012346911],"domain_scores_gemma":[0.99561167,0.0013406621,0.0006547091,0.0010483759,0.0007393343,0.00060526124],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0034479941,0.0007705119,0.0010938945,0.00033525232,0.00062927516,0.0005483363,0.0011654898,0.0020341845,0.004192311],"category_scores_gemma":[0.0022329541,0.00072637363,0.00031114786,0.0003899584,0.0005922009,0.0006134248,0.0004649481,0.0023523872,0.0011132994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002673951,0.0007891834,0.014729471,0.0016691944,0.00037870448,0.0011398159,0.10241671,0.00016243012,0.5260176,0.00082939,0.00053423777,0.34865928],"study_design_scores_gemma":[0.015857076,0.0015757526,0.11529863,0.007364516,0.0010667272,0.0013568333,0.05126008,0.013887084,0.7439235,0.0012221138,0.045508567,0.0016791201],"about_ca_topic_score_codex":0.07517748,"about_ca_topic_score_gemma":0.20451875,"teacher_disagreement_score":0.34698015,"about_ca_system_score_codex":0.015460787,"about_ca_system_score_gemma":0.039181318,"threshold_uncertainty_score":0.9999492},"labels":[],"label_agreement":null},{"id":"W161061911","doi":"10.1200/jco.2006.24.18_suppl.6601","title":"Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Fluorescence in situ hybridization; Internal medicine; Alemtuzumab; Chromosome instability; Gastroenterology; Cytogenetics; Chromosome; Trisomy 8; Trisomy; Progressive disease; Oncology; Pathology; Chemotherapy; Biology; Genetics; Gene","score_opus":0.044682266617835774,"score_gpt":0.39532079396820063,"score_spread":0.3506385273503649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W161061911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287134,0.0012186839,0.0007526898,0.0005572817,0.000560315,0.0024091145,0.000011147516,0.00003695882,0.001582464],"genre_scores_gemma":[0.9916673,0.00040014263,0.002997501,0.00095243193,0.0023435487,0.000071550545,0.00007773104,0.00011256118,0.0013772872],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99416757,0.00035702263,0.002599683,0.0006130138,0.0014695764,0.0007931134],"domain_scores_gemma":[0.9906747,0.003800255,0.0027157995,0.0005739674,0.001665966,0.000569338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016505261,0.0004547757,0.0020183483,0.00027415785,0.00013997084,0.000039663595,0.0003921459,0.00069287885,0.00019850969],"category_scores_gemma":[0.0013151913,0.00027449176,0.000512575,0.0002870241,0.000610339,0.00015955455,0.000055451892,0.0011297734,0.00011066437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.62615037,0.017473063,0.05293554,0.00059976854,0.0025212083,0.0027944339,0.00030423058,0.055034656,0.0002560747,0.00020059291,0.0134385135,0.22829156],"study_design_scores_gemma":[0.51585305,0.36326656,0.062331747,0.0010217747,0.0009791467,0.0009402242,0.000050339277,0.025936322,0.0015851546,0.00021750944,0.027245592,0.0005726286],"about_ca_topic_score_codex":0.0002099866,"about_ca_topic_score_gemma":0.000087570384,"teacher_disagreement_score":0.3457935,"about_ca_system_score_codex":0.052340597,"about_ca_system_score_gemma":0.09858229,"threshold_uncertainty_score":0.99997073},"labels":[],"label_agreement":null},{"id":"W1665627624","doi":"10.4049/jimmunol.1401569","title":"PU.1 Opposes IL-7–Dependent Proliferation of Developing B Cells with Involvement of the Direct Target Gene <i>Bruton Tyrosine Kinase</i>","year":2014,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Lawson Health Research Institute; Western University","funders":"BC Cancer Agency; Canadian Institutes of Health Research; University of British Columbia","keywords":"Bruton's tyrosine kinase; CD19; STAT5; B cell; Biology; Cancer research; Bone marrow; Molecular biology; Tyrosine kinase; Leukemia; Ectopic expression; Signal transduction; Cell biology; Immunology; Cell culture; Flow cytometry; Antibody","score_opus":0.016119517321374944,"score_gpt":0.25217603342124745,"score_spread":0.2360565160998725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1665627624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379224,0.0017826569,0.0016590892,0.0017758403,0.00023690664,0.00037773795,0.0000039512943,0.0000051800916,0.00036637858],"genre_scores_gemma":[0.99734074,0.0007256088,0.001309354,0.00021741496,0.000105955354,0.0000040044083,0.0000022307784,0.00001818785,0.00027652027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814683,0.0003891552,0.000576475,0.00009492714,0.0005525945,0.00023999249],"domain_scores_gemma":[0.99802566,0.0002569125,0.00069305656,0.00042556177,0.0005604385,0.000038394035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014634965,0.00013262875,0.00045616637,0.00010797092,0.0000744243,0.0000059697018,0.00038356642,0.00007687644,0.000025940624],"category_scores_gemma":[0.00020356508,0.00006230137,0.00008307047,0.00020253999,0.0003237424,0.00006131027,0.00014677293,0.00029200036,0.0000022945153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020440985,0.00017381382,0.0008523261,0.00015920337,0.00048041972,0.000011466355,0.0008067511,0.0009609235,0.99294275,0.00021888077,0.00029535368,0.0010540102],"study_design_scores_gemma":[0.006470721,0.0015261971,0.0019234054,0.00035150014,0.0001516233,0.0005448222,0.00018658357,0.00040943385,0.9872105,0.00009170355,0.0010680028,0.00006548632],"about_ca_topic_score_codex":0.00012437654,"about_ca_topic_score_gemma":0.000025700172,"teacher_disagreement_score":0.0057322322,"about_ca_system_score_codex":0.0014191831,"about_ca_system_score_gemma":0.003129022,"threshold_uncertainty_score":0.55507505},"labels":[],"label_agreement":null},{"id":"W1689754337","doi":"10.2353/jmoldx.2010.090046","title":"Multiplex Ligation-Dependent Probe Amplification Versus Multiprobe Fluorescence in Situ Hybridization To Detect Genomic Aberrations in Chronic Lymphocytic Leukemia","year":2010,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Multiplex ligation-dependent probe amplification; Fluorescence in situ hybridization; Chronic lymphocytic leukemia; Multiplex; Trisomy; Biology; Cytogenetics; Population; In situ hybridization; Leukemia; Pathology; Genetics; Medicine; Chromosome; Gene","score_opus":0.016840318667873774,"score_gpt":0.2990905535445353,"score_spread":0.2822502348766615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1689754337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799778,0.00043287966,0.017578864,0.00024263289,0.00045345674,0.0012044397,0.0000048973798,0.000019610663,0.00008543744],"genre_scores_gemma":[0.98358756,0.00050884753,0.015381716,0.00010720257,0.00025082767,0.00006839975,0.000023517407,0.0000520566,0.000019879131],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972269,0.000108987115,0.0010270183,0.0003493186,0.0008216519,0.00046612596],"domain_scores_gemma":[0.9976285,0.00062722893,0.00035513216,0.0005079638,0.00054940896,0.0003317844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077721226,0.00023615248,0.00040825413,0.00074652804,0.000059023685,0.00006905393,0.00033856777,0.00020798043,0.000022647066],"category_scores_gemma":[0.006859547,0.00023794483,0.00011474316,0.0007374972,0.000085703236,0.00018220636,0.00009836703,0.00076484354,0.00006218617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00047273783,0.00008165199,0.0009740577,0.00010266842,0.000039626597,0.00071343017,0.0004257844,0.06286774,0.92933834,0.0001211903,0.00010681153,0.00475595],"study_design_scores_gemma":[0.049095795,0.0013577705,0.054422237,0.0010087776,0.00019456456,0.00077068794,0.00016327466,0.1305018,0.76111305,0.0003072227,0.00049761054,0.00056723587],"about_ca_topic_score_codex":0.00049024326,"about_ca_topic_score_gemma":0.0024922402,"teacher_disagreement_score":0.16822532,"about_ca_system_score_codex":0.05685865,"about_ca_system_score_gemma":0.024023442,"threshold_uncertainty_score":0.98150945},"labels":[],"label_agreement":null},{"id":"W1763313829","doi":"10.1212/wnl.82.10_supplement.p7.221","title":"Switching from Injectable Therapy Leads to High Continuation Rate on Fingolimod (P7.221)","year":2014,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Novartis (Canada); University of British Columbia Hospital; Montreal Neurological Institute and Hospital","funders":"","keywords":"Fingolimod; Medicine; Continuation; Intensive care medicine; Internal medicine; Multiple sclerosis; Computer science; Psychiatry","score_opus":0.019892644016116193,"score_gpt":0.2894819919040546,"score_spread":0.2695893478879384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1763313829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896283,0.000031243224,0.00088862923,0.006028475,0.00040191857,0.0004295502,0.0000025769086,0.000103183935,0.0024861337],"genre_scores_gemma":[0.97506297,0.00002221411,0.00013635126,0.023739781,0.00060979545,0.000043168307,0.000023879218,0.000041816358,0.00032002633],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982904,0.00028873273,0.00022956343,0.0004745541,0.00026799316,0.00044872865],"domain_scores_gemma":[0.9983987,0.00075833156,0.000060893017,0.0005326301,0.0000883289,0.00016108954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040781693,0.00016361354,0.0003457,0.00015858514,0.00007392547,0.000023784312,0.00016784252,0.00017165905,0.00033323848],"category_scores_gemma":[0.00061098696,0.00013900809,0.00005218439,0.00017893738,0.000037573926,0.000045606714,0.00006699511,0.00039936628,0.00068902754],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029007172,0.00071809744,0.019972363,0.00006045418,0.00022434225,0.00046475197,0.0022311397,0.0047547454,0.81368816,0.0049587055,0.020469343,0.103450745],"study_design_scores_gemma":[0.11331775,0.035021998,0.34314644,0.00014994011,0.0001233156,0.0002640474,0.000021433214,0.11792382,0.21121852,0.006547698,0.17122462,0.0010404297],"about_ca_topic_score_codex":0.0041919267,"about_ca_topic_score_gemma":0.00022043382,"teacher_disagreement_score":0.6024696,"about_ca_system_score_codex":0.00055280374,"about_ca_system_score_gemma":0.00054314773,"threshold_uncertainty_score":0.88562846},"labels":[],"label_agreement":null},{"id":"W1792060848","doi":"10.3324/haematol.2014.117721","title":"Aging and malignant hemopathies","year":2015,"lang":"en","type":"editorial","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Incidence (geometry); Session (web analytics); Medicine; Gerontology; Plenary session; Library science; Computer science; Mathematics","score_opus":0.030407990995152814,"score_gpt":0.33102798289917235,"score_spread":0.30061999190401956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1792060848","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016804036,0.026631745,0.000027991664,0.0011711468,0.93111956,0.00140317,0.00010971458,0.0005494472,0.022183176],"genre_scores_gemma":[0.01726362,0.004259409,0.0014981679,0.0002565823,0.9608753,0.0001691374,0.0005070864,0.00015977262,0.015010941],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969205,0.0001006141,0.00039541707,0.0006792654,0.0013203479,0.0005838533],"domain_scores_gemma":[0.9976534,0.00074360723,0.00015155069,0.00064626645,0.0004320786,0.0003730433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077564374,0.00036818287,0.0011601761,0.00017844464,0.00009216969,0.00006884705,0.00022198143,0.0010759278,0.000118301665],"category_scores_gemma":[0.0036064142,0.00025694992,0.00010623273,0.00016307828,0.00036342102,0.00004698945,0.0004406748,0.0009413794,0.0002449332],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001636191,0.000039053873,0.000019590245,0.0012581496,0.00006720995,0.0054667643,0.00013208743,1.3815861e-7,0.000013474609,0.00014481721,0.9921,0.000595087],"study_design_scores_gemma":[0.005528907,0.00031731228,0.000004922585,0.00079058774,0.00014904185,0.0023959721,0.00010227213,0.00017159362,0.00018517935,0.0005271005,0.9895395,0.00028761802],"about_ca_topic_score_codex":0.0001967368,"about_ca_topic_score_gemma":0.000012644687,"teacher_disagreement_score":0.029755712,"about_ca_system_score_codex":0.0035332842,"about_ca_system_score_gemma":0.008902553,"threshold_uncertainty_score":0.99998826},"labels":[],"label_agreement":null},{"id":"W1809364733","doi":"10.1002/0471142956.cy0927s46","title":"Whole Blood Processing for Measurement of Signaling Proteins by Flow Cytometry","year":2008,"lang":"en","type":"article","venue":"Current Protocols in Cytometry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Flow cytometry; Signal transduction; Cell biology; Phosphorylation; Biology; Haematopoiesis; Phenotype; Immune system; Signaling proteins; Cytometry; Computational biology; Immunology; Stem cell; Genetics; Gene","score_opus":0.11726954431733856,"score_gpt":0.3956352512634671,"score_spread":0.27836570694612855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1809364733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47341374,0.010291229,0.07110665,0.000248669,0.0002777557,0.44335216,0.00024109725,0.00035038928,0.0007183111],"genre_scores_gemma":[0.83724856,0.000021745784,0.0066067176,0.000029376964,0.00025805732,0.15560722,0.000045753448,0.00008397018,0.00009857959],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995285,0.000096721546,0.0010354788,0.00069799676,0.0020449676,0.0008398432],"domain_scores_gemma":[0.9978249,0.00013933537,0.00032218214,0.0006086381,0.00082490937,0.0002800439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001799041,0.00035841795,0.00079200673,0.0009322496,0.00015094936,0.00003375318,0.00041298475,0.000180044,0.000055787805],"category_scores_gemma":[0.001499388,0.00032398416,0.0002203762,0.002092356,0.00026298454,0.0002167697,0.0001515147,0.00053823955,0.000014009418],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032003832,0.009864573,0.0554093,0.032997783,0.00025328522,0.00017995614,0.001006744,0.00010409352,0.755102,0.000020732325,0.006598578,0.13526262],"study_design_scores_gemma":[0.06435209,0.0017454092,0.001679541,0.010251683,0.00012838194,0.00029007677,0.00013898703,0.014713753,0.88210064,0.00009326332,0.023772078,0.0007341137],"about_ca_topic_score_codex":0.000016797314,"about_ca_topic_score_gemma":0.0000017693634,"teacher_disagreement_score":0.36383486,"about_ca_system_score_codex":0.0051054317,"about_ca_system_score_gemma":0.006810385,"threshold_uncertainty_score":0.9999212},"labels":[],"label_agreement":null},{"id":"W1818977891","doi":"10.1007/s00277-015-2487-8","title":"Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia","year":2015,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre","funders":"","keywords":"Ibrutinib; Autoimmune hemolytic anemia; Medicine; Chronic lymphocytic leukemia; Hematology; Internal medicine; Leukemia; Anemia; Hemolytic anemia; Immunology","score_opus":0.07872316819994295,"score_gpt":0.3517327384379987,"score_spread":0.2730095702380557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1818977891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97493225,0.0036192178,0.00012113479,0.014199501,0.00019561601,0.0037683572,0.000110684734,0.00011836995,0.0029348684],"genre_scores_gemma":[0.9708012,0.00025564787,0.00042316885,0.024662325,0.00023228695,0.00012827585,0.0012684232,0.0002527917,0.0019759205],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99442697,0.0002824703,0.0015398682,0.0009136658,0.0016192398,0.0012178042],"domain_scores_gemma":[0.99556285,0.0004333994,0.0011097671,0.0015622395,0.0011405897,0.00019118255],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004603956,0.0007468106,0.0029969055,0.0009291591,0.000038813676,0.000014380711,0.0005741829,0.0013461914,0.00023180286],"category_scores_gemma":[0.00034448472,0.0005056634,0.00014783905,0.00097325636,0.0010653018,0.00015347953,0.0002155286,0.0012142693,0.00003490493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.053426825,0.0010467034,0.05822942,0.06816474,0.00335062,0.014218425,0.002644917,0.0016345053,0.00036689185,0.00029947486,0.7916822,0.0049352865],"study_design_scores_gemma":[0.5432914,0.06959817,0.015974099,0.059833787,0.003504054,0.021855794,0.0007860722,0.059387334,0.057967335,0.0005695905,0.16051055,0.0067218407],"about_ca_topic_score_codex":0.001683136,"about_ca_topic_score_gemma":0.0002677312,"teacher_disagreement_score":0.63117164,"about_ca_system_score_codex":0.019420886,"about_ca_system_score_gemma":0.09118466,"threshold_uncertainty_score":0.9999503},"labels":[],"label_agreement":null},{"id":"W1850627739","doi":"10.3233/bd-140386","title":"Lymphocytopenia; induced by vinorelbine, doxorubicin and cisplatin in human cancer patients","year":2015,"lang":"en","type":"article","venue":"Breast Disease","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Centre for Drug Research and Development","funders":"","keywords":"Vinorelbine; Lymphocytopenia; Medicine; Chemotherapy; Cancer; Cisplatin; Oncology; Internal medicine; Lymphocyte","score_opus":0.024040727726503595,"score_gpt":0.32077601315190934,"score_spread":0.2967352854254057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1850627739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689853,0.0006049358,9.999264e-7,0.0005002844,0.000065067674,0.00065211987,0.00015084427,0.000041257546,0.0010859563],"genre_scores_gemma":[0.99831945,0.000020281672,0.0000112268335,0.0004269485,0.000102338294,0.00011716228,0.00017778532,0.000041342544,0.0007834483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980842,0.000069769165,0.00030652428,0.00044242982,0.00062878977,0.00046832778],"domain_scores_gemma":[0.998144,0.000033410957,0.00006218681,0.0003589679,0.00016312621,0.001238348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017639411,0.00021581414,0.00032057287,0.00015412143,0.000052794734,0.000036786227,0.00013339498,0.00008934503,0.00015193166],"category_scores_gemma":[0.00014692024,0.00018852085,0.000044173856,0.00029290808,0.00010201517,0.00013897463,0.00016306643,0.00015676962,0.000045413664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068153497,0.0026364874,0.91511154,0.0006182798,0.00012160583,0.00085215434,0.0010303262,0.000031325028,0.010249654,0.00020631046,0.036479045,0.02584792],"study_design_scores_gemma":[0.10652656,0.00037439488,0.8818282,0.00056523294,0.0001543695,0.00008086446,0.00015245812,0.006953846,0.0013120237,0.00021072295,0.001275574,0.00056576816],"about_ca_topic_score_codex":0.007890828,"about_ca_topic_score_gemma":0.00021753229,"teacher_disagreement_score":0.09971121,"about_ca_system_score_codex":0.0077607664,"about_ca_system_score_gemma":0.004981382,"threshold_uncertainty_score":0.9987157},"labels":[],"label_agreement":null},{"id":"W1861934603","doi":"10.1520/jfs14928j","title":"Polyclonal Systemic Immunoblast Proliferation: An Unusual Hematologic Entity Presenting as a Medical Examiner Case","year":2001,"lang":"en","type":"article","venue":"Journal of Forensic Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Office of the Chief Medical Examiner","funders":"","keywords":"Medicine; Autopsy; Polyclonal antibodies; Dyscrasia; Lymph; Pathology; Discontinuation; Dermatology; Rash; Lymphatic system; Internal medicine; Antibody; Immunology; Bone marrow","score_opus":0.04701681968374911,"score_gpt":0.37038980579012554,"score_spread":0.32337298610637644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1861934603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562716,0.00077608466,0.00015005608,0.0010476302,0.00047025885,0.00021556013,7.4490936e-7,0.000020614329,0.001691905],"genre_scores_gemma":[0.9976495,0.00008023168,0.00081121194,0.00019950207,0.0008730233,0.000004017351,0.000001285731,0.000009296715,0.00037194803],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.995777,0.00017908608,0.00079833786,0.0002714317,0.0024920164,0.0004820965],"domain_scores_gemma":[0.9981212,0.00029079572,0.00038709675,0.0002231056,0.0004833062,0.0004945221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030172414,0.00015638622,0.00044325585,0.00033228134,0.00031484227,0.00014206476,0.000379129,0.00013542463,0.00036695643],"category_scores_gemma":[0.0019739566,0.000099590194,0.00014476929,0.00068772875,0.0009242151,0.00058931985,0.00011174102,0.0004129429,0.000025484955],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003109488,0.0027947454,0.24856973,0.001095856,0.0008815036,0.65964144,0.008150798,0.00056378084,0.020372724,0.008401092,0.0075797867,0.038839046],"study_design_scores_gemma":[0.0048781442,0.0014176808,0.0012360093,0.00047763946,0.000065243825,0.9652838,0.0025816578,0.019682717,0.0037693393,0.0003242477,0.00015288705,0.00013059526],"about_ca_topic_score_codex":0.00033438148,"about_ca_topic_score_gemma":0.00012615783,"teacher_disagreement_score":0.3056424,"about_ca_system_score_codex":0.001320917,"about_ca_system_score_gemma":0.009574809,"threshold_uncertainty_score":0.99604},"labels":[],"label_agreement":null},{"id":"W1874333151","doi":"10.1158/1538-7445.am2014-4136","title":"Abstract 4136: Comparison of overall survival of Chronic Lymphocytic Leukemia (CLL) patients referred or not referred to a specialized CLL clinic: A Canadian population-based study","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Hazard ratio; Internal medicine; Proportional hazards model; Referral; Population; Cohort; Cancer registry; Cancer; Medical diagnosis; Pediatrics; Leukemia; Confidence interval; Pathology; Family medicine","score_opus":0.17535362228692705,"score_gpt":0.46852088222767524,"score_spread":0.2931672599407482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1874333151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937402,0.00012027732,0.000008457217,0.00017261587,0.0005204078,0.0035141225,0.00017396496,0.00004501941,0.0017049066],"genre_scores_gemma":[0.9971469,0.000029865076,0.000077301214,0.00010787093,0.00051988807,0.0003274376,0.00019371728,0.00011939226,0.0014775997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915579,0.0007879011,0.0016603963,0.0009913899,0.003465744,0.0015366785],"domain_scores_gemma":[0.993053,0.0018154014,0.00034960956,0.0016422301,0.0018460336,0.0012936854],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033002559,0.00039932915,0.0015429471,0.0012960209,0.00023046412,0.00005804984,0.0007925883,0.0003291111,0.0024387126],"category_scores_gemma":[0.0042142496,0.00034291652,0.00021944514,0.0015275037,0.00024445416,0.00011306241,0.00023542836,0.0008406814,0.0001745442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12760998,0.005718767,0.71853334,0.009599064,0.0020861262,0.00038702818,0.0076794326,0.017028011,0.0124828955,0.00022982291,0.04177368,0.05687183],"study_design_scores_gemma":[0.09100585,0.008060436,0.86091346,0.0015060215,0.00016468242,0.0000026070106,0.00061488565,0.022624038,0.005370418,0.000027965918,0.009041833,0.0006678212],"about_ca_topic_score_codex":0.7088345,"about_ca_topic_score_gemma":0.53682387,"teacher_disagreement_score":0.17201066,"about_ca_system_score_codex":0.16312371,"about_ca_system_score_gemma":0.11031305,"threshold_uncertainty_score":0.9999023},"labels":[],"label_agreement":null},{"id":"W1884424467","doi":"10.4049/jimmunol.176.6.3830","title":"Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity","year":2006,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"CD80; CD86; IL-2 receptor; T cell; STAT4; Acquired immune system; Biology; CD40; Immunology; Cancer research; Immune system; stat; Signal transduction; Cell biology; Cytotoxic T cell; STAT3","score_opus":0.012453985359392914,"score_gpt":0.2654846699590847,"score_spread":0.2530306845996918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1884424467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868354,0.008910803,0.0014843261,0.00056357885,0.00021381839,0.00013931289,0.0000024894534,0.000008230976,0.0018420287],"genre_scores_gemma":[0.9972594,0.0012547731,0.0006977467,0.00007513042,0.00024982344,7.279821e-7,0.0000038741205,0.000018996867,0.00043953123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981623,0.00027864525,0.00075031596,0.000091130416,0.0004240758,0.0002935171],"domain_scores_gemma":[0.9978989,0.00053763593,0.00064813497,0.00032152398,0.0005687715,0.000025039013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008792372,0.00013175837,0.0004527778,0.00011557447,0.00008902221,0.000007558454,0.0002705468,0.00014528573,0.00011452061],"category_scores_gemma":[0.00014865909,0.00008475753,0.00016221435,0.0002716605,0.0003845849,0.000114682196,0.00008199405,0.00025828657,0.000022321008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014849269,0.00019011759,0.00007347762,0.00005807334,0.0002062535,0.00006119512,0.0006135597,0.00040748224,0.9955673,0.00022199115,0.00029268037,0.00082289864],"study_design_scores_gemma":[0.009130494,0.00073455245,0.0015566574,0.00013327923,0.00019893124,0.0030157196,0.0005053494,0.00044139693,0.98237914,0.0012404607,0.0005839668,0.00008003097],"about_ca_topic_score_codex":0.0012528993,"about_ca_topic_score_gemma":0.000013235153,"teacher_disagreement_score":0.013188182,"about_ca_system_score_codex":0.0017149702,"about_ca_system_score_gemma":0.0022676568,"threshold_uncertainty_score":0.44845876},"labels":[],"label_agreement":null},{"id":"W1893429935","doi":"10.11124/01938924-201008161-00016","title":"Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: A systematic review","year":2010,"lang":"en","type":"review","venue":"The JBI Database of Systematic Reviews and Implementation Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Rituximab; Lymphoma; Hodgkin lymphoma; Adverse effect; Oncology; Internal medicine; Leukemia; Immunology","score_opus":0.024475336435791667,"score_gpt":0.35298707060851353,"score_spread":0.32851173417272184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1893429935","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021373788,0.94380426,0.000056834233,0.000008930593,0.00013714746,0.053514402,0.00026565918,0.000023750341,0.000051639283],"genre_scores_gemma":[0.0004946093,0.9911598,0.00035902823,0.000061175924,0.000054440374,0.0060148165,0.0016423638,0.00009850855,0.00011524258],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9878433,0.0012858544,0.008018029,0.00084584876,0.0015134686,0.0004935296],"domain_scores_gemma":[0.9838302,0.0008845098,0.011039491,0.003121228,0.00081640115,0.000308156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0056673265,0.0009117268,0.009325104,0.00040497887,0.0002022454,0.000043394277,0.00033778776,0.00024431697,0.00012336968],"category_scores_gemma":[0.0016674428,0.00046088116,0.0006660915,0.0008311233,0.00040628802,0.00039537976,0.00036632048,0.0003675566,0.000015774582],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000019187226,0.00006969373,0.000011912726,0.98727363,0.0008684117,0.00009364248,0.00012762602,6.214207e-8,0.0000045947577,0.0000150360975,0.0003798496,0.011136323],"study_design_scores_gemma":[0.0058652763,0.0004139994,0.000017567743,0.9521652,0.029756177,0.004317136,0.00014453093,0.00009878294,0.000011732046,0.0000016884369,0.0068223365,0.00038556056],"about_ca_topic_score_codex":0.0007663458,"about_ca_topic_score_gemma":0.00013722517,"teacher_disagreement_score":0.047499586,"about_ca_system_score_codex":0.008053295,"about_ca_system_score_gemma":0.009807466,"threshold_uncertainty_score":0.9997843},"labels":[],"label_agreement":null},{"id":"W1902656250","doi":"10.3109/10428194.2015.1088651","title":"A link between hypercholesterolemia and chronic lymphocytic leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Medicine; Incidence (geometry); Internal medicine; Cholesterol; Leukemia; Gastroenterology","score_opus":0.032955813149021185,"score_gpt":0.28930771969680397,"score_spread":0.2563519065477828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1902656250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734193,0.013020965,0.00020032995,0.0005886414,0.0005645694,0.001806001,0.00008973016,0.00095804187,0.009352408],"genre_scores_gemma":[0.9834843,0.0029093605,0.0015033946,0.0018132053,0.003930006,0.0003067458,0.00031454276,0.0004665917,0.0052718017],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9889746,0.00045437555,0.0020450193,0.0029110995,0.002493849,0.0031210722],"domain_scores_gemma":[0.9912184,0.00091704226,0.0005525627,0.0025198995,0.0006584194,0.0041337046],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017609384,0.0018873529,0.0027198403,0.00087207137,0.00069462607,0.0006029942,0.0010188668,0.0017506278,0.0000954212],"category_scores_gemma":[0.00081236596,0.001765454,0.00051394926,0.0015442205,0.0019227695,0.0010067185,0.0014151265,0.0007057969,0.0006640499],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004045251,0.00013009901,0.016711744,0.0030864137,0.0018475802,0.005367948,0.0045883064,0.00067252206,0.0064858687,0.0017754679,0.01660901,0.9386798],"study_design_scores_gemma":[0.33583513,0.005758813,0.089813605,0.0035102877,0.0031702311,0.036749557,0.0023697682,0.16980702,0.019373914,0.0032315522,0.3240582,0.0063219164],"about_ca_topic_score_codex":0.007145869,"about_ca_topic_score_gemma":0.00017934646,"teacher_disagreement_score":0.93235785,"about_ca_system_score_codex":0.3832112,"about_ca_system_score_gemma":0.15789355,"threshold_uncertainty_score":0.99954534},"labels":[],"label_agreement":null},{"id":"W1905683503","doi":"10.1002/gcc.22294","title":"Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population‐based analysis in British Columbia, Canada","year":2015,"lang":"en","type":"article","venue":"Genes Chromosomes and Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Royal Columbian Hospital; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"clone (Java method); Chronic lymphocytic leukemia; Biology; Locus (genetics); Interphase; Chromosome 13; Population; Cytogenetics; Gene deletion; Gene; Chromosome; Genetics; Leukemia; Medicine","score_opus":0.011021741420862676,"score_gpt":0.26268345321403924,"score_spread":0.2516617117931766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1905683503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805325,0.0013484651,0.0000023842108,0.000025551708,0.000018051656,0.0004986071,0.000040424777,0.000009152781,0.0000040875166],"genre_scores_gemma":[0.9992291,0.0003041424,0.000036737798,0.0001599926,0.000020788766,0.00007590672,0.000116873685,0.000019339279,0.00003715569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982137,0.000080682796,0.000467426,0.00040719702,0.0004997288,0.00033125468],"domain_scores_gemma":[0.9992419,0.0000661566,0.00012505408,0.00022571858,0.00016027299,0.00018089073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019665013,0.00013630444,0.00051994564,0.00021001871,0.000031268963,0.000035777415,0.000068168134,0.00011162225,0.000032227083],"category_scores_gemma":[0.00007055421,0.00016426202,0.00002325892,0.0011619886,0.000072064184,0.00013420758,0.000029924458,0.0001266198,1.9874575e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003110369,0.000038128743,0.8857927,0.00018047132,0.000040789586,0.000063217274,0.00007043003,0.109542094,0.000067916626,3.3764644e-7,0.0000057405164,0.0038871388],"study_design_scores_gemma":[0.018888945,0.0004708257,0.8791702,0.00035761282,0.000074447256,0.000008106459,0.000046169127,0.100773536,0.00003293452,0.0000050852454,0.000016086558,0.00015608505],"about_ca_topic_score_codex":0.9855847,"about_ca_topic_score_gemma":0.9955018,"teacher_disagreement_score":0.048311763,"about_ca_system_score_codex":0.065133184,"about_ca_system_score_gemma":0.01682142,"threshold_uncertainty_score":0.9887523},"labels":[],"label_agreement":null},{"id":"W1917919880","doi":"10.5737/23688076253341346","title":"Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients","year":2015,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rituximab; Medicine; Pharmacokinetics; Lymphoma; Internal medicine; Chemotherapy; Pharmacy; Oncology","score_opus":0.09058092522014807,"score_gpt":0.4118030314511987,"score_spread":0.32122210623105063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1917919880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98332864,0.001299339,0.00025528765,0.012281399,0.0010150201,0.00067669223,0.000082851744,0.0000050779086,0.0010557185],"genre_scores_gemma":[0.99530745,0.000022740964,0.0023910052,0.0012869461,0.00071837066,0.00003055978,0.00003072311,0.00003365975,0.00017852339],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99830276,0.0001275478,0.00038695981,0.00019968879,0.0003865404,0.0005964766],"domain_scores_gemma":[0.99725944,0.00048413506,0.00013664525,0.00018348909,0.0008366628,0.0010996002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006347065,0.00012607555,0.0003667088,0.00020475165,0.0002914273,0.00003102037,0.00020460875,0.000155377,0.00011161965],"category_scores_gemma":[0.00095970824,0.000100991,0.00008347852,0.0001886195,0.00015228428,0.000047633934,0.000008187905,0.00036305728,0.000010846128],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0038408665,0.0005078033,0.0009574275,0.0000374784,0.00033683848,0.00022023979,0.038205825,0.005945088,0.0005908242,0.00015308296,0.022217747,0.92698675],"study_design_scores_gemma":[0.404532,0.11209711,0.027854849,0.023897946,0.0065041995,0.03136008,0.020394165,0.28215435,0.0060792547,0.010784209,0.071486905,0.0028549512],"about_ca_topic_score_codex":0.11734393,"about_ca_topic_score_gemma":0.16607524,"teacher_disagreement_score":0.9241318,"about_ca_system_score_codex":0.05193697,"about_ca_system_score_gemma":0.051913977,"threshold_uncertainty_score":0.9534608},"labels":[],"label_agreement":null},{"id":"W1930759119","doi":"10.1200/jco.2001.19.22.4252","title":"Activity of Oral Fludarabine Phosphate in Previously Treated Chronic Lymphocytic Leukemia","year":2001,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Fludarabine; Leukemia; Cancer research; Internal medicine; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.12239556206196289,"score_gpt":0.47236688523374076,"score_spread":0.34997132317177787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1930759119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219966,0.0019239229,0.00006122605,0.0007307582,0.0004906692,0.00046123686,0.0000016039838,0.000016383832,0.0041145636],"genre_scores_gemma":[0.9911031,0.00590983,0.00060679327,0.00034211553,0.0005887699,0.0000071641603,0.000002313523,0.000034527417,0.0014053689],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99420047,0.0007215387,0.0033016524,0.000329385,0.0007876682,0.00065930205],"domain_scores_gemma":[0.9941296,0.0023237972,0.0018905968,0.00046026203,0.00058896537,0.0006067735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057479204,0.00024391315,0.0028471688,0.00035097136,0.000026235986,0.0000079179,0.0003773211,0.0006745569,0.0005594036],"category_scores_gemma":[0.0053614415,0.00017892045,0.0006742091,0.0006981167,0.000544258,0.00021047617,0.00012773559,0.001336971,0.000049415827],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06511167,0.0035790082,0.09764985,0.00060527615,0.0013988962,0.022093331,0.00023281387,0.0028068826,0.006239198,0.000115085524,0.006123088,0.7940449],"study_design_scores_gemma":[0.41789415,0.0803647,0.29816192,0.0019920738,0.0014684311,0.014058713,0.00009861565,0.089202635,0.012202425,0.0005942009,0.08328988,0.0006722516],"about_ca_topic_score_codex":0.001742382,"about_ca_topic_score_gemma":0.00052077323,"teacher_disagreement_score":0.79337263,"about_ca_system_score_codex":0.083957806,"about_ca_system_score_gemma":0.12847205,"threshold_uncertainty_score":0.9195587},"labels":[],"label_agreement":null},{"id":"W1940962425","doi":"10.1002/jemt.22278","title":"Morphology and expression status investigations of specific surface markers on B‐cell chronic lymphocytic leukemia cells","year":2013,"lang":"en","type":"article","venue":"Microscopy Research and Technique","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; National Research Council Canada; University of Ottawa","funders":"","keywords":"Chronic lymphocytic leukemia; Morphology (biology); Biology; Leukemia; Cell; Cell biology; Cancer research; Chemistry; Immunology; Genetics","score_opus":0.02990886624346176,"score_gpt":0.3287534814848578,"score_spread":0.298844615241396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1940962425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209225,0.0020366942,0.00025509557,0.00011874571,0.000033170138,0.002456499,0.000029328006,0.000073202566,0.002905022],"genre_scores_gemma":[0.98048574,0.0050257915,0.0115206,0.000056976725,0.000050506023,0.0002549089,0.000031477717,0.000059050937,0.0025149419],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969954,0.00026523106,0.0004082946,0.0006594276,0.0006359296,0.0010357092],"domain_scores_gemma":[0.99755514,0.0006278954,0.00008385049,0.00073602045,0.0003552864,0.00064184016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009064033,0.00025194822,0.00043578213,0.00044126928,0.00021930883,0.00007423064,0.00021190027,0.00031941908,0.00043277245],"category_scores_gemma":[0.00012597814,0.00021378006,0.00005013544,0.0005543739,0.0017765482,0.00012543003,0.00036017178,0.00075922825,0.000105857216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003188272,0.000059118065,0.00038775583,0.0005823863,0.0000145452605,0.00005185231,0.000105649764,0.000013692085,0.97720087,0.00006727024,0.020557132,0.0006408813],"study_design_scores_gemma":[0.0049566906,0.0019678948,0.00041457915,0.0005090416,0.0000071045174,0.000095506606,0.00014163926,0.0010688803,0.9861534,0.00059341826,0.0039249435,0.00016685002],"about_ca_topic_score_codex":0.0031932958,"about_ca_topic_score_gemma":0.00001302139,"teacher_disagreement_score":0.016632188,"about_ca_system_score_codex":0.018369496,"about_ca_system_score_gemma":0.011345429,"threshold_uncertainty_score":0.9942593},"labels":[],"label_agreement":null},{"id":"W1946080547","doi":"10.3109/10428194.2015.1080927","title":"Enhancing monoclonal antibody activity in chronic lymphocytic leukemia","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Monoclonal antibody; Medicine; Leukemia; Antibody; Monoclonal; Cancer research; Immunology","score_opus":0.023307284470340316,"score_gpt":0.30278116081969697,"score_spread":0.27947387634935666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1946080547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529018,0.014335957,0.00018122567,0.010788556,0.0022050433,0.004705143,0.0003757475,0.0013702326,0.013136302],"genre_scores_gemma":[0.74262875,0.009003273,0.0015026778,0.17701758,0.022950687,0.0016736784,0.005102612,0.0025757756,0.037544962],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97845554,0.0010911595,0.0034203841,0.005510982,0.0052630403,0.0062589115],"domain_scores_gemma":[0.9890256,0.0017660029,0.0014936557,0.004567543,0.00096001825,0.0021872027],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0025756445,0.0040950803,0.0059922263,0.0030507524,0.0007139352,0.0007417511,0.002219812,0.007551838,0.00040700674],"category_scores_gemma":[0.0009683778,0.00408529,0.0014176538,0.003032305,0.002022088,0.0012295558,0.0019639984,0.003808687,0.0012331975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005594069,0.00028571772,0.00066161493,0.013326406,0.0024335315,0.079613455,0.0019665628,0.0014827731,0.025564315,0.0001593465,0.77934486,0.08956734],"study_design_scores_gemma":[0.13408393,0.0019683654,0.004165501,0.006637753,0.0015669314,0.021897713,0.0002894442,0.13176577,0.015691413,0.0006091841,0.67534333,0.0059807],"about_ca_topic_score_codex":0.042888686,"about_ca_topic_score_gemma":0.0013705922,"teacher_disagreement_score":0.3182443,"about_ca_system_score_codex":0.7876294,"about_ca_system_score_gemma":0.46938512,"threshold_uncertainty_score":0.99954444},"labels":[],"label_agreement":null},{"id":"W1947519512","doi":"10.1007/s40273-015-0332-5","title":"Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Health Canada; Novartis Pharmaceuticals Canada; GlaxoSmithKline","keywords":"Chlorambucil; Ofatumumab; Medicine; Fludarabine; Quality-adjusted life year; Cost effectiveness; Life expectancy; Actuarial science; Internal medicine; Chronic lymphocytic leukemia; Population; Chemotherapy; Leukemia; Environmental health; Economics","score_opus":0.07660397386840974,"score_gpt":0.35768279047389434,"score_spread":0.2810788166054846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1947519512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948959,0.0015110568,0.00003402618,0.00012240038,0.0004522189,0.0012802281,0.000036392124,0.000018081608,0.0016496998],"genre_scores_gemma":[0.9988041,0.00049313105,0.000035732413,0.00018245968,0.00014563387,0.00014280816,0.000052543037,0.00005425288,0.000089361856],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99764997,0.00013489832,0.000729125,0.0004693598,0.00032221767,0.00069443445],"domain_scores_gemma":[0.99830836,0.0005494795,0.00015000302,0.00045340083,0.00012015862,0.0004185778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011725837,0.0002744395,0.0008564625,0.0002850768,0.000020433852,0.000012833649,0.00031480286,0.0001038001,0.00012379338],"category_scores_gemma":[0.00021731516,0.00029149093,0.000076653065,0.00038960975,0.000112780406,0.0001588348,0.00017801243,0.000383284,0.000055462948],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014013388,0.00033202858,0.04214622,0.005215346,0.00032598103,0.002044307,0.0009288828,0.9175071,0.0021782278,0.00021004623,0.002649167,0.012449294],"study_design_scores_gemma":[0.1410857,0.00023395475,0.0038482326,0.00059336616,0.00005920761,0.00020858164,0.00018693245,0.80671954,0.042624928,0.000092496935,0.00394812,0.00039892824],"about_ca_topic_score_codex":0.8963996,"about_ca_topic_score_gemma":0.84821,"teacher_disagreement_score":0.25970244,"about_ca_system_score_codex":0.46395162,"about_ca_system_score_gemma":0.20424917,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W1958629772","doi":"10.3747/co.22.2119","title":"Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia: A Literature-Based Analysis","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"NanoQuébec (Canada); Université de Montréal","funders":"Lundbeck Canada; H. Lundbeck A/S; American Society of Hematology","keywords":"Medicine; Internal medicine; Progression-free survival; Chronic lymphocytic leukemia; Population; Oncology; Clinical endpoint; Clinical trial; Overall survival; Leukemia","score_opus":0.1615577459848462,"score_gpt":0.4402545194651397,"score_spread":0.27869677348029354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958629772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98570436,0.010136772,0.00039645046,0.00063881004,0.0005964032,0.0008268281,0.00003764194,0.00010705875,0.0015556493],"genre_scores_gemma":[0.9980057,0.00010109292,0.00038106783,0.000034995657,0.00066762906,0.000118213866,0.00046153658,0.00003730974,0.00019248559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617624,0.0006889099,0.000681707,0.00073009,0.0009531074,0.0007699563],"domain_scores_gemma":[0.9960991,0.0018546989,0.00018949945,0.00087098626,0.0003164061,0.0006693087],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019733105,0.00033221874,0.0010756238,0.0009833283,0.000081799735,0.0000605202,0.0003362563,0.00047684734,0.000036889538],"category_scores_gemma":[0.0026399908,0.0002836957,0.00019399574,0.001919804,0.00034753938,0.00014554647,0.00031464503,0.0009122682,0.0000382358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010070606,0.00017671654,0.9844742,0.0006366477,0.00026486683,0.0004615946,0.0006876797,0.0011088351,0.000019220095,0.0010471124,0.0016244092,0.008491652],"study_design_scores_gemma":[0.14642583,0.0030917625,0.6441656,0.0009527194,0.0020105839,0.000127858,0.00021082356,0.18163319,0.00010915255,0.0028185977,0.01762382,0.0008300838],"about_ca_topic_score_codex":0.000389758,"about_ca_topic_score_gemma":0.00072946306,"teacher_disagreement_score":0.3403086,"about_ca_system_score_codex":0.15417422,"about_ca_system_score_gemma":0.063936755,"threshold_uncertainty_score":0.9999615},"labels":[],"label_agreement":null},{"id":"W1963919576","doi":"10.1158/1538-7445.am2013-932","title":"Abstract 932: Predictive markers of the <i>in vitro</i> anticancer effect of the pan class I PI3K inhibitor BKM120 in primary B-CLL lymphocytes.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"PI3K/AKT/mTOR pathway; Chronic lymphocytic leukemia; CD38; CD5; Protein kinase B; Apoptosis; Cancer research; Biology; Leukemia; PTEN; CD8; Immunology; Immune system; Flow cytometry; Cell biology; Genetics; Stem cell","score_opus":0.017487766335753534,"score_gpt":0.32732695568785114,"score_spread":0.3098391893520976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963919576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98264325,0.001829393,5.3171965e-7,0.0012123358,0.00024553988,0.0037528644,0.00005526048,0.000013238486,0.010247595],"genre_scores_gemma":[0.99716896,0.0005703441,0.000009907378,0.00014643394,0.00018979723,0.0008547936,0.000005082955,0.000056401885,0.000998291],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944857,0.0008136465,0.0006893844,0.0005582318,0.0023945745,0.0010584596],"domain_scores_gemma":[0.99618226,0.0017696943,0.00016868759,0.0012214477,0.00047233087,0.00018557446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002837127,0.00025721913,0.0007018313,0.00034373565,0.00008919042,0.000026282783,0.0009085794,0.00024556197,0.00032576444],"category_scores_gemma":[0.0010892405,0.00014474287,0.00023810039,0.0019400275,0.0016381334,0.00016162267,0.0006939297,0.0013042121,0.00002817119],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012831334,0.00042259484,0.07738022,0.0037595737,0.00021130362,0.000054438282,0.0007835852,0.00016149766,0.8744173,0.000021974132,0.011365602,0.01859055],"study_design_scores_gemma":[0.017273087,0.000503577,0.34405026,0.0019837855,0.00002839499,0.000013099592,0.00018724258,0.0012021295,0.6340321,0.000046471352,0.0005403767,0.00013953332],"about_ca_topic_score_codex":0.02128194,"about_ca_topic_score_gemma":0.00043554328,"teacher_disagreement_score":0.26667005,"about_ca_system_score_codex":0.025475211,"about_ca_system_score_gemma":0.015964352,"threshold_uncertainty_score":0.9896142},"labels":[],"label_agreement":null},{"id":"W1964315239","doi":"10.1016/s0145-2126(02)00062-0","title":"Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5− CLL","year":2002,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"CD5; Lymphocytosis; Chronic lymphocytic leukemia; Prolymphocytic leukemia; Medicine; Leukemia; Monoclonal; Pathology; Immunology; Lymphoma; Antibody; Monoclonal antibody","score_opus":0.05402939586775175,"score_gpt":0.3108194792010493,"score_spread":0.25679008333329756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964315239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914042,0.0034212347,0.00036359942,0.00010708781,0.00008051753,0.0014556207,0.00009095658,0.00009024626,0.00298657],"genre_scores_gemma":[0.99308765,0.002201925,0.0012378223,0.00003184466,0.00033415214,0.000209726,0.00010176876,0.00013167477,0.0026634093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9924286,0.0005410997,0.0011205444,0.0012661776,0.0032650882,0.0013784599],"domain_scores_gemma":[0.9947378,0.0017577027,0.00040567576,0.001606098,0.000846495,0.0006462526],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009880711,0.0005456934,0.0012286432,0.0008293743,0.00026675448,0.000079182064,0.0007045722,0.00052830373,0.0010358365],"category_scores_gemma":[0.0005289695,0.0004428412,0.00020795947,0.0013643242,0.0014792824,0.0003395706,0.000558391,0.0008741975,0.00008467279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007153985,0.00037202076,0.0052683377,0.0032018842,0.00065186946,0.00038808686,0.002051457,0.0015194782,0.95617926,0.00039206338,0.004102029,0.01871953],"study_design_scores_gemma":[0.04267439,0.002267511,0.006698327,0.0022729735,0.00018512766,0.00017878004,0.0005047592,0.35720053,0.5865547,0.00032829065,0.00059962075,0.0005349882],"about_ca_topic_score_codex":0.011080718,"about_ca_topic_score_gemma":0.00035937206,"teacher_disagreement_score":0.36962456,"about_ca_system_score_codex":0.121614456,"about_ca_system_score_gemma":0.028556535,"threshold_uncertainty_score":0.99987733},"labels":[],"label_agreement":null},{"id":"W1965641972","doi":"10.1111/j.1365-2141.2008.07309.x","title":"High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia","year":2008,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Fludarabine; Medicine; Cyclophosphamide; Neutropenia; Internal medicine; Minimal residual disease; Chronic lymphocytic leukemia; Gastroenterology; Toxicity; Chemotherapy; Surgery; Oncology; Leukemia","score_opus":0.00704996961039125,"score_gpt":0.22922121467544762,"score_spread":0.22217124506505637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965641972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916227,0.0074616913,0.00003649901,0.00006552433,0.0000635762,0.00065937755,0.000010012627,0.00001717955,0.000063467254],"genre_scores_gemma":[0.99617,0.0017338768,0.0017916828,0.00006314123,0.00003225336,0.000009453796,0.000024166307,0.000055279448,0.00012018875],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9972083,0.0001436483,0.00096174306,0.00035967169,0.0006749033,0.00065171596],"domain_scores_gemma":[0.9979649,0.0001969348,0.00057899783,0.00028989854,0.00064836326,0.00032085844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031960726,0.00027940693,0.0015285382,0.00028546504,0.000084036525,0.000017324297,0.00022161083,0.00018899018,0.00010542459],"category_scores_gemma":[0.00030413995,0.00023062514,0.00008380162,0.00053214864,0.0008698099,0.00021970435,0.00008689621,0.0004867872,0.000006474094],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.038595915,0.0030339016,0.51534605,0.0025792127,0.002389263,0.41061583,0.0014608529,0.0051620444,0.00025701887,0.00027134962,0.0025519289,0.017736608],"study_design_scores_gemma":[0.23699127,0.008262693,0.3149334,0.005600316,0.00043557506,0.4254962,0.0000833367,0.0009859907,0.0066025634,0.000041530962,0.0001075196,0.00045961936],"about_ca_topic_score_codex":0.0024372595,"about_ca_topic_score_gemma":0.00043829324,"teacher_disagreement_score":0.20041266,"about_ca_system_score_codex":0.0068206294,"about_ca_system_score_gemma":0.01127565,"threshold_uncertainty_score":0.996992},"labels":[],"label_agreement":null},{"id":"W1966423882","doi":"10.1016/j.leukres.2008.06.027","title":"Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia","year":2008,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Leukemia and Lymphoma Research; State Key Laboratory of Polymer Physics and Chemistry; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Plasma cell leukemia; Leukemia; Chromosome; Cancer research; Biology; Genetics; Medicine; Immunology; Bone marrow; Gene","score_opus":0.12189593627991017,"score_gpt":0.4022160662119751,"score_spread":0.2803201299320649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966423882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96747464,0.0017400599,0.000021843136,0.00024561322,0.00013391428,0.00088363036,0.000021837504,0.00007924343,0.029399231],"genre_scores_gemma":[0.98082554,0.0044932566,0.0023383107,0.00009161717,0.0006238089,0.00007977214,0.00002852738,0.00007796156,0.011441188],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9941303,0.0006040899,0.0010424302,0.00080078613,0.0021927853,0.0012296166],"domain_scores_gemma":[0.9950913,0.0022366676,0.000110141445,0.0010543067,0.00081039063,0.0006971904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022150395,0.00031603043,0.0008068977,0.0006838505,0.00065248343,0.000055643937,0.00049240544,0.0005006716,0.00025806465],"category_scores_gemma":[0.0014430134,0.00028084934,0.00022761477,0.0010122441,0.0025373248,0.00020966426,0.00078892364,0.0019294135,0.00013644001],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012685623,0.0035689701,0.2411209,0.01581121,0.0031305633,0.022078143,0.039138757,0.0017336997,0.21321154,0.008035101,0.37906635,0.060419165],"study_design_scores_gemma":[0.10577777,0.007707032,0.50458443,0.0018172022,0.00045097506,0.018106628,0.006612036,0.0841457,0.22746399,0.0013144963,0.039856855,0.002162872],"about_ca_topic_score_codex":0.0038062453,"about_ca_topic_score_gemma":0.00023360897,"teacher_disagreement_score":0.33920947,"about_ca_system_score_codex":0.018165411,"about_ca_system_score_gemma":0.032322578,"threshold_uncertainty_score":0.99996436},"labels":[],"label_agreement":null},{"id":"W1966766732","doi":"10.1038/icb.2012.31","title":"Phosphatidylinositol‐3 kinase activity in B cells is negatively regulated by <i>Lyn</i> tyrosine kinase","year":2012,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Medical Research Council; Dunhill Medical Trust; Medical Research Council; National Health and Medical Research Council; State Government of Victoria; Menzies Foundation; Australian Government","keywords":"LYN; FYN; Phosphatidylinositol; Tyrosine kinase; Tyrosine-protein kinase CSK; Kinase; PI3K/AKT/mTOR pathway; Cell biology; Src family kinase; breakpoint cluster region; Proto-oncogene tyrosine-protein kinase Src; Chemistry; Cancer research; Signal transduction; Biology; Molecular biology; Receptor; Biochemistry; SH2 domain","score_opus":0.011622032027284528,"score_gpt":0.2690422204912053,"score_spread":0.2574201884639208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966766732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787692,0.017492598,0.000025121855,0.0008616303,0.0003183998,0.00041637744,0.000038311653,0.00004647237,0.0020318904],"genre_scores_gemma":[0.9945958,0.0020345354,0.00011191977,0.00078924885,0.00007230212,0.000037459136,0.00006277193,0.000025222675,0.0022707297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997968,0.00028860697,0.0003064032,0.00044997662,0.00009155022,0.0008954168],"domain_scores_gemma":[0.9989369,0.00029152798,0.00011459158,0.00041518567,0.000060920098,0.00018090784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003544935,0.00027270502,0.000539845,0.00014947195,0.00009999379,0.000007987611,0.00014798029,0.00063315727,0.000315634],"category_scores_gemma":[0.00005759908,0.00023415267,0.00006666796,0.00027722877,0.0007641059,0.00012020588,0.000186589,0.00056676526,0.00014597285],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013000438,0.0006185298,0.0069299466,0.00006438481,0.00007971056,0.000047754027,0.00043767865,3.0693283e-7,0.98003787,0.00012098352,0.0031043808,0.0072583896],"study_design_scores_gemma":[0.011910515,0.0005614497,0.008798835,0.00003312779,0.000041876196,0.000079511075,0.00008391331,0.00020544358,0.953269,0.00007180207,0.024722503,0.00022203557],"about_ca_topic_score_codex":0.001303911,"about_ca_topic_score_gemma":0.00001365515,"teacher_disagreement_score":0.026768902,"about_ca_system_score_codex":0.0011644496,"about_ca_system_score_gemma":0.0005877874,"threshold_uncertainty_score":0.95484686},"labels":[],"label_agreement":null},{"id":"W1966842773","doi":"10.1016/j.jaad.2003.10.159","title":"Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839","year":2004,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Systems, Applications & Products in Data Processing (Canada)","funders":"","keywords":"Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Dermatology; Epidermal growth factor receptor; Cancer research; Receptor; Internal medicine; Cancer","score_opus":0.02426059917868966,"score_gpt":0.33379022692651306,"score_spread":0.3095296277478234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966842773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95138687,0.00058024935,0.00018365726,0.04725162,0.00017798344,0.00027122232,0.000049108243,0.00002238897,0.00007688282],"genre_scores_gemma":[0.99499434,0.0005264174,0.0011636012,0.002840205,0.0003287681,0.000004399765,0.0000059564863,0.000045778244,0.00009051181],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969252,0.00027068023,0.0011426574,0.0002452735,0.0008058709,0.00061036396],"domain_scores_gemma":[0.99728245,0.00025265414,0.0014353243,0.00030122104,0.00023390983,0.0004944226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025889205,0.00026925336,0.0011172607,0.00033348805,0.00012324705,0.000015244679,0.0006846613,0.00020638027,0.00009436199],"category_scores_gemma":[0.00060088316,0.00018154291,0.0003675618,0.00066341966,0.0014155207,0.0003216354,0.00016830611,0.0012259011,0.00003440247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028199654,0.0019954215,0.023678923,0.0004695757,0.0011070805,0.00055939204,0.0017254838,0.00014992346,0.8997148,0.0012564902,0.061368965,0.0051539554],"study_design_scores_gemma":[0.032274388,0.0018228372,0.0330288,0.0005488297,0.00046362862,0.030924983,0.0009110321,0.00030143512,0.87989306,0.0010423224,0.018237118,0.00055153214],"about_ca_topic_score_codex":0.00022180592,"about_ca_topic_score_gemma":0.000005054147,"teacher_disagreement_score":0.044411413,"about_ca_system_score_codex":0.0032731465,"about_ca_system_score_gemma":0.0027939233,"threshold_uncertainty_score":0.8559164},"labels":[],"label_agreement":null},{"id":"W1966939593","doi":"10.1503/cmaj.1041597","title":"Infliximab and serious hematologic events","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Infliximab; Medicine; Leukopenia; Rheumatoid arthritis; Neutropenia; Food and drug administration; Arthritis; Tumor necrosis factor alpha; Antirheumatic Agents; Disease; Immunology; Internal medicine; Pharmacology; Chemotherapy","score_opus":0.008195774422538877,"score_gpt":0.27087754448798623,"score_spread":0.26268177006544735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966939593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94167787,0.0004589079,0.000036461963,0.054582197,0.0002644602,0.00015396303,0.0000040820023,0.000020441797,0.0028016148],"genre_scores_gemma":[0.9895893,0.0002862468,0.00018910017,0.00882788,0.00056063174,0.0000048864804,0.000004521348,0.000014043932,0.00052342593],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976214,0.00005800677,0.0002997642,0.00013964158,0.0013562955,0.0005248456],"domain_scores_gemma":[0.9971477,0.000080851154,0.00009264441,0.000094748066,0.00023644388,0.002347613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00097401766,0.000096444084,0.00023479141,0.00016481282,0.0001776444,0.00003995109,0.00010855339,0.0003482117,0.0011306294],"category_scores_gemma":[0.0025824567,0.000080944876,0.000060239094,0.00019012776,0.00007227723,0.00008022736,0.000022997756,0.00079512194,0.00020889317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00048571706,0.0008323943,0.45647672,0.0006386452,0.0025608279,0.09177141,0.0061727418,0.00012257902,0.0002807241,0.013415102,0.2051257,0.22211742],"study_design_scores_gemma":[0.1400767,0.0011178234,0.15262651,0.0014526537,0.00025884138,0.1770845,0.0021770364,0.0022146108,0.00045033268,0.011941497,0.50959134,0.0010081909],"about_ca_topic_score_codex":0.007061532,"about_ca_topic_score_gemma":0.014526711,"teacher_disagreement_score":0.30446562,"about_ca_system_score_codex":0.025337148,"about_ca_system_score_gemma":0.03502478,"threshold_uncertainty_score":0.99978244},"labels":[],"label_agreement":null},{"id":"W1967214137","doi":"10.1172/jci40259","title":"Engaging the lysosomal compartment to combat B cell malignancies","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Investigation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Response Biomedical (Canada)","funders":"Medical Research Council; Novo Nordisk; H. Lundbeck A/S; Lundbeckfonden; Sundhed og Sygdom, Det Frie Forskningsråd; Danmarks Grundforskningsfond; National Research Foundation; European Commission; Novo Nordisk Fonden; Kræftens Bekæmpelse","keywords":"CD20; Rituximab; B cell; Programmed cell death; Lymphoma; Medicine; Immunology; Lysosome; Monoclonal antibody; Cancer research; Apoptosis; Antibody; Biology","score_opus":0.1314796178940679,"score_gpt":0.406458272408917,"score_spread":0.27497865451484915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967214137","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22985342,0.0005266057,0.0001198622,0.76671576,0.0010871303,0.0006105783,0.000004949101,0.000019331017,0.0010623643],"genre_scores_gemma":[0.0912405,0.0001972865,0.0029515256,0.8863456,0.016189087,0.0000089398,0.00006671847,0.00005290769,0.0029474034],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99389833,0.00088206335,0.0025759235,0.00030952727,0.0018712949,0.00046285335],"domain_scores_gemma":[0.9940676,0.0026427752,0.0014652715,0.0005900624,0.00075805676,0.00047624143],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0041451305,0.0003012155,0.001224112,0.00023525931,0.00012836739,0.0001015624,0.00053115713,0.0006481863,0.000068116824],"category_scores_gemma":[0.0026121621,0.00018242342,0.00063564454,0.00029763387,0.00039740757,0.00011444159,0.00010368753,0.0048234267,0.00012129938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015525687,0.00007868072,0.00055010227,0.00017574697,0.00012550341,0.0010507549,0.00021098452,0.00008309435,0.00022194254,0.00001856285,0.9955717,0.0017576922],"study_design_scores_gemma":[0.010359375,0.0023997538,0.0068958555,0.0018338278,0.00068019546,0.0010537241,0.000100141595,0.001308733,0.002482675,0.0013329529,0.97124285,0.00030990018],"about_ca_topic_score_codex":0.000031954274,"about_ca_topic_score_gemma":0.0000028377121,"teacher_disagreement_score":0.13861291,"about_ca_system_score_codex":0.0029134196,"about_ca_system_score_gemma":0.008872088,"threshold_uncertainty_score":0.99747247},"labels":[],"label_agreement":null},{"id":"W1968022162","doi":"10.1046/j.1365-2141.2001.02975.x","title":"Persistent polyclonal B‐cell lymphocytosis: further evidence for a genetic disorder associated with B‐cell abnormalities","year":2001,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Lymphocytosis; Haplotype; Immunology; Biology; Genetics; Human leukocyte antigen; Population; Allele; First-degree relatives; Polyclonal antibodies; Gene; Medicine; Antigen; Internal medicine; Family history","score_opus":0.03328294935528762,"score_gpt":0.29187458145625084,"score_spread":0.2585916321009632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968022162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548383,0.042205617,0.0009889072,0.0008362325,0.00014586182,0.00048222535,0.000012665804,0.000022604705,0.0004675984],"genre_scores_gemma":[0.9915959,0.0034181438,0.0018549742,0.00048433564,0.00017265018,0.000041137566,0.0000072431058,0.000060986167,0.0023645922],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99729747,0.0001915439,0.00077355216,0.00029277962,0.00070657866,0.0007380818],"domain_scores_gemma":[0.99748796,0.00072826346,0.00047616215,0.0002262774,0.00076077663,0.00032058716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000580822,0.00022502754,0.0008723681,0.00019988905,0.00014209293,0.000069235306,0.0003074404,0.00020832116,0.0003193989],"category_scores_gemma":[0.00060779124,0.0002067257,0.00041064227,0.00024864337,0.00033834318,0.00018109269,0.00006132554,0.00032208455,0.000015825877],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03700213,0.009468444,0.18071842,0.0066068647,0.0066853147,0.656592,0.0088620465,0.0026571832,0.0036458818,0.00017255894,0.05477229,0.03281687],"study_design_scores_gemma":[0.05071192,0.0040474455,0.0076664146,0.0037386091,0.0010198605,0.92251825,0.0027572555,0.0029951893,0.0010379107,0.00011407773,0.0029365616,0.0004565081],"about_ca_topic_score_codex":0.0005449876,"about_ca_topic_score_gemma":0.00032747394,"teacher_disagreement_score":0.26592624,"about_ca_system_score_codex":0.002981952,"about_ca_system_score_gemma":0.0055434443,"threshold_uncertainty_score":0.98338324},"labels":[],"label_agreement":null},{"id":"W1968363559","doi":"10.1016/j.leukres.2013.08.001","title":"Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway","year":2013,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Stromal cell; PI3K/AKT/mTOR pathway; Cytokine; Cancer research; Chronic lymphocytic leukemia; Signal transduction; Cell biology; CD40; Focal adhesion; Biology; Immunology; Chemistry; Leukemia; Cytotoxic T cell; In vitro","score_opus":0.016017212918031244,"score_gpt":0.2880966235796338,"score_spread":0.2720794106616025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968363559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99326,0.0016090673,0.000026070671,0.00052337383,0.00020267874,0.0030432593,0.00015169177,0.000057183348,0.001126665],"genre_scores_gemma":[0.98799014,0.0008092965,0.0001449422,0.000254635,0.00025723217,0.00028244357,0.000028314022,0.00013355345,0.010099445],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9909324,0.0005833082,0.0012405139,0.001190128,0.004248947,0.001804674],"domain_scores_gemma":[0.9944237,0.0011502022,0.00029244795,0.0019200547,0.0011420132,0.0010715907],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018221434,0.00056583295,0.0010638546,0.0005362872,0.0003042798,0.00009365281,0.0012501159,0.0006462119,0.0011611835],"category_scores_gemma":[0.00072986423,0.00041769072,0.0002949441,0.0018164626,0.0013352588,0.00023290451,0.001466682,0.0012030298,0.00035024327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00043757545,0.00009441593,0.000076102864,0.0010960456,0.000087417604,0.000024717318,0.00070788315,0.000065907996,0.8878942,0.000016697917,0.1041882,0.005310818],"study_design_scores_gemma":[0.013380681,0.0015104072,0.00016332642,0.0010740986,0.00003962785,0.000033423992,0.00047095199,0.009363749,0.9694026,0.000052711846,0.0041546104,0.00035379294],"about_ca_topic_score_codex":0.017828437,"about_ca_topic_score_gemma":0.00012302521,"teacher_disagreement_score":0.10003358,"about_ca_system_score_codex":0.07476454,"about_ca_system_score_gemma":0.052958805,"threshold_uncertainty_score":0.9998275},"labels":[],"label_agreement":null},{"id":"W1969320029","doi":"10.1007/s00280-010-1530-7","title":"A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Jewish General Hospital","funders":"Novartis Pharmaceuticals Canada","keywords":"Chlorambucil; Imatinib; Medicine; Fludarabine; Imatinib mesylate; Chronic lymphocytic leukemia; Tyrosine-kinase inhibitor; Pharmacology; Internal medicine; Chemotherapy; Leukemia; Gastroenterology; Oncology; Cancer; Cyclophosphamide","score_opus":0.015285900770481496,"score_gpt":0.3521121000178381,"score_spread":0.33682619924735663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969320029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702454,0.00043075625,0.000001873615,0.000077610384,0.0001126393,0.0021907298,0.0000053622034,0.000022787159,0.00013369272],"genre_scores_gemma":[0.9984285,0.0007186971,0.000019550407,0.00023259193,0.000060873994,0.00038112505,0.000016460177,0.00003333136,0.000108827844],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985341,0.00008649789,0.0003987347,0.00036987296,0.00022993951,0.00038084565],"domain_scores_gemma":[0.99932414,0.00009722581,0.00014446616,0.00018877884,0.00012671357,0.00011864615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002619245,0.00020200765,0.00051322137,0.00025270382,0.000029690265,0.0000074835393,0.00011178557,0.00013115356,0.00044902504],"category_scores_gemma":[0.000014679577,0.0001639806,0.000025785639,0.00048809164,0.00018664583,0.00008653557,0.000027216623,0.00035716285,0.000001763241],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.056289755,0.017584672,0.27969337,0.0027045528,0.0011296333,0.00059852836,0.030108836,0.0009466295,0.3539368,0.00003176192,0.0006601376,0.25631532],"study_design_scores_gemma":[0.7494672,0.013309968,0.025307318,0.00023975887,0.00017232381,0.00004325757,0.00020544644,0.06675045,0.14351393,0.00002588942,0.00063301966,0.0003314131],"about_ca_topic_score_codex":0.003286286,"about_ca_topic_score_gemma":0.0015645202,"teacher_disagreement_score":0.69317746,"about_ca_system_score_codex":0.015654573,"about_ca_system_score_gemma":0.0072019496,"threshold_uncertainty_score":0.9984263},"labels":[],"label_agreement":null},{"id":"W1969528062","doi":"10.1002/cncr.25655","title":"Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia","year":2010,"lang":"en","type":"article","venue":"Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; University of Toronto","funders":"National Institute of Nursing Research; National Cancer Institute","keywords":"Medicine; Interquartile range; Chronic lymphocytic leukemia; Logistic regression; Internal medicine; Proportional hazards model; Leukemia; Pediatrics; Emergency medicine","score_opus":0.025604512624820594,"score_gpt":0.3596020062666122,"score_spread":0.3339974936417916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969528062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208266,0.00581739,0.00013858966,0.00009954123,0.00033967782,0.0009945276,0.00009977028,0.00003750616,0.00039031327],"genre_scores_gemma":[0.99731326,0.0005524854,0.00044985444,0.00011392177,0.0005112903,0.0003903586,0.00006065832,0.000042964275,0.0005652094],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998407,0.000026785823,0.00032167035,0.00038214537,0.0004887348,0.00037365494],"domain_scores_gemma":[0.9976267,0.0009356503,0.00012095995,0.00049197307,0.0005679323,0.0002567517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002569492,0.00017452195,0.00046539222,0.000074247124,0.00007001514,0.0000106091165,0.00014489006,0.00016213079,0.0002228202],"category_scores_gemma":[0.0014702177,0.0001282083,0.00006324944,0.00019153056,0.00041720778,0.000055331002,0.00006840677,0.00021386352,0.0000055255855],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012837071,0.0002418345,0.19879368,0.05193911,0.001986964,0.00029554032,0.013251231,0.0015762066,0.09439254,0.0019772376,0.012255648,0.61045295],"study_design_scores_gemma":[0.37854886,0.0054920665,0.2043688,0.011247625,0.002373827,0.00058942585,0.003076298,0.058935426,0.21031292,0.00027235222,0.12211554,0.002666866],"about_ca_topic_score_codex":0.0033991288,"about_ca_topic_score_gemma":0.0035530457,"teacher_disagreement_score":0.60778606,"about_ca_system_score_codex":0.027076932,"about_ca_system_score_gemma":0.037468337,"threshold_uncertainty_score":0.9766579},"labels":[],"label_agreement":null},{"id":"W1969714279","doi":"10.3324/haematol.2009.017814","title":"Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Celgene","keywords":"Medicine; Hematopoietic stem cell transplantation; Macroglobulinemia; Transplantation; Stem cell; Haematopoiesis; Hematopoietic cell; Retrospective cohort study; Oncology; Immunology; Internal medicine; Multiple myeloma; Biology; Genetics","score_opus":0.013381095656380645,"score_gpt":0.2815847595531309,"score_spread":0.26820366389675027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969714279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774504,0.0003874031,0.00043350484,0.00042377168,0.00002861694,0.0006698029,0.00014369449,0.000029247954,0.0001389487],"genre_scores_gemma":[0.99750775,0.00067723286,0.0016132973,0.00006410819,0.000011263185,0.000029524506,0.00004074433,0.000018760575,0.00003730052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973833,0.000557817,0.000683033,0.00048521423,0.00044641254,0.00044420757],"domain_scores_gemma":[0.99796957,0.0006191891,0.00040832633,0.000695603,0.00014357224,0.00016375475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015788544,0.00022877066,0.00086812663,0.00012995122,0.00009692356,0.000012264082,0.00027931904,0.00034220912,0.000057339246],"category_scores_gemma":[0.00019174362,0.00015272341,0.00029136604,0.0006205842,0.00046716863,0.000039773087,0.00008632428,0.0006287666,9.96929e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013225478,0.00031808382,0.7590835,0.0009952992,0.00031764893,0.00026113665,0.0062964344,0.00025588772,0.23067021,0.00008537028,0.000032767926,0.00036108727],"study_design_scores_gemma":[0.00889836,0.00021436354,0.8300619,0.00021781719,0.0008794115,0.0003631698,0.00019670143,0.011118526,0.14751545,0.00038171254,0.0000035709468,0.00014899508],"about_ca_topic_score_codex":0.0015919459,"about_ca_topic_score_gemma":0.0011659589,"teacher_disagreement_score":0.083154775,"about_ca_system_score_codex":0.001274018,"about_ca_system_score_gemma":0.0012789236,"threshold_uncertainty_score":0.622788},"labels":[],"label_agreement":null},{"id":"W1970006069","doi":"10.1038/ng.626","title":"Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32","year":2010,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Follicular lymphoma; Biology; Chronic lymphocytic leukemia; Lymphoma; Genome-wide association study; Genetic association; Locus (genetics); Genetics; Leukemia; Single-nucleotide polymorphism; Immunology; Gene; Genotype","score_opus":0.007304496344641298,"score_gpt":0.2810534068355785,"score_spread":0.2737489104909372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970006069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948895,0.0025539866,0.000010867814,0.00012931431,0.00066067226,0.00096071354,0.000024198505,0.0000484865,0.0007222456],"genre_scores_gemma":[0.9959712,0.0003724738,0.0003471795,0.00013283116,0.00039856127,0.000027287479,0.000033360262,0.000050478226,0.002666611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970985,0.00011061738,0.00044493913,0.00043612614,0.0014556269,0.0004541911],"domain_scores_gemma":[0.9975718,0.0004036729,0.0003155702,0.00092530035,0.0005917875,0.0001918148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007511203,0.00021864468,0.00043429653,0.00018554214,0.00013066195,0.000033098782,0.00029935877,0.0007426127,0.00014536377],"category_scores_gemma":[0.002135664,0.00019202918,0.00015403448,0.00043386666,0.00007139455,0.00003567504,0.0002750194,0.0008035918,0.0000899107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003955853,0.0013375382,0.9428541,0.00020241288,0.0009624746,0.00025727216,0.0025168404,0.000105433435,0.043647274,0.000005076345,0.0046602376,0.0030557662],"study_design_scores_gemma":[0.025344701,0.0007336813,0.8957889,0.000031478998,0.000703763,0.000054462376,0.0005058994,0.000723744,0.055849813,0.00019670388,0.019752204,0.0003146628],"about_ca_topic_score_codex":0.00024356869,"about_ca_topic_score_gemma":0.0012730774,"teacher_disagreement_score":0.047065202,"about_ca_system_score_codex":0.005823082,"about_ca_system_score_gemma":0.0015130455,"threshold_uncertainty_score":0.9979934},"labels":[],"label_agreement":null},{"id":"W1970075810","doi":"10.4021/jmc.v4i7.1176","title":"Neutropenia in a Patient With Rheumatoid Arthritis Associated With αβ/γδ T-Cell Large Granular Lymphocyte Lymphoproliferative Disorder Manifesting as Felty’s Syndrome: From Diagnosis to Therapy","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Neutropenia; Rheumatoid arthritis; Immunology; Felty's syndrome; Concomitant; Methotrexate; Internal medicine; Gastroenterology; Chemotherapy","score_opus":0.012619505296353301,"score_gpt":0.2665914855937804,"score_spread":0.25397198029742707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970075810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960674,0.006168166,0.00007176964,0.002690679,0.0001209686,0.0011022651,0.000025602772,0.00003008194,0.00018371898],"genre_scores_gemma":[0.99138933,0.005892748,0.00033070263,0.0019075703,0.00010334708,0.0002144076,0.000024773757,0.00008194431,0.000055198154],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9938572,0.00037406877,0.0010490905,0.00043802176,0.003445785,0.00083580735],"domain_scores_gemma":[0.99578464,0.0015239065,0.0004870306,0.0003466084,0.0006321185,0.0012256893],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008646697,0.00040762156,0.0011272456,0.00035040022,0.00014049595,0.00012652228,0.00036948372,0.00026062704,0.002248832],"category_scores_gemma":[0.0025338312,0.00025386648,0.00014807653,0.00071659667,0.00018265021,0.00031342203,0.00013837332,0.0007056976,0.00008861188],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009413884,0.008290576,0.22669373,0.00016984486,0.0012502817,0.6719302,0.0075676176,0.00028992267,0.0003482597,0.00003575714,0.0055002715,0.06850963],"study_design_scores_gemma":[0.3918444,0.046558656,0.07669313,0.032608617,0.00026130473,0.4165445,0.010580236,0.0068334765,0.008114361,0.00018604257,0.007748623,0.0020266627],"about_ca_topic_score_codex":0.009114616,"about_ca_topic_score_gemma":0.0015814734,"teacher_disagreement_score":0.3824305,"about_ca_system_score_codex":0.0050954088,"about_ca_system_score_gemma":0.008887618,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W1971818445","doi":"10.1182/blood-2013-02-485425","title":"Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Cancer Research UK","keywords":"Biology; Identification (biology); Function (biology); Receptor; Genetics; Immunology; Cancer research; Cell biology","score_opus":0.011037443969455099,"score_gpt":0.2382314724415858,"score_spread":0.2271940284721307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971818445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99859715,0.0002064902,0.00025676115,0.000043665797,0.00002443917,0.0003925182,7.904182e-7,0.00001734227,0.00046085985],"genre_scores_gemma":[0.9987481,0.000022591223,0.0009851849,0.000015907452,0.00005977398,0.000042056694,0.000016053336,0.000014477063,0.00009584777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908745,0.000035383968,0.00023898897,0.00020394207,0.00027689777,0.00015735043],"domain_scores_gemma":[0.9994924,0.00008048411,0.00008978533,0.00017734304,0.00009354075,0.00006641218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020804517,0.00007426964,0.0001403937,0.00010591078,0.000029717114,0.000016979047,0.000037767044,0.00006646392,0.000105980245],"category_scores_gemma":[0.000065933236,0.00005939863,0.00001631502,0.00017110896,0.000048766284,0.00015176294,0.000032249583,0.00012838675,0.000017348277],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010496724,0.00035435622,0.026168264,0.00029703768,0.00001334209,0.000006963338,0.0002997229,0.000011677259,0.97090024,0.00001237733,0.000033457316,0.001797626],"study_design_scores_gemma":[0.035566736,0.0003351087,0.10305765,0.00064632954,0.00008436837,0.00013668105,0.000324794,0.007632615,0.8519441,0.0000980164,0.000021559305,0.00015202515],"about_ca_topic_score_codex":0.0003824534,"about_ca_topic_score_gemma":0.0000073217884,"teacher_disagreement_score":0.11895609,"about_ca_system_score_codex":0.00037724955,"about_ca_system_score_gemma":0.0003729267,"threshold_uncertainty_score":0.24222058},"labels":[],"label_agreement":null},{"id":"W1972241790","doi":"10.1016/j.leukres.2015.01.015","title":"Incidence of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis in Calgary, Alberta, Canada","year":2015,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Health Research Board; University of Calgary; World Health Organization","keywords":"Lymphocytosis; Incidence (geometry); Chronic lymphocytic leukemia; Medicine; Population; Leukemia; Demography; Immunology; Internal medicine; Environmental health","score_opus":0.04314567899309261,"score_gpt":0.32430468315694544,"score_spread":0.2811590041638528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972241790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761744,0.0041246307,0.00001670565,0.00024349823,0.00014193579,0.0011137621,0.000012012705,0.000031514315,0.018141536],"genre_scores_gemma":[0.9894213,0.0007467749,0.00038272186,0.00017746427,0.00022113802,0.00016538866,0.00003569788,0.0000934397,0.008756065],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9919571,0.000508302,0.0010044777,0.001065272,0.0035757069,0.0018891161],"domain_scores_gemma":[0.9944949,0.0018227845,0.00014951716,0.0012419169,0.000908022,0.0013828557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028173113,0.0004427252,0.0009870145,0.0008428731,0.00014363414,0.00006122386,0.00076097436,0.00041120622,0.00017775202],"category_scores_gemma":[0.0019430004,0.00041712864,0.00010705069,0.001981415,0.0009549423,0.00024352326,0.0009235552,0.0011687586,0.00009759385],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03783111,0.0019666962,0.1890893,0.029846657,0.0017451848,0.04471851,0.021273889,0.050293338,0.10117566,0.00849646,0.4066656,0.106897585],"study_design_scores_gemma":[0.09522716,0.002305085,0.008301003,0.0015506702,0.000097497876,0.002293826,0.0017208997,0.7822375,0.0868364,0.000558187,0.017775083,0.001096653],"about_ca_topic_score_codex":0.9824125,"about_ca_topic_score_gemma":0.82433605,"teacher_disagreement_score":0.7319442,"about_ca_system_score_codex":0.54181457,"about_ca_system_score_gemma":0.52757335,"threshold_uncertainty_score":0.99982804},"labels":[],"label_agreement":null},{"id":"W1972578692","doi":"10.1016/j.leukres.2009.04.009","title":"Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia","year":2009,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; CDKN2A; CpG site; Cancer research; DNA methylation; Biology; Biomarker; Oncology; Medicine; Internal medicine; Genetics; Cancer; Gene; Gene expression","score_opus":0.03828348548014472,"score_gpt":0.3431067613303727,"score_spread":0.304823275850228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972578692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99132913,0.0005329022,0.0000875199,0.0003692181,0.00007573849,0.0012577105,0.000036499707,0.000006136853,0.0063051395],"genre_scores_gemma":[0.9988473,0.00020607117,0.00016818597,0.00001889712,0.000044882247,0.000039199927,0.000008167286,0.000018569299,0.00064869976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99437755,0.000874699,0.00086850015,0.00041662896,0.0027191604,0.00074346014],"domain_scores_gemma":[0.99680483,0.0015212832,0.00022371381,0.00073306554,0.0006005023,0.00011658185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028744496,0.00017595428,0.000476078,0.00063689135,0.00008463587,0.000013000257,0.0005412673,0.00021448782,0.00014447741],"category_scores_gemma":[0.0014720162,0.000117211275,0.0001659388,0.0022561343,0.00049220776,0.00014400792,0.00014695071,0.0012234015,0.0000052460005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019068795,0.00039226282,0.028755466,0.0005434392,0.000042044092,0.000028542843,0.011028821,0.014010144,0.93785584,0.0019182696,0.000113966365,0.0034043326],"study_design_scores_gemma":[0.012245067,0.00034340867,0.33729485,0.0006139015,0.00001736619,0.000018434042,0.0021659178,0.03054962,0.61348486,0.0030761904,0.00007702942,0.00011333005],"about_ca_topic_score_codex":0.0101320585,"about_ca_topic_score_gemma":0.0040466157,"teacher_disagreement_score":0.32437095,"about_ca_system_score_codex":0.01799335,"about_ca_system_score_gemma":0.016813258,"threshold_uncertainty_score":0.99645954},"labels":[],"label_agreement":null},{"id":"W1974623973","doi":"10.1038/cddis.2014.391","title":"Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling","year":2014,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; University of Manitoba","funders":"CancerCare Manitoba Foundation; CLL Global Research Foundation","keywords":"Gefitinib; Syk; Chronic lymphocytic leukemia; Cancer research; Tyrosine kinase; Protein kinase B; Bruton's tyrosine kinase; Viability assay; breakpoint cluster region; Apoptosis; Signal transduction; Leukemia; Biology; Medicine; Immunology; Epidermal growth factor receptor; Receptor; Internal medicine; Cell biology","score_opus":0.0122857229256854,"score_gpt":0.24644626377914572,"score_spread":0.23416054085346033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974623973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97841215,0.014349191,0.00035754868,0.00007143537,0.00016124295,0.0005722976,0.000028818215,0.00013185198,0.0059154616],"genre_scores_gemma":[0.99329007,0.0012909882,0.0004940195,0.0007772483,0.00061501074,0.000039633487,0.00008107674,0.00008197962,0.003329998],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970597,0.00012505408,0.0004252676,0.0008263622,0.00069746276,0.0008661404],"domain_scores_gemma":[0.996248,0.00033269916,0.00011972718,0.0005466028,0.00011476139,0.0026381891],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004442953,0.0004006917,0.00048204244,0.00016343824,0.0002869836,0.00014887561,0.00016397728,0.00020604962,0.00043611243],"category_scores_gemma":[0.00033989694,0.00035852133,0.00012567842,0.00016409121,0.00023035833,0.00017022583,0.0002495061,0.00029110166,0.0001979542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004128141,0.0006445362,0.004039036,0.018229883,0.00015724442,0.0018592669,0.0014112474,0.0019196433,0.91564304,0.00047013804,0.019810133,0.031687714],"study_design_scores_gemma":[0.06784095,0.0007842292,0.00043776905,0.0018656744,0.0005593271,0.00013343981,0.00018095542,0.34065086,0.55876786,0.0005024489,0.0269305,0.0013459735],"about_ca_topic_score_codex":0.00021551627,"about_ca_topic_score_gemma":0.0000028626846,"teacher_disagreement_score":0.35687515,"about_ca_system_score_codex":0.010240625,"about_ca_system_score_gemma":0.019281222,"threshold_uncertainty_score":0.9998867},"labels":[],"label_agreement":null},{"id":"W1974843539","doi":"10.1189/jlb.0802396","title":"The improved survival of hematopoietic cells cultured with a fusion protein of insulin-like growth factor II (IGF-II) and interleukin 3 (IL-3) is associated with increases in Bcl-xL and phosphatidylinositol-3 kinase activity","year":2003,"lang":"en","type":"article","venue":"Journal of Leukocyte Biology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Biology; Propidium iodide; Haematopoiesis; Interleukin 3; Chimera (genetics); Cell biology; Protein kinase B; Molecular biology; Apoptosis; Phosphorylation; Immunology; Stem cell; T cell; Biochemistry; Programmed cell death; Immune system; Interleukin 21","score_opus":0.012303715955337951,"score_gpt":0.25906257143217576,"score_spread":0.24675885547683782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974843539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973036,0.0016836749,0.000039640894,0.00020289765,0.00005237431,0.0006529661,0.000023665887,0.000006049721,0.00003513661],"genre_scores_gemma":[0.9987087,0.00075192854,0.00032341635,0.000036545804,0.000028472774,0.000010100212,0.000002775514,0.000022360964,0.000115689014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99780875,0.000468917,0.0007118267,0.00026963415,0.00036804835,0.00037280543],"domain_scores_gemma":[0.99747217,0.00056431844,0.00097436743,0.00023051634,0.0005632547,0.00019539466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009659762,0.00026402477,0.0009400389,0.00018182331,0.00012231631,0.000014555418,0.0001656857,0.00023723267,0.000016202122],"category_scores_gemma":[0.00087159383,0.00013966643,0.00008218612,0.00036208227,0.00062501576,0.00011182591,0.00013977848,0.00049077027,1.6274471e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016869597,0.0013897178,0.027918499,0.00045989276,0.0007137905,0.00025208798,0.0025854046,0.0000013216412,0.9477457,0.00012645262,0.00007129713,0.0018662636],"study_design_scores_gemma":[0.04432989,0.01362711,0.021930164,0.0013416047,0.00019376972,0.00096682296,0.00084634277,0.0004963305,0.9155444,0.00012857796,0.0003098288,0.00028518884],"about_ca_topic_score_codex":0.0010404632,"about_ca_topic_score_gemma":0.00049616647,"teacher_disagreement_score":0.032201305,"about_ca_system_score_codex":0.0014522301,"about_ca_system_score_gemma":0.002846268,"threshold_uncertainty_score":0.5695432},"labels":[],"label_agreement":null},{"id":"W197484533","doi":"10.3747/co.2007.118","title":"Alemtuzumab in Chronic Lymphocytic Leukemia","year":2007,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; Cancer Care Ontario","funders":"","keywords":"Alemtuzumab; Medicine; CINAHL; Randomized controlled trial; MEDLINE; Chronic lymphocytic leukemia; Guideline; Cochrane Library; Critical appraisal; Intensive care medicine; Systematic review; Adverse effect; Internal medicine; Quality of life (healthcare); Meta-analysis; Family medicine; Oncology; Alternative medicine; Leukemia; Pathology; Transplantation; Psychological intervention; Nursing","score_opus":0.10406538885240449,"score_gpt":0.4531963673234235,"score_spread":0.34913097847101904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W197484533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96559376,0.0073944735,0.000467749,0.0001451377,0.0012036518,0.0007703015,0.0000027130022,0.00012618134,0.024296008],"genre_scores_gemma":[0.9970307,0.00075415114,0.00020456736,0.00016258552,0.00089338206,0.00004872458,0.00003767576,0.00004060877,0.0008276391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717724,0.00008515025,0.000626447,0.0005160737,0.0004767577,0.0011183535],"domain_scores_gemma":[0.9984283,0.00044327343,0.000100577294,0.00053349853,0.000121073426,0.00037329257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011710266,0.00023385082,0.0005691112,0.0004914358,0.00005247812,0.000010583327,0.00025034221,0.00029033545,0.0005031775],"category_scores_gemma":[0.00034183092,0.00021481153,0.00012851467,0.0006497302,0.00029295395,0.00007393096,0.00017758115,0.0006409042,0.00076934614],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028944132,0.0005327764,0.008192215,0.001489426,0.0001402021,0.0062910425,0.0014687646,0.0006371525,0.0077076694,0.0026965549,0.021172024,0.94677776],"study_design_scores_gemma":[0.10032909,0.0031150423,0.015481891,0.0006471843,0.00012301032,0.0030426627,0.00033999342,0.072290674,0.0060928487,0.00050073105,0.79742575,0.0006111437],"about_ca_topic_score_codex":0.0005738355,"about_ca_topic_score_gemma":0.0010001733,"teacher_disagreement_score":0.94616663,"about_ca_system_score_codex":0.56714165,"about_ca_system_score_gemma":0.10447492,"threshold_uncertainty_score":0.9888645},"labels":[],"label_agreement":null},{"id":"W1974934205","doi":"10.1016/j.leukres.2008.06.030","title":"Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia","year":2008,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Genotype; Apoptosis; Internal medicine; Oncology; Immunology; Leukemia; Cancer research; Medicine; Biology; Genetics; Gene","score_opus":0.08583140411174466,"score_gpt":0.3598572648351422,"score_spread":0.2740258607233975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974934205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933485,0.0020727797,0.00012426247,0.00011731059,0.00008812346,0.0032084465,0.000100276804,0.00014778768,0.0007925375],"genre_scores_gemma":[0.9927435,0.0011418153,0.0018355333,0.00008255662,0.00053440063,0.000478181,0.00010996098,0.00013806002,0.002935997],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9938013,0.00052100344,0.0008083567,0.0011007482,0.0021919934,0.0015766183],"domain_scores_gemma":[0.99448174,0.0019108301,0.00016648106,0.0012313448,0.0010998034,0.0011097995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018563236,0.00041834527,0.0007990193,0.000994085,0.0006924939,0.00007628769,0.000526975,0.0005027876,0.00020612116],"category_scores_gemma":[0.0033337502,0.0003748515,0.00019257226,0.0013651978,0.0019701156,0.00043348465,0.00033488843,0.0010292273,0.00012930536],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024019012,0.00059526705,0.124747396,0.021001969,0.0025149777,0.005635977,0.03851573,0.0023875954,0.63563275,0.0062512495,0.015182964,0.12351514],"study_design_scores_gemma":[0.08644461,0.014168548,0.09500061,0.0014471776,0.00031316406,0.005914256,0.00084929535,0.43281037,0.35473853,0.004802695,0.002284116,0.0012266185],"about_ca_topic_score_codex":0.012371544,"about_ca_topic_score_gemma":0.00020542977,"teacher_disagreement_score":0.43042278,"about_ca_system_score_codex":0.12110029,"about_ca_system_score_gemma":0.15350427,"threshold_uncertainty_score":0.99987036},"labels":[],"label_agreement":null},{"id":"W1975427151","doi":"10.1111/j.1939-1676.2007.0020.x","title":"Effect of Chemotherapy Schedule on Response in Waldenström's Macroglobulinemia in a Dog","year":2008,"lang":"en","type":"article","venue":"Journal of Veterinary Internal Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Reference range; Pallor; Polyuria; Lethargy; Neutrophilia; Complete blood count; Gastroenterology; Macroglobulinemia; Pathology; Internal medicine; Mean corpuscular hemoglobin concentration; Polydipsia; Anisocytosis; Anemia; Hematocrit; Mean corpuscular volume; Endocrinology","score_opus":0.028021231011074843,"score_gpt":0.38123557193773405,"score_spread":0.3532143409266592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975427151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957849,0.000725956,0.00002331637,0.0021578853,0.00032224265,0.00030227512,0.0000014860314,0.000006904223,0.0006750261],"genre_scores_gemma":[0.998026,0.00056647015,0.00024445064,0.00037157288,0.00041109105,0.0000055919572,9.517121e-7,0.000032284133,0.0003416004],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9967188,0.0004865989,0.001217773,0.00021335568,0.0009976543,0.0003657666],"domain_scores_gemma":[0.99764997,0.0012007228,0.00041603617,0.0003268502,0.00016530124,0.00024112832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027288531,0.00024912576,0.0010981534,0.0010502795,0.00001640108,0.0000029784937,0.00032473012,0.00014225705,0.00031140874],"category_scores_gemma":[0.0017572348,0.0001648307,0.00018144737,0.00045809383,0.0003637127,0.000090662434,0.00006298437,0.00092426536,0.000012503591],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4448821,0.0009774431,0.029428866,0.00084220717,0.00023085986,0.12942517,0.0027307917,0.00012029231,0.37473574,0.0000070035085,0.0016740509,0.014945484],"study_design_scores_gemma":[0.21973754,0.296824,0.13584869,0.022265898,0.0000914352,0.1974857,0.0003368971,0.0034340932,0.12047655,0.00003088844,0.0031009754,0.00036734377],"about_ca_topic_score_codex":0.00024971398,"about_ca_topic_score_gemma":0.0000031772602,"teacher_disagreement_score":0.29584655,"about_ca_system_score_codex":0.004476758,"about_ca_system_score_gemma":0.001289209,"threshold_uncertainty_score":0.9993449},"labels":[],"label_agreement":null},{"id":"W1977277090","doi":"10.1111/j.1368-5031.2004.0077.x","title":"Waldenström's macroglobulinaemia presenting as isolated epistaxis: a common complaint but a rare cause","year":2004,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Waldenstrom macroglobulinemia; Macroglobulinemia; Bone marrow; Complaint; Presentation (obstetrics); Dermatology; Multiple myeloma; Pediatrics; Surgery; Internal medicine; Lymphoma","score_opus":0.0764304977146332,"score_gpt":0.4917636069923808,"score_spread":0.4153331092777476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977277090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540005,0.00041497996,0.0013409216,0.03012961,0.0018338535,0.00030715583,0.0000130197195,0.000038452385,0.011921544],"genre_scores_gemma":[0.9860878,0.00059843913,0.0071792146,0.003490969,0.0019586817,0.0000033345832,0.000014564222,0.000037201247,0.0006297856],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99416965,0.0004171138,0.00246353,0.00031785967,0.002252298,0.00037956986],"domain_scores_gemma":[0.9900783,0.004269968,0.0018452022,0.00037371274,0.0028771916,0.0005556687],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020691429,0.00021476333,0.0007327399,0.00021172431,0.000086197426,0.00016415265,0.0007216198,0.00026004337,0.00036033135],"category_scores_gemma":[0.027740022,0.00017877201,0.00049848756,0.000197335,0.00027111176,0.0007455108,0.00031236876,0.0019716455,0.00033265437],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03811142,0.0055579804,0.0070467377,0.00015624618,0.007312088,0.8914552,0.0010991032,0.00072330097,0.00084076007,0.0040876446,0.011292427,0.032317102],"study_design_scores_gemma":[0.06100203,0.003487241,0.007597916,0.00187206,0.0010553759,0.7849913,0.0011710264,0.008401256,0.001569184,0.005121438,0.12322989,0.00050124864],"about_ca_topic_score_codex":0.0011245322,"about_ca_topic_score_gemma":0.00003422404,"teacher_disagreement_score":0.11193747,"about_ca_system_score_codex":0.0045064306,"about_ca_system_score_gemma":0.0072795744,"threshold_uncertainty_score":0.9993151},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"case_report","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"case_report","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W1978481604","doi":"10.1016/j.jchromb.2013.05.012","title":"Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry","year":2013,"lang":"en","type":"article","venue":"Journal of Chromatography B","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"University of Calgary","keywords":"Chemistry; Chromatography; Fludarabine; Electrospray ionization; Selected reaction monitoring; Mass spectrometry; Liquid chromatography–mass spectrometry; Tandem mass spectrometry; Solid phase extraction; Sample preparation; Triple quadrupole mass spectrometer; Quantitative analysis (chemistry); Chemotherapy","score_opus":0.0160392006315157,"score_gpt":0.3254995945203761,"score_spread":0.3094603938888604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978481604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805502,0.0031187849,0.013918275,0.00062191585,0.000118812495,0.0011598642,0.000018203486,0.000033339336,0.00046059795],"genre_scores_gemma":[0.88969946,0.00043244596,0.10932727,0.000167576,0.0001582409,0.00007602758,0.000013072437,0.00007085712,0.00005502348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969303,0.00015602252,0.0011846509,0.00038564217,0.0006548192,0.0006885708],"domain_scores_gemma":[0.9974859,0.0006452388,0.0005878666,0.00031812867,0.00048751853,0.00047538127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001286338,0.00035421705,0.0011038263,0.0018330053,0.000114644405,0.00009598128,0.00027401542,0.0002422015,0.00014368542],"category_scores_gemma":[0.00025679148,0.00028431,0.0005487457,0.0013843012,0.00029715148,0.000406835,0.00005360417,0.00056241994,0.0000028466293],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095842907,0.00041399634,0.004352848,0.0005056919,0.0008195389,0.00010070384,0.00036938526,0.0000025123793,0.98326385,0.00060690194,0.008116304,0.0004898561],"study_design_scores_gemma":[0.1842582,0.044011854,0.03007079,0.0029136979,0.0011532201,0.0070050247,0.004585906,0.03942766,0.6699827,0.009351719,0.005235153,0.0020040786],"about_ca_topic_score_codex":0.00025733627,"about_ca_topic_score_gemma":0.000017870741,"teacher_disagreement_score":0.31328112,"about_ca_system_score_codex":0.0010032416,"about_ca_system_score_gemma":0.000933328,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W1978957651","doi":"10.1038/leu.2011.110","title":"ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro","year":2011,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; South East Regional Health Authority; Kreftforeningen; Leukemia and Lymphoma Society","keywords":"Chronic lymphocytic leukemia; In vitro; Leukemia; Cancer research; Medicine; Immunology; Internal medicine; Biology; Genetics","score_opus":0.035535395726893716,"score_gpt":0.26725897851514024,"score_spread":0.23172358278824653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978957651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97812325,0.0017192086,0.000012221375,0.008368308,0.00015850578,0.0049500307,0.000118590426,0.00032559692,0.0062243147],"genre_scores_gemma":[0.889794,0.00013382595,0.00023255221,0.10287539,0.0012961236,0.00089420425,0.0026858833,0.0005591237,0.0015289226],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98876333,0.00094599236,0.0014901223,0.0022458252,0.0034749152,0.003079796],"domain_scores_gemma":[0.99373645,0.0015944787,0.0007502978,0.003050915,0.0003106766,0.0005571624],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0010377531,0.001885992,0.0029275,0.0014913862,0.00027093577,0.00026304807,0.002365402,0.0018217169,0.00032736344],"category_scores_gemma":[0.00021108729,0.0012721544,0.00036940278,0.0022877941,0.0017304743,0.00025729835,0.00073722453,0.0055896756,0.0006629525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06775801,0.0010182523,0.0038317158,0.009063128,0.0054812976,0.1927038,0.010283898,0.007150202,0.011815159,0.000095589116,0.6888483,0.0019506008],"study_design_scores_gemma":[0.6536856,0.0069696605,0.031045258,0.01835524,0.0035305175,0.021066727,0.00096614263,0.059674785,0.034402885,0.00012639098,0.16229662,0.007880121],"about_ca_topic_score_codex":0.08469043,"about_ca_topic_score_gemma":0.0025935853,"teacher_disagreement_score":0.58592767,"about_ca_system_score_codex":0.40943265,"about_ca_system_score_gemma":0.19309247,"threshold_uncertainty_score":0.9994741},"labels":[],"label_agreement":null},{"id":"W1979497236","doi":"10.1038/leu.2011.329","title":"Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant Chronic Lymphocytic Leukemia","year":2011,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Health Canada; GlaxoSmithKline","keywords":"Ofatumumab; Fludarabine; Chronic lymphocytic leukemia; Medicine; Leukemia; Vidarabine; Internal medicine; Oncology; Cancer research; Immunology; Chemotherapy; Cyclophosphamide","score_opus":0.02322131647054599,"score_gpt":0.2723016917277518,"score_spread":0.24908037525720583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979497236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92193496,0.014650175,0.00004258952,0.040199157,0.0021809393,0.0061440007,0.00023962189,0.000982357,0.013626184],"genre_scores_gemma":[0.6102299,0.004863479,0.0025249969,0.3018336,0.013665176,0.0015133391,0.0027896143,0.0017231819,0.060856704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99051034,0.0003688676,0.0018630581,0.002365489,0.002010774,0.0028814853],"domain_scores_gemma":[0.9944288,0.00048279102,0.0005179214,0.0036071402,0.00029622082,0.0006670941],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0007758776,0.0015914082,0.0027356218,0.0013184736,0.00019203448,0.00018151675,0.0013484464,0.0031692036,0.0011972779],"category_scores_gemma":[0.00066662254,0.0014574983,0.00047704586,0.0011308482,0.0011501563,0.0003017664,0.0011535059,0.0054405495,0.0008691481],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025549629,0.00006147171,0.00016654187,0.006527341,0.00068240974,0.04415811,0.00052414427,0.0001217268,0.0029327776,0.0002895804,0.93448234,0.007498603],"study_design_scores_gemma":[0.16165034,0.0034988967,0.0055266134,0.006563437,0.0017847536,0.006489188,0.00010422952,0.030354362,0.0047122836,0.0025991423,0.7723844,0.0043323613],"about_ca_topic_score_codex":0.040642213,"about_ca_topic_score_gemma":0.0013595775,"teacher_disagreement_score":0.3117365,"about_ca_system_score_codex":0.47001544,"about_ca_system_score_gemma":0.15827893,"threshold_uncertainty_score":0.9999088},"labels":[],"label_agreement":null},{"id":"W1980557548","doi":"10.1038/sj.leu.2404456","title":"Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia","year":2006,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Cytotoxic T cell; Cancer research; Tumor microenvironment; Toll-like receptor; Immunology; Biology; Leukemia; Immune system; Innate immune system; In vitro","score_opus":0.047142453018663454,"score_gpt":0.3546140683536116,"score_spread":0.30747161533494816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980557548","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001484969,0.9866638,0.0000058973133,0.000023229337,0.0005534854,0.004115507,0.00010514153,0.00010251637,0.00694546],"genre_scores_gemma":[0.00042145533,0.985279,0.00012885526,0.00008393788,0.0014073789,0.001028251,0.000997787,0.00022349223,0.010429841],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99329495,0.00055945833,0.002052111,0.0012265898,0.0014609493,0.0014059587],"domain_scores_gemma":[0.9951359,0.001133632,0.00069614954,0.0026403847,0.00012725836,0.00026667217],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006837723,0.0012290744,0.004396527,0.00071747846,0.00012568501,0.00007697371,0.0010867174,0.0011428632,0.00031437606],"category_scores_gemma":[0.00010705141,0.00075972796,0.0015953998,0.0016151695,0.0005272701,0.000087281165,0.00013071334,0.00080507743,0.00079823367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015577827,0.0003154622,0.000004514173,0.033551544,0.00058681343,0.0015803277,0.0004361998,0.0001348637,0.0000060884154,0.00015399308,0.020286085,0.9427883],"study_design_scores_gemma":[0.014268015,0.001402912,0.000006072639,0.012071509,0.0014553108,0.0014677484,0.000038498387,0.0012521652,0.00003377884,0.000016929389,0.9674087,0.0005783375],"about_ca_topic_score_codex":0.009208652,"about_ca_topic_score_gemma":0.00068528374,"teacher_disagreement_score":0.94712263,"about_ca_system_score_codex":0.63018423,"about_ca_system_score_gemma":0.21707612,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W1982193331","doi":"10.1158/1538-7445.am2011-2015","title":"Abstract 2015: Effect of valproic acid on fludarabine activity in chronic lymphocytic leukemia patients","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Research Manitoba; CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Fludarabine; Chronic lymphocytic leukemia; Medicine; Pharmacology; Apoptosis; Immunology; Leukemia; Cancer research; Internal medicine; Chemotherapy; Chemistry; Cyclophosphamide; Biochemistry","score_opus":0.07036853108156604,"score_gpt":0.40470299198644333,"score_spread":0.3343344609048773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982193331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896652,0.0009974843,0.0000016111445,0.000039546623,0.00016226362,0.0019028764,0.000025143929,0.000044689972,0.007161145],"genre_scores_gemma":[0.9979502,0.0005250536,0.0000127907215,0.000020912561,0.00020272139,0.00048552995,0.000015763351,0.00007893881,0.0007080795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949633,0.00041633242,0.00047185353,0.0007553923,0.0020690567,0.0013240862],"domain_scores_gemma":[0.9973414,0.0005914851,0.00011386676,0.0010866388,0.0004536099,0.0004130049],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002422419,0.00032023856,0.00074652047,0.0008517283,0.00009554072,0.000017865894,0.0005163736,0.0002827008,0.0013626181],"category_scores_gemma":[0.0008307893,0.0002543938,0.00016953396,0.001224675,0.0005668109,0.00017498601,0.00027151013,0.001212762,0.00042359642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0608832,0.0013622738,0.046038654,0.0142584,0.0007166539,0.0015482116,0.002526474,0.0007052271,0.681545,0.00016600406,0.013439012,0.17681089],"study_design_scores_gemma":[0.038734898,0.0053741434,0.11672565,0.0014692696,0.000032063166,0.000010826584,0.0000180281,0.0019935179,0.8350202,0.00004611822,0.0003201413,0.0002551802],"about_ca_topic_score_codex":0.017040737,"about_ca_topic_score_gemma":0.0004611711,"teacher_disagreement_score":0.18158238,"about_ca_system_score_codex":0.22832945,"about_ca_system_score_gemma":0.046747085,"threshold_uncertainty_score":0.9999908},"labels":[],"label_agreement":null},{"id":"W1982422376","doi":"10.1016/j.cancergen.2014.08.006","title":"Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization","year":2014,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Royal Columbian Hospital; BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Chronic lymphocytic leukemia; Fluorescence in situ hybridization; Population; Concordance; Cohort; Medicine; Internal medicine; Oncology; Leukemia; Biology; Chromosome; Genetics; Environmental health","score_opus":0.007939912613134138,"score_gpt":0.22916156429092735,"score_spread":0.2212216516777932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982422376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972388,0.0006376537,0.00023685918,0.000009325273,0.00016193162,0.0012137659,0.00048213583,0.000005841422,0.000013700575],"genre_scores_gemma":[0.99933964,0.00004902377,0.0001642836,0.000043005253,0.00012999783,0.00010678339,0.00011431343,0.000034525983,0.000018427452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827975,0.000105318104,0.0005893994,0.00021363069,0.0005716516,0.00024022219],"domain_scores_gemma":[0.9980968,0.00018767262,0.0004238504,0.0003840681,0.0008559422,0.00005165213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020511477,0.0000991345,0.0003185821,0.000042092222,0.00006902076,0.000015911997,0.00020329382,0.00009194204,0.000014756306],"category_scores_gemma":[0.0005981015,0.00010276397,0.000046712983,0.0005199485,0.00009526661,0.000017496814,0.000046234665,0.00007174624,5.849169e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006673344,0.00002816279,0.9295271,0.00068649586,0.000024638292,3.5162984e-7,0.00006132635,0.03351957,0.016332718,0.0000011817782,0.00003148368,0.019720208],"study_design_scores_gemma":[0.005115727,0.00018996479,0.751456,0.00035319987,0.00007144504,9.652185e-7,0.000014003716,0.22352293,0.01893284,0.000010778241,0.00025336855,0.0000787781],"about_ca_topic_score_codex":0.52397907,"about_ca_topic_score_gemma":0.8411151,"teacher_disagreement_score":0.31713605,"about_ca_system_score_codex":0.020205993,"about_ca_system_score_gemma":0.057999816,"threshold_uncertainty_score":0.98355526},"labels":[],"label_agreement":null},{"id":"W1982531740","doi":"10.1038/mt.2010.188","title":"VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia","year":2010,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; Jewish General Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research; Jewish General Hospital; McGill University","keywords":"Chronic lymphocytic leukemia; Apoptosis; Leukemia; Cancer research; Acquired resistance; Biology; Virology; Medicine; Drug resistance; Immunology; Microbiology; Biochemistry","score_opus":0.009141371729863679,"score_gpt":0.27192095805127153,"score_spread":0.26277958632140785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982531740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932615,0.0019455774,0.0001248975,0.001422932,0.00009112762,0.0013482682,0.0000022019806,0.00005873243,0.0017447375],"genre_scores_gemma":[0.9969518,0.00044598707,0.00035135786,0.0007317529,0.00009107815,0.00034151558,0.000019471127,0.00007338174,0.0009936377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973798,0.0001871564,0.00038950754,0.00053294224,0.0008965627,0.00061407575],"domain_scores_gemma":[0.99844986,0.0002051873,0.000113650225,0.0009789029,0.00012274389,0.00012963876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068680494,0.00030192497,0.00046640667,0.00034469838,0.000088583096,0.00006729581,0.00037146895,0.00023003433,0.00010455061],"category_scores_gemma":[0.00008932804,0.0002055019,0.00012340906,0.001287013,0.0002807911,0.00012511651,0.00006216419,0.0006971631,0.00004958942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0045910245,0.0003910343,0.0025433032,0.0003427306,0.0003490215,0.0010546364,0.0026674776,0.0014607284,0.9640554,0.004333146,0.0013343275,0.016877122],"study_design_scores_gemma":[0.16144153,0.0016165709,0.013779132,0.0009295192,0.0000961582,0.00016169496,0.00044453258,0.027413283,0.7557961,0.0012229782,0.03602015,0.0010783494],"about_ca_topic_score_codex":0.0018897633,"about_ca_topic_score_gemma":0.0053407997,"teacher_disagreement_score":0.20825936,"about_ca_system_score_codex":0.07190852,"about_ca_system_score_gemma":0.02012284,"threshold_uncertainty_score":0.98543215},"labels":[],"label_agreement":null},{"id":"W1982656232","doi":"10.1038/srep07613","title":"Decreased deformability of lymphocytes in chronic lymphocytic leukemia","year":2015,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"Grand Challenges Canada; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"Chronic lymphocytic leukemia; Stiffness; Medicine; Metastasis; Leukemia; Cancer; Cell; Cancer research; Pathology; Immunology; Chemistry; Materials science; Internal medicine","score_opus":0.03519628538363756,"score_gpt":0.312531674282803,"score_spread":0.2773353888991654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982656232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903651,0.0013338033,0.000034144447,0.000024131263,0.001547907,0.00082265376,0.000002007478,0.00008944892,0.0057807863],"genre_scores_gemma":[0.99735624,0.000012450882,0.0004160132,0.000026084243,0.00009341905,0.000050527175,0.000063542066,0.000030961233,0.0019507704],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99522465,0.00010381206,0.001226527,0.00096903177,0.001697684,0.0007782638],"domain_scores_gemma":[0.9962226,0.00012478285,0.0003374957,0.0020050167,0.0006250919,0.00068497664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004413544,0.00024783608,0.00063998415,0.00054879213,0.000077988145,0.000072203926,0.00023610628,0.00017998231,0.00016702413],"category_scores_gemma":[0.002235677,0.0002086529,0.00019372175,0.0015777688,0.00095682655,0.00025866873,0.00021590602,0.00017515116,0.00008630744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008644137,0.0022474502,0.26223844,0.011736556,0.0008994059,0.061699737,0.015379892,0.095023096,0.37766823,0.0013197453,0.10224477,0.06089851],"study_design_scores_gemma":[0.05378644,0.0010146656,0.0071419356,0.0013999786,0.000203766,0.014717944,0.0010471916,0.31968534,0.5643241,0.011958818,0.023706729,0.0010131244],"about_ca_topic_score_codex":0.0055117463,"about_ca_topic_score_gemma":0.00044799302,"teacher_disagreement_score":0.25509652,"about_ca_system_score_codex":0.2581537,"about_ca_system_score_gemma":0.24222024,"threshold_uncertainty_score":0.85086185},"labels":[],"label_agreement":null},{"id":"W1982692072","doi":"10.3109/10428194.2011.570394","title":"Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Deoxyadenosine; Cladribine; Deoxycoformycin; Deoxycytidine kinase; Biochemistry; Chemistry; Pentostatin; Adenosine deaminase; Molecular biology; Adenosine; Biology; Deoxycytidine","score_opus":0.052419454122607866,"score_gpt":0.32326350376375945,"score_spread":0.2708440496411516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982692072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112478815,0.87748873,0.00006426707,0.000009561069,0.0004369401,0.0029985092,0.0002028958,0.00014608316,0.006174187],"genre_scores_gemma":[0.05070886,0.9444087,0.001129033,0.000094235365,0.00027846347,0.0003176382,0.0003839846,0.00040252725,0.0022765584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99019253,0.00063224055,0.0037586603,0.0022440485,0.0014288666,0.0017436565],"domain_scores_gemma":[0.99334073,0.0010728929,0.0021620106,0.0020446456,0.00040948816,0.00097025087],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014109844,0.001946782,0.0067084744,0.0021286209,0.00017935205,0.000075291755,0.0008750094,0.002418572,0.0002114596],"category_scores_gemma":[0.00035916528,0.0017428509,0.001040104,0.0017985678,0.0011565216,0.00043071076,0.00097245345,0.00076868734,0.000063410276],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010152846,0.0004083875,0.0000702693,0.077159084,0.0005785489,0.0007568247,0.0011862195,0.0000038866274,0.0005238146,0.0023884699,0.00071796146,0.91519123],"study_design_scores_gemma":[0.14940517,0.0043531293,0.0014113337,0.0845852,0.008982746,0.015133445,0.002174318,0.00907568,0.015627429,0.0018920795,0.7015476,0.0058118673],"about_ca_topic_score_codex":0.012270612,"about_ca_topic_score_gemma":0.00035560955,"teacher_disagreement_score":0.90937936,"about_ca_system_score_codex":0.07219717,"about_ca_system_score_gemma":0.06230974,"threshold_uncertainty_score":0.99932754},"labels":[],"label_agreement":null},{"id":"W1983078946","doi":"10.1038/sj.onc.1208377","title":"G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression","year":2005,"lang":"en","type":"article","venue":"Oncogene","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Biology; Molecular biology; Gene; Gene expression; Promoter; Bcl-2-associated X protein; Messenger RNA; Mutant; Apoptosis; Genetics; Programmed cell death; Caspase 3","score_opus":0.03555694069289688,"score_gpt":0.31453687407377484,"score_spread":0.27897993338087795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983078946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819111,0.00090740575,0.000034891633,0.0026131254,0.0000955944,0.0007949592,0.0000037235152,0.00006358465,0.013575612],"genre_scores_gemma":[0.99260014,0.000033037497,0.001806485,0.0011859827,0.0013625412,0.000065469816,0.000033397315,0.000054459884,0.0028584732],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777454,0.00017127124,0.00029175624,0.0004215542,0.0007425949,0.000598278],"domain_scores_gemma":[0.9987784,0.000120713725,0.000071208335,0.0008079207,0.000044544715,0.0001771856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060868333,0.00021978814,0.00030575471,0.00017060943,0.00012594595,0.000042560252,0.0003324752,0.00015011459,0.00043769312],"category_scores_gemma":[0.00008348499,0.00014616617,0.00011402903,0.00031223753,0.00012048716,0.00011005528,0.00014244665,0.00032376123,0.00030795884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090663845,0.00051628705,0.00036053418,0.00005327802,0.00001890782,0.00060307904,0.0009702227,0.000010221293,0.97430927,0.000029852432,0.0050174743,0.018020192],"study_design_scores_gemma":[0.013751911,0.0005139511,0.0015512382,0.00029991416,0.000047132504,0.00077552255,0.00008480933,0.0008513768,0.9454222,0.00006344562,0.03638389,0.00025463456],"about_ca_topic_score_codex":0.00020466464,"about_ca_topic_score_gemma":0.00013842246,"teacher_disagreement_score":0.031366415,"about_ca_system_score_codex":0.004906834,"about_ca_system_score_gemma":0.00093187985,"threshold_uncertainty_score":0.99891317},"labels":[],"label_agreement":null},{"id":"W1984455044","doi":"10.1080/10428190701760029","title":"Alemtuzumab in clinical practice: A British Columbia experience","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lions Gate Hospital; University of British Columbia; Royal Columbian Hospital; Interior Health; Vancouver General Hospital; Eagle Ridge Hospital","funders":"","keywords":"Alemtuzumab; Medicine; Neutropenia; Internal medicine; Adverse effect; Chronic lymphocytic leukemia; Clinical trial; Surgery; Oncology; Leukemia; Chemotherapy; Transplantation","score_opus":0.02706911312920365,"score_gpt":0.32807800209074184,"score_spread":0.3010088889615382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984455044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97547394,0.004084864,0.00004706602,0.00020045493,0.00060192216,0.001390417,0.000031442218,0.00038201042,0.01778791],"genre_scores_gemma":[0.9730977,0.008041929,0.0030802856,0.0036009678,0.00080071564,0.0003592347,0.00008325952,0.0002045793,0.010731342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99069744,0.0005182808,0.0024554217,0.0022525927,0.0019691503,0.0021071073],"domain_scores_gemma":[0.9943052,0.0014917041,0.00050571625,0.0017027915,0.00050978275,0.0014848033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015162799,0.0007243482,0.0018375282,0.0003292675,0.00073668046,0.0004896687,0.00075300405,0.0011287866,0.0004968598],"category_scores_gemma":[0.0030985489,0.0009838623,0.0005178905,0.0015378053,0.0020993184,0.0010378794,0.00066394336,0.0005982074,0.00029360378],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004445058,0.0027253625,0.20511824,0.0008614318,0.00068692176,0.10028234,0.007153762,0.000046473997,0.0006401075,0.00026886418,0.092795394,0.5849761],"study_design_scores_gemma":[0.11306202,0.0011675155,0.56640726,0.0009677024,0.00022633815,0.11535287,0.0021836592,0.014087226,0.00029527835,0.00018284612,0.18448494,0.0015823608],"about_ca_topic_score_codex":0.147828,"about_ca_topic_score_gemma":0.01002501,"teacher_disagreement_score":0.5833937,"about_ca_system_score_codex":0.0654554,"about_ca_system_score_gemma":0.048925653,"threshold_uncertainty_score":0.9992612},"labels":[],"label_agreement":null},{"id":"W1985094563","doi":"10.1084/jem.191.5.781","title":"A Dual Role for Src Homology 2 Domain–Containing Inositol-5-Phosphatase (Ship) in Immunity","year":2000,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Medical Research Council Canada","keywords":"Biology; B cell; Cell biology; Antigen; Receptor; Molecular biology; Immunology; Antibody; Biochemistry","score_opus":0.025347523835777812,"score_gpt":0.34984900930421176,"score_spread":0.32450148546843394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985094563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720783,0.022261856,0.000024938709,0.0027489027,0.0002078617,0.0005741192,0.0000043119003,0.000010597414,0.0020890704],"genre_scores_gemma":[0.9971329,0.00033449606,0.0005020515,0.0009360727,0.00075434305,0.000021613498,0.000012758214,0.000030229618,0.0002755225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977251,0.0002520145,0.00080540136,0.00014369712,0.00058941223,0.00048437103],"domain_scores_gemma":[0.9983455,0.00069423864,0.000214968,0.00037382418,0.000114083574,0.00025741415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020093084,0.00020622715,0.0006573593,0.00020837328,0.00013173504,0.0000079217125,0.00032041688,0.000105593565,0.0013954047],"category_scores_gemma":[0.0002499907,0.00012292682,0.000111514404,0.00026670186,0.0005094251,0.00012525622,0.00006831425,0.0005861982,0.000017189857],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1228513,0.0041245855,0.001968486,0.00030551315,0.0012446211,0.0065479684,0.11405077,0.0001470484,0.6801135,0.0030750518,0.021162337,0.044408817],"study_design_scores_gemma":[0.27428007,0.044380233,0.004077168,0.0029856295,0.0006222344,0.048168007,0.101820014,0.0027131804,0.47879428,0.0029166576,0.03850837,0.00073413964],"about_ca_topic_score_codex":0.0011003558,"about_ca_topic_score_gemma":0.000028425982,"teacher_disagreement_score":0.20131922,"about_ca_system_score_codex":0.0034786197,"about_ca_system_score_gemma":0.0012508432,"threshold_uncertainty_score":0.99951744},"labels":[],"label_agreement":null},{"id":"W1985600634","doi":"10.1038/leu.2008.96","title":"Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Minimal residual disease; Medicine; Donor lymphocyte infusion; Internal medicine; Transplantation; Oncology; Leukemia; Stem cell; Hematopoietic stem cell transplantation; Chronic lymphocytic leukemia; Immunology; Biology","score_opus":0.0493512382754655,"score_gpt":0.3138478957526695,"score_spread":0.264496657477204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985600634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911966,0.0018267257,0.0013846223,0.00018703294,0.0012309172,0.0028524,0.0010091,0.000190774,0.000121866855],"genre_scores_gemma":[0.99116224,0.0012832336,0.00042899733,0.00013090292,0.0018142632,0.0009014215,0.00043688476,0.00014024465,0.0037017898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947459,0.0005958782,0.0012262075,0.0011602673,0.0012040476,0.0010677141],"domain_scores_gemma":[0.9910765,0.0066796755,0.0003672553,0.0012650386,0.00029260886,0.000318893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013265371,0.000590693,0.00078264746,0.00019798616,0.00053768116,0.00012151495,0.0005896326,0.00043447397,0.00005920509],"category_scores_gemma":[0.0005895514,0.0004497863,0.00048413506,0.00040753503,0.00039590267,0.00029222097,0.00012659866,0.0005846108,0.00020659539],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.94322735,0.00011352511,0.002113894,0.001075313,0.00062213,0.0038163837,0.01776441,0.0013509732,0.024830816,0.000014462818,0.0032986186,0.0017721102],"study_design_scores_gemma":[0.6620714,0.0063825096,0.12919258,0.002407415,0.001584886,0.0009679729,0.0032795174,0.024544556,0.16545849,0.00009311424,0.002373276,0.0016443095],"about_ca_topic_score_codex":0.0065986346,"about_ca_topic_score_gemma":0.0007425762,"teacher_disagreement_score":0.28115597,"about_ca_system_score_codex":0.10489587,"about_ca_system_score_gemma":0.04036346,"threshold_uncertainty_score":0.9997954},"labels":[],"label_agreement":null},{"id":"W1985767613","doi":"10.2310/7070.2005.4112","title":"Skull Base, Orbital, and Perineural Involvement in Waldenström’s Macroglobulinemia","year":2006,"lang":"en","type":"article","venue":"The Journal of Otolaryngology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Macroglobulinemia; Skull; Waldenstrom macroglobulinemia; Anatomy; Dermatology; Pathology; Multiple myeloma; Internal medicine","score_opus":0.014836126794498718,"score_gpt":0.27407721279887937,"score_spread":0.25924108600438067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985767613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939004,0.0017886318,0.000025898242,0.003054016,0.00011489643,0.00023109242,0.0000013885655,0.000007052446,0.00087660865],"genre_scores_gemma":[0.9982097,0.00023494461,0.00041264208,0.00041228617,0.00028997916,0.000002861357,0.0000028382285,0.000016479267,0.00041824815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998478,0.00016304616,0.0005678367,0.00011557739,0.00033060234,0.00034496034],"domain_scores_gemma":[0.99912816,0.00022788928,0.00017806969,0.00022609373,0.00013157293,0.00010818374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086904404,0.00013307633,0.0003865673,0.00019181863,0.00004474389,0.000012263329,0.00018800148,0.00009408813,0.0001748394],"category_scores_gemma":[0.0001254997,0.000081900245,0.00006848848,0.00018687628,0.00026713024,0.000075285636,0.00012533819,0.00050304376,0.000016981996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013265406,0.0020312374,0.63502795,0.0012438927,0.0006064197,0.045433156,0.0032485272,0.0010662517,0.25062788,0.0026088043,0.038070813,0.006769684],"study_design_scores_gemma":[0.06383718,0.004344028,0.698227,0.00049155764,0.00038890546,0.1810302,0.001094005,0.014266741,0.023676647,0.001916755,0.010241552,0.00048545335],"about_ca_topic_score_codex":0.0012177962,"about_ca_topic_score_gemma":0.00030567127,"teacher_disagreement_score":0.22695124,"about_ca_system_score_codex":0.0015801617,"about_ca_system_score_gemma":0.0011940559,"threshold_uncertainty_score":0.4132068},"labels":[],"label_agreement":null},{"id":"W1987460161","doi":"10.1021/jm501759m","title":"Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents","year":2015,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Agentschap voor Innovatie door Wetenschap en Technologie; Canada Foundation for Innovation; Ontario Ministry of Economic Development and Innovation; Seventh Framework Programme; AbbVie; Canadian Institutes of Health Research; Wellcome; GlaxoSmithKline; National Institute of Allergy and Infectious Diseases; Bayer; Eli Lilly and Company; Boehringer Ingelheim; National Center for Advancing Translational Sciences; Wellcome Trust; American Cancer Society; Doris Duke Charitable Foundation; Stanford University; Pfizer","keywords":"Kinase; Chemistry; Cyclin; Biochemistry; Virology; Biology; Cell cycle; Cell","score_opus":0.028454967528027484,"score_gpt":0.33131403309252844,"score_spread":0.30285906556450093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987460161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886316,0.0009519326,0.0000106582975,0.0005931661,0.0002778197,0.00013207179,0.0000069410958,0.000013635072,0.009382189],"genre_scores_gemma":[0.9975209,0.00025433392,0.00010612105,0.00016044849,0.00090837677,0.000002127914,0.000012760583,0.000029928407,0.0010049639],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99629134,0.00007946305,0.00095314725,0.00019273756,0.0021042903,0.00037900952],"domain_scores_gemma":[0.9963705,0.00021045872,0.0008366043,0.00024541724,0.0015454891,0.0007915176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014890793,0.00020317275,0.00079528755,0.00012626054,0.00003266862,0.000009770943,0.00024400854,0.00026279123,0.0002745981],"category_scores_gemma":[0.006232059,0.00016233067,0.00022660724,0.0004556727,0.0002501384,0.00010154587,0.000073689545,0.00083078427,0.000016306802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0056842854,0.0035280494,0.16195661,0.0024288187,0.00299047,0.018648973,0.005535006,0.0002046159,0.5538227,0.000010811502,0.23975179,0.005437872],"study_design_scores_gemma":[0.048013728,0.002445942,0.01348423,0.003375138,0.0006442531,0.006443252,0.0018311226,0.0012084267,0.91932815,0.000273294,0.002645517,0.00030693613],"about_ca_topic_score_codex":0.00047401816,"about_ca_topic_score_gemma":0.00000480678,"teacher_disagreement_score":0.36550546,"about_ca_system_score_codex":0.007886046,"about_ca_system_score_gemma":0.011464625,"threshold_uncertainty_score":0.9959225},"labels":[],"label_agreement":null},{"id":"W1988040543","doi":"10.1016/j.jval.2011.02.355","title":"PSY22 ANALYSING THE BENEFITS AND COST SAVING OF ORAL VERSUS IV FLUDARABINE FOR MANAGEMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Fludarabine; Medicine; Adverse effect; Dose; Internal medicine; Cyclophosphamide; Gastroenterology; Chemotherapy","score_opus":0.13124816543485762,"score_gpt":0.3501985851498948,"score_spread":0.2189504197150372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988040543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885888,0.007980892,0.00017804393,0.00015977609,0.00014903069,0.0018241935,0.000016161224,0.000016093676,0.0010870049],"genre_scores_gemma":[0.99376917,0.0026394678,0.0032969257,0.000056098987,0.000043118867,0.000056269193,0.000012571469,0.00003208364,0.00009430591],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99784946,0.00011757634,0.0007141776,0.00033909283,0.00042855353,0.0005511349],"domain_scores_gemma":[0.99857134,0.00035311887,0.00026686746,0.0005496855,0.00010218325,0.00015679497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015351298,0.00016872668,0.0005407289,0.00022383867,0.00008317825,0.0000069782172,0.00020551786,0.000076300974,0.000030854415],"category_scores_gemma":[0.00007982823,0.00013009898,0.00009919354,0.00051742414,0.00018955454,0.00005508821,0.00013558393,0.0001486713,0.000002925067],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034985848,0.002997069,0.014874364,0.12111482,0.0033457284,0.00040531103,0.023152974,0.093005694,0.008099865,0.054343864,0.0017762393,0.6418982],"study_design_scores_gemma":[0.16249706,0.0057611284,0.012809669,0.006310513,0.00071573566,0.00010912782,0.0027567912,0.7885884,0.01810613,0.0005052407,0.0013136122,0.0005265729],"about_ca_topic_score_codex":0.017079007,"about_ca_topic_score_gemma":0.00038497717,"teacher_disagreement_score":0.69558275,"about_ca_system_score_codex":0.019879993,"about_ca_system_score_gemma":0.0067335805,"threshold_uncertainty_score":0.9988973},"labels":[],"label_agreement":null},{"id":"W1988367968","doi":"10.1182/blood-2012-02-408773","title":"A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; University of British Columbia; London Health Sciences Centre; Jewish General Hospital; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Obinutuzumab; Medicine; Neutropenia; Internal medicine; Maintenance therapy; Tolerability; Regimen; Rituximab; Phases of clinical research; Population; CD20; Gastroenterology; Surgery; Lymphoma; Oncology; Clinical trial; Chemotherapy; Adverse effect","score_opus":0.009608775374167903,"score_gpt":0.25755991999633626,"score_spread":0.24795114462216836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988367968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835956,0.00015538542,0.0000047255908,0.0000050126673,0.00004547143,0.0010712773,0.00002550051,0.000010979162,0.0003220671],"genre_scores_gemma":[0.9994683,0.0000071155955,0.00013434907,0.0000100934385,0.000020656658,0.000039128907,0.000028113614,0.000023339348,0.00026886095],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99855316,0.000072150404,0.0003184425,0.00019313939,0.0005357585,0.00032733343],"domain_scores_gemma":[0.99920696,0.000060404458,0.00016165484,0.0003103655,0.00016570043,0.00009492869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023193478,0.00011731575,0.00034652295,0.0001358336,0.000014793622,0.000002903146,0.00008683192,0.00007193446,0.000015815413],"category_scores_gemma":[0.000099126926,0.00009773839,0.00003849101,0.00038909484,0.000088717905,0.00011338724,0.000045757188,0.00014803495,0.0000051387988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018699827,0.2412132,0.5834898,0.00089851965,0.0010958106,0.00025102298,0.040719025,0.000016520817,0.1073544,0.000041622086,0.0026258812,0.0035943622],"study_design_scores_gemma":[0.6436188,0.016505376,0.19742161,0.0005866786,0.00047413047,0.000025046467,0.0041555203,0.000039967726,0.13682976,0.0000038253384,0.000069615555,0.00026964067],"about_ca_topic_score_codex":0.00071578124,"about_ca_topic_score_gemma":0.000018815002,"teacher_disagreement_score":0.624919,"about_ca_system_score_codex":0.0017450447,"about_ca_system_score_gemma":0.0009865001,"threshold_uncertainty_score":0.45632312},"labels":[],"label_agreement":null},{"id":"W1988787726","doi":"10.1016/j.critrevonc.2014.10.007","title":"Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?","year":2014,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Pleiotrophin; Midkine; Angiogenesis; Angiogenin; Cancer research; Basic fibroblast growth factor; Haematopoiesis; Growth factor; Immunology; Vascular endothelial growth factor; Chronic lymphocytic leukemia; Placental growth factor; Medicine; Angiopoietin; Biology; Internal medicine; Leukemia; Stem cell; Cell biology; Receptor; VEGF receptors","score_opus":0.10254896086678436,"score_gpt":0.46684396905452313,"score_spread":0.36429500818773874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988787726","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000060477745,0.9893747,0.00009330536,0.00044093048,0.00094289903,0.0051677693,0.00003278465,0.00010942638,0.0037776844],"genre_scores_gemma":[0.0003686839,0.99587727,0.0004030429,0.00016587318,0.0005290341,0.0017897806,0.00008116052,0.00027115655,0.0005140216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98457843,0.0039732084,0.0052372958,0.0023961335,0.0007949013,0.0030200134],"domain_scores_gemma":[0.9851252,0.01047154,0.00070391916,0.0024701892,0.00021738373,0.0010118133],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0038227658,0.0017231009,0.016089557,0.001603986,0.00011170037,0.00005413894,0.001463202,0.0041296813,0.001826767],"category_scores_gemma":[0.01296689,0.0013113279,0.002187272,0.0020972276,0.0018365687,0.00014345904,0.00082856853,0.003497786,0.0028525766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00010225864,0.00034462087,0.00005404417,0.24271351,0.00021043525,0.0053409524,0.00011584324,9.944156e-7,0.0000012636425,0.025913054,0.010361408,0.7148416],"study_design_scores_gemma":[0.0068160496,0.0008395031,0.0000013811795,0.1470619,0.0010509563,0.006570317,0.00004295665,0.00018955619,0.0000035908283,0.00069629983,0.8358968,0.0008306865],"about_ca_topic_score_codex":0.00018682083,"about_ca_topic_score_gemma":0.0006694287,"teacher_disagreement_score":0.8255354,"about_ca_system_score_codex":0.21538065,"about_ca_system_score_gemma":0.09389165,"threshold_uncertainty_score":0.99955153},"labels":[],"label_agreement":null},{"id":"W1988877261","doi":"10.1016/s0165-4608(03)00217-6","title":"Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin","year":2003,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Ontario Medical Association","keywords":"Biology; Fluorescence in situ hybridization; Chronic lymphocytic leukemia; Chromosomal translocation; Multiple myeloma; Trisomy; Somatic evolution in cancer; Interphase; Cytogenetics; Cancer research; Molecular cytogenetics; Comparative genomic hybridization; Leukemia; Molecular biology; Immunology; Genetics; Chromosome; Cancer; Gene","score_opus":0.01824695187360097,"score_gpt":0.2888925608732239,"score_spread":0.2706456089996229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988877261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95808333,0.04055497,0.0003799774,0.00001847517,0.00007384313,0.0007858895,0.00005686128,0.000009942927,0.000036737918],"genre_scores_gemma":[0.99072415,0.008596075,0.0004139906,0.000058029174,0.000031048916,0.00006243782,0.000034424127,0.00004738194,0.000032483385],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751675,0.0001195159,0.0006076209,0.00059914676,0.0005967315,0.00056024775],"domain_scores_gemma":[0.99879086,0.0001482492,0.0001548271,0.00039172373,0.00023786546,0.00027646986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002034903,0.0003469307,0.00050972897,0.00017652483,0.000046992667,0.000038895956,0.0001648078,0.00012502307,0.000029581508],"category_scores_gemma":[0.00013970285,0.00031873235,0.000040801497,0.00041761855,0.0005676727,0.00005434654,0.00012221804,0.00019029365,9.635384e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006993318,0.00013257048,0.9556119,0.0013066153,0.00008346545,0.00011030466,0.00046429606,0.0063449554,0.023350704,0.000076169774,0.000054805514,0.011764912],"study_design_scores_gemma":[0.061631292,0.003928164,0.30646944,0.004580905,0.00032292327,0.00016120162,0.00022397524,0.06863518,0.5511727,0.000048995225,0.0015481685,0.0012770868],"about_ca_topic_score_codex":0.00037884273,"about_ca_topic_score_gemma":0.00056151144,"teacher_disagreement_score":0.64914244,"about_ca_system_score_codex":0.010473776,"about_ca_system_score_gemma":0.009009898,"threshold_uncertainty_score":0.99992645},"labels":[],"label_agreement":null},{"id":"W1988964337","doi":"10.4021//jmc.v3i1.404","title":"Secondary Hairy Cell Leukemia in a Patient With Chronic Myelogenous Leukemia Following Treatment With Tyrosine Kinase Inhibitors: Report of an Extremely Rare Case and Review of the Literature","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic myelogenous leukemia; Hairy cell leukemia; Tyrosine kinase; Leukemia; Cancer research; CD135; Tyrosine-kinase inhibitor; Internal medicine; Cancer; Receptor","score_opus":0.016716586305601626,"score_gpt":0.28681582186147503,"score_spread":0.2700992355558734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988964337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8042843,0.19474384,0.0000032117946,0.0002862812,0.0001038018,0.00048648872,0.00001241802,0.000004342058,0.00007534774],"genre_scores_gemma":[0.9915275,0.00741383,0.00036357236,0.0002264221,0.00036208032,0.000014377205,0.00001378809,0.00003280231,0.000045620214],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99618995,0.00024969038,0.0011372137,0.00022531752,0.0017906431,0.00040720197],"domain_scores_gemma":[0.99746084,0.00030878608,0.0007844884,0.00050370774,0.00030345283,0.0006387083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013071818,0.0002732217,0.000950021,0.00018332008,0.000059001508,0.0000134672055,0.0001473097,0.00019104639,0.00009360315],"category_scores_gemma":[0.00063211547,0.0001312174,0.00020930354,0.00049799576,0.00028538366,0.00025596225,0.000088672205,0.000697816,2.5505184e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021200315,0.0010907208,0.0048878435,0.014685711,0.0003610573,0.8999205,0.0040199026,0.000018383153,0.0013455092,0.0000032618775,0.0010530044,0.070494056],"study_design_scores_gemma":[0.021628208,0.0104920035,0.0007224792,0.064345956,0.0006974607,0.8809944,0.0010765357,0.00015499811,0.016938988,0.000001833796,0.0027385529,0.00020859456],"about_ca_topic_score_codex":0.0011959366,"about_ca_topic_score_gemma":0.0005007395,"teacher_disagreement_score":0.18733001,"about_ca_system_score_codex":0.012483114,"about_ca_system_score_gemma":0.029807752,"threshold_uncertainty_score":0.9913078},"labels":[],"label_agreement":null},{"id":"W1989321952","doi":"10.1007/s11864-001-0035-3","title":"Hairy cell leukemia","year":2001,"lang":"en","type":"review","venue":"Current Treatment Options in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Deoxycoformycin; Neutropenia; Regimen; Hairy cell leukemia; Hairy Cell; Pentostatin; Febrile neutropenia; Internal medicine; Leukopenia; Gastroenterology; Cladribine; Leukemia; Surgery; Chemotherapy; Rituximab; Lymphoma","score_opus":0.1982134664980968,"score_gpt":0.49475473741481496,"score_spread":0.29654127091671817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989321952","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006300954,0.9757792,0.000019405714,0.000043946624,0.0012724428,0.002874457,0.00005568007,0.000106199805,0.019785695],"genre_scores_gemma":[0.000011317284,0.9887089,0.00052720634,0.000013280254,0.0006727783,0.0021257084,0.0011272241,0.00009766449,0.006715916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963596,0.00040125585,0.0010724104,0.0009388772,0.00034595662,0.0008819428],"domain_scores_gemma":[0.9975857,0.0006604931,0.00027560614,0.0010529443,0.00008159491,0.00034366245],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002683302,0.00071577355,0.0029448986,0.0010150757,0.00009347891,0.000022402257,0.00029839433,0.0008171675,0.0006866672],"category_scores_gemma":[0.000080677346,0.000536156,0.00084380584,0.001095492,0.0002464405,0.000053990276,0.0001705891,0.0009341833,0.002112427],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00003439617,0.0022330969,0.000009494394,0.005924574,0.00016959547,0.0011041644,0.00006075173,0.000009746304,9.409767e-8,0.00014321061,0.0029656838,0.9873452],"study_design_scores_gemma":[0.011710457,0.001449499,0.000002805338,0.006102599,0.0015824699,0.001483504,0.00002602363,0.00019861272,4.8815383e-7,0.000023073864,0.977085,0.00033549825],"about_ca_topic_score_codex":0.00019028476,"about_ca_topic_score_gemma":0.00012339577,"teacher_disagreement_score":0.9870097,"about_ca_system_score_codex":0.24378678,"about_ca_system_score_gemma":0.052487932,"threshold_uncertainty_score":0.999709},"labels":[],"label_agreement":null},{"id":"W1989511082","doi":"10.1016/j.jmoldx.2014.11.006","title":"High-Throughput Sequencing Using the Ion Torrent Personal Genome Machine for Clinical Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia","year":2014,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Somatic hypermutation; Sanger sequencing; Ion semiconductor sequencing; Personal genomics; Biology; DNA sequencing; Chronic lymphocytic leukemia; Population; Deep sequencing; Genome; Computational biology; Genetics; Leukemia; Gene; Genomics; Medicine; Antibody; B cell","score_opus":0.08207631165015761,"score_gpt":0.400406058833724,"score_spread":0.3183297471835664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989511082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389154,0.005669748,0.054045737,0.000089753834,0.00039304415,0.00085558475,0.000009799067,0.0000054503093,0.000015520322],"genre_scores_gemma":[0.9916671,0.001075056,0.006492848,0.00013370637,0.0005448343,0.0000160337,0.00002657578,0.000041048315,0.0000028181123],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9958365,0.00062609866,0.0013555296,0.00022068001,0.001554247,0.00040693223],"domain_scores_gemma":[0.99562895,0.0020053335,0.0008183086,0.00030738057,0.0010682953,0.00017172798],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051939315,0.00019068566,0.0006129696,0.00023709695,0.000065082,0.000026844273,0.00018213781,0.00015323408,0.00002254818],"category_scores_gemma":[0.009211378,0.00014098454,0.00027934267,0.0002710537,0.00015428355,0.00010528327,0.000059579757,0.0003693555,0.0000023882849],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010120246,0.0002556307,0.0028224834,0.001581659,0.0007006691,0.00026688402,0.001895915,0.8151562,0.13606632,0.00038682864,0.000117821044,0.03973755],"study_design_scores_gemma":[0.023786508,0.0012074737,0.0031144442,0.00076846784,0.0010048118,0.00042312618,0.00017422422,0.95893186,0.009260005,0.001140772,0.000056000896,0.00013228685],"about_ca_topic_score_codex":0.00038013957,"about_ca_topic_score_gemma":0.000042710148,"teacher_disagreement_score":0.14377566,"about_ca_system_score_codex":0.095954224,"about_ca_system_score_gemma":0.04376764,"threshold_uncertainty_score":0.9991345},"labels":[],"label_agreement":null},{"id":"W1989992323","doi":"10.1016/s0168-8278(11)61361-5","title":"1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL","year":2011,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of British Columbia","funders":"","keywords":"Ribavirin; Medicine; Interim analysis; Virology; Interim; Internal medicine; Pharmacology; Clinical trial; Virus; Hepatitis C virus","score_opus":0.05552744191615485,"score_gpt":0.2987421881019374,"score_spread":0.24321474618578257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989992323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929642,0.0004576304,0.0001530602,0.005102416,0.00022659189,0.00076828385,0.0000884075,0.00001273182,0.00022664276],"genre_scores_gemma":[0.9983662,0.00015480217,0.0003092028,0.0005730909,0.0002881114,0.000021463358,0.00017676341,0.000043152882,0.000067214336],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969244,0.00052266533,0.0009278023,0.00047605485,0.0006072272,0.0005418564],"domain_scores_gemma":[0.99644804,0.00089786464,0.00075900584,0.0013629742,0.00030208484,0.00023000821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005273842,0.0003748641,0.0012868783,0.0004335125,0.00013465974,0.0000399168,0.00096492324,0.00014111085,0.000386507],"category_scores_gemma":[0.00025881405,0.00016398131,0.0002321265,0.0008853221,0.00062514725,0.0002620229,0.0002803397,0.0005949992,0.00001989138],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39068833,0.0044843587,0.5699222,0.0000338405,0.011767634,0.003628958,0.007307204,0.000036818834,0.00013212943,0.000035232333,0.0091950605,0.002768202],"study_design_scores_gemma":[0.7445694,0.07759894,0.13159086,0.00067668693,0.01454462,0.0015973046,0.0059987507,0.00978681,0.003907507,0.00004948313,0.008721658,0.0009579663],"about_ca_topic_score_codex":0.015984995,"about_ca_topic_score_gemma":0.028656995,"teacher_disagreement_score":0.43833137,"about_ca_system_score_codex":0.0030391566,"about_ca_system_score_gemma":0.002405361,"threshold_uncertainty_score":0.9905676},"labels":[],"label_agreement":null},{"id":"W1990175055","doi":"10.1038/sj.leu.2401721","title":"P53 mutations in hairy cell leukemia","year":2000,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Alexander von Humboldt-Stiftung","keywords":"Hairy cell leukemia; Leukemia; Cancer research; Mutation; Biology; Genetics; Gene","score_opus":0.01617999130065075,"score_gpt":0.2880168064529689,"score_spread":0.27183681515231817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990175055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80944854,0.00037422875,0.000030573035,0.00024725177,0.00008475052,0.0004730437,0.000007601876,0.0001419252,0.18919206],"genre_scores_gemma":[0.9461403,0.00018848386,0.001085943,0.00087020727,0.00026057733,0.00008369143,0.00008105048,0.00006418225,0.051225577],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974956,0.00007529781,0.0004975779,0.0005347213,0.00061976037,0.00077703607],"domain_scores_gemma":[0.9986146,0.00019535347,0.000048985872,0.0007363979,0.00007258632,0.0003320534],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000299491,0.0002586978,0.0004108086,0.00027793125,0.000094959,0.000040467876,0.00025811803,0.00026134285,0.0050355],"category_scores_gemma":[0.000102533275,0.00024628965,0.00014523485,0.0007894792,0.00019056398,0.00016714685,0.00005882401,0.0006473455,0.0036545857],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0063824323,0.0022530055,0.028190732,0.003923784,0.00055541773,0.025649289,0.018367192,0.056984216,0.04112555,0.0035747243,0.206448,0.6065456],"study_design_scores_gemma":[0.15983187,0.0013541396,0.06823094,0.0013088778,0.0003807922,0.0030446262,0.0015524313,0.34573224,0.052274883,0.0028850292,0.36092815,0.0024760053],"about_ca_topic_score_codex":0.0034946778,"about_ca_topic_score_gemma":0.00030084472,"teacher_disagreement_score":0.60406965,"about_ca_system_score_codex":0.050571356,"about_ca_system_score_gemma":0.017034283,"threshold_uncertainty_score":0.9999989},"labels":[],"label_agreement":null},{"id":"W1990211195","doi":"10.1111/j.1600-0609.2007.00903.x","title":"Analysis of 6q deletion in Waldenstrom macroglobulinemia","year":2007,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Waldenstrom macroglobulinemia; Macroglobulinemia; Fluorescence in situ hybridization; Interphase; Cytogenetics; Biology; Pathology; Multiple myeloma; Chromosome; Medicine; Immunology; Genetics; Gene; Lymphoma","score_opus":0.01728273097224054,"score_gpt":0.3187438329478327,"score_spread":0.30146110197559217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990211195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917423,0.0005118941,0.0028382349,0.00035274297,0.00010351217,0.00007173795,0.0000013876404,0.00000592675,0.0043722657],"genre_scores_gemma":[0.99733585,0.000078446035,0.0022802453,0.000113749156,0.000083410494,1.1737275e-7,0.0000046802043,0.000017493829,0.00008602931],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9977507,0.0003045288,0.001127508,0.00013453553,0.0003746556,0.00030804373],"domain_scores_gemma":[0.99861276,0.00022094933,0.00046288324,0.0002422312,0.00030001838,0.00016118614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028120282,0.000102797225,0.00079069595,0.001215957,0.000014389553,0.0000043438913,0.00019543935,0.000048936305,0.00019470087],"category_scores_gemma":[0.0004748627,0.00008300277,0.0002512846,0.0009365609,0.00015337962,0.000041702242,0.00005857777,0.00035103416,0.000028518592],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009272738,0.0015111567,0.3592518,0.0007648816,0.006949236,0.50763184,0.004474259,0.0025269678,0.040206455,0.0014934663,0.004926429,0.06099077],"study_design_scores_gemma":[0.06330595,0.003691085,0.6889854,0.0010574908,0.0049741697,0.18187271,0.0022418485,0.013528569,0.03088087,0.00011432859,0.00879176,0.0005558082],"about_ca_topic_score_codex":0.000032783057,"about_ca_topic_score_gemma":0.000050884846,"teacher_disagreement_score":0.3297336,"about_ca_system_score_codex":0.001155154,"about_ca_system_score_gemma":0.00073931424,"threshold_uncertainty_score":0.33847547},"labels":[],"label_agreement":null},{"id":"W1990517558","doi":"10.1038/modpathol.3800632","title":"Pathway-specific apoptotic gene expression profiling in chronic lymphocytic leukemia and follicular lymphoma","year":2006,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Chronic lymphocytic leukemia; Follicular lymphoma; MCL1; Leukemia; Survivin; Lymphoma; Pathology; CD20; Gene expression profiling; Cancer research; Medicine; Biology; Immunology; Gene expression; Gene; Internal medicine; Downregulation and upregulation; Cancer","score_opus":0.016937417930110943,"score_gpt":0.25949687131409876,"score_spread":0.24255945338398782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990517558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98252267,0.010536137,0.0046708635,0.00005223772,0.00013355925,0.00087482313,0.000009293483,0.00015141681,0.0010490051],"genre_scores_gemma":[0.9944427,0.00045642,0.003570988,0.000103519684,0.0003800218,0.00016944439,0.00010192326,0.00009427298,0.0006806901],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996571,0.00019394782,0.00064584747,0.0010460977,0.00050651166,0.0010365805],"domain_scores_gemma":[0.99860126,0.00013734182,0.00011890806,0.00084797514,0.000088318186,0.00020622734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005176514,0.00038926819,0.0007152148,0.00040884418,0.00012462933,0.000038871833,0.00020853333,0.0004533274,0.000050431318],"category_scores_gemma":[0.00006796517,0.00035324495,0.00012154076,0.00034049465,0.0003253265,0.00012326008,0.00026378018,0.00026655264,0.00010241948],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00044479294,0.00009679592,0.0011210665,0.00034948124,0.000018993873,0.00753838,0.00031737427,0.0071235956,0.97023314,0.000508666,0.00014742953,0.012100259],"study_design_scores_gemma":[0.048108865,0.00051251403,0.0065588867,0.0003835459,0.000048977774,0.0074107074,0.000075163756,0.37093845,0.5612999,0.0031265449,0.00091151247,0.0006249282],"about_ca_topic_score_codex":0.00046310647,"about_ca_topic_score_gemma":0.000067984365,"teacher_disagreement_score":0.40893325,"about_ca_system_score_codex":0.07442119,"about_ca_system_score_gemma":0.0138600515,"threshold_uncertainty_score":0.99989194},"labels":[],"label_agreement":null},{"id":"W1991758119","doi":"10.1007/s00262-005-0010-0","title":"Monoclonal antibody therapy of chronic lymphocytic leukemia","year":2005,"lang":"en","type":"review","venue":"Cancer Immunology Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Georgetown Hospital","funders":"","keywords":"Alemtuzumab; Chronic lymphocytic leukemia; Rituximab; Medicine; Fludarabine; Monoclonal antibody; Monoclonal antibody therapy; Immunology; Chemotherapy; Oncology; Leukemia; Antibody; Cancer research; Internal medicine; Cyclophosphamide","score_opus":0.06360689097298267,"score_gpt":0.4219103626378996,"score_spread":0.35830347166491694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991758119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00110347,0.9940185,0.000038120237,0.000046047626,0.0010768805,0.00273166,0.00011195218,0.00020276978,0.0006706298],"genre_scores_gemma":[0.000117086674,0.9936287,0.00015658858,0.0002163182,0.0011850392,0.00097365654,0.00040943368,0.00043046242,0.002882751],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99407953,0.0004217922,0.002074519,0.0012094214,0.0007554824,0.001459283],"domain_scores_gemma":[0.99527586,0.00048043157,0.001180049,0.0025271103,0.00036259045,0.00017399037],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005211292,0.0013229547,0.00547395,0.0009420359,0.00016449142,0.000038159695,0.0013993166,0.0017120533,0.0035800915],"category_scores_gemma":[0.00004905596,0.0010561051,0.0018523032,0.0011510933,0.001408376,0.00015081938,0.000213995,0.0015519785,0.0003831686],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008605806,0.00012462738,0.0000024210328,0.004587393,0.00609766,0.0001062939,0.00013708236,0.000022786544,0.0013565131,0.0000830681,0.00055498653,0.9860666],"study_design_scores_gemma":[0.022768555,0.0011109329,0.000016382375,0.0127452575,0.00048224602,0.0015487486,0.000013214961,0.00027070288,0.0005128243,0.000013186159,0.95973754,0.0007804052],"about_ca_topic_score_codex":0.0017935836,"about_ca_topic_score_gemma":0.000016614542,"teacher_disagreement_score":0.9852862,"about_ca_system_score_codex":0.20142466,"about_ca_system_score_gemma":0.18907407,"threshold_uncertainty_score":0.9999522},"labels":[],"label_agreement":null},{"id":"W1992085012","doi":"10.3109/10428194.2013.802313","title":"2-[18F]fluoro-2-deoxy-<scp>d</scp>-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta","keywords":"Medicine; Positron emission tomography; Nuclear medicine; Chronic lymphocytic leukemia; Positron Emission Tomography-Computed Tomography; Standardized uptake value; Positron emission; Radiology; PET-CT; Leukemia; Internal medicine","score_opus":0.005696234891551276,"score_gpt":0.2163362870837772,"score_spread":0.21064005219222592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992085012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859486,0.0030375782,0.0002930763,0.00008672396,0.0004200964,0.0048418934,0.00006027158,0.0007278075,0.004583949],"genre_scores_gemma":[0.9927925,0.0005833928,0.0013233438,0.0008200955,0.0004687246,0.00082034554,0.0011436407,0.00037227766,0.0016756929],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9885583,0.00065594463,0.0023514738,0.0024740591,0.0028929857,0.0030672236],"domain_scores_gemma":[0.99375355,0.000935641,0.0007927407,0.0018933564,0.0009539548,0.001670752],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011495885,0.0019235163,0.002076219,0.0026728408,0.00070271245,0.0005731488,0.0009775043,0.001331301,0.0001324463],"category_scores_gemma":[0.0002653324,0.0016663813,0.00063085515,0.0038942967,0.00088143797,0.0022941653,0.00039325145,0.00067800534,0.00027030913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005519064,0.0023074818,0.15771404,0.007241181,0.0026050704,0.0017464039,0.011710964,0.0025541482,0.025221743,0.0008530903,0.021730065,0.7607967],"study_design_scores_gemma":[0.118728444,0.0027372781,0.7769493,0.0020328043,0.0005446881,0.0010061046,0.0005415304,0.07106377,0.020451969,0.00020578774,0.004464586,0.0012737666],"about_ca_topic_score_codex":0.008067688,"about_ca_topic_score_gemma":0.00019033716,"teacher_disagreement_score":0.759523,"about_ca_system_score_codex":0.20972563,"about_ca_system_score_gemma":0.03221211,"threshold_uncertainty_score":0.9999652},"labels":[],"label_agreement":null},{"id":"W1992703709","doi":"10.1002/ajh.21970","title":"Concurrent chronic lymphocytic leukemia and prolymphocytic leukemia derived from two separate B‐cell clones","year":2010,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Prolymphocytic leukemia; CD5; Chronic lymphocytic leukemia; Biology; Population; Immunophenotyping; Molecular biology; Chlorambucil; Gene rearrangement; CD23; Lymphocytosis; Pathology; Leukemia; Flow cytometry; Immunology; Medicine; Antibody; Gene; Chemotherapy; Genetics","score_opus":0.009449893434788895,"score_gpt":0.2977117687352977,"score_spread":0.2882618753005088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992703709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283,0.00487356,0.00044154725,0.00027322318,0.0007350361,0.00039022366,0.00000947274,0.00005103308,0.00039591294],"genre_scores_gemma":[0.9962218,0.00085808284,0.001604749,0.00040336602,0.00067228044,0.000017368615,0.0000120827235,0.00007906548,0.00013123154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964591,0.0002242489,0.0011807722,0.000557345,0.0006687054,0.0009097815],"domain_scores_gemma":[0.99624157,0.00084455573,0.0010501815,0.0006397219,0.00041911448,0.0008048305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049697794,0.00046588902,0.0017164556,0.00037691987,0.00013027742,0.000054748318,0.00045306032,0.0001916097,0.00027519692],"category_scores_gemma":[0.00031559597,0.0003770748,0.00027725656,0.00042315345,0.001969104,0.00018472559,0.00020721939,0.0010676609,0.00013124652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006657748,0.00037190868,0.022405243,0.0016108273,0.0030532985,0.02081637,0.004399297,0.001539215,0.7242281,0.0029349192,0.0049597058,0.20702337],"study_design_scores_gemma":[0.19144703,0.011143997,0.005954985,0.0013355499,0.0022212465,0.19303335,0.002335666,0.15543741,0.42077464,0.0013397132,0.012875196,0.0021012041],"about_ca_topic_score_codex":0.002423134,"about_ca_topic_score_gemma":0.00021357775,"teacher_disagreement_score":0.30345345,"about_ca_system_score_codex":0.03725262,"about_ca_system_score_gemma":0.06939223,"threshold_uncertainty_score":0.9998681},"labels":[],"label_agreement":null},{"id":"W1993985043","doi":"10.1002/gepi.20284","title":"Linkage analyses of rheumatoid arthritis and related quantitative phenotypes: the GAW15 experience","year":2007,"lang":"en","type":"article","venue":"Genetic Epidemiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Public Health Service","keywords":"Linkage (software); Rheumatoid arthritis; Genetic linkage; Phenotype; Medicine; Genetics; Computational biology; Biology; Immunology; Gene","score_opus":0.10662544472471787,"score_gpt":0.43528440509259536,"score_spread":0.3286589603678775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993985043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93952125,0.05215847,0.0054621235,0.0006811451,0.0001043957,0.00030534834,0.0000027098158,0.000024141613,0.0017403954],"genre_scores_gemma":[0.9691498,0.018496344,0.01169561,0.00045000017,0.000033503005,0.000015110807,0.0000061447763,0.000016076754,0.00013736237],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976701,0.00043211994,0.0008575111,0.00036393132,0.00017428635,0.00050206296],"domain_scores_gemma":[0.99382436,0.0051550074,0.00022710163,0.00049345405,0.0001357057,0.00016435652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023603938,0.0001483562,0.0006417919,0.000116959556,0.00008209405,0.0000025925194,0.00015751457,0.00018228915,0.00019482203],"category_scores_gemma":[0.0065003918,0.00009677365,0.000093469214,0.0003180684,0.00125977,0.00002238119,0.00010952131,0.00025923242,0.000036164598],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003712099,0.0007137142,0.2543077,0.00083949405,0.0028651536,0.0017760962,0.05550011,0.0019026448,0.14699687,0.06132655,0.0066109407,0.46344867],"study_design_scores_gemma":[0.028064167,0.003929967,0.80707395,0.0014840612,0.00019072328,0.0068765976,0.014290204,0.05367192,0.04541051,0.030853475,0.0072499397,0.0009045148],"about_ca_topic_score_codex":0.0010815376,"about_ca_topic_score_gemma":0.000085411484,"teacher_disagreement_score":0.55276626,"about_ca_system_score_codex":0.00039480327,"about_ca_system_score_gemma":0.0006412555,"threshold_uncertainty_score":0.77820456},"labels":[],"label_agreement":null},{"id":"W1995133375","doi":"10.1002/ajh.10453","title":"Mcl‐1 and Bcl‐2/Bax ratio are associated with treatment response but not with Rai stage in B‐cell chronic lymphocytic leukemia","year":2003,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Saskatchewan; Royal University Hospital","funders":"Saskatchewan Health Research Foundation","keywords":"Chronic lymphocytic leukemia; Chlorambucil; Prednisone; Internal medicine; Medicine; Stage (stratigraphy); Gastroenterology; Apoptosis; Complete response; Bcl-2-associated X protein; Blot; Leukemia; Immunology; Chemotherapy; Chemistry; Biology; Caspase 3; Programmed cell death; Cyclophosphamide; Gene; Biochemistry","score_opus":0.013810373300852078,"score_gpt":0.2753354294564033,"score_spread":0.26152505615555127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995133375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756205,0.0011269421,0.0002069463,0.00039090906,0.00003399084,0.00037881854,0.000006706026,0.000018731733,0.00027492575],"genre_scores_gemma":[0.9973484,0.00028197985,0.00058161776,0.0002861466,0.000029153443,0.000021007478,0.0000029523865,0.00005598083,0.0013927331],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705845,0.0007241387,0.0006562791,0.00035527337,0.0005246993,0.0006811367],"domain_scores_gemma":[0.9970493,0.001135851,0.0008147338,0.00037346827,0.00025721276,0.0003694593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077855866,0.0003286163,0.0013443598,0.0004451696,0.00007370924,0.000023603154,0.00013275376,0.00010793945,0.00007594518],"category_scores_gemma":[0.00053972926,0.00021609305,0.00008541532,0.0005904644,0.00088716863,0.000106187166,0.000024666695,0.00037381548,0.000009912769],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.30862215,0.0042877207,0.3306429,0.0018664442,0.008523378,0.2401541,0.01650408,0.016940309,0.054558758,0.0033174814,0.0022255983,0.012357038],"study_design_scores_gemma":[0.4249922,0.11336841,0.04105117,0.0039381078,0.0015293333,0.17209375,0.023308335,0.012949973,0.19944644,0.00008409156,0.0052931136,0.0019450719],"about_ca_topic_score_codex":0.0007112196,"about_ca_topic_score_gemma":0.0005767783,"teacher_disagreement_score":0.28959173,"about_ca_system_score_codex":0.064255476,"about_ca_system_score_gemma":0.04700783,"threshold_uncertainty_score":0.95839477},"labels":[],"label_agreement":null},{"id":"W1995362916","doi":"10.1002/ajh.10044","title":"CD5‐negative phenotype of monoclonal B‐lymphocytosis of undetermined significance (MLUS)","year":2002,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Lymphocytosis; Immunophenotyping; CD5; Chronic lymphocytic leukemia; Monoclonal; Phenotype; Immunology; Pathology; Medicine; Leukemia; Monoclonal antibody; Biology; Lymphoma; Flow cytometry; Antibody; Genetics","score_opus":0.02587918797391073,"score_gpt":0.2973255777432644,"score_spread":0.27144638976935365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995362916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954764,0.0009778668,0.00075364555,0.00067658647,0.00009937307,0.00017394882,0.000008079323,0.000008158467,0.0018259268],"genre_scores_gemma":[0.99394387,0.00028339578,0.0053916164,0.00015446293,0.0000738206,0.0000040794575,7.972117e-7,0.00002669219,0.00012126541],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976127,0.00017851325,0.0010535156,0.0001971837,0.0005883649,0.00036973474],"domain_scores_gemma":[0.9965771,0.00091420684,0.001332892,0.00035161793,0.0005991322,0.0002250583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030983856,0.00018177548,0.0013736631,0.0003405768,0.000026502714,0.0000032499838,0.0003076377,0.00007722332,0.00053094415],"category_scores_gemma":[0.0006244657,0.0001466164,0.00026199134,0.00058269664,0.0014301975,0.000075653676,0.00006247621,0.00027108478,0.000019594083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044034723,0.011312016,0.08165597,0.00541533,0.013764088,0.014243451,0.028520519,0.0011271347,0.37529096,0.027645132,0.028200565,0.3687901],"study_design_scores_gemma":[0.06821139,0.028813612,0.006730995,0.0019273272,0.0013291698,0.04062885,0.0074105235,0.024654984,0.8145429,0.0032841382,0.0014871277,0.0009789887],"about_ca_topic_score_codex":0.00038806573,"about_ca_topic_score_gemma":0.000009410373,"teacher_disagreement_score":0.43925193,"about_ca_system_score_codex":0.0016777085,"about_ca_system_score_gemma":0.0023932667,"threshold_uncertainty_score":0.5978843},"labels":[],"label_agreement":null},{"id":"W1995389617","doi":"10.1007/s00280-002-0443-5","title":"Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute on Aging","keywords":"Fludarabine; Medicine; Toxicity; Creatinine; Internal medicine; Renal function; Gastroenterology; Chronic lymphocytic leukemia; Anemia; Neutropenia; Clinical endpoint; Interquartile range; Leukemia; Surgery; Cyclophosphamide; Chemotherapy; Clinical trial","score_opus":0.030700621468147726,"score_gpt":0.3453199439162757,"score_spread":0.31461932244812796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995389617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498564,0.0024812985,0.000013652905,0.00005326027,0.00006302207,0.002262051,0.00006524308,0.000033566863,0.000042255673],"genre_scores_gemma":[0.996933,0.0021883207,0.000061253995,0.00016204262,0.000017157508,0.0004001979,0.00004762402,0.000028664146,0.00016178392],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981207,0.0001294644,0.0006307546,0.0005280233,0.00019539004,0.0003956398],"domain_scores_gemma":[0.99889797,0.00031326036,0.00025698356,0.0002175351,0.00015956521,0.00015466429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018291379,0.00029243156,0.0012467336,0.00041654627,0.00004278144,0.000006358735,0.00011371808,0.00017783217,0.00045801152],"category_scores_gemma":[0.000058750393,0.00024086822,0.00011643263,0.0009529841,0.00041462784,0.000052553216,0.000043969216,0.0001435322,5.5240065e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021943603,0.003133655,0.91313297,0.0016827383,0.013504593,0.00015760052,0.0052606924,0.003989515,0.023885818,0.0000044554,0.00057507487,0.0127292955],"study_design_scores_gemma":[0.17516059,0.015281492,0.20447797,0.00032975405,0.0047912123,0.00002225296,0.00016587332,0.45783213,0.14150451,0.000009578984,0.000039461167,0.00038520072],"about_ca_topic_score_codex":0.002237302,"about_ca_topic_score_gemma":0.00015493932,"teacher_disagreement_score":0.708655,"about_ca_system_score_codex":0.011123573,"about_ca_system_score_gemma":0.0008504903,"threshold_uncertainty_score":0.99267256},"labels":[],"label_agreement":null},{"id":"W1995468478","doi":"10.1188/14.onf.95-98","title":"Second Malignancies in Chronic Lymphocytic Leukemia","year":2013,"lang":"en","type":"article","venue":"Oncology nursing forum","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Lymphocytosis; Asymptomatic; Rash; Biopsy; Chlorambucil; White blood cell; Leukemia; Complete blood count; Leukemia cutis; Dermatology; Internal medicine; Chemotherapy","score_opus":0.01873424114472745,"score_gpt":0.3275263863619733,"score_spread":0.30879214521724585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995468478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9071103,0.001986219,0.000055579483,0.0028675697,0.0005277086,0.0009831694,0.0000026395683,0.00012979128,0.08633706],"genre_scores_gemma":[0.98509234,0.000089179375,0.0007050565,0.0011182385,0.00024026143,0.0001816466,0.000020359785,0.000054470915,0.012498419],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99735665,0.00009766747,0.00046651802,0.00048096987,0.0003357114,0.0012624565],"domain_scores_gemma":[0.9987384,0.00023192275,0.00009522573,0.0005300621,0.00011846327,0.0002859311],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030012167,0.00024683503,0.000583722,0.00034632205,0.00010890641,0.000033482695,0.00022960517,0.0004127122,0.0028043967],"category_scores_gemma":[0.00013580873,0.00022630021,0.00011757693,0.00043655632,0.0005897816,0.00020940954,0.00008052697,0.0004315723,0.0015661559],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011442064,0.0005693711,0.0035457816,0.001064315,0.00029087122,0.003011826,0.0046116696,0.0011825367,0.13171725,0.007028659,0.47457466,0.37125888],"study_design_scores_gemma":[0.14468062,0.008926612,0.03496416,0.0050875028,0.00027830992,0.012407916,0.006170937,0.35804522,0.05090655,0.012797445,0.3639123,0.0018224266],"about_ca_topic_score_codex":0.0011815403,"about_ca_topic_score_gemma":0.0005809333,"teacher_disagreement_score":0.41261685,"about_ca_system_score_codex":0.49705192,"about_ca_system_score_gemma":0.084435076,"threshold_uncertainty_score":0.99921125},"labels":[],"label_agreement":null},{"id":"W1996227012","doi":"10.1016/j.clim.2009.03.425","title":"S.42. Potential Role for Serum Soluble CD200 in Human Chronic Lymphocytic Leukemia","year":2009,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Leukemia; Immunology; Medicine; Cancer research","score_opus":0.03562233132551081,"score_gpt":0.3909260613307588,"score_spread":0.355303730005248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996227012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899671,0.0036403374,0.0002586323,0.00093181035,0.00085703726,0.0012274288,0.0000072112994,0.00017250875,0.0029378983],"genre_scores_gemma":[0.99119866,0.00049187907,0.00040346937,0.0010724008,0.00092531514,0.00008051373,0.00007928079,0.000052887543,0.0056955763],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958139,0.00020697988,0.0013555019,0.0008257572,0.00029524826,0.0015026028],"domain_scores_gemma":[0.99785686,0.00048834836,0.00017949934,0.0010173112,0.00017691948,0.0002810894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001314612,0.00031288964,0.0010371152,0.0002646124,0.00015879452,0.000032404005,0.00051388494,0.0008362246,0.0004584253],"category_scores_gemma":[0.00092201185,0.0002952791,0.00044227735,0.00033485892,0.0005774505,0.00012021779,0.00019576555,0.00084911054,0.00033005016],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.025005385,0.0044595767,0.008539098,0.0010892709,0.0033367134,0.0052300477,0.000989353,0.0041216747,0.28441918,0.018643253,0.03372202,0.6104444],"study_design_scores_gemma":[0.42257708,0.0335756,0.15251124,0.001040047,0.00088181277,0.0027683561,0.00047743693,0.2506509,0.020294655,0.027875215,0.08522673,0.0021209065],"about_ca_topic_score_codex":0.0006005034,"about_ca_topic_score_gemma":0.00014579274,"teacher_disagreement_score":0.6083235,"about_ca_system_score_codex":0.0577323,"about_ca_system_score_gemma":0.027946703,"threshold_uncertainty_score":0.99994993},"labels":[],"label_agreement":null},{"id":"W1996903818","doi":"10.1038/sj.bmt.1705130","title":"Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease","year":2005,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver Hospital and Health Sciences Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Cumulative incidence; Internal medicine; Chronic lymphocytic leukemia; Leukemia; Incidence (geometry); Regimen; Graft-versus-host disease; Surgery; Gastroenterology; Relative risk; Total body irradiation; Confidence interval; Immunology; Transplantation; Chemotherapy; Cyclophosphamide","score_opus":0.04337975199462386,"score_gpt":0.3274287746393229,"score_spread":0.28404902264469906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996903818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971036,0.0024954008,0.015446444,0.00074558455,0.0004582636,0.00848716,0.0004322191,0.00051545625,0.0003834342],"genre_scores_gemma":[0.991949,0.00068067946,0.0020480978,0.00016793956,0.00061762414,0.0020582082,0.0015529477,0.0001716925,0.0007537882],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9952846,0.00022964018,0.00080102857,0.001138672,0.0011911199,0.0013549117],"domain_scores_gemma":[0.9927708,0.005134985,0.0003669042,0.00058257923,0.0005082867,0.0006364584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012776321,0.00069310644,0.0008840511,0.00035235,0.00046775807,0.000109533335,0.00028544682,0.00034187792,0.000053627173],"category_scores_gemma":[0.0014751737,0.0005995913,0.000504254,0.0006548899,0.00029609384,0.0006467752,0.000034576417,0.0003747858,0.000034456913],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7747906,0.0005511078,0.0025320093,0.0219662,0.0064882124,0.002126373,0.0058069667,0.076408386,0.050956175,0.0010810038,0.0034036327,0.05388934],"study_design_scores_gemma":[0.36871815,0.012409328,0.011084384,0.006250871,0.008320246,0.00024252049,0.00021994789,0.56456465,0.025273107,0.00006406594,0.0011100532,0.0017426552],"about_ca_topic_score_codex":0.00054579694,"about_ca_topic_score_gemma":0.001688291,"teacher_disagreement_score":0.4881563,"about_ca_system_score_codex":0.123602666,"about_ca_system_score_gemma":0.025717001,"threshold_uncertainty_score":0.99964553},"labels":[],"label_agreement":null},{"id":"W1997044577","doi":"10.3816/clm.2009.n.003","title":"Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Cancerfonden; McMaster University","keywords":"Monoclonal gammopathy of undetermined significance; Macroglobulinemia; Waldenstrom macroglobulinemia; Gammopathy; Medicine; Immunology; Immunoglobulin M; Polyclonal antibodies; Antibody; Etiology; Population; Monoclonal; Pathology; Multiple myeloma; Immunoglobulin G; Monoclonal antibody; Lymphoma","score_opus":0.05563567867414868,"score_gpt":0.3574969234013634,"score_spread":0.3018612447272147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997044577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918654,0.0007510817,0.00040648974,0.0031879398,0.00027781617,0.001021615,0.00008321634,0.00007483552,0.0023315812],"genre_scores_gemma":[0.99014896,0.000076447206,0.0068492265,0.0013047624,0.000816718,0.000031782416,0.000034639033,0.000054371856,0.00068309007],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946877,0.00022966342,0.0021617713,0.00092894223,0.0011812153,0.0008107098],"domain_scores_gemma":[0.9932013,0.0038248287,0.00058458047,0.0011584248,0.00047625368,0.0007545708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018361816,0.00045930906,0.0012743584,0.0002479144,0.00017897847,0.00004117303,0.00060565345,0.00044688536,0.00006652704],"category_scores_gemma":[0.0056275013,0.00035037898,0.0004585523,0.000891456,0.00086396316,0.000111211535,0.0002803106,0.00047463577,0.000043785945],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015174349,0.003479225,0.27988905,0.0006917435,0.00047913176,0.0014748242,0.0016322598,0.00026062553,0.032703638,0.012552772,0.005372003,0.64629036],"study_design_scores_gemma":[0.01722147,0.0026709267,0.96009666,0.0005724313,0.0002327671,0.00198205,0.00026520636,0.010120379,0.004242905,0.0009583187,0.0012183768,0.0004185154],"about_ca_topic_score_codex":0.00031441532,"about_ca_topic_score_gemma":0.00006233042,"teacher_disagreement_score":0.6802076,"about_ca_system_score_codex":0.0015175209,"about_ca_system_score_gemma":0.005933968,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W1997050616","doi":"10.1158/1535-7163.targ-11-a201","title":"Abstract A201: The potent STAT3/5 inhibitor, BP-1–102, demonstrates significant antitumor activity against Waldenstrom macroglobulinemia.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"STAT3; Cancer research; Macroglobulinemia; Waldenstrom macroglobulinemia; Biology; Cell growth; Transcription factor; Carcinogenesis; STAT5; Lymphoma; Signal transduction; Gene; Immunology; Multiple myeloma; Cell biology; Genetics","score_opus":0.05389147754549747,"score_gpt":0.3120570654793618,"score_spread":0.25816558793386435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997050616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876723,0.0039003773,0.00074765325,0.0012218531,0.0004181141,0.001076131,0.000068766734,0.00013223419,0.0047625266],"genre_scores_gemma":[0.9948938,0.0013748995,0.00054107606,0.002345846,0.00023191462,0.0001283411,0.000018499682,0.000108260814,0.0003573593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99676216,0.0001327412,0.00045081953,0.0006345018,0.0009770689,0.0010426965],"domain_scores_gemma":[0.9980356,0.00008860032,0.00020244239,0.0010696993,0.0002607628,0.00034287863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045316367,0.00045359103,0.00047497658,0.00010524266,0.00021679843,0.000083497776,0.00046871265,0.00022389136,0.00030190646],"category_scores_gemma":[0.000024003068,0.00031856424,0.00029023812,0.00038273822,0.00056490535,0.000087261426,0.00014839345,0.0007785916,0.000092093265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001580913,0.0010334995,0.0023977484,0.00029730695,0.0015424563,0.0035664628,0.0016054104,0.00013499867,0.8534573,0.00031385853,0.0008048003,0.13326526],"study_design_scores_gemma":[0.010398047,0.0004949025,0.016753258,0.00031141925,0.00053117506,0.00022259053,0.0007680926,0.0036839726,0.955817,0.0002303281,0.0100288205,0.0007603787],"about_ca_topic_score_codex":0.0017698448,"about_ca_topic_score_gemma":0.00006584786,"teacher_disagreement_score":0.13250488,"about_ca_system_score_codex":0.0038569851,"about_ca_system_score_gemma":0.0051140925,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W1997316354","doi":"10.3109/10428194.2014.999326","title":"A classification tree approach for improving the utilization of flow cytometry testing of blood specimens for B-cell non-Hodgkin lymphoproliferative disorders","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Health Research Board; University of Calgary","keywords":"Flow cytometry; Logistic regression; Medicine; Receiver operating characteristic; Cytometry; Lymphoproliferative disorders; Immunology; Pathology; Internal medicine; Lymphoma","score_opus":0.055364893703796506,"score_gpt":0.2964314999325053,"score_spread":0.2410666062287088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997316354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9285345,0.0018880062,0.058536984,0.00009354432,0.00022471011,0.005147305,0.0001924205,0.00013035903,0.0052521816],"genre_scores_gemma":[0.9516978,0.00013433263,0.04542651,0.00015333155,0.00042965423,0.0009305298,0.00034787893,0.00017145406,0.00070848357],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9950003,0.00016986023,0.001493648,0.0011794929,0.0011038473,0.001052864],"domain_scores_gemma":[0.99444604,0.0016353737,0.0009792248,0.0011752453,0.0012652455,0.0004988823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017441227,0.00070873694,0.0012588252,0.0005490606,0.00036202502,0.00009070616,0.00059261965,0.00056803215,0.0000055992173],"category_scores_gemma":[0.0019508413,0.00055887626,0.00042298462,0.0014858245,0.0007839132,0.00032141636,0.00025059422,0.00013806646,0.000003065943],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016048552,0.0043211817,0.015487017,0.013896529,0.0018645047,0.000038187274,0.013149253,0.0032809034,0.28291053,0.0028507907,0.0050292118,0.64112335],"study_design_scores_gemma":[0.08688538,0.0021220918,0.006482154,0.00022212451,0.0010505288,0.0002945063,0.0035687229,0.8084284,0.08918306,0.00040516932,0.00078193215,0.0005759027],"about_ca_topic_score_codex":0.001171565,"about_ca_topic_score_gemma":0.000045197783,"teacher_disagreement_score":0.8051475,"about_ca_system_score_codex":0.015254283,"about_ca_system_score_gemma":0.024861652,"threshold_uncertainty_score":0.9996863},"labels":[],"label_agreement":null},{"id":"W1997766168","doi":"10.1182/blood-2010-03-276683","title":"Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies","year":2010,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Relative risk; Chronic lymphocytic leukemia; Incidence (geometry); Meta-analysis; Lymphoma; Publication bias; Cohort study; Observational study; Funnel plot; Non-Hodgkin's lymphoma; Leukemia; Confidence interval","score_opus":0.25617793931876187,"score_gpt":0.41429120796920377,"score_spread":0.1581132686504419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997766168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03134817,0.96695185,0.000013000909,0.00005022594,0.000030272726,0.0010913428,0.0003140478,0.000015853759,0.00018522414],"genre_scores_gemma":[0.0014855309,0.9888134,0.00785343,0.000009523453,0.000089862595,0.0002508867,0.0005118087,0.000050939227,0.000934636],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99598664,0.00019680664,0.001725626,0.00053195894,0.0012298251,0.00032912754],"domain_scores_gemma":[0.99572784,0.0018270443,0.0010881191,0.00054714264,0.000661781,0.00014807493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015778049,0.00041744922,0.006270258,0.0007196171,0.00009013851,0.000009824803,0.00022996854,0.00056242937,0.00010964558],"category_scores_gemma":[0.00057219254,0.00030471932,0.0016381686,0.0013243811,0.000102933875,0.000032403943,0.00014951141,0.00031005943,0.0000040407567],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013222944,0.0018116871,0.0007861583,0.025881141,0.8990119,0.000022489305,0.001151762,6.3719267e-7,0.000095246985,0.0000059929584,0.0000920977,0.07112762],"study_design_scores_gemma":[0.008954643,0.00008926304,0.001252627,0.0006758194,0.9156613,0.000010931155,0.000042869793,0.000007297225,0.0007645,0.000004077556,0.07228833,0.0002483795],"about_ca_topic_score_codex":0.00006497849,"about_ca_topic_score_gemma":0.000121281744,"teacher_disagreement_score":0.07219623,"about_ca_system_score_codex":0.0014898167,"about_ca_system_score_gemma":0.01056111,"threshold_uncertainty_score":0.9999405},"labels":[],"label_agreement":null},{"id":"W1998679305","doi":"10.1016/s0168-8278(09)60958-2","title":"956 PHARMACOKINETICS, TOLERABILITY AND EFFECT OF FOOD ON HCV POLYMERASE INHIBITOR ABT-333 FOLLOWING SINGLE ASCENDING DOSES IN HEALTHY ADULT VOLUNTEERS","year":2009,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Pharmacokinetics; Tolerability; Pharmacology; Medicine; Bioequivalence; Adverse effect","score_opus":0.014708674378381135,"score_gpt":0.32800292902786027,"score_spread":0.31329425464947913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998679305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945204,0.0022433724,0.000011759064,0.0022183387,0.00048804397,0.00032216878,0.000003054103,0.000010216806,0.00018259884],"genre_scores_gemma":[0.9987541,0.00014652024,0.00016833955,0.00067523227,0.00022770357,0.000002182297,0.0000015757294,0.000017324937,0.000007039765],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99748427,0.00036831925,0.00094085507,0.00024941188,0.000490882,0.00046628725],"domain_scores_gemma":[0.9982667,0.00080710335,0.00030651691,0.00020723887,0.00013336231,0.00027905556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094714476,0.00020425783,0.0010300283,0.00048821984,0.000042511223,0.000010366012,0.00012476044,0.00016215767,0.00002250552],"category_scores_gemma":[0.0012729596,0.00016057985,0.00022000153,0.00024574957,0.0001280136,0.00009655615,0.000036262638,0.0005765006,0.000001912745],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056547344,0.003434804,0.6496198,0.0020818121,0.0007600371,0.0055560065,0.0021853973,0.00012300228,0.19895281,0.00015210587,0.0018310728,0.07875578],"study_design_scores_gemma":[0.16385804,0.115276486,0.023399046,0.002694828,0.00061500876,0.007181182,0.00037963927,0.0074479165,0.6777416,0.00023292765,0.00056551606,0.00060782174],"about_ca_topic_score_codex":0.0001823967,"about_ca_topic_score_gemma":0.0000525866,"teacher_disagreement_score":0.62622076,"about_ca_system_score_codex":0.0033965784,"about_ca_system_score_gemma":0.001300035,"threshold_uncertainty_score":0.8881934},"labels":[],"label_agreement":null},{"id":"W1998900344","doi":"10.1188/08.cjon.417-423","title":"Caring for Patients With Chronic Lymphocytic Leukemia","year":2008,"lang":"en","type":"review","venue":"Clinical journal of oncology nursing","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Anxiety; Quality of life (healthcare); Depression (economics); Incidence (geometry); Disease; Intensive care medicine; Population; Leukemia; Psychiatry; Internal medicine; Nursing","score_opus":0.12066241587566197,"score_gpt":0.48674211284536206,"score_spread":0.3660796969697001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998900344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015442169,0.99342847,0.00030253854,0.000047020392,0.0020699624,0.0017729329,0.000010437795,0.000025677333,0.00079873856],"genre_scores_gemma":[0.00032026882,0.99221224,0.0033324528,0.00011348599,0.0035677203,0.000029471965,0.000045827474,0.00016064514,0.00021790605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99384826,0.00048597515,0.003404694,0.0005726753,0.0008164305,0.0008719644],"domain_scores_gemma":[0.9899914,0.004904999,0.0026965612,0.00059233536,0.00106827,0.0007464038],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012519861,0.00056355743,0.0056800735,0.00050087145,0.00016698362,0.000024428153,0.00057781686,0.0013750037,0.000026998905],"category_scores_gemma":[0.0019290518,0.0003732411,0.0019581844,0.0004006687,0.001144441,0.00012503368,0.00007951347,0.002140627,0.000030420575],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0013027228,0.00038873358,0.00006716307,0.005064713,0.0010851785,0.00096980226,0.000048673315,0.000017271215,3.272441e-8,0.000008586283,0.0066308263,0.9844163],"study_design_scores_gemma":[0.043488596,0.014078229,0.000056154968,0.064865306,0.004212834,0.011756128,0.0000116942665,0.00032242906,3.268045e-7,0.000020863252,0.8608688,0.0003186519],"about_ca_topic_score_codex":0.000009782229,"about_ca_topic_score_gemma":0.0000025650363,"teacher_disagreement_score":0.98409766,"about_ca_system_score_codex":0.32751402,"about_ca_system_score_gemma":0.34429336,"threshold_uncertainty_score":0.99992144},"labels":[],"label_agreement":null},{"id":"W1999005132","doi":"10.3816/clm.2009.n.001","title":"Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; International Waldenstrom's Macroglobulinemia Foundation","keywords":"Waldenstrom macroglobulinemia; Macroglobulinemia; Medicine; Immunology; Lymphoma; Multiple myeloma","score_opus":0.0522128022844153,"score_gpt":0.42570897067548746,"score_spread":0.37349616839107214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999005132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97293264,0.004146691,0.000029572402,0.016204195,0.00056884636,0.0010708763,0.00007749737,0.000054604556,0.0049150614],"genre_scores_gemma":[0.98873466,0.005879846,0.0006269907,0.0024291999,0.0015320135,0.00007252073,0.00018496692,0.000029731918,0.0005100598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955332,0.00041397839,0.0016797328,0.0009884428,0.0007600792,0.00062451116],"domain_scores_gemma":[0.9935169,0.004219574,0.00048261904,0.0013390104,0.00019941521,0.00024244562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010950166,0.00043615137,0.0010080058,0.000112252696,0.0001245213,0.00006075552,0.0007409191,0.00047808312,0.00013172456],"category_scores_gemma":[0.0020497758,0.00023845231,0.00038224488,0.00040076365,0.0009058983,0.000103456994,0.00016132275,0.00038999316,0.000047963193],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002777645,0.0014303768,0.059349336,0.000011959621,0.00016342335,0.0039685587,0.000397276,0.000010959545,0.00011816436,0.00059433474,0.0017497727,0.9294282],"study_design_scores_gemma":[0.04299624,0.0041274563,0.81287676,0.0006887246,0.00031345512,0.006391182,0.0011874972,0.0033317867,0.00066736795,0.003584287,0.12328666,0.00054858247],"about_ca_topic_score_codex":0.0006500637,"about_ca_topic_score_gemma":0.0003085819,"teacher_disagreement_score":0.9288796,"about_ca_system_score_codex":0.0024486377,"about_ca_system_score_gemma":0.0018331043,"threshold_uncertainty_score":0.9723803},"labels":[],"label_agreement":null},{"id":"W1999410989","doi":"10.1007/s00281-010-0196-x","title":"ZAP70: a master regulator of adaptive immunity","year":2010,"lang":"en","type":"review","venue":"Seminars in Immunopathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"ZAP70; Biology; T cell; Cell biology; Immunology; Natural killer T cell; Immune system","score_opus":0.055113725573657374,"score_gpt":0.36012156695496234,"score_spread":0.305007841381305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999410989","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058940086,0.9881244,0.0000047434532,0.000014925209,0.00057931774,0.001585665,0.00004245559,0.00003579649,0.0037187461],"genre_scores_gemma":[0.00057879125,0.99404764,0.0011575178,0.000025361149,0.0001288504,0.0002254095,0.00013782812,0.00013755269,0.0035610353],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580866,0.00072708644,0.0015146049,0.0006869619,0.0004605706,0.00080212305],"domain_scores_gemma":[0.9960974,0.00075466454,0.0006444609,0.0021737698,0.0001947789,0.00013493051],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0016280321,0.000613517,0.0038532473,0.00093597744,0.00004645397,0.000009265776,0.0007557601,0.0016999082,0.00033814978],"category_scores_gemma":[0.00082144735,0.0005105394,0.00063966296,0.00081398606,0.00107717,0.000058567763,0.00070587365,0.002978442,0.0002362887],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00032585944,0.00030576022,0.000025043617,0.011581748,0.00013154514,0.001952974,0.000471637,1.2495698e-7,0.00019142311,0.00017534419,0.00019549772,0.98464304],"study_design_scores_gemma":[0.006491114,0.0012521184,0.00010939091,0.05253252,0.00091550086,0.017044595,0.00020838683,0.000028266213,0.00015278594,0.00015714834,0.9205044,0.0006037769],"about_ca_topic_score_codex":0.00013940048,"about_ca_topic_score_gemma":0.000018841709,"teacher_disagreement_score":0.98403925,"about_ca_system_score_codex":0.005873549,"about_ca_system_score_gemma":0.010311964,"threshold_uncertainty_score":0.99973464},"labels":[],"label_agreement":null},{"id":"W1999436010","doi":"10.1182/blood-2007-05-091561","title":"A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Cancer Research UK; McMaster University","keywords":"Genetics; Single-nucleotide polymorphism; Chronic lymphocytic leukemia; Genetic linkage; Biology; Linkage disequilibrium; Locus (genetics); SNP array; Tag SNP; SNP; Gene; Leukemia; Genotype","score_opus":0.023511494643919655,"score_gpt":0.2996658984186277,"score_spread":0.276154403774708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999436010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357945,0.0017479119,0.0016881356,0.000053160005,0.00017583354,0.0018781368,0.000047329508,0.00016058926,0.0006694459],"genre_scores_gemma":[0.99445987,0.00038597046,0.0015346266,0.000095103205,0.0006375328,0.00004933818,0.00016446707,0.000085022366,0.0025880523],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99554014,0.00009947414,0.0009924059,0.00087008206,0.0011882326,0.0013096621],"domain_scores_gemma":[0.99600124,0.0011782186,0.0001857994,0.0014163624,0.0007935501,0.00042481732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026537282,0.0003927519,0.0009924273,0.00041052158,0.00020597587,0.000045813835,0.00047368484,0.0003802899,0.0002267955],"category_scores_gemma":[0.0011163553,0.00036475377,0.00040655394,0.0006656222,0.00078351615,0.00014891525,0.0003589882,0.0004155706,0.00015776591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009579428,0.0042371955,0.039932694,0.03488803,0.0048959847,0.0029645234,0.008033231,0.002462043,0.867936,0.0012809994,0.0049500777,0.018839775],"study_design_scores_gemma":[0.082831055,0.0015875228,0.10158589,0.00036934513,0.0008055749,0.00030603964,0.0010403001,0.003221271,0.80620456,0.00048519424,0.00093249045,0.0006307603],"about_ca_topic_score_codex":0.009237391,"about_ca_topic_score_gemma":0.0022552735,"teacher_disagreement_score":0.07325163,"about_ca_system_score_codex":0.04788532,"about_ca_system_score_gemma":0.028614078,"threshold_uncertainty_score":0.99988043},"labels":[],"label_agreement":null},{"id":"W1999588603","doi":"10.1182/blood-2010-05-285999","title":"Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; University of Toronto","keywords":"Chronic lymphocytic leukemia; STAT3; Cancer research; Biology; Phosphorylation; Signal transduction; STAT1; STAT protein; Interferon; Tyrosine phosphorylation; Protein tyrosine phosphatase; Leukemia; Immunology; Cell biology","score_opus":0.03430936399196056,"score_gpt":0.26136207185677274,"score_spread":0.2270527078648122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999588603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98614186,0.0017743007,0.00007617939,0.00002638538,0.000094458,0.0005971223,0.000012722428,0.00022598609,0.011050979],"genre_scores_gemma":[0.99620694,0.00011838591,0.00034114215,0.00031374113,0.00021979831,0.000075141084,0.000032207918,0.000100227946,0.002592435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972333,0.000078541954,0.00042901532,0.0006113827,0.0007471603,0.0009006125],"domain_scores_gemma":[0.99818796,0.00014823608,0.00029202717,0.0007278178,0.00027243875,0.0003715303],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031007838,0.000361119,0.0006179268,0.00019603134,0.00012857362,0.000034923294,0.00032391128,0.00024360497,0.0010927801],"category_scores_gemma":[0.00025873532,0.0002754421,0.0001583146,0.00046027612,0.00028882048,0.00012827222,0.00014590296,0.00040571683,0.00035624503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040143292,0.019485284,0.033454385,0.0112468675,0.07320511,0.22405416,0.16707988,0.00094851037,0.30686283,0.0023832659,0.05662831,0.06450811],"study_design_scores_gemma":[0.24970207,0.0074231117,0.003640011,0.007927519,0.0029804274,0.007408275,0.00076578953,0.017681407,0.700077,0.0002713617,0.0006547981,0.0014682155],"about_ca_topic_score_codex":0.0013902517,"about_ca_topic_score_gemma":0.00009842574,"teacher_disagreement_score":0.3932142,"about_ca_system_score_codex":0.054966837,"about_ca_system_score_gemma":0.038350612,"threshold_uncertainty_score":0.9999698},"labels":[],"label_agreement":null},{"id":"W2000996016","doi":"10.1586/14737167.2014.861742","title":"Cost–effectiveness of abatacept for moderate-to-severe rheumatoid arthritis","year":2013,"lang":"en","type":"review","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Abatacept; Medicine; Rheumatoid arthritis; Rituximab; Internal medicine; Rheumatology; Antirheumatic Agents; Antirheumatic drugs; Clinical trial; Intensive care medicine; Physical therapy","score_opus":0.11924781409295578,"score_gpt":0.5584130695508618,"score_spread":0.439165255457906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000996016","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000068129564,0.9700741,0.00013718886,0.00025478206,0.00045517497,0.027420852,0.00058415806,0.000038355178,0.0009672621],"genre_scores_gemma":[0.000026580106,0.9835632,0.00180109,0.00041178352,0.00023430388,0.012244616,0.00055312744,0.0003165957,0.0008487143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99062663,0.0018382301,0.003284443,0.0014196126,0.0012709651,0.0015601085],"domain_scores_gemma":[0.9867151,0.0076660397,0.0007864941,0.0020204536,0.0018632392,0.0009486764],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008536031,0.0009992268,0.009658521,0.0011853664,0.00015298414,0.000069640395,0.0016150724,0.00048998505,0.0019345853],"category_scores_gemma":[0.002532934,0.0007892465,0.002496879,0.00088613713,0.0004619918,0.00025390956,0.0010197969,0.0013018433,0.0007392487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002247126,0.00022577126,0.0000025062773,0.3483749,0.000992182,0.0000152361945,0.000064793596,0.0000028404033,0.000023108732,0.00014308933,0.02837557,0.62155527],"study_design_scores_gemma":[0.007123838,0.0002897383,9.16725e-7,0.21988228,0.00014188157,0.00017142872,0.000025871414,0.000234645,0.00048085485,0.000024692938,0.7711293,0.0004945195],"about_ca_topic_score_codex":0.0005047759,"about_ca_topic_score_gemma":0.000005596127,"teacher_disagreement_score":0.74275374,"about_ca_system_score_codex":0.012813628,"about_ca_system_score_gemma":0.017698858,"threshold_uncertainty_score":0.99945587},"labels":[],"label_agreement":null},{"id":"W2002092032","doi":"10.1016/j.clml.2015.03.002","title":"A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia","year":2015,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Hôpital du Sacré-Cœur de Montréal; Ottawa Hospital; Dalhousie University; Foothills Medical Centre","funders":"Lundbeck Canada","keywords":"Medicine; Fludarabine; Bendamustine; Chlorambucil; Obinutuzumab; Rituximab; Ofatumumab; Chronic lymphocytic leukemia; Ibrutinib; Chemoimmunotherapy; Alemtuzumab; Internal medicine; Oncology; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma; Transplantation","score_opus":0.12119501693494986,"score_gpt":0.42049155741971544,"score_spread":0.2992965404847656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002092032","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022065719,0.9704333,0.0000032578603,0.00061042205,0.0011918918,0.005839307,0.00039570619,0.00021328864,0.019106276],"genre_scores_gemma":[0.005052629,0.9826212,0.000051055755,0.0007020383,0.003773431,0.00095873565,0.00037310988,0.00047895996,0.00598886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9880324,0.0010302671,0.0040096133,0.0025317979,0.0020315258,0.0023644175],"domain_scores_gemma":[0.984382,0.0054435423,0.0014816885,0.004765491,0.001218909,0.002708382],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0023649503,0.00208815,0.008071879,0.0010295529,0.00043828934,0.00012407317,0.0018628027,0.0025672296,0.0006239396],"category_scores_gemma":[0.0030750523,0.0012914009,0.0040319515,0.0019868063,0.0017851784,0.00011546272,0.00039457373,0.0010912673,0.003494156],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005318446,0.00029501712,0.0000062665445,0.00398664,0.002385674,0.0023407503,0.000231578,0.00004443808,8.7375575e-8,0.0019419161,0.012938129,0.97529763],"study_design_scores_gemma":[0.019972095,0.006791871,0.00014459284,0.013644815,0.003812043,0.0019288321,0.00013240222,0.0033578076,0.0000075300954,0.00036878942,0.9487739,0.0010652774],"about_ca_topic_score_codex":0.223345,"about_ca_topic_score_gemma":0.044428088,"teacher_disagreement_score":0.9742324,"about_ca_system_score_codex":0.8437404,"about_ca_system_score_gemma":0.63599193,"threshold_uncertainty_score":0.999186},"labels":[],"label_agreement":null},{"id":"W2002970935","doi":"10.1038/sj.leu.2405042","title":"The BCL-2 promoter (−938C&gt;A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia","year":2007,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancerfonden; Cancer Research Society","keywords":"IGHV@; Chronic lymphocytic leukemia; Genotype; Biology; CD38; Oncology; Internal medicine; Immunology; Gene; Leukemia; Genetics; Medicine; Stem cell","score_opus":0.03896092242002661,"score_gpt":0.3598508428679902,"score_spread":0.32088992044796355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002970935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98541075,0.0015117057,0.00028791252,0.0011366913,0.0016110669,0.002081568,0.000019819621,0.0003741406,0.0075663733],"genre_scores_gemma":[0.97273684,0.00072497834,0.00040607675,0.0016235397,0.0024233907,0.00012322167,0.000036675632,0.00017248216,0.021752829],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9911512,0.00032982617,0.002729767,0.0013387053,0.0019427749,0.0025077132],"domain_scores_gemma":[0.99382925,0.00234812,0.00040664847,0.0023045596,0.00022164117,0.0008897579],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0066276975,0.0007089057,0.0012358872,0.00043412464,0.00038423715,0.0001528746,0.0011478753,0.0008888385,0.00025429664],"category_scores_gemma":[0.0018263723,0.00043003887,0.0006019822,0.0009581634,0.0011823456,0.00026069727,0.00058979535,0.001888664,0.0009465076],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.032680575,0.0010073341,0.2933979,0.0052687456,0.0033660568,0.031138439,0.0044410154,0.002215604,0.0640976,0.010596954,0.04447703,0.5073128],"study_design_scores_gemma":[0.1892179,0.003530007,0.33719328,0.002087454,0.0007614035,0.003937284,0.000624745,0.18079737,0.032700755,0.0012581444,0.2448909,0.003000782],"about_ca_topic_score_codex":0.003217946,"about_ca_topic_score_gemma":0.0022678624,"teacher_disagreement_score":0.504312,"about_ca_system_score_codex":0.3399936,"about_ca_system_score_gemma":0.07908624,"threshold_uncertainty_score":0.9998314},"labels":[],"label_agreement":null},{"id":"W2004660087","doi":"10.1515/dmdi.2008.23.3-4.291","title":"Pharmacokinetics of Cladribine in a Rat Model Following Subcutaneous and Intra-arterial Injections","year":2008,"lang":"en","type":"article","venue":"Drug metabolism and drug interactions","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Pharmacokinetics; Bioavailability; Chemistry; Pharmacology; Intravenous bolus; Plasma concentration; Subcutaneous injection; Cladribine; Plasma levels; Bolus (digestion); Plasma clearance; Internal medicine; Medicine","score_opus":0.020257041333493233,"score_gpt":0.3058825685285855,"score_spread":0.28562552719509227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004660087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571925,0.0011344615,0.00021279912,0.00050473865,0.0006974707,0.00035364923,0.000026511922,0.00003790072,0.0013131882],"genre_scores_gemma":[0.99486744,0.0014562071,0.00096708525,0.00013665584,0.0002108701,0.000037335594,0.000020675185,0.000026664115,0.0022770478],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986176,0.00007267186,0.00044319438,0.0003118914,0.00026155793,0.0002930945],"domain_scores_gemma":[0.9992011,0.00020332256,0.00007478161,0.00023576035,0.00009357821,0.00019144721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016628082,0.00018345584,0.00045766486,0.00039023225,0.00014115177,0.000019487292,0.00006883659,0.000042799213,0.000061452505],"category_scores_gemma":[0.00012634136,0.00016918851,0.000107777625,0.00033638955,0.00018125837,0.00022401012,0.00009086848,0.0003650676,0.0000056590366],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008335761,0.00428222,0.0059795207,0.0011521771,0.0014582276,0.004167765,0.09631075,0.0076747,0.79881084,0.0040156865,0.037998047,0.029814292],"study_design_scores_gemma":[0.08493039,0.00028197697,0.0032454154,0.00078540423,0.0018882398,0.020477843,0.006898025,0.71350205,0.112828635,0.0014102855,0.05226138,0.0014903367],"about_ca_topic_score_codex":0.0010455174,"about_ca_topic_score_gemma":0.00027405535,"teacher_disagreement_score":0.70582736,"about_ca_system_score_codex":0.0003990904,"about_ca_system_score_gemma":0.00080955523,"threshold_uncertainty_score":0.68993074},"labels":[],"label_agreement":null},{"id":"W2005900338","doi":"10.1182/blood-2011-08-371989","title":"Fludarabine and rituximab for relapsed or refractory hairy cell leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency","keywords":"Cladribine; Pentostatin; Fludarabine; Rituximab; Medicine; Purine analogue; Refractory (planetary science); Internal medicine; Hairy cell leukemia; Oncology; Leukemia; Gastroenterology; Chemotherapy; Lymphoma; Purine; Cyclophosphamide; Biology","score_opus":0.028515785185283162,"score_gpt":0.3005836549119431,"score_spread":0.27206786972665997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005900338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886331,0.004790025,0.00009953466,0.00017127555,0.00019138725,0.0008442379,0.000019285202,0.00010581235,0.005145363],"genre_scores_gemma":[0.9823569,0.0002664519,0.004680583,0.00030307463,0.0008094314,0.0001065293,0.000036793717,0.000063912295,0.011376347],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998426,0.000034323086,0.0002644872,0.00029314874,0.00032941898,0.00065257464],"domain_scores_gemma":[0.9986384,0.0003395889,0.00006281644,0.00046040933,0.000093755196,0.00040504808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043892162,0.00018530565,0.0003796384,0.000100683596,0.00009606158,0.000019014673,0.00010197192,0.00019037326,0.0001555197],"category_scores_gemma":[0.00040237067,0.00013878032,0.0000837425,0.00014213669,0.00011817348,0.00015473623,0.00008988565,0.00024013354,0.00011679096],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03451584,0.06661489,0.024775496,0.024120945,0.0029679434,0.0023040685,0.011934368,0.0000058896508,0.42764977,0.0025052186,0.29163527,0.110970296],"study_design_scores_gemma":[0.5544461,0.0029078869,0.004716941,0.0003756283,0.0012576358,0.0020501707,0.00049024203,0.0018558834,0.17116436,0.0001177929,0.25982177,0.000795544],"about_ca_topic_score_codex":0.00009419919,"about_ca_topic_score_gemma":0.000011644303,"teacher_disagreement_score":0.5199303,"about_ca_system_score_codex":0.002481084,"about_ca_system_score_gemma":0.003519637,"threshold_uncertainty_score":0.6487949},"labels":[],"label_agreement":null},{"id":"W2007650429","doi":"10.1111/j.1365-2249.2009.04003.x","title":"Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells","year":2009,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Immunogenicity; Immunology; Chronic lymphocytic leukemia; Medicine; Microtubule; Biology; Virology; Leukemia; Antibody; Cell biology","score_opus":0.032544594612560394,"score_gpt":0.3901428019795532,"score_spread":0.3575982073669928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007650429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771619,0.019847568,0.00006273968,0.00036553646,0.0006566747,0.0009322459,0.0000035806759,0.00007732682,0.0008924276],"genre_scores_gemma":[0.9970037,0.0012787696,0.00024505777,0.0005219224,0.0003372213,0.000055575198,0.000019849402,0.000028845085,0.00050907297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99681926,0.0003379984,0.0012045712,0.0005745764,0.00036127688,0.00070233305],"domain_scores_gemma":[0.9979305,0.00048973766,0.00032931313,0.0010064781,0.00012483573,0.00011908082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008461594,0.0002909965,0.0007880918,0.000098597215,0.00017439027,0.00002224601,0.00056452135,0.0003838095,0.00037987638],"category_scores_gemma":[0.00020426183,0.00020934227,0.00043948388,0.00029201634,0.0013989856,0.00011621611,0.00025333525,0.00060829904,0.00028889297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015583753,0.0006678882,0.00005928782,0.0000329091,0.00024419194,0.000050137918,0.0003347343,0.000015440706,0.99008685,0.0002306647,0.00029573377,0.0064237756],"study_design_scores_gemma":[0.01360823,0.0044266963,0.0019127998,0.00014161294,0.0000824752,0.00032531144,0.00038613318,0.00203932,0.9754513,0.00008762475,0.0013440038,0.00019450071],"about_ca_topic_score_codex":0.0002603955,"about_ca_topic_score_gemma":0.000004613016,"teacher_disagreement_score":0.019841785,"about_ca_system_score_codex":0.012665915,"about_ca_system_score_gemma":0.0054439846,"threshold_uncertainty_score":0.9911243},"labels":[],"label_agreement":null},{"id":"W2007718183","doi":"10.2217/imt.13.81","title":"Ustekinumab for the Treatment of Crohn‘s Disease","year":2013,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Genentech; ActoGeniX; Zalicus; Janssen Biotech; Wyeth","keywords":"Ustekinumab; Medicine; Crohn's disease; Psoriasis; Monoclonal antibody; Disease; Immunology; Immune system; Monoclonal; Crohn disease; Inflammatory bowel disease; Antibody; Tumor necrosis factor alpha; Internal medicine; Adalimumab","score_opus":0.09589915221036092,"score_gpt":0.41507802521478165,"score_spread":0.3191788730044207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007718183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004374121,0.9919026,0.00009656829,0.000082448954,0.00023900495,0.0073821256,0.00009998921,0.000028683793,0.00012482647],"genre_scores_gemma":[0.000007575712,0.9835545,0.00015959318,0.000047647012,0.00038067508,0.0031786258,0.00010097332,0.00012688144,0.012443544],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982812,0.00007323539,0.00058743986,0.00033053843,0.00035041463,0.00037717153],"domain_scores_gemma":[0.9969922,0.0010658483,0.00025755417,0.0014274297,0.00013734757,0.00011966899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014387438,0.00040280263,0.0016042558,0.000116832605,0.000081525424,0.0000323072,0.00033161332,0.0001815013,0.00048593263],"category_scores_gemma":[0.00004408205,0.000189704,0.0013528015,0.00018687763,0.00020155103,0.000027050159,0.000018360854,0.0001150386,0.00012776408],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003883885,0.00034786522,2.4866682e-7,0.007483382,0.0013796375,0.000030774852,0.0001035834,3.450962e-7,0.0000011518838,0.00011252556,0.0011391948,0.9890129],"study_design_scores_gemma":[0.009538817,0.0006377037,0.0000089521845,0.003318058,0.0011324483,0.000044820586,0.00001027518,0.00019869934,0.0000053992317,0.000022092896,0.984927,0.00015575686],"about_ca_topic_score_codex":0.00033720987,"about_ca_topic_score_gemma":0.000002205715,"teacher_disagreement_score":0.98885715,"about_ca_system_score_codex":0.008232607,"about_ca_system_score_gemma":0.00928878,"threshold_uncertainty_score":0.99632764},"labels":[],"label_agreement":null},{"id":"W2008591960","doi":"10.1097/00002371-200501000-00004","title":"Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells","year":2004,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Immunogenicity; Chronic lymphocytic leukemia; Immune system; Protein kinase C; Immunology; Chemistry; Cancer research; Cell biology; Leukemia; Biology; Signal transduction","score_opus":0.008655550279923095,"score_gpt":0.2739041142319836,"score_spread":0.2652485639520605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008591960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992609,0.006124452,0.000034964738,0.0001457787,0.00010236886,0.0008768651,0.000008177994,0.000009738643,0.000088637],"genre_scores_gemma":[0.99746925,0.00212073,0.00009965172,0.00006976502,0.000089688496,0.000007762213,5.5579443e-7,0.000044938988,0.00009766825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975549,0.00028942153,0.0008441596,0.00017183421,0.0007925024,0.00034720675],"domain_scores_gemma":[0.997862,0.00042556095,0.00079021987,0.00054520275,0.00027895826,0.00009806042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016040287,0.00025864292,0.000808554,0.00023602096,0.00007476556,0.000018301362,0.0003264384,0.00014814458,0.00012683248],"category_scores_gemma":[0.00019481787,0.00014966963,0.0003154392,0.00038870468,0.0003766231,0.00011485088,0.000046417405,0.0004534348,0.000006163677],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007866846,0.00009840275,0.000041863666,0.00040732825,0.00057006587,0.0001061097,0.0002759424,0.0005603049,0.978154,0.00004373286,0.00001684183,0.0118585685],"study_design_scores_gemma":[0.044843595,0.009202649,0.0011155213,0.00224284,0.00007025248,0.0005162996,0.00004112123,0.0002699234,0.94142133,0.000060610055,0.00010617975,0.000109687695],"about_ca_topic_score_codex":0.00049807585,"about_ca_topic_score_gemma":0.0000030199494,"teacher_disagreement_score":0.036976747,"about_ca_system_score_codex":0.024147388,"about_ca_system_score_gemma":0.013932991,"threshold_uncertainty_score":0.9916571},"labels":[],"label_agreement":null},{"id":"W2009619208","doi":"10.4161/cc.22387","title":"The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells","year":2012,"lang":"en","type":"article","venue":"Cell Cycle","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Unfolded protein response; Cancer research; Myeloid leukemia; Biology; Phosphorylation; Downregulation and upregulation; Imatinib; Imatinib mesylate; Immunology; Endoplasmic reticulum; Cell biology","score_opus":0.021191483025069454,"score_gpt":0.2817901159933057,"score_spread":0.26059863296823627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009619208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869803,0.004287757,0.000052273677,0.00021161456,0.00011407273,0.0012224906,0.000012917736,0.000023565395,0.0070950096],"genre_scores_gemma":[0.9947274,0.0004240303,0.0004033718,0.000059146972,0.00014484231,0.000113014976,0.000008347069,0.000037281327,0.0040825643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980998,0.0000965379,0.00041642768,0.00031799282,0.00044691202,0.00062230485],"domain_scores_gemma":[0.99871117,0.00036060959,0.00012153635,0.00046076,0.00009074197,0.0002551564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068159157,0.00020953563,0.0003567871,0.00008211212,0.00012369851,0.000030544004,0.0001277876,0.00010399463,0.00011249991],"category_scores_gemma":[0.000062952684,0.00015263078,0.00007539494,0.00026085717,0.00014904341,0.000090774956,0.000073122974,0.00016223833,0.00006019536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018632384,0.0005655546,0.0025539596,0.0012087977,0.00012876633,0.000046870893,0.021664126,0.00077580934,0.95180017,0.0005048169,0.0008830008,0.018004887],"study_design_scores_gemma":[0.00930385,0.0004759884,0.0013171013,0.00022842373,0.00004549218,0.0000059177155,0.0014403523,0.00512886,0.9699825,0.000064802865,0.011807395,0.00019932492],"about_ca_topic_score_codex":0.0007653395,"about_ca_topic_score_gemma":0.00021231477,"teacher_disagreement_score":0.020223774,"about_ca_system_score_codex":0.015255856,"about_ca_system_score_gemma":0.004191104,"threshold_uncertainty_score":0.9885244},"labels":[],"label_agreement":null},{"id":"W2010241557","doi":"10.1038/sj.leu.2403661","title":"Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Lymphoma Research Foundation","keywords":"Chromosomal translocation; Follicular lymphoma; Lymphoma; Biology; Immunoglobulin heavy chain; Gene rearrangement; Karyotype; Cytogenetics; Cancer research; Fusion gene; Immunology; Antibody; Chromosome; Genetics; Gene","score_opus":0.013295007816813257,"score_gpt":0.25425943796400846,"score_spread":0.2409644301471952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010241557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319375,0.003926717,0.00027348782,0.0006006193,0.000038240752,0.00050829945,0.000006490012,0.000037228237,0.0014151694],"genre_scores_gemma":[0.9977388,0.000319202,0.001137873,0.000108054555,0.00011558577,0.00002949012,0.00002783695,0.000032903346,0.00049026415],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983507,0.000051832933,0.00041830388,0.0003409232,0.00045659512,0.00038166065],"domain_scores_gemma":[0.99919695,0.00011188228,0.00009934922,0.0003586492,0.00008588499,0.00014729406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002180837,0.00019432236,0.00041251633,0.00017295833,0.00002930865,0.000015815624,0.00011917969,0.00013903542,0.00006958308],"category_scores_gemma":[0.000027939654,0.00016012316,0.000045189932,0.0003746068,0.00023929072,0.00010583636,0.000035888035,0.00020854523,0.000026305746],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035344397,0.0038441785,0.008225524,0.0032260064,0.00034025317,0.0007136081,0.011011142,0.0039366814,0.44783795,0.0024198024,0.0020925512,0.51281786],"study_design_scores_gemma":[0.18495022,0.0023723652,0.010580117,0.0017212504,0.00021306492,0.0009509637,0.0007483748,0.032936502,0.75495595,0.00014379519,0.009694686,0.0007326947],"about_ca_topic_score_codex":0.0024723439,"about_ca_topic_score_gemma":0.0004156432,"teacher_disagreement_score":0.51208514,"about_ca_system_score_codex":0.013528404,"about_ca_system_score_gemma":0.005704669,"threshold_uncertainty_score":0.99993205},"labels":[],"label_agreement":null},{"id":"W2010753128","doi":"10.4161/cc.24928","title":"Induction of prolonged early G<sub>1</sub>arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1","year":2013,"lang":"en","type":"article","venue":"Cell Cycle","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"National Center for Advancing Translational Sciences; National Human Genome Research Institute; U.S. Public Health Service","keywords":"Cyclin-dependent kinase 6; PI3K/AKT/mTOR pathway; Biology; Cancer research; Protein kinase B; Cell cycle; Mantle cell lymphoma; Growth inhibition; Cyclin D1; Cell growth; Apoptosis; Cell biology; Signal transduction; Immunology; Lymphoma; Biochemistry","score_opus":0.013272337761144564,"score_gpt":0.2476900024324606,"score_spread":0.23441766467131603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010753128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99286133,0.00030803127,0.0006371517,0.0004683659,0.00032299443,0.003480069,0.000036012465,0.00017119196,0.0017148532],"genre_scores_gemma":[0.99655163,0.0001472261,0.00087843783,0.00015474138,0.00032836336,0.00087269355,0.00036530622,0.00010081839,0.00060079736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99702126,0.00010218998,0.00069345906,0.00074327516,0.00067938585,0.0007604358],"domain_scores_gemma":[0.9980539,0.00013838013,0.0003280088,0.0007268566,0.0005100882,0.00024274598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043775508,0.00032025238,0.0004956238,0.00014039385,0.00020440416,0.000084017585,0.00011682652,0.0003928173,0.000094170355],"category_scores_gemma":[0.00013150186,0.00030723592,0.00021492751,0.00052021735,0.0002975469,0.00065172825,0.00009149097,0.0002442617,0.0003744296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039991195,0.0008204663,0.000097345226,0.0006708649,0.000048082034,0.000016047383,0.000664946,0.000022058932,0.9706213,0.000027131988,0.018551001,0.008060849],"study_design_scores_gemma":[0.016222471,0.0010232325,0.0006079993,0.00023401077,0.00009374185,0.000047343376,0.00032564878,0.0016600845,0.9772415,0.0010662142,0.001190109,0.00028762728],"about_ca_topic_score_codex":0.0020973186,"about_ca_topic_score_gemma":0.00003345198,"teacher_disagreement_score":0.017360892,"about_ca_system_score_codex":0.0032513146,"about_ca_system_score_gemma":0.0011108249,"threshold_uncertainty_score":0.99993795},"labels":[],"label_agreement":null},{"id":"W2010881438","doi":"10.1182/blood-2005-09-3613","title":"Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunoglobulin class switching; Biology; Waldenstrom macroglobulinemia; Cytidine deaminase; B cell; Isotype; Molecular biology; Macroglobulinemia; Somatic hypermutation; Monoclonal gammopathy of undetermined significance; Immunology; Antibody; Monoclonal; Monoclonal antibody; Multiple myeloma; Lymphoma","score_opus":0.013600924212857959,"score_gpt":0.27710648628433476,"score_spread":0.2635055620714768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010881438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916699,0.0006365162,0.000046351903,0.0020763276,0.00015820943,0.0007125866,0.000015619135,0.00015847724,0.004526048],"genre_scores_gemma":[0.99464345,0.0001342463,0.0018777248,0.00038540838,0.000584343,0.000075884935,0.0001513067,0.000063402586,0.0020842387],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970812,0.000103740254,0.00065747416,0.0005574693,0.0007601113,0.00083998387],"domain_scores_gemma":[0.9986545,0.00012723444,0.00012503836,0.00061805896,0.00015081636,0.00032435724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058897276,0.0003049948,0.00047241777,0.00033991077,0.000081312515,0.000053692147,0.00028281024,0.00026454087,0.00032919628],"category_scores_gemma":[0.00025145634,0.00028561027,0.00015854555,0.0005709671,0.00009130543,0.00021838148,0.00017094043,0.0005774012,0.00037910652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060433364,0.029007979,0.35131153,0.0027947964,0.0016768592,0.008207953,0.0054727015,0.0017064055,0.1567947,0.0014525194,0.035661507,0.3998697],"study_design_scores_gemma":[0.4295128,0.0025032249,0.20602591,0.0015606757,0.0010097905,0.0075518074,0.0006186405,0.17942835,0.13729309,0.0006086902,0.03152725,0.0023597644],"about_ca_topic_score_codex":0.0007745765,"about_ca_topic_score_gemma":0.00063678675,"teacher_disagreement_score":0.42346948,"about_ca_system_score_codex":0.005469901,"about_ca_system_score_gemma":0.0026397367,"threshold_uncertainty_score":0.9999596},"labels":[],"label_agreement":null},{"id":"W2011389852","doi":"10.1016/j.bbmt.2006.04.010","title":"Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenstrom’s Macroglobulinemia","year":2006,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Medicine; Total body irradiation; Transplantation; Surgery; Internal medicine; Hematopoietic stem cell transplantation; Chemotherapy; Waldenstrom macroglobulinemia; Gastroenterology; Oncology; Cyclophosphamide; Lymphoma","score_opus":0.0067523093018954684,"score_gpt":0.22809750058905115,"score_spread":0.22134519128715568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011389852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984544,0.00028039815,0.00021358354,0.00005495795,0.000034066215,0.0004912912,0.00010781434,0.00002713521,0.00033638006],"genre_scores_gemma":[0.9975015,0.0005556926,0.0009855052,0.000030395442,0.000025169747,0.00002003093,0.0007309391,0.000014695276,0.0001360997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889284,0.000067003144,0.00034056,0.00028638827,0.00015165508,0.00026152443],"domain_scores_gemma":[0.9995879,0.000089839494,0.00008929732,0.000110864785,0.000066174594,0.000055945264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010977911,0.00015423539,0.00030245073,0.00015715508,0.000032459044,0.000004516697,0.00005505611,0.0001836994,0.000021399206],"category_scores_gemma":[0.0000018228394,0.00011025717,0.00003177933,0.00014577778,0.00015501991,0.000050665865,0.0000040326286,0.000108783315,0.0000021112087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013189502,0.0008252084,0.8263213,0.002643737,0.00011776535,0.00054696004,0.000635945,0.00007852891,0.14865746,0.00019163091,0.00002641819,0.006765574],"study_design_scores_gemma":[0.07587325,0.0032877135,0.75810826,0.00033176254,0.000863617,0.0007162683,0.000066938424,0.0001698222,0.16016613,0.000060975675,0.00004411176,0.00031116552],"about_ca_topic_score_codex":0.0005848278,"about_ca_topic_score_gemma":0.00059327617,"teacher_disagreement_score":0.06821303,"about_ca_system_score_codex":0.00014920354,"about_ca_system_score_gemma":0.000498963,"threshold_uncertainty_score":0.4496157},"labels":[],"label_agreement":null},{"id":"W2011803705","doi":"10.1002/cyto.b.20135","title":"An optimized whole blood method for flow cytometric measurement of ZAP‐70 protein expression in chronic lymphocytic leukemia","year":2006,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Flow cytometry; Antibody; Cytometry; Whole blood; Leukemia; Epitope; Molecular biology; Immunology; Biology; Medicine","score_opus":0.06631579908189425,"score_gpt":0.4032981549737052,"score_spread":0.3369823558918109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011803705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82270455,0.005447423,0.16294289,0.00013174531,0.0006732674,0.0064552124,0.00017113189,0.00038587404,0.0010879283],"genre_scores_gemma":[0.8889611,0.00024724702,0.106587425,0.00018628592,0.0015904625,0.000887773,0.0002564098,0.00025697227,0.0010263271],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9849454,0.0013342685,0.004574873,0.0022843746,0.0047747474,0.0020863062],"domain_scores_gemma":[0.99049693,0.0033307846,0.001056716,0.0026991935,0.0011340491,0.0012823428],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016808039,0.00095671724,0.003203817,0.00489618,0.0002021728,0.00011197261,0.0014049237,0.0015872156,0.0006228554],"category_scores_gemma":[0.012292175,0.00086122315,0.0012279116,0.010312701,0.000559859,0.000471509,0.00047472434,0.0014369286,0.00016131006],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02140237,0.010572472,0.023261854,0.009432376,0.0018543034,0.0019051655,0.00012189102,0.028047046,0.84179896,0.00020935985,0.008269687,0.05312454],"study_design_scores_gemma":[0.14503963,0.0064179637,0.0073731644,0.0029414578,0.0006962128,0.00030548833,0.00009158825,0.37885913,0.44905084,0.00021929371,0.007631249,0.0013739882],"about_ca_topic_score_codex":0.0006813841,"about_ca_topic_score_gemma":0.00007896425,"teacher_disagreement_score":0.3927481,"about_ca_system_score_codex":0.059832387,"about_ca_system_score_gemma":0.045192704,"threshold_uncertainty_score":0.99970895},"labels":[],"label_agreement":null},{"id":"W2012741632","doi":"10.1182/blood-2009-03-213058","title":"TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Cell biology; Cytoskeleton; Cell adhesion; Phosphoinositide 3-kinase; Cell adhesion molecule; Cell; Biology; Signal transduction; Chemistry; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.024578615594846503,"score_gpt":0.2826943971642419,"score_spread":0.2581157815693954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012741632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99410427,0.00030243734,0.0007059254,0.0004926353,0.000033918663,0.0023999505,0.000009992562,0.00007810695,0.0018727486],"genre_scores_gemma":[0.985224,0.000019152694,0.013637621,0.00041128858,0.00020226657,0.00010620401,0.000040435392,0.0000705821,0.0002884237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99657875,0.00015693464,0.0007473852,0.00074249523,0.0010361378,0.0007382794],"domain_scores_gemma":[0.99810463,0.00026700372,0.0003772316,0.00077153207,0.00023248921,0.00024713489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049257796,0.00043075747,0.00064096285,0.00021030447,0.0001831124,0.00005427195,0.00039997,0.00029706507,0.00007304647],"category_scores_gemma":[0.00012072663,0.00029798064,0.00017597926,0.00070856855,0.00009792681,0.0002450962,0.00020045429,0.0011056876,0.000038338905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013516276,0.0033102708,0.00006839378,0.0005403518,0.0000135330765,0.0002806735,0.002298309,0.00050986547,0.99093956,0.00000964504,0.0002003309,0.00047743123],"study_design_scores_gemma":[0.037983168,0.002344749,0.00021503413,0.0021777018,0.00010139191,0.000109499066,0.0010429192,0.004220655,0.9512326,0.000014540512,0.00024377237,0.00031395405],"about_ca_topic_score_codex":0.0009831184,"about_ca_topic_score_gemma":0.000029765932,"teacher_disagreement_score":0.039706953,"about_ca_system_score_codex":0.0027122132,"about_ca_system_score_gemma":0.001718347,"threshold_uncertainty_score":0.99994725},"labels":[],"label_agreement":null},{"id":"W2012876387","doi":"10.1038/leu.2012.329","title":"PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; York University; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; CD5; Peroxisome proliferator-activated receptor; Downregulation and upregulation; Biology; Lipoprotein lipase; Cancer research; Peroxisome proliferator-activated receptor alpha; Internal medicine; Endocrinology; Receptor; Leukemia; Nuclear receptor; Immunology; Adipose tissue; Antibody; Medicine; Transcription factor; Biochemistry","score_opus":0.03439344377669197,"score_gpt":0.3255027107052507,"score_spread":0.29110926692855876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012876387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9272289,0.030389339,0.0073912092,0.0009065493,0.0020527178,0.0053376774,0.00012843598,0.0009873757,0.025577776],"genre_scores_gemma":[0.9737119,0.00032737944,0.0026144406,0.003306426,0.0028392917,0.00056291104,0.00012004338,0.00021603658,0.016301576],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951878,0.000087525805,0.000707647,0.00076254643,0.0009869284,0.0022675053],"domain_scores_gemma":[0.9968123,0.0004842683,0.0001856436,0.0013703726,0.0002463011,0.0009011526],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00084726483,0.0005906568,0.00087146065,0.0002843724,0.0002778729,0.000074423726,0.00050308957,0.00050311926,0.0016498496],"category_scores_gemma":[0.00024200042,0.00051283895,0.0005175643,0.0006185614,0.00031256783,0.0003795462,0.00019293981,0.00050210964,0.0016180851],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010054686,0.0008309858,0.009482462,0.012782711,0.0059567653,0.0006450239,0.014117161,0.0026332678,0.10530777,0.022050083,0.62177706,0.19436201],"study_design_scores_gemma":[0.062305514,0.0016381635,0.0015741859,0.00045099997,0.0007057678,0.0015380725,0.00026346988,0.18365951,0.10313126,0.001477309,0.6419689,0.0012868445],"about_ca_topic_score_codex":0.0007998658,"about_ca_topic_score_gemma":0.000015103499,"teacher_disagreement_score":0.25305963,"about_ca_system_score_codex":0.32634827,"about_ca_system_score_gemma":0.07328864,"threshold_uncertainty_score":0.9997323},"labels":[],"label_agreement":null},{"id":"W2013018139","doi":"10.1159/000206834","title":"Coexistence of Double Gammopathy (IgM Kappa and IgM Lambda) in the Serum of a Single Individual with Chronic Lymphocytic Leukemia","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; St. Boniface Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Kappa; Gammopathy; Immunoglobulin M; Medicine; Leukemia; Immunology; Antibody; Pathology; Immunoglobulin G; Monoclonal","score_opus":0.04010699375764831,"score_gpt":0.2886516604656831,"score_spread":0.24854466670803477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013018139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925406,0.0014629201,0.0000064804926,0.0007898004,0.000018723602,0.0008363209,0.000008948008,0.000036258443,0.0042999657],"genre_scores_gemma":[0.99896955,0.00017840021,0.00033640824,0.0003528181,0.000028112634,0.000031642252,0.000011553335,0.000016060645,0.00007542135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975677,0.00010010607,0.00054205034,0.00041831893,0.0008154862,0.00055633934],"domain_scores_gemma":[0.9984437,0.00035285283,0.00025779245,0.0007170947,0.000113306865,0.00011521587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064987247,0.00025384116,0.00079933845,0.0001781891,0.000064136664,0.00002637419,0.00047268765,0.0002000682,0.000047703874],"category_scores_gemma":[0.00014293089,0.00014952003,0.000076232216,0.000670407,0.00062391005,0.00011783886,0.00012674481,0.00028409736,0.0000055626365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09699173,0.013001775,0.18776105,0.03783491,0.0041241874,0.057418402,0.1474749,0.0029360517,0.24673675,0.09443758,0.026259322,0.08502335],"study_design_scores_gemma":[0.2814007,0.05150325,0.24643436,0.008656916,0.0016556609,0.06456185,0.014087309,0.019303732,0.29967538,0.004257142,0.005783399,0.002680315],"about_ca_topic_score_codex":0.00056275417,"about_ca_topic_score_gemma":0.00017563577,"teacher_disagreement_score":0.18440896,"about_ca_system_score_codex":0.006048258,"about_ca_system_score_gemma":0.007479373,"threshold_uncertainty_score":0.9981473},"labels":[],"label_agreement":null},{"id":"W2013173657","doi":"10.1002/dc.20760","title":"Hairy cell leukemia presenting as a discrete liver mass: Diagnosis by fine needle aspiration biopsy","year":2008,"lang":"en","type":"article","venue":"Diagnostic Cytopathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hairy cell leukemia; Pancytopenia; Fine-needle aspiration; Biopsy; Hairy Cell; Bone marrow; Pathology; Leukemia; Liver biopsy; Spleen; Radiology; Internal medicine","score_opus":0.019741048731109663,"score_gpt":0.2727044122019387,"score_spread":0.25296336347082904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013173657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98594445,0.004219713,0.0009598604,0.0006382489,0.0003254211,0.0010661124,0.00006188251,0.00021583114,0.006568478],"genre_scores_gemma":[0.99047464,0.0019166234,0.0012029901,0.00069312187,0.00050084904,0.0005943865,0.00035069528,0.00009741134,0.0041692685],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99652237,0.00023809941,0.0006512602,0.00087804376,0.00068612094,0.0010241171],"domain_scores_gemma":[0.99564093,0.0026900473,0.00020236698,0.00083929335,0.00020853968,0.000418821],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038630058,0.00041814698,0.0006838896,0.0002776745,0.00029826057,0.000037492075,0.00031782154,0.00040593132,0.0010400931],"category_scores_gemma":[0.0052091833,0.0003916723,0.00022101683,0.00050958653,0.0005528688,0.00020735226,0.00026401624,0.0005785105,0.0014617615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009351504,0.002015016,0.6018772,0.001657299,0.00026960313,0.11877913,0.0068684816,0.0004970851,0.07713405,0.00060890155,0.17542022,0.013937883],"study_design_scores_gemma":[0.09655072,0.009672399,0.24438281,0.0016424377,0.0018448355,0.074811846,0.001552792,0.042358823,0.44399926,0.0012289556,0.07733148,0.004623656],"about_ca_topic_score_codex":0.0014283609,"about_ca_topic_score_gemma":0.000038144473,"teacher_disagreement_score":0.3668652,"about_ca_system_score_codex":0.004220829,"about_ca_system_score_gemma":0.0029944892,"threshold_uncertainty_score":0.9998731},"labels":[],"label_agreement":null},{"id":"W2013683617","doi":"10.1111/j.1365-4632.2008.03598.x","title":"A distinct cutaneous reaction to sorafenib and a multikinase inhibitor","year":2008,"lang":"en","type":"letter","venue":"International Journal of Dermatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Scalp; Dermatology; Papule; Follicular hyperplasia; Hyperkeratosis; Folliculitis; Pathology; Hyperplasia","score_opus":0.019789705629510542,"score_gpt":0.31528413050600573,"score_spread":0.2954944248764952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013683617","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23324065,0.00034783166,0.00014751141,0.76331586,0.0019821583,0.00029143674,0.00003207675,0.000021863414,0.0006206335],"genre_scores_gemma":[0.78822553,0.0006857198,0.0014495653,0.19719814,0.010138061,0.000016100325,0.00015219247,0.00010104013,0.0020336877],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9974782,0.00009703151,0.00078619394,0.0002635174,0.0010588464,0.00031623716],"domain_scores_gemma":[0.9977278,0.00039415024,0.0004763141,0.00019703287,0.000995729,0.00020896936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004407039,0.00024270918,0.00067442877,0.00078576343,0.000039468312,0.000034845114,0.00032113938,0.00053248904,0.000047578156],"category_scores_gemma":[0.00075547915,0.00020556063,0.00019543747,0.000094914874,0.00017278314,0.00008945121,0.00014926033,0.0016099648,0.00007070026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008600187,0.00007231345,0.00022304097,0.00008689023,0.00042910784,0.39827865,0.00021022474,7.166887e-7,0.00085473474,0.00000605371,0.5970539,0.0019243697],"study_design_scores_gemma":[0.0038152428,0.0001394196,0.000071640556,0.00024205455,0.00006023247,0.551158,0.000010330802,0.00016347737,0.00047408446,0.000032413787,0.4437342,0.000098910736],"about_ca_topic_score_codex":0.00010814875,"about_ca_topic_score_gemma":0.000011500377,"teacher_disagreement_score":0.5661177,"about_ca_system_score_codex":0.0045276647,"about_ca_system_score_gemma":0.0031280885,"threshold_uncertainty_score":0.9992938},"labels":[],"label_agreement":null},{"id":"W2013768460","doi":"10.1038/leu.2008.321","title":"Caspase-independent type III PCD: a new means to modulate cell death in chronic lymphocytic leukemia","year":2008,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"Ligue Contre le Cancer; Canadian Institutes of Health Research; Fondation de France; Association pour la Recherche sur le Cancer","keywords":"Chronic lymphocytic leukemia; Programmed cell death; Leukemia; Apoptosis; Caspase; Cancer research; Immunology; Medicine; Hematology; Biology; Genetics","score_opus":0.033716042398247985,"score_gpt":0.29016451868140697,"score_spread":0.256448476283159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013768460","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81724304,0.012559001,0.0009412097,0.07421347,0.0053081387,0.014779719,0.00031179996,0.0019635165,0.072680086],"genre_scores_gemma":[0.1916267,0.00389647,0.0023352266,0.4342543,0.02217321,0.00049479783,0.002246537,0.0015887032,0.34138405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98841864,0.00027439912,0.0017785361,0.0027387748,0.0032778042,0.003511867],"domain_scores_gemma":[0.99390787,0.00043836414,0.0004246211,0.0034316008,0.00038349946,0.0014140668],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.000535066,0.0017503026,0.0026368736,0.0017591855,0.00021868838,0.00014649444,0.0015944397,0.0033251517,0.0011902249],"category_scores_gemma":[0.00029155766,0.0017118226,0.0006869029,0.0019834598,0.00021817017,0.00021969475,0.0008591558,0.005828365,0.0053054197],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00078476185,0.000027062199,0.00005319971,0.0013475067,0.0002647108,0.04799789,0.0008720594,0.018904971,0.0010796753,0.000011596397,0.9276118,0.0010447286],"study_design_scores_gemma":[0.060150824,0.0015164872,0.0003335002,0.0025038265,0.0005542624,0.006606633,0.000048186295,0.08667693,0.004465827,0.00013123664,0.8344781,0.00253421],"about_ca_topic_score_codex":0.071364775,"about_ca_topic_score_gemma":0.0019946601,"teacher_disagreement_score":0.6256164,"about_ca_system_score_codex":0.7069571,"about_ca_system_score_gemma":0.36536542,"threshold_uncertainty_score":0.99972284},"labels":[],"label_agreement":null},{"id":"W2014050718","doi":"10.1038/leu.2008.175","title":"BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Lymphoma Research Foundation","keywords":"Bortezomib; Chronic lymphocytic leukemia; Proteasome inhibitor; MAPK/ERK pathway; Kinase; Biology; Cancer research; Phosphorylation; Apoptosis; Leukemia; Pharmacology; Biochemistry; Immunology","score_opus":0.020814705753791504,"score_gpt":0.2719792681412461,"score_spread":0.2511645623874546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014050718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508464,0.001301033,0.00030574307,0.00032633895,0.0002429049,0.0015954113,0.00001115092,0.00013991691,0.0009928776],"genre_scores_gemma":[0.99602115,0.0006476984,0.00029123767,0.00035313208,0.00040484752,0.00014334606,0.000037403515,0.000094792165,0.0020063948],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99636114,0.00025227296,0.0006333671,0.0009552087,0.0008825375,0.00091545295],"domain_scores_gemma":[0.9976622,0.0006868942,0.00019399052,0.00081195455,0.00023848496,0.0004064716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007096534,0.0005048888,0.0006995095,0.00038496303,0.00031541503,0.00008293988,0.000212199,0.0002693235,0.00007675313],"category_scores_gemma":[0.00035815814,0.000367259,0.00010308634,0.0010469453,0.00035370231,0.0003249564,0.00018820078,0.000680356,0.00032933927],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006069897,0.00015757006,0.0012512307,0.0013704614,0.00061178854,0.0064162277,0.007964662,0.4231298,0.5255128,0.0002772426,0.008660029,0.01857827],"study_design_scores_gemma":[0.013525014,0.0007624038,0.008776033,0.000963587,0.00018508249,0.0028509318,0.00037722447,0.7145397,0.25542793,0.000027048869,0.0019530484,0.0006119665],"about_ca_topic_score_codex":0.0071445205,"about_ca_topic_score_gemma":0.0011662012,"teacher_disagreement_score":0.29140994,"about_ca_system_score_codex":0.16809429,"about_ca_system_score_gemma":0.029660724,"threshold_uncertainty_score":0.9998779},"labels":[],"label_agreement":null},{"id":"W2014246201","doi":"10.1016/j.leukres.2008.08.021","title":"Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade","year":2008,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"José Carreras Leukämie-Stiftung","keywords":"Blockade; Chronic lymphocytic leukemia; Cancer research; Leukemia; T cell; Immunology; Medicine; Internal medicine; Receptor; Immune system","score_opus":0.04986831443506784,"score_gpt":0.35710647795066497,"score_spread":0.30723816351559713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014246201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836377,0.0031960418,0.00004692714,0.00011496145,0.000112931986,0.0014097076,0.000029872817,0.00010082359,0.011351041],"genre_scores_gemma":[0.9790537,0.0033317406,0.00028148206,0.000048392736,0.00032601182,0.00018553704,0.0001439098,0.000120197976,0.016509058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.991921,0.00058149814,0.0010671045,0.0010756762,0.0033414895,0.00201325],"domain_scores_gemma":[0.99620515,0.0009220201,0.00015812661,0.0015198281,0.00053945056,0.00065541547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019982334,0.0004273623,0.00090227247,0.0011778083,0.0002987034,0.0000329453,0.0007771854,0.0006297109,0.00071111467],"category_scores_gemma":[0.00062364363,0.0003858259,0.00024012047,0.002376984,0.0012211619,0.00027503457,0.0005730065,0.0018030098,0.0005559556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023283807,0.00025301424,0.0023353372,0.0020738114,0.00006769828,0.0021169435,0.001350155,0.0025874306,0.9372962,0.00009506488,0.047246266,0.0022496767],"study_design_scores_gemma":[0.048131254,0.0015192232,0.0031112686,0.0010344272,0.00003772446,0.0010242498,0.0003577148,0.16682434,0.7643595,0.00013533635,0.012912389,0.00055259705],"about_ca_topic_score_codex":0.01178997,"about_ca_topic_score_gemma":0.0001450249,"teacher_disagreement_score":0.22010829,"about_ca_system_score_codex":0.34506285,"about_ca_system_score_gemma":0.124954574,"threshold_uncertainty_score":0.9998594},"labels":[],"label_agreement":null},{"id":"W2014709975","doi":"10.1007/s00262-004-0626-5","title":"A phase I/II trial of oxidized autologous tumor vaccines during the “watch and wait” phase of chronic lymphocytic leukemia","year":2004,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Stage (stratigraphy); Leukemia; Internal medicine; Clinical trial; Vaccination; Cancer; Gastroenterology; Surgery; Oncology; Immunology","score_opus":0.019490794958685425,"score_gpt":0.3403630314449678,"score_spread":0.3208722364862824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014709975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94270325,0.054130234,0.000047620808,0.0006295012,0.0005104172,0.0018069851,0.000031711246,0.000086183056,0.000054082735],"genre_scores_gemma":[0.9823161,0.016251838,0.0000885083,0.00014085117,0.00021335218,0.00039956332,0.000012023752,0.00008069243,0.0004971172],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99710786,0.00016423233,0.0010516064,0.00052509946,0.00039488444,0.00075633253],"domain_scores_gemma":[0.99771947,0.00023888523,0.0005330178,0.0011704112,0.0002514594,0.00008677467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046214685,0.00041922604,0.0012439393,0.00022622902,0.00027485605,0.000014574354,0.000525787,0.00026759203,0.00033940878],"category_scores_gemma":[0.00014414545,0.00029893473,0.0002828864,0.00054558145,0.0012495534,0.00012181299,0.00018690336,0.00045842858,0.000006486782],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.15157327,0.0010325174,0.000008493259,0.0002669807,0.001427515,0.000102450256,0.0015876117,0.0001627974,0.8261986,0.00012164733,0.000038045066,0.017480075],"study_design_scores_gemma":[0.5920479,0.010035962,0.00011159305,0.00029212274,0.00014463536,0.0007492713,0.00014174992,0.0006108146,0.39418167,0.00012228149,0.0013629149,0.00019906998],"about_ca_topic_score_codex":0.0043529384,"about_ca_topic_score_gemma":0.00006568637,"teacher_disagreement_score":0.44047466,"about_ca_system_score_codex":0.033258945,"about_ca_system_score_gemma":0.029141033,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W2015730117","doi":"10.1159/000206098","title":"Leukaemic Meningitis in Chronic Lymphocytic Leukaemia","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Meningitis; Chemotherapy; Methotrexate; Coma (optics); Chronic lymphocytic leukemia; Pathology; Immunology; Leukemia; Internal medicine; Surgery","score_opus":0.02451913799853197,"score_gpt":0.31912292882746257,"score_spread":0.2946037908289306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015730117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96920645,0.0018317155,0.00002457414,0.0016898395,0.000084897285,0.0007179647,0.0000026716389,0.0002629075,0.026178977],"genre_scores_gemma":[0.99663717,0.0004963723,0.0005737752,0.000984447,0.00012586058,0.000053858013,0.000029860053,0.000032059943,0.0010665793],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99687254,0.00009864568,0.00062678434,0.00069426215,0.0006144128,0.0010933464],"domain_scores_gemma":[0.9983541,0.00025810974,0.00012138778,0.00087343826,0.00008157375,0.0003114138],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038496798,0.00035182596,0.0008769046,0.00034838085,0.00009900605,0.000045568326,0.00041542618,0.00036298152,0.0006533934],"category_scores_gemma":[0.0005041966,0.00028931626,0.0001819357,0.000752256,0.00019800111,0.00017964478,0.00012407349,0.00049898255,0.0004988338],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010399136,0.0024121618,0.015412273,0.004183569,0.001066218,0.15656383,0.005350142,0.0021446105,0.40493834,0.046552565,0.18324159,0.16773558],"study_design_scores_gemma":[0.24048045,0.016030025,0.08685296,0.005714298,0.0007347728,0.12621517,0.0011726433,0.22601415,0.18894297,0.020563163,0.08184769,0.005431688],"about_ca_topic_score_codex":0.00045659795,"about_ca_topic_score_gemma":0.000080322316,"teacher_disagreement_score":0.23008132,"about_ca_system_score_codex":0.06576448,"about_ca_system_score_gemma":0.014728396,"threshold_uncertainty_score":0.9999559},"labels":[],"label_agreement":null},{"id":"W2016326833","doi":"10.1080/10245330500094870","title":"Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells","year":2005,"lang":"en","type":"review","venue":"Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Leukemia Research Foundation","keywords":"Immune system; Immunotherapy; Context (archaeology); Immunology; Chronic lymphocytic leukemia; Medicine; Dendritic cell; Disease; Ex vivo; Leukemia; Biology; In vivo; Pathology","score_opus":0.08084343313940714,"score_gpt":0.4151507828463217,"score_spread":0.33430734970691456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016326833","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021637396,0.99616045,0.0000816161,0.000023057464,0.00027421227,0.0012106168,0.000012183244,0.000025512541,0.0019959705],"genre_scores_gemma":[0.000089975336,0.9984533,0.00082100957,0.000053932297,0.000110273846,0.00006328933,0.000020899175,0.00008985822,0.00029745593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968688,0.00028846506,0.0012800033,0.00052768626,0.00037301212,0.00066205143],"domain_scores_gemma":[0.9980749,0.000546385,0.00038819073,0.00076036615,0.00011346932,0.00011672788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034672266,0.0004088318,0.0034262703,0.00057015754,0.000023046425,0.0000058621113,0.00030984837,0.00062011107,0.00067311747],"category_scores_gemma":[0.00012111301,0.00034022136,0.00034691737,0.00054586877,0.000254242,0.00006291744,0.000099243305,0.00055573037,0.000084322],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000110371504,0.00030184435,0.0000018811152,0.036190234,0.00015554228,0.00065398705,0.000081178165,0.000021590447,0.000049403832,0.00097392214,0.00013875306,0.9613213],"study_design_scores_gemma":[0.0052450597,0.00008626794,8.3299035e-8,0.015530731,0.00021199946,0.0041959784,0.000025039968,0.0006342849,0.00037328835,0.000067814115,0.9733802,0.0002492614],"about_ca_topic_score_codex":0.00006869508,"about_ca_topic_score_gemma":0.0000474971,"teacher_disagreement_score":0.97324145,"about_ca_system_score_codex":0.007355055,"about_ca_system_score_gemma":0.00810252,"threshold_uncertainty_score":0.999905},"labels":[],"label_agreement":null},{"id":"W2017202925","doi":"10.1038/bcj.2015.14","title":"Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development","year":2015,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Ontario Ministry of Research and Innovation; University of California, San Diego; National Cancer Institute; Ontario Genomics; National Institutes of Health; National Center for Advancing Translational Sciences; Ontario Institute for Cancer Research; Government of Canada; Canadian Institutes of Health Research; Ontario Genomics Institute; China Scholarship Council; Genome Canada","keywords":"Epigenetics; DNA methylation; Somatic evolution in cancer; Biology; Chronic lymphocytic leukemia; Tumor progression; Genetics; Somatic cell; Methylation; Leukemia; CpG site; Disease; Cancer research; Cancer; DNA; Medicine; Gene; Pathology; Gene expression","score_opus":0.03955269313648678,"score_gpt":0.32959255775537166,"score_spread":0.29003986461888487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017202925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97681534,0.021542253,0.00039999306,0.00033881335,0.000069327,0.0007592602,0.0000028297816,0.000014146688,0.00005800902],"genre_scores_gemma":[0.9816577,0.00024258383,0.017611854,0.000039973347,0.00015725404,0.000073812684,0.000002551298,0.000023648081,0.00019063613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822956,0.00012427999,0.00047157845,0.00022998224,0.0006391873,0.00030542782],"domain_scores_gemma":[0.9982796,0.000085746215,0.00018252087,0.0001828162,0.00032581465,0.0009435583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062003575,0.0001396482,0.00025437254,0.00021960084,0.000117222684,0.00003421729,0.00007385431,0.00006628713,0.000011555015],"category_scores_gemma":[0.0005320694,0.00011301056,0.00002869462,0.0002459349,0.000069813796,0.000064650325,0.00008591769,0.0002113627,0.0000039452007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010426327,0.00045923097,0.9605453,0.002145335,0.00014269316,0.000300226,0.0030597511,0.0005236822,0.01627,0.000014331473,0.00035440284,0.0151424175],"study_design_scores_gemma":[0.02698281,0.00085782737,0.9335361,0.0039849905,0.00067241484,0.0013388505,0.00050101196,0.005033887,0.026012227,0.0006501264,0.00008979454,0.00033995815],"about_ca_topic_score_codex":0.000029649296,"about_ca_topic_score_gemma":0.000012801018,"teacher_disagreement_score":0.027009195,"about_ca_system_score_codex":0.0021006828,"about_ca_system_score_gemma":0.008339125,"threshold_uncertainty_score":0.9972827},"labels":[],"label_agreement":null},{"id":"W2017341170","doi":"10.1155/2013/802376","title":"Spontaneous Retroperitoneal Hemorrhage in a Patient with Prolymphocytic Transformation of Chronic Lymphocytic Leukemia","year":2013,"lang":"en","type":"article","venue":"Case Reports in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Chlorambucil; Chronic lymphocytic leukemia; Prolymphocytic leukemia; Etiology; Pathology; Radiology; Leukemia; Surgery; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.00946000840467035,"score_gpt":0.251362766576537,"score_spread":0.24190275817186666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017341170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935725,0.0010116852,0.000080272046,0.000050344064,0.000108660686,0.0023701924,0.0000018825189,0.00005593445,0.0027485355],"genre_scores_gemma":[0.9988117,0.000036860423,0.00044319086,0.00005672174,0.00002885358,0.00046509944,0.000023428538,0.000051765288,0.00008238539],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9965329,0.00011771884,0.0015178969,0.0005678923,0.00050729286,0.00075626606],"domain_scores_gemma":[0.9982686,0.00017064998,0.00033976615,0.00080952933,0.00019607242,0.00021538271],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035208877,0.00031100403,0.0010013251,0.0005549486,0.000037714824,0.000014604181,0.00007165224,0.00030553818,0.00026618777],"category_scores_gemma":[0.0002317566,0.00024905027,0.00009290942,0.00068884395,0.000322624,0.00019466432,0.00005849278,0.00034071115,0.000029807545],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005612735,0.00013050635,0.0004357408,0.0019199351,0.00003280041,0.9883328,0.001273041,0.0015691296,0.00083134836,0.00015642683,0.000022336637,0.0047346456],"study_design_scores_gemma":[0.008545541,0.00092419446,0.00008125238,0.00052554987,0.00003619025,0.84208804,0.00057741377,0.13594195,0.01097317,0.00007115629,0.000037382317,0.0001981734],"about_ca_topic_score_codex":0.010207525,"about_ca_topic_score_gemma":0.0015995073,"teacher_disagreement_score":0.14624478,"about_ca_system_score_codex":0.09178257,"about_ca_system_score_gemma":0.029332854,"threshold_uncertainty_score":0.9999962},"labels":[],"label_agreement":null},{"id":"W2017547913","doi":"10.1309/fngc-yemj-e3ma-e5l2","title":"Diagnostic Significance of CD20 and FMC7 Expression in B-Cell Disorders","year":2003,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"CD20; Chronic lymphocytic leukemia; Medicine; Lymphoma; Flow cytometry; Leukemia; B cell; Immunology","score_opus":0.02710062707952355,"score_gpt":0.38374418357704865,"score_spread":0.3566435564975251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017547913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688536,0.00086592993,0.00056109705,0.00035256217,0.00018184954,0.00016953803,0.0000013342354,0.0000030096546,0.0009793012],"genre_scores_gemma":[0.9931903,0.0026991807,0.0036919224,0.00026425542,0.00008692762,0.000004008617,4.4168013e-7,0.000015405943,0.000047577018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711955,0.0008321906,0.0012748194,0.00021660901,0.00028778103,0.00026908255],"domain_scores_gemma":[0.9926666,0.005937162,0.0007527079,0.00023895298,0.00014917411,0.000255385],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020493201,0.00011166978,0.0009676914,0.00015565232,0.000014173068,0.0000028044924,0.00012640774,0.00009743528,0.000045576882],"category_scores_gemma":[0.013837262,0.00008422217,0.00015048448,0.00025834382,0.0012923892,0.000045114168,0.00004015824,0.00060210243,0.0000043714317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026239082,0.0022832577,0.83563226,0.00021850558,0.00005993288,0.0029072065,0.00071725354,0.000107934946,0.011279036,0.00013392858,0.00076446816,0.1432723],"study_design_scores_gemma":[0.106417224,0.036556076,0.81245303,0.0014384567,0.00033540447,0.004320223,0.004440787,0.00053897535,0.01761445,0.0041058133,0.01109776,0.0006817832],"about_ca_topic_score_codex":0.000035084733,"about_ca_topic_score_gemma":0.000013284037,"teacher_disagreement_score":0.14259051,"about_ca_system_score_codex":0.00024442415,"about_ca_system_score_gemma":0.002028808,"threshold_uncertainty_score":0.9944696},"labels":[],"label_agreement":null},{"id":"W2017848739","doi":"10.1016/j.leukres.2009.06.013","title":"High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort","year":2009,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Manitoba; CancerCare Manitoba","funders":"Microsoft","keywords":"Cancer registry; Chronic lymphocytic leukemia; Medicine; Immunophenotyping; Incidence (geometry); Population; Epidemiology; Cohort; Relative survival; Internal medicine; Lymphoma; Leukemia; Oncology; Immunology; Flow cytometry; Environmental health","score_opus":0.02041312935278395,"score_gpt":0.32311435822261675,"score_spread":0.3027012288698328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017848739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909063,0.0025081506,0.0001088145,0.00070771854,0.0001770477,0.0023994232,0.00007348404,0.00016089632,0.00295814],"genre_scores_gemma":[0.9951968,0.00036213358,0.0004561148,0.0006165345,0.0003606332,0.00020926134,0.00059025106,0.00011110988,0.002097162],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9911073,0.00052650226,0.0011664948,0.0011980527,0.0034436942,0.002557997],"domain_scores_gemma":[0.9935229,0.001438231,0.00021230872,0.0021304819,0.0012239555,0.0014721126],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030026427,0.00053206267,0.0010996491,0.0015088273,0.00055975287,0.00013284586,0.0011725165,0.0006529852,0.0009180915],"category_scores_gemma":[0.002576764,0.0005219788,0.00027507893,0.0027921498,0.0006142312,0.0002749511,0.00016560347,0.0015763781,0.0004011228],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013800572,0.001645269,0.13063128,0.007965195,0.0025706147,0.015312469,0.0027606296,0.12585604,0.24753928,0.020218374,0.2769267,0.15477356],"study_design_scores_gemma":[0.0772601,0.0057474095,0.27052408,0.0034621418,0.00030242716,0.0005143275,0.00029920798,0.55294496,0.07402637,0.0025529836,0.010215472,0.0021505053],"about_ca_topic_score_codex":0.8153822,"about_ca_topic_score_gemma":0.053118553,"teacher_disagreement_score":0.7622636,"about_ca_system_score_codex":0.51725554,"about_ca_system_score_gemma":0.2707443,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W2017930389","doi":"10.1111/jth.12724","title":"Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma","year":2014,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Rannís; Stockholms Läns Landsting; Karolinska Institutet; Landspítali Háskólasjúkrahús; Cancerfonden; Háskóli Íslands; Icelandic Centre for Research","keywords":"Medicine; Waldenstrom macroglobulinemia; Internal medicine; Thrombosis; Lymphoplasmacytic Lymphoma; Venous thrombosis; Hazard ratio; Macroglobulinemia; Population; Gastroenterology; Surgery; Confidence interval; Multiple myeloma; Lymphoma","score_opus":0.03517224604414567,"score_gpt":0.31280386401642024,"score_spread":0.2776316179722746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017930389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774575,0.0003181934,0.000093052426,0.0007828342,0.00035982052,0.00031019244,0.00006181838,0.000016761858,0.00031157798],"genre_scores_gemma":[0.9931047,0.004292493,0.0019161329,0.00024050385,0.00034682767,0.0000053715853,0.000007969222,0.00005349147,0.000032489756],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99628645,0.0002738086,0.0014671042,0.00036257555,0.0010120629,0.0005980259],"domain_scores_gemma":[0.9971111,0.0005546966,0.00094648026,0.0005027463,0.0004902786,0.0003947339],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014371378,0.00034817922,0.0015850265,0.00050630263,0.00010978424,0.00006020993,0.00030393753,0.00028202886,0.00020580937],"category_scores_gemma":[0.00091069913,0.0002795096,0.0003617817,0.0005195162,0.00035938993,0.00019317078,0.00015462344,0.0003559134,0.00001844627],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02271051,0.010958262,0.11531664,0.004301391,0.008937532,0.0013046757,0.008923554,0.0007437392,0.38982117,0.00070558436,0.012314568,0.42396238],"study_design_scores_gemma":[0.160705,0.0075805415,0.41683537,0.0030926585,0.003486846,0.004845325,0.0017840358,0.022013972,0.3737892,0.0007652878,0.0039534383,0.0011483254],"about_ca_topic_score_codex":0.0013110951,"about_ca_topic_score_gemma":0.00008346501,"teacher_disagreement_score":0.42281404,"about_ca_system_score_codex":0.0032793325,"about_ca_system_score_gemma":0.002367584,"threshold_uncertainty_score":0.9999657},"labels":[],"label_agreement":null},{"id":"W2018222754","doi":"10.1007/s12156-007-0016-2","title":"To fast or not to fast? How food could impact on the absorption of kinase inhibitors and its economical value","year":2007,"lang":"en","type":"article","venue":"Oncology Reviews","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Sorafenib; Meal; Pharmacology; Stomach; Kinase; Value (mathematics); Stomach cancer; Internal medicine; Biochemistry","score_opus":0.08372853653558743,"score_gpt":0.40763474022960605,"score_spread":0.3239062036940186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018222754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855117,0.0016550224,0.00003908179,0.008956057,0.00016209095,0.002411249,0.000015868796,0.000013168935,0.0012357389],"genre_scores_gemma":[0.9931705,0.0015382575,0.00028289162,0.0036679201,0.0003939425,0.000082783525,0.00000566094,0.000026187452,0.00083183724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828774,0.00020984579,0.0005044546,0.00035638703,0.00020882711,0.00043273647],"domain_scores_gemma":[0.9981894,0.0007111937,0.00015671494,0.0004315384,0.000086314794,0.00042483475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024734407,0.00020662759,0.000813142,0.00015766971,0.000050848987,0.000012955799,0.00016511646,0.000201244,0.00021254698],"category_scores_gemma":[0.0014186562,0.00010941695,0.0001497332,0.00027160122,0.00009457915,0.0000419524,0.00013122971,0.00030687565,0.000348469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012558958,0.0010125873,0.0006485799,0.0012407292,0.00033071492,0.00033070467,0.0029522653,0.00006217136,0.08519855,0.0022798534,0.11720266,0.77618223],"study_design_scores_gemma":[0.015128985,0.028162125,0.009611331,0.0015556501,0.00027784868,0.0008751768,0.0005242834,0.0012291097,0.062005367,0.000032979573,0.8800848,0.0005123508],"about_ca_topic_score_codex":0.000044928096,"about_ca_topic_score_gemma":0.00015328043,"teacher_disagreement_score":0.7756699,"about_ca_system_score_codex":0.0067673363,"about_ca_system_score_gemma":0.001819832,"threshold_uncertainty_score":0.9970455},"labels":[],"label_agreement":null},{"id":"W2018665096","doi":"10.1080/10428190500054426","title":"Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; Grace (Canada); Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"National Institute on Aging","keywords":"Imiquimod; Chronic lymphocytic leukemia; Medicine; Agonist; Dermatology; Cancer research; Toll-like receptor; Toll; Leukemia; Receptor; Internal medicine; Oncology; Immunology","score_opus":0.008737558601018448,"score_gpt":0.24396892048485078,"score_spread":0.23523136188383234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018665096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98223454,0.009562756,0.00007380814,0.0003114297,0.00022680363,0.002722173,0.00006236091,0.0004288014,0.0043773022],"genre_scores_gemma":[0.9907751,0.0026124027,0.0010070922,0.0012416708,0.00061295193,0.0006025294,0.00021690039,0.00038998315,0.0025413898],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9892217,0.0006088019,0.0023996588,0.00240272,0.002576097,0.0027910324],"domain_scores_gemma":[0.9934617,0.0009215884,0.0010929448,0.0027925174,0.00055159134,0.0011796049],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00092662475,0.0019298748,0.002628867,0.0011016706,0.0007410343,0.00025675027,0.0012363254,0.0012342882,0.00016439536],"category_scores_gemma":[0.00018004,0.001297984,0.00064752036,0.002589875,0.0017616446,0.000736495,0.00078201055,0.0005321864,0.0001881644],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024894593,0.0010802206,0.006173391,0.0035107299,0.0021337296,0.0059478213,0.010228391,0.017468471,0.04794483,0.00095947366,0.024254588,0.8554038],"study_design_scores_gemma":[0.25675622,0.0067689246,0.0372614,0.007965024,0.0016519069,0.028287789,0.004050806,0.3044975,0.2615095,0.00009551928,0.08641641,0.004738995],"about_ca_topic_score_codex":0.013731902,"about_ca_topic_score_gemma":0.0024177672,"teacher_disagreement_score":0.8506648,"about_ca_system_score_codex":0.38660848,"about_ca_system_score_gemma":0.10391675,"threshold_uncertainty_score":0.99934447},"labels":[],"label_agreement":null},{"id":"W2018918776","doi":"10.1002/pbc.21420","title":"Fatal skin and liver toxicity in a patient treated with clofarabine","year":2007,"lang":"en","type":"letter","venue":"Pediatric Blood & Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Medicine; Clofarabine; Toxicity; Surgery; Internal medicine","score_opus":0.012787234867312583,"score_gpt":0.26419245397543495,"score_spread":0.25140521910812236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018918776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96340114,0.016568366,0.0000045966485,0.017371422,0.00011145158,0.0013912035,0.00014726444,0.000074296535,0.00093025883],"genre_scores_gemma":[0.5762646,0.032254677,0.00068733987,0.35785043,0.024336541,0.0010398129,0.00089634204,0.0005434995,0.006126762],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963557,0.00007808122,0.0005164291,0.00091009843,0.0011362442,0.0010034107],"domain_scores_gemma":[0.99860674,0.00022512695,0.00020157183,0.00054072065,0.00018708098,0.00023876496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000201177,0.00053325575,0.00085704576,0.00069599476,0.0000506857,0.000033976616,0.0001671019,0.0008574612,0.00047548144],"category_scores_gemma":[0.000060458475,0.00040660152,0.00010662653,0.00095663697,0.00017084666,0.00007418569,0.00014879594,0.0020983536,0.000027243128],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019578426,0.00081887934,0.058512375,0.005955654,0.00071060174,0.06360323,0.00096830336,0.000015641734,0.000039226365,0.000001907359,0.8572725,0.010143807],"study_design_scores_gemma":[0.21233894,0.010484937,0.045975752,0.0032158387,0.013455487,0.011854709,0.00019844797,0.0020528727,0.0069474285,0.000019241774,0.68792146,0.0055349036],"about_ca_topic_score_codex":0.013733472,"about_ca_topic_score_gemma":0.00093758723,"teacher_disagreement_score":0.38713655,"about_ca_system_score_codex":0.005233407,"about_ca_system_score_gemma":0.005145642,"threshold_uncertainty_score":0.9998386},"labels":[],"label_agreement":null},{"id":"W2019189961","doi":"10.1016/j.mcp.2014.10.004","title":"One-step molecular detection of the MYD88 L265P mutation by unlabeled probe genotyping analysis","year":2014,"lang":"en","type":"article","venue":"Molecular and Cellular Probes","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University Health Network","keywords":"Sanger sequencing; Biology; Genotyping; Amplicon; Mutation; Computational biology; Bone marrow; Molecular biology; Genetics; Polymerase chain reaction; Immunology; Genotype; Gene","score_opus":0.005957018489092513,"score_gpt":0.2263551961712481,"score_spread":0.22039817768215558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019189961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74403274,0.0020212014,0.25277936,0.00013184697,0.00002423459,0.0005601695,0.000002087849,0.000027601578,0.00042075242],"genre_scores_gemma":[0.99861324,0.000023970562,0.0008520807,0.00014919264,0.000020703756,0.00004569489,0.00003649393,0.00003332979,0.00022530238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981458,0.0002399567,0.00033487854,0.00039397992,0.00058361253,0.000301754],"domain_scores_gemma":[0.99899143,0.000036710753,0.00013569181,0.0005477381,0.00017337655,0.000115070216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045629527,0.00017639161,0.0003719545,0.00017404692,0.000110054105,0.000032902833,0.0001466624,0.00014234957,0.000022572369],"category_scores_gemma":[0.0001704459,0.00014242018,0.00023099162,0.00080417504,0.00015181194,0.000045697125,0.00010676289,0.00019646817,0.0000069684206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007121096,0.00009484433,0.00017276904,0.00028258783,0.00054679613,0.00001761232,0.00012736321,0.00023087769,0.9901449,0.00035095768,0.0000067401975,0.00795333],"study_design_scores_gemma":[0.0028208147,0.0001941623,0.0002406796,0.00006571351,0.0011184694,0.000021235897,0.0000391973,0.049771313,0.9449239,0.0003494216,0.00031144876,0.00014368967],"about_ca_topic_score_codex":0.0003199892,"about_ca_topic_score_gemma":0.000024207193,"teacher_disagreement_score":0.2545805,"about_ca_system_score_codex":0.0005442367,"about_ca_system_score_gemma":0.00031938995,"threshold_uncertainty_score":0.58077264},"labels":[],"label_agreement":null},{"id":"W2019239152","doi":"10.1111/j.1365-2141.2009.07790.x","title":"Common genetic variants in candidate genes and risk of familial lymphoid malignancies","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; McMaster University","keywords":"Chronic lymphocytic leukemia; Genetics; Biology; Germline; Allele; Lymphoma; Gene; Single-nucleotide polymorphism; Immunology; Family aggregation; Leukemia; Medicine; Genotype; Disease; Internal medicine","score_opus":0.010635021783382229,"score_gpt":0.27334576001617544,"score_spread":0.26271073823279323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019239152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97895086,0.020402655,0.0000641811,0.00014925377,0.00010124464,0.00014383467,0.000013226471,0.0000045475063,0.00017022411],"genre_scores_gemma":[0.97942007,0.019234505,0.00113119,0.00010098639,0.00006648653,0.0000012586468,0.0000016638975,0.000010952621,0.000032918975],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9982933,0.00019568509,0.0007491627,0.00014898992,0.00029643497,0.00031643047],"domain_scores_gemma":[0.99906224,0.0001408468,0.00032987818,0.00014815586,0.00016992162,0.00014898473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047647493,0.00010723833,0.00082887575,0.00022369847,0.000038252754,0.000014953437,0.00014411344,0.00013305045,0.000033333574],"category_scores_gemma":[0.00031153427,0.00010813881,0.000080712714,0.00016199735,0.0002220189,0.00006864296,0.000044676075,0.00023840231,0.0000021344981],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024042092,0.00086423167,0.38365963,0.00068121165,0.00047105848,0.3715512,0.0008857873,0.00015738393,0.015641259,0.00027112378,0.0023311854,0.22108172],"study_design_scores_gemma":[0.015692776,0.0006965882,0.29782444,0.0007352993,0.0001263348,0.6786348,0.00012753558,0.00084713724,0.0041117403,0.0009579298,0.00014074842,0.00010463882],"about_ca_topic_score_codex":0.003267734,"about_ca_topic_score_gemma":0.0009010732,"teacher_disagreement_score":0.30708364,"about_ca_system_score_codex":0.0006220746,"about_ca_system_score_gemma":0.0017934727,"threshold_uncertainty_score":0.49398583},"labels":[],"label_agreement":null},{"id":"W2019447757","doi":"10.1159/000206328","title":"Lymphocytotoxic Activity of Monoclonal Immunoglobulins in Plasmalymphocytic Diseases","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wellesley Institute; University of Toronto","funders":"","keywords":"Monoclonal antibody; Antibody; Immunology; Medicine","score_opus":0.020418275627315085,"score_gpt":0.3043588158239453,"score_spread":0.28394054019663023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019447757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942981,0.00083921634,0.000017345446,0.00070970866,0.000058932357,0.0006271928,0.000018715771,0.00010124894,0.003329511],"genre_scores_gemma":[0.9986789,0.0003117136,0.00045539884,0.0003118588,0.00003634728,0.000033973272,0.000017337552,0.000019165336,0.00013528776],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99754435,0.00011988203,0.00054620195,0.00050114095,0.00062091224,0.0006675343],"domain_scores_gemma":[0.99830526,0.0003987611,0.00018689857,0.0007514181,0.00009840476,0.00025926292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021919204,0.000295079,0.0009925434,0.0002971972,0.00006209249,0.00001799399,0.00035585844,0.0002475377,0.00024499837],"category_scores_gemma":[0.0006691946,0.00023564429,0.0002359161,0.00065608823,0.00025710536,0.0001602508,0.00012677012,0.00024354323,0.00006556101],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08480361,0.031204414,0.16268876,0.0049285498,0.0018281012,0.051196445,0.0034208777,0.0010203624,0.5075143,0.012532488,0.01304156,0.12582053],"study_design_scores_gemma":[0.0793766,0.0042518307,0.64557356,0.0011297499,0.00034045195,0.009821498,0.0002840533,0.03611003,0.21731658,0.0037425237,0.0008877645,0.001165341],"about_ca_topic_score_codex":0.00036392792,"about_ca_topic_score_gemma":0.000019696246,"teacher_disagreement_score":0.48288482,"about_ca_system_score_codex":0.007454915,"about_ca_system_score_gemma":0.005549518,"threshold_uncertainty_score":0.9963553},"labels":[],"label_agreement":null},{"id":"W2019849294","doi":"10.1038/bcj.2013.50","title":"Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; Leukemia and Lymphoma Society","keywords":"Fludarabine; Cathepsin B; Chronic lymphocytic leukemia; Cancer research; Vorinostat; Cathepsin; Apoptosis; Histone deacetylase; Medicine; Immunology; Chemistry; Leukemia; Histone; Internal medicine; Chemotherapy; Biochemistry","score_opus":0.021099606938949234,"score_gpt":0.29001114830507463,"score_spread":0.2689115413661254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019849294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98304373,0.013206369,0.000042507498,0.0017168212,0.00018745275,0.0016638848,0.000015059771,0.00004415351,0.0000800228],"genre_scores_gemma":[0.99540496,0.0012000576,0.00023406852,0.00027932948,0.0013456263,0.0003850474,0.000004824001,0.00008926296,0.0010567971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957845,0.0006187287,0.00086445175,0.0005620683,0.001008926,0.0011612952],"domain_scores_gemma":[0.99744445,0.0005778791,0.00028554676,0.00069959497,0.00026445152,0.0007281008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016327406,0.00044361834,0.0007247436,0.00040016213,0.00034379668,0.00025616295,0.0005024671,0.00022795501,0.0005315512],"category_scores_gemma":[0.0006026759,0.00029819313,0.00017390236,0.00065084785,0.0005421061,0.00029282182,0.00022178957,0.0011841616,0.00011995114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0049404358,0.0004910094,0.021079876,0.0022250419,0.0015807109,0.003219551,0.0036256183,0.0017579882,0.93248063,0.00006616017,0.004547227,0.023985734],"study_design_scores_gemma":[0.1723211,0.0056537353,0.13173836,0.0072059585,0.0033357986,0.010458642,0.0013466647,0.03730498,0.62370175,0.002019094,0.002626974,0.0022869257],"about_ca_topic_score_codex":0.003987858,"about_ca_topic_score_gemma":0.00018511187,"teacher_disagreement_score":0.30877888,"about_ca_system_score_codex":0.035767406,"about_ca_system_score_gemma":0.040212393,"threshold_uncertainty_score":0.999947},"labels":[],"label_agreement":null},{"id":"W2022098505","doi":"10.1182/blood-2012-08-447359","title":"Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Ministerio de Economía y Competitividad; Canadian Institutes of Health Research; European Hematology Association","keywords":"Uridine; Chronic lymphocytic leukemia; Leukemia; Glucuronosyltransferase; Cancer research; Medicine; Chemistry; Internal medicine; Biochemistry; RNA; Gene; Enzyme","score_opus":0.01021234217395131,"score_gpt":0.2600313849349879,"score_spread":0.24981904276103659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022098505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915422,0.0064616497,0.000042506912,0.000025839963,0.00016001717,0.0007024569,0.000039548322,0.00008009308,0.00094564195],"genre_scores_gemma":[0.9973259,0.0012791033,0.00036671493,0.000046283563,0.00047375317,0.00006474674,0.000050931114,0.000073691255,0.00031889207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970067,0.00013460858,0.00065673725,0.00042781595,0.00076219277,0.001011944],"domain_scores_gemma":[0.9981193,0.0003047855,0.00014507676,0.0008896461,0.00008667682,0.00045450998],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006023519,0.0003248155,0.000708845,0.0002657188,0.000061446735,0.000012046488,0.00026627188,0.00026303183,0.00048397895],"category_scores_gemma":[0.00035448626,0.00027788724,0.00017902847,0.0005453962,0.00018387598,0.00023539885,0.00014262491,0.00043240463,0.00014871357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0048282114,0.006210087,0.253256,0.0054983725,0.001183779,0.00080850814,0.003469812,0.0018885207,0.70337355,0.0018331938,0.0022914913,0.015358488],"study_design_scores_gemma":[0.12311627,0.0008359305,0.049627,0.0013680196,0.00045503603,0.00037184724,0.00007184748,0.0037838256,0.81878954,0.00009044569,0.0010598494,0.00043038712],"about_ca_topic_score_codex":0.0074806875,"about_ca_topic_score_gemma":0.0000759075,"teacher_disagreement_score":0.20362899,"about_ca_system_score_codex":0.035087503,"about_ca_system_score_gemma":0.016152088,"threshold_uncertainty_score":0.99996734},"labels":[],"label_agreement":null},{"id":"W2022373990","doi":"10.1111/ijlh.12080","title":"Immunophenotyping of selected hematologic disorders – focus on lymphoproliferative disorders with more than one malignant cell population","year":2013,"lang":"en","type":"review","venue":"International Journal of Laboratory Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Immunophenotyping; Lymphoproliferative disorders; Population; CD5; CD19; Immunology; Cytometry; CD20; Medicine; Flow cytometry; Antigen; Lymphoma","score_opus":0.01982858490235195,"score_gpt":0.3263281677760282,"score_spread":0.30649958287367624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022373990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025371691,0.9708685,0.000486829,0.0006475674,0.00059673697,0.0015479893,0.000086687396,0.00003925582,0.00035468562],"genre_scores_gemma":[0.15193373,0.84596926,0.0014062083,0.00007067976,0.00019505972,0.000091081376,0.00014622309,0.00012647084,0.00006127373],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99552923,0.00042587105,0.0018231436,0.00044486756,0.0013303068,0.00044655547],"domain_scores_gemma":[0.99347216,0.0006377197,0.0026861248,0.0004294844,0.0025744552,0.00020005934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038796756,0.00057207793,0.0028492257,0.0010884027,0.000060490125,0.000035899415,0.0007052559,0.00052646553,0.00014588333],"category_scores_gemma":[0.0005321113,0.00039301944,0.00037323643,0.0009191833,0.0002985401,0.00019780065,0.00011826115,0.0008212749,0.000035308956],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.020806257,0.020213673,0.020505121,0.13177472,0.05496338,0.008902872,0.0047719423,0.00080746884,0.0010798903,0.0624971,0.0044437526,0.6692338],"study_design_scores_gemma":[0.19057488,0.028868495,0.0036393863,0.3985094,0.019766701,0.069928564,0.0040644617,0.0026854367,0.016503634,0.01329465,0.24228187,0.009882499],"about_ca_topic_score_codex":0.00020696786,"about_ca_topic_score_gemma":0.000062902975,"teacher_disagreement_score":0.65935135,"about_ca_system_score_codex":0.004732767,"about_ca_system_score_gemma":0.010099753,"threshold_uncertainty_score":0.9998522},"labels":[],"label_agreement":null},{"id":"W2023847862","doi":"10.3747/co.19.1064","title":"A Canadian Perspective on Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; University of British Columbia; McGill University; Dalhousie University; University of Ottawa","funders":"Lundbeck Canada; European Society for Medical Oncology","keywords":"Bendamustine; Medicine; Fludarabine; Rituximab; Chronic lymphocytic leukemia; Chlorambucil; Internal medicine; Oncology; Mantle cell lymphoma; Chemoimmunotherapy; Vincristine; Lymphoma; Cyclophosphamide; Leukemia; Chemotherapy","score_opus":0.07599145827251824,"score_gpt":0.41511992384826835,"score_spread":0.3391284655757501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023847862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96546483,0.026511822,0.000106492604,0.0011877861,0.0013292299,0.002477891,0.00007844115,0.000028105818,0.0028154282],"genre_scores_gemma":[0.995049,0.0027514976,0.000079583304,0.000097774144,0.0011868945,0.00040590743,0.000027784125,0.00003475081,0.00036679968],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982809,0.000060487982,0.00028234493,0.0003249559,0.00022100832,0.0008303465],"domain_scores_gemma":[0.9978091,0.0009286958,0.00010280104,0.00042949457,0.00020330556,0.0005266026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029020722,0.00024107694,0.00051078334,0.00022872997,0.00015958972,0.000008845193,0.0001345512,0.00016088902,0.00010117078],"category_scores_gemma":[0.00019902221,0.00015680594,0.00014646378,0.00020214726,0.00031894183,0.000042973876,0.000034070395,0.00009261561,0.000035746805],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003485359,0.002152308,0.0035600925,0.00068078435,0.0010851764,0.00009087739,0.014948892,0.00020063543,0.0006163501,0.0072182287,0.012944602,0.9530167],"study_design_scores_gemma":[0.1086464,0.025907272,0.014035099,0.00032588484,0.001204519,0.00089801784,0.0035340744,0.10522227,0.0040040505,0.00023187384,0.7354914,0.0004991164],"about_ca_topic_score_codex":0.08166259,"about_ca_topic_score_gemma":0.028745785,"teacher_disagreement_score":0.95251757,"about_ca_system_score_codex":0.41278306,"about_ca_system_score_gemma":0.06042771,"threshold_uncertainty_score":0.9889771},"labels":[],"label_agreement":null},{"id":"W2025391536","doi":"10.1182/blood-2013-12-538975","title":"PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Health Sciences Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Internal medicine; Fludarabine; PTK2; Oncology; Rituximab; Cyclophosphamide; Immunology; Cancer research; Leukemia; Chemotherapy; Lymphoma; Receptor","score_opus":0.016687310438296358,"score_gpt":0.2965285665735104,"score_spread":0.27984125613521404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025391536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940442,0.0022823664,0.000059255657,0.00007444507,0.000055983073,0.0003791095,0.0000011140846,0.00008184104,0.0030216912],"genre_scores_gemma":[0.99714667,0.00038649447,0.0005785778,0.000278482,0.00023123603,0.000039406703,0.000008407315,0.00004695582,0.0012837535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982784,0.000073245166,0.0003699488,0.00040502197,0.00037751716,0.00049590203],"domain_scores_gemma":[0.9989536,0.00017007971,0.00006018774,0.00059695396,0.000038453392,0.00018076456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044225203,0.00020290217,0.0004314812,0.00017690977,0.0000548823,0.000029063352,0.00015473612,0.00017356327,0.0001166954],"category_scores_gemma":[0.00019082715,0.00016792207,0.000068166424,0.00021354048,0.00012881026,0.00007836928,0.00011297269,0.00024053836,0.00008893634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009886128,0.00052702473,0.03447752,0.0020215623,0.00022734079,0.00059630646,0.0014265608,0.00021414533,0.92119384,0.00056258036,0.0009488256,0.036815688],"study_design_scores_gemma":[0.41308102,0.0015168497,0.04567297,0.0016562266,0.00021231356,0.0020087878,0.00016339603,0.072664015,0.44723862,0.0006581354,0.01414272,0.0009849281],"about_ca_topic_score_codex":0.00072067074,"about_ca_topic_score_gemma":0.000030230101,"teacher_disagreement_score":0.4739552,"about_ca_system_score_codex":0.031227803,"about_ca_system_score_gemma":0.008117663,"threshold_uncertainty_score":0.99750537},"labels":[],"label_agreement":null},{"id":"W2026542497","doi":"10.1371/journal.pone.0070428","title":"Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University; CancerCare Manitoba; Jewish General Hospital","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Fludarabine; Telomerase; Ku70; Cancer research; Ku80; Chronic lymphocytic leukemia; Telomere; Medicine; Immunology; Biology; Leukemia; Chemotherapy; DNA damage; Internal medicine; DNA; Genetics; DNA-binding protein; Cyclophosphamide; Transcription factor","score_opus":0.033393603487995784,"score_gpt":0.2632676012785659,"score_spread":0.22987399779057013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026542497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981658,0.0020495967,0.000009090464,0.0027006483,0.000022279972,0.001878844,0.000011054791,0.00012786782,0.011542664],"genre_scores_gemma":[0.97789955,0.00012494675,0.0026036382,0.0021619142,0.00016299551,0.0005449355,0.000071212584,0.000061211635,0.016369611],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972867,0.00006932743,0.00054762926,0.00052909355,0.0008001193,0.00076713593],"domain_scores_gemma":[0.998215,0.00026819477,0.00006550769,0.0007683176,0.00032412133,0.00035884572],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035023273,0.00024603357,0.00071670493,0.00041162755,0.00008998967,0.000057103498,0.00028116954,0.00014605295,0.00059354125],"category_scores_gemma":[0.00069334166,0.00022899771,0.00006711892,0.00075031916,0.0001491759,0.0001603952,0.00018471363,0.00029010334,0.0013716731],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073968363,0.002441529,0.014711433,0.0014143478,0.00035414967,0.00029092317,0.00034412238,0.0000040248497,0.9635232,0.00054083474,0.014986888,0.0006488707],"study_design_scores_gemma":[0.08738417,0.0009005319,0.25856963,0.00684303,0.00033973917,0.00004168292,0.00018506168,0.001345546,0.6378474,0.002663536,0.0027926404,0.0010870325],"about_ca_topic_score_codex":0.0013055021,"about_ca_topic_score_gemma":0.00026352072,"teacher_disagreement_score":0.3256758,"about_ca_system_score_codex":0.028766688,"about_ca_system_score_gemma":0.00367566,"threshold_uncertainty_score":0.99940586},"labels":[],"label_agreement":null},{"id":"W2026909379","doi":"10.1159/000205024","title":"Chronic Lymphocytic Leukemia in a Patient with Systemic Lupus erythematosus","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Malignancy; Pathogenesis; Autoimmunity; Immunology; Leukemia; Lupus erythematosus; Pathology; Antibody","score_opus":0.015035169126205075,"score_gpt":0.26399729625829166,"score_spread":0.2489621271320866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026909379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872578,0.0024537002,0.000031016934,0.000485977,0.000098913944,0.001366683,0.000002664574,0.00026226876,0.00804099],"genre_scores_gemma":[0.99810004,0.00023038842,0.00039952312,0.00055383483,0.00007516271,0.0001271974,0.000017292206,0.000039010338,0.00045752703],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9967076,0.00011251165,0.0006610015,0.00071384665,0.0007734021,0.0010316257],"domain_scores_gemma":[0.99816376,0.00022239353,0.00019039433,0.0009860588,0.00011982737,0.0003175643],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025036745,0.0004080322,0.0010228857,0.0003117228,0.00009258214,0.00004508908,0.00032631826,0.00029253308,0.00016184464],"category_scores_gemma":[0.0002134788,0.00027237317,0.00012982376,0.00075463415,0.00018614548,0.00013832576,0.00010037519,0.00040918324,0.0002312868],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03490081,0.0021907743,0.027783955,0.016933044,0.002062478,0.6509074,0.018963628,0.013843725,0.04952957,0.0246165,0.05406362,0.10420451],"study_design_scores_gemma":[0.0763742,0.0105574755,0.0016526125,0.005477383,0.0002562504,0.8363483,0.0015072742,0.051625103,0.009404864,0.0008073559,0.0045951987,0.0013940055],"about_ca_topic_score_codex":0.00036420932,"about_ca_topic_score_gemma":0.000086394284,"teacher_disagreement_score":0.18544088,"about_ca_system_score_codex":0.11562964,"about_ca_system_score_gemma":0.024406802,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W2027061435","doi":"10.1111/j.1600-6143.2008.02383.x","title":"Chronic Lymphocytic Leukemia: A Hazardous Condition Before Kidney Transplantation","year":2008,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; CD20; Transplantation; Regimen; Kidney transplantation; Rituximab; Leukemia; Surgery; Kidney; Kidney disease; Internal medicine; Lymphoma","score_opus":0.01126705699406537,"score_gpt":0.27912323586318233,"score_spread":0.26785617886911695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027061435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987616,0.00025467566,0.010499208,0.00037827852,0.00022336422,0.00032479502,0.000056100056,0.000053794465,0.0005938026],"genre_scores_gemma":[0.99244773,0.004474981,0.0015712347,0.0004578893,0.0005857602,0.000012520197,0.00023833594,0.000047320354,0.00016422417],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99740714,0.00013290234,0.0008016002,0.00025189054,0.0009789995,0.00042746865],"domain_scores_gemma":[0.9982698,0.00013950627,0.00051710365,0.00021773636,0.00037004973,0.00048578976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032609823,0.00024655403,0.0005995095,0.0004608078,0.00016021832,0.000019341398,0.00017472956,0.000101081474,0.00012022413],"category_scores_gemma":[0.00005919104,0.00021480421,0.00028010595,0.00055462384,0.00052069355,0.0003961525,0.0000046176624,0.00039190333,0.000055096716],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06528072,0.0009491625,0.024774902,0.015190231,0.0059702215,0.13476568,0.096766785,0.04382045,0.2521936,0.001384079,0.011877455,0.3470267],"study_design_scores_gemma":[0.15679802,0.026168482,0.08160167,0.004745154,0.004454333,0.5775151,0.0015178617,0.030868223,0.11101373,0.00038820755,0.0035397327,0.0013894705],"about_ca_topic_score_codex":0.0006175799,"about_ca_topic_score_gemma":0.000047064063,"teacher_disagreement_score":0.4427494,"about_ca_system_score_codex":0.030155826,"about_ca_system_score_gemma":0.031371716,"threshold_uncertainty_score":0.9741195},"labels":[],"label_agreement":null},{"id":"W2027086834","doi":"10.1016/s0140-6736(02)09487-4","title":"Possibilities of monoclonal antibodies","year":2002,"lang":"en","type":"article","venue":"The Lancet","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Monoclonal antibody; Intensive care medicine; Immunology; Antibody","score_opus":0.08512391906575725,"score_gpt":0.33228759780951245,"score_spread":0.2471636787437552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027086834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9522729,0.0014157527,0.0000050198846,0.003074235,0.00004049372,0.00012058813,0.0000103848715,0.00002887015,0.04303176],"genre_scores_gemma":[0.991566,0.00035755796,0.00032103393,0.00029702086,0.00044679898,0.0000042016954,0.0000020463672,0.0000074830646,0.006997837],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993089,0.000027872547,0.00012367808,0.000089078705,0.00024517163,0.00020530933],"domain_scores_gemma":[0.9992671,0.00014033564,0.000028075789,0.0004826681,0.000049040053,0.0000327634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019676302,0.000055985434,0.00025770086,0.000025282508,0.000031323492,0.0000069252796,0.00015533085,0.00002705214,0.0007247406],"category_scores_gemma":[0.00014741112,0.00003136215,0.00004844052,0.00008545161,0.00024250503,0.000023875786,0.000054213106,0.00010461966,0.00010806602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022560882,0.000731006,0.075919576,0.0024988686,0.00087019167,0.00033928725,0.022625055,0.00008766806,0.024286125,0.0291469,0.80826336,0.032975852],"study_design_scores_gemma":[0.15221335,0.003913959,0.2729622,0.002104145,0.00063236215,0.0035022877,0.0062914696,0.1916876,0.18769294,0.03816826,0.13946868,0.0013627507],"about_ca_topic_score_codex":0.00021269705,"about_ca_topic_score_gemma":0.0000069785406,"teacher_disagreement_score":0.6687947,"about_ca_system_score_codex":0.00045959983,"about_ca_system_score_gemma":0.00020512626,"threshold_uncertainty_score":0.7935401},"labels":[],"label_agreement":null},{"id":"W2027723382","doi":"10.1038/sj.thj.6200360","title":"CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia","year":2004,"lang":"en","type":"article","venue":"The Hematology Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Universität Ulm","keywords":"CD38; Trisomy; Hazard ratio; Internal medicine; Multivariate analysis; Stage (stratigraphy); Medicine; Oncology; Correlation; Gastroenterology; Confidence interval; Biology; Genetics; Mathematics","score_opus":0.017611850279612727,"score_gpt":0.3187702138694901,"score_spread":0.3011583635898774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027723382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913677,0.0040521743,0.00016215781,0.0021882155,0.000239531,0.00056447205,6.4061237e-7,0.000050562885,0.001374538],"genre_scores_gemma":[0.9982062,0.0003906445,0.00030490255,0.00045115693,0.00032321946,0.000056429028,0.0000031094594,0.000043299187,0.00022105328],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99736327,0.00019845658,0.0006166218,0.00031077166,0.0006443481,0.0008665333],"domain_scores_gemma":[0.9984257,0.00039734127,0.0002168468,0.0005295268,0.00007708994,0.00035345752],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088162214,0.00023900258,0.00053161464,0.00034920138,0.0002496844,0.00004195512,0.0004708706,0.00026937615,0.00047000093],"category_scores_gemma":[0.0008962914,0.00014704972,0.00014735946,0.00039411488,0.00044911247,0.00011898664,0.00018270098,0.0011666593,0.0010182386],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.026276557,0.0056754593,0.12447475,0.0072044763,0.0038731496,0.33027256,0.053629685,0.027039664,0.23433608,0.10653418,0.053265918,0.02741753],"study_design_scores_gemma":[0.13731071,0.0023095608,0.010069785,0.0054145562,0.00033386468,0.6877857,0.0011966653,0.0045776567,0.12058837,0.026403595,0.0032247156,0.0007848368],"about_ca_topic_score_codex":0.0001735868,"about_ca_topic_score_gemma":0.000032015894,"teacher_disagreement_score":0.35751313,"about_ca_system_score_codex":0.052848782,"about_ca_system_score_gemma":0.050553426,"threshold_uncertainty_score":0.99975955},"labels":[],"label_agreement":null},{"id":"W2028322499","doi":"10.1038/sj.bmt.1705748","title":"Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience","year":2007,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cyclophosphamide; Transplantation; Methotrexate; Stem cell; Surgery; Graft-versus-host disease; Internal medicine; Retrospective cohort study; Waldenstrom macroglobulinemia; Gastroenterology; Hematopoietic stem cell transplantation; Chemotherapy; Lymphoma","score_opus":0.025437686335656556,"score_gpt":0.2916172771219651,"score_spread":0.26617959078630854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028322499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206483,0.0019998178,0.003363287,0.00010263734,0.00026686196,0.0009582672,0.000042655163,0.000090800095,0.0011108329],"genre_scores_gemma":[0.997053,0.00097064255,0.0012251994,0.000059446957,0.00010464421,0.00005058876,0.0001014522,0.00004612601,0.00038885992],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99688244,0.00014734069,0.0007157373,0.0005703774,0.0010297581,0.0006543422],"domain_scores_gemma":[0.9980704,0.0008658636,0.00017264394,0.00042397607,0.00018003448,0.00028703953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063423987,0.00033477793,0.00048049472,0.00022523817,0.00007693676,0.00002812595,0.00017335432,0.00022540388,0.00021257323],"category_scores_gemma":[0.000027025102,0.00031201803,0.00022090139,0.00047131328,0.00021352022,0.00028220232,0.000014834524,0.00023301723,0.00005495952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07488018,0.00042452963,0.022125239,0.010531654,0.00013411405,0.009518417,0.014188159,0.00009729441,0.84999776,0.00004011986,0.000057654026,0.018004892],"study_design_scores_gemma":[0.02222394,0.0016063706,0.016101776,0.0020318136,0.0006553091,0.00121814,0.00051084586,0.00025789754,0.95492506,0.0000057479356,0.000075652606,0.00038743886],"about_ca_topic_score_codex":0.0002002018,"about_ca_topic_score_gemma":0.00033026945,"teacher_disagreement_score":0.104927324,"about_ca_system_score_codex":0.0019549406,"about_ca_system_score_gemma":0.0007024641,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W2029440792","doi":"10.1080/10428190500301231","title":"Generation of<i>in vitro</i>B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Leukemia Research Foundation","keywords":"CTL*; In vitro; Dendritic cell; Immunology; Cancer research; Lysis; Human leukocyte antigen; Class (philosophy); Chemistry; Biology; Molecular biology; Immune system; Cytotoxic T cell; Antigen; Biochemistry; Computer science","score_opus":0.034461594973760036,"score_gpt":0.2773981374998455,"score_spread":0.24293654252608546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029440792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937845,0.0022269003,0.0002797102,0.0002121582,0.00030317067,0.0016228892,0.000072985524,0.000260013,0.0012376598],"genre_scores_gemma":[0.9867591,0.0009452993,0.008982487,0.0006320674,0.00075164356,0.000119362776,0.00015653779,0.00024907658,0.0014043875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923781,0.0005549166,0.0018388465,0.0017112113,0.001578602,0.0019383071],"domain_scores_gemma":[0.99575204,0.00074324093,0.0005798418,0.0016184936,0.00047678954,0.00082957634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007893556,0.0010771822,0.0018468376,0.0013011951,0.00038711925,0.00020268855,0.0005719699,0.000797564,0.000092912385],"category_scores_gemma":[0.00027650507,0.00097156037,0.00031908634,0.0019192653,0.0009970671,0.0005658811,0.00028870473,0.00040233182,0.00007843261],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012119074,0.00057647517,0.001059539,0.0006094987,0.00030403252,0.004112482,0.0011301638,0.0030092022,0.91899866,0.0002440282,0.0010286861,0.05680815],"study_design_scores_gemma":[0.07005855,0.000801867,0.01365891,0.0007001023,0.00038506804,0.00787078,0.00042908965,0.32259634,0.57512057,0.00003827658,0.0071612694,0.001179187],"about_ca_topic_score_codex":0.0029479116,"about_ca_topic_score_gemma":0.00022174488,"teacher_disagreement_score":0.34387812,"about_ca_system_score_codex":0.06662993,"about_ca_system_score_gemma":0.02902437,"threshold_uncertainty_score":0.9992735},"labels":[],"label_agreement":null},{"id":"W2029549447","doi":"10.1016/j.jval.2011.02.887","title":"PCN29 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING RITUXIMAB (R) WITH FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C): ASSESSING THE FINANCIAL IMPACT OF THE ROUTE OF ADMINISTRATION AT PRINCESS MARGARET HOSPITAL (PMH)","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Roche (Canada)","funders":"","keywords":"Medicine; Fludarabine; Rituximab; Dosing; Cyclophosphamide; Route of administration; Regimen; Internal medicine; Chemotherapy; Lymphoma","score_opus":0.048381589222184065,"score_gpt":0.3374780089602432,"score_spread":0.28909641973805916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029549447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544907,0.0028083348,0.000068556255,0.000073437135,0.000086254935,0.0013711413,0.000026561178,0.00001004118,0.000106631596],"genre_scores_gemma":[0.99852353,0.00068600563,0.0006304328,0.000013665336,0.00006155449,0.000020705,0.000008510311,0.000029910696,0.000025674895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766695,0.00022421891,0.00078493176,0.0003210663,0.00054665684,0.0004561596],"domain_scores_gemma":[0.9982842,0.00019958183,0.0006411711,0.0006120215,0.00013225184,0.00013075111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005629646,0.00024003793,0.00069416524,0.000103474726,0.00013230096,0.000009690694,0.00018121372,0.000112199305,0.000021304963],"category_scores_gemma":[0.00013293867,0.00012907703,0.00013577059,0.00047371082,0.00052139634,0.00011484352,0.00009249637,0.00014337513,4.926841e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008968035,0.0038085575,0.87093306,0.010600809,0.00088842656,0.00036639775,0.027762588,0.04088593,0.005720806,0.0013249032,0.000051649964,0.028688844],"study_design_scores_gemma":[0.037823837,0.011862883,0.7021689,0.0028435122,0.00018620542,0.00055310887,0.00034872186,0.21795128,0.025825975,0.00015422954,0.000024295277,0.00025707824],"about_ca_topic_score_codex":0.06960542,"about_ca_topic_score_gemma":0.00095237937,"teacher_disagreement_score":0.17706536,"about_ca_system_score_codex":0.08370877,"about_ca_system_score_gemma":0.075429045,"threshold_uncertainty_score":0.93659014},"labels":[],"label_agreement":null},{"id":"W2029827415","doi":"10.1016/j.cmonc.2012.09.019","title":"Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice","year":2012,"lang":"en","type":"article","venue":"Community Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Research Society; American Society of Hematology; Leukemia and Lymphoma Society; Georgia Cancer Coalition","keywords":"Medicine; Chemoimmunotherapy; Chronic lymphocytic leukemia; Fludarabine; Quality of life (healthcare); Internal medicine; Rituximab; Regimen; Adverse effect; Oncology; Intensive care medicine; Leukemia; Cyclophosphamide; Lymphoma; Chemotherapy","score_opus":0.11117153704166961,"score_gpt":0.44226433856920033,"score_spread":0.33109280152753073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029827415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8239837,0.0064982963,0.0034057458,0.0035497504,0.0012524832,0.0034729904,0.000008482689,0.0002768954,0.15755166],"genre_scores_gemma":[0.96046257,0.00083554344,0.033074968,0.0022084096,0.00036271065,0.00030215672,0.000032794862,0.000054781412,0.0026660885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692875,0.0008320938,0.00071900844,0.00019183499,0.000533894,0.00079442986],"domain_scores_gemma":[0.9957612,0.001495718,0.00022131541,0.0015382839,0.00053836394,0.00044507947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035574276,0.00022420798,0.00063309947,0.00024119751,0.0002539755,0.000009695887,0.00058090285,0.00026709438,0.0001825307],"category_scores_gemma":[0.0016236532,0.0002115367,0.000120627075,0.0006004197,0.00020421867,0.00019103826,0.0010915201,0.00083230477,0.0004720854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0074490346,0.0031719191,0.00080492505,0.008427111,0.003377504,0.0014277218,0.016923377,0.004472378,0.021472737,0.012284331,0.14736365,0.7728253],"study_design_scores_gemma":[0.028056096,0.0031101261,0.0007144917,0.000817802,0.00072428014,0.002140118,0.0105804885,0.0052585974,0.003969431,0.000120573044,0.9441267,0.00038126513],"about_ca_topic_score_codex":0.003873663,"about_ca_topic_score_gemma":0.00011046403,"teacher_disagreement_score":0.79676306,"about_ca_system_score_codex":0.14926061,"about_ca_system_score_gemma":0.016198387,"threshold_uncertainty_score":0.98937887},"labels":[],"label_agreement":null},{"id":"W2031119437","doi":"10.1038/bcj.2013.43","title":"Pharmacological targeting of eIF4E in primary CLL lymphocytes","year":2013,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"EIF4E; Chronic lymphocytic leukemia; Medicine; Cancer research; Myeloid leukemia; Leukemia; Immunology; PI3K/AKT/mTOR pathway; Oncology; Biology; Translation (biology); Signal transduction; Genetics; Messenger RNA","score_opus":0.018326670456457937,"score_gpt":0.31478625160718254,"score_spread":0.2964595811507246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031119437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98572236,0.009815337,0.000011704496,0.00064039015,0.00019955254,0.00033189522,0.0000026351106,0.000016799133,0.0032593084],"genre_scores_gemma":[0.9937187,0.0033643355,0.0011398381,0.00059805124,0.0006988264,0.00005563482,0.0000025364304,0.000022342338,0.00039972833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806535,0.0000950368,0.00055401423,0.00019437597,0.0005815697,0.0005096328],"domain_scores_gemma":[0.9990492,0.00014135918,0.00017504623,0.00011346877,0.00024562454,0.00027533696],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052546524,0.00014085828,0.00040942553,0.00017403267,0.000054660493,0.000028539072,0.0002008292,0.00010620418,0.0033917103],"category_scores_gemma":[0.00015054771,0.00010444548,0.000118944554,0.00028454885,0.00012339662,0.0001581595,0.00009596355,0.0005097206,0.000038958213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00121422,0.0018465029,0.12034715,0.00088261045,0.00094695546,0.0021251559,0.0010030717,0.0004600306,0.77489626,0.000038844617,0.04051947,0.055719703],"study_design_scores_gemma":[0.21851915,0.0020380868,0.1816919,0.0023552033,0.0010714707,0.009813863,0.0009655401,0.011585319,0.562879,0.00072318735,0.0074057733,0.0009514919],"about_ca_topic_score_codex":0.0009362663,"about_ca_topic_score_gemma":0.0000082423985,"teacher_disagreement_score":0.21730493,"about_ca_system_score_codex":0.006384425,"about_ca_system_score_gemma":0.008137762,"threshold_uncertainty_score":0.9975193},"labels":[],"label_agreement":null},{"id":"W2031747016","doi":"10.1517/14712598.2014.922535","title":"Obinutuzumab for B-cell malignancies","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Obinutuzumab; Rituximab; Medicine; CD20; Chronic lymphocytic leukemia; Lymphoma; Oncology; Monoclonal antibody; Immunology; Internal medicine; Antibody; Leukemia","score_opus":0.25522970632836395,"score_gpt":0.4601535520919414,"score_spread":0.20492384576357747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031747016","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011743595,0.9933545,0.00016443316,0.00013573481,0.00087632105,0.0032779647,0.000036346162,0.00016902578,0.0019739273],"genre_scores_gemma":[0.000016427004,0.99242276,0.00062560407,0.0015388015,0.0022689472,0.0016861927,0.0006690048,0.000097945725,0.00067429506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691623,0.00031329168,0.00072138663,0.00094576494,0.00039456255,0.0007087751],"domain_scores_gemma":[0.99714833,0.001352535,0.00024916485,0.0008656205,0.00011277974,0.00027157058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005386618,0.0006742411,0.0025542073,0.00017447288,0.00012623271,0.000039194292,0.0004886766,0.0010602114,0.00046138413],"category_scores_gemma":[0.00026046805,0.00035826158,0.0013014568,0.00023126448,0.00022610177,0.000019649804,0.00008601989,0.00044552088,0.00044532248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004998417,0.00025036163,1.04307894e-7,0.0010459764,0.00012481629,0.000009509633,0.000029593844,1.1848192e-7,0.000028754539,0.00086732587,0.024339804,0.9728038],"study_design_scores_gemma":[0.008241779,0.0040304167,2.5794688e-7,0.004312147,0.0000025365132,0.00008423521,0.000009696627,0.000032768276,0.00010920309,0.0000750757,0.9826802,0.00042166887],"about_ca_topic_score_codex":0.000015696409,"about_ca_topic_score_gemma":8.032697e-8,"teacher_disagreement_score":0.9723821,"about_ca_system_score_codex":0.0071174093,"about_ca_system_score_gemma":0.0036675704,"threshold_uncertainty_score":0.99988693},"labels":[],"label_agreement":null},{"id":"W2032331743","doi":"10.4081/hr.2014.5288","title":"Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib","year":2014,"lang":"en","type":"article","venue":"Hematology Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Nilotinib; Medicine; Myasthenia gravis; Myeloid leukemia; Adverse effect; Tyrosine kinase; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Immunology; Imatinib; Cancer","score_opus":0.011109757962447673,"score_gpt":0.2555353076211821,"score_spread":0.24442554965873442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032331743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969869,0.000273651,0.00008818877,0.000048041016,0.000035640744,0.0008213742,4.147165e-7,0.00005267256,0.001693114],"genre_scores_gemma":[0.99340594,0.000012751952,0.0059044543,0.000019052279,0.00002512143,0.00023651375,0.000017706943,0.000046741843,0.00033172566],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99748003,0.000052021143,0.00082633353,0.00056700275,0.00048749923,0.0005871041],"domain_scores_gemma":[0.9985488,0.00007280716,0.00037318666,0.0007001728,0.0001173234,0.0001877136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023435825,0.00028573678,0.00082530384,0.00024260579,0.00006567373,0.000006063703,0.000061683044,0.00013239434,0.000062240884],"category_scores_gemma":[0.000051595387,0.00018576675,0.000052924275,0.00029144203,0.0002117041,0.00004156586,0.00006421503,0.00016195409,0.000012685717],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013504592,0.004331231,0.61181575,0.008483418,0.002753393,0.1978662,0.03571769,0.0008950597,0.04749692,0.0012513783,0.00015544743,0.075728945],"study_design_scores_gemma":[0.046513874,0.007059914,0.03332687,0.003001805,0.00022780737,0.28235766,0.0006044664,0.0010587341,0.6141566,0.000054655487,0.010794742,0.00084289734],"about_ca_topic_score_codex":0.00029234137,"about_ca_topic_score_gemma":0.0011462576,"teacher_disagreement_score":0.5784888,"about_ca_system_score_codex":0.013651018,"about_ca_system_score_gemma":0.01193674,"threshold_uncertainty_score":0.9936647},"labels":[],"label_agreement":null},{"id":"W2032765229","doi":"10.1111/bjh.12785","title":"Long‐term follow‐up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia","year":2014,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Neutropenia; Cytopenia; Internal medicine; Rituximab; Febrile neutropenia; Gastroenterology; Phases of clinical research; Multiple myeloma; Oncology; Toxicity; Lymphoma; Bone marrow","score_opus":0.0249349140721326,"score_gpt":0.2948622606583417,"score_spread":0.2699273465862091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032765229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906674,0.004269833,0.00008947859,0.0021959639,0.00064340787,0.0019416872,0.000047965576,0.000013899668,0.00013038993],"genre_scores_gemma":[0.99110967,0.00089293206,0.00014645225,0.0057487004,0.0011490033,0.000046017805,0.00033295542,0.00017835446,0.00039592062],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930096,0.00076026196,0.0030426346,0.0005507273,0.001608839,0.001027885],"domain_scores_gemma":[0.9942323,0.0006649171,0.002984668,0.00068565406,0.001167853,0.00026459023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089486956,0.00053919636,0.004179374,0.0009621936,0.00004084453,0.00003586742,0.0006650753,0.0011083652,0.00026478866],"category_scores_gemma":[0.0010111058,0.00049388397,0.0006607119,0.00047404977,0.0007304905,0.00013944259,0.00013848522,0.0016995925,0.000010513908],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.19883288,0.00392038,0.0025774164,0.01680352,0.0040714797,0.49452037,0.0004829837,0.00008018413,0.00037708887,0.000005321702,0.2625773,0.015751084],"study_design_scores_gemma":[0.7829068,0.016519265,0.00019973045,0.017172936,0.001415949,0.17600372,0.00000941483,0.000117943586,0.0017482197,0.0000238786,0.0034392478,0.00044291676],"about_ca_topic_score_codex":0.001432093,"about_ca_topic_score_gemma":0.00056548795,"teacher_disagreement_score":0.5840739,"about_ca_system_score_codex":0.023873933,"about_ca_system_score_gemma":0.025040003,"threshold_uncertainty_score":0.99975127},"labels":[],"label_agreement":null},{"id":"W2032810181","doi":"10.1016/j.bbmt.2009.11.021","title":"Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia","year":2009,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; Health Resources and Services Administration; Association of Medical Microbiology and Infectious Disease Canada; Society for Healthcare Epidemiology of America; Hospira; Infectious Diseases Society of America; CellGenix; Medical College of Wisconsin; Blue Cross and Blue Shield Association; American Society for Blood and Marrow Transplantation; Kiadis Pharma; Therakos; Centers for Disease Control and Prevention; Celgene; Osiris Therapeutics; WellPoint; Teva Pharmaceutical Industries; Oncology Nursing Society; Aetna; National Marrow Donor Program; AABB; U.S. Department of Health and Human Services; Astellas Pharma US; Amgen; U.S. Department of Defense; National Heart, Lung, and Blood Institute; Sysmex Corporation","keywords":"Medicine; Prolymphocytic leukemia; Internal medicine; Cumulative incidence; Confidence interval; Oncology; Population; Incidence (geometry); Hematopoietic cell; Leukemia; Transplantation; Surgery; Haematopoiesis; Stem cell; Chronic lymphocytic leukemia","score_opus":0.013132333049281903,"score_gpt":0.2717403369524214,"score_spread":0.2586080039031395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032810181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941617,0.0022143496,0.0018672615,0.0002289454,0.00004810415,0.0007879204,0.00007256068,0.000038982675,0.00058016874],"genre_scores_gemma":[0.9954942,0.0023174158,0.0014979292,0.0001889425,0.00005585112,0.000040133124,0.00026357538,0.000013013676,0.00012894324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989261,0.00003590542,0.0003236089,0.00029982967,0.00011368803,0.00030088783],"domain_scores_gemma":[0.99946785,0.00013338427,0.00007232435,0.00015040257,0.00006169971,0.00011432218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019193288,0.00015908365,0.00035224887,0.00011696773,0.00005518875,0.000005040357,0.0000741975,0.00019876315,0.000013698078],"category_scores_gemma":[0.000009691161,0.00013258596,0.000098573226,0.000086178,0.00013159991,0.000039240487,0.0000029063403,0.000076918186,0.0000022695133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017945374,0.00016965266,0.0011206389,0.001783401,0.00009315295,0.000056049445,0.00086470385,0.0000077506875,0.98963535,0.0010539832,0.000034746892,0.0033860398],"study_design_scores_gemma":[0.03880105,0.0029919017,0.0020641459,0.00027019234,0.0012849162,0.0016983688,0.00005950844,0.0006359495,0.95035434,0.0013891365,0.00020030266,0.00025019533],"about_ca_topic_score_codex":0.00004833174,"about_ca_topic_score_gemma":0.000009624801,"teacher_disagreement_score":0.03928101,"about_ca_system_score_codex":0.0002645578,"about_ca_system_score_gemma":0.0013306376,"threshold_uncertainty_score":0.54066986},"labels":[],"label_agreement":null},{"id":"W2033489247","doi":"10.1073/pnas.0406927102","title":"Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap","year":2004,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Leukemia and Lymphoma Society; University of Rochester; National Cancer Institute; National Institutes of Health; Valeant Pharmaceuticals International; Harvard University","keywords":"EIF4E; Guanosine; Translation (biology); Messenger RNA; Biology; Ribavirin; Protein biosynthesis; Cancer research; Cell biology; Biochemistry; Gene","score_opus":0.031864815780506414,"score_gpt":0.33073409185833513,"score_spread":0.2988692760778287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033489247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98823947,0.00027266727,0.00000133394,0.008999641,0.000019790352,0.00041469783,0.00005048034,0.000010676659,0.001991251],"genre_scores_gemma":[0.9992998,0.00008228347,0.00018947928,0.0002360588,0.0000740665,0.000012493432,0.0000011769854,0.0000065478334,0.00009804316],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99686354,0.00001110309,0.00043065337,0.00021423107,0.0022584354,0.00022201722],"domain_scores_gemma":[0.9989343,0.00020661295,0.00035308633,0.000021561951,0.0004279152,0.000056486988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000921579,0.00011845772,0.00025743167,0.0001319114,0.00013659128,0.000012191798,0.0008123604,0.00010387519,0.000014051539],"category_scores_gemma":[0.00096271845,0.00006512431,0.00016331248,0.0011622196,0.0015791986,0.00038043765,0.00011751142,0.00027368177,0.0000025933987],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006755825,0.00018844954,0.0002655664,0.00024352894,0.00003445183,1.1650998e-8,0.00073995336,0.00014667699,0.99316317,0.0038876552,0.0010666568,0.00019630449],"study_design_scores_gemma":[0.0026960461,0.00010759326,0.006185245,0.0002432946,0.000044147255,0.00002630058,0.00020052803,0.0017419346,0.98164034,0.0067652813,0.0002834922,0.000065796965],"about_ca_topic_score_codex":0.00008908125,"about_ca_topic_score_gemma":2.4856385e-7,"teacher_disagreement_score":0.011522846,"about_ca_system_score_codex":0.000905201,"about_ca_system_score_gemma":0.0010882069,"threshold_uncertainty_score":0.58186233},"labels":[],"label_agreement":null},{"id":"W2034457052","doi":"10.1038/sj.leu.2403247","title":"Imatinib sensitizes CLL lymphocytes to chlorambucil","year":2003,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Jewish General Hospital; Leukemia Research Foundation","keywords":"Chlorambucil; Imatinib; Cancer research; Medicine; Chronic lymphocytic leukemia; Leukemia; Hematology; Imatinib mesylate; Immunology; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.02185953892160975,"score_gpt":0.30061950718219543,"score_spread":0.2787599682605857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034457052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90364796,0.0003147119,0.00029503444,0.00057104405,0.00043998478,0.0007295547,0.0000089911655,0.00025543058,0.09373728],"genre_scores_gemma":[0.96842843,0.000049842336,0.0060810745,0.0032542853,0.0003108695,0.00006256795,0.000020570053,0.00008169525,0.02171065],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997264,0.00009455642,0.00041759445,0.00058284955,0.0007852839,0.00085566955],"domain_scores_gemma":[0.9978784,0.00025877892,0.00006126985,0.00092091324,0.00022926732,0.000651373],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005340576,0.00029856578,0.000501528,0.00021102627,0.00012533015,0.00006732985,0.00018120553,0.0001971849,0.000744469],"category_scores_gemma":[0.0012949958,0.00026252118,0.00016287052,0.0006369039,0.00012729836,0.0000956601,0.000104187515,0.000272456,0.003295488],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006045812,0.0010926975,0.0062241284,0.0033373921,0.0016064815,0.013800044,0.012487771,0.0033871625,0.19453014,0.05829686,0.6214226,0.07776892],"study_design_scores_gemma":[0.056472775,0.0010607879,0.0029037397,0.0006647624,0.00022939587,0.006002805,0.0011384494,0.013175193,0.44254225,0.0014829084,0.4729788,0.0013481303],"about_ca_topic_score_codex":0.0005118217,"about_ca_topic_score_gemma":0.0000374708,"teacher_disagreement_score":0.24801213,"about_ca_system_score_codex":0.032403782,"about_ca_system_score_gemma":0.014737836,"threshold_uncertainty_score":0.9999827},"labels":[],"label_agreement":null},{"id":"W2035688890","doi":"10.1016/j.bbmt.2014.05.020","title":"Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Onyx Pharmaceuticals; Medac; Swedish Orphan Biovitrum; Incyte; Genentech; Seattle Genetics; University of Utah; Blue Cross and Blue Shield Association; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Chimerix; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; University of Minnesota; Otsuka America Pharmaceutical; Amgen; Allos Therapeutics; Actinium Pharmaceuticals; Ariad Pharmaceuticals; National Marrow Donor Program; St. Baldrick's Foundation; National Institute of Allergy and Infectious Diseases; Fred Hutchinson Cancer Research Center; Osiris Therapeutics; Celgene; WellPoint; Sanofi; Merck; GlaxoSmithKline; Leukemia and Lymphoma Society; Be The Match Foundation","keywords":"Medicine; Internal medicine; Transplantation; Gastroenterology; Confidence interval; Chronic lymphocytic leukemia; Hematopoietic stem cell transplantation; Surgery; Leukemia; Oncology","score_opus":0.02126447397024744,"score_gpt":0.29497797673087167,"score_spread":0.2737135027606242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035688890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977098,0.00043809332,0.0005924965,0.000045521494,0.0001077819,0.00047433167,0.000028155264,0.000056480072,0.0005473154],"genre_scores_gemma":[0.9972759,0.001754197,0.000443066,0.000028377324,0.0000453528,0.000021955633,0.00036842635,0.000028834032,0.000033878023],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817467,0.00015718029,0.00068033865,0.00041633824,0.00021170052,0.0003597682],"domain_scores_gemma":[0.9987822,0.00046662084,0.00028390548,0.00022066094,0.00014620856,0.000100385696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046826465,0.0002420017,0.00076922553,0.00038570166,0.00008148782,0.0000074261484,0.00009959688,0.0002787046,0.00001591128],"category_scores_gemma":[0.0000436503,0.00022635043,0.00011275062,0.00024855518,0.0003912821,0.00011837798,0.000013081626,0.00020545642,0.0000024978926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020852715,0.00006348947,0.012108176,0.0025877731,0.0002192752,0.000053985597,0.002909275,0.00034403158,0.97868854,0.0007587026,0.000004819264,0.00017666064],"study_design_scores_gemma":[0.048370518,0.0013833784,0.036763646,0.0006529808,0.00077633036,0.00022843576,0.00042347304,0.0026283977,0.9081709,0.0003372113,0.0000041364474,0.0002605856],"about_ca_topic_score_codex":0.0014537243,"about_ca_topic_score_gemma":0.00026627546,"teacher_disagreement_score":0.07051763,"about_ca_system_score_codex":0.0022817792,"about_ca_system_score_gemma":0.0023368436,"threshold_uncertainty_score":0.92303026},"labels":[],"label_agreement":null},{"id":"W2035860257","doi":"10.2147/btt.s61600","title":"Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia","year":2015,"lang":"en","type":"review","venue":"Biologics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Obinutuzumab; Chemoimmunotherapy; Rituximab; Medicine; Chronic lymphocytic leukemia; CD20; Monoclonal antibody; Oncology; Immunology; Monoclonal antibody therapy; Lymphoma; Ofatumumab; Leukemia; Antibody","score_opus":0.0957161881886593,"score_gpt":0.4039952895686591,"score_spread":0.3082791013799998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035860257","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030266486,0.9659301,7.279992e-7,0.0000014897548,0.00009433296,0.0027831367,0.0001047205,0.000015829168,0.000803161],"genre_scores_gemma":[0.006885139,0.9920241,0.0001115534,0.000012091241,0.00020185745,0.00016739016,0.00044623285,0.00003697906,0.00011464498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965688,0.0005781177,0.0012976225,0.0005143928,0.00059459347,0.00044645916],"domain_scores_gemma":[0.9968685,0.0009290796,0.00071487355,0.0010776857,0.000281922,0.00012793203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079693284,0.00045368003,0.0029458369,0.00017265989,0.000021181108,0.0000060040534,0.0004970925,0.00067424047,0.000025922902],"category_scores_gemma":[0.00026270622,0.00019577408,0.0005339599,0.0005410069,0.000586777,0.000020391226,0.00008941787,0.00029810608,0.00003850409],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004721732,0.00046948847,0.0011937448,0.0057463837,0.0005142384,0.000075119206,0.00023797952,0.000014622952,1.5743333e-7,0.00005971372,0.00019255288,0.99102384],"study_design_scores_gemma":[0.021366445,0.015537165,0.0003014149,0.0059444834,0.0011605107,0.00007202468,0.00008738856,0.00026976972,0.0000032442074,0.000031234038,0.95496935,0.00025695993],"about_ca_topic_score_codex":0.0008989163,"about_ca_topic_score_gemma":0.00005659183,"teacher_disagreement_score":0.9907669,"about_ca_system_score_codex":0.18156621,"about_ca_system_score_gemma":0.12027217,"threshold_uncertainty_score":0.8847151},"labels":[],"label_agreement":null},{"id":"W2036050286","doi":"10.1016/j.bbmt.2013.11.032","title":"Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Osiris Therapeutics; Celgene; U.S. Navy; Genentech; Health Resources and Services Administration; Therakos; Sigma-Tau Pharmaceuticals; Kiadis Pharma; U.S. Department of Defense; Onyx Pharmaceuticals; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; Swedish Orphan Biovitrum; Teva Pharmaceutical Industries; WellPoint; HistoGenetics; Otsuka America; Amgen; Allos Therapeutics; Ariad Pharmaceuticals; GlaxoSmithKline; Sanofi","keywords":"Medicine; Total body irradiation; Fludarabine; Internal medicine; Chronic lymphocytic leukemia; Transplantation; Sibling; Gastroenterology; Confidence interval; Oncology; Leukemia; Cancer; Immunology; Chemotherapy; Surgery; Cyclophosphamide","score_opus":0.011638983147246785,"score_gpt":0.2948767863175492,"score_spread":0.28323780317030245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036050286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405307,0.00027977262,0.003769131,0.00008930761,0.0001415708,0.0012304564,0.00026721534,0.000039551094,0.00012991783],"genre_scores_gemma":[0.99677706,0.0006340135,0.0011576252,0.000029573035,0.00009572712,0.00015736655,0.000955118,0.000022579798,0.00017091978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983445,0.0000730549,0.0007073126,0.00035282614,0.00018548591,0.0003368538],"domain_scores_gemma":[0.9987342,0.00051436626,0.00024794118,0.00015642031,0.00023457751,0.00011251746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025250835,0.00020595301,0.0005296028,0.0002858597,0.00015563518,0.00001670489,0.000077549885,0.00022706819,0.000070144],"category_scores_gemma":[0.000061680155,0.00015003195,0.00015093594,0.00013645113,0.00038422216,0.00023226181,0.000008693532,0.00011592125,0.000003000166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023235248,0.00005629512,0.011884979,0.0016209213,0.0005090544,0.00000683409,0.0009006422,0.000084976775,0.9816624,0.0024482799,0.0000071226723,0.00058614084],"study_design_scores_gemma":[0.03468212,0.0018729067,0.111724205,0.00039455594,0.0016237971,0.00017637786,0.00035909723,0.014106617,0.8327922,0.0019234566,0.000009814788,0.0003348048],"about_ca_topic_score_codex":0.0014370056,"about_ca_topic_score_gemma":0.00011324921,"teacher_disagreement_score":0.14887016,"about_ca_system_score_codex":0.0012842715,"about_ca_system_score_gemma":0.0023375906,"threshold_uncertainty_score":0.61181253},"labels":[],"label_agreement":null},{"id":"W2036365736","doi":"10.1158/1538-7445.am10-3207","title":"Abstract 3207: Telomerase inhibition affects fludarabine sensitivity in quiescent primary chronic lymphocytic leukemia lymphocytes","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Parks Canada; McGill University","funders":"","keywords":"Telomerase; Chronic lymphocytic leukemia; Fludarabine; Telomere; Medicine; Cancer; Cancer research; Leukemia; Shelterin; Immunology; Oncology; Internal medicine; Biology; Chemotherapy; Genetics; DNA; Cyclophosphamide","score_opus":0.032693441251548085,"score_gpt":0.364059816966657,"score_spread":0.3313663757151089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036365736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902428,0.0021361078,0.0000068143486,0.0007531088,0.00049521273,0.002063514,0.000038380178,0.00018353829,0.0040805177],"genre_scores_gemma":[0.99458027,0.0016525561,0.00009123502,0.00028670763,0.0014811405,0.00055168447,0.0001249604,0.00013756134,0.0010938707],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9930119,0.0003353066,0.00062482065,0.0012393242,0.002584604,0.002204038],"domain_scores_gemma":[0.99604106,0.001061338,0.00011598065,0.0013427365,0.00059843244,0.00084042666],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043057515,0.0004827137,0.00083792524,0.001174543,0.0003195884,0.00014990268,0.00030031212,0.00053317705,0.001131823],"category_scores_gemma":[0.0010124679,0.00044869914,0.00020451775,0.0019575502,0.0011465155,0.00039009715,0.00048961694,0.0025814727,0.00061415334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017376232,0.00020222085,0.0019235819,0.0023363447,0.000079600606,0.0044509997,0.00027298153,0.000551504,0.957797,0.00015940523,0.006000226,0.024488518],"study_design_scores_gemma":[0.048100747,0.00063750613,0.07082725,0.002419158,0.000050240822,0.001163511,0.0001421584,0.013431102,0.85455227,0.0001597881,0.007684259,0.0008320253],"about_ca_topic_score_codex":0.017115138,"about_ca_topic_score_gemma":0.008985589,"teacher_disagreement_score":0.17087811,"about_ca_system_score_codex":0.30601043,"about_ca_system_score_gemma":0.13513231,"threshold_uncertainty_score":0.99979645},"labels":[],"label_agreement":null},{"id":"W2039165751","doi":"10.1007/s00467-010-1476-3","title":"New therapies, new concerns: rituximab-associated lung injury","year":2010,"lang":"en","type":"review","venue":"Pediatric Nephrology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital","funders":"","keywords":"Rituximab; Medicine; Nephrology; Nephrotic syndrome; Internal medicine; Disease; Interstitial lung disease; Monoclonal; Monoclonal antibody; Immunology; Intensive care medicine; Lung; Antibody","score_opus":0.03848436431671379,"score_gpt":0.37181155444060193,"score_spread":0.3333271901238881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039165751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010610028,0.9939712,0.00010706777,0.00040327047,0.0014250166,0.002320111,0.00006499306,0.00032802296,0.0012742011],"genre_scores_gemma":[0.000011206106,0.96886396,0.0007713771,0.001015029,0.013675826,0.00011889957,0.00044559155,0.00026604117,0.014832088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99440503,0.00044579423,0.0014160397,0.0012465323,0.0009009397,0.0015856841],"domain_scores_gemma":[0.99505943,0.0012983679,0.00083106663,0.0014727149,0.00019892545,0.0011395087],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0007358018,0.0010114103,0.0044557727,0.0008935336,0.00013211326,0.00006580473,0.0009619224,0.002901628,0.0042950585],"category_scores_gemma":[0.0009827147,0.00082360586,0.001041856,0.0016130167,0.0001952544,0.00013029348,0.00045872308,0.0034208158,0.0019376089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000105613195,0.00014472923,0.000047007234,0.0038037738,0.0006278443,0.00029649853,0.00007765942,3.699042e-8,9.284467e-7,0.00013190665,0.3045148,0.6902492],"study_design_scores_gemma":[0.011645273,0.00041062947,0.000012293019,0.00048277463,0.0053204717,0.0005785714,0.0000027425997,0.000026499849,3.6671534e-7,0.00020380749,0.9807198,0.000596777],"about_ca_topic_score_codex":0.0025479044,"about_ca_topic_score_gemma":0.00013754115,"teacher_disagreement_score":0.68965244,"about_ca_system_score_codex":0.009902023,"about_ca_system_score_gemma":0.08569996,"threshold_uncertainty_score":0.9994215},"labels":[],"label_agreement":null},{"id":"W2040039314","doi":"10.3109/10428190109097717","title":"A Multicentric Study of 41 Cases of B-Prolymphocytic Leukemia: Two Evolutive Forms: The Groupe Français d'Hématologie Cellulaire","year":2001,"lang":"fr","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Prolymphocytic leukemia; Medicine; Chronic lymphocytic leukemia; Internal medicine; Immunophenotyping; Univariate analysis; Leukemia; CD5; Gastroenterology; Anemia; Concordance; Multivariate analysis; Immunology; Lymphoma; Antigen","score_opus":0.022949868926353215,"score_gpt":0.28775321473783533,"score_spread":0.2648033458114821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040039314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8833823,0.1025681,0.00012605479,0.00023876362,0.0022676738,0.0057116854,0.00030886335,0.0003012367,0.0050952937],"genre_scores_gemma":[0.97856236,0.013583483,0.00028542962,0.0005092634,0.001276396,0.00061821163,0.00011225664,0.00048590728,0.004566684],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98105055,0.0017610282,0.0049708737,0.0032293424,0.0040790164,0.004909166],"domain_scores_gemma":[0.9832549,0.006580284,0.0023411908,0.004520293,0.0015169394,0.0017863687],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","sts"],"category_scores_codex":[0.0027984574,0.0027812433,0.004883761,0.001509857,0.0013571561,0.00025808797,0.002811812,0.001957132,0.0005367997],"category_scores_gemma":[0.0026067884,0.0022286596,0.0013543074,0.005127423,0.005256437,0.0011711153,0.0021938314,0.0010535598,0.0003728822],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03344172,0.0149579095,0.11712518,0.016077902,0.012697423,0.055894695,0.077019125,0.007766035,0.0071105263,0.009296043,0.010273903,0.6383395],"study_design_scores_gemma":[0.3920789,0.011798575,0.123228855,0.007012493,0.009783762,0.04750798,0.07577898,0.29486755,0.017787175,0.0010681116,0.014281396,0.004806249],"about_ca_topic_score_codex":0.13222578,"about_ca_topic_score_gemma":0.0038732635,"teacher_disagreement_score":0.6335333,"about_ca_system_score_codex":0.16416802,"about_ca_system_score_gemma":0.075046144,"threshold_uncertainty_score":0.99994296},"labels":[],"label_agreement":null},{"id":"W2040154764","doi":"10.1016/j.cyto.2010.07.011","title":"HL-2 Lost in translation","year":2010,"lang":"en","type":"article","venue":"Cytokine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Translation (biology); Chemistry; Computational biology; Biology; Biochemistry","score_opus":0.026910341500883034,"score_gpt":0.32011378056703627,"score_spread":0.2932034390661532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040154764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666106,0.00008038733,0.00006956263,0.0012310094,0.0001341109,0.00025491032,0.0000033708275,0.00003073728,0.031585272],"genre_scores_gemma":[0.99750006,0.000018051212,0.0007863337,0.00016319736,0.0002411023,0.000008575042,0.00002188083,0.00001653231,0.0012442918],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992037,0.000011710771,0.00015723,0.00016648047,0.00023564951,0.00022523991],"domain_scores_gemma":[0.9995012,0.00006589432,0.000016061595,0.000278028,0.00003938737,0.00009939306],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020578067,0.000073415424,0.0001425562,0.00012598035,0.000014916897,0.000008351016,0.00006827432,0.0000987986,0.0010110803],"category_scores_gemma":[0.00011639593,0.000063088024,0.000037105114,0.0002509595,0.000065357555,0.000052282696,0.000016111222,0.00033528198,0.0004525014],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093287625,0.0004960894,0.019004619,0.0003014542,0.000041863626,0.0010021097,0.0010484891,0.000022101485,0.87070054,0.0022804614,0.0033480576,0.10082136],"study_design_scores_gemma":[0.11788103,0.0007486079,0.15791868,0.00034737607,0.00010033207,0.0018584072,0.00016311671,0.073203295,0.307603,0.0015582104,0.33787724,0.0007407005],"about_ca_topic_score_codex":0.00022920582,"about_ca_topic_score_gemma":0.0005414537,"teacher_disagreement_score":0.56309754,"about_ca_system_score_codex":0.0009694255,"about_ca_system_score_gemma":0.0011670291,"threshold_uncertainty_score":0.9999021},"labels":[],"label_agreement":null},{"id":"W2040267768","doi":"10.1002/ajh.20680","title":"Waldenstrom's macroglobulinemia presenting with spinal cord compression: A case report","year":2006,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Hepatosplenomegaly; Waldenstrom macroglobulinemia; Bone marrow; Cytopenia; Pathology; Lymphoplasmacytic Lymphoma; Macroglobulinemia; Spinal cord compression; Hyperviscosity syndrome; Back pain; Spinal cord; Lymphoma; Internal medicine; Disease; Multiple myeloma","score_opus":0.014939438870727854,"score_gpt":0.3321530409717257,"score_spread":0.31721360210099786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040267768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447715,0.00042060326,0.0015846192,0.0015037066,0.00010422974,0.0001661556,0.0000012774198,0.000023621982,0.0017186541],"genre_scores_gemma":[0.98683006,0.000008321989,0.012239809,0.000120791876,0.0003566014,0.000004258264,0.0000037666562,0.000030566465,0.00040582818],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9976893,0.00010858021,0.0008748019,0.0002533409,0.0005746399,0.0004993515],"domain_scores_gemma":[0.99766463,0.00016847698,0.0010196035,0.00039162883,0.0004919775,0.00026367526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003450169,0.00019021108,0.00090213976,0.0002075586,0.00008874499,0.000019675213,0.00015851921,0.00006077162,0.00009748496],"category_scores_gemma":[0.00015297454,0.00013044907,0.00014820279,0.0003584843,0.0007969224,0.00007447705,0.00008206014,0.00050188415,0.00001108829],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037862654,0.00018814088,0.020867528,0.00009585273,0.00016213926,0.9661161,0.000029603143,0.000025004958,0.00039740987,0.00025770647,0.004411974,0.0036622833],"study_design_scores_gemma":[0.0059986264,0.0035803257,0.0014545239,0.00023087139,0.00014399285,0.9834422,0.00052471005,0.00051456725,0.002077529,0.00006862655,0.0018415131,0.0001225454],"about_ca_topic_score_codex":0.0009690764,"about_ca_topic_score_gemma":0.000035768397,"teacher_disagreement_score":0.019413006,"about_ca_system_score_codex":0.0011026096,"about_ca_system_score_gemma":0.0029506274,"threshold_uncertainty_score":0.5319559},"labels":[],"label_agreement":null},{"id":"W2041013986","doi":"10.1016/j.jmoldx.2012.07.006","title":"Sequencing of t(2;7) Translocations Reveals a Consistent Breakpoint Linking CDK6 to the IGK Locus in Indolent B-Cell Neoplasia","year":2012,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Breakpoint; Chromosomal translocation; Biology; Genetics; Locus (genetics); Gene rearrangement; Recombination signal sequences; Molecular biology; Gene; Recombination-activating gene; Recombination","score_opus":0.021765246050530842,"score_gpt":0.2933680142393105,"score_spread":0.2716027681887797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041013986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98108953,0.0066051376,0.008925878,0.0021570472,0.0002196938,0.0005733971,0.000007870812,0.000005052669,0.00041636475],"genre_scores_gemma":[0.99511045,0.0007451601,0.0030440136,0.00083399203,0.00019918187,0.000011128033,0.0000032747903,0.000029911811,0.000022891267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744475,0.00018767305,0.00093599805,0.00012320023,0.0008668467,0.00044156064],"domain_scores_gemma":[0.99751663,0.0009435865,0.00033449198,0.00038819475,0.00046506687,0.00035200338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015288449,0.00015855124,0.00045622163,0.00031520563,0.000039868788,0.000018481118,0.0002495691,0.00010910697,0.00001777642],"category_scores_gemma":[0.001919596,0.0001141719,0.00021344598,0.0004844874,0.00008417056,0.00006713538,0.0000729351,0.00053851254,0.000015347048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001934204,0.0064321244,0.056515887,0.0038326792,0.0015963339,0.012883968,0.06296774,0.06268435,0.7476063,0.0038702628,0.010430843,0.029245313],"study_design_scores_gemma":[0.04924393,0.0036724624,0.023446029,0.013894671,0.0021920344,0.017797936,0.0064370767,0.0035859663,0.8704021,0.00083805004,0.007486098,0.0010036709],"about_ca_topic_score_codex":0.00014557899,"about_ca_topic_score_gemma":0.000051039002,"teacher_disagreement_score":0.12279578,"about_ca_system_score_codex":0.0038522813,"about_ca_system_score_gemma":0.0037215156,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W2041313070","doi":"10.1016/s1535-6108(03)00136-3","title":"Escape from Cbl-mediated downregulation","year":2003,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Receptor tyrosine kinase; Endocytosis; Downregulation and upregulation; Ubiquitin; Cell biology; Biology; Receptor; Lysosome; Signal transduction; Cancer research; Genetics; Biochemistry; Gene","score_opus":0.01826539337311441,"score_gpt":0.2899037747678703,"score_spread":0.27163838139475593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041313070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90675056,0.006524821,0.00015425334,0.00026124925,0.00032607306,0.0003754557,0.000026016563,0.000084974905,0.08549659],"genre_scores_gemma":[0.99182135,0.0005177415,0.00039667435,0.00039008356,0.00023866414,0.00004242326,0.00008818473,0.000028400571,0.0064764973],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989212,0.000041125553,0.00016401918,0.00026455548,0.0003228301,0.00028625486],"domain_scores_gemma":[0.99923575,0.000103653416,0.00004221194,0.00034562277,0.000087683125,0.00018505834],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010312896,0.00011056948,0.00017880804,0.000033674263,0.000037528862,0.000013842223,0.000068087444,0.00010558252,0.007283154],"category_scores_gemma":[0.00007894239,0.0000964395,0.00005486655,0.0001744927,0.000053105585,0.000063695006,0.000017935725,0.000120481855,0.0005023965],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014486552,0.00096928916,0.024510419,0.00089510024,0.0005300134,0.00065163354,0.0037212432,0.00085797795,0.7125478,0.0010901663,0.21853724,0.034240503],"study_design_scores_gemma":[0.04783862,0.000227612,0.018029254,0.0002306478,0.0002366527,0.000035248944,0.0004545768,0.01832272,0.3810394,0.00053472916,0.53247625,0.0005742809],"about_ca_topic_score_codex":0.0026187156,"about_ca_topic_score_gemma":0.00016147358,"teacher_disagreement_score":0.33150837,"about_ca_system_score_codex":0.007629542,"about_ca_system_score_gemma":0.0035034616,"threshold_uncertainty_score":0.99618},"labels":[],"label_agreement":null},{"id":"W2041968741","doi":"10.1080/10428190290026295","title":"The Development of Marked Elevation in White Blood Cell Count Does Not Predict Inferior Outcome in Chronic Lymphocytic Leukemia","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; White blood cell; Internal medicine; Stage (stratigraphy); Gastroenterology; Clinical significance; Leukemia; Surgery","score_opus":0.02907200730900288,"score_gpt":0.3000358864022648,"score_spread":0.2709638790932619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041968741","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23706886,0.75353366,0.000021014617,0.00002718715,0.00070612825,0.0054551894,0.00014870088,0.00025947587,0.0027797574],"genre_scores_gemma":[0.07849146,0.9103741,0.0006371994,0.00016786672,0.0005873134,0.0018490554,0.0004436031,0.0005639271,0.0068854736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9817835,0.0009769838,0.0077123335,0.002980676,0.0031199264,0.0034265418],"domain_scores_gemma":[0.99026406,0.002669722,0.0024828685,0.0031242757,0.00045360008,0.0010055035],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003740376,0.0028409834,0.0068994625,0.002334196,0.00062518765,0.00036459893,0.0020539279,0.0027444537,0.00018797595],"category_scores_gemma":[0.0008658192,0.0019909146,0.0012257971,0.0032314383,0.0012340384,0.0005302038,0.0012651018,0.0012065902,0.0002047729],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001123895,0.00033842315,0.0024191488,0.059074204,0.0010183334,0.0016424828,0.0018015924,0.00020024602,0.00016180502,0.00014029382,0.00047626666,0.9316033],"study_design_scores_gemma":[0.13639498,0.0010243148,0.011653976,0.04758877,0.003838287,0.0033912866,0.0006571449,0.04143213,0.001361206,0.00006649754,0.7478578,0.004733619],"about_ca_topic_score_codex":0.0032121218,"about_ca_topic_score_gemma":0.0022173342,"teacher_disagreement_score":0.9268697,"about_ca_system_score_codex":0.54332364,"about_ca_system_score_gemma":0.266445,"threshold_uncertainty_score":0.9985502},"labels":[],"label_agreement":null},{"id":"W2042464208","doi":"10.1016/j.annder.2011.10.265","title":"Taux de survenue de cancer dans le programme de développement clinique de l’ustekinumab : mise à jour avec jusqu’à 4 ans de suivi et comparaison avec la population générale des États-Unis","year":2011,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Gynecology","score_opus":0.15200036845454107,"score_gpt":0.41799906336982223,"score_spread":0.26599869491528116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042464208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9418535,0.00899574,0.031222276,0.0137188975,0.00039844794,0.0013865593,0.00017527193,0.0005328141,0.0017164655],"genre_scores_gemma":[0.93918204,0.01679059,0.038219158,0.0034816444,0.00032479755,0.0008035936,0.00021316572,0.00021783022,0.00076720305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.983812,0.006598871,0.0014466818,0.001125722,0.00072284276,0.006293919],"domain_scores_gemma":[0.9931611,0.002798471,0.00064846646,0.0011713007,0.00045640612,0.0017642993],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0102859,0.00096222066,0.0014362579,0.00045864302,0.00073820073,0.000269665,0.0014182528,0.0017299104,0.00020634868],"category_scores_gemma":[0.0056522735,0.0010652215,0.000569488,0.0007728338,0.0020526329,0.00046534403,0.0005619631,0.0022208455,0.000077004705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011876023,0.0017735865,0.89615256,0.0022996361,0.0006937,0.0127171045,0.051691342,0.0028612914,0.001938473,0.002378882,0.0129692,0.01333662],"study_design_scores_gemma":[0.012542472,0.00085724314,0.8273781,0.00230229,0.0007046425,0.01804011,0.007741458,0.061741184,0.035652634,0.023343377,0.008168937,0.0015275596],"about_ca_topic_score_codex":0.041557215,"about_ca_topic_score_gemma":0.026434131,"teacher_disagreement_score":0.06877447,"about_ca_system_score_codex":0.04589815,"about_ca_system_score_gemma":0.065790564,"threshold_uncertainty_score":0.9995661},"labels":[],"label_agreement":null},{"id":"W2043595799","doi":"10.1002/ajh.20747","title":"Aberrant expression of T‐cell‐associated markers CD4 and CD7 on B‐cell chronic lymphocytic leukemia","year":2006,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Immunophenotyping; Chronic lymphocytic leukemia; CD5; Fluorescence in situ hybridization; CD20; Biology; Trisomy; Cancer research; Leukemia; Gene rearrangement; Pathology; Immunology; Flow cytometry; Antibody; Medicine; Chromosome; Gene; Genetics","score_opus":0.006723992156853539,"score_gpt":0.2558490728327741,"score_spread":0.24912508067592054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043595799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941822,0.0021164857,0.00012248263,0.0001630552,0.00011167208,0.0001931079,0.000003929902,0.00001715995,0.0030898969],"genre_scores_gemma":[0.99822676,0.00036758845,0.00064754253,0.00014217962,0.0001012762,0.000004235112,0.0000055547052,0.00004265765,0.00046218684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99738705,0.00023466769,0.0009316261,0.00027502794,0.0006239612,0.0005476506],"domain_scores_gemma":[0.99741775,0.0006511927,0.0011004489,0.00033985535,0.00024483676,0.00024594378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048647347,0.0002483749,0.0011813072,0.00037874715,0.000060169208,0.000009612713,0.00021552881,0.00013944601,0.00011212638],"category_scores_gemma":[0.00018122217,0.00019284712,0.00020297074,0.00036844407,0.00082175655,0.00006329711,0.00007633219,0.00040551426,0.000016396027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01715146,0.0017764319,0.016864821,0.002855958,0.0008634941,0.010805518,0.0014339837,0.0030272363,0.877624,0.0009990116,0.05420347,0.012394639],"study_design_scores_gemma":[0.08204957,0.017525919,0.0073067667,0.0027958588,0.00063493877,0.019768286,0.0019660734,0.01206515,0.8529403,0.00055243756,0.001650496,0.00074415933],"about_ca_topic_score_codex":0.00090528827,"about_ca_topic_score_gemma":0.000020990019,"teacher_disagreement_score":0.06489811,"about_ca_system_score_codex":0.020883154,"about_ca_system_score_gemma":0.01333141,"threshold_uncertainty_score":0.99226207},"labels":[],"label_agreement":null},{"id":"W2043688074","doi":"10.1111/j.1365-2141.2008.07418.x","title":"Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine <i>in vitro</i>","year":2008,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; CancerCare Manitoba; Jewish General Hospital","funders":"Leukemia and Lymphoma Society; Canadian Institutes of Health Research; Bristol-Myers Squibb","keywords":"Chlorambucil; Fludarabine; Dasatinib; Chronic lymphocytic leukemia; Cancer research; Medicine; Immunology; Internal medicine; Leukemia; Chemotherapy; Imatinib; Myeloid leukemia","score_opus":0.015242801933903328,"score_gpt":0.25840118592357314,"score_spread":0.24315838398966982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043688074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805494,0.017031917,0.000078421865,0.0006636988,0.00034116907,0.00045806935,0.000012270783,0.000035649926,0.0008293958],"genre_scores_gemma":[0.989882,0.0052395463,0.0023717806,0.001496038,0.00038615701,0.000015097804,0.000014556876,0.000065550164,0.0005292985],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9964781,0.00020620367,0.0012385071,0.00046471553,0.0007565541,0.0008559572],"domain_scores_gemma":[0.99785006,0.00046157153,0.0003155819,0.00034938194,0.00041487973,0.0006085343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079244346,0.00030128073,0.0016431604,0.00051776035,0.00014946969,0.000044902532,0.00026528773,0.00027549342,0.000070628696],"category_scores_gemma":[0.00086289336,0.00032200618,0.00019788579,0.0005171359,0.0005479483,0.00022053294,0.00022009922,0.00054484716,0.000056800192],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0060495217,0.00037660872,0.0013197244,0.0016505857,0.00041091506,0.87175745,0.0013548201,0.00034143138,0.06822539,0.00007896883,0.018447502,0.02998709],"study_design_scores_gemma":[0.033082508,0.0006934299,0.0031500433,0.0010759688,0.00007899472,0.929069,0.000125079,0.0013251724,0.028739229,0.00007960654,0.0022926843,0.00028832324],"about_ca_topic_score_codex":0.00078232033,"about_ca_topic_score_gemma":0.00016555123,"teacher_disagreement_score":0.05731152,"about_ca_system_score_codex":0.023466107,"about_ca_system_score_gemma":0.023490002,"threshold_uncertainty_score":0.9999232},"labels":[],"label_agreement":null},{"id":"W2043831614","doi":"10.1182/blood-2008-09-177329","title":"Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"National Cancer Institute","keywords":"Medicine; Fludarabine; Rituximab; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Neutropenia; Gastroenterology; Surgery; Lymphoma; Chemotherapy; Cyclophosphamide; Multiple myeloma","score_opus":0.029377076162113058,"score_gpt":0.3144924683044922,"score_spread":0.28511539214237913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043831614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964069,0.0006811259,0.000010991785,0.0011735652,0.000053130607,0.0005223626,0.0000073781175,0.00006156311,0.0010829695],"genre_scores_gemma":[0.99570274,0.0001925143,0.0010570368,0.0005599287,0.000115162475,0.000034451874,0.000013110812,0.000030119623,0.002294903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838823,0.000025895884,0.0003017132,0.0003834288,0.0004189388,0.00048177727],"domain_scores_gemma":[0.9990694,0.00008784674,0.000027234011,0.0004251737,0.00006336636,0.00032700325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014522012,0.0001833972,0.00045362365,0.00019299034,0.000055332297,0.000014206604,0.000126843,0.00011122254,0.00010662176],"category_scores_gemma":[0.00024207312,0.00015333344,0.000060835777,0.00029431898,0.00012346325,0.000051750354,0.0001667586,0.00022579516,0.00022802713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002776735,0.0031471527,0.9765149,0.00024749938,0.000110709836,0.011159967,0.0005762586,0.0000014075912,0.0021948207,0.000032105563,0.0007896823,0.004947821],"study_design_scores_gemma":[0.122461274,0.0002748585,0.8635204,0.00016145594,0.00007116188,0.0057708067,0.000021867723,0.00009808323,0.007071713,0.000014895551,0.00030795825,0.00022554665],"about_ca_topic_score_codex":0.000312665,"about_ca_topic_score_gemma":0.00015874406,"teacher_disagreement_score":0.1221836,"about_ca_system_score_codex":0.001150276,"about_ca_system_score_gemma":0.0012985016,"threshold_uncertainty_score":0.6252756},"labels":[],"label_agreement":null},{"id":"W2045790063","doi":"10.1038/jhg.2013.2","title":"Exome sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2","year":2013,"lang":"en","type":"article","venue":"Journal of Human Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Graduate School of Frontier Sciences, University of Tokyo; University of Tokyo; Ministry of Education, Culture, Sports, Science and Technology","keywords":"Single-nucleotide polymorphism; Genetics; Biology; Sanger sequencing; Linkage disequilibrium; Odds ratio; Haplotype; Exome sequencing; Allele; Genotype; Gene; DNA sequencing; Internal medicine; Medicine; Mutation","score_opus":0.04572306155684206,"score_gpt":0.3145430416615698,"score_spread":0.26881998010472774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045790063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946231,0.0029266085,0.00016078864,0.00040567704,0.00018725358,0.00031010664,0.0000013758025,0.0000071256604,0.0013779163],"genre_scores_gemma":[0.99605024,0.0018018965,0.0010973532,0.00027092232,0.00032670592,0.0000076232222,0.000001902501,0.000027149752,0.00041617893],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976806,0.00008205409,0.00078762264,0.00014718244,0.00090340176,0.00039912708],"domain_scores_gemma":[0.99869984,0.00013902636,0.00027201016,0.0003878638,0.00035685557,0.00014440763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010162634,0.00014691554,0.0003673261,0.00027955812,0.00011018274,0.00015384995,0.00040459324,0.00009669342,0.000537532],"category_scores_gemma":[0.00018152651,0.0001012807,0.0001287523,0.000249316,0.00014952144,0.00016723358,0.00008176073,0.00052663195,0.000095660434],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009039743,0.0005895216,0.0058222194,0.00028582168,0.0002489963,0.0017386304,0.010509841,0.00055332837,0.95462364,0.0006092699,0.019835817,0.0050925124],"study_design_scores_gemma":[0.18130283,0.012655947,0.42522088,0.011791012,0.0003803179,0.11098559,0.055714794,0.031632785,0.1326374,0.02501013,0.010154949,0.0025133854],"about_ca_topic_score_codex":0.00025850724,"about_ca_topic_score_gemma":0.00012135095,"teacher_disagreement_score":0.82198626,"about_ca_system_score_codex":0.0024845279,"about_ca_system_score_gemma":0.00228931,"threshold_uncertainty_score":0.6496954},"labels":[],"label_agreement":null},{"id":"W2047634988","doi":"10.1111/j.1365-2141.2009.07836.x","title":"Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non‐Hodgkin lymphoma","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Research Resources; National Cancer Institute; Case Comprehensive Cancer Center, Case Western Reserve University","keywords":"Bortezomib; Mantle cell lymphoma; Fludarabine; Medicine; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Follicular lymphoma; Lymphoma; Regimen; Oncology; Aggressive lymphoma; Gastroenterology; Multiple myeloma; Chemotherapy; Leukemia; Cyclophosphamide","score_opus":0.014462302663390188,"score_gpt":0.315413557958335,"score_spread":0.30095125529494476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047634988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876523,0.010593859,0.0002159538,0.00045334242,0.00014532165,0.00062658737,0.000018684801,0.000006123426,0.0002878052],"genre_scores_gemma":[0.99368376,0.0042053144,0.0016509101,0.0001661661,0.00015317205,0.0000065801764,0.000005690462,0.000019220488,0.00010919549],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982802,0.00009172938,0.00079566333,0.00023373953,0.00028287835,0.00031577153],"domain_scores_gemma":[0.998621,0.00031098945,0.000412443,0.00014910092,0.00024432415,0.00026213186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006949386,0.00014673172,0.0010429655,0.00020860232,0.00006749342,0.000029127355,0.000092374954,0.0002058445,0.000019211753],"category_scores_gemma":[0.0004365077,0.0001467461,0.00010068624,0.00008240281,0.00029407392,0.00012346958,0.000044020937,0.00022000085,7.1244466e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19637725,0.013863035,0.00017334832,0.0027095163,0.0005109161,0.06320931,0.0011067619,9.231519e-7,0.022057718,0.00034843854,0.020431893,0.6792109],"study_design_scores_gemma":[0.7686094,0.011171654,0.00078535004,0.0005162828,0.00024150696,0.20741254,0.00016791679,0.00057315844,0.0078012734,0.0005532177,0.0020150852,0.00015263117],"about_ca_topic_score_codex":0.00006632738,"about_ca_topic_score_gemma":0.000012007681,"teacher_disagreement_score":0.67905825,"about_ca_system_score_codex":0.00036839928,"about_ca_system_score_gemma":0.0014172327,"threshold_uncertainty_score":0.5984132},"labels":[],"label_agreement":null},{"id":"W2050064417","doi":"10.3389/fimmu.2012.00256","title":"Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies","year":2012,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Gilead Sciences (Canada)","funders":"Canadian Institutes of Health Research","keywords":"B cell; B-cell receptor; Cancer research; Immunology; PI3K/AKT/mTOR pathway; Biology; Idelalisib; T cell; Receptor; Chronic lymphocytic leukemia; Cell biology; Signal transduction; Ibrutinib; Leukemia; Immune system","score_opus":0.00438042822068095,"score_gpt":0.21318731483055275,"score_spread":0.20880688660987182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050064417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790331,0.016211534,0.0033991928,0.000013183372,0.00043021937,0.00075204193,0.00002393006,0.000025765534,0.000111041285],"genre_scores_gemma":[0.9952514,0.00021515721,0.004112117,0.0000107006235,0.00006216727,0.000097227465,0.00003811468,0.000038530485,0.00017459382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984775,0.0000844848,0.0004676147,0.00025628426,0.00020797508,0.0005061321],"domain_scores_gemma":[0.9990794,0.00011214255,0.0002672953,0.00027142643,0.00018797201,0.00008172849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022098173,0.00020715428,0.0005909538,0.00036228902,0.00006462893,0.000004675874,0.00008305286,0.00018586389,0.000006693859],"category_scores_gemma":[0.000103656086,0.00018160319,0.00009499944,0.00028343586,0.0005139137,0.00018081654,0.00007753396,0.00018055463,5.704939e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01571294,0.0015470864,0.46356604,0.0024072854,0.00079301867,0.000040254312,0.0030343868,0.00042149742,0.50533074,0.00020187961,0.0012149524,0.005729908],"study_design_scores_gemma":[0.03843931,0.0025491777,0.2427296,0.0004424879,0.000526304,0.000072764466,0.004317221,0.00509436,0.7051456,0.00016045255,0.00017891909,0.00034380204],"about_ca_topic_score_codex":0.00038564726,"about_ca_topic_score_gemma":0.0000060579414,"teacher_disagreement_score":0.22083643,"about_ca_system_score_codex":0.0016868091,"about_ca_system_score_gemma":0.0012640631,"threshold_uncertainty_score":0.7405563},"labels":[],"label_agreement":null},{"id":"W2050530938","doi":"10.1016/j.carpath.2005.07.006","title":"Chronic lymphocytic leukemia involving the coronary arteries with accompanying acute myocardial infarction","year":2005,"lang":"en","type":"article","venue":"Cardiovascular Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Autopsy; Coronary arteries; Cardiology; Myocardial infarction; Chronic lymphocytic leukemia; Internal medicine; Infiltration (HVAC); Artery; Leukemia","score_opus":0.014292070435593954,"score_gpt":0.25128794061449944,"score_spread":0.2369958701789055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050530938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760478,0.01889406,0.0016213866,0.0004065505,0.00035161318,0.0009967783,0.000006570823,0.00025145442,0.0014237581],"genre_scores_gemma":[0.99405307,0.001722885,0.00070556527,0.00064192375,0.0021687192,0.00023339971,0.000054516644,0.000092028386,0.00032787188],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9966666,0.00038046442,0.00040764452,0.0007322617,0.00089871057,0.0009142834],"domain_scores_gemma":[0.9976225,0.00015242129,0.0000906629,0.0017035382,0.0002199877,0.0002108718],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010063242,0.00038793875,0.00090141967,0.00019044177,0.00037959917,0.00006622703,0.00034356985,0.000277128,0.00007265888],"category_scores_gemma":[0.00010467145,0.0002635764,0.000798105,0.00043955675,0.0008028792,0.00025959293,0.00027120803,0.000587929,0.00028523582],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0045875935,0.00014083841,0.006447805,0.0009620521,0.03863935,0.029541608,0.007555382,0.13518567,0.03616227,0.0009437719,0.0051706275,0.734663],"study_design_scores_gemma":[0.1258935,0.0031493,0.11656897,0.0007423266,0.011450462,0.33330825,0.0023554417,0.0833739,0.013531135,0.00018014542,0.3070777,0.0023688555],"about_ca_topic_score_codex":0.00018693708,"about_ca_topic_score_gemma":0.000046579313,"teacher_disagreement_score":0.73229414,"about_ca_system_score_codex":0.058404297,"about_ca_system_score_gemma":0.016022934,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W2051528563","doi":"10.1016/j.abb.2007.06.029","title":"Insulin inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site (IRES) initiation","year":2007,"lang":"en","type":"article","venue":"Archives of Biochemistry and Biophysics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Wortmannin; Apolipoprotein B; Messenger RNA; Translation (biology); Translational regulation; Luciferase; Internal ribosome entry site; PI3K/AKT/mTOR pathway; Cell biology; Five prime untranslated region; Untranslated region; Biology; Molecular biology; Signal transduction; Chemistry; Transfection; Biochemistry; Gene","score_opus":0.013167569446371945,"score_gpt":0.25274195700345137,"score_spread":0.2395743875570794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051528563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966928,0.00035410703,0.0018191825,0.0003929717,0.00002797197,0.00028158448,0.0001938017,0.000017283477,0.00022030667],"genre_scores_gemma":[0.99830765,0.00022254081,0.00068744196,0.0001130772,0.00031782233,0.0000052339337,0.0002872276,0.000015273337,0.000043730237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986188,0.000035624365,0.00043134709,0.00026163645,0.0004091795,0.00024345996],"domain_scores_gemma":[0.9989373,0.00036920197,0.00024717275,0.00025411436,0.000077093064,0.00011508213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022195351,0.00016820915,0.00024362186,0.00006225291,0.00007759585,0.000012230589,0.000116020994,0.00012596685,0.000018906385],"category_scores_gemma":[0.00009921609,0.00011985192,0.000121803394,0.00014956192,0.00051076163,0.00007319286,0.000086972796,0.00026105743,0.0000025104946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013122694,0.00014112754,0.00029567402,0.0006941004,0.00007846237,0.00001918949,0.0025226583,0.0000021459348,0.98022145,0.000012421931,0.0000063693997,0.014694151],"study_design_scores_gemma":[0.0040168865,0.00014885404,0.0010346327,0.00047311647,0.00007050585,0.000020750927,0.00040813617,0.0057770563,0.9872148,0.0007010851,0.000010547855,0.00012363301],"about_ca_topic_score_codex":0.00064599415,"about_ca_topic_score_gemma":0.000012110917,"teacher_disagreement_score":0.014570517,"about_ca_system_score_codex":0.00015658239,"about_ca_system_score_gemma":0.0003786698,"threshold_uncertainty_score":0.48874193},"labels":[],"label_agreement":null},{"id":"W2051531643","doi":"10.1016/j.jval.2012.08.1227","title":"PCN34 Relationship Between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Context (archaeology); Progression-free survival; Chronic lymphocytic leukemia; Oncology; Surrogate endpoint; Population; Clinical endpoint; Overall survival; Clinical trial; Leukemia","score_opus":0.10165529097467764,"score_gpt":0.3796639260114467,"score_spread":0.2780086350367691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051531643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879773,0.007776094,0.00003453291,0.0009956518,0.00035359347,0.0012743325,0.000014966175,0.00008691889,0.0014866134],"genre_scores_gemma":[0.9973616,0.0004824048,0.00068135426,0.000104083236,0.0008433839,0.00006859873,0.000049455994,0.00006605302,0.00034306955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99522245,0.00080522476,0.0009410328,0.0005144818,0.0010484175,0.0014683895],"domain_scores_gemma":[0.9958686,0.0023228363,0.00017856003,0.00083371095,0.000050934115,0.0007453274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0047056386,0.00029281754,0.0007628631,0.00048634966,0.0001277715,0.000029161127,0.000262613,0.00029208092,0.000043080923],"category_scores_gemma":[0.0018964908,0.0002682292,0.00006992323,0.00072649017,0.00019181942,0.00027066845,0.0002889034,0.0007815736,0.00006487222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00022993296,0.00006390774,0.98665315,0.001813782,0.000021667827,0.000060130966,0.0010771229,0.0010339818,0.000018225539,0.0057708584,0.0003408653,0.0029163617],"study_design_scores_gemma":[0.029311066,0.00045450722,0.9366959,0.001558346,0.000020045389,0.00010078427,0.00015814263,0.028570062,0.000045269197,0.0015458468,0.0012333118,0.00030675158],"about_ca_topic_score_codex":0.029775376,"about_ca_topic_score_gemma":0.0005540129,"teacher_disagreement_score":0.12857385,"about_ca_system_score_codex":0.1792936,"about_ca_system_score_gemma":0.050719753,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W2053116598","doi":"10.1016/j.transci.2007.04.008","title":"The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia","year":2007,"lang":"en","type":"review","venue":"Transfusion and Apheresis Science","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Transplantation; Medicine; Hematopoietic stem cell transplantation; Chronic lymphocytic leukemia; Stem cell; Disease; Immunology; Purine analogue; Leukemia; Population; Oncology; Internal medicine; Purine; Biology","score_opus":0.03123166950092817,"score_gpt":0.3350448629363146,"score_spread":0.30381319343538643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053116598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015143823,0.97958803,0.000033660817,0.0000052657165,0.00006188994,0.0011527968,0.000007687321,0.000024071118,0.0039827945],"genre_scores_gemma":[0.026313135,0.9731134,0.000035100064,0.000008801697,0.000034158384,0.00003960127,0.0000044401027,0.000030325506,0.0004210264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672955,0.00010533868,0.000819835,0.000616501,0.0010799383,0.00064884726],"domain_scores_gemma":[0.9983929,0.00059782027,0.00016128205,0.00052342034,0.000084188985,0.0002403925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015716092,0.00032108533,0.0009856044,0.00040334018,0.0002524124,0.000052686704,0.0005062057,0.00024044965,0.00005107602],"category_scores_gemma":[0.000015014997,0.0001984133,0.00022518044,0.0017563954,0.001147259,0.00009957024,0.000048291582,0.0003724342,0.000021331296],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000079431695,0.000016701224,0.0000025071147,0.01856478,0.000010140263,0.000058017096,0.0005109143,0.000010328314,0.00076996133,0.00022507235,0.0000053169365,0.9797468],"study_design_scores_gemma":[0.026322784,0.0011921764,0.000120223696,0.08607282,0.001970381,0.00313937,0.003094433,0.015186997,0.02736033,0.00025450494,0.8335988,0.0016872166],"about_ca_topic_score_codex":0.0009569503,"about_ca_topic_score_gemma":0.00040898265,"teacher_disagreement_score":0.9780596,"about_ca_system_score_codex":0.029551044,"about_ca_system_score_gemma":0.05210623,"threshold_uncertainty_score":0.9741743},"labels":[],"label_agreement":null},{"id":"W2053255222","doi":"10.1038/modpathol.2008.110","title":"Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia","year":2008,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Chronic lymphocytic leukemia; Immunohistochemistry; Fludarabine; Vidarabine; Medicine; Internal medicine; Nucleoside analogue; Staining; Leukemia; Pathology; Nucleoside; Biology; Chemotherapy; Biochemistry","score_opus":0.02798037647127491,"score_gpt":0.30577671981757887,"score_spread":0.277796343346304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053255222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938984,0.0007103249,0.0063183345,0.00009945572,0.000060173516,0.002257552,0.000060285212,0.00014060535,0.0009634372],"genre_scores_gemma":[0.9964702,0.000042101405,0.0006305238,0.00019263221,0.00022959699,0.0005299974,0.0002213079,0.00008091028,0.001602696],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99702716,0.00011701761,0.00062871876,0.00085002626,0.00039147303,0.0009855866],"domain_scores_gemma":[0.9986247,0.0001132411,0.00013483445,0.0007245514,0.00017971167,0.00022299144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046755685,0.0003725552,0.0008116524,0.00014278675,0.00019501631,0.00000845996,0.00016560974,0.00043786643,0.00007462873],"category_scores_gemma":[0.00012885037,0.0003686204,0.00020306541,0.00018784081,0.0008272775,0.000103178514,0.00006067416,0.0004801529,0.00002662323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001053471,0.000103471524,0.00048410593,0.00050521514,0.00006526284,0.008439485,0.0020431688,0.0009958529,0.9854234,0.00014035527,0.00015645161,0.00058978156],"study_design_scores_gemma":[0.101876765,0.002047581,0.013652001,0.00075406604,0.0001641993,0.012204746,0.000113410766,0.3137105,0.55247796,0.0016603039,0.00039532068,0.0009431413],"about_ca_topic_score_codex":0.00064952887,"about_ca_topic_score_gemma":0.00018735633,"teacher_disagreement_score":0.43294543,"about_ca_system_score_codex":0.090647735,"about_ca_system_score_gemma":0.025119387,"threshold_uncertainty_score":0.99987656},"labels":[],"label_agreement":null},{"id":"W2053445686","doi":"10.1111/j.1365-2141.2006.06474.x","title":"Biomolecular characterisation of leucocytes by infrared spectroscopy","year":2007,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Institute for Biodiagnostics","funders":"","keywords":"Hematology; Infrared spectroscopy; Spectroscopy; Personalized medicine; Chemotherapy; Medicine; Immunology; Chemistry; Biology; Bioinformatics; Internal medicine","score_opus":0.042035958297221496,"score_gpt":0.38413949484269605,"score_spread":0.34210353654547454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053445686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041817566,0.99375975,0.00056784577,0.000027022166,0.00030508742,0.0005066951,0.00006625961,0.000012251044,0.00057331077],"genre_scores_gemma":[0.00019566478,0.998052,0.00096364197,0.000056622015,0.00022731569,0.000007230571,0.000137625,0.00007425825,0.00028562284],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99612504,0.00028705952,0.002127011,0.00027409266,0.00069818227,0.00048861693],"domain_scores_gemma":[0.9967142,0.00034013527,0.0018754208,0.0003253442,0.0004889249,0.0002559798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009502877,0.0003053555,0.0039440105,0.00062345533,0.000038989878,0.000032035656,0.00038380898,0.00063771533,0.00027950996],"category_scores_gemma":[0.0007552283,0.00030039265,0.00080548594,0.00043955175,0.00033639334,0.0000967678,0.00009049491,0.000921637,0.00002521541],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002080395,0.00040617297,0.0000061680694,0.039297845,0.0013436525,0.1246712,0.000050683164,4.4109214e-8,0.000648331,0.000058240243,0.029011678,0.8042979],"study_design_scores_gemma":[0.0027614462,0.00032247585,0.000002283764,0.019741364,0.0006371615,0.44932747,0.0000108704135,0.0000029017408,0.0011334678,0.00003157923,0.5258942,0.00013474881],"about_ca_topic_score_codex":0.000098368735,"about_ca_topic_score_gemma":0.000004299748,"teacher_disagreement_score":0.8041632,"about_ca_system_score_codex":0.0032506313,"about_ca_system_score_gemma":0.008235598,"threshold_uncertainty_score":0.9999448},"labels":[],"label_agreement":null},{"id":"W2054507477","doi":"10.1016/j.bcmd.2007.02.010","title":"Human B lymphocytes and non-Hodgkin's lymphoma cells become polyploid in response to the protein kinase inhibitor SU6656","year":2007,"lang":"en","type":"article","venue":"Blood Cells Molecules and Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec","funders":"Canadian Institutes of Health Research; Bayer Canada","keywords":"Lymphoma; Cancer research; Polyploid; Mitosis; Biology; Immunology; Cell biology; Ploidy; Genetics","score_opus":0.006879566700022585,"score_gpt":0.26010782820462036,"score_spread":0.25322826150459776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054507477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933947,0.0040034377,0.000020968388,0.0005690992,0.000057225745,0.0015813607,0.00006110569,0.000053909018,0.000258195],"genre_scores_gemma":[0.99731475,0.00009971221,0.00027159296,0.00071183365,0.0002187764,0.000109198,0.00001235414,0.00006357787,0.0011982325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99735725,0.00015463514,0.0004570368,0.00066224264,0.00057035906,0.00079845614],"domain_scores_gemma":[0.9980879,0.0002999421,0.00007897141,0.00060600345,0.00008217819,0.00084504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064726936,0.00035733767,0.00042986393,0.0003394569,0.00022471782,0.00012546561,0.00021125506,0.00013428749,0.00004394074],"category_scores_gemma":[0.00018391281,0.00026658355,0.00010882109,0.0004405625,0.00029139072,0.0000790603,0.00034660255,0.00012014975,0.000029638297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061173886,0.0013567131,0.0021396636,0.00051819114,0.00008939605,0.002637752,0.0006714529,0.0000149360385,0.9810126,0.00006492542,0.0011527161,0.0042243055],"study_design_scores_gemma":[0.038273398,0.001866753,0.073594585,0.00070223835,0.00029253637,0.00018644502,0.0010372096,0.0002762702,0.87871075,0.00008420243,0.0043182303,0.0006574046],"about_ca_topic_score_codex":0.0010317015,"about_ca_topic_score_gemma":0.00022357472,"teacher_disagreement_score":0.10230183,"about_ca_system_score_codex":0.0010446497,"about_ca_system_score_gemma":0.0016642939,"threshold_uncertainty_score":0.99997866},"labels":[],"label_agreement":null},{"id":"W2054709506","doi":"10.1111/j.1365-2141.2012.09170.x","title":"Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20‐year cohort","year":2012,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Stem cell; Haematopoiesis; Transplantation; Medicine; Cohort; Hematology; Oncology; Immunology; Hematopoietic stem cell transplantation; Internal medicine; Biology; Genetics","score_opus":0.024302804094947922,"score_gpt":0.30568320253903714,"score_spread":0.28138039844408924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054709506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809106,0.015538895,0.0015099839,0.00016979115,0.00049896596,0.0009224198,0.000019958952,0.000021394211,0.0004079937],"genre_scores_gemma":[0.99556535,0.0021356887,0.0012679453,0.00017494783,0.0003118611,0.00006639834,0.000023294637,0.00006404718,0.00039044028],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9966476,0.00020104092,0.001386657,0.0002660418,0.0005395874,0.0009590956],"domain_scores_gemma":[0.9982329,0.00044711583,0.00042138968,0.00025092563,0.00025695958,0.00039073438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014786088,0.00023156726,0.0012728182,0.00037978697,0.000076287666,0.00003215858,0.00027736888,0.00035079248,0.00013211693],"category_scores_gemma":[0.00012690153,0.00024390192,0.00032982265,0.0002675403,0.00017987502,0.00026254586,0.000039006532,0.0004953792,0.000059041933],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007138298,0.0024790026,0.65462536,0.029694902,0.0016560783,0.24868922,0.003934012,0.0017028709,0.009459208,0.0021638623,0.01478321,0.023673972],"study_design_scores_gemma":[0.05335283,0.0008311925,0.016839456,0.0015186972,0.0007101521,0.91369396,0.00042433589,0.0014756827,0.008765803,0.00016542916,0.001802901,0.00041958553],"about_ca_topic_score_codex":0.0002052051,"about_ca_topic_score_gemma":0.00017337473,"teacher_disagreement_score":0.66500473,"about_ca_system_score_codex":0.014457931,"about_ca_system_score_gemma":0.007173934,"threshold_uncertainty_score":0.99845445},"labels":[],"label_agreement":null},{"id":"W2055127103","doi":"10.3816/clml.2010.n.015","title":"Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia","year":2010,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Rituximab; Waldenstrom macroglobulinemia; Macroglobulinemia; Internal medicine; Oncology; Proteasome inhibitor; Multiple myeloma; Lymphoma","score_opus":0.0433455937624061,"score_gpt":0.3944574783435849,"score_spread":0.3511118845811788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055127103","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17480767,0.81148,0.000007086577,0.000077998906,0.0011240266,0.0073668794,0.00017265399,0.00033870648,0.0046250164],"genre_scores_gemma":[0.0025256043,0.9875618,0.0012842335,0.00026552228,0.0015009174,0.0007568251,0.0019470291,0.00044152208,0.0037165454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9896373,0.00060851144,0.0038000795,0.0025222148,0.0016663736,0.0017655115],"domain_scores_gemma":[0.9924098,0.0015894417,0.0011858551,0.0029244674,0.00045954558,0.0014308669],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010670513,0.0017442614,0.0065237093,0.00069153536,0.00015877033,0.00014267028,0.0008946485,0.0033184476,0.0003806083],"category_scores_gemma":[0.0012634334,0.0011940042,0.0018537403,0.001276864,0.00093451247,0.00019134983,0.00041336607,0.0018911766,0.0027363894],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015979111,0.0012905209,0.0015827066,0.0034018152,0.00058736873,0.0026274978,0.000028964278,0.000001009717,1.3775004e-7,0.000089198664,0.00038946824,0.9884034],"study_design_scores_gemma":[0.051660527,0.0039919345,0.03192471,0.013923551,0.0022482607,0.0012827344,0.0000096381345,0.00017010374,0.0000026063597,0.000039269096,0.8935719,0.0011747251],"about_ca_topic_score_codex":0.0008594824,"about_ca_topic_score_gemma":0.0001959356,"teacher_disagreement_score":0.9872287,"about_ca_system_score_codex":0.081717394,"about_ca_system_score_gemma":0.07426788,"threshold_uncertainty_score":0.9995303},"labels":[],"label_agreement":null},{"id":"W2056080086","doi":"10.1053/sonc.2003.50061","title":"The malignant clone in Waldenstrom's macroglobulinemia","year":2003,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Waldenstrom macroglobulinemia; Macroglobulinemia; Immunoglobulin D; Immunology; Bone marrow; Medicine; Immunoglobulin M; Antibody; Immunoglobulin gene; CD20; Biology; Pathology; B cell; Immunoglobulin G; Multiple myeloma; Lymphoma; Genetics; Gene","score_opus":0.01666658269212918,"score_gpt":0.3431467620100544,"score_spread":0.3264801793179252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056080086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94106394,0.0039192787,0.000009309424,0.0032776394,0.00040510733,0.0006332243,0.0000019339693,0.000025215419,0.05066432],"genre_scores_gemma":[0.98837626,0.0031363934,0.0015123056,0.0005583003,0.00009208929,0.00011430503,0.0000062838735,0.00002948363,0.006174561],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977206,0.0003021194,0.00048728305,0.0003596311,0.00031926585,0.00081107375],"domain_scores_gemma":[0.998299,0.00092915917,0.00006938248,0.0005034554,0.000057887588,0.00014114044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001577926,0.00016013328,0.00041063328,0.00016211657,0.000067205256,0.000011869487,0.00022579488,0.00028457821,0.00019597397],"category_scores_gemma":[0.0012164677,0.000113615126,0.0000649054,0.0005300002,0.00035760846,0.000028637507,0.000099361256,0.0006034399,0.00013348361],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0071062353,0.0038086546,0.13696736,0.00056408875,0.00026646056,0.07845056,0.0065341336,0.00041027993,0.048602883,0.045483828,0.13237421,0.5394313],"study_design_scores_gemma":[0.057569668,0.0034417487,0.0074252123,0.0008472082,0.000060578437,0.012310158,0.0038880971,0.0043470985,0.01823695,0.004791457,0.8865211,0.0005607127],"about_ca_topic_score_codex":0.00036713478,"about_ca_topic_score_gemma":0.000997896,"teacher_disagreement_score":0.7541469,"about_ca_system_score_codex":0.018062957,"about_ca_system_score_gemma":0.006610714,"threshold_uncertainty_score":0.9990209},"labels":[],"label_agreement":null},{"id":"W2056376654","doi":"10.1182/blood-2010-03-272765","title":"Effect of FCGR2A and FCGR3A variants on CLL outcome","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta","funders":"","keywords":"Hazard ratio; Rituximab; Medicine; Antibody-dependent cell-mediated cytotoxicity; Chronic lymphocytic leukemia; Internal medicine; Fludarabine; Cyclophosphamide; Progression-free survival; Immunology; Monoclonal antibody; Regimen; Monoclonal; Antibody; Gastroenterology; Leukemia; Confidence interval; Chemotherapy","score_opus":0.011319256124485802,"score_gpt":0.3242386685967386,"score_spread":0.3129194124722528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056376654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910484,0.00007337095,0.0000014837661,0.00013001551,0.000130928,0.0003392746,0.0000054351085,0.0000288383,0.00824224],"genre_scores_gemma":[0.99870455,0.00001184242,0.00014060315,0.000089265246,0.00014027419,0.000011457004,0.0000036918407,0.000019961637,0.0008783311],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900544,0.000045764482,0.00018691897,0.000207874,0.00032281803,0.00023119904],"domain_scores_gemma":[0.998913,0.00041953317,0.000039945775,0.00042978517,0.000042598,0.00015514552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052455615,0.00011303317,0.00030507435,0.00008441216,0.000028722938,0.00000851828,0.00008849359,0.00011846551,0.00013107117],"category_scores_gemma":[0.0007955646,0.000079354184,0.000056068973,0.00010051875,0.000115017116,0.000025467445,0.000065543216,0.0002973007,0.00008114132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041861366,0.0044259015,0.29035452,0.0051554726,0.0010274481,0.0021861824,0.00076853705,0.0000016367873,0.62598497,0.0045833425,0.0023077838,0.05901808],"study_design_scores_gemma":[0.19074365,0.007904858,0.13168609,0.00032384138,0.00081407314,0.0016578643,0.000019546462,0.0010381141,0.66245663,0.0001440179,0.0028291482,0.0003821398],"about_ca_topic_score_codex":0.00015698263,"about_ca_topic_score_gemma":0.000014008093,"teacher_disagreement_score":0.18655753,"about_ca_system_score_codex":0.00015380107,"about_ca_system_score_gemma":0.0006215459,"threshold_uncertainty_score":0.32359695},"labels":[],"label_agreement":null},{"id":"W2056534555","doi":"10.1016/j.leukres.2010.06.031","title":"Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Foothills Medical Centre; University of Calgary","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; National Cancer Research Institute","keywords":"CD20; Chronic lymphocytic leukemia; Flow cytometry; Leukemia; Messenger RNA; Population; Molecular biology; B cell; Biology; Real-time polymerase chain reaction; Antibody; Cancer research; Immunology; Gene; Medicine; Biochemistry","score_opus":0.057326997000381054,"score_gpt":0.36791973138580897,"score_spread":0.3105927343854279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056534555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379754,0.0010778274,0.00004904481,0.0003837553,0.00010427701,0.0023917477,0.000044580895,0.00007575317,0.0020754884],"genre_scores_gemma":[0.9958352,0.00012369927,0.0006547621,0.000046414483,0.0002894741,0.00037937608,0.000077111894,0.00008925651,0.0025046964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99395263,0.00044761167,0.000885993,0.0010198993,0.002314476,0.001379415],"domain_scores_gemma":[0.99620235,0.00084337575,0.00013147837,0.0012180363,0.0010846816,0.0005200812],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042448337,0.00035664334,0.00068207644,0.0013031999,0.00020613628,0.00009212697,0.0005545742,0.000579153,0.00046477493],"category_scores_gemma":[0.0020798692,0.00033028072,0.00020288315,0.0016198475,0.001358177,0.0002970605,0.00026870685,0.002274739,0.00020129842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010128318,0.00006686841,0.0011358127,0.0014573073,0.000073515395,0.00024093856,0.0005220432,0.00018808724,0.98515636,0.006234484,0.00021356961,0.0036981835],"study_design_scores_gemma":[0.061342236,0.0026572368,0.17007054,0.0021156385,0.00009886589,0.0017758178,0.00059084303,0.1351555,0.61742115,0.0023398977,0.005424797,0.0010074625],"about_ca_topic_score_codex":0.01477285,"about_ca_topic_score_gemma":0.0043664314,"teacher_disagreement_score":0.36773518,"about_ca_system_score_codex":0.11609824,"about_ca_system_score_gemma":0.12688011,"threshold_uncertainty_score":0.99991494},"labels":[],"label_agreement":null},{"id":"W2058663390","doi":"10.3324/haematol.10317","title":"APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival","year":2007,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Universidad de Jaén; Fondation de France; Association pour la Recherche sur le Cancer","keywords":"B-cell activating factor; Chronic lymphocytic leukemia; Clinical significance; Medicine; Immunology; CD20; Leukemia; Lymphocyte; Internal medicine; Oncology; B cell; Antibody","score_opus":0.0689201530676397,"score_gpt":0.32353673284256834,"score_spread":0.25461657977492863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058663390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.907982,0.0076933894,0.0012864537,0.059951343,0.0015270533,0.014779572,0.0019950145,0.0008268432,0.00395832],"genre_scores_gemma":[0.8839802,0.0006385795,0.0027207967,0.10190806,0.0029290207,0.0012182292,0.0007064257,0.00044894972,0.0054497398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.991187,0.00040667492,0.0021070424,0.0018075291,0.0020349545,0.0024567968],"domain_scores_gemma":[0.9897414,0.0060746316,0.00114291,0.0019684301,0.0007383578,0.00033427268],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0017812126,0.0011503081,0.0038323181,0.0009190558,0.0001455923,0.00004905679,0.0011199911,0.003298144,0.0003487943],"category_scores_gemma":[0.006627173,0.00097588694,0.00072291086,0.001017168,0.0009287563,0.00011614392,0.00046472123,0.0027853448,0.0001943685],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009678117,0.00059056113,0.003811165,0.11346727,0.0022449107,0.115315095,0.00053919,0.0009730139,0.0044414536,0.00060328486,0.74159276,0.0067431736],"study_design_scores_gemma":[0.23872906,0.007907297,0.023481065,0.03433136,0.0038476768,0.022811374,0.00074046676,0.08613311,0.11595598,0.002279769,0.4555043,0.008278555],"about_ca_topic_score_codex":0.0017989031,"about_ca_topic_score_gemma":0.0004180705,"teacher_disagreement_score":0.28608847,"about_ca_system_score_codex":0.11898234,"about_ca_system_score_gemma":0.061396066,"threshold_uncertainty_score":0.9995153},"labels":[],"label_agreement":null},{"id":"W2060187897","doi":"10.1038/sj.thj.6200325","title":"Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia","year":2004,"lang":"en","type":"article","venue":"The Hematology Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Biology; Flow cytometry; Population; Exon; Chronic lymphocytic leukemia; Allele; Molecular biology; Chromosome; Pathology; Immunology; Genetics; Gene; Medicine; Leukemia","score_opus":0.02168011348374968,"score_gpt":0.3073575107378335,"score_spread":0.2856773972540838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060187897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952367,0.0019567078,0.0001467045,0.0012457883,0.00018976339,0.0002061529,0.0000010920918,0.000015587713,0.0010015024],"genre_scores_gemma":[0.99879664,0.00051128236,0.00012068424,0.0001566211,0.00019861385,0.000011259317,0.0000034797117,0.000018065104,0.00018335666],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"case_report","domain_scores_codex":[0.9983578,0.0001196577,0.0005920363,0.0001309135,0.00036529553,0.000434318],"domain_scores_gemma":[0.9990327,0.00021062123,0.00022311411,0.0003172118,0.00011385421,0.00010252058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008391131,0.00013135091,0.0004321096,0.00022953324,0.00009261925,0.000014379161,0.00022806373,0.00013616153,0.00021167172],"category_scores_gemma":[0.0002318896,0.000086234024,0.00010785104,0.00023498396,0.00036735332,0.00012337093,0.00006452736,0.00048246092,0.00007719191],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02289901,0.0027290813,0.09565266,0.012531556,0.0049400087,0.0429516,0.1202336,0.04678982,0.19073166,0.40957785,0.009061855,0.04190131],"study_design_scores_gemma":[0.16636045,0.0025008828,0.06390633,0.0045625246,0.00045231017,0.49254787,0.0047611194,0.014230531,0.21911798,0.028436122,0.0022883003,0.00083555194],"about_ca_topic_score_codex":0.00040104773,"about_ca_topic_score_gemma":0.00007134866,"teacher_disagreement_score":0.4495963,"about_ca_system_score_codex":0.033757478,"about_ca_system_score_gemma":0.023146952,"threshold_uncertainty_score":0.9823909},"labels":[],"label_agreement":null},{"id":"W2060449244","doi":"10.1093/ndt/gfl353","title":"IgM monoclonal protein presenting as pseudohypercreatininaemia","year":2006,"lang":"en","type":"letter","venue":"Nephrology Dialysis Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital; Dalhousie University","funders":"","keywords":"Medicine; Monoclonal; Monoclonal antibody; Immunology; Antibody","score_opus":0.015953349293477886,"score_gpt":0.2805843401601915,"score_spread":0.2646309908667136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060449244","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80251503,0.0002640318,0.00040672556,0.1757094,0.00019254933,0.002332647,0.00015112513,0.0003664494,0.018062046],"genre_scores_gemma":[0.29482883,0.00055102346,0.004921434,0.589984,0.015634535,0.0022810064,0.043484036,0.0005839919,0.047731165],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99520993,0.00043970626,0.00089733757,0.0011260404,0.0012633996,0.0010635598],"domain_scores_gemma":[0.99805146,0.0004833803,0.00029109113,0.00076783553,0.00026611064,0.00014011048],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00037167477,0.0006260351,0.0011588925,0.0007122381,0.00019867251,0.00007008619,0.0003450857,0.0023008164,0.0009562323],"category_scores_gemma":[0.00007763751,0.0005982611,0.0005255457,0.0005246866,0.0003551282,0.00015035311,0.00003832067,0.0024974428,0.0007637118],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014826062,0.00023557681,0.0016425468,0.0035636867,0.0019052213,0.027630191,0.0008056559,0.00016771669,0.018478906,0.00009156387,0.9426677,0.001328618],"study_design_scores_gemma":[0.059781764,0.0017488768,0.008414164,0.0013462523,0.016441645,0.0129249375,0.000056345118,0.010067951,0.03297767,0.0023128411,0.85089916,0.00302837],"about_ca_topic_score_codex":0.0033223778,"about_ca_topic_score_gemma":0.0001539183,"teacher_disagreement_score":0.5076862,"about_ca_system_score_codex":0.0030619267,"about_ca_system_score_gemma":0.004260506,"threshold_uncertainty_score":0.999957},"labels":[],"label_agreement":null},{"id":"W2062418841","doi":"10.3747/co.v18i1.756","title":"Acute Liver Failure Because of Chronic Lymphocytic Leukemia: Case Report and Review of the Literature","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Infiltration (HVAC); Lymphocytic infiltration; Liver failure; Pathology; Chronic liver disease; Disease; Disease entity; Leukemia; Internal medicine; Cirrhosis","score_opus":0.07852146974712754,"score_gpt":0.3821431981960616,"score_spread":0.30362172844893404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062418841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7109767,0.28510904,0.000015781567,0.00025884248,0.0006537153,0.0013635664,0.000042663403,0.000028805907,0.001550836],"genre_scores_gemma":[0.90063465,0.09772851,0.00031114425,0.00022077546,0.00027152893,0.00008009799,0.00004154635,0.000036974045,0.00067478314],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9981079,0.00017739767,0.00067160215,0.0003664528,0.00034351565,0.00033310655],"domain_scores_gemma":[0.9979073,0.00014957017,0.00041829364,0.00090715586,0.00044958337,0.00016812529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005295753,0.00020231832,0.0007319127,0.00010325995,0.00004934858,0.000003683929,0.0002114043,0.00023646594,0.0002739891],"category_scores_gemma":[0.00048651153,0.00012777644,0.00019407779,0.00045176642,0.0005665363,0.00007049914,0.0003397336,0.0004658736,0.000009471287],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015576627,0.0015219707,0.0023187904,0.19736901,0.0022862477,0.49031892,0.01400898,0.0000033061654,0.0042868047,0.0018845815,0.13304015,0.15140359],"study_design_scores_gemma":[0.019297272,0.0021184767,0.0004386604,0.031057006,0.002179731,0.85443634,0.00014960607,0.0015499722,0.009269705,0.00010653728,0.079071544,0.00032516182],"about_ca_topic_score_codex":0.00023105353,"about_ca_topic_score_gemma":0.00010289147,"teacher_disagreement_score":0.3641174,"about_ca_system_score_codex":0.026679786,"about_ca_system_score_gemma":0.029422082,"threshold_uncertainty_score":0.9770566},"labels":[],"label_agreement":null},{"id":"W2062840204","doi":"10.1016/s0304-3835(02)00378-6","title":"Association of a novel single nucleotide polymorphism, G(−248)A, in the 5′-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance","year":2002,"lang":"en","type":"article","venue":"Cancer Letters","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Single-nucleotide polymorphism; Gene; Biology; Genotype; Leukemia; Untranslated region; Cancer research; Gene expression; Allele; Genetics; Immunology; Messenger RNA","score_opus":0.02575193418321986,"score_gpt":0.2772344367725122,"score_spread":0.25148250258929233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062840204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897268,0.005401732,0.00001073917,0.0038229604,0.0000315428,0.0007539494,0.000021741607,0.00001050112,0.00022002586],"genre_scores_gemma":[0.9979294,0.00069332053,0.00017161095,0.0005423628,0.000103168495,0.00016204952,0.0000075257753,0.000024345289,0.0003662499],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983923,0.00007122924,0.0003251701,0.000294616,0.000567342,0.00034937],"domain_scores_gemma":[0.9991607,0.0001588349,0.00020272583,0.00034339118,0.00004396199,0.000090405265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020567187,0.0001644981,0.000340637,0.00015088369,0.00002802726,0.000012106053,0.00011997201,0.000055929548,0.000027683825],"category_scores_gemma":[0.00004915498,0.00010976872,0.000049685677,0.00042979853,0.00017837493,0.000077267374,0.000032607593,0.00010523602,0.0000012895014],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009804183,0.0017376875,0.12686013,0.003367916,0.0007281742,0.0018414361,0.012883042,0.008475813,0.8017057,0.00014171244,0.007888587,0.024565576],"study_design_scores_gemma":[0.3839232,0.003678816,0.2942383,0.015550066,0.0014154564,0.00015494658,0.000763634,0.12939568,0.15696372,0.00003115798,0.012338643,0.001546387],"about_ca_topic_score_codex":0.0018444284,"about_ca_topic_score_gemma":0.002214049,"teacher_disagreement_score":0.644742,"about_ca_system_score_codex":0.120076366,"about_ca_system_score_gemma":0.0041233203,"threshold_uncertainty_score":0.8833015},"labels":[],"label_agreement":null},{"id":"W2062857204","doi":"10.1016/j.leukres.2015.04.016","title":"Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70","year":2015,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Canada Research Chairs; CancerCare Manitoba Foundation; Manitoba Health Research Council","keywords":"Chronic lymphocytic leukemia; Stromal cell; Cancer research; Biology; Ectopic expression; Leukemia; Immunology; Signal transduction; Cell biology; Cell culture","score_opus":0.07459560821292835,"score_gpt":0.3570972380758317,"score_spread":0.2825016298629034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062857204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99100345,0.0021574718,0.0003012881,0.00005378607,0.00025884708,0.0010277018,0.0000065743975,0.00008558193,0.00510528],"genre_scores_gemma":[0.99542284,0.00061340677,0.00024182192,0.000039611034,0.00054295326,0.00011925893,0.000033268978,0.00009690623,0.0028899563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923381,0.0006686983,0.00087357353,0.0009765746,0.0036873631,0.0014556893],"domain_scores_gemma":[0.99632365,0.000742527,0.00014769059,0.0011097819,0.00065983174,0.0010165361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002540957,0.00038105604,0.00081262813,0.0011529359,0.00016806388,0.00010763562,0.00050999003,0.00062418194,0.00047510295],"category_scores_gemma":[0.0010411687,0.00033240093,0.00013129514,0.0012400044,0.0008130586,0.0003527803,0.00096092524,0.0014465455,0.00014177518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0056722485,0.0001321302,0.0011244395,0.002187514,0.00009282028,0.00091321545,0.0016935265,0.0023781375,0.9577801,0.00031599842,0.0077033113,0.020006564],"study_design_scores_gemma":[0.062335704,0.0016982392,0.0017579948,0.0030358117,0.000055086817,0.00030012065,0.0011576152,0.29621017,0.62925524,0.00062907935,0.0030521648,0.0005127876],"about_ca_topic_score_codex":0.006210861,"about_ca_topic_score_gemma":0.00026922053,"teacher_disagreement_score":0.32852486,"about_ca_system_score_codex":0.21196486,"about_ca_system_score_gemma":0.115813576,"threshold_uncertainty_score":0.9999128},"labels":[],"label_agreement":null},{"id":"W2063430427","doi":"10.1002/cyto.b.20132","title":"Evaluation of ZAP‐70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process","year":2006,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Immunophenotyping; Flow cytometry; clone (Java method); Biology; Somatic cell; Leukemia; Immunology; Gene; Cancer research; Genetics","score_opus":0.058546827382758036,"score_gpt":0.4144973869818134,"score_spread":0.35595055959905536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063430427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98472744,0.0047620754,0.0038768882,0.00013285468,0.0011903306,0.0019199899,0.00011072763,0.00021360851,0.0030660671],"genre_scores_gemma":[0.9947619,0.0009978764,0.0007083932,0.00021468039,0.0014747891,0.00022053043,0.0008141799,0.00014271813,0.00066495646],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9849858,0.0010069995,0.0034502915,0.0016193436,0.0077099176,0.0012276109],"domain_scores_gemma":[0.99257076,0.002011578,0.0010100026,0.0012669136,0.0024904204,0.0006503472],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0109430775,0.0006594325,0.0015290194,0.0033106455,0.00013729009,0.00010222714,0.0010523353,0.0012713084,0.0023923218],"category_scores_gemma":[0.015848372,0.00062633824,0.0005103686,0.008710212,0.0005463303,0.0006240199,0.0004571024,0.0013265414,0.00032751524],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008015599,0.009112121,0.6218768,0.0056316094,0.001989306,0.0013260477,0.00041045967,0.058517076,0.07843594,0.00008082852,0.049782135,0.16482209],"study_design_scores_gemma":[0.06894563,0.000705386,0.03294445,0.0016050066,0.0005668613,0.00021285069,0.00016036948,0.8174095,0.074735574,0.00013235601,0.0017858469,0.00079613953],"about_ca_topic_score_codex":0.00038039265,"about_ca_topic_score_gemma":0.00003904582,"teacher_disagreement_score":0.7588925,"about_ca_system_score_codex":0.09682449,"about_ca_system_score_gemma":0.040530097,"threshold_uncertainty_score":0.99961877},"labels":[],"label_agreement":null},{"id":"W2063503125","doi":"10.1007/s11926-014-0460-5","title":"Economics of Non-Adherence to Biologic Therapies in Rheumatoid Arthritis","year":2014,"lang":"en","type":"review","venue":"Current Rheumatology Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Pharmacy; Biologic Agents; Rheumatology; Health care; Internal medicine; Arthritis; Intensive care medicine; Physical therapy; Family medicine","score_opus":0.059405980965689796,"score_gpt":0.3844767148582721,"score_spread":0.32507073389258234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063503125","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027200125,0.9689827,0.000043504144,0.000023269482,0.0014308462,0.0020191935,0.00002019374,0.000049662744,0.00023050999],"genre_scores_gemma":[0.0077568884,0.9911653,0.00018022503,0.000011514604,0.00003224723,0.00051312323,0.0002233612,0.00007511536,0.00004226905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99449337,0.00023955392,0.0031301507,0.001123541,0.00023389953,0.0007794679],"domain_scores_gemma":[0.99601436,0.0005391378,0.0015014663,0.00148643,0.00015481097,0.00030377525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011779944,0.000653397,0.0058552288,0.00081710296,0.000041138894,0.000018618735,0.0003691892,0.0006945916,0.00017556963],"category_scores_gemma":[0.0009687804,0.00052042736,0.00063377834,0.00050494936,0.00040392752,0.000044656106,0.0003616214,0.00078074,0.00023898318],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000259029,0.00017337667,0.0024973692,0.021043262,0.00016981241,0.00036112903,0.00011929738,0.0000016503063,3.3021809e-7,0.00011366539,0.0013485957,0.9741456],"study_design_scores_gemma":[0.0018955786,0.00034633375,0.000037891226,0.06667342,0.000060229195,0.020765617,0.00001833587,0.00004881799,0.000006001018,0.00019217162,0.9094848,0.00047079372],"about_ca_topic_score_codex":0.00028745327,"about_ca_topic_score_gemma":0.000094812676,"teacher_disagreement_score":0.97367483,"about_ca_system_score_codex":0.0030406888,"about_ca_system_score_gemma":0.010522641,"threshold_uncertainty_score":0.99972475},"labels":[],"label_agreement":null},{"id":"W2065011146","doi":"10.1016/s1083-8791(03)80127-1","title":"126Alternative donor hematopoetic stem cell transplantation (HSCT) for acute and chronic lymphoid malignancies: 20 year experience of the leukemia/BMT program of British Columbia","year":2003,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Transplantation; Chronic leukemia; Stem cell; Oncology; Hematopoietic stem cell transplantation; Leukemia; Acute leukemia; Internal medicine","score_opus":0.010440735734009299,"score_gpt":0.26670680418935705,"score_spread":0.2562660684553478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065011146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963228,0.0014383321,0.00033697483,0.000012861561,0.0000633416,0.001190898,0.00045557367,0.000012386929,0.00016681552],"genre_scores_gemma":[0.9933716,0.00515029,0.00096885505,0.000012356944,0.000014851873,0.00013396479,0.00007472956,0.000013351251,0.0002599836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890286,0.000081065904,0.0003881298,0.00026665154,0.00014935019,0.00021196454],"domain_scores_gemma":[0.99933165,0.00014957022,0.00019408621,0.0001386448,0.0001279604,0.000058083893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017927153,0.00010454946,0.0003518967,0.000042242642,0.00005276507,0.000009540668,0.00008792536,0.00013516599,0.000011411472],"category_scores_gemma":[0.000008709249,0.00010709603,0.00007783694,0.00011838638,0.0005096365,0.00006036788,0.000007090853,0.000060522605,1.4623842e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063636247,0.00027483152,0.02529451,0.006588201,0.0003009821,0.000025912706,0.004506926,0.0000061499677,0.9580333,0.0003234777,0.00003594936,0.0039733523],"study_design_scores_gemma":[0.023663303,0.002006212,0.0049205646,0.00084905064,0.0011077395,0.0013066974,0.00079494267,0.0002114036,0.96470577,0.00016130935,0.00010330942,0.00016969397],"about_ca_topic_score_codex":0.0013885677,"about_ca_topic_score_gemma":0.001383742,"teacher_disagreement_score":0.023026941,"about_ca_system_score_codex":0.00018527177,"about_ca_system_score_gemma":0.0010566072,"threshold_uncertainty_score":0.43672493},"labels":[],"label_agreement":null},{"id":"W2067201516","doi":"10.1182/blood-2013-04-491787","title":"Jump-starting the T cells in CLL","year":2013,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Lenalidomide; Immune system; Lymphocytosis; Immunology; Medicine; Leukemia; Cancer research; Multiple myeloma","score_opus":0.02225573793311002,"score_gpt":0.2693427936704702,"score_spread":0.24708705573736017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067201516","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.184984,0.0017017381,0.0000030809952,0.7838426,0.00050692906,0.0022076096,0.000022800772,0.0001167465,0.026614489],"genre_scores_gemma":[0.019810928,0.00021051987,0.00030881766,0.91818434,0.010217484,0.00027777313,0.00014120508,0.000193883,0.050655033],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99743277,0.00012612931,0.00040791617,0.00042775265,0.00083013123,0.0007752936],"domain_scores_gemma":[0.9983065,0.0004644033,0.000111811336,0.0009574599,0.00008317399,0.00007661162],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043170503,0.00026322986,0.0004498269,0.00017079893,0.000051261104,0.000062796986,0.00044050848,0.0006391443,0.00069161225],"category_scores_gemma":[0.00018431555,0.00016655667,0.00015354838,0.00025360906,0.00013697792,0.00003802419,0.0002102963,0.0026215445,0.0018131422],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008100875,0.00010831729,0.00005980613,0.00042475824,0.000089157635,0.0025895936,0.00018750624,0.0000010432981,0.00049544,0.0000022837648,0.9956075,0.0004264909],"study_design_scores_gemma":[0.0184707,0.00009451036,0.00009514785,0.00051879225,0.0002350432,0.000269125,0.00005090535,0.0005351833,0.0056976657,0.000113631824,0.9736468,0.0002724564],"about_ca_topic_score_codex":0.0018572315,"about_ca_topic_score_gemma":0.00003709,"teacher_disagreement_score":0.16517307,"about_ca_system_score_codex":0.002708672,"about_ca_system_score_gemma":0.0037747296,"threshold_uncertainty_score":0.99967945},"labels":[],"label_agreement":null},{"id":"W2067493438","doi":"10.1182/blood.v99.9.3197","title":"Modulation of p210BCR-ABL activity in transduced primary human hematopoietic cells controls lineage programming","year":2002,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Haematopoiesis; Biology; Progenitor cell; CD34; Stem cell; Cell biology; Cancer research; Tyrosine kinase; Cord blood; Molecular biology; Immunology; Signal transduction","score_opus":0.027258975885427236,"score_gpt":0.28055444059181184,"score_spread":0.2532954647063846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067493438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965255,0.0003111267,0.00014655627,0.00008748408,0.000026536112,0.0010376314,0.0000038059218,0.000055401102,0.0018059226],"genre_scores_gemma":[0.99864376,0.00002597484,0.00071782374,0.000030287778,0.0000864187,0.000056833906,0.000010509881,0.000030511319,0.00039786904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837124,0.00008231463,0.00038997352,0.00029709804,0.0004790797,0.00038028212],"domain_scores_gemma":[0.9991811,0.00012748103,0.00010192748,0.00040168615,0.00007023317,0.00011757505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034714496,0.00015408036,0.0004842605,0.00016555219,0.000037907386,0.000013905016,0.00011069988,0.00014175299,0.00012318803],"category_scores_gemma":[0.000057009882,0.00014442154,0.00011881166,0.00030920506,0.000094460374,0.00009538545,0.000029617768,0.00024892052,0.000018310073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011704702,0.0037236416,0.0009835578,0.0010309425,0.00009779373,0.00017136274,0.00092778186,0.000048497626,0.9844514,0.000032454238,0.000023745893,0.008391782],"study_design_scores_gemma":[0.08395956,0.00063219067,0.012963006,0.00045349193,0.00024607775,0.00011183366,0.000052873143,0.019657517,0.88142294,0.00003387484,0.00019831532,0.0002683077],"about_ca_topic_score_codex":0.00020823366,"about_ca_topic_score_gemma":0.00002746968,"teacher_disagreement_score":0.10302844,"about_ca_system_score_codex":0.001107492,"about_ca_system_score_gemma":0.00039325733,"threshold_uncertainty_score":0.588934},"labels":[],"label_agreement":null},{"id":"W2068473940","doi":"10.1158/0008-5472.can-14-2607","title":"When Will Resistance Be Futile?","year":2014,"lang":"en","type":"review","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Drug resistance; Cancer; Drug; Biology; Cancer research; Pharmacology; Medicine; Genetics","score_opus":0.2093229256531513,"score_gpt":0.510930318427078,"score_spread":0.30160739277392673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068473940","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010354403,0.96767294,0.000012704889,0.0013071467,0.0003369421,0.0029106967,0.0001220607,0.00011492203,0.027512228],"genre_scores_gemma":[0.000011798023,0.8527102,0.000134245,0.00015923906,0.0023412795,0.0018719292,0.00014708865,0.00025037458,0.14237384],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908192,0.001114931,0.0009535141,0.0014794804,0.0035616842,0.0020711725],"domain_scores_gemma":[0.993644,0.0015907404,0.00020048434,0.0026245576,0.0010134099,0.00092678354],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0037608587,0.0006244904,0.0030524554,0.0009825482,0.0003124085,0.00015174948,0.001359825,0.0008606333,0.0038473143],"category_scores_gemma":[0.0015051449,0.00047843545,0.0007320815,0.0015097408,0.0010019044,0.00012096415,0.00077934103,0.003409469,0.0012756339],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014560741,0.000062579034,6.3746916e-7,0.09720604,0.00035570914,0.00042184032,0.0001173401,1.2977897e-7,0.0000030123392,0.000824501,0.37439096,0.5264717],"study_design_scores_gemma":[0.0028053457,0.0001257861,3.283992e-7,0.042712077,0.00031800463,0.0001272148,0.000019513644,0.00001166998,0.000012707873,0.00021345206,0.95326644,0.00038743365],"about_ca_topic_score_codex":0.00084065,"about_ca_topic_score_gemma":0.00038533087,"teacher_disagreement_score":0.57887554,"about_ca_system_score_codex":0.049827535,"about_ca_system_score_gemma":0.059367653,"threshold_uncertainty_score":0.9997667},"labels":[],"label_agreement":null},{"id":"W2068483646","doi":"10.1093/jncimonographs/lgu002","title":"Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project","year":2014,"lang":"en","type":"article","venue":"JNCI Monographs","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute on Deafness and Other Communication Disorders; National Institute on Drug Abuse; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research","keywords":"Medicine; Lymphoplasmacytic Lymphoma; Lymphoma; Family history; Hodgkin lymphoma; Waldenstrom macroglobulinemia; Macroglobulinemia; Medical history; Internal medicine; Oncology; Pathology; Multiple myeloma","score_opus":0.02423000792041198,"score_gpt":0.285757337369041,"score_spread":0.26152732944862905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068483646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98923725,0.0030447363,0.0016382813,0.0003433104,0.0015349715,0.0019148724,0.000095562646,0.00025219406,0.0019388059],"genre_scores_gemma":[0.99297935,0.0008129165,0.0016557449,0.0014054022,0.00081893196,0.0005080562,0.00023061971,0.00016000938,0.001428978],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99451834,0.00034028717,0.0010120253,0.0011643365,0.0017835983,0.001181413],"domain_scores_gemma":[0.9952333,0.0019633095,0.00046503893,0.0011719374,0.0004179603,0.000748451],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017347184,0.0007390054,0.0009900793,0.0006605514,0.00033806326,0.000068347,0.00077605207,0.0006385566,0.00016414358],"category_scores_gemma":[0.0023737638,0.0005291322,0.0006076949,0.00043448995,0.00140278,0.00020558537,0.0002948334,0.000318621,0.000049150618],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007098059,0.0019850826,0.20724742,0.0015786868,0.0021223794,0.000352271,0.00835331,0.000025608393,0.0007628615,0.0018281458,0.606317,0.16232917],"study_design_scores_gemma":[0.0616879,0.0023057696,0.18393344,0.0004750991,0.0010064928,0.0014557373,0.0011259875,0.14762494,0.00042466866,0.00023628927,0.59840745,0.0013162466],"about_ca_topic_score_codex":0.0066401805,"about_ca_topic_score_gemma":0.00033037044,"teacher_disagreement_score":0.16101292,"about_ca_system_score_codex":0.023177342,"about_ca_system_score_gemma":0.017972315,"threshold_uncertainty_score":0.99997467},"labels":[],"label_agreement":null},{"id":"W2068659286","doi":"10.1097/mpg.0b013e31829ae499","title":"More on Lymphoproliferative Disorders Associated With Crohn Disease Treatments","year":2013,"lang":"en","type":"letter","venue":"Journal of Pediatric Gastroenterology and Nutrition","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Disease; Lymphoma; Epidemiology; Lymphoproliferative disorders; Inflammatory bowel disease; Cancer; Infliximab; Crohn's disease; Pediatrics; Internal medicine; Immunology","score_opus":0.011692771752096763,"score_gpt":0.25938384749384047,"score_spread":0.2476910757417437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068659286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83110243,0.0007801389,0.000025906575,0.16708569,0.00017193041,0.0007307672,0.000067980734,0.000013682199,0.000021485865],"genre_scores_gemma":[0.74130833,0.014761707,0.00025682108,0.22808178,0.012960922,0.00024828064,0.00095276424,0.00015918733,0.001270188],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99768525,0.00024868525,0.0005177779,0.00032762837,0.00069828867,0.00052235345],"domain_scores_gemma":[0.99826086,0.00022279989,0.00066605094,0.00019996891,0.00034762037,0.00030267923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016095175,0.0003683287,0.0007520264,0.00062529155,0.000093521696,0.000032540785,0.00012092248,0.0004826165,0.000063498956],"category_scores_gemma":[0.0001607797,0.00025455884,0.00021796358,0.00014525466,0.00021114753,0.0001351593,0.000031997093,0.0013531601,0.000009838783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0149657745,0.0016228373,0.08349082,0.0005958732,0.0012369939,0.010387047,0.00008750618,0.000005127671,0.0000021669582,8.254081e-7,0.88743126,0.00017376781],"study_design_scores_gemma":[0.21872818,0.050979916,0.70126355,0.0021123036,0.010612885,0.0049297223,0.00014911767,0.00060035486,0.000010435618,0.00044661033,0.009489779,0.0006771358],"about_ca_topic_score_codex":0.000015412072,"about_ca_topic_score_gemma":0.0000036782035,"teacher_disagreement_score":0.8779415,"about_ca_system_score_codex":0.0031996812,"about_ca_system_score_gemma":0.0011825885,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W2069068402","doi":"10.1139/o01-100","title":"Processing of the insulin-like growth factor-IImannose 6-phosphate receptor in isolated liver subcellular fractions","year":2001,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Endosome; Golgi apparatus; Mannose 6-phosphate; Leupeptin; Receptor; Biology; Biochemistry; Insulin-like growth factor 2 receptor; Mannose 6-phosphate receptor; Mannose; Vesicle; Cell surface receptor; Asialoglycoprotein receptor; Molecular biology; Hepatocyte; Growth factor; Endoplasmic reticulum; Membrane; Lysosome; Insulin-like growth factor 1 receptor; Enzyme; In vitro","score_opus":0.014513202169309536,"score_gpt":0.26104885481324774,"score_spread":0.2465356526439382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069068402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114454,0.0068701077,0.000034538632,0.00016614076,0.00006881579,0.00017689748,0.000010586001,0.000017156472,0.0015112475],"genre_scores_gemma":[0.99566907,0.0022970089,0.000054503736,0.00009251787,0.00006333172,0.000009653146,0.000035471563,0.000011122391,0.0017673201],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990564,0.000045956564,0.00024544218,0.0002871251,0.00009480563,0.0002702542],"domain_scores_gemma":[0.9994123,0.00006705429,0.00009726702,0.00023416143,0.00010083259,0.00008837201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112652975,0.00013199639,0.0002131592,0.00003850388,0.00006573282,0.0000067513192,0.00012645095,0.00027855253,0.00020510037],"category_scores_gemma":[0.00009216371,0.0000936822,0.00005324509,0.00030336762,0.0002859794,0.000029289116,0.000094540635,0.00027605158,0.000010172795],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000433806,0.00023154505,0.016675526,0.00039740506,0.000021289556,0.00003754062,0.00020669251,9.436461e-7,0.9792847,0.000007636479,0.00019156068,0.0025113286],"study_design_scores_gemma":[0.0049849306,0.0001428266,0.002361379,0.00012622452,0.00002741811,0.000121727506,0.00015969758,0.001968799,0.9809579,0.000031252537,0.008967343,0.00015045417],"about_ca_topic_score_codex":0.00030177052,"about_ca_topic_score_gemma":0.0000057226334,"teacher_disagreement_score":0.014314148,"about_ca_system_score_codex":0.00049461116,"about_ca_system_score_gemma":0.0009916555,"threshold_uncertainty_score":0.38202494},"labels":[],"label_agreement":null},{"id":"W2069162303","doi":"10.1038/bjc.2013.381","title":"Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study","year":2013,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"CancerCare Manitoba Foundation; Manitoba Health Research Council","keywords":"Chronic lymphocytic leukemia; Medicine; Follicular lymphoma; Lymphoma; Incidence (geometry); Internal medicine; Immunosuppression; Cohort; Population; Cancer; Oncology; Gastroenterology; Leukemia","score_opus":0.007210907487999676,"score_gpt":0.2524244376014164,"score_spread":0.24521353011341673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069162303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633414,0.0018524101,0.0000022572897,0.000016668002,0.00010020586,0.001447537,0.00009992419,0.000007831216,0.00013902022],"genre_scores_gemma":[0.99929684,0.00009477575,0.00007983184,0.00018011348,0.00008803326,0.000095679585,0.000048956346,0.000051140963,0.00006461865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967257,0.0002256168,0.0009975078,0.00028345318,0.0011921003,0.0005756335],"domain_scores_gemma":[0.99683094,0.00013234114,0.0006713482,0.0002942333,0.0014959647,0.00057515496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003632464,0.00023731099,0.0007947696,0.00049789663,0.00010101509,0.00007402624,0.0002644882,0.00011392526,0.0011356181],"category_scores_gemma":[0.00036251105,0.00022388536,0.00014651963,0.0005707719,0.00009471315,0.00029275738,0.000029958032,0.00023482105,0.0000119142705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005740192,0.0004694687,0.9850924,0.00019912739,0.000322637,0.0005745117,0.00019828258,0.002200634,0.00002269737,6.9337534e-7,0.00046917165,0.009876327],"study_design_scores_gemma":[0.07621151,0.0014673346,0.9170497,0.0018217352,0.00019938062,0.00012891834,0.00018977438,0.0023039116,0.00020133206,0.000013036767,0.0002039725,0.0002093718],"about_ca_topic_score_codex":0.90660155,"about_ca_topic_score_gemma":0.7736597,"teacher_disagreement_score":0.13294184,"about_ca_system_score_codex":0.080182776,"about_ca_system_score_gemma":0.05086973,"threshold_uncertainty_score":0.9997775},"labels":[],"label_agreement":null},{"id":"W2069327083","doi":"10.1016/j.leukres.2013.04.014","title":"Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression","year":2013,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Ectodomain; Disintegrin; Transfection; Molecular biology; Biology; ADAM10; Metalloproteinase; Cell culture; Glycoprotein; Cell biology; Enzyme; Receptor; Genetics; Biochemistry","score_opus":0.033153868947830935,"score_gpt":0.3298452281077127,"score_spread":0.29669135915988176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069327083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98218715,0.0028237577,0.00007565561,0.0017948044,0.00008111419,0.0016795499,0.00007196293,0.00007947157,0.011206536],"genre_scores_gemma":[0.975659,0.0004518774,0.001303634,0.0002948118,0.00022073119,0.00008274085,0.0001109614,0.000102397855,0.02177381],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99313796,0.0008131232,0.0006884456,0.00084786257,0.003096025,0.0014165979],"domain_scores_gemma":[0.9933986,0.0031413385,0.00013948945,0.0019381902,0.0008635866,0.0005187767],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022402895,0.00032457832,0.0005926608,0.00017538623,0.0003655858,0.00013089036,0.0010651137,0.00043778363,0.0062770983],"category_scores_gemma":[0.00078539294,0.00021676024,0.00019562946,0.0012458258,0.00076147245,0.00024165884,0.00078738714,0.0015977637,0.0011693124],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002978637,0.00009903067,0.00061709696,0.00012275988,0.000049746403,0.000037714035,0.0008598148,0.000042300442,0.5960437,0.000016111066,0.40092486,0.00088900136],"study_design_scores_gemma":[0.012552104,0.00039754747,0.0010848274,0.00057657616,0.000030180243,0.000027272219,0.0013350284,0.0306483,0.94062775,0.00072466594,0.011731985,0.00026378664],"about_ca_topic_score_codex":0.03695968,"about_ca_topic_score_gemma":0.000042321393,"teacher_disagreement_score":0.38919288,"about_ca_system_score_codex":0.014690992,"about_ca_system_score_gemma":0.007750461,"threshold_uncertainty_score":0.9996084},"labels":[],"label_agreement":null},{"id":"W2070487917","doi":"10.3109/10428194.2015.1022770","title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Gilead Sciences","keywords":"Idelalisib; Medicine; Adverse effect; Internal medicine; Diarrhea; Intensive care medicine; Ibrutinib","score_opus":0.07781209335968814,"score_gpt":0.3511248248391235,"score_spread":0.27331273147943536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070487917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010915141,0.9755473,0.000025400705,0.00002047829,0.0005868771,0.0044947467,0.00035272024,0.00037100888,0.0076863393],"genre_scores_gemma":[0.003213077,0.98447937,0.00062171073,0.00011016498,0.0004814593,0.0010396108,0.0024238045,0.0005357206,0.007095058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98993653,0.00059491995,0.0025088177,0.0023760535,0.0025859184,0.001997744],"domain_scores_gemma":[0.9932269,0.0005730712,0.0016146457,0.0025390713,0.00057084474,0.0014754578],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00096799707,0.0023980194,0.0063878912,0.0009933211,0.00030543233,0.00004630254,0.00095834176,0.0018128752,0.0001089905],"category_scores_gemma":[0.00012581638,0.001759681,0.0013482347,0.0018662151,0.00074607105,0.00037540914,0.0006755177,0.0003302151,0.00018489822],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011324775,0.00080340484,0.000044099834,0.017092478,0.006317613,0.0033683304,0.0006428214,0.000014085328,0.0000016593286,0.0002947546,0.001737145,0.96855116],"study_design_scores_gemma":[0.08059497,0.0020982823,0.00031411866,0.057410207,0.0054393956,0.0045739086,0.00061163347,0.0010268313,0.00003331022,0.00006613946,0.84593254,0.0018986766],"about_ca_topic_score_codex":0.002856337,"about_ca_topic_score_gemma":0.000041053627,"teacher_disagreement_score":0.96665245,"about_ca_system_score_codex":0.20222163,"about_ca_system_score_gemma":0.05651086,"threshold_uncertainty_score":0.999483},"labels":[],"label_agreement":null},{"id":"W2070812863","doi":"10.1016/j.jval.2013.08.448","title":"Potential Long-Term Cost Savings Due to Significant Clinical Benefit of Obinutuzumab (Ga101) in Combination with Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Obinutuzumab; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Bendamustine; Population; Ofatumumab; Rituximab; Internal medicine; Leukemia; Oncology; Chemotherapy; Lymphoma; Environmental health; Cyclophosphamide","score_opus":0.0337281984678595,"score_gpt":0.329314392531407,"score_spread":0.29558619406354747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070812863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99229115,0.00061874604,0.00012209892,0.00063373154,0.00013953826,0.006037788,0.000008598563,0.000054789984,0.00009355138],"genre_scores_gemma":[0.9978707,0.00063739094,0.00034435905,0.00031420917,0.000103102924,0.0003630771,0.000079880025,0.00007559756,0.00021172843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99433994,0.00045442235,0.0020772493,0.00088367163,0.00096741127,0.0012773292],"domain_scores_gemma":[0.9973654,0.00051789253,0.00039917848,0.0008187317,0.00028707436,0.00061169075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023127832,0.000368404,0.0013347265,0.0008334134,0.00004932393,0.000042089767,0.0003684827,0.00031994857,0.00015499815],"category_scores_gemma":[0.0004999856,0.00032458096,0.00010577776,0.0016364628,0.00024045,0.00020167149,0.0001566073,0.00070015265,0.00012314234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011240244,0.002644751,0.46214238,0.013754458,0.00026272133,0.0054639336,0.00638547,0.36682382,0.0015247364,0.0009885292,0.0007605869,0.12800838],"study_design_scores_gemma":[0.070560195,0.005729153,0.5752446,0.0061350125,0.000032391297,0.00035642387,0.00014894053,0.3406772,0.00056096265,0.00013423919,0.000024802874,0.00039607543],"about_ca_topic_score_codex":0.2102106,"about_ca_topic_score_gemma":0.0070913294,"teacher_disagreement_score":0.20311928,"about_ca_system_score_codex":0.2545,"about_ca_system_score_gemma":0.08224641,"threshold_uncertainty_score":0.9999206},"labels":[],"label_agreement":null},{"id":"W2071244122","doi":"10.1002/(sici)1097-0320(20000415)42:2<114::aid-cyto5>3.0.co;2-l","title":"Diagnosis of unexpected acute myeloid leukemia and chronic lymphocytic leukemia: A case report demonstrating the perils of restricted panels in flow cytometric immunophenotyping","year":2000,"lang":"en","type":"article","venue":"Cytometry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunophenotyping; Myeloid leukemia; Chronic lymphocytic leukemia; Flow cytometry; Leukemia; Immunology; Medicine","score_opus":0.01791409167057785,"score_gpt":0.2922141887900045,"score_spread":0.27430009711942666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071244122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914343,0.008405307,0.00005360807,0.000053390773,0.000085330146,0.0010800951,0.000035819434,0.00008659118,0.0010564458],"genre_scores_gemma":[0.99477744,0.0034224202,0.0010237348,0.000050187125,0.00015048732,0.00015304275,0.000038465863,0.00007704805,0.00030716084],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99535733,0.00025019853,0.0016958071,0.0007663963,0.0010200315,0.0009102179],"domain_scores_gemma":[0.9958372,0.0017606626,0.0004907463,0.001320294,0.00032042124,0.0002706535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010442024,0.0004457527,0.0011983907,0.0018639404,0.0001966859,0.000049665316,0.00038369023,0.00041391002,0.00038307765],"category_scores_gemma":[0.0021625366,0.0003546063,0.00023203906,0.009457081,0.0007307553,0.00022051261,0.00022830853,0.00076378515,0.000013752431],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004620832,0.00057578663,0.036149945,0.0058704573,0.0034093084,0.29913253,0.008172775,0.0091314465,0.21527721,0.00007573437,0.0005710911,0.4170129],"study_design_scores_gemma":[0.061328843,0.002195612,0.10998555,0.003861937,0.0015999372,0.34912363,0.004167252,0.2571469,0.20862295,0.000076075274,0.0004218502,0.001469488],"about_ca_topic_score_codex":0.005649554,"about_ca_topic_score_gemma":0.00006824109,"teacher_disagreement_score":0.4155434,"about_ca_system_score_codex":0.057252094,"about_ca_system_score_gemma":0.026677052,"threshold_uncertainty_score":0.99989057},"labels":[],"label_agreement":null},{"id":"W2072043914","doi":"10.1038/ng.419","title":"Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma","year":2009,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Follicular lymphoma; Chronic lymphocytic leukemia; Lymphoma; Biology; Follicular phase; Allele; Genetic association; Genome-wide association study; Leukemia; Genetics; Single-nucleotide polymorphism; Immunology; Gene; Genotype","score_opus":0.01167607600136909,"score_gpt":0.2837860582958836,"score_spread":0.2721099822945145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072043914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938484,0.0021914446,0.000115743445,0.0010052532,0.00017001767,0.0010937762,0.00004784803,0.00013075984,0.0013967766],"genre_scores_gemma":[0.9905846,0.000095704156,0.0035833102,0.003273361,0.00034977923,0.000016946211,0.000054038963,0.00006153929,0.0019806942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647564,0.00010636432,0.0003696165,0.0008273425,0.0013387474,0.000882278],"domain_scores_gemma":[0.9973338,0.00011455357,0.00012662247,0.0012421896,0.0005434949,0.00063933205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033250396,0.0003706716,0.00055167585,0.00016037351,0.0001541011,0.000044446675,0.00035195905,0.0007842272,0.00014928433],"category_scores_gemma":[0.00079303957,0.0002968596,0.00014000766,0.00087584,0.000098421406,0.00002864832,0.00015248975,0.00047102862,0.00014653505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011015477,0.0075886096,0.61325216,0.0008749351,0.0030970327,0.018999059,0.003466101,0.004887798,0.07943644,0.00018508846,0.13978505,0.11741227],"study_design_scores_gemma":[0.015198398,0.0015003411,0.96251345,0.00024376043,0.00022907612,0.00042686381,0.000040181014,0.0027156812,0.009090995,0.0001299823,0.0074706925,0.00044059957],"about_ca_topic_score_codex":0.00003105411,"about_ca_topic_score_gemma":0.00036933954,"teacher_disagreement_score":0.34926128,"about_ca_system_score_codex":0.013607616,"about_ca_system_score_gemma":0.002770076,"threshold_uncertainty_score":0.9999484},"labels":[],"label_agreement":null},{"id":"W2072795240","doi":"10.1385/ir:35:1:75","title":"Antibody Diversification: Mutational Mechanisms and Oncogenesis","year":2006,"lang":"en","type":"review","venue":"Immunologic Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Somatic hypermutation; Cytidine deaminase; Biology; Antibody; Immunoglobulin class switching; Genetics; Gene; Gene conversion; Effector; DNA; Virology; Immunology; B cell; Recombination","score_opus":0.2306691935226974,"score_gpt":0.5048897801612066,"score_spread":0.2742205866385091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072795240","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010365018,0.99051136,0.0001531058,0.000118554555,0.00010596974,0.0019888168,0.000053233874,0.00008838273,0.0068769543],"genre_scores_gemma":[0.00022490844,0.98962194,0.00082812493,0.000012308594,0.0001899919,0.00032465992,0.0013442856,0.00006731305,0.007386468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948996,0.00084592326,0.00065599027,0.0009523621,0.0017161701,0.0009299722],"domain_scores_gemma":[0.9963927,0.0016198404,0.00015961564,0.0009782427,0.0006663384,0.00018326042],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002299853,0.00040304562,0.0014569842,0.0010510634,0.00043303944,0.00013165518,0.00058401236,0.00077239005,0.0003637388],"category_scores_gemma":[0.0006115641,0.00029950344,0.00033163046,0.001346208,0.0009068098,0.00008762202,0.00076916604,0.0013809324,0.0009826099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000082556915,0.00023093614,0.0000039663014,0.012479099,0.0005011389,0.0012364062,0.00005134019,4.425677e-7,0.00011175432,0.0029834209,0.0012489628,0.98107],"study_design_scores_gemma":[0.0025563657,0.0004544181,0.000078980775,0.003995063,0.00032241605,0.0022319502,0.00013868602,0.00008001107,0.00001874249,0.00081118284,0.9889943,0.00031785987],"about_ca_topic_score_codex":0.00066969864,"about_ca_topic_score_gemma":0.000003637138,"teacher_disagreement_score":0.98774534,"about_ca_system_score_codex":0.010061423,"about_ca_system_score_gemma":0.0120594185,"threshold_uncertainty_score":0.9999457},"labels":[],"label_agreement":null},{"id":"W2073210499","doi":"10.3109/10428194.2010.535183","title":"In a patient with biclonal Waldenstrom macroglobulinemia only one clone expands in three-dimensional culture and includes putative cancer stem cells","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"clone (Java method); Waldenstrom macroglobulinemia; Bone marrow; Biology; Stem cell; Macroglobulinemia; Molecular biology; Antibody; Immunology; Cancer research; Gene; Multiple myeloma; Cell biology; Lymphoma; Genetics","score_opus":0.010021286159338694,"score_gpt":0.25830142249239174,"score_spread":0.24828013633305304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073210499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940856,0.002650854,0.000015475973,0.0004860083,0.0003104672,0.0015011794,0.00016418597,0.00012270157,0.0006635156],"genre_scores_gemma":[0.99331784,0.0006411919,0.0026353102,0.0013373513,0.0003648667,0.00035658144,0.00008839916,0.000162051,0.001096427],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993551,0.00016506173,0.00121964,0.0017987401,0.0016039701,0.0016615961],"domain_scores_gemma":[0.9970784,0.00041038526,0.0003676485,0.000815138,0.00035217626,0.0009762404],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052833284,0.0010604704,0.0015546224,0.00069230783,0.00029920068,0.00016872998,0.00038034498,0.00092982734,0.00015155597],"category_scores_gemma":[0.00006499476,0.00086421013,0.0001643404,0.001246625,0.0013302125,0.00052897213,0.0005998057,0.0008552699,0.000031301573],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0306856,0.0037313406,0.116132274,0.0030768116,0.001645455,0.039303184,0.021398153,0.0016314548,0.36103442,0.0030045062,0.0039678263,0.41438898],"study_design_scores_gemma":[0.34204137,0.0055597527,0.2434729,0.0054774806,0.00086898706,0.03910101,0.0037995982,0.13511778,0.20553607,0.0018946344,0.01187262,0.0052577816],"about_ca_topic_score_codex":0.020795455,"about_ca_topic_score_gemma":0.011716035,"teacher_disagreement_score":0.4091312,"about_ca_system_score_codex":0.03161213,"about_ca_system_score_gemma":0.026683515,"threshold_uncertainty_score":0.9993809},"labels":[],"label_agreement":null},{"id":"W2073746430","doi":"10.1007/s002800000223","title":"Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum; BioPhage Pharma (Canada)","funders":"","keywords":"Cytidine; Cytidine deaminase; In vivo; Leukemia; Nucleoside; Cytarabine; Cancer research; Chemistry; Biology; Pharmacology; Biochemistry; Immunology; Enzyme","score_opus":0.059812744456622755,"score_gpt":0.39303638163254234,"score_spread":0.3332236371759196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073746430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996938,0.0009284143,0.00010468212,0.00031807277,0.0001534699,0.0013375906,0.000044924313,0.000051008752,0.00012387021],"genre_scores_gemma":[0.99646926,0.0014122284,0.00015270227,0.0010084088,0.00043142936,0.00019521081,0.000015728123,0.00004831094,0.0002667478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795943,0.00014556394,0.00042242603,0.0006339634,0.00028396148,0.00055467564],"domain_scores_gemma":[0.998733,0.00027688703,0.0002583772,0.0002647629,0.00015988752,0.00030708086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024429784,0.00037224687,0.0010065265,0.00022331113,0.00022386968,0.000024018918,0.00015753532,0.00012237558,0.00034317543],"category_scores_gemma":[0.000016659946,0.00030519432,0.00006448379,0.00040251584,0.0005607682,0.00016281083,0.000089437,0.00042278448,0.0000011056666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009657382,0.0023795525,0.0036588935,0.00037113926,0.0006398703,0.0003448547,0.0036388116,0.0001468449,0.97201514,0.0000056355575,0.0008808881,0.0062609673],"study_design_scores_gemma":[0.2002911,0.004737624,0.037380196,0.00045476688,0.0006021685,0.00053809566,0.0019439479,0.027603738,0.72390383,0.000016619366,0.0017716176,0.00075629004],"about_ca_topic_score_codex":0.0016492567,"about_ca_topic_score_gemma":0.0004006562,"teacher_disagreement_score":0.24811132,"about_ca_system_score_codex":0.002046034,"about_ca_system_score_gemma":0.0013837365,"threshold_uncertainty_score":0.99994004},"labels":[],"label_agreement":null},{"id":"W2074584895","doi":"10.1182/blood-2010-03-275420","title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":304,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Amgen","keywords":"Alemtuzumab; Fludarabine; Medicine; Transplantation; Internal medicine; Chronic lymphocytic leukemia; Minimal residual disease; Oncology; Leukemia; Immunology; Cyclophosphamide; Chemotherapy","score_opus":0.016884207317919685,"score_gpt":0.30618732176142066,"score_spread":0.289303114443501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074584895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370307,0.0006730763,0.000008023466,0.00007664529,0.0003388054,0.0049836673,0.00010282159,0.00004438063,0.00006953938],"genre_scores_gemma":[0.99832106,0.00060606305,0.00001739974,0.00006317782,0.0004634966,0.00019493073,0.000029066105,0.00004741481,0.00025741875],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960058,0.00068169803,0.0012816712,0.0007287038,0.0007507028,0.000551448],"domain_scores_gemma":[0.99732226,0.00087845325,0.00037924078,0.0009488284,0.00010282728,0.00036839512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020204505,0.00030242914,0.0007099499,0.00014782013,0.00012109483,0.000042149783,0.00036543273,0.00026774558,0.000013313819],"category_scores_gemma":[0.0002909197,0.00021088753,0.00022647294,0.00028526215,0.00042687677,0.00012681996,0.00009146001,0.0007793345,0.000010837076],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21534681,0.008979539,0.739154,0.0031080842,0.00081713416,0.0026480863,0.0023735017,0.00013603571,0.019890532,0.000027602833,0.00013713038,0.007381551],"study_design_scores_gemma":[0.6079865,0.0020763534,0.38269436,0.00019138287,0.001397192,0.000101371596,0.000058211743,0.0029883387,0.0022730038,0.000017277092,0.000018295877,0.00019772873],"about_ca_topic_score_codex":0.0014230582,"about_ca_topic_score_gemma":0.003836281,"teacher_disagreement_score":0.39263967,"about_ca_system_score_codex":0.0034840265,"about_ca_system_score_gemma":0.015123071,"threshold_uncertainty_score":0.9904603},"labels":[],"label_agreement":null},{"id":"W2074599609","doi":"10.1111/j.1365-2141.2009.07814.x","title":"Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib <i>in vitro</i>","year":2009,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; CancerCare Manitoba; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Jewish General Hospital; McGill University","keywords":"Dasatinib; Chronic lymphocytic leukemia; Lymphocyte; Immunology; Tyrosine kinase; Cancer research; Cytotoxicity; Biology; Medicine; Leukemia; In vitro; Internal medicine; Receptor","score_opus":0.0155208006435872,"score_gpt":0.2702042294054852,"score_spread":0.25468342876189803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074599609","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64838547,0.07682139,0.0002275029,0.25681046,0.00252069,0.0038807876,0.00036157132,0.00020911275,0.010783016],"genre_scores_gemma":[0.08260843,0.0057069403,0.004037592,0.8926246,0.009571351,0.00008128799,0.0004964869,0.0004771731,0.0043961313],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9920651,0.000642899,0.0024554513,0.001045344,0.0018248694,0.0019663554],"domain_scores_gemma":[0.9949801,0.0010471395,0.0014416443,0.000849191,0.0010621913,0.0006197462],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010393158,0.0008483679,0.0044336673,0.001429944,0.00014378355,0.00013655004,0.0009151734,0.0020532284,0.00014772348],"category_scores_gemma":[0.0012505023,0.0009463483,0.0008587877,0.00079476775,0.00048820028,0.00023398975,0.00030289855,0.0041974816,0.00022863795],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00080006797,0.000071384144,0.000011268316,0.0008501734,0.00025076594,0.4812354,0.00009057794,0.00007286645,0.00051604887,0.0000015028075,0.5078107,0.0082892105],"study_design_scores_gemma":[0.027374035,0.00084058987,0.00025980105,0.0075788726,0.0004291318,0.818171,0.00013657894,0.00037990173,0.0026362813,0.00008870498,0.14136279,0.00074228033],"about_ca_topic_score_codex":0.0010463994,"about_ca_topic_score_gemma":0.00022985793,"teacher_disagreement_score":0.63581413,"about_ca_system_score_codex":0.113647476,"about_ca_system_score_gemma":0.05895922,"threshold_uncertainty_score":0.9992987},"labels":[],"label_agreement":null},{"id":"W2075128381","doi":"10.1111/j.1365-2141.2004.05240.x","title":"Effect of IL‐2R<i>β</i>‐binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy","year":2004,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"CD80; CD86; Immunology; CD38; Immunotherapy; Cancer research; Chronic lymphocytic leukemia; CD40; Biology; T cell; Immune system; Cytotoxic T cell; Cell biology; Leukemia; Stem cell; In vitro","score_opus":0.02028842482611792,"score_gpt":0.30829855182407145,"score_spread":0.28801012699795353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075128381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867103,0.011360736,0.00045960114,0.00019141647,0.0002355693,0.0009146739,0.00003439653,0.000016259144,0.00007701811],"genre_scores_gemma":[0.99770916,0.001563245,0.00036473788,0.00006797214,0.00014239164,0.00004548677,0.000006036638,0.000055735003,0.00004522559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771816,0.00015262251,0.0011019199,0.00022937264,0.00036241248,0.0004355377],"domain_scores_gemma":[0.9976516,0.00059980183,0.0007068385,0.0003479858,0.00055525335,0.00013851534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008673544,0.00020845892,0.0012813295,0.00032068253,0.00009863259,0.00001605719,0.00033509574,0.0002093131,0.00002345203],"category_scores_gemma":[0.0005673525,0.00018520362,0.00040249206,0.00022829381,0.0004718036,0.00010721697,0.00004527674,0.00028611868,0.0000068963245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006825401,0.0005830451,0.00026679185,0.006360497,0.0010241899,0.0024113045,0.00032028212,0.0049755904,0.95020276,0.00075880374,0.0011018566,0.025169455],"study_design_scores_gemma":[0.044774804,0.0061669215,0.00013890977,0.0043684244,0.00022249435,0.08551467,0.000038723672,0.00044118465,0.85759467,0.0001949562,0.00038288973,0.00016132343],"about_ca_topic_score_codex":0.00024392124,"about_ca_topic_score_gemma":0.000022057291,"teacher_disagreement_score":0.09260809,"about_ca_system_score_codex":0.010309751,"about_ca_system_score_gemma":0.010548179,"threshold_uncertainty_score":0.9950611},"labels":[],"label_agreement":null},{"id":"W2077062621","doi":"10.1111/j.1542-4758.2009.00395.x","title":"Renal dysfunction due to leukemic infiltration of kidneys in a case of chronic lymphocytic leukemia","year":2009,"lang":"en","type":"article","venue":"Hemodialysis International","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Fludarabine; Cyclophosphamide; Prednisolone; Infiltration (HVAC); Hemodialysis; Renal biopsy; Leukemia; Chlorambucil; Pathology; Leukostasis; Biopsy; Internal medicine; Chemotherapy","score_opus":0.01557226032225518,"score_gpt":0.3003902028557113,"score_spread":0.2848179425334561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077062621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911948,0.00007832314,0.0037075495,0.00029502457,0.00018920311,0.00041922805,0.000021382573,0.000029122068,0.0040653865],"genre_scores_gemma":[0.9977173,0.000041202853,0.0010059163,0.00024036739,0.00031456558,0.00002993268,0.000113521804,0.000016592054,0.0005205612],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976556,0.000070393544,0.0008531968,0.00038331252,0.00074809976,0.00028941582],"domain_scores_gemma":[0.99861556,0.00014608148,0.00022483057,0.00042810832,0.0004069876,0.0001784349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052310096,0.00018408021,0.00051168684,0.0009873643,0.000027597154,0.000015392645,0.00020428175,0.00015204574,0.00044203096],"category_scores_gemma":[0.0006657656,0.00018240469,0.0001965204,0.0008290695,0.00008362477,0.0001719774,0.000058795726,0.00018444436,0.00004253819],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0063567,0.0008556546,0.0024640637,0.0005734787,0.0009743611,0.0073972084,0.002914753,0.13712981,0.6736616,0.0042699445,0.0073365555,0.15606588],"study_design_scores_gemma":[0.034442898,0.0014635243,0.008872225,0.00075033645,0.00024320278,0.00934889,0.00018777254,0.7341249,0.20867978,0.00060383586,0.0008956539,0.0003869885],"about_ca_topic_score_codex":0.0028846792,"about_ca_topic_score_gemma":0.000392886,"teacher_disagreement_score":0.59699506,"about_ca_system_score_codex":0.07424355,"about_ca_system_score_gemma":0.01606733,"threshold_uncertainty_score":0.98951066},"labels":[],"label_agreement":null},{"id":"W2079080812","doi":"10.3747/co.v15i5.196","title":"Treating Recurrent Cases of Squamous Cell Carcinoma with Radiotherapy","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiation therapy; Chronic lymphocytic leukemia; Wide local excision; Surgery; Radiology; Leukemia; Internal medicine","score_opus":0.1062264689916006,"score_gpt":0.3926960027124183,"score_spread":0.2864695337208177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079080812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98392755,0.01102921,0.000115176284,0.000117860414,0.00028972942,0.0005144467,0.000008780379,0.000038193582,0.0039590383],"genre_scores_gemma":[0.9978091,0.00060963305,0.0008066786,0.000032150412,0.0002946049,0.000048862967,0.00002568194,0.00003172695,0.00034153718],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983926,0.000117118754,0.00035770613,0.0003322936,0.00037469945,0.0004255911],"domain_scores_gemma":[0.99856675,0.00048354652,0.00016324478,0.00038178335,0.00019708222,0.00020758815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014055279,0.00018816814,0.0005580427,0.00016897843,0.00007924812,0.0000026892772,0.0001284756,0.000105264335,0.00022417119],"category_scores_gemma":[0.0001225439,0.00013881811,0.00010153672,0.00027062403,0.00039268666,0.000036575268,0.000043078795,0.00029402124,0.000016988248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014716594,0.012963403,0.44124696,0.004274566,0.00022609743,0.013881909,0.014688478,0.00012067405,0.01291263,0.00024853452,0.037882682,0.44683748],"study_design_scores_gemma":[0.32229865,0.10343934,0.078954645,0.0008657731,0.0009284707,0.055771243,0.0024138766,0.026459645,0.092376165,0.00003958624,0.31461883,0.0018337657],"about_ca_topic_score_codex":0.00023063991,"about_ca_topic_score_gemma":0.00003694985,"teacher_disagreement_score":0.44500372,"about_ca_system_score_codex":0.007078787,"about_ca_system_score_gemma":0.007067861,"threshold_uncertainty_score":0.99856114},"labels":[],"label_agreement":null},{"id":"W2079270178","doi":"10.1200/jco.2002.12.047","title":"Phase I and Pharmacokinetic Study of Novel <scp>l</scp>-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Rash; Toxicity; Nausea; Pharmacokinetics; Dysgeusia; Gastroenterology; Pharmacology; Adverse effect; Nucleoside analogue; Internal medicine; Nucleoside","score_opus":0.15747020853399482,"score_gpt":0.47566146979791435,"score_spread":0.3181912612639195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079270178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930019,0.0011055882,0.000084515996,0.0013869853,0.0005219168,0.00061573414,0.000008357023,0.000012804255,0.0032622167],"genre_scores_gemma":[0.99400824,0.0019581497,0.0008557701,0.0010240772,0.0010536447,0.0000070189412,0.000002118118,0.00003480579,0.0010561855],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943647,0.0005427072,0.0032052766,0.0003717059,0.0010430027,0.00047259947],"domain_scores_gemma":[0.9897392,0.0065252804,0.0017955933,0.00037671195,0.0007209633,0.0008422879],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035292744,0.0002503924,0.0021378943,0.0003901749,0.000061707986,0.000014508048,0.00033526827,0.00039198913,0.00049820764],"category_scores_gemma":[0.01201669,0.00018629582,0.0003818036,0.00038846774,0.00046102345,0.00017423411,0.00026012052,0.0014263457,0.00003783466],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0152996,0.1820384,0.024328176,0.0007027107,0.0055071497,0.021589266,0.0076176357,0.00028097414,0.06837221,0.000070751084,0.111668296,0.56252486],"study_design_scores_gemma":[0.60143006,0.2210995,0.03206804,0.00046739288,0.0027674325,0.0065397792,0.002725889,0.040837675,0.0010419183,0.00013549722,0.09066302,0.0002237773],"about_ca_topic_score_codex":0.00012196412,"about_ca_topic_score_gemma":0.000025092828,"teacher_disagreement_score":0.5861305,"about_ca_system_score_codex":0.0014986132,"about_ca_system_score_gemma":0.0034955645,"threshold_uncertainty_score":0.9963055},"labels":[],"label_agreement":null},{"id":"W2079316702","doi":"10.3816/clm.2005.n.010","title":"Potential Impact of a Single Nucleotide Polymorphism in the Hyaluronan Synthase 1 Gene in Waldenström's Macroglobulinemia","year":2005,"lang":"en","type":"article","venue":"Clinical Lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"RNA splicing; Single-nucleotide polymorphism; Hyaluronan synthase; Gene; Biology; Intron; Genetics; Molecular biology; Genotype; RNA","score_opus":0.03790136286088836,"score_gpt":0.37230771499822624,"score_spread":0.3344063521373379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079316702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562293,0.000604422,0.00001599005,0.001476176,0.00016463551,0.00062513683,0.000030237017,0.000032718814,0.0014277332],"genre_scores_gemma":[0.9972182,0.00010456531,0.0007952226,0.0007103652,0.00083899684,0.000021492006,0.00002969783,0.000047425874,0.00023404333],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959157,0.00041308027,0.0015432368,0.00057579303,0.00076146604,0.00079071906],"domain_scores_gemma":[0.99743795,0.0009301627,0.00022165186,0.0009933063,0.000101411155,0.00031550237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017785304,0.0002902326,0.00081657997,0.00024483952,0.00004069448,0.000029206656,0.0005542318,0.00033481052,0.00037172274],"category_scores_gemma":[0.0012840404,0.00019914634,0.00059909356,0.0006385216,0.00057325186,0.000104831524,0.00019886515,0.00037748643,0.00018365712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078360075,0.013378085,0.0964465,0.00018141548,0.0003402472,0.010783103,0.0009067363,0.0006171024,0.02341021,0.00012218703,0.004655536,0.8413229],"study_design_scores_gemma":[0.084563114,0.004039716,0.8635104,0.0004896006,0.00018062713,0.0033778124,0.00022754053,0.03663098,0.0039709173,0.00019220586,0.0022880214,0.0005290935],"about_ca_topic_score_codex":0.0027966138,"about_ca_topic_score_gemma":0.00037267746,"teacher_disagreement_score":0.8407938,"about_ca_system_score_codex":0.0068561053,"about_ca_system_score_gemma":0.005176132,"threshold_uncertainty_score":0.9969564},"labels":[],"label_agreement":null},{"id":"W2079502160","doi":"10.1038/leu.2013.289","title":"A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia","year":2013,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; Leukemia and Lymphoma Society","keywords":"Chronic lymphocytic leukemia; Allele; Mutation; Leukemia; Allele frequency; Mutation frequency; Oncology; Internal medicine; Immunology; Medicine; Biology; Cancer research; Genetics; Gene","score_opus":0.02554217843366553,"score_gpt":0.29812992508165825,"score_spread":0.27258774664799273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079502160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8972239,0.007460676,0.000070876726,0.067826845,0.0016704866,0.012732107,0.00016170966,0.0008064301,0.012046977],"genre_scores_gemma":[0.8933021,0.0014994389,0.00047196043,0.058930155,0.024602462,0.0025220115,0.0037976652,0.0008820113,0.0139922295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98878455,0.0008875695,0.0018342364,0.0019080169,0.0035858413,0.0029998138],"domain_scores_gemma":[0.9937979,0.0011578889,0.0008905889,0.0029133642,0.00063674554,0.0006035208],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0015399187,0.0014254297,0.0019397644,0.0007890656,0.0002899723,0.00038090625,0.0015800241,0.002836689,0.00092195143],"category_scores_gemma":[0.0012083559,0.0010117664,0.0005708825,0.0013873611,0.00075034995,0.0005631503,0.00054420676,0.0055625876,0.0018468054],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007448822,0.000045038785,0.000704399,0.008051418,0.0007944443,0.014899189,0.005626027,0.0021254327,0.0021440003,0.000037493995,0.95328623,0.011541449],"study_design_scores_gemma":[0.13509105,0.005445945,0.020176768,0.027987735,0.0020941924,0.0050127427,0.00056317204,0.25389972,0.00207454,0.0009102806,0.5412717,0.0054722014],"about_ca_topic_score_codex":0.061675813,"about_ca_topic_score_gemma":0.00088459364,"teacher_disagreement_score":0.41201457,"about_ca_system_score_codex":0.5478425,"about_ca_system_score_gemma":0.22167309,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W2080155184","doi":"10.1111/j.1365-2141.2007.06810.x","title":"Family studies in chronic lymphocytic leukaemia and other lymphoproliferative tumours","year":2007,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; McMaster University","keywords":"Chronic lymphocytic leukemia; Lymphocytosis; Lymphoma; Immunology; Family aggregation; Lymphoproliferative disorders; Population; Medicine; Biology; Genetics; Leukemia","score_opus":0.1723417138094271,"score_gpt":0.4585856399438753,"score_spread":0.2862439261344482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080155184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01733799,0.9807636,0.00001542355,0.000019394272,0.00042938697,0.0008845493,0.000016729993,0.000017869193,0.0005150136],"genre_scores_gemma":[0.0012935274,0.997139,0.00026689476,0.00025820214,0.0005681776,0.000038615493,0.000006212708,0.00012722418,0.00030216435],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99484384,0.0005600999,0.0023908326,0.00055478036,0.0007123226,0.00093812286],"domain_scores_gemma":[0.9965465,0.0011854954,0.0011112401,0.0003307924,0.00045453454,0.00037141878],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018973281,0.0005782012,0.006281924,0.0011362721,0.00008848842,0.00005524717,0.00038678636,0.0007518504,0.000046439993],"category_scores_gemma":[0.001122178,0.00051812455,0.0005914161,0.000633231,0.0011265515,0.00012755315,0.00024042978,0.0013230874,0.00004318578],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018597078,0.000082577666,0.000030983934,0.043297153,0.0013659595,0.38421825,0.0002746631,0.0000052661508,0.0000012377121,0.00015379822,0.0033620908,0.567022],"study_design_scores_gemma":[0.009815827,0.00037858498,0.000007841019,0.0710085,0.0007882923,0.6685167,0.00023829735,0.000044670236,0.000004455182,0.000082942024,0.24882771,0.0002861502],"about_ca_topic_score_codex":0.0005476623,"about_ca_topic_score_gemma":0.00033339797,"teacher_disagreement_score":0.5667359,"about_ca_system_score_codex":0.07193649,"about_ca_system_score_gemma":0.056765657,"threshold_uncertainty_score":0.999727},"labels":[],"label_agreement":null},{"id":"W2080905329","doi":"10.1016/j.chembiol.2012.01.020","title":"Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase","year":2012,"lang":"en","type":"article","venue":"Chemistry & Biology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Knut och Alice Wallenbergs Stiftelse; Wellcome Trust; Stiftelsen för Strategisk Forskning; Canadian Institutes of Health Research; Genome Canada","keywords":"Biology; Tyrosine kinase; Protein kinase A; Biochemistry; Kinase; MAP kinase kinase kinase; Cell biology; Signal transduction; Chemistry","score_opus":0.02465598790943717,"score_gpt":0.2839294249955598,"score_spread":0.2592734370861226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080905329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231565,0.0015327908,0.000004424265,0.0005314863,0.00009947827,0.0003150915,0.000007781625,0.00002600223,0.005167303],"genre_scores_gemma":[0.99666727,0.000013550029,0.000076085154,0.00009756953,0.0004768237,0.00003813155,0.000023743609,0.000017461938,0.0025893901],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989743,0.00003700804,0.00023234113,0.00019320658,0.00012643634,0.0004367069],"domain_scores_gemma":[0.9990777,0.000041853884,0.00009215778,0.00054549094,0.00008933273,0.00015351412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019682143,0.00013455651,0.00023776629,0.00001627819,0.000042404536,0.000002929022,0.00020397513,0.0002138082,0.00032649186],"category_scores_gemma":[0.00031308236,0.00008542955,0.00011438015,0.00017495264,0.00046083183,0.000016297561,0.00021756403,0.00022788353,0.000024700308],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005805852,0.00011341859,0.004470535,0.00026253267,0.000032739696,0.0000051797274,0.00006279642,7.824503e-8,0.9934954,0.00006249301,0.0006518572,0.00078492134],"study_design_scores_gemma":[0.0025458052,0.00004758008,0.0007898005,0.000079347585,0.000027659124,0.00011416491,0.00006166728,0.000012848715,0.98971415,0.000021376942,0.0065036095,0.00008201639],"about_ca_topic_score_codex":0.0001315531,"about_ca_topic_score_gemma":0.000001942269,"teacher_disagreement_score":0.005851752,"about_ca_system_score_codex":0.0011565425,"about_ca_system_score_gemma":0.0014505065,"threshold_uncertainty_score":0.35748568},"labels":[],"label_agreement":null},{"id":"W2081437221","doi":"10.1016/s0740-2570(03)00028-5","title":"Update in the pathologic features of mature B-cell and T/NK-cell leukemias","year":2003,"lang":"en","type":"review","venue":"Seminars in Diagnostic Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pathology; Disease; Medicine","score_opus":0.024452952571918707,"score_gpt":0.3289219206592963,"score_spread":0.3044689680873776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081437221","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008902224,0.98193115,0.0000027544668,0.00009247903,0.00024311591,0.0022458436,0.000082137354,0.00002018215,0.006480107],"genre_scores_gemma":[0.0021898334,0.99511623,0.0006735874,0.0005582769,0.000083616185,0.00042725768,0.00019831804,0.00008638608,0.00066649204],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946718,0.0015767737,0.0012581287,0.0010188435,0.0005188258,0.00095559435],"domain_scores_gemma":[0.98956096,0.008409967,0.0005008348,0.0013195646,0.00006754448,0.00014114135],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0023680804,0.00072147284,0.0028841023,0.0007370614,0.000045989465,0.000021226819,0.0007282615,0.0015719024,0.00005818161],"category_scores_gemma":[0.0048326566,0.00047030798,0.00032027045,0.0010342051,0.0007635069,0.00004128134,0.00034467434,0.0024793856,0.00005683948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001731916,0.0021423248,0.0006668553,0.098009996,0.000078254365,0.17011984,0.003008641,0.000009642177,0.000049874605,0.00072645466,0.027988084,0.69702685],"study_design_scores_gemma":[0.01662011,0.00135072,0.00040749603,0.04490518,0.0016116258,0.059409883,0.0009589036,0.0000146163065,0.00014375405,0.001090872,0.8722724,0.0012144381],"about_ca_topic_score_codex":0.00006481607,"about_ca_topic_score_gemma":0.000037818605,"teacher_disagreement_score":0.8442843,"about_ca_system_score_codex":0.002965545,"about_ca_system_score_gemma":0.004096543,"threshold_uncertainty_score":0.99982196},"labels":[],"label_agreement":null},{"id":"W2081644148","doi":"10.1042/bst0350181","title":"Regulation of B-lymphocyte activation by the PH domain adaptor protein Bam32/DAPP1","year":2007,"lang":"en","type":"article","venue":"Biochemical Society Transactions","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Pleckstrin homology domain; Signal transducing adaptor protein; Cell biology; Second messenger system; GRB2; Signal transduction; SH3 domain; breakpoint cluster region; Effector; B-cell receptor; Proto-oncogene tyrosine-protein kinase Src; Phosphoinositide 3-kinase; Chemistry; Kinase; Biology; B cell; Receptor; PI3K/AKT/mTOR pathway; Biochemistry; Antibody; Immunology","score_opus":0.01293233245390508,"score_gpt":0.2699718686195687,"score_spread":0.2570395361656636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081644148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7943472,0.0002480542,0.20163548,0.0019676448,0.000043120308,0.00097134995,0.00003238716,0.000083170526,0.00067156006],"genre_scores_gemma":[0.9940895,0.00003770115,0.0039856145,0.00015955468,0.00014317426,0.00006219516,0.000068509034,0.00002796104,0.0014257913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983067,0.000031935047,0.000378376,0.00028064093,0.0006434335,0.00035894138],"domain_scores_gemma":[0.9990241,0.00018791351,0.00009988196,0.0003709579,0.00015877321,0.00015840774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005392738,0.00015610424,0.00020632714,0.000030846528,0.00017662997,0.000012236629,0.00013453269,0.00027978822,0.00018903665],"category_scores_gemma":[0.000044733337,0.000116265786,0.00032852413,0.0005592591,0.00036418258,0.00008312625,0.000009766917,0.00029549154,0.000009403119],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031039855,0.0002102486,0.0000044430453,0.00010076342,0.00011479506,4.1899563e-7,0.0003978955,0.0000064306864,0.9908573,0.0000890526,0.0050450857,0.0028631608],"study_design_scores_gemma":[0.005137119,0.00007937168,0.00023474052,0.00009004893,0.000058537793,0.00002470715,0.00060466805,0.0018436662,0.98372346,0.00011536913,0.007970755,0.00011758275],"about_ca_topic_score_codex":0.00032214247,"about_ca_topic_score_gemma":0.0000042064084,"teacher_disagreement_score":0.19974226,"about_ca_system_score_codex":0.0048434865,"about_ca_system_score_gemma":0.0012786007,"threshold_uncertainty_score":0.99897677},"labels":[],"label_agreement":null},{"id":"W2083042132","doi":"10.1016/j.leukres.2011.01.004","title":"Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy","year":2011,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Jewish General Hospital; Leukemia and Lymphoma Society","keywords":"Chlorambucil; RAD51; Chronic lymphocytic leukemia; DNA repair; Homologous recombination; Non-homologous end joining; Cancer research; DNA; DNA damage; Biology; Leukemia; Homologous chromosome; Genetics; Chemotherapy; Gene","score_opus":0.07937477045542254,"score_gpt":0.3175927071213793,"score_spread":0.23821793666595678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083042132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810503,0.0031121525,0.00000752175,0.00032153723,0.00017530307,0.0022236297,0.000013377682,0.00018279155,0.012913373],"genre_scores_gemma":[0.99535614,0.0017273364,0.00035075017,0.00027458929,0.00023863555,0.000453954,0.000021707634,0.000078385776,0.0014984921],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99276954,0.0018498204,0.0010306692,0.0009170666,0.0021305284,0.0013023483],"domain_scores_gemma":[0.99506736,0.002246917,0.00023128196,0.0015687827,0.0006518423,0.00023383318],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.008343819,0.00037408064,0.00074680604,0.00064145244,0.0005013284,0.000038750983,0.000522284,0.00047442102,0.00037988153],"category_scores_gemma":[0.0020228003,0.00022881856,0.00042166252,0.0017500733,0.0036656505,0.00019886938,0.0008546499,0.0019002468,0.000055487923],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09507595,0.0028577803,0.04197103,0.009371941,0.0050040297,0.023070704,0.13596088,0.0036590153,0.115199156,0.38154575,0.051825162,0.1344586],"study_design_scores_gemma":[0.3020367,0.0073732506,0.15024002,0.0034408935,0.00023777019,0.011826785,0.0053951624,0.34253865,0.12920189,0.04229821,0.0037404008,0.0016702795],"about_ca_topic_score_codex":0.014167521,"about_ca_topic_score_gemma":0.00069080945,"teacher_disagreement_score":0.33924752,"about_ca_system_score_codex":0.12438079,"about_ca_system_score_gemma":0.075414546,"threshold_uncertainty_score":0.9990458},"labels":[],"label_agreement":null},{"id":"W2083269457","doi":"10.1016/s1873-9954(08)70010-7","title":"9 ASSESSMENT OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF CROHN'S DISEASE IN PATIENTS FOR WHOM INFLIXIMAB TREATMENT WAS NOT SUCCESSFUL: OPEN-LABEL INDUCTION PRELIMINARY RESULTS FROM THE WELCOME STUDY","year":2008,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis Supplements","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Certolizumab pegol; Infliximab; Medicine; Crohn's disease; Open label; Adalimumab; Disease; Internal medicine; Clinical trial","score_opus":0.06588458941485871,"score_gpt":0.3734134110423851,"score_spread":0.3075288216275264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083269457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324,0.0002154372,0.0000038604207,0.0010436334,0.00012869538,0.004437939,0.00087692286,0.0000017508426,0.000051746498],"genre_scores_gemma":[0.9982143,0.0008898023,0.00017978811,0.000032988642,0.000119069446,0.0002990144,0.00015490518,0.000020060077,0.000090062174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966897,0.0003277883,0.0013614985,0.00029423897,0.0009727406,0.00035405235],"domain_scores_gemma":[0.9978486,0.00054367114,0.0006513731,0.000472981,0.00032749318,0.00015592249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033031925,0.00024269134,0.0007362521,0.00019729068,0.00016565672,0.000059794682,0.00036220616,0.000060463197,0.00003406763],"category_scores_gemma":[0.00010303014,0.00013440986,0.00011311776,0.00023062051,0.00016458429,0.00024318983,0.000109964276,0.00014313478,2.9882133e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16713952,0.059479132,0.73101234,0.00014496717,0.0009971851,0.0033103575,0.02332675,0.00004295289,0.000020094933,0.000047922673,0.001229767,0.013248998],"study_design_scores_gemma":[0.16958635,0.019523859,0.8064343,0.00018965937,0.00025450904,0.00006315162,0.0023069067,0.0004111608,0.00011931185,0.000048696005,0.0009741803,0.00008793019],"about_ca_topic_score_codex":0.011162008,"about_ca_topic_score_gemma":0.0009959815,"teacher_disagreement_score":0.075421944,"about_ca_system_score_codex":0.0045075943,"about_ca_system_score_gemma":0.003114434,"threshold_uncertainty_score":0.99931395},"labels":[],"label_agreement":null},{"id":"W2083588754","doi":"10.1038/sj.leu.2404695","title":"A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation","year":2007,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Chromosomal translocation; Biology; Chronic lymphocytic leukemia; Fluorescence in situ hybridization; B cell; Fusion gene; Trisomy; Cytogenetics; Breakpoint; Molecular biology; Gene rearrangement; Locus (genetics); Leukemia; Gene; Genetics; Cancer research; Chromosome; Antibody","score_opus":0.029370437840654736,"score_gpt":0.3068619537983945,"score_spread":0.27749151595773974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083588754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266727,0.0048997547,0.010913923,0.000058698526,0.000113513124,0.000571728,0.000013231117,0.000074041076,0.00068786537],"genre_scores_gemma":[0.99249524,0.00065050245,0.005120377,0.00022829034,0.00010361355,0.000027534057,0.000040390547,0.0000351185,0.0012989488],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99720275,0.00011826121,0.0007659367,0.0006106706,0.00069404824,0.0006083186],"domain_scores_gemma":[0.9978802,0.00049504533,0.00024069315,0.0007024121,0.00040080506,0.00028081072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000704349,0.00029290805,0.00079683587,0.0006531681,0.00014181182,0.0000394988,0.00021726915,0.00019560325,0.00011736099],"category_scores_gemma":[0.00022000054,0.0002391512,0.00021588683,0.0013221684,0.0004430787,0.00009606246,0.0001226614,0.00027352752,0.000018245517],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030267248,0.00039710154,0.02302521,0.004114044,0.0013569396,0.009866861,0.013682688,0.0026220493,0.9315873,0.00044182118,0.00064506393,0.009234198],"study_design_scores_gemma":[0.082249835,0.0020394658,0.49063674,0.0011044074,0.008725611,0.007758731,0.009964467,0.07879893,0.31260103,0.0009905614,0.0030452616,0.002084945],"about_ca_topic_score_codex":0.0047505153,"about_ca_topic_score_gemma":0.0010092995,"teacher_disagreement_score":0.61898625,"about_ca_system_score_codex":0.0073816846,"about_ca_system_score_gemma":0.003289926,"threshold_uncertainty_score":0.9964288},"labels":[],"label_agreement":null},{"id":"W2084577194","doi":"10.1016/j.jpainsymman.2003.09.001","title":"Chronic lymphocytic leukemia resembling metastatic bone disease— an unusual manifestation","year":2003,"lang":"en","type":"review","venue":"Journal of Pain and Symptom Management","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Pathology; Chronic lymphocytic leukemia; Lumpectomy; Bone marrow; Axillary Lymphadenopathy; Breast cancer; Leukemia; Cancer; Internal medicine; Mastectomy","score_opus":0.058694643625770676,"score_gpt":0.3781815914316251,"score_spread":0.3194869478058544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084577194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042046612,0.9959684,0.0010308279,0.000034259636,0.0002686172,0.0014017704,0.000008113016,0.00002843928,0.0008391348],"genre_scores_gemma":[0.00045305718,0.9944347,0.001082288,0.00015991676,0.0005953557,0.00005278875,0.000076777396,0.00011579787,0.0030293192],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99434215,0.0012114375,0.0017467219,0.0005436923,0.0014942514,0.0006617677],"domain_scores_gemma":[0.996705,0.00047469954,0.0010524654,0.0006674095,0.00022825444,0.00087216106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005137286,0.00058770884,0.0021295338,0.0012870613,0.00014195369,0.00018277213,0.00032698485,0.00015804713,0.000091466],"category_scores_gemma":[0.00027423995,0.00044274202,0.0006235886,0.00062098703,0.00013521008,0.0002588405,0.00014469896,0.0005886953,0.000034131805],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013341878,0.00008083911,0.0000022619843,0.07930997,0.0016205289,0.009008266,0.00009827337,0.00015172672,4.8466296e-7,0.0009109857,0.001749508,0.9069337],"study_design_scores_gemma":[0.010610688,0.0013211882,0.00002072351,0.033665325,0.007488661,0.0029102226,0.00031122347,0.00876275,3.7827715e-7,0.00023602154,0.93415594,0.0005168716],"about_ca_topic_score_codex":0.0000319553,"about_ca_topic_score_gemma":0.0000067397973,"teacher_disagreement_score":0.9324064,"about_ca_system_score_codex":0.082493305,"about_ca_system_score_gemma":0.024495296,"threshold_uncertainty_score":0.9998024},"labels":[],"label_agreement":null},{"id":"W2084749922","doi":"10.1007/s12032-010-9555-7","title":"The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia","year":2010,"lang":"en","type":"article","venue":"Medical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Hematology; Autocrine signalling; Chronic lymphocytic leukemia; Motility; Cancer research; Internal medicine; Receptor; Leukemia; Immunology; Biology; Medicine; Cell biology","score_opus":0.021566598148324987,"score_gpt":0.329589577789861,"score_spread":0.30802297964153597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084749922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842625,0.00023416356,0.000012301248,0.010329359,0.0009266083,0.0009782255,0.000032754087,0.000047582293,0.0031764943],"genre_scores_gemma":[0.9951862,0.0005383263,0.000078043464,0.0015507035,0.0003982458,0.000057831323,0.000010230312,0.000036056957,0.0021443279],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959135,0.00044127714,0.0008012861,0.0005055602,0.001488951,0.00084943953],"domain_scores_gemma":[0.99239093,0.0056048436,0.00019236402,0.0012149699,0.00015353688,0.00044336673],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020456351,0.00027088454,0.00070148834,0.000077950535,0.00012239549,0.000014650864,0.00087383855,0.000594311,0.008347729],"category_scores_gemma":[0.0039478047,0.00014090435,0.00016747443,0.00044178154,0.0015657793,0.000036171157,0.00032321262,0.001742479,0.00037248086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0064599332,0.0017045408,0.0025708906,0.001237739,0.00064960186,0.0011519337,0.0032242595,0.00042456362,0.591581,0.004830911,0.28775862,0.09840606],"study_design_scores_gemma":[0.03680361,0.003594377,0.005016998,0.00034652636,0.000059006034,0.00018048422,0.00019246779,0.1737512,0.20347796,0.00028582677,0.57597524,0.00031631248],"about_ca_topic_score_codex":0.0026803517,"about_ca_topic_score_gemma":0.0011322465,"teacher_disagreement_score":0.38810298,"about_ca_system_score_codex":0.04345169,"about_ca_system_score_gemma":0.066759884,"threshold_uncertainty_score":0.9925588},"labels":[],"label_agreement":null},{"id":"W2085854997","doi":"10.1038/sj.bmt.1702191","title":"Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia","year":2000,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Cumulative incidence; Surgery; Transplantation; Methotrexate; Total body irradiation; Chronic lymphocytic leukemia; Leukemia; Lymphoma; Bone marrow; Cyclophosphamide; Chemotherapy","score_opus":0.014061453457356411,"score_gpt":0.2675447680273973,"score_spread":0.25348331457004086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085854997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905716,0.0027351852,0.002096932,0.00035104834,0.00017710384,0.0022155147,0.00026981373,0.00027821696,0.0013045482],"genre_scores_gemma":[0.9796932,0.0121011995,0.0015585917,0.00041447056,0.0003931623,0.0004354771,0.0018133203,0.00013735284,0.0034532358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99626595,0.00012912929,0.0008624866,0.00094074634,0.0008166007,0.0009850698],"domain_scores_gemma":[0.99844813,0.00034384086,0.00013968046,0.0004994322,0.00013070543,0.00043818544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051377644,0.0005395184,0.00072840403,0.0003563582,0.00030348683,0.00009304527,0.00016984479,0.0004086211,0.0004954292],"category_scores_gemma":[0.000027568938,0.00053784315,0.00026708108,0.00043188664,0.00026626833,0.00036241233,0.0000098252585,0.00018077545,0.00013263646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029665759,0.00048756352,0.0008225676,0.025916873,0.00083981175,0.0049157506,0.0055382294,0.006911489,0.61729413,0.0010419248,0.0022723014,0.30429357],"study_design_scores_gemma":[0.29317078,0.0036846735,0.025491016,0.0038403687,0.0045342254,0.03567971,0.0002775752,0.26093268,0.35530496,0.0012382554,0.012745833,0.003099917],"about_ca_topic_score_codex":0.00088251656,"about_ca_topic_score_gemma":0.0006586894,"teacher_disagreement_score":0.30119365,"about_ca_system_score_codex":0.022228222,"about_ca_system_score_gemma":0.009321416,"threshold_uncertainty_score":0.9997073},"labels":[],"label_agreement":null},{"id":"W2086152189","doi":"10.1034/j.1600-0609.2003.02838.x","title":"Surface antigen expression and correlation with variable heavy‐chain gene mutation status in chronic lymphocytic leukemia","year":2003,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Tays; Fondation pour la Recherche Médicale; Cancer Research Society","keywords":"Chronic lymphocytic leukemia; CD38; CD5; Antigen; Biology; IGHV@; Immunoglobulin D; Molecular biology; Surface Immunoglobulin; Immunophenotyping; CD23; CD20; Immunology; Antibody; Leukemia; B cell; Genetics; Immunoglobulin E","score_opus":0.015145554584080817,"score_gpt":0.2645746928100752,"score_spread":0.24942913822599436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086152189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98199207,0.0031335857,0.012399463,0.000045155408,0.0001244495,0.0002571342,0.0000011945166,0.00001608062,0.002030858],"genre_scores_gemma":[0.98889375,0.00046810997,0.01024835,0.00006527814,0.000050727336,9.880474e-7,0.0000068878103,0.00004643988,0.00021946651],"study_design_codex":"simulation_or_modeling","study_design_gemma":"case_report","domain_scores_codex":[0.9974381,0.0008306966,0.0006593791,0.00024737758,0.00036561597,0.00045883338],"domain_scores_gemma":[0.99877286,0.00019137646,0.00036560127,0.00023260519,0.00019664201,0.00024090326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014217669,0.00017993095,0.0005212913,0.00025283862,0.00009827998,0.000020145253,0.00009358927,0.00006985728,0.00008014934],"category_scores_gemma":[0.0003675398,0.00013812206,0.000038613125,0.0003223142,0.00015921127,0.00017624191,0.00005159152,0.0003586046,0.000019458164],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011999434,0.00043392504,0.03221453,0.0018908341,0.00068607915,0.17716856,0.011702127,0.4963101,0.2552944,0.0042721657,0.003481681,0.004546137],"study_design_scores_gemma":[0.18266289,0.011353612,0.014668327,0.0043415553,0.00034470772,0.45807272,0.0016564216,0.18202157,0.13098674,0.0006106932,0.012217542,0.0010632111],"about_ca_topic_score_codex":0.00008080416,"about_ca_topic_score_gemma":0.0000120814375,"teacher_disagreement_score":0.31428853,"about_ca_system_score_codex":0.017768623,"about_ca_system_score_gemma":0.01568748,"threshold_uncertainty_score":0.98989266},"labels":[],"label_agreement":null},{"id":"W2087285106","doi":"10.1016/j.bbmt.2011.12.508","title":"Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) in Chronic Lymphocytic Leukemia (CLL): Impact of Myeloablative (MA) Vs. Reduced-Intensity Conditioning (RIC) Regimens, and Impact of Total Body Irradiation (TBI)-Based MA Versus Chemotherapy (CT)-Based MA Conditioning","year":2012,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Total body irradiation; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Conditioning; Gastroenterology; Conditioning regimen; Incidence (geometry); Regimen; Cumulative incidence; Graft-versus-host disease; Stem cell; Surgery; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.015528034340425566,"score_gpt":0.3031613571283748,"score_spread":0.28763332278794923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087285106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973699,0.000997469,0.00038799943,0.000025003474,0.00006597825,0.0007042801,0.00036805845,0.00002119772,0.0000601018],"genre_scores_gemma":[0.9975723,0.0007084976,0.00036819928,0.00001554111,0.00003037888,0.00002483266,0.0012446495,0.000028617525,0.000006973762],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980074,0.00020275716,0.0007788199,0.00033492656,0.00026170255,0.00041437236],"domain_scores_gemma":[0.99824786,0.000625174,0.00057833054,0.00020991008,0.00019295415,0.00014575043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047245936,0.00031025213,0.00090002274,0.00046160247,0.000058347247,0.0000054477073,0.00007033708,0.00023099975,0.0000739541],"category_scores_gemma":[0.00004698354,0.00027324268,0.0002401032,0.00026776147,0.00048572055,0.00018173414,0.000006640268,0.00015946422,7.8792976e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009002501,0.0002112428,0.1808595,0.002473514,0.0006300949,0.000024028528,0.001437851,0.003944702,0.80116034,0.00007556768,0.000006790906,0.00017385464],"study_design_scores_gemma":[0.042200346,0.0026422802,0.49222788,0.00044944495,0.0007388881,0.0001930405,0.000121767785,0.006307823,0.4548906,0.000029886325,1.6161123e-7,0.0001978652],"about_ca_topic_score_codex":0.0028083085,"about_ca_topic_score_gemma":0.000047629546,"teacher_disagreement_score":0.34626973,"about_ca_system_score_codex":0.0035999652,"about_ca_system_score_gemma":0.004646821,"threshold_uncertainty_score":0.999972},"labels":[],"label_agreement":null},{"id":"W2087682045","doi":"10.1080/10717540500466097","title":"Preparation and In Vitro Analysis of Microcapsule Thalidomide Formulation for Targeted Suppression of TNF-α","year":2006,"lang":"en","type":"article","venue":"Drug Delivery","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McGill University","funders":"","keywords":"Materials science; Thalidomide; In vitro; Tumor necrosis factor alpha; Nanotechnology; Medicine; Chemistry; Immunology; Biochemistry","score_opus":0.010705177436878346,"score_gpt":0.2966414490482358,"score_spread":0.2859362716113575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087682045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99844843,0.00057355524,0.0002810786,0.00003090685,0.000016361724,0.0004559958,0.00004076502,0.000007841725,0.00014503543],"genre_scores_gemma":[0.99807686,0.000038400274,0.0011440356,0.0000107188625,0.000023433557,0.000019484281,0.00050058897,0.000008246296,0.00017824568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908245,0.00003186845,0.00036191486,0.00017006692,0.00020382123,0.00014990589],"domain_scores_gemma":[0.9993401,0.00018045554,0.0001221848,0.00016998466,0.00015636382,0.00003090635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002808353,0.00007298202,0.0003246224,0.00041804212,0.000017971523,0.0000042797487,0.000038394224,0.00006329019,0.000013996564],"category_scores_gemma":[0.000060452137,0.000064816464,0.00009752344,0.00041896512,0.000030337133,0.00009440752,0.000028014978,0.000040274375,4.79487e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031477732,0.000123896,0.002731012,0.00022338366,0.00014605606,0.0000028627026,0.0005702127,0.0017388954,0.9900326,0.00002672128,0.0004490033,0.00080759847],"study_design_scores_gemma":[0.005647545,0.000036478246,0.012065531,0.000039758834,0.00028163835,0.0000016109603,0.00007166734,0.26232624,0.7193615,0.00006320399,0.00005920007,0.0000456105],"about_ca_topic_score_codex":0.0025147856,"about_ca_topic_score_gemma":0.00030753086,"teacher_disagreement_score":0.27067107,"about_ca_system_score_codex":0.00079990743,"about_ca_system_score_gemma":0.00040890608,"threshold_uncertainty_score":0.38016206},"labels":[],"label_agreement":null},{"id":"W2087992115","doi":"10.1016/j.chembiol.2011.06.001","title":"“Going KiNativ”: Probing the Native Kinome","year":2011,"lang":"en","type":"letter","venue":"Chemistry & Biology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Kinome; Biology; Kinase; Computational biology; Profiling (computer programming); Biochemistry; Computer science","score_opus":0.04041498815992353,"score_gpt":0.3051539833706344,"score_spread":0.26473899521071087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087992115","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060904555,0.0060438337,0.00008377119,0.5575293,0.0011072105,0.0025395884,0.0001327781,0.00045059892,0.37120837],"genre_scores_gemma":[0.17114423,0.0004703695,0.00034684697,0.56960255,0.025822451,0.0008759509,0.0032641143,0.00038983746,0.22808364],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753934,0.00010983317,0.0004022674,0.0007861916,0.0002789899,0.00088335696],"domain_scores_gemma":[0.9979114,0.0005082748,0.00024930688,0.0010032542,0.00023289873,0.00009488479],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0003325861,0.00044248096,0.00067649054,0.00005274426,0.00023984745,0.000044063905,0.0006923601,0.0015831749,0.0012051008],"category_scores_gemma":[0.00054461544,0.0002834572,0.00024145648,0.00020606112,0.0009787598,0.000025626718,0.00040384152,0.0034210172,0.0002550365],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010014663,0.000049346687,0.00006350141,0.0018853702,0.0005593592,0.001479039,0.0005107287,1.6741286e-7,0.04866769,0.00004397378,0.9451401,0.0015005564],"study_design_scores_gemma":[0.002590312,0.000082170656,0.00000819559,0.00029526418,0.00012114681,0.0011257917,0.00003951262,0.00009142726,0.055159096,0.00038825726,0.93978465,0.00031416732],"about_ca_topic_score_codex":0.00016339352,"about_ca_topic_score_gemma":0.0000013466572,"teacher_disagreement_score":0.14312474,"about_ca_system_score_codex":0.00674064,"about_ca_system_score_gemma":0.0053414437,"threshold_uncertainty_score":0.99996173},"labels":[],"label_agreement":null},{"id":"W2089775846","doi":"10.1158/1538-7445.am2011-4162","title":"Abstract 4162: The importance of age-related cytokines in chronic lymphocytic leukemia","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Cytokine; Internal medicine; Population; Proinflammatory cytokine; CD38; Immunology; Disease; Interleukin 6; Gastroenterology; Leukemia; Inflammation; Biology","score_opus":0.11168896844047446,"score_gpt":0.3968589435594796,"score_spread":0.2851699751190051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089775846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707171,0.006885537,0.0000014102569,0.0002199275,0.000117185766,0.0011283742,0.000010520265,0.00004580999,0.02087419],"genre_scores_gemma":[0.99460006,0.0020888275,0.00003142797,0.00006995255,0.00020045106,0.00033329407,0.000010170953,0.0000657719,0.0026000496],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99582356,0.00018674742,0.0007375859,0.0005709021,0.0014921828,0.0011890465],"domain_scores_gemma":[0.99747,0.0004749729,0.00013088487,0.0012190198,0.00045141572,0.00025367778],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024763118,0.00022972054,0.000511834,0.00047509297,0.00012534959,0.000023417908,0.0007773432,0.000241537,0.0027689133],"category_scores_gemma":[0.0005372393,0.00015773467,0.00014778927,0.0018122206,0.0014544863,0.00013120701,0.00030761518,0.0011441124,0.00018348549],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015034535,0.0009475612,0.095414646,0.013411036,0.0023746402,0.024033062,0.033157,0.0044988147,0.6847341,0.01728779,0.045282837,0.063823976],"study_design_scores_gemma":[0.08572363,0.00219458,0.46868107,0.0060472433,0.00019386687,0.00079480954,0.0027467627,0.021375585,0.38979676,0.008068346,0.013018868,0.0013584718],"about_ca_topic_score_codex":0.027400706,"about_ca_topic_score_gemma":0.003784216,"teacher_disagreement_score":0.37326643,"about_ca_system_score_codex":0.13550365,"about_ca_system_score_gemma":0.076654695,"threshold_uncertainty_score":0.9981427},"labels":[],"label_agreement":null},{"id":"W2090784428","doi":"10.1080/10428190500158797","title":"Cyclin D expression in chronic lymphocytic leukemia","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"University of Manitoba; Leukemia and Lymphoma Society","keywords":"Cyclin D2; Cyclin D1; Cyclin D3; Chronic lymphocytic leukemia; Biology; Cyclin B; Cyclin D; Cyclin; Cancer research; Cyclin A2; Cell cycle; Cyclin A; Molecular biology; Immunology; Leukemia; Cell; Genetics","score_opus":0.014543074738468446,"score_gpt":0.2814525180491777,"score_spread":0.26690944331070926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090784428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696547,0.010454503,0.00018653301,0.00030342446,0.00048328866,0.0019414064,0.000040785577,0.00080512505,0.016130272],"genre_scores_gemma":[0.97939306,0.0042848787,0.0027214063,0.0022212507,0.002225887,0.000491922,0.0002085354,0.00041328275,0.008039788],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98854095,0.00040644026,0.0024734195,0.0028795486,0.002265969,0.0034336932],"domain_scores_gemma":[0.99382395,0.00085475226,0.0005666613,0.00261107,0.00032193455,0.0018216069],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013845286,0.0017570269,0.0023663214,0.0015075976,0.0006076231,0.0003355443,0.0011582633,0.0016294792,0.00064862496],"category_scores_gemma":[0.00053009397,0.0016532054,0.0006753823,0.002017603,0.0011085006,0.0011529331,0.0009943078,0.0006904586,0.0013317683],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008172656,0.00063805317,0.0046402197,0.0033615162,0.0007526203,0.008415884,0.0046989755,0.016981041,0.12224559,0.00221889,0.029204791,0.79866976],"study_design_scores_gemma":[0.19596533,0.0013328729,0.035617627,0.0034037263,0.0004710633,0.0109074265,0.00080505473,0.47103012,0.10493974,0.00059462426,0.17151032,0.003422096],"about_ca_topic_score_codex":0.0068882867,"about_ca_topic_score_gemma":0.0009853515,"teacher_disagreement_score":0.7952477,"about_ca_system_score_codex":0.601335,"about_ca_system_score_gemma":0.15290149,"threshold_uncertainty_score":0.9997249},"labels":[],"label_agreement":null},{"id":"W2091086478","doi":"10.1074/jbc.m001460200","title":"A 3′-5′ Exonuclease in Human Leukemia Cells","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Exonuclease; Leukemia; Molecular biology; Acute myeloblastic leukemia; Chronic lymphocytic leukemia; Exon; Nucleotide; Nucleoside; DNA; Biology; Chemistry; Cancer research; Biochemistry; DNA polymerase; Immunology; Gene","score_opus":0.03143632121629075,"score_gpt":0.3071457744755769,"score_spread":0.27570945325928614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091086478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98386437,0.0002912898,0.000001609496,0.00012958645,0.000018807506,0.00006685617,0.0000018630993,0.0000113742535,0.015614249],"genre_scores_gemma":[0.9968557,0.00023265339,0.0002153724,0.00019401031,0.00035239963,0.0000016690681,0.000003479952,0.000009669876,0.002135066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986673,0.000033699907,0.0005292046,0.0001653841,0.00029851898,0.000305892],"domain_scores_gemma":[0.9992464,0.00008390249,0.000113530696,0.00019458894,0.000075423246,0.000286142],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038108998,0.0001266481,0.0003888104,0.000038512622,0.000027892136,0.000013454122,0.00020721875,0.00023978516,0.007102414],"category_scores_gemma":[0.00014122388,0.00008429549,0.0001782722,0.0001689818,0.00016120872,0.00003877458,0.000035482855,0.00060794194,0.00005394803],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008107049,0.00026834826,0.0010177202,0.000100843914,0.000034079647,0.0033848851,0.00004518666,0.00005115559,0.9874755,0.0000034735738,0.001970415,0.00483769],"study_design_scores_gemma":[0.025109502,0.0009198957,0.008962303,0.0004748793,0.000047071197,0.005425282,0.00015987016,0.0006189238,0.9381021,0.00038125794,0.019489033,0.00030984535],"about_ca_topic_score_codex":0.000027521242,"about_ca_topic_score_gemma":4.6133908e-7,"teacher_disagreement_score":0.04937336,"about_ca_system_score_codex":0.005134077,"about_ca_system_score_gemma":0.0015186801,"threshold_uncertainty_score":0.99868506},"labels":[],"label_agreement":null},{"id":"W2091115695","doi":"10.3816/clm.2009.n.008","title":"Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter Study","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; University Health Network","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Clinical significance; Fluorescence in situ hybridization; Macroglobulinemia; Waldenstrom macroglobulinemia; Internal medicine; Gastroenterology; Biology; Monoclonal gammopathy of undetermined significance; Abnormality; In situ hybridization; Pathology; Medicine; Multiple myeloma; Antibody; Chromosome; Immunology; Genetics; Gene; Monoclonal; Gene expression; Lymphoma; Monoclonal antibody","score_opus":0.035326875047981744,"score_gpt":0.382843954020466,"score_spread":0.34751707897248424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091115695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574107,0.00041724608,0.000025605854,0.00067898445,0.00023072738,0.0020007344,0.000006459758,0.00009391214,0.0008052776],"genre_scores_gemma":[0.99682826,0.00014060066,0.0015778627,0.00063165295,0.00032353293,0.000052667958,0.000015780348,0.00003806674,0.00039156835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953869,0.00033005286,0.001905518,0.00081817753,0.00085273583,0.00070658774],"domain_scores_gemma":[0.996721,0.0013366768,0.00029700447,0.000935682,0.00034677904,0.000362842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013716395,0.00031247642,0.0010497549,0.00020323691,0.00004796731,0.000022480037,0.00035739664,0.0003482667,0.0000864293],"category_scores_gemma":[0.0054330034,0.00026966239,0.0002905899,0.0006702333,0.00031124306,0.000110215784,0.00014715358,0.00039625092,0.00018015073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037078476,0.0078076557,0.5573222,0.00015982587,0.000090715934,0.0027935267,0.0003970852,0.000014282657,0.00037531074,0.000043432145,0.00063247763,0.42665562],"study_design_scores_gemma":[0.044349696,0.003648037,0.93869495,0.00051189185,0.00012650609,0.00028348988,0.00030471306,0.010582124,0.00057345594,0.000137814,0.0005535382,0.0002337942],"about_ca_topic_score_codex":0.0002142582,"about_ca_topic_score_gemma":0.00010431792,"teacher_disagreement_score":0.42642182,"about_ca_system_score_codex":0.0031008555,"about_ca_system_score_gemma":0.0026664976,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W2091214711","doi":"10.1158/1538-7445.am2013-911","title":"Abstract 911: Tyrosine kinase inhibitor Gefitinib selectivley induces apoptosis in Zap70+ chronic lymphocytic leukemia cells and inhibits B cell receptor signaling.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"ZAP70; Chronic lymphocytic leukemia; Gefitinib; Cancer research; Tyrosine kinase; Syk; Jurkat cells; Tyrosine phosphorylation; Bruton's tyrosine kinase; T cell; Biology; IL-2 receptor; Leukemia; Immunology; Cell biology; Signal transduction; Receptor; Epidermal growth factor receptor; Biochemistry; Immune system","score_opus":0.03923150567184174,"score_gpt":0.3347939954721717,"score_spread":0.29556248980032995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091214711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98772854,0.0068074553,0.000002106217,0.0005430899,0.00025254695,0.0026299588,0.00004214864,0.00011277567,0.001881392],"genre_scores_gemma":[0.9902822,0.0036934637,0.00015787416,0.00018462959,0.0011450433,0.001266641,0.0000422317,0.00016312122,0.003064794],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931825,0.00033615387,0.00087068416,0.0013559747,0.0020097112,0.0022450255],"domain_scores_gemma":[0.99610394,0.0009517554,0.00015136521,0.0008110683,0.0009924616,0.0009893897],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001897971,0.000528797,0.0008278325,0.0011057388,0.00031895036,0.0003039642,0.00048292687,0.0005491716,0.0030026422],"category_scores_gemma":[0.00046500875,0.00048119496,0.00013413717,0.0021800522,0.00079462293,0.0004962252,0.00049481634,0.0019610813,0.001125589],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00045386556,0.00013350506,0.00023327243,0.0016315156,0.000054175576,0.000066496475,0.00072190556,0.00024367585,0.97161525,0.000012445531,0.015673842,0.0091600465],"study_design_scores_gemma":[0.016655445,0.00065546844,0.00074955483,0.0014995433,0.000024848772,0.000025395595,0.00046673208,0.0020863328,0.9746919,0.000061702085,0.002601457,0.00048157357],"about_ca_topic_score_codex":0.030644126,"about_ca_topic_score_gemma":0.00039132425,"teacher_disagreement_score":0.076261975,"about_ca_system_score_codex":0.1293304,"about_ca_system_score_gemma":0.05306843,"threshold_uncertainty_score":0.99976397},"labels":[],"label_agreement":null},{"id":"W2091264926","doi":"10.1111/j.1365-2141.2010.08387.x","title":"Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia","year":2010,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Clofarabine; Medicine; Cytarabine; Internal medicine; Refractory (planetary science); Nucleoside analogue; Fludarabine; Oncology; Regimen; Gastroenterology; Chemotherapy; Nucleoside; Biology","score_opus":0.02900181210569678,"score_gpt":0.37947960225634775,"score_spread":0.35047779015065095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091264926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507976,0.0008520437,0.00023432994,0.000353974,0.0011644033,0.0021355862,0.000051939995,0.000023563101,0.00010438281],"genre_scores_gemma":[0.99512976,0.00069784216,0.002971125,0.0001750162,0.0005696701,0.00008628649,0.000021958118,0.00006784611,0.000280492],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961395,0.0003124361,0.0018951778,0.00043621752,0.000593227,0.0006234157],"domain_scores_gemma":[0.9958457,0.001424488,0.001067252,0.00043516647,0.00075529405,0.0004721028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021205049,0.00028601632,0.002220821,0.00042179303,0.00013412136,0.000036414232,0.00036984158,0.00050030026,0.00020412065],"category_scores_gemma":[0.0031422332,0.0002504231,0.0003067627,0.00028120462,0.00072105933,0.00019154577,0.00014100772,0.0010338635,0.0000057015277],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63807434,0.014403164,0.0003750248,0.0010415161,0.0029852414,0.22963148,0.0016920109,0.0000032179498,0.033194266,0.00026457643,0.0073825056,0.07095263],"study_design_scores_gemma":[0.5507755,0.0402341,0.00015209941,0.0002278473,0.0009766091,0.40124667,0.00058943394,0.00040693762,0.0008167915,0.00013151034,0.004256583,0.00018590606],"about_ca_topic_score_codex":0.00055397896,"about_ca_topic_score_gemma":0.0010994553,"teacher_disagreement_score":0.1716152,"about_ca_system_score_codex":0.0026296866,"about_ca_system_score_gemma":0.012276506,"threshold_uncertainty_score":0.9999948},"labels":[],"label_agreement":null},{"id":"W2091386197","doi":"10.1159/000206883","title":"An Antigen Shared by Human Granulocytes, Monocytes, Marrow Granulocyte Precursors and Leukemic Blasts","year":2009,"lang":"en","type":"article","venue":"Acta Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Acute myeloblastic leukemia; Granulocyte; Leukemia; Immunology; Antibody; Bone marrow; Antigen; Chronic myelogenous leukemia; Medicine; Acute lymphocytic leukemia; Acute leukemia; Precursor cell; THP1 cell line; Biology; Lymphoblastic Leukemia; Cell culture; Cell","score_opus":0.018002224254493535,"score_gpt":0.3128247392462817,"score_spread":0.29482251499178813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091386197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975325,0.0033769906,0.00003377787,0.0012885698,0.00005640449,0.001119699,0.0000454183,0.0004517093,0.003874184],"genre_scores_gemma":[0.9957086,0.0009736303,0.00086916744,0.001026165,0.000090117974,0.000052812942,0.00036950933,0.000057406516,0.00085259276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962748,0.00018732621,0.0006381711,0.0010863243,0.00070781825,0.0011055339],"domain_scores_gemma":[0.9976127,0.00016425028,0.00018573641,0.0011397859,0.00014630867,0.0007512075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043319786,0.0005416849,0.0010318531,0.0002425257,0.0003773359,0.00015299824,0.0005722478,0.00045349446,0.00045787482],"category_scores_gemma":[0.00021072572,0.0004443468,0.00015542735,0.00042232854,0.0004198804,0.00040799708,0.00013180342,0.000556276,0.00008715401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004845383,0.002970576,0.016740603,0.0010538076,0.00061905687,0.005769053,0.002838653,0.000012345536,0.67307645,0.0028954905,0.2515988,0.037579793],"study_design_scores_gemma":[0.13513437,0.02501884,0.19534303,0.0022665418,0.001221432,0.03190913,0.0017313358,0.03126638,0.4453452,0.012638325,0.11138319,0.00674222],"about_ca_topic_score_codex":0.00045491458,"about_ca_topic_score_gemma":0.000046259036,"teacher_disagreement_score":0.22773123,"about_ca_system_score_codex":0.0022333304,"about_ca_system_score_gemma":0.0010376705,"threshold_uncertainty_score":0.9998008},"labels":[],"label_agreement":null},{"id":"W2092325648","doi":"10.1186/1753-6561-3-s7-s103","title":"Genome-wide association analyses of North American Rheumatoid Arthritis Consortium and Framingham Heart Study data utilizing genome-wide linkage results","year":2009,"lang":"en","type":"article","venue":"BMC Proceedings","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Single-nucleotide polymorphism; Linkage (software); Genetic linkage; Genome; Framingham Heart Study; Genome-wide association study; Genetic association; SNP; SNP array; Computational biology; Medicine; Tag SNP; Genetics; Biology; Gene; Framingham Risk Score; Genotype; Internal medicine; Disease","score_opus":0.062143130183413615,"score_gpt":0.346133463483256,"score_spread":0.2839903332998424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092325648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961733,0.0009854179,0.000042485502,0.0005258102,0.000031251435,0.0011548289,0.00007677207,0.00012752377,0.0008825941],"genre_scores_gemma":[0.99576426,0.00153516,0.0017301287,0.0004015469,0.00013090682,0.00001968809,0.00017055796,0.000041175343,0.00020657631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608076,0.00005171376,0.0010537163,0.0009633366,0.0011407131,0.0007097798],"domain_scores_gemma":[0.9969782,0.0007451459,0.0006708368,0.0006660336,0.000600936,0.00033881015],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016149271,0.00031929577,0.0009934258,0.0003678427,0.00017624223,0.000119088436,0.00042175702,0.00009863152,0.000011064117],"category_scores_gemma":[0.008506332,0.00030669293,0.00009076477,0.0010921408,0.00021235186,0.00038572316,0.00037306003,0.00043750246,0.000017049264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050490367,0.00041910345,0.99311244,0.00015894244,0.0001958724,0.000027196122,0.0015806926,0.0000046743903,0.0014634999,0.0000021918033,0.00093200005,0.0015984584],"study_design_scores_gemma":[0.009669098,0.0011937956,0.98236454,0.00016536907,0.000113897826,0.00004799332,0.002236612,0.0012442172,0.0008964285,0.000009895583,0.0017860685,0.00027210853],"about_ca_topic_score_codex":0.0008965738,"about_ca_topic_score_gemma":0.0003944047,"teacher_disagreement_score":0.01074795,"about_ca_system_score_codex":0.0026634685,"about_ca_system_score_gemma":0.0017319333,"threshold_uncertainty_score":0.9999385},"labels":[],"label_agreement":null},{"id":"W2092884620","doi":"10.1016/j.cancergencyto.2003.11.015","title":"Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting","year":2004,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Biology; Interphase; Fluorescence in situ hybridization; Chronic lymphocytic leukemia; In situ; Myelocytic leukemia; Fluorescence; Cell sorting; In situ hybridization; Molecular biology; Leukemia; Genetics; Flow cytometry; Gene; Gene expression; Chemistry; Chromosome","score_opus":0.025376859154651835,"score_gpt":0.32276229578639815,"score_spread":0.2973854366317463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092884620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94719875,0.051431123,0.00018834177,0.00010182015,0.000083138504,0.0009154869,0.000022437038,0.000011686352,0.000047213765],"genre_scores_gemma":[0.9583293,0.041043002,0.00025165634,0.00007444109,0.00012922489,0.00007181668,0.000020214222,0.00004680069,0.000033521817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99679184,0.00012257072,0.0009546755,0.0006546178,0.0008092345,0.00066706934],"domain_scores_gemma":[0.99840575,0.00022122421,0.00035722394,0.00057081133,0.00023105751,0.00021392186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055491086,0.00038297847,0.00062119577,0.0002193747,0.000070811715,0.00004334015,0.00040251584,0.00024843408,0.000023828832],"category_scores_gemma":[0.000113613656,0.00032325112,0.00007491765,0.0007369969,0.00068076793,0.0000904938,0.00022120959,0.0003960264,0.0000018429165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00051285006,0.00011072531,0.009999521,0.0018443068,0.00006399096,0.00015932987,0.0019489622,0.03647254,0.9302098,0.000047233232,0.000050043745,0.018580662],"study_design_scores_gemma":[0.01510285,0.0014879197,0.005726187,0.0027649403,0.0001534054,0.0002081991,0.00053235627,0.05713243,0.9163161,0.00012025828,0.00009481218,0.00036054908],"about_ca_topic_score_codex":0.0035944656,"about_ca_topic_score_gemma":0.0013700502,"teacher_disagreement_score":0.020659888,"about_ca_system_score_codex":0.047305383,"about_ca_system_score_gemma":0.04951267,"threshold_uncertainty_score":0.999922},"labels":[],"label_agreement":null},{"id":"W2094252783","doi":"10.3109/10428194.2013.827785","title":"Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Chronic lymphocytic leukemia; Incidence (geometry); Demography; Medicine; Cancer registry; Cancer incidence; Population; Standardized rate; Chinese population; Leukemia; Internal medicine; Biology; Genetics","score_opus":0.010671169226739606,"score_gpt":0.2565736229097232,"score_spread":0.24590245368298358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094252783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928959,0.0027340525,0.000034685818,0.000042246902,0.0003725627,0.0029358505,0.00020100383,0.00015275496,0.0006309323],"genre_scores_gemma":[0.99446154,0.0015106708,0.00067183375,0.0003814943,0.00026853316,0.00048144258,0.0002418268,0.00025077572,0.0017318648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990475,0.00064077944,0.0029343632,0.0019602475,0.0021406922,0.0018489148],"domain_scores_gemma":[0.99389195,0.0015529982,0.0007580868,0.001979066,0.00086923747,0.0009486722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016661107,0.0008417891,0.002514012,0.000949552,0.00016128259,0.00032076752,0.0012214427,0.0010489476,0.00065356726],"category_scores_gemma":[0.0027125399,0.00109196,0.00033840875,0.0036152252,0.00077488454,0.0012386456,0.0010216346,0.0004017269,0.00020941626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0031004313,0.0005338718,0.9254373,0.0019023283,0.0003723374,0.0019530883,0.0017132901,0.0032716691,0.014251868,0.00002127624,0.010361146,0.037081398],"study_design_scores_gemma":[0.05202496,0.0008655942,0.88259876,0.0029084347,0.000078502286,0.00048372868,0.00027728945,0.057899684,0.0013707726,0.00047335515,0.00017277492,0.00084616954],"about_ca_topic_score_codex":0.91845345,"about_ca_topic_score_gemma":0.4907937,"teacher_disagreement_score":0.42765975,"about_ca_system_score_codex":0.2358126,"about_ca_system_score_gemma":0.08552586,"threshold_uncertainty_score":0.9991531},"labels":[],"label_agreement":null},{"id":"W2094431079","doi":"10.1158/1538-7445.am10-lb-100","title":"Abstract LB-100: Optimal modulation of DNA repair in CLL therapy","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Nilotinib; Imatinib; Cancer research; Chronic lymphocytic leukemia; Sensitization; Tyrosine kinase; DNA damage; Chlorambucil; ABL; DNA repair; Pharmacology; Chemistry; Leukemia; DNA; Medicine; Immunology; Chemotherapy; Biochemistry; Internal medicine; Receptor; Myeloid leukemia","score_opus":0.09851134286018154,"score_gpt":0.45117826284608603,"score_spread":0.3526669199859045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094431079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464846,0.00056822126,0.000003856272,0.0007496686,0.0001289924,0.0007997014,0.000013650828,0.000043313357,0.0030441387],"genre_scores_gemma":[0.9972338,0.00066165125,0.00030458046,0.000040875257,0.0003563951,0.00015901543,0.000012205216,0.00003791107,0.0011935303],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99722123,0.00008898747,0.00035993042,0.00039759558,0.0012874868,0.0006447772],"domain_scores_gemma":[0.9981895,0.00030954732,0.000048657537,0.0007141851,0.0005305867,0.00020749419],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021584595,0.000119091834,0.00028471233,0.00048120765,0.0000589305,0.0000140695,0.00025060776,0.00020379746,0.001731562],"category_scores_gemma":[0.00043535285,0.00010046339,0.00010299454,0.0007875818,0.00040079176,0.000118068834,0.00010172962,0.0011897132,0.00006451639],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001863443,0.00033860965,0.0073327473,0.000316666,0.00006102948,0.00015866748,0.00077340426,0.0002957748,0.9592466,0.0002940132,0.00451677,0.024802282],"study_design_scores_gemma":[0.032098576,0.00091036485,0.4348547,0.0005358754,0.000010199421,0.0000699484,0.0003817778,0.03213294,0.47281617,0.00043167945,0.025400985,0.00035679253],"about_ca_topic_score_codex":0.0066491347,"about_ca_topic_score_gemma":0.000729215,"teacher_disagreement_score":0.4864304,"about_ca_system_score_codex":0.0039666034,"about_ca_system_score_gemma":0.007981314,"threshold_uncertainty_score":0.99996567},"labels":[],"label_agreement":null},{"id":"W2095913486","doi":"10.3324/haematol.2010.025338","title":"Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Research Institute; Cancer Research Institute","keywords":"IGHV@; Internal medicine; Randomization; Oncology; Randomized controlled trial; Medicine; Beta-2 microglobulin; Chronic lymphocytic leukemia; Relative risk; Progression-free survival; Overall survival; Leukemia; Confidence interval","score_opus":0.05414269921170813,"score_gpt":0.32897521799457874,"score_spread":0.2748325187828706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095913486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586135,0.000107581036,0.000065844535,0.0002794783,0.00021325174,0.0026198076,0.0000068744057,0.00004017664,0.0008056148],"genre_scores_gemma":[0.99928534,0.000088424735,0.00012250635,0.000030478623,0.000057858648,0.00029913193,0.000036991176,0.000013910831,0.0000653301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808466,0.00019004654,0.0005085746,0.00033723886,0.00054330064,0.00033617494],"domain_scores_gemma":[0.99797934,0.00090526236,0.00021732139,0.0007218344,0.00008969337,0.00008655299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080165005,0.00018891793,0.0004971537,0.00014371649,0.00008001316,0.000029123326,0.0002958136,0.0002247689,0.00021323976],"category_scores_gemma":[0.0014665154,0.00009794925,0.0001439449,0.00030503355,0.00020377076,0.000056168927,0.00006316384,0.00039428836,0.00005907442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030950459,0.009695374,0.8912869,0.0008900875,0.00087776966,0.0020721748,0.0141700655,0.00005403287,0.012239301,0.022568151,0.0015412562,0.0136544425],"study_design_scores_gemma":[0.2259939,0.0070517063,0.7320438,0.00019324488,0.0006987768,0.0011851622,0.0031300255,0.004398383,0.017128045,0.006817279,0.00085521437,0.0005044514],"about_ca_topic_score_codex":0.0021745686,"about_ca_topic_score_gemma":0.0033965039,"teacher_disagreement_score":0.19504344,"about_ca_system_score_codex":0.0012508633,"about_ca_system_score_gemma":0.0014101255,"threshold_uncertainty_score":0.39942545},"labels":[],"label_agreement":null},{"id":"W2096196471","doi":"10.3389/fimmu.2012.00224","title":"The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions","year":2012,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"PI3K/AKT/mTOR pathway; Phosphoinositide 3-kinase; Germinal center; B cell; Cell biology; Signal transduction; PTEN; Biology; Chronic lymphocytic leukemia; B-cell receptor; Cancer research; Immunology; Leukemia; Antibody","score_opus":0.010197539566231503,"score_gpt":0.24038213881155257,"score_spread":0.23018459924532106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096196471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883593,0.0037334212,0.006136478,0.00019173887,0.00048329536,0.00042925778,0.000003819973,0.000017995319,0.0001680535],"genre_scores_gemma":[0.9983934,0.00025447202,0.00088104495,0.00004912529,0.000057339217,0.00004253821,0.000026176473,0.000019914734,0.00027594503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868464,0.00016635952,0.00026028248,0.00022055916,0.00016757709,0.0005005534],"domain_scores_gemma":[0.9993571,0.00020461649,0.000075593765,0.0002534198,0.000033372802,0.000075865755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000678725,0.00015153945,0.00023463267,0.00026769927,0.00014554877,0.000021569409,0.00006237855,0.00017568324,0.000023304061],"category_scores_gemma":[0.000099172685,0.00010984795,0.00003568761,0.00023259645,0.0001650126,0.00016609578,0.00006444069,0.0003260523,0.0000060770863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003948317,0.0002945361,0.0147577515,0.00007995293,0.00019388727,0.00006821945,0.0020340814,0.00037450058,0.93781364,0.0023877055,0.0011042331,0.036943164],"study_design_scores_gemma":[0.01095629,0.00079030707,0.04327279,0.00023477108,0.000034165474,0.000115769646,0.003006655,0.011748775,0.92667997,0.0014778705,0.0014197823,0.0002628605],"about_ca_topic_score_codex":0.0005823506,"about_ca_topic_score_gemma":0.000013564473,"teacher_disagreement_score":0.036680304,"about_ca_system_score_codex":0.0034146183,"about_ca_system_score_gemma":0.00048204264,"threshold_uncertainty_score":0.8929108},"labels":[],"label_agreement":null},{"id":"W2097554693","doi":"10.4212/cjhp.v61i4.67","title":"Oral Methotrexate: Preventing Inadvertent Daily Administration","year":2008,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Methotrexate; Medicine; Rheumatoid arthritis; Dosing; Psoriasis; Antimetabolite; Adverse effect; Pharmacology; Drug; Intensive care medicine; Internal medicine; Immunology","score_opus":0.05352702138994621,"score_gpt":0.3423458451158448,"score_spread":0.2888188237258986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097554693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898685,0.0012067325,0.0000405378,0.0058403206,0.00049999676,0.00027845925,0.000004576085,0.0000075345033,0.0022532924],"genre_scores_gemma":[0.9972486,0.000116851195,0.00041710754,0.00042166028,0.00044620025,0.0000032212113,0.0000041893254,0.000022888122,0.0013193086],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844044,0.00010902654,0.0004219921,0.00011513005,0.00049100706,0.00042238893],"domain_scores_gemma":[0.9983507,0.00007486621,0.00021146223,0.00020548991,0.00034851738,0.0008089924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007415609,0.0001304656,0.0002489849,0.00016414601,0.00033067088,0.000043738975,0.0002992221,0.00003499963,0.00034371397],"category_scores_gemma":[0.00033596088,0.00008900896,0.00017106204,0.00025028017,0.0002496697,0.00022849096,0.000020976773,0.0004970185,0.000045150533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0046282494,0.0018041366,0.12659162,0.00095985003,0.005072936,0.15396838,0.036563158,0.00068949023,0.008746168,0.0019746698,0.46509492,0.19390641],"study_design_scores_gemma":[0.1387471,0.012559838,0.14134693,0.0017202202,0.0024998826,0.14572386,0.0031242638,0.019301338,0.107673936,0.002251089,0.42285174,0.0021998077],"about_ca_topic_score_codex":0.015203452,"about_ca_topic_score_gemma":0.006224848,"teacher_disagreement_score":0.1917066,"about_ca_system_score_codex":0.0045296545,"about_ca_system_score_gemma":0.02723596,"threshold_uncertainty_score":0.9992918},"labels":[],"label_agreement":null},{"id":"W2100595321","doi":"10.1093/jncimonographs/lgu001","title":"Medical History, Lifestyle, Family History, and Occupational Risk Factors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project","year":2014,"lang":"en","type":"article","venue":"JNCI Monographs","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute on Deafness and Other Communication Disorders; National Institute on Drug Abuse; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research","keywords":"Medicine; Chronic lymphocytic leukemia; Hodgkin lymphoma; Lymphoma; Family history; Internal medicine; Oncology; Medical history; Leukemia","score_opus":0.030424959874643456,"score_gpt":0.28060236937876304,"score_spread":0.2501774095041196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100595321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797449,0.010100128,0.0026269082,0.000109399625,0.0019312552,0.0029210227,0.00007936468,0.00042689103,0.0020601042],"genre_scores_gemma":[0.99060565,0.001946901,0.0009954065,0.0014453654,0.0013710635,0.0010085539,0.00028882964,0.00028181382,0.00205641],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9923757,0.000537399,0.0014554412,0.001722038,0.0020917165,0.0018177426],"domain_scores_gemma":[0.99321353,0.0027052974,0.0006979078,0.0018199913,0.00052415906,0.0010390911],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002540831,0.0011294609,0.0014618492,0.0010567954,0.0005137362,0.00010655413,0.0012365787,0.0009100608,0.0001841],"category_scores_gemma":[0.0026473133,0.0008353792,0.0008956739,0.0006930457,0.0019403493,0.0003007427,0.00044796744,0.00039084334,0.00009185434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016320195,0.0019517384,0.06508584,0.007565143,0.006578501,0.0008765672,0.022874437,0.0007127621,0.0023114644,0.005343437,0.52940637,0.34097356],"study_design_scores_gemma":[0.07832016,0.003159231,0.06081709,0.000739989,0.0012132503,0.0011914498,0.0008190396,0.4998008,0.00053368544,0.00025103838,0.35150418,0.0016500958],"about_ca_topic_score_codex":0.0215262,"about_ca_topic_score_gemma":0.00096249976,"teacher_disagreement_score":0.49908802,"about_ca_system_score_codex":0.28542694,"about_ca_system_score_gemma":0.13628036,"threshold_uncertainty_score":0.9994097},"labels":[],"label_agreement":null},{"id":"W2101820986","doi":"10.1016/j.jval.2014.03.464","title":"Health Care Resource Utilization in the Management of Chronic Lymphocytic Leukemia at an Ontario Cancer Centre","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Credit Valley Hospital; McMaster University; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Fludarabine; Chlorambucil; Chronic lymphocytic leukemia; Cohort; Internal medicine; Alemtuzumab; Rituximab; Retrospective cohort study; Chemotherapy regimen; Cancer; Chemotherapy; Oncology; Leukemia; Transplantation; Lymphoma; Cyclophosphamide","score_opus":0.05192244247625553,"score_gpt":0.3482144586261496,"score_spread":0.29629201614989403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101820986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98684424,0.007236971,0.00003607804,0.0019515875,0.00011918207,0.0019085655,0.000008685214,0.000032915334,0.0018617905],"genre_scores_gemma":[0.99590343,0.0014355114,0.00021640978,0.0013967067,0.00011805013,0.00005810934,0.00010675459,0.000035576373,0.00072945864],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99649596,0.00069921464,0.00074622605,0.0004730559,0.00079743087,0.00078810495],"domain_scores_gemma":[0.99853873,0.00013071914,0.00022275808,0.00082216645,0.000053794476,0.00023181488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016967468,0.0001896493,0.00049593137,0.00022030866,0.00011564476,0.000011789726,0.00029655683,0.00009457011,0.00009184399],"category_scores_gemma":[0.000024336248,0.00014990801,0.000055935932,0.0005908148,0.00008627249,0.00005449703,0.00010938064,0.00028846745,0.000012963263],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0022275676,0.0006249333,0.051430658,0.044710316,0.00017411957,0.00027182742,0.21220198,0.42147583,0.000022097473,0.008501637,0.007850627,0.25050843],"study_design_scores_gemma":[0.059115957,0.0031189658,0.11628383,0.010910008,0.000068070105,0.00016378191,0.012634817,0.63303983,0.00020288852,0.0001675318,0.16373898,0.0005553446],"about_ca_topic_score_codex":0.6801781,"about_ca_topic_score_gemma":0.4329549,"teacher_disagreement_score":0.3836363,"about_ca_system_score_codex":0.4363549,"about_ca_system_score_gemma":0.052718602,"threshold_uncertainty_score":0.9526516},"labels":[],"label_agreement":null},{"id":"W2102070406","doi":"10.3816/clm.2005.n.002","title":"Origins of Waldenström's Macroglobulinemia: Does It Arise from an Unusual B-Cell Precursor?","year":2005,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Canada Research Chairs","keywords":"Immunoglobulin class switching; Somatic hypermutation; Waldenstrom macroglobulinemia; Immunoglobulin D; Macroglobulinemia; B cell; Biology; Immunoglobulin M; CD40; Cytidine deaminase; Monoclonal gammopathy of undetermined significance; Immunology; Molecular biology; Antibody; Monoclonal; Genetics; Monoclonal antibody; Immunoglobulin G; Multiple myeloma; Cytotoxic T cell; Lymphoma","score_opus":0.09611683324481807,"score_gpt":0.4676728339755265,"score_spread":0.37155600073070844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102070406","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011117951,0.98018426,0.00001661315,0.00018131184,0.0014887475,0.0021386961,0.0009928915,0.00019334546,0.0036861927],"genre_scores_gemma":[0.0009448976,0.98564905,0.0018953963,0.00041853578,0.005242692,0.00011978628,0.0013386317,0.00027373244,0.0041172695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900248,0.00087906123,0.004415204,0.0020231968,0.001479121,0.0011786197],"domain_scores_gemma":[0.98982686,0.0038190035,0.0014186051,0.0030414273,0.00042311757,0.0014709982],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014477392,0.0011462457,0.0064564366,0.0003233906,0.00009110642,0.00007180866,0.0014545816,0.0027805504,0.0011044355],"category_scores_gemma":[0.0015864997,0.00076339976,0.002472515,0.00068940216,0.0011053856,0.00015689054,0.00063863606,0.0013402053,0.0016606529],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00038528707,0.0027240345,0.00005164682,0.008053953,0.0006440518,0.0010895459,0.000057914818,4.501747e-7,7.887736e-7,0.00011240505,0.0040671686,0.98281276],"study_design_scores_gemma":[0.018618219,0.0009953203,0.00003884205,0.010383441,0.0037068257,0.00037974515,0.000045192308,0.00035635894,0.000035788315,0.000050088474,0.964662,0.00072816096],"about_ca_topic_score_codex":0.0015703252,"about_ca_topic_score_gemma":0.00021046968,"teacher_disagreement_score":0.9820846,"about_ca_system_score_codex":0.024745835,"about_ca_system_score_gemma":0.03633261,"threshold_uncertainty_score":0.99980867},"labels":[],"label_agreement":null},{"id":"W2102640163","doi":"10.1016/s0145-2126(01)00010-8","title":"CD8+ T cells in large granular lymphocyte leukemia are not defective in activation- and replication-related apoptosis","year":2001,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Institutes of Health","keywords":"Apoptosis; Programmed cell death; CD28; CD8; Cell biology; Fas ligand; Biology; CD3; Lymphocyte; Cytotoxic T cell; Chemistry; Molecular biology; Immunology; In vitro; Antigen; Biochemistry","score_opus":0.043982405355010995,"score_gpt":0.3521894276525018,"score_spread":0.30820702229749075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102640163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895131,0.00046550375,0.000071573566,0.0010030315,0.000064693566,0.0021455365,0.000018653831,0.00010362562,0.006614275],"genre_scores_gemma":[0.99338704,0.0023345293,0.00017388069,0.0002922612,0.0001230709,0.0005257341,0.00007951465,0.00010740378,0.002976576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9929173,0.0007367147,0.00092612475,0.0016194028,0.0019295223,0.0018709503],"domain_scores_gemma":[0.9950399,0.0019282761,0.00015941783,0.0017473688,0.00060052477,0.00052454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004608166,0.00041051363,0.00079306733,0.0019130993,0.00033762347,0.00011482842,0.00050169276,0.0006583735,0.0002615159],"category_scores_gemma":[0.0029150832,0.00040409004,0.00013809217,0.0042147906,0.00048067298,0.00039534725,0.00049911335,0.0020155732,0.000336032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019787198,0.0031272622,0.3946479,0.0037591963,0.00066806894,0.0059460048,0.016940778,0.0036382254,0.49139425,0.009549476,0.0098092975,0.040732328],"study_design_scores_gemma":[0.120734155,0.00082703034,0.30606788,0.0030462316,0.00007091506,0.00066886126,0.0048943474,0.14917655,0.39725858,0.002154424,0.013665054,0.0014359469],"about_ca_topic_score_codex":0.011437198,"about_ca_topic_score_gemma":0.0015261677,"teacher_disagreement_score":0.14553833,"about_ca_system_score_codex":0.10262516,"about_ca_system_score_gemma":0.0147420745,"threshold_uncertainty_score":0.9998411},"labels":[],"label_agreement":null},{"id":"W2102886762","doi":"","title":"Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Chromatography; High-performance liquid chromatography; Pharmacokinetics; Chemistry; Cladribine; Coefficient of variation; Standard curve; Extraction (chemistry); Pharmacology; Medicine; Internal medicine","score_opus":0.1132400557486244,"score_gpt":0.3591494099913999,"score_spread":0.2459093542427755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102886762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690896,0.0011436724,0.00032921898,0.00009891218,0.00004600645,0.0011762751,0.0000040754267,0.0000052241157,0.00028765303],"genre_scores_gemma":[0.9955273,0.00056481385,0.003529739,0.000022014896,0.000046137415,0.00010777425,0.000008543728,0.000008990089,0.00018463035],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908096,0.000023328532,0.00031809066,0.00015083571,0.00020583493,0.00022096485],"domain_scores_gemma":[0.9991592,0.00042472323,0.000075929805,0.00007440775,0.00019570286,0.00007003137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015303938,0.00007443501,0.000261255,0.00016186615,0.000013392498,0.0000025421282,0.000020236472,0.0000380205,0.0000011126534],"category_scores_gemma":[0.00031445982,0.000063442996,0.000014984371,0.00015485361,0.000155322,0.000026814287,0.000048547437,0.000054696327,1.4150754e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004730678,0.00049321796,0.007611639,0.0039142924,0.0007428541,0.00018698582,0.014158393,0.00002124353,0.06605787,0.0005676177,0.0012309109,0.9002843],"study_design_scores_gemma":[0.012234822,0.000053970038,0.087773725,0.000102444676,0.00004101188,0.000036567217,0.0010383718,0.00023563964,0.89609635,0.000038745475,0.0022731184,0.0000752075],"about_ca_topic_score_codex":0.000010551189,"about_ca_topic_score_gemma":0.000012160082,"teacher_disagreement_score":0.90020907,"about_ca_system_score_codex":0.0011892118,"about_ca_system_score_gemma":0.00025274054,"threshold_uncertainty_score":0.31097475},"labels":[],"label_agreement":null},{"id":"W2103243005","doi":"10.1016/j.leukres.2007.10.003","title":"The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia","year":2007,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancerfonden; Swedish Cancer Foundation; Cancer Research Society","keywords":"IGHV@; Chronic lymphocytic leukemia; GNAS complex locus; Single-nucleotide polymorphism; SNP; Oncology; Internal medicine; Genotype; CD38; Cohort; Medicine; Leukemia; Immunology; Biology; Genetics; Gene","score_opus":0.16642233714392834,"score_gpt":0.4781560145288114,"score_spread":0.31173367738488306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103243005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792177,0.0072772657,0.000052656225,0.00058825134,0.00022956163,0.0020255444,0.000005877039,0.00007314084,0.010529998],"genre_scores_gemma":[0.9910445,0.0032685655,0.00029758437,0.00014442738,0.0008192913,0.00009446069,0.000013904228,0.000102520615,0.004214728],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9901699,0.0009999009,0.0021105304,0.0011044344,0.0030619833,0.0025532695],"domain_scores_gemma":[0.9851757,0.011496354,0.00017858436,0.0016114345,0.00067036704,0.0008675028],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.021523882,0.00039383364,0.0010494253,0.00080476253,0.00039535662,0.000101819765,0.00089632336,0.00065814133,0.000086050764],"category_scores_gemma":[0.008208905,0.0002846423,0.0002616217,0.0021608137,0.0032467674,0.00016337998,0.0008967599,0.002580501,0.00021994668],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.042652078,0.0011934825,0.17714751,0.011724218,0.0023991924,0.02266429,0.006482002,0.004302572,0.061142705,0.08314406,0.04568003,0.54146785],"study_design_scores_gemma":[0.13928333,0.0070407754,0.30161816,0.004143397,0.00025723534,0.0028820196,0.002445523,0.45326433,0.032978754,0.0053221937,0.049287062,0.0014772298],"about_ca_topic_score_codex":0.011586555,"about_ca_topic_score_gemma":0.0012812373,"teacher_disagreement_score":0.53999066,"about_ca_system_score_codex":0.17540267,"about_ca_system_score_gemma":0.14405733,"threshold_uncertainty_score":0.9999606},"labels":[],"label_agreement":null},{"id":"W2103252719","doi":"10.1093/annonc/mdh408","title":"Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems","year":2004,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Quarter (Canadian coin); Pediatrics; Leukemia; Internal medicine; Oncology","score_opus":0.02125600361656128,"score_gpt":0.3464367489054979,"score_spread":0.32518074528893665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103252719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.928369,0.006422436,0.0000062364975,0.000086747146,0.062477656,0.0020290448,0.00011267775,0.00003133879,0.00046489405],"genre_scores_gemma":[0.9539713,0.00096421,0.00009937507,0.000039697836,0.04431142,0.00022938263,0.00023673457,0.000090742855,0.00005711249],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958465,0.0002574344,0.0010982649,0.0006987826,0.0012850773,0.0008139031],"domain_scores_gemma":[0.9967794,0.0007976768,0.0007427754,0.00049157423,0.0009696507,0.00021892494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008085269,0.00044963934,0.0018403663,0.0007262149,0.00002862943,0.00004301493,0.0002225093,0.0011218973,0.00002573996],"category_scores_gemma":[0.00043608886,0.0003606181,0.00012692202,0.00043686322,0.0004917472,0.00018203042,0.00017367263,0.00077017274,0.0000038095802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.047350924,0.004660441,0.09106295,0.10894386,0.005940013,0.006358023,0.008547711,0.0025402082,0.00027213345,0.0000744159,0.66396314,0.06028619],"study_design_scores_gemma":[0.41667598,0.08432301,0.046836138,0.066964604,0.0020360986,0.00024650164,0.0014384157,0.006079228,0.0007871411,0.00007043267,0.37170354,0.0028389299],"about_ca_topic_score_codex":0.0051763724,"about_ca_topic_score_gemma":0.0002276704,"teacher_disagreement_score":0.36932504,"about_ca_system_score_codex":0.058893066,"about_ca_system_score_gemma":0.11349794,"threshold_uncertainty_score":0.9998846},"labels":[],"label_agreement":null},{"id":"W2104410141","doi":"10.1016/j.ijrobp.2010.10.013","title":"Palliation by Low-Dose Local Radiation Therapy for Indolent Non-Hodgkin Lymphoma","year":2010,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Southlake Regional Health Center; University of Toronto","funders":"","keywords":"Medicine; Histology; Lymphoma; Non-Hodgkin's lymphoma; Radiation therapy; Regimen; Follicular lymphoma; Internal medicine; Palliative care; Gastroenterology","score_opus":0.01786705104094482,"score_gpt":0.35761791709579777,"score_spread":0.33975086605485294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104410141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9189814,0.00048541426,0.07165417,0.003386916,0.0041991537,0.00085434807,0.00010238291,0.000045234337,0.00029102346],"genre_scores_gemma":[0.98963904,0.0013004426,0.002285646,0.001621737,0.004469048,0.0000697332,0.00045738037,0.000057208727,0.00009975299],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749506,0.00015402591,0.000998761,0.00034759127,0.00060346135,0.00040108798],"domain_scores_gemma":[0.99617386,0.00078663253,0.0011383648,0.00025974517,0.0013868625,0.00025452123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011043852,0.00027386117,0.0005553383,0.00025256258,0.00010595055,0.00005292146,0.0005157034,0.0005184697,0.00010454909],"category_scores_gemma":[0.00060553494,0.00024035557,0.00034809962,0.00021342529,0.0002840316,0.00035482095,0.000055825032,0.00056162477,0.000048388607],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028935054,0.001221659,0.015446321,0.00002326457,0.0007117865,0.000030124338,0.00057199836,0.00035670967,0.058114983,0.0027629936,0.010142096,0.90772456],"study_design_scores_gemma":[0.21765003,0.008496109,0.04812769,0.0001876022,0.00029871296,0.0008223989,0.00022936988,0.17675646,0.14056712,0.013112093,0.39281124,0.00094117934],"about_ca_topic_score_codex":0.00006841691,"about_ca_topic_score_gemma":0.0000097418815,"teacher_disagreement_score":0.9067834,"about_ca_system_score_codex":0.007327926,"about_ca_system_score_gemma":0.0059638526,"threshold_uncertainty_score":0.9996714},"labels":[],"label_agreement":null},{"id":"W2104441610","doi":"10.5858/2005-129-395-hclvwf","title":"Hairy Cell Leukemia Variant With Features of Intrasinusoidal Bone Marrow Involvement","year":2005,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Pathology; Red pulp; Bone marrow; Hairy cell leukemia; Medicine; CD20; Hairy Cell; Leukemia; Biopsy; Immunostaining; Lymphoma; Spleen; Immunohistochemistry; Immunology","score_opus":0.009210675823529586,"score_gpt":0.2583273234897531,"score_spread":0.24911664766622355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104441610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792407,0.0054682046,0.0005020115,0.002013141,0.00012971486,0.0006572042,0.000056318244,0.000059858197,0.0118728075],"genre_scores_gemma":[0.9854475,0.00051941565,0.011628581,0.00096982927,0.000474827,0.000034536508,0.00006893707,0.000056284793,0.00080006587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99708575,0.0002585393,0.00079070794,0.00054325315,0.0007426372,0.00057912053],"domain_scores_gemma":[0.99758554,0.0005270833,0.0003758056,0.0009055197,0.00026206722,0.00034401292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066837406,0.00034415527,0.0010522002,0.0004952812,0.00006014613,0.0000028854668,0.00029960345,0.00017367995,0.00022554756],"category_scores_gemma":[0.00029678302,0.00024036145,0.00008865598,0.000493399,0.0026046608,0.00008318798,0.00014744049,0.00057595834,0.00001153695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004287918,0.00085261394,0.0038407198,0.0017966296,0.00034106703,0.006965098,0.009687766,0.00015801276,0.9498501,0.0021044055,0.0067365966,0.013379102],"study_design_scores_gemma":[0.11285833,0.016175978,0.073394336,0.0034866962,0.0014366508,0.0060680136,0.0055205394,0.002282277,0.7601274,0.0005806908,0.017027363,0.0010416843],"about_ca_topic_score_codex":0.00022461195,"about_ca_topic_score_gemma":0.00021383663,"teacher_disagreement_score":0.18972263,"about_ca_system_score_codex":0.0012009911,"about_ca_system_score_gemma":0.0069402037,"threshold_uncertainty_score":0.99868953},"labels":[],"label_agreement":null},{"id":"W2105466569","doi":"10.1136/mp.56.4.205","title":"Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia","year":2003,"lang":"en","type":"article","venue":"Molecular Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Nucleotide; Chronic lymphocytic leukemia; Molecular biology; B cell; Biology; Gene; Cancer research; Genetics; Leukemia; Antibody","score_opus":0.013705490492819404,"score_gpt":0.26675306398352766,"score_spread":0.2530475734907083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105466569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99168605,0.0021740901,0.0009205861,0.00013467048,0.00021939367,0.0012802832,0.0000030262051,0.000033773336,0.0035481555],"genre_scores_gemma":[0.9986185,0.00005426314,0.0002745818,0.0006315045,0.000040891016,0.00017083003,0.000004969595,0.00007170695,0.00013279817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99726677,0.00056805066,0.00045560696,0.0005445922,0.00047254487,0.0006924104],"domain_scores_gemma":[0.9985383,0.000046043235,0.00014262779,0.0010398559,0.00010583811,0.00012730788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052485795,0.00026567225,0.00046232587,0.000254373,0.0000492464,0.000009496148,0.00027541252,0.000312165,0.00010415178],"category_scores_gemma":[0.00029484232,0.00021449549,0.00022932707,0.0006857281,0.00029202164,0.00005030984,0.0001547639,0.0004191681,0.00005932088],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078516954,0.00011699657,0.00054670783,0.0003251507,0.00002626146,0.0033580468,0.00034881945,0.00022401524,0.9921799,0.0004703771,0.000008760409,0.002316455],"study_design_scores_gemma":[0.011148883,0.00050723343,0.0021199107,0.00012873633,0.00007891159,0.0016954324,0.00002896162,0.0059446595,0.9771517,0.00027946703,0.0007097361,0.00020639437],"about_ca_topic_score_codex":0.00045550423,"about_ca_topic_score_gemma":0.000111759946,"teacher_disagreement_score":0.015028219,"about_ca_system_score_codex":0.015123526,"about_ca_system_score_gemma":0.0046457164,"threshold_uncertainty_score":0.98865724},"labels":[],"label_agreement":null},{"id":"W2106030629","doi":"10.14740/jh223w","title":"A Rare Variant of Aggressive T-Cell Large Granular Lymphocyte Leukemia Associated With Hepatic Fibrosis and Trisomy 8: A Case Report and Literature Review","year":2015,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pathology; Trisomy; Lymphocyte; Leukemia; Immunology; Fibrosis; Biology; Genetics","score_opus":0.014650552844582651,"score_gpt":0.28798227256730957,"score_spread":0.2733317197227269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106030629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7916326,0.2073448,0.00009224195,0.00039088604,0.000047134774,0.00036813648,0.00001460784,0.0000072436465,0.000102355225],"genre_scores_gemma":[0.9825523,0.015713591,0.0011811663,0.0002683363,0.000047377755,0.000009671113,0.000018239212,0.000030177569,0.00017915468],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9976612,0.0002733953,0.00097337,0.00023767908,0.0005196846,0.0003346725],"domain_scores_gemma":[0.9958165,0.00035653028,0.0020356462,0.00031622974,0.001051454,0.00042361012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013713564,0.00021303153,0.0013786205,0.00022371575,0.000048102454,0.000018798259,0.000087515175,0.00022347886,0.00001572343],"category_scores_gemma":[0.0032157402,0.00013764003,0.00011635557,0.0003957189,0.00017400274,0.00012922009,0.000083510175,0.0003958095,8.952865e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011300192,0.0001871367,0.004449644,0.005296,0.00030191295,0.9829765,0.0009767883,0.0000011414824,0.00012453037,0.000060423667,0.00434133,0.00015457737],"study_design_scores_gemma":[0.028767454,0.0012540655,0.00011786667,0.017506506,0.0007085018,0.9491753,0.00022551327,0.0005617125,0.001082451,0.00009409149,0.00038249308,0.00012402207],"about_ca_topic_score_codex":0.000049528753,"about_ca_topic_score_gemma":0.000017335244,"teacher_disagreement_score":0.1916312,"about_ca_system_score_codex":0.0022889986,"about_ca_system_score_gemma":0.0073407716,"threshold_uncertainty_score":0.99828666},"labels":[],"label_agreement":null},{"id":"W2106082064","doi":"10.1016/j.clml.2015.07.649","title":"Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective","year":2015,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Toronto; Jewish General Hospital; McGill University; BC Cancer Agency; Princess Margaret Cancer Centre; Foothills Medical Centre","funders":"","keywords":"Ibrutinib; Obinutuzumab; Venetoclax; Idelalisib; Chemoimmunotherapy; Chronic lymphocytic leukemia; Fludarabine; Medicine; Rituximab; Ofatumumab; Oncology; Internal medicine; Cyclophosphamide; Bendamustine; Leukemia; Immunology; Lymphoma; Chemotherapy","score_opus":0.14684593771245646,"score_gpt":0.4434761803015968,"score_spread":0.29663024258914034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106082064","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024439945,0.9776943,0.00015347959,0.00019906167,0.0021361161,0.008154573,0.0009178466,0.00052055327,0.009979726],"genre_scores_gemma":[0.00040555105,0.97667426,0.0018691503,0.00095177384,0.0074001746,0.0022291567,0.0011382716,0.0009266132,0.008405024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98571014,0.0006470031,0.004313651,0.0036948607,0.0019152868,0.0037190586],"domain_scores_gemma":[0.9835171,0.004227197,0.0013779786,0.0038538792,0.002348047,0.004675793],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004245972,0.0024661827,0.009347534,0.0014642767,0.0005851364,0.00033106515,0.0022999789,0.004594964,0.00032404411],"category_scores_gemma":[0.0057552676,0.0020527155,0.004907114,0.0019111994,0.0019400091,0.0003115473,0.0006593718,0.0018372423,0.0022559757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004799847,0.00010108079,0.00000175286,0.013042806,0.0025962836,0.0012448218,0.00023376198,0.000010826796,9.1583087e-7,0.0020290418,0.027838487,0.95242023],"study_design_scores_gemma":[0.032859806,0.0017558321,0.00011825891,0.012617427,0.00491882,0.006576729,0.00023078462,0.0031242145,0.000002230555,0.00059734186,0.9353019,0.0018966249],"about_ca_topic_score_codex":0.13294496,"about_ca_topic_score_gemma":0.024393959,"teacher_disagreement_score":0.9505236,"about_ca_system_score_codex":0.79308957,"about_ca_system_score_gemma":0.7726949,"threshold_uncertainty_score":0.9988075},"labels":[],"label_agreement":null},{"id":"W2106319246","doi":"10.4049/jimmunol.167.1.42","title":"Expression of Active Protein Kinase B in T Cells Perturbs Both T and B Cell Homeostasis and Promotes Inflammation","year":2001,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Inflammation; Biology; Cell biology; T cell; Autoimmunity; CD8; ZAP70; Protein kinase B; B cell; CD40; Immunology; Cancer research; Cytotoxic T cell; Immune system; Signal transduction; Interleukin 21; Antibody; In vitro","score_opus":0.012536889595922831,"score_gpt":0.2607946403518632,"score_spread":0.2482577507559404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106319246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398243,0.0048685507,0.000027964015,0.0006336146,0.00002153389,0.00033601793,7.5306457e-7,0.0000032302303,0.00012591411],"genre_scores_gemma":[0.9961325,0.0034725629,0.0002388841,0.000011326704,0.000034099634,0.0000030533738,3.616892e-7,0.000010625723,0.000096595475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905485,0.00022128473,0.00032691055,0.00006958218,0.00016952107,0.00015782398],"domain_scores_gemma":[0.999203,0.00023384494,0.00026433836,0.00014608078,0.00011242044,0.000040305633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005876752,0.00008161963,0.00026352922,0.00018819548,0.000031391886,0.0000051838,0.00008903858,0.00008856156,0.000029761843],"category_scores_gemma":[0.00018655238,0.00004825185,0.000024586336,0.0001227258,0.00021794798,0.00010445913,0.00008048956,0.00030727964,0.0000013601008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027706923,0.00007608562,0.00011698258,0.0000864359,0.000027015667,0.000080890844,0.0030624135,0.0000041553576,0.97301495,0.000006551935,0.000014786987,0.020739043],"study_design_scores_gemma":[0.008861717,0.0010830737,0.0050811246,0.00036172027,0.00003338837,0.0009655618,0.0015603208,0.00022636264,0.9814251,0.000203221,0.00015134703,0.0000470508],"about_ca_topic_score_codex":0.00017412986,"about_ca_topic_score_gemma":0.000011058813,"teacher_disagreement_score":0.02069199,"about_ca_system_score_codex":0.0005971666,"about_ca_system_score_gemma":0.0006263528,"threshold_uncertainty_score":0.19676535},"labels":[],"label_agreement":null},{"id":"W2108145697","doi":"10.1016/j.leukres.2010.05.029","title":"p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; CancerCare Manitoba; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Dasatinib; Autophagy; Chronic lymphocytic leukemia; Cancer research; Endoplasmic reticulum; Medicine; Leukemia; Cytotoxic T cell; Immunology; In vitro; Apoptosis; Biology; Imatinib; Cell biology; Myeloid leukemia","score_opus":0.030326447120379046,"score_gpt":0.36152442372722693,"score_spread":0.3311979766068479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108145697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624088,0.0011424522,0.000023630519,0.002576883,0.00015970616,0.0016622867,0.000026214826,0.00010244507,0.031897597],"genre_scores_gemma":[0.97481555,0.0002921954,0.0049962862,0.000877124,0.00043860477,0.0003267925,0.000041985913,0.00008480513,0.018126644],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942998,0.00030963437,0.0006044115,0.0010211482,0.0020299652,0.0017350275],"domain_scores_gemma":[0.9953255,0.0017572155,0.000053937314,0.0012725162,0.0006182204,0.00097262324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004340548,0.000297641,0.0006628303,0.00090710114,0.0002413495,0.00015073878,0.0005542445,0.00041486754,0.00027056754],"category_scores_gemma":[0.0038758542,0.00027093824,0.00007996389,0.0016743534,0.0006958524,0.00018524831,0.0007347406,0.002079384,0.000456282],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021502016,0.0011495703,0.029320013,0.005258465,0.00036704715,0.013905933,0.007943391,0.00005004029,0.67007893,0.039897807,0.12841444,0.08211233],"study_design_scores_gemma":[0.113014996,0.0014728919,0.3080873,0.0016571648,0.000054512453,0.0011898865,0.0006116852,0.0066421805,0.0926212,0.004427186,0.46876156,0.0014594564],"about_ca_topic_score_codex":0.002078445,"about_ca_topic_score_gemma":0.0027624425,"teacher_disagreement_score":0.5774577,"about_ca_system_score_codex":0.031385675,"about_ca_system_score_gemma":0.024580656,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W2108305936","doi":"10.1038/ng.2652","title":"Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia","year":2013,"lang":"en","type":"review","venue":"Nature Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Human Genome Research Institute; National Institutes of Health","keywords":"Chronic lymphocytic leukemia; Genome-wide association study; Biology; Single-nucleotide polymorphism; Locus (genetics); Genetics; Genetic association; Leukemia; Gene; Genotype","score_opus":0.030421998552550258,"score_gpt":0.35079895933046834,"score_spread":0.3203769607779181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108305936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009047745,0.97645205,0.00008320118,0.000013675213,0.0011083119,0.012685154,0.00027584904,0.00017496286,0.00015903956],"genre_scores_gemma":[0.0027404851,0.9794226,0.00061861565,0.00009177363,0.0026491494,0.0017444723,0.0011718939,0.0003493847,0.011211599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936235,0.00041363505,0.0014623833,0.0013800309,0.001765573,0.0013549003],"domain_scores_gemma":[0.9923989,0.003161996,0.0012585083,0.0017907807,0.00097620016,0.00041361744],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001426974,0.0010202712,0.0030742106,0.00053591275,0.00030873535,0.00023412965,0.00089438126,0.0030273104,0.00016078838],"category_scores_gemma":[0.00584848,0.00084254314,0.0011754328,0.0007936143,0.00010223225,0.0000813242,0.0004409875,0.00261727,0.0007470071],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00019309054,0.00047719438,0.0031650509,0.10167846,0.010368523,0.00026920083,0.0008139054,0.00048190274,0.000010513444,0.0000031932652,0.07052099,0.812018],"study_design_scores_gemma":[0.014209704,0.00073007005,0.00052340137,0.0021432687,0.0067340718,0.00004655704,0.00008301189,0.0026714837,0.000022584414,0.000033443906,0.97203827,0.00076413],"about_ca_topic_score_codex":0.00031452885,"about_ca_topic_score_gemma":0.0002900077,"teacher_disagreement_score":0.9015173,"about_ca_system_score_codex":0.3584157,"about_ca_system_score_gemma":0.07058612,"threshold_uncertainty_score":0.99968374},"labels":[],"label_agreement":null},{"id":"W2109151188","doi":"10.1038/leu.2009.205","title":"Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia","year":2009,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Queen Elizabeth II Health Sciences Centre; Moncton Hospital; Hôpital Charles-Le Moyne; Alberta Cancer Foundation; McGill University Health Centre","funders":"National Cancer Institute","keywords":"Fludarabine; Chronic lymphocytic leukemia; Medicine; Leukemia; Vidarabine; Hematology; Internal medicine; Immunology; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.010149224251827413,"score_gpt":0.24440445713149683,"score_spread":0.23425523287966943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109151188","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9167254,0.0030358266,0.000039534978,0.035446055,0.0008126073,0.007837848,0.00025634014,0.0011454225,0.034700986],"genre_scores_gemma":[0.3617057,0.0007100877,0.0011851212,0.5236372,0.00798393,0.00058747426,0.014503729,0.0013991606,0.08828764],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908865,0.0002841341,0.0013505311,0.002056558,0.0026466805,0.0027755774],"domain_scores_gemma":[0.9957653,0.00032472055,0.0004833807,0.0024291626,0.0004984543,0.00049896125],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00037137824,0.0015815411,0.0023629172,0.0012607701,0.00014434491,0.00014638944,0.0009701693,0.0027046162,0.0007921753],"category_scores_gemma":[0.00015575359,0.0012813269,0.00040039126,0.0017805663,0.00048644235,0.00026261245,0.00026080976,0.005048246,0.001367053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001724945,0.00013263403,0.0016856423,0.0023307498,0.00029990912,0.016974417,0.0001418332,0.001527114,0.00008550042,0.0000050878266,0.97021246,0.0048796954],"study_design_scores_gemma":[0.2341268,0.004482449,0.0062148827,0.004548542,0.0010988924,0.0008464692,0.000020397352,0.025027905,0.0014431651,0.00009076835,0.719058,0.0030417407],"about_ca_topic_score_codex":0.007817006,"about_ca_topic_score_gemma":0.000463635,"teacher_disagreement_score":0.5550197,"about_ca_system_score_codex":0.6133346,"about_ca_system_score_gemma":0.1672504,"threshold_uncertainty_score":0.9996933},"labels":[],"label_agreement":null},{"id":"W2111030516","doi":"10.1111/j.1365-2141.2009.07946.x","title":"<i>IRF4</i> polymorphism rs872071 and risk of Hodgkin lymphoma","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"IRF4; Odds ratio; Genotype; Lymphoma; Chronic lymphocytic leukemia; Hematology; Oncology; Confidence interval; Internal medicine; Genetics; Biology; Medicine; Immunology; Gene; Transcription factor; Leukemia","score_opus":0.008592146408013122,"score_gpt":0.2646952606401587,"score_spread":0.25610311423214555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111030516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787813,0.01860589,0.00015310764,0.0007476952,0.00013725799,0.00014004207,0.000009922761,0.000011448555,0.0014133642],"genre_scores_gemma":[0.9896354,0.0079181725,0.0017556289,0.00035553926,0.00014507488,9.037463e-7,0.0000018445012,0.00001752856,0.00016987036],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9980379,0.00017394422,0.0007945711,0.00018071648,0.00044595049,0.0003669407],"domain_scores_gemma":[0.9984487,0.0002336137,0.00052063743,0.00020654229,0.0003094108,0.00028104568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006708633,0.00013269857,0.00093677023,0.00022457147,0.000060821912,0.000020473912,0.00018216338,0.00018390597,0.00009825823],"category_scores_gemma":[0.0007198655,0.00013279871,0.00017851724,0.00019099523,0.00033094652,0.00010244028,0.000051751143,0.00030304733,0.000008101319],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025221612,0.0016002663,0.013902999,0.000611097,0.0012470752,0.34696713,0.00069643557,0.000010518192,0.007325056,0.002774149,0.03396701,0.5883761],"study_design_scores_gemma":[0.022316584,0.0010789525,0.0234515,0.0006915079,0.00027952128,0.9411096,0.00009697404,0.00020371344,0.006338902,0.0023447636,0.0019531385,0.00013481772],"about_ca_topic_score_codex":0.00047885726,"about_ca_topic_score_gemma":0.00003279619,"teacher_disagreement_score":0.5941425,"about_ca_system_score_codex":0.00065112684,"about_ca_system_score_gemma":0.002071437,"threshold_uncertainty_score":0.54153746},"labels":[],"label_agreement":null},{"id":"W2113968909","doi":"10.1017/s0317167100011483","title":"The Neuropathies of Waldenström's Macroglobulinemia (WM) and IgM-MGUS","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke; Georgia Clinical and Translational Science Alliance","keywords":"Macroglobulinemia; Waldenstrom macroglobulinemia; Medicine; Monoclonal gammopathy of undetermined significance; Gammopathy; Lymphoplasmacytic Lymphoma; Pathology; Multiple myeloma; Peripheral neuropathy; Immunoglobulin M; Gastroenterology; Internal medicine; Immunology; Monoclonal; Lymphoma; Immunoglobulin G; Antibody; Endocrinology","score_opus":0.05034369281376299,"score_gpt":0.28594812578464734,"score_spread":0.23560443297088435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113968909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892013,0.0033447267,0.000008160111,0.0026862149,0.00055620825,0.000173795,0.000005642654,0.000010850206,0.0040130955],"genre_scores_gemma":[0.9955195,0.0017054132,0.0012610474,0.001260377,0.00018601974,0.0000017017184,8.175641e-8,0.000011707961,0.000054123808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955359,0.0007429665,0.0009846117,0.000431324,0.0009858574,0.0013193226],"domain_scores_gemma":[0.9955068,0.0009194616,0.0007107899,0.00022136755,0.00066756504,0.001973974],"candidate_categories":["sts"],"consensus_categories":["sts"],"category_scores_codex":[0.004814751,0.00028087868,0.000538808,0.00060995616,0.002287458,0.00032349842,0.001637373,0.00016708922,0.000109680936],"category_scores_gemma":[0.0042772107,0.00015188266,0.0002160174,0.0011099172,0.017266871,0.000466288,0.00013234958,0.0012372747,0.0000023082275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009725057,0.00008229647,0.9290854,0.000054197713,0.00006710556,0.035697985,0.0018335534,0.00020768576,0.00033525817,0.004493971,0.00139502,0.025775025],"study_design_scores_gemma":[0.0032534793,0.17254882,0.39166102,0.00020090367,0.00020313835,0.38909593,0.0013752508,0.004494495,0.0023031814,0.02806992,0.0061869514,0.0006069113],"about_ca_topic_score_codex":0.0035457744,"about_ca_topic_score_gemma":0.02491372,"teacher_disagreement_score":0.5374244,"about_ca_system_score_codex":0.00065992674,"about_ca_system_score_gemma":0.014034272,"threshold_uncertainty_score":0.99901146},"labels":[],"label_agreement":null},{"id":"W2115093629","doi":"10.1038/leu.2012.257","title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut Bergonié; Institut National Du Cancer; Ligue Contre le Cancer","keywords":"IGHV@; Biology; Waldenstrom macroglobulinemia; Lymphoplasmacytic Lymphoma; Macroglobulinemia; Immunoglobulin heavy chain; Lymphoma; Gene rearrangement; Antibody; Cancer research; Gene; Immunology; Genetics; Chronic lymphocytic leukemia; Leukemia; Multiple myeloma","score_opus":0.014378370570253981,"score_gpt":0.26924617946737595,"score_spread":0.25486780889712196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115093629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815107,0.0128329815,0.00018660526,0.00073746656,0.0003910547,0.00077083247,0.000034418874,0.00014315323,0.003392795],"genre_scores_gemma":[0.9895148,0.0011320122,0.0012800609,0.00078375294,0.0008845385,0.000097727614,0.00008340062,0.000085069965,0.006138614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967902,0.00012432855,0.0004820099,0.0005887129,0.000874621,0.001140173],"domain_scores_gemma":[0.9979761,0.00043452432,0.00016888784,0.00070567674,0.00016212247,0.0005526837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062753854,0.0004963921,0.0005635952,0.00019466589,0.0004448862,0.00020386536,0.00024774455,0.00031646757,0.00016584487],"category_scores_gemma":[0.00018277614,0.00035671704,0.00012617528,0.00037965798,0.0007953342,0.0003791177,0.0003433431,0.00028210858,0.0001520841],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012452317,0.0014337342,0.17005433,0.006356638,0.0045964755,0.009304776,0.027145583,0.0007062786,0.048446745,0.03096636,0.08025614,0.6082806],"study_design_scores_gemma":[0.13004352,0.0012942478,0.48602095,0.00097449095,0.002335913,0.16068211,0.0035685473,0.06275271,0.08982326,0.0026437875,0.057004232,0.002856207],"about_ca_topic_score_codex":0.001970027,"about_ca_topic_score_gemma":0.00025039478,"teacher_disagreement_score":0.6054244,"about_ca_system_score_codex":0.011140188,"about_ca_system_score_gemma":0.003945166,"threshold_uncertainty_score":0.9998885},"labels":[],"label_agreement":null},{"id":"W2116137820","doi":"10.3747/co.22.2431","title":"An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Manitoba; University of Calgary; Hôpital de l'Enfant-Jésus; Dalhousie University; University of Toronto; McMaster University; Université du Québec à Montréal; Juravinski Cancer Centre","funders":"National Cancer Institute; Lundbeck Canada","keywords":"Bendamustine; Medicine; Tolerability; Neutropenia; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Adverse effect; Nausea; Refractory (planetary science); Oncology; Lymphoma; Leukemia; Chemotherapy","score_opus":0.17067449409888838,"score_gpt":0.46028880184718385,"score_spread":0.28961430774829544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116137820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915164,0.0008338321,0.000045088218,0.000039127244,0.0011027844,0.005545056,0.00005067018,0.00008604595,0.00078096054],"genre_scores_gemma":[0.9974469,0.0003693069,0.0002250465,0.000071399554,0.00048960594,0.000579351,0.0005680608,0.00011772305,0.00013259884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944111,0.0005506448,0.0014032219,0.0011349139,0.0012312316,0.001268861],"domain_scores_gemma":[0.99586236,0.00035652978,0.00071058323,0.0013148913,0.00081673695,0.0009389119],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011351893,0.0006349921,0.00198813,0.0006383821,0.000085203115,0.00008834434,0.0013976565,0.00050429575,0.00024986826],"category_scores_gemma":[0.0006115381,0.00046438418,0.0000766786,0.0011352019,0.0005270908,0.0007211803,0.00083533063,0.0005478703,0.000055476074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5517793,0.03151861,0.022297136,0.0014784836,0.000443298,0.00084693555,0.0020932052,0.00045671008,0.00018451718,0.000022058759,0.0034898345,0.3853899],"study_design_scores_gemma":[0.89838594,0.07145677,0.00903932,0.0010939903,0.00030878177,0.0001234179,0.00014673543,0.013071398,0.0005886481,0.000015488824,0.005223811,0.00054571434],"about_ca_topic_score_codex":0.0032625112,"about_ca_topic_score_gemma":0.0017417102,"teacher_disagreement_score":0.38484418,"about_ca_system_score_codex":0.17449123,"about_ca_system_score_gemma":0.1470286,"threshold_uncertainty_score":0.9997808},"labels":[],"label_agreement":null},{"id":"W2117585236","doi":"10.1371/journal.pone.0087645","title":"Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; McGill University and Génome Québec Innovation Centre","funders":"National Institute for Health and Care Research; National Institute of General Medical Sciences; Qatar National Research Fund; Japan Society for the Promotion of Science; U.S. Public Health Service; Japan Science and Technology Agency; National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Versus Arthritis; Fonds National de la Recherche Luxembourg; Canadian Institutes of Health Research; Burroughs Wellcome Fund","keywords":"Genetics; Population; Allele frequency; Pedigree chart; Allele; Candidate gene; Biology; Locus (genetics); Medicine; Gene","score_opus":0.09977477278799306,"score_gpt":0.31876392873724085,"score_spread":0.21898915594924778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117585236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99009556,0.0017943874,0.0024099268,0.00008175049,0.000044672117,0.00065282173,0.0047877524,0.0000830785,0.000050043713],"genre_scores_gemma":[0.9473855,0.0024580574,0.020140992,0.00008707462,0.0001727077,0.000023115274,0.029628528,0.000050184808,0.00005383639],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969624,0.00024223588,0.00056523556,0.0008847562,0.0010430326,0.00030231677],"domain_scores_gemma":[0.9952503,0.00029772866,0.00031090912,0.0036758927,0.0002537589,0.00021143598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040064933,0.00022565259,0.0006052145,0.000119684264,0.00008891766,0.000085540974,0.00083099614,0.00012337822,0.00020483843],"category_scores_gemma":[0.0014625586,0.00019518414,0.0000218248,0.00019561229,0.00020123774,0.00042626605,0.00044273402,0.0002471055,0.00009282674],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025411157,0.0017289892,0.052016217,0.00022977953,0.0019439292,0.00032256093,0.0018155058,0.00007802198,0.92001724,0.000017926863,0.0009971323,0.018291596],"study_design_scores_gemma":[0.019236498,0.00097372447,0.10625121,0.0032480794,0.000819426,0.00010783953,0.0004771801,0.7978009,0.069632754,0.00085619825,0.000069851456,0.0005263466],"about_ca_topic_score_codex":0.24543492,"about_ca_topic_score_gemma":0.02573216,"teacher_disagreement_score":0.8503845,"about_ca_system_score_codex":0.00082843116,"about_ca_system_score_gemma":0.0014800836,"threshold_uncertainty_score":0.9920457},"labels":[],"label_agreement":null},{"id":"W2117953619","doi":"10.1093/ndt/gfr251","title":"Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases","year":2011,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; St. Paul's Hospital; University of British Columbia","funders":"University of British Columbia","keywords":"Medicine; Chronic lymphocytic leukemia; Glomerulonephritis; Monoclonal; Monoclonal antibody; Immunology; Leukemia; Pathology; Antibody; Kidney; Internal medicine","score_opus":0.022501117659295366,"score_gpt":0.284604008093377,"score_spread":0.26210289043408164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117953619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091375,0.00039725009,0.0046014134,0.00008452874,0.00006839511,0.0011109432,0.000053983986,0.0001064382,0.0026633064],"genre_scores_gemma":[0.99354374,0.00032730514,0.0043620216,0.0006081071,0.00018377967,0.0002975488,0.00042195377,0.000054049688,0.0002015173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701434,0.00018403106,0.00078976183,0.0007230306,0.00068566896,0.00060318824],"domain_scores_gemma":[0.99820733,0.00026359214,0.00024704178,0.0005670882,0.00038919956,0.0003257676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037074092,0.00034467533,0.0008158161,0.00049936824,0.0001231598,0.000015442887,0.0001948183,0.00022674582,0.00034742203],"category_scores_gemma":[0.00006027118,0.00029815154,0.00017685493,0.0007373965,0.00036024526,0.00022339718,0.000031112624,0.00028780597,0.00005964136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10517389,0.0015581505,0.095473476,0.009061625,0.014033567,0.26224685,0.057047438,0.016956534,0.38279372,0.0027436388,0.0019933584,0.05091774],"study_design_scores_gemma":[0.08256145,0.009892212,0.115849115,0.0006844874,0.005523316,0.1513048,0.00029232784,0.007831196,0.62419707,0.0002453065,0.00048413238,0.0011346176],"about_ca_topic_score_codex":0.006049715,"about_ca_topic_score_gemma":0.00716486,"teacher_disagreement_score":0.24140333,"about_ca_system_score_codex":0.012748983,"about_ca_system_score_gemma":0.020792173,"threshold_uncertainty_score":0.9999471},"labels":[],"label_agreement":null},{"id":"W2118236177","doi":"10.1158/1078-0432.ccr-04-0657","title":"Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"","keywords":"Pharmacokinetics; Pharmacodynamics; Pharmacology; Toxicity; Bolus (digestion); In vitro; Nucleoside; Dose–response relationship; Intracellular; Biology; Medicine; Internal medicine; Biochemistry","score_opus":0.30468296612125617,"score_gpt":0.5476224035942685,"score_spread":0.24293943747301233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118236177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98741716,0.002786151,0.000039264134,0.0060412674,0.00022123846,0.0007043421,0.000018185989,0.000035747806,0.002736625],"genre_scores_gemma":[0.9747916,0.021448119,0.00022020462,0.00033894012,0.00068809994,0.00011013273,0.000007141001,0.0000323455,0.0023634592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964207,0.00027733785,0.0006525303,0.00061006297,0.0011770847,0.0008622831],"domain_scores_gemma":[0.9976908,0.0010615438,0.000045518023,0.0003518963,0.00031698364,0.0005332637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025135977,0.00017231924,0.0005421956,0.00033067452,0.000097740296,0.00005609825,0.00028764465,0.00016920087,0.0005590924],"category_scores_gemma":[0.001020031,0.00013817912,0.000093173105,0.0008443856,0.0014266032,0.00008579301,0.00034151127,0.0016513594,0.000056864086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01226204,0.0045639807,0.76912457,0.0023288212,0.00063691975,0.004284491,0.0021565605,0.00024264018,0.019753994,0.0070027458,0.006961066,0.17068215],"study_design_scores_gemma":[0.20619106,0.0038768323,0.69835263,0.0017909245,0.00018589712,0.00027329577,0.0012648371,0.037181698,0.00854047,0.0064618783,0.03484965,0.0010308269],"about_ca_topic_score_codex":0.0014321078,"about_ca_topic_score_gemma":0.0004662495,"teacher_disagreement_score":0.19392902,"about_ca_system_score_codex":0.0050759143,"about_ca_system_score_gemma":0.005754984,"threshold_uncertainty_score":0.99988145},"labels":[],"label_agreement":null},{"id":"W2118480932","doi":"10.1093/qjmed/hcv017","title":"Primary care management of early stage chronic lymphocytic leukaemia is safe and effective","year":2015,"lang":"en","type":"article","venue":"QJM","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Wellcome Trust","keywords":"Stage (stratigraphy); Medicine; Primary care; Chronic lymphocytic leukemia; Intensive care medicine; Family medicine; Immunology; Leukemia; Biology","score_opus":0.018997274159765345,"score_gpt":0.3007591592427142,"score_spread":0.28176188508294886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118480932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94495535,0.0069375033,0.000053413634,0.000040732553,0.00009182832,0.0011340965,0.000020365991,0.00004163619,0.04672508],"genre_scores_gemma":[0.9923209,0.00031544623,0.000507848,0.00013373952,0.00009916262,0.000066143024,0.00002629696,0.000036788686,0.0064936723],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99828446,0.00005273726,0.00024152861,0.0003729183,0.0006631743,0.0003851552],"domain_scores_gemma":[0.99884,0.00007331775,0.00007051714,0.0005449312,0.00017931372,0.00029194294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025143364,0.0001830244,0.0003856208,0.00011781246,0.000036730795,0.000017016715,0.00013661404,0.00010768647,0.000076677126],"category_scores_gemma":[0.000022938366,0.00015876436,0.00007234354,0.00022955968,0.00019893986,0.000084780215,0.0002499783,0.00014282516,0.00012578943],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014742536,0.000689496,0.037026998,0.10057945,0.005721456,0.0100125605,0.058988135,0.00062801974,0.008698763,0.0061872923,0.03390581,0.7228195],"study_design_scores_gemma":[0.45433733,0.019469732,0.22922222,0.009475814,0.002679151,0.0011943057,0.01462784,0.0150255235,0.10930243,0.0008103078,0.14118545,0.0026698897],"about_ca_topic_score_codex":0.0011824735,"about_ca_topic_score_gemma":0.000013431086,"teacher_disagreement_score":0.7201496,"about_ca_system_score_codex":0.061462786,"about_ca_system_score_gemma":0.008187996,"threshold_uncertainty_score":0.9974347},"labels":[],"label_agreement":null},{"id":"W2120319857","doi":"10.1056/nejmoa1313984","title":"Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1500,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chlorambucil; Obinutuzumab; Medicine; Rituximab; Internal medicine; Hazard ratio; Gastroenterology; Chronic lymphocytic leukemia; Oncology; Chemotherapy; Confidence interval; Leukemia; Cyclophosphamide; Lymphoma","score_opus":0.014663474163761828,"score_gpt":0.28022515317738406,"score_spread":0.2655616790136222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120319857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948562,0.0002658843,0.0002642523,0.0016287034,0.00014547596,0.00018391607,0.0000016241313,0.0000081404005,0.0026458332],"genre_scores_gemma":[0.9975011,0.000056881872,0.0003788289,0.000381218,0.001337747,0.0000010822965,0.000012069769,0.000017361004,0.0003137403],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99838275,0.000074928525,0.00045679207,0.00013664206,0.0007008013,0.00024811004],"domain_scores_gemma":[0.9985327,0.00041648638,0.0002067043,0.00016037564,0.0002840299,0.00039966547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000911078,0.00013111385,0.0005124049,0.0002659549,0.000043139706,0.000009897079,0.00008264767,0.00005866252,0.000113656126],"category_scores_gemma":[0.0011838357,0.00007819519,0.000024101133,0.00021564969,0.00020775589,0.00008914344,0.000025204845,0.00042656847,0.0000033584722],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039856296,0.0007390659,0.5455213,0.001578075,0.00095496373,0.003613056,0.016284062,0.0016510235,0.0011965496,0.0034174167,0.039409265,0.3457789],"study_design_scores_gemma":[0.7910997,0.008686102,0.16606453,0.0028751746,0.00023944241,0.0026096464,0.000319245,0.0052388436,0.00006562978,0.00060925126,0.021999205,0.00019320982],"about_ca_topic_score_codex":0.00040665834,"about_ca_topic_score_gemma":0.000087040986,"teacher_disagreement_score":0.7512434,"about_ca_system_score_codex":0.0028844853,"about_ca_system_score_gemma":0.0027941796,"threshold_uncertainty_score":0.7542829},"labels":[],"label_agreement":null},{"id":"W2121228422","doi":"10.1182/blood-2004-09-3473","title":"Quantitative RT-PCR analysis of activation-induced cytidine deaminase expression in tissue samples from mantle cell lymphoma and B-cell chronic lymphocytic leukemia patients","year":2005,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Cytidine deaminase; Activation-induced (cytidine) deaminase; Somatic hypermutation; Germinal center; Mantle cell lymphoma; Chronic lymphocytic leukemia; Immunoglobulin class switching; Molecular biology; Biology; Cytidine; B cell; Antibody; Cancer research; Lymphoma; Leukemia; Immunology; Enzyme; Biochemistry","score_opus":0.02248725891153662,"score_gpt":0.2794664427859763,"score_spread":0.2569791838744397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121228422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947215,0.0017557038,0.00005902014,0.0010538342,0.00007648146,0.0011665912,0.0005498967,0.000053691318,0.0005632999],"genre_scores_gemma":[0.9826353,0.00076858635,0.0021525428,0.0050983937,0.0008915438,0.00014870579,0.006623112,0.00019775059,0.0014840561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949544,0.00029449325,0.0011690765,0.0013062716,0.001393854,0.00088187424],"domain_scores_gemma":[0.99608755,0.0014114769,0.00072982506,0.0012125229,0.00032857995,0.00023007017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025679034,0.0007518906,0.0018568909,0.0016616696,0.000094534334,0.000051100986,0.00043919316,0.0011934132,0.00040030404],"category_scores_gemma":[0.00030076632,0.0006973745,0.00030078753,0.0013850811,0.00019721029,0.00020403424,0.00032483236,0.00076170574,0.00008372847],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003884323,0.009198663,0.01174852,0.011851285,0.008632976,0.0050757197,0.0065667434,0.0016453037,0.76467854,0.000009156288,0.16419896,0.01250978],"study_design_scores_gemma":[0.12266408,0.0011472554,0.0090706665,0.0018455844,0.0054867226,0.000017206361,0.00023023863,0.011825335,0.83541226,0.00001974404,0.011228633,0.0010522797],"about_ca_topic_score_codex":0.0088343695,"about_ca_topic_score_gemma":0.0004275111,"teacher_disagreement_score":0.15297033,"about_ca_system_score_codex":0.04177103,"about_ca_system_score_gemma":0.015484459,"threshold_uncertainty_score":0.9995477},"labels":[],"label_agreement":null},{"id":"W2121229095","doi":"10.1158/1078-0432.ccr-04-0506","title":"Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Ligue Contre le Cancer; Association pour la Recherche sur le Cancer","keywords":"Gemcitabine; Deoxycytidine kinase; Ribonucleotide reductase; In vivo; L1210 cells; Nucleoside analogue; Deoxycytidine; Biology; Nucleoside; Prodrug; Antimetabolite; Cell culture; Cancer research; Molecular biology; In vitro; Pharmacology; Cytotoxicity; Chemotherapy; Biochemistry; Gene; Protein subunit","score_opus":0.17151313713702143,"score_gpt":0.49568231001022267,"score_spread":0.32416917287320124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121229095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993307,0.0006849961,0.0001411283,0.0024202394,0.0002080822,0.0010132489,0.000050715757,0.000052646687,0.0021219347],"genre_scores_gemma":[0.9907293,0.0028862988,0.0002645197,0.00022276802,0.00094314845,0.00014171263,0.000076967066,0.000061958126,0.0046733804],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953819,0.0002869713,0.001138112,0.00065068615,0.0017075039,0.00083485333],"domain_scores_gemma":[0.99658674,0.0006081507,0.00016311277,0.00091139594,0.001197668,0.0005329093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033078936,0.00018723462,0.00067055377,0.00033992185,0.000106547275,0.000026317612,0.000413344,0.00028117085,0.00076477655],"category_scores_gemma":[0.0013958948,0.00015494457,0.00024253232,0.0011377274,0.0008773396,0.00010191297,0.00034777418,0.0012299757,0.00022265088],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0074264435,0.0017366352,0.0024699823,0.001700161,0.00014233236,0.00039121252,0.00027015473,0.00008470898,0.97634125,0.0005694627,0.0007514029,0.00811628],"study_design_scores_gemma":[0.11307306,0.00802036,0.065490104,0.0022673435,0.00018313173,0.000083373496,0.00021696568,0.0027916166,0.7809898,0.0013387605,0.024887778,0.0006576962],"about_ca_topic_score_codex":0.0022991307,"about_ca_topic_score_gemma":0.00012789095,"teacher_disagreement_score":0.1953514,"about_ca_system_score_codex":0.008470144,"about_ca_system_score_gemma":0.019774567,"threshold_uncertainty_score":0.9953362},"labels":[],"label_agreement":null},{"id":"W2121961802","doi":"10.1016/j.jcjo.2012.11.010","title":"Intravenous rituximab for the treatment of cancer-associated retinopathy","year":2013,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Autoantibody; Retinopathy; Retinal; Fundus (uterus); Diabetic retinopathy; Retinal detachment; Rituximab; Ophthalmology; Immunology; Antibody; Diabetes mellitus; Endocrinology","score_opus":0.045143101680733856,"score_gpt":0.3244491032895765,"score_spread":0.2793060016088426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121961802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53254056,0.03242089,0.000008215833,0.42435396,0.004051547,0.0028058875,0.0007253835,0.0000064766264,0.003087071],"genre_scores_gemma":[0.91495854,0.0012397687,0.0003176407,0.03399493,0.01126742,0.0003843313,0.0002660588,0.00030108538,0.037270233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976095,0.00015255311,0.0007911549,0.0002374693,0.00034188645,0.0008674649],"domain_scores_gemma":[0.99630183,0.0009637346,0.00077703706,0.00047362788,0.0010475155,0.00043624837],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003235399,0.00031067908,0.0012723715,0.000446595,0.00012080733,0.000024361421,0.00046950867,0.0009078954,0.0021977082],"category_scores_gemma":[0.0004827941,0.00020019166,0.0004944276,0.00018730471,0.0004970615,0.000027943192,0.000009863964,0.00094108086,0.000016771359],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00031238602,0.00024884383,0.0010628527,0.00042937658,0.00292298,0.13947515,0.0010024012,0.000017608452,0.000032466836,0.000011881304,0.8499383,0.0045457534],"study_design_scores_gemma":[0.031377856,0.014754674,0.001789887,0.0007235061,0.0020552624,0.30105552,0.00014440465,0.00034708722,0.00049755897,0.0003357313,0.64651084,0.0004076843],"about_ca_topic_score_codex":0.09848551,"about_ca_topic_score_gemma":0.0013415284,"teacher_disagreement_score":0.39035904,"about_ca_system_score_codex":0.02305994,"about_ca_system_score_gemma":0.050189268,"threshold_uncertainty_score":0.99871445},"labels":[],"label_agreement":null},{"id":"W2124433242","doi":"10.3816/clm.2009.n.019","title":"Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia","year":2009,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Waldenstrom macroglobulinemia; Macroglobulinemia; Proteasome inhibitor; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Peripheral neuropathy; Lymphoma; Endocrinology; Biology","score_opus":0.1287236890803222,"score_gpt":0.4669914693417026,"score_spread":0.3382677802613804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124433242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029509878,0.98589456,0.000002390747,0.00018992549,0.001102448,0.0031433,0.00007411447,0.00034526046,0.006297034],"genre_scores_gemma":[0.00022605201,0.9806894,0.0010597402,0.0010268084,0.0026618722,0.00022641073,0.00036513477,0.0003367251,0.013407821],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98673385,0.0012084974,0.006006856,0.0025042836,0.0015889013,0.001957637],"domain_scores_gemma":[0.98918515,0.0045273453,0.0012674934,0.0032601217,0.00029886648,0.0014610442],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0029782604,0.0015076216,0.008663293,0.0007916883,0.00012508992,0.000107844775,0.0014213836,0.0037289548,0.0010702738],"category_scores_gemma":[0.006902487,0.0010818955,0.0026867841,0.0019081832,0.00083209306,0.00011817992,0.00059583137,0.0023951617,0.0032655606],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012506642,0.0012458643,0.00006389017,0.0091761,0.00032412595,0.02010521,0.000018038458,1.7751863e-7,1.6950881e-7,0.000039818795,0.015165113,0.95261085],"study_design_scores_gemma":[0.025008067,0.0017387504,0.0012014821,0.031021189,0.0012751768,0.0072903195,0.000016917375,0.00020394941,0.0000010017127,0.00005352185,0.9311824,0.0010072525],"about_ca_topic_score_codex":0.00022757932,"about_ca_topic_score_gemma":0.00012495734,"teacher_disagreement_score":0.9516036,"about_ca_system_score_codex":0.028717088,"about_ca_system_score_gemma":0.06279638,"threshold_uncertainty_score":0.99990636},"labels":[],"label_agreement":null},{"id":"W2125250265","doi":"10.1309/wb56et6agm44tm5t","title":"Cytogenetic Aberrations and Immunoglobulin<i>V</i><i><sub>H</sub></i>Gene Mutations in Clinically Benign CD5– Monoclonal B-Cell Lymphocytosis","year":2007,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Lymphocytosis; CD5; Chronic lymphocytic leukemia; Biology; Population; Immunology; Isochromosome; Gene rearrangement; Lymphocyte; Pathology; Leukemia; Lymphoma; Genetics; Karyotype; Medicine; Chromosome; Gene","score_opus":0.031537154604328904,"score_gpt":0.3805392484505524,"score_spread":0.3490020938462235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125250265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934419,0.0009053742,0.0032494464,0.0010296013,0.00038400624,0.00030373252,0.000011662997,0.000018399956,0.00065589783],"genre_scores_gemma":[0.976427,0.0029002852,0.018036053,0.0019865236,0.00054681173,0.000008438025,0.000013589618,0.00004842894,0.000032851858],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9933588,0.00072505063,0.0040096375,0.00053441804,0.00064038334,0.00073172397],"domain_scores_gemma":[0.99201983,0.0046558706,0.001448012,0.0005144689,0.00058106927,0.00078077073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0063878014,0.00028778982,0.0015592299,0.0004784249,0.000098929166,0.000024684148,0.00032957084,0.00030953702,0.00002857166],"category_scores_gemma":[0.0034169324,0.0002568323,0.00048265673,0.00077672926,0.0020372632,0.000110369634,0.0001539161,0.0012034611,0.000045484387],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012889599,0.0045078956,0.32622892,0.00009846522,0.0005856891,0.015999136,0.0014853072,0.00059732463,0.1785671,0.0001083694,0.00060916523,0.45832303],"study_design_scores_gemma":[0.07421454,0.022000322,0.8330697,0.00030756753,0.00085706275,0.024763808,0.001989215,0.001306398,0.038137756,0.0012605847,0.0012373388,0.0008557113],"about_ca_topic_score_codex":0.000073844676,"about_ca_topic_score_gemma":0.00007867366,"teacher_disagreement_score":0.50684077,"about_ca_system_score_codex":0.0013067557,"about_ca_system_score_gemma":0.0070160306,"threshold_uncertainty_score":0.9999884},"labels":[],"label_agreement":null},{"id":"W2125959523","doi":"10.1111/j.1751-553x.2007.00952.x","title":"Quantitation of cytological parameters of malignant lymphocytes using computerized image analysis","year":2007,"lang":"en","type":"article","venue":"International Journal of Laboratory Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Prolymphocytic leukemia; Chronic lymphocytic leukemia; Morphological analysis; Quantitative analysis (chemistry); Pathology; Mantle cell lymphoma; Leukemia; Digital image analysis; Image analysis; Cell; Lymphoma; Biology; Medicine; Immunology; Image processing; Chemistry; Image (mathematics); Digital image; Computer science; Artificial intelligence","score_opus":0.03519562775519723,"score_gpt":0.38349742081949817,"score_spread":0.3483017930643009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125959523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9400599,0.00040749053,0.05893927,0.00014122101,0.00030092464,0.000082980194,0.000021009491,0.0000060349294,0.00004119791],"genre_scores_gemma":[0.9500382,0.00005525055,0.04974205,0.00008822799,0.000054545042,4.8456906e-7,0.000008619012,0.000009945508,0.0000026714374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974581,0.0001050585,0.0012987813,0.00014908175,0.0007855555,0.00020344373],"domain_scores_gemma":[0.99515915,0.0006705068,0.0011428328,0.0001712469,0.002734093,0.00012219668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011493096,0.00012229555,0.00083948893,0.0010612912,0.000015498097,0.000009383474,0.00030257177,0.00013592264,0.00008071219],"category_scores_gemma":[0.0007183803,0.00009800027,0.00029446342,0.0006922016,0.0003494884,0.00013298934,0.00006814679,0.00014658725,0.000002562013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008546641,0.0011496933,0.10504245,0.00036850123,0.009872821,0.007570716,0.0006480868,0.0013651337,0.8522331,0.012103601,0.00014593992,0.00095328974],"study_design_scores_gemma":[0.02412589,0.0011234627,0.030343799,0.00057279755,0.001658371,0.007867251,0.0009659443,0.03608481,0.89624625,0.0005996967,0.00014222582,0.000269509],"about_ca_topic_score_codex":0.00007732964,"about_ca_topic_score_gemma":0.000010183072,"teacher_disagreement_score":0.07469866,"about_ca_system_score_codex":0.0016357775,"about_ca_system_score_gemma":0.0025507784,"threshold_uncertainty_score":0.45249712},"labels":[],"label_agreement":null},{"id":"W2126105762","doi":"10.1016/j.ajhg.2012.11.012","title":"Rare, Low-Frequency, and Common Variants in the Protein-Coding Sequence of Biological Candidate Genes from GWASs Contribute to Risk of Rheumatoid Arthritis","year":2012,"lang":"en","type":"article","venue":"The American Journal of Human Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"U.S. National Library of Medicine; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of General Medical Sciences; Vetenskapsrådet; National Institutes of Health; Versus Arthritis; European Commission","keywords":"Genetics; Genotyping; Nonsynonymous substitution; Gene; Biology; Genetic association; Haplotype; Locus (genetics); Genome-wide association study; Minor allele frequency; Allele frequency; Missense mutation; Exon; Allele; Candidate gene; Single-nucleotide polymorphism; Genotype; Genome; Mutation","score_opus":0.03134227535539375,"score_gpt":0.3150845026400234,"score_spread":0.28374222728462967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126105762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924668,0.006623815,0.00013591531,0.00022611917,0.000032856467,0.00040276605,0.00008153708,0.0000027576818,0.000027402353],"genre_scores_gemma":[0.99079746,0.007850951,0.001099316,0.00011885338,0.00010741815,0.0000069818207,0.000003905764,0.00001324591,0.0000018954945],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977356,0.00060446956,0.00071255973,0.00011824221,0.00047117376,0.00035795465],"domain_scores_gemma":[0.9979997,0.00045542116,0.0007923694,0.00040536874,0.00018083777,0.00016624668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017254777,0.0001431743,0.0006742424,0.00011219126,0.00008029724,0.000015457072,0.00044705794,0.000040158062,0.00002185507],"category_scores_gemma":[0.00028563902,0.000078625984,0.00008099357,0.0002754377,0.0008007802,0.000043202333,0.00012666252,0.00033534775,0.0000014987756],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010007313,0.00028662308,0.3274448,0.000052600695,0.000336561,0.00019509226,0.006521022,0.00007906137,0.63452464,0.00025128582,0.00007517285,0.029232409],"study_design_scores_gemma":[0.016847085,0.008410838,0.76961935,0.0025967776,0.00018365942,0.0026906547,0.00560801,0.0006687636,0.18933938,0.0033848316,0.00017732284,0.00047333646],"about_ca_topic_score_codex":0.0029938773,"about_ca_topic_score_gemma":0.00014175405,"teacher_disagreement_score":0.44518527,"about_ca_system_score_codex":0.00045582428,"about_ca_system_score_gemma":0.00059390947,"threshold_uncertainty_score":0.45258668},"labels":[],"label_agreement":null},{"id":"W2127611395","doi":"10.3389/fimmu.2014.00557","title":"PI3K Signaling in B Cell and T Cell Biology","year":2014,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Biotechnology and Biological Sciences Research Council; Wellcome Trust","keywords":"Cell biology; PI3K/AKT/mTOR pathway; Cell; Biology; Immunology; Signal transduction; Genetics","score_opus":0.009095408902121859,"score_gpt":0.2526857713643178,"score_spread":0.24359036246219595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127611395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814156,0.0070701255,0.001779907,0.00023470134,0.0005665637,0.0002628118,0.0000012288665,0.000025149253,0.008643903],"genre_scores_gemma":[0.9927493,0.0005924094,0.0055733556,0.00019749817,0.00005763893,0.000023895058,0.00001276539,0.000021723481,0.0007714147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985242,0.00020662056,0.00030102592,0.0003543494,0.00007717475,0.0005366108],"domain_scores_gemma":[0.99938434,0.00016397894,0.00005127816,0.00031435105,0.000026388434,0.00005963131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046817228,0.00013952883,0.0004458991,0.00047068068,0.00002707541,0.0000064892133,0.00015244323,0.00029955132,0.000050577335],"category_scores_gemma":[0.00015671158,0.00013208487,0.00003390898,0.00024630188,0.0003339856,0.000036121757,0.00012978772,0.0004478107,0.000029908413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028520199,0.00090232235,0.36354798,0.0008273134,0.0001636813,0.0005536859,0.0040379576,0.00022263141,0.5298652,0.0014213517,0.008072222,0.08753361],"study_design_scores_gemma":[0.2456314,0.0065148603,0.048201602,0.0006651195,0.00016985845,0.00063939655,0.00626621,0.11970335,0.33977395,0.020415094,0.2099723,0.0020468591],"about_ca_topic_score_codex":0.0005875215,"about_ca_topic_score_gemma":0.00002717813,"teacher_disagreement_score":0.3153464,"about_ca_system_score_codex":0.0021903566,"about_ca_system_score_gemma":0.0007289163,"threshold_uncertainty_score":0.57277066},"labels":[],"label_agreement":null},{"id":"W2129141528","doi":"10.1016/j.ccell.2015.02.003","title":"Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia","year":2015,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; Cancer Research UK; Wellcome Trust; Howard Hughes Medical Institute","keywords":"breakpoint cluster region; Cancer research; Biology; BCL6; Tyrosine kinase; Signal transduction; Leukemia; Kinase; Receptor; Cell biology; Immunology; B cell; Genetics; Antibody","score_opus":0.02639569403894095,"score_gpt":0.28850698599495916,"score_spread":0.26211129195601823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129141528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306065,0.0012087533,0.00054400583,0.00005456896,0.00014388266,0.0005265103,0.000034412442,0.0000769958,0.004350197],"genre_scores_gemma":[0.99588907,0.00030151772,0.001534303,0.00004457887,0.0004330651,0.000043087937,0.00006617878,0.00005740873,0.0016307918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981802,0.000052924497,0.0004084431,0.00040083064,0.00052580744,0.00043177462],"domain_scores_gemma":[0.9984481,0.00028973792,0.00023248741,0.00033491955,0.00032467028,0.00037009543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003011076,0.00024084919,0.00047201742,0.000091259746,0.00006481313,0.000029014205,0.00015026165,0.00016965863,0.00012641949],"category_scores_gemma":[0.0000975992,0.0002118654,0.00007237866,0.00030756101,0.000111291156,0.00018680886,0.00012962102,0.00018355533,0.000030832667],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007959591,0.0006392937,0.16011666,0.017403176,0.0017485153,0.00011853431,0.020915482,0.0020154747,0.7547245,0.00010136389,0.018662635,0.015594775],"study_design_scores_gemma":[0.027567403,0.0008720286,0.004510634,0.00081682147,0.0009468207,0.00002655717,0.0005675424,0.014655825,0.94458234,0.00007056808,0.00485892,0.0005245667],"about_ca_topic_score_codex":0.002787292,"about_ca_topic_score_gemma":0.000027584509,"teacher_disagreement_score":0.18985781,"about_ca_system_score_codex":0.01480784,"about_ca_system_score_gemma":0.009157417,"threshold_uncertainty_score":0.9964597},"labels":[],"label_agreement":null},{"id":"W2129783860","doi":"10.1182/blood-2008-04-150854","title":"Thalidomide and rituximab in Waldenstrom macroglobulinemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Thalidomide; Medicine; Rituximab; Internal medicine; Gastroenterology; Waldenstrom macroglobulinemia; Macroglobulinemia; Population; Adverse effect; Immunology; Surgery; Multiple myeloma; Lymphoma","score_opus":0.019476463062325502,"score_gpt":0.26903342529079416,"score_spread":0.24955696222846865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129783860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331945,0.0012771128,0.0000043492805,0.00037468862,0.000028359516,0.00024723858,0.0000040528666,0.000042569773,0.0047021843],"genre_scores_gemma":[0.99686176,0.00044847996,0.0012865948,0.00017321082,0.00013344317,0.000016167704,0.000007986954,0.000019362386,0.001052975],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988837,0.000026912305,0.0002012451,0.00026080498,0.00028689246,0.0003403931],"domain_scores_gemma":[0.9994227,0.0000794817,0.000023572822,0.0002755969,0.000036831174,0.00016176298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013743347,0.000113179995,0.00027716014,0.00009962233,0.000044005137,0.000008294868,0.000072982395,0.00009376474,0.000074541866],"category_scores_gemma":[0.00014995708,0.00009866021,0.000040577648,0.00017552523,0.00015918177,0.00004243476,0.000083394254,0.0002105602,0.0000983015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042402404,0.035111476,0.70065266,0.002258544,0.0010178859,0.13927636,0.0075774854,0.000014261828,0.060625263,0.00158211,0.020142145,0.027501568],"study_design_scores_gemma":[0.7486917,0.00060074637,0.13107638,0.00045246177,0.00022831869,0.05153644,0.0002696922,0.0025305343,0.056933142,0.00037066452,0.006713654,0.00059626775],"about_ca_topic_score_codex":0.0005887764,"about_ca_topic_score_gemma":0.000049782793,"teacher_disagreement_score":0.74445146,"about_ca_system_score_codex":0.00083727035,"about_ca_system_score_gemma":0.0015436335,"threshold_uncertainty_score":0.40232465},"labels":[],"label_agreement":null},{"id":"W2130193156","doi":"10.1309/0yyf-17gf-kfjf-np5g","title":"Molecular Characterization of Chronic Lymphocytic Leukemia With Two Distinct Cell Populations: Evidence for Separate Clonal Origins","year":2006,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Biology; clone (Java method); CD5; Immunophenotyping; Chronic lymphocytic leukemia; Molecular biology; Population; Fluorescence in situ hybridization; Polymerase chain reaction; Gene rearrangement; Lymphocytosis; Immunoglobulin heavy chain; Genetics; Flow cytometry; Gene; Leukemia; Immunology; Chromosome","score_opus":0.06941184924223447,"score_gpt":0.43284201102581243,"score_spread":0.36343016178357795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130193156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96650827,0.00030854958,0.032195725,0.00022613035,0.00022607084,0.0004021048,0.000014840105,0.000013651748,0.00010468211],"genre_scores_gemma":[0.9926117,0.000132213,0.006060999,0.00022308773,0.0007638457,0.000016618007,0.000042588,0.00004054661,0.00010839071],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964776,0.00038016873,0.0018600299,0.00033816215,0.0005352261,0.00040883705],"domain_scores_gemma":[0.99545145,0.0012001662,0.0019680923,0.000390672,0.00076544436,0.00022418378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014351433,0.00020788155,0.0011931049,0.0001908112,0.000049380837,0.000012443326,0.00024780116,0.00010258959,0.000029314278],"category_scores_gemma":[0.0008983108,0.00015524335,0.0003604638,0.00043344966,0.0010399369,0.00014157695,0.00004473645,0.00036569295,0.0000090283],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.059069835,0.0025874248,0.2674835,0.0019842526,0.0010620655,0.011672562,0.0003754438,0.034581352,0.49500355,0.0058327885,0.0008028655,0.11954438],"study_design_scores_gemma":[0.15260316,0.077594824,0.5328053,0.003200163,0.0032008388,0.017726492,0.00015455902,0.16042905,0.04378274,0.0018595773,0.0052462,0.0013970839],"about_ca_topic_score_codex":0.00033610564,"about_ca_topic_score_gemma":0.000033807468,"teacher_disagreement_score":0.4512208,"about_ca_system_score_codex":0.010771238,"about_ca_system_score_gemma":0.025720386,"threshold_uncertainty_score":0.99302626},"labels":[],"label_agreement":null},{"id":"W2130303066","doi":"10.1016/j.cancergen.2011.03.004","title":"Molecular characterization of a t(2;7) translocation linking CDK6 to the IGK locus in CD5− monoclonal B-cell lymphocytosis","year":2011,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation; Mount Sinai Hospital","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Recombination signal sequences; Splenic marginal zone lymphoma; CD5; Lymphocytosis; Biology; Breakpoint; Gene rearrangement; Molecular biology; Genetics; Population; breakpoint cluster region; Locus (genetics); B cell; Gene; Antibody; T-cell receptor; Chromosomal translocation; T cell; Immunology; Medicine; Immune system","score_opus":0.037289165780583874,"score_gpt":0.2901464579943685,"score_spread":0.2528572922137846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130303066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922062,0.0015345721,0.0047395327,0.00029394604,0.00011234118,0.0006407781,0.000014238925,0.0000130626,0.00044529574],"genre_scores_gemma":[0.9969648,0.0014968126,0.00071509223,0.0004483339,0.00010050317,0.000129938,0.000024152374,0.00003250207,0.000087841225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876016,0.000047655176,0.00032561607,0.0002420888,0.00035643208,0.00026803795],"domain_scores_gemma":[0.9992438,0.000020936382,0.00007628185,0.00039003402,0.00016379004,0.00010514581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018583043,0.00012467962,0.00021076448,0.00013234616,0.000026743997,0.000008418411,0.00019959286,0.00009812961,0.00007525462],"category_scores_gemma":[0.000017477194,0.00010280933,0.000056998088,0.00048133268,0.000058700436,0.000025801526,0.000046079345,0.00010719345,0.00001626962],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054136745,0.00022202978,0.005160857,0.00037856266,0.000063473075,0.000056163437,0.010137007,0.0015447622,0.9048527,0.00006433489,0.000030038207,0.07694873],"study_design_scores_gemma":[0.004932347,0.00017153661,0.010258351,0.00024665674,0.00005879751,0.00001627,0.00007857871,0.018857194,0.9640457,0.000028164746,0.001177115,0.00012925529],"about_ca_topic_score_codex":0.0009815813,"about_ca_topic_score_gemma":0.00021012478,"teacher_disagreement_score":0.07681948,"about_ca_system_score_codex":0.0032067236,"about_ca_system_score_gemma":0.0031349498,"threshold_uncertainty_score":0.83854705},"labels":[],"label_agreement":null},{"id":"W2130979463","doi":"10.1038/ng.479","title":"Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk","year":2009,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto","funders":"National Center for Research Resources; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Human Genome Research Institute; National Institute for Health and Care Research; Canadian Institutes of Health Research; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Versus Arthritis; National Heart, Lung, and Blood Institute","keywords":"Single-nucleotide polymorphism; Genome-wide association study; Biology; Genetics; Rheumatoid arthritis; Genetic association; Replication (statistics); Arthritis; Gene; Bioinformatics; Genotype; Immunology; Virology","score_opus":0.007128330863492305,"score_gpt":0.25385256817739704,"score_spread":0.24672423731390475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130979463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633642,0.034156494,0.000039053815,0.00041997977,0.00012589598,0.000623015,0.000060137332,0.00009967488,0.0011115855],"genre_scores_gemma":[0.97822016,0.017869344,0.0020971461,0.00074844994,0.00017674932,0.000011185103,0.00004349544,0.000057568464,0.00077591557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997334,0.0001043179,0.00033326342,0.00060883857,0.00093686144,0.000682718],"domain_scores_gemma":[0.99827933,0.00014934817,0.00020838469,0.00064977485,0.0003093312,0.00040385412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026021185,0.0003235117,0.00050943973,0.00013386094,0.00020386977,0.000055381737,0.00018023934,0.00071626593,0.00008969334],"category_scores_gemma":[0.000616129,0.00026618905,0.00006922096,0.00042200743,0.00017183759,0.000035885645,0.00010930831,0.0010035313,0.00003790477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036408675,0.0018341979,0.6852694,0.00041806774,0.002078772,0.013782036,0.0025034212,0.0008509198,0.004530741,0.00013735841,0.058846638,0.22610754],"study_design_scores_gemma":[0.024836835,0.0013279648,0.9540443,0.00078419695,0.000136277,0.0028058027,0.000052587744,0.006461097,0.0025828008,0.00034015454,0.006131479,0.00049652404],"about_ca_topic_score_codex":0.000034111297,"about_ca_topic_score_gemma":0.00034479512,"teacher_disagreement_score":0.26877484,"about_ca_system_score_codex":0.0030697521,"about_ca_system_score_gemma":0.0015330273,"threshold_uncertainty_score":0.999979},"labels":[],"label_agreement":null},{"id":"W2131325565","doi":"10.1093/jnci/dji120","title":"RESPONSE: Re: Prognostic Significance of a Short Sequence Insertion in the MCL-1 Promoter in Chronic Lymphocytic Leukemia","year":2005,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Sequence (biology); Cancer research; Medicine; Genetics; Biology; Leukemia; Molecular biology","score_opus":0.09173732024769209,"score_gpt":0.3889809745690293,"score_spread":0.2972436543213372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131325565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919725,0.0010823854,0.000032695087,0.0054200436,0.0003036345,0.0008093337,0.000013745656,0.0000056651074,0.00036001424],"genre_scores_gemma":[0.9975887,0.00021620713,0.00026370672,0.0009684999,0.0006572671,0.000085676795,0.000002317716,0.000015134189,0.00020248909],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99632096,0.00031635055,0.00090680644,0.00020302119,0.0019358792,0.00031696746],"domain_scores_gemma":[0.9982891,0.00041186606,0.0003353415,0.00025042906,0.0006404692,0.00007276055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030281493,0.00016310952,0.00033509775,0.00035475573,0.00006676768,0.000023515007,0.0006297008,0.00011684148,0.000041608215],"category_scores_gemma":[0.0020329237,0.00009744678,0.00014747723,0.0010755693,0.0003452439,0.00042074415,0.00006569028,0.00063263526,0.000005390694],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018834848,0.00054391305,0.016457653,0.001245523,0.00038636028,0.00072350976,0.006472057,0.57943547,0.3460529,0.0011499063,0.008368165,0.020329656],"study_design_scores_gemma":[0.06701593,0.002491326,0.44189128,0.01283124,0.00043329972,0.008287721,0.00047232475,0.24619193,0.13620465,0.0022614272,0.08089797,0.0010209021],"about_ca_topic_score_codex":0.0006585446,"about_ca_topic_score_gemma":0.0018759582,"teacher_disagreement_score":0.42543364,"about_ca_system_score_codex":0.1591851,"about_ca_system_score_gemma":0.0998996,"threshold_uncertainty_score":0.90520316},"labels":[],"label_agreement":null},{"id":"W2133983117","doi":"10.1080/10428190290016935","title":"Bcl-3/IgH translocation (14;19)(q32;q13) in Non-Hodgkin's Lymphomas","year":2002,"lang":"zh","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Chromosomal translocation; Lymphoma; Chronic lymphocytic leukemia; Medicine; Pathology; Abnormality; Non-Hodgkin's lymphoma; Leukemia; Internal medicine; Biology; Gene","score_opus":0.02022337419519823,"score_gpt":0.26642772729422054,"score_spread":0.2462043530990223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133983117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85753906,0.05406221,0.00036046546,0.0016002055,0.002950189,0.0047947173,0.00026049672,0.0008007099,0.077631935],"genre_scores_gemma":[0.9298369,0.042036794,0.000796717,0.0035441085,0.0026861003,0.0008247938,0.00040243068,0.0008558714,0.019016242],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.97735244,0.0012431799,0.004944363,0.0054358956,0.0045027556,0.0065213568],"domain_scores_gemma":[0.9869985,0.0021994254,0.0013193215,0.004650984,0.00082260557,0.004009158],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","insufficient_payload"],"category_scores_codex":[0.002974998,0.0037866137,0.0047588353,0.002990881,0.0014095167,0.0009793319,0.0026020806,0.0039982633,0.0029678065],"category_scores_gemma":[0.0014226453,0.0039435946,0.0013694523,0.0052988017,0.002736643,0.001793217,0.0010948506,0.0012974638,0.0037575294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0053910483,0.004008372,0.007457085,0.0059856903,0.002056206,0.013165518,0.022474324,0.0013759988,0.0047898805,0.0065912013,0.056911062,0.8697936],"study_design_scores_gemma":[0.35685706,0.0031435778,0.067116916,0.007791039,0.001865729,0.013612034,0.004747712,0.4209422,0.005634737,0.0026148204,0.107890375,0.007783799],"about_ca_topic_score_codex":0.03076584,"about_ca_topic_score_gemma":0.0016667522,"teacher_disagreement_score":0.8620098,"about_ca_system_score_codex":0.22488835,"about_ca_system_score_gemma":0.04175525,"threshold_uncertainty_score":0.99997735},"labels":[],"label_agreement":null},{"id":"W2134103116","doi":"10.1200/jco.2010.29.8133","title":"Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Institute on Aging; Celgene; Genentech; Amgen","keywords":"Lenalidomide; Medicine; Neutropenia; Chronic lymphocytic leukemia; Regimen; Internal medicine; Multiple myeloma; Tumor lysis syndrome; Oncology; Rituximab; Gastroenterology; Chemotherapy; Leukemia; Lymphoma","score_opus":0.13373254987909994,"score_gpt":0.4623345683900938,"score_spread":0.32860201851099385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134103116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926021,0.0014922585,0.000013752037,0.0015151107,0.00091418106,0.0005879108,0.0000018237087,0.000008479626,0.0028643522],"genre_scores_gemma":[0.9936705,0.0030497413,0.0006794076,0.000508329,0.0016264736,0.000013616517,0.000003228319,0.00002480934,0.00042386536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945126,0.0007745187,0.0032003983,0.00025782434,0.0007516859,0.0005029295],"domain_scores_gemma":[0.9916365,0.005438142,0.0015331943,0.00059428095,0.00042278023,0.00037511712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045711696,0.00021988993,0.0019054085,0.00023521326,0.00003431514,0.0000130997005,0.00043847377,0.00054853596,0.00027564255],"category_scores_gemma":[0.0038098472,0.00011769413,0.0007571998,0.00035729245,0.000612765,0.00007908607,0.0000422497,0.0010009778,0.000041643827],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03167019,0.013706716,0.020422857,0.00048343986,0.0024227654,0.018996065,0.0038747317,0.0012653037,0.026205294,0.0005624973,0.0074284696,0.87296164],"study_design_scores_gemma":[0.3493485,0.19178708,0.039154433,0.00071528915,0.0021428803,0.0149018,0.00061262166,0.013407159,0.012065407,0.0006816466,0.37474298,0.0004402114],"about_ca_topic_score_codex":0.00082271826,"about_ca_topic_score_gemma":0.0012783926,"teacher_disagreement_score":0.87252146,"about_ca_system_score_codex":0.06082598,"about_ca_system_score_gemma":0.09971304,"threshold_uncertainty_score":0.94277936},"labels":[],"label_agreement":null},{"id":"W2134184719","doi":"10.1158/1055-9965.1065.13.6","title":"The <i>P2X7</i> Receptor Gene A1513C Polymorphism Does Not Contribute to Risk of Familial or Sporadic Chronic Lymphocytic Leukemia","year":2004,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Chronic lymphocytic leukemia; Odds ratio; Allele; Genotyping; Confidence interval; Genotype; Leukemia; Internal medicine; Allele frequency; Immunology; Oncology; Genetics; Biology; Medicine; Gene","score_opus":0.03461615817841759,"score_gpt":0.35201851819867397,"score_spread":0.3174023600202564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134184719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649102,0.01948065,0.0040652594,0.0061177965,0.002263046,0.0026726325,0.00027024085,0.00014795581,0.00007222227],"genre_scores_gemma":[0.96465856,0.02491947,0.002977473,0.0014702536,0.0013372392,0.00072666764,0.00019845273,0.000100156605,0.003611742],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944686,0.0010252966,0.0016405071,0.0009956158,0.00051579095,0.0013541499],"domain_scores_gemma":[0.9951079,0.0019622091,0.0008735468,0.001180689,0.0003128463,0.0005628215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0049321996,0.0004792336,0.0012631526,0.00024892666,0.00038873797,0.000014704781,0.00057576573,0.0005333221,0.00027169706],"category_scores_gemma":[0.0037917912,0.00028522126,0.0005561166,0.00067540933,0.0010796854,0.00012841118,0.00023122842,0.0004383479,0.00015596258],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10406866,0.000549613,0.03565275,0.002428515,0.016237259,0.0005071604,0.0013146801,0.014141442,0.36399388,0.0031681135,0.08362645,0.37431148],"study_design_scores_gemma":[0.22840367,0.010854241,0.07861622,0.007238754,0.0056108255,0.0011405838,0.0007372792,0.020255717,0.51669323,0.025774615,0.101450235,0.0032245948],"about_ca_topic_score_codex":0.014943804,"about_ca_topic_score_gemma":0.0026264742,"teacher_disagreement_score":0.37108687,"about_ca_system_score_codex":0.10631981,"about_ca_system_score_gemma":0.04180511,"threshold_uncertainty_score":0.99996},"labels":[],"label_agreement":null},{"id":"W2134390751","doi":"10.1016/j.leukres.2014.07.008","title":"CLL—Clear sailing ahead for many, while rough waters remain for some","year":2014,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Environmental science","score_opus":0.1405077939171797,"score_gpt":0.4000109766601689,"score_spread":0.25950318274298917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134390751","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014637855,0.0019211575,0.002980692,0.9428279,0.0018600062,0.0238497,0.00066524924,0.00074930204,0.010508166],"genre_scores_gemma":[0.014562856,0.0010881462,0.013634627,0.51975924,0.07332631,0.011354332,0.009364318,0.0025162057,0.354394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98581034,0.00078564446,0.0014003599,0.0025811933,0.004264443,0.005158009],"domain_scores_gemma":[0.9872551,0.0068156985,0.0002630052,0.0031712092,0.0017753829,0.0007196179],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.008195929,0.0010133651,0.0020600192,0.0015787627,0.0008968329,0.00042514765,0.0019002482,0.0028241547,0.00029052963],"category_scores_gemma":[0.00341542,0.0008953518,0.0011141995,0.00080152135,0.001022757,0.000287804,0.0007898997,0.0075299866,0.0012538236],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025447274,0.000060860395,0.000005686923,0.0095712,0.00041524947,0.0010352896,0.00023474557,0.000054887016,0.0007069139,0.0006834888,0.98109967,0.00358729],"study_design_scores_gemma":[0.023756161,0.002045016,0.0000040089494,0.001489274,0.00018808196,0.0004477844,0.00011126883,0.033720136,0.003494435,0.0032510725,0.93065625,0.0008365348],"about_ca_topic_score_codex":0.0013384299,"about_ca_topic_score_gemma":0.00002388899,"teacher_disagreement_score":0.42306864,"about_ca_system_score_codex":0.0849542,"about_ca_system_score_gemma":0.02944412,"threshold_uncertainty_score":0.9995238},"labels":[],"label_agreement":null},{"id":"W2135979078","doi":"10.1345/aph.1c287","title":"Autoimmune Thrombocytopenia Due to Chronic Lymphocytic Leukemia Treated with Fludarabine","year":2003,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Fludarabine; Medicine; Chronic lymphocytic leukemia; Chlorambucil; Autoimmune thrombocytopenia; Refractory (planetary science); Splenectomy; Internal medicine; Gastroenterology; Immunology; Leukemia; Platelet; Chemotherapy; Cyclophosphamide; Spleen","score_opus":0.05210069877464194,"score_gpt":0.3727207306036841,"score_spread":0.32062003182904214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135979078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842789,0.0046766805,0.00022168279,0.0006948976,0.000088485336,0.0014417137,0.000018198622,0.00016928802,0.008410155],"genre_scores_gemma":[0.9893104,0.0019489082,0.0006583184,0.003257825,0.0001515195,0.00011331802,0.000021147456,0.0001347078,0.004403871],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99679065,0.00016776385,0.00059741706,0.0005986939,0.00090625684,0.000939194],"domain_scores_gemma":[0.99789876,0.00013603215,0.00016320162,0.0008380511,0.0004633106,0.00050062],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006375768,0.00043679745,0.0010243455,0.00034434508,0.00012045897,0.00003501735,0.00037046205,0.00013568091,0.0028057299],"category_scores_gemma":[0.0000700042,0.0003362109,0.00020709784,0.0011149895,0.00023691719,0.00016593818,0.000041060488,0.00025829277,0.00029069284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004217317,0.00024356802,0.00022529707,0.0003975896,0.0011465151,0.00088453054,0.0005208576,0.0016522874,0.95890105,0.0007646081,0.017349873,0.013696513],"study_design_scores_gemma":[0.033424363,0.0023653626,0.00094562065,0.00032486458,0.00009663839,0.00075302465,0.000034827975,0.0035253193,0.8908406,0.000043084205,0.067273185,0.0003730904],"about_ca_topic_score_codex":0.0010226758,"about_ca_topic_score_gemma":0.000023715373,"teacher_disagreement_score":0.06806043,"about_ca_system_score_codex":0.016738147,"about_ca_system_score_gemma":0.024452234,"threshold_uncertainty_score":0.999909},"labels":[],"label_agreement":null},{"id":"W2136242714","doi":"10.1200/jco.2005.05.0401","title":"Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Fludarabine; Chronic lymphocytic leukemia; Refractory (planetary science); Rituximab; Gastroenterology; Adverse effect; Phases of clinical research; Progressive disease; Oncology; Surgery; Clinical trial; Leukemia; Multiple myeloma; Toxicity; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.08788936020811099,"score_gpt":0.4740014396404239,"score_spread":0.3861120794323129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136242714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683726,0.000282214,0.000016076197,0.00019955999,0.00058768934,0.0011565504,0.000013792556,0.000011532239,0.00089530693],"genre_scores_gemma":[0.9970623,0.00024184767,0.00095001835,0.00013777957,0.0010332648,0.000005836869,0.000012003075,0.000047483623,0.00050943706],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98488015,0.0018514546,0.010536575,0.00054378656,0.0016079549,0.00058006815],"domain_scores_gemma":[0.9785803,0.012732493,0.0059758457,0.00083021476,0.0013975055,0.00048364443],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012255038,0.00031622665,0.004192993,0.0005054991,0.00004540148,0.000005639384,0.00054025726,0.00080669543,0.00009619612],"category_scores_gemma":[0.020786814,0.00019437842,0.00070855615,0.0007089235,0.0010305744,0.0001742188,0.00023192736,0.002076835,0.00000916746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6936935,0.07128906,0.1234734,0.0003084982,0.0015275382,0.0047823857,0.00036317887,0.0011345446,0.00012901514,0.00001718336,0.0064390576,0.096842594],"study_design_scores_gemma":[0.514143,0.25493526,0.22547631,0.00060459605,0.0005839709,0.00010961775,0.00010092798,0.00081130245,0.00007255774,0.000018738832,0.0030046473,0.00013907178],"about_ca_topic_score_codex":0.0010074932,"about_ca_topic_score_gemma":0.00071637554,"teacher_disagreement_score":0.1836462,"about_ca_system_score_codex":0.032732297,"about_ca_system_score_gemma":0.13954276,"threshold_uncertainty_score":0.9874615},"labels":[],"label_agreement":null},{"id":"W2136479118","doi":"","title":"Nadchodzi era spersonalizowanej onkologii","year":2009,"lang":"pl","type":"article","venue":"Via Medica Journals","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.04198404041298423,"score_gpt":0.36872211787666836,"score_spread":0.3267380774636841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136479118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38166755,0.25281325,0.003944698,0.22519544,0.009378025,0.0037241615,0.00010146314,0.00062605855,0.122549355],"genre_scores_gemma":[0.9371578,0.019715674,0.0009878402,0.014634099,0.008525928,0.000014576273,0.000033686953,0.00011214401,0.018818254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98920864,0.0007037903,0.0018259495,0.0010608975,0.004598486,0.0026022296],"domain_scores_gemma":[0.9933676,0.0009808539,0.00064744614,0.0013808553,0.00058883516,0.003034379],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004669015,0.0008164156,0.0016937897,0.00081990607,0.00048261305,0.00022244314,0.0012386146,0.0009901585,0.03765023],"category_scores_gemma":[0.003802059,0.00065952295,0.0006656162,0.0013124605,0.00075290306,0.0003317936,0.00020418786,0.0035899233,0.0052949237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016558877,0.0019292642,0.00086142705,0.0005925511,0.0016040616,0.02695661,0.0039352174,0.000020905296,0.014859183,0.00072140206,0.40679207,0.5400714],"study_design_scores_gemma":[0.14221697,0.012626757,0.03391793,0.016272698,0.0032294958,0.06290926,0.0025991877,0.028040275,0.013283871,0.011063404,0.66991806,0.003922085],"about_ca_topic_score_codex":0.0005015476,"about_ca_topic_score_gemma":0.000021608117,"teacher_disagreement_score":0.55549026,"about_ca_system_score_codex":0.016656497,"about_ca_system_score_gemma":0.022452563,"threshold_uncertainty_score":0.9995856},"labels":[],"label_agreement":null},{"id":"W2136776510","doi":"10.1177/0192623307310952","title":"Pharmacodynamic Monitoring of Molecular-Targeted Agents in the Peripheral Blood of Leukemia Patients Using Flow Cytometry","year":2008,"lang":"en","type":"review","venue":"Toxicologic Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Pharmacodynamics; Flow cytometry; Medicine; Leukemia; Pharmacology; Drug; Clinical trial; Pharmacokinetics; Oncology; Immunology; Internal medicine","score_opus":0.09935200430279573,"score_gpt":0.4097331235685713,"score_spread":0.31038111926577555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136776510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4818354,0.5164771,0.000017068684,0.000001941093,0.00023581133,0.0011865419,0.000044824217,0.000016694277,0.00018462108],"genre_scores_gemma":[0.16462964,0.8334875,0.0014240331,0.00004428957,0.00009903088,0.000112846195,0.00010871881,0.000064182765,0.000029762594],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952128,0.0011994957,0.0014034224,0.00064295507,0.00076732965,0.0007739917],"domain_scores_gemma":[0.9977158,0.0004176208,0.00075557304,0.00080926454,0.00018616949,0.00011557497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006337703,0.0005457778,0.0027281544,0.000740831,0.00005701519,0.000005619637,0.00077411486,0.0007465302,0.000088563014],"category_scores_gemma":[0.0006719306,0.00037546956,0.0006307812,0.0013335784,0.0004966239,0.000044141063,0.0003203492,0.0011035948,0.000008607534],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00068243535,0.007783607,0.013896758,0.06263449,0.002608572,0.05178248,0.0023487655,0.0013500142,0.015266754,0.000024125104,0.000196921,0.84142506],"study_design_scores_gemma":[0.37997213,0.039854478,0.05358373,0.12727942,0.043499816,0.15662877,0.0021340984,0.06335424,0.02627566,0.0003042419,0.09386995,0.013243456],"about_ca_topic_score_codex":0.000056120203,"about_ca_topic_score_gemma":0.0000011308365,"teacher_disagreement_score":0.8281816,"about_ca_system_score_codex":0.008923439,"about_ca_system_score_gemma":0.0063108318,"threshold_uncertainty_score":0.9998697},"labels":[],"label_agreement":null},{"id":"W2136985358","doi":"10.1093/jncimonographs/lgu004","title":"Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project","year":2014,"lang":"en","type":"article","venue":"JNCI Monographs","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Cancer Institute; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Michael Smith Health Research BC; University of California, San Francisco; National Institutes of Health; Yale University; Institut Bergonié; Institut de Veille Sanitaire; Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail; American Association for Cancer Research; Bundesamt für Strahlenschutz; José Carreras Leukämie-Stiftung; Agència de Gestió d'Ajuts Universitaris i de Recerca; Institut National Du Cancer; Università degli Studi di Cagliari; Institut National de la Santé et de la Recherche Médicale; European Commission; Ministero dell’Istruzione, dell’Università e della Ricerca; Alleanza Contro il Cancro; Région Normandie; Université de Bourgogne; Health Research Board; Fondation de France; Generalitat de Catalunya; Bundesministerium für Bildung und Forschung; University of Rochester","keywords":"Medicine; Odds ratio; Quartile; Confidence interval; Demography; Logistic regression; Internal medicine; Multivariate analysis; Etiology; Leukemia; Case-control study; Epidemiology","score_opus":0.021008937389523665,"score_gpt":0.2892514709256415,"score_spread":0.2682425335361179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136985358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927122,0.0009136693,0.0021279738,0.00021387257,0.00052050047,0.0012234648,0.000038685073,0.00011264591,0.0021369813],"genre_scores_gemma":[0.9962516,0.00034597353,0.0009617649,0.0005625901,0.0005166161,0.0002576688,0.000102417274,0.00006725294,0.00093410903],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713695,0.00018401892,0.0004891443,0.00058809266,0.0009875483,0.00061426836],"domain_scores_gemma":[0.9971307,0.0014474886,0.00020484485,0.0006440025,0.00019498424,0.00037798443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012967071,0.00033890727,0.00047487544,0.00034519605,0.00023269518,0.000042942618,0.00038418503,0.00036438167,0.00009735666],"category_scores_gemma":[0.0013186266,0.00021975616,0.00030186487,0.00029990534,0.00062896375,0.000117184114,0.00015699166,0.00031506806,0.000022236982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004492306,0.0012098319,0.41889873,0.0018416821,0.0010829933,0.00012551161,0.013041181,0.000028489501,0.0004972687,0.0012796028,0.4485022,0.1090002],"study_design_scores_gemma":[0.059968278,0.0034275223,0.29312044,0.00043105814,0.0007594753,0.00045221433,0.0018911937,0.24122347,0.0024425106,0.00048412764,0.3946135,0.0011862036],"about_ca_topic_score_codex":0.0038888818,"about_ca_topic_score_gemma":0.00028917764,"teacher_disagreement_score":0.24119498,"about_ca_system_score_codex":0.0062655164,"about_ca_system_score_gemma":0.009788526,"threshold_uncertainty_score":0.99754924},"labels":[],"label_agreement":null},{"id":"W2138255741","doi":"10.1158/1078-0432.ccr-08-3041","title":"Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Bendamustine; Medicine; Block (permutation group theory); Oncology; Internal medicine; Lymphoma; Rituximab","score_opus":0.20114278304669014,"score_gpt":0.4986546305078373,"score_spread":0.29751184746114717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138255741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83027023,0.001409497,0.0000024454798,0.13831387,0.00024109185,0.0017630395,0.000010244816,0.000047863658,0.027941732],"genre_scores_gemma":[0.9470678,0.0021924868,0.00004218661,0.00702468,0.00183979,0.00010778671,0.0000044288076,0.000039735114,0.041681107],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939932,0.00087200507,0.00082186016,0.00074610225,0.0022523205,0.0013144597],"domain_scores_gemma":[0.9915162,0.0058231587,0.00008214931,0.0016254591,0.00038832214,0.0005647433],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.008201926,0.00022761404,0.0004956721,0.00019162367,0.0002563566,0.00009365814,0.0010798579,0.0002750055,0.0017111384],"category_scores_gemma":[0.005608089,0.00011743276,0.00024216634,0.0015163447,0.00081943424,0.000049973823,0.0003111755,0.0032579384,0.0008979446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005674501,0.0016003656,0.0047561144,0.00015828335,0.000088796354,0.0006814996,0.00086230965,0.0001289515,0.0013461848,0.0060003437,0.9369992,0.041703425],"study_design_scores_gemma":[0.087628104,0.012063085,0.09025151,0.0028197956,0.0001392452,0.000141247,0.002489113,0.01011635,0.013441437,0.00811936,0.7717764,0.0010143416],"about_ca_topic_score_codex":0.0029281636,"about_ca_topic_score_gemma":0.00046639275,"teacher_disagreement_score":0.16522282,"about_ca_system_score_codex":0.0048870975,"about_ca_system_score_gemma":0.014121277,"threshold_uncertainty_score":0.99987996},"labels":[],"label_agreement":null},{"id":"W2138275899","doi":"10.1016/s0165-4608(00)00239-9","title":"Unusual Breakpoint Distribution of 8p Abnormalities in T-Prolymphocytic Leukemia","year":2000,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Biology; Breakpoint; Molecular biology; Genetics; Fluorescence in situ hybridization; Chromosome; Chromosomal region; Gene; Gene duplication; Prolymphocytic leukemia; Gene cluster; Leukemia; Chronic lymphocytic leukemia","score_opus":0.01786825157841737,"score_gpt":0.2978610983849539,"score_spread":0.2799928468065365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138275899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98559886,0.012567973,0.000047830403,0.00011151278,0.00006286609,0.00035064813,0.00011185571,0.000016250251,0.0011321823],"genre_scores_gemma":[0.9724556,0.025840122,0.00018134392,0.00012699838,0.00013597317,0.000045149354,0.00005980197,0.000030763404,0.0011242285],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827725,0.00004173663,0.00048485544,0.00033299258,0.00040560777,0.00045754286],"domain_scores_gemma":[0.9991766,0.000050097897,0.00006502009,0.00037191113,0.00012961411,0.00020675595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017031963,0.00020536903,0.0003873884,0.000084608844,0.000045706343,0.000020464175,0.00012545942,0.000165488,0.00030486382],"category_scores_gemma":[0.00002132125,0.00019615285,0.00007050564,0.00030943632,0.00033112415,0.000024859366,0.000071409675,0.00015021193,0.000009997016],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00334677,0.00056644925,0.17635868,0.0030821862,0.00048431076,0.00045693442,0.003871114,0.026140347,0.016082313,0.0011172926,0.002265113,0.7662285],"study_design_scores_gemma":[0.05206649,0.0023100371,0.3515988,0.001276086,0.0005560646,0.0010674921,0.0008554259,0.13920344,0.38950098,0.0012754679,0.05894735,0.0013423883],"about_ca_topic_score_codex":0.0013625635,"about_ca_topic_score_gemma":0.0002115663,"teacher_disagreement_score":0.7648861,"about_ca_system_score_codex":0.0051672673,"about_ca_system_score_gemma":0.004950388,"threshold_uncertainty_score":0.99865174},"labels":[],"label_agreement":null},{"id":"W2139334581","doi":"10.1081/ncn-200027609","title":"Fluorescence Studies of Substrate Binding to Human Recombinant Deoxycytidine Kinase","year":2004,"lang":"en","type":"article","venue":"Nucleosides Nucleotides & Nucleic Acids","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"National Cancer Institute; Vetenskapsrådet; Canada Research Chairs","keywords":"Deoxycytidine kinase; Quenching (fluorescence); Chemistry; Fluorescence; Enzyme; Deoxycytidine; Substrate (aquarium); Phosphorylation; Gemcitabine; Biophysics; Phosphate; Kinase; Biochemistry; Stereochemistry; Biology","score_opus":0.05142830422225328,"score_gpt":0.34471144220346916,"score_spread":0.29328313798121586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139334581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370867,0.00058202783,0.000024783238,0.0015712715,0.00046394402,0.001310217,0.000021648522,0.00036728338,0.0019501449],"genre_scores_gemma":[0.9874277,0.0003855774,0.010598363,0.0004729738,0.00023254153,0.000058813137,0.000021076221,0.00021692437,0.0005860027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99461967,0.00010959736,0.0013999224,0.0011407537,0.0012977155,0.001432325],"domain_scores_gemma":[0.9963601,0.00024263418,0.00034897577,0.0014980958,0.0006893981,0.00086078775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010295721,0.00070435274,0.001451929,0.0007696628,0.0004900936,0.00009324449,0.00078678754,0.0002688702,0.0003038835],"category_scores_gemma":[0.0010730088,0.0006326179,0.0004327638,0.0015101512,0.0009815873,0.000412755,0.00062256696,0.0006221712,0.00074798265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009778949,0.0010504852,0.005236258,0.0013806751,0.0007049909,0.0014602198,0.00406048,0.00030575282,0.9651565,0.011053879,0.003133236,0.005479635],"study_design_scores_gemma":[0.036876213,0.006441597,0.034116887,0.0070648934,0.000773682,0.0012056439,0.006860915,0.0004817342,0.8936922,0.0062112887,0.004292471,0.0019824686],"about_ca_topic_score_codex":0.000831207,"about_ca_topic_score_gemma":0.00012876667,"teacher_disagreement_score":0.071464285,"about_ca_system_score_codex":0.008406156,"about_ca_system_score_gemma":0.0017655486,"threshold_uncertainty_score":0.9996125},"labels":[],"label_agreement":null},{"id":"W2139569200","doi":"10.3109/10428194.2012.666662","title":"Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba; Research Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Medicine; Cohort; Immunology; Internal medicine; Beta-2 microglobulin; Interleukin 6; Interleukin; Stromal cell; Population; Tumor necrosis factor alpha; Leukemia; Oncology; Cytokine","score_opus":0.006982895544242365,"score_gpt":0.23207738180895285,"score_spread":0.22509448626471049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139569200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245006,0.0025763698,0.000051266743,0.00011207119,0.0002487059,0.0022340894,0.00005605341,0.00023034577,0.0020410619],"genre_scores_gemma":[0.99519414,0.0006638967,0.0009469381,0.0003766442,0.0003902429,0.0004070264,0.00017514666,0.00027722187,0.0015687334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919349,0.00032404295,0.0016270527,0.0015242272,0.002066698,0.0025230655],"domain_scores_gemma":[0.9954475,0.00079935597,0.0009670886,0.0009817422,0.0006339562,0.00117032],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001135887,0.0012993517,0.002037228,0.0010752272,0.0002720189,0.00018762452,0.00053240935,0.00093563774,0.00010292551],"category_scores_gemma":[0.00035042153,0.0010325217,0.0002439182,0.0016015834,0.0008733309,0.0011940099,0.00047036327,0.00045752816,0.00005271845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011466669,0.00078068423,0.8438436,0.0033400788,0.0017953017,0.00049467944,0.0042281635,0.00018975101,0.0017322584,0.00045574596,0.0017901647,0.12988292],"study_design_scores_gemma":[0.19540378,0.008155294,0.7460289,0.004407332,0.0014264426,0.0025070168,0.001084881,0.014768412,0.017760906,0.00006819467,0.0060994774,0.002289358],"about_ca_topic_score_codex":0.0075598094,"about_ca_topic_score_gemma":0.0012864976,"teacher_disagreement_score":0.26511288,"about_ca_system_score_codex":0.30678207,"about_ca_system_score_gemma":0.04166919,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W2139862760","doi":"10.1093/annonc/mdh128","title":"Treatment for Waldenstrom’s macroglobulinemia","year":2004,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Macroglobulinemia; Waldenstrom macroglobulinemia; Internal medicine; Multiple myeloma; Lymphoma","score_opus":0.3053993242944,"score_gpt":0.5401525840802325,"score_spread":0.2347532597858325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139862760","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001683302,0.99026674,0.000019625633,0.0008087864,0.0002228076,0.0027275253,0.00018850682,0.000033686094,0.0057154745],"genre_scores_gemma":[0.000020147447,0.99297714,0.0014980732,0.00014361618,0.00050017866,0.0005740996,0.00040028518,0.00007734179,0.0038091217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975896,0.000093816176,0.0009103135,0.00049778307,0.00026158147,0.000646919],"domain_scores_gemma":[0.99763715,0.0006927914,0.00044039782,0.00064585585,0.00032101868,0.00026279956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002729512,0.0004179416,0.0035113136,0.00025735298,0.00003736037,0.0000058435317,0.00024026663,0.00081659434,0.00015763332],"category_scores_gemma":[0.0002816772,0.00029299714,0.0013305943,0.00021516638,0.00023049183,0.00001951577,0.000081176986,0.00023750428,0.00014630484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020464747,0.0005079371,1.6573803e-7,0.028568875,0.000831866,0.00043982986,0.000035323672,7.956386e-7,8.949417e-7,0.0003879156,0.006017141,0.9630046],"study_design_scores_gemma":[0.010915354,0.011660681,1.5143446e-7,0.006662058,0.001273195,0.0019956033,0.000008237642,0.000011945416,0.00004326436,0.00013230735,0.96712184,0.00017536868],"about_ca_topic_score_codex":0.000254238,"about_ca_topic_score_gemma":0.00001977119,"teacher_disagreement_score":0.96282923,"about_ca_system_score_codex":0.01643505,"about_ca_system_score_gemma":0.055700723,"threshold_uncertainty_score":0.9999522},"labels":[],"label_agreement":null},{"id":"W2140874657","doi":"10.1038/gene.2011.8","title":"Fine mapping the TAGAP risk locus in rheumatoid arthritis","year":2011,"lang":"en","type":"article","venue":"Genes and Immunity","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Versus Arthritis; National Institute of General Medical Sciences; U.S. Public Health Service; Burroughs Wellcome Fund","keywords":"Single-nucleotide polymorphism; Imputation (statistics); Genome-wide association study; International HapMap Project; Biology; Locus (genetics); SNP; Genetics; Genetic association; Linkage disequilibrium; Haplotype; Allele; Odds ratio; Population stratification; Minor allele frequency; Allele frequency; Population; 1000 Genomes Project; Rheumatoid arthritis; Internal medicine; Genotype; Gene; Medicine; Immunology; Statistics; Missing data; Environmental health","score_opus":0.05206533364500842,"score_gpt":0.2608254372490662,"score_spread":0.20876010360405778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140874657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97605175,0.020613229,0.00006144331,0.00010901537,0.00005652179,0.00022097521,0.0000043931004,0.000018203646,0.0028644656],"genre_scores_gemma":[0.97750354,0.021976288,0.00017071002,0.00005357526,0.000031520172,0.000016911034,0.0000052409687,0.000011089767,0.00023112804],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991601,0.000117390504,0.00019344984,0.00012887892,0.00013933009,0.00026081761],"domain_scores_gemma":[0.99932915,0.00009063645,0.000042003314,0.00042618337,0.00004303529,0.000068995054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005784171,0.00009383191,0.00018418064,0.00006608221,0.0001575322,0.0000146119255,0.00012066435,0.000058984486,0.00026207662],"category_scores_gemma":[0.00013811018,0.00006240191,0.00003916619,0.00018554006,0.00016810576,0.000044730958,0.00017278692,0.00029900862,0.000038962964],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042462043,0.00029042005,0.08385634,0.00016511427,0.00013976083,0.00021001493,0.01127498,0.0000051806815,0.0046174014,0.000465425,0.00095433084,0.8975964],"study_design_scores_gemma":[0.040839113,0.000813497,0.8516288,0.0011429611,0.000038486884,0.002064331,0.009178102,0.008170738,0.025516428,0.0025023818,0.05745598,0.0006491805],"about_ca_topic_score_codex":0.019379927,"about_ca_topic_score_gemma":0.00097367394,"teacher_disagreement_score":0.89694726,"about_ca_system_score_codex":0.00043645865,"about_ca_system_score_gemma":0.0005369166,"threshold_uncertainty_score":0.98715013},"labels":[],"label_agreement":null},{"id":"W2140880663","doi":"10.1080/10428190701321277","title":"Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Lymphocytosis; Chronic lymphocytic leukemia; Medicine; Stage (stratigraphy); Internal medicine; Organomegaly; Gastroenterology; Immunophenotyping; Fludarabine; Monoclonal; Leukemia; Immunology; Disease; Cyclophosphamide; Chemotherapy; Monoclonal antibody; Antigen; Antibody","score_opus":0.017757468983474342,"score_gpt":0.32059903198838025,"score_spread":0.3028415630049059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140880663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913506,0.0018511512,0.00024982367,0.00006801282,0.00026214693,0.0014236402,0.00005194886,0.00019315291,0.0045495187],"genre_scores_gemma":[0.99107605,0.0006251861,0.005772258,0.0006490902,0.00032670965,0.000056331446,0.0001374695,0.00018243838,0.0011744412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992617,0.00018876279,0.0022007113,0.0015752851,0.001854478,0.0015637608],"domain_scores_gemma":[0.99491936,0.0010480488,0.00076267426,0.0012219466,0.00059662975,0.0014513332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018230774,0.0009345234,0.0018023702,0.0005782721,0.00033996496,0.00009581723,0.00044196058,0.00090308645,0.000070044014],"category_scores_gemma":[0.0003232968,0.0007182292,0.00035690612,0.0008706123,0.0015782258,0.00038138014,0.00056734675,0.00030569176,0.000039645878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008090566,0.0009746069,0.7019075,0.0010338359,0.00030023413,0.0005491029,0.00036182435,0.0000053345416,0.0003998662,0.0002155113,0.0006868849,0.28547475],"study_design_scores_gemma":[0.12810098,0.0024042458,0.84779024,0.0005876363,0.00052117504,0.00076486607,0.0002825232,0.0029990366,0.0070525035,0.000069741516,0.008490911,0.0009361332],"about_ca_topic_score_codex":0.0010029136,"about_ca_topic_score_gemma":0.00007075271,"teacher_disagreement_score":0.2845386,"about_ca_system_score_codex":0.0241467,"about_ca_system_score_gemma":0.012349853,"threshold_uncertainty_score":0.99952686},"labels":[],"label_agreement":null},{"id":"W2141589281","doi":"10.1016/j.cancergen.2012.05.011","title":"Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality","year":2012,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"Nepal Academy of Science and Technology; Vancouver Coastal Health Research Institute","keywords":"Chromosomal translocation; Concomitant; Medicine; Hazard ratio; Internal medicine; Chronic lymphocytic leukemia; Fluorescence in situ hybridization; Trisomy; Cytogenetics; Leukemia; Immunology; Oncology; Confidence interval; Biology; Chromosome; Genetics; Gene","score_opus":0.04310395998028851,"score_gpt":0.36092869271081734,"score_spread":0.31782473273052886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141589281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839083,0.0072611845,0.0047112494,0.0001100349,0.00042224646,0.0025432904,0.00073882216,0.000101518795,0.00020338132],"genre_scores_gemma":[0.9935466,0.0025793659,0.0005252119,0.000110848065,0.0009777024,0.0006116398,0.0008191461,0.00012204546,0.0007074481],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99668115,0.00019423377,0.0006525597,0.0005604953,0.0006127064,0.0012988743],"domain_scores_gemma":[0.9970887,0.0001801961,0.00019947457,0.0012133239,0.00060608087,0.00071225123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040200356,0.0005025324,0.0006638981,0.0001647996,0.0003178189,0.000057920566,0.000381794,0.00032742787,0.00021041118],"category_scores_gemma":[0.00011481243,0.0004373008,0.0003073437,0.0003840588,0.00025452118,0.0002668728,0.00007114085,0.00019843478,0.00002781272],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.033286825,0.0070668957,0.32470194,0.004547038,0.009249112,0.00008539374,0.042330727,0.12794922,0.016008608,0.0005730804,0.011688924,0.42251223],"study_design_scores_gemma":[0.10903613,0.009210232,0.23268916,0.00036855956,0.0011907619,0.000084924744,0.00035292553,0.60151345,0.03711282,0.00014124991,0.007038731,0.0012610645],"about_ca_topic_score_codex":0.011334661,"about_ca_topic_score_gemma":0.002033915,"teacher_disagreement_score":0.47356424,"about_ca_system_score_codex":0.19917424,"about_ca_system_score_gemma":0.030311031,"threshold_uncertainty_score":0.9998079},"labels":[],"label_agreement":null},{"id":"W2143715586","doi":"10.1016/j.ctrv.2015.07.003","title":"Obinutuzumab in hematologic malignancies: Lessons learned to date","year":2015,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Pfizer; F. Hoffmann-La Roche; Amgen","keywords":"Medicine; Obinutuzumab; Hematologic Neoplasms; Oncology; Intensive care medicine; Internal medicine; Cancer; Leukemia; Chronic lymphocytic leukemia","score_opus":0.4738322693286079,"score_gpt":0.5435361784067422,"score_spread":0.06970390907813429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143715586","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022132277,0.9868294,0.0000034725533,0.00040949628,0.00025175777,0.008805663,0.000101371275,0.000071544804,0.0035051866],"genre_scores_gemma":[0.0000025732659,0.97694963,0.00035835162,0.00021255287,0.00026525295,0.010678738,0.00034773568,0.00012428682,0.011060882],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951132,0.0005113779,0.0015337074,0.0013203642,0.0005195815,0.0010017798],"domain_scores_gemma":[0.9967492,0.00015464754,0.00044986614,0.001841691,0.00011089419,0.00069370394],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008420106,0.0010288017,0.007252051,0.0004598905,0.00005300785,0.00004663126,0.0004809168,0.0004441658,0.0005613858],"category_scores_gemma":[0.0002602616,0.00061216566,0.00097178575,0.0013720435,0.0000954481,0.00006215469,0.00022125972,0.00041401575,0.0035800051],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000036544156,0.00013726609,0.0000025342376,0.029762823,0.00021178421,0.0009501651,0.00017018562,0.0000019869046,4.460452e-7,0.000052075422,0.013446594,0.9552276],"study_design_scores_gemma":[0.004478018,0.00041886783,3.085538e-7,0.06569,0.0015401336,0.00049450074,0.000019359666,0.0000097145585,0.0000038791304,0.000013154338,0.92688644,0.00044559178],"about_ca_topic_score_codex":0.001622718,"about_ca_topic_score_gemma":0.00034991693,"teacher_disagreement_score":0.954782,"about_ca_system_score_codex":0.12776534,"about_ca_system_score_gemma":0.041347396,"threshold_uncertainty_score":0.99963295},"labels":[],"label_agreement":null},{"id":"W2144203487","doi":"10.1093/ndt/gfm617","title":"Acute renal failure and chronic lymphocytic leukaemia","year":2007,"lang":"en","type":"letter","venue":"Nephrology Dialysis Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Chronic renal failure; Chronic lymphocytic leukemia; Kidney disease; Internal medicine; Intensive care medicine; Leukemia","score_opus":0.01249554858607054,"score_gpt":0.2769835865528269,"score_spread":0.26448803796675635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144203487","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5036964,0.0044114934,0.006836549,0.47507685,0.00073371583,0.00395452,0.00058430515,0.0008815515,0.0038246263],"genre_scores_gemma":[0.10061485,0.011239496,0.0017790424,0.8525487,0.0120168505,0.00022111731,0.016751193,0.00036237205,0.0044663637],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956382,0.00024029668,0.0007905981,0.0011559898,0.00100223,0.0011727102],"domain_scores_gemma":[0.9979482,0.0006084891,0.00025948946,0.00075452705,0.00019606439,0.00023321515],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00044107318,0.0006696419,0.0012560325,0.0010300789,0.0001810173,0.00006122381,0.00027909546,0.0028439863,0.00044421418],"category_scores_gemma":[0.00003081556,0.000621072,0.0003812798,0.00057162007,0.0006344925,0.00015489255,0.000042653657,0.0022742564,0.0002554535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0031782903,0.000052055126,0.000117628275,0.004022657,0.0059894016,0.051689647,0.0009562703,0.00015360322,0.031021962,0.000044791846,0.8983263,0.004447434],"study_design_scores_gemma":[0.061835613,0.0015402066,0.00061646174,0.0006822972,0.021539079,0.02782698,0.000022351827,0.008197823,0.012796054,0.00018256907,0.86329097,0.0014696094],"about_ca_topic_score_codex":0.00037468394,"about_ca_topic_score_gemma":0.00055415015,"teacher_disagreement_score":0.40308154,"about_ca_system_score_codex":0.022454867,"about_ca_system_score_gemma":0.011883161,"threshold_uncertainty_score":0.9996241},"labels":[],"label_agreement":null},{"id":"W2145138842","doi":"10.3109/08830185.2013.818140","title":"B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies","year":2013,"lang":"en","type":"review","venue":"International Reviews of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Signal transduction; Immunology; Receptor; Medicine; B cell; Biology; Cell biology; Internal medicine; Antibody","score_opus":0.046631307797482056,"score_gpt":0.3478084873731445,"score_spread":0.3011771795756625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145138842","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002166938,0.99318147,0.000015710459,0.000041709318,0.000542986,0.0035599133,0.00016674929,0.0000174636,0.0003070712],"genre_scores_gemma":[0.00012345111,0.9941858,0.001050353,0.000010069441,0.00020404262,0.0012046408,0.00039188663,0.00006306133,0.0027667012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683297,0.00019609161,0.0019169088,0.00044084163,0.000302483,0.00031068883],"domain_scores_gemma":[0.9966135,0.0008949728,0.0014410377,0.0005373013,0.00042758207,0.000085631975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030436518,0.00046918547,0.0032385548,0.00042512847,0.000033440236,0.00001366007,0.00036510805,0.00033242302,0.0003935783],"category_scores_gemma":[0.00051532645,0.00032978714,0.0010154038,0.00013178674,0.00037942827,0.000078945326,0.00016978459,0.00012670233,0.00008545324],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014660192,0.0007245398,0.000015188206,0.05572897,0.0010205307,0.000011207149,0.00011109847,3.884661e-7,0.0051319017,0.00020354203,0.0017498974,0.9351561],"study_design_scores_gemma":[0.0047781747,0.0007785658,0.0000040408822,0.014174096,0.0009296515,0.00006240768,0.000024702491,0.000013994804,0.0021547389,0.000019049856,0.97685367,0.000206921],"about_ca_topic_score_codex":0.00009513365,"about_ca_topic_score_gemma":6.4373376e-7,"teacher_disagreement_score":0.97510374,"about_ca_system_score_codex":0.0034845464,"about_ca_system_score_gemma":0.003258961,"threshold_uncertainty_score":0.9999154},"labels":[],"label_agreement":null},{"id":"W2146651952","doi":"10.3109/10428194.2012.731599","title":"Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; ROR1; Cancer research; Follicular lymphoma; Lymphoma; Mantle cell lymphoma; Leukemia; Internal medicine; Receptor; Platelet-derived growth factor receptor","score_opus":0.020076497107328888,"score_gpt":0.27465724116146906,"score_spread":0.25458074405414016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146651952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97722906,0.01666576,0.00003434029,0.0003976529,0.00041072853,0.0009797061,0.00003705904,0.00030344896,0.003942267],"genre_scores_gemma":[0.9906952,0.003074172,0.0013454692,0.0013691874,0.0006528981,0.00023046831,0.0001165258,0.00015129703,0.0023647787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99387044,0.00026590563,0.0011736078,0.0012806475,0.0010735027,0.0023359286],"domain_scores_gemma":[0.9964403,0.00067350996,0.0002641426,0.0009989934,0.00018179584,0.0014412949],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010169338,0.00097134226,0.0015935407,0.0006118687,0.00036149367,0.00017430776,0.00038941702,0.0008895164,0.00032601002],"category_scores_gemma":[0.0006651438,0.00081779703,0.00024705948,0.0010496926,0.0010535509,0.00072028843,0.0006268835,0.00030272716,0.00025455182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011857806,0.004190064,0.39708242,0.0066099428,0.00118529,0.007004811,0.011474252,0.000052814965,0.10098162,0.034991063,0.043848287,0.38072166],"study_design_scores_gemma":[0.15107447,0.0018593894,0.56567806,0.0029394936,0.0005462959,0.031524263,0.0038806903,0.008953816,0.09527226,0.0009428715,0.13347362,0.0038548035],"about_ca_topic_score_codex":0.002914983,"about_ca_topic_score_gemma":0.00011309259,"teacher_disagreement_score":0.37686685,"about_ca_system_score_codex":0.03390253,"about_ca_system_score_gemma":0.008470983,"threshold_uncertainty_score":0.99942726},"labels":[],"label_agreement":null},{"id":"W2147308092","doi":"10.1086/379810","title":"Enfuvirtide (T‐20) Cross‐Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide","year":2003,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Enfuvirtide; Gp41; Antibody; Regimen; Medicine; Internal medicine; Immunology; Virology; Pharmacology; Epitope","score_opus":0.012805255177215914,"score_gpt":0.3325877105286471,"score_spread":0.3197824553514312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147308092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952695,0.0010253633,0.00029628532,0.0004704487,0.0003029668,0.00090393086,0.000052760744,0.00004102155,0.0016377179],"genre_scores_gemma":[0.9976839,0.000704047,0.000034201003,0.0003420658,0.00043125855,0.000010802936,0.000004006155,0.000052693897,0.0007370366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962171,0.00078656245,0.0010581029,0.0002158654,0.0011684498,0.00055395724],"domain_scores_gemma":[0.9939733,0.0032316642,0.000876725,0.0008054824,0.00074274343,0.0003700719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017909447,0.00032461237,0.00072912074,0.00020748781,0.00037546185,0.000064731736,0.00046869426,0.000102672224,0.00059542654],"category_scores_gemma":[0.0062736,0.0001324669,0.00051370077,0.0005539933,0.0008608612,0.00024735645,0.000114231494,0.0006882877,0.000036817568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18384324,0.014102619,0.31435797,0.0026020773,0.011917929,0.0045195203,0.011279561,0.012251023,0.4164161,0.0032213891,0.005729698,0.019758845],"study_design_scores_gemma":[0.11902024,0.009793484,0.3364541,0.0023248533,0.004538939,0.020447139,0.0034618396,0.0008790148,0.4876263,0.0027391377,0.011602318,0.0011126448],"about_ca_topic_score_codex":0.00044200206,"about_ca_topic_score_gemma":0.00006378229,"teacher_disagreement_score":0.07121018,"about_ca_system_score_codex":0.0032034204,"about_ca_system_score_gemma":0.0074432218,"threshold_uncertainty_score":0.99818367},"labels":[],"label_agreement":null},{"id":"W2148614993","doi":"10.1128/jvi.80.8.4026-4037.2006","title":"Novel Insights into the Pathogenesis of the Graffi Murine Leukemia Retrovirus","year":2006,"lang":"en","type":"article","venue":"Journal of Virology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Université du Québec à Montréal","funders":"Canadian Institutes of Health Research","keywords":"Biology; Leukemia; Myeloid; Virology; Retrovirus; Haematopoiesis; Myeloid leukemia; Murine leukemia virus; Acute megakaryoblastic leukemia; Cancer research; Molecular biology; Virus; Immunology; Genetics; Stem cell","score_opus":0.011736417098319305,"score_gpt":0.263738026062277,"score_spread":0.2520016089639577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148614993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939519,0.0020453993,0.00022740682,0.0023326378,0.00032427217,0.00016409675,0.0000012986711,0.000005439909,0.0009475376],"genre_scores_gemma":[0.9974766,0.00022163334,0.00039810204,0.0006200626,0.00066994707,0.000002888216,8.4881583e-7,0.0000204337,0.0005895013],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981371,0.00015425392,0.0006858152,0.00013527871,0.00062136736,0.0002661569],"domain_scores_gemma":[0.9982848,0.00033769832,0.00050564774,0.0004958131,0.0002958388,0.0000802063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059397734,0.00013540155,0.0004346485,0.00015432535,0.000094179166,0.0000074676086,0.00045977643,0.00016461615,0.00006193064],"category_scores_gemma":[0.0003636921,0.000063050844,0.00027278604,0.00033955203,0.00047282412,0.00005143719,0.00016655712,0.0005029211,0.000009968917],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011676449,0.00030275583,0.002952309,0.00008269042,0.00021119438,0.00029847992,0.00067061523,0.0010146832,0.98476344,0.0012940645,0.0039638276,0.0032782631],"study_design_scores_gemma":[0.054031286,0.0042197243,0.6206501,0.0003283008,0.0010254451,0.015523118,0.0004602003,0.008170189,0.2010193,0.004785475,0.08938655,0.00040029795],"about_ca_topic_score_codex":0.0010277587,"about_ca_topic_score_gemma":0.00027574136,"teacher_disagreement_score":0.78374416,"about_ca_system_score_codex":0.003430563,"about_ca_system_score_gemma":0.0041479254,"threshold_uncertainty_score":0.8970803},"labels":[],"label_agreement":null},{"id":"W2148893624","doi":"10.3109/10428190903275586","title":"Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; Research Manitoba","funders":"CancerCare Manitoba Foundation; Manitoba Health Research Council; Friedreich's Ataxia Research Alliance","keywords":"Lysophosphatidic acid; Autocrine signalling; Chronic lymphocytic leukemia; Apoptosis; Receptor; Cancer research; Biology; Vascular endothelial growth factor; Endocrinology; Internal medicine; Leukemia; Immunology; Medicine; VEGF receptors; Biochemistry","score_opus":0.012765486987522282,"score_gpt":0.2597939234841367,"score_spread":0.24702843649661443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148893624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820286,0.008490662,0.0004167488,0.00021100945,0.0010800236,0.003155995,0.000197705,0.0009123295,0.0035068982],"genre_scores_gemma":[0.9851924,0.0052860593,0.0023257392,0.0020571153,0.0016406043,0.00034806013,0.00049246673,0.00044763598,0.002209872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98525923,0.0008212053,0.0026895138,0.0036445174,0.0036311725,0.003954332],"domain_scores_gemma":[0.9918873,0.0012228183,0.00070406724,0.0027792987,0.00057375437,0.0028327995],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001383739,0.0023589216,0.0031382865,0.0016547128,0.0007403434,0.0004051693,0.0016731779,0.0019632687,0.0006212349],"category_scores_gemma":[0.0014001732,0.0021410915,0.00089919975,0.002932958,0.00062945735,0.0011150276,0.0008859323,0.0008106798,0.0010739171],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005342474,0.00037474482,0.0015921608,0.0011650723,0.00016058702,0.0018684063,0.0031800654,0.00078787334,0.9497428,0.00016395483,0.006309088,0.029312782],"study_design_scores_gemma":[0.11489149,0.002417629,0.02092683,0.0026964494,0.00025708682,0.0006823251,0.00055444374,0.015355687,0.8238034,0.0002145209,0.015420342,0.0027797485],"about_ca_topic_score_codex":0.0033471752,"about_ca_topic_score_gemma":0.00014502177,"teacher_disagreement_score":0.27472013,"about_ca_system_score_codex":0.36842915,"about_ca_system_score_gemma":0.09370902,"threshold_uncertainty_score":0.9997039},"labels":[],"label_agreement":null},{"id":"W2149807213","doi":"10.3747/co.v18i2.731","title":"Chronic Lymphocytic Leukemia and Breast Cancer as Synchronous Primary in a Male—A Rare Combination","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Breast cancer; Cancer; Leukemia; Oncology; Cancer research; Right breast; Internal medicine; Dermatology; Pathology","score_opus":0.061815612869419743,"score_gpt":0.3697166742501596,"score_spread":0.30790106138073986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149807213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733345,0.012887654,0.000024364312,0.00025878343,0.00060476764,0.0008805448,0.000022291591,0.00006979273,0.011917288],"genre_scores_gemma":[0.9952196,0.0033243,0.000046490437,0.00014791655,0.0003099707,0.00023256587,0.000058629033,0.000037032893,0.000623507],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980437,0.00010495738,0.00040257513,0.0005118701,0.00032150125,0.0006153732],"domain_scores_gemma":[0.9989896,0.0001317376,0.000119178396,0.00034398035,0.00014579191,0.00026970933],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027305825,0.00023581393,0.00054023246,0.00029946896,0.000061291204,0.000016553266,0.00017341753,0.00024598205,0.00139142],"category_scores_gemma":[0.000079533216,0.00021757581,0.000064461194,0.00032276256,0.00034944946,0.00016210748,0.0002149321,0.00042911436,0.00021032392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0020612015,0.00071864005,0.06288685,0.0027339968,0.00016238214,0.0018951142,0.0032094782,0.000026991947,0.00078557344,0.0010246587,0.0037679442,0.9207272],"study_design_scores_gemma":[0.24178205,0.007950518,0.5546132,0.0039289854,0.00065376237,0.040531084,0.00093489996,0.07762017,0.0011288975,0.0018836942,0.06723744,0.0017353236],"about_ca_topic_score_codex":0.0022459845,"about_ca_topic_score_gemma":0.00032124767,"teacher_disagreement_score":0.91899186,"about_ca_system_score_codex":0.2377833,"about_ca_system_score_gemma":0.05940307,"threshold_uncertainty_score":0.99952143},"labels":[],"label_agreement":null},{"id":"W2149869428","doi":"10.1371/journal.pone.0137232","title":"Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; University of Alberta","funders":"","keywords":"IGHV@; Chronic lymphocytic leukemia; Biology; clone (Java method); Somatic evolution in cancer; Immunoglobulin heavy chain; Allelic exclusion; Dominance (genetics); Genetics; Macroglobulinemia; Gene rearrangement; Waldenstrom macroglobulinemia; Leukemia; Molecular biology; Antibody; Gene; Immunology; Multiple myeloma; T cell; Lymphoma; T-cell receptor; Immune system","score_opus":0.11626505756185161,"score_gpt":0.24301514407872885,"score_spread":0.12675008651687725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149869428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737203,0.0013832226,0.00006370052,0.000050784212,0.000024040326,0.00071346207,0.000007873441,0.000059598933,0.00032526447],"genre_scores_gemma":[0.9972419,0.00008737381,0.00163213,0.00008026192,0.00012963937,0.000049095626,0.00024812567,0.000049056885,0.00048241764],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99742675,0.00008882653,0.00032683247,0.0005395868,0.0010949303,0.00052310526],"domain_scores_gemma":[0.99860066,0.00011841281,0.00012297166,0.0005552496,0.0003001119,0.00030261546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003220819,0.0002618623,0.0006154522,0.0004940525,0.00008937499,0.00010219838,0.00013634522,0.00014722928,0.000043910306],"category_scores_gemma":[0.00023284921,0.00022313812,0.00007413931,0.0008713814,0.00016455886,0.0003340337,0.00010483835,0.00021912536,0.00002915852],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023985915,0.0017890251,0.8120316,0.001202804,0.0030041917,0.00020771583,0.00493056,0.0033964308,0.16931808,0.0000064160213,0.00009106092,0.0016234756],"study_design_scores_gemma":[0.07594444,0.0022530986,0.03288755,0.0006654857,0.0028824017,0.000018128187,0.0007131576,0.74433136,0.13963906,0.0000048941006,0.00003063081,0.0006298003],"about_ca_topic_score_codex":0.0048201694,"about_ca_topic_score_gemma":0.001894644,"teacher_disagreement_score":0.7791441,"about_ca_system_score_codex":0.12581216,"about_ca_system_score_gemma":0.011454732,"threshold_uncertainty_score":0.9941494},"labels":[],"label_agreement":null},{"id":"W2150584794","doi":"10.1158/1078-0432.ccr-06-2788","title":"Molecular Characterization of Waldenstrom's Macroglobulinemia Reveals Frequent Occurrence of Two B-Cell Clones Having Distinct IgH VDJ Sequences","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Biology; Bone marrow; Somatic cell; Macroglobulinemia; Germline; Waldenstrom macroglobulinemia; B cell; Germline mutation; Antibody; Immunology; Genetics; Mutation; Gene; Lymphoma; Multiple myeloma","score_opus":0.13103462314872952,"score_gpt":0.5109195788758971,"score_spread":0.37988495572716763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150584794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536276,0.00097412005,0.00064563507,0.0004911995,0.00027301902,0.0009455615,0.00016960932,0.000030006677,0.0011080833],"genre_scores_gemma":[0.9974099,0.0009422867,0.00063247007,0.000084122286,0.00038173544,0.00004933489,0.00010685665,0.000031739884,0.00036158945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937741,0.00053900864,0.0017601576,0.0007307773,0.002224969,0.0009709684],"domain_scores_gemma":[0.99474937,0.0017143511,0.00042926156,0.00088246685,0.0017103173,0.0005142388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007957834,0.00022438786,0.00084764994,0.00029925583,0.00009781907,0.000026157122,0.0006040974,0.00025664974,0.0004253767],"category_scores_gemma":[0.002535747,0.00018973535,0.000272241,0.0010884466,0.0016172106,0.00010541018,0.00037611226,0.001098952,0.00003107117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015964926,0.00071803643,0.14332199,0.0017011752,0.00010784078,0.00061753026,0.00017976527,0.000013163599,0.8309565,0.00032836187,0.0003894155,0.020069709],"study_design_scores_gemma":[0.018673465,0.0021087627,0.09529804,0.0024550334,0.00016363441,0.000088579945,0.00018862721,0.0015269332,0.8769961,0.000492772,0.0015536179,0.00045443128],"about_ca_topic_score_codex":0.0023416982,"about_ca_topic_score_gemma":0.00012240467,"teacher_disagreement_score":0.04802395,"about_ca_system_score_codex":0.002928906,"about_ca_system_score_gemma":0.0069270553,"threshold_uncertainty_score":0.99870276},"labels":[],"label_agreement":null},{"id":"W2150938787","doi":"10.1182/blood.v98.9.2837","title":"Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Daiwa Anglo-Japanese Foundation; Wellcome Trust; Kay Kendall Leukaemia Fund; Lady Tata Memorial Trust; Deutsche Krebshilfe","keywords":"Cancer research; Gene; Biology; Cyclin D3; Cyclin D1; Genetics; Molecular biology; Cell cycle","score_opus":0.014746707047740448,"score_gpt":0.270093906262556,"score_spread":0.2553471992148156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150938787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98441374,0.0040361607,0.000046051497,0.00032775287,0.00007226415,0.00037579358,0.000056568188,0.000037298065,0.010634381],"genre_scores_gemma":[0.98623854,0.0006997064,0.0042179488,0.00026332896,0.00018265891,0.000015877264,0.000028372537,0.00004162762,0.008311947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806637,0.000039130067,0.0004665165,0.00030519508,0.0006923153,0.00043045322],"domain_scores_gemma":[0.99862444,0.000093469556,0.00016161856,0.00069535064,0.0002575321,0.0001675846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026862355,0.00018381292,0.0005237615,0.00015280774,0.000028730974,0.000006598693,0.00023316263,0.00021427275,0.00074677577],"category_scores_gemma":[0.00014111958,0.00015362777,0.00018844388,0.00041215454,0.00017108557,0.000048857855,0.00011547426,0.00021005179,0.00007467621],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010457685,0.006514816,0.016007204,0.002668799,0.0006053097,0.0014035279,0.0024873328,0.000024562842,0.94615525,0.00015325179,0.021905653,0.0010285478],"study_design_scores_gemma":[0.032369927,0.00041301645,0.0018967321,0.00023511048,0.00022643604,0.0005200923,0.0001560389,0.000287786,0.9547012,0.00018202234,0.008847992,0.00016364669],"about_ca_topic_score_codex":0.00027976398,"about_ca_topic_score_gemma":0.0000080668615,"teacher_disagreement_score":0.03132416,"about_ca_system_score_codex":0.0004583132,"about_ca_system_score_gemma":0.0021761064,"threshold_uncertainty_score":0.81766707},"labels":[],"label_agreement":null},{"id":"W2151979638","doi":"10.1634/theoncologist.10-5-345","title":"HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Rash; Medicine; Dermatology; Acne; EGFR inhibitors; Adverse effect; Etiology; Epidermal growth factor receptor; Pathology; Internal medicine; Cancer","score_opus":0.06765387642643766,"score_gpt":0.36904424410560627,"score_spread":0.3013903676791686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151979638","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042998942,0.9668371,0.00003665835,0.015993327,0.0018928724,0.010824108,0.0003028295,0.00028906608,0.0033940466],"genre_scores_gemma":[0.0003203413,0.97106045,0.0008466061,0.0018187043,0.0028332178,0.002669672,0.00095175236,0.00016061646,0.019338615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952219,0.00065608945,0.0011866796,0.0010003337,0.0009616412,0.0009733287],"domain_scores_gemma":[0.9954547,0.0019991195,0.0007255999,0.0013820288,0.00017233346,0.0002662195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001742594,0.0008477163,0.002094452,0.00021965573,0.00086071354,0.00021942002,0.00081345637,0.00072106573,0.000119528624],"category_scores_gemma":[0.0003768025,0.00045933836,0.00074155326,0.0007671631,0.00074971514,0.00011782791,0.00087799155,0.0010061511,0.00013374868],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008916452,0.0002956603,0.00016642238,0.0046702363,0.00283228,0.00008559924,0.00031881148,0.000002887964,4.5740063e-7,0.0009735762,0.15465178,0.8359131],"study_design_scores_gemma":[0.0083155185,0.0001924832,0.00069197244,0.0049839537,0.0042310352,0.000040646104,0.0012984531,0.00008448099,0.0000021812523,0.00040096208,0.9792988,0.00045952798],"about_ca_topic_score_codex":0.0007082001,"about_ca_topic_score_gemma":0.00202077,"teacher_disagreement_score":0.8354536,"about_ca_system_score_codex":0.024640918,"about_ca_system_score_gemma":0.0017109034,"threshold_uncertainty_score":0.99978584},"labels":[],"label_agreement":null},{"id":"W2155791176","doi":"10.3109/10428194.2013.840889","title":"Genetic risk of chronic lymphocytic leukemia: a tale of two cities","year":2013,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Genetics; Family aggregation; Allele; Population; Disease; Biology; Medicine; Leukemia; Gene; Internal medicine","score_opus":0.011787878781792348,"score_gpt":0.2531573642100715,"score_spread":0.24136948542827916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155791176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547634,0.026898133,0.00018450673,0.0018316708,0.0013635019,0.0041764663,0.0009270996,0.00057486474,0.009280354],"genre_scores_gemma":[0.8818692,0.024330981,0.0036363415,0.046418723,0.011014442,0.001430629,0.0015635301,0.0017734544,0.027962692],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98267514,0.0009421196,0.0047475817,0.0034828344,0.004262884,0.0038894329],"domain_scores_gemma":[0.9864545,0.0023471545,0.0034940692,0.005008623,0.0014769136,0.0012187804],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011217843,0.0031896345,0.0062813303,0.0022854586,0.0005367067,0.0002635856,0.0022705754,0.004791991,0.0010691218],"category_scores_gemma":[0.00080794375,0.002970994,0.002076352,0.0020022865,0.004483584,0.00058856816,0.0015799361,0.0020726153,0.0005098766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0020838878,0.0003328884,0.0020670525,0.02809667,0.007115551,0.009712807,0.0022150865,0.002159546,0.0056742756,0.00044029905,0.81803656,0.12206537],"study_design_scores_gemma":[0.25348535,0.0063319937,0.012224021,0.012490013,0.011589596,0.028547743,0.0009224397,0.22378764,0.036193904,0.0030678427,0.4032719,0.008087542],"about_ca_topic_score_codex":0.06620459,"about_ca_topic_score_gemma":0.0002769741,"teacher_disagreement_score":0.41476464,"about_ca_system_score_codex":0.35957855,"about_ca_system_score_gemma":0.22967228,"threshold_uncertainty_score":0.999844},"labels":[],"label_agreement":null},{"id":"W2158196950","doi":"10.3324/haematol.13151","title":"Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","year":2008,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lymphocytosis; Dasatinib; Natural killer cell; Lymphocyte; Immunology; CD16; CD3; Biology; Medicine; Cytotoxicity; Myeloid leukemia; CD8; Imatinib; Immune system","score_opus":0.03405269464848501,"score_gpt":0.2943099288139732,"score_spread":0.2602572341654882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158196950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890337,0.003939864,0.00012965409,0.0013413602,0.00069295027,0.003335123,0.000089754576,0.00048021442,0.0009574058],"genre_scores_gemma":[0.9868779,0.001028567,0.0013966567,0.0025469726,0.00025909132,0.00044096014,0.0008584897,0.00014625242,0.006445088],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950731,0.00023672945,0.0007829298,0.0011247201,0.0011684392,0.0016140772],"domain_scores_gemma":[0.9965366,0.0012182569,0.00039166363,0.0008403934,0.00060159963,0.0004114521],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046559246,0.00076987105,0.0015923077,0.00026260203,0.00073652086,0.000055966295,0.00053431874,0.00059213873,0.0006261076],"category_scores_gemma":[0.0007681739,0.00046462548,0.00046867636,0.0008973517,0.0006934403,0.00023242099,0.00018166697,0.00079458806,0.00009790689],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.18494268,0.017962113,0.021810813,0.0045160055,0.01211153,0.11873836,0.025896858,0.00032658817,0.052328806,0.0042704977,0.5543073,0.0027884415],"study_design_scores_gemma":[0.5276347,0.018055389,0.050628807,0.0028597792,0.0012626057,0.038619343,0.0019174115,0.08099233,0.22310102,0.00023247543,0.04879929,0.0058968724],"about_ca_topic_score_codex":0.00013406994,"about_ca_topic_score_gemma":0.000057034576,"teacher_disagreement_score":0.505508,"about_ca_system_score_codex":0.009295838,"about_ca_system_score_gemma":0.0065834275,"threshold_uncertainty_score":0.99978054},"labels":[],"label_agreement":null},{"id":"W2158733289","doi":"10.1093/hmg/ddq304","title":"Locus category based analysis of a large genome-wide association study of rheumatoid arthritis","year":2010,"lang":"en","type":"article","venue":"Human Molecular Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Alliance for Research on Schizophrenia and Depression","keywords":"Genome-wide association study; Single-nucleotide polymorphism; Locus (genetics); Genetics; Biology; Linkage disequilibrium; SNP; Genetic association; Gene; Genotype","score_opus":0.010907541881015234,"score_gpt":0.29422479901733667,"score_spread":0.28331725713632144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158733289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973639,0.0006497964,0.00084532663,0.000031118594,0.000038010112,0.0005672317,0.000021626809,0.000020316002,0.00046266138],"genre_scores_gemma":[0.99922305,0.00010014737,0.00032069787,0.00010764821,0.000017917482,0.000022898605,0.0001036939,0.000036991896,0.00006692421],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99760234,0.00013303859,0.0006000224,0.00031658344,0.0009908641,0.00035712242],"domain_scores_gemma":[0.9980096,0.00013539985,0.00031688157,0.00089413504,0.0004997937,0.00014415092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066288555,0.0001620982,0.00062544557,0.000551421,0.00005958318,0.000013800957,0.00020416848,0.00016750321,0.00037884564],"category_scores_gemma":[0.0003979098,0.0001709298,0.00024006215,0.00083361386,0.00006907096,0.000014414955,0.00009657644,0.00027760223,0.000009194904],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011524888,0.0034963998,0.4040371,0.00016195439,0.004604648,0.00031727558,0.0020790335,0.002648114,0.5816437,0.00018695183,0.00021967308,0.0004898996],"study_design_scores_gemma":[0.039841175,0.002009411,0.82739395,0.00006696583,0.0020708495,0.000007817185,0.0008603568,0.021120435,0.10476829,0.00013881737,0.0012245787,0.0004973512],"about_ca_topic_score_codex":0.00046868104,"about_ca_topic_score_gemma":0.0016824508,"teacher_disagreement_score":0.47687542,"about_ca_system_score_codex":0.0010971568,"about_ca_system_score_gemma":0.0012758006,"threshold_uncertainty_score":0.69703144},"labels":[],"label_agreement":null},{"id":"W2158770214","doi":"10.1093/jnci/djh122","title":"Prognostic Significance of a Short Sequence Insertion in the MCL-1 Promoter in Chronic Lymphocytic Leukemia","year":2004,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Sequence (biology); Leukemia; Cancer research; Genetics; Biology; Medicine; Computational biology","score_opus":0.08679297032917604,"score_gpt":0.3781576778012183,"score_spread":0.29136470747204224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158770214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995832,0.00082035974,0.00007643245,0.0016356227,0.00039855935,0.000800654,0.000010956517,0.0000047809935,0.00042060888],"genre_scores_gemma":[0.9983902,0.00023078581,0.00019849135,0.0005429574,0.00049659226,0.00007563913,0.0000026740088,0.000012878311,0.000049789298],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99691415,0.00010494843,0.00077245093,0.00017909118,0.0017426445,0.00028673123],"domain_scores_gemma":[0.9987174,0.0001420795,0.0002895014,0.00019950308,0.0005863533,0.00006511183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013079003,0.00014939222,0.00031372902,0.00028765647,0.00005770546,0.000020459258,0.00056139496,0.00009954366,0.000017246537],"category_scores_gemma":[0.00092444423,0.00008708057,0.00014337702,0.0010074042,0.00033731008,0.00034892396,0.000056405126,0.0005690962,0.0000036312604],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002052042,0.0003812613,0.014587961,0.0013054821,0.00026449002,0.0006879012,0.003590622,0.83374906,0.13410129,0.0031658674,0.0006622076,0.0054518264],"study_design_scores_gemma":[0.113993436,0.0031047482,0.5567972,0.023286574,0.00065458775,0.014180008,0.0005753366,0.083933234,0.16990533,0.02163236,0.010667499,0.0012696486],"about_ca_topic_score_codex":0.0020501663,"about_ca_topic_score_gemma":0.0020813213,"teacher_disagreement_score":0.7498158,"about_ca_system_score_codex":0.16604477,"about_ca_system_score_gemma":0.11505894,"threshold_uncertainty_score":0.88995785},"labels":[],"label_agreement":null},{"id":"W2159428875","doi":"10.1158/0008-5472.can-12-1390","title":"Soluble CD200 Is Critical to Engraft Chronic Lymphocytic Leukemia Cells in Immunocompromised Mice","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Monoclonal antibody; Medicine; Immunology; Splenocyte; Spleen; Rituximab; Leukemia; Cancer research; CD20; Cancer; Antibody; Internal medicine","score_opus":0.07371061650272423,"score_gpt":0.43253032998626684,"score_spread":0.3588197134835426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159428875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97365534,0.0146685885,0.00004372438,0.0018619107,0.00082786375,0.0023884606,0.000027783668,0.00010840959,0.0064178896],"genre_scores_gemma":[0.9804667,0.0012564324,0.0004127906,0.0007960186,0.0013631589,0.0011188065,0.0000108679915,0.0001267679,0.0144484565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99275225,0.00037308614,0.00059881614,0.00082528125,0.0020713946,0.0033791729],"domain_scores_gemma":[0.99574363,0.0010060865,0.000031979045,0.0011830444,0.000609721,0.0014255099],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028098244,0.00034352695,0.0006505494,0.0008635995,0.000250525,0.00010955937,0.000718317,0.00033312847,0.003941939],"category_scores_gemma":[0.00075273425,0.00032582422,0.00016352185,0.0019856184,0.00058052276,0.00030509187,0.0006561658,0.0013881878,0.0036180129],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024304828,0.00031339464,0.00052766793,0.0020383114,0.00015444202,0.00036067137,0.0036754182,0.00037330066,0.8759737,0.0005142774,0.1033365,0.010301805],"study_design_scores_gemma":[0.028759891,0.000819014,0.0008622618,0.0014056017,0.000055205193,0.00016656662,0.0006976188,0.013273792,0.7503366,0.00010499534,0.20282061,0.0006978743],"about_ca_topic_score_codex":0.017774612,"about_ca_topic_score_gemma":0.00033370891,"teacher_disagreement_score":0.20911564,"about_ca_system_score_codex":0.28104743,"about_ca_system_score_gemma":0.0719318,"threshold_uncertainty_score":0.99991935},"labels":[],"label_agreement":null},{"id":"W2160457008","doi":"10.1111/j.1365-2141.2009.07881.x","title":"Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Pyrogenesis (Canada); Princess Margaret Cancer Centre; Ottawa Hospital; Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; D. Warren Brown Family Foundation; Leukemia and Lymphoma Society","keywords":"Fludarabine; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Concomitant; Histone deacetylase inhibitor; Histone deacetylase; Tolerability; Gastroenterology; Pharmacokinetics; Toxicity; Refractory (planetary science); Oncology; Pharmacology; Lymphoma; Leukemia; Chemotherapy; Adverse effect; Histone; Biology; Cyclophosphamide","score_opus":0.009130678814489193,"score_gpt":0.29054384125824373,"score_spread":0.2814131624437545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160457008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563426,0.0027713906,0.0000047809795,0.000117020994,0.0001240408,0.0012263862,0.0000047161802,0.000012704666,0.00010467824],"genre_scores_gemma":[0.9994753,0.000107330154,0.00005375635,0.00010072775,0.000074928335,0.0000101443475,0.00000469968,0.000030091534,0.00014299767],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99685633,0.0003103668,0.001184719,0.0002837692,0.0008275681,0.00053722446],"domain_scores_gemma":[0.9980873,0.00010313309,0.00066001556,0.00042582228,0.0005048175,0.00021892831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046862074,0.00022388397,0.0011828637,0.00029118737,0.000116276155,0.000016327613,0.00036574612,0.00016034134,0.0000671148],"category_scores_gemma":[0.00040636343,0.00016851985,0.0001548441,0.0005860933,0.0002671132,0.00014816086,0.00009374249,0.00056751946,0.0000035587498],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06390862,0.14224957,0.09328916,0.0028878867,0.0032668393,0.38632533,0.012747583,0.001726574,0.0053300485,0.00014881627,0.025424942,0.26269463],"study_design_scores_gemma":[0.6420203,0.09107033,0.043954276,0.0054224622,0.0008946304,0.20543061,0.0005905585,0.0009535858,0.008825337,0.000063796266,0.00026200485,0.0005121101],"about_ca_topic_score_codex":0.0008165148,"about_ca_topic_score_gemma":0.000755989,"teacher_disagreement_score":0.57811165,"about_ca_system_score_codex":0.01790298,"about_ca_system_score_gemma":0.010022774,"threshold_uncertainty_score":0.9955895},"labels":[],"label_agreement":null},{"id":"W2160542415","doi":"10.1200/jco.2006.07.8659","title":"Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Neutropenia; Internal medicine; Gastroenterology; Macroglobulinemia; Waldenstrom macroglobulinemia; Discontinuation; Toxicity; Peripheral neuropathy; Cancer; Surgery; Multiple myeloma; Lymphoma","score_opus":0.21261765092660903,"score_gpt":0.5550014234986691,"score_spread":0.3423837725720601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160542415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519473,0.00003963551,0.000008689992,0.0018221588,0.0013198009,0.0011724993,0.000057105914,0.0000024574344,0.00038289608],"genre_scores_gemma":[0.99760425,0.000078012104,0.00028295486,0.00112422,0.000632164,0.0000073363203,0.000004133919,0.000016961714,0.00024996157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890547,0.0014381893,0.0069305566,0.0003009573,0.0019012162,0.00037439854],"domain_scores_gemma":[0.98377055,0.008171303,0.005116515,0.00027739938,0.0022436806,0.0004205699],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016091866,0.00019415298,0.0029045132,0.00018276439,0.000058946196,0.0000030476501,0.00037727912,0.0004734146,0.0002297011],"category_scores_gemma":[0.029912842,0.00009738651,0.00037489823,0.0006508601,0.00054619723,0.00010797423,0.00014883715,0.0016455421,4.0178486e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.36759195,0.044738762,0.44545725,0.00008497951,0.0036677357,0.0018076489,0.000718366,0.00014906153,0.000050594157,0.000019074481,0.014928369,0.1207862],"study_design_scores_gemma":[0.38408527,0.07017474,0.5374634,0.0003767346,0.00077955995,0.00009663308,0.00045830768,0.0002682148,0.00020769324,0.000021743554,0.0059426306,0.00012506962],"about_ca_topic_score_codex":0.04760831,"about_ca_topic_score_gemma":0.36352855,"teacher_disagreement_score":0.31592026,"about_ca_system_score_codex":0.008150875,"about_ca_system_score_gemma":0.09189509,"threshold_uncertainty_score":0.99565667},"labels":[],"label_agreement":null},{"id":"W2160705179","doi":"","title":"Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"ELISPOT; Chronic lymphocytic leukemia; CD40; Medicine; Immunology; T cell; Antigen; Cancer research; Leukemia; Cytotoxic T cell; Immune system; Biology; In vitro","score_opus":0.008908773197403786,"score_gpt":0.23899276746365866,"score_spread":0.23008399426625487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160705179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873708,0.006226283,0.000008677665,0.00007411607,0.00022329013,0.002511205,0.000009550047,0.00017540871,0.0034007044],"genre_scores_gemma":[0.9920411,0.00018810629,0.00009892177,0.00013090992,0.0002675236,0.0033826127,0.000008003036,0.000082548235,0.003800278],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969309,0.00012382782,0.00037323945,0.00076988066,0.0005921779,0.0012099806],"domain_scores_gemma":[0.9979133,0.00013300072,0.000120950725,0.00065641326,0.00010481017,0.0010715534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034015055,0.0003666237,0.0004637845,0.00022034341,0.00013477945,0.0000645198,0.00013906363,0.00012855568,0.00012079123],"category_scores_gemma":[0.0002831222,0.000298267,0.000109343244,0.00032813652,0.00018090742,0.00018688876,0.00015715165,0.00031423062,0.00008691663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06099195,0.0036438757,0.143822,0.059173252,0.0029441256,0.1557403,0.0052352184,0.002798998,0.10413525,0.00075446215,0.009347587,0.45141298],"study_design_scores_gemma":[0.08146297,0.00036503817,0.57507056,0.00050738844,0.0007261477,0.002257464,0.00012620926,0.006774606,0.3224801,0.00016592213,0.008774363,0.0012892343],"about_ca_topic_score_codex":0.00008328304,"about_ca_topic_score_gemma":0.00001120543,"teacher_disagreement_score":0.45012373,"about_ca_system_score_codex":0.072160125,"about_ca_system_score_gemma":0.01380147,"threshold_uncertainty_score":0.99994695},"labels":[],"label_agreement":null},{"id":"W2160827709","doi":"10.1016/j.exphem.2007.05.022","title":"Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice","year":2007,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; Lauri Strauss Leukemia Foundation","keywords":"Waldenstrom macroglobulinemia; In vivo; Macroglobulinemia; Medicine; Cancer research; Immunology; Biology; Multiple myeloma; Genetics; Lymphoma","score_opus":0.014724740865776718,"score_gpt":0.3300461916361236,"score_spread":0.31532145077034684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160827709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915495,0.0029813156,0.00029069316,0.00025843797,0.00011566934,0.0023667281,0.000011786876,0.000025484878,0.002400379],"genre_scores_gemma":[0.99164027,0.000013439221,0.0072457064,0.00010979884,0.00007308901,0.0002574361,0.000024020159,0.000039399263,0.0005968331],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976188,0.000043821234,0.0006549035,0.0005868948,0.00036238538,0.0007331834],"domain_scores_gemma":[0.9990041,0.00020847113,0.00014156433,0.0003724867,0.000112338195,0.00016099784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005088179,0.00025216292,0.0006661145,0.00036189685,0.000028750466,0.0000063054295,0.00016528732,0.00016167884,0.00015420948],"category_scores_gemma":[0.000060605926,0.0002122285,0.000069573915,0.00041820965,0.00029628363,0.00007376115,0.00012356944,0.00021693773,0.000007406358],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038295545,0.017364005,0.026458533,0.0033493475,0.00030913227,0.00642672,0.016692946,0.00019178499,0.8660371,0.019624405,0.0035168892,0.0017336057],"study_design_scores_gemma":[0.025718354,0.0017044209,0.00015012614,0.00022144486,0.000015696778,0.0008281918,0.003484854,0.000525697,0.9664931,0.00004427696,0.0006387551,0.00017502702],"about_ca_topic_score_codex":0.0010744864,"about_ca_topic_score_gemma":0.00054694107,"teacher_disagreement_score":0.10045607,"about_ca_system_score_codex":0.006742057,"about_ca_system_score_gemma":0.0014302515,"threshold_uncertainty_score":0.9970709},"labels":[],"label_agreement":null},{"id":"W2163290737","doi":"10.1016/j.clml.2011.09.201","title":"5.47 Tyrosine Kinase Inhibitor, Gefitinib, is Cytotoxic Against Zeta-Chain-Associated Protein Kinase 70-Positive but not Zeta-Chain-Associated Protein Kinase 70-Negative CLL Cells","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Gefitinib; Tyrosine kinase; Syk; Cancer research; Cytotoxic T cell; LYN; Kinase; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-kinase inhibitor; Protein kinase B; Chemistry; Medicine; Epidermal growth factor receptor; Signal transduction; Cancer; Internal medicine; Biochemistry","score_opus":0.04686491458162083,"score_gpt":0.30493677093078114,"score_spread":0.2580718563491603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163290737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97701955,0.0005109901,0.00007182805,0.0012883459,0.0010202704,0.01092963,0.0017945865,0.0012428346,0.006121959],"genre_scores_gemma":[0.9726081,0.00021120675,0.0012552169,0.00617624,0.001600054,0.0017873541,0.0008952704,0.0007678385,0.014698719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9772285,0.0032673834,0.005989545,0.0046249097,0.0041115396,0.004778101],"domain_scores_gemma":[0.9832856,0.0032738904,0.0029882218,0.0037183366,0.003081107,0.003652841],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.006099004,0.0028463856,0.0050078337,0.0010125968,0.0011682047,0.00035966758,0.0020507195,0.0037062787,0.0011160265],"category_scores_gemma":[0.015183007,0.0026863688,0.0026893665,0.0029931066,0.0034581635,0.00094187073,0.0017520968,0.0033128697,0.002857312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03125769,0.017989043,0.0015233641,0.0017486863,0.007040614,0.04251597,0.0066760583,0.00003799089,0.774202,0.0016534664,0.018399164,0.09695595],"study_design_scores_gemma":[0.08532242,0.006642161,0.037015524,0.004810118,0.0011694726,0.000220327,0.0008314542,0.010104632,0.8480484,0.0008362355,0.00152952,0.0034697799],"about_ca_topic_score_codex":0.0048986096,"about_ca_topic_score_gemma":0.00040219398,"teacher_disagreement_score":0.09348617,"about_ca_system_score_codex":0.05445056,"about_ca_system_score_gemma":0.027186658,"threshold_uncertainty_score":0.9997971},"labels":[],"label_agreement":null},{"id":"W2164010178","doi":"10.5858/2007-131-50-fcdozi","title":"Flow Cytometric Detection of ZAP-70 in Chronic Lymphocytic Leukemia: Correlation With Immunocytochemistry and Western Blot Analysis","year":2007,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunocytochemistry; Chronic lymphocytic leukemia; Immunophenotyping; Western blot; Flow cytometry; Context (archaeology); Pathology; Blot; Leukemia; Cutoff; Medicine; Immunology; Biology; Physics","score_opus":0.00901280542787987,"score_gpt":0.28071310026451524,"score_spread":0.2717002948366354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164010178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846716,0.0053665913,0.0089799585,0.000036186968,0.000052887288,0.00036631463,0.000011489294,0.000032949705,0.0004820262],"genre_scores_gemma":[0.9982903,0.0008553053,0.00049409387,0.00006042737,0.00011056853,0.000015786569,0.00004818847,0.00003073637,0.00009460543],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973529,0.00014823148,0.00087118556,0.0004972724,0.00067269284,0.0004577144],"domain_scores_gemma":[0.99750143,0.0010605659,0.00038146632,0.0006174138,0.00021170005,0.0002274209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012682982,0.000262312,0.0010145516,0.0021771493,0.000044173747,0.000002642841,0.00018356128,0.00026003737,0.000046834342],"category_scores_gemma":[0.0007889168,0.00021039645,0.00007695257,0.0036310207,0.0015071149,0.000077555625,0.00009946937,0.0004619796,0.000002393459],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004421978,0.00013971604,0.14220741,0.0015767257,0.0010211616,0.003328791,0.002939928,0.0038163562,0.82017344,0.000026702068,0.0000050676117,0.020342726],"study_design_scores_gemma":[0.052014414,0.004657689,0.6015641,0.0014937,0.0019470375,0.0018430186,0.0011011912,0.11157147,0.22330336,0.000043150198,0.000058963753,0.00040191223],"about_ca_topic_score_codex":0.00055563863,"about_ca_topic_score_gemma":0.00079557823,"teacher_disagreement_score":0.59687006,"about_ca_system_score_codex":0.008681089,"about_ca_system_score_gemma":0.009872323,"threshold_uncertainty_score":0.9957408},"labels":[],"label_agreement":null},{"id":"W2164736957","doi":"10.1309/ajcpepx1c7hhfelk","title":"Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (<i>TP53)</i>Deletion in Chronic Lymphocytic Leukemia","year":2009,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Immunohistochemistry; Fluorescence in situ hybridization; Biology; Trisomy; Nuclear protein; In situ hybridization; Leukemia; Gene expression; Gene; Cancer research; Pathology; Molecular biology; Medicine; Chromosome; Immunology; Transcription factor; Genetics","score_opus":0.030392357084120088,"score_gpt":0.37916903507333505,"score_spread":0.34877667798921497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164736957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954721,0.0007545444,0.00029080713,0.0009979956,0.00046628359,0.0003125633,0.0000026369291,0.00005031233,0.001652783],"genre_scores_gemma":[0.9911165,0.0020109133,0.0030465384,0.00231108,0.0013230224,0.000003905098,0.000005805452,0.000049693845,0.00013248826],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99440014,0.0006899622,0.0026620566,0.00055088126,0.00086886087,0.0008280677],"domain_scores_gemma":[0.99604344,0.00094668806,0.0013318693,0.00067085226,0.00032933828,0.00067781104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002897044,0.00031691423,0.001874266,0.0004131085,0.000064748485,0.000020564497,0.0004825101,0.0003556403,0.00017407443],"category_scores_gemma":[0.0024246024,0.00025065517,0.000530964,0.0005982573,0.0010620301,0.00017511856,0.00010320616,0.0016430524,0.00011185392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021507805,0.0017639641,0.0050121723,0.0002736945,0.00029035727,0.051852934,0.00219545,0.0060495646,0.12158756,0.00021835501,0.013162545,0.7760856],"study_design_scores_gemma":[0.30584246,0.14540884,0.25203314,0.0068018762,0.0011369066,0.10293309,0.0029928358,0.12307067,0.00909676,0.0025192576,0.045686387,0.0024777635],"about_ca_topic_score_codex":0.00013998822,"about_ca_topic_score_gemma":0.000012314525,"teacher_disagreement_score":0.77360785,"about_ca_system_score_codex":0.029031891,"about_ca_system_score_gemma":0.02370157,"threshold_uncertainty_score":0.9999946},"labels":[],"label_agreement":null},{"id":"W2164859085","doi":"10.1002/gepi.20276","title":"Genetic association with rheumatoid arthritis—Genetic Analysis Workshop 15: summary of contributions from Group 2","year":2007,"lang":"en","type":"article","venue":"Genetic Epidemiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Rheumatoid arthritis; Genetic association; Candidate gene; Genome-wide association study; Association (psychology); Genetic analysis; Haplotype; Genetics; Biology; Medicine; Gene; Internal medicine; Genotype; Single-nucleotide polymorphism; Psychology","score_opus":0.01992026910401967,"score_gpt":0.31974198227567724,"score_spread":0.29982171317165757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164859085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85303044,0.023324301,0.12171264,0.00065575034,0.00015290616,0.00061249244,0.00010653635,0.000064370135,0.0003405394],"genre_scores_gemma":[0.9446422,0.008029351,0.04575883,0.00058774237,0.00028991877,0.000059682465,0.00031688192,0.00004539387,0.00027003125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99483275,0.0008086472,0.0016870564,0.00081776414,0.00058266026,0.001271103],"domain_scores_gemma":[0.99021,0.0070788926,0.00072429917,0.0010163918,0.00048475998,0.0004856403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026933535,0.0003401985,0.001736395,0.0005198905,0.00012010279,0.0000086957525,0.00028701837,0.0006221458,0.00054291065],"category_scores_gemma":[0.0047681504,0.00029860297,0.00039012003,0.0013716831,0.00039705998,0.00003227316,0.00013266379,0.000488408,0.00008199062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006011125,0.00022831513,0.9692518,0.000043420983,0.0032878222,0.00024012697,0.0001634172,0.0030674092,0.0016947645,0.00015232191,0.0027671736,0.018502302],"study_design_scores_gemma":[0.009956613,0.00050346134,0.9730347,0.0001947675,0.0009879845,0.0001659047,0.00013915231,0.0107353125,0.0007000023,0.0013970234,0.0018666538,0.00031842611],"about_ca_topic_score_codex":0.0040628836,"about_ca_topic_score_gemma":0.004080272,"teacher_disagreement_score":0.091611706,"about_ca_system_score_codex":0.004942894,"about_ca_system_score_gemma":0.0016097268,"threshold_uncertainty_score":0.9999466},"labels":[],"label_agreement":null},{"id":"W2166900896","doi":"10.1186/1746-1596-2-34","title":"Synchronously diagnosed lymph nodal collision tumor of malignant melanoma and chonic lymphocytic leukemia/small lymphocytic lymphoma: case report","year":2007,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; NOSM University","funders":"McMaster University","keywords":"Chronic lymphocytic leukemia; Medicine; Melanoma; Lymphoma; Pathology; Lymph node; Leukemia; Lymphoproliferative disorders; Lymph; NODAL; Cancer research; Immunology; Internal medicine","score_opus":0.015005799263599887,"score_gpt":0.27802811698388014,"score_spread":0.26302231772028023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166900896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900453,0.0043376954,0.0012059684,0.00007693786,0.0008409902,0.0018625202,0.00007620605,0.00023288855,0.0013215019],"genre_scores_gemma":[0.9953389,0.00087428896,0.0018771774,0.0005555599,0.00040510658,0.00020965049,0.0001357523,0.00017924441,0.00042431554],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9928534,0.00031844998,0.0021712428,0.0016999776,0.0009616262,0.001995309],"domain_scores_gemma":[0.98762715,0.008059399,0.00078436726,0.0018764477,0.00058153755,0.0010711186],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027979736,0.0008573439,0.0018957607,0.00086647883,0.00030577774,0.000051127576,0.00044018895,0.00068046176,0.00011616032],"category_scores_gemma":[0.011312352,0.0007857988,0.00036444044,0.00097610126,0.001407797,0.00016417084,0.0006003958,0.00029768076,0.00015608243],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010330285,0.00039914527,0.014118114,0.0008647198,0.00020246675,0.9706762,0.00068920804,0.0001794118,0.0028409876,0.00034555033,0.00029855748,0.008352622],"study_design_scores_gemma":[0.048213754,0.0013750315,0.04560932,0.0007977506,0.00067610625,0.87355614,0.000780543,0.010661647,0.01699329,0.00015353551,0.00039449264,0.00078836444],"about_ca_topic_score_codex":0.007760395,"about_ca_topic_score_gemma":0.00063522684,"teacher_disagreement_score":0.097120024,"about_ca_system_score_codex":0.061011624,"about_ca_system_score_gemma":0.035384964,"threshold_uncertainty_score":0.99945927},"labels":[],"label_agreement":null},{"id":"W2167673584","doi":"10.1182/blood-2004-03-1046","title":"Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Fondation de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Alberta Cancer Foundation","keywords":"Chronic lymphocytic leukemia; Fludarabine; Biology; Leukemia; Gene; Gene expression; Nucleoside transporter; Genetics; Cancer research; Transporter; Chemotherapy","score_opus":0.025238310660422317,"score_gpt":0.30608211591879825,"score_spread":0.28084380525837593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167673584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970358,0.0013893148,0.0008847211,0.000044710196,0.000020388348,0.00044131998,0.000091470254,0.00001414285,0.000078137135],"genre_scores_gemma":[0.9966793,0.00040170795,0.0027053636,0.000016085536,0.00002145189,0.000014272074,0.00011284222,0.0000200465,0.000028918295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829185,0.00007173941,0.00064330164,0.00039989033,0.00036872612,0.00022448244],"domain_scores_gemma":[0.99877846,0.000113860544,0.00031345306,0.00038679602,0.0002995844,0.0001078367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033548032,0.00017003488,0.00069620786,0.0007073093,0.00006701317,0.000014006384,0.000063337226,0.00011997981,0.0000071731333],"category_scores_gemma":[0.00021869568,0.00015676748,0.000121052704,0.0006802566,0.00034868467,0.00016330229,0.000040468574,0.00011532967,0.0000016869644],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038974543,0.00017539057,0.0013073125,0.00022805811,0.00093611545,0.00015518416,0.0040728804,0.003767478,0.9876166,0.000998531,0.0000018491879,0.0003508745],"study_design_scores_gemma":[0.02205171,0.0001301726,0.39020747,0.00026544358,0.0027768577,0.000058562084,0.00042330634,0.021031134,0.56270844,0.0002094856,0.0000013617978,0.0001360856],"about_ca_topic_score_codex":0.00386526,"about_ca_topic_score_gemma":0.00085321843,"teacher_disagreement_score":0.42490816,"about_ca_system_score_codex":0.005120114,"about_ca_system_score_gemma":0.0040855817,"threshold_uncertainty_score":0.99869907},"labels":[],"label_agreement":null},{"id":"W2168385579","doi":"10.1177/2040620715586528","title":"Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Fludarabine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide; Leukemia; Venetoclax; Immunology; Lymphoma","score_opus":0.06151108374895914,"score_gpt":0.40383932520121707,"score_spread":0.34232824145225793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168385579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003033878,0.99206734,0.00008973394,0.000014443375,0.000101958336,0.0071917786,0.000050436163,0.000034318633,0.00014660908],"genre_scores_gemma":[0.0012612257,0.9965869,0.00011926529,0.000023415443,0.00007277459,0.0015749783,0.00008937774,0.0001039372,0.00016812867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718785,0.00023041706,0.0008023535,0.0007231907,0.0003734701,0.00068269216],"domain_scores_gemma":[0.9963374,0.00178498,0.0005101166,0.00086496957,0.00036887976,0.00013361251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023958924,0.00065228564,0.0035030644,0.00023639256,0.000067041,0.0000102589265,0.000278177,0.000371492,0.00003095643],"category_scores_gemma":[0.00006812648,0.00033356066,0.00027500614,0.0005128421,0.0007770278,0.0000837588,0.000059235048,0.00022043691,0.000007972583],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012653458,0.00016523231,0.00003134321,0.027891245,0.0012519239,0.000054658176,0.0007163818,0.000061337596,1.8946196e-8,0.0046281843,0.000010290772,0.96392405],"study_design_scores_gemma":[0.037884373,0.0067856247,0.000005629139,0.010184438,0.004384061,0.00081896794,0.000236274,0.001341279,0.0000045698025,0.0011519899,0.93678015,0.00042262007],"about_ca_topic_score_codex":0.0003293423,"about_ca_topic_score_gemma":0.00024517748,"teacher_disagreement_score":0.9635014,"about_ca_system_score_codex":0.18307987,"about_ca_system_score_gemma":0.045590166,"threshold_uncertainty_score":0.99991167},"labels":[],"label_agreement":null},{"id":"W2169038235","doi":"10.3109/10428194.2011.605188","title":"Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency; University of British Columbia","keywords":"Fludarabine; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Discontinuation; Oncology; Clinical trial; Population; Lymphoma; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.16902655781496087,"score_gpt":0.4110555117732854,"score_spread":0.24202895395832455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169038235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98224974,0.0065996978,0.0008607837,0.00015002576,0.0014822974,0.0061166277,0.00021683217,0.0010186302,0.0013053897],"genre_scores_gemma":[0.9768345,0.0046451837,0.0064228186,0.0040626638,0.002075733,0.002274258,0.0005984796,0.0006563668,0.002429996],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.983153,0.001778013,0.0051964703,0.0041572424,0.0020702505,0.0036450168],"domain_scores_gemma":[0.985309,0.0062262067,0.0018208304,0.0029640738,0.00089165894,0.00278824],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0062896474,0.0026829324,0.0058737206,0.0012391909,0.0013744883,0.0006260576,0.001509934,0.0024620027,0.0006739728],"category_scores_gemma":[0.0052683675,0.0022041271,0.0016680532,0.0016519644,0.0024450838,0.0009895059,0.00071447936,0.00044372122,0.00026296536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09926279,0.0021084626,0.00884541,0.0039745793,0.0030125733,0.00480382,0.00553016,0.00027635702,0.0020908562,0.0023844868,0.004052529,0.86365795],"study_design_scores_gemma":[0.6312615,0.009349074,0.056142997,0.0022934193,0.0023340138,0.011225383,0.0019325655,0.22993234,0.023821412,0.0022210223,0.024391815,0.005094463],"about_ca_topic_score_codex":0.028592868,"about_ca_topic_score_gemma":0.00073121785,"teacher_disagreement_score":0.8585635,"about_ca_system_score_codex":0.23871256,"about_ca_system_score_gemma":0.2065082,"threshold_uncertainty_score":0.9999256},"labels":[],"label_agreement":null},{"id":"W2169100741","doi":"10.1016/j.bbmt.2013.12.148","title":"Incidence and Risk Factors for the Development of Idiopathic Pneumonitis Syndrome (IPS) after Autologous Hematopoietic Cell Transplantation (AutoHCT) for Patients with Lymphoma","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Incidence (geometry); Lymphoma; Carmustine; Hematopoietic cell; Oncology; Transplantation; Pneumonitis; Hematopoietic stem cell transplantation; Internal medicine; Etoposide; Haematopoiesis; Chemotherapy; Stem cell; Lung","score_opus":0.0074266301622314,"score_gpt":0.22993989981757926,"score_spread":0.22251326965534785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169100741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853216,0.00045056632,0.0130089745,0.000017214452,0.00003625859,0.0009884752,0.00015896944,0.000012442619,0.0000055196288],"genre_scores_gemma":[0.9958757,0.0006977831,0.0030624853,0.000009831356,0.0000081332355,0.0001646646,0.00016141057,0.000014352426,0.000005633236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990289,0.00006304672,0.00034695308,0.00023862206,0.00012918637,0.00019327486],"domain_scores_gemma":[0.9988908,0.0006640105,0.00016609051,0.00010577407,0.00011683013,0.000056472567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003148708,0.00014417848,0.00031625302,0.00008278564,0.00010323602,0.000004980937,0.000058109254,0.00012928814,0.000001859501],"category_scores_gemma":[0.000033772012,0.00009265649,0.000041301686,0.000056621517,0.0002274224,0.000048979047,0.000005594172,0.000047249305,1.8240226e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010072893,0.00065733265,0.87767124,0.018587781,0.0007269914,0.00002572484,0.023881782,0.000014935454,0.03859625,0.00022280418,0.0000015483485,0.029540718],"study_design_scores_gemma":[0.026642758,0.003295386,0.8821567,0.0005791461,0.0018159971,0.0003854565,0.00023689186,0.00050062913,0.08393436,0.0002275025,0.00001230642,0.0002128292],"about_ca_topic_score_codex":0.00006368994,"about_ca_topic_score_gemma":0.000069504385,"teacher_disagreement_score":0.04533811,"about_ca_system_score_codex":0.000061197374,"about_ca_system_score_gemma":0.00038925235,"threshold_uncertainty_score":0.37784222},"labels":[],"label_agreement":null},{"id":"W2169404246","doi":"10.1016/s0014-5793(02)03025-9","title":"Potentiation of hematopoietic cell migration with an IGF–interleukin‐3 fusion protein","year":2002,"lang":"en","type":"article","venue":"FEBS Letters","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Chimera (genetics); Haematopoiesis; Phosphatidylinositol; Long-term potentiation; Cell biology; Stimulation; Kinase; Interleukin 15; Chemistry; Protein kinase B; Biology; Interleukin; Signal transduction; Biochemistry; Endocrinology; Stem cell; Immunology; Receptor; Cytokine; Gene","score_opus":0.014392849566749556,"score_gpt":0.2350757834873687,"score_spread":0.22068293392061916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169404246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933997,0.00007349845,0.0013457128,0.0037653067,0.00003165457,0.0006715059,0.0000020383288,0.000049287486,0.00066133693],"genre_scores_gemma":[0.99674994,0.000008146694,0.0014676504,0.0006516629,0.00009156753,0.000035391018,0.000035026213,0.000028335393,0.00093225786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865425,0.00005662379,0.00024208926,0.0002591893,0.00053999166,0.00024784834],"domain_scores_gemma":[0.99926686,0.000021052234,0.00011242276,0.00040365508,0.000086323416,0.00010967468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012942086,0.00013021419,0.00019816878,0.00014095665,0.00004469114,0.000019995723,0.000099745936,0.00006563514,0.0004259404],"category_scores_gemma":[0.000022936018,0.000101990285,0.000056026904,0.00021287551,0.00008027257,0.00015818825,0.000025573558,0.00013713635,0.00008422952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004748154,0.0004228334,0.0011969231,0.0006500595,0.00004167956,0.00018249273,0.0019825369,0.0001223819,0.98839086,0.00003370336,0.0046285437,0.001873151],"study_design_scores_gemma":[0.024454905,0.0029360913,0.004296138,0.00097026746,0.00019407275,0.00048386824,0.00057494786,0.06590426,0.8980639,0.00003365365,0.0016076061,0.00048028998],"about_ca_topic_score_codex":0.00037358768,"about_ca_topic_score_gemma":0.00006841301,"teacher_disagreement_score":0.09032698,"about_ca_system_score_codex":0.0015561132,"about_ca_system_score_gemma":0.00021258705,"threshold_uncertainty_score":0.46637487},"labels":[],"label_agreement":null},{"id":"W2170549608","doi":"10.1667/rr1443.1","title":"Ionizing Radiation and Risk of Chronic Lymphocytic Leukemia in the 15-Country Study of Nuclear Industry Workers","year":2008,"lang":"en","type":"article","venue":"Radiation Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"National Institute for Occupational Safety and Health; U.S. Public Health Service; National Institutes of Health","keywords":"Ionizing radiation; Chronic lymphocytic leukemia; Leukemia; Occupational exposure; Nuclear industry; Environmental health; Business; Medicine; Immunology; Irradiation; Physics; Nuclear engineering; Nuclear physics; Engineering","score_opus":0.0487019160785126,"score_gpt":0.35108116242565784,"score_spread":0.30237924634714525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170549608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960809,0.001640458,0.000002772442,0.00007302506,0.000040830007,0.0013832314,0.000006234311,0.000017196267,0.0007554067],"genre_scores_gemma":[0.99722826,0.0023203641,0.00003118675,0.00002126632,0.00017619104,0.00005010185,0.000009445108,0.000030281046,0.0001329013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957865,0.0009548862,0.0005762537,0.0003614725,0.0018188873,0.0005019981],"domain_scores_gemma":[0.99757695,0.0012174962,0.00018797019,0.00063056475,0.00025275297,0.00013425613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035204873,0.00014323698,0.00036343135,0.0007282045,0.00025487703,0.000024990468,0.00029285593,0.00029345718,0.00009407097],"category_scores_gemma":[0.0016608058,0.000113223534,0.000048619382,0.0019276169,0.00044947307,0.00015944628,0.000112795926,0.0012118678,0.000017201113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024952933,0.0011693233,0.8734167,0.0011600724,0.0006834155,0.0005799451,0.053187348,0.019580161,0.0016469328,0.0004672085,0.009382389,0.03623118],"study_design_scores_gemma":[0.032052647,0.0020491667,0.73614013,0.00025925256,0.00008695251,0.00023000636,0.016946044,0.21057226,0.00053892244,0.0000484273,0.0008924007,0.00018378877],"about_ca_topic_score_codex":0.01758461,"about_ca_topic_score_gemma":0.00029025177,"teacher_disagreement_score":0.19099209,"about_ca_system_score_codex":0.039351273,"about_ca_system_score_gemma":0.020157369,"threshold_uncertainty_score":0.9889574},"labels":[],"label_agreement":null},{"id":"W2170617812","doi":"10.18433/j3f01c","title":"Profiles of Surface Mosaics on Chronic Lymphocytic Leukemias Distinguish Stable and Progressive Subtypes","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University of Leicester; Leukemia Research Foundation","keywords":"Chronic lymphocytic leukemia; Antigen; CD20; CD5; Antibody; CD19; Microarray; Medicine; Immunology; Disease; Leukemia; Biology; Internal medicine; Gene expression; Gene; Genetics","score_opus":0.06092169025568291,"score_gpt":0.3976982473995548,"score_spread":0.3367765571438719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170617812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848475,0.010840576,0.00001683928,0.0008510872,0.00025501515,0.000663964,0.0000072587145,0.000021227508,0.0024965613],"genre_scores_gemma":[0.9961048,0.0018957327,0.0010583983,0.00027992603,0.00041517892,0.000009217667,0.0000012225985,0.000021411997,0.00021411075],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99635214,0.00016810984,0.0008091003,0.00035810834,0.0015872119,0.00072534935],"domain_scores_gemma":[0.99726427,0.000729235,0.00047894474,0.00017356907,0.00065993523,0.0006940216],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013858377,0.00025900107,0.000587274,0.00018771071,0.00019116512,0.00011631631,0.0004512556,0.00006397098,0.0009952211],"category_scores_gemma":[0.0007488813,0.00017251425,0.00014745657,0.00067523186,0.0015811395,0.00046676912,0.00017377855,0.00053093897,0.000038121365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0058398424,0.0023758844,0.08200271,0.00728404,0.0013951814,0.0025659488,0.0024001147,0.007850855,0.61250997,0.0028910353,0.017406214,0.25547823],"study_design_scores_gemma":[0.02963412,0.003320219,0.0014848816,0.0013066453,0.00042805064,0.0025535815,0.0005032606,0.2917947,0.6493641,0.00033163035,0.018830063,0.00044876133],"about_ca_topic_score_codex":0.00026742546,"about_ca_topic_score_gemma":0.0000017379888,"teacher_disagreement_score":0.28394383,"about_ca_system_score_codex":0.007110501,"about_ca_system_score_gemma":0.0141344275,"threshold_uncertainty_score":0.999918},"labels":[],"label_agreement":null},{"id":"W2171667554","doi":"10.1053/ajkd.2000.16219","title":"Renal failure due to T-cell mediated lymphocytic vasculitis: An unusual complication of B-cell chronic lymphocytic leukemia","year":2000,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Vasculitis; Complication; Autopsy; Renal biopsy; Pathology; Acute lymphocytic leukemia; Biopsy; Leukemia; Immunology; Internal medicine; Lymphoblastic Leukemia; Disease","score_opus":0.00803313451475035,"score_gpt":0.26620114063009176,"score_spread":0.2581680061153414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171667554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605507,0.001067311,0.00027663595,0.00048735618,0.00007493122,0.00059192127,0.0002462894,0.00006994377,0.0011305187],"genre_scores_gemma":[0.9947116,0.0005454102,0.001424356,0.0019761778,0.0006022913,0.000029375284,0.00019026673,0.00009973703,0.0004208065],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953219,0.00035551673,0.0013314281,0.0005572247,0.0016008088,0.0008331018],"domain_scores_gemma":[0.99299085,0.00038044478,0.0007536055,0.000961073,0.0007012229,0.004212807],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039734677,0.00045392898,0.0013476533,0.0005756905,0.00011759055,0.000054564916,0.0007438312,0.000109577144,0.0011473425],"category_scores_gemma":[0.00085763633,0.0003958685,0.00049747236,0.0014070802,0.0007527666,0.0003479882,0.000085053056,0.0003168949,0.00021216639],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.041329157,0.007270801,0.004232328,0.0067502125,0.0043324935,0.012492122,0.0070605413,0.054386783,0.3698737,0.00018208612,0.18872114,0.30336863],"study_design_scores_gemma":[0.37448335,0.07220938,0.03397294,0.010072773,0.010064241,0.028309993,0.007434549,0.14345457,0.20184489,0.00049660174,0.11199742,0.0056593036],"about_ca_topic_score_codex":0.0015411329,"about_ca_topic_score_gemma":0.000020318392,"teacher_disagreement_score":0.3331542,"about_ca_system_score_codex":0.0629074,"about_ca_system_score_gemma":0.13578385,"threshold_uncertainty_score":0.9998493},"labels":[],"label_agreement":null},{"id":"W2177518224","doi":"10.1016/j.beha.2015.10.017","title":"Clinical features and diagnosis of hairy cell leukemia","year":2015,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; University of Toronto","funders":"","keywords":"Hairy cell leukemia; Hairy Cell; Lymphoproliferative disorders; Leukemia; Medicine; Immune system; Immunology; Pathology; Lymphoma","score_opus":0.37965414957013266,"score_gpt":0.6136137103463898,"score_spread":0.23395956077625712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2177518224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00082306814,0.9756818,0.0000053292424,0.0011317076,0.00076608214,0.0037945085,0.0000637178,0.000071192975,0.017662615],"genre_scores_gemma":[0.000150319,0.99117327,0.0028394698,0.0002456178,0.0012999162,0.0006451003,0.00012680374,0.0002274631,0.0032920288],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.969371,0.017177124,0.0057229055,0.0024408556,0.0033215247,0.0019665642],"domain_scores_gemma":[0.8821494,0.107147634,0.0018779286,0.003014222,0.0034784763,0.002332369],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.042774554,0.00087809836,0.009996681,0.0010032397,0.00021259466,0.000111903115,0.0014549308,0.0043743798,0.0002560636],"category_scores_gemma":[0.14892122,0.00066429924,0.0016212572,0.0015464498,0.0062988973,0.00036989714,0.0029589108,0.011945181,0.0015853255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012277866,0.0036883214,0.00052399747,0.0405954,0.0010536275,0.010206135,0.00005689039,7.878871e-8,3.599113e-8,0.00066430465,0.12351959,0.8184638],"study_design_scores_gemma":[0.009019904,0.005330153,0.000013997142,0.011357942,0.0031628155,0.016753456,0.00030640277,0.000036761146,0.0000015729076,0.00015740722,0.95339924,0.0004603542],"about_ca_topic_score_codex":0.001332314,"about_ca_topic_score_gemma":0.00009678429,"teacher_disagreement_score":0.82987964,"about_ca_system_score_codex":0.005920427,"about_ca_system_score_gemma":0.091927715,"threshold_uncertainty_score":0.9995808},"labels":[],"label_agreement":null},{"id":"W2177933356","doi":"10.1016/j.jcjo.2015.05.009","title":"An atypical case of bilateral posterior scleritis in a patient with chronic lymphocytic leukemia","year":2015,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine; McMaster University Medical Centre","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Chlorambucil; Cryotherapy; Leukemia; Surgery; Dermatology; Ophthalmology; Internal medicine; Cyclophosphamide; Chemotherapy","score_opus":0.02994543563421676,"score_gpt":0.2987843925105766,"score_spread":0.26883895687635984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2177933356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98989314,0.0017209287,0.0000012497635,0.0063828076,0.00047868886,0.00053565495,0.000104037375,0.0000042506704,0.00087922317],"genre_scores_gemma":[0.9916342,0.0000066747452,0.0003582847,0.006181241,0.0012822571,0.000014888261,0.0000756,0.0001194071,0.00032748337],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9962061,0.00039065874,0.0012103938,0.00045713954,0.0005620822,0.0011735992],"domain_scores_gemma":[0.9962442,0.00013924466,0.00059233635,0.0007504775,0.00084734056,0.0014263986],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045929145,0.0004481642,0.0015328813,0.0015488067,0.00005043753,0.000039179664,0.0004638048,0.0011664705,0.0011511545],"category_scores_gemma":[0.00019832824,0.00036882242,0.00020163141,0.00045302018,0.0007881095,0.00015446148,0.000043787666,0.0021888018,0.000018142218],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009438039,0.000017167346,0.0007573555,0.0004633721,0.00017512184,0.9674079,0.0005167335,0.00024007467,0.000038507595,0.0000011944537,0.028625766,0.00081301987],"study_design_scores_gemma":[0.01251294,0.010383432,0.00052375963,0.0013309673,0.00014606127,0.96827096,0.000095934694,0.0010477524,0.00006978271,0.000027815191,0.005275948,0.00031462856],"about_ca_topic_score_codex":0.10734469,"about_ca_topic_score_gemma":0.0072696544,"teacher_disagreement_score":0.15711263,"about_ca_system_score_codex":0.15961288,"about_ca_system_score_gemma":0.3167255,"threshold_uncertainty_score":0.9998764},"labels":[],"label_agreement":null},{"id":"W2183175945","doi":"","title":"Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"CD23; Chronic lymphocytic leukemia; Lymphoma; Leukemia; Pathology; Antigen; B cell; Medicine; Immunology; Antibody; Immunoglobulin E","score_opus":0.034614838515372066,"score_gpt":0.29226677456730804,"score_spread":0.257651936051936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2183175945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863976,0.0056359274,0.0000030296042,0.00007151505,0.000038083148,0.0011564846,0.000006603849,0.00003565792,0.006655068],"genre_scores_gemma":[0.9936725,0.0017085047,0.00007272232,0.0000623383,0.00007402847,0.00049447623,0.00000802791,0.000030191695,0.0038772249],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980909,0.00007160144,0.00040243976,0.00038498433,0.00045361454,0.00059640844],"domain_scores_gemma":[0.999048,0.00025265818,0.00006914375,0.00030916813,0.000071285715,0.00024977734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041149027,0.00017541804,0.00043991985,0.00022031346,0.0000365561,0.000014539094,0.0001287466,0.00014565577,0.00016188827],"category_scores_gemma":[0.00030172686,0.00014824994,0.000058701953,0.00041735914,0.0001560859,0.00015079603,0.0000733686,0.000189515,0.000046750338],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018190091,0.0006165621,0.0044064503,0.009012018,0.00053194846,0.0026774807,0.0088244425,0.006268183,0.17006503,0.002284036,0.005361575,0.7717622],"study_design_scores_gemma":[0.09291145,0.00089924043,0.10504962,0.0014414844,0.00014541205,0.00057593756,0.00040879808,0.103224255,0.6897164,0.00041523698,0.004492711,0.00071947713],"about_ca_topic_score_codex":0.0005949019,"about_ca_topic_score_gemma":0.00006724346,"teacher_disagreement_score":0.7710427,"about_ca_system_score_codex":0.04236443,"about_ca_system_score_gemma":0.008555195,"threshold_uncertainty_score":0.99706537},"labels":[],"label_agreement":null},{"id":"W2191219754","doi":"10.1016/s1470-2045(15)00465-9","title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":410,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; Juravinski Cancer Centre","funders":"Janssen Research and Development","keywords":"Bendamustine; Medicine; Rituximab; Ibrutinib; Internal medicine; Chronic lymphocytic leukemia; Placebo; Oncology; Gastroenterology; Lymphoma; Leukemia; Pathology","score_opus":0.13129195784477976,"score_gpt":0.38503411858453745,"score_spread":0.2537421607397577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2191219754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788823,0.002192649,0.00022852577,0.0009928191,0.00014280963,0.015851984,0.00008431864,0.00035268796,0.0012719224],"genre_scores_gemma":[0.9916122,0.00032696532,0.0017222492,0.0005654421,0.00080281845,0.0031024124,0.0002519831,0.0002084521,0.0014074568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939083,0.0006927122,0.0011502715,0.0014515923,0.0008639209,0.0019332087],"domain_scores_gemma":[0.9937594,0.0023710195,0.0006060019,0.0014853227,0.00074793067,0.0010303587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027990588,0.0010352015,0.003595498,0.00038596964,0.0004893611,0.00018390616,0.0006850158,0.0003925034,0.000067958594],"category_scores_gemma":[0.00052255334,0.0005919786,0.00013047109,0.00093805825,0.0014375306,0.00018874396,0.00039477277,0.00045623965,0.000037904134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9775483,0.004635626,0.0006297493,0.0012263547,0.0016491325,0.0020010236,0.003070029,0.00025711255,0.00010172141,0.000102744714,0.0020200107,0.0067581697],"study_design_scores_gemma":[0.866789,0.04515382,0.00012858612,0.00046812362,0.00267764,0.008700125,0.0016653505,0.06949015,0.00034785626,0.00002738809,0.0038700402,0.00068196136],"about_ca_topic_score_codex":0.002445562,"about_ca_topic_score_gemma":0.0049949274,"teacher_disagreement_score":0.11075937,"about_ca_system_score_codex":0.035793945,"about_ca_system_score_gemma":0.045895047,"threshold_uncertainty_score":0.99965316},"labels":[],"label_agreement":null},{"id":"W2201686281","doi":"10.1016/j.jcjo.2015.03.013","title":"Erlotinib-associated bilateral anterior uveitis: resolution with posterior sub-Tenon’s triamcinolone without erlotinib cessation","year":2015,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Erlotinib; Triamcinolone acetonide; Mortise and tenon; Ophthalmology; Internal medicine; Epidermal growth factor receptor","score_opus":0.0456717678429731,"score_gpt":0.30223283749277424,"score_spread":0.25656106964980113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2201686281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91554856,0.0015668039,0.000006704632,0.07657319,0.0016775787,0.0010997793,0.00022197458,0.00002514657,0.0032802387],"genre_scores_gemma":[0.9766262,0.00001744102,0.00024886822,0.012930868,0.003479646,0.000031599287,0.0005268466,0.00023787424,0.0059006386],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99432486,0.0007676597,0.0015121719,0.0006424361,0.0011143617,0.0016384803],"domain_scores_gemma":[0.9939944,0.00020646697,0.0015795394,0.00069687923,0.0021910395,0.0013316565],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0014264,0.0006735207,0.002014764,0.0017945146,0.00018874668,0.00014080765,0.00063576736,0.0019212441,0.00074179604],"category_scores_gemma":[0.0010517205,0.00055487663,0.0003374324,0.00057862356,0.00068781717,0.00026661746,0.00005442491,0.0034093417,0.000077309196],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0040191566,0.00010137362,0.018757464,0.00050179736,0.0015932112,0.61548734,0.0010246201,0.00001764364,0.0004075009,0.0000019771467,0.35767522,0.00041268783],"study_design_scores_gemma":[0.03226505,0.0073588276,0.01588555,0.00297102,0.0008122552,0.92704386,0.000118373646,0.0001845163,0.00018001343,0.000057052777,0.012380215,0.0007432543],"about_ca_topic_score_codex":0.020167787,"about_ca_topic_score_gemma":0.002113429,"teacher_disagreement_score":0.345295,"about_ca_system_score_codex":0.023821957,"about_ca_system_score_gemma":0.06670996,"threshold_uncertainty_score":0.9996903},"labels":[],"label_agreement":null},{"id":"W2202470170","doi":"10.1182/blood.v124.21.5670.5670","title":"A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Juravinski Cancer Centre; Kingston General Hospital; Princess Margaret Cancer Centre; CancerCare Manitoba; University of Toronto","funders":"","keywords":"Medicine; Tumor lysis syndrome; Internal medicine; Chronic lymphocytic leukemia; Regimen; Gastroenterology; Cytopenia; Febrile neutropenia; Oncology; Neutropenia; Leukemia; Immunology; Chemotherapy; Bone marrow","score_opus":0.012514800442363801,"score_gpt":0.2805970150934022,"score_spread":0.2680822146510384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202470170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953993,0.00015885275,0.0000067675496,0.000012798793,0.0001573475,0.0036272905,0.00000834997,0.000069748305,0.00055951905],"genre_scores_gemma":[0.9988465,0.000008881058,0.000058550067,0.00004691358,0.00046271298,0.00022826588,0.000034384753,0.000076783836,0.00023701332],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99605167,0.00022648221,0.000849939,0.0006879844,0.0014246221,0.00075932813],"domain_scores_gemma":[0.9979572,0.00020318203,0.00025729692,0.0010451967,0.00023916442,0.0002979187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006901926,0.00037178304,0.0009500421,0.00045581258,0.000103421975,0.000021342945,0.00031539277,0.00023421287,0.00007626603],"category_scores_gemma":[0.00045778535,0.00029250557,0.000111306304,0.00087999215,0.00018004855,0.00013357867,0.00027434534,0.0004459723,0.00003992541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.56530917,0.28525552,0.06255072,0.0039597107,0.0038103082,0.0018284104,0.01899506,0.00073445396,0.003953878,0.00018461836,0.001778782,0.051639374],"study_design_scores_gemma":[0.9108613,0.08005922,0.0029417155,0.00042021208,0.00043288394,0.000032780306,0.00015434003,0.0021418775,0.0024565223,0.00001305025,0.00019940951,0.0002866704],"about_ca_topic_score_codex":0.0023176798,"about_ca_topic_score_gemma":0.0006698669,"teacher_disagreement_score":0.34555215,"about_ca_system_score_codex":0.03192512,"about_ca_system_score_gemma":0.027125042,"threshold_uncertainty_score":0.99995273},"labels":[],"label_agreement":null},{"id":"W2208304134","doi":"10.1182/blood.v122.21.5378.5378","title":"Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Plasma cell leukemia; Bortezomib; Internal medicine; Cyclophosphamide; Gastroenterology; Dexamethasone; Median follow-up; Plasma cell dyscrasia; Melphalan; Multiple myeloma; Surgery; Chemotherapy; Immunology","score_opus":0.0133084105670059,"score_gpt":0.24151796921355104,"score_spread":0.22820955864654513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208304134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336296,0.0012768258,0.00013378523,0.00017603823,0.00006662073,0.0020281835,0.000008189348,0.0001005032,0.0028469053],"genre_scores_gemma":[0.9867563,0.0006936821,0.00915973,0.00038612934,0.00027224957,0.0005276251,0.000050505383,0.00008682242,0.0020669594],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983538,0.000051179642,0.00026411546,0.0004274561,0.00039971396,0.00050373573],"domain_scores_gemma":[0.99868155,0.00029413585,0.00009090485,0.00045519893,0.00020959238,0.000268631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002928573,0.00024714018,0.0003865941,0.00011347166,0.0001455662,0.00005714157,0.000116456824,0.00019470953,0.00008509364],"category_scores_gemma":[0.00008092284,0.00018283752,0.00006338241,0.00023726591,0.0001749215,0.00019802828,0.000052591502,0.00035638598,0.000041110987],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007358112,0.006116208,0.023219418,0.0034795632,0.0018340409,0.0003199422,0.0034013763,0.00004653454,0.45623773,0.00017053324,0.010983961,0.48683256],"study_design_scores_gemma":[0.28704605,0.0064650313,0.09894475,0.0003499087,0.0005407701,0.0018494854,0.0008690362,0.0021918237,0.5871111,0.0004702643,0.013204227,0.0009575219],"about_ca_topic_score_codex":0.0012809582,"about_ca_topic_score_gemma":0.000022815166,"teacher_disagreement_score":0.48587504,"about_ca_system_score_codex":0.0023926955,"about_ca_system_score_gemma":0.0038767618,"threshold_uncertainty_score":0.7455898},"labels":[],"label_agreement":null},{"id":"W2208724911","doi":"10.1016/j.exphem.2015.12.004","title":"Monoclonal antibody 1.6.1 against human MPL receptor allows HSC enrichment of CB and BM CD34+CD38− populations","year":2015,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Groupement des Entreprises Françaises dans la lutte contre le Cancer; Institut National Du Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"CD38; Monoclonal antibody; CD34; Antibody; Chemistry; Molecular biology; Biology; Immunology; Cell biology; Stem cell","score_opus":0.08519099220681613,"score_gpt":0.4205208521251382,"score_spread":0.33532985991832204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208724911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98654413,0.005190933,0.000047925012,0.00031223058,0.00021307931,0.0005569705,0.0000107063415,0.0000558356,0.0070681665],"genre_scores_gemma":[0.99654764,0.000025720712,0.0022406292,0.00016579224,0.0000949256,0.0000619846,0.00023287341,0.000033536748,0.0005968744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819005,0.00008549297,0.00049318984,0.00039121325,0.00043486187,0.0004051804],"domain_scores_gemma":[0.9989842,0.000052276395,0.000119825345,0.00038614648,0.00009358788,0.0003639693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020034742,0.00020933262,0.0005471749,0.0001648488,0.000091067996,0.000010647095,0.00013190668,0.0001613766,0.0002673076],"category_scores_gemma":[0.000058801877,0.00019164852,0.00008581171,0.00015102378,0.00035731102,0.000083684936,0.00023149914,0.00015750053,0.000090435635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012333137,0.0031046767,0.060937412,0.00036974222,0.00042386618,0.0005759345,0.0058555556,0.000018513178,0.67047554,0.23521014,0.02130289,0.00049238413],"study_design_scores_gemma":[0.03162692,0.0019810305,0.002280663,0.0002225935,0.000053881606,0.0019313684,0.0052651847,0.0023060145,0.9443624,0.00063347456,0.00881934,0.0005171095],"about_ca_topic_score_codex":0.0004195287,"about_ca_topic_score_gemma":0.000018005536,"teacher_disagreement_score":0.27388686,"about_ca_system_score_codex":0.0018910182,"about_ca_system_score_gemma":0.00089725223,"threshold_uncertainty_score":0.78151995},"labels":[],"label_agreement":null},{"id":"W2213329089","doi":"10.4049/jimmunol.1500630","title":"Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Phosphatidylinositol; Pleckstrin homology domain; Cell biology; Phosphatidylinositol 4,5-bisphosphate; Phosphatase; Chemotaxis; Cell migration; Inositol; Biology; Second messenger system; Motility; Signal transduction; Chemistry; Molecular biology; Biochemistry; Receptor; Cell; Phosphorylation","score_opus":0.02958558511493979,"score_gpt":0.2818115988362296,"score_spread":0.2522260137212898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2213329089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703036,0.027403444,0.000021143851,0.0014397049,0.000190804,0.00038727155,0.0000028023296,0.0000111521995,0.00024005491],"genre_scores_gemma":[0.99461603,0.0029565585,0.0003963964,0.000044572174,0.00008354152,0.0000036516535,0.0000013175246,0.000028338292,0.001869589],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979937,0.00021312176,0.00075123494,0.0001377477,0.00050184503,0.00040233642],"domain_scores_gemma":[0.9979769,0.0002223051,0.00065860886,0.00035801163,0.0006128131,0.00017135692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018457335,0.00018583648,0.0006408297,0.00019133878,0.00006516549,0.000012493492,0.00035818282,0.00016239824,0.000051363415],"category_scores_gemma":[0.0006263065,0.00011301874,0.00010134483,0.00029818134,0.00037695747,0.0001348782,0.0002061645,0.00034869363,0.000026699037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008897373,0.00022811878,0.0003310317,0.00028051104,0.0009759559,0.0004088255,0.0026242542,0.000047991005,0.9747924,0.0009024443,0.0006660233,0.009845037],"study_design_scores_gemma":[0.016442804,0.001693315,0.0005945694,0.00061863585,0.00017550064,0.0064118966,0.00078936375,0.0010813669,0.97075784,0.00029701635,0.0010198251,0.00011784889],"about_ca_topic_score_codex":0.0001973228,"about_ca_topic_score_gemma":0.0000031404566,"teacher_disagreement_score":0.024446886,"about_ca_system_score_codex":0.0022497107,"about_ca_system_score_gemma":0.003596156,"threshold_uncertainty_score":0.6379426},"labels":[],"label_agreement":null},{"id":"W2216110120","doi":"","title":"Dasatinib sensitizes chronic lymphocytic leukemia lymphocytes to chemotherapeutic agents","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Chlorambucil; Chronic lymphocytic leukemia; Fludarabine; Dasatinib; Cancer research; Medicine; Leukemia; Imatinib; Immunology; Pharmacology; Chemotherapy; Internal medicine","score_opus":0.10185933044397279,"score_gpt":0.45616625495048213,"score_spread":0.35430692450650936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216110120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98185664,0.0029765936,0.00020307668,0.0008957809,0.00051978306,0.0020545693,0.00001746776,0.00024992824,0.0112261465],"genre_scores_gemma":[0.9717647,0.0010105913,0.00036335262,0.0017704624,0.0018581359,0.00025609252,0.000025366951,0.00018239318,0.022768915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9921622,0.00020938517,0.00068686093,0.0011555424,0.0029951194,0.0027908455],"domain_scores_gemma":[0.99511063,0.0009241739,0.00007644511,0.0014496521,0.001015227,0.0014238871],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003889912,0.00042860472,0.0006856964,0.0010481791,0.00042085646,0.00013580464,0.000666013,0.00033693764,0.0019118432],"category_scores_gemma":[0.0006800433,0.00039017614,0.00021042573,0.0025499912,0.0006509676,0.00014206249,0.000512123,0.00081459526,0.0023065072],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0098739695,0.00024666017,0.00162358,0.0031418258,0.001256818,0.0043652817,0.006196458,0.002308558,0.69146633,0.0009770172,0.09927015,0.17927335],"study_design_scores_gemma":[0.041887853,0.0016244455,0.0055725505,0.0016005026,0.00011966534,0.0010090985,0.0010578911,0.016883919,0.7741118,0.00025142444,0.1549017,0.000979119],"about_ca_topic_score_codex":0.006627491,"about_ca_topic_score_gemma":0.000803735,"teacher_disagreement_score":0.28463563,"about_ca_system_score_codex":0.37927598,"about_ca_system_score_gemma":0.09464033,"threshold_uncertainty_score":0.9999875},"labels":[],"label_agreement":null},{"id":"W2223535813","doi":"10.3109/10428194.2016.1138292","title":"Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Ibrutinib; Bruton's tyrosine kinase; Daunorubicin; Myeloid leukemia; Tyrosine kinase; Cancer research; Leukemia; Tyrosine-kinase inhibitor; Cytotoxic T cell; Medicine; Pharmacology; Immunology; Chemistry; Internal medicine; Receptor; Chronic lymphocytic leukemia; Biochemistry; Cancer","score_opus":0.018939623820719117,"score_gpt":0.26311155212537624,"score_spread":0.24417192830465712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223535813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9136488,0.0043673916,0.0002115705,0.06840407,0.0014369369,0.0045048557,0.00075581763,0.0007420183,0.0059285536],"genre_scores_gemma":[0.650047,0.008043885,0.0015682825,0.2943932,0.015745591,0.0012333591,0.0015780773,0.0016208595,0.025769718],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9841071,0.0010844923,0.00311588,0.0040266747,0.003146472,0.0045194095],"domain_scores_gemma":[0.9888003,0.004515615,0.0013447996,0.003510116,0.00040635423,0.0014228091],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.002300312,0.003011582,0.004116242,0.0015019386,0.0010869098,0.00070653926,0.0020212291,0.004790472,0.00017308856],"category_scores_gemma":[0.0007673169,0.0021748692,0.0007423379,0.001644392,0.00308153,0.00060431956,0.0020960083,0.002891617,0.0003873189],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001067001,0.00012309423,0.002488111,0.007057077,0.0042163567,0.025666824,0.004021488,0.0000323264,0.027778186,0.0022958098,0.7322857,0.19296803],"study_design_scores_gemma":[0.13850518,0.0018493179,0.011476974,0.012787465,0.0058606295,0.013350323,0.0009614109,0.015264098,0.04315953,0.011003838,0.7376396,0.008141616],"about_ca_topic_score_codex":0.009742142,"about_ca_topic_score_gemma":0.00017311377,"teacher_disagreement_score":0.26360178,"about_ca_system_score_codex":0.11987108,"about_ca_system_score_gemma":0.05447726,"threshold_uncertainty_score":0.9996315},"labels":[],"label_agreement":null},{"id":"W2227531350","doi":"10.1182/blood.v124.21.930.930","title":"Lysosome Membrane Permeabilization Causes Cell Death in Primary Chronic Lymphocytic Leukemia Cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Lysosome; Chronic lymphocytic leukemia; Biology; Programmed cell death; Leukemia; Cancer research; Apoptosis; Immunology; Biochemistry","score_opus":0.01231879229911371,"score_gpt":0.24664632537343117,"score_spread":0.23432753307431747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227531350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819473,0.0008518528,0.000064478554,0.00003589937,0.00013740329,0.00076341804,0.00000522978,0.00015798256,0.01603644],"genre_scores_gemma":[0.99517107,0.0005556123,0.0004407593,0.0003225593,0.0004518508,0.000072445946,0.00007343422,0.00009005747,0.0028221812],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709076,0.00015462007,0.00053731404,0.00065728155,0.00075595046,0.0008041001],"domain_scores_gemma":[0.99829406,0.0003097274,0.00010683845,0.000873063,0.00011741756,0.00029889515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005289078,0.00032118437,0.00058744865,0.00033039448,0.00007862659,0.00004298683,0.0002755999,0.00026005626,0.00023703021],"category_scores_gemma":[0.00018493357,0.00029508513,0.00013377648,0.0005318702,0.00013030971,0.00014820423,0.00015013685,0.00029453277,0.00044101002],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005044357,0.0015524545,0.007989198,0.0070050796,0.00019597793,0.0009329982,0.0010719103,0.008181356,0.9693814,0.00040910352,0.00067647424,0.0020996488],"study_design_scores_gemma":[0.121186815,0.00087124674,0.00978838,0.00060905423,0.00042517317,0.00056192663,0.000052963635,0.077738,0.7850975,0.000111199595,0.002879502,0.0006782559],"about_ca_topic_score_codex":0.0010593133,"about_ca_topic_score_gemma":0.00012837216,"teacher_disagreement_score":0.18428388,"about_ca_system_score_codex":0.074477084,"about_ca_system_score_gemma":0.029073536,"threshold_uncertainty_score":0.9999501},"labels":[],"label_agreement":null},{"id":"W2231307019","doi":"10.1200/jco.2006.24.18_suppl.7580","title":"A phase I trial of PS-341 and fludarabine for relapsed and refractory indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Fludarabine; Mantle cell lymphoma; Chronic lymphocytic leukemia; Bendamustine; Follicular lymphoma; Internal medicine; Neutropenia; Gastroenterology; Macroglobulinemia; Oncology; Leukopenia; Lymphoma; Toxicity; Surgery; Leukemia; Chemotherapy; Multiple myeloma; Cyclophosphamide","score_opus":0.0743556789712439,"score_gpt":0.4604413004812773,"score_spread":0.3860856215100334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231307019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295765,0.0038753997,0.00022909621,0.00073574245,0.0006970928,0.0009862497,0.000011094439,0.000009631712,0.0004980391],"genre_scores_gemma":[0.99117196,0.003676751,0.0019626128,0.00031805012,0.0024264373,0.000022745813,0.0000063628245,0.000039005885,0.0003760786],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950858,0.00033306758,0.0031500862,0.00040353983,0.00057339296,0.00045414895],"domain_scores_gemma":[0.99180084,0.005053421,0.001794358,0.00030785953,0.0004988662,0.0005446344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004723805,0.00025526475,0.002306454,0.0002872231,0.000070691174,0.000019226287,0.00015984014,0.0007051959,0.000025466696],"category_scores_gemma":[0.0038466835,0.00019118458,0.00034931413,0.00015567895,0.00096065906,0.00015402655,0.00014061503,0.0005404495,0.0000017930477],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.47405687,0.0040950933,0.00060849363,0.0010833148,0.0008428428,0.0012381831,0.0002307059,0.000032701544,0.007958043,0.0002479271,0.008205729,0.5014001],"study_design_scores_gemma":[0.84020305,0.111719705,0.0040000784,0.00037414083,0.0007082366,0.0021098251,0.0000699586,0.011369084,0.0010545112,0.00055571366,0.027650323,0.00018535435],"about_ca_topic_score_codex":0.00027618153,"about_ca_topic_score_gemma":0.00008594412,"teacher_disagreement_score":0.50121474,"about_ca_system_score_codex":0.018416345,"about_ca_system_score_gemma":0.05863346,"threshold_uncertainty_score":0.9853518},"labels":[],"label_agreement":null},{"id":"W2234057389","doi":"10.1155/2014/780350","title":"Hepatitis B and Hepatitis C Viral Infections in Patients with Chronic Lymphocytic Leukemia","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Gastroenterology and Hepatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of Manitoba","funders":"Samsung Advanced Institute of Technology; Public Health Agency of Canada","keywords":"Medicine; Chronic lymphocytic leukemia; Immunology; Leukemia; Hepatitis B virus; CD38; Serology; Hepatitis C virus; Hepatitis B; Antibody; Virology; Virus; Biology","score_opus":0.004193200974039537,"score_gpt":0.20872616749662043,"score_spread":0.2045329665225809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234057389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998648,0.00029241602,0.00018248128,0.00041072298,0.00016783901,0.00016676523,0.000007991071,0.0000052710025,0.00011849992],"genre_scores_gemma":[0.99856806,0.0003609479,0.0001504309,0.00076997984,0.000089372996,0.0000065614013,0.000009404266,0.000018408808,0.000026860764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985154,0.00017497153,0.00039146852,0.00021454332,0.00011894829,0.00058466266],"domain_scores_gemma":[0.9988062,0.00009026735,0.00014588276,0.00015792617,0.00015121572,0.00064854464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024406254,0.00016561201,0.00055858004,0.0006009156,0.00010488838,0.000017154212,0.0000861728,0.00016924791,0.00007707693],"category_scores_gemma":[0.00013572982,0.00014198825,0.000042577703,0.00009722381,0.00064962474,0.00011382403,0.000026182139,0.0003996292,0.0000043404343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00057060947,0.0000139006115,0.9969863,0.000052341322,0.00007976298,0.00038312373,0.000092719856,0.000033803066,0.0000028674128,0.00017654426,0.00023532817,0.0013726578],"study_design_scores_gemma":[0.024047498,0.009063343,0.9546874,0.000121321435,0.00008288294,0.0066062,0.000006910417,0.0036660633,0.000005999701,0.00014015494,0.0014859049,0.000086322936],"about_ca_topic_score_codex":0.056785442,"about_ca_topic_score_gemma":0.47197253,"teacher_disagreement_score":0.4151871,"about_ca_system_score_codex":0.01395986,"about_ca_system_score_gemma":0.01231799,"threshold_uncertainty_score":0.99328125},"labels":[],"label_agreement":null},{"id":"W2240689260","doi":"10.1111/bjh.13848","title":"<scp>ROR</scp>1‐based immunomagnetic protocol allows efficient separation of <scp>CLL</scp> and healthy B cells","year":2015,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Agentura Pro Zdravotnický Výzkum České Republiky","keywords":"Immunomagnetic separation; Protocol (science); Medicine; Chemistry; Chromatography; Pathology","score_opus":0.024498568174911556,"score_gpt":0.32620084715174036,"score_spread":0.3017022789768288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240689260","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85550684,0.017306335,0.00052949303,0.033923328,0.0018135112,0.084346056,0.00018454326,0.000109302535,0.006280564],"genre_scores_gemma":[0.2036219,0.004639275,0.030308316,0.626697,0.02353021,0.06913857,0.0018966867,0.0030932096,0.037074827],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99311996,0.0008854227,0.0023884345,0.0006271177,0.0018191127,0.0011599691],"domain_scores_gemma":[0.9931053,0.0017979135,0.002168277,0.00062672864,0.0017876021,0.00051415863],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0019232667,0.00053888065,0.0026339858,0.00078471116,0.00013108345,0.00011058202,0.00058400433,0.0014564457,0.00006434573],"category_scores_gemma":[0.002121701,0.0005539841,0.00041859012,0.0003823846,0.0008168944,0.00010581691,0.00019000696,0.0030803788,0.000053720258],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016015973,0.00039713396,0.00004304035,0.00519032,0.00025460453,0.077504374,0.00024574652,0.00017141667,0.0005574183,0.000005325276,0.91492265,0.00054781866],"study_design_scores_gemma":[0.0357236,0.004589022,0.00012897461,0.0033155726,0.00041038255,0.34357375,0.00017148926,0.0043218406,0.002394924,0.000085380816,0.6051562,0.00012888343],"about_ca_topic_score_codex":0.00051093835,"about_ca_topic_score_gemma":0.000038031234,"teacher_disagreement_score":0.651885,"about_ca_system_score_codex":0.0032833538,"about_ca_system_score_gemma":0.017893957,"threshold_uncertainty_score":0.9998399},"labels":[],"label_agreement":null},{"id":"W2243326152","doi":"10.1200/jco.2007.25.18_suppl.8098","title":"Alemtuzumab in clinical practice: A British Columbia experience","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lions Gate Hospital; Vancouver General Hospital; Royal Columbian Hospital; BC Cancer Agency","funders":"","keywords":"Alemtuzumab; Medicine; Neutropenia; Internal medicine; Adverse effect; Surgery; Chronic lymphocytic leukemia; Gastroenterology; Chemotherapy; Leukemia; Transplantation","score_opus":0.15489513185330978,"score_gpt":0.574852698958226,"score_spread":0.4199575671049162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243326152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97588396,0.0007528581,0.00022909553,0.0024139779,0.002028293,0.00030181676,9.908118e-7,0.000012206232,0.01837682],"genre_scores_gemma":[0.9739848,0.0019041448,0.013933826,0.0056847828,0.002780135,0.0000036459871,0.0000010303995,0.000025557045,0.0016820712],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9901568,0.0009249143,0.0068043866,0.00036842367,0.0011126149,0.0006328077],"domain_scores_gemma":[0.9781963,0.017214952,0.002148142,0.00036586125,0.0010727571,0.0010019542],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031584997,0.00011060916,0.0019135354,0.000116727264,0.00004627451,0.000057491117,0.0003868597,0.0008758644,0.00066997594],"category_scores_gemma":[0.0989624,0.00012629511,0.00064088707,0.00041440505,0.0008082847,0.00030815002,0.00015967684,0.0029589448,0.000060397473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008051984,0.0055394466,0.2183878,0.0000402075,0.00023255669,0.07186558,0.00026894116,0.0000027319186,0.000022556795,0.000025234624,0.042749833,0.65281314],"study_design_scores_gemma":[0.053196948,0.014020084,0.5047949,0.00026259403,0.00013157727,0.022098,0.0010090065,0.00024053881,0.0000071008526,0.00018089393,0.40392295,0.00013540295],"about_ca_topic_score_codex":0.005357619,"about_ca_topic_score_gemma":0.018541664,"teacher_disagreement_score":0.6526777,"about_ca_system_score_codex":0.0058681355,"about_ca_system_score_gemma":0.032228712,"threshold_uncertainty_score":0.9993674},"labels":[],"label_agreement":null},{"id":"W2257464953","doi":"10.1309/ajcp6zodwv1cidme","title":"Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow","year":2015,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Lymphoplasmacytic Lymphoma; Bone marrow; Pathology; Medicine; Immunophenotyping; Biopsy; Waldenstrom macroglobulinemia; Lymphoma; Trephine; Pancytopenia; Immunology; Flow cytometry","score_opus":0.06325520843938709,"score_gpt":0.3949253731407198,"score_spread":0.3316701647013327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257464953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99109167,0.0011092051,0.00017944907,0.005665778,0.0003772821,0.00020477356,0.000002625839,0.000011031645,0.0013581928],"genre_scores_gemma":[0.9919837,0.00066168804,0.0026122755,0.0038622713,0.0006581061,0.0000071919626,0.0000022763197,0.000031064064,0.00018140212],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9949882,0.0014134808,0.0017909422,0.0003573449,0.00086675194,0.0005832621],"domain_scores_gemma":[0.9951206,0.0024757897,0.0008554736,0.0005249877,0.00035969232,0.00066344964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007239071,0.000233318,0.0014503043,0.00030737565,0.00004241034,0.000028331844,0.0004010254,0.00016670336,0.000026113883],"category_scores_gemma":[0.0044054594,0.00014853192,0.00026788056,0.0005888735,0.0022218502,0.00011362879,0.00014847517,0.0004346117,0.000052901967],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012468089,0.0017537909,0.12339807,0.000061596285,0.00019388787,0.052907005,0.0018696032,0.00002052921,0.00012760013,0.00038877397,0.004857012,0.80195403],"study_design_scores_gemma":[0.1470265,0.019745471,0.4777934,0.0003269782,0.00042720954,0.31031862,0.007461105,0.0031214613,0.00006257488,0.0013429284,0.031877253,0.0004964975],"about_ca_topic_score_codex":0.0002150021,"about_ca_topic_score_gemma":0.00004572831,"teacher_disagreement_score":0.8014575,"about_ca_system_score_codex":0.0018633925,"about_ca_system_score_gemma":0.008924949,"threshold_uncertainty_score":0.99669355},"labels":[],"label_agreement":null},{"id":"W2263077335","doi":"10.1200/jco.2006.24.18_suppl.7543","title":"Bortezomib is active in Waldenstrom’s Macroglobulinemia (WM)—Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Waldenstrom macroglobulinemia; Macroglobulinemia; Gastroenterology; Neutropenia; Multiple myeloma; Rituximab; Nausea; Progressive disease; Marginal zone B-cell lymphoma; Surgery; Lymphoma; Chemotherapy; Immunology; B cell; Antibody; Marginal zone","score_opus":0.11259471274370103,"score_gpt":0.5001755884203875,"score_spread":0.3875808756766864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263077335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944601,0.00017416786,0.0000018748106,0.0024337182,0.00035121464,0.00080913503,0.00014263719,0.0000040468917,0.0016231269],"genre_scores_gemma":[0.99771935,0.00021537307,0.0002391409,0.00029714845,0.00039898584,0.000017809596,0.000018644449,0.00001751358,0.0010760198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99295276,0.00044775242,0.0046264715,0.00032949937,0.0011968565,0.0004466565],"domain_scores_gemma":[0.99402684,0.0017270364,0.0022609236,0.00023028947,0.0014631909,0.00029173467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027037933,0.0002198989,0.0022279038,0.00039000422,0.000029861869,0.000003528775,0.00028385612,0.0003694505,0.00020272002],"category_scores_gemma":[0.0052331304,0.00015459134,0.0002225074,0.00079662737,0.00032086525,0.0001261085,0.00009815491,0.0009946765,8.073513e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.44363052,0.0722813,0.24601103,0.00044102353,0.0032906563,0.036359318,0.0031267197,0.0056081447,0.0020231514,0.00003913237,0.07586854,0.11132046],"study_design_scores_gemma":[0.62035096,0.066514716,0.28603178,0.0011430627,0.0006317327,0.00090561574,0.000792191,0.006763939,0.003874649,0.000084999534,0.012558803,0.00034750573],"about_ca_topic_score_codex":0.52552205,"about_ca_topic_score_gemma":0.83803904,"teacher_disagreement_score":0.312517,"about_ca_system_score_codex":0.018334663,"about_ca_system_score_gemma":0.13663687,"threshold_uncertainty_score":0.98543376},"labels":[],"label_agreement":null},{"id":"W2265704330","doi":"10.1007/s12307-016-0180-7","title":"Angiopoietins Modulate Survival, Migration, and the Components of the Ang-Tie2 Pathway of Chronic Lymphocytic Leukaemia (CLL) Cells In Vitro","year":2016,"lang":"en","type":"article","venue":"Cancer Microenvironment","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Korea Electrotechnology Research Institute; Wilhelm Sander-Stiftung","keywords":"Angiopoietin receptor; Angiopoietin; Cancer research; Bone marrow; Chronic lymphocytic leukemia; Biology; Haematopoiesis; Immunology; Stem cell; Leukemia; Angiogenesis; Cell biology; Vascular endothelial growth factor","score_opus":0.013506987687686055,"score_gpt":0.2362722868988403,"score_spread":0.22276529921115426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265704330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924651,0.0050643333,0.000036909,0.0012233537,0.00016217536,0.00088844454,0.00008728796,0.0000059813474,0.00006645166],"genre_scores_gemma":[0.99451745,0.00428173,0.000028672112,0.00011038232,0.000066793444,0.00007394985,0.0000058918563,0.000029207797,0.0008859422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815184,0.0001771861,0.000491362,0.00032930408,0.00048474447,0.0003655775],"domain_scores_gemma":[0.9987683,0.00018287118,0.00022119457,0.000715216,0.000027830083,0.000084566454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039579658,0.00019642182,0.00045135082,0.00007702953,0.00005336407,0.000005986749,0.00026909972,0.00008397546,0.00010947302],"category_scores_gemma":[0.000026472862,0.00009664679,0.00014205054,0.00018498852,0.0011089786,0.00004436473,0.00025141984,0.000111884976,0.000009816853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008248554,0.00008233068,0.002578174,0.00020804885,0.00008821004,0.0000057585858,0.00052251376,0.00032557143,0.99232227,0.000030021356,0.0001763093,0.002835929],"study_design_scores_gemma":[0.03183821,0.000091094094,0.028520843,0.00054401037,0.00008396415,0.00001983153,0.00007598853,0.003966381,0.9307299,0.000048624745,0.0039460626,0.00013507386],"about_ca_topic_score_codex":0.0034468344,"about_ca_topic_score_gemma":0.0003040081,"teacher_disagreement_score":0.06159236,"about_ca_system_score_codex":0.019856753,"about_ca_system_score_gemma":0.0019707067,"threshold_uncertainty_score":0.98390585},"labels":[],"label_agreement":null},{"id":"W2269544826","doi":"10.1182/blood.v122.21.4175.4175","title":"An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"","keywords":"Ofatumumab; Medicine; Fludarabine; Chronic lymphocytic leukemia; Internal medicine; Phases of clinical research; Oncology; Interim analysis; Refractory (planetary science); Pharmacology; Clinical trial; Leukemia; Cyclophosphamide; Chemotherapy; Biology","score_opus":0.02195042890963005,"score_gpt":0.3083522339784295,"score_spread":0.2864018050687994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269544826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991341,0.00010656161,0.0000061067276,0.000015365726,0.000018858262,0.008255984,0.000012219393,0.000050053226,0.00019383195],"genre_scores_gemma":[0.99850494,0.000008682267,0.00021328771,0.00003057077,0.000029102606,0.00085130683,0.0001362855,0.000088218796,0.00013758658],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966193,0.00016271578,0.00073640206,0.00072973483,0.0010579429,0.0006938993],"domain_scores_gemma":[0.99795794,0.00009710142,0.00024966453,0.00095704,0.00046032973,0.00027790442],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035641363,0.00037116432,0.000802497,0.00052069745,0.00005545082,0.00008842034,0.0005562843,0.00015387536,0.00006728525],"category_scores_gemma":[0.00011571599,0.00027196817,0.000020117677,0.0013221102,0.00014647239,0.000651282,0.00019386243,0.00031846858,0.000015558458],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02890148,0.39690354,0.50228447,0.0022090033,0.0013631977,0.0012823889,0.012726389,0.0011249151,0.03936261,0.00006250286,0.00022883494,0.0135506345],"study_design_scores_gemma":[0.8295691,0.048758063,0.089872696,0.0011457504,0.00024609812,0.000057671343,0.00049945177,0.021689557,0.0077715763,0.0000076153324,0.000005597598,0.00037680598],"about_ca_topic_score_codex":0.03534026,"about_ca_topic_score_gemma":0.007974867,"teacher_disagreement_score":0.80066764,"about_ca_system_score_codex":0.031903837,"about_ca_system_score_gemma":0.016076295,"threshold_uncertainty_score":0.99997324},"labels":[],"label_agreement":null},{"id":"W2272245864","doi":"10.1182/blood-2015-05-647552","title":"Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Chronic Disease Prevention and Health Promotion; Holden Comprehensive Cancer Center, University of Iowa; Centers for Medicare and Medicaid Services; U.S. Food and Drug Administration; Centers for Disease Control and Prevention; Hamilton Health Sciences Foundation; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; National Institute of Neurological Disorders and Stroke; California Department of Public Health; University of Southern California","keywords":"Medicine; Hypogammaglobulinemia; Adverse effect; Internal medicine; Myocardial infarction; Stroke (engine); Antibody; Immunology","score_opus":0.01408671154445772,"score_gpt":0.2510201641193053,"score_spread":0.23693345257484755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272245864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99760085,0.00057270663,0.000004169382,0.000053308206,0.000035660927,0.00064759987,0.0000037622035,0.000035717538,0.0010462245],"genre_scores_gemma":[0.9992469,0.000032887732,0.00048060445,0.000058828497,0.000027504546,0.000024727879,0.00002271664,0.00002287999,0.000082972954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859595,0.00004880358,0.00024808475,0.0002832829,0.00043836664,0.00038552273],"domain_scores_gemma":[0.9992453,0.000030214183,0.000059153554,0.00033672614,0.00010545064,0.00022314841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019585578,0.00015516803,0.00039528927,0.00010061857,0.000024806915,0.0000033175677,0.0001008923,0.00010028702,0.00002520583],"category_scores_gemma":[0.00013661326,0.00011373615,0.000026139078,0.00024829418,0.000087744585,0.000069166534,0.000105154744,0.0001597057,0.000069867914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008139438,0.0048013884,0.99077636,0.0002906612,0.00019036683,0.00075897935,0.0011572199,0.000007642978,0.000096430675,0.00014708593,0.000054977532,0.0009049696],"study_design_scores_gemma":[0.12276646,0.0012976227,0.87308854,0.00038545553,0.00011659771,0.00040594046,0.00020453075,0.000087003806,0.0011613683,0.00024108317,0.000048720853,0.000196694],"about_ca_topic_score_codex":0.00038967395,"about_ca_topic_score_gemma":0.000033825785,"teacher_disagreement_score":0.12195252,"about_ca_system_score_codex":0.0011225708,"about_ca_system_score_gemma":0.0016047372,"threshold_uncertainty_score":0.46380255},"labels":[],"label_agreement":null},{"id":"W2272599382","doi":"","title":"Rôle de Calnuc dans le triage endosomial des récepteurs lysosomiaux et implication potentielle dans les maladies du lysosome","year":2016,"lang":"fr","type":"article","venue":"Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de recherche du Québec – Nature et technologies; Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Réseau Québécois de Recherche sur les Médicaments","keywords":"Lysosome; Chemistry","score_opus":0.017155797166503835,"score_gpt":0.23570123094830286,"score_spread":0.21854543378179903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2272599382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8543569,0.012951708,0.09804054,0.0016409659,0.00069933035,0.0006550588,0.00010015747,0.000053307198,0.031502046],"genre_scores_gemma":[0.9651641,0.006218338,0.0023530226,0.000015089276,0.00031647837,0.0000028426946,0.000015378404,0.00003448309,0.025880232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99717885,0.0004941449,0.0005093042,0.00052277214,0.0006011994,0.00069373305],"domain_scores_gemma":[0.9979754,0.00039965406,0.00020489724,0.0007090837,0.000386838,0.000324096],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00064456,0.00036530834,0.0005849987,0.00022271542,0.0009926356,0.000020904625,0.0010679069,0.00037698803,0.00022646421],"category_scores_gemma":[0.00041503317,0.000299006,0.0005968551,0.00044210794,0.0050262753,0.0004709011,0.0007153797,0.00031341464,0.000120826306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0013637919,0.0014223398,0.027201692,0.0048912894,0.00079461676,0.00016958611,0.016226368,0.004332411,0.86012775,0.070200354,0.0024564874,0.010813344],"study_design_scores_gemma":[0.03236983,0.000568241,0.20404567,0.016177725,0.001285385,0.0013569583,0.0046196366,0.019453377,0.68933606,0.0014905797,0.02858063,0.0007158825],"about_ca_topic_score_codex":0.01801644,"about_ca_topic_score_gemma":0.0185085,"teacher_disagreement_score":0.17684397,"about_ca_system_score_codex":0.030047579,"about_ca_system_score_gemma":0.0066989865,"threshold_uncertainty_score":0.9999462},"labels":[],"label_agreement":null},{"id":"W2274774261","doi":"10.1038/leu.2016.4","title":"Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism","year":2016,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Sphingosine; Chronic lymphocytic leukemia; Sphingolipid; Lysosome; Biology; Sphingosine kinase; Programmed cell death; Cancer cell; Sphingosine-1-phosphate; Cell biology; Leukemia; Cancer research; Apoptosis; Biochemistry; Immunology; Cancer; Enzyme; Receptor","score_opus":0.017936935451636906,"score_gpt":0.2793650345160461,"score_spread":0.2614280990644092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274774261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850924,0.00084695965,0.0038332522,0.00062277453,0.0014863457,0.0020016402,0.000081165395,0.0005783236,0.0054571154],"genre_scores_gemma":[0.96962327,0.00025702882,0.0027794135,0.002023226,0.0033006582,0.00026403327,0.000033807133,0.00025830136,0.021460284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9932565,0.0002438967,0.0010044228,0.0016091294,0.0016094865,0.0022765484],"domain_scores_gemma":[0.99567384,0.00038484027,0.0002499562,0.0017954609,0.00042661783,0.0014693146],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005538034,0.0008420453,0.0013971886,0.0006469251,0.00027411387,0.00011041501,0.0009342414,0.00048794033,0.0021813859],"category_scores_gemma":[0.00058838364,0.0006167783,0.00045536144,0.0012538502,0.00030540433,0.00038562575,0.00056629535,0.00054558436,0.0065934258],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025038058,0.00017059069,0.00035574232,0.0011638413,0.001473739,0.003011016,0.0013855487,0.00306326,0.82998204,0.0011587382,0.105075486,0.050656166],"study_design_scores_gemma":[0.07881222,0.0013624401,0.013623843,0.0013645977,0.0005455064,0.0023025442,0.000068582514,0.03325057,0.6270427,0.0009614521,0.23870735,0.0019581905],"about_ca_topic_score_codex":0.0024362546,"about_ca_topic_score_gemma":0.00010200352,"teacher_disagreement_score":0.28067368,"about_ca_system_score_codex":0.35700136,"about_ca_system_score_gemma":0.076327704,"threshold_uncertainty_score":0.99962837},"labels":[],"label_agreement":null},{"id":"W2275948481","doi":"10.1182/blood-2004-03-0796","title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":407,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"State University of New York Upstate Medical University; University of North Carolina at Chapel Hill; University of Illinois at Urbana-Champaign; Virginia Commonwealth University; McGill University; Syracuse University; University of Pittsburgh; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; University of Rochester; University of Miami; York University; University of Missouri; Georgetown University; National Cancer Institute; Wake Forest University; University of Pennsylvania; Dartmouth College; State University of New York; University of Nebraska Medical Center; Kaiser Permanente; University of South Carolina; University of Minnesota; Massachusetts General Hospital; University of Pretoria; Ohio State University; D. Warren Brown Family Foundation; Leukemia and Lymphoma Society","keywords":"Fludarabine; Rituximab; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Leukemia; Surgery; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.011943521884834505,"score_gpt":0.2820362234149799,"score_spread":0.2700927015301454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275948481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971381,0.00030048192,0.000023338313,0.00003600129,0.00002120278,0.00196575,0.000306646,0.000045140216,0.00016335696],"genre_scores_gemma":[0.9982571,0.00003773211,0.00061003835,0.0000121584335,0.000030439647,0.00007735883,0.00092000206,0.00003284328,0.000022335422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968052,0.00021015873,0.0006623557,0.0007564855,0.0010130213,0.00055276905],"domain_scores_gemma":[0.9979692,0.0000963871,0.00028638568,0.00069970265,0.0006034367,0.00034484966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043774134,0.00036512487,0.001451317,0.00064280647,0.00006761049,0.000023411092,0.00019107378,0.00020107075,0.00005808189],"category_scores_gemma":[0.0001603472,0.00028676275,0.0000778647,0.0016827337,0.00041353458,0.00021091422,0.00018572484,0.00026428135,0.000001900991],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019230854,0.008001764,0.94996333,0.0011554467,0.0070384163,0.00044154943,0.0058920924,0.0033737773,0.0029763859,0.00070308795,0.000067236746,0.0011560778],"study_design_scores_gemma":[0.1604648,0.0059188535,0.8203126,0.00058542,0.0020078078,0.000023024886,0.00015352598,0.004167995,0.006005715,0.00005246705,0.0000034638879,0.00030431355],"about_ca_topic_score_codex":0.0063361344,"about_ca_topic_score_gemma":0.005206979,"teacher_disagreement_score":0.14123395,"about_ca_system_score_codex":0.015866477,"about_ca_system_score_gemma":0.0064141722,"threshold_uncertainty_score":0.99995846},"labels":[],"label_agreement":null},{"id":"W2279248099","doi":"","title":"Unusual presentation of hairy cell leukemia as isolated bone lesions","year":2014,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Gallium 67 scan; Avascular necrosis; Radiology; Hairy cell leukemia; Malignancy; Mantle cell lymphoma; Lymphoma; Sarcoidosis; Soft tissue; Bone marrow; Pathology; Femoral head; Leukemia; Surgery","score_opus":0.017025435180337348,"score_gpt":0.30977535249570765,"score_spread":0.2927499173153703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279248099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8623912,0.000094585266,0.003026492,0.00028222796,0.000077536955,0.00037048772,0.0000019479623,0.000089316585,0.13366622],"genre_scores_gemma":[0.968532,0.00003893182,0.000966855,0.0002147997,0.00010966222,0.000011401508,0.000037214195,0.000026371272,0.030062709],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848425,0.0000757718,0.00035021792,0.00025280332,0.000532373,0.000304576],"domain_scores_gemma":[0.9988242,0.00025524473,0.000079491605,0.0004450263,0.00018841366,0.00020767408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000287693,0.00012336526,0.00028327596,0.00016405652,0.00004886326,0.00001060013,0.0001054146,0.00013733249,0.0008795501],"category_scores_gemma":[0.00029798123,0.00009939462,0.00009123909,0.00030810136,0.00012203231,0.00007974426,0.000091583264,0.00018048435,0.00046260704],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044692876,0.0017323557,0.0040629446,0.0027575218,0.0004002375,0.00052337773,0.0032711453,0.001236473,0.7760815,0.015405633,0.1261021,0.06395743],"study_design_scores_gemma":[0.0419812,0.0022401907,0.004173517,0.00022985999,0.0002008525,0.0005170816,0.00079526065,0.41334537,0.5245296,0.00073578255,0.010873925,0.00037737438],"about_ca_topic_score_codex":0.0027328732,"about_ca_topic_score_gemma":0.000049688562,"teacher_disagreement_score":0.4121089,"about_ca_system_score_codex":0.0032071674,"about_ca_system_score_gemma":0.004206524,"threshold_uncertainty_score":0.9630457},"labels":[],"label_agreement":null},{"id":"W2281269448","doi":"10.4049/jimmunol.182.supp.50.43","title":"Characterization of Critical Residues of the Granzyme B Inhibitor, Serpina3n (50.43)","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Granzyme B; Mutant; Gamma-ray burst; Biology; Cytotoxic T cell; In vitro; Chemistry; Molecular biology; Biochemistry; Gene","score_opus":0.015717133829864425,"score_gpt":0.3003558035116764,"score_spread":0.28463866968181195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281269448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987783,0.0014431546,0.000097693875,0.009965255,0.00025215402,0.00013546292,0.000002640934,0.000004156569,0.00031644286],"genre_scores_gemma":[0.99877256,0.0005710539,0.000062617015,0.00022830586,0.00016765251,4.461169e-7,0.0000010896235,0.000008529685,0.00018775418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984146,0.00032773073,0.0006053907,0.000060429782,0.000386952,0.00020489647],"domain_scores_gemma":[0.99845254,0.00030148242,0.00035411702,0.00037942547,0.00047616375,0.00003626503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081960566,0.000088384855,0.00037365986,0.00011457255,0.00005429736,0.0000036728309,0.00035383247,0.00011250721,0.000070568785],"category_scores_gemma":[0.00081558217,0.000044790617,0.00012734914,0.00022292254,0.00059630105,0.00007741115,0.00007145264,0.00041462245,0.0000042393854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016091522,0.00018607757,0.00013022454,0.00005290705,0.00008302828,0.000016504835,0.000793858,0.0000022717463,0.99461955,0.0010437837,0.00016347058,0.0012991951],"study_design_scores_gemma":[0.0064591123,0.002477621,0.104170576,0.000495352,0.00020951073,0.0033153535,0.00034073368,0.000070464754,0.879989,0.001667937,0.00073716836,0.00006712036],"about_ca_topic_score_codex":0.0000457285,"about_ca_topic_score_gemma":0.000002862828,"teacher_disagreement_score":0.114630476,"about_ca_system_score_codex":0.0006409085,"about_ca_system_score_gemma":0.0015500312,"threshold_uncertainty_score":0.2749689},"labels":[],"label_agreement":null},{"id":"W2284946195","doi":"","title":"Transcriptional Control of Normal Lymphopoiesis and T-cell Neoplasia by Growth Factor Independent 1","year":2012,"lang":"en","type":"article","venue":"OhioLink ETD Center (Ohio Library and Information Network)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NHLBI Division of Intramural Research; College of Medicine, University of Cincinnati; National Institutes of Health; Pelotonia; CancerFree KIDS; Canadian Institutes of Health Research; Alex's Lemonade Stand Foundation for Childhood Cancer; University of Cincinnati; Leukemia and Lymphoma Society; National Institute of Allergy and Infectious Diseases; Division of Intramural Research, National Institute of Allergy and Infectious Diseases","keywords":"Lymphopoiesis; Control (management); Regulator; Biology; Growth factor; Transcription factor; Genetics; Cancer research; Computer science; Haematopoiesis; Gene; Stem cell","score_opus":0.007201091102230434,"score_gpt":0.20385776894040827,"score_spread":0.19665667783817783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284946195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5546593,0.0075400462,0.0046032746,0.0015892333,0.0007644723,0.0015883077,0.0008648099,0.00019285847,0.42819768],"genre_scores_gemma":[0.9941808,0.0021498513,0.00026225508,0.002112607,0.00032999666,0.000020813688,0.0005372341,0.000018475064,0.00038797862],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998332,0.00006813956,0.00056008156,0.00013366762,0.00038292844,0.0005231813],"domain_scores_gemma":[0.9991075,0.00011790911,0.00016414409,0.00016151048,0.000042751628,0.00040618773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001604322,0.00021248202,0.0003394685,0.00012829647,0.00009994445,0.00006403064,0.00010155997,0.00019189506,0.00063575996],"category_scores_gemma":[0.000011493964,0.00018082806,0.000084887884,0.0001757302,0.0001269864,0.0060459627,0.00007732484,0.00021586585,0.000018890754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0111437095,0.0016474918,0.21597,0.0057282527,0.0011276783,0.00002005077,0.007769125,0.00018156326,0.003352327,0.63614124,0.08896886,0.02794973],"study_design_scores_gemma":[0.08928378,0.0009272685,0.13658279,0.0005837017,0.00025071413,0.00081451447,0.00015253169,0.025491001,0.008603543,0.00021094143,0.7361036,0.0009956078],"about_ca_topic_score_codex":8.026915e-7,"about_ca_topic_score_gemma":1.630554e-7,"teacher_disagreement_score":0.6471348,"about_ca_system_score_codex":0.00016414127,"about_ca_system_score_gemma":0.00042671929,"threshold_uncertainty_score":0.7373954},"labels":[],"label_agreement":null},{"id":"W2286356945","doi":"10.3747/co.23.2810","title":"A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia","year":2016,"lang":"en","type":"review","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Vancouver General Hospital; University of British Columbia; BC Cancer Agency; Canadian Nutrition Society; McGill University Health Centre; University of Alberta; Université de Montréal","funders":"CSL Behring","keywords":"Medicine; Hypogammaglobulinemia; Chronic lymphocytic leukemia; Image-guided radiation therapy; Disease; Intensive care medicine; Leukemia; Immunology; Radiation therapy; Internal medicine; Antibody","score_opus":0.2788734813255585,"score_gpt":0.4870464606113918,"score_spread":0.20817297928583328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286356945","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012639419,0.989732,0.000010450722,0.0009400154,0.0005748516,0.004904404,0.00013882064,0.000037348393,0.002398166],"genre_scores_gemma":[0.0023901912,0.9951928,0.000016252214,0.00023071762,0.0003575225,0.0013960488,0.000059521182,0.000079308425,0.000277586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651563,0.00067727565,0.00087338797,0.000735468,0.0003693006,0.00082895736],"domain_scores_gemma":[0.9951958,0.0022190216,0.00034002462,0.0013978732,0.00042329662,0.0004239673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049678574,0.00048691028,0.0018547488,0.0010684442,0.00011374061,0.00002447868,0.0006196077,0.0004710699,0.00027196796],"category_scores_gemma":[0.0011105785,0.00029328666,0.0004289723,0.0011652156,0.00035445706,0.000043089458,0.00015268849,0.0009177061,0.0007760907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011328055,0.00012011172,0.000004337654,0.0012782047,0.00027489022,0.00005593905,0.00040816964,0.000035462588,0.000006592292,0.0028265044,0.008498253,0.98637825],"study_design_scores_gemma":[0.0054797074,0.0010926463,0.000032784686,0.013852815,0.00013367759,0.0003435811,0.000037702994,0.00016026433,0.0000051716956,0.00008013141,0.9785284,0.00025311435],"about_ca_topic_score_codex":0.14795884,"about_ca_topic_score_gemma":0.050212007,"teacher_disagreement_score":0.9861251,"about_ca_system_score_codex":0.72611743,"about_ca_system_score_gemma":0.34303325,"threshold_uncertainty_score":0.9999519},"labels":[],"label_agreement":null},{"id":"W2286492932","doi":"10.1002/cam4.559","title":"Comparison of outcome of patients with CLL who are referred or nonreferred to a specialized <scp>CLL</scp> clinic: a Canadian population‐based study","year":2016,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"CancerCare Manitoba Foundation; Roche","keywords":"Medicine; Referral; Chronic lymphocytic leukemia; Population; Internal medicine; Chemotherapy; Cancer; Pediatrics; Leukemia; Family medicine","score_opus":0.13493983635230536,"score_gpt":0.44286397612667505,"score_spread":0.3079241397743697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286492932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942154,0.00017647809,0.0000626168,0.0013137795,0.00036406817,0.0026809417,0.00023663123,0.000033440025,0.0009166286],"genre_scores_gemma":[0.99466574,0.000013302599,0.00013840798,0.00064557977,0.00034764456,0.00015297355,0.00008181826,0.00006794422,0.0038865763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957773,0.0001581985,0.0013734315,0.0005726445,0.0014788964,0.00063953974],"domain_scores_gemma":[0.9958177,0.0006903788,0.00059369596,0.0009850306,0.00096959376,0.0009435659],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058662373,0.00033661426,0.0018654619,0.0006699022,0.00006498912,0.000005278367,0.00031596818,0.00015112646,0.0013430973],"category_scores_gemma":[0.0029691695,0.00018054615,0.00008619742,0.0010032562,0.00020007347,0.00006799694,0.000063204105,0.00021377903,0.000025057736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026417933,0.0005100588,0.97984457,0.00033831786,0.00022114023,0.00004563644,0.0015776237,0.000013342899,0.000051966108,0.0000030645112,0.012299247,0.0024532666],"study_design_scores_gemma":[0.07014975,0.004077912,0.9133147,0.0023468516,0.00033703665,0.000001474351,0.0013319184,0.00011329916,0.00021321584,0.0000031930565,0.008001783,0.00010884991],"about_ca_topic_score_codex":0.15216714,"about_ca_topic_score_gemma":0.30461302,"teacher_disagreement_score":0.15244587,"about_ca_system_score_codex":0.008811666,"about_ca_system_score_gemma":0.0056291427,"threshold_uncertainty_score":0.99956983},"labels":[],"label_agreement":null},{"id":"W2287163366","doi":"10.1188/16.onf.18-21","title":"Hairy Cell Leukemia and Bone Pain","year":2016,"lang":"en","type":"review","venue":"Oncology nursing forum","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Hairy cell leukemia; Chemotherapy; Leukemia; Cladribine; Hip pain; Bone pain; Complete remission; Presentation (obstetrics); Physical therapy; Internal medicine; Surgery","score_opus":0.039713148955467806,"score_gpt":0.39649608198662323,"score_spread":0.35678293303115544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287163366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008346271,0.95956635,0.00017503872,0.001401478,0.00068188837,0.0011692165,0.000019036053,0.00011338695,0.03686523],"genre_scores_gemma":[0.000020796002,0.98151416,0.0008146379,0.00039784936,0.0006018582,0.00011760902,0.00007843511,0.00014428265,0.016310364],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963601,0.00059015467,0.0007264102,0.00078940677,0.00037909194,0.0011548158],"domain_scores_gemma":[0.9969722,0.0013920809,0.00033344285,0.0007502497,0.00008131403,0.00047071028],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014153719,0.0005334179,0.0026605634,0.00040049656,0.00016602007,0.000024954888,0.00022516109,0.001378527,0.00020262969],"category_scores_gemma":[0.00038457513,0.00036980055,0.00042148744,0.0002559058,0.00085659366,0.00005974755,0.00015044566,0.000906409,0.00046206135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000615532,0.00011285332,0.000001155032,0.008341162,0.00008529293,0.0006888539,0.000060451282,1.8080993e-8,0.000003203082,0.00012892905,0.085081644,0.9054349],"study_design_scores_gemma":[0.00598396,0.000942404,4.5401578e-7,0.043410454,0.00074224226,0.00375488,0.00007407635,0.00008677461,0.0000044025437,0.0001691561,0.94449854,0.00033265864],"about_ca_topic_score_codex":0.000038541162,"about_ca_topic_score_gemma":0.000009870851,"teacher_disagreement_score":0.90510225,"about_ca_system_score_codex":0.093053095,"about_ca_system_score_gemma":0.041935403,"threshold_uncertainty_score":0.99991786},"labels":[],"label_agreement":null},{"id":"W2290262197","doi":"10.1126/scitranslmed.aad7666","title":"A dominant gain-of-function mutation in universal tyrosine kinase <i>SRC</i> causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies","year":2016,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Heart, Lung, and Blood Institute; NIHR Cambridge Biomedical Research Centre; NIHR BioResource; Vlaamse regering; Fonds Wetenschappelijk Onderzoek; Onderzoeksraad, KU Leuven; Imperial College London; British Heart Foundation; KU Leuven; National Institute for Health and Care Research; Medical Research Council; British Society for Haematology; NHS Blood and Transplant","keywords":"Myelofibrosis; Gain of function; Medicine; Proto-oncogene tyrosine-protein kinase Src; Tyrosine kinase; Mutation; Function (biology); Platelet; Cancer research; Internal medicine; Bone marrow; Biology; Receptor; Genetics; Gene","score_opus":0.029170845546834676,"score_gpt":0.31209144357715773,"score_spread":0.28292059803032304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290262197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860285,0.0012954941,0.0030385884,0.008032871,0.00022436523,0.000506,0.0000128736465,0.000032677774,0.00082866015],"genre_scores_gemma":[0.9983829,0.00037615496,0.0008211968,0.000109789326,0.00011295005,0.000012807659,0.0000101293,0.000011332582,0.00016271186],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997672,0.000040932657,0.00042191727,0.00044848988,0.0010508752,0.00036577848],"domain_scores_gemma":[0.9987958,0.0004299997,0.0001082447,0.00021365176,0.00028472993,0.00016758847],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0012548246,0.00015762534,0.00038185055,0.0005750722,0.00011054568,0.000009761146,0.00012695677,0.00006382656,0.00012584907],"category_scores_gemma":[0.0006507154,0.00009685776,0.000031957927,0.0010161744,0.0027193523,0.0004723427,0.000039487484,0.00011054107,0.0000064070537],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095449726,0.00008923379,0.007127441,0.0001398465,0.000012611406,0.00015017179,0.0015015298,0.000033701843,0.97136176,0.0051885704,0.00010629185,0.013334329],"study_design_scores_gemma":[0.09376312,0.0051436145,0.5987275,0.0048372624,0.00039608032,0.0014861756,0.0035039934,0.008826548,0.2717081,0.009374013,0.0014969787,0.0007365739],"about_ca_topic_score_codex":0.00036474405,"about_ca_topic_score_gemma":0.00009801819,"teacher_disagreement_score":0.6996537,"about_ca_system_score_codex":0.001127433,"about_ca_system_score_gemma":0.0024197006,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W2291152756","doi":"10.1016/s2352-3026(16)00004-1","title":"Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Rituximab; Fludarabine; Clinical endpoint; Cyclophosphamide; Pharmacokinetics; Population; Internal medicine; Clinical trial; Surgery; Chemotherapy; Lymphoma","score_opus":0.06490262390275962,"score_gpt":0.4059350666630088,"score_spread":0.3410324427602492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291152756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97641,0.002087906,0.0006491348,0.003653086,0.000612435,0.015470979,0.00008362078,0.0000736325,0.00095923245],"genre_scores_gemma":[0.99071425,0.0061422894,0.00029877594,0.00033719023,0.0008809124,0.0009052402,0.00003104452,0.00008141665,0.00060890545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99663365,0.0003483552,0.001012618,0.0006520397,0.00035640708,0.0009969204],"domain_scores_gemma":[0.9925575,0.005542221,0.00044294825,0.0010153278,0.00020720976,0.00023476877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009876386,0.00048312597,0.004189887,0.00012225482,0.00018788165,0.000043002292,0.00064931443,0.000267875,0.00023059451],"category_scores_gemma":[0.0009918149,0.00026296094,0.00023168107,0.00016940302,0.00083181873,0.000065550936,0.0001917445,0.00017437838,0.000049143324],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9560397,0.0019738246,9.4092275e-7,0.00029695674,0.0014035185,0.0006894276,0.00046529944,0.000007594952,0.0071754185,0.00062294625,0.00048420273,0.030840125],"study_design_scores_gemma":[0.9484953,0.019493662,0.0000011894734,0.00017533578,0.0010755098,0.0030117673,0.00002605565,0.01085116,0.012951172,0.00019778377,0.0034534626,0.00026758204],"about_ca_topic_score_codex":0.000581543,"about_ca_topic_score_gemma":0.00007900969,"teacher_disagreement_score":0.030572543,"about_ca_system_score_codex":0.015651658,"about_ca_system_score_gemma":0.014284384,"threshold_uncertainty_score":0.99998224},"labels":[],"label_agreement":null},{"id":"W2291349339","doi":"10.1101/mcs.a000679","title":"Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing","year":2016,"lang":"en","type":"article","venue":"Molecular Case Studies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency; Canada's Michael Smith Genome Sciences Centre","funders":"Terry Fox Foundation; Michael Smith Health Research BC","keywords":"Chronic lymphocytic leukemia; Genome; Lymphoproliferative disorders; Biology; DNA sequencing; Transcriptome; Lymphoma; Gene expression profiling; Whole genome sequencing; Gene; Digital polymerase chain reaction; Genetics; Cancer genome sequencing; Leukemia; Computational biology; Gene expression; Polymerase chain reaction; Immunology","score_opus":0.025026123410136884,"score_gpt":0.3293395031984806,"score_spread":0.3043133797883437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291349339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899223,0.005581089,0.0027241178,0.00069059595,0.000057060657,0.0006688386,0.00009039508,0.00005135553,0.00021426634],"genre_scores_gemma":[0.9982856,0.00022682136,0.00054640166,0.00043692242,0.00004057494,0.00014300339,0.000031938387,0.000054796703,0.00023394995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99764663,0.00026899576,0.00048442732,0.00058184686,0.00045756632,0.00056052115],"domain_scores_gemma":[0.99838984,0.00015285595,0.0001360535,0.0006682985,0.00043910384,0.00021383021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033949508,0.00031794634,0.00070274924,0.00017381554,0.0001048362,0.000009211986,0.00014186249,0.00013916857,0.000026709173],"category_scores_gemma":[0.00063589885,0.00021291709,0.00016232164,0.00023862057,0.0006303395,0.00008547659,0.00025712038,0.00011988216,0.000023319446],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028945776,0.00012635374,0.00013248825,0.00020975708,0.0007276828,0.032840487,0.0015409088,0.000038931572,0.9598998,0.00011358367,0.000074320495,0.0040062177],"study_design_scores_gemma":[0.03459704,0.0031603912,0.00007446132,0.00048072854,0.0004968218,0.024854042,0.0040199663,0.0013376079,0.9279578,0.0004399012,0.001811287,0.00076997775],"about_ca_topic_score_codex":0.0001962921,"about_ca_topic_score_gemma":0.000043800555,"teacher_disagreement_score":0.03430758,"about_ca_system_score_codex":0.004348799,"about_ca_system_score_gemma":0.0014889932,"threshold_uncertainty_score":0.99947333},"labels":[],"label_agreement":null},{"id":"W2294562171","doi":"10.1200/jco.2013.31.15_suppl.tps7131","title":"A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Idelalisib; Ofatumumab; Medicine; Internal medicine; Chronic lymphocytic leukemia; Bendamustine; Alemtuzumab; Fludarabine; Oncology; Ibrutinib; CD20; IGHV@; Gastroenterology; Leukemia; Immunology; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.08759778079866323,"score_gpt":0.4827884970728645,"score_spread":0.3951907162742012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294562171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98391956,0.0014247312,0.00033478788,0.0008538251,0.0001784006,0.012941419,0.0000013750464,0.000010108978,0.00033579394],"genre_scores_gemma":[0.9975759,0.00062498514,0.0005458167,0.00022254333,0.00031773417,0.00041841267,0.0000043041496,0.000032000848,0.0002583101],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.989578,0.003072881,0.005630534,0.00033595398,0.00092792144,0.00045472794],"domain_scores_gemma":[0.957783,0.036311343,0.0036543866,0.00038816596,0.0015570652,0.0003060718],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025687708,0.00027032505,0.0055729602,0.00026938147,0.000085050466,0.000028190203,0.0002903233,0.00032262306,0.00010986811],"category_scores_gemma":[0.026687367,0.00013286881,0.0006021178,0.00032572213,0.0007606447,0.00017546955,0.000083690655,0.00081851473,0.000003254927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9245104,0.0034059228,0.00048197768,0.00013267456,0.0020820398,0.000118536984,0.0008528499,0.00082663016,0.00023070247,0.000073060255,0.00023606994,0.06704912],"study_design_scores_gemma":[0.7466191,0.081435,0.00122218,0.000380589,0.0018336308,0.00030593423,0.00040127386,0.16747652,0.00002510048,0.00015816333,0.00005020406,0.00009229791],"about_ca_topic_score_codex":0.001023037,"about_ca_topic_score_gemma":0.00021370342,"teacher_disagreement_score":0.1778913,"about_ca_system_score_codex":0.021513993,"about_ca_system_score_gemma":0.05445847,"threshold_uncertainty_score":0.9822422},"labels":[],"label_agreement":null},{"id":"W2294823670","doi":"10.1038/bcj.2016.9","title":"Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial","year":2016,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Deutsche Forschungsgemeinschaft; National Cancer Institute; Celgene","keywords":"IGHV@; Lenalidomide; Internal medicine; Chronic lymphocytic leukemia; Oncology; Medicine; Refractory (planetary science); Hematology; Fludarabine; Gastroenterology; Leukemia; Multiple myeloma; Chemotherapy; Biology; Cyclophosphamide","score_opus":0.05766062988039832,"score_gpt":0.36183303720276405,"score_spread":0.3041724073223657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294823670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98467827,0.010928004,0.000019660778,0.0011842287,0.0005319534,0.0023227548,0.00017099599,0.00003742798,0.00012670807],"genre_scores_gemma":[0.9829667,0.012100332,0.00015570843,0.0002063117,0.0026786516,0.0002815541,0.000023597673,0.00007206082,0.0015150628],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99658716,0.0003356284,0.0007931038,0.000770865,0.00071199186,0.0008012458],"domain_scores_gemma":[0.9967255,0.0013620199,0.00032881106,0.0010583181,0.00013773376,0.0003876247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091381965,0.00038830526,0.00065206015,0.00014985807,0.0003056011,0.00010551524,0.0005573305,0.00019091682,0.00096351595],"category_scores_gemma":[0.0011895488,0.00018060236,0.000119848744,0.0002614279,0.00028034253,0.00031996274,0.00032078425,0.00052383466,0.0000244666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7035703,0.0034494314,0.017466709,0.00023436468,0.004996321,0.00509036,0.0019205454,0.00003979436,0.01867199,0.000009848119,0.015314193,0.22923616],"study_design_scores_gemma":[0.9612621,0.011897773,0.0041218,0.00232411,0.0014170158,0.0012036287,0.00020579355,0.0045609884,0.0021789551,0.00004032299,0.010444485,0.00034303684],"about_ca_topic_score_codex":0.0036122345,"about_ca_topic_score_gemma":0.002839667,"teacher_disagreement_score":0.2576918,"about_ca_system_score_codex":0.092796125,"about_ca_system_score_gemma":0.056786116,"threshold_uncertainty_score":0.99994975},"labels":[],"label_agreement":null},{"id":"W2295530774","doi":"10.3324/haematol.2015.135418","title":"Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial","year":2016,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto East General Hospital; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Leukemia and Lymphoma Society of Canada; University of Toronto; Leukemia and Lymphoma Society","keywords":"Ruxolitinib; Idelalisib; Janus kinase; Myelofibrosis; Venetoclax; Medicine; Chronic lymphocytic leukemia; Ibrutinib; Oncology; STAT protein; Internal medicine; Janus kinase 1; Clinical trial; stat; Clinical endpoint; Cancer research; Tolerability; STAT3; Leukemia; Signal transduction; Chemistry; Adverse effect; Receptor; Bone marrow","score_opus":0.046861909385239535,"score_gpt":0.3334470027006804,"score_spread":0.28658509331544085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295530774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.928566,0.00072330894,0.0000047839503,0.060063448,0.0007600832,0.004146463,0.00054578535,0.00007817121,0.0051119574],"genre_scores_gemma":[0.9788432,0.00021936595,0.000043633823,0.012990018,0.0029064377,0.00034555755,0.00009603145,0.00009605511,0.0044596912],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99355257,0.0007279603,0.001777542,0.001069716,0.0016170219,0.0012552071],"domain_scores_gemma":[0.994089,0.0017170551,0.0013455088,0.0023969393,0.0002908282,0.00016069002],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011105661,0.0006764985,0.0026141305,0.0004678233,0.00011624161,0.000013722894,0.00096489233,0.0020961754,0.00023815819],"category_scores_gemma":[0.003153115,0.00038106204,0.0007867721,0.0007234257,0.001341094,0.0000892126,0.00088528456,0.0020979245,0.00004986729],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.15113541,0.0008686632,0.000006303547,0.0072155413,0.00046616525,0.011902723,0.00045737159,0.000012305932,0.01109516,0.00011593143,0.8091332,0.007591263],"study_design_scores_gemma":[0.6766503,0.0077508776,0.000017610124,0.005311877,0.0003591494,0.0014843774,0.000021810503,0.0009524267,0.10135784,0.00026029366,0.20523937,0.0005940896],"about_ca_topic_score_codex":0.002073592,"about_ca_topic_score_gemma":0.00008622481,"teacher_disagreement_score":0.6038938,"about_ca_system_score_codex":0.08504891,"about_ca_system_score_gemma":0.07700219,"threshold_uncertainty_score":0.9998641},"labels":[],"label_agreement":null},{"id":"W2296118977","doi":"10.3109/10428194.2015.1128540","title":"Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Lenalidomide; Medicine; Tolerability; Neutropenia; Internal medicine; Discontinuation; Refractory (planetary science); Chronic lymphocytic leukemia; Adverse effect; Gastroenterology; Oncology; Surgery; Leukemia; Chemotherapy; Multiple myeloma","score_opus":0.01989551389267892,"score_gpt":0.3024081237141699,"score_spread":0.282512609821491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296118977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341404,0.0005513245,0.000060439124,0.0000958726,0.00039218535,0.0045709056,0.00019703872,0.00013827963,0.00057990407],"genre_scores_gemma":[0.99543005,0.0021149672,0.00045406504,0.00013381455,0.000323945,0.00021051365,0.00026542856,0.00017645447,0.00089074206],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99056286,0.0007029036,0.003627785,0.0017827159,0.0019670802,0.0013566861],"domain_scores_gemma":[0.9918565,0.0032931096,0.0017748254,0.0015962129,0.0006620474,0.000817285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019986469,0.0011364679,0.0032642893,0.0010712362,0.000270625,0.00008531444,0.00070703484,0.0007326555,0.00011670578],"category_scores_gemma":[0.0020677522,0.0006873038,0.0004157271,0.0007171004,0.0017418177,0.0009605083,0.0006124028,0.0002849013,0.0000067582605],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8949283,0.0017369164,0.00061467604,0.0005029995,0.00086591113,0.0002283656,0.0013229428,0.00007948845,0.0029337541,0.00013291671,0.000044273685,0.096609496],"study_design_scores_gemma":[0.9492813,0.009097452,0.008906893,0.0029436655,0.00062867295,0.00012088403,0.00018854531,0.01267979,0.014733968,0.000040240655,0.0005758569,0.0008027429],"about_ca_topic_score_codex":0.00385048,"about_ca_topic_score_gemma":0.00041186166,"teacher_disagreement_score":0.09580675,"about_ca_system_score_codex":0.12422739,"about_ca_system_score_gemma":0.035901684,"threshold_uncertainty_score":0.9995578},"labels":[],"label_agreement":null},{"id":"W2312543879","doi":"10.1158/1535-7163.targ-13-a154","title":"Abstract A154: Inhibition of eIF4E with Ribavirin suppresses EMT and breast cancer invasiveness.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"EIF4E; Cancer research; Cancer; Metastasis; Oncogene; Carcinogenesis; Breast cancer; Triple-negative breast cancer; Medicine; Ribavirin; Epithelial–mesenchymal transition; Biology; Cell cycle; Immunology; Internal medicine; Translation (biology); Messenger RNA","score_opus":0.022314147813511237,"score_gpt":0.2965809079215373,"score_spread":0.2742667601080261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312543879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148005,0.005434989,0.00017916653,0.0017485288,0.00004245316,0.0006315485,0.000058502268,0.000028464907,0.00039630485],"genre_scores_gemma":[0.9959914,0.0024622262,0.0001567,0.00094118336,0.0000645582,0.00020718691,0.00001631585,0.000055274864,0.000105155064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859655,0.000034406447,0.00023984975,0.00030413005,0.0004888255,0.00033626804],"domain_scores_gemma":[0.99898946,0.0000471453,0.0001071993,0.00035098614,0.0003642362,0.00014099039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007907331,0.00020484564,0.00032174552,0.00009196116,0.00004428187,0.00003549311,0.000088416054,0.000116468655,0.00056911557],"category_scores_gemma":[0.000005427469,0.00015690432,0.00005489836,0.00022088288,0.00029187385,0.00011932569,0.00005642429,0.00019882913,0.000009490052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065846695,0.00023667363,0.013133006,0.0012142498,0.0007368482,0.00019710725,0.0005306391,0.000350574,0.9401025,0.00012860894,0.00022116386,0.042490132],"study_design_scores_gemma":[0.012741216,0.0002896729,0.10530609,0.0011352693,0.00038458212,0.00028688443,0.00021839573,0.0010998361,0.8762499,0.0002635064,0.0016412048,0.00038342053],"about_ca_topic_score_codex":0.006006106,"about_ca_topic_score_gemma":0.00020366194,"teacher_disagreement_score":0.09217308,"about_ca_system_score_codex":0.0013612596,"about_ca_system_score_gemma":0.00234946,"threshold_uncertainty_score":0.90794754},"labels":[],"label_agreement":null},{"id":"W2312603476","doi":"10.1182/blood-2015-09-670802","title":"Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions","year":2015,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Cilag; National Cancer Institute; H. Lundbeck A/S; Deutsche Forschungsgemeinschaft; F. Hoffmann-La Roche; Pharmacyclics; Genentech; Celgene; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Cytokine; Rituximab; CD20; Immunology; Monoclonal antibody; Cytokine release syndrome; Pathophysiology; Monoclonal; Leukemia; Internal medicine; Antibody; Immunotherapy; Immune system","score_opus":0.015864260023813706,"score_gpt":0.24273088327932188,"score_spread":0.22686662325550816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312603476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836819,0.00015624022,0.0000017064845,0.009776063,0.000022707218,0.0018631619,0.00009402645,0.00015217668,0.0042520002],"genre_scores_gemma":[0.97024834,0.000041949937,0.000774629,0.008894076,0.00038393,0.00025539164,0.0041585327,0.00032317033,0.014919983],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965631,0.00015522224,0.0005242216,0.0008115954,0.001272311,0.0006735466],"domain_scores_gemma":[0.9975397,0.00028262477,0.00029151922,0.0009609965,0.0006076414,0.00031753667],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00021752337,0.00054272014,0.0007569423,0.00070923957,0.00013125825,0.00005966652,0.0001498172,0.00084410014,0.00006916622],"category_scores_gemma":[0.00022876952,0.0003462943,0.000043210013,0.0012530114,0.0003305021,0.00019555214,0.000075117976,0.0025046114,0.000048534916],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01119579,0.0026995207,0.80489224,0.0017640556,0.0019499131,0.01561276,0.0009006482,0.0001605174,0.0000252471,0.000024203544,0.16036807,0.00040703506],"study_design_scores_gemma":[0.53037375,0.014027333,0.37403807,0.009528469,0.0044543357,0.0049065207,0.00016297019,0.0006056952,0.00020434146,0.000100876714,0.059446566,0.0021510883],"about_ca_topic_score_codex":0.002720639,"about_ca_topic_score_gemma":0.00030789958,"teacher_disagreement_score":0.519178,"about_ca_system_score_codex":0.007613655,"about_ca_system_score_gemma":0.011031888,"threshold_uncertainty_score":0.9998989},"labels":[],"label_agreement":null},{"id":"W2314324560","doi":"10.1097/wno.0000000000000138","title":"Isolated Optic Nerve, Chiasm, and Tract Involvement in Bing–Neel Syndrome","year":2014,"lang":"en","type":"article","venue":"Journal of Neuro-Ophthalmology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Macroglobulinemia; Optic nerve; Optic tract; Central nervous system; Infiltration (HVAC); Presentation (obstetrics); Pathology; Neuroscience; Anatomy; Surgery; Internal medicine; Biology; Physics","score_opus":0.03027561442592866,"score_gpt":0.30891391465573986,"score_spread":0.2786383002298112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314324560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678445,0.00042796115,0.00002351337,0.0015839394,0.00031927373,0.00023152404,9.754983e-7,0.000009741563,0.00061861845],"genre_scores_gemma":[0.99888194,0.000064644286,0.00036195613,0.00026126934,0.00013696597,0.0000043540317,0.000001869954,0.000037967362,0.00024901022],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9976917,0.00028933721,0.0008123827,0.00027792485,0.00043571254,0.0004929582],"domain_scores_gemma":[0.9983165,0.0005984119,0.00031627816,0.0003061882,0.00013531622,0.00032728043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091304025,0.00020941794,0.0007192254,0.0006021662,0.00004100778,0.000023355124,0.00021405943,0.00018360642,0.00016659884],"category_scores_gemma":[0.000613424,0.00016870546,0.00012662177,0.00033009786,0.00015495109,0.0001358121,0.00011493928,0.0008082552,0.000022232256],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059467764,0.0047044978,0.2261936,0.002083996,0.00074017263,0.62833583,0.0019405955,0.0013909591,0.121527806,0.00043329282,0.0024115744,0.0042908834],"study_design_scores_gemma":[0.016754163,0.0073930603,0.17607117,0.00025544534,0.00008004052,0.7759483,0.00006785783,0.022266576,0.00027948414,0.00031790326,0.00039261504,0.00017341116],"about_ca_topic_score_codex":0.00010630269,"about_ca_topic_score_gemma":0.0000010390551,"teacher_disagreement_score":0.14761244,"about_ca_system_score_codex":0.0013257771,"about_ca_system_score_gemma":0.0011172141,"threshold_uncertainty_score":0.6879609},"labels":[],"label_agreement":null},{"id":"W2314387514","doi":"10.1136/annrheumdis-2014-eular.2535","title":"THU0156 Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Golimumab; Rheumatoid arthritis; Employability; Placebo; Internal medicine; Physical therapy; Population; Methotrexate; Concomitant; Clinical trial; Adalimumab; Alternative medicine","score_opus":0.13422698196043062,"score_gpt":0.4520920778046343,"score_spread":0.31786509584420364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314387514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672323,0.00042791944,0.00005523628,0.00009121224,0.000063920554,0.00086519466,0.0017119141,0.000015875947,0.000045462733],"genre_scores_gemma":[0.9990323,0.00053029857,0.000029923041,0.00003688589,0.000050376653,0.000011399469,0.00027944017,0.000023353246,0.000006025745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625784,0.0009846939,0.0012356393,0.0003962144,0.00089056056,0.00023504572],"domain_scores_gemma":[0.99259686,0.0040461365,0.0008729757,0.0018889147,0.00033149883,0.00026358216],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019728418,0.00020807846,0.0015047003,0.00006478868,0.000041449173,0.000013108436,0.0003848801,0.00006991947,0.00016659961],"category_scores_gemma":[0.011194159,0.00011208992,0.00040371125,0.00016862061,0.00065593567,0.00014782608,0.0002733149,0.00014245977,0.0000060276902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.096177645,0.03048757,0.5367805,0.0018248494,0.0058648586,0.0000021912927,0.00058083533,0.000119700504,0.00010331687,0.00036283935,0.014678632,0.31301707],"study_design_scores_gemma":[0.08336953,0.0064530126,0.8952034,0.003550743,0.00046023857,0.0000011422907,0.00007753872,0.007117563,0.00039940822,0.0031674418,0.00002143124,0.0001785147],"about_ca_topic_score_codex":0.00066187815,"about_ca_topic_score_gemma":0.000010294119,"teacher_disagreement_score":0.35842294,"about_ca_system_score_codex":0.0001318635,"about_ca_system_score_gemma":0.0014491573,"threshold_uncertainty_score":0.997135},"labels":[],"label_agreement":null},{"id":"W2315493690","doi":"10.1155/2007/198172","title":"Treatment Strategy: Role of Enfuvirtide in Managing Treatment‐Limiting Side Effects","year":2007,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Enfuvirtide; Limiting; Medicine; Intensive care medicine; Pharmacology; Immunology; Antibody","score_opus":0.006745870772620053,"score_gpt":0.2672604059733205,"score_spread":0.26051453520070045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315493690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890189,0.008975665,0.000026349056,0.00019701962,0.000120574434,0.00021464333,0.00001353792,0.000005342914,0.0014279345],"genre_scores_gemma":[0.99868375,0.0008975225,0.000016155002,0.00015731913,0.00018336925,0.0000033478364,0.0000103272705,0.000013890676,0.00003432245],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99863565,0.00008219065,0.0004736045,0.00016020567,0.00008849445,0.00055985025],"domain_scores_gemma":[0.99786454,0.0004644493,0.00014172014,0.000111770525,0.00008231723,0.0013351932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026115892,0.00015577834,0.00051533995,0.00048519482,0.000057165526,0.000009262929,0.000065005566,0.00014874568,0.000072065544],"category_scores_gemma":[0.00047775081,0.00011330535,0.00013598819,0.0001609795,0.00030484656,0.00003587208,0.000012543215,0.00016730961,0.0000026539965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006142023,0.00054063834,0.38518003,0.00032219457,0.0007023239,0.019510917,0.00080316316,0.000039583203,0.0222783,0.0006290597,0.000056111403,0.5693235],"study_design_scores_gemma":[0.21223588,0.04869401,0.5336436,0.005379122,0.002609345,0.11669831,0.006563743,0.0016199218,0.0445973,0.0040048393,0.022519121,0.0014347938],"about_ca_topic_score_codex":0.025118506,"about_ca_topic_score_gemma":0.042032916,"teacher_disagreement_score":0.5678887,"about_ca_system_score_codex":0.006010109,"about_ca_system_score_gemma":0.01077576,"threshold_uncertainty_score":0.99780566},"labels":[],"label_agreement":null},{"id":"W2317357049","doi":"10.1136/annrheumdis-2012-eular.2085","title":"THU0120 Long-term safety of rituximab: 10-year follow-up in the rheumatoid arthritis global clinical trial programme","year":2012,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Rheumatoid arthritis; Rituximab; Internal medicine; Population; Adverse effect; Placebo; Methotrexate; Clinical trial; Rheumatology; Pathology; Lymphoma","score_opus":0.117532149327895,"score_gpt":0.41234445610826037,"score_spread":0.29481230678036535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317357049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869259,0.0077738794,0.000012124964,0.0013721812,0.0005102161,0.0022265275,0.00011696578,0.000030928244,0.0010312995],"genre_scores_gemma":[0.9947321,0.004567564,0.000045813224,0.00022626214,0.00015282207,0.000105207226,0.000037576523,0.000025783136,0.00010689976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99519837,0.000784692,0.0015538702,0.00028823523,0.0013506489,0.0008241939],"domain_scores_gemma":[0.99632454,0.0012673966,0.0005031332,0.0013150097,0.0002228376,0.00036708105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027239674,0.00026439189,0.0010369848,0.000068204805,0.0000863495,0.000033243618,0.00082501874,0.0001488353,0.00043775112],"category_scores_gemma":[0.005409055,0.00015100269,0.00087504234,0.00056159473,0.000741176,0.0001864353,0.00030856478,0.00023486333,0.00007973203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07702711,0.016590452,0.47504187,0.002294006,0.001287725,0.00004661115,0.0016226589,0.0000045679662,0.0000022544045,0.002981012,0.021989265,0.40111247],"study_design_scores_gemma":[0.2629477,0.0011941565,0.7280778,0.0048676603,0.00021402429,0.000119058095,0.0007100134,0.00016136047,0.0000889997,0.0006938042,0.00062461314,0.0003007644],"about_ca_topic_score_codex":0.00027902448,"about_ca_topic_score_gemma":0.00007125346,"teacher_disagreement_score":0.40081173,"about_ca_system_score_codex":0.00043697754,"about_ca_system_score_gemma":0.0026971316,"threshold_uncertainty_score":0.6475535},"labels":[],"label_agreement":null},{"id":"W2317597802","doi":"10.1016/j.cyto.2008.07.262","title":"199 Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia to VSV-induced oncolysis","year":2008,"lang":"en","type":"article","venue":"Cytokine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; Jewish General Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Apoptosis; Leukemia; Cancer research; Primary (astronomy); Medicine; Chemistry; Immunology; Biochemistry","score_opus":0.01885235622378325,"score_gpt":0.2507115276663517,"score_spread":0.23185917144256843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317597802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99060553,0.00070352573,0.00013988696,0.00094914285,0.0002491765,0.0015807189,0.000012955131,0.0003219757,0.005437095],"genre_scores_gemma":[0.9924648,0.00016615598,0.00082333863,0.0015602373,0.0017986024,0.00015737486,0.0000873001,0.00015759766,0.0027846007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953016,0.00018335454,0.00072860724,0.00091534975,0.0015844693,0.0012866133],"domain_scores_gemma":[0.9969877,0.000515645,0.00019649434,0.0013096116,0.00035068038,0.0006398791],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074376486,0.0005651778,0.0009310911,0.00032947923,0.0005870948,0.00005888455,0.00042144346,0.00023739591,0.00013478006],"category_scores_gemma":[0.0004651276,0.00036043354,0.00025403392,0.0015328793,0.00039785553,0.00016450055,0.00035646048,0.00063558517,0.0005857564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003978,0.00029527096,0.0006952984,0.0015170838,0.0012182121,0.011157587,0.0052943914,0.012268875,0.90897954,0.00014855203,0.03110147,0.023345744],"study_design_scores_gemma":[0.07064987,0.005678958,0.004947289,0.002210227,0.0007979452,0.011203426,0.001162951,0.04380043,0.7915101,0.000026697373,0.06582333,0.0021887748],"about_ca_topic_score_codex":0.001706126,"about_ca_topic_score_gemma":0.00013468409,"teacher_disagreement_score":0.117469415,"about_ca_system_score_codex":0.13437285,"about_ca_system_score_gemma":0.052238125,"threshold_uncertainty_score":0.9998848},"labels":[],"label_agreement":null},{"id":"W2317684280","doi":"10.1158/1538-7445.am2012-5232","title":"Abstract 5232: Tyrosine kinase inhibitor, gefitinib targets ZAP-70 over expressing chronic lymphocytic leukemia cells","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Gefitinib; Tyrosine kinase; Cancer research; LYN; Syk; Cytotoxic T cell; Medicine; Chronic lymphocytic leukemia; Tyrosine-kinase inhibitor; Kinase; Epidermal growth factor receptor; Cancer; Internal medicine; Chemistry; Leukemia; Biology; Receptor; Cell biology; Biochemistry; In vitro","score_opus":0.06487174804501919,"score_gpt":0.3910950851984509,"score_spread":0.32622333715343166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317684280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504995,0.037039135,0.00002337634,0.00028597043,0.0010273671,0.0013827417,0.00005693145,0.00021066911,0.009474327],"genre_scores_gemma":[0.9826953,0.0033418234,0.000121853314,0.0003276894,0.005802845,0.0004726012,0.00006074769,0.00022806227,0.0069491016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9899003,0.0002982611,0.00080880703,0.0010217932,0.0043502054,0.0036206231],"domain_scores_gemma":[0.99478626,0.0008034372,0.00015252568,0.0015333954,0.00073865603,0.0019856975],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003297106,0.0005459342,0.00078528386,0.0006985222,0.00055824243,0.00021778473,0.0007685321,0.0005963944,0.011095322],"category_scores_gemma":[0.00080870977,0.00048696063,0.00028313434,0.0012890686,0.0008967911,0.00069715676,0.00080193975,0.0019535602,0.0018488603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014200376,0.00030567124,0.0009357761,0.0027845872,0.00023638114,0.0012648565,0.001049127,0.00041952828,0.86642563,0.00020572018,0.101361,0.023591679],"study_design_scores_gemma":[0.025056787,0.00036568186,0.0032993588,0.0027380406,0.000068025874,0.00027191834,0.00021597685,0.0054685394,0.86331165,0.000049369395,0.09840183,0.00075281155],"about_ca_topic_score_codex":0.0082562715,"about_ca_topic_score_gemma":0.00016731709,"teacher_disagreement_score":0.1317512,"about_ca_system_score_codex":0.21994789,"about_ca_system_score_gemma":0.0881967,"threshold_uncertainty_score":0.9997582},"labels":[],"label_agreement":null},{"id":"W2318267216","doi":"10.1136/annrheumdis-2012-eular.460","title":"AB0460 Long-term remission with golimumab in active rheumatoid arthritis patients despite methotrexate through 2 years","year":2012,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Methotrexate; Medicine; Rheumatoid arthritis; Internal medicine; Golimumab; Gastroenterology; Complete remission; Adalimumab; Chemotherapy","score_opus":0.03869301267534495,"score_gpt":0.33954150178728226,"score_spread":0.3008484891119373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318267216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940453,0.004057837,0.000021775346,0.00024969276,0.000101559395,0.0008194619,0.00004440039,0.00003274183,0.0006272244],"genre_scores_gemma":[0.99459285,0.0046756323,0.0002089902,0.00020677093,0.000024620478,0.000055455443,0.000034380075,0.000048504342,0.00015282715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974069,0.00024375095,0.0005090926,0.00026804119,0.00091720134,0.0006549927],"domain_scores_gemma":[0.9980634,0.00035375752,0.00029981302,0.0007764889,0.00018981523,0.000316744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003030791,0.00024408632,0.0005803336,0.000115112496,0.00006841956,0.000021178235,0.0003071489,0.00008318154,0.00021192928],"category_scores_gemma":[0.0008861631,0.00015695208,0.00019675803,0.00046101765,0.00027851673,0.00042126598,0.00021040888,0.00019305017,0.00004582181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040668417,0.0042499127,0.64211035,0.0018217061,0.0008144828,0.00008215864,0.0071807555,0.000072336465,0.00009337845,0.00021072885,0.0035962858,0.33570105],"study_design_scores_gemma":[0.011095515,0.00026391115,0.9758424,0.0076110703,0.00005961918,0.000047862683,0.00020342073,0.0001055475,0.0040783905,0.00033731243,0.00012711808,0.00022783678],"about_ca_topic_score_codex":0.00033554094,"about_ca_topic_score_gemma":0.000023244731,"teacher_disagreement_score":0.3354732,"about_ca_system_score_codex":0.0007914171,"about_ca_system_score_gemma":0.0011966821,"threshold_uncertainty_score":0.64003205},"labels":[],"label_agreement":null},{"id":"W2318359473","doi":"10.1136/annrheumdis-2014-eular.3328","title":"THU0176 Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"AstraZeneca; Pfizer; Genentech; Amgen","keywords":"Medicine; Golimumab; Psoriatic arthritis; Placebo; Rheumatoid arthritis; Ankylosing spondylitis; Internal medicine; Incidence (geometry); Concomitant; Pathology; Adalimumab","score_opus":0.0833797178581337,"score_gpt":0.37678194755046285,"score_spread":0.29340222969232915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318359473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9250692,0.07057509,0.000066355926,0.00081594015,0.00009996988,0.0023363822,0.0009654926,0.00001970741,0.0000518784],"genre_scores_gemma":[0.92117983,0.07802173,0.00010125947,0.0001028805,0.000036680558,0.0000969223,0.0004103751,0.000032265005,0.000018074334],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942247,0.0015939578,0.002084165,0.0005558652,0.0010901738,0.0004511143],"domain_scores_gemma":[0.9870436,0.008675566,0.0010539397,0.0025358237,0.00047369275,0.00021736583],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0039039291,0.0003482667,0.003778145,0.0004123435,0.00015673917,0.00004857985,0.0008347105,0.00009873972,0.00017416668],"category_scores_gemma":[0.01045658,0.00020452375,0.00063974265,0.00082032837,0.001431538,0.00029860644,0.0006729122,0.00019680348,0.0000025497152],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8698784,0.001927347,0.016407683,0.0016754196,0.03310443,0.000044552653,0.005325576,0.00079593813,0.000070921444,0.002304232,0.0005833986,0.06788208],"study_design_scores_gemma":[0.87345266,0.00019406102,0.044271413,0.014465586,0.0055842665,0.000028237806,0.0024607037,0.05643777,0.00023766383,0.0025632102,0.000006699954,0.00029771368],"about_ca_topic_score_codex":0.0025377139,"about_ca_topic_score_gemma":0.0014900443,"teacher_disagreement_score":0.06758437,"about_ca_system_score_codex":0.00019270842,"about_ca_system_score_gemma":0.0010988265,"threshold_uncertainty_score":0.9978788},"labels":[],"label_agreement":null},{"id":"W2318424614","doi":"10.1158/1538-7445.am2012-5505","title":"Abstract 5505: Risk of second malignancies in patients with Chronic Lymphocytic Leukemia: A population based Canadian study","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Cancer; Cancer registry; Internal medicine; Standardized mortality ratio; Population; Relative survival; Incidence (geometry); Relative risk; Malignancy; Epidemiology; Oncology; Leukemia; Confidence interval","score_opus":0.0350687143105119,"score_gpt":0.3436964862447262,"score_spread":0.3086277719342143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318424614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996059,0.0008248075,9.1684956e-7,0.000025002417,0.000082064464,0.002237029,0.00008968929,0.000018566443,0.0006629428],"genre_scores_gemma":[0.99899703,0.0000344279,0.00002507289,0.000027591628,0.00016047424,0.0003236153,0.00006093259,0.00005926438,0.00031161678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958111,0.00026428,0.00043893812,0.0004136197,0.0016450053,0.0014270277],"domain_scores_gemma":[0.9976489,0.0002948951,0.000108312204,0.00070893014,0.0005689569,0.0006700224],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001973025,0.00021163792,0.0004478951,0.0010224275,0.00015258475,0.000027875356,0.0002584266,0.00016309046,0.0014679723],"category_scores_gemma":[0.00035230353,0.00017090022,0.00005811861,0.0012496798,0.00019290313,0.0002361174,0.00007188888,0.0007122211,0.000052896645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008809497,0.00020433454,0.9949199,0.00050700916,0.0000918675,0.00004286967,0.00062161154,0.0008430406,0.00016930987,0.000008757105,0.0003150491,0.0013953256],"study_design_scores_gemma":[0.023160623,0.00080586364,0.97302437,0.0004043488,0.000036944395,0.0000025473141,0.00026771336,0.0008441856,0.0010165689,0.0000053462895,0.00026814092,0.00016337135],"about_ca_topic_score_codex":0.77399063,"about_ca_topic_score_gemma":0.65320975,"teacher_disagreement_score":0.16342218,"about_ca_system_score_codex":0.2398167,"about_ca_system_score_gemma":0.07639451,"threshold_uncertainty_score":0.99944484},"labels":[],"label_agreement":null},{"id":"W2321144882","doi":"10.1136/annrheumdis-2012-eular.526","title":"AB0526 Sustained efficacy responses and a consistent safety profile with rituximab repeat treatment over 5 years in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors in the reflex study","year":2012,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Rheumatoid arthritis; Methotrexate; Placebo; Gastroenterology; Surgery; Lymphoma; Pathology","score_opus":0.029019696137970473,"score_gpt":0.328246413055332,"score_spread":0.2992267169173615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321144882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457335,0.000897945,3.2468347e-7,0.0007519345,0.000015891597,0.0036200278,0.000110855945,0.000017410484,0.000012229588],"genre_scores_gemma":[0.99921274,0.00030118547,0.00004492918,0.00012761012,0.000007873568,0.00019896096,0.000011863467,0.000033778942,0.0000610549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967969,0.0010588104,0.0005229398,0.0003531432,0.00075903453,0.0005091703],"domain_scores_gemma":[0.9977321,0.00093089655,0.00017011428,0.0007230218,0.00012157467,0.00032227425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000908896,0.00027606188,0.0006079765,0.0002524299,0.00010459656,0.000059881437,0.00016369777,0.00004348447,0.000018844663],"category_scores_gemma":[0.0012905493,0.00014252611,0.00005860169,0.00046869926,0.00028210614,0.00021775479,0.00013860212,0.00011617517,0.0000022323986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10732003,0.01159245,0.7984871,0.0002503453,0.00030449574,0.00011700529,0.031718485,0.000013375506,0.000030568353,0.000021640735,0.00017939844,0.04996508],"study_design_scores_gemma":[0.03619726,0.0048054038,0.9512574,0.0017097753,0.000050486156,0.000021723608,0.005598733,0.000034053024,0.00011604966,0.000010217257,0.000029553581,0.00016932005],"about_ca_topic_score_codex":0.0013040664,"about_ca_topic_score_gemma":0.00033962473,"teacher_disagreement_score":0.15277031,"about_ca_system_score_codex":0.00084026676,"about_ca_system_score_gemma":0.0012047002,"threshold_uncertainty_score":0.5812046},"labels":[],"label_agreement":null},{"id":"W2321436014","doi":"10.1158/1538-7445.am10-1762","title":"Abstract 1762: Clinical relevance of plasma IL-6 and IL-6 levels in chronic lymphocytic leukemia (CLL)","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Internal medicine; Clinical significance; Gastroenterology; Endocrinology; Leukemia; Cytokine; Plasma levels; Immunology","score_opus":0.11935197722133122,"score_gpt":0.4593718489228082,"score_spread":0.34001987170147696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321436014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932231,0.0017963649,0.0000034418815,0.00037028076,0.00034810352,0.0010469824,0.00006870171,0.000045544894,0.0030975284],"genre_scores_gemma":[0.99214387,0.0043990104,0.00023126206,0.00006221501,0.00078621635,0.00018705722,0.000008969474,0.000081649705,0.0020997766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99467057,0.00022711881,0.0010508198,0.00096057437,0.0017118247,0.0013790834],"domain_scores_gemma":[0.99493074,0.0024707788,0.00014624484,0.0011847069,0.00061882637,0.0006487237],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004579138,0.00028443823,0.000829526,0.00056029024,0.0001257135,0.00005089801,0.000579818,0.00053471606,0.0009316927],"category_scores_gemma":[0.00327912,0.00025328272,0.0001465921,0.0010484683,0.0020071142,0.00020083768,0.00045347775,0.0028708733,0.00017010499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0042194314,0.00027381873,0.012202409,0.0047051534,0.00032307042,0.0017178473,0.0009623067,0.000518596,0.7447691,0.0016488478,0.008275357,0.22038408],"study_design_scores_gemma":[0.13291062,0.0032441837,0.31392628,0.0048445174,0.00012567577,0.0009320755,0.00063841324,0.081077434,0.35389462,0.0019118729,0.104991,0.0015033036],"about_ca_topic_score_codex":0.008258977,"about_ca_topic_score_gemma":0.0046063825,"teacher_disagreement_score":0.39087445,"about_ca_system_score_codex":0.061632607,"about_ca_system_score_gemma":0.10549724,"threshold_uncertainty_score":0.99999195},"labels":[],"label_agreement":null},{"id":"W2321676231","doi":"10.1158/1538-7445.am2011-lb-109","title":"Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Protein phosphatase 2; Progenitor cell; Stem cell; Cancer research; CD38; Haematopoiesis; Biology; Tyrosine kinase; CD34; Cell biology; Signal transduction; Phosphatase; Phosphorylation","score_opus":0.17323417840581218,"score_gpt":0.3960053296568782,"score_spread":0.222771151251066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321676231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857934,0.00009974975,0.00006719237,0.0039246795,0.00015853248,0.005532971,0.00018429999,0.000037786634,0.004201364],"genre_scores_gemma":[0.986548,0.0004380066,0.000034030894,0.0003608234,0.00033824664,0.001770218,0.000013288515,0.00008108868,0.010416276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99544203,0.0004012104,0.00035356867,0.000987085,0.0016412938,0.0011748337],"domain_scores_gemma":[0.9954176,0.0020243954,0.00012391148,0.00088381954,0.0009691707,0.00058110134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018286174,0.00038848424,0.0007010709,0.00028139778,0.0005585219,0.000116713796,0.0002653635,0.00023021088,0.0006907936],"category_scores_gemma":[0.00035641596,0.00024656477,0.00016547323,0.0004991255,0.00014834931,0.00021023011,0.00023209104,0.00060980354,0.000115350005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053872265,0.0010154606,0.000113670256,0.00047067308,0.0002893314,0.00008102231,0.0068242257,0.000017425507,0.91493917,0.00008429307,0.005542108,0.016750332],"study_design_scores_gemma":[0.026161972,0.0015460588,0.0022173512,0.00045749452,0.000057184203,0.0000047667763,0.0016296281,0.0018275509,0.9644901,0.000010929593,0.0013636699,0.00023326692],"about_ca_topic_score_codex":0.0066638174,"about_ca_topic_score_gemma":0.0005225519,"teacher_disagreement_score":0.049550932,"about_ca_system_score_codex":0.012958988,"about_ca_system_score_gemma":0.004442737,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W2322800322","doi":"10.1136/annrheumdis-2013-eular.2606","title":"AB0284 Long term safety of iv golimumab and comparisons with sc golimumab in rheumatologic conditions: results from the 120-day safety report of go-further trial","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Golimumab; Internal medicine; Safety profile; Adverse effect; Rheumatoid arthritis; Physical therapy; Adalimumab","score_opus":0.043190332442442594,"score_gpt":0.3280958714096306,"score_spread":0.284905538967188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322800322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993015,0.0019179392,0.000029681103,0.0043516955,0.00008492961,0.002390594,0.0005883908,0.000023806891,0.0006827826],"genre_scores_gemma":[0.9979486,0.0013578329,0.00007054784,0.00010424756,0.000023660597,0.00009100169,0.00015446148,0.000030013676,0.0002196542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959935,0.0005072504,0.001793989,0.0004001078,0.00089325,0.0004118822],"domain_scores_gemma":[0.99320453,0.0034966883,0.0011757509,0.0015554143,0.00037704548,0.00019056999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010237454,0.00028538046,0.0011666485,0.0001187129,0.00011161292,0.000026218486,0.0005175518,0.00011444776,0.00028946507],"category_scores_gemma":[0.0035249426,0.00014899985,0.0002579221,0.0004098184,0.0013031865,0.00016751586,0.00027171624,0.000227145,0.00001366826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27182662,0.012823013,0.5535803,0.0065138317,0.009160047,0.0005384171,0.020478174,0.0020987787,0.00035012644,0.0020808424,0.08714436,0.03340551],"study_design_scores_gemma":[0.09623868,0.0005660965,0.89000624,0.006807909,0.00035112223,0.00016126843,0.0014745251,0.00224164,0.000559696,0.0012910286,0.000062114974,0.00023966022],"about_ca_topic_score_codex":0.004826825,"about_ca_topic_score_gemma":0.00030781014,"teacher_disagreement_score":0.336426,"about_ca_system_score_codex":0.00033861556,"about_ca_system_score_gemma":0.0023725042,"threshold_uncertainty_score":0.72967476},"labels":[],"label_agreement":null},{"id":"W2323364690","doi":"10.1136/annrheumdis-2013-eular.1854","title":"SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Cumulative incidence; Internal medicine; Rheumatoid arthritis; Adverse effect; Cumulative dose; Incidence (geometry); Clinical trial; MedDRA; Discontinuation; Abatacept; Gastroenterology; Cohort; Rituximab","score_opus":0.043077330683503626,"score_gpt":0.3355547840796279,"score_spread":0.2924774533961243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323364690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373025,0.0014272971,0.0000024036515,0.000862884,0.0001409703,0.003080596,0.0007283774,0.000020941525,0.000006288922],"genre_scores_gemma":[0.9960001,0.0034566056,0.00009379635,0.000085435815,0.000024759907,0.00007999149,0.00020274597,0.00002818439,0.00002834807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968988,0.00044314435,0.0012136016,0.0005101316,0.00060685014,0.00032752453],"domain_scores_gemma":[0.99637127,0.0013743531,0.00046659165,0.0012816231,0.0002742388,0.00023192646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068506814,0.00023702437,0.0008987825,0.0001206272,0.00006366758,0.000037430833,0.0003124284,0.00010308136,0.000049679886],"category_scores_gemma":[0.005822795,0.00013636891,0.00008437244,0.00023638172,0.00030468643,0.00023475023,0.00045776996,0.00016286818,0.0000061411415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15274821,0.006153048,0.5656609,0.0013597767,0.001794319,0.000043381875,0.0021135656,0.000033387692,0.000082202125,0.000015827176,0.0018153421,0.26818],"study_design_scores_gemma":[0.08795003,0.0038478568,0.90270656,0.0043728612,0.00009175073,0.000012825968,0.00007847902,0.00032083725,0.00021430591,0.0002355015,0.000007749837,0.00016121876],"about_ca_topic_score_codex":0.003905853,"about_ca_topic_score_gemma":0.000289557,"teacher_disagreement_score":0.33704567,"about_ca_system_score_codex":0.00010790484,"about_ca_system_score_gemma":0.0009032209,"threshold_uncertainty_score":0.697085},"labels":[],"label_agreement":null},{"id":"W2324623264","doi":"10.1097/icb.0000000000000228","title":"PIMASERTIB AND SEROUS RETINAL DETACHMENTS","year":2015,"lang":"en","type":"article","venue":"Retinal Cases & Brief Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Retinal; Serous fluid; Ophthalmology; Internal medicine","score_opus":0.047294578923874384,"score_gpt":0.33669018382179206,"score_spread":0.28939560489791766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324623264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982909,0.0019597565,0.00004336455,0.00043855034,0.0001645047,0.00050620514,0.0000043188893,0.00012685433,0.013847444],"genre_scores_gemma":[0.9938141,0.000082364626,0.000822733,0.00041307908,0.00032957434,0.000028864992,0.00005294764,0.00004921021,0.0044070925],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9968549,0.00009662598,0.0005949712,0.0006667649,0.0011679,0.0006188389],"domain_scores_gemma":[0.99761605,0.00012563281,0.0002173125,0.0007319874,0.0003793033,0.00092973904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010592749,0.00026459165,0.00045786297,0.000115513634,0.00010225608,0.000069256304,0.000072814066,0.0001415049,0.00013149211],"category_scores_gemma":[0.0017170602,0.0002323395,0.0001017217,0.00024863306,0.00025720886,0.00013464144,0.00020905882,0.00031557982,0.000043729804],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004701922,0.0005834026,0.20308779,0.00083887985,0.00024100339,0.72589546,0.0008018317,0.000012111323,0.0025881007,0.00024354829,0.04670403,0.014301923],"study_design_scores_gemma":[0.0108847385,0.0028271703,0.01838385,0.000567378,0.00038481987,0.839519,0.00042695456,0.0012045677,0.006234085,0.00054493104,0.1184385,0.00058400974],"about_ca_topic_score_codex":0.0018644676,"about_ca_topic_score_gemma":0.000034900575,"teacher_disagreement_score":0.18470395,"about_ca_system_score_codex":0.0037277418,"about_ca_system_score_gemma":0.0045997873,"threshold_uncertainty_score":0.9747915},"labels":[],"label_agreement":null},{"id":"W2325624679","doi":"10.1136/annrheumdis-2013-eular.2589","title":"AB0267 Five-year safety and efficacy of golimumab in patients with active rheumatoid arthritis despite prior treatment with methotrexate: final study results of the phase 3, randomized placebo-controlled go-forward trial","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Golimumab; Rheumatoid arthritis; Placebo; Internal medicine; Randomized controlled trial; Methotrexate; Adalimumab","score_opus":0.021600468137041973,"score_gpt":0.31379600676777936,"score_spread":0.2921955386307374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325624679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830595,0.0004972958,0.000005093505,0.00025401663,0.000035174107,0.015826292,0.00019629818,0.0000110744295,0.00011523696],"genre_scores_gemma":[0.99830747,0.0008879735,0.00008127145,0.000014729631,0.000008369891,0.0004794313,0.000016685472,0.000030337722,0.00017376375],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956551,0.0012644647,0.0013270742,0.0003583259,0.0010359542,0.00035904636],"domain_scores_gemma":[0.9937566,0.0036200846,0.0011005142,0.00089437416,0.00044888907,0.00017954088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093201816,0.00033892764,0.0022336473,0.00015879472,0.000087604785,0.000021617772,0.00029100524,0.00005825052,0.000058080648],"category_scores_gemma":[0.003536644,0.00014580542,0.00039002666,0.00032507937,0.00069631153,0.0001380523,0.00013295794,0.00012707541,0.000002521343],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9525525,0.0074643907,0.0011955546,0.00016522995,0.0021773695,0.000003690843,0.0031704109,0.00014249895,0.0000030709318,0.000008477207,0.000052516167,0.03306428],"study_design_scores_gemma":[0.94182307,0.007345169,0.04525273,0.0025542048,0.0005583291,0.0000034174964,0.00079562113,0.0010694339,0.00040929913,0.00004784685,0.0000030899869,0.0001378195],"about_ca_topic_score_codex":0.0016559334,"about_ca_topic_score_gemma":0.000093693554,"teacher_disagreement_score":0.044057176,"about_ca_system_score_codex":0.0004630989,"about_ca_system_score_gemma":0.0020900164,"threshold_uncertainty_score":0.59457725},"labels":[],"label_agreement":null},{"id":"W2326175431","doi":"10.1056/nejm200012143432402","title":"Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia","year":2000,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1004,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; McGill University","keywords":"Chlorambucil; Fludarabine; Chronic lymphocytic leukemia; Medicine; Internal medicine; Gastroenterology; Chemotherapy; Surgery; Leukemia; Cyclophosphamide","score_opus":0.023075937609354957,"score_gpt":0.29837637649937615,"score_spread":0.2753004388900212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326175431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705575,0.014856015,0.00050744857,0.004373678,0.0003101913,0.0010140251,0.000004314674,0.000054418426,0.008322422],"genre_scores_gemma":[0.9656609,0.0075325673,0.0013104813,0.0027010909,0.010783421,0.000018292409,0.000052620115,0.00010142229,0.011839147],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965845,0.00008539303,0.00090383587,0.00032553007,0.0014670168,0.0006337683],"domain_scores_gemma":[0.9972683,0.0005748169,0.00032340703,0.00049491704,0.00051860913,0.0008199246],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001291724,0.0003642641,0.0012286038,0.00029696547,0.000106947264,0.00002470118,0.00034384913,0.00013827467,0.0026553476],"category_scores_gemma":[0.0002490241,0.00021059494,0.00017393734,0.0004270063,0.00038254674,0.00016564317,0.000018536835,0.0005002906,0.000047100937],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.082662135,0.00017302089,0.00021743037,0.0006301003,0.0012096452,0.0026384552,0.0018435784,0.0036565757,0.01084405,0.000091222595,0.06820558,0.8278282],"study_design_scores_gemma":[0.575955,0.017425187,0.00079734105,0.0015970716,0.0003433891,0.019641604,0.00007424823,0.0048924917,0.002562637,0.00032684082,0.37613007,0.00025412443],"about_ca_topic_score_codex":0.00080532633,"about_ca_topic_score_gemma":0.000041475574,"teacher_disagreement_score":0.8275741,"about_ca_system_score_codex":0.035701737,"about_ca_system_score_gemma":0.057684835,"threshold_uncertainty_score":0.9982564},"labels":[],"label_agreement":null},{"id":"W2327541094","doi":"10.1038/sj.leu.2402579","title":"Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study","year":2002,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Mantle cell lymphoma; Nucleoside; Chemotherapy; Lymphoma; Nucleoside analogue; Cancer research; Medicine; Virology; Biology; Internal medicine; Oncology; Genetics","score_opus":0.017660610305329557,"score_gpt":0.2774025378247684,"score_spread":0.25974192751943886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327541094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95543617,0.0007280417,0.0004410985,0.032610357,0.00021312901,0.004268514,0.00008291607,0.000115889,0.0061039054],"genre_scores_gemma":[0.8418912,0.000058056485,0.0019507267,0.14265384,0.00040198085,0.0002542203,0.000074477546,0.0003020475,0.012413433],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951085,0.00024068342,0.0009787087,0.0011855543,0.0014390143,0.0010475782],"domain_scores_gemma":[0.9971029,0.00021760294,0.0002703921,0.0019520149,0.00020185126,0.00025520427],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047741842,0.00065554795,0.0014287697,0.000856541,0.00005496592,0.00003720313,0.0005874187,0.00095110916,0.00029814045],"category_scores_gemma":[0.000103118065,0.0006422479,0.00029088772,0.0011191455,0.000110045294,0.00005294103,0.00021646735,0.0012189506,0.00019169076],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004578327,0.00076809956,0.000056773883,0.0016630467,0.00024731318,0.5295379,0.0020762847,0.00004304459,0.0036243503,0.000017401948,0.46078908,0.00071884994],"study_design_scores_gemma":[0.376866,0.008039051,0.0009578901,0.0065941876,0.0020120377,0.03867972,0.009333646,0.00740839,0.12998922,0.0016269365,0.41192105,0.0065718475],"about_ca_topic_score_codex":0.0079477895,"about_ca_topic_score_gemma":0.0010166559,"teacher_disagreement_score":0.4908582,"about_ca_system_score_codex":0.033383347,"about_ca_system_score_gemma":0.00532939,"threshold_uncertainty_score":0.99960285},"labels":[],"label_agreement":null},{"id":"W2327847401","doi":"10.1158/1538-7445.am2012-lb-52","title":"Abstract LB-52: Relentless in the fight against blood cancer: the Leukemia &amp; Lymphoma Society","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Leukemia; Lymphoma; Disease; Multiple myeloma; Quality of life (healthcare); Family medicine; Internal medicine; Oncology; Nursing","score_opus":0.10722723644145146,"score_gpt":0.4226506969041498,"score_spread":0.3154234604626983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327847401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589156,0.019987265,0.0000019659033,0.008712212,0.00029340637,0.0017699839,0.000045628887,0.000047294347,0.010226637],"genre_scores_gemma":[0.9735454,0.0154717015,0.00002988612,0.002583909,0.0020484778,0.0022489177,0.000035819594,0.00008035613,0.003955555],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935552,0.00046746578,0.00047882888,0.0005599622,0.0027720914,0.0021664554],"domain_scores_gemma":[0.99616295,0.001410222,0.00008857585,0.0015205173,0.00041570066,0.000402025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053452323,0.00029980156,0.00040676448,0.00016626192,0.00058465084,0.00014346513,0.0012486419,0.00029105227,0.0010666798],"category_scores_gemma":[0.00042062148,0.0001675143,0.00027223415,0.0015918965,0.0008325138,0.00023003524,0.00039745582,0.0016755288,0.0003498077],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0013182287,0.0016273524,0.02332006,0.002193197,0.001021124,0.00038845767,0.03372794,0.00030490512,0.043775856,0.0010928074,0.76669556,0.1245345],"study_design_scores_gemma":[0.023556804,0.00012908212,0.054771163,0.0012601606,0.00014355019,0.00022011671,0.0051133935,0.0007436343,0.020522965,0.00012785823,0.89283305,0.0005782469],"about_ca_topic_score_codex":0.014302544,"about_ca_topic_score_gemma":0.0021136934,"teacher_disagreement_score":0.12613747,"about_ca_system_score_codex":0.026804388,"about_ca_system_score_gemma":0.01876508,"threshold_uncertainty_score":0.99984646},"labels":[],"label_agreement":null},{"id":"W2329254038","doi":"10.1385/cbb:43:1:077","title":"A New Method for Targeted Drug Delivery Using Polymeric Microcapsules: Implications for Treatment of Crohn's Disease","year":2005,"lang":"en","type":"article","venue":"Cell Biochemistry and Biophysics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McGill University","funders":"","keywords":"Thalidomide; Drug delivery; Crohn's disease; Drug; Pharmacology; Medicine; Targeted drug delivery; Disease; Chemistry; Immunology; Internal medicine; Multiple myeloma","score_opus":0.021276998396952632,"score_gpt":0.32330027636773984,"score_spread":0.3020232779707872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329254038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776505,0.004639771,0.016110007,0.00041494146,0.00001726906,0.0007182069,0.00039304284,0.000019651821,0.000036592468],"genre_scores_gemma":[0.89859253,0.0002997105,0.09820983,0.00008527551,0.00053629285,0.00007665668,0.0003493758,0.000028042947,0.0018223124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916565,0.0000068290988,0.00019070221,0.0003044545,0.000071438444,0.0002609146],"domain_scores_gemma":[0.9991098,0.000116048526,0.000085528656,0.00029535513,0.000105641564,0.00028761936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000038172948,0.00015924007,0.0002507994,0.00002523623,0.00008361745,0.000012159285,0.00006674205,0.00006260924,0.000006731769],"category_scores_gemma":[0.000015050848,0.00013724042,0.0001729795,0.00012687988,0.00007333157,0.00002904284,0.000024198895,0.00002328201,7.6349374e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005430952,0.00030077045,0.000016318416,0.00059884315,0.00006278984,0.00000176598,0.000099152814,0.000008853803,0.9725698,0.000011686315,0.0005346395,0.02525224],"study_design_scores_gemma":[0.006774369,0.000095531715,0.0000696332,0.00003553051,0.00032033643,0.000008064414,0.000067655266,0.008278523,0.9825523,0.00010990238,0.0015569822,0.00013115314],"about_ca_topic_score_codex":0.00011622562,"about_ca_topic_score_gemma":6.453489e-7,"teacher_disagreement_score":0.082099825,"about_ca_system_score_codex":0.0011821929,"about_ca_system_score_gemma":0.002922571,"threshold_uncertainty_score":0.5596502},"labels":[],"label_agreement":null},{"id":"W2331195506","doi":"10.1182/blood-2010-09-305375","title":"Stage C or not stage C…?","year":2010,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Stage (stratigraphy); Medicine; Geology; Paleontology","score_opus":0.04431605335968141,"score_gpt":0.3235188632264209,"score_spread":0.2792028098667395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331195506","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17909293,0.00064044364,0.000029416076,0.758691,0.0020931214,0.004040683,0.0013840547,0.0008504678,0.05317789],"genre_scores_gemma":[0.0012765242,0.00010443341,0.0007029073,0.45950758,0.0086763585,0.00009313626,0.0005255518,0.0002088143,0.5289047],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618423,0.00007508737,0.0004554902,0.000781439,0.0014839644,0.0010197783],"domain_scores_gemma":[0.9972156,0.0004007982,0.00016383681,0.0017917582,0.00017627027,0.0002516888],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.000329881,0.0004746171,0.00081615295,0.00020449278,0.00008164716,0.00007936327,0.00052552245,0.0028041487,0.008225099],"category_scores_gemma":[0.0005442179,0.00034443074,0.00025870575,0.00023569696,0.00023816884,0.0000570325,0.00027501208,0.007742097,0.0015655877],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027755162,0.00031637042,0.000023764975,0.0021033545,0.00038211024,0.039084993,0.00008182103,1.0158074e-7,0.0017044116,0.0000111742,0.95550066,0.0005137053],"study_design_scores_gemma":[0.030005962,0.00028773167,0.000037103484,0.00020540718,0.00036566608,0.0008783324,0.000014090906,0.000041230935,0.010024421,0.0000030748142,0.9577636,0.00037339734],"about_ca_topic_score_codex":0.0006805174,"about_ca_topic_score_gemma":0.00010088596,"teacher_disagreement_score":0.4757268,"about_ca_system_score_codex":0.002710089,"about_ca_system_score_gemma":0.016500872,"threshold_uncertainty_score":0.99990076},"labels":[],"label_agreement":null},{"id":"W2333494261","doi":"10.1200/jco.2015.33.15_suppl.tps8599","title":"A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Dalhousie University","funders":"","keywords":"Ibrutinib; Medicine; Bruton's tyrosine kinase; Waldenstrom macroglobulinemia; Tolerability; Rituximab; Macroglobulinemia; Internal medicine; Placebo; Oncology; Phases of clinical research; Gastroenterology; Pharmacology; Clinical trial; Tyrosine kinase; Adverse effect; Lymphoma; Chronic lymphocytic leukemia; Pathology; Leukemia; Receptor","score_opus":0.26018308480509883,"score_gpt":0.5382811004902589,"score_spread":0.27809801568516007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333494261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98425454,0.00038001256,0.0012929894,0.0026175373,0.0009566965,0.008135935,0.0000112340995,0.000022385924,0.0023286685],"genre_scores_gemma":[0.9859473,0.00012443398,0.008744675,0.0005133291,0.002100929,0.00029650185,0.000007545358,0.00006883538,0.0021964412],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894448,0.0013391986,0.0063144267,0.0005087682,0.0016863123,0.0007065183],"domain_scores_gemma":[0.97809947,0.012220934,0.0044918247,0.0006366321,0.0031975782,0.0013535375],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020888232,0.0004218873,0.009033533,0.00037818617,0.00006588522,0.000030885618,0.0005657394,0.0006481648,0.0002268983],"category_scores_gemma":[0.017009648,0.00022249119,0.0011849572,0.00035193647,0.0009839141,0.00018220235,0.00014991417,0.00151582,0.000030450103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9576291,0.02147625,0.00076285854,0.00012725167,0.0038782323,0.0020137143,0.00061712565,0.00008770081,0.000019802663,0.00003086478,0.0065373387,0.0068197707],"study_design_scores_gemma":[0.86942804,0.10715751,0.000008585616,0.00020633182,0.0040817983,0.0031700328,0.001951129,0.007823009,0.00006981667,0.00007465309,0.0058330656,0.00019603416],"about_ca_topic_score_codex":0.00022289298,"about_ca_topic_score_gemma":0.00033166027,"teacher_disagreement_score":0.08820106,"about_ca_system_score_codex":0.0029914016,"about_ca_system_score_gemma":0.049827375,"threshold_uncertainty_score":0.9912705},"labels":[],"label_agreement":null},{"id":"W2333739416","doi":"10.1038/ncomms10933","title":"Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia","year":2016,"lang":"en","type":"review","venue":"Nature Communications","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; Canadian Transplant Association; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Center for Chronic Disease Prevention and Health Promotion; National Institute of Environmental Health Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; Agència de Gestió d'Ajuts Universitaris i de Recerca; Cancer Council NSW; Medical Research Council; University of Texas MD Anderson Cancer Center; Institut National Du Cancer; Centers for Disease Control and Prevention; National Institutes of Health; Leukemia and Lymphoma Research; National Health and Medical Research Council; University at Buffalo; Regione Autonoma della Sardegna; Associazione Italiana per la Ricerca sul Cancro; University of Pittsburgh; Stockholms Läns Landsting; University of Utah; Fondation de France; Generalitat de Catalunya; Canadian Institutes of Health Research; Bundesamt für Strahlenschutz; MedStar Health Research Institute; Cancerfonden; Bundesministerium für Bildung und Forschung; Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail; Instituto de Salud Carlos III; Wake Forest University; Ohio State University; National Natural Science Foundation of China; U.S. Department of Health and Human Services; University of California, San Francisco; Michael Smith Health Research BC; University of Sydney; Division of Cancer Prevention, National Cancer Institute; Health Research Board; National Cancer Research Institute; Division of Cancer Epidemiology and Genetics, National Cancer Institute; Huntsman Cancer Institute; José Carreras Leukämie-Stiftung; Yale University; Karolinska Institutet; Utah State University; World Health Organization; University of Southern California; Cancer Research UK; American Cancer Society; National Human Genome Research Institute; Cancer Council Victoria; Compagnia di San Paolo; U.S. Department of Veterans Affairs; European Commission; Utah Department of Health; Brigham and Women's Hospital; Memorial Sloan-Kettering Cancer Center","keywords":"Chronic lymphocytic leukemia; Genome-wide association study; Genetics; Locus (genetics); Biology; SNP; Genetic association; Leukemia; Single-nucleotide polymorphism; Gene; Genotype","score_opus":0.1872520685799256,"score_gpt":0.44464203074139785,"score_spread":0.25738996216147225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333739416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005791525,0.99408567,0.00011842752,0.0007009552,0.00010229201,0.0029985886,0.001579891,0.00007336002,0.0003350016],"genre_scores_gemma":[0.0015191609,0.9872735,0.0012499209,0.00018580935,0.00013795006,0.0018152567,0.0027868026,0.00011166442,0.004919899],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955596,0.00062124705,0.0015733402,0.0006816973,0.0009450399,0.00061908644],"domain_scores_gemma":[0.9639736,0.027658166,0.0016922763,0.0051743747,0.0013320495,0.00016955448],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016984435,0.0006256473,0.0066745793,0.0011290195,0.00029564515,0.000035953602,0.0019079322,0.0013423712,0.00009976758],"category_scores_gemma":[0.011213367,0.00040740086,0.0063368306,0.0022397083,0.00038247148,0.0001293152,0.0009052631,0.0012286337,0.000056444052],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000040790364,0.000090365094,0.000025887863,0.014797105,0.9541322,0.0000040411087,0.00025023735,0.00015074364,0.0000019037536,0.0005427368,0.010434804,0.019529203],"study_design_scores_gemma":[0.0018805214,0.0000495721,0.0000060340535,0.00061074574,0.3943454,0.000003715012,0.000031974214,0.0010224133,0.0000021238077,0.000017196004,0.60180867,0.00022163914],"about_ca_topic_score_codex":0.00014691093,"about_ca_topic_score_gemma":0.0011387815,"teacher_disagreement_score":0.59137386,"about_ca_system_score_codex":0.28228545,"about_ca_system_score_gemma":0.044130888,"threshold_uncertainty_score":0.9999541},"labels":[],"label_agreement":null},{"id":"W2333953137","doi":"10.1016/j.clml.2011.09.190","title":"5.36 Effect of Valproic Acid on Fludarabine Activity in Chronic Lymphocytic Leukemia","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Fludarabine; Chronic lymphocytic leukemia; Apoptosis; Medicine; XIAP; Pharmacology; Histone deacetylase inhibitor; Cancer research; Histone deacetylase; Programmed cell death; Leukemia; Immunology; Histone; Caspase; Internal medicine; Chemotherapy; Biology; Biochemistry","score_opus":0.0516179069728787,"score_gpt":0.3532618317112995,"score_spread":0.3016439247384208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333953137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798751,0.0008092747,0.000046466495,0.000049491966,0.00073900877,0.0020673948,0.000024382958,0.00030695926,0.016081944],"genre_scores_gemma":[0.99639004,0.00046601155,0.00033216167,0.00033485668,0.00079634826,0.0002493322,0.00004119052,0.0002200535,0.0011699757],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9906898,0.0012143049,0.002539355,0.0019658164,0.001681061,0.0019096584],"domain_scores_gemma":[0.9922715,0.0027894876,0.000731467,0.0028455886,0.00028176632,0.0010801823],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039444836,0.0010739352,0.003033851,0.0007740475,0.00014544946,0.000036336663,0.0011261625,0.0013109924,0.00066645077],"category_scores_gemma":[0.0034570808,0.00089282525,0.0012079419,0.0015967389,0.0014881066,0.00032857113,0.00059087697,0.0011592369,0.0013664786],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.049343124,0.00080150575,0.015119677,0.0029658102,0.00092370313,0.004988559,0.00048962346,0.00025184028,0.029959695,0.0006175437,0.0022725214,0.8922664],"study_design_scores_gemma":[0.086901136,0.013731507,0.60272163,0.001760158,0.00041144982,0.00067434274,0.000025498488,0.031100793,0.26046938,0.00027566432,0.00095816,0.0009703025],"about_ca_topic_score_codex":0.0032880523,"about_ca_topic_score_gemma":0.00016265867,"teacher_disagreement_score":0.8912961,"about_ca_system_score_codex":0.2510769,"about_ca_system_score_gemma":0.08556637,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W2334820410","doi":"10.1136/annrheumdis-2012-eular.486","title":"AB0486 New, provisional american college of rheumatology and european league against rheumatism remission criteria: Results from 2 randomized, controlled golimumab trials in patients with rheumatoid arthritis","year":2012,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Golimumab; Rheumatism; Rheumatoid arthritis; Rheumatology; Internal medicine; Methotrexate; Randomized controlled trial; Physical therapy; Etanercept","score_opus":0.025430768003247076,"score_gpt":0.3076862996416509,"score_spread":0.28225553163840383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334820410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872433,0.0062797945,0.00003056716,0.0012387641,0.0001786949,0.003660515,0.0009658981,0.000032644137,0.00036981475],"genre_scores_gemma":[0.9896319,0.009311394,0.0005189011,0.000131837,0.000022921433,0.000069371905,0.00015781561,0.000061047285,0.000094848736],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904931,0.0038088656,0.0034230486,0.00045239917,0.0011884877,0.00063406694],"domain_scores_gemma":[0.9860128,0.009610062,0.0024870655,0.0009351538,0.0003692565,0.0005856279],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0053015267,0.00044059087,0.0053180815,0.0003063741,0.00009737841,0.000024885145,0.00037734705,0.00009586816,0.00009482092],"category_scores_gemma":[0.033756077,0.00024739036,0.0006033988,0.00041310352,0.0011046653,0.00025581731,0.00029427558,0.00022731042,0.000009428485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8338134,0.0034000666,0.051115356,0.0010348203,0.003083216,0.00002589953,0.0034948965,0.0000644452,0.00007847158,0.0005853508,0.018322736,0.08498133],"study_design_scores_gemma":[0.8717106,0.00047046383,0.10727437,0.016805822,0.00025360635,0.00003429429,0.0006042515,0.0015539451,0.0002427235,0.00060952106,0.00007925419,0.00036117574],"about_ca_topic_score_codex":0.0020994393,"about_ca_topic_score_gemma":0.00003712986,"teacher_disagreement_score":0.084620155,"about_ca_system_score_codex":0.00027549465,"about_ca_system_score_gemma":0.0020907444,"threshold_uncertainty_score":0.99999785},"labels":[],"label_agreement":null},{"id":"W2334892627","doi":"10.1158/1538-7445.am2013-597","title":"Abstract 597: The combination of valproic acid and fludarabine treatment induces a synergistic apoptotic response in chronic lymphocytic leukemia (CLL) patients involving the lysosomal protease cathepsin B.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Fludarabine; XIAP; Chronic lymphocytic leukemia; Cathepsin B; Cancer research; Cathepsin; Apoptosis; Vorinostat; Caspase; Chemistry; Pharmacology; Histone deacetylase; Leukemia; Programmed cell death; Medicine; Immunology; Biochemistry; Internal medicine; Histone; Chemotherapy; Enzyme","score_opus":0.05297574096075227,"score_gpt":0.35615709543771934,"score_spread":0.3031813544769671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334892627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99006337,0.0039495006,0.0000014113442,0.0010345802,0.000066767665,0.0047103693,0.000014226577,0.00002513623,0.00013465926],"genre_scores_gemma":[0.99594426,0.0007340155,0.00001130637,0.00004496972,0.000119702694,0.0025423442,0.000017074344,0.00005357769,0.00053274055],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.995596,0.0008518624,0.0005933006,0.000561098,0.0014674647,0.0009302673],"domain_scores_gemma":[0.99639106,0.0016098614,0.00015369106,0.0009032055,0.00068620406,0.00025600207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002356226,0.00028672055,0.00044862585,0.0004599146,0.00033499394,0.00011749395,0.00046161388,0.000164549,0.00022258703],"category_scores_gemma":[0.0019542002,0.00016170775,0.000089475885,0.0010670847,0.0010862715,0.00020904992,0.0002672539,0.00066482177,0.000063489],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015744876,0.001124882,0.006699067,0.0033764124,0.00059295725,0.0002546571,0.012453982,0.0017382309,0.90661764,0.0005607277,0.0012012745,0.049635284],"study_design_scores_gemma":[0.078308806,0.009594628,0.4859477,0.0037205487,0.00021317879,0.00008587735,0.0029127577,0.07274621,0.34406036,0.0013106553,0.00035225233,0.00074701634],"about_ca_topic_score_codex":0.032249678,"about_ca_topic_score_gemma":0.00061299064,"teacher_disagreement_score":0.5625573,"about_ca_system_score_codex":0.12759374,"about_ca_system_score_gemma":0.041580927,"threshold_uncertainty_score":0.97419465},"labels":[],"label_agreement":null},{"id":"W2337142758","doi":"10.1136/annrheumdis-2015-eular.3155","title":"FRI0132 Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results Through 2 Years","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Golimumab; Rheumatoid arthritis; Internal medicine; Population; Incidence (geometry); Adalimumab","score_opus":0.04562457894680351,"score_gpt":0.32324592043897116,"score_spread":0.27762134149216766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337142758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863996,0.011243781,0.000018147777,0.00056204514,0.00006001868,0.0007756641,0.00012233558,0.000030666644,0.0007877752],"genre_scores_gemma":[0.9935535,0.0060613994,0.00013849273,0.00007712527,0.00001596443,0.00001800722,0.000031646476,0.00003709097,0.000066740075],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99712366,0.0001849436,0.0009856616,0.00032695793,0.0009121686,0.00046659372],"domain_scores_gemma":[0.99778694,0.00043410846,0.00041841666,0.00083599536,0.00024317873,0.00028137848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043025007,0.00024034794,0.0009268465,0.000121486715,0.000044052125,0.0000253478,0.00033209738,0.00008984982,0.000020648376],"category_scores_gemma":[0.00087464735,0.00016818462,0.000119614924,0.0003880591,0.00064525125,0.00014635907,0.0002160428,0.00020033034,0.000009913884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12287252,0.013404211,0.16685091,0.012507805,0.0040795286,0.00368785,0.090284474,0.006327366,0.00016741008,0.0026083,0.019170161,0.5580395],"study_design_scores_gemma":[0.15091646,0.008046629,0.7539897,0.04950249,0.0004431991,0.0052251364,0.010342639,0.009665462,0.004740637,0.005083202,0.0005722367,0.001472245],"about_ca_topic_score_codex":0.0015118595,"about_ca_topic_score_gemma":0.0003190531,"teacher_disagreement_score":0.5871388,"about_ca_system_score_codex":0.00056730356,"about_ca_system_score_gemma":0.0027082341,"threshold_uncertainty_score":0.685837},"labels":[],"label_agreement":null},{"id":"W2337697646","doi":"10.5737/23688076262145154","title":"CONFÉRENCE SUR LA PRATIQUE CLINIQUE DE L’ACIO-CANO Élaboration et mise en place par ActionCancer Manitoba d’un programme d’administration d’immunoglobuline par voie sous-cutanée","year":2016,"lang":"fr","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Political science; Humanities; Medicine; Art","score_opus":0.024713720982586358,"score_gpt":0.34335534181954724,"score_spread":0.3186416208369609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337697646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6010374,0.014046802,0.014594629,0.34588653,0.009115956,0.0026867094,0.00036085575,0.00015773172,0.012113424],"genre_scores_gemma":[0.9711103,0.011574005,0.0049164793,0.002920009,0.00457557,0.00012518249,0.00008035495,0.00013411981,0.004563998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923792,0.003028554,0.0012004158,0.00065699726,0.0005975233,0.0021373155],"domain_scores_gemma":[0.99300987,0.0020607389,0.000724846,0.0005299111,0.0010997835,0.0025748743],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004138279,0.0005210957,0.00075355446,0.00042654233,0.0007361326,0.00031963375,0.00045887378,0.0015808581,0.00092863047],"category_scores_gemma":[0.0030444397,0.00047471715,0.0001913861,0.0004719521,0.0014241507,0.0007460355,0.000028338702,0.002188621,0.0001534523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035761078,0.0012732948,0.0054430766,0.0002705729,0.0007838441,0.016863864,0.0076797875,0.00019941153,0.011490417,0.0028197956,0.11814934,0.83145046],"study_design_scores_gemma":[0.026495619,0.005177382,0.0058209538,0.008393719,0.0007249645,0.063700065,0.0035163823,0.0064717396,0.008618145,0.0015926425,0.8685513,0.00093709154],"about_ca_topic_score_codex":0.021214297,"about_ca_topic_score_gemma":0.19046935,"teacher_disagreement_score":0.8305134,"about_ca_system_score_codex":0.17146374,"about_ca_system_score_gemma":0.38491467,"threshold_uncertainty_score":0.9999847},"labels":[],"label_agreement":null},{"id":"W2340003990","doi":"10.1212/wnl.80.7_supplement.p01.177","title":"Oral Cladribine Safety Profile in Patients with a First Demyelinating Event: Top Line Results from the Phase III ORACLE MS Study (P01.177)","year":2013,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Cladribine; Medicine; Adverse effect; Internal medicine; Placebo; Multiple sclerosis; Gastroenterology; Dermatology; Surgery; Immunology; Pathology","score_opus":0.01778579437390339,"score_gpt":0.29881936586357055,"score_spread":0.2810335714896672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340003990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989994,0.000040386793,0.00003594351,0.0061208513,0.00012277004,0.0032061168,0.000066768895,0.000060358532,0.00035280752],"genre_scores_gemma":[0.99759734,0.000009920186,0.00015825519,0.0013330367,0.00021637593,0.00019647494,0.00024826662,0.000046480814,0.00019385753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970034,0.00040769452,0.00070860214,0.0006790978,0.00056904706,0.0006322075],"domain_scores_gemma":[0.99735224,0.0012404642,0.00018559043,0.0008131913,0.00024344742,0.00016508019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006285956,0.00024646719,0.00049226295,0.00010430529,0.00015542145,0.00002485185,0.00032239044,0.00015300458,0.0005475973],"category_scores_gemma":[0.0012416437,0.00015196914,0.000049084167,0.00045868312,0.00016249975,0.00011727446,0.00029338556,0.00074585626,0.00017891452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16925715,0.021389801,0.70353216,0.00014933068,0.00062757276,0.0020506463,0.015743168,0.0013489239,0.0003131185,0.000041890267,0.012142193,0.07340403],"study_design_scores_gemma":[0.32844755,0.01926674,0.5855251,0.00009242625,0.0001095585,0.00003887329,0.00021439625,0.062338248,0.00013643518,0.00004026276,0.0035065645,0.000283849],"about_ca_topic_score_codex":0.014962287,"about_ca_topic_score_gemma":0.005501678,"teacher_disagreement_score":0.1591904,"about_ca_system_score_codex":0.0008484655,"about_ca_system_score_gemma":0.0010207489,"threshold_uncertainty_score":0.9915972},"labels":[],"label_agreement":null},{"id":"W2340770670","doi":"10.1200/jco.2005.23.16_suppl.3149","title":"Preclinical evaluation of apoptosis induction by the novel small molecule BCL-2 inhibitor, GX015–070, in ex vivo chronic lymphoid leukemia (CLL) cells","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Immunophenotyping; Medicine; Ex vivo; CD38; Apoptosis; Chronic lymphocytic leukemia; Flow cytometry; Leukemia; Stage (stratigraphy); Pathology; Cancer research; Immunology; In vivo; Internal medicine; Biology; CD34; Stem cell","score_opus":0.18310686263895748,"score_gpt":0.4718065075792079,"score_spread":0.2886996449402504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340770670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881552,0.0018421619,0.00025263004,0.0053158267,0.0013900477,0.0008070984,0.000006787707,0.000010808373,0.002219432],"genre_scores_gemma":[0.9925819,0.0015243924,0.0012078058,0.0009253664,0.0032494504,0.000022448321,0.0000056063036,0.00004116381,0.00044188474],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99046856,0.0016896018,0.0049592745,0.0004589278,0.0018645684,0.00055904064],"domain_scores_gemma":[0.99073124,0.004447725,0.0024208364,0.0005831447,0.0013816953,0.00043534514],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021689676,0.00026382625,0.0016910046,0.0002713605,0.000052411535,0.000017080383,0.0005353978,0.0010635543,0.0003864146],"category_scores_gemma":[0.009295799,0.00017878509,0.00066919596,0.00049633346,0.0006522177,0.00020841352,0.00018497491,0.0019908103,0.000046716585],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012358234,0.011384864,0.0030481238,0.00030961115,0.0012966391,0.000084843676,0.0007577578,0.012237022,0.31731978,0.00009022827,0.058557604,0.5825553],"study_design_scores_gemma":[0.28520107,0.034150247,0.008611685,0.0012755704,0.002832021,0.0023246806,0.0007384309,0.20612742,0.3515311,0.00033299177,0.106123455,0.0007513351],"about_ca_topic_score_codex":0.0003522855,"about_ca_topic_score_gemma":0.00039231384,"teacher_disagreement_score":0.5818039,"about_ca_system_score_codex":0.030967623,"about_ca_system_score_gemma":0.057356052,"threshold_uncertainty_score":0.9990493},"labels":[],"label_agreement":null},{"id":"W2341618130","doi":"10.5737/23688076262137144","title":"CANO-ACIO CLINICAL LECTURESHIP The development and implementation of a subcutaneous immunoglobulin (SCIG) program at CancerCare Manitoba","year":2016,"lang":"en","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Privilege (computing); Nursing; Adept; Family medicine; Political science","score_opus":0.04828801719127356,"score_gpt":0.4233071429669379,"score_spread":0.3750191257756643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341618130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98627657,0.0020048968,0.00003769975,0.009594064,0.00060371147,0.0006186655,0.000011986791,0.000012552238,0.000839866],"genre_scores_gemma":[0.9975531,0.00030228315,0.0010788887,0.0004299274,0.00036447137,0.000024828014,0.0000068982363,0.000022586562,0.00021698752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796283,0.000236332,0.0006257264,0.00022322881,0.0003013565,0.0006505032],"domain_scores_gemma":[0.99829763,0.00029644495,0.0002165496,0.00021182872,0.00025141618,0.00072614825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009109247,0.00014432699,0.00033899563,0.000169886,0.00040409586,0.000026714479,0.00018255926,0.00019918004,0.00029551933],"category_scores_gemma":[0.00016398462,0.00008515162,0.00007701657,0.00013819493,0.00064493535,0.000038659626,0.00002871172,0.00038057147,0.000011094745],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00051517616,0.000044753655,0.014001382,0.000020204408,0.0001487032,0.0011131763,0.0023514386,5.545946e-7,0.00032214387,0.000030907042,0.00876223,0.97268933],"study_design_scores_gemma":[0.046738405,0.009444482,0.2778357,0.0030746253,0.00064725266,0.1264718,0.013426388,0.00014243295,0.0057813316,0.0005483059,0.5151724,0.0007168527],"about_ca_topic_score_codex":0.017611554,"about_ca_topic_score_gemma":0.65511495,"teacher_disagreement_score":0.97197247,"about_ca_system_score_codex":0.11922812,"about_ca_system_score_gemma":0.07724398,"threshold_uncertainty_score":0.9889303},"labels":[],"label_agreement":null},{"id":"W2344648292","doi":"10.1186/s12967-016-0865-1","title":"GIFT4 fusokine converts leukemic B cells into immune helper cells","year":2016,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health","keywords":"Immune system; Immunology; Medicine; Cancer research; Biology","score_opus":0.01738864918741631,"score_gpt":0.295033659778338,"score_spread":0.2776450105909217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344648292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88029337,0.010405543,0.015445568,0.08601735,0.002985245,0.00085826416,0.00002386802,0.000061600105,0.003909214],"genre_scores_gemma":[0.9907971,0.0012886621,0.0018829375,0.00078208005,0.002028121,0.0000042298616,0.000008177929,0.000048346537,0.0031603535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996091,0.00010010071,0.001319772,0.00025696962,0.0018088946,0.00042327776],"domain_scores_gemma":[0.99710476,0.0008669981,0.00040471446,0.0003432663,0.0007852624,0.0004949655],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012103884,0.00027166764,0.0008248736,0.000478508,0.00007293255,0.000008662411,0.00029412797,0.00017511316,0.0033697295],"category_scores_gemma":[0.00023160831,0.00014923452,0.00028012245,0.00033511562,0.0005061782,0.00025584007,0.000026329237,0.00041562712,0.0001436512],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018954935,0.00016475309,0.0003213006,0.00022372416,0.00032933807,0.0005834496,0.0008358829,0.000036741145,0.96797055,0.00025469135,0.011029403,0.01635468],"study_design_scores_gemma":[0.18500866,0.005422076,0.011000397,0.007504911,0.0011474803,0.0077203396,0.00042088583,0.002067194,0.64754313,0.004683758,0.12670328,0.0007778623],"about_ca_topic_score_codex":0.00011722312,"about_ca_topic_score_gemma":0.000007165331,"teacher_disagreement_score":0.3204274,"about_ca_system_score_codex":0.0030075053,"about_ca_system_score_gemma":0.004410943,"threshold_uncertainty_score":0.9975413},"labels":[],"label_agreement":null},{"id":"W2344998323","doi":"10.1016/j.jval.2015.03.973","title":"Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Merck Canada Inc. (Canada)","funders":"","keywords":"Etanercept; Medicine; Reimbursement; Medical prescription; Family medicine; Retrospective cohort study; Internal medicine; Rheumatoid arthritis; Pharmacology; Economic growth","score_opus":0.06513608121172984,"score_gpt":0.332143952977266,"score_spread":0.2670078717655362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344998323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607545,0.00017403715,0.000095127805,0.002618586,0.000039587376,0.00078336056,0.00014139798,0.000012122263,0.000060333106],"genre_scores_gemma":[0.99852484,0.00014746367,0.0006081179,0.00029474858,0.000024672012,0.000039814182,0.0003097112,0.000014329366,0.000036318743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979162,0.00026122804,0.0005726338,0.00034518866,0.00052226766,0.00038245803],"domain_scores_gemma":[0.9989672,0.00012270444,0.00008819513,0.0003354397,0.000061148436,0.00042532975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068951363,0.00012948754,0.0005513722,0.0007125901,0.000021599733,0.000013587498,0.00007565444,0.000049210383,0.000051234958],"category_scores_gemma":[0.00008206753,0.000111823654,0.0000504361,0.0005900496,0.000025618225,0.00005591255,0.00003621813,0.000108320004,0.0000043544464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031993366,0.00056358514,0.9608619,0.00013953556,0.0002455053,0.000030932955,0.02665627,0.0045186677,0.000009473333,0.000035696557,0.00007723607,0.0065412507],"study_design_scores_gemma":[0.027601875,0.00163134,0.9166194,0.00066858804,0.00018208138,0.0000022008346,0.0017100691,0.050621305,0.00014594004,0.00010548099,0.00054044387,0.00017125114],"about_ca_topic_score_codex":0.17016253,"about_ca_topic_score_gemma":0.010788224,"teacher_disagreement_score":0.1593743,"about_ca_system_score_codex":0.013410946,"about_ca_system_score_gemma":0.0022960834,"threshold_uncertainty_score":0.9903764},"labels":[],"label_agreement":null},{"id":"W2345859162","doi":"10.1182/blood.v122.21.5143.5143","title":"Small Molecule PRIMA-1 met Sensitizes Waldenstrom Macroglobulinemia Cells To Apoptosis and Displays Synergistic Cytotoxicity With Bortezomib","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; Viability assay; Apoptosis; Waldenstrom macroglobulinemia; Cancer research; MTT assay; Bone marrow; Dexamethasone; Multiple myeloma; Chemistry; Medicine; Molecular biology; Biology; Immunology; Internal medicine; Lymphoma; Biochemistry","score_opus":0.010641687648834278,"score_gpt":0.22699745948425654,"score_spread":0.21635577183542226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345859162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615014,0.00011579629,0.00053623354,0.00044581742,0.000035759844,0.0012853858,0.000036874444,0.00010849493,0.0012855182],"genre_scores_gemma":[0.98287624,0.000031846084,0.015025815,0.0006371338,0.00016122591,0.00012623431,0.0000291737,0.00006683827,0.0010455142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977511,0.00006128076,0.00032199456,0.00063189433,0.00051548093,0.0007182089],"domain_scores_gemma":[0.9981599,0.0001824251,0.00007147304,0.0006509951,0.00022787279,0.0007073245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001513053,0.0003278501,0.00053378893,0.00013136383,0.00010249781,0.00010050638,0.00016064952,0.00014369297,0.00013167657],"category_scores_gemma":[0.00015248577,0.00025030912,0.00007414106,0.00030323814,0.00018517197,0.00006380836,0.00021859004,0.00026511992,0.00023728979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003240472,0.0007097103,0.0007739878,0.00045207268,0.0004263445,0.000653153,0.00027868478,0.000044211964,0.9928195,0.00006273106,0.0026809073,0.0007746802],"study_design_scores_gemma":[0.020499779,0.00092478545,0.001982348,0.0002554122,0.00053389865,0.0006857021,0.00013108218,0.0021461938,0.97228175,0.000015462818,0.00015142531,0.00039215214],"about_ca_topic_score_codex":0.0017036648,"about_ca_topic_score_gemma":0.00006230109,"teacher_disagreement_score":0.02053771,"about_ca_system_score_codex":0.0010176158,"about_ca_system_score_gemma":0.0012288319,"threshold_uncertainty_score":0.99999493},"labels":[],"label_agreement":null},{"id":"W2346781103","doi":"10.16966/2471-5026.104","title":"Microcellular Variant of T-Prolymphocytic Leukemia Mimicking CLL","year":2016,"lang":"en","type":"article","venue":"Journal of Blood Disorders and Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group; University of Toronto","funders":"","keywords":"Prolymphocytic leukemia; Leukemia; Materials science; Chronic lymphocytic leukemia; Biology; Immunology","score_opus":0.01148558773464969,"score_gpt":0.2658071745569926,"score_spread":0.2543215868223429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346781103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728235,0.020162884,0.0010884206,0.0041295225,0.00022066837,0.00022929272,0.0000024637657,0.000009625081,0.0013336027],"genre_scores_gemma":[0.9868503,0.011310961,0.0005503428,0.0002868523,0.00039872003,0.0000017628955,0.0000010905071,0.000029025052,0.0005709123],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99784225,0.000050868155,0.0008649462,0.00020205844,0.00068826415,0.00035158297],"domain_scores_gemma":[0.9982712,0.0003145882,0.00047872722,0.00027385532,0.00030282183,0.0003587584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008512658,0.00019315837,0.0007789166,0.00034486616,0.000047316465,0.000005223276,0.00016591158,0.00012196098,0.00018046136],"category_scores_gemma":[0.0007031274,0.00010251498,0.00014258284,0.00023379592,0.0004834151,0.0001052095,0.00006264464,0.00019757445,0.0000031869988],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030637998,0.0006464688,0.004980119,0.0015453789,0.0016113735,0.0021893813,0.002145422,0.000008845405,0.87119937,0.000920896,0.0057287947,0.10596017],"study_design_scores_gemma":[0.60836315,0.024104668,0.007514917,0.023432344,0.009356447,0.0566248,0.005017936,0.0020969615,0.19872914,0.009583368,0.053943478,0.0012327866],"about_ca_topic_score_codex":0.00023153768,"about_ca_topic_score_gemma":0.000012364803,"teacher_disagreement_score":0.6724702,"about_ca_system_score_codex":0.0012206172,"about_ca_system_score_gemma":0.004153955,"threshold_uncertainty_score":0.7368937},"labels":[],"label_agreement":null},{"id":"W2388017278","doi":"10.1016/j.bcmd.2016.05.003","title":"High abundance of circulating megakaryocytic cells in chronic myeloid leukemia in Indian patients. Revisiting George Minot to re-interpret megakaryocytic maturation","year":2016,"lang":"en","type":"article","venue":"Blood Cells Molecules and Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Platelet; Immunology; Myeloid; Biology; Peripheral blood; Myeloid leukemia; Medicine","score_opus":0.0061681282778089635,"score_gpt":0.2377118032053273,"score_spread":0.23154367492751834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2388017278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967089,0.0017242408,0.000067918525,0.00012933204,0.000081209706,0.000983176,0.000100155434,0.000033559827,0.00017149714],"genre_scores_gemma":[0.99865764,0.0003452629,0.00038389905,0.00021808954,0.00013702181,0.000061710205,0.00004610648,0.000054338412,0.0000959193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970861,0.0001374509,0.00083023676,0.00069452677,0.0005644122,0.00068726676],"domain_scores_gemma":[0.99844795,0.00035328936,0.00017413209,0.0005100548,0.000118338285,0.00039622895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000220087,0.00033108884,0.00064234005,0.00042603188,0.00005702593,0.000044754303,0.00020115288,0.00013818672,0.000053030995],"category_scores_gemma":[0.00035685874,0.00026678643,0.00011937754,0.00049339444,0.00013217682,0.0001944709,0.0002078122,0.00017127204,0.000021748148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025693455,0.00076446845,0.039292157,0.007428688,0.00022076968,0.0023160519,0.002158771,0.0019534251,0.9130725,0.00038831387,0.000314298,0.029521175],"study_design_scores_gemma":[0.06439483,0.0019805904,0.16480331,0.017680136,0.0005749391,0.00008845685,0.0006403351,0.009223589,0.7385704,0.0003977336,0.0001656892,0.0014800082],"about_ca_topic_score_codex":0.0013594344,"about_ca_topic_score_gemma":0.00018907852,"teacher_disagreement_score":0.17450216,"about_ca_system_score_codex":0.008144991,"about_ca_system_score_gemma":0.0034140332,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W2396557572","doi":"","title":"Enfuvirtide, a new treatment for HIV infection.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Enfuvirtide; Regimen; Medicine; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Internal medicine; Maraviroc; Clinical trial; Salvage therapy; Oncology; Pharmacology; Intensive care medicine; Immunology; Chemotherapy; Gp41; Antibody","score_opus":0.06226207662537214,"score_gpt":0.30812781365607395,"score_spread":0.2458657370307018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396557572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83022606,0.0019497625,0.0058182366,0.0043152436,0.00094545033,0.013177077,0.000020273968,0.00045434406,0.14309356],"genre_scores_gemma":[0.88513887,0.00013418155,0.0009688592,0.00028716272,0.00038130613,0.0048726117,0.000016825255,0.000036651527,0.108163536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891925,0.000019893665,0.00015960816,0.00023221245,0.00018586623,0.0004831802],"domain_scores_gemma":[0.9991597,0.00011026377,0.000028767132,0.000289967,0.000051625564,0.00035967474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001909564,0.00011473905,0.0001969554,0.0000908643,0.00005139004,0.0000203724,0.00003403939,0.00006514937,0.00012310565],"category_scores_gemma":[0.0004983859,0.00008900566,0.00012495839,0.00017141823,0.000030577346,0.000046501977,0.00000973208,0.00005213204,0.00009141938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012320287,0.001014595,0.021400983,0.0002686081,0.00080055365,0.00013250054,0.00042933406,0.00006551198,0.00013829621,0.01039494,0.16440731,0.79971534],"study_design_scores_gemma":[0.03875323,0.00022537757,0.02440897,0.000010204427,0.00012840466,0.00022978653,0.000013439514,0.0002869388,0.011198784,0.0007186608,0.9238873,0.0001388757],"about_ca_topic_score_codex":0.00048149755,"about_ca_topic_score_gemma":0.00005084874,"teacher_disagreement_score":0.79957646,"about_ca_system_score_codex":0.0106314365,"about_ca_system_score_gemma":0.0029575913,"threshold_uncertainty_score":0.99316657},"labels":[],"label_agreement":null},{"id":"W2397837817","doi":"10.1182/blood.v124.21.5630.5630","title":"A Link Between Hypercholesterolemia and Chronic Lymphocytic Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Dyslipidemia; Internal medicine; Chronic lymphocytic leukemia; Statin; Hyperlipidemia; Lipid profile; Chemoimmunotherapy; Gastroenterology; Oncology; Leukemia; Cholesterol; Diabetes mellitus; Disease; Endocrinology","score_opus":0.017147439307659794,"score_gpt":0.27473195763755975,"score_spread":0.2575845183299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397837817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929792,0.0012772606,0.000102911035,0.00031637575,0.00005026253,0.00037125385,0.000004924202,0.00016623591,0.0047315303],"genre_scores_gemma":[0.99569434,0.00020925968,0.00054830225,0.00028782772,0.0020671189,0.000032723587,0.00002597715,0.000061546205,0.0010729253],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979735,0.000082168975,0.0003319453,0.00051038596,0.0004820588,0.00061992666],"domain_scores_gemma":[0.9984245,0.00028486646,0.000059829534,0.00070164865,0.000076259246,0.00045289804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044402538,0.0002436149,0.00050624204,0.0001158667,0.00010189067,0.000054698125,0.00018758501,0.00023731546,0.000056128207],"category_scores_gemma":[0.0002746277,0.0002116406,0.00009020152,0.00021826153,0.00022320531,0.00008761732,0.00019386351,0.00033517947,0.0002991814],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00062161946,0.00033917636,0.0693704,0.006073246,0.0022078252,0.0011992335,0.0018388112,0.0001516262,0.072943114,0.0016367069,0.0028965368,0.8407217],"study_design_scores_gemma":[0.4819355,0.005554308,0.14180318,0.0025959203,0.0038034895,0.008123305,0.00013084336,0.061608747,0.12680687,0.0017387166,0.16364957,0.002249556],"about_ca_topic_score_codex":0.00029238727,"about_ca_topic_score_gemma":0.000019235282,"teacher_disagreement_score":0.8384721,"about_ca_system_score_codex":0.022231914,"about_ca_system_score_gemma":0.012711992,"threshold_uncertainty_score":0.992885},"labels":[],"label_agreement":null},{"id":"W2398552012","doi":"10.1016/b978-0-12-374279-7.09019-6","title":"B Cell Leukemia and Lymphoma","year":2016,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Leukemia; Cancer research; Lymphoma; Medicine; Internal medicine","score_opus":0.015132132945620396,"score_gpt":0.2556928515149371,"score_spread":0.24056071856931668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398552012","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007500547,0.005429396,0.0000019637357,0.000092265414,0.00020397262,0.0008775487,0.000034737997,0.00011082014,0.99249923],"genre_scores_gemma":[0.0034634946,0.0010099089,0.0002004261,0.00055105437,0.00084452,0.00003773154,0.000016978016,0.00021722102,0.99365866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973314,0.000022042836,0.0004968131,0.0007854451,0.00076438556,0.0005999593],"domain_scores_gemma":[0.99790716,0.00017918892,0.00018131029,0.0010482518,0.00015893181,0.00052514096],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002658969,0.0005705937,0.0008821632,0.0002513567,0.0000970029,0.00004083383,0.0002276236,0.0006948629,0.00079299853],"category_scores_gemma":[0.000037233724,0.00042099753,0.00026079282,0.000012015243,0.0004979981,0.000034747896,0.00034814552,0.0003651769,0.0014123934],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014010213,0.0000075236244,0.000002621439,0.0005993062,0.00013304157,0.00078256807,0.0000891635,1.5138516e-8,0.00014081667,0.003017352,0.0014816856,0.9936058],"study_design_scores_gemma":[0.01168212,0.00020283418,0.0000121883,0.0014256361,0.00025357626,0.00082873367,0.000004378388,0.000026471887,0.00047761836,0.0035237384,0.9810995,0.00046322864],"about_ca_topic_score_codex":0.0000031934057,"about_ca_topic_score_gemma":0.0000072120574,"teacher_disagreement_score":0.9931426,"about_ca_system_score_codex":0.015208393,"about_ca_system_score_gemma":0.010837695,"threshold_uncertainty_score":0.99982417},"labels":[],"label_agreement":null},{"id":"W2399143411","doi":"10.1016/j.jval.2016.03.1045","title":"BUDGET IMPACT ANALYSIS FOR THE FIRST-LINE AND SECOND-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal","funders":"","keywords":"Ibrutinib; Bendamustine; Chlorambucil; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Oncology; Rituximab; Incrementalism; Internal medicine; Ofatumumab; Leukemia; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.03223058491051058,"score_gpt":0.32911253656157347,"score_spread":0.2968819516510629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399143411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927316,0.0034388034,0.0007800334,0.00085430196,0.000038417373,0.0019209353,0.00020082147,0.000019001382,0.000016109629],"genre_scores_gemma":[0.99714917,0.0019262865,0.00016599109,0.000112352696,0.000109952736,0.0001292708,0.000046458226,0.00003261949,0.0003279158],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980183,0.00007387775,0.0005601028,0.00038691776,0.00038187703,0.00057887624],"domain_scores_gemma":[0.9975721,0.0012067694,0.00021803992,0.0006286935,0.00013989267,0.0002344878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004971059,0.00022691878,0.0007249111,0.00030973842,0.000091161535,0.0000093634535,0.000111872745,0.00008003587,0.00012577305],"category_scores_gemma":[0.00012083865,0.00009929905,0.00016872895,0.00064983196,0.00017926522,0.00005649812,0.00003390265,0.000058274705,0.000004149611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016836325,0.0013485968,0.6513917,0.005330325,0.007498649,0.00006678155,0.0032682777,0.14586543,0.00009588152,0.00024714996,0.000756573,0.16729434],"study_design_scores_gemma":[0.14915176,0.023308387,0.38039824,0.0008114701,0.00088636694,0.00003793797,0.000046238987,0.43944708,0.00103305,0.0001227681,0.004426561,0.00033013785],"about_ca_topic_score_codex":0.020176506,"about_ca_topic_score_gemma":0.003244569,"teacher_disagreement_score":0.29358166,"about_ca_system_score_codex":0.117209226,"about_ca_system_score_gemma":0.02611532,"threshold_uncertainty_score":0.9863482},"labels":[],"label_agreement":null},{"id":"W2401652628","doi":"10.1016/j.revmed.2012.01.013","title":"Manifestations cutanées des thérapies ciblées","year":2012,"lang":"fr","type":"article","venue":"La Revue de Médecine Interne","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Sunitinib; Dermatology; Papulopustular; Adverse effect; Internal medicine; Cancer; Acne","score_opus":0.02980451022296911,"score_gpt":0.3292380631731171,"score_spread":0.299433552950148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401652628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87949246,0.06672547,0.0028015529,0.0061248555,0.0022439687,0.00048103373,0.0000627183,0.00014591981,0.04192202],"genre_scores_gemma":[0.9004113,0.0048390105,0.003502323,0.00030407176,0.0051476774,0.00007101561,0.000040247574,0.00011432182,0.085570015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965747,0.0003252961,0.0006302543,0.00040543676,0.00042843795,0.0016358619],"domain_scores_gemma":[0.9967174,0.0013876831,0.00014141185,0.0007474733,0.00021330989,0.000792728],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011120406,0.00040233377,0.0005503058,0.00030824167,0.00013545863,0.0001079584,0.00041732358,0.00033397687,0.0036205442],"category_scores_gemma":[0.001473711,0.00039509143,0.0002574032,0.0004975788,0.00089794496,0.00048651494,0.00030396492,0.00066709955,0.0024783493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008317032,0.0040773246,0.6403773,0.007994378,0.0021938465,0.009150061,0.026142063,0.00013282511,0.0072496943,0.14621113,0.049152285,0.106487416],"study_design_scores_gemma":[0.02678734,0.0010549327,0.5354601,0.012055991,0.0015795142,0.07868378,0.005909465,0.013074072,0.008060773,0.007712426,0.30834872,0.0012728719],"about_ca_topic_score_codex":0.002317302,"about_ca_topic_score_gemma":0.0003136535,"teacher_disagreement_score":0.25919643,"about_ca_system_score_codex":0.01119775,"about_ca_system_score_gemma":0.0017728203,"threshold_uncertainty_score":0.9998501},"labels":[],"label_agreement":null},{"id":"W2404392077","doi":"10.1016/j.jval.2016.03.1063","title":"ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal","funders":"","keywords":"Bendamustine; Chlorambucil; Obinutuzumab; Medicine; Ofatumumab; Rituximab; Internal medicine; Oncology; Chronic lymphocytic leukemia; Clinical trial; Fludarabine; Combination therapy; Chemoimmunotherapy; Leukemia; Chemotherapy; Lymphoma","score_opus":0.05512079532798101,"score_gpt":0.33619575051494494,"score_spread":0.2810749551869639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404392077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995434,0.0013851358,0.000018586747,0.0006686147,0.00006755408,0.002232546,0.00004247451,0.000009353061,0.00014172962],"genre_scores_gemma":[0.99880415,0.00076025975,0.000081136306,0.000049461374,0.00008295221,0.00013415342,0.000031873682,0.000024021125,0.000031977277],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973598,0.00029455157,0.0008093409,0.00032777485,0.00076940964,0.00043911856],"domain_scores_gemma":[0.9983338,0.00051951775,0.00030332163,0.0006125769,0.00014185999,0.00008889649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016259262,0.00017891388,0.00059696066,0.0002786981,0.000031639487,0.0000035694015,0.00015806424,0.00007776439,0.00010049215],"category_scores_gemma":[0.00015309278,0.00009420423,0.00006082398,0.0002850788,0.00015232268,0.00006655432,0.00002740873,0.00007095677,0.000020255828],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011513176,0.004338644,0.15881947,0.0060563325,0.00038003855,0.00007665425,0.0108098285,0.54093176,0.00007152227,0.0011818184,0.00040842805,0.26541233],"study_design_scores_gemma":[0.33717015,0.008786495,0.13011606,0.0024026826,0.00011896252,0.00003495487,0.00010688477,0.5194552,0.00069414446,0.00021856203,0.00069861877,0.00019729862],"about_ca_topic_score_codex":0.044095468,"about_ca_topic_score_gemma":0.004814442,"teacher_disagreement_score":0.32565695,"about_ca_system_score_codex":0.30210912,"about_ca_system_score_gemma":0.078387685,"threshold_uncertainty_score":0.96226996},"labels":[],"label_agreement":null},{"id":"W2405133210","doi":"10.3760/cma.j.issn.0366-6999.20140120","title":"Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia","year":2014,"lang":"en","type":"article","venue":"Chinese Medical Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Univariate analysis; Multivariate analysis; International Prognostic Scoring System; Malignancy; Asymptomatic; Gastroenterology; Multiple myeloma; Lymphoma; Myelodysplastic syndromes; Bone marrow","score_opus":0.009011120982037976,"score_gpt":0.27524767515897175,"score_spread":0.26623655417693376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405133210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987486,0.00013977753,0.00985904,0.0008670773,0.00058500946,0.0006727406,0.000013161102,0.00007364861,0.00030354585],"genre_scores_gemma":[0.99431884,0.000022170705,0.0016095914,0.00017985371,0.0035246252,0.000021435264,0.00006418895,0.000067061745,0.00019225325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967065,0.00007669117,0.00065087766,0.00038185748,0.0015441055,0.00063999527],"domain_scores_gemma":[0.99647623,0.0006762651,0.00023395507,0.00031009325,0.00039257307,0.0019108526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085130864,0.00035521865,0.0007334725,0.00013643912,0.00024937047,0.00012540995,0.00026483802,0.00018785427,0.000096262214],"category_scores_gemma":[0.007582376,0.00019244854,0.0001158072,0.0002591413,0.00021626163,0.00010966505,0.00014162323,0.0007454945,0.00001740394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001268156,0.00018348395,0.91914856,0.0012653305,0.00014924833,0.00049582886,0.000155665,0.0000010738061,0.000029531744,0.00004646988,0.0004905282,0.07676612],"study_design_scores_gemma":[0.043012947,0.0011913921,0.9120184,0.0025061872,0.00020948434,0.008286145,0.000022657034,0.031249598,0.000008242555,0.00014495257,0.0010197458,0.00033025525],"about_ca_topic_score_codex":0.000033540513,"about_ca_topic_score_gemma":0.0000141457585,"teacher_disagreement_score":0.076435864,"about_ca_system_score_codex":0.0017586406,"about_ca_system_score_gemma":0.0035347885,"threshold_uncertainty_score":0.90773594},"labels":[],"label_agreement":null},{"id":"W2407217237","doi":"10.1111/his.12999","title":"Issues in diagnosis of small B cell lymphoid neoplasms involving the bone marrow and peripheral blood. Report on the Bone Marrow Workshop of the XVIIth meeting of the European Association for Haematopathology and the Society for Hematopathology","year":2016,"lang":"en","type":"article","venue":"Histopathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Bone marrow; Immunophenotyping; Medicine; Pathology; Lymphoproliferative disorders; B cell; Lymphoma; Immunology; Flow cytometry; Antibody","score_opus":0.016975345279209565,"score_gpt":0.2522345680352496,"score_spread":0.23525922275604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407217237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97424465,0.005359112,0.00008949329,0.017409157,0.0002723367,0.0019946445,0.000030527248,0.000014098948,0.0005859666],"genre_scores_gemma":[0.9948719,0.00092531455,0.00060684787,0.00067866116,0.0001238828,0.00040134703,0.0000033153349,0.00005369519,0.0023350082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961358,0.0015303312,0.000982477,0.00049832126,0.00034634987,0.0005067205],"domain_scores_gemma":[0.9915071,0.005946907,0.0011969763,0.0010135461,0.00029155702,0.000043883796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008518452,0.00026176605,0.00085896906,0.00006303009,0.00031086267,0.000011660769,0.00043684526,0.00024657717,0.000009436063],"category_scores_gemma":[0.006211922,0.00010425643,0.00044633434,0.0002260412,0.002002804,0.000036867517,0.0004616632,0.000303749,4.501122e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029092403,0.00093216216,0.70886314,0.0024847682,0.00019003313,0.00046518692,0.04346659,0.000060788396,0.21672477,0.013794283,0.007168424,0.0029406087],"study_design_scores_gemma":[0.18903147,0.0042185346,0.4367024,0.007404316,0.005836611,0.046159517,0.022157887,0.006170225,0.24315283,0.019430574,0.017659646,0.0020759779],"about_ca_topic_score_codex":0.00018161951,"about_ca_topic_score_gemma":0.00034886636,"teacher_disagreement_score":0.27216074,"about_ca_system_score_codex":0.00092370674,"about_ca_system_score_gemma":0.00064931175,"threshold_uncertainty_score":0.7436699},"labels":[],"label_agreement":null},{"id":"W2407327553","doi":"10.1200/jco.2014.32.15_suppl.tps8615","title":"A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Ibrutinib; Medicine; Vincristine; Internal medicine; Oncology; Rituximab; CHOP; Diffuse large B-cell lymphoma; Cyclophosphamide; Lymphoma; Chemotherapy; Chronic lymphocytic leukemia; Leukemia","score_opus":0.036916130827688375,"score_gpt":0.3859590774920135,"score_spread":0.34904294666432517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407327553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370617,0.0004350586,0.00019875163,0.00032451216,0.00019343515,0.004042871,0.0000054882453,0.000008842864,0.0010849036],"genre_scores_gemma":[0.9980373,0.00045165588,0.000888269,0.00017019719,0.00016450208,0.00009917517,0.000007848491,0.000050242947,0.00013080769],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99077666,0.0022238728,0.004714295,0.0005102861,0.0011607985,0.0006140799],"domain_scores_gemma":[0.98197204,0.012384391,0.0037726448,0.0004505396,0.00094387436,0.00047650124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011582868,0.0003980766,0.0057950662,0.0007262756,0.00003938156,0.00001821503,0.00032173953,0.000462487,0.000031392043],"category_scores_gemma":[0.004198484,0.00025276147,0.00033119574,0.0005891863,0.00061666756,0.00019509252,0.00012836557,0.0009925992,0.0000029591572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.790257,0.15586275,0.048118263,0.00029228692,0.0003459887,0.0018385987,0.00085431075,0.000029675679,0.00010385359,0.000023456472,0.000056665034,0.002217182],"study_design_scores_gemma":[0.9294102,0.05287841,0.008100301,0.0005002339,0.00081406423,0.00033927584,0.0006440511,0.006595395,0.00039137423,0.000026989657,0.00009491786,0.00020478838],"about_ca_topic_score_codex":0.0009779822,"about_ca_topic_score_gemma":0.002090629,"teacher_disagreement_score":0.13915323,"about_ca_system_score_codex":0.0013745647,"about_ca_system_score_gemma":0.0072329454,"threshold_uncertainty_score":0.9999925},"labels":[],"label_agreement":null},{"id":"W2411005995","doi":"10.1136/annrheumdis-2015-eular.3704","title":"AB0460 Remission After Discontinuation of Abatacept for Good Response: Results from the ORA Registry","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Abatacept; Medicine; Discontinuation; Rheumatoid arthritis; Internal medicine; Methotrexate; Arthritis; Surgery; Rituximab","score_opus":0.08334310221856803,"score_gpt":0.36507399932640705,"score_spread":0.28173089710783905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411005995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833669,0.002445958,0.00007424913,0.011888587,0.00011824761,0.00090854167,0.0008865828,0.000018477578,0.00029246454],"genre_scores_gemma":[0.9969438,0.00011877632,0.00020485873,0.00019442794,0.00007605238,0.000068951864,0.000097960045,0.000022833661,0.0022723952],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99787474,0.0003065973,0.0006248376,0.00023704105,0.00071868586,0.00023810849],"domain_scores_gemma":[0.9952414,0.0023312673,0.0004382549,0.0013524325,0.00043961292,0.0001970509],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0013135521,0.00014525345,0.0003613087,0.00003792864,0.000056106852,0.000022158723,0.00042908502,0.00007059527,0.000040173083],"category_scores_gemma":[0.01789403,0.000074101714,0.00025562118,0.00020090569,0.00028227046,0.00010386858,0.0001792509,0.00008825694,0.000008573958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19426575,0.0025937671,0.0074690157,0.0018996339,0.0014512453,0.00004181007,0.013906158,0.00032339423,0.0017579356,0.00047219353,0.6862881,0.08953099],"study_design_scores_gemma":[0.11768576,0.0036573461,0.6455195,0.03609097,0.0023667593,0.00007382436,0.014588608,0.027612943,0.08133378,0.03039212,0.039453045,0.0012253666],"about_ca_topic_score_codex":0.0005157641,"about_ca_topic_score_gemma":0.000017561028,"teacher_disagreement_score":0.6468351,"about_ca_system_score_codex":0.0003350508,"about_ca_system_score_gemma":0.003265124,"threshold_uncertainty_score":0.9903787},"labels":[],"label_agreement":null},{"id":"W2412272480","doi":"","title":"A survey on diagnostic methods and treatment strategies used in patients with Waldenström's macroglobulinaemia in The Netherlands.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Rituximab; Lymphoplasmacytic Lymphoma; Waldenstrom macroglobulinemia; Asymptomatic; Chlorambucil; Fludarabine; Bendamustine; Disease; Pediatrics; Intensive care medicine; Internal medicine; Lymphoma; Chemotherapy; Cyclophosphamide","score_opus":0.03577135470183523,"score_gpt":0.3135835046540804,"score_spread":0.2778121499522452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412272480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568635,0.00016804396,0.0000061525884,0.00031296746,0.000026003227,0.003079765,0.0000072979055,0.000013826304,0.00069957494],"genre_scores_gemma":[0.99697673,0.00006429094,0.00014865112,0.000109459026,0.000025133311,0.0025048777,0.00003626265,0.000018855166,0.00011574588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981626,0.0005240638,0.0002067249,0.00028661528,0.00032868615,0.0004912766],"domain_scores_gemma":[0.99710953,0.0023398995,0.00004107937,0.00033846791,0.000049606653,0.000121397396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008028723,0.0001721528,0.0002952789,0.000118481184,0.000026600726,0.00008141755,0.0001062476,0.00007730184,0.00002016536],"category_scores_gemma":[0.0005913202,0.00008893275,0.000021729691,0.00030737158,0.0001104644,0.0000817652,0.000027948978,0.0001762298,0.000009852138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038092365,0.0003802206,0.8247659,0.000020797337,0.00003592805,0.00009919039,0.0008133223,0.000019047608,6.485808e-7,0.000011807933,0.00013757669,0.1733346],"study_design_scores_gemma":[0.018322129,0.0004993455,0.9803718,0.000033407618,0.000016525833,0.00000884315,0.00023582223,0.0002542154,0.000043569955,0.00005104774,0.00007002443,0.000093271825],"about_ca_topic_score_codex":0.012922975,"about_ca_topic_score_gemma":0.0044462197,"teacher_disagreement_score":0.17324133,"about_ca_system_score_codex":0.002988326,"about_ca_system_score_gemma":0.0005753595,"threshold_uncertainty_score":0.9936501},"labels":[],"label_agreement":null},{"id":"W2413174267","doi":"10.1136/annrheumdis-2015-eular.3807","title":"OP0035 Tolerance of Rituximab, Abatacept and Tocilizumab in Common Practice: Analysis of the 3 Registries of the French Society of Rheumatology (Air, Ora and Regate)","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Tocilizumab; Abatacept; Rituximab; Internal medicine; Rheumatoid arthritis; Discontinuation; Rheumatology; Lymphoma","score_opus":0.04577598675378617,"score_gpt":0.3493294515922446,"score_spread":0.3035534648384584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413174267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98559743,0.009507247,0.000006232383,0.0038950387,0.000039475213,0.00060358347,0.00015019234,0.000004063857,0.00019671126],"genre_scores_gemma":[0.99752384,0.0021466997,0.00010808997,0.00008481162,0.0000024048986,0.000016262691,0.000005437256,0.000010562091,0.000101902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744743,0.00042027596,0.00092916575,0.00020523218,0.00078684074,0.00021107263],"domain_scores_gemma":[0.9957215,0.0013118252,0.0011429803,0.0011732137,0.000558674,0.00009179679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007931554,0.00015950412,0.0011406605,0.000090254085,0.00005000444,0.0000060064126,0.00049237453,0.000090712565,0.000016782205],"category_scores_gemma":[0.003588341,0.000084738145,0.00035108675,0.001028436,0.001877161,0.00012232565,0.00046362483,0.00014608336,1.8084015e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003336691,0.004492221,0.8848619,0.019174522,0.008616998,0.0000056387603,0.025917396,0.0022525466,0.0003332412,0.002989934,0.03347936,0.014539553],"study_design_scores_gemma":[0.03292497,0.00078520825,0.85584587,0.011946884,0.0053721014,0.00014581904,0.023165297,0.042918485,0.019963648,0.0059369975,0.00055654196,0.00043815232],"about_ca_topic_score_codex":0.008672715,"about_ca_topic_score_gemma":0.00056385336,"teacher_disagreement_score":0.04066594,"about_ca_system_score_codex":0.0001746512,"about_ca_system_score_gemma":0.0019820752,"threshold_uncertainty_score":0.9979286},"labels":[],"label_agreement":null},{"id":"W2414700129","doi":"10.1159/000446696","title":"A Unique Hairy Cell Leukemia Variant","year":2016,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Hairy cell leukemia; Leukemia; Computational biology; Cancer research; Dermatology; Immunology; Biology","score_opus":0.024460659333438904,"score_gpt":0.3385687874929258,"score_spread":0.3141081281594869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414700129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9174656,0.00031211498,0.00052179117,0.0011472561,0.0005312465,0.00064239214,0.0000025981183,0.00009007951,0.07928689],"genre_scores_gemma":[0.98916405,0.00016552123,0.0012789787,0.0004579681,0.0002471036,0.00010508918,0.000004432923,0.000038332208,0.008538509],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99772906,0.00016468354,0.00070064486,0.00055237394,0.0002650219,0.00058821094],"domain_scores_gemma":[0.99785805,0.0006357226,0.00019302504,0.00086384173,0.0001356126,0.00031375405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001213832,0.00017564803,0.0005044289,0.0002483169,0.00004334806,0.000006707278,0.000057364377,0.00040025113,0.0006428128],"category_scores_gemma":[0.0009971416,0.00011680484,0.00009529835,0.00026436785,0.00026314385,0.0000671779,0.00015972172,0.00032017584,0.00009607872],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018469064,0.00018263083,0.00061089004,0.000086313645,0.000022767092,0.96570355,0.000195576,0.000005863492,0.0077933394,0.00021165302,0.0057125012,0.019290227],"study_design_scores_gemma":[0.009401289,0.0006618301,0.00018621533,0.00014206466,0.000038004742,0.8709049,0.00010755471,0.00041533084,0.006742128,0.0005657659,0.11067238,0.00016254514],"about_ca_topic_score_codex":0.0014316839,"about_ca_topic_score_gemma":0.0005067395,"teacher_disagreement_score":0.104959875,"about_ca_system_score_codex":0.05075425,"about_ca_system_score_gemma":0.030858012,"threshold_uncertainty_score":0.97463614},"labels":[],"label_agreement":null},{"id":"W2416239197","doi":"","title":"Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Hepatocellular carcinoma; Macroglobulinemia; Medicine; Waldenstrom macroglobulinemia; Hyperviscosity syndrome; Carcinoma; Internal medicine; Gastroenterology; Oncology; Pathology; Multiple myeloma; Lymphoma","score_opus":0.018177699536394577,"score_gpt":0.2470443998375526,"score_spread":0.22886670030115802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416239197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727976,0.0012862298,0.000015050381,0.0012198411,0.00014721935,0.0019116505,0.000030071404,0.00019350625,0.022398883],"genre_scores_gemma":[0.9290985,0.00005300052,0.000143811,0.00041616854,0.00031372046,0.0013547753,0.00011173229,0.000066920795,0.068441354],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99676645,0.00006909903,0.00058510416,0.00069267926,0.00075290876,0.0011337772],"domain_scores_gemma":[0.9978391,0.00009174502,0.00008768089,0.0010571466,0.0001203953,0.0008039108],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005822053,0.0002892537,0.00048730976,0.00010196385,0.00012989683,0.000055326953,0.0001807859,0.00025243318,0.0014289828],"category_scores_gemma":[0.00028984417,0.00025846518,0.00022970811,0.0004309666,0.00017242193,0.000095471056,0.00007848407,0.00040182818,0.0002646646],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042726516,0.00021596819,0.013193194,0.0001215172,0.000113663664,0.8212006,0.00008553227,0.0000018757302,0.00016421873,0.000008287616,0.07530697,0.08916088],"study_design_scores_gemma":[0.022467116,0.00010504709,0.0047234786,0.000026678297,0.0002643905,0.8027615,0.00007236763,0.005422209,0.009830315,0.000032932323,0.1538029,0.0004910597],"about_ca_topic_score_codex":0.0029041774,"about_ca_topic_score_gemma":0.000028183735,"teacher_disagreement_score":0.08866982,"about_ca_system_score_codex":0.0061052674,"about_ca_system_score_gemma":0.0015436872,"threshold_uncertainty_score":0.99998677},"labels":[],"label_agreement":null},{"id":"W2417672353","doi":"10.1136/annrheumdis-2015-eular.3822","title":"FRI0154 Incidence of Cancers in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Abatacept; Rituximab; Cancer; Internal medicine; Rheumatoid arthritis; Incidence (geometry); Oncology; Lymphoma","score_opus":0.0348785620371985,"score_gpt":0.3009865286675026,"score_spread":0.26610796663030406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417672353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818934,0.01715368,0.000001767198,0.00011043304,0.000027530074,0.000576593,0.000096614145,0.000008794541,0.00013114681],"genre_scores_gemma":[0.9959654,0.003655896,0.00005597097,0.000053251675,0.00000330252,0.00005421318,0.000008159247,0.000020867572,0.00018293233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982842,0.0000811203,0.0004349345,0.00019290965,0.00077345816,0.00023336505],"domain_scores_gemma":[0.9983681,0.00015593763,0.0003583789,0.0004481846,0.00046861832,0.00020077596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016068359,0.00015909997,0.0006432878,0.0001272648,0.000013508026,0.0000035600087,0.00017911466,0.00003794377,0.00008527592],"category_scores_gemma":[0.00047851357,0.0000869861,0.000049753748,0.00029891537,0.00066787377,0.0001352689,0.00007947694,0.00007468673,7.9978423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01484954,0.0015667682,0.93194824,0.0026873373,0.0006190104,0.000030888412,0.004124273,0.00043225987,0.000011446648,0.000030219571,0.007947061,0.035752933],"study_design_scores_gemma":[0.08878124,0.0033738858,0.8636447,0.037277866,0.00022257233,0.000031957814,0.0014459454,0.002750835,0.0017122517,0.000091887276,0.0002638763,0.0004029569],"about_ca_topic_score_codex":0.021232963,"about_ca_topic_score_gemma":0.0021000833,"teacher_disagreement_score":0.073931694,"about_ca_system_score_codex":0.0020355654,"about_ca_system_score_gemma":0.010795068,"threshold_uncertainty_score":0.9948128},"labels":[],"label_agreement":null},{"id":"W2418319718","doi":"10.1016/j.revmed.2015.12.022","title":"Polyglobulies héréditaires primitives et secondaires","year":2016,"lang":"fr","type":"review","venue":"La Revue de Médecine Interne","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Computer science","score_opus":0.02858566712440673,"score_gpt":0.35959171539505796,"score_spread":0.3310060482706512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418319718","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012314381,0.8982904,0.00065543846,0.009387794,0.0020675056,0.0016065033,0.0004218572,0.00021422771,0.08612486],"genre_scores_gemma":[0.011858133,0.88790935,0.0008086666,0.0011819026,0.0061537153,0.00033895887,0.0002175093,0.00038778546,0.09114395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99142325,0.0018226234,0.002045163,0.0016275849,0.0009657677,0.0021156261],"domain_scores_gemma":[0.9881519,0.0076702293,0.00075053744,0.0019577916,0.0004676469,0.0010018904],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0024469441,0.0014609322,0.0037760388,0.00068402226,0.00011930505,0.00023790251,0.0015057698,0.0012865548,0.008134849],"category_scores_gemma":[0.006505264,0.0010976046,0.0015070083,0.00056604337,0.0013172767,0.00038033465,0.0012677828,0.0018971997,0.008375022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00045693893,0.00081672514,0.00058273907,0.049270004,0.0026525431,0.009544153,0.0011122621,0.0000029842515,0.000092598435,0.043155666,0.028746177,0.86356723],"study_design_scores_gemma":[0.009978211,0.0006036769,0.0009455555,0.16314521,0.0010679462,0.015693868,0.0002325888,0.00014522385,0.00014180031,0.0005112434,0.80666727,0.00086738955],"about_ca_topic_score_codex":0.00097600924,"about_ca_topic_score_gemma":0.00012436758,"teacher_disagreement_score":0.8626998,"about_ca_system_score_codex":0.028646503,"about_ca_system_score_gemma":0.017006915,"threshold_uncertainty_score":0.99981403},"labels":[],"label_agreement":null},{"id":"W2428539785","doi":"10.1182/blood-2016-03-707786","title":"Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Imperial Experimental Cancer Medicine Centre; Gilead Sciences; University of Southampton; Cancer Research UK; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research","keywords":"DNA methylation; Biology; Methylation; Immunology; Genetics; DNA; Gene expression; Cancer research; Gene","score_opus":0.03560816049409988,"score_gpt":0.3102328562786294,"score_spread":0.2746246957845295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2428539785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985071,0.00079641497,0.000051443127,0.00010180808,0.000035675705,0.0003599948,0.000008264046,0.00003368049,0.000105636485],"genre_scores_gemma":[0.9988262,0.00030128562,0.00022590336,0.00003676724,0.000055973527,0.000018438412,0.000010500647,0.000019219233,0.00050570886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871737,0.00016978654,0.00027785497,0.00029311283,0.00031410993,0.0002277492],"domain_scores_gemma":[0.9991331,0.00036423825,0.000096515665,0.00019347649,0.00007473801,0.00013795016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057062326,0.00010907087,0.00024140644,0.000057866575,0.00003926033,0.000016275644,0.000035089877,0.00016929502,0.000033697535],"category_scores_gemma":[0.0003023212,0.00006835096,0.000020974023,0.00010937369,0.00012587474,0.0000944449,0.000056222238,0.00013601605,0.000004111717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050843775,0.0006644843,0.9700564,0.00006366282,0.00006001315,0.00018004165,0.00014304594,0.0000011651488,0.02140419,0.000007921262,0.00010346553,0.0068071294],"study_design_scores_gemma":[0.04010228,0.00050008687,0.9505877,0.0004921208,0.00018232864,0.000081864026,0.00008691895,0.00010291437,0.0076074707,0.00003320581,0.00011352108,0.00010959734],"about_ca_topic_score_codex":0.00012427384,"about_ca_topic_score_gemma":0.00016986472,"teacher_disagreement_score":0.039593842,"about_ca_system_score_codex":0.00057967025,"about_ca_system_score_gemma":0.00057254784,"threshold_uncertainty_score":0.2787271},"labels":[],"label_agreement":null},{"id":"W2432682623","doi":"10.14740/jh269w","title":"Monoclonal B-Cell Lymphocytosis Among Egyptian Elderly Healthy Adults","year":2016,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lymphocytosis; Medicine; Monoclonal; Immunology; Pathology; Monoclonal antibody; Antibody","score_opus":0.013498869860479688,"score_gpt":0.28810423770911886,"score_spread":0.27460536784863915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2432682623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898529,0.0016204884,0.00092097884,0.005475182,0.00036946344,0.00021318476,0.0000033852878,0.000022520833,0.0015218625],"genre_scores_gemma":[0.9964605,0.00048499304,0.0015314717,0.00048499406,0.00036768895,0.000006870889,0.000001032775,0.000037052963,0.0006253942],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99741054,0.00012917432,0.0009436957,0.0002512439,0.0006359499,0.00062942225],"domain_scores_gemma":[0.9975546,0.00050074403,0.00053597975,0.00037393745,0.00044990602,0.000584832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005089207,0.00020057867,0.0008063059,0.00037554954,0.00006476897,0.000011801394,0.00027866286,0.0002563404,0.000522571],"category_scores_gemma":[0.0003674753,0.00012006525,0.000287142,0.00019965632,0.00027467252,0.00017120251,0.000075871736,0.0003021919,0.00020545568],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11580154,0.0078077833,0.3052337,0.006712762,0.003057028,0.06323295,0.0042116214,0.000022881375,0.048549294,0.009277074,0.22906666,0.2070267],"study_design_scores_gemma":[0.47167176,0.038890045,0.024126714,0.00660002,0.00078397803,0.26884934,0.0017736958,0.0032428654,0.1421029,0.0030680771,0.03741485,0.001475752],"about_ca_topic_score_codex":0.000121481055,"about_ca_topic_score_gemma":0.000034270288,"teacher_disagreement_score":0.35587022,"about_ca_system_score_codex":0.0054685264,"about_ca_system_score_gemma":0.007545229,"threshold_uncertainty_score":0.9983493},"labels":[],"label_agreement":null},{"id":"W2434582744","doi":"10.1182/blood.v122.21.1638.1638","title":"TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Neutropenia; Bendamustine; Chronic lymphocytic leukemia; Oncology; Gastroenterology; Refractory (planetary science); Febrile neutropenia; Chemotherapy; Leukemia; Multiple myeloma; Biology","score_opus":0.028865155415544973,"score_gpt":0.2854078378169268,"score_spread":0.25654268240138184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2434582744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950781,0.000749978,0.000038553517,0.00011435959,0.000079835976,0.0032502327,0.0000024787537,0.00015412754,0.0005323554],"genre_scores_gemma":[0.9966873,0.00016917173,0.00048974995,0.00017872058,0.00026396543,0.0003506421,0.000034838125,0.00010455817,0.001721067],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964678,0.00025296575,0.0007308922,0.0008264907,0.0009403021,0.0007815435],"domain_scores_gemma":[0.9978525,0.000586416,0.00022412346,0.0007473279,0.00022402016,0.00036561402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054766034,0.00042067986,0.0006612049,0.00042141852,0.00013447517,0.0001174926,0.00020562959,0.00023783902,0.0003257647],"category_scores_gemma":[0.000728359,0.0002848059,0.00006637823,0.0007576746,0.00017286256,0.00024510332,0.00012449679,0.00042492893,0.00023626394],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11299191,0.11919302,0.022450462,0.013736144,0.008788346,0.07088039,0.046274498,0.008402033,0.23582628,0.00023797313,0.0095181335,0.3517008],"study_design_scores_gemma":[0.8806182,0.021096904,0.032409035,0.0021217538,0.001331605,0.004631143,0.0029544914,0.033527225,0.018611033,0.00003970667,0.0014399681,0.0012189114],"about_ca_topic_score_codex":0.004327802,"about_ca_topic_score_gemma":0.002142305,"teacher_disagreement_score":0.76762635,"about_ca_system_score_codex":0.049828216,"about_ca_system_score_gemma":0.02084538,"threshold_uncertainty_score":0.9999604},"labels":[],"label_agreement":null},{"id":"W2464833189","doi":"10.1182/blood.v124.21.4674.4674","title":"Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Obinutuzumab; Medicine; Antibody-dependent cell-mediated cytotoxicity; Chronic lymphocytic leukemia; Rituximab; CD20; Immunology; Cytokine; Cytokine release syndrome; Neutropenia; Leukemia; Pharmacology; Internal medicine; Immunotherapy; Antibody; Monoclonal antibody; Chemotherapy; Immune system","score_opus":0.00836036145291262,"score_gpt":0.22179892688005476,"score_spread":0.21343856542714212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464833189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983978,0.00006927509,0.00008973212,0.000010921347,0.0000068028407,0.0007949541,0.0000068178038,0.000044914686,0.000578747],"genre_scores_gemma":[0.99831116,0.00001210453,0.0011555951,0.000008614654,0.0000115858575,0.000045671273,0.00012235354,0.00005128798,0.0002816328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979156,0.000084483836,0.0006159698,0.00039643116,0.0006376071,0.00034988936],"domain_scores_gemma":[0.99852586,0.00018756808,0.0003095656,0.00050985627,0.00029064392,0.00017652857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025847738,0.00024788908,0.00048713235,0.0003839309,0.00008506526,0.000009802056,0.00009401964,0.0001495622,0.000027119208],"category_scores_gemma":[0.000109521905,0.00016740464,0.000025461442,0.00083443563,0.00022501577,0.0001275327,0.000055978235,0.00025433974,0.0000059743966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0034200307,0.0006377596,0.9864927,0.0011544537,0.000356249,0.00006377363,0.0011975614,0.0012658569,0.001504607,0.000037216094,0.000008746965,0.0038610732],"study_design_scores_gemma":[0.13500871,0.0035086884,0.8368713,0.0028600136,0.00033921146,0.00017751477,0.00007610389,0.0050959163,0.015744146,0.000011302586,0.000037399852,0.0002696992],"about_ca_topic_score_codex":0.002354097,"about_ca_topic_score_gemma":0.0008497031,"teacher_disagreement_score":0.14962137,"about_ca_system_score_codex":0.018813923,"about_ca_system_score_gemma":0.018072532,"threshold_uncertainty_score":0.9874941},"labels":[],"label_agreement":null},{"id":"W2467487080","doi":"10.4103/1319-2442.185271","title":"Minimal change disease: A case report of an unusual relationship","year":2016,"lang":"en","type":"article","venue":"Saudi Journal of Kidney Diseases and Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint-Vincent Hospital","funders":"","keywords":"Medicine; Membranoproliferative glomerulonephritis; Nephrotic syndrome; Chronic lymphocytic leukemia; Renal biopsy; Glomerulonephritis; Rituximab; Biopsy; Kidney disease; Pathology; Lymphoproliferative disorders; Minimal change disease; Bone marrow; Acute kidney injury; Leukemia; Kidney; Internal medicine; Lymphoma; Focal segmental glomerulosclerosis","score_opus":0.03680551758654141,"score_gpt":0.32753004699563737,"score_spread":0.290724529409096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467487080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960135,0.0010973874,0.000529569,0.0016496652,0.000086274245,0.0002072551,0.00035809522,0.000009201637,0.000049051043],"genre_scores_gemma":[0.998273,0.00089406996,0.0002753316,0.00012237817,0.00027500142,0.0000070579467,0.00006153527,0.000014591831,0.00007701462],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9987191,0.00007515636,0.00047470082,0.00014624979,0.0004291238,0.00015567701],"domain_scores_gemma":[0.99789166,0.00019150917,0.0002688753,0.00015296017,0.00023869677,0.0012562847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023739868,0.000103570004,0.00022904722,0.00018745393,0.00005657259,0.000010600524,0.00004493994,0.000045916502,0.00004826489],"category_scores_gemma":[0.00066144374,0.00006678238,0.0000989663,0.00012020788,0.0001293616,0.0003952332,0.0000063477687,0.0000738992,0.0000013056],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01735557,0.0011161728,0.21201387,0.0044251997,0.00040630673,0.7277039,0.001585231,0.000003826009,0.0037546193,0.0006543099,0.00084139034,0.0301396],"study_design_scores_gemma":[0.028401176,0.0014617069,0.58495986,0.0026715067,0.002203204,0.3769051,0.000218116,0.0003363266,0.0013660138,0.00080395036,0.0004507314,0.0002222872],"about_ca_topic_score_codex":0.00006352379,"about_ca_topic_score_gemma":0.000006014129,"teacher_disagreement_score":0.372946,"about_ca_system_score_codex":0.00033530922,"about_ca_system_score_gemma":0.0031141238,"threshold_uncertainty_score":0.55243224},"labels":[],"label_agreement":null},{"id":"W2467680685","doi":"10.1016/j.bbmt.2016.09.013","title":"Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","year":2016,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Hematopoietic cell; Transplantation; Chronic lymphocytic leukemia; Hematopoietic stem cell transplantation; Clinical Practice; Haematopoiesis; Leukemia; Immunology; Oncology; Stem cell; Internal medicine; Family medicine","score_opus":0.10037565688806649,"score_gpt":0.411478286149147,"score_spread":0.3111026292610805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467680685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44200724,0.5369517,0.0026742963,0.0010633424,0.00043351093,0.009628925,0.007169249,0.000029232766,0.00004249506],"genre_scores_gemma":[0.09913605,0.895,0.0047651567,0.000101571306,0.0000713225,0.00022182861,0.0006298951,0.000042266576,0.000031907086],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99637413,0.00056140136,0.0020020637,0.000504765,0.00025987733,0.00029776595],"domain_scores_gemma":[0.9922207,0.0051796683,0.0017449042,0.00042088053,0.00036686636,0.00006695138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012154784,0.000362079,0.001599716,0.0001703256,0.00008529025,0.0000060872776,0.00025238245,0.0004363349,0.0000045754578],"category_scores_gemma":[0.00021850322,0.00022167129,0.0007713549,0.0002884309,0.00088009867,0.00009684294,0.000018645405,0.00023828752,1.9975894e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009267201,0.0014127204,0.003100664,0.42569062,0.0054280604,0.000020265004,0.0033517734,0.000109661385,0.07663656,0.0016266503,0.0007031173,0.4726527],"study_design_scores_gemma":[0.2588709,0.02405132,0.0052053994,0.21662076,0.18513979,0.005841874,0.0012583835,0.0025956417,0.19505632,0.0011492266,0.100727856,0.003482524],"about_ca_topic_score_codex":0.00047973948,"about_ca_topic_score_gemma":0.00021518554,"teacher_disagreement_score":0.46917015,"about_ca_system_score_codex":0.00072658237,"about_ca_system_score_gemma":0.00589489,"threshold_uncertainty_score":0.9997408},"labels":[],"label_agreement":null},{"id":"W2469051128","doi":"10.1200/jco.2015.33.18_suppl.lba7005","title":"Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bendamustine; Ibrutinib; Internal medicine; Clinical endpoint; Rituximab; Chronic lymphocytic leukemia; Gastroenterology; Interim analysis; Progression-free survival; Neutropenia; Placebo; Phases of clinical research; Refractory (planetary science); Surgery; Randomized controlled trial; Lymphoma; Chemotherapy; Leukemia; Pathology","score_opus":0.12314359975747771,"score_gpt":0.42100886763294876,"score_spread":0.2978652678754711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469051128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839545,0.0033382182,0.000071535746,0.0012098871,0.00075182697,0.008234925,0.000026218593,0.000083590116,0.002329305],"genre_scores_gemma":[0.99358183,0.0019052868,0.0009669259,0.0004755577,0.001642443,0.00033545,0.00006934316,0.00013191275,0.00089126907],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98305017,0.002914036,0.009444287,0.0013165812,0.0018443366,0.0014306062],"domain_scores_gemma":[0.96993333,0.020177925,0.004840161,0.0011688521,0.0015357425,0.0023439701],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.020256573,0.0009645094,0.011336421,0.00092226185,0.00016255195,0.0001243079,0.00083336956,0.0011801277,0.000086719076],"category_scores_gemma":[0.01652396,0.000632597,0.0010075256,0.0009725812,0.0015353897,0.00036419267,0.00040905108,0.0014986065,0.00006597004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.962166,0.0075460337,0.00047658387,0.00012431672,0.0034122742,0.013317296,0.0015354601,0.0013465009,0.00001024452,0.00002552296,0.0008761676,0.009163601],"study_design_scores_gemma":[0.8554317,0.058499787,0.00017619721,0.000942875,0.0039143246,0.003154429,0.0008175948,0.07498184,0.000051433017,0.00007287004,0.001448995,0.00050795247],"about_ca_topic_score_codex":0.012386436,"about_ca_topic_score_gemma":0.008579248,"teacher_disagreement_score":0.1067343,"about_ca_system_score_codex":0.11048303,"about_ca_system_score_gemma":0.19253252,"threshold_uncertainty_score":0.9996125},"labels":[],"label_agreement":null},{"id":"W2471503382","doi":"10.1182/blood.v126.23.469.469","title":"Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Ibrutinib; Temsirolimus; Mantle cell lymphoma; Medicine; Internal medicine; Clinical endpoint; Phases of clinical research; International Prognostic Index; Oncology; Lymphoma; Febrile neutropenia; Neutropenia; Randomized controlled trial; Gastroenterology; Surgery; Rituximab; Clinical trial; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03903562922247449,"score_gpt":0.3292918694018239,"score_spread":0.2902562401793494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471503382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893251,0.00017055504,0.0000033057452,0.00011036461,0.00013320846,0.006343853,0.00018886814,0.00006503962,0.0036596963],"genre_scores_gemma":[0.99702084,0.000029723811,0.0004369992,0.00015016003,0.00009811506,0.00031097225,0.00070709,0.000067248846,0.0011788751],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996393,0.00039808394,0.0008611373,0.00077417237,0.0010526124,0.00052094663],"domain_scores_gemma":[0.99772835,0.00042455262,0.00026595432,0.0008396898,0.0004027727,0.00033870162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010555473,0.00033604656,0.00095281366,0.00023901672,0.00004536873,0.00013950895,0.00061930926,0.0001179844,0.000069751004],"category_scores_gemma":[0.00090125174,0.00023818457,0.000056363497,0.00032751873,0.00012455316,0.00025588894,0.00042393504,0.00017972065,0.0001633653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8098717,0.12518649,0.05283891,0.000043037337,0.0010143135,0.0010892968,0.007142588,0.0000048830625,0.00004985737,0.000001258288,0.0013746475,0.0013830347],"study_design_scores_gemma":[0.987699,0.0028147462,0.0035121765,0.0002878275,0.0005094786,0.000010071103,0.000610302,0.0026530027,0.0009807743,0.0000051009492,0.0006616292,0.00025589913],"about_ca_topic_score_codex":0.009570891,"about_ca_topic_score_gemma":0.00031752972,"teacher_disagreement_score":0.17782731,"about_ca_system_score_codex":0.0026814262,"about_ca_system_score_gemma":0.0021091644,"threshold_uncertainty_score":0.9970245},"labels":[],"label_agreement":null},{"id":"W2471630753","doi":"10.4049/jimmunol.186.supp.165.36","title":"A novel NOD.SCID mouse model suggests CD200-mediated regulation may be important for both growth and therapy of CLL (165.36)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Nod; CD19; Splenocyte; CD5; Immunology; Spleen; Cancer research; Biology; Medicine; Leukemia; Antibody; In vivo","score_opus":0.05097243413494868,"score_gpt":0.29891584340455835,"score_spread":0.24794340926960967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471630753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99296594,0.0030162637,0.0023595146,0.0009519276,0.000083547326,0.00043145227,0.000018203313,0.000010618809,0.00016251756],"genre_scores_gemma":[0.9915524,0.0052966536,0.0025715274,0.00019868405,0.00006538546,0.0000061823707,0.0000065244258,0.000033472355,0.0002691347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847734,0.000088193505,0.0007055052,0.000119325974,0.00029202504,0.00031761406],"domain_scores_gemma":[0.9982159,0.00036655954,0.0006129979,0.00033081404,0.00039209926,0.00008161796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011912073,0.00015083699,0.0004704004,0.0002148237,0.0000596292,0.0000049020787,0.00025362358,0.00016790102,0.000042553023],"category_scores_gemma":[0.00035957043,0.00009101971,0.00010752979,0.0001365594,0.0004061754,0.000107042855,0.00006208386,0.00030351817,9.782638e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013164131,0.00034506194,0.00048320432,0.00005758468,0.0005572447,0.000013203543,0.0031002082,0.000023897861,0.9805435,0.00063048006,0.00030243382,0.00077906786],"study_design_scores_gemma":[0.10253875,0.0096404515,0.028685652,0.0002848154,0.00046642584,0.0070356494,0.0013468404,0.05571262,0.78938633,0.004060313,0.00040367607,0.00043845788],"about_ca_topic_score_codex":0.00035646983,"about_ca_topic_score_gemma":0.00001661012,"teacher_disagreement_score":0.19115713,"about_ca_system_score_codex":0.00061389327,"about_ca_system_score_gemma":0.0021225417,"threshold_uncertainty_score":0.37652978},"labels":[],"label_agreement":null},{"id":"W2472025541","doi":"10.14740/jmc.v7i7.2558","title":"Diffuse Infiltrative Lymphocytosis Syndrome: A Case With Multiple Extra-Glandular Infiltrations","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lymphocytosis; Differential diagnosis; Pathology; Presentation (obstetrics); Radiology","score_opus":0.034657796418463456,"score_gpt":0.31825122382209253,"score_spread":0.2835934274036291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472025541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922683,0.0006312116,0.0021477162,0.0043500713,0.00012902681,0.00026722244,0.000027548118,0.00002719201,0.0001516823],"genre_scores_gemma":[0.9976149,0.0005216117,0.0007979902,0.00042090085,0.00037158083,0.00001665631,0.000003045497,0.000033338416,0.00021992867],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99598837,0.00016638658,0.00075620523,0.0002262658,0.0024246702,0.0004381172],"domain_scores_gemma":[0.99510044,0.0025619192,0.00030613618,0.00036039363,0.00048515297,0.0011859626],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008837444,0.0002283682,0.00061925716,0.00029509127,0.00011828058,0.00003794622,0.00023421986,0.0002313663,0.0013557018],"category_scores_gemma":[0.0068247835,0.0001111284,0.00019393735,0.00036650628,0.0005119698,0.0002946867,0.000062199295,0.00042241547,0.000033519867],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026131903,0.001312553,0.014093454,0.00020815343,0.0007211846,0.95462,0.00080303085,0.000005026441,0.0015374521,0.00014667159,0.0054564234,0.018482856],"study_design_scores_gemma":[0.049879905,0.0032691339,0.0020768954,0.0016416247,0.00025724628,0.93529695,0.0006409844,0.0004844008,0.0027210943,0.000025464517,0.0035215542,0.00018473358],"about_ca_topic_score_codex":0.0006362258,"about_ca_topic_score_gemma":0.00039524786,"teacher_disagreement_score":0.047266714,"about_ca_system_score_codex":0.0035548408,"about_ca_system_score_gemma":0.012588543,"threshold_uncertainty_score":0.9995572},"labels":[],"label_agreement":null},{"id":"W2474545869","doi":"10.1182/blood.v106.11.446.446","title":"A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pharmacokinetics; Apoptosis; Pharmacology; Adverse effect; Chronic lymphocytic leukemia; Pharmacodynamics; Medicine; In vivo; Cmax; Bcl-2 family; Internal medicine; Immunology; Leukemia; Programmed cell death; Chemistry; Biology; Biochemistry","score_opus":0.016700143308142294,"score_gpt":0.2672895160565252,"score_spread":0.2505893727483829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474545869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99233913,0.000594338,0.000024133806,0.00012121194,0.00016796126,0.00544392,0.00007553495,0.00012970218,0.0011040408],"genre_scores_gemma":[0.996506,0.0000661018,0.00029309295,0.00044164836,0.0007682686,0.00034447623,0.000081136845,0.00014016357,0.0013591199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953781,0.00023559612,0.0010395544,0.0008499666,0.0013919456,0.0011048346],"domain_scores_gemma":[0.99689835,0.00019439273,0.0003575696,0.0015790851,0.0004155404,0.0005550308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000407426,0.00056505896,0.0009750765,0.00025921417,0.0001528045,0.00006527159,0.00068287627,0.00030678583,0.000064082815],"category_scores_gemma":[0.0003868122,0.00038201245,0.00031035003,0.0008884801,0.00027998822,0.00011607538,0.000299553,0.00040167884,0.0001228319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.56765276,0.07340236,0.0033500616,0.005528906,0.007488975,0.0020562462,0.011785666,0.0008401213,0.1582234,0.00009592612,0.009715263,0.1598603],"study_design_scores_gemma":[0.8687474,0.021777404,0.0011899713,0.0012423908,0.0012493221,0.00017405231,0.0000828242,0.0015990364,0.10122492,0.000003696017,0.002117398,0.00059156015],"about_ca_topic_score_codex":0.0014041832,"about_ca_topic_score_gemma":0.0005529079,"teacher_disagreement_score":0.30109465,"about_ca_system_score_codex":0.033965293,"about_ca_system_score_gemma":0.039628375,"threshold_uncertainty_score":0.9998632},"labels":[],"label_agreement":null},{"id":"W2483350877","doi":"10.1182/blood.v126.23.1742.1742","title":"A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"","keywords":"Ofatumumab; Medicine; Fludarabine; Internal medicine; Chronic lymphocytic leukemia; Refractory (planetary science); Regimen; Gastroenterology; Neutropenia; Phases of clinical research; Pharmacodynamics; Oncology; Pharmacology; Pharmacokinetics; Leukemia; Clinical trial; Cyclophosphamide; Chemotherapy","score_opus":0.018305244616029948,"score_gpt":0.28747154493414,"score_spread":0.26916630031811006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483350877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953349,0.00032492905,0.0000026509963,0.000013060453,0.000023981429,0.003951951,0.0000064340825,0.000058274883,0.00028376645],"genre_scores_gemma":[0.9992603,0.0000106544585,0.000056279503,0.000015458927,0.000038329665,0.00032136022,0.0000814115,0.000067869834,0.00014831929],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965986,0.00020729796,0.0006622943,0.00057037995,0.0013339062,0.00062751124],"domain_scores_gemma":[0.99829245,0.00009783165,0.00021516245,0.0006927547,0.00043018095,0.0002716285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045558187,0.00032896092,0.0007480561,0.0005800414,0.000028827944,0.000025153098,0.00023445358,0.00014198235,0.000014429369],"category_scores_gemma":[0.00024856572,0.00023892873,0.000039680956,0.0014248053,0.00013977767,0.0002072705,0.00010415531,0.00030524467,0.000012635973],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04180794,0.1114536,0.8101943,0.0016861539,0.0009977677,0.0038936592,0.01946571,0.0011235023,0.001214696,0.000023355768,0.0002812574,0.007858033],"study_design_scores_gemma":[0.8898689,0.047862567,0.046532728,0.0013366337,0.00036506733,0.000098073695,0.00097023183,0.006216067,0.0063649453,0.000011520564,0.000021310958,0.00035194342],"about_ca_topic_score_codex":0.011083653,"about_ca_topic_score_gemma":0.007075651,"teacher_disagreement_score":0.84806097,"about_ca_system_score_codex":0.05038923,"about_ca_system_score_gemma":0.026199093,"threshold_uncertainty_score":0.99550164},"labels":[],"label_agreement":null},{"id":"W2489240616","doi":"10.1182/blood.v126.23.2745.2745","title":"Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Royal Victoria Hospital; Dalhousie University","funders":"","keywords":"Ibrutinib; Rituximab; Medicine; Waldenstrom macroglobulinemia; Macroglobulinemia; Open label; Internal medicine; Refractory (planetary science); Lymphoplasmacytic Lymphoma; Phases of clinical research; Oncology; Clinical trial; Lymphoma; Leukemia; Multiple myeloma; Chronic lymphocytic leukemia","score_opus":0.09222182345165915,"score_gpt":0.4035739745569185,"score_spread":0.3113521511052594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489240616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952856,0.00013231792,0.000004535033,0.00028955124,0.0003581663,0.0016421098,0.0004957825,0.00007548005,0.0017164941],"genre_scores_gemma":[0.99508363,0.00007992165,0.001576553,0.00053188764,0.00036782084,0.00007758806,0.0020746908,0.000069817885,0.00013806994],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99659353,0.00015733879,0.0007511357,0.0008097935,0.0011386618,0.00054951105],"domain_scores_gemma":[0.99753153,0.0001575615,0.000228327,0.0008955912,0.0007576807,0.00042931677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005513529,0.00033571865,0.0005348528,0.00022765102,0.00005847638,0.00016264785,0.0008248917,0.00019220676,0.00010899638],"category_scores_gemma":[0.00054134696,0.00026621838,0.0000311204,0.00041618425,0.00016331425,0.0006253579,0.0003359691,0.00053291075,0.00010943651],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21708192,0.4550577,0.21159476,0.00007560308,0.002174344,0.0092978375,0.01134303,0.0000124003045,0.003971631,0.000039143037,0.0040142867,0.08533732],"study_design_scores_gemma":[0.9667381,0.0049890424,0.016158734,0.00023389049,0.000084325846,0.000042167194,0.00037661073,0.0013560413,0.005971636,0.000019754027,0.0036541969,0.00037551156],"about_ca_topic_score_codex":0.0051543075,"about_ca_topic_score_gemma":0.00047508004,"teacher_disagreement_score":0.74965614,"about_ca_system_score_codex":0.002371013,"about_ca_system_score_gemma":0.0031993503,"threshold_uncertainty_score":0.999979},"labels":[],"label_agreement":null},{"id":"W2489746138","doi":"10.1182/blood.v126.23.2944.2944","title":"Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ibrutinib; Chemoimmunotherapy; Bendamustine; Internal medicine; Rituximab; Clinical endpoint; Ofatumumab; Oncology; Placebo; Progression-free survival; Chronic lymphocytic leukemia; Surgery; Clinical trial; Leukemia; Lymphoma; Chemotherapy; Pathology","score_opus":0.09230312178758879,"score_gpt":0.30836650103277735,"score_spread":0.21606337924518856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489746138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98726535,0.008196625,0.0000075857492,0.00003308935,0.0001498136,0.0035179027,0.00005193663,0.00015429147,0.00062339235],"genre_scores_gemma":[0.99856967,0.00014469851,0.00034738696,0.000065273845,0.00021928256,0.00011919615,0.00014243013,0.00014651199,0.0002455614],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929012,0.0010255239,0.001980449,0.0012516718,0.0015004323,0.0013407392],"domain_scores_gemma":[0.99567354,0.0007157231,0.00094572036,0.001335536,0.00044991935,0.00087956747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022244672,0.0008310877,0.0030589052,0.0005580291,0.0002242882,0.00015539087,0.0005840384,0.0004092865,0.000029592622],"category_scores_gemma":[0.0014227191,0.0005923708,0.00018589583,0.0011709509,0.00076409266,0.00025243143,0.0006361777,0.00037336798,0.00001772777],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09540025,0.017619457,0.75024176,0.011056732,0.0054517672,0.0013707157,0.031278554,0.011941167,0.004642844,0.00014222776,0.0010201226,0.06983438],"study_design_scores_gemma":[0.7244861,0.007973906,0.09956817,0.0039659827,0.002511458,0.0008323869,0.0008560179,0.13368794,0.024336169,0.000018965191,0.0005596303,0.0012032314],"about_ca_topic_score_codex":0.006180781,"about_ca_topic_score_gemma":0.0018501249,"teacher_disagreement_score":0.65067357,"about_ca_system_score_codex":0.06917291,"about_ca_system_score_gemma":0.035744965,"threshold_uncertainty_score":0.99965274},"labels":[],"label_agreement":null},{"id":"W2489914332","doi":"10.1038/srep30384","title":"Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Children's Hospital of Pittsburgh; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Gilead Sciences","keywords":"Cytokine; Protein kinase B; PI3K/AKT/mTOR pathway; Cell biology; CD28; Phosphoinositide 3-kinase; Inflammation; Biology; T cell; Cancer research; Signal transduction; Chemistry; Immunology; Immune system","score_opus":0.015523251332030983,"score_gpt":0.26844300319805103,"score_spread":0.25291975186602006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489914332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910605,0.00033452924,0.00043884222,0.0004888438,0.006384166,0.00081842375,0.0000981991,0.000082526414,0.00029396065],"genre_scores_gemma":[0.98477197,0.00002394698,0.00067102787,0.000020571772,0.00028392722,0.000036408444,0.00015347224,0.00003958788,0.013999107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99564904,0.000044884484,0.00083966996,0.0012569728,0.0017128709,0.0004965668],"domain_scores_gemma":[0.99696517,0.000097539894,0.00042811965,0.0017017162,0.0004858987,0.00032153694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013039777,0.00021789914,0.00039030617,0.00019756015,0.00014473661,0.00006365738,0.00015627043,0.00013977877,0.00055201905],"category_scores_gemma":[0.0006966079,0.00014112609,0.0001367738,0.00043885031,0.0004846481,0.00024805526,0.00021955757,0.00014242715,0.00006849983],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002444051,0.0003984752,0.00052134064,0.00006975341,0.00003322807,0.00048713418,0.00013646476,0.000005026698,0.89326143,0.0000021498195,0.101700544,0.003140036],"study_design_scores_gemma":[0.003967474,0.000099235534,0.00021270932,0.0006149624,0.00005815229,0.0004551818,0.000044232405,0.00010953463,0.97409153,0.00018986799,0.019993702,0.00016342147],"about_ca_topic_score_codex":0.0011634292,"about_ca_topic_score_gemma":0.000035381647,"teacher_disagreement_score":0.081706844,"about_ca_system_score_codex":0.0030757994,"about_ca_system_score_gemma":0.0030617702,"threshold_uncertainty_score":0.80431086},"labels":[],"label_agreement":null},{"id":"W2497213588","doi":"10.1002/ijc.30272","title":"Night shift work and chronic lymphocytic leukemia in the MCC‐Spain case–control study","year":2016,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; World Health Organization","keywords":"Chronic lymphocytic leukemia; Medicine; Odds ratio; Confidence interval; Shift work; Confounding; Case-control study; Internal medicine; Circadian rhythm; Etiology; Population; Logistic regression; Leukemia; Demography; Environmental health","score_opus":0.015806281020072015,"score_gpt":0.33917950229907606,"score_spread":0.32337322127900403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2497213588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986506,0.0039903824,0.00026428726,0.0048179515,0.0004916399,0.00035357062,0.000010702744,0.000006350533,0.00020002676],"genre_scores_gemma":[0.9973935,0.00041852795,0.000017409564,0.00062564464,0.0012369103,0.00003003873,2.2280773e-7,0.00001731059,0.0002604523],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978029,0.00018795572,0.00051637186,0.00017332281,0.0010623047,0.0002571183],"domain_scores_gemma":[0.9984589,0.0007260818,0.00021361193,0.00019475672,0.00028989973,0.00011675378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012361931,0.00013841735,0.0002856876,0.0002586609,0.000035729085,0.00005533401,0.00037860393,0.000060299906,0.0004125409],"category_scores_gemma":[0.0002747044,0.00006874239,0.00009646769,0.00017026435,0.00012427542,0.00016991554,0.00005679478,0.00024955938,0.000010865232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014107657,0.0005528231,0.2993858,0.0001441416,0.005981201,0.16467272,0.011035315,0.003459601,0.0014299211,0.0011787459,0.0065418887,0.49151018],"study_design_scores_gemma":[0.39707687,0.0041113254,0.48984274,0.004461476,0.0012182739,0.05503417,0.0023401396,0.0065840394,0.00096962566,0.0015042428,0.036000486,0.00085659407],"about_ca_topic_score_codex":0.00078473566,"about_ca_topic_score_gemma":0.0011409028,"teacher_disagreement_score":0.4906536,"about_ca_system_score_codex":0.07712482,"about_ca_system_score_gemma":0.016574163,"threshold_uncertainty_score":0.989001},"labels":[],"label_agreement":null},{"id":"W2498089677","doi":"10.2147/blctt.s84157","title":"Waldenstr&amp;ouml;m macroglobulinemia: biology, genetics, and therapy","year":2016,"lang":"en","type":"review","venue":"Blood and Lymphatic Cancer Targets and Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Stephen's University","funders":"","keywords":"Ibrutinib; Waldenstrom macroglobulinemia; Bruton's tyrosine kinase; Medicine; Lymphoplasmacytic Lymphoma; Rituximab; Oncology; Lymphoma; Macroglobulinemia; CXCR4; Internal medicine; Germline mutation; Cancer research; Immunology; Leukemia; Chronic lymphocytic leukemia; Biology; Mutation; Tyrosine kinase; Genetics; Multiple myeloma; Receptor","score_opus":0.06055768449692186,"score_gpt":0.3826594748749941,"score_spread":0.32210179037807224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498089677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059051155,0.99147236,0.000007961374,0.0003416666,0.0002599964,0.00153596,0.00020230153,0.00005372033,0.00022089346],"genre_scores_gemma":[0.00044438284,0.9958816,0.0002214901,0.0004870822,0.0010476126,0.0002842178,0.000081618084,0.000117298645,0.0014346607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99723667,0.00015097554,0.00065279636,0.000967082,0.00028067382,0.00071182987],"domain_scores_gemma":[0.9983208,0.00029888997,0.00026415943,0.00055427535,0.000111202986,0.0004506551],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033288178,0.0007422174,0.0021230162,0.00019662004,0.00018750978,0.00009292846,0.00018207791,0.00058496575,0.00046389757],"category_scores_gemma":[0.000029814231,0.00042882017,0.00023824438,0.00016858918,0.0006737959,0.000047564547,0.00013723232,0.00020974521,0.000012876995],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115816496,0.00011314933,0.0001563482,0.0033254158,0.0012353085,0.000046082954,0.00012186406,1.0076424e-8,0.000056008175,0.000088623616,0.0004938384,0.99424756],"study_design_scores_gemma":[0.018833686,0.00042451514,0.000030072159,0.004807313,0.00047818993,0.0009563044,0.000008776453,0.0000103199245,0.000047781275,0.00027666567,0.9736188,0.0005075909],"about_ca_topic_score_codex":0.0006218699,"about_ca_topic_score_gemma":0.000026844087,"teacher_disagreement_score":0.99373996,"about_ca_system_score_codex":0.00061168784,"about_ca_system_score_gemma":0.0035553619,"threshold_uncertainty_score":0.99981636},"labels":[],"label_agreement":null},{"id":"W2499987971","doi":"10.1002/cyto.b.21402","title":"Characteristics of Lymphoproliferative Disorders with More Than One Aberrant Cell Population as Detected by 10‐Color Flow Cytometry","year":2016,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Electricity Association; University of Ottawa; Ottawa Hospital; University Health Network","funders":"","keywords":"Population; Biology; B cell; Immunoglobulin light chain; Lymphoproliferative disorders; Plasma cell; Flow cytometry; Lymphocyte; Immunology; Lymphoplasmacytic Lymphoma; Cell; clone (Java method); Immunophenotyping; Chronic lymphocytic leukemia; Cytometry; Pathology; Molecular biology; Lymphoma; Bone marrow; Antibody; Leukemia; Genetics; Medicine; Waldenstrom macroglobulinemia; Gene","score_opus":0.028179272141854842,"score_gpt":0.340839079105804,"score_spread":0.3126598069639492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2499987971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103355,0.00042136808,0.0036131754,0.0008057343,0.00042858705,0.0016659248,0.00056156033,0.00028953946,0.0011805802],"genre_scores_gemma":[0.98979545,0.0009867019,0.0019817026,0.00042807596,0.0006900379,0.00014262616,0.0004699076,0.00022397,0.005281528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910599,0.000534313,0.002642521,0.001662003,0.0026233662,0.0014778816],"domain_scores_gemma":[0.9911274,0.0036729372,0.0011180347,0.0018536326,0.0009236596,0.0013043839],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021074389,0.000868862,0.0023865448,0.0016246325,0.00024586625,0.00007361036,0.0007283005,0.0010481424,0.0021122077],"category_scores_gemma":[0.0064926897,0.00059722405,0.00063732144,0.004970743,0.0013389268,0.00040479776,0.00040006376,0.0008720198,0.0007673136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01703198,0.0057429424,0.8986556,0.0013312122,0.0015780625,0.00026525583,0.00019875735,0.0000047063554,0.026632367,0.000025615664,0.0047368146,0.04379668],"study_design_scores_gemma":[0.07164285,0.011089898,0.8405865,0.0018048523,0.0012095377,0.00027973446,0.00030749824,0.0027955538,0.06341617,0.000095421165,0.0048792968,0.0018926917],"about_ca_topic_score_codex":0.00020040988,"about_ca_topic_score_gemma":0.000022504491,"teacher_disagreement_score":0.058069106,"about_ca_system_score_codex":0.004410406,"about_ca_system_score_gemma":0.003076636,"threshold_uncertainty_score":0.9996479},"labels":[],"label_agreement":null},{"id":"W2501188869","doi":"10.1182/blood.v126.23.5282.5282","title":"Ten Percent of Newly Diagnosed CLL Patients Are Treated within the First Year of Diagnosis: Results of a Canadian Retrospective Population-Based Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Population; Chronic lymphocytic leukemia; Incidence (geometry); Referral; Watchful waiting; Internal medicine; Pediatrics; Cancer; Leukemia; Family medicine; Prostate cancer","score_opus":0.025330566044579124,"score_gpt":0.2688225816794429,"score_spread":0.24349201563486378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501188869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732006,0.000055649707,7.278453e-8,0.0002695267,0.0000414052,0.0015346,0.0002467204,0.000012270142,0.0005197259],"genre_scores_gemma":[0.99964625,0.000006350225,0.000039713872,0.00003940147,0.000034301494,0.00008285525,0.000076618504,0.000023991395,0.000050527276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806285,0.00010562391,0.00054241373,0.00025680877,0.0008043172,0.00022797362],"domain_scores_gemma":[0.99785405,0.00021483094,0.00033265114,0.0006147392,0.00073402683,0.0002496791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041584944,0.0001393772,0.00042690517,0.00033027373,0.000042456184,0.0000059103213,0.00019481005,0.00008621059,0.000012002685],"category_scores_gemma":[0.0025700745,0.00009573903,0.000079030266,0.0007516547,0.000082547616,0.00003137576,0.00003871802,0.00013103607,0.000010465186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066875253,0.0028747795,0.99174047,0.00006224939,0.00018026515,0.00004958552,0.003551425,0.0000872291,0.000004335664,0.000007988551,0.000746054,0.000026876112],"study_design_scores_gemma":[0.06991179,0.001968219,0.92291033,0.00029511907,0.00026755076,0.0000014771672,0.0028767812,0.00017418191,0.0014822736,0.000011249247,0.000022282231,0.0000787174],"about_ca_topic_score_codex":0.71734494,"about_ca_topic_score_gemma":0.37217692,"teacher_disagreement_score":0.34516805,"about_ca_system_score_codex":0.0027516696,"about_ca_system_score_gemma":0.0037411898,"threshold_uncertainty_score":0.71955204},"labels":[],"label_agreement":null},{"id":"W2507008765","doi":"10.1158/1538-7445.am2016-281","title":"Abstract 281: Bendamustine has the biochemical properties of an alkylating agent that synergizes with nucleoside analogues in chronic lymphocytic leukemia","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"George & Fay Yee Centre for Healthcare Innovation; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Pentostatin; Nucleoside analogue; Bendamustine; Chlorambucil; Fludarabine; Cladribine; Medicine; Cancer research; Programmed cell death; Leukemia; Nucleoside; Pharmacology; Apoptosis; Immunology; Biology; Chemotherapy; Lymphoma; Biochemistry; Internal medicine","score_opus":0.14330996894288175,"score_gpt":0.37017232212438095,"score_spread":0.2268623531814992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507008765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150187,0.0058169723,0.0000067101564,0.0012119359,0.000040581013,0.0009568384,0.000017442393,0.000050870807,0.00039676097],"genre_scores_gemma":[0.9973822,0.0011775088,0.00006154262,0.000046770456,0.00034664726,0.000316802,0.000009150383,0.00007562649,0.0005837258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956443,0.00022122117,0.0004838983,0.0006638189,0.0018131256,0.0011736912],"domain_scores_gemma":[0.99759394,0.0005177824,0.00011615572,0.0009926773,0.00045959014,0.00031985296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017237634,0.00027018963,0.0004991844,0.00037956602,0.0002157547,0.00007546927,0.00062775303,0.000169596,0.000358492],"category_scores_gemma":[0.0005558087,0.00012823807,0.000088111345,0.0008168706,0.0021842564,0.00023406529,0.00029930577,0.0005973297,0.000038500384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002209578,0.000068711364,0.0010090567,0.0010549872,0.00015310878,0.00032009327,0.0010189454,0.0006958425,0.9765929,0.00004207747,0.00096426136,0.015870411],"study_design_scores_gemma":[0.014969887,0.0008130042,0.007560405,0.005482568,0.000042362255,0.00014044232,0.0010062555,0.0075158617,0.9610476,0.000045267407,0.0010948697,0.00028150022],"about_ca_topic_score_codex":0.020969184,"about_ca_topic_score_gemma":0.0029799168,"teacher_disagreement_score":0.037019048,"about_ca_system_score_codex":0.09192653,"about_ca_system_score_gemma":0.054907486,"threshold_uncertainty_score":0.9855503},"labels":[],"label_agreement":null},{"id":"W2507477543","doi":"10.1182/blood.v116.21.2434.2434","title":"Impact of Immunoglobulin Heavy Chain (IGH) Translocations In Chronic Lymphocytic Leukemia (CLL): Negative Effect on Patients with Isolated Deletion 13q Abnormality","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Chronic lymphocytic leukemia; Internal medicine; Chromosome abnormality; Medicine; Trisomy; IGHV@; Chromosomal translocation; Oncology; Biology; Leukemia; Karyotype; Chromosome; Genetics","score_opus":0.006105677215318659,"score_gpt":0.274013505344532,"score_spread":0.2679078281292133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507477543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973723,0.00010588192,0.0000593731,0.000021263733,0.0000619407,0.0017962191,0.000049707873,0.000070846516,0.00046244272],"genre_scores_gemma":[0.99937826,0.000023307228,0.000112934365,0.000022282824,0.000081257334,0.00011257031,0.00016768696,0.000055173357,0.000046546833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742776,0.00021352066,0.0005706504,0.0004832952,0.0006673956,0.00063735753],"domain_scores_gemma":[0.99808556,0.00041117545,0.00018427096,0.00079656066,0.000292358,0.0002300682],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054648233,0.00035740496,0.0006300882,0.00033674788,0.00009386484,0.000020383695,0.00022899217,0.00028199548,0.0001520866],"category_scores_gemma":[0.00028015958,0.00026240892,0.00020083545,0.00091255415,0.00028562747,0.00014682094,0.00003821217,0.0006826754,0.000054639913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.106999524,0.02028635,0.5022345,0.0066346466,0.007942561,0.0012959333,0.01102884,0.029531801,0.26230878,0.0006644748,0.00038696214,0.050685603],"study_design_scores_gemma":[0.21097168,0.017477194,0.67543554,0.000936899,0.00041053197,0.00019018886,0.000022821145,0.031253338,0.062737964,0.00004126152,0.0000132252135,0.0005093735],"about_ca_topic_score_codex":0.011677542,"about_ca_topic_score_gemma":0.001132568,"teacher_disagreement_score":0.19957082,"about_ca_system_score_codex":0.040406134,"about_ca_system_score_gemma":0.026130615,"threshold_uncertainty_score":0.99998283},"labels":[],"label_agreement":null},{"id":"W2507865108","doi":"10.1158/1078-0432.ccr-16-0594","title":"Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Broad Institute; National Human Genome Research Institute; Leukemia and Lymphoma Society; American Cancer Society","keywords":"Somatic cell; Chronic lymphocytic leukemia; Mutation; Somatic evolution in cancer; Biology; Germline mutation; Genetics; Survival analysis; Cancer research; Cancer; Oncology; Leukemia; Internal medicine; Medicine; Gene","score_opus":0.45392629328106837,"score_gpt":0.5684538915852584,"score_spread":0.11452759830419001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507865108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348646,0.00037391778,0.000095237505,0.003193889,0.00014521409,0.0005752778,0.000030633953,0.000023898063,0.0020754666],"genre_scores_gemma":[0.997221,0.0009831514,0.00021068144,0.00009723462,0.0003568325,0.000059104805,0.0000056835697,0.00003109765,0.0010352278],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963371,0.00067438866,0.0006811288,0.00049611204,0.0012512992,0.0005599513],"domain_scores_gemma":[0.99397236,0.004437952,0.000092922455,0.00058699184,0.0005044485,0.0004053447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004503364,0.00012353288,0.0005059444,0.00019972348,0.00009346424,0.000016955137,0.0002331207,0.00017192197,0.00066718576],"category_scores_gemma":[0.0029944794,0.00007863165,0.00011146387,0.00029325424,0.001516903,0.00005825565,0.00025581784,0.00051684945,0.00017996806],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02164248,0.0023144698,0.31494564,0.0030181136,0.000756566,0.00081515545,0.0007813133,0.000014236452,0.040099327,0.018158246,0.008706425,0.58874804],"study_design_scores_gemma":[0.07761423,0.0066984496,0.8692829,0.0020429476,0.00012211583,0.00012356264,0.0003636629,0.0056807115,0.015568418,0.01770152,0.0043211645,0.00048032025],"about_ca_topic_score_codex":0.0011525697,"about_ca_topic_score_gemma":0.0005228013,"teacher_disagreement_score":0.5882677,"about_ca_system_score_codex":0.0036199656,"about_ca_system_score_gemma":0.0064223106,"threshold_uncertainty_score":0.99921036},"labels":[],"label_agreement":null},{"id":"W2510150379","doi":"10.1158/1078-0432.ccr-15-2899","title":"IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Nephelometry; Immunoglobulin M; Serum protein electrophoresis; Waldenstrom macroglobulinemia; Medicine; Immunology; Antibody; Immunoglobulin G; Monoclonal; Monoclonal antibody; Lymphoma","score_opus":0.29176124911133,"score_gpt":0.5591102016073598,"score_spread":0.2673489524960298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510150379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903597,0.0005427241,0.0004624481,0.0052410234,0.00014948449,0.0024467222,0.00008221222,0.00001543591,0.00070019835],"genre_scores_gemma":[0.9965685,0.00085620006,0.0007000197,0.00011488463,0.00026254848,0.00042308547,0.0000055187097,0.000034780773,0.0010344686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609584,0.0002710579,0.0005488452,0.00050027267,0.0019455688,0.0006384162],"domain_scores_gemma":[0.993225,0.0039517293,0.00010775214,0.000681731,0.001714223,0.00031961538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004204621,0.0001363939,0.00041319474,0.00008411187,0.00016805784,0.000024434694,0.00032364187,0.00013549151,0.000292835],"category_scores_gemma":[0.0018118868,0.00005970823,0.00010511774,0.00027507107,0.001390826,0.00006155528,0.00027029458,0.00042285802,0.000008507337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041343025,0.00046549403,0.83915114,0.00036662276,0.000420669,0.000013414554,0.000037783877,0.000001444936,0.00033697565,0.00021062794,0.007853802,0.14700772],"study_design_scores_gemma":[0.053318564,0.0031308827,0.9225746,0.00081242237,0.0001503524,0.0000070008487,0.000059020465,0.0006601499,0.0014368776,0.00023968349,0.017436882,0.0001735589],"about_ca_topic_score_codex":0.00030921857,"about_ca_topic_score_gemma":0.00013692859,"teacher_disagreement_score":0.14683416,"about_ca_system_score_codex":0.0034373703,"about_ca_system_score_gemma":0.0074870074,"threshold_uncertainty_score":0.9981396},"labels":[],"label_agreement":null},{"id":"W2510710599","doi":"10.1182/blood-2015-12-687814","title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Venetoclax; Cancer research; Medicine; Chronic lymphocytic leukemia; Leukemia; Internal medicine","score_opus":0.03884744232875944,"score_gpt":0.26862778532933745,"score_spread":0.229780343000578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510710599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99715513,0.0008509415,0.00003996692,0.00048428008,0.00021516287,0.00052655075,0.000017421913,0.00009001868,0.00062054285],"genre_scores_gemma":[0.99195033,0.00015646106,0.0005408424,0.00008910076,0.00022380966,0.000050201892,0.000008896911,0.000048466878,0.006931916],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776083,0.00009182481,0.00036867472,0.00048433934,0.0006849244,0.00060939946],"domain_scores_gemma":[0.99868065,0.0002901928,0.00010793631,0.00061429956,0.00009525879,0.00021166935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038320606,0.00021881283,0.0003920624,0.00024453914,0.000059890634,0.000037978712,0.00020208948,0.00015947422,0.00012949682],"category_scores_gemma":[0.00026048542,0.00015517951,0.00010723688,0.00033245547,0.00014990254,0.00021488704,0.0001548533,0.00022616205,0.00011077205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008125686,0.0003462724,0.0038489248,0.0002078112,0.0001263888,0.0012572438,0.0002569019,0.0000036295096,0.9903746,0.00012674657,0.0014582801,0.0011806177],"study_design_scores_gemma":[0.03842214,0.00008440885,0.013689481,0.0015017063,0.00005751255,0.000028434117,0.00010970786,0.000010416511,0.94415444,0.00014540914,0.001590916,0.00020542392],"about_ca_topic_score_codex":0.0014022578,"about_ca_topic_score_gemma":0.00050793187,"teacher_disagreement_score":0.046220172,"about_ca_system_score_codex":0.004891433,"about_ca_system_score_gemma":0.0015225,"threshold_uncertainty_score":0.9989286},"labels":[],"label_agreement":null},{"id":"W2511310313","doi":"10.1182/blood.v112.11.3179.3179","title":"Richter Transformation of Chronic Lymphocytic Leukemia: Incidence, Risk Factors and Outcome","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; St. Paul's Hospital; University of British Columbia Hospital","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Cytopenia; Internal medicine; Univariate analysis; Gastroenterology; Incidence (geometry); Lymph node; Stage (stratigraphy); Leukemia; Surgery; Multivariate analysis; Bone marrow","score_opus":0.024770050498074774,"score_gpt":0.28002272916793164,"score_spread":0.25525267866985685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511310313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967937,0.0010311104,0.0001340126,0.000016391956,0.000051618328,0.0004116199,0.000014896458,0.000060157585,0.0014865332],"genre_scores_gemma":[0.99830484,0.0011303794,0.00015672202,0.000028799393,0.00008624209,0.000014072686,0.000015788273,0.000024532816,0.00023864664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833286,0.00004881702,0.00048796533,0.00024208387,0.00054192176,0.00034632965],"domain_scores_gemma":[0.9990816,0.00017422947,0.00012681122,0.00034916983,0.000083728926,0.00018442883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022817081,0.00018701126,0.0004333279,0.00019475492,0.00010552257,0.000007733197,0.00011125676,0.00015965066,0.00007480536],"category_scores_gemma":[0.00018983205,0.0001415667,0.000113389535,0.00028590282,0.00021188123,0.00017723003,0.00004713481,0.00022478004,0.000033298824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006308066,0.00092963036,0.96188325,0.0030355977,0.0011938489,0.0009301074,0.013412374,0.00044683315,0.011537594,0.00043153187,0.00057962764,0.0049888194],"study_design_scores_gemma":[0.18260524,0.0024781898,0.5693155,0.0004974275,0.0017795209,0.006398299,0.0005931754,0.048290018,0.18556195,0.00017347716,0.0014445967,0.0008625813],"about_ca_topic_score_codex":0.0021850422,"about_ca_topic_score_gemma":0.000049480605,"teacher_disagreement_score":0.39256772,"about_ca_system_score_codex":0.014125581,"about_ca_system_score_gemma":0.009855349,"threshold_uncertainty_score":0.9957579},"labels":[],"label_agreement":null},{"id":"W2515655827","doi":"10.1182/blood.v112.11.2399.2399","title":"Diagnostic Patterns of Care and Outcomes for Patients with Chronic Lymphocytic Leukemia in the Surveillance, Epidemiology, and End-Results (SEER)-Medicare Database","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Epidemiology; Population; Surveillance, Epidemiology, and End Results; Medical diagnosis; Diagnosis code; Logistic regression; Cancer registry; Chronic lymphocytic leukemia; Proportional hazards model; Internal medicine; Pediatrics; Emergency medicine; Leukemia; Pathology","score_opus":0.01888014995081654,"score_gpt":0.29038376065084665,"score_spread":0.2715036107000301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515655827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942663,0.0032217277,0.000019735533,0.0001238075,0.00003865637,0.0014295392,0.0008177656,0.000018920804,0.00006355682],"genre_scores_gemma":[0.99696034,0.0016585955,0.00024154478,0.00018697277,0.00007845478,0.000162123,0.000661431,0.000027133918,0.000023372844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796396,0.0001822425,0.0005029347,0.0004632949,0.00038298377,0.0005046064],"domain_scores_gemma":[0.991918,0.0070286677,0.00014951151,0.00058864383,0.00015252146,0.00016263711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063807255,0.00022843105,0.00066607003,0.000120076744,0.000090815396,0.000005181876,0.00018047375,0.00011754592,0.000006184434],"category_scores_gemma":[0.004868529,0.00013564689,0.00005713535,0.00015417275,0.00042347773,0.000059158807,0.000118922704,0.00018365985,0.0000013392333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00038411823,0.00011002704,0.9954066,0.0011418579,0.00010312395,0.00014567745,0.0011257216,0.000015009588,0.000003566176,0.000019396164,0.00018865723,0.0013562413],"study_design_scores_gemma":[0.09045995,0.0014253608,0.90606946,0.00043278773,0.00012318096,0.00022037662,0.0003194212,0.00046823575,0.000059137623,0.0000062690933,0.00026475143,0.00015105077],"about_ca_topic_score_codex":0.0030831576,"about_ca_topic_score_gemma":0.0020555495,"teacher_disagreement_score":0.09007583,"about_ca_system_score_codex":0.0047120187,"about_ca_system_score_gemma":0.0067175454,"threshold_uncertainty_score":0.99910873},"labels":[],"label_agreement":null},{"id":"W2516958630","doi":"10.1016/j.cgh.2016.08.019","title":"Thalidomide in Refractory Crohn’s Disease: Risk-Benefit Ratio","year":2016,"lang":"en","type":"letter","venue":"Clinical Gastroenterology and Hepatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Thalidomide; Medicine; Infliximab; Crohn's disease; Azathioprine; Inflammatory bowel disease; Refractory (planetary science); Internal medicine; Gastroenterology; Disease; Surgery; Multiple myeloma","score_opus":0.03936071371977981,"score_gpt":0.35521864521594176,"score_spread":0.3158579314961619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516958630","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58635044,0.0009888402,0.00008430028,0.41055098,0.00093389966,0.0006247845,0.00011626796,0.000059053353,0.00029140126],"genre_scores_gemma":[0.24634902,0.007895521,0.00013544456,0.73485035,0.005677114,0.0002081605,0.00032479857,0.00011603942,0.0044435603],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939421,0.0013368679,0.0015686287,0.0014399197,0.00031419977,0.0013982828],"domain_scores_gemma":[0.9952439,0.0025109549,0.00051709433,0.0011199607,0.00012223815,0.00048582687],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0011871161,0.0005225598,0.0020175332,0.00037430684,0.000083865714,0.00001632982,0.0003723956,0.0024098505,0.00068049127],"category_scores_gemma":[0.0012881188,0.00039423286,0.00041207395,0.00006776005,0.0019793941,0.00006629929,0.00040685904,0.0049764635,0.00028613192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059422865,0.00013447551,0.58864594,0.00021598168,0.00024395394,0.020075595,0.000011518637,1.794691e-7,0.0000010617465,0.000036000714,0.38309088,0.0016021109],"study_design_scores_gemma":[0.032374255,0.001798428,0.3862144,0.00034785876,0.00047459625,0.0014293118,0.0000056373824,0.00042737904,0.0000011084254,0.001375462,0.57525766,0.00029389746],"about_ca_topic_score_codex":0.00020967357,"about_ca_topic_score_gemma":0.00045377843,"teacher_disagreement_score":0.34000143,"about_ca_system_score_codex":0.001975046,"about_ca_system_score_gemma":0.0027673782,"threshold_uncertainty_score":0.9998509},"labels":[],"label_agreement":null},{"id":"W2517685568","doi":"","title":"Differentiating Chronic Lymphocytic Leukemia from Small Lymphocytic Lymphoma: A Manitoba Cancer Registry Perspective.","year":2016,"lang":"en","type":"article","venue":"PubMed","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Lymphocytosis; Lymphoma; Cancer; Leukemia; Cancer registry; Disease; Oncology; Internal medicine","score_opus":0.035419835417053215,"score_gpt":0.2637740556314997,"score_spread":0.22835422021444648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517685568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98241466,0.0074863373,0.00039234236,0.00070026837,0.000869734,0.0021184965,0.0001248529,0.0005440165,0.005349291],"genre_scores_gemma":[0.982732,0.0013723818,0.00015670154,0.00043613638,0.0024656393,0.004007229,0.000031997068,0.00020537456,0.008592535],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99412704,0.00018040213,0.0008125001,0.0015458625,0.0011776389,0.0021565522],"domain_scores_gemma":[0.99577427,0.0007363167,0.000373213,0.0017104248,0.00042479415,0.000980953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044429055,0.0007077672,0.001004352,0.000332683,0.00026320224,0.00014482596,0.0007603203,0.00044647814,0.0004993296],"category_scores_gemma":[0.001220033,0.00050884293,0.0004287421,0.0006053047,0.0005243491,0.0002601605,0.00048117162,0.00023951643,0.00037946613],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037294184,0.0003412295,0.014316225,0.0012530844,0.003385327,0.0030720318,0.0011517301,0.00015418507,0.011182852,0.001521794,0.007849517,0.9520426],"study_design_scores_gemma":[0.30610028,0.00048965577,0.56539947,0.0035550478,0.0025705993,0.0023162733,0.0024474435,0.028859356,0.06442405,0.0035829593,0.016426813,0.0038280652],"about_ca_topic_score_codex":0.06047032,"about_ca_topic_score_gemma":0.004726662,"teacher_disagreement_score":0.94821453,"about_ca_system_score_codex":0.6362115,"about_ca_system_score_gemma":0.061762884,"threshold_uncertainty_score":0.9997363},"labels":[],"label_agreement":null},{"id":"W2518387705","doi":"10.1182/blood.v126.23.496.496","title":"Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Open label; Off-label use; Internal medicine; Phases of clinical research; Phase (matter); Oncology; Randomized controlled trial; Clinical trial; Leukemia; Chronic lymphocytic leukemia; Chemistry","score_opus":0.032577453587854424,"score_gpt":0.34248132132296,"score_spread":0.3099038677351056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518387705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879343,0.00037575548,0.000009079761,0.00014302031,0.000024878922,0.011001633,0.00025340205,0.0000109817265,0.00024697458],"genre_scores_gemma":[0.9992912,0.000084649495,0.00023785477,0.000039499795,0.00002641244,0.00017121354,0.000088730456,0.000029026862,0.00003142726],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99649024,0.0005523478,0.0011800844,0.00054306525,0.00085735356,0.0003769237],"domain_scores_gemma":[0.99680096,0.0014576941,0.00048961386,0.0005146475,0.00038912374,0.00034799136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020112721,0.00030093864,0.0014708914,0.00014892772,0.0001053493,0.00003331398,0.00024459613,0.00010613887,0.000008081411],"category_scores_gemma":[0.0024931685,0.00016190516,0.000032114815,0.0005518031,0.0013671771,0.000118619224,0.00038229898,0.00034608663,1.8806325e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98405486,0.0032501272,0.0052095326,0.00027886662,0.00042155737,0.000047801823,0.0059198253,0.00003402807,0.00008419801,0.000063529296,0.00003894674,0.00059671106],"study_design_scores_gemma":[0.9788384,0.0051032817,0.006658165,0.0023301155,0.00054730446,0.00006877567,0.0005343199,0.0051875785,0.000518022,0.000012374615,0.000031025214,0.00017063199],"about_ca_topic_score_codex":0.003368119,"about_ca_topic_score_gemma":0.0014362128,"teacher_disagreement_score":0.011356911,"about_ca_system_score_codex":0.0018503449,"about_ca_system_score_gemma":0.0056378995,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W2518479252","doi":"10.1182/blood.v124.21.1949.1949","title":"Soluble CD23 (sCD23): A Forgotten Indicator of Prognosis and Identifier of Outcome in Patients with Chronic Lymphocytic Leukemia Utilizing a Novel Cba Approach","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"CD23; Immunoglobulin E; CD38; Chronic lymphocytic leukemia; Immunology; Antibody; Molecular biology; Immunoassay; Medicine; Leukemia; Biology; Gastroenterology; Internal medicine","score_opus":0.01896315766870237,"score_gpt":0.26026357011270096,"score_spread":0.24130041244399858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518479252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975952,0.0002861085,0.00012752408,0.000011017782,0.000031624768,0.0011612055,0.000010369232,0.000029088274,0.00074784213],"genre_scores_gemma":[0.997673,0.000016064943,0.0019220713,0.000030135932,0.000043133696,0.000105434134,0.000029220388,0.000054111762,0.00012685485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738294,0.000049705326,0.00070743484,0.0005033812,0.0008097799,0.00054675475],"domain_scores_gemma":[0.998665,0.0001356846,0.00029487038,0.00056202203,0.00014938819,0.00019308862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005896025,0.00024476284,0.00075539376,0.00038870616,0.000041421157,0.00001771275,0.00023259928,0.0001787315,0.000018436227],"category_scores_gemma":[0.00025188044,0.00019230002,0.000086523825,0.0004985561,0.00031961157,0.00013094173,0.00021327441,0.00021725518,0.0000052215914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005722915,0.0014678079,0.98976415,0.0036622782,0.00034378865,0.000008129136,0.0006395014,0.000039545677,0.0019845509,0.00016668682,0.000037267528,0.0013139958],"study_design_scores_gemma":[0.2364304,0.0022713912,0.70533836,0.0012768451,0.0007285422,0.00009204438,0.00022245412,0.026268864,0.026700512,0.000033763936,0.00012610643,0.00051072123],"about_ca_topic_score_codex":0.0011441696,"about_ca_topic_score_gemma":0.000058891354,"teacher_disagreement_score":0.2844258,"about_ca_system_score_codex":0.007544125,"about_ca_system_score_gemma":0.0062950836,"threshold_uncertainty_score":0.9993383},"labels":[],"label_agreement":null},{"id":"W2519484468","doi":"10.1182/blood.v126.23.2938.2938","title":"Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Bendamustine; Chronic lymphocytic leukemia; Ibrutinib; Rituximab; Medicine; Ofatumumab; Internal medicine; Lymphoma; Placebo; Oncology; Leukemia; Immunology; Pathology","score_opus":0.05272534709758657,"score_gpt":0.31698921871421276,"score_spread":0.2642638716166262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519484468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98733723,0.0030085654,0.00060842244,0.00017972008,0.00022996974,0.0070153424,0.00050178665,0.00038345033,0.00073548424],"genre_scores_gemma":[0.9906872,0.00020355417,0.004005948,0.00020107823,0.00046311956,0.0009948387,0.00040731026,0.00034553467,0.0026914398],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894129,0.000621045,0.0031093773,0.00191182,0.002528363,0.0024165097],"domain_scores_gemma":[0.9896516,0.0022397237,0.0016282409,0.0028672619,0.0022073623,0.0014057669],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004573889,0.0013461905,0.0037117172,0.0008395897,0.00023220293,0.00008588368,0.0011711853,0.00074908073,0.00011771501],"category_scores_gemma":[0.003781248,0.001152057,0.00075581926,0.0014946955,0.0011323986,0.00028033202,0.0006058954,0.00037881377,0.00007059878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.80820274,0.0113076065,0.0010441764,0.032283954,0.007557689,0.00215426,0.0078080553,0.010338955,0.09831596,0.00084875955,0.003099277,0.017038537],"study_design_scores_gemma":[0.72843444,0.01627235,0.00091931043,0.0022508653,0.0029577888,0.0016704818,0.0011389091,0.05527047,0.18830898,0.000064368636,0.001303737,0.0014082771],"about_ca_topic_score_codex":0.009825507,"about_ca_topic_score_gemma":0.00086739653,"teacher_disagreement_score":0.08999302,"about_ca_system_score_codex":0.1646947,"about_ca_system_score_gemma":0.21908736,"threshold_uncertainty_score":0.9999289},"labels":[],"label_agreement":null},{"id":"W2520825437","doi":"10.1182/blood.v120.21.2895.2895","title":"An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Dexamethasone; Internal medicine; Multiple myeloma; Thalidomide; Dosing; Gastroenterology; Tumor lysis syndrome; Oncology; Pharmacology; Surgery; Chemotherapy","score_opus":0.03143025138109407,"score_gpt":0.3372177764847709,"score_spread":0.30578752510367685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520825437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404716,0.0003280951,0.000011746176,0.000014690116,0.000019665978,0.005365211,0.0000050781973,0.000031580832,0.00017674103],"genre_scores_gemma":[0.99901533,0.000017965902,0.00029046417,0.000058248745,0.00003295676,0.00042042314,0.000073433286,0.000059592003,0.000031559313],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965632,0.0005998342,0.00060020975,0.00041492315,0.0010875541,0.0007342771],"domain_scores_gemma":[0.9981191,0.00029723177,0.00024172143,0.00096460956,0.00018071375,0.00019661791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014583126,0.00031142306,0.00069941976,0.00031730576,0.00006611873,0.000066228575,0.00064885203,0.00010201575,0.00003266467],"category_scores_gemma":[0.00014415348,0.00018597623,0.000018608205,0.0011762644,0.00015584403,0.0005603706,0.00012608996,0.00028329372,0.00001231208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011863643,0.14709799,0.8043319,0.001285679,0.0008936596,0.00057494367,0.023207702,0.0005492682,0.00076037005,0.00012873749,0.000053005624,0.009253097],"study_design_scores_gemma":[0.8278512,0.03065464,0.1262545,0.001008787,0.00079218106,0.00021850318,0.0017942874,0.009629789,0.001427733,0.000013970049,0.000007621746,0.00034680843],"about_ca_topic_score_codex":0.009116783,"about_ca_topic_score_gemma":0.0031981273,"teacher_disagreement_score":0.8159875,"about_ca_system_score_codex":0.020805582,"about_ca_system_score_gemma":0.009105155,"threshold_uncertainty_score":0.9974816},"labels":[],"label_agreement":null},{"id":"W2523420660","doi":"","title":"Psychological Distress and Symptom Burden: Vulnerabilities in Chronic Lymphocytic Leukemia Patients","year":2013,"lang":"en","type":"article","venue":"OhioLink ETD Center (Ohio Library and Information Network)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Chronic lymphocytic leukemia; Distress; Medicine; Psychological distress; Leukemia; Intensive care medicine; Clinical psychology; Psychiatry; Internal medicine; Anxiety","score_opus":0.009266174559714919,"score_gpt":0.2382174826117815,"score_spread":0.22895130805206657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523420660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8280072,0.00064480107,0.0000258277,0.00037816635,0.00020651342,0.0010130005,0.000028503115,0.00013164134,0.1695643],"genre_scores_gemma":[0.9938243,0.002372774,0.00017579044,0.0017097049,0.0004512265,0.00012587849,0.0007306754,0.000022182969,0.00058747036],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99790865,0.00010592759,0.0007025075,0.00030683773,0.0003125145,0.00066355965],"domain_scores_gemma":[0.99896723,0.00017209836,0.00012921411,0.0003531247,0.000044543154,0.00033380615],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013224763,0.00028369474,0.00039086855,0.00017417464,0.00012847959,0.00024269587,0.00016526914,0.00025085834,0.00092605635],"category_scores_gemma":[0.000038033588,0.00022558836,0.0000642347,0.00030814897,0.00025435557,0.005366542,0.00027660467,0.0003831874,0.00010021353],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00420156,0.0005028434,0.072496705,0.0071020527,0.00048814938,0.00012274331,0.006763935,0.01560763,0.000056100806,0.3674508,0.10063322,0.42457426],"study_design_scores_gemma":[0.06879468,0.0019028167,0.25935978,0.0022026428,0.000056872872,0.0003595657,0.00015349787,0.47603053,0.00010140941,0.0023517404,0.18751436,0.0011721088],"about_ca_topic_score_codex":0.0000061820588,"about_ca_topic_score_gemma":0.0000014797494,"teacher_disagreement_score":0.4604229,"about_ca_system_score_codex":0.0038693908,"about_ca_system_score_gemma":0.0010096029,"threshold_uncertainty_score":0.99998724},"labels":[],"label_agreement":null},{"id":"W2523424222","doi":"10.1016/j.leukres.2016.09.016","title":"Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia","year":2016,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Manitoba Beekeepers' Association; University of Winnipeg; George & Fay Yee Centre for Healthcare Innovation; University of Manitoba; Research Institute in Oncology and Hematology","funders":"Canadian Institutes of Health Research","keywords":"Bendamustine; Chronic lymphocytic leukemia; Chlorambucil; Pentostatin; Fludarabine; Cladribine; Nucleoside analogue; Nucleoside; Deoxyadenosine; Cytotoxicity; Cytotoxic T cell; Medicine; Cancer research; Leukemia; Cross-resistance; Pharmacology; Biology; In vitro; Immunology; Chemotherapy; Virology; Lymphoma; Biochemistry; Internal medicine; Adenosine","score_opus":0.035868452944270934,"score_gpt":0.3611571789687671,"score_spread":0.32528872602449616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523424222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97962886,0.002722051,0.000092525486,0.0006534883,0.00005614809,0.001065085,0.00001920332,0.00014915205,0.015613509],"genre_scores_gemma":[0.9505287,0.001368712,0.00040608723,0.000103847735,0.00040838393,0.00028513957,0.000013759326,0.0001327923,0.046752594],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992892,0.00032726573,0.00067749096,0.0013916324,0.0023952606,0.002316324],"domain_scores_gemma":[0.9953606,0.0016609299,0.000068354566,0.0014355207,0.0006746706,0.00079993694],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023950876,0.00045639588,0.000750615,0.00097483204,0.00029838955,0.00016160308,0.0005761269,0.00039894014,0.0005710091],"category_scores_gemma":[0.0012202018,0.00028945427,0.00009143044,0.0018470632,0.00221858,0.00039104687,0.0005480298,0.0010008763,0.00036262788],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0644445,0.0005305767,0.06904437,0.016845684,0.0016769397,0.05662152,0.0035283205,0.0052226274,0.5019556,0.04849196,0.03239796,0.1992399],"study_design_scores_gemma":[0.41635332,0.0071446723,0.11967232,0.018485732,0.00018992512,0.006425192,0.0007020025,0.06461906,0.15793484,0.0025361937,0.20229957,0.0036371672],"about_ca_topic_score_codex":0.0050399997,"about_ca_topic_score_gemma":0.0037735675,"teacher_disagreement_score":0.35190883,"about_ca_system_score_codex":0.4057129,"about_ca_system_score_gemma":0.12351725,"threshold_uncertainty_score":0.9999558},"labels":[],"label_agreement":null},{"id":"W2523564648","doi":"10.1182/blood.v118.21.5209.5209","title":"Clinical, Phenotypic, and Genetic Characteristics of Non-CLL Type Monoclonal B Lymphocytosis (MBL)","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; University of Ottawa","funders":"","keywords":"Lymphocytosis; CD5; clone (Java method); Chronic lymphocytic leukemia; Immunophenotyping; Lymphoplasmacytic Lymphoma; IGHV@; Biology; Splenic marginal zone lymphoma; Immunology; Lymphoma; Leukemia; Waldenstrom macroglobulinemia; B cell; Flow cytometry; Genetics; Antibody","score_opus":0.05198640457573206,"score_gpt":0.3189161861868372,"score_spread":0.26692978161110514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523564648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964184,0.0006915817,0.000039267088,0.000018241175,0.0001407482,0.00027583318,0.000012026919,0.000025361613,0.002378527],"genre_scores_gemma":[0.98951304,0.0018775114,0.007868569,0.0001294804,0.00024659137,0.000009442436,0.000010182696,0.00003399196,0.00031118793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851865,0.00004440642,0.0005335414,0.00031537507,0.00028659162,0.00030142898],"domain_scores_gemma":[0.9987957,0.00013017125,0.00013379837,0.00048807135,0.00019598725,0.00025630184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022127145,0.00015003394,0.00046918148,0.00007973683,0.00003503917,0.000008030292,0.00014496208,0.00016339203,0.0002549417],"category_scores_gemma":[0.0002526769,0.00013034756,0.00008704016,0.00016478775,0.00026466334,0.000031743886,0.00014245466,0.00015058291,0.00010484595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034816014,0.0072623296,0.7863584,0.0014288462,0.0016962202,0.0013948948,0.0019488747,2.7519602e-7,0.02145988,0.0001691233,0.0013830648,0.17341648],"study_design_scores_gemma":[0.033531707,0.0014449883,0.94301665,0.0001785083,0.000685007,0.0005426942,0.00004717672,0.0011502188,0.01811141,0.00009608009,0.00095454766,0.00024103154],"about_ca_topic_score_codex":0.00027962567,"about_ca_topic_score_gemma":0.0000056172253,"teacher_disagreement_score":0.17317545,"about_ca_system_score_codex":0.0003347107,"about_ca_system_score_gemma":0.002603603,"threshold_uncertainty_score":0.53154194},"labels":[],"label_agreement":null},{"id":"W2524129486","doi":"10.1182/blood.v126.23.2936.2936","title":"Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Ibrutinib; Bendamustine; Medicine; Internal medicine; Adverse effect; Chronic lymphocytic leukemia; Placebo; Rituximab; Ofatumumab; Oncology; Clinical endpoint; Neutropenia; Phases of clinical research; Randomized controlled trial; Lymphoma; Leukemia; Clinical trial; Chemotherapy; Pathology","score_opus":0.019031699791781185,"score_gpt":0.2684478979602277,"score_spread":0.24941619816844654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524129486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934428,0.0007925731,0.00001040821,0.000013162551,0.000062101746,0.005401469,0.000011793956,0.000060443195,0.00020524902],"genre_scores_gemma":[0.9988425,0.00006857643,0.0001927616,0.000048192313,0.000049662034,0.00052241655,0.00008895827,0.00008323338,0.000103735074],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99531746,0.00034162693,0.0010272984,0.0008275328,0.0017881165,0.00069794705],"domain_scores_gemma":[0.9965525,0.00027567096,0.00051525224,0.001850065,0.0004965208,0.00030995876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037358413,0.00056558003,0.0010099598,0.00022347526,0.00013930618,0.0000113946,0.00093460636,0.00012700392,0.00001986346],"category_scores_gemma":[0.00008980253,0.00029810585,0.000103882136,0.0014764348,0.0004831694,0.00016880628,0.00043116638,0.00018517862,0.000018999917],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13960774,0.11106907,0.45013905,0.0040623443,0.0141388625,0.004603344,0.2534277,0.0090907505,0.0006527612,0.00017306222,0.00011945257,0.012915868],"study_design_scores_gemma":[0.86915946,0.017341029,0.07838605,0.0024415303,0.0022345914,0.00004485808,0.017417535,0.007457796,0.0049201497,0.0000222839,0.0000462891,0.0005284411],"about_ca_topic_score_codex":0.014236525,"about_ca_topic_score_gemma":0.0018923517,"teacher_disagreement_score":0.72955173,"about_ca_system_score_codex":0.03249916,"about_ca_system_score_gemma":0.016499816,"threshold_uncertainty_score":0.99994713},"labels":[],"label_agreement":null},{"id":"W2525803372","doi":"10.1182/blood.v104.11.1359.1359","title":"Mutator Genes UDG and AID Appear To Be Normal in Class-Switch Deficient and Clonally Homogeneous Waldenstrom’s Macroglobulinemias Having Either Germline or Hypermutated Clonotypic IgH VDJ.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Somatic hypermutation; Biology; Germline; Immunoglobulin class switching; Molecular biology; Activation-induced (cytidine) deaminase; Cytidine deaminase; Genetics; clone (Java method); Mutation; Gene rearrangement; Germline mutation; Transversion; Point mutation; IGHV@; Immunoglobulin heavy chain; Gene; B cell; Antibody; Chronic lymphocytic leukemia; Leukemia","score_opus":0.018089453760460485,"score_gpt":0.2744380265701668,"score_spread":0.2563485728097063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525803372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395525,0.0030152502,0.00005331727,0.0016296799,0.00007214098,0.00095121586,0.00004000165,0.000091479254,0.00019163209],"genre_scores_gemma":[0.9930039,0.00030027432,0.0046304082,0.00094303524,0.0001975216,0.000060815382,0.000037982158,0.00008562582,0.00074041897],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715143,0.000052008225,0.00056292454,0.00074862054,0.0006151363,0.0008698566],"domain_scores_gemma":[0.9986648,0.00010728211,0.000080210695,0.00044776982,0.00015380271,0.0005461314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032257035,0.00037079165,0.00057360047,0.00029083234,0.00012853475,0.000080731144,0.00018113593,0.00023257884,0.000100956924],"category_scores_gemma":[0.00020243888,0.00030263665,0.000073437266,0.0005077885,0.00019525328,0.00007839971,0.0002911518,0.00035947197,0.00004780526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01946487,0.014484357,0.11441954,0.0042651216,0.0020977964,0.09034298,0.016982932,0.0066007124,0.6154514,0.00083608815,0.000649336,0.11440485],"study_design_scores_gemma":[0.44063392,0.009385718,0.105279244,0.0027746814,0.0021376247,0.103778176,0.0034879777,0.013347582,0.2928861,0.00021880047,0.022092478,0.003977666],"about_ca_topic_score_codex":0.0011227945,"about_ca_topic_score_gemma":0.0012234774,"teacher_disagreement_score":0.42116907,"about_ca_system_score_codex":0.0017683839,"about_ca_system_score_gemma":0.0030395298,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W2527605644","doi":"10.1016/j.cjca.2016.07.442","title":"CARDIOVASCULAR COMPLICATIONS OF IBRUTINIB: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Internal medicine; Atrial fibrillation; Oncology; Lymphoma; Clinical trial; Tyrosine kinase; Leukemia; Receptor","score_opus":0.12250929512283112,"score_gpt":0.3705796469063888,"score_spread":0.24807035178355766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527605644","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.1937874e-7,0.9958742,0.00059829495,0.00027640068,0.000043458953,0.0015281321,0.00023777138,0.0000027617511,0.0014388439],"genre_scores_gemma":[0.00014221635,0.9991448,0.00007782646,0.00011475194,0.00013444448,0.00009168809,0.000021045562,0.000036066853,0.00023715425],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956548,0.0012889857,0.001974904,0.00030396917,0.00038464522,0.00039267418],"domain_scores_gemma":[0.9951015,0.0006705676,0.0011173696,0.0013697069,0.0008582911,0.0008825422],"candidate_categories":["metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0026514488,0.0003453386,0.02078866,0.0012323052,0.000048826383,0.000011262807,0.0004465297,0.00031388603,0.00009087365],"category_scores_gemma":[0.0014104339,0.00019055321,0.011898444,0.0007884602,0.0003974191,0.00003296673,0.000038281552,0.00041195258,0.000024012139],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[8.260747e-7,7.1310103e-7,5.452885e-7,0.48979303,0.50720346,0.0001887493,0.0000057204315,0.0000028799775,1.1062623e-8,0.00006667207,0.0010719014,0.001665506],"study_design_scores_gemma":[0.00030316392,0.00003831632,8.167224e-7,0.026128523,0.57700545,0.0064870906,0.0000028799113,3.2494927e-7,2.6972241e-8,0.0000066900006,0.389943,0.00008370344],"about_ca_topic_score_codex":0.0005453778,"about_ca_topic_score_gemma":0.00011205112,"teacher_disagreement_score":0.46366453,"about_ca_system_score_codex":0.0032815519,"about_ca_system_score_gemma":0.024729634,"threshold_uncertainty_score":0.99799716},"labels":[],"label_agreement":null},{"id":"W2527858519","doi":"10.1007/978-3-319-22584-5_15","title":"The Bing-Neel Syndrome","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Neuromyelitis optica; Waldenstrom macroglobulinemia; Lymphoplasmacytic Lymphoma; Pathology; Plasmapheresis; Magnetic resonance imaging; Cerebrospinal fluid; Hyperintensity; Radiation therapy; Macroglobulinemia; Central nervous system; Lymphoma; Multiple sclerosis; Antibody; Internal medicine; Radiology; Immunology; Multiple myeloma","score_opus":0.02381689279328262,"score_gpt":0.2802370475837155,"score_spread":0.25642015479043284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527858519","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000079458616,0.0015162075,0.000029898387,0.0020763811,0.00028599778,0.0005675848,0.000010068504,0.00011949989,0.9953149],"genre_scores_gemma":[0.0044860216,0.0013635042,0.00003869485,0.00035301966,0.00038988906,0.000017189874,0.000008423465,0.000108038286,0.99323523],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979732,0.000009424026,0.0003235517,0.00038268015,0.0008413444,0.00046980052],"domain_scores_gemma":[0.9978895,0.0005148239,0.00008283267,0.0011254817,0.00014627096,0.00024108237],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00031584417,0.00028994228,0.0004194614,0.00011438989,0.0001352665,0.000037428224,0.0003064354,0.00038052583,0.00509491],"category_scores_gemma":[0.00011514531,0.00013226633,0.00023853779,0.000022180842,0.00037604274,0.000027233447,0.00023154294,0.00042934748,0.008927903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020923374,0.000016349575,0.0000027736555,0.00024419086,0.00068193814,0.0031180368,0.000032245094,1.0902815e-7,0.000043055315,0.83381313,0.12106593,0.040773],"study_design_scores_gemma":[0.0046564783,0.00016162814,0.000006860118,0.0006433018,0.00008885626,0.0032589564,0.000005737616,0.00006269564,0.000028875633,0.00986725,0.9810084,0.00021096991],"about_ca_topic_score_codex":0.000033571665,"about_ca_topic_score_gemma":0.000014474504,"teacher_disagreement_score":0.85994244,"about_ca_system_score_codex":0.0104290135,"about_ca_system_score_gemma":0.0070947455,"threshold_uncertainty_score":0.9985341},"labels":[],"label_agreement":null},{"id":"W2529895151","doi":"10.1182/blood.v118.21.269.269","title":"Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Rituximab; Medicine; Obinutuzumab; Internal medicine; Follicular lymphoma; Clinical endpoint; Regimen; Population; CD20; Neutropenia; Phases of clinical research; Clinical trial; Oncology; Lymphoma; Surgery; Gastroenterology; Chemotherapy","score_opus":0.02219480741726867,"score_gpt":0.27055187853694834,"score_spread":0.24835707111967967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529895151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99172646,0.00007850359,0.00002589601,0.000008304746,0.00006570636,0.006683353,0.000011716668,0.000029822388,0.0013702664],"genre_scores_gemma":[0.99908096,0.0000060320135,0.00022752097,0.000022550488,0.000038270424,0.00037862745,0.000041753392,0.00005044132,0.00015384973],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99605745,0.0005295386,0.0009573181,0.00061234215,0.0013058885,0.00053745887],"domain_scores_gemma":[0.9975836,0.0002951133,0.00047910426,0.0012074889,0.00025393767,0.00018071823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011743986,0.00036841066,0.0020194508,0.00058729685,0.00012831115,0.000016195265,0.0004403154,0.00012057814,0.000064907814],"category_scores_gemma":[0.00017326826,0.00020634482,0.00032503108,0.0017734005,0.00033971446,0.000097259064,0.00031467617,0.00029543432,0.000005129028],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8707798,0.08776242,0.030006276,0.000098269156,0.0035574005,0.00014713443,0.0073517095,0.00005646429,0.000020168227,0.0000023688,0.000017421806,0.00020053393],"study_design_scores_gemma":[0.941757,0.01592141,0.02476476,0.00023607489,0.009657018,0.000008753749,0.00068169495,0.0050645107,0.0016741538,0.0000020360624,0.0000021589447,0.00023042622],"about_ca_topic_score_codex":0.0025659453,"about_ca_topic_score_gemma":0.00036756648,"teacher_disagreement_score":0.07184102,"about_ca_system_score_codex":0.00203719,"about_ca_system_score_gemma":0.0033903306,"threshold_uncertainty_score":0.84144974},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2530252650","doi":"10.1182/blood.v124.21.3344.3344","title":"Comparison of Outcomes in Chronic Lymphocytic Leukemia (CLL) with the Addition of Rituximab to Initial Treatment: A Comparative Effectiveness Analysis in the Province of British Columbia (BC), Canada","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Chemoimmunotherapy; Internal medicine; Chronic lymphocytic leukemia; Rituximab; Hazard ratio; Population; Alemtuzumab; Proportional hazards model; Cohort; Oncology; Progression-free survival; Fludarabine; Chemotherapy; Cyclophosphamide; Leukemia; Lymphoma; Confidence interval; Transplantation","score_opus":0.01773383806693,"score_gpt":0.31428806678711785,"score_spread":0.29655422872018783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530252650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997791,0.00016270584,0.000038952603,0.000026286458,0.00001174914,0.0014464846,0.00016010244,0.0000056351923,0.00035710103],"genre_scores_gemma":[0.9995865,0.000005995755,0.000040489165,0.00002452326,0.000020887954,0.0001983848,0.000056383116,0.000012410545,0.00005443012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976709,0.00052910135,0.00052120065,0.00029081432,0.0006865781,0.00030141967],"domain_scores_gemma":[0.9976558,0.0013814245,0.00024014145,0.00049628405,0.0001637911,0.00006254812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005008738,0.00014928299,0.0012482754,0.00014379802,0.0000396444,0.0000180027,0.00025746346,0.00006422005,0.000027595655],"category_scores_gemma":[0.00011233997,0.00011625874,0.000111009314,0.0011811217,0.0002624043,0.000044434848,0.00004551479,0.00013870299,8.8972e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0053551947,0.011157026,0.8790828,0.004529086,0.00932242,0.0010957861,0.01080017,0.06414063,0.0026718278,0.00012745708,0.0016681455,0.0100494595],"study_design_scores_gemma":[0.09965865,0.0041780765,0.8466304,0.00097627135,0.001997307,0.000084113824,0.0017046758,0.030441154,0.013958522,0.00001226238,0.00011209653,0.00024644294],"about_ca_topic_score_codex":0.9644217,"about_ca_topic_score_gemma":0.9954148,"teacher_disagreement_score":0.09430346,"about_ca_system_score_codex":0.024460007,"about_ca_system_score_gemma":0.027796142,"threshold_uncertainty_score":0.97928494},"labels":[],"label_agreement":null},{"id":"W2531421379","doi":"10.1182/blood.v124.21.4476.4476","title":"A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lenalidomide; Medicine; Ibrutinib; Neutropenia; Mantle cell lymphoma; Internal medicine; Febrile neutropenia; Gastroenterology; Mucositis; Rituximab; Oncology; Lymphoma; Toxicity; Multiple myeloma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.007940417553765325,"score_gpt":0.26130985553531333,"score_spread":0.253369437981548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531421379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981122,0.00011242071,0.000003596313,0.000013756625,0.000015908972,0.000834455,0.000003509829,0.000013322309,0.00089085376],"genre_scores_gemma":[0.99958545,0.000017573597,0.0001673277,0.000036942318,0.00003060939,0.000022359889,0.000007173407,0.000027263102,0.00010529143],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986136,0.00009197675,0.00029077832,0.0003344773,0.00041351022,0.00025565695],"domain_scores_gemma":[0.9990836,0.00018855608,0.000103713646,0.0003787123,0.00008657189,0.00015885162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003520915,0.00015069876,0.00039742072,0.00016138743,0.000031398802,0.0000116389165,0.000070463626,0.00007424909,0.00000924498],"category_scores_gemma":[0.00014429033,0.00011386701,0.000017793189,0.00017705424,0.00011558919,0.000065304346,0.000086207845,0.000111282905,0.000002777392],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017019827,0.11883145,0.8145925,0.0013080369,0.00044445,0.00041241158,0.008641128,0.0000025993522,0.005122888,0.000014571507,0.00022787448,0.03338229],"study_design_scores_gemma":[0.7721112,0.016750602,0.20523825,0.00022812915,0.00022995488,0.000030113057,0.0005061438,0.0004195828,0.0041275825,0.000007667956,0.00017587023,0.00017493914],"about_ca_topic_score_codex":0.00047072177,"about_ca_topic_score_gemma":0.000048627822,"teacher_disagreement_score":0.7550913,"about_ca_system_score_codex":0.00035522366,"about_ca_system_score_gemma":0.0006597101,"threshold_uncertainty_score":0.46433622},"labels":[],"label_agreement":null},{"id":"W2531664488","doi":"10.1182/blood.v120.21.718.718","title":"Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Gastroenterology; Rash; Anemia; Febrile neutropenia; Tumor lysis syndrome; Adverse effect; Rituximab; Surgery; Multiple myeloma; Toxicity; Lymphoma; Chemotherapy","score_opus":0.03407372071081178,"score_gpt":0.32033588549665765,"score_spread":0.2862621647858459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531664488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206287,0.0047592814,0.000012292159,0.000006860121,0.00014692037,0.0025100058,0.000008481005,0.000065025386,0.0004282767],"genre_scores_gemma":[0.99888605,0.00014429107,0.000054134358,0.000019480949,0.00017585901,0.00015328074,0.00002849513,0.00007719515,0.00046120334],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960789,0.0002408425,0.0011928297,0.00044245285,0.0010459065,0.0009990712],"domain_scores_gemma":[0.99769104,0.00029387703,0.00037361286,0.0010964548,0.00016270844,0.00038234037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008220349,0.00037421743,0.0011427649,0.00046824012,0.00004176421,0.000016978747,0.00037034412,0.00017601914,0.00021948678],"category_scores_gemma":[0.0003692477,0.00032291393,0.00022214989,0.0007845083,0.00017551144,0.00018113923,0.0002273009,0.00020853875,0.000059758182],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010797703,0.11331666,0.45254403,0.025231957,0.008237656,0.004603829,0.049048137,0.0006686235,0.30842456,0.00009245379,0.00049845834,0.026535923],"study_design_scores_gemma":[0.75093347,0.011198192,0.0240681,0.0037642254,0.003302536,0.0013678726,0.0011634142,0.003258553,0.20026894,0.000012209485,0.000024552159,0.00063795317],"about_ca_topic_score_codex":0.0024676954,"about_ca_topic_score_gemma":0.0005336824,"teacher_disagreement_score":0.7401357,"about_ca_system_score_codex":0.041320886,"about_ca_system_score_gemma":0.012756574,"threshold_uncertainty_score":0.9999223},"labels":[],"label_agreement":null},{"id":"W2535821575","doi":"10.1182/blood.v118.21.3100.3100","title":"Outcomes for Patients Aged 60 and Over Are Similar to Younger Patients Following Reduced-Intensity Allogeneic Stem Cell Transplant for CLL","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Hospital and Health Sciences Centre; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Hematopoietic stem cell transplantation; Pediatrics; Leukemia; Transplantation; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.03430782214299646,"score_gpt":0.27027694589054735,"score_spread":0.23596912374755089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535821575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962999,0.00007433389,0.00006600271,0.000052574982,0.0003118535,0.002800105,0.00022573264,0.00004909695,0.00012038541],"genre_scores_gemma":[0.99721247,0.000010951474,0.0011369692,0.000695396,0.00005773725,0.00021081415,0.000093693016,0.000064360866,0.0005175885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980961,0.000028287332,0.00035317644,0.0005138464,0.00043170128,0.00057689793],"domain_scores_gemma":[0.99883866,0.00015285735,0.00008782504,0.00038584997,0.00020650696,0.00032831708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023148913,0.00025741177,0.000536651,0.00011196043,0.00012382277,0.000018559458,0.00015510395,0.00015183869,0.000011822964],"category_scores_gemma":[0.00010333489,0.00020882061,0.0002608638,0.00008777561,0.000030382109,0.00009034229,0.00007070496,0.000107566,0.0000073334686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030186218,0.0040049185,0.97883284,0.0010298255,0.0007677815,0.00012701814,0.0048087235,7.7554716e-7,0.003850062,0.000005139364,0.0027248024,0.00082948257],"study_design_scores_gemma":[0.1153503,0.002054173,0.8332746,0.00029605697,0.0012411118,0.000008936057,0.00022454896,0.000116555326,0.046217587,0.000032830954,0.00069984223,0.00048347647],"about_ca_topic_score_codex":0.0000994671,"about_ca_topic_score_gemma":0.000033259294,"teacher_disagreement_score":0.14555827,"about_ca_system_score_codex":0.00073174527,"about_ca_system_score_gemma":0.00035707746,"threshold_uncertainty_score":0.8515457},"labels":[],"label_agreement":null},{"id":"W2536558537","doi":"10.1093/jnci/djw226","title":"The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study","year":2016,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Chronic lymphocytic leukemia; Dyslipidemia; Association (psychology); Medicine; Leukemia; Population; Internal medicine; Environmental health; Psychology; Obesity","score_opus":0.028307974875977172,"score_gpt":0.3379689241020102,"score_spread":0.309660949226033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536558537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938749,0.00039510126,0.0001368624,0.0036047786,0.0010400105,0.00056899834,0.000020841098,0.0000098411465,0.00034865297],"genre_scores_gemma":[0.99706167,0.00004722193,0.00007104027,0.00025077446,0.0011274101,0.000030208785,0.0000012607958,0.000016769269,0.0013936481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961559,0.00014338014,0.0006829948,0.00014256993,0.0026260584,0.0002490544],"domain_scores_gemma":[0.99591666,0.0008550273,0.0010714327,0.00022479965,0.0018391142,0.00009296746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016870229,0.00013811757,0.00032112413,0.00013779472,0.00022631603,0.000024002175,0.00039133403,0.00008835011,0.000037744932],"category_scores_gemma":[0.0021183887,0.00005601388,0.00017521958,0.00046573183,0.00012165097,0.00023025436,0.000048950336,0.00026646588,0.000004866194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008060256,0.00040474086,0.77277696,0.0003878319,0.0037789147,0.0000747349,0.0004660371,0.16593204,0.0071917106,0.0024818336,0.0222153,0.016229603],"study_design_scores_gemma":[0.10417481,0.0019803953,0.83747333,0.0027751303,0.0010655173,0.00026286521,0.00008751615,0.012775952,0.0065881587,0.00089203345,0.031522445,0.000401855],"about_ca_topic_score_codex":0.0006647861,"about_ca_topic_score_gemma":0.0021770466,"teacher_disagreement_score":0.1531561,"about_ca_system_score_codex":0.23016383,"about_ca_system_score_gemma":0.08494588,"threshold_uncertainty_score":0.92024165},"labels":[],"label_agreement":null},{"id":"W2537189179","doi":"10.1182/blood.v126.23.3935.3935","title":"Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital","funders":"","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Idelalisib; Lymphoma; Phases of clinical research; Chronic lymphocytic leukemia; Oncology; Progressive disease; Aggressive lymphoma; Clinical endpoint; Gastroenterology; Clinical trial; Ibrutinib; Rituximab; Leukemia; Disease","score_opus":0.019449860810403036,"score_gpt":0.2655987216363375,"score_spread":0.24614886082593448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537189179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975242,0.00037873705,0.0000010073471,0.000021411557,0.00006165715,0.0014025707,0.0003551519,0.000010343395,0.0002449251],"genre_scores_gemma":[0.9996542,0.000010070138,0.00010078147,0.000030031786,0.00004655267,0.000032207547,0.00005191129,0.00002973105,0.000044563887],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975698,0.000110651425,0.00055647123,0.00040434833,0.0010604066,0.00029831595],"domain_scores_gemma":[0.99815685,0.00015984412,0.00044735442,0.00071954937,0.00032288983,0.00019351605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002852447,0.0002066393,0.00050201826,0.00014475931,0.000028094399,0.000011599774,0.00022559383,0.000099183584,0.000004319225],"category_scores_gemma":[0.00035218088,0.0001311013,0.00004124695,0.00042346632,0.00019687225,0.000067613175,0.00028024212,0.00009262636,0.0000029495668],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059333067,0.296381,0.5670418,0.0006626963,0.0010246357,0.0011770895,0.05452148,0.000031720425,0.005940093,0.000006473383,0.0018281305,0.01205178],"study_design_scores_gemma":[0.7432682,0.0063276524,0.20325603,0.00072650774,0.00026745076,0.000034361663,0.0027075645,0.00023381093,0.04295518,0.000007032948,0.000052121413,0.00016409617],"about_ca_topic_score_codex":0.0054968377,"about_ca_topic_score_gemma":0.0005372885,"teacher_disagreement_score":0.6839351,"about_ca_system_score_codex":0.0010676596,"about_ca_system_score_gemma":0.0033673015,"threshold_uncertainty_score":0.83096105},"labels":[],"label_agreement":null},{"id":"W2537944738","doi":"10.1182/blood.v124.21.2549.2549","title":"Prognostic Factors and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Vs. Non-Transplant Chronic Lymphocytic Leukemia (CLL) Patients: A Comparative Analysis with the Leukemia/BMT Program of British Columbia (BC) and the BC Provincial CLL Database","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fludarabine; Chronic lymphocytic leukemia; Hematopoietic stem cell transplantation; Internal medicine; Busulfan; Transplantation; Cohort; Population; Alemtuzumab; Cyclophosphamide; Oncology; Leukemia; Chemotherapy","score_opus":0.008856801126883319,"score_gpt":0.23552950443492304,"score_spread":0.22667270330803974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537944738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440205,0.00060337025,0.00006199301,0.00003418553,0.000026163367,0.004376883,0.00032578915,0.000055116514,0.00011443554],"genre_scores_gemma":[0.99861336,0.0002712833,0.00008923508,0.000054257987,0.000037220416,0.00049628,0.00023187477,0.00004501086,0.00016145676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632514,0.00038473544,0.0007749776,0.0007942006,0.00094986253,0.00077111396],"domain_scores_gemma":[0.99741554,0.0011067407,0.00030008287,0.00073246367,0.00017362286,0.000271543],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007078052,0.00042318448,0.0015026598,0.00016574551,0.00020223418,0.00017839948,0.00039581544,0.00017620897,0.000017058452],"category_scores_gemma":[0.000037275327,0.00028939557,0.00021017747,0.0007930657,0.0012601638,0.00013452572,0.000119309676,0.0004412113,0.0000028442646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0013476919,0.0012302408,0.9834718,0.0028259256,0.0021518685,0.00025641295,0.0073757996,0.00022101548,0.0001514636,0.000014754968,0.000088825866,0.00086420466],"study_design_scores_gemma":[0.17967789,0.0039949305,0.7552583,0.0016063827,0.012652951,0.0004624711,0.0015493063,0.041697845,0.0020885442,0.000011723559,0.00010773863,0.00089187385],"about_ca_topic_score_codex":0.088884555,"about_ca_topic_score_gemma":0.17527673,"teacher_disagreement_score":0.22821346,"about_ca_system_score_codex":0.0052665006,"about_ca_system_score_gemma":0.0077828835,"threshold_uncertainty_score":0.99995583},"labels":[],"label_agreement":null},{"id":"W2539088980","doi":"10.1182/blood.v108.11.4624.4624","title":"Molecular Characterization of Clonotypic VDJ Sequences in Waldenstrom’s Macroglobulinemia Suggests Independent Transformation Events in the Development of Biclonal B Cells.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Biology; Waldenstrom macroglobulinemia; Germline; B cell; Macroglobulinemia; Molecular biology; Immunology; Antibody; Genetics; Gene; Multiple myeloma; Lymphoma","score_opus":0.009768541110468978,"score_gpt":0.2553325074792774,"score_spread":0.2455639663688084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539088980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998841,0.00005700082,0.00015393802,0.00010885025,0.000030612868,0.0005594045,0.0000088723555,0.000006279055,0.0002340737],"genre_scores_gemma":[0.9992364,0.000017274806,0.0005218267,0.000018486524,0.00001862743,0.000034236196,0.00012692488,0.0000087893195,0.000017433884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982908,0.00008059294,0.0006288193,0.00015038865,0.00063577463,0.0002136195],"domain_scores_gemma":[0.9995854,0.00003260502,0.00012447262,0.00016002417,0.000070093156,0.000027391254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049887283,0.00010647877,0.00022190045,0.00019449704,0.000016050575,0.000003999861,0.00015205715,0.00009461179,0.00001618692],"category_scores_gemma":[0.000015382926,0.00008205259,0.00004321453,0.00037302217,0.000043941553,0.00006669799,0.000020588686,0.00014116651,0.000004224627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017520481,0.0013765441,0.045714468,0.00048611872,0.000034871526,0.00007773698,0.0030135978,0.00011657685,0.9473464,0.00016603767,0.0000016177322,0.0014908448],"study_design_scores_gemma":[0.010269281,0.00006288202,0.32348636,0.00019794371,0.000024453377,0.000047011115,0.00011038939,0.0005252969,0.6651441,0.000045306617,0.000018295079,0.00006869587],"about_ca_topic_score_codex":0.0004157299,"about_ca_topic_score_gemma":0.0003280262,"teacher_disagreement_score":0.2822023,"about_ca_system_score_codex":0.0008277376,"about_ca_system_score_gemma":0.0019164231,"threshold_uncertainty_score":0.33996522},"labels":[],"label_agreement":null},{"id":"W2544390755","doi":"10.1182/blood.v124.21.3928.3928","title":"The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hypogammaglobulinemia; Medicine; Hematopoietic stem cell transplantation; Transplantation; Immunology; Univariate analysis; Internal medicine; Graft-versus-host disease; Population; Multivariate analysis; Oncology; Antibody","score_opus":0.012489935231819755,"score_gpt":0.27586789096823616,"score_spread":0.2633779557364164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544390755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766326,0.00069178996,0.00014530683,0.00018196242,0.00006907276,0.00088079803,0.00016648667,0.000045029814,0.00015628609],"genre_scores_gemma":[0.9983826,0.0008252993,0.000048467387,0.000087151166,0.000077998506,0.000102773214,0.000035648594,0.00004000416,0.00040002615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985003,0.00009039112,0.00028071812,0.00032013716,0.0003643832,0.00044407023],"domain_scores_gemma":[0.9980119,0.001328469,0.000073519645,0.00031522074,0.00005510573,0.00021580853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037245417,0.0002513687,0.00033418217,0.000064387255,0.00015125335,0.000038867103,0.00012173492,0.00012646071,0.000015989412],"category_scores_gemma":[0.000042276308,0.00013285894,0.00020508505,0.00007372745,0.000053885487,0.000040602015,0.000010301861,0.00017718355,0.000021555028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02389306,0.005489677,0.8760688,0.010984386,0.0044734483,0.00085920026,0.027419709,0.0007287563,0.028545992,0.00086145,0.0010068171,0.019668737],"study_design_scores_gemma":[0.14431193,0.004424174,0.4947496,0.00053259725,0.004576154,0.00081226235,0.0005338364,0.009534915,0.33787513,0.00028654654,0.0012934171,0.0010694423],"about_ca_topic_score_codex":0.000060016897,"about_ca_topic_score_gemma":0.000031467192,"teacher_disagreement_score":0.38131917,"about_ca_system_score_codex":0.00040244582,"about_ca_system_score_gemma":0.00043917663,"threshold_uncertainty_score":0.54178303},"labels":[],"label_agreement":null},{"id":"W2546713708","doi":"10.1182/blood.v126.23.1732.1732","title":"Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Chemoimmunotherapy; Bendamustine; Chronic lymphocytic leukemia; Population; Oncology; Clinical endpoint; Rituximab; Placebo; Randomized controlled trial; Lymphoma; Leukemia; Pathology","score_opus":0.048080154085712694,"score_gpt":0.32360163818068133,"score_spread":0.2755214840949686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546713708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892589,0.00022214233,0.00008084793,0.000050478095,0.00023047085,0.008277587,0.0017636379,0.000077318036,0.00003863913],"genre_scores_gemma":[0.9965847,0.000046135854,0.0012770649,0.000073401585,0.00027942986,0.00069387525,0.0008741712,0.0001237888,0.000047426183],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99559295,0.00021441771,0.0011292737,0.00090508384,0.0012795138,0.00087876304],"domain_scores_gemma":[0.9939211,0.0026832472,0.00075500214,0.0012183124,0.0007416364,0.00068068894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006754556,0.00064082263,0.0014196403,0.00036801724,0.00014594772,0.000065845445,0.00044119847,0.0002990826,0.000039694947],"category_scores_gemma":[0.002743566,0.00040248054,0.0003834598,0.0006746834,0.00039299644,0.00014615216,0.0001689424,0.00020205518,0.000024542007],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.950063,0.01021375,0.015840184,0.0007025079,0.004545158,0.00009792163,0.0016043324,0.0024913508,0.000261555,0.00006451262,0.0010979058,0.01301786],"study_design_scores_gemma":[0.94061345,0.03446761,0.01244787,0.00080143556,0.0025420515,0.0000433688,0.00010743736,0.004318571,0.004100666,0.0000873225,0.000036589598,0.00043364533],"about_ca_topic_score_codex":0.011481505,"about_ca_topic_score_gemma":0.00022221525,"teacher_disagreement_score":0.02425386,"about_ca_system_score_codex":0.03142699,"about_ca_system_score_gemma":0.036123894,"threshold_uncertainty_score":0.9998427},"labels":[],"label_agreement":null},{"id":"W2547445136","doi":"10.1182/blood.v112.11.933.933","title":"Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Lymphocytosis; Dasatinib; Natural killer cell; Cytotoxicity; CD16; Immunology; K562 cells; Lymphokine-activated killer cell; Lymphocyte; CD3; Cancer research; Biology; Medicine; Leukemia; Myeloid leukemia; T cell; Interleukin 21; Imatinib; Immune system; CD8; In vitro","score_opus":0.024829255352907958,"score_gpt":0.2789961110279713,"score_spread":0.2541668556750633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547445136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925632,0.003042298,0.00008331646,0.00030068844,0.00021849178,0.0024774955,0.00021040051,0.00026208244,0.0008420398],"genre_scores_gemma":[0.9889115,0.0014101033,0.00081748527,0.0012887822,0.00059992267,0.00031803153,0.0007817527,0.00018791136,0.005684529],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99607396,0.00013506174,0.0005663716,0.00085080316,0.001101991,0.001271786],"domain_scores_gemma":[0.99729794,0.00073011685,0.0002457935,0.0007489146,0.0005773768,0.00039984618],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043417586,0.0005630656,0.0009513074,0.00022421508,0.00046490697,0.00004385983,0.0003702488,0.00040059083,0.00031739168],"category_scores_gemma":[0.00039573121,0.00038742367,0.00032841615,0.000755916,0.0002942771,0.0001940523,0.00010685887,0.00050384563,0.000058584475],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11683172,0.08145025,0.028272064,0.0060955584,0.026059764,0.053186424,0.041375488,0.00029218607,0.4792198,0.000572196,0.16367783,0.002966716],"study_design_scores_gemma":[0.5087755,0.0060800086,0.009118185,0.001008421,0.0009597162,0.0027974003,0.00037471025,0.0073787537,0.45436233,0.00001748357,0.0076985657,0.0014289607],"about_ca_topic_score_codex":0.00020666387,"about_ca_topic_score_gemma":0.000060179314,"teacher_disagreement_score":0.39194372,"about_ca_system_score_codex":0.007468627,"about_ca_system_score_gemma":0.011361598,"threshold_uncertainty_score":0.9998578},"labels":[],"label_agreement":null},{"id":"W2547876185","doi":"10.1016/j.cancergen.2016.10.006","title":"Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada","year":2016,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Royal Columbian Hospital; BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"Lundbeck Canada; Roche Canada","keywords":"Fluorescence in situ hybridization; Chronic lymphocytic leukemia; Population; Cohort; Trisomy; Internal medicine; CD38; Medicine; Oncology; Leukemia; Biology; Immunology; Chromosome; Genetics","score_opus":0.005453442487723006,"score_gpt":0.23255640913756562,"score_spread":0.2271029666498426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547876185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985204,0.000314636,0.00014553448,0.000017184353,0.00004263466,0.0006276554,0.00031321196,0.000012359603,0.0000064354035],"genre_scores_gemma":[0.99913317,0.00007643084,0.000037092035,0.00006492619,0.000014671824,0.000072987474,0.00045972306,0.00003384095,0.000107130756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748576,0.00012887556,0.0005468642,0.00046833174,0.00089437113,0.00047580982],"domain_scores_gemma":[0.9987856,0.00016668612,0.00022889857,0.00029724892,0.00037913813,0.00014243311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016097826,0.00016393837,0.00051773863,0.00030237262,0.000027615128,0.000026752818,0.00014145707,0.00011943561,0.00015062373],"category_scores_gemma":[0.00024593616,0.00018117858,0.000040794894,0.0020339945,0.000099127355,0.00007060533,0.000031088948,0.00013687953,4.5443528e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005374324,0.00007650328,0.978748,0.00005975979,0.00017311057,0.00008130902,0.000048467613,0.018059626,0.000649213,1.8973412e-7,0.00009362515,0.0014727655],"study_design_scores_gemma":[0.02684804,0.0002595278,0.8569252,0.0010471549,0.00016714692,0.0000014668378,0.000010169068,0.113821596,0.00071485067,0.0000026899681,0.0000059818217,0.00019616554],"about_ca_topic_score_codex":0.97522765,"about_ca_topic_score_gemma":0.9989326,"teacher_disagreement_score":0.21108277,"about_ca_system_score_codex":0.2754982,"about_ca_system_score_gemma":0.064415425,"threshold_uncertainty_score":0.94088846},"labels":[],"label_agreement":null},{"id":"W2548051034","doi":"10.1182/blood.v104.11.4832.4832","title":"Successful Treatment of Cutaneous Chronic Lymphocytic Leukemia with a Topical Toll Receptor 7/8 Antagonist (Imiquimod).","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Imiquimod; Population; Chronic lymphocytic leukemia; Skin biopsy; Lymphoma; Pathology; Dermatology; Leukemia; Biopsy; Immunology","score_opus":0.013112132884904171,"score_gpt":0.26768396342049444,"score_spread":0.2545718305355903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548051034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944409,0.001331304,0.000063,0.00020198448,0.000081533035,0.00085676386,0.000022459295,0.00012420402,0.002877828],"genre_scores_gemma":[0.9960545,0.0006847376,0.0014071502,0.00006034238,0.00043256182,0.00008127456,0.000046823996,0.0000618702,0.0011707452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763376,0.000037746195,0.0004450055,0.0005423948,0.00066699804,0.0006740796],"domain_scores_gemma":[0.9985022,0.000103338134,0.000117836986,0.00080663135,0.00011635701,0.00035362775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006578202,0.00033671453,0.00070019177,0.000134864,0.000093250914,0.000029350307,0.00020913946,0.00019422403,0.000319898],"category_scores_gemma":[0.000038882783,0.00024151403,0.0001772423,0.00027939826,0.0003725261,0.00006765881,0.0000579844,0.0001366337,0.00015881477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.060689226,0.049270794,0.043716084,0.018187614,0.021680936,0.1234766,0.01904693,0.027186824,0.48458362,0.0148318475,0.002190512,0.13513903],"study_design_scores_gemma":[0.28323486,0.021979379,0.00060264656,0.00089719414,0.0012761676,0.019425929,0.00028013616,0.0017312691,0.66146666,0.00015265131,0.008220444,0.0007326385],"about_ca_topic_score_codex":0.0042006467,"about_ca_topic_score_gemma":0.0003697081,"teacher_disagreement_score":0.22254565,"about_ca_system_score_codex":0.09106447,"about_ca_system_score_gemma":0.050620653,"threshold_uncertainty_score":0.9848656},"labels":[],"label_agreement":null},{"id":"W2548371395","doi":"10.1182/blood.v124.21.3039.3039","title":"Transfusion History and Risk of Non-Hodgkin Lymphoma (NHL): an Interlymph Pooled Analysis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Odds ratio; Internal medicine; Confidence interval; Relative risk; Blood transfusion; Follicular lymphoma; Risk factor; Chronic lymphocytic leukemia; Confounding; Cohort; Lymphoma; Leukemia","score_opus":0.009105009205201192,"score_gpt":0.25619581730963703,"score_spread":0.24709080810443584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548371395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953186,0.0008413688,0.0011331022,0.00002874043,0.000054499706,0.00022660755,0.000007927977,0.00004190768,0.0023472682],"genre_scores_gemma":[0.99788445,0.0005127677,0.0009148355,0.000056792232,0.000109080014,0.0000131291945,0.000024095561,0.000028184173,0.00045668162],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99837214,0.00016834908,0.00034847428,0.00040230493,0.00042863213,0.0002801271],"domain_scores_gemma":[0.99869406,0.00015008418,0.00011154381,0.00065987906,0.00011634078,0.00026809884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063939753,0.00016754752,0.00055436156,0.00039981076,0.00004205024,0.000008405237,0.00015062743,0.00014108648,0.00019616945],"category_scores_gemma":[0.00015508468,0.000142574,0.00019417096,0.00035478504,0.00019039617,0.00007667694,0.0000495606,0.00009678198,0.000012162992],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035406854,0.010419883,0.20458709,0.0016757833,0.01766474,0.00037587393,0.014702021,0.000079212405,0.17248866,0.00026689994,0.0011028151,0.57309633],"study_design_scores_gemma":[0.2245321,0.0052959565,0.43652079,0.00038881274,0.040290557,0.0005451726,0.00070764095,0.20115313,0.08405358,0.00016425975,0.0054331594,0.0009148519],"about_ca_topic_score_codex":0.004826135,"about_ca_topic_score_gemma":0.00052104064,"teacher_disagreement_score":0.57218146,"about_ca_system_score_codex":0.0019860698,"about_ca_system_score_gemma":0.0012867684,"threshold_uncertainty_score":0.72957045},"labels":[],"label_agreement":null},{"id":"W2548392800","doi":"10.1097/01.cot.0000471143.28320.70","title":"3 Questions on... Why ‘Whatʼs Old Is New’ in CML with Carlo Gambacorti-Passerini, MD","year":2015,"lang":"en","type":"article","venue":"Oncology Times","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Imatinib; Bosutinib; Dasatinib; Medicine; Imatinib mesylate; Ponatinib; Oncology; Tyrosine-kinase inhibitor; Internal medicine; Myeloid leukemia; Pharmacology","score_opus":0.04563207950593276,"score_gpt":0.36023499104450213,"score_spread":0.31460291153856934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548392800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6149117,0.002311266,0.00012172898,0.039069787,0.00053419225,0.0014057213,0.000013891346,0.0002792833,0.34135243],"genre_scores_gemma":[0.7634582,0.000606818,0.006433329,0.013426164,0.0009995871,0.00023068921,0.00004477414,0.00013521586,0.2146652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998142,0.0001121964,0.00029743416,0.00043898195,0.00045158566,0.00055782456],"domain_scores_gemma":[0.9983983,0.00023564753,0.00007717655,0.0005789832,0.0001646069,0.0005452726],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034587234,0.00021440914,0.0005014258,0.00025570302,0.000041589137,0.000020190599,0.00019136941,0.0002850429,0.00087401434],"category_scores_gemma":[0.00028833206,0.00016623447,0.000059409933,0.00042352418,0.00023647591,0.000107916356,0.00009389844,0.00046445755,0.0009035005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0020058663,0.00077215227,0.008358388,0.0000495564,0.00017613808,0.002444609,0.002212068,0.00022284158,0.00028193838,0.0016483754,0.9693413,0.012486776],"study_design_scores_gemma":[0.04125817,0.007306253,0.0039286627,0.000312825,0.00014426693,0.0012895393,0.0009562824,0.0026465352,0.0019319658,0.00059976964,0.9392327,0.00039299202],"about_ca_topic_score_codex":0.005251342,"about_ca_topic_score_gemma":0.0018225856,"teacher_disagreement_score":0.14854653,"about_ca_system_score_codex":0.011863918,"about_ca_system_score_gemma":0.019642903,"threshold_uncertainty_score":0.9998744},"labels":[],"label_agreement":null},{"id":"W2549403704","doi":"10.1182/blood.v126.23.267.267","title":"Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Chemoimmunotherapy; Internal medicine; Bendamustine; Ibrutinib; Chronic lymphocytic leukemia; Placebo; Randomized controlled trial; Rituximab; Gastroenterology; Leukemia; Lymphoma","score_opus":0.03389796985584335,"score_gpt":0.27046127765652356,"score_spread":0.23656330780068022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549403704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99517703,0.00059651514,0.00003571755,0.00009055051,0.00013171951,0.0018252716,0.00007831932,0.00019981574,0.0018650814],"genre_scores_gemma":[0.9967451,0.000049632195,0.000264653,0.00008836003,0.00019793538,0.00021241808,0.00031180118,0.00015333881,0.0019767336],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955587,0.00020062886,0.0006660937,0.0010359281,0.0013805132,0.0011581788],"domain_scores_gemma":[0.99733657,0.00022214241,0.00032425014,0.0008642642,0.0004971371,0.0007556574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004893876,0.000619683,0.0009942224,0.0004771405,0.0001931882,0.00010150812,0.00028317265,0.00043545733,0.0001029882],"category_scores_gemma":[0.00053665315,0.00047662354,0.00008644772,0.0009343953,0.0006934269,0.0004318905,0.00019751157,0.000774812,0.00003607126],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03021211,0.007335663,0.8730486,0.0027413939,0.007119853,0.006585378,0.041127253,0.011046709,0.00045483574,0.0002091493,0.017167324,0.002951731],"study_design_scores_gemma":[0.7665681,0.005395601,0.18707508,0.0038860508,0.0015471955,0.00083264697,0.001516565,0.028315946,0.002897601,0.00003046162,0.00040717004,0.0015275567],"about_ca_topic_score_codex":0.005011066,"about_ca_topic_score_gemma":0.0018206188,"teacher_disagreement_score":0.736356,"about_ca_system_score_codex":0.072494954,"about_ca_system_score_gemma":0.039022326,"threshold_uncertainty_score":0.99976856},"labels":[],"label_agreement":null},{"id":"W2549408553","doi":"10.1182/blood.v106.11.979.979","title":"Establishment of a Waldenstrom’s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Waldenstrom macroglobulinemia; Biology; Bone marrow; Macroglobulinemia; CD19; CD38; Immunophenotyping; Lymphoplasmacytic Lymphoma; CD5; Pathology; B cell; CD20; Molecular biology; Immunology; Flow cytometry; Stem cell; Multiple myeloma; CD34; Medicine; Antibody; Lymphoma; Cell biology","score_opus":0.009216784020834328,"score_gpt":0.2585757654293875,"score_spread":0.24935898140855314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549408553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934935,0.00079130667,0.0000093188055,0.0009050429,0.000027279648,0.0013299164,0.000018101513,0.000029043318,0.0033964778],"genre_scores_gemma":[0.9917901,0.00011382353,0.005839203,0.000094104435,0.0002215404,0.00011636226,0.000014264027,0.00003726361,0.0017733225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975814,0.00006206373,0.0005315229,0.0005566161,0.0006678946,0.0006004849],"domain_scores_gemma":[0.9989297,0.00007512566,0.00011990127,0.00053620077,0.00016423089,0.00017488927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045314062,0.00023996766,0.00050025486,0.00034996407,0.00001984481,0.00001452398,0.00019133794,0.00010993812,0.00016657947],"category_scores_gemma":[0.000101413774,0.00019151771,0.00005976655,0.00067694444,0.00014936629,0.00010261655,0.0001206278,0.0003527901,0.000023934068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014171099,0.08974788,0.13255234,0.00644709,0.0012087609,0.009751766,0.023549763,0.005882904,0.68515015,0.00036068543,0.007009436,0.024168132],"study_design_scores_gemma":[0.087683104,0.0013499532,0.0026009055,0.0006780862,0.00014523364,0.00033559694,0.00050734915,0.0014550841,0.9026879,0.000017983626,0.0022721442,0.0002666418],"about_ca_topic_score_codex":0.0015342499,"about_ca_topic_score_gemma":0.0015633156,"teacher_disagreement_score":0.21753778,"about_ca_system_score_codex":0.0049969964,"about_ca_system_score_gemma":0.0038936017,"threshold_uncertainty_score":0.9988226},"labels":[],"label_agreement":null},{"id":"W2549513283","doi":"10.1182/blood.v124.21.1945.1945","title":"Autoimmune Cytopenia in Chronic Lymphocytic Leukemia: Effect on Outcome and Survival, a Population Based Analysis in British Columbia, Canada","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; St. Paul's Hospital; Vancouver General Hospital; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Medicine; Cytopenia; Internal medicine; Autoimmune hemolytic anemia; Gastroenterology; Population; Bone marrow; Immunology; Anemia","score_opus":0.008768652625857309,"score_gpt":0.2558261640616351,"score_spread":0.2470575114357778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549513283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985968,0.0003045525,0.0000069895696,0.000041131672,0.000066135,0.0006614555,0.000011647453,0.00003871035,0.00027257527],"genre_scores_gemma":[0.9990368,0.000016977681,0.000036803274,0.0001685769,0.000058648267,0.00007231998,0.00012241206,0.000036689264,0.0004507751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972597,0.0003347083,0.0005795563,0.0005631768,0.0006859071,0.00057696446],"domain_scores_gemma":[0.9984749,0.00064432685,0.00009555157,0.0005645177,0.000042286174,0.00017840102],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001077547,0.00018238465,0.0009320895,0.0003057154,0.000071849594,0.00011491403,0.00015530337,0.00017615789,0.0001138668],"category_scores_gemma":[0.00070171535,0.00025015324,0.00010302316,0.0012391253,0.000049467653,0.000059927082,0.00006916375,0.00032298526,0.000007045013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00007398553,0.00007671036,0.99299514,0.00036808514,0.0001580946,0.00062642863,0.000011285222,0.0025627923,0.00019406348,0.0000024422152,0.000035996854,0.0028949652],"study_design_scores_gemma":[0.049627576,0.00035993982,0.8374616,0.000256971,0.00035808183,0.000050513387,0.0000069906846,0.11151803,0.000086571206,0.0000038548587,0.00007303973,0.00019686468],"about_ca_topic_score_codex":0.994052,"about_ca_topic_score_gemma":0.99833775,"teacher_disagreement_score":0.15553358,"about_ca_system_score_codex":0.099691235,"about_ca_system_score_gemma":0.021465076,"threshold_uncertainty_score":0.99999505},"labels":[],"label_agreement":null},{"id":"W2549876270","doi":"10.1182/blood.v124.21.5399.5399","title":"Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow: Paratrabecular Involvement As an Important Distinguishing Feature","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Lymphoplasmacytic Lymphoma; Bone marrow; Waldenstrom macroglobulinemia; Pathology; Medicine; Marginal zone B-cell lymphoma; Lymphoma; Splenic marginal zone lymphoma; Macroglobulinemia; Marginal zone; Immunology; B cell; Multiple myeloma; Antibody","score_opus":0.01238119350136022,"score_gpt":0.26700206865361187,"score_spread":0.2546208751522516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549876270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99359626,0.0022052645,0.000023692895,0.001051265,0.00009231569,0.0007896903,0.000007906328,0.00007784477,0.002155751],"genre_scores_gemma":[0.99647284,0.0002246411,0.00084507745,0.001328446,0.00044259577,0.000108905115,0.00008527574,0.000065634544,0.0004265669],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963789,0.00030118224,0.0005480929,0.00076958595,0.001120392,0.00088183436],"domain_scores_gemma":[0.997981,0.00030376573,0.00016394626,0.0010376992,0.00010427195,0.00040928822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001876756,0.00040290027,0.000579226,0.00019660787,0.00021651303,0.00019676541,0.00038211382,0.00023069553,0.0000366232],"category_scores_gemma":[0.000620937,0.00029111977,0.00011648483,0.00046716136,0.0002476441,0.00016175045,0.00017689588,0.0002114475,0.000033904493],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009591828,0.03935669,0.48289075,0.0077653774,0.0027874038,0.08571064,0.036892716,0.00006679382,0.04744733,0.041543882,0.01075219,0.2351944],"study_design_scores_gemma":[0.47215807,0.005810858,0.30521116,0.0025386193,0.0023625554,0.06036606,0.008027369,0.05035153,0.021336878,0.004379015,0.06451647,0.0029414068],"about_ca_topic_score_codex":0.0022385418,"about_ca_topic_score_gemma":0.00080183765,"teacher_disagreement_score":0.46256626,"about_ca_system_score_codex":0.0023393207,"about_ca_system_score_gemma":0.0027697016,"threshold_uncertainty_score":0.9999541},"labels":[],"label_agreement":null},{"id":"W2550524043","doi":"10.1182/blood.v118.21.2859.2859","title":"Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Tolerability; Bendamustine; Regimen; Internal medicine; Chronic lymphocytic leukemia; Interim analysis; Refractory (planetary science); Tumor lysis syndrome; Neutropenia; Oncology; Clinical trial; Pharmacology; Adverse effect; Leukemia; Chemotherapy; Multiple myeloma","score_opus":0.046875741056579774,"score_gpt":0.3025787118389563,"score_spread":0.2557029707823765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550524043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951984,0.0008036809,0.000032473345,0.000062286286,0.00006892632,0.0031302508,0.000012598904,0.000057134333,0.0006341912],"genre_scores_gemma":[0.99839944,0.0003078739,0.00022458461,0.00005235764,0.00013213084,0.00014435999,0.000012727953,0.000070967195,0.0006555877],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99691755,0.00020668335,0.00095731625,0.000663153,0.0005669866,0.0006883066],"domain_scores_gemma":[0.9963036,0.0018972346,0.00037201855,0.0010616059,0.00016317607,0.00020234095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011494107,0.0003601143,0.00077167223,0.00021419719,0.0001302176,0.000024446272,0.00031313513,0.0001429019,0.00001710089],"category_scores_gemma":[0.0013444127,0.00020063424,0.00009996665,0.00037538313,0.00027040028,0.00010349808,0.00021134737,0.00037487605,0.000004415206],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.75979567,0.037071347,0.014223918,0.0065796417,0.0072836853,0.0046947147,0.10476466,0.00033299255,0.036425557,0.0005864363,0.0010795364,0.02716181],"study_design_scores_gemma":[0.86815894,0.016581027,0.06310086,0.002205731,0.001282619,0.00031180773,0.0037450786,0.006250798,0.03753533,0.00003311194,0.0002568681,0.000537836],"about_ca_topic_score_codex":0.0023614422,"about_ca_topic_score_gemma":0.0025060412,"teacher_disagreement_score":0.10836324,"about_ca_system_score_codex":0.016436609,"about_ca_system_score_gemma":0.012072114,"threshold_uncertainty_score":0.99352854},"labels":[],"label_agreement":null},{"id":"W2550586814","doi":"10.1136/annrheumdis-2016-eular.4126","title":"SAT0166 An Analysis of Laboratory Results from 2 Randomized, Double-Blind Studies of Sirukumab in Patients with Active Rheumatoid Arthritis Refractory To Disease-Modifying Anti-Rheumatic Drug Treatment","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Southlake Regional Health Center","funders":"","keywords":"Medicine; Rheumatoid arthritis; Concomitant; Methotrexate; Internal medicine; Placebo; Gastroenterology; Alanine transaminase; Refractory (planetary science); Pharmacology; Pathology","score_opus":0.05779955863381384,"score_gpt":0.3560743928772639,"score_spread":0.29827483424345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550586814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99073374,0.004104684,0.00001177384,0.00042283023,0.00005929901,0.0023159424,0.0023081352,0.000023755663,0.000019851437],"genre_scores_gemma":[0.9927955,0.00668316,0.00007903468,0.000037126058,0.000009709068,0.00019057696,0.00012900447,0.00004178312,0.000034099714],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952053,0.000688454,0.0016971051,0.00058455794,0.0013763866,0.00044820865],"domain_scores_gemma":[0.9924556,0.0032911072,0.0011675888,0.0016170605,0.0010261578,0.00044246193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007568181,0.0004144395,0.0028094521,0.00075125066,0.00007575272,0.000016004118,0.0004067815,0.00006304514,0.000056198543],"category_scores_gemma":[0.0034737643,0.00021172126,0.000560378,0.0012557907,0.0007856565,0.0003378888,0.00018208228,0.00008048201,0.000005460341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8534776,0.0074318317,0.059955716,0.0011582031,0.023934852,0.000026576607,0.012627512,0.001752933,0.00008600353,0.00009503231,0.00020331028,0.03925041],"study_design_scores_gemma":[0.66311705,0.00074161374,0.30911565,0.016338678,0.0026818975,4.071337e-7,0.0021792045,0.00081849255,0.004271537,0.00034202842,0.000006254532,0.0003872036],"about_ca_topic_score_codex":0.0023505862,"about_ca_topic_score_gemma":0.0004203636,"teacher_disagreement_score":0.24915995,"about_ca_system_score_codex":0.0013572815,"about_ca_system_score_gemma":0.0025685169,"threshold_uncertainty_score":0.86337423},"labels":[],"label_agreement":null},{"id":"W2550627817","doi":"10.1182/blood.v116.21.2278.2278","title":"Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Imatinib; CD38; Medicine; Imatinib mesylate; Internal medicine; Oncology; Cancer research; CD34; Population; Immunology; Gastroenterology; Myeloid leukemia; Stem cell; Biology; Genetics","score_opus":0.022299262848101662,"score_gpt":0.31692635000594077,"score_spread":0.2946270871578391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550627817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420696,0.0029079579,0.000057055917,0.00002986672,0.00001866866,0.0025164033,0.00022360803,0.00000784696,0.00003161881],"genre_scores_gemma":[0.9964516,0.000802411,0.0022239415,0.0000050927697,0.00001607065,0.00038190762,0.00002383408,0.00002802909,0.00006712346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984551,0.000076777345,0.0006443039,0.00034212414,0.0002276074,0.00025407906],"domain_scores_gemma":[0.998198,0.0006963937,0.00039649388,0.00032848938,0.0002636569,0.00011697842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011994371,0.00021126855,0.0005420951,0.00021925819,0.000038778107,0.000006464975,0.000090548136,0.00007937046,0.0000139652875],"category_scores_gemma":[0.00004843533,0.00016332479,0.000042769843,0.00046652817,0.0002684761,0.000058328573,0.00002973971,0.000090534886,2.2852642e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014135339,0.004716795,0.3047769,0.0009792364,0.00038057152,0.000010456165,0.014143569,0.0021023045,0.6021249,0.000021227075,0.0000018721393,0.069328606],"study_design_scores_gemma":[0.16229846,0.00426588,0.32108018,0.0010038872,0.00077169255,0.000019200363,0.0006301009,0.025680257,0.4839066,0.000043036052,0.00004171444,0.0002589933],"about_ca_topic_score_codex":0.0027721524,"about_ca_topic_score_gemma":0.0027292445,"teacher_disagreement_score":0.16088492,"about_ca_system_score_codex":0.0022491224,"about_ca_system_score_gemma":0.004022934,"threshold_uncertainty_score":0.71365124},"labels":[],"label_agreement":null},{"id":"W2550682660","doi":"10.1182/blood.v126.23.3567.3567","title":"International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Daratumumab; Dithiothreitol; Medicine; CD38; Antibody; Immunology; Chemistry; Monoclonal antibody; Biology; Biochemistry","score_opus":0.09017427219985029,"score_gpt":0.3673204824453358,"score_spread":0.2771462102454855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550682660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491137,0.000044713484,0.038110953,0.0010569047,0.000093068345,0.0009264746,0.000022216862,0.000070584945,0.0105613815],"genre_scores_gemma":[0.9049257,6.621158e-7,0.09463077,0.00015754042,0.00013441133,0.00005022822,0.000022843435,0.000019846571,0.000057996844],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979553,0.00019083804,0.0003728632,0.0003681358,0.00086694636,0.00024591543],"domain_scores_gemma":[0.9973785,0.0006767752,0.0001501575,0.0006778938,0.0009114733,0.00020517266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013186858,0.00015440986,0.00028967386,0.000120882876,0.000052209318,0.000037168113,0.0003742848,0.00006252689,0.00002934966],"category_scores_gemma":[0.0021299582,0.000096747135,0.000048087077,0.000498988,0.0001337651,0.00007179779,0.00015123177,0.00025350414,0.000015236055],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025765074,0.034946352,0.4652376,0.0031957682,0.00629811,0.001667889,0.0262884,0.01798986,0.33338174,0.0020486184,0.0064081983,0.07677241],"study_design_scores_gemma":[0.08229341,0.0043682777,0.0101767415,0.0013068927,0.00086777,0.0007399439,0.00064230204,0.06588343,0.8318692,0.00028698094,0.0011506698,0.0004143618],"about_ca_topic_score_codex":0.0006447344,"about_ca_topic_score_gemma":0.00004564055,"teacher_disagreement_score":0.49848747,"about_ca_system_score_codex":0.0008200673,"about_ca_system_score_gemma":0.0037081179,"threshold_uncertainty_score":0.6578042},"labels":[],"label_agreement":null},{"id":"W2550739463","doi":"10.1182/blood.v126.23.5268.5268","title":"The Association of Dyslipidemia with the Development of Chronic Lymphocytic Leukemia: A Population-Based Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Dyslipidemia; Chronic lymphocytic leukemia; Internal medicine; Comorbidity; Cancer registry; Population; Metabolic syndrome; Diabetes mellitus; Cohort; Cancer; Incidence (geometry); Leukemia; Obesity; Environmental health; Endocrinology","score_opus":0.022195788371205404,"score_gpt":0.28887815894833746,"score_spread":0.26668237057713207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550739463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997929,0.00031361252,0.000061024257,0.00016828776,0.000048996662,0.00097194995,0.0000018179132,0.000025278983,0.00048005662],"genre_scores_gemma":[0.9988836,0.0000016869953,0.00030933972,0.000027434198,0.000098400866,0.00009070956,0.000011200551,0.00002198449,0.0005556683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997565,0.0001708532,0.0004937283,0.00019292721,0.001271116,0.00030642856],"domain_scores_gemma":[0.99779165,0.0007663695,0.00036341036,0.00053048565,0.00044678032,0.000101284415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020550939,0.00013613807,0.00031881273,0.00006398729,0.00013306981,0.000014564084,0.00023680604,0.000083978644,0.0000071255367],"category_scores_gemma":[0.0007199693,0.00006851797,0.000053713535,0.0004083771,0.000060532766,0.000034260276,0.00006326145,0.00016203936,0.000010946522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033403833,0.0038138956,0.93949306,0.0011512319,0.004866335,0.0000736794,0.01615909,0.01283291,0.0018494974,0.00031875158,0.003365036,0.012736109],"study_design_scores_gemma":[0.3474553,0.005238434,0.5477564,0.00080602494,0.0026050578,0.000047417656,0.008418386,0.04589142,0.037471294,0.00008517572,0.0035541113,0.0006710129],"about_ca_topic_score_codex":0.00064074906,"about_ca_topic_score_gemma":0.0019708213,"teacher_disagreement_score":0.39173672,"about_ca_system_score_codex":0.059455674,"about_ca_system_score_gemma":0.06889451,"threshold_uncertainty_score":0.9441549},"labels":[],"label_agreement":null},{"id":"W2551183227","doi":"10.1182/blood.v106.11.4983.4983","title":"Clinical Progression and Outcome of Patients with Monoclonal Lymphocytosis of Undetermined Significance.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Lymphocytosis; Organomegaly; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gastroenterology; Immunophenotyping; Lymphocyte; Monoclonal; Leukocytosis; Immunology; Leukemia; Antigen; Monoclonal antibody; Polyneuropathy; Antibody","score_opus":0.029788433931925835,"score_gpt":0.35390370927618353,"score_spread":0.3241152753442577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551183227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988735,0.00017908184,0.000012729089,0.00006045831,0.000017850782,0.00045951793,0.00001503904,0.000015117949,0.00036672613],"genre_scores_gemma":[0.9943092,0.000038856753,0.0053903027,0.000036352485,0.00007160315,0.000015201101,0.000011854315,0.000017890174,0.0001087802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984606,0.000043213142,0.0005503486,0.00024053434,0.0005065892,0.00019871173],"domain_scores_gemma":[0.99900776,0.00018039242,0.00018977368,0.00029930734,0.00016923985,0.00015349982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025153108,0.000113269794,0.00043393328,0.000071508846,0.000018947136,0.000003811357,0.00008609935,0.0000959415,0.000041293326],"category_scores_gemma":[0.00014579862,0.000076236,0.000067426794,0.00013044672,0.0002870956,0.000049647766,0.00007104831,0.000093909104,0.0000036536353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011619516,0.002192229,0.96738124,0.0002863066,0.00012723594,0.0000136274375,0.000060013197,0.0000012684653,0.00037087663,0.000014293694,0.000029639332,0.028361307],"study_design_scores_gemma":[0.11497077,0.0025376803,0.84894323,0.00036458633,0.00037816988,0.000032234326,0.000025389634,0.00091285125,0.031304814,0.000009333322,0.00035851126,0.00016240818],"about_ca_topic_score_codex":0.000035123834,"about_ca_topic_score_gemma":0.000009000736,"teacher_disagreement_score":0.118438,"about_ca_system_score_codex":0.000442502,"about_ca_system_score_gemma":0.0013324535,"threshold_uncertainty_score":0.31088138},"labels":[],"label_agreement":null},{"id":"W2551184473","doi":"10.1136/annrheumdis-2016-eular.1846","title":"THU0174 A Safety Analysis of Tofacitinib 5 mg Twice Daily Administered as Monotherapy or in Combination with Background Conventional Synthetic Dmards in A Phase 3 Rheumatoid Arthritis Population","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Tofacitinib; Adverse effect; Rheumatoid arthritis; Internal medicine; Combination therapy; Methotrexate; Population; Gastroenterology","score_opus":0.04997734749271165,"score_gpt":0.3691876380807219,"score_spread":0.31921029058801026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551184473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966611,0.00061946,0.00017809293,0.0011858561,0.000027605896,0.0007986078,0.0003798987,0.000015078081,0.00013427497],"genre_scores_gemma":[0.9972508,0.0021561708,0.000063366664,0.00009791048,0.0000043036007,0.00008055112,0.00013586732,0.000023055702,0.00018794961],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972274,0.00030220658,0.0009993542,0.0003073413,0.0008664147,0.00029729045],"domain_scores_gemma":[0.9976909,0.00084799883,0.000480529,0.00061222055,0.00023452511,0.00013382817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006007638,0.00019844862,0.00084503944,0.0005599816,0.000042074436,0.000018669618,0.00023284998,0.00006921207,0.0011080387],"category_scores_gemma":[0.00084811426,0.00011237439,0.00027966595,0.0011670497,0.00027057625,0.00021114772,0.00005634592,0.00006354272,0.000005630118],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11778284,0.022316156,0.30448276,0.0038827187,0.010313452,0.0002630388,0.0037621479,0.0007834554,0.0013457235,0.011969751,0.000765666,0.5223323],"study_design_scores_gemma":[0.13638677,0.0029254672,0.80675745,0.021067249,0.0006921558,0.0001220224,0.0012700072,0.02466705,0.002070524,0.0032196157,0.0002652258,0.00055648654],"about_ca_topic_score_codex":0.0012323329,"about_ca_topic_score_gemma":0.00071538845,"teacher_disagreement_score":0.5217758,"about_ca_system_score_codex":0.0007299079,"about_ca_system_score_gemma":0.0017554687,"threshold_uncertainty_score":0.9998051},"labels":[],"label_agreement":null},{"id":"W2552111400","doi":"10.1182/blood.v124.21.2648.2648","title":"Clinical Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion in British Columbia (BC), Canada: Results of a Population-Based Cohort","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; St. Paul's Hospital; Royal Columbian Hospital; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Population; Chronic lymphocytic leukemia; Oncology; Hazard ratio; Cohort; Trisomy; Survival analysis; Leukemia; Confidence interval; Biology; Genetics","score_opus":0.010096903613272654,"score_gpt":0.2655742751269964,"score_spread":0.25547737151372374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552111400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777323,0.000035179557,0.000051402076,0.000036478195,0.00011307184,0.0016961647,0.00013244958,0.00003394483,0.0001280998],"genre_scores_gemma":[0.9976259,0.000008848985,0.00073706446,0.00017223069,0.00010847725,0.0001347166,0.000798493,0.00004739682,0.0003668805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970333,0.00012771806,0.0010083359,0.0005260839,0.0008105135,0.0004940624],"domain_scores_gemma":[0.9975922,0.0009961795,0.00027493096,0.0005551677,0.00036660317,0.00021493019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008307313,0.00015388033,0.0007280687,0.000074031064,0.00006812906,0.00003592715,0.00016688505,0.0001826153,0.00002667502],"category_scores_gemma":[0.0021618656,0.00018510717,0.00012333535,0.0002713236,0.00010172028,0.000052548505,0.000036178295,0.00017534656,0.0000022892082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00040948446,0.00031634548,0.994033,0.00031688204,0.00012531961,0.000026482652,0.0000064035753,0.00048588894,0.00000195703,0.0000022351792,0.0012431985,0.0030328268],"study_design_scores_gemma":[0.13612944,0.0008075851,0.842242,0.00040783957,0.00019280867,0.000010873305,0.0000047344506,0.019508652,0.000027008487,0.000009819472,0.00049165176,0.0001675664],"about_ca_topic_score_codex":0.97042066,"about_ca_topic_score_gemma":0.9890991,"teacher_disagreement_score":0.15179096,"about_ca_system_score_codex":0.039701477,"about_ca_system_score_gemma":0.048634075,"threshold_uncertainty_score":0.96398497},"labels":[],"label_agreement":null},{"id":"W2552124982","doi":"10.1182/blood.v114.22.2631.2631","title":"Analysis of the Serum Free Light Chain Ratio and Its Prognostic Value in a Cohort of Patients with Chronic Lymphocytic Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Internal medicine; Gastroenterology; Fludarabine; Proportional hazards model; Survival analysis; Population; Cohort; Log-rank test; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.005933703671480233,"score_gpt":0.22709867192789804,"score_spread":0.2211649682564178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552124982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726176,0.0010111963,0.000005344684,0.000104097446,0.0000149032685,0.0012337322,0.000026646841,0.000014622174,0.00032769935],"genre_scores_gemma":[0.99962795,0.000062127976,0.000036628302,0.000053660664,0.00002595794,0.00002721265,0.000016715461,0.000015784752,0.00013393597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980566,0.000092074966,0.0004417616,0.00032580437,0.0007481842,0.00033559068],"domain_scores_gemma":[0.99870235,0.00013255305,0.0001784286,0.00069096894,0.0001925957,0.000103102946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000311584,0.00017471355,0.0006156179,0.0003396071,0.00003533365,0.00000852285,0.000247245,0.00010451995,0.000024948307],"category_scores_gemma":[0.00043466096,0.000111179106,0.00010231783,0.0016530439,0.00010022474,0.00006132803,0.0001018255,0.00014519357,0.0000013618586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00039500836,0.00088741095,0.98976594,0.00054098055,0.0020347275,0.000057932197,0.00076239975,0.0028472508,0.001778097,0.0003007452,0.000031138276,0.0005983729],"study_design_scores_gemma":[0.037495676,0.0007409666,0.8889915,0.00036996117,0.0026547266,0.000014277857,0.000018172223,0.055104863,0.014459588,0.000023629553,0.000008039474,0.00011862675],"about_ca_topic_score_codex":0.00042623,"about_ca_topic_score_gemma":0.00031445984,"teacher_disagreement_score":0.10077447,"about_ca_system_score_codex":0.008602413,"about_ca_system_score_gemma":0.011030486,"threshold_uncertainty_score":0.9952034},"labels":[],"label_agreement":null},{"id":"W2552363071","doi":"10.1182/blood.v104.11.3481.3481","title":"The Effect of a Toll Receptor-7 Agonist (S28690) on the Immunogenicity of Chronic Lymphocytic Leukemia Cells.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"CD80; Chronic lymphocytic leukemia; Biology; TLR7; Immunogenicity; Molecular biology; T cell; CD40; Immunology; Toll-like receptor; Leukemia; Immune system; Cytotoxic T cell; Innate immune system; In vitro","score_opus":0.008072363663069935,"score_gpt":0.24998551979396136,"score_spread":0.24191315613089143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552363071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918244,0.0032396931,0.000006441541,0.00023219897,0.00019889371,0.0011589478,0.0000174455,0.00004392888,0.003278072],"genre_scores_gemma":[0.99828345,0.00064522744,0.00003387616,0.000055890927,0.00020089923,0.00007939278,0.000008615169,0.00004768746,0.0006449799],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99734074,0.00023382028,0.0005696096,0.00034575316,0.00091827335,0.0005918028],"domain_scores_gemma":[0.99660516,0.0014822566,0.00024400011,0.0014175881,0.00012543004,0.00012558339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011898839,0.00028582886,0.0005632063,0.000075058546,0.0002466226,0.000026748208,0.00063145376,0.00016850868,0.00009363836],"category_scores_gemma":[0.0005476368,0.00014725338,0.00037187984,0.000441682,0.0007528193,0.000033076733,0.00018519725,0.00037607536,0.00016633896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008789039,0.0012561217,0.0002947985,0.0031478566,0.0032928518,0.00028918622,0.0014630213,0.0032846194,0.9579208,0.0041960413,0.0038847183,0.012180955],"study_design_scores_gemma":[0.046584368,0.0032183263,0.00013543548,0.0004872905,0.00032323503,0.00013514541,0.00005384397,0.0005622931,0.9464676,0.00007037955,0.00182617,0.00013594232],"about_ca_topic_score_codex":0.0023762814,"about_ca_topic_score_gemma":0.00006949601,"teacher_disagreement_score":0.037795328,"about_ca_system_score_codex":0.033041887,"about_ca_system_score_gemma":0.022059154,"threshold_uncertainty_score":0.98348486},"labels":[],"label_agreement":null},{"id":"W2552407180","doi":"10.1182/blood.v114.22.3366.3366","title":"First Line Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma (MCL).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Fludarabine; Transplantation; Surgery; Salvage therapy; Chemotherapy; Mantle cell lymphoma; Autologous stem-cell transplantation; Hematopoietic stem cell transplantation; Internal medicine; Chemotherapy regimen; Stem cell; Cyclophosphamide; Busulfan; Oncology; Lymphoma","score_opus":0.014747762836063388,"score_gpt":0.25475151521269884,"score_spread":0.24000375237663546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552407180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890549,0.0017312662,0.00007310351,0.00029886945,0.000049101593,0.0004429075,0.000011025653,0.00006266292,0.00827614],"genre_scores_gemma":[0.9960199,0.0011655793,0.00029140615,0.0002623618,0.00011371737,0.000017286988,0.000048771002,0.000025970265,0.0020550208],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984658,0.000038723425,0.00031995052,0.0003396354,0.0003939281,0.00044197572],"domain_scores_gemma":[0.9993351,0.000080203,0.000050123093,0.00035470375,0.00004383794,0.00013601355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019204666,0.00017251838,0.00026908683,0.00017157603,0.00004656504,0.000017721966,0.0001482969,0.00015108417,0.00008530011],"category_scores_gemma":[0.0000065991812,0.00015781746,0.00008152358,0.0002983394,0.000031162992,0.00006076822,0.000016005868,0.00012078972,0.00022550924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009084644,0.08783281,0.027417904,0.015425585,0.00051233365,0.046966925,0.026321923,0.0032062312,0.5411193,0.00050423964,0.0040686233,0.23753951],"study_design_scores_gemma":[0.18925722,0.0013455022,0.03498889,0.00039593165,0.00035526484,0.001107886,0.00026049535,0.0036052077,0.76504946,0.00011240787,0.0030326308,0.00048908376],"about_ca_topic_score_codex":0.000250748,"about_ca_topic_score_gemma":0.00011644103,"teacher_disagreement_score":0.23705043,"about_ca_system_score_codex":0.0014284323,"about_ca_system_score_gemma":0.00129953,"threshold_uncertainty_score":0.64356095},"labels":[],"label_agreement":null},{"id":"W2554246898","doi":"10.1212/wnl.86.16_supplement.p3.035","title":"Efficacy of Cladribine Tablets in ORACLE Study Patients Who Retrospectively Met 2010 McDonald Multiple Sclerosis (MS) Criteria at Baseline (P3.035)","year":2016,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Cladribine; Multiple sclerosis; Medicine; Relapsing remitting; Internal medicine; Immunology","score_opus":0.044127061619257356,"score_gpt":0.29996881865335384,"score_spread":0.2558417570340965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554246898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964093,0.000074138065,0.000029017263,0.0014549653,0.0003419943,0.0013594648,0.00009196883,0.000050428425,0.00018873485],"genre_scores_gemma":[0.9980741,0.00007370698,0.00012421401,0.0007656128,0.00014296576,0.00007067277,0.000028633012,0.00006831964,0.0006517818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964582,0.0005431817,0.0007459014,0.000844493,0.000675891,0.000732357],"domain_scores_gemma":[0.9968394,0.0013855888,0.000205891,0.00086584315,0.00042295255,0.00028031785],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007687858,0.00028895578,0.0008379135,0.00036087024,0.00006496726,0.000007902741,0.00030943193,0.00023592488,0.0014684667],"category_scores_gemma":[0.004316009,0.00021022902,0.000101093,0.00059729203,0.0002856007,0.00011563486,0.0004902424,0.0003691117,0.0001519504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025062617,0.004655581,0.8657123,0.00007899681,0.00013337482,0.00033157683,0.0004189698,0.000013187125,0.09208279,0.000011166056,0.006749137,0.004750334],"study_design_scores_gemma":[0.08149662,0.008735713,0.8986708,0.00007983954,0.0000604463,0.000032336466,0.0000073639853,0.0017504893,0.0073399795,0.000013150878,0.0016382262,0.00017505238],"about_ca_topic_score_codex":0.0022333756,"about_ca_topic_score_gemma":0.0012131407,"teacher_disagreement_score":0.08474281,"about_ca_system_score_codex":0.0021958444,"about_ca_system_score_gemma":0.0008592989,"threshold_uncertainty_score":0.9994443},"labels":[],"label_agreement":null},{"id":"W2555162116","doi":"10.1182/blood.v106.11.4371.4371","title":"Short Nucleotide Insertions in the MCL-1 Promoter Affect Its Gene Expression.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"","keywords":"Luciferase; Transfection; Molecular biology; HeLa; Biology; Reporter gene; Plasmid; Phorbol; K562 cells; Cell culture; Gene; Gene expression; Signal transduction; Biochemistry; Protein kinase C; Genetics","score_opus":0.03127767896194254,"score_gpt":0.3132241160925438,"score_spread":0.28194643713060125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555162116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200666,0.000576097,0.000011656086,0.0019302554,0.000030181045,0.0007989455,0.0000042294237,0.00005322045,0.0045887823],"genre_scores_gemma":[0.997142,0.000063486215,0.0008303319,0.00066530006,0.00038994948,0.00013012037,0.0000125351025,0.000026582427,0.00073964975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985263,0.00010758182,0.00022155281,0.00026630316,0.00048579846,0.00039248774],"domain_scores_gemma":[0.99914455,0.0001261618,0.000018903746,0.0005472304,0.000048327416,0.00011479664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043539234,0.00013069565,0.0001822058,0.00010641208,0.00007605617,0.000026398433,0.00023608579,0.00008923,0.00018362426],"category_scores_gemma":[0.00020809735,0.00008174225,0.000078979916,0.0002703541,0.000051452702,0.000096319956,0.000084477455,0.00029344799,0.00032095],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043859213,0.012375841,0.01727893,0.0004930424,0.00028573826,0.0022437104,0.007573213,0.000107101354,0.9178309,0.00028514324,0.020928001,0.020159801],"study_design_scores_gemma":[0.029591333,0.00031974923,0.048087403,0.0003770907,0.0001785459,0.0014798904,0.00018179188,0.001991162,0.9038873,0.000041715426,0.0135665955,0.00029746353],"about_ca_topic_score_codex":0.00003348773,"about_ca_topic_score_gemma":0.000054440836,"teacher_disagreement_score":0.030808473,"about_ca_system_score_codex":0.0009560589,"about_ca_system_score_gemma":0.0009149554,"threshold_uncertainty_score":0.412527},"labels":[],"label_agreement":null},{"id":"W2555733469","doi":"10.1016/j.hoc.2016.10.001","title":"The Increasing Complexity of Aggressive B-cell Lymphoma","year":2016,"lang":"en","type":"editorial","venue":"Hematology/Oncology Clinics of North America","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Fludarabine; Ibrutinib; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Population; Stage (stratigraphy); Lymphoma; Gastroenterology; Chemotherapy; Leukemia; Cyclophosphamide","score_opus":0.027983456246659037,"score_gpt":0.36836010564705135,"score_spread":0.3403766494003923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555733469","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24246706,0.018942235,0.00024126645,0.0023772686,0.71579295,0.0037294566,0.0015652445,0.00022697671,0.01465756],"genre_scores_gemma":[0.27196568,0.07440634,0.0134343365,0.0009569174,0.6321756,0.0006215736,0.002454398,0.0007463813,0.0032387392],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99235487,0.0012727081,0.002726219,0.00097534683,0.0015057685,0.0011650951],"domain_scores_gemma":[0.9509796,0.036850657,0.0076296246,0.0019894943,0.0021468129,0.00040381408],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016542592,0.000627632,0.0038437974,0.00031500714,0.00025265216,0.000009957881,0.0013651246,0.002020298,0.00009164714],"category_scores_gemma":[0.027125822,0.00042443076,0.00074010674,0.0005007212,0.010551246,0.00005405406,0.00095808343,0.0013520366,0.00016315552],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009673689,0.0024143811,0.0043708533,0.0021641552,0.0014661137,0.0009928697,0.00020284067,0.000001099646,0.000021380929,0.00018115029,0.91159225,0.066919245],"study_design_scores_gemma":[0.031715613,0.0036323974,0.0006564209,0.0011561208,0.0009072441,0.00050974597,0.00013047861,0.00018083246,0.00026111963,0.0005967271,0.9597795,0.00047378367],"about_ca_topic_score_codex":0.00072166167,"about_ca_topic_score_gemma":0.00034343146,"teacher_disagreement_score":0.08361731,"about_ca_system_score_codex":0.0048251343,"about_ca_system_score_gemma":0.046192482,"threshold_uncertainty_score":0.99982077},"labels":[],"label_agreement":null},{"id":"W2556182164","doi":"10.1182/blood.v124.21.2226.2226","title":"Ibrutinib Sensitizes AML Cells to ROS Inducers Via a BTK-Independent Mechanism","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Mount Sinai Hospital; University of Toronto; University Health Network","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Cancer research; Tyrosine kinase; Cytotoxicity; Pharmacology; Leukemia; Cell culture; Immunology; Chronic lymphocytic leukemia; Medicine; Chemistry; Biology; Signal transduction; In vitro; Biochemistry","score_opus":0.012707387365654065,"score_gpt":0.2623440579190436,"score_spread":0.2496366705533895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556182164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986715,0.000033276403,0.0015117972,0.0008000426,0.00027957303,0.00081802503,0.0000068021336,0.00016806475,0.0065152533],"genre_scores_gemma":[0.9929877,0.000010677175,0.0021930835,0.001833595,0.0005452231,0.000040438546,0.000011331288,0.00006332502,0.0023146323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99746907,0.000100279656,0.00031177342,0.0005369761,0.00087978004,0.0007021432],"domain_scores_gemma":[0.9982784,0.00015953767,0.000060356204,0.000759931,0.00013995402,0.0006018318],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005815329,0.00023979844,0.0004129973,0.00018805289,0.00009020625,0.00004504816,0.00020834104,0.00020555113,0.00026606125],"category_scores_gemma":[0.00022072061,0.00021303628,0.00012945452,0.00027460232,0.000051453666,0.00004791747,0.00022673121,0.0003168998,0.0018176967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027364693,0.0009435962,0.00006237824,0.00022851845,0.000298823,0.0008131202,0.001055752,0.000021033065,0.9855788,0.0011221684,0.0038105869,0.0057915775],"study_design_scores_gemma":[0.028776897,0.00065651076,0.0002477307,0.000121724275,0.00020437066,0.000654951,0.00011689003,0.002180716,0.96198386,0.00047134003,0.004285198,0.00029979786],"about_ca_topic_score_codex":0.0005773689,"about_ca_topic_score_gemma":0.000040798826,"teacher_disagreement_score":0.02850325,"about_ca_system_score_codex":0.0018161007,"about_ca_system_score_gemma":0.0017332188,"threshold_uncertainty_score":0.9989595},"labels":[],"label_agreement":null},{"id":"W2556190467","doi":"10.1016/j.bcmd.2016.11.003","title":"Corrigendum to “High abundance of circulating megakaryocytic cells in chronic myeloid leukemia in Indian patients. Revisiting George Minot to re-interpret megakaryocytic maturation” [Blood Cell Mol. Dis. 60 (2016) 28–32]","year":2016,"lang":"en","type":"erratum","venue":"Blood Cells Molecules and Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"George (robot); Myeloid leukemia; Myeloid; Immunology; Medicine; Cancer research; Biology; History","score_opus":0.007288052522072548,"score_gpt":0.2374115465286298,"score_spread":0.23012349400655727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556190467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694223,0.017003063,0.00006983028,0.00017352015,0.0033872603,0.004603661,0.0018497179,0.000109611196,0.0033810348],"genre_scores_gemma":[0.98010737,0.0026515615,0.00044746036,0.0006407682,0.0012619712,0.0003323305,0.0010170406,0.00031185377,0.013229666],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99206567,0.00033622838,0.0020987818,0.0020807555,0.0015642133,0.0018543659],"domain_scores_gemma":[0.99566567,0.00037951875,0.00064613944,0.0015616514,0.00038355103,0.001363495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003999863,0.001226145,0.0021523847,0.001336042,0.00016491827,0.0001768282,0.0008102306,0.000754204,0.00016701569],"category_scores_gemma":[0.00060764264,0.0011097426,0.00041513273,0.0010994093,0.0002452639,0.00025316785,0.00085200823,0.0010482332,0.000097420256],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010973601,0.00834172,0.013289864,0.12935762,0.0029472073,0.037218336,0.013467888,0.0049324953,0.35488987,0.0002909555,0.40077737,0.023513084],"study_design_scores_gemma":[0.20515032,0.013759448,0.06002769,0.18688412,0.010723344,0.0005384759,0.0030943395,0.017984534,0.44436365,0.00064311665,0.040887937,0.015943015],"about_ca_topic_score_codex":0.003330095,"about_ca_topic_score_gemma":0.0004779365,"teacher_disagreement_score":0.35988942,"about_ca_system_score_codex":0.013524046,"about_ca_system_score_gemma":0.017020771,"threshold_uncertainty_score":0.99913526},"labels":[],"label_agreement":null},{"id":"W2556217933","doi":"10.1182/blood.v112.11.lba-1.lba-1","title":"Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Fludarabine; Medicine; Rituximab; Internal medicine; Tolerability; Clinical endpoint; Regimen; Progression-free survival; Gastroenterology; Refractory (planetary science); Cyclophosphamide; Surgery; Randomized controlled trial; Oncology; Chemotherapy; Adverse effect; Lymphoma","score_opus":0.034452724998572305,"score_gpt":0.3069382083251383,"score_spread":0.27248548332656597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556217933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99073416,0.0024683618,0.00001913351,0.0006353688,0.00038178184,0.0046010767,0.00019103201,0.00015270944,0.00081639586],"genre_scores_gemma":[0.9943024,0.0010670506,0.0009779024,0.00012965909,0.0010169597,0.00059837924,0.0007877674,0.000083845625,0.0010360209],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99423295,0.0006553192,0.0013740078,0.0010736238,0.0018911513,0.0007729639],"domain_scores_gemma":[0.9948222,0.0028259873,0.0005056559,0.0012611606,0.0002653242,0.0003196475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025088044,0.000529477,0.0016527971,0.00021016836,0.00027092238,0.00007820255,0.0007485409,0.00032146997,0.000114253504],"category_scores_gemma":[0.0035582886,0.0003093191,0.00019071977,0.00051289663,0.0010751223,0.00019582012,0.000354122,0.0008730479,0.000032554137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.98797774,0.0020658378,0.000144343,0.00006683502,0.0005858833,0.0034371985,0.001337626,0.00005405323,0.0006535739,0.000008788841,0.0021435544,0.0015245773],"study_design_scores_gemma":[0.9681836,0.002762928,0.00058537896,0.00084577844,0.00043003948,0.0010192145,0.00011699899,0.022994312,0.0016072319,0.000036734786,0.0010520709,0.00036575372],"about_ca_topic_score_codex":0.007944983,"about_ca_topic_score_gemma":0.002193616,"teacher_disagreement_score":0.022940258,"about_ca_system_score_codex":0.017019823,"about_ca_system_score_gemma":0.030963704,"threshold_uncertainty_score":0.99993587},"labels":[],"label_agreement":null},{"id":"W2556280457","doi":"10.1182/blood.v126.23.3119.3119","title":"Influence of Fludarabine Pharmacokinetics on Outcome of Allogeneic Stem Cell Transplantation with Fludarabine-Busulfan Conditioning","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fludarabine; Busulfan; Medicine; Transplantation; Total body irradiation; Pharmacokinetics; Internal medicine; Surgery; Gastroenterology; Hematopoietic stem cell transplantation; Urology; Cyclophosphamide; Chemotherapy","score_opus":0.03258313300281569,"score_gpt":0.30516925668600553,"score_spread":0.27258612368318985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556280457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997506,0.00020255471,0.00010875118,0.000062476975,0.000026675018,0.00046274567,0.00005028947,0.000033629312,0.0015468398],"genre_scores_gemma":[0.9987593,0.0000716293,0.0006445743,0.000087025976,0.00004874975,0.000020015228,0.00006144432,0.00003139953,0.00027580332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981543,0.00005971037,0.00049348455,0.00025028345,0.0007793917,0.00026284636],"domain_scores_gemma":[0.998735,0.00011817113,0.00019661244,0.0003398975,0.00040435104,0.00020592767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029203307,0.00017486152,0.00040251188,0.00016403582,0.000027272137,0.0000059560884,0.00014746284,0.00008181955,0.000028093871],"category_scores_gemma":[0.000031716347,0.00013887869,0.000058906026,0.00028650663,0.00016730453,0.00007149941,0.000020162615,0.0001743462,0.000026237863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065097557,0.0049602757,0.18446384,0.0063126865,0.00079872913,0.0012975065,0.0045155226,0.05275245,0.73642814,0.00040287548,0.00026600654,0.0012921948],"study_design_scores_gemma":[0.0606834,0.001913284,0.025678221,0.0003733957,0.0006020834,0.00028016273,0.00015621817,0.0004686427,0.9095853,0.000013366127,0.0000732383,0.00017267402],"about_ca_topic_score_codex":0.00010745614,"about_ca_topic_score_gemma":0.0000060945567,"teacher_disagreement_score":0.17315716,"about_ca_system_score_codex":0.00049412425,"about_ca_system_score_gemma":0.0015078677,"threshold_uncertainty_score":0.56633085},"labels":[],"label_agreement":null},{"id":"W2557010481","doi":"10.1182/blood.v124.21.800.800","title":"Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Tolerability; Mantle cell lymphoma; Oncology; Bruton's tyrosine kinase; Follicular lymphoma; Clinical endpoint; Lymphoma; Clinical trial; Chronic lymphocytic leukemia; Adverse effect; Leukemia; Tyrosine kinase","score_opus":0.022535855873941347,"score_gpt":0.3137643005637181,"score_spread":0.29122844468977677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557010481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927516,0.00089979975,0.000027621136,0.00022976506,0.00017991113,0.0014456484,0.000027409373,0.000071598784,0.0043666693],"genre_scores_gemma":[0.9976925,0.00015065045,0.00044496363,0.00016526443,0.00040981063,0.00010853507,0.000051214534,0.000059796123,0.0009172308],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968503,0.00029114913,0.0010010351,0.0005687836,0.000729347,0.0005593483],"domain_scores_gemma":[0.9975885,0.0006973673,0.00028400272,0.0010458293,0.0001312589,0.00025303932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00125313,0.00026625177,0.0007399732,0.0003116155,0.0000435259,0.00001425989,0.0002644802,0.00030183038,0.00007066752],"category_scores_gemma":[0.0014681367,0.00023425117,0.00022993692,0.00041397338,0.00022679467,0.000067863584,0.00008304222,0.00023406076,0.00004946814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85987175,0.03870433,0.00038174193,0.0006129202,0.0007333913,0.001577185,0.0029019034,0.000028216275,0.0373889,0.0002988257,0.0036532595,0.053847615],"study_design_scores_gemma":[0.9223303,0.011813777,0.00056217524,0.0003054275,0.00018418742,0.00018903486,0.00009126586,0.002918804,0.050494067,0.000079023346,0.010798764,0.00023317253],"about_ca_topic_score_codex":0.0005684195,"about_ca_topic_score_gemma":0.000018686022,"teacher_disagreement_score":0.062458586,"about_ca_system_score_codex":0.0012503952,"about_ca_system_score_gemma":0.003830301,"threshold_uncertainty_score":0.95524853},"labels":[],"label_agreement":null},{"id":"W2557038733","doi":"10.1136/annrheumdis-2016-eular.4199","title":"AB0206 Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from The Ontario Best Practice Research Initiatives Cohort","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; St Joseph's Health Centre","funders":"","keywords":"Medicine; Hydroxychloroquine; Discontinuation; Rheumatoid arthritis; Internal medicine; Leflunomide; Sulfasalazine; Methotrexate; Cohort; Disease","score_opus":0.16683013144668365,"score_gpt":0.43019678875837863,"score_spread":0.26336665731169495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557038733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97886074,0.0074950885,0.000023692979,0.00987192,0.00010429926,0.0014128265,0.001123868,0.000019390889,0.0010881566],"genre_scores_gemma":[0.9651591,0.033113834,0.0001016511,0.00036522152,0.000055934262,0.00031664828,0.00009518113,0.00003951111,0.0007529155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950824,0.0014403483,0.00072373566,0.0006050389,0.0014978831,0.0006506107],"domain_scores_gemma":[0.9871241,0.008919921,0.00024635042,0.0030578782,0.00040100585,0.00025073465],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018362926,0.00027160216,0.00061919005,0.0001252948,0.00013733674,0.000073017225,0.0010877108,0.00008446358,0.0013771352],"category_scores_gemma":[0.0074204803,0.00012166666,0.00018057524,0.00035125267,0.00062922196,0.00060915545,0.00092144543,0.00026243425,0.00019732029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004756263,0.0056542684,0.7757789,0.00030269907,0.0030828244,0.00057138636,0.010389174,0.000007716581,0.000045857018,0.00017743696,0.015706385,0.18352708],"study_design_scores_gemma":[0.0124316,0.0006549306,0.9591349,0.013068256,0.00022599557,0.000084382256,0.003390186,0.0002457563,0.0012117655,0.0018600133,0.007384703,0.0003075106],"about_ca_topic_score_codex":0.18525265,"about_ca_topic_score_gemma":0.060026973,"teacher_disagreement_score":0.183356,"about_ca_system_score_codex":0.0023488821,"about_ca_system_score_gemma":0.0059046275,"threshold_uncertainty_score":0.99973094},"labels":[],"label_agreement":null},{"id":"W2557267400","doi":"10.1182/blood.v116.21.1511.1511","title":"Descriptive Analysis and Review of Utilization of Rituximab In the Maintenance Treatment of Non-Hodgkin's Lymphoma In Five University Teaching Hospitals In Quebec, Canada.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Centre Hospitalier Universitaire de Sherbrooke; Hôpital Notre-Dame","funders":"","keywords":"Rituximab; Medicine; Follicular lymphoma; Pharmacy; Lymphoma; Internal medicine; Thrombocytopenic purpura; Bendamustine; Population; CD20; Oncology; Pediatrics; Family medicine","score_opus":0.010824389544470202,"score_gpt":0.2649733400692523,"score_spread":0.25414895052478215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557267400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969993,0.0019572587,0.000014578049,0.0001831469,0.000008505727,0.00046976845,0.000018495944,0.0000011766559,0.0003477718],"genre_scores_gemma":[0.9961578,0.0035236797,0.00016663058,0.000018816143,0.000004308039,0.000004238839,0.000012404377,0.0000040936748,0.000107999746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903154,0.00013585646,0.0002877832,0.00016199397,0.00023844354,0.00014439705],"domain_scores_gemma":[0.9993127,0.00016488657,0.00013557564,0.0002658588,0.0000888878,0.000032084485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004255099,0.00008501085,0.0005047911,0.00023684445,0.000011099489,0.0000016413835,0.00010286534,0.000047804187,0.000007854266],"category_scores_gemma":[0.0002781448,0.00006215151,0.000052591437,0.00074666744,0.00009948425,0.000046945766,0.000028497492,0.00008003446,7.246696e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010582603,0.015704185,0.86324036,0.009830371,0.0016814799,0.0018653277,0.03547643,0.000044701857,0.005199564,0.00088009104,0.0004003699,0.06461884],"study_design_scores_gemma":[0.055625908,0.00033038572,0.9240322,0.0037845206,0.0009136884,0.000021987824,0.0057310886,0.0027802119,0.0064100265,0.000015240255,0.00022127945,0.00013347113],"about_ca_topic_score_codex":0.92549115,"about_ca_topic_score_gemma":0.96040785,"teacher_disagreement_score":0.06448537,"about_ca_system_score_codex":0.002501578,"about_ca_system_score_gemma":0.0036888092,"threshold_uncertainty_score":0.6543789},"labels":[],"label_agreement":null},{"id":"W2557309119","doi":"10.1182/blood.v106.11.4982.4982","title":"Presenting Features Predictive of Long-Term Stability in Chronic Lymphocytic Leukemia.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Internal medicine; Gastroenterology; Group B; Group A; B cell; CD38; Stage (stratigraphy); Leukemia; Immunology; Antibody; Biology","score_opus":0.019691240370425557,"score_gpt":0.2983537377978847,"score_spread":0.27866249742745913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557309119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991481,0.003114814,0.000018363547,0.000051361894,0.000044822656,0.0008996008,0.000013330883,0.00008033971,0.004296373],"genre_scores_gemma":[0.9984232,0.00018735616,0.00022125088,0.00003146087,0.00044149597,0.00006224614,0.00002430726,0.000038700797,0.00056996144],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974428,0.00010414441,0.0005540508,0.000510186,0.0007262253,0.0006625919],"domain_scores_gemma":[0.9984959,0.0002630631,0.0001321022,0.0007568758,0.00015513522,0.00019692043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050540915,0.00022695844,0.00053534616,0.0002167768,0.000043897195,0.000017393582,0.0002629409,0.00020434782,0.0002328508],"category_scores_gemma":[0.00044154713,0.0002036209,0.00014976214,0.0004442545,0.0002740259,0.00016406979,0.00021803348,0.0003764841,0.000033860208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005616278,0.0057928306,0.7480342,0.013961113,0.002417399,0.0037981144,0.011710018,0.008325326,0.15406722,0.00030936644,0.0012916167,0.044676546],"study_design_scores_gemma":[0.096593715,0.0005916094,0.41467333,0.0008734529,0.0003526902,0.0007939978,0.00014239203,0.021315021,0.46420932,0.00003541126,0.00007815802,0.0003409061],"about_ca_topic_score_codex":0.0009577673,"about_ca_topic_score_gemma":0.0007148232,"teacher_disagreement_score":0.33336085,"about_ca_system_score_codex":0.07308312,"about_ca_system_score_gemma":0.032352243,"threshold_uncertainty_score":0.97313344},"labels":[],"label_agreement":null},{"id":"W2557492947","doi":"10.1182/blood.v120.21.2892.2892","title":"The Valproic Acid-Fludarabine Combination Induces a Synergistic Response in Chronic Lymphocytic Leukemia Via a Mechanism Involving the Lysosomal Protease Cathepsin B.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Fludarabine; Chronic lymphocytic leukemia; XIAP; Cancer research; Cathepsin B; Vorinostat; Caspase; Histone deacetylase; Chemistry; Apoptosis; Leukemia; Programmed cell death; Biology; Immunology; Medicine; Biochemistry; Histone; Internal medicine; Chemotherapy","score_opus":0.020177939974214073,"score_gpt":0.2797355347718299,"score_spread":0.2595575947976158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557492947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990844,0.0055262605,0.00012799943,0.00065139565,0.00021973335,0.002320612,0.000004240393,0.00012161995,0.0001841435],"genre_scores_gemma":[0.9975533,0.00014324505,0.00009232534,0.00017671622,0.00043649884,0.000847784,0.000013940981,0.00008184147,0.0006543886],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956625,0.000882528,0.00064417295,0.0004643655,0.0010799792,0.0012664221],"domain_scores_gemma":[0.9968828,0.0012495391,0.00021461303,0.0011479768,0.00017101022,0.0003340801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003933755,0.00037799796,0.0004269665,0.00026647406,0.00052857725,0.00011297755,0.00058054866,0.00024658782,0.000040915016],"category_scores_gemma":[0.0027526466,0.00022917503,0.00015359312,0.00092394074,0.00036560677,0.0002575115,0.00030812348,0.0006705673,0.00016849722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0064474368,0.0015559763,0.0006400219,0.00083254173,0.0005610935,0.0007800464,0.0061379503,0.00014583684,0.9664965,0.011700674,0.00024722103,0.004454697],"study_design_scores_gemma":[0.13735162,0.003040195,0.019155944,0.0016324783,0.0011545204,0.0028563894,0.0016108492,0.12462155,0.7001471,0.0062551824,0.00089882547,0.0012753502],"about_ca_topic_score_codex":0.0017069012,"about_ca_topic_score_gemma":0.00013187226,"teacher_disagreement_score":0.2663494,"about_ca_system_score_codex":0.068355195,"about_ca_system_score_gemma":0.03636175,"threshold_uncertainty_score":0.9691012},"labels":[],"label_agreement":null},{"id":"W2557622830","doi":"10.1182/blood.v124.21.4472.4472","title":"Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; Jewish General Hospital","funders":"","keywords":"Bendamustine; Rituximab; Medicine; Chronic lymphocytic leukemia; Internal medicine; Neutropenia; Population; Fludarabine; Adverse effect; Gastroenterology; Tolerability; Leukemia; Immunology; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.02092777761060369,"score_gpt":0.3141411403582586,"score_spread":0.29321336274765486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557622830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671465,0.0014273049,0.0000043019527,0.00007356643,0.00006258708,0.0011681614,0.000046588197,0.000047361867,0.00045546566],"genre_scores_gemma":[0.9985485,0.00037869302,0.00030415566,0.000034520675,0.00019551674,0.00004431464,0.000031708183,0.00005722302,0.00040534843],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964483,0.00022379911,0.0012046867,0.00072849495,0.00082658743,0.00056817045],"domain_scores_gemma":[0.99724436,0.0009492501,0.00037924407,0.0008821281,0.00021667799,0.00032832535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013645656,0.00034643558,0.0012443672,0.0004885146,0.000058140486,0.000013395375,0.00021682697,0.0002287756,0.00006184464],"category_scores_gemma":[0.0026353505,0.0002755286,0.00005978869,0.00062802667,0.0004119652,0.000090792055,0.00027698302,0.0004015054,0.0000048079296],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.22816087,0.123885974,0.014434095,0.04115004,0.005776677,0.011913178,0.05631528,0.0009428947,0.29102305,0.00042620004,0.0046768636,0.22129488],"study_design_scores_gemma":[0.9053098,0.025701774,0.0064318734,0.0014922309,0.0009574501,0.00085886725,0.001138747,0.04268196,0.013977976,0.000027987342,0.0009941546,0.00042718567],"about_ca_topic_score_codex":0.0036950856,"about_ca_topic_score_gemma":0.0012674708,"teacher_disagreement_score":0.67714894,"about_ca_system_score_codex":0.0070887255,"about_ca_system_score_gemma":0.011070998,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W2558211192","doi":"10.1016/j.ebiom.2016.12.001","title":"Lipids and Their Effects in Chronic Lymphocytic Leukemia","year":2016,"lang":"en","type":"letter","venue":"EBioMedicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Leukemia; Medicine; Immunology","score_opus":0.012316329275990632,"score_gpt":0.2747390972178217,"score_spread":0.26242276794183106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558211192","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061230067,0.051880438,0.00042514098,0.86012405,0.0040292717,0.0069702035,0.00012843474,0.0007840292,0.014428356],"genre_scores_gemma":[0.095185466,0.005396003,0.00017395927,0.77442944,0.06820984,0.0006036927,0.00096638326,0.0006852024,0.05435001],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950006,0.00020268832,0.0008174889,0.0012679868,0.0010251224,0.001686088],"domain_scores_gemma":[0.9963238,0.0015172156,0.00020308486,0.0014238051,0.00012385167,0.00040824333],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007245436,0.00091072515,0.0018849879,0.0013435401,0.00007436045,0.00003342138,0.00043196138,0.0016411545,0.0003912587],"category_scores_gemma":[0.00044259147,0.00055317924,0.00020365199,0.0007476166,0.0010832512,0.00009526499,0.00035466524,0.0021380344,0.00041508029],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00021512943,0.000009427662,0.000044194785,0.006802975,0.00027235667,0.009220528,0.00027899764,0.0000010118181,0.0039485274,0.000014304422,0.9468449,0.032347664],"study_design_scores_gemma":[0.05040074,0.0014530808,0.0002286369,0.009200699,0.00017278323,0.002570523,0.000019934143,0.0034366623,0.0014254358,0.00028012446,0.930197,0.0006143661],"about_ca_topic_score_codex":0.0013084866,"about_ca_topic_score_gemma":0.00004037148,"teacher_disagreement_score":0.19271013,"about_ca_system_score_codex":0.24448209,"about_ca_system_score_gemma":0.051771946,"threshold_uncertainty_score":0.99969196},"labels":[],"label_agreement":null},{"id":"W2558427779","doi":"10.1182/blood.v108.11.78.78","title":"Physician Adherence to Local Treatment Policies and American Society of Hematology (ASH) Quality Metrics in Chronic Lymphocytic Leukemia (CLL) Management.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Internal medicine; Stage (stratigraphy); Hematology; Cancer; Leukemia","score_opus":0.03147614589071248,"score_gpt":0.3402858005656068,"score_spread":0.30880965467489435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558427779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574506,0.0011373133,0.00028675894,0.00010263407,0.000017298516,0.00065680215,0.000013976806,0.000045641995,0.0019945276],"genre_scores_gemma":[0.99710643,0.0004736297,0.0013897497,0.00024305905,0.000080297774,0.000082848885,0.000016067674,0.000027435945,0.0005804743],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794006,0.00007847891,0.0004985453,0.00045813277,0.00043084455,0.0005939089],"domain_scores_gemma":[0.9989531,0.00019223405,0.00013888904,0.0004964537,0.00006638961,0.00015293893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002213745,0.00024195193,0.00073446234,0.00025194776,0.000044697423,0.000014055511,0.00015239527,0.000085006846,0.000010141628],"category_scores_gemma":[0.000023466417,0.00021242564,0.0001404483,0.0013047386,0.00051309867,0.000043509004,0.00016422478,0.00009958632,0.000020660353],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003362256,0.012339062,0.11044717,0.018542673,0.006362363,0.0025198418,0.010344413,0.008798066,0.07635806,0.045935072,0.01008554,0.69490546],"study_design_scores_gemma":[0.32244498,0.0153445555,0.23386073,0.0017395904,0.0020917102,0.0008876196,0.012849895,0.048745923,0.3501299,0.0016156475,0.007968068,0.0023213888],"about_ca_topic_score_codex":0.06288254,"about_ca_topic_score_gemma":0.002068974,"teacher_disagreement_score":0.6925841,"about_ca_system_score_codex":0.047457248,"about_ca_system_score_gemma":0.005888729,"threshold_uncertainty_score":0.999747},"labels":[],"label_agreement":null},{"id":"W2558871324","doi":"10.1182/blood-2016-01-689422","title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":289,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Alberta; University of Manitoba","funders":"National Cancer Institute; Cancer Research UK","keywords":"Medicine; Intensive care medicine; Pancytopenia; Minimal residual disease; Clinical trial; Disease; Transplantation; Disease management; Quality of life (healthcare); Leukemia; Immunology; Internal medicine; Nursing","score_opus":0.04892216517246414,"score_gpt":0.31038624141703014,"score_spread":0.261464076244566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558871324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548584,0.0010390087,0.00012587188,0.0015176513,0.000038792296,0.0011788245,0.000036595033,0.000017518583,0.0005598943],"genre_scores_gemma":[0.9943479,0.0010527988,0.0026493433,0.0001648039,0.00006693358,0.00023446286,0.0000046958144,0.000024137382,0.0014549297],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99906063,0.000013723101,0.0002174396,0.00019619886,0.00030074298,0.00021129138],"domain_scores_gemma":[0.9987283,0.00047308413,0.00007139503,0.00033924612,0.00031538398,0.00007262965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016188127,0.000102015,0.00017734776,0.000035478206,0.00004584509,0.0000061724886,0.000088023546,0.000040834548,0.00002131597],"category_scores_gemma":[0.00011016491,0.00004457821,0.000040865594,0.000075982774,0.0001835132,0.000015441841,0.000076544005,0.000033281238,0.0000051745146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006033273,0.004985533,0.4734881,0.009548593,0.0047389967,0.00035221936,0.00047263605,0.000031114378,0.0014495946,0.001482386,0.19341032,0.30400726],"study_design_scores_gemma":[0.5400711,0.0035696218,0.2770217,0.0036024381,0.0044247797,0.00007288218,0.0006550351,0.001416523,0.07624645,0.00023742992,0.09198466,0.0006973177],"about_ca_topic_score_codex":0.00005712988,"about_ca_topic_score_gemma":0.00001535717,"teacher_disagreement_score":0.5340379,"about_ca_system_score_codex":0.00059047056,"about_ca_system_score_gemma":0.00066766166,"threshold_uncertainty_score":0.18178467},"labels":[],"label_agreement":null},{"id":"W2559034347","doi":"10.1182/blood.v106.11.4392.4392","title":"BCL11AXL Protein: Its Distribution in Normal and Malignant Tissues and Use as a Marker for Plasmacytoid Dendritic Cells.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; B cell; Molecular biology; Germinal center; Thymocyte; Antibody; Cancer research; Immunology; Antigen; CD8","score_opus":0.016072468799134317,"score_gpt":0.27709898768581187,"score_spread":0.26102651888667755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559034347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966866,0.0013052241,0.000021083393,0.00043896737,0.000019099767,0.0012970266,0.00006364885,0.000026132977,0.00014223644],"genre_scores_gemma":[0.99614805,0.0002474498,0.0009263454,0.000059086124,0.00010236479,0.00017584095,0.000052299387,0.000021882075,0.0022666906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988307,0.000032743887,0.00021708451,0.00029664423,0.00022642921,0.0003964446],"domain_scores_gemma":[0.9994206,0.00014036914,0.00003158446,0.00016215854,0.00006855054,0.00017673221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002289707,0.00013614028,0.00021879263,0.00006657679,0.000055374483,0.000052681367,0.00004825673,0.00010499256,0.00004181875],"category_scores_gemma":[0.00029401307,0.00012019711,0.00002846753,0.0000978644,0.000077356715,0.00017228522,0.00007572737,0.000120862824,0.000028642484],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01417962,0.01198877,0.048504632,0.014025739,0.0011322055,0.0070901117,0.005426951,0.0000324858,0.80625886,0.008621087,0.0070616305,0.07567794],"study_design_scores_gemma":[0.09874857,0.0009778148,0.011470612,0.001049074,0.00025280856,0.0025294435,0.00014854906,0.012393217,0.84018344,0.00011459429,0.031661026,0.00047086625],"about_ca_topic_score_codex":0.00019147515,"about_ca_topic_score_gemma":0.0001338982,"teacher_disagreement_score":0.084568955,"about_ca_system_score_codex":0.00074626337,"about_ca_system_score_gemma":0.0006940696,"threshold_uncertainty_score":0.4901496},"labels":[],"label_agreement":null},{"id":"W2559378733","doi":"10.1182/blood.v110.11.1351.1351","title":"Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Bendamustine; Rituximab; Medicine; Internal medicine; Follicular lymphoma; Refractory (planetary science); Chronic lymphocytic leukemia; Neutropenia; Lymphoma; Oncology; Clinical endpoint; Non-Hodgkin's lymphoma; Salvage therapy; Gastroenterology; Surgery; Chemotherapy; Leukemia; Clinical trial","score_opus":0.003795729831162938,"score_gpt":0.23946237270392845,"score_spread":0.2356666428727655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559378733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426174,0.00028919536,0.000039475475,0.000042733893,0.000047522466,0.0012649551,0.000013809101,0.000028214345,0.0040123733],"genre_scores_gemma":[0.9987071,0.000030166284,0.0005617311,0.00024304516,0.000106275584,0.000031913798,0.00002746502,0.000046582667,0.00024568033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791664,0.00003988378,0.00030986653,0.00047971727,0.00065032794,0.00060356886],"domain_scores_gemma":[0.99883944,0.00024594855,0.00008723043,0.00038987503,0.00014463239,0.0002928943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045207966,0.00024881595,0.0004280148,0.0002754166,0.000054001935,0.000019071997,0.00010544029,0.00015841659,0.00006650879],"category_scores_gemma":[0.000094700896,0.00019485505,0.00004475765,0.00036472935,0.00013978775,0.000086696185,0.00011779075,0.00023826802,0.000064217274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008700088,0.030912295,0.83498484,0.0012459852,0.0004081208,0.001664473,0.0038214044,0.0000022188542,0.0019777021,0.000012689246,0.0007741817,0.11549598],"study_design_scores_gemma":[0.26542643,0.0020631994,0.70651495,0.00030209837,0.00013241386,0.000054063967,0.00008582754,0.00008527922,0.024143595,0.000005942469,0.0009557624,0.00023044278],"about_ca_topic_score_codex":0.0005832785,"about_ca_topic_score_gemma":0.00008890614,"teacher_disagreement_score":0.25672632,"about_ca_system_score_codex":0.002508691,"about_ca_system_score_gemma":0.0011129631,"threshold_uncertainty_score":0.79459584},"labels":[],"label_agreement":null},{"id":"W2559455083","doi":"10.1182/blood.v112.11.4190.4190","title":"CD38 Expression above 20% Predicts Disease Progression in Chronic Lymphocytic Leukemia and Is a Useful Prognostic Marker Where Cytogenetic and Molecular Markers Are Not Available","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; St. Paul's Hospital; University of British Columbia Hospital","funders":"","keywords":"CD38; Chronic lymphocytic leukemia; Medicine; Internal medicine; Univariate analysis; Stage (stratigraphy); Oncology; Leukemia; Gastroenterology; Lymphocyte; Disease; Immunology; Multivariate analysis; Biology","score_opus":0.01639218791434852,"score_gpt":0.259159605116991,"score_spread":0.24276741720264247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559455083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669079,0.030267844,0.000008392771,0.0001681891,0.000043087857,0.0020082537,0.000040949668,0.000104442224,0.00045090014],"genre_scores_gemma":[0.9922112,0.0048726955,0.00050241617,0.00024843446,0.00011723501,0.00032910574,0.000032933396,0.00010697423,0.0015790113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625015,0.00017524882,0.00051761203,0.0010922053,0.0010277607,0.00093700294],"domain_scores_gemma":[0.99780685,0.00019234484,0.00016441235,0.0008064359,0.00012755879,0.0009024047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003147544,0.00046918966,0.00059087237,0.00028030082,0.0001790111,0.00006111485,0.00019621305,0.00028280687,0.0002709119],"category_scores_gemma":[0.0004040714,0.00040358442,0.00009760647,0.00041856602,0.0004633597,0.00018471415,0.00039110612,0.0003628452,0.00007262806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008637973,0.0015121499,0.79619074,0.01144641,0.00056218525,0.036809254,0.0013877293,0.00018969238,0.12351089,0.000006494334,0.016308809,0.0034376779],"study_design_scores_gemma":[0.22079039,0.002220128,0.516276,0.021154301,0.001445287,0.0059800395,0.00025075316,0.10394833,0.120832786,0.00007996876,0.0051071662,0.001914828],"about_ca_topic_score_codex":0.00018427172,"about_ca_topic_score_gemma":0.000034534594,"teacher_disagreement_score":0.2799147,"about_ca_system_score_codex":0.012473898,"about_ca_system_score_gemma":0.018341469,"threshold_uncertainty_score":0.99984163},"labels":[],"label_agreement":null},{"id":"W2559590288","doi":"10.1016/j.ebiom.2016.11.033","title":"Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells","year":2016,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Chronic lymphocytic leukemia; Signal transduction; Cancer research; Internal medicine; Cytokine; Endocrinology; Biology; Leukemia; Cholesterol; Lymphocyte; Receptor; Immunology; Medicine; Cell biology","score_opus":0.01641075645726226,"score_gpt":0.28054227601498377,"score_spread":0.2641315195577215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559590288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934332,0.00075301947,0.0017534579,0.0008959442,0.0004617928,0.0012490831,0.000021390017,0.0002489033,0.001183229],"genre_scores_gemma":[0.9923541,0.00041004075,0.0004177735,0.0006545784,0.001659244,0.00008136939,0.000038090322,0.00010168733,0.004283139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954467,0.000117428,0.0008814662,0.00092671165,0.0012755063,0.0013521807],"domain_scores_gemma":[0.99730384,0.00048300414,0.00017297055,0.0011779363,0.00019546557,0.000666788],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001086623,0.00047888444,0.0009619823,0.0007589629,0.00010425629,0.000023630688,0.00039696763,0.00039385108,0.0011091951],"category_scores_gemma":[0.00046216973,0.00031313565,0.00016358218,0.001120063,0.0006371507,0.00016317778,0.00023735313,0.00047056485,0.0012019228],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00058860687,0.000065278306,0.000261023,0.00053038116,0.00009530628,0.0023257926,0.0002710703,0.00007402795,0.9727529,0.00008558122,0.0029133414,0.020036662],"study_design_scores_gemma":[0.075536385,0.0015165688,0.0018867652,0.0045435117,0.00013546745,0.0010966541,0.00011058802,0.0066118375,0.8934397,0.00025865863,0.014213777,0.00065006135],"about_ca_topic_score_codex":0.0044220695,"about_ca_topic_score_gemma":0.0003399157,"teacher_disagreement_score":0.16863213,"about_ca_system_score_codex":0.20293087,"about_ca_system_score_gemma":0.03429873,"threshold_uncertainty_score":0.99993205},"labels":[],"label_agreement":null},{"id":"W2559607846","doi":"10.1182/blood.v108.11.2810.2810","title":"The Vascular Endothelial Growth Factor (VEGF) Autocrine Survival Signaling Pathway in Chronic Lymphocytic Leukemia (CLL) Is Regulated by Lysophosphatidic Acid (LPA).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Autocrine signalling; Vascular endothelial growth factor; Cancer research; Angiogenesis; Lysophosphatidic acid; Vascular endothelial growth factor A; Biology; Chronic lymphocytic leukemia; Protein kinase B; Receptor; Internal medicine; Endocrinology; Signal transduction; Immunology; Leukemia; Cell biology; Medicine; VEGF receptors","score_opus":0.010853041335017402,"score_gpt":0.2417009393627176,"score_spread":0.2308478980277002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559607846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98473,0.011860292,0.00006376525,0.00019582939,0.00025383694,0.0012493898,0.00011065004,0.00026659353,0.0012696297],"genre_scores_gemma":[0.99581563,0.0005148133,0.000075335614,0.00013149471,0.0007080899,0.00014714024,0.00016185256,0.00015553665,0.0022900954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947402,0.0002604363,0.0010145077,0.00094451924,0.0014686703,0.0015716675],"domain_scores_gemma":[0.99761957,0.00055486563,0.00022049755,0.0010365722,0.00024476286,0.0003237366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078734296,0.00059254345,0.00082604354,0.00022000927,0.0003343264,0.00014371407,0.0005944308,0.00034258098,0.0004196878],"category_scores_gemma":[0.00037996133,0.00044988876,0.0003778239,0.000945801,0.00036295466,0.0001709914,0.00023148203,0.00058300624,0.0002082801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010330202,0.0009281442,0.0025447477,0.0010407986,0.001501458,0.001904214,0.00067090883,0.0004294984,0.97981155,0.001027088,0.0034807946,0.005627806],"study_design_scores_gemma":[0.08206243,0.00044215965,0.0014296055,0.0002932836,0.00023940903,0.00024818676,0.00006428171,0.01284948,0.89321864,0.00039569527,0.008139416,0.0006174379],"about_ca_topic_score_codex":0.010241095,"about_ca_topic_score_gemma":0.00039035722,"teacher_disagreement_score":0.086592905,"about_ca_system_score_codex":0.059009925,"about_ca_system_score_gemma":0.030113243,"threshold_uncertainty_score":0.99979526},"labels":[],"label_agreement":null},{"id":"W2560062761","doi":"10.1182/blood.v106.11.2239.2239","title":"A Prospective Cost Analysis of Non-Myeloablative Hematopoietic Stem Cell Transplantation.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Hôpital Maisonneuve-Rosemont; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Transplantation; Hematopoietic stem cell transplantation; Emergency medicine; Hematopoietic cell; Activity-based costing; Psychological intervention; Indirect costs; Intensive care medicine; Health care; Surgery; Stem cell; Haematopoiesis; Nursing","score_opus":0.01206114277188204,"score_gpt":0.2825017095740649,"score_spread":0.27044056680218287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560062761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98475724,0.0002871325,0.00074223196,0.00009277985,0.000011485295,0.00075622066,0.000044457804,0.00003054379,0.013277896],"genre_scores_gemma":[0.99731827,0.00009488991,0.00082960067,0.000043939286,0.000056396926,0.000067668756,0.00003193476,0.000018460825,0.001538852],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862826,0.00003280954,0.00032189942,0.0002825373,0.00047268625,0.00026180872],"domain_scores_gemma":[0.99909276,0.00015984302,0.000097283926,0.00032775267,0.00018865424,0.00013368987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001700862,0.00013323671,0.00046497906,0.00032345703,0.00003854132,0.0000090218855,0.000101035206,0.00007946294,0.00021800555],"category_scores_gemma":[0.000011325557,0.00011380437,0.00019316588,0.0011234268,0.00009816989,0.00006767056,0.000019665908,0.00013733526,0.00006716298],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008072101,0.04487757,0.31772667,0.012668882,0.06434664,0.0041615423,0.2732321,0.011774775,0.21731009,0.0028036071,0.0021355208,0.04089051],"study_design_scores_gemma":[0.07313372,0.0005513176,0.09369133,0.00024673986,0.015259175,0.0002556523,0.0017323238,0.026104873,0.78841126,0.000031445365,0.00020968069,0.00037248802],"about_ca_topic_score_codex":0.000116505864,"about_ca_topic_score_gemma":0.00007230823,"teacher_disagreement_score":0.5711012,"about_ca_system_score_codex":0.0013418345,"about_ca_system_score_gemma":0.0014480327,"threshold_uncertainty_score":0.46408075},"labels":[],"label_agreement":null},{"id":"W2560357275","doi":"10.1182/blood.v122.21.3785.3785","title":"The Eukaryotic Translation Initiation Factor 4E (eIF4E) Has Oncogenic Functions and May Represent a New Therapeutic Target In Diffuse Large B Cell Lymphoma (DLBCL)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"EIF4E; Biology; Cancer research; Eukaryotic translation; Eukaryotic initiation factor; Gene expression; Diffuse large B-cell lymphoma; Translation (biology); Gene; Oncogene; Messenger RNA; EIF4A1; Molecular biology; Lymphoma; Genetics; Cell cycle; Immunology","score_opus":0.04030467544395052,"score_gpt":0.2785872854694714,"score_spread":0.2382826100255209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560357275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893018,0.0048602377,0.00038236633,0.0026749813,0.00011321294,0.0013108659,0.000012120058,0.00006806639,0.0012763196],"genre_scores_gemma":[0.99626124,0.00044796846,0.00015183276,0.00018349214,0.00018854307,0.00011249066,0.00004604211,0.00004054849,0.0025678687],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99811316,0.00015478834,0.0003863857,0.00037265097,0.0004575219,0.0005155262],"domain_scores_gemma":[0.99865085,0.0004514512,0.00008291294,0.0004996915,0.00008096785,0.00023414548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025148544,0.00019579465,0.00024430623,0.00014640314,0.00022431776,0.00013333176,0.0001272504,0.00015089403,0.00018806076],"category_scores_gemma":[0.00010969215,0.0001402026,0.00009454452,0.00034164844,0.000097722994,0.00020231116,0.00005116906,0.00019786149,0.00018842859],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033443759,0.09138028,0.2841605,0.0021239202,0.0029437453,0.000890758,0.043568753,0.000083392486,0.11477687,0.0013364882,0.014895152,0.44049576],"study_design_scores_gemma":[0.47779733,0.0009793097,0.43977898,0.00024063453,0.00068628986,0.00047669036,0.0018750799,0.035874918,0.018717445,0.0022548945,0.020514805,0.0008036386],"about_ca_topic_score_codex":0.0013995237,"about_ca_topic_score_gemma":0.00033686886,"teacher_disagreement_score":0.47445294,"about_ca_system_score_codex":0.0011751531,"about_ca_system_score_gemma":0.0027950006,"threshold_uncertainty_score":0.5717296},"labels":[],"label_agreement":null},{"id":"W2560524290","doi":"10.1182/blood.v128.22.5583.5583","title":"Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Idelalisib; Ofatumumab; Bendamustine; Internal medicine; Placebo; Population; Rituximab; Immunology; Chronic lymphocytic leukemia; Lymphoma; Leukemia; Ibrutinib","score_opus":0.006812006081608902,"score_gpt":0.23602123687365067,"score_spread":0.22920923079204178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560524290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840224,0.00014196505,0.000017146775,0.000081532395,0.000020874466,0.00081646844,0.000007470054,0.000019546365,0.00049278664],"genre_scores_gemma":[0.99957544,0.00006811793,0.000031020223,0.000019927711,0.000019179975,0.000048447815,0.00001701167,0.000016206142,0.0002046231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895746,0.00009385842,0.00024323064,0.00017831777,0.00034160857,0.00018550566],"domain_scores_gemma":[0.9992899,0.0001900798,0.000106278625,0.00022525422,0.00012918025,0.00005933445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024453833,0.00010504276,0.00023082523,0.000101865044,0.000028218015,0.0000034958161,0.000054886055,0.00006913644,0.00001627623],"category_scores_gemma":[0.00021062137,0.00004771279,0.000027261543,0.00022286692,0.0001941167,0.00008058516,0.00004338166,0.00006014233,0.000010210992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013651362,0.00040386326,0.99593735,0.00005950304,0.000076069904,0.000017487675,0.00021594061,0.0000017665292,0.00016783152,0.000065693894,0.000017384093,0.0016719748],"study_design_scores_gemma":[0.2849836,0.000529007,0.7049267,0.00062150374,0.00014330831,0.00013325308,0.00003258457,0.00050179247,0.007832631,0.00015345003,0.0000299306,0.00011222418],"about_ca_topic_score_codex":0.0015380371,"about_ca_topic_score_gemma":0.00020152856,"teacher_disagreement_score":0.29101062,"about_ca_system_score_codex":0.0009361325,"about_ca_system_score_gemma":0.0009379418,"threshold_uncertainty_score":0.2447954},"labels":[],"label_agreement":null},{"id":"W2560546162","doi":"10.1182/blood.v106.11.1334.1334","title":"CLL/SLL Is More Common Than Registry Incidence Suggests: A Population-Based Study in Manitoba, Canada.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Cancer registry; Medicine; Incidence (geometry); Population; Immunophenotyping; Chronic lymphocytic leukemia; Cancer; Epidemiology; Internal medicine; Leukemia; Immunology; Flow cytometry; Environmental health","score_opus":0.021641843046053582,"score_gpt":0.29995669862698204,"score_spread":0.27831485558092844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560546162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961679,0.00026883907,0.0000010636028,0.0021780059,0.000041685787,0.00084346964,0.00001869762,0.000043224147,0.00043709503],"genre_scores_gemma":[0.9980623,0.000006206351,0.00015208901,0.0009758306,0.00021133466,0.00006363805,0.00004832592,0.000031936615,0.0004483534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977569,0.00007647046,0.0003984522,0.00038952215,0.0009370219,0.00044164635],"domain_scores_gemma":[0.9986211,0.00017309918,0.000088102424,0.0008229241,0.00008735894,0.00020742434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002824988,0.00018583826,0.00034087634,0.00013117965,0.000069705806,0.000024503635,0.00026938663,0.000098458826,0.00009325883],"category_scores_gemma":[0.00022009137,0.00017536212,0.000044053468,0.00039122134,0.000036405763,0.000067145316,0.00007767969,0.00033123992,0.000021948375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011394433,0.0013909744,0.99435216,0.00009110638,0.00004427384,0.0013034159,0.00037476828,0.0000956246,0.000043283533,0.000006480887,0.0016146199,0.00056936004],"study_design_scores_gemma":[0.02895861,0.00018456348,0.962924,0.0002316668,0.00009663146,0.00013103381,0.0012741874,0.004016372,0.001302239,0.000007604053,0.00065686106,0.00021624511],"about_ca_topic_score_codex":0.9258972,"about_ca_topic_score_gemma":0.984152,"teacher_disagreement_score":0.05825483,"about_ca_system_score_codex":0.0113316225,"about_ca_system_score_gemma":0.010689989,"threshold_uncertainty_score":0.99491847},"labels":[],"label_agreement":null},{"id":"W2560708148","doi":"10.1016/s1470-2045(16)30632-5","title":"Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Royal Victoria Hospital; Dalhousie University","funders":"Pharmacyclics","keywords":"Rituximab; Medicine; Ibrutinib; Internal medicine; Population; Waldenstrom macroglobulinemia; Oncology; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.10975313428633213,"score_gpt":0.454956165901559,"score_spread":0.3452030316152269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560708148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927904,0.000020880509,0.00006226933,0.0015135179,0.00055026385,0.0034907798,0.00021953142,0.000043965843,0.001308415],"genre_scores_gemma":[0.99469846,0.000053979118,0.0030016073,0.0005005107,0.00086837733,0.0002533087,0.00018662833,0.00004327385,0.00039384994],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977619,0.00026039284,0.0005112894,0.00045289332,0.00046793305,0.00054560526],"domain_scores_gemma":[0.99727285,0.0006597445,0.00034631425,0.00090562436,0.000645111,0.00017036239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001014993,0.00020225292,0.0007796208,0.000087055785,0.00009315627,0.000029253457,0.0010931217,0.00016188042,0.0002521218],"category_scores_gemma":[0.00057741784,0.00010385498,0.0000337319,0.00016508505,0.00039205202,0.0003194936,0.00026340707,0.000203905,0.000030128811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.794345,0.03701985,0.003163285,0.00010717449,0.0006133705,0.00017939425,0.0009003841,9.942744e-7,0.0061845076,0.00093331205,0.0037274286,0.15282528],"study_design_scores_gemma":[0.9372995,0.033352926,0.0018556232,0.00008862187,0.0001424949,0.00005159631,0.00012291329,0.00067592436,0.0016514851,0.00013138622,0.024455369,0.00017214447],"about_ca_topic_score_codex":0.00020460262,"about_ca_topic_score_gemma":0.00016246524,"teacher_disagreement_score":0.15265313,"about_ca_system_score_codex":0.0034755317,"about_ca_system_score_gemma":0.0028967324,"threshold_uncertainty_score":0.90883946},"labels":[],"label_agreement":null},{"id":"W2560781244","doi":"10.1182/blood.v118.21.5101.5101","title":"The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenstrom Macroglobulinemia","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"STAT3; Cancer research; Macroglobulinemia; Transcription factor; Biology; Angiogenesis; Lymphoma; Waldenstrom macroglobulinemia; Carcinogenesis; Signal transduction; Medicine; Immunology; Cancer; Gene; Cell biology; Multiple myeloma; Genetics","score_opus":0.026279873232991996,"score_gpt":0.25939152377977037,"score_spread":0.23311165054677838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560781244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832107,0.00068116415,0.000046636804,0.0003146177,0.00027087165,0.00084282603,0.000036974303,0.00015901652,0.009326853],"genre_scores_gemma":[0.99754626,0.0002847853,0.00063883624,0.00017901683,0.0003595358,0.00007191919,0.0000137359075,0.000061819,0.00084410113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969329,0.00014346719,0.000440731,0.0005784265,0.0008048846,0.0010995717],"domain_scores_gemma":[0.9979633,0.00024497134,0.0001612283,0.00093675056,0.000192477,0.00050124153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063277467,0.00033979124,0.0004357794,0.0000874484,0.00033619368,0.00008394234,0.00037924023,0.00014315957,0.00010278644],"category_scores_gemma":[0.00022856022,0.0002264859,0.00020539411,0.00032238767,0.0005148672,0.00009752626,0.00021851779,0.0005684706,0.00023289482],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004081257,0.018112166,0.045522083,0.0010641081,0.003537409,0.02794027,0.0034402192,0.000017266395,0.7422375,0.0016850784,0.016714316,0.13564831],"study_design_scores_gemma":[0.04627513,0.0011542302,0.041846503,0.0003332636,0.0005610605,0.0016783053,0.0015476865,0.0016792865,0.8998884,0.0001951506,0.0040575657,0.0007834283],"about_ca_topic_score_codex":0.0007416097,"about_ca_topic_score_gemma":0.00004919208,"teacher_disagreement_score":0.15765087,"about_ca_system_score_codex":0.0016820878,"about_ca_system_score_gemma":0.0049368,"threshold_uncertainty_score":0.92358273},"labels":[],"label_agreement":null},{"id":"W2561344970","doi":"10.1182/blood.v110.11.2042.2042","title":"A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL).","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Lenalidomide; Medicine; Neutropenia; Internal medicine; Tumor lysis syndrome; Gastroenterology; Chronic lymphocytic leukemia; Rituximab; Febrile neutropenia; Immunology; Surgery; Multiple myeloma; Leukemia; Lymphoma; Chemotherapy","score_opus":0.018716855911150805,"score_gpt":0.325668133740166,"score_spread":0.3069512778290152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561344970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358314,0.0019073741,0.000020214131,0.000015949854,0.000062283034,0.0025235845,0.000004142036,0.000121442165,0.0017618561],"genre_scores_gemma":[0.99862814,0.00011119363,0.00011928108,0.000051227424,0.00018285296,0.00009298458,0.000016230037,0.000071274655,0.0007268084],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960398,0.00012656131,0.0011630163,0.0005913807,0.0010479799,0.0010312396],"domain_scores_gemma":[0.99785537,0.0003648341,0.00023065144,0.00104066,0.00015809866,0.00035037042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014735002,0.00035775124,0.00093462295,0.0006251209,0.000090806534,0.000019588402,0.0003770024,0.00019371639,0.00016827729],"category_scores_gemma":[0.0004102639,0.00031106285,0.00015090985,0.0011299074,0.00016198946,0.00011185816,0.00025147232,0.00032089328,0.000075483964],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.039092574,0.27787596,0.050641544,0.02551037,0.013047377,0.07726172,0.098158605,0.0044259476,0.23696585,0.000769448,0.0029909709,0.17325963],"study_design_scores_gemma":[0.87546307,0.028509514,0.0025416834,0.0019121561,0.0014288394,0.0022078138,0.0021236525,0.015520408,0.06943398,0.000058521826,0.0002018904,0.00059849664],"about_ca_topic_score_codex":0.005368334,"about_ca_topic_score_gemma":0.0018157179,"teacher_disagreement_score":0.83637047,"about_ca_system_score_codex":0.058578,"about_ca_system_score_gemma":0.024410345,"threshold_uncertainty_score":0.99993414},"labels":[],"label_agreement":null},{"id":"W2562003278","doi":"10.1182/blood.v114.22.2477.2477","title":"Costs to Medicare of Treating Chronic Lymphocytic Leukemia Patients with Alemtuzumab.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Alemtuzumab; Medicine; Chronic lymphocytic leukemia; Leukemia; Internal medicine; Adverse effect; Cytopenia; Transplantation; Bone marrow","score_opus":0.006612052808214281,"score_gpt":0.2581684653623194,"score_spread":0.2515564125541051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562003278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120736,0.00039771694,0.000030638428,0.000088049615,0.000034274446,0.00084140385,0.000016010257,0.00008763545,0.007296908],"genre_scores_gemma":[0.9980829,0.00002441464,0.0008638189,0.00026288786,0.00017653717,0.000026961872,0.000057735768,0.000037905393,0.00046687206],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974691,0.0000402044,0.00040659693,0.00042497652,0.0010712184,0.00058789045],"domain_scores_gemma":[0.99834496,0.00012334336,0.0001142884,0.000665766,0.0003085257,0.00044313233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000169779,0.00024035628,0.0004995819,0.00020295708,0.000065634646,0.000014469379,0.00023013102,0.00012461098,0.00013445107],"category_scores_gemma":[0.00032860154,0.00018195898,0.00008710794,0.00056322705,0.000102069214,0.00007017451,0.00006578514,0.00016720414,0.00007139826],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0090982495,0.006425722,0.11447502,0.0039804345,0.0031810442,0.0034571758,0.0082046585,0.0019094833,0.024838159,0.0008887644,0.012779484,0.8107618],"study_design_scores_gemma":[0.53548574,0.02736735,0.2891303,0.0072883284,0.0020233204,0.00088361383,0.0004797224,0.007638221,0.12497129,0.00005628129,0.0031455534,0.0015302701],"about_ca_topic_score_codex":0.0006719665,"about_ca_topic_score_gemma":0.000070213246,"teacher_disagreement_score":0.8092315,"about_ca_system_score_codex":0.058447924,"about_ca_system_score_gemma":0.024586955,"threshold_uncertainty_score":0.9809427},"labels":[],"label_agreement":null},{"id":"W2562165295","doi":"10.1182/blood.v108.11.306.306","title":"Clinical Efficacy of Lenalidomide {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase II Clinical Trial.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Fludarabine; Gastroenterology; Rituximab; Rash; Thalidomide; Tumor lysis syndrome; Bendamustine; Chronic lymphocytic leukemia; Pomalidomide; Refractory (planetary science); Progressive disease; Febrile neutropenia; Multiple myeloma; Leukemia; Toxicity; Lymphoma; Chemotherapy; Cyclophosphamide","score_opus":0.043796044907813976,"score_gpt":0.3750465100802808,"score_spread":0.3312504651724668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562165295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552256,0.00034178345,0.000006694779,0.000039120187,0.00024154385,0.0027613835,0.00008237827,0.00007885186,0.00092566357],"genre_scores_gemma":[0.996904,0.00018911297,0.0006510432,0.000061134495,0.00058597146,0.000036901612,0.0004269307,0.00009252415,0.0010523595],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9914783,0.00076058507,0.0045776353,0.0010368003,0.0013277129,0.00081894547],"domain_scores_gemma":[0.9937982,0.0022819964,0.0013573156,0.0016756073,0.0005141731,0.00037268447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032467698,0.00044253885,0.002054958,0.0004118012,0.000068573565,0.000012754824,0.00048548842,0.0006390877,0.00012921872],"category_scores_gemma":[0.0043896474,0.0003130321,0.00046291383,0.0010748215,0.0008927611,0.00014360146,0.00024882753,0.00084930303,0.000029193017],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9291276,0.04273463,0.008818707,0.00054847746,0.00092921645,0.00072037993,0.00012222634,0.00014879102,0.00046718842,0.000024707042,0.0047930405,0.011565046],"study_design_scores_gemma":[0.9268704,0.03844366,0.027179642,0.0010648018,0.00078207435,0.000030012357,0.000015902335,0.0013776098,0.0021578583,0.0000094263,0.0017489799,0.00031961338],"about_ca_topic_score_codex":0.0016936165,"about_ca_topic_score_gemma":0.0002897211,"teacher_disagreement_score":0.04121468,"about_ca_system_score_codex":0.01468138,"about_ca_system_score_gemma":0.05589606,"threshold_uncertainty_score":0.99993217},"labels":[],"label_agreement":null},{"id":"W2562167373","doi":"10.1182/blood.v104.11.753.753","title":"Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Fludarabine; Rituximab; Medicine; Neutropenia; Macroglobulinemia; Waldenstrom macroglobulinemia; Internal medicine; Gastroenterology; Surgery; Chemotherapy; Lymphoma; Multiple myeloma; Cyclophosphamide","score_opus":0.010835678723124739,"score_gpt":0.25912982323051975,"score_spread":0.248294144507395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562167373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960583,0.0008948688,0.000026665357,0.0013447689,0.000016086262,0.00045584503,0.0000024167682,0.00004460979,0.0011564558],"genre_scores_gemma":[0.99774015,0.00035498306,0.0013715761,0.0001823952,0.000050784558,0.000028717144,0.00001766219,0.000021714268,0.00023203439],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989824,0.000018014602,0.00016018147,0.00024713212,0.00032238776,0.00026985785],"domain_scores_gemma":[0.9995383,0.000030418725,0.000029300429,0.00022653613,0.00006892216,0.000106512336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014597537,0.000121661986,0.0002296058,0.000110397086,0.000033146443,0.000019625462,0.00006018629,0.00007592132,0.000030058736],"category_scores_gemma":[0.000037093232,0.00009131108,0.000021492748,0.00024379126,0.00011348833,0.00006148335,0.000028109685,0.00018253153,0.000022776027],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023936143,0.14194362,0.29813185,0.003700341,0.0027514051,0.04029354,0.015026037,0.0004700553,0.21611427,0.03420581,0.001337694,0.22208923],"study_design_scores_gemma":[0.847547,0.0030468926,0.06140897,0.0005500446,0.00009873567,0.004497396,0.0001765872,0.0005276077,0.07957289,0.0013051218,0.0009013817,0.0003673725],"about_ca_topic_score_codex":0.0004986571,"about_ca_topic_score_gemma":0.00010695145,"teacher_disagreement_score":0.82361084,"about_ca_system_score_codex":0.0012606375,"about_ca_system_score_gemma":0.0015511807,"threshold_uncertainty_score":0.37235576},"labels":[],"label_agreement":null},{"id":"W2562903607","doi":"10.1182/blood-2016-05-718494","title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; Norges Forskningsråd; National Cancer Institute; Kreftforeningen","keywords":"Syk; Bruton's tyrosine kinase; breakpoint cluster region; Cancer research; B-cell receptor; Chronic lymphocytic leukemia; Signal transduction; Phosphorylation; Biology; Ibrutinib; Cell signaling; B cell; Receptor; Immunology; Leukemia; Cell biology; Tyrosine kinase; Genetics; Antibody","score_opus":0.016204084570724118,"score_gpt":0.2555248375093678,"score_spread":0.23932075293864366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562903607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632835,0.00028872272,0.00036283373,0.000073242765,0.0001178153,0.00061433035,0.000063841675,0.000045985544,0.002104889],"genre_scores_gemma":[0.9953044,0.00003865513,0.00079113955,0.000028305512,0.0001493669,0.00004553157,0.00004580779,0.000065540335,0.0035312332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99755156,0.00009095392,0.0006347364,0.0005049064,0.0006291995,0.00058864226],"domain_scores_gemma":[0.99855554,0.00039943997,0.0001892305,0.00053026696,0.0001267735,0.000198767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053876126,0.0002315243,0.00046496987,0.0001852081,0.00003586911,0.00002131841,0.00025527057,0.00016791021,0.00034128517],"category_scores_gemma":[0.00024590595,0.00017115433,0.00012731817,0.00026637997,0.00008878601,0.00009750967,0.00014302335,0.00014702188,0.00012606388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001788123,0.0022272996,0.026747407,0.0006523414,0.00003541032,0.00010300508,0.00019239385,4.300893e-7,0.9685006,0.000003921591,0.00025953597,0.0010988332],"study_design_scores_gemma":[0.04982404,0.0002865228,0.00050944684,0.00080487394,0.00007637595,0.000027211463,0.00013279545,0.00009101277,0.9478653,0.0000145136955,0.00016974975,0.0001981496],"about_ca_topic_score_codex":0.00043834813,"about_ca_topic_score_gemma":0.000026246034,"teacher_disagreement_score":0.049645226,"about_ca_system_score_codex":0.0023011083,"about_ca_system_score_gemma":0.0013932119,"threshold_uncertainty_score":0.6979471},"labels":[],"label_agreement":null},{"id":"W2564248509","doi":"10.1371/journal.pone.0167641","title":"Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Research Foundation of Korea; Seoul National University; Ministry of Science, ICT and Future Planning; National Research Foundation; Cancer Research Institute","keywords":"Sanger sequencing; Biology; Genetics; Mutation; CDKN2A; Chronic lymphocytic leukemia; Mutation frequency; Exome sequencing; Leukemia; Gene","score_opus":0.03890416360836296,"score_gpt":0.2595725757702039,"score_spread":0.2206684121618409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564248509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536294,0.0015480577,0.000048816157,0.00009806401,0.00003989264,0.0009914797,0.000049357484,0.00009008891,0.0017713276],"genre_scores_gemma":[0.9915507,0.00039712267,0.00046701933,0.000057309015,0.00014731135,0.00012026662,0.00004870966,0.00006910189,0.0071425037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99719274,0.000086244814,0.0006541464,0.0005095485,0.0008428239,0.00071451644],"domain_scores_gemma":[0.9984632,0.00023619566,0.00016408555,0.0007437385,0.00017254996,0.00022023119],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046447213,0.00022919272,0.0006667823,0.00028892318,0.000037144368,0.0000132050045,0.000286314,0.00019181048,0.0010182289],"category_scores_gemma":[0.00049881515,0.00017426236,0.00009303495,0.00043121463,0.00023853677,0.00014302511,0.00015688698,0.00019063965,0.0004901017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00029281093,0.00016392156,0.0011532553,0.0009307425,0.00023857021,0.00010772822,0.00017869634,0.000013679814,0.9950592,0.000036001275,0.0009858406,0.00083957124],"study_design_scores_gemma":[0.023950743,0.0003771648,0.0010626591,0.0021432803,0.00014206982,0.00004104967,0.000051764535,0.02522597,0.94661134,0.00009499938,0.00005989695,0.00023904855],"about_ca_topic_score_codex":0.0024086137,"about_ca_topic_score_gemma":0.00011990269,"teacher_disagreement_score":0.22122471,"about_ca_system_score_codex":0.2660543,"about_ca_system_score_gemma":0.04482959,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W2564350518","doi":"10.1124/jpet.116.236224","title":"Bruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats","year":2016,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bruton's tyrosine kinase; Medicine; Inflammation; Endocrinology; Internal medicine; Tyrosine kinase; Pharmacology; Cancer research; Receptor","score_opus":0.03696822092133551,"score_gpt":0.3545127738757606,"score_spread":0.3175445529544251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564350518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915465,0.0060383515,0.000021355538,0.0016856143,0.0003112712,0.00022770358,0.0000025510367,0.000008635302,0.00015799912],"genre_scores_gemma":[0.9974989,0.000506346,0.00011228265,0.0013972031,0.00029577332,0.000009513583,7.0100987e-7,0.000020576454,0.0001586757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870485,0.00015211522,0.0004453606,0.00016276226,0.00021949633,0.00031539204],"domain_scores_gemma":[0.9993269,0.00016339107,0.00016853955,0.00008988311,0.000076674885,0.00017464794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034814444,0.0001654636,0.0003751908,0.00016360429,0.000048062313,0.000010129074,0.00010901121,0.00012323343,0.00023372377],"category_scores_gemma":[0.000017591736,0.0001055317,0.00008189088,0.00013965592,0.00025006334,0.00009330348,0.00007646209,0.00028296377,0.0000070225406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019003697,0.00059552526,0.0028469232,0.000026162794,0.00018866178,0.0007099966,0.0005248188,6.401706e-7,0.99032396,0.00001799664,0.0003185699,0.002546378],"study_design_scores_gemma":[0.020811975,0.0012555257,0.0012314596,0.00011641258,0.00012760941,0.00094520574,0.00024988223,0.00011703306,0.9740648,0.00003085638,0.0009332884,0.0001159282],"about_ca_topic_score_codex":0.000028118595,"about_ca_topic_score_gemma":0.000005812997,"teacher_disagreement_score":0.018911606,"about_ca_system_score_codex":0.0029467535,"about_ca_system_score_gemma":0.0012565291,"threshold_uncertainty_score":0.7705658},"labels":[],"label_agreement":null},{"id":"W2564650550","doi":"10.14740/jmc.v8i1.2708","title":"First Report of Treatment of Chronic Lymphocytic Leukemia in a Patient With Cystic Fibrosis","year":2017,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Ibrutinib; Bendamustine; Chronic lymphocytic leukemia; Internal medicine; Immunosuppression; Malignancy; Population; Antibiotics; Leukemia","score_opus":0.02958111471727381,"score_gpt":0.32998016827847315,"score_spread":0.30039905356119934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564650550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642295,0.0023960846,0.00004848121,0.00044730376,0.00013780638,0.00025776407,0.000006371972,0.0000041970966,0.00027904945],"genre_scores_gemma":[0.99806917,0.0011966564,0.0003293373,0.000019553367,0.00025289154,0.000009345847,0.0000027753472,0.000020517286,0.00009974731],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99620426,0.00005676862,0.0011896488,0.00018838527,0.0020408179,0.00032009406],"domain_scores_gemma":[0.996635,0.00069079775,0.0012177065,0.00068838376,0.00031962997,0.00044848307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006564504,0.00017953927,0.00094202417,0.00024182661,0.00006355677,0.000015099331,0.0002986027,0.00016645687,0.00030428072],"category_scores_gemma":[0.0037319856,0.00010816781,0.00021278094,0.0001338963,0.00055614207,0.000101245234,0.000083350635,0.00020186117,0.0000027885364],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01664533,0.0021978908,0.01676149,0.005194023,0.0015299765,0.8798236,0.00305137,0.004505916,0.0013307319,0.00008484716,0.0033952617,0.065479524],"study_design_scores_gemma":[0.14778145,0.07867043,0.015833732,0.022977583,0.0012689874,0.6343183,0.0010861155,0.057120856,0.028695606,0.00007186932,0.011672773,0.0005023062],"about_ca_topic_score_codex":0.007292982,"about_ca_topic_score_gemma":0.000888799,"teacher_disagreement_score":0.24550535,"about_ca_system_score_codex":0.07452308,"about_ca_system_score_gemma":0.08229536,"threshold_uncertainty_score":0.9993175},"labels":[],"label_agreement":null},{"id":"W2566019957","doi":"10.1182/blood.v104.11.4225.4225","title":"CERA (Continuous Erythropoietin Receptor Activator): Dose-Response Trial of Subcutaneous (SC) Administration Once Every 3 Weeks (Q3W) to Patients with Aggressive Non-Hodgkin’s Lymphoma and Anemia Receiving Chemotherapy.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Anemia; Internal medicine; Gastroenterology; Chemotherapy; Chemotherapy regimen; Surgery","score_opus":0.007099199901736731,"score_gpt":0.2591046772744383,"score_spread":0.25200547737270157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566019957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996709,0.00010247001,0.000030752482,0.00053429307,0.00016042215,0.002170317,0.000034399392,0.000065421445,0.00019293616],"genre_scores_gemma":[0.99677193,0.00011949556,0.0021774212,0.00013348107,0.00026829488,0.00007532487,0.000033484175,0.00008830375,0.0003322854],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971529,0.0001517928,0.0005581867,0.0006656065,0.0009112003,0.0005603022],"domain_scores_gemma":[0.99783623,0.00039782733,0.00043322207,0.00062002207,0.00033135485,0.000381342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004336004,0.00036169766,0.00063826266,0.00018844953,0.00013432211,0.000054626376,0.0001954801,0.00025831396,0.00009000035],"category_scores_gemma":[0.0006817691,0.0003063286,0.00009628409,0.00040295912,0.00022387384,0.00016144585,0.00006977024,0.00021210071,0.000021441916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8749608,0.008104865,0.0055212667,0.00047277493,0.00056734704,0.0016210316,0.0056181853,0.000023410897,0.06446647,0.0000073972865,0.0004110506,0.038225446],"study_design_scores_gemma":[0.68842334,0.027153417,0.04342738,0.001950305,0.00027368224,0.0012248419,0.00038466844,0.000018785275,0.23586173,0.000017526794,0.00058427796,0.00068005593],"about_ca_topic_score_codex":0.0006228671,"about_ca_topic_score_gemma":0.00008898131,"teacher_disagreement_score":0.18653743,"about_ca_system_score_codex":0.0029300882,"about_ca_system_score_gemma":0.007190821,"threshold_uncertainty_score":0.9999389},"labels":[],"label_agreement":null},{"id":"W2566190653","doi":"10.1158/1538-7445.am2015-2555","title":"Abstract 2555: The mechanism of action of bendamustine alone or in combination with nucleoside analogs in chronic lymphocytic leukemia","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Pentostatin; Bendamustine; Chronic lymphocytic leukemia; Cladribine; Nucleoside analogue; Fludarabine; Chlorambucil; Cytotoxicity; Pharmacology; Medicine; Deoxycoformycin; MTT assay; Leukemia; Nucleoside; Cancer research; Immunology; Apoptosis; Chemistry; In vitro; Chemotherapy; Lymphoma; Biochemistry; Adenosine; Adenosine deaminase; Internal medicine","score_opus":0.14535627696262285,"score_gpt":0.42463775318634744,"score_spread":0.27928147622372457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566190653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966112,0.0007344863,0.000027596487,0.00047549926,0.000054055818,0.0011548286,0.000009424026,0.00001538862,0.000917538],"genre_scores_gemma":[0.9983914,0.0006568239,0.000060615366,0.000026491003,0.00009045322,0.00018834039,0.000015628759,0.00003925358,0.00053103216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99644417,0.0002345173,0.00056103634,0.0003657344,0.0017603552,0.0006341695],"domain_scores_gemma":[0.9977895,0.00053530553,0.00015289123,0.00058083324,0.00075753964,0.0001839016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031395096,0.00015819179,0.00047831138,0.0007339609,0.00004539709,0.000015579504,0.0003398009,0.00015410178,0.00023603131],"category_scores_gemma":[0.00070506067,0.000100633835,0.00004384354,0.002027014,0.0004897309,0.00015795359,0.00014174687,0.0006900228,0.000015113743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06015679,0.0014595216,0.0070711044,0.01176797,0.0007218873,0.0027367976,0.013688517,0.05015499,0.7745022,0.0086694965,0.007608837,0.061461873],"study_design_scores_gemma":[0.15113123,0.0066300835,0.040977165,0.005609978,0.00009917762,0.0003259953,0.0070085768,0.14127225,0.643282,0.0022098008,0.0009380424,0.00051570113],"about_ca_topic_score_codex":0.061494637,"about_ca_topic_score_gemma":0.023297008,"teacher_disagreement_score":0.13122022,"about_ca_system_score_codex":0.1370573,"about_ca_system_score_gemma":0.08466781,"threshold_uncertainty_score":0.99452525},"labels":[],"label_agreement":null},{"id":"W2566813663","doi":"10.1182/blood.v120.21.4701.4701","title":"Effectiveness and Cost of Rituximab for CLL in the Province of Manitoba Prior to Its Approval As Part of First Line Treatment","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Formulary; Rituximab; Regimen; Population; Cohort; Internal medicine; Oncology; Family medicine; Lymphoma","score_opus":0.03269511178432509,"score_gpt":0.3218280623678805,"score_spread":0.28913295058355537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566813663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951296,0.000912942,0.000031329186,0.000090835725,0.000025517707,0.0035411525,0.000038793314,0.0000041546073,0.00022571244],"genre_scores_gemma":[0.9992034,0.00006423068,0.0002223529,0.000011306188,0.00007958721,0.00034390404,0.000006811356,0.0000127869935,0.000055634995],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990868,0.00006455898,0.0002388284,0.000144235,0.00023635657,0.0002292313],"domain_scores_gemma":[0.99890673,0.0005851134,0.00007412977,0.00026118435,0.00009954184,0.00007331727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005600097,0.00009981694,0.00036225648,0.000063636326,0.000018536908,0.0000025506067,0.00008821285,0.000054949534,0.0000038803437],"category_scores_gemma":[0.00032469738,0.00006295993,0.000053024476,0.00012757088,0.000070197166,0.000034499037,0.00004587832,0.000045719986,0.000002539767],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044220623,0.18471217,0.26871943,0.077259175,0.0036668903,0.0004068714,0.022408826,0.00012400986,0.110958986,0.0048362757,0.0007302202,0.2819565],"study_design_scores_gemma":[0.13836557,0.006110876,0.043963365,0.0009885144,0.0005018035,0.00017096986,0.00047039185,0.0003203138,0.80566317,0.00002830927,0.00327376,0.00014293134],"about_ca_topic_score_codex":0.000527779,"about_ca_topic_score_gemma":0.00046331916,"teacher_disagreement_score":0.69470423,"about_ca_system_score_codex":0.0006401556,"about_ca_system_score_gemma":0.00087300234,"threshold_uncertainty_score":0.25674313},"labels":[],"label_agreement":null},{"id":"W2567613149","doi":"10.1158/1538-7445.am2015-5452","title":"Abstract 5452: Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Gefitinib; Erlotinib; Sorafenib; Dasatinib; Pharmacology; Lapatinib; Sunitinib; Vandetanib; Tyrosine-kinase inhibitor; Tyrosine kinase; Chemistry; IC50; Imatinib; Medicine; Biochemistry; Cancer research; Internal medicine; Cancer; In vitro; Epidermal growth factor receptor; Receptor","score_opus":0.05912482178897417,"score_gpt":0.36292261986793095,"score_spread":0.3037977980789568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567613149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907932,0.003906751,0.00001371772,0.00096761744,0.00016759077,0.0010208056,0.00017305669,0.00005898872,0.002898253],"genre_scores_gemma":[0.99621135,0.00094184815,0.00003087355,0.00007109936,0.0003529964,0.00019237756,0.00008029919,0.00007552981,0.0020436314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948678,0.00014735955,0.0005438798,0.00066456414,0.0028542506,0.0009221547],"domain_scores_gemma":[0.99758524,0.00020196983,0.00011127798,0.0005765908,0.0006348053,0.00089009263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00215493,0.00027608906,0.0005274851,0.00046689934,0.00014696048,0.000054749886,0.00019333464,0.0002654476,0.00041826552],"category_scores_gemma":[0.00020830729,0.00024889625,0.00010651171,0.0005128121,0.0008728431,0.00032724495,0.00017914189,0.0009583788,0.000036306126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0056785517,0.0010115097,0.004617715,0.0018285913,0.00019691324,0.0010652627,0.0025811386,0.000021684393,0.9445419,0.00018879087,0.025983218,0.012284729],"study_design_scores_gemma":[0.020473279,0.00078744546,0.0018529799,0.0006586057,0.000054628345,0.00009520485,0.00216228,0.0001460593,0.9695272,0.00015061638,0.0038009367,0.00029076525],"about_ca_topic_score_codex":0.009824669,"about_ca_topic_score_gemma":0.00055428705,"teacher_disagreement_score":0.024985302,"about_ca_system_score_codex":0.008714648,"about_ca_system_score_gemma":0.008642246,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W2567715886","doi":"10.1182/blood.v116.21.2389.2389","title":"Significant Improvement In Overall Survival In Patients Who Underwent Autologous Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Population; Hematopoietic cell; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Lymphoma; Statistical significance; Surgery; Oncology; Haematopoiesis; Stem cell","score_opus":0.010717401703579906,"score_gpt":0.23886544637503287,"score_spread":0.22814804467145297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567715886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981013,0.000052985866,0.0000010284697,0.0003784334,0.00007789695,0.0009805236,0.000039428563,0.000006982166,0.00036143776],"genre_scores_gemma":[0.99947315,0.000047027497,0.000024491665,0.00019504869,0.000044401804,0.00004857819,0.000032123728,0.000018296621,0.00011687553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794436,0.00009133187,0.00042743207,0.00033348595,0.0006055841,0.0005978286],"domain_scores_gemma":[0.99916,0.0002806968,0.00005299977,0.00033940666,0.000015834627,0.00015105761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005292475,0.00017950962,0.0003801797,0.00011536577,0.000028449664,0.00001922469,0.00020207548,0.00011676688,0.00003789748],"category_scores_gemma":[0.000037327256,0.00011750634,0.00002562563,0.00016975557,0.00006777589,0.00003088583,0.00005049202,0.0005387629,0.0000017213448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037765055,0.0020155148,0.99077016,0.00053458626,0.00004554624,0.0016749679,0.002035607,0.00001388937,0.0013790947,0.000045756322,0.00024624408,0.0008609691],"study_design_scores_gemma":[0.06465751,0.00056166353,0.9284673,0.00018039612,0.00007466593,0.00003926362,0.0002936196,0.0003832374,0.00457208,0.000042140025,0.00047125565,0.00025688965],"about_ca_topic_score_codex":0.49972108,"about_ca_topic_score_gemma":0.82245564,"teacher_disagreement_score":0.32273453,"about_ca_system_score_codex":0.0018624086,"about_ca_system_score_gemma":0.005209858,"threshold_uncertainty_score":0.92420644},"labels":[],"label_agreement":null},{"id":"W2567954139","doi":"10.1182/blood.v112.11.2072.2072","title":"Disruption of T Cell Suppression in Chronic Lymphocytic Leukemia by CD200 Blockade.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"CD40; Antigen; Antigen-presenting cell; ELISPOT; FOXP3; Immunology; T cell; Chronic lymphocytic leukemia; IL-2 receptor; Flow cytometry; Biology; Immune system; Cancer research; Cytotoxic T cell; Leukemia; In vitro","score_opus":0.01508472783213163,"score_gpt":0.2702129272114141,"score_spread":0.2551281993792825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567954139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294466,0.0031642437,0.000018188304,0.00002615337,0.00006510801,0.00047714097,0.000014838658,0.00005688569,0.003232781],"genre_scores_gemma":[0.9953223,0.0012431679,0.0001893798,0.000030142175,0.00015115706,0.000036143538,0.00006591983,0.000043788106,0.002917999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99781084,0.00007062583,0.00049001805,0.00040556485,0.0006777013,0.00054522883],"domain_scores_gemma":[0.9989079,0.000121503814,0.00011198147,0.00057821494,0.00007650603,0.00020387094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020262576,0.00021087065,0.0004463078,0.00021340464,0.000058896458,0.000005965216,0.00019966881,0.00022636632,0.00024347236],"category_scores_gemma":[0.00009558828,0.0001859575,0.00011710675,0.0004461782,0.00020867558,0.00009705094,0.0001103902,0.00026661681,0.00011295308],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037894287,0.0007454535,0.0029778178,0.00091068394,0.00005786184,0.0008560116,0.0006546748,0.0003184842,0.9881605,0.0000085257,0.004312066,0.0006189922],"study_design_scores_gemma":[0.074276835,0.0005165615,0.0027368674,0.00038588486,0.000103425125,0.00089505163,0.00005359062,0.013863084,0.9052468,0.000016217158,0.0016799561,0.00022572561],"about_ca_topic_score_codex":0.0016483254,"about_ca_topic_score_gemma":0.00003156679,"teacher_disagreement_score":0.08291368,"about_ca_system_score_codex":0.04303247,"about_ca_system_score_gemma":0.02494277,"threshold_uncertainty_score":0.9805849},"labels":[],"label_agreement":null},{"id":"W2569292446","doi":"10.1182/blood.v116.21.2454.2454","title":"Fludarabine and Rituximab (FR) Is a Safe and Effective Treatment Alternative for Relapsed or Refractory Hairy Cell Leukemia (HCL)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Fludarabine; Medicine; Cladribine; Rituximab; Tolerability; Internal medicine; Gastroenterology; Refractory (planetary science); Neutropenia; Surgery; Oncology; Lymphoma; Adverse effect; Chemotherapy; Cyclophosphamide","score_opus":0.014138254240143963,"score_gpt":0.29616663364564494,"score_spread":0.28202837940550096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569292446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994144,0.0009367719,0.000041528463,0.00024802366,0.00014921454,0.0022259003,0.00008423268,0.000054819277,0.0021155088],"genre_scores_gemma":[0.9903873,0.00053524063,0.0030203147,0.00021742568,0.00043315528,0.0004441718,0.000030685675,0.00006246745,0.004869226],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99833137,0.00005179922,0.0002582062,0.0006146754,0.00029683323,0.00044709074],"domain_scores_gemma":[0.99815667,0.0008159946,0.00009479939,0.00045719233,0.00014553785,0.00032983476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002599166,0.00029909733,0.0005400339,0.00013431624,0.00013735879,0.000037630572,0.00009011052,0.00021879097,0.000095758216],"category_scores_gemma":[0.0003189955,0.00020896106,0.00009426932,0.000115711024,0.0002540402,0.00010188655,0.00008980762,0.00033043034,0.000029926172],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038315285,0.02672368,0.004401934,0.0055735847,0.0051630302,0.0043017566,0.025352094,0.00000271245,0.5566825,0.0007574362,0.011423836,0.32130215],"study_design_scores_gemma":[0.4832844,0.010615515,0.002562645,0.00025089763,0.0012155033,0.0012230386,0.00029718477,0.004332877,0.45363817,0.0003332677,0.04169513,0.000551345],"about_ca_topic_score_codex":0.0007929095,"about_ca_topic_score_gemma":0.00020132425,"teacher_disagreement_score":0.44496912,"about_ca_system_score_codex":0.0027482244,"about_ca_system_score_gemma":0.0027832699,"threshold_uncertainty_score":0.8521185},"labels":[],"label_agreement":null},{"id":"W2569660516","doi":"10.1182/blood.v112.11.1560.1560","title":"The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003).","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Lenalidomide; Bortezomib; Medicine; Mantle cell lymphoma; Internal medicine; Thalidomide; Gastroenterology; Regimen; Multiple myeloma; Phases of clinical research; Proteasome inhibitor; Progressive disease; Oncology; Surgery; Lymphoma; Clinical trial; Chemotherapy","score_opus":0.030769926103399917,"score_gpt":0.3065380049983145,"score_spread":0.2757680788949146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569660516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125487,0.0071485587,0.0000048522747,0.000082107144,0.00001052609,0.0012746368,0.00010270244,0.000026254373,0.000095472635],"genre_scores_gemma":[0.9950265,0.0040679774,0.00039231678,0.000048119335,0.000040136067,0.000021138956,0.00016074919,0.000046186957,0.00019683804],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99811673,0.0001147401,0.00040431682,0.0005183506,0.00046871472,0.0003771594],"domain_scores_gemma":[0.9982486,0.000417525,0.00016178029,0.0008857243,0.00014812633,0.00013826234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027189587,0.00025936225,0.0006015884,0.000082264036,0.00020568531,0.000017537046,0.0002308956,0.000058398236,0.000011244004],"category_scores_gemma":[0.00010798046,0.0001450771,0.000019745909,0.00027739425,0.00050273514,0.00013027548,0.00021776611,0.00010953626,0.0000018935518],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1585,0.02923047,0.7323937,0.0005950756,0.0075957766,0.001690461,0.012749539,0.000031666827,0.0024495858,0.000019229277,0.00186499,0.05287951],"study_design_scores_gemma":[0.8566537,0.0047847503,0.12694357,0.00048793436,0.0008647918,0.00010399752,0.000430746,0.0012219214,0.0076709837,0.0000094598045,0.0005092699,0.0003189044],"about_ca_topic_score_codex":0.0015996237,"about_ca_topic_score_gemma":0.0004890387,"teacher_disagreement_score":0.6981537,"about_ca_system_score_codex":0.0004041774,"about_ca_system_score_gemma":0.0011563555,"threshold_uncertainty_score":0.5916072},"labels":[],"label_agreement":null},{"id":"W2570200366","doi":"10.1182/blood.v126.23.1542.1542","title":"Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Ibrutinib; Temsirolimus; Clinical endpoint; Lymphoma; Phases of clinical research; International Prognostic Index; Oncology; Randomized controlled trial; Gastroenterology; Clinical trial; Rituximab; Leukemia; Chronic lymphocytic leukemia","score_opus":0.0463762389773181,"score_gpt":0.3297237700807319,"score_spread":0.2833475311034138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570200366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98898983,0.00033569697,0.00000845669,0.00005720115,0.00008069061,0.008044522,0.00043754154,0.00012554311,0.0019205073],"genre_scores_gemma":[0.99439484,0.000042971737,0.00042723544,0.00015310786,0.00009477396,0.00047715535,0.0033319118,0.00014035498,0.0009376473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99500424,0.00051050313,0.0009043536,0.0013589473,0.0014469924,0.000774985],"domain_scores_gemma":[0.9960981,0.0003898039,0.0003603106,0.0021386514,0.00051305175,0.00050009676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008748406,0.0005957169,0.0014612337,0.00035143626,0.000077087454,0.00025100773,0.0015695611,0.00016501339,0.00014280993],"category_scores_gemma":[0.0003733922,0.0003942722,0.000050212195,0.00060302444,0.0002561631,0.00060745963,0.0010078324,0.00016223015,0.00015362991],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53246224,0.13779584,0.3183875,0.00007350888,0.0028372062,0.0022076555,0.0019304345,0.000004829648,0.000032787368,0.0000011096315,0.00089215033,0.0033747295],"study_design_scores_gemma":[0.97107524,0.0047473535,0.010649822,0.000500412,0.0016323297,0.000050934854,0.00039724587,0.00921334,0.00069118536,0.0000018725897,0.00056917325,0.00047109643],"about_ca_topic_score_codex":0.01378258,"about_ca_topic_score_gemma":0.00075170514,"teacher_disagreement_score":0.438613,"about_ca_system_score_codex":0.003562921,"about_ca_system_score_gemma":0.0035235065,"threshold_uncertainty_score":0.9998509},"labels":[],"label_agreement":null},{"id":"W2570700343","doi":"10.1182/blood.v104.11.4788.4788","title":"Lysophosphatidic Acid (LPA) Protects Primary Chronic Lymphocytic Leukemia (CLL) Cells from Apoptosis: Role for LPA as a Survival Factor in CLL.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Lysophosphatidic acid; Apoptosis; Chronic lymphocytic leukemia; Cancer research; Biology; Protein kinase B; Endocrinology; Receptor; Internal medicine; Leukemia; Immunology; Medicine; Biochemistry","score_opus":0.014293771041563538,"score_gpt":0.2615403819868656,"score_spread":0.24724661094530204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570700343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887329,0.0046929196,0.00020402159,0.00017571915,0.0003444789,0.0042749224,0.00014342954,0.000252395,0.0011792404],"genre_scores_gemma":[0.9952697,0.0003558934,0.0014741255,0.00034569897,0.0008092055,0.0008650129,0.00022343287,0.000187333,0.00046960355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99513596,0.00011481533,0.00084994576,0.0012014743,0.0011958702,0.0015019047],"domain_scores_gemma":[0.9975876,0.00034613485,0.00022703543,0.0010792674,0.00018441587,0.0005755521],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048076015,0.0006222762,0.0011133292,0.00032795724,0.00018419462,0.00013026531,0.0006019012,0.00053796434,0.00028204796],"category_scores_gemma":[0.00041890444,0.00058712956,0.00036477405,0.0007480459,0.0002460324,0.00024734743,0.00028923835,0.0005658255,0.00055022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0039310483,0.002568865,0.0006534799,0.0034176297,0.0014462938,0.0009555508,0.0031551926,0.0012800487,0.9678359,0.00024442904,0.00026952385,0.014242035],"study_design_scores_gemma":[0.14233744,0.0013189723,0.0012746078,0.00081173104,0.00029324563,0.000102053724,0.00017272294,0.0014062418,0.84957635,0.0011871153,0.0009088918,0.0006106264],"about_ca_topic_score_codex":0.0121838525,"about_ca_topic_score_gemma":0.00072377635,"teacher_disagreement_score":0.1384064,"about_ca_system_score_codex":0.10831736,"about_ca_system_score_gemma":0.092342064,"threshold_uncertainty_score":0.999658},"labels":[],"label_agreement":null},{"id":"W2572245593","doi":"10.1182/blood.v114.22.2085.2085","title":"Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital Maisonneuve-Rosemont; Université de Montréal; McMaster University Medical Centre; Institute for Research in Immunology and Cancer; Jewish General Hospital","funders":"","keywords":"Ribavirin; Myeloid leukemia; EIF4E; Medicine; Immunology; Leukemia; Internal medicine; Oncology; Cytarabine; Cancer research; Virology; Translation (biology); Biology; Virus; Hepatitis C virus; Messenger RNA","score_opus":0.018203294085038693,"score_gpt":0.28087988638565126,"score_spread":0.2626765923006126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572245593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278957,0.0020269079,0.00017192434,0.001721061,0.00003946463,0.00069382344,0.0000071554746,0.00006346713,0.002486601],"genre_scores_gemma":[0.9963109,0.0002108107,0.0008218312,0.0014476643,0.00027156447,0.00004144807,0.000016756825,0.000036881924,0.00084214297],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99812317,0.000052263607,0.00028377128,0.00036593142,0.00057374244,0.0006011463],"domain_scores_gemma":[0.9990329,0.00012635149,0.00007485384,0.0005589587,0.00007659227,0.00013034634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045288733,0.00021325717,0.00033377367,0.00010389054,0.00010369621,0.00003748075,0.0002805486,0.000114615716,0.00003325814],"category_scores_gemma":[0.00007167248,0.0001304406,0.00007282083,0.0005153893,0.0001249412,0.00006902493,0.00005703996,0.00048580905,0.00006171767],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035419413,0.005922741,0.008180208,0.00029831546,0.0019671703,0.006305185,0.0068877055,0.000936536,0.89874405,0.0013078796,0.0015251541,0.06438312],"study_design_scores_gemma":[0.4584565,0.007320617,0.10581332,0.002111352,0.003126607,0.015285251,0.0016683844,0.030034943,0.3273676,0.0011010392,0.045339953,0.0023744348],"about_ca_topic_score_codex":0.00022101968,"about_ca_topic_score_gemma":0.000042631298,"teacher_disagreement_score":0.57137644,"about_ca_system_score_codex":0.0031056707,"about_ca_system_score_gemma":0.0044046077,"threshold_uncertainty_score":0.8121221},"labels":[],"label_agreement":null},{"id":"W2574014792","doi":"10.1016/j.leukres.2017.01.023","title":"Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada","year":2017,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); St. Paul's Hospital; Canada's Michael Smith Genome Sciences Centre; Royal Columbian Hospital; University of British Columbia; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Fludarabine; Medicine; Rituximab; Hazard ratio; Internal medicine; Chemoimmunotherapy; Population; Chronic lymphocytic leukemia; Confidence interval; Regimen; Proportional hazards model; Oncology; Cohort; Alemtuzumab; Vincristine; Surgery; Cyclophosphamide; Chemotherapy; Leukemia; Transplantation; Lymphoma","score_opus":0.03724798008251208,"score_gpt":0.3164581650059118,"score_spread":0.2792101849233997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574014792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657255,0.0000489026,0.0000049603204,0.00002365946,0.00002922985,0.0030758583,0.00015902884,0.000008987301,0.000076841],"genre_scores_gemma":[0.9984131,0.000033178036,0.00021806757,0.000011764068,0.000027669515,0.00043365674,0.00032834045,0.00004874279,0.0004854868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971138,0.00012806508,0.0006617606,0.00052712794,0.0008892518,0.00067996926],"domain_scores_gemma":[0.9974177,0.00074573566,0.0002702263,0.0007577767,0.0006320801,0.00017652268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007000712,0.00016517712,0.00074108964,0.00026294042,0.00020001446,0.00010305462,0.00025998987,0.00014828987,0.000021363749],"category_scores_gemma":[0.0015095455,0.00019300485,0.000043600365,0.00038830363,0.00026979824,0.00011330083,0.00010059172,0.00020018328,3.73858e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003944539,0.000067791596,0.9922909,0.0007481569,0.000053498068,0.00004865258,0.000037585378,0.0004274167,0.0014070965,0.0000015297325,0.000008048756,0.0045148395],"study_design_scores_gemma":[0.033794623,0.0010893611,0.92300403,0.000850087,0.000029431227,0.0000073300025,0.000018757064,0.040162418,0.00086676615,0.000010417162,0.000022705917,0.00014407178],"about_ca_topic_score_codex":0.98710227,"about_ca_topic_score_gemma":0.9849136,"teacher_disagreement_score":0.1057535,"about_ca_system_score_codex":0.21971735,"about_ca_system_score_gemma":0.11396385,"threshold_uncertainty_score":0.89105916},"labels":[],"label_agreement":null},{"id":"W2574859067","doi":"10.1182/blood.v124.21.1995.1995","title":"Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Rituximab; Medicine; Fludarabine; Internal medicine; Cyclophosphamide; Gastroenterology; Chronic lymphocytic leukemia; CD20; Pharmacokinetics; Pharmacology; Urology; Chemotherapy; Leukemia; Lymphoma","score_opus":0.00815180799116277,"score_gpt":0.2675118212815842,"score_spread":0.2593600132904214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574859067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939822,0.00024058181,0.00006612032,0.000060194558,0.000023037303,0.005481594,0.000050905,0.00003914947,0.000056193738],"genre_scores_gemma":[0.9990758,0.00007857869,0.00027406367,0.000055915734,0.000025119674,0.00022067266,0.000089100075,0.00009254273,0.00008821423],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99684197,0.00029426176,0.00069320237,0.00071692775,0.00074243377,0.00071120705],"domain_scores_gemma":[0.9978444,0.0005751878,0.0003247324,0.00063725846,0.0004141767,0.00020421893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070565747,0.0005106233,0.0011666158,0.00027364132,0.00017290097,0.000054028085,0.00021837883,0.00010835295,0.000011156651],"category_scores_gemma":[0.00009182057,0.00030679937,0.000030279944,0.00088840484,0.0005984252,0.00012702907,0.00009035113,0.00032809246,0.0000016191613],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.57593197,0.018866744,0.3839584,0.0014490596,0.0011506068,0.000852093,0.004679786,0.008979084,0.0016685874,0.000015734491,0.00004879132,0.0023991305],"study_design_scores_gemma":[0.71646506,0.05332583,0.14057294,0.0015124344,0.000950502,0.0006947688,0.00042043335,0.07728595,0.008107371,0.000005566411,0.00013314215,0.00052604167],"about_ca_topic_score_codex":0.001575448,"about_ca_topic_score_gemma":0.003371545,"teacher_disagreement_score":0.24338546,"about_ca_system_score_codex":0.008023329,"about_ca_system_score_gemma":0.0069783772,"threshold_uncertainty_score":0.9999384},"labels":[],"label_agreement":null},{"id":"W2574885367","doi":"10.1182/blood-2016-09-742957","title":"Near-triploid B lymphoblastic leukemia with Burkitt-like morphology","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Ottawa Hospital","funders":"","keywords":"Pancytopenia; Bone marrow; Lymphoblastic Leukemia; Platelet; Biopsy; Pathology; Leukemia; Medicine; Hemoglobin; Immunology; Biology; Internal medicine","score_opus":0.017765884112402573,"score_gpt":0.2805400125723233,"score_spread":0.2627741284599207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574885367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98520404,0.0003110714,0.00006939232,0.00035442773,0.00017784847,0.00044941207,0.0000073683104,0.00012595364,0.013300492],"genre_scores_gemma":[0.9913438,0.00006654842,0.0015063949,0.00034350454,0.00036315303,0.000055032546,0.000015846941,0.000071568684,0.006234129],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997788,0.00003832489,0.00026186928,0.00055145216,0.000618122,0.0007422095],"domain_scores_gemma":[0.9973421,0.00012490556,0.0001558846,0.0018177271,0.00017075943,0.0003886142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002403755,0.000262274,0.00047284146,0.00008801147,0.0005079826,0.00016237819,0.0005306664,0.00020686726,0.0003087809],"category_scores_gemma":[0.00042790108,0.00019868405,0.00009781454,0.00011275571,0.00076880824,0.00013592506,0.00028110557,0.0003116959,0.00077453366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023476433,0.016702507,0.38481638,0.005787447,0.011247021,0.16788761,0.0054847077,0.00082002865,0.2513079,0.0047014146,0.07605553,0.051713012],"study_design_scores_gemma":[0.5643373,0.006169572,0.21886636,0.0014201376,0.0030390602,0.048124623,0.0003114117,0.013151555,0.085049756,0.00045245473,0.056971975,0.002105798],"about_ca_topic_score_codex":0.0014115556,"about_ca_topic_score_gemma":0.00007329578,"teacher_disagreement_score":0.5408609,"about_ca_system_score_codex":0.0037400988,"about_ca_system_score_gemma":0.011365648,"threshold_uncertainty_score":0.99553216},"labels":[],"label_agreement":null},{"id":"W2575001609","doi":"10.1182/blood.v126.23.3976.3976","title":"A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Neutropenia; Lymphoma; Internal medicine; Gastroenterology; Follicular lymphoma; Mycosis fungoides; Antibody-drug conjugate; Mantle cell lymphoma; Alemtuzumab; Oncology; Immunology; Antibody; Toxicity; Transplantation; Monoclonal antibody","score_opus":0.04012392533851929,"score_gpt":0.360985348569889,"score_spread":0.32086142323136974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575001609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519134,0.00050911,0.0000020685213,0.00021043951,0.00021217593,0.001446691,0.000035126403,0.000043499716,0.0023495825],"genre_scores_gemma":[0.9986942,0.000052009662,0.000078075784,0.000106121086,0.00007793958,0.00004096098,0.000017595887,0.000035473142,0.0008976582],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973559,0.00019493072,0.00069898716,0.00046015566,0.0008090045,0.00048104583],"domain_scores_gemma":[0.99812716,0.00012131016,0.00020108897,0.0010700305,0.00026644563,0.00021398053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091738877,0.00021970719,0.0005663237,0.00016297036,0.00004089805,0.000018205237,0.0004200771,0.00007464981,0.000012074554],"category_scores_gemma":[0.0009926211,0.00015067558,0.00009517041,0.0006791831,0.00019231265,0.000105924824,0.0003482438,0.00022565895,0.000029293717],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023401702,0.16311887,0.07890069,0.0014288169,0.0014354876,0.007765515,0.07148022,0.0003720415,0.63743466,0.00017456629,0.0056290687,0.0088583715],"study_design_scores_gemma":[0.7582542,0.004075382,0.0066957246,0.0010829342,0.0002704085,0.0007486169,0.009036506,0.0015178791,0.21609885,0.000045816098,0.0018155636,0.00035816155],"about_ca_topic_score_codex":0.0016602776,"about_ca_topic_score_gemma":0.00024512064,"teacher_disagreement_score":0.7348525,"about_ca_system_score_codex":0.0016288786,"about_ca_system_score_gemma":0.004441035,"threshold_uncertainty_score":0.7878205},"labels":[],"label_agreement":null},{"id":"W2576001050","doi":"10.1182/blood.v110.11.3132.3132","title":"First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bone marrow; Neutropenia; Leukemia; Immunology; Anemia; Internal medicine; Gastroenterology; Toxicity","score_opus":0.04392034777098774,"score_gpt":0.3770399509250474,"score_spread":0.33311960315405964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576001050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098986,0.004313272,0.0014000669,0.0001814896,0.00025185687,0.0015520658,0.000039366685,0.00003547975,0.001236523],"genre_scores_gemma":[0.9940003,0.002146415,0.0014558055,0.000067069916,0.000537226,0.0000719121,0.000045038105,0.000044792276,0.0016314037],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99731916,0.00003623042,0.0011575002,0.00037436132,0.00058864045,0.0005241091],"domain_scores_gemma":[0.9963464,0.0017213835,0.00034279027,0.0011050389,0.00029278395,0.00019159897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002055945,0.000192593,0.0007006354,0.000094729774,0.00009630038,0.000005401779,0.00020215708,0.00020575599,0.000058037815],"category_scores_gemma":[0.0007586129,0.00012025279,0.0005409229,0.00024479965,0.0002826027,0.000027342283,0.000049107635,0.00009813983,0.00001235773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043634243,0.1294271,0.42363688,0.010988483,0.024420286,0.031443562,0.012309345,0.00033285122,0.017041098,0.0072192512,0.020632373,0.2789145],"study_design_scores_gemma":[0.30137488,0.0074146716,0.0396692,0.00038285405,0.0033500802,0.0038636853,0.0005021457,0.004897004,0.19263375,0.0001599185,0.44535068,0.00040113085],"about_ca_topic_score_codex":0.00061215804,"about_ca_topic_score_gemma":0.00020425157,"teacher_disagreement_score":0.4247183,"about_ca_system_score_codex":0.0033974887,"about_ca_system_score_gemma":0.005606211,"threshold_uncertainty_score":0.9945177},"labels":[],"label_agreement":null},{"id":"W2576914903","doi":"10.1182/blood.v120.21.1637.1637","title":"Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Rituximab; Medicine; Tolerability; Fludarabine; Cyclophosphamide; Internal medicine; Population; Phases of clinical research; Pharmacokinetics; Oncology; Gastroenterology; Adverse effect; Pharmacology; Clinical trial; Chemotherapy; Lymphoma","score_opus":0.016747515598104817,"score_gpt":0.30809539563626565,"score_spread":0.2913478800381608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576914903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498737,0.00024474578,0.00015205599,0.00006530071,0.000041976287,0.004129734,0.00023291794,0.000017356579,0.00012852292],"genre_scores_gemma":[0.9979142,0.0000566245,0.0016744296,0.000043079388,0.000041101313,0.000102213955,0.00009775062,0.000047359477,0.000023266226],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99783707,0.000069809954,0.00057537114,0.00037851828,0.00062267156,0.0005165482],"domain_scores_gemma":[0.9985322,0.00030883425,0.00020983632,0.00033394716,0.00036617048,0.0002490263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005025526,0.0002714276,0.00083686644,0.00023618889,0.000064812724,0.00001635055,0.0001079206,0.000082273174,0.00000711454],"category_scores_gemma":[0.00012472089,0.00021174755,0.000028884462,0.00034656454,0.00020672518,0.00013859934,0.00009341056,0.00018435638,0.0000010529783],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29283684,0.29852617,0.34639046,0.0033481831,0.0015605015,0.00065090426,0.025429908,0.00007926888,0.0049957316,0.00005468121,0.00017761666,0.025949737],"study_design_scores_gemma":[0.85964614,0.031430397,0.07920543,0.0005312338,0.00085177814,0.00030364923,0.00071269943,0.0016003652,0.025162814,0.000009589857,0.00016789699,0.0003780015],"about_ca_topic_score_codex":0.0004846729,"about_ca_topic_score_gemma":0.00015234342,"teacher_disagreement_score":0.5668093,"about_ca_system_score_codex":0.00047331498,"about_ca_system_score_gemma":0.0006539923,"threshold_uncertainty_score":0.86348146},"labels":[],"label_agreement":null},{"id":"W2577318470","doi":"10.1182/blood.v104.11.900.900","title":"Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Bone marrow; Cyclophosphamide; Etoposide; Fludarabine; Cytarabine; Internal medicine; Gastroenterology; Surgery; Total body irradiation; Hematopoietic stem cell transplantation; Chemotherapy; Transplantation","score_opus":0.018602419170159284,"score_gpt":0.2764058195543053,"score_spread":0.25780340038414606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577318470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985666,0.0006845146,0.0033411656,0.00018205922,0.00007086978,0.0019223092,0.000075952725,0.00015628216,0.0037101717],"genre_scores_gemma":[0.99262357,0.00016314142,0.0014917237,0.00030494682,0.00011519214,0.00043495116,0.0003948436,0.00008381875,0.0043878206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99703676,0.00006598933,0.0005806053,0.0008587492,0.0006600308,0.0007978951],"domain_scores_gemma":[0.99794257,0.00014685356,0.00010427888,0.0009127546,0.00015383966,0.0007396872],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002470953,0.00044106587,0.00085859525,0.000512729,0.0001421383,0.000061912746,0.00024033243,0.00019474451,0.000060764673],"category_scores_gemma":[0.000012540087,0.00035765418,0.00057499186,0.0007982035,0.000068319314,0.00011010755,0.000038217127,0.000061341685,0.00024052974],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027979506,0.20440814,0.010161483,0.016815152,0.013613149,0.014593183,0.054332722,0.0049463315,0.54884785,0.0023684632,0.00050448603,0.10142953],"study_design_scores_gemma":[0.29698935,0.011975204,0.0023416393,0.00042576136,0.018671485,0.0016448356,0.0012857864,0.0016570601,0.6629534,0.0002604963,0.0008321945,0.00096280285],"about_ca_topic_score_codex":0.0016744601,"about_ca_topic_score_gemma":0.0001966758,"teacher_disagreement_score":0.26900986,"about_ca_system_score_codex":0.012915733,"about_ca_system_score_gemma":0.005134867,"threshold_uncertainty_score":0.9998875},"labels":[],"label_agreement":null},{"id":"W2577541416","doi":"10.1182/blood.v106.11.1543.1543","title":"Analysis of Validated Clonotypic Igh VDJ Sequences from a Large Cohort of MM Patients.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Isotype; Biology; Immunoglobulin gene; Molecular biology; Antibody; Chronic lymphocytic leukemia; Immunology; Leukemia; Monoclonal antibody","score_opus":0.012921530007855628,"score_gpt":0.2856867852749593,"score_spread":0.27276525526710366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577541416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976495,0.00037709967,0.000030318206,0.000052478685,0.000023083363,0.00027651305,0.00024028191,0.000024615432,0.0013261052],"genre_scores_gemma":[0.9984297,0.00007253421,0.00069134525,0.00005976868,0.0000619766,0.0000115998255,0.00047379106,0.000013713441,0.00018558455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826795,0.00006251346,0.00047528138,0.0002766057,0.0006422745,0.00027538673],"domain_scores_gemma":[0.9987749,0.00014403558,0.00016868116,0.0005263281,0.00026943238,0.00011662597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002637704,0.000119396485,0.0005936311,0.0002917142,0.000023143102,0.000005565288,0.00017422948,0.0001077891,0.0009016483],"category_scores_gemma":[0.00020897535,0.0000979923,0.00020179886,0.00095190847,0.00010327903,0.000056935496,0.00007495566,0.00010814125,0.000029390914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017027982,0.002558077,0.98383117,0.00007492276,0.0056828153,0.000022482647,0.0004897626,0.00005172245,0.006054084,0.000058810194,0.00019381737,0.00081204233],"study_design_scores_gemma":[0.042929836,0.0003801684,0.7151788,0.0001260098,0.010785193,0.0000046882383,0.00011028701,0.0071862424,0.22187167,0.00003600251,0.0011752524,0.00021584902],"about_ca_topic_score_codex":0.0027795446,"about_ca_topic_score_gemma":0.00026191256,"teacher_disagreement_score":0.26865238,"about_ca_system_score_codex":0.0007566736,"about_ca_system_score_gemma":0.0013115451,"threshold_uncertainty_score":0.9872416},"labels":[],"label_agreement":null},{"id":"W2577872721","doi":"10.1182/blood.v120.21.3897.3897","title":"Comprehensive Assessment of Clinical Outcomes for CLL Patients with Trisomy 12 (+12): Results of a Population-Based Analysis of 822 CLL Patients in British Columbia (BC), Canada","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Royal Columbian Hospital; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Population; Internal medicine; Cohort; Oncology; Hazard ratio; Exact test; Proportional hazards model; Clinical trial; Confidence interval","score_opus":0.02991756457431923,"score_gpt":0.34473883324647664,"score_spread":0.31482126867215743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577872721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719733,0.000022065176,0.000015404852,0.000015467609,0.00008764582,0.0013771498,0.0012032539,0.0000059792656,0.00007572458],"genre_scores_gemma":[0.99644756,0.000005397514,0.0016767439,0.00006502495,0.000022389066,0.000047355115,0.001647506,0.00002309231,0.0000649356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963512,0.00017338034,0.0016435091,0.0003164309,0.0011235649,0.00039193686],"domain_scores_gemma":[0.9962564,0.0014141276,0.0007871951,0.0005026178,0.00082825037,0.00021140905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004821153,0.00013522674,0.0013335778,0.00018859946,0.000029568351,0.000008962281,0.00014944529,0.00012797199,0.000032760603],"category_scores_gemma":[0.00094391796,0.0001509784,0.0002616398,0.0005475769,0.00009533552,0.0000633591,0.00005247683,0.0001547089,1.18438585e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058789406,0.005171018,0.99114484,0.0003404581,0.0013639579,0.0000044812737,0.000035676443,0.00018396713,0.0000013915662,9.146466e-7,0.00042366437,0.0007417515],"study_design_scores_gemma":[0.103487246,0.0007892359,0.8914651,0.00017645932,0.0014195843,3.3186285e-7,0.000051710955,0.002371062,0.000028270619,0.0000012611262,0.00009364902,0.00011606391],"about_ca_topic_score_codex":0.9316512,"about_ca_topic_score_gemma":0.9471464,"teacher_disagreement_score":0.10289935,"about_ca_system_score_codex":0.0015549867,"about_ca_system_score_gemma":0.005186872,"threshold_uncertainty_score":0.9201289},"labels":[],"label_agreement":null},{"id":"W2578216260","doi":"10.1182/blood.v118.21.986.986","title":"ERN1/IRE1 and XBP1 Are Dispensable for Myeloma Cell Survival but Are Required for the Anti-Myeloma Activity of Bortezomib","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"XBP1; Bortezomib; Unfolded protein response; Gene silencing; ATF6; Endoplasmic reticulum; Biology; RNA interference; Gene knockdown; Cancer research; Molecular biology; Small interfering RNA; Cell biology; Transfection; Cell culture; Multiple myeloma; Immunology; Gene; Genetics; RNA","score_opus":0.061933096656635114,"score_gpt":0.2925165551521706,"score_spread":0.23058345849553552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578216260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519414,0.0006461292,0.00048526982,0.00027781448,0.00015935506,0.001959494,0.00023160702,0.000045107074,0.0010011024],"genre_scores_gemma":[0.9963426,0.00013808892,0.0010048602,0.00004904666,0.00025134132,0.00018113635,0.000013190809,0.0000619981,0.0019577106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822515,0.000053715365,0.00030836,0.00044849917,0.00039458528,0.00056966924],"domain_scores_gemma":[0.9977504,0.0007814663,0.00026267406,0.0007429679,0.0002782087,0.00018429177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005412661,0.00023173411,0.0005992893,0.00006931142,0.00017124692,0.00002274543,0.00025732396,0.00016988248,0.00004608711],"category_scores_gemma":[0.00047246378,0.00016310078,0.00019030637,0.00015485157,0.00027461917,0.00011207331,0.00015114651,0.00014849404,0.0000068806894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029049568,0.01961552,0.21007988,0.027085222,0.006261536,0.0013159467,0.0074958038,0.00001731497,0.6156379,0.0019765033,0.022742394,0.058722407],"study_design_scores_gemma":[0.07870053,0.0011702611,0.20653938,0.00039119393,0.0012346741,0.00020511016,0.0011898058,0.004901648,0.70129573,0.00028817123,0.0036172036,0.0004662614],"about_ca_topic_score_codex":0.0005064413,"about_ca_topic_score_gemma":0.00022718543,"teacher_disagreement_score":0.08565786,"about_ca_system_score_codex":0.00041787678,"about_ca_system_score_gemma":0.0011854833,"threshold_uncertainty_score":0.66510564},"labels":[],"label_agreement":null},{"id":"W2579967746","doi":"10.1182/blood.v112.11.2375.2375","title":"Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Fludarabine; Alemtuzumab; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Population; Cyclophosphamide; Oncology; Surgery; Leukemia; Transplantation; Chemotherapy; Lymphoma","score_opus":0.011123878659167119,"score_gpt":0.239181564093093,"score_spread":0.22805768543392588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579967746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626034,0.00245924,8.5919334e-7,0.000024452509,0.00004322683,0.0002888651,0.000020541567,0.000012272721,0.00089019927],"genre_scores_gemma":[0.9984762,0.0010712431,0.00004378195,0.000049546063,0.00004422801,0.000023888813,0.000033244458,0.000024973,0.00023290765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980455,0.00006536268,0.0006377673,0.00042621588,0.000343629,0.00048153254],"domain_scores_gemma":[0.99889004,0.0002450156,0.00011715565,0.00052744494,0.000034741963,0.0001856221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023154487,0.00019218522,0.00081182574,0.0007449512,0.000028712695,0.000004279134,0.00015490658,0.000114834525,0.00017394323],"category_scores_gemma":[0.0001086578,0.0001912006,0.000094697716,0.0008049512,0.00015300713,0.000076022254,0.00008153679,0.00023822406,0.000009083529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016485673,0.00063275546,0.87503946,0.0015539904,0.005333714,0.012488208,0.0025462864,0.0837788,0.0112818815,0.00013307355,0.0013434336,0.004219837],"study_design_scores_gemma":[0.11847427,0.0003843183,0.5826836,0.00027374097,0.001190234,0.0007102977,0.00023484085,0.28574198,0.009410425,0.000013142726,0.00042755043,0.00045555638],"about_ca_topic_score_codex":0.9600099,"about_ca_topic_score_gemma":0.96004987,"teacher_disagreement_score":0.2923558,"about_ca_system_score_codex":0.2583994,"about_ca_system_score_gemma":0.21646157,"threshold_uncertainty_score":0.7879804},"labels":[],"label_agreement":null},{"id":"W2580156340","doi":"10.1182/blood.v128.22.5986.5986","title":"A Distributed International Patient Data Registry for Hairy Cell Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Medicine; Data quality; Electronic data capture; Health informatics; Disease registry; Computer science; Disease; Family medicine; Pathology; Public health; Business; Clinical trial","score_opus":0.03544397970725752,"score_gpt":0.3052788525166183,"score_spread":0.2698348728093608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580156340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749143,0.00046086012,0.0087565705,0.0031407466,0.00057086354,0.0011957578,0.004942394,0.00017624887,0.005842245],"genre_scores_gemma":[0.9924899,0.00006957091,0.0022810667,0.00016333553,0.0004607685,0.00006949728,0.0014546133,0.00003066311,0.0029805969],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862057,0.000015444597,0.00023778062,0.00040947826,0.00040746527,0.00030926225],"domain_scores_gemma":[0.998293,0.00020667072,0.00007720327,0.0011129405,0.00014851995,0.00016169978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016410614,0.00011395788,0.00017091203,0.000047563964,0.000040372754,0.000020100915,0.00046807082,0.00009160939,0.00014276779],"category_scores_gemma":[0.0006848129,0.00007528638,0.0000613374,0.00007534534,0.00008169852,0.000103316204,0.0003767102,0.000081514154,0.00008612113],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030613707,0.00511879,0.0045056017,0.0010585076,0.0013666875,0.0014017274,0.00035314116,0.0000065595978,0.11833086,0.0007287172,0.7679434,0.09612464],"study_design_scores_gemma":[0.15780458,0.000709801,0.0010583623,0.0005922977,0.00040027688,0.00076061836,0.00015435574,0.0060666674,0.16243345,0.00028159175,0.66928005,0.00045796632],"about_ca_topic_score_codex":0.00008209737,"about_ca_topic_score_gemma":0.000010790991,"teacher_disagreement_score":0.15474321,"about_ca_system_score_codex":0.0036335532,"about_ca_system_score_gemma":0.004127803,"threshold_uncertainty_score":0.9501615},"labels":[],"label_agreement":null},{"id":"W2581607653","doi":"","title":"A COST-EFFECTIVENESS EVALUATION OF IBRUTINIB FOR PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN BRITISH COLUMBIA, CANADA","year":2016,"lang":"en","type":"article","venue":"38th Annual North American Meeting of the Society for Medical Decision Making","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Chemoimmunotherapy; Oncology; Leukemia; Internal medicine","score_opus":0.017421650897456144,"score_gpt":0.31544353922909374,"score_spread":0.2980218883316376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581607653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932883,0.00019797252,0.0020587218,0.00006162804,0.00018620989,0.0038637558,0.00030921516,0.000017546525,0.000016674128],"genre_scores_gemma":[0.9966631,0.00003388616,0.002524497,0.00018925646,0.0000860553,0.0003937672,0.000030089097,0.000053882148,0.000025459682],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941332,0.00025012493,0.00088626466,0.0005515933,0.003482528,0.0006963157],"domain_scores_gemma":[0.99114203,0.005758937,0.0007025112,0.00050239015,0.0016373263,0.0002567811],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035310816,0.0001920352,0.00079311,0.00004582685,0.00021424168,0.00002510856,0.00048889115,0.0001251352,0.000033783792],"category_scores_gemma":[0.01620056,0.00015489945,0.000492006,0.0008795142,0.0009630002,0.000084361214,0.00019196543,0.00020641729,3.2890273e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0018641644,0.00013156084,0.29067984,0.00085386715,0.00031053319,0.0000069434313,0.00030074155,0.0018383884,0.00002619615,0.0000017235063,0.002839937,0.7011461],"study_design_scores_gemma":[0.10426511,0.002444251,0.7865453,0.015975114,0.00062087737,0.00004633803,0.0010274868,0.08686994,0.00014271334,0.00014118142,0.0014099611,0.00051176123],"about_ca_topic_score_codex":0.36706585,"about_ca_topic_score_gemma":0.7730682,"teacher_disagreement_score":0.70063436,"about_ca_system_score_codex":0.049539726,"about_ca_system_score_gemma":0.08807905,"threshold_uncertainty_score":0.9920864},"labels":[],"label_agreement":null},{"id":"W2581928354","doi":"10.1200/jco.2015.33.7_suppl.475","title":"Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Everolimus; Medicine; Internal medicine; Oncology; Clinical endpoint; Biomarker; Urology; Randomized controlled trial","score_opus":0.2568634252205198,"score_gpt":0.5349604265872128,"score_spread":0.27809700136669296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581928354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828404,0.0003030033,0.000064298016,0.015312218,0.000244993,0.00041780423,0.0000033867916,0.00000323,0.0008106287],"genre_scores_gemma":[0.99467945,0.0006969625,0.0017290591,0.0016059631,0.0010007304,0.000003989755,0.0000015757157,0.000013700301,0.00026855725],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99388975,0.00194696,0.0027985638,0.00020203477,0.0009129523,0.0002497648],"domain_scores_gemma":[0.98296714,0.013927471,0.0018021276,0.00021903784,0.0006618062,0.00042241268],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.031037664,0.00012439003,0.0016546428,0.000104287596,0.000018078676,0.000012333567,0.00015375706,0.00039632744,0.00001493783],"category_scores_gemma":[0.02629534,0.000060048915,0.00013948674,0.00018555662,0.00042613363,0.00010191899,0.000060207953,0.0013228693,0.000002294313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17383552,0.0022464225,0.7949034,0.00006109994,0.00040611567,0.0011946489,0.00026049773,0.000010378409,0.000002811079,0.00006548157,0.0055124857,0.021501126],"study_design_scores_gemma":[0.564414,0.07387101,0.33255205,0.00019461967,0.00070635224,0.00160468,0.000890551,0.0011476757,0.0000040565546,0.0001910366,0.024300033,0.00012390608],"about_ca_topic_score_codex":0.00010994022,"about_ca_topic_score_gemma":0.00042364496,"teacher_disagreement_score":0.46235138,"about_ca_system_score_codex":0.0014640506,"about_ca_system_score_gemma":0.009632935,"threshold_uncertainty_score":0.99775064},"labels":[],"label_agreement":null},{"id":"W2582331875","doi":"10.1182/blood.v116.21.2886.2886","title":"Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Leukemia; Cytarabine; Medicine; Daunorubicin; Myeloid leukemia; Acute lymphocytic leukemia; Chronic lymphocytic leukemia; Bone marrow; Immunology; Myeloid; Pharmacology; Internal medicine","score_opus":0.017768961389472825,"score_gpt":0.27705234054049777,"score_spread":0.25928337915102495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582331875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99094653,0.00021132972,0.000020000818,0.000055472905,0.0006397916,0.0014281025,0.000021628157,0.00010596148,0.006571201],"genre_scores_gemma":[0.9986123,0.00010801241,0.00037691812,0.00011662852,0.0003833633,0.00008020903,0.000063096646,0.0000631025,0.00019639773],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99568945,0.000255545,0.00056142255,0.0006009075,0.0023393617,0.000553339],"domain_scores_gemma":[0.99726623,0.00018121087,0.00031517027,0.0010097097,0.0009704529,0.00025723004],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017453453,0.00031042987,0.0005801551,0.0003413941,0.00010890626,0.000026622703,0.00021481953,0.00035962745,0.00017078155],"category_scores_gemma":[0.0005541909,0.00028381476,0.00020352694,0.0005512782,0.0002147118,0.00024368092,0.00016475856,0.00081190263,0.00010703411],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020661643,0.0012331802,0.0008026634,0.0002926056,0.00021722601,0.000032036492,0.00036696796,0.00042167568,0.9454068,0.000008417115,0.000318426,0.050693378],"study_design_scores_gemma":[0.034510292,0.0007857673,0.023611182,0.00018966045,0.0009383349,0.00026301,0.0000621448,0.020027349,0.9189366,0.000058668928,0.00030402053,0.00031297145],"about_ca_topic_score_codex":0.00087513844,"about_ca_topic_score_gemma":0.00008833836,"teacher_disagreement_score":0.050380405,"about_ca_system_score_codex":0.00982643,"about_ca_system_score_gemma":0.017091595,"threshold_uncertainty_score":0.9999614},"labels":[],"label_agreement":null},{"id":"W2582640753","doi":"10.1182/blood.v126.23.3313.3313","title":"The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Internal medicine; Refractory (planetary science); Health care; Pediatrics; Leukemia","score_opus":0.028163136077747997,"score_gpt":0.3098915925780989,"score_spread":0.2817284565003509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582640753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937937,0.0046365964,0.0000012119336,0.00023695083,0.000048087702,0.0005977379,0.0000066826665,0.000027582139,0.0006513984],"genre_scores_gemma":[0.99912834,0.0004304829,0.00004396266,0.000035295816,0.00006129446,0.000017722416,0.00003413151,0.00001841591,0.00023036505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987204,0.00011988207,0.0002434608,0.00019702941,0.000517817,0.00020143064],"domain_scores_gemma":[0.99888575,0.00014663581,0.00011211573,0.00029239216,0.00028066777,0.00028241274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004352461,0.00008934808,0.00015965305,0.00004912003,0.00009621409,0.00001502698,0.00006685951,0.00010359797,0.0000014329148],"category_scores_gemma":[0.00083336217,0.000056513632,0.000016126301,0.0001387021,0.00030190102,0.000054402757,0.000108375476,0.00014955287,9.302517e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052676076,0.0004626445,0.97565126,0.00027417555,0.00006417103,0.000014797467,0.0015852452,1.9365001e-7,0.00004123109,0.00006024035,0.003805429,0.017513834],"study_design_scores_gemma":[0.08253577,0.00320115,0.8743582,0.001274923,0.00021976697,0.00007092766,0.00188151,0.00075229973,0.0031878916,0.00008382475,0.03221701,0.00021671958],"about_ca_topic_score_codex":0.00017005326,"about_ca_topic_score_gemma":0.000040838873,"teacher_disagreement_score":0.10129307,"about_ca_system_score_codex":0.0006730391,"about_ca_system_score_gemma":0.0011539998,"threshold_uncertainty_score":0.2304559},"labels":[],"label_agreement":null},{"id":"W2583015793","doi":"10.1182/blood.v126.23.5530.5530","title":"Myeloablative Allogeneic Stem Cell Transplantation in CLL: A Single Centre Retrospective Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Fludarabine; Thymoglobulin; Cumulative incidence; Internal medicine; Transplantation; Busulfan; Oncology; Chronic lymphocytic leukemia; Hematopoietic stem cell transplantation; Surgery; Graft-versus-host disease; Leukemia; Cyclophosphamide; Chemotherapy; Tacrolimus","score_opus":0.036322149226960386,"score_gpt":0.2835768403285401,"score_spread":0.2472546911015797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583015793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908714,0.00026541942,0.000017705408,0.00007870535,0.00005585522,0.0010831235,0.000010465551,0.0000524517,0.0075648157],"genre_scores_gemma":[0.99836385,0.000017083381,0.00013899525,0.000033369768,0.00008636014,0.00002767924,0.000018295468,0.000028138975,0.0012862204],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983017,0.00014921917,0.00025691194,0.00036737928,0.0005774276,0.00034736414],"domain_scores_gemma":[0.9992483,0.0000551294,0.000056695746,0.0002734015,0.00016379736,0.00020267173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036363484,0.00014911755,0.0002923536,0.00014995813,0.000026232801,0.000017221659,0.00009700877,0.000085661,0.000027552624],"category_scores_gemma":[0.000039122177,0.00013231888,0.00004606339,0.00040127905,0.00004443357,0.000079340854,0.000031702024,0.00020152966,0.000083640145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029745554,0.028149132,0.8134017,0.00045246797,0.0005143592,0.008869787,0.12273214,0.00012441482,0.019435016,0.00007790472,0.00052440347,0.0027441005],"study_design_scores_gemma":[0.4168766,0.007072294,0.37503353,0.00042307944,0.001079813,0.0005668366,0.045123048,0.0012227311,0.1511982,0.00028127135,0.00030260926,0.00081998005],"about_ca_topic_score_codex":0.00046767233,"about_ca_topic_score_gemma":0.0007354187,"teacher_disagreement_score":0.43836817,"about_ca_system_score_codex":0.00501903,"about_ca_system_score_gemma":0.0019737363,"threshold_uncertainty_score":0.9988005},"labels":[],"label_agreement":null},{"id":"W2583258861","doi":"10.3324/haematol.2016.159905","title":"Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia","year":2017,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Institut National Du Cancer","keywords":"CD22; Refractory (planetary science); Regimen; Medicine; Salvage therapy; Oncology; Internal medicine; B cell; Immunology; Biology; Chemotherapy; Antibody","score_opus":0.016730707934114904,"score_gpt":0.2785180608918325,"score_spread":0.2617873529577176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583258861","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67078334,0.005634399,0.00025508183,0.12508307,0.0032725413,0.033862226,0.0029784471,0.0018980816,0.15623282],"genre_scores_gemma":[0.19253159,0.0011802113,0.0073311976,0.44908884,0.005701123,0.0072968095,0.016995056,0.0019516959,0.3179235],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917679,0.00032938932,0.0010498045,0.0024451746,0.002128991,0.0022787561],"domain_scores_gemma":[0.9920118,0.0013726013,0.0013893392,0.0035541686,0.0011442485,0.00052783696],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00044644094,0.0015447263,0.0029655558,0.00048409333,0.00071486935,0.00029546383,0.0015371349,0.0032712119,0.00037839572],"category_scores_gemma":[0.0008961463,0.0011021295,0.0007494856,0.0002641459,0.0011033867,0.00047006336,0.0005450425,0.0031089361,0.0015819686],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006609362,0.00031772806,0.00009764653,0.002080717,0.001493143,0.017928833,0.00038480447,0.000002154172,0.00005113967,0.000043737728,0.970386,0.00060473196],"study_design_scores_gemma":[0.09414532,0.0091316085,0.00036474923,0.0029388687,0.004006635,0.006868388,0.00006750629,0.00045718142,0.0021784033,0.0002964659,0.87724525,0.0022996538],"about_ca_topic_score_codex":0.0006043867,"about_ca_topic_score_gemma":0.000012075362,"teacher_disagreement_score":0.47825173,"about_ca_system_score_codex":0.060000382,"about_ca_system_score_gemma":0.03586366,"threshold_uncertainty_score":0.9997301},"labels":[],"label_agreement":null},{"id":"W2584583937","doi":"10.1038/leu.2017.47","title":"Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Saint John Regional Hospital","funders":"Università degli Studi di Brescia","keywords":"Chlorambucil; Lenalidomide; Chronic lymphocytic leukemia; Internal medicine; Medicine; Randomized controlled trial; Oncology; Hematology; Fludarabine; Leukemia; Chemotherapy; Cyclophosphamide; Multiple myeloma","score_opus":0.05146143683170001,"score_gpt":0.36742473943474935,"score_spread":0.31596330260304933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584583937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97996145,0.00049155916,0.00014609395,0.00020426414,0.0007823821,0.017521722,0.000025938425,0.00009377035,0.0007727977],"genre_scores_gemma":[0.99398583,0.0003567435,0.00008717787,0.00014732426,0.0008865871,0.0022942815,0.00009115329,0.00014931525,0.0020015996],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950157,0.00026802393,0.0011917074,0.00093923206,0.0016113749,0.0009739988],"domain_scores_gemma":[0.9925071,0.0023573376,0.0010350775,0.0030171187,0.0007448679,0.00033852295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019055245,0.00065183506,0.002011793,0.00020768614,0.0008697079,0.00019250195,0.001163639,0.00026884797,0.00025561254],"category_scores_gemma":[0.0023680613,0.00038261904,0.0005396043,0.00028073238,0.0009381777,0.0002927482,0.00022169862,0.00044944606,0.000070070644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9847583,0.0009571825,0.00010910684,0.00025043133,0.0017659741,0.0000686971,0.0011822202,0.00075824343,0.00003287152,0.000097336386,0.00079288404,0.009226722],"study_design_scores_gemma":[0.95760316,0.014905815,0.00021634832,0.0002933359,0.00092211546,0.000015652837,0.00016993498,0.019907534,0.0018908298,0.00007196812,0.003594739,0.0004085556],"about_ca_topic_score_codex":0.008687309,"about_ca_topic_score_gemma":0.0005304052,"teacher_disagreement_score":0.036495656,"about_ca_system_score_codex":0.08449256,"about_ca_system_score_gemma":0.047996905,"threshold_uncertainty_score":0.99986255},"labels":[],"label_agreement":null},{"id":"W2584875660","doi":"10.1182/blood.v120.21.4132.4132","title":"Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Transplantation; Gastroenterology; Cohort; Population; Hematopoietic stem cell transplantation; Leukemia; Chronic lymphocytic leukemia; Graft-versus-host disease","score_opus":0.016796364268190696,"score_gpt":0.26737291703621,"score_spread":0.2505765527680193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584875660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98731333,0.0006351077,0.005777706,0.000022531913,0.00020132953,0.005600078,0.00029016036,0.00012409528,0.000035651603],"genre_scores_gemma":[0.9961426,0.000017973929,0.0005185917,0.00004047995,0.00032341687,0.0015257485,0.0012376634,0.00010260926,0.00009088463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971507,0.00007607246,0.000626283,0.0005312065,0.000601165,0.0010145383],"domain_scores_gemma":[0.9985374,0.0006046391,0.00013410373,0.00033483046,0.00008159855,0.0003073986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054255244,0.00038942762,0.0006503149,0.00029103085,0.00015316949,0.00002789791,0.00017511118,0.00033335362,0.000013111109],"category_scores_gemma":[0.000040813648,0.0003420808,0.00043038835,0.00028371162,0.0000424091,0.00020921952,0.000010706248,0.00017962774,0.0000046438013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035708935,0.0012861203,0.9440327,0.014509821,0.0010502707,0.00016511792,0.008489713,0.0064178514,0.019622184,0.0001600342,0.000103059414,0.0005922174],"study_design_scores_gemma":[0.29660213,0.0030387403,0.31359982,0.0023470924,0.007793094,0.00029763184,0.0008794441,0.08721273,0.2860739,0.00010912678,0.0002671581,0.0017791293],"about_ca_topic_score_codex":0.000931434,"about_ca_topic_score_gemma":0.00076770654,"teacher_disagreement_score":0.6304329,"about_ca_system_score_codex":0.03799454,"about_ca_system_score_gemma":0.017771728,"threshold_uncertainty_score":0.99990314},"labels":[],"label_agreement":null},{"id":"W2585665669","doi":"10.1182/blood.v116.21.1191.1191","title":"Molecular Characterization of a Chromosomal Translocation Linking CDK6 to the IGK Locus In CD5- Monoclonal B-Cell Lymphocytosis (MBL).","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; Mount Sinai Hospital","funders":"","keywords":"Biology; Lymphocytosis; Breakpoint; Chromosomal translocation; Comparative genomic hybridization; Molecular biology; Locus (genetics); Genetics; CD5; Gene rearrangement; Chromosome abnormality; Fluorescence in situ hybridization; Karyotype; Chromosome; Gene; Immunology; Antibody","score_opus":0.007778699166129864,"score_gpt":0.2478790830427772,"score_spread":0.24010038387664734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585665669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726975,0.000115396884,0.0004896171,0.0007678078,0.00009936614,0.00076643017,0.00001246717,0.00002911487,0.00045005314],"genre_scores_gemma":[0.9987352,0.00004658434,0.0005201499,0.00023695064,0.00019405856,0.00009416685,0.00007334044,0.000035631743,0.00006394698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983859,0.000058697125,0.00038802493,0.00030625548,0.0005295948,0.0003314964],"domain_scores_gemma":[0.9990765,0.0000642238,0.00008622692,0.0005034613,0.00013743962,0.00013215907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037558837,0.0001539844,0.00026383216,0.00018738088,0.000045970995,0.00002248804,0.00024154576,0.00016170969,0.000058264162],"category_scores_gemma":[0.00009144419,0.00012323087,0.000087510685,0.00056345336,0.00006746644,0.00007016434,0.00005732366,0.0002728125,0.000044997327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013304687,0.00067539193,0.00077731576,0.00014136003,0.00003448183,0.00009160139,0.0009978748,0.00003506441,0.99086285,0.00007808936,0.0000036939741,0.0061692363],"study_design_scores_gemma":[0.018012034,0.0001719299,0.004639597,0.00017505485,0.00008396112,0.00018117887,0.000036119865,0.0050869705,0.9709952,0.00001729057,0.00046872467,0.00013194767],"about_ca_topic_score_codex":0.000374208,"about_ca_topic_score_gemma":0.00015307448,"teacher_disagreement_score":0.019867653,"about_ca_system_score_codex":0.00072465726,"about_ca_system_score_gemma":0.0027013677,"threshold_uncertainty_score":0.5025209},"labels":[],"label_agreement":null},{"id":"W2586313031","doi":"10.1182/blood.v126.23.3983.3983","title":"Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lenalidomide; Medicine; Ibrutinib; Mantle cell lymphoma; Neutropenia; Internal medicine; Febrile neutropenia; Gastroenterology; Rituximab; Tumor lysis syndrome; Lymphoma; Oncology; Multiple myeloma; Toxicity; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.017122600569353594,"score_gpt":0.284229050499581,"score_spread":0.2671064499302274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586313031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979607,0.0001552477,6.2821243e-7,0.000015462121,0.000016867794,0.0009594588,0.000027478727,0.000011228767,0.00085291715],"genre_scores_gemma":[0.99958855,0.000015286714,0.00018193996,0.000013357143,0.000015849128,0.000011756051,0.000038004673,0.000023704279,0.00011156639],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99827397,0.000103251026,0.0004929971,0.00033301383,0.00056316884,0.00023357698],"domain_scores_gemma":[0.9987654,0.00012224402,0.00020950074,0.00043238126,0.00025780115,0.0002126872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053263933,0.0001520299,0.00047892987,0.0002080865,0.000015620883,0.000006813708,0.00008329218,0.000086925764,0.000003469426],"category_scores_gemma":[0.00026736542,0.00011506048,0.000017059823,0.00030607198,0.00015018728,0.00007895254,0.000105159204,0.000106944644,0.0000013315756],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1992011,0.19092153,0.54611415,0.0014420251,0.0012129283,0.0015272009,0.034327563,0.000016201046,0.010486651,0.0000068769154,0.0024328965,0.012310852],"study_design_scores_gemma":[0.89605707,0.016033899,0.07458335,0.00023785487,0.0002487084,0.000026330175,0.0015681717,0.0002543226,0.010721041,0.0000045283223,0.00011745298,0.00014725643],"about_ca_topic_score_codex":0.0012930386,"about_ca_topic_score_gemma":0.00007182847,"teacher_disagreement_score":0.69685596,"about_ca_system_score_codex":0.0004555422,"about_ca_system_score_gemma":0.0017677699,"threshold_uncertainty_score":0.469203},"labels":[],"label_agreement":null},{"id":"W2586467807","doi":"10.1182/blood.v108.11.4618.4618","title":"Chlorambucil Induced Angioedema of the Tongue in a Patient with Lymphoma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chlorambucil; Medicine; Pancytopenia; Surgery; Gastroenterology; Respiratory distress; Tongue; Prednisone; Internal medicine; Chemotherapy; Pathology; Bone marrow; Cyclophosphamide","score_opus":0.009971939716354515,"score_gpt":0.23396865183425702,"score_spread":0.2239967121179025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586467807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991148,0.00019684035,0.0000011680517,0.00019197249,0.000027499002,0.0004657874,0.0000031235797,0.00001715183,0.007948469],"genre_scores_gemma":[0.9994467,0.000003000107,0.00010041736,0.000081323495,0.000057924557,0.000032353015,0.0000038614553,0.00001873612,0.00025566912],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875855,0.000036023,0.00023994934,0.00019078041,0.00050234905,0.00027236113],"domain_scores_gemma":[0.99927986,0.000051765797,0.00007008286,0.00046547715,0.000081318605,0.000051519673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011816664,0.00010613891,0.00021709663,0.000081321356,0.000024521567,0.0000070277324,0.0001243804,0.000076561926,0.000024145906],"category_scores_gemma":[0.00006563695,0.000061796694,0.000062012565,0.0004891921,0.00008734199,0.000029052777,0.0000787035,0.00008123135,0.0000088841225],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006578117,0.058202557,0.50089365,0.0031647407,0.0016642387,0.017078025,0.011571316,0.0005880636,0.30723944,0.0066172504,0.0059479172,0.080454685],"study_design_scores_gemma":[0.1174026,0.0011717356,0.24244022,0.00086650305,0.00021515656,0.0023262282,0.00040695787,0.00062287407,0.63293755,0.00018310527,0.0011258773,0.00030118745],"about_ca_topic_score_codex":0.0045673847,"about_ca_topic_score_gemma":0.00071797206,"teacher_disagreement_score":0.3256981,"about_ca_system_score_codex":0.001347997,"about_ca_system_score_gemma":0.0031078449,"threshold_uncertainty_score":0.69045496},"labels":[],"label_agreement":null},{"id":"W2586496161","doi":"10.1182/blood.v112.11.3305.3305","title":"Impact of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell Transplantation for Chronic Lymphocytic Leukemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Fludarabine; Chronic lymphocytic leukemia; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Surgery; Leukemia; Refractory (planetary science); Gastroenterology; Chemotherapy; Cyclophosphamide","score_opus":0.03776748838264262,"score_gpt":0.31299995685496473,"score_spread":0.27523246847232213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586496161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712974,0.0003477445,0.00051155523,0.000009993402,0.000036894417,0.0012219978,0.00005988149,0.000069345646,0.0006128362],"genre_scores_gemma":[0.9986536,0.00024583767,0.00020574761,0.000035041656,0.0001079965,0.00009456931,0.00006700453,0.00006549569,0.00052469556],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789417,0.00004884928,0.0004740589,0.00040318767,0.00064273184,0.00053699454],"domain_scores_gemma":[0.9985825,0.00027156266,0.00016923685,0.00057921524,0.00016214297,0.00023534684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001957908,0.0002895509,0.00063646847,0.00019373832,0.000097790326,0.000008226323,0.00018653467,0.00016971157,0.0000550232],"category_scores_gemma":[0.00001808648,0.00020976881,0.00027823757,0.00027934957,0.0001956292,0.00006246844,0.0000193881,0.00017926695,0.000032813252],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.037506238,0.00989026,0.68352485,0.037363004,0.00620659,0.01069756,0.009778597,0.060317017,0.13598137,0.00042053522,0.0020943228,0.006219692],"study_design_scores_gemma":[0.3523904,0.016081093,0.24073696,0.0009644511,0.001743424,0.010781248,0.0001266733,0.023606433,0.35246813,0.000034064877,0.00009848287,0.000968633],"about_ca_topic_score_codex":0.0008201943,"about_ca_topic_score_gemma":0.000054763183,"teacher_disagreement_score":0.44278786,"about_ca_system_score_codex":0.028557561,"about_ca_system_score_gemma":0.026510004,"threshold_uncertainty_score":0.9790088},"labels":[],"label_agreement":null},{"id":"W2586541672","doi":"10.1182/blood.v112.11.4351.4351","title":"Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Rituximab; Hypogammaglobulinemia; Medicine; Internal medicine; Regimen; Autologous stem-cell transplantation; Salvage therapy; Lymphoma; Transplantation; Gastroenterology; Oncology; Surgery; Immunology; Chemotherapy; Antibody","score_opus":0.017288657268934533,"score_gpt":0.2390230450724723,"score_spread":0.22173438780353777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586541672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97208494,0.026913933,0.000010787745,0.00008641468,0.000052520307,0.0006376245,0.000019101888,0.000064402986,0.0001302888],"genre_scores_gemma":[0.9921231,0.0069553647,0.0006586544,0.000041010084,0.00004061628,0.000025645526,0.0000072742787,0.00002490114,0.00012342936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982532,0.00007328983,0.00037603464,0.0004316134,0.00047070457,0.00039512015],"domain_scores_gemma":[0.9990945,0.0002547906,0.00009430006,0.0003063506,0.00006852247,0.00018153645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034053402,0.00023176009,0.00055776566,0.00012398766,0.00016822979,0.00001760747,0.00012424971,0.0001715234,0.000005962927],"category_scores_gemma":[0.000050413004,0.00018687715,0.00006181391,0.00020670502,0.0005625276,0.0001147928,0.000083225714,0.00022918129,0.000002080509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005158979,0.005249228,0.7054186,0.0026669498,0.0011642583,0.007457726,0.030398143,0.000012986189,0.21903227,0.00011305527,0.00014215671,0.023185687],"study_design_scores_gemma":[0.2217172,0.0037656908,0.5996222,0.00070324354,0.00085307116,0.0135144405,0.00082520914,0.0017954526,0.15620066,0.000077038014,0.00020087499,0.00072495017],"about_ca_topic_score_codex":0.00041357506,"about_ca_topic_score_gemma":0.000016900096,"teacher_disagreement_score":0.2165582,"about_ca_system_score_codex":0.00020587129,"about_ca_system_score_gemma":0.0013072777,"threshold_uncertainty_score":0.7620629},"labels":[],"label_agreement":null},{"id":"W2586836514","doi":"10.1182/blood.v108.11.4941.4941","title":"Cytogenetic Aberrations and Ig VH Gene Mutations of Clinically Benign CD5-Monoclonal B-Cell Lymphocytosis (MLUS).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Lymphocytosis; Biology; CD5; Isochromosome; Chromosome abnormality; Population; Gene rearrangement; Immunology; Lymphocyte; Karyotype; Genetics; Chromosome; Lymphoma; Gene; Medicine","score_opus":0.015142396905851223,"score_gpt":0.27926449262207836,"score_spread":0.26412209571622713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586836514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899593,0.0013666775,0.00031090394,0.00023271979,0.000046514462,0.00046205684,0.000057752077,0.0000469293,0.0075171664],"genre_scores_gemma":[0.9855168,0.00021164877,0.012105322,0.00010810018,0.00024202908,0.00005489376,0.00012823711,0.000037292135,0.00159568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979234,0.000067616886,0.0007565859,0.00039640645,0.00049277954,0.00036325373],"domain_scores_gemma":[0.99858385,0.00035840107,0.00015864149,0.00047058304,0.00022544869,0.00020305092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030873256,0.0001792376,0.000377009,0.00016029112,0.00011841166,0.000025323165,0.00013490093,0.00016687236,0.00013614245],"category_scores_gemma":[0.00017220191,0.00017042912,0.00013665977,0.00031651484,0.0002817928,0.000051107058,0.00009072285,0.00014280144,0.00005252862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000989141,0.01726443,0.09187824,0.0013231526,0.0012062936,0.00087039167,0.0015158011,0.0012393217,0.86877084,0.0021464438,0.0051562553,0.0076396666],"study_design_scores_gemma":[0.17437139,0.0023779098,0.072556,0.00025602162,0.0026615486,0.002537638,0.00033466818,0.010787216,0.7284588,0.0022233017,0.002530276,0.000905235],"about_ca_topic_score_codex":0.0008229658,"about_ca_topic_score_gemma":0.00010533268,"teacher_disagreement_score":0.17338225,"about_ca_system_score_codex":0.00074889534,"about_ca_system_score_gemma":0.00458156,"threshold_uncertainty_score":0.812749},"labels":[],"label_agreement":null},{"id":"W2586851400","doi":"10.1182/blood.v120.21.1401.1401","title":"Clonal Evolution Predicts Poor Prognosis in Chronic Lymphocytic Leukaemia and Is Possibly a Worse Prognostic Factor Than 17p Deletion: A Population Based Cohort study of FISH Testing in British Columbia, Canada","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Royal Columbian Hospital; St. Paul's Hospital; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Population; Incidence (geometry); Oncology; Cohort; Chronic lymphocytic leukemia; Trisomy; Leukemia; Biology; Genetics","score_opus":0.01701396843390706,"score_gpt":0.24913012061049616,"score_spread":0.2321161521765891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586851400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578476,0.0005622882,0.0000022598697,0.000031026957,0.000063776824,0.0034260366,0.00006638744,0.0000396324,0.000023855242],"genre_scores_gemma":[0.99902695,0.000008377176,0.00013805105,0.00005625537,0.00014966982,0.00045491094,0.000080881546,0.00004004915,0.000044865377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969042,0.0001736191,0.00069526717,0.00048765546,0.0010126536,0.0007266013],"domain_scores_gemma":[0.998751,0.00032794083,0.00019070032,0.00024075725,0.00020401501,0.00028561993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005113367,0.00018826575,0.0005148475,0.00019137343,0.00008814139,0.00006580139,0.000116729934,0.00016212724,0.0000515309],"category_scores_gemma":[0.0010534781,0.00026608186,0.00003961846,0.0009803236,0.00006326544,0.00020516386,0.000082457474,0.00026502085,9.555872e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000055179284,0.0012707707,0.99653476,0.00056873565,0.00007192973,0.000214008,0.00021447221,0.000046760877,0.00012637762,1.7005242e-7,0.000087352164,0.0008094833],"study_design_scores_gemma":[0.031030148,0.0007232451,0.94711024,0.00121345,0.00020537205,0.00035642096,0.00020790439,0.018836876,0.00010300816,0.0000029269434,0.0000040707973,0.00020631841],"about_ca_topic_score_codex":0.9628442,"about_ca_topic_score_gemma":0.98113847,"teacher_disagreement_score":0.049424503,"about_ca_system_score_codex":0.03658579,"about_ca_system_score_gemma":0.026236834,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W2587075560","doi":"10.1182/blood.v104.11.3278.3278","title":"Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Alberta Hospital; Alberta Hospital Edmonton; Juravinski Cancer Centre; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Rituximab; Waldenstrom macroglobulinemia; Gastroenterology; Macroglobulinemia; Lenalidomide; Chlorambucil; Fludarabine; Cladribine; Thalidomide; Multiple myeloma; Regimen; Lymphoplasmacytic Lymphoma; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.01537208609548834,"score_gpt":0.301797900612425,"score_spread":0.28642581451693666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587075560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969088,0.00006183572,0.000003422457,0.000030586805,0.000017498327,0.0027178852,0.0000799036,0.0000530086,0.00012706265],"genre_scores_gemma":[0.9994085,0.000023492148,0.00018996159,0.000010922406,0.000027611848,0.00006377679,0.000059591795,0.000048986174,0.00016715695],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99738467,0.00009239837,0.00064114615,0.0005133556,0.0008250767,0.0005433462],"domain_scores_gemma":[0.9984114,0.00007350957,0.00029593997,0.0006831742,0.00032434147,0.0002116475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020450194,0.0003124442,0.00095889875,0.00029721324,0.000054121574,0.000008520173,0.0002101192,0.00013616677,0.000088238034],"category_scores_gemma":[0.00021059667,0.00021772561,0.00007679702,0.0010286641,0.00017380521,0.00010858698,0.00012820386,0.00028877848,0.000005206599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055874933,0.29349732,0.59950566,0.00165833,0.0022796276,0.00589817,0.0075219553,0.00017224975,0.025107106,0.000008833418,0.00008024413,0.008395541],"study_design_scores_gemma":[0.63351107,0.037927195,0.19854675,0.00090627925,0.0010485837,0.00015128963,0.0003440686,0.0001772972,0.12705268,0.0000033672095,0.0000133248395,0.00031809328],"about_ca_topic_score_codex":0.0059762984,"about_ca_topic_score_gemma":0.0015175379,"teacher_disagreement_score":0.5776361,"about_ca_system_score_codex":0.0021258814,"about_ca_system_score_gemma":0.0041147494,"threshold_uncertainty_score":0.90344155},"labels":[],"label_agreement":null},{"id":"W2587295203","doi":"10.1182/blood.v128.22.234.234","title":"Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Ibrutinib; Chronic lymphocytic leukemia; Chlorambucil; Internal medicine; Bendamustine; Oncology; Leukemia; Chemotherapy; Gastroenterology; Cyclophosphamide","score_opus":0.015178035812554546,"score_gpt":0.2728574033801529,"score_spread":0.25767936756759835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587295203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464446,0.0016504267,0.000011421472,0.000225094,0.00006120563,0.0031422724,0.00008122615,0.00011332927,0.0000705607],"genre_scores_gemma":[0.99693954,0.0016750627,0.00009010449,0.00015597921,0.00020268747,0.00015963681,0.0001606713,0.00009495975,0.0005213643],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966308,0.00021525392,0.0006427104,0.0010281348,0.00070255325,0.0007805561],"domain_scores_gemma":[0.9976847,0.00066942966,0.00017638375,0.000979585,0.00012417558,0.00036571277],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038791812,0.00051409483,0.00073628296,0.00018358897,0.00019186019,0.000077608565,0.00024545778,0.00022216613,0.000108553366],"category_scores_gemma":[0.0002093475,0.0002905105,0.00006814932,0.00043147113,0.00036606405,0.00015113251,0.00023010066,0.00019347815,0.000079662925],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.1014699,0.019594554,0.23584409,0.0007771281,0.0081029935,0.00919222,0.020274255,0.0018750881,0.004068898,0.00015252359,0.0014424464,0.5972059],"study_design_scores_gemma":[0.727658,0.009751108,0.25075927,0.0010951854,0.0010110022,0.00022685925,0.00020372815,0.0047910647,0.0018586745,0.000030218958,0.002075782,0.000539098],"about_ca_topic_score_codex":0.01453668,"about_ca_topic_score_gemma":0.0022610691,"teacher_disagreement_score":0.6261881,"about_ca_system_score_codex":0.10092366,"about_ca_system_score_gemma":0.018036164,"threshold_uncertainty_score":0.9999547},"labels":[],"label_agreement":null},{"id":"W2587436946","doi":"10.1093/ecco-jcc/jjx002.478","title":"P353 Long-term safety of adalimumab in patients with Crohn's disease: final data from PYRAMID registry","year":2017,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; MedDRA; Discontinuation; Adalimumab; Adverse effect; Observational study; Internal medicine; Postmarketing surveillance; Disease registry; Hazard ratio; Pediatrics; Disease; Pharmacovigilance; Confidence interval","score_opus":0.034682013480158334,"score_gpt":0.3180925837579027,"score_spread":0.2834105702777444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587436946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975716,0.00088001037,0.00003589774,0.00042603767,0.00009078533,0.00021882572,0.00038790272,0.0000026321093,0.00038633685],"genre_scores_gemma":[0.99857134,0.00052381505,0.00015404804,0.000053557505,0.00022277576,0.0000015042206,0.000075807046,0.000017504508,0.00037964084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982015,0.000039919472,0.0005148422,0.00022937178,0.00074536976,0.00026903485],"domain_scores_gemma":[0.99757916,0.00009011449,0.0005820387,0.0011084663,0.00029801246,0.00034221305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000282656,0.00013597775,0.00048236296,0.00008480347,0.000106932064,0.000089859706,0.0005482545,0.000074213625,0.00018241041],"category_scores_gemma":[0.00035368899,0.00009986755,0.000057198984,0.00004952684,0.00040055363,0.00037269547,0.00030101908,0.00029249935,0.0000019231827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06736076,0.00064682437,0.89935404,0.0004683502,0.00027674696,0.010162609,0.00012793166,0.0000038685985,0.000004877929,0.000059965612,0.0019357627,0.019598281],"study_design_scores_gemma":[0.027764004,0.00036331103,0.9690421,0.0015073018,0.0001364111,0.00010672476,0.00002511168,0.0001616483,0.000023864362,0.0000840824,0.0006868061,0.00009861341],"about_ca_topic_score_codex":0.0008633764,"about_ca_topic_score_gemma":0.00028160648,"teacher_disagreement_score":0.069688104,"about_ca_system_score_codex":0.0010456393,"about_ca_system_score_gemma":0.0036981471,"threshold_uncertainty_score":0.6560354},"labels":[],"label_agreement":null},{"id":"W2587523829","doi":"10.1038/ncomms14175","title":"Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia","year":2017,"lang":"en","type":"article","venue":"Nature Communications","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Center for Chronic Disease Prevention and Health Promotion; National Institute of Environmental Health Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging; Cancer Council NSW; National Human Genome Research Institute; Cancer Council Victoria; Medical Research Council; University of Texas MD Anderson Cancer Center; Institut National Du Cancer; Centers for Disease Control and Prevention; National Institutes of Health; Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail; U.S. Public Health Service; University at Buffalo; Regione Autonoma della Sardegna; Associazione Italiana per la Ricerca sul Cancro; University of Utah; Fondation de France; Generalitat de Catalunya; Canadian Institutes of Health Research; Bundesamt für Strahlenschutz; MedStar Health Research Institute; Cancerfonden; Ministerio de Economía y Competitividad; Bundesministerium für Bildung und Forschung; University of Sydney; Division of Cancer Prevention, National Cancer Institute; Health Research Board; National Health and Medical Research Council; Leukemia and Lymphoma Research; Stockholms Läns Landsting; University of Pittsburgh; Division of Cancer Epidemiology and Genetics, National Cancer Institute; Huntsman Cancer Institute; José Carreras Leukämie-Stiftung; Wellcome Trust; Memorial Sloan-Kettering Cancer Center; Yale University; Karolinska Institutet; Utah State University; European Commission; U.S. Department of Veterans Affairs; Compagnia di San Paolo; Leukemia and Lymphoma Society; Utah Department of Health; Brigham and Women's Hospital; University of California, San Francisco; U.S. Department of Health and Human Services; Instituto de Salud Carlos III; Wake Forest University; Ohio State University; Cancer Research UK; World Health Organization; University of Southern California; American Cancer Society; Michael Smith Health Research BC","keywords":"Gene; Genetics; Biology; Immune dysregulation; Genome; Transcription factor; Genome-wide association study; Immune system; Chromatin; Single-nucleotide polymorphism; Genotype","score_opus":0.028907774781107516,"score_gpt":0.35993012058122476,"score_spread":0.33102234580011725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587523829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980801,0.011719762,0.000056800072,0.002749782,0.000045957633,0.0005883686,0.000036756705,0.0000474111,0.003954147],"genre_scores_gemma":[0.9949931,0.0029609168,0.0009832776,0.00008510682,0.00005389609,0.00007341006,0.000438376,0.000023637967,0.00038826844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980977,0.00022179568,0.0005621234,0.0002703328,0.00049829343,0.0003497488],"domain_scores_gemma":[0.9922664,0.001105082,0.00062654546,0.0053558736,0.0005448359,0.00010123462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010418599,0.00017155998,0.000541543,0.0005474097,0.00048666412,0.000068788,0.0016429763,0.0005260557,0.000053385047],"category_scores_gemma":[0.0025116801,0.00016926,0.00025201848,0.0008893491,0.0002688808,0.0002777693,0.00072949484,0.0008721289,0.000025551219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014417304,0.00025708342,0.9691755,0.00020170181,0.0018649017,0.000007011484,0.00050024665,0.0023567001,0.019972958,0.0015539677,0.0002814238,0.0036843275],"study_design_scores_gemma":[0.004151118,0.000045669076,0.9443295,0.000060845767,0.000594486,0.000005142412,0.000050731844,0.04485082,0.0025049245,0.00021492474,0.0030467182,0.00014512279],"about_ca_topic_score_codex":0.0035276953,"about_ca_topic_score_gemma":0.008713667,"teacher_disagreement_score":0.05643676,"about_ca_system_score_codex":0.06377085,"about_ca_system_score_gemma":0.007334094,"threshold_uncertainty_score":0.9982934},"labels":[],"label_agreement":null},{"id":"W2587728357","doi":"10.1182/blood.v106.11.1002.1002","title":"Clonotypic IgG B Cells in Waldenstrom Macroglobulinemia Cells Are Derived from Multiple Post-Transformed B Cells That Have Undergone Isotype Switch Recombination.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunoglobulin class switching; Biology; Waldenstrom macroglobulinemia; Macroglobulinemia; Isotype; Somatic hypermutation; Molecular biology; Cytidine deaminase; Immunoglobulin M; Antibody; B cell; Immunoglobulin heavy chain; Immunoglobulin gene; Genetics; Immunology; Multiple myeloma; Immunoglobulin G; Monoclonal antibody; Lymphoma","score_opus":0.01643063475570199,"score_gpt":0.25124884265408703,"score_spread":0.23481820789838503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587728357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941011,0.00089020643,0.00020502806,0.0018082501,0.00037134672,0.0014410833,0.00021942383,0.00015701525,0.0008065565],"genre_scores_gemma":[0.99036825,0.0008069177,0.0050585545,0.00070891296,0.0003926703,0.00006991092,0.00029500137,0.00011904206,0.0021807677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961821,0.00014407576,0.00076855754,0.0009344716,0.0008853935,0.001085439],"domain_scores_gemma":[0.9975328,0.0005807873,0.00022215242,0.00091695663,0.00027976092,0.00046757655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003282134,0.00051178294,0.00080938305,0.000321353,0.00012646116,0.00007650297,0.0004503949,0.00050820253,0.0008221676],"category_scores_gemma":[0.00013032908,0.00049309066,0.000248483,0.00037552183,0.00015578666,0.00023864096,0.00014554553,0.0007815639,0.0009621398],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013203793,0.0037335895,0.007978657,0.00030168393,0.00036574685,0.0008140612,0.0016819704,0.00034690523,0.97680706,0.000008452746,0.0016840285,0.004957469],"study_design_scores_gemma":[0.063749924,0.0002690179,0.012913263,0.0003192675,0.00024254303,0.00006427407,0.0008431461,0.0077302614,0.9117264,0.0000661877,0.0015739503,0.00050173025],"about_ca_topic_score_codex":0.0035308194,"about_ca_topic_score_gemma":0.0055080084,"teacher_disagreement_score":0.06508062,"about_ca_system_score_codex":0.0047912057,"about_ca_system_score_gemma":0.0026893057,"threshold_uncertainty_score":0.9998157},"labels":[],"label_agreement":null},{"id":"W2587866472","doi":"10.1182/blood.v108.11.4664.4664","title":"Fludarabine Monophosphate in Indolent Non Hodgkin’s Lymphoma (NHL) - Clinical Experience (1995–2006).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fludarabine; Medicine; Internal medicine; Vincristine; Cyclophosphamide; Gastroenterology; Non-Hodgkin's lymphoma; Prednisone; Performance status; Lymphoma; Surgery; Chemotherapy; Oncology","score_opus":0.02251837139570574,"score_gpt":0.3336341002078854,"score_spread":0.3111157288121797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587866472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928124,0.0014169218,0.000041794243,0.00024769545,0.00027129787,0.0007153395,0.00000842984,0.00009537965,0.0043907263],"genre_scores_gemma":[0.9957482,0.00028204027,0.001036537,0.00033219627,0.0005778271,0.00014507484,0.000034049164,0.000055515975,0.0017885553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965639,0.0001034973,0.000993567,0.00072925695,0.00077105087,0.00083873986],"domain_scores_gemma":[0.9984146,0.00020237175,0.00013869794,0.0008412517,0.000106312975,0.00029679807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068390655,0.00029350258,0.00064038363,0.00020818014,0.00006530296,0.000040461095,0.0003231747,0.00028439608,0.000120943],"category_scores_gemma":[0.0002587071,0.00026039645,0.00019380816,0.00056767894,0.0002809446,0.00012686038,0.00020359606,0.00030461478,0.0004416125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004657851,0.03763324,0.78372216,0.0009231582,0.00044715745,0.019347394,0.003354119,0.0001981745,0.021260412,0.00056849915,0.012781078,0.11510676],"study_design_scores_gemma":[0.22455527,0.0014731428,0.6591341,0.0006729724,0.00018765613,0.0010439911,0.00032298264,0.00715401,0.08998601,0.00030701,0.014353766,0.0008091098],"about_ca_topic_score_codex":0.004368842,"about_ca_topic_score_gemma":0.00024532244,"teacher_disagreement_score":0.21989742,"about_ca_system_score_codex":0.002804629,"about_ca_system_score_gemma":0.0034195955,"threshold_uncertainty_score":0.9999848},"labels":[],"label_agreement":null},{"id":"W2588150126","doi":"10.1182/blood.v114.22.2338.2338","title":"FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Health Sciences Centre","funders":"","keywords":"Fludarabine; Rituximab; Internal medicine; Medicine; Cyclophosphamide; Oncology; Progression-free survival; Gastroenterology; Immunology; Chemotherapy; Lymphoma","score_opus":0.01312360996817118,"score_gpt":0.26011895442554994,"score_spread":0.24699534445737875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588150126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930606,0.0033475233,0.000003159877,0.00088365545,0.000083279585,0.0018827161,0.00019356816,0.00013490146,0.0004106327],"genre_scores_gemma":[0.9931886,0.0021318719,0.0011773418,0.0009955944,0.00011819588,0.000078058154,0.000095618336,0.00011186723,0.0021028304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523807,0.0001852855,0.0011953233,0.0011520284,0.0012290651,0.0010002443],"domain_scores_gemma":[0.99641687,0.0007326547,0.0004839284,0.0012200956,0.0004676134,0.0006788692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055498024,0.0007667255,0.0013841378,0.00028353964,0.00030557154,0.00011248915,0.000390463,0.0004150503,0.00015582159],"category_scores_gemma":[0.0011997493,0.0004444564,0.00010786806,0.000875501,0.0010369407,0.0004033486,0.00022927858,0.00072237826,0.000039707906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09148815,0.01015044,0.81350267,0.0019455489,0.0017751822,0.0028774755,0.0041828994,0.000020999843,0.02731096,0.00016488273,0.0036954363,0.042885367],"study_design_scores_gemma":[0.16824579,0.01267818,0.78997344,0.0012235086,0.0010724049,0.0011422144,0.00030068448,0.00019220756,0.021304019,0.00004053448,0.0027505853,0.0010764139],"about_ca_topic_score_codex":0.0013336772,"about_ca_topic_score_gemma":0.00021750027,"teacher_disagreement_score":0.07675765,"about_ca_system_score_codex":0.00097547524,"about_ca_system_score_gemma":0.0017303121,"threshold_uncertainty_score":0.99980074},"labels":[],"label_agreement":null},{"id":"W2588865636","doi":"10.1182/blood.v116.21.2357.2357","title":"Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Fludarabine; Transplantation; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Hematopoietic stem cell transplantation; Leukemia; Gastroenterology; Immunology; Chemotherapy; Cyclophosphamide","score_opus":0.017859198200497053,"score_gpt":0.2864295989912406,"score_spread":0.26857040079074357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588865636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960867,0.0003269299,0.0000069802873,0.000105681676,0.00024115024,0.00249378,0.0003069863,0.00004491737,0.00038684427],"genre_scores_gemma":[0.9985515,0.00018845646,0.000049113256,0.00004852063,0.00051905203,0.00012159954,0.0003409805,0.00004722854,0.00013356218],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99708706,0.0002839927,0.000815272,0.0004811647,0.00078210584,0.00055041385],"domain_scores_gemma":[0.99670666,0.0018036216,0.00030099583,0.00091235415,0.000119880584,0.00015646762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009510207,0.00029053696,0.00043264776,0.0001356679,0.000107867905,0.000030192612,0.0004317129,0.00025966618,0.000064606436],"category_scores_gemma":[0.00031141375,0.0001692439,0.00027305243,0.00052322284,0.00025168908,0.000091152324,0.00005092839,0.00059777335,0.000036817008],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.25442883,0.0035591512,0.020089319,0.0021168606,0.003095591,0.0053195707,0.04565757,0.029906405,0.61532944,0.00020922386,0.0011995882,0.01908844],"study_design_scores_gemma":[0.75534326,0.0029324908,0.15411033,0.00045757552,0.0015995074,0.00062698463,0.000568821,0.024644425,0.05909914,0.000100882615,0.00007748326,0.00043910713],"about_ca_topic_score_codex":0.030978974,"about_ca_topic_score_gemma":0.008701519,"teacher_disagreement_score":0.5562303,"about_ca_system_score_codex":0.018954286,"about_ca_system_score_gemma":0.038941562,"threshold_uncertainty_score":0.9848118},"labels":[],"label_agreement":null},{"id":"W2589069501","doi":"10.1182/blood.v110.11.892.892","title":"A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chills; Neutropenia; Internal medicine; Febrile neutropenia; Nausea; Tolerability; Gastroenterology; Adverse effect; Leukemia; Chemotherapy","score_opus":0.029615988848254057,"score_gpt":0.29868314500775756,"score_spread":0.2690671561595035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589069501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991822,0.00009491105,0.0005462207,0.00022191406,0.00024449563,0.0064598774,0.00013896199,0.000049601895,0.00042201488],"genre_scores_gemma":[0.99690896,0.000005343392,0.0010257196,0.0007031662,0.00014182844,0.000287941,0.000043351778,0.000052577176,0.0008311125],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99709386,0.00007271266,0.00071783905,0.0005283755,0.00085527916,0.00073192513],"domain_scores_gemma":[0.9979311,0.00029382968,0.00020039336,0.0006949324,0.00043866478,0.00044107967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060742156,0.00029525286,0.0006895451,0.00011891214,0.00010018606,0.000027966835,0.00034753775,0.00020990371,0.000015839425],"category_scores_gemma":[0.0010739657,0.00018113655,0.0001838765,0.00045854502,0.00011226655,0.000034706198,0.00026401592,0.00018163821,0.00001769637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5304697,0.031943943,0.0072452654,0.0013853726,0.0010332537,0.0007966378,0.0040094084,0.0000029994512,0.37156546,0.0003182688,0.029644711,0.021584976],"study_design_scores_gemma":[0.6766665,0.01916335,0.001034332,0.00052560214,0.00031373926,0.000084594045,0.00023340156,0.000043864802,0.2954584,0.00001398621,0.00610504,0.00035716468],"about_ca_topic_score_codex":0.000116489915,"about_ca_topic_score_gemma":0.00006235914,"teacher_disagreement_score":0.1461968,"about_ca_system_score_codex":0.0008885055,"about_ca_system_score_gemma":0.0019243285,"threshold_uncertainty_score":0.7386534},"labels":[],"label_agreement":null},{"id":"W2589157782","doi":"10.1182/blood-2016-10-742437","title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","year":2017,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Ibrutinib; Medicine; Bruton's tyrosine kinase; Food and drug administration; Internal medicine; Cardiology; Ventricular fibrillation; Tyrosine kinase; Pharmacology; Leukemia; Receptor","score_opus":0.027904621790663102,"score_gpt":0.291713119591134,"score_spread":0.2638084978004709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589157782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95992965,0.001741864,0.0000010941214,0.031108405,0.0002542765,0.0011559653,0.000034197587,0.000049811722,0.0057247356],"genre_scores_gemma":[0.8818285,0.0003477908,0.00044885083,0.097745545,0.010665527,0.00017209194,0.0011722079,0.00031308414,0.007306444],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741524,0.000074582196,0.00034984373,0.0006145812,0.0008393844,0.00070637104],"domain_scores_gemma":[0.9984018,0.00013726624,0.0002809993,0.0009488473,0.00010350866,0.00012757846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025058215,0.00032127707,0.00065363175,0.0003001111,0.00009420669,0.000089568144,0.00025645335,0.0007788725,0.000090139685],"category_scores_gemma":[0.00069568236,0.0002821752,0.00011674339,0.000093413306,0.00010309122,0.00006644543,0.00026776988,0.0014651235,0.00008388927],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002579086,0.0010737077,0.21062362,0.0036973679,0.0009510334,0.20946135,0.0003885548,8.119014e-7,0.000009898899,0.000015236407,0.5673498,0.0061706873],"study_design_scores_gemma":[0.16385949,0.0007042313,0.14392978,0.004135782,0.0011332545,0.0042992756,0.0000128994525,0.00015697228,0.0005210013,0.0001310195,0.679966,0.0011503291],"about_ca_topic_score_codex":0.00055866764,"about_ca_topic_score_gemma":0.000007858065,"teacher_disagreement_score":0.20516208,"about_ca_system_score_codex":0.0020993997,"about_ca_system_score_gemma":0.002333046,"threshold_uncertainty_score":0.99996305},"labels":[],"label_agreement":null},{"id":"W2589324897","doi":"10.1200/jco.2014.32.30_suppl.22","title":"Cost of treatment failure in patients with chronic lymphocytic leukemia: Results of a large U.S. observational study.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Observational study; Hematologic malignancy; Malignancy; Internal medicine; Incidence (geometry); Retrospective cohort study; Leukemia","score_opus":0.15912669978009505,"score_gpt":0.46339520996889483,"score_spread":0.30426851018879975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589324897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798816,0.000057279885,0.000047215945,0.00041659863,0.00019295797,0.0008051301,0.000018202649,0.0000040877667,0.00047039182],"genre_scores_gemma":[0.9982658,0.00007889595,0.0009510037,0.00015641242,0.00036060158,0.00001147631,0.000016560778,0.000019891444,0.00013937676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432445,0.00065753167,0.0034981067,0.0002625783,0.0009024519,0.0003548832],"domain_scores_gemma":[0.99229723,0.003608589,0.002321113,0.00040609567,0.0010784302,0.0002885152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004282927,0.00018154722,0.002062896,0.0002478589,0.000021295897,0.0000034802124,0.00024186134,0.00033970032,0.000057223897],"category_scores_gemma":[0.005206822,0.00011313627,0.00029054147,0.00035569232,0.00027078594,0.00010272314,0.00007901848,0.00054523424,0.0000070026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.057932477,0.00986218,0.8907945,0.00021110725,0.0011846112,0.00034773676,0.00064937153,0.0032752804,0.000039618222,0.00012821928,0.0018480129,0.033726852],"study_design_scores_gemma":[0.27782804,0.098186195,0.6110327,0.00027625315,0.0002673063,0.000045118326,0.00012178816,0.0041407687,0.00005404093,0.00002856894,0.007937155,0.000082060986],"about_ca_topic_score_codex":0.0005588081,"about_ca_topic_score_gemma":0.0023005814,"teacher_disagreement_score":0.27976185,"about_ca_system_score_codex":0.057490345,"about_ca_system_score_gemma":0.09610898,"threshold_uncertainty_score":0.9461278},"labels":[],"label_agreement":null},{"id":"W2589546648","doi":"10.1182/blood.v104.11.4610.4610","title":"Impaired Clonogenic Capacity Contributes to Bone Marrow Hypoplasia and Late Hematological Recovery after Zevalin in the Low-Grade NHL Patients.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bone marrow; Clonogenic assay; Medicine; Erythropoietin; Granulocyte colony-stimulating factor; Peripheral blood mononuclear cell; Haematopoiesis; Erythropoiesis; Pathology; Internal medicine; Anemia; Stem cell; Biology; Chemotherapy; Cell culture; In vitro","score_opus":0.015220309839231224,"score_gpt":0.24859090921058571,"score_spread":0.2333705993713545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589546648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569374,0.0009794855,0.000009994977,0.0020074632,0.00005743105,0.0010881929,0.00003267485,0.00003804663,0.000092951814],"genre_scores_gemma":[0.9979564,0.00008206661,0.000318398,0.0013407052,0.00005317753,0.00015430803,0.000021536503,0.000020131289,0.0000532541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981333,0.00012631831,0.00037830655,0.00039193398,0.000419001,0.0005511141],"domain_scores_gemma":[0.9990272,0.00024321761,0.000049486025,0.0004161088,0.00007236644,0.00019164187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005201733,0.00020131348,0.0004294693,0.00012816819,0.000057089463,0.00004240131,0.00014438832,0.00018655465,0.000029490822],"category_scores_gemma":[0.0006595152,0.00013273094,0.00010419609,0.00035189686,0.00015135515,0.00006419367,0.00011586254,0.0003060151,0.00007236895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019235464,0.032003507,0.87236273,0.0026618196,0.0017578019,0.01504339,0.010003937,0.00015347188,0.03583594,0.0014362198,0.004325518,0.005180214],"study_design_scores_gemma":[0.17176268,0.0021541524,0.77160037,0.0007802758,0.0004280035,0.0018136583,0.00022025747,0.00012269523,0.045148678,0.0045609423,0.00079277204,0.000615534],"about_ca_topic_score_codex":0.00033987119,"about_ca_topic_score_gemma":0.00024548263,"teacher_disagreement_score":0.15252721,"about_ca_system_score_codex":0.0015174631,"about_ca_system_score_gemma":0.0007760619,"threshold_uncertainty_score":0.5412611},"labels":[],"label_agreement":null},{"id":"W2589687802","doi":"10.1182/blood.v118.21.552.552","title":"Calpain Drives Megakaryopoiesis by Targeting the 7SK snRNP Complex: A Connection to Down Syndrome Megakaryocytic Neoplasia","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"snRNP; Biology; Cell biology; Small nuclear RNA; Calpain; P-TEFb; Molecular biology; Biochemistry; RNA; Gene expression; RNA splicing; Non-coding RNA; Enzyme","score_opus":0.026503231563810965,"score_gpt":0.2628492445985824,"score_spread":0.23634601303477143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589687802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893128,0.0005671564,0.00029173045,0.0012413722,0.00017021393,0.0011810602,0.000029223784,0.00022466021,0.006981782],"genre_scores_gemma":[0.9955023,0.0000445361,0.0016722389,0.0009098294,0.00016787453,0.00015935909,0.00005740464,0.00006983598,0.0014166011],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971808,0.00022133606,0.0004865692,0.00058163464,0.0007165773,0.0008130851],"domain_scores_gemma":[0.9981208,0.0004370781,0.000105368905,0.0007482614,0.0001513405,0.0004371824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007896556,0.0003182833,0.0005033895,0.00017625514,0.00033099554,0.000055277254,0.00040932524,0.00015993588,0.00087175774],"category_scores_gemma":[0.0007442798,0.00022680523,0.0001708852,0.00062882865,0.00023142635,0.00012140389,0.00023604305,0.00037391137,0.0005154119],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004371165,0.012066097,0.02985825,0.0026827739,0.007125763,0.0101931095,0.05176926,0.00008180267,0.2968889,0.004381942,0.5715145,0.009066482],"study_design_scores_gemma":[0.23602217,0.012801306,0.11837491,0.0022520998,0.0061850226,0.042290468,0.021978283,0.023357203,0.3873685,0.0027007305,0.14129397,0.0053753345],"about_ca_topic_score_codex":0.002742268,"about_ca_topic_score_gemma":0.00010946021,"teacher_disagreement_score":0.43022048,"about_ca_system_score_codex":0.0020358078,"about_ca_system_score_gemma":0.0014367164,"threshold_uncertainty_score":0.9545136},"labels":[],"label_agreement":null},{"id":"W2590530680","doi":"10.1182/blood.v112.11.4185.4185","title":"A Scoring System Based on Clinical, Blood Count and Immunophenotypic Data Can Predict the Risk of Disease Progression in Patients with Chronic Lymphocytic Leukemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; St. Paul's Hospital; University of British Columbia Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Univariate analysis; Internal medicine; Oncology; Risk factor; Hematology; Leukemia; Pathological; Univariate; Complete blood count; Immunology; Multivariate analysis","score_opus":0.024312960698751857,"score_gpt":0.28822430141926386,"score_spread":0.26391134072051203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590530680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600416,0.0018643773,0.0000064022584,0.000019704092,0.00006488926,0.0017348666,0.00016426604,0.000059046142,0.000082290855],"genre_scores_gemma":[0.99896723,0.0004302154,0.00013867051,0.000034318804,0.00013382653,0.00008246694,0.00014349105,0.00005128348,0.00001847026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967387,0.00032031213,0.00067867176,0.0006825028,0.0011038929,0.00047592746],"domain_scores_gemma":[0.9966353,0.00049799,0.00030942642,0.002113972,0.00014266046,0.0003006122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001006564,0.0002671431,0.00055365026,0.00013912938,0.00018541145,0.000020567417,0.0004820572,0.000111406,0.000006168932],"category_scores_gemma":[0.0005643577,0.00015768992,0.0000623937,0.00037467157,0.0005238414,0.00008533981,0.0002963525,0.00041321982,0.000004482315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005029708,0.0016637573,0.9883502,0.001549859,0.00040846397,0.00042114482,0.00013967101,0.0006567625,0.000017890612,0.0000075695416,0.00005304231,0.0017018946],"study_design_scores_gemma":[0.1515214,0.0032449076,0.75241834,0.0047466466,0.0012657724,0.000051834977,0.00004405768,0.08626585,0.000177685,0.0000015856415,0.000043638734,0.00021828357],"about_ca_topic_score_codex":0.0013439796,"about_ca_topic_score_gemma":0.00010419499,"teacher_disagreement_score":0.23593189,"about_ca_system_score_codex":0.009922449,"about_ca_system_score_gemma":0.033491798,"threshold_uncertainty_score":0.9938783},"labels":[],"label_agreement":null},{"id":"W2590655338","doi":"10.71781/31652","title":"Étude protéomique et bioinformatique du phagosome de la drosophile","year":2005,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology","score_opus":0.025226484626766313,"score_gpt":0.3797584033124702,"score_spread":0.3545319186857039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590655338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6429822,0.0013335645,0.000081403516,0.0012911181,0.00043754952,0.005111212,0.00013306747,0.0000092812925,0.34862062],"genre_scores_gemma":[0.9024908,0.002683905,0.017806683,0.0007440451,0.0022764727,0.001250332,0.0033458953,0.00023377803,0.06916808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957789,0.0006072025,0.0010145656,0.0007091071,0.0007548884,0.0011353424],"domain_scores_gemma":[0.99696666,0.0008082084,0.00043220219,0.0008486419,0.0002955435,0.00064875005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003291466,0.00064574555,0.0009431682,0.00030323726,0.0002257014,0.00065505423,0.0013371818,0.0012840829,0.015404236],"category_scores_gemma":[0.0010918756,0.000624208,0.00023797952,0.00042628992,0.00031638207,0.00083448127,0.00043700708,0.0015273022,0.007532099],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0072591677,0.0049679913,0.0025622994,0.007631717,0.002617951,0.0067861183,0.19991584,0.0019229902,0.03404309,0.013834547,0.01410125,0.704357],"study_design_scores_gemma":[0.07234029,0.0015916612,0.008130231,0.012076323,0.0009703835,0.0049103415,0.014895029,0.08879176,0.23031889,0.00052219746,0.56282157,0.0026313108],"about_ca_topic_score_codex":0.0033628447,"about_ca_topic_score_gemma":0.0024551807,"teacher_disagreement_score":0.7017257,"about_ca_system_score_codex":0.020220071,"about_ca_system_score_gemma":0.04975576,"threshold_uncertainty_score":0.9996209},"labels":[],"label_agreement":null},{"id":"W2591056031","doi":"10.1182/blood.v128.22.2054.2054","title":"Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Venetoclax; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Internal medicine; IGHV@; Oncology; Randomized controlled trial; Leukemia; Bendamustine","score_opus":0.014868334353418191,"score_gpt":0.28853567708742517,"score_spread":0.273667342734007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591056031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617684,0.0007449983,0.0000023676068,0.000063423155,0.000032355852,0.0027920206,0.00007628073,0.0000073731308,0.00010432861],"genre_scores_gemma":[0.999441,0.00035441562,0.000021928761,0.000012679995,0.00003574434,0.00003908664,0.000013996315,0.000017261818,0.000063850115],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971726,0.000491142,0.0010154705,0.0003260866,0.00069743773,0.00029725477],"domain_scores_gemma":[0.99648535,0.0023976543,0.0004351818,0.00044126215,0.00012245399,0.000118082586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013394476,0.00018674764,0.00092352345,0.00011541624,0.000051050447,0.0000058008427,0.00016889567,0.00015276062,0.000018273333],"category_scores_gemma":[0.0047259205,0.00008672253,0.000077368684,0.00034575202,0.0014091345,0.00004810968,0.00016794058,0.00017631763,2.46927e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9869746,0.0006607055,0.004827221,0.0007747168,0.0003834863,0.000040922998,0.0010906012,0.000050260667,0.0007728393,0.00014125985,0.000022492974,0.004260921],"study_design_scores_gemma":[0.97345334,0.0013083129,0.015457441,0.003925385,0.00034145487,0.00006115726,0.000026341262,0.0028869428,0.0024020243,0.00003515126,0.000009285131,0.00009313425],"about_ca_topic_score_codex":0.0018535636,"about_ca_topic_score_gemma":0.00036683682,"teacher_disagreement_score":0.013521203,"about_ca_system_score_codex":0.008435158,"about_ca_system_score_gemma":0.021154089,"threshold_uncertainty_score":0.9953713},"labels":[],"label_agreement":null},{"id":"W2591137922","doi":"10.1182/blood.v104.11.1363.1363","title":"Polymorphisms in the Hyaluronan Synthase 1 Gene May Be Predisposing Factors for Waldenstrom’s Macroglobulinemia.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Hyaluronan synthase; Biology; Molecular biology; Exon; splice; Intron; Gene; RNA splicing; Genetics; RNA","score_opus":0.03221589051560325,"score_gpt":0.30376390142880244,"score_spread":0.2715480109131992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591137922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476534,0.00059636834,0.00015515993,0.0024655734,0.00011142112,0.0012630746,0.0000928259,0.000061988205,0.00048824388],"genre_scores_gemma":[0.99612546,0.000021219508,0.0024052197,0.0005370002,0.00032426202,0.000115863964,0.00011859362,0.00005013964,0.0003022225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979073,0.000047275487,0.0003540993,0.0004108283,0.00059520395,0.00068529794],"domain_scores_gemma":[0.998773,0.00030896295,0.00006625945,0.0006087809,0.000062728446,0.0001803149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039203648,0.00023614382,0.00032139552,0.00013116971,0.00012196873,0.000046271976,0.00032502855,0.00015391393,0.000048563063],"category_scores_gemma":[0.0004020035,0.00016037305,0.000170408,0.0002884022,0.00015399471,0.00006933176,0.00007337752,0.00027551418,0.000016127771],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009453436,0.05355352,0.107498206,0.0044866195,0.00404353,0.027271712,0.06046962,0.0021918048,0.6526109,0.0143413525,0.010302814,0.05377651],"study_design_scores_gemma":[0.25180808,0.0036604693,0.035798434,0.0009310418,0.001388656,0.005552598,0.002562492,0.0013846859,0.6884817,0.0009379689,0.0063686906,0.0011251728],"about_ca_topic_score_codex":0.0010528995,"about_ca_topic_score_gemma":0.00012494616,"teacher_disagreement_score":0.24235465,"about_ca_system_score_codex":0.0024534075,"about_ca_system_score_gemma":0.0029671995,"threshold_uncertainty_score":0.6539823},"labels":[],"label_agreement":null},{"id":"W2591311294","doi":"10.1182/blood.v118.21.4613.4613","title":"The Saskatchewan Experience for Using FCR in Treatment of CLL – A Comparison of Oral Versus IV Regimens","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; Saskatchewan Cancer Agency","funders":"","keywords":"Fludarabine; Medicine; Cyclophosphamide; Rituximab; Tolerability; Regimen; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Surgery; Chemotherapy; Leukemia; Adverse effect; Lymphoma","score_opus":0.18307658965297108,"score_gpt":0.40551548883019084,"score_spread":0.22243889917721976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591311294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981516,0.0006204174,0.000027240823,0.000017142478,0.00006009635,0.0005344932,0.0000039000647,0.0000067559113,0.00057836703],"genre_scores_gemma":[0.9969461,0.000020339387,0.0028139115,0.0000025757831,0.000021597925,0.000046605976,0.0000021201447,0.000011440168,0.00013530064],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911106,0.000028244314,0.00027834537,0.00014457581,0.00019758994,0.00024017066],"domain_scores_gemma":[0.9992428,0.000188174,0.00009455132,0.00034855973,0.00006990939,0.00005604925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012510657,0.000085062995,0.00029297403,0.000046225054,0.000033802822,0.0000027201484,0.00009878021,0.000051071398,0.000013232307],"category_scores_gemma":[0.000075284726,0.00005592057,0.00007339602,0.00013300737,0.00017488345,0.00002246461,0.000028326745,0.000036742997,0.0000010736757],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058014326,0.042083483,0.11109205,0.0013823105,0.0026853853,0.00036474265,0.5890742,0.00006828385,0.12860157,0.0025527766,0.0003200129,0.063760854],"study_design_scores_gemma":[0.14000207,0.0055888155,0.0017667317,0.00017554108,0.00035080028,0.000035539822,0.03562251,0.009445342,0.8059284,0.00006562571,0.000870101,0.00014850579],"about_ca_topic_score_codex":0.003842943,"about_ca_topic_score_gemma":0.0011953516,"teacher_disagreement_score":0.67732686,"about_ca_system_score_codex":0.0012908165,"about_ca_system_score_gemma":0.0018171271,"threshold_uncertainty_score":0.5809406},"labels":[],"label_agreement":null},{"id":"W2591384843","doi":"10.1182/blood.v112.11.565.565","title":"Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Fludarabine; Alemtuzumab; Medicine; Internal medicine; Transplantation; Chronic lymphocytic leukemia; Cyclophosphamide; Minimal residual disease; Busulfan; Oncology; Surgery; Hematopoietic stem cell transplantation; Leukemia; Chemotherapy","score_opus":0.0514493279026734,"score_gpt":0.3053333784551641,"score_spread":0.25388405055249075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591384843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98807925,0.0002687719,0.00012062125,0.000010546177,0.0001991235,0.010275857,0.0008117798,0.00007640971,0.00015766363],"genre_scores_gemma":[0.99767375,0.00016329851,0.00045676777,0.000013338724,0.000280063,0.00062062975,0.00028943497,0.000083963976,0.0004187644],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99539626,0.0003025948,0.0015409706,0.0010399666,0.00092981925,0.0007904078],"domain_scores_gemma":[0.99626887,0.002036088,0.0005621562,0.00060938887,0.00028962802,0.00023388836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059477426,0.00050071767,0.0011082558,0.00037928665,0.0001501235,0.000019889725,0.0003122179,0.00028958186,0.000020829606],"category_scores_gemma":[0.00058580434,0.00042185723,0.00032681003,0.000519836,0.00022722497,0.00017449746,0.00007074624,0.00043973688,0.000023192792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.27405718,0.008772626,0.66600627,0.0013153265,0.0016973057,0.0021510192,0.03806186,0.0014322815,0.005834082,0.0000061159953,0.000046768153,0.0006191376],"study_design_scores_gemma":[0.66582143,0.006480896,0.2886458,0.00026949882,0.0012712601,0.000058299745,0.0011618213,0.0069459677,0.028943172,0.000013848775,0.000008653939,0.0003793557],"about_ca_topic_score_codex":0.006761129,"about_ca_topic_score_gemma":0.0014693508,"teacher_disagreement_score":0.39176422,"about_ca_system_score_codex":0.026251834,"about_ca_system_score_gemma":0.014479635,"threshold_uncertainty_score":0.99985296},"labels":[],"label_agreement":null},{"id":"W2591782002","doi":"10.1016/j.neurol.2017.01.197","title":"Analyse rétrospective d’efficacité chez les patients atteints de (SEP) répondant aux critères de McDonald 2010 dans l’étude ORACLE-MS","year":2017,"lang":"fr","type":"article","venue":"Revue Neurologique","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Gynecology","score_opus":0.02924178455884983,"score_gpt":0.3203182845255023,"score_spread":0.29107649996665247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591782002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97831047,0.0023863288,0.001179279,0.012153436,0.0014274179,0.0012871287,0.00019536004,0.00016889218,0.002891699],"genre_scores_gemma":[0.9810901,0.0038055093,0.00081141246,0.0014166706,0.0023190114,0.00015218437,0.000044886787,0.00018468757,0.010175495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930331,0.0013242357,0.00093129865,0.0014849836,0.0008339834,0.0023924082],"domain_scores_gemma":[0.9937515,0.0012643412,0.0006631996,0.0026129014,0.00065404206,0.0010539915],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0020506408,0.0007768966,0.0012016101,0.00029175074,0.0010219838,0.0003042371,0.0017936744,0.0012470259,0.0007373616],"category_scores_gemma":[0.0114963995,0.0007664433,0.0005572459,0.00031026456,0.0018842265,0.00036926515,0.0010046614,0.0028087862,0.0005214499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028844744,0.0031758053,0.90866625,0.0016618987,0.000955484,0.012562121,0.004922369,0.0011874951,0.020830197,0.0016805856,0.0080603,0.033413015],"study_design_scores_gemma":[0.013256381,0.0028953557,0.90376407,0.00079794804,0.0006894467,0.0010816886,0.00018104196,0.05024995,0.014509356,0.00073117897,0.011089604,0.00075397146],"about_ca_topic_score_codex":0.017061202,"about_ca_topic_score_gemma":0.0053504575,"teacher_disagreement_score":0.049062453,"about_ca_system_score_codex":0.014137191,"about_ca_system_score_gemma":0.008305767,"threshold_uncertainty_score":0.99949175},"labels":[],"label_agreement":null},{"id":"W259247391","doi":"10.1188/15.onf.200-203","title":"Richter Syndrome: An Aggressive Transformation","year":2015,"lang":"en","type":"review","venue":"Oncology nursing forum","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Fludarabine; Nausea; Chronic lymphocytic leukemia; Cyclophosphamide; Rituximab; Chemotherapy; Internal medicine; Surgery; Gastroenterology; Leukemia; Lymphoma","score_opus":0.11122057579428357,"score_gpt":0.4849416441628679,"score_spread":0.3737210683685843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W259247391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042067582,0.9691403,0.000098809884,0.0007673006,0.0010427957,0.0018103726,0.000031528958,0.00013293944,0.026933916],"genre_scores_gemma":[0.00010553765,0.9960089,0.0005039777,0.00016331334,0.00028982342,0.00019544733,0.00091779017,0.00012301185,0.001692241],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967597,0.0003960645,0.0007708773,0.0005467028,0.0006127946,0.0009138364],"domain_scores_gemma":[0.99781346,0.00016568611,0.0005216128,0.00071466,0.00022613793,0.0005584392],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068677927,0.00047414316,0.002502856,0.00050320465,0.00013241707,0.00003335741,0.00033165116,0.0012888459,0.00016415866],"category_scores_gemma":[0.00013093303,0.00036755356,0.00041325833,0.00045754504,0.00033470555,0.00022970964,0.000039701135,0.0009956954,0.0006733637],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00008328479,0.00034667732,2.1500534e-7,0.0036982417,0.00016921721,0.0015026394,0.00059832534,3.498578e-7,1.4402755e-7,0.00022138336,0.016246172,0.97713333],"study_design_scores_gemma":[0.005130652,0.0021513382,5.9747407e-7,0.024711413,0.0017479613,0.03686569,0.00026275267,0.00027578245,7.893794e-7,0.00021053904,0.9283468,0.00029568648],"about_ca_topic_score_codex":0.000026436697,"about_ca_topic_score_gemma":0.000010300723,"teacher_disagreement_score":0.97683764,"about_ca_system_score_codex":0.07245495,"about_ca_system_score_gemma":0.03660919,"threshold_uncertainty_score":0.99987763},"labels":[],"label_agreement":null},{"id":"W2592549712","doi":"10.2147/cmar.s94059","title":"New developments in the management of Waldenstr&amp;ouml;m macroglobulinemia","year":2017,"lang":"en","type":"review","venue":"Cancer Management and Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Lymphoplasmacytic Lymphoma; Waldenstrom macroglobulinemia; Medicine; Macroglobulinemia; Lymphoma; Hematology; Internal medicine; Lenalidomide; Oncology; Leukemia; Multiple myeloma; Chronic lymphocytic leukemia","score_opus":0.37549665901824836,"score_gpt":0.5471592874097043,"score_spread":0.17166262839145596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592549712","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049468563,0.93403745,0.000010978608,0.00027600626,0.00016380621,0.0040114704,0.000011669203,0.000013701383,0.06142548],"genre_scores_gemma":[0.000050797866,0.8989226,0.0012012965,0.000026865246,0.00021296699,0.00067983044,0.000064168235,0.000053807027,0.09878766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995022,0.00027563918,0.00076516694,0.00080826884,0.0021268013,0.00100211],"domain_scores_gemma":[0.99769723,0.00017240849,0.0002107706,0.0015389683,0.00014260851,0.00023800644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028120521,0.00041164955,0.0013289504,0.0008433857,0.0002482485,0.00016116894,0.0014716618,0.00025980108,0.0002509251],"category_scores_gemma":[0.000029560037,0.000255529,0.00022757846,0.00095953286,0.0003886683,0.00006546221,0.0016389311,0.0010432713,0.00013779619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006662172,0.000059468115,0.000024686637,0.08012932,0.00089758454,0.0009098115,0.00016123177,2.4900058e-7,4.879871e-8,0.001063896,0.024534179,0.8921529],"study_design_scores_gemma":[0.003997186,0.000045760517,0.00022424427,0.036467712,0.00055665686,0.000057835452,0.00018813086,0.000005475887,7.108752e-7,0.00010199089,0.9581402,0.00021408562],"about_ca_topic_score_codex":0.0008146355,"about_ca_topic_score_gemma":0.000108169705,"teacher_disagreement_score":0.933606,"about_ca_system_score_codex":0.0055059223,"about_ca_system_score_gemma":0.003989315,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W2592658930","doi":"10.3747/co.24.3182","title":"Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario","year":2017,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; University of Toronto; Hamilton Health Sciences; Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Janssen Canada","keywords":"Medicine; Cohort; Medical record; Total cost; Retrospective cohort study; Activity-based costing; Chronic lymphocytic leukemia; Fludarabine; Emergency medicine; Internal medicine; Leukemia","score_opus":0.18220407689138676,"score_gpt":0.4174384841940756,"score_spread":0.23523440730268882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592658930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890342,0.005907718,0.000017564125,0.00023621754,0.00026082067,0.00040261282,0.0000010480716,0.000013449058,0.0041263746],"genre_scores_gemma":[0.9975116,0.0019465457,0.000019376908,0.000058782152,0.00012691125,0.000027279943,0.000013516624,0.000015671845,0.000280262],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983079,0.00018883009,0.00038884432,0.00034041982,0.00044827943,0.00032571357],"domain_scores_gemma":[0.9982461,0.00068491756,0.00022202289,0.0005816328,0.00006860688,0.00019672445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012171122,0.00013790968,0.00040888463,0.00011565068,0.00015911102,0.00002155364,0.00025144542,0.00025703956,0.00011736645],"category_scores_gemma":[0.0018760695,0.00010032041,0.000025884861,0.0000652649,0.0009986754,0.00007837208,0.00037807974,0.0006123393,0.0000047335884],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0013433822,0.00016547226,0.106137134,0.00059924845,0.00009601555,0.0005641909,0.004561458,0.000022869624,0.00055956014,0.0008805097,0.0022493347,0.88282084],"study_design_scores_gemma":[0.09123925,0.0038036695,0.5009787,0.0035265712,0.00022850865,0.0019358117,0.0010443494,0.11444143,0.00044632563,0.00017251779,0.28176928,0.0004135582],"about_ca_topic_score_codex":0.01893223,"about_ca_topic_score_gemma":0.06867128,"teacher_disagreement_score":0.88240725,"about_ca_system_score_codex":0.10767006,"about_ca_system_score_gemma":0.051456813,"threshold_uncertainty_score":0.9876008},"labels":[],"label_agreement":null},{"id":"W2593453782","doi":"10.1182/blood.v106.11.3120.3120","title":"Trend of Drug Approval on Hematological Malignancies in the U.S. and Japan.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Drug; Drug approval; Approved drug; Drug development; Clinical research; Internal medicine; Pharmacology","score_opus":0.021966871190867134,"score_gpt":0.2824456067603153,"score_spread":0.26047873556944817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593453782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99133515,0.00080952,4.011358e-7,0.0011822564,0.000007398767,0.00019621538,0.0000024602803,0.000010721572,0.0064558554],"genre_scores_gemma":[0.9990982,0.00006528307,0.00021885897,0.00023025827,0.00006574903,0.000016707152,0.0000030733872,0.0000056821914,0.00029619783],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99917984,0.00004488316,0.00015940308,0.00014542922,0.00028723685,0.00018320119],"domain_scores_gemma":[0.99950826,0.000199539,0.000025760253,0.00021607976,0.000009377387,0.000041008603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030070663,0.00007261379,0.00018962282,0.000058520636,0.000018407309,0.000006490445,0.000092103706,0.00004818153,0.00002949242],"category_scores_gemma":[0.00010556212,0.000040272134,0.00003448645,0.00012917237,0.00014222339,0.00001927488,0.000036490463,0.00013061674,0.000009630318],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007935462,0.07843642,0.17387897,0.00863899,0.0016025482,0.007910219,0.14043513,0.0001520329,0.0723591,0.17774515,0.05695648,0.2739495],"study_design_scores_gemma":[0.33951217,0.0039709317,0.24325925,0.0018671759,0.0007717962,0.01526785,0.014140109,0.005530935,0.33510402,0.0019739587,0.03747383,0.0011279712],"about_ca_topic_score_codex":0.00006305992,"about_ca_topic_score_gemma":0.00006808188,"teacher_disagreement_score":0.3315767,"about_ca_system_score_codex":0.00018407161,"about_ca_system_score_gemma":0.00027139063,"threshold_uncertainty_score":0.164225},"labels":[],"label_agreement":null},{"id":"W2594646846","doi":"10.1016/s2352-3026(17)30019-4","title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"Gilead Sciences; Lymphoma Research Foundation","keywords":"Ofatumumab; Idelalisib; Medicine; Internal medicine; Population; IGHV@; Clinical endpoint; Chronic lymphocytic leukemia; Ibrutinib; Rituximab; Clinical trial; Oncology; Gastroenterology; Lymphoma; Leukemia","score_opus":0.09379685803426602,"score_gpt":0.4174588566744332,"score_spread":0.3236619986401672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594646846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929584,0.0005368013,0.00015298564,0.0010938795,0.000073246454,0.0081081465,0.000016591352,0.00003067535,0.0006918124],"genre_scores_gemma":[0.9983819,0.00032286317,0.00028576303,0.00009260706,0.00012893199,0.0005162674,0.00007868112,0.000038038077,0.0001549214],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997902,0.00031586815,0.000586253,0.0004204661,0.00023776901,0.0005376393],"domain_scores_gemma":[0.99708986,0.00087701844,0.00044287572,0.0013175855,0.0001530048,0.0001196272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015840717,0.00021988679,0.0017249242,0.0001029663,0.0002464803,0.000070010574,0.0007707727,0.00019040683,0.00002600506],"category_scores_gemma":[0.0010489519,0.0001371361,0.00003404752,0.00011396311,0.0006956849,0.00021390001,0.00020650677,0.00021607925,0.0000034881075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9847146,0.0010329195,0.00013036288,0.0008155611,0.00022012412,0.00022377302,0.0006057353,0.000023567405,0.001168962,0.004400827,0.0004072657,0.006256248],"study_design_scores_gemma":[0.964321,0.007899914,0.00021598663,0.0004023568,0.00026166145,0.0008493622,0.00003370324,0.023043197,0.0021530797,0.00043744236,0.00023689336,0.000145382],"about_ca_topic_score_codex":0.0010739255,"about_ca_topic_score_gemma":0.0006607085,"teacher_disagreement_score":0.023019629,"about_ca_system_score_codex":0.0044361935,"about_ca_system_score_gemma":0.0060141324,"threshold_uncertainty_score":0.99962085},"labels":[],"label_agreement":null},{"id":"W2594851455","doi":"10.1182/blood.v128.22.2053.2053","title":"Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Minimal residual disease; Cyclophosphamide; Internal medicine; Interim analysis; Rituximab; Surgery; Fludarabine; Chemotherapy; Melphalan; Bone marrow; Progression-free survival; Chemotherapy regimen; Oncology; Randomized controlled trial; Lymphoma","score_opus":0.011283592042245275,"score_gpt":0.2674695994931097,"score_spread":0.25618600745086445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594851455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980995,0.00005334264,0.000011566785,0.00013162638,0.000037568436,0.0015799516,0.000035209283,0.000019208823,0.000031994565],"genre_scores_gemma":[0.9995964,0.00002512216,0.000025261743,0.00007422619,0.000053699176,0.000049938608,0.00005557483,0.00004484316,0.00007489263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969887,0.00042167897,0.00079169974,0.0005552395,0.0008841136,0.0003585276],"domain_scores_gemma":[0.99783343,0.0005496896,0.00044415036,0.0006878606,0.00036455176,0.00012028731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006192692,0.0003146498,0.0007717573,0.0004913971,0.00011890734,0.000034891553,0.00026426258,0.00012917157,0.00003059438],"category_scores_gemma":[0.00073342666,0.0001646125,0.00008206762,0.0022884377,0.00065741834,0.0001801177,0.0001811385,0.00014470416,9.090408e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011372291,0.0011451084,0.97325814,0.00022871708,0.0038083962,0.00006084813,0.004791625,0.00015449522,0.0033927788,0.0001492947,0.00006969593,0.0015685909],"study_design_scores_gemma":[0.17380649,0.0012394858,0.81142783,0.00053553935,0.001589553,0.0000049838486,0.00034533613,0.00034864878,0.010511295,0.000017493425,0.0000023843497,0.00017097611],"about_ca_topic_score_codex":0.0033102767,"about_ca_topic_score_gemma":0.00093100657,"teacher_disagreement_score":0.16243419,"about_ca_system_score_codex":0.0125968605,"about_ca_system_score_gemma":0.008302608,"threshold_uncertainty_score":0.9973194},"labels":[],"label_agreement":null},{"id":"W2595699847","doi":"10.1182/blood.v108.11.3032.3032","title":"Long-Term Follow-Up of Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Transplantation; Busulfan; Internal medicine; Chronic lymphocytic leukemia; Cyclophosphamide; Surgery; Gastroenterology; Alemtuzumab; Rituximab; Chemotherapy; Leukemia; Lymphoma","score_opus":0.016587828997562278,"score_gpt":0.26758239290600494,"score_spread":0.25099456390844266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595699847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290955,0.0031535784,0.0010597049,0.000015966418,0.00015609086,0.0011995482,0.00005610007,0.00008263326,0.0013668296],"genre_scores_gemma":[0.99356383,0.0003563848,0.000326675,0.000031105115,0.00037633558,0.00013602886,0.00025387472,0.00006678939,0.004888955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979297,0.00003947275,0.0005308049,0.00041988218,0.0005144747,0.0005656471],"domain_scores_gemma":[0.9988618,0.00020071548,0.00014761978,0.0004873416,0.00016685086,0.00013568962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023900124,0.00023768595,0.00047830297,0.00016286406,0.00006895317,0.00001709502,0.0002044391,0.0002010803,0.00007614822],"category_scores_gemma":[0.000011167951,0.00021869327,0.00027053256,0.0002203334,0.00010878951,0.00007531631,0.000027368791,0.000104998166,0.000058896992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005896474,0.002274913,0.022961125,0.036134597,0.0013644159,0.0019309984,0.0013851842,0.0026512307,0.89853895,0.00081393344,0.0026109528,0.023437256],"study_design_scores_gemma":[0.16382775,0.00095510675,0.011696408,0.00040667038,0.001311756,0.0006525708,0.000027227197,0.002778549,0.8177506,0.000054588458,0.00022161457,0.000317199],"about_ca_topic_score_codex":0.00056579424,"about_ca_topic_score_gemma":0.00021075644,"teacher_disagreement_score":0.15793127,"about_ca_system_score_codex":0.019437822,"about_ca_system_score_gemma":0.019057972,"threshold_uncertainty_score":0.98650306},"labels":[],"label_agreement":null},{"id":"W2597083162","doi":"10.1182/blood.v128.22.1849.1849","title":"A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Rituximab; Tolerability; Medicine; Diffuse large B-cell lymphoma; Internal medicine; Phases of clinical research; Lymphoma; Ibrutinib; Refractory (planetary science); Pharmacology; Adverse effect; Oncology; Clinical trial; Leukemia; Chronic lymphocytic leukemia","score_opus":0.062468978753671314,"score_gpt":0.36699496717822594,"score_spread":0.30452598842455464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597083162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952727,0.0007282455,0.00011183458,0.00019197709,0.0001050051,0.0024583365,0.00034465862,0.000047284746,0.00073996815],"genre_scores_gemma":[0.99704766,0.00027496874,0.0006910358,0.000082326354,0.000049528073,0.00017730186,0.000057903406,0.00008404068,0.0015352585],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633336,0.00018403478,0.0010231659,0.0007723065,0.000881643,0.0008054597],"domain_scores_gemma":[0.99730664,0.00047396717,0.00034740198,0.0010926621,0.00040664073,0.00037267743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008343446,0.00040312984,0.0010613112,0.00047118514,0.000117163276,0.000045915753,0.00068064797,0.00021700995,0.0000016877264],"category_scores_gemma":[0.00058712694,0.00031432672,0.00008251952,0.00063442625,0.00028182357,0.00030972893,0.0008912211,0.0002135056,0.000037239824],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005160743,0.994512,0.00009118831,0.00030314326,0.0002931488,0.00021139003,0.001319236,2.4320396e-10,0.00026858924,0.00018800439,0.0003157953,0.0019814018],"study_design_scores_gemma":[0.99031943,0.0026221657,0.00002630351,0.0004391155,0.00033303731,0.00012120706,0.0008393441,0.0018529138,0.0025045308,0.00002048897,0.00060842815,0.00031303847],"about_ca_topic_score_codex":0.0015914332,"about_ca_topic_score_gemma":0.0007500497,"teacher_disagreement_score":0.99188983,"about_ca_system_score_codex":0.0014831249,"about_ca_system_score_gemma":0.001901911,"threshold_uncertainty_score":0.99993086},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2597212472","doi":"10.5489/cuaj.3283","title":"INVOLVEMENT OF THE PROSTATE BY CHRONIC LYMPHOCYTIC LYMPHOMA, CLINICAL AND PATHOLOGICAL CHARACTERIZATION","year":2016,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate; Rectal examination; Prostate biopsy; Pathological; Pathology; Hyperplasia; Cohort; Chronic lymphocytic leukemia; Biopsy; Internal medicine; Leukemia; Cancer","score_opus":0.016818738608866467,"score_gpt":0.2633998467339431,"score_spread":0.24658110812507666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597212472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849549,0.00026142102,0.00007931222,0.013859912,0.0002522955,0.00035360872,0.000070103415,0.000013252068,0.00015521796],"genre_scores_gemma":[0.9952526,0.0008845987,0.000025177831,0.002296883,0.00029575868,0.000012374531,0.000012876885,0.000012337365,0.0012073603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997581,0.00043191225,0.0006485432,0.00026018708,0.0005478957,0.0005304349],"domain_scores_gemma":[0.9981789,0.00030164167,0.0003951172,0.00019509299,0.00028231367,0.0006469461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015408744,0.00014027434,0.00034133974,0.00007964734,0.000190237,0.000040721497,0.00018103806,0.00032179654,0.00024826577],"category_scores_gemma":[0.0018437546,0.00006929905,0.00014919922,0.00019704794,0.000293794,0.00009219518,0.00006941286,0.0002325313,0.000025540732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020569994,0.00009418643,0.92277557,0.000026346208,0.00015317695,0.00009321855,0.00008800007,0.0000015708102,0.011914082,0.00025354195,0.006332836,0.05806178],"study_design_scores_gemma":[0.015521967,0.0008047415,0.9280221,0.000091497495,0.00008125701,0.0004985461,0.000018036548,0.0006004837,0.0006455315,0.0004262974,0.053140804,0.00014876518],"about_ca_topic_score_codex":0.0003860244,"about_ca_topic_score_gemma":0.00013745198,"teacher_disagreement_score":0.057913013,"about_ca_system_score_codex":0.030305473,"about_ca_system_score_gemma":0.012546559,"threshold_uncertainty_score":0.9930514},"labels":[],"label_agreement":null},{"id":"W2597243443","doi":"10.1182/blood.v106.11.934.934","title":"A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Phases of clinical research; Diffuse large B-cell lymphoma; Neutropenia; Febrile neutropenia; Transplantation; Progressive disease; Toxicity; Oncology; Pharmacology; Surgery; Chemotherapy; Gastroenterology","score_opus":0.018796161994482884,"score_gpt":0.3007050673734482,"score_spread":0.28190890537896535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597243443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944259,0.0011924704,0.0000015610922,0.00013543181,0.000020550284,0.0036565056,0.000028293554,0.000027145063,0.00051213824],"genre_scores_gemma":[0.99839455,0.00008299928,0.00013276494,0.000039373648,0.00016716751,0.00044502423,0.000013956449,0.00003679548,0.000687375],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974009,0.00022194193,0.0006753089,0.00038802577,0.00081161055,0.00050221285],"domain_scores_gemma":[0.99847454,0.000110675624,0.00018106798,0.0009906573,0.000103974824,0.00013907837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045866973,0.00026659176,0.0005805184,0.00024699443,0.00007413368,0.000009524848,0.00024274948,0.00010962466,0.000035050074],"category_scores_gemma":[0.00009854385,0.00016972185,0.00015557157,0.0005196906,0.000090543705,0.000061585786,0.00009251577,0.000116177674,0.000014975239],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022286063,0.93025804,0.00047714586,0.00026064296,0.00022338597,0.0009490223,0.025031725,0.0000013959112,0.032544725,0.0000338993,0.00015724817,0.007834161],"study_design_scores_gemma":[0.7517664,0.033451654,0.00024223657,0.00015638002,0.00042665168,0.00007059124,0.0033376885,0.00043375706,0.20776585,0.0000068893573,0.0021912735,0.0001506393],"about_ca_topic_score_codex":0.00096525945,"about_ca_topic_score_gemma":0.0005429247,"teacher_disagreement_score":0.89680636,"about_ca_system_score_codex":0.0019703258,"about_ca_system_score_gemma":0.00213599,"threshold_uncertainty_score":0.69210565},"labels":[],"label_agreement":null},{"id":"W2597924550","doi":"10.1182/blood.v128.22.230.230","title":"Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Bendamustine; Maintenance therapy; Clinical endpoint; Progression-free survival; Oncology; Randomization; IGHV@; Chronic lymphocytic leukemia; Minimal residual disease; Neutropenia; Phases of clinical research; Randomized controlled trial; Clinical trial; Leukemia; Multiple myeloma; Chemotherapy","score_opus":0.0315961884502852,"score_gpt":0.3215981640664695,"score_spread":0.2900019756161843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597924550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99074924,0.00028053642,0.00000858711,0.00011162994,0.00029709598,0.00820098,0.00008895396,0.000023626506,0.00023936496],"genre_scores_gemma":[0.99644816,0.0000680324,0.000028688217,0.00002636635,0.00019002476,0.00057694444,0.0000125730985,0.000050825256,0.0025983613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974097,0.00018485059,0.0007332462,0.00045288846,0.00072427175,0.0004950405],"domain_scores_gemma":[0.99632204,0.0016519271,0.00046005327,0.0011793779,0.00028107892,0.000105520696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006151052,0.00029459165,0.00069590914,0.000072466144,0.000117282296,0.000011917208,0.00037066,0.00008611483,0.000032232358],"category_scores_gemma":[0.00078286714,0.00011592166,0.0003232586,0.00026067244,0.00021359371,0.00006705655,0.0000713203,0.0000822187,0.000005702624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9640983,0.008303027,0.0003681701,0.000112281356,0.004263145,0.000052184772,0.0019478742,0.00002551148,0.0066298237,0.000017764638,0.0004917543,0.013690196],"study_design_scores_gemma":[0.87549955,0.042143762,0.0001968739,0.00034993008,0.0006812401,0.000008728406,0.00025126315,0.00010377869,0.0792689,0.000011132186,0.0013539272,0.0001309007],"about_ca_topic_score_codex":0.00082138786,"about_ca_topic_score_gemma":0.0007364139,"teacher_disagreement_score":0.088598706,"about_ca_system_score_codex":0.01774352,"about_ca_system_score_gemma":0.015092083,"threshold_uncertainty_score":0.99049145},"labels":[],"label_agreement":null},{"id":"W2600875206","doi":"10.1200/jco.2015.33.15_suppl.e22119","title":"The role of IL-17/IL-6 axis in the development of chronic lymphocytic leukemia.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Bone marrow; Peripheral blood mononuclear cell; Immunology; Cancer research; Leukemia; Interleukin; Interleukin 4; Tumor microenvironment; Cytokine; In vitro; Biology; Immune system","score_opus":0.13215124661092476,"score_gpt":0.45952233563395295,"score_spread":0.3273710890230282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600875206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838996,0.003467617,0.000048718448,0.0014987759,0.0005327677,0.00034792873,0.0000018536856,0.000004276882,0.010198465],"genre_scores_gemma":[0.996452,0.0007299785,0.001420319,0.00032956066,0.00071295036,0.000009245111,0.0000012449992,0.000016932972,0.00032780124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99321675,0.00088517816,0.003974612,0.00018240632,0.0012994397,0.00044162164],"domain_scores_gemma":[0.9894373,0.0070513524,0.0018608283,0.000497867,0.00081283913,0.00033985433],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01687237,0.00015625513,0.0013937707,0.00015307311,0.000049801154,0.000008452836,0.00081234414,0.00038143925,0.00004179079],"category_scores_gemma":[0.009270016,0.00007758023,0.0003764509,0.00037870265,0.0007486015,0.00007477342,0.00018941546,0.0010417794,0.00002519404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016259503,0.0022123693,0.007953576,0.0002757489,0.0012973811,0.0010571599,0.007322133,0.0014510506,0.0013603523,0.0012527251,0.019904906,0.9396531],"study_design_scores_gemma":[0.099989675,0.024661433,0.022185007,0.0006388597,0.0003977899,0.0022762727,0.007404493,0.01779047,0.0047578854,0.0037434075,0.81589365,0.00026103194],"about_ca_topic_score_codex":0.00020316026,"about_ca_topic_score_gemma":0.0005421854,"teacher_disagreement_score":0.9393921,"about_ca_system_score_codex":0.042340655,"about_ca_system_score_gemma":0.25217426,"threshold_uncertainty_score":0.9990753},"labels":[],"label_agreement":null},{"id":"W2601024426","doi":"10.1200/jco.2013.31.15_suppl.7066","title":"Post hoc analysis of sustained efficacy/tolerability of ≥12 cycles of omacetaxine mepesuccinate in chronic myeloid leukemia (CML).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Imatinib; Post-hoc analysis; Clinical trial; Gastroenterology; Regimen; Myeloid leukemia; Oncology","score_opus":0.06646397282880954,"score_gpt":0.4469472522296863,"score_spread":0.38048327940087673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601024426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949219,0.001001485,0.000049548584,0.0022481482,0.00019673305,0.0005569802,0.000013123902,0.0000063286634,0.0010057223],"genre_scores_gemma":[0.99723214,0.0010326396,0.0010915884,0.00014304362,0.00027685208,0.000005639539,0.000008605821,0.000023160905,0.00018633505],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99026453,0.0011591187,0.0066006994,0.00036466727,0.0010643497,0.00054662063],"domain_scores_gemma":[0.98424983,0.007888621,0.004077444,0.00074428803,0.0025508811,0.0004889105],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008187115,0.00024886156,0.004886488,0.0010987611,0.000020438783,0.0000053000012,0.00057367206,0.00068178785,0.0010547464],"category_scores_gemma":[0.013573695,0.00017997494,0.0015194062,0.0013030984,0.0010308754,0.00017279522,0.00021719723,0.0013108605,0.0000088092365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06928355,0.01740181,0.32783198,0.00420799,0.022634313,0.0018910178,0.002172772,0.015617765,0.1042863,0.0006888253,0.0024761087,0.43150756],"study_design_scores_gemma":[0.06335176,0.026167247,0.8774855,0.00033806945,0.0025725875,0.00011706564,0.00058584363,0.023501601,0.0048395447,0.00022778084,0.0006260267,0.00018695313],"about_ca_topic_score_codex":0.0022703845,"about_ca_topic_score_gemma":0.0011351586,"teacher_disagreement_score":0.54965353,"about_ca_system_score_codex":0.013074115,"about_ca_system_score_gemma":0.039646097,"threshold_uncertainty_score":0.99985844},"labels":[],"label_agreement":null},{"id":"W2601943785","doi":"10.1182/blood.v128.22.4778.4778","title":"The Efficacy and Cost Effectiveness of Subcutaneous Immunoglobulin (SCIG) Replacement in Patients with Immune Deficiency Secondary to Chronic Lymphocytic Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Hypogammaglobulinemia; Medicine; Chronic lymphocytic leukemia; Population; Internal medicine; Quality of life (healthcare); Ambulatory; Pediatrics; Leukemia; Surgery; Immunology; Antibody","score_opus":0.006313302183648464,"score_gpt":0.24626345919126047,"score_spread":0.23995015700761202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601943785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463236,0.0022804907,0.000029554274,0.00004624628,0.00006635589,0.0024160624,0.000015014763,0.000029233093,0.000484678],"genre_scores_gemma":[0.9993616,0.00018339987,0.000046198114,0.000022659882,0.000026657854,0.000121236415,0.000008974355,0.00003914483,0.00019014886],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975645,0.00018563578,0.00047767532,0.00048471952,0.00066761597,0.0006198826],"domain_scores_gemma":[0.9974037,0.0012334508,0.00011891341,0.00084739545,0.0002277441,0.0001687909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095512473,0.00024099849,0.00047228183,0.00014228164,0.000117264135,0.000025804808,0.00028350914,0.0000934156,0.000033946297],"category_scores_gemma":[0.000495738,0.00012830066,0.000051210354,0.00041462688,0.00032345342,0.000063401174,0.0002503748,0.0001564571,0.000034252727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.24793491,0.008144152,0.19175798,0.008753621,0.0027581316,0.0027016264,0.002741353,0.0012650763,0.18203431,0.0011192642,0.00035891755,0.35043067],"study_design_scores_gemma":[0.3493083,0.012799009,0.5713826,0.0037783664,0.00026366353,0.0006849658,0.00007758704,0.00015074565,0.060428735,0.000032288022,0.00059776567,0.0004959435],"about_ca_topic_score_codex":0.0005883159,"about_ca_topic_score_gemma":0.00007223964,"teacher_disagreement_score":0.37962463,"about_ca_system_score_codex":0.030772476,"about_ca_system_score_gemma":0.014063874,"threshold_uncertainty_score":0.9915255},"labels":[],"label_agreement":null},{"id":"W2602198097","doi":"10.1177/1078155217702214","title":"Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation","year":2017,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Rituximab; Neutropenia; Autologous stem-cell transplantation; Transplantation; Febrile neutropenia; Internal medicine; Absolute neutrophil count; Lymphoma; Chemotherapy; Surgery; Hematopoietic stem cell transplantation; Incidence (geometry); Gastroenterology; Immunology","score_opus":0.047840597583751185,"score_gpt":0.3740233987825826,"score_spread":0.3261828011988314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602198097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601424,0.00013911653,0.000044823217,0.0008075043,0.0002419183,0.00040707935,0.000012807663,0.000009119585,0.0023234126],"genre_scores_gemma":[0.99657536,0.0014383441,0.0012128818,0.00040260708,0.00004358781,0.0000050929816,0.000007682114,0.000030978645,0.00028345943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690187,0.0008022087,0.0009164208,0.00023198836,0.0007513033,0.00039618538],"domain_scores_gemma":[0.9915086,0.0039030188,0.0030489757,0.00032204235,0.0010076581,0.00020973067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017527054,0.00019574122,0.0007115081,0.000278722,0.00015915491,0.0000646061,0.00041013057,0.00014784276,0.00003145802],"category_scores_gemma":[0.0014583868,0.00015958278,0.00009428811,0.00017614062,0.00021540055,0.0019890536,0.00007772524,0.0006979761,0.000015090836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12201249,0.027463011,0.7209357,0.0015616385,0.0013389228,0.06809782,0.007321021,0.0013306089,0.013175131,0.000010336706,0.0023634334,0.034389857],"study_design_scores_gemma":[0.43894726,0.007905097,0.49794412,0.0012220877,0.0023232044,0.0077062165,0.00054378714,0.0064911577,0.033360843,0.000013295035,0.003152701,0.00039024165],"about_ca_topic_score_codex":0.0007784519,"about_ca_topic_score_gemma":0.00038518402,"teacher_disagreement_score":0.31693476,"about_ca_system_score_codex":0.0077130985,"about_ca_system_score_gemma":0.012960704,"threshold_uncertainty_score":0.99609613},"labels":[],"label_agreement":null},{"id":"W2602605464","doi":"10.1182/blood-2017-01-761973","title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","year":2017,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Venetoclax; Obinutuzumab; Chronic lymphocytic leukemia; Chlorambucil; Medicine; Internal medicine; Fludarabine; Ibrutinib; Leukemia; IGHV@; Oncology; Bendamustine; Immunology; Chemotherapy; Cyclophosphamide","score_opus":0.023312772086532346,"score_gpt":0.29351931831963235,"score_spread":0.27020654623310003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602605464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8716228,0.036963865,0.000004169349,0.05063655,0.0010596198,0.0048507047,0.00012768249,0.00045685863,0.034277722],"genre_scores_gemma":[0.56791997,0.008546868,0.0006086742,0.28008235,0.039073996,0.0011821244,0.0016903281,0.0011952203,0.09970046],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962009,0.000096762655,0.0005371397,0.001046758,0.00090877054,0.0012096716],"domain_scores_gemma":[0.99727315,0.00023789748,0.00023474835,0.0019410553,0.0000911165,0.00022201809],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00033281877,0.00058226153,0.0011899828,0.00045046164,0.00013932041,0.00014253154,0.00059110357,0.0015892407,0.00016760091],"category_scores_gemma":[0.0003071134,0.0005436093,0.00019247507,0.0001604391,0.0004637653,0.00010756905,0.00040550414,0.0023970217,0.0003320886],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018886439,0.000031030726,0.00011542284,0.0064737075,0.00067092857,0.074544996,0.00023299677,0.00007473684,0.00055779354,0.000016676247,0.91420484,0.002888039],"study_design_scores_gemma":[0.109101556,0.0006371606,0.00041326712,0.0033750325,0.00080592016,0.009827473,0.00001073179,0.010165087,0.0013979292,0.0001784984,0.86314875,0.0009385984],"about_ca_topic_score_codex":0.007007636,"about_ca_topic_score_gemma":0.00019882803,"teacher_disagreement_score":0.30370283,"about_ca_system_score_codex":0.4332169,"about_ca_system_score_gemma":0.26141214,"threshold_uncertainty_score":0.9999045},"labels":[],"label_agreement":null},{"id":"W2603510719","doi":"10.1182/blood.v128.22.4362.4362","title":"High Cumulative Illness Rating Scale (CIRS) Score in CLL Correlates with Short CLL Telomere Length and Decreased Survival","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Internal medicine; Medicine; Telomere; Buccal swab; Gastroenterology; Cancer; Surrogate endpoint; Oncology; Leukemia; Biology; Genetics","score_opus":0.01817511774152435,"score_gpt":0.27059866827796136,"score_spread":0.252423550536437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603510719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727577,0.00026160304,0.000074756026,0.00018902072,0.000066936795,0.00063270744,0.00001609432,0.000066721295,0.0014163834],"genre_scores_gemma":[0.9985583,0.00010786936,0.00058471283,0.000039657072,0.0001444767,0.00004809868,0.000016298123,0.000052968855,0.0004476426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798054,0.000105548206,0.00032533018,0.00051133096,0.00054553297,0.0005317425],"domain_scores_gemma":[0.99847555,0.00064093876,0.000060814902,0.00038882598,0.00014741432,0.00028644464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043018485,0.00024543056,0.00047727214,0.00015321687,0.000093400966,0.00002659501,0.00012050191,0.00015070401,0.0000898482],"category_scores_gemma":[0.00035760936,0.00014930275,0.00004212406,0.0003264972,0.00031013295,0.00015912598,0.0001121189,0.00024575202,0.000023904066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018711442,0.0014118693,0.96173257,0.00045721227,0.00046912787,0.0011820906,0.0018285742,0.00002494083,0.01247584,0.00057701877,0.00009594561,0.017873699],"study_design_scores_gemma":[0.30635044,0.0026886074,0.49302563,0.0071561537,0.0011512537,0.0018214735,0.0036757884,0.0049537322,0.17620696,0.0006944679,0.000347873,0.0019276075],"about_ca_topic_score_codex":0.0011165135,"about_ca_topic_score_gemma":0.00092237815,"teacher_disagreement_score":0.4687069,"about_ca_system_score_codex":0.001174992,"about_ca_system_score_gemma":0.0019209994,"threshold_uncertainty_score":0.608839},"labels":[],"label_agreement":null},{"id":"W2604372815","doi":"10.1093/pch/14.suppl_b.6a","title":"Le dépistage des maladies de surcharge lysosomiale pouvant être traitées : l’importance d’un diagnostic précoce","year":2009,"lang":"fr","type":"article","venue":"Paediatrics & Child Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Gynecology","score_opus":0.013723161827330422,"score_gpt":0.28298658726751574,"score_spread":0.26926342544018533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604372815","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37703797,0.5476615,0.0009478563,0.04729156,0.0016417695,0.0026880975,0.0004686455,0.00034498482,0.021917626],"genre_scores_gemma":[0.8036899,0.17765859,0.002898826,0.006946697,0.005446677,0.000056988723,0.0001606128,0.00014318964,0.0029985292],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99079686,0.0006922284,0.0015927415,0.0012318245,0.0013120935,0.0043742214],"domain_scores_gemma":[0.9928153,0.0027015666,0.0005964663,0.0011495535,0.00031086165,0.0024262567],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037301725,0.0007940413,0.0014728623,0.00048396346,0.0012739635,0.00012916664,0.00071175187,0.0005442044,0.00054590666],"category_scores_gemma":[0.00580832,0.0008404551,0.00043891676,0.0015759652,0.0006808317,0.00035581732,0.00017819385,0.0016586249,0.0003747288],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014264501,0.010203954,0.2844329,0.026769059,0.0008506288,0.009959496,0.04335814,0.0008506771,0.00013576938,0.08987794,0.16674729,0.36538774],"study_design_scores_gemma":[0.07785342,0.007589226,0.6900407,0.008547437,0.0012416965,0.007823289,0.0046088616,0.011403109,0.0012390168,0.028433286,0.15725009,0.0039698863],"about_ca_topic_score_codex":0.0037419198,"about_ca_topic_score_gemma":0.0015673083,"teacher_disagreement_score":0.42665192,"about_ca_system_score_codex":0.02410528,"about_ca_system_score_gemma":0.046776894,"threshold_uncertainty_score":0.9994046},"labels":[],"label_agreement":null},{"id":"W2604822177","doi":"10.1007/s00277-017-2982-1","title":"Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia","year":2017,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; Ottawa Hospital; BC Cancer Agency; Université Laval; University of Calgary; McGill University Health Centre","funders":"","keywords":"Ibrutinib; Chemoimmunotherapy; Medicine; Fludarabine; Venetoclax; Idelalisib; Chronic lymphocytic leukemia; Alemtuzumab; Rituximab; Oncology; Internal medicine; Hematology; Cyclophosphamide; Salvage therapy; Transplantation; Leukemia; Immunology; Lymphoma; Chemotherapy","score_opus":0.18479468047227215,"score_gpt":0.4725117241757338,"score_spread":0.28771704370346163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604822177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003883601,0.99196833,0.000001914024,0.00006795047,0.00016646151,0.0014683157,0.000026046959,0.000014965526,0.0058976747],"genre_scores_gemma":[0.0039168335,0.9951678,0.000018639026,0.000037604666,0.00015399477,0.00026308483,0.00007754731,0.000054504915,0.00031002675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99650407,0.00039307206,0.0013858303,0.0005324087,0.00051490596,0.0006697115],"domain_scores_gemma":[0.99505115,0.0014732694,0.0012003602,0.0020422095,0.00012469596,0.000108310975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005045679,0.0005041488,0.0044269357,0.0004724752,0.000060451253,0.000008734136,0.00081576564,0.0006276477,0.000075746335],"category_scores_gemma":[0.00040706276,0.00029137236,0.0009362358,0.00026638835,0.00079653796,0.00009648612,0.00008053057,0.00032749065,0.00007168743],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013693167,0.00028206132,0.0000064973533,0.048391163,0.00033927066,0.0009842301,0.0002345231,0.0000038424278,7.0481167e-7,0.0015353257,0.0006655988,0.9474198],"study_design_scores_gemma":[0.0055329213,0.0022746287,0.000002515839,0.015165485,0.0004949106,0.0024482203,0.000037100144,0.00005972709,0.000117437085,0.00017390448,0.9734989,0.00019427936],"about_ca_topic_score_codex":0.0006100758,"about_ca_topic_score_gemma":0.00014612904,"teacher_disagreement_score":0.9728333,"about_ca_system_score_codex":0.01678688,"about_ca_system_score_gemma":0.058755033,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W2604984698","doi":"10.1200/jco.2017.35.8_suppl.50","title":"Effect of the establishment of a hematological multidisciplinary oral chemotherapy clinic at a community hospital on the number of emergency department visits.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto East General Hospital","funders":"","keywords":"Medicine; Emergency department; Adverse effect; Pharmacist; Emergency medicine; Medical record; Internal medicine; Pharmacy; Family medicine","score_opus":0.12107626743658084,"score_gpt":0.5189730152565961,"score_spread":0.3978967478200153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604984698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892117,0.000108315115,0.000003775439,0.006518454,0.0010183343,0.0007283513,0.000008552232,0.0000030758486,0.0023994525],"genre_scores_gemma":[0.99859214,0.00057596876,0.0002165896,0.00015391587,0.00018776287,0.000011259013,0.0000012021652,0.000016656059,0.00024450064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925709,0.0030613274,0.00298105,0.00017231354,0.00092136033,0.0002930718],"domain_scores_gemma":[0.9830893,0.010260641,0.004620671,0.0013246477,0.00048802866,0.00021666016],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013553533,0.00019677391,0.0021281536,0.000039981005,0.00022522356,0.0000048659163,0.0012023253,0.0004129778,0.0007547941],"category_scores_gemma":[0.014335513,0.00008500092,0.0013020341,0.00010297788,0.0011367509,0.000062809115,0.00082371524,0.0015897248,0.00001660163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035885,0.013194218,0.91507894,0.0005290042,0.0016334433,0.000240089,0.00075605273,0.0000088518145,0.00058712566,0.00019635497,0.010541685,0.021349223],"study_design_scores_gemma":[0.05259626,0.07137846,0.85802907,0.00066098623,0.00063651585,0.0004008561,0.00025203725,0.00036700992,0.013289861,0.0006946272,0.0015450624,0.00014922356],"about_ca_topic_score_codex":0.00011886483,"about_ca_topic_score_gemma":0.000046242225,"teacher_disagreement_score":0.058184247,"about_ca_system_score_codex":0.0013752688,"about_ca_system_score_gemma":0.0031268352,"threshold_uncertainty_score":0.9939672},"labels":[],"label_agreement":null},{"id":"W2605606572","doi":"10.1200/jco.2014.32.15_suppl.e19542","title":"Safety and use of bendamustine from the Bendamustine Expanded Access Trial in Canada (Bend-ACT).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; CancerCare Manitoba; University of Calgary; Hôpital de l'Enfant-Jésus; Dalhousie University; BC Cancer Agency; University of Manitoba; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Bendamustine; Rituximab; Internal medicine; Regimen; Adverse effect; Chronic lymphocytic leukemia; Refractory (planetary science); Surgery; Leukemia; Lymphoma","score_opus":0.21031669238799813,"score_gpt":0.48222720906942623,"score_spread":0.27191051668142807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605606572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891765,0.00019154394,0.00009037812,0.00857325,0.0011284889,0.00034286865,0.000017497317,0.000002775636,0.00047670372],"genre_scores_gemma":[0.99487275,0.00079121446,0.0006205284,0.0018570737,0.0017451291,0.0000022241131,0.000006919325,0.000016413573,0.000087766784],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99460745,0.0009553262,0.0031652634,0.0002277944,0.0007196654,0.00032447773],"domain_scores_gemma":[0.97440904,0.022783717,0.0016221587,0.0003635939,0.00039392695,0.00042756842],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045247246,0.00015224768,0.0018217576,0.000087929984,0.00003561409,0.000016011836,0.00038623268,0.00027121912,0.00031433275],"category_scores_gemma":[0.026304906,0.00008909979,0.00020199534,0.00020164122,0.00031650052,0.00015608595,0.00023831638,0.0012702566,0.0000011604014],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.42099145,0.0014746628,0.18348856,0.00010222594,0.0007624646,0.0013886179,0.00022990597,0.00035744812,0.00020800145,0.00018688697,0.017914351,0.37289542],"study_design_scores_gemma":[0.42076197,0.008572289,0.45784116,0.00025438663,0.00037299294,0.00036062024,0.00016426278,0.006092242,0.0001453478,0.00023341893,0.105048545,0.00015275864],"about_ca_topic_score_codex":0.52839607,"about_ca_topic_score_gemma":0.65718496,"teacher_disagreement_score":0.37274268,"about_ca_system_score_codex":0.003844973,"about_ca_system_score_gemma":0.049244292,"threshold_uncertainty_score":0.9999791},"labels":[],"label_agreement":null},{"id":"W2605943665","doi":"10.1182/blood.v128.22.1218.1218","title":"Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cégep de l'Outaouais; Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Refractory (planetary science); Phases of clinical research; Lymphoma; Clinical endpoint; Oncology; Regimen; Salvage therapy; Clinical trial; Chemotherapy","score_opus":0.024602021958420383,"score_gpt":0.3463210955347562,"score_spread":0.32171907357633583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605943665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773747,0.000022556827,0.00003481733,0.000119877564,0.00006337815,0.0016028949,0.000012191221,0.000022497046,0.00038432912],"genre_scores_gemma":[0.99957585,0.0000116426145,0.00013366262,0.000041002735,0.00007753007,0.000063529995,0.000002910706,0.000032087155,0.0000617599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973021,0.0003726814,0.0006401865,0.00043684038,0.0008550995,0.00039310666],"domain_scores_gemma":[0.99762124,0.00095131743,0.00027701285,0.00081213284,0.00017647943,0.00016184583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013411574,0.00019444397,0.00051205023,0.000115480274,0.000057533125,0.000010790358,0.0002381051,0.00013244942,0.000028106],"category_scores_gemma":[0.00092985167,0.000095232754,0.00009364159,0.0003235251,0.00027830922,0.00011575104,0.00014398978,0.0002640289,0.000012499484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006897584,0.04941848,0.80241597,0.00007372231,0.00039387142,0.00024731943,0.00087692076,5.8142246e-7,0.0013506006,0.0000041289127,0.000053136035,0.13826768],"study_design_scores_gemma":[0.2966404,0.0068959366,0.6932853,0.0003906136,0.00015774155,0.000014441867,0.00024221509,0.00014845627,0.002073642,0.0000032420712,0.000025443642,0.00012260844],"about_ca_topic_score_codex":0.00034404124,"about_ca_topic_score_gemma":0.00019024813,"teacher_disagreement_score":0.2897428,"about_ca_system_score_codex":0.0015315451,"about_ca_system_score_gemma":0.0041264445,"threshold_uncertainty_score":0.7320136},"labels":[],"label_agreement":null},{"id":"W2606627097","doi":"10.1084/jem.20160894","title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2","year":2017,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Hertz Foundation; National Institutes of Health; National Science Foundation","keywords":"KRAS; Cancer research; Lymphoma; Biology; Enteropathy; Mutation; T-cell lymphoma; Genetics; Gene; Medicine; Disease; Immunology; Internal medicine","score_opus":0.021514969052558394,"score_gpt":0.3070130836189852,"score_spread":0.2854981145664268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606627097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920083,0.005787409,0.000032436696,0.00060062663,0.0004346322,0.0002854492,0.00001381507,0.0000060010666,0.0008313073],"genre_scores_gemma":[0.9982819,0.00060428685,0.000013313358,0.00013986664,0.00034373903,0.0000034339535,0.000009912381,0.00002634619,0.0005772094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977311,0.00015377051,0.000806571,0.000115705174,0.0009463845,0.00024646326],"domain_scores_gemma":[0.9967797,0.00016900177,0.0020032143,0.00052562356,0.00034876718,0.00017372085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011320978,0.0001786554,0.00079057046,0.00011835196,0.00012008707,0.000007722895,0.00044618998,0.00009173703,0.00029860836],"category_scores_gemma":[0.00029767046,0.00010309933,0.00014293632,0.00008461749,0.00071701995,0.00014520725,0.000118859316,0.00018500739,0.0000061356027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006154814,0.00095877325,0.003491038,0.0001381731,0.00025310484,0.00009273279,0.0013989263,2.7240776e-7,0.98456454,0.000004206322,0.0021710412,0.00077234855],"study_design_scores_gemma":[0.05544294,0.004991614,0.021456333,0.0013635716,0.00036007346,0.00047014066,0.003156642,0.00009998478,0.91182417,0.000016790726,0.00071550335,0.00010225636],"about_ca_topic_score_codex":0.0002738151,"about_ca_topic_score_gemma":0.0000024150006,"teacher_disagreement_score":0.07274042,"about_ca_system_score_codex":0.0016931788,"about_ca_system_score_gemma":0.0005842647,"threshold_uncertainty_score":0.44276035},"labels":[],"label_agreement":null},{"id":"W2606644796","doi":"10.1182/blood.v128.22.5572.5572","title":"Atypical Chronic Lymphocytic Leukemia with CD200 Expression Shares Similar Outcomes to Classical Chronic Lymphocytic Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chronic lymphocytic leukemia; Immunophenotyping; Mantle cell lymphoma; Hairy cell leukemia; Macroglobulinemia; Medicine; Leukemia; CD5; Prolymphocytic leukemia; Lymphoplasmacytic Lymphoma; Pathology; Splenic marginal zone lymphoma; IGHV@; Immunology; Lymphoma; Waldenstrom macroglobulinemia; B cell; Flow cytometry; Antibody; Multiple myeloma","score_opus":0.015754796762661668,"score_gpt":0.27718427580725186,"score_spread":0.2614294790445902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606644796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165106,0.0019711275,0.0007447532,0.0009160191,0.0002827711,0.001995214,0.000068885995,0.0007587982,0.0016113466],"genre_scores_gemma":[0.9852655,0.00037061528,0.0013040229,0.00088878087,0.0014754699,0.00047527012,0.000048163394,0.00029507428,0.00987714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99199516,0.00021539372,0.0010862595,0.0019073476,0.0023335,0.002462327],"domain_scores_gemma":[0.99421376,0.0009755251,0.00023207399,0.0024518343,0.00034414153,0.0017826366],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00049647957,0.0010653482,0.0016284023,0.0005253682,0.00034097172,0.00013550611,0.0010395736,0.0006988322,0.0015759254],"category_scores_gemma":[0.00091231393,0.0006359248,0.00046857915,0.0008894627,0.0006711944,0.00039298562,0.00076393806,0.0005667028,0.0027810761],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.028335568,0.002123337,0.020622715,0.007191316,0.0061894725,0.02410739,0.0019485955,0.009351634,0.7007531,0.0023406816,0.11793336,0.07910283],"study_design_scores_gemma":[0.40451676,0.0103528695,0.02425555,0.011124572,0.0021699443,0.0063614924,0.00015491046,0.025823006,0.43165562,0.0002684375,0.07948739,0.00382946],"about_ca_topic_score_codex":0.00044013097,"about_ca_topic_score_gemma":0.00029379546,"teacher_disagreement_score":0.3761812,"about_ca_system_score_codex":0.46994883,"about_ca_system_score_gemma":0.18435118,"threshold_uncertainty_score":0.99960923},"labels":[],"label_agreement":null},{"id":"W2609953542","doi":"10.1111/ijlh.12666","title":"Flow cytometry—Recognizing unusual populations in leukemia and lymphoma diagnosis","year":2017,"lang":"en","type":"review","venue":"International Journal of Laboratory Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Victoria Hospital; London Health Sciences Centre","funders":"","keywords":"Immunophenotyping; Minimal residual disease; Medicine; Lymphoma; Leukemia; Pathology; Flow cytometry; Cytometry; Disease; Bone marrow; Immunology","score_opus":0.1844141625302086,"score_gpt":0.476288107792317,"score_spread":0.2918739452621084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609953542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038928457,0.99358433,0.0000574521,0.00023263958,0.0015575396,0.00032935123,0.000100145386,0.000013065195,0.0002325979],"genre_scores_gemma":[0.0057432274,0.9919847,0.001243475,0.00010316865,0.00069481105,0.00004542635,0.000051250216,0.00006561204,0.00006828345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965912,0.00026161116,0.0016153738,0.00035731803,0.0008161471,0.00035831658],"domain_scores_gemma":[0.9960308,0.00074832875,0.0014605181,0.0003798292,0.001100646,0.00027987955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008960929,0.00036844081,0.0023372704,0.002004865,0.0000706677,0.00010374212,0.000715708,0.0005671395,0.000105608786],"category_scores_gemma":[0.002876863,0.00030767624,0.0003534394,0.0003749418,0.00025087525,0.00028519216,0.00026431744,0.0006938439,0.00004575101],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014110206,0.00022736273,0.003852411,0.004139722,0.0011006889,0.013968447,0.00010021605,0.000004389195,9.250369e-7,0.0010309934,0.001882576,0.97355115],"study_design_scores_gemma":[0.008665566,0.00016191686,0.0003889464,0.023765286,0.0006205594,0.029177995,0.00004370636,0.00033441948,0.000018581388,0.00022586148,0.93626374,0.00033341156],"about_ca_topic_score_codex":0.00007245162,"about_ca_topic_score_gemma":0.00006900176,"teacher_disagreement_score":0.9732177,"about_ca_system_score_codex":0.012595012,"about_ca_system_score_gemma":0.01988156,"threshold_uncertainty_score":0.99993753},"labels":[],"label_agreement":null},{"id":"W2610303179","doi":"10.25011/cim.v30i4.2856","title":"High affinity IL-2 receptor (CD25) expression among Chronic Lymphocytic leukemia (CLL) patients is independent of mutational status and ZAP-70 positivitys","year":2007,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Somatic hypermutation; Chronic lymphocytic leukemia; Medicine; IL-2 receptor; Internal medicine; Correlation; Immunology; Oncology; Leukemia; T cell; B cell; Antibody; Immune system","score_opus":0.06831739452140931,"score_gpt":0.3429153398408964,"score_spread":0.2745979453194871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610303179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663717,0.00074059155,0.00009141145,0.0008312291,0.0003900389,0.0007324522,0.000051099607,0.000042901687,0.00048310403],"genre_scores_gemma":[0.99640626,0.000835106,0.0004882701,0.0010330734,0.0006328411,0.00001683135,0.00018586635,0.000037823924,0.000363943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534684,0.00028604132,0.0014353832,0.00077898626,0.0015168461,0.00063589937],"domain_scores_gemma":[0.99548227,0.0015506147,0.00047095836,0.0003927451,0.0005779442,0.0015254873],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0022107263,0.00036382765,0.0010411046,0.0002308482,0.00014803483,0.000012886217,0.00016086493,0.000433178,0.00057355233],"category_scores_gemma":[0.0059174867,0.0002623418,0.00010332299,0.0003978031,0.010964348,0.0002393671,0.00032617437,0.00075604836,0.00001964923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026077302,0.0005488671,0.9355557,0.0015842156,0.00051296013,0.00028117883,0.003997478,0.000013681597,0.011670679,0.0016888386,0.0059927297,0.035545938],"study_design_scores_gemma":[0.04390783,0.004055386,0.9092735,0.0023884922,0.00016618182,0.000036981262,0.00041252372,0.0014949994,0.034881316,0.0026538668,0.0004134136,0.00031551055],"about_ca_topic_score_codex":0.002407511,"about_ca_topic_score_gemma":0.00014787522,"teacher_disagreement_score":0.0413001,"about_ca_system_score_codex":0.007699052,"about_ca_system_score_gemma":0.009838721,"threshold_uncertainty_score":0.9999829},"labels":[],"label_agreement":null},{"id":"W2612366790","doi":"10.71781/27522","title":"Étude du mécanisme d'action du facteur bHLH hématopoïétique SCL","year":2004,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Chemistry; Molecular biology; Biology","score_opus":0.008761560513386283,"score_gpt":0.21175676751698802,"score_spread":0.20299520700360174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612366790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950412,0.020718196,0.00077074434,0.0009867939,0.004749606,0.00138606,0.00008734247,0.00043406017,0.020455223],"genre_scores_gemma":[0.95029855,0.0060603707,0.0004387865,0.00023677386,0.0018257148,0.000081196566,0.00096000603,0.00017402165,0.039924607],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9938408,0.00033613277,0.00094729464,0.0013837769,0.0021095574,0.0013824156],"domain_scores_gemma":[0.99592197,0.00032199582,0.00066651375,0.0009045277,0.0009572242,0.0012277983],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005139292,0.0010295386,0.0010530307,0.00075235625,0.00783605,0.00014689722,0.0007819386,0.0014637917,0.00050005584],"category_scores_gemma":[0.0003869859,0.0011887724,0.00077499915,0.000759351,0.0007041671,0.00075318856,0.00034879294,0.0014838005,0.0012644484],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.017533818,0.005178882,0.07345575,0.009980751,0.0075744535,0.15293485,0.2391626,0.04491892,0.20788911,0.21606024,0.005944825,0.019365828],"study_design_scores_gemma":[0.0670121,0.0018919008,0.31858295,0.008954711,0.0049912957,0.05991481,0.16023374,0.045569047,0.17894858,0.0012189976,0.14775223,0.00492964],"about_ca_topic_score_codex":0.2536853,"about_ca_topic_score_gemma":0.035286907,"teacher_disagreement_score":0.2451272,"about_ca_system_score_codex":0.24716717,"about_ca_system_score_gemma":0.06321311,"threshold_uncertainty_score":0.9998325},"labels":[],"label_agreement":null},{"id":"W2613195890","doi":"10.1016/j.clml.2017.04.001","title":"Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Royal Columbian Hospital; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Chronic lymphocytic leukemia; Cohort; Medicine; Oncology; Population; Leukemia; Internal medicine; Demography; Gerontology; Environmental health; Sociology","score_opus":0.02586023800880946,"score_gpt":0.30130201839262377,"score_spread":0.2754417803838143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613195890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521506,0.00016022265,0.000037759954,0.00015580161,0.000267234,0.00312106,0.00034329426,0.000061003706,0.0006385689],"genre_scores_gemma":[0.9961975,0.00012359966,0.0002745449,0.00027833236,0.00032940882,0.00016865818,0.0009341407,0.0001428264,0.0015509378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914662,0.00031465435,0.0031554739,0.0014448223,0.0024883444,0.0011304873],"domain_scores_gemma":[0.99310946,0.0012199173,0.0011252555,0.0026202954,0.0011548022,0.0007702645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020714789,0.0005068064,0.0020610588,0.00019154057,0.0003132287,0.00017435908,0.0009914534,0.0005275162,0.00023266331],"category_scores_gemma":[0.0032592607,0.0006118262,0.00035992806,0.00036753854,0.0005728284,0.00025157168,0.00035388872,0.0003493354,0.000021787477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004714225,0.0002905592,0.8813792,0.00037478216,0.00032472893,0.0005532895,0.00002264832,0.0022268877,0.00003723578,9.903973e-7,0.0013774622,0.10869801],"study_design_scores_gemma":[0.06317255,0.002238992,0.89719915,0.0021367122,0.00013736356,0.000033895834,0.000009424328,0.03352509,0.00023586035,0.0000104869505,0.0007649496,0.0005355426],"about_ca_topic_score_codex":0.9599525,"about_ca_topic_score_gemma":0.95694184,"teacher_disagreement_score":0.10816247,"about_ca_system_score_codex":0.16885738,"about_ca_system_score_gemma":0.090552576,"threshold_uncertainty_score":0.9996333},"labels":[],"label_agreement":null},{"id":"W2613723809","doi":"10.1182/bloodadvances.2016001883","title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"McMaster University; Canadian Institutes of Health Research; Hamilton Health Sciences","keywords":"Ibrutinib; Meta-analysis; Medicine; Confidence interval; Internal medicine; Relative risk; Clinical trial; Leukemia","score_opus":0.38906250886974897,"score_gpt":0.4683237556215452,"score_spread":0.07926124675179624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613723809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.6528124e-7,0.9958555,0.000121051075,0.000028125114,0.00002362123,0.0036385295,0.00007070294,0.00002515543,0.00023692165],"genre_scores_gemma":[0.00003910869,0.9985875,0.00037315665,0.000015837933,0.000032899134,0.0003734243,0.00004134721,0.000049990966,0.00048676433],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9965634,0.00023841069,0.0012799734,0.00066164025,0.0008695846,0.00038699672],"domain_scores_gemma":[0.99555624,0.0009020177,0.0018641377,0.0013024996,0.0001708071,0.0002043159],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010510996,0.00055590924,0.013380335,0.00046140148,0.00014017332,0.00009204709,0.00036013345,0.00011685789,0.00006536118],"category_scores_gemma":[0.0008584389,0.00029018408,0.0017920719,0.0007525784,0.0002886058,0.00026571448,0.00016044232,0.0003676973,0.000004929152],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003819742,0.000043895223,0.0000018433649,0.84244615,0.15613763,0.000046171714,0.0000137420875,2.4130532e-7,1.1007905e-8,0.00015868492,0.000010642571,0.001137143],"study_design_scores_gemma":[0.00071723835,0.00007585189,5.502812e-8,0.26857364,0.692263,0.00032581016,0.000017400887,0.00000459552,3.5800983e-7,0.000008160554,0.037818093,0.000195773],"about_ca_topic_score_codex":0.000028100883,"about_ca_topic_score_gemma":0.00002441163,"teacher_disagreement_score":0.5738725,"about_ca_system_score_codex":0.0014930258,"about_ca_system_score_gemma":0.002648932,"threshold_uncertainty_score":0.99995506},"labels":[],"label_agreement":null},{"id":"W2614021025","doi":"10.2217/fon-2017-0031","title":"Venetoclax for the treatment of patients with chronic lymphocytic leukemia","year":2017,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Venetoclax; Tumor lysis syndrome; Medicine; Chronic lymphocytic leukemia; Neutropenia; Oncology; Rituximab; Internal medicine; Clinical trial; Lymphoma; Leukemia; Immunology; Chemotherapy","score_opus":0.021146067308554253,"score_gpt":0.33432476656353816,"score_spread":0.3131786992549839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614021025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98963267,0.0021735295,0.00009848405,0.0009858897,0.0007464938,0.0029340875,0.000047381753,0.00003217786,0.003349269],"genre_scores_gemma":[0.9946136,0.0007027316,0.00047673873,0.00011451781,0.001745478,0.00039506488,0.000053617066,0.00003895113,0.0018593371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987974,0.000029709428,0.00021909851,0.00027874,0.00026803667,0.00040698436],"domain_scores_gemma":[0.9979942,0.00033315938,0.00023399742,0.0011088705,0.00021398783,0.00011580535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011842699,0.00017799651,0.00046221315,0.000047803584,0.0003104861,0.00001689947,0.0003133587,0.00019731358,0.00010709074],"category_scores_gemma":[0.00007031849,0.00009180375,0.00013279755,0.00005046057,0.00041614895,0.000043856966,0.000046009274,0.00008507398,0.000023061413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040388968,0.0013649919,0.0234212,0.0016346555,0.004241074,0.00046867214,0.0036898234,0.002149793,0.00079335953,0.0037989875,0.03061898,0.8874295],"study_design_scores_gemma":[0.101927936,0.023057872,0.049948134,0.00007057235,0.0005266425,0.00006501268,0.00008930888,0.010204884,0.0014705727,0.000048055597,0.81242985,0.00016115008],"about_ca_topic_score_codex":0.000821863,"about_ca_topic_score_gemma":0.00072824536,"teacher_disagreement_score":0.88726836,"about_ca_system_score_codex":0.18087134,"about_ca_system_score_gemma":0.053964373,"threshold_uncertainty_score":0.9513988},"labels":[],"label_agreement":null},{"id":"W2614021599","doi":"10.5489/cuaj.4316","title":"Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia","year":2017,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Everolimus; Medicine; Renal cell carcinoma; Cancer research; Chronic lymphocytic leukemia; Tyrosine-kinase inhibitor; Tyrosine kinase; Nivolumab; Internal medicine; Leukemia; Immune system; Immunology; Immunotherapy; Cancer; Receptor","score_opus":0.01701025732294543,"score_gpt":0.2653546462047145,"score_spread":0.24834438888176907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614021599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442244,0.00024460777,0.000018800149,0.0037907455,0.00017896474,0.000809472,0.00009234937,0.000013051201,0.00042954812],"genre_scores_gemma":[0.9978005,0.00001620591,0.00015159944,0.00086737453,0.00030542575,0.000054101594,0.000019925828,0.000028073631,0.0007567857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707925,0.00029249775,0.00071315805,0.00035855264,0.00058917614,0.00096738926],"domain_scores_gemma":[0.99685496,0.00048271343,0.0005318014,0.00043077796,0.00052013155,0.0011795992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016759989,0.00022039504,0.0005399102,0.00052177854,0.0003827933,0.00011193411,0.0003240293,0.00038555163,0.00015106726],"category_scores_gemma":[0.0055049853,0.00019110304,0.00021261249,0.00025888009,0.00008879356,0.00011140955,0.000068207504,0.00044400524,0.000029950425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06614045,0.0007495404,0.5804111,0.00053512456,0.00052975194,0.012423612,0.0045082057,0.0094101075,0.20013276,0.00022839422,0.101200014,0.023730982],"study_design_scores_gemma":[0.07843939,0.013298159,0.7739996,0.00038319125,0.00021080587,0.000872808,0.00014898238,0.026146075,0.062157642,0.00018260076,0.043456785,0.00070401],"about_ca_topic_score_codex":0.019716457,"about_ca_topic_score_gemma":0.0047211456,"teacher_disagreement_score":0.19358848,"about_ca_system_score_codex":0.21614131,"about_ca_system_score_gemma":0.06030839,"threshold_uncertainty_score":0.98681134},"labels":[],"label_agreement":null},{"id":"W2614912162","doi":"10.1080/10428194.2017.1318439","title":"Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia","year":2017,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Roche (Canada); University of Calgary; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Fluidigm (Canada); Foothills Medical Centre","funders":"","keywords":"Medicine; Minimal residual disease; Oncology; Clinical trial; Chronic lymphocytic leukemia; Clinical endpoint; Surrogate endpoint; Internal medicine; Complete remission; Leukemia; Intensive care medicine; Chemotherapy","score_opus":0.11134316876918608,"score_gpt":0.38885895669780457,"score_spread":0.2775157879286185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614912162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09879533,0.89312845,0.000008431781,0.000044304354,0.0004983382,0.005445675,0.0006433938,0.00012380096,0.0013122594],"genre_scores_gemma":[0.033053327,0.9599508,0.00039297342,0.000113527334,0.0010999573,0.0013216187,0.0009455033,0.00041630544,0.0027059808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863018,0.0013044319,0.004342975,0.0026897225,0.0029420045,0.002419092],"domain_scores_gemma":[0.98616886,0.0033677705,0.0028940833,0.005935559,0.00043013573,0.0012036171],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014723269,0.002656914,0.008188273,0.0016695372,0.0005431803,0.00039108624,0.0021791076,0.0017674796,0.000107139684],"category_scores_gemma":[0.00068376085,0.0018518064,0.0024444438,0.0013370715,0.002573791,0.0006162332,0.0006600285,0.00057271286,0.00006575434],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014417379,0.000866835,0.00018919846,0.034627713,0.0016077422,0.004875625,0.00088264316,0.00011119534,0.000017158354,0.00063964765,0.0017122484,0.95302826],"study_design_scores_gemma":[0.04948489,0.0033533173,0.0037484663,0.027468257,0.0070537142,0.0034333707,0.00022860366,0.010906074,0.00008868147,0.00007645426,0.8923485,0.0018096238],"about_ca_topic_score_codex":0.016060172,"about_ca_topic_score_gemma":0.0004794671,"teacher_disagreement_score":0.9512186,"about_ca_system_score_codex":0.44323438,"about_ca_system_score_gemma":0.3764756,"threshold_uncertainty_score":0.9995284},"labels":[],"label_agreement":null},{"id":"W2616453052","doi":"10.1016/s1155-1984(14)67982-6","title":"10.1016/s1155-1984(14)67982-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology","score_opus":0.009291240212304007,"score_gpt":0.22829630423746758,"score_spread":0.21900506402516356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616453052","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040305974,0.00015761284,7.5064463e-7,0.0007456086,0.000002087263,0.0004978939,0.000010930429,0.00019036084,0.99436414],"genre_scores_gemma":[0.0007876882,0.0000012877481,0.00017560626,0.00016756475,0.00035878518,0.000041469106,0.00003330409,0.000056561108,0.99837774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811053,0.00004537677,0.00026114893,0.00038611327,0.00059705833,0.00059976155],"domain_scores_gemma":[0.9985723,0.00011086913,0.000022748447,0.0007019357,0.000106251224,0.00048592678],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002678006,0.00019350261,0.00032631579,0.00013819519,0.000074687836,0.000033851746,0.00024262871,0.00012614513,0.9986289],"category_scores_gemma":[0.00016665814,0.00017163453,0.00010911192,0.0004019408,0.00008864241,0.00007206638,0.00008398377,0.00023847361,0.99811476],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054672017,0.00009943236,9.04387e-8,0.000040695013,0.000046994675,0.00016078977,0.000031378826,0.000026639831,0.00014194862,9.133277e-7,0.56830335,0.43060103],"study_design_scores_gemma":[0.005730213,0.00041023918,0.000018131312,0.00007780123,0.00004484147,0.00026367465,0.0000016512345,0.0018129828,0.00056471117,0.000005671762,0.9908868,0.00018328865],"about_ca_topic_score_codex":0.00018052013,"about_ca_topic_score_gemma":5.2757764e-7,"teacher_disagreement_score":0.43041775,"about_ca_system_score_codex":0.0038439431,"about_ca_system_score_gemma":0.0020109867,"threshold_uncertainty_score":0.99998015},"labels":[],"label_agreement":null},{"id":"W2619012808","doi":"10.1080/10428194.2017.1326034","title":"Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Janssen Research and Development","keywords":"Ibrutinib; Mantle cell lymphoma; Temsirolimus; Medicine; Quality of life (healthcare); Internal medicine; Oncology; Clinical trial; Lymphoma; Phases of clinical research; Randomized controlled trial; Leukemia; Discovery and development of mTOR inhibitors; Chronic lymphocytic leukemia","score_opus":0.07370496193561728,"score_gpt":0.3693687295541824,"score_spread":0.2956637676185651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619012808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626006,0.0010053552,0.000015462805,0.00018881146,0.00030812688,0.00840022,0.0009275394,0.0001690429,0.0027253844],"genre_scores_gemma":[0.9939965,0.0005136609,0.0004945311,0.00026678888,0.0001318994,0.00041995267,0.003120015,0.00024846641,0.0008082056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98915,0.0012598612,0.0031543532,0.00270651,0.0021305776,0.0015987306],"domain_scores_gemma":[0.9886148,0.0014850852,0.0027596292,0.005250993,0.00067171507,0.0012178046],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002453384,0.0013369794,0.004378041,0.00060267857,0.0006866151,0.0006451206,0.0033840614,0.0005585453,0.00016654244],"category_scores_gemma":[0.0013279096,0.000999423,0.00018594557,0.0006492258,0.0014271435,0.0014549504,0.002250296,0.00030026986,0.000059754857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.70674187,0.01671436,0.24057992,0.00046647614,0.0033235564,0.00085753785,0.0021343671,0.000017761888,0.00008584744,0.000026761207,0.00075733854,0.028294215],"study_design_scores_gemma":[0.74710006,0.0035894094,0.22781336,0.00087361684,0.0006802783,0.000035962523,0.00062150974,0.017917085,0.00025288868,0.000007148583,0.0002745621,0.00083410414],"about_ca_topic_score_codex":0.18438335,"about_ca_topic_score_gemma":0.005552835,"teacher_disagreement_score":0.17883052,"about_ca_system_score_codex":0.029141026,"about_ca_system_score_gemma":0.021409294,"threshold_uncertainty_score":0.99993813},"labels":[],"label_agreement":null},{"id":"W2619736384","doi":"10.1016/j.leukres.2017.05.017","title":"A novel spliced variant of the TIN2 shelterin is present in chronic lymphocytic leukemia","year":2017,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"CancerCare Manitoba Foundation","keywords":"Chronic lymphocytic leukemia; Biology; Shelterin; Exon; RNA splicing; Alternative splicing; Molecular biology; Leukemia; Promyelocytic leukemia protein; Telomere; Gene; Cancer research; RNA; Genetics; Nuclear protein; DNA-binding protein","score_opus":0.09683330156801429,"score_gpt":0.40200515823104815,"score_spread":0.30517185666303387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619736384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96697855,0.00059150707,0.00006837057,0.001936159,0.0003084048,0.0025620349,0.000040613042,0.000054473338,0.027459905],"genre_scores_gemma":[0.9827406,0.00035466804,0.00032336373,0.0001647126,0.0006464813,0.0002832647,0.000008744983,0.00011040867,0.015367782],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9921068,0.00034365978,0.0009839709,0.0011326562,0.0034204868,0.0020124414],"domain_scores_gemma":[0.99264354,0.00073671143,0.0002405765,0.0052237646,0.00066566875,0.0004897302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036473267,0.00042869285,0.00088293076,0.000594846,0.0007348551,0.0002453103,0.0029647462,0.00048708194,0.00064758887],"category_scores_gemma":[0.002164491,0.0003119496,0.00036162054,0.0010080242,0.0018679723,0.00029235723,0.0029836409,0.0018849277,0.00033286234],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0066298754,0.00065529894,0.005108784,0.008054723,0.0010112438,0.003994712,0.0061773392,0.005836753,0.8799383,0.006738299,0.048062578,0.027792104],"study_design_scores_gemma":[0.08273048,0.0010981074,0.0656768,0.0036562372,0.00011550766,0.0017834249,0.00046932456,0.5868808,0.22794606,0.0007897508,0.028018843,0.00083464134],"about_ca_topic_score_codex":0.062131148,"about_ca_topic_score_gemma":0.0014927429,"teacher_disagreement_score":0.65199226,"about_ca_system_score_codex":0.30985606,"about_ca_system_score_gemma":0.16364725,"threshold_uncertainty_score":0.99993324},"labels":[],"label_agreement":null},{"id":"W2620145341","doi":"10.1182/bloodadvances.2017004697","title":"Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine","year":2017,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"","keywords":"Cladribine; Rituximab; Medicine; Hairy cell leukemia; Leukemia; Internal medicine; Oncology; Immunology; Lymphoma","score_opus":0.010231672994868497,"score_gpt":0.26559551846557355,"score_spread":0.25536384547070506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620145341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397916,0.0020373666,0.000032089185,0.0004975462,0.000021889473,0.00089245284,0.0000113456235,0.000048978985,0.002479166],"genre_scores_gemma":[0.9963103,0.00030133754,0.0023380362,0.0002087324,0.00006011493,0.00012084792,0.000023876413,0.000040253002,0.00059650594],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99798244,0.000044260996,0.00028973212,0.0005867613,0.0005667126,0.0005300691],"domain_scores_gemma":[0.99863786,0.0001168346,0.00018101805,0.00070000073,0.00011695359,0.0002473272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016074309,0.00028423595,0.00048469703,0.00013402311,0.00020534771,0.0000921206,0.00020206942,0.00008715431,0.00002471294],"category_scores_gemma":[0.000091910944,0.00018504378,0.000031448744,0.00013709895,0.0004707889,0.00036662695,0.0001438322,0.00027344323,0.000008647464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017382013,0.0070421407,0.8182969,0.0035933557,0.0006202376,0.0271569,0.0038736525,0.00072304864,0.010942938,0.00018384191,0.0005972377,0.10958775],"study_design_scores_gemma":[0.5827412,0.021806236,0.11729612,0.0052466365,0.00072262064,0.0030360532,0.003877281,0.019691136,0.22179008,0.00012151503,0.021623356,0.0020477506],"about_ca_topic_score_codex":0.0030952217,"about_ca_topic_score_gemma":0.0063578156,"teacher_disagreement_score":0.70100075,"about_ca_system_score_codex":0.001902629,"about_ca_system_score_gemma":0.0021618227,"threshold_uncertainty_score":0.7545867},"labels":[],"label_agreement":null},{"id":"W2620245505","doi":"10.1007/s40266-017-0468-4","title":"Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies","year":2017,"lang":"en","type":"review","venue":"Drugs & Aging","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Bruton's tyrosine kinase; Tyrosine-kinase inhibitor; Pharmacotherapy; Tyrosine kinase; Pharmacology; Cancer research; Drug development; Internal medicine; Oncology; Drug; Cancer; Receptor","score_opus":0.09520824308548627,"score_gpt":0.3821820767176842,"score_spread":0.28697383363219797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620245505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020399591,0.97793597,0.0000031599186,0.000009734577,0.00023642204,0.0010166253,0.000030020583,0.000025074974,0.00034341298],"genre_scores_gemma":[0.002403555,0.9957359,0.00047542015,0.0000113705955,0.00014418387,0.00009410178,0.00014480413,0.00007499126,0.0009156933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996931,0.00009809815,0.000929157,0.0005892329,0.0006283559,0.00082412286],"domain_scores_gemma":[0.9980858,0.0002724064,0.00045802956,0.00073595176,0.0001287626,0.0003190514],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059282006,0.00045039563,0.0018476452,0.00056452275,0.000085317835,0.00008330513,0.0002250101,0.00017722276,0.00001633078],"category_scores_gemma":[0.0003312336,0.00036704776,0.00017617752,0.00022867885,0.00019340233,0.00014137272,0.0004845791,0.0005624524,0.000027943484],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000017782051,0.00014698583,0.00020716626,0.0594433,0.00004600318,0.00023151822,0.0017040964,1.7994874e-7,0.00000750868,0.000019668616,0.0003224211,0.9378534],"study_design_scores_gemma":[0.004407182,0.000025726227,0.000103480685,0.06743009,0.00020633082,0.000049522587,0.00004767372,0.00002604565,0.00031113453,0.0000018125743,0.92709106,0.0002999353],"about_ca_topic_score_codex":0.0012297994,"about_ca_topic_score_gemma":0.00008766887,"teacher_disagreement_score":0.93755347,"about_ca_system_score_codex":0.010468046,"about_ca_system_score_gemma":0.018781457,"threshold_uncertainty_score":0.99987817},"labels":[],"label_agreement":null},{"id":"W2621758445","doi":"10.1002/hon.2437_99","title":"INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ibrutinib; Internal medicine; Chronic lymphocytic leukemia; IGHV@; Ofatumumab; Oncology; Chlorambucil; Leukemia; Univariate analysis; Bendamustine; Multivariate analysis; Chemotherapy; Cyclophosphamide","score_opus":0.02770539388624377,"score_gpt":0.2986521199294849,"score_spread":0.27094672604324116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621758445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951672,0.00020897575,0.00029737115,0.00007912133,0.00013492058,0.0022970675,0.00009932758,0.00035161618,0.0013643763],"genre_scores_gemma":[0.99671006,0.00013808373,0.0016121647,0.000118127646,0.000054079082,0.00025277745,0.00045933234,0.000110175155,0.0005451717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99347496,0.00050008536,0.0015141696,0.0015551823,0.0012605173,0.0016951041],"domain_scores_gemma":[0.991825,0.0020611356,0.0017769443,0.002428361,0.0010641884,0.00084436795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005654125,0.0010627265,0.0040709386,0.00071090774,0.0005719118,0.00010966358,0.0011997974,0.0010818185,0.0005110747],"category_scores_gemma":[0.0029159978,0.000592914,0.0005502039,0.0012526829,0.0024452598,0.00022379239,0.0004983172,0.0008918252,0.00012370992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004462988,0.00044078904,0.9837152,0.0004457118,0.005498058,0.0017759985,0.00017720045,0.0017868751,0.00006369422,0.00039746202,0.00011180242,0.001124227],"study_design_scores_gemma":[0.074540235,0.01207438,0.8761219,0.0004973137,0.007846694,0.00046075316,0.00021515274,0.023817446,0.0031313857,0.00008544291,0.00028819757,0.00092110544],"about_ca_topic_score_codex":0.018572126,"about_ca_topic_score_gemma":0.003710008,"teacher_disagreement_score":0.107593305,"about_ca_system_score_codex":0.17524049,"about_ca_system_score_gemma":0.070600174,"threshold_uncertainty_score":0.9996522},"labels":[],"label_agreement":null},{"id":"W2622107576","doi":"10.1002/hon.2438_75","title":"Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 <scp>DAWN</scp> study","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Lymphoma; Gastroenterology; Regimen; Phases of clinical research; Flow cytometry; Oncology; Immunology; Toxicity","score_opus":0.047056738369999844,"score_gpt":0.37735109612119744,"score_spread":0.3302943577511976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622107576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341714,0.00006399865,0.000031748197,0.00020248843,0.000015619902,0.001626622,0.000014762714,0.00002900372,0.004598641],"genre_scores_gemma":[0.99927706,0.000009367365,0.0001742192,0.00016366033,0.000012000566,0.00018472361,0.00006854094,0.000017698298,0.00009274415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997097,0.0004664282,0.00055307004,0.00056252116,0.0007558421,0.00056511385],"domain_scores_gemma":[0.9966273,0.0012296584,0.00042984457,0.0012805609,0.00025981368,0.00017282908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007567578,0.00027214963,0.0014317712,0.00034867437,0.00018638723,0.000033949236,0.0005715079,0.00026106584,0.000093908144],"category_scores_gemma":[0.0010552849,0.00012389317,0.00016664348,0.0009817147,0.0008004812,0.000071835966,0.00016447148,0.00019323501,0.00001598058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026079554,0.014289492,0.9717068,0.00004787145,0.0023678911,0.0054033217,0.0007609386,0.000007629499,0.000037629983,0.0001354605,0.00025479012,0.0023802416],"study_design_scores_gemma":[0.08634341,0.0106981,0.89618784,0.000037940732,0.0021723863,0.00019436247,0.0012102734,0.0018990155,0.00020018102,0.000013139143,0.0009593,0.00008405432],"about_ca_topic_score_codex":0.0005740712,"about_ca_topic_score_gemma":0.0005173381,"teacher_disagreement_score":0.08373545,"about_ca_system_score_codex":0.0016094783,"about_ca_system_score_gemma":0.0013462357,"threshold_uncertainty_score":0.50522166},"labels":[],"label_agreement":null},{"id":"W2622353385","doi":"10.1002/hon.2438_80","title":"MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Minimal residual disease; Obinutuzumab; Population; Hazard ratio; Oncology; Gastroenterology; Follicular lymphoma; Surrogate endpoint; Bone marrow; Lymphoma; Confidence interval; Rituximab","score_opus":0.05161901287869262,"score_gpt":0.3889514008878156,"score_spread":0.33733238800912296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622353385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916311,0.0008330934,0.0000035956534,0.0050118286,0.00012308221,0.0015310786,0.000024914401,0.000022091202,0.0008192024],"genre_scores_gemma":[0.99844354,0.00031728944,0.00034709452,0.00039345425,0.00014358992,0.0001642153,0.00002330275,0.000019941428,0.00014759177],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99678475,0.00046971094,0.0009715587,0.0006285187,0.0005193274,0.00062615215],"domain_scores_gemma":[0.99636555,0.0020131413,0.0003819001,0.0008252182,0.00007747916,0.00033673487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014563737,0.00031059905,0.0015106493,0.00022128971,0.00016954655,0.000032211516,0.00040669035,0.0004410084,0.00009637802],"category_scores_gemma":[0.005654954,0.00019139759,0.00012669769,0.00014001493,0.0012954393,0.00008773942,0.0004349358,0.00046626283,0.000005473276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7686394,0.019025385,0.10064366,0.0017613118,0.00045623555,0.062211245,0.0033159559,0.000012768693,0.0016264056,0.011049836,0.003006611,0.028251207],"study_design_scores_gemma":[0.8280876,0.011142251,0.15046602,0.00026022107,0.00029858554,0.0017243387,0.000678008,0.002839369,0.00021960102,0.0009097825,0.003019294,0.0003548871],"about_ca_topic_score_codex":0.00056218257,"about_ca_topic_score_gemma":0.00031629278,"teacher_disagreement_score":0.060486905,"about_ca_system_score_codex":0.0021488012,"about_ca_system_score_gemma":0.0035746985,"threshold_uncertainty_score":0.7804967},"labels":[],"label_agreement":null},{"id":"W2622354226","doi":"10.1002/hon.2437_76","title":"CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Cancer Society","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Salvage therapy; Interim analysis; Oncology; Clinical endpoint; Gemcitabine; Febrile neutropenia; Diffuse large B-cell lymphoma; Population; Neutropenia; Ibrutinib; Chemotherapy regimen; Surgery; Chemotherapy; Randomized controlled trial; Lymphoma; Leukemia","score_opus":0.13571482489030035,"score_gpt":0.442831365213154,"score_spread":0.3071165403228537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622354226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850906,0.0026947455,0.00010039309,0.00085644046,0.00058746693,0.00824033,0.0002766891,0.00009532896,0.00205797],"genre_scores_gemma":[0.99542606,0.00071243616,0.00039521244,0.00059437234,0.00015311659,0.0015635148,0.000051095878,0.000086920634,0.0010172988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888029,0.0034687314,0.0035168813,0.0013029757,0.0010766945,0.0018317982],"domain_scores_gemma":[0.98845714,0.0068110507,0.0019540985,0.0016124814,0.00026181122,0.0009034029],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0124857295,0.0007720394,0.0065993583,0.00054214895,0.00062177726,0.000052517324,0.0011383928,0.0012204834,0.0006919055],"category_scores_gemma":[0.0025637373,0.0005270367,0.0008379081,0.00029076813,0.00074819964,0.00013518936,0.0003109353,0.00095459,0.000024773784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.60635006,0.22782081,0.04473223,0.0019086101,0.0021028041,0.019407738,0.025279876,0.00004072863,0.033647303,0.00083579577,0.0013406113,0.036533415],"study_design_scores_gemma":[0.9708825,0.012566488,0.0033189238,0.0002276483,0.0006569503,0.0004226367,0.0010054391,0.0066140736,0.0025889203,0.000060598275,0.0011017236,0.00055410585],"about_ca_topic_score_codex":0.0823807,"about_ca_topic_score_gemma":0.08154007,"teacher_disagreement_score":0.3645324,"about_ca_system_score_codex":0.010989406,"about_ca_system_score_gemma":0.011650395,"threshold_uncertainty_score":0.9997181},"labels":[],"label_agreement":null},{"id":"W2622725967","doi":"10.1002/hon.2437_107","title":"COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Progressive disease; Gastroenterology; Rituximab; Lymphoma; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Follicular lymphoma; Oncology; Surgery; Chemotherapy; Clinical trial","score_opus":0.03686729126405178,"score_gpt":0.3419778960514678,"score_spread":0.30511060478741603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622725967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726708,0.00011828046,0.000016664035,0.0007279583,0.00017282306,0.00095379626,0.0000046055884,0.00006752027,0.025267554],"genre_scores_gemma":[0.996682,0.00007111719,0.0010611092,0.00064384635,0.00007203804,0.00011038743,0.000026852773,0.000034069635,0.0012985832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730414,0.00018037,0.0005482129,0.00063745497,0.0005530239,0.0007767985],"domain_scores_gemma":[0.99749994,0.00052752893,0.0003319356,0.001109128,0.00016995183,0.00036148744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037397203,0.00028087373,0.0010150836,0.0001449312,0.00020054117,0.000035015164,0.0004907252,0.00058363576,0.00070817495],"category_scores_gemma":[0.001090852,0.00016583964,0.00008654912,0.00012981704,0.00071892864,0.0001358583,0.0003641471,0.00045166546,0.0003817583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06384883,0.024612358,0.8106879,0.0010775779,0.00022840282,0.0280037,0.00082314253,0.000009191113,0.0002807797,0.0014064226,0.015301437,0.053720288],"study_design_scores_gemma":[0.23215154,0.020988064,0.70525765,0.00040628226,0.000097683755,0.0009518988,0.00017389796,0.00050352205,0.0012971798,0.00013667229,0.03749312,0.0005425036],"about_ca_topic_score_codex":0.00020758605,"about_ca_topic_score_gemma":0.00019711272,"teacher_disagreement_score":0.1683027,"about_ca_system_score_codex":0.010330164,"about_ca_system_score_gemma":0.0064154943,"threshold_uncertainty_score":0.9992172},"labels":[],"label_agreement":null},{"id":"W2622897264","doi":"10.1002/hon.2437_57","title":"DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cégep de l'Outaouais; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Clinical endpoint; Regimen; Lymphoma; Surgery; Oncology; Clinical trial","score_opus":0.08567979818774954,"score_gpt":0.4524975538175632,"score_spread":0.36681775562981367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622897264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935776,0.000022476728,0.00004580255,0.0006035794,0.00014423976,0.002242478,0.0000043846226,0.000024685129,0.0033347742],"genre_scores_gemma":[0.9992801,0.000012512563,0.00029130196,0.00015246376,0.00006347299,0.00014745556,0.0000048090888,0.000019475652,0.000028419961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967024,0.0005496527,0.000916992,0.0005906924,0.0006719273,0.0005683666],"domain_scores_gemma":[0.9961205,0.0015120482,0.0007369809,0.0011690744,0.00022372567,0.00023763967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001823309,0.00025801177,0.0013205649,0.000096320655,0.00023795999,0.000029085191,0.00059672166,0.00042513077,0.00008437331],"category_scores_gemma":[0.001500435,0.00013783836,0.00014693287,0.0001546385,0.001222913,0.00012435218,0.00048210865,0.00070250593,0.000021759324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021807851,0.033015024,0.8721244,0.000104785606,0.00022691455,0.0017682313,0.00054672995,0.0000033552017,0.000074035575,0.00013990894,0.00011523062,0.07007354],"study_design_scores_gemma":[0.16962445,0.019303758,0.8082384,0.00011860522,0.00010661701,0.0001489619,0.0004254373,0.0013849132,0.0002814768,0.000025026788,0.00018138604,0.0001609761],"about_ca_topic_score_codex":0.00053232344,"about_ca_topic_score_gemma":0.00053260656,"teacher_disagreement_score":0.1478166,"about_ca_system_score_codex":0.0027616955,"about_ca_system_score_gemma":0.004680143,"threshold_uncertainty_score":0.8302373},"labels":[],"label_agreement":null},{"id":"W2623453597","doi":"10.1002/hon.2439_188","title":"IBRUTINIB IN ASSOCIATION WITH R‐DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Internal medicine; DHAP; Gastroenterology; Neutropenia; Mantle cell lymphoma; Febrile neutropenia; Nausea; Mucositis; Cytarabine; Rash; Ibrutinib; Rituximab; Surgery; Oncology; Lymphoma; Toxicity; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03194529137704255,"score_gpt":0.35223566715245574,"score_spread":0.3202903757754132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623453597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916354,0.000050481107,0.0000116747715,0.0010498532,0.000119716286,0.0034749003,0.00003735207,0.00003116985,0.0035894425],"genre_scores_gemma":[0.9982385,0.000012163754,0.0005031399,0.000121355115,0.000047749112,0.0003237003,0.00002751761,0.000027903965,0.0006979761],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971183,0.0003271419,0.00069962227,0.00055807596,0.00073129905,0.00056558655],"domain_scores_gemma":[0.99548864,0.0019168133,0.0010304318,0.000993383,0.00042409927,0.0001466472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009927842,0.00024229813,0.0009206338,0.000157469,0.00023483405,0.000020022886,0.00048791897,0.00042979696,0.00002279008],"category_scores_gemma":[0.0033889597,0.00012657196,0.00010437585,0.00027207244,0.00038500762,0.00011168986,0.0002656292,0.000328982,0.000011453695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11310019,0.057644922,0.81593305,0.00044424305,0.00030998394,0.0010042238,0.0015046758,0.000011409369,0.00016339865,0.00011502695,0.006012364,0.003756541],"study_design_scores_gemma":[0.4856425,0.08683607,0.41858494,0.0003065042,0.0003858814,0.00015724111,0.0007129452,0.00079308066,0.0022701253,0.00008480003,0.003918332,0.00030759405],"about_ca_topic_score_codex":0.00020383182,"about_ca_topic_score_gemma":0.00017154875,"teacher_disagreement_score":0.39734808,"about_ca_system_score_codex":0.0057902327,"about_ca_system_score_gemma":0.0034727987,"threshold_uncertainty_score":0.9980264},"labels":[],"label_agreement":null},{"id":"W2625960167","doi":"10.1182/blood.v128.22.682.682","title":"Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fludarabine; Cumulative incidence; Chronic lymphocytic leukemia; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Incidence (geometry); Surgery; Oncology; Leukemia; Cyclophosphamide; Chemotherapy","score_opus":0.029967683680596744,"score_gpt":0.29250807591740235,"score_spread":0.2625403922368056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625960167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535084,0.0006840812,0.0003420342,0.00006099466,0.00041623408,0.0026209764,0.00010908412,0.000047977468,0.00036776197],"genre_scores_gemma":[0.9930842,0.0002341312,0.000098901335,0.000029081008,0.0002935927,0.00017823381,0.000024132796,0.0000789606,0.0059787994],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968403,0.00013011668,0.0010541523,0.00049914507,0.00086017617,0.000616127],"domain_scores_gemma":[0.997515,0.0006094641,0.00041398456,0.0010432064,0.00023853677,0.00017977833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005886177,0.00031614583,0.00080879923,0.0001478969,0.000077355275,0.000012526648,0.0005217646,0.00028086285,0.000252066],"category_scores_gemma":[0.0001097583,0.00018875625,0.00062456395,0.0002731705,0.00028815103,0.000087997425,0.00008664825,0.000119534634,0.00007379469],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.21430077,0.0033539063,0.036283426,0.04242884,0.003492226,0.00047116264,0.0039641657,0.000137204,0.6807132,0.0013523934,0.0017824689,0.011720247],"study_design_scores_gemma":[0.5219241,0.0017749738,0.0032847147,0.00080045953,0.001379566,0.00022759898,0.000042623116,0.00010875315,0.4700982,0.000040398987,0.00007293543,0.00024571933],"about_ca_topic_score_codex":0.00010459758,"about_ca_topic_score_gemma":0.000074789976,"teacher_disagreement_score":0.30762327,"about_ca_system_score_codex":0.012312451,"about_ca_system_score_gemma":0.015034739,"threshold_uncertainty_score":0.9914791},"labels":[],"label_agreement":null},{"id":"W2636523834","doi":"","title":"Aberrations in Cytokine Signaling in Leukemia: Variations in Phosphorylation and O-GlcNAcylation","year":2012,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Phosphorylation; Cytokine; Cancer research; Leukemia; Cell biology; Medicine; Biology; Immunology","score_opus":0.005474115923684593,"score_gpt":0.1931541484978298,"score_spread":0.1876800325741452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2636523834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93261564,0.000989453,0.000013160458,0.00060513295,0.00013531923,0.0005834361,0.00005971803,0.0000055217774,0.06499264],"genre_scores_gemma":[0.9946323,0.0003348792,0.00034931416,0.0001114552,0.000054116626,0.000041784515,0.00030483102,0.000028879916,0.0041424474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975793,0.00007022444,0.00055654784,0.0002866535,0.0011810085,0.00032631587],"domain_scores_gemma":[0.99914217,0.00034746272,0.00017878889,0.00015946428,0.0000015825157,0.00017050306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043105967,0.00020024429,0.0003860721,0.00018792633,0.00005997644,0.0000152274115,0.000076269935,0.00011673173,0.000038388134],"category_scores_gemma":[0.000024084553,0.00022400303,0.000018762972,0.00027856053,0.000031886055,0.00035786754,0.000038571136,0.00039894506,4.2218167e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008971938,0.00055729586,0.6140927,0.0066893524,0.00033017402,0.0010211951,0.009798921,0.00586996,0.19458689,0.10225561,0.0004541962,0.055371776],"study_design_scores_gemma":[0.0052334024,0.000060280407,0.927173,0.0011861739,0.000046689158,0.0000134337,0.003876412,0.036663983,0.023923432,0.0008789433,0.0006185376,0.0003257047],"about_ca_topic_score_codex":0.050846815,"about_ca_topic_score_gemma":0.5636182,"teacher_disagreement_score":0.51277137,"about_ca_system_score_codex":0.00084719463,"about_ca_system_score_gemma":0.01731134,"threshold_uncertainty_score":0.9882596},"labels":[],"label_agreement":null},{"id":"W2642831584","doi":"10.1182/blood.v128.22.4403.4403","title":"Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Bendamustine; Ibrutinib; Rituximab; Medicine; Tolerability; Internal medicine; Pharmacology; Pharmacokinetics; Oncology; Chronic lymphocytic leukemia; Leukemia; Lymphoma; Adverse effect","score_opus":0.018075422548981607,"score_gpt":0.2785870912286461,"score_spread":0.2605116686796645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2642831584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933669,0.0025795924,0.00001573032,0.00091432995,0.0001871993,0.0012305019,0.00066951895,0.00006742826,0.0009687933],"genre_scores_gemma":[0.9978257,0.0002786912,0.000052866093,0.00014622792,0.0008059729,0.00006548229,0.000064898995,0.000035568602,0.000724583],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975363,0.00026244216,0.00065959233,0.00039537123,0.0007646486,0.00038162176],"domain_scores_gemma":[0.9969707,0.0016324328,0.00020183445,0.00086427835,0.00014676772,0.00018399584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006949616,0.00018697276,0.0004796282,0.000053841053,0.000051490017,0.000014081574,0.0003592789,0.00013437301,0.00020471409],"category_scores_gemma":[0.0014149667,0.00009521837,0.00014540594,0.00021691935,0.00018269998,0.000046344856,0.000111069676,0.00016617091,0.00017668174],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10629683,0.003978392,0.0006108859,0.00024762415,0.0010027542,0.00025638397,0.00064427045,3.7175434e-7,0.8340851,0.000023296167,0.04490711,0.007946986],"study_design_scores_gemma":[0.7791044,0.0006463846,0.00018472047,0.00072526047,0.00046978693,0.00014385654,0.0000721432,0.00004880847,0.21576025,0.000019608628,0.002697781,0.00012701671],"about_ca_topic_score_codex":0.0015079774,"about_ca_topic_score_gemma":0.000008807453,"teacher_disagreement_score":0.6728076,"about_ca_system_score_codex":0.00071677426,"about_ca_system_score_gemma":0.0022841112,"threshold_uncertainty_score":0.4051915},"labels":[],"label_agreement":null},{"id":"W2685612940","doi":"10.1016/j.ajo.2017.06.006","title":"Rituximab for the Treatment of Autoimmune Retinopathy","year":2017,"lang":"en","type":"letter","venue":"American Journal of Ophthalmology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia","funders":"","keywords":"Rituximab; Medicine; Retinopathy; Disease; Retrospective cohort study; Clinical trial; Internal medicine; Ophthalmology; Lymphoma; Diabetes mellitus","score_opus":0.046059410698746986,"score_gpt":0.3643225638061243,"score_spread":0.31826315310737735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2685612940","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3540039,0.011486624,0.00012766712,0.626613,0.0026756919,0.0018874116,0.00012329298,0.000013129129,0.0030692213],"genre_scores_gemma":[0.9172736,0.0032518632,0.0048785997,0.03242553,0.01543941,0.00020293353,0.000113137634,0.00034416863,0.026070762],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974902,0.00020471335,0.0009012278,0.00027330502,0.00056584616,0.00056466577],"domain_scores_gemma":[0.99371606,0.0019515228,0.0023854359,0.0012110908,0.00064073066,0.00009516391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052942935,0.0003344179,0.002105633,0.00026710198,0.0001264668,0.00001891498,0.0007888409,0.00032549445,0.0002236757],"category_scores_gemma":[0.00047762523,0.00019112257,0.0008621981,0.000109231245,0.0019426123,0.00003504003,0.00005470477,0.00093164394,0.000013510237],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010852777,0.0023563642,0.0010395864,0.0009880825,0.008626788,0.1837868,0.0018269821,0.00001698877,0.00060134596,0.000021293878,0.6740633,0.11581966],"study_design_scores_gemma":[0.022707665,0.03690953,0.0012260003,0.0003179332,0.001378486,0.33388847,0.00015229953,0.00015859332,0.00039183017,0.00010724054,0.6025366,0.0002252986],"about_ca_topic_score_codex":0.00057583343,"about_ca_topic_score_gemma":2.5114366e-7,"teacher_disagreement_score":0.5941875,"about_ca_system_score_codex":0.0043160506,"about_ca_system_score_gemma":0.0072179786,"threshold_uncertainty_score":0.9995062},"labels":[],"label_agreement":null},{"id":"W2734767620","doi":"10.1136/lupus-2017-000215.88","title":"88 Ixazomib, an oral proteasome inhibitor, depletes plasma cells reducing autoantibodies and pdcs in pre-clinical model of systemic lupus erythematosus","year":2017,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ixazomib; Medicine; Autoantibody; Proteasome inhibitor; Immunology; Antibody; Systemic lupus erythematosus; Anti-dsDNA antibodies; Multiple myeloma; Pharmacology; Internal medicine; Disease","score_opus":0.06370398382081068,"score_gpt":0.36556228154316284,"score_spread":0.3018582977223522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734767620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966185,0.00030430133,0.00009148781,0.00014109351,0.00024048191,0.0014611337,0.000011660287,0.000072964955,0.001058389],"genre_scores_gemma":[0.990682,0.0002927599,0.005582546,0.000021838481,0.0001429902,0.000054205473,0.0000054766247,0.000050897546,0.0031672942],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9970885,0.0001373284,0.0009787952,0.00065255613,0.00057246763,0.00057034934],"domain_scores_gemma":[0.9976268,0.0002773691,0.0003218976,0.0012785883,0.00016434139,0.00033103698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014640315,0.0002748995,0.0009674855,0.00019550303,0.00014636388,0.00009720364,0.0003697135,0.0002997248,0.000028913822],"category_scores_gemma":[0.0008921226,0.00021348271,0.00011247317,0.00007467479,0.0005941589,0.00036452877,0.00041575395,0.00041709785,0.000015672553],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010646545,0.0038924848,0.4296546,0.020444218,0.00092196313,0.0013703245,0.018319614,0.005058023,0.48026875,0.0032192331,0.0051256246,0.021078616],"study_design_scores_gemma":[0.026684737,0.0007732531,0.002213712,0.0026931397,0.000091284564,0.0014570914,0.0005467516,0.91115254,0.053738117,0.00030162596,0.000015527057,0.00033220992],"about_ca_topic_score_codex":0.0020442328,"about_ca_topic_score_gemma":0.00026878182,"teacher_disagreement_score":0.90609455,"about_ca_system_score_codex":0.0014255657,"about_ca_system_score_gemma":0.003365551,"threshold_uncertainty_score":0.87055725},"labels":[],"label_agreement":null},{"id":"W2734917394","doi":"10.1177/2054358117698667","title":"Rituximab in Minimal Change Disease","year":2017,"lang":"en","type":"review","venue":"Canadian Journal of Kidney Health and Disease","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Children's Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Rituximab; Disease; Internal medicine; Immunology; Intensive care medicine; Antibody","score_opus":0.2191631269588356,"score_gpt":0.4468873526814754,"score_spread":0.22772422572263978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734917394","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022141161,0.97663087,4.9282187e-7,0.021009402,0.0003699829,0.0011069197,0.00068961404,0.0000037677717,0.00016683538],"genre_scores_gemma":[0.00009927639,0.98083323,0.000026119249,0.01734181,0.0011031075,0.000047513047,0.0001660005,0.00005660933,0.000326326],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99710274,0.00020333903,0.0009798271,0.0003427569,0.00041373924,0.00095757714],"domain_scores_gemma":[0.86683863,0.00007655413,0.00060253346,0.0005546942,0.00013035968,0.13179725],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006691112,0.00036120618,0.0021052293,0.001131313,0.00022055436,0.00009765827,0.00035152907,0.00015826909,0.00012646435],"category_scores_gemma":[0.03424784,0.000291338,0.00037922902,0.00018349585,0.00026581564,0.00016898396,0.00003900396,0.0007543034,0.000035162902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00031490275,0.00012834289,0.00044197854,0.08281537,0.00006137008,0.020046486,0.00013593171,1.0468108e-8,6.892252e-10,0.000050488965,0.1861675,0.7098376],"study_design_scores_gemma":[0.007965217,0.00018954751,0.00009804506,0.05186154,0.00037329912,0.0005469805,0.000014966749,0.000019134164,9.90422e-10,0.00004507188,0.93868923,0.00019694102],"about_ca_topic_score_codex":0.010144307,"about_ca_topic_score_gemma":0.0015770603,"teacher_disagreement_score":0.7871526,"about_ca_system_score_codex":0.0116767315,"about_ca_system_score_gemma":0.7988293,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W2737663958","doi":"10.3324/haematol.2017.170340","title":"Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia","year":2017,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Università degli Studi del Piemonte Orientale; Institute for Oil Sands Innovation, University of Alberta; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute","keywords":"IGHV@; Trisomy; Chronic lymphocytic leukemia; Leukemia; Aneuploidy; Medicine; Oncology; Internal medicine; Biology; Chromosome; Genetics; Gene","score_opus":0.0332763963390192,"score_gpt":0.30400975155762583,"score_spread":0.27073335521860664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737663958","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26048076,0.049042407,0.00012533594,0.42869207,0.003010174,0.024650574,0.0012668879,0.0008161287,0.23191565],"genre_scores_gemma":[0.56148815,0.0058972193,0.0012266845,0.3648925,0.0036180862,0.0028140962,0.0027353608,0.00054819626,0.056779698],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99367166,0.00028145692,0.0012818455,0.0010902501,0.001783058,0.0018917623],"domain_scores_gemma":[0.99431664,0.001971299,0.0008868072,0.0022353986,0.0003711959,0.00021864171],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00071447424,0.0007109012,0.0018204749,0.00039449707,0.00026946448,0.00010325317,0.0011404454,0.0015426408,0.0014920167],"category_scores_gemma":[0.0018127167,0.00046036745,0.00039300747,0.00044001627,0.0012390224,0.00013051723,0.00046000947,0.0024659224,0.00046017344],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00043915721,0.00005039851,0.0014091774,0.0033396464,0.00028898788,0.013728064,0.0002034054,0.00008510383,0.000019852534,0.000065381806,0.979552,0.0008188515],"study_design_scores_gemma":[0.018971108,0.0006089476,0.002002532,0.0025756883,0.00047192973,0.0063501694,0.00006653724,0.0150886765,0.00046472315,0.00072769594,0.9519973,0.0006746921],"about_ca_topic_score_codex":0.004861803,"about_ca_topic_score_gemma":0.00013762635,"teacher_disagreement_score":0.3010074,"about_ca_system_score_codex":0.07071165,"about_ca_system_score_gemma":0.09377173,"threshold_uncertainty_score":0.99983543},"labels":[],"label_agreement":null},{"id":"W2737966976","doi":"10.1182/blood.v128.22.4359.4359","title":"Incidence and Implications of Skin Cancers in Cancercare Manitoba Chronic Lymphocytic Leukemia (CLL) Clinic Patients","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Hazard ratio; Internal medicine; Population; Confidence interval; Incidence (geometry); Proportional hazards model; Cancer; Cumulative incidence; Cancer registry; Leukemia; Oncology; Cohort","score_opus":0.016714996751474562,"score_gpt":0.2975111773936931,"score_spread":0.2807961806422185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737966976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966723,0.0015604653,0.00000980867,0.000093389775,0.000063263964,0.0006076226,0.000047168614,0.000028293534,0.0009177302],"genre_scores_gemma":[0.9975519,0.0017708209,0.00010292774,0.00008303225,0.00010537151,0.00012472257,0.000010563318,0.000030047042,0.00022059733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982341,0.000049037586,0.0004861454,0.00042711492,0.00036015565,0.00044346176],"domain_scores_gemma":[0.99862057,0.00027516356,0.00014061533,0.0005793313,0.00019531281,0.00018901045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002013675,0.00016887399,0.0003722771,0.00017756797,0.000042397507,0.000007916232,0.00020480165,0.00013347059,0.00012107837],"category_scores_gemma":[0.0003047103,0.00012655597,0.00006346816,0.00035779763,0.00026874192,0.00010608388,0.00014834925,0.00012152212,0.000046326033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005837642,0.00040757385,0.8593106,0.0015383572,0.00033295839,0.00012630755,0.0009537362,0.00004650033,0.012433333,0.0002201479,0.0013869567,0.12265971],"study_design_scores_gemma":[0.09836516,0.0008520542,0.87774223,0.0019515695,0.00021581387,0.00014497961,0.00018579002,0.00039200825,0.018870674,0.00030011198,0.00062610855,0.00035351212],"about_ca_topic_score_codex":0.018030856,"about_ca_topic_score_gemma":0.021127984,"teacher_disagreement_score":0.1223062,"about_ca_system_score_codex":0.11986487,"about_ca_system_score_gemma":0.03726168,"threshold_uncertainty_score":0.9967339},"labels":[],"label_agreement":null},{"id":"W2739393823","doi":"10.3324/haematol.2017.171041","title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","year":2017,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute; Pharmacyclics","keywords":"Ibrutinib; Medicine; Internal medicine; Discontinuation; Mantle cell lymphoma; Atrial fibrillation; Cumulative incidence; Adverse effect; Chronic lymphocytic leukemia; Hazard ratio; Oncology; Confidence interval; Leukemia; Lymphoma; Cohort","score_opus":0.08473874912293827,"score_gpt":0.384229192574077,"score_spread":0.29949044345113873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739393823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912586,0.00007046918,0.00027326803,0.0007693705,0.00025511696,0.004833202,0.0000060761254,0.00003632193,0.002497541],"genre_scores_gemma":[0.9983,0.00030088148,0.0002420448,0.000016987062,0.00019888715,0.00006377079,0.00014857092,0.000011142225,0.0007177105],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959578,0.0009116168,0.0020992726,0.0003002155,0.0005139425,0.00021716492],"domain_scores_gemma":[0.99489045,0.001222743,0.0028736219,0.00071422197,0.0002267787,0.00007219461],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0069155563,0.00015814452,0.003025692,0.00017012644,0.000104550396,0.00001678625,0.0001281772,0.00023710326,0.00019702397],"category_scores_gemma":[0.047761947,0.00010514201,0.0006761196,0.00009300716,0.00019091547,0.00016679104,0.00005136739,0.00010918035,0.000015519192],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95735276,0.000091521055,0.008079634,0.00029536724,0.00066434115,0.00043720994,0.00025116475,0.000046346515,0.029322628,0.0018261786,0.000049116483,0.001583732],"study_design_scores_gemma":[0.96513903,0.00013372401,0.011081661,0.00032232635,0.00041024794,0.00025044035,0.000021131435,0.015716141,0.006076631,0.00057117024,0.00015680474,0.000120675286],"about_ca_topic_score_codex":0.0002531418,"about_ca_topic_score_gemma":0.000021371345,"teacher_disagreement_score":0.040846393,"about_ca_system_score_codex":0.00066491455,"about_ca_system_score_gemma":0.0015641693,"threshold_uncertainty_score":0.96025914},"labels":[],"label_agreement":null},{"id":"W2739919047","doi":"10.1093/annonc/11.suppl_1.s59","title":"Allografting for indolent lymphoid neoplasms","year":2000,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre","funders":"BC Cancer Agency","keywords":"Medicine; Stage (stratigraphy); Surgery; Refractory (planetary science); Internal medicine; Lymphoma; Transplantation; Chronic lymphocytic leukemia; Leukemia; Gastroenterology","score_opus":0.11575796180668947,"score_gpt":0.4414156314809154,"score_spread":0.32565766967422594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739919047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416432,0.00052193867,0.000078237055,0.004869211,0.00009811724,0.0006178568,0.000011936073,0.000039603572,0.052119933],"genre_scores_gemma":[0.98976535,0.00071268197,0.0022708417,0.0031467204,0.0002595795,0.0000854637,0.00002744353,0.000025994124,0.0037059002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863404,0.00005166726,0.00036902525,0.00023918081,0.00022725822,0.00047884232],"domain_scores_gemma":[0.99878544,0.00047153636,0.00008116883,0.00027839898,0.0002169502,0.0001664954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053898164,0.00011188326,0.00043344917,0.00010654043,0.00004490382,0.0000044242174,0.00013836348,0.00018573718,0.00085963565],"category_scores_gemma":[0.0002738284,0.000097582684,0.00017227061,0.00015712393,0.00016736111,0.000039976923,0.00003713402,0.000105196785,0.00008936762],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028996603,0.000679731,0.0006706932,0.00025199712,0.00019045621,0.00013697987,0.0007122898,0.00009645814,0.0048876596,0.00040048023,0.03312819,0.95594543],"study_design_scores_gemma":[0.029379377,0.009137369,0.0006501031,0.00012044088,0.000071087605,0.0009350848,0.00014857792,0.00588001,0.039584585,0.00063308264,0.913278,0.0001822838],"about_ca_topic_score_codex":0.0002463489,"about_ca_topic_score_gemma":0.000030813724,"teacher_disagreement_score":0.9557631,"about_ca_system_score_codex":0.0010713933,"about_ca_system_score_gemma":0.004469294,"threshold_uncertainty_score":0.9412407},"labels":[],"label_agreement":null},{"id":"W2739919424","doi":"10.1158/1538-7445.am2017-ct158","title":"Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"IGHV@; Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Bendamustine; Oncology; Chlorambucil; Venetoclax; Rituximab; Fludarabine; Leukemia; Gastroenterology; Lymphoma; Chemotherapy; Cyclophosphamide","score_opus":0.08559694955695976,"score_gpt":0.38998828228705973,"score_spread":0.3043913327301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739919424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99399394,0.00032842043,0.000010218381,0.00023660663,0.00015772636,0.0039722472,0.00020884245,0.000103630235,0.0009883993],"genre_scores_gemma":[0.9962761,0.00037121054,0.00020021906,0.00033347902,0.0002957504,0.0006579456,0.00007801998,0.00024440317,0.0015428927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99110776,0.00024404885,0.0011020242,0.0016141135,0.0035927221,0.0023393505],"domain_scores_gemma":[0.9926052,0.00037119264,0.000430416,0.0035472298,0.0017410325,0.0013048995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016521069,0.00070852815,0.0013287839,0.0010858795,0.00051282765,0.00018901429,0.0018633996,0.00040860721,0.0007608612],"category_scores_gemma":[0.0004234572,0.0005221217,0.00016824578,0.0012019513,0.0015649963,0.0005740734,0.0005043104,0.00069169427,0.00018864348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.15443778,0.00237013,0.71826196,0.0050800657,0.0020967198,0.0034399915,0.008758094,0.008181485,0.014622273,0.00012333815,0.0016107003,0.08101744],"study_design_scores_gemma":[0.17968176,0.007996061,0.7670398,0.0024647266,0.000090329726,0.000057210753,0.00029096706,0.0055184513,0.0341769,0.000018783907,0.0017528548,0.000912183],"about_ca_topic_score_codex":0.06061924,"about_ca_topic_score_gemma":0.0060674306,"teacher_disagreement_score":0.09246389,"about_ca_system_score_codex":0.19753176,"about_ca_system_score_gemma":0.10506788,"threshold_uncertainty_score":0.999723},"labels":[],"label_agreement":null},{"id":"W2740477437","doi":"10.1158/1538-7445.am2017-ct149","title":"Abstract CT149: Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: Primary results of the pivotal Chronos-1 study","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Bendamustine; Neutropenia; Rituximab; Clinical endpoint; Febrile neutropenia; Follicular lymphoma; Lymphoma; Surgery; Chemotherapy; Clinical trial","score_opus":0.054265676133059305,"score_gpt":0.37646925240102275,"score_spread":0.3222035762679634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740477437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986559,0.00028355737,1.5007507e-7,0.00030077435,0.00017596476,0.0032582423,0.000078344165,0.000017340542,0.009326645],"genre_scores_gemma":[0.9957004,0.00013635814,0.000015364982,0.00003825496,0.0001681488,0.0002586193,0.000020321266,0.00006704307,0.0035954744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941968,0.0003232026,0.0006657517,0.00075109047,0.0031140759,0.0009490866],"domain_scores_gemma":[0.99534714,0.00048519493,0.00034399526,0.0027034432,0.0008369762,0.00028323193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022424674,0.0002610436,0.0005739376,0.0003114711,0.0004429902,0.00009136887,0.0012736996,0.00017615079,0.00014084214],"category_scores_gemma":[0.0012360682,0.00014990964,0.00008673595,0.00051235285,0.0010377085,0.000250333,0.0008824305,0.0010111564,0.00003812739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.1518796,0.0291677,0.74142104,0.002944619,0.00050982146,0.0014580745,0.0072265943,0.00007323194,0.006752612,0.000009645531,0.01725438,0.041302677],"study_design_scores_gemma":[0.13090473,0.0028435302,0.85959685,0.0008594706,0.000025365205,0.000003899204,0.00042003213,0.000021698736,0.0041157333,0.0000027807218,0.0010471174,0.00015876678],"about_ca_topic_score_codex":0.011594665,"about_ca_topic_score_gemma":0.0023152942,"teacher_disagreement_score":0.11817583,"about_ca_system_score_codex":0.019671494,"about_ca_system_score_gemma":0.024159255,"threshold_uncertainty_score":0.9949872},"labels":[],"label_agreement":null},{"id":"W2741116527","doi":"10.1158/1538-7445.am2017-2709","title":"Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Antibody-drug conjugate; Flow cytometry; Antibody; Lymphoma; Internal medicine; Pharmacology; Immunology; Cancer research; Monoclonal antibody","score_opus":0.08431074331432094,"score_gpt":0.45560902501239237,"score_spread":0.37129828169807144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741116527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938458,0.00040442892,0.0000022622107,0.00007556026,0.00022193103,0.0021611643,0.00058890495,0.000022492288,0.0026774616],"genre_scores_gemma":[0.9976381,0.00100271,0.00010458812,0.000023749864,0.00020644299,0.00014726307,0.00038942663,0.000078021556,0.0004096706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9934258,0.00049784867,0.0007311474,0.0008793624,0.003650959,0.00081487745],"domain_scores_gemma":[0.99451345,0.00048317216,0.0005192362,0.001601802,0.0023622669,0.00052009907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031250494,0.0003112704,0.0007242006,0.0006425772,0.0005586343,0.0001394302,0.00065401813,0.00024742968,0.00046580523],"category_scores_gemma":[0.0011651586,0.00027110148,0.000106814245,0.00043821987,0.0007666582,0.00039033467,0.00038424548,0.0004772223,0.000023502747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0036433546,0.001779398,0.008047765,0.0005275816,0.00018779692,0.00006604602,0.0015866294,0.00007469297,0.9617996,0.0000024819533,0.0013497727,0.02093486],"study_design_scores_gemma":[0.07429463,0.0011189957,0.07038896,0.0027267388,0.00013467636,0.0000018711304,0.0003217919,0.009381104,0.8412581,0.000028590724,0.00010859258,0.00023592552],"about_ca_topic_score_codex":0.005396929,"about_ca_topic_score_gemma":0.00028951044,"teacher_disagreement_score":0.12054149,"about_ca_system_score_codex":0.0040044347,"about_ca_system_score_gemma":0.008203636,"threshold_uncertainty_score":0.99997413},"labels":[],"label_agreement":null},{"id":"W2741738423","doi":"10.1158/1538-7445.am2017-4267","title":"Abstract 4267: Association of polygenic risk scores and family history with the risk of chronic lymphocytic leukemia (CLL)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Odds ratio; Chronic lymphocytic leukemia; Single-nucleotide polymorphism; Confidence interval; Medicine; Family history; Internal medicine; Case-control study; Logistic regression; SNP; Oncology; Leukemia; Genetics; Biology; Genotype; Gene","score_opus":0.04556132682735299,"score_gpt":0.3513485043354729,"score_spread":0.3057871775081199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741738423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97557425,0.020121682,0.0000066864573,0.00022953222,0.00011218362,0.00079511123,0.000064114785,0.000018129092,0.003078302],"genre_scores_gemma":[0.9799465,0.015859934,0.000023958846,0.000018929522,0.00030599124,0.000115960276,0.0000043343093,0.000048499216,0.0036759276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961392,0.0003028973,0.00037677723,0.00045630883,0.001983553,0.0007412254],"domain_scores_gemma":[0.9956901,0.0010953877,0.0006717034,0.0014526296,0.00086981105,0.0002203543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003474543,0.00019453547,0.0005045609,0.00024299187,0.0004666612,0.000047963254,0.00066169497,0.00019876148,0.00021730109],"category_scores_gemma":[0.0017012747,0.00012596253,0.00011900593,0.00020588565,0.001705249,0.00016552334,0.0003094348,0.00097328745,0.000022945194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014416667,0.0003887842,0.5066313,0.007720455,0.0059662918,0.00036546707,0.007825798,0.0023655219,0.22770663,0.0005428934,0.11821224,0.10785795],"study_design_scores_gemma":[0.028865984,0.0013615442,0.9259394,0.0012537627,0.0004801157,0.00003081403,0.0005529412,0.008678242,0.02280882,0.00014499997,0.00956462,0.000318771],"about_ca_topic_score_codex":0.1018923,"about_ca_topic_score_gemma":0.0050688065,"teacher_disagreement_score":0.4193081,"about_ca_system_score_codex":0.17259055,"about_ca_system_score_gemma":0.070449285,"threshold_uncertainty_score":0.9348204},"labels":[],"label_agreement":null},{"id":"W2743835996","doi":"10.1182/blood.v128.22.2037.2037","title":"Chemical Activation of the SHIP1 Inositol Lipid Phosphatase: A Novel Therapeutic Strategy to Suppress B-Cell Receptor Signaling and CXCR4 Expression in Malignant Human B Cells","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Inimex Pharmaceuticals (Canada)","funders":"","keywords":"breakpoint cluster region; Chronic lymphocytic leukemia; Cancer research; Signal transduction; B-cell receptor; Phosphorylation; Biology; Protein kinase B; Tyrosine phosphorylation; Receptor; B cell; Cell biology; Leukemia; Immunology; Biochemistry; Antibody","score_opus":0.023789231452606658,"score_gpt":0.2793902036280285,"score_spread":0.2556009721754219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743835996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870384,0.00019550882,0.00006610512,0.00020774202,0.000037421225,0.0006616615,0.000021829375,0.000014597464,0.00009128115],"genre_scores_gemma":[0.99919593,0.000017784289,0.00031099515,0.00007354333,0.00010757338,0.000044880908,0.000007438004,0.000025374395,0.00021649999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985839,0.000059695707,0.00031124166,0.00032597219,0.00041188725,0.000307288],"domain_scores_gemma":[0.99910796,0.0002140898,0.000090496935,0.00039300066,0.000065852255,0.00012859702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023353047,0.00015024313,0.00024293487,0.00007663973,0.00004287641,0.000016437492,0.0001991229,0.00013196388,0.0000955773],"category_scores_gemma":[0.000056893303,0.000084032814,0.000048775542,0.00019537481,0.00009053301,0.00007837157,0.00015480307,0.00014915307,0.000006785399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021958418,0.0008244418,0.0005012523,0.00015808544,0.000018298819,0.000003803075,0.0003759212,0.0000032477924,0.99689794,0.000035528683,0.00013239756,0.0008295322],"study_design_scores_gemma":[0.018811537,0.00016491715,0.00037802113,0.0010236029,0.00003557311,0.000010011514,0.00010327228,0.000038852133,0.9791502,0.000016473823,0.00015736138,0.00011022528],"about_ca_topic_score_codex":0.00011700382,"about_ca_topic_score_gemma":0.0000036869803,"teacher_disagreement_score":0.018591952,"about_ca_system_score_codex":0.00065010233,"about_ca_system_score_gemma":0.0006161008,"threshold_uncertainty_score":0.3426759},"labels":[],"label_agreement":null},{"id":"W2747656856","doi":"10.1182/blood.v128.22.2042.2042","title":"11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ibrutinib; Bendamustine; Chlorambucil; Internal medicine; Chronic lymphocytic leukemia; Ofatumumab; Gastroenterology; Chemotherapy; Leukemia; Cyclophosphamide","score_opus":0.0540131814922611,"score_gpt":0.32486603436649475,"score_spread":0.27085285287423366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747656856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97674733,0.0010123353,0.0030070846,0.00020841463,0.00017434848,0.013431252,0.005008485,0.00038543745,0.000025320642],"genre_scores_gemma":[0.98875475,0.0003982067,0.0037577392,0.00040619573,0.0003703611,0.0030241834,0.001940923,0.00030788194,0.0010397682],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934249,0.00025384166,0.0013777184,0.0020344357,0.0012914048,0.001617697],"domain_scores_gemma":[0.9884899,0.0063919937,0.00073559704,0.0024129963,0.0013667536,0.0006027372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069715566,0.0011330832,0.0029268092,0.00039335474,0.0003395484,0.00008029676,0.00087165023,0.00036312675,0.000107776745],"category_scores_gemma":[0.0043545193,0.0006191848,0.00047691088,0.00047204492,0.0007882957,0.00046902578,0.00035757892,0.00011747945,0.00009270661],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8929201,0.0067067672,0.018500222,0.004242675,0.03750359,0.00060951087,0.0019731717,0.000045770495,0.0034842722,0.00006847706,0.0012895429,0.03265591],"study_design_scores_gemma":[0.94812614,0.004523053,0.0014157682,0.0019650157,0.009436696,0.00008382351,0.00016530795,0.020161157,0.012602714,0.000037438265,0.00051585236,0.00096703536],"about_ca_topic_score_codex":0.0011619889,"about_ca_topic_score_gemma":0.00031550636,"teacher_disagreement_score":0.055206046,"about_ca_system_score_codex":0.05433458,"about_ca_system_score_gemma":0.036641564,"threshold_uncertainty_score":0.9996259},"labels":[],"label_agreement":null},{"id":"W2747740495","doi":"10.1016/j.exphem.2017.06.080","title":"Loss of functional Miz-1 impairs C-Myc-dependent B cell lymphomagenesis by interfering with proteasome activity","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Biology; Gene; Enhancer; Cancer research; Lymphoma; Transgene; Immunoglobulin heavy chain; B cell; Molecular biology; Gene expression; Antibody; Genetics; Immunology","score_opus":0.020052531444408,"score_gpt":0.30381341384297306,"score_spread":0.28376088239856506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747740495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344707,0.0013620792,0.00047133813,0.00015940439,0.00016025922,0.0006500852,0.000013221515,0.00004560606,0.0036909154],"genre_scores_gemma":[0.9977752,0.000009844293,0.0002547266,0.00003198764,0.0000556773,0.00017961088,0.0000117853415,0.00004385255,0.0016372986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830925,0.00005389461,0.00025998865,0.00045583988,0.0004757531,0.00044524865],"domain_scores_gemma":[0.9986325,0.000060352864,0.00022829013,0.00079810445,0.00007330247,0.00020746468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013975153,0.00023856925,0.00054677203,0.00008699247,0.00020424149,0.000027105114,0.0002766233,0.000148027,0.0005308957],"category_scores_gemma":[0.00003415878,0.00019406635,0.000105791354,0.000047912086,0.0005854681,0.00017842742,0.00033346558,0.00015276457,0.00007077383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090346625,0.0034693507,0.021664225,0.00085436576,0.0003727753,0.0012074882,0.00070443866,0.000008365954,0.958732,0.001129233,0.0022526393,0.00057042576],"study_design_scores_gemma":[0.015237436,0.0008408391,0.0018851485,0.0001004432,0.000026167503,0.0025673457,0.00036702584,0.00051442784,0.9781855,0.000008706116,0.00009372695,0.00017327175],"about_ca_topic_score_codex":0.00080051256,"about_ca_topic_score_gemma":0.000015855414,"teacher_disagreement_score":0.019779075,"about_ca_system_score_codex":0.0031882809,"about_ca_system_score_gemma":0.0013256698,"threshold_uncertainty_score":0.8337244},"labels":[],"label_agreement":null},{"id":"W2749194693","doi":"10.3899/jrheum.161161","title":"Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"National Institutes of Health; Pfizer; Eli Lilly and Company; Incyte; Amgen","keywords":"Medicine; Rheumatoid arthritis; Tolerability; Internal medicine; Adverse effect; Incidence (geometry); Surgery; Arthritis","score_opus":0.035562853001842705,"score_gpt":0.34283707287725906,"score_spread":0.30727421987541637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749194693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801844,0.00047615854,0.000014185176,0.00035165125,0.00009261697,0.0009036112,0.0000025511363,0.0000034555026,0.00013732255],"genre_scores_gemma":[0.9971494,0.0025667094,0.00020842804,0.000034849923,0.0000041441267,0.000002927834,0.0000021936794,0.000024955862,0.000006410375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752665,0.0004451131,0.000993454,0.00021547553,0.00047534553,0.00034398827],"domain_scores_gemma":[0.99744326,0.0005034182,0.00082675525,0.0008067435,0.0003037512,0.000116077485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001681102,0.0001764339,0.0010565458,0.00017609552,0.00015601068,0.00004185075,0.0007387552,0.00010639439,0.000042415944],"category_scores_gemma":[0.00076480885,0.00010719487,0.000020105388,0.0001255829,0.00049226504,0.000443171,0.00045132695,0.0005267732,0.000002596738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016726542,0.0027766824,0.967628,0.000048113958,0.000098373755,0.00021098209,0.0041542123,0.000022762946,0.000039008202,0.000105533356,0.000038541035,0.008151259],"study_design_scores_gemma":[0.14231561,0.0067994217,0.84535074,0.0014594259,0.00002491348,0.0025592274,0.00089585205,0.00033059527,0.00003301892,0.00011368392,0.0000132090445,0.00010426446],"about_ca_topic_score_codex":0.0036844856,"about_ca_topic_score_gemma":0.0023886417,"teacher_disagreement_score":0.12558907,"about_ca_system_score_codex":0.0006673015,"about_ca_system_score_gemma":0.0013118029,"threshold_uncertainty_score":0.55698645},"labels":[],"label_agreement":null},{"id":"W2752001050","doi":"10.1093/rheumatology/kex062.217","title":"216. BARICITINIB, METHOTREXATE, OR BARICITINIB PLUS METHOTREXATE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD RECEIVED LIMITED OR NO TREATMENT WITH DMARDS: EFFICACY AND SAFETY RESULTS FROM THE 52-WEEK PHASE 3 RA-BEGIN STUDY","year":2017,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); McMaster University","funders":"","keywords":"Medicine; Methotrexate; Rheumatoid arthritis; Internal medicine","score_opus":0.05011338968214165,"score_gpt":0.33214917053602433,"score_spread":0.2820357808538827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752001050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742026,0.00016129806,0.0001258988,0.0008062268,0.00010636424,0.007542016,0.0013034807,0.00012078791,0.0024136803],"genre_scores_gemma":[0.99147385,0.0015569752,0.0032303624,0.000353458,0.00013582123,0.00054730923,0.0004948497,0.00017834058,0.002029022],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99358976,0.0010610666,0.0010712761,0.001743971,0.0013362331,0.0011977092],"domain_scores_gemma":[0.99232674,0.0033424806,0.00061154674,0.0023736502,0.0006724202,0.000673178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011648496,0.000913006,0.0018618339,0.0002732749,0.00084461324,0.00041906966,0.0006958777,0.00026575392,0.00019105319],"category_scores_gemma":[0.00284176,0.00049004174,0.00010664736,0.00064790435,0.00044959056,0.00047276643,0.00039644237,0.0007476553,0.00008388333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82612234,0.00739588,0.003347302,0.000054888755,0.002605592,0.0033146308,0.02084732,0.00033447373,0.00006731528,0.000005131676,0.00066927855,0.13523586],"study_design_scores_gemma":[0.5567608,0.03875592,0.38111043,0.0025600975,0.00045935094,0.000113297196,0.00268646,0.008883547,0.0010316563,0.0000109048415,0.0065433024,0.0010842761],"about_ca_topic_score_codex":0.018485356,"about_ca_topic_score_gemma":0.006972852,"teacher_disagreement_score":0.37776312,"about_ca_system_score_codex":0.0053567463,"about_ca_system_score_gemma":0.004499648,"threshold_uncertainty_score":0.99975514},"labels":[],"label_agreement":null},{"id":"W2752063004","doi":"10.1136/annrheumdis-2001.1216","title":"OP0086 The fully human anti-tnf monoclonal antibody, adalimumab (d2e7), dose ranging study: the 24-week clinical results in patients with active ra on methotrexate therapy (the armada trial)","year":2001,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System","funders":"","keywords":"Adalimumab; Medicine; Rheumatoid arthritis; Methotrexate; Placebo; Internal medicine; Adverse effect; Dose-ranging study; Refractory (planetary science); Gastroenterology; Surgery; Double blind; Pathology","score_opus":0.14078556034577666,"score_gpt":0.4322839467827096,"score_spread":0.29149838643693293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752063004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682564,0.0005312665,0.0000039599427,0.00652011,0.00023434217,0.005438127,0.00006715641,0.00003480917,0.0003446124],"genre_scores_gemma":[0.9970849,0.0010508272,0.000009870266,0.0011662857,0.00014340821,0.00016959889,0.00003905568,0.000059009835,0.00027702627],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9928056,0.0026622813,0.0013322079,0.0005694709,0.0019267763,0.0007036728],"domain_scores_gemma":[0.99183285,0.0047136154,0.0007897676,0.0021061304,0.00036018118,0.00019747116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036230849,0.00042845926,0.00094035064,0.00014473622,0.00057551917,0.00009833475,0.0013445816,0.000085420324,0.000071965136],"category_scores_gemma":[0.0023777164,0.00016160407,0.0005132326,0.00087603123,0.000851407,0.00015843278,0.0003193917,0.00065612927,0.000019501847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58174443,0.036844324,0.07337539,0.00025326008,0.007512697,0.00023318974,0.013663576,0.0023280533,0.00002587226,0.00023649112,0.009671559,0.27411115],"study_design_scores_gemma":[0.20050278,0.004688419,0.7878844,0.0010126868,0.00038029486,0.000010267204,0.002930174,0.0013196013,0.000118420096,0.00041899647,0.0004569086,0.00027703837],"about_ca_topic_score_codex":0.0012062244,"about_ca_topic_score_gemma":0.000079773425,"teacher_disagreement_score":0.714509,"about_ca_system_score_codex":0.00044107132,"about_ca_system_score_gemma":0.0019091285,"threshold_uncertainty_score":0.65900224},"labels":[],"label_agreement":null},{"id":"W2752316483","doi":"10.1016/j.rbr.2017.07.536","title":"BARICITINIBE VS. PBO E ADALIMUMABE NA ARTRITE REUMATOIDE MOD A GRAVE ‐ RESULTADOS DO RA‐BEAM","year":2017,"lang":"pt","type":"article","venue":"Revista Brasileira de Reumatologia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Eli Lilly (Canada)","funders":"","keywords":"Medicine; Mod; Beam (structure); Traditional medicine; Nuclear medicine; Optics; Discrete mathematics; Physics","score_opus":0.03932642194812298,"score_gpt":0.3374168219002046,"score_spread":0.29809039995208164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752316483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95886606,0.020642424,0.0009094173,0.0010953373,0.0011700478,0.00414574,0.0004977953,0.0006716501,0.0120015545],"genre_scores_gemma":[0.9822913,0.005768957,0.00075602595,0.0007269701,0.0006298718,0.00029368364,0.00020658509,0.0004478927,0.008878714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98500764,0.0013219105,0.0034245665,0.003097177,0.0028033329,0.004345346],"domain_scores_gemma":[0.98189425,0.002407393,0.0026416408,0.009801262,0.0011137866,0.00214167],"candidate_categories":["metaresearch","metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0052770856,0.0019493378,0.0043118764,0.00084427104,0.0024797146,0.002860539,0.004460542,0.002187497,0.0012313894],"category_scores_gemma":[0.02236914,0.0018342963,0.0013012561,0.00095428276,0.002303234,0.00080529525,0.0024785707,0.0035144754,0.0036520308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016858464,0.003354215,0.60049546,0.031203574,0.005847812,0.041447032,0.006685217,0.0001599115,0.006538698,0.04548946,0.22052832,0.021391846],"study_design_scores_gemma":[0.22346132,0.006580189,0.44260418,0.0759507,0.0050792,0.047235925,0.0062377183,0.08976202,0.013565205,0.0010206143,0.07555939,0.012943535],"about_ca_topic_score_codex":0.0029142934,"about_ca_topic_score_gemma":0.000063176696,"teacher_disagreement_score":0.20660286,"about_ca_system_score_codex":0.019109754,"about_ca_system_score_gemma":0.018766388,"threshold_uncertainty_score":0.9996816},"labels":[],"label_agreement":null},{"id":"W2754791514","doi":"10.1136/annrheumdis-2017-eular.2887","title":"FRI0129 Comparative safety of biologic dmard initiation in ra: a population-based observational study of malignancy risk","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Janssen Pharmaceuticals; Pfizer Japan; Samsung; Astellas Pharma; Santen; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Celltrion; Kissei; Celgene; Biogen; GlaxoSmithKline; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Etanercept; Discontinuation; Internal medicine; Population; Observational study; Golimumab; Abatacept; Oncology; Rheumatoid arthritis; Rituximab","score_opus":0.27340327890147753,"score_gpt":0.43841175122348647,"score_spread":0.16500847232200894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754791514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979555,0.00023403109,0.00001592411,0.00035465398,0.000045796438,0.0010432673,0.00018365815,0.0000067233996,0.00016043372],"genre_scores_gemma":[0.99966305,0.0000859629,0.00007484182,0.000037063288,0.000010807783,0.000041470532,0.00006016782,0.000007487747,0.000019137224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801624,0.0003208163,0.0007754694,0.00016616374,0.0005624194,0.00015888442],"domain_scores_gemma":[0.9968489,0.0008529269,0.0010859299,0.00078393455,0.0003691148,0.00005922232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050764583,0.00012386244,0.00058192166,0.000117350864,0.000114145114,0.000008956842,0.00035960064,0.000045330034,0.00007949586],"category_scores_gemma":[0.0031435227,0.000082409366,0.00015381043,0.00018045508,0.00018587131,0.00011913808,0.000116533076,0.000079809484,0.000002375291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008749158,0.0015438261,0.9924441,0.00046221894,0.00016540335,0.0000019299941,0.0006306796,0.002432978,0.000022051114,0.00026721923,0.00011450285,0.001040176],"study_design_scores_gemma":[0.0072414037,0.00033945055,0.97821677,0.0012637954,0.00009930097,5.7994544e-7,0.0004190913,0.010209477,0.0005048656,0.0016368291,0.0000013031273,0.000067117755],"about_ca_topic_score_codex":0.004106232,"about_ca_topic_score_gemma":0.000343561,"teacher_disagreement_score":0.014227312,"about_ca_system_score_codex":0.00027778195,"about_ca_system_score_gemma":0.0013069533,"threshold_uncertainty_score":0.62074214},"labels":[],"label_agreement":null},{"id":"W2757870740","doi":"10.1177/1715163517732088","title":"Community pharmacist–led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer","year":2017,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Everolimus; Medicine; Adverse effect; Pharmacist; Breast cancer; Metastatic breast cancer; Cancer; Internal medicine; Oncology; Family medicine; Pharmacy","score_opus":0.0686293356286653,"score_gpt":0.3489679418079198,"score_spread":0.2803386061792545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757870740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595344,0.00016755496,0.00001019939,0.0001602009,0.0012076304,0.0014182439,0.0006079854,0.000019613975,0.0004551237],"genre_scores_gemma":[0.9961098,0.0016778099,0.00020397015,0.00060457544,0.00019984196,0.00011773122,0.000057849134,0.00011637168,0.00091205665],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9947855,0.0006193017,0.0010539895,0.00056834635,0.0013130746,0.0016597816],"domain_scores_gemma":[0.99350816,0.00009226022,0.000767779,0.0012430024,0.00106642,0.0033223701],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0015778579,0.0006264184,0.0010162989,0.00067698513,0.0014219469,0.00007823818,0.0015307192,0.00008476474,0.0007455522],"category_scores_gemma":[0.00010304827,0.000581131,0.00021088435,0.0006297051,0.00031482326,0.0008191054,0.00020092605,0.0016418088,0.000009938204],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.031221503,0.003673351,0.17561337,0.010458653,0.009070028,0.5472519,0.015452615,0.005238163,0.023013819,0.000043533757,0.005552012,0.17341107],"study_design_scores_gemma":[0.2751798,0.0012917212,0.016285583,0.002026697,0.0036883182,0.64020675,0.0007581989,0.035939906,0.019043224,0.00009605061,0.002646531,0.0028372346],"about_ca_topic_score_codex":0.34826085,"about_ca_topic_score_gemma":0.53013444,"teacher_disagreement_score":0.24395831,"about_ca_system_score_codex":0.04198537,"about_ca_system_score_gemma":0.023732638,"threshold_uncertainty_score":0.99987805},"labels":[],"label_agreement":null},{"id":"W2759462495","doi":"10.1016/s2352-3026(17)30168-0","title":"Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Celgene","keywords":"Medicine; Lenalidomide; Placebo; Maintenance therapy; Chronic lymphocytic leukemia; Internal medicine; Oncology; Physical therapy; Multiple myeloma; Leukemia; Chemotherapy; Alternative medicine; Pathology","score_opus":0.09344758497031419,"score_gpt":0.39512861509315317,"score_spread":0.301681030122839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759462495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714752,0.00361912,0.00005691914,0.003977781,0.0005034528,0.012943684,0.000008073845,0.00014906462,0.007266731],"genre_scores_gemma":[0.9874634,0.0029808658,0.00004990174,0.0005961367,0.0014941369,0.0033409519,0.000027946173,0.00009470862,0.0039519244],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947338,0.00071733416,0.0012828078,0.00086888304,0.0005754093,0.0018217574],"domain_scores_gemma":[0.99435705,0.001315121,0.00081358536,0.0030407761,0.00019585158,0.00027758785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034343018,0.00059656246,0.0041690096,0.00026036706,0.00045784347,0.00019366694,0.001562489,0.00044896966,0.0003504171],"category_scores_gemma":[0.0015647566,0.00035808826,0.00054022484,0.00023032686,0.0010865226,0.00021064456,0.00025914254,0.0008241406,0.00030805997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.98759323,0.0002826446,0.00016812762,0.0002142183,0.0005019492,0.0027946255,0.00039126727,0.00003393973,0.00063362974,0.00062695565,0.004297188,0.0024622178],"study_design_scores_gemma":[0.9795233,0.0014898514,0.000025560368,0.0004200694,0.00025872883,0.0033305902,0.00004349849,0.008004277,0.0034322713,0.0003570378,0.0027656995,0.00034909355],"about_ca_topic_score_codex":0.0027595689,"about_ca_topic_score_gemma":0.0022887513,"teacher_disagreement_score":0.015988255,"about_ca_system_score_codex":0.014009917,"about_ca_system_score_gemma":0.011847749,"threshold_uncertainty_score":0.9998871},"labels":[],"label_agreement":null},{"id":"W2761236690","doi":"10.1182/blood-2017-07-731588","title":"FCR achieves long-term durable remissions in patients with IGHV-mutated CLL","year":2017,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"IGHV@; Chemoimmunotherapy; Fludarabine; Chronic lymphocytic leukemia; Rituximab; Medicine; Internal medicine; Cyclophosphamide; Oncology; Alemtuzumab; Progression-free survival; Leukemia; Immunology; Chemotherapy; Transplantation; Lymphoma","score_opus":0.06436159046231887,"score_gpt":0.37783677114149145,"score_spread":0.31347518067917257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761236690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019908058,0.9738628,7.482639e-7,0.000026837606,0.00010957141,0.002595285,0.000060756134,0.00008146273,0.0033544519],"genre_scores_gemma":[0.0012489144,0.98950046,0.0001152897,0.000017486944,0.00017375883,0.00016538921,0.0008674305,0.0001572146,0.0077540264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967319,0.0001540682,0.0007048636,0.00075308373,0.0008853702,0.00077074306],"domain_scores_gemma":[0.9970977,0.00017862872,0.00041801026,0.0017193435,0.00016500526,0.00042133307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003294416,0.00055404555,0.0021367508,0.00037599544,0.00015830986,0.00008721243,0.00065856485,0.0005233294,0.00025047752],"category_scores_gemma":[0.00048764763,0.0003550975,0.00027954028,0.00035851315,0.00017546293,0.000107592634,0.0002823817,0.0009808356,0.00034158272],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004762716,0.0070819166,0.025623856,0.087566935,0.00179443,0.005852062,0.00011736522,2.976151e-7,0.0000013445513,0.000010786819,0.001450119,0.8700246],"study_design_scores_gemma":[0.12816791,0.0014147674,0.025584307,0.18394582,0.0071341023,0.0012367093,0.0000063749685,0.000008118092,0.000026727123,0.000008571841,0.65091723,0.0015493622],"about_ca_topic_score_codex":0.0001468577,"about_ca_topic_score_gemma":0.0000630103,"teacher_disagreement_score":0.86847526,"about_ca_system_score_codex":0.0041474896,"about_ca_system_score_gemma":0.013578586,"threshold_uncertainty_score":0.9998901},"labels":[],"label_agreement":null},{"id":"W2761245920","doi":"10.1200/jco.2014.32.15_suppl.3028","title":"Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Bendamustine; Medicine; Tolerability; Internal medicine; Neutropenia; Rituximab; Adverse effect; Nausea; Chronic lymphocytic leukemia; Population; Gastroenterology; Surgery; Leukemia; Toxicity; Lymphoma","score_opus":0.21176519100844415,"score_gpt":0.5352959847158193,"score_spread":0.32353079370737514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761245920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955591,0.0003513217,0.000015473728,0.0018587107,0.00044028176,0.00075915037,0.0000045482857,0.0000064782757,0.0010049375],"genre_scores_gemma":[0.99517405,0.00084156776,0.0028875777,0.0003022264,0.00057364604,0.000009539043,0.0000034979073,0.000030759544,0.00017714463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949642,0.0008122648,0.0027053116,0.00041196684,0.0007336603,0.00037259865],"domain_scores_gemma":[0.9885049,0.008188866,0.0016359228,0.00037661943,0.00063077774,0.0006629451],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006543904,0.00022310913,0.0024257703,0.00027739565,0.000046907604,0.000015569241,0.0003435143,0.00038930678,0.00010965079],"category_scores_gemma":[0.016353276,0.0001362896,0.00005843156,0.00031463004,0.0005935621,0.00021343521,0.00033617398,0.0015575422,0.000002886024],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5754999,0.07684459,0.008200884,0.00045732857,0.0007931767,0.005469083,0.0015027527,0.000007964728,0.00013550474,0.000054018623,0.0023051484,0.32872963],"study_design_scores_gemma":[0.7012341,0.2769666,0.009463022,0.0006020041,0.00043709207,0.0008616591,0.0013503084,0.0033749407,0.000017972847,0.000022183314,0.005538575,0.00013155978],"about_ca_topic_score_codex":0.000391348,"about_ca_topic_score_gemma":0.0018977972,"teacher_disagreement_score":0.32859808,"about_ca_system_score_codex":0.0011925462,"about_ca_system_score_gemma":0.00857303,"threshold_uncertainty_score":0.9970474},"labels":[],"label_agreement":null},{"id":"W2762485081","doi":"10.1093/annonc/mdx373.006","title":"Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Clinical endpoint; Follicular lymphoma; Subgroup analysis; Lymphoma; Rituximab; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Confidence interval","score_opus":0.16493439728604195,"score_gpt":0.44832213333161947,"score_spread":0.28338773604557754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762485081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943488,0.00036727544,0.0000013971096,0.00081071793,0.00010907062,0.001455069,0.000031997093,0.000013565728,0.002862092],"genre_scores_gemma":[0.99845725,0.0002727836,0.00006471993,0.0003218155,0.000118598444,0.00010384591,0.00004808029,0.000029088818,0.00058381323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977424,0.00032400806,0.0005024891,0.00044747605,0.0005389473,0.00044467082],"domain_scores_gemma":[0.99688995,0.00078282267,0.0004602171,0.0014463826,0.00026767832,0.00015293347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004374368,0.00024118331,0.000810373,0.00012484567,0.00016635392,0.000025794989,0.0004707955,0.00016225486,0.00015428486],"category_scores_gemma":[0.00038320755,0.00012365778,0.0001021648,0.00013664472,0.00039535054,0.00011979999,0.00018729034,0.00016269342,0.000038166825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.032563098,0.044079877,0.8135019,0.00006271995,0.0013209321,0.0015591558,0.0061876294,0.000021553398,0.00031957118,0.0000060011143,0.005056362,0.09532122],"study_design_scores_gemma":[0.12435939,0.04163384,0.82539684,0.00008577814,0.00020486063,0.000005248471,0.0010191282,0.00007605538,0.0020217258,0.000009099689,0.0050524804,0.00013556436],"about_ca_topic_score_codex":0.020703321,"about_ca_topic_score_gemma":0.0069840536,"teacher_disagreement_score":0.09518566,"about_ca_system_score_codex":0.0047493656,"about_ca_system_score_gemma":0.007051517,"threshold_uncertainty_score":0.99907124},"labels":[],"label_agreement":null},{"id":"W2763374265","doi":"10.1016/j.bbmt.2017.10.015","title":"Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia","year":2017,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Medicine; Human leukocyte antigen; Hematopoietic stem cell transplantation; Leukemia; Immunology; Chronic lymphocytic leukemia; Transplantation; Stem cell; Hematopoietic cell; Haematopoiesis; Oncology; Internal medicine; Antigen; Genetics; Biology","score_opus":0.02517823110711789,"score_gpt":0.3499453652591615,"score_spread":0.3247671341520436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763374265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977304,0.0005065621,0.00047967897,0.000014853091,0.00007003782,0.0006263089,0.00026121733,0.000007665212,0.00030332335],"genre_scores_gemma":[0.99654,0.002714861,0.00046026235,0.0000055511186,0.000018899,0.000018689856,0.00017982956,0.000016258491,0.000045650042],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987863,0.000057525103,0.00053724984,0.00023242363,0.0001833379,0.00020316543],"domain_scores_gemma":[0.9986438,0.0003142841,0.0004782153,0.00032964305,0.0001695275,0.00006448688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029813944,0.0001672538,0.00065464864,0.00015223649,0.00005095416,0.000003327308,0.00014487015,0.0001872951,0.00001847619],"category_scores_gemma":[0.000015015018,0.00012848628,0.00019224666,0.000050029696,0.00030762644,0.000051583473,0.00000852508,0.00006544136,4.6103239e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022534535,0.00015665515,0.06251753,0.008769234,0.00059505133,0.000011705816,0.00055344705,0.00031702366,0.9227989,0.00066409475,0.0000045025618,0.0013584032],"study_design_scores_gemma":[0.028479462,0.007024795,0.24104053,0.0005666191,0.0014744299,0.00010421635,0.000052129446,0.0014399491,0.7195458,0.00012714123,0.000001964339,0.00014299326],"about_ca_topic_score_codex":0.00064839417,"about_ca_topic_score_gemma":0.00004334524,"teacher_disagreement_score":0.20325314,"about_ca_system_score_codex":0.0010396846,"about_ca_system_score_gemma":0.0050377185,"threshold_uncertainty_score":0.8936696},"labels":[],"label_agreement":null},{"id":"W2763948152","doi":"","title":"Use of Obinutuzumab for B-cell Malignancies","year":2017,"lang":"en","type":"article","venue":"Medical Research Archives","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Obinutuzumab; Rituximab; CD20; Medicine; Chronic lymphocytic leukemia; Monoclonal antibody; Oncology; Monoclonal antibody therapy; Lymphoma; Monoclonal; Internal medicine; Immunology; Leukemia; Antibody","score_opus":0.1962971642212667,"score_gpt":0.44766041003444906,"score_spread":0.25136324581318237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763948152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9457624,0.0009500502,0.003206881,0.0064711776,0.00021402839,0.002551305,0.000086627544,0.000064037675,0.04069351],"genre_scores_gemma":[0.9729966,0.0013348388,0.0053106616,0.000084435764,0.0003704038,0.00020706744,0.000025638836,0.000046559162,0.019623794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994941,0.0002259862,0.00041533352,0.00046013424,0.002874602,0.0010829295],"domain_scores_gemma":[0.9916574,0.0054165074,0.00010462796,0.001511638,0.00033615503,0.0009736922],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.0020826056,0.00015594847,0.00047883848,0.0003271941,0.00055937713,0.00011295478,0.0010142375,0.00015195023,0.00043972905],"category_scores_gemma":[0.034487784,0.00011660174,0.00022753741,0.00011634704,0.0035672383,0.0001684798,0.00087122316,0.0006984145,0.000059205253],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015796028,0.002884797,0.008550672,0.010854768,0.00065888645,0.002402435,0.004243741,0.000009456612,0.16186135,0.024590641,0.10401129,0.66413593],"study_design_scores_gemma":[0.059049826,0.0059658866,0.024082918,0.0037975877,0.00009427454,0.00035908926,0.000653759,0.08165377,0.36210716,0.013150473,0.44846728,0.0006179581],"about_ca_topic_score_codex":0.0010400808,"about_ca_topic_score_gemma":0.000091879905,"teacher_disagreement_score":0.66351795,"about_ca_system_score_codex":0.00130836,"about_ca_system_score_gemma":0.019786611,"threshold_uncertainty_score":0.9991445},"labels":[],"label_agreement":null},{"id":"W2765147096","doi":"10.1016/j.jval.2017.08.751","title":"Cost Per Response for Abatacept Compared with Adalimumab In the Treatment of Patients with Rheumatoid Arthritis Based on Anti-Citrullinated Protein Antibody Titres In Italy","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada); Université de Montréal","funders":"","keywords":"Abatacept; Medicine; Adalimumab; Rheumatoid arthritis; Internal medicine; Cohort; Physical therapy; Rituximab","score_opus":0.04930851765117299,"score_gpt":0.3540597665934935,"score_spread":0.3047512489423205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765147096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908226,0.00031345506,0.000029689209,0.0018162386,0.00002315383,0.006854053,0.00009623023,0.000012505672,0.000032080334],"genre_scores_gemma":[0.99843067,0.00022733131,0.0005969233,0.00007897418,0.000010973508,0.00046530724,0.00012071356,0.00003701106,0.00003208343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973747,0.0005045789,0.00054980605,0.00039720398,0.00063111004,0.00054256286],"domain_scores_gemma":[0.9979658,0.00061255955,0.00028363412,0.00089857803,0.00012571835,0.00011369534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011767853,0.00022263988,0.00067242293,0.00036363048,0.00013041064,0.00003502337,0.00022823949,0.00007670964,0.0000130929575],"category_scores_gemma":[0.00029210318,0.00013413801,0.000047262496,0.00024655194,0.00016712192,0.00007933481,0.000015565405,0.00017642265,0.0000036143972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.15180771,0.013853445,0.7986038,0.001980633,0.00009455922,0.00056992826,0.009934018,0.013994804,0.00025445147,0.00009409642,0.00011879591,0.008693773],"study_design_scores_gemma":[0.16418044,0.017045863,0.7401875,0.007554629,0.0000065183526,0.000014943603,0.00055642176,0.0685636,0.0009066763,0.000013725196,0.0007416306,0.00022802218],"about_ca_topic_score_codex":0.030576302,"about_ca_topic_score_gemma":0.0035348898,"teacher_disagreement_score":0.05841626,"about_ca_system_score_codex":0.008203678,"about_ca_system_score_gemma":0.005903534,"threshold_uncertainty_score":0.9997321},"labels":[],"label_agreement":null},{"id":"W2765329477","doi":"10.1080/10428194.2017.1387904","title":"Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; St. John’s Health Sciences Centre; Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Chemoimmunotherapy; Rituximab; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Chemotherapy; Cohort; Population; Clinical trial; Purine analogue; Leukemia; Immunology; Lymphoma","score_opus":0.01682509996718804,"score_gpt":0.2938357957084521,"score_spread":0.277010695741264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765329477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238855,0.0007669914,0.00037012086,0.00016302493,0.0001808614,0.0047069043,0.0007971845,0.000041704247,0.0005846374],"genre_scores_gemma":[0.99695075,0.00016255063,0.00017946895,0.0004589675,0.00020150193,0.0012425728,0.0001801873,0.00008856807,0.0005354276],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943394,0.00057506125,0.0011480653,0.001212835,0.0015226747,0.001201975],"domain_scores_gemma":[0.99297863,0.0028789632,0.00094411656,0.0021300684,0.00072214624,0.00034605648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017323117,0.00065072946,0.0025507875,0.00027485864,0.0008215301,0.00039775184,0.0014462397,0.00037234306,0.000033572607],"category_scores_gemma":[0.0004132803,0.0005325139,0.0004982513,0.0010808297,0.0013984813,0.00035051507,0.00031058898,0.0002505098,0.0000019563224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09199942,0.0045228717,0.17821112,0.017005317,0.041550122,0.0093043875,0.016324813,0.017325819,0.016533466,0.0015114079,0.033218797,0.5724925],"study_design_scores_gemma":[0.1515875,0.002984672,0.78446853,0.00096275803,0.0016835401,0.0007428417,0.002147968,0.046768416,0.005135488,0.00007610493,0.0024120866,0.001030127],"about_ca_topic_score_codex":0.9320624,"about_ca_topic_score_gemma":0.9457703,"teacher_disagreement_score":0.6062574,"about_ca_system_score_codex":0.114033654,"about_ca_system_score_gemma":0.1434394,"threshold_uncertainty_score":0.99971265},"labels":[],"label_agreement":null},{"id":"W2765414225","doi":"10.1182/blood-2017-09-804641","title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Human Genome Research Institute","keywords":"Ibrutinib; Rituximab; Medicine; Follicular lymphoma; Oncology; Refractory (planetary science); Internal medicine; Idelalisib; Phases of clinical research; Clinical trial; Lymphoma; Leukemia; Chronic lymphocytic leukemia; Biology","score_opus":0.06832704270368069,"score_gpt":0.3612379891516637,"score_spread":0.29291094644798304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765414225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905085,0.00048281223,0.000005946406,0.00039141532,0.00043001588,0.0014251092,0.000012886656,0.00007874607,0.006664599],"genre_scores_gemma":[0.99498165,0.00007152566,0.0003070872,0.00016121035,0.00062376994,0.00012313783,0.000021632106,0.00005438087,0.0036555917],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973622,0.00011788507,0.00058739755,0.00055524014,0.000710501,0.0006667862],"domain_scores_gemma":[0.99743116,0.00023526415,0.00025784198,0.0016275862,0.00010023841,0.0003479034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068760244,0.0002509413,0.0006012762,0.00018004248,0.00021360442,0.00010648178,0.00040993566,0.00026000553,0.0003478888],"category_scores_gemma":[0.003167091,0.00019640889,0.00019137602,0.00014218513,0.00028448793,0.000113821094,0.00020418428,0.0002374198,0.00018465216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5387154,0.13195781,0.0022969372,0.0012796147,0.0020291554,0.08444756,0.0026029304,0.0000037788143,0.10986399,0.00037545915,0.01148109,0.11494625],"study_design_scores_gemma":[0.9397089,0.0032790683,0.00059633295,0.00027180839,0.00027882063,0.0005796002,0.0000855897,0.00040066332,0.026460323,0.000028760023,0.028045582,0.00026454247],"about_ca_topic_score_codex":0.00057508616,"about_ca_topic_score_gemma":0.00012793501,"teacher_disagreement_score":0.4009935,"about_ca_system_score_codex":0.0036139407,"about_ca_system_score_gemma":0.007564513,"threshold_uncertainty_score":0.99806166},"labels":[],"label_agreement":null},{"id":"W2765635337","doi":"10.1016/j.jval.2017.08.2679","title":"Treatment Patterns and Satisfaction For Rheumatoid Arthritis Patients In Latin America Undergoing Advanced Therapy","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Antirheumatic drugs; Biologic Agents; Rheumatology; Combination therapy; Physical therapy; Antirheumatic Agents","score_opus":0.049543698073820856,"score_gpt":0.3535058204042228,"score_spread":0.30396212233040193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765635337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964754,0.00079814735,0.00008574182,0.0010445677,0.000095988384,0.0014204645,0.000017257667,0.000014436539,0.000048022463],"genre_scores_gemma":[0.94483197,0.053958178,0.00087335,0.00011015559,0.000024290908,0.0001402041,0.000018597873,0.000020032916,0.000023240817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988407,0.000070587295,0.00031196306,0.0002630373,0.00017027212,0.0003434432],"domain_scores_gemma":[0.9991183,0.0002784545,0.0001533003,0.00030878294,0.000026410033,0.00011473577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000163841,0.000110718094,0.00030740723,0.00010725209,0.0001447987,0.000025915104,0.000042910902,0.000046311485,0.000008901065],"category_scores_gemma":[0.00021068667,0.00009698549,0.000028964729,0.000045560308,0.00004255381,0.00009306936,0.00002096851,0.00008467341,0.0000028061754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002666103,0.00009744202,0.5055489,0.00012548239,0.00000755854,0.0000072934,0.00071265287,0.00012573045,0.00000900001,0.000027327222,0.000008685605,0.4930633],"study_design_scores_gemma":[0.05144626,0.0021645525,0.92807853,0.001051161,7.9220536e-7,0.000011041979,0.00018183311,0.016025947,0.00010687979,0.00018122018,0.0006570726,0.00009469385],"about_ca_topic_score_codex":0.098367825,"about_ca_topic_score_gemma":0.00792834,"teacher_disagreement_score":0.49296862,"about_ca_system_score_codex":0.007653101,"about_ca_system_score_gemma":0.0019926399,"threshold_uncertainty_score":0.99615633},"labels":[],"label_agreement":null},{"id":"W2766447985","doi":"10.1002/cpdd.395","title":"Pharmacokinetics of the BCL‐2 Inhibitor Venetoclax in Healthy Chinese Subjects","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genentech; AbbVie","keywords":"Venetoclax; Medicine; Pharmacokinetics; Pharmacology; Internal medicine; Oncology; Leukemia","score_opus":0.056235550579271334,"score_gpt":0.45602244500090494,"score_spread":0.3997868944216336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766447985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889098,0.00035222943,0.0000013093111,0.004923899,0.0032578155,0.0012621705,0.0000026775765,0.000016966105,0.0012731449],"genre_scores_gemma":[0.9951089,0.0005686301,0.0003762248,0.0025962607,0.0005432598,0.000118853175,0.000004677248,0.00002905383,0.00065413397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996489,0.00040137523,0.0014776575,0.0005112602,0.0004863599,0.0006343667],"domain_scores_gemma":[0.9977057,0.00081589783,0.00041891445,0.0006601953,0.00012700865,0.00027230012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025152296,0.0002365794,0.00073838216,0.00017157465,0.00015139833,0.000012285427,0.00085355586,0.00021571573,0.00019204058],"category_scores_gemma":[0.0012151839,0.00016636068,0.00014079265,0.00028042987,0.00079296326,0.000065555585,0.00083680183,0.0011360663,0.000059764025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006809531,0.0024259393,0.93722427,0.00079436065,0.00027329804,0.0009427112,0.0024398607,0.00030336867,0.0048791417,0.000018087594,0.027139114,0.016750298],"study_design_scores_gemma":[0.05829802,0.00019467146,0.9026196,0.00028935296,0.000045023513,0.000042647054,0.000036931426,0.0030599653,0.017282415,0.00008107896,0.017806793,0.00024352885],"about_ca_topic_score_codex":0.00026384825,"about_ca_topic_score_gemma":0.00045205673,"teacher_disagreement_score":0.05148849,"about_ca_system_score_codex":0.0061643193,"about_ca_system_score_gemma":0.015736219,"threshold_uncertainty_score":0.99765086},"labels":[],"label_agreement":null},{"id":"W2767413682","doi":"10.1182/blood.v128.22.2963.2963","title":"Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Mantle cell lymphoma; Bendamustine; Internal medicine; Ibrutinib; Idelalisib; Tolerability; Gastroenterology; Adverse effect; Oncology; Surgery; Rituximab; Chronic lymphocytic leukemia; Lymphoma; Leukemia","score_opus":0.021673952974636417,"score_gpt":0.31747118032332516,"score_spread":0.29579722734868874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767413682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737895,0.00007684512,0.0000061165633,0.00004962728,0.000028688322,0.0012106887,0.000075808544,0.000009789189,0.0011634618],"genre_scores_gemma":[0.99919045,0.000029480976,0.00044318364,0.000008052881,0.00005387318,0.000015279822,0.000018818122,0.000020047137,0.00022079599],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980521,0.00010869202,0.000590014,0.00029578406,0.00067972305,0.0002736539],"domain_scores_gemma":[0.99855596,0.00054384925,0.00022811523,0.00039217997,0.00016837419,0.000111545676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071705296,0.00012751183,0.00040052473,0.0001247406,0.000017955485,0.0000035739586,0.00009496835,0.000076431475,0.000039019764],"category_scores_gemma":[0.0009121443,0.00007797655,0.000040126164,0.00020075138,0.00014348642,0.000041807965,0.00008020719,0.00005216284,0.0000052745236],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8510562,0.028157687,0.010981244,0.0006708971,0.00023895205,0.00008346465,0.0014928351,0.00000164772,0.021307347,0.000019779076,0.00014678344,0.085843146],"study_design_scores_gemma":[0.9338932,0.0083754985,0.015833054,0.0006570266,0.00013787881,0.000007313596,0.000029914978,0.000074892596,0.040788505,0.000004151708,0.000107628286,0.000090904425],"about_ca_topic_score_codex":0.00017539125,"about_ca_topic_score_gemma":0.000010372304,"teacher_disagreement_score":0.08575224,"about_ca_system_score_codex":0.00057196885,"about_ca_system_score_gemma":0.0018565301,"threshold_uncertainty_score":0.32934046},"labels":[],"label_agreement":null},{"id":"W2769684200","doi":"10.3324/haematol.2017.175380","title":"Survival adjusting for crossover: phase 3 study of ibrutinib <i>vs</i> . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2017,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Pharmacyclics","keywords":"Ibrutinib; Chlorambucil; Chronic lymphocytic leukemia; Internal medicine; Medicine; Leukemia; Lymphoma; Oncology; Hematology; Chemotherapy; Immunology; Cyclophosphamide","score_opus":0.04148799816424028,"score_gpt":0.3180868482053957,"score_spread":0.2765988500411554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769684200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842675,0.0006879927,0.00003912746,0.0017624192,0.0005943272,0.01078834,0.00041838008,0.00030152834,0.0011404397],"genre_scores_gemma":[0.9814235,0.00009360893,0.00025745595,0.010776588,0.0010900941,0.0015546385,0.0020784473,0.00046275745,0.002262908],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9894912,0.00044459745,0.002376665,0.0026160988,0.0022825042,0.0027889218],"domain_scores_gemma":[0.99076766,0.0018567193,0.0021381562,0.0035574867,0.0012653865,0.000414611],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009652935,0.0017612297,0.0049538175,0.0008706938,0.00053798227,0.00025132808,0.00177084,0.002205448,0.00019157014],"category_scores_gemma":[0.0017218895,0.001353421,0.00057727104,0.0008025891,0.0010387291,0.00025143672,0.0007191461,0.001271279,0.000081406084],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.1501828,0.02098585,0.05277113,0.08590695,0.011583146,0.15433055,0.008068313,0.0029008575,0.00015520303,0.000098241035,0.48675287,0.026264079],"study_design_scores_gemma":[0.89518523,0.024613215,0.006128399,0.008195023,0.0033538204,0.0024942225,0.0006321558,0.023994833,0.0013238455,0.000050923376,0.030675579,0.0033527808],"about_ca_topic_score_codex":0.007522261,"about_ca_topic_score_gemma":0.0007381428,"teacher_disagreement_score":0.7450024,"about_ca_system_score_codex":0.1442935,"about_ca_system_score_gemma":0.07321973,"threshold_uncertainty_score":0.9995133},"labels":[],"label_agreement":null},{"id":"W2769846020","doi":"10.1136/thoraxjnl-2017-210983.451","title":"M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf","year":2017,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Nintedanib; Medicine; Internal medicine; Idiopathic pulmonary fibrosis; Lung","score_opus":0.03751646694700131,"score_gpt":0.3361981558653461,"score_spread":0.2986816889183448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769846020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901929,0.00003235003,0.000054391287,0.0008414007,0.00017874876,0.0010696378,0.000051057414,0.00008150437,0.007498007],"genre_scores_gemma":[0.99448454,0.000043572745,0.0005441734,0.0011142028,0.0002640789,0.000041998064,0.0001106151,0.00006007795,0.0033367174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626553,0.000061642284,0.00057956873,0.0006537343,0.0016780895,0.00076145795],"domain_scores_gemma":[0.99699724,0.00009608496,0.00020474316,0.0019265731,0.0003083885,0.000466997],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075878965,0.00030932314,0.0005771731,0.0001480395,0.0001482862,0.00010414312,0.0005488737,0.00021611694,0.00095826027],"category_scores_gemma":[0.00088677387,0.00022000211,0.0001024367,0.00014488444,0.00036724895,0.00027554328,0.00068401016,0.00042072686,0.000216494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022859764,0.0008600815,0.99250615,0.00018391924,0.00016236382,0.00033936842,0.000080693004,0.000015366553,0.00018387265,0.00020240716,0.0017480156,0.0014318122],"study_design_scores_gemma":[0.05135547,0.00052493025,0.9393641,0.00024143385,0.00007955179,0.000012159333,0.000022300157,0.0030407791,0.0036866071,0.0000605044,0.0013615073,0.00025069292],"about_ca_topic_score_codex":0.016405668,"about_ca_topic_score_gemma":0.0069940328,"teacher_disagreement_score":0.05314206,"about_ca_system_score_codex":0.0053408537,"about_ca_system_score_gemma":0.0035533325,"threshold_uncertainty_score":0.999955},"labels":[],"label_agreement":null},{"id":"W2772285283","doi":"10.1038/s41598-017-18368-w","title":"Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition","year":2017,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University Health Network","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Cancer research; Medicine; Internal medicine","score_opus":0.029985124447609725,"score_gpt":0.34467358626664263,"score_spread":0.3146884618190329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772285283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914255,0.00025943367,0.00009209971,0.00049935165,0.004961927,0.0010846105,0.000045606765,0.00016157926,0.0014698484],"genre_scores_gemma":[0.9775262,0.00011282279,0.0010060597,0.00018365309,0.0005117453,0.000037712696,0.00008809132,0.00006173909,0.02047198],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994112,0.0001887824,0.001258406,0.0020235397,0.0014707048,0.00094656204],"domain_scores_gemma":[0.9935619,0.00024202048,0.000800429,0.0038841364,0.00054063497,0.0009708284],"candidate_categories":["metaepi_narrow","sts","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.006122146,0.00034430492,0.0007540347,0.00030468527,0.0013809912,0.0011174106,0.00020727183,0.0002875684,0.00010394392],"category_scores_gemma":[0.004370333,0.00029175033,0.00022489515,0.0002907585,0.001078458,0.00046511806,0.0010146075,0.0003304017,0.0001698752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003477466,0.017223094,0.2896318,0.002105432,0.00055814977,0.09674957,0.0040428694,0.000024305587,0.13388214,0.00052512635,0.37404692,0.07773313],"study_design_scores_gemma":[0.12209126,0.0015793609,0.09569114,0.0015567328,0.000697262,0.006525422,0.000984969,0.003952816,0.47511953,0.0035912874,0.28629288,0.0019173535],"about_ca_topic_score_codex":0.001681034,"about_ca_topic_score_gemma":0.00045962035,"teacher_disagreement_score":0.3412374,"about_ca_system_score_codex":0.0014673369,"about_ca_system_score_gemma":0.0032843123,"threshold_uncertainty_score":0.99995345},"labels":[],"label_agreement":null},{"id":"W2772425057","doi":"10.1016/j.cjca.2017.12.001","title":"Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Ibrutinib; Medicine; Dosing; Atrial fibrillation; Internal medicine; Cardiology; Drug; Pharmacology; Washout; Chronic lymphocytic leukemia; Leukemia","score_opus":0.023343480233605156,"score_gpt":0.27590225542273333,"score_spread":0.25255877518912817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772425057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976114,0.00091637415,0.000049329166,0.0003481172,0.0001641646,0.0004837347,0.00006722888,0.0000018490391,0.0003578206],"genre_scores_gemma":[0.9987769,0.000033553668,0.00024991733,0.0000153404,0.0008695377,0.0000040288623,0.0000107744645,0.000015596572,0.000024315583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986964,0.0001753933,0.0003957211,0.0001888711,0.00015304102,0.0003905673],"domain_scores_gemma":[0.998114,0.0002860433,0.00029178103,0.00036880522,0.0003919173,0.0005474653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097135565,0.00012517649,0.0009021197,0.0002724224,0.0000880461,0.000020888874,0.00015058067,0.0001696075,0.0000070310784],"category_scores_gemma":[0.0016828328,0.00009700591,0.00022908453,0.00008573165,0.0005037482,0.00006634183,0.000018283397,0.00020464913,5.727875e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019134987,0.000031784915,0.9382352,0.0006142915,0.002547271,0.014731176,0.0004859821,0.0009114516,0.008960582,0.00023098159,0.0026119961,0.011504285],"study_design_scores_gemma":[0.13982962,0.00831175,0.80896145,0.000741301,0.0015433151,0.009908821,0.00044938817,0.00034035364,0.008761075,0.000350564,0.020301152,0.0005012334],"about_ca_topic_score_codex":0.030814882,"about_ca_topic_score_gemma":0.0071135825,"teacher_disagreement_score":0.12927379,"about_ca_system_score_codex":0.003093274,"about_ca_system_score_gemma":0.011296753,"threshold_uncertainty_score":0.9943083},"labels":[],"label_agreement":null},{"id":"W2772753654","doi":"10.1016/j.bbagrm.2017.11.010","title":"5-Azacytidine engages an IRE1α-EGFR-ERK1/2 signaling pathway that stabilizes the LDL receptor mRNA","year":2017,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fondation Institut de Cardiologie de Montréal","keywords":"LDL receptor; Endoplasmic reticulum; Signal transduction; Kinase; Messenger RNA; Cell biology; Receptor; Chemistry; Biology; Molecular biology; Cancer research; Endocrinology; Cholesterol; Lipoprotein; Biochemistry; Gene","score_opus":0.05291493430112276,"score_gpt":0.3093632502871865,"score_spread":0.2564483159860637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772753654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919623,0.00031753126,0.00024097442,0.0037983318,0.00082150754,0.0017595661,0.00015835349,0.0003905673,0.0005508358],"genre_scores_gemma":[0.9925611,0.00031501896,0.0030888084,0.000681144,0.0013631945,0.00019600814,0.00020762024,0.00028541527,0.001301717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9934371,0.0007120624,0.0007936579,0.0016541797,0.0019820542,0.0014209574],"domain_scores_gemma":[0.9924542,0.00043365994,0.00078588206,0.0051506176,0.00035506862,0.0008205963],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0022848633,0.0009516286,0.0011300689,0.00024644044,0.0019391048,0.0005854418,0.002170381,0.00053182215,0.00037005293],"category_scores_gemma":[0.00047923785,0.00069107814,0.00062641065,0.00029559835,0.0009798263,0.0006985525,0.0009450853,0.0010402357,0.00020460392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005912704,0.00042852646,0.0000011281826,0.00014496518,0.00033909097,0.000062860774,0.0009731878,0.000009055646,0.9913761,0.0025973262,0.0007477529,0.0027287293],"study_design_scores_gemma":[0.0059805634,0.00092271314,0.00073125144,0.00029430405,0.00025634567,0.00011953868,0.00077616854,0.0018106716,0.9859221,0.0018020129,0.00057832716,0.0008059882],"about_ca_topic_score_codex":0.00022854413,"about_ca_topic_score_gemma":0.00002454385,"teacher_disagreement_score":0.0054539912,"about_ca_system_score_codex":0.0033773552,"about_ca_system_score_gemma":0.004465543,"threshold_uncertainty_score":0.99955404},"labels":[],"label_agreement":null},{"id":"W2776235297","doi":"","title":"De tyrosinekinaseremmer dasatinib voor behandeling van chemotherapie-refractaire chronische lymfatische leukemie: de D'ACCORD-studie","year":2009,"lang":"nl","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Dasatinib; Medicine; Gynecology; Internal medicine; Tyrosine kinase","score_opus":0.026173729566016976,"score_gpt":0.31356523027015504,"score_spread":0.28739150070413805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776235297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9388547,0.040062916,0.0067687645,0.0022622093,0.00041126847,0.0013505992,0.0006260256,0.0003535517,0.009309987],"genre_scores_gemma":[0.9724669,0.010175185,0.0048549436,0.003845611,0.0034815248,0.000037798192,0.002237111,0.00021304401,0.002687904],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99214673,0.0006287433,0.001228326,0.0020269223,0.0011013206,0.0028679415],"domain_scores_gemma":[0.9939076,0.0010382533,0.0005101079,0.0032036668,0.00015692819,0.0011835014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030249457,0.001123807,0.0013218868,0.00024756975,0.001173172,0.0006063472,0.0025704033,0.0005146178,0.000490734],"category_scores_gemma":[0.00021316357,0.0010162427,0.0001996232,0.0007722169,0.00047316946,0.00074710906,0.0015630616,0.0016709511,0.00026977487],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0071264715,0.002978644,0.054729123,0.010349175,0.004804344,0.003117248,0.045158193,0.007721369,0.043410618,0.00062492746,0.05561211,0.76436776],"study_design_scores_gemma":[0.016153537,0.0007492922,0.027686896,0.0057297177,0.001150997,0.00068122376,0.003458285,0.9088413,0.0014507553,0.0002762526,0.032542717,0.0012790023],"about_ca_topic_score_codex":0.0059798085,"about_ca_topic_score_gemma":0.0012454136,"teacher_disagreement_score":0.90111995,"about_ca_system_score_codex":0.0048362324,"about_ca_system_score_gemma":0.0061967787,"threshold_uncertainty_score":0.99943715},"labels":[],"label_agreement":null},{"id":"W2779669493","doi":"","title":"Richtlijn 'Chronische Lymfatische Leukemie'","year":2016,"lang":"nl","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine","score_opus":0.0285020305747756,"score_gpt":0.28876639307281443,"score_spread":0.26026436249803886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779669493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90798146,0.035748065,0.0072189854,0.0031301924,0.0019020144,0.0018900926,0.0029495438,0.00054988376,0.03862977],"genre_scores_gemma":[0.95462435,0.01913531,0.0014406141,0.0008063864,0.00397602,0.000048995185,0.0015906374,0.00023511895,0.018142557],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9921775,0.00074389996,0.0011239747,0.002296464,0.0013638092,0.002294344],"domain_scores_gemma":[0.99084127,0.0026285765,0.00040034074,0.0048003085,0.00012575967,0.0012037234],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002316959,0.00095370633,0.0012029706,0.00026482285,0.000728543,0.00033522124,0.003335041,0.00041372952,0.00081845693],"category_scores_gemma":[0.00020578588,0.0006271933,0.00015862822,0.00068644324,0.0009929874,0.0009786179,0.005078861,0.0008484804,0.0023664709],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070388136,0.001837559,0.09923006,0.021210829,0.0076874453,0.0048042503,0.02199391,0.00051938737,0.040911254,0.004346242,0.18420075,0.6062195],"study_design_scores_gemma":[0.036075767,0.0008585319,0.027535139,0.01572462,0.0017036194,0.0012426536,0.0023324643,0.5927014,0.0009273817,0.00049216923,0.31827313,0.0021331555],"about_ca_topic_score_codex":0.0046802047,"about_ca_topic_score_gemma":0.0016446026,"teacher_disagreement_score":0.60408634,"about_ca_system_score_codex":0.0037646373,"about_ca_system_score_gemma":0.004699863,"threshold_uncertainty_score":0.99961793},"labels":[],"label_agreement":null},{"id":"W2781400063","doi":"","title":"De plaats van alemtuzumab bij de behandeling van chronische lymfatische leukemie","year":2008,"lang":"nl","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine","score_opus":0.0401388001111463,"score_gpt":0.2986621201779444,"score_spread":0.2585233200667981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781400063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94492584,0.025858445,0.010451372,0.00038768782,0.00047480446,0.0009823071,0.00087546674,0.00032553315,0.015718535],"genre_scores_gemma":[0.9606713,0.021767082,0.0037051933,0.000955529,0.0033509017,0.000050594204,0.003400325,0.00024447884,0.005854606],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99183416,0.0008303982,0.0011551254,0.0019460025,0.0012375894,0.0029967353],"domain_scores_gemma":[0.9929864,0.0016282693,0.00038684352,0.003362789,0.00011535315,0.0015203857],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0026996178,0.0009804376,0.0011805231,0.0003195764,0.0015370847,0.00033952165,0.002832678,0.0005122308,0.0006904091],"category_scores_gemma":[0.00019467765,0.0009190047,0.0001855474,0.00070776977,0.00080549734,0.0007197515,0.0030910715,0.0016924216,0.000612722],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011716938,0.0038723187,0.20452791,0.035968173,0.011525455,0.02975585,0.19913857,0.1275033,0.03351197,0.0011228444,0.15495968,0.18639697],"study_design_scores_gemma":[0.011871384,0.0003811775,0.007740102,0.0037103463,0.0007543577,0.003487209,0.0020226522,0.9216486,0.0005072838,0.0001539041,0.046759564,0.0009634086],"about_ca_topic_score_codex":0.011753364,"about_ca_topic_score_gemma":0.0021695357,"teacher_disagreement_score":0.7941453,"about_ca_system_score_codex":0.006747208,"about_ca_system_score_gemma":0.012075235,"threshold_uncertainty_score":0.9997628},"labels":[],"label_agreement":null},{"id":"W2781711677","doi":"","title":"Chronische lymfatische leukemie in Nederland: Trends in incidentie, behandeling en overleving (1989-2008)","year":2013,"lang":"nl","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Political science; Medicine","score_opus":0.021958814406029224,"score_gpt":0.2968000637287061,"score_spread":0.2748412493226769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781711677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97498786,0.018076224,0.00027117805,0.0004305936,0.000508177,0.0008899825,0.000206592,0.00009959669,0.004529764],"genre_scores_gemma":[0.9830953,0.008883264,0.0008702555,0.0003496369,0.0013708447,0.00009982946,0.003056126,0.0001579781,0.002116759],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9920113,0.0009441015,0.0016542859,0.0019599844,0.0011433829,0.0022869594],"domain_scores_gemma":[0.99469846,0.0016212711,0.00036945968,0.002546739,0.00007507876,0.0006889711],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030599318,0.0008967279,0.0013387505,0.0010882395,0.00036352884,0.000599354,0.0023686592,0.00049077783,0.0007836028],"category_scores_gemma":[0.00016393479,0.00082781975,0.00012623142,0.001631314,0.00026803932,0.0015857005,0.0037575043,0.0018548339,0.000350774],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015152008,0.0015804382,0.5228026,0.007900123,0.0011466756,0.002715813,0.05691995,0.019267546,0.0043480117,0.00014338642,0.011756954,0.36990333],"study_design_scores_gemma":[0.012778171,0.00020898158,0.15753004,0.0063557657,0.00018704709,0.0001936614,0.00451018,0.8145431,0.000040845633,0.00006524135,0.0028251149,0.00076182856],"about_ca_topic_score_codex":0.11745403,"about_ca_topic_score_gemma":0.08142076,"teacher_disagreement_score":0.79527557,"about_ca_system_score_codex":0.0049713715,"about_ca_system_score_gemma":0.0023049517,"threshold_uncertainty_score":0.99941725},"labels":[],"label_agreement":null},{"id":"W2781752934","doi":"10.1080/10428194.2017.1416364","title":"Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Johnson and Johnson; Astellas Pharma; Celgene; Gilead Sciences","keywords":"Bendamustine; Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Placebo; Quality of life (healthcare); Rituximab; Clinical endpoint; Oncology; Clinical trial; Lymphoma; Leukemia; Pathology","score_opus":0.0091424588777352,"score_gpt":0.24512924548105156,"score_spread":0.23598678660331635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781752934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914584,0.0005379183,0.00017118755,0.00006202502,0.0001648994,0.0068278755,0.00003811637,0.0001409856,0.00059858424],"genre_scores_gemma":[0.9965786,0.00023614195,0.00050615834,0.0003557901,0.0003363784,0.0010658152,0.00023811993,0.00023591568,0.00044710436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919239,0.00047103784,0.0017652645,0.0022347106,0.0017443155,0.0018607483],"domain_scores_gemma":[0.9949017,0.0015837866,0.00086852326,0.001379018,0.0006762335,0.000590713],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002096185,0.0013706174,0.001979974,0.0009855222,0.00078564096,0.00023630833,0.00055199687,0.00049480883,0.00002777718],"category_scores_gemma":[0.00038468686,0.001013931,0.00019073539,0.0017100465,0.0015083709,0.0006028214,0.0006112783,0.0002730178,0.000008725726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06491352,0.009052085,0.6217577,0.008832851,0.0022443729,0.0014691302,0.046926685,0.0028150857,0.0025025348,0.00065051304,0.00077788363,0.23805763],"study_design_scores_gemma":[0.35490483,0.016380271,0.4169529,0.002367069,0.00078826776,0.00093021424,0.0036447356,0.19973573,0.0027005852,0.00011132566,0.000231827,0.0012522435],"about_ca_topic_score_codex":0.010769079,"about_ca_topic_score_gemma":0.005020913,"teacher_disagreement_score":0.2899913,"about_ca_system_score_codex":0.16523571,"about_ca_system_score_gemma":0.024653086,"threshold_uncertainty_score":0.99990445},"labels":[],"label_agreement":null},{"id":"W2782297997","doi":"10.1182/blood.v130.suppl_1.lba-2.lba-2","title":"Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"","keywords":"Rituximab; Bendamustine; Medicine; Chemoimmunotherapy; Tumor lysis syndrome; Internal medicine; Interim analysis; Venetoclax; Neutropenia; Gastroenterology; Refractory (planetary science); Obinutuzumab; Chronic lymphocytic leukemia; Oncology; Randomized controlled trial; Leukemia; Chemotherapy; Lymphoma","score_opus":0.0174912156410489,"score_gpt":0.30971087613635917,"score_spread":0.2922196604953103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782297997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284226,0.0003312825,0.00001529882,0.00009503268,0.00019344616,0.0053501553,0.00081857375,0.000057437403,0.0002965396],"genre_scores_gemma":[0.99828213,0.000037876245,0.00016765646,0.000109765766,0.00015229062,0.00030669986,0.00031892222,0.00009004241,0.00053458795],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941047,0.0005159149,0.001595754,0.0012436063,0.0016781727,0.00086185563],"domain_scores_gemma":[0.99386364,0.0007450938,0.000792964,0.003815613,0.000400663,0.0003820202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012642991,0.0005956055,0.0029572062,0.000675168,0.00032403108,0.00012841007,0.0013389583,0.00026107611,0.00019894537],"category_scores_gemma":[0.002598526,0.0003956452,0.0005101319,0.00096557784,0.00059408613,0.00024844045,0.00071341114,0.0005907123,0.000041238734],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.94754356,0.009267274,0.0079248855,0.00032342173,0.012110321,0.0006638994,0.016807,0.0025131362,0.0008976817,0.0000028235645,0.00035002877,0.0015959379],"study_design_scores_gemma":[0.90946335,0.00341513,0.03920979,0.0007974527,0.0069614756,0.000009469044,0.00029987734,0.03715303,0.0021920858,0.000003549179,0.00009873497,0.0003960717],"about_ca_topic_score_codex":0.044907235,"about_ca_topic_score_gemma":0.0051057963,"teacher_disagreement_score":0.039801437,"about_ca_system_score_codex":0.067214645,"about_ca_system_score_gemma":0.032058727,"threshold_uncertainty_score":0.99984956},"labels":[],"label_agreement":null},{"id":"W2782967915","doi":"10.1016/j.leukres.2018.01.006","title":"Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Chronic lymphocytic leukemia; Fludarabine; Cancer research; Bone marrow; In vivo; Immunology; In vitro; Leukemia; Mesenchymal stem cell; Interleukin 4; Interleukin; Cytokine; Medicine; Biology; Chemotherapy; Pathology; Internal medicine; Cyclophosphamide","score_opus":0.033310886801141915,"score_gpt":0.33809158004007767,"score_spread":0.30478069323893575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782967915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832833,0.0010212363,0.000036470756,0.0009633262,0.00022777413,0.002144351,0.000070348964,0.00008365694,0.012169548],"genre_scores_gemma":[0.9919413,0.0005438838,0.0002792955,0.0003329365,0.00131346,0.00032581654,0.00003969123,0.00014881838,0.005074837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9900104,0.0010512938,0.0013843874,0.001283437,0.0032436952,0.0030267825],"domain_scores_gemma":[0.99429065,0.00206738,0.000190381,0.0018259598,0.00110289,0.00052272715],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006912706,0.0005274754,0.0010553278,0.0015473498,0.00034830745,0.0001017714,0.0015418318,0.0005174319,0.0009065104],"category_scores_gemma":[0.0028664062,0.00040006544,0.00024746175,0.004062708,0.0025424936,0.00022823823,0.0010573814,0.0023141936,0.000324406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008124581,0.00030195335,0.0024955475,0.0030286158,0.00034877594,0.0029844053,0.008989825,0.0018936895,0.9026353,0.0014205327,0.059557103,0.008219669],"study_design_scores_gemma":[0.03313135,0.001484121,0.001075391,0.0011127589,0.00004213548,0.00036445804,0.0013856319,0.35677278,0.59469277,0.00093914603,0.008378187,0.0006212651],"about_ca_topic_score_codex":0.069113664,"about_ca_topic_score_gemma":0.0044787615,"teacher_disagreement_score":0.35487908,"about_ca_system_score_codex":0.38093126,"about_ca_system_score_gemma":0.1315387,"threshold_uncertainty_score":0.9999875},"labels":[],"label_agreement":null},{"id":"W2786789055","doi":"10.1016/j.jmoldx.2017.11.010","title":"Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management","year":2018,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"American Society for Investigative Pathology; Terry Fox Research Institute; Michael Smith Health Research BC; Genome British Columbia; Canadian Institutes of Health Research; Genome Canada","keywords":"Amplicon; Sanger sequencing; Concordance; Context (archaeology); DNA sequencing; Follicular lymphoma; Computational biology; Biology; Lymphoma; Gene; Polymerase chain reaction; Genetics; Immunology","score_opus":0.09562085929856652,"score_gpt":0.32874261141085914,"score_spread":0.23312175211229264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786789055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53474104,0.001298158,0.46252424,0.00059598667,0.00007395427,0.0006739783,0.000007302323,0.0000027288047,0.000082611026],"genre_scores_gemma":[0.85050184,0.00007783061,0.14883028,0.00039602027,0.00012235883,0.000026254296,0.000010635173,0.000018495602,0.000016310287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99836636,0.00004927034,0.00059224624,0.0001461884,0.0006542508,0.0001916986],"domain_scores_gemma":[0.9982799,0.00040007112,0.00031352745,0.00020988238,0.0006633132,0.00013329004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008692986,0.00013066402,0.00031610898,0.00016353987,0.00006576688,0.000020930487,0.00014396624,0.00006369097,0.00001091688],"category_scores_gemma":[0.00063980673,0.000089926405,0.000098548706,0.00018484735,0.000107840795,0.000029528637,0.000059398797,0.00007736137,3.322223e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020385406,0.0020700633,0.0026864884,0.005347353,0.004024409,0.0006175215,0.011803715,0.02377433,0.72139645,0.004916615,0.010358326,0.21096621],"study_design_scores_gemma":[0.022394843,0.0017801874,0.0074366974,0.0010864032,0.0011213776,0.00021912603,0.002996602,0.440016,0.5189754,0.00009974413,0.003567573,0.00030609858],"about_ca_topic_score_codex":0.000018748844,"about_ca_topic_score_gemma":0.0000159403,"teacher_disagreement_score":0.41624168,"about_ca_system_score_codex":0.0020404223,"about_ca_system_score_gemma":0.0037835634,"threshold_uncertainty_score":0.6711879},"labels":[],"label_agreement":null},{"id":"W2787624638","doi":"10.1182/blood-2017-06-792267","title":"Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","year":2018,"lang":"en","type":"letter","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Chronic lymphocytic leukemia; Tumor microenvironment; Stromal cell; Cancer research; Immune checkpoint; Immune system; Blockade; Ibrutinib; Leukemia; Medicine; Immunology; Biology; Immunotherapy; Receptor; Internal medicine","score_opus":0.028136847163922007,"score_gpt":0.2685611499825817,"score_spread":0.24042430281865967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787624638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97861934,0.004365695,0.000037146154,0.010914476,0.00034505315,0.0024679126,0.0000672729,0.0002112432,0.0029718538],"genre_scores_gemma":[0.856039,0.0012119764,0.010590303,0.0602504,0.0176881,0.001764862,0.0020979492,0.001461023,0.0488964],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9921099,0.00013966674,0.002246385,0.001401804,0.0021592362,0.0019429867],"domain_scores_gemma":[0.99639297,0.00024864578,0.0006609708,0.0019317495,0.0004532604,0.0003124294],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009036305,0.0010456437,0.0022485629,0.001017449,0.00009783131,0.000042524483,0.00083638466,0.0012991732,0.00037007986],"category_scores_gemma":[0.00043992538,0.0009718954,0.0004703063,0.0007541831,0.00055945636,0.00009955544,0.0006850201,0.0023892294,0.00044378778],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004684912,0.007991155,0.00027062092,0.07916726,0.011781606,0.09905479,0.00886328,0.00664479,0.27339312,0.00004535645,0.5013321,0.0067710215],"study_design_scores_gemma":[0.15599683,0.0015010583,0.00022159785,0.008384299,0.00135672,0.0061051883,0.00004673432,0.12029076,0.62690014,0.00008942336,0.076993085,0.0021141574],"about_ca_topic_score_codex":0.0013780752,"about_ca_topic_score_gemma":0.0001674121,"teacher_disagreement_score":0.424339,"about_ca_system_score_codex":0.13155814,"about_ca_system_score_gemma":0.17502716,"threshold_uncertainty_score":0.9999974},"labels":[],"label_agreement":null},{"id":"W2788918661","doi":"10.1182/blood-2017-09-808907","title":"Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Deutsche Krebshilfe; Michael Smith Health Research BC; Canadian Institutes of Health Research; Canada's Michael Smith Genome Sciences Centre; European Hematology Association","keywords":"stat; Biology; JAK-STAT signaling pathway; Gene; Cancer research; Somatic cell; Signal transduction; Immunology; Genetics; Receptor tyrosine kinase","score_opus":0.0192351612244417,"score_gpt":0.29143483890282246,"score_spread":0.27219967767838077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788918661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98274416,0.00006332524,0.0022288659,0.00026979123,0.00008842371,0.00081142434,0.000018073666,0.00007272661,0.013703238],"genre_scores_gemma":[0.994417,0.000005162222,0.004080495,0.0005294349,0.0003250963,0.00008769118,0.00008181669,0.00002976032,0.00044350725],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805355,0.000077309196,0.0003766729,0.00036758877,0.00057779637,0.0005470928],"domain_scores_gemma":[0.9987514,0.00039922073,0.000081060636,0.00030353456,0.00024229966,0.0002224529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003872369,0.00017817908,0.00030522834,0.00033584825,0.00013100995,0.000029785642,0.0001381145,0.000106935084,0.00013949454],"category_scores_gemma":[0.0006745688,0.00016997218,0.000056313056,0.00064093794,0.00021173764,0.00015345715,0.00010383151,0.00014206533,0.0005062233],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00211666,0.023336835,0.013171315,0.002464271,0.00053916295,0.0022662592,0.03307971,0.00011906277,0.901677,0.0012753553,0.0019432707,0.018011061],"study_design_scores_gemma":[0.16815732,0.0011673032,0.015796013,0.0015194785,0.00031251783,0.00051410607,0.0028744482,0.006301019,0.80118483,0.00036854434,0.0012286794,0.00057574006],"about_ca_topic_score_codex":0.00018179014,"about_ca_topic_score_gemma":0.00007676187,"teacher_disagreement_score":0.16604067,"about_ca_system_score_codex":0.003989544,"about_ca_system_score_gemma":0.006778886,"threshold_uncertainty_score":0.99983394},"labels":[],"label_agreement":null},{"id":"W2789388211","doi":"10.1016/s1634-6939(20)30484-1","title":"10.1016/s1634-6939(20)30484-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Macroglobulin; Internal medicine","score_opus":0.009108769918377587,"score_gpt":0.22697523536664124,"score_spread":0.21786646544826366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789388211","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040430906,0.00016557545,7.3485535e-7,0.00087349396,0.0000018590382,0.0004953778,0.000012538414,0.00019191338,0.9942154],"genre_scores_gemma":[0.0005963844,0.0000011338647,0.0001703021,0.00015814803,0.00038511865,0.000041359614,0.000040536328,0.000056718916,0.9985503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981067,0.000045106146,0.00026135528,0.00038568975,0.00059560564,0.0006055367],"domain_scores_gemma":[0.9985763,0.00010771982,0.000022751474,0.00070267014,0.00009844544,0.0004921408],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025816934,0.00019410333,0.00032715965,0.00013532753,0.00007372743,0.00003350677,0.00024309507,0.00012316357,0.9987349],"category_scores_gemma":[0.00013837792,0.00017173449,0.000107133164,0.00040606974,0.00008951196,0.00007226298,0.0000833728,0.00022502754,0.99807334],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005228907,0.000099315635,1.0848268e-7,0.000038922582,0.00004765168,0.00016564275,0.000032903205,0.000029686122,0.00019751489,6.5494623e-7,0.5954378,0.4034269],"study_design_scores_gemma":[0.005557194,0.00041591746,0.000012609312,0.000074794756,0.000045267272,0.00026994225,0.0000021096341,0.0022686229,0.0005696057,0.000005355701,0.9905953,0.00018328225],"about_ca_topic_score_codex":0.00016658155,"about_ca_topic_score_gemma":5.843395e-7,"teacher_disagreement_score":0.4032436,"about_ca_system_score_codex":0.0037467345,"about_ca_system_score_gemma":0.0020497781,"threshold_uncertainty_score":0.979758},"labels":[],"label_agreement":null},{"id":"W2789525108","doi":"10.1016/j.leukres.2018.03.002","title":"An autologous tumor vaccine for CLL","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Cytotoxic T cell; Immunology; Chronic lymphocytic leukemia; Antigen; Cancer research; CD8; Ionomycin; Antigen-presenting cell; Biology; CD40; Medicine; Leukemia; T cell; Immune system; In vitro; Stimulation; Endocrinology","score_opus":0.08414939493496212,"score_gpt":0.4536357256324654,"score_spread":0.36948633069750325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789525108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97270316,0.00026763554,0.00073055114,0.0014999068,0.00023003995,0.0025081781,0.000027536045,0.00031054288,0.021722464],"genre_scores_gemma":[0.98308873,0.000033600685,0.0045785327,0.0006592465,0.0022538481,0.00043584165,0.00007650081,0.00012316392,0.008750554],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946701,0.0003035829,0.00048619448,0.0009842406,0.0016173563,0.0019385525],"domain_scores_gemma":[0.99457705,0.0008968021,0.00005925801,0.0016972226,0.0019035452,0.0008661348],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0034822442,0.00027178432,0.0005394592,0.000654601,0.00057044195,0.00012077376,0.0007639554,0.00027350147,0.0009825323],"category_scores_gemma":[0.00189262,0.00022719268,0.0001600944,0.0011385004,0.0006858856,0.00020866735,0.00027920588,0.0009285125,0.001483071],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.031734526,0.0020780377,0.0047803274,0.0030753885,0.00077729236,0.0039608595,0.0033740161,0.0000580343,0.23638503,0.030474164,0.5673479,0.11595441],"study_design_scores_gemma":[0.07704054,0.019800775,0.008674337,0.00043180058,0.00012349851,0.00302984,0.0011060316,0.27356786,0.17397106,0.0062594083,0.43503234,0.0009625298],"about_ca_topic_score_codex":0.0013182517,"about_ca_topic_score_gemma":0.00025163442,"teacher_disagreement_score":0.27350983,"about_ca_system_score_codex":0.027326444,"about_ca_system_score_gemma":0.023113966,"threshold_uncertainty_score":0.9999307},"labels":[],"label_agreement":null},{"id":"W2789964027","doi":"10.1093/jcag/gwy009.102","title":"A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN’S DISEASE","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Tolerability; Discontinuation; Placebo; Maintenance therapy; Ustekinumab; Internal medicine; Randomized controlled trial; Gastroenterology; Randomization; Adverse effect; Surgery; Disease; Chemotherapy; Infliximab","score_opus":0.01803427270944602,"score_gpt":0.28085900387612667,"score_spread":0.26282473116668065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789964027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894313,0.000047365415,0.00002837524,0.009889967,0.00021667087,0.00033041195,0.000037220583,4.545855e-7,0.000018237117],"genre_scores_gemma":[0.9994249,0.000061644554,0.00007608659,0.00015028231,0.00011212963,0.000005264829,8.369895e-7,0.000004926689,0.00016398197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989271,0.00014462648,0.00045186363,0.00007092466,0.00020670773,0.0001987407],"domain_scores_gemma":[0.99829257,0.00018280417,0.00068575115,0.0001665713,0.00055154064,0.00012077867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007698785,0.000058999463,0.0003076399,0.00013130129,0.00003859115,0.0000031006161,0.00010484426,0.000058528516,0.00001602765],"category_scores_gemma":[0.0007967908,0.000034760953,0.0001243396,0.00008520474,0.00021739755,0.000032972188,0.000011122768,0.00008679582,1.2731094e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004599219,0.0002120108,0.9908684,0.00007458435,0.00026813947,0.000007981758,0.00088488613,0.000074019335,0.00027946074,0.00005176968,0.0013638532,0.0013156569],"study_design_scores_gemma":[0.009828489,0.0020220245,0.9857186,0.00007359133,0.00012002604,0.000037568105,0.00012702864,0.0009247356,0.00024767508,0.0001560288,0.000728467,0.000015748068],"about_ca_topic_score_codex":0.011436191,"about_ca_topic_score_gemma":0.24564719,"teacher_disagreement_score":0.234211,"about_ca_system_score_codex":0.01140139,"about_ca_system_score_gemma":0.0026284289,"threshold_uncertainty_score":0.99514675},"labels":[],"label_agreement":null},{"id":"W2790506909","doi":"10.1093/jcag/gwy009.178","title":"A178 RARE BENIGN LYMPHOID COLONIC POLYP","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"","keywords":"Lymphoid hyperplasia; Pathology; Malignancy; Medicine; Histopathology; Colonoscopy; Germinal center; Lymphatic system; Hyperplasia; Lymphoma; Internal medicine; Colorectal cancer; Cancer; B cell; Immunology","score_opus":0.010292389085871082,"score_gpt":0.25930444534378305,"score_spread":0.24901205625791198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790506909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764801,0.000032412256,0.00001304139,0.021486126,0.0007679963,0.00015581827,0.00002103164,0.0000033978592,0.0010400442],"genre_scores_gemma":[0.9944527,0.000017042817,0.00014872587,0.002942647,0.0005558837,0.0000013879098,0.000002064477,0.000014739651,0.0018647788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980562,0.00026967083,0.0005229378,0.000102344435,0.00055711775,0.0004917752],"domain_scores_gemma":[0.99750465,0.00009891334,0.0008375561,0.00024962705,0.00094087,0.00036837877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011078139,0.00009844128,0.00039145348,0.00029493362,0.00012282703,0.000014321744,0.00034335558,0.00016730737,0.00027116708],"category_scores_gemma":[0.0010721136,0.0000736131,0.00023104133,0.0001878744,0.00018002119,0.00006155209,0.000046569985,0.00030264817,0.000023394075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0013109257,0.00007580966,0.9004249,0.000029417137,0.0006116185,0.000087689885,0.0004385901,0.000019231182,0.0013349685,0.00010622173,0.0953347,0.00022589976],"study_design_scores_gemma":[0.053998724,0.009974336,0.8578404,0.0003903783,0.00068680564,0.007919419,0.00029883118,0.001329681,0.0037074126,0.00047487463,0.063182764,0.00019633773],"about_ca_topic_score_codex":0.013172126,"about_ca_topic_score_gemma":0.37072772,"teacher_disagreement_score":0.3575556,"about_ca_system_score_codex":0.032123473,"about_ca_system_score_gemma":0.011665622,"threshold_uncertainty_score":0.9939373},"labels":[],"label_agreement":null},{"id":"W2790823148","doi":"10.3747/co.25.4006","title":"Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Fluidigm (Canada); Princess Margaret Cancer Centre; Foothills Medical Centre; Impact; University of Calgary","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Ibrutinib; Mantle cell lymphoma; Bruton's tyrosine kinase; Medicine; Hematology; Internal medicine; Clinical trial; Lymphoma; Oncology; Tyrosine kinase; Leukemia; Chronic lymphocytic leukemia","score_opus":0.1218440385163899,"score_gpt":0.4531917502410344,"score_spread":0.3313477117246445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790823148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746902,0.019903919,0.000013972071,0.003202448,0.00054766505,0.00034501092,0.000020254098,0.000023816363,0.0012526889],"genre_scores_gemma":[0.9910039,0.006748062,0.001120982,0.0005031817,0.00043928137,0.000034728968,0.000017286324,0.000021179341,0.000111448484],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814767,0.00034560662,0.00040435782,0.00038397594,0.00025367943,0.00046473602],"domain_scores_gemma":[0.99586976,0.0029512136,0.00036801532,0.00037956127,0.0003441199,0.000087313536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094398996,0.00016607867,0.0006239304,0.000099216755,0.000113630675,0.0000053975823,0.00018044515,0.000118457574,0.000022603659],"category_scores_gemma":[0.0011347675,0.00011664516,0.00007359691,0.0003017118,0.0021970747,0.000067999455,0.0004089314,0.00027032857,0.000027454755],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006008176,0.006534884,0.05010016,0.0018114836,0.0016651792,0.0007151713,0.21164215,0.000003892942,0.008583619,0.00077890407,0.49634373,0.21581265],"study_design_scores_gemma":[0.046459343,0.005076536,0.006023934,0.0009732954,0.000540083,0.00089369656,0.21464868,0.0050798235,0.008851097,0.00044099172,0.710524,0.000488512],"about_ca_topic_score_codex":0.00057900377,"about_ca_topic_score_gemma":0.00015038348,"teacher_disagreement_score":0.21532415,"about_ca_system_score_codex":0.0029106485,"about_ca_system_score_gemma":0.0019825841,"threshold_uncertainty_score":0.8095214},"labels":[],"label_agreement":null},{"id":"W2791331105","doi":"10.1038/s41408-017-0039-2","title":"Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition","year":2018,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Faculty of Medicine, McGill University; McGill University","keywords":"Metabolism; Glutamine; Carbohydrate metabolism; Biology; Biochemistry; Medicine; Amino acid","score_opus":0.01505442161798423,"score_gpt":0.28737974831660995,"score_spread":0.27232532669862575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791331105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85903865,0.030205807,0.00015584572,0.107538365,0.0013220472,0.001114164,0.0004857566,0.00006366654,0.00007566806],"genre_scores_gemma":[0.44789737,0.031858213,0.00254415,0.39797,0.110902056,0.0006100026,0.0005293732,0.0008816091,0.006807233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937866,0.0007845764,0.0010535344,0.0011861216,0.0017784539,0.001410724],"domain_scores_gemma":[0.9964105,0.0004680833,0.0005285391,0.0006749287,0.00088128966,0.0010366496],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009822675,0.0009496381,0.0017288788,0.0010596357,0.000462477,0.00050091615,0.00030304393,0.0010254561,0.0005826434],"category_scores_gemma":[0.0004870629,0.00078774546,0.00032439656,0.0004510577,0.00056198693,0.00031303943,0.00052252493,0.002528652,0.000040517705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.033372,0.0005589557,0.00013017465,0.0014781357,0.006067636,0.01661478,0.0037385097,0.0000049421246,0.17163602,0.000020771402,0.7437168,0.022661293],"study_design_scores_gemma":[0.12637863,0.0023724705,0.008280672,0.0052497447,0.010134946,0.054158937,0.00021050716,0.00049088727,0.21491721,0.0003360433,0.57519424,0.0022757351],"about_ca_topic_score_codex":0.0007469886,"about_ca_topic_score_gemma":0.00005533587,"teacher_disagreement_score":0.4111413,"about_ca_system_score_codex":0.005105082,"about_ca_system_score_gemma":0.008172868,"threshold_uncertainty_score":0.99977255},"labels":[],"label_agreement":null},{"id":"W2791816654","doi":"10.3747/co.25.3756","title":"Improving Pneumococcal Vaccine Uptake in Veterans with Chronic Lymphocytic Leukemia through a Virtual Clinic","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Pneumococcal vaccine; Vaccination; Pneumococcal polysaccharide vaccine; Pneumococcal vaccination; Chronic lymphocytic leukemia; Pediatrics; Leukemia; Immunology; Streptococcus pneumoniae; Pneumococcal disease","score_opus":0.0793740102568294,"score_gpt":0.40999527700072,"score_spread":0.33062126674389064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791816654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908481,0.0015890588,0.0010187787,0.00022329504,0.0013791396,0.0012451273,0.000008072641,0.00016246118,0.0035259381],"genre_scores_gemma":[0.99574214,0.00046510837,0.00046183224,0.00024201107,0.0021048042,0.00020598099,0.000048570357,0.00008837597,0.0006411579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959734,0.00022100713,0.0009289498,0.0009900153,0.00056453847,0.0013220719],"domain_scores_gemma":[0.9978302,0.00045900833,0.00022980612,0.00085555,0.00028347218,0.00034196823],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00071089115,0.00044248652,0.001012624,0.00030418718,0.00013335473,0.000030620726,0.00041095004,0.0003816884,0.0011169929],"category_scores_gemma":[0.00037290042,0.00035243644,0.00015827216,0.00078609434,0.00057119183,0.00021834164,0.00027394295,0.00094284135,0.0011750916],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.025318572,0.0020757986,0.011671298,0.0025167102,0.0006807474,0.004748373,0.0098535195,0.00029444706,0.033180326,0.0008784305,0.009795364,0.8989864],"study_design_scores_gemma":[0.30699044,0.0653739,0.021166205,0.0024769045,0.00069346785,0.006450239,0.001217231,0.22745834,0.0053084237,0.00023642801,0.36090142,0.0017269838],"about_ca_topic_score_codex":0.0011608527,"about_ca_topic_score_gemma":0.0024871102,"teacher_disagreement_score":0.8972594,"about_ca_system_score_codex":0.16618659,"about_ca_system_score_gemma":0.074150816,"threshold_uncertainty_score":0.9998928},"labels":[],"label_agreement":null},{"id":"W2792132518","doi":"10.3389/fimmu.2018.00575","title":"Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases","year":2018,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Kinase; Phosphoinositide 3-kinase; Primary immunodeficiency; Biology; Immunodeficiency; Disease; Cancer research; Class (philosophy); Genetics; Cell biology; Medicine; PI3K/AKT/mTOR pathway; Signal transduction; Immune system; Pathology","score_opus":0.014894845695494159,"score_gpt":0.3135964551227283,"score_spread":0.29870160942723417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792132518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0123262005,0.98481464,0.00034671754,0.000033807926,0.00039291187,0.0015755194,0.00016904056,0.00003563683,0.0003055235],"genre_scores_gemma":[0.004754938,0.9920178,0.0006673285,0.00006466566,0.000017023876,0.000329543,0.0018564237,0.00010290412,0.00018936758],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962873,0.0004894829,0.0012799053,0.0007879912,0.00041731613,0.000737991],"domain_scores_gemma":[0.9981709,0.0002525517,0.0004320175,0.0008842063,0.00011299182,0.0001473106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049397524,0.00051161466,0.002480415,0.0011323493,0.000068721056,0.000014744292,0.0005060218,0.00063679955,0.0000498016],"category_scores_gemma":[0.0004887429,0.00048557093,0.00031350233,0.0009543698,0.0011619851,0.00007576188,0.0003566622,0.0007922874,0.000016638105],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004026039,0.010300257,0.0011507643,0.15616629,0.010120112,0.016163537,0.0024845358,0.000010901738,0.034250367,0.006561639,0.029661106,0.72910446],"study_design_scores_gemma":[0.117211014,0.008809588,0.002166076,0.118833825,0.012349389,0.0026814714,0.0021508706,0.0016305433,0.010916207,0.0174582,0.6987829,0.0070098853],"about_ca_topic_score_codex":0.0006160351,"about_ca_topic_score_gemma":0.0000151980985,"teacher_disagreement_score":0.72209454,"about_ca_system_score_codex":0.009687551,"about_ca_system_score_gemma":0.008122467,"threshold_uncertainty_score":0.9997596},"labels":[],"label_agreement":null},{"id":"W2792274945","doi":"10.1038/s41375-018-0012-5","title":"Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Research Manitoba; Leukemia and Lymphoma Society","keywords":"Idelalisib; PI3K/AKT/mTOR pathway; Stromal cell; Chronic lymphocytic leukemia; Cancer research; Cell migration; Cell biology; Jurkat cells; Biology; Chemokine; T cell; Cell; Immunology; Leukemia; Signal transduction; Ibrutinib; Biochemistry; Inflammation","score_opus":0.01601825668664608,"score_gpt":0.2885638050431393,"score_spread":0.2725455483564932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792274945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965527,0.00058732246,0.00021034983,0.00027578432,0.00006641843,0.00057045993,0.000016695434,0.00003960863,0.0016806712],"genre_scores_gemma":[0.99653983,0.000076052966,0.001008306,0.000256433,0.00029834337,0.00008432617,0.000052461517,0.000026920583,0.0016573268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988242,0.000022962546,0.000235789,0.00033269936,0.00021278742,0.00037160274],"domain_scores_gemma":[0.9992677,0.00019756444,0.000048299975,0.00025896696,0.00009625945,0.00013123442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002042629,0.00014120231,0.00023217213,0.00009799682,0.00007191716,0.0000302652,0.00007710006,0.00010099125,0.000054412914],"category_scores_gemma":[0.00016622043,0.00011843865,0.000048585753,0.00015864061,0.00017734985,0.000072750736,0.000043259046,0.00010231168,0.0000422621],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01641529,0.0010921478,0.28534773,0.0049375854,0.0002480342,0.0018309598,0.008868902,0.00006332,0.44778767,0.0031067429,0.15516864,0.07513295],"study_design_scores_gemma":[0.03601173,0.0015403491,0.095193855,0.00068984815,0.000117287236,0.00022189025,0.0004736724,0.053711094,0.7764415,0.0008668074,0.0342314,0.00050053035],"about_ca_topic_score_codex":0.0019468024,"about_ca_topic_score_gemma":0.0036053143,"teacher_disagreement_score":0.32865384,"about_ca_system_score_codex":0.0061136144,"about_ca_system_score_gemma":0.0023643144,"threshold_uncertainty_score":0.99770176},"labels":[],"label_agreement":null},{"id":"W2792470604","doi":"10.1093/jcag/gwy008.082","title":"A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN’S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Adverse effect; Safety profile; Internal medicine; Psoriasis; Mace; Methotrexate; Surgery; Dermatology; Disease; Infliximab","score_opus":0.01707336037202663,"score_gpt":0.3041677932804092,"score_spread":0.2870944329083826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792470604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97357976,0.00024340309,0.00005293256,0.02498412,0.00025068663,0.0002546459,0.00061138213,0.0000021461974,0.000020921909],"genre_scores_gemma":[0.9972079,0.000118298616,0.000047733993,0.0018721913,0.00055860396,0.0000024126996,0.000018560739,0.000009191547,0.00016513256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973375,0.0010331451,0.00072658074,0.00013642876,0.00046442664,0.00030187264],"domain_scores_gemma":[0.9967586,0.000850876,0.0011089168,0.00026760015,0.0004458689,0.00056816306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001979865,0.00011284465,0.0007241421,0.00023990058,0.00018325698,0.000040510662,0.00020358017,0.00007823974,0.00021608171],"category_scores_gemma":[0.005708064,0.000065272376,0.00030352286,0.00022713555,0.00024465108,0.00006661222,0.00005449334,0.00021278035,0.0000013240652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007127207,0.00011056899,0.9731657,0.000022448572,0.0065619126,0.000082828854,0.00046944796,0.000023103004,0.00006956924,0.00003282286,0.011214671,0.0011197525],"study_design_scores_gemma":[0.021660946,0.00049888977,0.96675533,0.00005614643,0.0072454037,0.00003338775,0.000092049595,0.0019014197,0.000009583584,0.0002228696,0.0014848203,0.00003912826],"about_ca_topic_score_codex":0.01396609,"about_ca_topic_score_gemma":0.21763921,"teacher_disagreement_score":0.20367312,"about_ca_system_score_codex":0.0062792045,"about_ca_system_score_gemma":0.0036587105,"threshold_uncertainty_score":0.9975355},"labels":[],"label_agreement":null},{"id":"W2792666902","doi":"10.1056/nejmoa1713976","title":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":909,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Venetoclax; Rituximab; Bendamustine; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Progression-free survival; Neutropenia; Leukemia; Gastroenterology; Immunology; Lymphoma; Chemotherapy","score_opus":0.03256968068832229,"score_gpt":0.3346197826151289,"score_spread":0.30205010192680665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792666902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98515344,0.0060760593,0.00020279358,0.0018354872,0.0013215636,0.0003959399,0.0000013029253,0.000036599675,0.0049768225],"genre_scores_gemma":[0.97704554,0.0013851839,0.000537781,0.0007633689,0.015946707,0.000003356137,0.0000051410834,0.00005714914,0.004255769],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996312,0.00018600696,0.001205185,0.000312467,0.0013196192,0.0006647208],"domain_scores_gemma":[0.9971814,0.0006482477,0.0004308404,0.00053752813,0.00045594064,0.00074605225],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002043694,0.00029800652,0.0010918409,0.0007202798,0.000065707696,0.000014016442,0.00037410902,0.00022705995,0.0020024844],"category_scores_gemma":[0.002388845,0.00018332008,0.00011869527,0.00075709034,0.00056729006,0.00013449426,0.000071565206,0.00089030823,0.00013214168],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0688731,0.00042146156,0.001543372,0.0013311822,0.0008930662,0.034167554,0.009186972,0.0007114065,0.03507986,0.00033827624,0.15594973,0.691504],"study_design_scores_gemma":[0.71780103,0.018421624,0.0013113747,0.004036885,0.00027187803,0.021147689,0.00025899374,0.012355056,0.002359828,0.00040636386,0.22135255,0.00027670228],"about_ca_topic_score_codex":0.0018466685,"about_ca_topic_score_gemma":0.0007024489,"teacher_disagreement_score":0.6912273,"about_ca_system_score_codex":0.11148277,"about_ca_system_score_gemma":0.100859635,"threshold_uncertainty_score":0.99890983},"labels":[],"label_agreement":null},{"id":"W2792760898","doi":"10.2217/imt-2017-0162","title":"CD19-specific Chimeric Antigen Receptor-Modified (CAR)-T cell Therapy for the Treatment of Chronic Lymphocytic Leukemia in the Ibrutinib Era","year":2018,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Chronic lymphocytic leukemia; Ibrutinib; Medicine; Chimeric antigen receptor; Leukemia; Oncology; Cancer; Immunology; Internal medicine; Immunotherapy","score_opus":0.026547901132691322,"score_gpt":0.3216215715794757,"score_spread":0.29507367044678434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792760898","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1555645,0.28863475,0.00032521458,0.0005504345,0.53279096,0.01929051,0.0006705196,0.00022959361,0.0019435198],"genre_scores_gemma":[0.031787146,0.46946228,0.00025118364,0.00023243317,0.4902411,0.0024897142,0.0010057503,0.00047252912,0.0040578367],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937703,0.0004554855,0.0013659063,0.0011559905,0.0019164061,0.0013359289],"domain_scores_gemma":[0.98994476,0.005415531,0.00072070124,0.003294325,0.00051125453,0.0001134283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015412392,0.0010809173,0.0017320456,0.00037847742,0.00037752464,0.00012149192,0.0017863269,0.0012176345,0.0005209462],"category_scores_gemma":[0.00010630672,0.0005866179,0.0010521302,0.0008790525,0.0008367351,0.000089779416,0.0000517738,0.00082507735,0.0001308223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013170376,0.00081642787,0.000008058807,0.00033432772,0.0014496165,0.000030711908,0.0066948254,0.00016094565,0.009689714,0.000037386963,0.9114397,0.05616789],"study_design_scores_gemma":[0.07028996,0.007856034,0.000049612285,0.00029639516,0.00009486583,0.00001547377,0.0003855546,0.00261695,0.008015098,0.000044210305,0.90983045,0.00050541124],"about_ca_topic_score_codex":0.0044601276,"about_ca_topic_score_gemma":0.000114104136,"teacher_disagreement_score":0.18082753,"about_ca_system_score_codex":0.07932212,"about_ca_system_score_gemma":0.06380812,"threshold_uncertainty_score":0.9996585},"labels":[],"label_agreement":null},{"id":"W2794302045","doi":"10.3747/co.25.4005","title":"Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Fluidigm (Canada); Vancouver General Hospital; University of British Columbia; BC Cancer Agency; Foothills Medical Centre; Impact; University of Calgary","funders":"University of Texas MD Anderson Cancer Center; Lundbeck Canada; Gilead Sciences; AstraZeneca","keywords":"Ibrutinib; Obinutuzumab; Medicine; Bendamustine; Fludarabine; Venetoclax; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Oncology; IGHV@; Alemtuzumab; Hematology; Cyclophosphamide; Minimal residual disease; Lymphoplasmacytic Lymphoma; Leukemia; Lymphoma; Chemotherapy; Waldenstrom macroglobulinemia; Transplantation","score_opus":0.13906977124623063,"score_gpt":0.47107701740482083,"score_spread":0.33200724615859023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794302045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677951,0.02676265,0.000051148683,0.0026065183,0.0009253679,0.0007360692,0.0000396581,0.000079227124,0.0010043001],"genre_scores_gemma":[0.99009794,0.007253679,0.00068980525,0.00056771014,0.0010811186,0.00009105659,0.00006312275,0.000037934267,0.00011761517],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996966,0.00048338535,0.000680991,0.0005729676,0.00041731333,0.00087931385],"domain_scores_gemma":[0.9945966,0.00339605,0.0005243934,0.0006514978,0.00070085365,0.00013059462],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0011083981,0.00028823462,0.001035697,0.00017461776,0.00016604405,0.000009441231,0.00038195672,0.00017595969,0.000074049975],"category_scores_gemma":[0.0019512922,0.00020173259,0.0001705451,0.000887128,0.0033161754,0.00011933184,0.00052892684,0.00047608596,0.00011395565],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008366331,0.0018937923,0.032411657,0.0026651295,0.0067417696,0.0014644394,0.16095144,0.00043632058,0.0068353023,0.0021438375,0.5628172,0.21327278],"study_design_scores_gemma":[0.08346511,0.0103773875,0.003169801,0.003723858,0.0017890339,0.003009222,0.15183514,0.13161796,0.018098392,0.00073779095,0.59100556,0.0011707534],"about_ca_topic_score_codex":0.0033671123,"about_ca_topic_score_gemma":0.0008638194,"teacher_disagreement_score":0.21210203,"about_ca_system_score_codex":0.07531348,"about_ca_system_score_gemma":0.02464947,"threshold_uncertainty_score":0.9993962},"labels":[],"label_agreement":null},{"id":"W2795150236","doi":"10.2217/fon-2018-0121","title":"Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Celgene; Sanofi; Genentech; Ariad Pharmaceuticals; Amgen","keywords":"Venetoclax; Medicine; Clinical trial; Refractory (planetary science); Oncology; Internal medicine; Drug development; Chronic lymphocytic leukemia; Chemotherapy; Cancer; Drug; Leukemia; Pharmacology","score_opus":0.061213522298303284,"score_gpt":0.3801271580229051,"score_spread":0.3189136357246018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795150236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959479,0.0011344595,0.000074852636,0.00021104579,0.00047031898,0.0015017799,0.0000029140617,0.000022758844,0.0006339901],"genre_scores_gemma":[0.9929671,0.00017206889,0.0048046918,0.00015395205,0.0012214972,0.00033842432,0.0000055389737,0.000030790925,0.00030590632],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977221,0.00022122236,0.00070517405,0.00042119905,0.0004013403,0.0005289494],"domain_scores_gemma":[0.9988522,0.0003291037,0.0002027132,0.00029675168,0.0002021657,0.0001170701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012061696,0.00019878765,0.0006129741,0.00048355578,0.00005566327,0.0000065892687,0.00022368378,0.00021573486,0.00017732666],"category_scores_gemma":[0.0002326879,0.00017378722,0.000033776185,0.00078924594,0.0001115192,0.00005568104,0.0001390193,0.0004479092,0.00002017352],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.028438013,0.038891833,0.3072578,0.0028452624,0.0006840225,0.006648735,0.28720582,0.0020661457,0.11601486,0.00036178486,0.020430656,0.18915506],"study_design_scores_gemma":[0.56789637,0.035894684,0.24876307,0.0011642377,0.00045294536,0.00050365087,0.029654045,0.020527465,0.034284562,0.000062132225,0.059024174,0.0017726361],"about_ca_topic_score_codex":0.0012710127,"about_ca_topic_score_gemma":0.004896155,"teacher_disagreement_score":0.5394584,"about_ca_system_score_codex":0.021939179,"about_ca_system_score_gemma":0.031923953,"threshold_uncertainty_score":0.9818154},"labels":[],"label_agreement":null},{"id":"W2796153899","doi":"10.1097/rhu.0000000000000780","title":"Systemic Large-Vessel Vasculitis and Retroperitoneal Fibrosis in the Setting of T-Cell Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"letter","venue":"JCR Journal of Clinical Rheumatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Chronic lymphocytic leukemia; Hematology; Rheumatology; General surgery; Family medicine; Leukemia","score_opus":0.029312257411959156,"score_gpt":0.35437974705775993,"score_spread":0.3250674896458008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796153899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498953,0.010046141,0.00007314117,0.0373279,0.001419644,0.0007179676,0.00003366907,0.000018177225,0.00046803217],"genre_scores_gemma":[0.9524654,0.014902103,0.0005494704,0.028048784,0.0035341107,0.00002068674,0.000042982665,0.00012682701,0.00030962127],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98904914,0.0022655162,0.005370167,0.0006664903,0.0015341196,0.0011145896],"domain_scores_gemma":[0.98682487,0.008026357,0.0030874417,0.0010689903,0.00073094084,0.0002614144],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0079762265,0.0005236001,0.0040306887,0.0005191772,0.000097644974,0.000050573166,0.0010919452,0.0024114419,0.000148612],"category_scores_gemma":[0.005230239,0.00034099442,0.00094712287,0.00046775246,0.0010657274,0.0001276492,0.00034117128,0.0054162145,0.00004900768],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0018877531,0.00020099037,0.019900538,0.018410008,0.0013033343,0.009205115,0.0014954715,0.000027249342,0.00020207561,0.000055812958,0.9453068,0.0020048462],"study_design_scores_gemma":[0.1951295,0.014384875,0.008836126,0.039922025,0.00318965,0.2775036,0.0020081464,0.024373632,0.0006343885,0.0005137975,0.43168882,0.0018154138],"about_ca_topic_score_codex":0.00065540796,"about_ca_topic_score_gemma":0.000050316477,"teacher_disagreement_score":0.513618,"about_ca_system_score_codex":0.017517457,"about_ca_system_score_gemma":0.050369095,"threshold_uncertainty_score":0.9999042},"labels":[],"label_agreement":null},{"id":"W2797999965","doi":"","title":"Molecular Characterization of a Recurrent t(2;7) Translocation Linking CDK6 to the IGK Locus in Chronic B-cell Neoplasia","year":2013,"lang":"en","type":"dissertation","venue":"TSpace (University of Toronto)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; University of Toronto","keywords":"Breakpoint; Chromosomal translocation; Chronic lymphocytic leukemia; Biology; CD5; Cyclin-dependent kinase 6; Molecular biology; Comparative genomic hybridization; Cancer research; Locus (genetics); Gene; Genetics; Antibody; Chromosome; Leukemia; Cyclin D1; Cell cycle","score_opus":0.010459038126437264,"score_gpt":0.2637844734610633,"score_spread":0.25332543533462604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797999965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893833,0.0018388015,0.00062470156,0.00046003226,0.0001721046,0.0015002382,0.00001342515,0.000020541642,0.006431833],"genre_scores_gemma":[0.9926216,0.0017043228,0.00015356604,0.000014504803,0.00005600024,0.000005265595,0.0008019721,0.000032957625,0.004609801],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984259,0.000095936644,0.00024254792,0.00035991851,0.000584444,0.00029125455],"domain_scores_gemma":[0.99871707,0.000040758165,0.00030998568,0.00050339126,0.00030984968,0.000118955395],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022041034,0.00021844984,0.00049478415,0.00016343399,0.000059266542,0.000009897674,0.00036080828,0.00030570728,0.0016500105],"category_scores_gemma":[0.00002484789,0.00022562295,0.00015958211,0.00023924236,0.0000538266,0.00017508525,0.00004656602,0.00028083855,0.0000398407],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019636173,0.00039059692,0.000044601828,0.004559957,0.00021973373,0.00009733204,0.07460825,0.00026373152,0.6687908,0.00016723212,0.00017313819,0.24872097],"study_design_scores_gemma":[0.0779924,0.007110205,0.23482537,0.02536309,0.002512058,0.000088712986,0.09622818,0.09460503,0.44728917,0.00003652697,0.010900971,0.0030482737],"about_ca_topic_score_codex":0.08879829,"about_ca_topic_score_gemma":0.0925122,"teacher_disagreement_score":0.2456727,"about_ca_system_score_codex":0.011626934,"about_ca_system_score_gemma":0.0044360985,"threshold_uncertainty_score":0.99926263},"labels":[],"label_agreement":null},{"id":"W2799276341","doi":"10.1182/blood-2017-11-814608","title":"Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; CancerCare Manitoba; BC Cancer Agency","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; National Center for Chronic Disease Prevention and Health Promotion; World Health Organization","keywords":"Lymphocytosis; Chronic lymphocytic leukemia; Medicine; Internal medicine; Leukemia; Oncology; Immunology","score_opus":0.007869645992896872,"score_gpt":0.23130352391642708,"score_spread":0.2234338779235302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799276341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951112,0.0028369073,0.000052055948,0.000057137135,0.00004638307,0.00055120944,0.00006412856,0.00003499592,0.0012459664],"genre_scores_gemma":[0.99636394,0.001776891,0.00034277808,0.000038913084,0.00033320725,0.000028437837,0.000009344097,0.00004565631,0.0010608406],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976012,0.00019397105,0.000430338,0.00038871894,0.0008973452,0.00048842916],"domain_scores_gemma":[0.9975323,0.0005725232,0.0006497285,0.00068726484,0.00039805155,0.00016014918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008448203,0.000238967,0.00050905166,0.00014050132,0.00016377434,0.00001828447,0.00024024153,0.00019720236,0.00009534245],"category_scores_gemma":[0.0003258313,0.00015278789,0.00014246606,0.00050907297,0.0005555164,0.00007508716,0.00014488873,0.0002399193,0.000031341442],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0071632946,0.002411546,0.87238663,0.0034582363,0.011196943,0.0001508169,0.006758706,0.00064648624,0.06863973,0.00016290725,0.0078123743,0.01921233],"study_design_scores_gemma":[0.20881228,0.0066268505,0.15205657,0.0007121942,0.008498831,0.0005704295,0.000551291,0.045412853,0.575002,0.00014334843,0.0009916137,0.0006216837],"about_ca_topic_score_codex":0.0055271112,"about_ca_topic_score_gemma":0.0006156096,"teacher_disagreement_score":0.72033006,"about_ca_system_score_codex":0.025557797,"about_ca_system_score_gemma":0.023710571,"threshold_uncertainty_score":0.9818241},"labels":[],"label_agreement":null},{"id":"W2799423586","doi":"10.14740/wjon1099w","title":"Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib","year":2018,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Mucormycosis; Posaconazole; Dermatology; Leukemia; Amphotericin B; Immunology; Antifungal; Surgery","score_opus":0.02130508252998251,"score_gpt":0.3345059451036448,"score_spread":0.31320086257366225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799423586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803232,0.0013592145,0.000016448526,0.0007086793,0.0014751784,0.00049280457,0.0000027756919,0.00003462895,0.015587099],"genre_scores_gemma":[0.9947051,0.00022843055,0.0005561654,0.0013949339,0.0016180093,0.000017906157,0.0000036080103,0.00006430092,0.0014115468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961451,0.0002660971,0.0012703572,0.00035856306,0.0009934371,0.0009663924],"domain_scores_gemma":[0.99737,0.0007411449,0.00055277033,0.0005041203,0.00035235655,0.00047962344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007694892,0.00033424282,0.0011151696,0.0012471462,0.00012740373,0.000030115096,0.0003928259,0.00025308173,0.0006423829],"category_scores_gemma":[0.0007068094,0.00027458998,0.00043723857,0.0010027565,0.00029105225,0.00010397062,0.00016448193,0.0009122815,0.00032303153],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040789977,0.0019458861,0.004974241,0.0008963932,0.002671237,0.23956458,0.014097926,0.0059551103,0.040173627,0.0006658983,0.09324555,0.55501956],"study_design_scores_gemma":[0.16906747,0.08941427,0.0013044197,0.0048010717,0.00082333165,0.10621515,0.0015689068,0.023824355,0.019205421,0.00054488896,0.5820714,0.0011592917],"about_ca_topic_score_codex":0.0005675063,"about_ca_topic_score_gemma":0.0015189953,"teacher_disagreement_score":0.55386025,"about_ca_system_score_codex":0.29957077,"about_ca_system_score_gemma":0.08124721,"threshold_uncertainty_score":0.9999706},"labels":[],"label_agreement":null},{"id":"W2800718803","doi":"10.1212/wnl.88.16_supplement.p2.217","title":"A rare case of CNS involvement with Chronic Lymphocytic Leukemia CLL (P2.217)","year":2017,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Leukemia; Pathology; Immunology","score_opus":0.028411576631793514,"score_gpt":0.30693114892050655,"score_spread":0.27851957228871305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800718803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936746,0.00037395995,0.000038287097,0.00070883933,0.00020313574,0.0007007338,0.000012838577,0.00006274838,0.004224858],"genre_scores_gemma":[0.9976672,0.00012273507,0.000112787384,0.0009430478,0.00028800467,0.00007066977,0.000013242452,0.00005889639,0.0007234087],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99781203,0.00009652684,0.00038580605,0.00059197843,0.00040568507,0.00070794125],"domain_scores_gemma":[0.9971305,0.00017720167,0.00027610466,0.0019406342,0.00018974234,0.00028578748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026065818,0.00026287333,0.000597256,0.0001695828,0.00025254005,0.000029956509,0.00042835253,0.0002392901,0.0003185205],"category_scores_gemma":[0.00022826987,0.00020631045,0.00011306989,0.00011181988,0.0008477333,0.00010544205,0.00036202904,0.00041344296,0.00011159389],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.047951873,0.001012461,0.053757604,0.008704601,0.0025452592,0.7614189,0.0039106724,0.0054494813,0.04587828,0.0065256106,0.02049978,0.042345516],"study_design_scores_gemma":[0.2838771,0.05400576,0.030195266,0.0007670964,0.001433738,0.30681914,0.00015546037,0.21730216,0.050348498,0.0005954436,0.05290135,0.001598963],"about_ca_topic_score_codex":0.012195602,"about_ca_topic_score_gemma":0.004575667,"teacher_disagreement_score":0.4545997,"about_ca_system_score_codex":0.018206479,"about_ca_system_score_gemma":0.029721506,"threshold_uncertainty_score":0.99438226},"labels":[],"label_agreement":null},{"id":"W2800993473","doi":"10.1093/rheumatology/key075.589","title":"e48 Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis","year":2018,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Internal medicine","score_opus":0.00960167154008131,"score_gpt":0.25708666039610645,"score_spread":0.24748498885602513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800993473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770015,0.00019354835,0.000016466078,0.000073987096,0.00009937727,0.0007373198,0.000011780175,0.000045239238,0.001122111],"genre_scores_gemma":[0.9988745,0.000076534,0.00054606627,0.0003501781,0.000030157325,0.000047893434,0.000020458587,0.00002942436,0.000024789646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813116,0.00012430847,0.00032054892,0.00035635827,0.0006290404,0.0004386092],"domain_scores_gemma":[0.9986647,0.00039894052,0.00009076897,0.00048063032,0.00019961799,0.00016535423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021187504,0.00018204469,0.0005366814,0.00016883896,0.00003665198,0.000012287054,0.0001454596,0.00016077462,0.0000580297],"category_scores_gemma":[0.00047982915,0.00013519386,0.000049982933,0.00045582594,0.00039077795,0.00006296149,0.00006651234,0.0002560585,0.00012838235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013103102,0.0052296952,0.9394962,0.0019144114,0.0005653957,0.0033232232,0.0024075569,0.000039599698,0.0013032615,0.0026135144,0.0058974675,0.02410658],"study_design_scores_gemma":[0.13212284,0.014221709,0.73126644,0.0058158953,0.00004884655,0.000107174375,0.00013138675,0.0007917563,0.11219115,0.00017139674,0.0024210017,0.0007103915],"about_ca_topic_score_codex":0.00015529232,"about_ca_topic_score_gemma":0.000033577668,"teacher_disagreement_score":0.20822975,"about_ca_system_score_codex":0.0012116677,"about_ca_system_score_gemma":0.0009824606,"threshold_uncertainty_score":0.5513045},"labels":[],"label_agreement":null},{"id":"W2801741011","doi":"10.1186/s12940-018-0387-9","title":"Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chornobyl cleanup workers","year":2018,"lang":"en","type":"article","venue":"Environmental Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Alberta; Damon Runyon Cancer Research Foundation; National Human Genome Research Institute; University of California, San Francisco; Blavatnik Family Foundation; Howard Hughes Medical Institute","keywords":"Chronic lymphocytic leukemia; Medicine; Population; Leukemia; Internal medicine; Oncology; Environmental health","score_opus":0.014134231725529583,"score_gpt":0.27860998897753425,"score_spread":0.2644757572520047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801741011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975351,0.00056614995,0.000110193156,0.00015396831,0.00018877859,0.0010017435,0.00003031913,0.00003514878,0.00037857905],"genre_scores_gemma":[0.9965731,0.0012248207,0.00014404891,0.00047112585,0.00043276153,0.000033026146,0.00032560193,0.0000554385,0.0007400938],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976325,0.00011582133,0.00068372156,0.00044739083,0.00048931607,0.0006312715],"domain_scores_gemma":[0.99888855,0.000051898398,0.00025046305,0.0005079895,0.000008143001,0.00029296143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000451001,0.0002114515,0.0004435525,0.000245449,0.00009891875,0.0000093799945,0.00016410503,0.00013585853,0.0007606953],"category_scores_gemma":[0.000020166317,0.00021751248,0.000080841535,0.00028471535,0.00036751933,0.00012202158,0.000094399904,0.00020385506,0.00047483246],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0029018808,0.0007622838,0.11666162,0.001548894,0.00020968782,0.00011547146,0.006240732,0.0006182862,0.5943774,0.00008653973,0.0010071119,0.2754701],"study_design_scores_gemma":[0.031044386,0.0027704337,0.85054207,0.00046020476,0.000030678195,0.00013935928,0.00035888547,0.07006155,0.038866416,0.000020583251,0.0053304792,0.00037493443],"about_ca_topic_score_codex":0.0012459867,"about_ca_topic_score_gemma":0.000117460484,"teacher_disagreement_score":0.73388046,"about_ca_system_score_codex":0.21778356,"about_ca_system_score_gemma":0.015043837,"threshold_uncertainty_score":0.99053997},"labels":[],"label_agreement":null},{"id":"W2802917867","doi":"10.1007/s00277-018-3356-z","title":"Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients","year":2018,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; March of Dimes Canada; Université Laval; Centre hospitalier universitaire de Québec","funders":"Universität Wien; Medizinische Universität Wien; European Commission; Canadian Institutes of Health Research; European Hematology Association; Université Laval","keywords":"Internal medicine; Hormone; Endocrinology; Testosterone (patch); Chronic lymphocytic leukemia; Luteinizing hormone; Dihydrotestosterone; Medicine; Hazard ratio; Sex hormone-binding globulin; Sex steroid; Estrogen; Hydroxysteroid; Androgen; Biology; Leukemia; Steroid; Enzyme; Dehydrogenase; Confidence interval","score_opus":0.03279791246085099,"score_gpt":0.3156505967715258,"score_spread":0.2828526843106748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802917867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742717,0.00101161,0.00001935575,0.00011334633,0.000046695146,0.0004466815,0.000021013784,0.000020222276,0.000893893],"genre_scores_gemma":[0.9992097,0.00033545052,0.00008402379,0.00005557804,0.00006045579,0.000021793789,0.00002574278,0.000027322636,0.00017995873],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979044,0.00015149983,0.000564912,0.0003518127,0.0005303147,0.0004970132],"domain_scores_gemma":[0.9984337,0.00038923183,0.00031868997,0.0004942858,0.0002569175,0.00010715076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039798542,0.00020331886,0.00083246117,0.00023493842,0.000042669937,0.0000061267006,0.00014470077,0.00020371973,0.000023306618],"category_scores_gemma":[0.0002930301,0.00016454884,0.00006113461,0.00019901399,0.00025444766,0.00009577822,0.0001339299,0.00010014208,0.000005418817],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016081417,0.00037824197,0.97640854,0.0013138223,0.0010167256,0.0003012939,0.0029380019,0.00011785306,0.00801663,0.00048281933,0.00047291757,0.0069450173],"study_design_scores_gemma":[0.17598929,0.023895184,0.15767267,0.0014577965,0.00049137854,0.0011582403,0.0019021457,0.030977523,0.6033792,0.0019877013,0.00012764217,0.0009612234],"about_ca_topic_score_codex":0.0035448868,"about_ca_topic_score_gemma":0.001168867,"teacher_disagreement_score":0.81873584,"about_ca_system_score_codex":0.013670045,"about_ca_system_score_gemma":0.006743817,"threshold_uncertainty_score":0.998887},"labels":[],"label_agreement":null},{"id":"W2804149848","doi":"10.1111/bjh.15230","title":"Machine learning algorithms for accurate differential diagnosis of lymphocytosis based on cell population data","year":2018,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lymphocytosis; Algorithm; Population; Differential diagnosis; Medicine; Computer science; Artificial intelligence; Pathology","score_opus":0.06015985908385949,"score_gpt":0.3357553190887895,"score_spread":0.27559546000492996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804149848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70022964,0.018978685,0.030400652,0.2265621,0.009029033,0.006819728,0.00688455,0.00021440361,0.0008811975],"genre_scores_gemma":[0.858997,0.006489125,0.014755538,0.0844737,0.015724298,0.00018668245,0.017138537,0.000701434,0.0015337153],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99569565,0.00046186167,0.0015236706,0.0005927136,0.0010721738,0.00065391586],"domain_scores_gemma":[0.9949087,0.0016547438,0.0017544708,0.0007583802,0.0007547049,0.00016901807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075492123,0.00037799423,0.0020366758,0.0006008608,0.00013682255,0.000068023895,0.00092889665,0.0010080193,0.0005535849],"category_scores_gemma":[0.0017428192,0.0003792397,0.00045751638,0.00020082157,0.00024581913,0.00014395529,0.00025110698,0.0017371641,0.000012986299],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014801569,0.00048570076,0.001150317,0.0043545165,0.00058358774,0.043834396,0.000031036678,0.00009025504,0.000030464893,0.0000023561424,0.9324747,0.0154825635],"study_design_scores_gemma":[0.09093821,0.0071475073,0.0008467786,0.012293742,0.0036819833,0.18779457,0.00003760692,0.35787085,0.004728917,0.00017876207,0.33321935,0.0012617225],"about_ca_topic_score_codex":0.0015395341,"about_ca_topic_score_gemma":0.00006334603,"teacher_disagreement_score":0.59925526,"about_ca_system_score_codex":0.0025432536,"about_ca_system_score_gemma":0.0032419907,"threshold_uncertainty_score":0.99986595},"labels":[],"label_agreement":null},{"id":"W2805032224","doi":"10.1136/jnnp-2018-anzan.66","title":"067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies","year":2018,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cladribine; Multiple sclerosis; Internal medicine; Placebo; Post-hoc analysis; Cohort; Lesion; Odds ratio; Gastroenterology; Surgery; Pathology; Psychiatry","score_opus":0.10265468675726755,"score_gpt":0.33722162621124435,"score_spread":0.2345669394539768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805032224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411905,0.0010706539,0.000006503527,0.0033872633,0.0009288012,0.00039266745,0.00007411363,0.000008608443,0.000012322782],"genre_scores_gemma":[0.99799144,0.00037604535,0.00020688472,0.0010454374,0.0003070474,0.0000024017888,0.000031807045,0.000034989065,0.000003972067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962317,0.00052291574,0.001439207,0.0005723363,0.00081817375,0.00041570835],"domain_scores_gemma":[0.99346095,0.0029317704,0.0016001374,0.0010968822,0.00075565034,0.00015459151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012392853,0.00027701055,0.0014360811,0.00072016014,0.00011592299,0.000017702101,0.0005226101,0.00019715438,0.000014749403],"category_scores_gemma":[0.0016318278,0.00017888311,0.00020352192,0.0014982389,0.00088155264,0.00027106775,0.0004165504,0.0010900957,8.4138173e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065543324,0.0010960562,0.92680377,0.00005644421,0.0031283048,0.000046775494,0.00033926734,0.000115836076,0.0014416734,0.0000037606121,0.001017478,0.0004073304],"study_design_scores_gemma":[0.049544547,0.0018913766,0.94389373,0.00036172816,0.0026625998,0.00004984248,0.00009837805,0.0010335451,0.00028044306,0.000017505252,0.000053023694,0.000113258335],"about_ca_topic_score_codex":0.00026042518,"about_ca_topic_score_gemma":0.00037630912,"teacher_disagreement_score":0.01709,"about_ca_system_score_codex":0.00021082263,"about_ca_system_score_gemma":0.001613411,"threshold_uncertainty_score":0.7294642},"labels":[],"label_agreement":null},{"id":"W2805081409","doi":"10.7759/cureus.2701","title":"Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience","year":2018,"lang":"en","type":"article","venue":"Cureus","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Medicine; Ibrutinib; Atrial fibrillation; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.04263803825814592,"score_gpt":0.37132652584562614,"score_spread":0.3286884875874802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805081409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960817,0.000085504355,0.000012503723,0.000026697586,0.00025364457,0.0004430215,0.000002754127,0.000014286935,0.009553429],"genre_scores_gemma":[0.99871504,0.000083964966,0.00030009737,0.000026381002,0.00027517095,0.0000037453383,0.000010382317,0.000011152597,0.00057407835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998871,0.000029768114,0.0002926561,0.00021449759,0.00039239816,0.00019967541],"domain_scores_gemma":[0.9993985,0.00006419543,0.000068695816,0.0003272794,0.00007881262,0.0000624938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018079496,0.000076977536,0.00016943319,0.000062389656,0.000021522186,0.000004966577,0.00008530816,0.00006539315,0.00036414107],"category_scores_gemma":[0.00011756501,0.00006511775,0.00005818396,0.00019055374,0.00010816604,0.0000424875,0.000073373,0.000060165,0.0001757549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017050246,0.0006208901,0.84391963,0.0006688968,0.00036781855,0.00017104158,0.007758349,0.00004605696,0.00010694845,0.0012171362,0.004486776,0.1235862],"study_design_scores_gemma":[0.062852755,0.0044069286,0.91634876,0.0008415669,0.00005822101,0.0000069845873,0.00043927043,0.002909737,0.0023007134,0.0002172474,0.009382191,0.00023562845],"about_ca_topic_score_codex":0.00011474654,"about_ca_topic_score_gemma":0.000012162185,"teacher_disagreement_score":0.12335057,"about_ca_system_score_codex":0.0017787263,"about_ca_system_score_gemma":0.00033096966,"threshold_uncertainty_score":0.46513075},"labels":[],"label_agreement":null},{"id":"W2805093224","doi":"10.1186/s13000-018-0714-z","title":"High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma","year":2018,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Lymphoma; Follicular lymphoma; Gene rearrangement; Chronic lymphocytic leukemia; Chromosomal translocation; Fluorescence in situ hybridization; Pathology; Immunoglobulin heavy chain; Biology; Biopsy; Cytogenetics; B cell; Mantle cell lymphoma; Somatic evolution in cancer; Large-cell lymphoma; B-cell lymphoma; Cancer research; Leukemia; Medicine; Cancer; Immunology; Antibody; Gene; Genetics; Chromosome","score_opus":0.01392210254290341,"score_gpt":0.27644141125442107,"score_spread":0.26251930871151763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805093224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953303,0.000823241,0.00026405175,0.00052132143,0.00017769022,0.0006351331,0.000012423086,0.00006900146,0.0021668612],"genre_scores_gemma":[0.99492735,0.00027970746,0.0032303864,0.00094002986,0.00022391517,0.00008201803,0.000042163738,0.0000538459,0.00022058694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976405,0.00017400816,0.00040757758,0.000650183,0.0003800238,0.0007477009],"domain_scores_gemma":[0.9979321,0.0010428162,0.0001085094,0.0005435913,0.000116476986,0.0002565262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004084176,0.0002747982,0.0005506604,0.00032558243,0.00010925149,0.000032344255,0.00016060485,0.00021111514,0.000055254335],"category_scores_gemma":[0.00067707343,0.00023024477,0.000038240192,0.00040916083,0.0007501411,0.00008203882,0.00018777871,0.00012768283,0.00017748107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069483505,0.010162049,0.62522775,0.0016045952,0.000481644,0.11553626,0.0127255395,0.000043787164,0.06787599,0.0017988321,0.006200382,0.15139481],"study_design_scores_gemma":[0.15382878,0.0040152776,0.7984297,0.0010269838,0.00029035308,0.010364879,0.0004577704,0.0027923195,0.024561187,0.00063765305,0.002872915,0.0007221399],"about_ca_topic_score_codex":0.0013856979,"about_ca_topic_score_gemma":0.0002779744,"teacher_disagreement_score":0.17320198,"about_ca_system_score_codex":0.0025008665,"about_ca_system_score_gemma":0.0012201262,"threshold_uncertainty_score":0.9389109},"labels":[],"label_agreement":null},{"id":"W2806968913","doi":"10.1016/j.leukres.2018.06.005","title":"Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells","year":2018,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; Research Institute in Oncology and Hematology","funders":"Canadian Cancer Society Research Institute; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Mefloquine; Lysosome; Programmed cell death; Chronic lymphocytic leukemia; Pharmacology; Leukemia; Primaquine; Myeloid leukemia; Apoptosis; Cancer research; Chemistry; Immunology; Medicine; Chloroquine; Biochemistry","score_opus":0.04492586500004525,"score_gpt":0.35592609796185143,"score_spread":0.3110002329618062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806968913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955675,0.0006508188,0.000027586175,0.00020588924,0.00056700205,0.0038790605,0.000030507395,0.00031001645,0.0386541],"genre_scores_gemma":[0.97291774,0.000500041,0.00033164365,0.00023999029,0.0028812033,0.00039183797,0.000103537524,0.00027645676,0.022357564],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98587865,0.0013358135,0.0015448203,0.0022226565,0.0048216325,0.004196428],"domain_scores_gemma":[0.99232763,0.0020604474,0.00020013748,0.0027229511,0.0013537476,0.0013350939],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006198033,0.00083400914,0.001460497,0.0026537906,0.00059361756,0.00029878545,0.0015844037,0.0009940221,0.0023242263],"category_scores_gemma":[0.0012078916,0.00075867004,0.00036795274,0.0050652046,0.0015824148,0.00045067057,0.001205156,0.0030883728,0.010114562],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03271628,0.0028365892,0.009228146,0.0056696045,0.0012279442,0.026418494,0.018483395,0.002940017,0.7366446,0.0011618856,0.15067758,0.011995423],"study_design_scores_gemma":[0.20304312,0.009288613,0.0052276724,0.0010870135,0.00020724302,0.0004883069,0.0019271602,0.45046192,0.28234723,0.00039190424,0.043626197,0.0019036086],"about_ca_topic_score_codex":0.022078114,"about_ca_topic_score_gemma":0.00085309974,"teacher_disagreement_score":0.4542974,"about_ca_system_score_codex":0.4844968,"about_ca_system_score_gemma":0.23061347,"threshold_uncertainty_score":0.99948645},"labels":[],"label_agreement":null},{"id":"W2808310542","doi":"10.1136/annrheumdis-2018-eular.2638","title":"AB0415 Disease flares among early rheumatoid arthritis patients treated with continued methotrexate either alone or in combination with adalimumab","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer Japan; Ono Pharmaceutical; AbbVie Canada; Amgen; Astellas Foundation for Research on Metabolic Disorders; Teijin Pharma; Novo Nordisk; GlaxoSmithKline; Pfizer; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Methotrexate; Rheumatoid arthritis; Placebo; Internal medicine; Flare; Surgery; Pathology","score_opus":0.023588056656982322,"score_gpt":0.2935004729738323,"score_spread":0.26991241631685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808310542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713534,0.00055509893,0.000017623,0.0003904969,0.00003327915,0.0014913392,0.00009187051,0.00006191737,0.00022304385],"genre_scores_gemma":[0.9983658,0.00044945712,0.00008341019,0.00016274846,0.000015309204,0.00014369063,0.00006197857,0.0000674042,0.0006501841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970166,0.00033537962,0.00060939824,0.00039877312,0.0011216935,0.00051812106],"domain_scores_gemma":[0.9972905,0.00035649174,0.0003976182,0.000854165,0.000712368,0.00038887208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002960341,0.00031906329,0.0007084112,0.00020592981,0.00012116951,0.000056883466,0.0003189906,0.0000629695,0.00025780027],"category_scores_gemma":[0.0010548292,0.0001703589,0.00012229975,0.00073095434,0.00088030257,0.00029111205,0.00010753149,0.00012940583,0.000026256253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019814951,0.002917915,0.9497038,0.0007356443,0.00083437643,0.00016693979,0.0013428315,0.000020705222,0.000015686359,0.000100317695,0.0020288704,0.02231793],"study_design_scores_gemma":[0.03216759,0.0019211047,0.9541647,0.007905057,0.00013109604,0.000011481763,0.00017721328,0.0012857519,0.0017203325,0.00021219517,0.00003659285,0.00026689016],"about_ca_topic_score_codex":0.0018382978,"about_ca_topic_score_gemma":0.00068637705,"teacher_disagreement_score":0.022051038,"about_ca_system_score_codex":0.00041556978,"about_ca_system_score_gemma":0.0016309039,"threshold_uncertainty_score":0.69470346},"labels":[],"label_agreement":null},{"id":"W2810389335","doi":"10.1158/1538-7445.am2018-1871","title":"Abstract 1871: Development of pelorol analogues to activate the SHIP1 lipid phosphatase; a novel paradigm to suppress B-cell receptor signaling in human B-cell cancers","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inimex Pharmaceuticals (Canada)","funders":"","keywords":"Cancer research; Protein kinase B; Chronic lymphocytic leukemia; Signal transduction; Cell biology; PI3K/AKT/mTOR pathway; breakpoint cluster region; Biology; B-cell receptor; Cell signaling; B cell; Chemistry; Receptor; Leukemia; Immunology; Biochemistry; Antibody","score_opus":0.10018194669799689,"score_gpt":0.4088280008356745,"score_spread":0.3086460541376776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810389335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937926,0.0006268962,0.000061286395,0.0011777286,0.00020302927,0.002145857,0.00008672431,0.000029462968,0.0018764493],"genre_scores_gemma":[0.99577516,0.000081615675,0.00083873974,0.0002947928,0.00061266526,0.00082875486,0.000047717345,0.00007945291,0.0014410826],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948224,0.00014896992,0.00071886525,0.0008405096,0.0019568198,0.0015124469],"domain_scores_gemma":[0.99707395,0.00054631475,0.000108566936,0.00095493475,0.0006254938,0.00069071294],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028031536,0.00030397944,0.0005403215,0.0006657173,0.00038371963,0.000082400504,0.0010358907,0.0001633671,0.0013082715],"category_scores_gemma":[0.00030194988,0.00023432027,0.00008862873,0.0018342696,0.0004941897,0.00012575311,0.00051298254,0.00090317224,0.00027803608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0020830638,0.00039308783,0.00048005724,0.00064513815,0.00008285073,0.000030985568,0.011092272,0.00037435594,0.96599925,0.00004445415,0.01468417,0.0040902914],"study_design_scores_gemma":[0.006915909,0.00047008556,0.0015892141,0.0008065303,0.000012077452,0.0000027118147,0.0014225551,0.00012555782,0.9450164,0.000010745322,0.043369994,0.00025823025],"about_ca_topic_score_codex":0.015858654,"about_ca_topic_score_gemma":0.004556366,"teacher_disagreement_score":0.028685825,"about_ca_system_score_codex":0.020057924,"about_ca_system_score_gemma":0.01600108,"threshold_uncertainty_score":0.99960464},"labels":[],"label_agreement":null},{"id":"W2810788428","doi":"10.1016/j.clml.2018.06.016","title":"Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Pharmacyclics","keywords":"Ibrutinib; Medicine; Mantle cell lymphoma; Chronic lymphocytic leukemia; Internal medicine; Adverse effect; Discontinuation; Oncology; Lymphoma; Leukemia","score_opus":0.039115926688504936,"score_gpt":0.33680849784259154,"score_spread":0.2976925711540866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810788428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98547906,0.0027926306,0.00022438049,0.000054410204,0.0008113183,0.0065226643,0.00017211822,0.00024078436,0.0037026647],"genre_scores_gemma":[0.99084973,0.0022879469,0.0017864447,0.0005230613,0.00067166274,0.000516372,0.00026522327,0.00031360536,0.0027859737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9791838,0.0025992785,0.009627544,0.0027855635,0.0031735294,0.002630299],"domain_scores_gemma":[0.9722911,0.015418807,0.004036098,0.0037263494,0.0033379942,0.0011896656],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.008103445,0.0019121872,0.015897727,0.002798805,0.00034828845,0.00008732928,0.0017601867,0.0014218291,0.0006390303],"category_scores_gemma":[0.010057704,0.0013062428,0.003864979,0.006479516,0.0071250647,0.00039729485,0.0010539885,0.00036805775,0.00021911475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8570135,0.0017347351,0.017135238,0.0020677228,0.024791168,0.0010002344,0.0010248589,0.0014455831,0.00016263782,0.00029312805,0.00049079995,0.09284034],"study_design_scores_gemma":[0.69871557,0.0042025894,0.18935941,0.0015417008,0.011045064,0.00011337395,0.00029500184,0.091263756,0.0019558717,0.00008426267,0.00035336468,0.0010700446],"about_ca_topic_score_codex":0.00345181,"about_ca_topic_score_gemma":0.0014277376,"teacher_disagreement_score":0.17222418,"about_ca_system_score_codex":0.19781068,"about_ca_system_score_gemma":0.14270997,"threshold_uncertainty_score":0.99987453},"labels":[],"label_agreement":null},{"id":"W2883071434","doi":"10.1182/bloodadvances.2017015396","title":"Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)","year":2018,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; National Institutes of Health; American College of Radiology Imaging Network","keywords":"Chemoimmunotherapy; Lenalidomide; Medicine; Consolidation (business); Internal medicine; Oncology; Chronic lymphocytic leukemia; Multiple myeloma; Leukemia","score_opus":0.01737723329979448,"score_gpt":0.2944825228539592,"score_spread":0.27710528955416475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883071434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902234,0.0022875746,0.00044198675,0.00048366436,0.00024009368,0.0016269919,0.00012001848,0.00011503484,0.00446122],"genre_scores_gemma":[0.98539835,0.0011039188,0.0105464915,0.00036300177,0.0006471417,0.00015164388,0.00020188706,0.00006326895,0.0015243147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809813,0.000030015512,0.00038629808,0.00049678196,0.0004884624,0.00050031336],"domain_scores_gemma":[0.9983438,0.00030731905,0.00019970459,0.00046680385,0.0005509635,0.00013135739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003019381,0.00021499551,0.00033767652,0.000067935536,0.00018557103,0.00003764634,0.0001706656,0.00009353475,0.000041547784],"category_scores_gemma":[0.0004918896,0.00016385218,0.00006730314,0.00025540995,0.00025966507,0.00029698035,0.00003657409,0.000120928846,0.00003916196],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10772961,0.0055161705,0.08228474,0.0030636373,0.0025827822,0.0000597276,0.005265979,0.0004490857,0.016743522,0.002251938,0.011221418,0.7628314],"study_design_scores_gemma":[0.3130124,0.009258328,0.048610598,0.003097859,0.000522727,0.00008388723,0.00024105854,0.0019056506,0.29607397,0.00073443825,0.32525653,0.0012025769],"about_ca_topic_score_codex":0.00007503196,"about_ca_topic_score_gemma":0.00020611109,"teacher_disagreement_score":0.7616288,"about_ca_system_score_codex":0.0010197394,"about_ca_system_score_gemma":0.0011467711,"threshold_uncertainty_score":0.6681698},"labels":[],"label_agreement":null},{"id":"W2883385515","doi":"10.1038/s41375-018-0215-9","title":"Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Heart, Lung, and Blood Institute; National Cancer Institute; Foundation Medicine; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology; American Society of Hematology; Cycle for Survival; Robert Wood Johnson Foundation","keywords":"Somatic evolution in cancer; Chronic lymphocytic leukemia; Biology; Mutation; Gene; Leukemia; Genetics; Cancer research","score_opus":0.035348244830359886,"score_gpt":0.3128845966772866,"score_spread":0.2775363518469267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883385515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743158,0.00027480684,0.00009426187,0.00009883094,0.00053692464,0.0008365224,0.000020415577,0.00028680472,0.023535587],"genre_scores_gemma":[0.9894625,0.00008393947,0.00037946456,0.00097016635,0.0014224108,0.000040072075,0.000053565007,0.00007339841,0.0075144754],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99543446,0.00011396988,0.0007714492,0.0009405322,0.0013514938,0.0013880719],"domain_scores_gemma":[0.99760425,0.00021794597,0.00015441846,0.001156476,0.00024319295,0.0006237224],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007434935,0.0004593524,0.0007786587,0.0004902373,0.00034447323,0.000029400748,0.00064942386,0.0004650064,0.0014227547],"category_scores_gemma":[0.00045759612,0.0004330692,0.00026825254,0.0009820393,0.00082309573,0.0003027068,0.001303022,0.00073434983,0.0026211923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016412461,0.0005177014,0.754786,0.0058881184,0.0017815437,0.025904724,0.012681569,0.011843543,0.021629618,0.0057236813,0.10815641,0.034674633],"study_design_scores_gemma":[0.16048954,0.0032205174,0.30446115,0.0013543357,0.00047064156,0.002257328,0.0005063752,0.47980213,0.010620902,0.0007660766,0.034240976,0.0018100257],"about_ca_topic_score_codex":0.009988809,"about_ca_topic_score_gemma":0.0012263863,"teacher_disagreement_score":0.4679586,"about_ca_system_score_codex":0.52146304,"about_ca_system_score_gemma":0.08324273,"threshold_uncertainty_score":0.9998121},"labels":[],"label_agreement":null},{"id":"W2883801974","doi":"10.4103/0366-6999.237411","title":"Hydroxychloroquine-Induced Psoriasis-form Erythroderma in a Patient with Systemic Lupus Erythematosus","year":2018,"lang":"en","type":"letter","venue":"Chinese Medical Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hydroxychloroquine; Medicine; Psoriasis; Erythroderma; Anti-nuclear antibody; Leukocytosis; Prednisone; Dermatology; Exfoliative dermatitis; Gastroenterology; Lupus erythematosus; Rheumatoid arthritis; Internal medicine; Erythema; Body surface area; Immunology; Antibody; Autoantibody","score_opus":0.014012046866625409,"score_gpt":0.28453598974069805,"score_spread":0.27052394287407266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883801974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8160842,0.0012411204,0.00007651551,0.1754741,0.0033485102,0.0011744575,0.0000125717,0.00010733648,0.0024811658],"genre_scores_gemma":[0.7021522,0.00085041707,0.00030218184,0.2507138,0.04285112,0.00022081345,0.00024634312,0.0005387355,0.00212441],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.98750275,0.00039200424,0.0020368146,0.0010454352,0.0070600896,0.0019628848],"domain_scores_gemma":[0.99516076,0.00062170037,0.00076879805,0.0013216289,0.0006592888,0.0014677983],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001628577,0.00113484,0.002411667,0.0011743293,0.00022461393,0.00017038974,0.0010890075,0.0023730407,0.001851749],"category_scores_gemma":[0.0020570348,0.00065462734,0.00052669214,0.0010742364,0.0005880926,0.0002224826,0.0003827088,0.010531011,0.000412653],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014230832,0.00034584952,0.0016865311,0.002344457,0.00069186336,0.2959295,0.002002556,0.0000025247077,0.000043465963,0.0000022343936,0.689949,0.0055789915],"study_design_scores_gemma":[0.04133928,0.0021097164,0.000096147465,0.012865159,0.0002601003,0.88142455,0.00019492811,0.0033657348,0.00004607431,0.00024230703,0.057216793,0.00083922053],"about_ca_topic_score_codex":0.0002104689,"about_ca_topic_score_gemma":0.000113025235,"teacher_disagreement_score":0.63273215,"about_ca_system_score_codex":0.017164195,"about_ca_system_score_gemma":0.024512071,"threshold_uncertainty_score":0.9995905},"labels":[],"label_agreement":null},{"id":"W2884707538","doi":"10.4236/jct.2018.97049","title":"Overall Survival and Health Care Costs of Medicare Patients with Previously Treated Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"Journal of Cancer Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Genentech","keywords":"Bendamustine; Medicine; Cohort; Chronic lymphocytic leukemia; Internal medicine; Rituximab; Leukemia; Lymphoma","score_opus":0.019245460135780375,"score_gpt":0.33982019453645756,"score_spread":0.3205747344006772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884707538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622443,0.0364083,0.00001985894,0.0002688558,0.00019658175,0.00054904504,0.00001478359,0.000012142752,0.00028616108],"genre_scores_gemma":[0.9854764,0.013236082,0.00009908479,0.00037860687,0.00065034314,0.000008689014,0.000009703783,0.00004481281,0.00009631904],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755925,0.000106674655,0.0005954242,0.00021120707,0.001108235,0.00041918413],"domain_scores_gemma":[0.9973946,0.00007467345,0.0005929259,0.0002931803,0.001258582,0.00038602267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038061562,0.00021231023,0.0007469904,0.00017348211,0.00007243577,0.000016622256,0.00017985713,0.00009889108,0.000189907],"category_scores_gemma":[0.000030563693,0.00013486743,0.000098760254,0.00023958102,0.00033714552,0.00011511516,0.000029601864,0.00023014119,0.0000015268995],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03511997,0.00033782452,0.25784773,0.0023105724,0.003966967,0.00027416577,0.015207425,0.0002046263,0.0013849869,0.00009868624,0.009991253,0.6732558],"study_design_scores_gemma":[0.50372374,0.06914374,0.36142436,0.011853507,0.0005653594,0.00065465743,0.0015138506,0.0019082901,0.016175449,0.000036658796,0.03210074,0.0008996386],"about_ca_topic_score_codex":0.0044618365,"about_ca_topic_score_gemma":0.000970494,"teacher_disagreement_score":0.6723562,"about_ca_system_score_codex":0.09570932,"about_ca_system_score_gemma":0.05853026,"threshold_uncertainty_score":0.946807},"labels":[],"label_agreement":null},{"id":"W2885983462","doi":"10.1158/1535-7163.targ-17-a152","title":"Abstract A152: Emerging indications for kinase-targeted therapies: screening for new targets","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SignalChem (Canada)","funders":"","keywords":"Kinome; Kinase; Vandetanib; Tyrosine kinase; Receptor tyrosine kinase; Medicine; Pharmacology; Cabozantinib; Cancer research; Sorafenib; Biology; Cancer; Biochemistry; Signal transduction; Internal medicine","score_opus":0.0617206210391006,"score_gpt":0.37740121309189767,"score_spread":0.3156805920527971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885983462","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112574585,0.026111161,0.8413188,0.013497291,0.00063639984,0.004583737,0.00018035455,0.0002837609,0.00081392546],"genre_scores_gemma":[0.9513563,0.00043089982,0.0398393,0.0051479363,0.0011548685,0.000624475,0.00015168764,0.00017253826,0.0011219766],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804777,0.000023466657,0.00035338354,0.00045842316,0.0004269148,0.0006900359],"domain_scores_gemma":[0.9984838,0.00015018616,0.00014449457,0.00055654795,0.00043164103,0.00023334868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028155794,0.00025962334,0.00032662097,0.0001720057,0.00027381864,0.000055825545,0.0002695026,0.00017515584,0.00028102478],"category_scores_gemma":[0.000076134456,0.00024073545,0.00024504153,0.00032938545,0.00017373232,0.00007684534,0.000040646923,0.00019841589,0.000015040946],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021883924,0.00028050662,0.0004009753,0.0005511586,0.003041419,0.000030443689,0.004680461,0.00019046078,0.60261834,0.0020527404,0.008333675,0.37563145],"study_design_scores_gemma":[0.023339922,0.0008502636,0.0012465295,0.0003216186,0.0005961679,0.000017871962,0.00039138415,0.02641844,0.3873949,0.0030319714,0.5557922,0.0005987158],"about_ca_topic_score_codex":0.00038510715,"about_ca_topic_score_gemma":0.0000698811,"teacher_disagreement_score":0.8387817,"about_ca_system_score_codex":0.001898953,"about_ca_system_score_gemma":0.00423818,"threshold_uncertainty_score":0.98169065},"labels":[],"label_agreement":null},{"id":"W2886059231","doi":"10.1158/1538-7445.am2018-5237","title":"Abstract 5237: Sex-dependent association of circulating sex steroids, pituitary hormones and treatment-free survival in patients with chronic lymphocytic leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Internal medicine; Hormone; Medicine; Chronic lymphocytic leukemia; Sex hormone-binding globulin; Endocrinology; Hazard ratio; Sex steroid; Luteinizing hormone; Cancer; Oncology; Leukemia; Androgen; Steroid","score_opus":0.036033832784782394,"score_gpt":0.33789495992203833,"score_spread":0.30186112713725594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886059231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960502,0.001270459,0.0000030120777,0.000076877164,0.00008290602,0.0011861047,0.00006259812,0.000031843505,0.0012359937],"genre_scores_gemma":[0.9970363,0.00077987165,0.00003477455,0.000014291203,0.00039836386,0.00014014087,0.00003574313,0.000060996972,0.0014995269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955551,0.0002194158,0.00046694977,0.0006187993,0.0021406594,0.0009990599],"domain_scores_gemma":[0.99764395,0.00053501327,0.00014976959,0.00076861354,0.00064269884,0.0002599769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014795824,0.00024827756,0.0005549412,0.00042192033,0.00016373323,0.000050044127,0.0002850853,0.00020741859,0.00016936827],"category_scores_gemma":[0.00036272386,0.00019982025,0.00005339318,0.0005541698,0.00039617132,0.00019553892,0.0002630291,0.00040350537,0.000022406148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032499237,0.00031229874,0.92649627,0.0009949605,0.000703411,0.0002052633,0.0028581698,0.00029951564,0.019512255,0.000022612112,0.00083323417,0.044512074],"study_design_scores_gemma":[0.11108028,0.0055113323,0.84192324,0.0010928564,0.00011289586,0.000021288552,0.0008300671,0.005055844,0.03344966,0.00011140634,0.00031303152,0.00049807853],"about_ca_topic_score_codex":0.027641272,"about_ca_topic_score_gemma":0.007192377,"teacher_disagreement_score":0.18115096,"about_ca_system_score_codex":0.20664562,"about_ca_system_score_gemma":0.025494656,"threshold_uncertainty_score":0.9800299},"labels":[],"label_agreement":null},{"id":"W2886093878","doi":"10.1159/000491920","title":"Leukoerythroblastosis with Cytopenia as an Initial Presentation of Lung Adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Pathology; Cytopenia; Rituximab; Bone marrow; Biopsy; Pancytopenia; Fludarabine; Chronic lymphocytic leukemia; Lung; Adenocarcinoma; Lung biopsy; Cyclophosphamide; Leukemia; Internal medicine; Lymphoma; Chemotherapy; Cancer","score_opus":0.03265752611162817,"score_gpt":0.4047824110129633,"score_spread":0.3721248849013351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886093878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981313,0.00009253438,0.00008188976,0.00015719791,0.00018628083,0.0007081174,0.0000017194477,0.00002922811,0.017430022],"genre_scores_gemma":[0.99793875,0.00001179594,0.001065178,0.00014229806,0.00037274498,0.00006721939,0.000022511016,0.000031648622,0.00034782937],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9980445,0.00015573796,0.00062158454,0.00045279745,0.00036733865,0.0003580719],"domain_scores_gemma":[0.9983405,0.0001931146,0.00027655295,0.0006159807,0.00036831145,0.00020557707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057670654,0.00014480989,0.00047163633,0.0002698537,0.00005563675,0.000009209593,0.000053945536,0.00021795837,0.0005441628],"category_scores_gemma":[0.00041580002,0.00012124559,0.000043645545,0.00036355402,0.00067422335,0.00015559727,0.00009265786,0.0002296581,0.000014581713],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035747155,0.0007451933,0.046527144,0.0002788626,0.00014539645,0.9307189,0.004084743,0.000027391543,0.003879007,0.00020138215,0.0012042728,0.008612994],"study_design_scores_gemma":[0.012215932,0.010207882,0.007921658,0.00017003655,0.00016730622,0.9280127,0.0013583868,0.0033282214,0.03468546,0.00017141004,0.0015636559,0.00019732938],"about_ca_topic_score_codex":0.0039186366,"about_ca_topic_score_gemma":0.0022997237,"teacher_disagreement_score":0.038605485,"about_ca_system_score_codex":0.0064464123,"about_ca_system_score_gemma":0.0112990765,"threshold_uncertainty_score":0.9973677},"labels":[],"label_agreement":null},{"id":"W2886434870","doi":"10.1158/1538-7445.am2018-3976","title":"Abstract 3976: Antihistamines as synergists with targeted therapies in chronic lymphocytic leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Pharmacology; Ibrutinib; Bendamustine; Cancer research; Bruton's tyrosine kinase; Chlorambucil; Medicine; Cancer cell; Programmed cell death; Cancer; Leukemia; Immunology; Apoptosis; Tyrosine kinase; Biology; Internal medicine; Receptor; Chemotherapy; Biochemistry; Cyclophosphamide","score_opus":0.04787148710888368,"score_gpt":0.4001497695578863,"score_spread":0.3522782824490026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886434870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97970027,0.0075059067,0.0000067810374,0.00046933498,0.00013423228,0.0010922322,0.000011588433,0.00011775601,0.010961922],"genre_scores_gemma":[0.98722744,0.0021805514,0.00008210732,0.00015915296,0.0011320878,0.00040017092,0.000023568467,0.00011876139,0.008676152],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99470335,0.0001753269,0.00045337935,0.00089983654,0.0020450675,0.0017230404],"domain_scores_gemma":[0.9969793,0.0004037628,0.00007664124,0.0010715342,0.0010185775,0.00045019638],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013707282,0.0003409571,0.0005649246,0.00083029224,0.00027612204,0.00011552965,0.00056447706,0.00024675735,0.0029347339],"category_scores_gemma":[0.00038046567,0.00025629334,0.00008588249,0.0020587794,0.0020506529,0.00022180835,0.00021232435,0.00088451453,0.00087780174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018758046,0.0003564435,0.0075703952,0.0048406324,0.0011867211,0.010249834,0.008618093,0.001152396,0.8587206,0.0017941783,0.03635719,0.050395455],"study_design_scores_gemma":[0.1127528,0.009159632,0.083557606,0.008210252,0.000119846074,0.0013564884,0.0029857522,0.023860566,0.6175329,0.00091464835,0.1374698,0.0020796868],"about_ca_topic_score_codex":0.038886942,"about_ca_topic_score_gemma":0.0063767214,"teacher_disagreement_score":0.2411877,"about_ca_system_score_codex":0.21439585,"about_ca_system_score_gemma":0.13118933,"threshold_uncertainty_score":0.9999889},"labels":[],"label_agreement":null},{"id":"W2886701506","doi":"10.1158/1538-7445.am2018-1891","title":"Abstract 1891: Cross-resistance and synergy between idelalisib and bendamustine in chronic lymphocytic leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Saint-Boniface; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Bendamustine; Idelalisib; Chronic lymphocytic leukemia; Peripheral blood mononuclear cell; Cancer research; Cytotoxic T cell; Cytotoxicity; In vitro; Leukemia; Biology; Immunology; Biochemistry; Ibrutinib","score_opus":0.07210203326680378,"score_gpt":0.4383313000038043,"score_spread":0.3662292667370005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886701506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822069,0.011550986,0.000008399088,0.00046543553,0.00007871323,0.0006987055,0.000042716016,0.000058547055,0.004889624],"genre_scores_gemma":[0.98994565,0.0029446722,0.00008049511,0.00008475157,0.0014300101,0.00016538861,0.000019771176,0.000077445286,0.0052518323],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99555635,0.0001358059,0.00055209483,0.00097454054,0.0013128892,0.0014683285],"domain_scores_gemma":[0.9972077,0.00074965256,0.00007247309,0.0007330976,0.00060262205,0.0006344536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020497034,0.0002898885,0.00057576364,0.00058560824,0.00033061326,0.00018779564,0.0002886301,0.0002921879,0.0006337224],"category_scores_gemma":[0.0007194194,0.00026299656,0.000052211006,0.0010809798,0.00251986,0.00025459786,0.00047606236,0.000891576,0.00009598433],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02203335,0.00035218522,0.24112466,0.03415103,0.0022324438,0.013869243,0.011544376,0.0010845524,0.3486429,0.010714987,0.07713814,0.23711216],"study_design_scores_gemma":[0.09016033,0.0020425154,0.70962757,0.0066593713,0.00013446316,0.00047352698,0.00053113804,0.013885754,0.08971389,0.0025801645,0.08260688,0.0015843881],"about_ca_topic_score_codex":0.01577029,"about_ca_topic_score_gemma":0.005839982,"teacher_disagreement_score":0.4685029,"about_ca_system_score_codex":0.11291995,"about_ca_system_score_gemma":0.044122487,"threshold_uncertainty_score":0.99998224},"labels":[],"label_agreement":null},{"id":"W2888496958","doi":"10.1002/ajh.25259","title":"Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies","year":2018,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cilag; Pharmacyclics","keywords":"Ibrutinib; Chlorambucil; Obinutuzumab; Chemoimmunotherapy; Medicine; Ofatumumab; Fludarabine; Chronic lymphocytic leukemia; Internal medicine; Rituximab; Bendamustine; Oncology; Cyclophosphamide; Alemtuzumab; Neutropenia; Venetoclax; Leukemia; Chemotherapy; Lymphoma; Transplantation","score_opus":0.0710266598013649,"score_gpt":0.43057955698391287,"score_spread":0.35955289718254796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888496958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513626,0.002676759,0.00036159402,0.000108128705,0.0005794077,0.0010089249,0.000014596874,0.000018698482,0.000095650736],"genre_scores_gemma":[0.9972745,0.00018018983,0.0018518199,0.000062183964,0.00044493822,0.000042474272,0.000012989587,0.000056272587,0.000074588395],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997221,0.000116227275,0.0011538864,0.0003276599,0.00055914,0.0006220718],"domain_scores_gemma":[0.99547535,0.0009413218,0.0015742978,0.0004874771,0.001317689,0.0002038415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000274498,0.00032959247,0.0020103366,0.00026602898,0.00012910874,0.000015889933,0.00024289262,0.00010074447,0.000049675145],"category_scores_gemma":[0.00039356964,0.00022518043,0.000304715,0.00036457006,0.0026312077,0.00009270696,0.000047231802,0.00014066746,0.000008913943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9325014,0.0038019132,0.0034109417,0.0004024068,0.008463874,0.00024192799,0.005236479,0.00006386517,0.0031685978,0.00020872123,0.0021535617,0.040346343],"study_design_scores_gemma":[0.7007091,0.22677672,0.00007825063,0.00037172518,0.0007116428,0.00071779476,0.0014788845,0.0008683064,0.064833365,0.000020379986,0.0031960395,0.00023776304],"about_ca_topic_score_codex":0.00015898567,"about_ca_topic_score_gemma":0.00004114523,"teacher_disagreement_score":0.23179224,"about_ca_system_score_codex":0.043387916,"about_ca_system_score_gemma":0.015848048,"threshold_uncertainty_score":0.9897312},"labels":[],"label_agreement":null},{"id":"W2889467068","doi":"10.1016/j.ebiom.2018.08.045","title":"Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia","year":2018,"lang":"en","type":"article","venue":"EBioMedicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; CSL Behring","keywords":"Medicine; Chronic lymphocytic leukemia; Immunology; Immunoglobulin G; Antibody; Immune system; Immunotherapy; Tumor necrosis factor alpha; Internal medicine; Leukemia","score_opus":0.016346801192677285,"score_gpt":0.3298917968721089,"score_spread":0.3135449956794316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889467068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996813,0.0010843761,0.000060825,0.00036798,0.00022981208,0.0005502786,0.000041649473,0.000050614784,0.00080148457],"genre_scores_gemma":[0.9961608,0.00034459558,0.00033475703,0.00018900119,0.00091924146,0.000010033146,0.000031018328,0.000045287914,0.0019652618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970115,0.00009227797,0.0009186237,0.00046095002,0.0009977267,0.0005189298],"domain_scores_gemma":[0.9972013,0.00059226184,0.00056311616,0.0006191583,0.00066311186,0.00036102385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010121311,0.00025795336,0.0010149338,0.00021842764,0.000057849982,0.000008277481,0.00017838247,0.00021366937,0.0003681677],"category_scores_gemma":[0.00066510803,0.00017919859,0.00011422051,0.0006402969,0.0014137042,0.00008090269,0.000107826956,0.0002646078,0.000021659938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012558892,0.003596279,0.61258745,0.009400271,0.015965374,0.0012341461,0.0069818436,0.0000109833145,0.2207836,0.00032753072,0.038801447,0.07775217],"study_design_scores_gemma":[0.31905463,0.058253247,0.3430343,0.006017237,0.007380731,0.0019564806,0.0007410453,0.034438502,0.2155538,0.00013176032,0.012373342,0.0010649381],"about_ca_topic_score_codex":0.0016299204,"about_ca_topic_score_gemma":0.00020287112,"teacher_disagreement_score":0.30649573,"about_ca_system_score_codex":0.022844706,"about_ca_system_score_gemma":0.032523073,"threshold_uncertainty_score":0.9809064},"labels":[],"label_agreement":null},{"id":"W2889637655","doi":"10.1200/jco.2018.36.15_suppl.8003","title":"Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Waldenstrom macroglobulinemia; Gastroenterology; Clinical endpoint; Placebo; Regimen; Macroglobulinemia; Randomized controlled trial; Surgery; Lymphoma; Pathology","score_opus":0.1359827613221785,"score_gpt":0.5320171864932534,"score_spread":0.39603442517107484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889637655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97902507,0.00041721042,0.00024160284,0.0064990534,0.0028341638,0.0015267978,0.0000075818307,0.000015875336,0.009432639],"genre_scores_gemma":[0.98650163,0.0009092546,0.0053979666,0.0011818465,0.0053344155,0.000019371662,0.000004888347,0.000038065333,0.00061256316],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98798656,0.0023278873,0.007393372,0.00039886136,0.0012346794,0.00065863715],"domain_scores_gemma":[0.980419,0.013595955,0.0033631902,0.0005513248,0.0013681565,0.00070237403],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.021716848,0.00028373496,0.0063757086,0.00046238388,0.000041734726,0.000014743189,0.0005260779,0.00095216074,0.0010258118],"category_scores_gemma":[0.044656254,0.00019842482,0.0014527154,0.00045794042,0.0022870805,0.0001469134,0.00019364925,0.0019522127,0.00014487191],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9224488,0.01566112,0.00008595319,0.00008613517,0.000493134,0.002343002,0.00015658954,0.0000018764409,0.0001352613,0.000150722,0.006145965,0.052291427],"study_design_scores_gemma":[0.9301286,0.0395914,0.000048190042,0.0003012197,0.0005295853,0.0015385495,0.00008410799,0.003344083,0.00075273844,0.00054107216,0.022993254,0.00014719299],"about_ca_topic_score_codex":0.00016570637,"about_ca_topic_score_gemma":0.00007728467,"teacher_disagreement_score":0.052144233,"about_ca_system_score_codex":0.003199487,"about_ca_system_score_gemma":0.032559466,"threshold_uncertainty_score":0.9998874},"labels":[],"label_agreement":null},{"id":"W2889729436","doi":"10.1016/j.molcel.2018.08.005","title":"Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease","year":2018,"lang":"en","type":"review","venue":"Molecular Cell","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":266,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Canadian Institutes of Health Research","keywords":"Biology; Kinase; Disease; Protein-Serine-Threonine Kinases; Phosphoinositide 3-kinase; Cell biology; Human disease; Computational biology; Signal transduction; Protein kinase A; Genetics; PI3K/AKT/mTOR pathway; Gene; Internal medicine","score_opus":0.04109922541070341,"score_gpt":0.3339861591482495,"score_spread":0.29288693373754604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889729436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034528274,0.9629363,0.00006286262,0.000010949979,0.000037811926,0.0021513333,0.000081569786,0.000011592627,0.0001793182],"genre_scores_gemma":[0.078483224,0.9192275,0.00038801393,0.000060977745,0.00011900307,0.0002948279,0.00091567147,0.00010969226,0.00040110562],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984232,0.000090774134,0.00050323055,0.00043967584,0.00025876617,0.0002843595],"domain_scores_gemma":[0.9988762,0.00011907249,0.0001989108,0.0005339471,0.00009964866,0.00017223132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021305341,0.00029790154,0.0009645022,0.00022232268,0.00003832527,0.00001553153,0.00013263743,0.00014643991,0.000049161805],"category_scores_gemma":[0.00009129875,0.00022409033,0.0003217887,0.00018699895,0.00015090643,0.000025470119,0.000125261,0.00012361289,0.0000021556314],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067186594,0.0005429799,0.00015061027,0.5098158,0.0008103471,0.0005820162,0.00082450674,0.000018928004,0.00564738,0.00084873044,0.0020151222,0.4780717],"study_design_scores_gemma":[0.030198744,0.002104823,0.0004656964,0.09732886,0.0045864508,0.00008958683,0.00018462402,0.005269635,0.08380746,0.0021107355,0.77185094,0.0020024637],"about_ca_topic_score_codex":0.00020785021,"about_ca_topic_score_gemma":0.00001702946,"teacher_disagreement_score":0.76983577,"about_ca_system_score_codex":0.0029414436,"about_ca_system_score_gemma":0.002310008,"threshold_uncertainty_score":0.9138138},"labels":[],"label_agreement":null},{"id":"W2889732469","doi":"10.1200/jco.2017.35.15_suppl.7565","title":"Results of a phase II trial of efficacy and safety of entospletinib (ENTO) in patients with lymphoplasmacytoid lymphoma/Waldenstrom's macroglubulinemia (LPL/WM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Gastroenterology; Nausea; Waldenstrom macroglobulinemia; Adverse effect; Clinical endpoint; Rash; Surgery; Oncology; Clinical trial; Lymphoma; Chemotherapy","score_opus":0.06514471723858213,"score_gpt":0.4508575970605035,"score_spread":0.3857128798219214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889732469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957779,0.00009801572,0.00000826157,0.001228579,0.0005148037,0.00083356176,0.00006523361,0.0000033489623,0.0014703015],"genre_scores_gemma":[0.99714404,0.00059520564,0.0016197363,0.000070905124,0.0003957934,0.0000032657451,0.000011244811,0.000025120333,0.00013467635],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921218,0.00049100886,0.0054512364,0.00034879713,0.0011804863,0.00040664815],"domain_scores_gemma":[0.9869537,0.0036735553,0.0069695557,0.00078642974,0.0011442618,0.00047249417],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0055660717,0.00023582106,0.0030290429,0.0002823015,0.000069887225,0.000008816096,0.0005424978,0.0005127599,0.000056523604],"category_scores_gemma":[0.019026605,0.00016469187,0.0003965933,0.00015888056,0.0014350732,0.00013985469,0.0003494997,0.000556202,0.000001541758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8135282,0.018773708,0.021397598,0.00018768122,0.00054047385,0.00038725932,0.0003047328,0.00001332984,0.0003130048,0.000029290375,0.0005315537,0.14399317],"study_design_scores_gemma":[0.7692722,0.099585064,0.12488171,0.0007006678,0.00033649334,0.00013714243,0.0000411648,0.00024047183,0.00096003193,0.000021337515,0.0037158993,0.00010779389],"about_ca_topic_score_codex":0.00033692285,"about_ca_topic_score_gemma":0.00009436829,"teacher_disagreement_score":0.14388537,"about_ca_system_score_codex":0.0017080483,"about_ca_system_score_gemma":0.015793461,"threshold_uncertainty_score":0.9897861},"labels":[],"label_agreement":null},{"id":"W2890395064","doi":"10.1182/bloodadvances.2017015560","title":"CD40L/IL-4–stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM","year":2018,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"Medical Research Council; Blood Cancer UK; Cancer Research UK","keywords":"Ataxia-telangiectasia; DNA damage; CD40; Biology; Gene; DNA repair; Chronic lymphocytic leukemia; Phosphorylation; Cancer research; Molecular biology; DNA; In vitro; Cell biology; Immunology; Genetics; Leukemia","score_opus":0.027885966507372555,"score_gpt":0.3332748335227997,"score_spread":0.3053888670154271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890395064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968694,0.00090550474,0.0006785277,0.0003425586,0.00007704218,0.00039974702,0.000015646678,0.00004613011,0.00066544785],"genre_scores_gemma":[0.9934413,0.000082586295,0.006009009,0.000025705582,0.0002008951,0.000013573176,0.000038177845,0.000020044095,0.00016874573],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99830025,0.00017415461,0.00048094706,0.00030399274,0.00047538913,0.00026528563],"domain_scores_gemma":[0.9987248,0.000554512,0.0001456281,0.00024595816,0.00025325734,0.00007582946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076090934,0.00014153484,0.0002737066,0.00027935763,0.000083355095,0.000013062469,0.000103583414,0.00011669411,0.00013825692],"category_scores_gemma":[0.00045030483,0.00013118966,0.000053251104,0.0006274736,0.00022071424,0.00033648626,0.000031624983,0.00010913265,0.000014138356],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004778073,0.00032629466,0.022248026,0.00019980011,0.00008830494,0.000037186037,0.0011897794,0.0024224813,0.9630625,0.0005870047,0.00001578619,0.005044725],"study_design_scores_gemma":[0.019942729,0.0007802253,0.51600266,0.00047902064,0.00013170774,0.00008555002,0.00012576926,0.09860548,0.36007997,0.002494816,0.0010287551,0.00024335214],"about_ca_topic_score_codex":0.00009587914,"about_ca_topic_score_gemma":0.00013629824,"teacher_disagreement_score":0.6029826,"about_ca_system_score_codex":0.0005759479,"about_ca_system_score_gemma":0.0016573318,"threshold_uncertainty_score":0.53497595},"labels":[],"label_agreement":null},{"id":"W2891361422","doi":"10.1097/dad.0000000000001253","title":"Pretibial Lymphoplasmacytic Plaque in Children: Case Report and Review of the Literature","year":2018,"lang":"en","type":"review","venue":"American Journal of Dermatopathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Epidermolytic hyperkeratosis; Hyperkeratosis; Medicine; Dermatology; Dermis; Pathology","score_opus":0.012739258903682818,"score_gpt":0.3389486124830314,"score_spread":0.32620935357934855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891361422","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027966378,0.97063535,0.0000024315334,0.00023682,0.00019196673,0.0008363613,0.000021969197,0.0000043724635,0.00010436921],"genre_scores_gemma":[0.0027115513,0.99616194,0.00025434676,0.00045894814,0.00029362694,0.000013039126,0.000012991371,0.00004893201,0.00004460392],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9956856,0.0010308346,0.0021001447,0.0003497193,0.00046618257,0.00036756494],"domain_scores_gemma":[0.99543107,0.0003463007,0.002839493,0.0008206946,0.0003613355,0.00020108552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013827594,0.0003735751,0.0035137848,0.00043347102,0.000037995276,0.000013729716,0.00036537717,0.00023174663,0.000018909697],"category_scores_gemma":[0.0013514118,0.00021450562,0.00063703273,0.0010499432,0.0012816228,0.00006345254,0.00023902571,0.0010546058,0.0000037706561],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001090492,0.0001571863,0.0030710767,0.10782442,0.00041382448,0.60919744,0.0004450899,1.1610657e-7,8.092915e-7,0.000014947627,0.002387703,0.27637833],"study_design_scores_gemma":[0.0014800378,0.0003242298,0.000050337898,0.1625909,0.0008712527,0.78759456,0.00001838391,0.0000017401189,0.0000029717971,0.0000053333356,0.046938572,0.00012166907],"about_ca_topic_score_codex":0.000045130113,"about_ca_topic_score_gemma":0.00000477867,"teacher_disagreement_score":0.27625665,"about_ca_system_score_codex":0.0023979316,"about_ca_system_score_gemma":0.012756241,"threshold_uncertainty_score":0.9928405},"labels":[],"label_agreement":null},{"id":"W2891505869","doi":"10.1136/jnnp-2018-abn.83","title":"THUR 178 Infections during grade 3/4 lymphopenia with cladribine tablets","year":2018,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Cladribine; Medicine; Internal medicine; Incidence (geometry); Pharyngitis; Respiratory tract infections; Placebo; Cohort; Gastroenterology; Respiratory system; Pathology","score_opus":0.013095152578542936,"score_gpt":0.27729753316486155,"score_spread":0.2642023805863186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891505869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812989,0.00029528467,0.000040098694,0.012775804,0.0043290085,0.00026476613,0.0000039299093,0.00006940974,0.0009227681],"genre_scores_gemma":[0.9901191,0.00024913935,0.00021677716,0.005856734,0.0029943292,0.00000786157,0.000002032665,0.00009891193,0.00045511196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966678,0.0002734085,0.0009893827,0.00048347792,0.0007759485,0.0008100086],"domain_scores_gemma":[0.99734426,0.00030467036,0.0006538594,0.0006853029,0.00049701973,0.00051491545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049078686,0.00035036798,0.0007934705,0.00078122475,0.00029911293,0.000051527717,0.00030454682,0.000237834,0.00027634425],"category_scores_gemma":[0.0003007604,0.00026560863,0.0003232635,0.0009187972,0.00058092317,0.0003022675,0.000118108095,0.0011843968,0.00008691449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013879195,0.0024932825,0.87738585,0.00032982693,0.0006370552,0.00904578,0.00015596475,0.00016864268,0.04714597,0.00017941718,0.048209976,0.000369048],"study_design_scores_gemma":[0.032583885,0.012957633,0.65089196,0.00031578468,0.00049295166,0.26541033,0.000026732869,0.0005070302,0.004036113,0.00026363283,0.0319968,0.0005171742],"about_ca_topic_score_codex":0.000030819763,"about_ca_topic_score_gemma":0.000046214016,"teacher_disagreement_score":0.25636455,"about_ca_system_score_codex":0.0005905166,"about_ca_system_score_gemma":0.0059759403,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W2891622817","doi":"10.3389/fonc.2018.00411","title":"Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes","year":2018,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Faculty of Medicine, McGill University; McGill University; Leukemia and Lymphoma Society","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Cancer research; Beta oxidation; Glutaminolysis; Idelalisib; Biochemistry; Leukemia; Pharmacology; Medicine; Metabolism; Tyrosine kinase; Chemistry; Biology; Glycolysis; Signal transduction; Immunology","score_opus":0.016339792502449157,"score_gpt":0.3192178389115551,"score_spread":0.3028780464091059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891622817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98490673,0.0014139556,0.00067707634,0.0009128567,0.00076756196,0.0006273009,0.000021622862,0.00003195191,0.010640964],"genre_scores_gemma":[0.9647927,0.00034565188,0.031259105,0.00096715055,0.00034380073,0.00007081712,0.000115323994,0.000040721912,0.0020646947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99766064,0.00025558507,0.0006526189,0.00052219495,0.00038547473,0.0005235061],"domain_scores_gemma":[0.99883115,0.0001082016,0.00019378756,0.0005427636,0.00017114406,0.00015297566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000775842,0.00017886878,0.00068694586,0.00039493662,0.000037657104,0.0000075734397,0.00026444488,0.000407066,0.00013438881],"category_scores_gemma":[0.000386573,0.00017921133,0.00005464677,0.00061339274,0.00065274216,0.00017158892,0.00010103902,0.00025785362,0.000020251364],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0093355095,0.001141535,0.026378198,0.00046296246,0.00007700622,0.00017765681,0.0038342227,0.000002008894,0.5069139,0.00004773364,0.41980666,0.03182261],"study_design_scores_gemma":[0.042458616,0.0028719695,0.014891268,0.00034775306,0.00003908547,0.000056828296,0.0011348124,0.0024135003,0.87032145,0.0005572988,0.06456298,0.00034443557],"about_ca_topic_score_codex":0.00033461116,"about_ca_topic_score_gemma":0.00029612365,"teacher_disagreement_score":0.36340755,"about_ca_system_score_codex":0.02625325,"about_ca_system_score_gemma":0.007964964,"threshold_uncertainty_score":0.99765897},"labels":[],"label_agreement":null},{"id":"W2891759256","doi":"10.1200/jco.2017.35.15_suppl.7503","title":"A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Chemoimmunotherapy; Fludarabine; Internal medicine; Chronic lymphocytic leukemia; Rituximab; Cyclophosphamide; Obinutuzumab; Gastroenterology; Randomized controlled trial; Interim analysis; Regimen; IGHV@; Lenalidomide; Oncology; Leukemia; Surgery; Multiple myeloma; Chemotherapy; Lymphoma","score_opus":0.07279910882673507,"score_gpt":0.4713194874257098,"score_spread":0.3985203785989747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891759256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935566,0.0020219686,0.00017641677,0.00051674835,0.0010091253,0.0020026295,0.00006388167,0.000020771906,0.0006318291],"genre_scores_gemma":[0.98623145,0.011791907,0.00089772185,0.000090882546,0.00065610243,0.000072892704,0.000023937588,0.000050047463,0.00018508275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9889201,0.002043729,0.0067476113,0.0006991147,0.0009807827,0.0006086541],"domain_scores_gemma":[0.98093325,0.010044524,0.006587461,0.0011467705,0.0006476012,0.00064036535],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0072377343,0.0004380643,0.004731849,0.0003508097,0.00020490932,0.00008046897,0.00084857055,0.0007011069,0.00013392842],"category_scores_gemma":[0.018681917,0.000324392,0.0006077441,0.0002620659,0.001546111,0.000316914,0.0003219294,0.0016739517,0.000014394248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7127039,0.013985381,0.036998726,0.0006045661,0.008268531,0.0059980312,0.0036564544,0.0029087279,0.0036526306,0.0001813233,0.0016177465,0.20942397],"study_design_scores_gemma":[0.7613896,0.015435393,0.09068237,0.0010103051,0.0016689403,0.00014631043,0.00030079982,0.12818252,0.00009771506,0.00067732227,0.00017614829,0.00023257421],"about_ca_topic_score_codex":0.029818105,"about_ca_topic_score_gemma":0.012481467,"teacher_disagreement_score":0.2091914,"about_ca_system_score_codex":0.03900868,"about_ca_system_score_gemma":0.049037367,"threshold_uncertainty_score":0.9999208},"labels":[],"label_agreement":null},{"id":"W2892188128","doi":"10.1200/jco.2017.35.15_suppl.e19037","title":"Cost burden of first-line antineoplastic treatment failure in patients with chronic lymphocytic leukemia.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Fludarabine; Rituximab; Internal medicine; Cyclophosphamide; Confidence interval; Regimen; Surgery; Lymphoma; Gastroenterology; Leukemia; Oncology; Chemotherapy","score_opus":0.09444569567659457,"score_gpt":0.43694260700121706,"score_spread":0.3424969113246225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892188128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965872,0.00016239528,0.00005229124,0.0013247716,0.00045854226,0.0006046248,0.0000074652303,0.000006272862,0.0007964438],"genre_scores_gemma":[0.99694806,0.00070954754,0.0007932864,0.00006870854,0.0010749922,0.000009075715,0.00000648651,0.000031617517,0.00035822357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958349,0.00019539215,0.0024388656,0.00029445317,0.00076272705,0.00047367765],"domain_scores_gemma":[0.9930772,0.0022950708,0.0026994331,0.0007199166,0.00073874195,0.00046962034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015144715,0.00024007366,0.0022249206,0.00022974936,0.00008681816,0.000019387891,0.0004703516,0.00045269637,0.0001525346],"category_scores_gemma":[0.0056497403,0.00014770651,0.0003669579,0.00012832586,0.00067927106,0.00017701201,0.00013724476,0.0006831325,0.000028589859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03669617,0.002711879,0.80063456,0.0004612312,0.0014319521,0.004473897,0.00032982233,0.008819036,0.00003139349,0.000034858596,0.0014712987,0.14290388],"study_design_scores_gemma":[0.34453294,0.08282412,0.52677155,0.0014193174,0.00072311575,0.00055304286,0.000065100074,0.01920913,0.00016555356,0.000045930894,0.023446204,0.00024402587],"about_ca_topic_score_codex":0.00132475,"about_ca_topic_score_gemma":0.0028361278,"teacher_disagreement_score":0.30783677,"about_ca_system_score_codex":0.059145015,"about_ca_system_score_gemma":0.08177311,"threshold_uncertainty_score":0.94446677},"labels":[],"label_agreement":null},{"id":"W2892935322","doi":"10.18632/oncotarget.26173","title":"Functional characterization of phospholipase C-γ2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder","year":2018,"lang":"en","type":"article","venue":"Oncotarget","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"International Graduate School in Molecular Medicine Ulm; Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg; Deutsche Forschungsgemeinschaft","keywords":"Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Mutation; Mutant; Germline mutation; LYN; Cancer research; Immune system; Biology; Somatic cell; Signal transduction; Immunology; Tyrosine kinase; Leukemia; Cell biology; Genetics; Gene","score_opus":0.013599425650405199,"score_gpt":0.26183221404562634,"score_spread":0.24823278839522114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892935322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964069,0.00039401784,0.0012962695,0.00044767058,0.00010870147,0.00081455533,0.00003130603,0.00006487348,0.0004356973],"genre_scores_gemma":[0.9938826,0.000044130236,0.0014272005,0.00010769089,0.00034134765,0.00006365002,0.000109856715,0.00004594891,0.0039775786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982013,0.000060889357,0.0004940494,0.00036110176,0.000522118,0.0003605244],"domain_scores_gemma":[0.99894124,0.000050306146,0.00021667258,0.00041006983,0.00021086606,0.00017082918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036630384,0.0001923985,0.0003699239,0.00012546693,0.00013264905,0.00002218657,0.00006226445,0.000115552546,0.00062727375],"category_scores_gemma":[0.0001984137,0.0001710734,0.00006899703,0.0002852685,0.00033483494,0.00014734562,0.000082752704,0.00015258048,0.00004294417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013079653,0.0002348641,0.0043243477,0.0008448305,0.0001159208,0.00011080445,0.0006933172,0.0000023599584,0.9911173,0.00029559212,0.00031204906,0.00064065977],"study_design_scores_gemma":[0.04631395,0.0012313375,0.27248636,0.0028047606,0.0003399565,0.00061295606,0.00024109875,0.07176768,0.5629972,0.0008779869,0.03928238,0.0010442778],"about_ca_topic_score_codex":0.00011294809,"about_ca_topic_score_gemma":0.0000663427,"teacher_disagreement_score":0.42812005,"about_ca_system_score_codex":0.0015169872,"about_ca_system_score_gemma":0.0028531079,"threshold_uncertainty_score":0.69761705},"labels":[],"label_agreement":null},{"id":"W2893082622","doi":"10.1200/jco.2018.36.30_suppl.103","title":"Impact of novel chronic lymphocytic leukemia drugs on public spending.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Ibrutinib; Chronic lymphocytic leukemia; Bendamustine; Obinutuzumab; Population; Ofatumumab; Rituximab; Fludarabine; Alemtuzumab; Leukemia; Internal medicine; Lymphoma; Environmental health; Chemotherapy; Cyclophosphamide; Transplantation","score_opus":0.20370372919790636,"score_gpt":0.5267540615955266,"score_spread":0.32305033239762027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893082622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774703,0.00026832276,0.00017972302,0.0008007379,0.00139779,0.00026725416,0.0000059815916,0.000017406386,0.019592501],"genre_scores_gemma":[0.9917003,0.00040788503,0.0011969771,0.00053658546,0.0054447493,0.0000023469195,0.0000028941347,0.000044815308,0.0006634512],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99396384,0.0003568822,0.0033949728,0.0003496933,0.0012110345,0.00072355627],"domain_scores_gemma":[0.9903282,0.004254339,0.002472127,0.0006411507,0.001266577,0.0010375958],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060484237,0.00026356432,0.0022928643,0.0005158837,0.00006207722,0.000019171148,0.0005927977,0.0006961295,0.0012170207],"category_scores_gemma":[0.011221144,0.00017353872,0.001400399,0.0005218619,0.001280817,0.00019279693,0.00018267054,0.00133358,0.0002471015],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07122121,0.011009452,0.043330785,0.0007152035,0.010109826,0.0043738517,0.0010431847,0.0011195021,0.013855709,0.0043698344,0.07535419,0.76349723],"study_design_scores_gemma":[0.34526855,0.33825624,0.1600677,0.0014309555,0.0011216026,0.009913634,0.00020994946,0.069058664,0.0024081469,0.00045960705,0.07112891,0.00067602476],"about_ca_topic_score_codex":0.00036119457,"about_ca_topic_score_gemma":0.00005036174,"teacher_disagreement_score":0.7628212,"about_ca_system_score_codex":0.14322068,"about_ca_system_score_gemma":0.25077146,"threshold_uncertainty_score":0.999696},"labels":[],"label_agreement":null},{"id":"W2893126727","doi":"10.1016/j.onsig.2018.09.003","title":"Novel agents in the Canadian therapeutic landscape of chronic lymphocytic leukemia","year":2018,"lang":"en","type":"article","venue":"Oncology Signaling","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Chronic lymphocytic leukemia; Leukemia; Medicine; Geography; Immunology","score_opus":0.06879930201465993,"score_gpt":0.3630973748410522,"score_spread":0.29429807282639225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893126727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605852,0.00083667913,0.00014332347,0.0006128481,0.00024911863,0.00065629,0.0000058568085,0.000023913637,0.036886804],"genre_scores_gemma":[0.9969625,0.000029326357,0.00021045182,0.0018880381,0.0004930424,0.000037059403,0.000014058025,0.000026354393,0.00033917747],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980884,0.00014080747,0.0003884995,0.00029405265,0.00041853386,0.00066967297],"domain_scores_gemma":[0.99869925,0.00040119325,0.00010206546,0.00045382555,0.00016069024,0.0001829857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012029799,0.0001603686,0.0003823422,0.00033237055,0.00015344437,0.000017390443,0.00038463797,0.00027339673,0.0007333534],"category_scores_gemma":[0.00014457105,0.00011485188,0.00008527624,0.00058656785,0.00045162102,0.00004511415,0.000049180926,0.00032960685,0.00011239723],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0063928636,0.0021725346,0.044307016,0.0029933716,0.0034816253,0.009551357,0.06597726,0.016431605,0.61877835,0.012319548,0.039356712,0.17823775],"study_design_scores_gemma":[0.10985371,0.009316006,0.022947097,0.0011899669,0.0007094576,0.0055016996,0.0034252536,0.66177285,0.033596702,0.0008069418,0.14986597,0.0010143616],"about_ca_topic_score_codex":0.15566215,"about_ca_topic_score_gemma":0.2862043,"teacher_disagreement_score":0.6453412,"about_ca_system_score_codex":0.11034076,"about_ca_system_score_gemma":0.108592294,"threshold_uncertainty_score":0.8964612},"labels":[],"label_agreement":null},{"id":"W2893349526","doi":"10.1101/430223","title":"A novel nonsense variant in <i>SUPT20H</i> gene associated with Rheumatoid Arthritis identified by Whole Exome Sequencing of multiplex families","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Exome sequencing; Pedigree chart; Genetics; Multiplex; Rheumatoid arthritis; Biology; Gene; Genetic association; Disease; Single-nucleotide polymorphism; Medicine; Immunology; Genotype; Mutation; Internal medicine","score_opus":0.02026162600198982,"score_gpt":0.23735783457228635,"score_spread":0.21709620857029652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893349526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930657,0.001981471,0.0011592663,0.00009138706,0.0004019757,0.0017959577,0.0011984549,0.00028236426,0.000023403536],"genre_scores_gemma":[0.9927771,0.0013736481,0.0049634534,0.00013512226,0.00015301704,0.00028573393,0.000010308989,0.00027574837,0.000025851565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99411327,0.0002328433,0.0014231786,0.0015877021,0.001418335,0.0012246848],"domain_scores_gemma":[0.9948802,0.000352169,0.0008577221,0.0020269002,0.0013935354,0.00048949197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017723902,0.0008581296,0.001765361,0.0007434556,0.00013393017,0.00015215186,0.0006095596,0.0009727361,0.000050599072],"category_scores_gemma":[0.0017686869,0.0008596779,0.0002220984,0.0013372774,0.0007033334,0.00018627579,0.0007152294,0.0012602513,0.000052580268],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004315419,0.0005657755,0.002280274,0.00071643846,0.00059275713,0.0014512264,0.000112872396,0.000105158295,0.9931097,0.00001817216,0.0006140973,0.0000020059902],"study_design_scores_gemma":[0.035828482,0.00045503568,0.02761635,0.013566315,0.00019246005,0.0000066219027,0.00006065868,0.012768087,0.90728295,0.0000018808096,0.0005584827,0.0016626688],"about_ca_topic_score_codex":0.0041196677,"about_ca_topic_score_gemma":0.00029537146,"teacher_disagreement_score":0.085826725,"about_ca_system_score_codex":0.012748099,"about_ca_system_score_gemma":0.016964424,"threshold_uncertainty_score":0.9993854},"labels":[],"label_agreement":null},{"id":"W2894619040","doi":"10.1038/s41467-018-06541-2","title":"Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"Common Fund; National Institute of Neurological Disorders and Stroke; NIH Office of the Director; National Heart, Lung, and Blood Institute; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Institute on Drug Abuse; National Human Genome Research Institute; World Health Organization","keywords":"Waldenstrom macroglobulinemia; Lymphoplasmacytic Lymphoma; Genome-wide association study; Allele; Biology; Genetics; Lymphoma; Macroglobulinemia; Medicine; Cancer research; Immunology; Gene; Single-nucleotide polymorphism; Genotype; Multiple myeloma","score_opus":0.02349356866043923,"score_gpt":0.36491002297455466,"score_spread":0.34141645431411544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894619040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779052,0.0065887347,0.00013206246,0.008473923,0.00018740646,0.0014988357,0.00023632022,0.00016863408,0.0048088436],"genre_scores_gemma":[0.97061586,0.0015256688,0.02460692,0.0006753385,0.0003760801,0.000108542714,0.00033699826,0.00004115838,0.001713401],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982909,0.00015564472,0.0003482187,0.00043916857,0.00033602864,0.00043004824],"domain_scores_gemma":[0.99445736,0.000961103,0.00012737933,0.003450673,0.0007428554,0.00026064087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066131545,0.0002032571,0.00033369628,0.000096192285,0.0007103476,0.000037622733,0.0007353599,0.00041761252,0.00017987029],"category_scores_gemma":[0.0014051516,0.00017649712,0.00011365569,0.00032901336,0.0011697444,0.0000889491,0.0010159082,0.0010503725,0.00011752986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005839154,0.002828989,0.22169276,0.001371323,0.001916669,0.000062370425,0.0056219795,0.000019111812,0.027662635,0.08016661,0.53962,0.113198414],"study_design_scores_gemma":[0.06963711,0.0019490648,0.095162064,0.0003307233,0.0012059473,0.0009743652,0.00068699237,0.05618539,0.017807163,0.006116952,0.74871284,0.0012313793],"about_ca_topic_score_codex":0.0012234639,"about_ca_topic_score_gemma":0.014356444,"teacher_disagreement_score":0.20909287,"about_ca_system_score_codex":0.0046374793,"about_ca_system_score_gemma":0.0014074818,"threshold_uncertainty_score":0.99918354},"labels":[],"label_agreement":null},{"id":"W2896048754","doi":"10.1016/j.cancergen.2018.07.004","title":"Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia","year":2018,"lang":"en","type":"review","venue":"Cancer Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"","keywords":"Loss of heterozygosity; Copy-number variation; Chronic lymphocytic leukemia; Biology; Cytogenetics; Copy number analysis; Comparative genomic hybridization; Karyotype; Genetics; Genome; Genomics; Leukemia; Computational biology; Chromosome; Gene; Allele","score_opus":0.17772086348950072,"score_gpt":0.4850319953298319,"score_spread":0.30731113184033115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896048754","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018304396,0.97307646,0.00043824108,0.0004717819,0.0009326757,0.006097286,0.00058657874,0.00004363119,0.00004894614],"genre_scores_gemma":[0.0049569476,0.98558694,0.0014099629,0.0018750137,0.0032964502,0.002178384,0.0003561959,0.0002410902,0.00009902362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940991,0.00078946556,0.0016906101,0.0014098614,0.0008461937,0.0011647595],"domain_scores_gemma":[0.99050725,0.004197102,0.0016924907,0.0023214023,0.0008617116,0.00042005992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020271346,0.00091536756,0.0023885488,0.00005796627,0.0008728608,0.00052152236,0.001320863,0.00058691384,0.00022072726],"category_scores_gemma":[0.0008548413,0.00060198986,0.0006246267,0.0006792654,0.0018113755,0.00034116962,0.00043565963,0.00094357866,0.000040431285],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009824892,0.00031779494,0.0010262147,0.19621505,0.005652871,0.0001878167,0.0025150103,0.0020785674,0.00035629145,0.000100863115,0.0068475446,0.7837195],"study_design_scores_gemma":[0.004073628,0.0003855039,0.00007585443,0.114871286,0.010227091,0.00034191276,0.000154492,0.0028148312,0.00014940916,0.000019646604,0.86612374,0.0007626344],"about_ca_topic_score_codex":0.007589304,"about_ca_topic_score_gemma":0.0029045083,"teacher_disagreement_score":0.8592762,"about_ca_system_score_codex":0.088069476,"about_ca_system_score_gemma":0.1066225,"threshold_uncertainty_score":0.99964315},"labels":[],"label_agreement":null},{"id":"W2896444571","doi":"10.1038/s41419-018-1122-8","title":"BTK: a two-faced effector in cancer and tumour suppression","year":2018,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Bruton's tyrosine kinase; Biology; Suppressor; Tyrosine kinase; Effector; Context (archaeology); Cancer research; Cancer; Gene; Cancer cell; Phenotype; Organism; Signal transduction; Genetics; Cell biology","score_opus":0.017650878871540775,"score_gpt":0.3236118944351496,"score_spread":0.30596101556360883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896444571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931092,0.0045393556,0.000007016578,0.00022104506,0.000066006556,0.000377556,0.00001817155,0.000021073887,0.0016405621],"genre_scores_gemma":[0.9977915,0.00025384952,0.000043280004,0.00031322558,0.00020115077,0.000045273242,0.000012679908,0.000014678528,0.0013243414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991329,0.000032815482,0.00010139231,0.00027803276,0.0001729813,0.00028190395],"domain_scores_gemma":[0.9988658,0.00006698581,0.000017469232,0.0001760152,0.000036433357,0.0008373344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092920156,0.00010974163,0.00015916803,0.000071992785,0.000052527495,0.000021344269,0.000039166443,0.0000370083,0.00020187946],"category_scores_gemma":[0.0001413039,0.00008252084,0.000024039819,0.00008440822,0.00011018328,0.00004678905,0.00008256015,0.000086111664,0.000035213652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014199378,0.001089527,0.79295844,0.0048182104,0.00006927327,0.0035748128,0.0016285405,0.000011563038,0.14104173,0.00020845268,0.02178382,0.018616255],"study_design_scores_gemma":[0.12088301,0.0009883229,0.7425921,0.0015001363,0.0004169385,0.00007644645,0.00013352172,0.075657785,0.049059987,0.0006608462,0.007343196,0.00068771036],"about_ca_topic_score_codex":0.0006899283,"about_ca_topic_score_gemma":0.000043275493,"teacher_disagreement_score":0.106683634,"about_ca_system_score_codex":0.0006745524,"about_ca_system_score_gemma":0.0017704878,"threshold_uncertainty_score":0.3365102},"labels":[],"label_agreement":null},{"id":"W2897636215","doi":"10.1038/s41375-018-0276-9","title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; Juravinski Cancer Centre","funders":"Cilag; Pharmacyclics; H. Lundbeck A/S; Astellas Pharma; Genentech; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Amgen","keywords":"Ibrutinib; Bendamustine; Chronic lymphocytic leukemia; Medicine; Internal medicine; Rituximab; Placebo; Ofatumumab; Hazard ratio; Alemtuzumab; Oncology; Lymphoma; Gastroenterology; Leukemia; Confidence interval; Pathology; Transplantation","score_opus":0.028886440725654154,"score_gpt":0.30821709139374126,"score_spread":0.2793306506680871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897636215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925456,0.0016674206,0.00002037401,0.00016052242,0.00048921595,0.002681098,0.00021517466,0.000220651,0.0019999542],"genre_scores_gemma":[0.9961321,0.00022022484,0.00031031598,0.00051692955,0.0012633805,0.0001337467,0.00029646876,0.00015909976,0.00096778624],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928102,0.00053502916,0.0021088044,0.0017081039,0.0013602886,0.0014775834],"domain_scores_gemma":[0.9942147,0.0015408251,0.00060491805,0.0026074995,0.000495976,0.0005360444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015566128,0.0008259388,0.0015522422,0.00053817633,0.00034692814,0.00011083432,0.001005819,0.00053555856,0.00022436457],"category_scores_gemma":[0.0016450346,0.00063748844,0.00020370242,0.0020089922,0.0012109004,0.00018138018,0.0007392572,0.0005778529,0.00029582172],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.26623288,0.024149688,0.010826034,0.0040389425,0.008905026,0.023508757,0.1291145,0.006705713,0.08028851,0.0009821561,0.0889323,0.35631552],"study_design_scores_gemma":[0.6766621,0.006310464,0.007347339,0.00115829,0.0006688796,0.00071190775,0.003499911,0.28488412,0.014078563,0.00011478026,0.0036811894,0.000882435],"about_ca_topic_score_codex":0.059127003,"about_ca_topic_score_gemma":0.0068889423,"teacher_disagreement_score":0.41042924,"about_ca_system_score_codex":0.18189262,"about_ca_system_score_gemma":0.07704456,"threshold_uncertainty_score":0.9996076},"labels":[],"label_agreement":null},{"id":"W2898630421","doi":"10.1182/blood-2018-99-116653","title":"Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Bendamustine; Ibrutinib; Rituximab; Chronic lymphocytic leukemia; Medicine; Alemtuzumab; Internal medicine; Progression-free survival; Ofatumumab; Oncology; Leukemia; Chemotherapy; Lymphoma; Transplantation","score_opus":0.015088365161569457,"score_gpt":0.28321230479839604,"score_spread":0.26812393963682657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898630421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941559,0.00012142425,0.0000097424945,0.00008242469,0.000055662375,0.005262557,0.0000881128,0.00012358812,0.00010060708],"genre_scores_gemma":[0.997843,0.000026003534,0.0010121382,0.0000226396,0.00011184749,0.00035358555,0.00039008763,0.00012206893,0.00011862419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99421686,0.0003398221,0.0011809333,0.0013463766,0.0018895583,0.0010264532],"domain_scores_gemma":[0.99652445,0.00025554237,0.000626656,0.0013984322,0.00092935486,0.0002655399],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005935934,0.00064985885,0.0016697085,0.0004765805,0.000119943565,0.000057412704,0.0005855362,0.00010676646,0.000026682852],"category_scores_gemma":[0.00038938902,0.00041295405,0.00004720693,0.00307277,0.0011836968,0.00031447338,0.00028086343,0.0004654059,0.000013846219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11677639,0.031022672,0.83754015,0.0010981411,0.0007426205,0.0014925553,0.006924835,0.00028087257,0.00015103687,0.0000022893278,0.00008687483,0.0038815464],"study_design_scores_gemma":[0.46542075,0.022792073,0.5010086,0.002364865,0.00027321395,0.00007660372,0.00089506083,0.0042370316,0.0024929193,4.4641357e-7,0.000016010106,0.0004223955],"about_ca_topic_score_codex":0.015444949,"about_ca_topic_score_gemma":0.1463584,"teacher_disagreement_score":0.34864435,"about_ca_system_score_codex":0.020005558,"about_ca_system_score_gemma":0.016458005,"threshold_uncertainty_score":0.9998322},"labels":[],"label_agreement":null},{"id":"W2899435684","doi":"10.3747/co.25.4092","title":"Canadian Evidence-Based Guideline for the First-Line Treatment of Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Leukemia & Lymphoma Society of Canada; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Toronto; McGill University; University of British Columbia; Jewish General Hospital; CancerCare Manitoba; Princess Margaret Cancer Centre; BC Cancer Agency; Foothills Medical Centre","funders":"H. Lundbeck A/S; CancerCare Manitoba Foundation; AstraZeneca; Celgene; Gilead Sciences; Research Manitoba; Pfizer","keywords":"Guideline; Chronic lymphocytic leukemia; Medicine; Front line; Family medicine; First line treatment; Leukemia; Intensive care medicine; Immunology; Pathology; Internal medicine; Chemotherapy; Political science","score_opus":0.20396673997641163,"score_gpt":0.456137416102449,"score_spread":0.2521706761260374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899435684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65853775,0.20168722,0.024708752,0.0746615,0.014659125,0.020865496,0.00046966982,0.00040112968,0.004009394],"genre_scores_gemma":[0.9911124,0.0030000352,0.000467811,0.00085236377,0.0032802853,0.00058084994,0.00009196644,0.000049368522,0.0005649297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767756,0.000065710636,0.00069958647,0.00043648455,0.0003323808,0.00078824547],"domain_scores_gemma":[0.99646133,0.001401249,0.0001871871,0.0008403738,0.00071337767,0.0003964864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059736386,0.00025726648,0.00058902527,0.0002458183,0.00023060928,0.000011994185,0.00033296226,0.00019445151,0.00062576635],"category_scores_gemma":[0.0007644495,0.00016433999,0.00024913973,0.0003628428,0.00061260175,0.000048542523,0.00004585471,0.000113138,0.00013175735],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0027365813,0.0004967355,0.00095982716,0.0008474853,0.00042167006,0.00009549827,0.00058283313,0.0020371992,0.00042197772,0.00033165916,0.12016518,0.8709034],"study_design_scores_gemma":[0.018312426,0.008452949,0.00009409994,0.00026414645,0.0002732841,0.000066446344,0.000023932218,0.33825293,0.0033971483,0.000039817955,0.63071656,0.00010623991],"about_ca_topic_score_codex":0.08767787,"about_ca_topic_score_gemma":0.21252802,"teacher_disagreement_score":0.8707971,"about_ca_system_score_codex":0.3577668,"about_ca_system_score_gemma":0.2139715,"threshold_uncertainty_score":0.91839737},"labels":[],"label_agreement":null},{"id":"W2899509505","doi":"10.1182/blood-2018-99-111178","title":"Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Ibrutinib; Waldenstrom macroglobulinemia; Macroglobulinemia; Lymphoplasmacytic Lymphoma; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Leukemia; Lymphoma; Multiple myeloma","score_opus":0.026874480907454215,"score_gpt":0.31492963179554817,"score_spread":0.28805515088809397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899509505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522847,0.00049852795,0.0000020566079,0.00091310975,0.00015257744,0.0015992128,0.000025448342,0.00005341321,0.0015272131],"genre_scores_gemma":[0.99792695,0.000101353486,0.0001592895,0.00020896891,0.0005927397,0.00005422003,0.00003022912,0.000030560226,0.00089568953],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998146,0.00011726117,0.00039815297,0.0004883039,0.0004031354,0.00044717285],"domain_scores_gemma":[0.99853027,0.00044476148,0.000058343026,0.00073057495,0.000102174796,0.0001338627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035202582,0.0002286227,0.00039888328,0.000071352355,0.00013168693,0.000041111933,0.00018223074,0.0001154793,0.00018543302],"category_scores_gemma":[0.00028730012,0.00013864775,0.000049734816,0.0004642784,0.00024556302,0.000037345442,0.0001956274,0.00022591537,0.00013019628],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0150307,0.028667048,0.6975386,0.000120073804,0.0038918196,0.007257536,0.037429113,0.0000026298876,0.010464706,0.00025949767,0.004575768,0.19476251],"study_design_scores_gemma":[0.54212385,0.0059255627,0.41816458,0.0002715816,0.00088336,0.00050869293,0.0029839454,0.00037148793,0.015352087,0.00009494453,0.012885643,0.00043425054],"about_ca_topic_score_codex":0.004626158,"about_ca_topic_score_gemma":0.0019194622,"teacher_disagreement_score":0.5270932,"about_ca_system_score_codex":0.0017409953,"about_ca_system_score_gemma":0.0017889597,"threshold_uncertainty_score":0.6993398},"labels":[],"label_agreement":null},{"id":"W2900694112","doi":"10.1182/blood-2018-99-111370","title":"Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Leukemia; Lymphoma; Internal medicine; Immunology; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.03171698714767747,"score_gpt":0.29276020909419587,"score_spread":0.2610432219465184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900694112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99100083,0.0006458098,0.000012298533,0.000093268354,0.00074602145,0.0034723233,0.0006863021,0.0004402138,0.0029029492],"genre_scores_gemma":[0.9908353,0.0005935496,0.00061071827,0.00019160527,0.0014362676,0.0004358528,0.0017423909,0.00031878636,0.0038354986],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9913085,0.00022510189,0.0016572088,0.0025048757,0.0018181056,0.0024862122],"domain_scores_gemma":[0.99340546,0.0011470674,0.0006073911,0.0029827524,0.00070611556,0.0011511964],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00048775505,0.0014467918,0.0018579848,0.00069833343,0.000454756,0.00019373377,0.0009058167,0.0007159953,0.0007287654],"category_scores_gemma":[0.0011759166,0.0010863263,0.0003704342,0.0017608728,0.0011222757,0.00036093718,0.0004337639,0.00033414437,0.0017145623],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.82278454,0.014051195,0.0012870185,0.0014695206,0.007981084,0.0231413,0.011515362,0.0032265629,0.0008119124,0.00011969569,0.0019773718,0.11163443],"study_design_scores_gemma":[0.8753395,0.043254722,0.002097547,0.0015275715,0.0015997251,0.00042262167,0.00025662416,0.038245484,0.02067786,0.000028435525,0.015115863,0.0014340341],"about_ca_topic_score_codex":0.049968578,"about_ca_topic_score_gemma":0.015612342,"teacher_disagreement_score":0.30989143,"about_ca_system_score_codex":0.5086357,"about_ca_system_score_gemma":0.19874425,"threshold_uncertainty_score":0.99982816},"labels":[],"label_agreement":null},{"id":"W2902460563","doi":"10.1200/jco.18.01580","title":"Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":301,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Genentech; Universiteit van Amsterdam","keywords":"Venetoclax; Rituximab; Bendamustine; Medicine; Internal medicine; Minimal residual disease; Hazard ratio; Gastroenterology; Neutropenia; Refractory (planetary science); Chronic lymphocytic leukemia; Oncology; Leukemia; Chemotherapy; Lymphoma; Confidence interval","score_opus":0.07805887314922061,"score_gpt":0.4367975780317877,"score_spread":0.3587387048825671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902460563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99559176,0.0012424699,0.0000035832252,0.000908493,0.0007902609,0.0013333235,0.000013614474,0.0000078150215,0.00010867601],"genre_scores_gemma":[0.9981108,0.0004722024,0.00010006696,0.00012276307,0.0008873806,0.000024454575,0.000005523119,0.000030434729,0.0002464123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936304,0.0012736486,0.0034248675,0.0003775554,0.0008948582,0.0003986526],"domain_scores_gemma":[0.99300826,0.0029628498,0.0022322387,0.00055836694,0.00078992755,0.00044837888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037409046,0.00025103302,0.001936567,0.0002474426,0.000072063805,0.000009564206,0.00035247672,0.00034986256,0.0000819676],"category_scores_gemma":[0.005897944,0.00015559467,0.0004001611,0.00032041487,0.001258484,0.00012827241,0.00016755996,0.0006178998,0.0000056977556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5912629,0.03890676,0.18919946,0.001143184,0.0066547072,0.005756216,0.012245804,0.00032738905,0.029561553,0.00014227885,0.0020168433,0.12278295],"study_design_scores_gemma":[0.55653477,0.14363213,0.28466958,0.0005452648,0.0019319371,0.00032079703,0.0011278382,0.0073140715,0.0023173841,0.000087644774,0.0013010909,0.0002175033],"about_ca_topic_score_codex":0.0011439183,"about_ca_topic_score_gemma":0.001724289,"teacher_disagreement_score":0.12256545,"about_ca_system_score_codex":0.031943206,"about_ca_system_score_gemma":0.1123347,"threshold_uncertainty_score":0.97177297},"labels":[],"label_agreement":null},{"id":"W2902706178","doi":"10.1016/s1470-2045(18)30788-5","title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":548,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Oncology; Internal medicine; Open label; Chronic lymphocytic leukemia; Venetoclax; Clinical trial; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.16909667303358808,"score_gpt":0.4438783636128727,"score_spread":0.2747816905792846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902706178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97489643,0.0021626754,0.00004799807,0.00088906084,0.0020077615,0.0088682845,0.00008194969,0.00010744956,0.010938382],"genre_scores_gemma":[0.9893438,0.0027869863,0.0003868274,0.0002749316,0.0037095018,0.0011965805,0.0001425422,0.0000967025,0.0020621275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944673,0.0007188064,0.0014329052,0.0009766138,0.00073262904,0.001671737],"domain_scores_gemma":[0.9941512,0.0026550256,0.00060215115,0.001886903,0.0003308876,0.0003738612],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017691832,0.0006341409,0.0029683276,0.00028123695,0.00026910438,0.00006260517,0.0013089008,0.00053417106,0.0010303073],"category_scores_gemma":[0.0011968671,0.00043643895,0.00023671726,0.00086218223,0.001541097,0.00017372638,0.00058961014,0.0004590179,0.00041429565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9694715,0.0012135911,0.0000023895545,0.00030306578,0.0006738472,0.0010633393,0.004450598,0.0011698011,0.00066589244,0.00023992745,0.0030350594,0.017710973],"study_design_scores_gemma":[0.7049532,0.03965658,0.0000034361015,0.00019579119,0.0004312973,0.00025813628,0.00030880637,0.21628615,0.0027620587,0.000051566145,0.034809537,0.00028346633],"about_ca_topic_score_codex":0.013366558,"about_ca_topic_score_gemma":0.009103237,"teacher_disagreement_score":0.3365853,"about_ca_system_score_codex":0.47276327,"about_ca_system_score_gemma":0.13617796,"threshold_uncertainty_score":0.9998829},"labels":[],"label_agreement":null},{"id":"W2902815908","doi":"10.1111/bjh.15690","title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis","year":2018,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Ibrutinib; Medicine; Discontinuation; Internal medicine; Population; Confidence interval; Oncology; Gastroenterology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.014358552172936766,"score_gpt":0.2956627147591522,"score_spread":0.28130416258621543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902815908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987119,0.00022950325,0.0006307192,0.00001610961,0.000024991172,0.00030533466,0.000049925035,0.0000067086457,0.000024810097],"genre_scores_gemma":[0.997635,0.00010331675,0.0021449116,0.000016624128,0.000023136812,0.0000037973757,0.000030858202,0.000017884284,0.000024486106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983623,0.00017686415,0.0006725774,0.00021113917,0.000289935,0.0002872052],"domain_scores_gemma":[0.99789107,0.00031589132,0.0005007411,0.00016948103,0.00093521806,0.00018761728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048339344,0.00012648113,0.0009768814,0.0005433418,0.00005191816,0.000018983606,0.00014516567,0.00013177458,0.00006731237],"category_scores_gemma":[0.0011985861,0.000102028716,0.00010099555,0.0006880989,0.00046253882,0.00015613013,0.000033171385,0.00024318162,6.7284594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024022246,0.0003522683,0.9868171,0.000108026245,0.0008074441,0.0036459253,0.00044870895,0.000009858362,0.000035952347,0.0000074754244,0.00011548926,0.005249476],"study_design_scores_gemma":[0.03870507,0.0080814995,0.9055678,0.0007397735,0.002108035,0.030519549,0.0009509993,0.008337872,0.0046616746,0.000057954145,0.000044683064,0.00022508494],"about_ca_topic_score_codex":0.0052997926,"about_ca_topic_score_gemma":0.004279118,"teacher_disagreement_score":0.08124934,"about_ca_system_score_codex":0.0006141263,"about_ca_system_score_gemma":0.0010455571,"threshold_uncertainty_score":0.8011736},"labels":[],"label_agreement":null},{"id":"W2902851034","doi":"10.7759/cureus.3660","title":"Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review","year":2018,"lang":"en","type":"article","venue":"Cureus","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Leptomeninges; Chronic lymphocytic leukemia; Central nervous system; Autopsy; Lymphoma; Pathology; Subclinical infection; Leukemia; Immunology; Internal medicine","score_opus":0.010172169328329836,"score_gpt":0.27083920394576866,"score_spread":0.26066703461743884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902851034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85268736,0.14245448,0.000025481304,0.000117474556,0.00020352463,0.0015739419,0.000011858094,0.00013618171,0.002789673],"genre_scores_gemma":[0.9915925,0.006558734,0.00026615034,0.00039709985,0.00048186106,0.00015145441,0.000040407787,0.000066021734,0.00044573768],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99708223,0.00010776835,0.0006315438,0.0007338676,0.00058307307,0.00086153334],"domain_scores_gemma":[0.9979307,0.00006960673,0.00018305032,0.0010363183,0.0003070216,0.00047331286],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003624172,0.00035324806,0.00069433387,0.00012795918,0.00011244236,0.00006278125,0.00012933003,0.00021975457,0.000049132686],"category_scores_gemma":[0.00022024314,0.00025338365,0.00008417714,0.0007494091,0.00029025058,0.00016144729,0.00015248157,0.00022350931,0.000028469156],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037333416,0.000048079248,0.00014435068,0.0095958505,0.00010694964,0.9744703,0.0010740701,0.000009901697,0.000052504827,0.00010666753,0.0026513846,0.01136658],"study_design_scores_gemma":[0.011731612,0.0013073321,0.00027668776,0.024290787,0.00017859928,0.9451561,0.00022716193,0.010983143,0.00029681955,0.0000036862332,0.005262914,0.00028518215],"about_ca_topic_score_codex":0.0032898143,"about_ca_topic_score_gemma":0.0013269081,"teacher_disagreement_score":0.13890515,"about_ca_system_score_codex":0.13853124,"about_ca_system_score_gemma":0.02701981,"threshold_uncertainty_score":0.99999183},"labels":[],"label_agreement":null},{"id":"W2902852748","doi":"10.1093/ofid/ofy210.963","title":"1130. Low Risk of Pneumocystis jiroveci Pneumonia in Patients With Waldenstrom’s Macroglobulinemia on Ibrutinib","year":2018,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Macroglobulinemia; Mantle cell lymphoma; Waldenstrom macroglobulinemia; Chronic lymphocytic leukemia; Oncology; Lymphoma; Leukemia; Multiple myeloma","score_opus":0.0048291996816641055,"score_gpt":0.26339800907171207,"score_spread":0.25856880939004795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902852748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98384666,0.000038466675,0.000009634019,0.00013593723,0.00015738921,0.0017932053,0.0003012413,0.000067416986,0.013650048],"genre_scores_gemma":[0.998723,0.000031319683,0.00006607184,0.00031651984,0.00009643625,0.00010157478,0.00011878528,0.00007142179,0.00047489672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972241,0.00012381434,0.00050440966,0.00063016533,0.000784498,0.0007330378],"domain_scores_gemma":[0.99788374,0.00020982647,0.00027449304,0.00090402237,0.00033185096,0.0003960527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001770747,0.0003399558,0.0006560804,0.0002547782,0.00017457278,0.00008806666,0.0004186258,0.00012791016,0.00052065233],"category_scores_gemma":[0.0004792661,0.00026261475,0.00012852064,0.00060766033,0.00043911423,0.0002234194,0.0004116656,0.0002935493,0.00026314598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037668832,0.0019262403,0.9848062,0.00013342242,0.00017375097,0.000093395785,0.000070042166,0.0000485842,0.000073606956,0.0001201532,0.0022474339,0.006540309],"study_design_scores_gemma":[0.03921452,0.0065776743,0.95005536,0.00075198687,0.00020221331,0.00004228165,0.00006204923,0.0006428156,0.0011733549,0.000264782,0.0006640051,0.00034895015],"about_ca_topic_score_codex":0.0025604,"about_ca_topic_score_gemma":0.0009684937,"teacher_disagreement_score":0.03544764,"about_ca_system_score_codex":0.0037516414,"about_ca_system_score_gemma":0.0025972552,"threshold_uncertainty_score":0.9999826},"labels":[],"label_agreement":null},{"id":"W2903424253","doi":"10.1182/blood-2018-99-114842","title":"Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Bendamustine; Common Terminology Criteria for Adverse Events; Regimen; Chemotherapy regimen; Gastroenterology; Clinical endpoint; Follicular lymphoma; Rituximab; Oncology; Surgery; Lymphoma; Cancer; Clinical trial","score_opus":0.014822651330837785,"score_gpt":0.27289593111506094,"score_spread":0.2580732797842232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903424253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969472,0.0003257861,0.000002769797,0.00005534346,0.0000827723,0.0020744605,0.000018947865,0.00004011635,0.00045259634],"genre_scores_gemma":[0.9990465,0.00005271452,0.00005828018,0.00016833191,0.00027381745,0.00003907203,0.000047777175,0.00004874022,0.0002647661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977742,0.00017829628,0.0003758328,0.00053825986,0.0007000571,0.0004333759],"domain_scores_gemma":[0.9982033,0.0004893762,0.00011080068,0.0008697524,0.00013677556,0.00019003321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003157763,0.00024325607,0.00038310513,0.000082544866,0.00013126503,0.00004024893,0.00025344794,0.00011115185,0.00017063208],"category_scores_gemma":[0.00019504216,0.00013447386,0.000029792654,0.0002954521,0.00031137306,0.00008572076,0.00022771196,0.0002313102,0.00008025232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012728877,0.017965209,0.9543579,0.00006323636,0.0002590268,0.00040061455,0.003932341,2.8976322e-7,0.00007973956,8.464964e-7,0.00021513239,0.009996744],"study_design_scores_gemma":[0.25531772,0.0047230264,0.73855925,0.00022976242,0.00017837071,0.000013137453,0.00018917043,0.000015211439,0.0005007468,6.2099093e-7,0.00013905959,0.00013390701],"about_ca_topic_score_codex":0.000859659,"about_ca_topic_score_gemma":0.0009501614,"teacher_disagreement_score":0.24258883,"about_ca_system_score_codex":0.0021258306,"about_ca_system_score_gemma":0.002689121,"threshold_uncertainty_score":0.55589736},"labels":[],"label_agreement":null},{"id":"W2903962322","doi":"10.1182/blood-2018-99-112988","title":"A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Ibrutinib; Vincristine; Rituximab; Medicine; Prednisone; Cyclophosphamide; Internal medicine; Phases of clinical research; Nuclear medicine; Oncology; Surgery; Chemotherapy; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.004923132404732803,"score_gpt":0.2569880009048837,"score_spread":0.2520648685001509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903962322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854748,0.00092164986,0.00005115434,0.000021341206,0.0001235762,0.0113565745,0.00017368302,0.00008944139,0.0017877842],"genre_scores_gemma":[0.9979074,0.0001404834,0.00033982203,0.00012249761,0.00014038784,0.0005226126,0.00012520133,0.00010274706,0.0005988542],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939597,0.0005287137,0.0015587532,0.0011835308,0.0014136318,0.0013556525],"domain_scores_gemma":[0.9964643,0.00053519075,0.00061646185,0.0011309742,0.00065463496,0.0005984116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012034767,0.0007866178,0.0029386734,0.00036059535,0.00017862034,0.0000754266,0.00040068963,0.00027435969,0.0000820483],"category_scores_gemma":[0.0004465661,0.0005722133,0.0002360823,0.00088227243,0.0006135305,0.00018459387,0.0003856712,0.0002658332,0.000041020423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70444685,0.22661592,0.06333394,0.00063276885,0.000854434,0.00078084006,0.0022762255,0.000001689948,0.000060238148,0.000002962209,0.00044528008,0.0005488518],"study_design_scores_gemma":[0.9786305,0.008097155,0.0053878417,0.0005257337,0.0018516115,0.00013289592,0.00048388357,0.003582907,0.0007198177,0.000004623471,0.00009045474,0.0004925839],"about_ca_topic_score_codex":0.0029798967,"about_ca_topic_score_gemma":0.00062044035,"teacher_disagreement_score":0.27418366,"about_ca_system_score_codex":0.0024409438,"about_ca_system_score_gemma":0.0028836213,"threshold_uncertainty_score":0.99967295},"labels":[],"label_agreement":null},{"id":"W2905558559","doi":"10.1182/blood-2018-07-862953","title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; National Institutes of Health; Harvard University; National Cancer Institute; Damon Runyon Cancer Research Foundation","keywords":"Bruton's tyrosine kinase; Ibrutinib; Mantle cell lymphoma; Cancer research; Tyrosine kinase; B cell; Lymphoma; Medicine; Biology; Immunology; Chronic lymphocytic leukemia; Signal transduction; Leukemia; Cell biology; Antibody","score_opus":0.05432628899998896,"score_gpt":0.3694761640136313,"score_spread":0.31514987501364233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905558559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932115,0.0017337677,0.00026417937,0.0006910074,0.00011431316,0.00076981797,0.000014285111,0.00006878568,0.0031323119],"genre_scores_gemma":[0.99252367,0.000110291185,0.00030425374,0.00048695365,0.00073369953,0.00015592818,0.000035129226,0.000032448475,0.005617622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989964,0.000019744106,0.00015503008,0.0002452751,0.00026313518,0.00032044126],"domain_scores_gemma":[0.99924463,0.00006819481,0.00004173398,0.0002904265,0.00023604823,0.00011896136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001509012,0.00011122821,0.00016493228,0.0000655411,0.000080620426,0.000024704672,0.0000869345,0.00008513338,0.00042311594],"category_scores_gemma":[0.00008338767,0.00008976023,0.0000599089,0.00017927948,0.000108364795,0.00005678911,0.000022042643,0.00007797242,0.00011520422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048920014,0.0059890538,0.005919431,0.001667781,0.0018159027,0.00031233564,0.0015346869,0.000015621603,0.5893193,0.01370595,0.010086451,0.36474147],"study_design_scores_gemma":[0.08739858,0.0033866868,0.004693479,0.00028664045,0.00078022643,0.00033573073,0.00015038288,0.008750405,0.8516236,0.0016367957,0.04060238,0.00035510733],"about_ca_topic_score_codex":0.0012407502,"about_ca_topic_score_gemma":0.00022519274,"teacher_disagreement_score":0.36438638,"about_ca_system_score_codex":0.0012400821,"about_ca_system_score_gemma":0.0041023744,"threshold_uncertainty_score":0.7277436},"labels":[],"label_agreement":null},{"id":"W2906204636","doi":"10.1016/j.critrevonc.2018.12.003","title":"Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?","year":2018,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Leukemia and Lymphoma Society","keywords":"Chronic lymphocytic leukemia; Leukemia; Cancer research; Biology; Metabolism; Immunology; Biochemistry","score_opus":0.09477210235360013,"score_gpt":0.44950691634630763,"score_spread":0.3547348139927075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906204636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006542913,0.9851097,0.00006545875,0.0013437229,0.0013868214,0.0058463956,0.000024042669,0.00015431436,0.006004136],"genre_scores_gemma":[0.0002552129,0.9910253,0.0014965823,0.0006405924,0.0014429799,0.0033501342,0.000104379666,0.00034147903,0.0013433401],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9830784,0.0040218774,0.004956761,0.00312558,0.0010085882,0.003808756],"domain_scores_gemma":[0.9846263,0.009755264,0.0008779969,0.003156906,0.00042721652,0.0011563478],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0059635118,0.0020208233,0.01753742,0.0022952373,0.00017004486,0.00010309421,0.0019972075,0.0048092585,0.0011547005],"category_scores_gemma":[0.025078503,0.0016090283,0.0018764243,0.0029511193,0.0030487126,0.00028527094,0.0015453823,0.0048453943,0.0034659149],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000108107146,0.00025271493,0.0000030550696,0.098296866,0.00026344962,0.008172365,0.00024028485,3.980055e-7,0.0000039920533,0.025486462,0.015427236,0.85174507],"study_design_scores_gemma":[0.008008768,0.0008075283,4.6922017e-7,0.10576875,0.0016183312,0.016031286,0.00008142686,0.0005032513,0.000020314832,0.0017412261,0.8643942,0.0010244594],"about_ca_topic_score_codex":0.00009996949,"about_ca_topic_score_gemma":0.000355207,"teacher_disagreement_score":0.8507206,"about_ca_system_score_codex":0.24815796,"about_ca_system_score_gemma":0.15021254,"threshold_uncertainty_score":0.99975836},"labels":[],"label_agreement":null},{"id":"W2906270512","doi":"10.1016/j.jval.2018.09.258","title":"PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN’S LYMPHOMA: A COST-EFFECTIVENESS ANALYSIS","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"ABVD; Brentuximab vedotin; Medicine; Dacarbazine; Hodgkin's lymphoma; Oncology; Internal medicine; Hodgkin lymphoma; Lymphoma; Chemotherapy; Vincristine","score_opus":0.044222356736891504,"score_gpt":0.3657062456429737,"score_spread":0.3214838889060822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906270512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869656,0.00042026996,0.005799766,0.00020220093,0.000092647526,0.0061158333,0.00021692873,0.00007684531,0.00010990422],"genre_scores_gemma":[0.9946777,0.00012473497,0.0038284725,0.00027640318,0.00009140824,0.0006445107,0.00021187423,0.00007542879,0.00006942888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964489,0.0003887701,0.00051473215,0.00074406806,0.0009653531,0.00093821005],"domain_scores_gemma":[0.99743146,0.0005684216,0.0002616757,0.0007312126,0.0006367798,0.0003704466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011890152,0.00032561677,0.0010795529,0.00050385325,0.00019775382,0.00003618459,0.00019748794,0.00009140172,0.00004833007],"category_scores_gemma":[0.00012226265,0.00022885989,0.000118213495,0.0016679122,0.00025503733,0.00012287959,0.000043569537,0.00015635294,0.000008319416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.18118657,0.005564077,0.6683757,0.0034947009,0.0028666344,0.00012286751,0.005383791,0.018916268,0.00004867515,0.00045501083,0.000375514,0.113210194],"study_design_scores_gemma":[0.3928901,0.036465023,0.45296276,0.0019302187,0.00031448482,0.000028338978,0.00062161766,0.09697458,0.001172185,0.0000732718,0.015774788,0.0007926499],"about_ca_topic_score_codex":0.0069457185,"about_ca_topic_score_gemma":0.000714057,"teacher_disagreement_score":0.21541294,"about_ca_system_score_codex":0.02233963,"about_ca_system_score_gemma":0.010555488,"threshold_uncertainty_score":0.9996671},"labels":[],"label_agreement":null},{"id":"W2906744624","doi":"10.1182/blood-2018-99-118235","title":"Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Phosphorylation; Cancer research; Chronic lymphocytic leukemia; Proteome; Serine; Chemistry; Biology; Leukemia; Tyrosine kinase; Biochemistry; Signal transduction; Immunology","score_opus":0.021671160244736063,"score_gpt":0.29613637393494185,"score_spread":0.27446521369020577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906744624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963256,0.0003643694,0.00033768642,0.00042377197,0.000026672684,0.002255895,0.000053930464,0.00003352776,0.00017851849],"genre_scores_gemma":[0.98812765,0.00003726675,0.010391635,0.000113437476,0.00017648666,0.00022996902,0.00012482975,0.000027227401,0.00077152275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850905,0.00003096798,0.00034188826,0.0004893544,0.00025287305,0.0003758479],"domain_scores_gemma":[0.99907523,0.00019134543,0.000077832825,0.00029010515,0.00019551929,0.00016993943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005334749,0.00017935496,0.00043300432,0.0003066428,0.000089401176,0.000044715667,0.00009823606,0.00013713978,0.00007384838],"category_scores_gemma":[0.0006798264,0.00015181782,0.00007391032,0.0006231323,0.00025581336,0.00007076319,0.00008225987,0.00017460628,0.000012172904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009881012,0.010297174,0.08993253,0.0019041771,0.0056016142,0.00024352802,0.0064094607,0.000044340857,0.8585237,0.0009560182,0.0034667403,0.0127397],"study_design_scores_gemma":[0.26198003,0.0023655081,0.23515703,0.0005095946,0.0025493836,0.0005290132,0.0003264986,0.065830275,0.42687246,0.00024976523,0.0027900734,0.0008403851],"about_ca_topic_score_codex":0.0008600803,"about_ca_topic_score_gemma":0.00032337615,"teacher_disagreement_score":0.43165126,"about_ca_system_score_codex":0.0007620848,"about_ca_system_score_gemma":0.0017389266,"threshold_uncertainty_score":0.6190951},"labels":[],"label_agreement":null},{"id":"W2906959486","doi":"10.1200/jco.2014.32.15_suppl.8581","title":"Efficacy, safety, and cost efficiency of rituximab, gemcitabine, dexamethasone, and oxaliplatin (RGDOx) in B-cell NHL: Report of the prospective multicentric trial NCT01019863.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Hôpital de l'Enfant-Jésus; BC Cancer Agency; Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Neutropenia; Rituximab; Internal medicine; Regimen; Gemcitabine; Gastroenterology; Surgery; Febrile neutropenia; Toxicity; Chemotherapy; Lymphoma","score_opus":0.061327356409881684,"score_gpt":0.4378011206439991,"score_spread":0.37647376423411744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906959486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925157,0.00047961037,0.0002109577,0.0012546711,0.0006147249,0.0013457158,0.000003500443,0.000003826089,0.0035713052],"genre_scores_gemma":[0.99671334,0.00052701304,0.00198228,0.00012332092,0.00041451803,0.0000047151193,9.0730043e-7,0.000018024892,0.00021588765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936468,0.0010769985,0.0038305179,0.0003228415,0.00078991026,0.0003329099],"domain_scores_gemma":[0.9830183,0.012656257,0.0029614938,0.00041200986,0.0006407844,0.00031115592],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011565605,0.000171424,0.0021263692,0.00022341202,0.00004010136,0.0000067379947,0.00025671892,0.00043343758,0.000037761547],"category_scores_gemma":[0.04313209,0.000104868595,0.00031598608,0.0004605539,0.0010300054,0.00006865301,0.00024518653,0.0012370402,0.0000021016372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4785828,0.030266184,0.34086737,0.00096042914,0.00069577736,0.0021586225,0.0014240509,0.00027570233,0.0023660737,0.0007897861,0.0013397689,0.14027344],"study_design_scores_gemma":[0.6460386,0.015661364,0.32249966,0.0003089225,0.00041564534,0.0018259089,0.00014021462,0.007050565,0.000852522,0.00021637375,0.0048517627,0.00013848297],"about_ca_topic_score_codex":0.00022021552,"about_ca_topic_score_gemma":0.00009204222,"teacher_disagreement_score":0.16745579,"about_ca_system_score_codex":0.001298409,"about_ca_system_score_gemma":0.007844554,"threshold_uncertainty_score":0.99778},"labels":[],"label_agreement":null},{"id":"W2907443362","doi":"10.1182/blood-2018-99-119302","title":"Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Internal medicine; Refractory (planetary science); Interleukin-3 receptor; Regimen; Oncology; Decitabine; Azacitidine; Gastroenterology; Leukemia; Myelodysplastic syndromes; Bone marrow; Biology","score_opus":0.0379540287808474,"score_gpt":0.34927666036952626,"score_spread":0.31132263158867884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907443362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501854,0.00019444746,0.000015880134,0.000046983714,0.00041231266,0.0016211793,0.00010794199,0.00006926106,0.0025134804],"genre_scores_gemma":[0.99692285,0.00010155711,0.0005800708,0.0000675149,0.0016422997,0.00003791624,0.00024690846,0.000077751865,0.00032313],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99522007,0.0002957762,0.0016674727,0.0009305848,0.0011377707,0.0007483407],"domain_scores_gemma":[0.9962392,0.0010868902,0.00052399316,0.001428882,0.00033483858,0.00038620978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012561447,0.00035006218,0.0009936279,0.0002848066,0.00007363474,0.000025633644,0.000387449,0.0004112324,0.00014959581],"category_scores_gemma":[0.002273299,0.00027992768,0.00020290248,0.0005765472,0.0006713803,0.00017561056,0.00019600091,0.0007941538,0.000160119],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8180576,0.03628063,0.024648108,0.00042049654,0.0017026773,0.0009602985,0.0019503247,0.000015963074,0.0017363994,0.00004859312,0.0027695321,0.11140938],"study_design_scores_gemma":[0.9507207,0.0237608,0.01573885,0.0008095573,0.00039982132,0.000010073353,0.00005085378,0.0010796712,0.0051580747,0.000030444373,0.0019175075,0.0003236175],"about_ca_topic_score_codex":0.0017535938,"about_ca_topic_score_gemma":0.0005510647,"teacher_disagreement_score":0.13266313,"about_ca_system_score_codex":0.008117394,"about_ca_system_score_gemma":0.01622927,"threshold_uncertainty_score":0.9999653},"labels":[],"label_agreement":null},{"id":"W2907573039","doi":"10.1182/blood-2018-99-115527","title":"Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Salvage therapy; Internal medicine; Oncology; Bendamustine; Diffuse large B-cell lymphoma; Transplantation; Rituximab; Venetoclax; Chemotherapy regimen; Lymphoma; Surgery; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.013170153013662008,"score_gpt":0.2739594107118696,"score_spread":0.26078925769820754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907573039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581355,0.0013859719,0.000044817127,0.00020949033,0.00013232567,0.0013994694,0.000114000446,0.00004945035,0.00085092837],"genre_scores_gemma":[0.9956801,0.00028158378,0.0017583126,0.00035475497,0.00018495326,0.000051154188,0.00014400117,0.00012646684,0.0014186675],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709255,0.00007486169,0.00089484785,0.0005839284,0.0007557116,0.0005980845],"domain_scores_gemma":[0.9959069,0.00025087953,0.00076039764,0.0011578286,0.0017428825,0.00018112668],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018395239,0.0005072645,0.0012757871,0.00026047076,0.00010594454,0.00001637175,0.0003234241,0.00024681076,0.0005620585],"category_scores_gemma":[0.00021521703,0.00036185022,0.00041115886,0.00048792665,0.00044800207,0.00011601068,0.00008800779,0.00018655896,0.000025584335],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048085887,0.04244241,0.5400156,0.004464797,0.028409429,0.001856823,0.05126604,0.000040203242,0.24280655,0.00007078127,0.0031648949,0.037376594],"study_design_scores_gemma":[0.17048566,0.010174237,0.012968754,0.0009386426,0.0005810066,0.000058868034,0.00069070904,0.000116428135,0.8025927,0.000029515784,0.0009697787,0.00039373426],"about_ca_topic_score_codex":0.0005254088,"about_ca_topic_score_gemma":0.00018965127,"teacher_disagreement_score":0.5597861,"about_ca_system_score_codex":0.002244186,"about_ca_system_score_gemma":0.0014805462,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W2907740859","doi":"","title":"Targeting Susceptible Signaling Pathways in Chronic Lymphocytic Leukemia","year":2014,"lang":"en","type":"dissertation","venue":"Mspace (University of Manitoba)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Cancer Society Research Institute; Leukemia and Lymphoma Society; Canadian Institutes of Health Research; University of Alberta; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Chronic lymphocytic leukemia; Signal transduction; Cancer research; Leukemia; Biology; Computational biology; Medicine; Cell biology; Immunology","score_opus":0.018567158853008924,"score_gpt":0.24191852450798731,"score_spread":0.2233513656549784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907740859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886644,0.001115549,0.0001452243,0.00004513589,0.00027249567,0.0007321706,0.00001134292,0.0001144797,0.0088992305],"genre_scores_gemma":[0.99288845,0.0005947619,0.00067995733,0.000021960825,0.0002876859,0.0000019476606,0.00076749746,0.00009250365,0.0046652462],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9971574,0.00013343683,0.00032609166,0.00070990436,0.0009169937,0.0007561871],"domain_scores_gemma":[0.9982767,0.00020474546,0.00039538398,0.0005934459,0.00029473804,0.00023500297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005759119,0.0004109435,0.0009816177,0.00078718906,0.00018703444,0.000024403444,0.0005121855,0.0006633237,0.00012879932],"category_scores_gemma":[0.0001597619,0.00052695203,0.00029292944,0.0006174293,0.00015206644,0.0001567206,0.00014136561,0.0007442474,0.0002888908],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012501936,0.00048669073,0.01548806,0.05784643,0.0022210937,0.012084962,0.013182331,0.08394024,0.73691446,0.0021121372,0.047815952,0.015405728],"study_design_scores_gemma":[0.10738433,0.0040247007,0.028393231,0.01841999,0.0019027641,0.00022792633,0.15185875,0.62217945,0.04038425,0.00041302652,0.021057349,0.003754199],"about_ca_topic_score_codex":0.02686912,"about_ca_topic_score_gemma":0.24324371,"teacher_disagreement_score":0.69653016,"about_ca_system_score_codex":0.15415412,"about_ca_system_score_gemma":0.040019915,"threshold_uncertainty_score":0.9997182},"labels":[],"label_agreement":null},{"id":"W2908094279","doi":"10.1182/blood-2018-184","title":"MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"","keywords":"Venetoclax; Medicine; Bendamustine; Rituximab; Internal medicine; Ven; Gastroenterology; Neutropenia; Minimal residual disease; Refractory (planetary science); Chronic lymphocytic leukemia; Oncology; Leukemia; Chemotherapy; Lymphoma","score_opus":0.03220331108193749,"score_gpt":0.306262982912542,"score_spread":0.27405967183060453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908094279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928098,0.0014450016,0.000007749216,0.00004807192,0.0003017076,0.002645517,0.000015533282,0.00013791854,0.0025887182],"genre_scores_gemma":[0.99772143,0.00038135838,0.00014043106,0.0000812048,0.0005927529,0.00011400967,0.00008383257,0.00007976254,0.0008051953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959424,0.0003698267,0.0010037585,0.0007724822,0.0011427318,0.00076879247],"domain_scores_gemma":[0.9971533,0.0005363858,0.0003141277,0.0012888466,0.00046681144,0.00024052939],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014063127,0.0003775631,0.0009508514,0.0004747178,0.00010301143,0.000045057288,0.00047245383,0.00044233282,0.00060789793],"category_scores_gemma":[0.0010101194,0.00034535397,0.00024346006,0.0010539461,0.00066023215,0.00022239395,0.00014411623,0.00044366688,0.0002493935],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.44125333,0.040671732,0.015695143,0.004543801,0.0029647797,0.0017015714,0.009120254,0.00068944454,0.40684083,0.0008724038,0.007725136,0.06792154],"study_design_scores_gemma":[0.89237434,0.010870125,0.0055261706,0.0005178445,0.00018298735,0.00013735729,0.000070539376,0.023597041,0.06512886,0.00033267224,0.0008393713,0.0004226866],"about_ca_topic_score_codex":0.0026263723,"about_ca_topic_score_gemma":0.00018005155,"teacher_disagreement_score":0.451121,"about_ca_system_score_codex":0.07624866,"about_ca_system_score_gemma":0.04728512,"threshold_uncertainty_score":0.99989986},"labels":[],"label_agreement":null},{"id":"W2908301161","doi":"10.1182/blood-2018-99-110560","title":"Forty Percent of MDS Patients Wish They Received Red Blood Cell Transfusions at Higher Hemoglobin Thresholds Than They Currently Are: A Multinational Transfusion Audit","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Blood transfusion; Anemia; Quality of life (healthcare); Pediatrics; Family medicine; Internal medicine","score_opus":0.01710499241444917,"score_gpt":0.26593320425830125,"score_spread":0.24882821184385207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908301161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904649,0.00019432121,0.000010974386,0.00047444267,0.00042509218,0.0015394244,0.00022392356,0.00009945268,0.0065674195],"genre_scores_gemma":[0.9963846,0.000536287,0.00040145798,0.000097296856,0.0003891738,0.00009153835,0.00020957303,0.00007904173,0.0018110205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621665,0.00015021738,0.00069827324,0.0007432217,0.0014865036,0.00070511],"domain_scores_gemma":[0.9977431,0.00016294079,0.0002225544,0.00079497835,0.0007028572,0.00037351926],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038090712,0.00038725117,0.00058532535,0.00020188944,0.00028278548,0.000019988254,0.00037924293,0.00031037416,0.001345092],"category_scores_gemma":[0.00011886369,0.0003111206,0.00034653963,0.000293087,0.00026910054,0.00012589252,0.00015914043,0.0003552057,0.00007378932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060811066,0.051494144,0.568408,0.0018351017,0.001397093,0.00024295715,0.014771088,0.000022990638,0.3415095,0.0001142896,0.00958221,0.004541525],"study_design_scores_gemma":[0.1930135,0.0032848625,0.62414426,0.0010976479,0.0016149046,0.00014983257,0.00026487862,0.00068010355,0.1708342,0.00026606172,0.0038466963,0.0008030684],"about_ca_topic_score_codex":0.0008596686,"about_ca_topic_score_gemma":0.0013812248,"teacher_disagreement_score":0.1869324,"about_ca_system_score_codex":0.0016959303,"about_ca_system_score_gemma":0.0014663389,"threshold_uncertainty_score":0.9999341},"labels":[],"label_agreement":null},{"id":"W2909116479","doi":"10.1182/blood-2018-99-118362","title":"Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Venetoclax; Obinutuzumab; Bendamustine; Chronic lymphocytic leukemia; Rituximab; Medicine; Ofatumumab; Ven; Internal medicine; Leukemia; Ibrutinib; Fludarabine; Oncology; Immunology; Lymphoma; Cyclophosphamide; Chemotherapy","score_opus":0.014411513921813463,"score_gpt":0.2837384014800938,"score_spread":0.2693268875582804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909116479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511683,0.00023131228,0.0000094328325,0.00001365522,0.000042192998,0.0041762735,0.000120234035,0.00006731472,0.00022273631],"genre_scores_gemma":[0.99875176,0.00006871785,0.00024570638,0.000020891443,0.00011143979,0.000089227455,0.00044622546,0.00007864005,0.00018738408],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99606645,0.00023114833,0.0010705661,0.000949528,0.000968314,0.0007140133],"domain_scores_gemma":[0.9975379,0.00045449173,0.000370268,0.0008985189,0.00048918533,0.00024962527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053410215,0.0004453359,0.0010808292,0.00043650306,0.000087857225,0.000032082604,0.00025373843,0.00018952994,0.00005956386],"category_scores_gemma":[0.00067445583,0.00031783603,0.000041380248,0.0012703302,0.00041616947,0.00018226379,0.00016308553,0.00033832353,0.000016372853],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.82949775,0.041726246,0.043988675,0.0020002846,0.002876204,0.0056699286,0.03633274,0.003984068,0.00091109076,0.000038385195,0.00021110228,0.032763537],"study_design_scores_gemma":[0.8609108,0.034229785,0.0680041,0.002108128,0.0005910666,0.000087867076,0.00036174408,0.0311466,0.0021074985,0.000004162602,0.00007476452,0.00037350622],"about_ca_topic_score_codex":0.022821372,"about_ca_topic_score_gemma":0.012318243,"teacher_disagreement_score":0.044689346,"about_ca_system_score_codex":0.08740255,"about_ca_system_score_gemma":0.04271321,"threshold_uncertainty_score":0.99992734},"labels":[],"label_agreement":null},{"id":"W2909446572","doi":"10.1080/10428194.2018.1562180","title":"Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Refractory (planetary science); Chronic lymphocytic leukemia; Adverse effect; Syk; Phases of clinical research; Leukemia; Oncology; Chemotherapy; Tyrosine kinase; Receptor","score_opus":0.008657355297071786,"score_gpt":0.25424940007524544,"score_spread":0.24559204477817365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909446572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877868,0.0011108064,0.000009176239,0.000027464832,0.00020911725,0.008253513,0.00015654216,0.00036450246,0.0020820466],"genre_scores_gemma":[0.99109405,0.0007533093,0.00047775146,0.0002533025,0.0002924553,0.0005517757,0.0005335336,0.00047652845,0.005567263],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98847145,0.0006396284,0.0027888648,0.0029374443,0.002771113,0.0023915146],"domain_scores_gemma":[0.9927727,0.0009509694,0.0014187895,0.002984812,0.0007511355,0.0011216088],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012640483,0.0018327143,0.003063739,0.0013025502,0.00025609112,0.00017596254,0.0009135167,0.00096116395,0.00030925413],"category_scores_gemma":[0.0002572066,0.0013096979,0.00034253774,0.0027351847,0.0008121526,0.0007763642,0.0003476139,0.0005665284,0.00019664921],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.61723435,0.015181473,0.176992,0.006144222,0.0034489988,0.004165655,0.016626213,0.0021254295,0.018074522,0.00004566779,0.005695185,0.13426627],"study_design_scores_gemma":[0.85797596,0.056661453,0.03641014,0.0038863714,0.0007765232,0.00044926247,0.0019788328,0.01254829,0.017576104,0.000005704543,0.009464492,0.0022668955],"about_ca_topic_score_codex":0.012997337,"about_ca_topic_score_gemma":0.0006450981,"teacher_disagreement_score":0.24074157,"about_ca_system_score_codex":0.25452447,"about_ca_system_score_gemma":0.10060454,"threshold_uncertainty_score":0.99944174},"labels":[],"label_agreement":null},{"id":"W2909590336","doi":"10.1182/blood-2018-99-118238","title":"Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Obinutuzumab; Internal medicine; Tolerability; Chlorambucil; Neutropenia; Chronic lymphocytic leukemia; Population; Gastroenterology; Placebo; Rituximab; Pharmacology; Adverse effect; Leukemia; Cyclophosphamide; Toxicity; Chemotherapy; Lymphoma","score_opus":0.011956630688166204,"score_gpt":0.2743807633454712,"score_spread":0.26242413265730496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909590336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919224,0.0003725185,0.0000030238223,0.00010013229,0.00006673129,0.006891385,0.00013438509,0.00008072591,0.0004287108],"genre_scores_gemma":[0.99816954,0.00014665248,0.00007011337,0.00009816017,0.00023490866,0.00034546727,0.00033125357,0.000066732944,0.0005371645],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633664,0.0003914794,0.00082353735,0.00083013874,0.00096369715,0.0006545207],"domain_scores_gemma":[0.9973144,0.0010133013,0.00025528274,0.00081612094,0.00023963217,0.00036124713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008399466,0.00046101643,0.0010774066,0.00019941755,0.0002059476,0.0000638504,0.00022272626,0.00021441486,0.00009277271],"category_scores_gemma":[0.00085335266,0.0002598836,0.000078272504,0.00051639474,0.0007208394,0.00015845499,0.00017068256,0.0003128303,0.000028819008],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9928483,0.0007768451,0.0009590941,0.000064791435,0.00081864116,0.00010844724,0.0026313702,0.000023154023,0.00010378617,0.0000077068225,0.00029817666,0.0013597278],"study_design_scores_gemma":[0.97838706,0.008568873,0.0053857774,0.0010406933,0.00072264764,0.00006723856,0.0001166552,0.0032036316,0.0020152468,0.000030428426,0.00012806317,0.00033369908],"about_ca_topic_score_codex":0.011490595,"about_ca_topic_score_gemma":0.0012454198,"teacher_disagreement_score":0.014461214,"about_ca_system_score_codex":0.021441769,"about_ca_system_score_gemma":0.015858253,"threshold_uncertainty_score":0.99998534},"labels":[],"label_agreement":null},{"id":"W2910162643","doi":"10.1182/blood.v130.suppl_1.1750.1750","title":"Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Chemoimmunotherapy; Chronic lymphocytic leukemia; Medicine; Venetoclax; Oncology; Internal medicine; Idelalisib; Leukemia; Immunology","score_opus":0.0438073010882187,"score_gpt":0.34324263776981506,"score_spread":0.2994353366815964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910162643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239707,0.0006731377,0.0000520264,0.00010381343,0.00036394942,0.004451073,0.00007410658,0.00015118612,0.00173364],"genre_scores_gemma":[0.9941306,0.0000673838,0.00084567734,0.00009535242,0.0007379909,0.00056883984,0.0002244134,0.00015138034,0.0031783222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99658114,0.000045810622,0.0006304245,0.0008467334,0.0008024745,0.0010934492],"domain_scores_gemma":[0.996422,0.000220059,0.00053291034,0.002133158,0.00034706978,0.00034480263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023906464,0.000532336,0.001008719,0.0001274287,0.0006860476,0.00037332135,0.000552127,0.00028725585,0.00012106145],"category_scores_gemma":[0.0002557739,0.00040340968,0.00032788012,0.00011270871,0.0005451036,0.00021605696,0.00012771063,0.00015317589,0.000100009565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.74358326,0.028649122,0.09915236,0.0026399787,0.012820649,0.0010583439,0.004119158,0.0005718352,0.023587393,0.0004427604,0.005321765,0.0780534],"study_design_scores_gemma":[0.88733566,0.017453803,0.0077561936,0.00035522348,0.0007529403,0.00007553644,0.000021952903,0.002821233,0.06939943,0.000024163082,0.013479034,0.00052483304],"about_ca_topic_score_codex":0.0015264241,"about_ca_topic_score_gemma":0.000163546,"teacher_disagreement_score":0.14375241,"about_ca_system_score_codex":0.07296437,"about_ca_system_score_gemma":0.022921149,"threshold_uncertainty_score":0.99984175},"labels":[],"label_agreement":null},{"id":"W2910748507","doi":"10.1182/blood-2018-99-117050","title":"First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Rituximab; Bendamustine; Medicine; Venetoclax; Minimal residual disease; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.09003169841071502,"score_gpt":0.448789138950056,"score_spread":0.358757440539341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910748507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413073,0.00022386559,0.0000057991174,0.00014349076,0.00044847676,0.003404595,0.0011174718,0.00011135009,0.00041420027],"genre_scores_gemma":[0.99717075,0.000032809898,0.00012600211,0.00008483745,0.0016139944,0.00017360719,0.00032993394,0.000113794675,0.0003542568],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99433047,0.0002480865,0.0011994567,0.0015723219,0.0016710634,0.0009785952],"domain_scores_gemma":[0.9937893,0.0012191226,0.00031829384,0.0033958545,0.00036761892,0.00090978347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009579143,0.00063134334,0.0015682483,0.0003012936,0.00019218242,0.00006277338,0.00094057334,0.00020330561,0.0006681301],"category_scores_gemma":[0.0024073916,0.00047730788,0.0004295732,0.00040330098,0.00085865863,0.00021142235,0.00089963403,0.0007139474,0.00034736344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4606552,0.07302903,0.4426864,0.0005245538,0.005444478,0.012039499,0.0013785566,0.000028112398,0.00002296768,0.000020319507,0.0030699698,0.001100915],"study_design_scores_gemma":[0.45400682,0.019688018,0.52232164,0.0003365103,0.0015581261,0.000041276413,0.00008874214,0.0014689337,0.00012213904,0.000003424839,0.000030890864,0.00033348164],"about_ca_topic_score_codex":0.0011378293,"about_ca_topic_score_gemma":0.00078677095,"teacher_disagreement_score":0.07963525,"about_ca_system_score_codex":0.00908872,"about_ca_system_score_gemma":0.01447923,"threshold_uncertainty_score":0.99976784},"labels":[],"label_agreement":null},{"id":"W2910821491","doi":"10.3324/haematol.2018.203943","title":"Resolution of celiac disease, IgA deficiency and platelet refractoriness after allogeneic bone marrow transplantation for acute leukemia","year":2019,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Transplantation; Stem cell; Immunology; Hematology; Immune system; Disease; Bone marrow; Leukemia; Acute leukemia; Platelet; Internal medicine","score_opus":0.02151216357234776,"score_gpt":0.29430982506398956,"score_spread":0.2727976614916418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910821491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9037053,0.0112136835,0.0009982025,0.07569226,0.00075048325,0.005165833,0.0016515572,0.0001665364,0.0006561639],"genre_scores_gemma":[0.8863603,0.010309002,0.00290438,0.08255737,0.0013905363,0.0016755803,0.007071193,0.00026613066,0.007465542],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99688923,0.00010646995,0.00069712056,0.0008458462,0.00074390613,0.00071744673],"domain_scores_gemma":[0.9980176,0.00050360465,0.00033501704,0.0007330689,0.0002687683,0.00014192071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028541835,0.0004553618,0.0012018138,0.00028570087,0.00007560065,0.00002768927,0.000217576,0.001033882,0.00011083442],"category_scores_gemma":[0.00017212974,0.00035263525,0.0002694053,0.0002110172,0.00028498765,0.00009900322,0.00008335228,0.0007355178,0.000037785176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021151148,0.00024100223,0.0020572867,0.0491031,0.00086617994,0.031903777,0.00047738015,0.00003610912,0.004008887,0.00023419486,0.8878058,0.0021150964],"study_design_scores_gemma":[0.059233546,0.0035286439,0.015880594,0.0063134963,0.008391152,0.01849953,0.000081976636,0.006249578,0.011122918,0.0016608298,0.86580765,0.0032301012],"about_ca_topic_score_codex":0.00008724072,"about_ca_topic_score_gemma":0.0000073517117,"teacher_disagreement_score":0.042789605,"about_ca_system_score_codex":0.0027039084,"about_ca_system_score_gemma":0.0030637379,"threshold_uncertainty_score":0.9998926},"labels":[],"label_agreement":null},{"id":"W2912598520","doi":"10.1080/10428194.2018.1498490","title":"Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders","year":2019,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Obinutuzumab; Rituximab; Medicine; Chronic lymphocytic leukemia; CD20; Follicular lymphoma; Lymphoma; Immunology; Antibody; Monoclonal antibody; Lymphoproliferative disorders; Oncology; Internal medicine; Leukemia","score_opus":0.03349201169399164,"score_gpt":0.34155322463289023,"score_spread":0.3080612129388986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912598520","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025770241,0.9586641,0.000048926147,0.000046612335,0.0010711878,0.0071274103,0.00018014398,0.0005071108,0.0065842476],"genre_scores_gemma":[0.0077533196,0.98167485,0.00035281896,0.0006566182,0.0010278168,0.0011717998,0.001330052,0.0009141606,0.005118577],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853822,0.0009418011,0.0034976301,0.004278148,0.0022773524,0.0036228509],"domain_scores_gemma":[0.9918277,0.0016041802,0.0014603894,0.0034248007,0.00032318707,0.0013597113],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014493663,0.0034774258,0.008667381,0.0024361364,0.0005157117,0.00055170036,0.0016401871,0.0033522637,0.00024330463],"category_scores_gemma":[0.00054341834,0.0029241915,0.0021263647,0.0030298077,0.0011248696,0.0007702844,0.0012544506,0.0011516756,0.00089751405],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00093511346,0.00029864008,0.00014583078,0.02574668,0.0009939623,0.0013738162,0.00069355045,0.00001908313,0.000041447653,0.00033721788,0.0008213774,0.9685933],"study_design_scores_gemma":[0.07724666,0.0011052988,0.000382093,0.020678926,0.0016392209,0.006502877,0.0003739727,0.012050982,0.00006777579,0.00014452444,0.8763864,0.0034212468],"about_ca_topic_score_codex":0.012340509,"about_ca_topic_score_gemma":0.00032492442,"teacher_disagreement_score":0.96517205,"about_ca_system_score_codex":0.2583163,"about_ca_system_score_gemma":0.1749903,"threshold_uncertainty_score":0.9998804},"labels":[],"label_agreement":null},{"id":"W2912749718","doi":"10.1182/blood.v130.suppl_1.2022.2022","title":"Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Carmustine; Medicine; Bendamustine; Regimen; Transplantation; Hematopoietic stem cell transplantation; Internal medicine; Oncology; Surgery; Lymphoma; Chemotherapy; Rituximab; Cyclophosphamide","score_opus":0.03213510006849791,"score_gpt":0.3491480611486845,"score_spread":0.3170129610801866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912749718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952184,0.000313739,0.0010249886,0.000358559,0.00004025795,0.0027508694,0.00015025029,0.000009203435,0.0001337572],"genre_scores_gemma":[0.9982977,0.000094809344,0.0008815446,0.000012425488,0.00008425076,0.0004395104,0.00008205381,0.000014207777,0.00009350669],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990414,0.00002785348,0.0002966796,0.000179183,0.00021051394,0.0002443905],"domain_scores_gemma":[0.99846816,0.0006329412,0.00018889109,0.00051986467,0.00014082475,0.000049342954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003133292,0.0001242338,0.00029677912,0.000077372,0.00019398319,0.000017917242,0.0001983026,0.00006524107,0.000008616615],"category_scores_gemma":[0.00019183182,0.00006798212,0.00017623736,0.000080698,0.0001315109,0.000042051714,0.000008604691,0.000028837323,0.0000011733459],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058307976,0.06042825,0.08956399,0.025265584,0.0066508306,0.001246084,0.17687425,0.01383654,0.38181502,0.009056459,0.00270941,0.1742456],"study_design_scores_gemma":[0.20892042,0.011225954,0.4082802,0.0006689396,0.0030431075,0.00074123684,0.001028457,0.00843114,0.35668805,0.00019843358,0.00047557746,0.0002985074],"about_ca_topic_score_codex":0.0011904073,"about_ca_topic_score_gemma":0.00012765007,"teacher_disagreement_score":0.3187162,"about_ca_system_score_codex":0.0010182323,"about_ca_system_score_gemma":0.0014893314,"threshold_uncertainty_score":0.27722305},"labels":[],"label_agreement":null},{"id":"W2913456279","doi":"10.1038/s41375-019-0381-4","title":"Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Glucocorticoid receptor; Cancer research; Biology; Leukemia; Internal medicine; Glucocorticoid; Pharmacology; Immunology; Medicine","score_opus":0.014529211504162443,"score_gpt":0.27968211880645083,"score_spread":0.2651529073022884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913456279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761593,0.0014952504,0.000018187093,0.00028007032,0.000922537,0.003194146,0.000008223348,0.00025172526,0.017670592],"genre_scores_gemma":[0.9718464,0.00046366005,0.00031064663,0.001045236,0.0006096399,0.00021993261,0.00006634717,0.00014852747,0.025289634],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9946394,0.00020910022,0.0009970515,0.0012440238,0.0012854665,0.0016249844],"domain_scores_gemma":[0.9959452,0.00062173797,0.00024265228,0.0026769857,0.00015341656,0.00036000175],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011308626,0.000539117,0.00090220256,0.0002708327,0.00011165202,0.00012655392,0.0008396055,0.00047279868,0.0021341855],"category_scores_gemma":[0.00025864306,0.00039166314,0.0003635153,0.0013667453,0.00035237876,0.00021020252,0.0004269113,0.0011318449,0.013409292],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008033041,0.0003863265,0.021396553,0.007708874,0.0013510269,0.0027236098,0.006459348,0.07079414,0.66518694,0.004170879,0.072800085,0.13898918],"study_design_scores_gemma":[0.09851997,0.0023461154,0.0061073615,0.002037149,0.00025064708,0.001110718,0.0012732255,0.4530638,0.1460865,0.00024283078,0.28727067,0.0016910358],"about_ca_topic_score_codex":0.0058479942,"about_ca_topic_score_gemma":0.00020089319,"teacher_disagreement_score":0.5191004,"about_ca_system_score_codex":0.37440866,"about_ca_system_score_gemma":0.10043522,"threshold_uncertainty_score":0.99985355},"labels":[],"label_agreement":null},{"id":"W2914088338","doi":"10.1182/blood-2018-176","title":"Resistance to Lenalidomide in Del(5q) MDS Is Mediated By Inhibition of Drug-Induced Megakaryocytic Differentiation","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"RUNX1; Cancer research; Lenalidomide; Biology; Immunology; Molecular biology; Medicine; Haematopoiesis; Stem cell; Genetics","score_opus":0.015403974334596985,"score_gpt":0.2805320959159446,"score_spread":0.2651281215813476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914088338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968628,0.0002195519,0.000048409693,0.00084230787,0.00006559351,0.000585239,0.000029473247,0.000039840153,0.0013067756],"genre_scores_gemma":[0.9981589,0.000034781864,0.00020555708,0.00040346826,0.00014422271,0.000048320577,0.0000767961,0.00003131766,0.0008966358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980268,0.0000907081,0.0004865708,0.0003663125,0.0006493998,0.0003802261],"domain_scores_gemma":[0.9988816,0.00015594553,0.00011065626,0.00042736236,0.00023815944,0.00018629729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000371964,0.00015987593,0.00035883833,0.00027105768,0.00004019574,0.000013100336,0.00011332525,0.00012441065,0.00012937207],"category_scores_gemma":[0.00048188548,0.00014830192,0.00006184993,0.00063657603,0.00008224582,0.0000883863,0.00007260289,0.00015839926,0.00012372991],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010694443,0.0011185049,0.0030970662,0.00038797333,0.000120244134,0.00006930909,0.0023693673,4.3795717e-7,0.9776061,0.00008873079,0.013722101,0.00035071644],"study_design_scores_gemma":[0.034952626,0.0002336488,0.007023802,0.00053258456,0.000092909366,0.00001385161,0.00009703439,0.0003443171,0.9560025,0.00011034749,0.00043711922,0.0001593107],"about_ca_topic_score_codex":0.0007604599,"about_ca_topic_score_gemma":0.0009034748,"teacher_disagreement_score":0.033883184,"about_ca_system_score_codex":0.0024020062,"about_ca_system_score_gemma":0.0013521372,"threshold_uncertainty_score":0.62811625},"labels":[],"label_agreement":null},{"id":"W2918542982","doi":"10.1182/blood-2018-09-876292","title":"Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"National Cancer Institute; CLL Global Research Foundation","keywords":"Ibrutinib; Idelalisib; Chronic lymphocytic leukemia; Somatic hypermutation; IGHV@; Cytidine deaminase; Activation-induced (cytidine) deaminase; Cancer research; Bruton's tyrosine kinase; Venetoclax; breakpoint cluster region; Leukemia; Immunology; Medicine; Oncology; Biology; Tyrosine kinase; B cell; Internal medicine; Antibody; Receptor","score_opus":0.0156079771638856,"score_gpt":0.2860090554580569,"score_spread":0.27040107829417126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918542982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899541,0.0044525024,0.0000044404046,0.00015210507,0.000070252296,0.0012839569,0.0000058305295,0.000090617934,0.003986172],"genre_scores_gemma":[0.9956967,0.0010468689,0.00014624315,0.00020981462,0.00023388033,0.000110319124,0.00002136557,0.0000443117,0.002490466],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981364,0.00007732108,0.00032714754,0.0005077614,0.00039785774,0.00055349624],"domain_scores_gemma":[0.99889386,0.00024351598,0.00007006784,0.0005193003,0.00008243847,0.00019080864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026110106,0.00024077925,0.00045189052,0.00022695494,0.00007571775,0.00004849381,0.00012486284,0.00019288615,0.00048269218],"category_scores_gemma":[0.00008567597,0.00019778869,0.000076110635,0.00038653877,0.00015035032,0.00017400944,0.00008352285,0.00032902986,0.00033627564],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008513668,0.0040566544,0.12544644,0.0040320884,0.004089857,0.0030347088,0.0150828995,0.0066802716,0.7782067,0.005831715,0.004764322,0.040260695],"study_design_scores_gemma":[0.4529274,0.0036801095,0.08495424,0.0012886479,0.00027157523,0.003639943,0.00088219857,0.093560904,0.3394501,0.0007307923,0.017369991,0.0012441138],"about_ca_topic_score_codex":0.0009695141,"about_ca_topic_score_gemma":0.00009166274,"teacher_disagreement_score":0.44441372,"about_ca_system_score_codex":0.029656915,"about_ca_system_score_gemma":0.023000699,"threshold_uncertainty_score":0.982538},"labels":[],"label_agreement":null},{"id":"W2920903135","doi":"10.1182/blood-2018-99-117063","title":"Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Regimen; Chemotherapy regimen; Common Terminology Criteria for Adverse Events; Tolerability; Neutropenia; Follicular lymphoma; Clinical endpoint; Gastroenterology; Surgery; Lymphoma; Chemotherapy; Clinical trial","score_opus":0.022655990364634494,"score_gpt":0.2685119626622047,"score_spread":0.24585597229757017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920903135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944771,0.00003857944,0.000003591342,0.000031845037,0.000051228057,0.005147776,0.00007538906,0.000081219165,0.00009328097],"genre_scores_gemma":[0.99796456,0.0000034640595,0.0006243852,0.00021500055,0.00011704193,0.00034247793,0.00021651026,0.0001217708,0.0003948005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968569,0.0001541471,0.0004853016,0.0007553589,0.0010445871,0.0007036583],"domain_scores_gemma":[0.99691033,0.0010433707,0.00027220524,0.0009407123,0.00063766044,0.0001957455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002442255,0.00044229688,0.000729506,0.00013166011,0.00022930524,0.00005253277,0.0002920075,0.00012690845,0.0000441697],"category_scores_gemma":[0.00046772597,0.00018335244,0.00004723767,0.00048430322,0.0002663941,0.00015725609,0.0001261636,0.0001958395,0.000014117418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021759503,0.016906139,0.9573291,0.00008577098,0.0004650815,0.00007345648,0.0012390567,0.0000014515663,0.000021347778,1.5548079e-7,0.00013307678,0.0019858757],"study_design_scores_gemma":[0.2648295,0.024934813,0.7077073,0.00053018134,0.0005151316,0.000002258535,0.0003778221,0.00016288088,0.000614214,4.6319283e-7,0.000084589425,0.00024085164],"about_ca_topic_score_codex":0.0013319146,"about_ca_topic_score_gemma":0.001391311,"teacher_disagreement_score":0.24962178,"about_ca_system_score_codex":0.0020816526,"about_ca_system_score_gemma":0.00251121,"threshold_uncertainty_score":0.74768955},"labels":[],"label_agreement":null},{"id":"W2920928707","doi":"10.1200/jco.2015.33.15_suppl.e18029","title":"Comparison of patient characteristics and chromosomal abnormalities by first-line treatment in chronic lymphoid leukemia (CLL) patients in Canada.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Fludarabine; Bendamustine; Medicine; Chlorambucil; Chronic lymphocytic leukemia; Internal medicine; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.10036165327814958,"score_gpt":0.43092141650057314,"score_spread":0.33055976322242353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920928707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712706,0.0012202967,0.000002087708,0.0004892851,0.00049574475,0.0003215451,0.00003097984,0.0000022365125,0.00031076968],"genre_scores_gemma":[0.99805033,0.0012957944,0.00011161509,0.00018998668,0.00025145037,0.000008102978,0.000024752488,0.000016801947,0.00005113763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486023,0.00035792135,0.0034717524,0.00020918026,0.0007004407,0.0004004634],"domain_scores_gemma":[0.99577177,0.0015565965,0.0014786393,0.0001996128,0.00042496997,0.00056840066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011319965,0.00019137286,0.0020899042,0.00015910875,0.000016897875,0.000005463041,0.00014663441,0.00027546374,0.000035737456],"category_scores_gemma":[0.0022069637,0.00014312583,0.00011869471,0.00016451898,0.00022985757,0.00008944886,0.00009668493,0.00053715287,0.000002087757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004326127,0.002067916,0.92115116,0.00012534458,0.0001308119,0.00073964725,0.00081059436,0.0002614313,0.000017459577,0.0000062712716,0.0023136842,0.068049535],"study_design_scores_gemma":[0.15993409,0.071652375,0.70160574,0.00067851425,0.00021734218,0.00049592275,0.0013158505,0.020009357,0.0009551713,0.000039197428,0.042776674,0.0003197457],"about_ca_topic_score_codex":0.37830153,"about_ca_topic_score_gemma":0.5756969,"teacher_disagreement_score":0.21954541,"about_ca_system_score_codex":0.09465982,"about_ca_system_score_gemma":0.12035523,"threshold_uncertainty_score":0.9088156},"labels":[],"label_agreement":null},{"id":"W2920968324","doi":"10.1002/cam4.2042","title":"Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial","year":2019,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; European Hematology Association; Institute of Cancer Research; Leukemia and Lymphoma Society","keywords":"Ibrutinib; Ruxolitinib; Medicine; Chronic lymphocytic leukemia; Janus kinase; Internal medicine; Tyrosine kinase 2; Bruton's tyrosine kinase; Oncology; Leukemia; Pharmacology; Immunology; Cytokine; Myelofibrosis; Bone marrow; Tyrosine kinase; Receptor","score_opus":0.04055665254502011,"score_gpt":0.3564501784535835,"score_spread":0.3158935259085634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920968324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878816,0.0022724585,0.000002201721,0.0003330771,0.0010215227,0.0024183064,0.000045832032,0.000043958975,0.0059810434],"genre_scores_gemma":[0.99608845,0.00037899177,0.000015044081,0.00044856084,0.0010152456,0.00012598807,0.00014185843,0.000056889665,0.0017289568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99580026,0.00012119628,0.0011529758,0.0007440042,0.0014305772,0.00075098977],"domain_scores_gemma":[0.9976633,0.00046013095,0.00034701178,0.00088225567,0.00028986856,0.0003574308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008644863,0.00035213688,0.0010922531,0.0005225894,0.00003934661,0.0000069543453,0.00029050675,0.00021203936,0.00086348626],"category_scores_gemma":[0.0008610128,0.00027027546,0.00021753952,0.0007689814,0.0003126199,0.00007206424,0.00008476145,0.0004452422,0.000106800944],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.83182985,0.0016220462,0.0021581715,0.0050473264,0.0010103212,0.0008990515,0.0078729745,0.014856096,0.056224514,0.00015141511,0.016657446,0.06167076],"study_design_scores_gemma":[0.927292,0.019743653,0.0004962038,0.005674583,0.00023163558,0.000018985302,0.00039185738,0.03024593,0.010201832,0.000010086458,0.0054050963,0.00028815016],"about_ca_topic_score_codex":0.006133911,"about_ca_topic_score_gemma":0.000098442586,"teacher_disagreement_score":0.11402344,"about_ca_system_score_codex":0.14711776,"about_ca_system_score_gemma":0.03309433,"threshold_uncertainty_score":0.99997497},"labels":[],"label_agreement":null},{"id":"W2921063124","doi":"10.1111/bjh.15865","title":"Expression and function of phosphoinositide 3‐kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow","year":2019,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Health Sciences Centre; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Idelalisib; Mesenchymal stem cell; Bone marrow; Stromal cell; PI3K/AKT/mTOR pathway; Haematopoiesis; Cancer research; Chronic lymphocytic leukemia; Phosphoinositide 3-kinase; Medicine; Biology; Immunology; Pathology; Leukemia; Stem cell; Cell biology; Signal transduction; Ibrutinib","score_opus":0.007748141663317778,"score_gpt":0.23961043869336562,"score_spread":0.23186229703004785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921063124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893028,0.009996977,0.000061761464,0.00008513911,0.00019035321,0.00019809032,0.000017969462,0.0000049332725,0.00014197647],"genre_scores_gemma":[0.9978918,0.0009643232,0.00092980865,0.00006069701,0.000060912775,0.0000020309203,0.000009544369,0.000017252292,0.00006366849],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99836487,0.0001273448,0.00065340684,0.000217771,0.00034161258,0.00029500466],"domain_scores_gemma":[0.99899477,0.0002454285,0.00029477465,0.00014273742,0.00014024517,0.00018203747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039142912,0.000121813275,0.0007452882,0.000192676,0.000027628532,0.000019001991,0.000082847815,0.00018118536,0.00025200573],"category_scores_gemma":[0.00012411825,0.00012567065,0.000069163405,0.000101433616,0.00017875106,0.00020483986,0.000116876596,0.00043312125,0.000005280304],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061044665,0.00040226727,0.090130776,0.0009479202,0.00017344819,0.07820905,0.00041578786,0.000042862957,0.80243504,0.00008897213,0.0032361583,0.017813224],"study_design_scores_gemma":[0.066397674,0.0024974484,0.10782899,0.0048886403,0.00024037201,0.4403512,0.0011541316,0.0029685793,0.3723516,0.0005435081,0.00040697548,0.00037089366],"about_ca_topic_score_codex":0.0015901346,"about_ca_topic_score_gemma":0.00018640356,"teacher_disagreement_score":0.43008348,"about_ca_system_score_codex":0.00045953476,"about_ca_system_score_gemma":0.00095173845,"threshold_uncertainty_score":0.51247},"labels":[],"label_agreement":null},{"id":"W2921140763","doi":"10.1182/blood-2018-99-118148","title":"Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Ven; Venetoclax; Medicine; Bendamustine; Rituximab; Ibrutinib; Internal medicine; Bristol-Myers; Neutropenia; Chronic lymphocytic leukemia; Oncology; Leukemia; Chemotherapy; Lymphoma","score_opus":0.010548661146973648,"score_gpt":0.2510935840606621,"score_spread":0.24054492291368848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921140763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951835,0.00082111824,0.0000015354067,0.000008216757,0.00017163003,0.003366915,0.00014507363,0.000026860738,0.00027510672],"genre_scores_gemma":[0.99907607,0.0001020713,0.000063488114,0.000034410128,0.0001807871,0.00015456606,0.000116749376,0.00007227203,0.00019958409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670017,0.00024410771,0.0008530315,0.000673814,0.00095530873,0.00057357847],"domain_scores_gemma":[0.9973667,0.00059617317,0.00033185852,0.0011496771,0.0003552534,0.00020031862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026435318,0.00041558617,0.0008379325,0.00015751818,0.000088018736,0.00001660513,0.00028206178,0.00018199168,0.00015783314],"category_scores_gemma":[0.00025695658,0.00026115513,0.00011909773,0.00043213877,0.00053583295,0.00012513228,0.00021440123,0.0002100159,0.000028134229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029758615,0.0051354947,0.9454856,0.00022583334,0.0014847841,0.0000945013,0.007985647,0.000029754936,0.00027799443,0.0000028335874,0.00009276609,0.009426156],"study_design_scores_gemma":[0.26667836,0.010272122,0.71924496,0.00051599013,0.0006213596,0.0000030187152,0.00018180859,0.00019953215,0.0017517438,0.0000042902357,0.00033132778,0.00019548526],"about_ca_topic_score_codex":0.0048252484,"about_ca_topic_score_gemma":0.0014051874,"teacher_disagreement_score":0.23691976,"about_ca_system_score_codex":0.026216915,"about_ca_system_score_gemma":0.014129674,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W2921143502","doi":"10.1093/jcag/gwz006.067","title":"A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN’S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adalimumab; Indirect costs; Randomization; Faecal calprotectin; Internal medicine; Physical therapy; Randomized controlled trial; Disease; Inflammatory bowel disease; Calprotectin","score_opus":0.016418121475040952,"score_gpt":0.29375452515607187,"score_spread":0.2773364036810309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921143502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367154,0.000034719356,0.000036175425,0.0024043238,0.00036673373,0.0023670637,0.0010264012,0.0000010496184,0.00009199098],"genre_scores_gemma":[0.99957067,0.0000028495879,0.000031063882,0.0001413713,0.00011963313,0.000040531595,0.000031375774,0.000017255328,0.00004524414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771035,0.00083833793,0.000501556,0.0001517501,0.0004682784,0.00032970653],"domain_scores_gemma":[0.9960472,0.0006573044,0.0011436,0.00024684158,0.0014736734,0.00043140695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018721133,0.00012940457,0.0006976244,0.00036566946,0.000047050704,0.000007638488,0.00017350721,0.000114907925,0.00013224715],"category_scores_gemma":[0.00074025115,0.00009306122,0.0002989804,0.000068808986,0.000092458984,0.000057519992,0.000005288586,0.00013016403,0.0000017149587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.21382785,0.00026470114,0.76333725,0.00010235257,0.003006794,0.000023492006,0.0003371988,0.018004967,0.00035120317,0.00015283257,0.00045733893,0.00013405204],"study_design_scores_gemma":[0.40074632,0.0060355486,0.5732841,0.00026088272,0.0018135026,0.000011543511,0.0001325552,0.016831756,0.0005149027,0.00018166097,0.00012049054,0.00006678132],"about_ca_topic_score_codex":0.550504,"about_ca_topic_score_gemma":0.9313216,"teacher_disagreement_score":0.38081756,"about_ca_system_score_codex":0.09221183,"about_ca_system_score_gemma":0.047413867,"threshold_uncertainty_score":0.9579864},"labels":[],"label_agreement":null},{"id":"W2921403167","doi":"10.1111/bjh.15827","title":"Genomic data in prognostic models—what is lost in translation? The case of deletion 17p and mutant<i>TP53</i>in chronic lymphocytic leukaemia","year":2019,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto","funders":"","keywords":"Copy-number variation; Chronic lymphocytic leukemia; Genomics; Mutation; Cytogenetics; Clinical significance; Bioinformatics; Medicine; Biology; Oncology; Chromosome; Computational biology; Internal medicine; Genetics; Leukemia; Gene; Genome","score_opus":0.09968734266479744,"score_gpt":0.3740238798445964,"score_spread":0.27433653717979894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921403167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14449234,0.85346,0.000040702704,0.000101594094,0.00014356572,0.0016549117,0.000067411216,0.000003085536,0.000036378115],"genre_scores_gemma":[0.0953211,0.90426177,0.000118745396,0.000048805952,0.000081899285,0.000021540622,0.0000664739,0.000065303124,0.000014371158],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99515694,0.0007459117,0.0024972036,0.00058793114,0.00040245467,0.00060954504],"domain_scores_gemma":[0.9965957,0.0014044751,0.0009288431,0.00078564725,0.00014808994,0.00013727893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021235596,0.0003679114,0.0033938312,0.0008361835,0.000033441585,0.00007266549,0.0007143468,0.00058257516,0.00006277456],"category_scores_gemma":[0.00032028527,0.0003179349,0.00023833883,0.00065372617,0.00037317106,0.00050302217,0.0002681982,0.0013215898,0.000015745863],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0001446256,0.000111714166,0.000042622527,0.034327924,0.0001969927,0.27690282,0.00033090025,0.00024817407,0.0000038202343,0.000042851243,0.00009705049,0.6875505],"study_design_scores_gemma":[0.012176086,0.00020959588,0.000014919533,0.06313621,0.00074499426,0.8751987,0.00019300672,0.041831493,0.000002693434,0.00019074086,0.006066529,0.00023500354],"about_ca_topic_score_codex":0.0030190437,"about_ca_topic_score_gemma":0.0064591267,"teacher_disagreement_score":0.6873155,"about_ca_system_score_codex":0.01695847,"about_ca_system_score_gemma":0.034849294,"threshold_uncertainty_score":0.9999273},"labels":[],"label_agreement":null},{"id":"W2922249564","doi":"10.1182/blood-2019-01-896290","title":"Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; Cancer Research UK; F. Hoffmann-La Roche","keywords":"Venetoclax; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Refractory (planetary science); Fludarabine; Leukemia; Bendamustine; Ibrutinib; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide; Biology","score_opus":0.013317298047628056,"score_gpt":0.29284353042942995,"score_spread":0.2795262323818019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922249564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927392,0.0033597331,5.4338483e-7,0.0000054017573,0.00007667455,0.002532637,0.0000059402446,0.00006914798,0.001210736],"genre_scores_gemma":[0.99802727,0.0003568352,0.00002821494,0.000025439536,0.00008979321,0.000079995414,0.000022857961,0.00006310392,0.0013064763],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973672,0.00014598075,0.00063288136,0.0006260804,0.0006098542,0.00061800814],"domain_scores_gemma":[0.99833626,0.00022098658,0.0001651814,0.0009333384,0.00010751888,0.00023674897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041444748,0.00029429168,0.0008061907,0.00033963996,0.000035790337,0.000019052311,0.00021505746,0.00020452669,0.00017589456],"category_scores_gemma":[0.00015223442,0.00026184166,0.00007710847,0.0005502464,0.00012409917,0.00012072398,0.0001708247,0.0003490743,0.000114337214],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.047048338,0.11920931,0.18151884,0.032519553,0.011680437,0.0280707,0.081152126,0.009836788,0.38064757,0.00059844047,0.003102003,0.10461589],"study_design_scores_gemma":[0.91991466,0.025275625,0.0056478744,0.0011967645,0.0007292755,0.0008096516,0.0012734847,0.030098855,0.013901128,0.000027255188,0.00061911653,0.00050633546],"about_ca_topic_score_codex":0.0060196947,"about_ca_topic_score_gemma":0.00045267493,"teacher_disagreement_score":0.8728663,"about_ca_system_score_codex":0.09242295,"about_ca_system_score_gemma":0.046071474,"threshold_uncertainty_score":0.9999834},"labels":[],"label_agreement":null},{"id":"W2922464087","doi":"10.1182/blood-2018-99-116806","title":"Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Ven; Medicine; Internal medicine; Venetoclax; Bendamustine; Rituximab; Gastroenterology; Clinical endpoint; Regimen; Chronic lymphocytic leukemia; Randomized controlled trial; Lymphoma; Leukemia","score_opus":0.02138922789065322,"score_gpt":0.3128269048354661,"score_spread":0.2914376769448129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922464087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967198,0.0003742502,0.00001575523,0.00001813268,0.00007126778,0.002575485,0.000060406655,0.000021801012,0.00014309556],"genre_scores_gemma":[0.99926794,0.000062134925,0.00026205688,0.00001631147,0.00008016739,0.00007115025,0.000093070514,0.000037020756,0.00011017716],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967856,0.00032361425,0.0009999825,0.0005378472,0.000898694,0.00045427264],"domain_scores_gemma":[0.99724984,0.00085556955,0.000409857,0.0007192887,0.0005487582,0.00021666825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010112331,0.0003015917,0.0019878715,0.00059004466,0.000091265196,0.0000092651335,0.0002022248,0.00014186397,0.00016680238],"category_scores_gemma":[0.0016229106,0.00021322482,0.00020708279,0.0013026668,0.0005648567,0.00008835749,0.00015480588,0.00016068191,0.000003713726],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9410896,0.036045745,0.0056251134,0.00018843009,0.008987321,0.0002888724,0.0023860692,0.00003584701,0.00035087502,0.000013431608,0.00003600421,0.0049526924],"study_design_scores_gemma":[0.9394593,0.019983793,0.026958868,0.0002526568,0.009129004,0.000010212477,0.0002040396,0.0024592916,0.0012331001,0.0000016211644,0.00010920181,0.00019886535],"about_ca_topic_score_codex":0.0012268227,"about_ca_topic_score_gemma":0.0004935969,"teacher_disagreement_score":0.021333754,"about_ca_system_score_codex":0.0017151025,"about_ca_system_score_gemma":0.003067183,"threshold_uncertainty_score":0.8695056},"labels":[],"label_agreement":null},{"id":"W2924114093","doi":"10.1016/j.neurol.2019.01.257","title":"Analyse primaire d’une étude de Phase 2 randomisée, contrôlée par placebo évaluant l’évobrutinib (M2951), un inhibiteur de la tyrosine kinase de Bruton, chez des patients atteints d’une forme récurrente de sclérose en plaques","year":2019,"lang":"fr","type":"article","venue":"Revue Neurologique","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Gynecology","score_opus":0.011644758085822715,"score_gpt":0.30013829316343776,"score_spread":0.28849353507761505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924114093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839627,0.0070817047,0.001029072,0.0019406924,0.00058244244,0.0038824836,0.00023955309,0.00030412982,0.0009772046],"genre_scores_gemma":[0.9837094,0.0094511965,0.0012268863,0.0024959883,0.0010436351,0.00041401904,0.0002283047,0.00028889583,0.0011416771],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98601526,0.0060689636,0.0016792979,0.0015992027,0.0009112305,0.003726027],"domain_scores_gemma":[0.989669,0.005926792,0.00074027636,0.001500722,0.0005376192,0.001625568],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.008288437,0.0011919257,0.0020621775,0.00050811964,0.00037447448,0.00020343199,0.0010197992,0.001622134,0.00052931055],"category_scores_gemma":[0.010405553,0.0011698911,0.00073278364,0.0012646596,0.0014688256,0.00044549702,0.00063292193,0.0030549362,0.0002897722],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08292322,0.012934284,0.5952141,0.008992025,0.0017121002,0.018676674,0.019624352,0.002612375,0.16941805,0.00048520428,0.0038957186,0.08351189],"study_design_scores_gemma":[0.42339316,0.010536266,0.14171664,0.0055374643,0.0024019908,0.0071918997,0.00046858116,0.17035873,0.22556958,0.0012392969,0.009454834,0.0021315673],"about_ca_topic_score_codex":0.0041055786,"about_ca_topic_score_gemma":0.00049729575,"teacher_disagreement_score":0.45349747,"about_ca_system_score_codex":0.015722668,"about_ca_system_score_gemma":0.012546188,"threshold_uncertainty_score":0.99967396},"labels":[],"label_agreement":null},{"id":"W2926578344","doi":"10.14740/jh469","title":"A Case of Waldenstrom’s Macroglobulinemia Morphologically Resembling Plasma Cell Myeloma","year":2019,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Macroglobulinemia; Waldenstrom macroglobulinemia; Multiple myeloma; Medicine; Bone marrow; Plasma cell; Pathology; Gammopathy; Monoclonal; Immunology; Antibody; Monoclonal antibody; Lymphoma","score_opus":0.021906581243357873,"score_gpt":0.3086628398409719,"score_spread":0.28675625859761406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926578344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948647,0.0005246731,0.00012158513,0.00061168394,0.0002624613,0.0002452892,0.000003428378,0.000011341356,0.0033548526],"genre_scores_gemma":[0.9931131,0.00006657988,0.005836495,0.00012180472,0.000114143,0.0000017591365,0.000001505627,0.000023261104,0.0007213574],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99775344,0.0001155123,0.0010281417,0.00020835559,0.00045869255,0.00043585748],"domain_scores_gemma":[0.9976198,0.000532039,0.0006351397,0.000393377,0.0005660773,0.00025358162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068461447,0.0001652134,0.0009828493,0.00033655344,0.000029428667,0.000008774604,0.00024552702,0.00027530422,0.000795498],"category_scores_gemma":[0.00047986067,0.00011864035,0.00027390724,0.00025563414,0.00016770462,0.000069082795,0.00013401764,0.0006292283,0.00014432099],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007530419,0.0011714083,0.015419054,0.0026134741,0.00057795795,0.574609,0.0008557334,0.00032920588,0.37615696,0.0024032982,0.0159114,0.0024221211],"study_design_scores_gemma":[0.020113166,0.0021257524,0.0002076211,0.00026299455,0.0001221558,0.8477167,0.00057138235,0.0039497693,0.123602405,0.00020969212,0.0009933088,0.00012504676],"about_ca_topic_score_codex":0.0000454416,"about_ca_topic_score_gemma":0.0000064249925,"teacher_disagreement_score":0.27310774,"about_ca_system_score_codex":0.0014681028,"about_ca_system_score_gemma":0.0033267848,"threshold_uncertainty_score":0.87101454},"labels":[],"label_agreement":null},{"id":"W2930854972","doi":"10.14740/jh482","title":"Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Bendamustine; Internal medicine; Bruton's tyrosine kinase; Chemoimmunotherapy; Oncology; Rituximab; Leukemia; Lymphoma; Tyrosine kinase","score_opus":0.05911591890846276,"score_gpt":0.39523305746200976,"score_spread":0.336117138553547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930854972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006115019,0.99456036,0.000026646141,0.00006809464,0.00027299524,0.004619114,0.0000056739145,0.00001526557,0.00037071318],"genre_scores_gemma":[0.00026050518,0.9987088,0.00015713008,0.00017050712,0.00014832403,0.00008863653,0.000020711557,0.00011710864,0.00032829662],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99049294,0.0011960369,0.0058767954,0.00048263426,0.0011757191,0.00077587453],"domain_scores_gemma":[0.9886948,0.00357993,0.0053928527,0.0015586425,0.00047946666,0.0002943496],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0030636129,0.0006877178,0.01567967,0.0014159307,0.000021972859,0.00001200318,0.0009862315,0.0008787651,0.00016748172],"category_scores_gemma":[0.004045953,0.00045659175,0.0021527107,0.0011618565,0.00025308717,0.000076258955,0.00016324106,0.0014785904,0.0002646208],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014110692,0.000076876655,6.820324e-7,0.9916196,0.00083415734,0.0026183415,0.000017470915,0.000022549266,9.100502e-7,0.00016555861,0.0016038044,0.0028989273],"study_design_scores_gemma":[0.017036978,0.00083663664,2.3857632e-7,0.8956203,0.009076308,0.04321799,0.000009042024,0.0004793146,0.0000138757505,0.000009281081,0.033423018,0.00027699798],"about_ca_topic_score_codex":0.00005419398,"about_ca_topic_score_gemma":0.0000050579456,"teacher_disagreement_score":0.097331166,"about_ca_system_score_codex":0.1446865,"about_ca_system_score_gemma":0.24201767,"threshold_uncertainty_score":0.9997886},"labels":[],"label_agreement":null},{"id":"W2936758797","doi":"10.2147/ott.s191179","title":"&lt;p&gt;Rituximab-based combination therapy in patients with Waldenstr&amp;ouml;m macroglobulinemia: a systematic review and meta-analysis&lt;/p&gt;","year":2019,"lang":"en","type":"review","venue":"OncoTargets and Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fourth Military Medical University","keywords":"Medicine; Rituximab; Waldenstrom macroglobulinemia; Macroglobulinemia; Meta-analysis; Internal medicine; Oncology; Lymphoma; Multiple myeloma","score_opus":0.0625034392856693,"score_gpt":0.34469866020691664,"score_spread":0.2821952209212473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936758797","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076433277,0.9878334,0.000016298653,0.00028201242,0.000045483925,0.010701677,0.00012916717,0.00004940919,0.00017824402],"genre_scores_gemma":[0.00079397927,0.9944236,0.00025999596,0.00095246185,0.000033657423,0.0009605624,0.00095120573,0.0001474114,0.0014770917],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99420047,0.0008719393,0.0016968853,0.0012112875,0.0013183372,0.0007010861],"domain_scores_gemma":[0.9961424,0.0005516218,0.0010126579,0.001491871,0.00048330065,0.0003181363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015833518,0.0011206778,0.012035602,0.0007295158,0.00011112302,0.00012575705,0.0003595806,0.00051885843,0.00048179866],"category_scores_gemma":[0.000112108675,0.0006146046,0.0014610633,0.0014151237,0.00019843968,0.00012566,0.00007523826,0.0006316661,0.00006301646],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041061782,0.0019444556,0.0000833772,0.85946405,0.10792874,0.00009421361,0.00010713647,0.0000017886305,8.881096e-7,0.00018396688,0.0005102459,0.029270522],"study_design_scores_gemma":[0.052569035,0.0023778845,0.0001081189,0.07437323,0.4864156,0.000113847134,0.000004018521,0.00022490752,0.0000013613754,0.000028339433,0.38226795,0.0015156996],"about_ca_topic_score_codex":0.000068934474,"about_ca_topic_score_gemma":0.00006700913,"teacher_disagreement_score":0.7850908,"about_ca_system_score_codex":0.0024235074,"about_ca_system_score_gemma":0.002644691,"threshold_uncertainty_score":0.9996305},"labels":[],"label_agreement":null},{"id":"W2941130110","doi":"10.1016/j.stemcr.2019.03.011","title":"Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes","year":2019,"lang":"en","type":"article","venue":"Stem Cell Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of British Columbia; University of Toronto; BC Children's Hospital; Simon Fraser University","funders":"Canadian Institutes of Health Research; Stem Cell Network; St. Paul's Foundation","keywords":"Bruton's tyrosine kinase; Ibrutinib; Tyrosine kinase; Biology; Cardiotoxicity; Induced pluripotent stem cell; Stem cell; Cancer research; Cell; Pharmacology; Signal transduction; Cell biology; Immunology; Leukemia; Biochemistry; Embryonic stem cell; Genetics; Chemotherapy; Chronic lymphocytic leukemia; Gene","score_opus":0.02081744247874157,"score_gpt":0.27317842636100814,"score_spread":0.2523609838822666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941130110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93036395,0.002145029,0.000018397663,0.00004373505,0.0008016907,0.0019066831,0.0000065297263,0.00012524078,0.064588726],"genre_scores_gemma":[0.97405034,0.00012823299,0.000057929956,0.000037030775,0.00040933545,0.000036161993,0.000050368268,0.00009136356,0.025139255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99524784,0.00018412659,0.0012822743,0.0011200539,0.001219294,0.0009464075],"domain_scores_gemma":[0.9969724,0.0002479426,0.00042640397,0.001801818,0.00016360299,0.00038784792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012894211,0.00041295466,0.0010375364,0.00029045696,0.00011299235,0.00007823238,0.00022399948,0.0003211856,0.00050344906],"category_scores_gemma":[0.00001494293,0.00036826712,0.00046016433,0.0005044748,0.00012334924,0.00014009365,0.00028016488,0.000523598,0.00034873944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011003631,0.00066800974,0.08400112,0.0029842237,0.00023562644,0.033553552,0.003153059,0.0008130966,0.85909283,0.00011398602,0.008982219,0.0053019025],"study_design_scores_gemma":[0.029046234,0.00088715344,0.009771833,0.0007035344,0.0001681506,0.0033511545,0.0023770842,0.0008370365,0.9051274,0.00006505506,0.046515,0.001150351],"about_ca_topic_score_codex":0.000489991,"about_ca_topic_score_gemma":0.000029503728,"teacher_disagreement_score":0.07422928,"about_ca_system_score_codex":0.007844158,"about_ca_system_score_gemma":0.0030473538,"threshold_uncertainty_score":0.9998769},"labels":[],"label_agreement":null},{"id":"W2943029043","doi":"10.1007/s11095-019-2605-8","title":"Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial","year":2019,"lang":"en","type":"article","venue":"Pharmaceutical Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"Janssen Research and Development; Pharmacyclics; F. Hoffmann-La Roche; AstraZeneca; Celgene; Gilead Sciences; H. Lundbeck A/S","keywords":"Rituximab; Bendamustine; Ibrutinib; Medicine; Pharmacokinetics; Population; Chronic lymphocytic leukemia; Placebo; Internal medicine; Cmin; Pharmacology; Ofatumumab; Oncology; Lymphoma; Leukemia; Cmax; Pathology","score_opus":0.16063657872043013,"score_gpt":0.4526326879843871,"score_spread":0.29199610926395697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943029043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98401845,0.0017457044,0.00006660626,0.003525257,0.00012286282,0.004122151,0.00008350753,0.00005334977,0.0062621185],"genre_scores_gemma":[0.9980526,0.0003469181,0.00004259569,0.0005083744,0.00023127682,0.00017806946,0.000033016626,0.00005840931,0.0005487578],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9929989,0.0013672091,0.00076121354,0.00074049894,0.0030597523,0.0010724439],"domain_scores_gemma":[0.9920263,0.0057813334,0.00007473189,0.000890046,0.0005884354,0.0006391083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075631407,0.00026590886,0.00061581464,0.00036098593,0.00016140398,0.00006632716,0.00048485698,0.00018876951,0.0005958084],"category_scores_gemma":[0.0035844853,0.00017603958,0.0001422212,0.00083996454,0.00048345316,0.00006691382,0.000286006,0.0016489592,0.00032336652],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6429888,0.003808271,0.00040913018,0.004248326,0.00043999645,0.00028230957,0.0005089141,0.0013725981,0.3229488,0.0011686849,0.013083499,0.008740621],"study_design_scores_gemma":[0.24375603,0.0014167145,0.0000057760726,0.00051072513,0.00006128558,0.000043301985,0.00013948188,0.7182321,0.033931833,0.000032816257,0.0017355059,0.00013445971],"about_ca_topic_score_codex":0.00027991712,"about_ca_topic_score_gemma":7.795662e-7,"teacher_disagreement_score":0.71685946,"about_ca_system_score_codex":0.0019163006,"about_ca_system_score_gemma":0.0034633463,"threshold_uncertainty_score":0.71786857},"labels":[],"label_agreement":null},{"id":"W2943086918","doi":"10.1182/blood.v130.suppl_1.5189.5189","title":"Case Report of Aggressive T-Cell Large Granular Lymphocytic Leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Université de Sherbrooke","funders":"","keywords":"Pancytopenia; Lymphocytosis; Medicine; Cytopenia; Leukemia; Pathology; Splenectomy; Bone marrow; Prolymphocytic leukemia; Immunology; Gastroenterology; Chronic lymphocytic leukemia; Spleen","score_opus":0.022470025270042566,"score_gpt":0.3068712634872941,"score_spread":0.28440123821725155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943086918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810305,0.0010004856,0.000031583815,0.00004443691,0.00015342803,0.00048077301,0.000027108934,0.00005656106,0.017175114],"genre_scores_gemma":[0.99450225,0.00010088489,0.0005044816,0.000052789805,0.00024055659,0.000029247045,0.000026205695,0.000049606915,0.0044939816],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9977471,0.000041356645,0.00050718774,0.00046684814,0.0006580499,0.00057942746],"domain_scores_gemma":[0.99598426,0.00009874164,0.0009557668,0.002358975,0.00028699948,0.00031527466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000557027,0.00021876355,0.00055976055,0.0001214216,0.0003209079,0.00004657361,0.00035079135,0.00019651026,0.00015900639],"category_scores_gemma":[0.0017963612,0.00018867488,0.0002162484,0.00009459008,0.00029229542,0.00011617819,0.00031543992,0.00022341708,0.00010854061],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015852014,0.0005631086,0.0027959663,0.0006576251,0.00017030581,0.9890713,0.00028575718,0.0000043035648,0.0044632955,0.00008197108,0.0012995087,0.00044830123],"study_design_scores_gemma":[0.101098716,0.000310848,0.0009310946,0.00041949665,0.00074577157,0.68470365,0.00015775127,0.0023661023,0.20700684,0.00011403358,0.0018465312,0.00029918496],"about_ca_topic_score_codex":0.002412487,"about_ca_topic_score_gemma":0.00006630995,"teacher_disagreement_score":0.30436772,"about_ca_system_score_codex":0.0068866364,"about_ca_system_score_gemma":0.017700411,"threshold_uncertainty_score":0.9969258},"labels":[],"label_agreement":null},{"id":"W2943920857","doi":"10.1016/j.ekir.2019.04.022","title":"Persistent Mixed Cryoglobulinemia Despite Successful Treatment of Hepatitis C, Aggressive B-Cell–Directed Therapies, and Long-term Plasma Exchanges","year":2019,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Jerome; Hôpital Maisonneuve-Rosemont; Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Cryoglobulins; Medicine; Cryoglobulinemia; Macroglobulinemia; Monoclonal; Immunology; Waldenstrom macroglobulinemia; Immunoglobulin M; Chronic lymphocytic leukemia; Rheumatoid factor; Polyclonal antibodies; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Virology; Hepatitis C virus; Monoclonal antibody; Immune system; Rheumatoid arthritis; Antigen; Antibody; Immunoglobulin G; Leukemia; Lymphoma; Virus","score_opus":0.014091444300496537,"score_gpt":0.2807747956485387,"score_spread":0.26668335134804216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943920857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991671,0.0016102259,0.000011022581,0.0009780194,0.000792987,0.00069986295,0.000056806326,0.00005856323,0.0041214996],"genre_scores_gemma":[0.9854011,0.0026634105,0.00035329632,0.00012284209,0.00017262298,0.000066246495,0.00036850126,0.000033339213,0.010818626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978954,0.00004117414,0.0004978685,0.00048462834,0.00080646167,0.00027442744],"domain_scores_gemma":[0.9981213,0.00013611441,0.0005192748,0.00042623203,0.00044993288,0.00034713338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013109115,0.00023301445,0.00042078833,0.00021371093,0.000037118563,0.00003744198,0.00010632964,0.00012417513,0.0012854651],"category_scores_gemma":[0.00035994104,0.00018718597,0.00019125294,0.0001211445,0.00012461127,0.00009628101,0.000086887,0.00008997658,0.000025238072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006747074,0.0008052802,0.9608987,0.00041617293,0.001354503,0.0060355924,0.0013789823,0.000009865131,0.009574598,0.000028661765,0.0031781653,0.015644753],"study_design_scores_gemma":[0.06483976,0.0061229127,0.68386394,0.0037585457,0.0010226007,0.027559344,0.00055962056,0.018691769,0.15160508,0.00014282689,0.040521484,0.0013121284],"about_ca_topic_score_codex":0.0011216198,"about_ca_topic_score_gemma":0.00009207004,"teacher_disagreement_score":0.2770348,"about_ca_system_score_codex":0.004014599,"about_ca_system_score_gemma":0.0022108061,"threshold_uncertainty_score":0.9998088},"labels":[],"label_agreement":null},{"id":"W2944175434","doi":"10.1111/cup.13491","title":"Cutaneous plasmacytosis and multinucleate cell angiohistiocytoma‐like lesion in a patient with hepatitis B: A fortuitous triad?","year":2019,"lang":"en","type":"article","venue":"Journal of Cutaneous Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Université de Montréal","funders":"","keywords":"Plasmacytosis; Pathology; Medicine; Biopsy; Papule; Lesion; Bone marrow","score_opus":0.008930485349602767,"score_gpt":0.24903412798551683,"score_spread":0.24010364263591405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944175434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722594,0.00072140107,0.000035673787,0.00018564798,0.00024512946,0.00064926635,0.000010726112,0.000021593332,0.00090463826],"genre_scores_gemma":[0.9960112,0.0008940711,0.0021047057,0.0003077772,0.00009445823,0.000006893994,0.000004017305,0.000059618884,0.000517289],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9975482,0.00016605038,0.00080453634,0.0003194631,0.0006149258,0.00054682343],"domain_scores_gemma":[0.99823475,0.0004188324,0.00048405517,0.00033596152,0.00023206059,0.0002943648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024761359,0.00026991934,0.0008917776,0.00050735887,0.000048560065,0.000025131643,0.00015116652,0.00023190242,0.00013124873],"category_scores_gemma":[0.00013287025,0.00020073328,0.00013884864,0.00022261537,0.00016201023,0.0000827372,0.00009865384,0.0005914955,0.000053561875],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02663189,0.0012709672,0.06679673,0.0007680874,0.00021995044,0.78690135,0.0069522164,0.001184519,0.0666446,0.000022362367,0.0009214048,0.041685898],"study_design_scores_gemma":[0.024899721,0.01613047,0.0010047661,0.0005498392,0.00018264195,0.9429311,0.0006050683,0.0060750237,0.004979773,0.000048162314,0.0022889425,0.0003044735],"about_ca_topic_score_codex":0.00023198016,"about_ca_topic_score_gemma":0.00020374212,"teacher_disagreement_score":0.15602975,"about_ca_system_score_codex":0.0031385194,"about_ca_system_score_gemma":0.001775723,"threshold_uncertainty_score":0.8207119},"labels":[],"label_agreement":null},{"id":"W2944582362","doi":"10.1056/nejmoa1901981","title":"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada); University of Toronto; St. Michael's Hospital","funders":"Merck KGaA","keywords":"Placebo; Multiple sclerosis; Medicine; Bruton's tyrosine kinase; Internal medicine; Clinical trial; Oncology; Pharmacology; Alternative medicine; Immunology; Pathology; Tyrosine kinase","score_opus":0.04527378136246739,"score_gpt":0.3088913223947608,"score_spread":0.2636175410322934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944582362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947636,0.00044722643,0.000025446208,0.0013894563,0.0010395749,0.0012988665,0.0000012286619,0.000008156319,0.0010264155],"genre_scores_gemma":[0.99448687,0.00017573919,0.00045930612,0.0001377082,0.0039707683,0.000005524516,0.0000046956407,0.000026132644,0.0007332739],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967551,0.00027103783,0.0012254224,0.00018768117,0.0012265568,0.00033416878],"domain_scores_gemma":[0.9974899,0.00094625703,0.00047313867,0.00033456017,0.000288345,0.0004677755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032424133,0.00018638073,0.0014612733,0.0005411264,0.000017563802,0.000007000184,0.00021155622,0.00013876327,0.0005638839],"category_scores_gemma":[0.0024727834,0.00011427401,0.00015768463,0.0003214288,0.00013210211,0.00015739801,0.00003535396,0.0005638629,0.0000129201035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93007714,0.00057707715,0.002931915,0.00012480146,0.0001914953,0.00042006822,0.0011821844,0.00012416778,0.024835343,0.000019660833,0.0015917987,0.03792435],"study_design_scores_gemma":[0.9771411,0.012302348,0.00096279406,0.0010430834,0.00015884994,0.000684223,0.00025150005,0.0034255313,0.0023285875,0.000064235515,0.0015450069,0.00009272791],"about_ca_topic_score_codex":0.00070564565,"about_ca_topic_score_gemma":0.00016730028,"teacher_disagreement_score":0.047063973,"about_ca_system_score_codex":0.001424534,"about_ca_system_score_gemma":0.004559037,"threshold_uncertainty_score":0.80875355},"labels":[],"label_agreement":null},{"id":"W2945068176","doi":"10.1002/jcph.1446","title":"Membrane‐Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population","year":2019,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Natural Science Foundation of China","keywords":"Odds ratio; Methotrexate; Single-nucleotide polymorphism; Rheumatoid arthritis; SNP; Medicine; Internal medicine; Pharmacology; Adverse effect; Confidence interval; Arthritis; Genotype; Bioinformatics; Genetics; Gene; Biology","score_opus":0.038734896236194846,"score_gpt":0.4362140282801865,"score_spread":0.39747913204399166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945068176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892949,0.0012235829,0.000041349664,0.0069322027,0.0010847818,0.001219301,0.0000011010444,0.000017992445,0.00018479631],"genre_scores_gemma":[0.995286,0.0010344418,0.00053320767,0.0022893886,0.0001898698,0.000012681821,0.0000012744166,0.000039529692,0.00061358965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950484,0.0016081507,0.0020989839,0.00022278768,0.0005756179,0.0004460375],"domain_scores_gemma":[0.996366,0.0021951087,0.000662188,0.00030568024,0.00017087624,0.00030012263],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0051183505,0.00020674108,0.0012127896,0.00031122405,0.000044985067,0.000011399096,0.00038731738,0.00020845633,0.00093336345],"category_scores_gemma":[0.0010237197,0.00012118035,0.00029705244,0.00048968726,0.000119450655,0.00010085524,0.00012120377,0.0012593932,0.00019400907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018754445,0.00148144,0.67974466,0.00015920174,0.0019399279,0.0014214551,0.0019854235,0.0069842963,0.2304382,0.00007282493,0.0005560892,0.056462053],"study_design_scores_gemma":[0.07154604,0.0030839713,0.90156406,0.0005384206,0.00018681126,0.002617899,0.00010558177,0.014515387,0.003776267,0.0010471743,0.00071040285,0.00030799911],"about_ca_topic_score_codex":0.00023231219,"about_ca_topic_score_gemma":0.0000186725,"teacher_disagreement_score":0.22666194,"about_ca_system_score_codex":0.0009381586,"about_ca_system_score_gemma":0.0014296572,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W2945203483","doi":"10.1017/cjn.2019.75","title":"Central Nervous System Involvement with Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"letter","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chronic lymphocytic leukemia; Content (measure theory); Medicine; Neuroscience; Central nervous system; Leukemia; Psychology; Internal medicine; Mathematics","score_opus":0.032215579514967126,"score_gpt":0.2626414929480219,"score_spread":0.2304259134330548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945203483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.924154,0.0033800092,0.000026313306,0.06497441,0.002366231,0.00086683646,0.000036595025,0.0000617408,0.004133877],"genre_scores_gemma":[0.8165327,0.0005308679,0.0007373228,0.17684448,0.004773088,0.000011658988,0.0000058962037,0.00007979269,0.00048421125],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9878079,0.0013684013,0.0017395712,0.0013532704,0.0033373449,0.004393502],"domain_scores_gemma":[0.99242824,0.0010820347,0.001773335,0.00058464875,0.0010851662,0.003046551],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity"],"consensus_categories":["sts"],"category_scores_codex":[0.0040043006,0.0009863215,0.0017933625,0.0022099782,0.0023781594,0.0013285395,0.0038895963,0.0011381631,0.00028606039],"category_scores_gemma":[0.0011416969,0.00060127984,0.00065623637,0.002072455,0.011164765,0.00083724584,0.00017865816,0.0066186944,0.000030408362],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000775697,0.000029206009,0.08568753,0.0011132893,0.00037040547,0.49891496,0.00053588784,0.045197275,0.000022823837,0.00028717166,0.36424604,0.0028197116],"study_design_scores_gemma":[0.005728175,0.2246271,0.007855058,0.001630287,0.00058671384,0.52340573,0.00029368888,0.02828944,0.000085453656,0.00050537445,0.20564434,0.0013486058],"about_ca_topic_score_codex":0.015605788,"about_ca_topic_score_gemma":0.05601455,"teacher_disagreement_score":0.2245979,"about_ca_system_score_codex":0.10567406,"about_ca_system_score_gemma":0.3197966,"threshold_uncertainty_score":0.9997082},"labels":[],"label_agreement":null},{"id":"W2947616753","doi":"10.1136/annrheumdis-2019-eular.2886","title":"OP0029 SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba","funders":"Sanofi Genzyme; Genentech; Regeneron Pharmaceuticals; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Internal medicine; Methotrexate; Placebo; Adverse effect; Gastroenterology; Pathology","score_opus":0.03605637087655619,"score_gpt":0.34789586733678785,"score_spread":0.3118394964602317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947616753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996447,0.00080025895,0.000015898206,0.0010369491,0.00032441254,0.0011417258,0.00006976882,0.000029716111,0.00013426317],"genre_scores_gemma":[0.99896395,0.0003924225,0.000019326975,0.00035519848,0.00006953431,0.000042667783,0.000021034777,0.000039907416,0.00009597323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966757,0.00051423826,0.0009005504,0.00042389444,0.00104313,0.0004424396],"domain_scores_gemma":[0.9943879,0.0041868463,0.00033106928,0.00057998515,0.00021578722,0.00029837774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012869678,0.00028524295,0.00083868793,0.000114016846,0.0003007913,0.000084400424,0.00023075477,0.00012394378,0.000053254564],"category_scores_gemma":[0.0039052148,0.00016902067,0.00042614512,0.0002288439,0.0005047826,0.0002775038,0.0004344762,0.00035380494,0.00001782336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012168862,0.00020016491,0.97563624,0.0001758093,0.00073706656,0.0000061449737,0.00046626714,0.000005560438,0.000008322258,0.000023048502,0.0011172302,0.02040728],"study_design_scores_gemma":[0.013788748,0.00034789473,0.9818414,0.0018285358,0.00011538121,0.000012633918,0.0004164214,0.00070373074,0.00015254694,0.0005672902,0.00004103563,0.00018438968],"about_ca_topic_score_codex":0.00024886033,"about_ca_topic_score_gemma":0.000015160945,"teacher_disagreement_score":0.02022289,"about_ca_system_score_codex":0.00019448524,"about_ca_system_score_gemma":0.0015228345,"threshold_uncertainty_score":0.6892463},"labels":[],"label_agreement":null},{"id":"W2948436219","doi":"10.1056/nejmoa1815281","title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":852,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Novo Nordisk Fonden","keywords":"Venetoclax; Obinutuzumab; Medicine; Ibrutinib; Internal medicine; Oncology; Cancer research; Chronic lymphocytic leukemia; Leukemia","score_opus":0.009446074225422615,"score_gpt":0.27136655057371634,"score_spread":0.26192047634829374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948436219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713314,0.0006320113,0.000012553284,0.00067598897,0.00009936753,0.00023177112,0.0000017190653,0.0000039161564,0.0012095298],"genre_scores_gemma":[0.9986727,0.00012157059,0.0002082308,0.00020029614,0.00046508748,6.462957e-7,0.0000073529523,0.00001241937,0.0003116541],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998903,0.000041105075,0.0003142961,0.00011714327,0.00044560418,0.00017887299],"domain_scores_gemma":[0.99904925,0.0002746046,0.00013877753,0.00011053222,0.0001527275,0.00027412357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045344926,0.000099338075,0.0003858301,0.0002014288,0.00002249882,0.0000071504637,0.00004549238,0.000046003195,0.0001266131],"category_scores_gemma":[0.00028441328,0.00005989519,0.000013113784,0.00013822406,0.00013358539,0.0000783996,0.0000229548,0.0003147448,0.0000026369905],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069163768,0.000081833125,0.94651306,0.0004619482,0.00021129003,0.0008464422,0.0032516292,0.00014644623,0.0008275276,0.0003516377,0.003128237,0.03726356],"study_design_scores_gemma":[0.5194593,0.007028296,0.45871115,0.0025440205,0.00014112033,0.0026467233,0.00035887814,0.0014633146,0.000046460103,0.000297033,0.00717483,0.00012888848],"about_ca_topic_score_codex":0.00029095603,"about_ca_topic_score_gemma":0.00003629606,"teacher_disagreement_score":0.5125429,"about_ca_system_score_codex":0.00199569,"about_ca_system_score_gemma":0.00235783,"threshold_uncertainty_score":0.52186596},"labels":[],"label_agreement":null},{"id":"W2949232069","doi":"10.1136/annrheumdis-2019-eular.3403","title":"THU0167 SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Rheumatoid arthritis; Discontinuation; Adverse effect; Placebo; Adalimumab; Internal medicine; Methotrexate; Phases of clinical research; Clinical trial; Pharmacology; Gastroenterology; Pathology","score_opus":0.04611880106264763,"score_gpt":0.39903815208864907,"score_spread":0.3529193510260014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949232069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180627,0.0038179483,0.00002032859,0.0010257154,0.000090187445,0.0021500422,0.0005474629,0.00004760883,0.00049444713],"genre_scores_gemma":[0.994973,0.0040176506,0.00018624403,0.00020860245,0.000022285076,0.00010660578,0.00025792548,0.000027750419,0.00019992467],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99597657,0.00068774563,0.0015649238,0.0004041846,0.0009149245,0.0004516756],"domain_scores_gemma":[0.99524677,0.002205489,0.000567089,0.0013962152,0.00038926143,0.0001951901],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001252873,0.0002470405,0.0012746843,0.00016809205,0.000054489792,0.000029179846,0.00067302235,0.00011689089,0.0015371937],"category_scores_gemma":[0.0032467819,0.00013197317,0.0008785639,0.0018056157,0.00052214426,0.00010608884,0.00021099298,0.0003285538,0.000069577385],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007912832,0.011191049,0.3657556,0.0010677427,0.009762825,0.00003431958,0.0015160241,0.00030590163,0.0001349448,0.0003541644,0.014340081,0.58762455],"study_design_scores_gemma":[0.07348173,0.0029234493,0.7398046,0.015089068,0.0018418867,0.00003333078,0.0035914343,0.15200396,0.0055519645,0.0016345194,0.0032673876,0.0007766579],"about_ca_topic_score_codex":0.002041739,"about_ca_topic_score_gemma":0.00019612774,"teacher_disagreement_score":0.5868479,"about_ca_system_score_codex":0.0002874024,"about_ca_system_score_gemma":0.0038919058,"threshold_uncertainty_score":0.9993755},"labels":[],"label_agreement":null},{"id":"W2949367253","doi":"10.1182/blood-2018-99-120129","title":"Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Ibrutinib; Medicine; Autoimmune hemolytic anemia; Chronic lymphocytic leukemia; Internal medicine; Anemia; Gastroenterology; Rituximab; Hemolysis; Context (archaeology); Immunology; Leukemia; Lymphoma","score_opus":0.00670622587491227,"score_gpt":0.23393850485983597,"score_spread":0.2272322789849237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949367253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955662,0.00082935253,0.0000071857703,0.0000344223,0.000055956865,0.0010533194,0.000009919013,0.000046980174,0.0023967007],"genre_scores_gemma":[0.99862427,0.000046549776,0.00040450436,0.000079984195,0.00012369444,0.000030872176,0.000026527678,0.000049929677,0.0006136467],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975845,0.000067057474,0.0005617412,0.00047047742,0.0006758252,0.0006403483],"domain_scores_gemma":[0.9985144,0.0001748524,0.00015906744,0.0006951084,0.00025589167,0.00020069412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003493353,0.00027351992,0.00073361536,0.00025640853,0.00006401569,0.000018327124,0.00017730542,0.0001651898,0.00020061676],"category_scores_gemma":[0.0002196269,0.00021180575,0.000062041574,0.0005072973,0.00055909227,0.00010060643,0.00013760652,0.00021520127,0.00005113967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.05581204,0.0068015996,0.84591347,0.009479646,0.003406279,0.0019787601,0.0057661957,0.00043662454,0.032318845,0.000695089,0.0020331205,0.03535834],"study_design_scores_gemma":[0.5661417,0.0069852793,0.39690673,0.001313472,0.00053956197,0.0002218077,0.000073170755,0.01054663,0.016205315,0.00006379658,0.00050313974,0.0004994029],"about_ca_topic_score_codex":0.0014703295,"about_ca_topic_score_gemma":0.00024947512,"teacher_disagreement_score":0.51032966,"about_ca_system_score_codex":0.021577379,"about_ca_system_score_gemma":0.024496302,"threshold_uncertainty_score":0.9821786},"labels":[],"label_agreement":null},{"id":"W2949663727","doi":"10.1136/annrheumdis-2019-eular.1460","title":"FRI0109 EFFECTIVENESS AND SAFETY OF INFLIXIMAB, GOLIMUMAB AND GOLIMUMAB-IV IN RHEUMATOID ARTHRITIS PATIENTS FROM A PROSPECTIVE OBSERVATIONAL REGISTRY","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; University of British Columbia; McMaster University; University of Saskatchewan; University of Alberta; Université Laval; Canadian Rheumatology Association; Université de Montréal; Ontario Rheumatology Association; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Golimumab; Rheumatoid arthritis; Internal medicine; Infliximab; Cohort; Incidence (geometry); Population; Cohort study; Physical therapy; Etanercept; Disease","score_opus":0.0203366777362768,"score_gpt":0.2902031857695247,"score_spread":0.2698665080332479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949663727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938913,0.003931312,0.0000035163182,0.00019249895,0.00006372148,0.0013725772,0.0002853297,0.00001341993,0.0002463327],"genre_scores_gemma":[0.9969951,0.0027187378,0.000048645972,0.00007184348,0.000009058258,0.000056372428,0.00004412824,0.0000229421,0.000033172888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979902,0.00019348932,0.0005855627,0.00033631342,0.00062854734,0.00026592542],"domain_scores_gemma":[0.9975712,0.0011473846,0.00030641115,0.00055084657,0.00028291644,0.00014129166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003016012,0.00019996606,0.0007038878,0.00009823865,0.00004580741,0.0000183409,0.00018746413,0.000085849984,0.000070692884],"category_scores_gemma":[0.0013729241,0.00014976654,0.000118424985,0.0002604029,0.00036815656,0.00019383444,0.00026932918,0.00014170865,0.0000058725755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002738156,0.000630005,0.98152745,0.0017630506,0.00028136818,0.000004344412,0.0008239299,0.000049579292,0.00009578704,0.0006679596,0.00015620887,0.011262167],"study_design_scores_gemma":[0.018979855,0.0002182698,0.96772605,0.0064917365,0.000025900452,0.000008416594,0.00020513416,0.0014434155,0.0008084565,0.003939675,0.000020746033,0.00013231821],"about_ca_topic_score_codex":0.0012295007,"about_ca_topic_score_gemma":0.00003623258,"teacher_disagreement_score":0.0162417,"about_ca_system_score_codex":0.00044575156,"about_ca_system_score_gemma":0.0012181175,"threshold_uncertainty_score":0.61073023},"labels":[],"label_agreement":null},{"id":"W2949797841","doi":"10.1136/annrheumdis-2019-eular.3543","title":"AB1216 CHECKING IN WITH IMMUNE CHECKPOINT INHIBITORS: RESULTS FROM A NEEDS ASSESSMENT SURVEY OF CANADIAN RHEUMATOLOGISTS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Ottawa; McGill University; University of British Columbia","funders":"","keywords":"Medicine; Rheumatology; Internal medicine; Polymyalgia rheumatica; Adverse effect; Family medicine; Myositis; Descriptive statistics; Physical therapy; Oncology; Disease; Vasculitis","score_opus":0.053470866286697664,"score_gpt":0.3239665947684579,"score_spread":0.27049572848176023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949797841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423033,0.0010533796,0.0000018456658,0.0011981548,0.000102931815,0.0008558857,0.0003812182,0.0000148836525,0.0021613585],"genre_scores_gemma":[0.99907666,0.00039485496,0.00009288066,0.000068053836,0.000008102683,0.000022423694,0.00015094843,0.000030353116,0.00015570973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970124,0.00028694555,0.0010972576,0.00028857935,0.0008164968,0.0004983421],"domain_scores_gemma":[0.9967385,0.000903939,0.00051954103,0.0011962368,0.00035452849,0.00028724957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012399924,0.00022530266,0.0008592361,0.00063455204,0.000037446443,0.000022561655,0.00045204393,0.000095659794,0.00010919876],"category_scores_gemma":[0.0020361731,0.00014319619,0.0001830519,0.001450961,0.00026211396,0.000106710046,0.00016873704,0.00020412944,0.00001781306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045341686,0.0013787663,0.9750898,0.0027098928,0.0012841864,0.00007851013,0.0035319475,0.0012187463,0.00063413027,0.000418226,0.0020973114,0.0070243306],"study_design_scores_gemma":[0.009923531,0.00021419094,0.9742064,0.006910137,0.000047528625,0.000012700732,0.00066380965,0.003394536,0.0043042777,0.00011656414,0.000038447884,0.00016790193],"about_ca_topic_score_codex":0.7734553,"about_ca_topic_score_gemma":0.095493734,"teacher_disagreement_score":0.6779616,"about_ca_system_score_codex":0.0012456448,"about_ca_system_score_gemma":0.010876229,"threshold_uncertainty_score":0.9947312},"labels":[],"label_agreement":null},{"id":"W2949973349","doi":"10.1097/01.hs9.0000562776.32990.9f","title":"PS1123 IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"IGHV@; Venetoclax; Rituximab; Chronic lymphocytic leukemia; Chemoimmunotherapy; Neuroblastoma RAS viral oncogene homolog; Bendamustine; Oncology; KRAS; Internal medicine; Medicine; Lenalidomide; Somatic evolution in cancer; CDKN2A; Lymphocytosis; Leukemia; Lymphoma; Multiple myeloma; Cancer","score_opus":0.02167245289051603,"score_gpt":0.33282394885288435,"score_spread":0.31115149596236835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949973349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946154,0.00028953943,0.000004268445,0.000007723931,0.00004830639,0.0034308776,0.000052343854,0.000028229862,0.0015233329],"genre_scores_gemma":[0.9988671,0.000016520074,0.000028736102,0.00003878234,0.000053398642,0.00011462199,0.00009272172,0.0000672647,0.0007208432],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972112,0.0002146546,0.000806726,0.00047432084,0.0007811989,0.0005118716],"domain_scores_gemma":[0.9977924,0.00033784265,0.00030920666,0.0012407438,0.00018720304,0.0001325775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035260848,0.0003524105,0.0008930404,0.00018559565,0.000055972785,0.000018625713,0.00034961058,0.00014204076,0.0007069795],"category_scores_gemma":[0.00008927688,0.00021376286,0.00021323487,0.00058464764,0.00014221789,0.000116751675,0.000064403685,0.00037286946,0.00017814344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03815796,0.0138389645,0.83969545,0.003510362,0.0028135718,0.0010051265,0.0136263035,0.06389342,0.017474826,0.0001480312,0.0016434656,0.0041925143],"study_design_scores_gemma":[0.6507887,0.04760444,0.22535378,0.0011539717,0.0006015996,0.00014509256,0.0018805688,0.06864335,0.0030064187,0.000011551599,0.00016107838,0.0006494346],"about_ca_topic_score_codex":0.008367278,"about_ca_topic_score_gemma":0.0006006289,"teacher_disagreement_score":0.6143417,"about_ca_system_score_codex":0.13313265,"about_ca_system_score_gemma":0.028025024,"threshold_uncertainty_score":0.99823606},"labels":[],"label_agreement":null},{"id":"W2950191394","doi":"10.1371/journal.pone.0213387","title":"A novel nonsense variant in SUPT20H gene associated with Rheumatoid Arthritis identified by Whole Exome Sequencing of multiplex families","year":2019,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Genopole; Fondation Arthritis","keywords":"Exome sequencing; Genetics; Pedigree chart; Multiplex; Biology; Gene; Genetic association; Genome-wide association study; Exome; Single-nucleotide polymorphism; Genotype; Mutation","score_opus":0.03989837371650361,"score_gpt":0.24143594285309855,"score_spread":0.20153756913659493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950191394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974217,0.0005633244,0.000060558184,0.00012335638,0.00002643858,0.0010447794,0.00015111295,0.000065019194,0.0005437562],"genre_scores_gemma":[0.99589366,0.00045984355,0.0015370535,0.000073455725,0.000018354447,0.00005196659,0.00017927916,0.00006225282,0.001724126],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997266,0.000078280864,0.00056070986,0.00045264565,0.0010755534,0.0005667951],"domain_scores_gemma":[0.99839014,0.0004037513,0.00017720036,0.0005756491,0.00029306702,0.00016016656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058170874,0.0002200024,0.0008124034,0.0002640466,0.000036750847,0.000025935822,0.00015779411,0.00017059912,0.00014360544],"category_scores_gemma":[0.00084201264,0.00020083018,0.0000640493,0.0005689166,0.0001537844,0.0001319058,0.00010136701,0.00032943801,0.00011836357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004997941,0.0017693414,0.0055068475,0.00030520273,0.0005114827,0.00039178578,0.0012322661,0.000046039604,0.98953557,0.000014147653,0.00009878453,0.000088723355],"study_design_scores_gemma":[0.11473613,0.001347706,0.018163616,0.012257853,0.00015412724,0.00064887374,0.0019722076,0.0790676,0.7708115,0.00003530941,0.000034043136,0.0007710332],"about_ca_topic_score_codex":0.0048846463,"about_ca_topic_score_gemma":0.0011874462,"teacher_disagreement_score":0.21872409,"about_ca_system_score_codex":0.0054482585,"about_ca_system_score_gemma":0.003139327,"threshold_uncertainty_score":0.99836963},"labels":[],"label_agreement":null},{"id":"W2950426289","doi":"10.1136/annrheumdis-2019-eular.8676","title":"LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"National Institute for Health and Care Research","keywords":"Medicine; Rheumatoid arthritis; Adalimumab; Internal medicine; Clinical endpoint; Methotrexate; Adverse effect; Placebo; Clinical trial","score_opus":0.026615921402139427,"score_gpt":0.3138811237535323,"score_spread":0.28726520235139286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950426289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938883,0.0004442731,0.00004299239,0.0016588233,0.000041187126,0.0030375523,0.0006568723,0.000024677884,0.00020532437],"genre_scores_gemma":[0.9971894,0.0003640712,0.0013658797,0.00029313145,0.000006227852,0.00006912484,0.00007100192,0.00004797993,0.00059317466],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99728435,0.00022135123,0.0008318113,0.0003864252,0.00085426,0.0004218267],"domain_scores_gemma":[0.99483943,0.002930114,0.00044182918,0.0010017318,0.00048150675,0.00030540768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092540524,0.00025505203,0.00088060054,0.0001569213,0.000073612086,0.000019158448,0.0002950443,0.000059179656,0.000042911583],"category_scores_gemma":[0.003897953,0.00014640538,0.00013818215,0.00037227388,0.00025487866,0.00011351226,0.00019653107,0.00010128728,0.00001187113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68534184,0.0043455223,0.10796987,0.010173149,0.0022555701,0.000026809637,0.0035535942,0.00085130363,0.0002727719,0.00027352525,0.009006047,0.17593],"study_design_scores_gemma":[0.08387703,0.0054469486,0.8967888,0.010229145,0.00013772283,0.00002368802,0.0001867122,0.00049266464,0.0013841068,0.00010760333,0.0009766105,0.00034900114],"about_ca_topic_score_codex":0.00012379844,"about_ca_topic_score_gemma":0.000009886782,"teacher_disagreement_score":0.7888189,"about_ca_system_score_codex":0.00030193495,"about_ca_system_score_gemma":0.0019918764,"threshold_uncertainty_score":0.5970238},"labels":[],"label_agreement":null},{"id":"W2950572195","doi":"10.1136/annrheumdis-2019-eular.230","title":"THU0250 EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation","funders":"","keywords":"Ustekinumab; Medicine; Internal medicine; Placebo; Randomized controlled trial; Gastroenterology; Immunology; Disease; Pathology","score_opus":0.018733296211888666,"score_gpt":0.30157886613954216,"score_spread":0.2828455699276535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950572195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980549,0.001967611,0.000005473189,0.0005575709,0.00038070613,0.01616014,0.000030776984,0.00002468902,0.00032404825],"genre_scores_gemma":[0.9969325,0.0003286014,0.000012082233,0.00008856038,0.000024843217,0.0013183769,0.0000056101135,0.000045546432,0.0012438503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915496,0.0028458228,0.0027056492,0.0005129121,0.0016394206,0.0007466026],"domain_scores_gemma":[0.9891836,0.0080111325,0.0009492847,0.0014267211,0.00022016284,0.00020908435],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007546444,0.00040170795,0.003265144,0.001102528,0.00002608932,0.000030550807,0.0006433807,0.00021965311,0.00013407257],"category_scores_gemma":[0.0133613255,0.00025938248,0.000763164,0.0008617076,0.0003087987,0.00017964248,0.0003081893,0.00035760138,0.000022655791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9862859,0.0014740719,0.0042137527,0.0024024427,0.00046343822,0.000057071775,0.0031880355,0.00090696046,0.00034473478,0.00009324563,0.00014454099,0.00042576098],"study_design_scores_gemma":[0.96596545,0.0012005423,0.0047780816,0.00949903,0.00016797757,0.00005697918,0.0013680442,0.015767267,0.00036272148,0.00062081846,0.000003042573,0.00021004985],"about_ca_topic_score_codex":0.0014997385,"about_ca_topic_score_gemma":0.00009765248,"teacher_disagreement_score":0.0203205,"about_ca_system_score_codex":0.0019786935,"about_ca_system_score_gemma":0.0068870215,"threshold_uncertainty_score":0.9999858},"labels":[],"label_agreement":null},{"id":"W2950604500","doi":"10.1097/01.hs9.0000562556.40615.f8","title":"PS1065 OPEN‐LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3‐MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Cohort; Chemotherapy; Surgery; Internal medicine; Gastroenterology; Adverse effect","score_opus":0.049429120927616754,"score_gpt":0.34203074886872575,"score_spread":0.292601627941109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950604500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822831,0.00016221566,0.000036555648,0.00095002475,0.0002883555,0.013186549,0.0011661872,0.00008056992,0.001846405],"genre_scores_gemma":[0.9921712,0.00024521138,0.0010734898,0.001478842,0.00021209326,0.0007244993,0.0015126643,0.00016915968,0.0024128212],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99471176,0.0002619227,0.0017921135,0.0012498932,0.001029296,0.0009550298],"domain_scores_gemma":[0.99397755,0.0021831095,0.0005043127,0.0016596329,0.0013924384,0.00028293603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008589805,0.00059574214,0.0017950581,0.00012288282,0.00013400879,0.00009984622,0.000994489,0.00028416264,0.0008830403],"category_scores_gemma":[0.0022967102,0.00041624508,0.00014763349,0.0009850125,0.00022072588,0.0002954663,0.00062267605,0.0005192738,0.000084100706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44185844,0.02854323,0.33946732,0.0027381007,0.0049214703,0.0029114888,0.036959868,0.0005647657,0.020289326,0.00016549643,0.09262355,0.028956935],"study_design_scores_gemma":[0.8305521,0.009553534,0.09938964,0.0030488102,0.00035400625,0.000096403295,0.025026904,0.011589513,0.0129582295,0.00011295456,0.006204846,0.0011130403],"about_ca_topic_score_codex":0.014384676,"about_ca_topic_score_gemma":0.0038609884,"teacher_disagreement_score":0.3886937,"about_ca_system_score_codex":0.0034284256,"about_ca_system_score_gemma":0.0029698794,"threshold_uncertainty_score":0.99982893},"labels":[],"label_agreement":null},{"id":"W2951075811","doi":"10.1097/01.hs9.0000562932.11356.53","title":"PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Ibrutinib; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Neutropenia; Discontinuation; Leukemia; Chemotherapy","score_opus":0.0057942809302078385,"score_gpt":0.2487847723173081,"score_spread":0.24299049138710027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951075811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920453,0.00039702316,0.000007804001,0.0001104278,0.000041551873,0.0056407475,0.000043234606,0.00007134273,0.0016425912],"genre_scores_gemma":[0.9952617,0.000037320213,0.000177425,0.00007908132,0.000042212854,0.00027836527,0.00039443708,0.00010128674,0.0036281226],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996413,0.00022098245,0.0007030474,0.000647135,0.0013626947,0.0006531274],"domain_scores_gemma":[0.997402,0.00028930124,0.0005793669,0.0009899612,0.00054038595,0.0001989745],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042829048,0.00042586896,0.0008512097,0.0001554793,0.00008096315,0.00002058954,0.00032053958,0.00022655664,0.0013087335],"category_scores_gemma":[0.000070313916,0.0002567763,0.0001128295,0.0010003594,0.00028501754,0.00015581053,0.0001465639,0.0002624647,0.00015487304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.19409208,0.007880125,0.49145004,0.0109721115,0.0038917733,0.00047680573,0.019483427,0.024634125,0.14070609,0.00078038295,0.03328279,0.07235025],"study_design_scores_gemma":[0.2580231,0.032696944,0.24858539,0.014517703,0.0003747323,0.00018359284,0.0006567771,0.03684725,0.40072745,0.000042456642,0.0058915373,0.0014530689],"about_ca_topic_score_codex":0.0007278146,"about_ca_topic_score_gemma":0.00031433033,"teacher_disagreement_score":0.26002136,"about_ca_system_score_codex":0.032664645,"about_ca_system_score_gemma":0.011099778,"threshold_uncertainty_score":0.99998844},"labels":[],"label_agreement":null},{"id":"W2951608335","doi":"10.1097/01.hs9.0000558816.91319.ce","title":"S149 FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION‐FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Minimal residual disease; Gastroenterology; Venetoclax; Hazard ratio; Clinical endpoint; Obinutuzumab; Population; Surrogate endpoint; Progression-free survival; Oncology; Surgery; Confidence interval; Randomized controlled trial; Chronic lymphocytic leukemia; Bone marrow; Leukemia; Chemotherapy","score_opus":0.0093089771667384,"score_gpt":0.25355556727727147,"score_spread":0.24424659011053307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951608335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648476,0.0007470135,0.0000020132093,0.00011324548,0.00005340813,0.0018852734,0.000042342766,0.000051956766,0.00062000926],"genre_scores_gemma":[0.99797225,0.00005109461,0.00030518643,0.000029766867,0.00006633217,0.00007662581,0.00014086276,0.000040208583,0.0013176675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802125,0.00012354697,0.00029398117,0.0004945942,0.000640535,0.00042611838],"domain_scores_gemma":[0.99877316,0.00019749666,0.00011147079,0.0004926405,0.00013232003,0.00029292065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020043459,0.00024971468,0.0004223649,0.000057745172,0.00007284572,0.00006198079,0.00009667171,0.000116736526,0.00011478764],"category_scores_gemma":[0.00024302068,0.000184641,0.00002686503,0.00017914044,0.00024364486,0.00024228779,0.00019090124,0.00022512238,0.000011430485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.025380375,0.00027693095,0.9568065,0.004017008,0.00020617589,0.00044904015,0.0024475923,0.00011015407,0.0005236345,0.0003555486,0.0020122628,0.0074147927],"study_design_scores_gemma":[0.07309794,0.0028485977,0.90322036,0.0015984346,0.00013645597,0.00003304593,0.00082688563,0.016480463,0.0008571938,0.00013002455,0.00030087633,0.0004697413],"about_ca_topic_score_codex":0.00096172956,"about_ca_topic_score_gemma":0.00064754114,"teacher_disagreement_score":0.05358614,"about_ca_system_score_codex":0.007338129,"about_ca_system_score_gemma":0.006947873,"threshold_uncertainty_score":0.9986818},"labels":[],"label_agreement":null},{"id":"W2951773279","doi":"10.1097/01.hs9.0000560744.31107.fc","title":"PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Ibrutinib; Rituximab; Medicine; Internal medicine; Oncology; Waldenstrom macroglobulinemia; Placebo; Lymphoma; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.027596417593564685,"score_gpt":0.3061365200328294,"score_spread":0.2785401024392647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951773279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98712146,0.00034130266,0.0000016278719,0.0011195954,0.0002670128,0.0019503324,0.00005756211,0.00006431683,0.009076814],"genre_scores_gemma":[0.99675137,0.000016556223,0.0003506375,0.00036231967,0.000078182675,0.000040385796,0.000087733155,0.00004922859,0.002263572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962462,0.00013938274,0.0013053522,0.000642704,0.0011130973,0.000553258],"domain_scores_gemma":[0.9969192,0.00068326655,0.00035967512,0.0016160568,0.00030196874,0.00011978963],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060561666,0.0003007846,0.0008716434,0.000073682204,0.000042634518,0.000025133342,0.00035381655,0.00019237082,0.0011898911],"category_scores_gemma":[0.00097527506,0.00019531419,0.00014379321,0.0008742332,0.00014294274,0.00008340989,0.0003372072,0.00054259674,0.00034543694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045590564,0.003672469,0.9526989,0.000251976,0.0006731602,0.0020158966,0.0063009392,0.000042233616,0.0026404476,0.000087837674,0.010072507,0.016984584],"study_design_scores_gemma":[0.3302294,0.002607655,0.6063552,0.0013609023,0.0003317681,0.00036233224,0.023787891,0.0030023204,0.015961751,0.00032597734,0.014719664,0.00095511205],"about_ca_topic_score_codex":0.009465441,"about_ca_topic_score_gemma":0.0008033519,"teacher_disagreement_score":0.34634367,"about_ca_system_score_codex":0.002091705,"about_ca_system_score_gemma":0.0027039796,"threshold_uncertainty_score":0.99972314},"labels":[],"label_agreement":null},{"id":"W2951802836","doi":"10.1182/blood.v128.22.5561.5561","title":"Revelance of Gammaglobulin Levels at Diagnosis and during Disease Course in Chronic Lymphocytic Leukemia","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Hypogammaglobulinemia; Chemoimmunotherapy; Chronic lymphocytic leukemia; Lymphocytosis; Rituximab; Internal medicine; Alemtuzumab; IGHV@; Bendamustine; Immunology; Pediatrics; Oncology; Leukemia; Transplantation; Antibody; Lymphoma","score_opus":0.02020083842510304,"score_gpt":0.2881160953476421,"score_spread":0.26791525692253904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951802836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911618,0.0077778,0.000004373593,0.00024308318,0.00003419987,0.0004974134,0.000053800057,0.000040128838,0.00018736342],"genre_scores_gemma":[0.9951356,0.002620442,0.000082757295,0.000037235623,0.00014893925,0.00011580801,0.0000035214348,0.000037757527,0.0018179299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809843,0.000056815235,0.00040326195,0.00045675092,0.00045191232,0.00053282344],"domain_scores_gemma":[0.9985748,0.00029403405,0.000100473044,0.0005850299,0.000070844835,0.00037479977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023500332,0.00019829063,0.0004399496,0.00012573137,0.00004471715,0.0000075974112,0.00014996041,0.00010076853,0.00023962324],"category_scores_gemma":[0.00044864567,0.0001447447,0.000077020486,0.00023545435,0.00028343435,0.000097504824,0.00022816542,0.00009422444,0.000070967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0029214055,0.0010844632,0.76448053,0.007578205,0.00059699983,0.0076552005,0.0006111881,0.00014202742,0.19707559,0.0002546631,0.0010930015,0.016506735],"study_design_scores_gemma":[0.11032352,0.00022053185,0.72591966,0.003396398,0.0002866092,0.0004070588,0.000014544428,0.0007903603,0.15781881,0.00009310852,0.00040595638,0.00032347522],"about_ca_topic_score_codex":0.00032527372,"about_ca_topic_score_gemma":0.00015909193,"teacher_disagreement_score":0.10740211,"about_ca_system_score_codex":0.04966306,"about_ca_system_score_gemma":0.018457217,"threshold_uncertainty_score":0.9871072},"labels":[],"label_agreement":null},{"id":"W2951809321","doi":"10.1097/hs9.0000000000000197","title":"Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Chronic lymphocytic leukemia; Leukemia; Medicine; Mathematics; Computational biology; Immunology; Biology","score_opus":0.047759829510846945,"score_gpt":0.3091606406097494,"score_spread":0.26140081109890245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951809321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813633,0.0014377374,0.000014058138,0.00013791346,0.00020557678,0.00103243,0.0000064506635,0.000044800272,0.015757758],"genre_scores_gemma":[0.9876647,0.00012973393,0.000050241328,0.00021193529,0.000118595584,0.000054367327,0.000014607506,0.000058828897,0.01169697],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99758136,0.00006315165,0.0005020162,0.0004382379,0.0007160573,0.0006991645],"domain_scores_gemma":[0.9984954,0.00021087038,0.0001351404,0.0008982006,0.000113091664,0.00014726768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045664032,0.0002538099,0.0005506762,0.00007993375,0.000048867107,0.000021994249,0.00034956535,0.00020317038,0.0017983421],"category_scores_gemma":[0.00011139784,0.00017401765,0.00015495789,0.00045953575,0.00014468723,0.000110739245,0.00023772889,0.00037138013,0.000758189],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010526459,0.0019515512,0.43529925,0.043076105,0.004343271,0.005130648,0.034675404,0.08690516,0.29137677,0.020832289,0.04651409,0.019369014],"study_design_scores_gemma":[0.1690987,0.0020442018,0.06436932,0.0067835716,0.00033729043,0.0015259086,0.00296633,0.5964736,0.1350959,0.00013787765,0.019946642,0.0012206635],"about_ca_topic_score_codex":0.0012769017,"about_ca_topic_score_gemma":0.00024341147,"teacher_disagreement_score":0.50956845,"about_ca_system_score_codex":0.05336428,"about_ca_system_score_gemma":0.018759314,"threshold_uncertainty_score":0.99911416},"labels":[],"label_agreement":null},{"id":"W2951924370","doi":"10.1002/hon.47_2630","title":"PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Ibrutinib; Rituximab; Medicine; Waldenstrom macroglobulinemia; Internal medicine; Oncology; Placebo; Lymphoma; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.028252088364664883,"score_gpt":0.3390303575365446,"score_spread":0.31077826917187973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951924370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893356,0.00004090171,9.069756e-7,0.001022444,0.00008750453,0.004171365,0.000004147463,0.000073421674,0.0052637383],"genre_scores_gemma":[0.9979996,0.0000075843072,0.00017100754,0.0012153822,0.000014039074,0.00034030888,0.000051563693,0.000027606198,0.00017289155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995876,0.00050820847,0.0011661003,0.0007706978,0.00081155536,0.0008673949],"domain_scores_gemma":[0.9977691,0.0008035039,0.00028611292,0.00077409076,0.00023700805,0.00013015345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070796534,0.000365212,0.0014324725,0.00029042506,0.000049738668,0.000022724531,0.00031834104,0.000396546,0.0003428749],"category_scores_gemma":[0.00066727516,0.00018688873,0.00008885276,0.0013536272,0.00024917218,0.00007167317,0.00022747734,0.00089057174,0.00025241773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022597634,0.010666235,0.97334397,0.00007117471,0.000088143745,0.010232817,0.0009055067,0.000004844429,0.0000306719,0.00015259664,0.00020994163,0.0020343428],"study_design_scores_gemma":[0.118656114,0.01217951,0.8623111,0.00011608193,0.000076570956,0.0019415251,0.0026006002,0.000434379,0.00016499104,0.000080246,0.0011002107,0.00033864685],"about_ca_topic_score_codex":0.00062602106,"about_ca_topic_score_gemma":0.00039438903,"teacher_disagreement_score":0.116396345,"about_ca_system_score_codex":0.0040842695,"about_ca_system_score_gemma":0.0016619655,"threshold_uncertainty_score":0.9997389},"labels":[],"label_agreement":null},{"id":"W2951994857","doi":"10.1002/hon.52_2629","title":"FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Capital District Health Authority","funders":"Università degli Studi di Perugia; Hospital de Clínicas de Porto Alegre; Monash University; F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Gastroenterology; Minimal residual disease; Obinutuzumab; Hazard ratio; Clinical endpoint; Population; Surrogate endpoint; Oncology; Venetoclax; Progression-free survival; Confidence interval; Surgery; Chronic lymphocytic leukemia; Randomized controlled trial; Bone marrow; Leukemia; Chemotherapy","score_opus":0.013142738743973956,"score_gpt":0.27572653323056384,"score_spread":0.26258379448658986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951994857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972025,0.0003407798,0.000003372804,0.00034249062,0.000039057744,0.0014410522,0.000013433793,0.000044455937,0.0005728288],"genre_scores_gemma":[0.99895114,0.00006881585,0.0002974967,0.00019782128,0.000028883946,0.00008288411,0.00007875223,0.000015723199,0.00027849528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982436,0.00021772113,0.00034852806,0.0004782594,0.00028256496,0.000429327],"domain_scores_gemma":[0.9986765,0.0005926122,0.000118003874,0.00023923631,0.000095172356,0.00027848917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020631513,0.0002038936,0.000672265,0.00009414181,0.00005218883,0.000022246544,0.00006964411,0.00023662337,0.00009018316],"category_scores_gemma":[0.00039791645,0.00013718072,0.000026563477,0.00014063831,0.00045932323,0.00011398238,0.00015331665,0.00027862104,0.000020615982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.038000867,0.0005790634,0.94757164,0.0018989922,0.00017463976,0.0022125293,0.0016017207,0.000075128555,0.00050141464,0.0025369397,0.0012714452,0.003575636],"study_design_scores_gemma":[0.06327177,0.010859543,0.9082426,0.00031448164,0.00013271726,0.00038072714,0.00032518807,0.014582472,0.0003624656,0.0004270184,0.00073672953,0.00036428048],"about_ca_topic_score_codex":0.0003480812,"about_ca_topic_score_gemma":0.000179025,"teacher_disagreement_score":0.039329015,"about_ca_system_score_codex":0.010767219,"about_ca_system_score_gemma":0.0064574024,"threshold_uncertainty_score":0.9991751},"labels":[],"label_agreement":null},{"id":"W2952131264","doi":"10.1097/01.hs9.0000558648.00957.de","title":"S107 FIVE‐YEAR FOLLOW‐UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Chlorambucil; Internal medicine; Hazard ratio; Adverse effect; Neutropenia; Progression-free survival; Bendamustine; Clinical endpoint; Oncology; Leukemia; Randomized controlled trial; Confidence interval; Toxicity; Chemotherapy","score_opus":0.021839086168430458,"score_gpt":0.28791569770824105,"score_spread":0.2660766115398106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952131264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919594,0.001183224,0.00013145123,0.000034552544,0.00037711553,0.0022852558,0.000075558295,0.0000509526,0.0039025089],"genre_scores_gemma":[0.9819427,0.00036903072,0.000746652,0.000023180395,0.00019288732,0.00011171735,0.00015322655,0.00008179917,0.0163788],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974713,0.000037225975,0.00072354294,0.0005163992,0.00063426467,0.00061728305],"domain_scores_gemma":[0.99767303,0.00051038066,0.00030531327,0.0009153064,0.0003957951,0.00020017284],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018391329,0.00031641187,0.0009415816,0.00009676751,0.00005479909,0.000009114897,0.00020598083,0.0002277658,0.0014172752],"category_scores_gemma":[0.00027287315,0.0002608434,0.00040694798,0.0003233656,0.00012262262,0.000087610606,0.00008996471,0.00008644443,0.0001684886],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06780622,0.00964883,0.28928596,0.085629545,0.0105759995,0.0003322294,0.026207276,0.02933939,0.032592993,0.0040475824,0.051456068,0.3930779],"study_design_scores_gemma":[0.57978487,0.034181952,0.01331924,0.004770201,0.0011800089,0.00008260559,0.0013716591,0.17038481,0.1521685,0.00044029774,0.040981717,0.0013341493],"about_ca_topic_score_codex":0.0007247493,"about_ca_topic_score_gemma":0.00021383564,"teacher_disagreement_score":0.5119786,"about_ca_system_score_codex":0.05752987,"about_ca_system_score_gemma":0.015609111,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W2952175842","doi":"10.1097/01.hs9.0000559784.51441.da","title":"PF393 A RANDOMISED JOINT AUSTRALASIAN (ALLG) AND FRENCH (FILO) STUDY OF LENALIDOMIDE CONSOLIDATION IN PATIENTS WITH RESIDUAL CLL AFTER FRONT‐LINE TREATMENT WITH FC/FCR (THE CLL6 TRIAL)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Lenalidomide; Medicine; Minimal residual disease; Fludarabine; Internal medicine; Oncology; Progression-free survival; Cyclophosphamide; Chronic lymphocytic leukemia; Surgery; Leukemia; Chemotherapy; Multiple myeloma","score_opus":0.015111516384380777,"score_gpt":0.2572424225864546,"score_spread":0.2421309062020738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952175842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909625,0.00012609772,0.000005403729,0.00015652049,0.000036119007,0.008061647,0.00001631007,0.000018254817,0.00061716116],"genre_scores_gemma":[0.9969039,0.000014876353,0.00021255402,0.000035417994,0.00006279556,0.0004622172,0.000055958306,0.000039162613,0.002213098],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976218,0.00024460748,0.00058587216,0.00046908442,0.00071045384,0.0003681945],"domain_scores_gemma":[0.998613,0.00021469666,0.0002118392,0.0006494832,0.00017238925,0.00013859934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003743651,0.00028910994,0.0008094824,0.000087781875,0.00003848224,0.000026083491,0.000084180814,0.0001031206,0.0007088637],"category_scores_gemma":[0.00006487866,0.00015304351,0.000052941064,0.00019784798,0.00014046286,0.00009493089,0.000048087295,0.00019956856,0.000031719785],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7629007,0.0053757406,0.21872276,0.0003636868,0.0009661145,0.0002240982,0.008820239,0.00014355205,0.000198358,0.000005989738,0.00031668256,0.001962059],"study_design_scores_gemma":[0.90304893,0.02196024,0.07040588,0.00039450015,0.00033907822,0.000018897554,0.0024228243,0.0003159278,0.0008085508,0.0000063283974,0.00008633892,0.00019248122],"about_ca_topic_score_codex":0.0023050553,"about_ca_topic_score_gemma":0.0039255,"teacher_disagreement_score":0.14831689,"about_ca_system_score_codex":0.002087268,"about_ca_system_score_gemma":0.0015481662,"threshold_uncertainty_score":0.776156},"labels":[],"label_agreement":null},{"id":"W2952182954","doi":"10.1136/annrheumdis-2019-eular.3083","title":"FRI0171 CLINICAL RESPONSES IN PATIENTS WITH INADEQUATE RESPONSE TO BDMARDS UPON TREATMENT WITH UPADACITINIB","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba","funders":"Regeneron Pharmaceuticals; Gilead Sciences; AbbVie; Sanofi; Amgen; Pfizer; Samsung; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Placebo; Adverse effect; Gastroenterology","score_opus":0.04816730546240868,"score_gpt":0.3694457898233973,"score_spread":0.32127848436098866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952182954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489135,0.00014248192,0.000003224042,0.002635188,0.00005830228,0.0019202912,0.00009621639,0.000025464922,0.00022749357],"genre_scores_gemma":[0.9974578,0.00007808726,0.0001227909,0.0004810595,0.000014395679,0.00008094914,0.000015587126,0.000040217477,0.0017090861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996837,0.0006968566,0.0006257626,0.0003889121,0.0009796922,0.000471753],"domain_scores_gemma":[0.9963269,0.0016330805,0.00021099605,0.0011943933,0.00026646504,0.00036813333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008451489,0.00025329957,0.00070843165,0.00021787485,0.000045737645,0.000023616405,0.00029786534,0.00006601145,0.00015819399],"category_scores_gemma":[0.0016788006,0.00012885763,0.00017643764,0.0004877807,0.00017554362,0.000102172824,0.00013177653,0.00012390532,0.00011067791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24867094,0.0033100077,0.6965616,0.00048884674,0.0006279203,0.00007323178,0.0008120527,0.00023658408,0.000011081767,0.000046702207,0.0011865057,0.047974564],"study_design_scores_gemma":[0.02897323,0.009484907,0.95692015,0.0025236162,0.00011846971,0.00000878341,0.00018863865,0.00035585588,0.00034025963,0.000044298133,0.00085194956,0.00018981981],"about_ca_topic_score_codex":0.0003130913,"about_ca_topic_score_gemma":0.000056765293,"teacher_disagreement_score":0.2603586,"about_ca_system_score_codex":0.0010719035,"about_ca_system_score_gemma":0.005090094,"threshold_uncertainty_score":0.90296084},"labels":[],"label_agreement":null},{"id":"W2952212829","doi":"10.1136/annrheumdis-2019-eular.1725","title":"FRI0118 INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; McGill University","funders":"Bristol-Myers Squibb","keywords":"Abatacept; Medicine; Rheumatoid arthritis; Internal medicine; Cohort; Incidence (geometry); Epidemiology; Healthcare delivery; Population; Rheumatology; Retrospective cohort study; Health care; Physical therapy; Environmental health","score_opus":0.01854146662557498,"score_gpt":0.29382671692915213,"score_spread":0.27528525030357714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952212829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99757457,0.000030144314,7.2684185e-7,0.00026212574,0.000044549914,0.0012902273,0.00028327532,0.000020969432,0.0004934201],"genre_scores_gemma":[0.9989649,0.000012173228,0.000024668092,0.00010501273,0.000009806918,0.000028456963,0.00007935624,0.0000236289,0.00075198954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841785,0.00010572263,0.0003244691,0.00027218007,0.0006991083,0.00018069388],"domain_scores_gemma":[0.9987662,0.00024199345,0.00018082722,0.0004840669,0.00023702717,0.00008987541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016291914,0.00016157594,0.00036294138,0.00012687132,0.00002665995,0.00002936688,0.00014797415,0.000034061788,0.00024106506],"category_scores_gemma":[0.00046998498,0.000084307685,0.0000582457,0.0001729516,0.0001006821,0.0001377684,0.00010576261,0.000080836,0.000026160635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073619746,0.0016254828,0.9880792,0.00007375587,0.00062165374,0.0000039465813,0.0007001605,0.000038464827,0.00000251325,0.000004885885,0.00027291916,0.0012150315],"study_design_scores_gemma":[0.034042884,0.0012375021,0.96290857,0.00065514474,0.00009570119,0.0000014652544,0.0004830777,0.00037568048,0.000046324643,0.000016179987,0.000036533445,0.00010093435],"about_ca_topic_score_codex":0.004731003,"about_ca_topic_score_gemma":0.00020990646,"teacher_disagreement_score":0.02668091,"about_ca_system_score_codex":0.00029437157,"about_ca_system_score_gemma":0.0004959203,"threshold_uncertainty_score":0.7151893},"labels":[],"label_agreement":null},{"id":"W2952260994","doi":"10.1097/01.hs9.0000563768.57648.ea","title":"PS1373 A TWENTY‐FOUR YEAR EXPERIENCE OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN AMYLOIDOSIS PATIENTS IN THE UNITED KINGDOM","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Univariate analysis; Internal medicine; Proportional hazards model; Cohort; AL amyloidosis; Amyloidosis; Survival analysis; Transplantation; Log-rank test; Oncology; Multivariate analysis; Surgery; Immunology; Immunoglobulin light chain","score_opus":0.028762564540519484,"score_gpt":0.2877169989745835,"score_spread":0.258954434434064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952260994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668574,0.000045617053,0.00011734648,0.00015452623,0.000090590685,0.0013879492,0.000015841624,0.00002114547,0.0014812195],"genre_scores_gemma":[0.99852914,0.00003175557,0.000268961,0.0001358761,0.000028414224,0.000121244564,0.0000490366,0.000023027475,0.0008125532],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862057,0.00008142199,0.0003018543,0.0002483711,0.00044147813,0.00030627585],"domain_scores_gemma":[0.99913365,0.00023986994,0.000099121266,0.00036016136,0.000110365385,0.000056840425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002303689,0.00012737325,0.00025425715,0.00008843545,0.000030807656,0.000010695598,0.0001978366,0.00011167201,0.00015251848],"category_scores_gemma":[0.000026394968,0.000089292,0.00008093712,0.00042312295,0.000043669206,0.000054742864,0.000020334088,0.00013433506,0.00004278112],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01426478,0.005185885,0.6086251,0.022860857,0.00037057148,0.0006039622,0.24298953,0.0013047471,0.068287544,0.0061534713,0.009536429,0.01981714],"study_design_scores_gemma":[0.23697603,0.0077558914,0.23376545,0.0044717663,0.0005592834,0.00032276488,0.049986016,0.06765819,0.36061394,0.000242433,0.035827704,0.0018205428],"about_ca_topic_score_codex":0.0007088562,"about_ca_topic_score_gemma":0.0000571636,"teacher_disagreement_score":0.37485963,"about_ca_system_score_codex":0.0008978615,"about_ca_system_score_gemma":0.0005225928,"threshold_uncertainty_score":0.3641222},"labels":[],"label_agreement":null},{"id":"W2952375224","doi":"10.1097/01.hs9.0000562928.03733.42","title":"PS1161 EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Venetoclax; Medicine; Bendamustine; Ibrutinib; Internal medicine; Rituximab; Hazard ratio; Chronic lymphocytic leukemia; Population; Oncology; Refractory (planetary science); Clinical endpoint; Confidence interval; Leukemia; Randomized controlled trial; Lymphoma","score_opus":0.010360389187044253,"score_gpt":0.2625796229925551,"score_spread":0.25221923380551087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952375224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99128324,0.0012729692,5.8756484e-7,0.000014672158,0.00003157797,0.0045028813,0.0000042003835,0.00003037545,0.0028594742],"genre_scores_gemma":[0.99892867,0.00014520963,0.000027077194,0.00004690632,0.000036140722,0.000097647404,0.000024611836,0.00005394739,0.00063977495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714196,0.00029104177,0.00064092444,0.0005648741,0.0007734498,0.00058773346],"domain_scores_gemma":[0.9981674,0.00052560447,0.00017176534,0.0009169158,0.000095044335,0.00012327504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060456234,0.00030812225,0.000704158,0.00012616096,0.0000414531,0.000017824566,0.00027226636,0.00016867915,0.0002649604],"category_scores_gemma":[0.00014506998,0.00019681241,0.000057183628,0.00073217787,0.00017065533,0.000087507484,0.00010575246,0.0004299679,0.00006109837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013684084,0.0015622752,0.9563089,0.0021417846,0.00029506048,0.00072901626,0.011126265,0.0035518259,0.00065740093,0.00004991256,0.0002970289,0.009596421],"study_design_scores_gemma":[0.21362355,0.008736153,0.7645611,0.002019324,0.00014798134,0.00012318234,0.0023018562,0.0071354266,0.00034889724,0.0000066941343,0.0006316154,0.00036423025],"about_ca_topic_score_codex":0.0034724497,"about_ca_topic_score_gemma":0.0011686955,"teacher_disagreement_score":0.19993946,"about_ca_system_score_codex":0.049165208,"about_ca_system_score_gemma":0.015525805,"threshold_uncertainty_score":0.99005526},"labels":[],"label_agreement":null},{"id":"W2952717710","doi":"10.1136/annrheumdis-2019-eular.418","title":"AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Université Laval; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Tolerability; Tofacitinib; Internal medicine; Adverse effect; Rheumatoid arthritis; Placebo; Combination therapy","score_opus":0.012848850966468492,"score_gpt":0.27323195870729433,"score_spread":0.26038310774082585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952717710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731183,0.0008688986,0.0000019742513,0.00015258288,0.000022763434,0.001439228,0.00004035831,0.000012382892,0.00014995887],"genre_scores_gemma":[0.9938364,0.005899158,0.000019572708,0.0000877836,0.0000022830154,0.0000448408,0.00003615473,0.00002361773,0.000050189592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847084,0.00010998331,0.0004686348,0.00022798909,0.0005165706,0.00020600905],"domain_scores_gemma":[0.99883646,0.00015026354,0.00030758223,0.00036430702,0.00023541682,0.00010595982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016492118,0.00017282201,0.00042961384,0.00013099822,0.00003923328,0.00000782996,0.00011408445,0.000058841273,0.00006146669],"category_scores_gemma":[0.00013403929,0.00011737919,0.00006462365,0.00024835236,0.0001526932,0.00024891336,0.000029528323,0.0000731027,0.000005575594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023856398,0.00080251426,0.97437406,0.00038930814,0.00020295965,0.000003836515,0.001805764,0.000013109132,0.00040592824,0.00010504573,0.000015984424,0.019495828],"study_design_scores_gemma":[0.028432375,0.0017041662,0.96329683,0.0023463166,0.000014302214,0.00001151776,0.00022818666,0.0008804987,0.002180391,0.0007771942,0.0000028976767,0.00012533167],"about_ca_topic_score_codex":0.0017247496,"about_ca_topic_score_gemma":0.000028729159,"teacher_disagreement_score":0.026046734,"about_ca_system_score_codex":0.00014505509,"about_ca_system_score_gemma":0.0005549424,"threshold_uncertainty_score":0.47865844},"labels":[],"label_agreement":null},{"id":"W2953212652","doi":"10.1097/01.hs9.0000559476.99472.fd","title":"PF316 THE CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH AGGRESSIVE LARGE CELL LYMPHOMA AND DIABETES MELLITUS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Single Center; Retrospective cohort study; Diabetes mellitus; Aggressive lymphoma; Epidemiology; Medical record; Gastroenterology; Rituximab","score_opus":0.00951737541155937,"score_gpt":0.2762648557919237,"score_spread":0.26674748038036433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953212652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971124,0.0013676926,0.000002809853,0.00011373422,0.000075036995,0.0005734067,0.00004079659,0.000013162796,0.00070094963],"genre_scores_gemma":[0.9981808,0.00032827936,0.00014688422,0.0002364185,0.00004030338,0.000009826021,0.000022109043,0.000025675476,0.0010097206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867666,0.000063928244,0.00031899413,0.0002688114,0.00036632625,0.00030526027],"domain_scores_gemma":[0.99848527,0.00057424355,0.0002281671,0.00042400864,0.0001444851,0.00014384706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025051428,0.00015237859,0.00049096276,0.000017633418,0.000044079396,0.000016543516,0.000088973866,0.00010628347,0.00016652203],"category_scores_gemma":[0.00019266832,0.00008047445,0.000051448464,0.00007795953,0.0002386431,0.000047408026,0.00014984087,0.00012620667,0.000030473444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020982634,0.00037064202,0.9906569,0.00039134972,0.0001017225,0.000016907603,0.00016815448,4.6833147e-8,0.000013176532,0.000056798333,0.00020545977,0.0078090006],"study_design_scores_gemma":[0.027183134,0.0005419916,0.968717,0.00018981389,0.00010268105,0.000005781154,0.0001963181,0.0004599612,0.0003503652,0.000018336781,0.0021230108,0.00011161234],"about_ca_topic_score_codex":0.000019106026,"about_ca_topic_score_gemma":0.000007968383,"teacher_disagreement_score":0.026973307,"about_ca_system_score_codex":0.00024622792,"about_ca_system_score_gemma":0.0006473168,"threshold_uncertainty_score":0.32816526},"labels":[],"label_agreement":null},{"id":"W2953283032","doi":"10.1136/annrheumdis-2019-eular.6404","title":"AB0452 SYSTEMATIC REVIEW OF GUIDELINES ON THE USE OF METHOTREXATE IN RHEUMATOID ARTHRITIS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Guideline; Rheumatoid arthritis; Methotrexate; Internal medicine; Family medicine; Pathology","score_opus":0.16022306344999146,"score_gpt":0.38500310103725277,"score_spread":0.2247800375872613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953283032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8670398,0.12317463,0.0000066332127,0.0053317645,0.00010381752,0.0039139413,0.000093309936,0.00001618867,0.00031991728],"genre_scores_gemma":[0.8296009,0.16766664,0.00015433299,0.0019435225,0.0000069270636,0.00010637735,0.000008020166,0.00003285787,0.00048046536],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9961069,0.00060139596,0.0017455993,0.00020012815,0.0010827967,0.00026313405],"domain_scores_gemma":[0.99415743,0.0025537785,0.0008883755,0.0016822546,0.0006270046,0.00009116103],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0016322203,0.00019722231,0.0014801569,0.00012506937,0.000021944561,0.0000100171155,0.0005126048,0.000046348214,0.0003197062],"category_scores_gemma":[0.017600443,0.000096413874,0.0004877562,0.00052601757,0.00020793232,0.00009025756,0.00016934576,0.00011338814,0.00004391918],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002695077,0.00061593944,0.001097299,0.9703308,0.00070473127,0.000008784016,0.00034532062,0.00027430308,0.00010584389,0.002320751,0.021196933,0.0027297998],"study_design_scores_gemma":[0.0023876554,0.00018154467,0.0015588637,0.9890697,0.00015925527,0.00002918803,0.00019563167,0.0034665074,0.0021928172,0.0005302002,0.00010621957,0.0001224046],"about_ca_topic_score_codex":0.000448761,"about_ca_topic_score_gemma":0.000009061333,"teacher_disagreement_score":0.044492006,"about_ca_system_score_codex":0.00018720276,"about_ca_system_score_gemma":0.0013755162,"threshold_uncertainty_score":0.99067473},"labels":[],"label_agreement":null},{"id":"W2953376933","doi":"10.1097/01.hs9.0000559544.58960.b9","title":"PF333 RISK OF BLEEDING COMPLICATIONS AND ATRIAL FIBRILLATION ASSOCIATED WITH IBRUTINIB TREATMENT: A SYSTEMATIC REVIEW AND META‐ANALYSIS","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atrial fibrillation; Medicine; Ibrutinib; Adverse effect; Internal medicine; Meta-analysis; Confidence interval; Randomized controlled trial; Cardiology; Chronic lymphocytic leukemia; Leukemia","score_opus":0.11408786172607231,"score_gpt":0.38178448752326927,"score_spread":0.26769662579719694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953376933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018505873,0.9930016,0.000018406992,0.00004223191,0.0000071718505,0.006016507,0.0001922478,0.000028247827,0.0006750827],"genre_scores_gemma":[0.00016220001,0.99784803,0.00018715543,0.000010895302,0.000038917977,0.0001490635,0.00040390898,0.000049215916,0.0011506131],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972686,0.00048218915,0.0010258986,0.00053791015,0.00043236115,0.00025300705],"domain_scores_gemma":[0.9957332,0.0017770255,0.0013459794,0.0007769911,0.00021384167,0.00015293733],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006693659,0.000445796,0.008277727,0.00016619322,0.00007801255,0.000028871911,0.000089160116,0.00024569163,0.00016938763],"category_scores_gemma":[0.00055329956,0.00025348537,0.0015094737,0.001082249,0.0001051116,0.000042911543,0.000063586245,0.00017603576,0.00001185973],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008153001,0.000012061572,0.000019024617,0.75663215,0.24112569,0.0000043957198,0.0000342382,0.000003704759,2.966206e-8,0.000028959288,0.0000126483465,0.0021189577],"study_design_scores_gemma":[0.0020351498,0.00020080766,0.0000049118366,0.122816734,0.869103,0.00014176875,0.000014016546,0.0005112896,1.2902792e-7,0.0000032176583,0.0049786535,0.00019033576],"about_ca_topic_score_codex":0.00024120789,"about_ca_topic_score_gemma":0.00006440306,"teacher_disagreement_score":0.6338154,"about_ca_system_score_codex":0.0023720274,"about_ca_system_score_gemma":0.0019786323,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W2954966588","doi":"10.1200/jco.2019.37.15_suppl.8018","title":"Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rituximab; Ibrutinib; Anemia; Internal medicine; Placebo; Visual analogue scale; Waldenstrom macroglobulinemia; Quality of life (healthcare); Refractory (planetary science); Randomized controlled trial; Gastroenterology; Surgery; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.07737395609271454,"score_gpt":0.4418125535232706,"score_spread":0.36443859743055607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954966588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833967,0.00014289161,0.000012523068,0.0079138605,0.001257329,0.0005885376,0.000019189067,0.000020745936,0.006648228],"genre_scores_gemma":[0.9899828,0.0001347431,0.005975953,0.0024792356,0.0005366821,0.0000047433878,0.00002580521,0.000039219976,0.0008208579],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99150723,0.0004338961,0.0057274285,0.00052006554,0.0012137778,0.0005976021],"domain_scores_gemma":[0.98993695,0.004748183,0.0031558138,0.0007128445,0.00093572243,0.0005104994],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039575743,0.00027923935,0.0028394733,0.00030853032,0.00002592663,0.000021123966,0.00032679757,0.00074618246,0.00035608895],"category_scores_gemma":[0.0100688515,0.00017475174,0.0003953236,0.00056649605,0.0003263969,0.00014999011,0.00018663892,0.0023813203,0.00021369665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.088775896,0.007487143,0.69968057,0.00008692826,0.0014919498,0.032123785,0.0004790015,0.00009416737,0.0005579676,0.000070757786,0.008247043,0.16090478],"study_design_scores_gemma":[0.47603768,0.029246107,0.42143056,0.00083469786,0.00039629423,0.004106386,0.00056594715,0.001788496,0.00068167754,0.00037551194,0.06410074,0.00043588938],"about_ca_topic_score_codex":0.00076214183,"about_ca_topic_score_gemma":0.00022255474,"teacher_disagreement_score":0.3872618,"about_ca_system_score_codex":0.0041592442,"about_ca_system_score_gemma":0.024068037,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W2955119360","doi":"10.14740/jh517","title":"Herpes Simplex Necrotic Lymphadenitis Masquerading as Richter’s Transformation in Treatment-Naive Patients With Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Context (archaeology); Lymphoma; Pathology; Biopsy; Herpes simplex virus; Leukemia; Dermatology; Immunology; Virus","score_opus":0.009566848291060089,"score_gpt":0.2736428839140522,"score_spread":0.26407603562299214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955119360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630845,0.0008141293,0.00011279911,0.0002587863,0.00018104639,0.0008635791,0.000002944881,0.00001999906,0.0014382752],"genre_scores_gemma":[0.99903524,0.00019725588,0.00019968436,0.00014503625,0.000088755354,0.00001707573,0.000016620732,0.000045075,0.00025522852],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974858,0.00013065216,0.00090770994,0.00025089065,0.0006086387,0.0006162713],"domain_scores_gemma":[0.9984894,0.0003039598,0.00041661126,0.00028929752,0.00026698105,0.00023374082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002094981,0.000287986,0.0009982078,0.00061818125,0.0000487656,0.000029352563,0.00018523292,0.0002094139,0.0004255896],"category_scores_gemma":[0.000083084895,0.0002035725,0.00017707598,0.00038150698,0.000109734254,0.00041253617,0.000024219687,0.00020346353,0.00021241907],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04577101,0.0038708989,0.61217594,0.009689364,0.006937948,0.036623504,0.02672936,0.018966502,0.0031467583,0.013505396,0.0021207067,0.22046264],"study_design_scores_gemma":[0.6599097,0.03566928,0.070900545,0.0055402927,0.001449978,0.10693487,0.0024220464,0.07649382,0.022563292,0.0018275321,0.014669314,0.0016193199],"about_ca_topic_score_codex":0.0006125186,"about_ca_topic_score_gemma":0.00011382724,"teacher_disagreement_score":0.6141387,"about_ca_system_score_codex":0.10096283,"about_ca_system_score_gemma":0.022391472,"threshold_uncertainty_score":0.98315066},"labels":[],"label_agreement":null},{"id":"W2955634477","doi":"10.14740/jh473","title":"Durable Response to Venetoclax Monotherapy in Richter’s Syndrome: A Case Report and Review of Literature","year":2019,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Venetoclax; Diffuse large B-cell lymphoma; Chronic lymphocytic leukemia; CHOP; Lymphoma; Internal medicine; Leukemia; Biopsy; Leukocytosis; Oncology; Pathology","score_opus":0.011882059865765704,"score_gpt":0.33150999847980644,"score_spread":0.31962793861404076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955634477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93820345,0.058178138,0.000012486741,0.002973218,0.00008907515,0.0004285341,0.0000014278386,0.00000273182,0.000110952125],"genre_scores_gemma":[0.99262583,0.0049768463,0.00092553685,0.00086026784,0.000019331617,0.0000061950777,9.2868225e-7,0.000016935139,0.0005681129],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9982969,0.00020571619,0.0008516777,0.00015855947,0.00027427793,0.00021283355],"domain_scores_gemma":[0.9985104,0.00034435006,0.0003558084,0.00035036652,0.00027676343,0.00016228917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018155945,0.00010623891,0.00089526613,0.00038932113,0.000009719079,0.0000064116753,0.00008630496,0.00011858769,0.00012807833],"category_scores_gemma":[0.0009624589,0.00007771005,0.00009125574,0.0004061555,0.00004023024,0.00006985583,0.00004001196,0.0003225842,0.000010558706],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054810373,0.0000909539,0.004015884,0.0064557213,0.00011606221,0.97490793,0.0005833585,0.0000068282598,0.004437239,0.0000811634,0.0035450577,0.00027873888],"study_design_scores_gemma":[0.006806191,0.0011050113,0.0010663641,0.013662205,0.000030259343,0.9729798,0.000055678465,0.00007199597,0.000970789,0.00006375815,0.003127567,0.000060410493],"about_ca_topic_score_codex":0.000037601203,"about_ca_topic_score_gemma":0.000005263025,"teacher_disagreement_score":0.05442241,"about_ca_system_score_codex":0.0018594199,"about_ca_system_score_gemma":0.003575705,"threshold_uncertainty_score":0.6343147},"labels":[],"label_agreement":null},{"id":"W2955661053","doi":"10.1080/10428194.2019.1620941","title":"Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"CancerCare Manitoba Foundation; Manitoba Health Research Council","keywords":"Medicine; Chronic lymphocytic leukemia; Skin cancer; Chemotherapy; Internal medicine; Cancer; Incidence (geometry); Leukemia; Oncology; Dermatology","score_opus":0.007728653774308125,"score_gpt":0.26915934534176517,"score_spread":0.261430691567457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955661053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919606,0.0025628896,0.00001945265,0.000037747115,0.00025875657,0.004194003,0.0004101516,0.00010093144,0.00045547987],"genre_scores_gemma":[0.9948974,0.0033030591,0.000074626274,0.0001496575,0.0002552367,0.00043296427,0.00017587146,0.00024373583,0.00046739817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99316305,0.00044983398,0.0014188437,0.001799455,0.0013307083,0.0018380936],"domain_scores_gemma":[0.9925184,0.004071514,0.0008725334,0.0013960056,0.00039980878,0.0007416871],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001276348,0.001327655,0.0026650936,0.0006287667,0.0003624705,0.00018057917,0.0005624758,0.0006281032,0.00006292514],"category_scores_gemma":[0.0006605098,0.0008511823,0.0004774696,0.00101611,0.0015451387,0.00037978558,0.00037282234,0.00038442918,0.000013460756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029250905,0.00031348804,0.88318944,0.0018851287,0.0016154407,0.00016432206,0.004326646,0.0126415845,0.00031142464,0.00049176853,0.00062733924,0.0651825],"study_design_scores_gemma":[0.20294042,0.002252546,0.7022319,0.00086237106,0.00021050475,0.0001205139,0.00042216445,0.08885928,0.00095325743,0.00011201862,0.0002015727,0.0008334516],"about_ca_topic_score_codex":0.10604014,"about_ca_topic_score_gemma":0.003218318,"teacher_disagreement_score":0.18095756,"about_ca_system_score_codex":0.1465837,"about_ca_system_score_gemma":0.049081262,"threshold_uncertainty_score":0.9999475},"labels":[],"label_agreement":null},{"id":"W2955699617","doi":"10.3389/fonc.2019.00606","title":"Inactivation of Prostaglandin E2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"Génome Québec; Compute Canada; McGill University; Canadian Institutes of Health Research; Université Laval","keywords":"Chronic lymphocytic leukemia; Cancer research; Cell growth; Glucuronidation; Prostaglandin E2; Transcriptome; Leukemia; Biology; Internal medicine; Gene expression; Enzyme; Chemistry; Endocrinology; Medicine; Immunology; Gene; Biochemistry; Microsome","score_opus":0.010159992806110013,"score_gpt":0.30298389884840965,"score_spread":0.29282390604229963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955699617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993134,0.00031396584,0.0018859484,0.00012571734,0.00095672667,0.0044577643,0.000007974869,0.000042949952,0.0022776104],"genre_scores_gemma":[0.99389774,0.00015117764,0.003686119,0.00035106906,0.00010531575,0.00056000147,0.00010255013,0.000051331797,0.0010947144],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99768716,0.00017283729,0.00059139176,0.00050181005,0.00036066145,0.0006861209],"domain_scores_gemma":[0.9983639,0.0007204649,0.0002212303,0.00041723132,0.000143036,0.00013413854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006832393,0.0002306517,0.00093665515,0.0008014144,0.00002207022,0.0000040097,0.00020470268,0.000526898,0.00005765063],"category_scores_gemma":[0.0011447391,0.00022056043,0.000114743394,0.000672749,0.00013683681,0.00012275293,0.0000850688,0.00033778188,0.00006551036],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08421686,0.00226744,0.100348786,0.032009304,0.0019339136,0.005035537,0.014629329,0.011234707,0.6105344,0.03298663,0.043830905,0.06097218],"study_design_scores_gemma":[0.26418656,0.015747793,0.0046084537,0.0015752235,0.00015939074,0.0003064799,0.0014433217,0.6177888,0.07539412,0.010273073,0.007873459,0.0006433067],"about_ca_topic_score_codex":0.0015962885,"about_ca_topic_score_gemma":0.00022166548,"teacher_disagreement_score":0.6065541,"about_ca_system_score_codex":0.2727772,"about_ca_system_score_gemma":0.050567113,"threshold_uncertainty_score":0.95481527},"labels":[],"label_agreement":null},{"id":"W2956956185","doi":"10.1016/j.leukres.2019.106193","title":"Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada","year":2019,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Transplantation; Immunology; Human leukocyte antigen; Stem cell; Leukemia; Chronic lymphocytic leukemia; Population; Internal medicine; Biology; Antigen; Genetics","score_opus":0.020211706848198577,"score_gpt":0.28614271253281076,"score_spread":0.2659310056846122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956956185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943653,0.0001710504,0.000033593868,0.0000658878,0.0000762753,0.0040848735,0.00092875806,0.000043305026,0.0002309952],"genre_scores_gemma":[0.99123645,0.00004500836,0.000301685,0.000067020126,0.00004674642,0.00044078592,0.0017771578,0.000112551366,0.0059725707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924879,0.0004764712,0.0014371296,0.0012607345,0.0028630043,0.001474739],"domain_scores_gemma":[0.99468654,0.00185609,0.00033982142,0.00141395,0.0012316975,0.0004718676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017547559,0.00037462657,0.0013734524,0.0008634165,0.00025064094,0.00020937633,0.00046329206,0.0003754786,0.00016784229],"category_scores_gemma":[0.00025936248,0.00044052894,0.00028668495,0.0025160355,0.00023518101,0.00024145049,0.000093027236,0.00066860387,0.000011787621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008021245,0.00019792102,0.9109753,0.0071847886,0.00086096313,0.006125907,0.0009892783,0.06273793,0.0002489365,0.000007230696,0.0007190938,0.0019314334],"study_design_scores_gemma":[0.21663478,0.003497704,0.6461836,0.0024613233,0.0013917562,0.0012277121,0.0032553102,0.12004156,0.003406724,0.000030225663,0.00040956985,0.0014597306],"about_ca_topic_score_codex":0.965695,"about_ca_topic_score_gemma":0.99020916,"teacher_disagreement_score":0.26479167,"about_ca_system_score_codex":0.20201474,"about_ca_system_score_gemma":0.10152296,"threshold_uncertainty_score":0.9998047},"labels":[],"label_agreement":null},{"id":"W2961471425","doi":"10.1016/j.clml.2019.07.004","title":"Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"Cilag; Janssen Pharmaceuticals; TG Therapeutics; H. Lundbeck A/S; BeiGene; Pharmacyclics; Genentech; Sunesis; Astellas Pharma; Exelixis; Sun Pharma; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; AbbVie; Janssen Biotech; Teva Pharmaceutical Industries; Gilead Sciences; Janssen Research and Development; MorphoSys; Pfizer; Biogen; Celgene; AstraZeneca; Amgen; Alexion Pharmaceuticals; Roche; GlaxoSmithKline","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Leukemia","score_opus":0.04643419086277679,"score_gpt":0.37937275578762464,"score_spread":0.33293856492484786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961471425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304736,0.002336966,0.000017119346,0.000078854915,0.0007630268,0.0023857667,0.00001601721,0.00019556604,0.0011593186],"genre_scores_gemma":[0.9958797,0.0011384056,0.00048860087,0.0006656056,0.0003162377,0.000096974356,0.000105800296,0.00021209918,0.0010965575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912712,0.00051032705,0.0029193736,0.0016786855,0.0019889814,0.0016314253],"domain_scores_gemma":[0.99237144,0.002880226,0.0009648674,0.002286646,0.0008951994,0.00060161995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017857661,0.00096732413,0.003235992,0.0005680854,0.00013958749,0.00009309498,0.00090414047,0.0007715977,0.00026711673],"category_scores_gemma":[0.0012898109,0.00070670625,0.00069352175,0.0012354704,0.0013263744,0.0005980425,0.00054968905,0.00068761484,0.00042083857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026789447,0.00034896217,0.83507097,0.0006702816,0.0010717666,0.00026620372,0.00019729759,0.00019228544,0.00009738119,0.000059669117,0.000175762,0.1591705],"study_design_scores_gemma":[0.1030234,0.003181414,0.88796705,0.0016128818,0.00018358999,0.00006548141,0.00012543045,0.002280816,0.00066572154,0.000046257337,0.00016660427,0.0006813471],"about_ca_topic_score_codex":0.0005086615,"about_ca_topic_score_gemma":0.00009201391,"teacher_disagreement_score":0.15848915,"about_ca_system_score_codex":0.14910379,"about_ca_system_score_gemma":0.073858365,"threshold_uncertainty_score":0.9995384},"labels":[],"label_agreement":null},{"id":"W2963361457","doi":"10.22374/jeleu.v2i3.50","title":"Chronic Lymphocytic Leukemia Presenting as Irritative Lower Urinary Tract Symptoms and Non-Visible Hematuria: An Atypical Urology Presentation","year":2019,"lang":"en","type":"article","venue":"Journal of Endoluminal Endourology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Urinary system; Lower urinary tract symptoms; Hematology; Internal medicine; Disease; Bladder cancer; Cancer; Leukemia; Surgery; Oncology","score_opus":0.012373973995768834,"score_gpt":0.31293496797781284,"score_spread":0.300560993982044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963361457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371326,0.0017845017,0.000118104945,0.00044367975,0.00071699044,0.0006792454,0.000003534826,0.00003146501,0.0025092135],"genre_scores_gemma":[0.9962263,0.00022302083,0.0005430904,0.00034370538,0.0013850383,0.000017646842,0.000013542178,0.00006806064,0.0011795624],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99629354,0.00042743774,0.0009896308,0.0005755725,0.0007957579,0.00091805484],"domain_scores_gemma":[0.9966787,0.0011810495,0.00064945326,0.00048708098,0.00043061542,0.0005731171],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009195931,0.00036462757,0.0010305038,0.0005515351,0.000111791276,0.000057293553,0.00035251604,0.00042497803,0.0006247384],"category_scores_gemma":[0.00063846627,0.00031521768,0.0002686261,0.00028366334,0.00046330295,0.0006190182,0.00021520132,0.0011963582,0.00016237207],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.2014342,0.0077524376,0.12494119,0.0077025746,0.008492015,0.23500426,0.017509425,0.026216876,0.3272144,0.0069652507,0.0075311717,0.029236225],"study_design_scores_gemma":[0.1173625,0.091533385,0.11988431,0.0003948874,0.0014913888,0.5085694,0.0011879095,0.14243655,0.0062787365,0.0021408778,0.0077471575,0.0009728811],"about_ca_topic_score_codex":0.00022294442,"about_ca_topic_score_gemma":0.000009318887,"teacher_disagreement_score":0.32093564,"about_ca_system_score_codex":0.011155026,"about_ca_system_score_gemma":0.014815146,"threshold_uncertainty_score":0.99992996},"labels":[],"label_agreement":null},{"id":"W2963646129","doi":"10.1200/jco.2006.24.18_suppl.6517","title":"Lenalidomide (L) induces high response rates with molecular remission in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lenalidomide; Neutropenia; Internal medicine; Gastroenterology; Rituximab; Febrile neutropenia; Toxicity; Chronic lymphocytic leukemia; Myelodysplastic syndromes; Immunology; Leukemia; Oncology; Bone marrow; Multiple myeloma; Lymphoma","score_opus":0.04624101192510237,"score_gpt":0.40455273321319996,"score_spread":0.3583117212880976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963646129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963632,0.0009147113,0.000046327255,0.0011342195,0.00033770746,0.000606386,0.0000029903563,0.000037533835,0.0005569217],"genre_scores_gemma":[0.9944026,0.0005476641,0.0023915188,0.0007763898,0.0006783375,0.000015975362,0.0000120065415,0.000108486594,0.0010670349],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99176747,0.0019191197,0.0033617576,0.0005897808,0.0015710179,0.00079083414],"domain_scores_gemma":[0.9897608,0.0056520244,0.002311178,0.0006346836,0.0009794848,0.00066178513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005947747,0.0004152656,0.0023159632,0.00055253494,0.00007686567,0.000027288137,0.00045473,0.0009166356,0.00013413362],"category_scores_gemma":[0.0068325615,0.00023321556,0.00029570717,0.00073270407,0.0006554657,0.0002988165,0.00012750571,0.0021311394,0.00003402289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8661143,0.0037094108,0.017749824,0.00037442602,0.0009130106,0.040383633,0.00017403201,0.00439347,0.008007767,0.00008113237,0.0077379914,0.05036098],"study_design_scores_gemma":[0.4941845,0.17277592,0.26923537,0.003808083,0.00086814613,0.0034616725,0.00020828912,0.0019629532,0.010456848,0.00028335492,0.04193659,0.0008182837],"about_ca_topic_score_codex":0.0011222014,"about_ca_topic_score_gemma":0.00039387154,"teacher_disagreement_score":0.37192982,"about_ca_system_score_codex":0.093390256,"about_ca_system_score_gemma":0.18000248,"threshold_uncertainty_score":0.9510254},"labels":[],"label_agreement":null},{"id":"W2963687945","doi":"10.1182/bloodadvances.2018026591","title":"IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba; Research Institute in Oncology and Hematology","funders":"","keywords":"Chronic lymphocytic leukemia; Immunology; Leukemia; Medicine; Internal medicine; Oncology","score_opus":0.017972039684874104,"score_gpt":0.3057286261187398,"score_spread":0.2877565864338657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963687945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894736,0.005826447,0.000012578577,0.0001116999,0.00013765959,0.0021861002,0.00008590075,0.000087951754,0.0020780617],"genre_scores_gemma":[0.9806787,0.0020557404,0.00032102538,0.00010058987,0.00029556802,0.001078611,0.000047063295,0.000058424113,0.015364326],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99823016,0.000046612626,0.00031319432,0.0005763083,0.0002602356,0.00057348126],"domain_scores_gemma":[0.99846226,0.0007607201,0.00006220393,0.00040257777,0.00006345386,0.00024878528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021632043,0.00025454056,0.0005256879,0.0002173177,0.0000838439,0.000026255386,0.000103636485,0.000110303576,0.00047844072],"category_scores_gemma":[0.00023768425,0.00021333681,0.00009461924,0.0003307878,0.00007978748,0.00019356301,0.00011147692,0.0000750431,0.0005057802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005055532,0.0018052463,0.6744683,0.0065175095,0.00223312,0.00051253155,0.0018767723,0.021885041,0.0637314,0.0005442434,0.003566645,0.21780366],"study_design_scores_gemma":[0.24893157,0.021178277,0.054435678,0.002156751,0.00097140507,0.0009268224,0.00019846036,0.0396419,0.11927189,0.00036095927,0.510343,0.0015832647],"about_ca_topic_score_codex":0.00061909837,"about_ca_topic_score_gemma":0.00077323185,"teacher_disagreement_score":0.6200326,"about_ca_system_score_codex":0.069359966,"about_ca_system_score_gemma":0.0094799725,"threshold_uncertainty_score":0.99613535},"labels":[],"label_agreement":null},{"id":"W2964484115","doi":"10.1038/s41598-019-47305-2","title":"Bruton’s tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes","year":2019,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Bruton's tyrosine kinase; Ibrutinib; Chronic lymphocytic leukemia; Tyrosine kinase; Metabolic adaptation; Cancer research; Lymphocytic infiltration; Leukemia; Bioenergetics; Crosstalk; Biology; Signal transduction; Immunology; Medicine; Cell biology; Mitochondrion; Metabolism; Endocrinology","score_opus":0.020990896198790628,"score_gpt":0.2911204741790304,"score_spread":0.2701295779802398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964484115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98910105,0.003232048,0.0000046872897,0.00020227848,0.001309869,0.0009790699,0.0000053463095,0.000025856132,0.0051398007],"genre_scores_gemma":[0.9445859,0.00003386475,0.000088906905,0.00012389064,0.00004867654,0.00003574102,0.00010803441,0.000025230034,0.05494971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963993,0.000074851305,0.00085605355,0.00080122636,0.0013768881,0.00049172377],"domain_scores_gemma":[0.99736,0.00008158079,0.00037820436,0.0017443312,0.0003063615,0.0001295372],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025488818,0.00018211734,0.000459173,0.00030632733,0.00018928557,0.00009051055,0.00018873639,0.00010013825,0.0011694608],"category_scores_gemma":[0.0001720055,0.00012242033,0.00016389196,0.0009341435,0.0006091512,0.00015643763,0.00026465865,0.00013202125,0.00016681846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003027716,0.00044000382,0.07595327,0.000654117,0.000094113704,0.0015160373,0.004677978,0.00037581866,0.89785385,0.000391082,0.013901184,0.0038397517],"study_design_scores_gemma":[0.008965847,0.00015657973,0.09584969,0.00048661616,0.00010959598,0.0018041974,0.00042075836,0.004023964,0.8342247,0.00081015035,0.052822165,0.00032574468],"about_ca_topic_score_codex":0.0017338801,"about_ca_topic_score_gemma":0.00020543826,"teacher_disagreement_score":0.06362919,"about_ca_system_score_codex":0.0044656424,"about_ca_system_score_gemma":0.0059128385,"threshold_uncertainty_score":0.9997436},"labels":[],"label_agreement":null},{"id":"W2965274063","doi":"10.1200/jco.2006.24.18_suppl.3081","title":"A phase I study of the pan-Bcl2 family inhibitor GX15–070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Pharmacodynamics; Adverse effect; Gastroenterology; Refractory (planetary science); Internal medicine; Pharmacology; Tolerability","score_opus":0.0772347158560779,"score_gpt":0.45532943602886095,"score_spread":0.37809472017278306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965274063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99623924,0.00007633805,0.000002812281,0.00068978337,0.0006637185,0.0010965923,0.000005419331,0.000009189478,0.0012168885],"genre_scores_gemma":[0.9975151,0.00003460103,0.00016906162,0.0006852668,0.00092163903,0.000012996693,0.0000027887122,0.00004085424,0.0006177389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99244523,0.0011287107,0.0040546297,0.0003457017,0.0015658964,0.00045982387],"domain_scores_gemma":[0.9928695,0.0024903796,0.0028528192,0.00056330627,0.00087328145,0.00035072296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003037291,0.00025802338,0.002064434,0.00030291625,0.00006202527,0.000013851564,0.00046259185,0.0004159115,0.000069497815],"category_scores_gemma":[0.0049904995,0.00013174483,0.00033712288,0.00055603316,0.00041735507,0.00015014721,0.00024477483,0.0012673689,0.00001290207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.25830656,0.17842515,0.43045533,0.00022156123,0.00074873515,0.008952457,0.0018176057,0.000052261723,0.0010799863,0.000013426587,0.008931716,0.110995226],"study_design_scores_gemma":[0.26365504,0.18157357,0.54741555,0.00054637576,0.00025634386,0.00028532528,0.0014974572,0.00012787752,0.00015945801,0.000036851005,0.0043034656,0.00014268344],"about_ca_topic_score_codex":0.0006083096,"about_ca_topic_score_gemma":0.0006867945,"teacher_disagreement_score":0.11696025,"about_ca_system_score_codex":0.0049772495,"about_ca_system_score_gemma":0.034143243,"threshold_uncertainty_score":0.9988425},"labels":[],"label_agreement":null},{"id":"W2965693298","doi":"10.1200/jco.2006.24.18_suppl.20020","title":"Risk of malignancy associated with chronic lymphocytic leukemia: A population based Canadian study","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Malignancy; Cancer registry; Cancer; Internal medicine; Confidence interval; Incidence (geometry); Population; Leukemia; Hematologic malignancy; Oncology","score_opus":0.053940034701942016,"score_gpt":0.4055751703828912,"score_spread":0.3516351356809492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965693298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687916,0.00029753422,0.000059320057,0.0002844552,0.00031643943,0.0005642318,0.000011213905,0.0000124790495,0.0015751495],"genre_scores_gemma":[0.9982495,0.00004859031,0.00044480874,0.00021418885,0.0006815988,0.000006842405,0.000016056782,0.000033640583,0.00030478774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99451876,0.001016538,0.0027834033,0.00025802627,0.0009289714,0.0004942873],"domain_scores_gemma":[0.99256086,0.0029525685,0.0026086743,0.00035533964,0.0009517009,0.00057083106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053254208,0.0001903793,0.001777421,0.0004138496,0.00007198443,0.000009967197,0.00023797064,0.0005169826,0.00016428459],"category_scores_gemma":[0.0060856207,0.0001323458,0.00038889694,0.0005034788,0.0001969838,0.000094991316,0.000028780565,0.00097116956,0.000011474396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003651618,0.0013677517,0.97038424,0.000064811895,0.0009224522,0.003907714,0.000044924527,0.009656393,0.000025356652,0.000038441343,0.001723161,0.008213153],"study_design_scores_gemma":[0.07622056,0.026965413,0.87598383,0.0003224585,0.0010909174,0.00027857255,0.000058553,0.018128581,0.000038816524,0.000116395844,0.0006670714,0.00012884624],"about_ca_topic_score_codex":0.34214875,"about_ca_topic_score_gemma":0.4511732,"teacher_disagreement_score":0.10902444,"about_ca_system_score_codex":0.1327391,"about_ca_system_score_gemma":0.23364687,"threshold_uncertainty_score":0.87059015},"labels":[],"label_agreement":null},{"id":"W2966036111","doi":"10.1007/s10637-019-00837-w","title":"Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","keywords":"Ibrutinib; Cancer research; Kinome; Downregulation and upregulation; XIAP; Tyrosine kinase; Bruton's tyrosine kinase; Apoptosis; Kinase; Signal transduction; Caspase; Pharmacology; Medicine; Biology; Programmed cell death; Cell biology; Immunology; Leukemia; Chronic lymphocytic leukemia; Biochemistry","score_opus":0.011200263854343957,"score_gpt":0.2952975540714463,"score_spread":0.28409729021710234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966036111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912051,0.0013952634,0.00011128319,0.005632719,0.000082838094,0.0007340178,0.000057907953,0.000017905135,0.00076295],"genre_scores_gemma":[0.99629825,0.000042212178,0.00073931867,0.0008839961,0.00030031952,0.00003667303,0.000038978666,0.000021475185,0.0016387784],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99885464,0.000036472527,0.00020459702,0.00021358444,0.0004884404,0.00020224068],"domain_scores_gemma":[0.99919677,0.00021673761,0.000101158956,0.00018739342,0.00015528892,0.00014266702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001947151,0.00010604104,0.0001631192,0.000048865495,0.00007045022,0.00003337124,0.00009152446,0.000066280154,0.0002449717],"category_scores_gemma":[0.00004213195,0.00007540789,0.00005993317,0.000108497145,0.00021763956,0.00011827372,0.000047499925,0.000110230445,0.0000177045],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032383348,0.00022580921,0.014152732,0.00096725,0.00078103447,0.000007592458,0.007351021,0.0031752638,0.7291119,0.09537771,0.0035455183,0.14206581],"study_design_scores_gemma":[0.057735663,0.00068948185,0.1042764,0.0019563478,0.0005638217,0.0012555979,0.0042139445,0.3964639,0.1186576,0.27811894,0.035275508,0.00079280086],"about_ca_topic_score_codex":0.0019306585,"about_ca_topic_score_gemma":0.0000071147942,"teacher_disagreement_score":0.6104543,"about_ca_system_score_codex":0.00073937123,"about_ca_system_score_gemma":0.0061113914,"threshold_uncertainty_score":0.99952304},"labels":[],"label_agreement":null},{"id":"W2966319593","doi":"10.1136/jnnp-2019-anzan.49","title":"056 Efficacy and safety of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study","year":2019,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; NeuroRx Research (Canada); University of Toronto","funders":"","keywords":"Placebo; Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Randomized controlled trial; Adverse effect; Surgery; Pathology","score_opus":0.010808563436888017,"score_gpt":0.25722447511400126,"score_spread":0.24641591167711324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966319593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046165,0.00056885596,0.000003308564,0.0018011327,0.0031643563,0.003922587,0.000011427911,0.00001554488,0.000051149353],"genre_scores_gemma":[0.9981952,0.00011011692,0.000043728698,0.0012338288,0.00024986741,0.000022737195,0.000002004465,0.000079467274,0.00006306934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99398935,0.0016529217,0.0020872087,0.0005573392,0.0011215823,0.0005916144],"domain_scores_gemma":[0.99416494,0.0029811761,0.0015314244,0.00074563234,0.00031363106,0.00026317284],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023761853,0.00042648104,0.0022799054,0.00063297496,0.00011565832,0.000033207696,0.00030412633,0.00021379595,0.00006607825],"category_scores_gemma":[0.002077456,0.00025777073,0.00049353484,0.0006569979,0.0004461963,0.00022389351,0.00018847169,0.0014542453,0.0000048271318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5299665,0.0038075256,0.46406594,0.00006987176,0.00021218715,0.00009852048,0.0001506224,0.000113436814,0.0008300248,0.0000035114438,0.0004774959,0.00020441353],"study_design_scores_gemma":[0.66908187,0.0038512647,0.3249123,0.00044160502,0.00035977524,0.00026898438,0.000037337835,0.00076387887,0.00006341427,0.000006837411,0.00007050981,0.0001422116],"about_ca_topic_score_codex":0.000054847405,"about_ca_topic_score_gemma":0.00002439672,"teacher_disagreement_score":0.13915363,"about_ca_system_score_codex":0.00039460202,"about_ca_system_score_gemma":0.002391508,"threshold_uncertainty_score":0.9999874},"labels":[],"label_agreement":null},{"id":"W2968109725","doi":"10.1182/blood-2018-99-111726","title":"Literature Review of All Cases of Aggressive T-Cell Large Granular Lymphocytic Leukemia Cases and Report of an Additional Case","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Hôpital Fleurimont; Université de Sherbrooke","funders":"","keywords":"Leukemia; Medicine; Immunology; Immunophenotyping; Lymphoproliferative disorders; Cytopenia; Chronic lymphocytic leukemia; Pathology; Lymphoma; Bone marrow; Antigen","score_opus":0.018976846275266804,"score_gpt":0.31106945743667974,"score_spread":0.29209261116141294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968109725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92319745,0.07368755,0.0000012871094,0.000018665667,0.000036602498,0.0004988789,0.0020451974,0.000016887436,0.0004974682],"genre_scores_gemma":[0.98666996,0.010467923,0.0009054565,0.00020135714,0.00021194652,0.00003032692,0.0012177707,0.000031821644,0.0002634548],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99784046,0.000113830036,0.0007473878,0.00038399626,0.0006073435,0.00030700705],"domain_scores_gemma":[0.99667996,0.0005381616,0.000829127,0.0007590508,0.0009573926,0.00023629169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046974517,0.00020842641,0.0007080257,0.00015992847,0.000047536676,0.0000072563553,0.00011304985,0.00015282759,0.00069622364],"category_scores_gemma":[0.0030173766,0.0001696753,0.00014764158,0.00035034178,0.0004460248,0.00011195001,0.00011025592,0.00013924052,0.0000040956484],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077498954,0.0022484877,0.0004387426,0.06576952,0.0005539211,0.89706105,0.0010186594,6.8420246e-7,0.0074661877,0.000108345426,0.023389436,0.0011699559],"study_design_scores_gemma":[0.02534011,0.0020322036,0.00016953028,0.031895004,0.0011340973,0.83714116,0.00013811723,0.00025018945,0.0973877,0.00003207047,0.0042513427,0.00022846276],"about_ca_topic_score_codex":0.0006527367,"about_ca_topic_score_gemma":0.000076979566,"teacher_disagreement_score":0.08992151,"about_ca_system_score_codex":0.001307928,"about_ca_system_score_gemma":0.007591255,"threshold_uncertainty_score":0.9980348},"labels":[],"label_agreement":null},{"id":"W2970030949","doi":"10.1016/j.clml.2019.07.205","title":"Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Chlorambucil; Medicine; Oncology; Bruton's tyrosine kinase; Internal medicine; Leukemia; Chemotherapy; Receptor; Tyrosine kinase","score_opus":0.038030738120085956,"score_gpt":0.34495970751860233,"score_spread":0.3069289693985164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970030949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856286,0.004104902,0.00012180077,0.0002553252,0.0018795517,0.0048021986,0.00015061484,0.00028027926,0.0027767445],"genre_scores_gemma":[0.9720488,0.0049680048,0.00084610394,0.0006412754,0.0020789322,0.00086289,0.00026983634,0.0002922799,0.017991873],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920229,0.00025603367,0.0027247975,0.0019418001,0.0012499122,0.00180461],"domain_scores_gemma":[0.99160725,0.0032262062,0.0006947147,0.0028203775,0.00068457815,0.00096686406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011383464,0.0010472597,0.0027981566,0.00037221197,0.00017978018,0.000076015924,0.00077441,0.0011517208,0.0013585052],"category_scores_gemma":[0.00082078384,0.0008428876,0.0021861414,0.0007552465,0.00084493606,0.00025066713,0.00026518782,0.0002883924,0.0016708574],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.062520176,0.0014193713,0.020825632,0.0018915193,0.0028226518,0.00066573307,0.0008746008,0.000583066,0.0013745916,0.0007548031,0.0073699104,0.89889795],"study_design_scores_gemma":[0.44781148,0.034577623,0.23501654,0.0014233381,0.0009100189,0.0005830894,0.00019794655,0.08896216,0.014443281,0.00077893725,0.17347771,0.0018178646],"about_ca_topic_score_codex":0.0010884677,"about_ca_topic_score_gemma":0.00019020821,"teacher_disagreement_score":0.89708006,"about_ca_system_score_codex":0.16057779,"about_ca_system_score_gemma":0.080264136,"threshold_uncertainty_score":0.9995544},"labels":[],"label_agreement":null},{"id":"W2970398865","doi":"10.1038/s41375-019-0554-1","title":"Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"F. Hoffmann-La Roche; Roche","keywords":"Fludarabine; Medicine; Obinutuzumab; Cyclophosphamide; Internal medicine; Chronic lymphocytic leukemia; Neutropenia; Tolerability; Gastroenterology; Clinical endpoint; Surgery; Oncology; Adverse effect; Leukemia; Chemotherapy; Clinical trial","score_opus":0.008137454278293835,"score_gpt":0.24417642207480791,"score_spread":0.23603896779651407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970398865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946969,0.0008510995,0.0000035783407,0.000026794636,0.00007764058,0.0036624225,0.000024681909,0.000057245987,0.0005996251],"genre_scores_gemma":[0.996627,0.00009991843,0.00003325204,0.0001156517,0.000044309407,0.00012205069,0.000057308225,0.00007310231,0.0028274509],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958848,0.00019278062,0.00083439174,0.000934714,0.0012942717,0.00085906003],"domain_scores_gemma":[0.99721473,0.00029713393,0.00031715544,0.0016722427,0.00025047385,0.000248231],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047808728,0.000485099,0.0014017136,0.0006016233,0.000087298016,0.00003745111,0.0005113622,0.00024227251,0.00020877091],"category_scores_gemma":[0.00012909282,0.0003126119,0.00022727251,0.0034396711,0.00030208408,0.0001726956,0.00042083807,0.00052827527,0.000044278135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028008812,0.00014916593,0.957304,0.00073263847,0.002311222,0.00019722193,0.0026734355,0.032080594,0.00012683505,0.000026641199,0.00008668143,0.0015107011],"study_design_scores_gemma":[0.08110272,0.0020667133,0.78262836,0.00050648017,0.0022748448,0.00004228914,0.0003057224,0.13033284,0.00024892457,0.000010281266,0.00011124519,0.00036959915],"about_ca_topic_score_codex":0.058393903,"about_ca_topic_score_gemma":0.011755152,"teacher_disagreement_score":0.23103733,"about_ca_system_score_codex":0.27620634,"about_ca_system_score_gemma":0.045169022,"threshold_uncertainty_score":0.9999326},"labels":[],"label_agreement":null},{"id":"W2970731184","doi":"10.1016/j.clml.2019.08.004","title":"Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Cancer Institute; Janssen Scientific Affairs; Sunesis; AbbVie; BeiGene; TG Therapeutics","keywords":"Medicine; Chemoimmunotherapy; Ibrutinib; Hazard ratio; Internal medicine; Ofatumumab; Rituximab; Chronic lymphocytic leukemia; Oncology; Leukemia; Confidence interval; Lymphoma","score_opus":0.07058158062732924,"score_gpt":0.3954478741314718,"score_spread":0.3248662935041426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970731184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190754,0.0018215689,0.000011991824,0.00015590023,0.00011346862,0.0036540919,0.000073931915,0.00014646658,0.0021150508],"genre_scores_gemma":[0.99456954,0.0003974174,0.00034210636,0.0016124438,0.00017125574,0.00009324419,0.0007535816,0.00017637317,0.0018840628],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99373513,0.00046577654,0.0022346147,0.00138179,0.0010551247,0.0011275514],"domain_scores_gemma":[0.9951937,0.001379602,0.00068318925,0.0015448126,0.00042298442,0.00077567034],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006541807,0.0007342208,0.0024218906,0.000476293,0.00013665522,0.0000644777,0.00043044786,0.0005420293,0.0007242138],"category_scores_gemma":[0.00052632287,0.0005478735,0.00021643197,0.0009810992,0.00043762085,0.00017625511,0.00019157179,0.0003407548,0.00068958016],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04848307,0.0009900515,0.14793925,0.000616468,0.0004888662,0.000097794175,0.001956099,0.0012597666,0.00010280906,0.000022965925,0.0026347316,0.7954081],"study_design_scores_gemma":[0.16497667,0.035992295,0.74690926,0.0029046193,0.00012313481,0.000046719942,0.0004455346,0.026380915,0.0014716974,0.0000025285335,0.01998554,0.00076109654],"about_ca_topic_score_codex":0.002064215,"about_ca_topic_score_gemma":0.0003976923,"teacher_disagreement_score":0.79464704,"about_ca_system_score_codex":0.19315444,"about_ca_system_score_gemma":0.07092841,"threshold_uncertainty_score":0.99969727},"labels":[],"label_agreement":null},{"id":"W2970918745","doi":"10.1016/j.leukres.2019.106220","title":"Buccal cell telomere length is not a useful marker for comorbidities in chronic lymphocytic leukemia","year":2019,"lang":"en","type":"letter","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"Research Manitoba","keywords":"Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Outbreak; Cluster (spacecraft); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Family medicine; Virology; Disease; Internal medicine; Infectious disease (medical specialty)","score_opus":0.09863748031594236,"score_gpt":0.37400464742956685,"score_spread":0.2753671671136245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970918745","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55874956,0.0126430895,0.00009466348,0.31867042,0.0034824386,0.034311857,0.0028156003,0.0010441683,0.06818821],"genre_scores_gemma":[0.21666832,0.0046468577,0.00079110195,0.3125759,0.022464635,0.005615667,0.0034754886,0.002125116,0.4316369],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9799222,0.001217906,0.0020807083,0.0035488198,0.006814321,0.006416041],"domain_scores_gemma":[0.9847846,0.008123373,0.00030611147,0.0045060506,0.0016204949,0.0006593455],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.004893776,0.001722935,0.0031903898,0.0035446414,0.0004933236,0.0005002274,0.0027191348,0.0051399325,0.0024679354],"category_scores_gemma":[0.0014886687,0.0016258574,0.001194768,0.0023409722,0.0017242164,0.00040177032,0.001636991,0.014107101,0.0050745658],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023680103,0.00005108635,0.0001261574,0.015985927,0.00037097628,0.0051475917,0.0005727478,0.0002141148,0.0012183586,0.000051263192,0.9728342,0.0010595145],"study_design_scores_gemma":[0.048227523,0.001614147,0.00018349354,0.0026074168,0.00019079878,0.0006780121,0.0002673357,0.07469732,0.009893242,0.00020823907,0.8599563,0.0014761344],"about_ca_topic_score_codex":0.014041717,"about_ca_topic_score_gemma":0.0003920064,"teacher_disagreement_score":0.36344868,"about_ca_system_score_codex":0.67038715,"about_ca_system_score_gemma":0.3737177,"threshold_uncertainty_score":0.9995517},"labels":[],"label_agreement":null},{"id":"W2971024070","doi":"10.1182/blood.v130.suppl_1.3111.3111","title":"Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Carfilzomib; Ibrutinib; Multiple myeloma; Medicine; Lenalidomide; Pomalidomide; Dexamethasone; Refractory (planetary science); Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia; Biology","score_opus":0.02258653904098449,"score_gpt":0.30556453754721075,"score_spread":0.28297799850622624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971024070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515826,0.00004099033,0.0000064049336,0.00008756597,0.00006289022,0.001042131,0.00012586391,0.00003779395,0.0034380779],"genre_scores_gemma":[0.99827623,0.000009031376,0.0009568739,0.00003217298,0.000089585694,0.000038804446,0.00014942473,0.000056017077,0.00039185944],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755484,0.00008611906,0.0005026859,0.0004887301,0.00086376246,0.0005038832],"domain_scores_gemma":[0.99726284,0.00031566035,0.00040754976,0.0014334655,0.00033626895,0.0002442262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003941791,0.00025617328,0.0006229692,0.00019181472,0.0001268847,0.000042815343,0.00034379773,0.00016470026,0.000027736214],"category_scores_gemma":[0.0014189468,0.00018377119,0.000058709917,0.00018150231,0.0004985464,0.00027877663,0.00014638025,0.00040000095,0.000014002228],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2877094,0.044206366,0.6389816,0.0009270182,0.001284011,0.003167669,0.0029139437,0.000018354178,0.0038913572,0.00006579273,0.0007149301,0.016119575],"study_design_scores_gemma":[0.6670317,0.010481813,0.2952613,0.0006581148,0.00019147909,0.0000342874,0.000082527215,0.00022348277,0.025476333,0.000005724536,0.00030124545,0.00025198673],"about_ca_topic_score_codex":0.0013452121,"about_ca_topic_score_gemma":0.00043497342,"teacher_disagreement_score":0.37932232,"about_ca_system_score_codex":0.00089445605,"about_ca_system_score_gemma":0.0029906065,"threshold_uncertainty_score":0.74939716},"labels":[],"label_agreement":null},{"id":"W2979365039","doi":"10.1182/blood.v106.11.2977.2977","title":"A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Phase II Study of Oral Fludarabine in Untreated B-Cell Chronic Lymphocytic Leukemia.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Fludarabine; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gastroenterology; Cancer; CD5; Leukemia; Oncology; Immunology; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.08770439753966136,"score_gpt":0.42592015847087195,"score_spread":0.3382157609312106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979365039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953946,0.0017481039,0.0000035197336,0.00011553852,0.00024877,0.0016738081,0.00008384344,0.000026479338,0.0007053479],"genre_scores_gemma":[0.99790263,0.00022824315,0.000122098,0.000111407106,0.0004872667,0.00013487252,0.000065215136,0.00003671807,0.0009115518],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946941,0.0004570427,0.002271273,0.0005440237,0.0014620457,0.00057150284],"domain_scores_gemma":[0.9977071,0.00054003875,0.00053114275,0.00050875184,0.00041761767,0.0002953352],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003334835,0.00029285694,0.0015955964,0.00031659254,0.00006956509,0.000007629947,0.00030616307,0.00019604835,0.00035036818],"category_scores_gemma":[0.0017220244,0.00024808422,0.00018321534,0.0008464696,0.00021484663,0.00012931938,0.00015933876,0.00035310627,0.000005762696],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07306472,0.31349772,0.055661585,0.010088258,0.019465309,0.009449896,0.010014699,0.11138675,0.1175419,0.0008428299,0.06814759,0.21083872],"study_design_scores_gemma":[0.88954705,0.008287836,0.003324012,0.00060923013,0.0012863302,0.0001360791,0.00025854597,0.06707606,0.022986492,0.000016986913,0.0059933737,0.0004779873],"about_ca_topic_score_codex":0.56631756,"about_ca_topic_score_gemma":0.7376335,"teacher_disagreement_score":0.81648237,"about_ca_system_score_codex":0.06887754,"about_ca_system_score_gemma":0.2099892,"threshold_uncertainty_score":0.99999714},"labels":[],"label_agreement":null},{"id":"W2979372680","doi":"10.1182/blood.v124.21.1701.1701","title":"Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Follicular lymphoma; Tolerability; Chronic lymphocytic leukemia; Bendamustine; Phases of clinical research; Lymphoma; Gastroenterology; Clinical endpoint; Progressive disease; Oncology; Adverse effect; Chemotherapy; Clinical trial; Leukemia","score_opus":0.013141868499546829,"score_gpt":0.27885855896993317,"score_spread":0.2657166904703863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979372680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806106,0.00003157594,0.000019205121,0.00001595043,0.000045568868,0.0011797576,0.000008667043,0.000025643814,0.00061258883],"genre_scores_gemma":[0.99955714,0.0000018147991,0.0001426409,0.00005492408,0.000083806226,0.000051257208,0.000017916906,0.000033954948,0.000056544897],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979736,0.00006136525,0.0003976808,0.00034291472,0.0008733715,0.00035105852],"domain_scores_gemma":[0.99888694,0.0000973173,0.000109970366,0.0005563474,0.00018657763,0.00016285985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029720456,0.00017274304,0.0004331213,0.00022316196,0.000026911877,0.000010637642,0.00014911345,0.00007465057,0.000021076414],"category_scores_gemma":[0.000200777,0.00013096567,0.000037322166,0.00040297795,0.00007923376,0.000061138155,0.00011126435,0.00012142945,0.000015605452],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008230306,0.41221008,0.5428438,0.0006324782,0.00058685924,0.00021963974,0.0067766835,0.000027510228,0.0031782687,0.000056302586,0.0002522972,0.02498572],"study_design_scores_gemma":[0.7924814,0.01957599,0.17758538,0.00036522132,0.00019234096,0.000027305854,0.0004497829,0.0005370755,0.008414499,0.0000037075265,0.00017030399,0.00019697538],"about_ca_topic_score_codex":0.00079255406,"about_ca_topic_score_gemma":0.00015580471,"teacher_disagreement_score":0.7842511,"about_ca_system_score_codex":0.0012979087,"about_ca_system_score_gemma":0.0017752359,"threshold_uncertainty_score":0.5340625},"labels":[],"label_agreement":null},{"id":"W2979430133","doi":"10.1182/blood.v106.11.447.447","title":"Results of Phase II Study of Lenalidomide (L) {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Internal medicine; Rituximab; Neutropenia; Gastroenterology; Bendamustine; Chronic lymphocytic leukemia; Pomalidomide; Refractory (planetary science); Multiple myeloma; Progressive disease; Phases of clinical research; Oncology; Immunology; Toxicity; Leukemia; Lymphoma; Disease","score_opus":0.018964499863187115,"score_gpt":0.2976178362957274,"score_spread":0.2786533364325403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979430133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968428,0.0003902187,0.0000016292493,0.00002678379,0.000041066523,0.0017930302,0.000038114555,0.000045353663,0.00082102534],"genre_scores_gemma":[0.99829304,0.00006842381,0.00026105443,0.000036142024,0.00014019295,0.000057769677,0.000049615486,0.000065565066,0.001028203],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996055,0.00016349912,0.0012565415,0.00059983716,0.0013236629,0.0006014749],"domain_scores_gemma":[0.9974939,0.00030043448,0.00046814262,0.0011804556,0.0003287832,0.00022828697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006637552,0.00032312836,0.0009264946,0.0004447267,0.00006260338,0.0000084306175,0.00035287303,0.00017799211,0.00011159599],"category_scores_gemma":[0.0006367497,0.00022980153,0.00009293839,0.00080117135,0.00021073979,0.00017602128,0.00019953353,0.00034859296,0.000017660212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4935891,0.2655083,0.031244861,0.0064550703,0.006095399,0.0036247314,0.03401255,0.007525475,0.028995914,0.000051538347,0.005471905,0.11742516],"study_design_scores_gemma":[0.9153573,0.046636242,0.010771427,0.0011344507,0.00061730697,0.00005530563,0.000496842,0.0027150402,0.0210231,0.000002540685,0.0008451876,0.00034527498],"about_ca_topic_score_codex":0.0019117619,"about_ca_topic_score_gemma":0.0012295282,"teacher_disagreement_score":0.42176816,"about_ca_system_score_codex":0.03340332,"about_ca_system_score_gemma":0.028020756,"threshold_uncertainty_score":0.9774895},"labels":[],"label_agreement":null},{"id":"W2979470196","doi":"10.1182/blood.v108.11.3335.3335","title":"Younger Patients with CLL/SLL Are Less Frequent and Have Favorable Survival in a Canadian Population Based Study: The Manitoba Cohort.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Cancer registry; Population; Incidence (geometry); Chronic lymphocytic leukemia; Internal medicine; Cancer; Cohort; Referral; Leukemia; Database; Pediatrics; Family medicine","score_opus":0.01485561576767083,"score_gpt":0.24086195886480347,"score_spread":0.22600634309713263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979470196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974409,0.00007956676,0.0000015465647,0.00022590964,0.000038537677,0.0014919814,0.000029341121,0.0000158454,0.0006763979],"genre_scores_gemma":[0.99945456,0.0000016736036,0.000025807973,0.00009648735,0.0000696004,0.00007208846,0.00012005631,0.000026781434,0.0001329489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843824,0.0001038145,0.0002012408,0.0002879956,0.00054200133,0.00042670383],"domain_scores_gemma":[0.99925387,0.00006320145,0.00005775167,0.0003460113,0.0001162487,0.00016291886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035207145,0.00014057706,0.00022725952,0.00014301063,0.00010912455,0.000046075602,0.00008608885,0.000065132255,0.000016827638],"category_scores_gemma":[0.00005085925,0.000093860304,0.000019798892,0.00018950988,0.000038887374,0.0000644161,0.000023158353,0.00016783603,0.000004674183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007909953,0.00073661015,0.99862105,0.000030116513,0.000049073038,0.00018525703,0.00007684054,0.000045749322,0.00000268543,0.000016180296,0.000046172834,0.00011118953],"study_design_scores_gemma":[0.025525507,0.00017160532,0.97262144,0.00006890855,0.00012343853,0.000007581442,0.00060611544,0.00063930306,0.0000261186,0.000011680086,0.00008924758,0.000109061075],"about_ca_topic_score_codex":0.9539595,"about_ca_topic_score_gemma":0.9833749,"teacher_disagreement_score":0.029415358,"about_ca_system_score_codex":0.0044395775,"about_ca_system_score_gemma":0.002148111,"threshold_uncertainty_score":0.9993822},"labels":[],"label_agreement":null},{"id":"W2979491005","doi":"10.1182/blood.v120.21.3677.3677","title":"MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Neutropenia; Refractory (planetary science); Internal medicine; Toxicity; Adverse effect; Tumor lysis syndrome; Phases of clinical research; Gastroenterology; Oncology; Chemotherapy; Biology","score_opus":0.025345979115550258,"score_gpt":0.3122596468222849,"score_spread":0.28691366770673465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979491005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518764,0.0010215193,0.0000074201876,0.00007708426,0.00014222541,0.0022738196,0.00014021648,0.00013702457,0.0010130581],"genre_scores_gemma":[0.9955272,0.00014717662,0.0019837725,0.00012226103,0.00041011063,0.00022761642,0.00021299049,0.00009655855,0.0012722966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959161,0.00021357772,0.00083656376,0.00080392725,0.0011965247,0.0010332668],"domain_scores_gemma":[0.9972244,0.00066901307,0.00025925032,0.0011233251,0.00019952498,0.0005244912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080343895,0.00041637506,0.0008326665,0.00027313278,0.000098960634,0.000025672909,0.00032167247,0.00020118193,0.0002697679],"category_scores_gemma":[0.0008950765,0.00029290497,0.000087521126,0.00064978545,0.00014924274,0.00032614009,0.00015479325,0.0005923262,0.0001297963],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35324028,0.28432417,0.038523193,0.0015416902,0.0021413045,0.027260894,0.12041016,0.000026003818,0.1604418,0.000025966647,0.0038022087,0.008262312],"study_design_scores_gemma":[0.94118583,0.0077490155,0.01258556,0.0014717885,0.00048987387,0.00023141294,0.008136164,0.00045549808,0.025155528,0.0000056423646,0.0019104443,0.0006232528],"about_ca_topic_score_codex":0.0020378632,"about_ca_topic_score_gemma":0.0006589607,"teacher_disagreement_score":0.5879455,"about_ca_system_score_codex":0.0022469226,"about_ca_system_score_gemma":0.004021654,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W2979506023","doi":"10.1182/blood.v128.22.2770.2770","title":"Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Idelalisib; Ofatumumab; Medicine; Rituximab; Chronic lymphocytic leukemia; Internal medicine; Immunology; Oncology; IGHV@; Gastroenterology; Leukemia; Ibrutinib; Lymphoma","score_opus":0.02836843321877025,"score_gpt":0.2900238229310968,"score_spread":0.26165538971232655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979506023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951841,0.0011555881,0.000033186647,0.00039247173,0.00028022437,0.0018843933,0.000035359462,0.00013445919,0.00090018037],"genre_scores_gemma":[0.9965228,0.00008066342,0.00034535246,0.0001242107,0.0002927634,0.00044784098,0.000075235854,0.00008502364,0.002026115],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99638397,0.00029593855,0.00085878384,0.00071202323,0.0008977606,0.00085151667],"domain_scores_gemma":[0.9977033,0.0004767952,0.0002941643,0.000959307,0.00028935424,0.00027708628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062399276,0.00040679623,0.0005206602,0.0002505819,0.00024281256,0.000070741684,0.0002858846,0.00020651771,0.00007240345],"category_scores_gemma":[0.000609464,0.00022175477,0.00017782116,0.00060220493,0.00032421763,0.00017603156,0.00012392405,0.00027131735,0.0003950734],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01122371,0.018245656,0.08917248,0.00683373,0.008660716,0.012742146,0.05077017,0.011463999,0.34844008,0.0064213783,0.0038463639,0.43217957],"study_design_scores_gemma":[0.7819743,0.012716864,0.03300567,0.019259471,0.0017620284,0.0018527565,0.0018460931,0.0491874,0.088932626,0.0023604624,0.004394329,0.0027079557],"about_ca_topic_score_codex":0.00075034285,"about_ca_topic_score_gemma":0.00044332515,"teacher_disagreement_score":0.77075064,"about_ca_system_score_codex":0.18298629,"about_ca_system_score_gemma":0.047792807,"threshold_uncertainty_score":0.9576053},"labels":[],"label_agreement":null},{"id":"W2979549320","doi":"10.1182/blood.v128.22.3032.3032","title":"Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; CHOP; Internal medicine; Ven; Rituximab; Gastroenterology; Venetoclax; Lymphoma; Oncology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.016160185981264712,"score_gpt":0.29477173776963367,"score_spread":0.27861155178836894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979549320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99756545,0.00003206049,0.000005176984,0.000014160012,0.000028709579,0.0014844544,0.000050657614,0.00001406824,0.0008052552],"genre_scores_gemma":[0.9988496,0.000011035359,0.00014725521,0.000011820011,0.000037190177,0.000048245343,0.000008619673,0.000033983222,0.0008522682],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978425,0.00007323211,0.00058485445,0.00036540924,0.00078046473,0.00035357603],"domain_scores_gemma":[0.9984358,0.0002478453,0.00021106258,0.00073308026,0.00022827109,0.0001439678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030331034,0.0001715225,0.0005218667,0.00022600364,0.000016052456,0.0000038189264,0.00020146044,0.00008562627,0.000039761486],"category_scores_gemma":[0.00028634307,0.00009461709,0.000043720218,0.00044875752,0.00011057575,0.000060144994,0.00010674852,0.000066624045,0.000014862077],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4057294,0.24730515,0.17778899,0.0030533925,0.0021730938,0.0042024,0.026369661,0.000104454484,0.047128092,0.000012285169,0.0022775156,0.08385554],"study_design_scores_gemma":[0.89893544,0.019081462,0.041049626,0.00070679985,0.00019088162,0.000016814629,0.00039163168,0.00021837837,0.039149817,0.0000023384064,0.000097305594,0.00015948997],"about_ca_topic_score_codex":0.0017516855,"about_ca_topic_score_gemma":0.00031841313,"teacher_disagreement_score":0.49320602,"about_ca_system_score_codex":0.0037431966,"about_ca_system_score_gemma":0.0077329082,"threshold_uncertainty_score":0.9978923},"labels":[],"label_agreement":null},{"id":"W2979625562","doi":"10.1182/blood.v120.21.3925.3925","title":"Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Bendamustine; Medicine; Tolerability; Lenalidomide; Regimen; Internal medicine; Chronic lymphocytic leukemia; Tumor lysis syndrome; Rituximab; Neutropenia; Phases of clinical research; Febrile neutropenia; Interim analysis; Clinical trial; Oncology; Pharmacology; Adverse effect; Leukemia; Chemotherapy; Lymphoma; Multiple myeloma","score_opus":0.018436055264159572,"score_gpt":0.2763225775722773,"score_spread":0.2578865223081177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979625562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702096,0.00045114596,0.0000015205177,0.000039120336,0.000103237355,0.0020425315,0.000030426465,0.000050890434,0.00026018725],"genre_scores_gemma":[0.999263,0.000090388705,0.00005518298,0.000037957227,0.00008931262,0.00002660247,0.00004043622,0.00008138116,0.00031572836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960523,0.00041844902,0.0012666106,0.0005191729,0.0009841751,0.000759288],"domain_scores_gemma":[0.99708307,0.0005634955,0.00065100106,0.0012240582,0.00021725017,0.0002611227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009052505,0.0003826175,0.00089844054,0.00023177853,0.00008722933,0.000014139882,0.00033187217,0.00017350818,0.00002272131],"category_scores_gemma":[0.0009891781,0.00021802107,0.0001010737,0.0005923275,0.00028522732,0.00016765304,0.00040834112,0.00046510942,0.000006011582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.2994817,0.07826731,0.53955334,0.004025686,0.0053065736,0.00038389358,0.035308592,0.00039003964,0.021327818,0.00014941668,0.0012329774,0.014572677],"study_design_scores_gemma":[0.4815946,0.0042023426,0.49471617,0.0014477608,0.00057838863,0.000027059301,0.00056424766,0.00046527322,0.015953181,0.0000029041869,0.00015600634,0.00029208805],"about_ca_topic_score_codex":0.0011699947,"about_ca_topic_score_gemma":0.00043214552,"teacher_disagreement_score":0.1821129,"about_ca_system_score_codex":0.019498723,"about_ca_system_score_gemma":0.007227304,"threshold_uncertainty_score":0.9984008},"labels":[],"label_agreement":null},{"id":"W2979728937","doi":"10.1182/blood.v116.21.3465.3465","title":"Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes.","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Vancouver Hospital and Health Sciences Centre; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Fludarabine; Medicine; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Refractory (planetary science); Gastroenterology; Oncology; Leukemia; Surgery; Immunology; Chemotherapy; Cyclophosphamide; Biology","score_opus":0.014760483570183803,"score_gpt":0.2518967631824073,"score_spread":0.23713627961222347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979728937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599165,0.00010899994,0.0018909317,0.00036195535,0.00005056248,0.0009890645,0.00007046949,0.00003085165,0.0005055335],"genre_scores_gemma":[0.99635285,0.00015383773,0.0028455644,0.00006957803,0.000041900115,0.000091225425,0.00010348767,0.000025728084,0.00031580115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989604,0.000019882467,0.00028460557,0.00023197097,0.00030070933,0.00020243012],"domain_scores_gemma":[0.99928665,0.00017327219,0.00007212734,0.00024571925,0.00009305642,0.00012918077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022878674,0.00012406548,0.00024431857,0.0001208977,0.000049751845,0.000013662679,0.00006748722,0.00010089499,0.000030517182],"category_scores_gemma":[0.000005925286,0.00009815415,0.000047371028,0.00011254726,0.00007031736,0.00007214672,0.0000050561,0.00011877827,0.0000037211469],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008426161,0.004877587,0.27944735,0.02221966,0.0011979734,0.00044848004,0.07083963,0.00022158127,0.5748584,0.010928171,0.0008892134,0.025645746],"study_design_scores_gemma":[0.056995124,0.0011991333,0.4331936,0.00025471958,0.0008439136,0.0011456077,0.0005585786,0.00026165025,0.5038017,0.00011452502,0.0012427379,0.00038869298],"about_ca_topic_score_codex":0.000048153666,"about_ca_topic_score_gemma":0.00008748507,"teacher_disagreement_score":0.15374625,"about_ca_system_score_codex":0.00014923429,"about_ca_system_score_gemma":0.00047288113,"threshold_uncertainty_score":0.400261},"labels":[],"label_agreement":null},{"id":"W2979752621","doi":"10.1182/blood.v114.22.2363.2363","title":"Fludarabine (F) and Rituximab (R) (FR) as Initial Therapy for Symptomatic Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): Population-Based Experience Matches Clinical Trials.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; St. Paul's Hospital; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Rituximab; Chronic lymphocytic leukemia; Population; Cyclophosphamide; Gastroenterology; Oncology; Surgery; Lymphoma; Leukemia; Chemotherapy","score_opus":0.11322839515593047,"score_gpt":0.429709454932312,"score_spread":0.3164810597763815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979752621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010634,0.0038846922,0.00041970235,0.0003193091,0.00038826535,0.004143043,0.00004335924,0.00044313667,0.00025212223],"genre_scores_gemma":[0.99079335,0.0010234528,0.0029647176,0.0022484078,0.0015259178,0.0006421901,0.00020516333,0.00015050327,0.00044628442],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99262935,0.00072254136,0.0026974997,0.0014543332,0.00109628,0.0014000102],"domain_scores_gemma":[0.99208254,0.004603954,0.0006718339,0.0014047396,0.00034941777,0.00088750327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033129659,0.00085310586,0.0025187307,0.00043400517,0.0003997452,0.0002434177,0.00059076067,0.0007177526,0.00027321692],"category_scores_gemma":[0.0059838346,0.0006586464,0.0007184847,0.00069019134,0.0004705174,0.0002594853,0.00010491204,0.00027676887,0.00011306598],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09008933,0.017013801,0.0057417443,0.0068975,0.004318877,0.0048706387,0.0048651537,0.0009954722,0.01160656,0.0021479814,0.0019925877,0.84946036],"study_design_scores_gemma":[0.74625385,0.011522471,0.010886687,0.0017570609,0.0015014483,0.0031249542,0.0003470369,0.18933749,0.030792342,0.0014335309,0.0014323633,0.0016107821],"about_ca_topic_score_codex":0.0016801017,"about_ca_topic_score_gemma":0.00009351831,"teacher_disagreement_score":0.84784955,"about_ca_system_score_codex":0.042999454,"about_ca_system_score_gemma":0.07673521,"threshold_uncertainty_score":0.99958646},"labels":[],"label_agreement":null},{"id":"W2979922329","doi":"10.1182/blood.v124.21.1288.1288","title":"Obinutuzumab and Chlorambucil Versus Chlorambucil Monotherapy for Treatment of Previously Untreated Chronic Lymphocytic Leukemia Where Fludarabine-Based Chemotherapy Is Considered Inappropriate: A Canadian Cost-Utility Analysis","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Chlorambucil; Obinutuzumab; Fludarabine; Medicine; Chronic lymphocytic leukemia; Internal medicine; Chemotherapy; Oncology; Leukemia; Cyclophosphamide","score_opus":0.02775496467073465,"score_gpt":0.2916717141451928,"score_spread":0.26391674947445815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979922329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038607,0.004153437,0.0002960949,0.00041697925,0.00008015343,0.0039245435,0.00023285254,0.00012626167,0.00038358042],"genre_scores_gemma":[0.9960331,0.0012943196,0.00079161505,0.000276982,0.00017220945,0.00055576675,0.00027445238,0.00011023418,0.000491331],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9962024,0.00014800832,0.0008026371,0.0010969546,0.00058471784,0.0011652639],"domain_scores_gemma":[0.9962643,0.0005491519,0.00029422375,0.001489968,0.0005264232,0.0008759329],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005217456,0.00064644957,0.0016685559,0.0006027333,0.00021411551,0.00008555191,0.00024717595,0.00045226314,0.00041420342],"category_scores_gemma":[0.00021809318,0.00055676774,0.0005549359,0.001130849,0.00045950877,0.0000889396,0.000025338766,0.00012443587,0.00001563316],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.16820104,0.009013973,0.05062842,0.016433997,0.123698935,0.0011682637,0.021643996,0.012185749,0.024869306,0.0008094767,0.007222255,0.5641246],"study_design_scores_gemma":[0.4195699,0.0075934697,0.002294444,0.00024617676,0.006291345,0.00006870182,0.00013945275,0.46924463,0.07963588,0.00006896061,0.014086732,0.0007602965],"about_ca_topic_score_codex":0.21788724,"about_ca_topic_score_gemma":0.105019175,"teacher_disagreement_score":0.56336427,"about_ca_system_score_codex":0.09325779,"about_ca_system_score_gemma":0.080146454,"threshold_uncertainty_score":0.9996884},"labels":[],"label_agreement":null},{"id":"W2980084028","doi":"10.1182/blood.v116.21.1390.1390","title":"Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Fludarabine; Minimal residual disease; Rituximab; Chronic lymphocytic leukemia; Cyclophosphamide; Medicine; IGHV@; Immunoglobulin heavy chain; Internal medicine; Bendamustine; Immunology; Oncology; Leukemia; Antibody; Chemotherapy","score_opus":0.008512637684117213,"score_gpt":0.2769209660103856,"score_spread":0.26840832832626843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980084028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976263,0.00009624138,0.000002166657,0.000091682465,0.00001903544,0.0010730608,0.000045484052,0.000043612374,0.0010023975],"genre_scores_gemma":[0.9959521,0.000029731904,0.0031727771,0.000042777396,0.00005185341,0.00008476517,0.00009049319,0.00005972705,0.00051573437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977943,0.00006210051,0.00039068714,0.00051533437,0.0007881304,0.00044946783],"domain_scores_gemma":[0.9985168,0.00013428401,0.00013581531,0.00058078935,0.00021485657,0.00041748473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024261515,0.00027395407,0.00059778616,0.00018869482,0.000052550524,0.000018907056,0.00012817791,0.00011635464,0.00007844866],"category_scores_gemma":[0.00018904702,0.00016824274,0.000031968317,0.0003877386,0.00035687396,0.00008350717,0.00008170355,0.0004341306,0.0000035080895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00929706,0.0056171846,0.98124546,0.00034287898,0.00016279198,0.0009245539,0.00016423901,0.0000020248501,0.0016991785,0.00003217905,0.00005620163,0.00045626954],"study_design_scores_gemma":[0.18404575,0.0029019737,0.8075935,0.0004010029,0.00040243095,0.00012755998,0.00007017436,0.0006220804,0.0035594706,0.0000052234027,0.000058525504,0.0002122751],"about_ca_topic_score_codex":0.0009070081,"about_ca_topic_score_gemma":0.0010345944,"teacher_disagreement_score":0.17474867,"about_ca_system_score_codex":0.0005658578,"about_ca_system_score_gemma":0.004630426,"threshold_uncertainty_score":0.8214176},"labels":[],"label_agreement":null},{"id":"W2980122808","doi":"10.3390/cancers11101519","title":"Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; H. Lundbeck A/S; Research Manitoba","keywords":"Idelalisib; Bendamustine; Chronic lymphocytic leukemia; Cancer research; Cytotoxicity; Biology; Cytotoxic T cell; DNA damage; breakpoint cluster region; Leukemia; Molecular biology; Chemistry; Receptor; DNA; In vitro; Immunology; Ibrutinib; Biochemistry","score_opus":0.011293231304284345,"score_gpt":0.2672967940884993,"score_spread":0.256003562784215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980122808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99315274,0.0017029662,0.00021377718,0.000110559355,0.00014685804,0.000682424,0.000024153072,0.00006963432,0.0038968648],"genre_scores_gemma":[0.99416554,0.00022125783,0.00015303485,0.0002490408,0.00016103176,0.00007927795,0.0001639185,0.000048571,0.0047583464],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980585,0.00003226667,0.00029828012,0.00046255285,0.00063816574,0.00051021134],"domain_scores_gemma":[0.99922353,0.00006874864,0.00006319699,0.00037394615,0.00009300442,0.00017754399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017746637,0.00020902666,0.00034950316,0.00017376237,0.000036476307,0.000020610267,0.00013362405,0.00012999843,0.0008231714],"category_scores_gemma":[0.000024194207,0.00017668497,0.00006617239,0.0004726972,0.00013771233,0.00018372443,0.000019574389,0.0002350832,0.0001283781],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002410832,0.000011641822,0.00140416,0.0008773988,0.00018302475,0.0001683263,0.00056068256,0.8848968,0.09826621,0.0010348315,0.006658109,0.003527946],"study_design_scores_gemma":[0.042740233,0.0006714372,0.0023585453,0.00064162805,0.000057104855,0.00017611567,0.00016216931,0.93418,0.0045559914,0.000035305173,0.014090408,0.00033104068],"about_ca_topic_score_codex":0.006983813,"about_ca_topic_score_gemma":0.00058120734,"teacher_disagreement_score":0.43189156,"about_ca_system_score_codex":0.5357898,"about_ca_system_score_gemma":0.10389821,"threshold_uncertainty_score":0.9996288},"labels":[],"label_agreement":null},{"id":"W2980171540","doi":"10.1182/blood.v122.21.6.6","title":"Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Interim analysis; Obinutuzumab; Rituximab; Chlorambucil; Chronic lymphocytic leukemia; Surgery; Oncology; Gastroenterology; Randomized controlled trial; Chemotherapy; Leukemia; Cyclophosphamide; Lymphoma","score_opus":0.07089950402949753,"score_gpt":0.3653070094932137,"score_spread":0.2944075054637162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980171540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944425,0.00023030775,0.000010924302,0.00011084811,0.00028770918,0.0029655192,0.00029358902,0.000051005987,0.0016075933],"genre_scores_gemma":[0.998684,0.000025378717,0.00016182623,0.00006602353,0.00023544069,0.00018100931,0.0002133627,0.00006005772,0.00037292056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946154,0.00025084056,0.0014289604,0.00068008614,0.0021709914,0.0008537249],"domain_scores_gemma":[0.9964143,0.0011961062,0.00050187967,0.0010094602,0.0003936641,0.00048459298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006563898,0.00041349957,0.001331231,0.0002912679,0.00018303581,0.00004484191,0.0005286162,0.00034035053,0.0002714993],"category_scores_gemma":[0.0019584293,0.00030569494,0.00015243099,0.0007177295,0.0009706127,0.00016434556,0.0003400011,0.00072367716,0.000042019627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8751612,0.013882755,0.035639193,0.010010328,0.0034408811,0.0010828521,0.018847238,0.012957442,0.001238943,0.0014888044,0.013957803,0.0122925965],"study_design_scores_gemma":[0.93093336,0.006786196,0.022309577,0.0016011173,0.00031688903,0.000056806955,0.0006132732,0.03445088,0.0020820743,0.000014778016,0.0004554852,0.00037958432],"about_ca_topic_score_codex":0.019352729,"about_ca_topic_score_gemma":0.004502008,"teacher_disagreement_score":0.055772178,"about_ca_system_score_codex":0.044149388,"about_ca_system_score_gemma":0.057335485,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W2980213505","doi":"10.1182/blood.v104.11.428.428","title":"Differential Effects of Three Small Molecules Blocking Phosphatidylinositol-3 Kinase or AKT in Hodgkin Disease Cell Lines: Induction of Apoptosis and Cell Cycle Arrest.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protein kinase B; PI3K/AKT/mTOR pathway; LY294002; Cancer research; Cell cycle; Propidium iodide; Biology; Phosphatidylinositol; Kinase; Apoptosis; Phosphorylation; Molecular biology; Chemistry; Cell biology; Signal transduction; Programmed cell death; Biochemistry","score_opus":0.011803989024415281,"score_gpt":0.24411431225805522,"score_spread":0.23231032323363993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980213505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976089,0.0010937911,0.00023584151,0.000056352423,0.00012897179,0.000785112,0.000009444288,0.000026277565,0.000055282944],"genre_scores_gemma":[0.99844676,0.00021611589,0.001065306,0.000015858492,0.0001336081,0.00004310087,0.000015793583,0.000037509457,0.00002597174],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998407,0.00005154398,0.0004210815,0.00037628447,0.00040238083,0.00034169536],"domain_scores_gemma":[0.99892634,0.00018949357,0.00015971987,0.00039461878,0.000086750515,0.00024309338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082165294,0.00021996001,0.00044924844,0.00021947581,0.00003587599,0.000013406559,0.00013492446,0.00013815144,0.000017586424],"category_scores_gemma":[0.00020692161,0.00018177436,0.00009669347,0.0003393384,0.0001491651,0.000053980802,0.00012847375,0.00020604866,0.0000025120478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025059038,0.010095106,0.015822353,0.012647972,0.00016341514,0.0005943086,0.0011460069,0.0006799313,0.9533819,0.00005984305,0.000009674462,0.0028936039],"study_design_scores_gemma":[0.0463941,0.00047930548,0.014094489,0.0010092694,0.00039042137,0.000009666911,0.0000674123,0.0009844865,0.93626565,0.00014598611,0.0000015682002,0.00015765242],"about_ca_topic_score_codex":0.0016161035,"about_ca_topic_score_gemma":0.000151394,"teacher_disagreement_score":0.043888193,"about_ca_system_score_codex":0.0005002704,"about_ca_system_score_gemma":0.0015381143,"threshold_uncertainty_score":0.7412543},"labels":[],"label_agreement":null},{"id":"W2980371692","doi":"10.1182/bloodadvances.2019000350","title":"Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1–derived peptides overcomes drug resistance","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Chronic lymphocytic leukemia; Drug; Drug resistance; Thrombospondin 1; Thrombospondin; Leukemia; Cancer research; Chemistry; Medicine; Pharmacology; Immunology; Biology; Biochemistry; Microbiology; Metalloproteinase; Enzyme; Angiogenesis","score_opus":0.005637323439451374,"score_gpt":0.25207909436016657,"score_spread":0.2464417709207152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980371692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96152246,0.02735947,0.000061981926,0.00013346436,0.00021456528,0.0011969811,0.000009230119,0.0003588916,0.009142978],"genre_scores_gemma":[0.9687442,0.0023222321,0.005021562,0.0001781149,0.00028370947,0.000074561336,0.00006092289,0.00012241877,0.023192232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961586,0.00011196947,0.00055874046,0.00096718664,0.0011051041,0.0010984181],"domain_scores_gemma":[0.9977443,0.00050996104,0.0002689562,0.0009165044,0.00025254168,0.00030771663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042614414,0.0005032054,0.0009010096,0.00022236514,0.00020155481,0.00008006688,0.00041030222,0.00014477364,0.0005269331],"category_scores_gemma":[0.00022405083,0.00038402303,0.0001566643,0.00082153594,0.0003614116,0.0005969678,0.00015524271,0.00043418296,0.00044729232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008889472,0.0006041756,0.031332884,0.013180262,0.0035430058,0.0038412497,0.0041800854,0.019975968,0.90044993,0.0031538631,0.005374973,0.005474144],"study_design_scores_gemma":[0.18440259,0.0030643945,0.009120148,0.0083833,0.0015798984,0.0013296795,0.0030897204,0.02785754,0.6315266,0.0012468849,0.12470012,0.0036991367],"about_ca_topic_score_codex":0.00030330042,"about_ca_topic_score_gemma":0.00020891333,"teacher_disagreement_score":0.2689233,"about_ca_system_score_codex":0.031070298,"about_ca_system_score_gemma":0.020339556,"threshold_uncertainty_score":0.9998612},"labels":[],"label_agreement":null},{"id":"W2980736094","doi":"10.1186/s40463-019-0376-1","title":"The infectious thyroid nodule: A case report of mucormycosis associated with ibrutinib therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Otolaryngology - Head and Neck Surgery","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ste. Anne's Hospital; McGill University; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Mucormycosis; Medicine; Ibrutinib; Thyroid; Nodule (geology); Biopsy; Chronic lymphocytic leukemia; Pathology; Radiology; Dermatology; Leukemia; Surgery; Internal medicine; Biology","score_opus":0.019643581205544845,"score_gpt":0.2861227136990197,"score_spread":0.2664791324934749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980736094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954701,0.002632484,0.0000043476944,0.0006070875,0.00030735848,0.00031023307,0.0000022485208,0.000013685927,0.000652434],"genre_scores_gemma":[0.9975465,0.0016817369,0.000028676395,0.0002335623,0.0001206384,0.000005616614,0.0000041019216,0.000026961301,0.00035222428],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9978923,0.0002246642,0.0008509578,0.00019108654,0.00045024318,0.00039072576],"domain_scores_gemma":[0.99542856,0.0026088154,0.00085714273,0.00036860633,0.0005462018,0.00019068294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002220915,0.00017345877,0.00086743425,0.00023888682,0.0001295852,0.00002045822,0.000082774284,0.00019417143,0.000068951405],"category_scores_gemma":[0.0011471785,0.000095828604,0.00022806828,0.00034963965,0.00027200117,0.0001307094,0.00004282041,0.00053716847,0.000004935022],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027531532,0.00038972904,0.88161916,0.00009613415,0.0009825551,0.108271845,0.0002464536,0.0000033194854,0.002074131,0.000019945379,0.0023026813,0.0012408855],"study_design_scores_gemma":[0.011112995,0.0021536166,0.39679846,0.00041371677,0.00009766946,0.5855679,0.000069871094,0.00017702395,0.0014903937,0.000033836244,0.0019540326,0.00013046914],"about_ca_topic_score_codex":0.0002249014,"about_ca_topic_score_gemma":0.0000746822,"teacher_disagreement_score":0.4848207,"about_ca_system_score_codex":0.0007154902,"about_ca_system_score_gemma":0.0039624632,"threshold_uncertainty_score":0.70292395},"labels":[],"label_agreement":null},{"id":"W2980937306","doi":"10.1038/s41375-019-0602-x","title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; TG Therapeutics; Astellas Pharma; BeiGene; Gilead Sciences; GlaxoSmithKline; Pharmacyclics; Genentech; Sunesis; Teva Pharmaceutical Industries; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Ibrutinib; Chlorambucil; Internal medicine; Neutropenia; Medicine; Chronic lymphocytic leukemia; IGHV@; Adverse effect; Hematology; Oncology; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.0243989745233313,"score_gpt":0.31682641648231563,"score_spread":0.29242744195898435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980937306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514717,0.00023073416,0.000022075954,0.00009081201,0.000096505595,0.0040785596,0.00023794419,0.000019105531,0.0000770847],"genre_scores_gemma":[0.9988234,0.00009644711,0.00012663333,0.000041115134,0.0000708034,0.00006388657,0.000217699,0.00004358712,0.0005164346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982374,0.0000579463,0.0004463586,0.00040898367,0.00053988333,0.0003094834],"domain_scores_gemma":[0.9976087,0.0011066409,0.00018912807,0.00079786463,0.00017542955,0.00012224364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002193253,0.00020918371,0.0005847287,0.00006154819,0.00005246209,0.000011130994,0.00018708457,0.00009138399,0.00008288454],"category_scores_gemma":[0.00017214146,0.00012841067,0.00010058424,0.00017888863,0.00014914614,0.000048534122,0.000099295554,0.000115568524,0.000009113764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056822646,0.0040786806,0.8651747,0.00034378527,0.0014452968,0.000061365274,0.0057012914,0.000054855947,0.00032837145,0.000018168052,0.00043893052,0.065531924],"study_design_scores_gemma":[0.37594348,0.014141169,0.60457,0.0004189527,0.0005201485,0.0000049370474,0.00025743397,0.0010048037,0.0014529116,0.000007923651,0.0015045548,0.00017370215],"about_ca_topic_score_codex":0.0014337174,"about_ca_topic_score_gemma":0.0003807659,"teacher_disagreement_score":0.31912082,"about_ca_system_score_codex":0.0037399663,"about_ca_system_score_gemma":0.0014448187,"threshold_uncertainty_score":0.9779882},"labels":[],"label_agreement":null},{"id":"W2981072465","doi":"10.1182/blood-2018-99-114440","title":"Protides of 5-Fluorotroxacitabine Display Potent Anti-Proliferative Properties and Circumvent Deoxycytidine Kinase-Mediated Resistance Associated with Cytotoxic Cytidine Analogues; A Novel Approach for Acute Myeloid Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Deoxycytidine kinase; Cytarabine; Cytidine deaminase; Deoxycytidine; Cytidine; Cancer research; Myeloid leukemia; Leukemia; Azacitidine; Nucleoside analogue; Gemcitabine; Pharmacology; Biology; Chemistry; Medicine; Chemotherapy; Nucleoside; Immunology; Internal medicine; Biochemistry; Enzyme; Antibody","score_opus":0.030740436558158703,"score_gpt":0.263421444057845,"score_spread":0.23268100749968632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981072465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905282,0.00075392623,0.0026389172,0.00017795326,0.000029229124,0.005042714,0.00040325487,0.00012111745,0.00030467007],"genre_scores_gemma":[0.99037075,0.00010964031,0.006857501,0.00008391228,0.00023496777,0.0010412183,0.0004912455,0.00010639973,0.0007043759],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965392,0.00009540744,0.00072782364,0.0008776482,0.00088439684,0.0008755449],"domain_scores_gemma":[0.9973523,0.00018236609,0.0003810685,0.00062439794,0.0011146014,0.00034525662],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068182155,0.00050846627,0.0011643193,0.00026782675,0.00024953828,0.00005066508,0.00025563675,0.00023664082,0.000007629632],"category_scores_gemma":[0.0009800122,0.00035348372,0.00014368726,0.0007554507,0.0010331975,0.00019912205,0.00014809432,0.00030799257,0.0000030891647],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061204988,0.0037212095,0.0050142384,0.0017913637,0.004119734,0.0001341562,0.00140437,0.000032168078,0.9769992,0.0002805026,0.00026180976,0.00012070725],"study_design_scores_gemma":[0.10556017,0.005681521,0.021615652,0.0020741785,0.002275396,0.00046950218,0.000396949,0.021893136,0.83908874,0.000036668276,0.00010665397,0.00080141297],"about_ca_topic_score_codex":0.00014537186,"about_ca_topic_score_gemma":0.00014999413,"teacher_disagreement_score":0.13791047,"about_ca_system_score_codex":0.0029560693,"about_ca_system_score_gemma":0.00436104,"threshold_uncertainty_score":0.9998917},"labels":[],"label_agreement":null},{"id":"W2981164630","doi":"10.1182/blood.v118.21.289.289","title":"Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Alemtuzumab; Chemoimmunotherapy; Fludarabine; Chlorambucil; Internal medicine; Chemotherapy regimen; Chronic lymphocytic leukemia; Rituximab; Leukemia; Regimen; Surgery; Chemotherapy; Oncology; Cyclophosphamide; Transplantation; Lymphoma","score_opus":0.03287535462621271,"score_gpt":0.31727444230787766,"score_spread":0.28439908768166494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981164630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971307,0.0011602861,0.0000021066355,0.000011177705,0.000027558237,0.0011178317,0.000016748978,0.000034683624,0.0004989287],"genre_scores_gemma":[0.99878526,0.0005384751,0.00036747108,0.000066055654,0.000022677652,0.000039745522,0.000016127242,0.000079033794,0.00008516424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767715,0.00007509699,0.0005837952,0.00047031793,0.00068509014,0.00050852733],"domain_scores_gemma":[0.99846375,0.00022677374,0.00028944862,0.00073484564,0.0001723766,0.00011278913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032054182,0.00039825475,0.0010904026,0.000289709,0.000044890126,0.000009058195,0.00018220824,0.00014314412,0.000015876964],"category_scores_gemma":[0.0000794542,0.00023910774,0.00016733426,0.00040555978,0.0003916946,0.00009609491,0.00004163279,0.00021862084,0.0000014645823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07727199,0.0060478733,0.8571531,0.00065708545,0.014391191,0.0012052333,0.02906372,0.00010766288,0.003756503,0.00003415826,0.000059713053,0.010251733],"study_design_scores_gemma":[0.3095404,0.014795351,0.6575655,0.0007664403,0.00014507333,0.000026289761,0.00010688618,0.00004421245,0.016725374,0.00001949705,0.0000053510726,0.00025967238],"about_ca_topic_score_codex":0.004849416,"about_ca_topic_score_gemma":0.00017722206,"teacher_disagreement_score":0.23226841,"about_ca_system_score_codex":0.011477505,"about_ca_system_score_gemma":0.00790592,"threshold_uncertainty_score":0.99771833},"labels":[],"label_agreement":null},{"id":"W2981221994","doi":"10.1182/blood-2018-99-113422","title":"A Descriptive Analysis of Obinutuzumab Usage in a Single Canadian Centre","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Obinutuzumab; Chlorambucil; Medicine; Internal medicine; Population; Chronic lymphocytic leukemia; Regimen; Asymptomatic; Oncology; Surgery; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.025284436526268123,"score_gpt":0.2722073062144316,"score_spread":0.2469228696881635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981221994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98612994,0.00011899339,0.0000061964115,0.00009384165,0.000026762167,0.00020715724,0.000025833902,0.000011437002,0.013379813],"genre_scores_gemma":[0.99862397,0.0000063357616,0.00037322854,0.000075203316,0.00006122659,0.0000046490613,0.000019902738,0.000012471029,0.0008230158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882287,0.00004344986,0.00021947079,0.00022955034,0.00027056754,0.00041406436],"domain_scores_gemma":[0.9991173,0.00004964904,0.000040208408,0.000358576,0.00016135673,0.00027287484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001797156,0.00009185331,0.00033458613,0.00080608204,0.000027044787,0.000009231436,0.00011106035,0.00008308307,0.0005999099],"category_scores_gemma":[0.00023988569,0.00008414114,0.00010173123,0.0017223075,0.00015784998,0.00003667135,0.00003522695,0.00009754387,0.000048097067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025168203,0.01157058,0.6290511,0.0010618067,0.02787197,0.012942248,0.12343784,0.00015897152,0.16195615,0.0020052525,0.008452631,0.01897463],"study_design_scores_gemma":[0.20878084,0.00385738,0.36564642,0.0014207345,0.017018259,0.00051472534,0.0121983765,0.06810464,0.30660594,0.00028277596,0.014117124,0.001452785],"about_ca_topic_score_codex":0.4086812,"about_ca_topic_score_gemma":0.7109138,"teacher_disagreement_score":0.30223256,"about_ca_system_score_codex":0.011827969,"about_ca_system_score_gemma":0.0097581055,"threshold_uncertainty_score":0.9958556},"labels":[],"label_agreement":null},{"id":"W2981316671","doi":"10.1182/blood-2018-99-119462","title":"The Impact from Frontline CLL Chemo Immunotherapy Regimen Outcomes Based on Patient Tolerability","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Tolerability; Medicine; Regimen; Obinutuzumab; Fludarabine; Internal medicine; Rituximab; Oncology; Chlorambucil; Cyclophosphamide; Adverse effect; Chemotherapy; Lymphoma","score_opus":0.014930298083944445,"score_gpt":0.3159438096415602,"score_spread":0.30101351155761574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981316671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931022,0.00037086496,0.000033125852,0.0017409598,0.00014552161,0.00067677116,0.000037011367,0.00007994733,0.0038136076],"genre_scores_gemma":[0.9977677,0.000021631135,0.000429447,0.0008897682,0.00029780186,0.00004578665,0.000035271503,0.000040458966,0.00047212208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803495,0.000113624235,0.00035034676,0.00038582095,0.0006392411,0.00047601413],"domain_scores_gemma":[0.99742067,0.000655742,0.00009689159,0.0014743925,0.00017488746,0.00017740873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004046621,0.0002272314,0.0003792362,0.000044707376,0.00018679933,0.000046686306,0.000256804,0.00011476943,0.00066764414],"category_scores_gemma":[0.00041380798,0.000121450335,0.00022988765,0.00014168835,0.00027292158,0.00003590697,0.0000597028,0.000242874,0.00023434186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037285417,0.04092086,0.4589468,0.0002231389,0.008095919,0.0007102247,0.009489324,0.00015564269,0.05656717,0.00017693776,0.076025814,0.31140277],"study_design_scores_gemma":[0.21967718,0.009993062,0.47467372,0.00032190827,0.000321555,0.00004106758,0.00033967133,0.039980926,0.2266674,0.0010675634,0.026049351,0.0008665846],"about_ca_topic_score_codex":0.003083712,"about_ca_topic_score_gemma":0.0000670767,"teacher_disagreement_score":0.31053618,"about_ca_system_score_codex":0.0032424654,"about_ca_system_score_gemma":0.0023857912,"threshold_uncertainty_score":0.8478934},"labels":[],"label_agreement":null},{"id":"W2981487409","doi":"10.3747/co.26.4957","title":"Descriptive Analysis of Dosing and Outcomes for Patients with Ibrutinib-Treated Relapsed or Refractory Chronic Lymphocytic Leukemia in a Canadian Centre","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Ibrutinib; Medicine; Dosing; Chronic lymphocytic leukemia; Refractory (planetary science); Internal medicine; Oncology; Leukemia","score_opus":0.04108176699538796,"score_gpt":0.3552572270065208,"score_spread":0.31417546001113283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981487409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738497,0.00045085777,0.000006584063,0.00004897802,0.00019252238,0.001558873,0.00008012402,0.000018287126,0.00025881856],"genre_scores_gemma":[0.9990475,0.00010044818,0.0001244001,0.000035686167,0.00002320397,0.000046450026,0.00026101634,0.00002935337,0.00033191417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979278,0.0001083372,0.00046571865,0.00048716253,0.0002760807,0.00073492463],"domain_scores_gemma":[0.9981908,0.00057872897,0.00019585527,0.0003714923,0.0002893002,0.00037382165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026991926,0.00023075203,0.001010633,0.001009069,0.000044309938,0.000010329755,0.00012197207,0.0002058201,0.00018249807],"category_scores_gemma":[0.00038072676,0.00016320642,0.00011362674,0.0009654404,0.00018327344,0.000084347936,0.000052374573,0.00022058756,0.00000987475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002833703,0.00017168141,0.98337674,0.00046317105,0.0009375242,0.000047381458,0.0013520914,0.00020507317,0.00006237069,0.000037739217,0.00018675429,0.010325767],"study_design_scores_gemma":[0.12610039,0.0060959067,0.725185,0.00078711146,0.002717124,0.000018495068,0.000865525,0.12432893,0.00014898156,0.0000100629195,0.013262502,0.00047998547],"about_ca_topic_score_codex":0.09623371,"about_ca_topic_score_gemma":0.2911066,"teacher_disagreement_score":0.25819176,"about_ca_system_score_codex":0.2101931,"about_ca_system_score_gemma":0.06453784,"threshold_uncertainty_score":0.9407654},"labels":[],"label_agreement":null},{"id":"W2982445863","doi":"10.1373/jalm.2019.029157","title":"A Puzzling Case of Hyperviscosity Syndrome","year":2019,"lang":"en","type":"article","venue":"The Journal of Applied Laboratory Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Hyperviscosity syndrome; Hyperviscosity; Medicine; Cardiology; Internal medicine; Blood viscosity; Multiple myeloma","score_opus":0.015265037905405284,"score_gpt":0.2882162769194552,"score_spread":0.27295123901404994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982445863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935551,0.001495601,0.000039938725,0.0007370479,0.00022620932,0.00041717105,0.0000040475484,0.000011149161,0.0035136868],"genre_scores_gemma":[0.9986873,0.00018690972,0.00018558264,0.00050472986,0.00029262237,0.0000016632755,0.0000012041734,0.000028630891,0.00011131006],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.997903,0.00008996495,0.00076857314,0.00012515271,0.0008373588,0.00027593906],"domain_scores_gemma":[0.99753195,0.0005086776,0.00053056894,0.0005885551,0.00059667195,0.00024355993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030422418,0.00016643335,0.000786481,0.00022886503,0.00005315311,0.000003688864,0.00028633382,0.00009495616,0.0005365577],"category_scores_gemma":[0.00019685485,0.00008995689,0.000071298164,0.0006642674,0.00034793484,0.000065398155,0.00007788047,0.0006113016,0.00004699354],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016397186,0.0009839504,0.0027722127,0.004311762,0.0024803022,0.04049371,0.016825242,0.0012296159,0.893371,0.003787905,0.010854025,0.006493113],"study_design_scores_gemma":[0.18881364,0.01421509,0.0046372446,0.006630128,0.0052695246,0.5887355,0.04628788,0.0069734175,0.114187926,0.0012865078,0.021873625,0.0010894771],"about_ca_topic_score_codex":0.00009034597,"about_ca_topic_score_gemma":0.0000055816263,"teacher_disagreement_score":0.77918303,"about_ca_system_score_codex":0.0012944064,"about_ca_system_score_gemma":0.0031307538,"threshold_uncertainty_score":0.58749306},"labels":[],"label_agreement":null},{"id":"W2984292213","doi":"10.1182/blood-2019-127148","title":"BIM Regulation Is BTK Dependent and Can be Targeted By Entospletinib in Ibrutinib Refractory Mutants","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; IGHV@; Phosphorylation; breakpoint cluster region; Cancer research; Chronic lymphocytic leukemia; Biology; Leukemia; Signal transduction; Cell biology; Immunology; Tyrosine kinase; Receptor; Biochemistry","score_opus":0.012174466878156345,"score_gpt":0.2676658743114875,"score_spread":0.25549140743333115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984292213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955765,0.00082585885,0.0000018808464,0.0008291489,0.00007331463,0.0006327036,0.0000545928,0.000039548722,0.0019664753],"genre_scores_gemma":[0.9957165,0.00016916801,0.000109229855,0.0004650329,0.000068938185,0.00001746322,0.00009661447,0.00003276087,0.0033242975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99821615,0.00006374564,0.00030168585,0.000427043,0.0005824282,0.00040895105],"domain_scores_gemma":[0.9991285,0.00010814882,0.00007707287,0.0004352067,0.000062403305,0.00018865908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003201785,0.0001582726,0.00028916026,0.00014302578,0.000030664316,0.00002309989,0.0000986594,0.00017168399,0.00080174505],"category_scores_gemma":[0.00014330127,0.00014584279,0.000037350736,0.00022029055,0.000057210073,0.00006747129,0.00008798873,0.00024028846,0.00007327586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014454017,0.003834102,0.30812,0.0011479382,0.00051328336,0.00071639573,0.0056109144,0.000005545925,0.6544543,0.0002236703,0.015280519,0.008647919],"study_design_scores_gemma":[0.21189095,0.0013722988,0.17918307,0.0006770662,0.0002952728,0.0007666871,0.0009231997,0.003658108,0.5601414,0.00023451632,0.039951924,0.00090549974],"about_ca_topic_score_codex":0.0012909523,"about_ca_topic_score_gemma":0.00015271638,"teacher_disagreement_score":0.21044555,"about_ca_system_score_codex":0.0015105943,"about_ca_system_score_gemma":0.0016269987,"threshold_uncertainty_score":0.8778546},"labels":[],"label_agreement":null},{"id":"W2984707601","doi":"10.1182/blood-2019-123904","title":"A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Becton Dickinson (Canada); Jewish General Hospital","funders":"","keywords":"Chronic lymphocytic leukemia; Minimal residual disease; Medicine; Immunophenotyping; CD20; CD5; Cytometry; Antibody; Immunology; Antigen; Leukemia; Pathology; Flow cytometry","score_opus":0.046441808139611,"score_gpt":0.28936821965014203,"score_spread":0.24292641151053104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984707601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904057,0.0062295306,0.000011153073,0.00016874712,0.000073746996,0.0025200255,0.000068916146,0.00007295232,0.00044927344],"genre_scores_gemma":[0.9954002,0.00032133303,0.0006334587,0.00015252818,0.000363392,0.00096806785,0.00004055972,0.00007609059,0.0020443634],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996796,0.00007583327,0.00046507013,0.00075702375,0.0010475462,0.0008585397],"domain_scores_gemma":[0.99816406,0.0004180756,0.00008423093,0.00065608503,0.00016114402,0.0005163861],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008476249,0.00031424707,0.00059626467,0.00035868157,0.00006804148,0.000053223885,0.00020992901,0.00017559872,0.0005762134],"category_scores_gemma":[0.0009881642,0.00028319284,0.00013941772,0.00040901484,0.00012760716,0.000117457574,0.0001761751,0.00018406242,0.00026592254],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10601103,0.017002076,0.38416654,0.091555774,0.009841552,0.015286801,0.0064876582,0.006603623,0.13124071,0.0008380837,0.09296764,0.13799849],"study_design_scores_gemma":[0.5308663,0.007497302,0.17908747,0.0037460842,0.0022354145,0.00046096652,0.00035069024,0.22370635,0.030662447,0.000159,0.019498145,0.0017297935],"about_ca_topic_score_codex":0.0003640242,"about_ca_topic_score_gemma":0.00012476051,"teacher_disagreement_score":0.42485532,"about_ca_system_score_codex":0.06940399,"about_ca_system_score_gemma":0.043314144,"threshold_uncertainty_score":0.99996203},"labels":[],"label_agreement":null},{"id":"W2985852779","doi":"10.1182/blood-2019-125189","title":"Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Providence Health Care; Vancouver General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Fludarabine; Chemoimmunotherapy; Alemtuzumab; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Ibrutinib; Bendamustine; Hazard ratio; Population; Proportional hazards model; Oncology; Univariate analysis; Neutropenia; Leukemia; Lymphoma; Multivariate analysis; Chemotherapy; Transplantation; Confidence interval; Cyclophosphamide","score_opus":0.010420385141144434,"score_gpt":0.2485973792946909,"score_spread":0.23817699415354646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985852779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952046,0.002095807,0.0000010862215,0.000020380197,0.00008457085,0.0022819052,0.00009056335,0.00005474331,0.0001663313],"genre_scores_gemma":[0.9975917,0.00036155307,0.00012284711,0.00011352956,0.00004612385,0.0001554873,0.00016720314,0.00006923968,0.00137237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750584,0.000064058884,0.0005830003,0.00068645255,0.00034976084,0.0008108836],"domain_scores_gemma":[0.9990134,0.00019378791,0.0000962745,0.0003787594,0.0001089443,0.00020883638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030169488,0.00025445793,0.0009176912,0.00019241635,0.00007203941,0.00018387064,0.00014686564,0.0002471258,0.00015650371],"category_scores_gemma":[0.00017702751,0.00032406324,0.000076399345,0.00029244644,0.00021561715,0.00020000925,0.0001702048,0.00026883726,0.000018200964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00019853366,0.0006495152,0.970666,0.0015582654,0.00011384621,0.00059950154,0.0002600941,0.0000030254553,0.0003473073,0.0000027162982,0.000115527,0.025485683],"study_design_scores_gemma":[0.18390098,0.00097099843,0.81172746,0.00073242583,0.00010663344,0.00043734018,0.000048697195,0.0012491455,0.00042963328,0.00002937271,0.000077188975,0.00029009566],"about_ca_topic_score_codex":0.06713147,"about_ca_topic_score_gemma":0.13961019,"teacher_disagreement_score":0.18370244,"about_ca_system_score_codex":0.01819754,"about_ca_system_score_gemma":0.0073770355,"threshold_uncertainty_score":0.99992114},"labels":[],"label_agreement":null},{"id":"W2986177105","doi":"10.1182/blood-2019-127800","title":"Characterization of the \"Immune Evasion\" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Immune checkpoint; Ibrutinib; Immune system; Immunology; Medicine; Chronic lymphocytic leukemia; Oncology; Immunotherapy; Cancer research; Internal medicine; Biology; Leukemia","score_opus":0.015573047606273784,"score_gpt":0.26546220049634944,"score_spread":0.24988915289007566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986177105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99512136,0.0010412143,0.000033484834,0.0017166422,0.000075243086,0.0018290586,0.00002222736,0.000008929482,0.00015181213],"genre_scores_gemma":[0.9990063,0.00023180316,0.000070691836,0.00006105306,0.000038665716,0.00009636216,0.000021286236,0.000018637018,0.00045520352],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914247,0.000052438052,0.00034604,0.00014061107,0.00018232457,0.00013609987],"domain_scores_gemma":[0.9987689,0.00020982568,0.0001868631,0.00062932936,0.00017980373,0.000025279187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039619618,0.000085257445,0.0002735148,0.000039171548,0.00005207931,0.0000071511795,0.00016181808,0.00006190051,0.000036854937],"category_scores_gemma":[0.000119140204,0.00004316736,0.00012684535,0.00017950092,0.00017712546,0.000040029583,0.000088336026,0.00008426129,0.000005357701],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041379573,0.0002985014,0.002203431,0.00016708119,0.00015764174,2.0371101e-7,0.00048055264,3.8391363e-7,0.9943495,0.0009630339,0.0000044401554,0.0009614374],"study_design_scores_gemma":[0.053122412,0.00032552634,0.41209978,0.00020837523,0.00016539659,0.00011224365,0.000054765413,0.00025448203,0.5328299,0.000406602,0.0003428443,0.00007771263],"about_ca_topic_score_codex":0.00006992287,"about_ca_topic_score_gemma":0.0000010582677,"teacher_disagreement_score":0.46151963,"about_ca_system_score_codex":0.00014746994,"about_ca_system_score_gemma":0.00065762055,"threshold_uncertainty_score":0.1760314},"labels":[],"label_agreement":null},{"id":"W2986944351","doi":"10.1182/blood-2019-122309","title":"Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Chlorambucil; Obinutuzumab; Venetoclax; Medicine; IGHV@; Ibrutinib; Internal medicine; Rituximab; Chronic lymphocytic leukemia; Oncology; Population; Progression-free survival; Chemotherapy; Leukemia; Cyclophosphamide; Lymphoma","score_opus":0.03753508059196313,"score_gpt":0.3754278861985978,"score_spread":0.33789280560663465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986944351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926821,0.00091989705,0.00001065217,0.00011580457,0.00008172487,0.005058221,0.00010169453,0.000044791126,0.0009851112],"genre_scores_gemma":[0.99079275,0.0007253421,0.0027102295,0.00007494927,0.00016959765,0.00035366815,0.00014703815,0.0000644785,0.004961949],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965553,0.00018436418,0.0011336722,0.00086797733,0.00071094517,0.00054770743],"domain_scores_gemma":[0.99627686,0.0019369063,0.00041035435,0.00077036215,0.00037569148,0.00022983369],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011384926,0.00033677035,0.00090074167,0.0002343488,0.000048304402,0.000029877061,0.0001615494,0.00014658186,0.000042020507],"category_scores_gemma":[0.0007973143,0.0002499289,0.00011532017,0.00033792123,0.00016840678,0.00018756656,0.00010318556,0.00022404894,0.00004105429],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.41155475,0.10595699,0.31357053,0.010606445,0.020383673,0.005859835,0.02741522,0.0065145507,0.012550868,0.0002253149,0.011221547,0.07414029],"study_design_scores_gemma":[0.8029335,0.028448995,0.018900985,0.0007528613,0.0013472144,0.00016594783,0.0015198124,0.13447621,0.003254603,0.0000053740914,0.00771805,0.00047645683],"about_ca_topic_score_codex":0.010945283,"about_ca_topic_score_gemma":0.0032485153,"teacher_disagreement_score":0.39137873,"about_ca_system_score_codex":0.0669324,"about_ca_system_score_gemma":0.029657561,"threshold_uncertainty_score":0.9999953},"labels":[],"label_agreement":null},{"id":"W2987417079","doi":"10.1182/blood-2019-124392","title":"Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Venetoclax; Ibrutinib; Prolymphocytic leukemia; Cancer research; Idelalisib; Medicine; Pharmacology; Leukemia; Oncology; Internal medicine; Chronic lymphocytic leukemia","score_opus":0.016006190310981563,"score_gpt":0.28668627713611833,"score_spread":0.2706800868251368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987417079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596304,0.0019350369,0.0000017147291,0.000054075812,0.000065182074,0.0011809638,0.0000047987064,0.000034943216,0.00076025765],"genre_scores_gemma":[0.9984818,0.0005398264,0.00038861204,0.0000806848,0.00004626117,0.000025712256,0.00001813392,0.000038257043,0.00038073014],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99765766,0.00012387102,0.0007449414,0.0005417051,0.0005914411,0.00034037716],"domain_scores_gemma":[0.9984723,0.00051392236,0.0002996165,0.00039711344,0.00014177956,0.00017528355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009062515,0.00021172775,0.00054616516,0.00023742429,0.000048247857,0.000035206693,0.00011296048,0.00025304267,0.000054030676],"category_scores_gemma":[0.0007218873,0.00020110588,0.00005732071,0.00022304438,0.00017977854,0.0001444242,0.00014796751,0.00029208144,0.00001654333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010475827,0.0062563843,0.5282608,0.009309235,0.0011030559,0.00054263865,0.012925584,0.00015679441,0.35834712,0.00036003397,0.0003250272,0.07193746],"study_design_scores_gemma":[0.25857872,0.0052848267,0.340059,0.0044867788,0.00088152406,0.0010624297,0.0011284206,0.042387545,0.3445272,0.0005103965,0.00015907857,0.0009340746],"about_ca_topic_score_codex":0.0010912801,"about_ca_topic_score_gemma":0.00001709284,"teacher_disagreement_score":0.24810289,"about_ca_system_score_codex":0.0044393297,"about_ca_system_score_gemma":0.0066200118,"threshold_uncertainty_score":0.99938244},"labels":[],"label_agreement":null},{"id":"W2987552010","doi":"10.1182/blood-2019-128404","title":"ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology","funders":"","keywords":"Medicine; Internal medicine; Chlorambucil; Gastroenterology; Clinical endpoint; Neutropenia; Obinutuzumab; Phases of clinical research; Adverse effect; Chronic lymphocytic leukemia; Pharmacology; Clinical trial; Leukemia; Toxicity; Chemotherapy","score_opus":0.01791496854483397,"score_gpt":0.2841616989684662,"score_spread":0.2662467304236322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987552010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925452,0.00015662398,0.0000026068112,0.000020947838,0.00008349316,0.0063774767,0.000043249118,0.00012340918,0.000647003],"genre_scores_gemma":[0.9962123,0.00007893407,0.00009639808,0.00006355776,0.00009139404,0.0003494439,0.000164428,0.00015962815,0.002783941],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949236,0.00017573021,0.0009184892,0.0011387179,0.0016482793,0.0011951808],"domain_scores_gemma":[0.9968725,0.00028160895,0.0004045579,0.0016096262,0.00040781783,0.00042390646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031408027,0.0007288535,0.0017276602,0.00044103697,0.0000922781,0.000049174098,0.00045989567,0.00024194764,0.00039088412],"category_scores_gemma":[0.00010261414,0.00046474492,0.00011786504,0.001282073,0.00026418437,0.00023224819,0.00019176467,0.00038779396,0.00021348195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5918795,0.08273696,0.2495935,0.005240117,0.012523812,0.012516633,0.02348252,0.008516665,0.0025548048,0.00008558852,0.00047739447,0.010392499],"study_design_scores_gemma":[0.822529,0.14203069,0.010352526,0.0009431696,0.0011330957,0.00023815216,0.0012646561,0.011297028,0.009422431,0.0000031906193,0.0001803842,0.0006056659],"about_ca_topic_score_codex":0.006888743,"about_ca_topic_score_gemma":0.0021026004,"teacher_disagreement_score":0.23924097,"about_ca_system_score_codex":0.13663273,"about_ca_system_score_gemma":0.067770325,"threshold_uncertainty_score":0.9997804},"labels":[],"label_agreement":null},{"id":"W2987673838","doi":"10.1182/blood-2019-126509","title":"Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Syk; Medicine; Autoimmune hemolytic anemia; Anemia; Internal medicine; Gastroenterology; Tolerability; Rituximab; Immunology; Pharmacology; Adverse effect; Tyrosine kinase; Antibody; Receptor","score_opus":0.06174651898453552,"score_gpt":0.38670916954462203,"score_spread":0.3249626505600865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987673838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754936,0.0012833116,0.000008565692,0.0005983652,0.00024506118,0.009750777,0.00028882068,0.000023035562,0.00025267052],"genre_scores_gemma":[0.99635386,0.0001355597,0.00045144514,0.000053141186,0.000113381444,0.0002112549,0.00008004031,0.000050369752,0.0025509326],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99726945,0.00013426661,0.00091807847,0.00049415854,0.00070146477,0.00048255152],"domain_scores_gemma":[0.99654067,0.00085436786,0.0004140903,0.001778538,0.0003065739,0.00010574629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007272317,0.00030638673,0.00075568724,0.00008943304,0.00013351649,0.00003883588,0.0007113659,0.00009872318,0.000040115665],"category_scores_gemma":[0.0004378674,0.00016428485,0.00018031412,0.00040359405,0.00020825534,0.00008397825,0.0003554185,0.00016081323,0.000016075808],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051422298,0.3575176,0.007876558,0.0025091798,0.0031523318,0.000322069,0.01590776,0.00004038166,0.52671796,0.000095315554,0.0021996694,0.032238893],"study_design_scores_gemma":[0.69325286,0.016043589,0.0032878628,0.00059674104,0.0013550009,0.00006727322,0.0011013073,0.008433833,0.2735198,0.0000079528945,0.002137085,0.00019668801],"about_ca_topic_score_codex":0.0019059371,"about_ca_topic_score_gemma":0.00005905853,"teacher_disagreement_score":0.64183056,"about_ca_system_score_codex":0.0011701323,"about_ca_system_score_gemma":0.0024920278,"threshold_uncertainty_score":0.66993415},"labels":[],"label_agreement":null},{"id":"W2988594495","doi":"10.1182/blood-2019-130052","title":"The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"IGHV@; Biology; Genetics; Chronic lymphocytic leukemia; Spliceosome; RNA; RNA splicing; Small nuclear RNA; Mutation; Epigenetics; Intron; Gene; Leukemia; Non-coding RNA","score_opus":0.02937847671128769,"score_gpt":0.32498329601110626,"score_spread":0.2956048192998186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988594495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955804,0.00016917178,0.000081595324,0.0000927579,0.00023260758,0.0013618565,0.000007069914,0.00008705053,0.002387521],"genre_scores_gemma":[0.9963362,0.00007134779,0.000109814355,0.00020096013,0.0002663591,0.00007135413,0.00003385348,0.00007735851,0.002832751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961644,0.00012616711,0.0009281224,0.000679483,0.001169785,0.00093207037],"domain_scores_gemma":[0.99727154,0.0011849927,0.0003074868,0.00078750553,0.00019914676,0.00024934858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015870843,0.000323853,0.00070898834,0.00019613557,0.0001464093,0.00009198498,0.00041326624,0.00037319597,0.0000705207],"category_scores_gemma":[0.0007632746,0.00022209833,0.00019385233,0.0006794144,0.00023051696,0.00018570635,0.00019415612,0.0008538558,0.00038914807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00513544,0.0030106974,0.931227,0.0011728706,0.004030911,0.0065500587,0.0023410553,0.0047319117,0.032750424,0.0011966499,0.00041885296,0.007434092],"study_design_scores_gemma":[0.2342254,0.001417829,0.6359524,0.0009274249,0.0005017981,0.0007526623,0.00032965734,0.121911615,0.0032303075,0.000028835575,0.00017707003,0.00054499233],"about_ca_topic_score_codex":0.0011643252,"about_ca_topic_score_gemma":0.00097465457,"teacher_disagreement_score":0.29527462,"about_ca_system_score_codex":0.06378188,"about_ca_system_score_gemma":0.0327354,"threshold_uncertainty_score":0.9727481},"labels":[],"label_agreement":null},{"id":"W2988597345","doi":"10.1182/blood-2019-131779","title":"Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematologic Neoplasms; Term (time); Internal medicine; Oncology; Cancer","score_opus":0.007933062820561141,"score_gpt":0.24588445209358917,"score_spread":0.23795138927302803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988597345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997388,0.00034059296,0.00000972088,0.000027144804,0.000019107481,0.0011550961,0.000051704574,0.00003590026,0.00097275345],"genre_scores_gemma":[0.9989904,0.000021810029,0.0003379394,0.000032225624,0.000010837364,0.000050470484,0.0001801033,0.000022346412,0.00035383966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793637,0.00007109895,0.00049732666,0.00041508273,0.00061459426,0.00046555174],"domain_scores_gemma":[0.9987758,0.00015328977,0.00017252893,0.0005313745,0.00024608642,0.00012094986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002505442,0.0002045679,0.0008633702,0.0004914895,0.000027828548,0.000017460558,0.0001579179,0.0001317619,0.0003731186],"category_scores_gemma":[0.000114304225,0.0001465271,0.00013392665,0.0017024557,0.00013421505,0.000102793136,0.00009377203,0.00017785234,0.000049998143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076095725,0.0020216943,0.993044,0.000557894,0.0011896775,0.00014965447,0.00021820486,0.000030776897,0.0018932642,0.00003500179,0.000014079567,0.00008475394],"study_design_scores_gemma":[0.045153458,0.0009379348,0.92774427,0.0006089385,0.0020766524,0.000037366284,0.00016535496,0.00085727405,0.022196738,0.000007772806,0.000003848403,0.00021036863],"about_ca_topic_score_codex":0.0002780331,"about_ca_topic_score_gemma":0.0002646466,"teacher_disagreement_score":0.06529975,"about_ca_system_score_codex":0.0009928527,"about_ca_system_score_gemma":0.0023435615,"threshold_uncertainty_score":0.5975202},"labels":[],"label_agreement":null},{"id":"W2988701053","doi":"10.1182/blood-2019-125716","title":"Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ibrutinib; breakpoint cluster region; B-cell receptor; Internal medicine; Bruton's tyrosine kinase; B cell; IGHV@; Waldenstrom macroglobulinemia; Rituximab; Chemistry; Cancer research; Immunology; Chronic lymphocytic leukemia; Leukemia; Medicine; Receptor; Lymphoma; Antibody; Tyrosine kinase","score_opus":0.01511424877564102,"score_gpt":0.28228305342772025,"score_spread":0.26716880465207926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988701053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99505764,0.00056166097,0.0000036434062,0.00031402748,0.00011110784,0.0017702747,0.000008460489,0.000029535142,0.0021436603],"genre_scores_gemma":[0.99766403,0.000096351,0.00023120343,0.0002793055,0.00013261796,0.00012016017,0.000037797,0.000028889568,0.001409653],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987385,0.000046871115,0.00022156654,0.000270062,0.0003566438,0.00036630937],"domain_scores_gemma":[0.99896985,0.00030251077,0.00005216676,0.00051833276,0.0000844779,0.00007265124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027808137,0.00012621928,0.00021538872,0.000064992295,0.0000462481,0.000020231866,0.00019229652,0.000104179104,0.00020403693],"category_scores_gemma":[0.00012081535,0.000072230345,0.00008787287,0.00014909072,0.00004647036,0.00005696019,0.000072812705,0.00013987151,0.000103699866],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010952221,0.016604036,0.47515887,0.001497786,0.00069067575,0.00009582802,0.009173773,0.00009626945,0.35625568,0.0008963831,0.029101672,0.0994768],"study_design_scores_gemma":[0.3234511,0.002119244,0.19732957,0.00070909614,0.00007310067,0.000042820197,0.00038112843,0.0018697337,0.42829612,0.000705652,0.044579748,0.00044269528],"about_ca_topic_score_codex":0.00007309109,"about_ca_topic_score_gemma":0.00000871154,"teacher_disagreement_score":0.31249887,"about_ca_system_score_codex":0.0005646634,"about_ca_system_score_gemma":0.00077863183,"threshold_uncertainty_score":0.29454678},"labels":[],"label_agreement":null},{"id":"W2989265170","doi":"10.1182/blood-2019-127562","title":"Ibrutinib in Combination with Venetoclax Decreases Mitochondrial Bioenergetics through the Impaired BTK, AKT and AMPK/SIRT/PGC-1α Signaling Pathway in CLL","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; AMPK; Protein kinase B; Chronic lymphocytic leukemia; Cancer research; Venetoclax; Signal transduction; Biology; AMP-activated protein kinase; Cell biology; Phosphorylation; Tyrosine kinase; Protein kinase A; Leukemia; Immunology","score_opus":0.015499333024374284,"score_gpt":0.26005913172775913,"score_spread":0.24455979870338485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989265170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700296,0.000781079,0.000022899647,0.0002972555,0.000106339015,0.0011413408,0.000005971101,0.000035739522,0.0006063941],"genre_scores_gemma":[0.9985357,0.00006324199,0.00077250786,0.00015904846,0.00014771456,0.00006268974,0.00004025276,0.00003851892,0.00018035684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810755,0.00015239266,0.00035281197,0.00038515026,0.00054395024,0.00045811888],"domain_scores_gemma":[0.99884725,0.00043611226,0.00009291227,0.00043409105,0.00008341136,0.00010622456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003189965,0.00020279297,0.00035819752,0.00013014619,0.000053287262,0.000051128012,0.00017290565,0.00014814771,0.00004673474],"category_scores_gemma":[0.0002437878,0.0001370323,0.00004896912,0.00046436768,0.0001598137,0.00011578682,0.0001035532,0.00029512052,0.00001984873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021735208,0.02233777,0.40189788,0.0042762533,0.0016621407,0.005416791,0.040834136,0.006414243,0.46816093,0.014443388,0.0018844426,0.010936843],"study_design_scores_gemma":[0.43940923,0.007292529,0.022850234,0.0032257317,0.00038714806,0.0012856234,0.0047605094,0.021903722,0.4900771,0.0027360553,0.00477744,0.0012946528],"about_ca_topic_score_codex":0.0021237973,"about_ca_topic_score_gemma":0.00056225655,"teacher_disagreement_score":0.41767403,"about_ca_system_score_codex":0.0015765161,"about_ca_system_score_gemma":0.0033457493,"threshold_uncertainty_score":0.59352154},"labels":[],"label_agreement":null},{"id":"W2990206078","doi":"10.1182/blood-2019-124443","title":"Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Hazard ratio; Internal medicine; Medicine; Population; Oncology; CHOP; Diffuse large B-cell lymphoma; Ibrutinib; Vincristine; Rituximab; Cyclophosphamide; Lymphoma; Confidence interval; Leukemia; Chronic lymphocytic leukemia; Chemotherapy","score_opus":0.03553825901606996,"score_gpt":0.4167700193018046,"score_spread":0.38123176028573463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990206078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968,0.00035588574,0.0000020758823,0.00006038712,0.000035490695,0.0013563959,0.000013481872,0.000012338187,0.0013639216],"genre_scores_gemma":[0.9993843,0.00011148001,0.0001107871,0.000045490127,0.00019618114,0.000022366494,0.000021953369,0.00002482343,0.00008261303],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99803185,0.00023122721,0.00056351017,0.0003479497,0.00043133018,0.00039413024],"domain_scores_gemma":[0.99840784,0.0007616532,0.00013520662,0.0005252552,0.0000459948,0.0001240227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011458831,0.00017894767,0.0006055542,0.00016577065,0.000023395873,0.000028128201,0.00016866771,0.00015703075,0.00007706062],"category_scores_gemma":[0.000222089,0.000100525656,0.00010951899,0.00037140245,0.00021124157,0.00007683047,0.00005005146,0.00035694576,0.000015403331],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19150822,0.021367926,0.71417207,0.0004838965,0.00079731387,0.0018367765,0.0051895995,0.000033525874,0.039066114,0.000007327511,0.0006176827,0.02491956],"study_design_scores_gemma":[0.9342444,0.0053540226,0.049886696,0.00045729722,0.00016194687,0.0002851103,0.0003282578,0.0021942987,0.006760939,0.000006397371,0.00016207293,0.00015854364],"about_ca_topic_score_codex":0.0016500152,"about_ca_topic_score_gemma":0.000058856946,"teacher_disagreement_score":0.7427362,"about_ca_system_score_codex":0.00052685256,"about_ca_system_score_gemma":0.0037782001,"threshold_uncertainty_score":0.67023647},"labels":[],"label_agreement":null},{"id":"W2991008189","doi":"10.1016/j.jns.2019.116603","title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature","year":2019,"lang":"en","type":"review","venue":"Journal of the Neurological Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica; Teva Pharmaceutical Industries; Ministry of Health, British Columbia; Biogen Idec; Fondazione Italiana Sclerosi Multipla; Biogen","keywords":"Ocrelizumab; Medicine; Multiple sclerosis; Neutropenia; Dermatology; Pediatrics; Internal medicine; Rituximab; Immunology; Chemotherapy; Lymphoma","score_opus":0.12454050633884277,"score_gpt":0.3556654381949115,"score_spread":0.2311249318560687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991008189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17419994,0.8233579,3.1211727e-8,0.0011453242,0.00013538323,0.0010861487,0.000014750384,0.0000028597537,0.000057698286],"genre_scores_gemma":[0.019925768,0.97930175,0.000019871011,0.00042677083,0.000044640023,0.0000132278055,0.0000011684526,0.0000103923385,0.00025639674],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9964951,0.0009723078,0.0009957802,0.0003399079,0.0008815678,0.0003153146],"domain_scores_gemma":[0.9966298,0.0009880101,0.0016430416,0.000453731,0.00016728604,0.000118147946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002048339,0.00026866578,0.0017031141,0.000103209466,0.00013062166,0.00005328569,0.00059790607,0.0001850518,0.000015487878],"category_scores_gemma":[0.0026345872,0.00008103733,0.00052924827,0.0012421455,0.0006311618,0.00007514958,0.00026128514,0.00086651806,0.0000011179598],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022023895,0.0031776037,0.014192621,0.111489944,0.0020984358,0.49995926,0.00079721224,0.00019145734,0.000018469997,0.000021244114,0.005104191,0.3607472],"study_design_scores_gemma":[0.006311904,0.005585559,0.0063632987,0.32996035,0.002070606,0.5787202,0.0000093103345,0.00025057627,0.0000028855395,0.00001942587,0.07046751,0.00023835634],"about_ca_topic_score_codex":0.000063583124,"about_ca_topic_score_gemma":0.00005054284,"teacher_disagreement_score":0.36050883,"about_ca_system_score_codex":0.0012933653,"about_ca_system_score_gemma":0.0051638084,"threshold_uncertainty_score":0.91603744},"labels":[],"label_agreement":null},{"id":"W2991203221","doi":"10.1182/blood-2019-123678","title":"Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Venetoclax; Rituximab; Medicine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Refractory (planetary science); Exome; Alemtuzumab; Exome sequencing; Leukemia; Immunology; Lymphoma; Antibody; Biology; Genetics; Mutation; Gene","score_opus":0.02810904450633598,"score_gpt":0.31883405356654804,"score_spread":0.29072500906021204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991203221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811928,0.014668174,0.0000074894983,0.000050513936,0.00025487773,0.0036316295,0.000039659135,0.000029769339,0.0001250341],"genre_scores_gemma":[0.99750525,0.0013205287,0.0001043603,0.000042030068,0.00030789376,0.0001552364,0.000018623428,0.00005348037,0.0004925738],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972376,0.0002195919,0.0007012023,0.00065768394,0.000591181,0.00059273065],"domain_scores_gemma":[0.9976342,0.0011365096,0.00026513386,0.0006502477,0.0001569731,0.00015694431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080797274,0.00032236608,0.0009962308,0.0002553963,0.000107459506,0.000023436696,0.00024169155,0.0002337372,0.000018708753],"category_scores_gemma":[0.00089519087,0.00023576508,0.00023199093,0.00037347563,0.0005450915,0.000102740254,0.00029660802,0.00032860792,0.000005652401],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.523201,0.0061501605,0.022476029,0.022794591,0.019700395,0.0010651583,0.011778807,0.009364235,0.37370068,0.00014746403,0.001319682,0.008301808],"study_design_scores_gemma":[0.90187633,0.0049980953,0.07336645,0.0009887841,0.0017587035,0.00022372737,0.0008311415,0.009906367,0.0053121313,0.0001212487,0.0002281544,0.00038886414],"about_ca_topic_score_codex":0.00053903594,"about_ca_topic_score_gemma":0.000052087747,"teacher_disagreement_score":0.37867534,"about_ca_system_score_codex":0.023516519,"about_ca_system_score_gemma":0.013774784,"threshold_uncertainty_score":0.9918162},"labels":[],"label_agreement":null},{"id":"W2991372896","doi":"10.1182/blood-2019-123930","title":"Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"","keywords":"Medicine; Venetoclax; Bendamustine; Internal medicine; Rituximab; Ven; Adverse effect; Chronic lymphocytic leukemia; Neutropenia; Gastroenterology; Tolerability; Oncology; Leukemia; Chemotherapy; Lymphoma","score_opus":0.012152290230249047,"score_gpt":0.2636337928031795,"score_spread":0.25148150257293045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991372896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946074,0.0010007364,0.000003272463,0.000015922706,0.00007043251,0.002212791,0.00004214785,0.00007002,0.001977305],"genre_scores_gemma":[0.9972435,0.00011553706,0.00007576971,0.000028111792,0.00007642883,0.000061173574,0.000102116916,0.00008845326,0.0022089113],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953165,0.00020247042,0.0013411421,0.00082912855,0.0014520609,0.000858703],"domain_scores_gemma":[0.99640644,0.00060660485,0.00047718929,0.0017755979,0.00047622292,0.0002579655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010485264,0.00043221365,0.0020324138,0.0016762721,0.000040746425,0.000019863224,0.0005859858,0.00034731659,0.001274462],"category_scores_gemma":[0.00035995137,0.00040502948,0.0004959191,0.0031116214,0.00022063119,0.00010588917,0.0002729842,0.00044464893,0.00021521302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018998014,0.0246662,0.55799496,0.009389948,0.0513967,0.0049214354,0.013269105,0.09600343,0.2171929,0.00079003326,0.0005390934,0.0048381784],"study_design_scores_gemma":[0.54572153,0.010154995,0.15010752,0.0011671735,0.01332862,0.0001516867,0.004363447,0.24788168,0.025581744,0.00007112886,0.0002860238,0.0011844346],"about_ca_topic_score_codex":0.0061534336,"about_ca_topic_score_gemma":0.00051334506,"teacher_disagreement_score":0.5267235,"about_ca_system_score_codex":0.049300574,"about_ca_system_score_gemma":0.028388375,"threshold_uncertainty_score":0.99984014},"labels":[],"label_agreement":null},{"id":"W2992277868","doi":"10.1182/blood.v106.11.2982.2982","title":"The Induction of Apoptosis by Histone Deacetylase Inhibition in Chronic Lymphocytic Leukemia (CLL) Cells Is Mediated through the TNF-Related Apoptosis-Inducing Ligand (TRAIL) Pathway.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Apoptosis; Histone deacetylase; Viability assay; Acridine orange; MTT assay; Molecular biology; Trichostatin A; Histone deacetylase inhibitor; Cell cycle; Jurkat cells; Cancer research; Chemistry; Biology; Immunology; Histone; Biochemistry; T cell; Immune system","score_opus":0.013721897743171809,"score_gpt":0.2652038972538385,"score_spread":0.25148199951066674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992277868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913178,0.004590275,0.000017766868,0.0014462393,0.00020978351,0.0012426219,0.000036765403,0.000111013185,0.0010277189],"genre_scores_gemma":[0.9956245,0.002414465,0.00007751976,0.0003464807,0.0003052779,0.00015110872,0.00009240807,0.000089137626,0.000899141],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958999,0.00024896648,0.0011630589,0.0006752931,0.0010910974,0.00092168467],"domain_scores_gemma":[0.9975786,0.0006096896,0.0004232616,0.0009993318,0.00019828136,0.0001907948],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010425617,0.0004260577,0.0006058793,0.00018416088,0.0003586444,0.000057354595,0.00030810793,0.00049528654,0.00010536999],"category_scores_gemma":[0.00031693582,0.00028872647,0.00022538866,0.0011735829,0.0005871088,0.00031495283,0.00015637462,0.0008393794,0.00015542025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002660788,0.00046510526,0.000009611068,0.00023501816,0.00036303396,0.000019568719,0.0046179234,0.0006777344,0.98025393,0.00011579895,0.0064208964,0.0065553105],"study_design_scores_gemma":[0.033219058,0.00032676948,0.000034504203,0.00046837583,0.0002731673,0.000152648,0.000665598,0.0061943084,0.95506126,0.000074647076,0.0032466613,0.0002830271],"about_ca_topic_score_codex":0.0046998574,"about_ca_topic_score_gemma":0.00033103896,"teacher_disagreement_score":0.040625546,"about_ca_system_score_codex":0.05671588,"about_ca_system_score_gemma":0.016090335,"threshold_uncertainty_score":0.9999565},"labels":[],"label_agreement":null},{"id":"W2994600119","doi":"10.1182/blood.v108.11.1151.1151","title":"Macrophage-Stimulating Protein Stimulates Erythropoietin Receptor Phosphorylation To Promote Enhanced Erk1/2 and Akt Activation in a Gab2-Dependent Pathway.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Phosphorylation; Tyrosine phosphorylation; Receptor tyrosine kinase; Signal transduction; Protein kinase B; Biology; Erythropoietin; Cell biology; Kinase; Autophosphorylation; Cancer research; Tyrosine kinase; Molecular biology; Protein kinase A; Endocrinology","score_opus":0.009634697270871358,"score_gpt":0.2623673144434139,"score_spread":0.25273261717254253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994600119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954392,0.00014695384,0.00082352216,0.00033742416,0.000031615906,0.0024833381,0.000006784626,0.00010088922,0.0006303274],"genre_scores_gemma":[0.9905702,0.0000044050503,0.007650569,0.000044300345,0.00018640055,0.00019181862,0.0000520198,0.00005331854,0.0012469613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978368,0.000071337774,0.00047301926,0.00055878895,0.00057394075,0.0004860582],"domain_scores_gemma":[0.9991739,0.000093913986,0.00011031414,0.0003195756,0.00014648969,0.00015583888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004397891,0.00023307306,0.00032646648,0.0002067462,0.00009501393,0.000057416557,0.00008477972,0.00017259162,0.00015213688],"category_scores_gemma":[0.00047394636,0.00022159729,0.000043760312,0.00045736777,0.000052805488,0.0001379626,0.00010659852,0.00027884386,0.000070821734],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004599389,0.00072499015,0.00079535786,0.00023521578,0.00002708373,0.000048057245,0.0005905357,0.0006968232,0.9830822,0.000034318233,0.000030341256,0.013275169],"study_design_scores_gemma":[0.023147902,0.00051672134,0.0036594875,0.0006718685,0.000026126807,0.00002123129,0.00008198967,0.007635225,0.9637217,0.0001668717,0.0001106489,0.00024024717],"about_ca_topic_score_codex":0.0013992077,"about_ca_topic_score_gemma":0.00009044587,"teacher_disagreement_score":0.022687962,"about_ca_system_score_codex":0.0022047325,"about_ca_system_score_gemma":0.0009157544,"threshold_uncertainty_score":0.90364754},"labels":[],"label_agreement":null},{"id":"W2994982266","doi":"10.1016/j.jval.2019.09.432","title":"PCN237 IMPACT OF ORAL TARGETED THERAPY ON THE ECONOMIC BURDEN OF CLL IN CANADA","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; CancerCare Manitoba; Ottawa Hospital; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"IGHV@; Chemoimmunotherapy; Medicine; Chronic lymphocytic leukemia; Fludarabine; Watchful waiting; Adverse effect; Incidence (geometry); Internal medicine; Leukemia; Cancer; Chemotherapy","score_opus":0.04563556119087507,"score_gpt":0.33886766914407607,"score_spread":0.293232107953201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994982266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671406,0.0005343856,1.4627415e-7,0.001346676,0.0000905421,0.0008384036,0.00002191236,0.0000029783323,0.0004508929],"genre_scores_gemma":[0.99928015,0.00037086604,0.000019970626,0.00020128925,0.000028713477,0.000007298166,0.000005919511,0.000015597669,0.00007017647],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985345,0.00021461296,0.00046554068,0.00016492019,0.00026409898,0.00035631686],"domain_scores_gemma":[0.9988555,0.0004475734,0.00013717393,0.00043874994,0.000025152041,0.00009586467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092555274,0.000095845506,0.00041992022,0.000134034,0.000008986834,0.0000018775731,0.00016089971,0.00004298729,0.00042527227],"category_scores_gemma":[0.00007410812,0.000060419614,0.00005766556,0.00019044643,0.00003631263,0.000019421508,0.000023250564,0.0002264534,0.000016914362],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0051835957,0.00033620928,0.39319232,0.001524885,0.00029052363,0.00008334527,0.008214978,0.5639294,0.0029925592,0.0019823462,0.009005536,0.013264353],"study_design_scores_gemma":[0.037798196,0.0039895386,0.31558508,0.0011513744,0.000004831723,0.00003402551,0.0011517821,0.63416624,0.004398073,0.0003667715,0.0011144595,0.00023964197],"about_ca_topic_score_codex":0.9983999,"about_ca_topic_score_gemma":0.52093303,"teacher_disagreement_score":0.4774669,"about_ca_system_score_codex":0.05113351,"about_ca_system_score_gemma":0.09195781,"threshold_uncertainty_score":0.95250905},"labels":[],"label_agreement":null},{"id":"W2998909083","doi":"10.1016/s0923-7534(20)33028-3","title":"Phase I Study to Compare Safety and Pharmacokinetics of Afatinib, An Oral Irreversible Erbb Family Blocker, in Non-Cancer Subjects with Hepatic Impairment to Matched Healthy Subjects","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Pharmacokinetics; Oncology; Internal medicine; Cancer; ErbB; Pharmacology; Erlotinib; Epidermal growth factor receptor","score_opus":0.09833943599749505,"score_gpt":0.46359237055575014,"score_spread":0.3652529345582551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998909083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949728,0.00046263053,0.000023169961,0.0013933558,0.0001135672,0.0027702928,0.00003498064,0.000015088982,0.0002140707],"genre_scores_gemma":[0.996343,0.0002714205,0.001065954,0.0020574615,0.00008781871,0.00007887877,0.000015915291,0.000032704193,0.00004684437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974093,0.00028850403,0.0006662315,0.00036067507,0.0004999097,0.000775389],"domain_scores_gemma":[0.99810004,0.00025738342,0.00018905221,0.00039016412,0.00032003896,0.0007432952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012840799,0.00023492516,0.0010895842,0.00037899855,0.000039534087,0.000004932188,0.00018043154,0.000064190186,0.000073866635],"category_scores_gemma":[0.00007655493,0.0001974008,0.000043287662,0.0007123619,0.00011147195,0.00010024625,0.00017396656,0.00021491155,0.000007991014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09945271,0.05932251,0.7077995,0.0023810815,0.00080760394,0.00046023325,0.061272226,0.00061209954,0.019504288,0.00001560624,0.006782657,0.041589506],"study_design_scores_gemma":[0.1621308,0.14641017,0.6503159,0.0005934664,0.00031398822,0.00010914348,0.0133204525,0.0030780388,0.02144553,0.000008342499,0.0017367126,0.000537487],"about_ca_topic_score_codex":0.009641959,"about_ca_topic_score_gemma":0.0033904628,"teacher_disagreement_score":0.08708765,"about_ca_system_score_codex":0.0018236733,"about_ca_system_score_gemma":0.0027226482,"threshold_uncertainty_score":0.9969529},"labels":[],"label_agreement":null},{"id":"W2999296276","doi":"10.1016/s0923-7534(20)33669-3","title":"Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; Université de Montréal","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Oncology; Progression-free survival; Overall survival; Leukemia; Internal medicine; Immunology; Cancer research","score_opus":0.15423032111716808,"score_gpt":0.4364968980467409,"score_spread":0.2822665769295728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999296276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806506,0.0031651268,0.000016332326,0.0012421078,0.00022271779,0.0005062612,0.000012932135,0.000039515253,0.014144385],"genre_scores_gemma":[0.9980267,0.00029018865,0.00030915494,0.00013087054,0.0006498891,0.000037940576,0.000036479083,0.0000352829,0.00048345633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722874,0.00037132783,0.0006183568,0.00031820952,0.0005938319,0.00086955744],"domain_scores_gemma":[0.99631536,0.0023492575,0.00019014701,0.00059365167,0.00015430126,0.0003972708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022590018,0.00020921319,0.0007650908,0.0003020417,0.00006079852,0.000008802624,0.0002437896,0.00041007577,0.00008982243],"category_scores_gemma":[0.0019855134,0.00018452205,0.000097040356,0.00034363283,0.00039904413,0.00021019364,0.0003338861,0.00041944883,0.000046738674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009261872,0.00017318466,0.96236175,0.0007262209,0.00013254768,0.0001403568,0.0007774008,0.000053819673,0.0004764406,0.00808239,0.0039495965,0.022200085],"study_design_scores_gemma":[0.029507875,0.002597296,0.95108765,0.00025819967,0.000082071805,0.00015209937,0.00014170828,0.0011075918,0.001338659,0.0021565515,0.011300668,0.00026961078],"about_ca_topic_score_codex":0.0012616211,"about_ca_topic_score_gemma":0.00022011955,"teacher_disagreement_score":0.028581688,"about_ca_system_score_codex":0.029478148,"about_ca_system_score_gemma":0.025860986,"threshold_uncertainty_score":0.97966146},"labels":[],"label_agreement":null},{"id":"W2999409300","doi":"10.1002/ccr3.2656","title":"Chronic lymphocytic leukemia with progressive anemia secondary to development of composite lymphoma","year":2020,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; Royal Columbian Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Lymphoma; Anemia; Internal medicine; Leukemia; Disease","score_opus":0.05050536759917878,"score_gpt":0.36182561964061244,"score_spread":0.31132025204143365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999409300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946787,0.00090920576,0.00037331323,0.00030254878,0.00014806457,0.0014622766,0.000006836121,0.00015369852,0.0019653991],"genre_scores_gemma":[0.9893775,0.000014866083,0.008388897,0.0011599925,0.00057744206,0.00009576542,0.00005253583,0.00008049719,0.00025249345],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9950264,0.00011344818,0.0021467106,0.0010705855,0.0009692687,0.00067359296],"domain_scores_gemma":[0.99598444,0.00040522253,0.00061745004,0.00094385573,0.00048041102,0.0015686278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088213594,0.00037490868,0.0011598852,0.0001145748,0.00012841467,0.000031312124,0.00013560995,0.00027953973,0.00030969596],"category_scores_gemma":[0.0008507855,0.00029150807,0.00023205453,0.00063981407,0.00043116786,0.00009177689,0.00037083865,0.000372341,0.000107321204],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002560401,0.00017313693,0.0037494174,0.0021949615,0.00050282024,0.8807902,0.0011942693,0.0004543693,0.0011114905,0.0000077859595,0.002313054,0.1049481],"study_design_scores_gemma":[0.051802583,0.00801655,0.011237595,0.0024107778,0.00075283175,0.811627,0.0005277282,0.011563306,0.057656344,0.000019415964,0.043083567,0.0013023231],"about_ca_topic_score_codex":0.00014070024,"about_ca_topic_score_gemma":0.000029112376,"teacher_disagreement_score":0.10364578,"about_ca_system_score_codex":0.035862166,"about_ca_system_score_gemma":0.13338411,"threshold_uncertainty_score":0.9999537},"labels":[],"label_agreement":null},{"id":"W2999552994","doi":"10.1093/ecco-jcc/jjz203.725","title":"P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis","year":2020,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Adverse effect; Rheumatoid arthritis; Internal medicine; Surgery","score_opus":0.042381314378489555,"score_gpt":0.35057016062445817,"score_spread":0.3081888462459686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999552994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922001,0.0067038964,0.00003579423,0.00061645004,0.000034578974,0.00017571244,0.00008624293,0.0000035609687,0.00014369833],"genre_scores_gemma":[0.993452,0.0058071115,0.00040333197,0.00021588684,0.0000807304,0.0000018394464,0.000009929645,0.000011985578,0.000017166985],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99840045,0.00006441977,0.0006780381,0.00013583987,0.0005298009,0.00019143672],"domain_scores_gemma":[0.99868464,0.00020475604,0.00031235878,0.00010553796,0.00046383153,0.00022889458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016898973,0.00011721938,0.00076185603,0.000108677625,0.000032378306,0.000015500582,0.00007557755,0.000045822726,0.00017175802],"category_scores_gemma":[0.00040237917,0.0000820473,0.00008303426,0.00023229985,0.00016424156,0.00011764572,0.000050327573,0.00020054205,0.0000015222763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33765617,0.005640512,0.23243275,0.0020745122,0.010943883,0.0123743825,0.029838644,0.00026209964,0.0015292448,0.00033959272,0.016067997,0.3508402],"study_design_scores_gemma":[0.16569714,0.0064679426,0.8139514,0.0030291225,0.00020460969,0.00017542309,0.0026137915,0.00058901834,0.0036826492,0.00016731079,0.003203367,0.0002182266],"about_ca_topic_score_codex":0.00028430455,"about_ca_topic_score_gemma":0.00006624146,"teacher_disagreement_score":0.58151865,"about_ca_system_score_codex":0.00059577613,"about_ca_system_score_gemma":0.0012630662,"threshold_uncertainty_score":0.3345792},"labels":[],"label_agreement":null},{"id":"W2999646328","doi":"10.1126/scitranslmed.aax9340","title":"Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance","year":2020,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Medical Research Council; Austrian Science Fund; Deutsche Forschungsgemeinschaft; CHILDREN with CANCER UK; National Cancer Institute; Cancer Research UK; Paracelsus Medizinische Privatuniversität; Wellcome Trust","keywords":"Stromal cell; Cancer research; Drug resistance; Protein kinase A; Cell; Chemosensitivity assay; Drug; Kinase; Chemistry; Medicine; Biology; Pharmacology; Cell biology; Tumor cells; Biochemistry; Genetics","score_opus":0.019602476290675745,"score_gpt":0.2759885735656913,"score_spread":0.25638609727501555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999646328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96535856,0.00094574114,0.00023664383,0.027992468,0.000036369922,0.0006433062,0.000009275454,0.00003512705,0.004742542],"genre_scores_gemma":[0.9967971,0.000046955833,0.0017397581,0.00068579515,0.00015517762,0.00002185774,0.000014548878,0.000011138152,0.0005277007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973012,0.000052536456,0.0003361126,0.0005599812,0.0013447355,0.0004054016],"domain_scores_gemma":[0.99911964,0.00016215174,0.00007051771,0.00015972953,0.00015968387,0.00032830375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090146635,0.0001695978,0.00031344956,0.00018998409,0.00013377551,0.00002077732,0.00010740884,0.000041266263,0.00009472624],"category_scores_gemma":[0.00026448804,0.00013817412,0.0000298821,0.0010852411,0.0015091541,0.00035129904,0.00003417007,0.00024750136,0.000010909501],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036793025,0.00007252904,0.0007977352,0.0005939333,0.0000020774712,0.00017168722,0.002957249,0.000013190739,0.9940077,0.0005341305,0.00020644415,0.00027538507],"study_design_scores_gemma":[0.015620604,0.0002820725,0.022403955,0.0009867515,0.000024906452,0.00003730311,0.00084607064,0.0061246785,0.95196635,0.000915266,0.0005323793,0.00025968446],"about_ca_topic_score_codex":0.0001308918,"about_ca_topic_score_gemma":0.00012441582,"teacher_disagreement_score":0.04204138,"about_ca_system_score_codex":0.0006994826,"about_ca_system_score_gemma":0.0028173767,"threshold_uncertainty_score":0.5634577},"labels":[],"label_agreement":null},{"id":"W3001625912","doi":"10.1182/blood-2019-121932","title":"Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Refractory (planetary science); Term (time); Medicine; Lymphoma; Oncology; Internal medicine; Materials science; Metallurgy","score_opus":0.01007010945681047,"score_gpt":0.258710851230747,"score_spread":0.24864074177393652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001625912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980084,0.00025086314,0.0000048217166,0.000026354497,0.000042769723,0.0010685307,0.000014586692,0.000023324947,0.0005603734],"genre_scores_gemma":[0.9983074,0.0000888138,0.00037625883,0.000040901254,0.000034383047,0.000012199942,0.00004874655,0.0000372747,0.001053988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831307,0.00005861172,0.0003533528,0.0003634422,0.00055853097,0.0003529811],"domain_scores_gemma":[0.9987965,0.00030167718,0.00011428341,0.000497644,0.00012782394,0.00016204432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019974029,0.00017593206,0.00044586236,0.00016403048,0.000022649774,0.00000920165,0.00011913405,0.00012305328,0.00017939182],"category_scores_gemma":[0.00016769928,0.00012226477,0.000032654825,0.00026529082,0.00014241638,0.00009276481,0.00009949249,0.00015596529,0.000041737436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020134032,0.004744308,0.96005535,0.0007896392,0.00017600619,0.0004541634,0.0004454549,0.0000032036505,0.0012113698,0.000009014146,0.00003121218,0.011946241],"study_design_scores_gemma":[0.23243168,0.0017464729,0.7635928,0.0006521017,0.000077661534,0.000090953465,0.00002647745,0.00008229366,0.001069643,3.7685527e-7,0.00010978295,0.00011979142],"about_ca_topic_score_codex":0.00021121721,"about_ca_topic_score_gemma":0.00008814345,"teacher_disagreement_score":0.21229765,"about_ca_system_score_codex":0.0013436785,"about_ca_system_score_gemma":0.0022340948,"threshold_uncertainty_score":0.49858126},"labels":[],"label_agreement":null},{"id":"W3002520968","doi":"10.1016/j.ebiom.2020.102634","title":"Molecular insight into the autoinhibition of a master regulator of lipid signalling in human disease","year":2020,"lang":"en","type":"letter","venue":"EBioMedicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Natural Sciences and Engineering Research Council of Canada; Michael Smith Health Research BC; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Diacylglycerol kinase; TREM2; Biology; Signal transduction; Phosphoinositide phospholipase C; Phospholipase C; Receptor; Phosphatidylinositol; Cell biology; Genetics; Protein kinase C","score_opus":0.023558466539242665,"score_gpt":0.28445451554608736,"score_spread":0.2608960490068447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002520968","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16595481,0.0033370266,0.00028140313,0.82668936,0.00026390364,0.0020060088,0.000037786453,0.00005994668,0.0013697663],"genre_scores_gemma":[0.8230417,0.000073176896,0.0001431711,0.17150573,0.0032809696,0.00007354861,0.0009045108,0.00012661894,0.0008506218],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603784,0.00020919184,0.0010974933,0.000573019,0.0016416946,0.00044076657],"domain_scores_gemma":[0.9980488,0.00023388247,0.0004010963,0.0008730774,0.00022479211,0.0002183616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040044493,0.00038100022,0.0010933683,0.00065850466,0.00004112062,0.000008766746,0.00037462072,0.00038090147,0.00033717818],"category_scores_gemma":[0.00033797557,0.0002552479,0.00026011223,0.00091962924,0.0008619515,0.000044753226,0.000220449,0.0014212605,0.000014732276],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001298695,0.0003545735,0.0002411453,0.018096676,0.00063918886,0.017321395,0.007943309,0.000047897578,0.41627246,0.00014782755,0.5362528,0.0013840407],"study_design_scores_gemma":[0.066432945,0.0041963416,0.0012336964,0.031229476,0.0021053809,0.0002508829,0.00046260064,0.015556729,0.14491963,0.0021794084,0.73000485,0.0014280872],"about_ca_topic_score_codex":0.00039354482,"about_ca_topic_score_gemma":0.0000061018077,"teacher_disagreement_score":0.65708685,"about_ca_system_score_codex":0.0026933195,"about_ca_system_score_gemma":0.00329867,"threshold_uncertainty_score":0.99999},"labels":[],"label_agreement":null},{"id":"W3003215342","doi":"10.1038/s41375-019-0702-7","title":"In search of genetic factors predisposing to familial hairy cell leukemia (HCL): exome-sequencing of four multiplex HCL pedigrees","year":2020,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Pedigree chart; Exome sequencing; Multiplex; Exome; Genetics; Leukemia; Hairy cell leukemia; Biology; Medicine; Oncology; Mutation; Gene","score_opus":0.04943081365974037,"score_gpt":0.29210880692044167,"score_spread":0.2426779932607013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003215342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821533,0.0005872517,0.00030618903,0.011328552,0.00069714885,0.0027780654,0.00030235227,0.00012571647,0.0017214401],"genre_scores_gemma":[0.9432284,0.0002175891,0.005391773,0.04177231,0.0045750756,0.00011181723,0.0004095634,0.0004708493,0.0038225797],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9909459,0.00037556762,0.0021287512,0.0016463267,0.0030705414,0.0018329492],"domain_scores_gemma":[0.995553,0.0011129411,0.00053721026,0.0016946922,0.00049294234,0.00060917926],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0004946287,0.0010529938,0.0024574555,0.0014148554,0.00009280852,0.000050952443,0.0013052396,0.0016504877,0.00026401706],"category_scores_gemma":[0.00088997785,0.0010086262,0.0006529417,0.0015049159,0.0005244347,0.00018720314,0.0008820852,0.004258463,0.00011950524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023505185,0.00017637192,0.02037805,0.033855785,0.0007256959,0.02464011,0.018526776,0.013083117,0.20072173,0.000006038745,0.6830339,0.0025019601],"study_design_scores_gemma":[0.10052883,0.007596939,0.042438738,0.01804604,0.0021884437,0.0015079511,0.006068691,0.19634272,0.48888746,0.00019973257,0.12889099,0.007303443],"about_ca_topic_score_codex":0.021910904,"about_ca_topic_score_gemma":0.00039415914,"teacher_disagreement_score":0.55414283,"about_ca_system_score_codex":0.07438177,"about_ca_system_score_gemma":0.04527086,"threshold_uncertainty_score":0.9996456},"labels":[],"label_agreement":null},{"id":"W3004727409","doi":"10.1016/j.jmoldx.2020.01.008","title":"Ultrasensitive Detection of NOTCH1 c.7544_7545delCT Mutations in Chronic Lymphocytic Leukemia by Droplet Digital PCR Reveals High Frequency of Subclonal Mutations and Predicts Clinical Outcome in Cases with Trisomy 12","year":2020,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Vancouver Coastal Health Research Institute; Terry Fox Research Institute","keywords":"Chronic lymphocytic leukemia; Frameshift mutation; Digital polymerase chain reaction; Trisomy; Biology; Leukemia; Mutation; Genetics; Cancer research; Molecular biology; Internal medicine; Immunology; Medicine; Polymerase chain reaction; Gene","score_opus":0.026250501552017986,"score_gpt":0.310314558332295,"score_spread":0.284064056780277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004727409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429035,0.0012166701,0.0034796724,0.00021078353,0.000058736958,0.0005283626,0.00018277511,0.000008238999,0.000024387466],"genre_scores_gemma":[0.99825996,0.00063210656,0.0007756389,0.00012353204,0.00008987286,0.000009003923,0.000068283414,0.000037330283,0.000004268921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966804,0.00020823852,0.0017325652,0.00027678392,0.0007945612,0.00030749998],"domain_scores_gemma":[0.99511766,0.0031199155,0.00074228283,0.00019294926,0.00049241283,0.0003347521],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00047974059,0.00022175674,0.00089312607,0.00034269952,0.000026996991,0.000022202323,0.00012559624,0.00018536199,0.000009174477],"category_scores_gemma":[0.009241446,0.00019331656,0.00016130113,0.00060797035,0.0004210676,0.00020338333,0.00004482905,0.0005576079,0.0000017038245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005661222,0.0016221626,0.6227384,0.002631117,0.0017063025,0.049168773,0.0028553396,0.04475213,0.25937524,0.00025526524,0.00048484642,0.0087491665],"study_design_scores_gemma":[0.19800937,0.028475363,0.41109046,0.0059855604,0.0028066428,0.0140267415,0.00245129,0.050653566,0.28383905,0.0013059154,0.000054114367,0.001301925],"about_ca_topic_score_codex":0.00070672884,"about_ca_topic_score_gemma":0.00019312462,"teacher_disagreement_score":0.21164799,"about_ca_system_score_codex":0.009953181,"about_ca_system_score_gemma":0.012180013,"threshold_uncertainty_score":0.99910414},"labels":[],"label_agreement":null},{"id":"W3006115592","doi":"10.1097/01.hs9.0000560972.91141.2d","title":"PF672 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Internal medicine; Refractory (planetary science); Oncology; Clinical trial; Interleukin-3 receptor; Gastroenterology; Leukemia; Myelodysplastic syndromes; Bone marrow","score_opus":0.030930928187522036,"score_gpt":0.3385047405346094,"score_spread":0.30757381234708736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006115592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892615,0.00044446244,0.000017779947,0.00006153676,0.0005424153,0.0025554649,0.00008458445,0.000075540906,0.0069566946],"genre_scores_gemma":[0.995699,0.00013750282,0.00059327745,0.000083129955,0.000551031,0.000044696215,0.0003475766,0.00010505468,0.0024387306],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946379,0.0002905271,0.0018202442,0.0010908217,0.0013348456,0.0008256297],"domain_scores_gemma":[0.99562925,0.0013755057,0.0006077569,0.0017361663,0.00024915097,0.00040218895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010811256,0.00042813347,0.001316892,0.00015545092,0.000047242313,0.000027835858,0.00039971512,0.0005196132,0.0010275865],"category_scores_gemma":[0.0011459125,0.00034325736,0.00028059207,0.0005858688,0.0002881154,0.00024094306,0.00020549621,0.0011231129,0.0004945446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8038009,0.008538579,0.049043205,0.0011926932,0.00094873883,0.0007605178,0.001328681,0.0004114113,0.0010538376,0.000114503964,0.005983019,0.12682392],"study_design_scores_gemma":[0.95654446,0.015342157,0.01245309,0.0017243427,0.00017869471,0.000008989168,0.00022591159,0.005544762,0.0011587463,0.000038726685,0.006299883,0.0004802434],"about_ca_topic_score_codex":0.0019637162,"about_ca_topic_score_gemma":0.00049205916,"teacher_disagreement_score":0.15274355,"about_ca_system_score_codex":0.016979886,"about_ca_system_score_gemma":0.01629385,"threshold_uncertainty_score":0.99990195},"labels":[],"label_agreement":null},{"id":"W3007085808","doi":"10.1002/ajh.25766","title":"Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group","year":2020,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Obinutuzumab; Chlorambucil; Medicine; Internal medicine; Ibrutinib; IGHV@; Rituximab; Oncology; Gastroenterology; Surgery; Chronic lymphocytic leukemia; Leukemia; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.07603734731203367,"score_gpt":0.4028478104530401,"score_spread":0.3268104631410064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007085808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871439,0.0015433031,0.0010847879,0.005852978,0.00011611273,0.004206134,0.00002400343,0.000014392092,0.000014422752],"genre_scores_gemma":[0.9982482,0.00027770657,0.00044457524,0.0005513495,0.00021324019,0.00016392577,0.000014102869,0.000037187496,0.000049707272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938681,0.002375135,0.0022721929,0.00042417998,0.0007098258,0.00035055508],"domain_scores_gemma":[0.9876288,0.008793566,0.0023260193,0.0004192746,0.0006053664,0.00022693357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056398725,0.00029367805,0.0022356866,0.00010987422,0.00013322741,0.000029391102,0.00033837036,0.00006608191,0.000009141941],"category_scores_gemma":[0.0038290916,0.0001345043,0.00032075023,0.00034267522,0.0013313658,0.000083085826,0.0000974187,0.0003513129,0.0000027959861],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.72321534,0.016428139,0.031171983,0.0007933631,0.025504952,0.0018844294,0.0677169,0.0016192497,0.0004977958,0.00067711866,0.025995653,0.10449508],"study_design_scores_gemma":[0.6657861,0.12923655,0.0034492146,0.00016727796,0.0031046192,0.0012297238,0.04726394,0.14698823,0.00020597897,0.000026541771,0.0022766774,0.0002651838],"about_ca_topic_score_codex":0.0013160517,"about_ca_topic_score_gemma":0.00022515905,"teacher_disagreement_score":0.14536898,"about_ca_system_score_codex":0.013153909,"about_ca_system_score_gemma":0.009738111,"threshold_uncertainty_score":0.9958758},"labels":[],"label_agreement":null},{"id":"W3007337352","doi":"10.1016/j.jdcr.2017.03.003","title":"Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib","year":2020,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Gefitinib; Intertriginous; Epidermal growth factor receptor; Medicine; Dermatology; Drug; Cancer research; Internal medicine; Pharmacology; Receptor","score_opus":0.026290210074855755,"score_gpt":0.2952018504805482,"score_spread":0.26891164040569243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007337352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052334,0.00070703996,0.000045461835,0.005292122,0.00042355392,0.0010472767,0.000038255843,0.00024464855,0.0016783162],"genre_scores_gemma":[0.9960899,0.000041084833,0.0005507816,0.0016460455,0.00062230503,0.00004906992,0.000048152117,0.00007861124,0.0008740916],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9964514,0.00011746068,0.001038805,0.0009497417,0.00072451204,0.0007181259],"domain_scores_gemma":[0.997053,0.00041903197,0.00021525545,0.00048435948,0.0002489978,0.0015793354],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004205145,0.00036575276,0.0007665679,0.0002230317,0.00012528412,0.00007526037,0.00006965713,0.0002333692,0.0010424241],"category_scores_gemma":[0.0027510782,0.00030798785,0.00019554078,0.0008224056,0.00015577186,0.0001816096,0.00034378868,0.0007851263,0.00017786243],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095866004,0.00029763588,0.0033346121,0.0010381923,0.00037342854,0.8856986,0.004873627,0.0000026091695,0.00860303,0.000055762695,0.047333572,0.047430243],"study_design_scores_gemma":[0.014549615,0.0016078289,0.0014703696,0.0004956095,0.0002220281,0.86067355,0.001098676,0.0025014437,0.08147563,0.00006123331,0.034836184,0.0010078149],"about_ca_topic_score_codex":0.0006764663,"about_ca_topic_score_gemma":0.000011955694,"teacher_disagreement_score":0.0728726,"about_ca_system_score_codex":0.0029313222,"about_ca_system_score_gemma":0.0026402283,"threshold_uncertainty_score":0.99993724},"labels":[],"label_agreement":null},{"id":"W3007551495","doi":"10.1016/j.leukres.2020.106335","title":"Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada","year":2020,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Richmond Hospital; St. Paul's Hospital; BC Cancer Agency; University of British Columbia, Okanagan Campus; Kelowna General Hospital; Abbotsford Veterinary Clinic; Kwantlen Polytechnic University; Surrey Memorial Hospital; University of British Columbia; Royal Columbian Hospital; Vernon Jubilee Hospital; University of British Columbia Hospital; Vancouver General Hospital; Columbia Bible College","funders":"","keywords":"Ibrutinib; Chemoimmunotherapy; Medicine; Chronic lymphocytic leukemia; Internal medicine; Population; Oncology; Leukemia","score_opus":0.03979922661886139,"score_gpt":0.34434966859959676,"score_spread":0.3045504419807354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007551495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944282,0.0005308037,0.0000020928958,0.00020841564,0.00002024553,0.002609852,0.00014802162,0.000010117506,0.0020422544],"genre_scores_gemma":[0.99748755,0.0005064945,0.00006977277,0.00006032683,0.000055384953,0.00027075104,0.000034914337,0.000034663684,0.0014801348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99468136,0.0005514489,0.0012287669,0.0007114959,0.0019519972,0.00087494665],"domain_scores_gemma":[0.9977657,0.0006549118,0.00018951923,0.00089826423,0.00024156168,0.00025004585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015159925,0.00020580638,0.0010080265,0.00022729737,0.000048046782,0.00003874016,0.0005334887,0.00013388612,0.000198855],"category_scores_gemma":[0.00019155639,0.00021561894,0.00009905354,0.0013950923,0.00070360117,0.000076924145,0.0004237885,0.0005892478,0.000002848604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014983807,0.00027290624,0.95814353,0.0104414215,0.000168332,0.0024128438,0.0026094443,0.00054967013,0.00024823967,0.00004180676,0.0033985162,0.020214926],"study_design_scores_gemma":[0.02216545,0.0021784646,0.93272334,0.0016232016,0.00006409889,0.000037143625,0.0026722986,0.035335895,0.0018508089,0.000042864078,0.0010999717,0.00020644683],"about_ca_topic_score_codex":0.98613226,"about_ca_topic_score_gemma":0.9970845,"teacher_disagreement_score":0.09813287,"about_ca_system_score_codex":0.18249181,"about_ca_system_score_gemma":0.08435894,"threshold_uncertainty_score":0.9208319},"labels":[],"label_agreement":null},{"id":"W3007662737","doi":"10.5114/ada.2019.91427","title":"Cutaneous manifestation of chronic lymphocytic leukemia: a case report and a literature review","year":2019,"lang":"en","type":"review","venue":"Advances in Dermatology and Allergology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Uniwersytet Mikolaja Kopernika w Toruniu","keywords":"Chronic lymphocytic leukemia; Medicine; Dermatology; Leukemia; Immunology","score_opus":0.020152683343302162,"score_gpt":0.3671202374329753,"score_spread":0.3469675540896731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007662737","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007153456,0.99681586,0.000010602535,0.000063954874,0.00021542893,0.0015387327,0.0000148439785,0.000025390205,0.0005998657],"genre_scores_gemma":[0.0006788083,0.99819714,0.00013280538,0.0001708408,0.000059160735,0.00016125792,0.00020262598,0.000045460667,0.00035189473],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9969684,0.00036133846,0.0012984318,0.00070503016,0.00016862896,0.00049817574],"domain_scores_gemma":[0.9974936,0.000976095,0.00063745986,0.0006546038,0.00011098529,0.00012724071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024070281,0.00046936324,0.0033557224,0.00040363043,0.000043678374,0.0000072233343,0.00014226577,0.00086406094,0.00003105944],"category_scores_gemma":[0.00045324242,0.00037297484,0.00017658265,0.00042047605,0.00057504704,0.00013583632,0.00021085155,0.0007605316,0.000014668151],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000041795287,0.000014714837,0.0000068608933,0.2726612,0.00012217683,0.52379215,0.00006396788,0.000002776509,1.13012135e-7,0.00024219412,0.00013085631,0.20292118],"study_design_scores_gemma":[0.0018622279,0.0001328658,2.3727573e-7,0.05597378,0.00046545328,0.6261662,0.000013473839,0.00026424963,5.9111943e-7,0.00006926562,0.31488675,0.00016486952],"about_ca_topic_score_codex":0.000058143858,"about_ca_topic_score_gemma":0.0001742219,"teacher_disagreement_score":0.3147559,"about_ca_system_score_codex":0.008153135,"about_ca_system_score_gemma":0.0140788425,"threshold_uncertainty_score":0.9998722},"labels":[],"label_agreement":null},{"id":"W3007802601","doi":"","title":"Males have a worse prognosis than females in chronic lymphocytic leukemia and this may be related to IgVH gene usage and mutational status.","year":2008,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Internal medicine; Incidence (geometry); Population; Cancer registry; CD38; Cancer; Relative survival; Leukemia; Oncology; Biology; Genetics","score_opus":0.10856324353903613,"score_gpt":0.4088365153981463,"score_spread":0.3002732718591102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007802601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98478013,0.010704272,0.0000038553253,0.0013530396,0.000040706316,0.0017482039,0.000056349792,0.000055317916,0.0012581054],"genre_scores_gemma":[0.98010755,0.009166411,0.0004326064,0.00015810659,0.00014037109,0.0008561587,0.000050992494,0.00007575031,0.009012081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952628,0.00032138458,0.00048128565,0.00092223147,0.0015634682,0.0014488423],"domain_scores_gemma":[0.99762267,0.0006501781,0.000054210454,0.00046555622,0.0003803305,0.00082704844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001306825,0.00028703708,0.0005042203,0.0009027147,0.00033534536,0.000075348675,0.00022565627,0.0002447968,0.00066942343],"category_scores_gemma":[0.0006314822,0.000258634,0.00006157961,0.0011975782,0.0012512685,0.00019099217,0.00043454202,0.000763702,0.000076981385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009488895,0.00045080108,0.7229226,0.005796592,0.0012176279,0.02233998,0.054421492,0.004049311,0.11742223,0.0013627139,0.020141637,0.040386107],"study_design_scores_gemma":[0.08817275,0.0037143133,0.69770837,0.0041843685,0.00016805434,0.0062858206,0.0039463714,0.07679606,0.09453412,0.0005963209,0.022011759,0.0018817203],"about_ca_topic_score_codex":0.01789621,"about_ca_topic_score_gemma":0.0034334594,"teacher_disagreement_score":0.07868385,"about_ca_system_score_codex":0.10286837,"about_ca_system_score_gemma":0.059169266,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W3007925874","doi":"10.1182/blood.2019002936","title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Juno Therapeutics; University of British Columbia; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Celgene","keywords":"Ibrutinib; Bruton's tyrosine kinase; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Leukemia; Tyrosine kinase; Receptor","score_opus":0.029870956478100286,"score_gpt":0.2892506916692684,"score_spread":0.25937973519116814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007925874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960261,0.001006915,0.000118866934,0.00061589095,0.000041018036,0.0018698599,0.00014947283,0.000055933935,0.00011594425],"genre_scores_gemma":[0.9974024,0.000029319663,0.0019449709,0.00022440041,0.00019102907,0.00006575212,0.000045303717,0.000038638726,0.000058167563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822384,0.000053766707,0.00035836294,0.00053621456,0.000409848,0.00041799207],"domain_scores_gemma":[0.9985838,0.00029515728,0.00009986978,0.00039875155,0.00020960341,0.00041281973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019821108,0.00021989045,0.0005267954,0.000044156048,0.000037783597,0.000017777462,0.00012376047,0.00012575902,0.00011270952],"category_scores_gemma":[0.00031418388,0.00016513042,0.00011852773,0.00021478295,0.00026479003,0.000048052447,0.000102669444,0.00021130222,0.000012977385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06351136,0.019326817,0.27028337,0.03422838,0.0055226358,0.0015894764,0.026429651,0.00008459884,0.54721165,0.0005647201,0.020044046,0.011203285],"study_design_scores_gemma":[0.39337143,0.0065784105,0.03625388,0.00068269426,0.0018038654,0.00022828678,0.000688046,0.0023980294,0.5411191,0.000028919363,0.016071098,0.00077626016],"about_ca_topic_score_codex":0.000036588925,"about_ca_topic_score_gemma":0.000017114271,"teacher_disagreement_score":0.32986006,"about_ca_system_score_codex":0.0003928822,"about_ca_system_score_gemma":0.00219429,"threshold_uncertainty_score":0.67338234},"labels":[],"label_agreement":null},{"id":"W3009667674","doi":"10.1080/16078454.2020.1730080","title":"Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction","year":2020,"lang":"en","type":"article","venue":"Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Platelet; Pharmacology; Adenosine diphosphate; Platelet activation; Medicine; Aspirin; Ristocetin; Agonist; Immunology; Chemistry; Internal medicine; Receptor; Tyrosine kinase; Leukemia; Von Willebrand factor; Platelet aggregation; Chronic lymphocytic leukemia","score_opus":0.016874501119081252,"score_gpt":0.26121623962319734,"score_spread":0.24434173850411608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009667674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966938,0.0005810766,0.0000770554,0.0017590217,0.00004397505,0.0007333615,0.000008623996,0.000031131865,0.00007195664],"genre_scores_gemma":[0.99814,0.00039781217,0.0005819103,0.0006932425,0.000042778895,0.000048006477,0.0000693712,0.0000232747,0.000003612494],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998507,0.00013504665,0.0003857664,0.00041660314,0.00022166717,0.00033390775],"domain_scores_gemma":[0.99853945,0.0009770278,0.00012430655,0.00017500696,0.00002988561,0.00015432824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013792481,0.00016688895,0.00064426806,0.00022335148,0.000021516375,0.0000055215855,0.000063366235,0.00019935989,0.000023902401],"category_scores_gemma":[0.0003617729,0.00013838235,0.0000268286,0.0003526819,0.00013322396,0.00005103544,0.000042473373,0.0003189095,0.000012172199],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24374443,0.004862063,0.41489887,0.024645593,0.0014574957,0.024019144,0.023882113,0.00088362733,0.17708062,0.010980619,0.0015845215,0.0719609],"study_design_scores_gemma":[0.082877055,0.0032199249,0.022392679,0.00081848644,0.00006458614,0.0008066829,0.00034953697,0.005268787,0.8834322,0.0003359376,0.00018675621,0.00024737063],"about_ca_topic_score_codex":0.004454789,"about_ca_topic_score_gemma":0.000724696,"teacher_disagreement_score":0.7063516,"about_ca_system_score_codex":0.0006375341,"about_ca_system_score_gemma":0.00087304745,"threshold_uncertainty_score":0.67343384},"labels":[],"label_agreement":null},{"id":"W3010847380","doi":"10.1016/j.msard.2019.11.078","title":"Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis Over 48 Weeks: A Randomized, Placebo-Controlled, Phase 2 Study","year":2020,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada); University of Toronto; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Gastroenterology; Internal medicine; Randomized controlled trial; Confidence interval; Adverse effect; Dimethyl fumarate; Multiple sclerosis; Immunology; Pathology","score_opus":0.017050431650200808,"score_gpt":0.2431664878634373,"score_spread":0.2261160562132365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010847380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883627,0.0016293665,0.000017387449,0.00084833894,0.00014039241,0.008773709,0.00004080939,0.000060027865,0.00012722697],"genre_scores_gemma":[0.998642,0.00076895166,0.00008507339,0.00013938641,0.00003076501,0.00016550857,0.00003115374,0.00008072915,0.000056432506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99610317,0.00057722384,0.0011240595,0.0008023738,0.0008245057,0.0005686831],"domain_scores_gemma":[0.9973513,0.0012749563,0.00038680134,0.0004896971,0.0001418484,0.0003554136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008715885,0.00047576654,0.0015258346,0.00019775082,0.00029511462,0.00005647123,0.00018703673,0.00025719547,0.00006461778],"category_scores_gemma":[0.0026593236,0.00028934047,0.00024462683,0.0008802587,0.00078198727,0.00017987496,0.0002853878,0.00066478003,0.000004395591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8145726,0.0049652876,0.16071212,0.00021189681,0.00095092575,0.000009784542,0.0066293837,0.0005175031,0.0019503767,0.0000084818075,0.00016303363,0.009308636],"study_design_scores_gemma":[0.8359392,0.001121991,0.1255831,0.0011154417,0.0005004905,0.0000016759927,0.00091491535,0.03429853,0.00019090022,0.000003408628,0.00003874304,0.0002915554],"about_ca_topic_score_codex":0.001144704,"about_ca_topic_score_gemma":0.00020879456,"teacher_disagreement_score":0.035129026,"about_ca_system_score_codex":0.0006493245,"about_ca_system_score_gemma":0.00052536704,"threshold_uncertainty_score":0.9999559},"labels":[],"label_agreement":null},{"id":"W3011197171","doi":"10.1002/ijc.32985","title":"Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Royal Victoria Regional Health Centre","funders":"","keywords":"Montelukast; Medicine; Premedication; Rituximab; Anesthesia; Internal medicine; Gastroenterology; Asthma; Lymphoma","score_opus":0.024434029861459185,"score_gpt":0.32840894826817635,"score_spread":0.30397491840671714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011197171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902737,0.0008466193,0.0011024021,0.007387588,0.000054214383,0.00017133054,0.00005512687,0.0000054609422,0.00010356974],"genre_scores_gemma":[0.995665,0.0021138785,0.0016888455,0.00023172378,0.0001674215,0.0000057194948,0.000016067914,0.000009700791,0.00010161943],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986606,0.000044175642,0.00045262268,0.000109010376,0.00065993896,0.000073641495],"domain_scores_gemma":[0.997966,0.00020459431,0.00036658172,0.00009620882,0.0011646827,0.00020191453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002361514,0.00007327007,0.00024151074,0.0001475786,0.000020096448,0.000011676125,0.0001050532,0.000048493574,0.0001703414],"category_scores_gemma":[0.00071185245,0.000054966302,0.0000345985,0.00014903455,0.00021472925,0.00024104309,0.00005010455,0.00017230806,7.7178476e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04420941,0.0029374445,0.16592865,0.0020438253,0.008726818,0.00058948493,0.007890101,0.0015627228,0.63085467,0.0013690593,0.022411954,0.11147588],"study_design_scores_gemma":[0.100359395,0.0031016653,0.60403407,0.006568158,0.0017133454,0.0029957478,0.0006390331,0.1416191,0.09657439,0.00035762758,0.041557167,0.0004803018],"about_ca_topic_score_codex":0.0011726083,"about_ca_topic_score_gemma":0.00010932196,"teacher_disagreement_score":0.53428024,"about_ca_system_score_codex":0.00060843804,"about_ca_system_score_gemma":0.0031069333,"threshold_uncertainty_score":0.55115664},"labels":[],"label_agreement":null},{"id":"W3011202496","doi":"10.1016/s0735-1097(20)31041-x","title":"INCREASED RISK OF ADVERSE CARDIOVASCULAR EVENTS ASSOCIATED WITH IBRUTINIB USE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A PROPENSITY-MATCHED POPULATION-BASED COHORT STUDY","year":2020,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Ibrutinib; Chronic lymphocytic leukemia; Internal medicine; Cohort; Oncology; Adverse effect; Propensity score matching; Cohort study; Leukemia","score_opus":0.021526474064054734,"score_gpt":0.26442978561866376,"score_spread":0.24290331155460904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011202496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997713,0.00015424614,0.00008353393,0.000090696914,0.000063008745,0.0017716374,0.00007923374,0.000011518617,0.000033114975],"genre_scores_gemma":[0.9994753,0.000057744874,0.00014741108,0.00011240915,0.00012424246,0.000019066038,0.0000074668824,0.00004203627,0.0000143347615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944723,0.0022921301,0.0011496654,0.00033485412,0.0013580592,0.00039295602],"domain_scores_gemma":[0.9956083,0.0008710563,0.0017896225,0.00076000084,0.0007461529,0.00022483354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022215631,0.00026816057,0.0030384548,0.00027913487,0.00005914358,0.0000026010869,0.00045114674,0.000108681925,0.000006847084],"category_scores_gemma":[0.003993155,0.00017367816,0.00089113985,0.0015521365,0.00043803957,0.000091710725,0.0001502621,0.00059106486,0.0000012628329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0045777345,0.00007137528,0.83513474,0.0000757927,0.004979449,0.00096977846,0.00006189734,0.15367663,0.00033434437,7.724472e-7,0.000086876564,0.000030590338],"study_design_scores_gemma":[0.034500673,0.0037835597,0.9458565,0.00030124674,0.0025016484,0.00041828695,0.00042394554,0.011658913,0.0003578805,0.0000037939758,0.00003702,0.00015651944],"about_ca_topic_score_codex":0.0064813914,"about_ca_topic_score_gemma":0.00027175594,"teacher_disagreement_score":0.14201772,"about_ca_system_score_codex":0.03615679,"about_ca_system_score_gemma":0.033715673,"threshold_uncertainty_score":0.9797968},"labels":[],"label_agreement":null},{"id":"W3011636463","doi":"10.3390/cancers12030650","title":"Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital; Children's Hospital Research Institute of Manitoba; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Leukemia; Cancer research; Oncology; Internal medicine","score_opus":0.019758761258792855,"score_gpt":0.2775790053251374,"score_spread":0.2578202440663446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011636463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936877,0.0030723615,0.000056415014,0.00045363314,0.000091612084,0.0015235279,0.000023997278,0.00007201845,0.0010187215],"genre_scores_gemma":[0.9968154,0.0008281663,0.00017720425,0.0009124067,0.00024210032,0.00024111649,0.0000672835,0.000047486832,0.0006688706],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998252,0.000056568744,0.00030466638,0.00054107077,0.00036884297,0.0004768746],"domain_scores_gemma":[0.99912554,0.00014582236,0.00008520468,0.00023990426,0.000052583422,0.00035093882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070935625,0.00025327507,0.00040786478,0.00008288192,0.00006307791,0.000039783274,0.00008480399,0.00013296778,0.00020361783],"category_scores_gemma":[0.0001276052,0.00019883449,0.00005141948,0.00041284977,0.0002238034,0.0001157808,0.00003506966,0.00016302406,0.000036360216],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.17853226,0.0001693,0.053382277,0.007830983,0.004337584,0.006818499,0.044455867,0.09967761,0.23018293,0.0002491551,0.25083637,0.12352717],"study_design_scores_gemma":[0.16559912,0.0089989435,0.00072066067,0.00084032054,0.0004016328,0.00022076916,0.0005537748,0.76477826,0.02452058,0.00000927228,0.032750756,0.0006059151],"about_ca_topic_score_codex":0.0053846585,"about_ca_topic_score_gemma":0.00037473725,"teacher_disagreement_score":0.66510063,"about_ca_system_score_codex":0.322415,"about_ca_system_score_gemma":0.08328103,"threshold_uncertainty_score":0.9219159},"labels":[],"label_agreement":null},{"id":"W3011711731","doi":"10.1200/jco.2012.30.15_suppl.10622","title":"Diurnal proteomics and biomarker discovery in indolent versus aggressive chronic lymphocytic leukemia patients.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Biomarker; Microarray; Transcriptome; Biomarker discovery; Leukemia; Gene expression; Oncology; Fold change; Internal medicine; Proteomics; Bioinformatics; Gene; Biology; Genetics","score_opus":0.13035543959525103,"score_gpt":0.46624465049795755,"score_spread":0.3358892109027065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011711731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929445,0.0028919554,0.000054830893,0.00037798274,0.0021714137,0.00047366522,0.000003353921,0.0000065046324,0.0010757868],"genre_scores_gemma":[0.9943345,0.0025813247,0.00080971525,0.00036427754,0.001719884,0.000011608189,0.0000042115503,0.000030344554,0.00014413561],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953204,0.00054624514,0.0024666155,0.00024481947,0.0007255967,0.0006963649],"domain_scores_gemma":[0.99369293,0.0028508194,0.0020693766,0.0002652464,0.00032283962,0.0007987899],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037802367,0.00022113233,0.0014555273,0.00030204028,0.00004362556,0.000024198383,0.00022313421,0.0005655566,0.000055146716],"category_scores_gemma":[0.008934087,0.000155755,0.00034937932,0.00024766292,0.0005370149,0.000534588,0.00024531127,0.0013104065,0.000025296775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11039889,0.004016678,0.43304226,0.000622902,0.0018892175,0.0043375106,0.0010130764,0.00020871575,0.0007791068,0.00028721863,0.0067720995,0.43663234],"study_design_scores_gemma":[0.30314714,0.023575053,0.6513158,0.0010163127,0.0004990214,0.002011058,0.00020386909,0.0045949155,0.00047613753,0.00011809571,0.0126842875,0.00035830235],"about_ca_topic_score_codex":0.0001431185,"about_ca_topic_score_gemma":0.00004733717,"teacher_disagreement_score":0.43627405,"about_ca_system_score_codex":0.07964016,"about_ca_system_score_gemma":0.07779411,"threshold_uncertainty_score":0.9994141},"labels":[],"label_agreement":null},{"id":"W3012118048","doi":"10.1080/10428194.2020.1734594","title":"IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University Health Network; McGill University; University of Alberta; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Chronic lymphocytic leukemia; Toxicity; Gastroenterology; Oncology; Leukemia","score_opus":0.012710099089056265,"score_gpt":0.25567834900218644,"score_spread":0.24296824991313018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012118048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075186,0.005134879,0.000011119042,0.000106318425,0.00011725166,0.0031283924,0.000113360235,0.00022812378,0.00040867267],"genre_scores_gemma":[0.9967407,0.0014942631,0.00017639951,0.0005750541,0.00017209054,0.00017787666,0.00017790671,0.00024223402,0.00024349938],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920836,0.0004863288,0.0017900984,0.0023536738,0.0016754495,0.0016108112],"domain_scores_gemma":[0.995411,0.00072821026,0.0008007487,0.0010729814,0.00039441904,0.0015926365],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008892646,0.0013431787,0.0024506834,0.0008325037,0.00054358644,0.0001861461,0.00044568893,0.00091342215,0.000058291404],"category_scores_gemma":[0.00077403255,0.0011842827,0.00015126773,0.0016817524,0.001345808,0.0007332564,0.0010128849,0.00048393817,0.0000076045067],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10242456,0.00862267,0.38641867,0.008691515,0.008624648,0.006222683,0.055692293,0.00031701222,0.012270851,0.00034781065,0.006105786,0.4042615],"study_design_scores_gemma":[0.56511617,0.031012742,0.3384935,0.0016647134,0.0012484947,0.00058506767,0.0036161318,0.05344158,0.0012209661,0.000046388148,0.0016298575,0.0019243674],"about_ca_topic_score_codex":0.007405919,"about_ca_topic_score_gemma":0.00052690034,"teacher_disagreement_score":0.46269163,"about_ca_system_score_codex":0.09334176,"about_ca_system_score_gemma":0.033855006,"threshold_uncertainty_score":0.99993193},"labels":[],"label_agreement":null},{"id":"W3012448436","doi":"10.1200/jco.2006.24.18_suppl.16513","title":"Inhibition of DNA repair in chronic lymphocytic leukemia: Therapeutic implications","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Chlorambucil; Fludarabine; Chronic lymphocytic leukemia; Cancer research; Nitrogen mustard; DNA repair; Cytotoxicity; Leukemia; Medicine; DNA; Biology; Immunology; Chemotherapy; In vitro; Genetics; Internal medicine; Cyclophosphamide","score_opus":0.09953962008648945,"score_gpt":0.45577829265360537,"score_spread":0.35623867256711594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012448436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99023396,0.0016564865,0.00019373054,0.0017783142,0.00028344168,0.00031843415,0.0000040278996,0.000021249018,0.005510383],"genre_scores_gemma":[0.9961758,0.0007279533,0.0009055076,0.0006648642,0.0011380423,0.000009775313,0.000005341685,0.000022344571,0.00035034283],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99503726,0.000419994,0.0034703035,0.00023114913,0.00048575609,0.00035553146],"domain_scores_gemma":[0.9948903,0.0024931629,0.0014795925,0.0003861476,0.000541102,0.00020969931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037130471,0.00014023564,0.0013790093,0.00033215742,0.000027233853,0.0000037242016,0.00017050994,0.0005360782,0.000116796626],"category_scores_gemma":[0.0016004841,0.00010799563,0.00064009556,0.00046340527,0.00044107722,0.00011852623,0.00006530868,0.0008699745,0.000027853956],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034281086,0.011790539,0.12923823,0.0030214868,0.0033555687,0.011446695,0.00082639966,0.020822855,0.1941753,0.027861267,0.101676635,0.46150392],"study_design_scores_gemma":[0.19555597,0.034437966,0.6406954,0.0012770654,0.0010926229,0.0064688255,0.00021422432,0.03059791,0.009439366,0.018988486,0.060741786,0.0004903727],"about_ca_topic_score_codex":0.000712507,"about_ca_topic_score_gemma":0.0003988062,"teacher_disagreement_score":0.51145715,"about_ca_system_score_codex":0.08479803,"about_ca_system_score_gemma":0.12873906,"threshold_uncertainty_score":0.91871524},"labels":[],"label_agreement":null},{"id":"W3013949886","doi":"10.1055/s-0040-1703970","title":"Bilateral Sudden Sensorineural Hearing Loss in Waldenström’s Macroglobulinemia: Case Report and Review of the Literature","year":2019,"lang":"en","type":"article","venue":"Annals of Otology and Neurotology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Hearing loss; Sudden Hearing Loss; Audiology; Sensorineural hearing loss; Pediatrics","score_opus":0.04034484243358259,"score_gpt":0.360953641904652,"score_spread":0.3206087994710694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013949886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98069173,0.010132925,8.8055266e-8,0.00791839,0.00012548607,0.0008658054,0.000007696611,0.0000068771033,0.00025097857],"genre_scores_gemma":[0.9899725,0.0068014422,0.00002249432,0.0029420236,0.000027952185,0.000014771653,0.0000047546523,0.000010848266,0.00020322861],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99848413,0.00022445571,0.0005244236,0.0003431626,0.00012283387,0.0003009943],"domain_scores_gemma":[0.99885863,0.00028974877,0.00017701303,0.0004508747,0.00015439748,0.00006935572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003856915,0.00014208493,0.0006638024,0.00009178472,0.000023762683,0.000003065915,0.00008836839,0.00020999543,0.000035725483],"category_scores_gemma":[0.0005153799,0.00009577394,0.0000802681,0.00023542836,0.0004097163,0.000043922253,0.00021328621,0.0004457367,0.000001864796],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070872525,0.00009459745,0.7486,0.010921421,0.00007263956,0.23457748,0.00029905082,0.0000015369258,0.0027388434,0.0003349576,0.00073862093,0.0009121231],"study_design_scores_gemma":[0.0034419259,0.000421067,0.07021941,0.0031253095,0.000035131387,0.9135361,0.000018344956,0.00012537974,0.007948736,0.00009584086,0.0009325266,0.00010022831],"about_ca_topic_score_codex":0.00025568012,"about_ca_topic_score_gemma":0.000043340173,"teacher_disagreement_score":0.67895865,"about_ca_system_score_codex":0.000037549908,"about_ca_system_score_gemma":0.00038917016,"threshold_uncertainty_score":0.3905548},"labels":[],"label_agreement":null},{"id":"W3015876203","doi":"10.1080/16078454.2020.1749473","title":"Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment","year":2020,"lang":"en","type":"article","venue":"Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Leukemia; Internal medicine; Oncology; Cancer research; Immunology","score_opus":0.034018482027230824,"score_gpt":0.3052071261607171,"score_spread":0.27118864413348626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015876203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644744,0.0002575708,0.00007208143,0.0011901744,0.00008302417,0.0012529218,0.000013564698,0.00005814114,0.00062507886],"genre_scores_gemma":[0.9981186,0.000061620536,0.00021951123,0.00082372024,0.00006501702,0.00019834458,0.00004199428,0.000050211285,0.00042100626],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99776715,0.000085864944,0.0005304585,0.0005613861,0.0004245313,0.000630584],"domain_scores_gemma":[0.9985767,0.0002647866,0.00011287637,0.0005238975,0.00011871269,0.00040304786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084198924,0.00027238173,0.0009220465,0.00019522493,0.000029510036,0.000006439654,0.00018828022,0.00018352838,0.00026454913],"category_scores_gemma":[0.00030190797,0.00020685967,0.00008830143,0.0005479103,0.00017812951,0.00006596265,0.000117864045,0.0001384972,0.0002700832],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0815061,0.0027541718,0.63952047,0.022105718,0.0033487629,0.04369393,0.063390315,0.012147514,0.012927431,0.049859475,0.017443776,0.05130233],"study_design_scores_gemma":[0.5159641,0.04575969,0.050687633,0.0028691029,0.00063703983,0.002288853,0.0018497463,0.07132787,0.26190758,0.000107138505,0.044620104,0.0019811313],"about_ca_topic_score_codex":0.0033640221,"about_ca_topic_score_gemma":0.0012094463,"teacher_disagreement_score":0.58883286,"about_ca_system_score_codex":0.07436532,"about_ca_system_score_gemma":0.023791898,"threshold_uncertainty_score":0.9817423},"labels":[],"label_agreement":null},{"id":"W3016538158","doi":"10.1016/s0140-6736(20)30262-2","title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Obinutuzumab; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gastroenterology; Oncology; Leukemia; Cyclophosphamide; Chemotherapy","score_opus":0.10719131978790081,"score_gpt":0.37326921958529247,"score_spread":0.26607789979739166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016538158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774411,0.002043964,0.0002721774,0.0025324887,0.00031208532,0.015329891,0.0001529336,0.00026718283,0.0016481804],"genre_scores_gemma":[0.9879795,0.00097621686,0.00039404683,0.0009632415,0.0047415458,0.002695345,0.00010983671,0.00012774723,0.0020125546],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963879,0.0002234296,0.0006771117,0.0008509788,0.00069753046,0.0011630378],"domain_scores_gemma":[0.99572724,0.0022268833,0.00030088495,0.0009895345,0.00020526802,0.00055021665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066533044,0.0006216026,0.002734075,0.0000781299,0.0003180192,0.00015923979,0.0004489995,0.00022127717,0.00027004682],"category_scores_gemma":[0.0013690395,0.0003123292,0.0003237611,0.00039878848,0.0005688317,0.00014444254,0.000114771094,0.00028911183,0.00007855],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.98832566,0.00009084071,0.000006492772,0.0003645125,0.0015450147,0.0002224872,0.0013247518,0.00016123723,0.000625034,0.00012037372,0.0037962093,0.003417405],"study_design_scores_gemma":[0.8222634,0.023647184,0.000001232651,0.00015156952,0.0014293215,0.00023108129,0.00034513968,0.13311099,0.0016875583,0.000018688701,0.016786562,0.00032724254],"about_ca_topic_score_codex":0.0005934138,"about_ca_topic_score_gemma":0.00015667816,"teacher_disagreement_score":0.1660622,"about_ca_system_score_codex":0.055146493,"about_ca_system_score_gemma":0.04694984,"threshold_uncertainty_score":0.9999329},"labels":[],"label_agreement":null},{"id":"W3016691518","doi":"10.1096/fasebj.2020.34.s1.08716","title":"Phosphorylated Connexin 43 is Associated with Increased Susceptibility for Atrial Fibrillation in Mice Treated with a Single High Dose of Ibrutinib but not Acalabrutinib","year":2020,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Ibrutinib; Connexin; Atrial fibrillation; Pharmacology; Medicine; Bruton's tyrosine kinase; Internal medicine; Chemistry; Tyrosine kinase; Gap junction; Biochemistry; Receptor","score_opus":0.03837297810425275,"score_gpt":0.2821977376275045,"score_spread":0.24382475952325175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016691518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654907,0.00011018622,0.000081482736,0.0015740016,0.000030595605,0.0013689043,0.00016129228,0.00004528709,0.000079159676],"genre_scores_gemma":[0.99880934,0.000019854579,0.00028294302,0.00033448252,0.0003019989,0.00000544778,0.00010538425,0.00005017873,0.00009037951],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99722314,0.00035868757,0.00072510145,0.0003651761,0.0007908641,0.00053700374],"domain_scores_gemma":[0.9970028,0.0012288279,0.0005351492,0.00029123574,0.00060527265,0.00033673225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012892898,0.0002710359,0.0007224544,0.00011465553,0.00014739556,0.000050637012,0.00021943203,0.0001917878,0.0002535989],"category_scores_gemma":[0.0017653765,0.00016264858,0.00019255305,0.0008132769,0.00031643448,0.00012041405,0.000050370454,0.00052788417,0.000007401083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20891571,0.00047006796,0.047943156,0.00029497241,0.001850662,0.0005453798,0.0043804934,0.002578457,0.7302935,0.00003727734,0.00076258753,0.0019277375],"study_design_scores_gemma":[0.1592631,0.008404504,0.022506474,0.00077046506,0.00078320946,0.00056176656,0.0009337897,0.04969632,0.7565858,0.000047603135,0.0000607143,0.00038625515],"about_ca_topic_score_codex":0.0018928266,"about_ca_topic_score_gemma":0.00019671506,"teacher_disagreement_score":0.049652614,"about_ca_system_score_codex":0.0035707203,"about_ca_system_score_gemma":0.004434203,"threshold_uncertainty_score":0.93373096},"labels":[],"label_agreement":null},{"id":"W3016845921","doi":"10.1182/blood.v110.11.3553.3553","title":"A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF).","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chills; Nausea; Anemia; Internal medicine; Peripheral edema; Erythropoietin; Adverse effect; Gastroenterology; Rash","score_opus":0.01368548042332383,"score_gpt":0.2639499997712481,"score_spread":0.25026451934792426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016845921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351984,0.0008778694,0.00005884984,0.00016921062,0.00036751348,0.0042670756,0.000104285275,0.00008516071,0.0005501846],"genre_scores_gemma":[0.9978411,0.000045725963,0.00017748066,0.00032043413,0.00037946439,0.00015377263,0.000056662488,0.00010194695,0.00092339574],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955858,0.00018177013,0.0010429298,0.00072754815,0.0014790692,0.0009828745],"domain_scores_gemma":[0.9973135,0.00016114215,0.0004080081,0.0011965154,0.00043176394,0.00048906775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087110314,0.0004641619,0.0008911367,0.0002255901,0.00022378395,0.000041177384,0.0004840455,0.00033397332,0.000026667662],"category_scores_gemma":[0.0005041937,0.00031590927,0.0002706364,0.0008479225,0.0002510395,0.000090531874,0.0005228849,0.00049652846,0.000033687917],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21689558,0.03846373,0.003472037,0.0013330863,0.0011250746,0.0004808891,0.0031385012,0.0000037042084,0.6955983,0.000026313877,0.00398146,0.035481323],"study_design_scores_gemma":[0.68938154,0.04250898,0.0023431303,0.001668431,0.0006220263,0.000067198955,0.0001345827,0.000096611424,0.259896,0.000006362733,0.0027676425,0.0005074623],"about_ca_topic_score_codex":0.00068765145,"about_ca_topic_score_gemma":0.00024550437,"teacher_disagreement_score":0.472486,"about_ca_system_score_codex":0.0031112046,"about_ca_system_score_gemma":0.0067283357,"threshold_uncertainty_score":0.9999293},"labels":[],"label_agreement":null},{"id":"W3017752412","doi":"10.1093/rheumatology/keaa110.008","title":"O09 Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Rheumatoid arthritis; Internal medicine; Surgery","score_opus":0.07523140364624066,"score_gpt":0.3863672624073214,"score_spread":0.31113585876108074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017752412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724084,0.0008562346,0.0000515823,0.0006907354,0.000037956943,0.00049086724,0.00013586962,0.00003210764,0.00046380566],"genre_scores_gemma":[0.9982878,0.00008218206,0.0007020774,0.00047371292,0.00009794744,0.000012570264,0.00020884324,0.000024405137,0.00011045369],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99829954,0.00008021226,0.00040812892,0.00033625192,0.0005936294,0.0002822265],"domain_scores_gemma":[0.99892443,0.0002550103,0.0001083216,0.00034436374,0.00019909859,0.00016878817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013054702,0.000164121,0.0006520532,0.00008809715,0.000027768523,0.0000074668733,0.00015121145,0.00006693095,0.00023871481],"category_scores_gemma":[0.0005917793,0.00011872415,0.00007413335,0.0004989628,0.00013875116,0.000075371965,0.00012578347,0.000196853,0.00003545423],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.107310675,0.009897735,0.7224565,0.0032973448,0.013037578,0.0028120226,0.040052243,0.0015605204,0.035470445,0.0001718299,0.023082057,0.040851012],"study_design_scores_gemma":[0.61204445,0.010297982,0.2842381,0.00202717,0.0018946524,0.00000978513,0.0045626857,0.020962918,0.0535648,0.00015423248,0.009155418,0.001087829],"about_ca_topic_score_codex":0.0006058894,"about_ca_topic_score_gemma":0.00006952549,"teacher_disagreement_score":0.50473374,"about_ca_system_score_codex":0.001411901,"about_ca_system_score_gemma":0.0010852963,"threshold_uncertainty_score":0.48414302},"labels":[],"label_agreement":null},{"id":"W3018868482","doi":"10.1182/bloodadvances.2020001726","title":"Bendamustine-induced immune hemolytic anemia: a case report and systematic review of the literature","year":2020,"lang":"en","type":"review","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Bendamustine; Autoimmune hemolytic anemia; Medicine; Immunosuppression; Hemolytic anemia; Fludarabine; Anemia; Immunology; Internal medicine; Chemotherapy; Rituximab; Antibody; Cyclophosphamide","score_opus":0.023774130815769654,"score_gpt":0.3495339668743425,"score_spread":0.32575983605857284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018868482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040870003,0.9937954,5.5695637e-7,0.00017864179,0.00015718509,0.005429347,0.000049583825,0.00003972602,0.00030870704],"genre_scores_gemma":[0.000094950396,0.9981901,0.00013724,0.00013125731,0.000197591,0.00032092322,0.000062166306,0.00007176992,0.0007940124],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9959662,0.0003392951,0.001932846,0.0006614576,0.0007492864,0.00035092796],"domain_scores_gemma":[0.9959632,0.00056633604,0.0014423073,0.0015483747,0.00026605872,0.00021370478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007338254,0.00055929984,0.004934384,0.00010890567,0.000087086984,0.00003301279,0.00036422143,0.00029143278,0.000018569515],"category_scores_gemma":[0.0047964193,0.00029157454,0.00075202907,0.0011963281,0.00014117488,0.00009157051,0.00033789745,0.000933614,0.0000080629625],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004287116,0.0000452354,1.6364152e-7,0.86327446,0.000301918,0.121215284,0.000055798984,1.0076929e-8,0.0000021557423,0.000011007761,0.000035146128,0.015054549],"study_design_scores_gemma":[0.0008391313,0.000069438844,3.389711e-8,0.5428089,0.007393613,0.41390973,0.000019792082,0.000001877248,0.000016024405,0.0000026418138,0.03480404,0.00013481012],"about_ca_topic_score_codex":0.000023679162,"about_ca_topic_score_gemma":0.0000033343035,"teacher_disagreement_score":0.3204656,"about_ca_system_score_codex":0.0010236733,"about_ca_system_score_gemma":0.006181772,"threshold_uncertainty_score":0.9999536},"labels":[],"label_agreement":null},{"id":"W3019499149","doi":"10.1093/rheumatology/keaa111.204","title":"P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Rheumatoid arthritis; Discontinuation; Adverse effect; Internal medicine; Methotrexate; Clinical trial; Phases of clinical research; Safety profile; Gastroenterology; Pharmacology","score_opus":0.04914932440058782,"score_gpt":0.35687391637486554,"score_spread":0.3077245919742777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019499149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992092,0.0017721041,0.000599652,0.0030001325,0.000050847215,0.0012658193,0.0002883342,0.00010366546,0.0008274429],"genre_scores_gemma":[0.9954867,0.0011688097,0.0014040179,0.0007168772,0.00017424313,0.00007980347,0.00085091364,0.00003454566,0.00008410554],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99659777,0.00043911109,0.0011755436,0.0005765208,0.0006569026,0.0005541377],"domain_scores_gemma":[0.9977175,0.00088489277,0.00020639639,0.00063151435,0.00022137086,0.00033829792],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001140264,0.00022509442,0.0010452721,0.000113001166,0.000051966337,0.000036080823,0.00038207692,0.00021467717,0.001093563],"category_scores_gemma":[0.0022915592,0.00015584806,0.00039512725,0.0024632772,0.00029864258,0.00007661796,0.00014476727,0.0007740013,0.00011579622],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024269333,0.005799408,0.33151582,0.00039918013,0.009834832,0.0021382908,0.009493058,0.0001377191,0.004915606,0.0005122265,0.020441113,0.5905434],"study_design_scores_gemma":[0.26836982,0.0061627715,0.07649662,0.001826987,0.0016753778,0.00014511179,0.005272884,0.48145607,0.012920121,0.00022965691,0.14416094,0.0012836155],"about_ca_topic_score_codex":0.003688319,"about_ca_topic_score_gemma":0.0008746139,"teacher_disagreement_score":0.5892598,"about_ca_system_score_codex":0.0011055312,"about_ca_system_score_gemma":0.004119167,"threshold_uncertainty_score":0.9998196},"labels":[],"label_agreement":null},{"id":"W3019770355","doi":"10.1093/rheumatology/keaa111.205","title":"P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Clinical endpoint; Adverse effect; Adalimumab; Methotrexate; Placebo; Clinical trial; Gastroenterology; Surgery","score_opus":0.0312903499562968,"score_gpt":0.3111833690485898,"score_spread":0.27989301909229297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019770355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911238,0.0000497955,0.0006198771,0.0048293723,0.00003015159,0.0024580273,0.00029864302,0.000057743895,0.00053259585],"genre_scores_gemma":[0.97986615,0.0000125481265,0.017080462,0.001538802,0.00007868653,0.0000715307,0.00020122714,0.000073477706,0.0010771335],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976092,0.0001498741,0.00054909027,0.0005684449,0.00066523184,0.00045816228],"domain_scores_gemma":[0.9970726,0.0014624498,0.00016686354,0.00053240696,0.0002941211,0.00047159873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008303993,0.00024614503,0.00067061104,0.000115044364,0.00007028787,0.000020229565,0.00019382146,0.000108321285,0.000019695552],"category_scores_gemma":[0.0024951512,0.00017055485,0.00005697442,0.000475753,0.00014055865,0.000084314976,0.00017470721,0.00022893953,0.000015618552],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9477179,0.00069160195,0.01639077,0.0018195894,0.00054831937,0.00028102004,0.0055055744,0.00020516304,0.0030419629,0.00006283453,0.0049039638,0.018831301],"study_design_scores_gemma":[0.35583505,0.025794681,0.53708476,0.0009948601,0.00050777214,0.0000591593,0.00022131912,0.002153596,0.005346417,0.000013156621,0.07117519,0.0008140162],"about_ca_topic_score_codex":0.00008410381,"about_ca_topic_score_gemma":0.000012668606,"teacher_disagreement_score":0.5918828,"about_ca_system_score_codex":0.0012504992,"about_ca_system_score_gemma":0.0018775989,"threshold_uncertainty_score":0.6955025},"labels":[],"label_agreement":null},{"id":"W3021624220","doi":"10.1002/ajh.25851","title":"Management of <scp>CLL</scp> patients early in the <scp>COVID</scp>‐19 pandemic: An international survey of <scp>CLL</scp> experts","year":2020,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genentech; National Institutes of Health; National Cancer Institute; Gilead Sciences","keywords":"Medicine; Discontinuation; Pandemic; Immunosenescence; Immunology; Chronic lymphocytic leukemia; Intensive care medicine; Internal medicine; Disease; Coronavirus disease 2019 (COVID-19); Leukemia; Immune system","score_opus":0.05015140238158752,"score_gpt":0.3411833603282778,"score_spread":0.29103195794669023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021624220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606925,0.00052463834,0.00059484545,0.000245345,0.00027867526,0.00054714817,0.000044845325,0.000022645123,0.0016726189],"genre_scores_gemma":[0.99682516,0.00058563106,0.000892924,0.0013006952,0.000131223,0.000022812192,0.000050842944,0.000060874507,0.00012986556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939728,0.0011467468,0.0018320697,0.0005343047,0.0017088549,0.00080521876],"domain_scores_gemma":[0.9921098,0.0040119127,0.0017644854,0.00066428963,0.00083790993,0.00061160413],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019915327,0.00039201567,0.0015275278,0.0005421112,0.00006347323,0.00003243203,0.0014721397,0.00017178117,0.000028853841],"category_scores_gemma":[0.005262591,0.00029462538,0.00028519536,0.0011397983,0.0009574029,0.0002826211,0.00036019424,0.0007389953,0.00002173232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015107448,0.0010369027,0.9701098,0.00031234545,0.0008601242,0.0014052364,0.014194546,0.000099966055,0.00038683641,0.00042707767,0.007247154,0.0037688971],"study_design_scores_gemma":[0.03259415,0.0091327485,0.89702183,0.00069732184,0.00035900477,0.0045664017,0.039138556,0.0021115234,0.0016981128,0.00034855757,0.012212901,0.00011890801],"about_ca_topic_score_codex":0.0016249939,"about_ca_topic_score_gemma":0.00009093514,"teacher_disagreement_score":0.07308803,"about_ca_system_score_codex":0.0015770801,"about_ca_system_score_gemma":0.0020804617,"threshold_uncertainty_score":0.9999506},"labels":[],"label_agreement":null},{"id":"W3022359034","doi":"10.1002/hon.2437_133","title":"IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Mantle cell lymphoma; Temsirolimus; Refractory (planetary science); Ibrutinib; Progression-free survival; Gastroenterology; Phases of clinical research; Neutropenia; Tolerability; Toxicity; Surgery; Adverse effect; Lymphoma; Chemotherapy; Leukemia","score_opus":0.06600161204894871,"score_gpt":0.3834560218168101,"score_spread":0.3174544097678614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022359034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841034,0.00014588983,0.00006579013,0.0009912435,0.00028055764,0.005293955,0.000056925288,0.00004406146,0.009018178],"genre_scores_gemma":[0.9976208,0.0000815401,0.0005879513,0.00030555387,0.00008879159,0.00042766458,0.000119360215,0.00003483535,0.00073345454],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967495,0.00054655486,0.0008335612,0.0006533283,0.0007100745,0.0005069343],"domain_scores_gemma":[0.99510485,0.0021939664,0.0007547239,0.0013327642,0.0003938552,0.00021981812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010922628,0.0003208357,0.0018905007,0.00006620314,0.00029570982,0.00010195412,0.0016497385,0.00028968006,0.0008116254],"category_scores_gemma":[0.0018227638,0.00015933481,0.00016556714,0.000109379784,0.0010063209,0.00014707026,0.001010556,0.00026151305,0.00013200649],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67617923,0.03393851,0.27226767,0.00009490934,0.0018421058,0.0015609391,0.0013907665,0.0000015225902,0.00010190149,0.0005688004,0.006256857,0.0057967617],"study_design_scores_gemma":[0.972795,0.0067372834,0.014968602,0.000114620954,0.00056108,0.00005203043,0.00030495264,0.0010252829,0.0003941544,0.00024796426,0.0025953092,0.0002037355],"about_ca_topic_score_codex":0.0019608978,"about_ca_topic_score_gemma":0.00039851197,"teacher_disagreement_score":0.29661572,"about_ca_system_score_codex":0.0016569074,"about_ca_system_score_gemma":0.0018796714,"threshold_uncertainty_score":0.8886729},"labels":[],"label_agreement":null},{"id":"W3022709841","doi":"10.1097/md.0000000000020106","title":"Extranodal NK/T cell lymphoma and lymphomatoid granulomatosis in a patient with chronic lymphocytic leukaemia","year":2020,"lang":"en","type":"article","venue":"Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lymphomatoid granulomatosis; Lymphoma; Lymphoproliferative disorders; Immunosuppression; Chronic lymphocytic leukemia; Aggressive lymphoma; Immunology; Leukemia; T-cell lymphoma; Pathology; Rituximab","score_opus":0.013887353523457267,"score_gpt":0.24092580880588088,"score_spread":0.2270384552824236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022709841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98156047,0.009075377,0.00014451458,0.003705874,0.00008431478,0.0011335977,0.0000069800467,0.00016745049,0.004121416],"genre_scores_gemma":[0.99496067,0.0011547726,0.00032383582,0.0027907572,0.000353551,0.000115189345,0.00003724593,0.00010446407,0.00015950936],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961154,0.00010830246,0.0007377681,0.00091534987,0.0011924668,0.00093071355],"domain_scores_gemma":[0.9979474,0.00023707227,0.00014720245,0.00058819284,0.00012060827,0.0009595114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028037,0.00051061803,0.0010531557,0.0003312044,0.00009959548,0.000025115134,0.00023651392,0.00020505252,0.00032661],"category_scores_gemma":[0.00019871628,0.00036478924,0.000079598285,0.0011288027,0.0006652474,0.00013956615,0.0001574295,0.00024004282,0.00010407149],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04055159,0.0032861661,0.08251323,0.038718294,0.0014828603,0.12092552,0.080560684,0.0012734273,0.18266185,0.0016206346,0.04470913,0.40169662],"study_design_scores_gemma":[0.60792035,0.022323499,0.021795793,0.0074395267,0.00088950427,0.023808021,0.0046996465,0.19785626,0.06695191,0.00014624359,0.043847464,0.0023217744],"about_ca_topic_score_codex":0.0023605837,"about_ca_topic_score_gemma":0.00020368956,"teacher_disagreement_score":0.56736875,"about_ca_system_score_codex":0.021413049,"about_ca_system_score_gemma":0.010947741,"threshold_uncertainty_score":0.99988043},"labels":[],"label_agreement":null},{"id":"W3022990851","doi":"10.1182/blood.v120.21.1603.1603","title":"Elevated Risk of Venous but Not Arterial Thrombosis in Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Venous thrombosis; Hyperviscosity syndrome; Internal medicine; Population; Thrombosis; Waldenstrom macroglobulinemia; Macroglobulinemia; Pulmonary embolism; Monoclonal gammopathy of undetermined significance; Surgery; Multiple myeloma; Lymphoma; Immunology; Monoclonal","score_opus":0.016331595068018234,"score_gpt":0.2706823743605549,"score_spread":0.2543507792925367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022990851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982288,0.00052400056,0.0000047691146,0.000056531193,0.00017613122,0.00045546298,0.00006154859,0.000049140614,0.0004436437],"genre_scores_gemma":[0.99830127,0.00042914881,0.0006994624,0.00006170669,0.00031978285,0.000027677243,0.000023539667,0.000044645316,0.00009274933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978142,0.00011010744,0.00050619984,0.00032467395,0.0005006291,0.00074423215],"domain_scores_gemma":[0.9987287,0.00022913924,0.00015259653,0.00048427383,0.00008990047,0.0003154257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046713246,0.00023840643,0.00061909354,0.00019413634,0.00005195413,0.00001757333,0.00013701597,0.00021157677,0.000106803265],"category_scores_gemma":[0.00040515926,0.00021401736,0.000093844195,0.00032924034,0.00022317983,0.00010768825,0.00014172765,0.00014563104,0.000064505126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040748892,0.015872834,0.3262014,0.0016990681,0.0016889415,0.0008108105,0.004344587,0.000013058287,0.6247852,0.00022567804,0.00046196245,0.019821564],"study_design_scores_gemma":[0.15044151,0.0007664326,0.40143713,0.00034869704,0.0009946693,0.0024025687,0.0003205164,0.0017772131,0.44074255,0.000047080888,0.00029815166,0.00042344496],"about_ca_topic_score_codex":0.0020836645,"about_ca_topic_score_gemma":0.000049902,"teacher_disagreement_score":0.18404265,"about_ca_system_score_codex":0.0020939503,"about_ca_system_score_gemma":0.002060689,"threshold_uncertainty_score":0.87273747},"labels":[],"label_agreement":null},{"id":"W3023432596","doi":"10.1007/s11864-020-00746-8","title":"PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma","year":2020,"lang":"en","type":"review","venue":"Current Treatment Options in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Idelalisib; Medicine; PI3K/AKT/mTOR pathway; Adverse effect; Lymphoma; Clinical trial; Targeted therapy; Oncology; Cancer research; Pharmacology; Immunology; Internal medicine; Cancer; Signal transduction; Chronic lymphocytic leukemia; Ibrutinib; Leukemia; Biology","score_opus":0.14918485012211347,"score_gpt":0.45621544531539787,"score_spread":0.3070305951932844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023432596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029414773,0.9897822,0.000015148379,0.00021693211,0.00060757395,0.005862923,0.00019704446,0.00004780414,0.0003288548],"genre_scores_gemma":[0.0006075806,0.99283355,0.00028461916,0.00003827111,0.0003525121,0.004600289,0.0009922201,0.00008350552,0.00020747492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972677,0.00021603484,0.00086835836,0.0008611419,0.00018078276,0.0006059547],"domain_scores_gemma":[0.99827754,0.0007569217,0.00021839772,0.00042555403,0.00006363438,0.00025793735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024068519,0.0006225941,0.0023395559,0.00069537567,0.00007198426,0.00002270042,0.00018951109,0.00052670256,0.00006340367],"category_scores_gemma":[0.00017193037,0.0004319945,0.00043978472,0.0006732567,0.00017945649,0.00005208206,0.00012581047,0.00030537284,0.00006160507],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00019236386,0.0030973307,0.000025350537,0.0016185661,0.00031080542,0.00008107679,0.00059095584,0.0000022386262,0.000004439401,0.0002144403,0.00028389983,0.99357855],"study_design_scores_gemma":[0.03123294,0.0033091714,0.000028634988,0.0030453373,0.00024050301,0.0003033998,0.00014597445,0.00061917846,0.000009348746,0.000081556966,0.9607106,0.00027336497],"about_ca_topic_score_codex":0.00019268978,"about_ca_topic_score_gemma":0.00010135766,"teacher_disagreement_score":0.99330515,"about_ca_system_score_codex":0.04366191,"about_ca_system_score_gemma":0.0151195675,"threshold_uncertainty_score":0.9998132},"labels":[],"label_agreement":null},{"id":"W3025515234","doi":"10.1038/s41416-020-0887-6","title":"UGT2B17 modifies drug response in chronic lymphocytic leukaemia","year":2020,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; March of Dimes Canada; Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Chronic lymphocytic leukemia; Drug; Medicine; Drug response; Immunology; Leukemia; Cancer research; Pharmacology","score_opus":0.02609349524528102,"score_gpt":0.3257147506949732,"score_spread":0.29962125544969215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025515234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94568497,0.05079399,0.000038741604,0.002547452,0.00018049934,0.0002247404,0.000011393902,0.000019098043,0.00049912825],"genre_scores_gemma":[0.9884666,0.00819371,0.00013668365,0.0012422554,0.0009831198,0.000014432759,0.0000014329848,0.000043698707,0.00091804384],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975375,0.00018844692,0.00070307794,0.00023942473,0.0008587481,0.00047283628],"domain_scores_gemma":[0.99864405,0.00021984591,0.00022419979,0.00016513013,0.0002970601,0.00044970895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007938955,0.00015501092,0.0005787367,0.00016521502,0.000051617968,0.00007388847,0.00029090772,0.000101605176,0.0006073569],"category_scores_gemma":[0.0008683194,0.00016553579,0.00019680362,0.00047115234,0.00016217919,0.00022548184,0.00008450368,0.0006366253,0.000036628364],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09930284,0.00038114167,0.0058774147,0.0040478916,0.0014435607,0.16636592,0.0089823445,0.06324679,0.07757559,0.00010654802,0.18797478,0.38469517],"study_design_scores_gemma":[0.31768852,0.005436089,0.07349578,0.021388723,0.00077018014,0.073649086,0.0023567693,0.157898,0.0512186,0.0004602988,0.29374322,0.0018947413],"about_ca_topic_score_codex":0.0031691915,"about_ca_topic_score_gemma":0.00077236426,"teacher_disagreement_score":0.38280043,"about_ca_system_score_codex":0.0649833,"about_ca_system_score_gemma":0.057086796,"threshold_uncertainty_score":0.94825864},"labels":[],"label_agreement":null},{"id":"W3026914868","doi":"10.1111/j.1365-2370.2001.00239.x","title":"A new coding region polymorphism of human IgLC2","year":2001,"lang":"en","type":"article","venue":"European Journal of Immunogenetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Allele; Biology; Genetics; Gene; Coding region; Restriction fragment length polymorphism; Allele frequency; Molecular biology; Genotype","score_opus":0.04632246537658568,"score_gpt":0.3028316069766973,"score_spread":0.2565091416001116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026914868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781612,0.0053918813,0.003132294,0.0003216899,0.00020354397,0.00011290229,5.7243557e-7,0.000011883454,0.012663996],"genre_scores_gemma":[0.9918213,0.0015880653,0.0027469674,0.00009197416,0.00059582375,9.196737e-8,0.0000015997258,0.000055920777,0.0030982543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980086,0.00020887557,0.0008190488,0.00011741919,0.00056948594,0.0002765343],"domain_scores_gemma":[0.99847686,0.000052599604,0.0004888459,0.00041862103,0.00031289746,0.0002501859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007042986,0.00014159318,0.00036149894,0.00024323081,0.000057662834,0.000020516654,0.00034852402,0.000033655713,0.00015346565],"category_scores_gemma":[0.00016454652,0.00011985748,0.00020913307,0.00026795184,0.000109953726,0.000049967024,0.00010968781,0.00030896364,0.000034215576],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016502816,0.0002879546,0.004081878,0.00014634692,0.00057644764,0.014360576,0.001815009,0.0000904842,0.8850532,0.0002950764,0.015171446,0.07647131],"study_design_scores_gemma":[0.15182905,0.0213509,0.12502638,0.0070924642,0.0015305243,0.15175802,0.0016378147,0.00077750935,0.40095463,0.00034616774,0.13639803,0.0012985273],"about_ca_topic_score_codex":0.000039561142,"about_ca_topic_score_gemma":9.552134e-7,"teacher_disagreement_score":0.48409855,"about_ca_system_score_codex":0.0011401302,"about_ca_system_score_gemma":0.0017710448,"threshold_uncertainty_score":0.4887646},"labels":[],"label_agreement":null},{"id":"W3027285142","doi":"10.1016/j.jval.2020.04.1806","title":"PCN350 USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF CANADIANS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; AstraZeneca (Canada); Sunnybrook Hospital","funders":"","keywords":"Medicine; Activity-based costing; Chronic lymphocytic leukemia; Cohort; Total cost; Cancer; Cancer registry; Health care; Cost driver; Emergency medicine; Family medicine; Pediatrics; Leukemia; Internal medicine","score_opus":0.1461978433614025,"score_gpt":0.36675676022454073,"score_spread":0.22055891686313822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027285142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004984,0.001639472,0.00033373365,0.003990389,0.00014729415,0.0032028672,0.00023705058,0.00012989053,0.00026943936],"genre_scores_gemma":[0.9931084,0.00036227278,0.0030827788,0.0027265947,0.00040345176,0.00003799156,0.00012011394,0.00010342364,0.000054975633],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9950557,0.00044889256,0.0012139304,0.00095657905,0.0009516687,0.0013732642],"domain_scores_gemma":[0.9954219,0.0005037507,0.00041002518,0.0015556329,0.000117562944,0.0019911565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014545352,0.0003296085,0.0012976179,0.00052378693,0.000121633835,0.000024801087,0.00065552903,0.00007590245,0.000016881053],"category_scores_gemma":[0.00033945355,0.00029938426,0.000051153842,0.0022398618,0.0001590963,0.00012135928,0.00028875784,0.00039231597,0.000027531585],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00973373,0.00041017667,0.050780844,0.08600543,0.00076272566,0.0131594185,0.023399938,0.70682895,0.0013704976,0.002884086,0.02113767,0.083526544],"study_design_scores_gemma":[0.016733782,0.0025985173,0.0021723504,0.0074314335,0.000033465873,0.00033888462,0.0007844776,0.9680558,0.00010042291,8.189402e-7,0.0014653387,0.0002847508],"about_ca_topic_score_codex":0.91810703,"about_ca_topic_score_gemma":0.4170685,"teacher_disagreement_score":0.50103855,"about_ca_system_score_codex":0.39970753,"about_ca_system_score_gemma":0.28504586,"threshold_uncertainty_score":0.9999458},"labels":[],"label_agreement":null},{"id":"W3028905201","doi":"10.1200/jco.2020.38.15_suppl.8015","title":"Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Medicine; Lenalidomide; Bendamustine; Internal medicine; Chronic lymphocytic leukemia; Hazard ratio; Progression-free survival; Gastroenterology; Rituximab; Oncology; Leukemia; Multiple myeloma; Overall survival; Confidence interval; Lymphoma","score_opus":0.27551387914436715,"score_gpt":0.48009032939852325,"score_spread":0.2045764502541561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028905201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95404404,0.0049558887,0.00030660068,0.020189682,0.0054254658,0.0015667343,0.000112100926,0.00016808865,0.013231369],"genre_scores_gemma":[0.97936887,0.0038086034,0.0028601498,0.004361996,0.0077725225,0.000026440146,0.000053674376,0.00015804594,0.0015896913],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98423696,0.0014121274,0.0088167135,0.0013131805,0.0024509302,0.0017700834],"domain_scores_gemma":[0.9779923,0.013581104,0.0037296175,0.0010358606,0.0011075846,0.0025535522],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007824249,0.00079571485,0.005623849,0.00058520865,0.00016188847,0.000065637985,0.0014206691,0.002151517,0.0012047909],"category_scores_gemma":[0.05309672,0.00061083265,0.0013606737,0.0013982719,0.0013248132,0.00044924713,0.0007183953,0.0068529607,0.0006985156],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6664007,0.00388743,0.00026184812,0.0012419767,0.0019101133,0.06312366,0.0012527201,0.007606831,0.00053414464,0.00031736397,0.14926651,0.10419674],"study_design_scores_gemma":[0.6372179,0.051143706,0.0018870115,0.0008954628,0.0009104201,0.0032550264,0.00046332742,0.09245481,0.00018353501,0.00008706217,0.21086143,0.000640335],"about_ca_topic_score_codex":0.0008658443,"about_ca_topic_score_gemma":0.0006628822,"teacher_disagreement_score":0.1397502,"about_ca_system_score_codex":0.1620735,"about_ca_system_score_gemma":0.30182368,"threshold_uncertainty_score":0.99970824},"labels":[],"label_agreement":null},{"id":"W3029558579","doi":"10.3747/co.27.6291","title":"Updates from the American Society of Hematology 2019 Annual Meeting: Practice-Changing Studies in Treatment-Naïve Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Impact; Fluidigm (Canada); University of Manitoba; Southlake Regional Health Center; CancerCare Manitoba","funders":"Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; Research Manitoba; Gilead Sciences; Canadian Institutes of Health Research; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Celgene; AstraZeneca; Amgen","keywords":"Medicine; Chronic lymphocytic leukemia; Hematology; Hematologic Neoplasms; Internal medicine; Leukemia; Immunology; Cancer","score_opus":0.1602645493577104,"score_gpt":0.46091015654360157,"score_spread":0.3006456071858912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029558579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92991745,0.057374574,0.000048447335,0.010817236,0.00047081418,0.00093434885,0.00007749399,0.00008028325,0.0002793339],"genre_scores_gemma":[0.9730903,0.02316415,0.0007555887,0.0016537553,0.0009705831,0.00013998972,0.00010849991,0.000049180067,0.000067956484],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971388,0.0004538555,0.00066295284,0.0006031938,0.0003764235,0.00076478114],"domain_scores_gemma":[0.99481124,0.0037713721,0.0005171208,0.00043307422,0.00028255244,0.00018464729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049529324,0.00031434806,0.0012679674,0.00010010295,0.00009697033,0.0000083992,0.00030024015,0.0001292879,0.00004582441],"category_scores_gemma":[0.0013612211,0.00021551122,0.0002501227,0.0008038843,0.0012205279,0.000107942156,0.00039681297,0.00041279936,0.00008830553],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010610128,0.002173334,0.028447581,0.0030384704,0.009078386,0.002184193,0.23732969,0.0028148363,0.008012203,0.0014518857,0.3708729,0.32398638],"study_design_scores_gemma":[0.0894377,0.014616681,0.0013326564,0.00141913,0.0019481814,0.0011556129,0.16429147,0.14554675,0.010733334,0.00025563076,0.5683142,0.0009486489],"about_ca_topic_score_codex":0.0022510746,"about_ca_topic_score_gemma":0.00019766077,"teacher_disagreement_score":0.32303774,"about_ca_system_score_codex":0.08653319,"about_ca_system_score_gemma":0.02527827,"threshold_uncertainty_score":0.9802475},"labels":[],"label_agreement":null},{"id":"W3029637120","doi":"10.1200/jco.19.03355","title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Idelalisib; Medicine; Rituximab; Chronic lymphocytic leukemia; Refractory (planetary science); Internal medicine; Oncology; Leukemia; Lymphoma; Ibrutinib","score_opus":0.20716221785901862,"score_gpt":0.5057558719860992,"score_spread":0.29859365412708055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029637120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823403,0.0021258502,0.00035309378,0.004787802,0.004361278,0.00328856,0.000028401666,0.00006474442,0.002649967],"genre_scores_gemma":[0.98460144,0.00417642,0.0022279834,0.0017643131,0.0061239447,0.00006143848,0.000027447013,0.00010812337,0.0009089108],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9821843,0.0026703896,0.011051755,0.00084651704,0.0021144105,0.0011326628],"domain_scores_gemma":[0.96049565,0.030420212,0.0056058723,0.00079825387,0.001028312,0.001651676],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.013952238,0.00061666075,0.010772885,0.0005521682,0.000081132464,0.00002834777,0.0010057942,0.0016473397,0.0023676127],"category_scores_gemma":[0.09644115,0.00039920598,0.0019454845,0.0011102173,0.0015462115,0.00028352594,0.0004001073,0.0040311823,0.00011011053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9460105,0.003717092,0.0000018477683,0.00041215995,0.0013402357,0.010913195,0.00048636264,0.00063049264,0.00018378094,0.000055709457,0.008368178,0.027880482],"study_design_scores_gemma":[0.81852615,0.07638508,0.000006056435,0.0005387063,0.0015338763,0.0007524462,0.0002826987,0.080244265,0.00019025632,0.00003618706,0.021197991,0.00030631092],"about_ca_topic_score_codex":0.00086356443,"about_ca_topic_score_gemma":0.00029411938,"teacher_disagreement_score":0.25970903,"about_ca_system_score_codex":0.09414819,"about_ca_system_score_gemma":0.35385722,"threshold_uncertainty_score":0.999846},"labels":[],"label_agreement":null},{"id":"W3030076241","doi":"10.1200/jco.2020.38.15_suppl.e20011","title":"Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"AbbVie","keywords":"Neutropenia; Medicine; Internal medicine; Febrile neutropenia; Venetoclax; Absolute neutrophil count; Chronic lymphocytic leukemia; Gastroenterology; Leukemia; Chemotherapy","score_opus":0.25492279895530584,"score_gpt":0.5023426091357484,"score_spread":0.2474198101804425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030076241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964289,0.0016563706,0.00008322983,0.0009017157,0.0002067179,0.0005659088,0.0000864121,0.000008979588,0.000061736326],"genre_scores_gemma":[0.994249,0.0023886934,0.0011402591,0.0012558242,0.00075814116,0.0000047912163,0.000116676514,0.000038064616,0.00004858374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923229,0.0014487305,0.0044368613,0.0005673918,0.00086153415,0.00036254182],"domain_scores_gemma":[0.98783714,0.0068741506,0.0033603648,0.000807499,0.00042579763,0.00069506565],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0050477143,0.00025335295,0.0047057234,0.00040006262,0.000040241903,0.000014015062,0.00067887397,0.0005553106,0.0004959114],"category_scores_gemma":[0.010968154,0.00015600852,0.0004094569,0.0010665543,0.00036734168,0.00026420556,0.00032028623,0.001256029,0.0000061894693],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.72695136,0.004108296,0.043449614,0.00026097827,0.026993493,0.0040684226,0.0011907045,0.0036355825,0.0015278753,0.0000110262135,0.0064821546,0.18132047],"study_design_scores_gemma":[0.59958893,0.102927625,0.10353546,0.00036535942,0.011880316,0.00003803566,0.000112427995,0.16419682,0.000115130904,0.000023131008,0.016923008,0.0002937712],"about_ca_topic_score_codex":0.00082016416,"about_ca_topic_score_gemma":0.0004928896,"teacher_disagreement_score":0.18102671,"about_ca_system_score_codex":0.026613126,"about_ca_system_score_gemma":0.10399363,"threshold_uncertainty_score":0.99736285},"labels":[],"label_agreement":null},{"id":"W3031038545","doi":"10.1200/jco.2020.38.15_suppl.e20004","title":"Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"National Institutes of Health","keywords":"Medicine; Bendamustine; Interquartile range; Internal medicine; Discontinuation; Adverse effect; Gastroenterology; Rituximab; Tolerability; Chronic lymphocytic leukemia; IGHV@; Toxicity; Leukemia; Lymphoma","score_opus":0.08658744931163549,"score_gpt":0.4047673319118335,"score_spread":0.318179882600198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031038545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050826,0.0006014043,0.0002025237,0.006017624,0.00034910606,0.0009268705,0.000007516828,0.000042028623,0.0013446788],"genre_scores_gemma":[0.9870484,0.0008439663,0.005344885,0.0037837184,0.0022239117,0.000018057179,0.000011113606,0.00008837915,0.00063756376],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929636,0.0006175444,0.0032493263,0.00072643027,0.0015049119,0.0009382048],"domain_scores_gemma":[0.9918922,0.0032790932,0.0021276695,0.0005276401,0.0010068411,0.0011665672],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0025213175,0.00043402184,0.002896326,0.00017547829,0.00007903139,0.000035454872,0.0006145565,0.0006446021,0.0006637902],"category_scores_gemma":[0.00818927,0.0002638909,0.00028714977,0.0010129919,0.0006427964,0.00034113417,0.00023305947,0.0023612692,0.00007511529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.37539908,0.008507741,0.21354672,0.004141651,0.0048068105,0.055650357,0.004025082,0.018521886,0.00071994774,0.00012330661,0.05664495,0.25791246],"study_design_scores_gemma":[0.5951402,0.116208404,0.1748026,0.0052345255,0.0011182217,0.0029055304,0.00049085123,0.042974986,0.00041270268,0.0000455355,0.059668574,0.0009978733],"about_ca_topic_score_codex":0.00033613003,"about_ca_topic_score_gemma":0.00063105556,"teacher_disagreement_score":0.2569146,"about_ca_system_score_codex":0.051697563,"about_ca_system_score_gemma":0.12989834,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W3031257206","doi":"10.1200/jco.2020.38.15_suppl.e20001","title":"Clonal lineage analysis of CLL research samples by IGH chain sequencing to reveal novel CLL subgroups defined by ongoing class-switch recombination and somatic hypermutation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"Thermo Fisher Scientific","keywords":"Somatic hypermutation; Immunoglobulin class switching; Biology; Genetics; Chronic lymphocytic leukemia; breakpoint cluster region; Molecular biology; Gene; B cell; Antibody; Leukemia","score_opus":0.29517940042495433,"score_gpt":0.49828547135339674,"score_spread":0.2031060709284424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031257206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710132,0.00037757357,0.0050025918,0.02258191,0.00015769374,0.00040331765,0.000044561264,0.000012599563,0.00040659073],"genre_scores_gemma":[0.98422027,0.0003952593,0.012312795,0.0023091075,0.00048595338,0.000009121734,0.000060397626,0.00003166895,0.0001754409],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9929456,0.0010811156,0.0034912173,0.00046083124,0.0015111136,0.0005100934],"domain_scores_gemma":[0.9820194,0.013844159,0.0013611534,0.0002627834,0.0015477119,0.00096475217],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012252095,0.00019384288,0.0021445404,0.0006477761,0.000099226316,0.00003294489,0.00033322253,0.0004969252,0.00008869963],"category_scores_gemma":[0.03398191,0.00015902736,0.00044457105,0.0017336918,0.00033959295,0.00017532468,0.00019770594,0.0016176888,0.00001112839],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02343307,0.007955325,0.08343484,0.0021080943,0.011062747,0.0014059695,0.0077476026,0.0021584383,0.6249102,0.002265655,0.12596773,0.10755037],"study_design_scores_gemma":[0.16193923,0.08955515,0.11964647,0.0016155171,0.009128878,0.0015256177,0.006856751,0.54639417,0.02128453,0.0017386678,0.038941707,0.0013733442],"about_ca_topic_score_codex":0.00040296328,"about_ca_topic_score_gemma":0.000116604104,"teacher_disagreement_score":0.60362566,"about_ca_system_score_codex":0.004767921,"about_ca_system_score_gemma":0.010093187,"threshold_uncertainty_score":0.9990526},"labels":[],"label_agreement":null},{"id":"W3032719171","doi":"10.1200/jco.2020.38.15_suppl.e20003","title":"Retrospective cohort study of real-world treatment patterns and overall survival in patients with chronic lymphocytic leukemia (CLL) diagnosed between 2010 to 2017 in Ontario, Canada.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca Canada","keywords":"Ibrutinib; Medicine; Rituximab; Fludarabine; Discontinuation; Chronic lymphocytic leukemia; Chlorambucil; Alemtuzumab; Internal medicine; Cohort; Population; Cancer registry; Bendamustine; Cyclophosphamide; Retrospective cohort study; Oncology; Chemoimmunotherapy; Obinutuzumab; Cancer; Chemotherapy; Leukemia; Lymphoma; Transplantation","score_opus":0.07610665831292557,"score_gpt":0.3883402262317307,"score_spread":0.31223356791880513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032719171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973266,0.00001814782,0.0000020671607,0.0005460424,0.00028160113,0.0014299996,0.000015467294,0.000003711907,0.00037633447],"genre_scores_gemma":[0.99902976,0.0001234871,0.000056595174,0.00026525423,0.0003143327,0.000018406665,0.000009305318,0.000025000754,0.00015784302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531806,0.00048406058,0.0022936708,0.00044659895,0.0010214244,0.00043619424],"domain_scores_gemma":[0.99593157,0.0016885927,0.00096110825,0.00030743895,0.0003517127,0.000759591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014264772,0.00024386545,0.0027354932,0.00022586482,0.000023391185,0.000008273797,0.00022342212,0.00020222076,0.00009609166],"category_scores_gemma":[0.0011878599,0.00017360755,0.00010897557,0.000283114,0.000107069354,0.00008507808,0.00013093239,0.000969121,0.0000018769563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007345092,0.000903807,0.98557705,0.00003096094,0.0005280758,0.002445613,0.0007383601,0.00031224464,0.0000010140577,0.0000017895842,0.00054625125,0.0015697541],"study_design_scores_gemma":[0.10334443,0.046720624,0.8488445,0.00015488792,0.00024300635,0.000008664091,0.00010356449,0.0001558437,0.0000048663787,0.0000040823197,0.00029382878,0.000121678866],"about_ca_topic_score_codex":0.9829692,"about_ca_topic_score_gemma":0.9984702,"teacher_disagreement_score":0.13673252,"about_ca_system_score_codex":0.22809504,"about_ca_system_score_gemma":0.14084698,"threshold_uncertainty_score":0.8640236},"labels":[],"label_agreement":null},{"id":"W3033837361","doi":"10.1136/annrheumdis-2020-eular.1230","title":"FRI0131 SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Methotrexate; Internal medicine; Discontinuation; Placebo; Pathology","score_opus":0.027652398403556214,"score_gpt":0.31035286013459906,"score_spread":0.28270046173104285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033837361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897505,0.0010088189,0.000050540642,0.0073166266,0.00001078359,0.0015623772,0.0002596895,0.000029273124,0.000011403716],"genre_scores_gemma":[0.9990338,0.0003588101,0.00019808301,0.0002674231,0.0000074788964,0.00004360062,0.000009354991,0.00003585955,0.000045560588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661964,0.0010471789,0.0006869418,0.00040814126,0.00082711276,0.00041097205],"domain_scores_gemma":[0.99523205,0.0024810724,0.00031996984,0.0006585251,0.000617614,0.0006907645],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0012812404,0.00025140314,0.0008212547,0.00013949817,0.00011728428,0.000031573774,0.00024915373,0.000067282366,0.000033610417],"category_scores_gemma":[0.014787958,0.00016879043,0.00011957674,0.0004968882,0.0007716753,0.00016108081,0.00041539068,0.00014337586,0.0000020418893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16637893,0.00080078497,0.5567962,0.0061415425,0.0012120322,0.000072980416,0.012139499,0.00008718577,0.00013550195,0.00008581401,0.0016320987,0.25451747],"study_design_scores_gemma":[0.012042789,0.0017178119,0.97973233,0.002380882,0.00009966554,0.000006307826,0.0007936314,0.00033352614,0.0022164653,0.00035937905,0.000120866775,0.000196325],"about_ca_topic_score_codex":0.00032947055,"about_ca_topic_score_gemma":0.000008399015,"teacher_disagreement_score":0.42293617,"about_ca_system_score_codex":0.00031181876,"about_ca_system_score_gemma":0.0025928146,"threshold_uncertainty_score":0.9935109},"labels":[],"label_agreement":null},{"id":"W3034202212","doi":"10.1136/annrheumdis-2020-eular.3668","title":"THU0189 EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASE TREATED WITH DMARDS AND/OR GLUCOCORTICOIDS AT BASELINE","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Nintedanib; Azathioprine; Internal medicine; Interstitial lung disease; Rituximab; Placebo; Adverse effect; Population; Cyclophosphamide; Gastroenterology; Idiopathic pulmonary fibrosis; Lung; Disease; Chemotherapy; Pathology","score_opus":0.018261710222582824,"score_gpt":0.27621128980496884,"score_spread":0.257949579582386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034202212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395967,0.002050759,0.000020582022,0.0020760822,0.000017090677,0.0015059266,0.00028816372,0.000040609197,0.000041140036],"genre_scores_gemma":[0.9988394,0.0005587277,0.00002430353,0.00024152339,0.000009754219,0.000031245763,0.00013237288,0.000045132932,0.00011753465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997623,0.00020109449,0.0007001665,0.00039507952,0.0007318043,0.0003487993],"domain_scores_gemma":[0.9977998,0.00041657966,0.00028686452,0.0005458116,0.00023603156,0.0007149059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016369614,0.00029845483,0.00070144836,0.00011016132,0.000074152784,0.000016410135,0.00020611807,0.000040451563,0.00017438426],"category_scores_gemma":[0.0016856488,0.0001605805,0.00011030623,0.0005099421,0.0007166466,0.00012307958,0.00030663385,0.00014465835,0.0000022371646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20732039,0.002830536,0.75452,0.00693588,0.0016414847,0.00025605713,0.0012384553,0.00069326663,0.000032290263,0.000081422615,0.0011342514,0.02331597],"study_design_scores_gemma":[0.032351535,0.0010800236,0.9204189,0.0055646515,0.0007849974,0.000005483526,0.00007347267,0.039392643,0.00008246633,0.000015382402,0.000024270008,0.00020612765],"about_ca_topic_score_codex":0.00017931753,"about_ca_topic_score_gemma":0.000013005078,"teacher_disagreement_score":0.17496885,"about_ca_system_score_codex":0.0003878493,"about_ca_system_score_gemma":0.0017233605,"threshold_uncertainty_score":0.65482825},"labels":[],"label_agreement":null},{"id":"W3034621686","doi":"10.1136/annrheumdis-2020-eular.2059","title":"SAT0151 EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Abatacept; Rheumatoid arthritis; Internal medicine; Clinical endpoint; Adalimumab; Adverse effect; Methotrexate; Tofacitinib; Clinical trial; Gastroenterology; Rituximab","score_opus":0.059634229717229835,"score_gpt":0.3616093117384592,"score_spread":0.3019750820212294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034621686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98240966,0.002632997,0.000036388825,0.0021225782,0.00007390356,0.012483227,0.0001900643,0.000037369664,0.00001380228],"genre_scores_gemma":[0.9960586,0.0030283448,0.00007513257,0.0001977959,0.000018240939,0.00052885135,0.000038210153,0.000042557833,0.000012304546],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99508333,0.0012371336,0.0015907881,0.00059788435,0.0009423791,0.0005484707],"domain_scores_gemma":[0.98852485,0.008991554,0.0008476894,0.0005728957,0.0003490719,0.0007139352],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013123237,0.00045788143,0.003043324,0.00028485598,0.00014553861,0.000057431964,0.00032495116,0.00009223618,0.00005825531],"category_scores_gemma":[0.0219496,0.00026120883,0.00031559067,0.0007745132,0.00074241817,0.0002226937,0.00025553396,0.00023581169,0.000003377456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94888943,0.0012446747,0.00023085387,0.0008784792,0.0009323325,0.000013514654,0.0027220172,0.00008803107,0.000015332156,0.000020548536,0.000039576324,0.044925187],"study_design_scores_gemma":[0.9778271,0.0033464797,0.00822339,0.0061766277,0.00030681037,0.0000028381119,0.0004372127,0.003100986,0.00025021913,0.00003197147,0.000009650467,0.00028673455],"about_ca_topic_score_codex":0.00017208901,"about_ca_topic_score_gemma":0.000017931761,"teacher_disagreement_score":0.04463845,"about_ca_system_score_codex":0.00031522184,"about_ca_system_score_gemma":0.0028884963,"threshold_uncertainty_score":0.999984},"labels":[],"label_agreement":null},{"id":"W3035506578","doi":"10.1016/j.cancergen.2020.04.016","title":"12. Genetic evaluation of CLL using SNP-array CGH: Comparison with retrospective FISH data in our institution.","year":2020,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Sanger sequencing; Fish <Actinopterygii>; Chronic lymphocytic leukemia; Fluorescence in situ hybridization; Biology; Comparative genomic hybridization; Karyotype; SNP array; DNA sequencing; SNP; Genetics; Computational biology; Leukemia; Single-nucleotide polymorphism; Chromosome; Gene; Genotype; Fishery","score_opus":0.2586739903773015,"score_gpt":0.44006839139413906,"score_spread":0.18139440101683757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035506578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992117,0.0029409812,0.0026744625,0.000590367,0.00015041909,0.00089903007,0.00009475953,0.000017163582,0.00051581254],"genre_scores_gemma":[0.9940517,0.00039492792,0.00478084,0.00024900847,0.00039359694,0.000023384677,0.0000641316,0.000028159991,0.000014281624],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976575,0.000095800315,0.0003852234,0.0004780232,0.001105786,0.0002776815],"domain_scores_gemma":[0.9984959,0.000018186416,0.00014737267,0.0007117025,0.00046483698,0.00016204425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003607077,0.0001499492,0.00038132942,0.0000841519,0.000037235928,0.000015760297,0.0002905348,0.000096990414,0.00006697952],"category_scores_gemma":[0.0002555517,0.00013639782,0.000025369423,0.00039043665,0.00011423237,0.000065085245,0.00014219947,0.0002385318,0.0000044455646],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011557828,0.00028580884,0.7615812,0.00082373555,0.00034116406,0.00006673624,0.004618079,0.19708575,0.01904758,0.000015255533,0.004107179,0.010871769],"study_design_scores_gemma":[0.013621151,0.00039605162,0.16188326,0.00032237195,0.0004113689,0.000025933987,0.00054127624,0.80602676,0.015402451,0.000015718515,0.0011641514,0.00018948788],"about_ca_topic_score_codex":0.0012231591,"about_ca_topic_score_gemma":0.0024192613,"teacher_disagreement_score":0.608941,"about_ca_system_score_codex":0.009118413,"about_ca_system_score_gemma":0.012405701,"threshold_uncertainty_score":0.9946854},"labels":[],"label_agreement":null},{"id":"W3039421746","doi":"","title":"Résultats actualisés d’une l’étude de phase Ib/II chez des patients atteints de lymphome diffus à grandes cellules B (LDGCB) en rechute/réfractaire (R/R) traités par polatuzumab vedotin (Pola) plus bendamustine (B) et rituximab (R) ou obinutuzumab (G)","year":2019,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; McGill University; Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Gynecology; Medicine","score_opus":0.02032378919052187,"score_gpt":0.28690152291971116,"score_spread":0.2665777337291893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039421746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9518186,0.0053167967,0.021753527,0.00687771,0.0007626928,0.0030877236,0.0009844925,0.00053936115,0.008859096],"genre_scores_gemma":[0.9534495,0.005968115,0.018503547,0.00040597902,0.00029010215,0.00036833898,0.0050239055,0.00043193065,0.015558579],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.97561866,0.013660303,0.002391724,0.0027797022,0.0023735268,0.0031761029],"domain_scores_gemma":[0.97995365,0.0074788565,0.0016129896,0.004930346,0.004192347,0.0018317935],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.012019277,0.0018437606,0.0024366793,0.0008028341,0.0015665364,0.0007190134,0.0036029485,0.0019356816,0.00094796653],"category_scores_gemma":[0.011875394,0.0019620936,0.0010167521,0.0015393922,0.001977023,0.0006468715,0.0037933956,0.0033452897,0.0004528774],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0058273897,0.032545775,0.01133402,0.010273258,0.0035401676,0.0009374698,0.41308776,0.003274175,0.072957255,0.021035833,0.004514787,0.42067212],"study_design_scores_gemma":[0.23064253,0.00014074334,0.058311563,0.040482864,0.0022545129,0.0009958185,0.005623688,0.43377623,0.18411684,0.004840465,0.03337173,0.0054430296],"about_ca_topic_score_codex":0.031015579,"about_ca_topic_score_gemma":0.006742019,"teacher_disagreement_score":0.43050203,"about_ca_system_score_codex":0.05326406,"about_ca_system_score_gemma":0.028376693,"threshold_uncertainty_score":0.9999653},"labels":[],"label_agreement":null},{"id":"W3040343536","doi":"10.1038/s41467-020-17095-7","title":"IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University","funders":"Instituto de Salud Carlos III; Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; Institució Catalana de Recerca i Estudis Avançats; National Cancer Institute; Generalitat de Catalunya; Ministerio de Economía y Competitividad; Centres de Recerca de Catalunya; European Regional Development Fund; Deutsches Krebsforschungszentrum; Memorial Sloan-Kettering Cancer Center","keywords":"Sanger sequencing; Biology; Genome; Gene; Chromosomal translocation; Genetics; DNA sequencing; Fluorescence in situ hybridization; Computational biology; Immunoglobulin heavy chain; Chromosome","score_opus":0.06281667402160208,"score_gpt":0.3314885484398798,"score_spread":0.2686718744182777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040343536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9375349,0.027353218,0.001432732,0.028614115,0.00013379149,0.0023360557,0.0006126098,0.000156059,0.001826476],"genre_scores_gemma":[0.9328774,0.0014894439,0.06308453,0.001259675,0.00011142938,0.00018320816,0.0008914639,0.00004050752,0.00006235403],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984791,0.00011259044,0.00047089416,0.00038832964,0.00023285643,0.00031621053],"domain_scores_gemma":[0.9977114,0.0006315049,0.000099046076,0.0011645148,0.00018934214,0.00020418869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003030027,0.00017612685,0.00033622564,0.00012485433,0.00026040163,0.000044427616,0.000598177,0.0003155621,0.000038232694],"category_scores_gemma":[0.0006109953,0.00018249183,0.00009639804,0.0005119475,0.00018465443,0.00012728747,0.00023718101,0.0008245913,0.000023082714],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010862832,0.0003171147,0.011604728,0.00038180235,0.00083279394,0.000043406813,0.016527014,0.0004190019,0.9360074,0.0013899484,0.0015528955,0.029837642],"study_design_scores_gemma":[0.124677576,0.0010263323,0.019800268,0.0014317987,0.0013655314,0.0012332898,0.012089707,0.5119181,0.029404413,0.0024315529,0.292243,0.002378432],"about_ca_topic_score_codex":0.0005719923,"about_ca_topic_score_gemma":0.0006666408,"teacher_disagreement_score":0.906603,"about_ca_system_score_codex":0.004441352,"about_ca_system_score_gemma":0.0031377466,"threshold_uncertainty_score":0.9993804},"labels":[],"label_agreement":null},{"id":"W3041533404","doi":"10.3747/co.27.6769","title":"Management of Chronic Lymphocytic Leukemia in Canada during the Coronavirus Pandemic","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; Impact; Fluidigm (Canada); William Osler Health System; Brampton Civic Hospital; Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Janssen Canada","keywords":"Chronic lymphocytic leukemia; Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Hematology; Coronavirus; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Intensive care medicine; Immunology; Disease; Leukemia; Internal medicine; Virology; Infectious disease (medical specialty); Outbreak","score_opus":0.10972092874621577,"score_gpt":0.3857072695910942,"score_spread":0.27598634084487844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041533404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98950046,0.0075203376,0.0000150752485,0.00033367224,0.0004077827,0.0006886906,0.000007888096,0.000024945004,0.0015011285],"genre_scores_gemma":[0.99672776,0.0026996834,0.000016477861,0.00015588627,0.00018626044,0.000073213305,0.00001060854,0.000020301175,0.00010982411],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99811786,0.00010036089,0.00047798798,0.0003331769,0.00045556857,0.0005150505],"domain_scores_gemma":[0.9991211,0.00016519739,0.000118541975,0.00034554614,0.000050859333,0.00019871908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019005554,0.00016238503,0.00044381834,0.000053031494,0.00004165881,0.0000037134284,0.00032898618,0.000067294204,0.00023815065],"category_scores_gemma":[0.000050735922,0.000121479075,0.00006573827,0.000389768,0.00015140504,0.000028118275,0.00028723644,0.0003979838,0.000039352337],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005124183,0.00031880342,0.13167042,0.0176971,0.0010225223,0.010168803,0.003200238,0.020523151,0.0045585744,0.0010537844,0.0077934572,0.796869],"study_design_scores_gemma":[0.13897905,0.0020353028,0.1761519,0.001903968,0.0005176806,0.0013314437,0.003574012,0.39303762,0.0038782882,0.000091947106,0.2776502,0.0008485874],"about_ca_topic_score_codex":0.35398245,"about_ca_topic_score_gemma":0.34911066,"teacher_disagreement_score":0.7960204,"about_ca_system_score_codex":0.42024264,"about_ca_system_score_gemma":0.12230046,"threshold_uncertainty_score":0.8826753},"labels":[],"label_agreement":null},{"id":"W3042934496","doi":"10.3747/co.27.5371","title":"PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Melanoma; Oncology; Malignancy; Internal medicine; Leukemia; Cancer; Population; Immunology; Cancer research","score_opus":0.19829690398167113,"score_gpt":0.46068065010266523,"score_spread":0.26238374612099413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042934496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581987,0.00135881,0.0000037675447,0.0015774039,0.0001504464,0.0009624952,0.000013974729,0.000012090535,0.000101173406],"genre_scores_gemma":[0.99853945,0.00070744735,0.000035041434,0.00044328376,0.00013082332,0.00009122294,0.000026843461,0.000016227194,0.00000968617],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963203,0.0014024551,0.0011169817,0.00044395754,0.00029864765,0.00041766526],"domain_scores_gemma":[0.99792737,0.0013749719,0.00018135163,0.00028185782,0.00008143111,0.0001530366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021435977,0.00017382592,0.00072840985,0.00023748851,0.000022085038,0.000008556113,0.00010635622,0.00023788403,0.000042164767],"category_scores_gemma":[0.0025623136,0.0001298232,0.00007221399,0.0006127983,0.000447449,0.00009991294,0.00018482993,0.00059481536,0.00001872753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.16408752,0.003443707,0.49866423,0.006709691,0.00016238226,0.12959708,0.06425368,0.0014147799,0.0028090235,0.0013685223,0.0061182813,0.12137112],"study_design_scores_gemma":[0.39016095,0.047361564,0.33066335,0.0036020172,0.00022117405,0.018270195,0.010430902,0.16632894,0.0014459237,0.0006380638,0.029869895,0.0010070234],"about_ca_topic_score_codex":0.0008156929,"about_ca_topic_score_gemma":0.002303309,"teacher_disagreement_score":0.22607344,"about_ca_system_score_codex":0.050834626,"about_ca_system_score_gemma":0.03016138,"threshold_uncertainty_score":0.97533673},"labels":[],"label_agreement":null},{"id":"W3043531240","doi":"10.1016/j.exphem.2020.07.004","title":"MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells","year":2020,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"Natural Sciences and Engineering Research Council of Canada; Leukemia and Lymphoma Society of Canada","keywords":"Biology; Molecular biology; Apoptosis; Chronic lymphocytic leukemia; Immunology; Leukemia; Genetics","score_opus":0.022245696330701323,"score_gpt":0.3088961171713996,"score_spread":0.28665042084069825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043531240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97160697,0.025639754,0.00004356219,0.00045816955,0.00008218696,0.0008155014,0.0000042270317,0.000037503687,0.0013121022],"genre_scores_gemma":[0.99884766,0.00012109797,0.000121971425,0.00060779724,0.00008277455,0.00008354654,0.0000057516754,0.000027460828,0.00010194079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835134,0.000121363206,0.00044676638,0.00037523787,0.00029603657,0.000409279],"domain_scores_gemma":[0.9990711,0.0002796198,0.000098298784,0.0003295825,0.000026785465,0.0001945964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014247217,0.00019014085,0.0006016085,0.000067713154,0.00005093902,0.000009137004,0.00018953865,0.00015226258,0.00027362123],"category_scores_gemma":[0.000068981775,0.00013150267,0.00007636335,0.0001846175,0.00045658174,0.00005925683,0.00024899427,0.00021156868,0.00006155005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010427515,0.00005560915,0.00020085266,0.00040469915,0.000035163648,0.00030101047,0.002440962,0.00007580459,0.98858726,0.0049046553,0.001768234,0.0001830192],"study_design_scores_gemma":[0.020377006,0.00055907434,0.00003729058,0.00016027135,0.00001372273,0.00051317504,0.0011872993,0.018620748,0.9575188,0.00003310062,0.00087130535,0.00010819779],"about_ca_topic_score_codex":0.00038252326,"about_ca_topic_score_gemma":0.000010453605,"teacher_disagreement_score":0.03106843,"about_ca_system_score_codex":0.0168831,"about_ca_system_score_gemma":0.0062617385,"threshold_uncertainty_score":0.9993718},"labels":[],"label_agreement":null},{"id":"W3043664983","doi":"10.1016/j.leukres.2020.106423","title":"Antihistamines are synergistic with Bruton’s tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells","year":2020,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; Research Institute in Oncology and Hematology","funders":"Cancer Research Society","keywords":"Ibrutinib; Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Programmed cell death; Tyrosine kinase; Pharmacology; Cancer research; Apoptosis; Leukemia; Medicine; Immunology; Chemistry; Receptor; Biochemistry; Internal medicine","score_opus":0.04239485212341118,"score_gpt":0.3200529764841595,"score_spread":0.2776581243607483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043664983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990217,0.0030937358,0.00014673735,0.0017597507,0.00011721102,0.0023329135,0.00017600069,0.00035739393,0.001799305],"genre_scores_gemma":[0.9919513,0.0008909666,0.00016382718,0.00082267495,0.00078549056,0.00033977567,0.0006577018,0.00028149015,0.0041068047],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9893784,0.0007180933,0.0012601354,0.0020138966,0.003792132,0.0028373252],"domain_scores_gemma":[0.9944615,0.0013482345,0.0002763465,0.0014474579,0.0008608349,0.0016056531],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016805276,0.00084228115,0.0014098377,0.0010344164,0.0003441675,0.0002599289,0.00092042447,0.00067429757,0.0006645793],"category_scores_gemma":[0.0017119022,0.00070565374,0.00021659926,0.0046805823,0.0014085486,0.00046542665,0.0006840892,0.0023608143,0.0014781056],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009749843,0.00033174874,0.0043845037,0.006507422,0.00035847095,0.015976105,0.0019849062,0.0053298413,0.88957715,0.00023613287,0.06339551,0.0021683483],"study_design_scores_gemma":[0.109061785,0.004988736,0.0042680777,0.004194449,0.0002270837,0.00057309837,0.001437959,0.516702,0.32578352,0.000064421765,0.030587472,0.0021114373],"about_ca_topic_score_codex":0.0069121607,"about_ca_topic_score_gemma":0.00068934396,"teacher_disagreement_score":0.56379366,"about_ca_system_score_codex":0.28951484,"about_ca_system_score_gemma":0.072920166,"threshold_uncertainty_score":0.99994075},"labels":[],"label_agreement":null},{"id":"W3043987559","doi":"10.1002/jha2.67","title":"Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL Registry","year":2020,"lang":"en","type":"article","venue":"eJHaem","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Chemoimmunotherapy; Medicine; Chronic lymphocytic leukemia; Quality of life (healthcare); Rituximab; Internal medicine; Observational study; Leukemia; Pediatrics; Physical therapy; Lymphoma","score_opus":0.05282141469533935,"score_gpt":0.3005933488246032,"score_spread":0.24777193412926385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043987559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99056214,0.0019275704,0.000027757455,0.0050692395,0.00004670125,0.0014234281,0.0003795248,0.00012488669,0.00043877886],"genre_scores_gemma":[0.9973415,0.0002110728,0.0000766076,0.00086422294,0.0002575496,0.000038565217,0.0009177685,0.000068913476,0.00022380636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949064,0.00043777676,0.0017859825,0.00093279476,0.0011352596,0.0008017763],"domain_scores_gemma":[0.9956749,0.0015411115,0.0006705446,0.0012229995,0.00028736022,0.0006030514],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087874033,0.00041692707,0.0012741862,0.00009394352,0.00014714459,0.00002752584,0.0004887938,0.0002971692,0.00018756911],"category_scores_gemma":[0.0032970454,0.00028135764,0.00016595007,0.0011614397,0.0004729612,0.00011596446,0.00021327034,0.00077188184,0.0001058594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.121295266,0.0016828574,0.6381113,0.0052195215,0.0033874237,0.001954513,0.037141785,0.1286016,0.00016638785,0.00034824063,0.054849803,0.0072413236],"study_design_scores_gemma":[0.35551384,0.0056135994,0.37113968,0.002673363,0.00025795985,0.000060000995,0.0011919828,0.25962293,0.00068890606,0.00007319314,0.0022279338,0.0009366186],"about_ca_topic_score_codex":0.08709266,"about_ca_topic_score_gemma":0.0034542256,"teacher_disagreement_score":0.26697162,"about_ca_system_score_codex":0.046722814,"about_ca_system_score_gemma":0.037220843,"threshold_uncertainty_score":0.9999639},"labels":[],"label_agreement":null},{"id":"W3045062385","doi":"10.1038/s41416-020-1006-4","title":"Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”","year":2020,"lang":"en","type":"letter","venue":"British Journal of Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval; March of Dimes Canada","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Drug; Medicine; Chronic lymphocytic leukemia; Leukemia; Immunology; Pharmacology","score_opus":0.028905233874551697,"score_gpt":0.3272973650289938,"score_spread":0.29839213115444213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045062385","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047859285,0.018830014,0.000015037883,0.93071204,0.00088757963,0.00097613345,0.00011325343,0.00003451247,0.0005721267],"genre_scores_gemma":[0.020280201,0.0055126618,0.00015074637,0.96002334,0.008046838,0.000109735185,0.000027489074,0.00018384363,0.005665154],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940269,0.0005767009,0.001441869,0.00065330067,0.002324272,0.0009769482],"domain_scores_gemma":[0.99694496,0.00084485405,0.0005869043,0.0006146161,0.00048709838,0.0005215377],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011518244,0.00047661425,0.0015466368,0.0006818887,0.00009351015,0.00018342087,0.0007559134,0.00041352236,0.00065361086],"category_scores_gemma":[0.0012214058,0.0005112672,0.00047476884,0.00049142767,0.00018803688,0.00012823947,0.00021975649,0.004147419,0.00011904513],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007175389,0.00003437884,0.000008328027,0.00072413,0.00025165276,0.09478046,0.00037310767,0.0012803859,0.00010525253,9.605918e-7,0.8862493,0.00901667],"study_design_scores_gemma":[0.02043024,0.0014906474,0.00012984083,0.013372635,0.0001679691,0.007829445,0.000056827655,0.00069597876,0.00071278424,0.00005973144,0.95462626,0.00042764764],"about_ca_topic_score_codex":0.01420895,"about_ca_topic_score_gemma":0.0004690825,"teacher_disagreement_score":0.15987176,"about_ca_system_score_codex":0.23740163,"about_ca_system_score_gemma":0.07752988,"threshold_uncertainty_score":0.99973387},"labels":[],"label_agreement":null},{"id":"W3045900844","doi":"10.1002/ccr3.3170","title":"A case of LGL leukemia with paucity of erythropoiesis","year":2020,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia","funders":"","keywords":"Medicine; Lymphocytosis; Immunophenotyping; Neutropenia; Bone marrow; Leukemia; Differential diagnosis; Sepsis; Erythropoiesis; Pathology; Bone marrow examination; Biopsy; Immunology; Anemia; Internal medicine; Chemotherapy; Antigen","score_opus":0.10648081094823468,"score_gpt":0.399845111912424,"score_spread":0.2933643009641893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045900844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971454,0.00017589862,0.00017994978,0.0004287716,0.000081779195,0.00051228935,0.000012878721,0.00004681986,0.0014161789],"genre_scores_gemma":[0.99772274,0.000050283972,0.0015170517,0.0002942331,0.00022669762,0.0000109247085,0.00000849857,0.0000352659,0.00013429073],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9967135,0.00013180474,0.0017327606,0.00057744636,0.0005394279,0.00030503699],"domain_scores_gemma":[0.9963718,0.0008815009,0.00066768413,0.00094086933,0.0004757282,0.00066241313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001162976,0.00018526556,0.0010283459,0.000056247914,0.00004235086,0.0000061213527,0.000049076665,0.00022276289,0.0003263792],"category_scores_gemma":[0.0048248656,0.00013450619,0.0003139525,0.00044769712,0.00084861834,0.000057180852,0.00016387572,0.00043880317,0.000008732071],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094541145,0.00023976564,0.019836022,0.0008321884,0.0002294588,0.973307,0.00024375546,0.00001494797,0.000129031,0.000019872632,0.0019070833,0.0022954582],"study_design_scores_gemma":[0.0069885217,0.0023946417,0.0011392259,0.0002089504,0.00043665647,0.9807404,0.00023585474,0.0022147417,0.0044148504,0.000036892085,0.001021555,0.00016768646],"about_ca_topic_score_codex":0.003473099,"about_ca_topic_score_gemma":0.00019083834,"teacher_disagreement_score":0.018696794,"about_ca_system_score_codex":0.0013463001,"about_ca_system_score_gemma":0.0102026155,"threshold_uncertainty_score":0.9954086},"labels":[],"label_agreement":null},{"id":"W3046115938","doi":"10.1002/jlcr.3872","title":"Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [<sup>11</sup>C]Tolebrutinib, via palladium‐NiXantphos‐mediated carbonylation","year":2020,"lang":"en","type":"article","venue":"Journal of Labelled Compounds and Radiopharmaceuticals","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Canada Research Chairs; Canada Foundation for Innovation; Ontario Research Foundation; Azrieli Foundation; Sanofi","keywords":"Radiosynthesis; Bruton's tyrosine kinase; Chemistry; Carbonylation; Moiety; Palladium; Stereochemistry; Tyrosine kinase; Positron emission tomography; Biochemistry; Receptor; Nuclear medicine; Catalysis","score_opus":0.031948504278114666,"score_gpt":0.3058038718591569,"score_spread":0.27385536758104223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046115938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797566,0.011837339,0.00023005786,0.0070293644,0.00016446138,0.0005066659,0.000021975306,0.000039931263,0.0004135858],"genre_scores_gemma":[0.9940356,0.0028519728,0.001088636,0.0010268067,0.00085185666,0.000004631301,0.000010261575,0.000063540036,0.0000666756],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9960423,0.00029548365,0.0014981666,0.00038003657,0.0012002975,0.0005836984],"domain_scores_gemma":[0.99628884,0.0010051676,0.0005845426,0.00029445847,0.0005914234,0.0012355715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010646633,0.00038256223,0.0014235777,0.00034126238,0.0001232035,0.00005127002,0.00028551868,0.00025396724,0.00019343894],"category_scores_gemma":[0.00083683105,0.00029993348,0.00034175866,0.0007635992,0.00043032083,0.00018438527,0.00013482038,0.0007127729,0.000012982713],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010181971,0.002801338,0.0067097326,0.002270509,0.001878546,0.0031277675,0.003061122,0.00045706262,0.9554461,0.00023725568,0.0060074213,0.007821174],"study_design_scores_gemma":[0.16284147,0.003316035,0.0011696152,0.0014072491,0.0021553505,0.004834935,0.0004663298,0.47816414,0.2994504,0.00012463103,0.04521,0.00085984316],"about_ca_topic_score_codex":0.000047178648,"about_ca_topic_score_gemma":9.890466e-7,"teacher_disagreement_score":0.6559957,"about_ca_system_score_codex":0.0013312422,"about_ca_system_score_gemma":0.0020833577,"threshold_uncertainty_score":0.9999453},"labels":[],"label_agreement":null},{"id":"W3048067521","doi":"10.1080/10428194.2020.1795159","title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Ibrutinib; Bendamustine; Medicine; Chronic lymphocytic leukemia; Internal medicine; Rituximab; Ofatumumab; Placebo; Hazard ratio; Alemtuzumab; Oncology; Lymphoma; Gastroenterology; Leukemia; Confidence interval; Transplantation; Pathology","score_opus":0.02279744231098206,"score_gpt":0.2582515279847478,"score_spread":0.23545408567376575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048067521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901012,0.0037179077,0.000050713643,0.0001879773,0.00030527133,0.0044818055,0.00032891647,0.0003714549,0.0004547509],"genre_scores_gemma":[0.99500257,0.00090594386,0.0004417398,0.001415913,0.00070313545,0.00036136693,0.0004661717,0.00043212387,0.0002710269],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9877979,0.00067448645,0.0028244029,0.0032978065,0.002795586,0.002609821],"domain_scores_gemma":[0.99238265,0.0018786422,0.0010122068,0.0023690572,0.0006169433,0.0017405194],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009896046,0.0021031697,0.0034246577,0.00076990976,0.00076865795,0.0003549491,0.0015315459,0.0010587204,0.00020296861],"category_scores_gemma":[0.0009600634,0.0016566514,0.00042900245,0.0026021518,0.0016843987,0.00076607004,0.0013739703,0.0006627818,0.00014250746],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.24220943,0.018233722,0.22525895,0.009602859,0.00877781,0.0145823015,0.074361116,0.0063522845,0.0066399626,0.0008586314,0.009038593,0.38408434],"study_design_scores_gemma":[0.71899,0.011061027,0.16291471,0.0018382956,0.0015852232,0.0007053579,0.0050603407,0.0910971,0.0019990907,0.000059712613,0.0025260327,0.0021630672],"about_ca_topic_score_codex":0.021604922,"about_ca_topic_score_gemma":0.0010523804,"teacher_disagreement_score":0.4767806,"about_ca_system_score_codex":0.22048838,"about_ca_system_score_gemma":0.09826215,"threshold_uncertainty_score":0.99917096},"labels":[],"label_agreement":null},{"id":"W3049118620","doi":"10.14740/jh676","title":"Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ibrutinib; Dosing; Internal medicine; Chronic lymphocytic leukemia; Regimen; Clinical trial; Neutropenia; Oncology; Surgery; Leukemia; Toxicity","score_opus":0.08358807528998895,"score_gpt":0.358954524829178,"score_spread":0.27536644953918904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049118620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981064,0.0005079942,0.00004683417,0.00032545364,0.00025449213,0.0006101891,0.0000032738008,0.00001162487,0.0001336896],"genre_scores_gemma":[0.999094,0.000023363973,0.000610454,0.00011694457,0.00009813949,0.000005708237,0.0000026705172,0.000033158136,0.000015553045],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995884,0.0002971371,0.0021518823,0.0002835714,0.00091490604,0.00046850406],"domain_scores_gemma":[0.99742645,0.0005927382,0.0010342571,0.00034218756,0.00029823347,0.0003061516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006641605,0.00023910374,0.0018905324,0.00032834153,0.000041451873,0.000007356203,0.00036269476,0.0001109426,0.00014201885],"category_scores_gemma":[0.002332531,0.0001687423,0.0002557101,0.0005655639,0.0001457638,0.00012860034,0.00016026964,0.00043948682,0.000006310108],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024178827,0.0028523426,0.7579161,0.0037712972,0.0025700063,0.012813753,0.00838304,0.0008284509,0.18390651,0.00031039535,0.0010794207,0.0013898367],"study_design_scores_gemma":[0.5370501,0.1132598,0.16938376,0.0075487546,0.0021313694,0.007055436,0.005216645,0.029937452,0.12648492,0.0004655334,0.00025523338,0.0012109533],"about_ca_topic_score_codex":0.00038707608,"about_ca_topic_score_gemma":0.00003343417,"teacher_disagreement_score":0.5885323,"about_ca_system_score_codex":0.018796235,"about_ca_system_score_gemma":0.028716875,"threshold_uncertainty_score":0.98497045},"labels":[],"label_agreement":null},{"id":"W3082688334","doi":"","title":"C-KIT e Imatinib Mesylate em Melanoma Uveal","year":2012,"lang":"pt","type":"article","venue":"UNIFESP Institutional Repository (Universidade Federal de São Paulo)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Imatinib mesylate; Melanoma; Medicine; Imatinib; Dermatology; Internal medicine; Cancer research","score_opus":0.01911315407115274,"score_gpt":0.2703312088246081,"score_spread":0.2512180547534554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082688334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8883686,0.0035419017,0.00085523963,0.00058251084,0.0034769992,0.0010309657,0.000096964235,0.00027826393,0.10176853],"genre_scores_gemma":[0.91910887,0.00011197248,0.0007645776,0.0006180194,0.0030431543,0.00002496437,0.00021200207,0.00010318132,0.07601328],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9926005,0.00064251566,0.0009733668,0.000995388,0.0022252584,0.0025629485],"domain_scores_gemma":[0.9952985,0.00044278114,0.00045629253,0.0011070953,0.0005429412,0.0021523766],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010855302,0.00090152165,0.00096689933,0.0007704389,0.0027488607,0.00034733996,0.0008751018,0.0009737066,0.001499775],"category_scores_gemma":[0.00044055175,0.0009648475,0.0006422212,0.00089741626,0.00084959314,0.0016899088,0.0006644304,0.0016493005,0.0019152628],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.023131076,0.014049415,0.11005683,0.00988498,0.01655336,0.13481468,0.17046294,0.009055232,0.08929126,0.2354018,0.171897,0.015401442],"study_design_scores_gemma":[0.1260769,0.0049839336,0.28116834,0.0068900874,0.004623652,0.11596424,0.12876455,0.11287941,0.03349704,0.000890106,0.17543459,0.008827147],"about_ca_topic_score_codex":0.0014552145,"about_ca_topic_score_gemma":0.00016015458,"teacher_disagreement_score":0.23451169,"about_ca_system_score_codex":0.037884854,"about_ca_system_score_gemma":0.022076262,"threshold_uncertainty_score":0.999413},"labels":[],"label_agreement":null},{"id":"W3082899459","doi":"10.1016/s1470-2045(20)30443-5","title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Obinutuzumab; Chlorambucil; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Fludarabine; Open label; Clinical trial; Chemotherapy; Leukemia; Cyclophosphamide","score_opus":0.22414891033952375,"score_gpt":0.4279868705273332,"score_spread":0.20383796018780945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082899459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9568092,0.0033902547,0.00031797058,0.00386397,0.003487822,0.025471283,0.0010611381,0.00052256195,0.0050757783],"genre_scores_gemma":[0.9764201,0.0016217099,0.0012938414,0.003023563,0.008690153,0.0033118261,0.0022478874,0.00025917077,0.003131734],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924024,0.001011216,0.001725174,0.0017181303,0.0009386097,0.0022045],"domain_scores_gemma":[0.98966247,0.006108528,0.0008142917,0.0020575866,0.00043461504,0.0009225249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020157413,0.00084650225,0.0033879923,0.0001268728,0.00047356688,0.00023021092,0.002290241,0.00075968343,0.00040963737],"category_scores_gemma":[0.0066047073,0.0006313731,0.0004215971,0.0008043686,0.0006079522,0.0002566303,0.0009962927,0.0009958685,0.000567469],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.93296367,0.00010351939,1.9817409e-7,0.0003114744,0.0013206255,0.0007789631,0.0037732613,0.0050832317,0.0014695697,0.000097201104,0.04900737,0.005090915],"study_design_scores_gemma":[0.57432973,0.012998026,3.792801e-7,0.00017031812,0.0010810497,0.000067216424,0.00025219965,0.33894697,0.001047077,0.00005175523,0.07068523,0.00037007226],"about_ca_topic_score_codex":0.01265212,"about_ca_topic_score_gemma":0.0020691145,"teacher_disagreement_score":0.35863397,"about_ca_system_score_codex":0.49785936,"about_ca_system_score_gemma":0.27607533,"threshold_uncertainty_score":0.99961376},"labels":[],"label_agreement":null},{"id":"W3083669839","doi":"10.3747/co.27.7009","title":"Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; Impact; Fluidigm (Canada); Saint John Regional Hospital; Dalhousie University","funders":"Japan Society for the Promotion of Science","keywords":"Ibrutinib; Venetoclax; Medicine; Chronic lymphocytic leukemia; Oncology; Clinical Oncology; Pandemic; Internal medicine; Coronavirus disease 2019 (COVID-19); Leukemia; Intensive care medicine; Cancer; Disease; Infectious disease (medical specialty)","score_opus":0.10968025011245615,"score_gpt":0.38601947587378105,"score_spread":0.2763392257613249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083669839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97725743,0.010336928,0.000035427056,0.00792953,0.00086249766,0.0010274805,0.000058835853,0.00008935074,0.0024025254],"genre_scores_gemma":[0.9896185,0.007534466,0.000048876158,0.0005019032,0.0017772426,0.00012650313,0.00015108721,0.000037866495,0.00020354525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978416,0.00019262111,0.0004721917,0.00053630624,0.00046881198,0.0004884582],"domain_scores_gemma":[0.99781007,0.00096651487,0.00016622443,0.00062247686,0.00010859944,0.0003261011],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011368243,0.00028666644,0.000719064,0.000060901868,0.00008119292,0.000012431829,0.00031423708,0.0001733828,0.0016683906],"category_scores_gemma":[0.00017960329,0.00016947293,0.00022768852,0.00031364633,0.0003400808,0.00003326134,0.00008985507,0.00022654024,0.0010744231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012174468,0.0058839126,0.0020946837,0.0014036301,0.0035769476,0.0026797112,0.01581472,0.001291116,0.024076695,0.014033202,0.35444513,0.56252575],"study_design_scores_gemma":[0.033409603,0.013135535,0.00047537283,0.00020103385,0.00037859727,0.00005389214,0.00018369337,0.06567813,0.032770872,0.00023596053,0.8532395,0.00023784241],"about_ca_topic_score_codex":0.0004696683,"about_ca_topic_score_gemma":0.000051519382,"teacher_disagreement_score":0.5622879,"about_ca_system_score_codex":0.12043172,"about_ca_system_score_gemma":0.029108815,"threshold_uncertainty_score":0.99970335},"labels":[],"label_agreement":null},{"id":"W3085774902","doi":"10.7759/cureus.10451","title":"Acute Kidney Injury in a Patient With Cryoglobulinemia Secondary to Hepatic Mucosa-Associated Lymphoid Tissue Lymphoma: Case Report and Literature Review","year":2020,"lang":"en","type":"article","venue":"Cureus","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Medicine; Cryoglobulinemia; Lymphoma; Nephrology; Pathology; Acute kidney injury; Internal medicine; Fulminant hepatitis; Gastroenterology; Fulminant; Occult; Kidney; Hepatitis; Hepatitis C virus; Immunology; Virus","score_opus":0.01024499382000439,"score_gpt":0.29192825887626117,"score_spread":0.2816832650562568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085774902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96388686,0.02371275,0.000018011731,0.008145578,0.000115858995,0.0023548983,0.0003086457,0.00013687137,0.0013205131],"genre_scores_gemma":[0.9562896,0.010261303,0.0010927578,0.030463122,0.00021594233,0.0002894982,0.0006546009,0.000120466546,0.00061272125],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972431,0.00012317495,0.0007029478,0.00077876175,0.00058609294,0.000565912],"domain_scores_gemma":[0.99757123,0.00005988215,0.00018283735,0.00064923294,0.00030026422,0.0012365811],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031111838,0.00037101514,0.0008446324,0.00010577295,0.000072043105,0.000057553323,0.00014712344,0.00021018612,0.0001845588],"category_scores_gemma":[0.0018154661,0.0002908973,0.00007088121,0.0012320156,0.00007940051,0.00015765957,0.00025238338,0.00031828228,0.000039968992],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00077429344,0.00025985428,0.00082876545,0.0032702538,0.0002720805,0.8917271,0.0023450577,7.922053e-7,0.0007922777,0.00000645133,0.090178706,0.0095443735],"study_design_scores_gemma":[0.027644735,0.0038250887,0.00046268525,0.018162597,0.0007699386,0.8586292,0.00018527576,0.0018415119,0.0037935327,0.000019433079,0.083729714,0.00093627843],"about_ca_topic_score_codex":0.0006359795,"about_ca_topic_score_gemma":0.00010562817,"teacher_disagreement_score":0.033097878,"about_ca_system_score_codex":0.0062753656,"about_ca_system_score_gemma":0.007167758,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W3087469327","doi":"10.1016/j.clml.2020.08.022","title":"Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; AstraZeneca France; Servier; Incyte; AbbVie; Genentech; Bayer; Celgene; Bristol-Myers Squibb Canada; Gilead Sciences; Novartis; Roche","keywords":"Medicine; Idelalisib; Follicular lymphoma; Adverse effect; Oncology; PI3K/AKT/mTOR pathway; Clinical trial; Lymphoma; Targeted therapy; Internal medicine; Population; Cancer; Chronic lymphocytic leukemia; Ibrutinib; Leukemia","score_opus":0.05178835764682573,"score_gpt":0.31977349260169624,"score_spread":0.26798513495487053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087469327","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25816852,0.73016167,0.00000821441,0.000809061,0.0022042484,0.0072366083,0.00017261958,0.00012907859,0.0011099591],"genre_scores_gemma":[0.27982995,0.7144387,0.00011342343,0.00083615445,0.0028337906,0.00032226765,0.000515591,0.00039107984,0.0007190621],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888944,0.0017562476,0.0040417453,0.001719255,0.0023950508,0.0011933281],"domain_scores_gemma":[0.9928737,0.0013454085,0.0019315862,0.0026695163,0.00051243097,0.00066734006],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014616216,0.0012228998,0.004205764,0.0002964355,0.00027757636,0.00014017387,0.0018601776,0.001556033,0.000062409395],"category_scores_gemma":[0.0013917988,0.0006513341,0.0019605195,0.0021446736,0.0014560918,0.00015679636,0.0011066247,0.0012917627,0.00016680532],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007604297,0.000781047,0.0003785248,0.0045787967,0.0004300606,0.0002683122,0.00010039025,0.000017039896,0.000006820223,0.0000444883,0.0030074692,0.98962665],"study_design_scores_gemma":[0.08569009,0.0036717204,0.026885638,0.022800596,0.005256061,0.0006121698,0.00015867526,0.0047339555,0.00011639878,0.000056150213,0.84796137,0.0020571637],"about_ca_topic_score_codex":0.0006641995,"about_ca_topic_score_gemma":0.00024471036,"teacher_disagreement_score":0.98756945,"about_ca_system_score_codex":0.03157977,"about_ca_system_score_gemma":0.06496993,"threshold_uncertainty_score":0.9997402},"labels":[],"label_agreement":null},{"id":"W3088078660","doi":"10.1200/jco.20.00948","title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"National Cancer Institute; University of California, San Diego; University of Texas MD Anderson Cancer Center; National Institutes of Health; Apellis Pharmaceuticals; BeiGene; National Comprehensive Cancer Network; University of Nebraska Medical Center; Universiteit van Amsterdam; Leukemia and Lymphoma Society; Alexion Pharmaceuticals; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine; AstraZeneca; Loxo Oncology; TG Therapeutics; Amgen; Breast Cancer Research Foundation","keywords":"Medicine; Venetoclax; Internal medicine; Bendamustine; Rituximab; Chronic lymphocytic leukemia; Regimen; Hazard ratio; Oncology; Progression-free survival; Gastroenterology; Alemtuzumab; Minimal residual disease; Leukemia; Chemotherapy; Lymphoma; Confidence interval; Transplantation","score_opus":0.27852723156453724,"score_gpt":0.5228803570445849,"score_spread":0.24435312548004767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088078660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964168,0.0016411791,0.000022724682,0.00064593315,0.00010950901,0.0010048255,0.00005182113,0.0000037784894,0.00010341522],"genre_scores_gemma":[0.99859136,0.00044784884,0.0003806354,0.000115512215,0.00042440748,0.000006615598,0.0000145204485,0.000015223579,0.0000038523876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99431777,0.0015022448,0.0028879684,0.00028432373,0.00078428455,0.00022341024],"domain_scores_gemma":[0.9925478,0.004629144,0.0016316331,0.000286228,0.0005931233,0.0003120403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070667746,0.00014888587,0.0016463307,0.00010853458,0.00004245369,0.000008198866,0.00021196608,0.00024665604,0.00007447821],"category_scores_gemma":[0.0068065724,0.00009791143,0.0002426684,0.0002396445,0.0006946064,0.0000682865,0.00013689263,0.0007586842,0.0000034682357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5136901,0.010144687,0.046756145,0.00063625554,0.010780449,0.00308753,0.040894475,0.15491591,0.046118036,0.000110255416,0.0036753106,0.16919082],"study_design_scores_gemma":[0.44077137,0.023990497,0.19142298,0.00009390489,0.00092382147,0.00014204366,0.00083003973,0.34134543,0.000109345216,0.0002651792,0.000032876247,0.00007251453],"about_ca_topic_score_codex":0.0040621264,"about_ca_topic_score_gemma":0.0006035519,"teacher_disagreement_score":0.1864295,"about_ca_system_score_codex":0.045978792,"about_ca_system_score_gemma":0.12630308,"threshold_uncertainty_score":0.9576835},"labels":[],"label_agreement":null},{"id":"W3088874303","doi":"10.14740/jmc3576","title":"Hydroa Vacciniforme-Like Lymphoproliferative Disorder in an Adult Patient With Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hepatosplenomegaly; Chronic lymphocytic leukemia; Ibrutinib; Lymphoproliferative disorders; Dermatology; Dasatinib; Erythema; Context (archaeology); Prednisolone; Rash; Immunology; Leukemia; Pathology; Internal medicine; Lymphoma; Myeloid leukemia","score_opus":0.020962057024837936,"score_gpt":0.3038065561237085,"score_spread":0.28284449909887055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088874303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993629,0.001697336,0.00018783823,0.003701106,0.00013639002,0.00042492177,0.0000058515056,0.000030232755,0.00018734368],"genre_scores_gemma":[0.9941347,0.00075926614,0.00023608633,0.003886252,0.0008686164,0.000019182655,0.00001136356,0.000052877862,0.000031646567],"study_design_codex":"case_report","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9944469,0.00018707638,0.0010923638,0.00037221113,0.0032659841,0.0006354956],"domain_scores_gemma":[0.9966938,0.00042401193,0.00036350338,0.00030493594,0.0005017144,0.0017120547],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005262089,0.00031844992,0.00086673367,0.00024496613,0.00007020538,0.000049516497,0.00041320277,0.0002726287,0.0009214586],"category_scores_gemma":[0.0021285987,0.00020386954,0.00016974162,0.0006343546,0.00022688437,0.00036200712,0.00013145558,0.00086122705,0.000040436375],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.061103873,0.002986739,0.058215402,0.004525276,0.0019362009,0.57268083,0.02974096,0.019810341,0.0012698591,0.00060588634,0.029735798,0.21738887],"study_design_scores_gemma":[0.21813874,0.05713839,0.004884137,0.004975837,0.0005398033,0.14267375,0.0075033805,0.5476699,0.0042849192,0.00007784569,0.010968476,0.0011448518],"about_ca_topic_score_codex":0.0009463978,"about_ca_topic_score_gemma":0.00093168195,"teacher_disagreement_score":0.5278595,"about_ca_system_score_codex":0.04358527,"about_ca_system_score_gemma":0.085107096,"threshold_uncertainty_score":0.99999183},"labels":[],"label_agreement":null},{"id":"W3089794974","doi":"10.3390/cancers12102865","title":"Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Institut National de la Recherche Agronomique; Ligue Contre le Cancer; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Institut National Du Cancer; Association pour la Recherche sur le Cancer","keywords":"Crosstalk; Niche; Follicular lymphoma; Cell; Follicular phase; Medicine; Biology; Computational biology; Neuroscience; Lymphoma; Cell biology; Bioinformatics; Internal medicine; Genetics; Engineering; Ecology","score_opus":0.02655409815391171,"score_gpt":0.2893501085054814,"score_spread":0.2627960103515697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089794974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905441,0.00048364245,0.00026757875,0.00020076608,0.00006411533,0.0004469625,0.00016595557,0.00001768764,0.007809195],"genre_scores_gemma":[0.9986866,0.000093306684,0.00030412807,0.0004270002,0.000032916476,0.000035840025,0.000052115123,0.000020940139,0.0003471529],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981964,0.00009586708,0.00047559233,0.00034150176,0.0006283929,0.00026221038],"domain_scores_gemma":[0.9985567,0.000103862425,0.00035360394,0.0004406251,0.000360429,0.00018481107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021194016,0.00018231674,0.0006276762,0.00013167357,0.00004492788,0.000009391756,0.00024699947,0.00011536593,0.00029715543],"category_scores_gemma":[0.00032770907,0.000120470264,0.00046134985,0.0018512583,0.00045232067,0.000053749707,0.000115285824,0.0001644407,0.0000058942733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009305135,0.0006411878,0.010389971,0.0047699464,0.0135147255,0.0007587076,0.15973914,0.02386142,0.75891036,0.0016968382,0.014011499,0.0024010497],"study_design_scores_gemma":[0.009619413,0.00057777326,0.0018193518,0.00013703243,0.0024972376,0.0000073643882,0.0076247766,0.039547052,0.937741,0.000076520475,0.00018196146,0.00017055456],"about_ca_topic_score_codex":0.004013726,"about_ca_topic_score_gemma":0.00021416791,"teacher_disagreement_score":0.17883058,"about_ca_system_score_codex":0.015528282,"about_ca_system_score_gemma":0.022246595,"threshold_uncertainty_score":0.9882509},"labels":[],"label_agreement":null},{"id":"W3091228368","doi":"10.1136/annrheumdis-2020-eular.276","title":"THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Adverse effect; Placebo; Methotrexate; Internal medicine","score_opus":0.0409407264005392,"score_gpt":0.3105212033318787,"score_spread":0.2695804769313395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091228368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878698,0.0006722266,0.00017676648,0.007928737,0.000020984084,0.002316351,0.00090243417,0.000031070198,0.00008161643],"genre_scores_gemma":[0.99713016,0.000581187,0.0014774826,0.00052018376,0.000011299569,0.000074873555,0.000059100577,0.000046784775,0.00009892491],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9973879,0.00027977978,0.00071599014,0.0004031571,0.0008129903,0.0004002136],"domain_scores_gemma":[0.99530995,0.002624764,0.0003776109,0.00067198003,0.0005254514,0.00049026514],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00059993775,0.00025211475,0.0007587827,0.00009898306,0.00010124555,0.000022119993,0.00030206033,0.000052395346,0.000028892538],"category_scores_gemma":[0.008672173,0.00014814136,0.00012590588,0.00050743995,0.00032345435,0.00009762161,0.00019346488,0.00010437337,0.000006032294],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7534397,0.004300062,0.005928251,0.0060373633,0.00222993,0.000044482094,0.010474028,0.0010894244,0.00021101284,0.00024272957,0.026607,0.18939601],"study_design_scores_gemma":[0.2889053,0.03476516,0.6151517,0.030922491,0.000609906,0.00006156731,0.0015371082,0.006938667,0.013966487,0.0003867061,0.005538251,0.0012166755],"about_ca_topic_score_codex":0.000111638525,"about_ca_topic_score_gemma":0.000011189823,"teacher_disagreement_score":0.6092234,"about_ca_system_score_codex":0.00015332502,"about_ca_system_score_gemma":0.0019996513,"threshold_uncertainty_score":0.9996782},"labels":[],"label_agreement":null},{"id":"W3091858640","doi":"10.1080/14756366.2020.1825408","title":"Design of new disubstituted imidazo[1,2-<i>b</i>]pyridazine derivatives as selective Haspin inhibitors. Synthesis, binding mode and anticancer biological evaluation","year":2020,"lang":"en","type":"article","venue":"Journal of Enzyme Inhibition and Medicinal Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eshelman Institute for Innovation, University of North Carolina at Chapel Hill; Meso Scale Diagnostics; Janssen Biotech; Innovative Medicines Initiative; Ministero dello Sviluppo Economico; Région Bretagne; Labex; AbbVie; Novartis Pharma; Deutschen Konsortium für Translationale Krebsforschung; Canada Foundation for Innovation; Ontario Ministry of Economic Development and Innovation; Agence Nationale de la Recherche; Wellcome Trust; Cancéropôle Grand Ouest; Fundação de Amparo à Pesquisa do Estado de São Paulo; Diamond Light Source; Genome Canada; Takeda Pharmaceutical Company; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Pfizer; Ligue Contre le Cancer; Boehringer Ingelheim","keywords":"Pyridazine; Chemistry; Stereochemistry; Combinatorial chemistry","score_opus":0.07055397884432821,"score_gpt":0.3443127778255069,"score_spread":0.2737587989811787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091858640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235326,0.0020978774,0.0026282053,0.002342921,0.000035076842,0.00028774023,0.0000046451287,0.000012914942,0.00023736888],"genre_scores_gemma":[0.9971623,0.0011367414,0.00081142195,0.00024913915,0.000594825,0.000007150806,0.000009847859,0.000014466319,0.00001411048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980341,0.00009485564,0.0006200639,0.00024944218,0.0007836881,0.00021784696],"domain_scores_gemma":[0.9981884,0.00033280542,0.00041146248,0.00008450509,0.00046564397,0.00051722204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071146816,0.00018870347,0.0005476682,0.00008742322,0.00005866553,0.000016928121,0.000056897938,0.0001661609,0.00018315583],"category_scores_gemma":[0.0032478878,0.00013993865,0.00007100159,0.0002961708,0.00035417025,0.0001456535,0.000044933236,0.00041708868,0.0000014661457],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020295132,0.00009017894,0.0003822209,0.00035277678,0.00013165658,0.00013079676,0.00096071215,0.00016035343,0.9921657,0.000013614453,0.0014320427,0.002150478],"study_design_scores_gemma":[0.009177028,0.00074778084,0.00043389646,0.0014041074,0.00027495425,0.0014721554,0.00087092974,0.010129903,0.9751484,0.0001344676,0.00007330963,0.00013307782],"about_ca_topic_score_codex":0.00002920712,"about_ca_topic_score_gemma":3.334344e-7,"teacher_disagreement_score":0.017017268,"about_ca_system_score_codex":0.00089683995,"about_ca_system_score_gemma":0.0034771217,"threshold_uncertainty_score":0.6168265},"labels":[],"label_agreement":null},{"id":"W3091995045","doi":"10.1101/2020.10.08.331397","title":"Sleuthing biochemical evidence to elucidate unassigned electron density in a CBL/SLAP2 crystal complex","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Ubiquitin ligase; Signal transducing adaptor protein; Dimer; Chemistry; Tyrosine kinase; Tyrosine; Proto-oncogene tyrosine-protein kinase Src; Receptor tyrosine kinase; Mutant; SH2 domain; Cell biology; Ubiquitin; Kinase; Molecular biology; Biochemistry; Biology; Signal transduction; Gene","score_opus":0.04716476907699406,"score_gpt":0.30145704218904434,"score_spread":0.25429227311205027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091995045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910785,0.0009808225,0.0021015678,0.0023519155,0.0002701882,0.0023185746,0.00006354868,0.00080495817,0.000029921877],"genre_scores_gemma":[0.9896179,0.0001575584,0.007838953,0.0011648382,0.0006227772,0.00025214689,0.0000015969053,0.0003283494,0.000015922875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99393106,0.00028132703,0.0009200986,0.002124022,0.0013039996,0.0014394771],"domain_scores_gemma":[0.9957694,0.00024121423,0.00030687187,0.0020055403,0.0004608458,0.0012161178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001070186,0.00083601405,0.0013883332,0.00067055057,0.00010702502,0.0002077738,0.00094032363,0.0008232552,0.00008214919],"category_scores_gemma":[0.0024321168,0.00091434986,0.00025240637,0.0015702556,0.00021574309,0.00014360655,0.0018948594,0.001995314,0.00021057006],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007125324,0.00016548698,0.0028620462,0.0013963772,0.00016023962,0.0011965205,0.0000384835,0.000028167682,0.98917735,0.00011309552,0.0041486374,0.0000010702697],"study_design_scores_gemma":[0.00641141,0.00036992336,0.04448953,0.0048453608,0.0002343617,8.739212e-7,0.0000073340802,0.010228882,0.93015844,0.000004405538,0.0018534929,0.0013960003],"about_ca_topic_score_codex":0.0014816073,"about_ca_topic_score_gemma":0.000029000992,"teacher_disagreement_score":0.059018917,"about_ca_system_score_codex":0.015515427,"about_ca_system_score_gemma":0.011943068,"threshold_uncertainty_score":0.9993307},"labels":[],"label_agreement":null},{"id":"W3092419127","doi":"10.1080/03007995.2020.1835851","title":"Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia","year":2020,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Medicine; Chemoimmunotherapy; Medicare Advantage; Chronic lymphocytic leukemia; Internal medicine; Ofatumumab; Pharmacy; Health care; Oncology; Leukemia; Family medicine","score_opus":0.13488527936780695,"score_gpt":0.4044661884187354,"score_spread":0.26958090905092846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092419127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566903,0.025049843,0.00037072992,0.015065719,0.00007751142,0.0024228927,0.000050006565,0.00015136415,0.000121632824],"genre_scores_gemma":[0.9772183,0.020906715,0.000030847197,0.00033163323,0.00045304358,0.00021484698,0.000738888,0.000061325176,0.000044402284],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9943916,0.0002829578,0.0004611709,0.0008674791,0.0029515713,0.0010452186],"domain_scores_gemma":[0.99535775,0.0011695984,0.00009587454,0.00039474203,0.0005236506,0.0024584024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009219978,0.00035836035,0.0007012341,0.00022951176,0.000464125,0.00010642028,0.0002395018,0.00025647675,0.00012774505],"category_scores_gemma":[0.0023629465,0.00023844777,0.000043297023,0.0010958781,0.00096894824,0.00009776471,0.000221017,0.0007291889,0.0000117007085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.026104739,0.0008646254,0.04202009,0.0055633867,0.0010375127,0.00071104115,0.012707654,0.000325753,0.000071832794,0.00083779555,0.009979692,0.89977586],"study_design_scores_gemma":[0.17489369,0.053565662,0.058328476,0.03626173,0.00017313627,0.0003773935,0.0031886143,0.4494333,0.0016807382,0.00007319697,0.2205638,0.0014602662],"about_ca_topic_score_codex":0.0021490846,"about_ca_topic_score_gemma":0.003903412,"teacher_disagreement_score":0.8983156,"about_ca_system_score_codex":0.033712834,"about_ca_system_score_gemma":0.028169343,"threshold_uncertainty_score":0.97734004},"labels":[],"label_agreement":null},{"id":"W3092926650","doi":"10.1002/hon.2818","title":"Clinical trial risk in leukemia: Biomarkers and trial design","year":2020,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Celiac Association; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Clinical trial; Oncology; Chronic lymphocytic leukemia; Biomarker; Internal medicine; Drug; Leukemia; Pharmacology","score_opus":0.3097116344433638,"score_gpt":0.5104696459623587,"score_spread":0.20075801151899486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092926650","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006735187,0.9856913,0.00015430035,0.00029517306,0.0009878533,0.010097122,0.000015025706,0.00012827055,0.0019574494],"genre_scores_gemma":[0.00009143902,0.9939377,0.0033812348,0.00023127144,0.0011261405,0.0010056999,0.000048784495,0.00007424449,0.00010348695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98760486,0.0059257154,0.0033381877,0.0016193757,0.0005515755,0.00096031756],"domain_scores_gemma":[0.98134875,0.01608906,0.0009611418,0.00067875034,0.000065380525,0.00085692306],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004882868,0.0007293712,0.009334393,0.0003548952,0.00007769452,0.000031031574,0.00047624737,0.004167879,0.0003224396],"category_scores_gemma":[0.015530647,0.0004766327,0.0011775008,0.0007943183,0.001102291,0.00004039117,0.00060282403,0.0035761301,0.0004267722],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.29394937,0.00061091327,0.0000054668603,0.0034635954,0.0004783128,0.009912625,0.000013800144,9.882188e-8,2.5833797e-8,0.00015100325,0.0046350695,0.68677974],"study_design_scores_gemma":[0.40757546,0.013522018,9.254043e-7,0.0013232349,0.0010856568,0.0024925086,0.000011562387,0.00021065482,1.11113486e-7,0.00014548659,0.5733775,0.00025487604],"about_ca_topic_score_codex":0.00008267043,"about_ca_topic_score_gemma":0.000015753516,"teacher_disagreement_score":0.6865248,"about_ca_system_score_codex":0.016687473,"about_ca_system_score_gemma":0.04239848,"threshold_uncertainty_score":0.99976856},"labels":[],"label_agreement":null},{"id":"W3093432146","doi":"10.4049/jimmunol.2000478","title":"Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"Institute of Cancer Research; International Development Research Centre; Canadian Institutes of Health Research; European Hematology Association","keywords":"Ibrutinib; Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Cancer research; Leukemia; Tyrosine kinase; Signal transduction; Pharmacology; Ruxolitinib; Immunology; Biology; Bone marrow; Cell biology","score_opus":0.017414571550132048,"score_gpt":0.2887895426164642,"score_spread":0.2713749710663322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093432146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992631,0.0037947958,0.0000311757,0.0025543666,0.00020607197,0.00039024898,0.0000037907623,0.000008945131,0.0003796096],"genre_scores_gemma":[0.9983737,0.0008335058,0.000014935424,0.00036617453,0.00018678392,0.000002676002,4.976504e-7,0.000027601982,0.00019416683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99606997,0.0020776112,0.00080210925,0.00012034885,0.00057210407,0.0003578659],"domain_scores_gemma":[0.99107814,0.0072792596,0.00069849566,0.0006241426,0.00022739217,0.000092567345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004127638,0.00018837022,0.0007614054,0.00014191202,0.000063150386,0.0000048522597,0.0007654716,0.00014874905,0.0002904556],"category_scores_gemma":[0.0026003974,0.00008831906,0.0002788001,0.00038951242,0.0007975565,0.000037507354,0.00018249392,0.000713033,0.000083527666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08423118,0.000040679595,0.000011564519,0.00028131827,0.0007582591,0.00016759784,0.0015693773,0.0012021469,0.9056326,0.00009298872,0.0028914432,0.0031208498],"study_design_scores_gemma":[0.02046583,0.023924556,0.0003325684,0.00039159652,0.00032592684,0.0014664673,0.00026951922,0.0039372696,0.9474169,0.000022392427,0.0013719143,0.00007506878],"about_ca_topic_score_codex":0.0001275761,"about_ca_topic_score_gemma":0.000001250293,"teacher_disagreement_score":0.06376535,"about_ca_system_score_codex":0.015160399,"about_ca_system_score_gemma":0.01957879,"threshold_uncertainty_score":0.9886202},"labels":[],"label_agreement":null},{"id":"W3093652645","doi":"10.14309/01.ajg.0000705428.10562.bf","title":"S0845 Pharmacokinetics and Immunogenicity of Maintenance Therapy With Ustekinumab: 2-Year Results From the UNIFI Long-Term Extension Study","year":2020,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary","funders":"","keywords":"Medicine; Quartile; Dosing; Internal medicine; Regimen; Gastroenterology; Confidence interval","score_opus":0.028452969020975955,"score_gpt":0.2979532486051586,"score_spread":0.26950027958418266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093652645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070007,0.0002929806,0.00029066866,0.008260422,0.00004472489,0.0003787208,0.000017752447,0.00000622565,0.000008411053],"genre_scores_gemma":[0.99615777,0.0011158667,0.00025033657,0.002234028,0.00020600147,0.0000021184428,0.0000022307852,0.000023150678,0.000008505801],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978491,0.00057683967,0.00058048323,0.00021714074,0.0004625097,0.00031394],"domain_scores_gemma":[0.9978625,0.0003896201,0.0008359416,0.00043587183,0.00032081828,0.00015524449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006900002,0.00016885244,0.00067614083,0.000043205335,0.00005798409,0.000012741176,0.0004542864,0.000018354294,0.00001887851],"category_scores_gemma":[0.00014892005,0.000077431854,0.000095427706,0.00019997408,0.0011759591,0.00003924201,0.00015460879,0.00052455545,0.0000016756973],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5475272,0.00072539743,0.4103034,0.000018798766,0.0020979154,0.0011120996,0.0072714137,0.00021414596,0.022713605,0.0000021889136,0.0007298056,0.0072840103],"study_design_scores_gemma":[0.068573594,0.070207216,0.85187393,0.00014752305,0.00040349804,0.0026235208,0.0040791673,0.0006731346,0.0012526645,0.000008026059,0.000074315656,0.00008340067],"about_ca_topic_score_codex":0.0003322892,"about_ca_topic_score_gemma":0.00003058326,"teacher_disagreement_score":0.4789536,"about_ca_system_score_codex":0.00028232596,"about_ca_system_score_gemma":0.0004325825,"threshold_uncertainty_score":0.43328702},"labels":[],"label_agreement":null},{"id":"W3094852122","doi":"10.1182/blood-2020-138887","title":"Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Providence Health Care; Leukemia & Lymphoma Society of Canada; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Discontinuation; Internal medicine; Fludarabine; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.020626480551286817,"score_gpt":0.253403528309048,"score_spread":0.23277704775776117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094852122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629635,0.00039110158,0.000019293038,0.00005533983,0.00010147334,0.0025428217,0.00013736308,0.00011060919,0.000345677],"genre_scores_gemma":[0.9950447,0.0026035893,0.00028185316,0.0003907255,0.0002971495,0.00023979165,0.00045625502,0.00012084763,0.0005650533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687755,0.00010125549,0.0009102116,0.00081433856,0.00053896615,0.0007577033],"domain_scores_gemma":[0.998313,0.000237019,0.00029821132,0.00045964692,0.00028534504,0.0004067829],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028937234,0.0002881162,0.00088037737,0.00016437829,0.00010842827,0.00014861334,0.0002785054,0.00023763382,0.0001049812],"category_scores_gemma":[0.00024658343,0.00040458285,0.00016772379,0.0008147947,0.00022843633,0.00016290824,0.0001548389,0.000121642195,0.000013645455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006984336,0.0040901722,0.54159814,0.013331161,0.0017483784,0.0011534396,0.0042736316,0.00012873586,0.11319025,0.0001308069,0.0015438001,0.31182715],"study_design_scores_gemma":[0.31641483,0.002899395,0.62010354,0.0011889138,0.00029249146,0.00016041652,0.00007262807,0.032543525,0.023311118,0.000048874546,0.0022563166,0.00070792175],"about_ca_topic_score_codex":0.065572046,"about_ca_topic_score_gemma":0.02368301,"teacher_disagreement_score":0.31111923,"about_ca_system_score_codex":0.033304434,"about_ca_system_score_gemma":0.027296342,"threshold_uncertainty_score":0.9998406},"labels":[],"label_agreement":null},{"id":"W3095595977","doi":"10.1182/blood-2020-134066","title":"Chronic Lymphocytic Leukemia Treatment in México: Up to Half Patients May Not Requiere Treatment","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Lymphocytosis; Internal medicine; Anemia; Malignancy; Pediatrics; Gastroenterology; Constitutional symptoms; Leukemia; Surgery; Disease","score_opus":0.03877475028026526,"score_gpt":0.3041846582855278,"score_spread":0.26540990800526254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095595977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312794,0.00058895984,0.000005511044,0.0021074766,0.00015129118,0.0021679064,0.00004038351,0.00014405823,0.0016664773],"genre_scores_gemma":[0.9941906,0.00024019105,0.00020104714,0.0011513996,0.00057862216,0.000412313,0.00011248695,0.00008854664,0.0030247932],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99682057,0.00008979351,0.0005677405,0.00088629033,0.00068859174,0.0009470364],"domain_scores_gemma":[0.9980597,0.00012644961,0.00007992687,0.00075934856,0.00009195512,0.0008826074],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009615619,0.00046773293,0.0007614679,0.00020239415,0.00007704445,0.000044966117,0.00023497081,0.00019504606,0.00025200512],"category_scores_gemma":[0.00019215187,0.00037145967,0.00021799486,0.00061711925,0.00006939126,0.00008826597,0.00014395443,0.0001454749,0.0011782317],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02491876,0.016921813,0.14487539,0.0053045736,0.008963138,0.028850012,0.08009217,0.008065495,0.05680251,0.0011106713,0.01633709,0.6077584],"study_design_scores_gemma":[0.59004027,0.030653195,0.018665789,0.0007220939,0.0012296946,0.00030991266,0.00048429263,0.012362045,0.22309947,0.00001773374,0.121093154,0.0013223429],"about_ca_topic_score_codex":0.0060409987,"about_ca_topic_score_gemma":0.0007556285,"teacher_disagreement_score":0.606436,"about_ca_system_score_codex":0.23055837,"about_ca_system_score_gemma":0.025251025,"threshold_uncertainty_score":0.99987376},"labels":[],"label_agreement":null},{"id":"W3095661021","doi":"10.1182/blood-2020-136109","title":"Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"","keywords":"Venetoclax; Medicine; Rituximab; Minimal residual disease; Chronic lymphocytic leukemia; Refractory (planetary science); Internal medicine; Oncology; Ibrutinib; Complete remission; Leukemia; Gastroenterology; Chemotherapy; Lymphoma","score_opus":0.01908777022197527,"score_gpt":0.27137247247284646,"score_spread":0.2522847022508712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095661021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963427,0.0018276592,0.0000066551765,0.00002302425,0.000053593198,0.001509011,0.00008001274,0.00005951921,0.00009777947],"genre_scores_gemma":[0.9991959,0.00018351087,0.00011138304,0.00003090453,0.00010646352,0.00009198454,0.00017669878,0.00006596648,0.000037232257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99573344,0.00033983844,0.0012353207,0.0007868119,0.0012582564,0.0006463475],"domain_scores_gemma":[0.99793077,0.00039018225,0.00040109621,0.0007156981,0.00018864167,0.0003736111],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005154475,0.00038507662,0.0012119295,0.0006599701,0.00009218283,0.000032552973,0.00037278113,0.00018883712,0.00012140446],"category_scores_gemma":[0.0006446019,0.00037175315,0.00043891696,0.0020672476,0.00013991212,0.00026262307,0.00015697816,0.0003591018,0.000014112728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014005747,0.007926895,0.8832261,0.0018716282,0.010859384,0.0015062557,0.011708842,0.014153427,0.052202255,0.000017807177,0.00008961668,0.0024320378],"study_design_scores_gemma":[0.3195913,0.007466198,0.52604586,0.0008337495,0.007015798,0.000008220446,0.0042064716,0.081196435,0.05274071,0.000019817302,0.000027440117,0.0008479739],"about_ca_topic_score_codex":0.0021279592,"about_ca_topic_score_gemma":0.00036975893,"teacher_disagreement_score":0.35718024,"about_ca_system_score_codex":0.017657481,"about_ca_system_score_gemma":0.019655304,"threshold_uncertainty_score":0.99987346},"labels":[],"label_agreement":null},{"id":"W3095746683","doi":"10.1182/blood-2020-137415","title":"Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Venetoclax; Bendamustine; Internal medicine; Rituximab; Chronic lymphocytic leukemia; Clinical endpoint; Neutropenia; Progression-free survival; Oncology; Randomized controlled trial; Surgery; Gastroenterology; Chemotherapy; Leukemia; Lymphoma","score_opus":0.026034635969122012,"score_gpt":0.2662783070529347,"score_spread":0.2402436710838127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095746683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355865,0.0011333454,0.000012045897,0.00006486084,0.000023795721,0.004995542,0.000014249635,0.00009950431,0.0000979964],"genre_scores_gemma":[0.9989606,0.00009805587,0.00010246753,0.0001239142,0.000092658745,0.00028371706,0.00021204817,0.00010517743,0.000021348991],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99556136,0.0004439203,0.0010548988,0.00084967195,0.0013410385,0.0007490924],"domain_scores_gemma":[0.99785787,0.00033685318,0.00043396157,0.000920788,0.00025241065,0.00019814234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066187454,0.0004934844,0.00093512796,0.00030438005,0.00011226695,0.000044686312,0.0004824928,0.00020590182,0.000030485102],"category_scores_gemma":[0.00038579578,0.0003241224,0.000097931465,0.0018370751,0.0002039263,0.00021083631,0.000119773686,0.0006600202,0.000014294852],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.075249165,0.03816984,0.68853915,0.0036009313,0.0046484675,0.0051490506,0.10612234,0.023590993,0.0476655,0.000042784824,0.0001945626,0.007027211],"study_design_scores_gemma":[0.62473965,0.022198563,0.3202074,0.001976909,0.0009018387,0.00016015454,0.0023880354,0.018306287,0.008248706,0.0000028374307,0.00012860018,0.000741031],"about_ca_topic_score_codex":0.004467697,"about_ca_topic_score_gemma":0.00093287975,"teacher_disagreement_score":0.5494905,"about_ca_system_score_codex":0.040014174,"about_ca_system_score_gemma":0.017952831,"threshold_uncertainty_score":0.9999211},"labels":[],"label_agreement":null},{"id":"W3095967713","doi":"10.1182/blood-2020-134460","title":"Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Ibrutinib; Rituximab; Macroglobulinemia; Medicine; Waldenstrom macroglobulinemia; Internal medicine; Placebo; Lymphoplasmacytic Lymphoma; Fludarabine; Oncology; Gastroenterology; Lymphoma; Chronic lymphocytic leukemia; Chemotherapy; Cyclophosphamide; Leukemia; Multiple myeloma; Pathology","score_opus":0.03770505700756589,"score_gpt":0.3264207176106549,"score_spread":0.288715660603089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095967713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98794234,0.00079772534,0.0016342711,0.0023548251,0.00016410481,0.0059125614,0.00077358953,0.0001260567,0.00029451252],"genre_scores_gemma":[0.994574,0.000055327753,0.0025087108,0.000597714,0.0006661849,0.00041112164,0.00053940347,0.000079042184,0.0005684842],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99493885,0.00047938916,0.0014359414,0.0009954823,0.001341298,0.0008090342],"domain_scores_gemma":[0.9949857,0.0024606325,0.00041630215,0.0011415896,0.00063207536,0.0003637151],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015919635,0.00052227016,0.0031256003,0.00024074277,0.00021031799,0.00008697096,0.0007841962,0.0002571762,0.00055053376],"category_scores_gemma":[0.0029390021,0.00036680984,0.0011157116,0.001910634,0.00043756203,0.00009829263,0.00040221596,0.00065544335,0.00008986753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9406231,0.011283048,0.000865171,0.0004905611,0.024454242,0.000928906,0.0100485105,0.00025219913,0.001741647,0.00015989192,0.007979331,0.0011733774],"study_design_scores_gemma":[0.92986387,0.0015284704,0.00008322401,0.00008073978,0.014697443,0.000032704153,0.0023957319,0.045709193,0.0048485934,0.000035612702,0.00040934765,0.00031506666],"about_ca_topic_score_codex":0.0031935407,"about_ca_topic_score_gemma":0.00019688178,"teacher_disagreement_score":0.045456994,"about_ca_system_score_codex":0.001371161,"about_ca_system_score_gemma":0.0054238886,"threshold_uncertainty_score":0.9998784},"labels":[],"label_agreement":null},{"id":"W3096113916","doi":"10.1182/blood-2020-141183","title":"Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Internal medicine; Lymphoma; Diffuse large B-cell lymphoma; Population; Incidence (geometry); Hodgkin lymphoma; Gastroenterology; Oncology; Leukemia","score_opus":0.009184156539274162,"score_gpt":0.20205256935341637,"score_spread":0.19286841281414221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096113916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568635,0.00065457897,0.00005468773,0.000058018286,0.0002018219,0.0017102183,0.00013677064,0.00010934046,0.0013881992],"genre_scores_gemma":[0.9981337,0.0003062341,0.0001715306,0.0004398219,0.0002179951,0.00012433207,0.0002555187,0.00011413315,0.00023669757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949061,0.00019379126,0.0014516842,0.0008423377,0.0014262929,0.0011797721],"domain_scores_gemma":[0.99770314,0.00021530388,0.00034037096,0.0006567584,0.00033524024,0.0007491905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036286766,0.0003977149,0.0010969541,0.0001583956,0.00013436303,0.00015800454,0.00056502916,0.00034942705,0.000304686],"category_scores_gemma":[0.00045532116,0.0005729093,0.00022262338,0.0012291148,0.00024336709,0.00029379755,0.00017043544,0.00028823962,0.00003663883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005048836,0.007993654,0.5863552,0.03619805,0.006340988,0.044879165,0.01717305,0.019502165,0.0058732405,0.00015725677,0.031670418,0.23880795],"study_design_scores_gemma":[0.34263545,0.002333725,0.43708006,0.0026917993,0.0010886899,0.0013922582,0.0006337145,0.19986592,0.008305455,0.000051519968,0.0023664527,0.0015549742],"about_ca_topic_score_codex":0.97492635,"about_ca_topic_score_gemma":0.9683395,"teacher_disagreement_score":0.3375866,"about_ca_system_score_codex":0.14665338,"about_ca_system_score_gemma":0.13176109,"threshold_uncertainty_score":0.99967223},"labels":[],"label_agreement":null},{"id":"W3096271411","doi":"","title":"HemlibraMC (émicizumab), hémophilie A avec inhibiteurs du facteur VIII : avis d'introduction à la Liste des produits du système du sang du Québec : avis / rédigé par Simon Bélanger, Julie Nieminen ; coordination scientifique, Yannick Auclair ; sous la direction de Michèle de Guise","year":2019,"lang":"fr","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Dig; Art; Philosophy; Biology; Molecular biology","score_opus":0.00753925410552767,"score_gpt":0.2361279558644056,"score_spread":0.22858870175887794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096271411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513663,0.0058394894,0.0016079124,0.024874277,0.00259041,0.002626784,0.000064696826,0.0008754527,0.010154661],"genre_scores_gemma":[0.91159093,0.001227324,0.0006480461,0.00038523844,0.0045344974,0.0002314418,0.00026951078,0.00024529808,0.080867715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99307114,0.0012788109,0.0010816515,0.0016510165,0.0011726615,0.0017447119],"domain_scores_gemma":[0.9952848,0.0013198594,0.00045819717,0.0011821049,0.0010274845,0.0007275427],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0041806507,0.00080717687,0.000949815,0.00072434713,0.0005695634,0.0005026254,0.0005579732,0.00078064087,0.0013804706],"category_scores_gemma":[0.005505016,0.00079003954,0.00038827863,0.0013860924,0.0010653572,0.0010861581,0.00043482907,0.0008927765,0.0011353715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026741251,0.0025022535,0.061230235,0.007097055,0.0006821288,0.001318818,0.015440978,0.0027700353,0.061680716,0.0018674281,0.78107256,0.061663665],"study_design_scores_gemma":[0.022395806,0.0010348136,0.030317923,0.0031952125,0.0009300578,0.007312856,0.0013639482,0.14458132,0.075673066,0.0011394594,0.7099824,0.0020731515],"about_ca_topic_score_codex":0.049288854,"about_ca_topic_score_gemma":0.008285914,"teacher_disagreement_score":0.14181128,"about_ca_system_score_codex":0.03528642,"about_ca_system_score_gemma":0.012786596,"threshold_uncertainty_score":0.9996424},"labels":[],"label_agreement":null},{"id":"W3096278560","doi":"10.1182/blood-2020-133916","title":"Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rituximab; Ibrutinib; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Gastroenterology; Refractory (planetary science); Neutropenia; Progression-free survival; Phases of clinical research; Median follow-up; Surgery; Oncology; Clinical trial; Chemotherapy; Lymphoma; Leukemia; Multiple myeloma; Chronic lymphocytic leukemia","score_opus":0.1374803297596642,"score_gpt":0.39884000371614575,"score_spread":0.2613596739564815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096278560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481225,0.00037340654,0.000021621212,0.0005810455,0.00017469459,0.0034454353,0.00040517218,0.000012060346,0.00017430703],"genre_scores_gemma":[0.998909,0.000044393437,0.00017250377,0.00011240577,0.00015075752,0.00010784663,0.00007228395,0.00002986064,0.00040094025],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997322,0.00014494355,0.0009929913,0.00042958718,0.00075170654,0.0003587407],"domain_scores_gemma":[0.99753654,0.00035048512,0.0005318862,0.0010388773,0.00041546102,0.00012677541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040938647,0.00025808017,0.0012326124,0.00012650997,0.00008836342,0.00001767739,0.00088609813,0.00015028949,0.00014782691],"category_scores_gemma":[0.00056437915,0.0001439298,0.00055054476,0.0018009224,0.00031636443,0.00005472761,0.00043407496,0.00020048332,0.0000020654015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38644803,0.16873984,0.062136874,0.00310199,0.056981586,0.00035879857,0.009997728,0.00007008786,0.2693519,0.0004793596,0.0020158344,0.04031799],"study_design_scores_gemma":[0.75315166,0.004720328,0.0029845282,0.00011746528,0.009533447,0.00001618294,0.00014285078,0.0010195704,0.22806631,0.0000043330174,0.00011959201,0.00012375462],"about_ca_topic_score_codex":0.00044648047,"about_ca_topic_score_gemma":0.00015047185,"teacher_disagreement_score":0.36670363,"about_ca_system_score_codex":0.000848319,"about_ca_system_score_gemma":0.0047215614,"threshold_uncertainty_score":0.83758473},"labels":[],"label_agreement":null},{"id":"W3096713021","doi":"10.1182/blood-2020-134596","title":"Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; ABB (Canada); McMaster University","funders":"","keywords":"Obinutuzumab; Venetoclax; Medicine; Chemoimmunotherapy; Chlorambucil; Ofatumumab; Ibrutinib; Bendamustine; Population; Chronic lymphocytic leukemia; Fludarabine; Internal medicine; Rituximab; Oncology; IGHV@; Leukemia; Cyclophosphamide; Chemotherapy; Lymphoma","score_opus":0.03848499139418109,"score_gpt":0.2797604061445555,"score_spread":0.2412754147503744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096713021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755126,0.00042515248,0.000075621116,0.00006672738,0.00002763599,0.0016820279,0.000020182324,0.000009188043,0.00014222831],"genre_scores_gemma":[0.99954027,0.000083999046,0.00007812735,0.00003377467,0.0000115573985,0.00017239143,0.000042867232,0.000029950186,0.0000070902224],"study_design_codex":"simulation_or_modeling","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984954,0.00008812609,0.0004795688,0.00028430714,0.00039465126,0.00025795944],"domain_scores_gemma":[0.9990003,0.00044982167,0.00015610876,0.00022389174,0.00009780491,0.000072061084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029836476,0.00016704932,0.00049592304,0.00019520211,0.00001878439,0.000006317408,0.000111444024,0.00009141333,0.000014235234],"category_scores_gemma":[0.00019523116,0.00016085219,0.000025890866,0.0007086814,0.00009749875,0.00008238606,0.000036198315,0.00017923048,4.6544847e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.110602826,0.0065234695,0.23068108,0.023552395,0.0019288207,0.0012152939,0.01966816,0.3537872,0.23761319,0.004122218,0.000058687732,0.010246646],"study_design_scores_gemma":[0.49758735,0.0024334933,0.1014204,0.0015431042,0.00007025887,0.000036407295,0.00032835765,0.32700035,0.06926868,0.000023306622,0.000047632766,0.00024065896],"about_ca_topic_score_codex":0.73819,"about_ca_topic_score_gemma":0.8036136,"teacher_disagreement_score":0.38698453,"about_ca_system_score_codex":0.12847868,"about_ca_system_score_gemma":0.069883086,"threshold_uncertainty_score":0.9353898},"labels":[],"label_agreement":null},{"id":"W3096911669","doi":"10.1182/blood-2020-142182","title":"Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Ruxolitinib; Ibrutinib; Internal medicine; Tyrosine-kinase inhibitor; Imatinib; Oncology; Graft-versus-host disease; Hematopoietic stem cell transplantation; Janus kinase inhibitor; Transplantation; Pharmacology; Tofacitinib; Gastroenterology; Cancer; Leukemia; Myelofibrosis; Bone marrow; Chronic lymphocytic leukemia","score_opus":0.07223258988129425,"score_gpt":0.3598346977992248,"score_spread":0.2876021079179305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096911669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99013907,0.000754116,0.000021314156,0.0021020907,0.00016160206,0.0060461126,0.000103554834,0.00017241522,0.0004997567],"genre_scores_gemma":[0.9965136,0.00001984619,0.0015022046,0.00022378268,0.00052926363,0.00046444847,0.00005777457,0.00009906629,0.0005899892],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967791,0.00011387418,0.0005998706,0.0009868232,0.00066292746,0.00085743534],"domain_scores_gemma":[0.9981955,0.00030312687,0.00012274615,0.0005083136,0.00015409247,0.0007162019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031430428,0.000514636,0.0010614339,0.00014566076,0.00027493262,0.00009978051,0.00012300866,0.00008590232,0.00008633987],"category_scores_gemma":[0.0008385302,0.000391766,0.00032507445,0.00037156764,0.00005513648,0.00010453984,0.00021599625,0.00011100908,0.000046904606],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049902615,0.06777255,0.6402511,0.001454614,0.014159651,0.004489811,0.08782562,0.00007762231,0.0991018,0.00027604212,0.0010400862,0.07856084],"study_design_scores_gemma":[0.5841162,0.08491466,0.085998945,0.00049277506,0.0071729855,0.000087796885,0.007908384,0.0033622375,0.22071916,0.00008665837,0.003646301,0.0014938746],"about_ca_topic_score_codex":0.00027296296,"about_ca_topic_score_gemma":0.00014103041,"teacher_disagreement_score":0.57912594,"about_ca_system_score_codex":0.015005645,"about_ca_system_score_gemma":0.0021707998,"threshold_uncertainty_score":0.99985343},"labels":[],"label_agreement":null},{"id":"W3096933788","doi":"10.1182/blood-2020-136692","title":"A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; University of Ottawa; Hôpital Charles-Le Moyne; Western University; London Health Sciences Centre; McMaster University; Princess Margaret Cancer Centre; Foothills Medical Centre; Ottawa Hospital; University Health Network; Health Sciences Centre; Queen's University; Sunnybrook Hospital; Moncton Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Ibrutinib; Bendamustine; Medicine; Rituximab; Chronic lymphocytic leukemia; Internal medicine; Population; Quality-adjusted life year; Oncology; Cost effectiveness; Leukemia; Lymphoma; Environmental health","score_opus":0.04013205289859495,"score_gpt":0.34094271097395223,"score_spread":0.3008106580753573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096933788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936006,0.0013733909,0.000032263935,0.00014658243,0.00007155915,0.003988028,0.0005005848,0.000040918898,0.00024604725],"genre_scores_gemma":[0.99850184,0.00012300235,0.00027094362,0.0000667208,0.0000919895,0.00040217678,0.00046079373,0.000057324265,0.000025201844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956758,0.00042333963,0.0017600365,0.00080360536,0.0006060173,0.00073116994],"domain_scores_gemma":[0.996384,0.0011434959,0.0010039876,0.0005907313,0.0003166937,0.0005610563],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008643883,0.00043615047,0.004394221,0.0011611641,0.000059372887,0.000021144926,0.00028497627,0.00021787873,0.0005208023],"category_scores_gemma":[0.00089307217,0.00035746666,0.00051872723,0.0029712894,0.00041289348,0.000092072136,0.000048647067,0.00029264347,0.000009087622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.84038347,0.0039109415,0.06456633,0.0015623242,0.028619649,0.00027258802,0.0047532828,0.05299302,0.0010364475,0.00012540926,0.00045944974,0.0013171176],"study_design_scores_gemma":[0.75688666,0.0012657504,0.0032552406,0.00040622096,0.009108183,9.48256e-7,0.00010904331,0.220994,0.0076899887,9.684924e-7,0.000031025298,0.00025196417],"about_ca_topic_score_codex":0.37306777,"about_ca_topic_score_gemma":0.26677334,"teacher_disagreement_score":0.16800097,"about_ca_system_score_codex":0.04893582,"about_ca_system_score_gemma":0.058086157,"threshold_uncertainty_score":0.9998877},"labels":[],"label_agreement":null},{"id":"W3097057937","doi":"10.1182/blood-2020-138961","title":"Risk Factors for the Development of Skin Cancers in Patients with Chronic Lymphocytic Leukemia: A Retrospective Cohort Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Skin cancer; Cancer; Retrospective cohort study; Population; Cohort; Internal medicine; Hazard ratio; Basal cell carcinoma; Oncology; Leukemia; Confidence interval; Basal cell","score_opus":0.013772005400500859,"score_gpt":0.26010914150805375,"score_spread":0.2463371361075529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097057937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522567,0.00012779808,0.00007961306,0.000012981135,0.00003599626,0.004375366,0.000026384252,0.000027284836,0.00008893201],"genre_scores_gemma":[0.9992097,0.000016515683,0.00024145129,0.000023556157,0.00006377192,0.00035497348,0.000019502355,0.000039810042,0.000030696083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978912,0.00004925973,0.0004173354,0.0004414134,0.00080180756,0.00039902466],"domain_scores_gemma":[0.9988666,0.0002572526,0.00016960425,0.00036304045,0.00020237964,0.00014108338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033348185,0.00020987252,0.00050314364,0.00007582628,0.00010200983,0.000011049455,0.00021958268,0.00007041841,0.0000298463],"category_scores_gemma":[0.00039017646,0.000127889,0.00006592664,0.00049970753,0.00010832543,0.0000445776,0.00009519137,0.00023136742,0.0000046704695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008362378,0.00032127733,0.9896422,0.00012662842,0.000918444,0.000008177596,0.0071415724,0.0005378842,0.000011245718,0.00000203434,0.000039411305,0.00041489603],"study_design_scores_gemma":[0.082045905,0.001971846,0.9088143,0.000072428855,0.00042441883,0.0000011021625,0.0010584089,0.003030446,0.0024009445,0.0000016596528,0.000041642725,0.00013685733],"about_ca_topic_score_codex":0.0042224205,"about_ca_topic_score_gemma":0.0023468882,"teacher_disagreement_score":0.08120967,"about_ca_system_score_codex":0.08736045,"about_ca_system_score_gemma":0.04098893,"threshold_uncertainty_score":0.9644478},"labels":[],"label_agreement":null},{"id":"W3097160786","doi":"10.1182/blood-2020-140577","title":"Real-World Outcomes of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Chronic lymphocytic leukemia; Discontinuation; Tolerability; Adverse effect; Oncology; Leukemia","score_opus":0.08689948057481388,"score_gpt":0.33685235446792094,"score_spread":0.24995287389310705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097160786","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040989878,0.97889376,0.000020929836,0.000034223413,0.000033789234,0.019212421,0.00089630083,0.00020069136,0.00029799677],"genre_scores_gemma":[0.00074453565,0.9889469,0.0005900615,0.00026536232,0.00007830215,0.0047394847,0.0013699475,0.00041557953,0.0028498236],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9895093,0.0008641142,0.0043960614,0.0021553626,0.0017056651,0.0013695264],"domain_scores_gemma":[0.9900694,0.0021195093,0.0031385971,0.0029141859,0.000826179,0.0009321122],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010745252,0.0021162375,0.027952202,0.0013881408,0.00016407912,0.00011505686,0.0009759651,0.0005724078,0.00015505115],"category_scores_gemma":[0.001155651,0.0012911941,0.0065260967,0.0041030035,0.0003914613,0.000116408475,0.00043605547,0.00029708218,0.000064574444],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00008147648,0.00040228234,0.00001470108,0.7154813,0.28222513,0.00021386298,0.000036140045,0.000003286741,2.3488651e-7,0.000018563336,0.00005932278,0.0014637238],"study_design_scores_gemma":[0.029189806,0.0013075875,0.000010655559,0.06650368,0.892992,0.0003172434,0.00000910997,0.00033285818,0.000022296836,0.0000017669337,0.008314459,0.0009985205],"about_ca_topic_score_codex":0.0015603476,"about_ca_topic_score_gemma":0.00037055148,"teacher_disagreement_score":0.6489776,"about_ca_system_score_codex":0.10934988,"about_ca_system_score_gemma":0.058709405,"threshold_uncertainty_score":0.9991579},"labels":[],"label_agreement":null},{"id":"W3097563180","doi":"10.3324/haematol.2020.261107","title":"Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Celgene; MorphoSys; F. Hoffmann-La Roche; Pharmacyclics; Genentech; Gilead Sciences; BeiGene; Sanofi; Servier; Amgen; Pfizer; GlaxoSmithKline","keywords":"Bendamustine; Ven; Tumor lysis syndrome; Medicine; Venetoclax; Tolerability; Obinutuzumab; Neutropenia; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Discontinuation; Rituximab; Leukemia; Toxicity; Chemotherapy; Lymphoma; Adverse effect","score_opus":0.12996967499448986,"score_gpt":0.3799866589269263,"score_spread":0.25001698393243643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097563180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266297,0.0009431345,0.00007476561,0.00047280823,0.00012262554,0.0031975987,0.0001148005,0.00028064862,0.0021306498],"genre_scores_gemma":[0.99724966,0.0001481073,0.0007283254,0.0004111172,0.00029493807,0.00027041903,0.00011653081,0.00008330139,0.0006975926],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99368507,0.00031916954,0.0019579662,0.0013976074,0.0013453498,0.0012948625],"domain_scores_gemma":[0.9966302,0.00075908465,0.0005036208,0.0011661975,0.00029564375,0.0006452534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007712902,0.0006683404,0.0022904973,0.0003915589,0.00014194837,0.000043881228,0.0007875754,0.00043758805,0.0007623316],"category_scores_gemma":[0.0032114217,0.00050480425,0.00028577368,0.0018281236,0.0004623002,0.00015592002,0.0006080669,0.00091057195,0.00028816372],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4249458,0.006202132,0.00095982244,0.022970095,0.00269673,0.2896259,0.041490976,0.08574905,0.019712044,0.0013416373,0.07913541,0.025170391],"study_design_scores_gemma":[0.41213617,0.01881225,0.00034506634,0.00090217276,0.00043696366,0.0041651884,0.0026996268,0.54834515,0.00643883,0.00004045579,0.004895814,0.0007823063],"about_ca_topic_score_codex":0.0032462871,"about_ca_topic_score_gemma":0.00056095293,"teacher_disagreement_score":0.46259612,"about_ca_system_score_codex":0.17154606,"about_ca_system_score_gemma":0.1343386,"threshold_uncertainty_score":0.99974036},"labels":[],"label_agreement":null},{"id":"W3100169694","doi":"10.1101/125088","title":"Decoding the functional Fes kinase signaling network topology in a lymphocyte model","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canadian Institute for Advanced Research; Sanofi (Canada); Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; Occupational Cancer Research Centre; Sinai Health System","funders":"","keywords":"Proto-oncogene tyrosine-protein kinase Src; Tyrosine kinase; Cell biology; Cancer research; Biology; Signal transduction; breakpoint cluster region; Receptor; Biochemistry","score_opus":0.040601785494760075,"score_gpt":0.28165133930138836,"score_spread":0.2410495538066283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100169694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986526,0.005657942,0.0033765414,0.0010500199,0.0015456993,0.0014362485,0.000047287795,0.0002497319,0.00011050529],"genre_scores_gemma":[0.99222344,0.0007131071,0.0038345547,0.0006154987,0.0019565045,0.00043083064,9.3014324e-7,0.00016563802,0.000059521783],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99555314,0.000232079,0.00078266714,0.00128609,0.0008456064,0.0013004469],"domain_scores_gemma":[0.99567133,0.00037843955,0.00048814924,0.0025739556,0.00049849413,0.00038962343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020266338,0.00065953744,0.0009812916,0.00033664692,0.0005563523,0.00027796192,0.0009384273,0.0008793167,0.00010762933],"category_scores_gemma":[0.0009913913,0.00055849133,0.00030050593,0.00037534945,0.0005030247,0.00014139187,0.0013233081,0.0016580586,0.00008979842],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0057055308,0.0015109202,0.05313966,0.006247063,0.0031930464,0.008732472,0.00028516474,0.41300994,0.4772424,0.018033206,0.012725559,0.00017502732],"study_design_scores_gemma":[0.020745935,0.00016791861,0.036744248,0.0042101443,0.00062405,0.0000022186186,0.000018037093,0.87483597,0.056415718,0.00016468528,0.0041617635,0.0019093063],"about_ca_topic_score_codex":0.00063306274,"about_ca_topic_score_gemma":0.000044832857,"teacher_disagreement_score":0.46182603,"about_ca_system_score_codex":0.014124365,"about_ca_system_score_gemma":0.022608733,"threshold_uncertainty_score":0.99968666},"labels":[],"label_agreement":null},{"id":"W3101089240","doi":"10.1016/j.jaccao.2020.08.012","title":"Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats","year":2020,"lang":"en","type":"article","venue":"JACC CardioOncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Toronto General Hospital","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Cardiology; Electrophysiology; Calcium; Calcium channel blocker","score_opus":0.015391547534355753,"score_gpt":0.2784393963992086,"score_spread":0.2630478488648529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101089240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887524,0.0006937163,0.000030347675,0.0043839584,0.00034749514,0.0011651281,0.000006599994,0.00004848244,0.004571848],"genre_scores_gemma":[0.99594617,0.00014341364,0.00017330846,0.0027927642,0.00068585237,0.000059332564,0.000017683049,0.000036312485,0.00014514892],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797773,0.0002278422,0.00034779706,0.00047141965,0.00046884458,0.0005063386],"domain_scores_gemma":[0.99816024,0.00089664303,0.000099224715,0.00040892887,0.00015794864,0.00027698482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018671928,0.00021731065,0.0011769236,0.000178721,0.000024456916,0.00000538194,0.00014771915,0.00027530335,0.000044954457],"category_scores_gemma":[0.0011767935,0.00018182336,0.0002847736,0.0005201081,0.00013645254,0.000029012852,0.00012962738,0.00043219913,0.00020179807],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012084044,0.00032257382,0.0012890833,0.0014209552,0.0018163719,0.8539186,0.0019478746,0.0008444163,0.085733555,0.00046217273,0.017988715,0.022171613],"study_design_scores_gemma":[0.17036602,0.025264615,0.013741295,0.0011063606,0.002296093,0.08231627,0.0008784749,0.015094621,0.5193862,0.00013547909,0.16806781,0.001346807],"about_ca_topic_score_codex":0.00008490811,"about_ca_topic_score_gemma":0.000009244717,"teacher_disagreement_score":0.77160233,"about_ca_system_score_codex":0.00422681,"about_ca_system_score_gemma":0.0028674835,"threshold_uncertainty_score":0.99959576},"labels":[],"label_agreement":null},{"id":"W3103431438","doi":"10.1016/j.abdp.2019.11.004","title":"10.1016/j.abdp.2019.11.004","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.008300046717735536,"score_gpt":0.22750295993401068,"score_spread":0.21920291321627514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103431438","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006238163,0.00017476207,6.608481e-7,0.0008427203,0.0000018585341,0.00047571046,0.000011987283,0.00017592033,0.99207824],"genre_scores_gemma":[0.000646666,0.0000011692141,0.00015666388,0.0001400196,0.00035501184,0.000029376377,0.000037785238,0.00005226781,0.99858105],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982611,0.000039541002,0.00023965458,0.00035395625,0.0005496295,0.00055612694],"domain_scores_gemma":[0.99868345,0.00009598817,0.000021232972,0.0006670174,0.00008915733,0.00044316277],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00023420922,0.00017828804,0.00030196182,0.00012535733,0.00006637143,0.00003121971,0.00022929283,0.000115010414,0.9983894],"category_scores_gemma":[0.00012368438,0.0001566782,0.00010334427,0.00034249065,0.00008208971,0.00006819128,0.00007837953,0.0001832878,0.9979773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003614042,0.00009434869,1.7523185e-7,0.0000317189,0.00003635405,0.0001258642,0.000026322885,0.000025018804,0.00013663399,0.0000011716604,0.65127337,0.34788764],"study_design_scores_gemma":[0.0053554066,0.00033990174,0.000026590851,0.00007379344,0.000040952058,0.00022807962,0.0000013277877,0.0013673702,0.00048104086,0.000004785733,0.99191153,0.0001692354],"about_ca_topic_score_codex":0.00034332566,"about_ca_topic_score_gemma":9.030843e-7,"teacher_disagreement_score":0.3477184,"about_ca_system_score_codex":0.0036948824,"about_ca_system_score_gemma":0.0020493243,"threshold_uncertainty_score":0.9661989},"labels":[],"label_agreement":null},{"id":"W3104194802","doi":"10.14740/jh730","title":"Prognostic Role of Lymphocyte/Monocyte Ratio in Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Lymphocyte; Stage (stratigraphy); Internal medicine; Lymphoproliferative disorders; Monocyte; Gastroenterology; Leukemia; Disease; Immunology; Oncology; Pathology; Lymphoma","score_opus":0.02230681071524895,"score_gpt":0.29584506215848155,"score_spread":0.2735382514432326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104194802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852562,0.011998551,0.0004416198,0.0006958058,0.000119609285,0.00045144,0.0000022009872,0.000022100237,0.0010125025],"genre_scores_gemma":[0.9980966,0.0005333559,0.0006452154,0.00034011388,0.00027871135,0.000010341006,0.0000032139037,0.000040697872,0.00005177596],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969768,0.00015320512,0.0014369121,0.0002720994,0.00062283524,0.00053812936],"domain_scores_gemma":[0.9978531,0.00045583196,0.00065613724,0.00030381873,0.00034217926,0.00038891865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000453655,0.00023515717,0.0012738389,0.00039432125,0.000028152774,0.00001222194,0.00036752017,0.00024675322,0.00020151236],"category_scores_gemma":[0.0012452174,0.00019633329,0.00025898142,0.0006233533,0.00024368381,0.00015839704,0.00012959054,0.00045679213,0.00007711217],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040723078,0.0012829856,0.11728519,0.021959595,0.0042984267,0.060540725,0.016313763,0.057561405,0.58755505,0.036081024,0.014778519,0.041620236],"study_design_scores_gemma":[0.12293888,0.0076696994,0.005537327,0.0021851326,0.0006455718,0.05618476,0.0015400407,0.51344424,0.28098875,0.0016833752,0.0065119783,0.0006702013],"about_ca_topic_score_codex":0.00019255067,"about_ca_topic_score_gemma":0.00003047464,"teacher_disagreement_score":0.45588288,"about_ca_system_score_codex":0.05749663,"about_ca_system_score_gemma":0.08045497,"threshold_uncertainty_score":0.94612145},"labels":[],"label_agreement":null},{"id":"W3109601420","doi":"10.1002/hon.2828","title":"Obinutuzumab‐related adverse events: A systematic review and meta‐analysis","year":2020,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Adverse effect; Relative risk; Oncology; Meta-analysis; Hazard ratio; Follicular lymphoma; Lymphoma; Leukemia; Confidence interval","score_opus":0.11802474173356127,"score_gpt":0.4309193846730987,"score_spread":0.31289464293953745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109601420","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.1391817e-7,0.98947144,0.000021768674,0.0009871715,0.00003936444,0.0074523604,0.000037686063,0.00017085292,0.0018189294],"genre_scores_gemma":[0.000014574049,0.99384487,0.00039412273,0.0018425075,0.000022605383,0.002252979,0.00018242064,0.00006186556,0.0013840391],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99248993,0.0021782243,0.0027647472,0.001240945,0.00061522744,0.00071090326],"domain_scores_gemma":[0.99442416,0.0024265791,0.0011713059,0.0010605186,0.00016922825,0.0007481881],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012175175,0.0008758367,0.030488553,0.00040145896,0.00008026772,0.0000073739657,0.0004898679,0.0014316953,0.0029551734],"category_scores_gemma":[0.0027059147,0.0004793421,0.0052637598,0.0023139897,0.00032513886,0.000045871675,0.0005522206,0.0013568797,0.0013523608],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011784002,0.00009203313,8.8137675e-8,0.7877951,0.20653313,0.004042532,0.000014510374,1.2468827e-7,7.3396733e-9,0.00058407173,0.00041530316,0.00051129865],"study_design_scores_gemma":[0.0012283792,0.00040644372,3.2326508e-8,0.03969701,0.7434517,0.012968896,0.000011652091,0.00007072331,2.8489819e-8,0.000047408324,0.20181891,0.00029880123],"about_ca_topic_score_codex":0.000025343637,"about_ca_topic_score_gemma":0.0000058376363,"teacher_disagreement_score":0.7480981,"about_ca_system_score_codex":0.013194664,"about_ca_system_score_gemma":0.009900045,"threshold_uncertainty_score":0.99986464},"labels":[],"label_agreement":null},{"id":"W3110041392","doi":"10.1101/2020.12.01.406264","title":"Disease related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveals a path to selective inhibitors","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria","funders":"Innosuisse - Schweizerische Agentur für Innovationsförderung; Novartis Stiftung für Medizinisch-Biologische Forschung; Canadian Institutes of Health Research; Cancer Research Society; Novartis Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Michael Smith Health Research BC; National Institutes of Health; National Science Foundation","keywords":"Allosteric regulation; PI3K/AKT/mTOR pathway; Kinase; Mutant; P110α; Protein subunit; Cell biology; Phosphoinositide 3-kinase; Small molecule; Computational biology; Biology; Chemistry; Enzyme; Signal transduction; Biochemistry; Gene","score_opus":0.011816550953751991,"score_gpt":0.25976661315566785,"score_spread":0.24795006220191584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110041392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400336,0.00076013093,0.00016849955,0.0015684927,0.00033324555,0.0025128555,0.00034316586,0.00029363274,0.000016646994],"genre_scores_gemma":[0.9971598,0.00009917736,0.0014117477,0.00032887692,0.00028181454,0.00048574945,0.00000483897,0.00019851596,0.000029506044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562055,0.00024792977,0.00089721713,0.0016121146,0.00081919157,0.0008029759],"domain_scores_gemma":[0.9962897,0.00017362967,0.00029208625,0.0012233692,0.000500613,0.001520625],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065023155,0.0006476619,0.0009488822,0.000674088,0.00013580678,0.00013517897,0.00032592443,0.00056239136,0.000020135007],"category_scores_gemma":[0.0016624092,0.00070500514,0.00016980265,0.0014366375,0.00027202297,0.00014041195,0.00085027533,0.0015016268,0.000054961834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006117888,0.0030852421,0.45986894,0.025627257,0.0024780182,0.04283073,0.0020740323,0.0012155373,0.44375303,0.0077046645,0.005128829,0.00011583007],"study_design_scores_gemma":[0.009566676,0.00037935568,0.9265105,0.005439324,0.0006355283,0.0000013999446,0.000045615554,0.04655311,0.009082885,0.000059781712,0.00016914506,0.0015566403],"about_ca_topic_score_codex":0.00019935379,"about_ca_topic_score_gemma":0.000018482559,"teacher_disagreement_score":0.4666416,"about_ca_system_score_codex":0.016347345,"about_ca_system_score_gemma":0.01218846,"threshold_uncertainty_score":0.9995401},"labels":[],"label_agreement":null},{"id":"W3111110582","doi":"10.1111/bjh.17141","title":"Clinical and biological features of B‐cell neoplasms with <i>CDK6</i> translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and <i>TP53</i> abnormalities","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Splenic marginal zone lymphoma; Biology; CD5; IGHV@; Chronic lymphocytic leukemia; Gene rearrangement; Mantle cell lymphoma; Prolymphocytic leukemia; Molecular biology; Cancer research; B cell; Pathology; Lymphoma; Antibody; Immunology; Leukemia; Genetics; Medicine; Gene","score_opus":0.01806354584269679,"score_gpt":0.26378142896968043,"score_spread":0.24571788312698364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111110582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046504,0.0077375253,0.00079107255,0.00042991873,0.000044909182,0.00039316955,0.000036788362,0.000013884262,0.00008766689],"genre_scores_gemma":[0.989385,0.004040475,0.006158529,0.00024671262,0.00008719963,0.000011628026,0.000014474915,0.000027223005,0.000028727605],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99720174,0.0004182578,0.001086118,0.00033763848,0.0005941152,0.0003621118],"domain_scores_gemma":[0.9974987,0.0006265182,0.0008514582,0.00015993262,0.0004724547,0.00039092274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082099764,0.00020924723,0.0012293601,0.00010518418,0.00008461137,0.000035085435,0.00017578463,0.00027691398,0.000024099587],"category_scores_gemma":[0.00024556663,0.0001597299,0.00010517443,0.0002135091,0.00073381653,0.0002312693,0.00005586287,0.0004452153,4.736127e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053405777,0.0054414016,0.6882725,0.014072066,0.0026898973,0.06767018,0.01217496,0.000233705,0.13249403,0.0012728701,0.0042689284,0.018003715],"study_design_scores_gemma":[0.13587156,0.022905752,0.06807215,0.0066601066,0.0017211286,0.5869971,0.00750825,0.0016792379,0.16674523,0.00021273602,0.000671065,0.0009556913],"about_ca_topic_score_codex":0.00029434293,"about_ca_topic_score_gemma":0.00012159352,"teacher_disagreement_score":0.62020034,"about_ca_system_score_codex":0.00044373618,"about_ca_system_score_gemma":0.0027088183,"threshold_uncertainty_score":0.6513596},"labels":[],"label_agreement":null},{"id":"W3111164005","doi":"10.4049/jimmunol.2000599","title":"A Case for Phosphoinositide 3-Kinase–Targeted Therapy for Infectious Disease","year":2020,"lang":"en","type":"review","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"PI3K/AKT/mTOR pathway; Repurposing; Immune system; Infectious disease (medical specialty); Disease; Phosphoinositide 3-kinase; Limiting; Regulator; Biology; Immunology; Medicine; Signal transduction; Computational biology; Cell biology; Internal medicine; Genetics; Engineering","score_opus":0.05189440973440962,"score_gpt":0.3679633907338044,"score_spread":0.3160689809993948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111164005","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000711695,0.99396235,0.0006784112,0.00063329714,0.0005694041,0.0032907831,0.00010494243,0.000024058438,0.000025065776],"genre_scores_gemma":[0.00080209435,0.99725777,0.00020904618,0.00031402765,0.0008405139,0.000213775,0.000043373842,0.00011592875,0.00020349135],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975348,0.0003911704,0.0010890947,0.00022057455,0.00024803253,0.0005163451],"domain_scores_gemma":[0.99494094,0.0027332348,0.00099516,0.0005533904,0.0005262626,0.00025103695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009939602,0.0004067976,0.0022557501,0.00025617037,0.00018048749,0.000022619233,0.00046825127,0.00028938273,0.00006569313],"category_scores_gemma":[0.0015191357,0.00022595633,0.0013793883,0.0002974938,0.00025421332,0.000052446376,0.00010096821,0.00089625374,0.000019634484],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006828949,0.0002155765,5.360844e-7,0.007839154,0.0041880105,0.007751262,0.00022234592,0.0000020391076,0.00003692587,0.00010706445,0.0055926996,0.9672154],"study_design_scores_gemma":[0.015062782,0.0029941467,9.094693e-7,0.0025989406,0.0031471835,0.10181078,0.000048318507,0.00008278712,0.000053775613,0.00019133075,0.87382627,0.00018278162],"about_ca_topic_score_codex":0.000060063383,"about_ca_topic_score_gemma":0.000003551613,"teacher_disagreement_score":0.9670327,"about_ca_system_score_codex":0.005307711,"about_ca_system_score_gemma":0.018131912,"threshold_uncertainty_score":0.9985107},"labels":[],"label_agreement":null},{"id":"W3112032975","doi":"10.1016/s2152-2650(20)30789-8","title":"CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Ofatumumab; Rituximab; Chronic lymphocytic leukemia; Idelalisib; Medicine; Refractory (planetary science); Ibrutinib; CD20; Alemtuzumab; Leukemia; Immunology; Antibody; Biology","score_opus":0.13107819012937313,"score_gpt":0.38457676341337677,"score_spread":0.2534985732840036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112032975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684045,0.0045899292,0.00018463879,0.0031912134,0.0033331588,0.0038697599,0.0005498732,0.001442852,0.014434131],"genre_scores_gemma":[0.9768872,0.0025834243,0.0021063744,0.00435629,0.0066667325,0.00035227466,0.0010007623,0.0006380013,0.005408936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9773025,0.0013307236,0.00767596,0.005135856,0.0039420314,0.0046129385],"domain_scores_gemma":[0.9808542,0.008357853,0.0017657907,0.004037227,0.0009047397,0.0040801885],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0040925485,0.002407176,0.0056093135,0.000880559,0.0006470389,0.00035841693,0.002965875,0.003226593,0.0017212011],"category_scores_gemma":[0.022511825,0.0021882565,0.0018243871,0.0037870596,0.002685905,0.0008475568,0.0022144106,0.0041110613,0.0064844927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.39989832,0.002495521,0.00043173204,0.00408964,0.0023028187,0.048788764,0.0024636667,0.0063286135,0.001293164,0.0010750542,0.1645832,0.36624947],"study_design_scores_gemma":[0.585737,0.00988218,0.021294279,0.0020782782,0.0009991613,0.0018392948,0.00057910173,0.2646387,0.0009983531,0.00012266255,0.109184705,0.0026463289],"about_ca_topic_score_codex":0.004955827,"about_ca_topic_score_gemma":0.0010273037,"teacher_disagreement_score":0.36360314,"about_ca_system_score_codex":0.34955493,"about_ca_system_score_gemma":0.2604436,"threshold_uncertainty_score":0.99919134},"labels":[],"label_agreement":null},{"id":"W3113075182","doi":"10.1097/md.0000000000023632","title":"Tumor lysis syndrome in chronic lymphocytic leukemia: conventional treatment versus novel agents","year":2020,"lang":"en","type":"article","venue":"Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Medicine; Tumor lysis syndrome; Chronic lymphocytic leukemia; Leukemia; Lysis; Immunology; Oncology; Cancer research; Internal medicine; Chemotherapy","score_opus":0.08947880418693276,"score_gpt":0.34431076925913856,"score_spread":0.2548319650722058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113075182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98525774,0.0021157628,0.00023732944,0.0066093225,0.00047394005,0.0011313831,0.00002182419,0.00015676969,0.0039959042],"genre_scores_gemma":[0.9956111,0.00027847575,0.0001847137,0.0013262,0.0007627552,0.00012584044,0.00017772503,0.00005971473,0.0014734968],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967613,0.000054566193,0.00066774565,0.0007083514,0.0010861681,0.00072183966],"domain_scores_gemma":[0.9983363,0.00027713858,0.00011911726,0.00049842964,0.000096401905,0.0006726012],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002748154,0.0003710332,0.00092002173,0.00030106446,0.00006723642,0.000011553445,0.00024287216,0.00013022119,0.0030581946],"category_scores_gemma":[0.00053077395,0.00028713638,0.00018101707,0.0009866105,0.00034879646,0.00008438578,0.000109119625,0.00028108287,0.0006622184],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09887753,0.0043804673,0.016138395,0.021430967,0.019991385,0.2952329,0.026781853,0.048830863,0.16275069,0.010671127,0.19371107,0.10120275],"study_design_scores_gemma":[0.5078143,0.015128121,0.013982702,0.0015069217,0.0010467619,0.003241705,0.0007324675,0.39389753,0.0024426447,0.00004114254,0.05944922,0.00071651017],"about_ca_topic_score_codex":0.0030338299,"about_ca_topic_score_gemma":0.00013223711,"teacher_disagreement_score":0.40893677,"about_ca_system_score_codex":0.205061,"about_ca_system_score_gemma":0.02780403,"threshold_uncertainty_score":0.9999581},"labels":[],"label_agreement":null},{"id":"W3113256330","doi":"10.1158/1541-7786.mcr-20-0814","title":"Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy","year":2020,"lang":"en","type":"review","venue":"Molecular Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Bruton's tyrosine kinase; Ibrutinib; Medicine; Coronavirus disease 2019 (COVID-19); Outbreak; Tyrosine kinase; Immunology; Pandemic; Immune system; Disease; Virology; Internal medicine; Infectious disease (medical specialty); Leukemia","score_opus":0.17550109731903984,"score_gpt":0.5086712537179664,"score_spread":0.33317015639892655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113256330","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000085089094,0.9855588,0.00024207566,0.0043283612,0.00016526913,0.008647992,0.0002881164,0.000044211803,0.0006401044],"genre_scores_gemma":[0.00017492502,0.9912835,0.00027144546,0.0009402553,0.00037425957,0.0035943445,0.00010919365,0.0002376658,0.0030144253],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993168,0.0010407694,0.00080759113,0.0011120404,0.002740281,0.0011313024],"domain_scores_gemma":[0.9950433,0.0012462361,0.0002875841,0.0018688331,0.0007868004,0.00076726364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019762989,0.00050749065,0.0020536722,0.00037973336,0.00024370129,0.00005406093,0.0014159675,0.00047876165,0.0004744456],"category_scores_gemma":[0.0063825017,0.00032667496,0.0011861561,0.0024377375,0.00081985805,0.00003595979,0.00063799333,0.0016605983,0.00006927184],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016171865,0.0002711656,0.0000026658972,0.096833535,0.0011221368,0.0011932972,0.00027495145,0.000022424,0.0018936298,0.0014041865,0.029274324,0.8660905],"study_design_scores_gemma":[0.0067043444,0.0007380581,2.397863e-7,0.0075855944,0.00020121722,0.00013919733,0.000015861904,0.00014462588,0.005155134,0.00037524913,0.978677,0.00026352867],"about_ca_topic_score_codex":0.0025387919,"about_ca_topic_score_gemma":0.000032321845,"teacher_disagreement_score":0.94940263,"about_ca_system_score_codex":0.022238767,"about_ca_system_score_gemma":0.11077878,"threshold_uncertainty_score":0.9999185},"labels":[],"label_agreement":null},{"id":"W3113752789","doi":"10.1182/blood.2020006322","title":"Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"National Center for Advancing Translational Sciences; National Institute on Aging; Centers for Disease Control and Prevention; National Cancer Institute; CancerCare Manitoba Foundation; National Institutes of Health; Huntsman Cancer Foundation; University of Utah; U.S. Department of Veterans Affairs","keywords":"Cumulative incidence; Lymphocytosis; Incidence (geometry); Population; Medicine; Internal medicine; Immunology; Chronic lymphocytic leukemia; Cohort; Leukemia","score_opus":0.02188533929062256,"score_gpt":0.24356327027944077,"score_spread":0.22167793098881822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113752789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97654295,0.006765517,0.00000335346,0.00017536011,0.000082222374,0.0002632603,0.0000044193835,0.00004131615,0.01612159],"genre_scores_gemma":[0.9969775,0.00023438911,0.0005479088,0.0001857139,0.00009850526,0.00001639519,0.000011764878,0.00002630075,0.001901522],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985723,0.00006256148,0.00034159407,0.0003042406,0.00043174997,0.0002875804],"domain_scores_gemma":[0.9992804,0.00016283384,0.000086250664,0.0002333922,0.00006953363,0.00016761437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001274388,0.00014803011,0.0003781918,0.0001371007,0.000012882603,0.0000033896185,0.00015607687,0.00011130542,0.00010400622],"category_scores_gemma":[0.00027005453,0.00013401022,0.00011790521,0.0002570312,0.00027100742,0.000094384646,0.00010983285,0.00028637308,0.000040201256],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049585328,0.0073519195,0.36125118,0.0049909772,0.0010729427,0.0037262414,0.066665925,0.00016139634,0.5233496,0.00054798945,0.02120448,0.0047188117],"study_design_scores_gemma":[0.3201069,0.0020354725,0.29621372,0.0010020193,0.00072101614,0.00024047488,0.0044458224,0.046398498,0.3158899,0.00012769633,0.011638276,0.0011801802],"about_ca_topic_score_codex":0.0009311954,"about_ca_topic_score_gemma":0.00003458162,"teacher_disagreement_score":0.31514838,"about_ca_system_score_codex":0.006025688,"about_ca_system_score_gemma":0.0051514264,"threshold_uncertainty_score":0.99779},"labels":[],"label_agreement":null},{"id":"W3116445431","doi":"10.3747/co.27.6795","title":"Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Impact; Fluidigm (Canada); Dalhousie University; Research Institute in Oncology and Hematology; University of Ottawa; BC Cancer Agency; University of Manitoba; Canadian Blood Services; CancerCare Manitoba","funders":"","keywords":"Bruton's tyrosine kinase; Chemoimmunotherapy; Chronic lymphocytic leukemia; Medicine; Ibrutinib; Tyrosine kinase; Venetoclax; Clinical trial; Oncology; Immunology; Leukemia; Cancer research; Internal medicine; Receptor","score_opus":0.19564991989630315,"score_gpt":0.47120946486337184,"score_spread":0.2755595449670687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116445431","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042570857,0.9898334,0.00013111724,0.00021529006,0.0027774908,0.0064995047,0.0002444539,0.00008551384,0.00017067119],"genre_scores_gemma":[0.0001315388,0.99173206,0.0000953581,0.000026853766,0.00449656,0.0019275706,0.00078334805,0.00015763438,0.0006490769],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99589944,0.00026585412,0.0015264556,0.0009216947,0.0005285126,0.00085803366],"domain_scores_gemma":[0.9951842,0.0022475796,0.00079713634,0.0011105511,0.00026357037,0.00039700253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036965814,0.00082143553,0.0043408093,0.00028229138,0.00012750119,0.000017711716,0.0005184399,0.0006634607,0.00017444161],"category_scores_gemma":[0.00050952524,0.00048174907,0.0015953941,0.00060130167,0.0005536777,0.000036334222,0.00023048905,0.00049388286,0.00017018],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00030843928,0.00041795033,9.1334715e-7,0.029536163,0.0007586401,0.00013350764,0.00011506238,0.000012356088,0.0000052263395,0.0000733399,0.01072939,0.957909],"study_design_scores_gemma":[0.021687023,0.0069152266,5.7224696e-7,0.007189136,0.0057582557,0.0004483349,0.00002030669,0.008919697,0.000074036965,0.000010141438,0.94865334,0.00032393777],"about_ca_topic_score_codex":0.00028604822,"about_ca_topic_score_gemma":0.000068282076,"teacher_disagreement_score":0.9575851,"about_ca_system_score_codex":0.38142762,"about_ca_system_score_gemma":0.18687846,"threshold_uncertainty_score":0.9997634},"labels":[],"label_agreement":null},{"id":"W3119244553","doi":"10.1182/bloodadvances.2020002995","title":"Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Spinal Cord Injury BC","funders":"Broad Institute","keywords":"Notch signaling pathway; Biology; Cancer research; Lymphoma; Diffuse large B-cell lymphoma; Chronic lymphocytic leukemia; B cell; Splenic marginal zone lymphoma; Signal transduction; Cell biology; Leukemia; Immunology; Antibody","score_opus":0.02571232708116198,"score_gpt":0.33115807238932454,"score_spread":0.30544574530816254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119244553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396306,0.0022760378,0.000082890074,0.0024500631,0.00001998879,0.0006028059,0.000012600651,0.000013277963,0.0005793003],"genre_scores_gemma":[0.99655217,0.00050244026,0.0021309927,0.00030985416,0.000057887828,0.00020638289,0.000042261025,0.000020187534,0.00017781535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987649,0.000040195187,0.00033016122,0.00038423543,0.00016433129,0.00031622176],"domain_scores_gemma":[0.99897265,0.00055840117,0.00006530591,0.0002207036,0.00011320674,0.00006972356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022155755,0.00012275697,0.00028722055,0.00019829144,0.000038062135,0.00001953416,0.00007846796,0.00007453446,0.000015007416],"category_scores_gemma":[0.00036630462,0.00012243964,0.000037074435,0.0006812493,0.000044953482,0.00020000982,0.000054524317,0.00019535133,0.0000020645587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054927234,0.002540065,0.40623093,0.0019722714,0.00004224651,0.0002314004,0.0055973334,0.0009282566,0.5504006,0.00057780044,0.00011249504,0.03081733],"study_design_scores_gemma":[0.04901135,0.00027550192,0.08725755,0.0012294123,0.000045028053,0.000099611796,0.0037648517,0.0034788314,0.8493652,0.0027486486,0.0023738206,0.00035020246],"about_ca_topic_score_codex":0.0004390748,"about_ca_topic_score_gemma":0.0014577421,"teacher_disagreement_score":0.31897336,"about_ca_system_score_codex":0.0013504142,"about_ca_system_score_gemma":0.0018217267,"threshold_uncertainty_score":0.49929437},"labels":[],"label_agreement":null},{"id":"W3120167576","doi":"10.3390/curroncol28010037","title":"Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Foothills Medical Centre; Ottawa Hospital; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba; Université de Montréal","funders":"AbbVie Canada","keywords":"IGHV@; Medicine; Chemoimmunotherapy; Chronic lymphocytic leukemia; Fludarabine; Incidence (geometry); Watchful waiting; Health care; Internal medicine; Leukemia; Cancer; Chemotherapy","score_opus":0.07653187858319964,"score_gpt":0.3956191259834053,"score_spread":0.31908724740020566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120167576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934396,0.0045581395,0.0000017022277,0.0002123326,0.0004797096,0.0004004441,0.000031774005,0.000006583865,0.00086968136],"genre_scores_gemma":[0.9980422,0.0016016929,0.0000085484935,0.000041834293,0.0001450763,0.00003105219,0.000037833663,0.000020431655,0.00007128577],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982433,0.00023506986,0.0005151438,0.00028603213,0.0002735405,0.00044693061],"domain_scores_gemma":[0.9984358,0.0005863312,0.00017885695,0.0005483249,0.0001291068,0.00012156896],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030989654,0.00017420395,0.0006585013,0.00011370607,0.00002195665,0.000003461363,0.00024109286,0.00009872178,0.0014820722],"category_scores_gemma":[0.00019358899,0.00011689754,0.00016501648,0.00026497417,0.00017807177,0.00002420705,0.00009008381,0.00031563104,0.000021594995],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009752942,0.0011331501,0.056303676,0.0017013347,0.0030746441,0.002370581,0.0052776844,0.23438883,0.052269477,0.002440519,0.092948966,0.5383382],"study_design_scores_gemma":[0.11525017,0.008630981,0.0665233,0.0009292082,0.000159415,0.00069311424,0.0011125959,0.70399886,0.059153754,0.00032487675,0.042555448,0.0006682548],"about_ca_topic_score_codex":0.85685724,"about_ca_topic_score_gemma":0.53261083,"teacher_disagreement_score":0.53766996,"about_ca_system_score_codex":0.52806246,"about_ca_system_score_gemma":0.545162,"threshold_uncertainty_score":0.9994307},"labels":[],"label_agreement":null},{"id":"W3120636941","doi":"10.1016/j.clml.2021.01.007","title":"To Treat or Not? Remission Induction of Acquired von Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa","funders":"Takeda Pharmaceutical Company; CSL Behring; Bayer","keywords":"Medicine; Chronic lymphocytic leukemia; Von Willebrand factor; Immunology; Leukemia; Platelet","score_opus":0.04758273240337041,"score_gpt":0.3628521424247844,"score_spread":0.315269410021414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120636941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917371,0.000722757,0.00020554784,0.00087441434,0.0012817828,0.0018993238,0.000075358184,0.00033394675,0.0028697224],"genre_scores_gemma":[0.9725263,0.00027903853,0.0024823481,0.0021362593,0.0012675741,0.00021251816,0.00021668889,0.00024619786,0.020633057],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9893032,0.00060242525,0.003859621,0.0026434963,0.0019457289,0.00164558],"domain_scores_gemma":[0.990211,0.0017627032,0.00070621015,0.0034728232,0.001152676,0.0026945488],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025387246,0.0009415842,0.002754761,0.00064186833,0.00035885003,0.00012609549,0.00066181296,0.0014157903,0.0015497546],"category_scores_gemma":[0.008754322,0.00080497185,0.0009457048,0.002654923,0.0005848969,0.00039463016,0.0011499893,0.00050296163,0.00068987167],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010935567,0.00026383862,0.00030189095,0.0015249591,0.00044730766,0.5932915,0.0004178287,0.00038433724,0.027756251,0.000033606026,0.015495878,0.34914702],"study_design_scores_gemma":[0.049234558,0.0047519053,0.043438513,0.002698859,0.00077172637,0.77561986,0.00048608924,0.0042544547,0.0956092,0.00005886275,0.021831937,0.0012440291],"about_ca_topic_score_codex":0.0017579506,"about_ca_topic_score_gemma":0.0002788567,"teacher_disagreement_score":0.34790298,"about_ca_system_score_codex":0.18254972,"about_ca_system_score_gemma":0.19953318,"threshold_uncertainty_score":0.99988055},"labels":[],"label_agreement":null},{"id":"W3123384879","doi":"10.3899/jrheum.200591","title":"Hyperviscosity Syndrome in Rheumatoid Arthritis","year":2021,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Hyperviscosity syndrome; Rheumatoid arthritis; Context (archaeology); Macroglobulinemia; Waldenstrom macroglobulinemia; Pediatrics; Surgery; Dermatology; Internal medicine; Multiple myeloma; Lymphoma","score_opus":0.017902697231667007,"score_gpt":0.2795389676682263,"score_spread":0.2616362704365593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123384879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98489,0.010132134,0.0000971138,0.003932674,0.0002529741,0.00008994194,0.0000010028417,0.0000080567415,0.00059610273],"genre_scores_gemma":[0.97692746,0.022434684,0.00028289913,0.00019108933,0.00000575594,0.0000014111044,0.0000013836699,0.000015860698,0.0001394542],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9981467,0.0003355039,0.000668651,0.00010897264,0.00039449675,0.00034564384],"domain_scores_gemma":[0.99849033,0.00055024255,0.00020777919,0.0003618237,0.00025204732,0.00013778562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010831503,0.00011111952,0.0006532538,0.00016188482,0.000051821204,0.000010951586,0.00023547014,0.00011125285,0.00037195563],"category_scores_gemma":[0.0007254677,0.00007477095,0.00012085839,0.0003555864,0.00018769699,0.000079775884,0.0001253284,0.0005977769,0.000083965584],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053135757,0.002497672,0.83160275,0.0012111057,0.0018365375,0.0673994,0.007604105,0.00054377964,0.009051759,0.008942536,0.023131205,0.040865604],"study_design_scores_gemma":[0.016093113,0.00033028517,0.017781131,0.0010952014,0.00002275583,0.9589026,0.0007283243,0.0006184201,0.001435544,0.0009641131,0.0019239137,0.00010461759],"about_ca_topic_score_codex":0.00050103146,"about_ca_topic_score_gemma":0.00036369503,"teacher_disagreement_score":0.8915032,"about_ca_system_score_codex":0.0014270489,"about_ca_system_score_gemma":0.004950018,"threshold_uncertainty_score":0.8781119},"labels":[],"label_agreement":null},{"id":"W3124058658","doi":"10.1503/cmaj.201022","title":"Azathioprine-induced severe anemia potentiated by the concurrent use of allopurinol","year":2021,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Lethargy; Azathioprine; Allopurinol; Medicine; Weakness; Anemia; Presentation (obstetrics); Internal medicine; Pediatrics; Disease; Surgery","score_opus":0.021928376414486292,"score_gpt":0.277045543406988,"score_spread":0.2551171669925017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124058658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682048,0.0005481423,0.000033919347,0.028977217,0.0006571419,0.00019020795,0.00006229503,0.000014804486,0.0013114962],"genre_scores_gemma":[0.98994184,0.00034107236,0.000037285976,0.0056095445,0.0005221385,0.0000045298475,0.000058613616,0.000021330146,0.0034636636],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959585,0.00030438654,0.00059863046,0.00018457019,0.0023791073,0.0005747953],"domain_scores_gemma":[0.9962716,0.0003966007,0.00025199237,0.00022767055,0.0012520793,0.0016000373],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011178757,0.00012798586,0.00032320883,0.00009454909,0.00018408608,0.000083616476,0.00021140555,0.00038321703,0.00424684],"category_scores_gemma":[0.0062746964,0.00009504829,0.00016034266,0.0003998624,0.00006269545,0.00009326034,0.000047839076,0.0012973497,0.000061958825],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000069685615,0.0002616083,0.04263586,0.00014917199,0.0011263753,0.007760382,0.00064819853,0.000016482249,0.0059353346,0.00056507566,0.8485832,0.09224858],"study_design_scores_gemma":[0.029421281,0.00024636288,0.060902093,0.0006630774,0.00030485232,0.020763284,0.0010496688,0.0034573146,0.008609242,0.00005957943,0.8740119,0.0005113495],"about_ca_topic_score_codex":0.0065487786,"about_ca_topic_score_gemma":0.008145316,"teacher_disagreement_score":0.09173723,"about_ca_system_score_codex":0.013018402,"about_ca_system_score_gemma":0.050147515,"threshold_uncertainty_score":0.9966634},"labels":[],"label_agreement":null},{"id":"W3124264060","doi":"10.3390/proteomes9010003","title":"Proteomics-Based Regression Model for Assessing the Development of Chronic Lymphocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Proteomes","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Disease; Regression; Regression analysis; Leukemia; Statistics; Machine learning; Computer science","score_opus":0.05631168032578947,"score_gpt":0.3681074432243905,"score_spread":0.311795762898601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124264060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7782592,0.0011556348,0.21629243,0.00045101886,0.0000766924,0.0032336465,0.0000065551585,0.00007750701,0.00044731682],"genre_scores_gemma":[0.82005227,0.000016234551,0.17659268,0.0001194271,0.00013203642,0.0011966068,0.00004003874,0.000055338245,0.0017953692],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997797,0.00006709814,0.00055787025,0.00042391964,0.0006491826,0.0005049298],"domain_scores_gemma":[0.9983022,0.00024250287,0.00020077739,0.00066486764,0.00046225445,0.00012737678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075396366,0.0002236403,0.00042743722,0.00009803079,0.00026412396,0.000054722863,0.00023235481,0.0001473046,0.00008252388],"category_scores_gemma":[0.00061400904,0.00014294923,0.00016531625,0.00029387177,0.00016865868,0.00009101072,0.00014979983,0.0002007554,0.000015668022],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010019293,0.00033994767,0.0003896288,0.011982845,0.00049016764,0.000120762874,0.003556306,0.032515597,0.8736149,0.0005764044,0.00117814,0.074233375],"study_design_scores_gemma":[0.006715548,0.00004457255,0.00006318947,0.00064967666,0.000036266065,0.000025531092,0.00006160837,0.53476167,0.45703313,0.00019916898,0.00031128334,0.0000983318],"about_ca_topic_score_codex":0.000023586425,"about_ca_topic_score_gemma":0.000015374082,"teacher_disagreement_score":0.5022461,"about_ca_system_score_codex":0.056697905,"about_ca_system_score_gemma":0.19608675,"threshold_uncertainty_score":0.94692326},"labels":[],"label_agreement":null},{"id":"W3124543108","doi":"10.1016/j.critrevonc.2021.103238","title":"Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Ibrutinib; Atrial fibrillation; Meta-analysis; Medicine; Internal medicine; Cardiology; Leukemia","score_opus":0.19438187720026537,"score_gpt":0.4843117483147941,"score_spread":0.2899298711145287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124543108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000035795406,0.9917803,0.000089550056,0.00075193367,0.000021641094,0.006827452,0.0001197337,0.00002075442,0.00038509586],"genre_scores_gemma":[0.000071694354,0.99758947,0.0008346275,0.00013437588,0.00003216091,0.0009473225,0.00026997522,0.000043303586,0.0000770894],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.990197,0.0046684914,0.0033190693,0.0009777566,0.0003179236,0.00051973836],"domain_scores_gemma":[0.98087263,0.016025046,0.0014338867,0.0009840246,0.0003981958,0.00028619595],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0031708586,0.00064845517,0.026501546,0.00053989654,0.000093046474,0.000021210959,0.0001769236,0.0007514386,0.00015033524],"category_scores_gemma":[0.028098594,0.0003824238,0.0026009544,0.0018093939,0.0007659474,0.00005367402,0.00017181893,0.00056742004,0.000015805253],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000125731085,0.00011545016,0.000030438421,0.8794597,0.100149445,0.00019334434,0.000048205908,2.527865e-7,2.5203814e-8,0.006839377,0.000060521987,0.013090711],"study_design_scores_gemma":[0.0015573783,0.000423573,0.0000016184055,0.14453056,0.8116015,0.002330756,0.00001551391,0.00010930874,1.2085427e-7,0.000058430494,0.039126247,0.0002449666],"about_ca_topic_score_codex":0.0000459126,"about_ca_topic_score_gemma":0.00010723261,"teacher_disagreement_score":0.7349291,"about_ca_system_score_codex":0.00393484,"about_ca_system_score_gemma":0.0035199497,"threshold_uncertainty_score":0.9998889},"labels":[],"label_agreement":null},{"id":"W3124922392","doi":"10.1038/s41418-020-00692-w","title":"Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL","year":2021,"lang":"en","type":"article","venue":"Cell Death and Differentiation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Bcl-xL; Venetoclax; Cancer research; Chronic lymphocytic leukemia; Downregulation and upregulation; NF-κB; CD40; Context (archaeology); RELB; Signal transduction; Apoptosis; Chemistry; Jurkat cells; Drug resistance; Transcription factor; Cell biology; Biology; Leukemia; NFKB1; T cell; Immunology; Programmed cell death; Cytotoxic T cell; In vitro; Biochemistry; Genetics; Gene; Immune system","score_opus":0.01588734366679697,"score_gpt":0.2687994310725396,"score_spread":0.25291208740574267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124922392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586606,0.0011309334,0.00008398375,0.00029824997,0.00003430034,0.0002843498,0.0000064817123,0.0000031723312,0.0022924743],"genre_scores_gemma":[0.9985476,0.00018100163,0.00006627651,0.00005740153,0.000020060257,0.000012818913,0.0001289862,0.000007595279,0.0009782607],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99884737,0.00012357619,0.00035575937,0.00019675428,0.00031934874,0.00015719776],"domain_scores_gemma":[0.99928653,0.00021660957,0.00010371772,0.00024913604,0.0000990856,0.000044908018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027776233,0.00008421265,0.00024810873,0.000078712765,0.000020669364,0.000010313735,0.00006330159,0.0000859612,0.000038544324],"category_scores_gemma":[0.00012188255,0.00006488163,0.00004074459,0.00022871494,0.000039353916,0.000049291626,0.000028286131,0.00013429244,0.0000016196162],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011719164,0.001124051,0.060584493,0.0015584858,0.000035561305,0.000040403607,0.006811417,0.000004682449,0.91951907,0.0025569417,0.0027994402,0.0037935635],"study_design_scores_gemma":[0.018830353,0.000089296445,0.49265665,0.00038236723,0.000052955074,0.0000064526985,0.0009899226,0.0063252584,0.47960737,0.00066059286,0.00027520597,0.0001235733],"about_ca_topic_score_codex":0.00037865754,"about_ca_topic_score_gemma":0.0009510356,"teacher_disagreement_score":0.43991166,"about_ca_system_score_codex":0.0006384708,"about_ca_system_score_gemma":0.0008478327,"threshold_uncertainty_score":0.26457962},"labels":[],"label_agreement":null},{"id":"W3125089654","doi":"10.3390/cancers13020354","title":"Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Ibrutinib; Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Cancer research; Pharmacology; Respiration; breakpoint cluster region; Apoptosis; Biology; Leukemia; Immunology; Receptor; Biochemistry","score_opus":0.027002377576806118,"score_gpt":0.32869990758696915,"score_spread":0.30169753001016303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125089654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418944,0.0003154012,0.000106747786,0.0016540214,0.00050554256,0.00051605,0.000014600375,0.000035464993,0.0026627579],"genre_scores_gemma":[0.98656,0.00006742151,0.0021748468,0.0019045296,0.00075211906,0.000102825565,0.000022675287,0.000039991883,0.008375625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812824,0.00016181293,0.00031574303,0.00048570923,0.00045757045,0.00045092512],"domain_scores_gemma":[0.99874777,0.00025049679,0.000035677465,0.00051780033,0.00013468857,0.00031358056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003171446,0.00013801086,0.00027774557,0.00014959893,0.000029730258,0.000027437056,0.000121684716,0.00016254815,0.00065919175],"category_scores_gemma":[0.0010329807,0.00013915879,0.00008034729,0.00062799844,0.00007988196,0.000049572423,0.00009043587,0.000234437,0.00021886981],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007945408,0.000019802943,0.0000323606,0.00005240048,0.000017990553,0.0004846945,0.00054890447,0.00091447105,0.92856514,0.000018180748,0.061034795,0.00036586466],"study_design_scores_gemma":[0.014693154,0.0002645294,0.0002095236,0.00021246425,0.000017548533,0.000055137156,0.0002223643,0.0023813352,0.86826587,0.00002376055,0.113473676,0.00018065136],"about_ca_topic_score_codex":0.00066482485,"about_ca_topic_score_gemma":0.0002115928,"teacher_disagreement_score":0.06029927,"about_ca_system_score_codex":0.045043133,"about_ca_system_score_gemma":0.029634126,"threshold_uncertainty_score":0.975867},"labels":[],"label_agreement":null},{"id":"W3126404231","doi":"10.1097/md.0000000000024703","title":"Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy","year":2021,"lang":"en","type":"article","venue":"Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"National Natural Science Foundation of China","keywords":"Medicine; Venetoclax; Chronic lymphocytic leukemia; Myeloid leukemia; Internal medicine; Leukemia; Chlorambucil; Myeloid; White blood cell; Lymphocytosis; Immunophenotyping; Hematology; Bone marrow; Gastroenterology; Chemotherapy; Oncology; Immunology; Cyclophosphamide; Antigen","score_opus":0.015411662708995725,"score_gpt":0.29771455760227106,"score_spread":0.2823028948932753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126404231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95995176,0.03136176,0.00014186924,0.0009546932,0.00034891855,0.0005925162,0.000011553337,0.00009265547,0.0065442985],"genre_scores_gemma":[0.9776403,0.008684093,0.00046675006,0.0010808279,0.0010038395,0.00007937163,0.00010813908,0.00009809267,0.010838602],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968489,0.000082030405,0.00074302993,0.00073977833,0.0009208284,0.0006654299],"domain_scores_gemma":[0.9977646,0.00019493054,0.00016909731,0.0010403134,0.000311183,0.0005199058],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005016069,0.00038379245,0.0010119426,0.00025951763,0.00008600225,0.00001563091,0.00019331752,0.00030546542,0.0029235224],"category_scores_gemma":[0.00012300022,0.0003000301,0.000134812,0.00070810254,0.0006218647,0.00012513898,0.00020683119,0.0004975617,0.00004503357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016182976,0.000114525086,0.0016002891,0.0061533507,0.0019922806,0.0124044465,0.005403455,0.00039777975,0.7613323,0.00040233062,0.036254384,0.1577619],"study_design_scores_gemma":[0.24033558,0.0041179494,0.009657844,0.006533556,0.0010770761,0.010142494,0.00085763814,0.0596653,0.48396462,0.00055158173,0.18203394,0.0010624094],"about_ca_topic_score_codex":0.0015034692,"about_ca_topic_score_gemma":0.00007340356,"teacher_disagreement_score":0.27736765,"about_ca_system_score_codex":0.08909967,"about_ca_system_score_gemma":0.07902931,"threshold_uncertainty_score":0.99994516},"labels":[],"label_agreement":null},{"id":"W3126819005","doi":"10.1002/stem.3352","title":"Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"Stem Cells","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Deutsche Forschungsgemeinschaft; Boettcher Foundation","keywords":"Stromal cell; Biology; Chronic lymphocytic leukemia; Cancer research; Bone marrow; Protein kinase C; Cell biology; Tumor microenvironment; Glucose uptake; Kinase; Leukemia; Immunology; Endocrinology; Insulin","score_opus":0.017392523678397925,"score_gpt":0.2586050244751063,"score_spread":0.2412125007967084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126819005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848851,0.0115982825,0.000018006509,0.00017833215,0.00022477836,0.0015235042,0.00006480285,0.00002589725,0.0014812913],"genre_scores_gemma":[0.9945366,0.00064453046,0.0002053789,0.00009667161,0.00022889793,0.00012947543,0.00001764868,0.000055071076,0.0040857703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99611825,0.00041884623,0.0007827175,0.0005574352,0.0013824543,0.00074028235],"domain_scores_gemma":[0.99770176,0.00026343684,0.00030265425,0.0012806312,0.00027392397,0.00017757872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011416753,0.00032342406,0.0009517304,0.00025838165,0.00004509792,0.000025134905,0.00040499744,0.00021992474,0.00042284955],"category_scores_gemma":[0.000050798535,0.00024371434,0.0002290892,0.00077828066,0.00026018042,0.000073357405,0.0002725552,0.00037579914,0.0000717881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033221295,0.00022371097,0.000011397842,0.0022368834,0.00010488377,0.0016793361,0.00092446164,0.0003070318,0.98989844,0.00029357482,0.00026576506,0.003722314],"study_design_scores_gemma":[0.015035554,0.00041742268,0.00009459931,0.00064238184,0.00014824433,0.0002102129,0.0012310467,0.0036681143,0.97662765,0.000035675468,0.0016950245,0.00019406955],"about_ca_topic_score_codex":0.0016040419,"about_ca_topic_score_gemma":0.0006842973,"teacher_disagreement_score":0.014703341,"about_ca_system_score_codex":0.02218353,"about_ca_system_score_gemma":0.027196221,"threshold_uncertainty_score":0.99383825},"labels":[],"label_agreement":null},{"id":"W3127199063","doi":"10.1107/s2053230x21000911","title":"Sleuthing biochemical evidence to elucidate unassigned electron density in a CBL–SLAP2 crystal complex","year":2021,"lang":"en","type":"article","venue":"Acta Crystallographica Section F Structural Biology Communications","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Garron Family Cancer Centre; Canadian Institutes of Health Research; Cancer Research Society; American Brain Tumor Association","keywords":"Ubiquitin ligase; Signal transducing adaptor protein; Chemistry; Dimer; Cell biology; Proto-oncogene tyrosine-protein kinase Src; Tyrosine kinase; Mutant; Kinase; Ubiquitin; Biochemistry; Signal transduction; Biology; Gene","score_opus":0.053586750313159424,"score_gpt":0.36065011483183584,"score_spread":0.30706336451867644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127199063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872544,0.00079814106,0.00026323574,0.009906427,0.00011094317,0.0006454224,0.000020780986,0.0002661965,0.00073450047],"genre_scores_gemma":[0.9921061,0.0005895872,0.005738358,0.0008035655,0.00008693408,0.000085484,0.00042045923,0.00004654843,0.00012299701],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971764,0.0006102218,0.0005706985,0.0006945706,0.0002654972,0.00068261946],"domain_scores_gemma":[0.99652594,0.00058801344,0.00014130956,0.0020804044,0.00035416833,0.00031013408],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039180514,0.00029196238,0.0005123228,0.0006203918,0.0003598902,0.00005574555,0.0007208108,0.0003906508,0.00013941487],"category_scores_gemma":[0.0009842417,0.0002822798,0.00018504838,0.0022624037,0.00062855583,0.00016304044,0.00091787544,0.00092114694,0.0000027183971],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023763599,0.00007009542,0.011568254,0.000040750394,0.00011719509,0.000024719342,0.000214879,0.0000052168903,0.9860285,0.00049057935,0.001010457,0.00019175267],"study_design_scores_gemma":[0.035470136,0.0033817799,0.69287044,0.002178015,0.00084988476,0.012146649,0.0031203516,0.030904656,0.096646,0.009552663,0.108809605,0.0040698093],"about_ca_topic_score_codex":0.0019604657,"about_ca_topic_score_gemma":0.0028270197,"teacher_disagreement_score":0.8893825,"about_ca_system_score_codex":0.0022213787,"about_ca_system_score_gemma":0.0014070194,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W3127766909","doi":"10.1039/d0sc06122k","title":"Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations","year":2021,"lang":"en","type":"article","venue":"Chemical Science","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"De Beers (Canada)","funders":"Biotechnology and Biological Sciences Research Council; Engineering and Physical Sciences Research Council; University of Bristol","keywords":"Ibrutinib; QM/MM; Bruton's tyrosine kinase; Covalent bond; Chemistry; Mechanism (biology); Tyrosine kinase; Stereochemistry; Computational chemistry; Biochemistry; Medicine; Signal transduction; Organic chemistry; Physics; Internal medicine; Molecular dynamics; Leukemia; Quantum mechanics","score_opus":0.02498278646832576,"score_gpt":0.3287036087820385,"score_spread":0.3037208223137128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127766909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963454,0.00013039281,0.00068860746,0.00087045244,0.000064882515,0.00022477205,0.000029351802,0.000016966029,0.0016291811],"genre_scores_gemma":[0.99537957,0.000015598922,0.0035788664,0.000132434,0.000031532505,0.000008803225,0.000017248616,0.000009031049,0.0008269297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788517,0.00001750108,0.00034595162,0.0003942809,0.0009686858,0.00038838352],"domain_scores_gemma":[0.9985076,0.0001433072,0.00007608486,0.00045565557,0.00043093538,0.00038641004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052518165,0.000095987845,0.00028508052,0.00010024821,0.000060124075,0.000012064764,0.00027445419,0.000066049324,0.0002649714],"category_scores_gemma":[0.0020049848,0.00008424684,0.0000730803,0.0016948372,0.00049354,0.00006468568,0.00030945634,0.00012059917,0.000022796705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030472409,0.00012303946,0.00012546846,0.000108474786,0.0000067509286,0.00002394949,0.00010843424,0.000004318025,0.9964517,0.0017954169,0.0008260504,0.0003959567],"study_design_scores_gemma":[0.0020903032,0.000060149396,0.00015573841,0.00022351221,0.000021132693,0.00005978773,0.0000597389,0.0020196564,0.9946799,0.000103256374,0.00044645232,0.00008036864],"about_ca_topic_score_codex":0.00009732951,"about_ca_topic_score_gemma":0.000001546198,"teacher_disagreement_score":0.0028902588,"about_ca_system_score_codex":0.0026434825,"about_ca_system_score_gemma":0.0044972682,"threshold_uncertainty_score":0.7977961},"labels":[],"label_agreement":null},{"id":"W3127854364","doi":"10.12659/ajcr.928514","title":"Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?","year":2021,"lang":"en","type":"article","venue":"American Journal of Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital","funders":"","keywords":"Venetoclax; Autoimmune hemolytic anemia; Medicine; Chronic lymphocytic leukemia; Rituximab; Anemia; Immunology; Neutropenia; Leukemia; Lymphoma; Internal medicine; Chemotherapy","score_opus":0.015304379428119345,"score_gpt":0.30024984895788664,"score_spread":0.2849454695297673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127854364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950645,0.0033267674,0.00009681345,0.00040186915,0.00014950412,0.00057898206,0.000010262612,0.000022383378,0.00034894646],"genre_scores_gemma":[0.99634725,0.0005306364,0.0017350175,0.00014635091,0.0002746263,0.000050919436,0.000028040731,0.00006118526,0.00082594604],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99669886,0.000114647715,0.001301814,0.000463795,0.0007140546,0.00070683175],"domain_scores_gemma":[0.9966617,0.00036544385,0.0010486543,0.00081719644,0.0006482403,0.0004587226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063807133,0.00032507014,0.0011887769,0.00032184523,0.00008346458,0.000041168852,0.00007267257,0.00008467041,0.00004972903],"category_scores_gemma":[0.00038119135,0.00024392513,0.0002959204,0.00083206606,0.00036600154,0.000092672206,0.00004264192,0.0003017487,0.0000024007504],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017014823,0.000096266034,0.0004295028,0.00021807474,0.00042280526,0.94636244,0.0006311359,0.005569407,0.0031828594,0.0000062245986,0.00027309678,0.04110673],"study_design_scores_gemma":[0.021739915,0.0077783824,0.0003036341,0.0007485678,0.00046471463,0.94504386,0.0010035747,0.0052701114,0.012217178,0.00003276826,0.00513423,0.0002630407],"about_ca_topic_score_codex":0.0064572403,"about_ca_topic_score_gemma":0.0011288468,"teacher_disagreement_score":0.04084369,"about_ca_system_score_codex":0.2415544,"about_ca_system_score_gemma":0.21724881,"threshold_uncertainty_score":0.9946978},"labels":[],"label_agreement":null},{"id":"W3128028991","doi":"10.1016/j.ekir.2021.01.033","title":"Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia","year":2021,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Jerome; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Obinutuzumab; Rituximab; Belimumab; Bendamustine; Chlorambucil; Internal medicine; Gastroenterology; Immunology; Azathioprine; Cyclophosphamide; Lymphoma; B cell; Antibody; Chemotherapy; B-cell activating factor","score_opus":0.015502648545487399,"score_gpt":0.3073178243794253,"score_spread":0.2918151758339379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128028991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86012155,0.00047105833,0.000099011566,0.010785914,0.0022240109,0.000411714,0.00004182817,0.000113316746,0.1257316],"genre_scores_gemma":[0.972763,0.00010519361,0.0021209419,0.0015519166,0.00040892602,0.00005002663,0.00045478984,0.000036609323,0.022508595],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.996833,0.000061815015,0.00081205345,0.0006296467,0.001265882,0.00039756214],"domain_scores_gemma":[0.99799454,0.000101671336,0.00012952037,0.00070838357,0.0006262297,0.00043964983],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005590621,0.00018133965,0.00036583812,0.00023801014,0.00004162941,0.000060817263,0.00015159386,0.00015515475,0.001969441],"category_scores_gemma":[0.0076767253,0.00017580455,0.00015911259,0.00040060724,0.00008357993,0.000117756805,0.0002204754,0.0003717238,0.00012141286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026537122,0.0018906236,0.016687257,0.00056665106,0.00076599716,0.46870598,0.0005995402,0.00027331046,0.08114084,0.0058294525,0.41590098,0.0049856696],"study_design_scores_gemma":[0.037365034,0.0001913128,0.027579235,0.0017466431,0.00010251614,0.040975064,0.0003417907,0.012671331,0.07829547,0.0034988238,0.7965788,0.000653946],"about_ca_topic_score_codex":0.0011742585,"about_ca_topic_score_gemma":0.00029902635,"teacher_disagreement_score":0.42773092,"about_ca_system_score_codex":0.021161366,"about_ca_system_score_gemma":0.027533112,"threshold_uncertainty_score":0.9989429},"labels":[],"label_agreement":null},{"id":"W3128386210","doi":"10.3390/curroncol28010081","title":"Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Ibrutinib; Medicine; Aspergillosis; Tyrosine kinase; Tyrosine-kinase inhibitor; Adverse effect; Aspergillus fumigatus; Leukemia; Immunology; Aspergillus; Internal medicine; Biology; Cancer; Microbiology; Receptor","score_opus":0.05587387536633468,"score_gpt":0.37001499184693354,"score_spread":0.31414111648059884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128386210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98964095,0.0074984436,0.000025033412,0.00027495075,0.0005095102,0.00063468725,0.000024989597,0.000043812328,0.0013476189],"genre_scores_gemma":[0.99792963,0.0007181505,0.0002611796,0.00009794179,0.00041889353,0.00011072441,0.00009291432,0.000050841685,0.00031970898],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972655,0.00023965843,0.0006605758,0.0006727904,0.00042647048,0.0007350152],"domain_scores_gemma":[0.99788636,0.0004581731,0.00019011962,0.00066998694,0.00046338313,0.0003319531],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003000858,0.00030645763,0.0009168799,0.0003503615,0.000057996724,0.00001320086,0.0001507926,0.0002656299,0.0004902081],"category_scores_gemma":[0.00061237806,0.00026126578,0.00014510647,0.0010401725,0.00045835317,0.00010642187,0.00026722913,0.0005300317,0.000059824644],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011181337,0.007810204,0.079095624,0.018169992,0.00134289,0.5079439,0.0080488445,0.0032104354,0.1023311,0.0030834663,0.016055243,0.24172692],"study_design_scores_gemma":[0.27361578,0.015942428,0.0064676036,0.0069258916,0.0010977203,0.14937809,0.0031893728,0.06182975,0.44973028,0.00019958924,0.030090079,0.001533443],"about_ca_topic_score_codex":0.0016778889,"about_ca_topic_score_gemma":0.006661221,"teacher_disagreement_score":0.35856587,"about_ca_system_score_codex":0.16394201,"about_ca_system_score_gemma":0.13076462,"threshold_uncertainty_score":0.99998397},"labels":[],"label_agreement":null},{"id":"W3128585404","doi":"10.14740/jh767","title":"Histologic Transformation in an Untreated Waldenstrom’s Macroglobulinemia After 14 Years: Case Report and Review of the Literature","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Macroglobulinemia; Waldenstrom macroglobulinemia; Medicine; Transformation (genetics); Pathology; Immunology; Multiple myeloma; Biology; Lymphoma","score_opus":0.012695268691676262,"score_gpt":0.3112580192174152,"score_spread":0.29856275052573894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128585404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93451804,0.062434163,0.00000981506,0.0026804225,0.00008446363,0.00015390829,0.0000034262462,0.0000025981717,0.00011317375],"genre_scores_gemma":[0.9947966,0.0042193895,0.00037897573,0.00047062858,0.00002991108,0.0000033218632,0.0000072875237,0.000006852496,0.00008702941],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9986093,0.0001813315,0.00073754345,0.00010843586,0.00022031646,0.00014309354],"domain_scores_gemma":[0.998912,0.000063374995,0.00028145258,0.00024971092,0.00041469221,0.00007877532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045583837,0.00008201816,0.000510217,0.00009302888,0.000012528249,0.0000068512804,0.00006035341,0.00013410322,0.000104102706],"category_scores_gemma":[0.0004437082,0.000050660336,0.0001011805,0.00028938585,0.00009350416,0.00009161006,0.000026194826,0.00036050566,9.08419e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039297336,0.00016363864,0.0062154816,0.0064225593,0.00006468134,0.9819591,0.0013078497,0.0000014497064,0.0006485198,0.00014230725,0.0010263378,0.0016550686],"study_design_scores_gemma":[0.0036346565,0.00014596773,0.0018856918,0.0062584276,0.00009949532,0.9851694,0.00012714828,0.00007123301,0.0017699285,0.000089487534,0.00070633815,0.00004221428],"about_ca_topic_score_codex":0.000017541905,"about_ca_topic_score_gemma":0.00007360981,"teacher_disagreement_score":0.060278576,"about_ca_system_score_codex":0.0008559953,"about_ca_system_score_gemma":0.0018318787,"threshold_uncertainty_score":0.3249674},"labels":[],"label_agreement":null},{"id":"W3129359742","doi":"10.1016/j.kint.2020.08.038","title":"The Case | Nephrotic syndrome in a patient with chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"Kidney International","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Kidney Foundation of Canada","keywords":"Medicine; Chronic lymphocytic leukemia; Lymphocytosis; Asymptomatic; Nephrotic syndrome; Immunophenotyping; Chlorambucil; Watchful waiting; Internal medicine; Chemoimmunotherapy; Leukemia; Nephrology; Tumor lysis syndrome; Pediatrics; Immunology; Cancer; Flow cytometry; Cyclophosphamide; Chemotherapy","score_opus":0.010091242098154136,"score_gpt":0.26719748879779814,"score_spread":0.257106246699644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129359742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98546875,0.0005014028,0.00006853205,0.0036867475,0.00043643426,0.00041529734,0.000024407707,0.000047617406,0.00935079],"genre_scores_gemma":[0.9939581,0.000103474085,0.00031135022,0.0011756244,0.00014468985,0.00011490183,0.000076849676,0.00003172487,0.0040832767],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99810404,0.00006597557,0.00034354618,0.0003707583,0.0006811326,0.00043458035],"domain_scores_gemma":[0.99862176,0.00023965175,0.00006871484,0.00047753414,0.00027199357,0.00032034027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018873473,0.00016864957,0.0002038719,0.00012517224,0.000113182905,0.00009294169,0.00019595338,0.00007758994,0.00063425535],"category_scores_gemma":[0.00054701214,0.00011444254,0.0000777979,0.0003828795,0.00017000607,0.0001012862,0.00016364317,0.0002874606,0.00018532659],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009668815,0.00019047204,0.00084216875,0.00027830232,0.0009251346,0.9502163,0.00092491385,0.0026348238,0.0010491617,0.005360201,0.022798955,0.013812721],"study_design_scores_gemma":[0.029638883,0.0005650181,0.000882554,0.0008187561,0.00007868662,0.69634014,0.00056289724,0.18672603,0.0026908184,0.00024812526,0.081140496,0.0003076223],"about_ca_topic_score_codex":0.0019984783,"about_ca_topic_score_gemma":0.0013018551,"teacher_disagreement_score":0.25387615,"about_ca_system_score_codex":0.11002304,"about_ca_system_score_gemma":0.07039717,"threshold_uncertainty_score":0.9348728},"labels":[],"label_agreement":null},{"id":"W3130191480","doi":"10.1016/j.leukres.2021.106538","title":"Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada","year":2021,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vernon Jubilee Hospital; Richmond Hospital; St. Paul's Hospital; BC Cancer Agency; University of British Columbia, Okanagan Campus; Abbotsford Veterinary Clinic; Kwantlen Polytechnic University; Surrey Memorial Hospital; University of British Columbia; Royal Columbian Hospital; Kelowna General Hospital; Vancouver General Hospital; Columbia Bible College","funders":"","keywords":"Medicine; Fludarabine; Rituximab; Ibrutinib; Chronic lymphocytic leukemia; Internal medicine; Population; Stage (stratigraphy); Leukemia; Chemotherapy; Surgery; Pediatrics; Lymphoma; Cyclophosphamide","score_opus":0.042227606311361854,"score_gpt":0.3518739953660461,"score_spread":0.3096463890546842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130191480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709755,0.00045740185,8.581908e-7,0.000014763194,0.00006542528,0.0014498403,0.00020892378,0.000013457833,0.00069178897],"genre_scores_gemma":[0.9954704,0.0005926402,0.00004746116,0.000017682934,0.000045329245,0.00011533759,0.00031310573,0.000041221265,0.0033568318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671745,0.0001985307,0.00059565454,0.00056045345,0.001117368,0.00081052503],"domain_scores_gemma":[0.99727637,0.00077137153,0.00009899182,0.0005984845,0.00096455717,0.00029021726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043479088,0.00019010747,0.0008268535,0.00023828138,0.00011106976,0.000059077345,0.00016085918,0.0002089672,0.00014031505],"category_scores_gemma":[0.001353066,0.00021546351,0.00015789535,0.0010419464,0.00035399076,0.00007371502,0.00012140562,0.00028204484,0.0000032375383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0030703053,0.00058411085,0.94465125,0.0015403463,0.0009137461,0.0033676608,0.00032451868,0.0019832673,0.0026956762,0.000049652455,0.004418503,0.036400948],"study_design_scores_gemma":[0.05057255,0.005794735,0.93008524,0.0005953001,0.000059794533,0.00006075147,0.00009072229,0.008824671,0.003027332,0.000033185697,0.0006508737,0.00020485616],"about_ca_topic_score_codex":0.98082995,"about_ca_topic_score_gemma":0.9699494,"teacher_disagreement_score":0.19413552,"about_ca_system_score_codex":0.45867994,"about_ca_system_score_gemma":0.26454443,"threshold_uncertainty_score":0.87863475},"labels":[],"label_agreement":null},{"id":"W3130331670","doi":"10.1111/bjh.17326","title":"Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche","keywords":"Bendamustine; Medicine; Internal medicine; Chlorambucil; Fludarabine; Neutropenia; Obinutuzumab; Gastroenterology; Cyclophosphamide; Chemotherapy; Adverse effect; Oncology; Chronic lymphocytic leukemia; Surgery; Leukemia","score_opus":0.018755368573689667,"score_gpt":0.3081063094491247,"score_spread":0.28935094087543506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130331670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537265,0.0036689767,0.00002948053,0.00010702699,0.000053387932,0.0007080404,0.00002422902,0.000006348377,0.000029869596],"genre_scores_gemma":[0.99731064,0.0021221822,0.00013519707,0.0000752805,0.00003203047,0.0000071053164,0.000018134686,0.000033627362,0.0002658089],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99637777,0.000560246,0.0015578344,0.00035070104,0.00074042275,0.00041305544],"domain_scores_gemma":[0.99678105,0.0008443827,0.00095585576,0.000485817,0.00076400075,0.00016886444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006342216,0.0002278177,0.0020530063,0.00041350847,0.00006632231,0.000016159122,0.0002969224,0.0001674284,0.00041396194],"category_scores_gemma":[0.0011279631,0.00015020106,0.00022881926,0.0018425988,0.00046160718,0.0001161584,0.00011880858,0.0004541221,7.2822553e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.25143188,0.023493417,0.18839009,0.0043867324,0.035017308,0.33676723,0.010776161,0.0030778227,0.0014369566,0.0000344157,0.0012181808,0.14396982],"study_design_scores_gemma":[0.6035818,0.019194828,0.18524055,0.0047266716,0.006779458,0.17010356,0.0015103462,0.005310004,0.0027850212,0.000009439639,0.00033972145,0.00041860924],"about_ca_topic_score_codex":0.0026767065,"about_ca_topic_score_gemma":0.008157609,"teacher_disagreement_score":0.3521499,"about_ca_system_score_codex":0.011867622,"about_ca_system_score_gemma":0.026709344,"threshold_uncertainty_score":0.99192566},"labels":[],"label_agreement":null},{"id":"W3132531164","doi":"10.3324/haematol.2020.271304","title":"Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia","year":2021,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institutes of Health; Canadian Institutes of Health Research; Centre hospitalier régional universitaire de Lille; Medizinische Universität Wien; Oesterreichische Nationalbank; Universität Wien; Centre Hospitalier Universitaire de Québec; Austrian Science Fund; Institut National de la Santé et de la Recherche Médicale; Broad Institute; Université de Lille; Centre National de la Recherche Scientifique; Österreichischen Akademie der Wissenschaften; Vienna Science and Technology Fund; Université Laval","keywords":"Venetoclax; Ibrutinib; Prolymphocytic leukemia; Medicine; Leukemia; Oncology; Cancer research; Internal medicine; Chronic lymphocytic leukemia","score_opus":0.05991853302489981,"score_gpt":0.31065509164948746,"score_spread":0.25073655862458766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132531164","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24466334,0.023050644,0.00043464973,0.7147248,0.0007007795,0.011865651,0.00013339402,0.000114261864,0.0043125115],"genre_scores_gemma":[0.57273614,0.0027719212,0.002531582,0.402061,0.0015031117,0.00348606,0.002521002,0.00019495367,0.012194245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980938,0.00011730678,0.00050946313,0.0004275808,0.00048974564,0.00036210008],"domain_scores_gemma":[0.99671346,0.0023016343,0.00020985398,0.000502313,0.00023294699,0.000039811806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004085725,0.00022229139,0.00076316635,0.0001495907,0.000073320385,0.000026986088,0.00020024405,0.00065639394,0.00012835274],"category_scores_gemma":[0.00094551843,0.00014876988,0.00014157883,0.0002465311,0.00030854592,0.000032367374,0.00012885012,0.00063684135,0.000008282317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005759968,0.000070346476,0.00022956675,0.0061197225,0.00028475453,0.0023349433,0.00052140595,0.00006847166,0.00018937774,0.0027138623,0.9849963,0.0018952275],"study_design_scores_gemma":[0.06815695,0.0013232456,0.0022872377,0.0028459614,0.0007682632,0.008552593,0.00069254846,0.11411021,0.0073397667,0.0061076307,0.78687656,0.00093901646],"about_ca_topic_score_codex":0.00024083463,"about_ca_topic_score_gemma":0.000028762295,"teacher_disagreement_score":0.32807282,"about_ca_system_score_codex":0.008372967,"about_ca_system_score_gemma":0.012278454,"threshold_uncertainty_score":0.9954337},"labels":[],"label_agreement":null},{"id":"W3132537256","doi":"10.1038/s41408-021-00429-z","title":"Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"National Cancer Institute; Leukemia and Lymphoma Society","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Minimal residual disease; Medicine; Cancer research; Leukemia; Hematology; Drug development; Immunology; Oncology; Pharmacology; Drug; Internal medicine; Tyrosine kinase; Receptor","score_opus":0.02705962028518334,"score_gpt":0.34454831379110384,"score_spread":0.3174886935059205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132537256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98681515,0.009067826,0.0010813127,0.002036762,0.00015170692,0.00045959264,0.00018933027,0.000015353033,0.00018297312],"genre_scores_gemma":[0.99425685,0.00094081333,0.0032546727,0.00006535317,0.0006982219,0.00008058974,0.000117722484,0.000022875305,0.0005628686],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99886155,0.000050691142,0.00034361723,0.00020757658,0.00031611454,0.00022043967],"domain_scores_gemma":[0.99874973,0.00011732307,0.00018010414,0.00024009559,0.00040883757,0.00030392193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025267684,0.00009167493,0.00019462233,0.000068313806,0.0001470713,0.000032346605,0.000069211506,0.00005180182,0.00016304538],"category_scores_gemma":[0.00027425398,0.000084406136,0.000077574085,0.0001525072,0.000074950534,0.00006344439,0.000032693264,0.00015351875,0.0000013177613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008754495,0.003007512,0.33967867,0.0076595726,0.0032745535,0.00079710234,0.0028096656,0.0040920307,0.4902923,0.008790012,0.07066985,0.06017419],"study_design_scores_gemma":[0.06099929,0.00076995435,0.5493747,0.0012706788,0.002834584,0.0020869577,0.00028458252,0.021925893,0.29732862,0.00749926,0.055003952,0.0006214987],"about_ca_topic_score_codex":0.0001075216,"about_ca_topic_score_gemma":0.00003241504,"teacher_disagreement_score":0.20969602,"about_ca_system_score_codex":0.001563724,"about_ca_system_score_gemma":0.009989754,"threshold_uncertainty_score":0.9956227},"labels":[],"label_agreement":null},{"id":"W3134855792","doi":"10.1182/blood.2020008654","title":"AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Chronic lymphocytic leukemia; Cancer research; Biology; Mutation; Gene; Somatic hypermutation; Leukemia; Cytidine deaminase; Activation-induced (cytidine) deaminase; Cancer; Lymphoma; Point mutation; Immunology; B cell; Genetics; Antibody","score_opus":0.02698113262165302,"score_gpt":0.32126205110735323,"score_spread":0.2942809184857002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134855792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942727,0.0012540234,0.000013615008,0.0007262513,0.0000648238,0.00041269136,0.000026714128,0.00006768773,0.00316149],"genre_scores_gemma":[0.9904444,0.00009783236,0.0029389195,0.00037292726,0.00010716573,0.00005922294,0.00012368022,0.000040468367,0.005815356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832994,0.000064292544,0.00023949881,0.00045786012,0.00049747236,0.00041094478],"domain_scores_gemma":[0.99870855,0.00014756159,0.00008754689,0.0005582479,0.00017455271,0.0003235396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011820128,0.00018765217,0.00031367945,0.00011218513,0.00019235314,0.00005962815,0.000116866126,0.000126278,0.000525649],"category_scores_gemma":[0.00035609608,0.00016704774,0.00007894121,0.0002708968,0.00010241213,0.00008647825,0.0002986064,0.00024579596,0.00017508077],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004407567,0.0023225292,0.012978483,0.000655394,0.00035842665,0.0068153,0.0024508117,0.000011139918,0.9676155,0.0003452282,0.0034909653,0.0025154958],"study_design_scores_gemma":[0.057746142,0.0006072858,0.024390344,0.001771351,0.0002966709,0.0038237218,0.00056364253,0.0001686752,0.90403926,0.00018485126,0.0060229404,0.00038511062],"about_ca_topic_score_codex":0.00032395002,"about_ca_topic_score_gemma":0.00011823734,"teacher_disagreement_score":0.06357621,"about_ca_system_score_codex":0.0008157186,"about_ca_system_score_gemma":0.0017867357,"threshold_uncertainty_score":0.6812009},"labels":[],"label_agreement":null},{"id":"W3135433679","doi":"10.3324/haematol.2020.267914","title":"T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective","year":2021,"lang":"en","type":"review","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Cancer Research UK","keywords":"Epigenetics; Chronic lymphocytic leukemia; Epigenomics; Immunology; T cell; Epigenetic therapy; Immune system; Immune Dysfunction; Tumor microenvironment; Biology; Cell; Immunotherapy; Chimeric antigen receptor; Cancer research; Leukemia; Medicine; DNA methylation; Genetics","score_opus":0.06693291355595138,"score_gpt":0.3874413583571703,"score_spread":0.32050844480121893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135433679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017567778,0.9901394,0.000048993967,0.000023900784,0.00031004654,0.002038356,0.000042442058,0.00019523251,0.0054448387],"genre_scores_gemma":[0.0022721286,0.9940554,0.00034493918,0.00011675168,0.00046427958,0.00053533114,0.00079644803,0.00015972198,0.0012550021],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99413836,0.0008331661,0.001240957,0.0018938225,0.0008185709,0.0010751156],"domain_scores_gemma":[0.99629444,0.00074235577,0.00041731328,0.0018301938,0.00025453026,0.0004611445],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00042616666,0.0009130138,0.0046916143,0.0005563981,0.00011416691,0.00008899969,0.0005741197,0.0013807113,0.00199244],"category_scores_gemma":[0.00051389186,0.0007179834,0.0008226936,0.0012085586,0.00029061676,0.00010960684,0.00036369366,0.0012551297,0.0013076016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004543,0.0008459492,0.00002050839,0.0799568,0.00165547,0.061907142,0.0014269322,0.0003574996,0.000037605856,0.0022354934,0.007718181,0.8433841],"study_design_scores_gemma":[0.019949127,0.0014685427,0.000021483416,0.03928336,0.0031297652,0.007387272,0.0009926151,0.0067452798,0.00012531743,0.0004950505,0.91868526,0.0017169409],"about_ca_topic_score_codex":0.0071694837,"about_ca_topic_score_gemma":0.00047146244,"teacher_disagreement_score":0.91096705,"about_ca_system_score_codex":0.3900578,"about_ca_system_score_gemma":0.15075369,"threshold_uncertainty_score":0.9999157},"labels":[],"label_agreement":null},{"id":"W3135673850","doi":"10.3390/cancers13051002","title":"Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Spinal Cord Injury BC; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Venetoclax; MCL1; Vincristine; Mantle cell lymphoma; Cancer research; Apoptosis; Lymphoma; Chronic lymphocytic leukemia; Doxorubicin; B cell; Follicular lymphoma; Medicine; Chemistry; Biology; Chemotherapy; Leukemia; Immunology; Internal medicine; Antibody; Downregulation and upregulation; Cyclophosphamide; Biochemistry","score_opus":0.01231629058363107,"score_gpt":0.2777437701108712,"score_spread":0.2654274795272401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135673850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582002,0.0030711633,0.00009174088,0.00017386505,0.00040214212,0.0005212047,0.000013307143,0.000051469844,0.03747492],"genre_scores_gemma":[0.9789736,0.00036940904,0.00063063105,0.0007953576,0.00018721508,0.000095719384,0.00013719793,0.000054188306,0.018756667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99780506,0.000053540316,0.0003725212,0.00056373404,0.0005709238,0.0006342099],"domain_scores_gemma":[0.9988814,0.0001162285,0.00006769696,0.00055695453,0.0001315819,0.00024613598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029469418,0.00019540662,0.00041220392,0.00012715082,0.000054828615,0.00004014965,0.00017367999,0.00015752351,0.00043396413],"category_scores_gemma":[0.00012793455,0.0001998463,0.00010303179,0.00063246867,0.000119195865,0.000083419836,0.00013246018,0.00030798384,0.00009429437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010757823,0.00027148958,0.0067726164,0.0037054182,0.00023411472,0.004978343,0.0019165009,0.0025328132,0.87025344,0.000050825918,0.09826285,0.00994583],"study_design_scores_gemma":[0.03408928,0.00014624631,0.0011253922,0.000643328,0.000101566286,0.00023564778,0.0010281076,0.023542758,0.93043476,0.000056151723,0.008128137,0.00046860302],"about_ca_topic_score_codex":0.0014487485,"about_ca_topic_score_gemma":0.00008573862,"teacher_disagreement_score":0.09013471,"about_ca_system_score_codex":0.090875246,"about_ca_system_score_gemma":0.04420866,"threshold_uncertainty_score":0.9612098},"labels":[],"label_agreement":null},{"id":"W3135715082","doi":"10.7554/elife.64691","title":"Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors","year":2021,"lang":"en","type":"article","venue":"eLife","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Innosuisse - Schweizerische Agentur für Innovationsförderung; Novartis Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Michael Smith Health Research BC; Stiftung FHNW; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Allosteric regulation; P110α; PI3K/AKT/mTOR pathway; Kinase; Mutant; Phosphoinositide 3-kinase; Biology; Protein subunit; Cell biology; Computational biology; Chemistry; Enzyme; Signal transduction; Biochemistry; Gene","score_opus":0.008677870258930905,"score_gpt":0.2909201028652079,"score_spread":0.282242232606277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135715082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965712,0.00047180662,0.000028816736,0.0017213493,0.000091485796,0.00040003014,0.000027724094,0.00004112528,0.000646463],"genre_scores_gemma":[0.99638015,0.000025385973,0.00037280598,0.00032968482,0.00009890989,0.000049168502,0.00010246122,0.000028876282,0.002612534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984336,0.000088567795,0.0002908585,0.0003891444,0.0004662,0.0003316497],"domain_scores_gemma":[0.9988168,0.000120461744,0.000035839905,0.0003776042,0.00018224254,0.00046707058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021121101,0.00013339818,0.00023723468,0.00015832049,0.000067763336,0.000022976279,0.00006748563,0.00007204517,0.000036094083],"category_scores_gemma":[0.0009971838,0.00013170068,0.00005278028,0.0006590328,0.00009928115,0.000069100155,0.00016197922,0.00026417561,0.000035354402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004179666,0.0031712176,0.7825843,0.0030122797,0.0008439233,0.06501331,0.029877443,0.001181457,0.01483528,0.0067657814,0.041149728,0.047385618],"study_design_scores_gemma":[0.017759575,0.00033711488,0.8912558,0.0012793915,0.00018667665,0.0013986251,0.0019274572,0.08055731,0.0036984296,0.00066936883,0.00041014332,0.0005201169],"about_ca_topic_score_codex":0.00016266668,"about_ca_topic_score_gemma":0.00031891628,"teacher_disagreement_score":0.1086715,"about_ca_system_score_codex":0.0068493374,"about_ca_system_score_gemma":0.005731886,"threshold_uncertainty_score":0.9999047},"labels":[],"label_agreement":null},{"id":"W3136538703","doi":"10.1002/ijc.33571","title":"Reply to: Comments on: Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein","year":2021,"lang":"en","type":"letter","venue":"International Journal of Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Royal Victoria Regional Health Centre","funders":"","keywords":"Nemaline myopathy; Medicine; Chemotherapy; Prednisone; Internal medicine; Oncology; Hematology; Pediatrics; Myopathy","score_opus":0.0567208426988924,"score_gpt":0.36509294584968505,"score_spread":0.30837210315079266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136538703","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049082365,0.0008927735,0.0009993002,0.94553715,0.0004987477,0.0022135966,0.000500277,0.000012847283,0.0002629227],"genre_scores_gemma":[0.02662322,0.00018069599,0.0034288166,0.95033014,0.007630179,0.00093974685,0.00047571366,0.00014006758,0.010251437],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964513,0.000090415815,0.00066684495,0.00041857568,0.002004141,0.00036867562],"domain_scores_gemma":[0.99716854,0.00023131532,0.00063024793,0.00047784447,0.0013339616,0.00015811087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032385605,0.00038697215,0.0006803072,0.00029211427,0.000059399546,0.0001107528,0.00060500315,0.00021605351,0.00041999866],"category_scores_gemma":[0.000070297174,0.0002181495,0.000427462,0.00017109724,0.000098951474,0.000053681564,0.000039979466,0.0008777526,0.0000052798114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0146512855,0.00058460876,0.00024789054,0.00020041518,0.0046941657,0.0021046198,0.00050007546,0.0007492535,0.00009603264,0.000003988876,0.9693423,0.006825383],"study_design_scores_gemma":[0.03236041,0.0024206422,0.00013900449,0.0021116317,0.00033043599,0.0006519665,0.00003919745,0.0030998688,0.0034875541,0.00003344842,0.95508975,0.00023607502],"about_ca_topic_score_codex":0.00047209044,"about_ca_topic_score_gemma":0.000012084171,"teacher_disagreement_score":0.022459146,"about_ca_system_score_codex":0.014743601,"about_ca_system_score_gemma":0.011524922,"threshold_uncertainty_score":0.9940788},"labels":[],"label_agreement":null},{"id":"W3136648532","doi":"10.1182/blood.2020009165","title":"MARCKS affects cell motility and response to BTK inhibitors in CLL","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health; Ministry of Science and Higher Education of the Russian Federation; Genome Canada; Skolkovo Institute of Science and Technology; Deutsche Forschungsgemeinschaft; Megagrants; José Carreras Leukämie-Stiftung; National Heart, Lung, and Blood Institute; Gilead Sciences","keywords":"Bruton's tyrosine kinase; IGHV@; MARCKS; Chronic lymphocytic leukemia; Phosphorylation; Ibrutinib; Biology; Tyrosine phosphorylation; Cancer research; Protein kinase B; Idelalisib; breakpoint cluster region; Signal transduction; B-cell receptor; Tyrosine kinase; Cell biology; Protein kinase C; Immunology; Biochemistry; B cell; Leukemia; Antibody; Receptor","score_opus":0.010416831276222404,"score_gpt":0.2761495664808537,"score_spread":0.2657327352046313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136648532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485254,0.0008697972,0.0000020035611,0.0009997862,0.000056824694,0.00038990282,0.000005244138,0.000030229712,0.0027936413],"genre_scores_gemma":[0.99686855,0.00002977394,0.00041441736,0.0003117878,0.00008790689,0.000022103966,0.00000438763,0.000020154164,0.0022409],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985031,0.00021751394,0.00016648829,0.00038959403,0.00036127513,0.00036204557],"domain_scores_gemma":[0.99879956,0.0003838957,0.000017696662,0.00043998254,0.00005915368,0.00029973505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007578972,0.0001164731,0.00024204399,0.00013274422,0.000028120077,0.000023029108,0.0000679815,0.00010690315,0.000085865344],"category_scores_gemma":[0.0010572523,0.000110551424,0.000042527423,0.00042189562,0.000053423268,0.000025176747,0.00022526951,0.00021931017,0.00006288906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008035756,0.0075490074,0.1865741,0.0023962501,0.00015900769,0.027801149,0.0058142478,0.00002112904,0.7417042,0.000035302237,0.008784486,0.011125306],"study_design_scores_gemma":[0.060184672,0.0006026166,0.22966723,0.00034666283,0.00007624415,0.00063833536,0.00043779882,0.00035724352,0.7034521,0.000052852145,0.0039694323,0.00021478707],"about_ca_topic_score_codex":0.00015133416,"about_ca_topic_score_gemma":0.00013657348,"teacher_disagreement_score":0.052148916,"about_ca_system_score_codex":0.0016164439,"about_ca_system_score_gemma":0.0037121607,"threshold_uncertainty_score":0.65852135},"labels":[],"label_agreement":null},{"id":"W3136678459","doi":"10.1101/2021.03.22.21253655","title":"The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; York University; University of Toronto","funders":"Canadian Cancer Society Research Institute","keywords":"Venetoclax; Chronic lymphocytic leukemia; Cancer research; Medicine; Kinase; Signal transduction; Leukemia; Lymphoma; Immunology; Biology; Cell biology","score_opus":0.0242825454107083,"score_gpt":0.3103508193819438,"score_spread":0.2860682739712355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136678459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93938005,0.036960773,0.0124455085,0.0019979966,0.003186021,0.004310101,0.00006432945,0.00038813442,0.0012670993],"genre_scores_gemma":[0.9673381,0.0020702262,0.0038497448,0.00046455345,0.0053884056,0.00070991035,0.0006146433,0.0003107779,0.019253679],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99380946,0.0002510234,0.001118199,0.0015321451,0.0016506596,0.001638494],"domain_scores_gemma":[0.9950969,0.0009157922,0.0003710858,0.0022448127,0.0005419465,0.0008294301],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015601333,0.00079570164,0.0012560457,0.00022860624,0.0005072657,0.0004729215,0.0012049082,0.0008984005,0.0008594984],"category_scores_gemma":[0.0017774061,0.0006079462,0.0011663487,0.00041814556,0.00036244633,0.000093008966,0.0011833844,0.0014905458,0.00021766676],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01619787,0.0007007486,0.000590106,0.035103507,0.020986184,0.020687947,0.011265663,0.35789773,0.15039334,0.0022885574,0.15889223,0.22499613],"study_design_scores_gemma":[0.059768856,0.0016608477,0.00017847776,0.003758268,0.002203833,0.002812712,0.0009472967,0.67365927,0.09556264,0.0049507036,0.15249348,0.0020036271],"about_ca_topic_score_codex":0.0036223684,"about_ca_topic_score_gemma":0.00018800229,"teacher_disagreement_score":0.31576154,"about_ca_system_score_codex":0.14313427,"about_ca_system_score_gemma":0.28341308,"threshold_uncertainty_score":0.9996372},"labels":[],"label_agreement":null},{"id":"W3136857533","doi":"10.1016/j.celrep.2021.108845","title":"Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients","year":2021,"lang":"en","type":"article","venue":"Cell Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont; McMaster University","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Canada Research Chairs; Associazione Italiana per la Ricerca sul Cancro; Canadian Cancer Society; Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation","keywords":"Chronic lymphocytic leukemia; Induced pluripotent stem cell; Cancer research; Trisomy; Lymphocytosis; Malignancy; Leukemia; Cancer; Stem cell; Cancer stem cell; Biology; Medicine; Immunology; Bioinformatics; Gene; Internal medicine; Embryonic stem cell; Genetics","score_opus":0.0147021620072726,"score_gpt":0.27948921191681264,"score_spread":0.26478704990954005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136857533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911905,0.003406652,0.000049968807,0.000011790712,0.00040071463,0.00086638256,0.000004275207,0.000049290833,0.0060918727],"genre_scores_gemma":[0.991843,0.00014418252,0.00011882712,0.000071322975,0.000082645274,0.000050214305,0.00008534209,0.00008037607,0.0075241076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99546516,0.00014077606,0.0014308651,0.00087984314,0.0013078919,0.000775489],"domain_scores_gemma":[0.9973,0.00006211802,0.0004954158,0.0013794523,0.00041660122,0.00034639746],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053980923,0.00033321156,0.0008060442,0.00029618462,0.000063277286,0.000032127977,0.00017492678,0.00026670287,0.00034054517],"category_scores_gemma":[0.00009416852,0.00033496047,0.00032503292,0.00052738516,0.00014722701,0.00010196581,0.00030959467,0.0003506935,0.000052380907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011279054,0.0005146604,0.006049555,0.0030703256,0.00017621531,0.06672269,0.0005039303,0.004749315,0.9138122,0.000022100525,0.0027036371,0.0015625795],"study_design_scores_gemma":[0.016316885,0.00029597574,0.0049691745,0.00053578505,0.00013301143,0.0005524695,0.00010349732,0.00218352,0.9715475,0.00008429056,0.0029505405,0.0003273854],"about_ca_topic_score_codex":0.0010174054,"about_ca_topic_score_gemma":0.00006784394,"teacher_disagreement_score":0.06617022,"about_ca_system_score_codex":0.10113135,"about_ca_system_score_gemma":0.04127862,"threshold_uncertainty_score":0.99991024},"labels":[],"label_agreement":null},{"id":"W3139928419","doi":"10.14740/wjnu177w","title":"Plasma Cell Leukemia Presenting as Acute Kidney Injury With Heavy Proteinuria","year":2014,"lang":"en","type":"article","venue":"World Journal of Nephrology and Urology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Acute kidney injury; Proteinuria; Malignancy; Plasma cell leukemia; Renal biopsy; Biopsy; Nephropathy; Kidney; Transplantation; Plasma cell; Kidney transplantation; Renal function; Pathology; Urology; Gastroenterology; Internal medicine; Bone marrow; Endocrinology; Diabetes mellitus","score_opus":0.006835534717137878,"score_gpt":0.26088382537137483,"score_spread":0.25404829065423695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139928419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98279107,0.00023048537,0.00016185733,0.008285359,0.00017436854,0.00032525597,0.0000023269374,0.000021955642,0.008007318],"genre_scores_gemma":[0.9851058,0.00012564493,0.0013095072,0.009672865,0.0006715417,0.0000117321515,0.0000038873245,0.000035610392,0.003063387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979367,0.00032798375,0.00051966315,0.00029906305,0.00031070044,0.0006058461],"domain_scores_gemma":[0.9983241,0.00028117996,0.00037429854,0.00029906761,0.00020717425,0.00051417726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007645276,0.00022574808,0.00065828423,0.00043929895,0.00013136209,0.000019173991,0.00021407586,0.00024670118,0.00028928978],"category_scores_gemma":[0.00020779921,0.00016188831,0.000094327115,0.00025106006,0.00057720987,0.00011832471,0.00012662799,0.0010615723,0.000043204633],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24134773,0.0019414948,0.07079026,0.001601116,0.007924305,0.03038327,0.0042895465,0.00038464446,0.21452712,0.0114288805,0.37194043,0.043441206],"study_design_scores_gemma":[0.0487406,0.015683578,0.006735122,0.000098431934,0.0011552948,0.05553266,0.000035517052,0.007916942,0.015061907,0.0024005643,0.8462342,0.00040520917],"about_ca_topic_score_codex":0.000060787544,"about_ca_topic_score_gemma":0.00003108764,"teacher_disagreement_score":0.47429377,"about_ca_system_score_codex":0.0007666856,"about_ca_system_score_gemma":0.004459893,"threshold_uncertainty_score":0.7911658},"labels":[],"label_agreement":null},{"id":"W3145595393","doi":"10.1503/cmaj.201022-f","title":"Anémie grave induite par l’azathioprine et potentialisée par l’emploi concomitant d’allopurinol","year":2021,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Azathioprine; Allopurinol; Medicine; Concomitant; Gynecology; Surgery; Internal medicine","score_opus":0.015022273220995051,"score_gpt":0.28273462764863394,"score_spread":0.2677123544276389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145595393","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31734446,0.036156505,0.00051314925,0.58287936,0.020519003,0.0009143312,0.00053602806,0.00010234398,0.041034803],"genre_scores_gemma":[0.8847359,0.017537229,0.000511402,0.046551708,0.016915608,0.000029726118,0.00024567632,0.00018419865,0.03328858],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879941,0.0016445109,0.0016285243,0.0006765525,0.0052436464,0.0028126882],"domain_scores_gemma":[0.98658293,0.00094032806,0.0005765912,0.00056312216,0.0023140286,0.009022969],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.006288399,0.0005068578,0.0010600751,0.000417753,0.0006713021,0.00050386204,0.0006367935,0.0019830603,0.02924546],"category_scores_gemma":[0.015057172,0.00052753696,0.0005166983,0.0010267004,0.000370952,0.00033890162,0.0002060044,0.005432732,0.0019122605],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012524458,0.0006194798,0.05055525,0.00047578942,0.003657583,0.20118171,0.0025629404,0.000056350887,0.0005973434,0.01237238,0.5934819,0.13431406],"study_design_scores_gemma":[0.019409705,0.00027341038,0.024248904,0.0017060518,0.00040562497,0.01989243,0.0009636214,0.0021868553,0.0009818566,0.0006786801,0.92865074,0.0006021402],"about_ca_topic_score_codex":0.020414582,"about_ca_topic_score_gemma":0.102219775,"teacher_disagreement_score":0.5673914,"about_ca_system_score_codex":0.06738779,"about_ca_system_score_gemma":0.20403378,"threshold_uncertainty_score":0.9997176},"labels":[],"label_agreement":null},{"id":"W3145985993","doi":"10.14740/jh118w","title":"Anaplastic Large-Cell Lymphoma T Anaplastic Lymphoma Kinase-Positive Associated With Crohn’s Disease Undergoing Treatment With Azathioprine: A Case Report","year":2014,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Anaplastic large-cell lymphoma; Lymphoma; Anaplastic lymphoma kinase; Azathioprine; Disease; Crohn's disease; Cancer research; Internal medicine","score_opus":0.010535702723119794,"score_gpt":0.26445815615064416,"score_spread":0.2539224534275244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145985993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99139327,0.0005241387,0.006386691,0.0003953527,0.00014660528,0.00044108726,0.000015739457,0.0000488189,0.0006483026],"genre_scores_gemma":[0.99823135,0.000039181883,0.0005796739,0.00017204222,0.00015497424,0.000023276587,0.00003084464,0.00008693642,0.0006817399],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9965694,0.00029546468,0.0009256584,0.0004971515,0.0008401436,0.0008721944],"domain_scores_gemma":[0.99485874,0.0018947419,0.0010124452,0.0005633004,0.00073915324,0.00093162555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005638088,0.00045643427,0.0012501584,0.00045661745,0.00022558373,0.000051323103,0.00016090559,0.00019507874,0.000059733527],"category_scores_gemma":[0.0014495624,0.00029355273,0.00022297008,0.00046539397,0.00028035895,0.00015851093,0.00006980513,0.00020425973,0.000024306502],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010428163,0.0034986786,0.008691366,0.00031440007,0.0010970845,0.9739931,0.00028077592,0.00021468608,0.000036883273,0.00048935896,0.00030984674,0.00064565206],"study_design_scores_gemma":[0.10947101,0.012828609,0.010414348,0.0015221582,0.0016765099,0.8496685,0.00047387433,0.011985246,0.001173868,0.000086976244,0.000303718,0.00039516707],"about_ca_topic_score_codex":0.00012336577,"about_ca_topic_score_gemma":0.0008943847,"teacher_disagreement_score":0.12432458,"about_ca_system_score_codex":0.010616294,"about_ca_system_score_gemma":0.013995605,"threshold_uncertainty_score":0.99995166},"labels":[],"label_agreement":null},{"id":"W3154877229","doi":"10.71781/31218","title":"Nouvelles approches dans l’immunothérapie de la leucémie aigüe lymphoblastique utilisant les récepteurs chimériques d’antigène","year":2020,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fondation ARC pour la Recherche sur le Cancer; Institut National de la Santé et de la Recherche Médicale","keywords":"Medicine; Molecular biology; Biology","score_opus":0.006844408094504003,"score_gpt":0.21087114202611779,"score_spread":0.20402673393161377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154877229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80377346,0.079100244,0.0022797557,0.0005786549,0.0013151984,0.001211728,0.00017114195,0.00041060988,0.11115918],"genre_scores_gemma":[0.9418806,0.011613819,0.0020504596,0.0001621391,0.00079971313,0.00010688622,0.0011922293,0.00018015834,0.042014003],"study_design_codex":"bench_or_experimental","study_design_gemma":"qualitative","domain_scores_codex":[0.9934275,0.0008362728,0.0010051802,0.00151304,0.0017100844,0.001507935],"domain_scores_gemma":[0.9956299,0.0010782202,0.0006482586,0.00087352033,0.00052723725,0.0012428595],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00070291525,0.0012077017,0.0012797161,0.0005848659,0.006791164,0.00019179507,0.0011554076,0.0017623731,0.0002708855],"category_scores_gemma":[0.0007458175,0.001338366,0.0008981351,0.0007892118,0.00229845,0.0004342299,0.0005211704,0.0016880429,0.00022501596],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011251005,0.0021004563,0.018368635,0.0055523277,0.004692901,0.05155958,0.3959554,0.006364914,0.42582598,0.060717378,0.0039772824,0.013634122],"study_design_scores_gemma":[0.021554252,0.0010357709,0.05468412,0.005634217,0.0024551589,0.016483521,0.39188936,0.061967388,0.28182402,0.00041720198,0.15933459,0.0027203753],"about_ca_topic_score_codex":0.10299947,"about_ca_topic_score_gemma":0.0063970457,"teacher_disagreement_score":0.1553573,"about_ca_system_score_codex":0.10860888,"about_ca_system_score_gemma":0.062529214,"threshold_uncertainty_score":0.99953353},"labels":[],"label_agreement":null},{"id":"W3156845972","doi":"10.3899/jrheum.201622","title":"The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed Journal","year":2021,"lang":"en","type":"letter","venue":"The Journal of Rheumatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bruton's tyrosine kinase; Medicine; Clinical trial; Tyrosine kinase; Immunology; Internal medicine","score_opus":0.29167087143112597,"score_gpt":0.47560076343604923,"score_spread":0.18392989200492327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156845972","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10408636,0.0115316035,0.000025170404,0.8795796,0.0031282462,0.00095113,0.000025079415,0.000008515023,0.0006642959],"genre_scores_gemma":[0.12769143,0.45583293,0.0019170782,0.37281138,0.008216725,0.00006393639,0.0003369375,0.0006387007,0.0324909],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9618242,0.021059182,0.012939431,0.00040868451,0.0028314134,0.00093709666],"domain_scores_gemma":[0.914017,0.06141194,0.016741239,0.0019201256,0.00557671,0.00033296584],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.08151822,0.0004935104,0.005561627,0.00053301913,0.00018427332,0.00006472664,0.0013715464,0.0015895024,0.00033105374],"category_scores_gemma":[0.19711223,0.0002302778,0.0015682613,0.00079435186,0.0014326829,0.00009897626,0.00030104216,0.013108813,0.000013995821],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006954787,0.00013102149,0.0003385964,0.000322211,0.0028261477,0.0069456887,0.0007345148,0.0000064743244,0.000051942523,0.0000129373,0.9798288,0.0018469037],"study_design_scores_gemma":[0.044742037,0.001151771,0.0001705662,0.0043273238,0.0017038572,0.24795131,0.0010102353,0.0001884247,0.00020747837,0.00066514715,0.69764316,0.00023871227],"about_ca_topic_score_codex":0.0008697915,"about_ca_topic_score_gemma":0.00024588627,"teacher_disagreement_score":0.5067682,"about_ca_system_score_codex":0.0030586093,"about_ca_system_score_gemma":0.031083293,"threshold_uncertainty_score":0.9997066},"labels":[],"label_agreement":null},{"id":"W3157229838","doi":"10.1093/rheumatology/keab247.129","title":"P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data","year":2021,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Placebo; Adverse effect; Adalimumab; Internal medicine; Rheumatoid arthritis; Physical therapy","score_opus":0.04566671996640901,"score_gpt":0.3282120078401639,"score_spread":0.2825452878737549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157229838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960676,0.00014099787,0.00005904765,0.0020306462,0.00006548534,0.0012166157,0.00008491924,0.000058845417,0.0002758741],"genre_scores_gemma":[0.9911753,0.000015057706,0.0058823274,0.0009156612,0.000023315712,0.000055919183,0.0004711372,0.000072688854,0.0013885796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963446,0.00039469087,0.00057015754,0.0010129379,0.0010406871,0.0006368993],"domain_scores_gemma":[0.99616396,0.00084723555,0.00015561875,0.0020916392,0.00032270563,0.00041884676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008318888,0.00031169815,0.00068046217,0.00023621606,0.00007661907,0.00006843382,0.0002798439,0.00012327473,0.00010806653],"category_scores_gemma":[0.0031104416,0.00022160079,0.000031035936,0.000936125,0.000116109266,0.00018089486,0.0006682354,0.00039165342,0.000031171854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11522999,0.005497931,0.7617464,0.000613236,0.0015848702,0.025331462,0.008150043,0.00027008337,0.0012703871,0.00004138073,0.008733512,0.07153071],"study_design_scores_gemma":[0.059897736,0.0029478555,0.9200851,0.00056299387,0.00016960732,0.00023813965,0.00031563634,0.00067193893,0.001238005,0.0000071860227,0.013443039,0.00042280668],"about_ca_topic_score_codex":0.000630111,"about_ca_topic_score_gemma":0.00033493928,"teacher_disagreement_score":0.15833865,"about_ca_system_score_codex":0.0018573294,"about_ca_system_score_gemma":0.0039854785,"threshold_uncertainty_score":0.9036618},"labels":[],"label_agreement":null},{"id":"W3158136113","doi":"10.1038/s41375-021-01257-7","title":"Hairy cell leukemia and COVID-19 adaptation of treatment guidelines","year":2021,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Cilag; Canadian Institutes of Health Research; Kite Pharma; Genentech; Ascentage Pharma; Pharmacyclics; Agios Pharmaceuticals; Astellas Pharma; Adaptive Biotechnologies; Astex Pharmaceuticals; H. Lundbeck A/S; TG Therapeutics; Royal Marsden NHS Foundation Trust; CancerCare Manitoba Foundation; MEI Pharma; MacroGenics; Sunesis; University of Pittsburgh; AbbVie; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Celgene; Novartis; Pfizer; Biogen; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; BeiGene; Hairy Cell Leukemia Research Foundation; GlaxoSmithKline","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Medicine; Hairy cell leukemia; Immunosuppression; Intensive care medicine; Life expectancy; Leukemia; 2019-20 coronavirus outbreak; Immunology; Disease; Virology; Internal medicine; Infectious disease (medical specialty)","score_opus":0.1891866795627362,"score_gpt":0.4336963452685132,"score_spread":0.244509665705777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158136113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014833931,0.9951183,0.00046459973,0.00007076382,0.00017463474,0.00159303,0.00010367748,0.00008959858,0.0022370566],"genre_scores_gemma":[0.000033317145,0.9837425,0.0032940505,0.00026248934,0.0005062148,0.00023127644,0.0008986363,0.00013650705,0.010895014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959179,0.00027643595,0.0015458225,0.0009898868,0.0006929721,0.0005769464],"domain_scores_gemma":[0.9962473,0.00083317474,0.00059899775,0.0011893415,0.0003870036,0.00074416964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005111861,0.00074494694,0.0032980726,0.000424164,0.00010456579,0.00004350248,0.00025140613,0.0007787566,0.0002913652],"category_scores_gemma":[0.0011094834,0.0005678361,0.000770971,0.0006504678,0.00026894675,0.00007206118,0.0002296286,0.00045965932,0.00007840685],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000055249584,0.00006117296,0.0000040208524,0.053895567,0.00048185702,0.0008184744,0.00036355504,0.00027860963,0.0000051894567,0.00010682429,0.011349593,0.9325799],"study_design_scores_gemma":[0.008387472,0.0004653251,4.6941562e-7,0.008899462,0.0021834457,0.00126082,0.00024169599,0.0063377363,0.000033871205,0.0000124363505,0.9717754,0.00040183577],"about_ca_topic_score_codex":0.007350176,"about_ca_topic_score_gemma":0.00021085065,"teacher_disagreement_score":0.96042585,"about_ca_system_score_codex":0.14809367,"about_ca_system_score_gemma":0.20012872,"threshold_uncertainty_score":0.9996773},"labels":[],"label_agreement":null},{"id":"W3158929441","doi":"10.3389/fonc.2021.674492","title":"Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Manitoba Health; Research Institute in Oncology and Hematology; University of Manitoba","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; Research Manitoba; Leukemia and Lymphoma Society","keywords":"Chronic lymphocytic leukemia; T cell; clone (Java method); CD40; Immunology; Bone marrow; Biology; Immunophenotyping; Cancer research; Leukemia; Cytotoxic T cell; Flow cytometry; Immune system; In vitro","score_opus":0.014612444917476444,"score_gpt":0.28982636797997313,"score_spread":0.2752139230624967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158929441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750665,0.016553314,0.0008434966,0.00032860896,0.0013066907,0.0005255596,0.0000032085522,0.000039766677,0.0053328574],"genre_scores_gemma":[0.990935,0.002534052,0.0024105166,0.0007220564,0.00033121303,0.00010258782,0.00006397775,0.000046060162,0.0028545235],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976725,0.00025351043,0.0004518793,0.0006247385,0.00030042822,0.00069697475],"domain_scores_gemma":[0.999064,0.00013497676,0.00007118503,0.00044147525,0.00008163855,0.00020671886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045573505,0.00021453937,0.00067975215,0.00038571807,0.000044083514,0.000017974387,0.00011465596,0.00042910597,0.00018494592],"category_scores_gemma":[0.00017744095,0.00021778441,0.00008185028,0.0006155671,0.00020035914,0.00009749185,0.0001528474,0.000455113,0.000052584048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012404617,0.0013790688,0.15370345,0.005342555,0.0009935934,0.054643244,0.006760592,0.013003885,0.14670368,0.0006790349,0.3085429,0.29584336],"study_design_scores_gemma":[0.20383713,0.0035899237,0.033495117,0.0006324045,0.0003401975,0.003226761,0.00298508,0.46704957,0.030279675,0.0020277617,0.25150228,0.0010341201],"about_ca_topic_score_codex":0.00088124233,"about_ca_topic_score_gemma":0.00094096956,"teacher_disagreement_score":0.45404568,"about_ca_system_score_codex":0.2235003,"about_ca_system_score_gemma":0.05439168,"threshold_uncertainty_score":0.95096904},"labels":[],"label_agreement":null},{"id":"W3160583968","doi":"10.1161/circ.142.suppl_3.17405","title":"Abstract 17405: Chronic Treatment of Ibrutinib Reduces PI3K Activation and Causes Increased Mitochondrial Oxidative Stress Leading to Heightened AF in <i> Pitx2c <sup>+/-</sup> </i> Mice","year":2020,"lang":"en","type":"article","venue":"Circulation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ibrutinib; Medicine; Atrial fibrillation; Internal medicine; Pharmacology; Oxidative stress; Endocrinology; Chronic lymphocytic leukemia; Leukemia","score_opus":0.0388468722511345,"score_gpt":0.3073278949139032,"score_spread":0.26848102266276874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160583968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971293,0.00027421705,0.00016681416,0.0008406669,0.000035449055,0.0012427039,0.000025834886,0.00004085696,0.00024411251],"genre_scores_gemma":[0.99879795,0.00007917135,0.0002867764,0.00008851686,0.00045251456,0.00006295078,0.00018823094,0.000029939984,0.000013941698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834055,0.00008112512,0.000402102,0.00047670657,0.0004023906,0.0002971313],"domain_scores_gemma":[0.998976,0.00030687643,0.00015071433,0.00020795247,0.0001278853,0.00023059189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009505156,0.00020966683,0.00042856022,0.00020063302,0.000059973565,0.000030707466,0.00007219151,0.00013546218,0.00007330238],"category_scores_gemma":[0.00038494423,0.00019590817,0.00006442722,0.00046695714,0.000074766715,0.0002469087,0.00003251468,0.00011164334,0.000018684304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013952614,0.00025518707,0.007914321,0.00035985114,0.00012619265,0.000035263183,0.0066934177,0.0069611957,0.9690248,0.000035478253,0.00010221804,0.00709683],"study_design_scores_gemma":[0.020452296,0.0008367916,0.0760458,0.0006302363,0.00010495208,0.000016568598,0.00095197326,0.031415336,0.8690009,0.000028947909,0.00024877038,0.0002674448],"about_ca_topic_score_codex":0.001246255,"about_ca_topic_score_gemma":0.000067223846,"teacher_disagreement_score":0.100023896,"about_ca_system_score_codex":0.0059188805,"about_ca_system_score_gemma":0.0018715548,"threshold_uncertainty_score":0.9978972},"labels":[],"label_agreement":null},{"id":"W3160737069","doi":"10.1007/978-3-030-71155-9_16","title":"Ibrutinib and Cardiac Arrythmias","year":2021,"lang":"en","type":"book-chapter","venue":"Clinical cases in cardiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Medicine; Cardiology; Internal medicine; Ejection fraction; Atrial fibrillation; Sinus rhythm; Amiodarone; Heart failure","score_opus":0.12324774728999836,"score_gpt":0.41733860771794434,"score_spread":0.29409086042794597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160737069","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053031888,0.058654528,0.000009973167,0.00079705514,0.0030306387,0.0011699079,0.00019771674,0.00009350076,0.8830148],"genre_scores_gemma":[0.1621468,0.062390395,0.00059802097,0.0018481988,0.010654552,0.00008679725,0.0007089004,0.00029805058,0.76126826],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963593,0.00032500637,0.0012129637,0.0011760378,0.0003703346,0.000556376],"domain_scores_gemma":[0.99226385,0.005787759,0.00016502128,0.0011640226,0.00020419738,0.00041514979],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015117357,0.00041915916,0.0028788943,0.00019182386,0.00003936241,0.0000163085,0.00015283542,0.0018932022,0.00042970185],"category_scores_gemma":[0.004019232,0.0003829198,0.00090134516,0.000056641707,0.0014266408,0.000021950013,0.0005992013,0.0019796551,0.00019576929],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004000041,0.00016856071,0.039334524,0.002247553,0.005457624,0.50249755,0.000112131784,0.000022106338,0.000020705136,0.0943543,0.11529684,0.23648806],"study_design_scores_gemma":[0.009262906,0.0011000147,0.0032955697,0.0006504115,0.00058888947,0.012358545,0.000040533265,0.000045596258,0.0000043224854,0.0018318935,0.9703118,0.00050949235],"about_ca_topic_score_codex":0.00006076559,"about_ca_topic_score_gemma":0.000017039438,"teacher_disagreement_score":0.855015,"about_ca_system_score_codex":0.002714239,"about_ca_system_score_gemma":0.006756287,"threshold_uncertainty_score":0.99986225},"labels":[],"label_agreement":null},{"id":"W3162249178","doi":"10.1080/10428194.2021.1919658","title":"A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Minimal residual disease; Immunophenotyping; Medicine; Flow cytometry; Multilocus sequence typing; clone (Java method); Leukemia; Immunology; Oncology; Biology","score_opus":0.02986774142796106,"score_gpt":0.2905386127932589,"score_spread":0.2606708713652978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162249178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97126013,0.022797205,0.00009353007,0.00042973383,0.00036616216,0.0025865952,0.00045407683,0.00040332033,0.0016092634],"genre_scores_gemma":[0.97136575,0.006460032,0.002674992,0.001522023,0.0014708695,0.0024114456,0.0007484229,0.00042651634,0.012919949],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9894962,0.00041012545,0.00199747,0.0032768117,0.0017429787,0.003076418],"domain_scores_gemma":[0.9920009,0.0024724002,0.00043495945,0.0020444111,0.0006367852,0.002410589],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011893939,0.0016207123,0.002429768,0.0012016695,0.0006883168,0.0004909919,0.0007042317,0.0012026626,0.00078178284],"category_scores_gemma":[0.0024331058,0.0016317966,0.00064714596,0.002176167,0.0012309938,0.0007141244,0.0010695,0.00040705374,0.00026337706],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.050185017,0.0016737068,0.032915413,0.02368093,0.0035093823,0.051427927,0.004848832,0.0074415607,0.016401105,0.0028307051,0.066017285,0.73906815],"study_design_scores_gemma":[0.2174319,0.002569014,0.100094415,0.0032652216,0.0017215338,0.0064962762,0.0010113257,0.5523805,0.018386504,0.0008020547,0.0923603,0.003480934],"about_ca_topic_score_codex":0.0032459714,"about_ca_topic_score_gemma":0.00057167996,"teacher_disagreement_score":0.7355872,"about_ca_system_score_codex":0.33471158,"about_ca_system_score_gemma":0.19911395,"threshold_uncertainty_score":0.99965405},"labels":[],"label_agreement":null},{"id":"W3162966937","doi":"10.1007/s00277-021-04536-6","title":"Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study","year":2021,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"Janssen Research and Development; Pharmacyclics; Paracelsus Medizinische Privatuniversität","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; Pharmacology; Oncology; Immunology; Leukemia; Chemotherapy","score_opus":0.028575980671565436,"score_gpt":0.3096534037363102,"score_spread":0.28107742306474476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162966937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997717,0.00036930534,0.000003636979,0.0009015439,0.000017253842,0.00078856735,0.000038888516,0.000008103511,0.00015566614],"genre_scores_gemma":[0.9995303,0.00019372605,0.000052907,0.000033636104,0.0000062417334,0.00004184038,0.00009909104,0.000012962961,0.000029284447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981172,0.0004699257,0.00044929743,0.0003324723,0.00041574537,0.0002153666],"domain_scores_gemma":[0.9976844,0.0008622439,0.00036997508,0.0006047543,0.00041753604,0.0000610988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003647762,0.00015623299,0.00061649753,0.00016125159,0.00008924805,0.000007838765,0.00010685283,0.00009709522,0.000052470466],"category_scores_gemma":[0.00042424514,0.00007531346,0.00007431657,0.0011569826,0.00027282484,0.00005055594,0.00008137421,0.00023998704,0.0000014065038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026716175,0.0014809865,0.98077375,0.0000505754,0.0063589276,0.00016306902,0.0053620837,0.00021039366,0.0014076652,0.0001475292,0.0000382103,0.0013352063],"study_design_scores_gemma":[0.013296412,0.002508032,0.9334656,0.0002499323,0.001758699,0.000062336825,0.00507967,0.001153521,0.04220441,0.00009888566,0.000013634452,0.00010887722],"about_ca_topic_score_codex":0.0051296414,"about_ca_topic_score_gemma":0.0021258418,"teacher_disagreement_score":0.047308147,"about_ca_system_score_codex":0.00026618628,"about_ca_system_score_gemma":0.0012426814,"threshold_uncertainty_score":0.7754518},"labels":[],"label_agreement":null},{"id":"W3163152086","doi":"10.5737/23688076312175185","title":"Modèle de soins partagés pour les hémopathies malignes chroniques complexes","year":2021,"lang":"fr","type":"article","venue":"Canadian Oncology Nursing Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Humanities; Political science; Medicine; Gynecology; Art","score_opus":0.10592441246219599,"score_gpt":0.37353184469362183,"score_spread":0.26760743223142586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163152086","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2026737,0.42046803,0.0056700762,0.28304794,0.01087153,0.0005573655,0.00020375884,0.00010058377,0.07640702],"genre_scores_gemma":[0.8966334,0.017059404,0.013191229,0.004664146,0.015128064,0.000024888648,0.00007121477,0.0002099721,0.053017683],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939768,0.00137763,0.00078125484,0.00051984057,0.0005020999,0.002842394],"domain_scores_gemma":[0.9943576,0.00064899784,0.00024667982,0.0004761366,0.0007986193,0.0034719899],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001535374,0.00043232157,0.00092298083,0.0005868313,0.001235454,0.00027107156,0.00042536846,0.00092081464,0.0071781245],"category_scores_gemma":[0.0011497587,0.000479708,0.0003241969,0.0004636015,0.0018047697,0.00023770153,0.000053364467,0.0020085182,0.0003286734],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020224015,0.0006681112,0.0037272715,0.000459677,0.0005787974,0.081943765,0.0068638674,0.0004405413,0.0052299253,0.021092216,0.59711796,0.28167564],"study_design_scores_gemma":[0.014522545,0.0015116024,0.003976749,0.012588877,0.0008965687,0.20972621,0.01871557,0.031940635,0.010914852,0.013105614,0.681253,0.00084774394],"about_ca_topic_score_codex":0.051155414,"about_ca_topic_score_gemma":0.19361052,"teacher_disagreement_score":0.6939597,"about_ca_system_score_codex":0.24467777,"about_ca_system_score_gemma":0.43999395,"threshold_uncertainty_score":0.99976546},"labels":[],"label_agreement":null},{"id":"W3163972164","doi":"10.1136/annrheumdis-2021-eular.544","title":"POS0594 MEANINGFUL IMPROVEMENT AND WORSENING IN PATIENTS WHO DO NOT ACHIEVE LDA AND SWITCH THERAPY TO A NEW BIOLOGIC OR TARGETED THERAPY: RESULTS FROM THE CORRONA REGISTRY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Instituto de Investigación Marqués de Valdecilla; Canadian Institutes of Health Research; Regeneron Pharmaceuticals; Patient-Centered Outcomes Research Institute; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Combination therapy; Physical therapy; Disease","score_opus":0.058254993974295156,"score_gpt":0.3206503309199542,"score_spread":0.26239533694565903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163972164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835841,0.0062114503,0.000005736488,0.0089347325,0.00007741947,0.0009433562,0.00018232889,0.000016835382,0.00004406132],"genre_scores_gemma":[0.99035746,0.005333622,0.00010529322,0.0035617533,0.000043979882,0.000030420215,0.00005255748,0.000024161502,0.00049072417],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99790233,0.00019563653,0.0005424721,0.00044560328,0.000547902,0.00036607502],"domain_scores_gemma":[0.9974385,0.001064948,0.0002334762,0.000842115,0.00017461175,0.00024634026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038201013,0.00023465217,0.00048341372,0.000052708205,0.000105931475,0.00007525819,0.00030429283,0.000073561714,0.00006960965],"category_scores_gemma":[0.0026047018,0.00011553482,0.0001018158,0.00036751412,0.00015336186,0.00006858951,0.00032896755,0.00016583741,0.0000029096238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044614293,0.0018126477,0.10686516,0.00037459476,0.0015723745,0.00008776915,0.019483943,0.00010164814,0.002980211,0.00007387729,0.03502304,0.78701043],"study_design_scores_gemma":[0.044878155,0.0021771577,0.9309894,0.0038645817,0.000094874435,0.000017375487,0.003241556,0.0009694711,0.010127141,0.0022013986,0.0010030149,0.00043590905],"about_ca_topic_score_codex":0.0024807586,"about_ca_topic_score_gemma":0.00011094795,"teacher_disagreement_score":0.8241242,"about_ca_system_score_codex":0.0002364508,"about_ca_system_score_gemma":0.001791474,"threshold_uncertainty_score":0.47113734},"labels":[],"label_agreement":null},{"id":"W3164016517","doi":"10.1182/blood.v130.suppl_1.3994.3994","title":"Deciphering Discordance between MYC mRNA and MYC IHC in DLBCL: The Role of MYC Exon 2 Mutations and N11S Polymorphism","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; Simon Fraser University; BC Cancer Agency","funders":"","keywords":"Exon; Biology; Cancer research; Immunohistochemistry; Molecular biology; Medicine; Gene; Genetics; Immunology","score_opus":0.018150772771551898,"score_gpt":0.2958433537674796,"score_spread":0.2776925809959277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164016517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389213,0.0026304764,0.00001384782,0.00060875807,0.000025858453,0.00033795167,0.000013877442,0.000013657843,0.0024634497],"genre_scores_gemma":[0.99891263,0.00021974677,0.00033841986,0.000021806547,0.00018259398,0.000027661501,0.0000053761623,0.000021967537,0.00026979827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890447,0.000036175217,0.0002426267,0.00025075706,0.00027923257,0.00028675952],"domain_scores_gemma":[0.9988861,0.00023582646,0.00011569227,0.00060169736,0.000037575624,0.00012307533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002841294,0.00012340109,0.0002761441,0.00006437708,0.00019547886,0.000055034903,0.00020959933,0.000068123256,0.000013709128],"category_scores_gemma":[0.00029305302,0.00009047912,0.000035227433,0.00008079093,0.0003765107,0.00012727607,0.0002291865,0.00019319112,0.00000469835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018618898,0.0007071318,0.87627006,0.0003521055,0.00038707492,0.00028297436,0.006002321,0.000006225088,0.036244653,0.00069814525,0.00005974982,0.07880336],"study_design_scores_gemma":[0.027320504,0.00017692478,0.93669987,0.00041382547,0.00023880608,0.00021228829,0.00095243985,0.0009842957,0.031095602,0.0011226443,0.0006016434,0.00018117315],"about_ca_topic_score_codex":0.0022269774,"about_ca_topic_score_gemma":0.00030193682,"teacher_disagreement_score":0.078622185,"about_ca_system_score_codex":0.00028033834,"about_ca_system_score_gemma":0.0006517612,"threshold_uncertainty_score":0.36896315},"labels":[],"label_agreement":null},{"id":"W3164881564","doi":"10.1177/23247096211022484","title":"Abetalipoproteinemia Due to a Novel Splicing Variant in <i>MTTP</i> in 3 Siblings","year":2021,"lang":"en","type":"article","venue":"Journal of Investigative Medicine High Impact Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; Queen's University","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Microsomal triglyceride transfer protein; Medicine; Apolipoprotein B; Malabsorption; Pediatrics; Genetics; Internal medicine; Endocrinology; Biology; Very low-density lipoprotein; Lipoprotein; Cholesterol","score_opus":0.04657255979630549,"score_gpt":0.3487031214277661,"score_spread":0.3021305616314606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164881564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754424,0.00094136945,0.0005350604,0.009516129,0.00036751368,0.0006749775,0.000005334227,0.000015443966,0.0003999208],"genre_scores_gemma":[0.99143857,0.00004767111,0.0055353343,0.0019217479,0.00078898337,0.00001701122,0.000011107303,0.0000612741,0.00017830291],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9942917,0.0002122139,0.0025936333,0.00053693884,0.0015716029,0.000793905],"domain_scores_gemma":[0.99492145,0.0005011141,0.0010926498,0.0006734455,0.0012703389,0.0015409992],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004103878,0.00043058716,0.0018591932,0.0016179048,0.000055276734,0.000034079923,0.00010269414,0.0002095068,0.00028561207],"category_scores_gemma":[0.01697974,0.00030366064,0.0002192301,0.0031881398,0.00047693713,0.00029834348,0.00014675064,0.0013621245,0.000006411276],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002840219,0.00031848048,0.0021854509,0.00022759692,0.0001471043,0.8549163,0.002625053,0.00066948315,0.13674155,0.00008052606,0.0012654826,0.0005389916],"study_design_scores_gemma":[0.017292568,0.001527002,0.011903195,0.0061265216,0.00014916154,0.90925694,0.0011676546,0.00076639216,0.050279595,0.0010164696,0.00025267396,0.00026180467],"about_ca_topic_score_codex":0.013719021,"about_ca_topic_score_gemma":0.0008887551,"teacher_disagreement_score":0.08646196,"about_ca_system_score_codex":0.012096101,"about_ca_system_score_gemma":0.018577246,"threshold_uncertainty_score":0.9999415},"labels":[],"label_agreement":null},{"id":"W3165403689","doi":"10.1136/annrheumdis-2021-eular.2137","title":"POS0222 PREDICTORS OF RESPONSE: BASELINE CHARACTERISTICS AND EARLY TREATMENT RESPONSES ASSOCIATED WITH ACHIEVEMENT OF REMISSION AND LOW DISEASE ACTIVITY AMONG UPADACITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ABB (Canada); MaRS","funders":"Monash University","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Logistic regression; Concordance; Confidence interval; Univariate analysis; Methotrexate; Disease; Multivariate analysis","score_opus":0.016361041112897944,"score_gpt":0.2664683847085647,"score_spread":0.2501073435956668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165403689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965264,0.0009557572,0.0000041442286,0.00034744854,0.000016624108,0.00081069686,0.0013136078,0.000019995867,0.0000053142903],"genre_scores_gemma":[0.99776626,0.0017965139,0.00002247098,0.000018124036,0.0000047026037,0.00003398107,0.00011691665,0.000033144537,0.00020789588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972945,0.00067683915,0.0005511745,0.00032953187,0.0008673728,0.00028059614],"domain_scores_gemma":[0.99635917,0.001292569,0.000597755,0.00063981564,0.0007031289,0.0004075726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040109537,0.00026684313,0.0007731699,0.00012011448,0.00009349535,0.000021942898,0.00010103735,0.00005986061,0.000028366687],"category_scores_gemma":[0.004137122,0.00015909472,0.0001122537,0.000322929,0.0006183243,0.00013016279,0.00012857433,0.0000813555,1.7095184e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035996687,0.0025850327,0.9530759,0.0007205131,0.0008713227,0.00005998505,0.00039718323,0.0000052219902,0.00036449055,0.0000030190897,0.000056370613,0.0058643166],"study_design_scores_gemma":[0.01240726,0.0020028038,0.9663403,0.009669578,0.00028359404,0.000006296927,0.00009500666,0.00034756443,0.008692706,0.000010200694,0.0000056484146,0.00013904204],"about_ca_topic_score_codex":0.0002184299,"about_ca_topic_score_gemma":0.000015960863,"teacher_disagreement_score":0.023589425,"about_ca_system_score_codex":0.0003335831,"about_ca_system_score_gemma":0.0025550479,"threshold_uncertainty_score":0.64876944},"labels":[],"label_agreement":null},{"id":"W3165476304","doi":"10.1136/annrheumdis-2021-eular.850","title":"POS0446 FILGOTINIB-TREATED RHEUMATOID ARTHRITIS PATIENTS WITH HIGH BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO SHOW BETTER CLINICAL RESPONSE RATES AND PATIENT-REPORTED OUTCOMES","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Arthritis Network; Vrije Universiteit Amsterdam; Canadian Institutes of Health Research; University of Leeds; Ontario Ministry of Health and Long-Term Care; Bristol-Myers Squibb; Universitätsspital Basel; Università degli Studi di Milano; Sanofi; Université Paris-Saclay; Pfizer","keywords":"Medicine; Internal medicine; Rheumatoid arthritis; Population; Post-hoc analysis; Rituximab; Methotrexate; Adalimumab; Neutrophil to lymphocyte ratio; Clinical trial; TNF inhibitor; Lymphocyte; Immunology; Gastroenterology; Lymphoma","score_opus":0.02917616228633254,"score_gpt":0.32424270681192835,"score_spread":0.29506654452559583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165476304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877775,0.0016364558,0.0000143726475,0.008906232,0.00016175397,0.001111849,0.0003061412,0.00006599936,0.000019704099],"genre_scores_gemma":[0.9940591,0.0013334698,0.00036594423,0.0036439418,0.000022923557,0.00007610431,0.00018954102,0.000069553505,0.00023943171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952408,0.0009706784,0.0014227176,0.0006572432,0.0011403852,0.00056816393],"domain_scores_gemma":[0.99411315,0.0022366617,0.0004985575,0.0013716074,0.0011389044,0.0006411255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006160276,0.00040993522,0.001151255,0.00016433194,0.0001759766,0.00008608208,0.000246971,0.00012023641,0.00030707827],"category_scores_gemma":[0.008063145,0.00025724457,0.0003312018,0.0005881412,0.0004187559,0.00017544793,0.00036809416,0.0001960607,0.000030830975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016728275,0.003206432,0.8818395,0.00048211354,0.0022829273,0.00057559623,0.00046077897,0.00012380737,0.00013400875,0.00003883618,0.015595322,0.07853239],"study_design_scores_gemma":[0.022136955,0.0010414892,0.9679506,0.0024679098,0.0001918398,0.000100495505,0.00014770814,0.00066528394,0.004420265,0.0001015828,0.00043372766,0.00034213433],"about_ca_topic_score_codex":0.0002698849,"about_ca_topic_score_gemma":0.000028670916,"teacher_disagreement_score":0.08611109,"about_ca_system_score_codex":0.0003247995,"about_ca_system_score_gemma":0.003515555,"threshold_uncertainty_score":0.99998796},"labels":[],"label_agreement":null},{"id":"W3168546078","doi":"10.1093/ecco-jcc/jjab076.436","title":"P312 Erythrocyte methotrexate polyglutamate concentrations in patients with Crohn’s Disease: towards a new therapeutic drug monitoring tool","year":2021,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methotrexate; Medicine; Thiopurine methyltransferase; Therapeutic drug monitoring; Drug; Internal medicine; Concomitant; Crohn's disease; Gastroenterology; Pharmacology; Disease; Infliximab; Dosing; Inflammatory bowel disease","score_opus":0.017525927755252545,"score_gpt":0.2946407458647193,"score_spread":0.27711481810946675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168546078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927662,0.0052872063,0.00017386874,0.0011160403,0.00016445256,0.00023677277,0.000013891305,0.0000081655135,0.00023338168],"genre_scores_gemma":[0.9961084,0.0012843873,0.000794307,0.00020935836,0.00028516926,0.000005728694,0.0000043524287,0.000022850501,0.0012854558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825865,0.000100611986,0.0004523639,0.00017977726,0.0006449207,0.0003636561],"domain_scores_gemma":[0.99868596,0.0000906669,0.00016754647,0.00019901265,0.0004248573,0.00043194942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021449219,0.00015088025,0.00040216377,0.00011171788,0.000076086915,0.000120176686,0.00008420104,0.000047087855,0.0001393214],"category_scores_gemma":[0.00011248056,0.00011460838,0.00009131855,0.00029780273,0.00008347764,0.0002478141,0.000049411174,0.00028820214,0.000002453123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04609859,0.0018387933,0.6192982,0.0011992813,0.0017736361,0.031781707,0.007314076,0.0002679027,0.00032776032,0.0016926334,0.0024369687,0.28597045],"study_design_scores_gemma":[0.015608043,0.00015794177,0.9792759,0.00070171535,0.00015863693,0.00026016784,0.000246127,0.00017535758,0.001013842,0.00023234394,0.0020456617,0.00012429034],"about_ca_topic_score_codex":0.000290369,"about_ca_topic_score_gemma":0.000039541883,"teacher_disagreement_score":0.35997766,"about_ca_system_score_codex":0.0020098253,"about_ca_system_score_gemma":0.008925658,"threshold_uncertainty_score":0.99669284},"labels":[],"label_agreement":null},{"id":"W3168988530","doi":"10.1016/j.jval.2021.04.019","title":"CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (ELEVATE-TN)","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Obinutuzumab; Chlorambucil; Medicine; Internal medicine; Chronic lymphocytic leukemia; Randomized controlled trial; Quality of life (healthcare); Oncology; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.11065497743286437,"score_gpt":0.3871581889329666,"score_spread":0.27650321150010226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168988530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840138,0.0023402479,0.000091763286,0.00028961565,0.0005849138,0.0122953225,0.00013530294,0.00012642614,0.00012261055],"genre_scores_gemma":[0.99523014,0.0006911789,0.0006741913,0.00026732875,0.00022696868,0.0016925895,0.0003117364,0.00014694252,0.0007589059],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99224544,0.0012440291,0.0023911777,0.0012743498,0.0015096124,0.0013354098],"domain_scores_gemma":[0.9888413,0.007087135,0.0010516025,0.0019868908,0.00054183777,0.0004912516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015868815,0.0007371746,0.003549352,0.00023675268,0.00029754013,0.00006914292,0.00038514662,0.0002489678,0.00022148884],"category_scores_gemma":[0.0027489509,0.00041429035,0.0004253863,0.0011196745,0.00043760214,0.0001417412,0.00017235322,0.00037791592,0.000016120284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9107211,0.001557553,0.0011291393,0.0011908952,0.0050937645,0.0018945343,0.024523,0.04307416,0.00014861202,0.000104733386,0.00035085235,0.010211636],"study_design_scores_gemma":[0.7293223,0.013183919,0.00009149644,0.0006757715,0.00078722223,0.00016154803,0.0061896956,0.24772938,0.0010380495,0.000026573442,0.00048087622,0.00031317933],"about_ca_topic_score_codex":0.17814216,"about_ca_topic_score_gemma":0.008048084,"teacher_disagreement_score":0.20465522,"about_ca_system_score_codex":0.38513383,"about_ca_system_score_gemma":0.3492581,"threshold_uncertainty_score":0.9998309},"labels":[],"label_agreement":null},{"id":"W3169270290","doi":"10.1016/j.leukres.2021.106628","title":"Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines","year":2021,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"Janssen Canada","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gastroenterology; Immunology; Oncology; Leukemia","score_opus":0.034291604812851754,"score_gpt":0.32793218762742576,"score_spread":0.293640582814574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169270290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941309,0.0022946573,0.000002951163,0.00088876864,0.000105922576,0.0014259049,0.000005378728,0.000040811392,0.0011047189],"genre_scores_gemma":[0.9965849,0.0018549191,0.000012970839,0.00019046679,0.00025962136,0.00049114134,0.00007027833,0.0000542892,0.0004814235],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99483234,0.0009826926,0.00057542644,0.00088654476,0.0014597271,0.0012632712],"domain_scores_gemma":[0.99663925,0.0023374401,0.00008887643,0.00052333204,0.00021150755,0.00019957095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042456496,0.00030939374,0.0007587728,0.0008396276,0.00017850628,0.00015288514,0.00020102753,0.0003266029,0.00003982576],"category_scores_gemma":[0.0022994669,0.00024858763,0.00009619926,0.0023429666,0.0004916953,0.0002329177,0.00053969474,0.0013846823,0.000017479184],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03001528,0.0013142738,0.073344074,0.007016115,0.0017631281,0.015652072,0.043968257,0.0063760164,0.3459501,0.008101219,0.0013866624,0.4651128],"study_design_scores_gemma":[0.16845936,0.0013685864,0.06262269,0.0019105473,0.000084394174,0.00015710208,0.003020058,0.7402619,0.019746872,0.0014233881,0.0004636901,0.00048142616],"about_ca_topic_score_codex":0.0067693116,"about_ca_topic_score_gemma":0.011859112,"teacher_disagreement_score":0.7338859,"about_ca_system_score_codex":0.18298931,"about_ca_system_score_gemma":0.033626378,"threshold_uncertainty_score":0.99999666},"labels":[],"label_agreement":null},{"id":"W3170059348","doi":"10.1093/ecco-jcc/jjab075.024","title":"OP25 Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial","year":2021,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Ulcerative colitis; Vedolizumab; Internal medicine; Placebo; Regimen; Maintenance therapy; Clinical trial; Phases of clinical research; Gastroenterology; Surgery; Chemotherapy; Disease; Pathology","score_opus":0.019328111584424785,"score_gpt":0.32801335962298844,"score_spread":0.3086852480385637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170059348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985188,0.00032964145,0.000017534772,0.00028240628,0.00004490905,0.0005332107,0.00002941775,0.0000010152207,0.0002430178],"genre_scores_gemma":[0.99909043,0.00048434458,0.00007341591,0.00009931898,0.0001122929,0.00000750591,0.000011397432,0.000008644291,0.00011266973],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983767,0.0002342681,0.0005862266,0.000106566644,0.00052324345,0.00017294276],"domain_scores_gemma":[0.9986749,0.00032621098,0.00029059194,0.00010217052,0.0005363977,0.000069711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051559194,0.00009032954,0.0004443068,0.00011888802,0.000023551635,0.000017193659,0.00007006104,0.00006343443,0.00012705046],"category_scores_gemma":[0.00025368694,0.000056348537,0.00006586206,0.00039455833,0.00010639764,0.000079720856,0.000013518387,0.00025962468,1.5701208e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90837395,0.009276088,0.0075448463,0.00022986949,0.00038655323,0.00066387723,0.0061758244,0.000032706153,0.00045000776,0.00023871068,0.002859108,0.06376847],"study_design_scores_gemma":[0.5449598,0.014588038,0.42765504,0.0004958748,0.00004195106,0.00021249907,0.000644262,0.00020978943,0.009542073,0.00006152574,0.001507995,0.000081177124],"about_ca_topic_score_codex":0.00027136094,"about_ca_topic_score_gemma":0.00014605239,"teacher_disagreement_score":0.4201102,"about_ca_system_score_codex":0.0006391304,"about_ca_system_score_gemma":0.002683617,"threshold_uncertainty_score":0.47606212},"labels":[],"label_agreement":null},{"id":"W3170399786","doi":"10.1200/jco.2021.39.15_suppl.tps7572","title":"ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Population; Diffuse large B-cell lymphoma; CHOP; Gastroenterology; Rituximab; Vincristine; Phases of clinical research; Ibrutinib; Oncology; Cyclophosphamide; Surgery; Lymphoma; Chronic lymphocytic leukemia; Clinical trial; Leukemia; Chemotherapy","score_opus":0.027573694381186314,"score_gpt":0.3926581560045246,"score_spread":0.3650844616233383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170399786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667114,0.00020119392,0.00026612304,0.00035916397,0.00029132076,0.001724638,0.00004416946,0.000010377233,0.00043187643],"genre_scores_gemma":[0.9962956,0.00031563098,0.0021928586,0.00041334773,0.00017702482,0.00004792936,0.000056486268,0.00006567967,0.0004354698],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99405533,0.00051779504,0.0030686622,0.0006179981,0.0010527624,0.0006874678],"domain_scores_gemma":[0.99219304,0.002697545,0.0020005787,0.00045060302,0.0020213951,0.0006368094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021190604,0.0003852999,0.0025788345,0.00032295662,0.00008516926,0.0000260201,0.00025750854,0.00048528542,0.000037842052],"category_scores_gemma":[0.0015122959,0.00026735905,0.0002377911,0.0005920924,0.00035673162,0.00020068481,0.00018699636,0.0008467597,0.0000040678174],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10143344,0.51144516,0.35504466,0.0007304237,0.0006393187,0.0053430093,0.0011857017,0.00000784595,0.0003911733,0.0000055362766,0.0017914417,0.02198226],"study_design_scores_gemma":[0.76125634,0.094207294,0.13534328,0.00047800242,0.0007027748,0.00048876496,0.0009962438,0.0034176644,0.0007988009,0.000014601108,0.0020597235,0.00023651456],"about_ca_topic_score_codex":0.00017741782,"about_ca_topic_score_gemma":0.00028771488,"teacher_disagreement_score":0.6598229,"about_ca_system_score_codex":0.002368015,"about_ca_system_score_gemma":0.010671245,"threshold_uncertainty_score":0.9999779},"labels":[],"label_agreement":null},{"id":"W3170863384","doi":"10.14740/jh814","title":"Early Onset Neutropenia due to Rituximab Therapy in Mantle Cell Lymphoma: A Case Report","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Mantle cell lymphoma; Rituximab; Neutropenia; Lymphoma; Dermatology; Immunology; Internal medicine; Chemotherapy","score_opus":0.02194924675858833,"score_gpt":0.3195169714391863,"score_spread":0.29756772468059794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170863384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373037,0.0018368845,0.00011874256,0.0026687786,0.0002522371,0.0002119775,0.0000022633685,0.0000083987625,0.0011703435],"genre_scores_gemma":[0.99655443,0.00010031686,0.001573879,0.0006705925,0.000118862794,0.000007869124,0.0000023856278,0.000030068428,0.0009416204],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9978385,0.00017697268,0.00089017826,0.00025610745,0.0004004341,0.00043783078],"domain_scores_gemma":[0.9982775,0.00024193946,0.00026290515,0.00046615445,0.00043424053,0.00031727503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063723384,0.00015400501,0.0008961639,0.0003342283,0.00003985878,0.000024361005,0.00014896505,0.00015912575,0.00027986363],"category_scores_gemma":[0.00038635544,0.00012388581,0.00016979926,0.00042575135,0.00006563838,0.00008222944,0.0001021596,0.00032530542,0.00011796244],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000991698,0.0010694623,0.0030487785,0.00008038853,0.000066053755,0.987505,0.00037492596,0.000004356892,0.0012494406,0.000072112176,0.0046575307,0.0008802424],"study_design_scores_gemma":[0.03642436,0.0006362813,0.0023375007,0.00011614315,0.00002816545,0.92825574,0.00030287492,0.00011020633,0.028218593,0.00013859387,0.0033304805,0.00010106651],"about_ca_topic_score_codex":0.0004963289,"about_ca_topic_score_gemma":0.00022003069,"teacher_disagreement_score":0.05924928,"about_ca_system_score_codex":0.0024436072,"about_ca_system_score_gemma":0.0083360635,"threshold_uncertainty_score":0.9972857},"labels":[],"label_agreement":null},{"id":"W3170908410","doi":"10.1158/2159-8290.cd-21-0145","title":"Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Cancer Institute; Ontario Institute for Cancer Research; National Institutes of Health; Canadian Cancer Society; Damon Runyon Cancer Research Foundation","keywords":"Enhancer; Stem cell; Biology; Cancer research; Leukemia; Lineage (genetic); Cell biology; Gene; Genetics; Gene expression","score_opus":0.021399032567903986,"score_gpt":0.3059097712941333,"score_spread":0.28451073872622934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170908410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97374034,0.019833207,0.00029700605,0.00016311332,0.0006801297,0.0003900709,0.000026491667,0.000066998706,0.0048026587],"genre_scores_gemma":[0.96658635,0.005645535,0.00020621045,0.0006728792,0.000685282,0.0001702474,0.00004974537,0.000084239866,0.025899487],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970509,0.000094245624,0.00052690256,0.00082536315,0.0007361773,0.00076645555],"domain_scores_gemma":[0.99851817,0.00014303681,0.0001310262,0.0008188092,0.00014699805,0.00024198394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021974677,0.00031640028,0.0005957993,0.00014853213,0.00008855013,0.00011258765,0.00023914775,0.00023489747,0.00045932244],"category_scores_gemma":[0.000047999176,0.00028652753,0.00023021443,0.0006084639,0.00013531938,0.00045367336,0.00033431555,0.0005965999,0.00009357944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007327106,0.00033134286,0.0038836144,0.0012758345,0.0001024745,0.00307813,0.0022125542,0.0018666905,0.95922303,0.000018528946,0.0056926943,0.021582387],"study_design_scores_gemma":[0.011774182,0.000081905826,0.0015667401,0.0015658769,0.00007160339,0.00008967458,0.0010820981,0.0018744837,0.97465307,0.00001742586,0.0068758093,0.00034714714],"about_ca_topic_score_codex":0.0011380342,"about_ca_topic_score_gemma":0.00039352867,"teacher_disagreement_score":0.02123524,"about_ca_system_score_codex":0.024681525,"about_ca_system_score_gemma":0.020828374,"threshold_uncertainty_score":0.9999587},"labels":[],"label_agreement":null},{"id":"W3171413004","doi":"10.1200/jco.2021.39.15_suppl.7523","title":"Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Chlorambucil; Medicine; Hazard ratio; Chronic lymphocytic leukemia; IGHV@; Internal medicine; Oncology; Neutropenia; Progression-free survival; Confidence interval; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.11741288571340827,"score_gpt":0.45220317969151624,"score_spread":0.334790293978108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171413004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969561,0.0002892175,0.000023499764,0.00072004466,0.00051178364,0.0013289669,0.000012708752,0.0000032033424,0.00015446033],"genre_scores_gemma":[0.99805063,0.0002817196,0.0005187102,0.00026819544,0.00035177823,0.000040551728,0.000007752737,0.000026124002,0.00045456248],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953807,0.0005620228,0.0025136769,0.00029193575,0.00088336354,0.00036828028],"domain_scores_gemma":[0.99102247,0.006126952,0.001116686,0.0005120238,0.0009731649,0.00024873333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002786774,0.00017081176,0.0018135177,0.0001832725,0.000030272638,0.0000062806184,0.00034031723,0.0002478517,0.000051386964],"category_scores_gemma":[0.005384056,0.00010218953,0.0003991086,0.0004830061,0.00015838441,0.00005292731,0.000103765946,0.0003937106,0.000004474926],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.18758927,0.029613368,0.27917254,0.0009505561,0.0056539173,0.0061949673,0.02096783,0.007845699,0.00011989244,0.00010073493,0.00798601,0.4538052],"study_design_scores_gemma":[0.48673815,0.27683833,0.19368033,0.00070487754,0.0012278482,0.00031616268,0.0033147093,0.0023992655,0.00032250074,0.00010497846,0.034137312,0.00021552466],"about_ca_topic_score_codex":0.00052709994,"about_ca_topic_score_gemma":0.003401738,"teacher_disagreement_score":0.45358968,"about_ca_system_score_codex":0.026925841,"about_ca_system_score_gemma":0.059456058,"threshold_uncertainty_score":0.9768096},"labels":[],"label_agreement":null},{"id":"W3171624023","doi":"10.1007/s00277-021-04545-5","title":"Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","year":2021,"lang":"en","type":"erratum","venue":"Annals of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Hospital","funders":"","keywords":"Medicine; Randomized controlled trial; Cytarabine; Internal medicine; Myeloid leukemia; Hematology; Oncology; Term (time); Clinical trial","score_opus":0.030088834126722988,"score_gpt":0.3805823575140232,"score_spread":0.3504935233873002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171624023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924015,0.0018178037,0.00009194915,0.00021876472,0.002670095,0.002192678,0.00019532046,0.000013455316,0.00039843412],"genre_scores_gemma":[0.98827296,0.003260227,0.00019836274,0.00036640646,0.00029974914,0.00017003575,0.0027434328,0.00008322393,0.004605588],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944303,0.00056512695,0.0027589486,0.00084425154,0.0007802363,0.0006211342],"domain_scores_gemma":[0.99452055,0.0018215873,0.0014250027,0.0008967126,0.0010027419,0.00033340394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016735505,0.00047217822,0.007263533,0.0015906319,0.000038748305,0.000008326127,0.00028671432,0.0010235786,0.00023003678],"category_scores_gemma":[0.0027141445,0.00038559505,0.0009180142,0.0014239709,0.00080356904,0.00007169572,0.0003514413,0.0012579999,0.0000011252046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95584184,0.0027537674,0.0038856745,0.0017582016,0.012883123,0.0007753953,0.0004459688,0.000044202505,0.000035825648,0.000026150077,0.018893696,0.0026561546],"study_design_scores_gemma":[0.9744859,0.008121658,0.004415967,0.0021154338,0.005717429,0.00022846553,0.00003605683,0.0031591845,0.0013249249,0.000016646321,0.00007791313,0.00030041946],"about_ca_topic_score_codex":0.0009409299,"about_ca_topic_score_gemma":0.0012693611,"teacher_disagreement_score":0.018815784,"about_ca_system_score_codex":0.0012009441,"about_ca_system_score_gemma":0.017626056,"threshold_uncertainty_score":0.9998596},"labels":[],"label_agreement":null},{"id":"W3173172916","doi":"10.1002/ajh.26274","title":"Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (<scp>FILO</scp>)","year":2021,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Chronic lymphocytic leukemia; Leukemia cutis; Merkel cell carcinoma; IGHV@; Leukemia; Medicine; Pathology; Carcinoma; Immunology","score_opus":0.02323319188451987,"score_gpt":0.32291421686711275,"score_spread":0.29968102498259286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173172916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983321,0.00069531886,0.00018020326,0.0000916156,0.0002060261,0.000371784,0.000008846375,0.000009565001,0.0001045641],"genre_scores_gemma":[0.99853253,0.0006724367,0.00040089988,0.00016757334,0.0001279464,0.0000056855692,0.000008294578,0.00003421467,0.000050388855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953385,0.0008888317,0.0023117987,0.00041411255,0.0005834227,0.0004633529],"domain_scores_gemma":[0.99391824,0.0018145929,0.0018855485,0.00056494924,0.0016328403,0.0001838036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010705685,0.00027573723,0.0020531453,0.00033319718,0.00005899283,0.000011577536,0.00040887174,0.00025683115,0.000035598925],"category_scores_gemma":[0.0067308904,0.00019103105,0.00014400568,0.0027632082,0.0019222472,0.00008028944,0.00042134195,0.00096265296,0.0000035784042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00022602736,0.0004287556,0.9819481,0.0002967663,0.00067407626,0.0017835277,0.0025776548,0.00011074658,0.0047426187,0.0008471406,0.0004576516,0.005906978],"study_design_scores_gemma":[0.026273038,0.0069301315,0.9271559,0.0007156016,0.00027509587,0.014444337,0.007866063,0.0018058901,0.014064475,0.00012633187,0.00018450024,0.0001585986],"about_ca_topic_score_codex":0.0008080271,"about_ca_topic_score_gemma":0.00010963282,"teacher_disagreement_score":0.05479212,"about_ca_system_score_codex":0.018886408,"about_ca_system_score_gemma":0.06540164,"threshold_uncertainty_score":0.9848799},"labels":[],"label_agreement":null},{"id":"W3174136736","doi":"10.1159/000516748","title":"Lymphocytosis with Smudge Cells Is Not Equivalent to Chronic Lymphocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; Western University","funders":"","keywords":"Lymphocytosis; Medicine; Chronic lymphocytic leukemia; Leukocytosis; Pathology; Bone marrow; Hairy cell leukemia; Leukemia; Lymph node biopsy; Lymphoproliferative disorders; Gastroenterology; Lymph node; Lymphoma; Internal medicine","score_opus":0.034207420029476646,"score_gpt":0.3486808900265752,"score_spread":0.3144734699970986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174136736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810336,0.0011492711,0.00016661815,0.001109996,0.00066143245,0.0011412366,0.000013499481,0.00012291834,0.014601428],"genre_scores_gemma":[0.9843935,0.0004016131,0.001924514,0.0048432904,0.00042743766,0.00030527922,0.000026644124,0.00011010351,0.0075676446],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99490654,0.00019946386,0.0011944486,0.0014363441,0.00095119607,0.001312018],"domain_scores_gemma":[0.9960596,0.0005182116,0.00027922308,0.001845146,0.0004410775,0.00085673656],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095642137,0.00045009324,0.001199883,0.00042654225,0.00012470358,0.000047882648,0.00014633308,0.00049453595,0.0017929353],"category_scores_gemma":[0.0005006344,0.00039838234,0.00020808246,0.0011237711,0.00031302715,0.00009599976,0.0005156418,0.00047239134,0.0003902787],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007569708,0.00017127066,0.00022752564,0.0004316415,0.0001747747,0.95643926,0.0006601787,0.0016282663,0.020963853,0.00004364139,0.008934811,0.009567804],"study_design_scores_gemma":[0.016024835,0.0018656476,0.00010202501,0.0003690623,0.0001993084,0.67098147,0.0003728151,0.0047862357,0.19852877,0.000028946459,0.1063182,0.0004227026],"about_ca_topic_score_codex":0.0025426724,"about_ca_topic_score_gemma":0.0014431076,"teacher_disagreement_score":0.2854578,"about_ca_system_score_codex":0.40620974,"about_ca_system_score_gemma":0.2124228,"threshold_uncertainty_score":0.9998468},"labels":[],"label_agreement":null},{"id":"W3174662807","doi":"10.1002/hon.7_2881","title":"T‐CELL SUBSET COMPOSITION AND FUNCTIONALITY IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Cytotoxic T cell; Chronic lymphocytic leukemia; CD19; Waldenstrom macroglobulinemia; CD8; T cell; Immunology; Macroglobulinemia; B cell; Cancer research; Lymphoma; Leukemia; Immune system; Biology; Multiple myeloma; Antibody","score_opus":0.01834866805480126,"score_gpt":0.29696716183461686,"score_spread":0.2786184937798156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174662807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926825,0.000231996,0.00005507964,0.0013470072,0.000049192422,0.0002829604,0.000009777092,0.000031325457,0.005310167],"genre_scores_gemma":[0.9967872,0.00003133461,0.0019407526,0.0008460898,0.000027683513,0.000025394085,0.00014399373,0.000008390775,0.00018917453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861604,0.00014773896,0.00027398716,0.00037339973,0.0002790858,0.0003097189],"domain_scores_gemma":[0.9991094,0.000291093,0.000055442622,0.00018691772,0.00018783001,0.00016933533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014538928,0.00012371471,0.00045859048,0.000046481935,0.000042974843,0.000009176276,0.00004320485,0.0002484143,0.0006749308],"category_scores_gemma":[0.000097549746,0.000087926106,0.000035379628,0.00021144899,0.00022902017,0.000033696047,0.00010132842,0.00030176842,0.00004313082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039919815,0.0035068963,0.975423,0.00042086007,0.00005910868,0.00681728,0.000093751674,0.000013715158,0.0011920662,0.0023775767,0.004324602,0.0017792039],"study_design_scores_gemma":[0.081922956,0.0033789917,0.89086765,0.0001675441,0.000116734795,0.006150366,0.00018808598,0.0011113618,0.006762017,0.00070037367,0.008247781,0.00038616505],"about_ca_topic_score_codex":0.000031242813,"about_ca_topic_score_gemma":0.00003598753,"teacher_disagreement_score":0.084555335,"about_ca_system_score_codex":0.0027945794,"about_ca_system_score_gemma":0.001680991,"threshold_uncertainty_score":0.7390019},"labels":[],"label_agreement":null},{"id":"W3174994842","doi":"10.3390/curroncol28040223","title":"Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Università degli Studi di Ferrara; Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Ibrutinib; Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Cancer research; Tumor microenvironment; Apoptosis; Leukemia; Medicine; Tyrosine kinase; Pharmacology; Immunology; Chemistry; Receptor; Internal medicine; Tumor cells; Biochemistry","score_opus":0.05089760093461793,"score_gpt":0.3420464756975857,"score_spread":0.29114887476296775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174994842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919131,0.0058907103,0.0000598688,0.00015201837,0.00037227187,0.0011204825,0.000010391145,0.000030773263,0.00045042404],"genre_scores_gemma":[0.99471277,0.003798039,0.00021792707,0.00011854196,0.00035104787,0.0003824729,0.000025930503,0.00003046262,0.00036279872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806505,0.00018035814,0.00036955925,0.0005764125,0.00035923722,0.00044937924],"domain_scores_gemma":[0.99914503,0.00015756219,0.00013260213,0.0002833908,0.00006155053,0.00021985482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015119337,0.00027033858,0.00057988655,0.000115424795,0.000059613812,0.000010222306,0.000053287087,0.00017569309,0.00027340773],"category_scores_gemma":[0.000018028933,0.00019624796,0.00010253967,0.00016492102,0.00035229215,0.000045699344,0.00013390562,0.0002908259,0.00003788257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009899619,0.0025965467,0.0024607936,0.002046227,0.0006680381,0.002916815,0.00088670844,0.00056329573,0.6699535,0.000018277648,0.0009266022,0.30706358],"study_design_scores_gemma":[0.07918954,0.0215031,0.004097573,0.00096292817,0.00085383514,0.001747074,0.00015911621,0.0070929127,0.77843505,0.000016745862,0.10549377,0.00044838426],"about_ca_topic_score_codex":0.00005661266,"about_ca_topic_score_gemma":0.000023289345,"teacher_disagreement_score":0.3066152,"about_ca_system_score_codex":0.17348634,"about_ca_system_score_gemma":0.017726457,"threshold_uncertainty_score":0.98784214},"labels":[],"label_agreement":null},{"id":"W3175785263","doi":"10.1002/hon.164_2880","title":"ESCALADE: A PHASE 3 STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP FOR PATIENTS ≤65Y WITH UNTREATED NON‐GERMINAL CENTER B‐CELL–LIKE DIFFUSE LARGE B‐CELL LYMPHOMA","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Internal medicine; Population; CHOP; Vincristine; Rituximab; Ibrutinib; Oncology; Gastroenterology; Lymphoma; Cyclophosphamide; Chronic lymphocytic leukemia; Chemotherapy; Leukemia","score_opus":0.020527705995499818,"score_gpt":0.33695050610101684,"score_spread":0.31642280010551704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175785263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955084,0.000052902105,0.00021103762,0.00020014148,0.00006286977,0.002564948,0.00003116337,0.00004126521,0.0013273197],"genre_scores_gemma":[0.9977091,0.000019465073,0.00084986765,0.0002704916,0.000020028547,0.0004070622,0.00022465097,0.0000403997,0.00045896842],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99689263,0.00029996017,0.00073044543,0.0007243477,0.0005822736,0.00077031803],"domain_scores_gemma":[0.9976286,0.00075176294,0.0002819424,0.0004598084,0.00060510734,0.00027273278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028109783,0.00032307688,0.0012148274,0.0001982281,0.00007785754,0.000013497827,0.00018450314,0.00038064696,0.00014099959],"category_scores_gemma":[0.00022284333,0.0002125272,0.000091972164,0.0006596736,0.00022224867,0.00006974383,0.00016843564,0.00028250006,0.000017852493],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041151654,0.61359596,0.32170397,0.0014905714,0.00027920798,0.012182219,0.003154182,0.0000061835694,0.0011897155,0.00020401392,0.0014100651,0.0036322556],"study_design_scores_gemma":[0.8971644,0.060309287,0.02345002,0.00025826535,0.00030680603,0.0010223369,0.0028569258,0.005105778,0.007171004,0.000032238044,0.0019353,0.00038764527],"about_ca_topic_score_codex":0.00006699055,"about_ca_topic_score_gemma":0.0002386768,"teacher_disagreement_score":0.85601276,"about_ca_system_score_codex":0.0031879554,"about_ca_system_score_gemma":0.002978554,"threshold_uncertainty_score":0.8666608},"labels":[],"label_agreement":null},{"id":"W3176725278","doi":"10.3390/ijms22137071","title":"Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"Compute Canada","keywords":"Ibrutinib; Bruton's tyrosine kinase; Virtual screening; Pharmacology; Docking (animal); Medicine; Computational biology; Tyrosine kinase; Bioinformatics; Immunology; Biology; Drug discovery; Receptor; Internal medicine; Leukemia","score_opus":0.021957446670843372,"score_gpt":0.3503096360884676,"score_spread":0.32835218941762423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176725278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97948027,0.0010386627,0.009665731,0.008272372,0.00050819357,0.00011477567,0.000011685134,0.000013377638,0.0008949493],"genre_scores_gemma":[0.9835127,0.00008992126,0.008995609,0.006953552,0.00026475763,0.0000010046778,0.000013621005,0.000012067857,0.00015676592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961996,0.00018466015,0.0005582573,0.00034327057,0.0024323603,0.00028182307],"domain_scores_gemma":[0.9978848,0.00025320743,0.00036533197,0.00017479341,0.0008548443,0.00046700318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012004778,0.0001490319,0.0002859553,0.00037293177,0.00014626289,0.00023705022,0.0005078503,0.00008582066,0.00024365791],"category_scores_gemma":[0.002698327,0.0001231386,0.00018033742,0.0003481155,0.0005327607,0.00018970358,0.00018177032,0.00030129415,0.000003844656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002262704,0.00031217266,0.0028945156,0.000089006804,0.0008926494,0.047646128,0.0012439879,0.023297055,0.86244994,0.00498517,0.0014982781,0.052428413],"study_design_scores_gemma":[0.08192996,0.003313053,0.0037852246,0.0016544892,0.0004048643,0.054079514,0.00646626,0.07553089,0.74859256,0.007960134,0.01516444,0.0011186121],"about_ca_topic_score_codex":0.00005728613,"about_ca_topic_score_gemma":0.000003803037,"teacher_disagreement_score":0.11385736,"about_ca_system_score_codex":0.0012432392,"about_ca_system_score_gemma":0.01353746,"threshold_uncertainty_score":0.9920549},"labels":[],"label_agreement":null},{"id":"W3177326348","doi":"10.20517/jtgg.2021.08","title":"Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes","year":2021,"lang":"en","type":"article","venue":"Journal of Translational Genetics and Genomics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; Kræftens Bekæmpelse; National Human Genome Research Institute; Deutsche Krebshilfe; National Center for Chronic Disease Prevention and Health Promotion; National Heart, Lung, and Blood Institute; National Institute on Aging; BC Cancer Agency; World Cancer Research Fund; National Center for Advancing Translational Sciences; Medical Research Council; Institut National Du Cancer; Centers for Disease Control and Prevention; National Institutes of Health; National Institute of Environmental Health Sciences; Hellenic Health Foundation; Cancer Research UK; Blood Cancer UK; Institut Gustave-Roussy; Associazione Italiana per la Ricerca sul Cancro; Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail; NordForsk; Vetenskapsrådet; Canadian Institutes of Health Research; MedStar Health Research Institute; Cancerfonden; Michael Smith Health Research BC; Centres de Recerca de Catalunya; Institut National de la Santé et de la Recherche Médicale; U.S. Department of Health and Human Services; Frederick National Laboratory for Cancer Research; Generalitat de Catalunya; Fondation de France; Deutsches Krebsforschungszentrum; Ligue Contre le Cancer; European Regional Development Fund; Bundesministerium für Bildung und Forschung; Ministerio de Economía y Competitividad; University of Pittsburgh; World Health Organization; National Cancer Institute; Ohio State University; Instituto de Salud Carlos III; Wake Forest University; American Cancer Society; Brigham and Women's Hospital; University at Buffalo; European Commission","keywords":"Lymphoma; Genome; Runs of Homozygosity; Genetics; Biology; Hodgkin lymphoma; Medicine; Genotype; Single-nucleotide polymorphism; Gene; Immunology","score_opus":0.01634754712487878,"score_gpt":0.2604938279321859,"score_spread":0.2441462808073071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177326348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843198,0.01239784,0.0024805856,0.00042283174,0.000060297072,0.000093960356,0.00003670994,0.0000014502276,0.00018653504],"genre_scores_gemma":[0.96378934,0.019984258,0.015868377,0.00005543827,0.00018736508,4.6360984e-7,0.000007587617,0.000015666692,0.00009147974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988526,0.000044742774,0.00046550826,0.00013928075,0.00034628468,0.00015159296],"domain_scores_gemma":[0.9988223,0.0002226929,0.00021135136,0.00013328738,0.00042738867,0.00018301466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040375578,0.000106685,0.00033148768,0.00010475374,0.000060408584,0.00002225111,0.000066961766,0.00008926643,0.000027969687],"category_scores_gemma":[0.000068964284,0.00009568286,0.0001145703,0.00010674224,0.000117446194,0.00003522022,0.00003373913,0.00013396906,9.2840077e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029742904,0.0007566861,0.74944925,0.0011159233,0.003082266,0.0012342725,0.004071972,0.008645097,0.12361587,0.0002758421,0.00021600694,0.10456251],"study_design_scores_gemma":[0.011734565,0.00039362334,0.9571092,0.00006521745,0.00046475584,0.0024017328,0.00010858636,0.009108804,0.011495775,0.0017081428,0.0052706283,0.00013897638],"about_ca_topic_score_codex":0.000019830517,"about_ca_topic_score_gemma":0.000032420594,"teacher_disagreement_score":0.20765993,"about_ca_system_score_codex":0.00030636156,"about_ca_system_score_gemma":0.0031685766,"threshold_uncertainty_score":0.5620919},"labels":[],"label_agreement":null},{"id":"W3177359439","doi":"10.1002/hon.50_2880","title":"UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Bendamustine; Venetoclax; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Oncology; Gastroenterology; Minimal residual disease; clone (Java method); Refractory (planetary science); Progression-free survival; Leukemia; Lymphoma; Chemotherapy; Genetics; Biology","score_opus":0.05772649493114061,"score_gpt":0.42696265845663306,"score_spread":0.36923616352549243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177359439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897217,0.0058085457,0.000046464582,0.00078682543,0.0002720532,0.0019452703,0.000026886508,0.00018589511,0.0012063463],"genre_scores_gemma":[0.9926019,0.0010567321,0.0019876738,0.0010437435,0.0001606593,0.00043125017,0.00007827806,0.00009045972,0.0025493195],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931243,0.001506861,0.0013347507,0.0014117811,0.000863893,0.001758438],"domain_scores_gemma":[0.9941042,0.0027822931,0.00022774907,0.0014811031,0.00033689136,0.0010677385],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014485463,0.0006340077,0.0022062284,0.00044331947,0.0001642421,0.00004458915,0.0004300771,0.0010188199,0.0030398297],"category_scores_gemma":[0.0034708087,0.000459008,0.00036541387,0.0017025665,0.00037846243,0.00006958511,0.00046032466,0.00092046976,0.0010792216],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.30440566,0.01451103,0.006239196,0.0014877866,0.0015884916,0.46048456,0.003029068,0.0067364867,0.15086336,0.00044769785,0.0164337,0.033772938],"study_design_scores_gemma":[0.57282054,0.11516758,0.010952928,0.0014300485,0.0008230191,0.053649906,0.0016003607,0.06512289,0.07796749,0.00048662856,0.09777288,0.0022057502],"about_ca_topic_score_codex":0.0005680794,"about_ca_topic_score_gemma":0.000885379,"teacher_disagreement_score":0.40683466,"about_ca_system_score_codex":0.38298455,"about_ca_system_score_gemma":0.1637713,"threshold_uncertainty_score":0.99978614},"labels":[],"label_agreement":null},{"id":"W3179993901","doi":"10.1016/j.clml.2021.06.011","title":"A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Ottawa; University of Toronto; Western University; Santé Montérégie; Juravinski Cancer Centre; Victoria Hospital; Princess Margaret Cancer Centre; Foothills Medical Centre; Moncton Hospital; Centre intégré de santé et de services sociaux de la Montérégie-Centre; McMaster University; Queen's University; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Janssen Pharmaceuticals; National Cancer Institute; Pharmacyclics; National Institutes of Health","keywords":"Bendamustine; Ibrutinib; Rituximab; Alliance; Internal medicine; Medicine; Oncology; Randomized controlled trial; Political science; Lymphoma; Chronic lymphocytic leukemia; Leukemia","score_opus":0.04909731416074531,"score_gpt":0.36561030297382136,"score_spread":0.31651298881307605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179993901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219143,0.0006189424,0.00022658963,0.00015450116,0.00024770695,0.0049541644,0.0012445312,0.00010185487,0.00026024782],"genre_scores_gemma":[0.9937446,0.0001306406,0.0010463294,0.00023071287,0.00030959016,0.00029422037,0.003864828,0.00014026245,0.00023882264],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9886357,0.0015103105,0.004675731,0.0024103292,0.0016085004,0.0011594231],"domain_scores_gemma":[0.9825187,0.00889886,0.0022484262,0.0048416196,0.000956638,0.0005357676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002760147,0.0009418886,0.006491446,0.00041351884,0.00015711506,0.00009547914,0.0015671002,0.00058713794,0.00050500827],"category_scores_gemma":[0.002573721,0.00062645564,0.0010366322,0.002741441,0.0025905522,0.0003280574,0.0006359233,0.0006953617,0.00005018683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8608739,0.002234136,0.116005,0.00021996931,0.010222685,0.00063499395,0.00037598255,0.0045775888,0.000034947847,0.00005650966,0.00032563094,0.0044387016],"study_design_scores_gemma":[0.5643899,0.0014563801,0.26153696,0.0006211227,0.0052759494,0.000010812692,0.000074953816,0.16585077,0.0003306885,0.00001142027,0.000043521883,0.00039753082],"about_ca_topic_score_codex":0.017140511,"about_ca_topic_score_gemma":0.005125457,"teacher_disagreement_score":0.29648393,"about_ca_system_score_codex":0.062406003,"about_ca_system_score_gemma":0.1035593,"threshold_uncertainty_score":0.99961865},"labels":[],"label_agreement":null},{"id":"W3182533416","doi":"10.1080/10428194.2021.1938027","title":"A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Cancer research; Pharmacodynamics; Pharmacology; Internal medicine; Oncology; Lymphoma; Pharmacokinetics; Tyrosine kinase; Chronic lymphocytic leukemia; Biology; Leukemia; Receptor","score_opus":0.00943998338930477,"score_gpt":0.2521259848472878,"score_spread":0.24268600145798305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182533416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961373,0.0009132161,0.000005377185,0.0000480492,0.00012008817,0.0013840978,0.000028971586,0.000037811675,0.0013250472],"genre_scores_gemma":[0.9986378,0.00019509178,0.00016042328,0.00017110465,0.000028445314,0.00006841647,0.00004540842,0.000077559445,0.0006157621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99580276,0.00032742467,0.0010717761,0.0008577151,0.0012946421,0.00064569403],"domain_scores_gemma":[0.99711394,0.00040914986,0.000504186,0.0010973676,0.00059665495,0.00027870233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045434976,0.0004962094,0.0010667015,0.00030519522,0.00017557164,0.000045768866,0.00031381205,0.00032331914,0.00003077672],"category_scores_gemma":[0.00031624956,0.00036274243,0.00012668023,0.0011940417,0.000617711,0.0002515074,0.00045078402,0.00021170123,0.0000034714471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016621528,0.039908417,0.8213907,0.0040103775,0.0008834977,0.0011367133,0.019762453,0.000074342846,0.022436917,0.000977971,0.0008293364,0.071967736],"study_design_scores_gemma":[0.31061935,0.0048785424,0.6559516,0.00078953116,0.0003278971,0.00018984049,0.0031900986,0.0019095683,0.021200445,0.000077393175,0.0004403905,0.00042531372],"about_ca_topic_score_codex":0.0019602252,"about_ca_topic_score_gemma":0.00022223203,"teacher_disagreement_score":0.29399782,"about_ca_system_score_codex":0.013008388,"about_ca_system_score_gemma":0.014065799,"threshold_uncertainty_score":0.99988246},"labels":[],"label_agreement":null},{"id":"W3184852669","doi":"10.1016/j.soncn.2021.151177","title":"Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse","year":2021,"lang":"en","type":"review","venue":"Seminars in Oncology Nursing","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Oncology nursing; Oncology; Internal medicine; Tyrosine kinase; Bruton's tyrosine kinase; Outpatient clinic; Nursing; Family medicine; Nurse education","score_opus":0.02557840495403198,"score_gpt":0.38543682892221975,"score_spread":0.3598584239681878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184852669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035493302,0.9751049,0.0000019209162,0.0007825505,0.0008288673,0.0024075082,0.000015502708,0.000027928056,0.017281467],"genre_scores_gemma":[0.002990089,0.99407166,0.0006610821,0.00013249756,0.0006115413,0.00032048312,0.00009481752,0.00014654908,0.00097128487],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946753,0.001613407,0.0013210364,0.0007826752,0.0007291385,0.00087844447],"domain_scores_gemma":[0.9949221,0.0023417585,0.0010031045,0.001312309,0.0002528236,0.0001678769],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012964923,0.0005877878,0.0029853228,0.00033735752,0.0002009278,0.00001859905,0.0006115922,0.0011441968,0.000060565668],"category_scores_gemma":[0.0008373229,0.00031393496,0.0005369686,0.0014720968,0.0016853776,0.000051217863,0.0002171611,0.0021706042,0.000010659273],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002202679,0.0011915965,0.00009519508,0.0021298951,0.00016617536,0.00058640045,0.004109614,0.000010513176,0.00002387966,0.00013649317,0.0013361892,0.98999375],"study_design_scores_gemma":[0.0048142686,0.002340079,0.000009334757,0.13095118,0.001726905,0.003721495,0.0057187187,0.00022282577,0.00038602613,0.00004161468,0.84977525,0.00029227295],"about_ca_topic_score_codex":0.00029670238,"about_ca_topic_score_gemma":0.00016497502,"teacher_disagreement_score":0.9897015,"about_ca_system_score_codex":0.06512063,"about_ca_system_score_gemma":0.037322536,"threshold_uncertainty_score":0.9999313},"labels":[],"label_agreement":null},{"id":"W3186824000","doi":"10.1038/s41375-021-01342-x","title":"Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Ibrutinib; Bendamustine; Medicine; Internal medicine; Adverse effect; Rituximab; Cumulative incidence; Gastroenterology; Chronic lymphocytic leukemia; Lymphoma; Leukemia; Cohort","score_opus":0.018122859463453794,"score_gpt":0.29060930895170584,"score_spread":0.27248644948825207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186824000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258447,0.00055741,0.00009036926,0.0008464867,0.00022794674,0.0010789764,0.000024489596,0.000114651266,0.0044752294],"genre_scores_gemma":[0.97086245,0.00024893414,0.0030981065,0.00074412365,0.00036587025,0.00011044118,0.00021178609,0.000107643515,0.02425063],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99619323,0.0001308931,0.00065644574,0.0009146079,0.0011342496,0.00097057165],"domain_scores_gemma":[0.9977398,0.00028304456,0.00017613635,0.0010353159,0.00040651206,0.00035921694],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003675049,0.00038132217,0.00072987826,0.00014017365,0.00009828654,0.00003514036,0.00026959198,0.0002457559,0.0014900506],"category_scores_gemma":[0.0008704326,0.00029959664,0.00012081158,0.0010180105,0.00015208515,0.00020576805,0.00028667584,0.000726395,0.00030480008],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0819399,0.012470842,0.24234447,0.02049975,0.0043000416,0.14219952,0.042349994,0.04024638,0.0067559476,0.0012187961,0.23059064,0.17508373],"study_design_scores_gemma":[0.54539925,0.0021701176,0.24624145,0.014371925,0.00059029576,0.0017027946,0.0037091738,0.0660513,0.0072753313,0.00009579311,0.109912686,0.0024798992],"about_ca_topic_score_codex":0.0012175079,"about_ca_topic_score_gemma":0.0007259048,"teacher_disagreement_score":0.46345934,"about_ca_system_score_codex":0.034546472,"about_ca_system_score_gemma":0.020324614,"threshold_uncertainty_score":0.99994564},"labels":[],"label_agreement":null},{"id":"W3186866316","doi":"10.1016/j.jcjo.2021.06.021","title":"Central nervous system hemorrhage due to chronic lymphocytic leukemia","year":2021,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Diplopia; Dysphagia; Weakness; Leukemia; Pediatrics; Surgery; Internal medicine","score_opus":0.02566174239914626,"score_gpt":0.2726732665261912,"score_spread":0.24701152412704497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186866316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63425815,0.028060362,0.00022851114,0.23533481,0.020360563,0.0029624924,0.0004753811,0.000088673514,0.07823107],"genre_scores_gemma":[0.88001204,0.00001320397,0.00074727135,0.07166427,0.021834614,0.00003672304,0.0002841278,0.0003696589,0.025038091],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9936418,0.0004453659,0.0014165745,0.00075434934,0.0010523222,0.0026895716],"domain_scores_gemma":[0.993767,0.00032313095,0.0005765334,0.00123032,0.0009598554,0.0031431094],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006200791,0.00071345276,0.0023001488,0.0015240904,0.00019081049,0.00015533896,0.0012073652,0.0019078964,0.003921379],"category_scores_gemma":[0.0006786666,0.0006821872,0.00074991415,0.00077185774,0.00035176543,0.00009579366,0.00012750176,0.0036688314,0.00034554963],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000056759276,0.0000029670232,0.00003389059,0.0015408414,0.00029075064,0.63814193,0.00009522842,0.00046111562,0.00002464464,0.000010298934,0.35905516,0.00028641208],"study_design_scores_gemma":[0.005135275,0.0010179569,0.0002517352,0.0015099746,0.00037743707,0.8642542,0.00010967841,0.001218407,0.00015622053,0.000009145206,0.1255059,0.0004541195],"about_ca_topic_score_codex":0.0364439,"about_ca_topic_score_gemma":0.00062102615,"teacher_disagreement_score":0.24575391,"about_ca_system_score_codex":0.4648594,"about_ca_system_score_gemma":0.501096,"threshold_uncertainty_score":0.9995629},"labels":[],"label_agreement":null},{"id":"W3186993723","doi":"10.1182/blood.2021011787","title":"BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Radboud Universitair Medisch Centrum; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Ibrutinib; Bruton's tyrosine kinase; Asparaginase; Cancer research; Pharmacology; Medicine; Tyrosine kinase; Leukemia; Lymphoblastic Leukemia; Immunology; Internal medicine; Chronic lymphocytic leukemia; Receptor","score_opus":0.011995025791761545,"score_gpt":0.26634365839987123,"score_spread":0.2543486326081097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186993723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941949,0.00086469157,0.00023111833,0.0029932444,0.00013674705,0.00045827034,0.000093128205,0.00013001768,0.00089788577],"genre_scores_gemma":[0.9931174,0.000049472346,0.0005995529,0.0019964012,0.00026608663,0.000066808614,0.00012646095,0.00006482549,0.00371299],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99706906,0.00042773748,0.00036650806,0.0006049944,0.000825449,0.000706244],"domain_scores_gemma":[0.9976174,0.0006684963,0.000071498245,0.0009468504,0.00029062727,0.00040507957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065247883,0.00028026235,0.00038542136,0.000119000826,0.00025631438,0.00014697012,0.00014770127,0.0001683845,0.00013771316],"category_scores_gemma":[0.0012842102,0.00021390493,0.00014235254,0.0005966546,0.0001790013,0.000113540766,0.00028935677,0.00032068713,0.0003614722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016226921,0.000343568,0.00003661466,0.000071195995,0.00022025766,0.008783124,0.00071828085,0.000015934324,0.9744316,0.000023744175,0.012406161,0.0013268421],"study_design_scores_gemma":[0.021250611,0.00028962432,0.00062900904,0.00032956473,0.00034054226,0.006308245,0.00033307413,0.0007497148,0.96376395,0.000034337423,0.005731256,0.00024008253],"about_ca_topic_score_codex":0.00007249892,"about_ca_topic_score_gemma":0.000018745208,"teacher_disagreement_score":0.019627918,"about_ca_system_score_codex":0.005125126,"about_ca_system_score_gemma":0.010267198,"threshold_uncertainty_score":0.998694},"labels":[],"label_agreement":null},{"id":"W3187807747","doi":"","title":"BTK inhibitors approved in Canada for CLL: Strategies for adverse event management","year":2021,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Adverse effect; Chronic lymphocytic leukemia; Medicine; Tyrosine kinase; Oncology; Intensive care medicine; Pharmacology; Leukemia; Internal medicine","score_opus":0.19588206596716276,"score_gpt":0.5435071818024639,"score_spread":0.3476251158353012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187807747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765963,0.009545779,0.001796022,0.00082174066,0.0010358035,0.0042410186,0.000115454044,0.000025878642,0.005822027],"genre_scores_gemma":[0.9934227,0.0030081826,0.0009707278,0.0005733416,0.0002359862,0.0003101197,0.00009674122,0.00007732306,0.0013049089],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965368,0.0001191201,0.0010641507,0.00058345654,0.0009906208,0.00070585695],"domain_scores_gemma":[0.99760175,0.0005105676,0.00041484786,0.00059642864,0.0005108418,0.0003655724],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011748195,0.00030886143,0.0008821906,0.00049911573,0.00013154726,0.00031986885,0.0010611141,0.000096303156,0.0015139277],"category_scores_gemma":[0.00038585186,0.00028674476,0.0002610644,0.0008423418,0.0000765386,0.00081465906,0.00069803465,0.00029931735,0.0000025703612],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011219452,0.0032036412,0.10251413,0.01691335,0.0046279007,0.0059220684,0.0016823297,0.008732054,0.109489225,0.004370024,0.6467853,0.08454048],"study_design_scores_gemma":[0.11936025,0.00025346671,0.24028176,0.009971205,0.0015049862,0.00041875918,0.03305263,0.025982695,0.22830284,0.029457612,0.30821347,0.0032003038],"about_ca_topic_score_codex":0.29039496,"about_ca_topic_score_gemma":0.33619148,"teacher_disagreement_score":0.33857185,"about_ca_system_score_codex":0.011894888,"about_ca_system_score_gemma":0.024747338,"threshold_uncertainty_score":0.99995846},"labels":[],"label_agreement":null},{"id":"W3188472626","doi":"10.1158/1078-0432.ccr-21-1497","title":"Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pharmacyclics","keywords":"Ibrutinib; Medicine; Rituximab; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Refractory (planetary science); Gastroenterology; Phases of clinical research; Progression-free survival; Neutropenia; Response Evaluation Criteria in Solid Tumors; Surgery; Clinical trial; Oncology; Lymphoma; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.4036895078357418,"score_gpt":0.5643537866182178,"score_spread":0.16066427878247597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188472626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915822,0.0013340059,0.000036687725,0.0031688046,0.0008076644,0.00237716,0.00025041657,0.000013020912,0.0004300159],"genre_scores_gemma":[0.9952658,0.00034977682,0.00010203335,0.00026970403,0.0007067187,0.0002122158,0.000041360727,0.000037092665,0.0030153373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99256676,0.0012462358,0.0019667991,0.0007769224,0.002600999,0.0008422645],"domain_scores_gemma":[0.99005497,0.004292528,0.0003976116,0.0019835185,0.0030133966,0.00025800726],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006392154,0.0002204115,0.0013714049,0.00026874573,0.000258571,0.000035056193,0.0010059803,0.0003506904,0.0009971323],"category_scores_gemma":[0.008356546,0.00012942823,0.001326192,0.004779534,0.0019469975,0.000046461842,0.000995605,0.0016171006,0.000007000505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.55861115,0.060883116,0.040537164,0.0030295576,0.021386089,0.00055682025,0.002560172,0.00044601032,0.07143686,0.0013109581,0.054090198,0.18515189],"study_design_scores_gemma":[0.8062527,0.005260787,0.01150403,0.0006888447,0.003919569,0.000030358782,0.0012360656,0.009136311,0.1267989,0.00015564924,0.034647226,0.0003695593],"about_ca_topic_score_codex":0.0012346121,"about_ca_topic_score_gemma":0.00087495655,"teacher_disagreement_score":0.24764153,"about_ca_system_score_codex":0.0038421669,"about_ca_system_score_gemma":0.023097595,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W3189823930","doi":"10.1007/s11912-021-01102-1","title":"Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation","year":2021,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University; Université de Montréal","funders":"","keywords":"Medicine; Ibrutinib; Atrial fibrillation; Cardiotoxicity; Cardiomyopathy; Internal medicine; Cardiology; Bruton's tyrosine kinase; Tyrosine kinase; Intensive care medicine; Heart failure; Chemotherapy; Leukemia; Chronic lymphocytic leukemia; Receptor","score_opus":0.11751151450979999,"score_gpt":0.4510314285064964,"score_spread":0.33351991399669645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189823930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002946098,0.9884214,0.0000054604125,0.00012842866,0.0053936965,0.0024496075,0.000030883115,0.00010519025,0.00051927945],"genre_scores_gemma":[0.00044590113,0.9902468,0.000058097172,0.0000148517465,0.0071052965,0.00007390029,0.0013333539,0.00011009955,0.0006117087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950215,0.00042435498,0.0016818619,0.0013304083,0.0008599919,0.0006818847],"domain_scores_gemma":[0.996531,0.0004514997,0.0010133354,0.0011190491,0.00034557533,0.00053951464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010740997,0.00066866475,0.0040529515,0.00041942004,0.00014326378,0.00005573191,0.00010086748,0.0010999581,0.00008960367],"category_scores_gemma":[0.0014866719,0.00055371306,0.001342326,0.00062038767,0.00041062015,0.00008262095,0.0005112795,0.0011055048,0.00002265454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000029100494,0.00006569742,0.0003702689,0.01788285,0.00050564675,0.0115749,0.0001062831,0.0000023891234,0.000001631616,0.000010387037,0.0072115026,0.9622393],"study_design_scores_gemma":[0.0025649806,0.0002472787,0.000034188753,0.015257282,0.003461757,0.03662275,0.000030141347,0.000039924973,0.00000959866,0.0000049001032,0.9413805,0.0003466884],"about_ca_topic_score_codex":0.00010247369,"about_ca_topic_score_gemma":0.000014603806,"teacher_disagreement_score":0.96189266,"about_ca_system_score_codex":0.019127673,"about_ca_system_score_gemma":0.03737555,"threshold_uncertainty_score":0.9996914},"labels":[],"label_agreement":null},{"id":"W3193493833","doi":"10.1212/wnl.96.15_supplement.4069","title":"Prognostic Value of Serum NfL for Subclinical Disease Activity and Worsening in Patients with RMS: Results from the Phase 3 ASCLEPIOS I and II Trials (4069)","year":2021,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Subclinical infection; Internal medicine; Medicine; Disease; Value (mathematics); Statistics; Mathematics","score_opus":0.05121344693596858,"score_gpt":0.36401279180756535,"score_spread":0.3127993448715968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193493833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940516,0.00015242335,0.00002052709,0.0042158975,0.00007412219,0.0011726944,0.0002911439,0.000010256251,0.000011372705],"genre_scores_gemma":[0.99906766,0.000039927014,0.00008708235,0.00057855365,0.000098534525,0.000043186705,0.000050576255,0.000017510487,0.00001695489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797654,0.00063143333,0.0004257594,0.0004615597,0.00023327609,0.00027145902],"domain_scores_gemma":[0.9911727,0.008047994,0.0001551534,0.00035287358,0.00010752915,0.00016377708],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009100614,0.00012118755,0.00054021965,0.00004292858,0.0000618798,0.0000097161865,0.000065935856,0.000105515996,0.0000107743435],"category_scores_gemma":[0.013635724,0.00007717234,0.00005137298,0.00013433224,0.00025745283,0.00004412136,0.00016425618,0.00027571904,4.2587277e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3010012,0.0031996577,0.6494756,0.0003003714,0.0003273571,0.0008762354,0.001184003,0.00006622546,0.0010533243,0.000110494504,0.00022526826,0.042180303],"study_design_scores_gemma":[0.12969741,0.0050524864,0.85496867,0.000091159025,0.0002423909,0.000013885835,0.000013403965,0.009031846,0.00038818267,0.00020023156,0.00021924163,0.000081077225],"about_ca_topic_score_codex":0.0001926875,"about_ca_topic_score_gemma":0.00013437204,"teacher_disagreement_score":0.20549312,"about_ca_system_score_codex":0.0001064802,"about_ca_system_score_gemma":0.001599212,"threshold_uncertainty_score":0.99467283},"labels":[],"label_agreement":null},{"id":"W3194477562","doi":"10.1021/acsptsci.1c00091","title":"Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B","year":2021,"lang":"en","type":"article","venue":"ACS Pharmacology & Translational Science","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Simon Fraser University; University of British Columbia; Memorial University of Newfoundland","funders":"International Development Research Centre; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Cytidine deaminase; Small molecule; Activation-induced (cytidine) deaminase; Chemistry; Oxidoreductase; Enzyme; Mutant; Biochemistry; Biology; Antibody; Somatic hypermutation; Genetics; Gene; B cell","score_opus":0.037728689917769793,"score_gpt":0.31441377089015476,"score_spread":0.276685080972385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194477562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335575,0.00093626976,0.0027221702,0.0023176612,0.00014633965,0.00043887773,0.000016339418,0.000009296354,0.000057275625],"genre_scores_gemma":[0.99654454,0.000032270666,0.0029513077,0.00030479208,0.00009735707,0.000013247132,0.00003132623,0.000009140824,0.000016010026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833643,0.000118462805,0.00033203105,0.00033397155,0.0006070141,0.00027208214],"domain_scores_gemma":[0.99874395,0.00043946586,0.00010819007,0.00015026187,0.00045268357,0.000105443854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080974714,0.00011255929,0.00019386834,0.00011667605,0.00021628958,0.000012557542,0.00018978347,0.00006633377,0.00012788741],"category_scores_gemma":[0.00015118884,0.0000863301,0.000043518412,0.000708134,0.0010519382,0.00010407984,0.000042681182,0.0001616108,0.0000010753055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090390495,0.000057952413,0.0014160238,0.0000784098,0.00003232418,0.000017249227,0.00040644448,0.012954967,0.9840459,0.0000968406,0.00016299113,0.0006404607],"study_design_scores_gemma":[0.0037150653,0.00007594094,0.0010724576,0.000018321985,0.00008972727,0.0000443629,0.000038318245,0.13959096,0.8551651,0.00007117255,0.000054005857,0.00006455931],"about_ca_topic_score_codex":0.00011537799,"about_ca_topic_score_gemma":0.00005078306,"teacher_disagreement_score":0.12888084,"about_ca_system_score_codex":0.00044693073,"about_ca_system_score_gemma":0.0072156833,"threshold_uncertainty_score":0.9984125},"labels":[],"label_agreement":null},{"id":"W3195231412","doi":"","title":"Inhibiteurs de la BTK approuvés au Canada contre la LLC : Stratégies de gestion des effets indésirables","year":2021,"lang":"fr","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bruton's tyrosine kinase; Gynecology; Medicine; Political science; Tyrosine kinase; Internal medicine","score_opus":0.15398689791927303,"score_gpt":0.5096908288708166,"score_spread":0.3557039309515436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195231412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8066934,0.16902182,0.00024222201,0.0011643589,0.0008948288,0.00061537407,0.000116537165,0.000036621805,0.021214845],"genre_scores_gemma":[0.94501656,0.04744696,0.0004423608,0.0004005194,0.00092869764,0.00006683301,0.000044396198,0.00013882121,0.0055148406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991202,0.0032488953,0.0012695347,0.0007899464,0.0017367639,0.0017528535],"domain_scores_gemma":[0.990953,0.0053752954,0.0006513175,0.0008090917,0.00092711725,0.0012841534],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005433879,0.00065569027,0.0014348283,0.00056988647,0.00053067895,0.0018716514,0.0019140735,0.0006467915,0.0069878437],"category_scores_gemma":[0.006758708,0.0006604616,0.0002802775,0.0015739137,0.0013506983,0.0016708326,0.0012334062,0.0018256361,0.0000151588065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014081624,0.0017600365,0.5991517,0.006200996,0.0020492866,0.020604277,0.0032826362,0.005518875,0.084077574,0.0018696545,0.10481613,0.1692607],"study_design_scores_gemma":[0.016485598,0.000060045324,0.728932,0.015966153,0.000947174,0.0046094833,0.003594616,0.0027282464,0.17449585,0.0075212945,0.043493506,0.0011660482],"about_ca_topic_score_codex":0.79434407,"about_ca_topic_score_gemma":0.38450465,"teacher_disagreement_score":0.40983942,"about_ca_system_score_codex":0.03462012,"about_ca_system_score_gemma":0.10631958,"threshold_uncertainty_score":0.9995847},"labels":[],"label_agreement":null},{"id":"W3196898846","doi":"10.1016/s2152-2650(21)01833-4","title":"MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Context (archaeology); Myelofibrosis; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Clinical trial; Bone marrow; Biology","score_opus":0.045024014868734766,"score_gpt":0.37888645680329724,"score_spread":0.3338624419345625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196898846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630904,0.0002303022,0.00001207648,0.0001908779,0.0003787324,0.002110026,0.00022209722,0.0000458397,0.00050102436],"genre_scores_gemma":[0.9980049,0.00020928751,0.00034672697,0.00016292787,0.00025592215,0.0001211168,0.00054231065,0.000093646326,0.00026317575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897597,0.0015181215,0.004711632,0.0016465505,0.0015269208,0.00083708845],"domain_scores_gemma":[0.9902384,0.0048022396,0.0012575361,0.0023059289,0.00091046025,0.00048540224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017487939,0.0006625046,0.0030208328,0.00060305774,0.00009148282,0.000054887925,0.0007249101,0.0006415008,0.00028936783],"category_scores_gemma":[0.00317224,0.00048339381,0.001207221,0.0034426798,0.00096495735,0.00021922552,0.0006000019,0.00063730875,0.00003259557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009443871,0.037453946,0.8127077,0.00011389533,0.0020193567,0.0006050025,0.0011871353,0.00004675404,0.00019112721,0.00008839879,0.00006380063,0.13607897],"study_design_scores_gemma":[0.15332508,0.008799978,0.82862574,0.0007285261,0.0016502185,0.000017484217,0.0012806931,0.0027978567,0.0022296342,0.000076347926,0.000116014206,0.00035243973],"about_ca_topic_score_codex":0.0058831475,"about_ca_topic_score_gemma":0.005608736,"teacher_disagreement_score":0.1438812,"about_ca_system_score_codex":0.013327414,"about_ca_system_score_gemma":0.009127766,"threshold_uncertainty_score":0.99976176},"labels":[],"label_agreement":null},{"id":"W3197000240","doi":"10.1016/s2152-2650(21)01747-x","title":"CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; IGHV@; Gastroenterology; Oncology; Leukemia; Chemotherapy","score_opus":0.09057944067365786,"score_gpt":0.39874494230696444,"score_spread":0.3081655016333066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197000240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896298,0.0020728374,0.000079742706,0.000506245,0.0013713532,0.005543621,0.00009782987,0.00015668072,0.00054187735],"genre_scores_gemma":[0.98929876,0.0010022529,0.0003194749,0.00093097036,0.0014525539,0.0011653785,0.000290526,0.00021944211,0.005320628],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98988664,0.00087601907,0.003332229,0.0022129214,0.0018022163,0.0018899861],"domain_scores_gemma":[0.9893731,0.0050415616,0.00055784563,0.0034627283,0.00067635125,0.00088844664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002712407,0.00095819845,0.0025766068,0.00044824235,0.00029028615,0.00014397572,0.0013792813,0.00082028314,0.00025934994],"category_scores_gemma":[0.0034681545,0.00075227045,0.0012155884,0.0019533297,0.0005239159,0.00018405322,0.0007163508,0.0005321949,0.0002965835],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022415401,0.0041047214,0.05439557,0.0015805657,0.0024519835,0.012546368,0.008733732,0.001403113,0.00069175224,0.00035636465,0.010182743,0.88113767],"study_design_scores_gemma":[0.24855497,0.017223269,0.68714166,0.0013824278,0.0012462919,0.0012588357,0.001869308,0.01338297,0.0033450846,0.00018309992,0.023201898,0.0012101566],"about_ca_topic_score_codex":0.0026935635,"about_ca_topic_score_gemma":0.008195008,"teacher_disagreement_score":0.8799275,"about_ca_system_score_codex":0.14923938,"about_ca_system_score_gemma":0.07466608,"threshold_uncertainty_score":0.9994928},"labels":[],"label_agreement":null},{"id":"W3197298513","doi":"10.1111/bjh.17806","title":"Convalescent plasma and remdesivir for protracted COVID‐19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; IGHV@; Rituximab; Fludarabine; Internal medicine; Case fatality rate; Immunology; Cyclophosphamide; Antibody; Chronic lymphocytic leukemia; Chemotherapy; Epidemiology; Leukemia","score_opus":0.025218921200069765,"score_gpt":0.302841886507987,"score_spread":0.27762296530791725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197298513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641221,0.010570421,0.000056666322,0.022406157,0.0002621718,0.0024352935,0.000108171276,0.000016942087,0.000022056487],"genre_scores_gemma":[0.9632439,0.0018757209,0.0015886612,0.031157078,0.0007373659,0.0005382925,0.00019171413,0.000229056,0.0004381817],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9937957,0.00115721,0.002503317,0.00074120203,0.00091550057,0.0008870614],"domain_scores_gemma":[0.99409056,0.0019191816,0.0018442601,0.0005778974,0.0011173369,0.00045079124],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018199305,0.00047576716,0.0026221238,0.00079058955,0.000082146544,0.00006166697,0.0001960047,0.0013298301,0.00016241663],"category_scores_gemma":[0.004508461,0.00046388878,0.0003477973,0.0003629756,0.000854153,0.00014147638,0.00016237983,0.002614312,0.0000021184585],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.026735991,0.00016203527,0.00006547494,0.0064143515,0.0005338522,0.92474866,0.0003729587,0.00002231025,0.00009684344,9.004187e-7,0.03903206,0.001814587],"study_design_scores_gemma":[0.04439185,0.0034249066,0.000061358616,0.007972266,0.0005213888,0.9051614,0.0001191628,0.00040391085,0.0006424786,0.000018326851,0.03693091,0.00035204698],"about_ca_topic_score_codex":0.00091697375,"about_ca_topic_score_gemma":0.0009002731,"teacher_disagreement_score":0.06796244,"about_ca_system_score_codex":0.025607098,"about_ca_system_score_gemma":0.09356954,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W3197728703","doi":"10.1016/j.idcr.2021.e01263","title":"Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"IDCases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Ibrutinib; Medicine; Rituximab; Fludarabine; Voriconazole; Chronic lymphocytic leukemia; Cyclophosphamide; Pancytopenia; Dermatology; Leukemia; Chemotherapy; Surgery; Internal medicine; Lymphoma; Antifungal; Bone marrow","score_opus":0.020069455699239538,"score_gpt":0.2828285489508966,"score_spread":0.2627590932516571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197728703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962158,0.0013861249,0.00001698236,0.0000754209,0.00006389534,0.00033441055,0.000019962526,0.000031021595,0.0018563343],"genre_scores_gemma":[0.9991522,0.00013077681,0.00034941424,0.00010379549,0.000063946805,0.000038034104,0.00005344779,0.000026065869,0.00008232371],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983766,0.000054209966,0.00037112355,0.0003374529,0.0004904545,0.00037014327],"domain_scores_gemma":[0.99915326,0.00022066389,0.000082024104,0.00029502646,0.00010690371,0.0001421182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011537193,0.00016815713,0.000394061,0.00018100355,0.000074102136,0.00002248697,0.000055658842,0.000105809726,0.0001410933],"category_scores_gemma":[0.0003467008,0.00013972812,0.000092705326,0.00049189787,0.00011066753,0.00015029116,0.00011925561,0.00014479946,0.000008281106],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009802104,0.0019894415,0.3751486,0.0087171225,0.0027503313,0.090960264,0.024821058,0.008462044,0.11873658,0.003572643,0.0017859117,0.35325393],"study_design_scores_gemma":[0.17420772,0.007279495,0.19454443,0.008433161,0.0010982523,0.0142696835,0.007208674,0.06810984,0.51902866,0.00038053832,0.0037089395,0.0017306271],"about_ca_topic_score_codex":0.0018508654,"about_ca_topic_score_gemma":0.0013885291,"teacher_disagreement_score":0.40029207,"about_ca_system_score_codex":0.02689692,"about_ca_system_score_gemma":0.024570694,"threshold_uncertainty_score":0.98095906},"labels":[],"label_agreement":null},{"id":"W3198626816","doi":"10.1182/bloodadvances.2021004865","title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Office of Naval Research; Legend Biotech; Pharmacyclics; Sanofi Genzyme; Takeda Oncology; Genentech; Health Resources and Services Administration; National Institutes of Health; Astellas Pharma; bluebird bio; Kiadis Pharma; Daiichi-Sankyo; Omeros Corporation; Pfizer; Incyte; National Institute of Allergy and Infectious Diseases; Angiocrine Bioscience; Cancer Moonshot; Medical College of Wisconsin; StemCyte; Bristol-Myers Squibb; CSL Behring; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; U.S. Navy; Celgene; U.S. Department of Defense; Moonshot Research and Development Program; Sanofi; Astellas Pharma US; Biomedical Advanced Research and Development Authority; Amgen; Jazz Pharmaceuticals; Be The Match Foundation; Actinium Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences","keywords":"Hematopoietic cell; Lymphoma; Diffuse large B-cell lymphoma; Hematopoietic stem cell transplantation; Transplantation; Medicine; Haematopoiesis; Cancer research; Pathology; Oncology; Internal medicine; Biology; Stem cell; Genetics","score_opus":0.010620727828908683,"score_gpt":0.27504908834132746,"score_spread":0.2644283605124188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198626816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729237,0.024633562,0.0007185656,0.00016539413,0.00015738208,0.0004790472,0.000042248175,0.00006926555,0.0008108449],"genre_scores_gemma":[0.987888,0.0045888117,0.004385505,0.0002813388,0.00006466942,0.00006462302,0.000121232806,0.00003965688,0.0025661932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984865,0.000045244502,0.0002605375,0.0004538412,0.00028098552,0.0004728901],"domain_scores_gemma":[0.99908257,0.00025344733,0.000064911634,0.00029423274,0.00013011252,0.00017472451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013489695,0.00018990577,0.000368908,0.00007216863,0.000107484775,0.000028875602,0.00008882686,0.00011571087,0.000048233556],"category_scores_gemma":[0.00005919074,0.0001657044,0.00008426691,0.00020762152,0.00007515832,0.000117673415,0.000039731643,0.000074859534,0.00002831778],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007870738,0.07115572,0.059219483,0.07959589,0.0022922955,0.0756958,0.014567187,0.00017076763,0.62141776,0.0035520217,0.003179046,0.061283275],"study_design_scores_gemma":[0.26929513,0.0022818935,0.010283721,0.0005634551,0.0020296727,0.027410313,0.00097284035,0.0012377704,0.6407077,0.001129427,0.043093797,0.000994329],"about_ca_topic_score_codex":0.000009603056,"about_ca_topic_score_gemma":0.00002564109,"teacher_disagreement_score":0.2614244,"about_ca_system_score_codex":0.00034556448,"about_ca_system_score_gemma":0.0013354128,"threshold_uncertainty_score":0.67572296},"labels":[],"label_agreement":null},{"id":"W3198781344","doi":"10.1200/jco.21.00693","title":"Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; Population Health Research Institute; McMaster University; Women's College Hospital; Toronto General Hospital; Hamilton Health Sciences; University of Toronto; University Health Network","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Chronic lymphocytic leukemia; Atrial fibrillation; Population; Myocardial infarction; Cohort; Leukemia","score_opus":0.08873278683277927,"score_gpt":0.42102028761526383,"score_spread":0.3322875007824846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198781344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714494,0.000989696,0.00013827719,0.00014855852,0.0004268559,0.0008071297,0.000005319857,0.00002278187,0.0003164693],"genre_scores_gemma":[0.99768317,0.0003827448,0.00059800426,0.00039308367,0.00062223186,0.000021177006,0.00002186658,0.000048552803,0.00022915902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99097496,0.003098219,0.0031193062,0.0005302256,0.0017100255,0.000567288],"domain_scores_gemma":[0.9874249,0.00840073,0.0015612039,0.00077936804,0.0012997744,0.0005339885],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0115593355,0.0002587706,0.0032097264,0.00029053673,0.00007227365,0.000035831472,0.0002419492,0.0006435972,0.00014559164],"category_scores_gemma":[0.033787258,0.00019003876,0.0010388172,0.00088675926,0.000202496,0.00017814094,0.00009596562,0.0020468032,0.000018616212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0027696127,0.0012145,0.9246776,0.000037543356,0.0037692976,0.02057893,0.00004630519,0.04124017,0.0000052480545,0.0000032424693,0.00025367254,0.0054038875],"study_design_scores_gemma":[0.10642878,0.010009747,0.85212207,0.00032203554,0.0020770896,0.000653168,0.00010969421,0.026866192,0.000020856196,0.000019293599,0.0011993784,0.00017170173],"about_ca_topic_score_codex":0.005188863,"about_ca_topic_score_gemma":0.006149153,"teacher_disagreement_score":0.10365916,"about_ca_system_score_codex":0.16140877,"about_ca_system_score_gemma":0.25625047,"threshold_uncertainty_score":0.9743516},"labels":[],"label_agreement":null},{"id":"W3201018181","doi":"10.15353/cjo.v83i3.1786","title":"Waldenstrom Macroglobulinemia and the Eye: A case report and review","year":2021,"lang":"en","type":"article","venue":"Canadian journal of optometry/CJO. Canadian journal of optometry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Hyperviscosity syndrome; Macroglobulinemia; Waldenstrom macroglobulinemia; Medicine; Hyperviscosity; Lymphoproliferative disorders; Retina; Pathology; Internal medicine; Lymphoma; Multiple myeloma; Blood viscosity; Neuroscience; Biology","score_opus":0.014679038001599986,"score_gpt":0.34954304305600975,"score_spread":0.3348640050544098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201018181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80493283,0.17744227,0.00008807873,0.0153224785,0.00075437705,0.0003470262,0.00007349517,0.0000038320463,0.0010356077],"genre_scores_gemma":[0.9820442,0.010852913,0.002228633,0.0025833806,0.0008428245,0.0000029086189,0.000009122244,0.00008183512,0.0013541772],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99456745,0.00040907296,0.0022273082,0.0004204479,0.0011229775,0.001252725],"domain_scores_gemma":[0.98667604,0.0006022698,0.0013751346,0.00073583913,0.0031032714,0.0075074593],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047665965,0.00048945565,0.0018330072,0.002775298,0.00050679565,0.00041268108,0.0005464516,0.0003243331,0.0010567097],"category_scores_gemma":[0.0057107816,0.00036556317,0.0005834803,0.0030712371,0.0013000518,0.00042297263,0.000069813614,0.0020531993,0.000010565162],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014199478,0.000020173371,0.22388263,0.0010025367,0.0008505118,0.75061995,0.00031688766,0.000008075895,0.00003280451,0.000011374615,0.02050515,0.0026078941],"study_design_scores_gemma":[0.011610412,0.0002152933,0.054874413,0.003952249,0.0009455593,0.9080884,0.0008752283,0.00011363454,0.00015603552,0.000005597552,0.018838735,0.00032443012],"about_ca_topic_score_codex":0.00906738,"about_ca_topic_score_gemma":0.003995414,"teacher_disagreement_score":0.17711136,"about_ca_system_score_codex":0.007976391,"about_ca_system_score_gemma":0.07612585,"threshold_uncertainty_score":0.99987966},"labels":[],"label_agreement":null},{"id":"W3201257126","doi":"10.1093/bioadv/vbab021","title":"CRIS: complete reconstruction of immunoglobulin <i>V-D-J</i> sequences from RNA-seq data","year":2021,"lang":"en","type":"article","venue":"Bioinformatics Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"National Cancer Institute; National Human Genome Research Institute; Canadian Institutes of Health Research","keywords":"RNA-Seq; Computational biology; Antibody; Biology; Genetics; Gene; Transcriptome; Gene expression","score_opus":0.061407976704869756,"score_gpt":0.3298371960912405,"score_spread":0.26842921938637077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201257126","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82793576,0.06807673,0.017494665,0.0020273458,0.003041318,0.001509235,0.0045299963,0.00034907355,0.07503589],"genre_scores_gemma":[0.47350666,0.021316571,0.49931437,0.00078914186,0.00057425845,0.000024078958,0.0037502395,0.000053513886,0.0006711847],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980883,0.00003635773,0.0007593488,0.00024400053,0.0005880609,0.0002839483],"domain_scores_gemma":[0.9978404,0.00023981922,0.0002921891,0.0012061478,0.00030530375,0.00011614438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026045975,0.00015843737,0.00043535742,0.0000750947,0.00007609579,0.000043636526,0.00041265044,0.00008572138,0.00030641418],"category_scores_gemma":[0.00047750343,0.00013402918,0.000071295835,0.0003475226,0.0003041139,0.00085419154,0.0003551345,0.00017832397,0.00009391964],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008549942,0.00037736446,0.0031075808,0.003934447,0.0010338406,0.0003406131,0.0024629324,0.00036879594,0.04341821,0.0014222519,0.007198715,0.93548024],"study_design_scores_gemma":[0.026658019,0.00063517626,0.0011432237,0.0032872239,0.0005577048,0.002997089,0.017621502,0.47354487,0.20082822,0.0054084742,0.2662137,0.0011048191],"about_ca_topic_score_codex":0.00048443067,"about_ca_topic_score_gemma":0.00009115839,"teacher_disagreement_score":0.93437546,"about_ca_system_score_codex":0.00095988193,"about_ca_system_score_gemma":0.004029973,"threshold_uncertainty_score":0.7148999},"labels":[],"label_agreement":null},{"id":"W3201456240","doi":"10.15353/cjo.v83i3.4358","title":"Macroglobulinémie de Waldenström et atteinte oculaire : rapport de cas et examen","year":2021,"lang":"fr","type":"article","venue":"Canadian journal of optometry/CJO. Canadian journal of optometry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology","score_opus":0.026278578901871963,"score_gpt":0.3650451845739416,"score_spread":0.3387666056720696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201456240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8559596,0.09196292,0.0020355263,0.034442328,0.0063252565,0.00039686347,0.00057099573,0.000012453445,0.00829406],"genre_scores_gemma":[0.96299034,0.0049979216,0.0077310833,0.006251093,0.0037552144,0.0000046424443,0.00004289877,0.00035023454,0.01387654],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.98575217,0.0018542898,0.0037495682,0.0008253293,0.0024679843,0.0053506666],"domain_scores_gemma":[0.9659682,0.0012503068,0.0023123312,0.0012319464,0.0052305306,0.024006672],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.011058316,0.0012484338,0.002877167,0.009011438,0.00066025,0.0012095085,0.0023268522,0.0014596225,0.009477838],"category_scores_gemma":[0.006320438,0.0013615229,0.001894792,0.006612612,0.0015632014,0.0013986795,0.00014453144,0.006440614,0.00023964453],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00023133926,0.000172447,0.594011,0.00095823,0.0031839423,0.28913674,0.0036947588,0.0014906968,0.00054925564,0.00007095406,0.097436324,0.009064309],"study_design_scores_gemma":[0.018368708,0.0013022986,0.38256013,0.008734094,0.0019055345,0.42109615,0.008698578,0.0013180838,0.0044835205,0.000036479953,0.14992912,0.0015672895],"about_ca_topic_score_codex":0.05253882,"about_ca_topic_score_gemma":0.026887864,"teacher_disagreement_score":0.3951746,"about_ca_system_score_codex":0.09288437,"about_ca_system_score_gemma":0.48805898,"threshold_uncertainty_score":0.9998367},"labels":[],"label_agreement":null},{"id":"W3201943516","doi":"10.3390/curroncol28050326","title":"Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"St. John’s Health Sciences Centre; CancerCare Manitoba; McMaster University; University of Manitoba; Joseph Brant Hospital; Memorial University of Newfoundland","funders":"Janssen Canada","keywords":"Ibrutinib; Medicine; Fludarabine; Rituximab; Chemoimmunotherapy; Population; Chronic lymphocytic leukemia; Internal medicine; Oncology; Cyclophosphamide; Intensive care medicine; Leukemia; Chemotherapy; Lymphoma; Environmental health","score_opus":0.21519394059366306,"score_gpt":0.48290798230019266,"score_spread":0.26771404170652957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201943516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020476764,0.99113584,0.0000014370612,0.00027117174,0.0010207571,0.0024259551,0.00021667118,0.000012703512,0.0047107204],"genre_scores_gemma":[0.00033295964,0.9978128,0.00005157128,0.000022309616,0.0003548142,0.00044590805,0.00016975345,0.000057189405,0.0007527031],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975279,0.0003674513,0.0005393753,0.00057531014,0.0004249913,0.0005649547],"domain_scores_gemma":[0.99765414,0.00021313353,0.00033591274,0.0009027605,0.0004909784,0.00040308238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010216786,0.00041998178,0.0023428514,0.00023414392,0.0000781523,0.000009230684,0.0002374503,0.0003341149,0.00037165935],"category_scores_gemma":[0.0001797,0.00021636477,0.0006058175,0.00048912683,0.00031660165,0.000014387694,0.00010197003,0.00047063638,0.00004086566],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000052547715,0.001122323,0.000046787463,0.0028071564,0.00086961646,0.000981892,0.0014882945,8.1356023e-7,3.7827252e-8,0.00022659946,0.004666892,0.98773706],"study_design_scores_gemma":[0.0046439646,0.0026844784,0.000008502517,0.0074441736,0.0020654064,0.0027114328,0.0004824537,0.00002985278,0.0000015071631,0.0000052970727,0.979746,0.00017697153],"about_ca_topic_score_codex":0.082574174,"about_ca_topic_score_gemma":0.16726209,"teacher_disagreement_score":0.9875601,"about_ca_system_score_codex":0.1417074,"about_ca_system_score_gemma":0.12634657,"threshold_uncertainty_score":0.92353505},"labels":[],"label_agreement":null},{"id":"W3203864709","doi":"10.1200/jco.21.00838","title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"National Cancer Institute; Pharmacyclics","keywords":"Rituximab; Medicine; Ibrutinib; Internal medicine; Placebo; Waldenstrom macroglobulinemia; Clinical endpoint; Adverse effect; Regimen; Gastroenterology; Surgery; Oncology; Randomized controlled trial; Lymphoma; Chronic lymphocytic leukemia; Leukemia; Pathology","score_opus":0.20186389114135905,"score_gpt":0.5228453159033778,"score_spread":0.32098142476201874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203864709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740515,0.0017539299,0.0045861723,0.013373127,0.0028772606,0.0022384783,0.00007942801,0.000028952125,0.0010111926],"genre_scores_gemma":[0.98538923,0.00064347696,0.006700195,0.002098182,0.003982396,0.000081958264,0.00009869725,0.000049660597,0.0009561819],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9880322,0.0028835873,0.006058122,0.00072761386,0.0014992664,0.00079917646],"domain_scores_gemma":[0.9490152,0.044048686,0.0026451019,0.0009818192,0.0026537937,0.00065541],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.015760932,0.00042435073,0.0075029195,0.00029813492,0.00022788858,0.00008649318,0.0007733982,0.00076487573,0.0009937908],"category_scores_gemma":[0.032909267,0.0002631573,0.0029408066,0.0013991869,0.00091713655,0.00014343897,0.00041541338,0.0026829864,0.000055357763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.92197484,0.010043098,0.00021139627,0.000035228288,0.01927054,0.008884718,0.00060017843,0.0003488899,0.000042938627,0.000108149354,0.0086023705,0.02987764],"study_design_scores_gemma":[0.9220491,0.0092744855,0.000264637,0.000073947565,0.016872909,0.00054706977,0.001899667,0.036237687,0.00012120064,0.00016220762,0.01227063,0.00022648033],"about_ca_topic_score_codex":0.00076609105,"about_ca_topic_score_gemma":0.0007620042,"teacher_disagreement_score":0.04519546,"about_ca_system_score_codex":0.006789547,"about_ca_system_score_gemma":0.051985007,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W3204330487","doi":"10.1007/s12026-021-09233-0","title":"How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative","year":2021,"lang":"en","type":"article","venue":"Immunologic Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Anti-nuclear antibody; Autoantibody; Antibody; Immunology; Test (biology); Medicine; Immunofluorescence; Titer; Antibody titer; Biology","score_opus":0.17706185891760098,"score_gpt":0.4140334490701855,"score_spread":0.23697159015258454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204330487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87525713,0.006590778,0.000024368326,0.09478104,0.00040515923,0.0014963377,0.000089589106,0.00013849727,0.021217074],"genre_scores_gemma":[0.9605252,0.0069264392,0.0009799656,0.0025796744,0.00082395435,0.0001058147,0.0000924618,0.00008815042,0.027878352],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99266607,0.0012421245,0.0007786414,0.001225908,0.0025681672,0.0015190706],"domain_scores_gemma":[0.9840661,0.008747431,0.00018574693,0.0032259747,0.0035552846,0.00021940708],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004360085,0.00042626224,0.0007391149,0.00024226545,0.0011382037,0.00064044085,0.0014281254,0.00030949357,0.00042848245],"category_scores_gemma":[0.029720014,0.00022244728,0.0002808227,0.0017545234,0.0015308866,0.00015645588,0.002008804,0.002148955,0.0013842003],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009053795,0.0013763527,0.008126079,0.00016663627,0.0007186586,0.02093813,0.0037034515,0.00004659455,0.5626997,0.00049692835,0.39244017,0.008381913],"study_design_scores_gemma":[0.007801527,0.0018401954,0.04171449,0.00096690207,0.00010646985,0.001300065,0.029558985,0.0010544609,0.55052245,0.0008420307,0.36363965,0.0006527824],"about_ca_topic_score_codex":0.0013045747,"about_ca_topic_score_gemma":0.00006100839,"teacher_disagreement_score":0.09220137,"about_ca_system_score_codex":0.0022533722,"about_ca_system_score_gemma":0.0056831515,"threshold_uncertainty_score":0.9999537},"labels":[],"label_agreement":null},{"id":"W3204866712","doi":"10.1080/2162402x.2021.1943234","title":"The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; York University; University of Toronto","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Venetoclax; Chronic lymphocytic leukemia; Medicine; Cancer research; Kinase; Leukemia; Lymphoma; Immunology; Biology; Cell biology","score_opus":0.01566190881699383,"score_gpt":0.30334040842277543,"score_spread":0.2876784996057816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204866712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8724442,0.09678451,0.008530829,0.0073950817,0.0027952981,0.0023523036,0.000029186835,0.0004357057,0.009232872],"genre_scores_gemma":[0.9394785,0.00192726,0.0030881073,0.00084101676,0.001645435,0.00021371133,0.0001687469,0.00012997289,0.052507225],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969858,0.00016942131,0.0005717204,0.00063352694,0.00045869336,0.0011808705],"domain_scores_gemma":[0.9974958,0.00079588994,0.00013666123,0.0010032286,0.0003316548,0.00023679364],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050222356,0.000308233,0.00060399674,0.00010776371,0.0004745297,0.00008843645,0.0004436358,0.0003980883,0.0009713946],"category_scores_gemma":[0.0010259078,0.00024014624,0.0003850738,0.00040529037,0.00039862137,0.000086585685,0.00024436665,0.00047533086,0.0005440672],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0080851875,0.00023669889,0.0000325773,0.0008416955,0.0042256312,0.0054013715,0.002015422,0.0068358155,0.58250266,0.011997887,0.052677635,0.32514742],"study_design_scores_gemma":[0.07472878,0.0034165867,0.0001353148,0.00030424978,0.0005493129,0.011314991,0.0013080247,0.060465302,0.15899634,0.00668346,0.68142927,0.0006683587],"about_ca_topic_score_codex":0.0016206027,"about_ca_topic_score_gemma":0.00013912664,"teacher_disagreement_score":0.62875164,"about_ca_system_score_codex":0.082207,"about_ca_system_score_gemma":0.16403309,"threshold_uncertainty_score":0.9999418},"labels":[],"label_agreement":null},{"id":"W3205380564","doi":"10.3390/curroncol28050349","title":"Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Université Laval; Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale; Institut Universitaire en Santé Mentale de Québec","funders":"","keywords":"Dosing; Medicine; Rituximab; Incidence (geometry); Retrospective cohort study; Internal medicine; Lymphoma","score_opus":0.039511362947929604,"score_gpt":0.3762117624182807,"score_spread":0.3367003994703511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205380564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997197,0.0012065393,0.000012030279,0.00031638777,0.00030829248,0.00047623122,0.000015654156,0.000013253536,0.00045466077],"genre_scores_gemma":[0.9993321,0.00026025088,0.000092346985,0.00006329801,0.00009572607,0.000025850375,0.00008273518,0.000019248637,0.000028470997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834293,0.00010555787,0.00036375757,0.00029459374,0.00048648563,0.00040665735],"domain_scores_gemma":[0.99860644,0.00028311863,0.00013453161,0.0004748394,0.00039734095,0.00010374995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026947583,0.00015893052,0.00048639215,0.00011564791,0.00006340708,0.000011610908,0.00014759552,0.00011513172,0.00027491542],"category_scores_gemma":[0.00022322898,0.000093600414,0.00009510811,0.0004925513,0.00023051978,0.00005615639,0.00019545399,0.00029707278,0.00003111593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0045751724,0.0058336784,0.89923686,0.00050715776,0.00018653504,0.00027387156,0.0013033248,0.00017692152,0.00012829684,0.000262543,0.0020719143,0.08544372],"study_design_scores_gemma":[0.08855463,0.0024144186,0.89084464,0.00059024297,0.000093600545,0.00010838924,0.00007385804,0.0023293581,0.0003421429,0.000045783352,0.014452319,0.0001505968],"about_ca_topic_score_codex":0.00081185234,"about_ca_topic_score_gemma":0.00029008745,"teacher_disagreement_score":0.08529312,"about_ca_system_score_codex":0.024898682,"about_ca_system_score_gemma":0.012662322,"threshold_uncertainty_score":0.99293494},"labels":[],"label_agreement":null},{"id":"W3206013053","doi":"10.1097/cm9.0000000000001811","title":"Chronic lymphocytic leukemia in China","year":2021,"lang":"en","type":"editorial","venue":"Chinese Medical Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Mainland China; Population; IGHV@; Incidence (geometry); Context (archaeology); Demography; China; Internal medicine; Pediatrics; Leukemia; Geography; Environmental health","score_opus":0.007138379380148847,"score_gpt":0.3212857629431026,"score_spread":0.3141473835629538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206013053","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04071912,0.029054584,0.000116236835,0.00092550286,0.92175287,0.00058878976,0.000033258,0.00012787474,0.006681786],"genre_scores_gemma":[0.014297573,0.012982425,0.000117938536,0.00022348299,0.9651182,0.000043971428,0.0005348985,0.00024273148,0.006438775],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853505,0.00049322535,0.0019310022,0.0010892691,0.009368026,0.0017679903],"domain_scores_gemma":[0.9932836,0.0018130607,0.00046019114,0.0011923858,0.00065456185,0.0025961956],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0034439187,0.0009819008,0.0025038288,0.0009377808,0.00021042838,0.0002488667,0.0013606396,0.0034510698,0.0076920576],"category_scores_gemma":[0.03181922,0.00070328166,0.0008476119,0.0014467597,0.0005600896,0.00018768467,0.00073559163,0.011580373,0.00036994982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00035781332,0.00006343412,0.000096254174,0.0013906352,0.00032530638,0.06533866,0.0002010322,0.00013480215,0.000029716133,0.0000045722422,0.9199203,0.012137433],"study_design_scores_gemma":[0.06646689,0.0006467988,0.00052800484,0.010223731,0.0002581435,0.020381514,0.000036930647,0.031625707,0.000025091082,0.0003249256,0.86858,0.0009023034],"about_ca_topic_score_codex":0.0014523523,"about_ca_topic_score_gemma":0.00060988514,"teacher_disagreement_score":0.18190086,"about_ca_system_score_codex":0.43745998,"about_ca_system_score_gemma":0.6193608,"threshold_uncertainty_score":0.9995418},"labels":[],"label_agreement":null},{"id":"W3207226644","doi":"10.26508/lsa.202101054","title":"Kinomics platform using GBM tissue identifies BTK as being associated with higher patient survival","year":2021,"lang":"en","type":"article","venue":"Life Science Alliance","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; European Regional Development Fund; Biotechnology and Biological Sciences Research Council; Directorate for Biological Sciences; European Commission; Fundacja na rzecz Nauki Polskiej; University of Edinburgh; Hashemite University; Cancer Research UK","keywords":"Bruton's tyrosine kinase; Ex vivo; Cancer research; SOX2; Tyrosine kinase; Biology; In vivo; Cell culture; Population; Medicine; Signal transduction; Cell biology; Embryonic stem cell; Genetics; Gene","score_opus":0.051974645407656714,"score_gpt":0.33716355219040234,"score_spread":0.2851889067827456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207226644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992827,0.00047406126,0.00009696481,0.00048706762,0.0007899221,0.00026344892,0.000005003937,0.00006528916,0.0049912184],"genre_scores_gemma":[0.9938031,0.00008037731,0.0011839733,0.0007666552,0.00019086158,0.0000095368605,0.000014849346,0.000029787885,0.0039208787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964887,0.000034220433,0.00032659943,0.0006697954,0.0016713111,0.00080940145],"domain_scores_gemma":[0.9981187,0.00016185171,0.00014297191,0.00058018195,0.0005806021,0.00041570258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060468295,0.00019288197,0.00034038513,0.00008153528,0.0003727746,0.00023031185,0.00034136,0.000090855596,0.000272441],"category_scores_gemma":[0.001288995,0.00016431743,0.000048040347,0.001493758,0.0007780072,0.0005340004,0.0002704055,0.00026731283,0.00017757069],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021385585,0.0028864741,0.09434884,0.0014441002,0.0017033876,0.021229733,0.017215379,0.014855825,0.79021084,0.028167317,0.0056035183,0.020196058],"study_design_scores_gemma":[0.026077535,0.0014663829,0.058764145,0.00427356,0.00043452668,0.0007841087,0.0041004494,0.06879577,0.8084295,0.001984076,0.022740284,0.0021496573],"about_ca_topic_score_codex":0.0002993644,"about_ca_topic_score_gemma":0.00009172176,"teacher_disagreement_score":0.053939946,"about_ca_system_score_codex":0.006869416,"about_ca_system_score_gemma":0.015130549,"threshold_uncertainty_score":0.99694306},"labels":[],"label_agreement":null},{"id":"W3209302665","doi":"10.1007/s43678-021-00202-y","title":"Out of the closet and into the waiting room: improving care of 2SLGBTQIA+ patients in the emergency department","year":2021,"lang":"en","type":"editorial","venue":"Canadian Journal of Emergency Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Closet; Medicine; Emergency department; Medical emergency; Emergency medicine; Nursing; Engineering","score_opus":0.03245821283425435,"score_gpt":0.33649601355826275,"score_spread":0.3040378007240084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209302665","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36516714,0.036273703,0.0000024249987,0.0025361495,0.59374624,0.0010137755,0.00013451205,0.0000020394764,0.0011239856],"genre_scores_gemma":[0.76785153,0.006212807,0.000016141415,0.000058237572,0.22513817,0.000021136073,0.00016083189,0.000069646725,0.00047148464],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99439955,0.00045425698,0.0021512022,0.00030929345,0.002111438,0.000574264],"domain_scores_gemma":[0.9946479,0.0004747541,0.0013972427,0.00082506594,0.0021956349,0.00045936593],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020192976,0.00036151224,0.0010158978,0.00035208635,0.00020307153,0.000006407601,0.001002331,0.00035990574,0.00062146556],"category_scores_gemma":[0.0094464235,0.00017550235,0.00032103283,0.00068120105,0.0003340415,0.00006506251,0.00012223358,0.0016206938,8.0605366e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009948358,0.000050528,0.015958467,0.0018231904,0.0003080204,0.00016842502,0.030930392,0.0000050466115,0.00007326728,0.000020766443,0.94518834,0.005374079],"study_design_scores_gemma":[0.018079849,0.0029513407,0.016004577,0.009300295,0.0023815052,0.000050358893,0.038570303,0.00019502598,0.00021518106,0.00020815177,0.911458,0.0005854156],"about_ca_topic_score_codex":0.059266657,"about_ca_topic_score_gemma":0.18409216,"teacher_disagreement_score":0.4026844,"about_ca_system_score_codex":0.0037828013,"about_ca_system_score_gemma":0.023294348,"threshold_uncertainty_score":0.99889743},"labels":[],"label_agreement":null},{"id":"W3210086718","doi":"10.1161/jaha.121.022369","title":"Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis","year":2021,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary; Western University","funders":"Canadian Institutes of Health Research","keywords":"Ibrutinib; Atrial fibrillation; Sinoatrial node; Electrophysiology; Atrial action potential; Dofetilide","score_opus":0.008281449814846348,"score_gpt":0.2831264053907258,"score_spread":0.27484495557587946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210086718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703413,0.00054250855,0.000006041907,0.0020801509,0.00016090725,0.00015456486,0.000004648174,0.0000039083343,0.000013163723],"genre_scores_gemma":[0.9979774,0.000635604,0.0002503034,0.00028006206,0.0007229216,9.07951e-7,9.798415e-7,0.0000126701325,0.00011915198],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998405,0.00047652546,0.00034308925,0.00014374674,0.00042447346,0.00020719507],"domain_scores_gemma":[0.9972541,0.00176775,0.00051881553,0.00013829667,0.0002151036,0.00010596964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057371426,0.00010104823,0.00065508584,0.000067260524,0.0000736131,0.000017134163,0.000041314455,0.000065916814,0.0000035344565],"category_scores_gemma":[0.004517744,0.0000695278,0.00016762043,0.00022116154,0.00015306855,0.000038101025,0.00007383843,0.00025737163,7.01868e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057110325,0.00016317147,0.2179251,0.0002491966,0.0008313262,0.00009106642,0.0003432418,0.000018671006,0.7647313,0.00003472101,0.0015503996,0.008350793],"study_design_scores_gemma":[0.024581969,0.003671854,0.8214492,0.00021666873,0.00070268544,0.0010611732,0.00010303244,0.00069422624,0.14629604,0.00014653134,0.00090355356,0.00017306607],"about_ca_topic_score_codex":0.0000992246,"about_ca_topic_score_gemma":0.0000061083756,"teacher_disagreement_score":0.61843526,"about_ca_system_score_codex":0.0014789614,"about_ca_system_score_gemma":0.0011750825,"threshold_uncertainty_score":0.5408488},"labels":[],"label_agreement":null},{"id":"W3211353714","doi":"10.1182/blood-2021-146001","title":"Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Foothills Medical Centre; Ottawa Hospital; Moncton Hospital; Jewish General Hospital; ABB (Canada); Thunder Bay Regional Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Tumor lysis syndrome; Venetoclax; Interim analysis; Internal medicine; Ibrutinib; Chronic lymphocytic leukemia; Fludarabine; Chemoimmunotherapy; Incidence (geometry); Clinical trial; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.00951893093795496,"score_gpt":0.3000948973313526,"score_spread":0.2905759663933976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211353714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979908,0.00061417033,0.0000073475117,0.000101065896,0.000068534064,0.000759743,0.000010907847,0.0000214895,0.00042592923],"genre_scores_gemma":[0.99725705,0.0001934019,0.0016630848,0.00053115305,0.00006139312,0.00008094314,0.000091644804,0.00003754723,0.000083796476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966711,0.00024765718,0.0008084292,0.00065396854,0.00095847563,0.00066039944],"domain_scores_gemma":[0.99828786,0.0005327459,0.00021590645,0.00048665697,0.0002506036,0.0002262256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009176444,0.00022668343,0.0005217656,0.00009115797,0.00008151668,0.000054572356,0.00013336138,0.00010499582,0.000023363062],"category_scores_gemma":[0.0013067551,0.0002163487,0.000039855346,0.0009837241,0.00011529541,0.00023919274,0.00027783215,0.00040643176,0.00000703074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010506217,0.00071831787,0.92680216,0.0019838875,0.0008366299,0.05364706,0.0006526454,0.0020958434,0.000018573352,0.00005843059,0.000121843295,0.012014004],"study_design_scores_gemma":[0.08903979,0.00039883758,0.8969861,0.0013677864,0.00027846472,0.0013261752,0.0005816445,0.0091775,0.0002857653,0.0000102118365,0.0002574184,0.00029029502],"about_ca_topic_score_codex":0.21268559,"about_ca_topic_score_gemma":0.37124628,"teacher_disagreement_score":0.15856071,"about_ca_system_score_codex":0.07994645,"about_ca_system_score_gemma":0.050354768,"threshold_uncertainty_score":0.95502883},"labels":[],"label_agreement":null},{"id":"W3211527733","doi":"10.1182/blood-2021-154279","title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Venetoclax; Obinutuzumab; Medicine; Internal medicine; Oncology; Pembrolizumab; Rituximab; Cancer; Immunotherapy; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.015558274020095164,"score_gpt":0.2694863837476252,"score_spread":0.25392810972753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211527733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962096,0.00037434502,0.00042709272,0.00017783305,0.00005712655,0.002226921,0.0000877049,0.000035733818,0.00040359728],"genre_scores_gemma":[0.995398,0.00008178636,0.0027548692,0.00006718572,0.00017193778,0.00053901516,0.00046341564,0.00004072177,0.00048308496],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988112,0.000016667866,0.00026064002,0.00030680178,0.00025743502,0.00034728993],"domain_scores_gemma":[0.9991813,0.00010106642,0.000051346848,0.00024642205,0.00027117252,0.00014873239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007667668,0.00017613432,0.00030457057,0.000058639707,0.000092926646,0.00003366004,0.00003637813,0.00009515515,0.000019207657],"category_scores_gemma":[0.00005663399,0.000128906,0.000100622856,0.000108123146,0.000044491404,0.00009581552,0.000016022705,0.000042299835,0.0000053697886],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1310782,0.04707099,0.027500883,0.032476258,0.019679392,0.0014890251,0.079659484,0.00052493287,0.05821583,0.005726093,0.008315388,0.5882635],"study_design_scores_gemma":[0.60388225,0.013500769,0.0074174744,0.00061208714,0.0018192229,0.00041855004,0.00052116776,0.007127447,0.33356667,0.0003104172,0.030222982,0.00060096546],"about_ca_topic_score_codex":0.000046950216,"about_ca_topic_score_gemma":0.00003979104,"teacher_disagreement_score":0.5876626,"about_ca_system_score_codex":0.006466165,"about_ca_system_score_gemma":0.004443644,"threshold_uncertainty_score":0.99734783},"labels":[],"label_agreement":null},{"id":"W3211568627","doi":"10.1182/blood-2021-146570","title":"Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Fludarabine; Progression-free survival; Neutropenia; Oncology; Ibrutinib; Toxicity; Chemotherapy; Leukemia; Lymphoma","score_opus":0.032711779869195344,"score_gpt":0.3020224346088241,"score_spread":0.2693106547396288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211568627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917097,0.003163396,0.00001777764,0.0003593944,0.00089433487,0.0015779199,0.000048202164,0.000100518766,0.0021287343],"genre_scores_gemma":[0.99259293,0.00043073893,0.00033967927,0.00024246996,0.000760708,0.000111316665,0.000047317,0.00012567919,0.0053491374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950754,0.00026563802,0.0012285543,0.0008838694,0.0015009949,0.0010455509],"domain_scores_gemma":[0.9962826,0.00077316683,0.00033294395,0.0019379434,0.00035875136,0.00031463124],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009810036,0.0004546497,0.0013452609,0.00023826331,0.00013115013,0.000044033037,0.0006769461,0.0004996049,0.0010739925],"category_scores_gemma":[0.003059707,0.00032036143,0.00047789686,0.0015779979,0.00039094387,0.00011678411,0.00061379216,0.0009472474,0.00014743026],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.64449203,0.027176972,0.010707217,0.023106838,0.0103245815,0.039508995,0.010769118,0.003301082,0.11766433,0.008174362,0.07317964,0.031594828],"study_design_scores_gemma":[0.9454523,0.0015570879,0.0016482136,0.001440117,0.0007891716,0.0010083851,0.0002802179,0.0066049783,0.034528084,0.00015931403,0.0060817185,0.00045044004],"about_ca_topic_score_codex":0.002312965,"about_ca_topic_score_gemma":0.0035518764,"teacher_disagreement_score":0.30096024,"about_ca_system_score_codex":0.051137112,"about_ca_system_score_gemma":0.12941019,"threshold_uncertainty_score":0.99992484},"labels":[],"label_agreement":null},{"id":"W3211785283","doi":"10.1002/cam4.4378","title":"Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Ruxolitinib; Ibrutinib; Medicine; Janus kinase; Internal medicine; Concomitant; Chronic lymphocytic leukemia; Pharmacology; Leukemia; Cancer research; Immunology; Oncology; Bone marrow; Cytokine","score_opus":0.0381862828364274,"score_gpt":0.3618438891079292,"score_spread":0.3236576062715018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211785283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98855364,0.002638906,0.000003199457,0.00082840864,0.0011513043,0.0013377786,0.00014918146,0.000049261096,0.0052882936],"genre_scores_gemma":[0.9934401,0.0010084064,0.00003246941,0.0006191514,0.0014477713,0.00012572395,0.00026675087,0.00005864721,0.0030009958],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99542195,0.00021503647,0.0013382292,0.00082287705,0.0014219924,0.00077993865],"domain_scores_gemma":[0.9971448,0.00063956436,0.000342696,0.0010560299,0.00040071647,0.00041616042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007991501,0.0003676231,0.0012154538,0.000389924,0.00007701196,0.0000075245302,0.00025987875,0.00023950866,0.0007303578],"category_scores_gemma":[0.0025227207,0.00029809377,0.00015380014,0.0011258252,0.0005180806,0.000068208064,0.00014926856,0.00048024024,0.00002696667],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6386084,0.0054541347,0.00034158537,0.00396915,0.00086252677,0.00697039,0.0065026972,0.0024906474,0.06826544,0.0002783118,0.11770322,0.14855348],"study_design_scores_gemma":[0.8750123,0.020930465,0.0006805452,0.004546124,0.0002191178,0.000030673087,0.00019022773,0.0037484127,0.0811182,0.00003416145,0.013208069,0.00028174053],"about_ca_topic_score_codex":0.0043709613,"about_ca_topic_score_gemma":0.0003971759,"teacher_disagreement_score":0.23640385,"about_ca_system_score_codex":0.08355048,"about_ca_system_score_gemma":0.061159555,"threshold_uncertainty_score":0.99994713},"labels":[],"label_agreement":null},{"id":"W3211864651","doi":"10.1182/blood-2021-151711","title":"Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and <i>TP53</i> Aberrations Treated with Ibrutinib, with or without Rituximab","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Medicine; Rituximab; Internal medicine; Neutropenia; Progression-free survival; Oncology; Chronic lymphocytic leukemia; Lymphocytosis; Refractory (planetary science); Median follow-up; Leukemia; Chemotherapy; Lymphoma","score_opus":0.02149044637896687,"score_gpt":0.2866232311997149,"score_spread":0.26513278482074804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211864651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975624,0.00040643534,0.000016850894,0.000068465066,0.000011264916,0.00086916116,0.000064890235,0.000052803327,0.00094771985],"genre_scores_gemma":[0.995402,0.00014273028,0.0012364882,0.00006576983,0.0000349584,0.00006361441,0.00016953677,0.00006492976,0.0028199735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822646,0.00006325261,0.0003319281,0.0005449964,0.0004548273,0.00037850466],"domain_scores_gemma":[0.9984833,0.00015168621,0.00015563471,0.00057305396,0.00034814267,0.00028817673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006595996,0.00032543243,0.00071064377,0.000110813315,0.00011021295,0.000041429223,0.00006026379,0.00011820792,0.000070202856],"category_scores_gemma":[0.000054012056,0.00017857781,0.000035598518,0.00035481964,0.00037590327,0.00015753509,0.000050041184,0.00017437394,0.0000047438257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032447916,0.003935632,0.9892584,0.00029584736,0.00077080034,0.00071990263,0.00051233824,8.666432e-7,0.0002718498,0.000008272071,0.000016585156,0.0009647289],"study_design_scores_gemma":[0.35049337,0.015061022,0.61855215,0.00083601056,0.002749502,0.0019788353,0.0003081689,0.00009023235,0.009254667,0.0000020862344,0.0001989706,0.000475001],"about_ca_topic_score_codex":0.00034251958,"about_ca_topic_score_gemma":0.001318453,"teacher_disagreement_score":0.37070626,"about_ca_system_score_codex":0.0008075463,"about_ca_system_score_gemma":0.0029580207,"threshold_uncertainty_score":0.72821915},"labels":[],"label_agreement":null},{"id":"W3212313924","doi":"10.1182/blood-2021-146228","title":"Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Ibrutinib; Tolerability; Adverse effect; Internal medicine; Incidence (geometry); Cumulative incidence; Chronic lymphocytic leukemia; Gastroenterology; Surgery; Cohort; Leukemia","score_opus":0.02485270191560354,"score_gpt":0.3096979181604436,"score_spread":0.2848452162448401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212313924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960934,0.00041839885,0.000003024587,0.000082927276,0.0003651461,0.0025962798,0.000046976467,0.00006224209,0.00033162814],"genre_scores_gemma":[0.99811816,0.00030320662,0.00007534112,0.000035562596,0.0001894858,0.00013904048,0.00053172844,0.000079016514,0.00052848354],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953407,0.00037141857,0.0017245408,0.0007843688,0.00095060776,0.00082833075],"domain_scores_gemma":[0.99779856,0.00027961083,0.00039928645,0.00088089966,0.0003210585,0.00032060902],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007322854,0.000403843,0.0012256068,0.0006912185,0.000034449648,0.0000067685114,0.0002650213,0.000466597,0.00021278707],"category_scores_gemma":[0.0013788064,0.00041080124,0.000252204,0.0026497399,0.00013626991,0.00016291287,0.00023404502,0.00041734442,0.00005837435],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09617039,0.004367338,0.005278324,0.0017614637,0.0004105225,0.0013280564,0.001352752,0.00045279838,0.88606113,0.000040124054,0.000018831524,0.0027582508],"study_design_scores_gemma":[0.5735823,0.0027562785,0.017237088,0.0025227503,0.00029280316,0.00008411267,0.000058189664,0.0033189263,0.3997477,0.0000054614834,0.00011051814,0.00028385958],"about_ca_topic_score_codex":0.0024991941,"about_ca_topic_score_gemma":0.0010705988,"teacher_disagreement_score":0.48631343,"about_ca_system_score_codex":0.030808305,"about_ca_system_score_gemma":0.033236958,"threshold_uncertainty_score":0.99983436},"labels":[],"label_agreement":null},{"id":"W3212985656","doi":"10.1182/blood-2021-146947","title":"IL-4 Mediated Upregulation of AMPK/SIRT1/PGC-1α Signalling Pathway Is Bypassed By Mitochondrial Complex I Downregulation By NAMPT Inhibition in Venetoclax and Ibrutinib Treated CLL Cells","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Biology; Cancer research; AMPK; Downregulation and upregulation; Leukemia; Pharmacology; Cell biology; Immunology; Biochemistry; Kinase; Protein kinase A","score_opus":0.016498775524927834,"score_gpt":0.25325367415602945,"score_spread":0.2367548986311016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212985656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752134,0.00059687987,0.00021003507,0.00019795196,0.00005669165,0.0007977409,0.00030985984,0.000057070705,0.00025240862],"genre_scores_gemma":[0.9952807,0.00011181826,0.0006147825,0.00009271205,0.0001300649,0.000037656635,0.003359546,0.000044861747,0.000327882],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740565,0.00020912972,0.0007132949,0.0005602595,0.0007006021,0.00041106393],"domain_scores_gemma":[0.9986572,0.00031614982,0.00022513818,0.00033192127,0.00027659256,0.0001929631],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002493964,0.00025298147,0.0005332698,0.00017600085,0.0000653543,0.00004050334,0.000059905302,0.00032557343,0.0002988702],"category_scores_gemma":[0.00016334622,0.00025868684,0.00009017862,0.00064404646,0.00013375288,0.00013839689,0.00006484107,0.00021912518,0.000013397572],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044150278,0.00056571944,0.00038014122,0.0002076632,0.00009430821,0.000070127986,0.0006186986,0.00009792185,0.99454737,0.00001218907,0.002498649,0.0004656982],"study_design_scores_gemma":[0.044252105,0.00026048862,0.0016714354,0.0003094676,0.00012380337,0.000054798787,0.00012310114,0.027594687,0.9245068,0.00006758939,0.00081552425,0.00022018641],"about_ca_topic_score_codex":0.0005533553,"about_ca_topic_score_gemma":0.0000693778,"teacher_disagreement_score":0.07004057,"about_ca_system_score_codex":0.00140246,"about_ca_system_score_gemma":0.0016999056,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W3213015981","doi":"10.1182/blood-2021-146738","title":"Frontline Therapy with Bendamustine-Rituximab (BR) in Patients with Treatment-Naïve Waldenstrom's Macroglobulinemia Confers Similar Long-Term Outcomes to R-CVP in a Real-World Setting: A Population-Based Analysis","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Rituximab; Medicine; Bendamustine; Waldenstrom macroglobulinemia; Internal medicine; Population; Macroglobulinemia; Prednisone; Oncology; Lymphoplasmacytic Lymphoma; Vincristine; Cyclophosphamide; Lymphoma; Immunology; Chemotherapy; Multiple myeloma","score_opus":0.018608643665092593,"score_gpt":0.30814377243699803,"score_spread":0.28953512877190546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213015981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970387,0.00008748385,0.00003447764,0.0010902737,0.000021192607,0.001379252,0.00010690627,0.000070598784,0.00017106965],"genre_scores_gemma":[0.99329466,0.00002260886,0.0038315423,0.00047232088,0.000049025315,0.00014880463,0.0016474377,0.00007309186,0.0004604852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967365,0.00013968935,0.0006463375,0.00086323346,0.0008740701,0.0007401297],"domain_scores_gemma":[0.99808216,0.00023503212,0.0001571871,0.0008664732,0.00032476583,0.00033438284],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017606629,0.00046797688,0.0011941058,0.000901059,0.000063002786,0.000061341736,0.00015898833,0.00012498142,0.00023106323],"category_scores_gemma":[0.00011581576,0.00033330588,0.0001883741,0.0023361319,0.000060369268,0.00007794399,0.000047838686,0.00025532418,0.000010846254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00221908,0.0054158443,0.9860988,0.000070540096,0.0013659522,0.0018582478,0.00026551198,0.001244816,0.00004603303,0.0000037734687,0.000012454801,0.0013989283],"study_design_scores_gemma":[0.1493095,0.00096717634,0.8457442,0.00023812987,0.00088679575,0.000011298464,0.00005974061,0.0015701868,0.000896914,0.0000013315163,0.000016228165,0.0002984954],"about_ca_topic_score_codex":0.008227889,"about_ca_topic_score_gemma":0.061004598,"teacher_disagreement_score":0.14709042,"about_ca_system_score_codex":0.0054387585,"about_ca_system_score_gemma":0.003814586,"threshold_uncertainty_score":0.9999119},"labels":[],"label_agreement":null},{"id":"W3213181298","doi":"10.3389/fnume.2021.772289","title":"Radiosynthesis of [11C]Ibrutinib via Pd-Mediated [11C]CO Carbonylation: Preliminary PET Imaging in Experimental Autoimmune Encephalomyelitis Mice","year":2021,"lang":"en","type":"article","venue":"Frontiers in Nuclear Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Ontario Ministry of Research and Innovation; Canada Research Chairs; Canada Excellence Research Chairs, Government of Canada; Canada Foundation for Innovation; Azrieli Foundation; Centre for Addiction and Mental Health","keywords":"Ibrutinib; Chemistry; Radiosynthesis; Bruton's tyrosine kinase; Positron emission tomography; Experimental autoimmune encephalomyelitis; Nuclear medicine; Radiochemistry; Medicine; Internal medicine; Tyrosine kinase; Immunology; Multiple sclerosis; Receptor; Biochemistry; Leukemia","score_opus":0.009376679009336319,"score_gpt":0.27336298441263135,"score_spread":0.26398630540329504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213181298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9522421,0.02933965,0.00015468769,0.004195313,0.0012049235,0.0008999769,0.000018067858,0.00012106206,0.01182424],"genre_scores_gemma":[0.9935558,0.00086677953,0.0041092783,0.00049101654,0.0002908189,0.000030224193,0.00014957083,0.000097679345,0.00040886825],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99620456,0.00029081627,0.0010592156,0.0006996042,0.0010189572,0.00072687055],"domain_scores_gemma":[0.9982989,0.0003335927,0.00020936449,0.00073927484,0.00015827484,0.00026060254],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078002585,0.00034961724,0.0011079771,0.0007100348,0.00006499257,0.000012061325,0.00031631335,0.00015965618,0.0015327991],"category_scores_gemma":[0.0010530839,0.00034365754,0.00013154604,0.0010967675,0.00075307046,0.00019207952,0.00016862039,0.00057461153,0.000029697672],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008371414,0.0023723547,0.06732301,0.0020358495,0.0005560727,0.030282546,0.036248524,0.0001610624,0.722425,0.00017758996,0.07628088,0.05376571],"study_design_scores_gemma":[0.13004354,0.0029075115,0.2816174,0.012193717,0.0005033347,0.007264781,0.07467638,0.37455526,0.077049986,0.0002967229,0.03697254,0.0019188356],"about_ca_topic_score_codex":0.0013851179,"about_ca_topic_score_gemma":0.0000122287665,"teacher_disagreement_score":0.645375,"about_ca_system_score_codex":0.005810869,"about_ca_system_score_gemma":0.0017745777,"threshold_uncertainty_score":0.99990153},"labels":[],"label_agreement":null},{"id":"W3213641350","doi":"10.1182/blood-2021-154195","title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Atezolizumab; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Ibrutinib; Rituximab; Internal medicine; Oncology; Bendamustine; Alemtuzumab; Leukemia; Pembrolizumab; Cancer; Immunotherapy; Lymphoma; Transplantation","score_opus":0.01772876279167776,"score_gpt":0.2684535897771648,"score_spread":0.25072482698548704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213641350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926806,0.002938631,0.00018996159,0.000118132426,0.00015449565,0.0034396197,0.00017406468,0.00010623571,0.00019825183],"genre_scores_gemma":[0.99269617,0.000628784,0.002156383,0.00009904639,0.0007241244,0.0011500319,0.0006749137,0.00014006413,0.0017304668],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99712646,0.00003126776,0.0005296152,0.00088289694,0.00052966067,0.00090009253],"domain_scores_gemma":[0.99784946,0.00035702044,0.0001462015,0.00075499533,0.0004923735,0.00039995954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014973915,0.00045636878,0.00074520044,0.00011901259,0.0002476365,0.00007619825,0.00013547819,0.00023073408,0.00005454994],"category_scores_gemma":[0.00026286862,0.00035756337,0.00023693024,0.0002688292,0.00016191232,0.00010363471,0.00012546379,0.000120038,0.000019173815],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.21346438,0.035363313,0.034779772,0.10415478,0.05085934,0.012427297,0.021849256,0.029679166,0.045752864,0.005842297,0.024567267,0.42126027],"study_design_scores_gemma":[0.71666694,0.022941887,0.0028004702,0.0016230219,0.0026258114,0.0010619956,0.00013757715,0.052450027,0.16181244,0.0003386718,0.036440246,0.0011009403],"about_ca_topic_score_codex":0.00046242104,"about_ca_topic_score_gemma":0.0005760095,"teacher_disagreement_score":0.50320256,"about_ca_system_score_codex":0.1559443,"about_ca_system_score_gemma":0.06446832,"threshold_uncertainty_score":0.99988765},"labels":[],"label_agreement":null},{"id":"W3213674163","doi":"10.1182/blood-2021-147731","title":"Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Venetoclax; Medicine; Bendamustine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Ven; Minimal residual disease; Tumor lysis syndrome; Rituximab; KRAS; Lenalidomide; Leukemia; Gastroenterology; Lymphoma; Cancer; Multiple myeloma; Chemotherapy","score_opus":0.011383762729242167,"score_gpt":0.2960673765236078,"score_spread":0.28468361379436563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213674163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485713,0.0001904857,0.000037349677,0.00009935015,0.00011343786,0.004293846,0.00006497689,0.000016120097,0.00032727342],"genre_scores_gemma":[0.9976839,0.00010622554,0.00009954998,0.000022168962,0.000042791653,0.00053048716,0.0013575709,0.000032564123,0.00012476783],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960232,0.001005618,0.0011584407,0.00039933616,0.0010622992,0.0003511437],"domain_scores_gemma":[0.997498,0.00086233177,0.00054083194,0.0006963509,0.0003343224,0.00006820509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086457876,0.00027599256,0.0009224663,0.00023434097,0.00008276428,0.000024090745,0.0001963102,0.00017790834,0.00007184952],"category_scores_gemma":[0.00036037236,0.00016646573,0.0002556164,0.0008564875,0.00031084567,0.00013264945,0.00004797834,0.00015915175,0.0000017453593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.81463534,0.09174953,0.035791177,0.0019222664,0.0041234135,0.0016612153,0.010419221,0.013026126,0.0076121907,0.0033755312,0.00009672162,0.015587258],"study_design_scores_gemma":[0.89507073,0.0032323354,0.011078914,0.0003385232,0.0007715249,0.000054947628,0.0002800523,0.083503395,0.0054512112,0.0000769792,0.000007341772,0.00013401367],"about_ca_topic_score_codex":0.0016592195,"about_ca_topic_score_gemma":0.001503406,"teacher_disagreement_score":0.08851719,"about_ca_system_score_codex":0.060024362,"about_ca_system_score_gemma":0.03684149,"threshold_uncertainty_score":0.96861875},"labels":[],"label_agreement":null},{"id":"W3213933946","doi":"10.1182/blood-2021-153146","title":"Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chemoimmunotherapy; Bendamustine; Ibrutinib; Rituximab; Medicine; Internal medicine; Oncology; Lymphoma; Chronic lymphocytic leukemia; Leukemia","score_opus":0.022792972030502113,"score_gpt":0.2977375818499089,"score_spread":0.27494460981940677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213933946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271685,0.0028695578,0.0001304296,0.00046423887,0.000059962724,0.00073877454,0.00018690997,0.000068879854,0.0027644183],"genre_scores_gemma":[0.99231297,0.00022288902,0.0042199665,0.00014041192,0.00009134968,0.000028146738,0.00036626693,0.00006742893,0.0025505803],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99708426,0.00009941921,0.0007961542,0.0005822361,0.0008977106,0.0005402388],"domain_scores_gemma":[0.997041,0.00035221956,0.00042865015,0.0012985405,0.0007020948,0.0001775372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035600417,0.00030420354,0.0011114033,0.00009537022,0.000048203045,0.000016912729,0.00028730088,0.00014893706,0.0002041656],"category_scores_gemma":[0.00029902364,0.00026132067,0.00018054659,0.00057134056,0.00041485735,0.00006436739,0.00008465465,0.0003023548,0.000012197056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05412696,0.01988646,0.019944165,0.00683043,0.0033521603,0.007957981,0.0023453936,0.00026246277,0.879672,0.0001588576,0.0022579955,0.0032051217],"study_design_scores_gemma":[0.30549303,0.0007980664,0.0114583615,0.0017905458,0.00036002984,0.00035190248,0.00017488515,0.0011285569,0.6774325,0.0000027505812,0.00074646395,0.00026291655],"about_ca_topic_score_codex":0.00016871422,"about_ca_topic_score_gemma":0.00012880386,"teacher_disagreement_score":0.25136608,"about_ca_system_score_codex":0.00092845986,"about_ca_system_score_gemma":0.0069640777,"threshold_uncertainty_score":0.9999839},"labels":[],"label_agreement":null},{"id":"W3213981466","doi":"10.1182/blood-2021-148155","title":"Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Venetoclax; Obinutuzumab; Ibrutinib; Medicine; Chronic lymphocytic leukemia; IGHV@; Internal medicine; Neutropenia; Tumor lysis syndrome; Oncology; Regimen; Leukemia; Chemotherapy","score_opus":0.06305773727376265,"score_gpt":0.3625124696844897,"score_spread":0.29945473241072706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213981466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760193,0.005385364,0.000046870606,0.000029120796,0.0008945775,0.014635589,0.000088710876,0.0002198712,0.0026805655],"genre_scores_gemma":[0.987175,0.0026429747,0.0014709231,0.00012724866,0.0006483425,0.0027580727,0.0003642518,0.0002879516,0.00452523],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99054617,0.0011524434,0.0024870127,0.002078515,0.0015518339,0.0021840446],"domain_scores_gemma":[0.99281555,0.0023273425,0.0008532887,0.0023475636,0.00080053374,0.00085570343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018260994,0.0011467133,0.0042155124,0.0006010158,0.00021296048,0.00024789933,0.0014113195,0.0008018745,0.0005000113],"category_scores_gemma":[0.004720504,0.0009858609,0.0005862594,0.0023492025,0.00088763883,0.0003441828,0.0013280404,0.0005696492,0.00018618656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9752084,0.0014547111,0.000008007287,0.0017709144,0.0022592177,0.008436423,0.0010856407,0.0037340426,0.0021329802,0.00015798828,0.00016215976,0.003589533],"study_design_scores_gemma":[0.7254347,0.0048979395,0.00000902457,0.0018099512,0.0018743287,0.0011472158,0.00020050745,0.24200611,0.021432422,0.000031473213,0.00048618382,0.00067012134],"about_ca_topic_score_codex":0.014371092,"about_ca_topic_score_gemma":0.0025695332,"teacher_disagreement_score":0.24977367,"about_ca_system_score_codex":0.6458672,"about_ca_system_score_gemma":0.5878464,"threshold_uncertainty_score":0.9992592},"labels":[],"label_agreement":null},{"id":"W3213986007","doi":"10.1182/blood-2021-153691","title":"A Phase Ib Pilot Study of Itacitinib Combined with Alemtuzumab in Patients with T-Cell Prolymphocytic Leukemia (T-PLL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prolymphocytic leukemia; Alemtuzumab; Medicine; Leukemia; Internal medicine; Oncology; Cancer research; Chronic lymphocytic leukemia; Transplantation","score_opus":0.01614263831618313,"score_gpt":0.26476546369620696,"score_spread":0.24862282538002384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213986007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954469,0.00012965882,0.0000050372837,0.000021691567,0.000025636222,0.0023306275,0.000017964549,0.000050489343,0.0019719454],"genre_scores_gemma":[0.9986397,0.00000785535,0.00030752283,0.0000646902,0.000033006465,0.00017453273,0.00009221066,0.00007729688,0.0006031868],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996849,0.00014310583,0.00055831624,0.00064452447,0.0012070894,0.00059794605],"domain_scores_gemma":[0.9979984,0.00014946162,0.00017437142,0.0009302176,0.00049396016,0.00025356538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021467927,0.00032051592,0.0007524072,0.00022419433,0.00005434477,0.000026762826,0.0002036734,0.000067211855,0.0001022831],"category_scores_gemma":[0.00012357518,0.00023908057,0.000042142954,0.00097428664,0.00014161585,0.000108851316,0.00012960457,0.0003092198,0.000021387777],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.103551835,0.53989625,0.31912306,0.0032518622,0.0021869896,0.014015687,0.0063336315,0.00019465276,0.008628374,0.00006879348,0.00028304305,0.0024658213],"study_design_scores_gemma":[0.8480769,0.100001685,0.018041063,0.0005273998,0.0005919921,0.00017062621,0.0011820362,0.00049227796,0.03052886,0.000007335568,0.000028989545,0.00035082456],"about_ca_topic_score_codex":0.0006517372,"about_ca_topic_score_gemma":0.00051230984,"teacher_disagreement_score":0.7445251,"about_ca_system_score_codex":0.0056186183,"about_ca_system_score_gemma":0.016479064,"threshold_uncertainty_score":0.9981986},"labels":[],"label_agreement":null},{"id":"W3214698409","doi":"10.1136/gutjnl-2021-bsg.9","title":"OMO-2 Filgotinib efficacy in patients with ulcerative colitis by line of therapy: Phase 2b/3 selection results","year":2021,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Vedolizumab; Internal medicine; Regimen; Placebo; Maintenance therapy; Ulcerative colitis; Clinical trial; Gastroenterology; Phases of clinical research; Surgery; Chemotherapy; Disease; Pathology","score_opus":0.019277384921250168,"score_gpt":0.32407422715895634,"score_spread":0.3047968422377062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214698409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310696,0.00006509351,0.00007452196,0.00037799904,0.000030308875,0.00076023093,0.000080925456,0.000031523068,0.0054724477],"genre_scores_gemma":[0.9937979,0.000072951276,0.0005194353,0.00021105041,0.00004954983,0.000021842836,0.0005128169,0.000024048659,0.0047904076],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99825704,0.00012854084,0.00040327868,0.00035844074,0.0005485075,0.0003042162],"domain_scores_gemma":[0.9987056,0.00023902947,0.00008803123,0.00027189075,0.00056898885,0.00012643404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022332132,0.00014365723,0.00034347808,0.00010018076,0.000032610078,0.000013166658,0.00005984393,0.0000919461,0.0004675467],"category_scores_gemma":[0.00039636754,0.00010591162,0.000043436965,0.0007043545,0.00008597431,0.00007241598,0.000030865434,0.00020959521,0.00001305276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35798293,0.08241796,0.032369625,0.0009890334,0.0023287777,0.0010808443,0.013446727,0.00048769137,0.035293456,0.00068653777,0.13488854,0.33802786],"study_design_scores_gemma":[0.49400386,0.008496741,0.046012867,0.00037113938,0.000038634127,0.000040554627,0.0002731876,0.005750567,0.43915117,0.000011136713,0.005569013,0.00028113127],"about_ca_topic_score_codex":0.00072001474,"about_ca_topic_score_gemma":0.0003823726,"teacher_disagreement_score":0.4038577,"about_ca_system_score_codex":0.0025954663,"about_ca_system_score_gemma":0.0036966167,"threshold_uncertainty_score":0.6787054},"labels":[],"label_agreement":null},{"id":"W3214721421","doi":"10.1182/blood-2021-146432","title":"Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with <i>TP53</i> alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tyrosine-kinase inhibitor; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Tyrosine kinase; Leukemia; Oncology; Internal medicine; Cancer research; Cancer","score_opus":0.012037388453728903,"score_gpt":0.2399911795046364,"score_spread":0.2279537910509075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214721421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99665415,0.00059051695,0.001095786,0.000089443456,0.000025333127,0.0009315143,0.00013999223,0.00011753905,0.00035571578],"genre_scores_gemma":[0.99715525,0.00007954465,0.00078519195,0.00011984592,0.000117782234,0.00010120556,0.0013789745,0.00006952268,0.00019270022],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970111,0.00008622025,0.00046502645,0.00077226496,0.0011431922,0.00052218145],"domain_scores_gemma":[0.99695086,0.000098231736,0.0002693608,0.00097295793,0.0014606587,0.00024792476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012351302,0.00041716447,0.000885382,0.00047864934,0.00021097698,0.000057732064,0.00012902524,0.00014934392,0.00013439456],"category_scores_gemma":[0.000085003936,0.00028191024,0.00016497477,0.0037936885,0.00042702098,0.00018759274,0.000035609864,0.00022549658,0.0000056754575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.023588115,0.016132984,0.7439876,0.0011755428,0.021756545,0.0039672125,0.001018551,0.15119895,0.03467072,0.0002793973,0.00015508689,0.0020692935],"study_design_scores_gemma":[0.25975516,0.0127906585,0.1448021,0.0013684521,0.009346701,0.00013269356,0.000045206198,0.037001148,0.5336928,0.000003998741,0.00030541926,0.000755708],"about_ca_topic_score_codex":0.001389862,"about_ca_topic_score_gemma":0.0037997998,"teacher_disagreement_score":0.59918547,"about_ca_system_score_codex":0.033798676,"about_ca_system_score_gemma":0.027714357,"threshold_uncertainty_score":0.9999633},"labels":[],"label_agreement":null},{"id":"W3215258031","doi":"10.3390/curroncol28060408","title":"Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; AstraZeneca (Canada); Sunnybrook Health Science Centre","funders":"AstraZeneca; Government of Ontario; Institute for Clinical Evaluative Sciences; Cancer Care Ontario; Canadian Institutes of Health Research; AstraZeneca Canada","keywords":"Chemoimmunotherapy; Medicine; Obinutuzumab; Fludarabine; Chlorambucil; Chronic lymphocytic leukemia; Ibrutinib; Cancer registry; Alemtuzumab; Rituximab; Internal medicine; Cyclophosphamide; Population; Cohort; Oncology; Retrospective cohort study; Bendamustine; Cancer; Family medicine; Leukemia; Chemotherapy; Lymphoma; Environmental health; Transplantation","score_opus":0.4472185385922062,"score_gpt":0.49729923019641376,"score_spread":0.05008069160420753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215258031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996265,0.0010571701,0.0000182978,0.000083843806,0.00037318523,0.0005605352,0.000029743416,0.000022960687,0.0015892478],"genre_scores_gemma":[0.9971121,0.0010248238,0.00031587353,0.00004326971,0.0001212541,0.00005844014,0.00032379795,0.000028119939,0.00097231026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734235,0.00024296249,0.0006099048,0.00086659036,0.00028611856,0.00065208453],"domain_scores_gemma":[0.998119,0.0006054805,0.00011924299,0.0008802476,0.000059749287,0.00021631036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037390512,0.0002894656,0.0008995385,0.00032904246,0.000046942827,0.000028424605,0.00019938323,0.00015003444,0.0002702357],"category_scores_gemma":[0.00018534542,0.000257546,0.000044500102,0.00033803907,0.00015463374,0.00013862949,0.00049382297,0.000433126,0.000012212913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00022318227,0.00034062754,0.96648896,0.00021793765,0.00011531311,0.004741807,0.002077702,0.00009754329,0.00031686813,0.0000615906,0.000037504065,0.025280952],"study_design_scores_gemma":[0.057501107,0.0018183405,0.8643246,0.0010388924,0.00021851384,0.00090520567,0.0013087627,0.06175874,0.00070858304,0.00004387824,0.009950183,0.0004231445],"about_ca_topic_score_codex":0.27570432,"about_ca_topic_score_gemma":0.91636217,"teacher_disagreement_score":0.64065784,"about_ca_system_score_codex":0.4714453,"about_ca_system_score_gemma":0.17619482,"threshold_uncertainty_score":0.99998766},"labels":[],"label_agreement":null},{"id":"W3215272198","doi":"10.1016/j.hemonc.2021.09.008","title":"Outcomes of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Tertiary Care Center","year":2021,"lang":"en","type":"article","venue":"Hematology/Oncology and Stem Cell Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Hematopoietic stem cell transplantation; Chronic lymphocytic leukemia; Transplantation; Stem cell; Single Center; Total body irradiation; Surgery; Leukemia; Gastroenterology; Oncology; Chemotherapy; Confidence interval; Cyclophosphamide","score_opus":0.011302720513925961,"score_gpt":0.2569414265498929,"score_spread":0.2456387060359669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215272198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796704,0.01786859,0.000045547185,0.00012286844,0.00020125235,0.000968593,0.00021844811,0.0000590813,0.0008452235],"genre_scores_gemma":[0.9931786,0.0046527325,0.00022254273,0.0006844508,0.000045329747,0.00021173396,0.00040611657,0.00006420915,0.00053428],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967512,0.00041060755,0.0008822642,0.0008797438,0.0004306871,0.000645504],"domain_scores_gemma":[0.997433,0.000954034,0.00029826205,0.0007536062,0.0003016438,0.00025947584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015899549,0.0004586107,0.0012482922,0.0001438882,0.00011078051,0.000015644557,0.00019846212,0.0005758883,0.00017420333],"category_scores_gemma":[0.000005302898,0.0003422464,0.00019344655,0.00020855365,0.00048571045,0.000085893844,0.00007736016,0.00032595664,0.00003650311],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0253236,0.0015178769,0.8866079,0.0050646025,0.0014380877,0.018913334,0.04752889,0.00011161873,0.00314285,0.000048668688,0.0005367795,0.0097657805],"study_design_scores_gemma":[0.375547,0.004959918,0.29326037,0.0012376538,0.00096971355,0.0027490945,0.009279674,0.0005470971,0.3057549,0.00004870231,0.004285856,0.0013600393],"about_ca_topic_score_codex":0.00017912443,"about_ca_topic_score_gemma":0.00037075166,"teacher_disagreement_score":0.59334755,"about_ca_system_score_codex":0.008075291,"about_ca_system_score_gemma":0.010719792,"threshold_uncertainty_score":0.99990296},"labels":[],"label_agreement":null},{"id":"W3215874969","doi":"10.1182/blood-2021-146610","title":"New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Pharmacology; Medicine; Pharmacokinetics; Tolerability; Adverse effect","score_opus":0.013132787101375125,"score_gpt":0.2782734632806179,"score_spread":0.2651406761792428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215874969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971657,0.000075382006,0.00007410364,0.00029384837,0.000025267098,0.0015261112,0.000003972176,0.00003373279,0.00080191554],"genre_scores_gemma":[0.9970671,0.000017304163,0.001761263,0.00008856597,0.00010572957,0.00007204753,0.00012598242,0.000028118082,0.00073388166],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984007,0.000041715997,0.00029667115,0.00037964125,0.00051443407,0.00036687587],"domain_scores_gemma":[0.9992432,0.00005013211,0.000061317674,0.00024253107,0.0001620185,0.0002408194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019762288,0.0001561573,0.0002472692,0.00013472572,0.00007176717,0.000080431455,0.000048949772,0.00011441112,0.0000434533],"category_scores_gemma":[0.00021459397,0.00013370288,0.000023336052,0.0004162476,0.00002477945,0.00019728637,0.00005198589,0.00015151799,0.000013857689],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072770594,0.005152711,0.8605593,0.0041411323,0.00044878694,0.0015566242,0.008055981,0.00035947558,0.08174469,0.00082708435,0.0012871107,0.028590078],"study_design_scores_gemma":[0.07093212,0.0014885399,0.06663177,0.0009669788,0.000108381246,0.00012657068,0.00031702616,0.00096005586,0.8562542,0.00009119336,0.0018129455,0.0003101746],"about_ca_topic_score_codex":0.00054596085,"about_ca_topic_score_gemma":0.00033655207,"teacher_disagreement_score":0.7939275,"about_ca_system_score_codex":0.0016322208,"about_ca_system_score_gemma":0.005364014,"threshold_uncertainty_score":0.951553},"labels":[],"label_agreement":null},{"id":"W3217726622","doi":"10.1182/blood-2021-153719","title":"Risk of Major Bleeding with Ibrutinib in Patients with Thrombocytopenia - a Retrospective Single-Center Canadian Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Victoria Hospital; Western University; London Health Sciences Centre; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Ibrutinib; Single Center; Retrospective cohort study; Univariate analysis; Internal medicine; Adverse effect; Population; Surgery; Multivariate analysis; Chronic lymphocytic leukemia; Leukemia","score_opus":0.010821093530594674,"score_gpt":0.23892522704136193,"score_spread":0.22810413351076725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217726622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484867,0.000038039943,0.000001348916,0.000045911413,0.000025890065,0.0010455509,0.00004692155,0.00001410621,0.0039335615],"genre_scores_gemma":[0.99929684,0.0000029453781,0.0003869458,0.000036258363,0.000035993493,0.00002666943,0.00002587502,0.000037085338,0.00015138743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981585,0.00007914782,0.0002518874,0.00041343144,0.0006365843,0.00046042353],"domain_scores_gemma":[0.99877274,0.000050662748,0.00009414634,0.0004433557,0.00039340043,0.00024570266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020027168,0.00016427414,0.0004706731,0.00019117662,0.000058773712,0.000024921897,0.00010740586,0.00006367638,0.00014766163],"category_scores_gemma":[0.00018459157,0.00012132903,0.00003374113,0.00069031765,0.000088892535,0.00008021575,0.00006810596,0.00028129658,0.000009340953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052041654,0.0046250722,0.99198496,0.000047491336,0.00048252364,0.0008170929,0.001319143,0.0000016359893,0.00009179666,0.000008163708,0.000028035904,0.00007365785],"study_design_scores_gemma":[0.11564433,0.0028451697,0.8769513,0.00031514792,0.000334268,0.000074213014,0.0010564023,0.000018877774,0.0025906945,0.000004858264,0.000021993685,0.00014277412],"about_ca_topic_score_codex":0.0671389,"about_ca_topic_score_gemma":0.29855353,"teacher_disagreement_score":0.23141463,"about_ca_system_score_codex":0.004740118,"about_ca_system_score_gemma":0.005442405,"threshold_uncertainty_score":0.9990805},"labels":[],"label_agreement":null},{"id":"W4200118158","doi":"10.3390/curroncol28060430","title":"CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"CD5; Bone marrow; Lymphoproliferative disorders; Marginal zone; Red pulp; Medicine; Spleen; Pathology; B cell; Lymphoplasmacytic Lymphoma; Lymphoma; White pulp; Splenic marginal zone lymphoma; Leukemia; Immunology; Waldenstrom macroglobulinemia; Antibody","score_opus":0.12627742535941897,"score_gpt":0.45488691976870027,"score_spread":0.32860949440928133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200118158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030153335,0.9859815,0.000027839476,0.0003304063,0.0019604785,0.0039527495,0.00020352223,0.00004135541,0.007200569],"genre_scores_gemma":[0.0004206391,0.995986,0.0001873812,0.00006740807,0.0005791141,0.00063859456,0.00019878754,0.0001220862,0.0018000272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993801,0.0017975788,0.0014160506,0.0010896457,0.0009919886,0.00090376684],"domain_scores_gemma":[0.9937666,0.0029317364,0.0010963033,0.001361717,0.0005072683,0.000336371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005759624,0.0008373641,0.0042783087,0.00033404122,0.00016734151,0.000024027608,0.0009180704,0.0008065004,0.0005085605],"category_scores_gemma":[0.0019089337,0.0005319906,0.0016017031,0.0014668048,0.0013733546,0.000069119546,0.0009799463,0.0017508401,0.00014502877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009110406,0.0025283175,0.000057563833,0.042217538,0.0010034264,0.00010207231,0.0014622476,0.0000028643028,0.0000032028784,0.00042296993,0.014308125,0.9378006],"study_design_scores_gemma":[0.011245929,0.00054592063,0.000010715644,0.018175736,0.0018531717,0.00025222474,0.00031307535,0.0001466648,0.00016345063,0.000189593,0.966657,0.0004465606],"about_ca_topic_score_codex":0.00018066494,"about_ca_topic_score_gemma":0.00016470687,"teacher_disagreement_score":0.9523488,"about_ca_system_score_codex":0.023708645,"about_ca_system_score_gemma":0.055982288,"threshold_uncertainty_score":0.9997132},"labels":[],"label_agreement":null},{"id":"W4200388098","doi":"10.3390/curroncol29010011","title":"Introduction to a Special Issue on Low-Grade B Cell Lymphoma in the Spleen","year":2021,"lang":"en","type":"editorial","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Splenectomy; Spleen; Lymphoma; NODAL; Lymphoproliferative disorders; Lymphatic system; Pathology; Immunology; Internal medicine","score_opus":0.04135894751605451,"score_gpt":0.4031755482397304,"score_spread":0.3618166007236759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200388098","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052843424,0.00095752993,0.0000048644943,0.010588222,0.9718531,0.0015403099,0.00006254694,0.000036896367,0.009672231],"genre_scores_gemma":[0.00026726644,0.00094347604,0.00004337057,0.00026234172,0.99306345,0.00027595012,0.0011545172,0.000068393965,0.0039212476],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99502033,0.0006638306,0.0006541597,0.0011272553,0.0016945861,0.0008398543],"domain_scores_gemma":[0.9965226,0.0015530064,0.00017955055,0.0011463084,0.00034093062,0.00025757568],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011282262,0.0004485743,0.0010472378,0.0004962098,0.00008186132,0.000056632478,0.00064037263,0.0010992358,0.0013729141],"category_scores_gemma":[0.0029604833,0.0003418566,0.00022488079,0.0008052686,0.00016542448,0.000036020567,0.00029240942,0.0018571954,0.0017446432],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008999658,0.0023487266,0.000003449058,0.00056822126,0.000034254845,0.00081352127,0.0013466984,0.000008112828,0.00002955823,0.000022366405,0.9372895,0.056635633],"study_design_scores_gemma":[0.01793736,0.0018480623,0.000024293284,0.00033324552,0.00011665569,0.00007391665,0.00036161265,0.00006058886,0.00022933606,0.000020074294,0.9787225,0.0002723624],"about_ca_topic_score_codex":0.0002104751,"about_ca_topic_score_gemma":0.00029269734,"teacher_disagreement_score":0.05636327,"about_ca_system_score_codex":0.042403195,"about_ca_system_score_gemma":0.024113962,"threshold_uncertainty_score":0.9999033},"labels":[],"label_agreement":null},{"id":"W4200480616","doi":"10.1158/2159-8290.cd-21-1225","title":"Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Chromatin; Mitochondrial DNA; DNA; DNA sequencing; Mutation; Somatic evolution in cancer; Deep sequencing; Selection (genetic algorithm)","score_opus":0.025119585892793134,"score_gpt":0.34463645752800776,"score_spread":0.31951687163521464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200480616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141777,0.0016112207,0.0022101756,0.0018857473,0.0008989381,0.00030451285,0.000050724422,0.000024609768,0.001596328],"genre_scores_gemma":[0.9925714,0.000057446614,0.0005643756,0.0004781244,0.00094816496,0.00014093898,0.00009893955,0.000023539254,0.0051170588],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986373,0.000045843473,0.00022478323,0.00035849647,0.00039254842,0.00034103935],"domain_scores_gemma":[0.99933153,0.000083502506,0.000029345842,0.00029015334,0.00012021579,0.00014525533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007410555,0.00010552753,0.00020913077,0.0001277961,0.000057871348,0.00007141201,0.00007300526,0.00007363402,0.00025501242],"category_scores_gemma":[0.00027363692,0.000103766484,0.00007489237,0.0006047114,0.000051941435,0.00029596427,0.00009051659,0.00018953269,0.00007353807],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076889414,0.0022598896,0.12113991,0.0026744143,0.0007762251,0.008601764,0.009867491,0.06315018,0.65238106,0.018558117,0.07026847,0.04263357],"study_design_scores_gemma":[0.12573402,0.00067718374,0.53023976,0.008060137,0.00064990943,0.001412613,0.007186188,0.056385096,0.19279544,0.0052936273,0.06923212,0.0023339193],"about_ca_topic_score_codex":0.001440754,"about_ca_topic_score_gemma":0.002200296,"teacher_disagreement_score":0.4595856,"about_ca_system_score_codex":0.017072234,"about_ca_system_score_gemma":0.016853632,"threshold_uncertainty_score":0.9887199},"labels":[],"label_agreement":null},{"id":"W4200594151","doi":"10.1158/1535-7163.targ-21-p251","title":"Abstract P251: Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paraza Pharma (Canada)","funders":"","keywords":"Allosteric regulation; PI3K/AKT/mTOR pathway; Mutant; Gene isoform; Kinase; Protein kinase B; P110α; Protein kinase domain; Small molecule; Chemistry; Phosphoinositide 3-kinase; Pharmacology; Biochemistry; Biology; Phosphorylation; Enzyme; Signal transduction; Gene","score_opus":0.01830301609038135,"score_gpt":0.28625230891469156,"score_spread":0.2679492928243102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200594151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428415,0.0034861153,0.00036730364,0.0012188917,0.00006495824,0.0003304279,0.00004356685,0.00000765322,0.00019692851],"genre_scores_gemma":[0.995927,0.0030647304,0.00004325411,0.0007512737,0.00005317104,0.00002251384,0.000021045795,0.000028625756,0.0000884327],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989504,0.000032940003,0.00026263978,0.0002266525,0.0003289133,0.00019842183],"domain_scores_gemma":[0.9992531,0.000067952904,0.00013367043,0.00028660902,0.00021002942,0.000048634483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011410661,0.00013769537,0.00027975216,0.000046178295,0.00005117825,0.000028035762,0.0000694632,0.000087999215,0.000020516018],"category_scores_gemma":[0.000019426232,0.00010110224,0.00005872191,0.00023435276,0.00023823912,0.000093025184,0.00009076457,0.00014812416,4.606558e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029513787,0.00008601677,0.0020429443,0.00041445464,0.0003443586,0.000051687774,0.0011253465,0.0000052154255,0.9877458,0.00009768742,0.000004856612,0.0077864714],"study_design_scores_gemma":[0.0038504675,0.00019733877,0.04898389,0.00027230603,0.00021031935,0.00009268783,0.0001638187,0.0010302782,0.9431531,0.00008130939,0.0018411295,0.00012338728],"about_ca_topic_score_codex":0.0001550422,"about_ca_topic_score_gemma":0.000053003227,"teacher_disagreement_score":0.046940945,"about_ca_system_score_codex":0.00062737544,"about_ca_system_score_gemma":0.001451195,"threshold_uncertainty_score":0.41228297},"labels":[],"label_agreement":null},{"id":"W4205825534","doi":"10.1038/s41375-021-01485-x","title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"AstraZeneca","keywords":"Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Ibrutinib; Internal medicine; Bruton's tyrosine kinase; Oncology; Clinical endpoint; Leukemia; Clinical trial; Chemotherapy; Tyrosine kinase; Cyclophosphamide","score_opus":0.04697134715739797,"score_gpt":0.3070144821862215,"score_spread":0.26004313502882354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205825534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863912,0.0008261295,0.0000020625805,0.0012732219,0.00076410815,0.008485844,0.000080009195,0.0001586317,0.0020188214],"genre_scores_gemma":[0.9852361,0.0004349711,0.0000658186,0.003207384,0.0009027328,0.0010636536,0.0003404806,0.0004083946,0.008340461],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9899402,0.0008650591,0.0019836295,0.0022953674,0.0027251292,0.0021905599],"domain_scores_gemma":[0.9940449,0.0016321139,0.00081846735,0.0029992033,0.00018562928,0.0003197145],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009653304,0.0015938982,0.003763272,0.0009630586,0.0003393888,0.00012858344,0.0014091044,0.0011368614,0.0005323],"category_scores_gemma":[0.00047453312,0.0010732386,0.00039451604,0.0025429267,0.0008602855,0.00020910313,0.0012703065,0.0045212395,0.000043766515],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.69547105,0.0010107533,0.036389515,0.011579299,0.010569213,0.044250645,0.04320714,0.085892476,0.00034605633,0.00011506915,0.063952155,0.007216627],"study_design_scores_gemma":[0.82698697,0.01707989,0.005915364,0.0039801635,0.0020861337,0.0012753806,0.004245053,0.08680954,0.0003050274,0.000010897343,0.049221855,0.002083711],"about_ca_topic_score_codex":0.056718696,"about_ca_topic_score_gemma":0.022279173,"teacher_disagreement_score":0.49195614,"about_ca_system_score_codex":0.76474977,"about_ca_system_score_gemma":0.27279362,"threshold_uncertainty_score":0.9996809},"labels":[],"label_agreement":null},{"id":"W4205969691","doi":"10.3324/haematol.2021.279012","title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab &lt;i&gt;versus&lt;/i&gt; chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"Cilag; Juno Therapeutics; Kite Pharma; Cancer Research UK; Genentech; Horizon Therapeutics; Pfizer; Moderna; Incyte; Pharmacyclics; Agios Pharmaceuticals; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; Teva Pharmaceutical Industries; AstraZeneca; Barts Charity; Exelixis; Karyopharm Therapeutics; Unum Therapeutics; Daiichi Sankyo Europe; Calithera Biosciences; Gilead Sciences; MorphoSys; Celgene; TG Therapeutics; Amgen; GlaxoSmithKline","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hazard ratio; Leukemia; Chemotherapy; Confidence interval; Cyclophosphamide","score_opus":0.04504888166279691,"score_gpt":0.308024079257522,"score_spread":0.2629751975947251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205969691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855472,0.00443143,0.00025189653,0.00018362944,0.00055225176,0.006088244,0.00023807524,0.00015603684,0.002551278],"genre_scores_gemma":[0.992657,0.0011562292,0.00018381735,0.00006653169,0.00017808813,0.0017353637,0.00029452503,0.000083216524,0.0036452159],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99196225,0.000902639,0.0021495232,0.0012676268,0.0024517833,0.0012661822],"domain_scores_gemma":[0.99294424,0.0023682667,0.0015222097,0.002360838,0.0004223564,0.00038209994],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014770685,0.00087838137,0.005260473,0.00080246374,0.0006956901,0.000040380306,0.001053033,0.0003286028,0.002888191],"category_scores_gemma":[0.00078931206,0.0005305194,0.0020805139,0.0034977014,0.0021787824,0.000113604605,0.0006725813,0.0004292452,0.000025454707],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.81769836,0.00045146124,0.0000020296407,0.0003904195,0.0072460435,0.0013246214,0.0017977327,0.167874,0.00032906613,0.0015850471,0.00059380423,0.00070743234],"study_design_scores_gemma":[0.5896574,0.008300942,0.0000042704773,0.00010578625,0.006997587,0.00056482526,0.00021636514,0.38808778,0.001565447,0.000030185322,0.004134812,0.00033458596],"about_ca_topic_score_codex":0.0025352826,"about_ca_topic_score_gemma":0.0010639651,"teacher_disagreement_score":0.22804093,"about_ca_system_score_codex":0.33171478,"about_ca_system_score_gemma":0.11571017,"threshold_uncertainty_score":0.9997146},"labels":[],"label_agreement":null},{"id":"W4206167951","doi":"10.2217/nmt-2021-0041","title":"Side Effects That Occurred Early in People With Multiple Sclerosis During the First Year of Treatment With Cladribine Tablets: A Plain Language Summary","year":2022,"lang":"en","type":"letter","venue":"Neurodegenerative Disease Management","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Cladribine; Medicine; Placebo; Multiple sclerosis; Side effect (computer science); Dosing; Internal medicine; Alternative medicine; Psychiatry; Pathology","score_opus":0.016150902755551755,"score_gpt":0.2300972813157672,"score_spread":0.21394637856021545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206167951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680486,0.0011159938,0.000019934514,0.022743972,0.00011227271,0.0064639836,0.0005927076,0.00008263823,0.0008199348],"genre_scores_gemma":[0.95863587,0.00067491183,0.0001301772,0.02707454,0.0004665899,0.004618664,0.0014007237,0.00026487582,0.006733623],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9961307,0.00036694747,0.0003548443,0.0010639868,0.0013258185,0.0007577253],"domain_scores_gemma":[0.99780923,0.00037715302,0.00022396035,0.0013505523,0.0000617975,0.00017732964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001392987,0.0006557889,0.00080670905,0.000429805,0.00023135217,0.00007229705,0.00039770888,0.00009890992,0.00012989325],"category_scores_gemma":[0.00003324978,0.00040731567,0.00019414003,0.00070222805,0.00018917175,0.000090498885,0.00042612068,0.000788151,0.00001204077],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06508616,0.006120489,0.26894084,0.046822254,0.0109562455,0.17559803,0.015906494,0.022521377,0.0014340905,0.00009378581,0.3838778,0.0026424436],"study_design_scores_gemma":[0.20471908,0.014167338,0.5906793,0.008780238,0.0060406574,0.00013135828,0.0030917781,0.008746485,0.008529458,0.0000062503163,0.15187334,0.0032347513],"about_ca_topic_score_codex":0.0017681491,"about_ca_topic_score_gemma":0.0015632018,"teacher_disagreement_score":0.32173845,"about_ca_system_score_codex":0.008983137,"about_ca_system_score_gemma":0.0011172753,"threshold_uncertainty_score":0.9998379},"labels":[],"label_agreement":null},{"id":"W4207010819","doi":"10.1016/j.jtct.2022.01.017","title":"Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Janssen Pharmaceuticals; National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; U.S. Public Health Service; Health Resources and Services Administration; U.S. Food and Drug Administration; Astellas Pharma; Daiichi-Sankyo; Bayer Fund; Kiadis Pharma; TG Therapeutics; Medical College of Wisconsin; Chimerix; Jazz Pharmaceuticals; Takeda Pharmaceuticals U.S.A.; AbbVie; Merck; Spectrum Pharmaceuticals; National Cancer Institute; Gilead Sciences; Karyopharm Therapeutics; Novartis; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Amgen; Falk Foundation; CareDx; Amyloidosis Foundation; Pfizer; Alexion Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Internal medicine; Hazard ratio; Transplantation; Prolymphocytic leukemia; Regimen; Cumulative incidence; Gastroenterology; Hematopoietic stem cell transplantation; Alemtuzumab; Oncology; Confidence interval; Leukemia; Surgery; Chronic lymphocytic leukemia","score_opus":0.0394564369277786,"score_gpt":0.3046050989104168,"score_spread":0.2651486619826382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207010819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282956,0.003362553,0.00089156756,0.0004005854,0.000081638675,0.0013498247,0.0007536062,0.00001654079,0.00031410626],"genre_scores_gemma":[0.99118376,0.006245491,0.00015033493,0.00022988445,0.0000339482,0.00030989313,0.0016301989,0.000028864471,0.00018762465],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976586,0.000356496,0.0005227872,0.00043835022,0.0007309223,0.0002928587],"domain_scores_gemma":[0.9987274,0.0006964366,0.000102842176,0.0002399094,0.00013923341,0.00009420927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009834758,0.0001942072,0.0004289884,0.00037714685,0.00018205942,0.000029684976,0.00021560272,0.000089361114,0.0001505469],"category_scores_gemma":[0.000008038463,0.00014892285,0.00016704267,0.00042130717,0.00016157948,0.00007517288,0.000015473155,0.00029939137,0.0000011362077],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02158687,0.0019378145,0.610819,0.00200532,0.0026430048,0.00083127967,0.06165198,0.0007167724,0.2959194,0.00022474362,0.00010999102,0.0015538656],"study_design_scores_gemma":[0.23053132,0.0021367732,0.15404926,0.0002773167,0.00275497,0.0003116893,0.007414564,0.014573349,0.58477217,0.00062927837,0.0016548485,0.0008944661],"about_ca_topic_score_codex":0.0011932492,"about_ca_topic_score_gemma":0.00012453044,"teacher_disagreement_score":0.4567697,"about_ca_system_score_codex":0.0005611634,"about_ca_system_score_gemma":0.0009958134,"threshold_uncertainty_score":0.60728973},"labels":[],"label_agreement":null},{"id":"W4207064025","doi":"10.1093/ecco-jcc/jjab232.644","title":"P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies","year":2022,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Ulcerative colitis; Maintenance therapy; Internal medicine; Post-hoc analysis; Intention-to-treat analysis; Randomized controlled trial; Placebo; Clinical trial; Surgery; Chemotherapy; Disease","score_opus":0.026054077837044616,"score_gpt":0.32141966763737806,"score_spread":0.29536558980033345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207064025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987986,0.00041126783,0.000009435376,0.00024021776,0.00004457002,0.0003829657,0.000017198425,0.0000026895386,0.0000930449],"genre_scores_gemma":[0.99906737,0.00031012547,0.00008545534,0.000034713587,0.00003129856,0.00004249176,0.0000043915165,0.000008511016,0.00041566713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998795,0.00015161431,0.00031419747,0.00014708437,0.00043346314,0.00015866464],"domain_scores_gemma":[0.9992337,0.00010382146,0.0002418751,0.00008990397,0.00026225136,0.00006839657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018243867,0.00012002985,0.0005048167,0.00027331672,0.00019894795,0.000020545529,0.000033513064,0.00002132009,0.000043213146],"category_scores_gemma":[0.000021808877,0.000064907865,0.00010613392,0.0007568945,0.00007879526,0.00008207658,0.000034496374,0.000120551646,4.6253763e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036461428,0.0014542657,0.9013191,0.00010571856,0.018822173,0.00042570697,0.019626683,0.0015436568,0.000013982209,0.000072149145,0.00014563542,0.020009536],"study_design_scores_gemma":[0.016934397,0.0115929535,0.9635338,0.00014974568,0.0017484584,0.00022259438,0.0042928616,0.0008121989,0.00017253954,0.0000127734875,0.00045838155,0.000069257905],"about_ca_topic_score_codex":0.0007662319,"about_ca_topic_score_gemma":0.0037670895,"teacher_disagreement_score":0.062214773,"about_ca_system_score_codex":0.007194446,"about_ca_system_score_gemma":0.0011341526,"threshold_uncertainty_score":0.9966168},"labels":[],"label_agreement":null},{"id":"W4210796934","doi":"10.1186/s12885-022-09256-2","title":"Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia","year":2022,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"University of Manitoba; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Obinutuzumab; Chlorambucil; Medicine; Internal medicine; Regimen; Chronic lymphocytic leukemia; Oncology; Leukemia; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.03108479141437788,"score_gpt":0.3245049609677902,"score_spread":0.2934201695534123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210796934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935295,0.0020830112,0.0009089653,0.000008441822,0.0001451635,0.0022338314,0.00059008837,0.00004559467,0.0004554263],"genre_scores_gemma":[0.99338615,0.000534483,0.0009765754,0.000012737271,0.00015237977,0.0013335698,0.00012442509,0.00007281202,0.0034068918],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99792916,0.0001955111,0.00046043622,0.00046376348,0.0005779146,0.00037320246],"domain_scores_gemma":[0.99813056,0.0006300686,0.00036088328,0.0005267086,0.00021079463,0.00014098288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050696585,0.00025158882,0.0008022093,0.00024804074,0.00017739492,0.0000078569265,0.00013418338,0.000063980355,0.0003962198],"category_scores_gemma":[0.00006901964,0.00020199266,0.00013560659,0.00038191336,0.00023234045,0.00006793327,0.00014090419,0.0001877701,0.0000019426716],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.16571693,0.000674357,0.07490958,0.011501732,0.004928016,0.000059297534,0.0025029879,0.68455756,0.046030853,0.00029807995,0.0017016436,0.0071189697],"study_design_scores_gemma":[0.23230089,0.0055183317,0.057948887,0.0020095028,0.0024314285,0.00010983567,0.00045646576,0.6662564,0.026013872,0.000113178525,0.006296982,0.0005441849],"about_ca_topic_score_codex":0.13536659,"about_ca_topic_score_gemma":0.019179687,"teacher_disagreement_score":0.15181345,"about_ca_system_score_codex":0.19971696,"about_ca_system_score_gemma":0.04790351,"threshold_uncertainty_score":0.9987177},"labels":[],"label_agreement":null},{"id":"W4210833548","doi":"10.51731/cjht.2022.253","title":"Zanubrutinib (Brukinsa)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Lymphoplasmacytic Lymphoma; Medicine; Family medicine; Waldenstrom macroglobulinemia; Political science; Lymphoma; Internal medicine; Health care","score_opus":0.04150092911836314,"score_gpt":0.31990717976881616,"score_spread":0.27840625065045305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210833548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6503365,0.15371841,0.00017345192,0.18766525,0.0020895668,0.0009931467,0.00006400983,0.0003217303,0.004637936],"genre_scores_gemma":[0.997746,0.00020642737,0.00042362104,0.0011909325,0.00002377551,0.0000110288665,0.0000030939211,0.000018468687,0.00037667013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981805,0.00007976979,0.0005244532,0.00013247054,0.00044125883,0.0006415599],"domain_scores_gemma":[0.9989672,0.00006956367,0.00028356488,0.00035027103,0.00014228231,0.00018715468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011961003,0.000098839184,0.00038042007,0.00095476775,0.0004801498,0.000017012151,0.0004442296,0.00007061631,0.0003585552],"category_scores_gemma":[0.000794983,0.00008818211,0.000098030825,0.00061679364,0.00023807718,0.000050063,0.00008166737,0.00097577745,0.000013007008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015345852,0.00007773229,0.0037821028,0.00031081133,0.00013661975,0.0041850917,0.0009162104,0.00013112038,0.00008558018,0.0039358395,0.15417409,0.83211136],"study_design_scores_gemma":[0.004129003,0.0014541274,0.0013703898,0.00009103569,0.000013059363,0.010658825,0.0065694298,0.00012687387,0.0002432956,0.0015985435,0.97364205,0.000103350794],"about_ca_topic_score_codex":0.009629705,"about_ca_topic_score_gemma":0.0010397115,"teacher_disagreement_score":0.832008,"about_ca_system_score_codex":0.021715516,"about_ca_system_score_gemma":0.07914543,"threshold_uncertainty_score":0.9969652},"labels":[],"label_agreement":null},{"id":"W4212986433","doi":"10.1111/bcp.15278","title":"Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy","year":2022,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Physiologically based pharmacokinetic modelling; Pharmacology; Fluconazole; Pharmacokinetics; CYP3A; Drug; Chemistry; Itraconazole; Adverse effect; Therapeutic drug monitoring; Medicine; Internal medicine; Cytochrome P450; Antifungal","score_opus":0.1526650105576577,"score_gpt":0.5050098290107358,"score_spread":0.3523448184530781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212986433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867463,0.0017969583,0.0006180651,0.0059410743,0.0030337952,0.0012530341,0.000072592506,0.000046484824,0.00049169565],"genre_scores_gemma":[0.9776817,0.0034667498,0.0020099964,0.013708032,0.002271569,0.00012858416,0.000053581716,0.000042222215,0.0006375466],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9918907,0.0021170126,0.0036290064,0.000560161,0.0011643871,0.0006387078],"domain_scores_gemma":[0.9907384,0.0058597503,0.0009884748,0.00021391695,0.0009640927,0.0012353644],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007609646,0.0002640041,0.001292336,0.0003052679,0.00035121464,0.00004910896,0.00049511995,0.00011363342,0.005809391],"category_scores_gemma":[0.0022293301,0.00026503686,0.00056908285,0.00060734246,0.00042386114,0.00020308017,0.00045957297,0.0033686566,0.00006225571],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021419672,0.008918985,0.0013710376,0.00023325719,0.0018432215,0.005543179,0.00022814359,0.2560952,0.002930851,0.000026821603,0.29769784,0.40369177],"study_design_scores_gemma":[0.10760482,0.0055019828,0.029325437,0.0003178174,0.0015571635,0.0066428897,0.00046531126,0.72905844,0.00022112184,0.000266411,0.11846744,0.00057116465],"about_ca_topic_score_codex":0.00009071945,"about_ca_topic_score_gemma":0.000012247089,"teacher_disagreement_score":0.47296324,"about_ca_system_score_codex":0.0017087924,"about_ca_system_score_gemma":0.0076326705,"threshold_uncertainty_score":0.9999802},"labels":[],"label_agreement":null},{"id":"W4213090277","doi":"10.17925/ohr.2021.17.2.73","title":"Bruton's Tyrosine Kinase Inhibitors for the Treatment of Waldenström's Macroglobulinaemia: A Canadian Perspective","year":2021,"lang":"en","type":"article","venue":"touchREVIEWS in Oncology & Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Canada; BeiGene","keywords":"Bruton's tyrosine kinase; Perspective (graphical); Waldenstrom macroglobulinemia; Medicine; Tyrosine kinase; Ibrutinib; Internal medicine; Computer science; Leukemia; Receptor; Lymphoma","score_opus":0.04450833492793894,"score_gpt":0.38975086359372274,"score_spread":0.3452425286657838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213090277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.645841,0.27314022,0.00012459263,0.06287692,0.0014900368,0.0068004937,0.00010718931,0.000055671127,0.009563849],"genre_scores_gemma":[0.9460554,0.045022547,0.0029372468,0.002190504,0.00043972343,0.0015922056,0.0000822653,0.00007361652,0.0016065029],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971407,0.0003548045,0.0008505953,0.00061376934,0.00019697522,0.000843136],"domain_scores_gemma":[0.9965352,0.0015348619,0.00020997383,0.00084228074,0.000569727,0.0003079913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047956014,0.00030895235,0.0017570012,0.00025514868,0.00012529013,0.000007762964,0.00023236056,0.00046492665,0.00045527384],"category_scores_gemma":[0.0011919324,0.00021310759,0.0003854926,0.0006284888,0.0006852903,0.000034003882,0.00006820115,0.00029938284,0.00006343897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0040902174,0.009501362,0.015910828,0.0039401622,0.0029524884,0.13124757,0.020722745,0.0001111205,0.0042288825,0.10420611,0.07099327,0.6320953],"study_design_scores_gemma":[0.024870249,0.0035422745,0.0006379146,0.00045513676,0.0007386765,0.021969138,0.0030343025,0.0009619744,0.017397262,0.0011544373,0.92491245,0.0003261609],"about_ca_topic_score_codex":0.07334517,"about_ca_topic_score_gemma":0.28790197,"teacher_disagreement_score":0.8539192,"about_ca_system_score_codex":0.028624011,"about_ca_system_score_gemma":0.025966184,"threshold_uncertainty_score":0.97955567},"labels":[],"label_agreement":null},{"id":"W4213300222","doi":"10.3747/co.21.1855","title":"A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events","year":2014,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; Juravinski Cancer Centre; Princess Margaret Cancer Centre; McGill University Health Centre; Ottawa Hospital","funders":"U.S. Food and Drug Administration; Lundbeck Canada; National Comprehensive Cancer Network","keywords":"Bendamustine; Medicine; Adverse effect; Intensive care medicine; Nausea; Chronic lymphocytic leukemia; Pharmacology; Internal medicine; Leukemia","score_opus":0.0574892443949074,"score_gpt":0.408878254492656,"score_spread":0.35138901009774864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213300222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825208,0.00037440864,0.000061607185,0.00610364,0.00012640472,0.0009574962,0.000006089474,0.0000030750637,0.009846475],"genre_scores_gemma":[0.9992127,0.00040951467,0.0000501906,0.00004228859,0.000039606843,0.000035288656,0.0000063259804,0.00000407451,0.00020004397],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9992616,0.00016707473,0.00016267732,0.00013083006,0.00015636638,0.00012140835],"domain_scores_gemma":[0.9993512,0.00022661845,0.00009106035,0.00016656485,0.000092093884,0.00007247583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060701463,0.00006185797,0.00016704011,0.00006124603,0.00004685202,9.142757e-7,0.00005859617,0.00003806096,0.000044692104],"category_scores_gemma":[0.00016094597,0.00003498745,0.00003198823,0.0000790294,0.00024395084,0.000013761451,0.000041743373,0.00010512132,0.0000024795886],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0099760825,0.0014409606,0.0057482207,0.002235218,0.00091119687,0.00004991791,0.008333367,0.000025644784,0.00020921083,0.79790395,0.0027447334,0.1704215],"study_design_scores_gemma":[0.29025048,0.02953408,0.36593977,0.0057242992,0.0037671358,0.0009950524,0.045384914,0.07834986,0.0034004324,0.056810487,0.11896727,0.0008762468],"about_ca_topic_score_codex":0.0038673356,"about_ca_topic_score_gemma":0.0086746635,"teacher_disagreement_score":0.74109346,"about_ca_system_score_codex":0.0024133443,"about_ca_system_score_gemma":0.0013307565,"threshold_uncertainty_score":0.63108116},"labels":[],"label_agreement":null},{"id":"W4214662486","doi":"10.14740/jh942","title":"Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Mantle cell lymphoma; Hairy cell leukemia; CD5; Immunophenotyping; Bone marrow; Population; Pathology; CD20; Medicine; Splenic marginal zone lymphoma; Gene rearrangement; Lymphoma; B cell; Cancer research; Leukemia; Molecular biology; Biology; Immunology; Antigen; Genetics; Antibody","score_opus":0.016686380822101103,"score_gpt":0.28520260456573504,"score_spread":0.26851622374363393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214662486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932101,0.003483842,0.00073116674,0.00017786826,0.0005207095,0.00038880936,0.000025348349,0.000015999532,0.0014461724],"genre_scores_gemma":[0.99816227,0.00021291916,0.00081924885,0.00015238997,0.0001460213,0.000014913358,0.00003508983,0.000047018548,0.00041015315],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99683625,0.00034810038,0.0011068166,0.0003412259,0.0008920241,0.00047559018],"domain_scores_gemma":[0.9977007,0.00033924152,0.0008897987,0.00038894618,0.00032509462,0.0003562256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064214965,0.00025525983,0.0009552874,0.00046209843,0.0001721716,0.000022602022,0.0003738055,0.00015200218,0.0003771498],"category_scores_gemma":[0.000052495307,0.00023305613,0.00019667426,0.00028924245,0.00025106422,0.00021288866,0.0003191157,0.0003292363,0.000009666101],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024371121,0.016397351,0.04866945,0.014142906,0.0021261256,0.07026505,0.021626703,0.0043307776,0.63499403,0.0034303067,0.06463297,0.09501324],"study_design_scores_gemma":[0.24845403,0.009991241,0.027295358,0.000551638,0.0012514956,0.25805593,0.008638035,0.16774048,0.26862752,0.00072128314,0.007591292,0.0010816907],"about_ca_topic_score_codex":0.0003007931,"about_ca_topic_score_gemma":0.000010052834,"teacher_disagreement_score":0.3663665,"about_ca_system_score_codex":0.00625027,"about_ca_system_score_gemma":0.0082655605,"threshold_uncertainty_score":0.99756455},"labels":[],"label_agreement":null},{"id":"W4214663833","doi":"10.1182/blood.v126.23.4163.4163","title":"An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Dexamethasone; Internal medicine; Multiple myeloma; Regimen; Gastroenterology; Tumor lysis syndrome; Thalidomide; Surgery; Oncology; Chemotherapy","score_opus":0.021142130278443975,"score_gpt":0.3059574708397,"score_spread":0.284815340561256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214663833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963865,0.00021052508,0.000018199242,0.000007575459,0.00001912016,0.003177994,0.0000043293894,0.000059478698,0.00011627055],"genre_scores_gemma":[0.9992515,0.00001054161,0.00031989635,0.000018150162,0.000022827853,0.00019227286,0.000080231555,0.00006492738,0.000039689006],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967104,0.0003435225,0.000643561,0.0005236947,0.0011964078,0.0005823754],"domain_scores_gemma":[0.9982044,0.00013967982,0.00022351992,0.00076054555,0.00034874046,0.0003231296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079711253,0.0003118509,0.00079370814,0.0005345393,0.000027020824,0.000029802475,0.00026197723,0.00011752783,0.000019631576],"category_scores_gemma":[0.00020191535,0.00022845261,0.000029572988,0.0011771102,0.00014770924,0.00029030212,0.00006267809,0.00024002093,0.0000118321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015460961,0.047615286,0.9071306,0.0012458464,0.00069323747,0.0018799149,0.0125773195,0.006379873,0.00037500256,0.00002561698,0.00003099229,0.006585372],"study_design_scores_gemma":[0.85172796,0.040614724,0.064161725,0.0012713242,0.0005592403,0.00016815629,0.001391825,0.03718581,0.0025255245,0.000023787039,0.000004184106,0.00036575057],"about_ca_topic_score_codex":0.011628598,"about_ca_topic_score_gemma":0.006667647,"teacher_disagreement_score":0.8429688,"about_ca_system_score_codex":0.043654926,"about_ca_system_score_gemma":0.021422734,"threshold_uncertainty_score":0.99495304},"labels":[],"label_agreement":null},{"id":"W4214695390","doi":"10.3390/curroncol29030122","title":"Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Venetoclax; Ibrutinib; Myelofibrosis; Chronic lymphocytic leukemia; Cancer; Targeted therapy; Disease; Oncology; Leukemia; Intensive care medicine; Internal medicine; Bone marrow","score_opus":0.09025125860480127,"score_gpt":0.41132796577398134,"score_spread":0.3210767071691801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214695390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98142534,0.0145683745,0.0001386564,0.00008155325,0.0012377212,0.0018490395,0.00006911578,0.00012641723,0.0005037672],"genre_scores_gemma":[0.9962324,0.00060714845,0.00038635152,0.000109221284,0.0006177364,0.001332136,0.0002713791,0.00007334876,0.00037029217],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99678683,0.00018619835,0.00086621346,0.0006813191,0.0006793127,0.0008001105],"domain_scores_gemma":[0.997739,0.0006360577,0.0004304228,0.00072680885,0.00024780008,0.00021988431],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007879498,0.00028360292,0.0008926579,0.00036001598,0.0003181695,0.000009950934,0.00032262443,0.00010819614,0.00045193802],"category_scores_gemma":[0.00037652472,0.00027554622,0.00034081237,0.00052040763,0.0002528205,0.0000779003,0.00048215417,0.0004693606,0.000008402489],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034892045,0.004748949,0.031953394,0.01993969,0.0030434313,0.025663782,0.006027602,0.017646145,0.49228588,0.0010538666,0.041197404,0.3215478],"study_design_scores_gemma":[0.29333913,0.019617723,0.007604766,0.00065934006,0.0007967247,0.06979701,0.0009808952,0.05386224,0.103562385,0.00042190377,0.44782978,0.0015280735],"about_ca_topic_score_codex":0.00041554667,"about_ca_topic_score_gemma":0.00002110491,"teacher_disagreement_score":0.4066324,"about_ca_system_score_codex":0.22542919,"about_ca_system_score_gemma":0.07312718,"threshold_uncertainty_score":0.99996966},"labels":[],"label_agreement":null},{"id":"W4214748721","doi":"10.14740/jmc3846","title":"Lymphoepithelioma-Like Gastric Carcinoma and Gastric Involvement of Chronic Lymphocytic Leukemia: Two Rare Identities Coexisting in One Patient","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Esophagogastroduodenoscopy; Stomach; Gastroenterology; Chronic lymphocytic leukemia; Gastrectomy; Internal medicine; Epigastric pain; Leukemia; Pathology; Cancer; Endoscopy; Vomiting","score_opus":0.0412987886714178,"score_gpt":0.3041428254416482,"score_spread":0.26284403677023044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214748721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815668,0.017120466,0.00004063681,0.00034079837,0.00041717495,0.00034096363,0.000024700581,0.000012683133,0.0001358104],"genre_scores_gemma":[0.99771965,0.0010852799,0.00018645762,0.0003548914,0.00038386855,0.00002918597,0.0000111905,0.00003603245,0.00019343787],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9930508,0.0003453094,0.001497029,0.00029964285,0.0042039617,0.0006032711],"domain_scores_gemma":[0.9973251,0.00079116167,0.00069131603,0.00030562226,0.00027724242,0.0006095198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019470887,0.00024567082,0.0008911447,0.0011284328,0.00014278147,0.000028148714,0.00038745772,0.000106618296,0.0012900457],"category_scores_gemma":[0.001380495,0.00021543681,0.00019623994,0.0010775613,0.00036028196,0.00013644464,0.0006897656,0.00076809863,0.0000029190799],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018046884,0.006627118,0.11675926,0.020237865,0.0026347039,0.47377217,0.012594425,0.014500118,0.014462167,0.0011680814,0.041824695,0.2773725],"study_design_scores_gemma":[0.30100098,0.039394464,0.027484806,0.008691959,0.0015114615,0.45219606,0.027068604,0.12522818,0.0072110095,0.0006517086,0.00808866,0.0014721163],"about_ca_topic_score_codex":0.0030058983,"about_ca_topic_score_gemma":0.00010367109,"teacher_disagreement_score":0.2829541,"about_ca_system_score_codex":0.076495856,"about_ca_system_score_gemma":0.04518714,"threshold_uncertainty_score":0.9996229},"labels":[],"label_agreement":null},{"id":"W4220853110","doi":"10.1016/j.cancergen.2021.05.071","title":"57. A rare case of near-tetraploidy in CLL: An investigation by MLPA, FISH, and chromosome analysis","year":2022,"lang":"en","type":"article","venue":"Cancer Genetics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario","funders":"","keywords":"Multiplex ligation-dependent probe amplification; Trisomy; Chronic lymphocytic leukemia; Peripheral blood; Fish <Actinopterygii>; Biology; Chromosome; Multiplex; Leukemia; Pathology; Molecular biology; Genetics; Medicine; Immunology; Gene","score_opus":0.02471415447176094,"score_gpt":0.32323832960835674,"score_spread":0.2985241751365958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220853110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954735,0.003599629,0.000011111025,0.0003044341,0.000042016654,0.00030852377,0.00021145785,0.000013759198,0.000035573896],"genre_scores_gemma":[0.99818254,0.00059321953,0.00026581917,0.0004332755,0.000046066267,0.00010296439,0.00014457296,0.00002333325,0.0002082242],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99869716,0.00010900929,0.00028470292,0.00031605523,0.00035394813,0.00023913637],"domain_scores_gemma":[0.99920946,0.00005153735,0.00008023151,0.00037496493,0.00007908799,0.00020471223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021922508,0.000111853944,0.00030757202,0.0002051182,0.00008666449,0.000017025066,0.000099705176,0.00005913885,0.0004195935],"category_scores_gemma":[0.000031939286,0.0001179496,0.00005015451,0.0012335893,0.00019354462,0.000039653994,0.000118577664,0.0002094804,5.8354294e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011097998,0.0010291984,0.7253926,0.0020713,0.002500762,0.008793846,0.03962531,0.04812495,0.08657523,0.00006041535,0.020129608,0.06458703],"study_design_scores_gemma":[0.031022402,0.002548819,0.057806298,0.00012448923,0.0020771048,0.00224571,0.0053856703,0.8358241,0.051941156,0.00020699715,0.010010338,0.0008069649],"about_ca_topic_score_codex":0.0074367747,"about_ca_topic_score_gemma":0.0041896957,"teacher_disagreement_score":0.7876991,"about_ca_system_score_codex":0.0040197284,"about_ca_system_score_gemma":0.002859016,"threshold_uncertainty_score":0.99980366},"labels":[],"label_agreement":null},{"id":"W4220876838","doi":"10.1177/2050313x221086321","title":"Hypergammaglobulinemic purpura of Waldenström—Unusual and impressive case in a patient with myeloma: A case report","year":2022,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Purpura (gastropod); Multiple myeloma; Dermatology; Immune dysregulation; Lymphoma; Rituximab; Immunology; Disease; Pathology","score_opus":0.013911244786511588,"score_gpt":0.31122320255398017,"score_spread":0.2973119577674686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220876838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938027,0.0010902557,0.000020861617,0.00044290037,0.00014595602,0.0023236028,0.000040563868,0.00002846885,0.0021046915],"genre_scores_gemma":[0.9980598,0.000029618262,0.00050977035,0.00021867876,0.00007757756,0.00049374887,0.00005677691,0.00005786726,0.0004961431],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9945471,0.00028154202,0.0015508666,0.0010066123,0.0019709975,0.0006428785],"domain_scores_gemma":[0.99668926,0.00035329504,0.00063716265,0.0011370508,0.00021138055,0.00097187265],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023547371,0.00031943654,0.0009270515,0.00026142146,0.00025854018,0.00004526803,0.00012901251,0.00017645492,0.0018189228],"category_scores_gemma":[0.002389308,0.00025105485,0.00009245111,0.0007192987,0.00047806546,0.00015170027,0.001797073,0.001001692,0.0000013496289],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008013026,0.00048909825,0.0008051603,0.0002343379,0.00011284038,0.9628776,0.0013092879,0.000015476146,0.00010274949,0.0000054391153,0.0006000121,0.032646745],"study_design_scores_gemma":[0.00920793,0.0012587178,0.000038475748,0.00031875548,0.00015210299,0.9788552,0.0058697234,0.0019921171,0.0005239867,0.000020432662,0.001502328,0.0002602182],"about_ca_topic_score_codex":0.031420782,"about_ca_topic_score_gemma":0.0031758873,"teacher_disagreement_score":0.032386526,"about_ca_system_score_codex":0.0033167119,"about_ca_system_score_gemma":0.01262656,"threshold_uncertainty_score":0.99999416},"labels":[],"label_agreement":null},{"id":"W4221097587","doi":"10.3390/curroncol29040176","title":"Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ibrutinib; Neutropenia; Internal medicine; Clinical endpoint; Gastroenterology; Adverse effect; Oncology; Cancer; Chemotherapy; Leukemia; Clinical trial; Chronic lymphocytic leukemia","score_opus":0.10776956957260282,"score_gpt":0.40491068570305133,"score_spread":0.2971411161304485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221097587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938801,0.002549909,0.000004009679,0.00037186506,0.0005827608,0.0018362004,0.00004803426,0.000009461118,0.0007176688],"genre_scores_gemma":[0.99950206,0.000010327072,0.000022841987,0.000022900977,0.00007863961,0.00015812615,0.000015398633,0.0000142968975,0.00017542344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754393,0.00057185773,0.00063903636,0.00038212715,0.000519397,0.00034366004],"domain_scores_gemma":[0.9985671,0.0004603966,0.0002540158,0.00052510976,0.00010470916,0.00008867222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009264994,0.00013679781,0.0005266768,0.00021105392,0.00007761473,0.0000029927858,0.00030362912,0.000060098213,0.00008035055],"category_scores_gemma":[0.000520191,0.00010108575,0.00007406808,0.0007497297,0.00032320624,0.000023747712,0.00075197546,0.00057316956,0.0000010539231],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012460429,0.023215942,0.6185297,0.0011871149,0.00029133176,0.000741829,0.06360891,0.0005956695,0.0012988428,0.0005191516,0.013586528,0.26396456],"study_design_scores_gemma":[0.31795326,0.02905191,0.5554017,0.00025535157,0.0005086067,0.0012662514,0.034284916,0.007926412,0.010548862,0.0004440343,0.041781723,0.0005770114],"about_ca_topic_score_codex":0.0005648572,"about_ca_topic_score_gemma":0.00010071062,"teacher_disagreement_score":0.30549282,"about_ca_system_score_codex":0.004598324,"about_ca_system_score_gemma":0.0056868014,"threshold_uncertainty_score":0.99995005},"labels":[],"label_agreement":null},{"id":"W4223947293","doi":"10.3390/curroncol29040227","title":"Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Medicine; Leukemia; Disease; Oncology; Cancer research; Internal medicine; Immunology; Receptor; Tyrosine kinase","score_opus":0.09136583425893001,"score_gpt":0.4408094434581005,"score_spread":0.3494436091991705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223947293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543065,0.00041821835,0.00015025125,0.00014814088,0.001647141,0.0014547975,0.00010587371,0.000049649214,0.0005953043],"genre_scores_gemma":[0.99844706,0.00009009438,0.00006384307,0.00019716966,0.0003505485,0.0003508873,0.000367713,0.000044641813,0.000088036526],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957996,0.00077279535,0.0012763058,0.00067596266,0.0007790063,0.0006963155],"domain_scores_gemma":[0.998077,0.00059032853,0.00025861125,0.0005787362,0.00015648911,0.00033887674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012419652,0.00024335325,0.0008796953,0.0003941334,0.00009589141,0.0000057291513,0.00035505838,0.00014280101,0.00084746664],"category_scores_gemma":[0.00042175112,0.0002452673,0.00024659152,0.0006042403,0.0001686618,0.000037401627,0.00038155407,0.0008797981,0.00007711454],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015771957,0.0051250076,0.48471773,0.0028488575,0.0003696102,0.001222067,0.0056197946,0.025433116,0.0007847779,0.00054060534,0.00971725,0.4478492],"study_design_scores_gemma":[0.34025404,0.03235381,0.30432752,0.0010714199,0.00046512543,0.0004224085,0.00080197374,0.21619828,0.0006065346,0.00026075568,0.102176234,0.00106191],"about_ca_topic_score_codex":0.0009829135,"about_ca_topic_score_gemma":0.00037514282,"teacher_disagreement_score":0.4467873,"about_ca_system_score_codex":0.2436548,"about_ca_system_score_gemma":0.05174723,"threshold_uncertainty_score":0.99999994},"labels":[],"label_agreement":null},{"id":"W4224138250","doi":"10.1182/bloodadvances.2021006434","title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia ","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Pharmacyclics","keywords":"Ibrutinib; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Hazard ratio; Adverse effect; Oncology; Confidence interval; Leukemia; Gastroenterology; Chemotherapy; Cyclophosphamide","score_opus":0.017817559125266835,"score_gpt":0.2833469322780211,"score_spread":0.26552937315275427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224138250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908908,0.0037150267,0.00012146136,0.00024169967,0.0006442418,0.0030892245,0.00067695294,0.00016647737,0.00045414342],"genre_scores_gemma":[0.98695207,0.00038185492,0.0018326889,0.0002875007,0.0004930144,0.001934256,0.00077047653,0.00012056036,0.0072275805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966828,0.00005865959,0.00044635974,0.0009150153,0.0010297964,0.0008673247],"domain_scores_gemma":[0.99797857,0.00048115608,0.00014744829,0.00080699835,0.00018511422,0.00040070858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015566716,0.0004076912,0.00065155985,0.00018359133,0.00047448854,0.000037945832,0.0003522563,0.00007427937,0.0005815467],"category_scores_gemma":[0.00019436855,0.00031913084,0.00019365591,0.0005071328,0.00009692275,0.00015105409,0.00024313253,0.0001661387,0.00008124535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.21897557,0.0076460065,0.13985278,0.004088153,0.01120686,0.002501465,0.0177683,0.09098915,0.0024048064,0.0016590919,0.032398947,0.47050887],"study_design_scores_gemma":[0.28546593,0.02341206,0.0016872716,0.0003358521,0.00086839683,0.000055003296,0.0005060699,0.0053829337,0.007415304,0.00025178373,0.6738424,0.00077701366],"about_ca_topic_score_codex":0.0015694108,"about_ca_topic_score_gemma":0.001075776,"teacher_disagreement_score":0.64144343,"about_ca_system_score_codex":0.071104184,"about_ca_system_score_gemma":0.01558298,"threshold_uncertainty_score":0.9999261},"labels":[],"label_agreement":null},{"id":"W4224239226","doi":"10.1177/13524585221091060","title":"All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Bruton's tyrosine kinase; Tyrosine kinase; Medicine; Multiple sclerosis; Internal medicine; Immunology; Receptor","score_opus":0.11141581419808595,"score_gpt":0.31920957465301625,"score_spread":0.2077937604549303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224239226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99359345,0.0023265667,0.000038114988,0.0022279962,0.00063424546,0.0005695543,0.000046621397,0.000076218384,0.00048722312],"genre_scores_gemma":[0.99498683,0.0009019303,0.0009731532,0.001216974,0.0009791807,0.00004617958,0.000030158257,0.00008279966,0.000782816],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965163,0.00027247905,0.0006126087,0.00047391918,0.0013298725,0.00079482404],"domain_scores_gemma":[0.9979223,0.0003908204,0.00021448616,0.00046038855,0.00025206883,0.00075993215],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012299903,0.00030097557,0.0004844293,0.00032557108,0.00080438657,0.00015108279,0.00028175782,0.000105435814,0.0013991393],"category_scores_gemma":[0.0010802172,0.00026983267,0.00020650555,0.00027613927,0.0002107976,0.0001715707,0.00055037206,0.0013756083,0.000089278925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012069702,0.0053105676,0.12767345,0.0005555714,0.0017512282,0.005250319,0.007314805,0.0048720883,0.44412938,0.000042389005,0.28086582,0.1101647],"study_design_scores_gemma":[0.22846027,0.004643391,0.22098279,0.001011022,0.0007298223,0.010322014,0.0023180987,0.11013272,0.03271506,0.00007625086,0.38703543,0.0015731317],"about_ca_topic_score_codex":0.00061169354,"about_ca_topic_score_gemma":0.000025135781,"teacher_disagreement_score":0.41141433,"about_ca_system_score_codex":0.008047519,"about_ca_system_score_gemma":0.0018871987,"threshold_uncertainty_score":0.9999754},"labels":[],"label_agreement":null},{"id":"W4224245023","doi":"10.1038/s41408-022-00659-9","title":"Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota","year":2022,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Mayo Clinic","keywords":"Monoclonal gammopathy of undetermined significance; Internal medicine; Medicine; Hazard ratio; Gastroenterology; Macroglobulinemia; Population; Waldenstrom macroglobulinemia; Body mass index; Proportional hazards model; Univariate analysis; AL amyloidosis; Multiple myeloma; Amyloidosis; Confidence interval; Oncology; Lymphoma; Immunology; Monoclonal; Multivariate analysis; Antibody; Immunoglobulin light chain; Monoclonal antibody","score_opus":0.016868981811633883,"score_gpt":0.3038341216571848,"score_spread":0.28696513984555094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224245023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962503,0.0019737745,0.000030165638,0.000404312,0.00018359403,0.00062795717,0.00007729957,0.000026229734,0.00042638564],"genre_scores_gemma":[0.9984308,0.00029434974,0.000163829,0.00011116037,0.00018857699,0.00021169247,0.000023591298,0.000054562206,0.00052143243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961825,0.00027540507,0.00065820105,0.0003595327,0.0018842089,0.0006401518],"domain_scores_gemma":[0.9983951,0.00016112153,0.00054240035,0.00030174621,0.0003365724,0.00026305314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010702945,0.00023652508,0.00057581026,0.00034794465,0.00019243029,0.000034868495,0.00034421956,0.00010159907,0.0006556546],"category_scores_gemma":[0.00014589065,0.00019222984,0.00010694062,0.00095793593,0.00016729202,0.0001315952,0.00012652446,0.0010987347,0.0000010540298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0145532,0.0043063345,0.85234857,0.00068095874,0.0015570031,0.013584154,0.0013642055,0.004236714,0.09663174,0.000051630668,0.0028760857,0.007809427],"study_design_scores_gemma":[0.35847214,0.015159074,0.40796933,0.008562436,0.0018832545,0.016020121,0.003375228,0.10714594,0.074316464,0.00046899257,0.0045027295,0.0021243151],"about_ca_topic_score_codex":0.00049617764,"about_ca_topic_score_gemma":0.00021280487,"teacher_disagreement_score":0.44437924,"about_ca_system_score_codex":0.010131232,"about_ca_system_score_gemma":0.014916939,"threshold_uncertainty_score":0.9936687},"labels":[],"label_agreement":null},{"id":"W4224294899","doi":"10.21203/rs.3.rs-1571423/v1","title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Thrombosis; Internal medicine; Chronic lymphocytic leukemia; Multivariate analysis; Low molecular weight heparin; Retrospective cohort study; Coronavirus disease 2019 (COVID-19); Disease; Surgery; Leukemia","score_opus":0.16446804307405793,"score_gpt":0.44070835958061205,"score_spread":0.2762403165065541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224294899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98144495,0.0009533729,0.000008759374,0.000635025,0.00003355158,0.009704091,0.000103529725,0.0000505184,0.007066221],"genre_scores_gemma":[0.997469,0.00071188004,0.00003279313,0.0000872425,0.00011205761,0.0011473091,0.00015192608,0.00012475396,0.0001630531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98513997,0.0065330504,0.00075106166,0.0015132651,0.00477466,0.0012879753],"domain_scores_gemma":[0.99055886,0.005372905,0.00020895287,0.0019336023,0.0012425152,0.0006831797],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011008445,0.00042036796,0.00084000017,0.0018261789,0.0010886686,0.00018329437,0.000939198,0.00017280798,0.00015688884],"category_scores_gemma":[0.003549863,0.0002995526,0.000068239206,0.0023074334,0.0020067398,0.00009169081,0.005418392,0.0047237757,0.0000199624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01906042,0.011117162,0.65683323,0.048670843,0.0036987322,0.0039733895,0.17650054,0.05585689,0.00019731748,0.0044695493,0.008708559,0.010913355],"study_design_scores_gemma":[0.04985063,0.01545145,0.8799127,0.003510288,0.00011338182,0.000048624242,0.029955566,0.019329151,0.000016478261,0.00063604716,0.00068239326,0.0004933259],"about_ca_topic_score_codex":0.010585334,"about_ca_topic_score_gemma":0.001143796,"teacher_disagreement_score":0.22307941,"about_ca_system_score_codex":0.13349298,"about_ca_system_score_gemma":0.057010215,"threshold_uncertainty_score":0.99994564},"labels":[],"label_agreement":null},{"id":"W4224318531","doi":"10.3390/curroncol29050246","title":"Cutaneous Involvement in Diseases with Plasma Cell Differentiation: Diagnostic Approach","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Plasma cell; Computational biology; Bioinformatics; Pathology; Immunology; Biology; Multiple myeloma","score_opus":0.05682965910018145,"score_gpt":0.34093030664067214,"score_spread":0.2841006475404907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224318531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360514,0.0018313273,0.000109910245,0.00028851285,0.00045430937,0.0011295879,0.000033231354,0.000052963464,0.0024949946],"genre_scores_gemma":[0.9976749,0.00021375206,0.000100889265,0.00009307084,0.00015706623,0.0010012737,0.00037460146,0.00002722775,0.0003572634],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980584,0.00021350075,0.00028830074,0.00037738835,0.0006055735,0.00045684297],"domain_scores_gemma":[0.9987013,0.000610163,0.00009039372,0.00033537849,0.00005310753,0.000209705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012532843,0.00017055294,0.00037647004,0.00021741621,0.00011821795,0.000011205939,0.00019246012,0.00004683855,0.0006103229],"category_scores_gemma":[0.00013294326,0.00014230047,0.000059100672,0.00037381292,0.000122066725,0.000030478419,0.0003176685,0.0004965333,0.000029616169],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008803946,0.055362776,0.7526924,0.0049850363,0.00040598554,0.009752133,0.016151516,0.012348158,0.0005781882,0.0015442765,0.040746074,0.096629515],"study_design_scores_gemma":[0.20467733,0.024546083,0.041198924,0.00042204862,0.001289382,0.008012326,0.020856053,0.27730486,0.0011419848,0.00051368884,0.4182009,0.0018364054],"about_ca_topic_score_codex":0.00006759681,"about_ca_topic_score_gemma":0.00005558408,"teacher_disagreement_score":0.7114935,"about_ca_system_score_codex":0.020228487,"about_ca_system_score_gemma":0.0053342585,"threshold_uncertainty_score":0.98353267},"labels":[],"label_agreement":null},{"id":"W4224325972","doi":"10.1111/bcp.15362","title":"Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects","year":2022,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Cmax; Pharmacology; Bioavailability; Medicine; Adverse effect; Pharmacokinetics; Proton-pump inhibitor; Tolerability; Gastroenterology","score_opus":0.07034042919406505,"score_gpt":0.42703478897960173,"score_spread":0.35669435978553665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224325972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952368,0.00090833317,0.000009561028,0.0012673985,0.0006069061,0.0018969332,0.000017732513,0.000004464313,0.000051876003],"genre_scores_gemma":[0.9971487,0.0014635228,0.0001913991,0.00080087007,0.0002910018,0.00006280213,0.0000029225348,0.000014859696,0.000023946079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919941,0.0030945449,0.0029554274,0.00035337522,0.001124632,0.00047794275],"domain_scores_gemma":[0.99220216,0.005738007,0.0010782457,0.0002436689,0.00051100017,0.00022694275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010706796,0.00013499743,0.0010912346,0.00026789308,0.000062125466,0.000006103293,0.0006036398,0.00015838082,0.0009458342],"category_scores_gemma":[0.0067631095,0.00011057027,0.00024121339,0.0011908901,0.00068433647,0.00011376317,0.0003577054,0.0021821212,0.000002506005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30295435,0.036314826,0.36243808,0.005448905,0.00053977093,0.058350455,0.0028866555,0.0025975117,0.06112944,0.000024352537,0.02790264,0.139413],"study_design_scores_gemma":[0.27217454,0.052180853,0.57475704,0.0021088475,0.00031298492,0.040857367,0.0022145452,0.026061567,0.022466006,0.00037076112,0.005924053,0.000571412],"about_ca_topic_score_codex":0.0015735623,"about_ca_topic_score_gemma":0.00022403356,"teacher_disagreement_score":0.21231899,"about_ca_system_score_codex":0.0017787353,"about_ca_system_score_gemma":0.011350679,"threshold_uncertainty_score":0.99996746},"labels":[],"label_agreement":null},{"id":"W4224327104","doi":"10.1093/rheumatology/keac132.027","title":"OA27 Sustainability of response between upadacitinib and adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE trial","year":2022,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Internal medicine; Discontinuation; Placebo; Concordance; Methotrexate; Pathology","score_opus":0.01685899838297507,"score_gpt":0.2829870362960179,"score_spread":0.26612803791304285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224327104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620444,0.00049439137,0.0000052814494,0.0006669024,0.00004747795,0.0018645817,0.00059271464,0.00003050179,0.00009373015],"genre_scores_gemma":[0.9992288,0.00004492545,0.00010435227,0.000072416646,0.000062920924,0.00011324229,0.0002788924,0.000030319465,0.00006414083],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99665916,0.00086534786,0.00058092293,0.00047689967,0.0009874097,0.0004302615],"domain_scores_gemma":[0.9972612,0.0015710463,0.00016821585,0.00072581286,0.00017876115,0.00009491199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014453116,0.00017070888,0.00054721,0.00007723503,0.00014277786,0.00002438185,0.00026271594,0.0000659135,0.00007284641],"category_scores_gemma":[0.0013605367,0.0001329424,0.00006243028,0.0005398773,0.00028022085,0.00009484089,0.00031881212,0.0005119964,0.000002375794],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6860678,0.0007678561,0.2928823,0.000077219476,0.00024369976,0.000219877,0.011816089,0.00008375604,0.000018855682,0.00006111329,0.0020213705,0.0057400507],"study_design_scores_gemma":[0.34859627,0.002723145,0.6391932,0.00015436317,0.000028965464,0.000011517209,0.0021030423,0.0000916737,0.000092904,0.0004697673,0.0063533313,0.0001818581],"about_ca_topic_score_codex":0.006037347,"about_ca_topic_score_gemma":0.00031117722,"teacher_disagreement_score":0.34631085,"about_ca_system_score_codex":0.0038820384,"about_ca_system_score_gemma":0.004485039,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W4225399187","doi":"10.3390/curroncol29050264","title":"Invasive Fungal Disease in Patients with Chronic Lymphocytic Leukemia in Japan: A Retrospective Database Study","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Retrospective cohort study; Disease; Leukemia; Database; Pathology; Immunology","score_opus":0.04349342838248715,"score_gpt":0.3569470926411912,"score_spread":0.313453664258704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225399187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456215,0.0009448106,0.0000024640735,0.0000566113,0.00050773955,0.0035333727,0.000111392925,0.000046618654,0.00023482663],"genre_scores_gemma":[0.9978934,0.00005631301,0.00001242676,0.00007950622,0.00014574626,0.0013284665,0.00033600384,0.000050205254,0.00009795511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599177,0.00056613685,0.00054672925,0.0009380771,0.0011084697,0.0008488138],"domain_scores_gemma":[0.9982081,0.0002901487,0.00016248478,0.0007994802,0.00015189724,0.0003878618],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064563856,0.00030993775,0.00072566286,0.00065430644,0.0001356405,0.000013766464,0.00036883316,0.000060787435,0.00054813613],"category_scores_gemma":[0.0005454479,0.000280577,0.00006959466,0.0012592709,0.00021897914,0.00014400184,0.0008507251,0.0011188566,0.000052193747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006887554,0.0028537528,0.98125523,0.0002264338,0.000068636036,0.002268316,0.0018198251,0.0015827337,0.000009246739,0.00004928346,0.00068365096,0.0022953416],"study_design_scores_gemma":[0.12043205,0.009748469,0.85665745,0.00018942266,0.00012005966,0.000041711966,0.0010769534,0.010277732,0.000007887792,0.000029149896,0.0011127895,0.0003063179],"about_ca_topic_score_codex":0.0019533513,"about_ca_topic_score_gemma":0.0036266465,"teacher_disagreement_score":0.4131471,"about_ca_system_score_codex":0.52521694,"about_ca_system_score_gemma":0.11206986,"threshold_uncertainty_score":0.99996465},"labels":[],"label_agreement":null},{"id":"W4226046585","doi":"10.1097/01.hs9.0000829592.26407.09","title":"P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Bible College","funders":"","keywords":"Daratumumab; Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Hematology; Oncology; Family medicine","score_opus":0.03345863001137283,"score_gpt":0.2901135033741483,"score_spread":0.2566548733627755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226046585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274135,0.001948069,0.000018733357,0.00065317244,0.00022938536,0.0032470943,0.0005394015,0.000084421175,0.0005383686],"genre_scores_gemma":[0.99704075,0.00010598608,0.00064486725,0.00015825134,0.00027184654,0.0002662772,0.0006730137,0.00010694663,0.0007320878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947926,0.00090423407,0.0008539679,0.0011322732,0.001413302,0.0009036239],"domain_scores_gemma":[0.99496007,0.0032968943,0.0003251206,0.0009058618,0.00015277002,0.00035930803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013120687,0.0005341213,0.001154074,0.000116657735,0.00049137406,0.000100754005,0.00031129847,0.00018288188,0.00034393856],"category_scores_gemma":[0.0016715393,0.00038359486,0.000119989534,0.0006761613,0.00041332262,0.00020127036,0.0005289297,0.00092460506,0.000009080536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97793305,0.0013744476,0.0061557093,0.000102373226,0.00064847054,0.00067914947,0.0032591827,0.00013202212,0.0003922547,0.000026534643,0.0021867196,0.007110089],"study_design_scores_gemma":[0.97313714,0.0046360837,0.012109929,0.00017646088,0.00037647923,0.00005859091,0.0014643602,0.004464462,0.0006023224,0.000020295587,0.0024601002,0.0004937558],"about_ca_topic_score_codex":0.014195607,"about_ca_topic_score_gemma":0.0034049712,"teacher_disagreement_score":0.010790636,"about_ca_system_score_codex":0.0053980025,"about_ca_system_score_gemma":0.0020779704,"threshold_uncertainty_score":0.9998616},"labels":[],"label_agreement":null},{"id":"W4229074086","doi":"10.3390/curroncol29050252","title":"Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Dalhousie University; Nova Scotia Health Authority; Health Sciences Centre","funders":"","keywords":"Medicine; Adverse effect; Toxicity; Intensive care medicine; Immune system; Bioinformatics; Pharmacology; Immunology; Internal medicine; Biology","score_opus":0.22276319795950936,"score_gpt":0.5000795275125808,"score_spread":0.2773163295530714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229074086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96051806,0.0012226909,0.0011752425,0.005654639,0.0061320188,0.006792716,0.00011317022,0.00025596024,0.018135488],"genre_scores_gemma":[0.9324953,0.00088031264,0.00819851,0.0013887889,0.00062093907,0.0054415762,0.00048917986,0.0001113269,0.050374053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973364,0.00018166174,0.0007726744,0.000530519,0.0005557806,0.0006229684],"domain_scores_gemma":[0.9984958,0.00018461485,0.00015868714,0.0005470423,0.0003440087,0.0002698202],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001258916,0.00019411815,0.00046923116,0.00034087614,0.00022003734,0.0000030595143,0.00039564795,0.00005806335,0.0013728245],"category_scores_gemma":[0.00036439914,0.00018680411,0.00021025678,0.00066273886,0.00006083606,0.00003632706,0.0008413643,0.00033936743,0.00018642443],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044505442,0.003942369,0.004370376,0.0014146644,0.00080812955,0.000563205,0.0014262395,0.0022307425,0.0029050217,0.0071756183,0.39459878,0.5761143],"study_design_scores_gemma":[0.030750295,0.004270245,0.0033736003,0.0001949074,0.00025629075,0.00011642732,0.000886585,0.014348611,0.00053223374,0.0009119827,0.94400465,0.0003541949],"about_ca_topic_score_codex":0.00023825456,"about_ca_topic_score_gemma":0.00011116587,"teacher_disagreement_score":0.5757601,"about_ca_system_score_codex":0.021746662,"about_ca_system_score_gemma":0.0027711848,"threshold_uncertainty_score":0.99954003},"labels":[],"label_agreement":null},{"id":"W4232213056","doi":"10.1038/sj.labinvest.3700743","title":"Quality Assurance","year":2008,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; Royal Columbian Hospital","funders":"","keywords":"Quality assurance; Medicine; Pathology; External quality assessment","score_opus":0.056557673788071264,"score_gpt":0.33132111938851544,"score_spread":0.2747634456004442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232213056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497455,0.00020694647,0.000103797756,0.0008218507,0.00010189001,0.0002185676,0.000010264725,0.00013767541,0.0034244377],"genre_scores_gemma":[0.9951347,0.000048121827,0.0019909658,0.0016280762,0.00019844527,0.000026399373,0.000035312998,0.000017406295,0.000920582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987295,0.00011277563,0.0002428114,0.00022104484,0.0004906615,0.0002031914],"domain_scores_gemma":[0.9989075,0.00010726791,0.00006841757,0.00037009892,0.00032231983,0.00022441799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034295436,0.0000948193,0.00017564965,0.00006155289,0.00011159184,0.000008274805,0.00006696222,0.000092864895,0.00009354696],"category_scores_gemma":[0.0007792857,0.000088212684,0.00003364416,0.0005141656,0.00030346587,0.00015869163,0.000019195195,0.00016153004,0.00033631877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000354132,0.00022779919,0.48223418,0.0009194292,0.00015053531,0.0007724816,0.003571218,0.00009481017,0.402821,0.011558984,0.0960934,0.0012020367],"study_design_scores_gemma":[0.0140816085,0.00021025454,0.7006176,0.00016300999,0.000030393881,0.00030032266,0.00012904039,0.0022619907,0.23872824,0.0011838158,0.041876364,0.00041733572],"about_ca_topic_score_codex":0.00012336254,"about_ca_topic_score_gemma":0.00001574119,"teacher_disagreement_score":0.21838346,"about_ca_system_score_codex":0.0024748666,"about_ca_system_score_gemma":0.008122503,"threshold_uncertainty_score":0.99750054},"labels":[],"label_agreement":null},{"id":"W4232330966","doi":"10.1038/sj.modpathol.3801047","title":"Quality Assurance","year":2008,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Royal Columbian Hospital; Vancouver General Hospital","funders":"","keywords":"Quality assurance; Medical physics; Medicine; Pathology; External quality assessment","score_opus":0.07106120806468168,"score_gpt":0.36147869474288274,"score_spread":0.29041748667820105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232330966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712301,0.0005081656,0.007934169,0.00066687923,0.000102330465,0.00018272549,0.0000049723094,0.00010099529,0.019269656],"genre_scores_gemma":[0.99163544,0.000119859804,0.0017034244,0.00080760045,0.00012456757,0.000025035457,0.000011236567,0.000020055058,0.0055527915],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986624,0.00011454236,0.00022464378,0.0003298397,0.0002973336,0.0003712175],"domain_scores_gemma":[0.9990513,0.0001366434,0.000039857816,0.0005516135,0.000091884525,0.00012870766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000308473,0.000102979255,0.00030705013,0.00006111264,0.0000789358,0.0000025702918,0.00010564697,0.0001388901,0.0001479532],"category_scores_gemma":[0.00034792488,0.000089077796,0.000079100886,0.00010334392,0.00026939635,0.00003606929,0.000067502326,0.00020995947,0.0004409474],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004327436,0.002698312,0.3061031,0.0014142962,0.00043628484,0.10763912,0.015825564,0.00057502865,0.39284432,0.007293351,0.05677838,0.10406482],"study_design_scores_gemma":[0.0632331,0.0011025191,0.75018144,0.00009656874,0.000069341084,0.08042694,0.00009806195,0.045109432,0.022495095,0.008063398,0.028185675,0.0009384221],"about_ca_topic_score_codex":0.00009483243,"about_ca_topic_score_gemma":0.000020455762,"teacher_disagreement_score":0.44407836,"about_ca_system_score_codex":0.0016870308,"about_ca_system_score_gemma":0.002309075,"threshold_uncertainty_score":0.56676334},"labels":[],"label_agreement":null},{"id":"W4233825533","doi":"10.4161/cbt.6.3.4165","title":"Clinical Benefit of Antisense Therapy in a Phase III Trial in Patients with CLL","year":2007,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fludarabine; Chronic lymphocytic leukemia; Chemotherapy; Oncology; Internal medicine; Clinical trial; Cancer; Leukemia; Population; Cyclophosphamide","score_opus":0.05949674630688416,"score_gpt":0.4390387247558386,"score_spread":0.37954197844895443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233825533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582344,0.0019737245,0.000016989332,0.00012140871,0.00028228937,0.0016063829,0.000018549415,0.0000147093315,0.00014251526],"genre_scores_gemma":[0.9936053,0.005200373,0.000085084066,0.0006668269,0.00026401697,0.00005555147,0.000036705605,0.000025756803,0.000060390128],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980112,0.00012234363,0.00076747115,0.0004097821,0.00019921357,0.00049004325],"domain_scores_gemma":[0.9988489,0.0003170087,0.00017374472,0.00039471337,0.00014637395,0.00011927311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011070919,0.00017816671,0.00073968153,0.0002442139,0.000017217782,0.0000027165988,0.00015333248,0.00029075833,0.00020102899],"category_scores_gemma":[0.000044450557,0.00011950772,0.00009776044,0.0004255502,0.00041399826,0.00003259894,0.000021845553,0.00034410763,0.000003154259],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39536506,0.0018538662,0.36948806,0.000007554101,0.0001264736,0.00004342156,0.00030049632,0.000001953209,0.0011574378,0.000031289685,0.00004390442,0.23158048],"study_design_scores_gemma":[0.802548,0.011776355,0.18026745,0.00009429749,0.000007959341,0.0000031520574,0.00003175562,0.000043876047,0.0025311776,0.000059536455,0.0025013178,0.00013512524],"about_ca_topic_score_codex":0.0013765598,"about_ca_topic_score_gemma":0.00058866333,"teacher_disagreement_score":0.40718293,"about_ca_system_score_codex":0.00170066,"about_ca_system_score_gemma":0.0022104133,"threshold_uncertainty_score":0.48733833},"labels":[],"label_agreement":null},{"id":"W4234888428","doi":"10.1111/j.1538-7836.2005.01303.x","title":"Talking about …","year":2005,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Medicine; Food and drug administration; Thrombocytopenic purpura; Drug Company; Family medicine; Management; Immune system; Pharmacology; Immunology","score_opus":0.05656906484084867,"score_gpt":0.36781782925725837,"score_spread":0.3112487644164097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234888428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98678607,0.0034238605,0.00010578405,0.0061776466,0.00009507462,0.000095958356,0.0000025679792,0.000009326929,0.003303695],"genre_scores_gemma":[0.98962384,0.004071022,0.004748087,0.0007499617,0.00057421706,9.64302e-7,7.921937e-7,0.000017562495,0.00021356909],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998758,0.000026136711,0.00040658956,0.0001100999,0.00046819326,0.00023098453],"domain_scores_gemma":[0.99912494,0.00008666191,0.00018370776,0.0001586293,0.00020437344,0.00024168093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004555002,0.000104369305,0.00039304225,0.00015776789,0.00007666361,0.000045502708,0.00009220363,0.000071939416,0.00039863665],"category_scores_gemma":[0.00012575199,0.0000755081,0.0001491086,0.00014164628,0.00009649795,0.00018476637,0.00005710538,0.000242686,0.000022021322],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009512722,0.0007860132,0.013684773,0.0004906539,0.0017009357,0.0003692765,0.0030438665,0.00007528588,0.011765404,0.00089089025,0.10040216,0.8658395],"study_design_scores_gemma":[0.074707225,0.002835455,0.15839736,0.0026965016,0.0018384373,0.013051454,0.0019810498,0.007027804,0.06710071,0.00053287286,0.6690272,0.0008039168],"about_ca_topic_score_codex":0.000036225578,"about_ca_topic_score_gemma":0.0000075448734,"teacher_disagreement_score":0.86503553,"about_ca_system_score_codex":0.0017794863,"about_ca_system_score_gemma":0.0010030604,"threshold_uncertainty_score":0.46532947},"labels":[],"label_agreement":null},{"id":"W4236466662","doi":"10.1136/annrheumdis-2017-eular.1073","title":"SAT0072 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Discontinuation; Rheumatoid arthritis; Internal medicine; Adverse effect","score_opus":0.020334620699256612,"score_gpt":0.30907591177198274,"score_spread":0.2887412910727261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236466662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957013,0.0005825332,0.000004116795,0.00046371887,0.000051273353,0.0027563004,0.00022364741,0.000013914867,0.00020316757],"genre_scores_gemma":[0.9995192,0.00026047687,0.000019522666,0.00001268028,0.000012523619,0.000076911056,0.000016142247,0.000026378502,0.000056130142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722576,0.0002168736,0.0008944271,0.00032297775,0.0010110199,0.0003289338],"domain_scores_gemma":[0.9963012,0.00026601064,0.0010278585,0.0014293164,0.00076863915,0.00020699714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057549414,0.00020691346,0.0007937714,0.00017502999,0.00014197598,0.00002672719,0.00042692397,0.000038778395,0.000016041027],"category_scores_gemma":[0.0060445326,0.00013453061,0.00018912919,0.00022598024,0.0005910063,0.00023397172,0.0001934373,0.00012416784,0.0000011950938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03732212,0.007654764,0.9382538,0.0014247722,0.0007538925,0.000027699536,0.0021593948,0.0002084634,0.000016852578,0.00020671291,0.00029147355,0.011680042],"study_design_scores_gemma":[0.05423029,0.0012235247,0.9373875,0.004627727,0.00011200215,0.0000021661303,0.0013288382,0.0003860807,0.00018592492,0.00039881998,0.0000014006,0.00011572008],"about_ca_topic_score_codex":0.0012147994,"about_ca_topic_score_gemma":0.000049982656,"teacher_disagreement_score":0.01690817,"about_ca_system_score_codex":0.00038329276,"about_ca_system_score_gemma":0.0022748213,"threshold_uncertainty_score":0.72363067},"labels":[],"label_agreement":null},{"id":"W4236716089","doi":"10.33790/jcrc1100105","title":"Surgical Management of Necrotic Wounds Following Rituximab Therapy for Waldenstrom’s Macroglobulinemia: A Case Report","year":2020,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rituximab; Macroglobulinemia; Waldenstrom macroglobulinemia; Medicine; Lymphoplasmacytic Lymphoma; Dermatology; Internal medicine; Lymphoma; Multiple myeloma","score_opus":0.04650781595699388,"score_gpt":0.35150055283195936,"score_spread":0.3049927368749655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236716089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807365,0.00062452874,0.002400458,0.0038637086,0.0001299836,0.0021071066,0.000008787481,0.00013244106,0.00999649],"genre_scores_gemma":[0.9840334,0.00008359674,0.011649504,0.000432904,0.00018721883,0.00012142882,0.000038537364,0.000044988916,0.0034084178],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99775994,0.000027520913,0.00062492647,0.0005062421,0.00059929263,0.00048208804],"domain_scores_gemma":[0.9987781,0.00015598122,0.00009566711,0.0004954903,0.00013138141,0.0003433987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043425817,0.00020509529,0.0005997501,0.000059660393,0.0000712001,0.000023500223,0.00014302139,0.00012527684,0.00034467786],"category_scores_gemma":[0.00008644987,0.00016074315,0.00043506877,0.00033510366,0.00008183918,0.000055469194,0.00012864194,0.00018186161,0.000026585898],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026951046,0.00063835346,0.00047399846,0.001404691,0.0012068327,0.97292477,0.00033411558,0.000019479015,0.0004748798,0.0010519354,0.006320937,0.012454921],"study_design_scores_gemma":[0.37879145,0.004159193,0.00017872194,0.0006341947,0.0011132263,0.45717868,0.0032707423,0.064376816,0.017765049,0.00028268615,0.07128535,0.0009638939],"about_ca_topic_score_codex":0.0002599195,"about_ca_topic_score_gemma":0.000006030127,"teacher_disagreement_score":0.51574606,"about_ca_system_score_codex":0.0017389533,"about_ca_system_score_gemma":0.0013312689,"threshold_uncertainty_score":0.65549153},"labels":[],"label_agreement":null},{"id":"W4238442067","doi":"10.1182/blood.v112.11.3057.3057","title":"Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Waldenstrom macroglobulinemia; Fludarabine; Rituximab; Gastroenterology; Macroglobulinemia; Internal medicine; Neutropenia; Regimen; Surgery; Chemotherapy; Lymphoma; Cyclophosphamide; Multiple myeloma","score_opus":0.0239040858792998,"score_gpt":0.3029738346164581,"score_spread":0.2790697487371583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238442067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966482,0.0009906401,0.000009992001,0.00090314756,0.000036571193,0.00047832064,0.000009550761,0.00005834395,0.00086524454],"genre_scores_gemma":[0.99472445,0.00023223179,0.0014689242,0.00032633965,0.00015545367,0.000034935892,0.000009974206,0.000028825956,0.003018876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984403,0.000050474453,0.0002762351,0.00038096102,0.00038729332,0.00046472778],"domain_scores_gemma":[0.99906725,0.00012852174,0.000025517167,0.0004059569,0.00006571891,0.0003070442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022033283,0.00016078718,0.00035201368,0.00023830649,0.000064289416,0.000014923548,0.000115218405,0.000103490114,0.0000790205],"category_scores_gemma":[0.0004237484,0.00014373954,0.000044876448,0.00033067074,0.00014409411,0.000052007756,0.00015124635,0.0002265439,0.00015016545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005906333,0.008991049,0.8570289,0.0007600147,0.00024920396,0.05419839,0.0027242308,0.0000029126393,0.049493466,0.000074417345,0.00460511,0.015965955],"study_design_scores_gemma":[0.16192693,0.00069514976,0.7890956,0.000381043,0.00008874831,0.016611284,0.000051361472,0.0001436776,0.029724795,0.000017084574,0.0009528702,0.00031150933],"about_ca_topic_score_codex":0.00027674445,"about_ca_topic_score_gemma":0.00010141262,"teacher_disagreement_score":0.1560206,"about_ca_system_score_codex":0.0012439804,"about_ca_system_score_gemma":0.0020073068,"threshold_uncertainty_score":0.5861528},"labels":[],"label_agreement":null},{"id":"W4238463982","doi":"10.1002/cytob.21135","title":"Soluble CD23 measurement by CBA: A convenient and reliable quantification method in Chronic Lymphocytic Leukemia","year":2013,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"BD Biosciences","keywords":"Chronic lymphocytic leukemia; Reproducibility; Repeatability; Medicine; CD23; Coefficient of variation; Immunology; Antibody; Internal medicine; Immunoglobulin E; Chromatography; Gastroenterology; Oncology; Leukemia; Chemistry","score_opus":0.090404816095081,"score_gpt":0.39842483893955155,"score_spread":0.30802002284447055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238463982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702851,0.012789292,0.008015373,0.0008805497,0.0012558674,0.0036007517,0.000025205825,0.00037438274,0.0027734549],"genre_scores_gemma":[0.98856276,0.002543932,0.0033540393,0.0011261493,0.00052774523,0.0004778472,0.00009243836,0.00013157152,0.0031835397],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99132055,0.0005932504,0.0024899568,0.0017854199,0.0022281464,0.0015826955],"domain_scores_gemma":[0.99408615,0.0017859464,0.00046701825,0.0016805306,0.0007481249,0.0012322295],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00835523,0.0006137301,0.0016605078,0.0012375367,0.00019669255,0.00020464815,0.0005426541,0.0008258528,0.001090189],"category_scores_gemma":[0.0045549925,0.00055644504,0.0003630229,0.003642469,0.0006321747,0.0004445821,0.00047863447,0.0012992418,0.0019278916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033110057,0.0027854217,0.16800094,0.006275375,0.0021739511,0.00060076825,0.00040265743,0.0007693394,0.13246271,0.0007321894,0.5841327,0.09835293],"study_design_scores_gemma":[0.12869675,0.0055916025,0.075414516,0.002952255,0.0008857923,0.0008630812,0.00076002214,0.47072726,0.062182147,0.0007872402,0.24803165,0.0031076907],"about_ca_topic_score_codex":0.0025073127,"about_ca_topic_score_gemma":0.000049207654,"teacher_disagreement_score":0.46995792,"about_ca_system_score_codex":0.0964174,"about_ca_system_score_gemma":0.021508012,"threshold_uncertainty_score":0.999823},"labels":[],"label_agreement":null},{"id":"W4240960183","doi":"10.1182/blood.v112.11.44.44","title":"A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Tumor lysis syndrome; Internal medicine; Multiple myeloma; Gastroenterology; Sepsis; Chronic lymphocytic leukemia; Immunology; Leukemia; Chemotherapy","score_opus":0.026420939464282662,"score_gpt":0.30825182400103057,"score_spread":0.2818308845367479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240960183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941467,0.0021549836,0.0000040920127,0.000019385072,0.000047907863,0.002387012,0.0000054517645,0.00012476752,0.0011097037],"genre_scores_gemma":[0.9979739,0.00038491932,0.000086958134,0.00004542894,0.00014395533,0.00020952334,0.000017610271,0.00007049701,0.0010672179],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99639976,0.00018006406,0.0009847926,0.00059509656,0.0010168909,0.0008233877],"domain_scores_gemma":[0.9980425,0.00022979233,0.00020618727,0.0010735763,0.00014891279,0.00029898642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048985437,0.00035780302,0.0010096204,0.00048710764,0.00013804082,0.000011847009,0.0003752619,0.00016890143,0.00018209226],"category_scores_gemma":[0.00034890638,0.00030966298,0.0001600358,0.00099644,0.0002310081,0.00012175402,0.00025262567,0.00029838763,0.00009350057],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.028266456,0.34232888,0.07521929,0.024406923,0.015325496,0.13384858,0.16717395,0.010410032,0.14804932,0.00038369125,0.007864731,0.04672267],"study_design_scores_gemma":[0.89484733,0.02840888,0.0021805621,0.0015577421,0.0011366871,0.0070424164,0.0010140819,0.029984346,0.03304413,0.000033871598,0.00016306645,0.0005868645],"about_ca_topic_score_codex":0.005789558,"about_ca_topic_score_gemma":0.0005684093,"teacher_disagreement_score":0.8665809,"about_ca_system_score_codex":0.04771151,"about_ca_system_score_gemma":0.037045486,"threshold_uncertainty_score":0.99993557},"labels":[],"label_agreement":null},{"id":"W4241496252","doi":"10.26434/chemrxiv.13132814.v1","title":"Calculating the Full Free Energy Profile for Covalent Modification of a Druggable Cysteine in Bruton’s Tyrosine Kinase","year":2020,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Natural Sciences and Engineering Research Council of Canada; Memorial University of Newfoundland; Government of Canada; Compute Canada","keywords":"Covalent bond; Chemistry; Cysteine; Ligand (biochemistry); Stereochemistry; Biochemistry; Enzyme; Organic chemistry","score_opus":0.058104502422329375,"score_gpt":0.3248457954693878,"score_spread":0.2667412930470584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241496252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748952,0.0040938775,0.006828966,0.006119897,0.00031061412,0.0042199674,0.00011399966,0.00013059418,0.0032869244],"genre_scores_gemma":[0.99346966,0.000111903115,0.002494685,0.00014497673,0.00040624038,0.0012313607,0.0005496137,0.00007569834,0.0015158723],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99751204,0.00006812065,0.0007391618,0.0006680715,0.00057809916,0.00043452397],"domain_scores_gemma":[0.99732196,0.0003879665,0.00035727306,0.0014299758,0.0003517974,0.00015100458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061747734,0.00029659815,0.00070199353,0.00014024047,0.000052272073,0.000025099436,0.0005581385,0.00031887236,0.00004467841],"category_scores_gemma":[0.0015733198,0.00022836798,0.00024815855,0.00035075724,0.00015998159,0.000031122006,0.00078825647,0.0004850391,0.0000074707627],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028682132,0.0013826033,0.00049684,0.028474694,0.00075193716,0.00021417536,0.00459318,0.008124153,0.9030383,0.0101564,0.03353674,0.006362768],"study_design_scores_gemma":[0.015166891,0.00027597207,0.00022689093,0.001454741,0.00018637533,0.000032238135,0.000235715,0.5476826,0.4291828,0.0015631387,0.003758455,0.00023419244],"about_ca_topic_score_codex":0.0021721004,"about_ca_topic_score_gemma":0.00009090908,"teacher_disagreement_score":0.5395585,"about_ca_system_score_codex":0.005224833,"about_ca_system_score_gemma":0.005082319,"threshold_uncertainty_score":0.9985939},"labels":[],"label_agreement":null},{"id":"W4241968959","doi":"10.1016/j.jval.2014.08.2267","title":"Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Ofatumumab; Chlorambucil; Medicine; Fludarabine; Population; Time horizon; Quality-adjusted life year; Cost effectiveness; Chronic lymphocytic leukemia; Internal medicine; Oncology; Leukemia; Chemotherapy; Mathematics; Risk analysis (engineering); Environmental health","score_opus":0.05877112671093143,"score_gpt":0.329355149885676,"score_spread":0.27058402317474456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241968959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942989,0.0022421973,0.00009592556,0.0002719132,0.00026705235,0.0023024846,0.000013252131,0.00002169747,0.00048658904],"genre_scores_gemma":[0.99847555,0.0008024241,0.000071429444,0.00021332112,0.00011087058,0.00018426127,0.00003234913,0.000051623334,0.000058146306],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9955929,0.0007368666,0.001130881,0.00058748265,0.00083142234,0.0011204443],"domain_scores_gemma":[0.99688977,0.0017373916,0.0002040129,0.0007304607,0.00009250025,0.00034584766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033850828,0.0002785963,0.0011601229,0.00053640304,0.00004012477,0.000008166605,0.00029494154,0.00016567906,0.000045198223],"category_scores_gemma":[0.0010483083,0.00027365016,0.0000644721,0.0013128904,0.00011893272,0.00007492243,0.00012772137,0.0006020861,0.000015449916],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017877357,0.000088889334,0.015806802,0.0131017985,0.000023806737,0.00039328943,0.00067929784,0.9588198,0.000082414816,0.00044529434,0.00013105816,0.008639825],"study_design_scores_gemma":[0.053127512,0.0006807284,0.03833037,0.00570795,0.0000066763537,0.00009550681,0.00010638421,0.8994803,0.0009842692,0.00014707368,0.0011081094,0.00022516547],"about_ca_topic_score_codex":0.9961388,"about_ca_topic_score_gemma":0.968356,"teacher_disagreement_score":0.2905292,"about_ca_system_score_codex":0.71443164,"about_ca_system_score_gemma":0.42390245,"threshold_uncertainty_score":0.99997157},"labels":[],"label_agreement":null},{"id":"W4242570503","doi":"10.21037/tcr.2016.07.22","title":"Functional and clinical impact of MYC mutations in diffuse large B cell lymphomas","year":2016,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Cancer research; Diffuse large B-cell lymphoma; Biology; Medicine; Lymphoma; Pathology","score_opus":0.13054395186280196,"score_gpt":0.48415276319071543,"score_spread":0.35360881132791344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242570503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947078,0.0009817486,0.00025598748,0.0016301423,0.000039612343,0.000471297,0.00018950476,0.000012901843,0.0017109833],"genre_scores_gemma":[0.99746084,0.0007012038,0.000119248536,0.000019821586,0.00017335043,0.00007022393,0.000034417695,0.000022674132,0.0013982445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972541,0.00023843699,0.00046582788,0.00035185367,0.0011986094,0.0004911886],"domain_scores_gemma":[0.99726474,0.0017624085,0.00004069127,0.00022900086,0.00044808752,0.00025509342],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016196944,0.000110709225,0.0002723738,0.0004170653,0.00007560832,0.000010975808,0.000097420016,0.00013241533,0.001955114],"category_scores_gemma":[0.0002404425,0.00007302863,0.00015007347,0.00055147393,0.0004931115,0.00013194067,0.000041442825,0.00029850804,0.000047333484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068233553,0.004809366,0.93978906,0.00037311143,0.00031421238,0.00011248809,0.00076079415,0.00008291619,0.016824534,0.0033267746,0.0029601753,0.02382324],"study_design_scores_gemma":[0.076276965,0.00043939304,0.91671664,0.00019255014,0.000024021962,0.000031435768,0.000043258602,0.0029845936,0.0010862836,0.0015574207,0.0005378569,0.00010960649],"about_ca_topic_score_codex":0.0016726919,"about_ca_topic_score_gemma":0.00062290905,"teacher_disagreement_score":0.069453605,"about_ca_system_score_codex":0.0032079485,"about_ca_system_score_gemma":0.012202007,"threshold_uncertainty_score":0.9989572},"labels":[],"label_agreement":null},{"id":"W4243059760","doi":"10.1200/jco.2002.20.1.205","title":"Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Discontinuation; Chemotherapy; Surgery; Regimen; Prolymphocytic leukemia; Alemtuzumab; Chemotherapy regimen; Adverse effect; Leukemia; Transplantation; Chronic lymphocytic leukemia","score_opus":0.16042065071058748,"score_gpt":0.41533585187470773,"score_spread":0.25491520116412025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243059760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445206,0.0006986566,0.00002943845,0.0016100202,0.00035639174,0.0013349779,0.0000072401303,0.000007940406,0.0015032864],"genre_scores_gemma":[0.9909153,0.0013601173,0.0029317401,0.00047033842,0.0006408999,0.000039009683,0.0000065211375,0.00004846879,0.0035876345],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951057,0.00031465339,0.0030076634,0.00034524046,0.00070194906,0.0005248029],"domain_scores_gemma":[0.9940843,0.0025500823,0.001890224,0.00042460227,0.0005735699,0.0004772276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015216423,0.00023890809,0.0022930682,0.00023728714,0.00006491897,0.000013781063,0.00025359838,0.0005686172,0.00038271502],"category_scores_gemma":[0.0017562393,0.00017497885,0.00067044294,0.00021315577,0.0004741626,0.00009648599,0.000055953547,0.00038323132,0.00004456925],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.1449127,0.04735705,0.1294033,0.001062638,0.0023995002,0.0010598324,0.0075248918,0.00022307968,0.0035928446,0.000026386322,0.033113208,0.62932456],"study_design_scores_gemma":[0.6875123,0.13905105,0.062389772,0.00054742256,0.0006858045,0.00021595373,0.00022109438,0.010006547,0.011254248,0.0001224795,0.08762298,0.00037039054],"about_ca_topic_score_codex":0.00013370457,"about_ca_topic_score_gemma":0.00010492886,"teacher_disagreement_score":0.6289542,"about_ca_system_score_codex":0.04875858,"about_ca_system_score_gemma":0.02136623,"threshold_uncertainty_score":0.9841817},"labels":[],"label_agreement":null},{"id":"W4244559152","doi":"10.3410/f.11068958.12017060","title":"Faculty Opinions recommendation of Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.","year":2011,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Whole genome sequencing; Computational biology; Genetics; DNA sequencing; Genome; Biology; Medicine; Gene","score_opus":0.06434766121043789,"score_gpt":0.38297528178307455,"score_spread":0.31862762057263666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244559152","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001256038,0.0044595865,0.000021756516,0.03315488,0.000896796,0.0029003334,0.9583795,0.00005073292,0.000123853],"genre_scores_gemma":[0.00008481333,0.0012470462,0.0003238326,0.0012343893,0.00039590304,0.0005707574,0.994481,0.000056555033,0.0016056804],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923298,0.0006409629,0.0028490014,0.0010669585,0.0023691112,0.00074418733],"domain_scores_gemma":[0.9891541,0.00028809108,0.0017730374,0.002328436,0.0059613097,0.00049499783],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023392856,0.0007325108,0.0016357898,0.0011422058,0.0002307688,0.00012429756,0.0017311244,0.0009851417,0.0008202824],"category_scores_gemma":[0.009718351,0.00051769335,0.000837657,0.003800129,0.000784127,0.00047074884,0.00078289164,0.0017509632,0.00020012095],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00004471872,0.0002483943,0.0000019572742,0.023561765,0.00022193913,0.0000046318273,0.0004062697,0.0000019964436,0.000025137768,0.000091665344,0.9741918,0.0011997444],"study_design_scores_gemma":[0.0046673743,0.00028694462,0.00046542057,0.031124607,0.0003820451,0.0002521797,0.00010748752,0.00018400082,0.00005866971,0.00004249343,0.96201545,0.00041331636],"about_ca_topic_score_codex":0.00092597445,"about_ca_topic_score_gemma":0.00010906481,"teacher_disagreement_score":0.03610152,"about_ca_system_score_codex":0.025810163,"about_ca_system_score_gemma":0.031333994,"threshold_uncertainty_score":0.9997275},"labels":[],"label_agreement":null},{"id":"W4245401383","doi":"10.1097/00124743-900000000-99286","title":"Systemic Large-Vessel Vasculitis and Retroperitoneal Fibrosis in the Setting of T-Cell Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"JCR Journal of Clinical Rheumatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Chronic lymphocytic leukemia; Hematology; Rheumatology; Vasculitis; Family medicine; General surgery; Leukemia","score_opus":0.02610392245636845,"score_gpt":0.3661132380216631,"score_spread":0.3400093155652947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245401383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940898,0.0039254655,0.00016247958,0.00047226518,0.00049683824,0.0002944202,0.0000048265697,0.000010106371,0.00054380216],"genre_scores_gemma":[0.99426407,0.0044661146,0.0005892963,0.00020310267,0.00038350158,0.0000056181266,0.000002330298,0.000029480198,0.000056490502],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99442947,0.000980021,0.002916902,0.00032942544,0.00072791515,0.0006162508],"domain_scores_gemma":[0.99402,0.0035376856,0.0011424337,0.00054203556,0.0004967233,0.00026111703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063475305,0.0002134065,0.0016611306,0.0002341554,0.00008614581,0.00002400025,0.0004949238,0.00043136088,0.000093593546],"category_scores_gemma":[0.004148485,0.00013659576,0.00036333367,0.00040958158,0.0007865756,0.00012168286,0.00018155151,0.0009695345,0.000030993622],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016354667,0.0016717213,0.8571825,0.018490002,0.0025415965,0.0052107717,0.016066315,0.00024812302,0.0142839,0.0041194656,0.027454063,0.036376856],"study_design_scores_gemma":[0.35172898,0.028173676,0.19400579,0.019824516,0.0016680416,0.21141355,0.010729105,0.1540955,0.010080681,0.0012847957,0.015564831,0.001430535],"about_ca_topic_score_codex":0.00047554768,"about_ca_topic_score_gemma":0.00009395405,"teacher_disagreement_score":0.6631767,"about_ca_system_score_codex":0.0074043446,"about_ca_system_score_gemma":0.022661518,"threshold_uncertainty_score":0.9964061},"labels":[],"label_agreement":null},{"id":"W4246189088","doi":"10.26434/chemrxiv.13132814","title":"Calculating the Full Free Energy Profile for Covalent Modification of a Druggable Cysteine in Bruton’s Tyrosine Kinase","year":2020,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Natural Sciences and Engineering Research Council of Canada; Memorial University of Newfoundland; Government of Canada; Compute Canada","keywords":"Covalent bond; Chemistry; Cysteine; Stereochemistry; Ligand (biochemistry); Biochemistry; Enzyme; Organic chemistry","score_opus":0.058104502422329375,"score_gpt":0.3248457954693878,"score_spread":0.2667412930470584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246189088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748952,0.0040938775,0.006828966,0.006119897,0.00031061412,0.0042199674,0.00011399966,0.00013059418,0.0032869244],"genre_scores_gemma":[0.99346966,0.000111903115,0.002494685,0.00014497673,0.00040624038,0.0012313607,0.0005496137,0.00007569834,0.0015158723],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99751204,0.00006812065,0.0007391618,0.0006680715,0.00057809916,0.00043452397],"domain_scores_gemma":[0.99732196,0.0003879665,0.00035727306,0.0014299758,0.0003517974,0.00015100458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061747734,0.00029659815,0.00070199353,0.00014024047,0.000052272073,0.000025099436,0.0005581385,0.00031887236,0.00004467841],"category_scores_gemma":[0.0015733198,0.00022836798,0.00024815855,0.00035075724,0.00015998159,0.000031122006,0.00078825647,0.0004850391,0.0000074707627],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028682132,0.0013826033,0.00049684,0.028474694,0.00075193716,0.00021417536,0.00459318,0.008124153,0.9030383,0.0101564,0.03353674,0.006362768],"study_design_scores_gemma":[0.015166891,0.00027597207,0.00022689093,0.001454741,0.00018637533,0.000032238135,0.000235715,0.5476826,0.4291828,0.0015631387,0.003758455,0.00023419244],"about_ca_topic_score_codex":0.0021721004,"about_ca_topic_score_gemma":0.00009090908,"teacher_disagreement_score":0.5395585,"about_ca_system_score_codex":0.005224833,"about_ca_system_score_gemma":0.005082319,"threshold_uncertainty_score":0.9985939},"labels":[],"label_agreement":null},{"id":"W4246883272","doi":"10.1182/blood.v110.11.2560.2560","title":"Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Gastroenterology; Lymphoma; Follicular lymphoma; Regimen; Refractory (planetary science); Multiple myeloma; Oncology; Surgery","score_opus":0.030568181730450127,"score_gpt":0.3437606413345285,"score_spread":0.3131924596040784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246883272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967032,0.00047769822,0.000022529635,0.00006581638,0.00012329913,0.0013055915,0.000051343086,0.000047133446,0.0012033529],"genre_scores_gemma":[0.99863595,0.00008350286,0.0004360018,0.00013165062,0.00022951409,0.000037015947,0.000047522215,0.000057998706,0.00034086945],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664795,0.0001290108,0.0010845872,0.0006095778,0.0009250686,0.0006038167],"domain_scores_gemma":[0.9979091,0.00047533563,0.00024907384,0.0009691029,0.00013711113,0.00026022556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015023063,0.00027533324,0.0007110951,0.00043509947,0.00006236034,0.000012030717,0.00028838275,0.00020998946,0.00008900042],"category_scores_gemma":[0.00036298844,0.0002401948,0.00011937017,0.00053958857,0.00010731665,0.00007490439,0.00015129843,0.0003017396,0.000025918134],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16296054,0.32921693,0.016919695,0.000257307,0.0027302296,0.013184173,0.087791175,0.000079806356,0.15824018,0.000020406947,0.0026261865,0.22597337],"study_design_scores_gemma":[0.880936,0.011750295,0.024418326,0.00035063757,0.000219006,0.00006531796,0.0035358511,0.00059992424,0.07656784,0.000035975987,0.0012056447,0.0003151317],"about_ca_topic_score_codex":0.014033747,"about_ca_topic_score_gemma":0.0019806747,"teacher_disagreement_score":0.7179755,"about_ca_system_score_codex":0.0026832025,"about_ca_system_score_gemma":0.002781734,"threshold_uncertainty_score":0.9925319},"labels":[],"label_agreement":null},{"id":"W4247865494","doi":"10.1093/jnci/djx027","title":"Response","year":2017,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Business","score_opus":0.11490078622488037,"score_gpt":0.41889251484277146,"score_spread":0.3039917286178911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247865494","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00929649,0.0010755948,0.000009223428,0.97632617,0.00745718,0.00029620275,0.00011747762,0.000008216332,0.005413428],"genre_scores_gemma":[0.02362736,0.00041708606,0.00030062633,0.84949917,0.052462637,0.000028495588,0.000021122674,0.000076440905,0.07356709],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953452,0.00015566684,0.00057093083,0.00019019385,0.003438916,0.00029913287],"domain_scores_gemma":[0.9960147,0.00028320614,0.001091298,0.00044017093,0.0020668623,0.0001037268],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014388852,0.00021929115,0.0004990381,0.00031132062,0.00025911682,0.000084488885,0.0011154285,0.00048959284,0.00022402973],"category_scores_gemma":[0.003757176,0.00013178174,0.0005248775,0.00014397883,0.00044365035,0.0002561351,0.00017663746,0.0029277382,0.000042165426],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014323569,0.00001860297,0.000026783378,0.00012494743,0.00037926648,0.0015125773,0.000038536506,0.00011893175,0.00025663938,0.000018414965,0.99566025,0.0004126865],"study_design_scores_gemma":[0.0058139777,0.00008666621,0.00070872664,0.001085027,0.00018758317,0.0056992816,0.0000013413876,0.00008313986,0.00044346025,0.00032469994,0.98543954,0.00012658419],"about_ca_topic_score_codex":0.00015238284,"about_ca_topic_score_gemma":0.000020110521,"teacher_disagreement_score":0.12682705,"about_ca_system_score_codex":0.031194558,"about_ca_system_score_gemma":0.0727415,"threshold_uncertainty_score":0.99937254},"labels":[],"label_agreement":null},{"id":"W4249317336","doi":"10.14740/jmc2558w","title":"Diffuse Infiltrative Lymphocytosis Syndrome: A Case With Multiple Extra-Glandular Infiltrations","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lymphocytosis; Differential diagnosis; Pathology; Presentation (obstetrics); Radiology","score_opus":0.034657796418463456,"score_gpt":0.31825122382209253,"score_spread":0.2835934274036291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249317336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922683,0.0006312116,0.0021477162,0.0043500713,0.00012902681,0.00026722244,0.000027548118,0.00002719201,0.0001516823],"genre_scores_gemma":[0.9976149,0.0005216117,0.0007979902,0.00042090085,0.00037158083,0.00001665631,0.000003045497,0.000033338416,0.00021992867],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99598837,0.00016638658,0.00075620523,0.0002262658,0.0024246702,0.0004381172],"domain_scores_gemma":[0.99510044,0.0025619192,0.00030613618,0.00036039363,0.00048515297,0.0011859626],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008837444,0.0002283682,0.00061925716,0.00029509127,0.00011828058,0.00003794622,0.00023421986,0.0002313663,0.0013557018],"category_scores_gemma":[0.0068247835,0.0001111284,0.00019393735,0.00036650628,0.0005119698,0.0002946867,0.000062199295,0.00042241547,0.000033519867],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026131903,0.001312553,0.014093454,0.00020815343,0.0007211846,0.95462,0.00080303085,0.000005026441,0.0015374521,0.00014667159,0.0054564234,0.018482856],"study_design_scores_gemma":[0.049879905,0.0032691339,0.0020768954,0.0016416247,0.00025724628,0.93529695,0.0006409844,0.0004844008,0.0027210943,0.000025464517,0.0035215542,0.00018473358],"about_ca_topic_score_codex":0.0006362258,"about_ca_topic_score_gemma":0.00039524786,"teacher_disagreement_score":0.047266714,"about_ca_system_score_codex":0.0035548408,"about_ca_system_score_gemma":0.012588543,"threshold_uncertainty_score":0.9995572},"labels":[],"label_agreement":null},{"id":"W4249669240","doi":"10.14740/jmc2708w","title":"First Report of Treatment of Chronic Lymphocytic Leukemia in a Patient With Cystic Fibrosis","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Ibrutinib; Bendamustine; Chronic lymphocytic leukemia; Internal medicine; Immunosuppression; Malignancy; Population; Antibiotics; Cystic fibrosis; Leukemia","score_opus":0.02193863972574251,"score_gpt":0.30524932190511095,"score_spread":0.28331068217936844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249669240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612844,0.002621981,0.00017750559,0.0005974318,0.00010187865,0.00024443943,0.000008174529,0.0000057160005,0.00011440316],"genre_scores_gemma":[0.9977474,0.0015616207,0.00029385975,0.000024283572,0.00021327531,0.000010583874,0.00000167594,0.00002130087,0.00012596555],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9960614,0.000077573575,0.0012919129,0.00018917682,0.0020471232,0.00033283312],"domain_scores_gemma":[0.9967456,0.0014042376,0.00070243346,0.00037711748,0.00031588468,0.00045472887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005919383,0.00017726094,0.00086927257,0.0003097415,0.000018729304,0.0000040132136,0.00016303382,0.00015736194,0.00055783143],"category_scores_gemma":[0.0025336957,0.00008537955,0.00020118259,0.00030842068,0.0004037832,0.00007431175,0.000048437854,0.00012505762,0.0000044343196],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.025305472,0.0027893158,0.012071943,0.004865991,0.0018416905,0.76811814,0.0029279338,0.002130077,0.007926631,0.00012684774,0.00566198,0.16623399],"study_design_scores_gemma":[0.16056566,0.08918557,0.003918804,0.030248579,0.00094477483,0.6298057,0.000777919,0.011148462,0.05773201,0.00007695269,0.015139131,0.00045642524],"about_ca_topic_score_codex":0.0023073792,"about_ca_topic_score_gemma":0.00039524035,"teacher_disagreement_score":0.16577755,"about_ca_system_score_codex":0.10116675,"about_ca_system_score_gemma":0.08199444,"threshold_uncertainty_score":0.9232098},"labels":[],"label_agreement":null},{"id":"W4249829466","doi":"10.1007/978-3-662-44185-5_100005","title":"6-Hydroxypurine","year":2015,"lang":"en","type":"book-chapter","venue":"Encyclopedia of Astrobiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Computer science","score_opus":0.03013582592121339,"score_gpt":0.29723820758394603,"score_spread":0.26710238166273265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249829466","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016522653,0.0022892565,0.000024379531,0.00019914498,0.00046140995,0.00054036884,0.00008579656,0.00006031894,0.9946871],"genre_scores_gemma":[0.0039993757,0.0016222153,0.001175793,0.00006241996,0.0010364444,0.000014306198,0.00048775083,0.000103092185,0.9914986],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800336,0.000026136107,0.0006297679,0.00051000284,0.00037269702,0.00045804755],"domain_scores_gemma":[0.998124,0.00013796527,0.00028329116,0.0008003798,0.00034863225,0.00030575317],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028484542,0.00038927878,0.0011240302,0.00029111104,0.000018921435,0.0000024919896,0.00027334204,0.0007276141,0.0035729343],"category_scores_gemma":[0.00017217894,0.00033212075,0.00025144115,0.000039732182,0.0005278127,0.000025431062,0.0002855471,0.00066908624,0.0009800704],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031922068,0.00046807053,0.00052938197,0.0020647598,0.0027743503,0.0028977047,0.00049600785,0.00006277107,0.0010560023,0.14650846,0.7801117,0.059838645],"study_design_scores_gemma":[0.0061169155,0.0012314828,0.000028923463,0.0002234514,0.00018717733,0.0006575617,0.000006736346,0.000026872252,0.00006517163,0.0027880305,0.98842454,0.00024313532],"about_ca_topic_score_codex":0.00006058722,"about_ca_topic_score_gemma":0.000015470092,"teacher_disagreement_score":0.2083129,"about_ca_system_score_codex":0.0032837533,"about_ca_system_score_gemma":0.008208066,"threshold_uncertainty_score":0.9999131},"labels":[],"label_agreement":null},{"id":"W4249976656","doi":"10.1097/00007890-201007272-00310","title":"ANTI-BK VIRUS MECHANISMS OF SIROLIMUS AND LEFLUNOMIDE ALONE AND IN COMBINATION: TOWARDS A NEW THERAPY FOR BK VIRUS INFECTION","year":2010,"lang":"en","type":"article","venue":"Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"BK virus; Leflunomide; Medicine; Sirolimus; Internal medicine; Virus; Virology; Transplantation; Kidney transplantation","score_opus":0.022660876606613017,"score_gpt":0.3117218981270812,"score_spread":0.28906102152046814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249976656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885872,0.00014246811,0.009912654,0.00025606246,0.00010716147,0.0008437506,0.000023746506,0.000025943156,0.00010098442],"genre_scores_gemma":[0.9955286,0.0029583387,0.0011941718,0.00008809177,0.00004752109,0.00003468595,0.00007590668,0.000017870809,0.00005483571],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916047,0.000027044098,0.00023877757,0.00020761814,0.00020233548,0.00016376036],"domain_scores_gemma":[0.9995574,0.000115325645,0.000059382506,0.00011265826,0.00006817412,0.00008705995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003016303,0.00011126457,0.0002430309,0.00018848685,0.000040390787,0.000016886937,0.000033349952,0.0001295477,0.000026198177],"category_scores_gemma":[0.00002818167,0.000102508806,0.000032082116,0.00014171787,0.000065265805,0.0001412516,0.0000050196118,0.00013869992,0.0000015290383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025266574,0.000165397,0.0016679076,0.00051759166,0.00003998612,0.000018514133,0.0014857813,0.000016860622,0.96893567,0.0010417608,0.000016801367,0.023567079],"study_design_scores_gemma":[0.049350746,0.0007859328,0.11246751,0.00010141131,0.00007943675,0.00024993726,0.000024938941,0.006115508,0.8266592,0.003918871,0.000109320994,0.00013717663],"about_ca_topic_score_codex":0.0061558904,"about_ca_topic_score_gemma":0.0024625154,"teacher_disagreement_score":0.14227645,"about_ca_system_score_codex":0.00023781945,"about_ca_system_score_gemma":0.00070823,"threshold_uncertainty_score":0.9305906},"labels":[],"label_agreement":null},{"id":"W4250158065","doi":"10.3410/f.725658391.793508544","title":"Faculty Opinions recommendation of Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.","year":2015,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Ibrutinib; Lymphoma; Cancer research; Receptor; Diffuse large B-cell lymphoma; Computational biology; Chemistry; Medicine; Biology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.0298679560673918,"score_gpt":0.34778218635369756,"score_spread":0.3179142302863058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250158065","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032680295,0.0024037878,0.00002271831,0.04707504,0.00049500645,0.0025281475,0.94722325,0.000047836966,0.00017153256],"genre_scores_gemma":[0.00012436506,0.0005879811,0.0015125315,0.0022192907,0.00040069083,0.00028273338,0.9933189,0.00007139252,0.0014820917],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.992083,0.0007399871,0.002311054,0.0010362025,0.003007681,0.00082206115],"domain_scores_gemma":[0.98792744,0.00034022777,0.0018655871,0.0018344494,0.007351778,0.0006805482],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035846543,0.00075054576,0.0016591595,0.0006928877,0.00018711822,0.000117397736,0.0015069422,0.0010077817,0.000497673],"category_scores_gemma":[0.007382859,0.0004682608,0.0005411315,0.0034138022,0.00039122847,0.00033943355,0.00073114596,0.0014462731,0.000105521336],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014241123,0.0035141755,0.000012755938,0.023158502,0.00009829204,0.0000033098147,0.00031380885,2.883509e-7,0.000015624524,0.000015143353,0.97236955,0.00035615874],"study_design_scores_gemma":[0.021718541,0.00035123882,0.000057571247,0.019147951,0.0002249897,0.000057344725,0.0001703739,0.00007679382,0.000300629,0.000004150862,0.9574477,0.00044273323],"about_ca_topic_score_codex":0.0002466617,"about_ca_topic_score_gemma":0.000011274842,"teacher_disagreement_score":0.046095677,"about_ca_system_score_codex":0.0031480696,"about_ca_system_score_gemma":0.009452159,"threshold_uncertainty_score":0.9997769},"labels":[],"label_agreement":null},{"id":"W4250514733","doi":"10.22541/au.158938624.45527761","title":"A case LGL leukemia with paucity of erythropoiesis.","year":2020,"lang":"en","type":"preprint","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre; Royal Columbian Hospital","funders":"","keywords":"Immunophenotyping; Lymphocytosis; Erythropoiesis; Pathology; Medicine; Bone marrow; Neutropenia; Leukemia; Bone marrow examination; Immunohistochemistry; Biopsy; Anemia; Internal medicine; Immunology; Chemotherapy","score_opus":0.060971213375126426,"score_gpt":0.32438039540489794,"score_spread":0.2634091820297715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250514733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587352,0.00045184977,0.0032362167,0.002078649,0.00015861522,0.0018395014,0.000079640944,0.00026618686,0.03315409],"genre_scores_gemma":[0.9866817,0.00012900845,0.009834234,0.00039483272,0.00027049216,0.00006953669,0.00007418384,0.0000819597,0.0024640344],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9970455,0.00008011993,0.0005783066,0.0008518788,0.00097652274,0.00046767804],"domain_scores_gemma":[0.9972799,0.0002051707,0.00022787976,0.0014045329,0.00040353378,0.00047899247],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029025503,0.00041926684,0.0011702448,0.00016833041,0.00004826182,0.000028514856,0.00027693584,0.00045051947,0.001173128],"category_scores_gemma":[0.0003245683,0.00029537422,0.0002544682,0.00032051496,0.0005072386,0.000037633163,0.0012276494,0.001212008,0.000091671194],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015853485,0.0017099105,0.0060813553,0.06909129,0.009758697,0.68249685,0.009418725,0.002124067,0.0060747666,0.0056889625,0.17537138,0.016330544],"study_design_scores_gemma":[0.17705345,0.009997513,0.0038290776,0.011034355,0.0071146316,0.36296567,0.0044624,0.23328115,0.16179353,0.0051153842,0.017772993,0.0055798227],"about_ca_topic_score_codex":0.02692088,"about_ca_topic_score_gemma":0.001245346,"teacher_disagreement_score":0.31953114,"about_ca_system_score_codex":0.018274957,"about_ca_system_score_gemma":0.042335834,"threshold_uncertainty_score":0.9999498},"labels":[],"label_agreement":null},{"id":"W4254301808","doi":"10.15586/jptcp.v26i3.654","title":"Abstracts CAPT / ACTP Annual Meeting 2019","year":2019,"lang":"en","type":"article","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Statistics; Mathematics","score_opus":0.045044666297513795,"score_gpt":0.43712938636580395,"score_spread":0.39208472006829015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254301808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945064,0.00071790727,0.000018779854,0.0026850472,0.0014673991,0.00020288872,0.0000034281088,0.000007921592,0.0003902247],"genre_scores_gemma":[0.9943485,0.0010418416,0.00025742903,0.002778203,0.0010535979,4.6819815e-7,0.000005140429,0.000017007042,0.0004977763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981226,0.00016224997,0.001017104,0.00015052904,0.0003247144,0.00022281698],"domain_scores_gemma":[0.9981697,0.00066260947,0.0005476773,0.00010295697,0.00030279197,0.00021425234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015148808,0.00010412316,0.0004393221,0.000105935585,0.00003586511,0.000013653349,0.00009598768,0.0001896117,0.00028358283],"category_scores_gemma":[0.00009481444,0.000078610836,0.00016317981,0.0000850516,0.000075280564,0.00011163599,0.00004209375,0.00059810455,0.00004207905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01792183,0.0039163986,0.68619037,0.0006366076,0.0065493607,0.0010536119,0.0016458656,0.0029847668,0.06300121,0.0009810443,0.027353449,0.18776548],"study_design_scores_gemma":[0.07480144,0.0057670795,0.7916111,0.0002325924,0.001665463,0.0020917605,0.000677938,0.02388447,0.0018001011,0.0013953547,0.09563527,0.00043743968],"about_ca_topic_score_codex":0.00008043056,"about_ca_topic_score_gemma":0.0000035955918,"teacher_disagreement_score":0.18732804,"about_ca_system_score_codex":0.0005767342,"about_ca_system_score_gemma":0.000737328,"threshold_uncertainty_score":0.3205657},"labels":[],"label_agreement":null},{"id":"W4255380540","doi":"10.3410/f.732225847.793577571","title":"Faculty Opinions recommendation of Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Gastroenterology; Neutropenia; Pharmacodynamics; Chronic lymphocytic leukemia; Lymphoma; Anemia; Febrile neutropenia; Refractory (planetary science); Leukemia; Pharmacokinetics; Toxicity","score_opus":0.05916416612696335,"score_gpt":0.40590958347926576,"score_spread":0.3467454173523024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255380540","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024473304,0.0005148523,0.000024214869,0.14460333,0.0004888418,0.0025907212,0.8516833,0.000029379135,0.00004088197],"genre_scores_gemma":[0.00013090711,0.0006414002,0.002274978,0.006520193,0.00021431466,0.00030843975,0.9895387,0.000042056625,0.0003290003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917619,0.00047317415,0.0035969405,0.001068958,0.0025328023,0.0005661798],"domain_scores_gemma":[0.98737466,0.00054508494,0.0026054722,0.0017215646,0.0072538946,0.0004992961],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018998208,0.0006695296,0.0024261575,0.0005562714,0.00009771188,0.0000469223,0.0013461276,0.0011867251,0.00042921826],"category_scores_gemma":[0.027368087,0.00044169175,0.00095035404,0.0036807747,0.00079769565,0.00032791545,0.0010018832,0.001907624,0.00005687764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033080037,0.0012280482,0.000009575493,0.018108878,0.0002403504,0.0000038451485,0.00033064638,1.7061406e-7,0.00004010444,0.00010769728,0.9781272,0.0014727303],"study_design_scores_gemma":[0.008386037,0.0006896009,0.0008702645,0.024684189,0.00024281004,0.00015654281,0.00012666892,0.000056774916,0.00027580047,0.000016646125,0.9641532,0.00034152158],"about_ca_topic_score_codex":0.00016003412,"about_ca_topic_score_gemma":0.000012173833,"teacher_disagreement_score":0.13808315,"about_ca_system_score_codex":0.0016979111,"about_ca_system_score_gemma":0.008197093,"threshold_uncertainty_score":0.9998035},"labels":[],"label_agreement":null},{"id":"W4255635546","doi":"10.1136/annrheumdis-2018-eular.2000","title":"SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Rheumatoid arthritis; Internal medicine","score_opus":0.016091694757812455,"score_gpt":0.2963769753966236,"score_spread":0.28028528063881114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255635546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958123,0.0005493259,0.000009805108,0.00030072217,0.00005361284,0.0029007457,0.00020065304,0.000019480334,0.00015337333],"genre_scores_gemma":[0.99961114,0.00015017725,0.000030701638,0.000022192287,0.000020171812,0.0000754215,0.000018666022,0.000028664674,0.00004284321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697566,0.00029083155,0.0009875142,0.00033825473,0.0010563208,0.00035144383],"domain_scores_gemma":[0.996808,0.0003191367,0.00064390904,0.0008899069,0.0011302717,0.00020876263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056072074,0.00021191461,0.0007568762,0.00023538791,0.000068829264,0.000011548704,0.00026845583,0.000039253173,0.000030232532],"category_scores_gemma":[0.003802737,0.00013755762,0.0001651592,0.00066737126,0.0006826675,0.00015842213,0.00013603168,0.00011089784,0.00000226516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07802218,0.0137730045,0.88492155,0.0019665966,0.0012440413,0.000024232624,0.0059749447,0.00016310596,0.00005510994,0.000304014,0.0006878692,0.01286333],"study_design_scores_gemma":[0.053522903,0.0026814884,0.93579245,0.0044327653,0.00011937403,0.0000027846288,0.0019756125,0.0005889674,0.00035325173,0.00040147395,0.0000020111042,0.00012689545],"about_ca_topic_score_codex":0.0007054159,"about_ca_topic_score_gemma":0.000045611367,"teacher_disagreement_score":0.0508709,"about_ca_system_score_codex":0.00046691357,"about_ca_system_score_gemma":0.0025632817,"threshold_uncertainty_score":0.5609437},"labels":[],"label_agreement":null},{"id":"W4255715078","doi":"10.1515/iupac.84.0814","title":"Large Granular Lymphocyte (LGL)","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Immunology; Medicine; Immune system; Philosophy; Linguistics","score_opus":0.016662020881402825,"score_gpt":0.42078144788991945,"score_spread":0.4041194270085166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255715078","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047465018,0.004876088,0.00018056323,0.00083274976,0.0008891354,0.0010712717,0.9912523,0.00018496945,0.00023827828],"genre_scores_gemma":[0.00008310464,0.0063659046,0.000052581123,0.0010766328,0.0026867185,0.00005648493,0.9856729,0.00015894874,0.0038467061],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921646,0.0001704744,0.00094302994,0.0011971745,0.00390138,0.0016233433],"domain_scores_gemma":[0.994711,0.00025296284,0.00031292194,0.0027382805,0.0011310575,0.00085379736],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014563475,0.0008804235,0.0016802707,0.0006001428,0.00020258522,0.00007951143,0.0007668316,0.0010516365,0.011078171],"category_scores_gemma":[0.0017895505,0.0006310043,0.00057540846,0.00050380133,0.00038147523,0.00011582089,0.0006253441,0.0009868061,0.00007822377],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015761515,0.0005599545,0.0000055276996,0.001076866,0.00035162797,0.00315699,0.000020725662,3.1378588e-7,0.000024592528,0.000017979059,0.9907614,0.0024478545],"study_design_scores_gemma":[0.04003284,0.0005833747,0.000010453958,0.0017797475,0.0005083128,0.0008236281,0.00003216913,0.00008439197,0.00013953538,0.000088115325,0.9552728,0.00064461015],"about_ca_topic_score_codex":0.00059257535,"about_ca_topic_score_gemma":0.00072315376,"teacher_disagreement_score":0.03845669,"about_ca_system_score_codex":0.047236577,"about_ca_system_score_gemma":0.048994806,"threshold_uncertainty_score":0.9996141},"labels":[],"label_agreement":null},{"id":"W4255942265","doi":"10.1158/1538-7445.sabcs18-ct139","title":"Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Afatinib; Medicine; Oncology; Internal medicine; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.22928919311886034,"score_gpt":0.5331464358580582,"score_spread":0.3038572427391979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255942265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311423,0.000052853895,0.00015998264,0.00013874035,0.00012538394,0.006027796,0.000040144194,0.000034876815,0.00030600393],"genre_scores_gemma":[0.99849343,0.000018840934,0.00065523136,0.00013643323,0.00016362849,0.00023290528,0.00010705484,0.000052747568,0.00013970495],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943546,0.000737966,0.0027968255,0.0007239471,0.0009530207,0.00043364754],"domain_scores_gemma":[0.9848024,0.012317388,0.0011454888,0.00091726496,0.00057512237,0.00024233565],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008005743,0.00027470035,0.002214826,0.0003527813,0.00008285139,0.00003294668,0.00027323994,0.00023349226,0.00045986765],"category_scores_gemma":[0.016031599,0.00019819787,0.0005946409,0.0010540098,0.00011217252,0.00014258239,0.00007656372,0.00043295964,0.000017320885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05644432,0.104408845,0.5891706,0.00067335536,0.017899387,0.00011179045,0.004662275,0.0056264955,0.00727882,0.000064788226,0.00024786004,0.21341147],"study_design_scores_gemma":[0.6921658,0.05360559,0.23322953,0.00047136337,0.0019805192,0.00000174291,0.0024113778,0.0071530435,0.0075696055,0.00013627566,0.00065752957,0.00061765884],"about_ca_topic_score_codex":0.00064392446,"about_ca_topic_score_gemma":0.00008857743,"teacher_disagreement_score":0.63572145,"about_ca_system_score_codex":0.0009733287,"about_ca_system_score_gemma":0.0018646533,"threshold_uncertainty_score":0.99225676},"labels":[],"label_agreement":null},{"id":"W4256686146","doi":"10.1136/annrheumdis-2012-eular.3080","title":"SAT0133 Golimumab 3-year safety update: An analysis of pooled data from the long term extensions of randomized, double-blind, placebo-controlled studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","year":2012,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Golimumab; Psoriatic arthritis; Placebo; Rheumatoid arthritis; Concomitant; Ankylosing spondylitis; Internal medicine; Randomized controlled trial; Clinical trial; Surgery; Adalimumab; Pathology","score_opus":0.09185075273306532,"score_gpt":0.3832808226158837,"score_spread":0.2914300698828184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256686146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84539753,0.15014574,0.000028055354,0.0006010243,0.00012291799,0.0022491175,0.0014129662,0.000017161672,0.000025493537],"genre_scores_gemma":[0.88017136,0.11884466,0.00011724069,0.000096961565,0.000044313834,0.00009702487,0.0005846126,0.000031599466,0.000012247787],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943834,0.0013785695,0.002119525,0.000460902,0.0010811663,0.00057644414],"domain_scores_gemma":[0.9901228,0.005807886,0.0010275713,0.0023277705,0.00042492573,0.0002890534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038864275,0.00035780953,0.0035505374,0.00039670776,0.0001545443,0.000040270003,0.00074804394,0.000104551,0.00029131208],"category_scores_gemma":[0.006710024,0.00021123409,0.0006268604,0.00089536986,0.0013460814,0.0004976225,0.0007335088,0.00020788099,0.0000038462854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86205596,0.0028512296,0.043125506,0.0015015765,0.03689982,0.000039306833,0.0068744216,0.00031901652,0.000061838444,0.0018666975,0.0008771242,0.04352752],"study_design_scores_gemma":[0.87032855,0.00011672522,0.09162981,0.01158078,0.006963706,0.0000425098,0.00397555,0.013703813,0.00031448857,0.0009933629,0.00000953458,0.00034118118],"about_ca_topic_score_codex":0.0021799044,"about_ca_topic_score_gemma":0.0008372835,"teacher_disagreement_score":0.048504304,"about_ca_system_score_codex":0.00025684046,"about_ca_system_score_gemma":0.0010955258,"threshold_uncertainty_score":0.8613876},"labels":[],"label_agreement":null},{"id":"W4280582101","doi":"10.1111/bjh.18241","title":"Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; University of British Columbia","funders":"Servier; Gilead Sciences; AstraZeneca","keywords":"Medicine; ABVD; Internal medicine; Cohort; Population; Chronic lymphocytic leukemia; Gastroenterology; Oncology; Surgery; Chemotherapy; Leukemia; Vincristine; Cyclophosphamide","score_opus":0.013864597988323587,"score_gpt":0.2579462476717944,"score_spread":0.24408164968347082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280582101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990846,0.008692565,0.00009128148,0.00014379449,0.00024499142,0.0006205589,0.000032922148,0.000014642912,0.0002508141],"genre_scores_gemma":[0.99727744,0.0017961847,0.00036229478,0.00024236087,0.00004380383,0.00005538622,0.00001588114,0.000048850106,0.00015782051],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99573183,0.00052976824,0.0019160095,0.00036312966,0.0007450536,0.00071420026],"domain_scores_gemma":[0.99835014,0.0004254417,0.00055078976,0.00025534042,0.00019340802,0.00022487718],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016828952,0.00019253507,0.0016392645,0.00054713804,0.0001260232,0.00010413385,0.0003763131,0.00021267457,0.00042541197],"category_scores_gemma":[0.0004151423,0.00030436018,0.00022097281,0.00070940534,0.0003139744,0.00024833312,0.000197837,0.0005036241,0.0000036236415],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019305253,0.0014280762,0.09964208,0.003870545,0.00089160784,0.7091481,0.0035016434,0.0043370537,0.0009310088,0.00027322388,0.002367606,0.1716785],"study_design_scores_gemma":[0.070770875,0.00093919004,0.12293754,0.00112389,0.00013718715,0.7876686,0.00089299347,0.0140574025,0.00012919394,0.0005438947,0.0005111776,0.00028809666],"about_ca_topic_score_codex":0.0786786,"about_ca_topic_score_gemma":0.09392884,"teacher_disagreement_score":0.1713904,"about_ca_system_score_codex":0.050017115,"about_ca_system_score_gemma":0.023502886,"threshold_uncertainty_score":0.9999409},"labels":[],"label_agreement":null},{"id":"W4280633133","doi":"10.3389/fonc.2022.885150","title":"Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Shandong First Medical University; Natural Science Foundation of Shandong Province; Key Technology Research and Development Program of Shandong; National Natural Science Foundation of China","keywords":"Medicine; Chronic lymphocytic leukemia; Epidemiology; Internal medicine; Cohort; Oncology; Stage (stratigraphy); Young adult; Pediatrics; Leukemia","score_opus":0.012009003146795648,"score_gpt":0.35188175028677765,"score_spread":0.339872747139982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280633133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888779,0.0031791602,0.00013323208,0.00042135007,0.0009896032,0.0010458108,0.00001528161,0.000060130627,0.0052775387],"genre_scores_gemma":[0.9926221,0.0013387882,0.0036617413,0.00020671226,0.00015156202,0.00029812215,0.000077866585,0.000052561067,0.0015905554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961919,0.0010327836,0.00076090853,0.0007583235,0.00053679384,0.0007192553],"domain_scores_gemma":[0.99835104,0.0006238722,0.00022316979,0.0005142094,0.000039294457,0.00024842608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002013538,0.00028445182,0.0010644277,0.00048386207,0.00015792582,0.000018614752,0.00028780889,0.00029369554,0.00018849625],"category_scores_gemma":[0.00045790337,0.00022706056,0.000096114825,0.00088833424,0.00072951097,0.0000704672,0.00046203847,0.0021841053,0.000005040958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0031762058,0.00031360477,0.92962307,0.00012507217,0.00031070245,0.01036941,0.00068693695,0.003388778,0.00001474435,0.000072778006,0.016280994,0.035637688],"study_design_scores_gemma":[0.07988136,0.0055417996,0.7846159,0.00008025283,0.00014466397,0.0021475828,0.0006171037,0.11515247,0.0000024551314,0.000831042,0.010666767,0.00031865033],"about_ca_topic_score_codex":0.0042051864,"about_ca_topic_score_gemma":0.0036085672,"teacher_disagreement_score":0.17544827,"about_ca_system_score_codex":0.22693738,"about_ca_system_score_gemma":0.05148911,"threshold_uncertainty_score":0.95388806},"labels":[],"label_agreement":null},{"id":"W4281385697","doi":"10.1182/blood.2021015014","title":"Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Servier; BeiGene; Adaptive Biotechnologies; TG Therapeutics; Incyte; F. Hoffmann-La Roche; Amsterdam University Medical Centers; Gilead Sciences; Universiteit van Amsterdam; Leukemia and Lymphoma Society; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen; Breast Cancer Research Foundation; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine","keywords":"Rituximab; Medicine; Venetoclax; Bendamustine; Internal medicine; Regimen; Population; Progression-free survival; Oncology; Chemotherapy regimen; Gastroenterology; Chemotherapy; Surgery; Chronic lymphocytic leukemia; Leukemia; Lymphoma","score_opus":0.011650595634157547,"score_gpt":0.260368235767024,"score_spread":0.24871764013286646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281385697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712193,0.0010200819,0.000003157488,0.00020816966,0.00009506032,0.00048246776,0.00001493806,0.00006592569,0.0009882393],"genre_scores_gemma":[0.9971553,0.000038540933,0.00015801494,0.0002000986,0.00005862866,0.00020871675,0.000037969912,0.000036187368,0.0021065262],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99834293,0.0001073782,0.0003192991,0.00035896007,0.0004763233,0.00039508767],"domain_scores_gemma":[0.9993273,0.00010032568,0.000059013597,0.00036542938,0.00003147225,0.000116443814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003496589,0.00015084872,0.00031149853,0.00022832064,0.00010933295,0.000026074582,0.00010327567,0.00008100756,0.00068399834],"category_scores_gemma":[0.00011224137,0.00014611581,0.00005073591,0.0003124973,0.00005011896,0.000091872134,0.00025835124,0.00045960763,0.00003453734],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010550329,0.018528903,0.7814404,0.0023903667,0.0019842556,0.018403126,0.010799272,0.0008401895,0.13122551,0.0004906111,0.0036214688,0.019725576],"study_design_scores_gemma":[0.46491006,0.0033812546,0.4127929,0.00037350206,0.0007562676,0.0028158897,0.0026878626,0.015825473,0.06270841,0.00059875514,0.031549357,0.0016002785],"about_ca_topic_score_codex":0.0004923367,"about_ca_topic_score_gemma":0.00014899585,"teacher_disagreement_score":0.45435974,"about_ca_system_score_codex":0.005076632,"about_ca_system_score_gemma":0.0019846174,"threshold_uncertainty_score":0.9987427},"labels":[],"label_agreement":null},{"id":"W4281741129","doi":"10.1158/2159-8290.cd-21-1566","title":"<i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL","year":2022,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; BC Cancer Agency; Spinal Cord Injury BC","funders":"Biological and Environmental Research; National Institute of General Medical Sciences; Janssen Pharmaceuticals; Office of Science; National Cancer Institute; National Institutes of Health; Oregon Health and Science University; University of Massachusetts; Chemotherapy Foundation; Weill Cornell Medical College; U.S. Department of Energy","keywords":"Computational biology; Lymphoma; Biology; Computer science; Immunology","score_opus":0.07086758458928333,"score_gpt":0.3538555656119032,"score_spread":0.28298798102261985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281741129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484594,0.0069439546,0.0027230228,0.0011804296,0.0006305967,0.0013035843,0.00040476274,0.000075850156,0.001891837],"genre_scores_gemma":[0.9872367,0.00053758954,0.00031082638,0.000636179,0.00036271597,0.0018481717,0.0002335411,0.00005388902,0.008780384],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819833,0.000051844527,0.00028066014,0.00040288529,0.00065587857,0.00041040574],"domain_scores_gemma":[0.99887216,0.00042195283,0.00008596208,0.00040313645,0.00010839929,0.000108407454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036122766,0.00016043737,0.00026767,0.00011102523,0.0004496804,0.000066287714,0.0002165181,0.000040928502,0.00055048434],"category_scores_gemma":[0.00021799425,0.00013717264,0.00017913517,0.0003329712,0.00008859406,0.00021918886,0.00019217777,0.00015222112,0.000009534172],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.020887094,0.0045958324,0.08010509,0.0022112364,0.002466798,0.00080006476,0.010845114,0.014520371,0.12443945,0.011921923,0.4264561,0.30075094],"study_design_scores_gemma":[0.15410066,0.0038356911,0.026196234,0.00072569324,0.0006939728,0.0009955716,0.006435281,0.04059022,0.07476511,0.010054729,0.6796699,0.0019369257],"about_ca_topic_score_codex":0.00071244227,"about_ca_topic_score_gemma":0.00009700751,"teacher_disagreement_score":0.29881403,"about_ca_system_score_codex":0.009323769,"about_ca_system_score_gemma":0.006156916,"threshold_uncertainty_score":0.99947727},"labels":[],"label_agreement":null},{"id":"W4281742951","doi":"10.1200/jco.2022.40.16_suppl.7577","title":"Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Population; Leukemia; Proportional hazards model; Confidence interval; Clinical trial","score_opus":0.11348216683812196,"score_gpt":0.4868015602983076,"score_spread":0.37331939346018567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281742951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997941,0.00004538615,0.000014067917,0.0002496118,0.00025108238,0.00032548618,0.0000901717,0.0000061088995,0.0010770389],"genre_scores_gemma":[0.998433,0.000032891374,0.00056136184,0.00047922216,0.00014236948,0.0000047244816,0.000117918025,0.000027227432,0.0002012627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933779,0.0011828536,0.0029655208,0.000455007,0.001600862,0.0004178204],"domain_scores_gemma":[0.99260813,0.0023528477,0.0026771529,0.0014248508,0.00037863594,0.0005584037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00416479,0.00021533604,0.0025175526,0.0005670478,0.00005212594,0.0000088823135,0.000877861,0.0002636221,0.00047096165],"category_scores_gemma":[0.00242172,0.00013633634,0.00061687385,0.0007243029,0.0003089714,0.00018340164,0.0005281895,0.0020660902,0.0000034876164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013265939,0.0077244597,0.9540831,0.000027255335,0.0016609892,0.0010228931,0.00020389387,0.0069589857,0.000004214601,0.0000019267159,0.0028153532,0.012230989],"study_design_scores_gemma":[0.042410843,0.0650472,0.88428706,0.000031252493,0.0007635156,0.000043531694,0.00028059317,0.005823696,0.000007973251,0.000011726486,0.0011676269,0.00012500673],"about_ca_topic_score_codex":0.0010822973,"about_ca_topic_score_gemma":0.00025782973,"teacher_disagreement_score":0.06979606,"about_ca_system_score_codex":0.01467147,"about_ca_system_score_gemma":0.028993534,"threshold_uncertainty_score":0.989111},"labels":[],"label_agreement":null},{"id":"W4281761035","doi":"10.1200/jco.2022.40.16_suppl.e19522","title":"A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Chemoimmunotherapy; Internal medicine; Expanded access; Bruton's tyrosine kinase; Waldenstrom macroglobulinemia; Gastroenterology; Tyrosine kinase; Rituximab; Lymphoma","score_opus":0.15126326786819344,"score_gpt":0.5337357547382141,"score_spread":0.38247248687002067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281761035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965623,0.00007237261,0.000008694982,0.0006859763,0.0005864599,0.0008952202,0.000008468555,0.000007525607,0.0011729561],"genre_scores_gemma":[0.9985105,0.000056164266,0.00029388216,0.00058785186,0.00031704918,0.000026018964,0.0000064274636,0.000027421867,0.00017470986],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99304414,0.0011225095,0.0034854594,0.00033214182,0.0015919874,0.00042376548],"domain_scores_gemma":[0.9942337,0.00197533,0.0022502672,0.00041970483,0.00068792445,0.00043304055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004481306,0.00018562298,0.0020412046,0.00037189655,0.00006374294,0.000011335881,0.00065217144,0.00019261467,0.0007120149],"category_scores_gemma":[0.0028664193,0.00013191403,0.0002722597,0.0006181904,0.0002464856,0.00013793998,0.00052785006,0.0019753962,0.0000047034246],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11465022,0.11555699,0.6157791,0.0000953626,0.0008660157,0.009692049,0.0015955197,0.000345501,0.00006354451,0.000010684078,0.0050251638,0.13631988],"study_design_scores_gemma":[0.5661072,0.26728827,0.1555919,0.00012228625,0.00036318527,0.0010107663,0.0025295112,0.0006716605,0.00010031546,0.000058461486,0.0059627136,0.00019370328],"about_ca_topic_score_codex":0.00027908265,"about_ca_topic_score_gemma":0.0001708295,"teacher_disagreement_score":0.46018717,"about_ca_system_score_codex":0.005214669,"about_ca_system_score_gemma":0.01820285,"threshold_uncertainty_score":0.9986041},"labels":[],"label_agreement":null},{"id":"W4281784552","doi":"10.1200/jco.2022.40.16_suppl.7539","title":"Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chlorambucil; Medicine; Obinutuzumab; Internal medicine; Gastroenterology; Hazard ratio; Chronic lymphocytic leukemia; Leukemia; Chemotherapy; Confidence interval; Cyclophosphamide","score_opus":0.13043412768771115,"score_gpt":0.44409590525325937,"score_spread":0.31366177756554825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281784552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874226,0.0018575836,0.000009156461,0.0006245838,0.00402924,0.0007687452,0.00003199357,0.000030208746,0.0052258796],"genre_scores_gemma":[0.9917085,0.0023450889,0.00047699417,0.0003409861,0.0014406063,0.00005979486,0.00002606402,0.000080898666,0.0035210785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990189,0.0013630776,0.0049296436,0.0006696843,0.0017766223,0.0010719529],"domain_scores_gemma":[0.9885758,0.006470025,0.0026785189,0.00086281373,0.0006405699,0.0007722325],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00536145,0.00045451504,0.003681275,0.0006463621,0.00014380238,0.000017709028,0.00085600204,0.0007661037,0.00191784],"category_scores_gemma":[0.0063453387,0.00037251858,0.0014532345,0.0010370141,0.00067937374,0.00020575906,0.00053576415,0.0025181042,0.00010433258],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.56583256,0.0055399844,0.0079492675,0.0011487483,0.009550442,0.040457316,0.00422086,0.052446,0.0036241196,0.0024748093,0.04807367,0.25868222],"study_design_scores_gemma":[0.66964674,0.1528348,0.0034873283,0.00034114593,0.0014117517,0.0030855238,0.0025730638,0.034290038,0.0013111403,0.00041844713,0.13000895,0.0005910358],"about_ca_topic_score_codex":0.0023875844,"about_ca_topic_score_gemma":0.0005537728,"teacher_disagreement_score":0.2580912,"about_ca_system_score_codex":0.47550443,"about_ca_system_score_gemma":0.3827695,"threshold_uncertainty_score":0.9998727},"labels":[],"label_agreement":null},{"id":"W4281953617","doi":"10.1200/jco.2022.40.16_suppl.7538","title":"Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Internal medicine; Chronic lymphocytic leukemia; Tolerability; Gastroenterology; Rituximab; Refractory (planetary science); Toxicity; Progression-free survival; Oncology; Ibrutinib; Leukemia; Overall survival; Adverse effect; Lymphoma","score_opus":0.1575472935405038,"score_gpt":0.46104441983569244,"score_spread":0.30349712629518866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281953617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881307,0.0020113487,0.000005308086,0.0012406139,0.004628369,0.0005158363,0.00005406672,0.000023330771,0.003390454],"genre_scores_gemma":[0.9908279,0.001605281,0.0005908842,0.00054913986,0.0014344056,0.000019811516,0.000029675111,0.00006993071,0.004872955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9891681,0.0014521084,0.0058851363,0.00061028794,0.0020087562,0.00087563344],"domain_scores_gemma":[0.981927,0.012775232,0.0032775495,0.00079153175,0.0005092825,0.0007194522],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010246708,0.00031448907,0.0032318772,0.0005977985,0.000113045266,0.000009403796,0.0008278886,0.00076979224,0.0015469564],"category_scores_gemma":[0.025467524,0.000265312,0.00090610195,0.0009221803,0.00067258434,0.00013581966,0.00095647457,0.0035903659,0.00008292671],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7412454,0.0030974508,0.000845383,0.0004891012,0.0016656558,0.03858717,0.00134142,0.010993209,0.0008309819,0.00014156538,0.08878946,0.11197319],"study_design_scores_gemma":[0.6644254,0.06365177,0.006101202,0.00035238088,0.0006617998,0.003486056,0.0006904094,0.013498424,0.00018172171,0.00006350305,0.24654521,0.0003421322],"about_ca_topic_score_codex":0.0008884569,"about_ca_topic_score_gemma":0.0008375262,"teacher_disagreement_score":0.15775575,"about_ca_system_score_codex":0.21939978,"about_ca_system_score_gemma":0.21308236,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W4281986919","doi":"10.1200/jco.2022.40.16_suppl.7549","title":"Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Progressive disease; Progression-free survival; Bruton's tyrosine kinase; Phases of clinical research; Tolerability; Nausea; Ibrutinib; Oncology; Clinical trial; Surgery; Adverse effect; Chronic lymphocytic leukemia; Chemotherapy; Leukemia; Tyrosine kinase","score_opus":0.1423006420353606,"score_gpt":0.48529417237053707,"score_spread":0.34299353033517643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281986919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99318445,0.00019206629,0.000018134318,0.0018974231,0.0012008013,0.0014146394,0.000052754538,0.000006777456,0.0020329452],"genre_scores_gemma":[0.9947406,0.00016204656,0.002580212,0.0010737792,0.00041466815,0.00003334821,0.000030542167,0.000040796727,0.00092402],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905964,0.0018510484,0.0049555474,0.0004379166,0.0016303315,0.0005287663],"domain_scores_gemma":[0.9894992,0.0047360673,0.0038326476,0.00056664663,0.0007826117,0.0005828168],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010480465,0.00022787788,0.0024266068,0.00040543868,0.000079096106,0.000014222211,0.0008819035,0.00032929177,0.00035541292],"category_scores_gemma":[0.0093459925,0.00016617743,0.00025593364,0.0005651561,0.00043700062,0.00023606744,0.0007084762,0.0017978478,0.000011543762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.79744947,0.0763676,0.00411243,0.00004981658,0.00038399143,0.0023301595,0.00018570409,0.000017626087,0.000043471733,0.000018755489,0.007829781,0.11121118],"study_design_scores_gemma":[0.76031274,0.1511667,0.013033982,0.00016469012,0.00020597813,0.00016889,0.00016977964,0.0006962142,0.000024419525,0.000016130405,0.07391723,0.00012325271],"about_ca_topic_score_codex":0.0003124359,"about_ca_topic_score_gemma":0.000049016875,"teacher_disagreement_score":0.111087926,"about_ca_system_score_codex":0.008532936,"about_ca_system_score_gemma":0.030652381,"threshold_uncertainty_score":0.9989987},"labels":[],"label_agreement":null},{"id":"W4282039306","doi":"10.17975/sfj-2022-008","title":"Comparative analysis of NX-2127 and ibrutinib in treating B-cell malignancies","year":2022,"lang":"en","type":"article","venue":"STEM Fellowship Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Mary's University","funders":"","keywords":"Ibrutinib; Small molecule; Cancer research; Pharmacology; Medicine; Chemistry; Internal medicine; Biochemistry; Leukemia; Chronic lymphocytic leukemia","score_opus":0.045884729854651383,"score_gpt":0.3278531899280253,"score_spread":0.28196846007337395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282039306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98867357,0.0021524725,0.000036345406,0.0001219467,0.000057769565,0.00019915568,0.000015658261,0.000008688227,0.008734417],"genre_scores_gemma":[0.99737144,0.00007854525,0.00028163797,0.00005483241,0.000047432408,0.000012599361,0.000008557427,0.000011085756,0.0021338605],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9977865,0.00032379598,0.00057650876,0.00022445148,0.00072785217,0.0003608868],"domain_scores_gemma":[0.9988766,0.0003651854,0.00026197248,0.0002083071,0.00011017901,0.00017780186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012611252,0.00014043311,0.0007286465,0.00082364917,0.0001935533,0.000030980624,0.00015208924,0.000041505402,0.00049037865],"category_scores_gemma":[0.000038954648,0.00012118913,0.00018788295,0.0014536831,0.00012939032,0.00007255454,0.00015852555,0.0005506868,0.0000032025407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050175814,0.0023210444,0.78062105,0.0010848037,0.0062784683,0.005493587,0.09989676,0.022788294,0.06349935,0.0009037751,0.0035687655,0.008526509],"study_design_scores_gemma":[0.12758833,0.0063215145,0.19314842,0.0011002036,0.007861638,0.0088356035,0.2736125,0.31952527,0.05219294,0.00046022705,0.0077233156,0.001630054],"about_ca_topic_score_codex":0.0002331613,"about_ca_topic_score_gemma":0.00008517912,"teacher_disagreement_score":0.5874726,"about_ca_system_score_codex":0.0034949647,"about_ca_system_score_gemma":0.002054577,"threshold_uncertainty_score":0.9139211},"labels":[],"label_agreement":null},{"id":"W4282922002","doi":"10.3390/curroncol29060339","title":"Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Hazard ratio; Neutropenia; Adverse effect; Placebo; Discontinuation; Chronic lymphocytic leukemia; Confidence interval; Odds ratio; Maintenance therapy; Randomized controlled trial; Multiple myeloma; Oncology; Surgery; Leukemia; Chemotherapy","score_opus":0.2671745584863279,"score_gpt":0.5081030390629246,"score_spread":0.24092848057659677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282922002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012994213,0.9935855,0.00010737791,0.000014237162,0.00040920687,0.0040949215,0.00014070193,0.000037843074,0.00031074052],"genre_scores_gemma":[0.001690028,0.9939792,0.000029629235,0.000012971353,0.00025593006,0.002765345,0.0007402662,0.000077769495,0.00044884256],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9888629,0.0047273994,0.0026543569,0.0015974549,0.0011157012,0.0010422262],"domain_scores_gemma":[0.99120617,0.0052807755,0.0015021735,0.0015421257,0.000117737116,0.00035100055],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005729879,0.000945344,0.018534357,0.004685382,0.00008504571,0.000027363034,0.0006735487,0.00069871795,0.00327301],"category_scores_gemma":[0.001355856,0.0006614922,0.009685204,0.008148996,0.0005810482,0.0000638179,0.0007949868,0.0016248637,0.000028182621],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0073488783,0.00017467211,0.000008513508,0.042170517,0.43209702,0.0008799722,0.000075428215,0.00045421583,8.5833983e-7,0.00003428382,0.00029457817,0.5164611],"study_design_scores_gemma":[0.05337217,0.0022927914,5.8591434e-7,0.00028884903,0.5454502,0.0001534013,0.000005197301,0.0039220336,0.0000034195393,0.000004124372,0.39424306,0.0002641892],"about_ca_topic_score_codex":0.0021038377,"about_ca_topic_score_gemma":0.0009037463,"teacher_disagreement_score":0.51619685,"about_ca_system_score_codex":0.29945678,"about_ca_system_score_gemma":0.09015866,"threshold_uncertainty_score":0.9995836},"labels":[],"label_agreement":null},{"id":"W4283009479","doi":"10.1101/2022.06.13.495940","title":"Inhibition of the TPL2-MKK1/2-ERK1/2 pathway has cytostatic effect on B-Cell Lymphoma","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University Health Centre","keywords":"MAPK/ERK pathway; Cancer research; Diffuse large B-cell lymphoma; Lymphoma; Kinase; Signal transduction; Chemistry; Cell culture; Cell biology; Biology; Genetics; Immunology","score_opus":0.017215464053909998,"score_gpt":0.24087136254680075,"score_spread":0.22365589849289075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283009479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937421,0.0007967765,0.000041846353,0.0003764766,0.0011547639,0.002959439,0.0004000843,0.0002624402,0.00026608177],"genre_scores_gemma":[0.99779993,0.00009025791,0.00027717414,0.00044694412,0.00037016696,0.0006657824,0.000002494658,0.00026114593,0.00008612088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9941828,0.0007103763,0.00091901066,0.0013282563,0.0019817965,0.00087773055],"domain_scores_gemma":[0.9946243,0.0005540826,0.0007179658,0.003275942,0.00044575587,0.00038195393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015989487,0.00079040515,0.0011614364,0.0004756803,0.00036073948,0.0001315028,0.0007893943,0.00059603865,0.00036870487],"category_scores_gemma":[0.0009253995,0.00063532486,0.00056727644,0.0011074063,0.00046737224,0.00007939733,0.001534125,0.0014005717,0.00014450654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010833554,0.0017006444,0.0021868676,0.0073462375,0.00046540672,0.00092461635,0.0000942988,0.0002643374,0.98341525,0.00045229594,0.0020384088,0.000028264685],"study_design_scores_gemma":[0.01620018,0.0010468634,0.011508512,0.0019201547,0.00035657428,3.761485e-7,0.000009185436,0.0010907272,0.9603117,0.0000035540113,0.0068925344,0.0006596279],"about_ca_topic_score_codex":0.00036711697,"about_ca_topic_score_gemma":0.0000034837183,"teacher_disagreement_score":0.023103554,"about_ca_system_score_codex":0.016298223,"about_ca_system_score_gemma":0.018052146,"threshold_uncertainty_score":0.9996098},"labels":[],"label_agreement":null},{"id":"W4283311013","doi":"10.1097/01.hs9.0000848268.24972.7c","title":"P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cumulative incidence; Internal medicine; Transplantation; Incidence (geometry); Oncology; Lymphoma; Gastroenterology; Cancer; Immunotherapy","score_opus":0.010859275549186656,"score_gpt":0.22239159879390863,"score_spread":0.211532323244722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283311013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967908,0.0010171517,0.000029324125,0.00014748774,0.000060338625,0.0009644228,0.000040508166,0.00005679888,0.0008931671],"genre_scores_gemma":[0.99764407,0.000254281,0.00011693367,0.00055391894,0.000024598101,0.00035919237,0.00014492322,0.00004903234,0.00085303624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997968,0.00013603836,0.0003379303,0.00040774158,0.0006796038,0.00047066223],"domain_scores_gemma":[0.99933326,0.000061826206,0.000093495415,0.00034603188,0.00006486111,0.00010052722],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017816234,0.00021806243,0.00036980433,0.00008260813,0.000116842675,0.00001659059,0.00014067862,0.00007331395,0.0015292467],"category_scores_gemma":[0.0000024413794,0.0001711459,0.00007308086,0.0002922597,0.000054756198,0.00010116104,0.00005684622,0.00029197897,0.000032392174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078866296,0.0031908057,0.8644131,0.0033098732,0.00027023314,0.006441925,0.0124876695,0.0005361102,0.0144022675,0.00020299002,0.00039045583,0.015488302],"study_design_scores_gemma":[0.10856068,0.0028751337,0.8570638,0.0004334132,0.00009034282,0.0007283684,0.0014212902,0.00048274972,0.021161541,0.000023982004,0.0063663214,0.0007924181],"about_ca_topic_score_codex":0.00006909719,"about_ca_topic_score_gemma":0.000030732896,"teacher_disagreement_score":0.029694384,"about_ca_system_score_codex":0.0037301609,"about_ca_system_score_gemma":0.0012100874,"threshold_uncertainty_score":0.9993835},"labels":[],"label_agreement":null},{"id":"W4283315989","doi":"10.1097/01.hs9.0000843712.33707.fe","title":"S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Obinutuzumab; Internal medicine; Gastroenterology; Phases of clinical research; Follicular lymphoma; Progression-free survival; Refractory (planetary science); Randomized controlled trial; Surrogate endpoint; Surgery; Oncology; Clinical trial; Lymphoma; Chemotherapy; CD20","score_opus":0.013264919863490817,"score_gpt":0.27890062428605017,"score_spread":0.26563570442255935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283315989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908827,0.0007654286,0.00004270852,0.00012252474,0.00029627842,0.0057085427,0.00010065312,0.00008055955,0.002000613],"genre_scores_gemma":[0.99378735,0.00012614489,0.0002924975,0.0005482446,0.00010462635,0.0010989247,0.00032372327,0.00012698292,0.003591517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928858,0.0013499169,0.0015111314,0.0009386852,0.0025030691,0.00081136776],"domain_scores_gemma":[0.9959366,0.0008617371,0.00080740626,0.0018889643,0.0002600897,0.0002452557],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016663724,0.0005438222,0.0026623204,0.0004495527,0.0002891668,0.000035145298,0.0007170135,0.00023729139,0.0034659705],"category_scores_gemma":[0.0005912743,0.00033381354,0.001097413,0.003737339,0.00041829265,0.00015325217,0.00036203244,0.00062133244,0.000010650001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9821133,0.0031739138,0.0003938275,0.00019206903,0.0037889436,0.00028536847,0.001565035,0.0013513162,0.00024977824,0.00007837463,0.0011719009,0.005636168],"study_design_scores_gemma":[0.9731329,0.0048652673,0.00084202876,0.00014716202,0.0023225995,0.00003865577,0.00050365174,0.012813588,0.000633326,0.00002697226,0.0042735925,0.0004002666],"about_ca_topic_score_codex":0.0017255567,"about_ca_topic_score_gemma":0.00024920233,"teacher_disagreement_score":0.018681215,"about_ca_system_score_codex":0.04146889,"about_ca_system_score_gemma":0.022787673,"threshold_uncertainty_score":0.99991137},"labels":[],"label_agreement":null},{"id":"W4283318495","doi":"10.1097/01.hs9.0000844896.35718.c4","title":"P502: CLINICAL IMPLEMENTATION OF GERMLINE GENETIC TESTING FOR HEMATOLOGIC DISORDERS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hematology; Genetic testing; Internal medicine; Germline; Cancer; Oncology; Germline mutation; Lynch syndrome; Population; Referral; Family medicine; Mutation; Genetics; Biology","score_opus":0.0748785243221959,"score_gpt":0.4288595605038129,"score_spread":0.353981036181617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283318495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954761,0.00081138854,0.0010538624,0.00045792855,0.00012617896,0.0011258938,0.000029143504,0.000050673545,0.00086879416],"genre_scores_gemma":[0.9778057,0.00002200525,0.021113006,0.00017560442,0.00010283866,0.0002822257,0.00005326137,0.000030116675,0.0004152613],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983696,0.000080088095,0.0005857381,0.00028695664,0.0003733565,0.00030431338],"domain_scores_gemma":[0.9986757,0.00062567566,0.00017102057,0.00030287114,0.00013182213,0.000092935414],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050163985,0.00010354299,0.0003322019,0.00003613767,0.00011822722,0.0000046154796,0.00012656783,0.00004648121,0.001723178],"category_scores_gemma":[0.00048080398,0.00009593348,0.00013108717,0.00033701214,0.000082742576,0.000021472399,0.00016316402,0.000169248,0.000008285507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015090642,0.0017708219,0.51838225,0.0037992154,0.00053753064,0.00021751638,0.0010748063,0.00079112843,0.005509862,0.0018575982,0.029265322,0.4352849],"study_design_scores_gemma":[0.29477465,0.032472998,0.2486222,0.00053796096,0.0017120418,0.0040826267,0.042817224,0.24866942,0.020760767,0.013566389,0.08969488,0.002288862],"about_ca_topic_score_codex":0.00029492658,"about_ca_topic_score_gemma":0.000084634106,"teacher_disagreement_score":0.43299603,"about_ca_system_score_codex":0.0012684563,"about_ca_system_score_gemma":0.0028045923,"threshold_uncertainty_score":0.9991894},"labels":[],"label_agreement":null},{"id":"W4283328977","doi":"10.1097/01.hs9.0000845556.79615.3f","title":"P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Tolerability; Rituximab; Progression-free survival; Oncology; Ibrutinib; Chemotherapy; Leukemia; Adverse effect; Lymphoma","score_opus":0.030805073093128868,"score_gpt":0.3009799521374058,"score_spread":0.27017487904427695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283328977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532516,0.0042283596,0.0000067158767,0.00027942454,0.00069318403,0.0013660556,0.00025121623,0.00017699596,0.007672919],"genre_scores_gemma":[0.95089215,0.00038912066,0.0003239485,0.00027746943,0.00031896302,0.00020361767,0.00025805572,0.00016428108,0.047172412],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936116,0.00032828678,0.0015361856,0.0011584612,0.0020435147,0.0013219522],"domain_scores_gemma":[0.99634415,0.0009281088,0.00046753875,0.0016280168,0.00018242167,0.00044977164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013298456,0.0004983818,0.0014103357,0.00032587725,0.00023404336,0.000022402915,0.00068744685,0.00039186087,0.006689806],"category_scores_gemma":[0.0014275032,0.0004881329,0.0003547455,0.0015707255,0.00036109312,0.00013537165,0.0012860612,0.0012874511,0.00034194614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.28222325,0.003871256,0.0021362123,0.013718944,0.0024501758,0.06079539,0.021733303,0.06436542,0.033319186,0.0019785475,0.46610618,0.047302127],"study_design_scores_gemma":[0.57741016,0.0072028083,0.0026392057,0.0017745445,0.000510719,0.0045271395,0.0034003092,0.09020625,0.008379738,0.00010698066,0.30229214,0.0015500011],"about_ca_topic_score_codex":0.004159596,"about_ca_topic_score_gemma":0.0019663963,"teacher_disagreement_score":0.29518694,"about_ca_system_score_codex":0.24866745,"about_ca_system_score_gemma":0.06376139,"threshold_uncertainty_score":0.99975705},"labels":[],"label_agreement":null},{"id":"W4283516356","doi":"10.3390/cancers14133130","title":"CD73 Promotes Chronic Lymphocytic Leukemia","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Chronic lymphocytic leukemia; Leukemia; Cancer research; Medicine; Immunology","score_opus":0.02109844166100887,"score_gpt":0.2957089005216474,"score_spread":0.2746104588606385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283516356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743315,0.004404916,0.000045611378,0.00022725564,0.0006580855,0.0009725503,0.000026737942,0.00026698553,0.019066362],"genre_scores_gemma":[0.98740363,0.00013030334,0.00010803102,0.00072563585,0.00044981268,0.0004269799,0.000043421947,0.00006031504,0.010651884],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9977739,0.00006462327,0.00024611517,0.00045347557,0.0008092344,0.00065267924],"domain_scores_gemma":[0.99890596,0.00007963639,0.000067688816,0.00061581424,0.000064192034,0.00026671033],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029101907,0.00018139358,0.00030770994,0.00015252765,0.00029340305,0.000020743408,0.00028713606,0.00005597887,0.0042756074],"category_scores_gemma":[0.00009523075,0.00017777675,0.00013321731,0.00057475746,0.00018247876,0.000062858024,0.00028629001,0.00038743718,0.00020048225],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0043322104,0.000071405884,0.0007993091,0.003656762,0.0016446607,0.0076811123,0.006264305,0.4630403,0.055709533,0.004156437,0.36205712,0.090586826],"study_design_scores_gemma":[0.034417234,0.0017568839,0.00015970157,0.00014292718,0.00015982767,0.0020882303,0.00080416666,0.6008617,0.012048373,0.00022057802,0.34681305,0.0005272977],"about_ca_topic_score_codex":0.005048625,"about_ca_topic_score_gemma":0.00006509719,"teacher_disagreement_score":0.514316,"about_ca_system_score_codex":0.8390213,"about_ca_system_score_gemma":0.3247053,"threshold_uncertainty_score":0.9966346},"labels":[],"label_agreement":null},{"id":"W4283518065","doi":"10.1016/j.jval.2022.04.264","title":"EE12 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Foothills Medical Centre","funders":"","keywords":"Obinutuzumab; Venetoclax; Medicine; Bendamustine; Fludarabine; Rituximab; Chlorambucil; Internal medicine; Ibrutinib; Population; Oncology; Chronic lymphocytic leukemia; Alemtuzumab; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma; Transplantation","score_opus":0.046311378443070615,"score_gpt":0.3219957015005659,"score_spread":0.2756843230574953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283518065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926071,0.0031113445,0.000010677608,0.0001496778,0.00009213352,0.0039106603,0.000042901807,0.000015462687,0.000060004633],"genre_scores_gemma":[0.99725676,0.0011767413,0.000026751346,0.00016000337,0.000028757253,0.00117667,0.000105780455,0.000034989218,0.000033556043],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9956607,0.0010639207,0.0010753805,0.0006316034,0.0008500792,0.00071826496],"domain_scores_gemma":[0.9976134,0.0012811399,0.00027028064,0.00054473296,0.00007649811,0.0002139822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021281498,0.0002483566,0.0010543314,0.0010171985,0.000105341765,0.000012408103,0.000197417,0.00008552243,0.00010154019],"category_scores_gemma":[0.0005442722,0.0002519458,0.00008327063,0.0029891615,0.00008900964,0.00007237641,0.00012401899,0.00047523293,0.0000010181257],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001963802,0.000052002822,0.018254371,0.0013998904,0.00012992474,0.00029191768,0.0012555602,0.97259915,0.000109698965,0.00012893588,0.000015567579,0.003799155],"study_design_scores_gemma":[0.022796173,0.0014018496,0.08630548,0.000444298,0.000047232705,0.00006763191,0.00030699017,0.8879925,0.00012350752,0.00014475865,0.00019563848,0.00017392896],"about_ca_topic_score_codex":0.9952351,"about_ca_topic_score_gemma":0.9696834,"teacher_disagreement_score":0.35674846,"about_ca_system_score_codex":0.73643667,"about_ca_system_score_gemma":0.3796882,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W4283588791","doi":"10.14740/jh1006","title":"Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Adverse effect; Internal medicine; Cancer; Pediatrics; Autoimmune hemolytic anemia; Chronic lymphocytic leukemia; Anemia; Intensive care medicine; Oncology; Leukemia","score_opus":0.12498579780140788,"score_gpt":0.43791803813301033,"score_spread":0.31293224033160244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283588791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941644,0.0017925381,0.0000832545,0.0021552874,0.0011751133,0.00034432404,0.000126426,0.0000139775275,0.00014466923],"genre_scores_gemma":[0.9980368,0.00012224197,0.001033434,0.000081328566,0.0005213809,0.000011198898,0.000015773436,0.000026661883,0.00015119612],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9925952,0.0013712572,0.0045688245,0.00031477545,0.00073637115,0.00041359462],"domain_scores_gemma":[0.9943409,0.0021508941,0.002396424,0.00057124696,0.0002330985,0.00030741745],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0056490144,0.00019164172,0.0019721147,0.00027338942,0.00011109703,0.00001644924,0.00030626653,0.0001612532,0.0006603448],"category_scores_gemma":[0.009205727,0.0001521314,0.0006547008,0.00027790052,0.00042172868,0.00015066117,0.0003610005,0.00094025413,0.000008108577],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20111717,0.018324835,0.0060471133,0.00058944355,0.002185584,0.55302626,0.024963517,0.000040287046,0.17445375,0.00056295993,0.012842312,0.00584676],"study_design_scores_gemma":[0.14063594,0.012328725,0.0001011858,0.0003741167,0.00024174195,0.59944165,0.008524819,0.0004361488,0.2328749,0.00047708786,0.004339531,0.00022418986],"about_ca_topic_score_codex":0.00040214654,"about_ca_topic_score_gemma":0.000030169927,"teacher_disagreement_score":0.060481235,"about_ca_system_score_codex":0.0021245186,"about_ca_system_score_gemma":0.003355744,"threshold_uncertainty_score":0.99914014},"labels":[],"label_agreement":null},{"id":"W4283709628","doi":"10.1136/annrheumdis-2022-eular.1268","title":"POS0643 SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS THROUGH 3 YEARS FROM THE SELECT-COMPARE TRIAL","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Odense Universitetshospital; Amgen; National Institute of Allergy and Infectious Diseases; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Internal medicine; Discontinuation; Placebo; Methotrexate; Post-hoc analysis; Clinical trial; Pathology","score_opus":0.02712574030222329,"score_gpt":0.30762124868896323,"score_spread":0.2804955083867399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283709628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930444,0.0015625054,0.0000016679943,0.0020198792,0.00004009628,0.0019144004,0.0013692422,0.000016530657,0.00003128118],"genre_scores_gemma":[0.99940807,0.00017850722,0.000022654434,0.00011676331,0.00001546399,0.00009682074,0.00010872752,0.000024040679,0.000028959072],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99611217,0.0011896258,0.00081008294,0.00033389937,0.0011945401,0.0003596694],"domain_scores_gemma":[0.9953695,0.002877386,0.00040100628,0.0009563944,0.00028728784,0.000108443724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011524811,0.0001801223,0.000656892,0.000072379175,0.00015701013,0.00002008653,0.00043785496,0.000034396926,0.00006665762],"category_scores_gemma":[0.004511274,0.000111826135,0.00014775079,0.00053322857,0.00051378633,0.00010215724,0.000425431,0.00024227267,8.66125e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6405846,0.0026848994,0.3148654,0.000562585,0.000898725,0.00003389402,0.01115097,0.00040915495,0.0000027802885,0.0001362732,0.0077826628,0.020888077],"study_design_scores_gemma":[0.12631057,0.0015068201,0.8659473,0.0009107861,0.00006251008,0.0000035304327,0.0024282096,0.00009826428,0.0000734366,0.0022094136,0.00030985769,0.00013929834],"about_ca_topic_score_codex":0.0031655487,"about_ca_topic_score_gemma":0.000066811015,"teacher_disagreement_score":0.5510819,"about_ca_system_score_codex":0.00076212024,"about_ca_system_score_gemma":0.004306021,"threshold_uncertainty_score":0.76386964},"labels":[],"label_agreement":null},{"id":"W4283733194","doi":"10.3390/curroncol29070363","title":"Concurrent Waldenstrom’s Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Waldenstrom macroglobulinemia; Chromosomal translocation; Medicine; Cancer research; Macroglobulinemia; Myeloid; Bone marrow; Myelopoiesis; Lymphoplasmacytic Lymphoma; Myelodysplastic syndromes; Haematopoiesis; Immunology; Biology; Lymphoma; Multiple myeloma; Genetics; Stem cell; Gene","score_opus":0.06743536507840901,"score_gpt":0.37632120097909605,"score_spread":0.308885835900687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283733194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98891103,0.0053202617,0.00073398097,0.001794275,0.00096327334,0.0012683539,0.0000673177,0.000118100594,0.0008233846],"genre_scores_gemma":[0.9977385,0.0003998397,0.00014598109,0.000120031626,0.00014797189,0.0005211453,0.0002387496,0.000043973385,0.00064380607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725074,0.00023867287,0.0004604295,0.00064859784,0.000750954,0.00065059407],"domain_scores_gemma":[0.9986697,0.00025257745,0.0001480548,0.00036866203,0.00016658868,0.00039441482],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042480865,0.0002879368,0.0006102501,0.00022602412,0.0002518214,0.000021652104,0.00020204856,0.00009835208,0.0017886419],"category_scores_gemma":[0.00008718102,0.0002474178,0.000081221595,0.00040158356,0.00040189124,0.000060678463,0.00022426997,0.0007783897,0.00008552302],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006647792,0.006519849,0.011067935,0.0040088207,0.0012312781,0.014973007,0.0068558366,0.0016997017,0.0049354755,0.0026255285,0.039954245,0.8994805],"study_design_scores_gemma":[0.1199578,0.026266417,0.00908562,0.0007927114,0.0012004074,0.10115077,0.0021154217,0.07775529,0.0006896802,0.00018880858,0.65945494,0.0013421471],"about_ca_topic_score_codex":0.00008594141,"about_ca_topic_score_gemma":0.00006318093,"teacher_disagreement_score":0.8981384,"about_ca_system_score_codex":0.01424975,"about_ca_system_score_gemma":0.0074875928,"threshold_uncertainty_score":0.9999978},"labels":[],"label_agreement":null},{"id":"W4283746005","doi":"10.1111/ejh.13824","title":"Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high‐risk features and reduced treatment‐free‐intervals","year":2022,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Irish Research eLibrary","keywords":"Medicine; Internal medicine; CD38; Stage (stratigraphy); Cohort; Gastroenterology; Biology","score_opus":0.017552632825233675,"score_gpt":0.27480311968981974,"score_spread":0.25725048686458607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283746005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454707,0.0030690092,0.000020822372,0.0009811305,0.00023167892,0.00042902332,0.00002640329,0.000034105306,0.0006607421],"genre_scores_gemma":[0.99750304,0.00074582116,0.00031477245,0.00023154855,0.00014752729,0.000017434888,0.000026301956,0.00009510347,0.0009184556],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99497145,0.0024742687,0.000844109,0.00042162562,0.00066697755,0.0006215548],"domain_scores_gemma":[0.9974502,0.00075701217,0.0007782738,0.0005548506,0.00013836213,0.0003213011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013772252,0.00033605203,0.0011073761,0.0005108129,0.00019976454,0.000037689046,0.00045103376,0.000074650714,0.00036744942],"category_scores_gemma":[0.0010476437,0.00024070493,0.00015979019,0.00038851198,0.00027837048,0.00012474666,0.00036067807,0.00080221076,0.00000932933],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.020978289,0.0028494094,0.021892065,0.00077682297,0.0030363603,0.80098313,0.012243784,0.008868518,0.040223356,0.00022910295,0.067472726,0.020446427],"study_design_scores_gemma":[0.46224615,0.04192489,0.11660471,0.004626832,0.0014495205,0.2981381,0.0037326885,0.0030275732,0.06061047,0.00020225509,0.0060647996,0.0013720203],"about_ca_topic_score_codex":0.00028792338,"about_ca_topic_score_gemma":0.00016042797,"teacher_disagreement_score":0.50284505,"about_ca_system_score_codex":0.024210662,"about_ca_system_score_gemma":0.0067695105,"threshold_uncertainty_score":0.9988612},"labels":[],"label_agreement":null},{"id":"W4285498294","doi":"10.1016/j.clml.2022.07.004","title":"Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs; AbbVie; Merck","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Discontinuation; Stroke (engine); Atrial fibrillation; Lower risk; Oncology; Leukemia; Confidence interval","score_opus":0.04458121361638287,"score_gpt":0.3073229471894323,"score_spread":0.2627417335730494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285498294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912924,0.00025562622,0.000021538917,0.00008619404,0.00038637803,0.0066762976,0.0005687549,0.00021567856,0.0004971411],"genre_scores_gemma":[0.98745346,0.00036532318,0.0020579943,0.00027303598,0.0009386883,0.0005918779,0.0009810244,0.00033068715,0.0070078885],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98993045,0.0007760506,0.0023972401,0.002736833,0.0020214834,0.002137922],"domain_scores_gemma":[0.99146765,0.0037915818,0.0010913278,0.0017114525,0.00055506977,0.0013828919],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014257571,0.0012653812,0.0024201036,0.00092311145,0.0012515916,0.00018878545,0.0006899139,0.0004492556,0.00057727686],"category_scores_gemma":[0.0010073144,0.00097932,0.00064069347,0.0018070288,0.0006767893,0.0003988524,0.0012729616,0.00030824184,0.00025961542],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14542517,0.0004090483,0.33566877,0.000424521,0.0013567118,0.00049896614,0.0007015932,0.014447973,0.000044351993,0.000029371093,0.0005555145,0.50043803],"study_design_scores_gemma":[0.24480735,0.031907264,0.63446623,0.0005400965,0.0010775609,0.00018241566,0.00011710409,0.07685842,0.00016428255,0.000020565183,0.008529316,0.0013293786],"about_ca_topic_score_codex":0.0066211536,"about_ca_topic_score_gemma":0.0021217084,"teacher_disagreement_score":0.49910864,"about_ca_system_score_codex":0.5160893,"about_ca_system_score_gemma":0.078195915,"threshold_uncertainty_score":0.99999386},"labels":[],"label_agreement":null},{"id":"W4285736749","doi":"10.1016/j.leukres.2022.106919","title":"Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Quality of life (healthcare); Hairy cell leukemia; Prospective cohort study; Activities of daily living; Disease; Leukemia; Cancer; Physical therapy; Longitudinal study; Internal medicine; Pediatrics; Pathology","score_opus":0.12194974847105526,"score_gpt":0.4023675352351923,"score_spread":0.28041778676413703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285736749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98379636,0.00046847723,0.0000013488954,0.00045196142,0.0001338671,0.007470083,0.0007379358,0.00006812171,0.006871871],"genre_scores_gemma":[0.99653435,0.00006989381,0.00010503958,0.00007186839,0.00013472619,0.0009956609,0.0003892345,0.00013767302,0.0015615566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.971641,0.010626098,0.002698494,0.0016367285,0.011288777,0.0021088768],"domain_scores_gemma":[0.98203826,0.010120041,0.0007662328,0.0027849402,0.0034870468,0.00080348895],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018090611,0.0004497436,0.0014063857,0.0010354293,0.0020131087,0.00006294916,0.001291846,0.00023937733,0.0008145106],"category_scores_gemma":[0.0095812585,0.0003274734,0.00023380501,0.0039302683,0.0022392757,0.000225714,0.0042477287,0.0049986755,0.00007118647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.134529,0.01395414,0.5223975,0.0028169032,0.0022258726,0.00074307324,0.27688092,0.004790977,0.0044291858,0.00025227005,0.031207796,0.0057723746],"study_design_scores_gemma":[0.14235245,0.053540286,0.63727844,0.0013638781,0.00012693531,0.000051648385,0.142448,0.0118745295,0.008628135,0.00024882157,0.0010778527,0.0010090338],"about_ca_topic_score_codex":0.10002618,"about_ca_topic_score_gemma":0.004399579,"teacher_disagreement_score":0.13443293,"about_ca_system_score_codex":0.10543928,"about_ca_system_score_gemma":0.06942238,"threshold_uncertainty_score":0.99991775},"labels":[],"label_agreement":null},{"id":"W4286437560","doi":"10.1200/jco.2022.40.17_suppl.lba7502","title":"Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Neutropenia; Bendamustine; Phases of clinical research; Placebo; Ibrutinib; Chemoimmunotherapy; Rituximab; Surgery; Population; Hazard ratio; Gastroenterology; Chemotherapy; Randomized controlled trial; Confidence interval; Leukemia; Lymphoma; Chronic lymphocytic leukemia; Pathology","score_opus":0.07259979377230029,"score_gpt":0.4085435094493707,"score_spread":0.3359437156770704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286437560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156594,0.00022546425,0.000040819214,0.0029909012,0.00018791211,0.004510669,0.00007680606,0.0000058890028,0.0003956005],"genre_scores_gemma":[0.99811125,0.00012622785,0.0004684164,0.000405398,0.00016471179,0.00023505819,0.00008471121,0.000030362393,0.00037385416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953917,0.00048915605,0.0025004756,0.00040008425,0.0008814421,0.0003371321],"domain_scores_gemma":[0.9891035,0.007568791,0.0021949525,0.00036176795,0.0005782036,0.00019280166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032680586,0.00023384787,0.0019912107,0.00016337537,0.00013637445,0.0000136149865,0.00025401695,0.00013996309,0.000047640773],"category_scores_gemma":[0.0009473416,0.0001211201,0.00017899186,0.0002596971,0.00022252955,0.00009520156,0.0001449875,0.0005146428,9.490804e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.90138865,0.06637237,0.006904038,0.00003940439,0.0006922664,0.00052430114,0.0015738677,0.0002855935,0.000005159125,0.000013296437,0.0004639428,0.02173713],"study_design_scores_gemma":[0.8386011,0.13861507,0.015529447,0.00011649714,0.00071279454,0.000119362754,0.0012389582,0.0022560952,0.00001995817,0.000038882103,0.0026475233,0.00010428123],"about_ca_topic_score_codex":0.0010905414,"about_ca_topic_score_gemma":0.00091817655,"teacher_disagreement_score":0.0722427,"about_ca_system_score_codex":0.004103345,"about_ca_system_score_gemma":0.00750645,"threshold_uncertainty_score":0.99971974},"labels":[],"label_agreement":null},{"id":"W4286491901","doi":"10.1111/bjh.18368","title":"A phase 2, multicentre, open‐label trial (<scp>ACE‐LY</scp>‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Adverse effect; Discontinuation; Refractory (planetary science); Hazard ratio; Febrile neutropenia; Phases of clinical research; Progression-free survival; Surgery; Confidence interval; Toxicity; Chemotherapy","score_opus":0.03317684450859787,"score_gpt":0.33373213869567864,"score_spread":0.30055529418708077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286491901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590725,0.0013284803,0.000038560516,0.00016019058,0.00049595215,0.0016252293,0.00007541175,0.000012760844,0.0003561898],"genre_scores_gemma":[0.9963971,0.00023067111,0.0018781383,0.00023944465,0.00010996508,0.000063405896,0.00005117593,0.00007029279,0.00095981837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949856,0.0007908477,0.0016435152,0.00042291588,0.0013960617,0.00076110684],"domain_scores_gemma":[0.9964952,0.00094388064,0.001229969,0.00039945327,0.0005458718,0.00038561568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014815994,0.00026023557,0.0016836752,0.00050389767,0.00016000391,0.000048424394,0.0008021461,0.00019769513,0.0005818077],"category_scores_gemma":[0.0025597538,0.00024035848,0.00013187548,0.0007695113,0.0003469529,0.00029461892,0.00054655166,0.0009603167,0.000009352802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5117402,0.06107184,0.005914886,0.0008330291,0.001188724,0.3173925,0.0015101654,0.000034468867,0.00035560984,0.00011942456,0.037311364,0.06252775],"study_design_scores_gemma":[0.8603944,0.017691996,0.0021358684,0.00077556976,0.0002164053,0.10642839,0.0009549347,0.0004975585,0.0002937744,0.000021452523,0.010453196,0.00013644987],"about_ca_topic_score_codex":0.0006278935,"about_ca_topic_score_gemma":0.00018538833,"teacher_disagreement_score":0.34865418,"about_ca_system_score_codex":0.0042950604,"about_ca_system_score_gemma":0.010627944,"threshold_uncertainty_score":0.9995273},"labels":[],"label_agreement":null},{"id":"W4290994344","doi":"10.1200/jco.22.00597","title":"Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Janssen Biotech; National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Genentech; Janssen Scientific Affairs; Karyopharm Therapeutics; Conquer Cancer Foundation; Gilead Sciences; Sanofi; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb; American Society of Clinical Oncology; GlaxoSmithKline; Amgen","keywords":"Medicine; Lenalidomide; Ibrutinib; Rituximab; Chemoimmunotherapy; Internal medicine; Chemotherapy; Diffuse large B-cell lymphoma; Oncology; International Prognostic Index; Surgery; Lymphoma; Gastroenterology; Multiple myeloma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.047371172100373934,"score_gpt":0.3881505520512346,"score_spread":0.34077937995086066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290994344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994672,0.00045002822,0.00001911111,0.0020305056,0.0004903273,0.00040835672,0.000014669483,0.000007839981,0.0019071897],"genre_scores_gemma":[0.9949972,0.0002142294,0.001188721,0.0028620707,0.00030435776,0.000013759299,0.000009712583,0.00003025418,0.00037971724],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951923,0.0009164735,0.002056108,0.00030211516,0.0010211065,0.00051188265],"domain_scores_gemma":[0.9943185,0.0034883735,0.0010547558,0.00027516816,0.00032999253,0.0005332041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005266212,0.00016993562,0.0016021678,0.00026211745,0.00009476714,0.00001335825,0.00024535286,0.00021039665,0.0004332629],"category_scores_gemma":[0.0024848725,0.00012342725,0.00022227837,0.00031474087,0.00024175658,0.00012641777,0.00031661484,0.0011822485,0.000017347205],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.056937948,0.03456409,0.8219319,0.0001182232,0.00031645378,0.00885826,0.00042779767,0.000044731114,0.000010376334,0.000089197216,0.016620887,0.060080107],"study_design_scores_gemma":[0.5057991,0.025713636,0.35093585,0.00006413332,0.00014451676,0.00036178614,0.00029347345,0.00055937946,0.000012091108,0.00009192513,0.11588406,0.00014005249],"about_ca_topic_score_codex":0.00014207215,"about_ca_topic_score_gemma":0.00013308124,"teacher_disagreement_score":0.47099608,"about_ca_system_score_codex":0.0048815203,"about_ca_system_score_gemma":0.017060168,"threshold_uncertainty_score":0.99893856},"labels":[],"label_agreement":null},{"id":"W4291221799","doi":"10.1016/j.prp.2022.154077","title":"miR-574, miR-499, miR-125b, miR-106a, and miR-9 potentially target TGFBR-1 and TGFBR-2 genes involving in inflammatory response pathway: Potential novel biomarkers for chronic lymphocytic leukemia","year":2022,"lang":"en","type":"article","venue":"Pathology - Research and Practice","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"microRNA; Chronic lymphocytic leukemia; In silico; Gene; Cancer research; Microarray; Medicine; miR-155; Leukemia; Signal transduction; Immunology; Biology; Oncology; Bioinformatics; Gene expression; Genetics","score_opus":0.04930296598685495,"score_gpt":0.35518063098165403,"score_spread":0.30587766499479907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291221799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9580531,0.032610834,0.00033589418,0.0043911296,0.00042268864,0.0034123277,0.00031297054,0.00011320064,0.0003478272],"genre_scores_gemma":[0.97881794,0.0063057374,0.009025231,0.0008947439,0.0005390955,0.0017254228,0.0003066366,0.0002628809,0.002122295],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877846,0.0043088365,0.0011859185,0.0020411757,0.0019087406,0.0027707308],"domain_scores_gemma":[0.9877993,0.00881554,0.00039955726,0.0011159554,0.00077686034,0.0010927927],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.016779326,0.0006800546,0.001058724,0.0016388976,0.0015576958,0.00034001202,0.0006076561,0.00063169526,0.00027649713],"category_scores_gemma":[0.011497926,0.0006547994,0.00017271604,0.0011011433,0.0020525097,0.00088457897,0.0020411464,0.002011602,0.000027109603],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08446598,0.00068984996,0.0013775254,0.0022735032,0.00073275756,0.017592452,0.0036033094,0.00014567951,0.87560403,0.00032739676,0.005596993,0.007590543],"study_design_scores_gemma":[0.2221835,0.02342986,0.028151399,0.0011598535,0.00090296305,0.095714144,0.028678626,0.15636209,0.03385578,0.0028906849,0.40256852,0.0041025807],"about_ca_topic_score_codex":0.0027764929,"about_ca_topic_score_gemma":0.00052246836,"teacher_disagreement_score":0.84174824,"about_ca_system_score_codex":0.027076676,"about_ca_system_score_gemma":0.037298772,"threshold_uncertainty_score":0.99974215},"labels":[],"label_agreement":null},{"id":"W4291227654","doi":"10.1038/s41375-022-01658-2","title":"Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Ibrutinib; Mantle cell lymphoma; Temsirolimus; Oncology; Internal medicine; Blastoid; International Prognostic Index; Cohort; Medicine; CDKN2A; Hematology; Gene expression profiling; Lymphoma; Clinical trial; Splenic marginal zone lymphoma; Cancer research; Biology; Bioinformatics; Diffuse large B-cell lymphoma; Leukemia; Gene; Gene expression; Genetics; Cancer; Chronic lymphocytic leukemia; Discovery and development of mTOR inhibitors","score_opus":0.028188912443140247,"score_gpt":0.3080516541544759,"score_spread":0.2798627417113356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291227654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578255,0.000119420656,0.0000014956834,0.000102351354,0.00008957983,0.0018393416,0.000023793777,0.00003641049,0.0020050372],"genre_scores_gemma":[0.9951498,0.00002774225,0.00009471944,0.0004094388,0.000046078243,0.0003868459,0.000023832376,0.000068912115,0.0037926335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99632823,0.0005101657,0.0007872117,0.00052048196,0.0011657914,0.0006881349],"domain_scores_gemma":[0.99781513,0.0007763437,0.00024003412,0.0009960443,0.000051933635,0.00012049328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009231271,0.00031290538,0.0008415624,0.0004216822,0.00009166869,0.000017612425,0.00056316116,0.00016263989,0.00036039742],"category_scores_gemma":[0.00035651942,0.0001737904,0.00013082367,0.0011784409,0.00017333703,0.00005834875,0.00020049168,0.000503306,0.000017413735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.752797,0.008488979,0.10105348,0.0014629004,0.0003310678,0.09661284,0.008726988,0.0018966065,0.011646576,0.00005121078,0.002058794,0.0148735205],"study_design_scores_gemma":[0.9113816,0.012382324,0.037519425,0.00031575325,0.00021880874,0.0012542431,0.0039960193,0.0123157045,0.016044514,0.000021260024,0.0038881826,0.00066218834],"about_ca_topic_score_codex":0.0045476775,"about_ca_topic_score_gemma":0.00080254,"teacher_disagreement_score":0.15858454,"about_ca_system_score_codex":0.015443737,"about_ca_system_score_gemma":0.012684909,"threshold_uncertainty_score":0.99291223},"labels":[],"label_agreement":null},{"id":"W4292791021","doi":"10.1111/ijlh.13949","title":"T‐cell clonality testing for the diagnosis of T‐cell large granular lymphocytic leukemia: Are we identifying pathology or incidental clones?","year":2022,"lang":"en","type":"article","venue":"International Journal of Laboratory Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Lymphoproliferative disorders; Leukemia; Population; Medicine; T cell; Immunology; Monoclonal; Pathology; T-cell receptor; clone (Java method); Chronic lymphocytic leukemia; Lymphoma; Biology; Monoclonal antibody; Genetics; Antibody","score_opus":0.05764393398470906,"score_gpt":0.35799148051152496,"score_spread":0.3003475465268159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292791021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872391,0.007542222,0.0013911626,0.0012725837,0.0016855102,0.00048303357,0.00031726973,0.000020674628,0.000048415302],"genre_scores_gemma":[0.99686855,0.0004074063,0.0012000346,0.0008605389,0.00034943613,0.00014089867,0.000021756709,0.000044784672,0.00010661894],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99633676,0.00037789214,0.0012684292,0.00030483853,0.0012750805,0.00043703],"domain_scores_gemma":[0.9927597,0.0032193193,0.0015219203,0.00034082116,0.0020057126,0.00015253134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020064132,0.00022147523,0.00074121554,0.00040340715,0.0002520911,0.00002896039,0.0009432409,0.00014390635,0.0003875635],"category_scores_gemma":[0.0018963497,0.0001644125,0.00029016245,0.0005087534,0.00024693806,0.00016047458,0.00052517717,0.0006527781,0.0000064497503],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02504141,0.0052342955,0.7073076,0.0058740843,0.0035584215,0.088671,0.007199175,0.005892401,0.07150707,0.008267359,0.06968049,0.0017667444],"study_design_scores_gemma":[0.21885909,0.0073660826,0.022217097,0.0023260096,0.002911468,0.16582437,0.036305144,0.041459512,0.41447714,0.0060334103,0.080417246,0.0018034495],"about_ca_topic_score_codex":0.000078208155,"about_ca_topic_score_gemma":0.000033965705,"teacher_disagreement_score":0.6850905,"about_ca_system_score_codex":0.013804359,"about_ca_system_score_gemma":0.015086028,"threshold_uncertainty_score":0.9904975},"labels":[],"label_agreement":null},{"id":"W4293125198","doi":"10.1186/s13045-022-01333-0","title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Thrombosis; Hematology; Internal medicine; Chronic lymphocytic leukemia; Retrospective cohort study; Coronavirus disease 2019 (COVID-19); Disease; Intensive care medicine; Pediatrics; Leukemia; Infectious disease (medical specialty)","score_opus":0.08628222026284342,"score_gpt":0.39319395771899157,"score_spread":0.30691173745614814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293125198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950027,0.0005474704,0.000009130732,0.0016982019,0.000054909964,0.0010438877,0.000004383708,0.000006557732,0.0016327751],"genre_scores_gemma":[0.99913466,0.00009154099,0.00008030467,0.0005671429,0.000037870454,0.000043475397,0.0000029025327,0.000024322864,0.000017807131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953949,0.0024990023,0.00070252107,0.00029070245,0.0007121837,0.00040068058],"domain_scores_gemma":[0.99553967,0.0030869278,0.00047886837,0.00030941633,0.00035843338,0.00022670365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033134248,0.0001468656,0.0007489211,0.000605226,0.00038078876,0.000010211772,0.0003017767,0.00006727312,0.000058515714],"category_scores_gemma":[0.0008684561,0.000097469194,0.000036775862,0.00062515226,0.00081823923,0.000064134176,0.00046450133,0.0011750745,0.0000028391999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024935875,0.009300026,0.8234851,0.0019284554,0.0031036523,0.012788381,0.08768068,0.014281699,0.0005445097,0.007390873,0.0092721265,0.0052886433],"study_design_scores_gemma":[0.18425159,0.098654434,0.6311866,0.00046473995,0.0004842848,0.030453896,0.046779886,0.0038973396,0.000044730565,0.0009577905,0.002479888,0.00034480888],"about_ca_topic_score_codex":0.00031259685,"about_ca_topic_score_gemma":0.00026393,"teacher_disagreement_score":0.19229847,"about_ca_system_score_codex":0.04520784,"about_ca_system_score_gemma":0.024507584,"threshold_uncertainty_score":0.98102254},"labels":[],"label_agreement":null},{"id":"W4293367557","doi":"10.1002/cpdd.1153","title":"Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors","year":2022,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Bioavailability; Pharmacokinetics; Medicine; Pharmacology; Tolerability; Bioequivalence; Chemistry; Adverse effect","score_opus":0.23958492077186636,"score_gpt":0.4805594073694024,"score_spread":0.24097448659753604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293367557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925364,0.000260457,0.00008260399,0.0059808744,0.00043316407,0.003771568,0.0000040674818,0.000053083724,0.0001605279],"genre_scores_gemma":[0.992294,0.00015850167,0.0037025148,0.001327247,0.00013689342,0.0011598368,0.000023013972,0.00002041911,0.0011775728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967754,0.00052640977,0.00090371876,0.00074159406,0.0006028781,0.00045003177],"domain_scores_gemma":[0.99748254,0.0015986225,0.00020413923,0.0001998528,0.00016290843,0.00035196816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003150539,0.0002271638,0.0005456663,0.00019710381,0.0002532387,0.00001542006,0.0001636072,0.00009876618,0.00019728979],"category_scores_gemma":[0.0007162066,0.00018430222,0.000043104228,0.0005299061,0.0003590231,0.00016443996,0.00060847925,0.0007143082,0.000018881557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01829172,0.0035749367,0.8743407,0.0016316709,0.0016356567,0.0011271613,0.031220987,0.000482438,0.004071472,0.00026112294,0.0348546,0.028507523],"study_design_scores_gemma":[0.123746656,0.008438784,0.451172,0.0010425778,0.0007195319,0.0005635032,0.016031176,0.0044990554,0.22506566,0.0013428786,0.16526996,0.002108238],"about_ca_topic_score_codex":0.000062886895,"about_ca_topic_score_gemma":0.00008921944,"teacher_disagreement_score":0.42316872,"about_ca_system_score_codex":0.006628006,"about_ca_system_score_gemma":0.0103206495,"threshold_uncertainty_score":0.99718535},"labels":[],"label_agreement":null},{"id":"W4293393139","doi":"10.1016/j.onano.2022.100073","title":"Complex dispersions of poloxamers and mesoporous carriers with ibrutinib","year":2022,"lang":"en","type":"article","venue":"OpenNano","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Research Council Canada; Ministry of Education and Science of the Russian Federation","keywords":"Poloxamer; Ibrutinib; Solubility; Mesoporous material; Mesoporous silica; Bioavailability; Dissolution; Materials science; Chemistry; Aqueous solution; Chemical engineering; Chromatography; Organic chemistry; Pharmacology; Medicine; Polymer; Copolymer","score_opus":0.02473828667088154,"score_gpt":0.2923167288196647,"score_spread":0.2675784421487832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293393139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728111,0.00028330687,0.000010390239,0.0014017017,0.000038082308,0.0004941152,0.000053474134,0.000020102994,0.024887722],"genre_scores_gemma":[0.99453723,0.000028332328,0.0005709334,0.00028285192,0.000015741338,0.00003007117,0.0000390256,0.000021608814,0.0044742264],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998834,0.00005680264,0.0001512957,0.00023167708,0.00046216886,0.0002640385],"domain_scores_gemma":[0.999311,0.00006673535,0.000053811556,0.00033858913,0.00004556835,0.00018430494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020218255,0.00009629688,0.00026117344,0.000087128814,0.00018459433,0.000008504216,0.00013746673,0.000023002847,0.0019440638],"category_scores_gemma":[0.000038688424,0.00007537594,0.000037923062,0.000284322,0.0003413599,0.00003702923,0.00029348602,0.0001599472,0.000008410835],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029937794,0.003812987,0.17151845,0.0030992217,0.0048092417,0.0100410525,0.05327061,0.0013693672,0.2711679,0.028109487,0.34805086,0.074813046],"study_design_scores_gemma":[0.14429066,0.013904451,0.05011305,0.00039557737,0.0010097674,0.011245764,0.06635007,0.021718683,0.014274751,0.00018756499,0.6748878,0.0016218851],"about_ca_topic_score_codex":0.001759344,"about_ca_topic_score_gemma":0.000042136424,"teacher_disagreement_score":0.3268369,"about_ca_system_score_codex":0.001698493,"about_ca_system_score_gemma":0.0025516686,"threshold_uncertainty_score":0.9989683},"labels":[],"label_agreement":null},{"id":"W4293652654","doi":"10.1016/j.jtct.2022.08.021","title":"Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Janssen Pharmaceuticals; Incyte; Fondazione IRCCS Policlinico San Matteo; Pharmacyclics; AbbVie; Jazz Pharmaceuticals; Novartis; Teva Pharmaceutical Industries; Gilead Sciences; GlaxoSmithKline; Amgen","keywords":"Ibrutinib; Medicine; Internal medicine; Clinical endpoint; Hematopoietic stem cell transplantation; Adverse effect; Refractory (planetary science); Graft-versus-host disease; Transplantation; Gastroenterology; Clinical trial; Leukemia; Chronic lymphocytic leukemia","score_opus":0.04040375757232324,"score_gpt":0.3183749669695803,"score_spread":0.27797120939725706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293652654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835335,0.0135238925,0.000064194406,0.000506271,0.00012211506,0.0013257146,0.0007210117,0.000035104546,0.00016821426],"genre_scores_gemma":[0.9820392,0.015546508,0.000017566656,0.00007661624,0.0002492371,0.00011795587,0.0016557906,0.000023514753,0.00027360595],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99837816,0.0002120996,0.00032704606,0.0003296162,0.0005509366,0.00020211573],"domain_scores_gemma":[0.99903166,0.00033219543,0.000090540954,0.00038425886,0.000035522775,0.00012580214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022806607,0.00016582041,0.00024305187,0.000070885035,0.0002012136,0.0000149877715,0.000115332376,0.000020709604,0.0003142735],"category_scores_gemma":[0.0000048580946,0.0001131406,0.00009117066,0.0002442808,0.00007666948,0.00004247158,0.00001298599,0.000111198344,0.0000050612543],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5398884,0.034991086,0.024052447,0.00079413,0.0038394928,0.006271279,0.08973291,0.00046480526,0.16729732,0.00019653125,0.0014179567,0.13105367],"study_design_scores_gemma":[0.8875496,0.020722039,0.045799278,0.000035857604,0.0022343807,0.000054535998,0.0028291133,0.003969059,0.020872604,0.000038412178,0.015357147,0.0005379727],"about_ca_topic_score_codex":0.0006114367,"about_ca_topic_score_gemma":0.00002204251,"teacher_disagreement_score":0.34766123,"about_ca_system_score_codex":0.001327677,"about_ca_system_score_gemma":0.0015552595,"threshold_uncertainty_score":0.46137398},"labels":[],"label_agreement":null},{"id":"W4294287236","doi":"10.1016/j.leukres.2022.106943","title":"Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]","year":2022,"lang":"en","type":"erratum","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Quality of life (healthcare); Medicine; Hairy cell leukemia; Leukemia; Oncology; Gerontology; Internal medicine; Nursing","score_opus":0.13778950801035084,"score_gpt":0.4023719804040977,"score_spread":0.2645824723937469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294287236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9327337,0.0021746813,0.0000018837554,0.0007557537,0.0043885405,0.018683692,0.0040758112,0.00015527189,0.03703068],"genre_scores_gemma":[0.86590326,0.0008053809,0.00013013816,0.00018407223,0.001078957,0.0024199442,0.004109305,0.0005451897,0.12482378],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9482011,0.01534381,0.0056613986,0.004184913,0.022136135,0.004472613],"domain_scores_gemma":[0.9700675,0.009884581,0.0025139176,0.006836484,0.0084310165,0.0022665064],"candidate_categories":["metaresearch","metaepi_narrow","sts","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.024870303,0.001371402,0.0040303716,0.0032142093,0.0025532022,0.00018858198,0.0036593238,0.0014369265,0.0025660018],"category_scores_gemma":[0.029649945,0.0010444649,0.00061332603,0.007829632,0.003300514,0.00032620007,0.009162911,0.017396497,0.00027436877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.044589322,0.003679885,0.013167066,0.0031033186,0.0015088009,0.00060630566,0.060071804,0.00029017538,0.00020372773,0.000030426421,0.87137824,0.0013709461],"study_design_scores_gemma":[0.21503554,0.14908898,0.28074527,0.017937034,0.0008719667,0.00013548392,0.1704541,0.009323492,0.0035501227,0.00028776564,0.14706537,0.005504891],"about_ca_topic_score_codex":0.20369308,"about_ca_topic_score_gemma":0.025200654,"teacher_disagreement_score":0.72431284,"about_ca_system_score_codex":0.2198843,"about_ca_system_score_gemma":0.20432702,"threshold_uncertainty_score":0.9999037},"labels":[],"label_agreement":null},{"id":"W4294842594","doi":"10.1016/j.msard.2022.104164","title":"Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?","year":2022,"lang":"en","type":"review","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Bruton's tyrosine kinase; Multiple sclerosis; Immunology; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Oncology; Receptor; Cancer","score_opus":0.050399819930991664,"score_gpt":0.2694452851222424,"score_spread":0.21904546519125076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294842594","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76994854,0.2193215,0.0000018679112,0.0005787509,0.0004947206,0.009114365,0.00044334703,0.000045235694,0.000051681494],"genre_scores_gemma":[0.44881076,0.5505411,0.000028618262,0.00004972222,0.000016401793,0.0002622393,0.00009799395,0.00008441232,0.00010874169],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99405366,0.0009286786,0.00233033,0.00086775824,0.0011974233,0.0006221236],"domain_scores_gemma":[0.99134505,0.005563299,0.0014756551,0.0012777044,0.00016004141,0.0001782381],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0015403074,0.0006960482,0.0022899748,0.00026360713,0.00043221656,0.00008152537,0.0005332393,0.0005401996,0.000034284036],"category_scores_gemma":[0.00321578,0.0002360191,0.0007144574,0.0011519766,0.0029407786,0.00016102301,0.0008102651,0.0015966316,0.0000010526466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044813347,0.0023609546,0.47123316,0.008104494,0.0020196836,0.000011815033,0.003731825,0.00028142633,0.000019091538,0.000058164915,0.00027838562,0.50741965],"study_design_scores_gemma":[0.20575896,0.0019454465,0.653486,0.051466793,0.0051778336,0.000013762512,0.0022983085,0.004918775,0.00005535513,0.00007098848,0.07301684,0.0017909022],"about_ca_topic_score_codex":0.0052466705,"about_ca_topic_score_gemma":0.0011880673,"teacher_disagreement_score":0.50562876,"about_ca_system_score_codex":0.00091299246,"about_ca_system_score_gemma":0.0012609212,"threshold_uncertainty_score":0.99977267},"labels":[],"label_agreement":null},{"id":"W4294908193","doi":"10.1080/10428194.2022.2109157","title":"Development of a distributed international patient data registry for hairy cell leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University; University of Manitoba; Research Institute in Oncology and Hematology","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Cancer Research UK; Hairy Cell Leukemia Foundation","keywords":"Hairy cell leukemia; Excellence; Medicine; Disease registry; Leukemia; Disease; Pathology; Internal medicine; Political science","score_opus":0.03041926185656664,"score_gpt":0.2864874881111542,"score_spread":0.2560682262545876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294908193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863893,0.001706969,0.0019098752,0.00022008103,0.0010171159,0.0019464912,0.0029605362,0.00025633845,0.0035933095],"genre_scores_gemma":[0.9698875,0.00023111321,0.01651903,0.0007872132,0.00039830297,0.00083963096,0.008960632,0.00020466228,0.0021719304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924193,0.00017053662,0.001896567,0.0019283784,0.0022041737,0.0013810219],"domain_scores_gemma":[0.9947606,0.00055134227,0.00086271117,0.0026500856,0.00044199728,0.00073327037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011504828,0.0008287155,0.0012505354,0.0005202833,0.000920387,0.00012424961,0.0019652836,0.00039963867,0.00031936326],"category_scores_gemma":[0.0004388668,0.0008428736,0.00033991563,0.00084438926,0.0004965875,0.00039488205,0.003522093,0.00034162044,0.000028524966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018800905,0.002915106,0.0021496015,0.0046686237,0.002973999,0.0023638431,0.010445852,0.0022267092,0.044122547,0.0018907809,0.18439774,0.7230443],"study_design_scores_gemma":[0.07642787,0.00088708854,0.0032428901,0.0003426123,0.00044152394,0.0030136378,0.0048888093,0.14381139,0.030932529,0.00017950483,0.73444253,0.0013895958],"about_ca_topic_score_codex":0.0012479752,"about_ca_topic_score_gemma":0.000066854736,"teacher_disagreement_score":0.7216547,"about_ca_system_score_codex":0.1141712,"about_ca_system_score_gemma":0.070285715,"threshold_uncertainty_score":0.9994022},"labels":[],"label_agreement":null},{"id":"W4295901037","doi":"10.4049/jimmunol.2200199","title":"Enhanced IFN Sensing by Aggressive Chronic Lymphocytic Leukemia Cells","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"International Development Research Centre; Government of Canada; Institute of Cancer Research; University of Toronto; AstraZeneca","keywords":"Chronic lymphocytic leukemia; Ibrutinib; Autocrine signalling; IGHV@; Immunology; Cancer research; CD38; Leukemia; STAT1; Interferon; Biology; Medicine; Receptor; Internal medicine; Cell biology; Stem cell","score_opus":0.009859721934005583,"score_gpt":0.2646376135764536,"score_spread":0.254777891642448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295901037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97655374,0.02032839,0.0006022797,0.00055996433,0.00084667484,0.00026680125,0.000006175979,0.000022965918,0.000813003],"genre_scores_gemma":[0.9941804,0.0021569005,0.00009391233,0.00046354297,0.00027736984,0.0000035612863,0.0000048952697,0.000042548636,0.0027769112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973264,0.00060942094,0.0006426647,0.00016304792,0.00066815113,0.00059033657],"domain_scores_gemma":[0.997613,0.00062134815,0.0008760388,0.00054279924,0.00024083318,0.00010597207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011402463,0.00019395498,0.0005420693,0.00020952546,0.00035884097,0.0000140899365,0.00056172814,0.00009661348,0.0006996715],"category_scores_gemma":[0.00024965726,0.00013428826,0.00018569136,0.00037177317,0.0004144575,0.00007198975,0.00041941393,0.0011599882,0.00007586238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024074484,0.000034408753,6.7766535e-7,0.000039194303,0.00059338723,0.00088388426,0.0013304343,0.003467867,0.9608178,0.000015570356,0.017065804,0.013343529],"study_design_scores_gemma":[0.03738187,0.004958801,0.00004135451,0.0002550048,0.00047019194,0.055398628,0.003023155,0.013781343,0.8587829,0.00022181951,0.025381591,0.00030332597],"about_ca_topic_score_codex":0.00045956235,"about_ca_topic_score_gemma":0.0000057091065,"teacher_disagreement_score":0.102034874,"about_ca_system_score_codex":0.11802449,"about_ca_system_score_gemma":0.040235896,"threshold_uncertainty_score":0.9652051},"labels":[],"label_agreement":null},{"id":"W4295969902","doi":"10.2196/39229","title":"Photosensitivity From Avapritinib: Pharamacovigilance Analysis","year":2022,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Photosensitivity; Medicine; Odds ratio; Adverse effect; Adverse Event Reporting System; Population; Confidence interval; Food and drug administration; Meta-analysis; Internal medicine; Pharmacology; Environmental health","score_opus":0.01695529948364425,"score_gpt":0.32341863432778234,"score_spread":0.30646333484413807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295969902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916012,0.00030791407,0.00014504972,0.0017886183,0.000121676305,0.0004469436,0.00012046218,0.00014670283,0.0053214235],"genre_scores_gemma":[0.9959385,0.000017183162,0.0002283242,0.002335709,0.00008467035,0.00030117514,0.00032698474,0.000024616484,0.0007428332],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978888,0.0002967682,0.00030607244,0.0004994624,0.00051936693,0.00048950413],"domain_scores_gemma":[0.99866796,0.00035311215,0.00009063772,0.00064277416,0.000064936896,0.0001805795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000145631,0.0001593668,0.00064524874,0.00032109197,0.00020580002,0.00000993701,0.00020278849,0.00008985543,0.0031405322],"category_scores_gemma":[0.00006210965,0.00016359957,0.00025170814,0.0010193072,0.00015170441,0.000044715533,0.00034192795,0.00050089875,0.00023964423],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007958437,0.0048415116,0.5917754,0.00070976047,0.016661584,0.10037106,0.0051395707,0.001457905,0.1124757,0.0027523367,0.14175513,0.014101588],"study_design_scores_gemma":[0.059066527,0.00049518025,0.18153982,0.000039447597,0.0030682134,0.023108061,0.0012581252,0.2786512,0.07240512,0.001084895,0.37792528,0.0013581265],"about_ca_topic_score_codex":0.0008571077,"about_ca_topic_score_gemma":0.00006865063,"teacher_disagreement_score":0.41023558,"about_ca_system_score_codex":0.002995641,"about_ca_system_score_gemma":0.0013761516,"threshold_uncertainty_score":0.9977707},"labels":[],"label_agreement":null},{"id":"W4296148508","doi":"10.1515/biol-2022-0448","title":"<i>Babesia microti-</i>induced fulminant sepsis in an immunocompromised host: A case report and the case-specific literature review","year":2022,"lang":"en","type":"article","venue":"Open Life Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"University of Toronto","keywords":"Babesiosis; Fulminant; Malignancy; Chronic lymphocytic leukemia; Babesia; Immunology; Pancytopenia; Sepsis; Biology; Immune system; Obligate; Leukemia; Medicine; Virology; Pathology","score_opus":0.059505989105721156,"score_gpt":0.36991193370996817,"score_spread":0.31040594460424703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296148508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91927433,0.0690366,5.6962534e-7,0.0063088373,0.00014451912,0.0033456958,0.000014780414,0.000015199926,0.0018594397],"genre_scores_gemma":[0.9887393,0.006173006,0.00056224037,0.0028056656,0.000083844,0.0006542869,0.00001850977,0.000020136296,0.00094300474],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9968068,0.0006865876,0.00059530983,0.00080695126,0.00063097075,0.00047335925],"domain_scores_gemma":[0.9982489,0.00027341326,0.00020047491,0.0009142911,0.00011631953,0.0002466282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007019183,0.00020165519,0.0005845585,0.00015548071,0.0010896177,0.0004314283,0.000821446,0.00004862579,0.00039116014],"category_scores_gemma":[0.00038330877,0.00012203347,0.000081369064,0.0018961221,0.00069243705,0.00043583507,0.001100822,0.0005320074,0.0000075092184],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006147814,0.00024050384,0.00025404236,0.0005317512,0.000032353357,0.9792573,0.003939202,0.0000036544939,0.0029741782,0.00029610517,0.0072447327,0.0046114004],"study_design_scores_gemma":[0.0123589765,0.00043938574,0.00022950539,0.001301597,0.00004764571,0.96536404,0.004382983,0.0015419848,0.00025758834,0.000037987345,0.013799529,0.00023877677],"about_ca_topic_score_codex":0.0033631325,"about_ca_topic_score_gemma":0.00025933218,"teacher_disagreement_score":0.06946495,"about_ca_system_score_codex":0.0013363175,"about_ca_system_score_gemma":0.0049856706,"threshold_uncertainty_score":0.88443655},"labels":[],"label_agreement":null},{"id":"W4296468443","doi":"10.1016/s2152-2650(22)01478-1","title":"HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Refractory (planetary science); Phases of clinical research; Gastroenterology; Population; Adverse effect; Dosing; Surgery; Toxicity; Lymphoma; Hodgkin lymphoma","score_opus":0.059413759715631224,"score_gpt":0.3922615825630272,"score_spread":0.33284782284739595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306,0.00013354368,0.000006230787,0.00013505934,0.00033827728,0.005676548,0.0001843911,0.0001618092,0.0003041613],"genre_scores_gemma":[0.99648494,0.00007306426,0.00062130496,0.00057255453,0.00017126433,0.0003727597,0.0007230969,0.00022274767,0.00075826386],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98917186,0.0020574701,0.0031586778,0.0022293746,0.0020962309,0.0012864039],"domain_scores_gemma":[0.99268734,0.002328963,0.00092171464,0.0023706274,0.0005167998,0.001174574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024842843,0.0008248876,0.0023625463,0.00052987016,0.00048194607,0.00012467963,0.0016123918,0.00045035742,0.0005561015],"category_scores_gemma":[0.001987859,0.0006575381,0.00011887413,0.0016854937,0.0009777881,0.00057175325,0.0026088324,0.0009864336,0.000030875126],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.29361096,0.093677856,0.092354104,0.00019546271,0.0006393406,0.0038979568,0.0011168907,0.000033550492,0.00031195584,0.000038672846,0.0014185618,0.5127047],"study_design_scores_gemma":[0.39250448,0.04673936,0.5463693,0.0001590852,0.00025412065,0.00010908282,0.0007761311,0.008809892,0.000048951973,0.000005364809,0.0037062806,0.0005179294],"about_ca_topic_score_codex":0.001307104,"about_ca_topic_score_gemma":0.0004896017,"teacher_disagreement_score":0.51218677,"about_ca_system_score_codex":0.022994414,"about_ca_system_score_gemma":0.015652515,"threshold_uncertainty_score":0.9995876},"labels":[],"label_agreement":null},{"id":"W4296468472","doi":"10.1016/s2152-2650(22)01343-x","title":"CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Discontinuation; Atrial fibrillation; Oncology; Leukemia","score_opus":0.05117018586394753,"score_gpt":0.3203578797929642,"score_spread":0.26918769392901665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850406,0.00025053075,0.000010841081,0.00006298892,0.00035225786,0.013211823,0.00056136283,0.00022427634,0.0002852995],"genre_scores_gemma":[0.98806167,0.00031318748,0.0009957881,0.0001542918,0.0008343119,0.001425101,0.0008166551,0.00034051947,0.0070585064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98879397,0.001128498,0.0026290263,0.003159,0.0021084498,0.002181083],"domain_scores_gemma":[0.9911978,0.003725949,0.0011474557,0.0019895367,0.00052196276,0.0014172728],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00137537,0.0015278121,0.0028983352,0.0009898464,0.0013963752,0.00021406104,0.00065087725,0.0003923611,0.00043777667],"category_scores_gemma":[0.00069609756,0.0011211383,0.00069801987,0.0018654795,0.0005524077,0.00036933538,0.0011177494,0.0002547142,0.00021419492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12846932,0.0012440662,0.46590537,0.0001857963,0.0019563285,0.00064245693,0.0015633352,0.009328415,0.000015820186,0.0000073564847,0.000166149,0.3905156],"study_design_scores_gemma":[0.2840961,0.08137058,0.586966,0.000300634,0.0016625837,0.00012942454,0.00035833046,0.0398962,0.00008326026,0.000008103273,0.0039915666,0.0011372471],"about_ca_topic_score_codex":0.012725408,"about_ca_topic_score_gemma":0.00595432,"teacher_disagreement_score":0.51065207,"about_ca_system_score_codex":0.5894055,"about_ca_system_score_gemma":0.07875341,"threshold_uncertainty_score":0.9999037},"labels":[],"label_agreement":null},{"id":"W4296529771","doi":"10.1016/s2152-2650(22)01353-2","title":"CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cascades (Canada)","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Incidence (geometry); Adverse effect; Retrospective cohort study; Oncology; Leukemia","score_opus":0.036764102197981624,"score_gpt":0.3554531914982372,"score_spread":0.3186890893002555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99062365,0.00021792606,0.000015972828,0.00072129734,0.0011942353,0.0010030265,0.00006446341,0.00020466199,0.005954747],"genre_scores_gemma":[0.9876622,0.00013070377,0.0006910345,0.003969526,0.000683245,0.00013675078,0.00023997344,0.00015102731,0.006335517],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99241966,0.00088017026,0.00235359,0.0013746645,0.0019096833,0.0010622122],"domain_scores_gemma":[0.9946279,0.0011857426,0.0006056782,0.0022505536,0.00029810297,0.0010320134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002505,0.0005139958,0.0015133802,0.00030865884,0.0003853239,0.000029274423,0.0009356217,0.00040586674,0.004413886],"category_scores_gemma":[0.001242453,0.00040929008,0.00089281367,0.0006902744,0.0009073131,0.00021365724,0.0013172984,0.00076000235,0.001033334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.027422227,0.008794311,0.0598681,0.0016206366,0.001744406,0.039601676,0.0025370603,0.00054868095,0.023726152,0.0029343555,0.07145732,0.75974506],"study_design_scores_gemma":[0.062325057,0.006179317,0.81435394,0.0004147444,0.0006240494,0.0058463374,0.002533762,0.011569161,0.005627646,0.0019546016,0.08738061,0.0011908007],"about_ca_topic_score_codex":0.0014134487,"about_ca_topic_score_gemma":0.000030731433,"teacher_disagreement_score":0.7585543,"about_ca_system_score_codex":0.01625678,"about_ca_system_score_gemma":0.016233597,"threshold_uncertainty_score":0.9998359},"labels":[],"label_agreement":null},{"id":"W4296531778","doi":"10.1016/s2152-2650(22)00998-3","title":"Poster: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Classical Hodgkin lymphoma; Refractory (planetary science); Open label; Medicine; Phases of clinical research; Oncology; Internal medicine; Multicenter study; Hodgkin lymphoma; Lymphoma; Dermatology; Clinical trial; Materials science; Randomized controlled trial","score_opus":0.05618524231538953,"score_gpt":0.38786569538728344,"score_spread":0.3316804530718939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296531778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278593,0.00013801776,0.000003524661,0.00016213053,0.00034903554,0.0058638253,0.00021598987,0.00015974099,0.0003218028],"genre_scores_gemma":[0.9965883,0.000066743334,0.00040518053,0.0006968021,0.00016363688,0.00033465293,0.00080780406,0.00022812358,0.00070875173],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98907083,0.002107386,0.0032150613,0.0022409908,0.0020690844,0.001296674],"domain_scores_gemma":[0.99271226,0.002236461,0.0009410694,0.002399447,0.0005353343,0.0011754486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023539683,0.00084496586,0.0023715307,0.00054411584,0.00046927604,0.0001359923,0.0016316785,0.0004552592,0.00050461426],"category_scores_gemma":[0.0017207187,0.000673639,0.00012298799,0.0015748636,0.0009322367,0.00060356356,0.002805171,0.00096982194,0.0000316737],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.31646904,0.087678656,0.11679991,0.00020318826,0.0006453996,0.004170267,0.0012592457,0.000018356863,0.00035363247,0.000024301069,0.0011235507,0.47125444],"study_design_scores_gemma":[0.38240552,0.05172385,0.55640674,0.00017161295,0.00025726942,0.00014225279,0.00066004146,0.004890279,0.00005787874,0.000004049057,0.002759588,0.00052091613],"about_ca_topic_score_codex":0.0012639253,"about_ca_topic_score_gemma":0.0004833176,"teacher_disagreement_score":0.47073352,"about_ca_system_score_codex":0.021952817,"about_ca_system_score_gemma":0.014441988,"threshold_uncertainty_score":0.9995715},"labels":[],"label_agreement":null},{"id":"W4296532110","doi":"10.1016/s2152-2650(22)00749-2","title":"Poster: AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Hematologic Neoplasms; Medicine; Oncology; Interleukin-3 receptor; Internal medicine; Intensive care medicine; Leukemia; Cancer","score_opus":0.021351125916885073,"score_gpt":0.29769149897282654,"score_spread":0.27634037305594145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616575,0.00049805234,0.000018666857,0.0001809256,0.00020004205,0.0015022437,0.00039174844,0.00027010232,0.0007724741],"genre_scores_gemma":[0.9959283,0.00014303451,0.00048389798,0.0007864113,0.00004473146,0.00019921653,0.001824835,0.00009340505,0.00049618346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99224085,0.0011761223,0.0025125886,0.0012833365,0.0017245044,0.001062576],"domain_scores_gemma":[0.995029,0.0015031463,0.0007621349,0.0015069555,0.00074531743,0.00045345092],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017679993,0.0006075544,0.0026347593,0.001240255,0.00022793624,0.00003420621,0.0007950099,0.0003971256,0.0017221787],"category_scores_gemma":[0.0012779309,0.00046066075,0.00080783444,0.0068076365,0.00079941587,0.00014362806,0.00057550863,0.00075222604,0.000029845169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.026429143,0.0027095275,0.89064103,0.00012760809,0.0040125065,0.0009425722,0.0005887684,0.0003861233,0.00035344038,0.00012445956,0.0011509178,0.0725339],"study_design_scores_gemma":[0.04312558,0.00331804,0.94059074,0.00013382865,0.00069390173,0.00006906619,0.00028908983,0.008463546,0.00051858055,0.000035072746,0.0022808316,0.00048174764],"about_ca_topic_score_codex":0.001929126,"about_ca_topic_score_gemma":0.00026791106,"teacher_disagreement_score":0.07205214,"about_ca_system_score_codex":0.019816704,"about_ca_system_score_gemma":0.012451732,"threshold_uncertainty_score":0.9997845},"labels":[],"label_agreement":null},{"id":"W4296532114","doi":"10.1016/s2152-2650(22)00866-7","title":"Poster: CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Atrial fibrillation; Internal medicine; Persistence (discontinuity); Stroke (engine); Oncology; Lymphoma; Cardiology; Leukemia","score_opus":0.048856901715748684,"score_gpt":0.3180669262570643,"score_spread":0.2692100245413156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847443,0.0002545457,0.000006640346,0.00007275999,0.00035866958,0.013417716,0.00062689144,0.00021946114,0.00029899413],"genre_scores_gemma":[0.9890599,0.0002847882,0.00068603916,0.00018105091,0.0007859817,0.0012824581,0.00088533654,0.00034273058,0.00649168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98879606,0.001149788,0.0026584733,0.003146657,0.002076345,0.002172664],"domain_scores_gemma":[0.99133164,0.0035677578,0.0011593807,0.0020010672,0.00053339574,0.0014067666],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013139934,0.0015404378,0.0028873547,0.0009999295,0.0013471394,0.00022717023,0.0006577958,0.0003933947,0.00040170786],"category_scores_gemma":[0.0006183348,0.0011309248,0.00070183835,0.0017534274,0.0005296767,0.0003854408,0.0011888484,0.0002517026,0.00021244115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13441929,0.0011709719,0.5047441,0.00018363059,0.0018714394,0.0006595541,0.0016489382,0.0051908116,0.000017000326,0.000004857307,0.00013261326,0.34995675],"study_design_scores_gemma":[0.27760583,0.08744665,0.60401857,0.00031463496,0.001637217,0.00015880381,0.00031058353,0.024227912,0.00009398301,0.0000063386665,0.0030585267,0.0011209137],"about_ca_topic_score_codex":0.012111588,"about_ca_topic_score_gemma":0.0057370244,"teacher_disagreement_score":0.49882454,"about_ca_system_score_codex":0.57181054,"about_ca_system_score_gemma":0.07298599,"threshold_uncertainty_score":0.999953},"labels":[],"label_agreement":null},{"id":"W4296532460","doi":"10.1016/s2152-2650(22)00702-9","title":"Oral Abstract: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Classical Hodgkin lymphoma; Refractory (planetary science); Open label; Medicine; Internal medicine; Oncology; Phases of clinical research; Multicenter study; Lymphoma; Gastroenterology; Adverse effect; Clinical trial; Hodgkin lymphoma; Biology; Randomized controlled trial","score_opus":0.06725159472618122,"score_gpt":0.39759381578532066,"score_spread":0.33034222105913946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336284,0.00010993165,0.000003374425,0.0001267948,0.00034645494,0.005336198,0.00021257391,0.00016169417,0.0003401487],"genre_scores_gemma":[0.99667966,0.000060708302,0.0005952604,0.0005020262,0.00015763147,0.00031941666,0.00081679615,0.00022400952,0.0006444675],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98964435,0.001380152,0.0033115873,0.0021999408,0.0021339222,0.0013300437],"domain_scores_gemma":[0.9928548,0.0021775584,0.0010029939,0.002237594,0.00051957817,0.0012075113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026596284,0.0008550453,0.0023989885,0.0005152883,0.00047276283,0.00014173321,0.0015923127,0.00048515265,0.0007559243],"category_scores_gemma":[0.0018072808,0.0006844852,0.00012496788,0.0014990852,0.0009853657,0.00065908517,0.0022555406,0.0010980163,0.000036396996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.26083785,0.090965256,0.0825462,0.00019607056,0.00058357365,0.004388959,0.0009116902,0.00003631425,0.0003290574,0.000027456777,0.0013532601,0.5578243],"study_design_scores_gemma":[0.36306372,0.03615956,0.5902332,0.00015117902,0.00023663559,0.00010038482,0.00070478045,0.0055097956,0.00004788774,0.0000051741777,0.0032684985,0.00051913445],"about_ca_topic_score_codex":0.001780724,"about_ca_topic_score_gemma":0.00069767557,"teacher_disagreement_score":0.5573052,"about_ca_system_score_codex":0.021216832,"about_ca_system_score_gemma":0.015119169,"threshold_uncertainty_score":0.99956065},"labels":[],"label_agreement":null},{"id":"W4296532744","doi":"10.1016/s2152-2650(22)00871-0","title":"Poster: CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Lymphoma; Oncology; Leukemia; Internal medicine","score_opus":0.04370418158202723,"score_gpt":0.3126730898348428,"score_spread":0.2689689082528156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855405,0.0008287304,0.00008316714,0.0003299992,0.0015036298,0.005038628,0.0002770611,0.00089096715,0.0055073076],"genre_scores_gemma":[0.98384875,0.000526837,0.0009261541,0.0033715994,0.0012977248,0.0011898471,0.0006646651,0.0005984663,0.0075759823],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9828892,0.0011056196,0.004283457,0.0043033324,0.0036476927,0.0037707496],"domain_scores_gemma":[0.98677266,0.0032635934,0.0013822656,0.0038983289,0.00094322994,0.0037399062],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0026774565,0.0020453464,0.0033974452,0.0012282741,0.0016362034,0.0004183553,0.0021630304,0.000850721,0.0011771935],"category_scores_gemma":[0.0018643936,0.0018847431,0.0009555912,0.003578589,0.0020990388,0.000528391,0.0040129516,0.0010989254,0.0007868794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029114965,0.0022159086,0.20217197,0.0020356956,0.0020419348,0.006514146,0.001398896,0.0051257424,0.00032321239,0.0003970325,0.010306682,0.73835385],"study_design_scores_gemma":[0.11847344,0.018136665,0.80201435,0.0014723674,0.001005595,0.0013444298,0.00018999535,0.026031334,0.00094789854,0.000118438584,0.027622867,0.0026426099],"about_ca_topic_score_codex":0.011107202,"about_ca_topic_score_gemma":0.0035614546,"teacher_disagreement_score":0.7357112,"about_ca_system_score_codex":0.37748033,"about_ca_system_score_gemma":0.097504996,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W4296620568","doi":"10.3390/curroncol29100534","title":"Therapeutic Management of Chronic Lymphocytic Leukemia Presenting with Recurrent Massive Ascites","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ascites; Chronic lymphocytic leukemia; Malignancy; Bone marrow; CD5; Pathology; Chemotherapy; Lymphoma; Leukemia; Internal medicine; Gastroenterology","score_opus":0.07338444877757222,"score_gpt":0.38708637126001527,"score_spread":0.31370192248244305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296620568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96296656,0.020193413,0.00043518635,0.00037927117,0.0014980292,0.002365384,0.00002668266,0.00014573245,0.011989721],"genre_scores_gemma":[0.9964693,0.0012180514,0.00029247467,0.000054098105,0.00021813068,0.00063355896,0.00007941814,0.000053519376,0.0009814185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968185,0.0002857678,0.0005331016,0.0005975132,0.0010193225,0.00074583216],"domain_scores_gemma":[0.9983581,0.00031154256,0.0003150443,0.00065620383,0.00016678401,0.00019234019],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052600366,0.00027281768,0.00061375625,0.0002889496,0.00021758633,0.000013071644,0.00042323553,0.00006829397,0.0012088461],"category_scores_gemma":[0.00003224924,0.00022751339,0.00015903628,0.00071457704,0.0003385751,0.00006199558,0.0007294388,0.0005599575,0.000039861185],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009211393,0.0042366493,0.008276653,0.017387237,0.005129429,0.0063000587,0.004212178,0.022380637,0.0030661705,0.01658902,0.017836498,0.88537407],"study_design_scores_gemma":[0.119629286,0.020626036,0.005813241,0.0016285868,0.0023950823,0.0033857976,0.0048457086,0.3314449,0.0043001086,0.0013041719,0.5032978,0.0013292986],"about_ca_topic_score_codex":0.00006136682,"about_ca_topic_score_gemma":0.000017205059,"teacher_disagreement_score":0.88404477,"about_ca_system_score_codex":0.15521969,"about_ca_system_score_gemma":0.030093836,"threshold_uncertainty_score":0.9997042},"labels":[],"label_agreement":null},{"id":"W4296633325","doi":"10.51731/cjht.2022.453","title":"Zanubrutinib (Brukinsa)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Family medicine; Political science; Health care","score_opus":0.04150092911836314,"score_gpt":0.31990717976881616,"score_spread":0.27840625065045305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296633325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6503365,0.15371841,0.00017345192,0.18766525,0.0020895668,0.0009931467,0.00006400983,0.0003217303,0.004637936],"genre_scores_gemma":[0.997746,0.00020642737,0.00042362104,0.0011909325,0.00002377551,0.0000110288665,0.0000030939211,0.000018468687,0.00037667013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981805,0.00007976979,0.0005244532,0.00013247054,0.00044125883,0.0006415599],"domain_scores_gemma":[0.9989672,0.00006956367,0.00028356488,0.00035027103,0.00014228231,0.00018715468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011961003,0.000098839184,0.00038042007,0.00095476775,0.0004801498,0.000017012151,0.0004442296,0.00007061631,0.0003585552],"category_scores_gemma":[0.000794983,0.00008818211,0.000098030825,0.00061679364,0.00023807718,0.000050063,0.00008166737,0.00097577745,0.000013007008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015345852,0.00007773229,0.0037821028,0.00031081133,0.00013661975,0.0041850917,0.0009162104,0.00013112038,0.00008558018,0.0039358395,0.15417409,0.83211136],"study_design_scores_gemma":[0.004129003,0.0014541274,0.0013703898,0.00009103569,0.000013059363,0.010658825,0.0065694298,0.00012687387,0.0002432956,0.0015985435,0.97364205,0.000103350794],"about_ca_topic_score_codex":0.009629705,"about_ca_topic_score_gemma":0.0010397115,"teacher_disagreement_score":0.832008,"about_ca_system_score_codex":0.021715516,"about_ca_system_score_gemma":0.07914543,"threshold_uncertainty_score":0.9969652},"labels":[],"label_agreement":null},{"id":"W4296964454","doi":"10.1016/s2152-2650(22)00874-6","title":"Poster: CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cascades (Canada)","funders":"","keywords":"Ibrutinib; Adverse effect; Medicine; Event (particle physics); Internal medicine; Oncology; Chronic lymphocytic leukemia; Leukemia; Physics","score_opus":0.034980729570881185,"score_gpt":0.3508717584928351,"score_spread":0.3158910289219539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296964454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900698,0.00023002656,0.000008008046,0.00089527684,0.0012366065,0.0010807221,0.000080443235,0.00020407853,0.006195046],"genre_scores_gemma":[0.9875732,0.00011952126,0.00041081858,0.0049355854,0.0006476066,0.00012368597,0.000281785,0.00015886828,0.0057489467],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99221855,0.00092728756,0.002442416,0.0014126692,0.0019062862,0.0010928061],"domain_scores_gemma":[0.9945263,0.0011593868,0.0006332047,0.0023145366,0.0003177652,0.0010487925],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0023762067,0.0005416132,0.0015512428,0.00032581418,0.00037988534,0.00003395438,0.00097123545,0.0004197568,0.0038605274],"category_scores_gemma":[0.001066981,0.0004316566,0.00091711496,0.0006529595,0.0008680367,0.00023476826,0.0014713848,0.0007597344,0.0010355113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03553277,0.009257679,0.08976138,0.0018498729,0.0019433664,0.046227023,0.0032153723,0.00028364992,0.028594796,0.0017496798,0.057861578,0.7237228],"study_design_scores_gemma":[0.058236036,0.0068069245,0.8549702,0.00042825664,0.0005940838,0.0071327672,0.0019193055,0.0052584526,0.00607912,0.0012175328,0.056231186,0.0011261232],"about_ca_topic_score_codex":0.0013768112,"about_ca_topic_score_gemma":0.000032418815,"teacher_disagreement_score":0.76520884,"about_ca_system_score_codex":0.0155687155,"about_ca_system_score_gemma":0.014832552,"threshold_uncertainty_score":0.9998135},"labels":[],"label_agreement":null},{"id":"W4297464661","doi":"10.3390/curroncol29100560","title":"A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Fluidigm (Canada); Princess Margaret Cancer Centre; Foothills Medical Centre; Impact; University of Calgary; Spinal Cord Injury BC; Nova Scotia Health Authority; Dalhousie University; Jewish General Hospital","funders":"","keywords":"Medicine; Lymphoplasmacytic Lymphoma; Rituximab; Bendamustine; Ibrutinib; Waldenstrom macroglobulinemia; Chemoimmunotherapy; Bortezomib; Bruton's tyrosine kinase; Oncology; Purine analogue; Fludarabine; Internal medicine; Immunology; Multiple myeloma; Lymphoma; Chronic lymphocytic leukemia; Tyrosine kinase; Chemotherapy; Leukemia; Cyclophosphamide","score_opus":0.10208322313083419,"score_gpt":0.42931966672921784,"score_spread":0.32723644359838366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297464661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95312756,0.0023071552,0.0000015078198,0.01664524,0.00076485093,0.0009549005,0.00009086602,0.000019140789,0.0260888],"genre_scores_gemma":[0.99790937,0.00029805896,0.00001650293,0.00027540963,0.00019777124,0.00026310285,0.000025693455,0.000014084607,0.001000012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987478,0.00016623635,0.00017351798,0.0002406112,0.0003093223,0.0003624779],"domain_scores_gemma":[0.9989642,0.0002841961,0.000058133224,0.00036284167,0.000121167395,0.0002094786],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017068558,0.00011301835,0.0002712172,0.00015372997,0.00017616204,0.000003362352,0.00015834683,0.000042834807,0.0023721163],"category_scores_gemma":[0.000099587975,0.000074507974,0.0001187187,0.00025231112,0.00014678712,0.000006656066,0.00005056969,0.00026003146,0.00006933838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0065107066,0.017216314,0.012195101,0.00020055687,0.0015762664,0.0054686842,0.05349589,0.00049618847,0.0012592312,0.12692368,0.23536228,0.5392951],"study_design_scores_gemma":[0.012083688,0.010397303,0.00060402707,0.000019621093,0.00010831755,0.00055667,0.0070581282,0.002494724,0.00064754055,0.0005608287,0.96535826,0.000110876],"about_ca_topic_score_codex":0.080964305,"about_ca_topic_score_gemma":0.024779433,"teacher_disagreement_score":0.729996,"about_ca_system_score_codex":0.13742849,"about_ca_system_score_gemma":0.019249797,"threshold_uncertainty_score":0.99853987},"labels":[],"label_agreement":null},{"id":"W4299598591","doi":"10.17615/2qt3-6p69","title":"Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Cancer Council NSW; Medical Research Council; University of Texas MD Anderson Cancer Center; Institut National Du Cancer; Centers for Disease Control and Prevention; National Institutes of Health; Agència de Gestió d'Ajuts Universitaris i de Recerca; Leukemia and Lymphoma Research; National Health and Medical Research Council; University at Buffalo; Regione Autonoma della Sardegna; Associazione Italiana per la Ricerca sul Cancro; University of Pittsburgh; Stockholms Läns Landsting; University of Utah; Fondation de France; Generalitat de Catalunya; Canadian Institutes of Health Research; Bundesamt für Strahlenschutz; MedStar Health Research Institute; Cancerfonden; Bundesministerium für Bildung und Forschung; Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail; Instituto de Salud Carlos III; Ohio State University; Wake Forest University; National Natural Science Foundation of China; University of Southern California; Cancer Research UK; Division of Cancer Prevention, National Cancer Institute; University of Sydney; U.S. Department of Veterans Affairs; Compagnia di San Paolo; European Commission; U.S. Department of Health and Human Services; University of California, San Francisco; Michael Smith Health Research BC; Health Research Board; National Cancer Research Institute; Division of Cancer Epidemiology and Genetics, National Cancer Institute; Huntsman Cancer Institute; José Carreras Leukämie-Stiftung; Memorial Sloan-Kettering Cancer Center; Yale University; Karolinska Institutet; Utah State University; Cancer Council Victoria; Utah Department of Health; Brigham and Women's Hospital","keywords":"Chronic lymphocytic leukemia; Genetics; Biology; Genome-wide association study; Computational biology; Leukemia; Gene; Single-nucleotide polymorphism; Genotype","score_opus":0.1363682759606036,"score_gpt":0.32476352677413206,"score_spread":0.18839525081352845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299598591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7581395,0.15889262,0.028425377,0.038640983,0.0005429337,0.008921013,0.0020634735,0.001124986,0.003249112],"genre_scores_gemma":[0.98719835,0.00024248085,0.00420737,0.0026956117,0.00029594402,0.00022114249,0.00049932493,0.00006904817,0.004570709],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99733967,0.00009708816,0.0006904792,0.00052536174,0.00081883307,0.0005285819],"domain_scores_gemma":[0.9939272,0.0046873535,0.00037487742,0.00047217042,0.00031713367,0.00022127594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039961823,0.00029244635,0.0019673228,0.00027045517,0.00012631272,0.00007033789,0.00026442498,0.00015981837,0.00033502476],"category_scores_gemma":[0.0063083046,0.00022424785,0.0014598138,0.0013277646,0.0002492896,0.00043197654,0.0002238723,0.00014944727,0.000029074161],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016974299,0.000070272305,0.009848762,0.0027825772,0.8844275,0.0000568262,0.011500772,0.05036089,0.0011364373,0.007000698,0.030961778,0.00015606296],"study_design_scores_gemma":[0.03172864,0.001416421,0.0021864725,0.000033981825,0.6027543,0.0000036726296,0.004181728,0.29144192,0.03437694,0.0032534995,0.027807381,0.00081504846],"about_ca_topic_score_codex":0.0002823574,"about_ca_topic_score_gemma":0.00009475309,"teacher_disagreement_score":0.2816732,"about_ca_system_score_codex":0.049959566,"about_ca_system_score_gemma":0.019275663,"threshold_uncertainty_score":0.98628414},"labels":[],"label_agreement":null},{"id":"W4300352883","doi":"","title":"Abstracts of the 13th Annual International Congress on Hematologic Malignancies. February 11-15, 2009. Whistler, British Columbia, Canada.","year":2009,"lang":"en","type":"other","venue":"PubMed","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hematologic Neoplasms; Library science; Geography; Medicine; History; Internal medicine; Computer science; Cancer","score_opus":0.012351350823803979,"score_gpt":0.22580680009413356,"score_spread":0.21345544927032958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300352883","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06752948,0.0038249572,6.961732e-7,0.0024340495,0.00735186,0.0048338315,0.0037096057,0.00018901487,0.9101265],"genre_scores_gemma":[0.16546156,0.00020436256,0.000016547132,0.001153481,0.00043258313,0.00030984505,0.00013133182,0.00016535138,0.83212495],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676603,0.000063638356,0.0005006084,0.0004968562,0.001486676,0.00068617],"domain_scores_gemma":[0.9982934,0.00011081507,0.00043012315,0.00068088324,0.00021255662,0.00027220717],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028768773,0.0002399731,0.0006464574,0.00010356181,0.000053687334,0.000073943826,0.0006932872,0.00038422697,0.0017618486],"category_scores_gemma":[0.0005989532,0.00025379637,0.00014528805,0.00022586744,0.00029458007,0.000031701056,0.00014564215,0.0004376618,0.000015885573],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000345628,0.00015694395,0.0018034881,0.00021438532,0.00016275037,0.00096690824,0.000008690771,0.0000027995868,9.2463426e-7,0.000013496317,0.9905938,0.006041241],"study_design_scores_gemma":[0.0051395223,0.00002547186,0.23779729,0.0008079362,0.00006840636,0.00082631974,0.000038078848,0.000008378677,0.000066551045,0.000018570312,0.7549491,0.00025438264],"about_ca_topic_score_codex":0.946566,"about_ca_topic_score_gemma":0.98495793,"teacher_disagreement_score":0.2359938,"about_ca_system_score_codex":0.008016505,"about_ca_system_score_gemma":0.010281704,"threshold_uncertainty_score":0.9999914},"labels":[],"label_agreement":null},{"id":"W4301522731","doi":"","title":"Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia","year":2015,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Obinutuzumab; Chronic lymphocytic leukemia; Medicine; CD20; Leukemia; Oncology; Internal medicine; Immunology; Lymphoma","score_opus":0.23690146616163252,"score_gpt":0.5567972750269718,"score_spread":0.3198958088653393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301522731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97910404,0.016179457,0.000008610625,0.000022215498,0.00016712441,0.0015883755,0.000029941104,0.000011903646,0.00288834],"genre_scores_gemma":[0.99221045,0.0071178568,0.00011184194,0.00006762345,0.00017141584,0.00007694472,0.000027421838,0.000053860833,0.00016256147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949741,0.0005619558,0.0016228136,0.00048809042,0.0018153486,0.00053771905],"domain_scores_gemma":[0.9956941,0.00091540406,0.0010881403,0.0010774565,0.00082708924,0.0003978087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018469971,0.00036496427,0.0015471668,0.0006194238,0.00006175051,0.000119885764,0.0018390832,0.00018640362,0.0008680843],"category_scores_gemma":[0.0005254575,0.00022029282,0.0002941031,0.001210441,0.0005663881,0.00061530806,0.00036175948,0.0003413844,0.000015234185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0074115586,0.0017446689,0.94849026,0.00034289187,0.0009083517,0.00021395262,0.0022659756,0.0017974664,0.0012256991,0.000054242293,0.0040987288,0.03144619],"study_design_scores_gemma":[0.08115407,0.0024916055,0.8853799,0.0020129445,0.00060484407,0.00009889845,0.00087295816,0.004394917,0.015105235,0.00108316,0.0062992335,0.00050224346],"about_ca_topic_score_codex":0.012569708,"about_ca_topic_score_gemma":0.00033590684,"teacher_disagreement_score":0.07374252,"about_ca_system_score_codex":0.058444273,"about_ca_system_score_gemma":0.042033873,"threshold_uncertainty_score":0.9940057},"labels":[],"label_agreement":null},{"id":"W4306254512","doi":"10.1016/j.htct.2022.09.222","title":"LEUCEMIA LINFOCÍTICA CRÔNICA (LLC) ASSOCIADA A NEOPLASIAS HEMATOLÓGICAS (NH): FENÔMENOS RELACIONADOS OU NÃO? DISCUSSÃO BASEADA NO RELATO DE DOIS CASOS","year":2022,"lang":"pt","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology; Surgery","score_opus":0.019508094493702083,"score_gpt":0.2801900983176913,"score_spread":0.2606820038239892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306254512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94831693,0.032462843,0.00052368746,0.0056549255,0.0012306996,0.0033983174,0.00024168221,0.0002758013,0.00789511],"genre_scores_gemma":[0.93892735,0.028790409,0.0003584813,0.0030672718,0.00023163731,0.0005999803,0.00015018461,0.0003019262,0.027572772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906444,0.0017401867,0.0017041252,0.0018189165,0.0018271751,0.0022652273],"domain_scores_gemma":[0.99466985,0.0017674277,0.00045759918,0.0015122716,0.00027170553,0.0013211648],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019117701,0.0011137768,0.0022194511,0.0004753831,0.0018707691,0.00009653098,0.00081651425,0.0011673529,0.0135583645],"category_scores_gemma":[0.00019652623,0.0009932133,0.0006640316,0.0011168242,0.00068853085,0.0001716151,0.00042056348,0.0031803523,0.00040451178],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.11270055,0.03668708,0.06803932,0.015935866,0.010686532,0.08583974,0.17562708,0.00095828157,0.14070784,0.03403076,0.29541954,0.023367401],"study_design_scores_gemma":[0.2717526,0.013337135,0.0011586233,0.001979018,0.002513227,0.064170994,0.034701012,0.11166388,0.03830432,0.0009831758,0.45346776,0.005968249],"about_ca_topic_score_codex":0.001715951,"about_ca_topic_score_gemma":0.0002615636,"teacher_disagreement_score":0.15905206,"about_ca_system_score_codex":0.0075114234,"about_ca_system_score_gemma":0.01248768,"threshold_uncertainty_score":0.9994287},"labels":[],"label_agreement":null},{"id":"W4307059187","doi":"10.1016/j.canep.2022.102279","title":"Patterns and predictors of referral to the specialized chronic lymphocytic leukemia clinic in Manitoba, Canada","year":2022,"lang":"en","type":"article","venue":"Cancer Epidemiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"Manitoba Centre for Health Policy, University of Manitoba; Canada Research Chairs; Research Manitoba","keywords":"Medicine; Referral; Chronic lymphocytic leukemia; Confidence interval; Odds ratio; Logistic regression; Internal medicine; Pediatrics; Leukemia; Family medicine","score_opus":0.0834796772901705,"score_gpt":0.3613559264857125,"score_spread":0.277876249195542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307059187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98833245,0.005094027,0.000014859156,0.0039712223,0.0012716536,0.00088117464,0.00012400528,0.00001666453,0.00029393437],"genre_scores_gemma":[0.99204576,0.00096755853,0.000024665422,0.004524604,0.0007557904,0.0005248965,0.000035535308,0.000031129173,0.0010900375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968003,0.00079427235,0.0008475182,0.0005103552,0.00033700516,0.000710572],"domain_scores_gemma":[0.9973517,0.0015650529,0.00019734983,0.0005952294,0.000054641332,0.00023602333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001838085,0.0001896745,0.0008546867,0.00013909908,0.000109732646,0.0000023066725,0.0003605607,0.000092762966,0.0013871365],"category_scores_gemma":[0.0010177623,0.00014458112,0.00007748654,0.00033411078,0.00016068542,0.000021675321,0.00046294,0.0005153537,0.000008199686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025743137,0.000037378777,0.7466009,0.0008067179,0.00039198858,0.0004385792,0.00097182876,0.019755535,0.00018825577,0.00034959102,0.21916814,0.008716763],"study_design_scores_gemma":[0.028393647,0.001512936,0.5891067,0.0003350044,0.00018580684,0.0004240979,0.001633442,0.024000753,0.00023655596,0.00025941295,0.35344845,0.00046318592],"about_ca_topic_score_codex":0.9149177,"about_ca_topic_score_gemma":0.92080826,"teacher_disagreement_score":0.1574942,"about_ca_system_score_codex":0.1904801,"about_ca_system_score_gemma":0.07226715,"threshold_uncertainty_score":0.9995257},"labels":[],"label_agreement":null},{"id":"W4307066835","doi":"10.5272/jimab.2022284.4622","title":"A STUDY ON THE ROLE OF THE RB1 GENE AS A PROGNOSTIC FACTOR IN UNTREATED PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA","year":2022,"lang":"en","type":"article","venue":"Journal of IMAB - Annual Proceeding (Scientific Papers)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Chronic lymphocytic leukemia; Fluorescence in situ hybridization; Gene; Chromosome; Oncology; Retinoblastoma; Medicine; Leukemia; Disease; Copy-number variation; Internal medicine; Cancer research; Immunology; Biology; Genetics; Genome","score_opus":0.013107227784196892,"score_gpt":0.2572998641460143,"score_spread":0.2441926363618174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307066835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968549,0.00023135428,3.0081432e-7,0.000117934054,0.0002714571,0.001645344,0.00004528408,0.000014422817,0.0008189956],"genre_scores_gemma":[0.9990643,0.0000032113269,0.000009577607,0.00006446612,0.000074578544,0.000059282756,0.0000052020505,0.000040580846,0.00067876506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951891,0.00018438906,0.00078175473,0.0004252986,0.0028442251,0.0005752377],"domain_scores_gemma":[0.9976053,0.00029781123,0.00067280256,0.0004333754,0.00081471674,0.00017598135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013953061,0.000275097,0.0005032863,0.0004660259,0.0005258179,0.00012053446,0.00082125835,0.000052869178,0.00022340407],"category_scores_gemma":[0.000938184,0.00013999538,0.00018780935,0.0018797893,0.0003583516,0.00019297864,0.00036217828,0.0008521701,0.00001040752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0093230605,0.0053473436,0.8434302,0.0003534521,0.0014898577,0.0007929467,0.064445406,0.0056027663,0.061893117,0.0002414853,0.002208716,0.00487163],"study_design_scores_gemma":[0.16921878,0.041388463,0.5176354,0.0027207416,0.0016061625,0.0032751379,0.19270779,0.01668485,0.04621204,0.00054759765,0.006540554,0.0014624948],"about_ca_topic_score_codex":0.00022892519,"about_ca_topic_score_gemma":0.000020688027,"teacher_disagreement_score":0.32579482,"about_ca_system_score_codex":0.037997045,"about_ca_system_score_gemma":0.02489194,"threshold_uncertainty_score":0.980636},"labels":[],"label_agreement":null},{"id":"W4307130134","doi":"10.51731/cjht.2022.478","title":"Ruxolitinib (Jakavi)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Ruxolitinib; Medicine; Family medicine; Drug; Pharmacology; Internal medicine; Political science; Health care; Myelofibrosis","score_opus":0.04092840541870764,"score_gpt":0.3241599007891345,"score_spread":0.28323149537042686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307130134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71043634,0.13973027,0.00008739248,0.14376242,0.001043467,0.00074548286,0.00006325112,0.00024170267,0.0038896909],"genre_scores_gemma":[0.99775726,0.00023304157,0.0003783924,0.0011759006,0.000018857465,0.00001321289,0.0000035146752,0.000017999982,0.0004018205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982113,0.000080035235,0.0005162977,0.00012525561,0.00040769376,0.0006593886],"domain_scores_gemma":[0.9990011,0.00006884527,0.00025661485,0.00033176463,0.0001459853,0.00019568531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011578188,0.00009396411,0.0003686019,0.00067480974,0.0004459771,0.000016582508,0.00041410004,0.00006742492,0.00039949003],"category_scores_gemma":[0.0007601783,0.00008399049,0.00009496721,0.00053113594,0.000231564,0.000048907037,0.00007591292,0.0009516916,0.000013600473],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0001643261,0.00008999217,0.003829691,0.00044133153,0.00015503385,0.007780482,0.0013518215,0.00012860326,0.00008668637,0.008292952,0.12713735,0.8505417],"study_design_scores_gemma":[0.0042530047,0.0014460568,0.0011745491,0.00010664674,0.000013741452,0.012389868,0.010789312,0.00010875169,0.0002467051,0.0026992336,0.9666614,0.00011071881],"about_ca_topic_score_codex":0.009471004,"about_ca_topic_score_gemma":0.0007792936,"teacher_disagreement_score":0.850431,"about_ca_system_score_codex":0.023272179,"about_ca_system_score_gemma":0.078700304,"threshold_uncertainty_score":0.997125},"labels":[],"label_agreement":null},{"id":"W4308254443","doi":"10.1007/s41669-022-00375-x","title":"A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Foothills Medical Centre","funders":"AbbVie","keywords":"Obinutuzumab; Venetoclax; Medicine; Chlorambucil; Rituximab; Bendamustine; Internal medicine; Fludarabine; Chronic lymphocytic leukemia; Ibrutinib; Oncology; Population; Ofatumumab; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma","score_opus":0.04922340262774139,"score_gpt":0.3689317120683685,"score_spread":0.3197083094406271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308254443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939042,0.0011180433,0.000001948829,0.00008040199,0.00009127591,0.004116302,0.00011234765,0.000008394027,0.00056710397],"genre_scores_gemma":[0.99642265,0.0009889334,0.000012782599,0.00045065157,0.000027842154,0.0018398511,0.000106023435,0.00004201836,0.00010923784],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975809,0.0002911591,0.0006828629,0.000645966,0.00027434045,0.00052477245],"domain_scores_gemma":[0.9983527,0.0007158234,0.00019322186,0.00048259806,0.000051567862,0.00020408239],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012298299,0.00025023666,0.0010599876,0.0005597911,0.000090430214,0.0000374924,0.0005993592,0.000044738357,0.0011504047],"category_scores_gemma":[0.000083136896,0.000269461,0.00009500099,0.0011690004,0.000090365735,0.00014072395,0.000767033,0.00036413237,0.00000445322],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0041151457,0.000038132614,0.0058199563,0.00030780895,0.0009008592,0.00034195074,0.00043117304,0.9822661,0.000561547,0.000112243215,0.00010699849,0.004998039],"study_design_scores_gemma":[0.043884855,0.00043209188,0.00980232,0.00006857964,0.00025560282,0.00008343171,0.00015828517,0.9405372,0.0015724162,0.00012765967,0.002817429,0.00026011356],"about_ca_topic_score_codex":0.97930264,"about_ca_topic_score_gemma":0.87436914,"teacher_disagreement_score":0.40460974,"about_ca_system_score_codex":0.7097142,"about_ca_system_score_gemma":0.30510446,"threshold_uncertainty_score":0.99997574},"labels":[],"label_agreement":null},{"id":"W4308949853","doi":"10.1038/s41573-022-00582-5","title":"Beyond PI3Ks: targeting phosphoinositide kinases in disease","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Michael Smith Health Research BC; National Cancer Institute; National Science Foundation","keywords":"Phosphoinositide 3-kinase; Kinase; Disease; Medicine; Biology; Cancer research; Signal transduction; Cell biology; PI3K/AKT/mTOR pathway; Internal medicine","score_opus":0.033588309359759774,"score_gpt":0.37365987703614184,"score_spread":0.3400715676763821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308949853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004703293,0.9900309,0.0000012796025,0.00013288853,0.00091979426,0.005784293,0.00029588852,0.00008319603,0.002704771],"genre_scores_gemma":[0.000022533639,0.98694164,0.00011685284,0.00094508426,0.0009946779,0.0017869093,0.0030683826,0.00026114788,0.0058627604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.991957,0.0012571375,0.002217587,0.0017160181,0.0016258816,0.0012263468],"domain_scores_gemma":[0.99517095,0.0013851947,0.0008582677,0.0018960675,0.00005894165,0.00063054776],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024149723,0.0012442408,0.0057274764,0.0007454126,0.00018623154,0.00016840374,0.0010003536,0.0006485445,0.0013914069],"category_scores_gemma":[0.0040735654,0.000913306,0.0025742461,0.0021755989,0.00017629376,0.00046101812,0.0009713273,0.0058351224,0.00033859772],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012342422,0.00043116862,0.000022180111,0.17282756,0.00019547841,0.0043694247,0.000102251244,0.000002059084,2.7274947e-7,0.0003408463,0.06441926,0.7571661],"study_design_scores_gemma":[0.002045826,0.00003750883,0.0000036721888,0.05798575,0.0015945811,0.0002261932,0.000044253557,0.000015240851,0.0000011504112,0.000057915924,0.9372263,0.0007616292],"about_ca_topic_score_codex":0.00021845268,"about_ca_topic_score_gemma":0.00003834851,"teacher_disagreement_score":0.872807,"about_ca_system_score_codex":0.027258886,"about_ca_system_score_gemma":0.020667063,"threshold_uncertainty_score":0.99952143},"labels":[],"label_agreement":null},{"id":"W4308963956","doi":"10.1097/hs9.0000000000000801","title":"Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"Janssen Biotech; Novo Nordisk; Ascentage Pharma; Servier; Moderna; Celltrion; Incyte; Pharmacyclics; MEI Pharma; Karyopharm Therapeutics; Gilead Sciences; BeiGene; Sanofi; Cilag; TG Therapeutics; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Bendamustine; Chronic lymphocytic leukemia; Tolerability; Ofatumumab; Gastroenterology; Adverse effect; Oncology; Leukemia","score_opus":0.07152014511977556,"score_gpt":0.33529776259184485,"score_spread":0.2637776174720693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308963956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971468,0.003054276,0.0000020611383,0.0006219083,0.0016551169,0.0017409291,0.000053449272,0.00023277856,0.021171492],"genre_scores_gemma":[0.9826602,0.000117849566,0.00020333868,0.0005881799,0.0015122417,0.0005201862,0.00018996501,0.00013275818,0.014075315],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941876,0.00045778253,0.0011013276,0.0011359784,0.0018187666,0.0012985314],"domain_scores_gemma":[0.9961385,0.0013447456,0.00028687125,0.0013461354,0.00010443522,0.00077927625],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013040561,0.00047504072,0.00082106923,0.00024623142,0.00034191203,0.000045689452,0.00059991935,0.000355101,0.0034730113],"category_scores_gemma":[0.004126677,0.0004869902,0.00027245737,0.0013089804,0.000347533,0.00014732846,0.000677428,0.002007885,0.00046337664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6186721,0.0013203624,0.00043124953,0.0016839523,0.00065554125,0.009717964,0.0023106216,0.015763003,0.0035278047,0.0010441549,0.32730487,0.017568413],"study_design_scores_gemma":[0.7278039,0.0052903574,0.00033129842,0.0002407996,0.00012442928,0.00028827996,0.00048346122,0.02065491,0.00096997066,0.000058478843,0.2432011,0.0005530145],"about_ca_topic_score_codex":0.0046892213,"about_ca_topic_score_gemma":0.00088778866,"teacher_disagreement_score":0.13744491,"about_ca_system_score_codex":0.265405,"about_ca_system_score_gemma":0.1279601,"threshold_uncertainty_score":0.9997582},"labels":[],"label_agreement":null},{"id":"W4309048303","doi":"10.1097/ppo.0000000000000635","title":"Antibody-Drug Conjugates in Myeloid Leukemias","year":2022,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Gemtuzumab ozogamicin; Myeloid leukemia; Antibody-drug conjugate; Medicine; Calicheamicin; Monoclonal antibody; Cancer research; Targeted therapy; Leukemia; Cytotoxic T cell; Drug; Antibody; Immunology; Cancer; Oncology; Pharmacology; CD33; Internal medicine; Stem cell; Biology; In vitro","score_opus":0.10130601808362984,"score_gpt":0.44695587109849483,"score_spread":0.345649853014865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309048303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017027243,0.9946062,0.0000033525243,0.00042558945,0.00079655345,0.000877049,0.000030622326,0.000025250665,0.0030651279],"genre_scores_gemma":[0.000034355126,0.9939141,0.00001682386,0.00034990723,0.0017963474,0.0001798582,0.00007453135,0.00011700291,0.003517066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961267,0.00061800826,0.0009822258,0.00041485755,0.00107714,0.0007810414],"domain_scores_gemma":[0.99772274,0.00067835074,0.0004920274,0.0007461566,0.000078031255,0.00028271874],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002304329,0.00043897392,0.0018841759,0.0003966883,0.00030324873,0.00010486798,0.0010572837,0.00016543164,0.0077702105],"category_scores_gemma":[0.00027527456,0.0002519322,0.0006572069,0.0008313602,0.00022666616,0.00008004112,0.00041559606,0.0040640365,0.00012527523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00010139337,0.000054246248,0.000015866108,0.009062627,0.00048770467,0.0022556388,0.0004975074,0.000027780216,0.0000033031117,0.000037365593,0.013466136,0.97399044],"study_design_scores_gemma":[0.004113668,0.00005968997,0.000004261139,0.01228808,0.00066815806,0.0108267,0.00015659023,0.00009288453,0.0000029363084,0.00009099129,0.9714493,0.0002467053],"about_ca_topic_score_codex":0.0009156674,"about_ca_topic_score_gemma":0.000074364725,"teacher_disagreement_score":0.97374374,"about_ca_system_score_codex":0.05972414,"about_ca_system_score_gemma":0.05513755,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W4310105226","doi":"10.1182/blood-2022-163257","title":"Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Chemoimmunotherapy; Ibrutinib; Population; Fludarabine; Internal medicine; Oncology; Hazard ratio; Clinical trial; Venetoclax; Chronic lymphocytic leukemia; Chemotherapy; Leukemia; Confidence interval; Cyclophosphamide","score_opus":0.021645680935883663,"score_gpt":0.28933510428412695,"score_spread":0.2676894233482433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310105226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979651,0.00006804936,0.0000190525,0.000040380397,0.00011362387,0.0014608811,0.000039362476,0.000100925594,0.0001926187],"genre_scores_gemma":[0.9972529,0.0000065513455,0.0016879551,0.00012546137,0.00010967252,0.00019688939,0.00041592662,0.00010042802,0.00010421368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962041,0.00021299394,0.00095796585,0.00064755266,0.0012451141,0.0007322768],"domain_scores_gemma":[0.9982413,0.00033275379,0.0003739188,0.00068275025,0.00013073305,0.00023852794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083055196,0.0003394847,0.0008602488,0.00039630962,0.00017088478,0.00004815549,0.00034098048,0.00010899132,0.000099286175],"category_scores_gemma":[0.00059725175,0.00031567214,0.000109877394,0.0007437618,0.000069668495,0.00024482352,0.000424757,0.00038761328,0.000009613027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026909232,0.0026546791,0.9326033,0.002229981,0.00061644835,0.00053054234,0.007240507,0.03702621,0.005436621,0.0001825069,0.000034686298,0.00875357],"study_design_scores_gemma":[0.11823526,0.004139108,0.8157589,0.0004914051,0.00023411734,0.00005352168,0.0006999576,0.05688544,0.0026985314,0.000119086726,0.000036209298,0.0006484643],"about_ca_topic_score_codex":0.010079161,"about_ca_topic_score_gemma":0.0013154106,"teacher_disagreement_score":0.11684442,"about_ca_system_score_codex":0.02634311,"about_ca_system_score_gemma":0.006302563,"threshold_uncertainty_score":0.99992955},"labels":[],"label_agreement":null},{"id":"W4310109034","doi":"10.1182/blood-2022-169909","title":"Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Thrombosis; Chronic lymphocytic leukemia; Internal medicine; Retrospective cohort study; Coronavirus disease 2019 (COVID-19); Pediatrics; Disease; Leukemia; Infectious disease (medical specialty)","score_opus":0.07382600572879541,"score_gpt":0.3406315379864103,"score_spread":0.26680553225761494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310109034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994745,0.00022369083,0.000001725261,0.00019687646,0.000011760034,0.0020191283,0.000019175854,0.000022672564,0.0027599703],"genre_scores_gemma":[0.9994284,0.000037278496,0.000021981234,0.00021818792,0.000029655896,0.00016763479,0.000016445809,0.000034898658,0.00004554486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969358,0.00092728186,0.00028621094,0.00044001898,0.0010348724,0.00037580586],"domain_scores_gemma":[0.9981453,0.00092472415,0.00009227091,0.0005037497,0.00014042086,0.00019354733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015917653,0.00014483549,0.00028036602,0.0002879343,0.000496139,0.000029739203,0.00024942128,0.000024088875,0.000038279075],"category_scores_gemma":[0.00038854257,0.00010267968,0.00001771866,0.00086309074,0.00037783192,0.00005278016,0.00061498024,0.0005308894,0.0000048428838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005680207,0.016687514,0.83794296,0.0029039257,0.0021700815,0.0014291235,0.11376451,0.011177538,0.00065438496,0.0017250082,0.0018678922,0.0039968803],"study_design_scores_gemma":[0.13561763,0.009868135,0.8372966,0.00022816923,0.00019575411,0.00021840724,0.012729744,0.003285605,0.000038544393,0.00010434485,0.00020052049,0.00021656117],"about_ca_topic_score_codex":0.001507682,"about_ca_topic_score_gemma":0.00024146776,"teacher_disagreement_score":0.12993743,"about_ca_system_score_codex":0.023036292,"about_ca_system_score_gemma":0.010857946,"threshold_uncertainty_score":0.99474955},"labels":[],"label_agreement":null},{"id":"W4310112286","doi":"10.1182/blood-2022-157583","title":"Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Adverse effect; Rash; Phases of clinical research; Clinical trial; Oncology; Mucositis; Surgery; Toxicity; Lymphoma; Hodgkin lymphoma","score_opus":0.07230352578196757,"score_gpt":0.3474594734599858,"score_spread":0.2751559476780182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310112286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996786,0.00023727551,0.000004003495,0.000013745329,0.000031806554,0.0017047813,0.0011900886,0.00001535776,0.000016915395],"genre_scores_gemma":[0.9989946,0.000032944852,0.00012597877,0.000028907332,0.000017019385,0.000040965435,0.0006998251,0.00003806147,0.000021716198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964702,0.0004908974,0.0008624791,0.00063084834,0.0012690385,0.0002765404],"domain_scores_gemma":[0.99550647,0.0014893652,0.0005845237,0.0020237507,0.00024260166,0.00015331684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006400221,0.00023919353,0.000981984,0.0002544577,0.0001552204,0.000017029415,0.0011037509,0.000059435428,0.00015800005],"category_scores_gemma":[0.00088687806,0.00014742804,0.000044008535,0.0012835385,0.0002698089,0.00021110279,0.0021557328,0.0002602195,4.2966778e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07748362,0.16320302,0.70429075,0.00030593615,0.019351244,0.00023948532,0.020116778,0.00008940633,0.0072812326,0.0000043696105,0.00029652796,0.0073376535],"study_design_scores_gemma":[0.4515507,0.010088804,0.5132811,0.00014448032,0.00758131,0.0000025775832,0.011829786,0.0035642965,0.0015457362,4.1324904e-7,0.000195155,0.00021562986],"about_ca_topic_score_codex":0.002807317,"about_ca_topic_score_gemma":0.000458713,"teacher_disagreement_score":0.37406707,"about_ca_system_score_codex":0.0010886731,"about_ca_system_score_gemma":0.002616847,"threshold_uncertainty_score":0.60119414},"labels":[],"label_agreement":null},{"id":"W4310112932","doi":"10.1182/blood-2022-156749","title":"Quality of Life in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice across Canada: Results from the Devote Study","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta; ABB (Canada); CancerCare Manitoba; Alberta Health Services; Ottawa Hospital","funders":"","keywords":"Venetoclax; Chronic lymphocytic leukemia; Medicine; Leukemia; Quality of life (healthcare); Family medicine; Gerontology; Internal medicine; Intensive care medicine; Oncology; Immunology; Nursing","score_opus":0.04395929401260058,"score_gpt":0.3616856000968255,"score_spread":0.3177263060842249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310112932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973311,0.0003504218,9.713673e-7,0.0001537605,0.000113474576,0.001586283,0.0002679031,0.000017540635,0.00017854365],"genre_scores_gemma":[0.9988934,0.00001173912,0.00010866939,0.00052325294,0.00015660695,0.00010873531,0.00014146327,0.000037106834,0.000019061945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99333614,0.0017031991,0.0018322065,0.0006391738,0.0018561733,0.0006330839],"domain_scores_gemma":[0.9929195,0.004985963,0.0006755712,0.0010093763,0.00023118201,0.00017841518],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0053176447,0.00021708434,0.00074450724,0.000042656615,0.00016258904,0.00001840397,0.00045809813,0.0000797521,0.00002479767],"category_scores_gemma":[0.011845895,0.00016436147,0.000060276805,0.0008337141,0.00013372995,0.00010070528,0.0006199061,0.00096573686,0.0000024320839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010524846,0.0022448353,0.976882,0.00006821954,0.000365184,0.0004895058,0.0038445857,0.004408093,0.0000043508016,0.0000039590977,0.00013807676,0.0010263722],"study_design_scores_gemma":[0.21700321,0.001224475,0.77439016,0.00010028559,0.00008179797,0.000009519467,0.004310925,0.0025367036,0.000018457464,0.0000021959195,0.00017169502,0.00015059195],"about_ca_topic_score_codex":0.9399049,"about_ca_topic_score_gemma":0.83750933,"teacher_disagreement_score":0.20647837,"about_ca_system_score_codex":0.09863749,"about_ca_system_score_gemma":0.15300873,"threshold_uncertainty_score":0.9964777},"labels":[],"label_agreement":null},{"id":"W4310117789","doi":"10.1007/s00277-022-05060-x","title":"EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia","year":2022,"lang":"en","type":"letter","venue":"Annals of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Alemtuzumab; Prolymphocytic leukemia; Hematology; Medicine; Lymphoma; Internal medicine; Leukemia; Oncology; Cancer research; Pathology; Immunology; Chronic lymphocytic leukemia; Transplantation","score_opus":0.04180540435871588,"score_gpt":0.3331331674825112,"score_spread":0.2913277631237953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310117789","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6215331,0.049958028,0.0005285019,0.28943807,0.002692573,0.015332489,0.0019280738,0.0005583592,0.018030824],"genre_scores_gemma":[0.43892947,0.0022217128,0.0004951176,0.53709877,0.0016245636,0.0024501476,0.0040535135,0.00068534404,0.012441341],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928397,0.00045834406,0.0014302222,0.00151172,0.0014326663,0.0023273833],"domain_scores_gemma":[0.99459994,0.0021404698,0.0008403726,0.0017563325,0.00038329145,0.00027958828],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007851772,0.0009914646,0.0029268807,0.00079645315,0.00032420247,0.000039991326,0.0010312232,0.0017151851,0.00042477658],"category_scores_gemma":[0.0002971146,0.0009216044,0.0017903048,0.0004995454,0.00031095571,0.00012061222,0.00050659425,0.001338044,0.00008480824],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033932654,0.0028699678,0.000044055778,0.0041769086,0.0013047184,0.009198869,0.00067908684,0.0000020797338,0.0008160388,0.00022061823,0.9765199,0.0007744919],"study_design_scores_gemma":[0.17255837,0.004515774,0.000009176163,0.0005059206,0.00050955685,0.002559446,0.00024964925,0.0014883337,0.113227606,0.00058109715,0.70268416,0.0011109224],"about_ca_topic_score_codex":0.0004488027,"about_ca_topic_score_gemma":0.0000073844362,"teacher_disagreement_score":0.27383575,"about_ca_system_score_codex":0.007772031,"about_ca_system_score_gemma":0.025113864,"threshold_uncertainty_score":0.9995808},"labels":[],"label_agreement":null},{"id":"W4310119573","doi":"10.1182/blood-2022-157060","title":"Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Ibrutinib; Adverse effect; Internal medicine; Chronic lymphocytic leukemia; Incidence (geometry); Post-hoc analysis; Oncology; Leukemia","score_opus":0.049784226107076286,"score_gpt":0.36965476884858345,"score_spread":0.31987054274150717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310119573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489164,0.0005024585,0.0000017885209,0.00015057354,0.00023108258,0.00292036,0.00001564092,0.000037486338,0.0012489466],"genre_scores_gemma":[0.99883753,0.00005339185,0.00007943015,0.000035833586,0.00023292778,0.00035916586,0.00003786655,0.000056646124,0.00030722975],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99545944,0.0006361758,0.0011609356,0.0005747105,0.0013476943,0.00082103297],"domain_scores_gemma":[0.997611,0.000834628,0.00031662403,0.00095408387,0.00009779859,0.0001858523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018345425,0.00029651844,0.0009067186,0.00054286775,0.00009708396,0.000006483138,0.0006335548,0.00015376582,0.0002495237],"category_scores_gemma":[0.0009846983,0.0002460562,0.00023692897,0.0019416041,0.00016389892,0.000113516035,0.0005579879,0.00060708844,0.000019598478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6030307,0.015633876,0.02651372,0.0068529835,0.003655724,0.005251096,0.039877973,0.1746646,0.09159327,0.0003048154,0.00083914056,0.031782143],"study_design_scores_gemma":[0.9485171,0.0055117835,0.0060703363,0.0010340397,0.00045149532,0.00017471009,0.0022197259,0.026497653,0.008499185,0.000025264935,0.0006541171,0.00034462503],"about_ca_topic_score_codex":0.016739024,"about_ca_topic_score_gemma":0.0005608516,"teacher_disagreement_score":0.3454864,"about_ca_system_score_codex":0.053490978,"about_ca_system_score_gemma":0.04112964,"threshold_uncertainty_score":0.99999917},"labels":[],"label_agreement":null},{"id":"W4310127303","doi":"10.1182/blood-2022-167235","title":"The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; McMaster University; ABB (Canada); Université de Montréal","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Intensive care medicine; Leukemia","score_opus":0.026732157363686563,"score_gpt":0.2922066515171132,"score_spread":0.26547449415342667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310127303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683964,0.0015765679,6.6136914e-7,0.0000045642832,0.000063390595,0.00091389276,0.000023546152,0.000004173046,0.0005735892],"genre_scores_gemma":[0.99941725,0.0002897256,0.00002546288,0.000012827896,0.000035597233,0.00012472914,0.000009519658,0.000021008322,0.000063878986],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982508,0.0001534576,0.00049469125,0.00023440331,0.00039600418,0.00047064418],"domain_scores_gemma":[0.99893296,0.00020991219,0.00015495108,0.0006337659,0.000015177982,0.00005321361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005124737,0.00016194857,0.00036266135,0.00011305413,0.00010111879,0.000008885463,0.0003602333,0.000025668283,0.00006640016],"category_scores_gemma":[0.000008486491,0.00010314771,0.00012002673,0.00033080028,0.00007182482,0.000027747255,0.00016862676,0.0001559395,0.0000012544451],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0001985214,0.000004364323,0.00022158251,0.00014518396,0.0003287658,0.00054237567,0.00065683224,0.99693954,0.0004223731,0.000064295185,0.000023537463,0.0004526416],"study_design_scores_gemma":[0.031929247,0.0006965367,0.0008343232,0.00015322269,0.00017890446,0.00047918552,0.0032265044,0.96073556,0.0015212114,0.00002899168,0.00010955528,0.00010677924],"about_ca_topic_score_codex":0.9907539,"about_ca_topic_score_gemma":0.70817745,"teacher_disagreement_score":0.28257647,"about_ca_system_score_codex":0.98208684,"about_ca_system_score_gemma":0.7662686,"threshold_uncertainty_score":0.42062414},"labels":[],"label_agreement":null},{"id":"W4310273448","doi":"10.1038/s41375-022-01762-3","title":"Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Bristol-Myers Squibb Canada; Janssen Biotech; Associazione Italiana per la Ricerca sul Cancro; Sanofi; Meso Scale Diagnostics; AbbVie; Pfizer; Novartis Pharmaceuticals Corporation; Gilead Foundation; Celgene; Bayer; Celltrion Healthcare; European Hematology Association; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Amgen; Roche","keywords":"Waldenstrom macroglobulinemia; Macroglobulinemia; Medicine; Immunology; Multiple myeloma; Lymphoma","score_opus":0.020630221361695348,"score_gpt":0.29052392489038853,"score_spread":0.2698937035286932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310273448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843141,0.0008396934,0.00008283788,0.0034737086,0.0007619431,0.003044382,0.00065470644,0.00009450398,0.0067341267],"genre_scores_gemma":[0.99311435,0.00014592794,0.0015873031,0.0011160289,0.00025041398,0.00033410592,0.00012582075,0.00011468985,0.0032113858],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99494547,0.00056582683,0.0014054879,0.0007228265,0.0012319963,0.0011284027],"domain_scores_gemma":[0.99670637,0.0010428034,0.00045197023,0.0012128192,0.00029707802,0.00028894743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019086219,0.00040252358,0.0007377406,0.00021248961,0.0002947466,0.000029372588,0.0007464491,0.0001271292,0.00040031996],"category_scores_gemma":[0.0014846954,0.0003321555,0.00035566944,0.00078567176,0.0005258494,0.000030907388,0.0010604595,0.0010209351,0.00003378645],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011339799,0.0036764797,0.102471426,0.006723653,0.0018032233,0.016128575,0.008390795,0.038074832,0.051961716,0.0073227435,0.67895955,0.07314722],"study_design_scores_gemma":[0.23211408,0.0044281124,0.054908432,0.0019475602,0.001572967,0.010436185,0.009152911,0.099228576,0.07444652,0.002229964,0.5064055,0.0031292473],"about_ca_topic_score_codex":0.0011403343,"about_ca_topic_score_gemma":0.0002448409,"teacher_disagreement_score":0.22077428,"about_ca_system_score_codex":0.025570761,"about_ca_system_score_gemma":0.01205526,"threshold_uncertainty_score":0.99991304},"labels":[],"label_agreement":null},{"id":"W4311395644","doi":"10.1016/j.fander.2022.09.576","title":"Efficacité du baricitinib associé aux TCS chez les patients atteints de DA modérée à sévère ayant présenté un échec, une intolérance ou une contre-indication à la ciclosporine : analyse post-hoc de la cohorte européenne de BREEZE-AD4","year":2022,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.02569524568906701,"score_gpt":0.3406786700412798,"score_spread":0.31498342435221277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311395644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440229,0.011520587,0.0021714878,0.036731664,0.00054263044,0.0015908893,0.0006454953,0.00063551415,0.002138848],"genre_scores_gemma":[0.97591144,0.012886747,0.0019714145,0.0051474413,0.00038423215,0.0005443314,0.001344049,0.00026170543,0.0015486543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9831735,0.007465744,0.001909736,0.0017123047,0.0016452286,0.0040934975],"domain_scores_gemma":[0.9881926,0.006769942,0.0012150061,0.0016846729,0.0008914416,0.0012463338],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.006130408,0.0012472346,0.0019125852,0.00072421395,0.00096314965,0.0002792762,0.0021820026,0.0014051318,0.0004774711],"category_scores_gemma":[0.010504853,0.001324057,0.0007222652,0.0025314249,0.002241139,0.0003648095,0.0016329837,0.0035497716,0.00017492956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0043589226,0.0062273797,0.8122677,0.0017196542,0.0029751959,0.03377658,0.0091570765,0.0136163635,0.004237382,0.005992259,0.024576815,0.081094645],"study_design_scores_gemma":[0.04569318,0.0027631603,0.7319966,0.0010346614,0.00244424,0.01714693,0.0092107905,0.11047414,0.01266765,0.005744622,0.058228996,0.0025950475],"about_ca_topic_score_codex":0.008314073,"about_ca_topic_score_gemma":0.0011237107,"teacher_disagreement_score":0.09685778,"about_ca_system_score_codex":0.02341249,"about_ca_system_score_gemma":0.02140734,"threshold_uncertainty_score":0.9998913},"labels":[],"label_agreement":null},{"id":"W4311851732","doi":"10.1101/2022.12.15.520623","title":"SGC-CLK-1 (CAF-170) a chemical probe for the Cdc2-Like kinases CLK1, CLK2, and CLK4","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Ontario Genomics; National Institutes of Health; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Genome Canada; McGill University; Pfizer; Northwestern University; Bayer; Bristol-Myers Squibb","keywords":"Kinase; Phosphorylation; Serine; Protein-Serine-Threonine Kinases; Cyclin-dependent kinase 1; Small molecule; Subcellular localization; Cell biology; Biology; Chemistry; Biochemistry; Cell cycle; Protein kinase A; Gene","score_opus":0.024523872966266343,"score_gpt":0.2734057257025271,"score_spread":0.24888185273626073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311851732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969029,0.014057761,0.001094021,0.003069007,0.0021981143,0.008884401,0.00081538246,0.00078991015,0.000062363295],"genre_scores_gemma":[0.9872997,0.0016665346,0.0042724297,0.0011505306,0.0012569904,0.0038626844,0.0000045965185,0.00035581744,0.00013075619],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946429,0.00017756385,0.00085392664,0.0018051205,0.0012377852,0.0012827134],"domain_scores_gemma":[0.9947285,0.00096757483,0.00040847325,0.002602341,0.0006497461,0.0006433462],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001278797,0.00085021387,0.0011345138,0.00031136736,0.000468824,0.00027626398,0.0010094467,0.00072786247,0.00032406786],"category_scores_gemma":[0.0014270954,0.00070200866,0.0004140609,0.0006661999,0.0005980694,0.00011305753,0.0023011495,0.0019463252,0.000037500668],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0042080516,0.0020595388,0.006482167,0.015541414,0.0035529013,0.0015533044,0.00024681256,0.00009188368,0.91516083,0.0049669263,0.04598336,0.00015281628],"study_design_scores_gemma":[0.047181137,0.0015041286,0.023564061,0.0033711316,0.0036679222,0.0000071560466,0.00013543497,0.025755301,0.34993625,0.00006345606,0.54022294,0.0045910478],"about_ca_topic_score_codex":0.00038656913,"about_ca_topic_score_gemma":0.0000065104646,"teacher_disagreement_score":0.5652246,"about_ca_system_score_codex":0.008481519,"about_ca_system_score_gemma":0.013222697,"threshold_uncertainty_score":0.99954313},"labels":[],"label_agreement":null},{"id":"W4311874266","doi":"10.1002/acr2.11511","title":"Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled Dose‐Ranging</scp> Trial","year":2022,"lang":"en","type":"article","venue":"ACR Open Rheumatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University Health Network","funders":"EMD Serono; Merck KGaA","keywords":"Double blind; Placebo; Dose-ranging study; Medicine; Pharmacology; Pathology","score_opus":0.0248153372419936,"score_gpt":0.31871822235040376,"score_spread":0.2939028851084102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311874266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652369,0.0059837624,0.000026940386,0.000484587,0.0016976297,0.022599597,0.00022519931,0.00009451133,0.003650884],"genre_scores_gemma":[0.9898323,0.0009463277,0.00014305476,0.00012478267,0.0001192348,0.002493183,0.0001749605,0.00016093382,0.0060052415],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98715806,0.0034369265,0.0044600493,0.0015428478,0.0016946619,0.0017074568],"domain_scores_gemma":[0.96794766,0.026414966,0.0025058317,0.0021597436,0.0004761281,0.00049566675],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01114879,0.0009071903,0.0061928746,0.00096725015,0.0006333202,0.00010014555,0.0020005114,0.00061933335,0.000039480805],"category_scores_gemma":[0.03191949,0.0006751161,0.00081595546,0.0018826575,0.0013840643,0.0002897548,0.0035596897,0.0014679743,0.000024984567],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95210546,0.0033799878,0.00027201674,0.0014612594,0.0016538581,0.00044688405,0.017285787,0.0003390361,0.0041302782,0.0024852278,0.016158415,0.00028176644],"study_design_scores_gemma":[0.96558577,0.0019344355,0.000014085777,0.0014067353,0.00063411077,0.006583553,0.0069591682,0.005183086,0.006552705,0.00013151579,0.004901863,0.000112990456],"about_ca_topic_score_codex":0.0024024162,"about_ca_topic_score_gemma":0.00016710127,"teacher_disagreement_score":0.024595391,"about_ca_system_score_codex":0.0028589328,"about_ca_system_score_gemma":0.007968425,"threshold_uncertainty_score":0.99957},"labels":[],"label_agreement":null},{"id":"W4312058341","doi":"10.1002/ccr3.6722","title":"Plasma cell myeloma following a prior diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2022,"lang":"en","type":"article","venue":"Clinical Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Multiple myeloma; Plasma Cell Myeloma; Lymphoma; Immunoglobulin light chain; Plasma cell neoplasm; Plasma cell; Pathology; Leukemia; CD20; Cancer research; Internal medicine; Immunology; Plasmacytoma; Antibody","score_opus":0.044776068282028944,"score_gpt":0.3407141990627162,"score_spread":0.29593813078068726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312058341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890137,0.0030374348,0.000033651242,0.000075051285,0.0020671536,0.0019749117,0.000032668428,0.00028763924,0.0034778393],"genre_scores_gemma":[0.99381036,0.00037331157,0.00061181094,0.0004290581,0.0006817439,0.0008779902,0.00008345143,0.00021682674,0.0029154727],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9899312,0.0006893374,0.0039877547,0.0018632743,0.0020419285,0.0014865071],"domain_scores_gemma":[0.99104625,0.0033295369,0.0014088533,0.0027465792,0.00029862951,0.0011701342],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043448745,0.00069039373,0.0021456946,0.0004806062,0.00061065605,0.00005730939,0.00039183648,0.0004751695,0.001092697],"category_scores_gemma":[0.00329606,0.0006807951,0.001906585,0.0013240757,0.0005475485,0.00015239467,0.00147247,0.00074191374,0.00009731462],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011924793,0.0010574841,0.006970594,0.0013461575,0.00071791635,0.93258333,0.00037661564,0.0023630692,0.00044822437,0.000024088711,0.0035385606,0.049381495],"study_design_scores_gemma":[0.082886875,0.0061618406,0.0013735908,0.0007190711,0.0023288943,0.7169561,0.0009935992,0.122788236,0.01944467,0.00016265691,0.044689033,0.0014954489],"about_ca_topic_score_codex":0.0030478043,"about_ca_topic_score_gemma":0.00010429845,"teacher_disagreement_score":0.21562722,"about_ca_system_score_codex":0.2371854,"about_ca_system_score_gemma":0.16663341,"threshold_uncertainty_score":0.9998204},"labels":[],"label_agreement":null},{"id":"W4312114026","doi":"10.1038/s41408-022-00760-z","title":"Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University of Manitoba; CancerCare Manitoba","funders":"Cilag; Pharmacyclics; Kite Pharma; Canadian Institutes of Health Research; Ipsen; MorphoSys; Associazione Italiana per la Ricerca sul Cancro; Aptitude Health; Cancer Research UK; Ascentage Pharma; BeiGene; Celltrion; Hairy Cell Leukemia Foundation; Adaptive Biotechnologies; Astex Pharmaceuticals; TG Therapeutics; Genentech; Blood Cancer UK; Amicus Therapeutics; Incyte; Pfizer; Biogen; University of Rochester; CancerCare Manitoba Foundation; MEI Pharma; Daiichi-Sankyo; MacroGenics; Sunesis; University of Pittsburgh; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Sanofi; Ipsen Biopharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; GlaxoSmithKline","keywords":"Minimal residual disease; Oncology; Medicine; Bone marrow; Internal medicine; Leukemia; Flow cytometry; Hematology; Hairy cell leukemia; Disease; Cancer research; Immunology","score_opus":0.10005170867196604,"score_gpt":0.40304154366956174,"score_spread":0.3029898349975957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114026","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066538807,0.9892236,0.0000012735244,0.000101156846,0.0017812136,0.0006475861,0.0004413215,0.000020001631,0.00112995],"genre_scores_gemma":[0.0010488941,0.9955352,0.00013379495,0.00010754151,0.0021813738,0.00017864596,0.0004002547,0.00010352095,0.00031077754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99522793,0.0006159568,0.0011686976,0.0006108104,0.0018827778,0.0004938127],"domain_scores_gemma":[0.9974758,0.00045792438,0.00068482454,0.0006468394,0.00013416902,0.00060043077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007997653,0.00042678387,0.0014536527,0.0006107761,0.00011060123,0.00005855854,0.00066217734,0.0002232799,0.0029608416],"category_scores_gemma":[0.00029647935,0.00035678805,0.00044586646,0.00031842245,0.000115078175,0.00010360535,0.00018690943,0.0015081145,0.000008642129],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037770343,0.0026071023,0.00089079223,0.013014449,0.001889317,0.009071021,0.0006882688,0.000434878,0.000031402404,0.00005226619,0.01416187,0.9533816],"study_design_scores_gemma":[0.019044666,0.0005708353,0.00013916973,0.024337335,0.0009616673,0.00080323714,0.00013849323,0.00031204804,0.00002759673,0.000042762564,0.95318586,0.00043632582],"about_ca_topic_score_codex":0.003605387,"about_ca_topic_score_gemma":0.00011752515,"teacher_disagreement_score":0.9529453,"about_ca_system_score_codex":0.026828036,"about_ca_system_score_gemma":0.04025908,"threshold_uncertainty_score":0.9998884},"labels":[],"label_agreement":null},{"id":"W4312114220","doi":"10.1002/1878-0261.13364","title":"<scp>JAK–STAT</scp> signalling shapes the <scp>NF‐κB</scp> response in <scp>CLL</scp> towards venetoclax sensitivity or resistance via <scp>Bcl‐XL</scp>","year":2022,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"European Hematology Association","keywords":"Venetoclax; stat; Signalling; Cell biology; Biology; Signal transduction; Immunology; Leukemia; STAT3; Chronic lymphocytic leukemia","score_opus":0.024216778063178547,"score_gpt":0.3122897424201715,"score_spread":0.2880729643569929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96999913,0.0071473466,0.003494851,0.0015657275,0.0009212956,0.0038775217,0.00023217486,0.0004883382,0.0122736],"genre_scores_gemma":[0.9641281,0.0006396987,0.002043951,0.0059854006,0.0007273504,0.0014576139,0.00024788248,0.00052042864,0.02424962],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.97890025,0.008227195,0.0021840052,0.002896634,0.0036231729,0.0041687516],"domain_scores_gemma":[0.96713984,0.027409993,0.0010015608,0.002439223,0.00080017454,0.001209182],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.010897008,0.0015027988,0.0026392946,0.0013612765,0.0012008738,0.00022363361,0.0019031409,0.0012172825,0.00012186972],"category_scores_gemma":[0.031376854,0.0013423769,0.00089630147,0.0036283527,0.0014292067,0.0003054517,0.0024259172,0.0042488105,0.00041554973],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021635685,0.0027613759,0.0009268608,0.0013255498,0.0020719236,0.12528364,0.026846666,0.03459489,0.6552966,0.0009882414,0.14193292,0.005807713],"study_design_scores_gemma":[0.02863427,0.006578972,0.004421154,0.00045805503,0.00076563883,0.005714937,0.014759384,0.045838393,0.095542006,0.0015023941,0.79553515,0.00024966648],"about_ca_topic_score_codex":0.00157514,"about_ca_topic_score_gemma":0.0017969518,"teacher_disagreement_score":0.6536022,"about_ca_system_score_codex":0.038299005,"about_ca_system_score_gemma":0.031967234,"threshold_uncertainty_score":0.99977213},"labels":[],"label_agreement":null},{"id":"W4312339113","doi":"10.1007/978-3-031-10131-1_23","title":"Non-pharmacological Management of Paraproteinemia","year":2022,"lang":"en","type":"book-chapter","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Paraproteins; Paraproteinemia; Plasmapheresis; Medicine; Daratumumab; clone (Java method); Macroglobulinemia; Hyperviscosity; Intensive care medicine; Multiple myeloma; Immunology; Internal medicine; Biology; Monoclonal; Lenalidomide; Antibody","score_opus":0.038356450968470145,"score_gpt":0.3298531105345794,"score_spread":0.29149665956610926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312339113","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005558754,0.0005242191,0.000030894316,0.00022391813,0.00013531378,0.0015335628,0.000015278014,0.000059110567,0.99692184],"genre_scores_gemma":[0.012459593,0.0016229802,0.0010098902,0.00027755808,0.00013060853,0.00012142415,0.00008824031,0.00006428568,0.9842254],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977453,0.000008367296,0.000440848,0.0004511125,0.0010469133,0.0003074746],"domain_scores_gemma":[0.9990511,0.0000479103,0.00012754036,0.0005239378,0.0000729807,0.00017655038],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023702928,0.0002734566,0.0006019525,0.0001693026,0.000041303192,0.0000046538453,0.00026756723,0.00022129409,0.1054928],"category_scores_gemma":[0.0000037026036,0.00021693065,0.00027387368,0.00005294756,0.0001620023,0.000017560147,0.0006216258,0.0006039363,0.00036139484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028939394,0.0005126081,0.00000982738,0.007133064,0.0058930507,0.020903924,0.00008231957,0.000042255404,0.0010420403,0.72527325,0.1970926,0.039121117],"study_design_scores_gemma":[0.018778106,0.0010701817,0.000031459767,0.0004526353,0.00099415,0.00029815646,0.00002912056,0.00067567464,0.0016819104,0.0020848564,0.9734958,0.0004079459],"about_ca_topic_score_codex":0.00006485165,"about_ca_topic_score_gemma":8.767837e-7,"teacher_disagreement_score":0.7764032,"about_ca_system_score_codex":0.0076582655,"about_ca_system_score_gemma":0.0018612859,"threshold_uncertainty_score":0.99615115},"labels":[],"label_agreement":null},{"id":"W4313214036","doi":"10.1101/2022.12.16.520129","title":"CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to Navitoclax","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Hydro-Québec; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Acute megakaryoblastic leukemia; Cancer research; Phenotype; Mutation; Medicine; Chemistry; Myeloid leukemia; Gene; Biochemistry","score_opus":0.010465270821992497,"score_gpt":0.2533439740325033,"score_spread":0.2428787032105108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313214036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902669,0.001635473,0.00041548564,0.00067595916,0.0012777845,0.003125078,0.0020308183,0.0005195103,0.000052958163],"genre_scores_gemma":[0.9923853,0.0015296823,0.0018826438,0.0014466256,0.001342839,0.00073761254,0.0000068238774,0.00040174482,0.00026671827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99240637,0.00030455078,0.0009981078,0.0026444234,0.0021158743,0.0015306997],"domain_scores_gemma":[0.9944097,0.0003505364,0.00046052196,0.0023575358,0.0008518835,0.0015698212],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00088296895,0.0011692025,0.0015537607,0.000846952,0.00040037447,0.0003167252,0.0008152186,0.0008819795,0.0004031961],"category_scores_gemma":[0.0005836917,0.0012604427,0.00031504242,0.0012743258,0.00023248505,0.00018685567,0.0035299065,0.0026350527,0.00026124888],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0030120192,0.0010224471,0.01599785,0.0063727982,0.0048883865,0.015749136,0.0007716787,0.0009571015,0.855656,0.00031647732,0.09522549,0.0000305643],"study_design_scores_gemma":[0.06406993,0.004662853,0.09008123,0.003334912,0.012199398,0.000022098024,0.0002786529,0.032965057,0.7259304,0.000011894407,0.054216612,0.012226978],"about_ca_topic_score_codex":0.0007003808,"about_ca_topic_score_gemma":0.000007837189,"teacher_disagreement_score":0.12972566,"about_ca_system_score_codex":0.03247139,"about_ca_system_score_gemma":0.01897288,"threshold_uncertainty_score":0.9996659},"labels":[],"label_agreement":null},{"id":"W4313260726","doi":"10.3390/curroncol30010022","title":"A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fondazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Discontinuation; Antibody; Chronic lymphocytic leukemia; Adverse effect; Incidence (geometry); Internal medicine; Retrospective cohort study; Primary immunodeficiency; Hypogammaglobulinemia; Cumulative incidence; Cohort; Immunology; Pediatrics; Gastroenterology; Leukemia; Immune system","score_opus":0.030967678298872786,"score_gpt":0.3549654513441819,"score_spread":0.3239977730453091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313260726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952454,0.00041429375,0.0000094535535,0.000059247235,0.00021697978,0.003487986,0.000021600841,0.00002383018,0.00052122015],"genre_scores_gemma":[0.9996293,0.000016096166,0.000010959292,0.000052148516,0.000037185888,0.00014835177,0.00006401056,0.000025041772,0.0000168909],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758554,0.00030069085,0.0004605973,0.00047494343,0.0007069173,0.00047129564],"domain_scores_gemma":[0.9987391,0.00034464555,0.00017769216,0.00046835578,0.00015719981,0.000112970985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005442474,0.00020397131,0.0005505463,0.0002905347,0.00019420117,0.000011408991,0.00024137931,0.000051668365,0.00016691364],"category_scores_gemma":[0.00025183946,0.00014821174,0.000044358545,0.0007015559,0.00014333334,0.000033669086,0.00031720553,0.0005703747,0.000016026577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07528857,0.017735532,0.75627315,0.00066438684,0.00056590536,0.0015375271,0.049209997,0.015384303,0.0016631035,0.0019593681,0.00046639523,0.07925176],"study_design_scores_gemma":[0.055889666,0.04717505,0.8895926,0.000118220356,0.00009551584,0.000277551,0.0015965118,0.0045245662,0.000059652168,0.000061836756,0.00040547142,0.0002033856],"about_ca_topic_score_codex":0.0007080919,"about_ca_topic_score_gemma":0.0001393048,"teacher_disagreement_score":0.13331942,"about_ca_system_score_codex":0.12427298,"about_ca_system_score_gemma":0.01857836,"threshold_uncertainty_score":0.9869854},"labels":[],"label_agreement":null},{"id":"W4313349588","doi":"10.4049/jimmunol.190.supp.198.4","title":"The tandem PH domain-containing protein 2 regulates chemokine-induced cytoskeletal reorganization and malignant B cell migration (P5194)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Cell biology; Actin; Cell migration; Cytoskeleton; Chemotaxis; Actin cytoskeleton; Chemistry; Biology; Cell; Receptor; Biochemistry","score_opus":0.008713934071652047,"score_gpt":0.23800842850552933,"score_spread":0.22929449443387728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313349588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990269,0.002188213,0.00014859975,0.006492933,0.00009725718,0.0005357127,1.9543195e-7,0.000011520158,0.0002565788],"genre_scores_gemma":[0.998355,0.0005781295,0.00024757627,0.00008147343,0.00015117369,0.000008930144,0.0000017564556,0.000022672248,0.0005533273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985643,0.00027185993,0.0004778958,0.00010073174,0.00028233096,0.00030290196],"domain_scores_gemma":[0.99851596,0.0002943376,0.00040524334,0.00029140894,0.0004331797,0.000059896396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011730767,0.00012925782,0.00026162819,0.00008148158,0.00026155973,0.000045897326,0.00022376372,0.00012458178,0.000061004004],"category_scores_gemma":[0.0003359794,0.00006397249,0.000052240168,0.00018737705,0.00023009386,0.00014337883,0.00009702281,0.00041781287,0.000022245375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004370507,0.000031579435,0.00013608574,0.000018339175,0.00012982821,0.000023046801,0.0012706255,0.0000030167228,0.9948728,0.0002484808,0.00023044062,0.0025987027],"study_design_scores_gemma":[0.014169673,0.0026446974,0.009808041,0.00023853552,0.0001452664,0.006503778,0.0055651264,0.0012919784,0.9551358,0.0030819292,0.0012417042,0.00017342623],"about_ca_topic_score_codex":0.00022882856,"about_ca_topic_score_gemma":0.000019498228,"teacher_disagreement_score":0.03973696,"about_ca_system_score_codex":0.0013108121,"about_ca_system_score_gemma":0.0011482039,"threshold_uncertainty_score":0.34277278},"labels":[],"label_agreement":null},{"id":"W4313380161","doi":"10.4049/jimmunol.196.supp.198.5","title":"Control of B cell activation and migration by PI 3-kinase: role of inositol polyphosphate 4-phosphatases","year":2016,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Phosphorylation; Phosphatase; Cell biology; Protein kinase B; Kinase; Biology; PI3K/AKT/mTOR pathway; Inositol; Signal transduction; breakpoint cluster region; Biochemistry; Molecular biology; Receptor","score_opus":0.005618648827535384,"score_gpt":0.24052716468645927,"score_spread":0.2349085158589239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313380161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826943,0.014761042,0.00086658663,0.0014082815,0.00004906279,0.00016037282,0.00001619491,0.0000028211998,0.000041291863],"genre_scores_gemma":[0.9973479,0.0023777166,0.000064754684,0.000052294836,0.00003312961,0.0000014850433,0.0000019272375,0.000008921387,0.000111876725],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897593,0.00014128031,0.0004423664,0.00006049944,0.00022744406,0.00015247327],"domain_scores_gemma":[0.9983697,0.00059833075,0.0005254785,0.00019546316,0.00027177442,0.000039246257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004467268,0.000082442355,0.00031731912,0.0000944098,0.000028667084,0.0000025527665,0.00013733184,0.000081515915,0.00006528971],"category_scores_gemma":[0.00023271576,0.000042302574,0.000051179024,0.00009134119,0.00029231462,0.0001159944,0.00003420514,0.00012846099,0.0000025470208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033436574,0.00011276551,0.0008515324,0.00003221503,0.00015639763,0.0000038018327,0.0002478249,0.000001495803,0.9848687,0.00009250318,0.00077495613,0.009514117],"study_design_scores_gemma":[0.013449712,0.0013171395,0.0036008926,0.00017378965,0.00011110866,0.00023021577,0.0002666029,0.0000920908,0.97955817,0.00014306797,0.0010185511,0.000038670547],"about_ca_topic_score_codex":0.00063968217,"about_ca_topic_score_gemma":0.000005237258,"teacher_disagreement_score":0.014653548,"about_ca_system_score_codex":0.0005435868,"about_ca_system_score_gemma":0.000806157,"threshold_uncertainty_score":0.17250489},"labels":[],"label_agreement":null},{"id":"W4313381726","doi":"10.4049/jimmunol.200.supp.166.28","title":"Abnormal T follicular helper cell subsets in Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Immunology; Immune system; B cell; T cell; CXCL13; Ibrutinib; Biology; Cytokine; Leukemia; Cancer research; Chemokine; Medicine; Antibody; Chemokine receptor","score_opus":0.014261072758350202,"score_gpt":0.2814487341013087,"score_spread":0.2671876613429585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313381726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856025,0.011043493,0.000096267824,0.0003338298,0.00040746026,0.00023191348,7.952061e-7,0.000013848279,0.0022698853],"genre_scores_gemma":[0.995957,0.0018661269,0.00011649391,0.00031600884,0.00067917304,0.000003469849,0.0000014943785,0.00003345653,0.001026741],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976959,0.000311652,0.0007126422,0.00014675326,0.00045925452,0.0006737906],"domain_scores_gemma":[0.9983769,0.0002876045,0.00030127275,0.00058370334,0.00033848247,0.00011201466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014759046,0.00019497941,0.0005246575,0.00034173322,0.00009917986,0.000013746347,0.0005822118,0.00021454056,0.0005318636],"category_scores_gemma":[0.00019267455,0.000121518446,0.0001625765,0.00043471952,0.0007064722,0.00013278547,0.00018080728,0.0007051018,0.00047793193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015196033,0.00028203413,0.0011978627,0.00039536742,0.0013865434,0.0052383724,0.0077161165,0.0021567224,0.9429246,0.0003984954,0.010595963,0.012511887],"study_design_scores_gemma":[0.16039695,0.014438176,0.023689674,0.0011713611,0.0007893865,0.078827985,0.002204912,0.034251533,0.6418663,0.00075208355,0.04079735,0.0008142669],"about_ca_topic_score_codex":0.0010232065,"about_ca_topic_score_gemma":0.00013349675,"teacher_disagreement_score":0.30105826,"about_ca_system_score_codex":0.08212521,"about_ca_system_score_gemma":0.03654041,"threshold_uncertainty_score":0.9689215},"labels":[],"label_agreement":null},{"id":"W4313381895","doi":"10.4049/jimmunol.200.supp.175.18","title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich rheumatoid arthritis, pre-rheumatoid arthritis and systemic lupus erythematosus","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Immunology; Rheumatoid arthritis; CD38; Plasma cell; Autoantibody; Arthritis; Autoimmunity; Daratumumab; Antibody; Monoclonal antibody; Biology; CD34","score_opus":0.011026415878146702,"score_gpt":0.2775828514181671,"score_spread":0.2665564355400204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313381895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8988653,0.096671,0.0021528022,0.00064830953,0.0004468482,0.0008183854,0.000016672391,0.000027342874,0.0003533676],"genre_scores_gemma":[0.907654,0.0904355,0.00083543774,0.00012344989,0.00013184722,0.000040520514,0.000007786336,0.000050307637,0.00072118867],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99659574,0.00063400174,0.0012744999,0.00030264206,0.0005011028,0.00069199275],"domain_scores_gemma":[0.99565244,0.0015596969,0.0009338425,0.0006583191,0.0010191859,0.00017649581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021382708,0.0003612998,0.001504643,0.0006043316,0.00030928227,0.000057098718,0.0005002243,0.0002767453,0.00023639576],"category_scores_gemma":[0.00067522214,0.00022477313,0.00035564057,0.00069993915,0.00095497904,0.0001646383,0.00015698253,0.00068086426,0.000057417044],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08548596,0.0028352723,0.016835593,0.0017428168,0.07812135,0.0018446733,0.13428985,0.00024629172,0.44150397,0.0076263477,0.028151428,0.20131645],"study_design_scores_gemma":[0.14332348,0.031008929,0.0019297398,0.010088536,0.002308604,0.5948162,0.03918983,0.013627962,0.1360786,0.015193945,0.010895262,0.0015389002],"about_ca_topic_score_codex":0.00019489886,"about_ca_topic_score_gemma":0.00008868202,"teacher_disagreement_score":0.59297156,"about_ca_system_score_codex":0.001986932,"about_ca_system_score_gemma":0.0026360028,"threshold_uncertainty_score":0.91659826},"labels":[],"label_agreement":null},{"id":"W4313387485","doi":"10.4049/jimmunol.190.supp.122.5","title":"Interaction of TAPP adapter proteins with phosphatidylinositol (3,4)-bisphosphate regulates germinal centre response and development of autoimmunity (P1107)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Germinal center; Autoimmunity; Cell biology; Biology; B cell; T cell; Immune system; Chemistry; Molecular biology; Immunology; Antibody","score_opus":0.015100349375761596,"score_gpt":0.2634461485856486,"score_spread":0.24834579920988697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313387485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963713,0.0020876566,0.00015493335,0.0008005321,0.000072770315,0.00045636864,8.781764e-7,0.0000056358085,0.000049904564],"genre_scores_gemma":[0.9959038,0.00021253292,0.0034200065,0.000021544596,0.000017494034,0.0000050289173,0.0000011624429,0.000015302636,0.00040313488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983115,0.00031916302,0.00071554125,0.00008625385,0.00032813105,0.00023939111],"domain_scores_gemma":[0.99779636,0.0004281716,0.0007336955,0.00030957375,0.0006696974,0.00006252516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010502813,0.0001415739,0.00045732604,0.00015952342,0.00007851446,0.000007803819,0.00021280859,0.000095847,0.00024647842],"category_scores_gemma":[0.00019302366,0.00007978076,0.00004728478,0.00013666673,0.00046614232,0.00016177133,0.00012234409,0.0004249136,0.000009244948],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07701508,0.00070369546,0.002489626,0.00037575574,0.0018589979,0.000109436645,0.022313256,0.000069105365,0.82933825,0.000058427544,0.00026235046,0.06540605],"study_design_scores_gemma":[0.010925166,0.0023838452,0.12745132,0.00090000173,0.00013862106,0.003686952,0.0043106927,0.0004464962,0.8483949,0.00004249998,0.001209618,0.000109903296],"about_ca_topic_score_codex":0.00045508234,"about_ca_topic_score_gemma":0.0000150258975,"teacher_disagreement_score":0.12496169,"about_ca_system_score_codex":0.0010202556,"about_ca_system_score_gemma":0.0028789311,"threshold_uncertainty_score":0.51071},"labels":[],"label_agreement":null},{"id":"W4313521367","doi":"10.14740/jh1073","title":"Bone Involvement as a Primary Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study","year":2022,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lymphoplasmacytic Lymphoma; Waldenstrom macroglobulinemia; Bone marrow; Diffuse large B-cell lymphoma; Marginal zone B-cell lymphoma; Bone pain; Population; Pathology; Lymphoma; Rituximab; Radiology; B cell; Antibody; Immunology; Marginal zone","score_opus":0.01512784451478184,"score_gpt":0.3158111735401028,"score_spread":0.30068332902532097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313521367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977175,0.00059964013,0.000045239976,0.0005585242,0.00007589828,0.0009349017,0.0000055588284,0.000005616978,0.000057103225],"genre_scores_gemma":[0.9989143,0.000017492328,0.00074631075,0.00012724503,0.000021774931,0.00005450879,0.000021267262,0.000012095134,0.00008499765],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99746114,0.00024036707,0.0011189946,0.00020098008,0.00081164605,0.00016687921],"domain_scores_gemma":[0.99834454,0.0003013908,0.00075038953,0.00021903303,0.00029504063,0.000089625784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016219754,0.00010059889,0.00053919596,0.00042758364,0.000063902065,0.000005968538,0.00007187968,0.000049065966,0.00012566177],"category_scores_gemma":[0.00059264264,0.00009281428,0.000059593283,0.0002620323,0.000047733683,0.00006722017,0.000094571114,0.00034290552,5.0547726e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000610766,0.0006412649,0.69079924,0.0005406638,0.00007089685,0.30626506,0.00043399783,0.0002734287,0.00012718022,0.00005933422,0.000087747474,0.00009044339],"study_design_scores_gemma":[0.012801999,0.0013480647,0.3056227,0.0001368629,0.00015423153,0.67584,0.001809674,0.001877853,0.0001597771,0.00016543697,0.000012250521,0.000071103204],"about_ca_topic_score_codex":0.0011663768,"about_ca_topic_score_gemma":0.00025238894,"teacher_disagreement_score":0.3851765,"about_ca_system_score_codex":0.0036901112,"about_ca_system_score_gemma":0.0036609776,"threshold_uncertainty_score":0.9649512},"labels":[],"label_agreement":null},{"id":"W4313575102","doi":"10.1016/j.leukres.2023.107016","title":"Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update","year":2023,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Toronto; Princess Margaret Cancer Centre; Foothills Medical Centre; Ottawa Hospital; Spinal Cord Injury BC; Jewish General Hospital; CancerCare Manitoba","funders":"","keywords":"Guideline; Chronic lymphocytic leukemia; Front line; Medicine; First line treatment; Leukemia; Family medicine; Intensive care medicine; Internal medicine; Political science; Pathology; Chemotherapy","score_opus":0.2859934808552033,"score_gpt":0.48700136605915856,"score_spread":0.20100788520395524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313575102","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007981833,0.98439115,0.000111233414,0.0006061869,0.00055570266,0.0123116495,0.0012819775,0.00024408483,0.0004181796],"genre_scores_gemma":[0.00007418006,0.96540236,0.00093671714,0.00013375517,0.0026926592,0.0054853484,0.003959048,0.0007121803,0.02060373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98474294,0.0011608233,0.0036417164,0.0024978213,0.003718109,0.004238612],"domain_scores_gemma":[0.98410684,0.006522445,0.0006881708,0.0040523037,0.0023179816,0.002312256],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0067109982,0.0014815951,0.005951722,0.004944183,0.0005771618,0.00016223216,0.0019228868,0.0019789184,0.0011467758],"category_scores_gemma":[0.0045383926,0.0011828981,0.0023424549,0.00482098,0.00089788437,0.00020135404,0.00044861043,0.0017228174,0.0023014792],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007154834,0.00012129208,0.0000015878927,0.08067631,0.0015689528,0.0019201852,0.000055493376,0.00068439083,0.0000144399455,0.00016890981,0.12432925,0.7897437],"study_design_scores_gemma":[0.016537605,0.003182134,4.7547152e-7,0.03765446,0.001568539,0.00024590554,0.00003613438,0.07593054,0.00015933569,0.00007159312,0.8638846,0.00072867237],"about_ca_topic_score_codex":0.4278539,"about_ca_topic_score_gemma":0.11078773,"teacher_disagreement_score":0.78901505,"about_ca_system_score_codex":0.8356285,"about_ca_system_score_gemma":0.7746173,"threshold_uncertainty_score":0.99979335},"labels":[],"label_agreement":null},{"id":"W4313891690","doi":"10.2217/fon-2022-0898","title":"Many People with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment up to 8 Years: A Plain Language Summary","year":2022,"lang":"en","type":"review","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"Pharmacyclics","keywords":"Ibrutinib; Medicine; Chlorambucil; Chronic lymphocytic leukemia; Internal medicine; Clinical trial; Oncology; Lymphoma; Leukemia; Chemotherapy","score_opus":0.04235839675099185,"score_gpt":0.3464954461082819,"score_spread":0.3041370493572901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313891690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011975598,0.9745836,0.000011819574,0.00015534012,0.002131713,0.006597911,0.0010380477,0.00047586914,0.0030300498],"genre_scores_gemma":[0.00013350481,0.95451325,0.0008886671,0.00077798875,0.005768875,0.0043544425,0.004502121,0.0006338091,0.028427318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99147993,0.0007077576,0.0015027942,0.0026381556,0.0013389816,0.0023323728],"domain_scores_gemma":[0.99253863,0.0022883848,0.0007630179,0.0029467915,0.00011367781,0.0013495071],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0005625973,0.0018978065,0.0065775155,0.0010876503,0.0003253258,0.000116590425,0.0014571476,0.0017282921,0.0067842896],"category_scores_gemma":[0.00019850698,0.0013439636,0.0011571794,0.0021156624,0.00024500836,0.00009526211,0.0010637358,0.0008836999,0.0017157497],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004352526,0.00020958885,0.0000024506433,0.0073326654,0.0025066845,0.021925637,0.0031215674,0.000066480316,0.0000046503083,0.00007060212,0.009952565,0.9504546],"study_design_scores_gemma":[0.04616347,0.009660413,0.000018177743,0.005694063,0.004369237,0.009785762,0.0012435946,0.0005440733,0.000008839702,0.0000048293687,0.92125815,0.0012494165],"about_ca_topic_score_codex":0.017654646,"about_ca_topic_score_gemma":0.022645783,"teacher_disagreement_score":0.94920516,"about_ca_system_score_codex":0.698003,"about_ca_system_score_gemma":0.3480107,"threshold_uncertainty_score":0.9995677},"labels":[],"label_agreement":null},{"id":"W4316086233","doi":"10.14309/01.ajg.0000859504.35531.82","title":"S716 Induction Combination Therapy With Guselkumab and Golimumab Followed by Guselkumab Monotherapy Maintenance: Results of the Phase 2a, Randomized, Double-Blind, Proof-of-Concept VEGA Study","year":2022,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Combination therapy; Internal medicine; Randomized controlled trial; Maintenance therapy; Surgery; Refractory (planetary science); Golimumab; Intention-to-treat analysis; Clinical trial; Gastroenterology; Adalimumab; Tumor necrosis factor alpha; Chemotherapy","score_opus":0.02105226348308446,"score_gpt":0.3101103659711639,"score_spread":0.28905810248807945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316086233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927274,0.0003434734,0.00041543078,0.004135923,0.00016437106,0.002165626,0.000019287016,0.0000075336225,0.00002096091],"genre_scores_gemma":[0.9990617,0.00015543707,0.00009645749,0.00036910197,0.00006663632,0.00010573265,0.0000059411495,0.000036794147,0.0001021712],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956333,0.001781523,0.0010399474,0.00026058473,0.0009087381,0.00037591663],"domain_scores_gemma":[0.9963529,0.00032996008,0.0022746555,0.0005515474,0.00039409506,0.000096837706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025661164,0.00022996326,0.0013145057,0.00023226923,0.00016996908,0.0000135056325,0.00053297664,0.000029416004,0.00002387349],"category_scores_gemma":[0.00009620062,0.00011774785,0.00022471324,0.00048295106,0.0018061528,0.00009384996,0.00012656895,0.00068753934,1.2761642e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98218477,0.002495069,0.00084329804,0.000009833644,0.0012750583,0.0000275794,0.005324299,0.000334097,0.0017782983,0.000014009653,0.0006867463,0.005026971],"study_design_scores_gemma":[0.906843,0.07958823,0.00028276406,0.000053474094,0.0003061213,0.0017753633,0.0053451625,0.0005089828,0.0050058593,0.000059491675,0.00015807782,0.00007349019],"about_ca_topic_score_codex":0.0004328985,"about_ca_topic_score_gemma":0.000020980666,"teacher_disagreement_score":0.077093154,"about_ca_system_score_codex":0.0012452264,"about_ca_system_score_gemma":0.0010093363,"threshold_uncertainty_score":0.6654845},"labels":[],"label_agreement":null},{"id":"W4317395238","doi":"10.3389/fonc.2022.1105779","title":"The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review","year":2023,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Hematopoietic cell; Transplantation; Leukemia; Hematopoietic stem cell transplantation; Oncology; Disease; Immunology; Graft-versus-host disease; Haematopoiesis; Internal medicine; Stem cell; Biology","score_opus":0.035175420447835504,"score_gpt":0.3746352043508093,"score_spread":0.3394597839029738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317395238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000058987566,0.99142563,0.000260272,0.00006483448,0.00086441415,0.0061533116,0.00006570856,0.000054719618,0.0011052104],"genre_scores_gemma":[0.0000070113388,0.9937811,0.0009119512,0.00008006512,0.00025579947,0.0028205963,0.0003330817,0.00015061625,0.001659784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580866,0.00046755056,0.001703684,0.00066470716,0.00046773674,0.0008876775],"domain_scores_gemma":[0.99628836,0.0018596995,0.00068879704,0.00085947267,0.00014065098,0.00016303509],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001700253,0.0004884978,0.003730483,0.00040294355,0.000098162476,0.000010303954,0.0007008075,0.0008605796,0.000025427327],"category_scores_gemma":[0.000397016,0.00033969467,0.00089728995,0.00085097353,0.00038433622,0.000032789892,0.00010118762,0.0006128602,0.00009896036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0001261149,0.000029293762,0.0000015267804,0.29401028,0.00029688698,0.00016260236,0.00007922107,0.000011678965,0.0000017292983,0.00006534653,0.016666172,0.6885491],"study_design_scores_gemma":[0.005834108,0.0007277035,4.2407595e-7,0.05285798,0.0028307135,0.0006282146,0.00007999616,0.00082352455,0.000020477004,0.00038164866,0.9355627,0.0002525513],"about_ca_topic_score_codex":0.00012845975,"about_ca_topic_score_gemma":0.000087114946,"teacher_disagreement_score":0.9188965,"about_ca_system_score_codex":0.15995556,"about_ca_system_score_gemma":0.12247582,"threshold_uncertainty_score":0.9999055},"labels":[],"label_agreement":null},{"id":"W4317989607","doi":"10.1182/bloodadvances.2022009389","title":"Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"H. Lundbeck A/S; Incyte; Teva Pharmaceutical Industries; Genentech; Celgene; University of Southampton; Karyopharm Therapeutics; Kite Pharma; Gilead Sciences; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Ibrutinib; Medicine; Oncology; Internal medicine; CHOP; Clinical trial; Bruton's tyrosine kinase; Phases of clinical research; Immunology; Lymphoma; Cancer research; Leukemia; Receptor","score_opus":0.07110328231378076,"score_gpt":0.48499045889072273,"score_spread":0.41388717657694196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317989607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960694,0.00197502,0.0000021131254,0.00017296555,0.00009398707,0.0008641564,0.000021498658,0.000036833637,0.00076404423],"genre_scores_gemma":[0.9981859,0.0012283999,0.000090448266,0.000045423178,0.00026157763,0.00003894972,0.000026149835,0.00001831881,0.000104880215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99784774,0.00027916257,0.00067278766,0.00034197606,0.00042390573,0.00043441352],"domain_scores_gemma":[0.99769694,0.0016520175,0.00013544492,0.00035749347,0.00004535005,0.00011273783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013727068,0.00016116275,0.00057775585,0.00022779011,0.000039638537,0.000023986493,0.00017901129,0.00011247205,0.000037296955],"category_scores_gemma":[0.0012575523,0.00009969972,0.00013067223,0.0008957513,0.00030052473,0.00014159335,0.00008376645,0.00033778077,0.000010005271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36129317,0.016595392,0.21367924,0.0018284349,0.0011184908,0.010453586,0.018790815,0.0013352309,0.027053606,0.00014771687,0.0042805797,0.34342372],"study_design_scores_gemma":[0.95445085,0.0038152644,0.025962606,0.0007149652,0.00014433524,0.00017768514,0.0011843272,0.009035045,0.0022073863,0.00017105824,0.0019159568,0.00022053067],"about_ca_topic_score_codex":0.000711789,"about_ca_topic_score_gemma":0.000107204665,"teacher_disagreement_score":0.59315765,"about_ca_system_score_codex":0.0006124062,"about_ca_system_score_gemma":0.0026547874,"threshold_uncertainty_score":0.4709479},"labels":[],"label_agreement":null},{"id":"W4318191396","doi":"10.1038/s41408-022-00781-8","title":"DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease","year":2023,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Government of Canada; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Hyperactivation; Drug; Chronic lymphocytic leukemia; Biomarker; DNA; Disease; Leukemia; Cancer research; Hematology; Medicine; Immunology; Biology; Pharmacology; Internal medicine; Genetics","score_opus":0.03328712576353946,"score_gpt":0.3199920189238956,"score_spread":0.28670489316035613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318191396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74796176,0.06943563,0.000115836934,0.17773679,0.00101424,0.0030258016,0.000528765,0.00011866094,0.00006248382],"genre_scores_gemma":[0.5986544,0.06055364,0.0006579264,0.30081755,0.021906285,0.0025640584,0.0010250442,0.0011577408,0.012663362],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962873,0.00018710358,0.0007376021,0.0007937104,0.0009949752,0.0009993311],"domain_scores_gemma":[0.9980488,0.0005027926,0.0004007853,0.00041457667,0.00022835685,0.00040471123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071940914,0.0005392331,0.00080007716,0.0007223658,0.0002602356,0.00021326225,0.00020613219,0.0004845965,0.00016110098],"category_scores_gemma":[0.00017430518,0.00046372588,0.00021807048,0.0004422297,0.00022309693,0.00017355946,0.000093218245,0.0013834637,0.000007630924],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006250067,0.00012542306,0.0022064461,0.009827525,0.0027797346,0.006516484,0.0010392711,0.00020053438,0.0062369625,0.000014207465,0.9394373,0.025366023],"study_design_scores_gemma":[0.13982414,0.0013904017,0.017599622,0.011222055,0.0047584875,0.0038851958,0.00027672478,0.082842216,0.0018451029,0.0019185523,0.7322425,0.0021949806],"about_ca_topic_score_codex":0.0014097008,"about_ca_topic_score_gemma":0.00016380861,"teacher_disagreement_score":0.2071948,"about_ca_system_score_codex":0.06437015,"about_ca_system_score_gemma":0.052109465,"threshold_uncertainty_score":0.9997814},"labels":[],"label_agreement":null},{"id":"W4319297492","doi":"10.3390/curroncol30020148","title":"Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Uniklinikum Giessen und Marburg","keywords":"Receiver operating characteristic; Medicine; Chronic lymphocytic leukemia; Population; Internal medicine; Oncology; Leukemia","score_opus":0.18217688790171133,"score_gpt":0.4421264289664381,"score_spread":0.2599495410647268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319297492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728334,0.000109243025,0.00036193564,0.00006697031,0.0006412176,0.0009953077,0.000016454882,0.00009887628,0.00042667595],"genre_scores_gemma":[0.9990461,0.00017775678,0.0001483534,0.000020123665,0.00018885892,0.00012411815,0.0001284749,0.000032507694,0.00013370613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971146,0.00016749975,0.000951194,0.00050382136,0.00065548165,0.0006073845],"domain_scores_gemma":[0.9982115,0.00060416554,0.00023756674,0.00046533425,0.00028423298,0.00019719357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086286553,0.00020717866,0.0008129489,0.0003978879,0.000046749377,0.000007724813,0.00019086426,0.00020553583,0.00009371225],"category_scores_gemma":[0.0005321259,0.00014364124,0.00009312558,0.0010183437,0.00047043542,0.00010154904,0.00012924032,0.00046042472,0.00013262573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0043628663,0.00070146285,0.85463095,0.0006675805,0.00014678971,0.00017761117,0.00037795672,0.0024441916,0.000008240324,0.0003831807,0.00064372714,0.13545541],"study_design_scores_gemma":[0.034841876,0.013932194,0.8276595,0.00092930027,0.00018543153,0.0000405054,0.000418752,0.11722286,0.00028383578,0.0002707924,0.0039303927,0.00028459294],"about_ca_topic_score_codex":0.00027185943,"about_ca_topic_score_gemma":0.00030333127,"teacher_disagreement_score":0.13517082,"about_ca_system_score_codex":0.049411107,"about_ca_system_score_gemma":0.037013493,"threshold_uncertainty_score":0.9684457},"labels":[],"label_agreement":null},{"id":"W4319439202","doi":"10.3389/fonc.2023.1098326","title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review","year":2023,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; CSL Behring","keywords":"Medicine; Lymphocytopenia; Internal medicine; Neutropenia; Hypogammaglobulinemia; Chronic lymphocytic leukemia; Multiple myeloma; Lymphoma; Cancer; Immunology; Ofatumumab; Oncology; Leukemia; Chemotherapy; Antibody; Lymphocyte","score_opus":0.017991876024063713,"score_gpt":0.32173695054884477,"score_spread":0.30374507452478106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319439202","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026477256,0.9827569,0.000091410526,0.000019005853,0.0007876153,0.013366217,0.00006181754,0.00007981015,0.00018949308],"genre_scores_gemma":[0.00047620185,0.99277484,0.0019351677,0.00032094514,0.000085156564,0.0029696138,0.000679742,0.00020493667,0.00055337604],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9920306,0.000820028,0.00279207,0.0014725133,0.0009383841,0.0019464061],"domain_scores_gemma":[0.9965675,0.00082140137,0.0008493576,0.0010532895,0.00028894944,0.00041948704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00285956,0.0010538361,0.007269035,0.0017852378,0.00016435877,0.000068313544,0.0007171187,0.0010223326,0.000017556386],"category_scores_gemma":[0.0018221501,0.0007977891,0.0002775409,0.0031490074,0.00019502621,0.0001355325,0.0008407956,0.001023537,0.00013124562],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00021645788,0.000116143616,0.00049723027,0.6694896,0.00043856117,0.0017813257,0.0005662999,0.000008075878,6.5527274e-8,0.0000012212604,0.002307019,0.324578],"study_design_scores_gemma":[0.02977663,0.0009933222,0.0011766589,0.80581343,0.0007846702,0.00047090775,0.000086011634,0.0009500806,5.3254365e-7,0.0000019561571,0.1591669,0.00077890255],"about_ca_topic_score_codex":0.0001406551,"about_ca_topic_score_gemma":0.00018530939,"teacher_disagreement_score":0.32379907,"about_ca_system_score_codex":0.34293956,"about_ca_system_score_gemma":0.1014477,"threshold_uncertainty_score":0.9994473},"labels":[],"label_agreement":null},{"id":"W4319826530","doi":"10.1002/hon.3126","title":"Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Ministero della Salute","keywords":"Ibrutinib; Atrial fibrillation; Medicine; Internal medicine; Cardiology; Prospective cohort study; Cohort; Incidence (geometry); Chronic lymphocytic leukemia; Leukemia","score_opus":0.0553593713309901,"score_gpt":0.3744604305517121,"score_spread":0.31910105922072196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319826530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927842,0.000087003915,0.0000054281904,0.00027924145,0.00036705437,0.0016411651,0.000016714108,0.00016322313,0.0046559772],"genre_scores_gemma":[0.99891514,0.00003793116,0.000090451475,0.0000133290205,0.0001955418,0.000029012965,0.000029792152,0.000018128609,0.00067068246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974273,0.0003241482,0.00078380626,0.00038982168,0.0006488972,0.00042603354],"domain_scores_gemma":[0.99730176,0.0015476,0.00031447265,0.00032902104,0.00035596782,0.00015117235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008792476,0.0001620008,0.0012016655,0.00020080383,0.000048851813,0.0000033768858,0.00015552003,0.00039081307,0.00035492086],"category_scores_gemma":[0.004515382,0.0001198504,0.00030476265,0.0011257748,0.00036701254,0.000032294844,0.00024007617,0.00024179193,0.00009792055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006139056,0.0007471924,0.98118293,0.00021400275,0.0011967465,0.00077110523,0.0024465309,0.0000597088,0.00058129936,0.0020106807,0.0041738437,0.0004768942],"study_design_scores_gemma":[0.24374357,0.052998357,0.6747243,0.00033377716,0.0012594716,0.00074101187,0.00811883,0.005580888,0.0057250536,0.0030279201,0.0031545516,0.0005922963],"about_ca_topic_score_codex":0.0000885524,"about_ca_topic_score_gemma":0.000035419744,"teacher_disagreement_score":0.30645865,"about_ca_system_score_codex":0.0025081271,"about_ca_system_score_gemma":0.0033394971,"threshold_uncertainty_score":0.65586656},"labels":[],"label_agreement":null},{"id":"W4321374903","doi":"10.1002/ajh.26881","title":"Impact of sex on outcomes in patients with hairy cell leukemia. An <scp>HCL</scp> patient data registry analysis","year":2023,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Hairy Cell Leukemia Foundation","keywords":"Medicine; Leukemia; Internal medicine; Oncology","score_opus":0.021657586152965563,"score_gpt":0.3240060220795596,"score_spread":0.302348435926594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321374903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951075,0.00007926468,0.00003560474,0.003780593,0.00012311486,0.0003634511,0.00028380024,0.000020092839,0.00020659601],"genre_scores_gemma":[0.9828663,0.00006841141,0.0006120342,0.0143816,0.00027601796,0.000009113766,0.0012468455,0.00016858465,0.00037108653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944267,0.0005330269,0.0016543394,0.0007541656,0.001716385,0.0009153569],"domain_scores_gemma":[0.9918922,0.0017334889,0.0029919788,0.0025490848,0.0004969612,0.00033623923],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00052153284,0.00057473534,0.003783989,0.0022395367,0.00003559542,0.000021453177,0.0012562105,0.0004518617,0.000039661463],"category_scores_gemma":[0.0008028448,0.00038058741,0.0005784438,0.0017643449,0.00078597653,0.00014653582,0.00031761642,0.0027298024,0.00001988879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00069338176,0.0008413482,0.72997636,0.00036867906,0.0061233356,0.01037604,0.0006173503,0.0006395534,0.0000037263223,9.967001e-7,0.24867658,0.0016826374],"study_design_scores_gemma":[0.09394322,0.11749019,0.72982585,0.0034406409,0.01426876,0.0070444606,0.0069954013,0.00653502,0.0004942085,0.00007171344,0.018143717,0.0017467985],"about_ca_topic_score_codex":0.002835399,"about_ca_topic_score_gemma":0.00008884131,"teacher_disagreement_score":0.23053285,"about_ca_system_score_codex":0.008172589,"about_ca_system_score_gemma":0.010880591,"threshold_uncertainty_score":0.9998646},"labels":[],"label_agreement":null},{"id":"W4321376636","doi":"10.1080/10428194.2023.2171729","title":"A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER)","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Ibrutinib; Tumor microenvironment; Stromal cell; Cancer research; Fludarabine; Leukemia; Medicine; Bone marrow; Immunology; Internal medicine; Tumor cells; Chemotherapy","score_opus":0.017058968566526552,"score_gpt":0.2730238147016377,"score_spread":0.25596484613511117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321376636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889245,0.0058298106,0.0011501651,0.0008675127,0.0001165657,0.0021423069,0.00016866573,0.00020840963,0.0005920838],"genre_scores_gemma":[0.98210305,0.002684573,0.0066437228,0.0019596529,0.00020435084,0.00059931626,0.00024516368,0.00024178483,0.005318366],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98968065,0.0012171838,0.002104655,0.0025146818,0.0022302687,0.0022525522],"domain_scores_gemma":[0.99274665,0.0026652508,0.0006010889,0.002718912,0.0001044683,0.0011636445],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0053024446,0.001293268,0.002386497,0.0026301586,0.0005015639,0.00021170783,0.0012411948,0.00066029787,0.00010620827],"category_scores_gemma":[0.000542495,0.0011020594,0.0006449955,0.005705143,0.0013279961,0.00033268915,0.0011485058,0.00042051368,0.00018597573],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02627498,0.0006699382,0.0062405984,0.004340334,0.0071093175,0.0073151686,0.048481505,0.03842145,0.78672856,0.0024489255,0.0120272795,0.059941936],"study_design_scores_gemma":[0.11990352,0.0013590626,0.30445284,0.0021441823,0.0070273355,0.002131685,0.006158125,0.38396662,0.07978707,0.0007055067,0.08864197,0.003722078],"about_ca_topic_score_codex":0.0074355784,"about_ca_topic_score_gemma":0.00086768455,"teacher_disagreement_score":0.7069415,"about_ca_system_score_codex":0.20210887,"about_ca_system_score_gemma":0.030489402,"threshold_uncertainty_score":0.9999819},"labels":[],"label_agreement":null},{"id":"W4321599750","doi":"10.2217/fon-2022-1015","title":"Plain Language Summary of the iNNOVATE Study: Ibrutinib Plus Rituximab is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia","year":2023,"lang":"en","type":"letter","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"Pharmacyclics","keywords":"Rituximab; Ibrutinib; Medicine; Internal medicine; Waldenstrom macroglobulinemia; Ofatumumab; Placebo; Oncology; Lymphoma; Chronic lymphocytic leukemia; Leukemia; Pathology; Alternative medicine","score_opus":0.008499668118011266,"score_gpt":0.29985058565332007,"score_spread":0.2913509175353088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321599750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76137084,0.00065769674,9.738549e-7,0.22808963,0.0008248607,0.0047840714,0.000179586,0.00009593167,0.003996423],"genre_scores_gemma":[0.54053646,0.00055074313,0.00038110183,0.39998755,0.015311698,0.001781723,0.001748644,0.0007524347,0.03894967],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623877,0.0006995914,0.00062664744,0.0008689949,0.00077248603,0.00079353544],"domain_scores_gemma":[0.99752,0.0008989394,0.00034431185,0.0009038706,0.0002443675,0.00008845941],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00067405304,0.00052647095,0.0017232771,0.00042404034,0.000087795874,0.000022119866,0.00043213327,0.001494108,0.0001917896],"category_scores_gemma":[0.00015260025,0.00033331843,0.0001099641,0.0015861623,0.00041993175,0.000029998384,0.0005348386,0.0037985696,0.00006435005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002816714,0.00040135026,0.0040785256,0.0016160879,0.0006814734,0.021610484,0.008805629,0.000005259347,0.00015246792,0.0000060426323,0.9565523,0.0032736326],"study_design_scores_gemma":[0.17829835,0.008970895,0.03146933,0.0023414453,0.0010922765,0.0049844715,0.011581551,0.0010454638,0.0009806684,0.000026792293,0.7580431,0.001165621],"about_ca_topic_score_codex":0.004888816,"about_ca_topic_score_gemma":0.0067768972,"teacher_disagreement_score":0.22083439,"about_ca_system_score_codex":0.0095462985,"about_ca_system_score_gemma":0.008940354,"threshold_uncertainty_score":0.9999119},"labels":[],"label_agreement":null},{"id":"W432292542","doi":"10.1007/s00280-015-2776-x","title":"Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Ottawa; Ottawa Hospital","funders":"Teva Pharmaceutical Industries","keywords":"Bendamustine; Medicine; Mantle cell lymphoma; Rituximab; Internal medicine; Regimen; Clinical endpoint; Population; QT interval; Lymphoma; Gastroenterology; Clinical trial","score_opus":0.010804804229402656,"score_gpt":0.32865101746843267,"score_spread":0.31784621323903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W432292542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998384,0.00012382702,0.00004559523,0.0002257518,0.00007943986,0.0009840365,0.0000059628287,0.000008844289,0.00014255363],"genre_scores_gemma":[0.99897116,0.0001577861,0.000112311034,0.00045776856,0.000038770224,0.00014767921,0.000019708916,0.00002371739,0.00007111883],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990091,0.00010808578,0.00020765257,0.00022996716,0.00020280857,0.00024239569],"domain_scores_gemma":[0.99950063,0.000121874175,0.000098580975,0.00009120422,0.000091276794,0.00009640977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002858511,0.00014858994,0.00034903528,0.00015817204,0.000013570103,0.0000039242677,0.00006103974,0.00008087236,0.00008677282],"category_scores_gemma":[0.000013036616,0.000099098565,0.000014362505,0.00024221967,0.00009692236,0.00006509262,0.00001579492,0.00013516795,0.0000012831924],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49718913,0.0070664007,0.21289538,0.002436194,0.00022451991,0.00039281626,0.0067659807,0.0011463813,0.03032203,0.0000069731423,0.00061773777,0.24093646],"study_design_scores_gemma":[0.45752215,0.01738371,0.026526289,0.000392809,0.00004675335,0.000024339677,0.00006175711,0.0067117224,0.49091074,0.0000038557814,0.0002653693,0.00015050432],"about_ca_topic_score_codex":0.00019902602,"about_ca_topic_score_gemma":0.00013080983,"teacher_disagreement_score":0.4605887,"about_ca_system_score_codex":0.0035831134,"about_ca_system_score_gemma":0.0013528302,"threshold_uncertainty_score":0.9369717},"labels":[],"label_agreement":null},{"id":"W4323802224","doi":"10.5281/zenodo.7717036","title":"Antibody Characterization Report for Serine/threonine-protein kinase PINK1","year":2023,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Threonine; Serine; Antibody; Chemistry; Biochemistry; Phosphorylation; Biology; Immunology","score_opus":0.040847947448259106,"score_gpt":0.3092197824181696,"score_spread":0.2683718349699105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323802224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8747315,0.000061702194,0.06640103,0.0056936415,0.00036909038,0.005455253,0.0006934215,0.0049687345,0.04162567],"genre_scores_gemma":[0.756635,0.00019324174,0.00084805035,0.00031038088,0.001074131,0.0000020791915,0.20976546,0.0039795893,0.027192082],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973524,0.00014883015,0.0004548717,0.00065871084,0.00069787184,0.0006873072],"domain_scores_gemma":[0.99757946,0.00003640681,0.0001524531,0.0008372963,0.0010631955,0.00033121803],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012508528,0.00020581677,0.00028764328,0.00047608846,0.001327245,0.00038824746,0.0005389141,0.0001223365,0.0038304038],"category_scores_gemma":[0.0022151854,0.00021037892,0.000113135946,0.0013478055,0.00016879244,0.00025092336,0.00084019103,0.00027011466,0.00719757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054273795,0.00018865758,0.0000120327,0.00065392774,0.00010489919,0.0008730617,0.00047080652,0.000020363823,0.95013815,0.001532314,0.016337283,0.029125793],"study_design_scores_gemma":[0.0047441013,0.00052208634,0.001669564,0.0001398192,0.000031366075,0.0012849323,0.00013161455,0.0075743515,0.007654824,0.00009231799,0.97592485,0.00023017763],"about_ca_topic_score_codex":0.000030581563,"about_ca_topic_score_gemma":2.2425957e-7,"teacher_disagreement_score":0.9595876,"about_ca_system_score_codex":0.0019272061,"about_ca_system_score_gemma":0.00012662061,"threshold_uncertainty_score":0.9999729},"labels":[],"label_agreement":null},{"id":"W4360874186","doi":"10.1016/j.clml.2023.03.010","title":"Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AbbVie","keywords":"Venetoclax; Discontinuation; Medicine; Internal medicine; Adverse effect; Regimen; Chronic lymphocytic leukemia; Pediatrics; Leukemia","score_opus":0.053800879809759505,"score_gpt":0.3791683002437791,"score_spread":0.3253674204340196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360874186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184537,0.000027174156,0.00006448732,0.0002887143,0.0009012001,0.004980586,0.0010325448,0.00041211376,0.0004478036],"genre_scores_gemma":[0.98790455,0.00023746477,0.000632688,0.00019231912,0.001160456,0.0011143364,0.0050771916,0.00018764703,0.0034933276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99248624,0.00036015187,0.0025285063,0.0020389084,0.0013067343,0.0012794894],"domain_scores_gemma":[0.9940969,0.0027619288,0.00065670547,0.0014797625,0.0004610094,0.0005437368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011814123,0.00074680895,0.0013844272,0.0007144473,0.00018177721,0.00015458683,0.000658184,0.00036959187,0.000060348513],"category_scores_gemma":[0.0016087462,0.0005864407,0.0004670976,0.0010265134,0.0002663139,0.00034105036,0.0003843347,0.00031020882,0.00035429763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018036684,0.0031491383,0.67572236,0.00009524562,0.0012094014,0.0011615228,0.0017032305,0.0006184429,0.000023177608,0.000017997112,0.0019067375,0.29635605],"study_design_scores_gemma":[0.2167574,0.003127161,0.6609022,0.00052749884,0.00017431422,0.00000950837,0.0002823218,0.114876784,0.00005265697,0.000012944263,0.0028679362,0.00040928394],"about_ca_topic_score_codex":0.014725101,"about_ca_topic_score_gemma":0.012217318,"teacher_disagreement_score":0.29594675,"about_ca_system_score_codex":0.25805068,"about_ca_system_score_gemma":0.031216769,"threshold_uncertainty_score":0.9996587},"labels":[],"label_agreement":null},{"id":"W4361027552","doi":"10.1016/j.neurol.2023.01.667","title":"Résultats cliniques et d’imagerie par résonance magnétique de l’évobrutinib (EVO), un inhibiteur de la tyrosine kinase de Bruton (BTKi), dans le traitement de la sclérose en plaques récurrente (SEP-R) sur une période de 2,5 ans dans l’extension en ouvert","year":2023,"lang":"fr","type":"article","venue":"Revue Neurologique","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Gynecology; Nuclear medicine","score_opus":0.014991163414606023,"score_gpt":0.321866640529638,"score_spread":0.30687547711503194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361027552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639843,0.004533649,0.010643901,0.015530667,0.0004917301,0.0017463919,0.00042463583,0.0009356669,0.0017090644],"genre_scores_gemma":[0.9235788,0.06083892,0.006541683,0.004234934,0.001136284,0.000536588,0.00024178173,0.0003804223,0.002510584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9798171,0.012620191,0.0015425773,0.0018028894,0.0007632704,0.0034540058],"domain_scores_gemma":[0.987162,0.009304442,0.00050217257,0.001394244,0.0003537396,0.0012834241],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.013543017,0.0011366731,0.0014062952,0.00056898885,0.00043894656,0.00027008288,0.0011027519,0.00206553,0.00007502105],"category_scores_gemma":[0.012903577,0.0012304534,0.0005305345,0.0018156482,0.001570156,0.00046349538,0.0007759295,0.00414572,0.000081546306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0038268857,0.0039395867,0.08359625,0.005127045,0.0003855156,0.06680912,0.061065014,0.011532909,0.7094786,0.0064601935,0.024226442,0.023552435],"study_design_scores_gemma":[0.021863915,0.0037706057,0.2726087,0.005267422,0.00062513765,0.0103010805,0.0020623768,0.22418056,0.38637823,0.006096102,0.06499915,0.0018467207],"about_ca_topic_score_codex":0.009815573,"about_ca_topic_score_gemma":0.0020614262,"teacher_disagreement_score":0.32310036,"about_ca_system_score_codex":0.013256954,"about_ca_system_score_gemma":0.024213275,"threshold_uncertainty_score":0.99923},"labels":[],"label_agreement":null},{"id":"W4361027931","doi":"10.1016/j.neurol.2023.01.692","title":"Sécurité d’emploi et efficacité clinique du tolébrutinib dans l’étude d’extension à long terme chez des patients atteints de SEP récurrente : résultats à 2 ans","year":2023,"lang":"fr","type":"article","venue":"Revue Neurologique","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Gynecology; Medicine; Philosophy","score_opus":0.031268878044015756,"score_gpt":0.31986381647433243,"score_spread":0.2885949384303167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361027931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985682,0.0009967609,0.00088470144,0.005626128,0.0023949256,0.0023076215,0.00018639458,0.0007729421,0.0011485029],"genre_scores_gemma":[0.9768235,0.012960031,0.0002729285,0.0030130812,0.0016930177,0.00024364042,0.0004218917,0.0002985531,0.004273326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9900945,0.0026839487,0.0014842552,0.0018874718,0.00092176377,0.00292807],"domain_scores_gemma":[0.9931605,0.0030609404,0.00044946463,0.0015584639,0.0006321674,0.001138505],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0034711454,0.00094892335,0.0012930748,0.00049462816,0.00039204516,0.000131492,0.0009776546,0.0013895088,0.00027321954],"category_scores_gemma":[0.008265945,0.00096048624,0.0005728571,0.0016192207,0.0011298667,0.00033501047,0.0010752206,0.002906882,0.0017367757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030420008,0.0042233593,0.84789723,0.0061000083,0.00051187613,0.029594861,0.012339849,0.0034403633,0.009885068,0.0008727664,0.01186956,0.07022303],"study_design_scores_gemma":[0.02477164,0.005676954,0.83732545,0.004072386,0.00048788358,0.0036440797,0.00016914996,0.096879244,0.0056200908,0.0006335244,0.019417632,0.0013019564],"about_ca_topic_score_codex":0.0009631113,"about_ca_topic_score_gemma":0.0011139095,"teacher_disagreement_score":0.09343888,"about_ca_system_score_codex":0.0047966945,"about_ca_system_score_gemma":0.0045846887,"threshold_uncertainty_score":0.9999069},"labels":[],"label_agreement":null},{"id":"W4361028085","doi":"10.1016/j.neurol.2023.01.705","title":"Données IRM, efficacité et sécurité d’emploi du tolébrutinib chez des patients atteints d’une SEP très active : données à 2 ans de l’étude de sécurité d’emploi à long terme de phase 2b (LTS, Long-Term Safety)","year":2023,"lang":"fr","type":"article","venue":"Revue Neurologique","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; University of Toronto","funders":"","keywords":"Medicine; Gynecology; Philosophy","score_opus":0.034533434636174455,"score_gpt":0.3126706136292907,"score_spread":0.27813717899311624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361028085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98206854,0.0019381432,0.0010064611,0.008138557,0.0010515652,0.003246763,0.000681093,0.0010004598,0.0008684295],"genre_scores_gemma":[0.9673028,0.022648346,0.00036515828,0.0030482416,0.0023135438,0.00057315384,0.00067113887,0.0005086867,0.002568932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98623574,0.0032842774,0.0018567812,0.0024013934,0.001219602,0.00500221],"domain_scores_gemma":[0.9902105,0.004602976,0.00070554175,0.0019601001,0.0005983393,0.0019225731],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.003226404,0.0015936113,0.002031217,0.0008775036,0.0007949672,0.00028407888,0.0017932652,0.0019546829,0.00059172336],"category_scores_gemma":[0.0056212177,0.0016664135,0.00087268313,0.002453603,0.0018840696,0.0007260294,0.0012711111,0.0036118731,0.0006531925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01407951,0.010032647,0.7396149,0.012332783,0.0017896607,0.05890371,0.024706813,0.0024380279,0.015368738,0.0010123028,0.0021982382,0.117522694],"study_design_scores_gemma":[0.05511684,0.007922572,0.8745147,0.0052192244,0.0011600851,0.0058029415,0.00039167216,0.01744844,0.024149895,0.0006218465,0.0056010517,0.002050759],"about_ca_topic_score_codex":0.0023711545,"about_ca_topic_score_gemma":0.003356225,"teacher_disagreement_score":0.1348998,"about_ca_system_score_codex":0.008875979,"about_ca_system_score_gemma":0.00755623,"threshold_uncertainty_score":0.9996812},"labels":[],"label_agreement":null},{"id":"W4361909386","doi":"10.1158/1078-0432.22454562.v1","title":"Supplemental Table S1 from On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fludarabine; Alemtuzumab; Chronic lymphocytic leukemia; Cyclophosphamide; Rituximab; Chlorambucil; Medicine; Internal medicine; CD38; Immunology; Cancer research; Leukemia; Chemotherapy; Biology; Antibody; Transplantation; Stem cell; CD34","score_opus":0.01585490817979108,"score_gpt":0.28895395865954576,"score_spread":0.2730990504797547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361909386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844917,0.0013689897,0.0001396378,0.0001307217,0.0012270077,0.0053863423,0.006000002,0.00046463334,0.00079098117],"genre_scores_gemma":[0.97362804,0.0018014652,0.00037160324,0.00016924803,0.0005027387,0.0010040428,0.019139295,0.0004204236,0.0029631103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9902421,0.00052643946,0.002189252,0.002464077,0.0024495164,0.0021285706],"domain_scores_gemma":[0.99378407,0.0026378012,0.00037656885,0.0021922127,0.00018403698,0.0008253084],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0013809799,0.0015359317,0.0031607845,0.00088373193,0.000103362894,0.00010002469,0.001076607,0.0014601874,0.004617824],"category_scores_gemma":[0.0004331788,0.0013548529,0.0007629796,0.0011183617,0.00033164799,0.0001293631,0.0010724431,0.0023266217,0.0013319886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016836025,0.0012371138,0.0064256787,0.014696696,0.0036541563,0.0018941351,0.0015172779,0.03228788,0.6694802,0.0000729723,0.25072524,0.0011726144],"study_design_scores_gemma":[0.06428002,0.0025912547,0.000117952746,0.0030786255,0.00040420334,0.000013468011,0.00008201258,0.09246218,0.8343817,0.00006776545,0.0015988227,0.000921977],"about_ca_topic_score_codex":0.1481108,"about_ca_topic_score_gemma":0.0016626397,"teacher_disagreement_score":0.2491264,"about_ca_system_score_codex":0.29469287,"about_ca_system_score_gemma":0.07159791,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W4362395504","doi":"10.1158/1078-0432.22454562","title":"Supplemental Table S1 from On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fludarabine; Alemtuzumab; Chronic lymphocytic leukemia; Rituximab; Cyclophosphamide; Chlorambucil; Internal medicine; Medicine; CD38; Leukemia; Cancer research; Immunology; Biology; Chemotherapy; Stem cell; Transplantation; Lymphoma; CD34","score_opus":0.01585490817979108,"score_gpt":0.28895395865954576,"score_spread":0.2730990504797547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362395504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844917,0.0013689897,0.0001396378,0.0001307217,0.0012270077,0.0053863423,0.006000002,0.00046463334,0.00079098117],"genre_scores_gemma":[0.97362804,0.0018014652,0.00037160324,0.00016924803,0.0005027387,0.0010040428,0.019139295,0.0004204236,0.0029631103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9902421,0.00052643946,0.002189252,0.002464077,0.0024495164,0.0021285706],"domain_scores_gemma":[0.99378407,0.0026378012,0.00037656885,0.0021922127,0.00018403698,0.0008253084],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0013809799,0.0015359317,0.0031607845,0.00088373193,0.000103362894,0.00010002469,0.001076607,0.0014601874,0.004617824],"category_scores_gemma":[0.0004331788,0.0013548529,0.0007629796,0.0011183617,0.00033164799,0.0001293631,0.0010724431,0.0023266217,0.0013319886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016836025,0.0012371138,0.0064256787,0.014696696,0.0036541563,0.0018941351,0.0015172779,0.03228788,0.6694802,0.0000729723,0.25072524,0.0011726144],"study_design_scores_gemma":[0.06428002,0.0025912547,0.000117952746,0.0030786255,0.00040420334,0.000013468011,0.00008201258,0.09246218,0.8343817,0.00006776545,0.0015988227,0.000921977],"about_ca_topic_score_codex":0.1481108,"about_ca_topic_score_gemma":0.0016626397,"teacher_disagreement_score":0.2491264,"about_ca_system_score_codex":0.29469287,"about_ca_system_score_gemma":0.07159791,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W4362472973","doi":"10.1016/j.msard.2022.104360","title":"MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Placebo; Multiple sclerosis; Double blind; Magnetic resonance imaging; Internal medicine; Nuclear medicine; Tolerability; Gastroenterology; Adverse effect; Pathology; Immunology; Radiology","score_opus":0.09464708955712986,"score_gpt":0.3631750525634793,"score_spread":0.26852796300634946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362472973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502456,0.0007330254,0.000005358643,0.0009681535,0.00048702105,0.0026285935,0.00004858636,0.000044270084,0.00006042728],"genre_scores_gemma":[0.9962267,0.0029713593,0.0003004294,0.00013397704,0.000027360866,0.000053684664,0.0000213267,0.000058130536,0.00020700302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967665,0.0002653679,0.0011867569,0.000697175,0.000589124,0.0004950463],"domain_scores_gemma":[0.9974162,0.0012649907,0.00027635228,0.0006662681,0.000104998326,0.000271217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014791386,0.00026545854,0.0009089527,0.00035292952,0.00013837662,0.00004159841,0.00027678206,0.0003615995,0.000024475938],"category_scores_gemma":[0.003681182,0.00019830988,0.000191835,0.0014398746,0.00054393086,0.00014513258,0.00084722403,0.00047579466,0.000007040914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09947557,0.0128456205,0.52206886,0.00054436293,0.0010418791,0.000067277244,0.005382166,0.00049795,0.13741322,0.000092079346,0.0056809816,0.21489005],"study_design_scores_gemma":[0.4390409,0.0013580158,0.5294228,0.0016276204,0.00014835625,0.0000036756064,0.00045718,0.026532205,0.0008566288,0.00003985237,0.00027223447,0.00024052264],"about_ca_topic_score_codex":0.0037661365,"about_ca_topic_score_gemma":0.0007242692,"teacher_disagreement_score":0.3395653,"about_ca_system_score_codex":0.0004290936,"about_ca_system_score_gemma":0.0007148393,"threshold_uncertainty_score":0.8086842},"labels":[],"label_agreement":null},{"id":"W4362507295","doi":"10.1038/s41409-023-01978-6","title":"Allogeneic hematopoietic cell transplantation for Richter transformation of chronic lymphocytic leukemia: an intention-to-transplant analysis","year":2023,"lang":"en","type":"letter","venue":"Bone Marrow Transplantation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Hematopoietic cell; Chronic lymphocytic leukemia; Transplantation; Leukemia; Hematopoietic stem cell transplantation; Immunology; Haematopoiesis; Transformation (genetics); Transplantation Chimera; Stem cell; Internal medicine; Biology; Gene","score_opus":0.021749293076138106,"score_gpt":0.28730973386792946,"score_spread":0.26556044079179136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362507295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5482561,0.001072757,0.3895314,0.031808726,0.0015821259,0.015283478,0.010139464,0.0012568282,0.0010691193],"genre_scores_gemma":[0.9011449,0.0036466906,0.0016835144,0.01613327,0.0010089366,0.0014944838,0.07246169,0.0004147714,0.0020117394],"study_design_codex":"systematic_review","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9935532,0.0002754588,0.0020211108,0.0012757939,0.0017134632,0.0011609428],"domain_scores_gemma":[0.9971014,0.00055788417,0.0005127823,0.0009295638,0.0005537086,0.00034464043],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00091845094,0.00088570215,0.0017767919,0.0027301572,0.00019399013,0.00008443034,0.0004509328,0.0014423542,0.0001471567],"category_scores_gemma":[0.000022294915,0.00088304945,0.0012229633,0.0021245282,0.000159269,0.00039486753,0.000011089698,0.0008986162,0.00014049088],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0336329,0.001192393,0.0012259749,0.3663951,0.0189579,0.014746861,0.059550375,0.11292251,0.2732383,0.0003917069,0.106089495,0.011656487],"study_design_scores_gemma":[0.144735,0.012338337,0.008496329,0.012390814,0.15490247,0.007133443,0.001053374,0.32751998,0.29992065,0.0008641209,0.022806523,0.007838957],"about_ca_topic_score_codex":0.0018795116,"about_ca_topic_score_gemma":0.0013889035,"teacher_disagreement_score":0.38784787,"about_ca_system_score_codex":0.021246994,"about_ca_system_score_gemma":0.009583422,"threshold_uncertainty_score":0.99985397},"labels":[],"label_agreement":null},{"id":"W4362544072","doi":"10.1158/1538-7445.am2023-2516","title":"Abstract 2516: Analysis of CLL Celllular Environment and Response (ACCER) is a novel method to understand the microenvironment in CLL","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Alberta","funders":"","keywords":"Chronic lymphocytic leukemia; Tumor microenvironment; Stromal cell; Ibrutinib; Cancer research; Cell culture; Bone marrow; Fludarabine; Medicine; Leukemia; Chemistry; Immunology; Biology; Internal medicine; Chemotherapy; Tumor cells; Genetics","score_opus":0.14163263964478942,"score_gpt":0.45270551414889826,"score_spread":0.3110728745041088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362544072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98888266,0.0012304314,0.0006023049,0.007844101,0.00001770946,0.0011166615,0.00011548006,0.000012223777,0.00017839827],"genre_scores_gemma":[0.9936287,0.0019146918,0.00056614756,0.00027322583,0.00004229302,0.00018011802,0.000012812681,0.000041515465,0.0033405276],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960747,0.00041141367,0.00043789396,0.00066498684,0.0015893219,0.00082172506],"domain_scores_gemma":[0.9970348,0.001610697,0.00005599187,0.0009182072,0.00005735921,0.00032295447],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0070057455,0.00017547175,0.00048572756,0.0013545139,0.00012205208,0.000036884907,0.00034957245,0.00012169616,0.0012547121],"category_scores_gemma":[0.00024013093,0.00013075858,0.00013568306,0.002613329,0.00044325998,0.000043766937,0.000570394,0.0005683704,0.00009970637],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071253492,0.00029851505,0.0027553,0.00034411516,0.0013283088,0.00026960083,0.015005874,0.004747726,0.95565045,0.00006373537,0.004722797,0.0076882415],"study_design_scores_gemma":[0.024798848,0.0011371004,0.57207227,0.0006022591,0.0009326225,0.000039249684,0.028560044,0.03217176,0.28800574,0.00019143439,0.050801314,0.00068733934],"about_ca_topic_score_codex":0.0037366012,"about_ca_topic_score_gemma":0.00019775011,"teacher_disagreement_score":0.6676447,"about_ca_system_score_codex":0.013260836,"about_ca_system_score_gemma":0.0019734418,"threshold_uncertainty_score":0.9996583},"labels":[],"label_agreement":null},{"id":"W4362575420","doi":"10.1016/j.leukres.2023.107073","title":"Corrigendum to “Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update” [Leukemia Research 125 (2023) 107016]","year":2023,"lang":"en","type":"erratum","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Toronto; Princess Margaret Cancer Centre; Foothills Medical Centre; Ottawa Hospital; Spinal Cord Injury BC; Jewish General Hospital; CancerCare Manitoba","funders":"","keywords":"Guideline; Chronic lymphocytic leukemia; Leukemia; Medicine; Internal medicine; Oncology; Cancer research; Pathology","score_opus":0.2076538861783778,"score_gpt":0.4403279693230669,"score_spread":0.2326740831446891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362575420","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029635988,0.36621848,0.0032117951,0.083959475,0.17856495,0.19071774,0.034805585,0.0054374924,0.10744849],"genre_scores_gemma":[0.008174346,0.034642715,0.002282207,0.001412012,0.020148698,0.011686106,0.01534999,0.002001543,0.90430236],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9621335,0.0027539534,0.004905211,0.0057957047,0.01346245,0.0109491395],"domain_scores_gemma":[0.96241874,0.0062859366,0.00075808546,0.008489779,0.015640471,0.0064070197],"candidate_categories":["metaresearch","metaepi_narrow","bibliometrics","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.020830883,0.0025117754,0.0051837247,0.013789257,0.0020465925,0.0005963889,0.0051137023,0.005115484,0.0046355044],"category_scores_gemma":[0.023079159,0.0023302906,0.001783506,0.014855375,0.002712226,0.0004611523,0.0018545804,0.007814585,0.009239926],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005564105,0.0002395965,0.000016415355,0.0057359138,0.0011305737,0.0035824676,0.00033351852,0.0029875648,0.0014009799,0.00025540864,0.9590737,0.019679708],"study_design_scores_gemma":[0.025183616,0.009910059,0.00004141275,0.0069627897,0.00042407957,0.00015700176,0.0004252333,0.20946187,0.004479275,0.0002941258,0.7412986,0.0013619117],"about_ca_topic_score_codex":0.59973526,"about_ca_topic_score_gemma":0.2675135,"teacher_disagreement_score":0.7968539,"about_ca_system_score_codex":0.8636296,"about_ca_system_score_gemma":0.8133142,"threshold_uncertainty_score":0.999331},"labels":[],"label_agreement":null},{"id":"W4362596072","doi":"10.1158/1538-7445.am2023-3099","title":"Abstract 3099: Hnd-01: a potent inhibitor of wild type mutant BTK","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bruton's tyrosine kinase; Ibrutinib; Dasatinib; Tyrosine kinase; Cancer research; Chemistry; Chronic lymphocytic leukemia; LYN; Pharmacology; breakpoint cluster region; Biology; Biochemistry; Signal transduction; Leukemia; Receptor; Immunology","score_opus":0.12255677442471503,"score_gpt":0.44540527916648814,"score_spread":0.3228485047417731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362596072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894255,0.001156337,0.0000014637527,0.0024285857,0.0003112145,0.00084413507,0.000035719248,0.000104483086,0.005692568],"genre_scores_gemma":[0.99061126,0.0024183418,0.00002903023,0.00007790567,0.0006779016,0.00014027856,0.000029817009,0.00006692406,0.0059485743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99564904,0.00009990224,0.0004070774,0.00049839215,0.0022512467,0.0010943473],"domain_scores_gemma":[0.99746937,0.00040656317,0.000056011777,0.00078632124,0.0008463311,0.0004354102],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016249729,0.00016438558,0.00039441255,0.0006086476,0.00012958051,0.000032939595,0.00035952567,0.00017687996,0.0015289217],"category_scores_gemma":[0.0009386185,0.00013536446,0.00011793332,0.0025177342,0.00048668557,0.00007916036,0.00037203953,0.0008485506,0.0012900017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033476602,0.00040342344,0.0015078668,0.0026294966,0.00036878043,0.0026301013,0.0013804754,0.00017679896,0.7804177,0.0004411083,0.16340016,0.04329644],"study_design_scores_gemma":[0.02665607,0.0019394627,0.027169561,0.0028653322,0.000079682155,0.00020210672,0.0019455265,0.004121905,0.7901281,0.0007152744,0.14357461,0.0006023423],"about_ca_topic_score_codex":0.0030110744,"about_ca_topic_score_gemma":0.0001203186,"teacher_disagreement_score":0.0426941,"about_ca_system_score_codex":0.008295302,"about_ca_system_score_gemma":0.014362167,"threshold_uncertainty_score":0.99948764},"labels":[],"label_agreement":null},{"id":"W4362704219","doi":"10.1007/s12288-023-01649-y","title":"In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia","year":2023,"lang":"en","type":"article","venue":"Indian Journal of Hematology and Blood Transfusion","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Alexandria University","keywords":"Chronic lymphocytic leukemia; Medicine; Hematology; Internal medicine; In vitro; Agonist; PI3K/AKT/mTOR pathway; Cancer research; Leukemia; Endocrinology; Receptor; Chemistry; Signal transduction; Biochemistry","score_opus":0.01103418466892875,"score_gpt":0.2752429946611833,"score_spread":0.26420880999225455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362704219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509263,0.003705123,0.000033095963,0.00059170614,0.00013534317,0.00031789325,0.000009860597,0.0000139523645,0.00010042297],"genre_scores_gemma":[0.9958251,0.0038224293,0.00009418213,0.00006012066,0.000074143536,0.0000072947028,0.000017651782,0.000026367441,0.00007269326],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976674,0.00019432156,0.0009644994,0.00026610005,0.00043247358,0.00047524582],"domain_scores_gemma":[0.99891996,0.00034862154,0.00022289241,0.00021237125,0.00010187671,0.0001942485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008090607,0.00019753927,0.0007921146,0.00094169675,0.0000675648,0.000009943125,0.00016216016,0.0003559888,0.000062582636],"category_scores_gemma":[0.0001343419,0.0001731766,0.00013728885,0.00082312786,0.0002634619,0.00018739582,0.000033907858,0.000518893,0.000010446766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009604094,0.0005166709,0.0124819735,0.0038717694,0.00047918895,0.026413435,0.007763678,0.0016576294,0.92274565,0.00031161305,0.0012688157,0.012885488],"study_design_scores_gemma":[0.11666935,0.0030230035,0.016718954,0.0027162891,0.0003399604,0.032875307,0.0011567586,0.023183405,0.80055106,0.0018290231,0.00040371166,0.0005331644],"about_ca_topic_score_codex":0.0006639026,"about_ca_topic_score_gemma":0.00022405853,"teacher_disagreement_score":0.122194566,"about_ca_system_score_codex":0.006790551,"about_ca_system_score_gemma":0.009695881,"threshold_uncertainty_score":0.9970222},"labels":[],"label_agreement":null},{"id":"W4364377006","doi":"10.3389/fonc.2023.1043694","title":"Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"International Development Research Centre; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Ruxolitinib; Chronic lymphocytic leukemia; In vivo; In vitro; Cancer research; Leukemia; CD20; Medicine; Immunology; Chemistry; Biology; Bone marrow; Lymphoma; Genetics; Myelofibrosis; Biochemistry","score_opus":0.014725810656520835,"score_gpt":0.30715073116291475,"score_spread":0.2924249205063939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364377006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966115,0.00057611644,0.00012666082,0.0003221763,0.000331381,0.00060182804,0.000013399481,0.000031810192,0.0013851374],"genre_scores_gemma":[0.997287,0.0009283464,0.00068419194,0.00015038339,0.00007875687,0.00009606103,0.000035745925,0.000027704225,0.00071184867],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99788755,0.00019375926,0.0005675335,0.00041401814,0.00028667907,0.0006504328],"domain_scores_gemma":[0.99905854,0.0004331923,0.00009456161,0.00025835843,0.00002805343,0.00012729663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006848964,0.00016329941,0.0007096592,0.00078347005,0.000016790877,0.000005202933,0.00014618566,0.00039499745,0.00004485317],"category_scores_gemma":[0.00028755714,0.00016623815,0.000044866887,0.001008822,0.0003168727,0.00007867255,0.00011551277,0.00038622567,0.000013071633],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010335894,0.00057276536,0.014373212,0.0015254691,0.00011724161,0.002078053,0.0030021307,0.0033866214,0.73915535,0.00011868754,0.15848076,0.0668538],"study_design_scores_gemma":[0.071492545,0.001280036,0.004482226,0.0004071495,0.000029008545,0.000106661915,0.0014936143,0.4977629,0.40132695,0.00090683077,0.020351164,0.0003608986],"about_ca_topic_score_codex":0.0017058601,"about_ca_topic_score_gemma":0.00014739328,"teacher_disagreement_score":0.49437627,"about_ca_system_score_codex":0.121661015,"about_ca_system_score_gemma":0.017257739,"threshold_uncertainty_score":0.9883135},"labels":[],"label_agreement":null},{"id":"W4364395789","doi":"","title":"CD24 as a Potential Therapeutic Target in Patients with B-Cell Leukemia and Lymphoma: Current Insights","year":2022,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lymphoma; Leukemia; Cancer research; Medicine; CD24; Current (fluid); Oncology; Immunology; Internal medicine; Cancer; Geology; Breast cancer","score_opus":0.09364801259440979,"score_gpt":0.48179462296170195,"score_spread":0.38814661036729214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364395789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.951215,0.04526752,0.000027934657,0.000052352014,0.0003626668,0.001240281,0.000023478697,0.00002495465,0.0017857596],"genre_scores_gemma":[0.9951595,0.0038169369,0.000060646686,0.0002984909,0.00009966078,0.00012816554,0.000049745875,0.00008282029,0.00030405298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554414,0.00041544824,0.0007860704,0.00066113874,0.001976084,0.000617123],"domain_scores_gemma":[0.9980228,0.00018383106,0.00049265113,0.00058374024,0.00028662264,0.00043033957],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078688865,0.00038573492,0.0008923342,0.0011337438,0.00033349195,0.0004072242,0.0013685472,0.00008669192,0.0052792183],"category_scores_gemma":[0.000087752676,0.00031061005,0.00012903051,0.001299763,0.00022021947,0.0009146795,0.0017220636,0.0007007675,0.000014718562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012307971,0.0056010718,0.8791741,0.00087901606,0.0006707071,0.0013607482,0.0016920392,0.0014190937,0.008542038,0.00011268598,0.009933172,0.07830732],"study_design_scores_gemma":[0.059812192,0.0003806657,0.9064563,0.00057839,0.00026432582,0.00019808275,0.00031461497,0.0025412596,0.0051350105,0.0026201045,0.020890176,0.0008088657],"about_ca_topic_score_codex":0.0018676867,"about_ca_topic_score_gemma":0.000028846858,"teacher_disagreement_score":0.07749846,"about_ca_system_score_codex":0.00836128,"about_ca_system_score_gemma":0.00629723,"threshold_uncertainty_score":0.9999346},"labels":[],"label_agreement":null},{"id":"W4366274714","doi":"10.3390/curroncol30040322","title":"How We Manage Patients with Indolent B-Cell Malignancies on Bruton’s Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Impact; Hôpital de l'Enfant-Jésus; Fluidigm (Canada); Université Laval; Princess Margaret Cancer Centre","funders":"BeiGene","keywords":"Bruton's tyrosine kinase; Ibrutinib; Medicine; Chronic lymphocytic leukemia; Chemoimmunotherapy; Tyrosine kinase; Adverse effect; Oncology; Cancer research; Internal medicine; Leukemia; Receptor","score_opus":0.12670913507193488,"score_gpt":0.4223184639123699,"score_spread":0.295609328840435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366274714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844476,0.00057303853,0.000057591602,0.010578367,0.0014293207,0.0022758143,0.00010258588,0.00012002021,0.00041568963],"genre_scores_gemma":[0.99668163,0.00053644174,0.00030920404,0.00023176301,0.0003531227,0.00042862812,0.00015620701,0.00003784752,0.0012651552],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839056,0.000091761736,0.00022578026,0.0004349591,0.00039336673,0.00046355804],"domain_scores_gemma":[0.9980435,0.0010882525,0.00010650333,0.00025170838,0.00027219608,0.00023784234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020284895,0.00019999711,0.00034703556,0.00023217767,0.00013887999,0.000055606906,0.00004121743,0.00010562797,0.000031902713],"category_scores_gemma":[0.000755615,0.00015307017,0.00005347002,0.00021505688,0.00028675562,0.00011138656,0.00009048666,0.00026703716,0.000043630793],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006155087,0.011883019,0.019738013,0.00455934,0.0004570129,0.0028390796,0.0047279047,0.000028630131,0.0047487174,0.005221676,0.8579017,0.08173982],"study_design_scores_gemma":[0.17218168,0.014498687,0.0060996255,0.0012277329,0.0008860132,0.0005275773,0.0011480271,0.006674427,0.037152793,0.0012001544,0.7575074,0.0008959103],"about_ca_topic_score_codex":0.0000039483048,"about_ca_topic_score_gemma":0.000010630191,"teacher_disagreement_score":0.16602659,"about_ca_system_score_codex":0.0026584375,"about_ca_system_score_gemma":0.0021209274,"threshold_uncertainty_score":0.6951722},"labels":[],"label_agreement":null},{"id":"W4366280595","doi":"10.1038/s41467-023-37648-w","title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Deutsche Forschungsgemeinschaft; F. Hoffmann-La Roche","keywords":"Venetoclax; Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Oncology; Minimal residual disease; Hazard ratio; Bendamustine; Clinical endpoint; Leukemia; Gastroenterology; Randomized controlled trial; Chemotherapy; Confidence interval; Cyclophosphamide","score_opus":0.04807670329651975,"score_gpt":0.3432482560445208,"score_spread":0.29517155274800105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366280595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981958,0.0109192915,0.0000022302665,0.00053983217,0.000299581,0.0046134945,0.0001914181,0.0001912222,0.0012849856],"genre_scores_gemma":[0.9927045,0.005138087,0.00021894595,0.000077911965,0.00014926463,0.00065942405,0.00056950806,0.00006936432,0.00041298292],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99582154,0.0009832716,0.0011047892,0.0006385724,0.00087139476,0.00058045756],"domain_scores_gemma":[0.9888406,0.006508426,0.00028704066,0.0039375364,0.00026182565,0.00016460134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019066846,0.00036754046,0.0011762772,0.00035586423,0.00032275368,0.000065188324,0.0016334535,0.0005191368,0.000024912692],"category_scores_gemma":[0.0024728614,0.00027442092,0.00021873596,0.0016688723,0.0009104451,0.00013245216,0.00075862784,0.0018296257,0.00005787653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7392485,0.00020306476,0.00020014502,0.00080029137,0.0043365224,0.00033302387,0.09851328,0.122058764,0.0041705975,0.0062872563,0.021047676,0.002800872],"study_design_scores_gemma":[0.54037404,0.00036274391,0.0009119394,0.00035497913,0.0003564395,0.000015095027,0.0053420747,0.4501221,0.00023536438,0.00009256524,0.001612911,0.00021972306],"about_ca_topic_score_codex":0.034087285,"about_ca_topic_score_gemma":0.017568676,"teacher_disagreement_score":0.32806334,"about_ca_system_score_codex":0.33713955,"about_ca_system_score_gemma":0.1219113,"threshold_uncertainty_score":0.9999708},"labels":[],"label_agreement":null},{"id":"W4366759859","doi":"10.1080/10428194.2023.2199340","title":"Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; University of British Columbia","funders":"AbbVie; Lundbeck Canada; University of British Columbia; GlaxoSmithKline","keywords":"Ibrutinib; Discontinuation; Medicine; Chronic lymphocytic leukemia; Adverse effect; Internal medicine; Population; Oncology; Leukemia","score_opus":0.020516141504062696,"score_gpt":0.28692706116083677,"score_spread":0.2664109196567741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366759859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928473,0.0018290002,0.00003562327,0.000043368156,0.0005468218,0.0026190646,0.0008859168,0.00036986635,0.0008230309],"genre_scores_gemma":[0.9888599,0.0010900479,0.000375647,0.00031354817,0.000595338,0.0005751354,0.0013657125,0.0003194702,0.0065051913],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99105203,0.00021046268,0.0022519873,0.0018933213,0.0017931424,0.0027990302],"domain_scores_gemma":[0.99471384,0.0014271506,0.00063723844,0.0015363145,0.0005314771,0.0011539572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011757083,0.00091135205,0.0023984856,0.0007263267,0.00051700557,0.00036653294,0.00081603206,0.0009240012,0.00025272288],"category_scores_gemma":[0.0010509201,0.0012219967,0.0007885031,0.0029756129,0.000566154,0.00046027676,0.000494384,0.00029306606,0.000046595404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0046010776,0.00035402869,0.31181005,0.010515477,0.0030109137,0.008834675,0.0016155723,0.030513657,0.0060977065,0.00036724514,0.1573722,0.46490738],"study_design_scores_gemma":[0.07886876,0.0009043812,0.68320143,0.0014124303,0.00026402847,0.0028823386,0.00038435965,0.22620925,0.00058264093,0.00040152992,0.0036503794,0.0012384738],"about_ca_topic_score_codex":0.9888633,"about_ca_topic_score_gemma":0.9338035,"teacher_disagreement_score":0.4636689,"about_ca_system_score_codex":0.5791635,"about_ca_system_score_gemma":0.3585317,"threshold_uncertainty_score":0.99902296},"labels":[],"label_agreement":null},{"id":"W4366768299","doi":"10.7759/cureus.37980","title":"A Rare Case of Recurrent Cutaneous Non-Hodgkin’s Lymphoma in the Extremity: Long-Term Follow-Up and Review of the Literature Written With the Assistance of ChatGPT","year":2023,"lang":"en","type":"article","venue":"Cureus","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Western University; London Health Sciences Centre","funders":"","keywords":"Medicine; Lymphoma; Presentation (obstetrics); Chronic lymphocytic leukemia; Hodgkin lymphoma; Complete response; Case presentation; Radiation therapy; Dermatology; Surgery; Chemotherapy; Leukemia; Internal medicine","score_opus":0.019898884992612515,"score_gpt":0.30721451263044686,"score_spread":0.28731562763783436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366768299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9163362,0.079545036,0.0000028187808,0.0022037355,0.00009778138,0.0012517393,0.00006117274,0.000010779043,0.00049074],"genre_scores_gemma":[0.9801849,0.018857826,0.000018176954,0.0002833585,0.000057353354,0.00006951599,0.00001692534,0.000023419416,0.0004885393],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99816203,0.00022461894,0.0004114828,0.00027902413,0.0006371187,0.00028571198],"domain_scores_gemma":[0.99781835,0.00047335107,0.0002494539,0.0011484985,0.00025056634,0.000059797145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079101213,0.00018827649,0.000515054,0.00006238011,0.00006266804,0.000015729327,0.00042724021,0.00009605183,0.000024894582],"category_scores_gemma":[0.0004003824,0.00008016846,0.00013749949,0.0011941917,0.00035874796,0.00004716868,0.00018291906,0.00025325723,0.0000014703832],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089859655,0.0025613306,0.09880065,0.23109429,0.00214461,0.086947896,0.12125735,0.0000136488325,0.0058949925,0.0013334946,0.089247756,0.35171804],"study_design_scores_gemma":[0.087655164,0.0047551603,0.24536432,0.43043998,0.0034467722,0.18593097,0.0118929865,0.0039067985,0.0084538115,0.00041327334,0.016007073,0.0017337016],"about_ca_topic_score_codex":0.00019182201,"about_ca_topic_score_gemma":0.00078950915,"teacher_disagreement_score":0.34998432,"about_ca_system_score_codex":0.00084615545,"about_ca_system_score_gemma":0.0014846819,"threshold_uncertainty_score":0.3269175},"labels":[],"label_agreement":null},{"id":"W4366991268","doi":"10.3390/curroncol30050339","title":"Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Foothills Medical Centre; Ottawa Hospital; University of Manitoba; CancerCare Manitoba; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"AbbVie Canada","keywords":"Medicine; Chronic lymphocytic leukemia; Duration (music); Leukemia; Oncology; Internal medicine; Bioinformatics; Biology","score_opus":0.07068412634235963,"score_gpt":0.39047493247437537,"score_spread":0.3197908061320157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366991268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975094,0.0008487676,0.000001899182,0.00027382345,0.0004705382,0.0005423303,0.000035744844,0.000018331533,0.00029916634],"genre_scores_gemma":[0.99900573,0.0006045188,0.0000036457675,0.000015981013,0.00016391471,0.0000534931,0.00006857725,0.000019421943,0.000064729495],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983585,0.00018567502,0.00053361466,0.00023284982,0.00027118,0.00041821512],"domain_scores_gemma":[0.9985292,0.0007127129,0.00020570442,0.00039168764,0.00007688297,0.0000838063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045919514,0.00015772515,0.00050869194,0.00022716723,0.000030134048,0.0000038603057,0.00022667964,0.00009096066,0.00048594596],"category_scores_gemma":[0.00022258263,0.000104925435,0.0001173177,0.0003783452,0.00017335414,0.00003602955,0.00007833954,0.00023828053,0.000058842055],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0077916677,0.0004033073,0.06952396,0.0026250633,0.0023392984,0.0006246582,0.014217479,0.40465537,0.04098251,0.0027381447,0.15008095,0.3040176],"study_design_scores_gemma":[0.021384576,0.002948596,0.05377991,0.00034087582,0.000066532884,0.000058285154,0.0009801382,0.9092492,0.0038814675,0.0001846624,0.006902076,0.00022369891],"about_ca_topic_score_codex":0.78490525,"about_ca_topic_score_gemma":0.47406948,"teacher_disagreement_score":0.5045938,"about_ca_system_score_codex":0.428361,"about_ca_system_score_gemma":0.27461472,"threshold_uncertainty_score":0.72949755},"labels":[],"label_agreement":null},{"id":"W4367050222","doi":"10.1038/s41375-023-01898-w","title":"Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation","year":2023,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Venetoclax; Ibrutinib; CD40; Cancer research; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Idelalisib; Medicine; Leukemia; Immunology; Biology; Receptor; Internal medicine; Cytotoxic T cell; Tyrosine kinase; In vitro; Biochemistry","score_opus":0.03847559440720295,"score_gpt":0.3173478667495473,"score_spread":0.27887227234234435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367050222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955362,0.00006686651,0.00030378115,0.0007705726,0.000109684544,0.0013662474,0.000012277678,0.00028718784,0.0015471745],"genre_scores_gemma":[0.9954032,0.000011967486,0.001068074,0.00022452409,0.00023818525,0.00007358223,0.00011132671,0.000057955123,0.0028112214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980409,0.000085228174,0.0003629306,0.00048941164,0.00050275144,0.0005187605],"domain_scores_gemma":[0.9990479,0.00016452873,0.00006711432,0.00035581182,0.00008625292,0.00027842404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048787845,0.00020820605,0.0003026835,0.00021769614,0.00011217933,0.000060782757,0.00009108247,0.00019845826,0.000046569097],"category_scores_gemma":[0.0001435372,0.00020324127,0.00006629044,0.00060894154,0.00005290514,0.00011629839,0.00008772238,0.00026221215,0.00030935762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003354635,0.00000920422,0.000045322,0.00024779025,0.000039235885,0.00007487179,0.0018085561,0.0003481268,0.9331336,0.00003215996,0.0044827024,0.05944299],"study_design_scores_gemma":[0.011825169,0.00048815305,0.0014478398,0.00070043345,0.00006258214,0.00010251074,0.00047371577,0.26746148,0.7076915,0.00014617061,0.009180737,0.00041975206],"about_ca_topic_score_codex":0.00070312293,"about_ca_topic_score_gemma":0.000044525936,"teacher_disagreement_score":0.26711336,"about_ca_system_score_codex":0.00886901,"about_ca_system_score_gemma":0.00224736,"threshold_uncertainty_score":0.99493575},"labels":[],"label_agreement":null},{"id":"W4367305551","doi":"10.1212/wnl.0000000000202933","title":"Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders (P7-3.015)","year":2023,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Safety profile; Medicine; Internal medicine; Adverse effect","score_opus":0.02098715940100143,"score_gpt":0.28685169813132216,"score_spread":0.26586453873032073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367305551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891832,0.00006624413,0.0004814314,0.0047590765,0.00014139301,0.0021228765,0.000010466425,0.00017174934,0.003063588],"genre_scores_gemma":[0.9946511,0.00007151666,0.0020797327,0.0009158622,0.000039409708,0.0007890229,0.00012900739,0.00008000187,0.001244359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997593,0.00006839826,0.00047930836,0.0006006072,0.00031164475,0.0009470784],"domain_scores_gemma":[0.9988839,0.00047025108,0.00007120282,0.00041343083,0.00005942585,0.00010179547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069511705,0.0002086769,0.00048853765,0.0004634344,0.00006831288,0.000009910866,0.00020430042,0.00021500225,0.0000694669],"category_scores_gemma":[0.00038664366,0.00017864293,0.000043385025,0.0010868673,0.00013701331,0.00004932962,0.0001673614,0.00048572742,0.00009728015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2281406,0.012021433,0.36844885,0.0075315647,0.0013379403,0.012950142,0.03903085,0.024985215,0.078770824,0.010815224,0.016639762,0.19932759],"study_design_scores_gemma":[0.1333593,0.0056524104,0.4944618,0.00027711754,0.0000436583,0.00068190217,0.00013050201,0.14564133,0.0013264222,0.0005613169,0.21715547,0.0007087701],"about_ca_topic_score_codex":0.0018573895,"about_ca_topic_score_gemma":0.0057198736,"teacher_disagreement_score":0.20051572,"about_ca_system_score_codex":0.0019093037,"about_ca_system_score_gemma":0.006839653,"threshold_uncertainty_score":0.9987906},"labels":[],"label_agreement":null},{"id":"W4368377563","doi":"10.3390/cells12091295","title":"A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome","year":2023,"lang":"en","type":"article","venue":"Cells","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. Georges-L.-Dumont University Hospital Centre; University of Manitoba; CancerCare Manitoba; Université Laval; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; CancerCare Manitoba Foundation; Ministerio de Economía y Competitividad; Canada Foundation for Innovation; Leukemia and Lymphoma Society of Canada; Université Laval","keywords":"Glycosyltransferase; Enzyme; Receptor; Non canonical; Biology; Computational biology; Chemistry; Biochemistry; Cell biology","score_opus":0.02026828980904834,"score_gpt":0.282670508803911,"score_spread":0.26240221899486266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368377563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97804457,0.0007657076,0.001087578,0.0034382134,0.0009111734,0.0045393356,0.00027735528,0.000090448055,0.010845604],"genre_scores_gemma":[0.98954654,0.00015065567,0.00013919221,0.00054826884,0.00025557628,0.00019782144,0.000017905952,0.000042089447,0.009101973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811286,0.000033297125,0.00036490906,0.0003291588,0.00063019805,0.00052959094],"domain_scores_gemma":[0.9976172,0.0012013756,0.00006700104,0.0007668053,0.00016005535,0.0001875869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053261936,0.00018223841,0.00033604674,0.0000710658,0.00014749792,0.000021390138,0.0004747598,0.00013626176,0.000490219],"category_scores_gemma":[0.00017890212,0.00010177925,0.00032332915,0.00051389216,0.0004440979,0.000031136467,0.0001438206,0.00028723644,0.00053011446],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006115855,0.00028550084,0.000024711384,0.00038464126,0.00011695693,0.000026755028,0.0006304096,0.00033907217,0.9727919,0.00047965976,0.023965394,0.00034338122],"study_design_scores_gemma":[0.013193565,0.00030928894,0.000027084325,0.00015716381,0.00014715239,0.000045177312,0.00038440718,0.018466618,0.9033588,0.000079992875,0.063697174,0.00013357136],"about_ca_topic_score_codex":0.0004093561,"about_ca_topic_score_gemma":0.000023780474,"teacher_disagreement_score":0.06943312,"about_ca_system_score_codex":0.00139835,"about_ca_system_score_gemma":0.0075645843,"threshold_uncertainty_score":0.9980616},"labels":[],"label_agreement":null},{"id":"W4368617708","doi":"10.14740/jh1096","title":"<i>De-Novo</i> B-Cell Prolymphocytic Leukemia","year":2023,"lang":"fa","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prolymphocytic leukemia; Medicine; Hairy cell leukemia; Chronic lymphocytic leukemia; Mantle cell lymphoma; Ibrutinib; Cladribine; Leukemia; Pathology; Bone marrow examination; Context (archaeology); Bone marrow; Lymphoma; Immunology; Internal medicine; Biology","score_opus":0.021323733752794203,"score_gpt":0.31098035255241696,"score_spread":0.28965661879962273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368617708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625042,0.017775169,0.0003100522,0.0036953331,0.002648695,0.0006060267,0.000012636825,0.00009633103,0.012351566],"genre_scores_gemma":[0.9771376,0.0037914796,0.00038422015,0.0009398405,0.0014685774,0.000014357059,0.000008190061,0.00013496685,0.016120737],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99402755,0.00044692526,0.001928091,0.0004438901,0.0013179318,0.0018356252],"domain_scores_gemma":[0.99510676,0.0014441021,0.0010625576,0.0007688229,0.00068681414,0.00093096413],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002766779,0.0004680091,0.0017623553,0.0010523604,0.00015778965,0.000077469835,0.0008632817,0.00074591656,0.0009007874],"category_scores_gemma":[0.0015795843,0.00039596978,0.00061242684,0.0014072802,0.0005266349,0.00020091534,0.00034650022,0.001470034,0.003910901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076476466,0.0017389684,0.008461118,0.014953612,0.0025064964,0.24294229,0.006037733,0.0017717958,0.032583497,0.010340755,0.6599238,0.011092273],"study_design_scores_gemma":[0.18361974,0.006797361,0.00087107805,0.004426531,0.0024517588,0.45721468,0.004644325,0.07054453,0.09964951,0.0052396497,0.16306184,0.0014789857],"about_ca_topic_score_codex":0.00011248362,"about_ca_topic_score_gemma":0.0000074385866,"teacher_disagreement_score":0.496862,"about_ca_system_score_codex":0.037551925,"about_ca_system_score_gemma":0.07539898,"threshold_uncertainty_score":0.9998492},"labels":[],"label_agreement":null},{"id":"W4376106464","doi":"10.3389/fimmu.2023.1115244","title":"Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Research Manitoba","keywords":"Idelalisib; PI3K/AKT/mTOR pathway; B cell; Autoantibody; Systemic lupus erythematosus; Germinal center; Immunology; Medicine; Cancer research; Plasma cell; Chronic lymphocytic leukemia; Biology; Antibody; Internal medicine; Signal transduction; Cell biology; Disease; Leukemia; Ibrutinib","score_opus":0.01518570395256286,"score_gpt":0.26424025358476066,"score_spread":0.2490545496321978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376106464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678725,0.002009775,0.00019175783,0.00023620554,0.0002051319,0.0004840718,0.000011391524,0.000028299539,0.000046131816],"genre_scores_gemma":[0.9952954,0.0032197325,0.00080752827,0.0000061369838,0.000025622081,0.00003585227,0.000067359266,0.000018555342,0.0005238189],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878454,0.00007628209,0.00037827532,0.0003133172,0.00016772473,0.000279868],"domain_scores_gemma":[0.9995066,0.000054794662,0.00013074685,0.00020726067,0.00007242801,0.000028178263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003114905,0.000120788536,0.00037642114,0.0007043526,0.000025573061,0.0000044039734,0.000043049888,0.000164611,0.0000032326514],"category_scores_gemma":[0.0002189609,0.00012342981,0.000025253734,0.00047994778,0.00039505874,0.00015605714,0.00009799722,0.00020920775,7.2597646e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010175889,0.00014522245,0.006214067,0.0005141571,0.000043709973,0.00001785707,0.0014734957,0.0013266939,0.9829148,0.000034994053,0.00076153583,0.005535868],"study_design_scores_gemma":[0.006820413,0.0003745835,0.0052869096,0.00027870046,0.000018130206,0.00004936393,0.0010906799,0.050168607,0.93547064,0.00033804195,0.000011023798,0.00009288571],"about_ca_topic_score_codex":0.00076676876,"about_ca_topic_score_gemma":0.00005683894,"teacher_disagreement_score":0.048841916,"about_ca_system_score_codex":0.0020531442,"about_ca_system_score_gemma":0.0012695546,"threshold_uncertainty_score":0.53689003},"labels":[],"label_agreement":null},{"id":"W4376167335","doi":"10.17615/jtnt-qj24","title":"Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia","year":2020,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Cancer Council NSW; Medical Research Council; University of Texas MD Anderson Cancer Center; Institut National Du Cancer; Centers for Disease Control and Prevention; National Institutes of Health; Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail; Leukemia and Lymphoma Research; National Health and Medical Research Council; José Carreras Leukämie-Stiftung; U.S. Public Health Service; University at Buffalo; Regione Autonoma della Sardegna; Associazione Italiana per la Ricerca sul Cancro; Fondation de France; Generalitat de Catalunya; Canadian Institutes of Health Research; Bundesamt für Strahlenschutz; MedStar Health Research Institute; Cancerfonden; U.S. Department of Veterans Affairs; Compagnia di San Paolo; European Commission; Ministerio de Economía y Competitividad; Bundesministerium für Bildung und Forschung; Division of Cancer Epidemiology and Genetics, National Cancer Institute; Huntsman Cancer Institute; Division of Cancer Prevention, National Cancer Institute; Health Research Board; Stockholms Läns Landsting; University of Pittsburgh; University of Southern California; Memorial Sloan-Kettering Cancer Center; Wellcome Trust; Cancer Research UK; Ohio State University; Instituto de Salud Carlos III; Wake Forest University; Yale University; Karolinska Institutet; Utah State University; Leukemia and Lymphoma Society; Utah Department of Health; Brigham and Women's Hospital; U.S. Department of Health and Human Services; University of California, San Francisco; Michael Smith Health Research BC; Cancer Council Victoria","keywords":"Gene; Immunity; Biology; Genome-wide association study; Genetics; Immune dysregulation; Genome; Genetic association; Immunology; Immune system; Single-nucleotide polymorphism; Genotype","score_opus":0.024500207970290507,"score_gpt":0.2679189159826498,"score_spread":0.24341870801235926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376167335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928192,0.0031573595,0.0007100432,0.0017176485,0.000023848084,0.00040927253,0.000020833615,0.000092125985,0.0010496711],"genre_scores_gemma":[0.9977867,0.000106815816,0.00092890585,0.0003362509,0.00014346193,0.00002552551,0.00033660742,0.000027996344,0.00030772053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801046,0.00013255412,0.00058042497,0.0003323803,0.0005479915,0.0003961636],"domain_scores_gemma":[0.99829656,0.0007177131,0.0002471714,0.00043677713,0.00013879388,0.00016299255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003114465,0.00018421808,0.0006369472,0.00036822524,0.00006536082,0.000056545916,0.00023753483,0.00019273562,0.00033433217],"category_scores_gemma":[0.0009797023,0.00017275107,0.00020621452,0.0022111142,0.0001305773,0.00046680035,0.0001893067,0.00019676489,0.00004422438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012538229,0.00014039945,0.89645946,0.0015789059,0.0033290118,0.00007506328,0.0051869564,0.025894566,0.054384008,0.0076250955,0.000849695,0.0032230334],"study_design_scores_gemma":[0.014968205,0.0004653434,0.7230934,0.00009177414,0.0011767839,0.000006289625,0.0005159435,0.14092448,0.11114214,0.00496031,0.0022316095,0.00042372945],"about_ca_topic_score_codex":0.0012526386,"about_ca_topic_score_gemma":0.00012706277,"teacher_disagreement_score":0.17336605,"about_ca_system_score_codex":0.030769682,"about_ca_system_score_gemma":0.012545053,"threshold_uncertainty_score":0.9930529},"labels":[],"label_agreement":null},{"id":"W4376619718","doi":"10.1016/j.jcjo.2023.04.010","title":"Spontaneous hyphema in a patient receiving acalabrutinib","year":2023,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto and Region Conservation Authority; University of Toronto","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Internal medicine; Leukemia","score_opus":0.04058243563996496,"score_gpt":0.3051331443300084,"score_spread":0.26455070869004343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376619718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75697434,0.0014464507,6.8888835e-7,0.20707102,0.0029698387,0.00060623745,0.00006094313,0.000012185426,0.030858291],"genre_scores_gemma":[0.9192431,0.000038262868,0.00027473798,0.05818933,0.00486922,0.000022808385,0.00010887161,0.00027974395,0.016973939],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9963094,0.00028878683,0.0010836709,0.0003907273,0.0005970562,0.0013303399],"domain_scores_gemma":[0.9970554,0.00076823955,0.0004402508,0.00051230984,0.00037211608,0.0008516526],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006437059,0.00035221712,0.0011789543,0.0019986914,0.00006172369,0.000036370897,0.0005017486,0.0013713548,0.0025896346],"category_scores_gemma":[0.0020645978,0.00032829042,0.00030346945,0.00063176383,0.00028151495,0.000048719918,0.000057376965,0.0043016174,0.0002805502],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00007210619,0.000008973295,0.0004429447,0.00016763619,0.00009492452,0.6807606,0.00025045118,0.000011987994,0.000004841399,0.0000019407642,0.31765833,0.00052522484],"study_design_scores_gemma":[0.0027212037,0.0008906414,0.000661477,0.0008821771,0.00005721663,0.85086894,0.00007531162,0.00004157643,0.000012280543,0.00013306383,0.14344487,0.00021123412],"about_ca_topic_score_codex":0.020676889,"about_ca_topic_score_gemma":0.0014950563,"teacher_disagreement_score":0.17421347,"about_ca_system_score_codex":0.024414847,"about_ca_system_score_gemma":0.05724081,"threshold_uncertainty_score":0.9999251},"labels":[],"label_agreement":null},{"id":"W4376869035","doi":"10.1016/j.leukres.2023.107315","title":"Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Chronic lymphocytic leukemia; Immune system; Immunology; Disease; Medicine; Leukemia; Tumor microenvironment; Cancer research; Pathology","score_opus":0.029947984987117895,"score_gpt":0.3184048372239828,"score_spread":0.2884568522368649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376869035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562913,0.0017482192,0.000013327319,0.00034832838,0.00003850672,0.0015243026,0.000046246205,0.00013370084,0.0005182131],"genre_scores_gemma":[0.99137294,0.0016040677,0.000059529008,0.000049862825,0.00015403044,0.00026760515,0.00020895936,0.00012739224,0.006155612],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99319464,0.00052997697,0.00089127215,0.0010468089,0.0024962248,0.001841086],"domain_scores_gemma":[0.9966822,0.0009205491,0.00017534006,0.001218918,0.00028966472,0.00071332406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002585995,0.00043681823,0.0008682662,0.0013633562,0.00020380603,0.000069342124,0.0005705469,0.00034114285,0.00041602395],"category_scores_gemma":[0.00085321907,0.00036145147,0.00014003854,0.0025894311,0.0011337305,0.00022829795,0.0010366589,0.001250721,0.00020515853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013557331,0.00018407816,0.008559765,0.0038789844,0.0005536278,0.008566004,0.0044324566,0.006556675,0.93684155,0.00014917168,0.007877596,0.008842777],"study_design_scores_gemma":[0.10214764,0.0030240468,0.0965984,0.0112830065,0.00017774093,0.00031914873,0.0019655067,0.32261738,0.45712528,0.00045672845,0.0031430272,0.001142092],"about_ca_topic_score_codex":0.0065237675,"about_ca_topic_score_gemma":0.00019761754,"teacher_disagreement_score":0.47971624,"about_ca_system_score_codex":0.29012898,"about_ca_system_score_gemma":0.049961638,"threshold_uncertainty_score":0.9998838},"labels":[],"label_agreement":null},{"id":"W4378348239","doi":"10.1111/bjh.18879","title":"Real‐world management of small lymphocytic lymphoma as chronic lymphocytic leukaemia versus an indolent <scp>non‐Hodgkin</scp> lymphoma","year":2023,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Lymphoma; Classical Hodgkin lymphoma; Chronic lymphocytic leukemia; Hodgkin lymphoma; Medicine; Internal medicine; Oncology; Leukemia","score_opus":0.03610100405571235,"score_gpt":0.3133634652034648,"score_spread":0.27726246114775244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378348239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96232694,0.011830897,0.00008520553,0.0054042516,0.0061565833,0.002544808,0.00015644186,0.00031415414,0.011180699],"genre_scores_gemma":[0.5732708,0.17109779,0.009741577,0.1099042,0.036094904,0.0013456879,0.003975494,0.0059059607,0.088663585],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.98609763,0.0009977538,0.004501841,0.001783546,0.003470087,0.0031491267],"domain_scores_gemma":[0.98936707,0.002340478,0.0034486307,0.0022602794,0.001464616,0.0011189501],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002046639,0.0015259957,0.005495316,0.0027967487,0.00031525752,0.00026104582,0.0027755608,0.002494516,0.0002615393],"category_scores_gemma":[0.0008665537,0.0017241859,0.0016920336,0.0020236429,0.0013944244,0.00038666232,0.0011243032,0.002001305,0.00075951277],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009633709,0.00031292095,0.00003175441,0.0086604785,0.004191971,0.60050803,0.00025618364,0.00022998867,0.000047272955,0.00013535742,0.3593483,0.02531441],"study_design_scores_gemma":[0.1583389,0.0050240974,0.0010222489,0.020111637,0.004760893,0.61852694,0.00091836095,0.004067599,0.0021474345,0.00063167163,0.1833846,0.0010656173],"about_ca_topic_score_codex":0.009577777,"about_ca_topic_score_gemma":0.001245898,"teacher_disagreement_score":0.38905615,"about_ca_system_score_codex":0.1339341,"about_ca_system_score_gemma":0.07759452,"threshold_uncertainty_score":0.9997489},"labels":[],"label_agreement":null},{"id":"W4378839078","doi":"10.52768/2692-563x/1089","title":"In-Situ Follicular Neoplasia: A Case Series","year":2023,"lang":"en","type":"article","venue":"Journal on oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Hematopathology; Lymphocytosis; Pathology; Lymphoma; Follicular lymphoma; Monoclonal; Enteropathy; Biology; Medicine; Immunology; Disease; Monoclonal antibody; Cytogenetics","score_opus":0.03459191958114353,"score_gpt":0.37715836250928153,"score_spread":0.342566442928138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378839078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621756,0.00012292908,0.0000067061737,0.018467579,0.0006747463,0.0002109891,0.0000010316601,0.000042925927,0.018297512],"genre_scores_gemma":[0.98668844,0.0005920846,0.00025831905,0.0020783984,0.0008595467,0.000022609061,0.0000029737612,0.000030233878,0.009467421],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99842286,0.00015471128,0.00035640236,0.00018822987,0.00036021235,0.0005175817],"domain_scores_gemma":[0.9989918,0.00032087334,0.00008428637,0.00021505047,0.00009246596,0.00029554992],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008274404,0.00012224137,0.00040462753,0.0005156422,0.00009906565,0.000021395737,0.000096002404,0.00021148945,0.00030306797],"category_scores_gemma":[0.00045823975,0.00009444688,0.00011962282,0.00064067735,0.00008966278,0.0001133791,0.00007422506,0.0008103061,0.0011186596],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009585493,0.00019413543,0.00020789854,0.0000425364,0.000081472775,0.930977,0.0005658603,0.000091530084,0.003251594,0.0006779794,0.056782477,0.0061689955],"study_design_scores_gemma":[0.015498944,0.0030456434,0.00036369718,0.00006949873,0.000030808216,0.70794106,0.0006515551,0.00049367774,0.0011711743,0.00061865157,0.27002692,0.00008836521],"about_ca_topic_score_codex":0.00005512096,"about_ca_topic_score_gemma":0.0003486696,"teacher_disagreement_score":0.2230359,"about_ca_system_score_codex":0.013376478,"about_ca_system_score_gemma":0.0066726925,"threshold_uncertainty_score":0.99965906},"labels":[],"label_agreement":null},{"id":"W4379281889","doi":"10.1200/jco.2023.41.16_suppl.tps7582","title":"BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bruton's tyrosine kinase; Ibrutinib; Bendamustine; Chronic lymphocytic leukemia; Idelalisib; Rituximab; Medicine; Venetoclax; Internal medicine; Pharmacology; Oncology; Immunology; Leukemia; Lymphoma; Tyrosine kinase","score_opus":0.33510161085826223,"score_gpt":0.5299669314419019,"score_spread":0.19486532058363965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98886263,0.0018515001,0.000031927975,0.0005651716,0.0024625643,0.0051816637,0.000056663976,0.000097546974,0.00089030754],"genre_scores_gemma":[0.99351543,0.0020044765,0.00117897,0.00048022025,0.0014973859,0.00021740889,0.0000559161,0.00019144815,0.0008587403],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97678256,0.0047413786,0.012939738,0.0013377137,0.0025163407,0.0016822603],"domain_scores_gemma":[0.9563737,0.03096801,0.0070737083,0.0015729996,0.0020582736,0.001953296],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018579543,0.0009833918,0.0123415645,0.0018482478,0.00015007553,0.000077250654,0.0022303094,0.0015233901,0.0002988411],"category_scores_gemma":[0.085416645,0.0007390899,0.0010451518,0.0038262089,0.0022640303,0.0005538252,0.0015354563,0.001786139,0.000110675384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9276685,0.020656977,0.00031105473,0.0015178109,0.0041225534,0.012551383,0.0017408403,0.00358075,0.0008991203,0.0000766561,0.0061983173,0.020676041],"study_design_scores_gemma":[0.80504394,0.054208957,0.00030580745,0.0016813949,0.0024076777,0.00077588274,0.0010953312,0.13165294,0.00093529484,0.00007416449,0.0013244206,0.0004941832],"about_ca_topic_score_codex":0.01230086,"about_ca_topic_score_gemma":0.0039058912,"teacher_disagreement_score":0.2506033,"about_ca_system_score_codex":0.1453475,"about_ca_system_score_gemma":0.3959508,"threshold_uncertainty_score":0.99977285},"labels":[],"label_agreement":null},{"id":"W4379333780","doi":"10.1200/jco.2023.41.16_suppl.tps7590","title":"MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"BeiGene","keywords":"Medicine; Obinutuzumab; Lenalidomide; Rituximab; Internal medicine; Ibrutinib; Oncology; Idelalisib; Follicular lymphoma; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Gastroenterology; Lymphoma; Leukemia; Multiple myeloma; Tyrosine kinase","score_opus":0.11818073334886847,"score_gpt":0.4680301710243539,"score_spread":0.34984943767548543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379333780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529815,0.0001548556,0.00007066557,0.0015892345,0.0012898067,0.0011987437,0.000025266334,0.000031845215,0.0003414083],"genre_scores_gemma":[0.9939958,0.0012659932,0.0016576012,0.0004826616,0.0010508791,0.000016804612,0.000031165222,0.00006992921,0.0014291579],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910991,0.0011325758,0.004633226,0.00051148277,0.0018049406,0.00081863574],"domain_scores_gemma":[0.98864585,0.0062884395,0.0028378987,0.0005954256,0.0009833033,0.0006490965],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0068680034,0.00036808953,0.0043648873,0.000791115,0.00007053538,0.000019321202,0.0004993326,0.0007660447,0.00031757946],"category_scores_gemma":[0.014463886,0.00021596016,0.00064719573,0.0011009914,0.00079996313,0.00025433983,0.00022970646,0.0012566576,0.000065953885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9301945,0.013890411,0.0043297797,0.00029723716,0.0009279969,0.01764075,0.00025734806,0.000056277713,0.000070611524,0.00001675449,0.0053230296,0.026995294],"study_design_scores_gemma":[0.864,0.0898437,0.022847356,0.00079427805,0.0005427056,0.0005364217,0.0002554998,0.0018621061,0.00011031581,0.000022659584,0.018953525,0.00023142784],"about_ca_topic_score_codex":0.00023317117,"about_ca_topic_score_gemma":0.00014126011,"teacher_disagreement_score":0.07595329,"about_ca_system_score_codex":0.0069065588,"about_ca_system_score_gemma":0.055417124,"threshold_uncertainty_score":0.99690574},"labels":[],"label_agreement":null},{"id":"W4379510832","doi":"10.1136/annrheumdis-2023-eular.2670","title":"POS0827 CLINICAL OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO DISCONTINUED TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM ORAL SURVEILLANCE","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Western University","funders":"","keywords":"Medicine; Tofacitinib; Rheumatoid arthritis; Janus kinase inhibitor; Internal medicine; Adverse effect","score_opus":0.06375875872143158,"score_gpt":0.3549152026700373,"score_spread":0.29115644394860574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379510832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974925,0.0002627121,0.0000025669428,0.0013361516,0.00022079682,0.0009205755,0.0073615382,0.00008855097,0.000057851066],"genre_scores_gemma":[0.99706614,0.0016589528,0.000057465277,0.00014086135,0.00003175436,0.000034165947,0.00044389084,0.000054754393,0.0005120094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955742,0.00035675068,0.0016546004,0.0004948611,0.0013626692,0.00055696105],"domain_scores_gemma":[0.994432,0.002780582,0.00080084807,0.0011318837,0.00050077017,0.00035395153],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0005599052,0.00033165602,0.0014557062,0.00013540943,0.000092070695,0.000044865057,0.0005020135,0.00010927758,0.00017806981],"category_scores_gemma":[0.009421799,0.00018111986,0.0005380362,0.00066048815,0.00059568434,0.00018186969,0.00034807294,0.00018812931,0.000045581543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053682514,0.00092544034,0.9489777,0.00032044633,0.00092241314,0.000023976683,0.00056379894,0.000015389407,0.000007744956,0.000010596078,0.019466748,0.0233975],"study_design_scores_gemma":[0.020989176,0.00044161125,0.97381854,0.003119707,0.000043320968,0.0000016778671,0.00020962518,0.00029730736,0.00052822987,0.00014584554,0.00018757052,0.0002173797],"about_ca_topic_score_codex":0.001655834,"about_ca_topic_score_gemma":0.0002793945,"teacher_disagreement_score":0.024840852,"about_ca_system_score_codex":0.0001727901,"about_ca_system_score_gemma":0.0019632194,"threshold_uncertainty_score":0.9989223},"labels":[],"label_agreement":null},{"id":"W4379649237","doi":"10.1136/annrheumdis-2023-eular.3273","title":"POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Celgene; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Joint (building); Intensive care medicine","score_opus":0.06387673655282537,"score_gpt":0.3239866740049901,"score_spread":0.2601099374521647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379649237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686676,0.0009619785,5.8865726e-7,0.00084553624,0.000020111302,0.0011745082,0.00006163094,0.000009126012,0.000059749644],"genre_scores_gemma":[0.99832827,0.001409651,0.000015583171,0.000103946164,0.0000061806118,0.000044594537,0.000032897857,0.00001316113,0.00004569021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983746,0.00013111053,0.0004360765,0.00015928324,0.0006819431,0.00021702042],"domain_scores_gemma":[0.99824053,0.00061553245,0.00023454492,0.00061002304,0.00022398186,0.000075404845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017873054,0.0001367545,0.0004472486,0.00014800027,0.000032204076,0.000006082589,0.00015383391,0.000026469956,0.000019934143],"category_scores_gemma":[0.00049818127,0.00006264729,0.00013459519,0.0004870285,0.00029789173,0.000033210872,0.000071576214,0.000038316295,0.0000030002611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01847641,0.048577737,0.51352334,0.015604582,0.0072930697,0.00020917454,0.080846876,0.001965227,0.00045514386,0.0012833657,0.019678041,0.29208702],"study_design_scores_gemma":[0.01585813,0.0021169262,0.9750707,0.0018105396,0.0002256244,0.0000029077653,0.0014974731,0.0010728075,0.0019309204,0.00030579968,0.000034104272,0.000074033385],"about_ca_topic_score_codex":0.0005313571,"about_ca_topic_score_gemma":0.000019684487,"teacher_disagreement_score":0.46154737,"about_ca_system_score_codex":0.00025494,"about_ca_system_score_gemma":0.00070087047,"threshold_uncertainty_score":0.25546825},"labels":[],"label_agreement":null},{"id":"W4379650133","doi":"10.1136/annrheumdis-2023-eular.1316","title":"AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES","year":2023,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"UCB Pharma; Nordic Pharma Group; Celgene; Gilead Sciences; Sanofi; Galápagos; Amgen; Pfizer; Eli Lilly and Company; Biogen; GlaxoSmithKline","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Placebo; Internal medicine; Methotrexate; Visual analogue scale; Arthritis; Gastroenterology; Physical therapy; Pathology","score_opus":0.017419717565339166,"score_gpt":0.33356259452165365,"score_spread":0.3161428769563145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379650133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979352,0.00038198766,0.0000013015797,0.00027215495,0.0000142296085,0.0008795478,0.0000056548133,0.000020425034,0.0004895049],"genre_scores_gemma":[0.998928,0.00070156937,0.000018175708,0.00010940576,0.000008324383,0.0000822924,0.000020741449,0.000012090244,0.00011936262],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985679,0.00028223984,0.00023843406,0.00020043868,0.00045323424,0.00025774643],"domain_scores_gemma":[0.9978978,0.0017625095,0.00003423633,0.00022400373,0.000041931118,0.000039514052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019432071,0.00011718644,0.00036700087,0.00020397184,0.000024323583,0.000006742465,0.000071063325,0.000040195544,0.000032822707],"category_scores_gemma":[0.0009894855,0.000059458507,0.000022660059,0.00056221086,0.00013296152,0.000030271363,0.000052142717,0.00015279198,0.000017399654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0091611445,0.0016013855,0.45283884,0.0017378955,0.00026338783,0.00091357366,0.009456606,0.000048218822,0.00010130672,0.00027038428,0.016220285,0.507387],"study_design_scores_gemma":[0.6081838,0.061060242,0.29843852,0.008697863,0.00003198375,0.000053988017,0.0052619833,0.009924588,0.0053502,0.00015842578,0.002293672,0.0005447333],"about_ca_topic_score_codex":0.00027889144,"about_ca_topic_score_gemma":0.00030808034,"teacher_disagreement_score":0.5990227,"about_ca_system_score_codex":0.0006884019,"about_ca_system_score_gemma":0.00031107356,"threshold_uncertainty_score":0.24246477},"labels":[],"label_agreement":null},{"id":"W4379979709","doi":"10.1002/hon.3164_421","title":"A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Mantle cell lymphoma; Internal medicine; Follicular lymphoma; Gastroenterology; Lymphoma; Phases of clinical research; Marginal zone B-cell lymphoma; Oncology; Clinical trial; Immunology; B cell; Marginal zone","score_opus":0.06263963328599681,"score_gpt":0.38228564150884176,"score_spread":0.31964600822284495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942682,0.00004913232,0.0000045519573,0.0002639465,0.00017273572,0.0043742927,0.000019170895,0.00010918218,0.00073880743],"genre_scores_gemma":[0.99750173,0.000030451936,0.0005966023,0.00036667095,0.00003429229,0.00045618822,0.0000938793,0.00006193215,0.00085825747],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954572,0.0005226826,0.0011891356,0.0009740043,0.00083689747,0.0010201184],"domain_scores_gemma":[0.9972999,0.0007751361,0.0003832319,0.00083229144,0.00031592292,0.00039352337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007526882,0.0004293838,0.0017253418,0.00044418423,0.00013319566,0.000022798948,0.00060636614,0.0005180453,0.00032649405],"category_scores_gemma":[0.0007939916,0.00026862847,0.00008088095,0.0012271827,0.00036561931,0.00018489474,0.0011898794,0.00049967546,0.00018687302],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19745837,0.5212998,0.16178615,0.0013302078,0.0007980735,0.04393779,0.014657396,0.000021374317,0.006174878,0.00007248274,0.015610277,0.036853194],"study_design_scores_gemma":[0.7287088,0.2215531,0.035703428,0.00040803352,0.00024551837,0.000196538,0.005637924,0.0025687583,0.002695527,0.00003784777,0.0016673822,0.00057715806],"about_ca_topic_score_codex":0.0010226219,"about_ca_topic_score_gemma":0.00077569496,"teacher_disagreement_score":0.5312504,"about_ca_system_score_codex":0.0052177715,"about_ca_system_score_gemma":0.0041579213,"threshold_uncertainty_score":0.9999766},"labels":[],"label_agreement":null},{"id":"W4379981083","doi":"10.1002/hon.3163_t04","title":"MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pharmacyclics; Seagen; BeiGene; Celgene; Gilead Sciences","keywords":"Obinutuzumab; Medicine; Lenalidomide; Rituximab; Ibrutinib; Internal medicine; Idelalisib; Oncology; Bruton's tyrosine kinase; Follicular lymphoma; Salvage therapy; Chronic lymphocytic leukemia; Lymphoma; Chemotherapy; Leukemia; Multiple myeloma; Tyrosine kinase","score_opus":0.060030952773189254,"score_gpt":0.3721584572127411,"score_spread":0.31212750443955184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469626,0.00013464042,0.000072695184,0.00059088075,0.000502311,0.002283371,0.000029570103,0.00017150486,0.0015187537],"genre_scores_gemma":[0.9978745,0.00012857036,0.00071948115,0.00016572412,0.0001329568,0.00023732969,0.00017045063,0.000055841723,0.00051517674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953195,0.00047013166,0.0011397178,0.0008333605,0.001101025,0.0011362802],"domain_scores_gemma":[0.9961687,0.0020718768,0.00039728437,0.0006986604,0.0002503235,0.00041319773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089700945,0.0004231625,0.002269369,0.00050589285,0.000089144356,0.000014255745,0.00037615965,0.00074432587,0.0006279781],"category_scores_gemma":[0.0019638834,0.00027622466,0.000243235,0.0013494703,0.0007205462,0.000108560096,0.0003217065,0.0005197274,0.00033427155],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.95803696,0.011298862,0.0009635369,0.00045405686,0.00035143163,0.018955072,0.00028404678,0.000036920395,0.00014587009,0.0006883056,0.0025281094,0.006256833],"study_design_scores_gemma":[0.95287657,0.030966528,0.0018509361,0.00022723794,0.0002034145,0.0004780636,0.0003059432,0.0029569785,0.00047308346,0.000039215458,0.009292231,0.00032981174],"about_ca_topic_score_codex":0.0002511591,"about_ca_topic_score_gemma":0.000083006475,"teacher_disagreement_score":0.019667665,"about_ca_system_score_codex":0.010297499,"about_ca_system_score_gemma":0.0112047,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W4379981345","doi":"10.1002/hon.3166_ot29","title":"LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH <i>R</i>/<i>R</i> DLBCL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Oncology; Clinical endpoint; Diffuse large B-cell lymphoma; Phases of clinical research; Refractory (planetary science); Neutropenia; Randomized controlled trial; Lymphoma; Clinical trial; Chemotherapy","score_opus":0.03914161227868253,"score_gpt":0.3791918403689819,"score_spread":0.3400502280902994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940351,0.00009857607,0.000050041188,0.00030460107,0.000091305265,0.0038800482,0.0000066855814,0.00019583505,0.0013377571],"genre_scores_gemma":[0.99817616,0.000046772926,0.00095614954,0.00017879964,0.0000392743,0.0003676186,0.0000910994,0.000066651344,0.00007746627],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957374,0.00064937834,0.0010107325,0.00078733574,0.00092755805,0.0008876062],"domain_scores_gemma":[0.9963421,0.0019194073,0.00034853868,0.00076921866,0.00033886175,0.0002818438],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012083653,0.0004233327,0.0027932292,0.00042708265,0.00008667716,0.000016881371,0.00033702876,0.00029455643,0.00017351174],"category_scores_gemma":[0.0005469237,0.0002568479,0.00012814265,0.0013820338,0.0007498452,0.00013991253,0.00017250459,0.0005736089,0.000065988934],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8841598,0.06042957,0.043179102,0.0002676148,0.00075487985,0.00422776,0.0018689366,0.000053088574,0.00020126312,0.00022658051,0.00020688352,0.004424513],"study_design_scores_gemma":[0.9447171,0.04568636,0.0045504584,0.00013771933,0.00021068199,0.00021606521,0.0011973451,0.0022392604,0.0005116639,0.000031532978,0.0002141479,0.00028765886],"about_ca_topic_score_codex":0.00033209843,"about_ca_topic_score_gemma":0.00021835243,"teacher_disagreement_score":0.0605573,"about_ca_system_score_codex":0.0025629953,"about_ca_system_score_gemma":0.0020506433,"threshold_uncertainty_score":0.9999884},"labels":[],"label_agreement":null},{"id":"W4379981441","doi":"10.1002/hon.3164_163","title":"Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Ibrutinib; Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Medicine; Oncology; Progression-free survival; Fludarabine; Cancer research; Internal medicine; Immunology; Leukemia; Tyrosine kinase; Chemotherapy; Receptor","score_opus":0.07190435046110251,"score_gpt":0.3793572972091509,"score_spread":0.3074529467480484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956609,0.00012691198,0.0001620867,0.00032186395,0.00025517528,0.0021509915,0.00006239347,0.00010717323,0.0011524891],"genre_scores_gemma":[0.9979243,0.00026973907,0.0008744081,0.00006243572,0.00008508173,0.00022013858,0.00023308124,0.000035924342,0.00029484395],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958551,0.00045883266,0.001635102,0.00065243134,0.0006632566,0.00073527626],"domain_scores_gemma":[0.9962825,0.0019170382,0.0006500326,0.0006678349,0.0002353978,0.000247173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089331844,0.00029262557,0.0021163132,0.00046320874,0.000030290517,0.0000043603195,0.0003632855,0.00059262547,0.0002461031],"category_scores_gemma":[0.0020735927,0.00024396369,0.00022633065,0.0018670652,0.0004720844,0.000053230826,0.00024875085,0.00030645906,0.00009708157],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.40540126,0.0011123344,0.000511066,0.001911802,0.00037760285,0.0013273876,0.0012672541,0.00012457267,0.57386273,0.008587789,0.000322228,0.0051939697],"study_design_scores_gemma":[0.5993744,0.02828207,0.008945332,0.0019690953,0.00034656722,0.00008899782,0.00032038524,0.009544925,0.34700018,0.001891481,0.001709234,0.00052733143],"about_ca_topic_score_codex":0.0014649212,"about_ca_topic_score_gemma":0.0014612613,"teacher_disagreement_score":0.22686256,"about_ca_system_score_codex":0.025728319,"about_ca_system_score_gemma":0.016444018,"threshold_uncertainty_score":0.99485505},"labels":[],"label_agreement":null},{"id":"W4379981642","doi":"10.1002/hon.3164_313","title":"Final analysis of Australasian Leukaemia &amp; Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"Cilag","keywords":"Medicine; Ibrutinib; Rituximab; Vincristine; Internal medicine; Diffuse large B-cell lymphoma; International Prognostic Index; Prednisone; CHOP; Lymphoma; Cyclophosphamide; Gastroenterology; Surgery; Oncology; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.05034906859150347,"score_gpt":0.3679076374841846,"score_spread":0.31755856889268114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817157,0.00006680484,0.000013677225,0.00019421363,0.00003645939,0.0011115022,0.00002836897,0.00005743736,0.00031999766],"genre_scores_gemma":[0.9990732,0.00003984289,0.00046402946,0.00006140327,0.00001635996,0.000114291586,0.00012484545,0.000021353215,0.000084639876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966992,0.0003228267,0.0009999415,0.0006727994,0.00065453036,0.00065067376],"domain_scores_gemma":[0.9974375,0.0013217877,0.000329662,0.00046207782,0.00017251911,0.0002764871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053130183,0.00029080623,0.0020242208,0.00093030883,0.00007680364,0.000008454299,0.00023624266,0.000395153,0.0002264716],"category_scores_gemma":[0.0007431373,0.00021152486,0.0001615979,0.0026334706,0.00054096774,0.00007385787,0.00029429462,0.00027885457,0.000016550432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019560939,0.08811328,0.83789426,0.00069679774,0.0027388462,0.0075617563,0.0059603313,0.00008991172,0.00046732574,0.00032493373,0.0014102324,0.035181392],"study_design_scores_gemma":[0.3012385,0.044964842,0.64677775,0.00015788373,0.0014878658,0.00019942559,0.0023780088,0.0018299067,0.00008313477,0.00006172665,0.00052499125,0.0002959655],"about_ca_topic_score_codex":0.0008535521,"about_ca_topic_score_gemma":0.0016964861,"teacher_disagreement_score":0.28167757,"about_ca_system_score_codex":0.0018017917,"about_ca_system_score_gemma":0.0013535655,"threshold_uncertainty_score":0.8625734},"labels":[],"label_agreement":null},{"id":"W4379981780","doi":"10.1002/hon.3164_282","title":"Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada); Precision Nanosystems (Canada)","funders":"BeiGene","keywords":"Medicine; Internal medicine; Progression-free survival; Logistic regression; Percentile; Hazard ratio; Oncology; Urology; Gastroenterology; Overall survival; Confidence interval; Statistics; Mathematics","score_opus":0.10490629633047638,"score_gpt":0.3881888356474517,"score_spread":0.28328253931697533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97779214,0.000643915,0.000037474,0.0010517967,0.00071508565,0.00092811795,0.000017304761,0.00039284248,0.018421339],"genre_scores_gemma":[0.99698097,0.0002885218,0.0012173756,0.00022451917,0.00013797104,0.00013212582,0.00013834023,0.000060158833,0.000820026],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945177,0.00067512674,0.0015553657,0.00090538245,0.0009560223,0.0013904388],"domain_scores_gemma":[0.99394196,0.004166191,0.00048131467,0.0007725154,0.00017773849,0.00046030685],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014796344,0.00045929046,0.00237513,0.000779623,0.000109772336,0.000015481235,0.0005267454,0.0011165299,0.00092182367],"category_scores_gemma":[0.001437147,0.00038191237,0.00030526513,0.0018870966,0.0008020591,0.00007652585,0.00055443356,0.0008981963,0.0010659948],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2005523,0.037691906,0.22638164,0.008315536,0.003308677,0.10611455,0.021354426,0.0011313647,0.037156668,0.05693305,0.11037422,0.19068566],"study_design_scores_gemma":[0.4636408,0.032703735,0.2849321,0.0020213919,0.0007309947,0.009470283,0.014484909,0.024401842,0.02678456,0.0037829736,0.1342718,0.002774583],"about_ca_topic_score_codex":0.0006577408,"about_ca_topic_score_gemma":0.00031018164,"teacher_disagreement_score":0.26308852,"about_ca_system_score_codex":0.0070715714,"about_ca_system_score_gemma":0.005298819,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W4379981910","doi":"10.1002/hon.3164_340","title":"Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Pharmacyclics","keywords":"Medicine; Ibrutinib; Adverse effect; Internal medicine; Ven; Chronic lymphocytic leukemia; Oncology; Venetoclax; Gastroenterology; Leukemia","score_opus":0.14501260973266877,"score_gpt":0.46213556874558415,"score_spread":0.3171229590129154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583584,0.00010031193,0.0002342391,0.00008665482,0.00014959207,0.003087101,0.000055302877,0.000056980134,0.0003939823],"genre_scores_gemma":[0.9977347,0.00022967542,0.0009909765,0.00003482552,0.000040563762,0.0004506334,0.00032401178,0.000023232664,0.000171382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99450916,0.0010124642,0.002546451,0.00066296314,0.0006852883,0.0005836906],"domain_scores_gemma":[0.9942374,0.0036103118,0.000959128,0.00066799385,0.0003135838,0.0002115874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053353207,0.00023801616,0.0033722497,0.00068541325,0.000034261444,0.0000017516162,0.00027158498,0.00054636924,0.00008042207],"category_scores_gemma":[0.0016250287,0.00016570206,0.000807375,0.002243077,0.0003125176,0.000054683314,0.00018164917,0.0002359677,0.00003807992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.062339935,0.0032433255,0.8505797,0.0045914324,0.02505736,0.00050673157,0.00047959446,0.013575083,0.00028490086,0.0067856084,0.00089670834,0.031659644],"study_design_scores_gemma":[0.07983777,0.0054795053,0.8612122,0.00027007484,0.0058319797,0.0000039861875,0.00015618402,0.046341978,0.00024662196,0.0001879599,0.00022588186,0.0002058403],"about_ca_topic_score_codex":0.00020892882,"about_ca_topic_score_gemma":0.00002598246,"teacher_disagreement_score":0.032766894,"about_ca_system_score_codex":0.016806573,"about_ca_system_score_gemma":0.008562119,"threshold_uncertainty_score":0.9970584},"labels":[],"label_agreement":null},{"id":"W4379981977","doi":"10.1002/hon.3164_288","title":"Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Canadian Red Cross Society; Health Canada; Baker Hughes (Canada); Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Sunnybrook Health Science Centre; Agricultural Research Institute of Ontario; Health Sciences North; Juravinski Cancer Centre; McGill University Health Centre","funders":"","keywords":"Bendamustine; Medicine; Rituximab; Adverse effect; Internal medicine; Waldenstrom macroglobulinemia; Lymphoplasmacytic Lymphoma; Clinical trial; Ibrutinib; Oncology; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.0431760209306247,"score_gpt":0.37044516589517396,"score_spread":0.3272691449645493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854445,0.0005391562,0.00001845324,0.0060395077,0.00017346554,0.00065820507,0.000009682878,0.00028860103,0.0068284366],"genre_scores_gemma":[0.9962827,0.0005226288,0.0012311368,0.0009458559,0.00013334132,0.00013188286,0.000055268974,0.000029796825,0.00066739693],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99696124,0.0001882982,0.0006787502,0.0007143697,0.00043632888,0.0010210393],"domain_scores_gemma":[0.99805546,0.00096947193,0.000101006495,0.0003745177,0.000086301734,0.00041326202],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067589997,0.00027846312,0.001097292,0.00032116714,0.0000807329,0.000018445686,0.00020464777,0.00066387444,0.0004257025],"category_scores_gemma":[0.0012475285,0.00021310341,0.000107306754,0.00091395114,0.0005818492,0.000049153932,0.00052802655,0.00048419385,0.0008618136],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011968436,0.013278739,0.15188324,0.00431562,0.0005964723,0.22859183,0.0032398703,0.000087076856,0.0126436185,0.048231915,0.11486952,0.41029367],"study_design_scores_gemma":[0.37406024,0.009288019,0.2683598,0.0010763776,0.0003391983,0.081666045,0.0030426485,0.06714571,0.007978176,0.007697293,0.17736062,0.001985848],"about_ca_topic_score_codex":0.00013597179,"about_ca_topic_score_gemma":0.0000702966,"teacher_disagreement_score":0.40830782,"about_ca_system_score_codex":0.004131575,"about_ca_system_score_gemma":0.0025276851,"threshold_uncertainty_score":0.99991614},"labels":[],"label_agreement":null},{"id":"W4380077901","doi":"10.1002/hon.3166_ot11","title":"A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B‐CELL MALIGNANCIES","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Gilead Sciences","keywords":"Lymphoma; Mantle cell lymphoma; Cancer research; Medicine; Aggressive lymphoma; Follicular lymphoma; B cell; Chronic lymphocytic leukemia; B-cell lymphoma; Internal medicine; Oncology; Rituximab; Immunology; Leukemia; Antibody","score_opus":0.042266537325065905,"score_gpt":0.36924586721374025,"score_spread":0.32697932988867434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380077901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957129,0.00015935097,0.000009645383,0.00029288503,0.00007161519,0.0025811526,0.0000047422236,0.00017278339,0.0009949631],"genre_scores_gemma":[0.9984281,0.000027442953,0.0005670477,0.00019607638,0.000045342753,0.00040945254,0.000030874442,0.00003578295,0.00025985794],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964683,0.00058470696,0.0005862308,0.0007734244,0.00076281367,0.0008245432],"domain_scores_gemma":[0.9978083,0.0010663181,0.00017713645,0.0002961073,0.00038883946,0.0002632924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001040219,0.00029816042,0.0009605106,0.00035008782,0.0001255155,0.00001843486,0.00012895775,0.0003191685,0.000042633135],"category_scores_gemma":[0.0012604366,0.00020139769,0.000051208386,0.0013521351,0.00026377532,0.00008591671,0.00024570854,0.0006719599,0.0000908241],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039003007,0.070655055,0.8145734,0.001267271,0.0006286891,0.019568335,0.0133746965,0.00011437826,0.0089581115,0.0003058232,0.0069571594,0.024594046],"study_design_scores_gemma":[0.43219036,0.283436,0.26213235,0.00049751456,0.0004265112,0.0009748749,0.004720191,0.009573971,0.0038799709,0.00037346722,0.00083026174,0.00096452323],"about_ca_topic_score_codex":0.000114532064,"about_ca_topic_score_gemma":0.00007759539,"teacher_disagreement_score":0.55244106,"about_ca_system_score_codex":0.005514096,"about_ca_system_score_gemma":0.0043606977,"threshold_uncertainty_score":0.99830353},"labels":[],"label_agreement":null},{"id":"W4380078158","doi":"10.1002/hon.3163_156","title":"MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (<i>R</i>/<i>R</i> CLL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"F. Hoffmann-La Roche; AstraZeneca","keywords":"Medicine; Bendamustine; Internal medicine; Hazard ratio; Rituximab; Regimen; Confidence interval; Gastroenterology; Chronic lymphocytic leukemia; Refractory (planetary science); Progression-free survival; Surgery; Leukemia; Overall survival; Lymphoma","score_opus":0.02797735490506649,"score_gpt":0.3028320781248924,"score_spread":0.2748547232198259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565154,0.00064369716,0.000014559644,0.00017444028,0.00010773859,0.0011554806,0.000022346247,0.00026237252,0.00196782],"genre_scores_gemma":[0.99694395,0.00059206143,0.000290219,0.00021959831,0.000057094418,0.00026408688,0.00034014945,0.000053116866,0.0012396956],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99598116,0.00032147425,0.0007534437,0.001060484,0.0007302299,0.0011532162],"domain_scores_gemma":[0.9976374,0.00084368757,0.00021276523,0.00069120724,0.00016750299,0.0004474323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045262376,0.00046674735,0.0017516734,0.0007521007,0.0001349923,0.000027913698,0.00023350885,0.00068304135,0.000383272],"category_scores_gemma":[0.0003486405,0.00033250437,0.00025160148,0.0026871,0.0005240365,0.000102544676,0.0002542187,0.0005848267,0.0004933639],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02877677,0.0024901915,0.8966483,0.001517633,0.005464876,0.034377623,0.0016074348,0.003615802,0.00065926794,0.001296152,0.008556133,0.014989832],"study_design_scores_gemma":[0.43691173,0.026243323,0.42413822,0.00078230863,0.004118952,0.0016180305,0.0005617465,0.08526765,0.0011006484,0.0004828328,0.01708753,0.0016870182],"about_ca_topic_score_codex":0.00092419126,"about_ca_topic_score_gemma":0.0007140556,"teacher_disagreement_score":0.47251007,"about_ca_system_score_codex":0.10039052,"about_ca_system_score_gemma":0.014617342,"threshold_uncertainty_score":0.9999127},"labels":[],"label_agreement":null},{"id":"W4380078645","doi":"10.1002/hon.3164_355","title":"Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle Trial","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; University Health Network; University of Toronto; Dalhousie University; Sunnybrook Health Science Centre; Hôpital de l'Enfant-Jésus; BC Cancer Agency; Centre hospitalier universitaire de Québec; McMaster University; Spinal Cord Injury BC","funders":"AstraZeneca","keywords":"Mantle cell lymphoma; Ibrutinib; Medicine; Rituximab; Internal medicine; Autologous stem-cell transplantation; Oncology; Transplantation; Diffuse large B-cell lymphoma; Surgery; Chemotherapy; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02952925078592086,"score_gpt":0.31925459144591384,"score_spread":0.289725340659993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742956,0.00013833365,0.000068814705,0.0062549757,0.000107298925,0.0022315287,0.000005284443,0.00016144091,0.0036027639],"genre_scores_gemma":[0.99664193,0.0003185571,0.00064875494,0.0010240272,0.000051103696,0.00033805025,0.000018667566,0.000028754235,0.0009301586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978178,0.0002944479,0.0004366514,0.00050509954,0.00033284392,0.00061313924],"domain_scores_gemma":[0.9980018,0.0013550295,0.0000918183,0.00030085078,0.000052630843,0.00019783023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006670417,0.00021650307,0.00080241676,0.00016156919,0.00010606263,0.000018448698,0.00019363425,0.00037293177,0.00008387922],"category_scores_gemma":[0.0000564369,0.00012409374,0.00006198847,0.0007160342,0.0002571563,0.00003241085,0.00007203943,0.00027374932,0.000219953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7653899,0.013977794,0.0043497076,0.0026874612,0.00021943184,0.033815138,0.014390511,0.00006428974,0.009261759,0.002951464,0.014218411,0.13867414],"study_design_scores_gemma":[0.91742516,0.025412265,0.010400384,0.00016315505,0.0001541688,0.0045562913,0.0018993248,0.003588898,0.021688767,0.00035979683,0.013838701,0.00051308225],"about_ca_topic_score_codex":0.00007369843,"about_ca_topic_score_gemma":0.00010353176,"teacher_disagreement_score":0.15203527,"about_ca_system_score_codex":0.0017438686,"about_ca_system_score_gemma":0.0016379697,"threshold_uncertainty_score":0.50603956},"labels":[],"label_agreement":null},{"id":"W4380078977","doi":"10.1002/hon.3164_442","title":"First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada; BeiGene; Regeneron Pharmaceuticals","keywords":"Medicine; Lenalidomide; Internal medicine; Refractory (planetary science); Interim analysis; Diffuse large B-cell lymphoma; Oncology; Lymphoma; Gastroenterology; Clinical trial; Multiple myeloma","score_opus":0.038378589875354925,"score_gpt":0.35861039738261186,"score_spread":0.32023180750725694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751866,0.00008380106,0.00003026107,0.00009602762,0.00007188619,0.0012560014,0.000040771625,0.00007617032,0.00082644494],"genre_scores_gemma":[0.9992849,0.000060020007,0.00011038025,0.00009832278,0.000015296588,0.00013555013,0.00011605989,0.000031339885,0.00014808764],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960942,0.00042511645,0.00127775,0.00067833834,0.00077525,0.000749335],"domain_scores_gemma":[0.9965767,0.0015914615,0.00051756453,0.0007770901,0.0002778347,0.0002593256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008096568,0.0003120841,0.0022309937,0.0011690882,0.000055898607,0.0000058280066,0.0003536483,0.00038532677,0.00034338766],"category_scores_gemma":[0.00086101517,0.00021504317,0.00026058275,0.0029242889,0.0003473901,0.0000696188,0.00040363308,0.00032118638,0.000054046774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03080152,0.31751782,0.63322204,0.0008362054,0.0026641493,0.0048780716,0.0066508525,0.00007357283,0.0003367969,0.00024887754,0.0010772547,0.0016928613],"study_design_scores_gemma":[0.66048783,0.038014065,0.2828973,0.00024879377,0.0017631712,0.000059159614,0.004646663,0.009063674,0.0008062734,0.000040145347,0.0015491165,0.00042382194],"about_ca_topic_score_codex":0.0003468751,"about_ca_topic_score_gemma":0.0006450253,"teacher_disagreement_score":0.6296863,"about_ca_system_score_codex":0.0030262813,"about_ca_system_score_gemma":0.0014989062,"threshold_uncertainty_score":0.8769206},"labels":[],"label_agreement":null},{"id":"W4380078993","doi":"10.1002/hon.3163_80","title":"SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Calvary Mater Newcastle; National Institutes of Health; Masarykova Univerzita; Barts Health NHS Trust; BeiGene; Institut Bergonié; Tianjin Medical University; Peking University; Università degli Studi dell'Insubria; Jewish General Hospital; Harbin Medical University","keywords":"Medicine; Rituximab; Follicular lymphoma; Ibrutinib; Internal medicine; Hazard ratio; Ofatumumab; Randomized controlled trial; Clinical endpoint; Lymphoma; Placebo; Randomization; International Prognostic Index; Surgery; Oncology; Gastroenterology; Confidence interval; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.0345031175598008,"score_gpt":0.35621661827911133,"score_spread":0.32171350071931054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908166,0.00010728766,0.00016893377,0.00031921058,0.00006674043,0.007893152,0.00001553571,0.000086585635,0.00052594487],"genre_scores_gemma":[0.99522173,0.00017648395,0.0028967694,0.00012017528,0.000025543266,0.0012417401,0.00010335763,0.000040578525,0.00017364165],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99699295,0.00037038632,0.0009896007,0.0004844012,0.00055820757,0.00060447236],"domain_scores_gemma":[0.99528664,0.0033025532,0.0004508183,0.00041037778,0.00039572918,0.00015385979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087636226,0.00029322229,0.0031969887,0.00029858196,0.000037318285,0.0000044706244,0.00019479872,0.00039076104,0.000102830105],"category_scores_gemma":[0.0015719476,0.0001440535,0.00021706178,0.001008708,0.0007598033,0.000048260106,0.00006516047,0.0001439243,0.0000085152815],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98617876,0.003479441,0.0037878132,0.00025656977,0.0003538509,0.00030106746,0.00022759492,0.00002678841,0.00022365162,0.0003112816,0.000102973136,0.0047501847],"study_design_scores_gemma":[0.96982974,0.02197678,0.0006050596,0.00025104402,0.00013879818,0.00010355797,0.00016828359,0.0024461306,0.0036658968,0.00016418676,0.00047962554,0.00017090555],"about_ca_topic_score_codex":0.000113582275,"about_ca_topic_score_gemma":0.00006738181,"teacher_disagreement_score":0.018497339,"about_ca_system_score_codex":0.0013254683,"about_ca_system_score_gemma":0.003860492,"threshold_uncertainty_score":0.6848347},"labels":[],"label_agreement":null},{"id":"W4380080925","doi":"10.1002/hon.3163_81","title":"ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Seoul National University; Seoul National University Hospital; Institut National de la Santé et de la Recherche Médicale; Regeneron Pharmaceuticals; Cleveland Clinic","keywords":"Medicine; Obinutuzumab; Internal medicine; Follicular lymphoma; Rituximab; Refractory (planetary science); Oncology; International Prognostic Index; Clinical endpoint; Progression-free survival; Neutropenia; Salvage therapy; Gastroenterology; Surgery; Chemotherapy; Lymphoma; Randomized controlled trial","score_opus":0.032784762104367975,"score_gpt":0.3275913327918503,"score_spread":0.29480657068748234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380080925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957247,0.00006775901,0.000004468891,0.000152598,0.00026646702,0.0018489971,0.000019466239,0.00014058196,0.001774958],"genre_scores_gemma":[0.9991407,0.000016895565,0.00006760727,0.00011810605,0.000022812319,0.00016773904,0.00016748205,0.00003517935,0.00026351106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562573,0.00065045,0.0009490278,0.0007934068,0.0011349259,0.00084648345],"domain_scores_gemma":[0.99687696,0.001093564,0.00036094422,0.0011495197,0.00029499552,0.00022401316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007180771,0.0003508084,0.0018067997,0.0006719651,0.00012134982,0.000012601007,0.00055346504,0.0005073561,0.00031180392],"category_scores_gemma":[0.00093441195,0.00020212783,0.00035249448,0.0057235844,0.00049701624,0.00006829642,0.0005409962,0.00048133364,0.00010848563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08490586,0.014241026,0.8427515,0.00042578246,0.016171053,0.011327554,0.0058270018,0.010753824,0.00021364428,0.0023437093,0.007266481,0.0037725389],"study_design_scores_gemma":[0.21794192,0.013289036,0.74151504,0.00007953581,0.0029965942,0.00007114954,0.002251848,0.019059027,0.0001943959,0.000049663,0.0021203961,0.00043137113],"about_ca_topic_score_codex":0.0006570112,"about_ca_topic_score_gemma":0.00064581895,"teacher_disagreement_score":0.13303605,"about_ca_system_score_codex":0.038950004,"about_ca_system_score_gemma":0.011975501,"threshold_uncertainty_score":0.9936257},"labels":[],"label_agreement":null},{"id":"W4380186961","doi":"10.1002/hon.3164_352","title":"Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Venetoclax; Ibrutinib; Obinutuzumab; Medicine; Internal medicine; Mantle cell lymphoma; Bendamustine; Adverse effect; Regimen; Oncology; Gastroenterology; Lymphoma; Rituximab; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03096810663968442,"score_gpt":0.3221062621097234,"score_spread":0.29113815547003896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380186961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581957,0.00014543436,0.00002997354,0.0009846842,0.000106217114,0.0006981987,0.0000038908615,0.00008715628,0.0021248797],"genre_scores_gemma":[0.9989762,0.00006420102,0.00007479568,0.00017145966,0.000023091585,0.000049536688,0.00006783462,0.00001726523,0.0005556244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984722,0.0001582946,0.00030272914,0.00030419472,0.00036271248,0.0003998481],"domain_scores_gemma":[0.9983717,0.0009243759,0.00013838978,0.00027144133,0.00017024369,0.00012379966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003160467,0.00015045457,0.0005228367,0.00010659004,0.00011584258,0.000010940627,0.00012674069,0.00024869162,0.0001267561],"category_scores_gemma":[0.0003337488,0.00008157663,0.000058183163,0.00046088075,0.0005503827,0.000042185777,0.00016716958,0.0002537094,0.00006615222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103311315,0.0013074455,0.886766,0.0017312419,0.0009020452,0.0032578465,0.003321864,0.00008916662,0.0017689193,0.016377317,0.018843176,0.055303853],"study_design_scores_gemma":[0.11865092,0.012834001,0.8455574,0.0007134331,0.00047993893,0.0017530776,0.00066879933,0.009550742,0.003776375,0.0011309406,0.00438412,0.0005002351],"about_ca_topic_score_codex":0.00006232517,"about_ca_topic_score_gemma":0.000035880144,"teacher_disagreement_score":0.10831979,"about_ca_system_score_codex":0.004045064,"about_ca_system_score_gemma":0.0020719648,"threshold_uncertainty_score":0.9997782},"labels":[],"label_agreement":null},{"id":"W4380767820","doi":"10.1016/j.jgo.2023.101538","title":"Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia","year":2023,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; ECOG-ACRIN Cancer Research Group; National Institutes of Health; Canadian Cancer Society; Genentech; Pharmacyclics; BeiGene; Karyopharm Therapeutics; American College of Radiology Imaging Network; Leukemia and Lymphoma Society; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Chronic lymphocytic leukemia; Leukemia; Internal medicine; Intensive care medicine; Oncology","score_opus":0.031131751651500155,"score_gpt":0.3746098854390622,"score_spread":0.34347813378756203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380767820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340534,0.0016718429,0.00018606916,0.0006189495,0.0010351606,0.0006537881,0.000013510843,0.000046477493,0.0023688364],"genre_scores_gemma":[0.9945811,0.0027415734,0.0007900245,0.000076673845,0.000826246,0.00003080922,0.0000055440137,0.000049077513,0.00089892704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954272,0.00041695958,0.0017561582,0.000330891,0.0013335561,0.0007352211],"domain_scores_gemma":[0.9959533,0.0012837801,0.0013440576,0.00043256074,0.00066835864,0.00031789296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002649016,0.00028759998,0.0017781103,0.0021439192,0.000054150216,0.00001529727,0.00043374093,0.00040741215,0.0001628042],"category_scores_gemma":[0.0012732742,0.0002242481,0.00043784644,0.0023241956,0.00019266209,0.0001667681,0.0002100467,0.0007585883,0.00005200353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022868378,0.003143714,0.42669508,0.007475835,0.0084818015,0.054695748,0.0059530656,0.17342636,0.06420451,0.0006238064,0.1017075,0.13072422],"study_design_scores_gemma":[0.11970906,0.016809646,0.7843607,0.0006117072,0.001223991,0.0047223736,0.001996766,0.05745447,0.00206597,0.00085125945,0.009614284,0.00057978334],"about_ca_topic_score_codex":0.00045146214,"about_ca_topic_score_gemma":0.00010445777,"teacher_disagreement_score":0.35766563,"about_ca_system_score_codex":0.22870877,"about_ca_system_score_gemma":0.13590796,"threshold_uncertainty_score":0.9144572},"labels":[],"label_agreement":null},{"id":"W4380795499","doi":"10.1161/circ.146.suppl_1.14372","title":"Abstract 14372: Case Series: Non-Lipid Plaque Formation as the Mechanism for Ponatinib-Induced Vascular Toxicity Using Operator-Assisted Virtual Histology Optical Coherence Tomography","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prince Albert Grand Council","funders":"","keywords":"Medicine; Ponatinib; Coronary artery disease; Internal medicine; Cardiology; Dasatinib; Myeloid leukemia; Imatinib","score_opus":0.04623347763033093,"score_gpt":0.312619283778442,"score_spread":0.2663858061481111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380795499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984361,0.000024219862,0.012517734,0.0004463187,0.0003505806,0.0018750041,0.000025550082,0.000066404624,0.00033318924],"genre_scores_gemma":[0.99821997,0.000003130963,0.0006635986,0.0003474268,0.00017125277,0.0003854982,0.00015751463,0.000036450056,0.000015179217],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979448,0.0001367473,0.000481288,0.00038684226,0.0006581159,0.00039220895],"domain_scores_gemma":[0.9986229,0.00027802726,0.00016742802,0.000471077,0.00031861867,0.00014193643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008280224,0.00019728071,0.00030601484,0.00019477827,0.00082063547,0.000051777322,0.00016962821,0.00016723355,0.00023617713],"category_scores_gemma":[0.00033921178,0.0001745132,0.00019629665,0.0004189207,0.00009040461,0.0003037162,0.000108639644,0.0003749611,0.000009879305],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015360252,0.00059504755,0.00029664452,0.0005018248,0.00043914648,0.0015514906,0.004144382,0.008915043,0.9496323,0.021805475,0.00022311827,0.010359514],"study_design_scores_gemma":[0.02536117,0.0016318678,0.0050768405,0.00012641787,0.0005042057,0.04739346,0.0052815103,0.84386736,0.06754501,0.0012795744,0.0011416218,0.0007909538],"about_ca_topic_score_codex":0.00040868102,"about_ca_topic_score_gemma":0.00004717387,"teacher_disagreement_score":0.8820873,"about_ca_system_score_codex":0.006916442,"about_ca_system_score_gemma":0.002188555,"threshold_uncertainty_score":0.99689585},"labels":[],"label_agreement":null},{"id":"W4382203678","doi":"","title":"ACUTE LYMPHOBLASTIC LEUKEMIA WITH PANCYTOPENIA AT PRESENTATION: CLINICAL CORRELATES, PROGNOSTIC IMPACT AND ASSOCIATION WITH SURVIVAL.","year":2014,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"","keywords":"Pancytopenia; Medicine; Lymphoblastic Leukemia; Presentation (obstetrics); Association (psychology); Overall survival; Oncology; Internal medicine; Leukemia; Pediatrics; Bone marrow; Psychology; Surgery","score_opus":0.14164728690634076,"score_gpt":0.5398706796883914,"score_spread":0.39822339278205066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382203678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992617,0.0025095786,0.00039129925,0.00018270101,0.00027407645,0.0014116443,0.000027760278,0.0000542458,0.002531699],"genre_scores_gemma":[0.9926943,0.004295274,0.0002599761,0.00015678906,0.0003078204,0.000075755066,0.000060189126,0.00010231153,0.0020475767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949049,0.00064522633,0.0010978176,0.00073545275,0.001900315,0.00071629864],"domain_scores_gemma":[0.9933481,0.0031914166,0.0012195292,0.0006549995,0.00082422345,0.00076173584],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028017578,0.00045473946,0.001414734,0.00042249585,0.00028505395,0.00078079785,0.0009395494,0.0002740972,0.0023323582],"category_scores_gemma":[0.0019567918,0.00030611196,0.00017607157,0.0009845514,0.00033249555,0.001313937,0.00072214345,0.00067500345,0.000047485428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048892163,0.0002108164,0.9764423,0.00018349671,0.0015020894,0.00023885451,0.00010826719,0.00025250856,0.001646193,0.00001605283,0.011004483,0.0035057566],"study_design_scores_gemma":[0.018344974,0.00042409555,0.9703398,0.0010857055,0.0010711527,0.0005582741,0.000033256943,0.004737631,0.0017512636,0.00019881404,0.0010293692,0.0004256848],"about_ca_topic_score_codex":0.0010758671,"about_ca_topic_score_gemma":0.00024350028,"teacher_disagreement_score":0.013455759,"about_ca_system_score_codex":0.009717412,"about_ca_system_score_gemma":0.00537807,"threshold_uncertainty_score":0.9999391},"labels":[],"label_agreement":null},{"id":"W4382468814","doi":"10.3389/fimmu.2023.1207631","title":"Platelet-derived microparticles provoke chronic lymphocytic leukemia malignancy through metabolic reprogramming","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atlantic Cancer Research Institute; Université de Moncton","funders":"","keywords":"Chronic lymphocytic leukemia; Cancer research; Biology; Cancer cell; Carcinogenesis; Leukemia; Cancer; Microvesicles; Reprogramming; Immunology; Cell; microRNA; Biochemistry; Genetics; Gene","score_opus":0.020676183991219566,"score_gpt":0.28719314759696196,"score_spread":0.2665169636057424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382468814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96308404,0.032009512,0.0006613374,0.00032257035,0.0014083182,0.0012441943,0.0000063424886,0.00058739743,0.00067629234],"genre_scores_gemma":[0.9778776,0.008720359,0.008980727,0.00022760482,0.00030328272,0.0005245124,0.00010529931,0.00015031222,0.0031103154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958589,0.00021546763,0.0008026154,0.0009400332,0.0004172317,0.0017657606],"domain_scores_gemma":[0.99828166,0.00012905223,0.00016163157,0.0011817624,0.000107970474,0.00013790977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057937414,0.0004040616,0.0010258148,0.00063026324,0.00016750759,0.0000476019,0.0004934313,0.00043763052,0.000100819554],"category_scores_gemma":[0.00043451425,0.00038663682,0.00021853097,0.0019053526,0.0007497721,0.00022724338,0.00039671754,0.0005895065,0.00063325185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0038756942,0.0002632378,0.010108863,0.0013725247,0.0027184973,0.011078828,0.007620255,0.0017975477,0.52739483,0.002212407,0.027855594,0.40370175],"study_design_scores_gemma":[0.089958586,0.0015958147,0.015168367,0.0010416168,0.0003465445,0.0033874817,0.004493642,0.06955561,0.59349287,0.003923524,0.21546711,0.0015688391],"about_ca_topic_score_codex":0.0018591714,"about_ca_topic_score_gemma":0.000067813795,"teacher_disagreement_score":0.4021329,"about_ca_system_score_codex":0.050236247,"about_ca_system_score_gemma":0.018068535,"threshold_uncertainty_score":0.99985856},"labels":[],"label_agreement":null},{"id":"W4382752021","doi":"10.1182/blood.2022018818","title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; BeiGene; AstraZeneca","keywords":"Ibrutinib; Medicine; Internal medicine; Hazard ratio; Adverse effect; Discontinuation; Chronic lymphocytic leukemia; Incidence (geometry); Confidence interval; Leukemia","score_opus":0.02521432312752855,"score_gpt":0.30397325027301203,"score_spread":0.2787589271454835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382752021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120486,0.0005604736,0.0000012804551,0.00016767523,0.00010142995,0.0044014715,0.000025174142,0.00016045244,0.003377158],"genre_scores_gemma":[0.9968241,0.0005440108,0.000044951244,0.00008510926,0.00030396692,0.00055300066,0.00018320135,0.000069807065,0.0013918392],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953049,0.00051746954,0.0012608441,0.0006624456,0.0010524543,0.0012019259],"domain_scores_gemma":[0.99736637,0.0010297883,0.00022002429,0.0011021273,0.00011097952,0.00017073276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025335115,0.00036372826,0.0009701434,0.0005566831,0.00007296337,0.000029617504,0.0006171405,0.00035416833,0.0003198858],"category_scores_gemma":[0.0013476704,0.00025876088,0.00023710779,0.0030438602,0.0002541101,0.00009938959,0.00020528733,0.00057646324,0.00039002637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6355197,0.013405977,0.10345973,0.020379804,0.0041054897,0.028458185,0.034900222,0.0062883114,0.08223436,0.0029752809,0.022381768,0.045891188],"study_design_scores_gemma":[0.9018461,0.0032582206,0.03057617,0.0011987324,0.00039065944,0.00035238624,0.00048378063,0.033062816,0.026834011,0.000093488234,0.0014248721,0.00047875772],"about_ca_topic_score_codex":0.0019390978,"about_ca_topic_score_gemma":0.0009295388,"teacher_disagreement_score":0.26632643,"about_ca_system_score_codex":0.035809662,"about_ca_system_score_gemma":0.042394165,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W4383375588","doi":"10.3390/curroncol30070472","title":"Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"Janssen Pharmaceuticals; Research Manitoba","keywords":"Medicine; Family medicine","score_opus":0.16744110749545896,"score_gpt":0.5114656291764598,"score_spread":0.34402452168100084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383375588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957793,0.0002289667,0.0000056769636,0.0016304096,0.000706981,0.0008764557,0.000065249726,0.00005488044,0.0006521026],"genre_scores_gemma":[0.99801826,0.00059700565,0.00002801724,0.0007226449,0.000066729895,0.00007986427,0.00016710044,0.000029610608,0.00029077168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748,0.00034630334,0.00053670723,0.00050911837,0.00024182271,0.0008860564],"domain_scores_gemma":[0.9975375,0.00122579,0.00006801991,0.00037646183,0.00003577794,0.00075644837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064994633,0.00022964811,0.00077310926,0.0005035371,0.000052900865,0.000010654268,0.00010576254,0.00029419726,0.00042433088],"category_scores_gemma":[0.000916259,0.00016806673,0.00022027617,0.00037041403,0.00012806752,0.000020539099,0.000052547188,0.00041130802,0.00020724654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037475745,0.0010281224,0.98557884,0.000049736132,0.00008507867,0.0010598712,0.00027687172,0.00000505159,0.000010752612,0.00006771899,0.002264282,0.00919891],"study_design_scores_gemma":[0.06588258,0.0025061462,0.7630583,0.00010305467,0.000106950756,0.000010600879,0.00013383919,0.014343343,0.000038822345,0.000047566828,0.15356497,0.00020382328],"about_ca_topic_score_codex":0.012978682,"about_ca_topic_score_gemma":0.051972378,"teacher_disagreement_score":0.22252055,"about_ca_system_score_codex":0.016207082,"about_ca_system_score_gemma":0.011114201,"threshold_uncertainty_score":0.9944919},"labels":[],"label_agreement":null},{"id":"W4383561176","doi":"10.14740/jh1132","title":"An Aggressive Course of Transformed Splenic Diffuse Red Pulp Small B-Cell Lymphoma With Novel Somatic Loss-of-Function Mutation in <i>RB1</i>","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Aalborg Universitetshospital; Aalborg Universitet","keywords":"Medicine; Somatic cell; Diffuse large B-cell lymphoma; Mutation; Lymphoma; Red pulp; Pathology; Cancer research; Spleen; Immunology; Genetics; Biology; Gene","score_opus":0.02072357774138484,"score_gpt":0.29827782485262777,"score_spread":0.27755424711124294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383561176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974354,0.00037993616,0.001162926,0.000423836,0.00012067277,0.0003730731,0.000008137103,0.000015550926,0.00008048353],"genre_scores_gemma":[0.99912554,0.00014448118,0.0005515402,0.000039045593,0.00003747457,0.000010961281,0.000019635912,0.000033507386,0.000037835038],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978337,0.000106923646,0.0010295771,0.000178134,0.00049671845,0.00035489543],"domain_scores_gemma":[0.99768317,0.000393697,0.0010538722,0.0002845873,0.00041838814,0.00016630968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057273445,0.00017074938,0.00086922507,0.00059885526,0.000024918738,0.0000066495795,0.00018204254,0.00018480961,0.000027801983],"category_scores_gemma":[0.0002085711,0.00012372358,0.00013683559,0.0006638994,0.00021805777,0.00015387748,0.000017122156,0.00022181249,0.0000048163292],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07020898,0.03608686,0.1326016,0.023366522,0.0032841372,0.04407478,0.027516594,0.004783095,0.6289713,0.003261236,0.0014767174,0.024368191],"study_design_scores_gemma":[0.37814966,0.017003229,0.051706366,0.0059686094,0.0013916778,0.08435392,0.00977994,0.08198501,0.3662649,0.002667845,0.00010138628,0.0006274385],"about_ca_topic_score_codex":0.00008210292,"about_ca_topic_score_gemma":0.00016188945,"teacher_disagreement_score":0.3079407,"about_ca_system_score_codex":0.0010920268,"about_ca_system_score_gemma":0.004703762,"threshold_uncertainty_score":0.8344272},"labels":[],"label_agreement":null},{"id":"W4384463914","doi":"10.58931/cht.2022.1215","title":"With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hematologist; Rating scale; Clinical trial; Intensive care medicine; Leukemia; Psychology; Disease","score_opus":0.013766826476670749,"score_gpt":0.27012322071496603,"score_spread":0.25635639423829526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893448,0.0027609393,0.000014843173,0.00051351165,0.00017045045,0.0014761947,0.000042402604,0.00005487513,0.005622004],"genre_scores_gemma":[0.9958452,0.000038801252,0.0001655912,0.00060342177,0.0000209416,0.00032167524,0.00005567451,0.00007882221,0.0028698985],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996687,0.00026010908,0.00052726315,0.00077409676,0.00053741346,0.0012141295],"domain_scores_gemma":[0.99723625,0.0007534314,0.00013198456,0.0011129754,0.00008627156,0.00067909784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042361766,0.00037700008,0.0010376537,0.0011935062,0.00021150541,0.000012499661,0.0003532974,0.0001846911,0.00048252288],"category_scores_gemma":[0.0002796291,0.00034274487,0.00013209658,0.0010183204,0.00043262856,0.00008470827,0.00018055407,0.0004555225,0.000031514723],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.027805869,0.001647336,0.38330612,0.021008525,0.009718606,0.39844954,0.019347014,0.030341817,0.017036337,0.043947972,0.021077937,0.026312945],"study_design_scores_gemma":[0.5334726,0.019611571,0.11434373,0.0064757685,0.002664538,0.107453965,0.0048105917,0.12266978,0.051798526,0.0015852596,0.03042606,0.0046876282],"about_ca_topic_score_codex":0.21221915,"about_ca_topic_score_gemma":0.17786993,"teacher_disagreement_score":0.50566673,"about_ca_system_score_codex":0.27467284,"about_ca_system_score_gemma":0.09467891,"threshold_uncertainty_score":0.9999024},"labels":[],"label_agreement":null},{"id":"W4384926029","doi":"10.2217/fon-2023-0436","title":"Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hazard ratio; Pharmacy; Leukemia; Confidence interval; Family medicine","score_opus":0.028625381904688885,"score_gpt":0.32189952807874594,"score_spread":0.29327414617405706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384926029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98937935,0.00012194664,0.000004620776,0.002205257,0.00031635753,0.0023579209,0.000034260054,0.00031124888,0.005269035],"genre_scores_gemma":[0.98147655,0.0002290404,0.00072810194,0.001634984,0.00238693,0.0006938768,0.0006377287,0.00017446595,0.012038327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653083,0.00015290394,0.0006335412,0.0007964884,0.0006115766,0.0012746622],"domain_scores_gemma":[0.99777716,0.00071948726,0.00014654144,0.0006895733,0.00017355532,0.00049367535],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00037531357,0.000440953,0.0009579652,0.0005658058,0.00015198803,0.000029768013,0.00027147544,0.0004605287,0.0022491554],"category_scores_gemma":[0.00036948128,0.00029758658,0.000104284074,0.0019217003,0.0001615905,0.00012234671,0.00023715066,0.00037033248,0.0056390534],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08333098,0.0032952467,0.02693828,0.002728096,0.002155558,0.024321308,0.014532725,0.028918913,0.0012451889,0.00020846086,0.1153487,0.69697654],"study_design_scores_gemma":[0.24729654,0.05518282,0.06759451,0.0010420623,0.0003364511,0.00053516234,0.00074002304,0.05696234,0.00062514,0.00002113215,0.56854045,0.0011233564],"about_ca_topic_score_codex":0.000619666,"about_ca_topic_score_gemma":0.0018448422,"teacher_disagreement_score":0.6958532,"about_ca_system_score_codex":0.21307835,"about_ca_system_score_gemma":0.05347647,"threshold_uncertainty_score":0.9999476},"labels":[],"label_agreement":null},{"id":"W4385295164","doi":"10.1007/s11886-023-01916-4","title":"Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors","year":2023,"lang":"en","type":"review","venue":"Current Cardiology Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Atrial fibrillation; Adverse effect; Heart failure; Intensive care medicine; Ibrutinib; Cardiology; Internal medicine; Chronic lymphocytic leukemia; Leukemia","score_opus":0.0632842956302339,"score_gpt":0.37136002498473003,"score_spread":0.3080757293544961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385295164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002029401,0.99209523,0.00001481737,0.0000035513033,0.0021641112,0.0034387803,0.000021378064,0.00006559363,0.00016711834],"genre_scores_gemma":[0.00094729476,0.99717134,0.000028964625,0.000001293169,0.00040054685,0.0010442756,0.00020396616,0.00010339015,0.00009894037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958387,0.00035827523,0.0015089798,0.0009920137,0.0007878595,0.0005141522],"domain_scores_gemma":[0.99660254,0.00051886245,0.0007140723,0.0017329128,0.00019745708,0.00023414902],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012126087,0.0005403597,0.0056778365,0.0005175972,0.000035212837,0.0000057642164,0.00014828554,0.00046436378,0.0000044386993],"category_scores_gemma":[0.00048325746,0.00042941215,0.0023433948,0.0007036483,0.0005070928,0.000027952281,0.00064846064,0.00046503468,0.000010433785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008518639,0.000057440346,0.00019528673,0.32717976,0.007929968,0.014651227,0.000013281615,0.0000056004087,3.715207e-7,0.000012726033,0.0016611578,0.6482847],"study_design_scores_gemma":[0.0019952825,0.00016994744,0.00016768761,0.08648078,0.018453458,0.0044208243,0.000006332259,0.00000215486,0.00007426189,0.000019670231,0.88789433,0.00031525444],"about_ca_topic_score_codex":0.00007298758,"about_ca_topic_score_gemma":3.367031e-7,"teacher_disagreement_score":0.8862332,"about_ca_system_score_codex":0.002035855,"about_ca_system_score_gemma":0.0020062595,"threshold_uncertainty_score":0.99981576},"labels":[],"label_agreement":null},{"id":"W4385334309","doi":"10.1200/jco.23.00775","title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Obinutuzumab; Internal medicine; Neutropenia; Gastroenterology; Clinical endpoint; Rituximab; Phases of clinical research; Hazard ratio; Adverse effect; Surgery; Randomized controlled trial; Lymphoma; Chemotherapy; Confidence interval","score_opus":0.11398352335244477,"score_gpt":0.4717419386539264,"score_spread":0.3577584153014816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385334309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552566,0.00016420218,0.00001606653,0.00026707922,0.0012592167,0.002316333,0.0000062058893,0.000033435877,0.00041177942],"genre_scores_gemma":[0.9976581,0.0005348389,0.00046963984,0.00022723954,0.0004150802,0.000057421206,0.000013411919,0.00006940696,0.0005548936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99019474,0.0020752253,0.004912849,0.0004884346,0.0016963126,0.0006324524],"domain_scores_gemma":[0.98414636,0.01069847,0.002986367,0.00069071696,0.00093247124,0.0005455979],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008413794,0.00034976713,0.0049094013,0.0007025294,0.00008210764,0.0000123037125,0.00048967876,0.00061928463,0.00019127839],"category_scores_gemma":[0.012441195,0.00020891815,0.0007371102,0.0011356854,0.0005295814,0.00018908881,0.00018879429,0.0011079506,0.000022688622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9468335,0.010501414,0.0009876152,0.000059566068,0.0020956434,0.0039664577,0.0018347767,0.00044427582,0.000022812246,0.00001163931,0.0013480315,0.031894293],"study_design_scores_gemma":[0.806012,0.1797688,0.004505471,0.00021476422,0.0005834261,0.00006604572,0.000946593,0.0047304,0.000023313218,0.000027181266,0.0029517743,0.00017024085],"about_ca_topic_score_codex":0.00047682037,"about_ca_topic_score_gemma":0.0002253496,"teacher_disagreement_score":0.16926739,"about_ca_system_score_codex":0.027196573,"about_ca_system_score_gemma":0.07010876,"threshold_uncertainty_score":0.99587744},"labels":[],"label_agreement":null},{"id":"W4385636839","doi":"10.1159/000531592","title":"Delayed Diagnosis of T-Cell Prolymphocytic Leukemia: Approach to Chronic Lymphocytosis","year":2023,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; Western University","funders":"","keywords":"Medicine; Lymphocytosis; Chronic lymphocytic leukemia; Hepatosplenomegaly; Prolymphocytic leukemia; Lymphoproliferative disorders; CD5; Immunology; Population; Alemtuzumab; Pathology; Leukemia; Gastroenterology; Internal medicine; Lymphoma; Antibody","score_opus":0.03544251760116716,"score_gpt":0.3410128336074422,"score_spread":0.30557031600627504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385636839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97120214,0.0009156826,0.00007573038,0.00021613369,0.00038568085,0.002100487,0.000011089477,0.00018402428,0.024909059],"genre_scores_gemma":[0.99425054,0.00065557915,0.0012938826,0.00027053335,0.0002395824,0.0017039551,0.00006651393,0.000094334384,0.0014250616],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9954795,0.00019467302,0.0014510796,0.0010200981,0.0007468819,0.0011077598],"domain_scores_gemma":[0.99676985,0.0007696067,0.00036671036,0.0013027536,0.00025292128,0.0005381377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018226999,0.00035451495,0.0011923661,0.0010774581,0.0000831936,0.000015163249,0.00018027086,0.0005753375,0.000116779964],"category_scores_gemma":[0.0011141422,0.00033290705,0.00023559896,0.0025752175,0.00029038583,0.00007871888,0.00046961068,0.0003954527,0.00015623782],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012041796,0.0016183358,0.0047725565,0.0027462486,0.0002995381,0.9180376,0.002355685,0.0083518205,0.009706188,0.00011503148,0.02364069,0.027152147],"study_design_scores_gemma":[0.047066122,0.0068592126,0.0010927287,0.0005958866,0.00057347305,0.728526,0.0019516452,0.06987408,0.10182931,0.00021461668,0.04032253,0.00109439],"about_ca_topic_score_codex":0.0030276803,"about_ca_topic_score_gemma":0.00032453783,"teacher_disagreement_score":0.18951158,"about_ca_system_score_codex":0.11563511,"about_ca_system_score_gemma":0.050401755,"threshold_uncertainty_score":0.9999123},"labels":[],"label_agreement":null},{"id":"W4385639452","doi":"10.1136/lupus-2023-kcr.25","title":"LO-024 Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort","year":2023,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Calgary; Arthritis Society; Mount Sinai Hospital; University Health Network; University of Toronto; Dalhousie University; University of Manitoba; Toronto Western Hospital; Université Laval; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Hydroxychloroquine; Interquartile range; Cohort; Internal medicine; Logistic regression; Hazard ratio; Proportional hazards model; Prednisone; Coronavirus disease 2019 (COVID-19); Disease; Confidence interval","score_opus":0.02509172941577064,"score_gpt":0.3226998368341016,"score_spread":0.29760810741833094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385639452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971244,0.000024308545,0.000017695114,0.0006779844,0.000086903165,0.0010432752,0.00008392782,0.000056376368,0.0008851304],"genre_scores_gemma":[0.99619234,0.00009674339,0.00004928766,0.00033440892,0.0001502918,0.00005664898,0.00041454204,0.000016863181,0.0026888538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817264,0.00007327651,0.0003092643,0.00041015397,0.00068738224,0.00034730707],"domain_scores_gemma":[0.99883896,0.00046986583,0.00006714706,0.00034020067,0.00011055722,0.00017325157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087527494,0.00014390747,0.00029508615,0.00009163932,0.00008292436,0.00006104738,0.00011710913,0.00014651039,0.00010353801],"category_scores_gemma":[0.0005405872,0.00010492995,0.000026013915,0.00053667073,0.000051438146,0.00013930256,0.00029517227,0.00023746256,0.00014448943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046617988,0.000029937299,0.98853725,0.000033489556,0.000078527555,0.000010792305,0.0007192501,0.000007691813,0.0002000385,0.0000039991646,0.007829456,0.0025029266],"study_design_scores_gemma":[0.0054418696,0.0001874518,0.98757994,0.00009861654,0.00006242332,8.372742e-7,0.00022598359,0.0054514557,0.00024785282,0.00014354291,0.00044158997,0.000118406126],"about_ca_topic_score_codex":0.018664965,"about_ca_topic_score_gemma":0.0027217858,"teacher_disagreement_score":0.015943179,"about_ca_system_score_codex":0.0036582693,"about_ca_system_score_gemma":0.0005406255,"threshold_uncertainty_score":0.98786986},"labels":[],"label_agreement":null},{"id":"W4385667085","doi":"10.1097/01.hs9.0000971256.60488.02","title":"P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Venetoclax; Ibrutinib; Medicine; Mantle cell lymphoma; Obinutuzumab; Internal medicine; Bendamustine; Regimen; Oncology; Adverse effect; Gastroenterology; Lymphoma; Rituximab; Leukemia; Chronic lymphocytic leukemia","score_opus":0.014988999691284768,"score_gpt":0.26361219385610113,"score_spread":0.24862319416481637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556535,0.0004136512,0.000018728402,0.00022040178,0.00009933045,0.00069856894,0.000010039185,0.000086952445,0.002886969],"genre_scores_gemma":[0.9937017,0.000057590518,0.000053897445,0.00006590662,0.00004104504,0.00003004117,0.000090720736,0.00004472094,0.005914356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998443,0.000052629995,0.00023397229,0.0002877407,0.00060524733,0.00037737965],"domain_scores_gemma":[0.9988769,0.00024344394,0.000099509096,0.00044645046,0.0002079521,0.00012569505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019648283,0.00017151806,0.00029506016,0.00006380622,0.00014345918,0.000028956303,0.00013159646,0.00010116616,0.0002339383],"category_scores_gemma":[0.00010776974,0.000108042135,0.00005791779,0.00058656826,0.00024801592,0.00008151122,0.00012979924,0.00018820759,0.00006942342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047509028,0.0005136262,0.84900343,0.0040314076,0.0015585719,0.00079103565,0.008988517,0.0003982199,0.0019751322,0.0025429109,0.04599991,0.07944635],"study_design_scores_gemma":[0.14871456,0.00262448,0.8127386,0.003151012,0.000633331,0.00022853298,0.0020630683,0.015767843,0.009248661,0.0003078373,0.0037662466,0.0007558515],"about_ca_topic_score_codex":0.00029034197,"about_ca_topic_score_gemma":0.00010026355,"teacher_disagreement_score":0.14396365,"about_ca_system_score_codex":0.0034430772,"about_ca_system_score_gemma":0.0023426134,"threshold_uncertainty_score":0.9003527},"labels":[],"label_agreement":null},{"id":"W4385667785","doi":"10.1097/01.hs9.0000969412.43267.61","title":"P627: LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Oncology; Progression-free survival; Chronic lymphocytic leukemia; Population; Bruton's tyrosine kinase; Chemotherapy; Leukemia; Tyrosine kinase","score_opus":0.011910645621016498,"score_gpt":0.2973486943511449,"score_spread":0.2854380487301284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969104,0.00013036854,0.00002447782,0.00007803714,0.000022538246,0.0015061729,0.00001950593,0.00015851953,0.0011499698],"genre_scores_gemma":[0.9928141,0.000012454977,0.0002500723,0.00007589927,0.00003120785,0.00012601832,0.00023213077,0.00007461706,0.0063834595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967386,0.00007822309,0.0005359947,0.00063105643,0.0012335283,0.0007825781],"domain_scores_gemma":[0.9981354,0.00023397934,0.00018084895,0.00087517075,0.00026129975,0.0003133147],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032248578,0.00033756113,0.0011719433,0.0005768821,0.00006057632,0.000025414265,0.0002451136,0.00016896972,0.0012413019],"category_scores_gemma":[0.00014749744,0.00021987753,0.00015605577,0.0041098176,0.00016767293,0.00009969249,0.0001799335,0.00024701556,0.0005755619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021915566,0.0001771234,0.9836484,0.000578662,0.0013850647,0.00061158254,0.00035843038,0.0038122453,0.00013435617,0.0000046696473,0.00066877087,0.006429142],"study_design_scores_gemma":[0.03545636,0.0021581522,0.9473085,0.0012943766,0.00095135893,0.000017052545,0.000066970664,0.011255695,0.0010625741,0.0000011957052,0.000091497444,0.00033628521],"about_ca_topic_score_codex":0.00047763277,"about_ca_topic_score_gemma":0.00059497176,"teacher_disagreement_score":0.036339916,"about_ca_system_score_codex":0.030606331,"about_ca_system_score_gemma":0.0111646075,"threshold_uncertainty_score":0.9996717},"labels":[],"label_agreement":null},{"id":"W4385703588","doi":"10.1097/01.hs9.0000969476.05517.0d","title":"P643: CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"MedDRA; Medicine; Chronic lymphocytic leukemia; Clinical trial; Population; Internal medicine; Cumulative incidence; Oncology; Adverse effect; Leukemia; Pharmacovigilance; Environmental health","score_opus":0.2531484660242522,"score_gpt":0.4870230859130047,"score_spread":0.23387461988875252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385703588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96722287,0.030537978,0.0000102529075,0.00041469646,0.000040387633,0.0015545079,0.00009062677,0.000023765135,0.00010491901],"genre_scores_gemma":[0.975475,0.021660788,0.0018998522,0.00027860652,0.00025457243,0.00006552006,0.00021234593,0.000043656597,0.0001096351],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954067,0.0015027558,0.0013708009,0.0006260038,0.00070747215,0.0003862803],"domain_scores_gemma":[0.99085295,0.007078925,0.0004122734,0.0013779014,0.0001545489,0.00012339711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005467397,0.00023750792,0.0014737656,0.00005691725,0.00005275218,0.000013572613,0.00032655222,0.00012429128,0.00042080675],"category_scores_gemma":[0.0049660867,0.00013516912,0.00013935618,0.00075584266,0.0004209036,0.000095977375,0.00018961815,0.00018063858,0.0000147287265],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.053658508,0.006272699,0.20174097,0.16945428,0.010404906,0.008826102,0.07218793,0.004543867,0.067516774,0.00036519,0.075798094,0.3292307],"study_design_scores_gemma":[0.14018165,0.0075275335,0.037558366,0.12734504,0.00270716,0.001163813,0.026114404,0.61736774,0.007988677,0.00006110904,0.030785106,0.001199381],"about_ca_topic_score_codex":0.0035711832,"about_ca_topic_score_gemma":0.00037897876,"teacher_disagreement_score":0.6128239,"about_ca_system_score_codex":0.008754943,"about_ca_system_score_gemma":0.015445738,"threshold_uncertainty_score":0.99505025},"labels":[],"label_agreement":null},{"id":"W4385705588","doi":"10.1097/01.hs9.0000976912.69182.0b","title":"PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Autoimmune hemolytic anemia; Medicine; B-cell activating factor; Rituximab; Pharmacodynamics; Pharmacokinetics; Immunology; Antibody; Pure red cell aplasia; Internal medicine; Autoantibody; Anemia; Pharmacology; B cell","score_opus":0.11378934319641971,"score_gpt":0.4204725488922121,"score_spread":0.3066832056957924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385705588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906422,0.0005455207,0.000893952,0.0005773294,0.000087200824,0.0060483734,0.00003853125,0.000064639564,0.0011022679],"genre_scores_gemma":[0.9961803,0.0003426823,0.0016001004,0.0001553775,0.000042522857,0.00015351844,0.000024313897,0.00009112742,0.0014100746],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966098,0.00042163947,0.00081378105,0.00059725,0.0009233972,0.00063411955],"domain_scores_gemma":[0.9974197,0.0009996556,0.00022507655,0.00082403154,0.00028946073,0.00024208195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001853412,0.00035400467,0.000982247,0.00019431445,0.000098159595,0.00005278901,0.00076135347,0.00008071281,0.00023098903],"category_scores_gemma":[0.00030160585,0.00024563642,0.000044448345,0.0019157786,0.0002515317,0.0001485812,0.000895367,0.00043272754,0.000032748187],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09959183,0.09532247,0.012840555,0.005657548,0.0050903894,0.009358667,0.04793344,0.014583051,0.5848849,0.0007333148,0.011132555,0.11287132],"study_design_scores_gemma":[0.6508647,0.014355363,0.012271479,0.0018941232,0.0011834077,0.0005115985,0.013169706,0.24381188,0.059308484,0.000046174573,0.0015518768,0.0010312],"about_ca_topic_score_codex":0.0011948638,"about_ca_topic_score_gemma":0.0002818199,"teacher_disagreement_score":0.55127287,"about_ca_system_score_codex":0.0012865856,"about_ca_system_score_gemma":0.003087766,"threshold_uncertainty_score":0.9999996},"labels":[],"label_agreement":null},{"id":"W4385707156","doi":"10.1097/01.hs9.0000971348.10013.c4","title":"P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Propensity score matching; Oncology; Internal medicine; Progression-free survival; Rituximab; Population; Overall survival; Lymphoma","score_opus":0.09647680593430397,"score_gpt":0.37119411444094036,"score_spread":0.2747173085066364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98003435,0.0010402947,0.000054149707,0.0002516384,0.0004310675,0.0012567103,0.000031759417,0.00033000976,0.016569996],"genre_scores_gemma":[0.99522555,0.00008381084,0.0009596959,0.000046948237,0.00017045117,0.00008230671,0.00022658844,0.00008804035,0.0031166035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99531996,0.00030763535,0.0011141518,0.0008064516,0.0013395743,0.0011122309],"domain_scores_gemma":[0.9966101,0.0015400363,0.0003344998,0.0009345888,0.00021626048,0.0003644943],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00079041836,0.00048948004,0.0017344876,0.00045328774,0.00012883406,0.000034241926,0.00043487066,0.00036298428,0.0009926729],"category_scores_gemma":[0.0003600161,0.00046852004,0.00027188586,0.0026382979,0.00038539254,0.000107902335,0.00031593718,0.0006024887,0.0013724788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2728759,0.04142116,0.061854616,0.014670074,0.007836364,0.023413433,0.13441022,0.01659283,0.03285926,0.011024464,0.23149177,0.1515499],"study_design_scores_gemma":[0.64508045,0.003988561,0.17885652,0.0038164868,0.00053498487,0.00054418005,0.024717294,0.085676625,0.0405237,0.00022491119,0.014208004,0.0018282835],"about_ca_topic_score_codex":0.0019748139,"about_ca_topic_score_gemma":0.0008666079,"teacher_disagreement_score":0.37220454,"about_ca_system_score_codex":0.0057686563,"about_ca_system_score_gemma":0.003955799,"threshold_uncertainty_score":0.99992055},"labels":[],"label_agreement":null},{"id":"W4385931148","doi":"10.3174/ajnr.a7974","title":"Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know","year":2023,"lang":"en","type":"review","venue":"American Journal of Neuroradiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Monoclonal antibody; Intensive care medicine; Adverse effect; Antibody; Monoclonal; Clinical Practice; Neuroradiologist; Disease; Differential diagnosis; Immunology; Bioinformatics; Pathology; Pharmacology; Radiology; Family medicine; Magnetic resonance imaging","score_opus":0.07614280632967736,"score_gpt":0.4055738698794665,"score_spread":0.3294310635497891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385931148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004535431,0.9879678,0.00003963476,0.00409593,0.0020484726,0.0011546277,0.000024278108,0.000061116065,0.00007274708],"genre_scores_gemma":[0.0004000623,0.9943783,0.00014640008,0.0022152006,0.002197117,0.000065585395,0.000021130758,0.00020287374,0.00037328948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939761,0.001754268,0.0018950627,0.00057759736,0.000715798,0.0010811787],"domain_scores_gemma":[0.9819054,0.014251851,0.0016041042,0.0011414607,0.00036813214,0.0007290744],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012459459,0.0007336857,0.0050872364,0.0014297328,0.0001468936,0.00012307963,0.0015861557,0.00024651823,0.000041000618],"category_scores_gemma":[0.007916906,0.00042080937,0.0013397826,0.0028728708,0.0018914549,0.00014679224,0.00044009235,0.0023341167,0.00048865407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020731731,0.00008656209,0.00005798981,0.0022652915,0.0009481168,0.008184765,0.00027501566,0.00005901663,0.000003909386,0.000064452644,0.0255761,0.96227145],"study_design_scores_gemma":[0.0011503967,0.005369975,0.000095925294,0.007519588,0.0013706961,0.06212348,0.00051557017,0.000027974113,5.834212e-7,0.000015738502,0.9214941,0.0003159181],"about_ca_topic_score_codex":0.000074992626,"about_ca_topic_score_gemma":0.0000048019015,"teacher_disagreement_score":0.96195555,"about_ca_system_score_codex":0.003234898,"about_ca_system_score_gemma":0.010020559,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W4385955746","doi":"10.1097/01.hs9.0000969496.68553.26","title":"P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Bendamustine; Rituximab; Ibrutinib; Internal medicine; IGHV@; Chlorambucil; Fludarabine; Oncology; Population; Chronic lymphocytic leukemia; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma","score_opus":0.04471865988519662,"score_gpt":0.3370424558678615,"score_spread":0.2923237959826649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689573,0.000109428634,0.0000057897823,0.00019552132,0.0001005399,0.0017838958,0.000021303997,0.00006420669,0.000823579],"genre_scores_gemma":[0.99712425,0.00085788156,0.000095324496,0.00007727596,0.00009849847,0.00022363094,0.00009429222,0.000049409977,0.0013794219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779767,0.000082121274,0.00044568704,0.00047455478,0.0007942836,0.00040570062],"domain_scores_gemma":[0.99857336,0.00036880618,0.0001298265,0.0006832084,0.00012794466,0.0001168489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004048246,0.00028193608,0.0004890718,0.00018058295,0.00009290487,0.000037066817,0.00026676504,0.00006469917,0.00020303126],"category_scores_gemma":[0.00007093926,0.00016107573,0.00006888006,0.0006622477,0.00011257303,0.00013895027,0.00009588581,0.0001610986,0.000014009426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011221116,0.0013511905,0.97386664,0.00011533346,0.00053929084,0.00016845856,0.0053433166,0.001781021,0.00005216899,0.00006201037,0.000107120504,0.015491319],"study_design_scores_gemma":[0.05100516,0.0032817128,0.92941314,0.0001631631,0.000064564745,0.000013188855,0.0010329387,0.01413102,0.00013629062,0.000012739031,0.0005814379,0.00016464191],"about_ca_topic_score_codex":0.014962798,"about_ca_topic_score_gemma":0.033845443,"teacher_disagreement_score":0.04988305,"about_ca_system_score_codex":0.03346279,"about_ca_system_score_gemma":0.0046719895,"threshold_uncertainty_score":0.99159664},"labels":[],"label_agreement":null},{"id":"W4385970980","doi":"10.32635/2176-9745.rbc.1968v24n36.4344","title":"Role of Surgery in the Treatment of Hodgkin’s Disease","year":2023,"lang":"pt","type":"article","venue":"Revista Brasileira de Cancerologia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Disease; Medicine; General surgery; Internal medicine","score_opus":0.06501467870643854,"score_gpt":0.3472437621530386,"score_spread":0.2822290834466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385970980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684539,0.02955094,0.0000039617435,0.00024194644,0.00012380493,0.0011545282,0.00023195092,0.000039319795,0.0001996601],"genre_scores_gemma":[0.9870739,0.011576194,0.000006764498,0.00015072248,0.00027446306,0.0002498227,0.0000921392,0.000047315658,0.00052865385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607486,0.00071724295,0.00097302883,0.0005220018,0.00077451457,0.0009383384],"domain_scores_gemma":[0.99507886,0.0028366428,0.0003751082,0.0012928512,0.00013978776,0.00027677196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016599335,0.00035445136,0.0011849097,0.0004532285,0.000053723914,0.000027341788,0.00047065562,0.00021450264,0.00027582867],"category_scores_gemma":[0.001043264,0.00024628761,0.00048045433,0.0018267735,0.00046444216,0.000052670326,0.000079549885,0.00024196753,0.00008826025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019319924,0.0008051298,0.9754846,0.002482586,0.00026239338,0.0009100998,0.0030485543,0.00031178616,0.0009809888,0.00043789748,0.0048587895,0.008485153],"study_design_scores_gemma":[0.0051156306,0.00077771564,0.9816747,0.0010157129,0.0003349331,0.00002514081,0.001348338,0.0065794527,0.0005173203,0.000028438166,0.002381865,0.00020080655],"about_ca_topic_score_codex":0.002748974,"about_ca_topic_score_gemma":0.00015839223,"teacher_disagreement_score":0.018620035,"about_ca_system_score_codex":0.011138777,"about_ca_system_score_gemma":0.014052956,"threshold_uncertainty_score":0.9999989},"labels":[],"label_agreement":null},{"id":"W4385971731","doi":"10.32635/2176-9745.rbc.1968v24n36.4345","title":"The Possibilities of Cure of the Hodgkin’s Disease Patient","year":2023,"lang":"pt","type":"article","venue":"Revista Brasileira de Cancerologia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Columbia College","funders":"","keywords":"Medicine; Disease; Internal medicine","score_opus":0.028721327782329605,"score_gpt":0.31663529398495016,"score_spread":0.28791396620262055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385971731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97516257,0.02096716,0.000007891358,0.0009860394,0.0005828005,0.0014816994,0.0005084943,0.000055962428,0.00024739714],"genre_scores_gemma":[0.9927602,0.0027074388,0.000007346106,0.00029288695,0.00023659717,0.00013055035,0.000021626465,0.000056217825,0.0037871727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550956,0.00074025436,0.0010369663,0.00052573136,0.0011813603,0.0010061511],"domain_scores_gemma":[0.9946568,0.0017784446,0.000636678,0.0021570532,0.0004378981,0.00033314936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001441188,0.00035554022,0.00072654604,0.000112904025,0.00029240327,0.000058474398,0.0010837137,0.00022090261,0.00020187345],"category_scores_gemma":[0.0034043244,0.00019769529,0.000513494,0.0013087513,0.0017271601,0.000057441473,0.0007032298,0.0006022983,0.0000666008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0042632045,0.00033281447,0.8315636,0.011152627,0.00093276746,0.00020057298,0.006684918,0.0011935751,0.0021700147,0.009072401,0.12403346,0.008400029],"study_design_scores_gemma":[0.007176385,0.0011818885,0.9585623,0.003974201,0.0006764465,0.000032486947,0.0045652436,0.011650854,0.0022268815,0.00022354715,0.009282517,0.00044726068],"about_ca_topic_score_codex":0.0009739618,"about_ca_topic_score_gemma":0.00009014174,"teacher_disagreement_score":0.12699866,"about_ca_system_score_codex":0.0077897618,"about_ca_system_score_gemma":0.018613378,"threshold_uncertainty_score":0.9960192},"labels":[],"label_agreement":null},{"id":"W4385972357","doi":"10.32635/2176-9745.rbc.1968v24n36.4346","title":"The Over-All Planning of the Treatment of the Hodgkin’s Disease Patient","year":2023,"lang":"pt","type":"article","venue":"Revista Brasileira de Cancerologia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Disease; Medicine; Hodgkin lymphoma; Internal medicine; Lymphoma","score_opus":0.047184828918352455,"score_gpt":0.3452490933114722,"score_spread":0.2980642643931197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385972357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97394186,0.022017103,0.000004930869,0.0007970412,0.0007429997,0.0019771024,0.0002787191,0.000041778778,0.00019847623],"genre_scores_gemma":[0.99384505,0.0031981138,0.0000034598345,0.00040032004,0.00026691266,0.00020664743,0.000014827625,0.00005721922,0.0020074411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579936,0.000736116,0.00085051724,0.0005124366,0.0011056957,0.0009958507],"domain_scores_gemma":[0.9950736,0.0015564401,0.00067678676,0.0022327132,0.0001755696,0.00028486102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070463604,0.00040268665,0.0006779432,0.00007828241,0.0003775829,0.000058446538,0.0010385243,0.00019000529,0.000099966994],"category_scores_gemma":[0.001110729,0.00018265334,0.0006394809,0.0010596195,0.0009789387,0.000037400452,0.00044449087,0.0003782867,0.000026861846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024949335,0.00047205924,0.9476944,0.0016211368,0.0010872027,0.00020834223,0.00590224,0.0033211138,0.0010294822,0.0009909937,0.0262349,0.008943162],"study_design_scores_gemma":[0.0065715834,0.0012616672,0.95350593,0.0016740252,0.00076354254,0.000019106388,0.0008316118,0.010685236,0.0013903314,0.000028173337,0.023043776,0.00022501263],"about_ca_topic_score_codex":0.0010835584,"about_ca_topic_score_gemma":0.00009159528,"teacher_disagreement_score":0.019903209,"about_ca_system_score_codex":0.01493737,"about_ca_system_score_gemma":0.010550304,"threshold_uncertainty_score":0.99505895},"labels":[],"label_agreement":null},{"id":"W4385972395","doi":"10.32635/2176-9745.rbc.1968v24n36.4139","title":"Clinical Staging of Hodgkin’s Disease: Round Table Luncheon","year":2023,"lang":"pt","type":"article","venue":"Revista Brasileira de Cancerologia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Columbia College","funders":"","keywords":"Disease; Medicine; Geography; Internal medicine","score_opus":0.07405097466049614,"score_gpt":0.40280793711455415,"score_spread":0.328756962454058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385972395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97688884,0.018122653,0.00048755456,0.0003794814,0.0010229797,0.0014576965,0.0004270839,0.0003279719,0.0008857717],"genre_scores_gemma":[0.9776047,0.0059664003,0.00011776906,0.00072952226,0.0014525128,0.00013039979,0.00021397618,0.00015818953,0.01362656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99233127,0.00097527803,0.0019025563,0.0013682334,0.0013561441,0.0020665103],"domain_scores_gemma":[0.9933791,0.0020923212,0.00071037834,0.0020453688,0.00048218368,0.0012906503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0051925,0.000624557,0.0018210734,0.00042228194,0.00020279452,0.00015361841,0.00081112754,0.0006027329,0.001384825],"category_scores_gemma":[0.004865351,0.0005956989,0.0005937544,0.0023215138,0.0009760251,0.00020557034,0.0007078696,0.0013288795,0.00075545977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0020466992,0.00028436346,0.8974436,0.0063531296,0.00063617475,0.0021246288,0.0002965726,0.0005318233,0.0004033801,0.0012473542,0.08362819,0.005004088],"study_design_scores_gemma":[0.015251802,0.0010276651,0.9065829,0.0033267364,0.0010288055,0.00006214684,0.00047996372,0.05363658,0.00013580147,0.00004688828,0.017695922,0.00072481635],"about_ca_topic_score_codex":0.0012377194,"about_ca_topic_score_gemma":0.000044413755,"teacher_disagreement_score":0.06593227,"about_ca_system_score_codex":0.018738316,"about_ca_system_score_gemma":0.03330056,"threshold_uncertainty_score":0.99964947},"labels":[],"label_agreement":null},{"id":"W4385972454","doi":"10.32635/2176-9745.rbc.1968v24n36.4129","title":"Clinical Aspects and Diagnosis of Hodgkin’s Disease","year":2023,"lang":"pt","type":"article","venue":"Revista Brasileira de Cancerologia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Disease; Medicine; Hodgkin lymphoma; Lymphoma; Pathology","score_opus":0.06844329385287344,"score_gpt":0.39324400940949494,"score_spread":0.3248007155566215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385972454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972387,0.02443473,0.000032530366,0.00064972625,0.00047293885,0.001151739,0.00027233709,0.00017493014,0.0004240455],"genre_scores_gemma":[0.97246665,0.023968931,0.000050256174,0.0007917568,0.0009158307,0.00021642208,0.00006224447,0.000093609364,0.0014343275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994857,0.0007320486,0.0012666241,0.0010861225,0.0008091225,0.0012490725],"domain_scores_gemma":[0.99378383,0.0029186371,0.00043053023,0.0012829035,0.0002515853,0.0013324968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002675282,0.00046305108,0.0014124068,0.00032793003,0.0001280288,0.00008335067,0.0005096111,0.0004728672,0.00068444136],"category_scores_gemma":[0.0063444423,0.00042596244,0.00040537224,0.0012579246,0.0011519539,0.00010188468,0.00060080684,0.0008275055,0.00035841847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010946648,0.00020175074,0.9435786,0.003977662,0.0003683354,0.0018284571,0.00020140673,0.00003201424,0.000038274233,0.0012275077,0.03956701,0.007884302],"study_design_scores_gemma":[0.009279635,0.00094839156,0.97493166,0.0018650432,0.0006735788,0.00004764756,0.0001526215,0.007940603,0.0000666381,0.000054648885,0.0036860493,0.00035348986],"about_ca_topic_score_codex":0.0005863878,"about_ca_topic_score_gemma":0.00005667343,"teacher_disagreement_score":0.03588096,"about_ca_system_score_codex":0.0063436357,"about_ca_system_score_gemma":0.014515606,"threshold_uncertainty_score":0.9998192},"labels":[],"label_agreement":null},{"id":"W4385998043","doi":"10.1016/j.leukres.2023.107372","title":"Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; University of Toronto; Spinal Cord Injury BC; Jewish General Hospital; Health Sciences Centre; CancerCare Manitoba; Leukemia & Lymphoma Society of Canada; Princess Margaret Cancer Centre; Ottawa Hospital; Foothills Medical Centre","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Guideline; Refractory (planetary science); Internal medicine; Intensive care medicine; Oncology; Leukemia; Pathology","score_opus":0.15840194623129275,"score_gpt":0.4246529317459071,"score_spread":0.26625098551461435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385998043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745938,0.00836736,0.00022438185,0.004488182,0.00054663967,0.006921346,0.0002483909,0.00049448997,0.0041154074],"genre_scores_gemma":[0.97256225,0.0036381085,0.00097644114,0.0003101519,0.001209181,0.0014039127,0.00057048176,0.00022801296,0.019101454],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99175185,0.00040226147,0.0012832382,0.0011996735,0.0024921065,0.0028708722],"domain_scores_gemma":[0.9904965,0.0039712256,0.00012499558,0.0020973822,0.0017572304,0.0015526523],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004165977,0.00050304923,0.0010734532,0.0026817408,0.0005011168,0.0000816249,0.0007791575,0.0006017631,0.000684112],"category_scores_gemma":[0.003682536,0.00043506426,0.00053135527,0.0034515352,0.0006996294,0.0002349504,0.00016059152,0.00046655332,0.001214802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012068937,0.00039690023,0.0016231011,0.0079480605,0.0014461763,0.005374325,0.0018902343,0.046355132,0.10175506,0.0018594132,0.6414725,0.17781013],"study_design_scores_gemma":[0.045936294,0.007760217,0.0004695703,0.0015515194,0.00015787205,0.00011443812,0.0003319228,0.5735922,0.061834253,0.00028016727,0.30745336,0.00051818544],"about_ca_topic_score_codex":0.40809938,"about_ca_topic_score_gemma":0.055123318,"teacher_disagreement_score":0.52723706,"about_ca_system_score_codex":0.6780065,"about_ca_system_score_gemma":0.5143921,"threshold_uncertainty_score":0.9998101},"labels":[],"label_agreement":null},{"id":"W4386000656","doi":"10.1002/jha2.771","title":"Molecular characterization and clonal evolution in Richter transformation: Insights from a case of plasmablastic lymphoma (RT‐PBL) arising from chronic lymphocytic leukaemia (CLL) and review of the literature","year":2023,"lang":"en","type":"article","venue":"eJHaem","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Plasmablastic lymphoma; Immunophenotyping; Lymphoma; Chronic lymphocytic leukemia; Pathology; Lymphocytosis; Context (archaeology); Bone marrow; Aggressive lymphoma; Leukemia; Internal medicine; Immunology; Rituximab; Flow cytometry; Biology","score_opus":0.008715977351772661,"score_gpt":0.2558249163241052,"score_spread":0.24710893897233255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386000656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97413623,0.024468321,0.00031383528,0.00019587658,0.000092770024,0.0006184343,0.00010658053,0.000022375805,0.00004559172],"genre_scores_gemma":[0.9949127,0.0044370457,0.00005930674,0.00012305098,0.00007558031,0.000025118097,0.00032190862,0.000022139997,0.000023161367],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99838316,0.00015011756,0.0005545646,0.00029998744,0.00039807384,0.00021409312],"domain_scores_gemma":[0.99907947,0.00020722703,0.00017045817,0.00033641062,0.000118691954,0.000087725435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018031594,0.00018358976,0.00044603457,0.00019641088,0.000057880403,0.000021726051,0.000089828056,0.00015817962,0.00002096943],"category_scores_gemma":[0.00017412686,0.0001363581,0.00007501361,0.00092181185,0.00015206933,0.00020554288,0.0000853126,0.00014545978,0.0000054153975],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020896047,0.00041354212,0.005206711,0.060238164,0.0011724425,0.010495112,0.05144211,0.00074064103,0.7672261,0.0036183302,0.0002728315,0.09708444],"study_design_scores_gemma":[0.06154796,0.00062633306,0.20010865,0.11419779,0.0011051625,0.0055151656,0.000816188,0.52429557,0.08782229,0.0021793055,0.0009076629,0.00087794714],"about_ca_topic_score_codex":0.0010199739,"about_ca_topic_score_gemma":0.00014942445,"teacher_disagreement_score":0.6794038,"about_ca_system_score_codex":0.0061082537,"about_ca_system_score_gemma":0.003028435,"threshold_uncertainty_score":0.9977071},"labels":[],"label_agreement":null},{"id":"W4386024076","doi":"10.1097/01.hs9.0000967492.06443.0a","title":"S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Obinutuzumab; Venetoclax; Medicine; Chronic lymphocytic leukemia; Internal medicine; Tolerability; Chlorambucil; Bendamustine; Oncology; Hazard ratio; Interquartile range; Clinical endpoint; Leukemia; Gastroenterology; Randomized controlled trial; Cyclophosphamide; Chemotherapy; Adverse effect; Confidence interval","score_opus":0.023674757635716876,"score_gpt":0.31049292788169774,"score_spread":0.2868181702459809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98256147,0.0011275463,0.000029903578,0.0001612687,0.0003503516,0.011113719,0.000061861734,0.00034259766,0.0042512966],"genre_scores_gemma":[0.9763194,0.00024302842,0.000121383506,0.00005707806,0.00034133223,0.0009795687,0.00008529203,0.000115891125,0.021737035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99579775,0.00040027362,0.0011107137,0.0007297988,0.0010217818,0.00093966926],"domain_scores_gemma":[0.99578977,0.0016326965,0.00034810803,0.0016304234,0.0003738547,0.00022515758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001987775,0.00039134888,0.0014027095,0.00012573684,0.00019330376,0.000033472283,0.0005338259,0.00026364365,0.00020691619],"category_scores_gemma":[0.002550913,0.0002526398,0.00063295447,0.0013961946,0.00040670566,0.000069807174,0.0003265354,0.0003130006,0.0002633126],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.71935505,0.0005819807,0.00062859384,0.009697509,0.006417632,0.0010415192,0.01399687,0.044726457,0.006185211,0.0016859003,0.18684804,0.008835256],"study_design_scores_gemma":[0.8672258,0.0014182527,0.00021454082,0.000875882,0.0008360375,0.0001055684,0.0014100833,0.11625435,0.007399514,0.00023362122,0.0037150139,0.00031130668],"about_ca_topic_score_codex":0.0029577913,"about_ca_topic_score_gemma":0.0004925134,"teacher_disagreement_score":0.18313304,"about_ca_system_score_codex":0.121916644,"about_ca_system_score_gemma":0.06929772,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W4386024134","doi":"10.1097/01.hs9.0000967716.49281.3f","title":"S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Bendamustine; Hazard ratio; Rituximab; Gastroenterology; Confidence interval; Neutropenia; Minimal residual disease; Chronic lymphocytic leukemia; Surgery; Oncology; Leukemia; Chemotherapy; Lymphoma","score_opus":0.02021042823609262,"score_gpt":0.26840182374875443,"score_spread":0.2481913955126618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616706,0.0013926605,0.000008543562,0.000019169567,0.000092115304,0.0011963007,0.00006519183,0.00019941422,0.0008595473],"genre_scores_gemma":[0.9936858,0.00037802698,0.00013302898,0.000026928254,0.00006210385,0.00011340767,0.000525842,0.00010038836,0.0049744826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627405,0.00012400154,0.0006419359,0.00087237987,0.0012521752,0.00083543576],"domain_scores_gemma":[0.99760985,0.00029523254,0.00025656648,0.0011168212,0.0003398581,0.00038165387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029886828,0.00047664123,0.0012622832,0.00046663903,0.00015895237,0.00003314086,0.0002180017,0.00027844057,0.00073907786],"category_scores_gemma":[0.0001366836,0.00037212204,0.0003036048,0.002911757,0.0003022268,0.00013861916,0.00017137466,0.00029777706,0.00021878674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.017303871,0.0013685585,0.91927326,0.0030026129,0.02315977,0.0026932308,0.00397127,0.007881851,0.0016174917,0.00015246758,0.008070708,0.011504931],"study_design_scores_gemma":[0.2735885,0.008341389,0.5990325,0.0013860019,0.011166625,0.00008490948,0.0014747684,0.0979112,0.0038041223,0.000033184882,0.001999544,0.0011772282],"about_ca_topic_score_codex":0.0032054184,"about_ca_topic_score_gemma":0.00086604693,"teacher_disagreement_score":0.32024074,"about_ca_system_score_codex":0.06528202,"about_ca_system_score_gemma":0.013938612,"threshold_uncertainty_score":0.9998731},"labels":[],"label_agreement":null},{"id":"W4386053311","doi":"10.2147/ppa.s417180","title":"Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia","year":2023,"lang":"en","type":"article","venue":"Patient Preference and Adherence","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Ofatumumab; Odds ratio; Logistic regression; Oncology; Leukemia","score_opus":0.10034083915968854,"score_gpt":0.3340186958778291,"score_spread":0.23367785671814056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386053311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707973,0.00031665846,0.000011789083,0.000025513747,0.00005318331,0.0015424616,0.000068047,0.0000963648,0.00080627465],"genre_scores_gemma":[0.9981593,0.00081495766,0.00014881633,0.000012234626,0.000043751028,0.00016275152,0.00020910215,0.00003738885,0.00041168308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966984,0.000095503325,0.00086398784,0.00082224107,0.0007590459,0.00076083257],"domain_scores_gemma":[0.9980601,0.0004839004,0.0003266043,0.0005700435,0.0001922421,0.00036710885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001760691,0.00043824947,0.0009393279,0.00038449184,0.00011961297,0.000041863805,0.00019446755,0.00015369769,0.00008229156],"category_scores_gemma":[0.000117515025,0.00032984448,0.000058127498,0.0010493507,0.00039781167,0.00017983213,0.00026616786,0.0002514269,0.00004216641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000882333,0.00027826862,0.92185485,0.0006336555,0.00009244648,0.000024334277,0.0016579032,0.00025154382,0.0001615813,0.000030861345,0.00006300522,0.07406922],"study_design_scores_gemma":[0.03619872,0.02221355,0.91112894,0.003061015,0.00020871384,0.0000056975396,0.00035126222,0.01585482,0.009767225,0.000091174574,0.00050210505,0.0006167548],"about_ca_topic_score_codex":0.0049551507,"about_ca_topic_score_gemma":0.0025743293,"teacher_disagreement_score":0.07345246,"about_ca_system_score_codex":0.013991352,"about_ca_system_score_gemma":0.004248447,"threshold_uncertainty_score":0.99991536},"labels":[],"label_agreement":null},{"id":"W4386101054","doi":"10.1097/01.hs9.0000974564.02780.6b","title":"PB1936: IDENTIFYING INEQUITIES IN SUPPORT - GLOBAL SURVEY OF PATIENT ORGANISATIONS DELIVERING SUPPORT SERVICES FOR CLL PATIENTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Service delivery framework; Medicine; Service (business); Business; Health care; Economic growth; Political science; Marketing","score_opus":0.04832421620977106,"score_gpt":0.34331737036039095,"score_spread":0.2949931541506199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386101054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738413,0.000048762075,0.000036927766,0.000047774345,0.00018788391,0.00081313687,0.00034477,0.00008313132,0.001053466],"genre_scores_gemma":[0.9978232,0.00004731239,0.0003037294,0.000107329324,0.00003273475,0.00007902276,0.0011472646,0.000037773414,0.00042167702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978022,0.00005323596,0.0006392949,0.0003319359,0.00064605207,0.00052727375],"domain_scores_gemma":[0.99868494,0.00019548282,0.00014773502,0.00035035756,0.00048251648,0.00013897377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004962848,0.00017291712,0.000409175,0.000104036815,0.000067851535,0.000023322962,0.00017273528,0.00011806037,0.00056524324],"category_scores_gemma":[0.00029154355,0.00017046269,0.000083208164,0.0008590762,0.00006328653,0.00016737767,0.000252334,0.00010018808,0.0001218811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049787626,0.00039433173,0.9787626,0.0035117366,0.00014060258,0.000115713636,0.004551335,0.00021992833,0.00042745803,0.00015711368,0.0062791356,0.0049421503],"study_design_scores_gemma":[0.019922355,0.0011727528,0.95719284,0.0005546829,0.00009352263,0.000038482172,0.0048478683,0.005545855,0.007141942,0.00025973984,0.0027889132,0.0004410549],"about_ca_topic_score_codex":0.00956144,"about_ca_topic_score_gemma":0.008184967,"teacher_disagreement_score":0.021569788,"about_ca_system_score_codex":0.0038019286,"about_ca_system_score_gemma":0.0027627468,"threshold_uncertainty_score":0.99703395},"labels":[],"label_agreement":null},{"id":"W4386102508","doi":"10.1097/01.hs9.0000975836.58931.97","title":"PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Obinutuzumab; Medicine; Ibrutinib; Lenalidomide; Rituximab; Internal medicine; Oncology; Follicular lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukemia; Salvage therapy; Phases of clinical research; Idelalisib; Lymphoma; Clinical trial; Chemotherapy; Leukemia; Multiple myeloma","score_opus":0.03128032831111953,"score_gpt":0.3233636286600862,"score_spread":0.2920833003489667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386102508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531215,0.00028730094,0.00006306699,0.0002206457,0.00028233524,0.002743924,0.000090793335,0.00020035476,0.00079941907],"genre_scores_gemma":[0.9894922,0.0002683053,0.0008767716,0.00011189769,0.00024782843,0.0001418659,0.00027870637,0.0001494524,0.008432989],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949292,0.0002219277,0.0010900098,0.000872205,0.0017659727,0.0011207111],"domain_scores_gemma":[0.9972316,0.0005571602,0.0003877991,0.0011014793,0.00035244267,0.00036953375],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007347649,0.0005419354,0.0017345538,0.000382524,0.0001262041,0.000043840522,0.0003692929,0.0003556925,0.0011281626],"category_scores_gemma":[0.0009648347,0.00036569676,0.00023907212,0.0017391903,0.00040135664,0.00025647876,0.00025631214,0.0003879709,0.00024308915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9587897,0.006759949,0.0023244848,0.0023598978,0.00066202425,0.010335841,0.0013640784,0.00008516418,0.0006409895,0.000059868238,0.008511226,0.00810676],"study_design_scores_gemma":[0.9699979,0.008523464,0.003528179,0.001734115,0.00025875837,0.00017049574,0.0009382792,0.0049335123,0.0025124692,0.000010715983,0.006859922,0.00053222844],"about_ca_topic_score_codex":0.0011023292,"about_ca_topic_score_gemma":0.00029833688,"teacher_disagreement_score":0.011208143,"about_ca_system_score_codex":0.006687527,"about_ca_system_score_gemma":0.013001374,"threshold_uncertainty_score":0.9998795},"labels":[],"label_agreement":null},{"id":"W4386142904","doi":"10.1097/01.hs9.0000969492.96103.aa","title":"P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Observational study; Clinical trial; IGHV@; Chronic lymphocytic leukemia; Demography; Pediatrics; Oncology; Leukemia","score_opus":0.02100252222309458,"score_gpt":0.306741845796958,"score_spread":0.28573932357386345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386142904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956576,0.000032202806,0.0000019116899,0.00021728394,0.00005326491,0.00061553036,0.000027297612,0.00009845541,0.003296452],"genre_scores_gemma":[0.9868637,0.00017243675,0.0000433047,0.00006187938,0.000055598335,0.00011285445,0.00009684118,0.00003805089,0.012555339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860126,0.000033538887,0.00021573865,0.00031420856,0.00039739851,0.000437851],"domain_scores_gemma":[0.99930686,0.00015039482,0.000040799878,0.0002964479,0.000041207455,0.00016426574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081133796,0.0001904258,0.0003820979,0.0001153581,0.000053443666,0.00002750628,0.000055012333,0.00006585957,0.00022139224],"category_scores_gemma":[0.0000376568,0.00012772724,0.000046024754,0.00032244023,0.00011094617,0.000086705935,0.000073963034,0.000117404714,0.000053547185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020666132,0.00015258703,0.9946126,0.00016445787,0.00006349715,0.0003054458,0.0005456079,0.0000072865346,9.055301e-7,0.0000699984,0.00042933424,0.0034416323],"study_design_scores_gemma":[0.017141271,0.00030443238,0.9808032,0.0002048353,0.000035877685,0.0000030277322,0.00024068951,0.00050759467,0.00006991711,0.000027950085,0.0005285261,0.00013269055],"about_ca_topic_score_codex":0.024864458,"about_ca_topic_score_gemma":0.06262717,"teacher_disagreement_score":0.03776271,"about_ca_system_score_codex":0.0033676012,"about_ca_system_score_gemma":0.0006186512,"threshold_uncertainty_score":0.9816291},"labels":[],"label_agreement":null},{"id":"W4386170848","doi":"10.1097/01.hs9.0000969780.55126.5b","title":"P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Regimen; Myelodysplastic syndromes; Dosing; International Prognostic Scoring System; Adverse effect; Oncology; Gastroenterology; Bone marrow","score_opus":0.029238519668841726,"score_gpt":0.35587358611237524,"score_spread":0.3266350664435335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386170848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407655,0.00019216564,0.0009668274,0.00013793542,0.00021958175,0.0037387533,0.00014620778,0.0001311596,0.0003908096],"genre_scores_gemma":[0.99795806,0.00030357414,0.0003822627,0.00004459832,0.000059614747,0.00013624366,0.00023592323,0.000086167274,0.0007935269],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994476,0.00078349654,0.0016125368,0.0010228694,0.0012317856,0.00087330124],"domain_scores_gemma":[0.9942848,0.0033206488,0.00034067893,0.0010576214,0.0004116772,0.00058456935],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025152569,0.00054580776,0.0028580034,0.0009025712,0.0001168875,0.000050493316,0.00035621208,0.0001579442,0.0012432354],"category_scores_gemma":[0.0062203375,0.00044062594,0.00046051823,0.0046282453,0.0002773358,0.00017708205,0.00059930177,0.00048026597,0.000131447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8492634,0.020894557,0.06625139,0.0021595345,0.01128151,0.0034187133,0.0085455645,0.009193239,0.00079818437,0.00009640757,0.00211204,0.025985442],"study_design_scores_gemma":[0.8660176,0.0032231526,0.075369276,0.0008165643,0.0028115057,0.00004001116,0.002692573,0.047938246,0.0002673278,0.000016882323,0.0002292094,0.00057765463],"about_ca_topic_score_codex":0.0012447559,"about_ca_topic_score_gemma":0.00090702943,"teacher_disagreement_score":0.03874501,"about_ca_system_score_codex":0.0028207232,"about_ca_system_score_gemma":0.0014860672,"threshold_uncertainty_score":0.99980456},"labels":[],"label_agreement":null},{"id":"W4386269965","doi":"10.1016/s2152-2650(23)00530-x","title":"POSTER: CLL-587 Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Chemoimmunotherapy; Ibrutinib; Chronic lymphocytic leukemia; Medicine; Oncology; Venetoclax; Internal medicine; Leukemia; Cancer research","score_opus":0.04926282876990089,"score_gpt":0.32450287670601624,"score_spread":0.27524004793611534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894763,0.0003472872,0.000015417141,0.0005945801,0.00053273403,0.0055726864,0.00018772099,0.0015459602,0.0022560062],"genre_scores_gemma":[0.9641554,0.0030431782,0.00040190486,0.0012865883,0.00072323706,0.0010262533,0.0013046229,0.0008578004,0.027201064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98470014,0.0007061444,0.004080624,0.0037667307,0.0026430425,0.0041032904],"domain_scores_gemma":[0.9874877,0.004221163,0.001316453,0.004353207,0.0007670007,0.0018544983],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013733322,0.0027047046,0.005294682,0.001783725,0.0006343849,0.00037527317,0.0015607894,0.0013437688,0.00049650006],"category_scores_gemma":[0.00078885944,0.0018161932,0.0011929099,0.0049124933,0.0017016334,0.00052638975,0.00065554434,0.00057947775,0.0014605906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10218772,0.0031919684,0.5702285,0.0014849422,0.004383304,0.012023058,0.00076904637,0.0026280624,0.0000864557,0.00006364287,0.0023943996,0.3005589],"study_design_scores_gemma":[0.22293359,0.018877657,0.72843486,0.002610442,0.000766623,0.00042483147,0.0000747737,0.013972002,0.0010624763,0.000017556178,0.009034892,0.0017902671],"about_ca_topic_score_codex":0.015983338,"about_ca_topic_score_gemma":0.018333804,"teacher_disagreement_score":0.33968028,"about_ca_system_score_codex":0.4624632,"about_ca_system_score_gemma":0.12278291,"threshold_uncertainty_score":0.9999527},"labels":[],"label_agreement":null},{"id":"W4386270530","doi":"10.14740/jh1140","title":"Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Science for Life Laboratory; Vetenskapsrådet; Cancerföreningen i Stockholm; Cancerfonden; Center for Innovative Medicine; Karolinska Institutet; BeiGene","keywords":"Medicine; Saliva; Ibrutinib; Immunology; Vaccination; Chronic lymphocytic leukemia; Antibody; Immunity; Immune system; Internal medicine; Gastroenterology; Leukemia","score_opus":0.014159151620335646,"score_gpt":0.2871681095855243,"score_spread":0.27300895796518865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99844456,0.00073199085,0.000051921397,0.00008717749,0.00008522318,0.00040068632,0.000003987608,0.000040163533,0.00015426567],"genre_scores_gemma":[0.99948996,0.00023424339,0.000033742566,0.000045096473,0.0000299992,0.000012583763,0.000016238904,0.00003516328,0.000102968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978728,0.00016700114,0.0007728654,0.00022207818,0.00043750077,0.0005277539],"domain_scores_gemma":[0.9985093,0.0003313273,0.000353978,0.0002940267,0.00037992507,0.00013147587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004063891,0.00020670518,0.00077123725,0.000813077,0.000100303005,0.000017585175,0.00018054238,0.00019161447,0.000009449999],"category_scores_gemma":[0.00029805876,0.00015700053,0.00007994364,0.00079195463,0.0001508985,0.0001514114,0.00013104331,0.00051140896,0.000040331517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015557845,0.0010261462,0.837466,0.014786261,0.0030178723,0.050558474,0.0059795035,0.013560101,0.04605724,0.00095466914,0.0049025486,0.00613335],"study_design_scores_gemma":[0.24108243,0.0036254725,0.5076208,0.007908869,0.00049136596,0.060361397,0.0021718391,0.11564042,0.059916478,0.00018303146,0.00013710614,0.0008607587],"about_ca_topic_score_codex":0.00058482314,"about_ca_topic_score_gemma":0.0002778739,"teacher_disagreement_score":0.32984516,"about_ca_system_score_codex":0.043276455,"about_ca_system_score_gemma":0.0114833815,"threshold_uncertainty_score":0.9941206},"labels":[],"label_agreement":null},{"id":"W4386271138","doi":"10.1016/s2152-2650(23)00894-7","title":"POSTER: CT-343 Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) for Lymphoma Patients: Single-Institution Experience","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Hematopoietic cell; Lymphoma; Medicine; Hematopoietic stem cell transplantation; Transplantation; Oncology; Haematopoiesis; Internal medicine; Stem cell; Biology","score_opus":0.048916569568724914,"score_gpt":0.35338594125318123,"score_spread":0.3044693716844563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438083,0.00016847289,0.00042724027,0.00022367526,0.0009835067,0.0018442037,0.00013200345,0.00034410588,0.001495973],"genre_scores_gemma":[0.9960683,0.0003454317,0.00068066467,0.0006443866,0.00024121438,0.00031196175,0.0005940936,0.000112997725,0.00100097],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99417716,0.00020723777,0.0022354578,0.0011293463,0.0011850977,0.001065692],"domain_scores_gemma":[0.99525875,0.0019507929,0.0005400871,0.001121446,0.00056474487,0.0005641813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009439898,0.0005432787,0.0013504316,0.00037034735,0.00022574465,0.00005259761,0.0005788755,0.0004105281,0.00008253686],"category_scores_gemma":[0.0014346855,0.00047945027,0.00084543775,0.00085403235,0.00082667376,0.00030610996,0.00018451594,0.0001503277,0.00047385896],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0072856746,0.0042212238,0.40363207,0.005254236,0.0007328295,0.0016463592,0.0036293215,0.00013856361,0.009293492,0.001041558,0.0045070606,0.5586176],"study_design_scores_gemma":[0.047865808,0.0017172678,0.9067883,0.00044489122,0.00036830353,0.00027705208,0.00031756583,0.0016977042,0.036672488,0.00025100188,0.002993709,0.00060590054],"about_ca_topic_score_codex":0.00018407,"about_ca_topic_score_gemma":0.000019783218,"teacher_disagreement_score":0.5580117,"about_ca_system_score_codex":0.008961383,"about_ca_system_score_gemma":0.006664474,"threshold_uncertainty_score":0.9997657},"labels":[],"label_agreement":null},{"id":"W4386277907","doi":"10.1016/s2152-2650(23)00548-7","title":"POSTER: CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Post-hoc analysis; Medicine; Post hoc; Oncology; Internal medicine; Pharmacology; Imatinib","score_opus":0.03539221462855332,"score_gpt":0.3543851135315048,"score_spread":0.3189928989029515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962466,0.00025907755,0.000015137679,0.0002977539,0.0002648929,0.0021037154,0.00067909993,0.00004981498,0.00008394918],"genre_scores_gemma":[0.99860656,0.00019390877,0.00036680192,0.0001519337,0.000069684844,0.00005784359,0.00042423359,0.00005853219,0.00007049853],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99172324,0.0018106948,0.0034418115,0.00066660397,0.0018411039,0.0005165464],"domain_scores_gemma":[0.98607206,0.008800153,0.0021935713,0.0016036232,0.0011397818,0.00019083162],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026014347,0.00032375703,0.0015533171,0.0004449544,0.00012334593,0.000025204228,0.0006272032,0.00026699185,0.00013844299],"category_scores_gemma":[0.010138348,0.0002087051,0.0007187223,0.003469293,0.0007302655,0.00012749,0.00052537344,0.00025434126,0.000009428083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5158153,0.009510191,0.13708438,0.00091407,0.020812547,0.00030220012,0.0345005,0.05107827,0.015523659,0.00023228097,0.003649122,0.21057744],"study_design_scores_gemma":[0.15197335,0.011551793,0.7340516,0.00050053484,0.0049898336,0.000007782811,0.015088762,0.07395168,0.007337049,0.000076812954,0.00010652854,0.00036427533],"about_ca_topic_score_codex":0.004097028,"about_ca_topic_score_gemma":0.00018303342,"teacher_disagreement_score":0.5969672,"about_ca_system_score_codex":0.00249756,"about_ca_system_score_gemma":0.00727987,"threshold_uncertainty_score":0.99834794},"labels":[],"label_agreement":null},{"id":"W4386282236","doi":"10.1016/s2152-2650(23)00531-1","title":"POSTER: CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Fludarabine; Chronic lymphocytic leukemia; Medicine; Rituximab; Oncology; Internal medicine; Leukemia; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.02448581812995936,"score_gpt":0.3018563122573838,"score_spread":0.2773704941274244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488926,0.0009923493,0.0000033599647,0.0001290781,0.00027139604,0.0029539543,0.00028494126,0.00025450072,0.00022115553],"genre_scores_gemma":[0.9946315,0.0010087726,0.00017345582,0.00068767165,0.00019901777,0.00044392524,0.00071943377,0.00022175997,0.0019144132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925494,0.0003227541,0.0022506784,0.0018783102,0.00094476464,0.0020540818],"domain_scores_gemma":[0.9957748,0.0015848161,0.0003864488,0.0009701878,0.0003622703,0.0009214765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013879329,0.000714743,0.0024843747,0.0004942681,0.0003188729,0.00045353262,0.00048787822,0.0008348173,0.00010169957],"category_scores_gemma":[0.0011918333,0.0008212072,0.00026716792,0.0012784118,0.001379228,0.00041110927,0.00052739115,0.0006450869,0.00004313626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001354249,0.00022649372,0.7303583,0.0010680453,0.00023500151,0.0049028983,0.00018695972,0.000014308839,0.00003621379,0.0000062993545,0.0014039698,0.26020727],"study_design_scores_gemma":[0.117220305,0.0024169148,0.87047696,0.0014792513,0.00019606779,0.0010789441,0.00011122737,0.0056698225,0.00006639186,0.00006734152,0.00043826154,0.00077851274],"about_ca_topic_score_codex":0.23966944,"about_ca_topic_score_gemma":0.5109057,"teacher_disagreement_score":0.27123624,"about_ca_system_score_codex":0.08946448,"about_ca_system_score_gemma":0.049571108,"threshold_uncertainty_score":0.99942386},"labels":[],"label_agreement":null},{"id":"W4386282375","doi":"10.1016/s2152-2650(23)01134-5","title":"CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Post hoc; Post-hoc analysis; Mutation; Oncology; Internal medicine; Genetics; Biology; Gene","score_opus":0.03633673717965375,"score_gpt":0.35773757400516276,"score_spread":0.321400836825509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965333,0.00025570046,0.000026086322,0.00024410355,0.00025251566,0.0019845483,0.0005777217,0.00004892764,0.00007712927],"genre_scores_gemma":[0.9984863,0.00022070858,0.00053773995,0.00012133064,0.00007154469,0.000061955216,0.00037245132,0.000055296903,0.0000727216],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99192,0.001746698,0.003344908,0.0006458276,0.0018421242,0.0005004308],"domain_scores_gemma":[0.9857601,0.009267496,0.002137821,0.0015567475,0.0010935508,0.00018430676],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027212342,0.00030769708,0.0015199009,0.00042382197,0.00012280035,0.000022275324,0.0006038327,0.00025917625,0.00014845518],"category_scores_gemma":[0.011947218,0.00019767624,0.0006978766,0.0036852425,0.00075475255,0.00011646951,0.00047267173,0.0002512557,0.000008972368],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4732482,0.009963822,0.10865129,0.0008967747,0.021490116,0.00027611273,0.031986706,0.09905496,0.0142863495,0.0003694069,0.0047873394,0.23498893],"study_design_scores_gemma":[0.1557224,0.010139421,0.6706206,0.00047042413,0.005077669,0.000005703808,0.018038513,0.13268371,0.0066405325,0.00010341288,0.00013941662,0.0003581816],"about_ca_topic_score_codex":0.004186009,"about_ca_topic_score_gemma":0.00017528313,"teacher_disagreement_score":0.56196934,"about_ca_system_score_codex":0.002557817,"about_ca_system_score_gemma":0.0078101447,"threshold_uncertainty_score":0.99781466},"labels":[],"label_agreement":null},{"id":"W4386320835","doi":"10.1182/hem.v20.5.202352","title":"Rilzabrutinib for Persistent ITP: New Kid on the Block?","year":2023,"lang":"en","type":"article","venue":"The Hematologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Block (permutation group theory); Computer science; Mathematics; Combinatorics","score_opus":0.12095763760708139,"score_gpt":0.36129284624893065,"score_spread":0.24033520864184926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386320835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7080073,0.0006698755,0.00007350907,0.25099677,0.0006896075,0.0035994067,0.000027336097,0.00062243454,0.03531379],"genre_scores_gemma":[0.96309793,0.00007101445,0.0000688138,0.0021479402,0.00029995485,0.0001634229,0.0000184124,0.000035378744,0.03409712],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984379,0.00006765352,0.00022619196,0.00027932302,0.00044338772,0.000545533],"domain_scores_gemma":[0.9969918,0.0018390156,0.000061021117,0.00090108736,0.00006635718,0.00014069989],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008218689,0.0001576423,0.0002809067,0.00005974404,0.00030668083,0.000034304645,0.00041646007,0.00009116689,0.00016276905],"category_scores_gemma":[0.0014886841,0.0000723851,0.0002745393,0.00038085043,0.00036139708,0.000013889601,0.00015779102,0.00024122706,0.0016709272],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000711295,0.000096913434,0.00008995564,0.00023721853,0.00026773984,0.00017585988,0.0010014435,0.00007835446,0.0002456608,0.042769883,0.9528814,0.0014442788],"study_design_scores_gemma":[0.03651982,0.0023226521,0.0007929613,0.000809833,0.0007184198,0.005513002,0.009170934,0.0954986,0.024924885,0.011537854,0.81138915,0.0008019137],"about_ca_topic_score_codex":0.00023836759,"about_ca_topic_score_gemma":0.000021499247,"teacher_disagreement_score":0.25509068,"about_ca_system_score_codex":0.0012997072,"about_ca_system_score_gemma":0.001861623,"threshold_uncertainty_score":0.9991064},"labels":[],"label_agreement":null},{"id":"W4386331412","doi":"10.1016/s2152-2650(23)01119-9","title":"CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Fludarabine; Chronic lymphocytic leukemia; Medicine; Rituximab; Oncology; Internal medicine; Immunology; Leukemia; Antibody; Chemotherapy; Cyclophosphamide","score_opus":0.025503224660656458,"score_gpt":0.30430110853862136,"score_spread":0.2787978838779649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386331412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950628,0.0009846614,0.0000057331094,0.0001095448,0.00026424188,0.0028554485,0.00024723777,0.00026036223,0.00020992503],"genre_scores_gemma":[0.9943855,0.0011382666,0.00025676715,0.000576373,0.00020967716,0.00049477955,0.00065223547,0.00021825702,0.0020681582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925934,0.00031139015,0.0022134709,0.0018734159,0.0009524945,0.002055823],"domain_scores_gemma":[0.995744,0.0016508397,0.00037725325,0.000954576,0.00035069184,0.0009226533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014595042,0.0007009571,0.0024845314,0.0004837306,0.0003265738,0.00042499075,0.0004785799,0.00083602587,0.00010981102],"category_scores_gemma":[0.0013696253,0.00080824306,0.0002625079,0.0013641801,0.0014539167,0.0003907753,0.000486646,0.00065630325,0.000042784315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011789581,0.00023146931,0.70644933,0.0010652794,0.00023484102,0.00468056,0.00016728319,0.00002534878,0.000032261356,0.000009736036,0.0017816552,0.2841433],"study_design_scores_gemma":[0.116513856,0.002069129,0.8677542,0.0013895521,0.00019053397,0.0008439902,0.00012495313,0.0096425535,0.000056252018,0.000088240144,0.00056045136,0.00076625415],"about_ca_topic_score_codex":0.25507253,"about_ca_topic_score_gemma":0.5310735,"teacher_disagreement_score":0.28337705,"about_ca_system_score_codex":0.094397016,"about_ca_system_score_gemma":0.05384675,"threshold_uncertainty_score":0.99943686},"labels":[],"label_agreement":null},{"id":"W4386438083","doi":"10.1007/s40744-023-00590-w","title":"Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses","year":2023,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Gilead Sciences","keywords":"Medicine; Rheumatoid arthritis; Placebo; Internal medicine; Post-hoc analysis; Methotrexate; Radiography; Surgery; Pathology","score_opus":0.13131910439501193,"score_gpt":0.4747900576888363,"score_spread":0.3434709532938244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386438083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25074503,0.7467875,0.0000012181134,0.000012226437,0.000059461487,0.002338387,0.000038202765,0.000013826926,0.00000416424],"genre_scores_gemma":[0.0048095235,0.9944926,0.00011917686,0.000008593589,0.0000048727857,0.00022219929,0.00028439274,0.000049658975,0.0000089790165],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9959394,0.0010064756,0.0017671366,0.00053089485,0.00040604742,0.00035008672],"domain_scores_gemma":[0.99703676,0.0006796535,0.0014754891,0.00040948426,0.00032225208,0.00007638947],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009985397,0.0004227299,0.0046961852,0.0010237044,0.0000587748,0.0000041316252,0.00014295391,0.00033315376,0.00005656719],"category_scores_gemma":[0.00027797546,0.00027686506,0.00031508922,0.0018214332,0.00053181,0.00008291609,0.00006790821,0.00047454916,0.0000012974538],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017496839,0.0011565299,0.0032772887,0.1515296,0.0023973258,0.00008844407,0.0014409058,6.2621416e-7,9.4639097e-7,0.000022623295,0.000052445623,0.8382836],"study_design_scores_gemma":[0.056295898,0.0031059422,0.00020063708,0.93441224,0.00029437957,0.00021660715,0.00038682416,0.00003332378,0.00000610388,0.00004669218,0.0046641286,0.00033721197],"about_ca_topic_score_codex":0.00029616794,"about_ca_topic_score_gemma":0.00009534727,"teacher_disagreement_score":0.83794636,"about_ca_system_score_codex":0.0006135101,"about_ca_system_score_gemma":0.0024897298,"threshold_uncertainty_score":0.99996835},"labels":[],"label_agreement":null},{"id":"W4386525844","doi":"10.3390/curroncol30090599","title":"Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Mucormycosis; Fulminant; Neutropenia; Dermatology; Chronic lymphocytic leukemia; Histopathology; Immunosuppression; Skin biopsy; Autopsy; Surgery; Pathology; Biopsy; Internal medicine; Chemotherapy; Leukemia","score_opus":0.041816974222532104,"score_gpt":0.36274939819960333,"score_spread":0.3209324239770712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386525844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96563756,0.031809267,0.0000010780718,0.00036353353,0.00010848165,0.0015382044,0.000029094002,0.000046940535,0.00046584883],"genre_scores_gemma":[0.98862314,0.010591527,0.000032877837,0.00011679986,0.00006253393,0.00023865407,0.00012311,0.000033193613,0.00017816777],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99785966,0.00018701385,0.0005515769,0.00048729018,0.00044617473,0.00046831602],"domain_scores_gemma":[0.9984217,0.00023243678,0.0002676417,0.00066225784,0.00025153102,0.00016441222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040713866,0.0002443218,0.00067437364,0.00019520767,0.00006127824,0.0000102984795,0.00011802854,0.00013962599,0.000038041977],"category_scores_gemma":[0.00033089815,0.00013124879,0.0000770753,0.0017166068,0.0003189359,0.00006079908,0.00019581383,0.00043792638,0.000008679503],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0029664545,0.0006960449,0.040215436,0.047340713,0.00041978035,0.7727763,0.004016023,0.00007112038,0.00018636593,0.00006634925,0.011099325,0.120146066],"study_design_scores_gemma":[0.029162196,0.004203767,0.0031417399,0.046894956,0.0004143099,0.89689624,0.00034348722,0.0030286268,0.00057500735,0.000009684041,0.014998638,0.0003313492],"about_ca_topic_score_codex":0.0005302062,"about_ca_topic_score_gemma":0.00068370305,"teacher_disagreement_score":0.124119915,"about_ca_system_score_codex":0.021615278,"about_ca_system_score_gemma":0.019633163,"threshold_uncertainty_score":0.9859246},"labels":[],"label_agreement":null},{"id":"W4386591641","doi":"10.1002/jlcr.4062","title":"Preliminary PET imaging of [<sup>11</sup>C]evobrutinib in mouse models of colorectal cancer, SARS‐CoV‐2, and lung damage: Radiosynthesis via base‐aided palladium‐NiXantphos‐mediated <sup>11</sup>C‐carbonylation","year":2023,"lang":"en","type":"article","venue":"Journal of Labelled Compounds and Radiopharmaceuticals","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Azrieli Foundation; Canada Excellence Research Chairs, Government of Canada; Canada Foundation for Innovation","keywords":"Radiosynthesis; In vivo; Colorectal cancer; Positron emission tomography; Ex vivo; Cancer research; Chemistry; Bruton's tyrosine kinase; Lung cancer; Medicine; Imaging agent; Cancer; Nuclear medicine; Pathology; Tyrosine kinase; Internal medicine; Biology; Receptor; Biochemistry","score_opus":0.033319494725938925,"score_gpt":0.33561445613598584,"score_spread":0.3022949614100469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386591641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883293,0.008864838,0.000095372634,0.0014856065,0.000098477205,0.0008655393,0.00008639433,0.000047974176,0.00012650738],"genre_scores_gemma":[0.9883832,0.010271881,0.0007747331,0.00015071231,0.00018588749,0.00002480241,0.000025552106,0.00009350149,0.00008977807],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99487084,0.0005392473,0.0019438522,0.0005374769,0.0012433772,0.0008651787],"domain_scores_gemma":[0.9956424,0.0021804818,0.0007045658,0.00036460054,0.00053413666,0.0005737879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002515972,0.0004962451,0.0017511095,0.0011707088,0.00014839534,0.000057588317,0.00036139862,0.00021452167,0.00006210232],"category_scores_gemma":[0.0005274384,0.0004254542,0.00027098495,0.0011632388,0.0006559348,0.00042613142,0.00026401668,0.00078395667,0.0000019520403],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014696382,0.0024742978,0.05695282,0.0045499983,0.0019024124,0.00437434,0.0067866454,0.03679843,0.8647555,0.0001568817,0.0033362275,0.0032160657],"study_design_scores_gemma":[0.04100279,0.00042203275,0.0018671645,0.0009777019,0.00060278695,0.0013817959,0.0005824887,0.8872878,0.06530691,0.00012264425,0.00011673412,0.00032913248],"about_ca_topic_score_codex":0.0005455471,"about_ca_topic_score_gemma":0.000018118628,"teacher_disagreement_score":0.8504894,"about_ca_system_score_codex":0.0020237484,"about_ca_system_score_gemma":0.002174917,"threshold_uncertainty_score":0.99981976},"labels":[],"label_agreement":null},{"id":"W4386769475","doi":"10.1016/j.celrep.2023.113084","title":"CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax","year":2023,"lang":"en","type":"article","venue":"Cell Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canada Research Chairs; Cole Foundation; Fonds de Recherche du Québec - Santé; Hydro-Québec; Canadian Cancer Society; Fondation de l’Hôpital Maisonneuve-Rosemont; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Acute megakaryoblastic leukemia; Cancer research; Mutation; Phenotype; Medicine; Gene; Biology; Myeloid leukemia; Genetics","score_opus":0.010195709397437058,"score_gpt":0.2766451652075693,"score_spread":0.26644945581013224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386769475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924484,0.00029472556,0.00008580687,0.0004234902,0.00052145385,0.001148071,0.000045999725,0.00028161492,0.0047504744],"genre_scores_gemma":[0.96397,0.00053173315,0.00016701405,0.00057985017,0.0005314372,0.00007800766,0.00013453508,0.000100190395,0.033907246],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960877,0.00005906328,0.0006527052,0.0010747934,0.0012188648,0.0009068811],"domain_scores_gemma":[0.9974887,0.00028186975,0.00019896726,0.00088439067,0.00027205414,0.00087401585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005027451,0.00036750684,0.00059229945,0.00037863888,0.00015858334,0.000077717596,0.0001213057,0.0002543959,0.00013849277],"category_scores_gemma":[0.0003627194,0.0003371779,0.00013909713,0.0009605102,0.000106191124,0.00011832972,0.00047435815,0.00043723953,0.00059551635],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006333512,0.00020816458,0.010695408,0.0010610658,0.000464443,0.14811046,0.0047085094,0.00035207495,0.10229875,0.000011334858,0.7283024,0.003154023],"study_design_scores_gemma":[0.04354113,0.004497289,0.028930742,0.00095692725,0.004589523,0.05104024,0.0034968315,0.041510604,0.7358331,0.0005832659,0.08040775,0.0046125697],"about_ca_topic_score_codex":0.00046499984,"about_ca_topic_score_gemma":0.000018645967,"teacher_disagreement_score":0.6478947,"about_ca_system_score_codex":0.0077860784,"about_ca_system_score_gemma":0.0051800953,"threshold_uncertainty_score":0.99990803},"labels":[],"label_agreement":null},{"id":"W4386809200","doi":"","title":"New developments in the management of Waldenstr&ouml;m macroglobulinemia","year":2017,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Waldenstrom macroglobulinemia; Macroglobulinemia; Medicine; Immunology; Multiple myeloma","score_opus":0.3067864306789438,"score_gpt":0.6021188948295869,"score_spread":0.2953324641506431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386809200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428936,0.005461127,0.00009530087,0.00074123545,0.00037124447,0.0012969555,0.000010367789,0.0000144054075,0.04911571],"genre_scores_gemma":[0.9849469,0.009383045,0.0019558133,0.0002611236,0.00015077772,0.000032260195,0.000008701608,0.000043033924,0.0032183388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99619776,0.00014126019,0.0010294734,0.00043701418,0.0016316031,0.0005628877],"domain_scores_gemma":[0.9969459,0.00018498699,0.0008587004,0.0014641908,0.0002471175,0.00029907987],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021192858,0.00029622574,0.000820277,0.00049630867,0.00026747378,0.00076431053,0.0052822484,0.00012387402,0.0041350964],"category_scores_gemma":[0.00026261865,0.00021180321,0.00017541852,0.0005535028,0.00022755058,0.0008830618,0.0021563142,0.000494172,0.000043967477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020707906,0.0008961736,0.5464013,0.0018594414,0.0016889684,0.0036877594,0.0014074396,0.00007250997,0.012110256,0.0008563448,0.13843878,0.29051018],"study_design_scores_gemma":[0.010132565,0.000019787214,0.95669675,0.0023630955,0.00016859609,0.00015727704,0.00029672714,0.000098042525,0.014851438,0.00181914,0.013108747,0.00028784847],"about_ca_topic_score_codex":0.0045649805,"about_ca_topic_score_gemma":0.0001351773,"teacher_disagreement_score":0.4102954,"about_ca_system_score_codex":0.002111405,"about_ca_system_score_gemma":0.002740865,"threshold_uncertainty_score":0.99677527},"labels":[],"label_agreement":null},{"id":"W4386841665","doi":"10.5281/zenodo.8356353","title":"Antibody Characterization Report for Rab-1A and Rab-1B","year":2023,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Rab; Chemistry; GTPase; Biochemistry","score_opus":0.0418064588050939,"score_gpt":0.31299719303025875,"score_spread":0.2711907342251648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386841665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86271745,0.00015348174,0.062101465,0.0066270023,0.00047867824,0.0049261646,0.0006673628,0.004275755,0.058052633],"genre_scores_gemma":[0.81206894,0.0008893494,0.000572097,0.0004726026,0.0009710043,0.0000010369242,0.15838818,0.0035995042,0.023037292],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978383,0.00013533015,0.00036460612,0.0005742591,0.0005461126,0.00054136297],"domain_scores_gemma":[0.99819916,0.0000660017,0.00011904119,0.0005766816,0.00074566796,0.00029343858],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001272963,0.00016372536,0.00025386468,0.000400434,0.0012376171,0.00039137647,0.00034035227,0.00010684711,0.0018476318],"category_scores_gemma":[0.0018980247,0.00016351484,0.00006823269,0.000900841,0.00019227626,0.00022300928,0.0007488649,0.0002151459,0.0028863957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010770102,0.00033328697,0.000066511886,0.0011849101,0.00023478136,0.00095069595,0.0020880462,0.000013832797,0.8357178,0.0020839975,0.061528515,0.09472062],"study_design_scores_gemma":[0.005419056,0.00045369606,0.003072784,0.000088378336,0.000038566526,0.0019121893,0.00018934355,0.007244816,0.0015030613,0.000087231085,0.97981226,0.0001786056],"about_ca_topic_score_codex":0.00001945955,"about_ca_topic_score_gemma":1.4661627e-7,"teacher_disagreement_score":0.91828376,"about_ca_system_score_codex":0.001162926,"about_ca_system_score_gemma":0.00008672823,"threshold_uncertainty_score":0.9990648},"labels":[],"label_agreement":null},{"id":"W4386945800","doi":"10.1016/j.crchbi.2023.100045","title":"SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4","year":2023,"lang":"en","type":"article","venue":"Current Research in Chemical Biology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of Neurological Disorders and Stroke; National Institute of Diabetes and Digestive and Kidney Diseases; Feinberg School of Medicine; Genentech; Ontario Genomics; National Institutes of Health; Ontario Genomics Institute; National Cancer Institute; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Genome Canada; McGill University; Pfizer; Northwestern University; Bayer; Bristol-Myers Squibb","keywords":"Kinase; Phosphorylation; Serine; Protein-Serine-Threonine Kinases; Cyclin-dependent kinase 1; Small molecule; Subcellular localization; Biology; Cell biology; Biochemistry; Chemistry; Cell cycle; Protein kinase A; Gene","score_opus":0.2440134421629458,"score_gpt":0.5036689020361471,"score_spread":0.2596554598732013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386945800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978268,0.007357998,0.000057106387,0.010108132,0.0004236643,0.0030735042,0.00007402519,0.00015236449,0.00048517983],"genre_scores_gemma":[0.99341494,0.0032511416,0.0001864426,0.000127308,0.00072500994,0.0016094344,0.00034661283,0.000048710022,0.0002903839],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.996026,0.00022456022,0.00048883224,0.00090951036,0.00064577785,0.0017053616],"domain_scores_gemma":[0.9926503,0.005887604,0.000045800276,0.00066964916,0.00031975633,0.00042689682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025614125,0.00025505348,0.00051184173,0.000376688,0.0001412259,0.000044697503,0.0005813718,0.00037228377,0.000078584584],"category_scores_gemma":[0.004205288,0.00016525062,0.00014827529,0.0013017859,0.0019062385,0.000047434674,0.0010639672,0.0014799696,0.00014795738],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003348863,0.00094752247,0.00605021,0.0025774422,0.00018684822,0.00016121437,0.00050789583,0.0000010660134,0.5998418,0.0063516893,0.10864328,0.27138218],"study_design_scores_gemma":[0.045217574,0.0016011513,0.0014696901,0.0014107772,0.000111060144,0.00055365654,0.00075739174,0.034339406,0.27693132,0.034800995,0.601793,0.0010139896],"about_ca_topic_score_codex":0.00014862104,"about_ca_topic_score_gemma":0.00001050398,"teacher_disagreement_score":0.4931497,"about_ca_system_score_codex":0.0028485367,"about_ca_system_score_gemma":0.0025822767,"threshold_uncertainty_score":0.7448824},"labels":[],"label_agreement":null},{"id":"W4387308181","doi":"10.1101/2023.10.02.560513","title":"Parallel nonfunctionalization of CK1δ/ε kinase ohnologs following a whole-genome duplication event","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke; PROTEO","funders":"National Institutes of Health","keywords":"Gene duplication; Event (particle physics); Genetics; Computational biology; Biology; Gene; Physics","score_opus":0.02752677400421497,"score_gpt":0.2765290475082015,"score_spread":0.24900227350398654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387308181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969753,0.001735748,0.022193415,0.0012452273,0.0013274319,0.002614356,0.00029312866,0.00081637036,0.000021317033],"genre_scores_gemma":[0.9952072,0.0003206345,0.0028736512,0.000117049836,0.00045598453,0.0006613658,0.000018409677,0.00021492847,0.00013079868],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9958998,0.00012653264,0.0009645745,0.0011988395,0.0011545621,0.00065571605],"domain_scores_gemma":[0.99612904,0.00013719872,0.00055526296,0.001978111,0.0008654843,0.000334924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010245801,0.00051691144,0.00086680736,0.00069879333,0.0001331847,0.00007008423,0.000489008,0.0007736611,0.0000618908],"category_scores_gemma":[0.000899643,0.00055146136,0.00042655025,0.0011169001,0.00015873417,0.00012015786,0.0006872134,0.0007526536,0.00036221143],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033856012,0.0005677237,0.0055336202,0.0029629013,0.001110276,0.0003709405,0.000037833783,0.004195065,0.9827971,0.0012390908,0.0008413705,0.0000055170703],"study_design_scores_gemma":[0.049112506,0.0012478542,0.5233803,0.009971709,0.0035108784,0.0000010535712,0.000059183705,0.09223203,0.26727906,0.00012461579,0.048462436,0.004618431],"about_ca_topic_score_codex":0.0003097336,"about_ca_topic_score_gemma":0.000005064282,"teacher_disagreement_score":0.71551806,"about_ca_system_score_codex":0.008216893,"about_ca_system_score_gemma":0.008662073,"threshold_uncertainty_score":0.9996937},"labels":[],"label_agreement":null},{"id":"W4387751649","doi":"10.14309/01.ajg.0000953908.33568.86","title":"S1067 Impact of Prior Biologic/Janus Kinase Inhibitor Therapy on the Efficacy of Etrasimod: Subgroup Analysis From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials","year":2023,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Clinical endpoint; Placebo; Internal medicine; Clinical trial; Subgroup analysis; Janus kinase inhibitor; Phases of clinical research; Gastroenterology; Janus kinase; Receptor; Confidence interval; Pathology","score_opus":0.06260338953047297,"score_gpt":0.38607121650791687,"score_spread":0.3234678269774439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387751649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99359566,0.0003294464,0.00012293691,0.005139826,0.00009405208,0.00057633116,0.000121933735,0.000013267396,0.0000065385975],"genre_scores_gemma":[0.99720895,0.0015338509,0.000057626636,0.00075044465,0.0003782632,0.000011047823,0.000016832297,0.000028806442,0.000014170613],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9942699,0.002917949,0.0012663478,0.00029100673,0.00062673964,0.0006280455],"domain_scores_gemma":[0.9900334,0.0064869677,0.0022009318,0.0008284895,0.00025053386,0.00019968569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005610883,0.00031414512,0.0020537248,0.00045140076,0.00011267085,0.000023132976,0.0007340341,0.000066352666,0.00016205908],"category_scores_gemma":[0.0018472084,0.00012326831,0.001010955,0.0010761559,0.0017793664,0.000046921967,0.00014423818,0.00064225355,0.000006085117],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38532773,0.0021441553,0.18154857,0.000035025543,0.024717975,0.00048142415,0.0043147635,0.0013310374,0.3542382,0.000031947475,0.0032592057,0.042569954],"study_design_scores_gemma":[0.08741108,0.115639076,0.76786965,0.00023188094,0.00374497,0.0005489316,0.0023701633,0.004009419,0.017480321,0.00028229994,0.00017571918,0.00023648127],"about_ca_topic_score_codex":0.0010240326,"about_ca_topic_score_gemma":0.000046516572,"teacher_disagreement_score":0.5863211,"about_ca_system_score_codex":0.000676049,"about_ca_system_score_gemma":0.0007747473,"threshold_uncertainty_score":0.655615},"labels":[],"label_agreement":null},{"id":"W4387873763","doi":"10.1038/s41467-023-42562-2","title":"Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","year":2023,"lang":"en","type":"erratum","venue":"Nature Communications","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Obinutuzumab; Chlorambucil; Venetoclax; Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.050231388592409096,"score_gpt":0.34776957055662305,"score_spread":0.29753818196421394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387873763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4977506,0.28560618,0.000023973733,0.0050766724,0.10598384,0.061936747,0.00489819,0.0022799335,0.036443863],"genre_scores_gemma":[0.92094225,0.016065778,0.00018392934,0.000095121024,0.0014813236,0.0019010637,0.0049092565,0.00028322602,0.054138064],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921541,0.0019342888,0.0021066319,0.0012930521,0.0016537224,0.0008581703],"domain_scores_gemma":[0.9823208,0.009055939,0.0009046978,0.0068137804,0.0006328905,0.00027192233],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002601821,0.0008771131,0.002790618,0.0006822672,0.00056246435,0.00014881241,0.0029010004,0.0023655533,0.00004953704],"category_scores_gemma":[0.005655392,0.00068605866,0.00052130374,0.002046127,0.0014619022,0.00015247906,0.0012583019,0.007953753,0.000072438],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.19926889,0.000071188355,0.0000049429077,0.0005838598,0.0026589895,0.00013333371,0.017574776,0.0120813195,0.00004700696,0.0002938974,0.76666623,0.0006155689],"study_design_scores_gemma":[0.4919032,0.0006875367,0.00019025018,0.002160874,0.0014526014,0.000045987676,0.0055268453,0.44888148,0.000028195542,0.000045763612,0.048548065,0.0005292295],"about_ca_topic_score_codex":0.0790467,"about_ca_topic_score_gemma":0.070809975,"teacher_disagreement_score":0.71811813,"about_ca_system_score_codex":0.574994,"about_ca_system_score_gemma":0.3302314,"threshold_uncertainty_score":0.99955904},"labels":[],"label_agreement":null},{"id":"W4387980211","doi":"","title":"Que peut-on faire pour arrêter le glyphosate ?","year":2023,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Glyphosate; Biology; Agronomy","score_opus":0.03937482013023055,"score_gpt":0.29684876770086055,"score_spread":0.25747394757063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387980211","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29152155,0.008474529,0.04571806,0.29909098,0.00461222,0.004700691,0.0005504758,0.0019458097,0.34338567],"genre_scores_gemma":[0.5913742,0.0026647374,0.008429054,0.00048717734,0.0004008402,0.0003135125,0.0011781381,0.00031959705,0.39483273],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98349947,0.009276628,0.0013901223,0.0022566998,0.0018022421,0.0017748518],"domain_scores_gemma":[0.98292065,0.00594049,0.0007371135,0.0059365504,0.0034600631,0.0010051477],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.011864352,0.0009952043,0.0012137428,0.0005932732,0.00085577066,0.00058905606,0.0025828788,0.0010667527,0.0012417063],"category_scores_gemma":[0.006733573,0.0010540349,0.0007576428,0.001094577,0.0010419718,0.0002141547,0.0033140758,0.0025639143,0.0075050457],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006381513,0.005298189,0.0024639126,0.004420824,0.0017826237,0.0013517127,0.031083206,0.001381853,0.02345953,0.7179036,0.07523506,0.13498133],"study_design_scores_gemma":[0.034487173,0.000013057826,0.02026735,0.051013753,0.00074736687,0.00060501334,0.002930153,0.29284307,0.21041188,0.024726473,0.3581668,0.0037879087],"about_ca_topic_score_codex":0.036552854,"about_ca_topic_score_gemma":0.0069186627,"teacher_disagreement_score":0.6931771,"about_ca_system_score_codex":0.01092205,"about_ca_system_score_gemma":0.020128505,"threshold_uncertainty_score":0.9997372},"labels":[],"label_agreement":null},{"id":"W4388343435","doi":"10.1016/j.hrcr.2023.10.033","title":"Atypical atrial flutter: Exploring the relationship between ibrutinib chemotherapy and atrial myopathy","year":2023,"lang":"en","type":"article","venue":"HeartRhythm Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"University Health Network","keywords":"Medicine; Ibrutinib; Atrial flutter; Cardiology; Internal medicine; Proinflammatory cytokine; Amiodarone; Atrial fibrillation; Inflammation; Leukemia","score_opus":0.13444282916480982,"score_gpt":0.3626364986331702,"score_spread":0.2281936694683604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388343435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934715,0.00041933122,0.00002432729,0.0040147547,0.0006647923,0.00095860526,0.0000067057986,0.000266219,0.0001737685],"genre_scores_gemma":[0.99201757,0.00012705178,0.000119096796,0.00011172922,0.006766732,0.00004565191,0.000040494986,0.000060898055,0.000710804],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972621,0.0001653027,0.00070260005,0.00055780687,0.00070535747,0.00060681644],"domain_scores_gemma":[0.9967429,0.0018850956,0.00013266697,0.00081748195,0.00007805834,0.00034379412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018895053,0.00022134505,0.00044447757,0.00017799532,0.00039934774,0.00007383417,0.000010320096,0.00016597715,0.00007427528],"category_scores_gemma":[0.0018735577,0.00016151695,0.00031443525,0.0006617516,0.00021397255,0.00013498866,0.00014139868,0.0005184057,0.00011939534],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009867753,0.000014637059,0.07215346,0.00019018663,0.00018555127,0.91174614,0.0016392332,0.000026642723,0.0000656137,0.00016872998,0.0045111524,0.008311887],"study_design_scores_gemma":[0.009097075,0.00023098367,0.12353071,0.00013628429,0.00017568043,0.83242905,0.0001970763,0.00077935104,0.00024343804,0.0005614452,0.032373328,0.0002455836],"about_ca_topic_score_codex":0.00022329044,"about_ca_topic_score_gemma":0.000016191978,"teacher_disagreement_score":0.07931709,"about_ca_system_score_codex":0.0012172107,"about_ca_system_score_gemma":0.0017373804,"threshold_uncertainty_score":0.65864694},"labels":[],"label_agreement":null},{"id":"W4388453280","doi":"10.1089/derm.2023.0208","title":"Interleukin-17 Monoclonal Antibody Successfully Treated Psoriasiform Drug Eruption Induced by Immune Checkpoint Inhibitors: A Case Report and Review of Literature","year":2023,"lang":"en","type":"review","venue":"Dermatitis","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Rheumatology; Internal medicine; Family medicine; Dermatology; Hematology; University hospital","score_opus":0.03203683921039454,"score_gpt":0.369087050055247,"score_spread":0.3370502108448525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388453280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038871784,0.99146867,0.0000040209206,0.00034871508,0.00019628002,0.0029257336,0.00048401102,0.00014071362,0.0005446528],"genre_scores_gemma":[0.0004621299,0.98530006,0.000057086578,0.0001403395,0.00031921247,0.00032606983,0.011354817,0.00015200833,0.0018882597],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9944788,0.00029488123,0.0030332932,0.0007925053,0.0008596394,0.0005408759],"domain_scores_gemma":[0.9963041,0.00023677613,0.0014843525,0.0011301754,0.0005190908,0.00032548382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012358909,0.0007507865,0.0035883975,0.000577728,0.000110834255,0.000108735396,0.0002535696,0.0006179682,0.00012807274],"category_scores_gemma":[0.00069894816,0.0005860038,0.0008095662,0.0014755343,0.0001615936,0.00026448254,0.00033862639,0.0010977924,0.00004978085],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001240535,0.00014825075,0.000005307993,0.6494544,0.0009013782,0.155524,0.00038794885,1.5332303e-8,0.00008638701,0.000010633354,0.04126605,0.15220317],"study_design_scores_gemma":[0.002321853,0.000113644506,0.000007141971,0.3916197,0.001192912,0.25804946,0.00002705525,0.000027300182,0.00021141263,0.000008781535,0.34604412,0.00037659094],"about_ca_topic_score_codex":0.0026579213,"about_ca_topic_score_gemma":0.000055988687,"teacher_disagreement_score":0.3047781,"about_ca_system_score_codex":0.005048615,"about_ca_system_score_gemma":0.0037121302,"threshold_uncertainty_score":0.9996591},"labels":[],"label_agreement":null},{"id":"W4388680196","doi":"10.1016/j.modpat.2023.100384","title":"Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study","year":2023,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; Royal University Hospital; SickKids Foundation; Hospital for Sick Children; Université de Montréal; Hôpital Maisonneuve-Rosemont; William Osler Health System; University of British Columbia; BC Cancer Agency; Sunnybrook Health Science Centre; Queen's University; University of Ottawa; Dalhousie University; McMaster University; Institut universitaire de cardiologie et de pneumologie de Québec; University of Manitoba; University of Calgary; Health Sciences Centre; University of Alberta; University Health Network; Ottawa Hospital; McGill University; McGill University Health Centre; University of Toronto; Saskatchewan Health Authority; Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"Bayer Canada","keywords":"Trk receptor; Immunohistochemistry; Staining; Medicine; Immunostaining; Monoclonal antibody; Pathology; H&E stain; Antibody; Biology; Internal medicine; Immunology; Neurotrophin","score_opus":0.022695377752655684,"score_gpt":0.3197230274370713,"score_spread":0.29702764968441564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388680196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569553,0.00047052724,0.00022028781,0.0006191594,0.00020930218,0.00080539164,0.000019191495,0.00020059061,0.00176],"genre_scores_gemma":[0.9941084,0.000077337565,0.00008437707,0.0002388693,0.00011979147,0.00010249726,0.0001759738,0.000050840077,0.00504192],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99806404,0.00009376726,0.00027907843,0.0004925964,0.00033431998,0.0007361934],"domain_scores_gemma":[0.9987291,0.00008103001,0.000049393428,0.0006716247,0.00015714795,0.000311715],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037717816,0.00017026978,0.0002999701,0.0003622298,0.0001610975,0.000020651929,0.00019690678,0.0001891109,0.00015421555],"category_scores_gemma":[0.00042238962,0.00016764832,0.000059164635,0.00066090666,0.00008507516,0.00003942225,0.00011232547,0.00028606996,0.0008419639],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016319172,0.0029566982,0.24692447,0.0010802645,0.0011380379,0.13540933,0.038033787,0.0018828581,0.39706388,0.00018668805,0.029335884,0.14435618],"study_design_scores_gemma":[0.07200611,0.0014294871,0.21059741,0.0001482966,0.00072301703,0.0036874386,0.0038524652,0.6869677,0.013548897,0.000711708,0.0049385894,0.0013889051],"about_ca_topic_score_codex":0.04152866,"about_ca_topic_score_gemma":0.007637725,"teacher_disagreement_score":0.6850848,"about_ca_system_score_codex":0.0106620975,"about_ca_system_score_gemma":0.005904615,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W4388723486","doi":"10.1080/24745332.2023.2276106","title":"Lymphoplasmacytic lymphoma and HIV: A case report","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Respiratory Critical Care and Sleep Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Lymphoplasmacytic Lymphoma; Lymphoma; Medicine; Human immunodeficiency virus (HIV); Pathology; Waldenstrom macroglobulinemia; Plasmablastic lymphoma; Macroglobulinemia; Dermatology; Internal medicine; Immunology; Multiple myeloma","score_opus":0.04009211778432476,"score_gpt":0.34039914330365073,"score_spread":0.300307025519326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388723486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97105783,0.022350969,0.00003262542,0.003591802,0.00041445374,0.00018105206,0.00001608562,0.000023624008,0.0023315563],"genre_scores_gemma":[0.9967768,0.000111287314,0.000086696054,0.0020347263,0.0007958008,0.0000050764124,0.0000071068494,0.00003615887,0.00014631674],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.997748,0.00009923517,0.0006839599,0.00030414684,0.00053831853,0.0006263373],"domain_scores_gemma":[0.99511886,0.0006284135,0.00008442943,0.00032456862,0.0008076098,0.0030361162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009582624,0.00021204064,0.0006028315,0.0008668959,0.00024312474,0.000041555333,0.00009895413,0.00017484117,0.00014714956],"category_scores_gemma":[0.005516675,0.00016475348,0.00008507939,0.0005238656,0.0012281139,0.00012290418,0.00003779195,0.0002771939,0.000017104683],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011492524,0.000008425732,0.00424008,0.00065847073,0.00007975917,0.9439557,0.0017647855,0.0000014194953,0.00009281995,0.00045239014,0.008397012,0.04023419],"study_design_scores_gemma":[0.017055938,0.0022830477,0.0027282545,0.0009019265,0.0005802478,0.8803629,0.011997575,0.00059951877,0.0001734189,0.00020800557,0.08284159,0.00026752247],"about_ca_topic_score_codex":0.0020230908,"about_ca_topic_score_gemma":0.0028127788,"teacher_disagreement_score":0.07444458,"about_ca_system_score_codex":0.0028458952,"about_ca_system_score_gemma":0.011858792,"threshold_uncertainty_score":0.99374306},"labels":[],"label_agreement":null},{"id":"W4388728839","doi":"10.1016/j.annonc.2023.10.790","title":"VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Amgen","keywords":"Medicine; Cmax; Internal medicine; Clinical endpoint; Gastroenterology; Pharmacokinetics; Confidence interval; Dosing; Randomized controlled trial","score_opus":0.16558930239500066,"score_gpt":0.4753252761831692,"score_spread":0.30973597378816853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388728839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497086,0.00050382316,0.0000026903501,0.0045661577,0.0005340041,0.00074162404,0.000022064125,0.00012827141,0.043792784],"genre_scores_gemma":[0.9928858,0.0012813073,0.00015062152,0.00048631325,0.00018054643,0.00011455206,0.000099807796,0.000045920293,0.0047551026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737,0.00018047176,0.0005786569,0.00048113786,0.00050587725,0.0008838387],"domain_scores_gemma":[0.9975655,0.0010407655,0.00015564811,0.00058577635,0.00039546995,0.00025681645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000781901,0.00022516724,0.0007907525,0.00055019354,0.000044308268,0.000007242726,0.00028396182,0.0003725321,0.00054231536],"category_scores_gemma":[0.0019210201,0.00020765427,0.00014475491,0.0016984185,0.00029053187,0.00010464246,0.00021891041,0.00039591588,0.000642797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06040785,0.003544243,0.011577869,0.0016551969,0.0015175907,0.0151311355,0.0052742194,0.0010030199,0.09257411,0.0016810995,0.33178055,0.4738531],"study_design_scores_gemma":[0.3302835,0.044913504,0.068203464,0.0015398714,0.0003310072,0.0004970633,0.004589845,0.019417724,0.081528634,0.002084034,0.44509944,0.0015118911],"about_ca_topic_score_codex":0.00095579383,"about_ca_topic_score_gemma":0.0006190998,"teacher_disagreement_score":0.4723412,"about_ca_system_score_codex":0.0031661964,"about_ca_system_score_gemma":0.0072455686,"threshold_uncertainty_score":0.99838245},"labels":[],"label_agreement":null},{"id":"W4388830038","doi":"10.3390/curroncol30110727","title":"Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Prolymphocytic leukemia; Medicine; Hepatosplenomegaly; Leukocytosis; Malignancy; Rare disease; Leukemia; Bone marrow; Chemotherapy; Internal medicine; Disease; Pathology; Oncology; Chronic lymphocytic leukemia","score_opus":0.18713121754314077,"score_gpt":0.482006932036974,"score_spread":0.2948757144938332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388830038","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013982657,0.994475,0.000002853906,0.00012122938,0.0013414392,0.0034334818,0.000045531357,0.000066622386,0.00037403574],"genre_scores_gemma":[0.000010274665,0.99742204,0.000024549952,0.00008291599,0.0004897133,0.000524657,0.00015809822,0.000104255385,0.0011835156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959017,0.00050089223,0.0016023519,0.0008289377,0.0005850144,0.00058111397],"domain_scores_gemma":[0.99613225,0.00078790216,0.00096454786,0.0015103646,0.00032825943,0.0002766841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013827974,0.00054609415,0.0035533623,0.00029104936,0.000096497024,0.000021949152,0.00036808886,0.00067406514,0.000049088525],"category_scores_gemma":[0.0026253543,0.00032362295,0.00084446353,0.0015044694,0.0004062138,0.00004251639,0.0009021367,0.0015748943,0.000044908607],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00000854905,0.000042431777,0.000002169566,0.44556567,0.00017490765,0.10006478,0.00006149749,3.7269512e-8,5.4822035e-8,0.0000110155825,0.0036554162,0.45041347],"study_design_scores_gemma":[0.0012254523,0.00008171917,5.076712e-7,0.26568142,0.0013583595,0.32297894,0.0000054184175,0.000019653959,3.6123075e-7,0.000005584902,0.40853226,0.000110300345],"about_ca_topic_score_codex":0.00006310698,"about_ca_topic_score_gemma":0.000027253793,"teacher_disagreement_score":0.45030317,"about_ca_system_score_codex":0.033277098,"about_ca_system_score_gemma":0.0537201,"threshold_uncertainty_score":0.99992156},"labels":[],"label_agreement":null},{"id":"W4389029637","doi":"10.1093/ofid/ofad500.2333","title":"2722. Risk of Infectious Adverse Events of Venetoclax Therapy in the Treatment of Hematologic Malignancies: A Systematic Review and Bayesian Meta-Analysis of Randomized Controlled Trials","year":2023,"lang":"en","type":"review","venue":"Open Forum Infectious Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; McGill University","funders":"","keywords":"Venetoclax; Medicine; Neutropenia; Internal medicine; Adverse effect; Randomized controlled trial; Febrile neutropenia; Regimen; Oncology; Leukemia; Chronic lymphocytic leukemia; Chemotherapy","score_opus":0.10761772354960186,"score_gpt":0.422199907288947,"score_spread":0.31458218373934516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389029637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007976498,0.94820696,0.000011347208,0.000016071064,0.00003294354,0.050011028,0.0007465434,0.000016240578,0.00016120372],"genre_scores_gemma":[0.02535618,0.9592904,0.0000061074584,0.000032133332,0.00000730381,0.014978271,0.00013797569,0.00005153644,0.00014012516],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9789802,0.012345602,0.006876198,0.00053812686,0.0008945279,0.00036539027],"domain_scores_gemma":[0.96791285,0.021046994,0.008976331,0.001503534,0.00043096385,0.00012930189],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.011098265,0.0007400291,0.06445535,0.001248634,0.00005649165,0.000015538411,0.00054072426,0.00024256026,0.00024141342],"category_scores_gemma":[0.014645498,0.0003147781,0.016506806,0.0024675874,0.0003453959,0.000070767426,0.00013681309,0.00014388452,0.0000031434952],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005921533,0.0012040214,0.00020811388,0.50251186,0.48928759,0.000028379638,0.00018052499,0.000032009862,1.3002706e-7,0.00011652171,0.000023286113,0.00048606828],"study_design_scores_gemma":[0.17343761,0.000997747,0.000005950898,0.059139732,0.7657551,0.000042134616,0.00009770199,0.00009229494,0.0000019162403,0.00018654973,0.00007128072,0.0001719879],"about_ca_topic_score_codex":0.0037300538,"about_ca_topic_score_gemma":0.00031088197,"teacher_disagreement_score":0.4433721,"about_ca_system_score_codex":0.0020105748,"about_ca_system_score_gemma":0.004825944,"threshold_uncertainty_score":0.99993044},"labels":[],"label_agreement":null},{"id":"W4389054625","doi":"10.1503/cmaj.231033","title":"Pseudohyperkalemia in chronic lymphocytic leukemia","year":2023,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Hyperkalemia; Chronic lymphocytic leukemia; Medicine; Leukemia; Internal medicine; Potassium; Gastroenterology; Endocrinology; Immunology; Chemistry","score_opus":0.013834267882699553,"score_gpt":0.2882866581892647,"score_spread":0.27445239030656515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389054625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763859,0.00046210154,0.000008810671,0.010626422,0.00078811904,0.0002839294,0.000010907243,0.00010654443,0.011327266],"genre_scores_gemma":[0.9839171,0.0010033768,0.000037430447,0.0052000503,0.002777379,0.000023875,0.000032062246,0.000049889288,0.006958796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950645,0.00016465799,0.00062843965,0.00027365272,0.0025453174,0.0013234202],"domain_scores_gemma":[0.99630046,0.00036321714,0.00012116807,0.00022615716,0.0002914233,0.0026975719],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003091638,0.00017174626,0.0003944723,0.00091599795,0.00018828062,0.00007844699,0.00030548288,0.0006420644,0.004881345],"category_scores_gemma":[0.003971822,0.00016117646,0.0001494174,0.0015847363,0.000073683834,0.00012592912,0.000045509318,0.0014884647,0.003649956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000102093014,0.00001997156,0.036494672,0.00021536692,0.00034468927,0.045772277,0.0008959195,0.0015832192,0.00034098327,0.00047856846,0.8428691,0.07088315],"study_design_scores_gemma":[0.039830886,0.0002926537,0.057002675,0.000922868,0.000067902234,0.010346179,0.00066636613,0.25675082,0.00015058948,0.0003895549,0.6330489,0.0005306397],"about_ca_topic_score_codex":0.023501221,"about_ca_topic_score_gemma":0.061208654,"teacher_disagreement_score":0.2551676,"about_ca_system_score_codex":0.5495699,"about_ca_system_score_gemma":0.3999122,"threshold_uncertainty_score":0.9971258},"labels":[],"label_agreement":null},{"id":"W4389196199","doi":"10.51731/cjht.2023.793","title":"Zanubrutinib (Brukinsa)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Family medicine; Political science; Health care","score_opus":0.06634469539270238,"score_gpt":0.35787450985986713,"score_spread":0.29152981446716475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389196199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7672953,0.046841536,0.00011059954,0.17926581,0.0015051095,0.0007145364,0.000025240484,0.00080244977,0.0034394348],"genre_scores_gemma":[0.99758524,0.000932612,0.00030117884,0.00054126675,0.00003737876,0.000004218625,0.0000037940579,0.000021047459,0.0005732892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981961,0.000036738365,0.0005258609,0.00013161416,0.00032282178,0.0007868224],"domain_scores_gemma":[0.9989012,0.00010257138,0.00021004732,0.00035040904,0.00020864648,0.00022712085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011054997,0.000106617634,0.0004003896,0.0014090629,0.00018429292,0.000023826236,0.00033513582,0.00016317812,0.000058877544],"category_scores_gemma":[0.0018226005,0.000086465276,0.00009540033,0.0011471743,0.00030014172,0.00006527311,0.00003579186,0.00055971317,0.00016521108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00004924507,0.000017947972,0.0033740443,0.00042982952,0.00009445559,0.0034719447,0.00048886053,0.000024341782,0.00008848386,0.001935986,0.19978188,0.79024297],"study_design_scores_gemma":[0.0059866784,0.0010864078,0.011542301,0.00070649333,0.00002009725,0.0051241294,0.005310069,0.00039815408,0.0010168396,0.003891508,0.96473956,0.00017774488],"about_ca_topic_score_codex":0.0062690815,"about_ca_topic_score_gemma":0.0017190591,"teacher_disagreement_score":0.7900652,"about_ca_system_score_codex":0.008291746,"about_ca_system_score_gemma":0.055787567,"threshold_uncertainty_score":0.9955152},"labels":[],"label_agreement":null},{"id":"W4389221984","doi":"10.1182/blood-2023-174750","title":"Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chlorambucil; Obinutuzumab; Internal medicine; Medicine; Hazard ratio; Neutropenia; Gastroenterology; Chronic lymphocytic leukemia; Leukemia; Chemotherapy; Confidence interval; Cyclophosphamide","score_opus":0.027542263893110604,"score_gpt":0.2925937077638187,"score_spread":0.2650514438707081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389221984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920332,0.0011107969,0.000003444611,0.00009005285,0.00039123098,0.0016126574,0.00008178532,0.00041596335,0.0042608995],"genre_scores_gemma":[0.9862023,0.0017745891,0.00011710468,0.00006856779,0.00045549194,0.00031303935,0.0002496315,0.0001669757,0.010652325],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946043,0.00016455712,0.0011309719,0.0011166282,0.0012893715,0.0016941654],"domain_scores_gemma":[0.9969418,0.0005294699,0.00026276943,0.0015241852,0.00026364758,0.00047812663],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066799717,0.0006488765,0.001440509,0.0008588358,0.00012708241,0.000048006557,0.00054335664,0.00057176687,0.00047873257],"category_scores_gemma":[0.0006281272,0.0005772201,0.00049136585,0.0025719232,0.00038469207,0.00019494777,0.000332024,0.0004983724,0.0016598237],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09322027,0.011159335,0.06712522,0.03497847,0.028740877,0.08871092,0.056646455,0.03519905,0.39294174,0.015305526,0.07829752,0.0976746],"study_design_scores_gemma":[0.66776174,0.008789432,0.0068494612,0.00219289,0.0016185663,0.0012813567,0.0018823954,0.06229541,0.23455375,0.0005496378,0.01064174,0.0015836285],"about_ca_topic_score_codex":0.0068921824,"about_ca_topic_score_gemma":0.00063178764,"teacher_disagreement_score":0.57454145,"about_ca_system_score_codex":0.2727005,"about_ca_system_score_gemma":0.12124339,"threshold_uncertainty_score":0.999721},"labels":[],"label_agreement":null},{"id":"W4389222015","doi":"10.1182/blood-2023-189835","title":"DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"DNA methylation; Splenic marginal zone lymphoma; Biology; Methylation; Hairy cell leukemia; Sanger sequencing; Leukemia; Cancer research; Epigenetics; Lymphoma; Mantle cell lymphoma; Molecular biology; Computational biology; DNA sequencing; Genetics; DNA; B cell; Gene; Immunology; Antibody","score_opus":0.026059454567857177,"score_gpt":0.2818296988702216,"score_spread":0.2557702443023644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335414,0.0004922233,0.00006582133,0.00016146469,0.0000519409,0.0003802801,0.000014103556,0.00011849645,0.005361515],"genre_scores_gemma":[0.9974104,0.0001155592,0.0005090326,0.000051192463,0.00008734172,0.000034910598,0.00009769403,0.000035793517,0.001658038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998512,0.00006287513,0.0003238387,0.00032405098,0.00047662124,0.00030057633],"domain_scores_gemma":[0.9987393,0.00038402693,0.00011371189,0.00048157864,0.00012446531,0.00015693787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039791092,0.00013704492,0.0002630992,0.0002588065,0.00005646989,0.000013755351,0.000110901434,0.00014512586,0.00006354357],"category_scores_gemma":[0.00013980984,0.00012712806,0.000082602266,0.0006082965,0.00012363416,0.000049473703,0.000055458182,0.000090694884,0.00016047894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041413368,0.0018281005,0.008153971,0.0032181507,0.00014729032,0.00021402213,0.00082522223,0.00012572734,0.9652964,0.00020974701,0.004006578,0.015560654],"study_design_scores_gemma":[0.06376894,0.0002904645,0.065052785,0.00011019293,0.00028820802,0.000028711662,0.00025514897,0.06547248,0.80303836,0.00009609082,0.0013940221,0.00020459967],"about_ca_topic_score_codex":0.00019245483,"about_ca_topic_score_gemma":0.000013371117,"teacher_disagreement_score":0.16225804,"about_ca_system_score_codex":0.0016391368,"about_ca_system_score_gemma":0.005590916,"threshold_uncertainty_score":0.9918045},"labels":[],"label_agreement":null},{"id":"W4389229390","doi":"10.1182/blood-2023-178660","title":"Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Discontinuation; Medicine; Lymphoma; Oncology; Internal medicine; Leukemia","score_opus":0.06969717517833665,"score_gpt":0.32570680477449615,"score_spread":0.25600962959615947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970109,0.0004256684,0.0000030732863,0.000046861216,0.00005329605,0.002221179,0.000033688037,0.00013032834,0.00007502451],"genre_scores_gemma":[0.99576354,0.0030520859,0.000030057954,0.00014690761,0.000091915186,0.0002888963,0.00019303418,0.00008882899,0.00034475053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957907,0.000549888,0.00093730754,0.00077633164,0.00091265084,0.0010331084],"domain_scores_gemma":[0.9970495,0.0013066637,0.00018285975,0.001116781,0.00014708318,0.00019707982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014893308,0.00044793318,0.0008321908,0.0017525258,0.00008728072,0.0000856963,0.00049560075,0.00015582344,0.00004711761],"category_scores_gemma":[0.00025826666,0.00033178958,0.00011793268,0.004170318,0.00021316478,0.0001391019,0.00024408982,0.00027510643,0.000033046545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0022356987,0.0020595267,0.9614893,0.0009910549,0.0007329414,0.010105797,0.014440399,0.004120276,0.0010132648,0.00009668994,0.00015373014,0.00256133],"study_design_scores_gemma":[0.13735372,0.0015511601,0.80196595,0.0005382155,0.00015775747,0.0002600024,0.0030976012,0.05360607,0.00096762134,0.0000501991,0.00012178103,0.00032990254],"about_ca_topic_score_codex":0.18170232,"about_ca_topic_score_gemma":0.037610166,"teacher_disagreement_score":0.15952332,"about_ca_system_score_codex":0.053220168,"about_ca_system_score_gemma":0.023552032,"threshold_uncertainty_score":0.9999134},"labels":[],"label_agreement":null},{"id":"W4389229577","doi":"10.1182/blood-2023-174751","title":"Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Ibrutinib; Medicine; Venetoclax; Chronic lymphocytic leukemia; Dosing; Internal medicine; Oncology; Leukemia","score_opus":0.1237754229891403,"score_gpt":0.36975347349213017,"score_spread":0.24597805050298988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743843,0.00014879112,0.00004013193,0.000013393144,0.000034298504,0.0021358659,0.000018456345,0.00008507373,0.00008554238],"genre_scores_gemma":[0.99908346,0.000015490681,0.0003656778,0.000010843525,0.00006590981,0.000135314,0.00013816079,0.00006226853,0.00012290188],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99737656,0.00021104756,0.0006229987,0.0005513396,0.00079991686,0.00043812403],"domain_scores_gemma":[0.99864453,0.00028298603,0.00031388507,0.00044026796,0.00021644335,0.000101910264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056969107,0.00026289557,0.00048591723,0.0004663338,0.00013589654,0.00005101492,0.00017157938,0.000088811605,0.000018024228],"category_scores_gemma":[0.00016080415,0.0002158901,0.00006812849,0.0011981425,0.00015917979,0.0002041947,0.00011787713,0.00018852907,0.0000071224467],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015939428,0.021805525,0.68777287,0.0049266447,0.005757627,0.00031103706,0.013775955,0.16581288,0.02658493,0.00054316287,0.00004594836,0.05672401],"study_design_scores_gemma":[0.14843492,0.003228416,0.21425855,0.0009689513,0.00036870825,0.000015907992,0.0004945509,0.62923783,0.0026823157,0.000054641554,0.0000020484201,0.00025312576],"about_ca_topic_score_codex":0.0018513899,"about_ca_topic_score_gemma":0.00016199403,"teacher_disagreement_score":0.4735143,"about_ca_system_score_codex":0.017585367,"about_ca_system_score_gemma":0.008430746,"threshold_uncertainty_score":0.99719054},"labels":[],"label_agreement":null},{"id":"W4389229579","doi":"10.1182/blood-2023-178698","title":"A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Internal medicine; Obinutuzumab; Oncology; Randomized controlled trial; Proportional hazards model; Leukemia","score_opus":0.053797107701676894,"score_gpt":0.34228377334425863,"score_spread":0.28848666564258174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954695,0.0011237734,0.0000032056985,0.000032571093,0.00008924919,0.0010816008,0.00002015995,0.0002379652,0.001941976],"genre_scores_gemma":[0.998204,0.000338289,0.00025119344,0.000013265711,0.00011850507,0.00012145463,0.00009317933,0.000083656916,0.0007764438],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970805,0.00011522133,0.0006064981,0.0006567605,0.0006925985,0.00084843306],"domain_scores_gemma":[0.99832773,0.0004521664,0.00020000772,0.0006490681,0.000089813104,0.00028124198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031331906,0.0003996799,0.001166622,0.0005362109,0.00008580479,0.000030378378,0.00019032118,0.00024525254,0.000054639222],"category_scores_gemma":[0.00012708569,0.00031317744,0.00009909427,0.0013524711,0.00032524703,0.00009474854,0.00014968206,0.0003055777,0.0000879765],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09722139,0.0067784553,0.58086044,0.014307762,0.015739666,0.0104679195,0.0865069,0.017367957,0.0591358,0.0015319352,0.0018281044,0.108253695],"study_design_scores_gemma":[0.7355831,0.013677374,0.06362923,0.002510454,0.0021473083,0.0012637144,0.0048602843,0.09463472,0.07977201,0.00008153436,0.00073328696,0.0011069761],"about_ca_topic_score_codex":0.006240926,"about_ca_topic_score_gemma":0.0023179587,"teacher_disagreement_score":0.6383617,"about_ca_system_score_codex":0.05216724,"about_ca_system_score_gemma":0.033982743,"threshold_uncertainty_score":0.99993205},"labels":[],"label_agreement":null},{"id":"W4389231814","doi":"10.1182/blood-2023-186284","title":"Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Medicine; Dosing; Internal medicine; Medical record; Tolerability; Chronic lymphocytic leukemia; Adverse effect; Oncology; Pediatrics; Leukemia","score_opus":0.018488278592711196,"score_gpt":0.32877485696167913,"score_spread":0.31028657836896795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701804,0.00024072934,0.000028591247,0.00010386554,0.000061645675,0.0023117654,0.00011899702,0.00007539465,0.0000409877],"genre_scores_gemma":[0.99778825,0.00049511605,0.00021159185,0.000040060997,0.0003808494,0.0001373969,0.0006958471,0.00006576615,0.00018510956],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9958224,0.00019166296,0.0009667293,0.0007966279,0.0012773061,0.00094526506],"domain_scores_gemma":[0.9978556,0.0007162058,0.00029215304,0.0005810225,0.00007661484,0.00047839756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007780656,0.00042627408,0.0013094663,0.0013475802,0.000100097786,0.000028825618,0.00020100288,0.00030250364,0.00034537254],"category_scores_gemma":[0.00042177856,0.0002858413,0.00024210427,0.0021000213,0.00009092771,0.00018082281,0.0001689554,0.00046010173,0.00002750965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.16613209,0.0059548463,0.53787935,0.0009728249,0.032193955,0.0011485106,0.009369061,0.17251115,0.012991155,0.00002270758,0.00022576413,0.060598563],"study_design_scores_gemma":[0.27232304,0.004940067,0.18997818,0.00060470344,0.0032860765,0.0000056862305,0.000032666157,0.5265977,0.0018443522,0.000017697343,0.000023740531,0.00034612813],"about_ca_topic_score_codex":0.035923425,"about_ca_topic_score_gemma":0.004135861,"teacher_disagreement_score":0.35408652,"about_ca_system_score_codex":0.059882425,"about_ca_system_score_gemma":0.02078177,"threshold_uncertainty_score":0.99995935},"labels":[],"label_agreement":null},{"id":"W4389232150","doi":"10.1182/blood-2023-181541","title":"Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Image-guided radiation therapy; Medicine; Hypogammaglobulinemia; Randomized controlled trial; Internal medicine; Radiation therapy; Oncology; Immunology; Antibody","score_opus":0.02778403653257089,"score_gpt":0.2924207048232959,"score_spread":0.264636668290725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862561,0.0013200864,0.00018524977,0.0052768732,0.00014446847,0.0063224738,0.00007547781,0.00006269926,0.00035652836],"genre_scores_gemma":[0.9853473,0.0033326473,0.0033527864,0.0019936012,0.00046799355,0.0029864209,0.00092314207,0.00006103813,0.0015350952],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99776745,0.00016404536,0.00059045386,0.00038197526,0.00077895913,0.00031710693],"domain_scores_gemma":[0.99671525,0.0021827822,0.00025548265,0.0003508635,0.0003542394,0.0001413764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023683181,0.00025137165,0.00051392696,0.00011544998,0.00055071333,0.00014363971,0.00020096208,0.000094131676,0.00006873787],"category_scores_gemma":[0.0010722119,0.0001270463,0.00012670342,0.00024660726,0.00079380214,0.0001685419,0.00015763464,0.00018947343,0.0000040400823],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9822456,0.0015457317,0.000071176815,0.000065938446,0.0010904808,0.000021841683,0.0031677694,0.00005661691,0.0004717745,0.0028100202,0.008113758,0.00033926032],"study_design_scores_gemma":[0.9867353,0.0011406643,0.000019697969,0.000088445595,0.0002507779,0.00004669116,0.00051571097,0.00524013,0.0014287712,0.00064499053,0.0037316354,0.0001572021],"about_ca_topic_score_codex":0.00005176907,"about_ca_topic_score_gemma":0.000005077824,"teacher_disagreement_score":0.005183513,"about_ca_system_score_codex":0.00037906805,"about_ca_system_score_gemma":0.0020514093,"threshold_uncertainty_score":0.51807976},"labels":[],"label_agreement":null},{"id":"W4389232602","doi":"10.1182/blood-2023-174913","title":"Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib from 5 Prospective Clinical Trials","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Obinutuzumab; Ibrutinib; Medicine; Internal medicine; Mantle cell lymphoma; Ofatumumab; Chronic lymphocytic leukemia; Oncology; Chlorambucil; Leukemia; Lymphoma; Chemotherapy; Cyclophosphamide","score_opus":0.0960004294500061,"score_gpt":0.4168035876570206,"score_spread":0.3208031582070145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980755,0.00057504827,0.00004026815,0.00013508907,0.0000296271,0.00063845364,0.000069099355,0.000063132684,0.00037380532],"genre_scores_gemma":[0.99870616,0.00022036686,0.00036057507,0.000031380245,0.0002631476,0.00003608372,0.0000921836,0.000020487701,0.00026960415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976694,0.00032431888,0.0006915794,0.00044997386,0.0005821693,0.00028255052],"domain_scores_gemma":[0.9968664,0.0020944793,0.00019800772,0.00046356308,0.0001611409,0.0002163808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025994703,0.0001368665,0.0012169759,0.00032962646,0.000035135952,0.000016456714,0.00008517389,0.00012557156,0.00012851409],"category_scores_gemma":[0.0031199118,0.000091507354,0.00027670214,0.0016256416,0.00014557518,0.000033421413,0.0001008381,0.00020812376,0.000031877073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013347842,0.0007302844,0.97444415,0.00007846607,0.016022246,0.004084318,0.0003408034,0.000023139655,0.00026644635,0.00011799804,0.00023853709,0.002318826],"study_design_scores_gemma":[0.0669466,0.0007578865,0.9023741,0.00015169692,0.01669404,0.00013997125,0.0002659381,0.0053705997,0.006722977,0.00016412542,0.00023051456,0.00018158426],"about_ca_topic_score_codex":0.0004968573,"about_ca_topic_score_gemma":0.000037565133,"teacher_disagreement_score":0.072070085,"about_ca_system_score_codex":0.0003331625,"about_ca_system_score_gemma":0.0016602181,"threshold_uncertainty_score":0.37350512},"labels":[],"label_agreement":null},{"id":"W4389233179","doi":"10.1182/blood-2023-174718","title":"Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Mantle cell lymphoma; Rituximab; Internal medicine; Oncology; Venetoclax; Ibrutinib; Chemoimmunotherapy; Lymphoma; Gastroenterology; Chronic lymphocytic leukemia; Leukemia","score_opus":0.02358003933382442,"score_gpt":0.3151918053041063,"score_spread":0.2916117659702819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431497,0.000055966175,0.0000011393487,0.000019003475,0.000011546249,0.0051244884,0.000014152164,0.000019812886,0.00043892537],"genre_scores_gemma":[0.99914414,0.000046512585,0.0000895042,0.000009215479,0.0000062368285,0.0003454675,0.000075170115,0.00002984085,0.00025392257],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983728,0.00019309061,0.0003444859,0.00036010487,0.00043082633,0.00029870908],"domain_scores_gemma":[0.9991745,0.0002499645,0.00011278978,0.00028229578,0.00008686709,0.00009357934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038637823,0.00018226117,0.00078549725,0.00031885257,0.000032207376,0.00002193741,0.00011518746,0.00006433067,0.000013031285],"category_scores_gemma":[0.000061024617,0.00012419595,0.000016363982,0.00071838277,0.00012000306,0.00009811111,0.000082218896,0.00007376569,0.000009244486],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53616667,0.34975713,0.086516745,0.00047158773,0.0008713252,0.0021840888,0.014459984,0.000023881918,0.00023716265,0.00003963344,0.000046326837,0.009225444],"study_design_scores_gemma":[0.9662595,0.010992576,0.017380588,0.00019239349,0.00027720927,0.000011793255,0.0011636163,0.0022768646,0.001304934,0.0000108314025,0.000007965984,0.00012172687],"about_ca_topic_score_codex":0.0022571262,"about_ca_topic_score_gemma":0.00036761744,"teacher_disagreement_score":0.4300928,"about_ca_system_score_codex":0.0019140703,"about_ca_system_score_gemma":0.0018077312,"threshold_uncertainty_score":0.50645643},"labels":[],"label_agreement":null},{"id":"W4389233810","doi":"10.1182/blood-2023-182390","title":"A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Diffuse large B-cell lymphoma; breakpoint cluster region; Cancer research; Chronic lymphocytic leukemia; Population; Biology; Surrogate endpoint; Internal medicine; Lymphoma; Immunology; Genetics; Medicine; Gene; Leukemia","score_opus":0.0129255657016233,"score_gpt":0.27091212401578585,"score_spread":0.25798655831416256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995727,0.00034283087,0.00007108409,0.0008690629,0.00018037799,0.0008363374,0.00020178384,0.00039723184,0.0013742952],"genre_scores_gemma":[0.98821646,0.00011924349,0.00023420839,0.0009603047,0.0004934879,0.00007642308,0.000518407,0.00008051572,0.009300932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739766,0.00008520678,0.00031646184,0.0006004365,0.0008005424,0.00079969096],"domain_scores_gemma":[0.99848115,0.00016506526,0.000062989304,0.0006086964,0.0002661436,0.00041597875],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041355778,0.00026997324,0.00038960806,0.00040758445,0.00015778746,0.000074306285,0.000112426846,0.00023408506,0.000099234654],"category_scores_gemma":[0.0003821312,0.00024830518,0.00015428997,0.00122308,0.000072268405,0.0001085194,0.00032673564,0.0002628464,0.0018438017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046053188,0.0050099534,0.00016757406,0.00047832885,0.00017875324,0.012332624,0.0020743618,0.000014031112,0.94768506,0.00014763925,0.031126453,0.00032466653],"study_design_scores_gemma":[0.08008155,0.00028483733,0.0023350513,0.00027369164,0.00020393795,0.00056329864,0.00044627782,0.0010285655,0.9121642,0.00006831949,0.0022394508,0.00031080228],"about_ca_topic_score_codex":0.00018842019,"about_ca_topic_score_gemma":0.000070170725,"teacher_disagreement_score":0.07962102,"about_ca_system_score_codex":0.0018951391,"about_ca_system_score_gemma":0.0016909903,"threshold_uncertainty_score":0.9999969},"labels":[],"label_agreement":null},{"id":"W4389235109","doi":"10.1182/blood-2023-173796","title":"Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Transplantation; Neutropenia; Gastroenterology; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Cytokine release syndrome; Rituximab; Adverse effect; Lymphoma; Clinical trial; Cancer; Toxicity; Immunotherapy; Chimeric antigen receptor","score_opus":0.011448898622576973,"score_gpt":0.25482436445354434,"score_spread":0.24337546583096736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970691,0.00004797916,0.00003304116,0.00014273755,0.000016388049,0.0010626263,0.000019468578,0.00009668914,0.0015119261],"genre_scores_gemma":[0.9984679,0.0001957128,0.00028332887,0.00003227346,0.00001867158,0.00007479442,0.00006183729,0.000028656374,0.00083679566],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99881285,0.000054842036,0.00019679581,0.00025343313,0.00035365002,0.00032842008],"domain_scores_gemma":[0.9994697,0.0001065606,0.000049312865,0.00023056263,0.000046915746,0.000096975855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022768018,0.00013942878,0.00024093507,0.00019560657,0.00006365041,0.000022212174,0.000060645823,0.00009995417,0.00006329194],"category_scores_gemma":[0.000036012138,0.00009746863,0.00002323587,0.0005843738,0.00006470958,0.00025070918,0.000019444775,0.00019562278,0.000030242862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10982518,0.01688786,0.39140666,0.0053687277,0.0023145266,0.0022513107,0.0174745,0.00031716214,0.011943523,0.00025631228,0.0021148087,0.43983942],"study_design_scores_gemma":[0.18680331,0.0025264528,0.78720075,0.00041457487,0.0001307212,0.0000502494,0.00031709654,0.013456663,0.007969372,0.000045594486,0.00075825385,0.00032697045],"about_ca_topic_score_codex":0.00032028003,"about_ca_topic_score_gemma":0.00017653758,"teacher_disagreement_score":0.43951246,"about_ca_system_score_codex":0.0010611074,"about_ca_system_score_gemma":0.0010730627,"threshold_uncertainty_score":0.39746556},"labels":[],"label_agreement":null},{"id":"W4389235230","doi":"10.1182/blood-2023-186347","title":"Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; Health Research Foundation; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McGill University Health Centre; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; Health Sciences North","funders":"","keywords":"Medicine; Bendamustine; Rituximab; Internal medicine; Ibrutinib; Clinical trial; Surgery; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.01091186289496117,"score_gpt":0.2550507896457149,"score_spread":0.24413892675075374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975059,0.0003731597,0.000008152117,0.0010110271,0.00005413516,0.0006528918,0.000023094351,0.00013225751,0.00023940852],"genre_scores_gemma":[0.99793375,0.0004042297,0.00058957626,0.00012116319,0.00014402292,0.00006943431,0.00010356256,0.00004352182,0.00059072376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998015,0.000083012616,0.00037252967,0.00054580474,0.00042390532,0.0005597903],"domain_scores_gemma":[0.9990572,0.00019630237,0.00008357566,0.0003308141,0.000092449125,0.00023970059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038155625,0.00024104674,0.00043120622,0.00025025653,0.00009604053,0.00006343539,0.00008971275,0.00016994849,0.000034121476],"category_scores_gemma":[0.00025518276,0.00019514836,0.000028462928,0.00065640814,0.00022022074,0.00011484049,0.0001775649,0.00021404211,0.000053898853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020779917,0.017156392,0.49580038,0.01119827,0.0027777606,0.06883546,0.014444052,0.00017542775,0.15893808,0.0037293881,0.013548031,0.19261685],"study_design_scores_gemma":[0.28820652,0.0011762783,0.66587186,0.00079341093,0.00034232123,0.003331256,0.00071395497,0.0063863755,0.03174332,0.00017762782,0.0007063459,0.00055073877],"about_ca_topic_score_codex":0.00059347245,"about_ca_topic_score_gemma":0.00019792205,"teacher_disagreement_score":0.26742658,"about_ca_system_score_codex":0.00086823915,"about_ca_system_score_gemma":0.0014793212,"threshold_uncertainty_score":0.7957919},"labels":[],"label_agreement":null},{"id":"W4389235362","doi":"10.1182/blood-2023-178819","title":"Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Bruton's tyrosine kinase; Ibrutinib; Chronic lymphocytic leukemia; Medicine; Progressive disease; Peripheral blood mononuclear cell; Somatic evolution in cancer; Immunology; Internal medicine; Cancer research; Oncology; Leukemia; Tyrosine kinase; Cancer; Chemotherapy; Biology; Genetics","score_opus":0.01767307885723865,"score_gpt":0.2852902259037935,"score_spread":0.2676171470465548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389235362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953279,0.00009191551,0.0000010560318,0.00017407416,0.000017829436,0.0004375717,0.0000143884,0.000091534785,0.0038437413],"genre_scores_gemma":[0.99351186,0.000047112047,0.00019655944,0.00004067531,0.000021452448,0.00006464153,0.00010236381,0.000024181814,0.0059911497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988897,0.000035220284,0.00017035501,0.00026938252,0.0003263657,0.0003089701],"domain_scores_gemma":[0.9993974,0.00012649664,0.000030883166,0.00023555804,0.00008909957,0.00012056095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012666667,0.000101981655,0.00018549977,0.00017307387,0.000049078506,0.000014413102,0.00005488393,0.000054117576,0.000024075138],"category_scores_gemma":[0.0002408224,0.00008007513,0.000021542746,0.0007803626,0.00008804209,0.00004905841,0.000039158433,0.00012297239,0.00005601684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053837667,0.004658415,0.95829463,0.0012406016,0.00073763245,0.0061163055,0.0048478064,0.0000073517854,0.00296074,0.0009912658,0.0073586316,0.007402833],"study_design_scores_gemma":[0.1591865,0.00045131656,0.8341568,0.00039136386,0.00017212865,0.000053056767,0.00027600853,0.00040303695,0.0036666256,0.00021909762,0.00082208466,0.00020198853],"about_ca_topic_score_codex":0.00015197627,"about_ca_topic_score_gemma":0.00041048173,"teacher_disagreement_score":0.15380272,"about_ca_system_score_codex":0.0006269285,"about_ca_system_score_gemma":0.0008931886,"threshold_uncertainty_score":0.3265369},"labels":[],"label_agreement":null},{"id":"W4389242944","doi":"10.1182/blood-2023-180920","title":"Bellwave-010: Phase 3, Open-Label, Randomized Study of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least One Prior Therapy","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Ibrutinib; Chronic lymphocytic leukemia; Tumor lysis syndrome; Rituximab; Medicine; Bruton's tyrosine kinase; Internal medicine; Oncology; Neutropenia; Lymphoma; Gastroenterology; Immunology; Leukemia; Chemotherapy; Tyrosine kinase; Receptor","score_opus":0.054291680657758315,"score_gpt":0.3259056005492849,"score_spread":0.2716139198915266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98240215,0.0027074143,0.000007889992,0.0000151867525,0.00061849493,0.013245374,0.000048397756,0.000323325,0.0006317483],"genre_scores_gemma":[0.9954909,0.0006576727,0.00022205722,0.00007875638,0.0002633426,0.0013940936,0.00038570998,0.00038233868,0.0011251384],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9901664,0.0009470625,0.0021808804,0.0019292047,0.0026243862,0.0021520238],"domain_scores_gemma":[0.99367917,0.0018953166,0.00087523105,0.00242108,0.00040929942,0.0007199085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022914994,0.0011589464,0.00398446,0.0010725466,0.0004655628,0.0001489275,0.0015275546,0.0005556741,0.00013700675],"category_scores_gemma":[0.0008888099,0.0010181242,0.00042065108,0.0026696157,0.0005541818,0.00041593413,0.0013490719,0.00053984334,0.0003297898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9444863,0.014795339,0.000977295,0.0010902712,0.006925363,0.0038545993,0.006312738,0.008619781,0.0017884977,0.0000261691,0.00019293907,0.010930713],"study_design_scores_gemma":[0.9289099,0.013574638,0.0012748899,0.0012606456,0.0015602151,0.00006400971,0.00051836844,0.049546394,0.002176405,0.000010410693,0.00017375822,0.0009303811],"about_ca_topic_score_codex":0.011813039,"about_ca_topic_score_gemma":0.0012948271,"teacher_disagreement_score":0.20861645,"about_ca_system_score_codex":0.35872495,"about_ca_system_score_gemma":0.15010849,"threshold_uncertainty_score":0.9992269},"labels":[],"label_agreement":null},{"id":"W4389243745","doi":"10.1182/blood-2023-182434","title":"A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Tolerability; Ibrutinib; Cancer research; Combination therapy; Medicine; Pharmacology; Internal medicine; Adverse effect; Leukemia; Chronic lymphocytic leukemia","score_opus":0.01611992263539499,"score_gpt":0.3019681617558525,"score_spread":0.28584823912045754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967602,0.00020030771,0.0000021466776,0.000060817118,0.000015494103,0.0027675987,0.000004005766,0.00006173716,0.00012768671],"genre_scores_gemma":[0.9992553,0.00004475127,0.00017105289,0.00004385429,0.00002025436,0.00022621594,0.000027009262,0.0000492251,0.00016235249],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977702,0.00020834152,0.00030821736,0.00052607566,0.00076337415,0.00042378413],"domain_scores_gemma":[0.99908423,0.00021437695,0.000113531285,0.00021089274,0.00026012125,0.00011687021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069125654,0.00022736161,0.00037185763,0.00044947723,0.00007685104,0.00003743162,0.000058809837,0.00008437445,0.0000034274876],"category_scores_gemma":[0.00018627198,0.00017339537,0.00001387175,0.001231623,0.00008704607,0.00014629081,0.000055102948,0.0003146312,0.00000496953],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017234119,0.042404875,0.8999904,0.00039716426,0.00033583448,0.00085689325,0.02182127,0.000048762835,0.008147984,0.000009659196,0.000063690786,0.008689358],"study_design_scores_gemma":[0.5388954,0.046160586,0.40125847,0.0005252186,0.00015181178,0.0000454747,0.0018410047,0.0027530023,0.008018649,0.00003639955,0.000008771887,0.0003051995],"about_ca_topic_score_codex":0.0005676816,"about_ca_topic_score_gemma":0.00023998704,"teacher_disagreement_score":0.5216613,"about_ca_system_score_codex":0.0013720929,"about_ca_system_score_gemma":0.0020893943,"threshold_uncertainty_score":0.7070858},"labels":[],"label_agreement":null},{"id":"W4389243774","doi":"10.1182/blood-2023-178879","title":"A Real-World Evidence Study of the Temporal Evolution in Treatment Patterns and Outcomes for Chronic Lymphocytic Leukemia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Population; Cohort; Retrospective cohort study; Asymptomatic; Disease; Pediatrics; Internal medicine; Intensive care medicine; Leukemia","score_opus":0.05157694726498536,"score_gpt":0.35470581568154075,"score_spread":0.3031288684165554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710107,0.00021331925,0.0000028760037,0.00012784492,0.0000645985,0.0023873665,0.0000113640135,0.000050087616,0.00004150265],"genre_scores_gemma":[0.9977377,0.00019956609,0.000018089158,0.000011223736,0.00006728671,0.00041151076,0.0000058032647,0.000024318462,0.001524477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984825,0.00008395966,0.00035726227,0.00033331534,0.00038885148,0.0003540679],"domain_scores_gemma":[0.99876714,0.00047473033,0.00008894788,0.00054121774,0.000052512332,0.00007543864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036638285,0.00015906677,0.00040386844,0.00023008342,0.00006306929,0.000011698258,0.00013892625,0.000053052965,0.0000076670885],"category_scores_gemma":[0.00021905317,0.00009980271,0.00009175547,0.00059607625,0.00006709623,0.000059686034,0.00012915047,0.00007277757,0.000006595543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00017680904,0.0004504178,0.99596727,0.0004403217,0.00017862089,0.0000758282,0.001240288,0.00014272529,0.0004546787,0.000030245961,0.000044902106,0.00079787226],"study_design_scores_gemma":[0.057347037,0.001486542,0.92800945,0.00050008646,0.00026777366,0.000025077241,0.0006552659,0.010415543,0.0011348804,0.000043740434,0.000019174826,0.000095432435],"about_ca_topic_score_codex":0.053015508,"about_ca_topic_score_gemma":0.034899373,"teacher_disagreement_score":0.06795784,"about_ca_system_score_codex":0.05130569,"about_ca_system_score_gemma":0.013317449,"threshold_uncertainty_score":0.99227613},"labels":[],"label_agreement":null},{"id":"W4389246619","doi":"10.1182/blood-2023-177808","title":"Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Thrombopoietin; Bruton's tyrosine kinase; Internal medicine; Gastroenterology; Platelet; Concomitant; Thrombopoietin receptor; Antibody; Immunology; Tyrosine kinase; Receptor","score_opus":0.02414532108354637,"score_gpt":0.32428107355702773,"score_spread":0.30013575247348134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654776,0.00010154419,0.0000043022987,0.0002369228,0.0001274953,0.0020839244,0.00021825467,0.000072379364,0.0006074161],"genre_scores_gemma":[0.9977429,0.00004144096,0.00031849038,0.000023124523,0.00016791829,0.00006922708,0.0011683413,0.000049779923,0.00041880805],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974154,0.000060757677,0.0009481541,0.000523892,0.0005730123,0.00047875886],"domain_scores_gemma":[0.99825263,0.00041469917,0.00025650105,0.0006437148,0.00026059657,0.0001718623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009147674,0.00021285997,0.000677857,0.00022956349,0.000073163115,0.000014888035,0.00010584399,0.00014552248,0.000014534758],"category_scores_gemma":[0.0017233767,0.00017218453,0.000065527915,0.0006743863,0.00021238849,0.000094460695,0.00013774862,0.00020743236,0.000009184896],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66022474,0.082584605,0.058757562,0.008065676,0.003202754,0.024665384,0.009192124,0.00010432609,0.088652894,0.0004910872,0.025162727,0.038896147],"study_design_scores_gemma":[0.78215384,0.00630346,0.107016854,0.0013374438,0.0003342144,0.00021461865,0.000078621866,0.0002843352,0.097815454,0.000017366458,0.004110143,0.00033367053],"about_ca_topic_score_codex":0.00017675631,"about_ca_topic_score_gemma":0.000025893582,"teacher_disagreement_score":0.1219291,"about_ca_system_score_codex":0.00061198906,"about_ca_system_score_gemma":0.002043094,"threshold_uncertainty_score":0.70214814},"labels":[],"label_agreement":null},{"id":"W4389247709","doi":"10.1182/blood-2023-189924","title":"A Multi-Modal Analysis of Acquired Resistance to Acalabrutinib and Pirtobrutinib Provides Potential Strategies to Augment Treatment Outcome with BTKi Drugs","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Bruton's tyrosine kinase; Cell culture; Ibrutinib; Carfilzomib; Biology; Chemistry; Cancer research; Genetics; Proteasome inhibitor; Chronic lymphocytic leukemia; Tyrosine kinase; Leukemia","score_opus":0.030795388579599573,"score_gpt":0.3369246149613652,"score_spread":0.30612922638176565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966147,0.00013289407,0.00019568574,0.0011715451,0.00002673246,0.0013411747,0.0000795661,0.0001175842,0.00032014886],"genre_scores_gemma":[0.9890462,0.000034625016,0.007100531,0.00009916243,0.00004526742,0.00021750074,0.00004972558,0.00003593213,0.0033710678],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99752295,0.0000591467,0.0004841249,0.0006239613,0.0007387704,0.0005710574],"domain_scores_gemma":[0.9985732,0.00013172548,0.00009368717,0.00061911595,0.00016582053,0.00041647203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031740652,0.0002713052,0.00076316856,0.0006456608,0.00008711421,0.00006131143,0.00015831362,0.00008577042,0.000037209265],"category_scores_gemma":[0.000112289745,0.00019494645,0.00015157659,0.001941004,0.00012571544,0.00007296694,0.00015548556,0.00005068084,0.00003391391],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046478596,0.026301092,0.2192351,0.006708424,0.0785093,0.010865362,0.09853027,0.015237817,0.47222644,0.002263066,0.0031542785,0.020490244],"study_design_scores_gemma":[0.21265072,0.009507893,0.63898015,0.0009745415,0.0216471,0.00013034775,0.01985558,0.019886743,0.07190252,0.00006933807,0.002727475,0.0016675844],"about_ca_topic_score_codex":0.0008989002,"about_ca_topic_score_gemma":0.0011458752,"teacher_disagreement_score":0.41974506,"about_ca_system_score_codex":0.0014421446,"about_ca_system_score_gemma":0.0020807951,"threshold_uncertainty_score":0.79496855},"labels":[],"label_agreement":null},{"id":"W4389247975","doi":"10.1182/blood-2023-181195","title":"Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Obinutuzumab; Medicine; Internal medicine; Quality of life (healthcare); Nausea; Vomiting; Progression-free survival; Clinical endpoint; Oncology; Clinical trial; Rituximab; Lymphoma; Chemotherapy","score_opus":0.03201026781181236,"score_gpt":0.29477895216608,"score_spread":0.26276868435426765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441344,0.00071218197,0.0000020540028,0.00029567038,0.00018469246,0.003535705,0.00005925758,0.00025546728,0.0005415613],"genre_scores_gemma":[0.9985181,0.00015303539,0.00005948707,0.0001267012,0.00010924246,0.00023257446,0.00030347242,0.00013955588,0.00035779938],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99418217,0.00074228813,0.0014377037,0.00082367647,0.0017611489,0.0010529864],"domain_scores_gemma":[0.99620914,0.000889718,0.00069054944,0.0014827847,0.0003112642,0.00041656123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014311911,0.00051028375,0.0014130678,0.00039739397,0.00019619694,0.000036219997,0.00044582796,0.00034236148,0.000069783244],"category_scores_gemma":[0.0006321986,0.0003167092,0.00023532409,0.0023346266,0.00038671127,0.00014681938,0.00011546966,0.00048894226,0.00006639104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.92859596,0.008258225,0.043117564,0.0008178896,0.00465735,0.00047181686,0.0047946987,0.0005793359,0.00021395931,0.00040124808,0.0010945444,0.006997404],"study_design_scores_gemma":[0.8750659,0.0118002575,0.11012172,0.00036262788,0.00023946361,0.000017576529,0.00047711644,0.0006117933,0.000498319,0.000020050946,0.0003820442,0.0004030954],"about_ca_topic_score_codex":0.0106805,"about_ca_topic_score_gemma":0.0006918018,"teacher_disagreement_score":0.06700415,"about_ca_system_score_codex":0.011700554,"about_ca_system_score_gemma":0.021808673,"threshold_uncertainty_score":0.9999285},"labels":[],"label_agreement":null},{"id":"W4389247985","doi":"10.1182/blood-2023-177567","title":"Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Incyte; BeiGene; F. Hoffmann-La Roche; TG Therapeutics; Gilead Sciences; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Venetoclax; Internal medicine; Bendamustine; Regimen; Progression-free survival; Rituximab; Randomized controlled trial; Oncology; Chronic lymphocytic leukemia; Surgery; Leukemia; Chemotherapy; Lymphoma","score_opus":0.014153826699321803,"score_gpt":0.2723629041360706,"score_spread":0.2582090774367488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222136,0.00042561765,0.0000018034714,0.00026666393,0.000046830264,0.006782169,0.00004900399,0.00010571547,0.000100817844],"genre_scores_gemma":[0.99718744,0.000028983102,0.00012890232,0.00017544614,0.00010318153,0.0010971399,0.00007752993,0.00009933528,0.0011020222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957691,0.00052620046,0.0005782104,0.00079232804,0.0013777241,0.0009564457],"domain_scores_gemma":[0.99741775,0.00082290056,0.0001257602,0.0011617875,0.00013334947,0.00033846212],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017576062,0.0004370234,0.0007482865,0.00048087843,0.00010836309,0.00007727686,0.0004896878,0.00018662422,0.00010229398],"category_scores_gemma":[0.0005440072,0.00026588587,0.0000685739,0.0015383271,0.00017172817,0.00012717675,0.00024154242,0.00039417716,0.0001427599],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.95202804,0.0033005278,0.012376975,0.0007806903,0.0007788158,0.002960142,0.012555008,0.002321194,0.0063230316,0.000011634888,0.001700169,0.004863805],"study_design_scores_gemma":[0.831948,0.01621829,0.145377,0.0016210476,0.00015506736,0.00011719264,0.000275733,0.0016602331,0.0006424028,0.000005893954,0.0014850356,0.0004941483],"about_ca_topic_score_codex":0.00078183506,"about_ca_topic_score_gemma":0.0010796002,"teacher_disagreement_score":0.13300002,"about_ca_system_score_codex":0.050141126,"about_ca_system_score_gemma":0.029952185,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W4389248231","doi":"10.1182/blood-2023-179198","title":"Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Venetoclax; Medicine; Internal medicine; Population; Regimen; Ibrutinib; Chronic lymphocytic leukemia; Discontinuation; Oncology; Leukemia","score_opus":0.023765827101584945,"score_gpt":0.32878074646954636,"score_spread":0.30501491936796143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635917,0.00020574439,0.0000022935383,0.000035632893,0.00014421085,0.002471019,0.000015075939,0.00024253302,0.00052431657],"genre_scores_gemma":[0.997218,0.0003024646,0.000030674863,0.000034604593,0.00040602105,0.0014264331,0.00014396512,0.00009892701,0.00033890182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972206,0.00025931167,0.00036123232,0.0007531819,0.00079052156,0.0006151994],"domain_scores_gemma":[0.99853,0.0002557378,0.00007549908,0.00078709045,0.00011759837,0.00023408687],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044136544,0.00037463097,0.0005154198,0.0007361598,0.00006514047,0.000055056506,0.00021555778,0.00011150959,0.00008126251],"category_scores_gemma":[0.000033418077,0.0002791517,0.00010066579,0.0012817644,0.00012462518,0.00015580881,0.00006293508,0.00019657641,0.00008741804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.035273146,0.010106301,0.80713683,0.00079185836,0.002199765,0.040776417,0.003311216,0.034229945,0.02761458,0.000036984497,0.000052025094,0.038470898],"study_design_scores_gemma":[0.2944004,0.012186651,0.5826175,0.00068643765,0.00024361021,0.000119543314,0.0001679318,0.03788645,0.070552796,0.000008211162,0.0006444753,0.0004860022],"about_ca_topic_score_codex":0.013111158,"about_ca_topic_score_gemma":0.005241976,"teacher_disagreement_score":0.25912726,"about_ca_system_score_codex":0.15684304,"about_ca_system_score_gemma":0.034911327,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W4389258289","doi":"10.1182/blood-2023-172977","title":"Real World Experience of Ibrutinib in an Ethnically Diverse Canadian Community Hospital","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Medicine; Chronic lymphocytic leukemia; Population; Internal medicine; Oncology; Leukemia; Tyrosine kinase; Environmental health","score_opus":0.059583395361537346,"score_gpt":0.3611031074298471,"score_spread":0.30151971206830974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389258289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164873,0.000013466327,1.1868389e-7,0.00017072637,0.000054286837,0.00025852758,0.00001759716,0.000050624305,0.007785927],"genre_scores_gemma":[0.9991224,0.000036589005,0.00010994231,0.00006295166,0.00004408906,0.000021917402,0.00004316119,0.000015481895,0.00054347585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987085,0.00013773316,0.00023016779,0.00016324973,0.00032442977,0.00043595425],"domain_scores_gemma":[0.9986907,0.00017414243,0.000033286102,0.0006193334,0.00007802591,0.00040449348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048140498,0.00009028305,0.00022044255,0.00032242437,0.00007542865,0.000009207186,0.00030138428,0.00007807887,0.00012785746],"category_scores_gemma":[0.0003259722,0.00008737153,0.00004394594,0.00091708894,0.00021723623,0.000077001954,0.00015276474,0.0003930756,0.000060074286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031369357,0.0038315447,0.9149533,0.00035781643,0.0001223294,0.004244331,0.061329033,0.000025395455,0.00752912,0.00075315434,0.0018864515,0.0046538156],"study_design_scores_gemma":[0.021417037,0.00064640044,0.9639441,0.0001826629,0.000036571306,0.000022678534,0.008106372,0.00074815186,0.004294278,0.0000731598,0.0003413962,0.00018718936],"about_ca_topic_score_codex":0.6838691,"about_ca_topic_score_gemma":0.7494125,"teacher_disagreement_score":0.06554336,"about_ca_system_score_codex":0.0017236107,"about_ca_system_score_gemma":0.0049269176,"threshold_uncertainty_score":0.8740141},"labels":[],"label_agreement":null},{"id":"W4389259078","doi":"10.1182/blood-2023-187573","title":"Clime: CLL Immune Micro-Environment and Risk of Infections Pre- and Post-Diagnosis: A Population-Based Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Leukemia and Lymphoma Society of Canada; CancerCare Manitoba Foundation; AstraZeneca","keywords":"Medicine; Population; Cancer; Chronic lymphocytic leukemia; Internal medicine; Cancer registry; Pediatrics; Leukemia","score_opus":0.010951435405460562,"score_gpt":0.2800887961759581,"score_spread":0.26913736077049755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791837,0.0008519308,0.0000021718147,0.00011827994,0.000023129294,0.00097103487,0.00003763075,0.000051451498,0.000025984204],"genre_scores_gemma":[0.99877095,0.00070172263,0.000105811036,0.000016526958,0.000033248896,0.00016609364,0.000038974205,0.000020835769,0.00014583628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894947,0.000089141475,0.00026301638,0.00025087257,0.0002544526,0.00019303375],"domain_scores_gemma":[0.9991434,0.00031715987,0.00007596843,0.00032826007,0.000035540354,0.00009964185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034496945,0.00010761789,0.00023656062,0.00017104755,0.0000958553,0.000013030673,0.0000417451,0.00006137117,0.000040337247],"category_scores_gemma":[0.000242104,0.000095147465,0.0000447883,0.00021375947,0.000060908504,0.00003356819,0.000101197016,0.00013287143,0.000018909464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000796253,0.0018769773,0.9937735,0.00012806666,0.0002776729,0.000027565327,0.00045516223,0.000048305752,0.0025572283,0.0000023701186,0.000023152914,0.0007503353],"study_design_scores_gemma":[0.023319507,0.0010950884,0.9711692,0.00006927948,0.0006100621,0.000025049716,0.00031756403,0.00052632304,0.0027313025,0.000011623484,0.000044683075,0.000080321304],"about_ca_topic_score_codex":0.0046856934,"about_ca_topic_score_gemma":0.00009737386,"teacher_disagreement_score":0.02323988,"about_ca_system_score_codex":0.00038612218,"about_ca_system_score_gemma":0.00038295035,"threshold_uncertainty_score":0.7083398},"labels":[],"label_agreement":null},{"id":"W4389366647","doi":"10.1212/wnl.98.18_supplement.2674","title":"Effects of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions: An Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis (S14.009)","year":2022,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada)","funders":"","keywords":"Multiple sclerosis; Medicine; Pathology; Bruton's tyrosine kinase; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Immunology; Cancer; Receptor","score_opus":0.027456018227483222,"score_gpt":0.30446201125960237,"score_spread":0.27700599303211915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389366647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959839,0.0015198399,0.000029771027,0.00091800257,0.00043774862,0.000919202,0.000014239735,0.000054274577,0.00012303134],"genre_scores_gemma":[0.9988013,0.00014785315,0.00007563539,0.00049120956,0.00015877436,0.00017225434,0.000024339217,0.00007471141,0.0000539505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99673593,0.0006177679,0.0006486212,0.0006548138,0.0006446065,0.00069828785],"domain_scores_gemma":[0.99782264,0.0010849596,0.0002192994,0.000629756,0.00007902152,0.00016433319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006998202,0.0002548166,0.00065283384,0.0006992503,0.00013971275,0.00000661623,0.00029877754,0.00010622933,0.00021444091],"category_scores_gemma":[0.00071875803,0.00026356202,0.00011004695,0.00069893576,0.00022729652,0.00009869132,0.00047691946,0.0007355753,0.000008818543],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00908396,0.0019363274,0.03082538,0.0012131763,0.00005439507,0.002635204,0.0010714161,0.0013143689,0.92679054,0.00015939446,0.0004125832,0.024503237],"study_design_scores_gemma":[0.0873066,0.018843658,0.14373036,0.0010068358,0.00017240735,0.0008797646,0.00017828922,0.105946474,0.63830703,0.00012842548,0.0028619205,0.0006382387],"about_ca_topic_score_codex":0.0018268505,"about_ca_topic_score_gemma":0.00012180459,"teacher_disagreement_score":0.28848353,"about_ca_system_score_codex":0.0026885604,"about_ca_system_score_gemma":0.0015775482,"threshold_uncertainty_score":0.99998164},"labels":[],"label_agreement":null},{"id":"W4389431718","doi":"10.1182/blood.2023022018","title":"A peculiar case of cyclin D1–positive lymphoplasmacytic lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Lymphoplasmacytic Lymphoma; Lymphoma; Medicine; Cyclin D1; Waldenstrom macroglobulinemia; Cancer research; Pathology; Internal medicine; Cancer; Cell cycle","score_opus":0.01907664835267038,"score_gpt":0.3091593842443556,"score_spread":0.2900827358916852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389431718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266547,0.0002280455,0.00001049442,0.0002063868,0.00013482929,0.00048991025,0.000049498303,0.00018468502,0.00603068],"genre_scores_gemma":[0.99637866,0.00011854176,0.00029768737,0.000105342864,0.00017155532,0.00004639742,0.00004430482,0.000052513646,0.0027849884],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980773,0.000069898306,0.00040042814,0.00039566745,0.0005012905,0.00055542996],"domain_scores_gemma":[0.9984471,0.00039652415,0.00008939618,0.0006009142,0.00018325612,0.00028279153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003553032,0.00019605715,0.00043861812,0.00030695036,0.00008090653,0.000014976435,0.00014432053,0.00014430744,0.00012063161],"category_scores_gemma":[0.0004830247,0.00017540198,0.00018940565,0.0009951337,0.00020049843,0.0000579415,0.00017783893,0.00009574627,0.0008226459],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032976,0.011651066,0.00811376,0.0045996727,0.004578368,0.78422725,0.01168175,0.00014596278,0.08057011,0.0034605297,0.0204865,0.067187466],"study_design_scores_gemma":[0.31153792,0.001763714,0.010797623,0.001190191,0.0019705624,0.20251906,0.0031177995,0.033583615,0.4293904,0.000663718,0.002501277,0.00096412876],"about_ca_topic_score_codex":0.0012622399,"about_ca_topic_score_gemma":0.000055650842,"teacher_disagreement_score":0.5817082,"about_ca_system_score_codex":0.0022087747,"about_ca_system_score_gemma":0.0048835315,"threshold_uncertainty_score":0.99995536},"labels":[],"label_agreement":null},{"id":"W4389436972","doi":"10.1212/wnl.90.15_supplement.p3.407","title":"Integrated Safety Analysis of Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg (P3.407)","year":2018,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cladribine; Medicine; Pharmacology; Internal medicine","score_opus":0.0218071785748893,"score_gpt":0.31056189858478006,"score_spread":0.2887547200098908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389436972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825346,0.000023623144,0.000052074352,0.00017657058,0.00017214479,0.00037885428,0.00004114501,0.000031078944,0.00087103434],"genre_scores_gemma":[0.9993057,0.00004546293,0.00009881648,0.00021108377,0.000057850382,0.000017139979,0.00007947995,0.00002872873,0.00015572537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977109,0.00023194734,0.0007764614,0.00043254168,0.00037208258,0.00047605904],"domain_scores_gemma":[0.99838024,0.00024830576,0.0003072743,0.0005718811,0.00037608808,0.00011620354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002859155,0.00019065687,0.000840422,0.001203215,0.00007108165,0.000006061367,0.00019614941,0.00022514444,0.0014978399],"category_scores_gemma":[0.0009299496,0.00015379195,0.00015005188,0.0029654892,0.00044734118,0.00007447461,0.00019229997,0.0003166299,0.000013527726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0151424995,0.0014125098,0.9532613,0.00025797254,0.0011910235,0.00020475102,0.0011010605,0.0007406194,0.024094058,0.000067748995,0.00010437682,0.0024220883],"study_design_scores_gemma":[0.022604162,0.004677097,0.93579936,0.00006591906,0.00057459006,0.00009173676,0.00002504092,0.028740082,0.0057301996,0.000006758683,0.0015321653,0.00015290618],"about_ca_topic_score_codex":0.0056026955,"about_ca_topic_score_gemma":0.0046233544,"teacher_disagreement_score":0.027999463,"about_ca_system_score_codex":0.001610506,"about_ca_system_score_gemma":0.0017703644,"threshold_uncertainty_score":0.9994149},"labels":[],"label_agreement":null},{"id":"W4389450046","doi":"10.1212/wnl.94.15_supplement.400","title":"Early Real-World Safety, Tolerability, and Efficacy of Cladribine Tablets: A Single Center Experience (400)","year":2020,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Tolerability; Cladribine; Single Center; Medicine; Center (category theory); Adverse effect; Medical physics; Pharmacology; Internal medicine; Chemistry","score_opus":0.03988477722312659,"score_gpt":0.3102274820927687,"score_spread":0.27034270486964207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389450046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98559666,0.00007725859,0.000027628024,0.008782815,0.000085800195,0.0004069229,0.000009124631,0.00005647376,0.004957333],"genre_scores_gemma":[0.99596417,0.0000788607,0.00010725242,0.003532475,0.00014889473,0.00001117491,0.000008447191,0.000025679077,0.00012305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982726,0.000112219845,0.00041328836,0.00050816685,0.00029272388,0.0004009895],"domain_scores_gemma":[0.99882406,0.00031540947,0.00007945255,0.00041084332,0.00008436429,0.00028588314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011422341,0.00014923721,0.00047825833,0.00008110909,0.00003780269,0.000010002041,0.00016556536,0.00010354733,0.0003044471],"category_scores_gemma":[0.00040231974,0.00013226709,0.000061052546,0.00032497713,0.00043830753,0.000059479164,0.00030770773,0.00031337666,0.000026425852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06801203,0.0042634723,0.57005495,0.0019042346,0.0003515442,0.00387277,0.022481898,0.00016152364,0.29340225,0.0021457071,0.0059578693,0.027391782],"study_design_scores_gemma":[0.12799016,0.03408997,0.656805,0.00019063555,0.00020371762,0.001990825,0.00011088773,0.018119963,0.026426485,0.00023548462,0.13299581,0.00084104785],"about_ca_topic_score_codex":0.00092558714,"about_ca_topic_score_gemma":0.00008930267,"teacher_disagreement_score":0.26697576,"about_ca_system_score_codex":0.00036449134,"about_ca_system_score_gemma":0.0005383872,"threshold_uncertainty_score":0.5393695},"labels":[],"label_agreement":null},{"id":"W4389455899","doi":"10.1182/blood-2023-191921","title":"Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Ibrutinib; Venetoclax; Mantle cell lymphoma; Internal medicine; Tumor lysis syndrome; Oncology; Bendamustine; Ven; Phases of clinical research; Neutropenia; Febrile neutropenia; Clinical endpoint; Tolerability; Rituximab; Clinical trial; Lymphoma; Chronic lymphocytic leukemia; Adverse effect; Leukemia; Chemotherapy","score_opus":0.010872215137858757,"score_gpt":0.25676972606899917,"score_spread":0.24589751093114043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389455899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948361,0.00011086073,0.000005959561,0.0000979289,0.00004361119,0.0036607797,0.0001310387,0.00012108618,0.0009926332],"genre_scores_gemma":[0.99755037,0.00003439865,0.00010487246,0.000106259584,0.00006285217,0.00025493995,0.0012624548,0.00006311208,0.00056072336],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99606234,0.0005818535,0.0007357727,0.0007172656,0.0013347557,0.0005680348],"domain_scores_gemma":[0.99576944,0.0022398876,0.00027984867,0.0013372794,0.00017877216,0.00019477578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013432745,0.0003304444,0.0012412231,0.00038474912,0.00012251355,0.00005063712,0.00034011927,0.000110953704,0.000043532928],"category_scores_gemma":[0.0004214212,0.0001813745,0.00017314084,0.002365369,0.00023028161,0.00008963367,0.00016314037,0.0002731661,0.00009026191],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8084085,0.03367038,0.138483,0.00012125041,0.007971335,0.0018676226,0.0072795846,0.0003651883,0.0000711559,0.0000039170723,0.00091684645,0.00084121135],"study_design_scores_gemma":[0.8398581,0.0025085474,0.15017502,0.00011236092,0.003999199,0.0000021600456,0.00054525613,0.0023342655,0.00020551193,0.0000061492087,0.00004777446,0.00020564992],"about_ca_topic_score_codex":0.0024851195,"about_ca_topic_score_gemma":0.00036373266,"teacher_disagreement_score":0.031449597,"about_ca_system_score_codex":0.0025434124,"about_ca_system_score_gemma":0.0037314212,"threshold_uncertainty_score":0.7396238},"labels":[],"label_agreement":null},{"id":"W4389464500","doi":"10.1212/wnl.92.15_supplement.s56.004","title":"Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomized, Placebo-Controlled, Phase 2 Study (S56.004)","year":2019,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; NeuroRx Research (Canada); University of Toronto","funders":"","keywords":"Placebo; Medicine; Randomized controlled trial; Tyrosine-kinase inhibitor; Internal medicine; Multiple sclerosis; Psychiatry; Alternative medicine; Pathology; Cancer","score_opus":0.011510241991260594,"score_gpt":0.259260521617082,"score_spread":0.2477502796258214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389464500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959774,0.00019363305,0.0000041209064,0.00043095357,0.0003580376,0.009137622,0.00001465672,0.000031104846,0.00023214128],"genre_scores_gemma":[0.99911374,0.000026139085,0.000024548093,0.0004050129,0.00006783464,0.0001444189,0.000009730766,0.000057853224,0.0001507333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962785,0.0010101415,0.00082369574,0.0006577267,0.0006784903,0.0005514249],"domain_scores_gemma":[0.9963333,0.0022430322,0.0003111934,0.0008057439,0.00015569992,0.00015103033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011440766,0.00031916337,0.0014858256,0.00025035543,0.000084538326,0.000017419845,0.00021408795,0.0001968367,0.00013028737],"category_scores_gemma":[0.0017196583,0.00019322429,0.00014890775,0.00041424547,0.00045051827,0.00009313252,0.00028207357,0.0006500379,0.000018233259],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8499812,0.0027445985,0.14438352,0.0000668404,0.00018066292,0.000043614542,0.0006427665,0.000082409,0.0010976125,0.000012598516,0.00007968335,0.000684491],"study_design_scores_gemma":[0.88710403,0.004677533,0.10163678,0.00017821505,0.00022881935,0.000020103402,0.000035284287,0.0056127445,0.00026454765,0.0000036664828,0.00009426642,0.00014402386],"about_ca_topic_score_codex":0.00081181497,"about_ca_topic_score_gemma":0.00018284305,"teacher_disagreement_score":0.042746738,"about_ca_system_score_codex":0.0007141309,"about_ca_system_score_gemma":0.0010094041,"threshold_uncertainty_score":0.7879458},"labels":[],"label_agreement":null},{"id":"W4389607722","doi":"10.1016/j.jcjo.2023.11.011","title":"Beyond the norm: unusual orbital manifestation of hairy cell leukemia","year":2023,"lang":"en","type":"letter","venue":"Canadian Journal of Ophthalmology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Queen's University; University of British Columbia","funders":"","keywords":"Hairy cell leukemia; Norm (philosophy); Leukemia; Physics; Medicine; Philosophy; Immunology; Epistemology","score_opus":0.03402431050765452,"score_gpt":0.29633126564453466,"score_spread":0.2623069551368801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389607722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.788383,0.0016355211,0.000005870521,0.14743261,0.00384616,0.0006660111,0.00022318486,0.000010530268,0.05779713],"genre_scores_gemma":[0.9369747,0.00002517451,0.00015782495,0.02211722,0.00609626,0.000013190991,0.00027381617,0.00020231704,0.034139495],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9968166,0.00026852885,0.0010289046,0.0002883383,0.00072623044,0.0008713987],"domain_scores_gemma":[0.99664843,0.0007746175,0.00077638146,0.0005702463,0.0007062414,0.00052407564],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082165486,0.00032477514,0.0008966726,0.0010329412,0.000119810495,0.00003086716,0.0007283737,0.0010011112,0.0011526287],"category_scores_gemma":[0.00053172087,0.00024086909,0.00037642402,0.00048815843,0.0007149623,0.00008089876,0.000056450463,0.0030292554,0.00016757748],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000068122805,0.000007707533,0.00039129812,0.0004117214,0.000199489,0.35835773,0.0003074155,0.00004041678,0.000029504692,0.00001795529,0.64008516,0.00008348769],"study_design_scores_gemma":[0.006015699,0.001821477,0.0036176657,0.00035908353,0.00045201892,0.9427839,0.00037045282,0.00022605548,0.0003919452,0.0008381216,0.04277183,0.00035177593],"about_ca_topic_score_codex":0.026324786,"about_ca_topic_score_gemma":0.00057276513,"teacher_disagreement_score":0.59731334,"about_ca_system_score_codex":0.0144425165,"about_ca_system_score_gemma":0.08435716,"threshold_uncertainty_score":0.99976045},"labels":[],"label_agreement":null},{"id":"W4389866816","doi":"10.1016/j.msard.2023.105288","title":"Effect of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Patient-Reported Vitality and Mental Health in Patients with Relapsing Multiple Sclerosis in a Phase 2 Trial","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada)","funders":"","keywords":"Medicine; Multiple sclerosis; Vitality; Internal medicine; Mental health; Tyrosine kinase; Oncology; Psychiatry; Genetics; Receptor","score_opus":0.022203950507527145,"score_gpt":0.2817896169211643,"score_spread":0.2595856664136371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389866816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944931,0.000552049,8.40639e-7,0.00046209325,0.00020632535,0.0040737814,0.00008723532,0.000083088016,0.000041464133],"genre_scores_gemma":[0.9983999,0.0009518485,0.000031448115,0.00005037354,0.0000121045105,0.00011331604,0.00036091637,0.00006382999,0.000016246582],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99644774,0.00040392444,0.0010198565,0.0007701258,0.0006674336,0.00069094263],"domain_scores_gemma":[0.9983491,0.0005567701,0.00033641825,0.00039427716,0.00006014367,0.00030332917],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010621357,0.00038325047,0.00089754077,0.000640582,0.00017592945,0.000029573897,0.00007271417,0.0002517263,0.000012934165],"category_scores_gemma":[0.0008922026,0.00029599373,0.000110932575,0.00140108,0.0003506673,0.00015116148,0.00013568868,0.0004762911,0.0000035480655],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26756877,0.006688151,0.5332818,0.000871801,0.00032357534,0.000040685907,0.004626908,0.0002678993,0.0053674118,0.0000044013677,0.00041019623,0.18054841],"study_design_scores_gemma":[0.7099938,0.015178771,0.2543282,0.0033055667,0.000053860018,0.0000036957601,0.0003545328,0.014732007,0.0016548219,0.0000055603764,0.000050164723,0.00033907112],"about_ca_topic_score_codex":0.003047093,"about_ca_topic_score_gemma":0.00051084696,"teacher_disagreement_score":0.44242498,"about_ca_system_score_codex":0.0016813827,"about_ca_system_score_gemma":0.0005259979,"threshold_uncertainty_score":0.9999492},"labels":[],"label_agreement":null},{"id":"W4389883767","doi":"10.1016/j.msard.2023.105329","title":"Update on Long-Term Efficacy and Safety of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Over 5 Years from an Ongoing Phase 2 Open-Label Extension","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Tyrosine-kinase inhibitor; Bruton's tyrosine kinase; Open label; Term (time); Extension (predicate logic); Tyrosine kinase; Pharmacology; Oncology; Adverse effect; Internal medicine; Receptor; Cancer; Computer science","score_opus":0.047042485512655066,"score_gpt":0.33179932538169954,"score_spread":0.2847568398690445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389883767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962403,0.001692318,0.000006746505,0.00045523528,0.00017148867,0.0011128047,0.00010014004,0.000115252624,0.00010570393],"genre_scores_gemma":[0.99184316,0.0071348203,0.00010203676,0.00015793608,0.00004205193,0.000019658564,0.00048749617,0.00007403092,0.00013883333],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99768543,0.0001163288,0.00051334273,0.0007583802,0.00045748753,0.00046905794],"domain_scores_gemma":[0.9984915,0.00034985182,0.00014718223,0.00058529474,0.00006844871,0.00035767755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004194383,0.00028164563,0.00053195254,0.00025598306,0.0002035559,0.000077170385,0.00017874119,0.00027068652,0.00012414921],"category_scores_gemma":[0.0003236676,0.00024375944,0.000060033646,0.0006061093,0.00033288266,0.00021831597,0.0003805571,0.00035942975,0.000038954142],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024750592,0.008741388,0.028023105,0.00043804367,0.0008612264,0.00043690598,0.0037593008,0.00043148108,0.29691187,0.00012308864,0.0027658292,0.6327572],"study_design_scores_gemma":[0.25456262,0.0019260375,0.69083685,0.0022852465,0.00022625121,0.000014257879,0.00022226007,0.045476545,0.0034043116,0.00005481157,0.00051867496,0.00047213276],"about_ca_topic_score_codex":0.0014003585,"about_ca_topic_score_gemma":0.0001575478,"teacher_disagreement_score":0.6628137,"about_ca_system_score_codex":0.00045671946,"about_ca_system_score_gemma":0.0003788315,"threshold_uncertainty_score":0.99402213},"labels":[],"label_agreement":null},{"id":"W4389893007","doi":"10.1016/j.msard.2023.105328","title":"Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Internal medicine; Relapsing remitting; Clinical trial; Physical therapy; Oncology; Immunology; Fingolimod","score_opus":0.1882112032418722,"score_gpt":0.3692451553097669,"score_spread":0.18103395206789472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389893007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224293,0.0033872658,0.00032894805,0.0004643256,0.0001813235,0.0032788075,0.00004450286,0.000042925807,0.000028946472],"genre_scores_gemma":[0.98202205,0.016925639,0.000740028,0.000013497914,0.000028193577,0.000092133225,0.000081815815,0.0000438492,0.00005280174],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963925,0.00078989257,0.0014346956,0.0005312437,0.0004205671,0.00043110902],"domain_scores_gemma":[0.9897241,0.009135425,0.00048598647,0.00033018895,0.0001390681,0.00018521203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070666526,0.00029530897,0.001061707,0.00032926732,0.00023945665,0.00004616565,0.00009529606,0.0002649551,0.000019950212],"category_scores_gemma":[0.0077090603,0.0002106126,0.00010641411,0.00067049236,0.0007288088,0.00012429216,0.00017532031,0.00034824925,0.0000013516094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59555346,0.00078024884,0.0060812896,0.00060725876,0.00068550964,0.0000063736998,0.0059291925,0.0014154651,0.18952657,0.000016085432,0.000089065965,0.19930945],"study_design_scores_gemma":[0.614617,0.0008820172,0.027715016,0.0010734134,0.000386362,0.0000066854486,0.0007270349,0.35339215,0.0009789187,0.000014680134,0.000020470028,0.00018627718],"about_ca_topic_score_codex":0.0006331498,"about_ca_topic_score_gemma":0.000041554944,"teacher_disagreement_score":0.3519767,"about_ca_system_score_codex":0.00036125738,"about_ca_system_score_gemma":0.00059650274,"threshold_uncertainty_score":0.9229022},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4390126617","doi":"10.1016/j.jval.2023.09.124","title":"CO52 Comparative Analysis of Tabelecleucel Versus Standard of Care in Patients with EBV+ PTLD Following Hematopoietic Cell Transplant (HCT) or Solid Organ Transplant (SOT)","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Hematopoietic cell; Solid organ; Medicine; Haematopoiesis; Standard of care; Internal medicine; Organ transplantation; Oncology; Transplantation; Biology; Stem cell; Genetics","score_opus":0.04066198766973922,"score_gpt":0.3452641387185456,"score_spread":0.3046021510488064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390126617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976853,0.00039985537,0.000039184702,0.00008886727,0.000080945756,0.0011552009,0.0003710985,0.000031567655,0.00014794264],"genre_scores_gemma":[0.99906915,0.00027537762,0.0001865219,0.000024392455,0.000009705317,0.000026569473,0.00034886246,0.000030430465,0.000029001676],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964564,0.00026764703,0.0010014627,0.00043050092,0.0011604897,0.0006835378],"domain_scores_gemma":[0.9983621,0.0006052988,0.00021827164,0.00042382083,0.00015761556,0.00023285006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068023807,0.0002407783,0.0015911012,0.001040976,0.000051318846,0.000006141567,0.0001855902,0.00011212771,0.000043265343],"category_scores_gemma":[0.000035752597,0.00018507673,0.00017093385,0.0037171126,0.00010514735,0.00005526523,0.000023203596,0.00031950284,0.0000047259728],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12678175,0.0019063626,0.4706923,0.02153601,0.0029759172,0.001416886,0.27017438,0.10295456,0.00062344375,0.0001983014,0.00012408047,0.00061600044],"study_design_scores_gemma":[0.4488604,0.05406552,0.22405934,0.018964909,0.0044252905,0.000023818806,0.04357137,0.15423597,0.049925737,0.00003107031,0.0001961666,0.001640396],"about_ca_topic_score_codex":0.0064942506,"about_ca_topic_score_gemma":0.0053154062,"teacher_disagreement_score":0.32207865,"about_ca_system_score_codex":0.0058219405,"about_ca_system_score_gemma":0.008330503,"threshold_uncertainty_score":0.99799454},"labels":[],"label_agreement":null},{"id":"W4390322679","doi":"10.1182/bloodadvances.2023011964","title":"Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs","year":2023,"lang":"en","type":"review","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; McGill University","funders":"Janssen Pharmaceuticals; Canadian Institutes of Health Research; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Venetoclax; Meta-analysis; Medicine; Adverse effect; Oncology; Hematologic Neoplasms; MEDLINE; Internal medicine; Intensive care medicine; Leukemia; Cancer; Biology; Chronic lymphocytic leukemia","score_opus":0.09874279848536982,"score_gpt":0.40978968672075566,"score_spread":0.31104688823538584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390322679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016960637,0.99149156,0.000021129572,0.0000044239914,0.000022475238,0.0077265035,0.0005195524,0.000023317689,0.000021446953],"genre_scores_gemma":[0.00020863774,0.9972612,0.00029030253,0.000018264944,0.000009512111,0.0018127988,0.000066102206,0.00004784502,0.0002853215],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959864,0.00048606415,0.0021619524,0.00048043122,0.00060043874,0.00028470423],"domain_scores_gemma":[0.99315095,0.0023598147,0.0030533324,0.00093540933,0.00040994634,0.00009055741],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.001566998,0.00043800476,0.014725043,0.0005755378,0.000029178726,0.0000017777745,0.00028736907,0.00018944993,0.000038617578],"category_scores_gemma":[0.0022851229,0.00024958147,0.0035990833,0.0017938993,0.00016407267,0.000054975917,0.00009034311,0.00014695624,0.0000031431512],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012201956,0.00009479882,0.000008084517,0.80021244,0.1992343,0.000008339175,0.000030992105,0.0000103127195,5.927249e-7,0.000032523796,0.000006057847,0.00034934375],"study_design_scores_gemma":[0.0019798458,0.0004151908,0.0000012680321,0.11480598,0.8804249,0.000078845354,0.000029384231,0.000022556156,0.000031175066,0.00007136266,0.0019739915,0.00016549941],"about_ca_topic_score_codex":0.000113385744,"about_ca_topic_score_gemma":0.00003278187,"teacher_disagreement_score":0.68540645,"about_ca_system_score_codex":0.0005794708,"about_ca_system_score_gemma":0.0025387462,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W4390340515","doi":"10.14740/jh1212","title":"Cryocrystalglobulinemia Leading to Multi-Organ Failure in Chronic Lymphocytic Leukemia Achieving Complete Renal Recovery","year":2023,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Cryoglobulinemia; Plasmapheresis; Cryoglobulins; Context (archaeology); Eculizumab; Monoclonal gammopathy of undetermined significance; Membranoproliferative glomerulonephritis; Multiple myeloma; Renal replacement therapy; Pathology; Kidney; Leukemia; Glomerulonephritis; Monoclonal; Immunology; Internal medicine; Antibody; Complement system; Monoclonal antibody","score_opus":0.038722806043264904,"score_gpt":0.33333922232055824,"score_spread":0.29461641627729335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390340515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945196,0.0007342269,0.0020643377,0.0015527004,0.00036155296,0.00042951395,0.0000059146673,0.000078830395,0.00025334707],"genre_scores_gemma":[0.9940488,0.00018506759,0.0040221047,0.00044008612,0.00046029055,0.000012531449,0.0000124643575,0.00007540543,0.000743281],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9963595,0.00018358558,0.0013446575,0.00039865624,0.0006869875,0.0010266154],"domain_scores_gemma":[0.9977475,0.00063860964,0.00040229168,0.00046035825,0.00027150736,0.00047976003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012430841,0.00030396835,0.001283224,0.0014860224,0.00009512064,0.000036111047,0.00045004103,0.0003012417,0.00015170233],"category_scores_gemma":[0.0015312062,0.00026545668,0.00027926898,0.0015057753,0.000136463,0.00019117832,0.00028303708,0.0008749591,0.00047496668],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005311268,0.00020889971,0.009214306,0.0038603873,0.0011708629,0.06976955,0.0032177402,0.09553776,0.6836971,0.0013512939,0.119451,0.007209818],"study_design_scores_gemma":[0.20847206,0.009614507,0.01571988,0.017164001,0.00075955,0.26779842,0.0042017647,0.3454277,0.056007676,0.0011869421,0.07099034,0.0026571457],"about_ca_topic_score_codex":0.00021626758,"about_ca_topic_score_gemma":0.0006097704,"teacher_disagreement_score":0.6276894,"about_ca_system_score_codex":0.095470086,"about_ca_system_score_gemma":0.030795397,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W4390406598","doi":"10.1080/10428194.2023.2290466","title":"Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia Hospital","funders":"","keywords":"Rituximab; Medicine; Bendamustine; Prednisone; Vincristine; Internal medicine; Waldenstrom macroglobulinemia; Regimen; Cyclophosphamide; Macroglobulinemia; Gastroenterology; Population; Surgery; Chemotherapy; Oncology; Lymphoma; Multiple myeloma","score_opus":0.013781753511820725,"score_gpt":0.2816441447738777,"score_spread":0.267862391262057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390406598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465156,0.000708371,0.000041568503,0.0004457519,0.00008682634,0.0029937525,0.00033514109,0.00046239092,0.0002746195],"genre_scores_gemma":[0.99171895,0.0010502244,0.0015484829,0.00053105765,0.00011884325,0.00053060375,0.003122454,0.00026528264,0.0011141251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99177307,0.0003034224,0.0017956845,0.0023369787,0.001724174,0.0020666437],"domain_scores_gemma":[0.9956701,0.0009211044,0.00061643566,0.0014964136,0.00038329815,0.00091265305],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006492143,0.001599948,0.0032277226,0.0025554593,0.0003746064,0.00023424074,0.0004197755,0.000562681,0.00009707792],"category_scores_gemma":[0.00017785905,0.0012149067,0.00035522698,0.0045454297,0.00059180433,0.00035972346,0.00023015536,0.0003488072,0.000026858925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0123068085,0.0021773512,0.94795835,0.0004034995,0.0015162088,0.002925597,0.0006409369,0.0016766881,0.000042225474,0.000029657185,0.00007085556,0.030251818],"study_design_scores_gemma":[0.23069933,0.0014848319,0.72283787,0.0005664999,0.0008821382,0.000100729376,0.0001371136,0.041916613,0.00028158203,0.00001438244,0.00014284266,0.0009360709],"about_ca_topic_score_codex":0.04477196,"about_ca_topic_score_gemma":0.022395024,"teacher_disagreement_score":0.22512048,"about_ca_system_score_codex":0.05060321,"about_ca_system_score_gemma":0.011237495,"threshold_uncertainty_score":0.99967486},"labels":[],"label_agreement":null},{"id":"W4390414369","doi":"10.31557/apjcp.2023.24.12.4025","title":"Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Asian Pacific Journal of Cancer Prevention","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Medicine; Graft-versus-host disease; Oncology; Internal medicine; Context (archaeology); Cochrane Library; Randomized controlled trial; Transplantation; Chronic lymphocytic leukemia; Leukemia; Biology","score_opus":0.0636222477093162,"score_gpt":0.42895849638842865,"score_spread":0.36533624867911246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390414369","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002353763,0.9912511,0.00018591588,0.00021737888,0.0005140143,0.007513371,0.00012733013,0.00001824305,0.00017026943],"genre_scores_gemma":[0.00007884088,0.9970037,0.00007419681,0.000006206974,0.0005168422,0.00042039424,0.000090803966,0.00010469243,0.0017043455],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99508303,0.0004661847,0.0027218657,0.00037096802,0.00094471034,0.00041325684],"domain_scores_gemma":[0.9948885,0.00070546067,0.002930414,0.000618072,0.00046188373,0.00039569367],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023372993,0.0004238391,0.0042261416,0.00041196492,0.00006794204,0.000028215925,0.00031120778,0.00021110257,0.00008964909],"category_scores_gemma":[0.0013273271,0.00030319294,0.0015084734,0.0006527264,0.00013984923,0.00012475888,0.00007997898,0.00048219447,0.000014572548],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006308974,0.00006883876,2.2743042e-7,0.8750178,0.0021368314,0.00005124028,0.00003184367,3.0203648e-7,5.5299085e-7,0.00005896821,0.0011028801,0.12089962],"study_design_scores_gemma":[0.010557148,0.0006977917,0.0000052813325,0.83950794,0.02085986,0.00027808422,0.00004219459,0.000015461685,7.4808827e-7,0.000029223203,0.12781142,0.00019484856],"about_ca_topic_score_codex":0.000006151424,"about_ca_topic_score_gemma":0.00000996102,"teacher_disagreement_score":0.12670854,"about_ca_system_score_codex":0.008522691,"about_ca_system_score_gemma":0.01916215,"threshold_uncertainty_score":0.999942},"labels":[],"label_agreement":null},{"id":"W4390589932","doi":"10.1093/clinchem/hvad147","title":"Chronic Lymphocytic Leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing","year":2024,"lang":"en","type":"article","venue":"Clinical Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; Spinal Cord Injury BC; Princess Margaret Cancer Centre; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"IGHV@; Somatic hypermutation; Sanger sequencing; Chronic lymphocytic leukemia; Biology; Computational biology; DNA sequencing; Multiplex; Genetics; Gene; Leukemia; Antibody; B cell","score_opus":0.07668167832355433,"score_gpt":0.34983067702651854,"score_spread":0.2731489987029642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390589932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871849,0.008038371,0.001587129,0.0002453572,0.000630532,0.00043354745,0.000016948115,0.00051235605,0.0013508479],"genre_scores_gemma":[0.9907542,0.00028999182,0.00016654115,0.00020797782,0.0029268612,0.0000802315,0.0005291972,0.00008481532,0.0049602143],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99693817,0.00009183017,0.00096192764,0.000833534,0.000642854,0.00053168583],"domain_scores_gemma":[0.9982821,0.00047813202,0.000119664895,0.0005743066,0.00015722688,0.0003885884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070485345,0.00031520068,0.00048569642,0.000059218677,0.00013247193,0.00017491395,0.00017604345,0.0006711406,0.0004694472],"category_scores_gemma":[0.0011742543,0.0002849917,0.00030263478,0.0004624117,0.00022322834,0.0002488554,0.00007132282,0.00086186227,0.00037532658],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006830404,0.000020395248,0.000040745206,0.0020616709,0.00017596112,0.00030109423,0.000106400475,0.00041767143,0.9719684,0.0000049025507,0.0054539177,0.01938051],"study_design_scores_gemma":[0.0036476105,0.000104888575,0.000013070225,0.00031704057,0.00017628963,0.0005101618,0.00008872715,0.6049804,0.38715687,0.00005058598,0.0027322522,0.0002220839],"about_ca_topic_score_codex":0.00023742749,"about_ca_topic_score_gemma":0.000016349833,"teacher_disagreement_score":0.60456276,"about_ca_system_score_codex":0.11509806,"about_ca_system_score_gemma":0.029000565,"threshold_uncertainty_score":0.99996024},"labels":[],"label_agreement":null},{"id":"W4390753808","doi":"10.1016/j.ccell.2023.12.019","title":"Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy","year":2024,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"National Cancer Institute; Cancer Research UK Cambridge Institute, University of Cambridge; Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge; NIHR Cambridge Biomedical Research Centre; Medical Research Council; Canadian Institutes of Health Research; Deutsche Forschungsgemeinschaft; Department of Health and Social Care; National Institute of General Medical Sciences; National Institute for Health and Care Research; Council for Chemical Research; National Institutes of Health; California Department of Fish and Game; Cancer Research UK; Memphis Research Consortium; BeiGene; Gilead Sciences; Merck KGaA; Wellcome Trust","keywords":"Bruton's tyrosine kinase; Autophagy; Tyrosine kinase; Cancer research; Protein-Tyrosine Kinases; Biology; Tyrosine-kinase inhibitor; Cell biology; Medicine; Signal transduction; Genetics; Cancer; Apoptosis","score_opus":0.013578451056532163,"score_gpt":0.3228372433575173,"score_spread":0.30925879230098513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390753808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525628,0.03630753,0.00004015352,0.0038517923,0.0010328966,0.0016995155,0.000047448288,0.00022117549,0.0042367047],"genre_scores_gemma":[0.98013496,0.00045957929,0.00015101685,0.0013304503,0.00087905384,0.00062141276,0.0000126762825,0.000108940745,0.016301896],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701315,0.00015436314,0.0004126235,0.00088719523,0.0006480302,0.0008846527],"domain_scores_gemma":[0.9982071,0.00034693684,0.000055395398,0.00055530266,0.00019619484,0.00063907873],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005547401,0.0003236933,0.00046068343,0.0005166588,0.000061547515,0.0000772627,0.00025477374,0.00020848362,0.0007536476],"category_scores_gemma":[0.00042263977,0.00029710992,0.00012623845,0.0017412206,0.00008405302,0.00012049097,0.00024153492,0.00037415768,0.0008302768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012298876,0.00039043633,0.00027917998,0.0015924642,0.00018184278,0.012786207,0.012002929,0.0024087527,0.78261167,0.00013176248,0.11715983,0.05815605],"study_design_scores_gemma":[0.019320788,0.0022955162,0.004949402,0.0045570466,0.00010613532,0.00021956822,0.00030792813,0.010999889,0.710822,0.000053012485,0.24564046,0.00072825205],"about_ca_topic_score_codex":0.00430785,"about_ca_topic_score_gemma":0.0014865685,"teacher_disagreement_score":0.12848063,"about_ca_system_score_codex":0.10584378,"about_ca_system_score_gemma":0.02930711,"threshold_uncertainty_score":0.9999481},"labels":[],"label_agreement":null},{"id":"W4390824558","doi":"10.1182/blood.2023021959","title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"National Cancer Institute","keywords":"Ibrutinib; Medicine; Internal medicine; Oncology; Chemotherapy regimen; Venetoclax; Chronic lymphocytic leukemia; Leukemia; Chemotherapy","score_opus":0.01905375860532399,"score_gpt":0.2983592519735472,"score_spread":0.2793054933682232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390824558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301445,0.0017268991,0.000041659765,0.0005266388,0.00020576196,0.0034758237,0.00011753803,0.00010151338,0.00078970153],"genre_scores_gemma":[0.9950988,0.000015911255,0.00028443674,0.00010332766,0.00041619744,0.00021167054,0.00005938941,0.00006289542,0.003747322],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980815,0.000071062,0.00033827766,0.00049743993,0.0006327205,0.0003790061],"domain_scores_gemma":[0.9973753,0.0014829104,0.00006494738,0.00078687293,0.00017149045,0.00011848871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004379171,0.00019868115,0.00042544372,0.000060371527,0.000063398766,0.000048167283,0.0002693138,0.00008732697,0.00014992619],"category_scores_gemma":[0.00038232375,0.00011264408,0.00016512987,0.00029196363,0.00012002925,0.000043190932,0.00009942646,0.00023112407,0.000036664314],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08263663,0.055733543,0.058345567,0.00814058,0.041651353,0.007418609,0.28791603,0.000025225823,0.022371778,0.0019248025,0.3248721,0.10896376],"study_design_scores_gemma":[0.84006655,0.0077036596,0.05393555,0.0059734867,0.007466508,0.00028619677,0.01799963,0.0039881677,0.04129726,0.00010175593,0.020374138,0.0008070706],"about_ca_topic_score_codex":0.00093095977,"about_ca_topic_score_gemma":0.00035760496,"teacher_disagreement_score":0.75742996,"about_ca_system_score_codex":0.0004261474,"about_ca_system_score_gemma":0.002281995,"threshold_uncertainty_score":0.45934922},"labels":[],"label_agreement":null},{"id":"W4390976218","doi":"10.1080/10428194.2024.2301738","title":"Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Queen's University; ABB (Canada); University of Alberta; Health Sciences North; Cégep de Rimouski; Moncton Hospital; CancerCare Manitoba; Thunder Bay Regional Health Sciences Centre; Jewish General Hospital; University of Ottawa; University of Manitoba","funders":"AbbVie Canada","keywords":"Venetoclax; Ibrutinib; Medicine; Chronic lymphocytic leukemia; Tumor lysis syndrome; Internal medicine; Rituximab; Lymphoma; Oncology; Observational study; Leukemia; Chemotherapy","score_opus":0.021181746894429886,"score_gpt":0.3121649750153639,"score_spread":0.290983228120934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390976218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858168,0.009879924,0.000033807144,0.00018928092,0.00029234297,0.002164129,0.000050233728,0.00022356439,0.0013499497],"genre_scores_gemma":[0.9911109,0.0040445365,0.002607719,0.0008169143,0.00031297095,0.0002024344,0.00013621507,0.00022649112,0.00054182217],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9914695,0.00066243624,0.0024810391,0.002046629,0.0016698476,0.0016705205],"domain_scores_gemma":[0.9948788,0.0022794765,0.0005019633,0.0012383694,0.0003349882,0.00076639524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019186896,0.0009715083,0.001772234,0.0013258044,0.00019133171,0.00031423382,0.0004137412,0.00078239216,0.000026322869],"category_scores_gemma":[0.0007489056,0.0008540585,0.00022678736,0.002114431,0.00089651917,0.001107265,0.0006974654,0.00061245606,0.000029432962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018956859,0.0005968344,0.36536556,0.01604811,0.0017384092,0.016712457,0.006821437,0.0035712258,0.000067814355,0.0045481035,0.0011750265,0.56439817],"study_design_scores_gemma":[0.11248673,0.0028831991,0.69431597,0.009961909,0.0006092539,0.001668593,0.0011069115,0.1517551,0.00018447748,0.00015894133,0.023553796,0.0013151512],"about_ca_topic_score_codex":0.024034657,"about_ca_topic_score_gemma":0.0011134789,"teacher_disagreement_score":0.563083,"about_ca_system_score_codex":0.25658765,"about_ca_system_score_gemma":0.05529311,"threshold_uncertainty_score":0.999391},"labels":[],"label_agreement":null},{"id":"W4391282760","doi":"10.1093/oncolo/oyad324","title":"Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck","keywords":"Chemoimmunotherapy; Chronic lymphocytic leukemia; Medicine; Internal medicine; Lymphoma; Health care; Rituximab; Leukemia; Oncology","score_opus":0.04775565335878256,"score_gpt":0.3283996721921445,"score_spread":0.28064401883336193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391282760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068826,0.0051435335,0.000035471097,0.0012073587,0.000089330315,0.002085284,0.00006320114,0.00008252809,0.0006050257],"genre_scores_gemma":[0.99622214,0.0018682393,0.000029157116,0.0005951412,0.00014196533,0.00024382872,0.0001220044,0.000055657292,0.0007218818],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973311,0.0004184996,0.00048288787,0.00053462764,0.0006323728,0.00060051],"domain_scores_gemma":[0.9975908,0.0011504579,0.00012954067,0.00085517165,0.00012817557,0.00014589189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005881432,0.00033993376,0.0005278184,0.0001751679,0.0001644572,0.00008004623,0.00037821522,0.00017371996,0.00004190741],"category_scores_gemma":[0.00016768489,0.00015032175,0.00007955597,0.00075889385,0.0006342397,0.00006149114,0.00013390624,0.00015624236,0.000021913294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021385727,0.0011640129,0.10770706,0.007311943,0.0012264574,0.006315944,0.014777972,0.0031392106,0.00004454379,0.0034729694,0.0035608239,0.82989335],"study_design_scores_gemma":[0.18683511,0.031786136,0.39495674,0.0070543527,0.0014603026,0.004334391,0.0051620933,0.26189962,0.000829591,0.00013133486,0.10425359,0.0012967591],"about_ca_topic_score_codex":0.019417511,"about_ca_topic_score_gemma":0.011356237,"teacher_disagreement_score":0.8285966,"about_ca_system_score_codex":0.22329947,"about_ca_system_score_gemma":0.049735587,"threshold_uncertainty_score":0.9871123},"labels":[],"label_agreement":null},{"id":"W4391304450","doi":"10.51985/jbumdc2023201","title":"Expression of ZAP 70 in Chronic Lymphocytic Leukemia (CLL) and its Correlation with Clinical Stages","year":2024,"lang":"en","type":"article","venue":"Journal of Bahria University Medical and Dental College","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"","keywords":"Chronic lymphocytic leukemia; Correlation; Expression (computer science); Leukemia; Medicine; Immunology; Cancer research; Mathematics; Computer science","score_opus":0.017580624881639223,"score_gpt":0.3009125673317183,"score_spread":0.2833319424500791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391304450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948749,0.0039573833,0.000112223715,0.00017693434,0.00018151903,0.00016969618,0.0000099339795,0.000010005749,0.0005073946],"genre_scores_gemma":[0.99441236,0.004286685,0.00007166725,0.000035416193,0.00016124957,1.5690533e-7,0.000002476761,0.0000096606955,0.0010203434],"study_design_codex":"case_report","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99790454,0.00013882041,0.00045442348,0.00019753953,0.001118502,0.0001861819],"domain_scores_gemma":[0.9986532,0.000504528,0.0001315475,0.00008439641,0.00010619622,0.0005201383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096703216,0.000115752926,0.00044434625,0.00032417264,0.000048265916,0.000011114201,0.00012775853,0.00025110488,0.00027941336],"category_scores_gemma":[0.00033580078,0.00008344607,0.00008475188,0.00035097208,0.00028282808,0.00023788087,0.00016086629,0.0005635403,0.0000041854587],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10129016,0.0021144894,0.20879571,0.021764113,0.0031015326,0.5327474,0.0057670777,0.001215578,0.016613428,0.020698255,0.030041646,0.055850606],"study_design_scores_gemma":[0.17472091,0.010596794,0.058395118,0.029085703,0.00079107354,0.039434165,0.0065154154,0.66350394,0.0047675264,0.00013924931,0.011381858,0.00066826807],"about_ca_topic_score_codex":0.0001326821,"about_ca_topic_score_gemma":0.00016332386,"teacher_disagreement_score":0.66228837,"about_ca_system_score_codex":0.012191014,"about_ca_system_score_gemma":0.025250502,"threshold_uncertainty_score":0.991601},"labels":[],"label_agreement":null},{"id":"W4391723447","doi":"10.51731/cjht.2024.825","title":"Ibrutinib (Imbruvica)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Venetoclax; Reimbursement; Medicine; Drug; Chronic lymphocytic leukemia; Oncology; Family medicine; Internal medicine; Leukemia; Pharmacology; Political science; Health care","score_opus":0.0390365717984071,"score_gpt":0.34989368745113497,"score_spread":0.3108571156527279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391723447","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18337178,0.5811719,0.00052731525,0.22598231,0.0016596828,0.00059536815,0.000023693898,0.00061568536,0.0060523143],"genre_scores_gemma":[0.9973099,0.000988809,0.0006353989,0.00045080393,0.00003993939,0.0000032954154,0.0000015864695,0.000021954776,0.0005483012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984516,0.000031181586,0.00050103274,0.00014716032,0.00027308022,0.00059596996],"domain_scores_gemma":[0.999165,0.00010594621,0.000092230795,0.0002854598,0.00014440689,0.0002069702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008678401,0.00010786409,0.00035185905,0.0010305296,0.00011600373,0.00006290012,0.0002722554,0.0001610236,0.000114440605],"category_scores_gemma":[0.0008384292,0.00008169538,0.00011079003,0.0006084571,0.0003061324,0.00008883488,0.000023247903,0.0007349266,0.00009133389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000025248968,0.000012323926,0.00035138358,0.000910882,0.00011091556,0.0057370635,0.0003541793,0.0000049115483,0.00007107213,0.0056376783,0.07631732,0.910467],"study_design_scores_gemma":[0.0015673363,0.0006800531,0.0005898941,0.0013660683,0.00002178524,0.008537379,0.0015322694,0.00040404627,0.0008084309,0.0030222328,0.98136747,0.00010301581],"about_ca_topic_score_codex":0.0045400783,"about_ca_topic_score_gemma":0.0010698978,"teacher_disagreement_score":0.91036403,"about_ca_system_score_codex":0.011717651,"about_ca_system_score_gemma":0.083804004,"threshold_uncertainty_score":0.9920762},"labels":[],"label_agreement":null},{"id":"W4392162534","doi":"10.3390/biomedicines12030524","title":"Analysis of Primary Chronic Lymphocytic Leukemia Cells’ Signaling Pathways","year":2024,"lang":"en","type":"article","venue":"Biomedicines","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hrvatska Zaklada za Znanost; University of Toronto","keywords":"Chronic lymphocytic leukemia; clone (Java method); Biology; Bone marrow; HES1; Signal transduction; microRNA; Cancer research; Leukemia; Gene; Immunology; breakpoint cluster region; Notch signaling pathway; Cell biology; Genetics","score_opus":0.02843429993393232,"score_gpt":0.2885521698440417,"score_spread":0.2601178699101094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392162534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96512944,0.027876122,0.00090789,0.0001552315,0.00077932904,0.0005178499,0.000058561865,0.00037193295,0.0042036353],"genre_scores_gemma":[0.99559397,0.00093497714,0.00029998575,0.00019573688,0.00087700016,0.000030859737,0.00022286885,0.00006049845,0.0017841142],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969513,0.00005273982,0.00072119595,0.0006191588,0.001079048,0.0005765846],"domain_scores_gemma":[0.9982141,0.0004900317,0.000095888514,0.0007075958,0.00018651046,0.0003058572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006409458,0.00029927358,0.0010106261,0.0019114113,0.000056916608,0.000033059747,0.0002526004,0.00020288378,0.0006611923],"category_scores_gemma":[0.00009509439,0.00022324441,0.00046784536,0.0044298237,0.0004738194,0.00009690667,0.0001260318,0.0002186555,0.00013980194],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00027068518,0.000058092406,0.0002739688,0.00609695,0.0057465998,0.0017374989,0.0011052066,0.0014356376,0.9467299,0.00029879846,0.0065988014,0.02964787],"study_design_scores_gemma":[0.014400684,0.0014404971,0.00210077,0.0031873428,0.012240882,0.00041075595,0.0004406662,0.76086384,0.17178115,0.00010537702,0.03237037,0.00065767125],"about_ca_topic_score_codex":0.0010774757,"about_ca_topic_score_gemma":0.00001971005,"teacher_disagreement_score":0.7749487,"about_ca_system_score_codex":0.07532901,"about_ca_system_score_gemma":0.041794077,"threshold_uncertainty_score":0.96363807},"labels":[],"label_agreement":null},{"id":"W4392162893","doi":"10.3390/genes15030292","title":"Translation of Data from Animal Models of Cancer to Immunotherapy of Breast Cancer and Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Genes","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Breast Cancer Research Foundation","keywords":"Chronic lymphocytic leukemia; Cancer; Immunotherapy; Breast cancer; Medicine; Leukemia; Translation (biology); Cancer immunotherapy; Cancer research; Oncology; Immunology; Internal medicine; Biology; Gene","score_opus":0.0669658302962418,"score_gpt":0.370549523084018,"score_spread":0.3035836927877762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392162893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.858069,0.13950191,0.00043808843,0.000191416,0.00007447033,0.0003040317,0.0013368481,0.000017568484,0.000066663786],"genre_scores_gemma":[0.98490775,0.014044587,0.00060679007,0.000025286174,0.00019126652,0.000026572783,0.00006160191,0.000032642412,0.000103521605],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987126,0.000021414946,0.00035968501,0.00034225473,0.0003708676,0.00019318273],"domain_scores_gemma":[0.9991165,0.00009954897,0.000058752365,0.00054517644,0.00010684967,0.00007320099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015450019,0.00012683659,0.00037811504,0.00012951261,0.000014457927,0.000008344643,0.00021545144,0.0000826281,0.00031183797],"category_scores_gemma":[0.0000044101475,0.000106018124,0.000050684732,0.00028580593,0.00012985314,0.00016095926,0.00008866973,0.00006123761,0.0000023759255],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012866192,0.000018122331,0.0003256229,0.0014970227,0.0005042673,0.000010029518,0.0011641152,0.005566834,0.7126091,0.000056354365,0.00027967317,0.27668223],"study_design_scores_gemma":[0.007866733,0.00022563545,0.0037633397,0.0015290412,0.00024560222,0.000031679567,0.000084714564,0.81689936,0.16801764,0.00012507309,0.001062447,0.00014873051],"about_ca_topic_score_codex":0.057575677,"about_ca_topic_score_gemma":0.0017389226,"teacher_disagreement_score":0.8113325,"about_ca_system_score_codex":0.0092768315,"about_ca_system_score_gemma":0.02121942,"threshold_uncertainty_score":0.9945264},"labels":[],"label_agreement":null},{"id":"W4392351859","doi":"10.1007/s00277-024-05676-1","title":"Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS","year":2024,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Venetoclax; Adverse Event Reporting System; Medicine; Adverse effect; Internal medicine; Randomized controlled trial; Odds ratio; Oncology; Neutropenia; Meta-analysis; Leukemia; Chemotherapy","score_opus":0.3613101957248982,"score_gpt":0.5259064205257676,"score_spread":0.16459622480086944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392351859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005236648,0.9900284,0.000014056778,0.00024320724,0.00016845303,0.008542967,0.00013037573,0.000007511168,0.00034136086],"genre_scores_gemma":[0.067560345,0.93111205,0.000027182337,0.000010858925,0.000040622643,0.0010406092,0.000029188972,0.00002970757,0.00014945751],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9838414,0.008567403,0.0050958,0.0005237036,0.0016836334,0.00028804646],"domain_scores_gemma":[0.98470896,0.008752901,0.0042355363,0.00093545974,0.0012756098,0.00009155502],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.032075495,0.00043191575,0.042918745,0.0010338734,0.000026344103,0.0000045021866,0.0002566523,0.00043797764,0.00023578611],"category_scores_gemma":[0.02904915,0.0001952201,0.019392693,0.0012526694,0.0005909112,0.000023602066,0.00017881423,0.00035656852,0.0000024022033],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0266215,0.000095241725,0.0000038213398,0.016131973,0.9501333,0.0000149244415,0.00026660782,0.00006430016,0.0000045329884,0.0027183595,0.00014462195,0.0038007898],"study_design_scores_gemma":[0.13408197,0.00009598449,0.000002302415,0.002502321,0.8597425,0.0000650779,0.000057358553,0.0016813304,0.00018581854,0.0004995506,0.0009817083,0.0001040263],"about_ca_topic_score_codex":0.00024565385,"about_ca_topic_score_gemma":0.00001107608,"teacher_disagreement_score":0.10746048,"about_ca_system_score_codex":0.0013586279,"about_ca_system_score_gemma":0.011581063,"threshold_uncertainty_score":0.996682},"labels":[],"label_agreement":null},{"id":"W4392582468","doi":"10.1016/s1470-2045(24)00070-6","title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Venetoclax; Open label; Medicine; Refractory (planetary science); Oncology; Internal medicine; Chronic lymphocytic leukemia; Clinical trial; Leukemia; Biology","score_opus":0.09800376265592863,"score_gpt":0.4116209237309606,"score_spread":0.31361716107503196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392582468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528086,0.0005393784,0.000009697501,0.00039198954,0.00036690087,0.0022272333,0.000057895195,0.000025903133,0.0011001447],"genre_scores_gemma":[0.9987895,0.00013180358,0.00008424118,0.00013315606,0.0002278906,0.000101864964,0.000029399856,0.000035444744,0.00046673339],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99708563,0.00073719793,0.00058311544,0.00044416284,0.00060910435,0.00054081436],"domain_scores_gemma":[0.99654526,0.0016825341,0.0003542976,0.0011808084,0.00014755338,0.000089565874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012148719,0.00022159837,0.0013601077,0.00026863074,0.00006089108,0.000022282413,0.0008179583,0.00024411055,0.00020113269],"category_scores_gemma":[0.0006516768,0.000111475674,0.00013114234,0.0020270457,0.00051984,0.0001224104,0.0003974074,0.0006145941,0.000010889381],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.89315003,0.01250033,0.0019095965,0.0017856208,0.0077376124,0.0005075033,0.0033760592,0.0027879628,0.0142290685,0.0003176081,0.0022695675,0.05942903],"study_design_scores_gemma":[0.85569596,0.029250128,0.004683882,0.0008018661,0.0042464947,0.000027262604,0.00010993314,0.09316125,0.0041919937,0.000030269774,0.007542147,0.00025883384],"about_ca_topic_score_codex":0.0018867662,"about_ca_topic_score_gemma":0.0025954414,"teacher_disagreement_score":0.090373285,"about_ca_system_score_codex":0.05986797,"about_ca_system_score_gemma":0.034339014,"threshold_uncertainty_score":0.9711354},"labels":[],"label_agreement":null},{"id":"W4392761823","doi":"10.1021/acs.jmedchem.4c00078","title":"Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein","year":2024,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health; Mirati Therapeutics","keywords":"PI3K/AKT/mTOR pathway; Chemistry; Mutant; Cancer research; Biochemistry; Biology; Signal transduction; Gene","score_opus":0.022231116478208954,"score_gpt":0.29918846425982126,"score_spread":0.2769573477816123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392761823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98437023,0.007859084,0.00023616469,0.0035676176,0.00019004743,0.00026561573,0.00000795255,0.00001943342,0.0034838463],"genre_scores_gemma":[0.99589306,0.00034186864,0.0000771025,0.000092874565,0.0013454217,0.000008525404,0.000002698491,0.00003516338,0.0022032685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970183,0.000052969837,0.0006826176,0.00022160771,0.0016706992,0.00035381623],"domain_scores_gemma":[0.99846697,0.0003730045,0.0003166272,0.00031097085,0.00033782484,0.00019462049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013583739,0.00021808113,0.00055570464,0.000107207496,0.00005502186,0.000050066894,0.0003342659,0.00014683325,0.0001764137],"category_scores_gemma":[0.0007093875,0.00011642964,0.00030084615,0.00043060948,0.00046265175,0.00020831414,0.00009377095,0.0011303552,0.000006270919],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012046966,0.0001606498,0.00018571994,0.0028850813,0.0005047503,0.0027022252,0.00077729154,0.00000743553,0.98520607,0.000071221824,0.0036818606,0.0026129894],"study_design_scores_gemma":[0.0041073905,0.00048184808,0.00023129275,0.00432008,0.00032351195,0.012392872,0.0013250819,0.00081306853,0.97296226,0.0003060771,0.0026188402,0.00011770626],"about_ca_topic_score_codex":0.000060400984,"about_ca_topic_score_gemma":0.0000012649152,"teacher_disagreement_score":0.012243846,"about_ca_system_score_codex":0.0031795271,"about_ca_system_score_gemma":0.0093848845,"threshold_uncertainty_score":0.99623096},"labels":[],"label_agreement":null},{"id":"W4393090947","doi":"10.1158/1538-7445.am2024-1294","title":"Abstract 1294: Cancer related fatigue and the additive effect of treatment in the context of lymphoma and CLL: An analysis of Lymphoma Coalition’s 2022 Global Patient Survey","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Lymphoma; Context (archaeology); Medicine; Cancer; Internal medicine; Oncology; History","score_opus":0.053617154632795004,"score_gpt":0.42104498796879103,"score_spread":0.36742783333599605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393090947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980634,0.015382908,7.6157016e-7,0.0003511337,0.000048560923,0.001501504,0.0017500536,0.000009343414,0.00032175521],"genre_scores_gemma":[0.9926051,0.0065565724,0.00000191109,0.000024438013,0.000024599773,0.00057537097,0.00014422662,0.00001698146,0.000050822033],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956109,0.001898801,0.00055535295,0.00044909076,0.0010875737,0.00039831537],"domain_scores_gemma":[0.9945009,0.0042929933,0.00011593661,0.00052402174,0.0004352411,0.00013090782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038887192,0.00018842042,0.0007675601,0.00038116454,0.00007851012,0.000035123903,0.00020716545,0.00012238589,0.00023096311],"category_scores_gemma":[0.00044925237,0.00009876954,0.00015066184,0.0021811514,0.0012359287,0.000081789,0.00010860582,0.00016050159,0.000001021436],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03114835,0.0016769915,0.20950237,0.003711232,0.016815484,0.000601289,0.055736654,0.0004690276,0.0026174567,0.0029082778,0.0029858097,0.6718271],"study_design_scores_gemma":[0.03996045,0.0039042884,0.90540904,0.0011614772,0.0013975245,0.000035664234,0.0060825753,0.029474147,0.011806032,0.00012076558,0.00044042332,0.00020763137],"about_ca_topic_score_codex":0.2697581,"about_ca_topic_score_gemma":0.02997147,"teacher_disagreement_score":0.69590664,"about_ca_system_score_codex":0.011490247,"about_ca_system_score_gemma":0.00613262,"threshold_uncertainty_score":0.9995017},"labels":[],"label_agreement":null},{"id":"W4393177495","doi":"10.1016/s1470-2045(24)00136-0","title":"Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Venetoclax; Medicine; Chronic lymphocytic leukemia; Lymphoma; Chemotherapy; Refractory (planetary science); Ibrutinib; Oncology; Internal medicine; Immunology; Leukemia; Biology","score_opus":0.03514648133347344,"score_gpt":0.3473009736240493,"score_spread":0.3121544922905759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393177495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98576814,0.0018319297,0.000015785885,0.001361278,0.00040480346,0.0009028516,0.000008225761,0.00015584605,0.009551165],"genre_scores_gemma":[0.9944794,0.00035075215,0.00015099056,0.0008256575,0.00086901605,0.00012431572,0.000034955217,0.00005685373,0.0031080237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793154,0.00021934313,0.00030602125,0.000407,0.00042771487,0.00070837233],"domain_scores_gemma":[0.9983497,0.0006968482,0.000054219316,0.0007165674,0.00006505149,0.00011756063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007012165,0.00019526652,0.0005905731,0.00015892772,0.00005540542,0.000026037516,0.0003126802,0.00021801883,0.00047990118],"category_scores_gemma":[0.00018899256,0.00010171437,0.000054139044,0.00057376,0.0003060814,0.00008011301,0.00012345014,0.0006869453,0.0004943858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.16231939,0.0017260694,0.043299634,0.012151043,0.00325658,0.034818552,0.012906391,0.0067209853,0.0031596373,0.010052227,0.30360746,0.40598202],"study_design_scores_gemma":[0.15620942,0.018186735,0.043971993,0.0020543032,0.00033578658,0.0010798585,0.0001772671,0.05042089,0.00041643783,0.00046331424,0.7260753,0.00060867384],"about_ca_topic_score_codex":0.00049096806,"about_ca_topic_score_gemma":0.0006566366,"teacher_disagreement_score":0.42246786,"about_ca_system_score_codex":0.15884179,"about_ca_system_score_gemma":0.059435677,"threshold_uncertainty_score":0.94589645},"labels":[],"label_agreement":null},{"id":"W4393251397","doi":"10.1101/2024.03.26.586690","title":"A Systems Biology Analysis of Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Chronic lymphocytic leukemia; Leukemia; Computational biology; Systems biology; Biology; Immunology","score_opus":0.018443003933300076,"score_gpt":0.27767286386563705,"score_spread":0.259229859932337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393251397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96259457,0.031644557,0.00057336595,0.000062319275,0.002038657,0.0016645751,0.00066426495,0.0006538918,0.000103793864],"genre_scores_gemma":[0.9966081,0.0012709423,0.00037576782,0.00006141062,0.0009648041,0.00040483143,0.0000042516804,0.00023884162,0.00007105268],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99438375,0.00025182634,0.0014354739,0.0018509645,0.0009305283,0.0011474551],"domain_scores_gemma":[0.994354,0.0002775101,0.00059478206,0.0032355036,0.00094916223,0.00058901333],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012297328,0.0008667288,0.0025994936,0.0026009197,0.00008183227,0.00015840813,0.00082472357,0.0013926586,0.00015906942],"category_scores_gemma":[0.00045510478,0.0008127097,0.00094622094,0.0037781578,0.0005137038,0.00005280866,0.0016634763,0.0014286191,0.00029963546],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00049094675,0.00027706212,0.0024776666,0.031426065,0.040944047,0.0021882814,0.000059584476,0.023555577,0.8869567,0.00941816,0.0021934558,0.000012437175],"study_design_scores_gemma":[0.008326022,0.0005346457,0.004672708,0.0046892185,0.019970512,7.2614415e-7,0.000009157733,0.8641197,0.08981222,0.0000076012534,0.006306657,0.0015508201],"about_ca_topic_score_codex":0.004027797,"about_ca_topic_score_gemma":0.000017334063,"teacher_disagreement_score":0.84056413,"about_ca_system_score_codex":0.15952991,"about_ca_system_score_gemma":0.115631156,"threshold_uncertainty_score":0.99990374},"labels":[],"label_agreement":null},{"id":"W4393433549","doi":"10.1186/s12885-024-12143-7","title":"Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vitalité Health Network; Université Laval; Dr. Georges-L.-Dumont University Hospital Centre; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; National Cancer Institute; National Institutes of Health; Canada Research Chairs; Canadian Institutes of Health Research; Université Laval","keywords":"Biology; Transcriptome; Cancer research; Chronic lymphocytic leukemia; Transcription factor; Gene; Exon; Gene expression; Genetics; Molecular biology; Leukemia","score_opus":0.024286691599550835,"score_gpt":0.3039020687305944,"score_spread":0.27961537713104356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393433549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905853,0.0074323975,0.00012380749,0.00016824031,0.00032517815,0.00083674217,0.000045579443,0.000026886246,0.000455826],"genre_scores_gemma":[0.9967244,0.00035370112,0.000088302884,0.000063912834,0.00031917347,0.00012059762,0.0000086825285,0.000031966676,0.0022892612],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99836576,0.00004407543,0.00035739405,0.00034784107,0.00053310295,0.000351803],"domain_scores_gemma":[0.99936235,0.00018870409,0.00004295204,0.00024249453,0.000060549977,0.000102950966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017855433,0.00015922645,0.00026431875,0.00013620853,0.000038562357,0.000030323094,0.00012681054,0.0001348679,0.0005573566],"category_scores_gemma":[0.000034725064,0.00011222526,0.00012041877,0.0004151176,0.00024590758,0.00011707734,0.00006118035,0.00024391066,0.000021828473],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014569364,0.00013216047,0.02894682,0.010066765,0.00028107557,0.000099535384,0.0021510469,0.0097651,0.9268143,0.0014429374,0.0031458829,0.015697416],"study_design_scores_gemma":[0.015967326,0.00026048324,0.4194342,0.002851021,0.000192287,0.00022950988,0.000052683936,0.5079633,0.047532562,0.00011038002,0.0051299296,0.00027633432],"about_ca_topic_score_codex":0.002560635,"about_ca_topic_score_gemma":0.0018486576,"teacher_disagreement_score":0.87928176,"about_ca_system_score_codex":0.03929161,"about_ca_system_score_gemma":0.04988985,"threshold_uncertainty_score":0.96439636},"labels":[],"label_agreement":null},{"id":"W4393735446","doi":"10.5281/zenodo.7094920","title":"hive-24hr","year":2022,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Computer science","score_opus":0.0387015403011306,"score_gpt":0.2841458509821054,"score_spread":0.24544431068097478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393735446","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014491886,0.0003119813,0.00003315953,0.00064325455,0.00026517737,0.0011578207,0.9608518,0.00069523836,0.035896644],"genre_scores_gemma":[0.00021121962,0.00075278984,0.00004202981,0.0004431347,0.00045334952,2.1571806e-7,0.9915298,0.0023456875,0.0042217528],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563664,0.00055783207,0.0004736234,0.0009219119,0.001592838,0.0008171653],"domain_scores_gemma":[0.9968656,0.00007355578,0.0001970608,0.0017429951,0.0006111175,0.000509704],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010739691,0.00035308764,0.0004976777,0.00070662616,0.002602502,0.0005767732,0.0019608676,0.00024074003,0.61431575],"category_scores_gemma":[0.0016902662,0.00037021466,0.00018852382,0.000958474,0.0003403929,0.00012666205,0.004824726,0.0015565614,0.027639702],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002753246,0.0002922996,5.210602e-8,0.0005474763,0.00017039786,0.0006001935,0.000115099116,0.000009060084,0.00009439314,0.00009088109,0.9869295,0.010875332],"study_design_scores_gemma":[0.004103937,0.00070744136,0.000009146321,0.00008444252,0.00011969362,0.002187866,0.00013875787,0.000106564534,0.000033646174,0.000025786847,0.99215716,0.00032555702],"about_ca_topic_score_codex":0.00025053177,"about_ca_topic_score_gemma":8.4670387e-7,"teacher_disagreement_score":0.58667606,"about_ca_system_score_codex":0.010360927,"about_ca_system_score_gemma":0.0002685452,"threshold_uncertainty_score":0.999875},"labels":[],"label_agreement":null},{"id":"W4393863976","doi":"10.1016/j.reval.2024.103861","title":"Analysis of safety data of remibrutinib from completed phase 2 studies in inflammatory immune-mediated diseases","year":2024,"lang":"en","type":"article","venue":"Revue française d'allergologie","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immune system; Medicine; Immunology; Psychology","score_opus":0.1585380852411885,"score_gpt":0.4206960625150651,"score_spread":0.2621579772738766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393863976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92083555,0.07370742,0.000073537725,0.0003964643,0.00024695304,0.00059325976,0.0036448839,0.00015096455,0.00035094778],"genre_scores_gemma":[0.98589844,0.008951221,0.00020955587,0.000027442904,0.00012858483,0.000028951514,0.0046203607,0.000039444218,0.000096030664],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99648416,0.00022642984,0.0014644851,0.00081712665,0.0005486303,0.00045917256],"domain_scores_gemma":[0.993804,0.003397419,0.00023528909,0.0021537556,0.00024379596,0.00016575378],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007588162,0.00030134508,0.0017368543,0.000994596,0.00003877254,0.000012336044,0.0007712693,0.00021085677,0.0004248938],"category_scores_gemma":[0.00418311,0.00025542246,0.00034663267,0.0023816915,0.00072715746,0.00016044457,0.0008319085,0.00038420432,0.0000361857],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048483856,0.012957562,0.23370914,0.050926838,0.18855098,0.041827153,0.051213533,0.012813567,0.18175691,0.0017262138,0.04302871,0.13300553],"study_design_scores_gemma":[0.046433646,0.000816845,0.116756074,0.0066046226,0.009758885,0.00003834606,0.0032953888,0.7904463,0.0019518486,0.00016688611,0.02281521,0.0009159416],"about_ca_topic_score_codex":0.0017589934,"about_ca_topic_score_gemma":0.00048370144,"teacher_disagreement_score":0.7776327,"about_ca_system_score_codex":0.001989857,"about_ca_system_score_gemma":0.0040595355,"threshold_uncertainty_score":0.9999898},"labels":[],"label_agreement":null},{"id":"W4393876948","doi":"10.51731/cjht.2024.865","title":"Ibrutinib (Imbruvica)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Leukemia","score_opus":0.0390365717984071,"score_gpt":0.34989368745113497,"score_spread":0.3108571156527279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393876948","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18337178,0.5811719,0.00052731525,0.22598231,0.0016596828,0.00059536815,0.000023693898,0.00061568536,0.0060523143],"genre_scores_gemma":[0.9973099,0.000988809,0.0006353989,0.00045080393,0.00003993939,0.0000032954154,0.0000015864695,0.000021954776,0.0005483012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984516,0.000031181586,0.00050103274,0.00014716032,0.00027308022,0.00059596996],"domain_scores_gemma":[0.999165,0.00010594621,0.000092230795,0.0002854598,0.00014440689,0.0002069702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008678401,0.00010786409,0.00035185905,0.0010305296,0.00011600373,0.00006290012,0.0002722554,0.0001610236,0.000114440605],"category_scores_gemma":[0.0008384292,0.00008169538,0.00011079003,0.0006084571,0.0003061324,0.00008883488,0.000023247903,0.0007349266,0.00009133389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000025248968,0.000012323926,0.00035138358,0.000910882,0.00011091556,0.0057370635,0.0003541793,0.0000049115483,0.00007107213,0.0056376783,0.07631732,0.910467],"study_design_scores_gemma":[0.0015673363,0.0006800531,0.0005898941,0.0013660683,0.00002178524,0.008537379,0.0015322694,0.00040404627,0.0008084309,0.0030222328,0.98136747,0.00010301581],"about_ca_topic_score_codex":0.0045400783,"about_ca_topic_score_gemma":0.0010698978,"teacher_disagreement_score":0.91036403,"about_ca_system_score_codex":0.011717651,"about_ca_system_score_gemma":0.083804004,"threshold_uncertainty_score":0.9920762},"labels":[],"label_agreement":null},{"id":"W4393880018","doi":"10.5281/zenodo.7094921","title":"hive-24hr","year":2022,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Computer science","score_opus":0.0387015403011306,"score_gpt":0.2841458509821054,"score_spread":0.24544431068097478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393880018","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014491886,0.0003119813,0.00003315953,0.00064325455,0.00026517737,0.0011578207,0.9608518,0.00069523836,0.035896644],"genre_scores_gemma":[0.00021121962,0.00075278984,0.00004202981,0.0004431347,0.00045334952,2.1571806e-7,0.9915298,0.0023456875,0.0042217528],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563664,0.00055783207,0.0004736234,0.0009219119,0.001592838,0.0008171653],"domain_scores_gemma":[0.9968656,0.00007355578,0.0001970608,0.0017429951,0.0006111175,0.000509704],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010739691,0.00035308764,0.0004976777,0.00070662616,0.002602502,0.0005767732,0.0019608676,0.00024074003,0.61431575],"category_scores_gemma":[0.0016902662,0.00037021466,0.00018852382,0.000958474,0.0003403929,0.00012666205,0.004824726,0.0015565614,0.027639702],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002753246,0.0002922996,5.210602e-8,0.0005474763,0.00017039786,0.0006001935,0.000115099116,0.000009060084,0.00009439314,0.00009088109,0.9869295,0.010875332],"study_design_scores_gemma":[0.004103937,0.00070744136,0.000009146321,0.00008444252,0.00011969362,0.002187866,0.00013875787,0.000106564534,0.000033646174,0.000025786847,0.99215716,0.00032555702],"about_ca_topic_score_codex":0.00025053177,"about_ca_topic_score_gemma":8.4670387e-7,"teacher_disagreement_score":0.58667606,"about_ca_system_score_codex":0.010360927,"about_ca_system_score_gemma":0.0002685452,"threshold_uncertainty_score":0.999875},"labels":[],"label_agreement":null},{"id":"W4393983276","doi":"10.1158/1538-7445.am2024-ct063","title":"Abstract CT063: Phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Phase (matter); Internal medicine; Pharmacology; Chemistry","score_opus":0.04407971436405525,"score_gpt":0.42376940895817367,"score_spread":0.3796896945941184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393983276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910228,0.0023835064,0.0000043542823,0.00071465736,0.0005634834,0.0038866221,0.00012560509,0.00011916087,0.0011797906],"genre_scores_gemma":[0.9953589,0.0004429063,0.00007675336,0.000046441775,0.0011592803,0.0007661436,0.00009224449,0.00017198843,0.0018853382],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922787,0.00026025035,0.0011532581,0.0011780792,0.003436297,0.0016934396],"domain_scores_gemma":[0.9962576,0.0008236598,0.00013154293,0.0010494555,0.0010376439,0.00070007227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019826414,0.00044784017,0.0009881112,0.0011166041,0.00014469327,0.00012926402,0.00052459206,0.0003009381,0.0007673003],"category_scores_gemma":[0.0011654848,0.0003504063,0.00023172642,0.002631134,0.00068310084,0.0004948464,0.0003132928,0.0018038756,0.00024113336],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5786452,0.010739237,0.006213973,0.010415598,0.0010270155,0.005430658,0.0045306394,0.00046897947,0.17969185,0.00020094634,0.037287354,0.16534851],"study_design_scores_gemma":[0.6774261,0.019402927,0.002868664,0.010155275,0.00012354134,0.00004384247,0.00070225756,0.0026542442,0.2683989,0.000119761375,0.017178183,0.000926295],"about_ca_topic_score_codex":0.0018695119,"about_ca_topic_score_gemma":0.00057975744,"teacher_disagreement_score":0.16442223,"about_ca_system_score_codex":0.015435444,"about_ca_system_score_gemma":0.01960758,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W4394564985","doi":"10.1109/ic2pct60090.2024.10486467","title":"IC2PCT 2024 TOC","year":2024,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Federated Co-operatives (Canada)","funders":"","keywords":"Computer science","score_opus":0.02348955057103893,"score_gpt":0.357883134625959,"score_spread":0.3343935840549201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394564985","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07630255,0.0034527066,0.0006258959,0.004603988,0.0007696709,0.0003696536,0.0000028061706,0.00045861764,0.9134141],"genre_scores_gemma":[0.61574453,0.000075537326,0.0004281785,0.00041279654,0.00036445927,0.000015341044,0.0000047828134,0.000019905889,0.38293445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99911076,0.000008870635,0.00011065217,0.00021593401,0.00031454468,0.00023922288],"domain_scores_gemma":[0.99947774,0.00009423706,0.0000029970622,0.0002562071,0.0000295889,0.00013922509],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015269274,0.00007273227,0.00011136036,0.000101413425,0.000017662725,0.00004711909,0.00005882421,0.00005430789,0.011735141],"category_scores_gemma":[0.000062573934,0.000049114507,0.00007484875,0.0002827195,0.000045683755,0.000047981088,0.000057259418,0.0001673735,0.006444457],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008576167,0.000055708457,0.000080442,0.00075375603,0.00017333598,0.0029388496,0.00022410137,0.0000030655483,0.003282189,0.021566054,0.91502434,0.05581242],"study_design_scores_gemma":[0.003366457,0.000208699,0.00013109158,0.00025380088,0.000057630645,0.0012268695,0.000099783836,0.05743617,0.0072083073,0.00074728625,0.9291382,0.00012572296],"about_ca_topic_score_codex":0.00022091015,"about_ca_topic_score_gemma":0.000012636699,"teacher_disagreement_score":0.539442,"about_ca_system_score_codex":0.004306306,"about_ca_system_score_gemma":0.0041328534,"threshold_uncertainty_score":0.999516},"labels":[],"label_agreement":null},{"id":"W4394596323","doi":"10.1182/bloodadvances.2023011000","title":"Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"NIH Clinical Center; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Quality of life (healthcare); Adverse effect; Immune system; Placebo; CD8; Internal medicine; Immune dysregulation; Clinical trial; Immunology; Lymphocyte; Pediatrics; Alternative medicine","score_opus":0.008652111482124279,"score_gpt":0.2821339996319304,"score_spread":0.2734818881498061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394596323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877713,0.008829497,0.000021773527,0.00019695831,0.0000820687,0.0012782444,0.000018746076,0.0002194962,0.0015819316],"genre_scores_gemma":[0.9964626,0.0011791557,0.00049684703,0.000032434586,0.0001776372,0.00031933482,0.000051122777,0.000078008416,0.0012028831],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769056,0.000055127322,0.0002698635,0.0007694467,0.00057858264,0.000636447],"domain_scores_gemma":[0.9990411,0.00020865045,0.00005556222,0.0003691539,0.000109491775,0.00021606882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000915828,0.00037239582,0.00053170265,0.00031683032,0.00007395303,0.000057262765,0.00011665148,0.00010446572,0.00006197785],"category_scores_gemma":[0.000029080831,0.00022400457,0.00006542194,0.0010402477,0.00019072036,0.0004235656,0.00003872016,0.00031418516,0.0000526135],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064382866,0.014951205,0.39308226,0.017438952,0.00991711,0.23282732,0.021948436,0.00065308134,0.03651534,0.0006509148,0.00038594415,0.20724657],"study_design_scores_gemma":[0.23497294,0.07017721,0.105849266,0.04209434,0.0018457415,0.04152841,0.0020921677,0.0014748959,0.49324107,0.00019683232,0.0039795474,0.0025475684],"about_ca_topic_score_codex":0.0004070197,"about_ca_topic_score_gemma":0.0012165282,"teacher_disagreement_score":0.45672575,"about_ca_system_score_codex":0.005395509,"about_ca_system_score_gemma":0.0043250807,"threshold_uncertainty_score":0.9984226},"labels":[],"label_agreement":null},{"id":"W4394602078","doi":"10.1212/wnl.0000000000204912","title":"Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)","year":2024,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Multiple sclerosis; Immune system; Medicine; Neuroscience; Immunology; Psychology","score_opus":0.034927506128715105,"score_gpt":0.30331402316191886,"score_spread":0.26838651703320376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394602078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958871,0.0015657857,0.000013144831,0.0010583922,0.00037956252,0.0004739527,0.00007316543,0.00012291108,0.00042598264],"genre_scores_gemma":[0.99864805,0.00036457463,0.00008649791,0.00041135462,0.00007072468,0.00005626542,0.00016316082,0.00003975226,0.00015962981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756616,0.00012098789,0.00069491967,0.00053093175,0.00040412377,0.0006828985],"domain_scores_gemma":[0.9983409,0.00088333804,0.000062351486,0.00044527402,0.00007660412,0.0001915198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042248465,0.00019249781,0.0004948659,0.00020810531,0.000051320123,0.00001380004,0.0001829944,0.00020891192,0.00027140148],"category_scores_gemma":[0.00073685835,0.00016989117,0.00010553034,0.00053098093,0.00029351836,0.000062398,0.00026858467,0.0004206197,0.0001544969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040701058,0.0034109838,0.5793993,0.0063936017,0.001152519,0.025354309,0.01745619,0.00067313435,0.17217635,0.00052537525,0.009330394,0.14342682],"study_design_scores_gemma":[0.02593462,0.0011969545,0.8545667,0.00051402365,0.00007255139,0.0005689782,0.00008962177,0.019348271,0.019058926,0.000056411085,0.07820482,0.0003881511],"about_ca_topic_score_codex":0.00056623854,"about_ca_topic_score_gemma":0.00030082048,"teacher_disagreement_score":0.2751674,"about_ca_system_score_codex":0.0014477905,"about_ca_system_score_gemma":0.005128196,"threshold_uncertainty_score":0.90971994},"labels":[],"label_agreement":null},{"id":"W4394909915","doi":"10.1021/acs.jmedchem.4c00072","title":"Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist","year":2024,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Innovative Medicines Initiative; Kungliga Tekniska Högskolan; European Commission; University of Oxford; Cancer Research UK; Directorate for Biological Sciences; European Federation of Pharmaceutical Industries and Associations; Wellcome Trust; Biotechnology and Biological Sciences Research Council; Ovarian Cancer Research Alliance; Diamond Light Source; McGill University","keywords":"Chemistry; Small molecule; Active site; Hydrolase; Drug discovery; Bruton's tyrosine kinase; Biochemistry; Structure–activity relationship; Enzyme; Computational biology; Stereochemistry; Signal transduction; Biology; Tyrosine kinase","score_opus":0.033399543965428706,"score_gpt":0.38871426036687706,"score_spread":0.35531471640144835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394909915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920383,0.002971139,0.00020749729,0.0019671898,0.00088063197,0.00020213153,0.000037012178,0.000018332317,0.0016777817],"genre_scores_gemma":[0.9948392,0.00042528557,0.00046379064,0.000082653765,0.0028795414,0.0000034728666,0.000008666619,0.000041750132,0.0012556346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949734,0.00010501602,0.0019422222,0.00036317078,0.0021949182,0.00042127562],"domain_scores_gemma":[0.99685323,0.0008378457,0.00066565594,0.0004547615,0.000584686,0.0006038478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023619097,0.0002757891,0.0014074284,0.00020194173,0.000031954634,0.000024346191,0.00029381004,0.00030879013,0.00021466642],"category_scores_gemma":[0.0026700944,0.00020220423,0.00065865007,0.00060997583,0.00053942343,0.00019104738,0.00016630447,0.0013707933,0.000006808676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007146929,0.0013296875,0.005601948,0.00510437,0.0008589526,0.0045122798,0.000630169,0.00003311154,0.94605696,0.000010211718,0.021995205,0.0067201657],"study_design_scores_gemma":[0.012524106,0.002477399,0.002712133,0.0053180684,0.00053150975,0.004570201,0.0006086829,0.0010096888,0.9652593,0.00002986425,0.004741813,0.00021719545],"about_ca_topic_score_codex":0.00006622616,"about_ca_topic_score_gemma":0.000002989139,"teacher_disagreement_score":0.019202368,"about_ca_system_score_codex":0.0028327813,"about_ca_system_score_gemma":0.014083305,"threshold_uncertainty_score":0.9915059},"labels":[],"label_agreement":null},{"id":"W4396587157","doi":"10.14740/jocmr5115","title":"Successful Implementation of Combined Treatment Methods for a Rare Recurrence of Waldenstrom Macroglobulinemia With Extramedullary Lesions","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Medicine Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lymphoplasmacytic Lymphoma; Macroglobulinemia; Rituximab; Waldenstrom macroglobulinemia; Lymphoma; Lesion; Surgery; Hematology; Chemotherapy; Radiation therapy; Weakness; Rare disease; Radiology; Internal medicine; Disease; Multiple myeloma","score_opus":0.2735668846184844,"score_gpt":0.6470328061040118,"score_spread":0.37346592148552743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396587157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9607185,0.009938854,0.01116901,0.014850483,0.0006560134,0.002125803,0.000050795996,0.0000183643,0.00047213398],"genre_scores_gemma":[0.94996536,0.0065639406,0.041799676,0.000041279684,0.001126963,0.000051848394,0.000028491655,0.00004685803,0.00037559858],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9932415,0.0010923946,0.002825621,0.00037189815,0.0019279083,0.00054067536],"domain_scores_gemma":[0.9796272,0.015769048,0.00059456745,0.00048443707,0.0029330205,0.0005917268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013787404,0.00020767702,0.0015808023,0.0007457802,0.000064529726,0.000016773436,0.0003747559,0.00020020119,0.00044290724],"category_scores_gemma":[0.0063676815,0.00011552104,0.00042305829,0.0011116422,0.001201878,0.000119054384,0.00009201901,0.0010433539,0.0000025101533],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012176675,0.0010018452,0.011225039,0.003296617,0.0014731289,0.0008190233,0.0010594188,0.000008810827,0.0057733306,0.0007803583,0.009194753,0.953191],"study_design_scores_gemma":[0.27417195,0.3578089,0.032317564,0.042948816,0.004637688,0.006340584,0.027392395,0.030756157,0.14407836,0.007205072,0.07153802,0.0008045244],"about_ca_topic_score_codex":0.0004495232,"about_ca_topic_score_gemma":0.00003896309,"teacher_disagreement_score":0.9523865,"about_ca_system_score_codex":0.0019269697,"about_ca_system_score_gemma":0.018765023,"threshold_uncertainty_score":0.9867977},"labels":[],"label_agreement":null},{"id":"W4396978251","doi":"10.1182/blood.2023023659","title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Leukemia; Internal medicine; Cancer research; Immunology","score_opus":0.014019304135587387,"score_gpt":0.3052712973451345,"score_spread":0.2912519932095471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396978251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931377,0.0008069237,0.0000048996526,0.00006987245,0.00008707999,0.0026082979,0.000032947057,0.00030819536,0.0029440427],"genre_scores_gemma":[0.995293,0.000048640268,0.0003611579,0.000076999,0.00023426392,0.0005047851,0.0004186366,0.00009787605,0.002964635],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99683756,0.00009212816,0.00046489373,0.000756496,0.0010943852,0.0007545147],"domain_scores_gemma":[0.99876016,0.00031484597,0.000071211616,0.0004532185,0.00014032082,0.0002602599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002722069,0.00034115106,0.00041704485,0.00036687078,0.00007584047,0.000081015394,0.00017431608,0.00021265898,0.0006595105],"category_scores_gemma":[0.00023840868,0.00021042128,0.000083939034,0.0010338214,0.00015775756,0.00014585015,0.00007864932,0.00041125805,0.0005122732],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08987828,0.025800912,0.19429867,0.0414085,0.0064527807,0.08341615,0.01032876,0.0040837396,0.0045197764,0.0027960269,0.02758924,0.50942713],"study_design_scores_gemma":[0.5533857,0.02753421,0.15262347,0.032937214,0.0014982442,0.00296064,0.00014227496,0.16318244,0.053279933,0.00010277154,0.010212554,0.0021405786],"about_ca_topic_score_codex":0.00020540507,"about_ca_topic_score_gemma":0.000073160045,"teacher_disagreement_score":0.50728655,"about_ca_system_score_codex":0.04494559,"about_ca_system_score_gemma":0.046427257,"threshold_uncertainty_score":0.9589786},"labels":[],"label_agreement":null},{"id":"W4397041498","doi":"10.1681/asn.20233411s1481c","title":"Acute and Chronic Kidney Dysfunction Associated with Anaplastic Lymphoma Kinase (ALK) Inhibitors","year":2023,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; University of Toronto; University Health Network","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Kidney disease; Cancer research; Internal medicine","score_opus":0.012107500635873486,"score_gpt":0.2708467261409527,"score_spread":0.2587392255050792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397041498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913138,0.00014795375,0.0000545912,0.008109528,0.0001296119,0.00016624281,0.000010157227,0.000024300578,0.000043801367],"genre_scores_gemma":[0.99500537,0.000759623,0.00020863314,0.0033305385,0.00033855657,0.0000038266635,0.000005508073,0.000030610594,0.00031735128],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982614,0.00014729095,0.00041590008,0.00017666233,0.00059632654,0.0004024197],"domain_scores_gemma":[0.9979592,0.00038861463,0.00087530626,0.0002570736,0.00027787438,0.00024193736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051887275,0.00016156607,0.0006271406,0.000119478485,0.00011181758,0.000010162563,0.00019131188,0.00009714927,0.00001877951],"category_scores_gemma":[0.0002967011,0.000099798686,0.00030568513,0.0011385686,0.0014635265,0.000079595775,0.00014569603,0.00032188892,0.0000048582356],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069748648,0.0004892108,0.008772527,0.0003210998,0.0077607646,0.0005692093,0.0019376511,0.0004776753,0.4252189,0.000026220087,0.52428967,0.02316219],"study_design_scores_gemma":[0.1500014,0.049372666,0.5953009,0.0022096848,0.0057148403,0.015857795,0.00612057,0.0706385,0.025150558,0.00043910157,0.07816877,0.0010252027],"about_ca_topic_score_codex":0.00010561555,"about_ca_topic_score_gemma":0.000018494895,"teacher_disagreement_score":0.58652836,"about_ca_system_score_codex":0.004066504,"about_ca_system_score_gemma":0.005391439,"threshold_uncertainty_score":0.9997567},"labels":[],"label_agreement":null},{"id":"W4398204532","doi":"10.12659/ajcr.941165","title":"A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments","year":2024,"lang":"en","type":"article","venue":"American Journal of Case Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Immunology; Leukemia; Antiviral therapy; Virology; Virus","score_opus":0.01935507311458265,"score_gpt":0.31243796022949516,"score_spread":0.2930828871149125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398204532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695843,0.00043190914,0.00026188005,0.00035666296,0.00013127383,0.0008611033,0.0000050281424,0.00007020883,0.00092346955],"genre_scores_gemma":[0.9971197,0.00031347456,0.00067469955,0.00051599107,0.00026088068,0.000043111515,0.0000048552474,0.000117793024,0.000949478],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9966244,0.00014931834,0.0006496553,0.0006354718,0.0012519899,0.0006891707],"domain_scores_gemma":[0.99767655,0.00018755498,0.00060069095,0.00066235394,0.00051305525,0.0003598091],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005218822,0.00046200366,0.00084748206,0.00061469385,0.000121842706,0.00011935451,0.00007346735,0.000063719875,0.000020798803],"category_scores_gemma":[0.0000791183,0.00026011694,0.00027000363,0.0011894571,0.00051445223,0.00022335851,0.000032220338,0.00047426598,0.000021471933],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02613394,0.00019384238,0.0029623557,0.00015338957,0.0032190229,0.92738295,0.0012809006,0.0018678452,0.0037371032,0.000017663358,0.0010184491,0.032032564],"study_design_scores_gemma":[0.013754491,0.06156838,0.001631062,0.0036457535,0.0007120478,0.894525,0.000738889,0.001192673,0.017155616,0.0000046730606,0.004648187,0.00042326289],"about_ca_topic_score_codex":0.004118599,"about_ca_topic_score_gemma":0.00030879196,"teacher_disagreement_score":0.061374538,"about_ca_system_score_codex":0.06321842,"about_ca_system_score_gemma":0.034824796,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W4398436822","doi":"10.7910/dvn/ktwyz6/ewwn8c","title":"MPL_risk.tex","year":2020,"lang":"en","type":"dataset","venue":"Harvard Dataverse","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HEC Montréal","funders":"","keywords":"Computer science; Risk analysis (engineering); Business","score_opus":0.02951878219290569,"score_gpt":0.3035868503544649,"score_spread":0.2740680681615592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398436822","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015796368,0.0000044091366,0.000012057325,0.00004631012,0.00047162644,0.0007239339,0.9976534,0.00011392538,0.00095854077],"genre_scores_gemma":[0.000011510023,0.0014029492,0.00028624697,0.0020456468,0.0012191281,0.000045577257,0.9934544,0.00006464911,0.001469918],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966599,0.0000883166,0.0004775751,0.0008977867,0.0011987168,0.0006777238],"domain_scores_gemma":[0.9962632,0.00015630764,0.00016118721,0.0025421497,0.0001283473,0.00074879214],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025841448,0.00046702032,0.000840906,0.00023616316,0.00009015451,0.00008430841,0.0008001082,0.00051786425,0.05870343],"category_scores_gemma":[0.0011929482,0.00042080812,0.0002590171,0.00036589152,0.00023055416,0.00013456383,0.0010462462,0.0011785345,0.70741576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00040026833,0.00011248157,0.0000013020283,0.00098777,0.00024314002,0.005200627,0.000017438268,7.6903257e-7,0.00002227575,0.000009513629,0.9925947,0.00040968505],"study_design_scores_gemma":[0.0084389215,0.00022127302,0.000008411145,0.00026952347,0.00049661344,0.0005836265,0.00003616932,0.00022231735,0.000058810816,0.000007735989,0.9892926,0.00036395207],"about_ca_topic_score_codex":0.0016275025,"about_ca_topic_score_gemma":0.00007879565,"teacher_disagreement_score":0.6487123,"about_ca_system_score_codex":0.0067185666,"about_ca_system_score_gemma":0.010834515,"threshold_uncertainty_score":0.99982435},"labels":[],"label_agreement":null},{"id":"W4399045499","doi":"10.1002/hem3.74","title":"First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Pharmacyclics","keywords":"Ibrutinib; Post-hoc analysis; Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Post hoc; Pooled analysis; Survival analysis; Population; Leukemia; Meta-analysis","score_opus":0.018026519877040136,"score_gpt":0.29915942787016636,"score_spread":0.28113290799312624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399045499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972122,0.00069461216,0.000043528016,0.00019192917,0.00005380187,0.0013667853,0.00014632478,0.00013222627,0.00015862625],"genre_scores_gemma":[0.99534076,0.00005481473,0.0007746082,0.00016377021,0.000118764336,0.00010351447,0.0014716991,0.00010471655,0.0018673344],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9965271,0.00015187444,0.00065980176,0.0008615395,0.0010813146,0.00071840436],"domain_scores_gemma":[0.99812615,0.0002149193,0.00014887008,0.0008121195,0.00031521943,0.00038270117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027812365,0.00050192344,0.0012312889,0.00036594947,0.00008007365,0.00008411188,0.00018622831,0.00022015446,0.00075181],"category_scores_gemma":[0.00008953889,0.00034954617,0.00022983311,0.002284223,0.00008893957,0.00020471502,0.00007612271,0.00018995533,0.000026427282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04357077,0.004187282,0.44551477,0.0037932019,0.03193404,0.010325839,0.01624374,0.42893076,0.001347704,0.00027598246,0.0009114895,0.012964423],"study_design_scores_gemma":[0.09174323,0.017396826,0.43607682,0.0025198997,0.0043863207,0.000038050937,0.00029744787,0.44385904,0.0022863445,0.000051131727,0.00028333263,0.001061547],"about_ca_topic_score_codex":0.013825031,"about_ca_topic_score_gemma":0.029441109,"teacher_disagreement_score":0.06541442,"about_ca_system_score_codex":0.07750218,"about_ca_system_score_gemma":0.01208776,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W4399245093","doi":"10.1002/ajh.27384","title":"Molecular landscape of mature B‐cell lymphoproliferative disorders with <i>BCL3</i>‐translocation: A Groupe Francophone de Cytogénétique Hématologique (GFCH)/French Innovative Leukemia Organization (FILO) study","year":2024,"lang":"fr","type":"letter","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Ligue Contre le Cancer","keywords":"Chromosomal translocation; Leukemia; French; Lymphoproliferative disorders; Medicine; Immunology; Biology; Genetics; Humanities; Philosophy; Lymphoma; Gene","score_opus":0.003968826039970044,"score_gpt":0.24739581251065076,"score_spread":0.24342698647068073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399245093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9291186,0.009561127,0.034298807,0.023675816,0.0008759018,0.0019263021,0.00005928378,0.00006235482,0.00042181349],"genre_scores_gemma":[0.98359954,0.001437912,0.0038856014,0.009593702,0.0007918807,0.00009293552,0.00014192813,0.00030902357,0.0001474523],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9911996,0.002321019,0.0027592352,0.00089719956,0.0014901788,0.0013327827],"domain_scores_gemma":[0.9909254,0.0014329277,0.003022275,0.000923382,0.0033136797,0.0003823767],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014921314,0.0011327307,0.0038962506,0.0014207537,0.0001532424,0.000068347166,0.0009941638,0.0011199388,0.0003480855],"category_scores_gemma":[0.0007455519,0.0008996775,0.0003161713,0.006941538,0.0021430263,0.00021588123,0.00019616431,0.0050749574,0.00006468081],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01238619,0.009842499,0.3343189,0.02690366,0.033000816,0.1423649,0.22710171,0.0100124,0.02275113,0.0041396315,0.16768344,0.009494714],"study_design_scores_gemma":[0.14489734,0.083570644,0.01172113,0.024474159,0.008271004,0.28316033,0.21740802,0.007448652,0.20347501,0.0023639554,0.0067408807,0.0064688707],"about_ca_topic_score_codex":0.0010509829,"about_ca_topic_score_gemma":0.00018799213,"teacher_disagreement_score":0.32259777,"about_ca_system_score_codex":0.008777287,"about_ca_system_score_gemma":0.043108933,"threshold_uncertainty_score":0.99934536},"labels":[],"label_agreement":null},{"id":"W4399360915","doi":"10.3390/ijms25116207","title":"Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton’s Tyrosine Kinase Inhibitor Acalabrutinib","year":2024,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Toronto General Hospital; Ted Rogers Centre for Heart Research; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Electrophysiology; Internal medicine; Cardiac electrophysiology; Cardiology; Medicine; Endocrinology","score_opus":0.042373771543355136,"score_gpt":0.33784625773268234,"score_spread":0.2954724861893272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399360915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623217,0.021500388,0.008828643,0.0050836727,0.0017390243,0.00012109815,0.000007319729,0.00002334939,0.00037480192],"genre_scores_gemma":[0.9955945,0.0004706165,0.0021040824,0.0004586386,0.0011508428,0.0000025857053,0.000013420577,0.000015487318,0.00018985284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99696904,0.000060663864,0.0005130034,0.00027035485,0.0019474603,0.00023949024],"domain_scores_gemma":[0.9989492,0.000068785295,0.00013321904,0.00011561376,0.00056203926,0.00017113535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010294277,0.0001278637,0.00018525979,0.00041865016,0.00006783624,0.0003474223,0.00038630175,0.00007383446,0.00012987445],"category_scores_gemma":[0.00035544496,0.000098087665,0.00021365698,0.00043865963,0.00017258168,0.00042329545,0.000085148764,0.00027275624,0.00003325361],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009322107,0.000109197965,0.000050484883,0.000034759076,0.00022100666,0.0075611714,0.00014558638,0.0024877978,0.96060085,0.0011411122,0.00561663,0.021938207],"study_design_scores_gemma":[0.0037002466,0.00053633103,0.000019177223,0.00079341,0.0001102646,0.01229234,0.00011450899,0.35155937,0.6071386,0.0005495321,0.022972396,0.00021387222],"about_ca_topic_score_codex":0.000037443664,"about_ca_topic_score_gemma":0.000001215541,"teacher_disagreement_score":0.35346228,"about_ca_system_score_codex":0.0024792852,"about_ca_system_score_gemma":0.003748219,"threshold_uncertainty_score":0.66491795},"labels":[],"label_agreement":null},{"id":"W4399389465","doi":"10.1161/jaha.123.032357","title":"Impaired Cardiac AMPK (5′‐Adenosine Monophosphate‐Activated Protein Kinase) and Ca <sup>2+</sup> ‐Handling, and Action Potential Duration Heterogeneity in Ibrutinib‐Induced Ventricular Arrhythmia Vulnerability","year":2024,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Alberta; Toronto General Hospital","funders":"","keywords":"Ibrutinib; Internal medicine; AMPK; Cardioprotection; Medicine; Endocrinology; Adenosine; Protein kinase A; Pharmacology; Cardiology; Chemistry; Myocardial infarction; Kinase; Biochemistry","score_opus":0.01594068905538327,"score_gpt":0.3031152007778567,"score_spread":0.28717451172247344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399389465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944436,0.00087679655,0.000032956414,0.0037463123,0.00020523618,0.00066197856,0.0000088127435,0.000021493468,0.0000028327925],"genre_scores_gemma":[0.99902153,0.00014982365,0.000121368415,0.00006535796,0.0005519218,0.000015685937,0.000005500209,0.000021800368,0.00004703311],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99748135,0.00065001106,0.0005796911,0.0002577916,0.00072813587,0.00030300312],"domain_scores_gemma":[0.9988179,0.00020786299,0.00039577723,0.00018597058,0.00024563825,0.0001468374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019290594,0.00016468832,0.0005859078,0.00019606536,0.00013264462,0.00011604748,0.000058129262,0.00011522444,0.0000071414315],"category_scores_gemma":[0.001176887,0.00012261789,0.0002122306,0.0006416459,0.000073034644,0.00028521815,0.000057980866,0.00058794656,0.0000029020941],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003432851,0.00036111983,0.2049553,0.0006663586,0.0013415259,0.0006188625,0.00258563,0.003290576,0.7609413,0.000006595375,0.0014868372,0.020313045],"study_design_scores_gemma":[0.008692626,0.0015947723,0.5973879,0.0009588675,0.0005420867,0.0012018699,0.00076688215,0.12863503,0.25848544,0.00014853732,0.0011958769,0.00039007908],"about_ca_topic_score_codex":0.0015011223,"about_ca_topic_score_gemma":0.000020621079,"teacher_disagreement_score":0.5024559,"about_ca_system_score_codex":0.009742614,"about_ca_system_score_gemma":0.0013703513,"threshold_uncertainty_score":0.9940588},"labels":[],"label_agreement":null},{"id":"W4399459365","doi":"10.1038/s41375-024-02280-0","title":"Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms","year":2024,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University; University of Alberta; University of Manitoba; CancerCare Manitoba","funders":"Università degli Studi di Perugia; Medical Center, University of Rochester; Skånes universitetssjukhus; Universität Zürich; Uniwersytet Łódzki; Ohio State University; Queen's University; Monash University; University of Southampton; Peter MacCallum Cancer Centre; Università degli Studi di Siena; University of Alberta; Northwell Health; Lunds Universitet; National Cancer Institute; University of Rochester; University of Texas MD Anderson Cancer Center; Northwestern University; Memorial Sloan-Kettering Cancer Center","keywords":"Hairy cell leukemia; Leukemia; Medicine; Pathology; Biology; Immunology","score_opus":0.03488911613471097,"score_gpt":0.29381392581385446,"score_spread":0.2589248096791435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399459365","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11731691,0.021993114,0.012102571,0.66179276,0.021911798,0.019500196,0.002433502,0.0062279436,0.1367212],"genre_scores_gemma":[0.14687532,0.009046365,0.0029693665,0.41835827,0.03755618,0.003214554,0.015356268,0.002350658,0.36427304],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98898274,0.00056613993,0.002063228,0.0032608048,0.003174393,0.001952708],"domain_scores_gemma":[0.9935591,0.0010315441,0.0010028573,0.003016854,0.00066804397,0.00072155264],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00135701,0.0016163366,0.0021392356,0.0014054485,0.0004768437,0.00078416907,0.0010593014,0.0035859335,0.0005585429],"category_scores_gemma":[0.0006707629,0.0015372274,0.00055004057,0.001585394,0.0009785923,0.0006852544,0.00055273256,0.0047304532,0.0024428456],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00058383046,0.000060887996,0.000078946694,0.005824929,0.00018405034,0.0077890335,0.0007317928,0.00001781863,0.0034638003,0.00040794178,0.9777115,0.0031454451],"study_design_scores_gemma":[0.012310283,0.00054852734,0.0007260372,0.006932402,0.001108281,0.012964487,0.0004866608,0.25514328,0.004611841,0.0006220782,0.7026483,0.0018978358],"about_ca_topic_score_codex":0.0018318633,"about_ca_topic_score_gemma":0.000074380936,"teacher_disagreement_score":0.27506325,"about_ca_system_score_codex":0.10402363,"about_ca_system_score_gemma":0.049960565,"threshold_uncertainty_score":0.9996584},"labels":[],"label_agreement":null},{"id":"W4399477840","doi":"10.1016/j.bneo.2024.100022","title":"Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Johnson and Johnson; Janssen Scientific Affairs","keywords":"Ibrutinib; Hazard ratio; Medicine; Chronic lymphocytic leukemia; Internal medicine; Confidence interval; Dosing; Oncology; Adverse effect; Leukemia","score_opus":0.045808562921494676,"score_gpt":0.3896346356456451,"score_spread":0.34382607272415044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399477840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964868,0.00051335956,0.00008729298,0.00013961564,0.00020189505,0.0011785198,0.000047385874,0.000077506804,0.0012676425],"genre_scores_gemma":[0.9979816,0.00017746692,0.00064876414,0.000021245305,0.00049057155,0.000038192546,0.00014404797,0.00004745417,0.00045066274],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972371,0.00012802954,0.00077873806,0.00055677205,0.0007973284,0.00050205615],"domain_scores_gemma":[0.9984758,0.00049068365,0.00013121635,0.0005967747,0.0000913494,0.0002141955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005998266,0.0002803954,0.00080113934,0.001566498,0.000040968094,0.000035479447,0.00012261533,0.00015499364,0.0005538233],"category_scores_gemma":[0.00023114822,0.00022192771,0.0005702136,0.0030127743,0.00006112404,0.00009091461,0.000073608375,0.00031898785,0.000031927517],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24085349,0.015841544,0.12951326,0.0040730746,0.029680507,0.0073142257,0.008425496,0.52850944,0.013701403,0.0020656069,0.0028842834,0.017137652],"study_design_scores_gemma":[0.16537613,0.00319762,0.07676222,0.00086005795,0.0034932897,0.00008378718,0.000041632087,0.74617475,0.003379754,0.000098702854,0.00020579083,0.0003262902],"about_ca_topic_score_codex":0.0074572745,"about_ca_topic_score_gemma":0.0016937657,"teacher_disagreement_score":0.21766527,"about_ca_system_score_codex":0.007381917,"about_ca_system_score_gemma":0.004851844,"threshold_uncertainty_score":0.9991521},"labels":[],"label_agreement":null},{"id":"W4399480781","doi":"10.1200/jco.2024.42.16_suppl.tps7089","title":"BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Medicine; Chronic lymphocytic leukemia; Rituximab; Refractory (planetary science); Lymphoma; Bendamustine; Internal medicine; Oncology; Leukemia","score_opus":0.09580237776698809,"score_gpt":0.43501506333247886,"score_spread":0.3392126855654908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399480781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870283,0.005926623,0.000038800306,0.00006319497,0.0023201427,0.0030462556,0.000022130236,0.000097844044,0.0014567239],"genre_scores_gemma":[0.99519247,0.0019791385,0.00034309644,0.00019131567,0.0013603809,0.000113894115,0.00004262659,0.0002160995,0.00056100363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9864604,0.0017395605,0.0067129354,0.0013031419,0.002193327,0.0015906517],"domain_scores_gemma":[0.9864452,0.00691954,0.002739203,0.0013246876,0.0012078406,0.0013635221],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004944325,0.0009081737,0.005215826,0.0012542884,0.00012761139,0.00007558704,0.0010568323,0.0013315188,0.0002519913],"category_scores_gemma":[0.004396232,0.00069150876,0.0009881656,0.001733658,0.00093582185,0.0004124247,0.00042072753,0.0020691054,0.00016154833],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4493575,0.016102124,0.004047394,0.00371979,0.008781951,0.06705624,0.007008471,0.045287598,0.00031806823,0.00007870672,0.003248329,0.3949938],"study_design_scores_gemma":[0.6429993,0.18329921,0.0033384545,0.0027086271,0.0026631234,0.0015923554,0.00077937654,0.15020359,0.00017665877,0.000032622287,0.011555693,0.0006510222],"about_ca_topic_score_codex":0.0056271,"about_ca_topic_score_gemma":0.0021632158,"teacher_disagreement_score":0.3943428,"about_ca_system_score_codex":0.5232563,"about_ca_system_score_gemma":0.46187165,"threshold_uncertainty_score":0.99996495},"labels":[],"label_agreement":null},{"id":"W4399481117","doi":"10.1200/jco.2024.42.16_suppl.7051","title":"A single-cell multiomics analysis of IRF4 in mediating treatment resistance in ibrutinib-treated chronic lymphocytic leukemia (CLL).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Alberta; Simon Fraser University; Spinal Cord Injury BC","funders":"Michael Smith Health Research BC","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Venetoclax; Cancer research; Leukemia; Oncology; Immunology; Internal medicine","score_opus":0.1185399246747633,"score_gpt":0.45946295791884434,"score_spread":0.340923033244081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894736,0.006506953,0.00003522132,0.00051955384,0.00042682682,0.00032757092,0.000011251273,0.000017786733,0.0026812828],"genre_scores_gemma":[0.99385077,0.0030717691,0.0017466594,0.00011452468,0.00048311567,0.000011017232,0.000015092907,0.000035416975,0.00067166146],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99303776,0.00069844513,0.004588803,0.00044790894,0.0006774875,0.00054961897],"domain_scores_gemma":[0.98918486,0.008504581,0.0012506024,0.00039861485,0.0002962924,0.00036507097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004283539,0.00025705804,0.00297196,0.001636163,0.000019612122,0.000017209086,0.00026645197,0.0006272825,0.00011763101],"category_scores_gemma":[0.004149294,0.0001918477,0.00095729856,0.002480975,0.00032797214,0.0001279272,0.00007797155,0.0009398743,0.000017368611],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04467607,0.014027643,0.29037896,0.0045306836,0.022223426,0.0957057,0.009404872,0.0673376,0.041916333,0.00055393716,0.0023387754,0.406906],"study_design_scores_gemma":[0.16903308,0.0245443,0.06435113,0.0027327326,0.0078082844,0.0004576138,0.000673313,0.7069267,0.0077958787,0.00023080321,0.014883146,0.0005630185],"about_ca_topic_score_codex":0.0014831832,"about_ca_topic_score_gemma":0.006616617,"teacher_disagreement_score":0.6395891,"about_ca_system_score_codex":0.17271322,"about_ca_system_score_gemma":0.09212259,"threshold_uncertainty_score":0.91302425},"labels":[],"label_agreement":null},{"id":"W4399481218","doi":"10.1200/jco.2024.42.16_suppl.7046","title":"Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Randomized controlled trial; Oncology; Internal medicine; Clinical endpoint; Lymphoma; Surrogate endpoint; Leukemia","score_opus":0.47920550893122277,"score_gpt":0.5875569842723763,"score_spread":0.10835147534115358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399481218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9066088,0.074878074,0.002379644,0.0029349953,0.0022573003,0.008915568,0.00006820927,0.000075250195,0.0018821446],"genre_scores_gemma":[0.9836617,0.005351099,0.005147956,0.0011834146,0.0016817469,0.00085187715,0.000029687824,0.00012264398,0.0019698618],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9553266,0.015331495,0.024435727,0.0011056752,0.0025509428,0.0012495583],"domain_scores_gemma":[0.77098614,0.21507494,0.009542849,0.0010057013,0.00242779,0.00096258847],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.1920114,0.0007743436,0.046813004,0.0030829564,0.00007768744,0.000106490654,0.00080144685,0.001258792,0.0015940148],"category_scores_gemma":[0.24346793,0.00045374405,0.033427957,0.0021008898,0.0009724134,0.00022956876,0.0002376942,0.0010140118,0.00005510517],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.54331917,0.0004946003,0.000008130748,0.0008476734,0.40808073,0.0024530161,0.00038921603,0.02129697,0.00074926903,0.0011528588,0.00036149463,0.020846866],"study_design_scores_gemma":[0.3999338,0.005128853,0.000019579544,0.00019680032,0.2568693,0.00039320783,0.00008092022,0.33522153,0.00025153323,0.0010121568,0.000723525,0.0001688376],"about_ca_topic_score_codex":0.0018202227,"about_ca_topic_score_gemma":0.00056820485,"teacher_disagreement_score":0.31392455,"about_ca_system_score_codex":0.15436183,"about_ca_system_score_gemma":0.3846455,"threshold_uncertainty_score":0.99979144},"labels":[],"label_agreement":null},{"id":"W4399483854","doi":"10.1136/annrheumdis-2024-eular.864","title":"AB0004 HEALTH INFORMATION USE BY PATIENTS LIVING WITH ANTIPHOSPHOLIPID ANTIBODIES AND ANTIPHOSPHOLIPID SYNDROME","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of Calgary","funders":"","keywords":"Antiphospholipid syndrome; Medicine; Antibody; Immunology","score_opus":0.01823598961640036,"score_gpt":0.29245571732949405,"score_spread":0.27421972771309366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399483854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048376,0.0067403414,0.000035074743,0.0014566034,0.00015399675,0.0006910577,0.00026604757,0.000084420855,0.00008869776],"genre_scores_gemma":[0.9945275,0.004303117,0.00007174778,0.00073334365,0.000010474907,0.000017415678,0.00006628394,0.000029029032,0.0002410819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801785,0.000074924246,0.0005088399,0.0002224702,0.00076393486,0.00041198864],"domain_scores_gemma":[0.9984636,0.00041258117,0.00018698024,0.00048434825,0.00019017074,0.000262325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027624093,0.00021931872,0.00046805796,0.00014070043,0.00013872472,0.0001826569,0.00017577386,0.000048301266,0.000049434846],"category_scores_gemma":[0.000677841,0.00013213535,0.00012191726,0.00039603424,0.0003034085,0.000879303,0.00018444902,0.00013526321,0.00002711443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009526162,0.0020989364,0.41182747,0.044299018,0.0028309382,0.000059161626,0.010088062,0.00012877841,0.000029873288,0.0013158579,0.3187209,0.2076484],"study_design_scores_gemma":[0.0045148134,0.0012204923,0.9551629,0.025740447,0.0002519769,0.00028273667,0.00062183634,0.0062302463,0.0005646486,0.00015858143,0.0048065805,0.0004447686],"about_ca_topic_score_codex":0.00086947076,"about_ca_topic_score_gemma":0.0000053620493,"teacher_disagreement_score":0.5433354,"about_ca_system_score_codex":0.00038774186,"about_ca_system_score_gemma":0.0018870266,"threshold_uncertainty_score":0.5388323},"labels":[],"label_agreement":null},{"id":"W4399706750","doi":"10.1016/j.jval.2024.03.1932","title":"PCR52 Early Real-World Experience With Abrilada Within the Canadian Patient Population","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Geography; Medicine","score_opus":0.04722766304208774,"score_gpt":0.34167395004473894,"score_spread":0.2944462870026512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399706750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901931,0.0006685519,0.0000061125074,0.0050072013,0.00028147094,0.0009308777,0.00000608856,0.000059250448,0.0028473334],"genre_scores_gemma":[0.9979727,0.000055276705,0.0002657119,0.0007674945,0.00012046612,0.00007603618,0.000015157665,0.000031557767,0.0006955989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799323,0.00014969814,0.0003833036,0.00033353586,0.0006282791,0.00051194703],"domain_scores_gemma":[0.9989305,0.00015885738,0.000052096053,0.00042140918,0.00004459067,0.00039251195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065752125,0.00012405297,0.00019572771,0.00030971022,0.00017361228,0.000074350486,0.000109962086,0.00005045826,0.000042173542],"category_scores_gemma":[0.000079108744,0.00007738701,0.000028055958,0.000947439,0.000091881375,0.00008810942,0.00002404772,0.00038160893,0.0000400319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014045563,0.0002981397,0.5136594,0.005118247,0.000209502,0.005880409,0.25270143,0.04337799,0.000068550435,0.118524,0.009346208,0.04941158],"study_design_scores_gemma":[0.006534598,0.0025250888,0.48082483,0.0069957045,0.00003604527,0.0008188603,0.0032883247,0.47089365,0.0003091837,0.00138855,0.02574001,0.00064517156],"about_ca_topic_score_codex":0.987791,"about_ca_topic_score_gemma":0.8699887,"teacher_disagreement_score":0.42751566,"about_ca_system_score_codex":0.029691428,"about_ca_system_score_gemma":0.022273751,"threshold_uncertainty_score":0.98326904},"labels":[],"label_agreement":null},{"id":"W4399727620","doi":"10.1080/10428194.2024.2363418","title":"Experience of using venetoclax in relapsed T- cell lymphoma","year":2024,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Venetoclax; Lymphoma; Medicine; Psychology; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.023643846805762852,"score_gpt":0.28762061089524205,"score_spread":0.2639767640894792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399727620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673099,0.014998522,0.000029422772,0.0044694273,0.0016663357,0.002421613,0.0002261076,0.0004422476,0.008436448],"genre_scores_gemma":[0.88076586,0.003206406,0.001993872,0.090130836,0.0051771956,0.00067212124,0.00085731345,0.0014287531,0.015767679],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9860014,0.000504793,0.0033329078,0.0036246914,0.0032068877,0.003329354],"domain_scores_gemma":[0.99326,0.0010603684,0.0010517595,0.0032625068,0.00047510926,0.00089024747],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009795227,0.0024442177,0.003982706,0.0025466557,0.0003059592,0.00031838648,0.0015576719,0.004829224,0.00024712173],"category_scores_gemma":[0.00035629285,0.0023764146,0.001145188,0.0028099362,0.0018417839,0.00039522062,0.0013223158,0.0015114185,0.00031867938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0059275213,0.0009938335,0.001957736,0.03990857,0.002057768,0.12353212,0.015385923,0.0012048926,0.021374697,0.00039853842,0.70946556,0.07779282],"study_design_scores_gemma":[0.1341996,0.0010974124,0.002060598,0.012630659,0.0020859342,0.019359784,0.0017462922,0.1674927,0.029809657,0.000888777,0.6234144,0.0052141515],"about_ca_topic_score_codex":0.021635309,"about_ca_topic_score_gemma":0.000119935044,"teacher_disagreement_score":0.16628781,"about_ca_system_score_codex":0.25320816,"about_ca_system_score_gemma":0.117753856,"threshold_uncertainty_score":0.9988295},"labels":[],"label_agreement":null},{"id":"W4399749722","doi":"10.3390/cells13121041","title":"Lysosome-Disrupting Agents in Combination with Venetoclax Increase Apoptotic Response in Primary Chronic Lymphocytic Leukemia (CLL) Cells Mediated by Lysosomal Cathepsin D Release and Inhibition of Autophagy","year":2024,"lang":"en","type":"article","venue":"Cells","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; Alberta Health Services; University of Alberta","funders":"National Institute of Environmental Health Sciences","keywords":"Venetoclax; Obinutuzumab; Chronic lymphocytic leukemia; Autophagy; Cancer research; Cathepsin B; Programmed cell death; Cathepsin; Lysosome; Ibrutinib; Vorinostat; Apoptosis; Carfilzomib; Leukemia; Biology; Pharmacology; Chemistry; Immunology; Bortezomib; Multiple myeloma; Biochemistry; Histone deacetylase","score_opus":0.011176934341745442,"score_gpt":0.263320768523523,"score_spread":0.25214383418177755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399749722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956613,0.0025717577,0.00002834285,0.000060097016,0.00010870194,0.0011629553,0.000041549833,0.00009392316,0.00027137488],"genre_scores_gemma":[0.9983402,0.00042950117,0.00012682276,0.00010227088,0.00004733406,0.00007510356,0.00021764259,0.00008736767,0.0005737531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99675286,0.00042424875,0.00075625617,0.0006982184,0.0007289751,0.00063944387],"domain_scores_gemma":[0.9981386,0.0009279146,0.000117484844,0.0004326144,0.000088976034,0.00029440096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011927165,0.00033942406,0.000605156,0.0008172811,0.000046307898,0.000053051237,0.00012965931,0.00026981777,0.00008250159],"category_scores_gemma":[0.00024016423,0.00031498828,0.000070251015,0.0012250285,0.0003039771,0.00024585112,0.00013473957,0.0004510868,0.0000664553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006326615,0.00020842582,0.000247029,0.0038736688,0.000074408585,0.0033769119,0.0013859072,0.0025948086,0.97951466,0.000019826904,0.0006171164,0.0017606502],"study_design_scores_gemma":[0.038686533,0.0015867545,0.004410126,0.003959174,0.00013078432,0.00024476633,0.00017859637,0.4067716,0.5432815,0.000042109783,0.00026552053,0.00044255407],"about_ca_topic_score_codex":0.0028095068,"about_ca_topic_score_gemma":0.00008110868,"teacher_disagreement_score":0.43623316,"about_ca_system_score_codex":0.114603244,"about_ca_system_score_gemma":0.029812688,"threshold_uncertainty_score":0.9999302},"labels":[],"label_agreement":null},{"id":"W4399787675","doi":"10.1093/neuonc/noae064.161","title":"TRLS-08. ROVER: A PHASE 1/2 TRIAL IN PROGRESS OF AVAPRITINIB IN PEDIATRIC PATIENTS WITH SOLID TUMORS DEPENDENT ON KIT OR PDGFRA SIGNALING","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"PDGFRA; Cancer research; Medicine; Internal medicine; Oncology","score_opus":0.03006075930259937,"score_gpt":0.37202751995279526,"score_spread":0.3419667606501959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399787675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955952,0.00021698837,0.0000045903826,0.00039805088,0.00049525144,0.002458877,0.000024091469,0.000057448593,0.0007494602],"genre_scores_gemma":[0.99873996,0.000066495675,0.000099869176,0.00025095328,0.00048347955,0.00020086851,0.000029259025,0.000064864784,0.000064256164],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965871,0.00033412545,0.00087726914,0.0006826835,0.00084395375,0.00067485165],"domain_scores_gemma":[0.9977942,0.0013756062,0.00016454063,0.0003484185,0.00010747272,0.00020973285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006414945,0.00026332928,0.00083086564,0.0008487095,0.000025977844,0.000023229355,0.0002240006,0.0002365401,0.0002197795],"category_scores_gemma":[0.0008029319,0.00019373091,0.00009174534,0.00097543537,0.00015510051,0.00009024065,0.000121878045,0.00086008455,0.00005052271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7628812,0.023379909,0.027702602,0.0037388941,0.0002026569,0.055971973,0.004202611,0.0010808229,0.009536425,0.00016487917,0.0024839218,0.10865409],"study_design_scores_gemma":[0.8912848,0.078622974,0.0012231626,0.0008309436,0.00025884222,0.00035355016,0.00025012338,0.010238722,0.012789284,0.000044763052,0.0036314903,0.00047135254],"about_ca_topic_score_codex":0.00010008942,"about_ca_topic_score_gemma":0.00015178016,"teacher_disagreement_score":0.12840357,"about_ca_system_score_codex":0.006350927,"about_ca_system_score_gemma":0.012346128,"threshold_uncertainty_score":0.9974635},"labels":[],"label_agreement":null},{"id":"W4400109243","doi":"10.1200/jco.2024.42.16_suppl.7007","title":"Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and <i>TP53</i> mutations in the SYMPATICO study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Ven; Venetoclax; Ibrutinib; Mantle cell lymphoma; Internal medicine; Hazard ratio; Population; Phases of clinical research; Bendamustine; Neutropenia; Gastroenterology; Oncology; Rituximab; Toxicity; Lymphoma; Confidence interval; Leukemia; Chronic lymphocytic leukemia","score_opus":0.04951817572860148,"score_gpt":0.41891423260579713,"score_spread":0.3693960568771957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658036,0.00087895885,0.000009608366,0.00080155965,0.00014533012,0.00067383924,0.0000033049284,0.0000029401465,0.000904106],"genre_scores_gemma":[0.99915814,0.00025503826,0.00021528594,0.00022057533,0.0000906868,0.000005775743,0.0000021285493,0.000012729387,0.000039624167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707204,0.0005490341,0.0015218302,0.00018550799,0.00047417908,0.00019739024],"domain_scores_gemma":[0.9934097,0.005806589,0.0003538608,0.00016932336,0.00013737268,0.0001231699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031172363,0.00010537289,0.000843549,0.00018723337,0.000022596996,0.000014144138,0.00013411668,0.00015529523,0.000016046552],"category_scores_gemma":[0.0011666124,0.000058767513,0.000068818765,0.00031086267,0.00030624343,0.00007260517,0.00007219536,0.00054141553,0.0000027732178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044055205,0.014014692,0.6094974,0.00081850507,0.0006616743,0.005454222,0.012372017,0.0006474827,0.000030339126,0.00022322222,0.00082354585,0.3114017],"study_design_scores_gemma":[0.11745843,0.018121732,0.85802126,0.0003885233,0.00024355484,0.00020966704,0.00090998673,0.0023441133,0.000009024277,0.00010122041,0.0021228557,0.00006963853],"about_ca_topic_score_codex":0.00010756579,"about_ca_topic_score_gemma":0.00012778852,"teacher_disagreement_score":0.31133205,"about_ca_system_score_codex":0.0020519358,"about_ca_system_score_gemma":0.010047965,"threshold_uncertainty_score":0.99556416},"labels":[],"label_agreement":null},{"id":"W4400264619","doi":"10.1200/jco.2024.42.16_suppl.e19026","title":"Therapeutic utilization in chronic lymphocytic leukemia: A cross-sectional analysis of the Lymphoma Coalition’s 2022 Global Patient Survey.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pharmacyclics","keywords":"Medicine; Chronic lymphocytic leukemia; Cross-sectional study; Lymphoma; Internal medicine; Oncology; Leukemia; Pathology","score_opus":0.18705913266333404,"score_gpt":0.5106715889936395,"score_spread":0.32361245633030544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400264619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175143,0.0047118478,0.0003456559,0.00033372315,0.0018190804,0.00028465944,0.000056883724,0.000012697667,0.0006840118],"genre_scores_gemma":[0.997721,0.0009565159,0.000046847457,0.00060177717,0.00041930517,0.000008875394,0.000024787529,0.00001702734,0.000203853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930918,0.0015364147,0.0034110423,0.00035395724,0.0012425663,0.00036419247],"domain_scores_gemma":[0.99346334,0.004042051,0.0010610125,0.0004004045,0.00080096244,0.00023222476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006946774,0.00017820323,0.0014160227,0.0004221142,0.0000537671,0.00003720997,0.0003529775,0.0005682927,0.0004398391],"category_scores_gemma":[0.0037904712,0.000113772985,0.0011701118,0.0028209595,0.00056702935,0.00013861089,0.0001503605,0.0006311393,0.000015539166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0059154825,0.00083829736,0.8593321,0.00028610916,0.0061780894,0.00092682714,0.00016771337,0.027337093,0.00013053729,0.0010449616,0.0018035534,0.096039236],"study_design_scores_gemma":[0.011676993,0.0026178826,0.8239588,0.00012869202,0.0008484672,0.00041636708,0.000030891453,0.15659901,0.00004764815,0.0004418172,0.003152158,0.00008126767],"about_ca_topic_score_codex":0.0014744108,"about_ca_topic_score_gemma":0.0022531452,"teacher_disagreement_score":0.12926191,"about_ca_system_score_codex":0.15326989,"about_ca_system_score_gemma":0.16703174,"threshold_uncertainty_score":0.84998053},"labels":[],"label_agreement":null},{"id":"W4400567135","doi":"10.21037/cco-24-18","title":"Zolbetuximab on the SPOTLIGHT—a light spot?","year":2024,"lang":"en","type":"editorial","venue":"Chinese Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Optometry; Ophthalmology","score_opus":0.051910506124716406,"score_gpt":0.462847934052958,"score_spread":0.41093742792824156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400567135","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00979634,0.0018696397,0.0000020441166,0.03639089,0.85890204,0.0013360771,0.00010194252,0.00030645673,0.09129457],"genre_scores_gemma":[0.006220818,0.0020815842,0.00006486632,0.0028866355,0.9351528,0.00021882266,0.0003742352,0.00028555514,0.05271463],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918329,0.00091839477,0.0022395563,0.0017672193,0.0021589382,0.0010829912],"domain_scores_gemma":[0.95386547,0.041701615,0.0004959708,0.0025348966,0.00062273885,0.00077933405],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0053345105,0.00089557166,0.0030887823,0.0003262926,0.00016938889,0.000097142976,0.0013181557,0.0052537555,0.0013889464],"category_scores_gemma":[0.04603647,0.000440574,0.0015272915,0.00079168583,0.0009787394,0.00004636497,0.0009553294,0.01014954,0.015792249],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025918612,0.0011304053,0.000022095453,0.0004597101,0.0007543903,0.005577477,0.00009211681,5.806716e-7,0.000009937855,0.00048539968,0.98258007,0.006295972],"study_design_scores_gemma":[0.014248922,0.005408998,0.000056285957,0.0006550315,0.00059601705,0.00014100468,0.000016893071,0.00039271964,0.00001160502,0.0022163526,0.97584647,0.00040972864],"about_ca_topic_score_codex":0.00011730999,"about_ca_topic_score_gemma":0.000117230586,"teacher_disagreement_score":0.07625081,"about_ca_system_score_codex":0.016663045,"about_ca_system_score_gemma":0.051567823,"threshold_uncertainty_score":0.9998046},"labels":[],"label_agreement":null},{"id":"W4400732442","doi":"10.1152/ajpendo.00205.2024","title":"Bruton’s tyrosine kinase (BTK) inhibitors alter blood glucose and insulin in obese mice but reduce inflammation independent of BTK","year":2024,"lang":"en","type":"article","venue":"American Journal of Physiology-Endocrinology and Metabolism","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University","funders":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","keywords":"Bruton's tyrosine kinase; Tyrosine kinase; Inflammation; Insulin; Endocrinology; Internal medicine; Medicine; Receptor","score_opus":0.009728455205949173,"score_gpt":0.2788586415744425,"score_spread":0.26913018636849334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400732442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623526,0.03585784,0.0000058702876,0.0011200658,0.00037399353,0.0002118882,0.000009620065,0.000016745787,0.000051418327],"genre_scores_gemma":[0.9814112,0.017398402,0.00038926673,0.00014687625,0.0005539252,0.000011059773,0.000005578232,0.000025113963,0.000058558508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772906,0.00032748497,0.00082890224,0.00036905444,0.00026950912,0.00047599332],"domain_scores_gemma":[0.9986726,0.00031608425,0.00036756217,0.00023099853,0.00020223449,0.00021051802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041434358,0.00024315788,0.0009697852,0.0007312405,0.00004343619,0.000014200211,0.00015108888,0.00011621527,0.000032681317],"category_scores_gemma":[0.00031882082,0.00019062815,0.00012218425,0.0004437006,0.001138303,0.00021324104,0.00017152552,0.00088499225,0.000005276312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012518297,0.00021337238,0.0005243823,0.0002689239,0.0003992468,0.0006469066,0.0011259202,0.000018834386,0.94541305,0.0008121478,0.000068629866,0.049256735],"study_design_scores_gemma":[0.020992305,0.0020957452,0.15233327,0.0007183309,0.0007845835,0.009472736,0.0017504538,0.0005412157,0.8066577,0.0013709269,0.002936316,0.00034646498],"about_ca_topic_score_codex":0.00047917626,"about_ca_topic_score_gemma":0.000021519156,"teacher_disagreement_score":0.15180889,"about_ca_system_score_codex":0.00031262808,"about_ca_system_score_gemma":0.0014717975,"threshold_uncertainty_score":0.77735907},"labels":[],"label_agreement":null},{"id":"W4401001314","doi":"10.14740/jmc4274","title":"Anterior Uveitis After Discontinuation of Janus Kinase Inhibitor, Ruxolitinib","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ruxolitinib; Discontinuation; Janus kinase inhibitor; Janus kinase; Tofacitinib; Dermatology; Pharmacology; Internal medicine; Receptor","score_opus":0.02336655579634733,"score_gpt":0.34980794173129043,"score_spread":0.3264413859349431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401001314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798374,0.014699953,0.00015348889,0.0040520756,0.00073412753,0.00012553742,0.000017024135,0.000014146403,0.00036624513],"genre_scores_gemma":[0.9965229,0.00093967497,0.00014933785,0.00025943344,0.0017487316,0.000005612225,0.0000034842963,0.000021175296,0.00034962903],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99650323,0.0000873631,0.00083125033,0.00014384332,0.002181355,0.00025296718],"domain_scores_gemma":[0.9983657,0.00060698757,0.00014289876,0.00016690002,0.00024393997,0.00047355492],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012029723,0.00012076037,0.00046785845,0.00027957905,0.000017274047,0.00003848048,0.00014030332,0.00015643795,0.002108369],"category_scores_gemma":[0.003182421,0.00008027915,0.00026775803,0.00023162313,0.00024975004,0.00016349225,0.00007917309,0.00050447404,0.000028724511],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060166134,0.0017305412,0.0036379974,0.005213455,0.0008597118,0.45770794,0.0029478432,0.0000024768503,0.007349997,0.00058026524,0.058602806,0.45535037],"study_design_scores_gemma":[0.10306011,0.020546176,0.03195296,0.0951982,0.0022595061,0.38300613,0.0045007677,0.016314354,0.11561722,0.00092029624,0.22543816,0.0011861331],"about_ca_topic_score_codex":0.0001551655,"about_ca_topic_score_gemma":0.000024962497,"teacher_disagreement_score":0.45416424,"about_ca_system_score_codex":0.0014539211,"about_ca_system_score_gemma":0.0064734872,"threshold_uncertainty_score":0.99915886},"labels":[],"label_agreement":null},{"id":"W4401049590","doi":"10.1038/s41598-024-68431-6","title":"Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis","year":2024,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Canadian Centre for Applied Research in Cancer Control; Simon Fraser University","funders":"Genome British Columbia; Genome Canada","keywords":"Medicine; Chronic lymphocytic leukemia; Cost effectiveness; Health care; Quality-adjusted life year; Cost-effectiveness analysis; Oncology; Internal medicine; Leukemia; Risk analysis (engineering)","score_opus":0.06233983254127708,"score_gpt":0.37277578339447837,"score_spread":0.3104359508532013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401049590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868291,0.0032296893,0.0006716671,0.00003538508,0.0027133015,0.0021971483,0.0000061050537,0.00032849022,0.0039890874],"genre_scores_gemma":[0.98914224,0.00006434899,0.00012501565,0.000016718363,0.00018619047,0.00048911496,0.0002071629,0.000057267975,0.009711946],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.994423,0.0002846323,0.0009839208,0.0019517463,0.0013394889,0.0010172431],"domain_scores_gemma":[0.9969617,0.00044946058,0.00014172461,0.0018158044,0.00022735947,0.00040391876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004961682,0.00039255657,0.0008870208,0.0020117348,0.00020430448,0.0005337284,0.00016158167,0.00020525474,0.00044061049],"category_scores_gemma":[0.00046758013,0.0003129585,0.00057719054,0.0061827153,0.00041160444,0.0002694294,0.00013121557,0.00026573517,0.00021872374],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00043448334,0.00016124615,0.008485084,0.0043743146,0.006755176,0.256126,0.004117574,0.43969184,0.22376855,0.0005447692,0.0071371305,0.048403837],"study_design_scores_gemma":[0.005161315,0.00024883496,0.0010623351,0.0010345492,0.0014237404,0.0059471857,0.0001214441,0.89936256,0.06461869,0.0007290219,0.019847289,0.00044305783],"about_ca_topic_score_codex":0.011675018,"about_ca_topic_score_gemma":0.0014863841,"teacher_disagreement_score":0.4866936,"about_ca_system_score_codex":0.69002247,"about_ca_system_score_gemma":0.20332885,"threshold_uncertainty_score":0.9999322},"labels":[],"label_agreement":null},{"id":"W4401091657","doi":"10.1080/14796694.2024.2355079","title":"Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"BeiGene","keywords":"Ibrutinib; Medicine; Nausea; Quality of life (healthcare); Waldenstrom macroglobulinemia; Vomiting; Internal medicine; Oncology; Population; Randomized controlled trial; Lymphoma; Nursing; Leukemia","score_opus":0.03221721800051643,"score_gpt":0.3559625639351439,"score_spread":0.3237453459346275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401091657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95833284,0.0017445415,0.0000027649023,0.034153007,0.0011574083,0.0015116028,0.00021569246,0.00005153649,0.0028306204],"genre_scores_gemma":[0.99677646,0.00008964732,0.0002660452,0.00090485887,0.0011162707,0.000030592375,0.00043984407,0.000027069405,0.0003491851],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968207,0.000611861,0.0011291174,0.00045444732,0.00058228953,0.00040158292],"domain_scores_gemma":[0.9974106,0.0014756311,0.0002438677,0.0005554386,0.00012816585,0.00018628886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014245193,0.00016894337,0.00083328347,0.00008900224,0.000042430413,0.00001269948,0.0002250397,0.0003867891,0.00020680121],"category_scores_gemma":[0.0009218569,0.00009528875,0.00009501254,0.00052663055,0.00021381184,0.000040567702,0.00011013659,0.0008624655,0.00006722463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.7379433,0.0021814525,0.015252527,0.0006432163,0.001085722,0.0007831942,0.008909107,0.000043368967,0.00005278055,0.0018823844,0.14241299,0.08880999],"study_design_scores_gemma":[0.75889885,0.009490939,0.16197217,0.0006223799,0.00011261889,0.000040495608,0.0009137818,0.0006142601,0.00003122079,0.0002932249,0.066748366,0.00026168543],"about_ca_topic_score_codex":0.012682995,"about_ca_topic_score_gemma":0.005010491,"teacher_disagreement_score":0.14671963,"about_ca_system_score_codex":0.0070617334,"about_ca_system_score_gemma":0.016419275,"threshold_uncertainty_score":0.99675},"labels":[],"label_agreement":null},{"id":"W4401178837","doi":"10.1182/blood.2024024631","title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Obinutuzumab; Ven; IGHV@; Venetoclax; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Chlorambucil; Population; Leukemia; Oncology; Chemotherapy; Cyclophosphamide","score_opus":0.018333618527857205,"score_gpt":0.32429537085623106,"score_spread":0.30596175232837386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401178837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98237914,0.0058201486,0.00004560082,0.000090217196,0.0003641304,0.009530389,0.00011349758,0.00022377961,0.0014331188],"genre_scores_gemma":[0.99382174,0.0002593298,0.00010868193,0.00003366494,0.0004960115,0.0007787231,0.00006475614,0.00009713682,0.0043399474],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99642247,0.00034207795,0.0010162763,0.00071672676,0.0008147335,0.0006877188],"domain_scores_gemma":[0.9966815,0.0014446264,0.00017836377,0.0012530125,0.00024745718,0.00019503146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018256826,0.00035136056,0.0011369165,0.00020680773,0.00012008563,0.000066530505,0.0004371714,0.0002007445,0.00006723021],"category_scores_gemma":[0.0016663218,0.00021723186,0.0006248971,0.0008027323,0.00035648656,0.00007666454,0.00019079408,0.00032494322,0.00006634901],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8673036,0.005365117,0.00006924615,0.015084217,0.020517012,0.0027704602,0.016456427,0.0039654984,0.024423348,0.0018348142,0.027070096,0.015140128],"study_design_scores_gemma":[0.9036418,0.0022285164,0.00001045065,0.0010524964,0.0031321764,0.0002652797,0.0002005585,0.06348215,0.02364224,0.00011282223,0.0020234734,0.00020800535],"about_ca_topic_score_codex":0.0017087762,"about_ca_topic_score_gemma":0.000114704875,"teacher_disagreement_score":0.059516653,"about_ca_system_score_codex":0.08144873,"about_ca_system_score_gemma":0.09500516,"threshold_uncertainty_score":0.9220774},"labels":[],"label_agreement":null},{"id":"W4401323243","doi":"10.2139/ssrn.4903912","title":"The Association of Pre-Existing Autoimmune Disease with Immune Related Adverse Events Secondary to Immune Checkpoint Inhibition Therapy in a Large Multi-Centre UK Population","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Adverse effect; Immune system; Medicine; Disease; Autoimmune disease; Immunology; Immune checkpoint; Association (psychology); Population; Immunotherapy; Internal medicine; Psychology; Environmental health","score_opus":0.009770690427458083,"score_gpt":0.28908382497453505,"score_spread":0.27931313454707696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401323243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97963053,0.015422693,0.00022542616,0.0020051461,0.00038304998,0.002114282,0.00003798418,0.0000663848,0.0001144949],"genre_scores_gemma":[0.98826146,0.0057529337,0.000097617245,0.00002258777,0.00014180162,0.00007942924,0.00037091345,0.00011334735,0.0051599317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936827,0.00046766564,0.001703129,0.00057237543,0.0012498166,0.0023243113],"domain_scores_gemma":[0.99735945,0.0001671706,0.0011689869,0.0006591864,0.0004496284,0.0001956021],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006878003,0.0004556009,0.0007564966,0.00049354555,0.0002631828,0.00005103749,0.00031259804,0.00039254045,0.000052179064],"category_scores_gemma":[0.00081867527,0.00032932873,0.00047776682,0.00065243436,0.000043450484,0.0001036449,0.0005047091,0.0072817677,0.000025738393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13988179,0.015386348,0.38581556,0.012217491,0.04012042,0.0032369469,0.053866833,0.05786864,0.06371617,0.027463645,0.00024059886,0.20018555],"study_design_scores_gemma":[0.086751014,0.001665062,0.7919868,0.015190433,0.0009607922,0.0007325518,0.0037350254,0.047198582,0.0015353515,0.048743676,0.00023281328,0.0012678844],"about_ca_topic_score_codex":0.0018347794,"about_ca_topic_score_gemma":0.0023585255,"teacher_disagreement_score":0.40617126,"about_ca_system_score_codex":0.07206719,"about_ca_system_score_gemma":0.032615718,"threshold_uncertainty_score":0.9999159},"labels":[],"label_agreement":null},{"id":"W4401352446","doi":"10.3390/onco4030013","title":"A Systems Biology Analysis of Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Onco","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Chronic lymphocytic leukemia; Biology; Leukemia; Computational biology; Evolutionary biology; Cancer research; Immunology","score_opus":0.022717864935592302,"score_gpt":0.35146867658159825,"score_spread":0.32875081164600595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401352446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934268,0.037557684,0.0015442626,0.0001083034,0.00083279895,0.0005653966,0.00006347435,0.00028965663,0.024770439],"genre_scores_gemma":[0.99341077,0.0004763666,0.000056631565,0.00003566423,0.00034261408,0.000039404105,0.00008645719,0.00003060701,0.005521466],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99833816,0.00006976921,0.00042626986,0.00041066643,0.00034896244,0.0004061725],"domain_scores_gemma":[0.9987562,0.00031582956,0.000053999203,0.0006073999,0.00010406369,0.00016254272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041374186,0.00015808483,0.0006863162,0.0008285987,0.00002773252,0.000029916111,0.0001687575,0.00018221467,0.00044763417],"category_scores_gemma":[0.00010883153,0.00012244923,0.00032360732,0.002167336,0.00019132816,0.000047088655,0.000085961125,0.0001719474,0.0003027632],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0023642941,0.0006216186,0.007365251,0.039074536,0.110218525,0.0115784155,0.0059467163,0.11181925,0.25755063,0.17216043,0.07993308,0.20136727],"study_design_scores_gemma":[0.0035252802,0.00040806975,0.00020002428,0.0003858082,0.0023451096,0.00021509783,0.000063809464,0.95141,0.0012852562,0.00004018184,0.039991982,0.00012940899],"about_ca_topic_score_codex":0.0052459063,"about_ca_topic_score_gemma":0.00009285914,"teacher_disagreement_score":0.8395907,"about_ca_system_score_codex":0.13369623,"about_ca_system_score_gemma":0.048200086,"threshold_uncertainty_score":0.95719576},"labels":[],"label_agreement":null},{"id":"W4401452359","doi":"10.1073/pnas.2405644121","title":"IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia","year":2024,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society; Swedish Orphan Biovitrum; Leukemia and Lymphoma Society","keywords":"Anakinra; Chronic lymphocytic leukemia; Downregulation and upregulation; Immunology; Receptor; Cytokine; Tumor necrosis factor alpha; Medicine; Cancer research; Signal transduction; Inflammation; NF-κB; Leukemia; Biology; Internal medicine; Cell biology","score_opus":0.0811092333051565,"score_gpt":0.36616946962963265,"score_spread":0.28506023632447614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401452359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948583,0.0015907107,0.0000016756834,0.0015584189,0.000026820502,0.00037161217,0.000017610575,0.000027945382,0.0015468814],"genre_scores_gemma":[0.9985455,0.000100828605,0.00051693735,0.00008150433,0.00025598556,0.00001878646,8.245187e-7,0.000011779317,0.00046784536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99745554,0.000016909644,0.0005482377,0.00040172748,0.0012934168,0.00028419498],"domain_scores_gemma":[0.9986586,0.00091884815,0.00017817508,0.000016020113,0.00014906036,0.000079309335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027863989,0.00013515535,0.0002848664,0.0005185813,0.0001314821,0.0000572278,0.00042139294,0.00016297653,0.000018889585],"category_scores_gemma":[0.0013948256,0.00009452541,0.000079231766,0.001409139,0.00093143486,0.00045846234,0.00021085108,0.00041754454,0.000007542639],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013500916,0.000017392227,0.0387009,0.003201499,0.00008088631,4.723387e-7,0.0016269445,0.00033632573,0.91076374,0.042000223,0.0013969861,0.0017396288],"study_design_scores_gemma":[0.006423353,0.00072566076,0.13761377,0.00978611,0.00016522726,0.0002611388,0.00087146217,0.06834469,0.6862804,0.08830466,0.00074725505,0.000476263],"about_ca_topic_score_codex":0.00007786834,"about_ca_topic_score_gemma":2.1290421e-7,"teacher_disagreement_score":0.22448333,"about_ca_system_score_codex":0.02025505,"about_ca_system_score_gemma":0.0047326507,"threshold_uncertainty_score":0.983506},"labels":[],"label_agreement":null},{"id":"W4401543054","doi":"10.1186/s12885-024-12745-1","title":"Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"Eli Lilly and Company","keywords":"Chronic lymphocytic leukemia; Mantle cell lymphoma; Medicine; Surgical oncology; Refractory (planetary science); Young adult; Lymphoma; Leukemia; Internal medicine; Oncology; Family medicine","score_opus":0.031936024021827845,"score_gpt":0.3767231491470536,"score_spread":0.3447871251252258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401543054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9059728,0.09232808,0.000047807927,0.000016052101,0.00013740617,0.001306517,0.000026797281,0.000034241366,0.00013029386],"genre_scores_gemma":[0.9813976,0.017571723,0.0000703704,0.000037098238,0.000058994032,0.00021150289,0.000011488481,0.000051430645,0.0005897729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747384,0.00048461565,0.0004995525,0.00068736105,0.00033780382,0.0005168309],"domain_scores_gemma":[0.9938408,0.0055122552,0.000093713345,0.00032790613,0.00009224788,0.00013307211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014685726,0.0003282746,0.00059828814,0.00054128614,0.00011860864,0.0001390186,0.00010649277,0.00011891854,0.000037209025],"category_scores_gemma":[0.00029162594,0.00021907676,0.000042754797,0.00096613314,0.00040526784,0.00013916317,0.00017897441,0.00024072752,0.000010230145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015481302,0.0032214324,0.6360358,0.008199642,0.0012931391,0.004192627,0.19257656,0.01156348,0.0006288251,0.00050307764,0.0011045751,0.12519954],"study_design_scores_gemma":[0.086391635,0.0010086923,0.4798328,0.0032595557,0.00016742616,0.00016905602,0.0037185405,0.42420587,0.00013157715,0.0001555528,0.0006015251,0.0003577623],"about_ca_topic_score_codex":0.058750153,"about_ca_topic_score_gemma":0.055277027,"teacher_disagreement_score":0.4126424,"about_ca_system_score_codex":0.048234157,"about_ca_system_score_gemma":0.014887448,"threshold_uncertainty_score":0.9906972},"labels":[],"label_agreement":null},{"id":"W4401715291","doi":"10.1111/bjh.19706","title":"<scp>PembroWM</scp> : A phase <scp>II</scp> trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Merck Sharp and Dohme","keywords":"Medicine; Rituximab; Internal medicine; Chemoimmunotherapy; Tolerability; Refractory (planetary science); Oncology; Pembrolizumab; Gastroenterology; Phases of clinical research; Clinical trial; Adverse effect; Immunotherapy; Lymphoma","score_opus":0.01723235397203564,"score_gpt":0.3111091422852666,"score_spread":0.29387678831323094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401715291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652907,0.031163635,0.0000424275,0.0011912194,0.00053042924,0.0009609089,0.000039653005,0.000032499276,0.000748519],"genre_scores_gemma":[0.9939706,0.0041575534,0.0004204435,0.00034132885,0.00035273822,0.000018550048,0.000007467814,0.00006574913,0.00066558656],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99588203,0.00047909378,0.0016112668,0.0005230668,0.00073406624,0.00077048736],"domain_scores_gemma":[0.99503887,0.0032938365,0.00038688703,0.000361624,0.00028633897,0.0006324534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016829888,0.00032350974,0.0015755888,0.00055624836,0.00016847126,0.000117574986,0.0003795228,0.00037809968,0.000018664638],"category_scores_gemma":[0.007508528,0.00027768133,0.00023384298,0.0006355864,0.00095728965,0.0001823962,0.00038815563,0.0015071656,0.00001495466],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036703214,0.0059277997,0.0007866862,0.0058455924,0.0023968413,0.6552085,0.01670251,0.00009567094,0.008674497,0.003722104,0.11655273,0.14738382],"study_design_scores_gemma":[0.34867483,0.0046788044,0.0013278316,0.0036485684,0.0004256529,0.59691715,0.000941958,0.0014855987,0.0027393147,0.00080819934,0.038248662,0.00010339045],"about_ca_topic_score_codex":0.000395656,"about_ca_topic_score_gemma":0.00016859513,"teacher_disagreement_score":0.31197163,"about_ca_system_score_codex":0.0013674439,"about_ca_system_score_gemma":0.0047686133,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W4401727780","doi":"10.1017/cjn.2024.275","title":"Multifocal Myelitis Associated with Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Chronic lymphocytic leukemia; Content (measure theory); Medicine; Leukemia; Immunology; Mathematics","score_opus":0.03287649231867627,"score_gpt":0.2926933986898358,"score_spread":0.2598169063711595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401727780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98749447,0.0055728,0.000051095605,0.0021989583,0.00091023854,0.00025840037,0.0000147818755,0.00006792724,0.0034313113],"genre_scores_gemma":[0.9962504,0.00055314,0.0006186204,0.0017014069,0.0006321603,0.000004944106,0.0000010000829,0.000030211771,0.00020813024],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9937327,0.00072354503,0.00096979097,0.0007768878,0.0016509785,0.0021461244],"domain_scores_gemma":[0.9942915,0.0013277848,0.00038247343,0.00021630686,0.00063224277,0.0031496861],"candidate_categories":["metaepi_narrow","sts","scholarly_communication"],"consensus_categories":["sts"],"category_scores_codex":[0.0046058972,0.00044119311,0.00073178246,0.0014913923,0.0019304362,0.001244953,0.0015627389,0.00031247817,0.00042246486],"category_scores_gemma":[0.0035797544,0.0002643873,0.00034768978,0.0027194289,0.010750313,0.001021851,0.00007982629,0.001973776,0.000020615607],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012512261,0.000094919174,0.3178388,0.00030444973,0.0005735143,0.54878527,0.002047848,0.0633715,0.00043211065,0.0046789404,0.011123651,0.04949779],"study_design_scores_gemma":[0.005532051,0.23590259,0.06318019,0.0014076321,0.00036572255,0.45152605,0.00028247992,0.21985424,0.00041809422,0.0066101435,0.013944905,0.0009759026],"about_ca_topic_score_codex":0.005786015,"about_ca_topic_score_gemma":0.09789991,"teacher_disagreement_score":0.25465858,"about_ca_system_score_codex":0.04050503,"about_ca_system_score_gemma":0.18769546,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W4401856276","doi":"10.3390/medicina60081351","title":"Atypical Plasma Cell Leukemia Mistaken for Acute Leukemia: A Case Report","year":2024,"lang":"en","type":"article","venue":"Medicina","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Immunophenotyping; Pathology; Plasma cell leukemia; Leukemia; Medicine; Plasma cell; Plasma cell neoplasm; Lymphoma; Acute leukemia; Immunology; Cancer research; Flow cytometry; Bone marrow; Plasmacytoma","score_opus":0.02671336792111543,"score_gpt":0.3475898540394737,"score_spread":0.32087648611835823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401856276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663324,0.0022056673,0.0032981215,0.0025225289,0.0015248957,0.0019772607,0.00006313678,0.00055305107,0.021522949],"genre_scores_gemma":[0.9474003,0.00012102271,0.0022484309,0.0005169346,0.0018057346,0.00019562594,0.00019605929,0.00013846037,0.047377437],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9964074,0.000045639987,0.0007462338,0.0009340852,0.00093467935,0.00093196204],"domain_scores_gemma":[0.9973488,0.0007269243,0.00008193674,0.00093981693,0.00021243586,0.0006901228],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009743261,0.00037268104,0.000721323,0.00027424828,0.00015981028,0.00007022771,0.00021420796,0.00039716292,0.000445024],"category_scores_gemma":[0.00068472116,0.00028870918,0.00032186892,0.00050063635,0.00033087333,0.00010891027,0.00012240603,0.00079374097,0.00035473894],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011803631,0.0000647447,0.000020968253,0.0016704291,0.00045922116,0.7722814,0.0011600745,0.00001589553,0.0033656918,0.00020378361,0.21031497,0.009262457],"study_design_scores_gemma":[0.016776301,0.0010544809,0.000025539153,0.0006835872,0.0013207865,0.56294847,0.0006922894,0.14701177,0.016236302,0.00019014352,0.25267878,0.000381529],"about_ca_topic_score_codex":0.0005966503,"about_ca_topic_score_gemma":0.00006991796,"teacher_disagreement_score":0.20933293,"about_ca_system_score_codex":0.03396909,"about_ca_system_score_gemma":0.02584635,"threshold_uncertainty_score":0.9999565},"labels":[],"label_agreement":null},{"id":"W4401876091","doi":"10.1016/s2152-2650(24)01267-9","title":"CLL-186 Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Interim; Interim analysis; Leukemia; Oncology; Internal medicine; Clinical trial","score_opus":0.036451679534786716,"score_gpt":0.3677568805810247,"score_spread":0.33130520104623795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991654,0.0009364279,0.000057845657,0.00011734919,0.0009668429,0.0033641844,0.00046872016,0.0004366785,0.0019979933],"genre_scores_gemma":[0.9961128,0.00019828981,0.0003449633,0.0002639389,0.0009991751,0.00015573826,0.0007903236,0.00027375962,0.0008609794],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98728895,0.00092737895,0.0048881248,0.002804931,0.0024446405,0.0016459782],"domain_scores_gemma":[0.9903984,0.004448613,0.00069040863,0.0028720107,0.00056707585,0.0010235129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028261272,0.0010850364,0.0027526594,0.0007377392,0.00015402597,0.00016721814,0.0011565053,0.001016481,0.00035166758],"category_scores_gemma":[0.0029862374,0.000865197,0.0006177586,0.0023311952,0.0010460105,0.00046725,0.00083411665,0.0013426418,0.0005431206],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12105972,0.0068124053,0.031113021,0.001384696,0.003501656,0.007470269,0.003806085,0.00087043125,0.00045708552,0.00015774582,0.0071250442,0.81624186],"study_design_scores_gemma":[0.30919966,0.01605204,0.60081196,0.004177903,0.0007422542,0.00011049121,0.000438911,0.06013375,0.00054204115,0.00008178751,0.006708572,0.0010006515],"about_ca_topic_score_codex":0.007980486,"about_ca_topic_score_gemma":0.0009057936,"teacher_disagreement_score":0.81524116,"about_ca_system_score_codex":0.18187475,"about_ca_system_score_gemma":0.09575624,"threshold_uncertainty_score":0.9993799},"labels":[],"label_agreement":null},{"id":"W4401876784","doi":"10.1016/s2152-2650(24)00886-3","title":"Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ibrutinib; Mantle cell lymphoma; Venetoclax; Medicine; Lymphoma; Oncology; Cancer research; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02119839309452989,"score_gpt":0.3245038845152921,"score_spread":0.30330549142076224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944972,0.0012609016,0.000009908722,0.00015172317,0.00013082776,0.0025801645,0.000027780776,0.000051895568,0.0012896045],"genre_scores_gemma":[0.9990294,0.00016143493,0.00016189356,0.00017372821,0.0000876112,0.0001045293,0.000057145407,0.00006581807,0.00015843046],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99567145,0.000522334,0.0014391205,0.00089577615,0.000871067,0.00060023135],"domain_scores_gemma":[0.9950957,0.0035773567,0.00016742942,0.0008037617,0.00012179137,0.00023401118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016784074,0.0003743837,0.0009307763,0.00033470718,0.00009953256,0.000089979956,0.00033023788,0.00027418934,0.000029967598],"category_scores_gemma":[0.00064878917,0.0002532683,0.00010764539,0.0010038167,0.000743243,0.00015772632,0.00026725527,0.00035337528,0.0000338874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011226146,0.0036764243,0.3857888,0.001323225,0.00038565422,0.002064994,0.009259555,0.0002175933,0.000026596716,0.0004697983,0.00032420878,0.585237],"study_design_scores_gemma":[0.07872399,0.00229342,0.90584856,0.0006831707,0.0002043978,0.000090737456,0.00090905,0.010299641,0.00003312637,0.000098104574,0.00056879135,0.0002470118],"about_ca_topic_score_codex":0.00072564086,"about_ca_topic_score_gemma":0.00016781136,"teacher_disagreement_score":0.58498996,"about_ca_system_score_codex":0.00874829,"about_ca_system_score_gemma":0.010148646,"threshold_uncertainty_score":0.99999195},"labels":[],"label_agreement":null},{"id":"W4401876864","doi":"10.1016/s2152-2650(24)01317-x","title":"CML-425 Dose-Optimization Study of 3 Starting Doses of Ponatinib: Long-Term Results From the OPTIC Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ponatinib; Term (time); Oncology; Internal medicine; Dasatinib; Myeloid leukemia; Imatinib","score_opus":0.07699754545939498,"score_gpt":0.39549925531204505,"score_spread":0.3185017098526501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930805,0.0009931563,0.00013121853,0.000413261,0.001222044,0.0024962188,0.00012777906,0.0001861612,0.0013496652],"genre_scores_gemma":[0.99599546,0.00020638498,0.0011097295,0.00014920147,0.0015844256,0.000075523,0.00019764925,0.000104638726,0.0005770029],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920705,0.00081844133,0.0036837154,0.0011563797,0.001630356,0.00064060424],"domain_scores_gemma":[0.98510426,0.011603706,0.00073884573,0.0017404748,0.00048141158,0.00033131367],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035174452,0.00043834752,0.0013490767,0.00021173849,0.0001462706,0.00010615487,0.0007640186,0.00045083987,0.00019965776],"category_scores_gemma":[0.009301702,0.00030204706,0.00057906023,0.0010479558,0.0007133149,0.00020887957,0.00050068024,0.00056156865,0.000078470744],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.23822992,0.0057921363,0.01341468,0.0011117168,0.003724287,0.0032964023,0.0079497695,0.005129608,0.0010439614,0.00040107506,0.0057803723,0.71412605],"study_design_scores_gemma":[0.442436,0.009617305,0.39446643,0.0024756028,0.001581243,0.00011660942,0.0018245237,0.14479557,0.0014483256,0.00020446385,0.00039836642,0.0006355745],"about_ca_topic_score_codex":0.0016731381,"about_ca_topic_score_gemma":0.00009250921,"teacher_disagreement_score":0.7134905,"about_ca_system_score_codex":0.0055766725,"about_ca_system_score_gemma":0.013955304,"threshold_uncertainty_score":0.99994314},"labels":[],"label_agreement":null},{"id":"W4401878297","doi":"10.1016/s2152-2650(24)00620-7","title":"Dose-Optimization Study of 3 Starting Doses of Ponatinib: Long-Term Results From the OPTIC Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ponatinib; Term (time); Oncology; Internal medicine; Dasatinib","score_opus":0.0779670394684194,"score_gpt":0.395783041813826,"score_spread":0.31781600234540663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367917,0.0008798289,0.000119860466,0.0003725379,0.001105878,0.0023108898,0.000110441644,0.00016725136,0.0012541686],"genre_scores_gemma":[0.9963891,0.00017545701,0.001039611,0.00012989693,0.0014465797,0.0000660747,0.00017246343,0.00009307837,0.00048774978],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927307,0.00073841267,0.0034177594,0.0010465123,0.0014958483,0.0005707642],"domain_scores_gemma":[0.9860238,0.010981123,0.0006675673,0.0015963836,0.00043528815,0.0002958288],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032611121,0.00038996153,0.0012271119,0.0001882583,0.00012838068,0.00009291821,0.0006844897,0.0004000699,0.00017812838],"category_scores_gemma":[0.008571846,0.00026570875,0.00052774453,0.00096113764,0.00065369764,0.00018718302,0.00044411496,0.00050077506,0.000067855886],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.23444702,0.0052283495,0.012770555,0.00094966026,0.0033593427,0.0029514257,0.0073480806,0.004637677,0.00090179825,0.00035452028,0.0047347117,0.72231686],"study_design_scores_gemma":[0.43607214,0.009321929,0.40751624,0.0022169477,0.00140505,0.00010315466,0.0016529451,0.13937284,0.001294786,0.00017845718,0.0003173848,0.00054812466],"about_ca_topic_score_codex":0.001539441,"about_ca_topic_score_gemma":0.000081233884,"teacher_disagreement_score":0.72176874,"about_ca_system_score_codex":0.0050474075,"about_ca_system_score_gemma":0.013054314,"threshold_uncertainty_score":0.9999795},"labels":[],"label_agreement":null},{"id":"W4401878485","doi":"10.1016/s2152-2650(24)00565-2","title":"Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Lymphoma; Leukemia","score_opus":0.04363337908781482,"score_gpt":0.33270961913500186,"score_spread":0.289076240047187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993752,0.0012137789,0.000024611712,0.00006662329,0.00077762426,0.0034502868,0.00023936972,0.00012050949,0.00035521184],"genre_scores_gemma":[0.9956227,0.0002629867,0.00017987125,0.00010599922,0.0002180158,0.00025045933,0.00014557327,0.00019303638,0.0030213655],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9894514,0.00067224354,0.0040998952,0.0019711393,0.0024008416,0.0014044787],"domain_scores_gemma":[0.9911499,0.0031844636,0.0009034103,0.0032313778,0.00081685185,0.00071400026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019340485,0.0009824989,0.003700685,0.0017155723,0.000127162,0.000063109,0.0014204379,0.0006848006,0.0003237538],"category_scores_gemma":[0.0018610937,0.00071519695,0.0017997179,0.0074379737,0.0011590642,0.00017701037,0.00082564796,0.0003036842,0.000108607666],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034028098,0.0025346274,0.29280233,0.002047177,0.013487639,0.0011850689,0.00424616,0.014106234,0.00016109983,0.00016546677,0.0008028462,0.63443327],"study_design_scores_gemma":[0.09683895,0.009382097,0.8276249,0.0017776178,0.0049947402,0.00004439614,0.00026284563,0.05494986,0.0015152176,0.000030046933,0.001961013,0.00061827793],"about_ca_topic_score_codex":0.0113315545,"about_ca_topic_score_gemma":0.0058158017,"teacher_disagreement_score":0.633815,"about_ca_system_score_codex":0.18878855,"about_ca_system_score_gemma":0.09878354,"threshold_uncertainty_score":0.9995299},"labels":[],"label_agreement":null},{"id":"W4401878668","doi":"10.1016/s2152-2650(24)00573-1","title":"Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Interim; Chronic lymphocytic leukemia; Interim analysis; Oncology; Internal medicine; Leukemia; Clinical trial; Law","score_opus":0.03560786394838119,"score_gpt":0.3675414112304161,"score_spread":0.33193354728203495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921288,0.00097086054,0.00006246266,0.00010469262,0.0009981154,0.003104564,0.00034506657,0.00039743676,0.0018880356],"genre_scores_gemma":[0.996526,0.00019213767,0.0002936402,0.00022730495,0.00088744774,0.00013766851,0.00070482184,0.00024529672,0.00078569993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9882941,0.0008270668,0.004534534,0.0025895217,0.002261256,0.0014935205],"domain_scores_gemma":[0.9911529,0.004142889,0.00061494444,0.002649888,0.00051264704,0.00092676346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025749642,0.0009844577,0.0025612446,0.0006893843,0.00013552833,0.0001483872,0.001041008,0.00090581586,0.00032716364],"category_scores_gemma":[0.0027365205,0.00077925035,0.00056121394,0.0021859775,0.00094926084,0.0004276085,0.00074426696,0.0012004995,0.0004839248],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10452981,0.005742875,0.032209765,0.0011111002,0.0029554116,0.007248282,0.003165863,0.0008609398,0.00029081816,0.00011590399,0.005456451,0.8363128],"study_design_scores_gemma":[0.2839254,0.014189695,0.6284736,0.003101673,0.00067227543,0.000090005226,0.00035117535,0.062085953,0.00041344613,0.00006815856,0.005793698,0.0008349506],"about_ca_topic_score_codex":0.007700028,"about_ca_topic_score_gemma":0.0009651208,"teacher_disagreement_score":0.8354778,"about_ca_system_score_codex":0.18008341,"about_ca_system_score_gemma":0.09383873,"threshold_uncertainty_score":0.9994658},"labels":[],"label_agreement":null},{"id":"W4401913715","doi":"10.1002/hem3.146","title":"Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Genentech; F. Hoffmann-La Roche; AbbVie","keywords":"Rituximab; Hypogammaglobulinemia; Medicine; Internal medicine; Chronic lymphocytic leukemia; CD20; Gastroenterology; Venetoclax; Refractory (planetary science); Antibody; Immune system; Immunology; Bendamustine; Leukemia","score_opus":0.011910906799896948,"score_gpt":0.264676162737068,"score_spread":0.2527652559371711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401913715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774057,0.018520782,0.00004001884,0.000057804966,0.00024463507,0.0016736202,0.000011285138,0.00026791243,0.0017781977],"genre_scores_gemma":[0.9929657,0.00043608944,0.00018675059,0.000054256365,0.0002531977,0.0003399459,0.00016610275,0.00018889472,0.0054090912],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99667406,0.00006731395,0.00040277062,0.00088150695,0.00096665515,0.0010077219],"domain_scores_gemma":[0.99846274,0.000162808,0.00008080688,0.0009157386,0.00007947517,0.00029845518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017230157,0.0005525552,0.0008627923,0.0002175571,0.00010472288,0.000097725235,0.00020449689,0.0002470552,0.00052456814],"category_scores_gemma":[0.000022151953,0.00037396266,0.00017302645,0.0007340726,0.00016417357,0.00022859644,0.00009745519,0.00041172854,0.00030584412],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.05933584,0.0038028199,0.1860128,0.033836592,0.016762374,0.1492266,0.022463981,0.016480166,0.0054586786,0.0005552728,0.0034212663,0.5026436],"study_design_scores_gemma":[0.69308317,0.047687065,0.10031217,0.035761625,0.0027315528,0.0016925952,0.00088414934,0.082854405,0.012488263,0.00003868931,0.018948687,0.0035176356],"about_ca_topic_score_codex":0.0025766818,"about_ca_topic_score_gemma":0.0028941508,"teacher_disagreement_score":0.63374734,"about_ca_system_score_codex":0.41068113,"about_ca_system_score_gemma":0.06669948,"threshold_uncertainty_score":0.99987125},"labels":[],"label_agreement":null},{"id":"W4402440559","doi":"10.4049/immunohorizons.2400045","title":"Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid Cells","year":2024,"lang":"en","type":"article","venue":"ImmunoHorizons","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Bruton's tyrosine kinase; Proinflammatory cytokine; Myeloid; Immune system; Tyrosine kinase; Biology; Cancer research; Cytokine; Immunology; Cell biology; Inflammation; Signal transduction","score_opus":0.012664210129693446,"score_gpt":0.273559266843263,"score_spread":0.26089505671356955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402440559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826478,0.016010445,0.00007247719,0.00026573366,0.00010229733,0.0006435973,0.000028096576,0.00011369138,0.00011587249],"genre_scores_gemma":[0.9964274,0.002779824,0.00012301274,0.000021385007,0.00017455195,0.000048583424,0.00011820544,0.000054625612,0.00025241473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832535,0.00010155423,0.000394579,0.00045783212,0.00032379662,0.00039690762],"domain_scores_gemma":[0.9992016,0.00016157287,0.000054857883,0.0002795236,0.00006722404,0.00023523445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030320225,0.00027127736,0.0004139491,0.00042876686,0.00013736158,0.00022903996,0.000050202438,0.0001659278,0.000054555647],"category_scores_gemma":[0.00010853082,0.00024262338,0.000054150252,0.00027254276,0.00024744164,0.00032473003,0.00016647043,0.00029531593,0.000011349599],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017779347,0.000069415626,0.00020511138,0.0005610995,0.00008687281,0.00021757654,0.0006934288,8.9385725e-7,0.99291396,0.00054598536,0.000039660266,0.0044882107],"study_design_scores_gemma":[0.007932389,0.00028701866,0.008598963,0.00061381544,0.00020315307,0.00014863709,0.00022840418,0.001022132,0.9801968,0.00023221604,0.0002953584,0.00024111274],"about_ca_topic_score_codex":0.0021282283,"about_ca_topic_score_gemma":0.00014351888,"teacher_disagreement_score":0.0137796085,"about_ca_system_score_codex":0.0011335172,"about_ca_system_score_gemma":0.000725253,"threshold_uncertainty_score":0.9893894},"labels":[],"label_agreement":null},{"id":"W4402469860","doi":"10.1016/j.cjca.2024.09.010","title":"Mycophenolic Acid for Desmoplakin-Related Cardiomyopathy: A Possible New Arrow in the Quiver","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Quiver; Desmoplakin; Cardiomyopathy; Mycophenolic acid; Internal medicine; Genetics; Pure mathematics; Transplantation","score_opus":0.028253901450336964,"score_gpt":0.29964733461246335,"score_spread":0.2713934331621264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402469860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9247763,0.0365189,0.0027906308,0.009181836,0.0023657964,0.0010729014,0.00004674493,0.00002258389,0.023224303],"genre_scores_gemma":[0.9970505,0.00009618722,0.0001411033,0.0003626077,0.0016081426,0.000012608206,0.0000085722695,0.000029534001,0.00069071224],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984058,0.00016761266,0.0004219101,0.00019194793,0.00021612596,0.00059656816],"domain_scores_gemma":[0.9986387,0.00030634244,0.000057614994,0.00028436817,0.000156575,0.0005564129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001203264,0.00014497785,0.000548155,0.000642348,0.000066023735,0.00005627016,0.00031113063,0.00021201152,0.000047064383],"category_scores_gemma":[0.00048033724,0.00009908386,0.00038157852,0.00050774886,0.0001801146,0.000086419815,0.000012268933,0.0005747413,0.000040040948],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016060856,0.000015609747,0.020446,0.0009902724,0.0047349343,0.06952254,0.020058146,0.007836602,0.0055861827,0.018440071,0.77111995,0.079643585],"study_design_scores_gemma":[0.01679453,0.0013751726,0.014684475,0.00065687945,0.00066598924,0.060196616,0.001235194,0.0015264141,0.00050796475,0.0065209744,0.89549553,0.00034027576],"about_ca_topic_score_codex":0.0038235418,"about_ca_topic_score_gemma":0.0025855382,"teacher_disagreement_score":0.12437555,"about_ca_system_score_codex":0.005160292,"about_ca_system_score_gemma":0.04548496,"threshold_uncertainty_score":0.9986587},"labels":[],"label_agreement":null},{"id":"W4402483853","doi":"10.1155/2024/5556426","title":"Unusual Cases of Monoclonal Gammopathy of Renal Significance","year":2024,"lang":"en","type":"article","venue":"Case Reports in Nephrology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Monoclonal gammopathy; Medicine; Monoclonal gammopathy of undetermined significance; Pathology; Monoclonal; Dermatology; Monoclonal antibody; Immunology; Antibody","score_opus":0.028447243891175603,"score_gpt":0.3347790298679674,"score_spread":0.30633178597679184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402483853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936892,0.0037040613,0.00009267052,0.00014661731,0.00022866814,0.0003410795,0.000013511626,0.000032380412,0.0017518043],"genre_scores_gemma":[0.9989387,0.00009098046,0.0003175249,0.00007834918,0.00015671097,0.000028154747,0.000013442659,0.000024335752,0.0003518071],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9979884,0.00008290382,0.0008527636,0.00042016388,0.00031758522,0.00033819856],"domain_scores_gemma":[0.99851644,0.00059336843,0.00015086688,0.0004937735,0.00013109476,0.000114479524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007042211,0.00014032844,0.0005113388,0.00035950798,0.000013466022,0.000004450577,0.00004347745,0.0001826687,0.00023045509],"category_scores_gemma":[0.0005336093,0.00012242187,0.00012188012,0.00046096268,0.00051562244,0.00004748365,0.00008263653,0.00029274847,0.000005807486],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046537994,0.00014026886,0.00094871176,0.0006307811,0.000104557854,0.96219164,0.00034081133,0.00017214166,0.029512715,0.00056183577,0.0015632919,0.0033678866],"study_design_scores_gemma":[0.0019851772,0.0007945244,0.0005299995,0.00027470986,0.00010408052,0.9440218,0.00012785706,0.0072842543,0.03723194,0.00062554213,0.0068982686,0.000121798956],"about_ca_topic_score_codex":0.0017466886,"about_ca_topic_score_gemma":0.000179768,"teacher_disagreement_score":0.018169772,"about_ca_system_score_codex":0.0015712221,"about_ca_system_score_gemma":0.006643013,"threshold_uncertainty_score":0.9989884},"labels":[],"label_agreement":null},{"id":"W4402507090","doi":"10.1016/j.humimm.2024.110967","title":"Impact of CD36-directed antibodies in a case of stem cell transplantation","year":2024,"lang":"en","type":"article","venue":"Human Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Héma-Québec","funders":"","keywords":"Transplantation; Stem cell; Antibody; CD36; Immunology; Biology; Medicine; Cell biology; Genetics; Internal medicine; Gene","score_opus":0.027534682624414743,"score_gpt":0.35931009785618095,"score_spread":0.33177541523176624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402507090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327105,0.0046925517,0.000009435303,0.000012179438,0.00005339632,0.00022706635,0.000022662694,0.00005217459,0.0016594966],"genre_scores_gemma":[0.99895424,0.00042195467,0.00003971436,0.0000018998253,0.000014497837,0.000008213393,0.000030301668,0.000017076502,0.00051211345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990889,0.000083705825,0.00034460195,0.00017112316,0.00009619575,0.00021551276],"domain_scores_gemma":[0.99947834,0.0001569113,0.00004721805,0.00022351767,0.00006941217,0.00002460262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015506805,0.00009897259,0.0003349635,0.0004428735,0.000017510058,0.0000043684936,0.00006269755,0.00011372097,0.00022110528],"category_scores_gemma":[0.0000083445575,0.000081146405,0.00011130342,0.00029010396,0.0002011957,0.000043327524,0.000021370483,0.00018887325,0.000015255027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010901254,0.00038738543,0.006104343,0.003340105,0.00053132913,0.017683964,0.012317329,0.000031169526,0.9502795,0.0006064056,0.00020718915,0.0074211657],"study_design_scores_gemma":[0.05256603,0.008131799,0.39433116,0.0032360512,0.00064160075,0.04557071,0.002862796,0.010812481,0.4806225,0.00045345575,0.00016024878,0.0006111567],"about_ca_topic_score_codex":0.005613415,"about_ca_topic_score_gemma":0.00031372395,"teacher_disagreement_score":0.46965697,"about_ca_system_score_codex":0.0017372497,"about_ca_system_score_gemma":0.0014514995,"threshold_uncertainty_score":0.84858423},"labels":[],"label_agreement":null},{"id":"W4402558385","doi":"10.1016/j.annonc.2024.08.1362","title":"1305P Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Amgen","keywords":"Medicine; KRAS; Pooled analysis; Clinical trial; Oncology; Term (time); Internal medicine; Cancer; Meta-analysis","score_opus":0.29656837332955427,"score_gpt":0.5859161466639741,"score_spread":0.2893477733344198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98257154,0.0035696772,0.00012738109,0.010077657,0.0008191085,0.0015314791,0.00016119458,0.0001233139,0.0010186401],"genre_scores_gemma":[0.99230564,0.003282386,0.00018878987,0.002378164,0.00044024928,0.00009891301,0.00033371025,0.0000519224,0.0009202574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888149,0.004593756,0.004110858,0.001018448,0.0007118838,0.0007501857],"domain_scores_gemma":[0.963316,0.034015663,0.0006256215,0.0011700159,0.0004671144,0.00040553915],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013806909,0.00038952372,0.00405573,0.0005182209,0.0000532417,0.00004519136,0.0005845691,0.00087553344,0.0010982454],"category_scores_gemma":[0.019230451,0.00023589349,0.0019728208,0.0018118792,0.0008351041,0.00012935589,0.0002661189,0.0012086695,0.00017546963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009710995,0.002101838,0.7458972,0.0000970922,0.018422915,0.0028400274,0.00040278607,0.000064685715,0.00030390383,0.000059383943,0.007711419,0.21238776],"study_design_scores_gemma":[0.03661515,0.0046225283,0.93795663,0.00041422207,0.005926259,0.000049239854,0.00015841777,0.009528394,0.00075695827,0.00031509416,0.0033282598,0.0003288263],"about_ca_topic_score_codex":0.0019564782,"about_ca_topic_score_gemma":0.0025470133,"teacher_disagreement_score":0.21205893,"about_ca_system_score_codex":0.0014605147,"about_ca_system_score_gemma":0.008965818,"threshold_uncertainty_score":0.99981487},"labels":[],"label_agreement":null},{"id":"W4402560060","doi":"10.1016/j.annonc.2024.08.674","title":"607O Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Royal Victoria Hospital","funders":"Seagen; Pfizer","keywords":"Medicine; Interim; Solid tumor; Phase (matter); Internal medicine; Oncology; Nuclear medicine; Cancer","score_opus":0.09569989157081261,"score_gpt":0.4662667078971952,"score_spread":0.3705668163263826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955215,0.00030126199,0.000008937052,0.00034671804,0.00010714827,0.00084174203,0.000045685898,0.000020162892,0.0028068821],"genre_scores_gemma":[0.9994719,0.000037724934,0.00013719009,0.00008083839,0.00004749524,0.000027313456,0.000022465789,0.000030562802,0.00014452904],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973506,0.00020796517,0.0010682746,0.00039670424,0.0005765054,0.00039996015],"domain_scores_gemma":[0.9981764,0.00044252633,0.00030850575,0.00049508613,0.00045535766,0.00012214122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008523394,0.00017831035,0.00094727625,0.0005424015,0.000016174696,0.0000067069377,0.00022630439,0.00012772255,0.000054708886],"category_scores_gemma":[0.0005613021,0.00013628432,0.00008548261,0.0005681774,0.000314681,0.00010881245,0.00019415241,0.00030364897,0.000006121222],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17876025,0.10560401,0.02955795,0.008538871,0.0035797036,0.006910377,0.0856728,0.00076298293,0.03687056,0.00018094557,0.030114587,0.513447],"study_design_scores_gemma":[0.4379981,0.3426369,0.03695355,0.011077815,0.00052025326,0.00019731525,0.011228645,0.012621234,0.13863906,0.00024554494,0.0070939814,0.00078758947],"about_ca_topic_score_codex":0.0012029916,"about_ca_topic_score_gemma":0.00017559214,"teacher_disagreement_score":0.5126594,"about_ca_system_score_codex":0.0010727046,"about_ca_system_score_gemma":0.004445894,"threshold_uncertainty_score":0.7886826},"labels":[],"label_agreement":null},{"id":"W4402568580","doi":"10.1002/hem3.70004","title":"Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier; Genesis Pharma; Associazione Italiana per la Ricerca sul Cancro; Ministerstvo Zdravotnictví Ceské Republiky; Incyte; BeiGene; Genentech; Sunesis; Gilead Sciences; AbbVie; European Commission; Sanofi; Cilag; TG Therapeutics; Amgen; Ministero della Salute; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Leukemia","score_opus":0.09932132477308753,"score_gpt":0.3667572029476041,"score_spread":0.2674358781745166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402568580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98565096,0.0006127217,0.000004234598,0.000033251075,0.000051890187,0.0011897131,0.0000052060777,0.000038740083,0.012413266],"genre_scores_gemma":[0.9993482,0.00012769598,0.000020993231,0.000025981324,0.000120441364,0.000071269205,0.000015462658,0.000046270863,0.00022368667],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997612,0.0005248803,0.0002669031,0.0004336189,0.0008288567,0.00033376555],"domain_scores_gemma":[0.9988928,0.0003763146,0.000040146744,0.000432275,0.00017482755,0.00008367718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000689881,0.00018474866,0.0002389791,0.00015947678,0.00008470195,0.00012526082,0.00018179246,0.000046029327,0.00008820666],"category_scores_gemma":[0.00003350331,0.00010264794,0.000028065733,0.00045245388,0.00023835641,0.0002630247,0.000085113854,0.00034180912,0.000023288552],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021382237,0.0063963355,0.11678916,0.004373075,0.008593673,0.014072032,0.34192792,0.052018367,0.0029993176,0.01634719,0.0004679047,0.41463277],"study_design_scores_gemma":[0.13415821,0.085085884,0.4389759,0.005552242,0.00042160286,0.00026091194,0.1786366,0.1522554,0.0017867011,0.0007189784,0.001226427,0.00092116],"about_ca_topic_score_codex":0.0026638315,"about_ca_topic_score_gemma":0.0015605774,"teacher_disagreement_score":0.4137116,"about_ca_system_score_codex":0.09392512,"about_ca_system_score_gemma":0.021766042,"threshold_uncertainty_score":0.9837796},"labels":[],"label_agreement":null},{"id":"W4402585357","doi":"10.3390/cancers16183182","title":"The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba; McMaster University; Université de Montréal","funders":"AbbVie Canada","keywords":"Venetoclax; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Leukemia; Cancer research","score_opus":0.034302702804985985,"score_gpt":0.3323040246161446,"score_spread":0.2980013218111586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402585357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907407,0.0078925565,0.0000023882733,0.0000026155622,0.00029875958,0.00051152706,0.00002130582,0.000014192607,0.0005159546],"genre_scores_gemma":[0.9984231,0.0011196521,0.000010820481,0.000013037215,0.00014628885,0.000053747397,0.000006991939,0.00003615818,0.00019022387],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99843574,0.000044749548,0.00040607873,0.0003190205,0.00019219029,0.0006022028],"domain_scores_gemma":[0.99916023,0.0002475983,0.000054917393,0.00038532322,0.000018549063,0.00013339297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019540923,0.00019435746,0.00039245762,0.00016468283,0.000040583232,0.00002560608,0.00014921975,0.000063666244,0.000077709505],"category_scores_gemma":[0.000026606063,0.00013678438,0.00011954308,0.0003374854,0.00011214625,0.00006752852,0.000039292536,0.00017093185,0.0000084008825],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00017638529,1.9994358e-8,0.000045405348,0.00015675697,0.00011689936,0.00044597598,0.00040055666,0.9962101,0.001310554,0.00002300635,0.0001543433,0.00096001243],"study_design_scores_gemma":[0.0061463322,0.00023785634,0.00005730208,0.000671449,0.00003342263,0.00015788763,0.000388236,0.9899465,0.0017751969,0.000016725964,0.00045426228,0.000114852104],"about_ca_topic_score_codex":0.9995171,"about_ca_topic_score_gemma":0.9853672,"teacher_disagreement_score":0.014149907,"about_ca_system_score_codex":0.99979615,"about_ca_system_score_gemma":0.9925284,"threshold_uncertainty_score":0.55779046},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":true,"about_ca_topic":true,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"simulation_or_modeling","genre":"empirical","about_ca_system":true,"about_ca_topic":true,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4402630414","doi":"10.1016/s1474-4422(24)00328-4","title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","year":2024,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Merck KGaA; Merck","keywords":"Multiple sclerosis; Medicine; Physical therapy; Phase (matter); Double blind; Physical medicine and rehabilitation; Internal medicine; Alternative medicine; Placebo; Psychiatry; Pathology; Physics","score_opus":0.12333061164448297,"score_gpt":0.3887133599125956,"score_spread":0.2653827482681126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402630414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98066634,0.008753114,0.00019084376,0.00589108,0.00034996725,0.003599331,0.00003847422,0.00007680309,0.0004340281],"genre_scores_gemma":[0.99516827,0.0036138776,0.00015098984,0.00029803277,0.0004915392,0.00011520176,0.000018918518,0.000034802288,0.00010836662],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99649477,0.0011208009,0.000942104,0.000546863,0.000313861,0.00058162573],"domain_scores_gemma":[0.9897202,0.009376334,0.0002006202,0.00047910877,0.00008178335,0.00014193957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036771188,0.00024684027,0.0016451959,0.00028449963,0.0001169346,0.00003484171,0.00016560325,0.00017233218,0.000071552226],"category_scores_gemma":[0.00363493,0.0001596028,0.00017663577,0.00039825062,0.00054882385,0.000115290946,0.00016481243,0.00068194297,0.0000131373035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96666884,0.00031735384,0.00053558673,0.00021716094,0.00038485118,0.000118773714,0.0010037947,0.00022851866,0.01160928,0.0007910793,0.00030677437,0.01781801],"study_design_scores_gemma":[0.8708415,0.00043919368,0.0038452724,0.00021263942,0.0003755931,0.00027757368,0.000044110613,0.12169085,0.00068762514,0.00014785668,0.001315697,0.00012207858],"about_ca_topic_score_codex":0.0005781377,"about_ca_topic_score_gemma":0.00019618477,"teacher_disagreement_score":0.12146233,"about_ca_system_score_codex":0.0005972333,"about_ca_system_score_gemma":0.0010857664,"threshold_uncertainty_score":0.6508413},"labels":[],"label_agreement":null},{"id":"W4402644953","doi":"10.51731/cjht.2024.980","title":"Tralokinumab (Adtralza)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Geology; Geography","score_opus":0.038193925976586225,"score_gpt":0.3464458702473919,"score_spread":0.30825194427080566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402644953","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26775706,0.5253729,0.00055295567,0.20021532,0.0014987431,0.00056254514,0.000024988256,0.00055260723,0.003462841],"genre_scores_gemma":[0.9974605,0.0009979177,0.000539811,0.00034990849,0.00003632756,0.0000034839177,0.0000015631583,0.000022500773,0.0005879947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998464,0.000029121173,0.0004882708,0.00014329041,0.00026462926,0.00061069336],"domain_scores_gemma":[0.999261,0.00007773855,0.00008133424,0.00025949915,0.00012374553,0.00019664226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073657633,0.00011036103,0.0003556446,0.0010514705,0.000106277126,0.00006167575,0.00026192176,0.00015818141,0.000100289],"category_scores_gemma":[0.0005120916,0.00008375241,0.00012221019,0.00057644304,0.00027782004,0.00010810832,0.0000141466935,0.0007340212,0.000055955574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000021889107,0.000011437969,0.00019740869,0.00080093276,0.00010908143,0.0060635577,0.0004231959,0.00000661965,0.00007139707,0.005374188,0.05423248,0.9326878],"study_design_scores_gemma":[0.0021540835,0.0008884469,0.00068095635,0.0016486122,0.00003105559,0.013427184,0.001867235,0.00048667463,0.0012216346,0.004690843,0.97277004,0.00013326402],"about_ca_topic_score_codex":0.0058639217,"about_ca_topic_score_gemma":0.0016043193,"teacher_disagreement_score":0.93255454,"about_ca_system_score_codex":0.013835991,"about_ca_system_score_gemma":0.077052385,"threshold_uncertainty_score":0.9899497},"labels":[],"label_agreement":null},{"id":"W4402663829","doi":"10.51731/cjht.2024.983","title":"Bimekizumab (Bimzelx)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.036952607970333055,"score_gpt":0.3438340482654081,"score_spread":0.306881440295075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402663829","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19477782,0.63416433,0.0005934678,0.16422868,0.0016069859,0.00054299313,0.000021892907,0.00055872597,0.0035050889],"genre_scores_gemma":[0.99724865,0.0012191863,0.0005879022,0.0003791308,0.00003855156,0.0000035835342,0.0000016155387,0.000023675128,0.0004976804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845123,0.000030636507,0.00049844483,0.00014776512,0.00027597873,0.0005959551],"domain_scores_gemma":[0.9991738,0.000093411174,0.00009058911,0.00029182568,0.00015297362,0.00019737029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007658674,0.00011192571,0.0003569519,0.0012365681,0.0001178831,0.0000637418,0.00027070474,0.00016187858,0.00010719639],"category_scores_gemma":[0.0007416573,0.000084311665,0.00011167163,0.0006652828,0.0002913028,0.00010077033,0.000023080254,0.0007310827,0.00009051882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000018558778,0.000008206923,0.00013366318,0.0005942715,0.00008389999,0.0045684143,0.00023815488,0.0000040317914,0.000036954327,0.0035351173,0.04257377,0.94820493],"study_design_scores_gemma":[0.0020886185,0.0008609231,0.00039265468,0.0016675534,0.000028499458,0.012703964,0.0017599978,0.00072845217,0.0009877998,0.004297881,0.97435737,0.00012629268],"about_ca_topic_score_codex":0.0072274357,"about_ca_topic_score_gemma":0.0014355059,"teacher_disagreement_score":0.9480787,"about_ca_system_score_codex":0.01583756,"about_ca_system_score_gemma":0.091070496,"threshold_uncertainty_score":0.9993835},"labels":[],"label_agreement":null},{"id":"W4402696194","doi":"10.1177/17562864241276204","title":"Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Collaboration On Repair Discoveries; University of British Columbia; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Ibrutinib; Odds ratio; Ofatumumab; Internal medicine; Epilepsy; Oncology; Adverse Event Reporting System; Population; Discontinuation; Adverse effect; Rituximab; Psychiatry; Leukemia; Lymphoma; Chronic lymphocytic leukemia","score_opus":0.07818901370015804,"score_gpt":0.3082756776405036,"score_spread":0.23008666394034558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402696194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772747,0.017673139,0.0007966526,0.0031025347,0.00012520855,0.0008726407,0.000007668567,0.0000666965,0.00008074988],"genre_scores_gemma":[0.9839596,0.01510401,0.00013899108,0.00031585348,0.000051452615,0.00037566441,0.000003510863,0.000025468873,0.000025413388],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987149,0.00010054066,0.00022158581,0.00032952602,0.00031720896,0.00031619647],"domain_scores_gemma":[0.997428,0.0022556644,0.00005275724,0.00017209978,0.000031327556,0.00006016441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034734068,0.00014890834,0.00023679821,0.000084360945,0.000078701785,0.00002663157,0.00010093127,0.000043653985,0.000006295142],"category_scores_gemma":[0.00023270003,0.00008203591,0.000074012016,0.00031063365,0.00026448735,0.00022681484,0.00004122673,0.00023348659,9.893108e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007907979,0.0003602041,0.3597562,0.0013024627,0.0002590995,0.000020957918,0.0026461296,0.0027435026,0.0010606436,0.0034536114,0.000017206023,0.620472],"study_design_scores_gemma":[0.03120102,0.005394804,0.7014284,0.0013293772,0.0005193353,0.000019211644,0.002377411,0.18686287,0.0008108579,0.029620504,0.039631743,0.00080444495],"about_ca_topic_score_codex":0.000014433204,"about_ca_topic_score_gemma":0.00005004484,"teacher_disagreement_score":0.6196676,"about_ca_system_score_codex":0.00027725374,"about_ca_system_score_gemma":0.00018585467,"threshold_uncertainty_score":0.33453274},"labels":[],"label_agreement":null},{"id":"W4402851848","doi":"10.1002/jha2.1009","title":"Concurrent hyperdiploid acute myeloid leukemia and trisomy 12+ chronic lymphocytic leukemia","year":2024,"lang":"en","type":"article","venue":"eJHaem","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Trisomy; Myeloid leukemia; Chronic lymphocytic leukemia; Medicine; Leukemia; Cancer research; Immunology; Biology; Genetics","score_opus":0.02012030499881464,"score_gpt":0.30768720463350746,"score_spread":0.28756689963469284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402851848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9424299,0.04194916,0.0004240468,0.0005351715,0.0014468761,0.0013054606,0.000053165953,0.00089532207,0.010960922],"genre_scores_gemma":[0.9776778,0.0050556236,0.00018123059,0.0003571058,0.0014988784,0.00014965038,0.00009267141,0.00015564014,0.014831386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960954,0.000090044254,0.0006339999,0.0010849222,0.0009714918,0.0011240995],"domain_scores_gemma":[0.99793226,0.00039542813,0.000069640875,0.0008126643,0.00010676702,0.00068322034],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004968393,0.00053457153,0.00080150156,0.00039015026,0.00018996031,0.00022732282,0.000314153,0.00033240058,0.0005817498],"category_scores_gemma":[0.00013929914,0.00044749552,0.0002838801,0.0006032607,0.0005085956,0.00028337436,0.00038487746,0.0007795736,0.0014848422],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011264988,0.00013218157,0.000632787,0.009806932,0.0050561787,0.022794986,0.005396979,0.00063732086,0.061279494,0.008003884,0.18872674,0.696406],"study_design_scores_gemma":[0.0413847,0.0016905072,0.0010639876,0.0023680432,0.0014760719,0.012282354,0.00033073855,0.37349963,0.026039653,0.00031965034,0.53826475,0.0012799194],"about_ca_topic_score_codex":0.0009082208,"about_ca_topic_score_gemma":0.00006983778,"teacher_disagreement_score":0.6951261,"about_ca_system_score_codex":0.2021933,"about_ca_system_score_gemma":0.07334689,"threshold_uncertainty_score":0.9997977},"labels":[],"label_agreement":null},{"id":"W4403036158","doi":"10.1080/10428194.2024.2402814","title":"Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; AbbVie Canada; Pharmacyclics; GlaxoSmithKline; Pfizer","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Lymphoma; Internal medicine; Oncology; Leukemia","score_opus":0.013125910070183586,"score_gpt":0.2702881273349522,"score_spread":0.2571622172647686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403036158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97821164,0.0049953563,0.00006530247,0.00016418104,0.0022849233,0.0038549737,0.00009831119,0.0019036189,0.008421709],"genre_scores_gemma":[0.9840444,0.001491505,0.0011556797,0.0005600842,0.0010253063,0.00081377226,0.0006810476,0.0008910697,0.009337181],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9837715,0.000560897,0.0032080063,0.0045619225,0.0034064355,0.0044912416],"domain_scores_gemma":[0.9922887,0.0012878629,0.0006447041,0.003237033,0.0004824722,0.0020591952],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017012062,0.0029369467,0.0036744017,0.0035236222,0.0008948191,0.0011080651,0.001370527,0.0015261144,0.00023502731],"category_scores_gemma":[0.00039920464,0.0025297012,0.0013245807,0.0054497463,0.0013078535,0.0016931439,0.0009579942,0.0006801815,0.00073275133],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022216825,0.001901468,0.16258186,0.014438845,0.00953045,0.031310067,0.008041684,0.008525841,0.0048351297,0.007609243,0.008011381,0.7209972],"study_design_scores_gemma":[0.2888539,0.0027462393,0.52099717,0.009125885,0.0027898948,0.003998186,0.00082261884,0.144491,0.0048181107,0.000714067,0.014892949,0.0057499562],"about_ca_topic_score_codex":0.037213087,"about_ca_topic_score_gemma":0.0022942196,"teacher_disagreement_score":0.7152473,"about_ca_system_score_codex":0.6244674,"about_ca_system_score_gemma":0.20284642,"threshold_uncertainty_score":0.9999289},"labels":[],"label_agreement":null},{"id":"W4403127906","doi":"10.1186/s13015-024-00267-1","title":"New generalized metric based on branch length distance to compare B cell lineage trees","year":2024,"lang":"en","type":"article","venue":"Algorithms for Molecular Biology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Natural Sciences and Engineering Research Council of Canada; Fonds Québécois de la Recherche sur la Nature et les Technologies; Université de Sherbrooke","keywords":"Metric (unit); Computer science; Lineage (genetic); Combinatorics; Mathematics; Biology; Genetics","score_opus":0.023887407299647584,"score_gpt":0.3531649598430179,"score_spread":0.3292775525433703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403127906","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030554224,0.005550264,0.95784265,0.0022134222,0.0006388261,0.0015290702,0.00017144551,0.00020838917,0.001291706],"genre_scores_gemma":[0.92348367,0.00006860625,0.068481095,0.002409552,0.0005935203,0.00020351603,0.00056084193,0.00010873338,0.0040904814],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979219,0.00008948984,0.00033051535,0.0007466302,0.00028189365,0.0006296035],"domain_scores_gemma":[0.9985077,0.00037863865,0.000034303608,0.0005893447,0.00010717333,0.00038286074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026770637,0.00028405085,0.0005067508,0.00048045386,0.000058318834,0.000040074578,0.0002570598,0.00014438333,0.00013660658],"category_scores_gemma":[0.00020408604,0.00023070489,0.00028513971,0.0009239712,0.00006575566,0.000021186377,0.00006622593,0.00022220782,0.00014316157],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054044686,0.0012228775,0.00029646914,0.0024840042,0.0014266799,0.0031191637,0.0006117457,0.008526041,0.4147099,0.026505418,0.11768027,0.41801295],"study_design_scores_gemma":[0.016563829,0.0020655426,0.000063552194,0.00017087681,0.00017804725,0.00005366309,0.000013896524,0.4244219,0.24284782,0.0003907685,0.31279087,0.00043924034],"about_ca_topic_score_codex":0.00047705712,"about_ca_topic_score_gemma":0.00004219258,"teacher_disagreement_score":0.89292943,"about_ca_system_score_codex":0.0020336336,"about_ca_system_score_gemma":0.002454268,"threshold_uncertainty_score":0.9407872},"labels":[],"label_agreement":null},{"id":"W4403231995","doi":"10.1080/03007995.2024.2409837","title":"Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial","year":2024,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"BeiGene","keywords":"Medicine; Obinutuzumab; Internal medicine; Refractory (planetary science); Oncology; Follicular lymphoma; Lymphoma; Rituximab","score_opus":0.07134928530396044,"score_gpt":0.3822081702828955,"score_spread":0.31085888497893505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403231995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087644,0.0033505568,0.000015861377,0.00083699333,0.0010266033,0.0034016396,0.00012774837,0.00012809117,0.00023606583],"genre_scores_gemma":[0.9951338,0.0024894753,0.000032457665,0.000050995473,0.00048721308,0.0003436404,0.0011653652,0.000086422704,0.00021058883],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99096894,0.00063948607,0.000973214,0.0012152032,0.005053926,0.0011492405],"domain_scores_gemma":[0.99271643,0.0047297264,0.00014229868,0.00104047,0.00043889016,0.00093216123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017491013,0.0004479583,0.00078050693,0.00040136135,0.00025520052,0.00019815551,0.00038548882,0.00037014915,0.00018927218],"category_scores_gemma":[0.0053218007,0.00021268621,0.0001203076,0.0013875341,0.00085695274,0.0002159601,0.00024859997,0.0014622897,0.0000374856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.80577755,0.0011013828,0.003013753,0.00023449506,0.0008144033,0.0013306431,0.0017261298,0.0000060997104,0.0000042846605,0.0000727053,0.004856939,0.18106164],"study_design_scores_gemma":[0.8793908,0.028009696,0.019081611,0.0049532186,0.00010495212,0.000039615024,0.000578112,0.011053147,0.000076759185,0.00005529165,0.056158017,0.0004987791],"about_ca_topic_score_codex":0.0037500714,"about_ca_topic_score_gemma":0.0003520619,"teacher_disagreement_score":0.18056285,"about_ca_system_score_codex":0.019271081,"about_ca_system_score_gemma":0.035166405,"threshold_uncertainty_score":0.9844938},"labels":[],"label_agreement":null},{"id":"W4403497619","doi":"10.3324/haematol.2024.286532","title":"Pirtobrutinib: the ‘brute’ with a softer side","year":2024,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Brute force; Side channel attack; Computer science; Computer security; Cryptography","score_opus":0.02305823980501282,"score_gpt":0.30563447598735743,"score_spread":0.2825762361823446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403497619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84228146,0.006484087,0.0009811211,0.027505385,0.0002741946,0.0012789303,0.000007213813,0.0009553028,0.1202323],"genre_scores_gemma":[0.9923067,0.00007372198,0.00065779407,0.0017006851,0.00012938541,0.00010785597,0.0000059689446,0.000031009546,0.0049868855],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851906,0.00005484506,0.00019272826,0.000359938,0.00044600217,0.00042741996],"domain_scores_gemma":[0.9987895,0.00047441918,0.000022239557,0.00053235056,0.000058846672,0.00012267304],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028299246,0.00016204298,0.000288583,0.00006878789,0.00010070212,0.000087406275,0.00018796102,0.000099362325,0.0006466003],"category_scores_gemma":[0.00017133799,0.00006882632,0.000097760174,0.00037185437,0.00032710633,0.000051749157,0.0001084081,0.00034878764,0.0013685508],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049259914,0.0008689324,0.004099536,0.006063779,0.0024831635,0.15489374,0.0073259464,0.00006106888,0.0028652232,0.16973118,0.5613943,0.08528715],"study_design_scores_gemma":[0.013509812,0.0021517854,0.0037379884,0.0020152077,0.00060388306,0.1072999,0.0011654109,0.024407612,0.011188198,0.005527754,0.8275854,0.00080702343],"about_ca_topic_score_codex":0.000080204205,"about_ca_topic_score_gemma":0.000023465269,"teacher_disagreement_score":0.26619115,"about_ca_system_score_codex":0.0009985446,"about_ca_system_score_gemma":0.002284804,"threshold_uncertainty_score":0.999409},"labels":[],"label_agreement":null},{"id":"W4403544229","doi":"10.51731/cjht.2024.998","title":"Bimekizumab (Bimzelx)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.036952607970333055,"score_gpt":0.3438340482654081,"score_spread":0.306881440295075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403544229","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19477782,0.63416433,0.0005934678,0.16422868,0.0016069859,0.00054299313,0.000021892907,0.00055872597,0.0035050889],"genre_scores_gemma":[0.99724865,0.0012191863,0.0005879022,0.0003791308,0.00003855156,0.0000035835342,0.0000016155387,0.000023675128,0.0004976804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845123,0.000030636507,0.00049844483,0.00014776512,0.00027597873,0.0005959551],"domain_scores_gemma":[0.9991738,0.000093411174,0.00009058911,0.00029182568,0.00015297362,0.00019737029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007658674,0.00011192571,0.0003569519,0.0012365681,0.0001178831,0.0000637418,0.00027070474,0.00016187858,0.00010719639],"category_scores_gemma":[0.0007416573,0.000084311665,0.00011167163,0.0006652828,0.0002913028,0.00010077033,0.000023080254,0.0007310827,0.00009051882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000018558778,0.000008206923,0.00013366318,0.0005942715,0.00008389999,0.0045684143,0.00023815488,0.0000040317914,0.000036954327,0.0035351173,0.04257377,0.94820493],"study_design_scores_gemma":[0.0020886185,0.0008609231,0.00039265468,0.0016675534,0.000028499458,0.012703964,0.0017599978,0.00072845217,0.0009877998,0.004297881,0.97435737,0.00012629268],"about_ca_topic_score_codex":0.0072274357,"about_ca_topic_score_gemma":0.0014355059,"teacher_disagreement_score":0.9480787,"about_ca_system_score_codex":0.01583756,"about_ca_system_score_gemma":0.091070496,"threshold_uncertainty_score":0.9993835},"labels":[],"label_agreement":null},{"id":"W4403568003","doi":"10.52609/jmlph.v4i4.158","title":"Recurrence of Non-Hodgkin Lymphoma at the Insulin Injection Site: Case Report","year":2024,"lang":"en","type":"article","venue":"The Journal of Medicine Law & Public Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Hodgkin lymphoma; Medicine; Lymphoma; Internal medicine; Insulin; Oncology","score_opus":0.055601829845330616,"score_gpt":0.39111785637685426,"score_spread":0.3355160265315236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403568003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7788167,0.02212757,0.0012666828,0.19142576,0.0016358139,0.0007505779,0.000009565593,0.000036753307,0.003930549],"genre_scores_gemma":[0.9909027,0.0028638386,0.000090739246,0.0033188234,0.0017019282,0.00000612116,0.00001166317,0.000036441746,0.001067704],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99499536,0.00072230416,0.0017166829,0.00023290068,0.0017471495,0.00058560015],"domain_scores_gemma":[0.99557114,0.0014547218,0.00083686475,0.0008339109,0.00071752653,0.0005858364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018815909,0.00021264332,0.00072012324,0.00028696272,0.0002998709,0.000027799542,0.0003490137,0.000114238355,0.0003262538],"category_scores_gemma":[0.002060491,0.0000967854,0.00015328672,0.001258041,0.0010331607,0.00020259341,0.00016415147,0.00079762033,0.00002714858],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021914484,0.0006437681,0.00040456292,0.0037802372,0.0009492143,0.09371505,0.03465119,0.00012232926,0.0010557038,0.0038237385,0.39987904,0.45878372],"study_design_scores_gemma":[0.008155337,0.0034472258,0.0005534433,0.0017861855,0.00015889462,0.79160243,0.0020104328,0.0051102857,0.00021791113,0.0001990281,0.1866626,0.0000962329],"about_ca_topic_score_codex":0.012543838,"about_ca_topic_score_gemma":0.0010933833,"teacher_disagreement_score":0.69788736,"about_ca_system_score_codex":0.0095154345,"about_ca_system_score_gemma":0.020665132,"threshold_uncertainty_score":0.99428684},"labels":[],"label_agreement":null},{"id":"W4403572946","doi":"10.14740/jh1310","title":"Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Histiocytic/Dendritic Cell Sarcoma","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Histiocytic sarcoma; Lymphoma; Pathology; Transformation (genetics); Histiocyte; Leukemia; Cancer research; Immunology; Biology; Gene","score_opus":0.0185611222461653,"score_gpt":0.29162616287169124,"score_spread":0.27306504062552595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403572946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677116,0.016876917,0.008548374,0.00066671055,0.0013283858,0.0007296317,0.00001456594,0.00009615822,0.00402761],"genre_scores_gemma":[0.99623597,0.00056486775,0.0013703115,0.00029957673,0.0004377644,0.000021662887,0.000010154869,0.000093728115,0.00096595805],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99548435,0.00017730052,0.002032982,0.00041950037,0.0010065429,0.00087929814],"domain_scores_gemma":[0.99707186,0.00075449364,0.00037524026,0.00058610504,0.0005924096,0.0006199085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009564746,0.00041649365,0.0014604109,0.0014005641,0.00007783801,0.00005649312,0.0005200104,0.00037959614,0.00030146955],"category_scores_gemma":[0.00036626688,0.00035228656,0.0005955486,0.0009601773,0.0002865398,0.0002743962,0.00010267088,0.00037418635,0.00038356602],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019726234,0.0027432302,0.0005158792,0.12833352,0.00641591,0.102268875,0.024703491,0.028655237,0.31884193,0.11770805,0.06869248,0.18139514],"study_design_scores_gemma":[0.06893739,0.007818443,0.00021714135,0.0072535505,0.0017911759,0.21872838,0.0010506918,0.28471607,0.37636876,0.002198248,0.02993984,0.0009803181],"about_ca_topic_score_codex":0.0002881552,"about_ca_topic_score_gemma":0.00003769021,"teacher_disagreement_score":0.2560608,"about_ca_system_score_codex":0.16256277,"about_ca_system_score_gemma":0.09548722,"threshold_uncertainty_score":0.9998929},"labels":[],"label_agreement":null},{"id":"W4403597428","doi":"10.58931/cht.2022.1s0628","title":"Safety and tolerability of Bruton's tyrosine kinase inhibitors in the treatment of Waldenström macroglobulinemia","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tolerability; Macroglobulinemia; Waldenstrom macroglobulinemia; Bruton's tyrosine kinase; Medicine; Ibrutinib; Tyrosine kinase; Internal medicine; Cancer research; Oncology; Dermatology; Pharmacology; Adverse effect; Leukemia; Lymphoma; Multiple myeloma; Chronic lymphocytic leukemia","score_opus":0.013813099664741544,"score_gpt":0.27124554376102017,"score_spread":0.25743244409627863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403597428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906277,0.0029573273,8.5169694e-7,0.0042857984,0.0000869217,0.00065012265,0.00011183602,0.0000059998897,0.0012734442],"genre_scores_gemma":[0.99924165,0.00012285444,0.000049808175,0.0002595202,0.000022436283,0.00005493942,0.0000386024,0.000011573045,0.00019858983],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984878,0.00019686764,0.00045156814,0.00026258317,0.00022839525,0.00037281733],"domain_scores_gemma":[0.998864,0.00028736884,0.0000830006,0.0004875322,0.000056391436,0.00022168233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039302936,0.00013056096,0.00053731265,0.00021632067,0.00009247992,0.0000026492612,0.00013989328,0.00008921845,0.00043072834],"category_scores_gemma":[0.00012984466,0.000099063785,0.000073882955,0.000379999,0.00038745019,0.00001624673,0.000041349296,0.00017108639,0.000002162988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004194052,0.003412664,0.83971363,0.002016932,0.00053032767,0.015467956,0.029516086,0.00040539293,0.0029547913,0.026603172,0.012379507,0.06280551],"study_design_scores_gemma":[0.1253345,0.013650337,0.23181458,0.000600488,0.00072353263,0.031843074,0.017310979,0.008934534,0.07743349,0.0017519586,0.48912504,0.0014774749],"about_ca_topic_score_codex":0.13096893,"about_ca_topic_score_gemma":0.09240528,"teacher_disagreement_score":0.607899,"about_ca_system_score_codex":0.0072055366,"about_ca_system_score_gemma":0.0061375434,"threshold_uncertainty_score":0.99949676},"labels":[],"label_agreement":null},{"id":"W4403622129","doi":"10.58931/cht.2024.3255","title":"Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia After BTK Inhibitor and/or BCL-2 Inhibitor Failure","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Refractory (planetary science); Bruton's tyrosine kinase; Ibrutinib; Medicine; Internal medicine; Cancer research; Leukemia; Biology; Receptor","score_opus":0.01358765583586513,"score_gpt":0.2729650758220165,"score_spread":0.2593774199861514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538855,0.040897835,0.0000072477346,0.0017948156,0.00078849256,0.0010302089,0.00010775344,0.00015166002,0.0013364913],"genre_scores_gemma":[0.9906664,0.0010257929,0.00014777879,0.00025801692,0.00058632786,0.00025986542,0.00005189594,0.00010358795,0.006900343],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712443,0.00009630818,0.0006198994,0.0007880077,0.00033375647,0.0010375812],"domain_scores_gemma":[0.997513,0.00039791752,0.000068314686,0.0007321585,0.000111675974,0.0011769626],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000150662,0.0004398678,0.0009118543,0.0007641605,0.00009781616,0.000044972217,0.00014523993,0.00062774273,0.0015069565],"category_scores_gemma":[0.00016100056,0.00033388982,0.00020876886,0.0005019986,0.000575234,0.00014677057,0.000059089187,0.0003127424,0.0004311373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010603076,0.00092963903,0.022695247,0.04031239,0.0082929265,0.3484657,0.02738172,0.00012447119,0.01867801,0.025936887,0.34095728,0.15562262],"study_design_scores_gemma":[0.041471384,0.006624513,0.001068971,0.0038301412,0.0009562179,0.035834108,0.000623049,0.017395101,0.03065663,0.00021313061,0.8600493,0.0012774693],"about_ca_topic_score_codex":0.04040812,"about_ca_topic_score_gemma":0.13303275,"teacher_disagreement_score":0.51909196,"about_ca_system_score_codex":0.141673,"about_ca_system_score_gemma":0.1243766,"threshold_uncertainty_score":0.9999113},"labels":[],"label_agreement":null},{"id":"W4403622168","doi":"10.58931/cht.2024.3s01-244","title":"Navigating the Paradigm Shift in Chronic Lymphocytic Leukemia Treatment from Chemotherapy to Targeted Therapies","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Paradigm shift; Chronic lymphocytic leukemia; Chemotherapy; Medicine; Oncology; Leukemia; Intensive care medicine; Internal medicine; Philosophy","score_opus":0.018349464783164363,"score_gpt":0.312699512954759,"score_spread":0.29435004817159466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9479456,0.026046878,0.00004338643,0.02363926,0.00036977557,0.0012083873,0.000052641244,0.00014419027,0.0005498874],"genre_scores_gemma":[0.99542,0.0003493967,0.000097811404,0.0029981048,0.00031210255,0.00033091148,0.00007817315,0.000084540414,0.00032895466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974242,0.00012850517,0.00043063416,0.0006693219,0.0002514909,0.0010958568],"domain_scores_gemma":[0.9978934,0.00061108876,0.0000335451,0.0007699893,0.00002074451,0.00067122927],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025848762,0.00035083308,0.0006003808,0.00021502019,0.0001539814,0.000086091,0.00031775047,0.00028555427,0.0010525801],"category_scores_gemma":[0.0000784795,0.00024230253,0.00014971088,0.0007352429,0.00023042264,0.00006853705,0.00003276353,0.0005085681,0.00075158814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0022446495,0.00024825244,0.022382887,0.002415773,0.008764965,0.087222636,0.25091165,0.00707164,0.008654127,0.11257474,0.06987533,0.42763335],"study_design_scores_gemma":[0.0537272,0.0025686515,0.019111423,0.007036763,0.0004900409,0.005718998,0.0029266549,0.22803657,0.03244804,0.02109341,0.624287,0.002555222],"about_ca_topic_score_codex":0.53317404,"about_ca_topic_score_gemma":0.4561262,"teacher_disagreement_score":0.5544117,"about_ca_system_score_codex":0.22865666,"about_ca_system_score_gemma":0.09330642,"threshold_uncertainty_score":0.9998606},"labels":[],"label_agreement":null},{"id":"W4403738904","doi":"10.1080/10428194.2024.2416577","title":"Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"BeiGene","keywords":"Ibrutinib; Rituximab; Refractory (planetary science); Medicine; Lymphoma; Internal medicine; Leukemia; Biology","score_opus":0.02549745069079592,"score_gpt":0.28914271282788556,"score_spread":0.26364526213708966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403738904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651709,0.019289358,0.0001581097,0.00032504348,0.0017899595,0.0017646535,0.00024153048,0.0006822999,0.01057815],"genre_scores_gemma":[0.9907939,0.0030173576,0.0015513866,0.00032059406,0.0008530661,0.00026536823,0.00034105766,0.00042426994,0.0024330085],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98853934,0.0006198194,0.002713491,0.0029374317,0.0021982244,0.0029916833],"domain_scores_gemma":[0.99297494,0.0024989673,0.0006416999,0.002016331,0.00032034205,0.0015477],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018217199,0.0018702113,0.0033176842,0.002107615,0.0005644509,0.00040767205,0.0009727722,0.0016096379,0.0003101046],"category_scores_gemma":[0.00046609898,0.0018242572,0.000659675,0.0027279388,0.0021542949,0.00077891693,0.0010541047,0.0008396921,0.00030726637],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.049536016,0.0069884155,0.018706402,0.017824166,0.004775266,0.022764409,0.021744264,0.00040845343,0.015866203,0.010676636,0.022187345,0.8085224],"study_design_scores_gemma":[0.5406765,0.00505073,0.19076471,0.010230438,0.0027944227,0.015987169,0.0080733085,0.09464446,0.020909024,0.0008976913,0.104467474,0.0055040917],"about_ca_topic_score_codex":0.028149603,"about_ca_topic_score_gemma":0.002219849,"teacher_disagreement_score":0.80301833,"about_ca_system_score_codex":0.074667916,"about_ca_system_score_gemma":0.04673162,"threshold_uncertainty_score":0.9996865},"labels":[],"label_agreement":null},{"id":"W4403830885","doi":"10.1681/asn.20242g7j152m","title":"Zanubrutinib for the Treatment of Primary Membranous Nephropathy (PMN): Results of a Single-Arm Feasibility Study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Membranous nephropathy; Urology; Intensive care medicine; Internal medicine; Oncology; Glomerulonephritis; Kidney","score_opus":0.06059301835501221,"score_gpt":0.3494563330625205,"score_spread":0.28886331470750826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403830885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895496,0.0028321506,0.00013756381,0.0057611843,0.00019369397,0.0013516855,0.00005983752,0.000009756159,0.00010456995],"genre_scores_gemma":[0.9960995,0.0011427411,0.0013835826,0.00079667434,0.00034707706,0.000014791749,0.0000019033463,0.000028913171,0.00018485913],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99718016,0.0003133696,0.0011933484,0.0002572566,0.0007161935,0.00033965317],"domain_scores_gemma":[0.99471164,0.0026428916,0.0012707727,0.00078210735,0.0004991452,0.000093429066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015790705,0.00020405659,0.0012207342,0.00007585997,0.00007456348,0.0000082933475,0.00047632406,0.00007715452,0.0000139450685],"category_scores_gemma":[0.00024671172,0.00010259273,0.0013726046,0.0005825446,0.0018990685,0.000045650777,0.00011397673,0.00027071786,6.4255204e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06794733,0.03417612,0.0037868498,0.0021393313,0.015834315,0.00015733283,0.06836343,0.00060194917,0.65150726,0.000042701933,0.05067544,0.10476794],"study_design_scores_gemma":[0.16954643,0.3522235,0.2072406,0.0010043493,0.011047075,0.0043785735,0.057671264,0.016027225,0.06495844,0.00091071456,0.114265524,0.00072635245],"about_ca_topic_score_codex":0.0008867749,"about_ca_topic_score_gemma":0.00003182771,"teacher_disagreement_score":0.5865488,"about_ca_system_score_codex":0.0038032036,"about_ca_system_score_gemma":0.0045746816,"threshold_uncertainty_score":0.9945245},"labels":[],"label_agreement":null},{"id":"W4403845046","doi":"10.1186/s12974-024-03267-5","title":"Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways","year":2024,"lang":"en","type":"article","venue":"Journal of Neuroinflammation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; F. Hoffmann-La Roche; Roche; U.S. Department of Defense","keywords":"Bruton's tyrosine kinase; Microglia; Neuroinflammation; Signal transduction; Biology; Cell biology; Chemokine; Tyrosine kinase; Immunology; Immune system; Inflammation; Cancer research","score_opus":0.029609915301054026,"score_gpt":0.3030447887922316,"score_spread":0.2734348734911776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403845046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962662,0.0007894624,0.00022362168,0.0009480055,0.000719032,0.00027416955,0.00000786828,0.000079524216,0.00069212617],"genre_scores_gemma":[0.9960557,0.00003945297,0.00030669314,0.000034574008,0.0028957478,0.0000036287647,0.0000163991,0.00005389617,0.0005938767],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973946,0.000099418656,0.0009994042,0.00025169487,0.00091330195,0.00034155787],"domain_scores_gemma":[0.9986189,0.00022111899,0.00028724843,0.0002500523,0.00036498508,0.000257668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000838979,0.0002116192,0.0003843405,0.0004495563,0.00012818766,0.00019142244,0.00015878289,0.000118151656,0.00016568709],"category_scores_gemma":[0.0004685954,0.00017258756,0.00029144873,0.00035173123,0.00008461091,0.00029810573,0.00007097749,0.0006536083,0.000054783617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029553362,0.000094159375,0.00008543475,0.00040894013,0.00006841933,0.006156421,0.00044897763,0.00008886286,0.98480135,0.00016486685,0.0019742253,0.00541282],"study_design_scores_gemma":[0.011540946,0.0017523171,0.0012182441,0.002281072,0.00035645647,0.012739241,0.00009333614,0.018093651,0.9413247,0.0006469956,0.009642693,0.00031036482],"about_ca_topic_score_codex":0.00002742209,"about_ca_topic_score_gemma":0.000006386467,"teacher_disagreement_score":0.043476656,"about_ca_system_score_codex":0.0031458456,"about_ca_system_score_gemma":0.0029640475,"threshold_uncertainty_score":0.8226277},"labels":[],"label_agreement":null},{"id":"W4403991971","doi":"","title":"Rituximab-based combination therapy in patients with Waldenstr&amp;ouml;m macroglobulinemia: a systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Rituximab; Waldenstrom macroglobulinemia; Medicine; Macroglobulinemia; Internal medicine; Oncology; Lymphoma; Multiple myeloma","score_opus":0.4203060956036666,"score_gpt":0.5932826566869723,"score_spread":0.17297656108330572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403991971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00093226664,0.9862309,0.000028253888,0.00009450304,0.000060024988,0.012280964,0.00016282804,0.000025914906,0.00018432522],"genre_scores_gemma":[0.0014094644,0.9956481,0.00013189529,0.0005509433,0.00002413396,0.0008937349,0.00045589227,0.00015318798,0.0007326604],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9905917,0.0018141032,0.0033311835,0.0011358751,0.002466476,0.00066066306],"domain_scores_gemma":[0.9914483,0.0013094763,0.0036192497,0.0019852114,0.0012085949,0.00042919317],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039916127,0.0010986195,0.01906723,0.0028933794,0.00011315635,0.00073346024,0.0023720055,0.00043678965,0.0061046937],"category_scores_gemma":[0.0008795112,0.0006603824,0.0022806907,0.0047455253,0.00020655968,0.00075157324,0.00060454884,0.001218513,0.00005956074],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022774242,0.0013871962,0.0022031942,0.88966185,0.097554326,0.000094977426,0.000024002167,0.000009252383,5.923808e-7,0.000007683303,0.0018284875,0.0070007],"study_design_scores_gemma":[0.0147285005,0.000110944784,0.0012875402,0.20111677,0.76854295,0.00007450435,0.000005183445,0.0000587805,0.0000047001004,0.00003723914,0.012972801,0.001060086],"about_ca_topic_score_codex":0.0008554835,"about_ca_topic_score_gemma":0.0000795064,"teacher_disagreement_score":0.68854505,"about_ca_system_score_codex":0.0046979543,"about_ca_system_score_gemma":0.004763278,"threshold_uncertainty_score":0.99958473},"labels":[],"label_agreement":null},{"id":"W4404130597","doi":"10.1016/b978-0-128-24465-4.00071-5","title":"Haematologic Malignancies of the B Lymphocyte Lineage","year":2024,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Lineage (genetic); Biology; Immunology; Genetics; Gene","score_opus":0.023136801934505992,"score_gpt":0.27555877653833116,"score_spread":0.25242197460382515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404130597","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010800319,0.01411217,5.879394e-7,0.00019132523,0.00063833897,0.0011842528,0.000056894885,0.000103600585,0.9826328],"genre_scores_gemma":[0.009505164,0.0005026087,0.00009314356,0.00039286693,0.0003822426,0.00004813374,0.0000142292065,0.00015417137,0.98890746],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717826,0.000026839816,0.00075669703,0.00058132404,0.0010073157,0.0004495566],"domain_scores_gemma":[0.9976831,0.00016538752,0.00026527184,0.0015035165,0.00022392857,0.00015877935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035488483,0.0004996678,0.0010942646,0.00020115059,0.000074439566,0.000029812249,0.0005303029,0.0005874729,0.00040989206],"category_scores_gemma":[0.000098005665,0.00029833842,0.0007774507,0.00004645951,0.0007975056,0.000016853726,0.00066600513,0.000734125,0.00075005094],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003869454,0.000055978027,0.000014075733,0.013378576,0.0018820479,0.0043694233,0.0010538836,0.0000036844158,0.00096881425,0.1614004,0.0037573338,0.8127288],"study_design_scores_gemma":[0.0026037854,0.00012461128,0.0000050926446,0.0056235986,0.00065548206,0.0016462269,0.000015977734,0.00016264222,0.004912116,0.0066738804,0.97727495,0.00030160855],"about_ca_topic_score_codex":0.000005600077,"about_ca_topic_score_gemma":0.000019137491,"teacher_disagreement_score":0.97351766,"about_ca_system_score_codex":0.0053752773,"about_ca_system_score_gemma":0.008559983,"threshold_uncertainty_score":0.9999469},"labels":[],"label_agreement":null},{"id":"W4404163529","doi":"10.51731/cjht.2024.1022","title":"Aflibercept 8 mg/0.07 mL (Eylea HD)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aflibercept; Medicine; Internal medicine","score_opus":0.03733900008348816,"score_gpt":0.3430989103266301,"score_spread":0.3057599102431419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404163529","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3018072,0.4884,0.0004835723,0.19967565,0.002183047,0.0008166027,0.000039587278,0.0008051325,0.0057892054],"genre_scores_gemma":[0.9953857,0.0018267351,0.0007057579,0.00071324944,0.00007445996,0.000006339103,0.0000029691657,0.000039655013,0.0012451494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781954,0.000048338323,0.00067029725,0.00021968612,0.00039935455,0.0008427839],"domain_scores_gemma":[0.9988161,0.0001350214,0.00013223164,0.0004146432,0.0001874889,0.0003145587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001052218,0.00016572846,0.0005014034,0.0012829825,0.00016847333,0.000084502004,0.00039502842,0.00025051233,0.00031114725],"category_scores_gemma":[0.0009247113,0.00012908457,0.00015033671,0.0006990392,0.0004261845,0.00013922606,0.000039522733,0.0010890326,0.0002625542],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000033232925,0.000017229451,0.00027557314,0.00096875057,0.00013497348,0.0052703903,0.00073103106,0.000008666595,0.000107777414,0.002992646,0.104140446,0.8853193],"study_design_scores_gemma":[0.0023156593,0.0009435206,0.0008891781,0.001811975,0.000039660823,0.009242659,0.0034432062,0.0005636124,0.0006262161,0.0039279247,0.9760136,0.0001827763],"about_ca_topic_score_codex":0.009157328,"about_ca_topic_score_gemma":0.0030575718,"teacher_disagreement_score":0.8851365,"about_ca_system_score_codex":0.018565953,"about_ca_system_score_gemma":0.07706677,"threshold_uncertainty_score":0.99744076},"labels":[],"label_agreement":null},{"id":"W4404212386","doi":"10.7759/cureus.73378","title":"Radiotherapeutic Treatment of an Epidermoid Tumor in a Patient With Zanubrutinib-Treated Mantle Cell Lymphoma: The First Report of Concomitant Treatment","year":2024,"lang":"en","type":"article","venue":"Cureus","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Ibrutinib; Mucositis; Radiation therapy; Mantle cell lymphoma; Adverse effect; Oncology; Neutropenia; Internal medicine; Chemotherapy; Lymphoma; Chronic lymphocytic leukemia; Leukemia","score_opus":0.02151584997188551,"score_gpt":0.2988467765817998,"score_spread":0.2773309266099143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404212386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869007,0.009229884,0.0000056185945,0.00028473858,0.000082322484,0.0013564781,0.000029437444,0.000047144382,0.0020636867],"genre_scores_gemma":[0.99844277,0.00038985134,0.00016595924,0.000037624242,0.00005385627,0.00017810937,0.000037260135,0.00005389508,0.0006406755],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981047,0.0000800464,0.00060691906,0.00044103686,0.0003998328,0.00036744526],"domain_scores_gemma":[0.9984791,0.00025745938,0.00015345532,0.0009018551,0.000080115984,0.00012796461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016330749,0.00027729158,0.000624647,0.00012164139,0.000039624258,0.0000155353,0.00011373127,0.000070950104,0.000095042655],"category_scores_gemma":[0.000019377614,0.00014263816,0.00014980765,0.00037622332,0.00023512986,0.00005219274,0.000022579192,0.000051302002,0.000009815348],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026931245,0.070248395,0.07417012,0.0061364216,0.008320813,0.5259026,0.07089304,0.0007832005,0.024251206,0.00096945965,0.0018450781,0.18954842],"study_design_scores_gemma":[0.110571705,0.060078986,0.015018561,0.0016914199,0.0019267638,0.04524705,0.0028079588,0.047941543,0.64404917,0.00008450197,0.06975579,0.0008265223],"about_ca_topic_score_codex":0.006481445,"about_ca_topic_score_gemma":0.0012780955,"teacher_disagreement_score":0.619798,"about_ca_system_score_codex":0.012202026,"about_ca_system_score_gemma":0.0040053143,"threshold_uncertainty_score":0.99158996},"labels":[],"label_agreement":null},{"id":"W4404511331","doi":"10.3389/fphar.2024.1513913","title":"Epidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias","year":2024,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"Jilin University; National Natural Science Foundation of China; Natural Science Foundation of Jilin Province","keywords":"Ibrutinib; Epidemiology; Medicine; Mechanism (biology); Cardiology; Internal medicine; Pharmacology; Intensive care medicine; Leukemia","score_opus":0.10242836553242375,"score_gpt":0.45866287098655145,"score_spread":0.3562345054541277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404511331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011287453,0.9852317,0.0005293006,0.00019421898,0.010766784,0.0019199162,0.00009421641,0.000049491566,0.00008562691],"genre_scores_gemma":[0.00086401775,0.9944739,0.0018516735,0.00024742226,0.001794948,0.00016653356,0.0001722951,0.000104320585,0.0003249188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937542,0.0015722404,0.0025368521,0.0010254018,0.00027318732,0.000838122],"domain_scores_gemma":[0.99755883,0.000820313,0.00068730704,0.0004520803,0.00009568928,0.00038579633],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003159255,0.00056215934,0.005579868,0.0008666903,0.00003495653,0.0000058666765,0.00033005464,0.0015039482,0.00011982351],"category_scores_gemma":[0.00095869735,0.00044907033,0.0008198916,0.00053690653,0.00053103606,0.00003445456,0.0005032674,0.002244108,0.00006545771],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044091864,0.00034479352,0.00012490101,0.05002776,0.0033910964,0.021994287,0.0000443427,3.4755138e-7,0.000007467118,0.0004970639,0.050424267,0.8727028],"study_design_scores_gemma":[0.010009735,0.0007800426,0.000029594086,0.0075609535,0.012066876,0.007072772,0.000029240728,0.005016057,0.000019966737,0.00088001334,0.95595044,0.00058428454],"about_ca_topic_score_codex":0.00002511938,"about_ca_topic_score_gemma":3.2980319e-7,"teacher_disagreement_score":0.9055262,"about_ca_system_score_codex":0.0036473498,"about_ca_system_score_gemma":0.0071343565,"threshold_uncertainty_score":0.9997961},"labels":[],"label_agreement":null},{"id":"W4404538532","doi":"10.1016/j.jcjd.2024.09.102","title":"Pattern of Semaglutide Prescription in a Real-World Patient Cohort","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Semaglutide; Cohort; Medical prescription; Internal medicine; Pharmacology; Endocrinology; Type 2 diabetes; Diabetes mellitus","score_opus":0.0162403269320453,"score_gpt":0.27382115726254624,"score_spread":0.25758083033050094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941741,0.0027649184,0.0000041186227,0.00045132457,0.0003150046,0.00019997616,0.000018677816,0.000005307436,0.0020665694],"genre_scores_gemma":[0.9993181,0.00003375306,0.00005577945,0.000102005295,0.00013487387,0.0000050010676,0.0000047135563,0.000020710051,0.00032501807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866384,0.00005247952,0.0004927715,0.00012034815,0.00031582202,0.00035472037],"domain_scores_gemma":[0.99898773,0.00010767349,0.00008356061,0.0001643783,0.00016127188,0.00049538264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042721682,0.000093830815,0.00031072964,0.0009316853,0.000016164628,0.00002865456,0.00010249122,0.000052413885,0.00024619553],"category_scores_gemma":[0.00016644492,0.00007891787,0.00010718341,0.00042231052,0.00009291344,0.00008086408,0.000011647926,0.0002872824,0.000012891675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011859711,0.00003501427,0.9490559,0.00075919804,0.00023044832,0.00089633843,0.0013135212,0.00014019481,0.0015923986,0.00006878117,0.010103863,0.035792504],"study_design_scores_gemma":[0.0060468363,0.0012830944,0.92959553,0.008455795,0.0002965056,0.0001409799,0.0004613658,0.025408281,0.009266681,0.00040397368,0.018325863,0.0003151107],"about_ca_topic_score_codex":0.023236841,"about_ca_topic_score_gemma":0.06968108,"teacher_disagreement_score":0.046444237,"about_ca_system_score_codex":0.0071045533,"about_ca_system_score_gemma":0.013033525,"threshold_uncertainty_score":0.996707},"labels":[],"label_agreement":null},{"id":"W4404621177","doi":"10.1017/cjn.2024.334","title":"Asymptomatic Optic Disc Oedema due to Haematologic Malignancy","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Kensington Health; University of Toronto","funders":"","keywords":"Asymptomatic; Content (measure theory); Malignancy; Medicine; Pathology; Mathematics","score_opus":0.03874235369142336,"score_gpt":0.3174043569185102,"score_spread":0.27866200322708684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404621177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732439,0.0042356974,0.00011273958,0.016286079,0.0013325937,0.00036704898,0.000009110841,0.000058220972,0.0043546148],"genre_scores_gemma":[0.9906163,0.00022309352,0.0039212736,0.0046081627,0.00044098182,0.000008290553,3.4398877e-7,0.00002464768,0.00015686979],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99342424,0.0008154105,0.001292547,0.00081220974,0.0015363448,0.0021192785],"domain_scores_gemma":[0.99350005,0.0012349337,0.00034400934,0.00026605287,0.00046473002,0.004190212],"candidate_categories":["metaepi_narrow","sts","scholarly_communication"],"consensus_categories":["sts"],"category_scores_codex":[0.005724926,0.00043980518,0.0009174489,0.002017167,0.0018203458,0.0014315402,0.0020792338,0.00025765327,0.00056688953],"category_scores_gemma":[0.005166085,0.00026759933,0.0004166718,0.0030489492,0.005587924,0.0009241919,0.0001422499,0.0015036447,0.00007410326],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044095883,0.000169124,0.22021097,0.00043011172,0.00019746661,0.718402,0.0026390133,0.0068509933,0.0003165907,0.01412263,0.01786433,0.01835578],"study_design_scores_gemma":[0.0012318345,0.10423183,0.034262657,0.00087123265,0.0001789735,0.8061097,0.00045674678,0.021114916,0.0002919032,0.024096452,0.0064888224,0.0006649226],"about_ca_topic_score_codex":0.0012729235,"about_ca_topic_score_gemma":0.014653804,"teacher_disagreement_score":0.18594831,"about_ca_system_score_codex":0.0030371724,"about_ca_system_score_gemma":0.02900145,"threshold_uncertainty_score":0.99997765},"labels":[],"label_agreement":null},{"id":"W4404731789","doi":"10.1016/j.rhum.2024.10.065","title":"Efficacité des biothérapies chez les patients atteints de SPA en fonction du niveau d’instruction des patients : données du registre marocain RBSMR","year":2024,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Privy Council Office","funders":"","keywords":"Medicine; Gynecology","score_opus":0.015193495928621834,"score_gpt":0.24285535490360338,"score_spread":0.22766185897498153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404731789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97609246,0.012985823,0.0028703504,0.0019260143,0.0031506612,0.0012389743,0.00018455814,0.00033876527,0.001212384],"genre_scores_gemma":[0.9739075,0.015700867,0.0019875446,0.00005622492,0.00317919,0.00011069084,0.00040592934,0.0002028921,0.0044492125],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995039,0.000694068,0.0010274085,0.0010336848,0.0008781152,0.0013277546],"domain_scores_gemma":[0.99712175,0.00084173353,0.0002814131,0.00069277064,0.00054009515,0.00052221527],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010104716,0.0007081654,0.00078979525,0.00054617604,0.00069259736,0.00034638654,0.00043544418,0.0006930393,0.0010834364],"category_scores_gemma":[0.0020883065,0.0007142343,0.00037888714,0.0008810025,0.0014948196,0.0007908083,0.00026991437,0.0007527247,0.00080060237],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040366262,0.00088226795,0.14975852,0.013489593,0.0006547547,0.00051327195,0.025495619,0.00017990006,0.00031555645,0.0026574784,0.0055843303,0.80006504],"study_design_scores_gemma":[0.04133901,0.0031747194,0.6855486,0.046346057,0.0016104726,0.0023651244,0.0051837564,0.10177897,0.003280087,0.004458264,0.10265575,0.0022591865],"about_ca_topic_score_codex":0.0044721835,"about_ca_topic_score_gemma":0.0006127619,"teacher_disagreement_score":0.79780585,"about_ca_system_score_codex":0.032993436,"about_ca_system_score_gemma":0.0019100523,"threshold_uncertainty_score":0.9999774},"labels":[],"label_agreement":null},{"id":"W4404761352","doi":"10.1016/j.revmed.2024.10.348","title":"Analyse rétrospective des prescriptions de dapsone dans le cadre d’un purpura thrombopénique immunologique chez 139 patients : efficacité et tolérance","year":2024,"lang":"fr","type":"article","venue":"La Revue de Médecine Interne","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Dapsone; Medicine; Gynecology; Dermatology","score_opus":0.011130624050587352,"score_gpt":0.2893928711852262,"score_spread":0.2782622471346389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404761352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91790265,0.024614092,0.041044664,0.0048437845,0.0010680689,0.0012030205,0.0002630716,0.00035621732,0.008704453],"genre_scores_gemma":[0.96269137,0.004207391,0.0027360807,0.00028335804,0.0009415389,0.00032196834,0.00015378455,0.00019412421,0.028470363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948329,0.0011194086,0.00093981414,0.0011308098,0.00047738844,0.0014997086],"domain_scores_gemma":[0.9967851,0.0010152189,0.00016986238,0.0011240379,0.0004063471,0.00049940724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016683195,0.0006548451,0.0009969578,0.00039973287,0.00019190364,0.00028905476,0.00079166587,0.00071467663,0.0008547163],"category_scores_gemma":[0.00185329,0.0006472167,0.0005058673,0.001160069,0.0011113376,0.0004562614,0.0005284502,0.002151426,0.00039590223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026377495,0.011315835,0.4309745,0.01014212,0.009683446,0.019576771,0.07130888,0.002548952,0.22984311,0.13493432,0.013389967,0.06364433],"study_design_scores_gemma":[0.022427516,0.0020037766,0.7860923,0.014585568,0.0011928241,0.005234863,0.0027710013,0.06724519,0.07915293,0.007847995,0.010345923,0.0011001077],"about_ca_topic_score_codex":0.013514153,"about_ca_topic_score_gemma":0.0020753045,"teacher_disagreement_score":0.35511777,"about_ca_system_score_codex":0.027830642,"about_ca_system_score_gemma":0.005438332,"threshold_uncertainty_score":0.9995979},"labels":[],"label_agreement":null},{"id":"W4404940529","doi":"10.1038/s41375-024-02487-1","title":"Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia","year":2024,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Oncology; Leukemia; Cancer research; Immunology; Chemotherapy; Cyclophosphamide","score_opus":0.03698168111577174,"score_gpt":0.313390055003235,"score_spread":0.2764083738874633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404940529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95574987,0.0036984375,0.0000038529847,0.000040332616,0.016143182,0.0075825537,0.00005584039,0.00026530455,0.016460653],"genre_scores_gemma":[0.8502829,0.0013567739,0.00003126925,0.00003335866,0.0011595715,0.00053176953,0.00020336243,0.00034882373,0.14605214],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99137205,0.00047018877,0.0019541965,0.0023104248,0.0021173314,0.0017758043],"domain_scores_gemma":[0.9951473,0.0010316253,0.0006356322,0.0024605,0.0002706538,0.00045432357],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.000887621,0.0016108183,0.0036661348,0.001015098,0.0002512606,0.000198306,0.00097545877,0.0013033123,0.00018742554],"category_scores_gemma":[0.0006560345,0.0010461838,0.0003990524,0.0031452994,0.00084958813,0.00021387347,0.00089591765,0.0037068697,0.00011080924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5558157,0.0013093104,0.016339991,0.018998846,0.013274221,0.017364832,0.054425288,0.06627371,0.00023085879,0.00024205445,0.2377292,0.017995965],"study_design_scores_gemma":[0.5294312,0.013929104,0.0066008917,0.017625585,0.0028737173,0.0014614953,0.006473165,0.39159322,0.00028714174,0.0000125525075,0.027824735,0.0018872116],"about_ca_topic_score_codex":0.05438285,"about_ca_topic_score_gemma":0.09010755,"teacher_disagreement_score":0.36947495,"about_ca_system_score_codex":0.74214256,"about_ca_system_score_gemma":0.37266758,"threshold_uncertainty_score":0.9999932},"labels":[],"label_agreement":null},{"id":"W4405035264","doi":"10.1182/blood-2024-198737","title":"CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Obinutuzumab; Venetoclax; Ibrutinib; Medicine; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.12741732976963152,"score_gpt":0.445436246826477,"score_spread":0.3180189170568455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405035264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847994,0.0009781615,0.00005060994,0.000119961194,0.0002629212,0.012678406,0.0002185145,0.00022265695,0.0006693874],"genre_scores_gemma":[0.9906703,0.000107165564,0.0018141321,0.00009605816,0.0007019475,0.0032240448,0.00030844586,0.00017332361,0.002904586],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961626,0.00017307948,0.00080604857,0.001168315,0.00083945016,0.00085050665],"domain_scores_gemma":[0.997177,0.00058876607,0.00017346998,0.0012329153,0.00031429625,0.0005135186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004897895,0.00051381474,0.0010390499,0.00026445405,0.00021051838,0.00020190957,0.0007160849,0.0002283697,0.00018664362],"category_scores_gemma":[0.00024765544,0.00042682022,0.00018261906,0.00052164606,0.0002065876,0.00029612493,0.00030875416,0.00022347417,0.000078486206],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07585504,0.3504941,0.0023147422,0.011565278,0.025651107,0.022177925,0.06735723,0.0006157572,0.17947142,0.004760212,0.06056347,0.19917375],"study_design_scores_gemma":[0.72123533,0.09415423,0.00018521414,0.0012358739,0.0032430475,0.00096493796,0.0026163317,0.07280334,0.051407818,0.00022403974,0.05096877,0.00096107164],"about_ca_topic_score_codex":0.004700256,"about_ca_topic_score_gemma":0.00043079336,"teacher_disagreement_score":0.6453803,"about_ca_system_score_codex":0.011518969,"about_ca_system_score_gemma":0.02146149,"threshold_uncertainty_score":0.9998184},"labels":[],"label_agreement":null},{"id":"W4405038833","doi":"10.1182/blood-2024-199281","title":"Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"MorphoSys; Swedish Orphan Biovitrum; Incyte; BeiGene; Gilead Sciences; Merck KGaA; Genentech; MEI Pharma; NYU Grossman School of Medicine; Regeneron Pharmaceuticals; Seagen; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Refractory (planetary science); Medicine; Salvage therapy; Ibrutinib; Internal medicine; Maximum tolerated dose; Oncology; Adverse effect; Chemotherapy; Leukemia; Biology","score_opus":0.00930047824764595,"score_gpt":0.2679317796691109,"score_spread":0.25863130142146495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721324,0.00061386364,0.000003929676,0.000051036648,0.000017901737,0.0019627109,0.000014878623,0.00002134251,0.00010109306],"genre_scores_gemma":[0.99960643,0.00007250928,0.000118939584,0.000008381982,0.000012294905,0.00007270969,0.000029977244,0.000028586139,0.00005014574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983148,0.00011343869,0.000438781,0.00039834084,0.00054052385,0.00019410046],"domain_scores_gemma":[0.999186,0.00019552473,0.00013468103,0.00019894479,0.00021890468,0.00006596405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003285469,0.00016818623,0.0003501951,0.00042563642,0.000022156912,0.000014721517,0.000043459153,0.00008830225,0.0000011235379],"category_scores_gemma":[0.00010664508,0.00012428059,0.000014180856,0.0006785625,0.00012080783,0.00017053181,0.0000373022,0.0001609248,3.6591976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2422619,0.09878564,0.5417002,0.0024365939,0.0010415884,0.0009629534,0.0725787,0.00012532479,0.013825584,0.00007980506,0.00007015901,0.026131563],"study_design_scores_gemma":[0.37872326,0.055922955,0.546158,0.0018126166,0.00017623186,0.00006972035,0.0012425644,0.0018470762,0.013833157,0.00003562039,0.000007922976,0.00017087709],"about_ca_topic_score_codex":0.00091781886,"about_ca_topic_score_gemma":0.00016196724,"teacher_disagreement_score":0.13646136,"about_ca_system_score_codex":0.0009101253,"about_ca_system_score_gemma":0.0014336057,"threshold_uncertainty_score":0.50680155},"labels":[],"label_agreement":null},{"id":"W4405039883","doi":"10.1182/blood-2024-202786","title":"Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Leukemia; Ibrutinib; Immunology; Lymphoma; Preference; Internal medicine","score_opus":0.03744102376382475,"score_gpt":0.30057432204871115,"score_spread":0.2631332982848864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671687,0.006197975,0.000029270503,0.000021948279,0.0001310228,0.00664379,0.0001316425,0.00010679535,0.000020712481],"genre_scores_gemma":[0.9980377,0.00044255203,0.00019767,0.000047061254,0.00009510681,0.0009363506,0.00013718735,0.00009049014,0.000015909214],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99606055,0.00026868048,0.00083675404,0.0012064355,0.0006806085,0.0009469788],"domain_scores_gemma":[0.9951796,0.003696426,0.00015234605,0.00058222836,0.00017248033,0.00021691593],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057344546,0.0006347066,0.00078270194,0.00081454794,0.00023831228,0.00032723247,0.0002021932,0.00019500857,0.00001387247],"category_scores_gemma":[0.0008682874,0.00042966186,0.000118725904,0.0014015287,0.00017055412,0.00019950786,0.000285823,0.00022026306,0.0000054321545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011761645,0.012246326,0.36106244,0.008334101,0.003036621,0.011845363,0.29925904,0.013003021,0.0051105795,0.00019433367,0.00021341469,0.2739331],"study_design_scores_gemma":[0.21448424,0.033403173,0.28517243,0.013132357,0.0016267451,0.0012770654,0.031386398,0.38761002,0.029128384,0.0005970922,0.00036962883,0.0018124387],"about_ca_topic_score_codex":0.008011028,"about_ca_topic_score_gemma":0.004185289,"teacher_disagreement_score":0.374607,"about_ca_system_score_codex":0.108284615,"about_ca_system_score_gemma":0.012598614,"threshold_uncertainty_score":0.9998155},"labels":[],"label_agreement":null},{"id":"W4405039971","doi":"10.1182/blood-2024-198028","title":"Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Research Canada; Providence Health Care; Providence Health Care Research Institute; Vancouver General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Chronic lymphocytic leukemia; Ibrutinib; Medicine; Lymphoma; Leukemia; Immunology; Cancer research","score_opus":0.02685232889152144,"score_gpt":0.3261727267738416,"score_spread":0.2993203978823202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774722,0.017688086,0.00024175686,0.000071620736,0.00016738469,0.0009954952,0.000017712931,0.00018749338,0.003158253],"genre_scores_gemma":[0.99798846,0.0006998405,0.00039900164,0.0000840155,0.0002332418,0.000104063925,0.0000527479,0.000085795036,0.00035282722],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.996643,0.00012265235,0.001058702,0.00066086976,0.00071747374,0.00079730543],"domain_scores_gemma":[0.99852365,0.00038825627,0.00010752604,0.0005766652,0.000108062595,0.000295836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006032376,0.00041425662,0.00089295453,0.00071579963,0.000069430396,0.000095844254,0.00024249514,0.00026753772,0.00009727338],"category_scores_gemma":[0.000097306525,0.0003721654,0.00019465506,0.0009975155,0.00023584122,0.0002581624,0.00011183874,0.00026487792,0.00013218727],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0068055964,0.0044466904,0.014652278,0.06641003,0.006037209,0.01044065,0.0694851,0.014886347,0.22283621,0.021627335,0.0024709925,0.55990154],"study_design_scores_gemma":[0.13745718,0.001056303,0.0029026964,0.0029566826,0.0009115165,0.002477083,0.0004582397,0.7644756,0.08424388,0.00045461775,0.0019945856,0.0006116581],"about_ca_topic_score_codex":0.003884294,"about_ca_topic_score_gemma":0.0008294484,"teacher_disagreement_score":0.7495892,"about_ca_system_score_codex":0.09827563,"about_ca_system_score_gemma":0.04751379,"threshold_uncertainty_score":0.99987304},"labels":[],"label_agreement":null},{"id":"W4405040132","doi":"10.1182/blood-2024-202826","title":"Decoding the Epigenetic and Transcriptional Signatures of Pathogenic B-Cells in Patients at High Risk of Transformation to Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University of British Columbia; University Health Network","funders":"","keywords":"Epigenetics; Lymphoma; Biology; Genetics; Transformation (genetics); Cancer research; Medicine; Immunology; Gene","score_opus":0.007769884272256131,"score_gpt":0.23861996388942588,"score_spread":0.23085007961716975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966541,0.0024573712,0.000056017765,0.000076850825,0.000060718077,0.00048188903,0.000101797385,0.0000089101995,0.00010232516],"genre_scores_gemma":[0.9993105,0.0003878867,0.00017005485,0.000023820197,0.000022322325,0.000015675685,0.000018788098,0.000011955962,0.000039031544],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990072,0.000056535948,0.00028363604,0.00014666948,0.0003554718,0.0001504657],"domain_scores_gemma":[0.9995818,0.00014882366,0.000028571305,0.00013481115,0.000048906804,0.000057082663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027163472,0.0000807495,0.00016296288,0.00014127421,0.000025708687,0.0000068504637,0.000067602654,0.00006537767,0.00003317068],"category_scores_gemma":[0.000040440125,0.000055525325,0.00006218625,0.00023639874,0.000056143148,0.000035922876,0.000020085541,0.00007140847,0.0000056802],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002294274,0.0032630884,0.025149236,0.0043079956,0.00097264745,0.00007209741,0.029365616,0.0009923641,0.7874717,0.0024598634,0.00024724094,0.14340387],"study_design_scores_gemma":[0.046175484,0.0009871589,0.51286364,0.0007720139,0.00057296647,0.000034099947,0.00018368132,0.0055885375,0.43190134,0.00035927494,0.00037900195,0.00018280209],"about_ca_topic_score_codex":0.00024395247,"about_ca_topic_score_gemma":0.00008358439,"teacher_disagreement_score":0.4877144,"about_ca_system_score_codex":0.00056733063,"about_ca_system_score_gemma":0.00048395927,"threshold_uncertainty_score":0.2264257},"labels":[],"label_agreement":null},{"id":"W4405040944","doi":"10.1182/blood-2024-209214","title":"Comparing Antihistamine Premedication Regimens for Preventing Rituximab-Associated Infusion Reactions in Hemato-Oncology Patients: A Retrospective Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Antihistamine; Medicine; Premedication; Rituximab; Loratadine; Tolerability; Diphenhydramine; Retrospective cohort study; Dosing; Anesthesia; Internal medicine; Adverse effect; Lymphoma; Histamine","score_opus":0.022720973810420264,"score_gpt":0.32943936569431703,"score_spread":0.30671839188389677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577004,0.00032179418,0.00050332706,0.0002483482,0.00010341621,0.0010478337,0.00002043662,0.00013719987,0.0018475913],"genre_scores_gemma":[0.9977117,0.00007637074,0.00065183814,0.000022356486,0.00008774889,0.0001912983,0.00046156012,0.000026894704,0.0007702036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817276,0.00008372816,0.00052520266,0.00044664455,0.00040761367,0.0003640284],"domain_scores_gemma":[0.99886703,0.00033655277,0.00014331617,0.00028898078,0.00026363478,0.00010048639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080898305,0.00013505474,0.00052607607,0.0006543817,0.00009029878,0.000030478575,0.00008764952,0.00016366888,0.000038610026],"category_scores_gemma":[0.001467591,0.00012852541,0.00017957247,0.0017070031,0.00006023863,0.0001157687,0.000077207274,0.00029155018,0.00001431454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064427475,0.024488442,0.9310735,0.0030093938,0.008773822,0.00037004132,0.006420539,0.00009254905,0.014896833,0.0016554821,0.0034183583,0.0051567685],"study_design_scores_gemma":[0.13527673,0.0016821595,0.51560605,0.0028622104,0.008292262,0.00010170003,0.0006524959,0.32141334,0.00702144,0.0007470203,0.0057576317,0.00058693945],"about_ca_topic_score_codex":0.00059877697,"about_ca_topic_score_gemma":0.0008444664,"teacher_disagreement_score":0.41546744,"about_ca_system_score_codex":0.009896024,"about_ca_system_score_gemma":0.0015530301,"threshold_uncertainty_score":0.9939048},"labels":[],"label_agreement":null},{"id":"W4405040982","doi":"10.1182/blood-2024-204788","title":"Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Quality (philosophy); Internal medicine","score_opus":0.016228905743434996,"score_gpt":0.2991573955909816,"score_spread":0.2829284898475466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99827814,0.00017092681,0.0000049047035,0.00012539494,0.00002923953,0.0012339992,0.0000054326665,0.000031195665,0.00012078941],"genre_scores_gemma":[0.99975,0.0000023353737,0.00001728426,0.000104681545,0.000015210187,0.000050816896,0.000006919001,0.000020705496,0.00003204593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810195,0.00013894726,0.0004383473,0.00032003832,0.00071079086,0.00028993437],"domain_scores_gemma":[0.9989119,0.00036541122,0.00009406252,0.00047327075,0.00007803059,0.00007728967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006569203,0.00013002304,0.00031396272,0.00011813331,0.000029919218,0.00002035021,0.00006995341,0.00004305672,0.000011414149],"category_scores_gemma":[0.000637833,0.00007028591,0.000042664306,0.00026912199,0.00006401404,0.000032558102,0.000053799882,0.00027675627,0.0000016981194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011037393,0.0043008137,0.99046797,0.00029960374,0.0003151406,0.00008399939,0.000914918,0.000013547191,0.00007538725,0.000029502338,0.000012743362,0.0023826566],"study_design_scores_gemma":[0.052281037,0.0050368267,0.93835676,0.0001603462,0.00019387828,0.0000045020633,0.0005137045,0.002844718,0.00045685365,0.000010857813,0.000018647926,0.00012185417],"about_ca_topic_score_codex":0.0014167143,"about_ca_topic_score_gemma":0.00026415833,"teacher_disagreement_score":0.052111175,"about_ca_system_score_codex":0.0010695977,"about_ca_system_score_gemma":0.0035553512,"threshold_uncertainty_score":0.63070405},"labels":[],"label_agreement":null},{"id":"W4405041581","doi":"10.1182/blood-2024-199134","title":"Macrophages in Waldenstrom Macroglobulinemia: Implications for the Tumor Microenvironment","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Macroglobulinemia; Waldenstrom macroglobulinemia; Medicine; Immunology; Cancer research; Multiple myeloma; Lymphoma","score_opus":0.018022482244600093,"score_gpt":0.30742209070826876,"score_spread":0.2893996084636687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96448565,0.016865682,0.0003915125,0.015741525,0.00013476152,0.0016325449,0.0001126877,0.00009173657,0.0005438971],"genre_scores_gemma":[0.9953232,0.00045740107,0.00119457,0.0003429131,0.00028071474,0.00047803827,0.000024536326,0.000034927994,0.001863731],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998993,0.0000143460375,0.00020951021,0.00029659638,0.00014772595,0.0003388638],"domain_scores_gemma":[0.99911773,0.00035017202,0.000016373178,0.0004200424,0.00001805898,0.000077647455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019927522,0.00011176357,0.00014745133,0.000065545166,0.00006513833,0.00004404518,0.00015911082,0.0000472408,0.00008898778],"category_scores_gemma":[0.00007061244,0.00007363504,0.000101219404,0.00018971122,0.00010292302,0.000025440582,0.00008082566,0.00019543857,0.0001168064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087639235,0.0067667724,0.018863665,0.005639087,0.0025381292,0.004750188,0.0025092564,0.00024655965,0.679111,0.0112348525,0.112144284,0.15531984],"study_design_scores_gemma":[0.12173896,0.0012562854,0.18340598,0.0016584047,0.002750446,0.013542548,0.0009259579,0.025440007,0.23644932,0.003559122,0.40816253,0.0011104324],"about_ca_topic_score_codex":0.0001055935,"about_ca_topic_score_gemma":0.000029824932,"teacher_disagreement_score":0.44266167,"about_ca_system_score_codex":0.0017506703,"about_ca_system_score_gemma":0.0011302745,"threshold_uncertainty_score":0.4577942},"labels":[],"label_agreement":null},{"id":"W4405041895","doi":"10.1182/blood-2024-203618","title":"Investigating the Metabolic Underpinnings of Venetoclax Resistance in DLBCL","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Gilead Sciences; AstraZeneca; Incyte; Amgen","keywords":"Venetoclax; Ibrutinib; Medicine; Internal medicine; Oncology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02608518767290764,"score_gpt":0.31000399486147656,"score_spread":0.28391880718856893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405041895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646411,0.026480485,0.000008969049,0.0011314724,0.00005360109,0.00026233916,0.0000026628334,0.000044685545,0.00737472],"genre_scores_gemma":[0.99732494,0.00017653931,0.0007379819,0.00016525298,0.000119602155,0.000027606135,0.000002824399,0.00002249577,0.0014227787],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989051,0.00005105049,0.0002492491,0.00019860505,0.00035684725,0.00023915504],"domain_scores_gemma":[0.9992787,0.00026634545,0.000031526604,0.0003232036,0.000037431215,0.00006279434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004981889,0.00008481997,0.00020068572,0.00010790337,0.00002690893,0.000021225487,0.00014016138,0.000055088043,0.000024510273],"category_scores_gemma":[0.00040656317,0.0000570266,0.000058641755,0.0006770947,0.00018616758,0.000042221593,0.00006673549,0.00025990786,0.000025449606],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051588315,0.0027033782,0.04915739,0.019953677,0.003817059,0.0052095135,0.06950268,0.00032796533,0.30593863,0.48997217,0.02571252,0.027189126],"study_design_scores_gemma":[0.1168237,0.000511587,0.12548035,0.017185772,0.0018824188,0.0012471018,0.002911928,0.03270553,0.46848616,0.044709425,0.18687803,0.0011779991],"about_ca_topic_score_codex":0.00053741393,"about_ca_topic_score_gemma":0.00017421192,"teacher_disagreement_score":0.44526276,"about_ca_system_score_codex":0.0009909025,"about_ca_system_score_gemma":0.005232364,"threshold_uncertainty_score":0.92819893},"labels":[],"label_agreement":null},{"id":"W4405042181","doi":"10.1182/blood-2024-201578","title":"Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Follicular lymphoma; Bruton's tyrosine kinase; Refractory (planetary science); Ibrutinib; Medicine; Cancer research; Lymphoma; Follicular phase; Internal medicine; Chronic lymphocytic leukemia; Oncology; Biology; Leukemia; Tyrosine kinase; Receptor","score_opus":0.034082989474657925,"score_gpt":0.33355987014664784,"score_spread":0.2994768806719899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98948973,0.0045778514,0.000004490972,0.0011470563,0.00055348274,0.0021786985,0.00017154892,0.00019066906,0.0016864389],"genre_scores_gemma":[0.9933989,0.00028994482,0.00021662265,0.00027444214,0.0010440056,0.00013310129,0.00011292922,0.000088714005,0.0044413516],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958547,0.00034985377,0.00086970994,0.001017927,0.00120553,0.00070228573],"domain_scores_gemma":[0.9965713,0.00153112,0.00010256728,0.0014237837,0.00009660462,0.00027460253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016125139,0.0003606097,0.00058068166,0.00024269984,0.0001486683,0.00011036427,0.000400528,0.00023327857,0.00020757019],"category_scores_gemma":[0.0015228922,0.00022610286,0.00021291598,0.0012649677,0.00013841112,0.00012285014,0.00031403714,0.00056529447,0.00037453492],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07387766,0.16234893,0.006441646,0.0022466928,0.009090645,0.24761525,0.08773282,0.000060375816,0.042468835,0.00017416276,0.2821364,0.08580657],"study_design_scores_gemma":[0.7805919,0.007105838,0.003283246,0.0033401607,0.0021661578,0.00086923724,0.008777064,0.0046863784,0.017231349,0.0000991945,0.17093518,0.0009143057],"about_ca_topic_score_codex":0.0042422893,"about_ca_topic_score_gemma":0.00070497754,"teacher_disagreement_score":0.7067142,"about_ca_system_score_codex":0.0048439903,"about_ca_system_score_gemma":0.010123757,"threshold_uncertainty_score":0.99897623},"labels":[],"label_agreement":null},{"id":"W4405042974","doi":"10.1182/blood-2024-203269","title":"First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Venetoclax; Ibrutinib; Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Adverse effect; Internal medicine; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.01900988019883937,"score_gpt":0.2961543045955663,"score_spread":0.27714442439672693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405042974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929334,0.004341875,0.000077639656,0.000095094205,0.00047681533,0.004857959,0.00017584646,0.00036727524,0.00031417006],"genre_scores_gemma":[0.99566483,0.00061057956,0.00030610897,0.000047627917,0.00042212763,0.0007485586,0.00028938177,0.00020465073,0.001706148],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9917466,0.00032122363,0.0013944914,0.0019618121,0.0029385644,0.0016373245],"domain_scores_gemma":[0.99490714,0.00069062994,0.00029799668,0.0029238942,0.00037036842,0.0008099779],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001277745,0.0009910018,0.0019730555,0.0010516698,0.0003088294,0.00022123184,0.0011504588,0.00041647613,0.00029016883],"category_scores_gemma":[0.00092660234,0.0007264441,0.00043233114,0.0035785409,0.00040294044,0.00037330535,0.0012213141,0.0008745617,0.00007749693],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.19118588,0.014504308,0.2080986,0.033039417,0.067809306,0.13522084,0.037595123,0.21123748,0.0001813542,0.00031987156,0.009725919,0.091081895],"study_design_scores_gemma":[0.43025997,0.018949294,0.023673411,0.003202258,0.008759809,0.00046498468,0.0010614196,0.5101348,0.00028262398,0.00004872779,0.0017728423,0.0013898632],"about_ca_topic_score_codex":0.015027604,"about_ca_topic_score_gemma":0.062723435,"teacher_disagreement_score":0.29889733,"about_ca_system_score_codex":0.18713437,"about_ca_system_score_gemma":0.09270419,"threshold_uncertainty_score":0.9995187},"labels":[],"label_agreement":null},{"id":"W4405043434","doi":"10.1182/blood-2024-200701","title":"Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); University of Calgary; Foothills Medical Centre; University of Ottawa","funders":"","keywords":"Obinutuzumab; Venetoclax; Chemoimmunotherapy; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Interim analysis; Fludarabine; Leukemia; Randomized controlled trial; Cyclophosphamide; Chemotherapy","score_opus":0.0857842112642104,"score_gpt":0.4075480686450218,"score_spread":0.32176385738081137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850712,0.0031834608,0.0012747209,0.00007898628,0.00045282775,0.009588953,0.00018570584,0.00006075825,0.000103392624],"genre_scores_gemma":[0.99469155,0.001351186,0.0005838846,0.000025773043,0.00029728704,0.0016223587,0.00026584405,0.000081159335,0.0010809425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99703795,0.00017100309,0.0011223799,0.00061279186,0.00059867045,0.00045718497],"domain_scores_gemma":[0.99664783,0.0015536027,0.00042110705,0.0010185878,0.00023788393,0.00012101347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006262265,0.0004080772,0.0019742784,0.00030198004,0.0001153608,0.00009261098,0.00047977775,0.00021888374,0.00019390378],"category_scores_gemma":[0.0003713008,0.00021874293,0.0004905782,0.0011442882,0.00042684635,0.00013033996,0.00012239834,0.00015802562,0.000005128686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9706031,0.0015596224,0.0000029312607,0.00070222304,0.01618216,0.000038817307,0.0012210339,0.0012315589,0.0037651258,0.000052464206,0.000049147908,0.0045918194],"study_design_scores_gemma":[0.59868777,0.009765439,8.8327187e-7,0.0004366188,0.009666821,0.000026485168,0.00006539714,0.35311824,0.027467787,0.000002784352,0.00062970613,0.00013207368],"about_ca_topic_score_codex":0.003035274,"about_ca_topic_score_gemma":0.0012039298,"teacher_disagreement_score":0.3719153,"about_ca_system_score_codex":0.07885749,"about_ca_system_score_gemma":0.052063115,"threshold_uncertainty_score":0.9533108},"labels":[],"label_agreement":null},{"id":"W4405044374","doi":"10.1182/blood-2024-198147","title":"BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bendamustine; Idelalisib; Rituximab; Chronic lymphocytic leukemia; Ibrutinib; Medicine; Ofatumumab; Obinutuzumab; Bruton's tyrosine kinase; Venetoclax; Internal medicine; Oncology; Leukemia; Lymphoma; Tyrosine kinase; Receptor","score_opus":0.037464516726009346,"score_gpt":0.3310610606163402,"score_spread":0.29359654389033085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662197,0.017428242,0.00023660986,0.00015479483,0.0025632007,0.009257351,0.00027843931,0.0009029506,0.0029586968],"genre_scores_gemma":[0.9884765,0.0024088873,0.00070774514,0.00012846991,0.0024133269,0.0013190692,0.0006243772,0.00045276547,0.0034688537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98653173,0.00096645055,0.0045251655,0.0025635967,0.0026763547,0.0027366714],"domain_scores_gemma":[0.9903462,0.0048053646,0.000781232,0.0023631721,0.0006089505,0.0010950628],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003740025,0.0016933418,0.0058226148,0.00206881,0.00025082618,0.0003139599,0.0011740477,0.0013035171,0.0009267868],"category_scores_gemma":[0.0048060273,0.0013972758,0.0015759828,0.0037138378,0.0014033808,0.00054575485,0.00075478235,0.0010095135,0.000491435],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9644564,0.0041229427,0.0000015924483,0.0038991494,0.0029769174,0.010603431,0.0013878783,0.0008805374,0.003005653,0.0003396665,0.0013730312,0.0069528483],"study_design_scores_gemma":[0.74178076,0.0043346663,0.0000017968966,0.0031353433,0.0035711268,0.0018331751,0.0002583838,0.22170857,0.02128066,0.00006437065,0.0010515128,0.0009796481],"about_ca_topic_score_codex":0.014094162,"about_ca_topic_score_gemma":0.0012912606,"teacher_disagreement_score":0.2226756,"about_ca_system_score_codex":0.20506553,"about_ca_system_score_gemma":0.22081374,"threshold_uncertainty_score":0.999993},"labels":[],"label_agreement":null},{"id":"W4405044640","doi":"10.1182/blood-2024-193274","title":"Oral Decitabine/Cedazuridine in Patients with MDS and <i>TP53</i> Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Propensity score matching; Decitabine; Internal medicine; Medicine; Oncology; Genetics; Biology; DNA methylation; Gene","score_opus":0.04574344996091538,"score_gpt":0.3246069895077334,"score_spread":0.27886353954681803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405044640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965069,0.0018496579,0.000071884024,0.00044315978,0.000025045896,0.0009416075,0.00007592804,0.00003683923,0.000048953018],"genre_scores_gemma":[0.99911785,0.000072942436,0.00033016555,0.000113126,0.000077457946,0.000044832435,0.00016359695,0.000019718525,0.000060334278],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984475,0.00016021557,0.00036560744,0.00038879464,0.000413233,0.0002246979],"domain_scores_gemma":[0.99883884,0.00061782385,0.00005931226,0.00028557357,0.00008194289,0.00011648152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097556907,0.00015575219,0.0005734854,0.0001911248,0.00012337214,0.00010142825,0.000073734336,0.000057253634,0.000044845965],"category_scores_gemma":[0.00042040987,0.00008490074,0.00006421214,0.0008438152,0.00012224044,0.00013422621,0.00013337955,0.00021196391,0.000002671991],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0141271185,0.01092583,0.83214146,0.0010022683,0.018144522,0.0028523447,0.025504332,0.00013483038,0.0049758125,0.0003433236,0.0011016028,0.08874656],"study_design_scores_gemma":[0.48639214,0.0034289306,0.4697468,0.0020364206,0.01993633,0.00016018872,0.0008738551,0.010806055,0.0041760607,0.0011152608,0.00060237,0.00072559575],"about_ca_topic_score_codex":0.002518866,"about_ca_topic_score_gemma":0.0006891032,"teacher_disagreement_score":0.47226503,"about_ca_system_score_codex":0.0003833468,"about_ca_system_score_gemma":0.0010482634,"threshold_uncertainty_score":0.38077888},"labels":[],"label_agreement":null},{"id":"W4405045589","doi":"10.1182/blood-2024-198728","title":"BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Waldenstrom macroglobulinemia; Macroglobulinemia; Ibrutinib; Medicine; Immunology; Leukemia; Multiple myeloma; Lymphoma; Chronic lymphocytic leukemia","score_opus":0.03512004748815195,"score_gpt":0.324881224338984,"score_spread":0.289761176850832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511194,0.0003092897,0.0000148888785,0.00006792317,0.0001802272,0.003842365,0.000037402395,0.00013370941,0.00030227524],"genre_scores_gemma":[0.9979324,0.000016074806,0.00044062914,0.00006312383,0.00057035085,0.00031707648,0.00023096918,0.00009387168,0.0003355162],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964092,0.00016368977,0.00074740703,0.0008143001,0.00126029,0.00060512155],"domain_scores_gemma":[0.9983988,0.000081687016,0.00011896521,0.0008087115,0.0002743659,0.00031751135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004558145,0.00036219612,0.0005781609,0.00044041392,0.000077419616,0.00012220876,0.00023355456,0.00019092114,0.00017436076],"category_scores_gemma":[0.00013344972,0.0002913569,0.00008624311,0.000861372,0.000114650764,0.00036360938,0.0001331639,0.00048876426,0.000047713977],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0153517565,0.24076137,0.37336984,0.006584115,0.004409096,0.014954864,0.044752516,0.0006696582,0.11976766,0.0003976966,0.009743113,0.1692383],"study_design_scores_gemma":[0.74358684,0.055849507,0.025141425,0.003475968,0.0021122575,0.0005378923,0.00405575,0.059227135,0.101125434,0.000059023958,0.0029550549,0.0018737278],"about_ca_topic_score_codex":0.0014776011,"about_ca_topic_score_gemma":0.0011862566,"teacher_disagreement_score":0.72823507,"about_ca_system_score_codex":0.0026188246,"about_ca_system_score_gemma":0.0042665387,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W4405046626","doi":"10.1182/blood-2024-208893","title":"Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcome in a Canadian Real-World Setting","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; Saskatchewan Health; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Discontinuation; Adverse effect; Chronic lymphocytic leukemia; Neutropenia; Fludarabine; Rash; Oncology; Leukemia; Chemotherapy","score_opus":0.00995485069152188,"score_gpt":0.28130562386847063,"score_spread":0.2713507731769488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405046626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902255,0.0007427287,0.0000018043522,0.00010731758,0.000081355545,0.0011764686,0.000013598907,0.00006972775,0.007581517],"genre_scores_gemma":[0.9970688,0.00016553496,0.00020027459,0.00012563105,0.00006960082,0.00011302251,0.000040027862,0.000054880693,0.0021622065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727666,0.000059143153,0.0005267083,0.00062074565,0.00053027854,0.000986434],"domain_scores_gemma":[0.9989315,0.00012572826,0.000049894443,0.00041229578,0.000040360257,0.00044021735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000547394,0.00026042757,0.00037310118,0.0012389652,0.00005747043,0.000050292798,0.00016008507,0.000112538124,0.00006899018],"category_scores_gemma":[0.00007157693,0.0002247587,0.00005163141,0.0012723146,0.00009856286,0.00017726558,0.00012838357,0.00039944783,0.00006738398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015186152,0.00011908727,0.9799474,0.0022061435,0.0001813833,0.009779027,0.000596679,0.00025079295,0.000008952943,0.00040218496,0.00023142947,0.006125092],"study_design_scores_gemma":[0.07700464,0.00058089924,0.8943063,0.004576064,0.00031047955,0.00022275797,0.00022247866,0.018843675,0.000083126986,0.00008173176,0.0032404042,0.0005274294],"about_ca_topic_score_codex":0.46966237,"about_ca_topic_score_gemma":0.739947,"teacher_disagreement_score":0.27028465,"about_ca_system_score_codex":0.098463885,"about_ca_system_score_gemma":0.027618656,"threshold_uncertainty_score":0.9778938},"labels":[],"label_agreement":null},{"id":"W4405047353","doi":"10.1182/blood-2024-205223","title":"Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Internal medicine; Oncology; Intensive care medicine; Chronic lymphocytic leukemia; Leukemia","score_opus":0.028670731014651975,"score_gpt":0.34203698722185527,"score_spread":0.3133662562072033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643123,0.00015665388,3.7072567e-7,0.00007215652,0.00007201441,0.0012835709,0.000024725527,0.00008315814,0.0018761258],"genre_scores_gemma":[0.9977773,0.00052347715,0.00006100982,0.000020882133,0.00006525279,0.00017695023,0.00009723759,0.000047708934,0.0012302225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836725,0.00008809503,0.0003307705,0.00038640053,0.00057422696,0.00025328668],"domain_scores_gemma":[0.9991946,0.00011907575,0.000051796316,0.00043998615,0.00010573613,0.000088809786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012140676,0.00022062157,0.00042207522,0.00036830324,0.00002395066,0.000036738413,0.00016281153,0.000049471877,0.00011455372],"category_scores_gemma":[0.00001348552,0.00013335262,0.000076278186,0.00039041854,0.000070929025,0.000118245494,0.000029822135,0.00011034796,0.000010443614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016840659,0.0054468717,0.97647196,0.00003201722,0.0015904179,0.00046009777,0.004240027,0.0000147762485,0.00011059054,0.000050657294,0.000011092106,0.009887441],"study_design_scores_gemma":[0.07924184,0.00820307,0.90773153,0.000108502245,0.00015608761,0.000015198237,0.0003820982,0.00080902467,0.0022006123,0.000011886332,0.0009893631,0.00015075246],"about_ca_topic_score_codex":0.0072047925,"about_ca_topic_score_gemma":0.00204288,"teacher_disagreement_score":0.07755778,"about_ca_system_score_codex":0.008226877,"about_ca_system_score_gemma":0.0027983931,"threshold_uncertainty_score":0.99940634},"labels":[],"label_agreement":null},{"id":"W4405047886","doi":"10.1182/blood-2024-194382","title":"Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Moderna; Juno Therapeutics; Incyte; BeiGene; Pharmacyclics; Genentech; MEI Pharma; TG Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; MorphoSys; Celgene; Seagen; Gilead Sciences","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Internal medicine; Medicine; Oncology; Population; Survival analysis; Leukemia; Immunology","score_opus":0.017889824188294642,"score_gpt":0.3004515958929991,"score_spread":0.2825617717047044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710757,0.00081952114,0.00004258213,0.000015141829,0.000033174925,0.0017469868,0.00017035911,0.000050666888,0.000013988941],"genre_scores_gemma":[0.99716467,0.00010005108,0.0017705306,0.0000073812475,0.00008084742,0.00010126854,0.0005668539,0.00006950465,0.00013887757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971935,0.00020389167,0.00083372585,0.0006830398,0.00065772544,0.0004281051],"domain_scores_gemma":[0.99810976,0.00056540605,0.00036549979,0.00059403584,0.00014214596,0.00022314329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059139426,0.00037163534,0.0016907493,0.00066718296,0.00005321932,0.0000694759,0.00013084037,0.00012589984,0.000037115566],"category_scores_gemma":[0.0002094755,0.00024136773,0.00014095429,0.0011820658,0.00011533816,0.00014093527,0.000058301157,0.00013310392,0.0000014405595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14942373,0.009131881,0.5179782,0.007699777,0.08474431,0.0022780914,0.016256083,0.08081994,0.027396958,0.00017241729,0.00003213522,0.104066454],"study_design_scores_gemma":[0.3524104,0.024713304,0.5423595,0.0011497572,0.020012321,0.00003728606,0.00019969135,0.0503869,0.008117612,0.000022915914,0.000012493837,0.0005778425],"about_ca_topic_score_codex":0.020588897,"about_ca_topic_score_gemma":0.009650423,"teacher_disagreement_score":0.20298667,"about_ca_system_score_codex":0.009772654,"about_ca_system_score_gemma":0.0057709566,"threshold_uncertainty_score":0.9998654},"labels":[],"label_agreement":null},{"id":"W4405048671","doi":"10.1182/blood-2024-193298","title":"Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Discontinuation; Chronic lymphocytic leukemia; Medicine; Population; Internal medicine; Leukemia","score_opus":0.015283897965878118,"score_gpt":0.26981718027974205,"score_spread":0.25453328231386396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405048671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967005,0.0017105045,0.000009889196,0.000012850518,0.00010097235,0.0011872844,0.00008693282,0.000038138267,0.00015289338],"genre_scores_gemma":[0.9995346,0.000029743043,0.00007100069,0.000007239055,0.00004380169,0.000033154123,0.00017001029,0.000039586565,0.000070857895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975307,0.00015262903,0.00066620007,0.00045921298,0.00083371624,0.00035753622],"domain_scores_gemma":[0.9986195,0.00024703195,0.00014254084,0.00055986526,0.00030951612,0.000121532175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059053925,0.00020847032,0.0005137487,0.0002977182,0.000018338824,0.000014670644,0.00011232564,0.00012880118,0.00004082654],"category_scores_gemma":[0.0004344382,0.00015777169,0.00009449427,0.00095902185,0.00022678275,0.00013372404,0.000101111815,0.00020237743,0.000008834604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0027304494,0.0032587326,0.97260594,0.00342766,0.0003283081,0.00019438952,0.0011754368,0.0004230298,0.0034689342,0.00006451077,0.0002031143,0.012119472],"study_design_scores_gemma":[0.06744795,0.0032855833,0.86083394,0.0027207083,0.00022850993,0.000018885214,0.00004429266,0.004813014,0.060305763,0.000019261775,0.000032944274,0.00024912736],"about_ca_topic_score_codex":0.0062679886,"about_ca_topic_score_gemma":0.0013595261,"teacher_disagreement_score":0.111772,"about_ca_system_score_codex":0.029529307,"about_ca_system_score_gemma":0.02220245,"threshold_uncertainty_score":0.98334074},"labels":[],"label_agreement":null},{"id":"W4405048799","doi":"10.1182/blood-2024-206125","title":"Validation and Implementation of Flow Cytometry Based Minimal Residual Disease (MRD) Assay for Chronic Lymphocytic Leukemia (CLL) Clinical Studies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Chronic lymphocytic leukemia; Minimal residual disease; Flow cytometry; Leukemia; Medicine; Immunology; Cancer research; Oncology","score_opus":0.05746857858536577,"score_gpt":0.428026771784263,"score_spread":0.37055819319889727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405048799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98755896,0.009812953,0.00059938384,0.0003004526,0.00023684389,0.00117847,0.00017731977,0.00009880196,0.000036819285],"genre_scores_gemma":[0.99552536,0.00059839326,0.0023832864,0.000077313,0.0007393918,0.00018494965,0.00024216964,0.00004984417,0.00019930239],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997613,0.00015089025,0.00072628836,0.0005497814,0.000573497,0.00038650492],"domain_scores_gemma":[0.99733573,0.0017153771,0.00010206278,0.00036115493,0.00023320438,0.0002524786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015883738,0.0002056595,0.00047244143,0.0002950117,0.000077100245,0.00004672604,0.00009904445,0.0001160914,0.000072501716],"category_scores_gemma":[0.0011334936,0.00017647579,0.00018673582,0.0003681852,0.00024140664,0.00013026243,0.0000967486,0.00014293438,0.000014207689],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02009083,0.0040157,0.08553191,0.14897065,0.023342375,0.0038592054,0.00600444,0.0019625428,0.077057496,0.0034526547,0.07973837,0.54597384],"study_design_scores_gemma":[0.25735894,0.0066434736,0.03822176,0.0034702914,0.009446999,0.00025071012,0.0020779094,0.46683812,0.21035168,0.00078079564,0.0034870405,0.0010722773],"about_ca_topic_score_codex":0.000086725224,"about_ca_topic_score_gemma":0.000027404016,"teacher_disagreement_score":0.54490155,"about_ca_system_score_codex":0.0134987105,"about_ca_system_score_gemma":0.034017723,"threshold_uncertainty_score":0.9902883},"labels":[],"label_agreement":null},{"id":"W4405049126","doi":"10.1182/blood-2024-203317","title":"Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Spinal Cord Injury BC; University Health Network; Ottawa Hospital; Concordia University; McGill University Health Centre; McGill University; University of Calgary; University of Toronto; Health Sciences North; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Bendamustine; Medicine; Rituximab; Ibrutinib; Lymphoplasmacytic Lymphoma; Internal medicine; Lymphoma; Oncology; Waldenstrom macroglobulinemia; Chronic lymphocytic leukemia; Leukemia","score_opus":0.06659272547137153,"score_gpt":0.3658344261726806,"score_spread":0.29924170070130907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98480123,0.010603532,0.00029017878,0.0014424915,0.0004971688,0.0017145574,0.00009565646,0.00025567904,0.00029950595],"genre_scores_gemma":[0.9902367,0.0019288388,0.003533609,0.0002377483,0.0010336479,0.00025270824,0.00025741573,0.00009107774,0.0024282548],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99670976,0.00020381424,0.00089296576,0.0009643059,0.0005274111,0.0007017157],"domain_scores_gemma":[0.99731946,0.001384244,0.00013129755,0.00054024527,0.0002030267,0.00042175123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084394147,0.00042589995,0.00076100655,0.00023033042,0.00020140661,0.00023375345,0.00015329561,0.00046024,0.00011755765],"category_scores_gemma":[0.0008816574,0.00034015288,0.00024914165,0.00025487953,0.00021863935,0.00017590831,0.00015877098,0.0002939828,0.00012339694],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04161561,0.035359014,0.045528535,0.0087565575,0.008435931,0.025887605,0.009687327,0.00004676535,0.028397152,0.001694662,0.017196367,0.7773945],"study_design_scores_gemma":[0.49357575,0.011153431,0.024449242,0.0035673515,0.005289025,0.010488893,0.0019627025,0.18762986,0.196074,0.00037671582,0.063483775,0.0019492637],"about_ca_topic_score_codex":0.00025919,"about_ca_topic_score_gemma":0.00017570551,"teacher_disagreement_score":0.7754452,"about_ca_system_score_codex":0.0032996878,"about_ca_system_score_gemma":0.004792415,"threshold_uncertainty_score":0.99990505},"labels":[],"label_agreement":null},{"id":"W4405052607","doi":"10.1182/blood-2024-201658","title":"Detection of Recurrent Mutations, Immunoglobulin Rearrangements and Copy Number Changes in Cell-Free DNA and Bone Marrow on Patients with Waldenstrom's Macroglobulinemia over a Course of Treatment","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Waldenstrom macroglobulinemia; Macroglobulinemia; Minimal residual disease; Bone marrow; Rituximab; Lymphoplasmacytic Lymphoma; Ibrutinib; Biology; Medicine; Cancer research; Multiple myeloma; Antibody; Internal medicine; Immunology; Chronic lymphocytic leukemia; Leukemia; Lymphoma","score_opus":0.007793197698363951,"score_gpt":0.26598375322855866,"score_spread":0.2581905555301947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405052607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684304,0.0019193072,0.0000018391498,0.000085760475,0.000056750247,0.00071826216,0.000120293626,0.000017199265,0.00023752151],"genre_scores_gemma":[0.9987971,0.0006772151,0.00017941312,0.000009224339,0.000030486486,0.00005562635,0.000052761254,0.000022930266,0.00017523787],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893814,0.000040163697,0.00023690764,0.00027940478,0.00031351074,0.00019186163],"domain_scores_gemma":[0.99942815,0.00008041024,0.00007235559,0.000267898,0.000074612304,0.00007658573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113154456,0.00015974922,0.00029131444,0.00012529941,0.000018838833,0.000013033332,0.00004050199,0.0000728452,0.000043016924],"category_scores_gemma":[0.000027963983,0.00011836367,0.00002984209,0.0002121135,0.00010948453,0.0000373471,0.000045710283,0.00009985766,0.0000032560686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015148568,0.02036982,0.4977954,0.009030093,0.0026030454,0.0011094847,0.009050044,0.000015789832,0.1344684,0.00005911513,0.0008878404,0.3094624],"study_design_scores_gemma":[0.21697938,0.014492799,0.25204775,0.0043692463,0.0015350096,0.00029114424,0.000641936,0.0015451163,0.5063552,0.00007946165,0.0011563336,0.0005066238],"about_ca_topic_score_codex":0.00042316865,"about_ca_topic_score_gemma":0.0003527439,"teacher_disagreement_score":0.3718868,"about_ca_system_score_codex":0.0011159797,"about_ca_system_score_gemma":0.0004780863,"threshold_uncertainty_score":0.48267302},"labels":[],"label_agreement":null},{"id":"W4405054612","doi":"10.1182/blood-2024-211127","title":"Type 2 Diabetes Mellitus Increases the Risk for Developing Monoclonal Gammopathy of Undetermined Significance in Asian Populations","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Medicine; Hazard ratio; Internal medicine; Multiple myeloma; Epidemiology; Type 2 Diabetes Mellitus; Diabetes mellitus; Immunology; Endocrinology; Monoclonal; Confidence interval; Antibody","score_opus":0.03979018242069634,"score_gpt":0.3232370056004411,"score_spread":0.2834468231797448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405054612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306846,0.0053262697,0.00012538696,0.00044644886,0.00009561958,0.0005764312,0.000041268446,0.000031167318,0.00028898023],"genre_scores_gemma":[0.99692845,0.00021121989,0.0024081382,0.000023613482,0.00013615863,0.000088301495,0.000030204901,0.00002096888,0.00015294412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906397,0.000049055187,0.00024439025,0.0002031503,0.00019959785,0.00023981837],"domain_scores_gemma":[0.99905545,0.00046508788,0.00005438475,0.00030119243,0.00007711636,0.000046745066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037076804,0.000094613875,0.00020000736,0.00010569175,0.00007326917,0.000031335258,0.00014108526,0.000055215613,0.000011718897],"category_scores_gemma":[0.00087186066,0.00006595467,0.00007143908,0.0002490439,0.000096732474,0.00005066212,0.00004450089,0.00012246324,0.000007282645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021938016,0.0046577817,0.5291777,0.014593686,0.0033887706,0.0013471873,0.0073960987,0.00040663066,0.041670643,0.04568802,0.0038171026,0.34566253],"study_design_scores_gemma":[0.05065835,0.0015351779,0.64014876,0.0056371856,0.0021793728,0.00023685576,0.00087334635,0.1256349,0.13559707,0.025908446,0.0105427485,0.0010477775],"about_ca_topic_score_codex":0.00077332807,"about_ca_topic_score_gemma":0.0003096579,"teacher_disagreement_score":0.34461474,"about_ca_system_score_codex":0.00073396915,"about_ca_system_score_gemma":0.003432686,"threshold_uncertainty_score":0.60894376},"labels":[],"label_agreement":null},{"id":"W4405096089","doi":"10.1182/blood-2024-205727","title":"Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Genotyping; Mutant; Biology; Transcriptome; Leukemia; Genetics; Cancer research; Molecular biology; Genotype; Gene; Gene expression","score_opus":0.02120031658623975,"score_gpt":0.2911469645347938,"score_spread":0.269946647948554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405096089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98060775,0.018202145,0.00012735887,0.00007138086,0.00009778598,0.0005465622,0.000031736716,0.000041214866,0.00027407063],"genre_scores_gemma":[0.99782014,0.0013258384,0.00046941603,0.000014426157,0.00014991843,0.000012459152,0.00001758617,0.000037272184,0.00015291822],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980922,0.00006702864,0.0006865685,0.0003692331,0.00044238468,0.00034263762],"domain_scores_gemma":[0.99906945,0.00016949288,0.00007148779,0.00041874236,0.00016275876,0.00010804069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004823094,0.00018026867,0.0005946414,0.0003433617,0.000029542696,0.00002640078,0.00015036957,0.0001664247,0.000025094689],"category_scores_gemma":[0.00012486866,0.00016364429,0.000071117865,0.000891115,0.00010030411,0.00011412976,0.0000619895,0.0001837943,0.0000052935366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00027063923,0.00007081235,0.00068295404,0.006763574,0.00034804165,0.00018384674,0.0021620742,0.0031495634,0.98432845,0.00038272393,0.000038994167,0.0016183063],"study_design_scores_gemma":[0.032956038,0.0012025294,0.0013048494,0.006389508,0.0011634075,0.00009842247,0.0006705291,0.4730138,0.48144352,0.00093181786,0.00036230008,0.00046328903],"about_ca_topic_score_codex":0.0009248823,"about_ca_topic_score_gemma":0.000116724244,"teacher_disagreement_score":0.5028849,"about_ca_system_score_codex":0.011922604,"about_ca_system_score_gemma":0.017218389,"threshold_uncertainty_score":0.99187046},"labels":[],"label_agreement":null},{"id":"W4405309932","doi":"10.1111/bjh.19951","title":"Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open‐label study ( <scp>ACE</scp> ‐ <scp>LY</scp> ‐003)","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Lenalidomide; Rituximab; Follicular lymphoma; Medicine; Open label; Refractory (planetary science); Oncology; Internal medicine; Lymphoma; Phases of clinical research; Pharmacology; Multiple myeloma; Chemotherapy; Clinical trial; Biology","score_opus":0.022463868599533244,"score_gpt":0.31535590560799254,"score_spread":0.2928920370084593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405309932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942151,0.0030353388,0.00002072497,0.0002520104,0.00018298636,0.0019103572,0.00003568425,0.000015307709,0.0003325288],"genre_scores_gemma":[0.9986105,0.00031915322,0.00035668872,0.00009904367,0.000032448635,0.000039441988,0.00001794693,0.00006344519,0.0004613384],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99562806,0.00074983836,0.0014406639,0.00052327884,0.0010887858,0.0005694016],"domain_scores_gemma":[0.99643815,0.0017178555,0.00066235947,0.00042264862,0.00054180075,0.0002171744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00206571,0.000290103,0.0013824297,0.000500379,0.00009681207,0.00013583191,0.0005405111,0.00024218645,0.0000052093565],"category_scores_gemma":[0.004262812,0.00019765882,0.000070198155,0.0011420555,0.00045503804,0.00047422855,0.00029691,0.0008351483,0.0000035038238],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038441144,0.16436742,0.11727819,0.004576549,0.0040209615,0.55650014,0.019582944,0.00006782196,0.0005652221,0.0006638672,0.044480376,0.049455363],"study_design_scores_gemma":[0.83999234,0.013466181,0.04899014,0.008257281,0.00044337823,0.07967683,0.0040342235,0.0009893416,0.0009702831,0.00017510985,0.00287799,0.0001269156],"about_ca_topic_score_codex":0.00096678815,"about_ca_topic_score_gemma":0.0013541548,"teacher_disagreement_score":0.80155116,"about_ca_system_score_codex":0.002095711,"about_ca_system_score_gemma":0.005051577,"threshold_uncertainty_score":0.8961281},"labels":[],"label_agreement":null},{"id":"W4405364989","doi":"10.1016/j.msard.2024.106117","title":"156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis","year":2024,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Multiple sclerosis; Medicine; Immune system; Immunology; Neuroscience; Biology","score_opus":0.029046992068251305,"score_gpt":0.26654000800382216,"score_spread":0.23749301593557084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405364989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825917,0.014664,0.000025569418,0.00050218636,0.00033981,0.0010739121,0.00018690273,0.00021123292,0.00040467642],"genre_scores_gemma":[0.9876841,0.010966272,0.00024870248,0.00004320583,0.000023573235,0.000097451135,0.0004556183,0.000090766196,0.00039035836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622405,0.00010956941,0.0012428302,0.00084107654,0.00067308574,0.00090937124],"domain_scores_gemma":[0.99805605,0.00082802796,0.00013622851,0.0005029445,0.00010162193,0.00037513013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006709563,0.00041105907,0.00074744585,0.00034525746,0.0002320244,0.000071043905,0.00019518494,0.00039596844,0.00025043156],"category_scores_gemma":[0.00082875,0.00034481226,0.00025088838,0.0011408806,0.0005530049,0.0002040938,0.00029447998,0.00054228853,0.00006987721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060942625,0.0035139832,0.43479452,0.0049309083,0.0023419433,0.00038919243,0.034507994,0.0013518375,0.08028888,0.00011273269,0.0021311839,0.42954257],"study_design_scores_gemma":[0.049322337,0.0002949175,0.86095554,0.0062896246,0.00019120425,0.000042878302,0.0035304332,0.06271354,0.0068592867,0.000065249485,0.008839595,0.00089542073],"about_ca_topic_score_codex":0.0016134616,"about_ca_topic_score_gemma":0.00056735676,"teacher_disagreement_score":0.42864716,"about_ca_system_score_codex":0.0021427535,"about_ca_system_score_gemma":0.0021761535,"threshold_uncertainty_score":0.9999004},"labels":[],"label_agreement":null},{"id":"W4405389146","doi":"10.51731/cjht.2024.1042","title":"Fruquintinib (Fruzaqla)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.038644650356632254,"score_gpt":0.35176466344841517,"score_spread":0.31312001309178294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405389146","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24761117,0.56099796,0.0006934767,0.18325052,0.0019242987,0.0005753035,0.000021945172,0.00058496656,0.004340401],"genre_scores_gemma":[0.99727607,0.0010171131,0.0006594083,0.00043634287,0.000044965258,0.0000036229687,0.0000016009075,0.000023522016,0.0005373707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842894,0.00003100848,0.00051377,0.00015030369,0.00027590586,0.0006000751],"domain_scores_gemma":[0.9991563,0.00009996621,0.00009693347,0.00028828866,0.00016148725,0.00019702953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009088475,0.00011101372,0.00036234927,0.0010991998,0.000112529946,0.000065805405,0.00027531196,0.00016462294,0.00012036115],"category_scores_gemma":[0.00090555346,0.000084667605,0.000116239586,0.0006040192,0.00030289014,0.00009855168,0.000024451456,0.00076359167,0.00009023743],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000019899406,0.000011031853,0.00038230975,0.0008184829,0.00010761935,0.0051715863,0.00036211804,0.0000044512544,0.00006755144,0.0049803914,0.07137112,0.91670346],"study_design_scores_gemma":[0.001561822,0.0007068452,0.0005762271,0.0015681154,0.00002399694,0.008473778,0.0018468861,0.00044037448,0.0008646646,0.0033294046,0.9804977,0.0001101404],"about_ca_topic_score_codex":0.005460688,"about_ca_topic_score_gemma":0.0013105894,"teacher_disagreement_score":0.9165933,"about_ca_system_score_codex":0.011494265,"about_ca_system_score_gemma":0.07507536,"threshold_uncertainty_score":0.99230045},"labels":[],"label_agreement":null},{"id":"W4405500883","doi":"10.51731/cjht.2024.1046","title":"Venetoclax (Venclexta)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Chronic lymphocytic leukemia; Reimbursement; Ibrutinib; Chlorambucil; Internal medicine; Intensive care medicine; Leukemia; Oncology; Chemotherapy; Health care; Political science","score_opus":0.03855962024480177,"score_gpt":0.35098683390007007,"score_spread":0.3124272136552683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405500883","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23896751,0.6512239,0.00053242804,0.1039183,0.0015066031,0.0005516821,0.000018121578,0.0004576235,0.0028238758],"genre_scores_gemma":[0.9977129,0.0010409385,0.00049342855,0.00033490424,0.000037818423,0.0000037780915,0.0000013479747,0.000020390306,0.00035448885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986206,0.000027885344,0.00043479016,0.0001322363,0.00024969407,0.0005347595],"domain_scores_gemma":[0.99927807,0.000077113706,0.00008189732,0.00025939225,0.00012554388,0.0001779597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007419001,0.00009686536,0.00031119655,0.0009268778,0.00010600049,0.000052829953,0.0002483366,0.00014469001,0.0000842763],"category_scores_gemma":[0.0005964721,0.00007537968,0.00009863715,0.0005443455,0.00026018528,0.000085150146,0.000020638037,0.00064582314,0.00006890451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000019763365,0.000006073093,0.00023216958,0.00079697475,0.000093469615,0.005533456,0.00032437465,0.00001937364,0.00008140008,0.0042783637,0.045774132,0.94284046],"study_design_scores_gemma":[0.0014028979,0.0007919367,0.0005886223,0.0016963093,0.000022715189,0.008695841,0.001311416,0.0009871166,0.0008982964,0.0048515964,0.97864413,0.000109134766],"about_ca_topic_score_codex":0.0063015344,"about_ca_topic_score_gemma":0.0012085914,"teacher_disagreement_score":0.9427313,"about_ca_system_score_codex":0.024779579,"about_ca_system_score_gemma":0.1200972,"threshold_uncertainty_score":0.9789641},"labels":[],"label_agreement":null},{"id":"W4405584069","doi":"10.1002/ajh.27563","title":"Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study","year":2024,"lang":"en","type":"letter","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Incyte; Pharmacyclics; Genentech; Grifols; Galápagos; MEI Pharma; BeiGene; National Cancer Institute; AbbVie; Seagen; Gilead Sciences; Loxo Oncology; TG Therapeutics; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Venetoclax; Medicine; Chronic lymphocytic leukemia; Discontinuation; Ibrutinib; Internal medicine; Oncology; Clinical trial; Idelalisib; Leukemia","score_opus":0.018615806460144102,"score_gpt":0.34243286789192356,"score_spread":0.32381706143177946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405584069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962855,0.0022006242,0.000011643555,0.0057513923,0.00084894925,0.0012964653,0.000026647824,0.000029901516,0.00020583198],"genre_scores_gemma":[0.9923728,0.0008752486,0.000091277696,0.0045628306,0.0015356529,0.00019503648,0.00007837495,0.00015570183,0.00013308192],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99493325,0.0011637763,0.0014979024,0.00068366906,0.001052185,0.0006692231],"domain_scores_gemma":[0.99656963,0.0010739235,0.0009637075,0.0008015246,0.0003926525,0.00019853849],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078050373,0.0006219158,0.0025658924,0.00217857,0.000024887684,0.000031262785,0.0005079715,0.00034459893,0.00012370416],"category_scores_gemma":[0.00008216006,0.00046710018,0.0004990214,0.00093238056,0.0007390155,0.00012346669,0.000091492875,0.0015020168,0.000019476638],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09354831,0.0050184363,0.1024501,0.010356015,0.016256612,0.64251286,0.00510343,0.0088648535,0.0069874576,0.00012366717,0.026367586,0.0824107],"study_design_scores_gemma":[0.36715153,0.24228081,0.04087737,0.029001437,0.0050855237,0.050323255,0.0017989798,0.031551357,0.08037864,0.00035286314,0.14712337,0.0040748985],"about_ca_topic_score_codex":0.00880258,"about_ca_topic_score_gemma":0.00045516706,"teacher_disagreement_score":0.59218955,"about_ca_system_score_codex":0.20636262,"about_ca_system_score_gemma":0.0677271,"threshold_uncertainty_score":0.9997781},"labels":[],"label_agreement":null},{"id":"W4405638499","doi":"10.1016/j.molcel.2024.11.033","title":"Mutability and hypermutation antagonize immunoglobulin codon optimality","year":2024,"lang":"en","type":"article","venue":"Molecular Cell","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centers for Disease Control and Prevention; National Cancer Institute; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation; Division of Intramural Research, National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Somatic hypermutation; Biology; Genetics; Antibody; Computational biology; B cell","score_opus":0.00868993809292268,"score_gpt":0.28757656663686565,"score_spread":0.27888662854394297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405638499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813771,0.0058795535,0.0022200472,0.0004946826,0.00010489703,0.00041214513,0.000010247876,0.0001225637,0.00937874],"genre_scores_gemma":[0.9974388,0.00012858184,0.0014737102,0.00016920314,0.000043639233,0.0000166913,0.00004813132,0.000030133122,0.00065110263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869114,0.000073365845,0.00020858299,0.00041390138,0.00034566264,0.00026731755],"domain_scores_gemma":[0.9993198,0.00008438526,0.000017119137,0.0003731479,0.000066717206,0.00013882462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038920093,0.00013621835,0.00019652574,0.00006909329,0.00004191582,0.00007213957,0.000065830136,0.000103585626,0.0001663493],"category_scores_gemma":[0.00009018761,0.00012056162,0.00008597545,0.00022335218,0.00013629044,0.00006125024,0.00008912159,0.00022373421,0.00015312718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039434677,0.00032773826,0.001306262,0.0035344628,0.00017862515,0.006362661,0.0010589801,0.00012383897,0.9587235,0.0008420521,0.0007952192,0.026352314],"study_design_scores_gemma":[0.012765201,0.0005714969,0.0057592723,0.00031704138,0.00036419943,0.001381737,0.00025445048,0.13370867,0.8194831,0.0008797857,0.023962768,0.0005522934],"about_ca_topic_score_codex":0.0003441066,"about_ca_topic_score_gemma":0.0000018076878,"teacher_disagreement_score":0.13924041,"about_ca_system_score_codex":0.0022084948,"about_ca_system_score_gemma":0.0015220027,"threshold_uncertainty_score":0.5775137},"labels":[],"label_agreement":null},{"id":"W4405850856","doi":"10.1111/ejh.14376","title":"Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"","keywords":"Chronic lymphocytic leukemia; Chemoimmunotherapy; Medicine; Clinical trial; Follicular lymphoma; Internal medicine; Oncology; Lymphoma; Cancer; Leukemia","score_opus":0.24920460784277412,"score_gpt":0.46771486865956996,"score_spread":0.21851026081679584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405850856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720236,0.011351123,0.0115463175,0.00039595691,0.0017366428,0.0009319355,0.000009721553,0.000048234528,0.0019564852],"genre_scores_gemma":[0.9953149,0.0011262688,0.0019609001,0.00015086684,0.0009103676,0.000010634429,0.000012810806,0.00010378924,0.0004094449],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99058783,0.0032749705,0.0045549814,0.00047675162,0.0005136443,0.00059182226],"domain_scores_gemma":[0.9920459,0.005694621,0.0010423474,0.0005068904,0.0003957988,0.000314478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016154075,0.0002889602,0.002176272,0.0009264839,0.000037747177,0.000045594243,0.00045574034,0.00017516562,0.00010362038],"category_scores_gemma":[0.007601019,0.00022605875,0.0009627827,0.00054780056,0.00042312033,0.00014487983,0.00013218401,0.00035022674,0.00010357697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03272102,0.0010473036,0.0026160418,0.025108807,0.0076273107,0.23120447,0.0050762515,0.018162468,0.015695205,0.017795797,0.04192538,0.6010199],"study_design_scores_gemma":[0.24229617,0.0104773175,0.0054171,0.009460109,0.0024356642,0.1655605,0.0011015701,0.52134967,0.0143125625,0.002985127,0.023700802,0.00090340065],"about_ca_topic_score_codex":0.00009050986,"about_ca_topic_score_gemma":0.000028566865,"teacher_disagreement_score":0.60011655,"about_ca_system_score_codex":0.046774045,"about_ca_system_score_gemma":0.06802484,"threshold_uncertainty_score":0.9568852},"labels":[],"label_agreement":null},{"id":"W4405860526","doi":"10.55905/oelv22n12-227","title":"Relato de caso – doença de castleman multicêntrica associada ao HIV","year":2024,"lang":"pt","type":"article","venue":"OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cascades (Canada)","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Virology","score_opus":0.020953360600552057,"score_gpt":0.3196861283148627,"score_spread":0.2987327677143107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405860526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7871075,0.15980183,0.001611497,0.0035781893,0.0010295141,0.0021373555,0.00047048065,0.0009972892,0.043266293],"genre_scores_gemma":[0.9246477,0.027187478,0.00515478,0.0020152626,0.0015272397,0.00028205747,0.00010793125,0.00053796783,0.038539574],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9916887,0.00123538,0.0014554062,0.0016088702,0.0007159911,0.0032956004],"domain_scores_gemma":[0.9902961,0.0057062157,0.00041411037,0.001580612,0.0001538846,0.0018490236],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0030127512,0.0009989925,0.0018487523,0.0005329858,0.00040853853,0.0006388401,0.0009619217,0.0009715515,0.0029348447],"category_scores_gemma":[0.0020734167,0.0010330402,0.00082989235,0.0017789504,0.00086661277,0.0004123619,0.0005315589,0.0024028185,0.002993809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009465901,0.0018645201,0.3016248,0.016120438,0.0105204005,0.07063503,0.06277612,0.0049681934,0.0012566327,0.009893637,0.2573023,0.2620913],"study_design_scores_gemma":[0.007415914,0.0004151568,0.01834844,0.0024639007,0.0016398393,0.003672176,0.0030748628,0.4911291,0.00018298598,0.00032893015,0.46985677,0.0014719245],"about_ca_topic_score_codex":0.032650117,"about_ca_topic_score_gemma":0.0011013594,"teacher_disagreement_score":0.4861609,"about_ca_system_score_codex":0.07867747,"about_ca_system_score_gemma":0.040330157,"threshold_uncertainty_score":0.9998987},"labels":[],"label_agreement":null},{"id":"W4406388681","doi":"10.1016/s2211-9698(17)77092-6","title":"10.1016/s2211-9698(17)77092-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Tyrosine kinase; Pharmacology; Internal medicine; Receptor","score_opus":0.009517943219646777,"score_gpt":0.2294886461117249,"score_spread":0.21997070289207812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406388681","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031533174,0.00016981253,7.4504624e-7,0.00080955523,0.0000016731681,0.000495553,0.000010495977,0.00018861257,0.99517024],"genre_scores_gemma":[0.0004710435,0.0000012569989,0.00018556719,0.00019346384,0.0003830288,0.00004123642,0.000033222965,0.00005452717,0.99863666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981202,0.000042075237,0.00026113045,0.00038403488,0.00059254136,0.0006000375],"domain_scores_gemma":[0.998592,0.00010298989,0.00002263286,0.0007008031,0.00009411605,0.00048744676],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002600465,0.0001936426,0.00032611296,0.00013587902,0.000073609335,0.00003392345,0.0002409703,0.00012350317,0.9989904],"category_scores_gemma":[0.00013539939,0.00017126331,0.00011062844,0.00039438915,0.00008677785,0.00007137388,0.00008323525,0.00023259052,0.9976622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004267827,0.00008611801,8.265703e-8,0.000028472381,0.000042614647,0.00014173101,0.00002607964,0.00002689865,0.00010957511,6.894327e-7,0.62310266,0.37600827],"study_design_scores_gemma":[0.0054468047,0.0004087322,0.00001986379,0.00007457859,0.000045220684,0.00026302325,0.0000018947874,0.002331764,0.00043846547,0.0000047321028,0.9907822,0.00018274436],"about_ca_topic_score_codex":0.00018412217,"about_ca_topic_score_gemma":5.162265e-7,"teacher_disagreement_score":0.37582555,"about_ca_system_score_codex":0.0036881214,"about_ca_system_score_gemma":0.0019598117,"threshold_uncertainty_score":0.9644309},"labels":[],"label_agreement":null},{"id":"W4406547363","doi":"10.1016/s1541-9800(05)70767-5","title":"10.1016/s1541-9800(05)70767-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chloroquine; Clofazimine; Medicine; Pharmacology; Malaria; Immunology; Leprosy","score_opus":0.009675893835869684,"score_gpt":0.22896570819561654,"score_spread":0.21928981435974687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406547363","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038207697,0.00015288085,7.164252e-7,0.00085758354,0.000002175388,0.0004926015,0.000010636593,0.00018968455,0.994473],"genre_scores_gemma":[0.00073466037,0.0000013455622,0.00017657381,0.00018653698,0.00037701076,0.00004092267,0.000033367,0.000056713554,0.9983929],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980976,0.00004489767,0.00026081578,0.00039522213,0.00059635186,0.00060513907],"domain_scores_gemma":[0.9985619,0.00010576138,0.000022754319,0.0007222968,0.000095329866,0.0004919573],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026524303,0.0001941503,0.0003255237,0.00013743051,0.00007385826,0.000034283108,0.00024288145,0.00012266875,0.99879974],"category_scores_gemma":[0.00015260429,0.00017156308,0.00009108448,0.0003933911,0.00008840988,0.000072526134,0.000084341744,0.00023122654,0.9981767],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045773192,0.00009084889,5.5147066e-8,0.000040635987,0.00004148601,0.00017687872,0.000027635038,0.00002098581,0.00017090281,8.476479e-7,0.6185262,0.38044578],"study_design_scores_gemma":[0.0055822567,0.00053797784,0.000017191234,0.00007478179,0.00005529627,0.00033433997,0.0000017910552,0.0019293156,0.00059364794,0.0000059603394,0.99068457,0.00018284735],"about_ca_topic_score_codex":0.00019890275,"about_ca_topic_score_gemma":4.9485607e-7,"teacher_disagreement_score":0.38026294,"about_ca_system_score_codex":0.0038809828,"about_ca_system_score_gemma":0.0019599223,"threshold_uncertainty_score":0.99994296},"labels":[],"label_agreement":null},{"id":"W4406552146","doi":"10.1016/s1553-3212(08)70319-4","title":"10.1016/s1553-3212(08)70319-4","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Insulin; Medicine; Internal medicine","score_opus":0.00941549831875664,"score_gpt":0.22768864946397838,"score_spread":0.21827315114522172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406552146","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034431939,0.000169174,0.0000011553046,0.0008213507,0.0000019476533,0.0004943127,0.000009077826,0.00019025909,0.99486953],"genre_scores_gemma":[0.00082214596,0.0000013746163,0.00017409406,0.00017774204,0.00039571474,0.00003960506,0.000031305724,0.000056604542,0.9983014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981255,0.000044784512,0.00026084436,0.00038198684,0.0005838965,0.0006029956],"domain_scores_gemma":[0.9985865,0.00010485337,0.000023071725,0.00070076965,0.00009475871,0.0004900822],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025315714,0.00019360222,0.00032659175,0.0001353226,0.000074428644,0.000035459005,0.0002424961,0.00012188158,0.9988232],"category_scores_gemma":[0.00014697126,0.00017147369,0.00010882967,0.00040683683,0.00008722427,0.00007408815,0.00008443564,0.00023305733,0.99857664],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052109326,0.00009578576,9.790084e-8,0.000036995174,0.000045238747,0.00015977037,0.00003298713,0.000022527594,0.00013927204,0.0000014608679,0.59608203,0.40286273],"study_design_scores_gemma":[0.005625743,0.00041510354,0.00002178075,0.0000718542,0.0000436989,0.00025598126,0.0000020100613,0.002918689,0.00042542792,0.000005334196,0.9900329,0.0001814656],"about_ca_topic_score_codex":0.00019724731,"about_ca_topic_score_gemma":3.4838106e-7,"teacher_disagreement_score":0.40268126,"about_ca_system_score_codex":0.0037220865,"about_ca_system_score_gemma":0.0020026136,"threshold_uncertainty_score":0.9733127},"labels":[],"label_agreement":null},{"id":"W4406562207","doi":"10.1016/j.slasd.2025.100214","title":"Single-plate kinome screening in live-cells to enable highly cost-efficient kinase inhibitor profiling","year":2025,"lang":"en","type":"article","venue":"SLAS DISCOVERY","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Deutschen Konsortium für Translationale Krebsforschung; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; McGill University; Innovative Health Initiative; Ontario Genomics; Genome Canada; Bayer; Pfizer; Deutsche Forschungsgemeinschaft; Deutsches Krebsforschungszentrum; Bristol-Myers Squibb","keywords":"Kinome; Profiling (computer programming); Kinase; Computational biology; Computer science; Cell biology; Biology","score_opus":0.026588746513300267,"score_gpt":0.2995148444599841,"score_spread":0.2729260979466838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406562207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988334,0.00054752256,0.001993126,0.0007578823,0.00057676743,0.0020875882,0.000028518387,0.000091760914,0.005582812],"genre_scores_gemma":[0.9840921,0.000017523495,0.0018794792,0.00072476274,0.00023452964,0.00017044137,0.000037319216,0.000047262085,0.012796584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971391,0.000079965335,0.0005349731,0.000707707,0.0006163839,0.00092189363],"domain_scores_gemma":[0.99865156,0.00028185363,0.00006698372,0.0006260655,0.00011717344,0.0002563609],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005376208,0.00028720775,0.00049103145,0.00064895104,0.000100683064,0.00016635667,0.00024054709,0.00015727204,0.00005686714],"category_scores_gemma":[0.00038302937,0.00026378696,0.00013394826,0.0010968096,0.000110303685,0.00021356702,0.00040925827,0.0004249954,0.00025470147],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00553316,0.0031542173,0.007402475,0.0023337875,0.00035571094,0.0040815626,0.0024375657,0.043343093,0.90372056,0.0059599383,0.0077226027,0.013955357],"study_design_scores_gemma":[0.019560285,0.0005774324,0.00086770894,0.0030193478,0.000090101705,0.00003945617,0.0012606047,0.036209952,0.9258533,0.000108961896,0.011872528,0.0005402813],"about_ca_topic_score_codex":0.0011455438,"about_ca_topic_score_gemma":0.00011339848,"teacher_disagreement_score":0.02213281,"about_ca_system_score_codex":0.007869547,"about_ca_system_score_gemma":0.0040102066,"threshold_uncertainty_score":0.99998146},"labels":[],"label_agreement":null},{"id":"W4406572418","doi":"10.1016/s2211-9698(12)57630-2","title":"10.1016/s2211-9698(12)57630-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.010364095017639323,"score_gpt":0.22672575613035587,"score_spread":0.21636166111271654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406572418","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036080522,0.00014108347,7.346349e-7,0.00071687385,0.0000018865506,0.0004989082,0.000009117244,0.00018867997,0.99483466],"genre_scores_gemma":[0.0007944722,0.000001452281,0.00017343315,0.00015919954,0.00038104056,0.000040407365,0.000030673615,0.00005708535,0.99836224],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981171,0.000045102755,0.00026079608,0.00038378395,0.0005940512,0.00059915986],"domain_scores_gemma":[0.9986079,0.00010250447,0.000022635975,0.0007000095,0.00008249013,0.00048448922],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002594019,0.00019347052,0.00032654218,0.00013488397,0.00007433595,0.00003411922,0.00024099214,0.00012355615,0.99876434],"category_scores_gemma":[0.00014705621,0.00017121439,0.00010923253,0.00031317654,0.000087423854,0.00007117713,0.000083909,0.00023099186,0.9979247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050481746,0.000094080744,1.3636142e-7,0.000035805082,0.00004746994,0.00015209372,0.000029426707,0.00002036751,0.00013610818,8.9135955e-7,0.5390803,0.4598985],"study_design_scores_gemma":[0.005520216,0.0004337059,0.000028683518,0.00007495717,0.000045939232,0.00025499883,0.0000018478318,0.00212914,0.00049207895,0.00000495668,0.9908309,0.0001825872],"about_ca_topic_score_codex":0.0002245869,"about_ca_topic_score_gemma":8.074923e-7,"teacher_disagreement_score":0.4597159,"about_ca_system_score_codex":0.003760432,"about_ca_system_score_gemma":0.0019337584,"threshold_uncertainty_score":0.98333985},"labels":[],"label_agreement":null},{"id":"W4406574589","doi":"10.1016/s1634-6939(20)30479-8","title":"10.1016/s1634-6939(20)30479-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.009132581768588536,"score_gpt":0.22731935189655084,"score_spread":0.2181867701279623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406574589","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035478235,0.00017035757,7.3810605e-7,0.0009121199,0.0000018640444,0.0004964902,0.000012181443,0.000192052,0.9946664],"genre_scores_gemma":[0.0005662648,0.0000011373309,0.00017108321,0.00015475457,0.00038651883,0.000041375173,0.00004010772,0.000056724846,0.998582],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981046,0.00004518547,0.00026156378,0.00038611033,0.000596591,0.00060595345],"domain_scores_gemma":[0.99857485,0.00010703703,0.000022768241,0.0007030881,0.00009970015,0.00049255934],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025970707,0.00019414352,0.0003272768,0.00013538287,0.00007355575,0.000034027005,0.00024307331,0.00012320682,0.9987624],"category_scores_gemma":[0.00014037413,0.00017178008,0.00010709792,0.00040814295,0.000089827074,0.00007239425,0.0000833919,0.00022534984,0.99808145],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052073435,0.000098052136,1.0609052e-7,0.000038409038,0.000047021258,0.00016429505,0.000027416338,0.00003036484,0.00018991524,7.276368e-7,0.57296634,0.42591658],"study_design_scores_gemma":[0.005542807,0.00041563224,0.000014207295,0.00007526382,0.000045279092,0.00027084432,0.00000178744,0.002340381,0.00056079816,0.000005446644,0.99054426,0.00018327696],"about_ca_topic_score_codex":0.00016513861,"about_ca_topic_score_gemma":5.900584e-7,"teacher_disagreement_score":0.42573333,"about_ca_system_score_codex":0.0037529957,"about_ca_system_score_gemma":0.0020478996,"threshold_uncertainty_score":0.98139536},"labels":[],"label_agreement":null},{"id":"W4406574831","doi":"10.1016/s1634-6939(20)30315-x","title":"10.1016/s1634-6939(20)30315-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chemistry","score_opus":0.009129118811281544,"score_gpt":0.22702222380019418,"score_spread":0.21789310498891265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406574831","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035159541,0.00016067427,7.3950906e-7,0.00087020406,0.0000018695613,0.000494654,0.000012332573,0.00019180181,0.99475175],"genre_scores_gemma":[0.0006070398,0.000001117424,0.00016754126,0.00015783314,0.00038750257,0.00004113999,0.000040357292,0.000056667643,0.9985408],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99810857,0.00004438117,0.000261242,0.00038521065,0.00059526286,0.0006053462],"domain_scores_gemma":[0.9985862,0.000104890496,0.000022739308,0.0007032896,0.00009650912,0.00048640923],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000260156,0.00019390645,0.0003267696,0.00013777906,0.00007398494,0.000033959845,0.00024289372,0.000123062,0.9987182],"category_scores_gemma":[0.00013674956,0.00017156628,0.00010802458,0.0004007672,0.00008961138,0.00007199037,0.00008361739,0.00022476904,0.9981222],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005114375,0.00009871112,1.02619154e-7,0.000038585167,0.000047083777,0.00016067823,0.00002694911,0.000030185422,0.00019436861,7.2729074e-7,0.58221155,0.41667962],"study_design_scores_gemma":[0.0055212234,0.00041353222,0.00001390122,0.00007560995,0.000044901757,0.00026617813,0.0000017577336,0.0023166018,0.00057742,0.0000055843016,0.9905802,0.00018309592],"about_ca_topic_score_codex":0.00016789234,"about_ca_topic_score_gemma":5.841534e-7,"teacher_disagreement_score":0.41649655,"about_ca_system_score_codex":0.0037537313,"about_ca_system_score_gemma":0.0020011193,"threshold_uncertainty_score":0.98158765},"labels":[],"label_agreement":null},{"id":"W4406579155","doi":"10.1016/s1541-9800(06)70926-7","title":"10.1016/s1541-9800(06)70926-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Rituximab; Toxicity; Medicine; Immunology; Internal medicine; Lymphoma","score_opus":0.009555837180016761,"score_gpt":0.22847076598894714,"score_spread":0.21891492880893038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579155","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004739945,0.00016624715,7.27099e-7,0.00079812336,0.0000012951596,0.0004967291,0.000010647377,0.0001896676,0.9935966],"genre_scores_gemma":[0.0009291764,0.0000013319772,0.00016685919,0.00016031926,0.00036968113,0.000041175157,0.000042877185,0.00005671978,0.9982319],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99810153,0.000045658668,0.0002628602,0.00038521056,0.00059958757,0.0006051268],"domain_scores_gemma":[0.99857134,0.00010864481,0.000022411548,0.000700465,0.000097458855,0.0004996954],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026512909,0.00019410926,0.00032747583,0.0001374695,0.00007391232,0.000034121218,0.00024233478,0.00012351607,0.9986553],"category_scores_gemma":[0.00015731835,0.00017171977,0.000109384506,0.00039968273,0.00008826154,0.00007070872,0.000084169005,0.00023453526,0.9986558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041179918,0.00010235206,1.3942488e-7,0.000040449206,0.00004812824,0.0001545882,0.000031711243,0.000027050695,0.0001479984,9.907196e-7,0.6728472,0.32618758],"study_design_scores_gemma":[0.0055356286,0.00036290305,0.000023077258,0.00007688004,0.000044523324,0.0002582827,0.000001986034,0.0023113666,0.0005213056,0.000005822798,0.9906749,0.00018330189],"about_ca_topic_score_codex":0.00016861802,"about_ca_topic_score_gemma":3.7526578e-7,"teacher_disagreement_score":0.3260043,"about_ca_system_score_codex":0.0037978485,"about_ca_system_score_gemma":0.001991955,"threshold_uncertainty_score":0.9931241},"labels":[],"label_agreement":null},{"id":"W4406579757","doi":"10.1016/s1541-9800(10)70630-x","title":"10.1016/s1541-9800(10)70630-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Methotrexate; Medicine; Internal medicine","score_opus":0.009936428593099834,"score_gpt":0.22910924355307077,"score_spread":0.21917281495997093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579757","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034042057,0.00017122758,5.815194e-7,0.00073162396,0.0000017908941,0.00049256795,0.000011501922,0.00019296342,0.9949935],"genre_scores_gemma":[0.0006406173,0.0000012939072,0.00015613671,0.00013895404,0.00039401534,0.000043732784,0.000040638268,0.000059997823,0.9985246],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980154,0.000049235765,0.00027722926,0.00040540926,0.00062573573,0.0006269616],"domain_scores_gemma":[0.99849695,0.00012065906,0.00002510948,0.0007409854,0.00011333933,0.0005029492],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027794554,0.00020614383,0.00034439616,0.00014475992,0.00007772851,0.0000367641,0.00025968262,0.00013160828,0.9994522],"category_scores_gemma":[0.00018425066,0.00018257921,0.000115213064,0.000412091,0.0000942149,0.00007450535,0.000091527596,0.00022277958,0.9988936],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006101849,0.00009890969,5.855395e-8,0.000038694096,0.0000469424,0.00014931959,0.000027242657,0.000022004584,0.00012430546,7.21994e-7,0.66666865,0.33221298],"study_design_scores_gemma":[0.005892211,0.00047219745,0.000014490899,0.0000780652,0.000047811092,0.00022554022,0.0000019085826,0.0019221089,0.0005786912,0.00000531804,0.9905677,0.00019395903],"about_ca_topic_score_codex":0.00018868121,"about_ca_topic_score_gemma":4.98959e-7,"teacher_disagreement_score":0.33201903,"about_ca_system_score_codex":0.0039886474,"about_ca_system_score_gemma":0.0021172096,"threshold_uncertainty_score":0.99983484},"labels":[],"label_agreement":null},{"id":"W4406643195","doi":"10.1016/b978-2-294-76306-9.50353-7","title":"10.1016/b978-2-294-76306-9.50353-7","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.014637316369444953,"score_gpt":0.22605132603867026,"score_spread":0.2114140096692253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406643195","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003566375,0.0009071037,4.854197e-7,0.00039063912,0.000006321681,0.0012261056,0.00012676587,0.0002843866,0.99705464],"genre_scores_gemma":[0.0000023781852,0.000006933605,0.00009327533,0.0001702658,0.0013089734,0.000049474318,0.00038869848,0.00031093546,0.99766904],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996312,0.000027643253,0.0006151782,0.0009128695,0.0012876855,0.0008445846],"domain_scores_gemma":[0.99713737,0.00018069445,0.00012202047,0.001521747,0.00022064515,0.00081749854],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030308124,0.00068157446,0.0010760832,0.00051923736,0.000095534495,0.00005766578,0.00050720887,0.0007585974,0.998988],"category_scores_gemma":[0.00011459876,0.00064292544,0.00039681245,0.00011506052,0.00022158673,0.00006155482,0.00028506835,0.0009257785,0.99863535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00071606535,0.000048306018,4.7207176e-9,0.00016538549,0.00026357832,0.0008108877,0.000014836262,0.000006325709,0.0000120701325,0.000057980564,0.49100077,0.50690377],"study_design_scores_gemma":[0.0051914197,0.0006125512,4.3993947e-7,0.00072200265,0.00027825029,0.0005992237,4.2062308e-7,0.00021251844,0.000045360117,0.0001581942,0.99158204,0.0005975738],"about_ca_topic_score_codex":0.00013178792,"about_ca_topic_score_gemma":7.83762e-7,"teacher_disagreement_score":0.50630623,"about_ca_system_score_codex":0.011584841,"about_ca_system_score_gemma":0.00681032,"threshold_uncertainty_score":0.9996022},"labels":[],"label_agreement":null},{"id":"W4406651515","doi":"10.1016/b978-1-4557-5414-4.00044-9","title":"10.1016/b978-1-4557-5414-4.00044-9","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.014368622308148485,"score_gpt":0.2254881318009172,"score_spread":0.21111950949276873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406651515","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002469589,0.0009301232,6.448434e-7,0.00036058298,0.0000064370593,0.0012280961,0.000099155564,0.00031607185,0.9970564],"genre_scores_gemma":[0.0000024032092,0.00000718118,0.0001246976,0.00013733705,0.0011591843,0.000049665043,0.00030795162,0.00032060037,0.997891],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99629796,0.00002799623,0.0006227074,0.0009191641,0.0012803408,0.0008518229],"domain_scores_gemma":[0.9970968,0.0002010359,0.00012272887,0.0015449715,0.000224561,0.00080992957],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029238246,0.0006829013,0.0010794626,0.0005214716,0.00009421922,0.000059506136,0.0005205695,0.00076200144,0.9989578],"category_scores_gemma":[0.00011687253,0.0006480697,0.00040610365,0.00011558241,0.0002217767,0.00006507643,0.0002955361,0.00093009835,0.9986841],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00070417346,0.00004649895,2.5397944e-9,0.00015509425,0.00025632244,0.00073897844,0.000014032088,0.000005917488,0.000010843105,0.000059142007,0.31766507,0.6803439],"study_design_scores_gemma":[0.0051102545,0.00082350307,3.333474e-7,0.0007414443,0.00027882005,0.0005885271,4.34646e-7,0.00020951548,0.00004630506,0.00015729955,0.991442,0.0006015205],"about_ca_topic_score_codex":0.00011725485,"about_ca_topic_score_gemma":8.5036686e-7,"teacher_disagreement_score":0.6797424,"about_ca_system_score_codex":0.0105739795,"about_ca_system_score_gemma":0.0062737097,"threshold_uncertainty_score":0.9995971},"labels":[],"label_agreement":null},{"id":"W4406652979","doi":"10.1016/b978-0-7020-7455-4.00017-0","title":"10.1016/b978-0-7020-7455-4.00017-0","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Immunology; Leukemia","score_opus":0.015314379125520604,"score_gpt":0.22738395107142356,"score_spread":0.21206957194590295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406652979","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000030175738,0.0008692154,4.817822e-7,0.00036258483,0.000005823623,0.001215788,0.00007995642,0.0003058012,0.99715734],"genre_scores_gemma":[0.0000027193562,0.000006766962,0.00009795942,0.00016486821,0.0011765527,0.000039592986,0.00030190567,0.00032042537,0.9978892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963127,0.000027120772,0.0006167781,0.000919207,0.0012794208,0.0008448123],"domain_scores_gemma":[0.9971179,0.00018648304,0.00012435442,0.0015439412,0.00021499467,0.0008123474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002774977,0.0006859911,0.0010710441,0.000497106,0.00009619338,0.00006073935,0.00051949214,0.00076421245,0.9991223],"category_scores_gemma":[0.0001036232,0.0006508213,0.00039816077,0.0001122453,0.0002234397,0.000064487154,0.000267158,0.00092614867,0.9987672],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00078975793,0.000052287847,3.4478846e-9,0.00014833895,0.000254651,0.0008153909,0.000015656704,0.0000067024375,0.000010269114,0.000076428456,0.43561465,0.56221586],"study_design_scores_gemma":[0.0052100015,0.00063428585,4.6539364e-7,0.00072987675,0.00026289976,0.0006193143,4.2339357e-7,0.00023501918,0.00004549393,0.00013180223,0.99152696,0.00060345605],"about_ca_topic_score_codex":0.00015086813,"about_ca_topic_score_gemma":0.0000013079501,"teacher_disagreement_score":0.5616124,"about_ca_system_score_codex":0.009511933,"about_ca_system_score_gemma":0.0073105344,"threshold_uncertainty_score":0.99959433},"labels":[],"label_agreement":null},{"id":"W4406707367","doi":"10.1021/acs.jmedchem.4c02531","title":"Development of a Second-Generation, <i>In Vivo</i> Chemical Probe for PIKfyve","year":2025,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium","funders":"University of North Carolina at Chapel Hill; National Institutes of Health; North Carolina Policy Collaboratory; Universidade Estadual de Campinas; NIH Office of the Director; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; North Carolina Biotechnology Center","keywords":"Chemistry; In vivo; Potency; Pharmacology; Kinome; Selectivity; Biochemistry; Kinase; In vitro; Biology","score_opus":0.02334122834464703,"score_gpt":0.3229948501460729,"score_spread":0.29965362180142585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406707367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271667,0.0009594127,0.0013593632,0.000828172,0.00010925767,0.0002583196,0.0000035144215,0.0000045340357,0.003760729],"genre_scores_gemma":[0.9815528,0.000027985647,0.014851627,0.0002856318,0.000556524,0.000022287944,0.000009503073,0.00001398582,0.0026796714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806726,0.000010745673,0.00096792897,0.00015320661,0.00056241214,0.00023847191],"domain_scores_gemma":[0.99877685,0.00013321315,0.0002756586,0.00016602245,0.0004937913,0.00015447015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009068193,0.00012646992,0.00049733504,0.000107922904,0.000023264494,0.000005541637,0.00017818237,0.0001466943,0.00028135598],"category_scores_gemma":[0.0006927688,0.000100445475,0.00012010165,0.00023237287,0.00010034553,0.00003957162,0.00004158027,0.0003343293,5.6813815e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071274186,0.00020363757,0.00013154924,0.0018641204,0.000117545926,0.00006706486,0.00038292736,0.000002725251,0.9808195,0.000019971874,0.013794153,0.0018840363],"study_design_scores_gemma":[0.014461844,0.000080979706,0.00005614619,0.0009654153,0.00007124863,0.0004987379,0.00032205312,0.0004953651,0.96257704,0.000066402434,0.020334804,0.000069962036],"about_ca_topic_score_codex":0.0000031384652,"about_ca_topic_score_gemma":0.000005871528,"teacher_disagreement_score":0.018242486,"about_ca_system_score_codex":0.0036015906,"about_ca_system_score_gemma":0.0135876,"threshold_uncertainty_score":0.99200445},"labels":[],"label_agreement":null},{"id":"W4406775014","doi":"10.1002/ajh.27539","title":"Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study","year":2025,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Chugai Pharmaceutical; Genentech; Grifols; AOP Orphan; Novo Nordisk; Argenx; Regeneron Pharmaceuticals; Bristol-Myers Squibb; CSL Behring; Celgene; CTI Biopharma; Swedish Orphan Biovitrum; Apellis Pharmaceuticals; BioCryst; Alnylam Pharmaceuticals; Sanofi; Alexion Pharmaceuticals; Amgen; Pfizer","keywords":"Immune thrombocytopenia; Bruton's tyrosine kinase; Medicine; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Immunology; Gastroenterology; Antibody; Receptor; Cancer","score_opus":0.011007295989296182,"score_gpt":0.3249805975566005,"score_spread":0.31397330156730435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406775014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978606,0.0002500329,0.000047924972,0.00073480053,0.000078404875,0.00082071364,0.000007817747,0.000014568826,0.00018509773],"genre_scores_gemma":[0.999083,0.000033786782,0.0005926582,0.0001583693,0.000037781363,0.000007694226,0.000015264104,0.0000276522,0.00004383911],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99726623,0.0003647331,0.0010147883,0.00038896466,0.00049778575,0.00046747495],"domain_scores_gemma":[0.9980249,0.0003161364,0.0005307674,0.0004903265,0.00038425482,0.00025365956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007489205,0.0002608682,0.0014902086,0.00042910528,0.000083341416,0.00002262403,0.00019902097,0.0000616276,0.000018063414],"category_scores_gemma":[0.0002957728,0.00016996705,0.000042770906,0.0008463829,0.00082504615,0.00017122994,0.0001030738,0.00054807233,0.0000022143765],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41837743,0.02623699,0.49392167,0.00022145286,0.0014780068,0.00809416,0.0038220133,0.00007038039,0.00038292445,0.00032127913,0.00082361966,0.046250056],"study_design_scores_gemma":[0.4877947,0.08678254,0.41432863,0.0013764476,0.0004893985,0.0024913286,0.0034624035,0.00015667663,0.0017007102,0.000015871996,0.001032571,0.0003687283],"about_ca_topic_score_codex":0.00050316233,"about_ca_topic_score_gemma":0.00019262424,"teacher_disagreement_score":0.07959303,"about_ca_system_score_codex":0.0013222356,"about_ca_system_score_gemma":0.0032851524,"threshold_uncertainty_score":0.6931055},"labels":[],"label_agreement":null},{"id":"W4407095407","doi":"10.1016/s1470-2045(24)00682-x","title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Janssen Alzheimer Immunotherapy Research And Development; Janssen Research and Development","keywords":"Ibrutinib; Venetoclax; Mantle cell lymphoma; Medicine; Placebo; Refractory (planetary science); Internal medicine; Oncology; Double blind; Phases of clinical research; Lymphoma; Clinical trial; Leukemia; Pathology; Chronic lymphocytic leukemia","score_opus":0.06933435470979207,"score_gpt":0.41336113665975854,"score_spread":0.3440267819499665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407095407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508475,0.0009797071,0.00003482888,0.0017607152,0.00059430435,0.012370744,0.000008761831,0.00011276455,0.033290643],"genre_scores_gemma":[0.98203534,0.00030049888,0.00017647767,0.0013298655,0.0005118739,0.0021534641,0.00002332716,0.00004941631,0.013419738],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953398,0.0012784454,0.0010818596,0.0006656204,0.00054544024,0.0010888458],"domain_scores_gemma":[0.99387413,0.004149743,0.00031622595,0.0013088679,0.00014894037,0.00020211686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00331887,0.0003904726,0.0021846711,0.00038235888,0.00017158194,0.000041829477,0.00070151786,0.00035563955,0.0004436755],"category_scores_gemma":[0.0009424503,0.00023949916,0.0002033016,0.00073032215,0.00027559052,0.000058302467,0.00031284502,0.0006921642,0.00025035805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.97684294,0.0045056446,0.00021790009,0.00026840626,0.0004795261,0.0021037452,0.0034704902,0.00029877853,0.0005323575,0.00006991705,0.005349023,0.0058612665],"study_design_scores_gemma":[0.9431031,0.00304977,0.00011664992,0.00014764088,0.0005352228,0.000103457125,0.0026041928,0.031794675,0.0005366368,0.000038612903,0.017757539,0.0002125124],"about_ca_topic_score_codex":0.0013100993,"about_ca_topic_score_gemma":0.0014761286,"teacher_disagreement_score":0.033739854,"about_ca_system_score_codex":0.024373064,"about_ca_system_score_gemma":0.022010641,"threshold_uncertainty_score":0.9835337},"labels":[],"label_agreement":null},{"id":"W4407133484","doi":"10.1097/cmr.0000000000001025","title":"Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia","year":2025,"lang":"en","type":"article","venue":"Melanoma Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Medicine; Chronic myelomonocytic leukemia; Azacitidine; Melanoma; Chronic lymphocytic leukemia; Oncology; Internal medicine; Venetoclax; Adverse effect; Leukemia; Incidence (geometry); Cancer research; Myelodysplastic syndromes","score_opus":0.07022703719261053,"score_gpt":0.4004040239241127,"score_spread":0.33017698673150214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407133484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572272,0.029328126,0.00009697728,0.0009907065,0.0001081969,0.0019274061,0.000015329593,0.000037553822,0.010268523],"genre_scores_gemma":[0.97825843,0.016012045,0.0004980562,0.000035306683,0.000053129515,0.0004928186,0.000015977159,0.000030866275,0.0046033445],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99660605,0.0003087272,0.0005119915,0.0006704952,0.0010616813,0.0008410374],"domain_scores_gemma":[0.99770945,0.0009572012,0.000060612372,0.0006784702,0.00028047938,0.00031379366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017024074,0.0002423372,0.00061505457,0.00074083253,0.00018445766,0.00006864971,0.00027590457,0.00010909064,0.00018607378],"category_scores_gemma":[0.00021417755,0.00020674932,0.00008063068,0.000983139,0.0009285634,0.00008791063,0.0008556554,0.00052205607,0.0000438475],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012615804,0.0007232217,0.028646851,0.036723092,0.003347884,0.0031296085,0.0010197605,0.000020843378,0.0027652602,0.05680209,0.013886825,0.851673],"study_design_scores_gemma":[0.1801646,0.0109655615,0.35455698,0.021202141,0.0029478031,0.0017325848,0.007029287,0.09842787,0.14892004,0.008663149,0.16319682,0.002193146],"about_ca_topic_score_codex":0.00061224884,"about_ca_topic_score_gemma":0.000069565016,"teacher_disagreement_score":0.84947985,"about_ca_system_score_codex":0.010347073,"about_ca_system_score_gemma":0.0045500416,"threshold_uncertainty_score":0.993452},"labels":[],"label_agreement":null},{"id":"W4407162998","doi":"10.1056/nejmoa2409804","title":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); University of Calgary; University of Ottawa","funders":"AstraZeneca","keywords":"Chronic lymphocytic leukemia; Medicine; Duration (music); Internal medicine; Leukemia; Oncology; Physics","score_opus":0.01588845400775228,"score_gpt":0.324055891713756,"score_spread":0.3081674377060037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407162998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649375,0.0055479133,0.0013222134,0.013233633,0.00094690954,0.0005563941,0.0000019103722,0.000043038803,0.013410471],"genre_scores_gemma":[0.99161947,0.0010059057,0.00016976932,0.0005787373,0.0013806369,0.00000426597,0.000022036478,0.000018407072,0.005200789],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974496,0.00015493136,0.0010832379,0.0002046253,0.0007328116,0.00037480643],"domain_scores_gemma":[0.99804085,0.00065829,0.0002832734,0.000302679,0.00040902896,0.00030588728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013337493,0.00020096355,0.00069109845,0.00095265225,0.000062454514,0.000016171687,0.00021683944,0.00015942112,0.00037268965],"category_scores_gemma":[0.002049457,0.00014211661,0.00008848254,0.0011414845,0.00019696954,0.00013625229,0.000044660752,0.00059781177,0.000019001747],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012570434,0.00062173186,0.017131992,0.0019315456,0.0015513015,0.008351587,0.0055278307,0.0077564986,0.036496494,0.014437681,0.1938736,0.6997493],"study_design_scores_gemma":[0.8438466,0.0034359973,0.014715355,0.005823164,0.0005726394,0.004461892,0.00038737257,0.054954935,0.005258952,0.002829217,0.063456446,0.00025741762],"about_ca_topic_score_codex":0.0016295238,"about_ca_topic_score_gemma":0.00037445442,"teacher_disagreement_score":0.8312762,"about_ca_system_score_codex":0.059086345,"about_ca_system_score_gemma":0.04776783,"threshold_uncertainty_score":0.95763046},"labels":[],"label_agreement":null},{"id":"W4407456423","doi":"10.1002/msc.70065","title":"Improving Knowledge Dissemination of Rheumatic Toxicities of Cancer Immunotherapy: A Web‐Based Educational Initiative","year":2025,"lang":"en","type":"article","venue":"Musculoskeletal Care","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Ottawa; Jewish General Hospital; McGill University; University of British Columbia; Dalhousie University","funders":"Canadian Rheumatology Association","keywords":"Medicine; Immunotherapy; Cancer; Internal medicine","score_opus":0.011523191427369133,"score_gpt":0.36407252826388287,"score_spread":0.35254933683651374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407456423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97737813,0.012631193,0.00020509593,0.0003394395,0.00018301766,0.0005627289,0.000059641465,0.000033065797,0.0086077005],"genre_scores_gemma":[0.99867713,0.00011244012,0.00025896798,0.000036218058,0.000044186196,0.00017677671,0.000070207105,0.000025249563,0.0005988396],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883854,0.00006733287,0.00037932044,0.00019696576,0.00032802904,0.00018981943],"domain_scores_gemma":[0.9982087,0.0005264885,0.00014684124,0.00028891966,0.0007852294,0.00004380052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014358887,0.00014028726,0.0003452076,0.00031940223,0.00004543521,0.000007670898,0.00012828351,0.00008710092,0.00027352181],"category_scores_gemma":[0.00045781268,0.00012410362,0.00019085091,0.0004758007,0.0002315898,0.00006710629,0.000051326497,0.00012911792,0.0000025376894],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001290467,0.001509784,0.020098418,0.0630098,0.0013216995,0.0000074623663,0.027980465,0.00012461045,0.29787907,0.007047254,0.0027205124,0.57701045],"study_design_scores_gemma":[0.057542402,0.0026642722,0.22229555,0.03076768,0.0009059396,0.000015373298,0.046854828,0.08028839,0.55399233,0.00085881306,0.0024187372,0.0013956717],"about_ca_topic_score_codex":0.00053819333,"about_ca_topic_score_gemma":0.00019579541,"teacher_disagreement_score":0.5756148,"about_ca_system_score_codex":0.004256683,"about_ca_system_score_gemma":0.012373265,"threshold_uncertainty_score":0.9995658},"labels":[],"label_agreement":null},{"id":"W4407744248","doi":"10.1182/bloodadvances.2024014407","title":"ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Primary (astronomy); MAPK/ERK pathway; Cancer research; Leukemia; Chemistry; Medicine; Internal medicine; Signal transduction; Biochemistry","score_opus":0.005626262265479921,"score_gpt":0.2563103083110505,"score_spread":0.2506840460455706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407744248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865691,0.0067206337,0.0003584277,0.00014910377,0.00005360653,0.00068380916,0.00000721944,0.000083156745,0.0053749518],"genre_scores_gemma":[0.9952255,0.0018540852,0.0008655866,0.00057458226,0.000108738845,0.000099082215,0.000046746427,0.000026370737,0.0011992945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99826336,0.00005202902,0.0003337898,0.00052504044,0.00040033,0.00042547993],"domain_scores_gemma":[0.9989542,0.00038560198,0.00009919562,0.00033981496,0.000090387475,0.00013083174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016400262,0.00023842326,0.0003981191,0.000277385,0.00009479947,0.000039966228,0.00008031297,0.00011389497,0.000046450623],"category_scores_gemma":[0.00014704993,0.00019637789,0.00004129737,0.00065724214,0.00025441963,0.00030455564,0.0000826707,0.00018819948,0.000012907211],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01421606,0.0019022502,0.032367386,0.030619243,0.001563238,0.0036583133,0.0020372998,0.010671569,0.71902615,0.004700986,0.004991938,0.17424558],"study_design_scores_gemma":[0.06278472,0.0010908784,0.011283947,0.0062752296,0.00043268088,0.00026454328,0.00026909605,0.008935038,0.9011051,0.0007841552,0.006231263,0.0005433548],"about_ca_topic_score_codex":0.0006449982,"about_ca_topic_score_gemma":0.00014044711,"teacher_disagreement_score":0.18207896,"about_ca_system_score_codex":0.027790848,"about_ca_system_score_gemma":0.021201413,"threshold_uncertainty_score":0.98434746},"labels":[],"label_agreement":null},{"id":"W4407953766","doi":"10.1182/blood.2024025525","title":"The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Occupational Cancer Research Centre; University of Calgary","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Rituximab; Bendamustine; Internal medicine; Refractory (planetary science); Gastroenterology; Progression-free survival; Tolerability; Neutropenia; Surgery; Overall survival; Chemotherapy; Lymphoma; Adverse effect","score_opus":0.012659531314095663,"score_gpt":0.29446798302515886,"score_spread":0.2818084517110632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407953766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733585,0.00041147837,0.00000778018,0.00007470397,0.000032908512,0.0015002321,0.000064813394,0.00001467226,0.0005575312],"genre_scores_gemma":[0.99727917,0.000050565184,0.00010435873,0.000020306554,0.00001930808,0.00009030665,0.000044639455,0.000012824171,0.0023785443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853224,0.00006194313,0.0003354543,0.00034207568,0.000467335,0.00026097824],"domain_scores_gemma":[0.99824494,0.00068551255,0.000120375036,0.0006105638,0.00027081702,0.00006776537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040327106,0.00013952453,0.00036769037,0.00015247776,0.00017292926,0.000028387027,0.00012780189,0.000057436748,0.000004192168],"category_scores_gemma":[0.0004292424,0.00008071294,0.00009539419,0.0006631082,0.00015513088,0.000038963008,0.000076676864,0.00011372278,0.0000013549345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017370794,0.009813896,0.95936376,0.00014251657,0.008427494,0.000050889557,0.0011622255,0.0000037155864,0.000054886186,0.000030130825,0.000632065,0.002947633],"study_design_scores_gemma":[0.1797594,0.0034346133,0.8104532,0.00006142749,0.004509834,0.0000019919785,0.0003592942,0.0000971805,0.00057836005,0.000018747318,0.0006458581,0.00008013409],"about_ca_topic_score_codex":0.00042246733,"about_ca_topic_score_gemma":0.00047574867,"teacher_disagreement_score":0.16238861,"about_ca_system_score_codex":0.00073302176,"about_ca_system_score_gemma":0.0011338477,"threshold_uncertainty_score":0.3291378},"labels":[],"label_agreement":null},{"id":"W4408114543","doi":"10.1007/978-1-0716-4442-3","title":"B-Cell Receptor Signaling","year":2025,"lang":"en","type":"book","venue":"Methods in molecular biology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Advanced Centre for Treatment, Research and Education in Cancer; Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg; Homi Bhabha National Institute; Universität Ulm; University of Cape Town; Trakya Üniversitesi; Turun Yliopisto; Albert-Ludwigs-Universität Freiburg; University College London; Queen's University Belfast; Karolinska Institutet; Tata Memorial Centre; Queen's University; National and Kapodistrian University of Athens; Inselspital, Universitätsspital Bern","keywords":"Cell biology; Receptor; Computational biology; Biology; Genetics","score_opus":0.030320710080775776,"score_gpt":0.4307843679841451,"score_spread":0.40046365790336935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408114543","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000726852,0.009807739,0.3989847,0.00021005096,0.00056036084,0.00089760165,0.00002037042,0.00006566435,0.5893808],"genre_scores_gemma":[0.0000044689527,0.00025069734,0.5044346,0.0007193183,0.00013724479,0.000058046953,0.00021107457,0.000052648324,0.49413192],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963315,0.0012670492,0.00064214267,0.00088902726,0.00022115587,0.00064913876],"domain_scores_gemma":[0.9975388,0.0010889703,0.00014932686,0.0009337624,0.00014276612,0.00014637383],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021409688,0.00041367684,0.0011538072,0.0007290434,0.000030390755,0.000011439844,0.00040932075,0.0014613773,0.0006404739],"category_scores_gemma":[0.0012318642,0.00038542217,0.00032942867,0.0002966743,0.00028527,0.000008540191,0.00039793272,0.0013758712,0.000111969406],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00040334702,0.00019095613,0.000021364724,0.002145328,0.00042087174,0.0013874369,0.00011153705,0.000026981184,0.89340955,0.012126097,0.045032028,0.044724476],"study_design_scores_gemma":[0.008474038,0.00037781612,3.9075601e-7,0.000814224,0.00018280654,0.00007181693,0.000012599299,0.0004894053,0.22836657,0.017805278,0.7429461,0.00045897427],"about_ca_topic_score_codex":0.00007114626,"about_ca_topic_score_gemma":0.0000020397613,"teacher_disagreement_score":0.69791406,"about_ca_system_score_codex":0.012214058,"about_ca_system_score_gemma":0.01799624,"threshold_uncertainty_score":0.99985975},"labels":[],"label_agreement":null},{"id":"W4408492440","doi":"10.1182/blood.2024027336","title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Placebo; Adverse effect; Internal medicine; Clinical endpoint; Gastroenterology; Platelet; Immune thrombocytopenia; Clinical trial; Surgery; Pathology","score_opus":0.010349923133356365,"score_gpt":0.3138072653652863,"score_spread":0.30345734223192994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408492440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916739,0.00093247736,0.000008999087,0.00048089674,0.000029533141,0.0023773408,0.0000065313016,0.00002270886,0.004467641],"genre_scores_gemma":[0.9990608,0.000121912926,0.00006484135,0.000053059626,0.000028943989,0.000045300603,0.0000071446216,0.000016090677,0.0006018733],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99848074,0.00013154872,0.00040946619,0.00032114852,0.00036464483,0.00029243084],"domain_scores_gemma":[0.9985734,0.0005605924,0.000072969255,0.0006435066,0.000085011365,0.000064524334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066252815,0.00015821002,0.0005498401,0.00012758633,0.000072823714,0.00001410767,0.0002010533,0.0000639528,0.000045947054],"category_scores_gemma":[0.00030873722,0.00009373965,0.000040728093,0.0005491975,0.00023717646,0.000039741648,0.00019403367,0.000290034,0.0000054842653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48918378,0.13958013,0.20166811,0.0061148303,0.008358137,0.0050909827,0.07130001,0.00012399934,0.010686357,0.0026320994,0.0013827084,0.06387886],"study_design_scores_gemma":[0.7873942,0.0035777898,0.19262469,0.0013658132,0.000614045,0.00017105213,0.0035233044,0.0007626599,0.009281117,0.000014574322,0.00049750257,0.00017324214],"about_ca_topic_score_codex":0.0010151388,"about_ca_topic_score_gemma":0.00031857545,"teacher_disagreement_score":0.29821044,"about_ca_system_score_codex":0.00058307825,"about_ca_system_score_gemma":0.0023373642,"threshold_uncertainty_score":0.4146384},"labels":[],"label_agreement":null},{"id":"W4408560952","doi":"10.1182/blood.2024026003","title":"Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and <i>TP53</i> mutation status","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Bendamustine; Ibrutinib; Medicine; Oncology; Internal medicine; Rituximab; Risk stratification; Clinical trial; Bioinformatics; Lymphoma; Leukemia; Biology; Chronic lymphocytic leukemia","score_opus":0.022847027365117036,"score_gpt":0.3161680054450819,"score_spread":0.2933209780799649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408560952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507236,0.0013122226,0.0000033100685,0.0006589686,0.00006274221,0.0015531763,0.00002559007,0.000015263748,0.0012963599],"genre_scores_gemma":[0.99954414,0.000083742,0.000019436011,0.00013205007,0.000078182355,0.000058231646,0.000035653316,0.000011667601,0.000036905767],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987976,0.00016394503,0.0002696378,0.00021838996,0.0003167833,0.00023365606],"domain_scores_gemma":[0.9974376,0.0020062358,0.00006376326,0.0003719544,0.00005646243,0.00006399688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027570478,0.00012556772,0.00022922778,0.00010764636,0.00005340086,0.0000260929,0.0001211645,0.00007624724,0.000026812077],"category_scores_gemma":[0.0016772834,0.00005933278,0.00007436164,0.00047474747,0.00017890013,0.000032384363,0.00006423172,0.0002014756,0.000004149491],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30306625,0.022203334,0.4651642,0.0015293079,0.014870547,0.0021201442,0.029181853,0.00035225757,0.06914532,0.00876444,0.02107173,0.06253058],"study_design_scores_gemma":[0.55364954,0.0028853586,0.41330415,0.0015036423,0.0006812766,0.000034154356,0.00089829846,0.0057222024,0.017453155,0.0034486698,0.00020012818,0.00021942524],"about_ca_topic_score_codex":0.006241354,"about_ca_topic_score_gemma":0.00037896543,"teacher_disagreement_score":0.25058326,"about_ca_system_score_codex":0.00091034506,"about_ca_system_score_gemma":0.0033920957,"threshold_uncertainty_score":0.94351023},"labels":[],"label_agreement":null},{"id":"W4408571971","doi":"10.1021/acs.jcim.4c01985","title":"Probing the Effect of Protein and Inhibitor Conformational Flexibility on the Reaction of Rocelitinib-Like Covalent Inhibitors of Epidermal Growth Factor Receptor. A Quantum Mechanics/Molecular Mechanics Study","year":2025,"lang":"en","type":"article","venue":"Journal of Chemical Information and Modeling","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"Thailand Science Research and Innovation; King Mongkut's Institute of Technology Ladkrabang; National Research Council of Thailand","keywords":"Molecular mechanics; Covalent bond; Flexibility (engineering); Epidermal growth factor receptor; Chemistry; Molecular dynamics; Biophysics; Receptor; Computational chemistry; Biochemistry; Biology; Mathematics; Organic chemistry","score_opus":0.025274591426019292,"score_gpt":0.29945981114874026,"score_spread":0.274185219722721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408571971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883003,0.00007944326,0.009518967,0.00043782225,0.000064709,0.0010199606,0.0000061565897,0.000004862286,0.000038072],"genre_scores_gemma":[0.99975073,0.000027487524,0.00010034015,0.00007208313,0.000023846844,0.000014487077,0.0000050523727,0.00000461523,0.000001333832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782234,0.00011563599,0.0012155717,0.0000737953,0.000649884,0.00012276595],"domain_scores_gemma":[0.9981059,0.0003301382,0.00067362253,0.00014408787,0.000683732,0.00006251778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020168535,0.00012432884,0.00037802977,0.00015892327,0.000046741636,0.000017563445,0.00009575687,0.00009568351,0.0000042144156],"category_scores_gemma":[0.0012363117,0.000068848545,0.00010963729,0.00017099945,0.000053310847,0.00031802474,0.00008021191,0.00037257033,2.2597958e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059047653,0.00030111807,0.000054362798,0.003948607,0.00043154124,0.0000015167961,0.005445404,0.002393347,0.96281534,0.0141916275,0.00007610711,0.0044362424],"study_design_scores_gemma":[0.004671271,0.00076359505,0.000004457877,0.0007204061,0.00007060131,0.000025871017,0.0013566305,0.35446924,0.6370836,0.00076948566,0.00001551907,0.000049323768],"about_ca_topic_score_codex":0.00003265338,"about_ca_topic_score_gemma":2.0815082e-7,"teacher_disagreement_score":0.3520759,"about_ca_system_score_codex":0.0004999957,"about_ca_system_score_gemma":0.0007431243,"threshold_uncertainty_score":0.28075624},"labels":[],"label_agreement":null},{"id":"W4408715532","doi":"10.1177/10781552251324522","title":"Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review","year":2025,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"","keywords":"Medicine; Venetoclax; Pharmacist; Tumor lysis syndrome; Adverse effect; Pharmacy; Psychological intervention; Retrospective cohort study; Internal medicine; Pediatrics; Chronic lymphocytic leukemia; Leukemia; Family medicine; Chemotherapy; Psychiatry","score_opus":0.12355402321022381,"score_gpt":0.5734759596261295,"score_spread":0.4499219364159057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408715532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89804244,0.07230589,0.00049138226,0.0068029673,0.0036404647,0.008606902,0.000059896425,0.00005059829,0.009999462],"genre_scores_gemma":[0.9393626,0.051073987,0.0013538369,0.005068606,0.0011140456,0.00024905716,0.000019599775,0.00006932554,0.0016889599],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99420106,0.0014805612,0.0021947576,0.00040302702,0.0010537156,0.0006668921],"domain_scores_gemma":[0.9834057,0.007971977,0.003331789,0.00057968334,0.0044367397,0.0002740939],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010053868,0.00036070726,0.001573823,0.00032543062,0.00020906722,0.000029717217,0.0006459856,0.00015194369,0.0007428768],"category_scores_gemma":[0.025990043,0.00023426808,0.0010299113,0.00096184906,0.00033617855,0.0005992886,0.00019469578,0.0014083819,0.0000468617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.16143617,0.0024696807,0.0025679772,0.013318505,0.020936118,0.0008482002,0.0022354384,0.0023009067,0.030586295,0.000110164605,0.5262435,0.23694706],"study_design_scores_gemma":[0.42112976,0.037323087,0.0015951085,0.009358207,0.017760053,0.007327414,0.00037462907,0.20689657,0.0074385297,0.00030581563,0.28987855,0.0006122927],"about_ca_topic_score_codex":0.00025864382,"about_ca_topic_score_gemma":0.000002770557,"teacher_disagreement_score":0.2596936,"about_ca_system_score_codex":0.2525817,"about_ca_system_score_gemma":0.220848,"threshold_uncertainty_score":0.98221445},"labels":[],"label_agreement":null},{"id":"W4408805949","doi":"10.14740/wjon2534","title":"CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Principia Biopharma; Seagen; Sanofi","keywords":"Medicine; CD19; B cell; Expression (computer science); Targeted therapy; Immunology; Cancer research; Oncology; Internal medicine; Antigen; Antibody; Cancer","score_opus":0.03841476797591926,"score_gpt":0.3936096532792444,"score_spread":0.35519488530332516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408805949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776876,0.0060729273,0.000024338422,0.006423804,0.00022289912,0.00028601236,8.2564384e-7,0.0000029763391,0.009278621],"genre_scores_gemma":[0.99583864,0.001522902,0.0011587157,0.0010363526,0.00009872208,0.0000046292885,9.3947165e-7,0.0000063125945,0.00033279374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978684,0.0006235305,0.0009505013,0.00012825715,0.00023581031,0.00019345629],"domain_scores_gemma":[0.9958239,0.0034787275,0.00027685708,0.00018546882,0.00017127459,0.00006377212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002409866,0.00008732686,0.00052133104,0.00055752654,0.00003634118,0.000011437989,0.00012651451,0.00012074792,0.00017598075],"category_scores_gemma":[0.00094117946,0.000049827373,0.000090133675,0.00042487046,0.00017513947,0.00006171815,0.000053086853,0.0005301302,0.0000011828355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038741431,0.0038116039,0.87927973,0.00019097117,0.00019488939,0.0028298378,0.0042581833,0.00012456163,0.027167965,0.0006406066,0.05319171,0.02443578],"study_design_scores_gemma":[0.19020513,0.0046938085,0.7465726,0.0016179011,0.00015472918,0.0015892584,0.0048859483,0.006160936,0.009932766,0.00422189,0.029728616,0.00023640087],"about_ca_topic_score_codex":0.0000697243,"about_ca_topic_score_gemma":0.0008018848,"teacher_disagreement_score":0.18633099,"about_ca_system_score_codex":0.0013338674,"about_ca_system_score_gemma":0.006889804,"threshold_uncertainty_score":0.9987402},"labels":[],"label_agreement":null},{"id":"W4408929030","doi":"10.6004/jnccn.2024.7259","title":"HSR25-164: Mapping Patient Reported Side-Effect Incidence to Degradation of Health-Related Quality of Life Dimensions in Lymphoma and Chronic Lymphocytic Leukemia – A Study From the Lymphoma Coalition’s 2024 Global Patient Survey on Lymphomas &amp; CLL","year":2025,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Lymphoma; Incidence (geometry); Quality of life (healthcare); Internal medicine; Leukemia; Health related quality of life; Oncology; Nursing","score_opus":0.08067527100508136,"score_gpt":0.3747189196011525,"score_spread":0.2940436485960711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408929030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843924,0.011477979,0.0000699627,0.00093435444,0.0010409635,0.001882146,0.00013452001,0.000010577143,0.000057101293],"genre_scores_gemma":[0.9975737,0.0002735615,0.000113664944,0.0017578552,0.00012678845,0.000057558165,0.00003355408,0.00001951713,0.0000438202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911977,0.0028741462,0.002906554,0.00045949925,0.0021401271,0.00042198825],"domain_scores_gemma":[0.98951656,0.004931859,0.0023350497,0.00052398647,0.0024849102,0.00020766558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025753437,0.00032998133,0.0012367198,0.0002496537,0.00025301173,0.00003074148,0.0003723639,0.00014788682,0.000022160864],"category_scores_gemma":[0.004396819,0.00022056587,0.00025094178,0.0021851838,0.00022916606,0.00009913316,0.00039306516,0.00025187878,0.0000018785358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013441809,0.00091499375,0.4859235,0.0005089881,0.0031913472,0.000057638896,0.0026280791,0.44228077,0.0007877609,0.0004352323,0.029851448,0.019978447],"study_design_scores_gemma":[0.0168436,0.001030891,0.9715572,0.0033768595,0.00012410119,0.00007050263,0.00044456444,0.0052219564,0.00015970622,0.00062785915,0.00037221334,0.00017055636],"about_ca_topic_score_codex":0.03793087,"about_ca_topic_score_gemma":0.006005204,"teacher_disagreement_score":0.4856337,"about_ca_system_score_codex":0.08551331,"about_ca_system_score_gemma":0.041593708,"threshold_uncertainty_score":0.96847564},"labels":[],"label_agreement":null},{"id":"W4408997591","doi":"10.1007/s00277-025-06280-7","title":"Comparative efficacy of venetoclax-based regiments in the management of chronic lymphocytic leukemia: a systematic review and metanalysis","year":2025,"lang":"en","type":"review","venue":"Annals of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Venetoclax; Medicine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Hematology; Lymphoma; Leukemia","score_opus":0.10868640549403825,"score_gpt":0.44769713419926704,"score_spread":0.3390107287052288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408997591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010071053,0.9931587,0.00001742351,0.000070939255,0.000018231654,0.0059471396,0.00002227875,0.0000070476085,0.00065751927],"genre_scores_gemma":[0.0050169793,0.9939502,0.00007540153,0.00015994748,0.0000056363797,0.0005838632,0.00006528733,0.000019729694,0.00012293937],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9947177,0.0011809386,0.0025763279,0.0004939745,0.00063512585,0.00039590173],"domain_scores_gemma":[0.99426347,0.0022893937,0.0016555166,0.0015107492,0.000211771,0.000069115515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016097877,0.00044581923,0.010016856,0.0006996025,0.000022880884,0.0000042950683,0.00066753296,0.00026386813,0.000025486945],"category_scores_gemma":[0.00029672292,0.00027386265,0.000880136,0.0016113691,0.00041095982,0.000023604427,0.00019489312,0.00028385245,0.0000066528596],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00004411925,0.000098757126,3.9223573e-7,0.9918863,0.0048530237,0.00015544753,0.000059364003,0.000019167479,1.8937783e-7,0.001238128,0.00032517783,0.0013199255],"study_design_scores_gemma":[0.0044939695,0.00031071733,0.000001376745,0.9599854,0.03243935,0.00034463336,0.00008577464,0.0006267396,0.000099917575,0.000032069882,0.0014006537,0.00017939837],"about_ca_topic_score_codex":0.00020302301,"about_ca_topic_score_gemma":0.000012262952,"teacher_disagreement_score":0.03190091,"about_ca_system_score_codex":0.0062819696,"about_ca_system_score_gemma":0.021145994,"threshold_uncertainty_score":0.99997133},"labels":[],"label_agreement":null},{"id":"W4409036834","doi":"10.1111/ijlh.14475","title":"Acquisition of <scp><i>SETBP1</i></scp> Mutation During Transformation of Mature Plasmacytoid Dendritic Cell Proliferation to Blastic Plasmacytoid Dendritic Cell Neoplasm in Chronic Myelomonocytic Leukemia","year":2025,"lang":"en","type":"letter","venue":"International Journal of Laboratory Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Chronic myelomonocytic leukemia; Transformation (genetics); Plasmacytoid dendritic cell; Mutation; Leukemia; Cancer research; Biology; Immunology; Dendritic cell; Antigen; Gene; Genetics; Bone marrow","score_opus":0.007618910472512189,"score_gpt":0.2731617678597027,"score_spread":0.2655428573871905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409036834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820294,0.0013072036,0.0017562114,0.011190961,0.0016177943,0.0012549822,0.00033152412,0.000034147743,0.00047781967],"genre_scores_gemma":[0.98973036,0.00034556308,0.0007368017,0.007191953,0.0010860421,0.00007737437,0.00041315847,0.00009262527,0.00032611532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99349934,0.0004287025,0.0028834674,0.0005407461,0.0019553453,0.00069238426],"domain_scores_gemma":[0.9931993,0.0014023109,0.0017054802,0.00042205784,0.003061536,0.0002093006],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006389306,0.00058409566,0.0015877719,0.0032928474,0.00006290484,0.00006367674,0.0007942357,0.0012281254,0.00006827138],"category_scores_gemma":[0.00080097176,0.0006051241,0.00034727936,0.0009733867,0.0002112635,0.0005305758,0.00012148319,0.0023368532,0.000039483082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007791853,0.0023137643,0.003103348,0.09457569,0.0040202304,0.05655431,0.016811952,0.06848148,0.5494121,0.00151693,0.19469918,0.0007191702],"study_design_scores_gemma":[0.030600099,0.0012679612,0.0005894732,0.00819472,0.0006568272,0.00849328,0.00075597916,0.008557274,0.93467695,0.00034897777,0.005465057,0.00039340582],"about_ca_topic_score_codex":0.000056128978,"about_ca_topic_score_gemma":0.00009198556,"teacher_disagreement_score":0.38526487,"about_ca_system_score_codex":0.02092955,"about_ca_system_score_gemma":0.022074673,"threshold_uncertainty_score":0.9999648},"labels":[],"label_agreement":null},{"id":"W4409132979","doi":"10.7759/cureus.81663","title":"From Prescription to Predicament: A Case of Semaglutide-Induced Discoid Lupus Erythematosus in an Adult Male Patient","year":2025,"lang":"en","type":"article","venue":"Cureus","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Sunnybrook Hospital; University of Toronto; SKiN Health; Sunnybrook Health Science Centre; Queen's University","funders":"","keywords":"Medicine; Semaglutide; Systemic lupus erythematosus; Dermatology; Discoid lupus erythematosus; Medical prescription; Pediatrics; Family medicine; Lupus erythematosus; Internal medicine; Endocrinology; Diabetes mellitus; Immunology; Pharmacology; Type 2 diabetes","score_opus":0.01864436144516664,"score_gpt":0.3234702700105579,"score_spread":0.30482590856539127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409132979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958603,0.00038095837,0.00010447418,0.0004136689,0.00035686267,0.0011558345,0.000059022557,0.000039364,0.0016295423],"genre_scores_gemma":[0.9980851,0.00001706474,0.0007439069,0.00017148531,0.000082940605,0.00014905364,0.000039088434,0.000021468311,0.0006898929],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982808,0.0000898143,0.0004788882,0.0004263579,0.00036950258,0.00035461946],"domain_scores_gemma":[0.99866384,0.000088631845,0.000071025286,0.00076741975,0.00016667385,0.00024240173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014719792,0.00016495271,0.0003612601,0.00019406907,0.000034405337,0.000018513434,0.00015388669,0.0001290918,0.00017132639],"category_scores_gemma":[0.00039584222,0.00014405098,0.0000663345,0.0003921082,0.000053834377,0.00009595694,0.00018499476,0.00018816118,0.000023940542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016302183,0.0151777975,0.0990145,0.0058366423,0.0015306021,0.06795503,0.11468904,0.00088105875,0.52201337,0.0057775863,0.045364622,0.105457574],"study_design_scores_gemma":[0.1730333,0.013951621,0.016012534,0.015729949,0.0013247179,0.026923474,0.06773872,0.20135741,0.47068465,0.0050477465,0.0058208634,0.002375021],"about_ca_topic_score_codex":0.01293332,"about_ca_topic_score_gemma":0.0033379667,"teacher_disagreement_score":0.20047635,"about_ca_system_score_codex":0.0047538118,"about_ca_system_score_gemma":0.0016763163,"threshold_uncertainty_score":0.99906677},"labels":[],"label_agreement":null},{"id":"W4409183810","doi":"10.51731/cjht.2025.1110","title":"Fruquintinib (Fruzaqla)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Geography","score_opus":0.025099684938005035,"score_gpt":0.3499035703777737,"score_spread":0.3248038854397687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409183810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42928398,0.23626362,0.0014420486,0.31285343,0.0016710047,0.0009851654,0.000015417563,0.00034800544,0.017137367],"genre_scores_gemma":[0.99627644,0.0005468655,0.0008374448,0.0013357837,0.000013446377,0.0000040171035,0.0000011152307,0.000010257494,0.0009746143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984914,0.000037725174,0.0005620774,0.00012866194,0.00020345632,0.00057664944],"domain_scores_gemma":[0.99894065,0.00008998858,0.00018783794,0.0003657889,0.00028044905,0.000135277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008050436,0.00010443867,0.0004305009,0.0012242518,0.0001673464,0.000026645399,0.0003525304,0.00017530737,0.00005274146],"category_scores_gemma":[0.0017999447,0.000084906256,0.000096011194,0.00068765355,0.00034057614,0.000058389058,0.000034631972,0.00061355403,0.000019603283],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000059839378,0.000028884282,0.004587431,0.0005528955,0.00013706047,0.0010525105,0.00017858345,0.000007174784,0.00006863079,0.0087745935,0.09125493,0.8932975],"study_design_scores_gemma":[0.006216516,0.00065802457,0.005778687,0.0014742535,0.00003412164,0.0017287408,0.0033619623,0.00013770454,0.0021877703,0.006904718,0.9713875,0.0001300119],"about_ca_topic_score_codex":0.0073971646,"about_ca_topic_score_gemma":0.0023198128,"teacher_disagreement_score":0.89316744,"about_ca_system_score_codex":0.011542716,"about_ca_system_score_gemma":0.08532314,"threshold_uncertainty_score":0.9992127},"labels":[],"label_agreement":null},{"id":"W4409228419","doi":"10.1212/wnl.0000000000210933","title":"Bing-Neel Syndrome: An Atypical Complication of Waldenström Macroglobulinemia – A Case Report (P11-2.004)","year":2025,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Macroglobulinemia; Waldenstrom macroglobulinemia; Complication; Medicine; Pediatrics; Dermatology; Internal medicine; Lymphoma; Multiple myeloma","score_opus":0.02168151662528296,"score_gpt":0.34301271477802603,"score_spread":0.3213311981527431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409228419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933426,0.00010332957,0.00029962353,0.0032043369,0.00022197519,0.0004738535,0.000007851253,0.000092315146,0.002254158],"genre_scores_gemma":[0.99749637,0.000012423947,0.00037171913,0.0013311909,0.00006275482,0.000037248425,0.000051496456,0.000021278098,0.000615519],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9981502,0.00012554693,0.00054899836,0.00053859066,0.00025919144,0.0003774431],"domain_scores_gemma":[0.9982495,0.00022530845,0.00012468605,0.0010108437,0.00021480274,0.00017486006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028834274,0.00015436321,0.00045130614,0.00023196262,0.00006476356,0.000008343495,0.00017632761,0.0002767141,0.00013828746],"category_scores_gemma":[0.0004167422,0.0001433955,0.00009071701,0.00042804566,0.0003243532,0.000041287887,0.00016521796,0.00042675447,0.000040124203],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074601504,0.001244425,0.018330663,0.00086217397,0.00028981426,0.9310394,0.00022026437,0.00019819992,0.016928338,0.0052102776,0.006003607,0.012212698],"study_design_scores_gemma":[0.00908831,0.0020979564,0.024413975,0.000046481295,0.00015182905,0.9278335,0.000016617823,0.027379781,0.0016322922,0.00037885827,0.0068216613,0.00013876302],"about_ca_topic_score_codex":0.0008358403,"about_ca_topic_score_gemma":0.000114694274,"teacher_disagreement_score":0.02718158,"about_ca_system_score_codex":0.0007177181,"about_ca_system_score_gemma":0.0024338444,"threshold_uncertainty_score":0.58474994},"labels":[],"label_agreement":null},{"id":"W4409252656","doi":"10.1053/j.seminhematol.2025.04.004","title":"Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors","year":2025,"lang":"en","type":"article","venue":"Seminars in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Pharmacyclics; BeiGene; Eli Lilly and Company","keywords":"Waldenstrom macroglobulinemia; Medicine; Macroglobulinemia; Ibrutinib; Bruton's tyrosine kinase; Intensive care medicine; Internal medicine; Immunology; Lymphoma; Chronic lymphocytic leukemia; Leukemia; Multiple myeloma","score_opus":0.020679086787591852,"score_gpt":0.3092122550952038,"score_spread":0.28853316830761194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409252656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98438334,0.00023246053,0.0000472941,0.009894525,0.0003225975,0.0010641988,0.000034781922,0.0000116874335,0.0040090913],"genre_scores_gemma":[0.9957258,0.000083463594,0.0011673415,0.0006639001,0.000022595555,0.00009493663,0.000029059425,0.000014369945,0.0021985474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979769,0.0000833828,0.00065381103,0.00040388992,0.0006229973,0.00025904688],"domain_scores_gemma":[0.9972804,0.0014184412,0.00023818189,0.0008258171,0.00019173743,0.00004540864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038904534,0.00017038187,0.00042718707,0.00012427638,0.00003812854,0.0000058731835,0.00037184847,0.000098070406,0.000084008345],"category_scores_gemma":[0.0005441193,0.00009152791,0.00005426492,0.00047161637,0.00035281474,0.000009005875,0.00019958305,0.00027863253,0.0000061552682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10839879,0.0044572586,0.4956329,0.0031467872,0.0035550797,0.020241214,0.0045885034,0.0015895418,0.00038330042,0.051866073,0.28392962,0.022210961],"study_design_scores_gemma":[0.12265042,0.0038955861,0.40974584,0.16716902,0.0011752372,0.0015013376,0.020018926,0.003655354,0.18220061,0.0060572987,0.08006229,0.001868072],"about_ca_topic_score_codex":0.00009746345,"about_ca_topic_score_gemma":0.00019820542,"teacher_disagreement_score":0.2038673,"about_ca_system_score_codex":0.0015937585,"about_ca_system_score_gemma":0.0006767088,"threshold_uncertainty_score":0.4167623},"labels":[],"label_agreement":null},{"id":"W4409255592","doi":"10.1182/blood.2024024476","title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"National Comprehensive Cancer Network; Gilead Sciences; AstraZeneca; National Cancer Institute; National Institutes of Health; Pfizer","keywords":"Obinutuzumab; Chlorambucil; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.018054785244153278,"score_gpt":0.30619122712006674,"score_spread":0.2881364418759135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409255592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989553,0.00091287325,0.0000026480807,0.00051597087,0.00013920332,0.0010037221,0.000011516498,0.000025363388,0.00783572],"genre_scores_gemma":[0.995971,0.00055745046,0.000090525304,0.00017552737,0.000066284796,0.000119617514,0.000022942675,0.000026181428,0.0029704627],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980724,0.00016686268,0.00048790796,0.00035952238,0.00042218989,0.00049112434],"domain_scores_gemma":[0.9986015,0.0004669623,0.00007978028,0.0007258291,0.0000786278,0.000047275153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000623467,0.00022341732,0.0005715891,0.00026363047,0.00003571603,0.000020269095,0.00033872898,0.00017918149,0.00007356896],"category_scores_gemma":[0.00024075429,0.00015094304,0.00016231906,0.0008277,0.0001489389,0.00005242565,0.00006740963,0.00028446168,0.000022223885],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04712302,0.029385474,0.24273577,0.003360962,0.0059132683,0.0026262316,0.04765188,0.000040081322,0.51384526,0.016579233,0.0035114437,0.08722736],"study_design_scores_gemma":[0.5850374,0.0033469372,0.12124173,0.00097483303,0.00046997846,0.000086571126,0.0057503455,0.0010652961,0.27323774,0.0010334642,0.007223819,0.0005319063],"about_ca_topic_score_codex":0.0044300444,"about_ca_topic_score_gemma":0.0006388999,"teacher_disagreement_score":0.5379144,"about_ca_system_score_codex":0.0047138855,"about_ca_system_score_gemma":0.005902901,"threshold_uncertainty_score":0.99973273},"labels":[],"label_agreement":null},{"id":"W4409259280","doi":"10.1053/j.seminhematol.2025.04.001","title":"Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease","year":2025,"lang":"en","type":"article","venue":"Seminars in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Macroglobulinemia; Medicine; Waldenstrom macroglobulinemia; Consensus conference; Intensive care medicine; Pediatrics; Internal medicine; Multiple myeloma; Lymphoma","score_opus":0.014322791936131797,"score_gpt":0.2883078627752115,"score_spread":0.2739850708390797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409259280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915085,0.00021811693,0.000030065796,0.0048479997,0.00024312065,0.00072452705,0.000083448576,0.00001112985,0.0023331137],"genre_scores_gemma":[0.9983584,0.00014118991,0.00040134665,0.00027819735,0.000018620098,0.000055591878,0.00009974152,0.000012616988,0.000634264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831766,0.000101541256,0.0004921915,0.00033519522,0.0005306917,0.00022273386],"domain_scores_gemma":[0.9971202,0.0015828499,0.00025446597,0.00085399236,0.0001373422,0.00005114773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030966182,0.00014874527,0.0003467839,0.000100913945,0.00003728737,0.000004729829,0.00032289117,0.000080493875,0.0001466623],"category_scores_gemma":[0.00054451096,0.00008064222,0.0000635109,0.00025818325,0.00042468891,0.00000767405,0.00019387928,0.0002949602,0.000006709304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01615519,0.001757847,0.8945325,0.00052865694,0.0017713,0.009920587,0.00042914797,0.00052730704,0.000017497601,0.038269874,0.026821094,0.009268976],"study_design_scores_gemma":[0.043646928,0.0007440156,0.91208965,0.015845798,0.0010222084,0.00032607545,0.0034597998,0.004104411,0.0065952316,0.009356134,0.0023874717,0.0004222828],"about_ca_topic_score_codex":0.0003528981,"about_ca_topic_score_gemma":0.000029582685,"teacher_disagreement_score":0.028913742,"about_ca_system_score_codex":0.0010339257,"about_ca_system_score_gemma":0.0006547211,"threshold_uncertainty_score":0.32884943},"labels":[],"label_agreement":null},{"id":"W4409285391","doi":"10.1182/bloodadvances.2024014523","title":"Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Air Liquide (Canada)","funders":"Cilag; Grifols; BeiGene; MEI Pharma; TG Therapeutics; Gilead Sciences; AstraZeneca; Eli Lilly and Company","keywords":"Ibrutinib; Hazard ratio; Internal medicine; Medicine; Oncology; Chronic lymphocytic leukemia; Bendamustine; Idelalisib; Confidence interval; Leukemia","score_opus":0.036254512643150244,"score_gpt":0.3441972454570205,"score_spread":0.3079427328138703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409285391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9040935,0.09238893,0.00016508838,0.00027275813,0.00016423436,0.0007950864,0.000033904646,0.000058133504,0.0020283442],"genre_scores_gemma":[0.99535346,0.0012900379,0.0017232074,0.0001091445,0.00012801471,0.00007261567,0.000047693327,0.000017365626,0.001258467],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99720305,0.00031683675,0.0008345501,0.0005796701,0.00058672606,0.000479183],"domain_scores_gemma":[0.99731046,0.0012927956,0.00034540708,0.00072133937,0.00019686746,0.00013310421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006634392,0.00029052162,0.0020644916,0.00058665464,0.00007662665,0.000015494867,0.0002295127,0.00013364025,0.00015972796],"category_scores_gemma":[0.00043560588,0.00022168591,0.00072485884,0.0032374978,0.00029319496,0.00016322201,0.00013495133,0.0004433019,0.000013893462],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010789887,0.015469636,0.2140963,0.0023332357,0.5050173,0.0013998238,0.0037619655,0.2100043,0.00609636,0.007318145,0.008188807,0.015524295],"study_design_scores_gemma":[0.123498514,0.0027897255,0.12320528,0.00074313476,0.58313173,0.00002890114,0.00097383396,0.008170745,0.11970835,0.0024455718,0.033982884,0.0013213238],"about_ca_topic_score_codex":0.0017588867,"about_ca_topic_score_gemma":0.0012800695,"teacher_disagreement_score":0.20183355,"about_ca_system_score_codex":0.0011157363,"about_ca_system_score_gemma":0.0017156998,"threshold_uncertainty_score":0.9040089},"labels":[],"label_agreement":null},{"id":"W4409446835","doi":"10.1038/s41375-025-02577-8","title":"Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ADD Centre","funders":"Helsinki Institute of Life Science, Helsingin Yliopisto; Syöpäjärjestöt; Institut National Du Cancer; Sächsisches Staatsministerium für Wissenschaft und Kunst; José Carreras Leukämie-Stiftung; Bundesministerium für Bildung und Forschung; Ligue Contre le Cancer; Fondation de France; Sigrid Juséliuksen Säätiö; Signe ja Ane Gyllenbergin Säätiö; Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; Wilhelm Sander-Stiftung; European Commission; Dr. Mildred Scheel Stiftung für Krebsforschung","keywords":"Cancer research; STAT5; Biology; Phosphorylation; Cell biology","score_opus":0.026410887587738418,"score_gpt":0.326483067400875,"score_spread":0.3000721798131366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409446835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9426569,0.0006534318,0.00024903924,0.00038055133,0.00018242322,0.0014334179,0.000033530287,0.00019069173,0.054220024],"genre_scores_gemma":[0.97645205,0.00029070335,0.00032060497,0.00094508205,0.00018978864,0.00032371594,0.00018483996,0.000065871245,0.021227343],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99621695,0.00009098924,0.0008140684,0.0009243781,0.00073871977,0.001214901],"domain_scores_gemma":[0.99818903,0.0002973515,0.000116861636,0.00089031557,0.00016124643,0.0003452114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041108023,0.00050817855,0.0007765124,0.0007364708,0.00013918297,0.00009770796,0.00016278219,0.0003911021,0.00032961124],"category_scores_gemma":[0.00025472807,0.00045244882,0.00021423987,0.001278433,0.00025204747,0.0002180393,0.00017083704,0.0004947882,0.0004898123],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0344939,0.0069159023,0.007827442,0.007065771,0.0037821652,0.045564502,0.010649582,0.048286397,0.35736075,0.10090304,0.05060744,0.32654312],"study_design_scores_gemma":[0.44914842,0.006655739,0.021072857,0.00412102,0.00091322983,0.0044175778,0.004565567,0.25297886,0.21300523,0.0074793445,0.033220362,0.0024218075],"about_ca_topic_score_codex":0.016783655,"about_ca_topic_score_gemma":0.0011706217,"teacher_disagreement_score":0.4146545,"about_ca_system_score_codex":0.23271477,"about_ca_system_score_gemma":0.081706144,"threshold_uncertainty_score":0.99979275},"labels":[],"label_agreement":null},{"id":"W4409487670","doi":"10.1182/blood.2024028064","title":"International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Genentech; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Conquer Cancer Foundation; Gilead Sciences; BeiGene; Sanofi; Deutsche Forschungsgemeinschaft; Amgen; National Institutes of Health; Incyte","keywords":"Statement (logic); Consensus conference; Medicine; Family medicine; Political science; Law; Internal medicine","score_opus":0.10050846989220998,"score_gpt":0.4492966184956321,"score_spread":0.34878814860342217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409487670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8769447,0.0006179792,0.000041072497,0.083526626,0.00019448301,0.0014372442,0.000032362263,0.00001531632,0.037190218],"genre_scores_gemma":[0.99765015,0.0008415121,0.0002826891,0.0002537983,0.00004637193,0.00031555528,0.000045351433,0.00000528648,0.00055928],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844104,0.0002156057,0.00030002455,0.00014234825,0.00075333787,0.00014765709],"domain_scores_gemma":[0.9981878,0.00085654063,0.000038342918,0.00023686676,0.0006406231,0.00003986552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020609212,0.00005913282,0.000101270234,0.00022084719,0.00011602639,0.000024178113,0.000106162996,0.00003513476,0.00040921159],"category_scores_gemma":[0.00060734263,0.00004055713,0.000028188542,0.0003612915,0.00015602863,0.00003045184,0.00004862076,0.00017249324,0.000014127495],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019580894,0.010486996,0.013831318,0.0013961421,0.0041214293,0.000055864115,0.023800422,0.0001222441,0.0029082783,0.052149165,0.4740372,0.41513285],"study_design_scores_gemma":[0.14786683,0.0015057673,0.046765845,0.0021052037,0.0011226247,0.00017497776,0.006688962,0.02730171,0.08273986,0.011657849,0.67172104,0.0003493266],"about_ca_topic_score_codex":0.00008653394,"about_ca_topic_score_gemma":0.000019955472,"teacher_disagreement_score":0.41478354,"about_ca_system_score_codex":0.0011369587,"about_ca_system_score_gemma":0.0019543204,"threshold_uncertainty_score":0.44805798},"labels":[],"label_agreement":null},{"id":"W4409522276","doi":"10.1093/bjd/ljaf144","title":"Monoclonal gammopathy of thrombotic significance","year":2025,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Women's College Hospital; University of Toronto","funders":"","keywords":"Monoclonal gammopathy; Medicine; Monoclonal gammopathy of undetermined significance; Differential diagnosis; Monoclonal; Dermatology; Pathology; Monoclonal antibody; Immunology; Antibody","score_opus":0.01133759398230168,"score_gpt":0.30098992309151007,"score_spread":0.2896523291092084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409522276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981944,0.009976131,0.0018711267,0.0018009482,0.00033611883,0.00017743978,0.000004993337,0.000010260268,0.0038789518],"genre_scores_gemma":[0.99704945,0.00092201075,0.0013465536,0.00027898813,0.00006680286,0.0000026757516,0.0000017069927,0.000010731456,0.0003210647],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99842197,0.00011232982,0.00073328725,0.00012735894,0.00032975894,0.00027529048],"domain_scores_gemma":[0.99874914,0.00025432758,0.00025985928,0.00016370593,0.00045385218,0.00011911161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021079437,0.000087956396,0.0006468662,0.00021596212,0.00003721043,0.000013278097,0.00021785965,0.00012304055,0.00012277094],"category_scores_gemma":[0.0005037879,0.00009420563,0.00017426732,0.00028629228,0.0003031175,0.00007301408,0.00005853094,0.0003791405,0.000009306604],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006304479,0.0044524497,0.10943663,0.0076476107,0.004483156,0.27024734,0.0012190136,0.0003072534,0.08040454,0.012814406,0.24914543,0.25353768],"study_design_scores_gemma":[0.039570734,0.0005135229,0.052198913,0.0034817574,0.00046182456,0.79557824,0.000480803,0.002459967,0.09398131,0.0036549468,0.0073557342,0.00026223433],"about_ca_topic_score_codex":0.00013488127,"about_ca_topic_score_gemma":0.000019858915,"teacher_disagreement_score":0.5253309,"about_ca_system_score_codex":0.0009957743,"about_ca_system_score_gemma":0.0061999443,"threshold_uncertainty_score":0.999434},"labels":[],"label_agreement":null},{"id":"W4409589766","doi":"10.1007/978-3-031-85870-3_10","title":"A New Metric to Classify B Cell Lineage Tree","year":2025,"lang":"en","type":"book-chapter","venue":"Studies in classification, data analysis, and knowledge organization","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Tree (set theory); Lineage (genetic); Metric (unit); Mathematics; Computer science; Combinatorics; Biology; Engineering; Genetics; Operations management","score_opus":0.10949832859698225,"score_gpt":0.3967340030190539,"score_spread":0.28723567442207165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409589766","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023222725,0.08879624,0.09071363,0.0034072,0.0011904592,0.003811441,0.0010168044,0.00041098954,0.810421],"genre_scores_gemma":[0.019528948,0.050470203,0.00391779,0.00017681837,0.00084363995,0.000021650832,0.011016887,0.000116301926,0.91390777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965364,0.000071606366,0.0010207363,0.0014968601,0.0005291743,0.0003452344],"domain_scores_gemma":[0.9950742,0.0004919247,0.0003001195,0.0023364837,0.0015141234,0.0002831641],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068451394,0.0004923388,0.0013143613,0.0032744354,0.00020161431,0.00007792946,0.0006158037,0.0004548649,0.0003230414],"category_scores_gemma":[0.0025144457,0.00045784382,0.00010051729,0.005746497,0.0002033302,0.00014593721,0.0012240745,0.00044518273,0.00021400682],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00017463566,0.00043117494,0.013067696,0.0036361434,0.010451919,0.00006865609,0.0037654042,0.000011664614,0.0001742499,0.031292766,0.87401056,0.06291512],"study_design_scores_gemma":[0.009238291,0.00022614225,0.01433043,0.001404103,0.02096016,0.000020466703,0.0010084086,0.01366776,0.0004164636,0.0006823517,0.93662554,0.0014198598],"about_ca_topic_score_codex":0.00021855008,"about_ca_topic_score_gemma":0.005777258,"teacher_disagreement_score":0.10348676,"about_ca_system_score_codex":0.005866557,"about_ca_system_score_gemma":0.007073031,"threshold_uncertainty_score":0.99978733},"labels":[],"label_agreement":null},{"id":"W4409591891","doi":"10.1002/cam4.70881","title":"Effect of Statins in the Watch and Wait Phase of Chronic Lymphocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Leukemia and Lymphoma Society of Canada; Cancer Research Society; Leukemia and Lymphoma Society","keywords":"Chronic lymphocytic leukemia; Medicine; Statin; Beta-2 microglobulin; Internal medicine; Leukemia; Cholesterol; Gastroenterology; Immunology; Oncology","score_opus":0.0174991683480354,"score_gpt":0.4024211242750498,"score_spread":0.3849219559270144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409591891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97841865,0.016136602,0.00005964396,0.001582553,0.00015383332,0.0009323731,0.000010678162,0.000013192175,0.0026924668],"genre_scores_gemma":[0.9959852,0.0026431596,0.000009745506,0.00032747796,0.00015829981,0.00011406376,0.000013229684,0.000014339619,0.0007344675],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99819905,0.00017498335,0.000511707,0.000269351,0.00052233075,0.00032259597],"domain_scores_gemma":[0.9980088,0.0011944101,0.000113518785,0.00049384567,0.0001051158,0.00008434159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012871706,0.00017840952,0.00073328597,0.00019884156,0.00002778157,0.0000027121305,0.00020973958,0.000089968955,0.00019755022],"category_scores_gemma":[0.00060876115,0.000099217476,0.000051659317,0.00079010014,0.00072999817,0.000033946235,0.00006518893,0.00023698343,0.0000015365196],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014632526,0.00041044626,0.009832727,0.04068372,0.0011296445,0.0008693536,0.016737245,0.0008804023,0.17353986,0.0023468519,0.046039082,0.69289815],"study_design_scores_gemma":[0.473685,0.020280285,0.004535994,0.018444622,0.0018424134,0.00029726018,0.0018990051,0.13856721,0.3188247,0.0003628176,0.020835118,0.0004255804],"about_ca_topic_score_codex":0.0074143163,"about_ca_topic_score_gemma":0.00024094024,"teacher_disagreement_score":0.6924726,"about_ca_system_score_codex":0.025580138,"about_ca_system_score_gemma":0.01723075,"threshold_uncertainty_score":0.9991954},"labels":[],"label_agreement":null},{"id":"W4409665556","doi":"10.1111/cts.70215","title":"Unlocking the Mysteries of Rare Disease Drug Development: A Beginner's Guide for Clinical Pharmacologists","year":2025,"lang":"en","type":"review","venue":"Clinical and Translational Science","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Drug development; Disease; Rare disease; Medicine; Data science; Intensive care medicine; Bioinformatics; Computer science; Drug; Pharmacology; Pathology; Biology","score_opus":0.22548460080877802,"score_gpt":0.549651174667454,"score_spread":0.3241665738586759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409665556","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002450358,0.99519485,0.0003393714,0.0011252933,0.00044325253,0.0018458946,0.000102189086,0.00002011864,0.0006839881],"genre_scores_gemma":[0.002515233,0.9936649,0.0016720576,0.0002558,0.00032566328,0.0001677575,0.00007168781,0.000011875166,0.0013150309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630994,0.00020990903,0.0017687125,0.000695542,0.00068213703,0.00033376698],"domain_scores_gemma":[0.9908871,0.00782929,0.00028715417,0.00031891908,0.00032503565,0.00035250964],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.005048538,0.00022222428,0.0011672364,0.00011838284,0.00032120474,0.00004064159,0.0005603069,0.0001413602,0.000034540062],"category_scores_gemma":[0.0028540227,0.00012425655,0.0005316671,0.00058459694,0.0039773267,0.00008529337,0.00017674724,0.00039157108,0.0000041071426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019101861,0.00014639323,0.0008268186,0.013499563,0.00013737247,0.000014639045,0.00005087993,0.0000011089555,6.8798336e-8,0.0015765375,0.00084443326,0.9827112],"study_design_scores_gemma":[0.0031129075,0.000046310168,0.0015608931,0.0076011415,0.00067173346,0.000013232022,0.000007702993,0.00043218408,8.747945e-7,0.00034293233,0.9860686,0.00014150713],"about_ca_topic_score_codex":0.00000517628,"about_ca_topic_score_gemma":0.0000065776658,"teacher_disagreement_score":0.9852241,"about_ca_system_score_codex":0.00024862267,"about_ca_system_score_gemma":0.046461195,"threshold_uncertainty_score":0.9987333},"labels":[],"label_agreement":null},{"id":"W4409666926","doi":"10.57264/cer-2024-0210","title":"A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases","year":2025,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Business; Internal medicine; Leukemia","score_opus":0.19096360683406274,"score_gpt":0.5109227883965701,"score_spread":0.31995918156250736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409666926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99326015,0.0014403784,0.0023319377,0.000058761692,0.000030216117,0.002399739,0.00009751635,0.000023002733,0.00035833014],"genre_scores_gemma":[0.9989651,0.00019300093,0.0003645401,0.000012274968,0.00013568616,0.00003973758,0.00013476014,0.00004940217,0.00010550083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928799,0.0024276704,0.001107587,0.00058219116,0.0021056377,0.0008969885],"domain_scores_gemma":[0.98781854,0.006930376,0.00068106,0.00057804893,0.0035536522,0.00043830962],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002911821,0.00041920043,0.0019803683,0.0015757601,0.00047647738,0.000069674556,0.0003383009,0.00012425435,0.00003212701],"category_scores_gemma":[0.0006111784,0.0002686428,0.0000980383,0.0034821697,0.0008762699,0.00032903661,0.00030269637,0.0010948908,0.0000021060255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.046870556,0.0005344444,0.9407492,0.0032170976,0.0009806334,0.00013191554,0.00044952505,0.0041389833,0.00033668152,0.00025959153,0.00015233245,0.002179027],"study_design_scores_gemma":[0.09140444,0.011475924,0.7854002,0.018803291,0.0005017947,0.00008030851,0.0005739055,0.057908207,0.03208694,0.00001391242,0.0014065207,0.0003445522],"about_ca_topic_score_codex":0.00510824,"about_ca_topic_score_gemma":0.0051043546,"teacher_disagreement_score":0.15534902,"about_ca_system_score_codex":0.05696269,"about_ca_system_score_gemma":0.037689425,"threshold_uncertainty_score":0.9999766},"labels":[],"label_agreement":null},{"id":"W4409786049","doi":"10.70962/cis2025abstract.63","title":"Never Say Never—Delayed and Unusual Presentations of XLA in Two Patients with a Kinase-Domain Variant","year":2025,"lang":"en","type":"article","venue":"Journal of Human Immunity","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; McMaster University","funders":"","keywords":"Domain (mathematical analysis); Medicine; Protein kinase domain; Virology; Genetics; Biology; Mathematics","score_opus":0.01288605403232843,"score_gpt":0.33806587643237357,"score_spread":0.3251798224000451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409786049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766093,0.00014936687,0.00012422982,0.00019590919,0.000048117854,0.00026412183,0.0000073244187,0.00000417153,0.0015458356],"genre_scores_gemma":[0.9991028,0.000014256113,0.00041581623,0.00011723701,0.000028248394,0.0000027196222,0.000012516482,0.000011486088,0.0002949312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843097,0.00024753503,0.0005649861,0.00009736559,0.00045445882,0.00020468021],"domain_scores_gemma":[0.9986983,0.00025413194,0.00024701326,0.00027923047,0.00042109087,0.000100267265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006379702,0.00011448281,0.00038379483,0.00046866806,0.00009734348,0.000019044066,0.00016648011,0.000047875004,0.000074960495],"category_scores_gemma":[0.00020116502,0.00008579794,0.00006116164,0.000420483,0.00020111026,0.00027043637,0.000116054,0.0005310587,8.622952e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028232675,0.013771668,0.8393373,0.00164377,0.004309751,0.0035181022,0.022872629,0.0006715454,0.030652927,0.028636215,0.020530056,0.0058233975],"study_design_scores_gemma":[0.065233655,0.0012003554,0.92768407,0.0005957725,0.00020149047,0.00017778958,0.0014391823,0.0003053518,0.0012387263,0.001462271,0.0003376237,0.00012372796],"about_ca_topic_score_codex":0.002315009,"about_ca_topic_score_gemma":0.00036626472,"teacher_disagreement_score":0.088346794,"about_ca_system_score_codex":0.0013296355,"about_ca_system_score_gemma":0.0024010062,"threshold_uncertainty_score":0.42592818},"labels":[],"label_agreement":null},{"id":"W4409831622","doi":"10.14740/jh2022","title":"Donor Cell-Derived Chronic Lymphocytic Leukemia Presenting After Allogenic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Hematopoietic stem cell transplantation; Chronic lymphocytic leukemia; Leukemia; Stem cell; Transplantation; Haematopoiesis; Immunology; Cancer research; Hematopoietic cell; Myeloid; Internal medicine; Biology","score_opus":0.011112788273489575,"score_gpt":0.2890602369008468,"score_spread":0.27794744862735726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409831622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764785,0.0072960034,0.013143065,0.00038273633,0.0006212042,0.0010753844,0.000014568701,0.000051106876,0.0009374098],"genre_scores_gemma":[0.99269027,0.0015729401,0.0015898573,0.00034277572,0.00025135584,0.00012883233,0.00001890143,0.00007002926,0.003335028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99629784,0.00016264372,0.0015376244,0.00049203937,0.0005636896,0.0009461496],"domain_scores_gemma":[0.99724466,0.00076968403,0.0006688072,0.00050812203,0.0005111334,0.00029758472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061212527,0.00041208096,0.0013393254,0.0006154957,0.00015186393,0.000055373883,0.00046339136,0.00045646634,0.000116848736],"category_scores_gemma":[0.00005549151,0.00035150675,0.0006400129,0.00041052542,0.00022003808,0.0002181912,0.00010423668,0.00057572953,0.00004792599],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.045658465,0.0009546969,0.005121242,0.078545146,0.009914675,0.034321036,0.011062905,0.009156067,0.7536208,0.0044065397,0.03821037,0.009028032],"study_design_scores_gemma":[0.08189901,0.0015067686,0.0008251365,0.0016927703,0.0046596327,0.03436586,0.00079705665,0.0297152,0.8403248,0.0010265328,0.0025124897,0.0006747003],"about_ca_topic_score_codex":0.000067635316,"about_ca_topic_score_gemma":0.000029912682,"teacher_disagreement_score":0.08670402,"about_ca_system_score_codex":0.048618168,"about_ca_system_score_gemma":0.045268495,"threshold_uncertainty_score":0.99989367},"labels":[],"label_agreement":null},{"id":"W4409918957","doi":"10.1007/978-3-031-39880-3_156","title":"Small Lymphocytic Lymphoma, Mesenteric Involvement","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Lymphoma; Medicine; Pathology","score_opus":0.046655299561182965,"score_gpt":0.2830442276546851,"score_spread":0.23638892809350215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409918957","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029444607,0.0030984445,0.00024036391,0.00043873937,0.0005520308,0.0015660304,0.000030751104,0.0003092761,0.9934699],"genre_scores_gemma":[0.0016887233,0.0018360611,0.000970917,0.0030118919,0.0004685508,0.000078005665,0.00029475937,0.00015684508,0.99149424],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99606353,0.000024585981,0.00086805504,0.0010915636,0.0011393203,0.000812961],"domain_scores_gemma":[0.9970029,0.00022860624,0.00018623137,0.0017206768,0.0003577618,0.0005038222],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003039993,0.0007976581,0.0012579467,0.0007278933,0.000103039994,0.00006855125,0.0004969087,0.00076181034,0.0058809747],"category_scores_gemma":[0.000097218144,0.0006772149,0.0006167294,0.00013033893,0.00028014905,0.00004194671,0.000735864,0.00033709852,0.00237537],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017702547,0.00045536508,0.00003531051,0.008451567,0.0048445407,0.007472297,0.00025778264,0.000010394404,0.0001875561,0.32110575,0.47371882,0.18169035],"study_design_scores_gemma":[0.028948136,0.00042128086,0.000013360989,0.0025614263,0.0008004896,0.0005954012,0.00003978945,0.0037126339,0.00054550037,0.0034711938,0.95811224,0.0007785286],"about_ca_topic_score_codex":0.0011164073,"about_ca_topic_score_gemma":0.00018310777,"teacher_disagreement_score":0.48439345,"about_ca_system_score_codex":0.09465501,"about_ca_system_score_gemma":0.046310067,"threshold_uncertainty_score":0.9995679},"labels":[],"label_agreement":null},{"id":"W4409993061","doi":"10.58931/cht.2025.4167","title":"Diagnosis and Management of Small Lymphocytic Lymphoma (SLL)Versus Chronic Lymphocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Lymphoma; Leukemia; Oncology; Immunology","score_opus":0.02322234478264082,"score_gpt":0.2895352835417574,"score_spread":0.26631293875911655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409993061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93989944,0.021504287,0.00006725604,0.000956578,0.00083625055,0.0015974689,0.000034903667,0.00012102509,0.03498277],"genre_scores_gemma":[0.98931855,0.004546596,0.0006391127,0.0007571046,0.00006228554,0.00037683628,0.00003944175,0.00005978283,0.004200261],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968222,0.00010006927,0.00069680734,0.0008140231,0.00031002949,0.001256922],"domain_scores_gemma":[0.9971992,0.00051444734,0.00012744976,0.0010876342,0.00017093627,0.0009003709],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032814432,0.00042389773,0.0009793248,0.0009441363,0.00019790663,0.000030929277,0.00042655176,0.00045333218,0.0003282363],"category_scores_gemma":[0.00020452336,0.00043114714,0.00018223735,0.0009269185,0.0007044422,0.000068530724,0.00024478964,0.00015942614,0.00013171653],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0057696486,0.00035118154,0.029367082,0.05062561,0.012654922,0.03908869,0.001615663,0.001336137,0.00028180185,0.40732443,0.10114822,0.35043663],"study_design_scores_gemma":[0.42462057,0.0028102188,0.039184082,0.016573016,0.006386215,0.010758205,0.0026623209,0.12191966,0.041054323,0.0037915579,0.3264292,0.0038106411],"about_ca_topic_score_codex":0.10691894,"about_ca_topic_score_gemma":0.08126035,"teacher_disagreement_score":0.4188509,"about_ca_system_score_codex":0.21576108,"about_ca_system_score_gemma":0.101444125,"threshold_uncertainty_score":0.99981403},"labels":[],"label_agreement":null},{"id":"W4410084209","doi":"10.1016/j.ymthe.2025.04.042","title":"Locking CBL TKBD in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukemia","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of Guelph","funders":"H2020 European Research Council; Horizon 2020 Framework Programme; Glasgow Children's Hospital Charity; European Research Council; Glasgow Children’s Hospital Charity; Cancer Research UK; Beatson Institute for Cancer Research; Cancer Research Society; Genome Canada","keywords":"Mutant; Leukemia; Chemistry; Cell biology; Cancer research; Biology; Computational biology; Genetics; Biochemistry; Gene","score_opus":0.04394923179772846,"score_gpt":0.3488868685475074,"score_spread":0.3049376367497789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410084209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848156,0.002111585,0.0034811536,0.00074730336,0.00011634948,0.0018195588,0.0000075997564,0.000051677136,0.006849161],"genre_scores_gemma":[0.996191,0.00068094156,0.00006153379,0.0020293933,0.00001764952,0.00015099302,0.000036894042,0.000032457083,0.00079910865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975654,0.00018014983,0.0005598779,0.00039946876,0.0007461547,0.0005489664],"domain_scores_gemma":[0.9989404,0.00013141631,0.000108135304,0.00048287484,0.00019344968,0.00014368765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007569635,0.0002630807,0.0004372493,0.0006141478,0.000055672223,0.00003759443,0.00028691828,0.00020950923,0.00010765904],"category_scores_gemma":[0.00022660717,0.0002360312,0.000100555924,0.000821712,0.000079596066,0.00016002828,0.00010785779,0.00055665884,0.0000253267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004872942,0.0019570442,0.004375643,0.0007111517,0.00094970566,0.0026978357,0.008923607,0.0037027108,0.8676963,0.006736759,0.0001310955,0.0972452],"study_design_scores_gemma":[0.09605582,0.0005050504,0.011516408,0.001257203,0.000051354942,0.00016718215,0.0014450677,0.2522258,0.6300073,0.0013488028,0.0047846907,0.0006353371],"about_ca_topic_score_codex":0.0010324819,"about_ca_topic_score_gemma":0.00013071092,"teacher_disagreement_score":0.24852307,"about_ca_system_score_codex":0.012662764,"about_ca_system_score_gemma":0.0070808353,"threshold_uncertainty_score":0.9985481},"labels":[],"label_agreement":null},{"id":"W4410170016","doi":"10.3390/kinasesphosphatases3020010","title":"Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging","year":2025,"lang":"en","type":"article","venue":"Kinases and Phosphatases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"SWORD; Bruton's tyrosine kinase; Tyrosine kinase; Cancer research; Medicine; Internal medicine; Computer science; World Wide Web","score_opus":0.02343333227252047,"score_gpt":0.3466697965272182,"score_spread":0.3232364642546977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410170016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85995716,0.13651863,0.000007580616,0.0019901588,0.00012215461,0.00043586642,0.00008043767,0.000040721025,0.0008472767],"genre_scores_gemma":[0.98841923,0.0082456665,0.00007972994,0.0008266386,0.00007828985,0.00009391284,0.00007524984,0.000016766464,0.002164538],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876696,0.000020378382,0.00023851247,0.00040108178,0.00019161974,0.00038141984],"domain_scores_gemma":[0.9992795,0.00020446726,0.000036355646,0.0002715048,0.000054540335,0.00015363579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001779304,0.00018395596,0.0003469898,0.00018854269,0.0001016933,0.000060068603,0.00007407841,0.00007595744,0.000140578],"category_scores_gemma":[0.0000921873,0.00015694909,0.000035916095,0.0004366248,0.00018816412,0.00010062309,0.00016467406,0.00017628261,0.000003746924],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009338509,0.0013453847,0.39308742,0.007441378,0.0005142847,0.0039524576,0.0013892652,0.00009816072,0.0037866465,0.024915507,0.058737136,0.49539384],"study_design_scores_gemma":[0.16673249,0.0009316796,0.2696218,0.011153983,0.0007297019,0.0004951072,0.0011958624,0.010009179,0.22348744,0.0015400958,0.31272796,0.0013747195],"about_ca_topic_score_codex":0.014875286,"about_ca_topic_score_gemma":0.0012564553,"teacher_disagreement_score":0.49401915,"about_ca_system_score_codex":0.0012061865,"about_ca_system_score_gemma":0.0014608871,"threshold_uncertainty_score":0.99168473},"labels":[],"label_agreement":null},{"id":"W4410276892","doi":"10.1164/ajrccm.2025.211.abstracts.a7745","title":"A Comparative Study With ING-006, Nintedanib, Nerandomilast and Bexotegrast Using the In Vivo CAM-Patient-Derived IPF Model","year":2025,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Bausch Health (Canada)","funders":"","keywords":"Medicine; Nintedanib; In vivo; Internal medicine; Idiopathic pulmonary fibrosis; Lung; Genetics","score_opus":0.03501291727405743,"score_gpt":0.3692709314234888,"score_spread":0.3342580141494314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410276892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362254,0.0031626315,0.0013501304,0.00093236956,0.000047221107,0.00046753194,0.000003070906,0.000006404372,0.00040809816],"genre_scores_gemma":[0.9981389,0.000032998236,0.0002816609,0.0014241668,0.000095445095,0.0000053823996,2.8738228e-7,0.00001364468,0.0000075394328],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99787605,0.00038681485,0.000583634,0.00025469877,0.00058812887,0.00031070225],"domain_scores_gemma":[0.99790215,0.00084285624,0.00014065672,0.00021164611,0.0006245308,0.0002781634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006034903,0.00021817374,0.000971933,0.0003272911,0.00016253295,0.0000243953,0.00011681594,0.000039418006,0.000012926548],"category_scores_gemma":[0.00054293475,0.00011659687,0.000045347846,0.0005699079,0.0025355238,0.000094532355,0.00006330271,0.00065880606,1.1416684e-7],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13745777,0.0037135384,0.20988931,0.0027311083,0.0031741413,0.01266287,0.38422707,0.0048025716,0.14039959,0.0029077,0.0019092435,0.096125096],"study_design_scores_gemma":[0.09726018,0.049682982,0.004273297,0.004875685,0.0017200125,0.0022798947,0.8043933,0.02899239,0.005186069,0.00012440201,0.00073129515,0.00048047976],"about_ca_topic_score_codex":0.00041292002,"about_ca_topic_score_gemma":0.00027329076,"teacher_disagreement_score":0.42016625,"about_ca_system_score_codex":0.00096932834,"about_ca_system_score_gemma":0.0025841573,"threshold_uncertainty_score":0.9342243},"labels":[],"label_agreement":null},{"id":"W4410304943","doi":"10.58931/cht.2025.4s0368","title":"Hypertension as a Cardiovascular Toxicity of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Bruton's tyrosine kinase; Tyrosine kinase; Toxicity; Internal medicine; Leukemia; Cardiology; Receptor","score_opus":0.014782015728558128,"score_gpt":0.27032406567773637,"score_spread":0.25554204994917823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410304943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677608,0.023325602,0.00023202042,0.0013647202,0.0007069045,0.0019025013,0.000050275474,0.00008836153,0.004568834],"genre_scores_gemma":[0.9955336,0.00018126372,0.00022678477,0.0012851208,0.00014610882,0.00017098943,0.00006490044,0.000049743805,0.0023415217],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973364,0.00009116252,0.0005906688,0.0006511199,0.0003403269,0.0009903609],"domain_scores_gemma":[0.9973449,0.0003321506,0.00008384395,0.001133385,0.00042955836,0.0006761659],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050131546,0.00030898346,0.0011947285,0.0007507453,0.00017725152,0.000013102614,0.00027336035,0.00052052416,0.00014200318],"category_scores_gemma":[0.0012668028,0.00029615586,0.00056984276,0.0006847697,0.00041913296,0.000060467075,0.000088329456,0.00024573042,0.000070597125],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005150701,0.0005718415,0.007921014,0.034468766,0.01653757,0.025844995,0.0019016971,0.006711357,0.10366162,0.14162461,0.5739383,0.081667535],"study_design_scores_gemma":[0.061128292,0.001237105,0.0008695296,0.0028881198,0.0018520185,0.0074827545,0.00030743433,0.042783063,0.6227517,0.0015686002,0.2561721,0.0009592698],"about_ca_topic_score_codex":0.14513825,"about_ca_topic_score_gemma":0.040328074,"teacher_disagreement_score":0.5190901,"about_ca_system_score_codex":0.108859,"about_ca_system_score_gemma":0.15113388,"threshold_uncertainty_score":0.99994904},"labels":[],"label_agreement":null},{"id":"W4410360697","doi":"10.1101/2025.05.11.25326925","title":"Measurement of Bone Marrow Tumour Burden and Minimal Residual Disease in Waldenstrom’s Macroglobulinemia through Cell-free Whole Genome Sequencing","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; University of Toronto","funders":"Princess Margaret Hospital Foundation; Princess Margaret Cancer Foundation; International Waldenstrom's Macroglobulinemia Foundation","keywords":"Minimal residual disease; Macroglobulinemia; Bone marrow; Waldenstrom macroglobulinemia; Residual; Medicine; Disease; Biology; Cancer research; Pathology; Internal medicine; Multiple myeloma; Computer science; Algorithm","score_opus":0.034834096339512566,"score_gpt":0.2898178442317783,"score_spread":0.25498374789226574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410360697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97687453,0.015540304,0.000056200344,0.003406343,0.00021750625,0.0015633525,0.00058044365,0.00006664115,0.0016947055],"genre_scores_gemma":[0.9935801,0.00065477204,0.0026736078,0.00009386602,0.0005513953,0.00014646536,0.00015068348,0.000065080654,0.0020840478],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99454135,0.00025306657,0.0011934388,0.0011963536,0.001990845,0.0008249549],"domain_scores_gemma":[0.99689955,0.00012297466,0.00033124615,0.0017539564,0.0004565732,0.0004356896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016379405,0.0005662434,0.0012809978,0.00041136268,0.00006316292,0.0000468535,0.00064068066,0.0003892275,0.000084550054],"category_scores_gemma":[0.0012121812,0.00054612465,0.00023106903,0.00033776957,0.00034039308,0.00006733017,0.0024811286,0.001210642,0.0000152455195],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009839761,0.0010793147,0.100961745,0.08302921,0.0013011269,0.02559194,0.010815532,0.0076006227,0.7480914,0.00022620901,0.00976517,0.0016979702],"study_design_scores_gemma":[0.24208277,0.0026085814,0.37067991,0.06861784,0.006961404,0.0011838386,0.005908882,0.062673084,0.20332715,0.009146918,0.019147627,0.007661984],"about_ca_topic_score_codex":0.003988213,"about_ca_topic_score_gemma":0.00028942554,"teacher_disagreement_score":0.5447643,"about_ca_system_score_codex":0.014598322,"about_ca_system_score_gemma":0.020733554,"threshold_uncertainty_score":0.99969906},"labels":[],"label_agreement":null},{"id":"W4410382461","doi":"10.1021/acs.jmedchem.4c03083","title":"Discovery of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitors","year":2025,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Science and Technology Innovation Talents in Universities of Henan Province; Henan Provincial Science and Technology Research Project; Education Department of Henan Province; National Natural Science Foundation of China; Henan Normal University","keywords":"Bruton's tyrosine kinase; Chemistry; Pyridazine; Tyrosine kinase; Stereochemistry; Biochemistry; Signal transduction","score_opus":0.007690525082136716,"score_gpt":0.2831167849496755,"score_spread":0.2754262598675388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410382461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984212,0.0065318733,0.00010859013,0.0034434255,0.00019737807,0.00018432715,0.000007369353,0.000011874754,0.0053031975],"genre_scores_gemma":[0.995809,0.000995642,0.00023496596,0.00029615936,0.00048538492,0.0000034743894,0.000007198332,0.000021582171,0.0021465807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744284,0.000048894522,0.00085861364,0.00028216824,0.0010052364,0.00036221702],"domain_scores_gemma":[0.99791926,0.0003430412,0.00050512515,0.0002824537,0.0006608066,0.00028929062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064492866,0.00026450053,0.0008165423,0.0002350758,0.00006955235,0.000023009321,0.00021783756,0.00018721021,0.00005105787],"category_scores_gemma":[0.0013752845,0.00020240096,0.00019847837,0.00058798544,0.00052278646,0.00022421527,0.00015921483,0.00074349646,0.0000018378998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042228065,0.00056120683,0.004760462,0.002752039,0.0007812938,0.0013398288,0.0005659909,0.000043363096,0.96978986,0.00009106667,0.012841499,0.0022506055],"study_design_scores_gemma":[0.016140847,0.0007181432,0.004468907,0.003177762,0.000439847,0.0023843807,0.0013379323,0.00029279725,0.9694716,0.00028476745,0.0011245394,0.00015849013],"about_ca_topic_score_codex":0.0001364828,"about_ca_topic_score_gemma":0.0000018849531,"teacher_disagreement_score":0.01191804,"about_ca_system_score_codex":0.003455296,"about_ca_system_score_gemma":0.0074031334,"threshold_uncertainty_score":0.99822396},"labels":[],"label_agreement":null},{"id":"W4410431776","doi":"10.1016/j.clml.2025.05.011","title":"Feasibility of Bruton’s Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Foundation for the National Institutes of Health","keywords":"Medicine; Discontinuation; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Perspective (graphical); Tyrosine-kinase inhibitor; Ibrutinib; Tyrosine kinase; Internal medicine; Oncology; Cancer research; Leukemia; Receptor; Cancer","score_opus":0.034815132707061984,"score_gpt":0.3708855288940279,"score_spread":0.33607039618696594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410431776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849244,0.0037744152,0.0000865829,0.0010702016,0.00078405795,0.0026192437,0.00003459937,0.00013654382,0.0065699928],"genre_scores_gemma":[0.9962052,0.00041441742,0.00018774219,0.0008221695,0.0005142728,0.0002183342,0.00005021326,0.000070296046,0.0015173545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9926327,0.0008208887,0.0027832575,0.0014875868,0.0011831339,0.0010924451],"domain_scores_gemma":[0.9933573,0.0025556802,0.0005999768,0.0022245157,0.00088299153,0.00037955877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024527689,0.00061324914,0.0015852429,0.00045467788,0.00021553713,0.00006896054,0.00074250525,0.0007257418,0.00012508723],"category_scores_gemma":[0.0061103585,0.00045441068,0.0007841121,0.0019609206,0.0018390296,0.00025676456,0.000709211,0.00079748704,0.000111843605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02035974,0.0026525029,0.07095782,0.0022523375,0.0014952446,0.0018672504,0.0042944034,0.0029550528,0.012662939,0.02740461,0.017010823,0.8360873],"study_design_scores_gemma":[0.06215155,0.0021567426,0.8483347,0.0022387477,0.00044323146,0.00016471464,0.0018283486,0.060366407,0.016028937,0.002690688,0.0029057711,0.00069013954],"about_ca_topic_score_codex":0.006767858,"about_ca_topic_score_gemma":0.0010475133,"teacher_disagreement_score":0.8353971,"about_ca_system_score_codex":0.39275604,"about_ca_system_score_gemma":0.14194305,"threshold_uncertainty_score":0.99984616},"labels":[],"label_agreement":null},{"id":"W4410692239","doi":"10.3390/curroncol32060296","title":"Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; Saskatoon Medical Imaging; Saskatchewan Health; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Janssen Biotech","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Adverse effect; Incidence (geometry); Internal medicine; Oncology; Intensive care medicine; Leukemia","score_opus":0.02196026998702834,"score_gpt":0.366915392494457,"score_spread":0.34495512250742866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410692239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855333,0.0006491996,0.00000782875,0.00034256664,0.0003703938,0.0016366957,0.000009433737,0.00003348547,0.011417118],"genre_scores_gemma":[0.9974103,0.00044520682,0.00012156607,0.00021169762,0.000036219662,0.00022325062,0.000053642558,0.000022630971,0.0014754748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972727,0.00014820768,0.0005993719,0.0006015234,0.00033437248,0.0010438293],"domain_scores_gemma":[0.9987607,0.00027724565,0.000113876165,0.00040832735,0.00008755211,0.00035232786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005586933,0.0002700803,0.0006244815,0.0016075664,0.0000781366,0.000014980523,0.00020927124,0.00015356815,0.000058054942],"category_scores_gemma":[0.00017020923,0.00023426424,0.000053205335,0.0011315782,0.00020128833,0.00010788904,0.00021681709,0.00050063303,0.000025203295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00030312644,0.00013467205,0.9499127,0.00071089424,0.000074806405,0.0006028031,0.00025981682,0.0001815357,0.0000012346453,0.00056309777,0.00084400823,0.046411272],"study_design_scores_gemma":[0.05025556,0.0006363735,0.9152319,0.0015315699,0.00010115189,0.000017753318,0.00019562554,0.00873887,0.000008295308,0.00011828119,0.022919344,0.0002453127],"about_ca_topic_score_codex":0.22986034,"about_ca_topic_score_gemma":0.8219638,"teacher_disagreement_score":0.5921034,"about_ca_system_score_codex":0.26511842,"about_ca_system_score_gemma":0.056675,"threshold_uncertainty_score":0.9553019},"labels":[],"label_agreement":null},{"id":"W4410803634","doi":"10.1200/jco.2025.43.16_suppl.tps7088","title":"Efficacy and safety of nemtabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Cohort J of the phase 2 BELLWAVE-003 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Refractory (planetary science); Cohort; Internal medicine; Oncology; Lymphoma; Leukemia","score_opus":0.07794495170972114,"score_gpt":0.45810909371942043,"score_spread":0.3801641420096993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914145,0.0025034149,0.000030071194,0.00046306127,0.001175827,0.0017818075,0.00000735344,0.0000130460585,0.0026109454],"genre_scores_gemma":[0.9948391,0.0026211385,0.00030664468,0.0005189674,0.00038145742,0.000015761827,0.0000022071576,0.000041184412,0.0012735941],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9892978,0.0018540992,0.0065632937,0.00057016476,0.0010595765,0.0006550385],"domain_scores_gemma":[0.9825104,0.01214306,0.003147734,0.0010562724,0.0007041225,0.0004384115],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009704998,0.0003835996,0.0037593846,0.0005543922,0.00009337351,0.000011215281,0.00081895926,0.0008246819,0.00012466822],"category_scores_gemma":[0.018419541,0.000236447,0.0006492839,0.0012273645,0.0014222527,0.00009315532,0.00055384496,0.0011588454,0.000005755898],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.32295147,0.024440171,0.10014903,0.0028628327,0.006939384,0.0070736976,0.001981008,0.0025127132,0.003697421,0.00049969583,0.0042523304,0.5226402],"study_design_scores_gemma":[0.65317935,0.043290604,0.27055162,0.0025364927,0.00238131,0.0015312799,0.0007988302,0.012506042,0.0012668695,0.00015918794,0.011467867,0.0003305516],"about_ca_topic_score_codex":0.0009874288,"about_ca_topic_score_gemma":0.00059196714,"teacher_disagreement_score":0.5223097,"about_ca_system_score_codex":0.08897145,"about_ca_system_score_gemma":0.27978614,"threshold_uncertainty_score":0.98984873},"labels":[],"label_agreement":null},{"id":"W4410819589","doi":"10.1200/jco.2025.43.16_suppl.e13058","title":"Comparative analysis of <i>PIK3CA</i> mutation detection methods in the first-in-human phase 1/1b study of inavolisib.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech","keywords":"Medicine; Mutation; Oncology; Internal medicine; Computational biology; Genetics; Gene; Biology","score_opus":0.2181846250729563,"score_gpt":0.6391249048324789,"score_spread":0.42094027975952253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410819589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995367,0.00016707502,0.0015980321,0.0006211143,0.00018996971,0.0004681821,0.0000010346864,0.0000017880975,0.001585816],"genre_scores_gemma":[0.9986336,0.00004867819,0.0009346261,0.0002649981,0.000078766585,0.000010156253,0.0000013770175,0.0000034470715,0.000024332543],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99323267,0.002645902,0.0033203897,0.00017054405,0.00047090344,0.00015958482],"domain_scores_gemma":[0.987824,0.009677496,0.0016104862,0.00027445305,0.0005473696,0.00006618962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012865594,0.0000979189,0.002163927,0.0010774535,0.000028227054,0.0000044077533,0.0002568938,0.00021566689,0.00002606769],"category_scores_gemma":[0.0040710624,0.00006255972,0.00039827166,0.0021994703,0.00023195628,0.00007051064,0.000054819633,0.000923884,4.4152648e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06611631,0.18664539,0.25619492,0.0007205048,0.021282531,0.0035715937,0.048205826,0.017011294,0.008739945,0.0007434809,0.0014958358,0.38927236],"study_design_scores_gemma":[0.22320285,0.06231311,0.62401074,0.00026653268,0.006804491,0.00010059406,0.01899007,0.057486773,0.0039416156,0.0008464805,0.00190496,0.00013178728],"about_ca_topic_score_codex":0.0009229297,"about_ca_topic_score_gemma":0.0064519043,"teacher_disagreement_score":0.38914058,"about_ca_system_score_codex":0.0022500677,"about_ca_system_score_gemma":0.0037089135,"threshold_uncertainty_score":0.65794533},"labels":[],"label_agreement":null},{"id":"W4410820514","doi":"10.1200/jco.2025.43.16_suppl.7017","title":"Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had <i>TP53</i> mutations in the SYMPATICO study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ibrutinib; Venetoclax; Mantle cell lymphoma; Medicine; Oncology; Internal medicine; Lymphoma; Cancer research; Chronic lymphocytic leukemia; Leukemia","score_opus":0.04735440968525347,"score_gpt":0.4183786760132616,"score_spread":0.37102426632800817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946967,0.0002759821,0.00004580158,0.002059093,0.00018180718,0.0012533639,0.0000051885477,0.0000033117483,0.0014787636],"genre_scores_gemma":[0.99836475,0.00026652994,0.0002895029,0.00070040417,0.000087078006,0.000014083222,0.000004314071,0.000014243865,0.00025911012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583757,0.0006087194,0.002422812,0.00024094075,0.0005942034,0.0002957495],"domain_scores_gemma":[0.99051505,0.007840236,0.0008359563,0.00033449434,0.00034002037,0.00013423877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003047304,0.0001605145,0.0014135841,0.00026032724,0.000050009985,0.000011091283,0.0002986283,0.0002550693,0.000051743085],"category_scores_gemma":[0.00278118,0.000087216504,0.000121467136,0.0005316951,0.00033327437,0.00007441197,0.0001233089,0.00068744563,0.0000029449586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08629555,0.023214146,0.77943516,0.00052824477,0.00056610757,0.0018555409,0.0039456347,0.0018079014,0.0000034228462,0.000076244316,0.0017945323,0.10047749],"study_design_scores_gemma":[0.21525897,0.015525783,0.76216877,0.0006294577,0.00026772093,0.000053886648,0.0007963766,0.0017279356,0.0000113943215,0.00005082347,0.0034314943,0.000077384095],"about_ca_topic_score_codex":0.00018888398,"about_ca_topic_score_gemma":0.0010083746,"teacher_disagreement_score":0.12896341,"about_ca_system_score_codex":0.003471646,"about_ca_system_score_gemma":0.015790634,"threshold_uncertainty_score":0.98978895},"labels":[],"label_agreement":null},{"id":"W4410849524","doi":"10.1212/nxi.0000000000200413","title":"Bruton Tyrosine Kinase in Lesions of Multiple Sclerosis and 3 of Its Models","year":2025,"lang":"en","type":"article","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; University of Saskatchewan; University of Calgary","funders":"","keywords":"Bruton's tyrosine kinase; Tyrosine kinase; Multiple sclerosis; Medicine; Neuroscience; Biology; Internal medicine; Immunology; Receptor","score_opus":0.039710728306211446,"score_gpt":0.27725753091143246,"score_spread":0.237546802605221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410849524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943481,0.0010247085,0.000060668302,0.002896431,0.00019446624,0.0008277398,0.000010774032,0.000049225597,0.0005878941],"genre_scores_gemma":[0.99791807,0.0014919617,0.00005985204,0.00030268522,0.000012702009,0.000034816218,0.000014768564,0.000027503485,0.00013765162],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976712,0.00037183982,0.0008340068,0.00052635616,0.00021018465,0.00038640655],"domain_scores_gemma":[0.99804425,0.00083280244,0.0002447421,0.0006143887,0.00020955665,0.00005426381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026258954,0.00022128885,0.00064213446,0.00091574487,0.0000590907,0.0000053265444,0.00020524496,0.0003007639,0.000015568865],"category_scores_gemma":[0.0010656592,0.00022808039,0.00008881392,0.0007100808,0.0005295105,0.00016561888,0.00028552636,0.0005699054,0.0000052050823],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023728146,0.00027150058,0.0102277035,0.00040412287,0.000036706744,0.0001694729,0.000133069,0.0014901067,0.9780628,0.0030189732,0.000051111667,0.0037616077],"study_design_scores_gemma":[0.018638164,0.0014547284,0.63187873,0.00024632335,0.00010381074,0.00035681718,0.000017425458,0.12538394,0.2208961,0.0006938547,0.00017825706,0.00015182751],"about_ca_topic_score_codex":0.00018702698,"about_ca_topic_score_gemma":0.000059853337,"teacher_disagreement_score":0.75716674,"about_ca_system_score_codex":0.00018222826,"about_ca_system_score_gemma":0.0009293479,"threshold_uncertainty_score":0.9300849},"labels":[],"label_agreement":null},{"id":"W4410946654","doi":"10.1093/jimmun/vkaf103","title":"Effect of statins on IL-10 signaling and production by chronic lymphocytic leukemia cells","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Dalhousie University; Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Hospital","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Geranylgeranyl pyrophosphate; Chronic lymphocytic leukemia; Cytokine; Prenylation; Cancer research; Chemistry; Pharmacology; Leukemia; Biology; Immunology; Biochemistry","score_opus":0.006178378369369712,"score_gpt":0.2836516716422835,"score_spread":0.2774732932729138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410946654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906885,0.0078348555,0.00007735704,0.000414656,0.0003322654,0.00031384773,0.0000026607731,0.000009032352,0.00032681262],"genre_scores_gemma":[0.9953838,0.0022982412,0.00003052862,0.000058622834,0.000103799866,0.0000032340427,0.0000017288309,0.000014796032,0.0021052333],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983572,0.00048308307,0.00048875244,0.00012701402,0.00027800642,0.00026593832],"domain_scores_gemma":[0.9979817,0.0011516986,0.0003179005,0.00031837347,0.00018810642,0.00004218791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017567013,0.00014393622,0.00048133679,0.0002307987,0.00007732228,0.00000723195,0.00019996212,0.00011030289,0.00007073994],"category_scores_gemma":[0.0005779698,0.00008554729,0.00008031336,0.0002501438,0.00038982075,0.000050357132,0.00007473376,0.0004275725,0.0000135210175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0063321427,0.000029596045,0.000010617165,0.00042502454,0.0005123495,0.000026332062,0.00029074267,0.0011350934,0.96762586,0.000030142712,0.004448416,0.019133676],"study_design_scores_gemma":[0.0133629115,0.00674804,0.00005559227,0.00062019797,0.00031708318,0.00074043754,0.00012457054,0.0014642947,0.9748029,0.00006187402,0.0016412637,0.000060847942],"about_ca_topic_score_codex":0.00017523642,"about_ca_topic_score_gemma":0.0000026552273,"teacher_disagreement_score":0.019072829,"about_ca_system_score_codex":0.022812594,"about_ca_system_score_gemma":0.009875502,"threshold_uncertainty_score":0.9957376},"labels":[],"label_agreement":null},{"id":"W4411058473","doi":"10.14740/jh2045","title":"Hairy Cell Leukemia With Splenic Rupture: Hematological Changes and Disappearance of Hairy Morphology After Splenectomy","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Splenectomy; Hairy cell leukemia; Medicine; Hairy Cell; Spleen; Pathology; Leukemia; Morphology (biology); Immunology; Biology","score_opus":0.00892479327638862,"score_gpt":0.27538994508372977,"score_spread":0.26646515180734115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411058473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781959,0.016651545,0.00085961906,0.0029800797,0.00017281984,0.00027515323,0.0000038577705,0.00001637599,0.0008446357],"genre_scores_gemma":[0.9961457,0.0006612757,0.0019856957,0.0006869579,0.00007411389,0.000017895218,0.0000017452446,0.0000216813,0.00040490722],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.998012,0.0001414477,0.00068847596,0.0003084141,0.00037018346,0.00047947853],"domain_scores_gemma":[0.9983073,0.00042039427,0.00040932736,0.00038058806,0.0002932003,0.0001891997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039406776,0.0002465486,0.0013238209,0.0004016891,0.000040420342,0.000009472394,0.00022577817,0.00034251064,0.00015169413],"category_scores_gemma":[0.00019899441,0.0001612245,0.00014122935,0.0003408207,0.00075210334,0.00006956713,0.00015808574,0.0006358987,0.000008251196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07974118,0.0044135978,0.5991561,0.03333591,0.0048833303,0.114486314,0.004059302,0.00020897826,0.06803299,0.028542586,0.051061954,0.0120777525],"study_design_scores_gemma":[0.13757752,0.012601907,0.076855935,0.00775832,0.0023150952,0.43072698,0.002489643,0.003179591,0.30295172,0.0049674357,0.017210023,0.0013658394],"about_ca_topic_score_codex":0.000039341205,"about_ca_topic_score_gemma":0.00006360876,"teacher_disagreement_score":0.5223002,"about_ca_system_score_codex":0.0010900217,"about_ca_system_score_gemma":0.0033313804,"threshold_uncertainty_score":0.65745443},"labels":[],"label_agreement":null},{"id":"W4411084855","doi":"10.1200/jco-25-00166","title":"Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bendamustine; Idelalisib; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Ofatumumab; Gastroenterology; Clinical endpoint; Hazard ratio; Venetoclax; Ibrutinib; Leukemia; Lymphoma; Oncology; Confidence interval; Randomized controlled trial","score_opus":0.12965460044835456,"score_gpt":0.4747918773236469,"score_spread":0.3451372768752924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411084855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293364,0.0040175663,0.00019408014,0.0010398901,0.006320514,0.002185841,0.000047506757,0.000081735016,0.0031792016],"genre_scores_gemma":[0.98947453,0.0038103457,0.0010879309,0.0008538134,0.002776886,0.00006927167,0.000057366953,0.00011906493,0.0017508024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9829709,0.0016149356,0.010699761,0.0011925291,0.0018909243,0.0016309364],"domain_scores_gemma":[0.98042095,0.011044334,0.004146958,0.0014123749,0.0017834663,0.0011919094],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0088204695,0.0009136497,0.0069404477,0.0017276146,0.00014794646,0.00005894282,0.0012125516,0.0019905781,0.0004852526],"category_scores_gemma":[0.021905527,0.00071776996,0.0017561963,0.002432831,0.00151836,0.0003476103,0.0006163743,0.0018530653,0.00008213791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8215061,0.018164916,0.00012381944,0.0010604626,0.0016036483,0.011320874,0.00017409294,0.0006896382,0.0017052803,0.0002545003,0.0059175105,0.13747916],"study_design_scores_gemma":[0.87368006,0.071547695,0.0002440545,0.0024211174,0.0018443905,0.0012845383,0.0002542214,0.02691108,0.0067781787,0.00011105614,0.014420223,0.00050337875],"about_ca_topic_score_codex":0.0026994604,"about_ca_topic_score_gemma":0.0011591777,"teacher_disagreement_score":0.1583436,"about_ca_system_score_codex":0.19804563,"about_ca_system_score_gemma":0.35638922,"threshold_uncertainty_score":0.99952734},"labels":[],"label_agreement":null},{"id":"W4411128846","doi":"10.1111/ijlh.14507","title":"A Single‐Center Retrospective Study of the Investigation of Monoclonal B‐Cell Lymphocytosis (<scp>MBL</scp>) and Chronic Lymphocytic Leukemia (<scp>CLL</scp>) in Southwestern Ontario: Are We Over‐Investigating?","year":2025,"lang":"en","type":"article","venue":"International Journal of Laboratory Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Lymphocytosis; Medicine; Chronic lymphocytic leukemia; Internal medicine; Retrospective cohort study; Immunology; Population; Stage (stratigraphy); Leukemia; Biology","score_opus":0.017711973440039424,"score_gpt":0.2833730709066079,"score_spread":0.26566109746656846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411128846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626327,0.0018948561,0.000026822341,0.00017974028,0.0006932462,0.0005746841,0.000040841704,0.000014563245,0.00031197272],"genre_scores_gemma":[0.99891555,0.00011333136,0.00017175777,0.00033454585,0.00012020612,0.0000227982,0.0000056599283,0.00003643098,0.00027969517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956906,0.0004012124,0.0017070088,0.00046416768,0.0013175271,0.00041952677],"domain_scores_gemma":[0.9948552,0.0009219841,0.0018436394,0.00045318273,0.0017161852,0.00020977213],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073615275,0.00036143503,0.0010966221,0.0008842489,0.00007131068,0.00004687536,0.0007255958,0.0003013822,0.000014314722],"category_scores_gemma":[0.0015708577,0.0002955609,0.00019442943,0.0008599288,0.0006868378,0.00027290374,0.00041533838,0.0006818392,0.0000026535756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015302625,0.00045980336,0.9648746,0.0003412629,0.0007441716,0.0003781563,0.006985675,0.00043640815,0.024101041,0.0003683229,0.0011108252,0.00004666394],"study_design_scores_gemma":[0.08340917,0.002303531,0.65290743,0.0057089915,0.00059665,0.0024574413,0.011391434,0.0044548754,0.2328224,0.002928074,0.00081736856,0.00020264636],"about_ca_topic_score_codex":0.0043502008,"about_ca_topic_score_gemma":0.01098736,"teacher_disagreement_score":0.31196722,"about_ca_system_score_codex":0.050414268,"about_ca_system_score_gemma":0.03421039,"threshold_uncertainty_score":0.99994963},"labels":[],"label_agreement":null},{"id":"W4411321377","doi":"10.1002/hon.70096_549","title":"549 | PROSPECTIVE PATIENT PREFERENCE STUDY FOR CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT ATTRIBUTES IMPACTING PATIENT SHARED‐DECISION MAKING","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"BeiGene","keywords":"Chronic lymphocytic leukemia; Preference; Medicine; Leukemia; Oncology; Intensive care medicine; Internal medicine; Statistics","score_opus":0.07115118766882485,"score_gpt":0.39899846669366196,"score_spread":0.3278472790248371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411321377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858304,0.0013120823,0.0014827736,0.00021900948,0.00035505474,0.007545002,0.000035374793,0.00022100088,0.0029992957],"genre_scores_gemma":[0.99397296,0.00006926655,0.00262207,0.00027673037,0.000090006266,0.0027142551,0.000032751115,0.000032669745,0.00018931134],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99597627,0.00023016312,0.0010359052,0.0011345464,0.0005243099,0.0010987796],"domain_scores_gemma":[0.9948532,0.0034597018,0.0003075986,0.00070266053,0.00042573037,0.0002511135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036054413,0.00048170015,0.0014374576,0.00027340036,0.00034763597,0.00005659662,0.00026441202,0.00045522346,0.00024012612],"category_scores_gemma":[0.0022397884,0.00032502832,0.00030112118,0.0005920498,0.00020873299,0.00009572899,0.00044891713,0.00033994258,0.00007816518],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04017468,0.013483929,0.07940232,0.002345889,0.0038274184,0.007931424,0.013307343,0.003808014,0.00237748,0.009527995,0.013721191,0.81009233],"study_design_scores_gemma":[0.2833838,0.32299432,0.053948566,0.0060695303,0.002980381,0.006514516,0.015531864,0.2235872,0.03184411,0.012770916,0.03756264,0.0028121609],"about_ca_topic_score_codex":0.00017788264,"about_ca_topic_score_gemma":0.00017389418,"teacher_disagreement_score":0.8072801,"about_ca_system_score_codex":0.26783454,"about_ca_system_score_gemma":0.030640692,"threshold_uncertainty_score":0.9999202},"labels":[],"label_agreement":null},{"id":"W4411325981","doi":"10.1002/hon.70094_443","title":"443 | A PHASE 1 STUDY OF PRT2527, A SELECTIVE CDK9 INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES: UPDATED ANALYSIS","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"BeiGene; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; Pharmacyclics; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Refractory (planetary science); Medicine; Oncology; Internal medicine; Cancer research; Biology","score_opus":0.020421365488204127,"score_gpt":0.36622796712773403,"score_spread":0.3458066016395299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411325981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956062,0.00042977283,0.00006517997,0.0003994443,0.000026139074,0.0016716612,0.000002489548,0.000038495094,0.001760618],"genre_scores_gemma":[0.9989256,0.000093620896,0.0001995197,0.00030749626,0.0000063885427,0.0002590979,0.000020682144,0.000012239163,0.00017534984],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973632,0.0005338129,0.00075654057,0.00060235144,0.00033534836,0.00040874426],"domain_scores_gemma":[0.9983194,0.0008309516,0.00021504618,0.00030957907,0.00021844376,0.00010660574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000662708,0.00022566247,0.0013527719,0.0010935903,0.000041469655,0.000008725538,0.00012900875,0.00036796625,0.00009136739],"category_scores_gemma":[0.00046535436,0.00016531578,0.000066146364,0.0031334318,0.0003112466,0.000054643246,0.000093124116,0.000395266,0.0000039491506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06727837,0.07926305,0.8076046,0.0005077102,0.0030372406,0.007997402,0.011320894,0.00023774628,0.010144488,0.0033399046,0.0006776522,0.008590935],"study_design_scores_gemma":[0.7015423,0.082368605,0.14565332,0.0006936301,0.0016730872,0.0014677098,0.016351378,0.027625605,0.017996972,0.002255356,0.0015434074,0.00082859304],"about_ca_topic_score_codex":0.0011129854,"about_ca_topic_score_gemma":0.0015911837,"teacher_disagreement_score":0.6619513,"about_ca_system_score_codex":0.0054268297,"about_ca_system_score_gemma":0.0038241511,"threshold_uncertainty_score":0.99839115},"labels":[],"label_agreement":null},{"id":"W4411332234","doi":"10.1002/hon.70093_134","title":"134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"Pharmacyclics","keywords":"Ibrutinib; Mantle cell lymphoma; Venetoclax; Lymphoma; Medicine; Cancer research; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02185390775549227,"score_gpt":0.33183458562934526,"score_spread":0.30998067787385297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411332234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929629,0.00025683412,0.000050922194,0.0008700552,0.000039909595,0.0028043373,0.0000074986447,0.000019655541,0.0029879145],"genre_scores_gemma":[0.99894917,0.000053084117,0.00021425517,0.00032869563,0.000009713017,0.00018934232,0.00002504617,0.000012530975,0.00021815582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775356,0.00032613595,0.000710075,0.000428226,0.0003589337,0.000423093],"domain_scores_gemma":[0.99664044,0.0026243376,0.00014107015,0.00041293408,0.000105326595,0.00007588904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048647332,0.0002072071,0.0009345671,0.00020644719,0.00008102729,0.000010485209,0.00023787227,0.00025152892,0.00013823189],"category_scores_gemma":[0.00055235677,0.00011180374,0.00004181397,0.00068801217,0.00036600698,0.000035770998,0.0001945849,0.00028344587,0.000010215984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030650383,0.027638426,0.9037311,0.0019175892,0.00030743348,0.003723722,0.010538177,0.00083221577,0.000013122421,0.0022752786,0.0010483068,0.01732426],"study_design_scores_gemma":[0.16904463,0.007920568,0.81292063,0.00053314964,0.00017258007,0.00014859375,0.0025523277,0.0046702866,0.00008567657,0.00016602382,0.0015924709,0.00019305167],"about_ca_topic_score_codex":0.00024237584,"about_ca_topic_score_gemma":0.0009616995,"teacher_disagreement_score":0.13839425,"about_ca_system_score_codex":0.003949275,"about_ca_system_score_gemma":0.0034364397,"threshold_uncertainty_score":0.9998744},"labels":[],"label_agreement":null},{"id":"W4411333669","doi":"10.1002/hon.70093_136","title":"136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Bendamustine; Mantle cell lymphoma; Rituximab; Medicine; Minimal residual disease; Oncology; Internal medicine; Lymphoma; Cancer research; Bone marrow","score_opus":0.02236552243145124,"score_gpt":0.31067040176261346,"score_spread":0.2883048793311622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411333669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987845,0.00014737595,0.000024398892,0.0022703381,0.00007651679,0.003923882,0.00012493484,0.00013578964,0.0054517444],"genre_scores_gemma":[0.99477655,0.000031985495,0.00179172,0.0009255315,0.00011946359,0.0003663417,0.00037317502,0.00004725606,0.0015679753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954423,0.00057431386,0.0009054392,0.0011809178,0.00084896426,0.0010480842],"domain_scores_gemma":[0.9954226,0.0025553314,0.00031850947,0.0009724921,0.00029811042,0.00043295955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005017688,0.00052144047,0.001501919,0.00016542731,0.00017852247,0.000046672692,0.00048036338,0.0004553954,0.00018369581],"category_scores_gemma":[0.001222804,0.00022547538,0.000078891826,0.0009466369,0.0009685422,0.00008617536,0.00027788623,0.000611754,0.00005824541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.85395926,0.0075951573,0.12917951,0.00017291208,0.00022486219,0.004236125,0.00043697437,0.0000131727675,0.0000046737146,0.00010309359,0.0027568326,0.0013174249],"study_design_scores_gemma":[0.89702445,0.01911424,0.0766891,0.0009087987,0.0007572489,0.00018192333,0.000569405,0.0007908097,0.00023685415,0.000048124926,0.003233174,0.00044586102],"about_ca_topic_score_codex":0.00076967594,"about_ca_topic_score_gemma":0.0016662574,"teacher_disagreement_score":0.052490406,"about_ca_system_score_codex":0.0039067767,"about_ca_system_score_gemma":0.0137162935,"threshold_uncertainty_score":0.99991703},"labels":[],"label_agreement":null},{"id":"W4411343965","doi":"10.1002/hon.70094_220","title":"220 | HIGH EFFICACY OF BRIEF BRAF AND MEK COINHIBITION, ALONE AND COMBINED WITH ANTI‐CD20 IMMUNOTHERAPY, IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: A PHASE‐2 TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Celgene; Leukemia and Lymphoma Society of Canada; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); CD20; Immunotherapy; Oncology; Leukemia; Cancer research; Internal medicine; Lymphoma; Cancer; Biology","score_opus":0.017579001975843826,"score_gpt":0.3244681010151445,"score_spread":0.3068890990393007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411343965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99230903,0.0017918671,0.00009740739,0.0014495751,0.0001079441,0.0015657917,0.000008149679,0.00006252212,0.0026076902],"genre_scores_gemma":[0.99737805,0.0006535599,0.00075208716,0.00072148547,0.00003990131,0.00008647682,0.000033825887,0.000022508077,0.00031212502],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974832,0.00034100958,0.0008040605,0.00059022463,0.00030453654,0.0004769757],"domain_scores_gemma":[0.99685967,0.002240363,0.00022503232,0.00037074983,0.00013195792,0.00017221905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057983,0.00027549514,0.0015341569,0.00027800526,0.00007611831,0.000013652457,0.00012818174,0.00059797213,0.0001337712],"category_scores_gemma":[0.00047113685,0.00019727413,0.00007645116,0.00048103058,0.0011316029,0.000052818843,0.00014822697,0.0006481288,0.0000051193642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.853066,0.024201738,0.006942381,0.0030483203,0.00081431743,0.010761262,0.0014171115,0.000030021003,0.052637126,0.019975487,0.010682263,0.016423963],"study_design_scores_gemma":[0.9466257,0.02675178,0.005350041,0.00046931749,0.00016442421,0.0012624891,0.00021221628,0.0007486827,0.013641714,0.0008510192,0.0036282889,0.00029433664],"about_ca_topic_score_codex":0.00044936495,"about_ca_topic_score_gemma":0.00010521147,"teacher_disagreement_score":0.09355968,"about_ca_system_score_codex":0.0026172285,"about_ca_system_score_gemma":0.0049376236,"threshold_uncertainty_score":0.8759132},"labels":[],"label_agreement":null},{"id":"W4411351237","doi":"10.1002/hon.70093_76","title":"76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; University College London; F. Hoffmann-La Roche; BeiGene; Sanofi","keywords":"Gemcitabine; Oxaliplatin; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Oncology; Lymphoma; Internal medicine; Chemotherapy; Materials science; Cancer; Colorectal cancer; Metallurgy","score_opus":0.012845842678706386,"score_gpt":0.28591853277589646,"score_spread":0.2730726900971901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411351237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892422,0.00080548285,0.000110884226,0.00049970474,0.00018856644,0.0011660066,0.000033939177,0.00007510963,0.007878126],"genre_scores_gemma":[0.9965006,0.0001535233,0.0012660006,0.0005443318,0.00002559065,0.00008326578,0.00008337524,0.000034241835,0.00130904],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965458,0.00029194893,0.0009057024,0.0007558201,0.0005966036,0.000904139],"domain_scores_gemma":[0.9974896,0.0010613792,0.00026136634,0.0006287448,0.0002613072,0.00029765893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051183824,0.0003821521,0.0015458091,0.00037482203,0.00008552554,0.000013788071,0.00027532497,0.0007014105,0.00020231081],"category_scores_gemma":[0.00080514274,0.0002736321,0.00012504101,0.0007153784,0.00053441647,0.000100727215,0.00046158888,0.00046595928,0.00003285979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046941113,0.04054671,0.8661659,0.0030785487,0.0005773848,0.0033436911,0.0015575377,0.000010378986,0.00066088216,0.017509317,0.011138387,0.008470192],"study_design_scores_gemma":[0.72818667,0.008970447,0.23922521,0.0006559488,0.0002939725,0.00020126814,0.0009551958,0.001918611,0.0010536696,0.00086229976,0.017054731,0.0006220094],"about_ca_topic_score_codex":0.00020829639,"about_ca_topic_score_gemma":0.00022960058,"teacher_disagreement_score":0.6812455,"about_ca_system_score_codex":0.006208538,"about_ca_system_score_gemma":0.0041884957,"threshold_uncertainty_score":0.99997157},"labels":[],"label_agreement":null},{"id":"W4411431344","doi":"10.1016/j.ard.2025.05.397","title":"LB0010 INHIBITION OF STRUCTURAL DAMAGE PROGRESSION WITH GUSELKUMAB, A SELECTIVE IL-23i, IN PARTICIPANTS WITH ACTIVE PsA: RESULTS THROUGH WEEK 24 OF THE PHASE 3b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED APEX STUDY","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Placebo; Randomized controlled trial; Internal medicine; Apex (geometry); Oncology; Pathology; Alternative medicine","score_opus":0.06337347291886843,"score_gpt":0.40028635559025183,"score_spread":0.3369128826713834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411431344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865344,0.00035551135,0.000015981146,0.0009839333,0.00005871441,0.011469896,0.0001187058,0.000020566915,0.00044226222],"genre_scores_gemma":[0.99872524,0.000054445085,0.00007018296,0.000053461015,0.000012692498,0.0008612017,0.000018965611,0.000026352402,0.00017747498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955692,0.0010564722,0.00122539,0.00041832429,0.0012548527,0.0004757235],"domain_scores_gemma":[0.9953986,0.0017465273,0.00110581,0.00093585637,0.00070520735,0.00010802431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011220813,0.00033955282,0.0017347513,0.00021068729,0.00012908583,0.000023765584,0.00037234978,0.000079839156,0.000019328354],"category_scores_gemma":[0.0024193171,0.00014911723,0.00031448714,0.0012208702,0.0009855616,0.00024428236,0.00022379772,0.00029615522,7.1472914e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.981806,0.004150407,0.00116398,0.00088593585,0.0024248797,0.000017189106,0.0073072957,0.00063074037,0.00013806038,0.00013665312,0.0002208168,0.0011180679],"study_design_scores_gemma":[0.9397676,0.001915882,0.005977319,0.007455484,0.0016133549,0.000007519976,0.0046987263,0.0054606255,0.032052144,0.00089550304,8.201829e-7,0.00015500086],"about_ca_topic_score_codex":0.0009412619,"about_ca_topic_score_gemma":0.00038758045,"teacher_disagreement_score":0.042038355,"about_ca_system_score_codex":0.0005289205,"about_ca_system_score_gemma":0.0044528665,"threshold_uncertainty_score":0.7899194},"labels":[],"label_agreement":null},{"id":"W4411729473","doi":"10.58931/cht.2025.4s0469","title":"Advancing BTK Inhibition: Non‑Covalent Bruton Tyrosine Kinase Inhibitors and Their Emerging Role in Canadian Practice","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"Hebrew University of Jerusalem","keywords":"Bruton's tyrosine kinase; Tyrosine kinase; Covalent bond; Chemistry; Biochemistry; Signal transduction","score_opus":0.005584451970101021,"score_gpt":0.2758105374282682,"score_spread":0.2702260854581672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411729473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91964334,0.008779671,0.000024384884,0.04124921,0.00046226624,0.0009887617,0.000033264714,0.00004548278,0.028773624],"genre_scores_gemma":[0.99300045,0.00017947676,0.00018926685,0.005574141,0.00009028816,0.000073483025,0.000049302726,0.000034999175,0.00080856966],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973744,0.00011635767,0.00045629108,0.00055562897,0.00015450749,0.00134277],"domain_scores_gemma":[0.99753106,0.00031781947,0.00006756091,0.00046989467,0.0001649184,0.0014487756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000680321,0.00027223027,0.0005211376,0.0014623498,0.0002398203,0.000034672816,0.00011524285,0.00032175542,0.00016907301],"category_scores_gemma":[0.0012259826,0.0002714501,0.00006097185,0.0008939373,0.00020483026,0.00020017306,0.000067616005,0.00055117504,0.000039104005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016718842,0.0009482511,0.43784285,0.0071453867,0.001460874,0.096160255,0.028180365,0.0006057965,0.017253833,0.09017366,0.23354417,0.08501269],"study_design_scores_gemma":[0.025054883,0.00036779215,0.010478083,0.004395903,0.00021941176,0.010407404,0.012198566,0.015332559,0.05396106,0.0013419475,0.86499083,0.0012515329],"about_ca_topic_score_codex":0.92101586,"about_ca_topic_score_gemma":0.9864082,"teacher_disagreement_score":0.63144666,"about_ca_system_score_codex":0.020197786,"about_ca_system_score_gemma":0.03545045,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W4411745299","doi":"10.1038/s43018-025-00980-9","title":"Charting human hematopoiesis to understand B cell leukemia","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Leukemia; Haematopoiesis; Biology; Immunology; Cell biology; Stem cell","score_opus":0.013673632427327971,"score_gpt":0.385147562264538,"score_spread":0.37147392983721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411745299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8791195,0.0074358927,0.00020118678,0.005021325,0.00052386755,0.0007640233,0.00001228417,0.00014122206,0.106780685],"genre_scores_gemma":[0.9665098,0.000058713646,0.00025241557,0.0055856816,0.00029397052,0.00004303167,0.000006947246,0.00002650226,0.027222924],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985318,0.000020566686,0.00021371809,0.00038177837,0.0004155624,0.00043656185],"domain_scores_gemma":[0.99909914,0.000083016545,0.000038942595,0.00042877704,0.00016342363,0.00018670103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019152524,0.00015940852,0.00029376807,0.00020739256,0.00014322772,0.00003256169,0.00017135235,0.00033030746,0.0005359004],"category_scores_gemma":[0.0001374388,0.00013744041,0.00008842017,0.0006543379,0.000057366433,0.00004222359,0.00012042315,0.0007037076,0.000054693137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009126895,0.00018617546,0.0029221685,0.0041480055,0.00048058268,0.0004686751,0.0034673375,0.00026037163,0.1686209,0.017808225,0.7920835,0.008641366],"study_design_scores_gemma":[0.032918375,0.00028975977,0.0040560453,0.0030572684,0.0003987526,0.000055845452,0.0028068752,0.0021941643,0.6645762,0.0018366991,0.2869804,0.0008296645],"about_ca_topic_score_codex":0.00041892895,"about_ca_topic_score_gemma":0.00027640734,"teacher_disagreement_score":0.5051031,"about_ca_system_score_codex":0.028558014,"about_ca_system_score_gemma":0.0066176965,"threshold_uncertainty_score":0.99901384},"labels":[],"label_agreement":null},{"id":"W4411779851","doi":"10.1038/s41375-025-02667-7","title":"Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms","year":2025,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Canada's Michael Smith Genome Sciences Centre; Simon Fraser University","funders":"Agencia Estatal de Investigación; European Regional Development Fund; AstraZeneca; Agència de Gestió d'Ajuts Universitaris i de Recerca; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; Eusko Jaurlaritza; Associazione Italiana per la Ricerca sul Cancro; National Cancer Institute; Knut och Alice Wallenbergs Stiftelse; Southern University of Science and Technology; Science for Life Laboratory; National Natural Science Foundation of China; Vetenskapsrådet; Karolinska Institutet; Institució Catalana de Recerca i Estudis Avançats; European Commission; Ministerio de Ciencia e Innovación; Ministerstvo Zdravotnictví Ceské Republiky; Fundación Española de Hematología y Hemoterapia; Generalitat de Catalunya; Radiumhemmets Forskningsfonder; Cancerfonden; European Hematology Association; Amgen; American Association for Cancer Research; Centres de Recerca de Catalunya","keywords":"Biology; RNA; Disease; Genetics; Mutation; Gene; Medicine; Pathology","score_opus":0.01469504721946702,"score_gpt":0.2821158762193912,"score_spread":0.2674208289999242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411779851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9234322,0.0022782735,0.0002195186,0.0015937315,0.0003257856,0.0007551093,0.000022834969,0.00013977748,0.07123278],"genre_scores_gemma":[0.97312695,0.00020092749,0.000700427,0.0008303473,0.0001894228,0.000102733255,0.00011312524,0.000037488524,0.024698565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979911,0.00005600463,0.0003806506,0.00052136916,0.0004702622,0.00058062875],"domain_scores_gemma":[0.9985579,0.0002463175,0.000049642626,0.0007484745,0.000091899645,0.0003057679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016497528,0.00022884783,0.0003340546,0.0003999758,0.000094272626,0.00005580246,0.00025493972,0.0002023021,0.00039399564],"category_scores_gemma":[0.00013366721,0.00021331439,0.00013701839,0.0010253642,0.00014612239,0.00010298412,0.00013633937,0.00062690885,0.0005216301],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014199256,0.004086334,0.060202334,0.010404465,0.00076231355,0.029353121,0.0062352857,0.01154901,0.097787976,0.08421958,0.60925317,0.07194717],"study_design_scores_gemma":[0.15094557,0.00043355342,0.2543403,0.0033374936,0.00053429534,0.00039054675,0.0017604647,0.11974199,0.038245652,0.009222032,0.41921544,0.0018326901],"about_ca_topic_score_codex":0.0003353726,"about_ca_topic_score_gemma":0.00008966386,"teacher_disagreement_score":0.19413795,"about_ca_system_score_codex":0.02064659,"about_ca_system_score_gemma":0.012561141,"threshold_uncertainty_score":0.99303675},"labels":[],"label_agreement":null},{"id":"W4411884054","doi":"10.3899/jrheum.2025-0314.110","title":"Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Placebo; Interim analysis; Urology; Internal medicine; Post-hoc analysis; Randomized controlled trial; Pathology","score_opus":0.026435272234982994,"score_gpt":0.3486359100565005,"score_spread":0.32220063782151753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411884054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098635,0.0008426202,0.00032803067,0.00057925656,0.000250203,0.00688714,0.000028491657,0.000005185577,0.00009274765],"genre_scores_gemma":[0.9979209,0.001294162,0.00018506408,0.000027943557,0.000010036909,0.00026518098,0.0000061654946,0.000026599533,0.00026396714],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99689704,0.00036947383,0.0016776057,0.00027234713,0.0003668027,0.00041673196],"domain_scores_gemma":[0.9961836,0.0022013118,0.00087975786,0.0002901409,0.0003051618,0.00014002548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012063063,0.00029504675,0.0019521108,0.00079171435,0.00007371046,0.000013126905,0.00018431425,0.0001969951,0.000016513688],"category_scores_gemma":[0.00030087764,0.0001951035,0.00019415253,0.00032016958,0.00025256886,0.00008732492,0.00007219661,0.00016888732,6.9209625e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.984223,0.0020394723,0.00058706786,0.00053607306,0.00093282503,0.00007629226,0.0044906056,0.00008318196,0.0025224986,0.00047220185,0.000020447073,0.0040163193],"study_design_scores_gemma":[0.96683,0.010343349,0.000056313762,0.0006827089,0.00029015666,0.0094704,0.0014795106,0.006826103,0.0032766848,0.00057761633,0.00003183466,0.00013531039],"about_ca_topic_score_codex":0.00057259016,"about_ca_topic_score_gemma":0.0003684368,"teacher_disagreement_score":0.017393002,"about_ca_system_score_codex":0.0026585169,"about_ca_system_score_gemma":0.0022313625,"threshold_uncertainty_score":0.795609},"labels":[],"label_agreement":null},{"id":"W4411983123","doi":"10.1016/s0016-5085(25)04438-5","title":"Tu1909: EFFECTIVENESS OF RISANKIZUMAB IN MODERATE-TO-SEVERE CROHN’S DISEASE: A CANADIAN MULTICENTRIC REAL-WORLD STUDY","year":2025,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crohn's disease; Medicine; Crohn disease; Internal medicine; Pediatrics; Disease","score_opus":0.011855629635803335,"score_gpt":0.3155544194738802,"score_spread":0.30369878983807685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411983123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577355,0.00006427136,0.0001279146,0.00039751572,0.00017760281,0.0023776935,0.000032545257,0.000025679978,0.0010232443],"genre_scores_gemma":[0.99864525,0.00001385522,0.00008899098,0.00041273373,0.000026947611,0.00026772992,0.000023820538,0.00002373808,0.0004969378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997189,0.0006577908,0.0004443736,0.0005480763,0.00027870553,0.00088203937],"domain_scores_gemma":[0.9983728,0.00025365502,0.00005134357,0.00062240526,0.0001487553,0.00055105734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063863513,0.00021788338,0.00066756277,0.0015038816,0.000052128624,0.000012440929,0.0002601537,0.000071781724,0.00009359872],"category_scores_gemma":[0.00030540995,0.00021012849,0.00008652976,0.0008367056,0.000104563485,0.000043231852,0.00017930099,0.00029961322,0.000027231408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024869874,0.0009086247,0.9680104,0.00051686174,0.00020563809,0.002499023,0.00026500595,0.0017787998,0.000077497105,0.00009687029,0.00034501232,0.00042635776],"study_design_scores_gemma":[0.03222905,0.0006456379,0.96043617,0.00030926714,0.0001063012,0.000022163389,0.000117173964,0.0058855014,0.00005474875,0.000054647207,0.0000653539,0.00007400492],"about_ca_topic_score_codex":0.25396687,"about_ca_topic_score_gemma":0.49525785,"teacher_disagreement_score":0.241291,"about_ca_system_score_codex":0.012765036,"about_ca_system_score_gemma":0.00581036,"threshold_uncertainty_score":0.9998258},"labels":[],"label_agreement":null},{"id":"W4412019395","doi":"10.1042/bst20253059","title":"Molecular insight on the role of the phosphoinositide PIP3 in regulating the protein kinases Akt, PDK1, and BTK","year":2025,"lang":"en","type":"article","venue":"Biochemical Society Transactions","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Pleckstrin homology domain; Bruton's tyrosine kinase; Kinase; Cell biology; Protein kinase B; Biology; Phosphatidylinositol; Biochemistry; Receptor tyrosine kinase; Tyrosine kinase; Chemistry; Signal transduction","score_opus":0.0069926389430422595,"score_gpt":0.24597972827940362,"score_spread":0.23898708933636137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412019395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857298,0.0015118517,0.00050735933,0.009838014,0.000021294763,0.00083531055,0.00000858713,0.000018179391,0.0015295992],"genre_scores_gemma":[0.9986764,0.000048490198,0.00012718844,0.00068605226,0.00001746429,0.000121636425,0.0000019971335,0.000010671621,0.0003100947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899256,0.00006911413,0.00020922774,0.00020949749,0.00030545777,0.00021413017],"domain_scores_gemma":[0.9991298,0.00033101274,0.000037557715,0.00040975568,0.000050615574,0.000041260042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002048437,0.00011545717,0.00015568984,0.000015954834,0.00019305728,0.00001612587,0.00017687984,0.00012064634,0.00003142538],"category_scores_gemma":[0.00012143576,0.00005810038,0.00021631429,0.0005266762,0.00046571073,0.000019122534,0.000031279753,0.0004390861,0.0000010014429],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011746918,0.00023424638,0.00024236692,0.00014849886,0.00016000766,0.0000019772194,0.0012167437,0.000060930946,0.9913539,0.002616428,0.000627322,0.0032200736],"study_design_scores_gemma":[0.0016729756,0.000029679095,0.0007358881,0.00036819055,0.000060653398,0.000008067512,0.00095211243,0.0048447526,0.9894689,0.00066865113,0.0011308513,0.000059318467],"about_ca_topic_score_codex":0.0006335116,"about_ca_topic_score_gemma":0.00001820981,"teacher_disagreement_score":0.012946601,"about_ca_system_score_codex":0.0010211327,"about_ca_system_score_gemma":0.00085587025,"threshold_uncertainty_score":0.26702267},"labels":[],"label_agreement":null},{"id":"W4412366400","doi":"10.1080/10428194.2025.2521656","title":"A charter for improving care for people living with chronic lymphocytic leukemia: six principles for excellence","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation; Alberta Health Services","funders":"AstraZeneca","keywords":"Charter; Chronic lymphocytic leukemia; Excellence; Medicine; Gerontology; Leukemia; Intensive care medicine; Political science; Immunology; Law","score_opus":0.012227065018911371,"score_gpt":0.26680979570576285,"score_spread":0.2545827306868515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412366400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94093,0.011109964,0.030810468,0.0003005827,0.0009886607,0.012517353,0.00040022435,0.00080047676,0.002142252],"genre_scores_gemma":[0.96690255,0.00065720733,0.008960874,0.0011906502,0.0013608561,0.008997086,0.00042062704,0.00044445798,0.011065694],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99130416,0.00012157051,0.0017214867,0.0026434234,0.0010474988,0.0031618688],"domain_scores_gemma":[0.99132276,0.003710507,0.00064072787,0.002049087,0.0013632213,0.0009136748],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001105124,0.0016104754,0.0024368812,0.0009016503,0.0016614966,0.00048553428,0.0010508631,0.0011622874,0.00003746955],"category_scores_gemma":[0.0013240369,0.0014317358,0.00093516486,0.0011504597,0.00071593537,0.0005999094,0.00060613174,0.0002703756,0.000021860405],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034127142,0.0007144665,0.007461681,0.13484113,0.0048335693,0.00041681537,0.023043102,0.00732531,0.031737033,0.020113442,0.018274354,0.71711195],"study_design_scores_gemma":[0.21650063,0.0055241613,0.0083305705,0.007173411,0.0030055316,0.0018261014,0.007231308,0.6089205,0.025087437,0.0004689461,0.1126955,0.003235913],"about_ca_topic_score_codex":0.0040702173,"about_ca_topic_score_gemma":0.0018538034,"teacher_disagreement_score":0.71387607,"about_ca_system_score_codex":0.30503955,"about_ca_system_score_gemma":0.16841638,"threshold_uncertainty_score":0.9996643},"labels":[],"label_agreement":null},{"id":"W4412390603","doi":"10.21203/rs.3.rs-6939271/v1","title":"TeloView ® technology predicts genomic instability in chronic lymphocytic leukemia","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; CancerCare Manitoba Foundation","keywords":"Chronic lymphocytic leukemia; Genome instability; Instability; Cancer research; Leukemia; Biology; Computational biology; Genetics; Physics; DNA; Mechanics; DNA damage","score_opus":0.054867597750341605,"score_gpt":0.40533691656067694,"score_spread":0.35046931881033533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412390603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92796504,0.038171515,0.000053769996,0.0012485902,0.00042388047,0.009530814,0.00025614523,0.000606931,0.02174333],"genre_scores_gemma":[0.98000795,0.0106954705,0.00039523482,0.00009246449,0.00055148714,0.0022923548,0.00032557955,0.00012753617,0.005511949],"study_design_codex":"systematic_review","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98881406,0.0010787761,0.001513486,0.0026279718,0.0029788204,0.0029868882],"domain_scores_gemma":[0.9919061,0.001200448,0.00018575974,0.0046304152,0.0014112629,0.00066600944],"candidate_categories":["metaepi_narrow","open_science","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005290451,0.00081565767,0.0019487364,0.005000698,0.0002613812,0.00014780353,0.0020055019,0.0024844664,0.00064147],"category_scores_gemma":[0.004662628,0.000784006,0.00046046675,0.0043342784,0.0017373844,0.00010917635,0.0083174035,0.007767669,0.000619281],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0102642095,0.002339865,0.061723135,0.44555244,0.0035343743,0.023819141,0.0048803226,0.058943413,0.011498887,0.013478947,0.033473738,0.3304915],"study_design_scores_gemma":[0.11569363,0.0049530677,0.04879456,0.09172005,0.00054194767,0.0012472022,0.0021840134,0.56333894,0.012557887,0.028977536,0.12615554,0.0038356392],"about_ca_topic_score_codex":0.010413609,"about_ca_topic_score_gemma":0.0021412794,"teacher_disagreement_score":0.5043955,"about_ca_system_score_codex":0.6705452,"about_ca_system_score_gemma":0.49407023,"threshold_uncertainty_score":0.9997031},"labels":[],"label_agreement":null},{"id":"W4412409096","doi":"10.4103/jfcm.jfcm_50_25","title":"Patterns and experiences of patients with undifferentiated lymphocytosis referred by primary care physicians in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Family and Community Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal Victoria Regional Health Centre; University of Ottawa","funders":"","keywords":"Medicine; Lymphocytosis; Primary care; Family medicine; Pediatrics; Medical emergency; Internal medicine","score_opus":0.016163515715912177,"score_gpt":0.26511262837713484,"score_spread":0.24894911266122266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412409096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963317,0.0028087082,0.000018207595,0.00012654548,0.00007267032,0.0001435078,0.00001236259,0.000002097004,0.00048421774],"genre_scores_gemma":[0.99853164,0.0008495736,0.000013131027,0.00052198075,0.000013213656,0.0000032886635,0.00003854588,0.0000063959633,0.000022211134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865955,0.00022871255,0.00041582272,0.00007492957,0.00046347486,0.00015748796],"domain_scores_gemma":[0.9989068,0.00033535718,0.00019313967,0.00020769628,0.0002612461,0.000095781856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021765113,0.000120681085,0.00055323174,0.00016604982,0.0000837746,0.0000045161796,0.00015095576,0.000042466814,0.0000064054857],"category_scores_gemma":[0.00007603731,0.00007916268,0.000018443181,0.00024777284,0.00020364592,0.00006063496,0.00007664816,0.00046056052,1.5927906e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036496022,0.00063843204,0.88599014,0.0026312463,0.00039564678,0.000087622226,0.060656965,0.0000031965644,0.0011335387,0.000004605727,0.0016891584,0.043119833],"study_design_scores_gemma":[0.023293026,0.001244106,0.78895295,0.0034895232,0.00011519205,0.000014220842,0.18223843,0.000057939138,0.00044127426,0.0000052909963,0.00007723697,0.000070788265],"about_ca_topic_score_codex":0.56585693,"about_ca_topic_score_gemma":0.17144799,"teacher_disagreement_score":0.3944089,"about_ca_system_score_codex":0.0038001179,"about_ca_system_score_gemma":0.0043706894,"threshold_uncertainty_score":0.9937176},"labels":[],"label_agreement":null},{"id":"W4412432201","doi":"10.1016/j.jval.2025.04.1781","title":"SA26 Economic Burden of Hairy Cell Leukemia: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Hairy cell leukemia; Leukemia; Medicine; Internal medicine","score_opus":0.07323545756030579,"score_gpt":0.3921173375359674,"score_spread":0.3188818799756616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412432201","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000018305092,0.9852448,0.000004615729,0.0001820535,0.00028397297,0.0109988805,0.00006478428,0.000041030788,0.0031780102],"genre_scores_gemma":[0.0000059111017,0.99524814,0.0001892634,0.00025768878,0.0001775927,0.0006638203,0.00009897666,0.00007934356,0.0032792538],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99260855,0.0014611309,0.0038951624,0.00073289307,0.0005529569,0.00074933266],"domain_scores_gemma":[0.9944498,0.0019893288,0.0013794757,0.0017862102,0.00007422423,0.00032095605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039191325,0.0005429062,0.009104217,0.00074972847,0.000038410606,0.000011809821,0.00061186583,0.00045232364,0.000098277706],"category_scores_gemma":[0.001045923,0.0004238827,0.00088106096,0.0007452374,0.0000885736,0.000037676207,0.00023835209,0.0009880911,0.0003592116],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000061895544,0.000034269993,1.3693477e-7,0.98454,0.00010780253,0.00007061825,0.000062099556,0.000055525332,8.225126e-9,0.00016258938,0.0024473227,0.012513441],"study_design_scores_gemma":[0.0018103273,0.00014004046,2.7963646e-8,0.8710348,0.0011077654,0.0002327409,0.000019976673,0.001346713,2.3404002e-7,0.000011720011,0.12410292,0.00019270611],"about_ca_topic_score_codex":0.01388706,"about_ca_topic_score_gemma":0.000028039847,"teacher_disagreement_score":0.1216556,"about_ca_system_score_codex":0.09784956,"about_ca_system_score_gemma":0.17345752,"threshold_uncertainty_score":0.9998213},"labels":[],"label_agreement":null},{"id":"W4412442860","doi":"10.1016/j.jval.2025.04.1411","title":"PCR91 Patient Reported Outcomes in BRUIN CLL-321: A Phase 3 Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bendamustine; Idelalisib; Chronic lymphocytic leukemia; Rituximab; Ibrutinib; Bruton's tyrosine kinase; Medicine; Ofatumumab; Internal medicine; Immunology; Oncology; Lymphoma; Leukemia","score_opus":0.07727139236211535,"score_gpt":0.3782010551301899,"score_spread":0.3009296627680746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412442860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838394,0.004017555,0.000046795278,0.00054159126,0.0019130053,0.008526754,0.00012145036,0.00024150478,0.00075196096],"genre_scores_gemma":[0.9954903,0.0012162178,0.00060573284,0.0004347869,0.0002675267,0.0007874359,0.0002471762,0.00017482566,0.0007759869],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9856944,0.0012636185,0.006294402,0.0020965685,0.0019341371,0.002716865],"domain_scores_gemma":[0.99220586,0.002927759,0.0014270827,0.0022636093,0.00040833958,0.0007673382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035721336,0.0011566757,0.0043110815,0.0033072196,0.00016863806,0.00007563451,0.00076564215,0.0008949184,0.00011779528],"category_scores_gemma":[0.0069730147,0.001046285,0.00049918174,0.005356021,0.0005288258,0.0002803818,0.0005839135,0.00095394265,0.00004522983],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.84237504,0.013867112,0.00188516,0.014705584,0.0010657115,0.014356601,0.0065562334,0.05953889,0.00047346964,0.0005603757,0.0014070083,0.04320882],"study_design_scores_gemma":[0.68475115,0.007053185,0.00047465845,0.004845211,0.00015298754,0.00028058578,0.00059704005,0.29916772,0.0015396705,0.00006463231,0.0005027808,0.00057036534],"about_ca_topic_score_codex":0.20172884,"about_ca_topic_score_gemma":0.010748327,"teacher_disagreement_score":0.23962882,"about_ca_system_score_codex":0.5082533,"about_ca_system_score_gemma":0.3457488,"threshold_uncertainty_score":0.99919873},"labels":[],"label_agreement":null},{"id":"W4412561079","doi":"10.1101/2025.07.22.25331923","title":"High-risk Molecular Features Eclipse Genomic Complexity in Predicting CLL Patient Outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE Trials","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Kay Kendall Leukaemia Fund; Cancer Research UK","keywords":"Eclipse; Arctic; Computational biology; Biology; Astrophysics; Ecology","score_opus":0.05439713789730267,"score_gpt":0.33317341781706283,"score_spread":0.2787762799197602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412561079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986619,0.0060475166,0.000041234,0.001860148,0.0012107675,0.0032742345,0.0005627105,0.000079583784,0.00030480092],"genre_scores_gemma":[0.9956993,0.00093917747,0.00089255074,0.0010139352,0.0005554999,0.00027327094,0.0003933019,0.00005704958,0.00017591602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935606,0.002032716,0.0014773824,0.0012798943,0.0010311488,0.00061824155],"domain_scores_gemma":[0.992931,0.00395506,0.00066795,0.001948376,0.00019003448,0.0003075557],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019240795,0.00065278134,0.00207968,0.0003211441,0.00019098142,0.0001280222,0.00066779915,0.0006558428,0.00013096977],"category_scores_gemma":[0.007887666,0.00042198054,0.00043534016,0.0002848064,0.00040070084,0.00003549183,0.002218808,0.0027495928,0.000017884024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022227108,0.00046695137,0.97155553,0.0015411655,0.002657833,0.0016077682,0.0079983305,0.0013662998,0.0007409002,0.0009861365,0.002331017,0.006525344],"study_design_scores_gemma":[0.02435493,0.0002646999,0.9425762,0.0028809188,0.0012720657,0.00004433225,0.0005424785,0.0045021186,0.0015430732,0.02018939,0.0011671025,0.0006626658],"about_ca_topic_score_codex":0.039841633,"about_ca_topic_score_gemma":0.0047571226,"teacher_disagreement_score":0.035084512,"about_ca_system_score_codex":0.006615646,"about_ca_system_score_gemma":0.0051749083,"threshold_uncertainty_score":0.9998232},"labels":[],"label_agreement":null},{"id":"W4412615633","doi":"10.1080/17410541.2025.2535276","title":"A scoping review of the cost-effectiveness of precision treatment in chronic lymphocytic leukemia","year":2025,"lang":"en","type":"review","venue":"Personalized Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; Leukemia; Intensive care medicine; Oncology; Bioinformatics; Immunology; Computational biology; Biology","score_opus":0.09417860314029478,"score_gpt":0.45831448019263876,"score_spread":0.36413587705234396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412615633","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026778294,0.97852695,0.000025809833,0.000045927973,0.00027416507,0.019095851,0.00003668293,0.000023245595,0.0019445899],"genre_scores_gemma":[0.000032205186,0.9956632,0.000034391727,0.00008382192,0.00017848512,0.002208818,0.00015321912,0.00006660145,0.0015792567],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9935623,0.0015570086,0.0020830908,0.0008108797,0.0014040184,0.0005827415],"domain_scores_gemma":[0.99189276,0.0051618977,0.0008966812,0.0015336189,0.00032815384,0.00018691922],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028695457,0.0007258064,0.0073439046,0.00064140285,0.000047445035,0.0000034228192,0.000591393,0.0004076387,0.00046962642],"category_scores_gemma":[0.003896549,0.00038379437,0.0011709278,0.002354538,0.00082368695,0.000038105485,0.00026162222,0.00047484576,0.000010361511],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00019930156,0.000040411305,0.0000022578913,0.700554,0.00027643327,0.000051288323,0.000073815325,0.000004044441,0.000010197616,0.000040433504,0.00012283948,0.29862496],"study_design_scores_gemma":[0.02222603,0.000618284,0.0000055110545,0.8806648,0.0034621628,0.00025952113,0.000014394845,0.00017041835,0.00007852376,0.000008467639,0.09229583,0.00019603786],"about_ca_topic_score_codex":0.002183138,"about_ca_topic_score_gemma":0.000078008416,"teacher_disagreement_score":0.29842892,"about_ca_system_score_codex":0.24084581,"about_ca_system_score_gemma":0.24223503,"threshold_uncertainty_score":0.9998614},"labels":[],"label_agreement":null},{"id":"W4412641806","doi":"10.1021/acs.jmedchem.5c00504","title":"Discovery of a Novel MNK Inhibitor (NSP-1047) with In Vivo Anti-acute Myeloid Leukemia Activity","year":2025,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Science and Technology Commission of Shanghai Municipality; National Natural Science Foundation of China","keywords":"Chemistry; Myeloid leukemia; In vivo; Leukemia; Pharmacology; Cancer research; Immunology; Biology; Genetics","score_opus":0.011709290520234786,"score_gpt":0.2972614683246103,"score_spread":0.28555217780437553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412641806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299735,0.0006777383,0.0007423006,0.00094437675,0.00014942298,0.00017127044,0.000014404128,0.000009060459,0.004294059],"genre_scores_gemma":[0.9961124,0.00028247442,0.00048429528,0.00013958829,0.0004724193,0.000004817138,0.0000024537985,0.000023572691,0.0024779988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972263,0.000028774542,0.0007919505,0.0002732283,0.0012635736,0.0004161558],"domain_scores_gemma":[0.99823266,0.00026944152,0.00051693694,0.0004009394,0.00036139152,0.00021861942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076551654,0.00025858646,0.0009932386,0.00024127195,0.00003758887,0.000019081925,0.0003064839,0.00022596151,0.00006648752],"category_scores_gemma":[0.00046606333,0.00018263729,0.00018817901,0.0006730596,0.00040126938,0.0002458225,0.0001110817,0.0010966313,6.9043136e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004608374,0.00053526775,0.0035603403,0.0017230036,0.00044277508,0.0017951983,0.00018743753,0.000043788372,0.98421526,0.000008952884,0.0018813722,0.000998212],"study_design_scores_gemma":[0.034644958,0.00053651974,0.0040015974,0.0054304725,0.0003814519,0.003906822,0.00053615525,0.0010109731,0.94875026,0.000012532193,0.00062557234,0.0001626694],"about_ca_topic_score_codex":0.00022470193,"about_ca_topic_score_gemma":0.000011899677,"teacher_disagreement_score":0.035465002,"about_ca_system_score_codex":0.008893376,"about_ca_system_score_gemma":0.019693505,"threshold_uncertainty_score":0.9949113},"labels":[],"label_agreement":null},{"id":"W4412725048","doi":"10.1155/crh/9912698","title":"A Hyperacute Presentation of Small Cell, Non‐Nodal Mantle Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Case Reports in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University","funders":"","keywords":"Medicine; Leukostasis; Mantle cell lymphoma; Tumor lysis syndrome; Pathology; Rasburicase; Leukapheresis; Gastroenterology; Immunophenotyping; Internal medicine; Lymphoma; Immunology; Leukemia; Chemotherapy; Flow cytometry","score_opus":0.01696570912589692,"score_gpt":0.31352165592487086,"score_spread":0.29655594679897396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412725048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96934134,0.00095306954,0.00039376572,0.00013804504,0.0002958595,0.0006879913,0.000002374929,0.00002774883,0.028159812],"genre_scores_gemma":[0.9947289,0.000054208405,0.0011477725,0.00009603794,0.000026471684,0.000080475096,0.00002142389,0.000021060656,0.0038236475],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9980394,0.00007029192,0.0008579835,0.0004429805,0.00020456771,0.0003847567],"domain_scores_gemma":[0.9985029,0.00030342274,0.00022679717,0.00070636225,0.0001593748,0.000101127924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003554698,0.00016105958,0.0005914737,0.00040343782,0.000036527315,0.000007203597,0.000060629198,0.00023299397,0.0000727869],"category_scores_gemma":[0.0002492753,0.00015188781,0.00010431817,0.00044073226,0.00016713951,0.000042077318,0.00014548186,0.00015048817,0.000013874097],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041545852,0.0012520187,0.026142484,0.004083808,0.00008363815,0.9522685,0.00067918736,0.000049887705,0.009553867,0.0007541638,0.002952604,0.0017643863],"study_design_scores_gemma":[0.018832812,0.00021507518,0.0017315114,0.0004115677,0.0001897588,0.62375075,0.0009415424,0.01561956,0.3357007,0.00068362005,0.0016853327,0.00023775421],"about_ca_topic_score_codex":0.001384751,"about_ca_topic_score_gemma":0.0001174904,"teacher_disagreement_score":0.32851774,"about_ca_system_score_codex":0.0019000584,"about_ca_system_score_gemma":0.004762949,"threshold_uncertainty_score":0.84492666},"labels":[],"label_agreement":null},{"id":"W4412726340","doi":"10.1021/jacs.5c07063","title":"Modulating the Binding Kinetics of Bruton’s Tyrosine Kinase Inhibitors through Transition-State Effects","year":2025,"lang":"en","type":"article","venue":"Journal of the American Chemical Society","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute of General Medical Sciences; Stony Brook University; Associazione Italiana per la Ricerca sul Cancro; Centro para el Desarrollo Tecnológico Industrial","keywords":"Bruton's tyrosine kinase; Chemistry; Selectivity; Kinetics; Rational design; Receptor–ligand kinetics; Tyrosine kinase; Protein engineering; Biophysics; Enzyme; Stereochemistry; Biochemistry; Signal transduction; Receptor; Nanotechnology; Catalysis","score_opus":0.009860419440516046,"score_gpt":0.2927408234578724,"score_spread":0.28288040401735637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412726340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188644,0.00040187445,0.0008546012,0.006324919,0.000156958,0.00021232711,0.000003884758,0.000009230832,0.00014976224],"genre_scores_gemma":[0.99587286,0.00016032072,0.0022199932,0.001403222,0.00021571886,0.0000028920147,0.0000010170179,0.000017698574,0.000106293075],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983027,0.00008887249,0.0005484672,0.00013334588,0.0006418943,0.0002846997],"domain_scores_gemma":[0.9981587,0.000687125,0.0005384209,0.00031314426,0.00022762583,0.00007501962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003682839,0.00014503242,0.00048390773,0.000025692018,0.00008116617,0.000016402493,0.00033227616,0.000053678952,0.0000060520047],"category_scores_gemma":[0.00046317323,0.00007764607,0.0006714192,0.0008723456,0.00082852977,0.000054051616,0.00013388004,0.0006222261,7.90277e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001645303,0.00014460305,0.0002714071,0.0002558216,0.00028809853,0.000012230632,0.0015184694,0.00029078938,0.98985386,0.000016291417,0.004591946,0.0025919536],"study_design_scores_gemma":[0.0039359964,0.00018230996,0.00069088006,0.0007937087,0.00023876858,0.00012810435,0.00065863965,0.003433826,0.9891873,0.00027025197,0.0004015189,0.00007871742],"about_ca_topic_score_codex":0.00016630169,"about_ca_topic_score_gemma":6.521582e-7,"teacher_disagreement_score":0.004921697,"about_ca_system_score_codex":0.003120429,"about_ca_system_score_gemma":0.0009485019,"threshold_uncertainty_score":0.8159814},"labels":[],"label_agreement":null},{"id":"W4412746936","doi":"10.1182/blood.2024028205","title":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"Incyte; Pharmacyclics; BeiGene; TG Therapeutics; Gilead Sciences; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Ibrutinib; Chlorambucil; Medicine; Internal medicine; Chronic lymphocytic leukemia; IGHV@; Peripheral edema; Nausea; Neutropenia; Gastroenterology; Adverse effect; Oncology; Surgery; Leukemia; Toxicity; Chemotherapy; Cyclophosphamide","score_opus":0.04988792393192714,"score_gpt":0.3568477804765986,"score_spread":0.30695985654467145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412746936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973241,0.0003096488,0.000024514926,0.00034357773,0.000075947246,0.0013456297,0.00011448842,0.000008805977,0.00045327994],"genre_scores_gemma":[0.9892482,0.000037039714,0.00018573835,0.000026958633,0.000025995565,0.00009069523,0.000017933136,0.000012317665,0.010355085],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99852544,0.000052259777,0.00048918184,0.0002652612,0.00044120816,0.00022663215],"domain_scores_gemma":[0.99831694,0.00043969098,0.00012892095,0.000787623,0.0002608164,0.00006599568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035617867,0.00012093295,0.00066807406,0.00034196358,0.000032766355,0.0000036537879,0.00023996517,0.00006819621,0.00010664217],"category_scores_gemma":[0.00059946335,0.000084998916,0.0004147135,0.0014031586,0.00007757459,0.0000120198965,0.0001378848,0.00005274862,0.0000025540373],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053970598,0.06679656,0.48659736,0.005870264,0.13483639,0.00026956247,0.043418165,0.0032986088,0.025998302,0.0020514547,0.021972844,0.15491988],"study_design_scores_gemma":[0.39260656,0.013163964,0.2385961,0.0009359337,0.04330678,0.000010654897,0.0031880117,0.008476017,0.27296382,0.00014956483,0.026187703,0.00041488014],"about_ca_topic_score_codex":0.0014859871,"about_ca_topic_score_gemma":0.0016057905,"teacher_disagreement_score":0.33863595,"about_ca_system_score_codex":0.0008841399,"about_ca_system_score_gemma":0.001976109,"threshold_uncertainty_score":0.35055324},"labels":[],"label_agreement":null},{"id":"W4412785474","doi":"10.1093/ajcp/aqaf075","title":"Methylation-based droplet digital polymerase chain reaction shows high concordance with chronic lymphocytic leukemia <i>IGHV</i> somatic mutation status","year":2025,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Genome Canada; University of Toronto; University Health Network","funders":"","keywords":"IGHV@; Somatic hypermutation; Digital polymerase chain reaction; Chronic lymphocytic leukemia; Concordance; Biology; Biomarker; Methylation; Polymerase chain reaction; DNA methylation; Oncology; Leukemia; Molecular biology; Genetics; Gene; Medicine; Antibody; B cell","score_opus":0.01582173158717004,"score_gpt":0.3523214698024803,"score_spread":0.33649973821531026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412785474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745156,0.00047347686,0.022604696,0.00097294175,0.00050562393,0.00040743538,0.000019977171,0.000051416657,0.0004487989],"genre_scores_gemma":[0.99499106,0.0001622726,0.002056969,0.001904067,0.00044181992,0.000020937801,0.000057641326,0.000045145476,0.00032009542],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99547887,0.0006336619,0.00204571,0.0004775647,0.00072934775,0.0006348217],"domain_scores_gemma":[0.9930049,0.003698627,0.0016755044,0.0005655287,0.00060050515,0.0004548995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001416381,0.0003070488,0.0015203829,0.0004448981,0.00009575553,0.000046837537,0.00024309217,0.00018127583,0.00004669558],"category_scores_gemma":[0.0029107921,0.00023514002,0.00033317666,0.00088649604,0.0015248677,0.00025887377,0.00004997352,0.0008590974,0.000037144848],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.028438596,0.0009864673,0.044318642,0.0007634786,0.00175505,0.014543534,0.0004950999,0.013476499,0.014055567,0.0007016821,0.0012482236,0.87921715],"study_design_scores_gemma":[0.32643375,0.0840559,0.1652897,0.004710023,0.0038314208,0.018600756,0.0030071796,0.36266267,0.017962754,0.0027033805,0.008444928,0.002297552],"about_ca_topic_score_codex":0.00054153585,"about_ca_topic_score_gemma":0.000078904115,"teacher_disagreement_score":0.8769196,"about_ca_system_score_codex":0.023165992,"about_ca_system_score_gemma":0.06504998,"threshold_uncertainty_score":0.9805839},"labels":[],"label_agreement":null},{"id":"W4413399775","doi":"10.1093/jimmun/vkaf201","title":"MKLN1-dependent GID4/CTLH E3 ubiquitin ligase complex assemblies are required to support B-cell antibody diversification","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; University of Toronto; Deutsche Forschungsgemeinschaft","keywords":"Ubiquitin ligase; Ubiquitin; Antibody; Diversification (marketing strategy); Chemistry; DNA ligase; Cell biology; Computational biology; Biology; Biochemistry; Business; Genetics; Enzyme; Gene","score_opus":0.04215754075885019,"score_gpt":0.3537449206213407,"score_spread":0.3115873798624905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413399775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98306453,0.0012908,0.0009256592,0.01023707,0.00039012436,0.00038644843,0.0000072619882,0.000024575134,0.0036735574],"genre_scores_gemma":[0.99375755,0.00084457523,0.00022558856,0.00093041436,0.00013333398,0.000003425974,0.00001409419,0.000017356166,0.0040736394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979587,0.00030338165,0.000671159,0.0001691051,0.00046956635,0.00042808073],"domain_scores_gemma":[0.9978435,0.00042045602,0.00042970496,0.00059308525,0.00060104544,0.000112232854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014114566,0.00016774268,0.0005078805,0.00047423632,0.00017900164,0.000030514515,0.0006441522,0.00013291287,0.00025970588],"category_scores_gemma":[0.0005125656,0.00011672508,0.00013675258,0.00041394486,0.00022046111,0.00011204614,0.00036250323,0.000513686,0.00019630368],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036789752,0.00040475442,0.0008440727,0.00013519949,0.000505652,0.0004924687,0.0012297527,0.00006899764,0.9649503,0.0002577886,0.022985766,0.0044462592],"study_design_scores_gemma":[0.055375796,0.0056317896,0.11670086,0.0011296134,0.0012944657,0.0074568097,0.018360777,0.00091143005,0.7481773,0.00068384403,0.043726236,0.00055112015],"about_ca_topic_score_codex":0.00018577038,"about_ca_topic_score_gemma":0.000018974877,"teacher_disagreement_score":0.21677305,"about_ca_system_score_codex":0.0036509363,"about_ca_system_score_gemma":0.0030562065,"threshold_uncertainty_score":0.95470715},"labels":[],"label_agreement":null},{"id":"W4413560610","doi":"10.1200/op-25-00087","title":"Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial","year":2025,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Randomized controlled trial; eHealth; Physical therapy; Intervention (counseling); Palliative care; Clinical trial; Internal medicine; Clinical endpoint; Health care; Psychiatry; Nursing","score_opus":0.03574477611127523,"score_gpt":0.42422426601076213,"score_spread":0.3884794898994869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413560610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98793423,0.00046049207,0.0002829684,0.0010679477,0.00043615582,0.00653135,0.0000018485723,0.000031260803,0.0032537738],"genre_scores_gemma":[0.9980461,0.00012758668,0.00020876403,0.0008098092,0.00009606495,0.0004837108,0.000019190386,0.000020249876,0.000188506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99097914,0.005918804,0.0015249738,0.00048010735,0.0006750637,0.00042194207],"domain_scores_gemma":[0.9730997,0.02466862,0.0011647877,0.00053018535,0.00037105245,0.00016564687],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00962261,0.00025121105,0.0022664473,0.00035132797,0.00013902537,0.000061608145,0.00018819873,0.0002793547,0.0000462473],"category_scores_gemma":[0.027866602,0.0001477542,0.000177808,0.00044418036,0.00060038146,0.0004701231,0.00010485676,0.00069791486,0.0000063603406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9924098,0.0010088953,0.0005495122,0.0004898121,0.0006882232,0.000038403603,0.0002841878,0.00022880807,0.000010007289,0.0008316943,0.00004914725,0.0034114819],"study_design_scores_gemma":[0.96030915,0.0060203043,0.008447353,0.0005649683,0.0007599228,0.000031713207,0.0006323159,0.022909025,0.0000061611995,0.000061347775,0.00014333542,0.00011439162],"about_ca_topic_score_codex":0.0034312108,"about_ca_topic_score_gemma":0.00054670474,"teacher_disagreement_score":0.032100666,"about_ca_system_score_codex":0.054902982,"about_ca_system_score_gemma":0.056006774,"threshold_uncertainty_score":0.98032206},"labels":[],"label_agreement":null},{"id":"W4413772343","doi":"10.1093/immadv/ltaf029","title":"CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis","year":2024,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; University of Southampton; Cancer Research UK; Leukaemia UK; National Institute for Health and Care Research; Wessex Medical Research","keywords":"Antibody-dependent cell-mediated cytotoxicity; Interleukin 15; Immunology; Chemistry; Cell biology; Cytokine; Interleukin; Medicine; Biology; Antibody","score_opus":0.013867831947297888,"score_gpt":0.3156228466059725,"score_spread":0.3017550146586746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413772343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7590446,0.23194575,0.0016466067,0.0014617598,0.0006898471,0.0011350552,0.000090017784,0.0003053083,0.0036810539],"genre_scores_gemma":[0.94089824,0.053967748,0.0003818484,0.0006260246,0.00035145282,0.00009447779,0.00006566863,0.00009923969,0.0035153152],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716026,0.00016293788,0.0004615442,0.00068366824,0.0008444356,0.0006871446],"domain_scores_gemma":[0.9980786,0.00078884227,0.000082124614,0.00083044823,0.00009937384,0.00012064274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000487707,0.00038090974,0.00048180134,0.000110557674,0.00026641026,0.00020601414,0.00040789208,0.00017147815,0.00059667975],"category_scores_gemma":[0.000074039315,0.00024272755,0.00017413984,0.00045898338,0.00058122794,0.0004908884,0.00013538898,0.00059722346,0.00017009374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009707562,0.00026644682,0.00024031979,0.0011063471,0.00043453753,0.00082122284,0.005369179,0.000069394286,0.97483325,0.00044325835,0.0010002154,0.014445077],"study_design_scores_gemma":[0.01020456,0.00063402695,0.00030232873,0.0005135514,0.00009209271,0.000381116,0.001330024,0.0043810485,0.56244814,0.0012415142,0.41795874,0.0005128179],"about_ca_topic_score_codex":0.000611835,"about_ca_topic_score_gemma":0.000024353278,"teacher_disagreement_score":0.41695854,"about_ca_system_score_codex":0.0014908961,"about_ca_system_score_gemma":0.0013342662,"threshold_uncertainty_score":0.9898142},"labels":[],"label_agreement":null},{"id":"W4413783186","doi":"10.1016/s2152-2650(25)01835-x","title":"CLL-122: A Late Surge in Major Cardiovascular Disease-Related Mortality Among Chronic Lymphocytic Leukemia Patients: Epidemiological Trends and Disparities in United States Adults Aged 25 and Above (1999–2020)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Epidemiology; Disease; Gerontology; Leukemia; Immunology; Internal medicine","score_opus":0.019716517864858698,"score_gpt":0.3137408335321797,"score_spread":0.294024315667321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98493785,0.01193281,0.000011482073,0.0003251641,0.00039510883,0.0015885349,0.00015986626,0.00025523113,0.00039397893],"genre_scores_gemma":[0.9849074,0.011609519,0.00006199956,0.0007776421,0.00015689478,0.00032030654,0.0011764606,0.000105558494,0.0008842298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888685,0.0021235053,0.0035702395,0.002470066,0.0010655136,0.0019022094],"domain_scores_gemma":[0.9918595,0.0043526785,0.0004297153,0.0017928856,0.00027934182,0.0012858781],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045032776,0.001051476,0.003205026,0.0011775703,0.00024226856,0.00012900068,0.0005480943,0.0012698917,0.00007297232],"category_scores_gemma":[0.0062408377,0.0009143413,0.00091423484,0.0029814073,0.0026012128,0.00039324522,0.000934629,0.0012443062,0.00002552933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037066676,0.00044576736,0.8930979,0.0015058469,0.0015327894,0.0035865132,0.00024757176,0.0015948119,0.000004219873,0.00026509812,0.0009540732,0.09305878],"study_design_scores_gemma":[0.07230931,0.00036695282,0.7628505,0.0020776659,0.0006001876,0.000041892006,0.00008614556,0.15956624,0.0000081389735,0.00083866157,0.00062102184,0.0006332638],"about_ca_topic_score_codex":0.03162451,"about_ca_topic_score_gemma":0.0023439447,"teacher_disagreement_score":0.15797143,"about_ca_system_score_codex":0.0742908,"about_ca_system_score_gemma":0.017396048,"threshold_uncertainty_score":0.9993307},"labels":[],"label_agreement":null},{"id":"W4413798012","doi":"10.3324/haematol.2025.288379","title":"The age of fit-equity: ignoring age and fitness in treatment selection for chronic lymphocytic leukemia","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Selection (genetic algorithm); Leukemia; Equity (law); Medicine; Internal medicine; Oncology; Gerontology; Computer science; Political science; Artificial intelligence","score_opus":0.059695221212627284,"score_gpt":0.37441940071600227,"score_spread":0.314724179503375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413798012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222124,0.00282518,0.00023751485,0.00025259441,0.00009345506,0.0013868741,0.000003504263,0.000055134144,0.0029244788],"genre_scores_gemma":[0.99590874,0.0010899651,0.00024407812,0.00006277824,0.000034410958,0.00039970383,0.000011484168,0.000012352803,0.0022364643],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985833,0.000064439315,0.00037962184,0.00032913074,0.00018922449,0.00045428908],"domain_scores_gemma":[0.99870545,0.0007922096,0.000073978874,0.0003103665,0.00006203103,0.00005598318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037701288,0.0001714442,0.0005282234,0.00014180926,0.00016785336,0.000032767162,0.00013959972,0.0001492634,0.000012913617],"category_scores_gemma":[0.00037345468,0.00010705459,0.00009456536,0.00038096157,0.00025584933,0.00003635318,0.00014395866,0.0001021914,0.0000032647588],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01721387,0.0013572602,0.028996268,0.026578672,0.0031510598,0.008181487,0.005747715,0.00685038,0.073942974,0.1356918,0.010105002,0.6821835],"study_design_scores_gemma":[0.20084561,0.009618582,0.038792323,0.00503082,0.001270878,0.0030495513,0.0021373027,0.38888693,0.2382809,0.021204054,0.089511834,0.0013712008],"about_ca_topic_score_codex":0.0014207824,"about_ca_topic_score_gemma":0.001737244,"teacher_disagreement_score":0.6808123,"about_ca_system_score_codex":0.049603876,"about_ca_system_score_gemma":0.009558349,"threshold_uncertainty_score":0.99605656},"labels":[],"label_agreement":null},{"id":"W4413806777","doi":"10.1111/bjh.70131","title":"Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Hospital; Health Sciences Centre; Queen's University; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Ibrutinib; Medicine; Odds ratio; Internal medicine; Concomitant; Population; CYP3A; Oncology; Pharmacology; Chronic lymphocytic leukemia; Leukemia; Cytochrome P450","score_opus":0.005669862241993579,"score_gpt":0.2795223042852576,"score_spread":0.27385244204326403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413806777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639696,0.0009344752,0.00024053988,0.0007419899,0.00036148314,0.00051689317,0.0000033628312,0.00001938236,0.00078491017],"genre_scores_gemma":[0.99745595,0.000024163794,0.0010278069,0.00049242034,0.000034424593,0.000022285689,0.000006049282,0.000030938852,0.0009059504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780786,0.00012180312,0.00074901077,0.00027981948,0.0005224626,0.0005190563],"domain_scores_gemma":[0.9986427,0.00031359776,0.00021028638,0.00027865308,0.00033525834,0.0002194961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003306152,0.00019655646,0.0010075832,0.0005957141,0.00008850531,0.00005176579,0.0002577424,0.000076216646,0.00007197368],"category_scores_gemma":[0.00041593882,0.00016320829,0.00015386243,0.00063152413,0.00011006477,0.0002134224,0.00009499462,0.00054858654,0.000017725344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0027788796,0.0005405598,0.9010711,0.0005360978,0.0012210944,0.07622655,0.00049628026,0.0009609575,0.000035784367,0.00015368318,0.0055883513,0.010390686],"study_design_scores_gemma":[0.16214319,0.0029369544,0.71200126,0.014964906,0.00065126945,0.10176066,0.00078312686,0.00034022323,0.0007735619,0.00012407539,0.0029156972,0.00060505525],"about_ca_topic_score_codex":0.0008907072,"about_ca_topic_score_gemma":0.003242805,"teacher_disagreement_score":0.1890698,"about_ca_system_score_codex":0.016243119,"about_ca_system_score_gemma":0.013549986,"threshold_uncertainty_score":0.99204224},"labels":[],"label_agreement":null},{"id":"W4414003038","doi":"10.14740/jh2104","title":"Mast Cell Leukemia: Comprehensive Review of Literature With Current Insights and Updates on Management","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Leukemia; Mast cell; Current (fluid); Computational biology; Neuroscience; Data science; Cognitive science; Biology; Immunology; Computer science; Psychology; Engineering","score_opus":0.010229800442945625,"score_gpt":0.30782572164661987,"score_spread":0.29759592120367423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414003038","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28621295,0.7041378,0.00014845112,0.0020111229,0.0002436604,0.0005842812,0.0000027547455,0.0000075623543,0.0066514155],"genre_scores_gemma":[0.6595115,0.3356336,0.0018646976,0.0023459215,0.000079137666,0.000010267501,0.000011489972,0.000021498907,0.00052188267],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988158,0.000075511954,0.0004942281,0.00014642975,0.0003053218,0.00016276323],"domain_scores_gemma":[0.9988152,0.00015679697,0.00028358842,0.00022945007,0.0004254894,0.00008948828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012682912,0.00013383367,0.00071238226,0.00031425076,0.000024262381,0.0000075675675,0.00011334896,0.00006948497,0.000024639361],"category_scores_gemma":[0.00003461885,0.00007986459,0.000077545206,0.00030008907,0.00012460575,0.000041933014,0.00007832318,0.0004199234,0.0000040539703],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008267859,0.0020371994,0.0025700817,0.585022,0.0029083122,0.020975282,0.001354734,0.000045266024,0.001092936,0.09443528,0.23751828,0.043772798],"study_design_scores_gemma":[0.067039564,0.0048407204,0.0021292057,0.3824194,0.0019696779,0.027570738,0.00082590606,0.00050084095,0.027279051,0.002695615,0.4822512,0.000478057],"about_ca_topic_score_codex":0.0000017740387,"about_ca_topic_score_gemma":7.4530345e-7,"teacher_disagreement_score":0.37329856,"about_ca_system_score_codex":0.0010781996,"about_ca_system_score_gemma":0.0012910626,"threshold_uncertainty_score":0.32567835},"labels":[],"label_agreement":null},{"id":"W4414003309","doi":"10.14740/jh2092","title":"B-Cell Lymphoma 2 Inhibition in Acute Lymphoblastic Leukemia: Mechanisms, Resistance, and Emerging Combinations With Venetoclax","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"King Faisal Specialist Hospital and Research Centre","keywords":"Venetoclax; Medicine; Lymphoblastic Leukemia; Lymphoma; Leukemia; Cancer research; Immunology; Chronic lymphocytic leukemia","score_opus":0.006130930099455842,"score_gpt":0.26753846802568926,"score_spread":0.2614075379262334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414003309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98586756,0.0018737399,0.007256653,0.0014814248,0.00012823982,0.00025316057,0.0000018899335,0.000013732382,0.0031236196],"genre_scores_gemma":[0.9962818,0.00026804963,0.0022289301,0.00026298646,0.00001694836,0.0000112213365,0.0000033920292,0.000015776659,0.000910909],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99859774,0.0000779081,0.0005477311,0.00018059499,0.00030166627,0.00029433655],"domain_scores_gemma":[0.9989852,0.0002557391,0.00023432329,0.00017294571,0.00024378345,0.00010802401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003354623,0.0001382633,0.0005338245,0.0007043926,0.00006897143,0.00001685296,0.00007073404,0.00014774791,0.000015968906],"category_scores_gemma":[0.000121123856,0.0001113373,0.000054259046,0.0005199144,0.00013601546,0.000109657616,0.000058719128,0.00022028817,0.000003987618],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021463484,0.00400711,0.006764599,0.0083588045,0.0025857033,0.08777766,0.0029695036,0.0011017243,0.04388376,0.7666442,0.05052648,0.0039169705],"study_design_scores_gemma":[0.5215091,0.0046723946,0.009318604,0.012555361,0.0021480196,0.113593675,0.003610029,0.027567621,0.18191616,0.114896,0.007119038,0.0010939601],"about_ca_topic_score_codex":0.000031104613,"about_ca_topic_score_gemma":0.00007858779,"teacher_disagreement_score":0.6517482,"about_ca_system_score_codex":0.009486868,"about_ca_system_score_gemma":0.009354488,"threshold_uncertainty_score":0.99626154},"labels":[],"label_agreement":null},{"id":"W4414081832","doi":"10.1007/s40477-025-01059-y","title":"Ibrutinib-associated hematoma of the liver: role of ultrasound in diagnosis and clinical management","year":2025,"lang":"en","type":"article","venue":"Journal of Ultrasound","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Università degli Studi di Pavia","keywords":"Ultrasound; Hematoma; Lymphoma; Mantle cell lymphoma; Ibrutinib; Complication","score_opus":0.015661499885852657,"score_gpt":0.32924476952273474,"score_spread":0.3135832696368821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414081832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376357,0.0031620043,0.000009627267,0.00024881246,0.00018946799,0.00035327504,0.000007045578,0.000004009068,0.0022622128],"genre_scores_gemma":[0.9912608,0.007932705,0.00027271314,0.000116506395,0.000053370655,0.000004123193,0.0000011083217,0.000011526013,0.00034713256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747026,0.00022042933,0.0012623476,0.0001611248,0.0006411622,0.00024465696],"domain_scores_gemma":[0.99460584,0.003999228,0.0006217915,0.00031687086,0.00035296186,0.000103298604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018128752,0.00013132894,0.00066403626,0.00024405117,0.000036667352,0.000016203507,0.00029384904,0.00014698357,0.00007055826],"category_scores_gemma":[0.0046958528,0.0000890048,0.0002823997,0.0005969829,0.00033867673,0.000073651,0.00010752884,0.00044252333,0.000001474057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006535228,0.0016498816,0.9806174,0.0006150707,0.0012475457,0.00012894055,0.0004904158,0.000014912252,0.0025522925,0.000803119,0.004927965,0.006298921],"study_design_scores_gemma":[0.01815821,0.00056707545,0.959455,0.0025558525,0.0005976056,0.000436437,0.0015671086,0.0001261876,0.012441223,0.0013894329,0.0025963648,0.00010951028],"about_ca_topic_score_codex":0.00021559368,"about_ca_topic_score_gemma":0.00007187285,"teacher_disagreement_score":0.02116242,"about_ca_system_score_codex":0.0016062233,"about_ca_system_score_gemma":0.0014214936,"threshold_uncertainty_score":0.56217134},"labels":[],"label_agreement":null},{"id":"W4414384075","doi":"10.58931/cht.2025.4272","title":"Front-line Treatment for Chronic Lymphocytic Leukemia in 2025: Finite Duration Versus Continuous Treatment","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Malignancy; Disease; Lymphoproliferative disease; Tyrosine kinase; Hematologic malignancy; Leukemia","score_opus":0.03534443402336911,"score_gpt":0.3317999994173451,"score_spread":0.296455565393976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9490803,0.014293471,0.00063790625,0.00512985,0.0022218956,0.007108919,0.00024854968,0.0001954294,0.021083683],"genre_scores_gemma":[0.97201186,0.0005017943,0.00028088878,0.0004799532,0.00017796864,0.0011804666,0.00041818793,0.000043905584,0.024904957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974951,0.00007868553,0.00059808616,0.0006305642,0.00013695772,0.0010605701],"domain_scores_gemma":[0.99783283,0.00080921693,0.000083276056,0.0006585965,0.00012382882,0.000492245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016716632,0.00036271985,0.00088907784,0.00074487773,0.00015163145,0.000026084763,0.00015273642,0.00040191368,0.00042810588],"category_scores_gemma":[0.00045906982,0.00032234206,0.0001973167,0.0003450394,0.0001650285,0.00005966413,0.00002238137,0.00012232293,0.00026605112],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.058512438,0.0020505101,0.030544093,0.007469562,0.015423777,0.04447766,0.012415772,0.037523896,0.0038922776,0.11192276,0.22689593,0.44887134],"study_design_scores_gemma":[0.29593316,0.007981947,0.00087553106,0.00088517094,0.0009530271,0.0006340304,0.0006226379,0.33331144,0.02377988,0.0006342466,0.33348888,0.0009000484],"about_ca_topic_score_codex":0.22907883,"about_ca_topic_score_gemma":0.62620187,"teacher_disagreement_score":0.44797128,"about_ca_system_score_codex":0.45958415,"about_ca_system_score_gemma":0.16165116,"threshold_uncertainty_score":0.9999229},"labels":[],"label_agreement":null},{"id":"W4414514303","doi":"10.5489/cuaj.9271","title":"Case series - Scrotal edema associated with zanubrutinib","year":2025,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Series (stratigraphy); Edema; Scrotum; Computed tomography; Ultrasonography","score_opus":0.015553539583992124,"score_gpt":0.261685648099269,"score_spread":0.24613210851527684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414514303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94792897,0.00017314997,0.000052700336,0.029476745,0.00028524973,0.0003417659,0.0000380564,0.00006260036,0.021640748],"genre_scores_gemma":[0.98377323,0.00001929963,0.00011870573,0.00408427,0.00023094605,0.000013066722,0.00002544981,0.000014362079,0.011720689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978155,0.00023373359,0.00036983678,0.0002458455,0.0005131285,0.0008219815],"domain_scores_gemma":[0.9978399,0.00035827796,0.00018948104,0.00016249242,0.00060123374,0.0008485772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010878654,0.00017380893,0.00036277092,0.0003088207,0.00055444235,0.00016493724,0.00013018037,0.0003771016,0.00076530565],"category_scores_gemma":[0.003977183,0.00012962097,0.00012204788,0.00064300606,0.000109868684,0.00013876888,0.00002971942,0.00089151086,0.000052761847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012177903,0.00036414157,0.69422716,0.000052109946,0.002479347,0.13558975,0.00048870384,0.00017810774,0.00012827085,0.0048287483,0.15404159,0.0064043053],"study_design_scores_gemma":[0.061230827,0.0038639975,0.34548375,0.00049980957,0.0011634043,0.29742414,0.0013553875,0.0049605668,0.00029556963,0.0039618863,0.2785708,0.0011898734],"about_ca_topic_score_codex":0.0031109178,"about_ca_topic_score_gemma":0.0085625965,"teacher_disagreement_score":0.3487434,"about_ca_system_score_codex":0.029162437,"about_ca_system_score_gemma":0.01583197,"threshold_uncertainty_score":0.98974735},"labels":[],"label_agreement":null},{"id":"W4414533110","doi":"10.1200/jco-25-00925","title":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Sunnybrook Health Science Centre; Health Sciences Centre; Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Prednisone; International Prognostic Index; Tolerability; Lymphoma; Overall survival; Population; Diffuse large B-cell lymphoma; Progression-free survival; Cohort","score_opus":0.04100241325133839,"score_gpt":0.42187365049220954,"score_spread":0.38087123724087113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414533110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964049,0.000116188006,0.000008830367,0.0010293819,0.0003712597,0.0004765719,0.0000025762702,0.0000032751916,0.0015870155],"genre_scores_gemma":[0.9985887,0.000034287004,0.00014984439,0.00064745813,0.000063068226,0.000001888585,4.282614e-7,0.000011115287,0.0005032345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966834,0.00054408103,0.0017109358,0.00019089914,0.00058645837,0.00028420106],"domain_scores_gemma":[0.99605626,0.002261949,0.00081872375,0.00033865534,0.0003438688,0.00018054876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025239326,0.00013255994,0.0014916031,0.00019513106,0.000044122768,0.000009364232,0.00029901008,0.00020503091,0.000012923349],"category_scores_gemma":[0.0028898683,0.00007001592,0.00019701416,0.00029861578,0.0002528398,0.0000708175,0.00031762908,0.00071072695,0.0000021587693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040614586,0.018877095,0.9738326,0.000048498394,0.0002921254,0.00009198283,0.000265125,0.0000025134398,0.0000044214953,0.00006199028,0.0002769545,0.0021852471],"study_design_scores_gemma":[0.21010831,0.004731905,0.78342974,0.00011237785,0.00018704588,0.000008963985,0.00048093926,0.00018577457,0.000008349568,0.000027367083,0.00067340606,0.00004582217],"about_ca_topic_score_codex":0.0002807546,"about_ca_topic_score_gemma":0.0003735193,"teacher_disagreement_score":0.20604685,"about_ca_system_score_codex":0.0018539389,"about_ca_system_score_gemma":0.007221705,"threshold_uncertainty_score":0.9984064},"labels":[],"label_agreement":null},{"id":"W4414570461","doi":"10.1016/j.leukres.2025.108113","title":"Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia","year":2025,"lang":"en","type":"review","venue":"Leukemia Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Bristol-Myers Squibb","keywords":"Chronic lymphocytic leukemia; Surrogate endpoint; Clinical endpoint; Confidence interval; Randomized controlled trial; Odds ratio; Proportional hazards model","score_opus":0.22145760030301562,"score_gpt":0.5080526382068011,"score_spread":0.2865950379037855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414570461","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011515195,0.968971,0.000007935276,0.00015046031,0.00056166993,0.008868483,0.00013417547,0.0003866195,0.009404426],"genre_scores_gemma":[0.0012743212,0.94048846,0.00027788422,0.00014897529,0.0008706784,0.002177898,0.000690692,0.00051453424,0.05355656],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9645501,0.015797952,0.0040594693,0.0041067167,0.0063233213,0.0051624835],"domain_scores_gemma":[0.9667235,0.024573851,0.0006100945,0.005019257,0.0014667729,0.001606547],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.034974188,0.0020089848,0.006462894,0.0065397397,0.0008413622,0.00039517938,0.0028301547,0.0028584676,0.001847943],"category_scores_gemma":[0.029113486,0.0017433263,0.0017007991,0.008118455,0.0013791079,0.00027046574,0.003248973,0.01061725,0.0046941554],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011545314,0.00019042063,0.000002561156,0.15335825,0.0007728074,0.0121528255,0.000528461,0.0007243453,0.0012131585,0.0002808395,0.008917097,0.81031394],"study_design_scores_gemma":[0.029814146,0.002343414,0.000016767473,0.13429154,0.0006176597,0.0011964745,0.00015047824,0.029995859,0.00016723892,0.00024013712,0.79987127,0.001295026],"about_ca_topic_score_codex":0.0069872458,"about_ca_topic_score_gemma":0.00028986848,"teacher_disagreement_score":0.8090189,"about_ca_system_score_codex":0.75965875,"about_ca_system_score_gemma":0.68199646,"threshold_uncertainty_score":0.9996253},"labels":[],"label_agreement":null},{"id":"W4414629458","doi":"10.3390/curroncol32100543","title":"Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System","year":2025,"lang":"en","type":"letter","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Manitoba; Université Laval; Queen Elizabeth II Health Sciences Centre; Western University; CancerCare Manitoba; Occupational Cancer Research Centre; Dalhousie University","funders":"AstraZeneca Canada","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Healthcare system; Health care; Disease; Alternative medicine","score_opus":0.13009317667072212,"score_gpt":0.4094273055253025,"score_spread":0.27933412885458037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414629458","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05807515,0.09673953,0.00024455617,0.82621354,0.0033956459,0.009177811,0.0011460943,0.00031176914,0.00469592],"genre_scores_gemma":[0.96137834,0.003366418,0.00008634519,0.019743042,0.0070083113,0.0021644414,0.0055575925,0.0000917104,0.00060378714],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947166,0.0010892652,0.0014918393,0.0011030583,0.00080032344,0.0007989441],"domain_scores_gemma":[0.9951298,0.002187799,0.00075387605,0.0013055946,0.0005093365,0.000113575516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008064152,0.00058982876,0.0016677622,0.00075219915,0.00019674523,0.000054131477,0.0005710142,0.0012528005,0.00005606239],"category_scores_gemma":[0.0003891794,0.00042941063,0.00042317895,0.00083651603,0.00031601384,0.00011348659,0.00019321853,0.0020534657,0.000034172037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008847763,0.0008388106,0.0011388416,0.014039714,0.0010973128,0.0023024306,0.011444312,0.00023421823,0.000018869418,0.0007065143,0.94667965,0.020614574],"study_design_scores_gemma":[0.045745086,0.0045646215,0.000742148,0.00694953,0.00076199207,0.0006083042,0.009589534,0.05455958,0.00005851169,0.00010971472,0.875719,0.0005919831],"about_ca_topic_score_codex":0.023327949,"about_ca_topic_score_gemma":0.00617554,"teacher_disagreement_score":0.9033032,"about_ca_system_score_codex":0.42955214,"about_ca_system_score_gemma":0.11715115,"threshold_uncertainty_score":0.99981576},"labels":[],"label_agreement":null},{"id":"W4414654223","doi":"10.3390/curroncol32100550","title":"From Chronic Lymphocytic Leukemia to Plasmablastic Myeloma: Beyond the Usual Richter Transformation","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chronic lymphocytic leukemia; Transformation (genetics); Malignant transformation; Plasmablastic lymphoma; Leukemia","score_opus":0.044623947077501495,"score_gpt":0.3961599136422335,"score_spread":0.351535966564732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414654223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96755165,0.00302929,0.005708342,0.0036549512,0.0033974182,0.0015750012,0.00004091965,0.00014357644,0.014898867],"genre_scores_gemma":[0.9960041,0.00021205853,0.00011759643,0.0011036814,0.0009791853,0.00029103924,0.00012999726,0.000028061178,0.0011342553],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976215,0.00017206874,0.00056221086,0.00048146417,0.0004719509,0.00069083454],"domain_scores_gemma":[0.9980265,0.0008923928,0.00007909408,0.0005906348,0.00016904689,0.00024235275],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037856904,0.00027180347,0.00051614176,0.00029121435,0.00018724057,0.000041721152,0.00039937277,0.00023023956,0.00038472255],"category_scores_gemma":[0.00029704312,0.00019193869,0.00015131559,0.0006918906,0.00025005505,0.000104630766,0.00018376173,0.0005167827,0.0009754421],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028235856,0.00041401354,0.00038505794,0.0010325204,0.0008133596,0.00019743179,0.009555181,0.0036559268,0.006190629,0.0051555037,0.19483455,0.7749422],"study_design_scores_gemma":[0.042022556,0.0016411677,0.0030500807,0.0005243007,0.00068107457,0.0001857986,0.0006804441,0.19594681,0.0055846134,0.0017007433,0.7475942,0.00038826404],"about_ca_topic_score_codex":0.00036708644,"about_ca_topic_score_gemma":0.00027960195,"teacher_disagreement_score":0.77455395,"about_ca_system_score_codex":0.16054086,"about_ca_system_score_gemma":0.049297623,"threshold_uncertainty_score":0.9998024},"labels":[],"label_agreement":null},{"id":"W4414975794","doi":"10.3324/haematol.2025.288780","title":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review","year":2025,"lang":"en","type":"review","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"CancerCare Manitoba Foundation; Biogen; Gilead Sciences; Leukemia and Lymphoma Society; BeiGene; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Obinutuzumab; Tolerability; Chronic lymphocytic leukemia; Hematology; Ibrutinib; Lymphoma","score_opus":0.03306404265306265,"score_gpt":0.3343913292221242,"score_spread":0.3013272865690616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414975794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009158434,0.9752825,0.000013603552,0.00004757011,0.00021262626,0.0093661845,0.00012454492,0.0001844501,0.0056101047],"genre_scores_gemma":[0.0025296295,0.9940836,0.00049457344,0.0002587032,0.0001483781,0.0009899371,0.00027661998,0.0001432547,0.0010753358],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.98883873,0.0012676616,0.0045780013,0.0025711905,0.0010959336,0.0016484587],"domain_scores_gemma":[0.99208975,0.00284059,0.0015714703,0.0024760673,0.00036923247,0.00065289985],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0027592957,0.0017683741,0.011711229,0.0014492595,0.00025088325,0.00007330979,0.0009387375,0.0014751408,0.00020804319],"category_scores_gemma":[0.0023315656,0.0013716045,0.0010218475,0.0029560374,0.0013316448,0.00016556241,0.0018848589,0.00061100075,0.000048165155],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00063632155,0.00008747378,0.000022373753,0.3777682,0.00021918312,0.0012275232,0.000069521724,0.000003886077,0.000002219768,0.00021827102,0.00038473503,0.6193603],"study_design_scores_gemma":[0.05242419,0.0020260466,0.0005938044,0.54415464,0.0051091374,0.009419971,0.000051077495,0.0065003373,0.000054413435,0.00018029001,0.37715027,0.0023358196],"about_ca_topic_score_codex":0.012675285,"about_ca_topic_score_gemma":0.0029141346,"teacher_disagreement_score":0.6170245,"about_ca_system_score_codex":0.3464404,"about_ca_system_score_gemma":0.28140205,"threshold_uncertainty_score":0.9998211},"labels":[],"label_agreement":null},{"id":"W4415063566","doi":"10.1080/10428194.2025.2562961","title":"Expert consensus opinion on the management of hairy cell leukemia in elderly patients","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Hairy cell leukemia; Cladribine; Expert opinion; Leukemia; MEDLINE","score_opus":0.01441489767900824,"score_gpt":0.2759394004783551,"score_spread":0.26152450279934686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415063566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9382877,0.0032225086,0.000038948,0.00048952294,0.0007369879,0.0021229018,0.000033930482,0.00015275062,0.054914773],"genre_scores_gemma":[0.98938537,0.0033735193,0.0006159234,0.0022053411,0.00015292746,0.00035630795,0.000093770024,0.000119805154,0.0036970165],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993731,0.00033161053,0.0015789539,0.0014630429,0.0014520875,0.0014432872],"domain_scores_gemma":[0.99595416,0.0010126679,0.0004022727,0.0018958651,0.00031226673,0.00042276867],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087582256,0.00093406276,0.0012769786,0.0008325595,0.00035901007,0.000109118075,0.0008318886,0.00067351665,0.00009769661],"category_scores_gemma":[0.00015977904,0.00072971714,0.00039200048,0.0016167164,0.00084225746,0.00014308767,0.0006380145,0.00037471444,0.000099795834],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01652272,0.00297541,0.01615022,0.008319484,0.0024082924,0.0025984147,0.005330706,0.0010175471,0.003780856,0.03477458,0.085932404,0.82018936],"study_design_scores_gemma":[0.36945453,0.0043327655,0.30236757,0.0147211235,0.0007140792,0.00063854695,0.008018212,0.066402294,0.06672487,0.0029537969,0.1600505,0.0036216984],"about_ca_topic_score_codex":0.00549185,"about_ca_topic_score_gemma":0.00008081937,"teacher_disagreement_score":0.81656766,"about_ca_system_score_codex":0.085625194,"about_ca_system_score_gemma":0.019178595,"threshold_uncertainty_score":0.9995154},"labels":[],"label_agreement":null},{"id":"W4415403106","doi":"10.51731/cjht.2025.1258","title":"Acalabrutinib (Calquence)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bendamustine; Mantle cell lymphoma; Debulking; Rituximab; Lymphoma; Primary central nervous system lymphoma","score_opus":0.028257548079617105,"score_gpt":0.35518305201837175,"score_spread":0.32692550393875464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415403106","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049060524,0.70623565,0.00093995733,0.23211567,0.0037895376,0.0011239736,0.000044047538,0.00014503532,0.00654558],"genre_scores_gemma":[0.98251486,0.012355801,0.0005272873,0.0023188358,0.000054052543,0.00000793327,0.0000023536252,0.00003305888,0.0021858215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941917,0.00026126934,0.0023070981,0.00042925263,0.00062898535,0.0021816986],"domain_scores_gemma":[0.99608594,0.00046091896,0.00093531905,0.0010330452,0.000965191,0.00051955873],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033523547,0.00040316794,0.0014523818,0.003485073,0.00068687747,0.00013114723,0.0015685265,0.0008648399,0.00030846114],"category_scores_gemma":[0.008440004,0.00035588077,0.00030434644,0.0024772342,0.0021032547,0.00019449528,0.00015025798,0.0027582853,0.000094446616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00010997868,0.000057156267,0.0018660518,0.001792299,0.00035126682,0.0023718167,0.0004488666,0.000022110251,0.00003035747,0.009830204,0.062195707,0.9209242],"study_design_scores_gemma":[0.013186816,0.0018620327,0.0028997178,0.010837575,0.00017190045,0.002340335,0.014353694,0.000660094,0.0018809267,0.012743767,0.93865305,0.00041007288],"about_ca_topic_score_codex":0.038387142,"about_ca_topic_score_gemma":0.0069814622,"teacher_disagreement_score":0.93345433,"about_ca_system_score_codex":0.06350645,"about_ca_system_score_gemma":0.4100721,"threshold_uncertainty_score":0.9999123},"labels":[],"label_agreement":null},{"id":"W4415475778","doi":"10.1681/asn.2025ma7ztv7r","title":"Zanubrutinib (zanu) in Anti-Phospholipase A2 Receptor (PLA2R)-Associated Primary Membranous Nephropathy (PMN): Preliminary Results of a Phase 2/3, Multicenter, Randomized, Open-Label Study","year":2025,"lang":"en","type":"article","venue":"Journal of the American Society of Nephrology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Membranous nephropathy; Phase (matter); Receptor; Glomerulonephritis; Kidney; Phases of clinical research","score_opus":0.02678802100635685,"score_gpt":0.35726408217432654,"score_spread":0.3304760611679697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415475778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027365,0.001007322,0.000040779665,0.005197559,0.00027750194,0.0028447981,0.00006166425,0.000013758413,0.00028293405],"genre_scores_gemma":[0.9896372,0.0018602432,0.0021799505,0.0057041314,0.00009485513,0.000040565978,0.000012639235,0.00004110688,0.00042930793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934157,0.0018823032,0.0026345141,0.0004528647,0.0009551349,0.00065947144],"domain_scores_gemma":[0.99188006,0.002609785,0.0036357662,0.0008992473,0.0007875675,0.00018755283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005507608,0.00037271777,0.003364214,0.00028267768,0.00011861044,0.000022630686,0.0014363622,0.00019684697,0.000026779651],"category_scores_gemma":[0.0022133426,0.00026095152,0.0008254551,0.0016103172,0.002338285,0.00017078884,0.000999805,0.0010895828,0.0000025196634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79575545,0.03427648,0.0018906507,0.0003404675,0.0045120968,0.00025250946,0.010435144,0.000083814746,0.09263469,0.000007939712,0.05426023,0.0055505396],"study_design_scores_gemma":[0.95908433,0.011393469,0.010679749,0.00074155757,0.0009980536,0.00019998247,0.0064446605,0.004682196,0.004168681,0.00004329136,0.0013430184,0.00022098959],"about_ca_topic_score_codex":0.0041104816,"about_ca_topic_score_gemma":0.000039508293,"teacher_disagreement_score":0.16332893,"about_ca_system_score_codex":0.0035217234,"about_ca_system_score_gemma":0.00712395,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W4415649326","doi":"10.1111/ijlh.70010","title":"The <scp>ABCs</scp> of <scp> <i>IGHV</i> </scp> Testing in Chronic Lymphocytic Leukaemia: Current Recommendations, Ongoing Challenges, and Future Directions","year":2025,"lang":"en","type":"review","venue":"International Journal of Laboratory Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"IGHV@; Somatic hypermutation; Chronic lymphocytic leukemia; Disease; Immunoglobulin heavy chain; Somatic evolution in cancer; Risk stratification","score_opus":0.04690380579466208,"score_gpt":0.37659606717961797,"score_spread":0.3296922613849559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415649326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066704385,0.99395746,0.000018690613,0.00048561674,0.0031374837,0.0005583947,0.00007944798,0.000025907535,0.001069935],"genre_scores_gemma":[0.00022000975,0.99759173,0.00029145947,0.00006536136,0.0015201977,0.00008132497,0.00004006391,0.000058641195,0.0001312017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949909,0.00070901343,0.0023437953,0.00048519977,0.00090943143,0.00056170055],"domain_scores_gemma":[0.98404914,0.011143737,0.0020453304,0.00047118703,0.0020564925,0.0002340945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001768814,0.0005053663,0.0021403946,0.001325719,0.00014511734,0.00006446196,0.0008893738,0.00054342434,0.0000073836227],"category_scores_gemma":[0.0073983413,0.0003744352,0.0003742535,0.0009986511,0.00032665848,0.00020798466,0.00037128778,0.0017611266,0.000011531985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000013273129,0.0002259101,0.000082272905,0.01757957,0.0013720432,0.00076465565,0.00045962253,0.0000088150655,0.000007561409,0.0060577844,0.0074137268,0.96601474],"study_design_scores_gemma":[0.003774322,0.00016131237,0.000025568883,0.030303199,0.00048311395,0.0053926264,0.0004800403,0.00013023362,0.00003201243,0.00020614146,0.9589528,0.000058620444],"about_ca_topic_score_codex":0.000029488694,"about_ca_topic_score_gemma":0.000118214324,"teacher_disagreement_score":0.96595615,"about_ca_system_score_codex":0.026318613,"about_ca_system_score_gemma":0.05964684,"threshold_uncertainty_score":0.9998708},"labels":[],"label_agreement":null},{"id":"W4415701428","doi":"10.58931/cht.2025.4s0676","title":"Double-Exposed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Clinical Approach and Management","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Lymphocytic infiltration; Ibrutinib; Immunotherapy; Clinical trial; Tyrosine kinase; Lymphoma; Refractory (planetary science)","score_opus":0.038119414519371064,"score_gpt":0.31643528583161257,"score_spread":0.2783158713122415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415701428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56052864,0.13534155,0.0012910131,0.0025568628,0.007286049,0.011967912,0.00014753675,0.00057599816,0.28030443],"genre_scores_gemma":[0.9326005,0.017870374,0.0011831678,0.005185015,0.00084412744,0.00081161514,0.0002351199,0.0002970744,0.040972985],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98467845,0.0010087689,0.003726465,0.0040722527,0.0009860698,0.0055280146],"domain_scores_gemma":[0.9884989,0.0014557707,0.0005733033,0.003993649,0.0005035769,0.004974756],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0031734514,0.0019000826,0.0040184036,0.0030993659,0.0012010867,0.00036098843,0.0020414733,0.003045941,0.00074511743],"category_scores_gemma":[0.00057013,0.0020159555,0.00086107233,0.0028025457,0.003933792,0.0002609035,0.0012836383,0.0012302081,0.0013747204],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011189808,0.0013084217,0.012394512,0.06729684,0.023815116,0.06653133,0.002817706,0.0021056805,0.000082850434,0.45833609,0.18548559,0.16863607],"study_design_scores_gemma":[0.38886464,0.0015823828,0.003970056,0.0070917886,0.0065241694,0.015406944,0.0023399217,0.36857063,0.0013690545,0.0012826844,0.19906303,0.0039346833],"about_ca_topic_score_codex":0.15656094,"about_ca_topic_score_gemma":0.09240354,"teacher_disagreement_score":0.4570534,"about_ca_system_score_codex":0.51682794,"about_ca_system_score_gemma":0.4358928,"threshold_uncertainty_score":0.9994028},"labels":[],"label_agreement":null},{"id":"W4415877993","doi":"10.51731/cjht.2025.1281","title":"Ibrutinib","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Reimbursement; Cancer; Antineoplastic Drugs; Cancer drugs; Drug","score_opus":0.02848752115301347,"score_gpt":0.3536033925155721,"score_spread":0.32511587136255865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415877993","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03266925,0.7580184,0.00062827073,0.1956814,0.0037077344,0.00090006104,0.000034279954,0.00011686178,0.008243754],"genre_scores_gemma":[0.9849773,0.01005466,0.0004224365,0.0018896158,0.00004931789,0.000006268848,0.0000020259977,0.000030164343,0.002568208],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949184,0.00021319924,0.0020558352,0.0003543186,0.00052435725,0.0019339108],"domain_scores_gemma":[0.9965583,0.00038711666,0.00086270715,0.0009576798,0.00081070483,0.00042350226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030033716,0.0003485277,0.0013174785,0.0036553934,0.000624529,0.00011749964,0.0013034504,0.0006835221,0.0002652364],"category_scores_gemma":[0.0066827647,0.00031126768,0.00028388604,0.0021495258,0.0015377279,0.00015767492,0.00012833717,0.002172374,0.00008633458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00010025363,0.00004771821,0.0015947067,0.0017152518,0.00036249025,0.0019510112,0.00042630703,0.000017166114,0.000015227961,0.008442501,0.08906258,0.8962648],"study_design_scores_gemma":[0.011474279,0.0014173603,0.0019208168,0.0075706504,0.00013032548,0.0017435929,0.012665262,0.00039111736,0.0011420342,0.007692214,0.95357424,0.0002781263],"about_ca_topic_score_codex":0.031988394,"about_ca_topic_score_gemma":0.0066744606,"teacher_disagreement_score":0.95230806,"about_ca_system_score_codex":0.05812175,"about_ca_system_score_gemma":0.42700884,"threshold_uncertainty_score":0.99993396},"labels":[],"label_agreement":null},{"id":"W4415956288","doi":"10.3389/fimmu.2025.1670408","title":"Biochemical analysis reveals aberrant and variable Immunoglobulin M composition in Waldenström macroglobulinemia and IgM monoclonal gammopathy of unknown significance","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Dutch Arthritis Association","keywords":"Waldenstrom macroglobulinemia; Immunoglobulin M; Macroglobulinemia; Monoclonal; Paraproteinemias; Monoclonal gammopathy of undetermined significance; Monoclonal antibody; Antibody; Gammopathy","score_opus":0.005961638642880322,"score_gpt":0.26077947174525395,"score_spread":0.25481783310237366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415956288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720067,0.02237772,0.0039051708,0.00043985154,0.00019600081,0.00046235567,0.00002133211,0.000017623453,0.00057324267],"genre_scores_gemma":[0.9797574,0.0020306252,0.01760975,0.00009136083,0.000015844798,0.0000466153,0.00007656404,0.000012068875,0.00035971365],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979913,0.00017993912,0.0006982237,0.0005059151,0.00017488378,0.00044969353],"domain_scores_gemma":[0.99912786,0.00018629104,0.00011969981,0.0004075382,0.00009810419,0.00006049966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053174567,0.00020327819,0.0009569143,0.0008920804,0.000037871414,0.000012846557,0.00017059935,0.00033983425,0.000028131022],"category_scores_gemma":[0.0001701671,0.0002036345,0.00007521012,0.0015269178,0.0006746012,0.000053694108,0.00018981197,0.0004442357,0.0000010705572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008374664,0.0008316477,0.47112966,0.001082412,0.003093414,0.00046710556,0.00087559095,0.00038402213,0.49365085,0.0035471767,0.0036283645,0.012935107],"study_design_scores_gemma":[0.072338454,0.001001703,0.69586796,0.002262719,0.002104751,0.0006584636,0.0016416522,0.11444693,0.096217245,0.0097379275,0.0026343092,0.0010878984],"about_ca_topic_score_codex":0.0014244076,"about_ca_topic_score_gemma":0.000029892894,"teacher_disagreement_score":0.3974336,"about_ca_system_score_codex":0.0026879956,"about_ca_system_score_gemma":0.0011371638,"threshold_uncertainty_score":0.83039737},"labels":[],"label_agreement":null},{"id":"W4416015139","doi":"10.1007/s41669-025-00610-1","title":"Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; ABB (Canada); CancerCare Manitoba; University of Calgary","funders":"","keywords":"Venetoclax; Obinutuzumab; Ven; Chronic lymphocytic leukemia; Ibrutinib; Bendamustine; IGHV@; Cancer","score_opus":0.019483530240405847,"score_gpt":0.3295830902794832,"score_spread":0.31009956003907735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416015139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987792,0.00018420916,0.000016859281,0.00019307419,0.000051868174,0.0050909733,0.00006017741,0.000026054344,0.006584778],"genre_scores_gemma":[0.9971298,0.0001570731,0.000071850794,0.00068680174,0.00001536883,0.00059398205,0.0004774018,0.000038334885,0.00082938845],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9974029,0.00014453442,0.00060884136,0.00078914297,0.00021005467,0.00084449403],"domain_scores_gemma":[0.9984518,0.00015588531,0.00014848443,0.0006676297,0.00017707072,0.00039907853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006300865,0.00032686724,0.0008442981,0.0012323641,0.00009887179,0.00015474958,0.0006231207,0.00014591584,0.0005063772],"category_scores_gemma":[0.00005478848,0.0002965009,0.000072443305,0.0019600994,0.0001350482,0.00038443087,0.00021231498,0.00039907402,0.000050262654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010018899,0.0002738993,0.7677886,0.00070549356,0.00269251,0.00064763083,0.00081888406,0.2017238,0.000011593024,0.00021557708,0.0017733158,0.013329818],"study_design_scores_gemma":[0.112921245,0.00039671262,0.1857493,0.00034766935,0.00080053153,0.000012895404,0.00004723144,0.6959579,0.00035871175,0.00003995048,0.0029933418,0.00037451606],"about_ca_topic_score_codex":0.7030901,"about_ca_topic_score_gemma":0.76927114,"teacher_disagreement_score":0.5820393,"about_ca_system_score_codex":0.51788026,"about_ca_system_score_gemma":0.16819793,"threshold_uncertainty_score":0.99994874},"labels":[],"label_agreement":null},{"id":"W4416257451","doi":"10.7759/cureus.96963","title":"Tonsillar Hypertrophy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Mini-Review","year":2025,"lang":"en","type":"review","venue":"Cureus","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Chronic lymphocytic leukemia; Tonsil; Tonsillectomy; Malignancy; Lymphocytosis; Ibrutinib; Lymphoma; Hypogammaglobulinemia; Airway","score_opus":0.044142143941272693,"score_gpt":0.356222433549056,"score_spread":0.3120802896077833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416257451","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014619544,0.9875958,0.0000072644298,0.000051245224,0.0004948337,0.005201528,0.00006835217,0.00022350863,0.0062112752],"genre_scores_gemma":[0.00003672005,0.9903838,0.0002863961,0.000837602,0.0005483389,0.0011634794,0.00031046613,0.00027000054,0.006163215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99221456,0.00055703253,0.0023051929,0.0021198532,0.0009829464,0.0018204073],"domain_scores_gemma":[0.99428403,0.0014819234,0.0005272805,0.002695379,0.00023832603,0.00077304285],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000995783,0.0016800775,0.007018197,0.00092495634,0.00015513154,0.000106554595,0.0010302172,0.0013518689,0.0002670354],"category_scores_gemma":[0.0016234181,0.0013879137,0.0012091888,0.0023121098,0.00052155595,0.00013870373,0.0010357794,0.00070823275,0.00046745446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000050695216,0.00005392653,8.095726e-7,0.35172725,0.00049545104,0.0023426341,0.00003247534,0.0000046790337,0.0000011591749,0.00012692084,0.00353781,0.6416262],"study_design_scores_gemma":[0.012937297,0.00031053918,0.0000020746986,0.24835584,0.0034439173,0.004585775,0.000011609219,0.0013329431,0.0000032075163,0.000023981012,0.72813207,0.0008607766],"about_ca_topic_score_codex":0.0034002524,"about_ca_topic_score_gemma":0.0004296409,"teacher_disagreement_score":0.72459424,"about_ca_system_score_codex":0.5486682,"about_ca_system_score_gemma":0.38660708,"threshold_uncertainty_score":0.99994457},"labels":[],"label_agreement":null},{"id":"W4416448128","doi":"10.1093/jimmun/vkaf283.1185","title":"Intravenous low-dose anti-CD20 Rituximab infusion contrasted with subsequent subcutaneous Rituximab injection during CLL patient treatment 3374","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Rituximab; CD20; Monoclonal antibody; Antibody; Monoclonal; Cytokine release syndrome; Chemotherapy","score_opus":0.007331163308923114,"score_gpt":0.25024539501956505,"score_spread":0.24291423171064194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416448128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933211,0.0040731775,0.00014081004,0.0009391244,0.0004252973,0.0007098069,0.000004012182,0.000033754844,0.00035290016],"genre_scores_gemma":[0.9969152,0.0024352667,0.00008382476,0.00012604281,0.00009907396,0.000010693436,0.0000059509043,0.000029114559,0.00029482963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976854,0.00035277088,0.00078120653,0.00020222808,0.00042882422,0.00054961967],"domain_scores_gemma":[0.99817,0.00029415853,0.00043527002,0.0005063395,0.0004943262,0.000099914745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003690394,0.00027971674,0.00080343196,0.00042978305,0.00024321383,0.000026566033,0.0002465577,0.00018259774,0.000081522776],"category_scores_gemma":[0.00013983253,0.00016015934,0.000145562,0.00042077905,0.00036405938,0.00008740586,0.00010789295,0.0006554505,0.00003448976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12694031,0.012273252,0.0012924287,0.0005523311,0.0067493655,0.016601117,0.009865642,0.002113148,0.71792346,0.0002772592,0.00025024492,0.10516141],"study_design_scores_gemma":[0.3026352,0.05107824,0.024961043,0.0027912585,0.0022619804,0.24500616,0.0055778385,0.0023959663,0.36059484,0.00028739314,0.0017384427,0.0006716667],"about_ca_topic_score_codex":0.0009669241,"about_ca_topic_score_gemma":0.00011910853,"teacher_disagreement_score":0.35732865,"about_ca_system_score_codex":0.011637924,"about_ca_system_score_gemma":0.004197931,"threshold_uncertainty_score":0.9921562},"labels":[],"label_agreement":null},{"id":"W4416612085","doi":"10.1016/j.isci.2025.114216","title":"High-content imaging of primary chronic lymphocytic leukemia cells predicts patient cohorts with distinct cellular drug responses","year":2025,"lang":"en","type":"article","venue":"iScience","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Sunnybrook Health Science Centre","funders":"Institute of Genetics; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Chronic lymphocytic leukemia; Epigenetics; Tumor microenvironment; Population; Drug response; Drug; Phenotype; Precision medicine; Cancer","score_opus":0.012676976324461183,"score_gpt":0.2445480654848719,"score_spread":0.23187108916041071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416612085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065834,0.0035624267,0.001089837,0.00018380824,0.00035836437,0.0009799439,0.000021743812,0.0000987085,0.0030468404],"genre_scores_gemma":[0.9941574,0.00008619133,0.0007593691,0.0002735096,0.00005848302,0.000060706763,0.000014533914,0.000025833931,0.004563971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964833,0.00011606526,0.00057454174,0.0007563056,0.0013265513,0.0007432223],"domain_scores_gemma":[0.9978193,0.0004110293,0.00020099958,0.0009920099,0.00032099787,0.00025563952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006698492,0.00028537304,0.00058109756,0.00033917426,0.00017969077,0.000050311686,0.0004592794,0.000058195346,0.000057566813],"category_scores_gemma":[0.0002581465,0.00021039163,0.00010164209,0.0009878172,0.0012164352,0.00019759641,0.00037728914,0.00022665215,0.000026020594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0059038387,0.0004629766,0.023144614,0.0045058997,0.00031271938,0.004127041,0.0026159827,0.0061876187,0.8888736,0.0008563841,0.010676469,0.052332863],"study_design_scores_gemma":[0.018286884,0.00081376993,0.024685554,0.0029184828,0.0002501769,0.00025466405,0.0003849373,0.047326725,0.9023635,0.0000822806,0.0021946437,0.00043837813],"about_ca_topic_score_codex":0.0031234755,"about_ca_topic_score_gemma":0.00006533069,"teacher_disagreement_score":0.051894486,"about_ca_system_score_codex":0.0779553,"about_ca_system_score_gemma":0.06851636,"threshold_uncertainty_score":0.9367643},"labels":[],"label_agreement":null},{"id":"W4416891896","doi":"10.1186/s13223-025-01002-0","title":"Clinical relevant Bruton’s X-linked tyrosine kinase deficiency in a female with extreme X-chromosome inactivation","year":2025,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital","funders":"","keywords":"Bruton's tyrosine kinase; Tyrosine kinase; Mutation; Disease; Kinase; Antibody","score_opus":0.040010255025455875,"score_gpt":0.3561493743138743,"score_spread":0.3161391192884184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416891896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892795,0.0031149662,0.00037565187,0.0028345706,0.00036219967,0.00052137533,0.0000020246227,0.000071779614,0.0034379035],"genre_scores_gemma":[0.9907794,0.0044393875,0.0007343354,0.00092119636,0.00011983966,0.00005223039,0.000032794953,0.000028528655,0.002892267],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962916,0.00048085346,0.0014417651,0.00088355946,0.00027130905,0.0006309504],"domain_scores_gemma":[0.9969865,0.0016799471,0.00020385439,0.00074434234,0.00021546955,0.00016990086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013303235,0.00027320703,0.00094002974,0.0002796099,0.00010658596,0.000023315977,0.0002368482,0.000651163,0.00016829163],"category_scores_gemma":[0.0017221385,0.00021372689,0.00016695178,0.00065491,0.0011518457,0.000119799624,0.00029024735,0.0011718649,0.00005853126],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048027694,0.016897328,0.32409713,0.00063259987,0.0038090798,0.0060019223,0.0008191888,0.000058201254,0.012705899,0.045972224,0.0021034179,0.53887534],"study_design_scores_gemma":[0.052803002,0.005357696,0.91119576,0.0007475978,0.0000736012,0.00036260916,0.00045892166,0.0036226965,0.00027200847,0.000730016,0.02400101,0.00037505935],"about_ca_topic_score_codex":0.0008609281,"about_ca_topic_score_gemma":0.0009992837,"teacher_disagreement_score":0.58709866,"about_ca_system_score_codex":0.0013704366,"about_ca_system_score_gemma":0.0038197287,"threshold_uncertainty_score":0.871553},"labels":[],"label_agreement":null},{"id":"W4417001967","doi":"10.1182/blood-2025-797","title":"Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Jewish General Hospital; Montreal General Hospital","funders":"","keywords":"Bruton's tyrosine kinase; Ibrutinib; Mutation; Gene; Mutant; Tyrosine kinase; Kinase; Phases of clinical research","score_opus":0.0389420738251895,"score_gpt":0.3898912402730499,"score_spread":0.3509491664478604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951746,0.00008785753,0.000019374032,0.00021689119,0.000009011198,0.002093346,0.000010505229,0.000017761577,0.0023706746],"genre_scores_gemma":[0.99913234,0.000010760061,0.00021621163,0.000072042,0.000013863415,0.00030062732,0.00002575245,0.000017222603,0.0002111781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821216,0.00022460942,0.00041151993,0.00030779562,0.0004315438,0.00041238553],"domain_scores_gemma":[0.9989564,0.00027684894,0.00008209425,0.0005418438,0.0000756364,0.000067193636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000622543,0.00015704577,0.00039430443,0.00026998797,0.00004819224,0.000018048031,0.00017945132,0.0000483284,0.000032942167],"category_scores_gemma":[0.00007166396,0.00009306119,0.000028550103,0.0011110251,0.00014025348,0.000043173983,0.00004831406,0.00012704311,0.0000030025462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023771736,0.0390012,0.9377506,0.00025429777,0.00090731616,0.0023953877,0.008988068,0.00048931764,0.0063648494,0.00021758006,0.000056440775,0.0011977886],"study_design_scores_gemma":[0.26589286,0.003967045,0.7091045,0.0004020824,0.0009150933,0.00007388593,0.009222085,0.00544658,0.004748246,0.000018949519,0.00004589567,0.00016278605],"about_ca_topic_score_codex":0.0017403825,"about_ca_topic_score_gemma":0.0025830888,"teacher_disagreement_score":0.26351568,"about_ca_system_score_codex":0.0012918258,"about_ca_system_score_gemma":0.005318402,"threshold_uncertainty_score":0.94346166},"labels":[],"label_agreement":null},{"id":"W4417002560","doi":"10.1182/blood-2025-519","title":"WM-voice: An international discrete choice experiment on treatment preferences in 1,455 patients with Waldenström macroglobulinemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Mining Association of Canada","funders":"","keywords":"Logit; Preference; Mixed logit; Choice set; Discrete choice; Set (abstract data type); Duration (music); Logistic regression","score_opus":0.016147797973792538,"score_gpt":0.33228748791516205,"score_spread":0.31613968994136954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886148,0.00009746001,0.0000041125627,0.00026640313,0.00012071121,0.0006853575,0.00002449113,0.000040786737,0.010145897],"genre_scores_gemma":[0.9972606,0.00005129911,0.0003550834,0.00013375086,0.00010528902,0.00016584017,0.00016645162,0.000015630392,0.0017460726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844944,0.000043454318,0.00024199947,0.00043468288,0.00052637706,0.00030406064],"domain_scores_gemma":[0.9992262,0.00008757076,0.00004793295,0.00041719284,0.00009170375,0.00012936699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006440256,0.00020193713,0.00024715482,0.00017377087,0.000042313408,0.000039015635,0.00019602058,0.00007847042,0.0001284619],"category_scores_gemma":[0.000064865824,0.00013161341,0.000043107266,0.00019491378,0.000068461835,0.00009367067,0.000065604356,0.00013397222,0.00003263659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038380024,0.01786398,0.9288389,0.00014478693,0.0011296138,0.00042711143,0.001833384,0.00011068641,0.00097030395,0.00047021272,0.0002934235,0.044079583],"study_design_scores_gemma":[0.20650907,0.0062556644,0.7188283,0.0012240747,0.0003075152,0.000029109384,0.00046491105,0.0016784365,0.05666615,0.0000723534,0.0074946526,0.0004697517],"about_ca_topic_score_codex":0.0011198232,"about_ca_topic_score_gemma":0.0004230183,"teacher_disagreement_score":0.2100106,"about_ca_system_score_codex":0.0048048794,"about_ca_system_score_gemma":0.0016074061,"threshold_uncertainty_score":0.9990155},"labels":[],"label_agreement":null},{"id":"W4417004116","doi":"10.1182/blood-2025-1805","title":"Long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine in British Columbia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cladribine; Hairy cell leukemia; Purine analogue; Rituximab; Cancer; Leukemia; Alemtuzumab; Monoclonal","score_opus":0.008816306317654938,"score_gpt":0.24396355938512118,"score_spread":0.23514725306746626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727184,0.00022217486,0.000014265996,0.000045066172,0.000023671806,0.001020599,0.000044848315,0.000054776356,0.0013027893],"genre_scores_gemma":[0.9924702,0.00007002121,0.00022518584,0.000091189984,0.00001816775,0.000058538382,0.0001659709,0.00003907781,0.0068616304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981733,0.000034209148,0.00042155376,0.00041981786,0.00051701686,0.00043412118],"domain_scores_gemma":[0.998831,0.00015214251,0.00010522775,0.000530222,0.00025073378,0.00013069637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010367584,0.0001718263,0.0006280836,0.00014363907,0.00005190076,0.00004852196,0.00017382292,0.00013924476,0.00015221981],"category_scores_gemma":[0.0000917553,0.00017760847,0.000064233216,0.0006892738,0.00018382262,0.00007157197,0.000092066184,0.00023960417,0.0000068948625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040564474,0.0025741553,0.99382085,0.0008031069,0.00023908554,0.00070542004,0.000041386116,0.000017482409,0.000024302217,5.858061e-7,0.00037137675,0.0009965913],"study_design_scores_gemma":[0.1154414,0.0008555987,0.8807279,0.0010985533,0.00028604822,0.000030164445,0.000016252932,0.000084851505,0.0012712167,0.0000025703675,0.000033807017,0.00015166274],"about_ca_topic_score_codex":0.02895307,"about_ca_topic_score_gemma":0.21156837,"teacher_disagreement_score":0.1826153,"about_ca_system_score_codex":0.002833739,"about_ca_system_score_gemma":0.0042074225,"threshold_uncertainty_score":0.9775132},"labels":[],"label_agreement":null},{"id":"W4417004908","doi":"10.1182/blood-2025-7923","title":"Evaluating patient preferences for chronic lymphocytic leukemia (CLL) in Korea: A discrete choice experiment","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Research Group (Canada); Group for Research in Decision Analysis","funders":"","keywords":"Chronic lymphocytic leukemia; Adverse effect; Quality of life (healthcare); Dosing; Logistic regression; Atrial fibrillation; Preference","score_opus":0.04822927713616006,"score_gpt":0.3880623121763555,"score_spread":0.33983303504019546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883669,0.0049716216,0.00008264583,0.00009022275,0.00016751056,0.0022463074,0.00001067197,0.00008173898,0.0039823973],"genre_scores_gemma":[0.9956384,0.00010151143,0.0014068654,0.0001572052,0.00017074305,0.0014271997,0.000040849838,0.000032666354,0.0010245648],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973852,0.000093522525,0.0005772131,0.00063019275,0.0005980702,0.00071579113],"domain_scores_gemma":[0.9984373,0.0005637842,0.00010118568,0.00060456793,0.00014294536,0.0001502559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044615407,0.00026462655,0.00047770338,0.00026253532,0.00010702549,0.00004665879,0.00024057944,0.00015300396,0.00007400277],"category_scores_gemma":[0.0008599764,0.00022162509,0.0001437382,0.0004730151,0.00011066289,0.00008550978,0.0002077377,0.00019857011,0.000021489475],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009606895,0.006704439,0.022909664,0.023161966,0.0061291177,0.0009835672,0.022871707,0.01718917,0.3288974,0.005456443,0.008717862,0.5473718],"study_design_scores_gemma":[0.2666448,0.0054498124,0.0064236843,0.0048897658,0.0009879109,0.00013431392,0.0014380045,0.312621,0.39443257,0.0012294576,0.004829701,0.0009189913],"about_ca_topic_score_codex":0.0023960466,"about_ca_topic_score_gemma":0.00039352366,"teacher_disagreement_score":0.5464528,"about_ca_system_score_codex":0.06725929,"about_ca_system_score_gemma":0.042401396,"threshold_uncertainty_score":0.9630273},"labels":[],"label_agreement":null},{"id":"W4417004913","doi":"10.1182/blood-2025-1814","title":"Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenström's macroglobulinemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Queen Elizabeth II Health Sciences Centre; Occupational Cancer Research Centre; Health Canada; Spinal Cord Injury BC; Health Sciences North; University of Toronto; University Health Network; McGill University Health Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Tolerability; Rituximab; Clinical trial; Clinical endpoint; Toxicity; Surrogate endpoint; Adverse effect; Bone marrow","score_opus":0.012779166908002154,"score_gpt":0.3115764928566705,"score_spread":0.29879732594866837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946992,0.0021283138,0.0000047192193,0.00064482685,0.000029983454,0.00070910266,0.000019547588,0.00002728784,0.0017370498],"genre_scores_gemma":[0.9983161,0.0003403305,0.00074150774,0.000044977667,0.000035538815,0.000027920998,0.000013015239,0.000010790309,0.00046979534],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99861276,0.000051723957,0.00040843512,0.00040856062,0.00020197964,0.00031655483],"domain_scores_gemma":[0.999043,0.00032707374,0.00005015876,0.00037124014,0.00007705648,0.00013148575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021408671,0.00017622608,0.00054780755,0.00013932929,0.00003635046,0.000014864436,0.000068908674,0.00014269112,0.00003656057],"category_scores_gemma":[0.00033936682,0.00014404563,0.00004637309,0.0002879064,0.00023999234,0.000031082785,0.000109748806,0.00017013091,0.0000031307231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051757204,0.023686485,0.27847043,0.0040139337,0.0010937039,0.0015925808,0.0024756715,0.000011122012,0.019781198,0.0013378965,0.00043386678,0.6619274],"study_design_scores_gemma":[0.47097385,0.0031598487,0.44596976,0.0012259654,0.00087726343,0.0007552753,0.0003873594,0.002348962,0.07110087,0.00040825194,0.0023971796,0.00039542932],"about_ca_topic_score_codex":0.0009938679,"about_ca_topic_score_gemma":0.00018376399,"teacher_disagreement_score":0.661532,"about_ca_system_score_codex":0.0010489217,"about_ca_system_score_gemma":0.0018056018,"threshold_uncertainty_score":0.58740103},"labels":[],"label_agreement":null},{"id":"W4417005124","doi":"10.1182/blood-2025-4513","title":"Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Calgary; Alberta Health Services","funders":"","keywords":"IGHV@; Chemoimmunotherapy; Chronic lymphocytic leukemia; Rituximab; Ibrutinib; Clinical trial; Bendamustine; Venetoclax; Lymphoma","score_opus":0.02508001714647555,"score_gpt":0.3109438261423497,"score_spread":0.28586380899587416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417005124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98706436,0.0020643887,0.00032410063,0.000097349046,0.00050919526,0.002480087,0.00003846897,0.0002834193,0.0071386513],"genre_scores_gemma":[0.9837237,0.0012875077,0.0012952617,0.000066917986,0.00047738134,0.00062971446,0.00016022264,0.00008692286,0.012272397],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996965,0.00011623579,0.0008904469,0.00074567745,0.000452189,0.0008304385],"domain_scores_gemma":[0.9973189,0.00094172126,0.00031181282,0.00076010416,0.00048299343,0.00018443812],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034648972,0.0004848795,0.0009911737,0.00064842735,0.00022996984,0.0000627772,0.00025739073,0.0002935509,0.00008702829],"category_scores_gemma":[0.00033193867,0.00043185215,0.0004172934,0.0010923734,0.00024201535,0.00013348235,0.0000728048,0.00007371119,0.000035679554],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.070623584,0.0075178607,0.009429202,0.01350801,0.028418016,0.00067526486,0.005088867,0.0030618839,0.40242693,0.02529421,0.007931518,0.42602465],"study_design_scores_gemma":[0.38101986,0.0053313,0.0026036317,0.00080551225,0.0031460505,0.00019757672,0.0003878528,0.06358427,0.53465194,0.0003013283,0.00736708,0.0006035885],"about_ca_topic_score_codex":0.0078537995,"about_ca_topic_score_gemma":0.0030394853,"teacher_disagreement_score":0.42542106,"about_ca_system_score_codex":0.17819849,"about_ca_system_score_gemma":0.078953385,"threshold_uncertainty_score":0.9998133},"labels":[],"label_agreement":null},{"id":"W4417005838","doi":"10.1182/blood-2025-6317","title":"Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Venetoclax; Obinutuzumab; Regimen; Chronic lymphocytic leukemia; Rituximab; IGHV@; Bendamustine; Neutropenia; Cohort","score_opus":0.014401138527520327,"score_gpt":0.2891758793130606,"score_spread":0.27477474078554026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417005838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969298,0.00047693143,0.000028235183,0.000078264966,0.000063682935,0.0016612692,0.00007408169,0.000050652376,0.000637058],"genre_scores_gemma":[0.99577355,0.001766098,0.00013499505,0.00008843148,0.00006405271,0.0002510953,0.00018580079,0.000029972996,0.0017059972],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870765,0.00004294318,0.00039813085,0.0003127205,0.00023140639,0.00030717227],"domain_scores_gemma":[0.99898726,0.00026391234,0.00013338406,0.00034813024,0.00017126116,0.000096074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000100869824,0.00019682449,0.0004702899,0.00024291642,0.00006483204,0.000018560822,0.00007878504,0.00009740521,0.00003925958],"category_scores_gemma":[0.00005457653,0.00016492422,0.00010092178,0.00024069723,0.00008106083,0.00003419768,0.000044997953,0.00006597156,0.0000062246845],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008069029,0.005264606,0.037180234,0.006150108,0.00571358,0.00031512504,0.0033352647,0.00013710897,0.10058648,0.0031538429,0.0022540933,0.8278405],"study_design_scores_gemma":[0.28580567,0.010957761,0.2408469,0.0017950973,0.0012572106,0.000085545755,0.000097171716,0.09775875,0.35393643,0.00030517814,0.0065943133,0.0005599567],"about_ca_topic_score_codex":0.0024330071,"about_ca_topic_score_gemma":0.000092256036,"teacher_disagreement_score":0.8272806,"about_ca_system_score_codex":0.046107814,"about_ca_system_score_gemma":0.017788647,"threshold_uncertainty_score":0.98777956},"labels":[],"label_agreement":null},{"id":"W4417006971","doi":"10.1182/blood-2025-682","title":"Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Immune system; Chronic lymphocytic leukemia; Clinical endpoint; Antibody; Lymphocyte; Minimal residual disease; Surrogate endpoint; Cytokine release syndrome","score_opus":0.023856536462730945,"score_gpt":0.30188347942102073,"score_spread":0.2780269429582898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908021,0.004822142,0.00014008193,0.0003231593,0.000696616,0.0022997165,0.00012338905,0.00008336561,0.00070939993],"genre_scores_gemma":[0.99545115,0.0010422656,0.00007153858,0.00012696772,0.0007535621,0.00032493897,0.0005797314,0.000034390723,0.0016154253],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966953,0.00017656179,0.0011608189,0.0008065342,0.0005327389,0.00062807335],"domain_scores_gemma":[0.99787796,0.0006037696,0.00021936842,0.0010122657,0.00013432748,0.00015234202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079187786,0.00037550274,0.0006573921,0.00023432224,0.00023981016,0.00012717217,0.00029665173,0.00034549367,0.00013609485],"category_scores_gemma":[0.00091968314,0.00030292876,0.00019437607,0.00055480114,0.00037425727,0.0002153186,0.00023062926,0.0005050953,0.00005286251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9282796,0.0018651137,0.0020225325,0.0015692622,0.0022091058,0.0044449456,0.004051294,0.0011425015,0.011377632,0.00047854133,0.0033743184,0.03918516],"study_design_scores_gemma":[0.96500057,0.0014820938,0.0056885215,0.001877805,0.000750002,0.00017125743,0.000083768056,0.015346451,0.007704625,0.00014988316,0.0013744625,0.00037056606],"about_ca_topic_score_codex":0.0072611836,"about_ca_topic_score_gemma":0.0063499943,"teacher_disagreement_score":0.038814593,"about_ca_system_score_codex":0.06449599,"about_ca_system_score_gemma":0.043315593,"threshold_uncertainty_score":0.9999423},"labels":[],"label_agreement":null},{"id":"W4417007456","doi":"10.1182/blood-2025-3885","title":"Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Ven; Tumor lysis syndrome; Obinutuzumab; Interim analysis; Observational study; Clinical endpoint; Intention-to-treat analysis; Population","score_opus":0.03227503016688986,"score_gpt":0.3235667561014786,"score_spread":0.29129172593458874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417007456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975541,0.00051874795,0.00000272566,0.000016306445,0.00003575753,0.0012297926,0.0000051933494,0.000020365313,0.00061698933],"genre_scores_gemma":[0.9992138,0.00005573156,0.00014831737,0.000009171486,0.000024465764,0.00016499597,0.000015042874,0.000016309752,0.0003521732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980265,0.000110670364,0.00034355372,0.00035489624,0.0009051883,0.0002592304],"domain_scores_gemma":[0.9990637,0.00013277325,0.000106820924,0.00031333286,0.00030383555,0.00007955322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006335865,0.00016100603,0.00033363045,0.0003332211,0.000059067497,0.00001758573,0.000068869245,0.00008566394,0.00001843705],"category_scores_gemma":[0.00034379764,0.00013077511,0.000024837671,0.00044646693,0.00013450944,0.00014432753,0.00014140313,0.00012012381,0.0000033705826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005365184,0.00024726035,0.98688185,0.0005377884,0.00014820725,0.000017375776,0.0016254253,0.00010956003,0.0020330285,0.000021417623,0.0000064223336,0.007835144],"study_design_scores_gemma":[0.06614214,0.0005141976,0.9128425,0.0006918455,0.0002384576,0.000008040208,0.00006658804,0.007884655,0.011454227,0.0000400391,0.0000025678426,0.00011473335],"about_ca_topic_score_codex":0.0014417589,"about_ca_topic_score_gemma":0.00029256573,"teacher_disagreement_score":0.07403935,"about_ca_system_score_codex":0.04386009,"about_ca_system_score_gemma":0.0107376985,"threshold_uncertainty_score":0.9948705},"labels":[],"label_agreement":null},{"id":"W4417009796","doi":"10.1182/blood-2025-2748","title":"Real world population-based outcome analysis of small lymphocytic lymphoma (SLL) in British Columbia (BC)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Chronic lymphocytic leukemia; Lymphoma; Epidemiology; Cohort; Somatic evolution in cancer; Natural history; Survival analysis; Bone marrow; Leukemia; Incidence (geometry)","score_opus":0.01871223548760332,"score_gpt":0.29803873841165396,"score_spread":0.27932650292405065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950334,0.00018091551,0.000020514737,0.000060255985,0.00007446376,0.00049933884,0.000034938726,0.00006901013,0.004027169],"genre_scores_gemma":[0.9916881,0.000028295939,0.0007800582,0.00021088184,0.000033388704,0.000055569988,0.00019058783,0.000026687168,0.0069864844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975025,0.00010425715,0.0009042104,0.0004946375,0.0005155223,0.00047883886],"domain_scores_gemma":[0.9983818,0.00043424708,0.00014304476,0.0007196036,0.00017020965,0.00015112892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045788745,0.00014842699,0.0009341094,0.0010307619,0.0000611742,0.000086620166,0.00024696343,0.00015316802,0.0003301894],"category_scores_gemma":[0.00044024666,0.00022275616,0.00033916414,0.0045838235,0.000094957046,0.00004168194,0.00009127277,0.00011329377,0.000010067353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009850004,0.0009597908,0.9925611,0.00038027763,0.0009191618,0.00040588435,0.000027556242,0.00040808148,0.000065796485,0.00003364497,0.000106752144,0.0040334496],"study_design_scores_gemma":[0.041062146,0.00006520215,0.9131462,0.00032665403,0.0021880746,0.000012282981,0.00003223696,0.04271357,0.00018039372,0.00005108903,0.00006668317,0.00015547762],"about_ca_topic_score_codex":0.65191823,"about_ca_topic_score_gemma":0.7743412,"teacher_disagreement_score":0.12242302,"about_ca_system_score_codex":0.012734064,"about_ca_system_score_gemma":0.008558228,"threshold_uncertainty_score":0.9970623},"labels":[],"label_agreement":null},{"id":"W4417010147","doi":"10.1182/blood-2025-8013","title":"A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Venetoclax; Ibrutinib; Chemoimmunotherapy; Obinutuzumab; Chronic lymphocytic leukemia; IGHV@; Rituximab; Bruton's tyrosine kinase; Leukemia","score_opus":0.005497961082703836,"score_gpt":0.22826581225323983,"score_spread":0.222767851170536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985772,0.00022902586,0.00000983454,0.00007927533,0.0000088924135,0.0008465589,0.0000150657,0.000011930407,0.00022222743],"genre_scores_gemma":[0.9991167,0.00006718179,0.000065394706,0.00008448979,0.000012855362,0.00008647006,0.00022309362,0.000022719361,0.00032106639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982236,0.000062996696,0.000515618,0.00038718607,0.0004121014,0.00039848802],"domain_scores_gemma":[0.9989376,0.00026311525,0.0001471499,0.0004342155,0.00014263521,0.00007527474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013446997,0.00020975008,0.00060002174,0.0006965516,0.00003751978,0.000011499289,0.00012937425,0.00008745487,0.00004219746],"category_scores_gemma":[0.000090833964,0.00015489952,0.000052285875,0.0026593732,0.00005992967,0.000052418898,0.00003236577,0.00014730508,9.1235484e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019647735,0.0003221529,0.9766269,0.00021913176,0.0016389341,0.000133263,0.0002884907,0.017442022,0.00027949142,0.000004892553,0.00002233651,0.0010576294],"study_design_scores_gemma":[0.102731206,0.00055560004,0.8125186,0.00044055545,0.00078735093,0.000005724675,0.0000417136,0.07903043,0.0036743295,0.0000013805635,0.00005018424,0.00016293216],"about_ca_topic_score_codex":0.90337443,"about_ca_topic_score_gemma":0.98255485,"teacher_disagreement_score":0.16410829,"about_ca_system_score_codex":0.06538948,"about_ca_system_score_gemma":0.055470448,"threshold_uncertainty_score":0.9498842},"labels":[],"label_agreement":null},{"id":"W4417013234","doi":"10.1182/blood-2025-7442","title":"Tonsillar hypertrophy as a rare presentation of chronic lymphocytic leukemia/small lymphocytic lymphoma: A mini-review","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Chronic lymphocytic leukemia; Asymptomatic; Lymphocytosis; Histopathology; Tonsil; Respiratory distress; Leukemia","score_opus":0.014967083852141384,"score_gpt":0.29419546848224193,"score_spread":0.2792283846301005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417013234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85611326,0.124789335,0.00007479849,0.00037157495,0.00029100812,0.0024303114,0.00002422133,0.00021190029,0.015693605],"genre_scores_gemma":[0.96534073,0.023057595,0.00075990724,0.001957587,0.00031494864,0.00040610184,0.00013204732,0.0001100189,0.0079210885],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99580926,0.00021689065,0.0011566482,0.0008918015,0.0010082475,0.00091715023],"domain_scores_gemma":[0.9967248,0.00050335814,0.00029604975,0.0015819955,0.0005369739,0.0003568111],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000470972,0.00050949136,0.0013196653,0.0005096723,0.00014096934,0.00004109885,0.00056082325,0.00032677443,0.0002665155],"category_scores_gemma":[0.0012057143,0.00047691958,0.00050741935,0.0016301556,0.0003709551,0.0001359465,0.0003547995,0.00018162563,0.00032952375],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008482975,0.012443752,0.0021455977,0.29474986,0.01667773,0.01688842,0.0027234268,0.0017363757,0.14695208,0.01119138,0.059070557,0.42693785],"study_design_scores_gemma":[0.45271087,0.004460747,0.0022349993,0.048339546,0.011987259,0.011622497,0.00056755234,0.05440673,0.35712463,0.00102483,0.053322736,0.0021976219],"about_ca_topic_score_codex":0.0031156505,"about_ca_topic_score_gemma":0.000068237125,"teacher_disagreement_score":0.4442279,"about_ca_system_score_codex":0.08416069,"about_ca_system_score_gemma":0.13829994,"threshold_uncertainty_score":0.99976826},"labels":[],"label_agreement":null},{"id":"W4417014291","doi":"10.1182/blood-2025-3903","title":"Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tolerability; Clinical trial; Clinical endpoint; Prospective cohort study; Adverse effect; Cohort study; Cohort; Discontinuation","score_opus":0.02364489091999106,"score_gpt":0.3028390251495863,"score_spread":0.27919413422959527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928368,0.0014666095,0.000026266547,0.00006482864,0.000059939626,0.004013818,0.0001420086,0.00013922832,0.0012505503],"genre_scores_gemma":[0.9940924,0.0027814857,0.00048428949,0.00007347182,0.000049880822,0.0005172678,0.00044256126,0.00008943271,0.001469211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931682,0.00063375983,0.002339386,0.001517071,0.00125802,0.0010835648],"domain_scores_gemma":[0.99401957,0.0015358827,0.0010294879,0.0017157875,0.0013804497,0.0003188098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001290848,0.00080035446,0.0029936621,0.0022833862,0.00017122639,0.00006878122,0.0003874229,0.00033877185,0.00002930371],"category_scores_gemma":[0.0013825783,0.0006833214,0.00036178905,0.0064855134,0.00090215885,0.00032751882,0.00040965684,0.0002710102,0.000004830228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008977199,0.0016469593,0.93283737,0.0052679908,0.034205917,0.000339673,0.0019947076,0.00919574,0.0009111867,0.00092670316,0.0003125874,0.003383942],"study_design_scores_gemma":[0.09922389,0.0017188237,0.81364733,0.0037772602,0.024375472,0.000039180686,0.00030116973,0.037881833,0.018153794,0.000112483445,0.000071498325,0.0006972545],"about_ca_topic_score_codex":0.061686765,"about_ca_topic_score_gemma":0.03852064,"teacher_disagreement_score":0.119190045,"about_ca_system_score_codex":0.13238186,"about_ca_system_score_gemma":0.043905906,"threshold_uncertainty_score":0.9995618},"labels":[],"label_agreement":null},{"id":"W4417014736","doi":"10.1182/blood-2025-3895","title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Bruton's tyrosine kinase; Ibrutinib; Chemoimmunotherapy; Tolerability; Chronic lymphocytic leukemia; Phases of clinical research; Lymphoma","score_opus":0.01228521462498295,"score_gpt":0.2723958621389367,"score_spread":0.26011064751395374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955574,0.00071223354,0.000012460512,0.0007703197,0.00006322199,0.0021159325,0.000072401366,0.0000186671,0.00067731756],"genre_scores_gemma":[0.9994457,0.00004785058,0.000050092713,0.00013760792,0.000039854902,0.000033494714,0.000044290027,0.000017495055,0.00018362899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981492,0.00019499673,0.0005299268,0.00031789733,0.000557427,0.00025053544],"domain_scores_gemma":[0.99836797,0.0006463391,0.0001228747,0.00068926835,0.00011181022,0.00006175493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039167385,0.00018007099,0.00030213883,0.00008446068,0.00013126664,0.000017580915,0.0002102524,0.00008336972,0.00001038835],"category_scores_gemma":[0.00030439757,0.000095000796,0.000044225377,0.00050906016,0.00017609308,0.00011459548,0.00009747891,0.00038422534,0.000001754616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19179237,0.09660656,0.51842624,0.0011696569,0.0028754123,0.0004182898,0.10711997,0.0002834767,0.0024260532,0.00016075929,0.0022871885,0.07643403],"study_design_scores_gemma":[0.27296618,0.0017648762,0.7200611,0.0009225012,0.00040607475,0.0000051873694,0.00073103176,0.00023926113,0.0023766533,0.0000067894243,0.00041697832,0.00010333919],"about_ca_topic_score_codex":0.0008541336,"about_ca_topic_score_gemma":0.0001815231,"teacher_disagreement_score":0.2016349,"about_ca_system_score_codex":0.0007345931,"about_ca_system_score_gemma":0.0012800993,"threshold_uncertainty_score":0.387402},"labels":[],"label_agreement":null},{"id":"W4417014766","doi":"10.1182/blood-2025-3898","title":"Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Amorfix (Canada); University of British Columbia Hospital","funders":"","keywords":"Chemoimmunotherapy; Obinutuzumab; Fludarabine; IGHV@; Bendamustine; Rituximab; Chronic lymphocytic leukemia; Exploratory analysis; Cyclophosphamide","score_opus":0.02722216714397908,"score_gpt":0.35542961506980825,"score_spread":0.3282074479258292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979091,0.00008896456,0.00041581623,0.00012070939,0.00004079881,0.00063733425,0.000093138355,0.00007389411,0.0006201979],"genre_scores_gemma":[0.99826294,0.000015345922,0.00048897846,0.00004774391,0.000022288952,0.00013547919,0.000843137,0.000022664142,0.00016140274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853027,0.00009820436,0.00036622534,0.0003241015,0.00044663996,0.00023458207],"domain_scores_gemma":[0.9980714,0.00071923307,0.00013764318,0.00067446526,0.00029163176,0.00010563923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014288524,0.00018764271,0.0004488898,0.0004977006,0.00010155122,0.000035742913,0.00015444224,0.00012030948,0.00014454973],"category_scores_gemma":[0.00035348197,0.00014141531,0.00018913855,0.0013681238,0.00013297338,0.00012305859,0.000026567219,0.00020115824,0.00001503147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061000837,0.014196553,0.9115022,0.00018625545,0.038474437,0.00010041024,0.0040519163,0.0034905388,0.016088353,0.0017302684,0.0002781342,0.0038008865],"study_design_scores_gemma":[0.083067976,0.0023712767,0.8928807,0.00013715016,0.004614689,0.0000029479843,0.000609381,0.005514833,0.010423049,0.00013883795,0.000022906916,0.00021630376],"about_ca_topic_score_codex":0.0011241438,"about_ca_topic_score_gemma":0.00036215314,"teacher_disagreement_score":0.07696789,"about_ca_system_score_codex":0.0025797398,"about_ca_system_score_gemma":0.005541795,"threshold_uncertainty_score":0.9830906},"labels":[],"label_agreement":null},{"id":"W4417015225","doi":"10.1182/blood-2025-8041","title":"Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Ibrutinib; Discontinuation; Adverse effect; Hazard ratio; Confidence interval; Retrospective cohort study; Bruton's tyrosine kinase","score_opus":0.030243247330094272,"score_gpt":0.3427940132156911,"score_spread":0.3125507658855968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417015225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481416,0.000055451022,0.0000060955226,0.00014857504,0.000049822327,0.0016142424,0.00008391722,0.00005183887,0.0031758724],"genre_scores_gemma":[0.99830693,0.00030514537,0.00027298857,0.00013744891,0.000024216679,0.00014359961,0.00023371643,0.000030144543,0.0005458262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783045,0.00048218702,0.00054423854,0.00030092653,0.00035486757,0.00048734562],"domain_scores_gemma":[0.9976363,0.0009999264,0.00017516785,0.0008209827,0.00022832726,0.00013925385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037387887,0.0002526137,0.00070754526,0.0003597325,0.0000940751,0.000010948669,0.0002391984,0.00016351692,0.000121039404],"category_scores_gemma":[0.00019197863,0.00018091407,0.00008624546,0.00078938354,0.00023014871,0.0000535408,0.00011988272,0.00043911196,0.0000049689925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019216662,0.0108427955,0.9731076,0.00014055647,0.00040377586,0.000066590444,0.001347936,0.0000044613694,0.0001502379,0.00003571213,0.000050011102,0.011928683],"study_design_scores_gemma":[0.12044344,0.002869208,0.8660646,0.00038893064,0.00013745573,0.0000043249597,0.00020669778,0.0001283632,0.008709291,0.000023945631,0.00089569204,0.00012801729],"about_ca_topic_score_codex":0.13368252,"about_ca_topic_score_gemma":0.04391953,"teacher_disagreement_score":0.11852177,"about_ca_system_score_codex":0.00507025,"about_ca_system_score_gemma":0.0049725706,"threshold_uncertainty_score":0.99874914},"labels":[],"label_agreement":null},{"id":"W4417016636","doi":"10.1182/blood-2025-7934","title":"Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Population; Acute lymphocytic leukemia; Clinical trial; Venetoclax; Randomized controlled trial","score_opus":0.11686154192662304,"score_gpt":0.39647440940937034,"score_spread":0.2796128674827473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710363,0.00086957484,0.000028997816,0.0001340086,0.00015095195,0.0013245896,0.00007775329,0.000037010825,0.00027345467],"genre_scores_gemma":[0.99663997,0.00202685,0.000045101,0.00050585065,0.00014986645,0.0003151173,0.00020422167,0.000031214156,0.00008180881],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968037,0.0005008096,0.00073481764,0.00059282046,0.00086624234,0.00050159707],"domain_scores_gemma":[0.996613,0.002025221,0.00020515769,0.00073869835,0.00020066866,0.0002172551],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046581973,0.00039675363,0.00073100335,0.00030831568,0.00023712257,0.00008826022,0.00018190387,0.000246131,0.00006027763],"category_scores_gemma":[0.0010007545,0.00024559928,0.00020997219,0.0005912293,0.0004440855,0.00017546497,0.000084938285,0.00015719203,0.0000060854372],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011875617,0.02709898,0.3947614,0.0023071235,0.010092116,0.0016655846,0.03936607,0.04500064,0.013713991,0.003816987,0.0021293873,0.4481721],"study_design_scores_gemma":[0.21111387,0.005411021,0.5721274,0.0021252374,0.00037333756,0.00006563451,0.0005353499,0.14763454,0.05924962,0.000101023776,0.0006269317,0.00063601835],"about_ca_topic_score_codex":0.005985941,"about_ca_topic_score_gemma":0.00043726785,"teacher_disagreement_score":0.44753605,"about_ca_system_score_codex":0.09243325,"about_ca_system_score_gemma":0.03837262,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W4417018713","doi":"10.1182/blood-2025-6285","title":"Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Retrospective cohort study; Chronic lymphocytic leukemia; Proportional hazards model; Cohort; Dosing; Cancer; Cohort study; Medical record; Survival analysis","score_opus":0.016122677369151454,"score_gpt":0.30544765046374334,"score_spread":0.2893249730945919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959928,0.0000809529,0.0000013668183,0.000056653098,0.00012298649,0.00060833,0.00002176837,0.000040018196,0.0030751657],"genre_scores_gemma":[0.99476576,0.00015760913,0.00020235576,0.00020301096,0.00004561509,0.000049131202,0.000018055205,0.000022650684,0.004535832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998436,0.000044383065,0.0004203325,0.00030568722,0.00044028304,0.0003533346],"domain_scores_gemma":[0.9989078,0.0002332972,0.00008832884,0.0004526216,0.00018453544,0.00013340182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018190999,0.00017524263,0.00041138427,0.00026159917,0.000052915602,0.000024830684,0.000112143156,0.00009546213,0.000077685014],"category_scores_gemma":[0.00027411178,0.00014318553,0.00008216734,0.0002997243,0.00025091547,0.000158335,0.00021409792,0.00019705444,0.00001584371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005277054,0.0006786274,0.9954895,0.00059119635,0.0001669546,0.000045856556,0.00016106218,4.808665e-7,0.0000356329,0.00002919378,0.00021518202,0.0020586113],"study_design_scores_gemma":[0.032746844,0.0002444307,0.9605439,0.00042491173,0.00024836522,0.0000038957537,0.00001739152,0.000297867,0.004925025,0.00000610676,0.00042707627,0.000114234084],"about_ca_topic_score_codex":0.00091810524,"about_ca_topic_score_gemma":0.00029074776,"teacher_disagreement_score":0.034945644,"about_ca_system_score_codex":0.0006738931,"about_ca_system_score_gemma":0.0013618116,"threshold_uncertainty_score":0.58389366},"labels":[],"label_agreement":null},{"id":"W4417018866","doi":"10.1182/blood-2025-6286","title":"Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Regimen; Chronic lymphocytic leukemia; Refractory (planetary science); Population; Ibrutinib; Venetoclax; Clinical trial; Dosing; Disease","score_opus":0.03675936140701149,"score_gpt":0.3451197157795975,"score_spread":0.308360354372586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98732936,0.00010942994,0.000005812439,0.000073869,0.000037550275,0.00051244406,0.000005795711,0.000013366656,0.011912374],"genre_scores_gemma":[0.999397,0.00002646921,0.00016057708,0.000066911394,0.000010635712,0.000021238311,0.00001078071,0.000009331244,0.00029707648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846613,0.000120038574,0.0002681586,0.00016634085,0.00084605574,0.00013328668],"domain_scores_gemma":[0.9988482,0.00028680835,0.000094887444,0.0003080937,0.0004228122,0.00003920315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009016374,0.000089133915,0.00026678928,0.00025374137,0.000023918183,0.0000047882445,0.000059419544,0.00004880227,0.00004201215],"category_scores_gemma":[0.0005775226,0.00006873065,0.000051510797,0.00024795558,0.000106283915,0.00003207419,0.000030796087,0.00007710061,0.0000010429297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013530623,0.00068571087,0.98588043,0.0004467887,0.00030042737,0.000003450581,0.00044523343,0.000083598534,0.0014648166,0.00016261627,0.00006784813,0.010323745],"study_design_scores_gemma":[0.042760935,0.00026399104,0.90459347,0.0005764299,0.0005808032,3.4437355e-7,0.00011350893,0.018083401,0.032724556,0.00022595176,0.00001204678,0.00006458657],"about_ca_topic_score_codex":0.0016537021,"about_ca_topic_score_gemma":0.0002860213,"teacher_disagreement_score":0.08128701,"about_ca_system_score_codex":0.0016269819,"about_ca_system_score_gemma":0.0030323698,"threshold_uncertainty_score":0.5379294},"labels":[],"label_agreement":null},{"id":"W4417019462","doi":"10.1182/blood-2025-3559","title":"Spatial profiling of the bone marrow microenvironment in patients with IgM gammopathies reveals a T cell–Enriched tumor niche associated with asymptomatic waldenstrom macroglobulinemia progression","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Integrity Testing Laboratory (Canada)","funders":"","keywords":"Waldenstrom macroglobulinemia; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Bone marrow; Asymptomatic; Macroglobulinemia; Immunoglobulin M; Monoclonal","score_opus":0.004096862065782521,"score_gpt":0.22378071027191812,"score_spread":0.2196838482061356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673706,0.00035196322,0.000014601,0.00017934208,0.00003716755,0.0023406353,0.000019168534,0.000035483423,0.0002845931],"genre_scores_gemma":[0.9975744,0.000008594327,0.0017130906,0.00008721187,0.000020137019,0.00014621684,0.000047227786,0.00003800649,0.00036513983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973108,0.00020275256,0.00057724863,0.00042908062,0.0009698386,0.0005102492],"domain_scores_gemma":[0.99863166,0.00014842063,0.00035860037,0.0006227511,0.00014505725,0.00009349063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043972133,0.0002732002,0.0005717155,0.00014597343,0.0000790087,0.000023339482,0.00023315006,0.00012072593,0.000021594402],"category_scores_gemma":[0.00034698818,0.00015807307,0.00007733833,0.00061527075,0.00024032593,0.0000521267,0.00021731248,0.00039529457,0.0000036666065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012071426,0.0037791254,0.9645076,0.0009765444,0.00020734794,0.00014334307,0.0003007695,0.00002216497,0.028229995,0.0000037923596,0.000074744836,0.000547461],"study_design_scores_gemma":[0.0784837,0.0010534249,0.75928205,0.004757959,0.0005745468,0.00003347702,0.00016833328,0.0008047087,0.15458028,0.000022478152,0.000005557949,0.00023350702],"about_ca_topic_score_codex":0.00011063723,"about_ca_topic_score_gemma":0.00005598142,"teacher_disagreement_score":0.20522554,"about_ca_system_score_codex":0.0024069515,"about_ca_system_score_gemma":0.0020876469,"threshold_uncertainty_score":0.64460325},"labels":[],"label_agreement":null},{"id":"W4417019600","doi":"10.1182/blood-2025-3570","title":"Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Ibrutinib; Chemoimmunotherapy; Idelalisib; Follicular lymphoma; Cohort; Mantle cell lymphoma; Refractory (planetary science); Bruton's tyrosine kinase; Phases of clinical research","score_opus":0.02038115090320793,"score_gpt":0.32389404522471726,"score_spread":0.30351289432150935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631274,0.00052943616,0.000005658933,0.00014866487,0.000056638884,0.0022229082,0.000025993058,0.000033508346,0.0006644543],"genre_scores_gemma":[0.9989378,0.00006784865,0.00007970671,0.00010760314,0.00002902828,0.00006120063,0.000028969891,0.000026242758,0.0006616371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977235,0.0002545377,0.0005514651,0.0004855155,0.0005524718,0.00043251424],"domain_scores_gemma":[0.9982881,0.0004215101,0.00012389463,0.00093374104,0.00009061383,0.00014216473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005867421,0.00021182152,0.00060241617,0.000121332225,0.000090283545,0.000015274387,0.00021481821,0.00012143457,0.00008365207],"category_scores_gemma":[0.00056024606,0.000122018595,0.000049400216,0.0008371172,0.0002192285,0.000049897466,0.00020660821,0.00021226371,0.000004735441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047598153,0.073360935,0.83430254,0.0004105619,0.0060479287,0.0037711156,0.0058425684,0.000033572225,0.015536392,0.00008556271,0.0010993271,0.011911357],"study_design_scores_gemma":[0.4287263,0.0014409212,0.5501552,0.0005922431,0.0016082685,0.000040613424,0.00084598205,0.0006611297,0.014616117,0.000013339218,0.0011170934,0.00018277476],"about_ca_topic_score_codex":0.0020247526,"about_ca_topic_score_gemma":0.0006635498,"teacher_disagreement_score":0.38112813,"about_ca_system_score_codex":0.0010712215,"about_ca_system_score_gemma":0.0048341667,"threshold_uncertainty_score":0.85756046},"labels":[],"label_agreement":null},{"id":"W4417020279","doi":"10.1182/blood-2025-3612","title":"A retrospective population-based study of long-term treatments and outcomes inwaldenstrom macroglobulinemia in Ontario, Canada","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; McMaster University; University of Toronto","funders":"","keywords":"Waldenstrom macroglobulinemia; Rituximab; Lymphoplasmacytic Lymphoma; Macroglobulinemia; Retrospective cohort study; Ibrutinib; Lymphoma; Chemotherapy regimen; Survival analysis; Cohort","score_opus":0.010375265890168154,"score_gpt":0.2864919621207499,"score_spread":0.27611669623058177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986785,0.00006463024,7.978133e-7,0.000077229386,0.0000440443,0.00083266146,0.000010854036,0.000010171978,0.0002811258],"genre_scores_gemma":[0.9987121,0.0000012951097,0.000059645266,0.000057666726,0.0000065058402,0.000036355876,0.00003097539,0.000008739486,0.0010867148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988615,0.00003288509,0.0002893684,0.00026555272,0.0003503207,0.00020039386],"domain_scores_gemma":[0.99943966,0.000076635,0.000054795637,0.0002938744,0.00006497947,0.000070078124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007132279,0.0001299759,0.00040005465,0.00013886018,0.000030819716,0.000008100862,0.00006653247,0.000052112497,0.000032950375],"category_scores_gemma":[0.00009378222,0.00010992208,0.000029161154,0.00021533905,0.000020138948,0.000019954054,0.000048942507,0.00014876088,6.4279124e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012773277,0.0016592125,0.99692774,0.00005821644,0.0002844179,0.0005254591,0.00017283674,0.000006908158,0.00002618042,0.000004980467,0.000016941003,0.00018940603],"study_design_scores_gemma":[0.056097783,0.00026779348,0.9427925,0.000116305906,0.00023267136,0.000009750772,0.00009728902,0.000060263563,0.00025460165,0.000008277178,7.420756e-7,0.00006206355],"about_ca_topic_score_codex":0.99352914,"about_ca_topic_score_gemma":0.9983411,"teacher_disagreement_score":0.05597005,"about_ca_system_score_codex":0.013745254,"about_ca_system_score_gemma":0.010082948,"threshold_uncertainty_score":0.99552894},"labels":[],"label_agreement":null},{"id":"W4417076368","doi":"10.1093/ajcp/aqaf120","title":"Reply to “Methylation-based droplet digital polymerase chain reaction shows high concordance with chronic lymphocytic leukemia <i>IGHV</i> somatic mutation status”","year":2025,"lang":"en","type":"letter","venue":"American Journal of Clinical Pathology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Genome Canada; University of Toronto; University Health Network","funders":"","keywords":"Digital polymerase chain reaction; Chronic lymphocytic leukemia; Concordance; Polymerase chain reaction; Somatic cell; Mutation; Germline mutation","score_opus":0.019168328902893366,"score_gpt":0.34197096831888196,"score_spread":0.3228026394159886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417076368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7498894,0.00052007794,0.015127194,0.22976495,0.0019854326,0.0017926092,0.00024685604,0.00014742304,0.0005260595],"genre_scores_gemma":[0.54076684,0.00016825883,0.003144256,0.44869167,0.0049528135,0.000069355374,0.0005562909,0.0001574441,0.0014930925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912298,0.0012321027,0.0036402245,0.0010751268,0.0016447336,0.0011780557],"domain_scores_gemma":[0.9861642,0.0069968402,0.0037319937,0.0012776688,0.0011268989,0.00070240896],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001811883,0.00071295287,0.003308645,0.0009776538,0.000116776355,0.00009639763,0.00054681057,0.00068792334,0.000076624834],"category_scores_gemma":[0.005559285,0.00056908815,0.00069615646,0.0011838109,0.0015783501,0.00025110226,0.000112046306,0.0038115252,0.000101057194],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.023752201,0.0005455801,0.0037932748,0.0024315966,0.0026563434,0.10627592,0.0005271306,0.006966538,0.0013632405,0.000030625917,0.5354609,0.31619665],"study_design_scores_gemma":[0.15671834,0.105405696,0.008698897,0.011055945,0.0050854827,0.031224553,0.00074879575,0.03144754,0.0022614216,0.000550983,0.6430435,0.0037588603],"about_ca_topic_score_codex":0.0013957468,"about_ca_topic_score_gemma":0.0000523068,"teacher_disagreement_score":0.3124378,"about_ca_system_score_codex":0.047544487,"about_ca_system_score_gemma":0.11819313,"threshold_uncertainty_score":0.99967605},"labels":[],"label_agreement":null},{"id":"W4417078037","doi":"10.1056/nejmoa2515458","title":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Janssen Biotech; Deutsche Forschungsgemeinschaft; AbbVie; Roche","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Chemoimmunotherapy; Leukemia; Clinical trial","score_opus":0.03444802679049667,"score_gpt":0.3530854083266298,"score_spread":0.31863738153613314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417078037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92805254,0.023088623,0.012961323,0.01472899,0.006084482,0.0021665292,0.000010053872,0.00009068874,0.01281674],"genre_scores_gemma":[0.9786012,0.0017872046,0.0007794857,0.0003715819,0.0075560967,0.000017697455,0.000028391089,0.000029146799,0.010829172],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99795115,0.000066815795,0.0008320761,0.00021478086,0.00054648955,0.000388689],"domain_scores_gemma":[0.99750507,0.0010863546,0.00030551292,0.00031633137,0.0004381955,0.00034853705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079347135,0.00023104541,0.00080924144,0.00038783255,0.00008421784,0.000017089485,0.00016298119,0.00012887816,0.00017413074],"category_scores_gemma":[0.0014555707,0.0001469933,0.00018717439,0.00030707268,0.000149717,0.00008692393,0.000022496848,0.00020592517,0.000009496939],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.039470788,0.00010652525,0.00024139695,0.000595077,0.0017739094,0.00093772245,0.0013105428,0.0009267421,0.012285312,0.0016362258,0.09291775,0.847798],"study_design_scores_gemma":[0.66667646,0.013810401,0.00018843923,0.0012390898,0.0010674824,0.001358778,0.00022287392,0.011611979,0.006481017,0.0003799411,0.2968341,0.0001294415],"about_ca_topic_score_codex":0.00075356715,"about_ca_topic_score_gemma":0.00016300326,"teacher_disagreement_score":0.8476686,"about_ca_system_score_codex":0.083673015,"about_ca_system_score_gemma":0.051730487,"threshold_uncertainty_score":0.95364535},"labels":[],"label_agreement":null},{"id":"W610485528","doi":"10.1182/blood-2014-12-618678","title":"Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; Sunnybrook Hospital","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Stromal cell; Toll-like receptor; Signal transduction; Immunology; Cancer research; Biology; Leukemia; Interleukin-1 receptor; Receptor; Cell biology; Interleukin 3; Cytokine; Interleukin; Immune system; Antigen-presenting cell; T cell; Innate immune system","score_opus":0.03197391298599731,"score_gpt":0.2929792186043396,"score_spread":0.2610053056183423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W610485528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921078,0.0007812321,0.000015420854,0.000120766745,0.00024008774,0.00063096575,0.000024448067,0.00008247194,0.005996792],"genre_scores_gemma":[0.9918947,0.00008337513,0.0023172526,0.00038710862,0.00038385918,0.000059921902,0.0001166285,0.000083388506,0.0046737595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99722505,0.00011311552,0.00055411254,0.00062367466,0.0007214446,0.00076259614],"domain_scores_gemma":[0.99873805,0.00011867838,0.00010206172,0.0006476556,0.00004920324,0.00034432218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003679319,0.00032629262,0.00052157574,0.00015174608,0.00007260471,0.000053417098,0.00036273038,0.00022083322,0.00068667595],"category_scores_gemma":[0.000069374604,0.00030605312,0.00013842196,0.00024078158,0.00025346305,0.00020531955,0.0003135398,0.00048173207,0.00043201662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032470314,0.001370279,0.0018975589,0.00019605462,0.00016932267,0.00079773297,0.0030602068,0.00007768158,0.96048576,0.000019081452,0.031435456,0.00016617693],"study_design_scores_gemma":[0.0472951,0.00056637207,0.0001722164,0.00035924447,0.0001346131,0.00039330803,0.0014915576,0.0001091729,0.9127701,0.000074716794,0.036259014,0.00037456726],"about_ca_topic_score_codex":0.0012899637,"about_ca_topic_score_gemma":0.00009611933,"teacher_disagreement_score":0.047715634,"about_ca_system_score_codex":0.010337586,"about_ca_system_score_gemma":0.002390327,"threshold_uncertainty_score":0.99993914},"labels":[],"label_agreement":null},{"id":"W611905905","doi":"10.2119/molmed.2015.00139","title":"A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo","year":2015,"lang":"en","type":"article","venue":"Molecular Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Chronic lymphocytic leukemia; Peroxisome proliferator-activated receptor; Biology; Cancer research; Apoptosis; Downregulation and upregulation; Cell growth; Cell biology; Receptor; Peroxisome; Leukemia; Immunology; Biochemistry; Gene","score_opus":0.023524992786516433,"score_gpt":0.28751705633317653,"score_spread":0.2639920635466601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W611905905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962991,0.0006771374,0.000070281334,0.0011767132,0.000060181967,0.0013338443,0.000012614571,0.000022944425,0.0003472164],"genre_scores_gemma":[0.9986507,0.00010129192,0.00060283684,0.0003406044,0.00008342917,0.000096773605,0.000030285495,0.000038633505,0.000055416745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99775577,0.0001383429,0.00055433536,0.00049887865,0.00066013145,0.00039257336],"domain_scores_gemma":[0.99891764,0.00009265423,0.00013239718,0.00024246454,0.00028961815,0.0003252129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076514843,0.0002561148,0.00069251435,0.00052465015,0.000028179491,0.000014652141,0.00007640021,0.00020894373,0.000011253766],"category_scores_gemma":[0.0007689727,0.00021170567,0.000024092613,0.0008680127,0.00034506514,0.00012756544,0.00008865378,0.0003877819,0.0000015016617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020785646,0.00026826895,0.0010664271,0.0003025474,0.00004423102,0.000037184313,0.0027410197,0.000008628084,0.9930443,0.000020736064,0.00010145358,0.00028659453],"study_design_scores_gemma":[0.026206568,0.0009079298,0.0006902683,0.000538855,0.00003462482,0.00007771313,0.0007108458,0.0016488386,0.968893,0.000027656268,0.00009751326,0.00016617124],"about_ca_topic_score_codex":0.000856844,"about_ca_topic_score_gemma":0.000036094618,"teacher_disagreement_score":0.024151329,"about_ca_system_score_codex":0.0022245506,"about_ca_system_score_gemma":0.0020847477,"threshold_uncertainty_score":0.8633107},"labels":[],"label_agreement":null},{"id":"W655102247","doi":"10.1684/hma.2013.0806","title":"Compte rendu","year":2013,"lang":"fr","type":"article","venue":"Hématologie","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Humanities; Philosophy","score_opus":0.056077615831738765,"score_gpt":0.33335782294985394,"score_spread":0.2772802071181152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W655102247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4572085,0.14373504,0.00055418926,0.049769644,0.010060089,0.0024517456,0.000033475386,0.0006107816,0.3355765],"genre_scores_gemma":[0.8718817,0.0038309523,0.002356223,0.0014363837,0.0011204256,0.00014562474,0.000032852662,0.00007472532,0.11912109],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967137,0.00019138795,0.0004996194,0.0005086006,0.00057564734,0.001511035],"domain_scores_gemma":[0.9974361,0.000705504,0.00009217736,0.0009831677,0.00022194516,0.00056111714],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003468617,0.00030579529,0.00061082025,0.00012964936,0.00011023603,0.00008597428,0.00042166258,0.00045381102,0.022055821],"category_scores_gemma":[0.0010235417,0.00026904343,0.00017061523,0.00037462355,0.00078242423,0.00022494007,0.0003603935,0.0006130007,0.08183842],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006116296,0.00035866862,0.0042987475,0.0013225524,0.00024888772,0.0022367772,0.00026502783,0.000021066955,0.00071775087,0.019294532,0.87994814,0.09122668],"study_design_scores_gemma":[0.023581808,0.0006133976,0.009453046,0.0017945977,0.00026610697,0.0058343103,0.0010835563,0.076641135,0.008163928,0.0059435708,0.8657715,0.00085307215],"about_ca_topic_score_codex":0.004330091,"about_ca_topic_score_gemma":0.000024858335,"teacher_disagreement_score":0.4146732,"about_ca_system_score_codex":0.011474337,"about_ca_system_score_gemma":0.0064720144,"threshold_uncertainty_score":0.99997616},"labels":[],"label_agreement":null},{"id":"W6901786172","doi":"10.60692/tryvg-yh212","title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Thrombosis; Chronic lymphocytic leukemia; Multivariate analysis; Retrospective cohort study; Risk factor; Low molecular weight heparin; Complication","score_opus":0.10766314307749897,"score_gpt":0.311977987549596,"score_spread":0.20431484447209702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901786172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940329,0.000009284632,0.00008249108,0.000058237354,0.000023893786,0.00241823,0.000038322007,0.000039475934,0.0032971608],"genre_scores_gemma":[0.99949986,5.628656e-7,0.000011002186,0.00015551926,0.000018714016,0.00025516396,0.000021042644,0.000016637641,0.000021476184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719787,0.0007393419,0.0005295044,0.00022787873,0.00100598,0.00029939882],"domain_scores_gemma":[0.99877936,0.00015720996,0.00021148416,0.00046074402,0.00023293901,0.00015824124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019908666,0.0001428167,0.0002767672,0.00054678094,0.00051106006,0.00006721718,0.00018348433,0.000026832558,0.000012681917],"category_scores_gemma":[0.00012649993,0.00009486462,0.000017566928,0.00077708624,0.00019942256,0.00019121452,0.00035682606,0.0003238016,0.00002292227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015075749,0.00006268255,0.53547174,0.0020682467,0.000220011,0.00003859041,0.44962892,0.010142589,0.0000013855179,0.00033469655,0.00014374404,0.00037982193],"study_design_scores_gemma":[0.036941983,0.0028129374,0.80364615,0.0003082746,0.00004909714,0.00010029333,0.12438356,0.031552058,0.0000057221387,0.0000016533454,0.00005897371,0.00013930791],"about_ca_topic_score_codex":0.0004468232,"about_ca_topic_score_gemma":0.00000787257,"teacher_disagreement_score":0.32524535,"about_ca_system_score_codex":0.0377196,"about_ca_system_score_gemma":0.0044952356,"threshold_uncertainty_score":0.96597445},"labels":[],"label_agreement":null},{"id":"W6902221626","doi":"10.6084/m9.figshare.27314727.v1","title":"Additional file 1 of Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Signal transduction; Tyrosine kinase; Kinase; Proto-oncogene tyrosine-protein kinase Src; MAP kinase kinase kinase; JAK-STAT signaling pathway; Pathway analysis; Receptor tyrosine kinase","score_opus":0.03943518201581493,"score_gpt":0.28842079539084425,"score_spread":0.24898561337502934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902221626","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027436954,0.0004620421,2.2542451e-7,0.00004472231,0.00005312151,0.00034118033,0.99075234,0.00018509844,0.0054176026],"genre_scores_gemma":[0.13902593,5.0932834e-7,0.0001728364,0.00007620246,0.0011714809,0.0006189273,0.8538308,0.000058578655,0.0050447476],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798346,0.000034000128,0.00041985343,0.00046786826,0.0006574693,0.0004373585],"domain_scores_gemma":[0.9976069,0.0014841763,0.000082501225,0.000334695,0.00026000376,0.00023172774],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006143325,0.00023325584,0.0003308121,0.00018256548,0.00011453812,0.00006795691,0.00018376666,0.0001775587,0.99406534],"category_scores_gemma":[0.0030927768,0.00021217662,0.00024440786,0.00036735088,0.000048495887,0.00008186181,0.0002194463,0.0003815827,0.0035323335],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045440407,0.00011010034,4.915162e-7,0.0011481723,0.000060178376,0.0011113399,0.000080818536,0.0000017684152,0.0097013,0.0000071270188,0.9865891,0.0011441762],"study_design_scores_gemma":[0.002266615,0.0002729911,0.000062103805,0.020162562,0.000034470617,0.00035393197,0.000030903586,0.0024149609,0.043402206,0.000039088707,0.9307191,0.00024108941],"about_ca_topic_score_codex":0.000042506515,"about_ca_topic_score_gemma":0.000015838756,"teacher_disagreement_score":0.990533,"about_ca_system_score_codex":0.002479106,"about_ca_system_score_gemma":0.0053587565,"threshold_uncertainty_score":0.9972435},"labels":[],"label_agreement":null},{"id":"W6920461138","doi":"10.60692/hm55f-6ca88","title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Thrombosis; Chronic lymphocytic leukemia; Multivariate analysis; Retrospective cohort study; Risk factor; Low molecular weight heparin; Complication","score_opus":0.10766314307749897,"score_gpt":0.311977987549596,"score_spread":0.20431484447209702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920461138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940329,0.000009284632,0.00008249108,0.000058237354,0.000023893786,0.00241823,0.000038322007,0.000039475934,0.0032971608],"genre_scores_gemma":[0.99949986,5.628656e-7,0.000011002186,0.00015551926,0.000018714016,0.00025516396,0.000021042644,0.000016637641,0.000021476184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719787,0.0007393419,0.0005295044,0.00022787873,0.00100598,0.00029939882],"domain_scores_gemma":[0.99877936,0.00015720996,0.00021148416,0.00046074402,0.00023293901,0.00015824124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019908666,0.0001428167,0.0002767672,0.00054678094,0.00051106006,0.00006721718,0.00018348433,0.000026832558,0.000012681917],"category_scores_gemma":[0.00012649993,0.00009486462,0.000017566928,0.00077708624,0.00019942256,0.00019121452,0.00035682606,0.0003238016,0.00002292227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015075749,0.00006268255,0.53547174,0.0020682467,0.000220011,0.00003859041,0.44962892,0.010142589,0.0000013855179,0.00033469655,0.00014374404,0.00037982193],"study_design_scores_gemma":[0.036941983,0.0028129374,0.80364615,0.0003082746,0.00004909714,0.00010029333,0.12438356,0.031552058,0.0000057221387,0.0000016533454,0.00005897371,0.00013930791],"about_ca_topic_score_codex":0.0004468232,"about_ca_topic_score_gemma":0.00000787257,"teacher_disagreement_score":0.32524535,"about_ca_system_score_codex":0.0377196,"about_ca_system_score_gemma":0.0044952356,"threshold_uncertainty_score":0.96597445},"labels":[],"label_agreement":null},{"id":"W6920592272","doi":"10.60692/8ck3k-vds92","title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Chronic lymphocytic leukemia; Thrombosis; Retrospective cohort study; Complication; Severe bleeding; Multicenter study; Coagulopathy","score_opus":0.09922945006150843,"score_gpt":0.30651153913051693,"score_spread":0.2072820890690085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920592272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405515,0.000009069368,0.00004863355,0.00005921804,0.000025749003,0.002459587,0.000048564885,0.000040462288,0.003253585],"genre_scores_gemma":[0.99949837,5.803938e-7,0.00001195786,0.00016465632,0.00001877876,0.00023912304,0.000023971435,0.000017322502,0.000025231682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971692,0.00074360153,0.00052699825,0.00023498334,0.0010204224,0.00030482316],"domain_scores_gemma":[0.99875635,0.000158924,0.00021508409,0.000466694,0.00024182118,0.00016113886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018608388,0.00014920389,0.00028354352,0.0005150493,0.0005236963,0.00006853051,0.00018775255,0.000029139917,0.000015038081],"category_scores_gemma":[0.00012121167,0.00009967593,0.000018235061,0.0007722284,0.00018238614,0.00020651892,0.00037264675,0.00033839166,0.000023651759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015235841,0.000057379453,0.56142193,0.0021649364,0.00022264416,0.00003881927,0.4232852,0.0105160605,0.0000010603652,0.0002574005,0.00015071628,0.0003602695],"study_design_scores_gemma":[0.039234314,0.002706937,0.80123186,0.00034741766,0.000051888415,0.00016130839,0.1341571,0.021887593,0.0000040352866,0.0000017960122,0.00006115676,0.00015461995],"about_ca_topic_score_codex":0.00043966432,"about_ca_topic_score_gemma":0.000008752148,"teacher_disagreement_score":0.2891281,"about_ca_system_score_codex":0.038485993,"about_ca_system_score_gemma":0.004647607,"threshold_uncertainty_score":0.9652051},"labels":[],"label_agreement":null},{"id":"W6920831459","doi":"10.6084/m9.figshare.26564556","title":"Additional file 2 of Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chronic lymphocytic leukemia; Repertoire; Leukemia; Immune system; T lymphocyte; Antibody","score_opus":0.02117654333946562,"score_gpt":0.2688899271000171,"score_spread":0.24771338376055146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920831459","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007894148,0.00089156156,5.70994e-7,0.000020962332,0.000054988122,0.00029751568,0.99255437,0.00006983475,0.00532081],"genre_scores_gemma":[0.07405228,0.000011958052,0.00015838808,0.000057712903,0.0003733876,0.0006687146,0.9181551,0.0000450433,0.006477415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981429,0.00003518539,0.00045055724,0.00037001545,0.000688454,0.0003128633],"domain_scores_gemma":[0.99750346,0.0017942794,0.00009121186,0.00031391048,0.00018675173,0.00011041014],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000053459273,0.00016525747,0.00031731537,0.0003427271,0.000026241249,0.000013815996,0.00013977634,0.00018741353,0.9914974],"category_scores_gemma":[0.0016643591,0.00015257987,0.00018720438,0.0006482957,0.000047074434,0.00011646368,0.000102726306,0.00024183358,0.0032917724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00008227038,0.00001864684,3.8814213e-7,0.0021267328,0.00004839531,0.00019378944,0.000027988968,0.0004045678,0.0012682987,0.000012478776,0.9941915,0.0016249061],"study_design_scores_gemma":[0.002778913,0.00025624954,0.00038646345,0.021118786,0.000016373759,0.00028198992,0.000022844652,0.1106399,0.008852089,0.000028834245,0.85545707,0.00016046739],"about_ca_topic_score_codex":0.00020042033,"about_ca_topic_score_gemma":0.000053917982,"teacher_disagreement_score":0.9882056,"about_ca_system_score_codex":0.05764012,"about_ca_system_score_gemma":0.05942183,"threshold_uncertainty_score":0.99748427},"labels":[],"label_agreement":null},{"id":"W6921111423","doi":"10.6084/m9.figshare.26700592.v1","title":"Additional file 1 of Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vitalité Health Network; Université Laval","funders":"","keywords":"Transcriptional regulation; Gene; Transcription factor; Mutation; Chronic lymphocytic leukemia; Regulation of gene expression; Transcription (linguistics)","score_opus":0.02179525762755712,"score_gpt":0.2644792746445973,"score_spread":0.24268401701704018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921111423","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020727234,0.0005448022,7.348621e-7,0.000040529496,0.000034473134,0.00061637594,0.97719395,0.00002109887,0.0008207924],"genre_scores_gemma":[0.7008411,0.0000060725592,0.00009149542,0.00003291418,0.00016227063,0.0004248262,0.29702207,0.000026040867,0.0013931796],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984391,0.00004148692,0.0003765836,0.0002860456,0.00058411126,0.00027266983],"domain_scores_gemma":[0.99801,0.0014996567,0.000074192874,0.00020295187,0.00012154417,0.000091704445],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004342996,0.00014887203,0.00025158707,0.00014685927,0.00003265506,0.000017743381,0.00015107963,0.0001526736,0.9196247],"category_scores_gemma":[0.0007385231,0.00011265172,0.000139863,0.00039468185,0.00008095396,0.000118110685,0.000086017855,0.00024443178,0.00035480037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00007381335,0.000031603682,0.000005213666,0.0023976276,0.000044642537,0.000027062504,0.00009263454,0.00015953301,0.009804919,0.000010092108,0.98576313,0.0015897262],"study_design_scores_gemma":[0.009447089,0.00056252704,0.09798569,0.042936053,0.000083113475,0.0004969926,0.000046773806,0.4364171,0.018129641,0.000056710225,0.3934545,0.00038381727],"about_ca_topic_score_codex":0.000058732094,"about_ca_topic_score_gemma":0.000057334866,"teacher_disagreement_score":0.91926986,"about_ca_system_score_codex":0.011018349,"about_ca_system_score_gemma":0.029203113,"threshold_uncertainty_score":0.9927782},"labels":[],"label_agreement":null},{"id":"W6923253299","doi":"10.14473/csda/8yads3/0v5buz","title":"TI_CHPS102-03, 202-03, 302-03, 402-04.pdf","year":2024,"lang":"cs","type":"dataset","venue":"Czech Social Science Data Archive","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Context (archaeology); Product (mathematics); Set (abstract data type)","score_opus":0.05550036587975919,"score_gpt":0.39378107719665584,"score_spread":0.33828071131689663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6923253299","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00074948434,0.0021226115,0.00006646959,0.0018558801,0.0065728617,0.0032060998,0.94357353,0.00029044427,0.0415626],"genre_scores_gemma":[0.0015870802,0.0053952676,0.00072344806,0.0015903031,0.01245225,0.00022006703,0.96973664,0.00027296372,0.008021966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97473353,0.0008385102,0.0023218554,0.0071314084,0.009068561,0.0059061083],"domain_scores_gemma":[0.9844685,0.0022069782,0.0008737411,0.008937593,0.0006671874,0.0028460012],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","open_science","research_integrity","insufficient_payload"],"category_scores_codex":[0.008289692,0.0021247652,0.002729952,0.0021250648,0.003575813,0.0021888667,0.019005835,0.0013313642,0.010796306],"category_scores_gemma":[0.0071248957,0.0019561048,0.0007019638,0.006868772,0.015994297,0.002124768,0.02528125,0.006535768,0.28977087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00039207263,0.0005798617,0.000015860727,0.0021649802,0.0005108635,0.0032166261,0.0025993646,0.0000017789182,0.0013963956,0.0011401348,0.979533,0.008449044],"study_design_scores_gemma":[0.006759323,0.0006032604,0.0001594359,0.0019866454,0.0014519502,0.00048640664,0.002687232,0.00726994,0.00028091454,0.002616647,0.97372484,0.0019734236],"about_ca_topic_score_codex":0.010287884,"about_ca_topic_score_gemma":0.002255377,"teacher_disagreement_score":0.27897456,"about_ca_system_score_codex":0.029253311,"about_ca_system_score_gemma":0.10070982,"threshold_uncertainty_score":0.99996513},"labels":[],"label_agreement":null},{"id":"W6926308885","doi":"10.24443/usi-arc-bib_fcor.4537","title":"Québec. Sainte-Foy-Sillery-Cap-Rouge","year":2000,"lang":"fr","type":"other","venue":"USI-Biblioteca","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Process (computing); Identification (biology); Product (mathematics)","score_opus":0.015112331818825304,"score_gpt":0.2833580226268395,"score_spread":0.2682456908080142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6926308885","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043029166,0.07382545,0.00021619188,0.0037910973,0.0029877075,0.002330368,0.00022699233,0.0005157771,0.9118035],"genre_scores_gemma":[0.016487995,0.02231766,0.0006243782,0.0027215155,0.010075302,0.00015827187,0.00022276862,0.0015113555,0.9458808],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98949677,0.0005037835,0.0015735582,0.00227063,0.002640853,0.0035143995],"domain_scores_gemma":[0.99293286,0.0010527708,0.0004777033,0.0035045976,0.0002503987,0.001781683],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0008990124,0.0017696583,0.0023984883,0.0094003165,0.000363575,0.000359084,0.0018023665,0.0029639446,0.55107945],"category_scores_gemma":[0.0008644165,0.0016554006,0.00100389,0.008794754,0.001591695,0.00026931177,0.0007228695,0.0030558824,0.08666634],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00074265595,0.000735182,0.00014440092,0.0020798533,0.0012373516,0.003715801,0.00091746805,0.00009880771,0.000632507,0.0015482304,0.86290926,0.12523851],"study_design_scores_gemma":[0.017571116,0.00072723354,0.00027552014,0.004215193,0.00059511495,0.0013143754,0.00015724867,0.005572093,0.00083240174,0.00016849715,0.9670758,0.0014953671],"about_ca_topic_score_codex":0.14141655,"about_ca_topic_score_gemma":0.031117834,"teacher_disagreement_score":0.4644131,"about_ca_system_score_codex":0.038311783,"about_ca_system_score_gemma":0.046247784,"threshold_uncertainty_score":0.9995049},"labels":[],"label_agreement":null},{"id":"W6930282372","doi":"10.5281/zenodo.12435041","title":"yamaha stryker service manual pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Service (business); Customer service; Training manual","score_opus":0.02981420878780095,"score_gpt":0.2867965323303415,"score_spread":0.2569823235425406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930282372","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014005527,0.0009015664,0.0001299642,0.0012406255,0.0003311294,0.0009977566,0.00040108224,0.0020136822,0.99384415],"genre_scores_gemma":[0.0015650672,0.000335883,0.00021512121,0.00056003185,0.0015704774,1.358626e-7,0.0039058279,0.017678747,0.9741687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967534,0.00021509505,0.00034247583,0.0009018335,0.0010731145,0.0007140845],"domain_scores_gemma":[0.9977886,0.000020983456,0.00011678091,0.0011353173,0.0004802816,0.00045803614],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00053015654,0.0003653902,0.00042793082,0.0007260648,0.00044084908,0.0006592558,0.0010282645,0.00038891187,0.39793283],"category_scores_gemma":[0.00036739247,0.00035478812,0.0001321479,0.0009848246,0.0002159204,0.00007557653,0.002015481,0.0009502194,0.5238267],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009006653,0.00011168721,1.1709254e-7,0.0016826964,0.00027974352,0.0004253952,0.00028771037,0.0000014756483,0.0002612178,0.000670538,0.98320735,0.012981986],"study_design_scores_gemma":[0.0027883484,0.00022860314,0.0000064445353,0.00074153533,0.00012817618,0.0011679558,0.00020749214,0.00040147954,0.000086106375,0.00007824941,0.99385124,0.00031434398],"about_ca_topic_score_codex":0.00024198164,"about_ca_topic_score_gemma":0.0000035872556,"teacher_disagreement_score":0.12589386,"about_ca_system_score_codex":0.0037753622,"about_ca_system_score_gemma":0.00015168212,"threshold_uncertainty_score":0.9998904},"labels":[],"label_agreement":null},{"id":"W6930966780","doi":"10.5281/zenodo.4095663","title":"[WATCH-Free]. Invisible Man (2020) . DVD4K. Full.Online.FULL. Movie@Shared ocj","year":2020,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"nobody; Government (linguistics); Download; Action (physics); Sign (mathematics); Alien","score_opus":0.04680333816195483,"score_gpt":0.27348311246359325,"score_spread":0.2266797743016384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930966780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63136274,0.001484838,0.00551188,0.11238911,0.00051215035,0.0058548106,0.003124769,0.007931347,0.23182835],"genre_scores_gemma":[0.9538271,0.0012006304,0.004067911,0.0073363413,0.002693606,6.312369e-7,0.012976435,0.007032896,0.010864437],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958698,0.00035047438,0.0005787169,0.0009706064,0.0012871671,0.00094323297],"domain_scores_gemma":[0.9965073,0.000061747436,0.00014987428,0.0013278044,0.0008795265,0.00107377],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00060942577,0.00034021155,0.00046451413,0.00021109686,0.0012259715,0.00065924885,0.0019082794,0.00018384769,0.03507244],"category_scores_gemma":[0.0033540728,0.00033956472,0.00016868713,0.0015528018,0.0003126795,0.00034525493,0.003385222,0.0008078689,0.021421796],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012290508,0.00038737585,0.000011718387,0.0006553743,0.00017843592,0.00065620214,0.0019186398,0.00007848706,0.027504656,0.0006667678,0.93883395,0.027879339],"study_design_scores_gemma":[0.009040971,0.0013406733,0.00021223613,0.00012080183,0.00006804416,0.0010210087,0.00049540994,0.009979042,0.0013336134,0.000095341384,0.97592646,0.0003663917],"about_ca_topic_score_codex":0.00006959829,"about_ca_topic_score_gemma":0.0000021954997,"teacher_disagreement_score":0.32246438,"about_ca_system_score_codex":0.0028143234,"about_ca_system_score_gemma":0.00019094985,"threshold_uncertainty_score":0.99990565},"labels":[],"label_agreement":null},{"id":"W6931593930","doi":"10.5281/zenodo.5133454","title":"Mesoceration distinctum Perkins & Balfour-Browne 1994","year":2008,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cape; Period (music); Quarter (Canadian coin); Geologist","score_opus":0.05205801662803273,"score_gpt":0.26464813118750424,"score_spread":0.21259011455947152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931593930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5408001,0.00039951326,0.00516159,0.0028844776,0.00025527854,0.0017195283,0.00017316783,0.0023154332,0.44629094],"genre_scores_gemma":[0.9895015,0.0002980584,0.00037934692,0.00027635886,0.0004243576,1.0843758e-7,0.001973686,0.0012624318,0.005884205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974471,0.00022699045,0.00033936155,0.00053051545,0.0008814378,0.0005746334],"domain_scores_gemma":[0.9982468,0.000042450392,0.00008562909,0.000676415,0.0005517648,0.0003969536],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005504468,0.00019478526,0.00025403756,0.00027809886,0.0024733553,0.000301425,0.0005701129,0.000109028355,0.018695528],"category_scores_gemma":[0.0010269671,0.00018606512,0.000102458725,0.00067605113,0.00038428727,0.00028242703,0.0007512398,0.00041582936,0.01008443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009566259,0.00096735073,0.00005136136,0.0004061816,0.00025068197,0.0010844449,0.004757331,0.00010517217,0.020863462,0.0055299974,0.86140364,0.10362378],"study_design_scores_gemma":[0.00474365,0.00050369714,0.001461803,0.00005232342,0.000031992215,0.0036135477,0.00021259148,0.0046130284,0.0016220658,0.000056933746,0.9828741,0.00021424696],"about_ca_topic_score_codex":0.00008038303,"about_ca_topic_score_gemma":6.1812517e-7,"teacher_disagreement_score":0.44870138,"about_ca_system_score_codex":0.003774849,"about_ca_system_score_gemma":0.0001368126,"threshold_uncertainty_score":0.9988253},"labels":[],"label_agreement":null},{"id":"W6931859205","doi":"10.5281/zenodo.6116104","title":"timghill/SaDS-Greenland:","year":2022,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Process (computing); Identification (biology); Product (mathematics); Work (physics)","score_opus":0.02985202320315373,"score_gpt":0.26798338484701745,"score_spread":0.23813136164386373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931859205","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013959073,0.00071400346,0.00016155027,0.0005085899,0.00016141972,0.0011184199,0.0005600314,0.0020090598,0.99462736],"genre_scores_gemma":[0.0030775904,0.0006899687,0.00029566043,0.00045173307,0.0009909553,2.528856e-7,0.012634649,0.02199666,0.95986253],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966711,0.00036604787,0.00031104335,0.00078078016,0.0011941006,0.0006769739],"domain_scores_gemma":[0.9978838,0.000033159333,0.00016870062,0.0012436191,0.00025855168,0.00041219257],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00066698866,0.00031112635,0.0004389311,0.0007809204,0.001155102,0.0003103455,0.0011959035,0.00022638479,0.5748153],"category_scores_gemma":[0.0006746338,0.0003143528,0.00014797793,0.0007591705,0.0002718761,0.00005869488,0.0025618295,0.0008676044,0.038201764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012941068,0.00015502296,0.0000011225442,0.00033347053,0.00018670924,0.00029625613,0.00019861317,0.0000030524998,0.0001092237,0.0005119994,0.9640326,0.034042526],"study_design_scores_gemma":[0.0044731293,0.00042048586,0.000020986816,0.00012163837,0.000070241986,0.0012168204,0.00013555583,0.00026255392,0.000024621468,0.000027408309,0.9929347,0.00029188042],"about_ca_topic_score_codex":0.00023327657,"about_ca_topic_score_gemma":0.0000014356353,"teacher_disagreement_score":0.5366135,"about_ca_system_score_codex":0.005930569,"about_ca_system_score_gemma":0.00014683921,"threshold_uncertainty_score":0.99993086},"labels":[],"label_agreement":null},{"id":"W6939683935","doi":"10.6084/m9.figshare.26700592","title":"Additional file 1 of Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vitalité Health Network; Université Laval","funders":"","keywords":"Transcriptional regulation; Gene; Transcription factor; Mutation; Chronic lymphocytic leukemia; Regulation of gene expression; Transcription (linguistics)","score_opus":0.02179525762755712,"score_gpt":0.2644792746445973,"score_spread":0.24268401701704018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939683935","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020727234,0.0005448022,7.348621e-7,0.000040529496,0.000034473134,0.00061637594,0.97719395,0.00002109887,0.0008207924],"genre_scores_gemma":[0.7008411,0.0000060725592,0.00009149542,0.00003291418,0.00016227063,0.0004248262,0.29702207,0.000026040867,0.0013931796],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984391,0.00004148692,0.0003765836,0.0002860456,0.00058411126,0.00027266983],"domain_scores_gemma":[0.99801,0.0014996567,0.000074192874,0.00020295187,0.00012154417,0.000091704445],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004342996,0.00014887203,0.00025158707,0.00014685927,0.00003265506,0.000017743381,0.00015107963,0.0001526736,0.9196247],"category_scores_gemma":[0.0007385231,0.00011265172,0.000139863,0.00039468185,0.00008095396,0.000118110685,0.000086017855,0.00024443178,0.00035480037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00007381335,0.000031603682,0.000005213666,0.0023976276,0.000044642537,0.000027062504,0.00009263454,0.00015953301,0.009804919,0.000010092108,0.98576313,0.0015897262],"study_design_scores_gemma":[0.009447089,0.00056252704,0.09798569,0.042936053,0.000083113475,0.0004969926,0.000046773806,0.4364171,0.018129641,0.000056710225,0.3934545,0.00038381727],"about_ca_topic_score_codex":0.000058732094,"about_ca_topic_score_gemma":0.000057334866,"teacher_disagreement_score":0.91926986,"about_ca_system_score_codex":0.011018349,"about_ca_system_score_gemma":0.029203113,"threshold_uncertainty_score":0.9927782},"labels":[],"label_agreement":null},{"id":"W6958498569","doi":"10.6084/m9.figshare.27314727","title":"Additional file 1 of Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Signal transduction; Tyrosine kinase; Kinase; Proto-oncogene tyrosine-protein kinase Src; MAP kinase kinase kinase; JAK-STAT signaling pathway; Pathway analysis; Receptor tyrosine kinase","score_opus":0.03943518201581493,"score_gpt":0.28842079539084425,"score_spread":0.24898561337502934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958498569","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027436954,0.0004620421,2.2542451e-7,0.00004472231,0.00005312151,0.00034118033,0.99075234,0.00018509844,0.0054176026],"genre_scores_gemma":[0.13902593,5.0932834e-7,0.0001728364,0.00007620246,0.0011714809,0.0006189273,0.8538308,0.000058578655,0.0050447476],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798346,0.000034000128,0.00041985343,0.00046786826,0.0006574693,0.0004373585],"domain_scores_gemma":[0.9976069,0.0014841763,0.000082501225,0.000334695,0.00026000376,0.00023172774],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006143325,0.00023325584,0.0003308121,0.00018256548,0.00011453812,0.00006795691,0.00018376666,0.0001775587,0.99406534],"category_scores_gemma":[0.0030927768,0.00021217662,0.00024440786,0.00036735088,0.000048495887,0.00008186181,0.0002194463,0.0003815827,0.0035323335],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045440407,0.00011010034,4.915162e-7,0.0011481723,0.000060178376,0.0011113399,0.000080818536,0.0000017684152,0.0097013,0.0000071270188,0.9865891,0.0011441762],"study_design_scores_gemma":[0.002266615,0.0002729911,0.000062103805,0.020162562,0.000034470617,0.00035393197,0.000030903586,0.0024149609,0.043402206,0.000039088707,0.9307191,0.00024108941],"about_ca_topic_score_codex":0.000042506515,"about_ca_topic_score_gemma":0.000015838756,"teacher_disagreement_score":0.990533,"about_ca_system_score_codex":0.002479106,"about_ca_system_score_gemma":0.0053587565,"threshold_uncertainty_score":0.9972435},"labels":[],"label_agreement":null},{"id":"W6976686588","doi":"10.60692/f140f-8hf04","title":"Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia","year":2017,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Gene; Immune system; Transcription factor; Genetic association; Chromatin; Immunity; Genome-wide association study; Chronic lymphocytic leukemia","score_opus":0.033256343782522305,"score_gpt":0.2737203820264479,"score_spread":0.2404640382439256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976686588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954061,0.000031231684,0.0015123353,0.000054477972,0.00007417019,0.0006301024,0.00005148136,0.00006546542,0.0021746673],"genre_scores_gemma":[0.9993797,0.0000033884294,0.000077637895,0.000025307536,0.00006929353,0.000069636684,0.0001450234,0.000013063665,0.00021693767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976083,0.00009770301,0.0010323253,0.00019070161,0.00068090594,0.00039003865],"domain_scores_gemma":[0.9969688,0.000059298447,0.0011655827,0.0012339402,0.00046259258,0.00010979946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011536937,0.00019389353,0.00062664977,0.00084701827,0.00022541954,0.00016563236,0.0003397041,0.00023748587,0.000040224073],"category_scores_gemma":[0.0003385609,0.00017157634,0.00021516248,0.0005294798,0.00006685813,0.00093492365,0.00015401158,0.00013600214,0.00021988862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015332206,0.0000028902414,0.98648065,0.0009561552,0.00055018696,0.000004854961,0.0069970726,0.0043481076,0.00009457558,0.000026290701,0.0000079007095,0.0003779668],"study_design_scores_gemma":[0.007241667,0.000052596242,0.8989637,0.00015070094,0.00033497674,0.000013642813,0.0010867964,0.08959531,0.002370901,0.0000017525958,0.000047895745,0.00014007417],"about_ca_topic_score_codex":0.0014336563,"about_ca_topic_score_gemma":0.00002807154,"teacher_disagreement_score":0.087516986,"about_ca_system_score_codex":0.07500074,"about_ca_system_score_gemma":0.0036292814,"threshold_uncertainty_score":0.9285502},"labels":[],"label_agreement":null},{"id":"W6976794186","doi":"10.60692/sh36b-wb069","title":"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Chronic lymphocytic leukemia; Thrombosis; Retrospective cohort study; Complication; Severe bleeding; Multicenter study; Coagulopathy","score_opus":0.09922945006150843,"score_gpt":0.30651153913051693,"score_spread":0.2072820890690085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976794186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405515,0.000009069368,0.00004863355,0.00005921804,0.000025749003,0.002459587,0.000048564885,0.000040462288,0.003253585],"genre_scores_gemma":[0.99949837,5.803938e-7,0.00001195786,0.00016465632,0.00001877876,0.00023912304,0.000023971435,0.000017322502,0.000025231682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971692,0.00074360153,0.00052699825,0.00023498334,0.0010204224,0.00030482316],"domain_scores_gemma":[0.99875635,0.000158924,0.00021508409,0.000466694,0.00024182118,0.00016113886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018608388,0.00014920389,0.00028354352,0.0005150493,0.0005236963,0.00006853051,0.00018775255,0.000029139917,0.000015038081],"category_scores_gemma":[0.00012121167,0.00009967593,0.000018235061,0.0007722284,0.00018238614,0.00020651892,0.00037264675,0.00033839166,0.000023651759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015235841,0.000057379453,0.56142193,0.0021649364,0.00022264416,0.00003881927,0.4232852,0.0105160605,0.0000010603652,0.0002574005,0.00015071628,0.0003602695],"study_design_scores_gemma":[0.039234314,0.002706937,0.80123186,0.00034741766,0.000051888415,0.00016130839,0.1341571,0.021887593,0.0000040352866,0.0000017960122,0.00006115676,0.00015461995],"about_ca_topic_score_codex":0.00043966432,"about_ca_topic_score_gemma":0.000008752148,"teacher_disagreement_score":0.2891281,"about_ca_system_score_codex":0.038485993,"about_ca_system_score_gemma":0.004647607,"threshold_uncertainty_score":0.9652051},"labels":[],"label_agreement":null},{"id":"W6977071520","doi":"10.6084/m9.figshare.19128605.v1","title":"Additional file 1 of Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Odds ratio; Fludarabine; Chemoimmunotherapy; Lymphocyte","score_opus":0.0296834016184315,"score_gpt":0.285522927422789,"score_spread":0.25583952580435754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977071520","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033579417,0.00020816749,0.00000525819,0.0000022946401,0.000016727743,0.0014265846,0.96387804,0.00003074707,0.00085276965],"genre_scores_gemma":[0.24452743,0.000012964871,0.00063521083,0.000008829181,0.00008788126,0.003845823,0.74833953,0.00005844839,0.002483891],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99818903,0.00013831507,0.00044611213,0.00036022085,0.00059038727,0.00027593045],"domain_scores_gemma":[0.99541235,0.0032248793,0.0004910045,0.00040581267,0.00034967138,0.00011627249],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012177659,0.00021632698,0.00068132,0.00024099537,0.00013244853,0.000005254155,0.00014362948,0.000069730464,0.76776016],"category_scores_gemma":[0.0008730125,0.00018334867,0.00014449585,0.0003438667,0.00007796715,0.00007142195,0.00017593779,0.00017874678,0.000025861962],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011346743,0.00022099854,0.000048767983,0.0041248514,0.0010317906,0.000026345047,0.00019355577,0.017916113,0.00070632825,0.000005651367,0.963448,0.00093086576],"study_design_scores_gemma":[0.12701334,0.008845144,0.016189843,0.023741648,0.0009155703,0.00023588836,0.00034067556,0.47713438,0.010064838,0.00006999832,0.33479464,0.00065404427],"about_ca_topic_score_codex":0.0041830507,"about_ca_topic_score_gemma":0.000805054,"teacher_disagreement_score":0.7677343,"about_ca_system_score_codex":0.06186427,"about_ca_system_score_gemma":0.027535371,"threshold_uncertainty_score":0.9779776},"labels":[],"label_agreement":null},{"id":"W6977078894","doi":"10.6084/m9.figshare.26564556.v1","title":"Additional file 2 of Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chronic lymphocytic leukemia; Repertoire; Leukemia; Immune system; T lymphocyte; Antibody","score_opus":0.02117654333946562,"score_gpt":0.2688899271000171,"score_spread":0.24771338376055146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977078894","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007894148,0.00089156156,5.70994e-7,0.000020962332,0.000054988122,0.00029751568,0.99255437,0.00006983475,0.00532081],"genre_scores_gemma":[0.07405228,0.000011958052,0.00015838808,0.000057712903,0.0003733876,0.0006687146,0.9181551,0.0000450433,0.006477415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981429,0.00003518539,0.00045055724,0.00037001545,0.000688454,0.0003128633],"domain_scores_gemma":[0.99750346,0.0017942794,0.00009121186,0.00031391048,0.00018675173,0.00011041014],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000053459273,0.00016525747,0.00031731537,0.0003427271,0.000026241249,0.000013815996,0.00013977634,0.00018741353,0.9914974],"category_scores_gemma":[0.0016643591,0.00015257987,0.00018720438,0.0006482957,0.000047074434,0.00011646368,0.000102726306,0.00024183358,0.0032917724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00008227038,0.00001864684,3.8814213e-7,0.0021267328,0.00004839531,0.00019378944,0.000027988968,0.0004045678,0.0012682987,0.000012478776,0.9941915,0.0016249061],"study_design_scores_gemma":[0.002778913,0.00025624954,0.00038646345,0.021118786,0.000016373759,0.00028198992,0.000022844652,0.1106399,0.008852089,0.000028834245,0.85545707,0.00016046739],"about_ca_topic_score_codex":0.00020042033,"about_ca_topic_score_gemma":0.000053917982,"teacher_disagreement_score":0.9882056,"about_ca_system_score_codex":0.05764012,"about_ca_system_score_gemma":0.05942183,"threshold_uncertainty_score":0.99748427},"labels":[],"label_agreement":null},{"id":"W6987065779","doi":"","title":"Rituximab-based combination therapy in patients with Waldenstr&amp;amp;ouml;m macroglobulinemia: a systematic review and meta-analysis","year":2019,"lang":"en","type":"other","venue":"Dove Medical Press (Taylor and Francis Group)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rituximab; Combination therapy; Adverse effect; Meta-analysis; Ibrutinib; Clinical Practice","score_opus":0.030121207757585877,"score_gpt":0.3005879200328668,"score_spread":0.2704667122752809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6987065779","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00095872005,0.88185406,0.055961065,0.0029523429,0.00034523165,0.031250548,0.0010255879,0.00042122696,0.025231224],"genre_scores_gemma":[0.89227664,0.007933679,0.002938894,0.027934005,0.00058561424,0.0064939037,0.008190573,0.002550457,0.051096216],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947084,0.00044046476,0.0009924136,0.0009885252,0.0023124693,0.0005576867],"domain_scores_gemma":[0.997104,0.00046773473,0.00047761228,0.0012275041,0.00020338314,0.0005197542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012032764,0.00068262167,0.005270168,0.0004986227,0.000043414577,0.000060395934,0.00034487556,0.0007154917,0.0034984455],"category_scores_gemma":[0.00068431796,0.0004041324,0.00052375504,0.0006613906,0.00038864568,0.000059331065,0.00012321281,0.0008448667,0.00008508675],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001473529,0.0046851966,0.0026345158,0.8219276,0.15008113,0.0003260086,0.00031978812,0.000004152616,0.0000015016708,0.0002659831,0.00882833,0.009452257],"study_design_scores_gemma":[0.17642209,0.0016504009,0.0006768174,0.006485852,0.7505008,0.00011371103,0.00002827926,0.048493568,0.000004935765,0.00005808097,0.013016162,0.0025493028],"about_ca_topic_score_codex":0.0017279412,"about_ca_topic_score_gemma":0.00063821336,"teacher_disagreement_score":0.89131796,"about_ca_system_score_codex":0.0007140503,"about_ca_system_score_gemma":0.00007680058,"threshold_uncertainty_score":0.99984103},"labels":[],"label_agreement":null},{"id":"W6989751563","doi":"","title":"Caracterización de una sub población tumoral proliferante en la leucemia linfoide crónica :articulando la modulación del microambiente inmunológico con la progresión de la leucemia","year":2014,"lang":"es","type":"dissertation","venue":"Americanae (AECID Library)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; North of England Children’s Cancer Research Fund; Wellcome Trust; Cancer Research Society; Agencia Nacional de Investigación e Innovación","keywords":"Perspective (graphical); Reflection (computer programming); Feature (linguistics); Interpretation (philosophy)","score_opus":0.004198448169825807,"score_gpt":0.2764791634769352,"score_spread":0.2722807153071094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6989751563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827253,0.0018556371,0.00027338605,0.00089789514,0.00034068362,0.0027811176,0.0002741286,0.0007236976,0.010128117],"genre_scores_gemma":[0.9805446,0.0038675403,0.0015465027,0.0012606325,0.0012241203,0.0009611824,0.0032533386,0.0009014186,0.006440647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98469275,0.0054169944,0.0022988506,0.002360236,0.0019008825,0.0033302924],"domain_scores_gemma":[0.98916066,0.0047937008,0.0015352386,0.002244045,0.000393229,0.001873113],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0022451452,0.0021963655,0.003140586,0.0012900522,0.00045546974,0.00072731986,0.0020461385,0.002272681,0.0003176889],"category_scores_gemma":[0.002156447,0.0021320628,0.001109149,0.0018629702,0.0026913458,0.0012498018,0.00072118494,0.0041191024,0.00037868173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.025090009,0.0031991731,0.59510326,0.0102158915,0.005090709,0.017077755,0.011435245,0.00055245,0.22099741,0.008091294,0.020468881,0.08267793],"study_design_scores_gemma":[0.04789646,0.003007517,0.66260916,0.010193768,0.0024587756,0.004689152,0.0017312462,0.029433636,0.18033324,0.0005797406,0.05205623,0.0050110626],"about_ca_topic_score_codex":0.034553286,"about_ca_topic_score_gemma":0.000074036114,"teacher_disagreement_score":0.077666864,"about_ca_system_score_codex":0.0071363533,"about_ca_system_score_gemma":0.033381104,"threshold_uncertainty_score":0.9990777},"labels":[],"label_agreement":null},{"id":"W6995969455","doi":"","title":"Promoción de turismo comunitario como práctica de desarrollo local en la parroquia San Lucas cantón Loja","year":2014,"lang":"es","type":"dissertation","venue":"Repositorio Institucional (Universidad de Cuenca)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tourism; Quarter (Canadian coin); Context (archaeology); Work (physics); Population","score_opus":0.010267793587181528,"score_gpt":0.2913596267848818,"score_spread":0.28109183319770026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995969455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9527113,0.0011979558,0.0036135195,0.0007128514,0.0022093665,0.0016132845,0.000082800434,0.0002789614,0.03757998],"genre_scores_gemma":[0.97782636,0.00062564336,0.002707428,0.00022161234,0.0025968945,0.00009359253,0.0013140761,0.0002503447,0.014364081],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909503,0.001524125,0.0010845911,0.0015507718,0.0025644118,0.00232581],"domain_scores_gemma":[0.9929028,0.0018136012,0.000740366,0.0015054194,0.0011115752,0.0019262044],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0022449433,0.0012745049,0.0016440958,0.0010105362,0.0012677026,0.0003937146,0.0015802142,0.0027347235,0.00036131527],"category_scores_gemma":[0.0011643495,0.001430504,0.00074662635,0.0010572094,0.0010053482,0.0005082858,0.00038408427,0.0036394529,0.00033246345],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03565748,0.009263057,0.116285846,0.029453205,0.017777719,0.19326267,0.16437869,0.018563973,0.09697475,0.21036439,0.06020225,0.047815986],"study_design_scores_gemma":[0.07420711,0.005055065,0.12836373,0.02363087,0.010265615,0.05160379,0.04561753,0.15686607,0.029872084,0.0021410226,0.46429962,0.008077464],"about_ca_topic_score_codex":0.0453336,"about_ca_topic_score_gemma":0.004999204,"teacher_disagreement_score":0.40409738,"about_ca_system_score_codex":0.075721115,"about_ca_system_score_gemma":0.08138523,"threshold_uncertainty_score":0.9994608},"labels":[],"label_agreement":null},{"id":"W6997306220","doi":"","title":"A validade da prova produzida pela inspeção física de celular apreendido em flagrante delito sem autorização judicial: um olhar sob a perspectiva do direito fundamental à privacidade no curso de investigação criminal","year":2021,"lang":"pt","type":"dissertation","venue":"LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Supreme court; The Right to Privacy; Context (archaeology); Possession (linguistics); Constitutional right; Fundamental rights; Order (exchange); Right to privacy; Dialectic","score_opus":0.030738394280405288,"score_gpt":0.29258738910449217,"score_spread":0.26184899482408686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6997306220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9223119,0.009077559,0.0023236016,0.007120528,0.007305752,0.009381876,0.00080170267,0.0017593022,0.03991775],"genre_scores_gemma":[0.9748744,0.0011295155,0.00478664,0.00046059472,0.0060507865,0.0020965568,0.004971175,0.00073568843,0.004894662],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9784907,0.0026609125,0.0034332445,0.004801427,0.0057647754,0.0048489175],"domain_scores_gemma":[0.9863362,0.0009259539,0.0020735257,0.0032367995,0.0035065426,0.0039209826],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0027171783,0.0030027665,0.003311496,0.0021069874,0.0026069663,0.0022718816,0.002837421,0.0037081756,0.0003621323],"category_scores_gemma":[0.0071437033,0.003212332,0.001733314,0.0030975176,0.00026323396,0.0012086257,0.0013186821,0.00573678,0.00025463],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022028511,0.017859431,0.0048234807,0.03658393,0.010975984,0.040803537,0.25687662,0.00057885173,0.2490948,0.3368109,0.01068115,0.012882845],"study_design_scores_gemma":[0.04890938,0.0029457158,0.0067193275,0.031126022,0.008221926,0.034222525,0.07173073,0.027408792,0.071432926,0.0006747826,0.6875001,0.00910775],"about_ca_topic_score_codex":0.000184917,"about_ca_topic_score_gemma":0.0008872043,"teacher_disagreement_score":0.67681897,"about_ca_system_score_codex":0.05138649,"about_ca_system_score_gemma":0.06416561,"threshold_uncertainty_score":0.99876386},"labels":[],"label_agreement":null},{"id":"W7000268026","doi":"","title":"Epidemiological study of chronic lymphocytic leukemia (CLL) in the province of Manitoba, Canada","year":2013,"lang":"en","type":"dissertation","venue":"Mspace (University of Manitoba)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Epidemiology; Relative survival; Relative risk; Risk factor; Population; Leukemia; Lymphoma","score_opus":0.025628191330818385,"score_gpt":0.25511325605225954,"score_spread":0.22948506472144115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000268026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396825,0.00066713645,0.0000061093247,0.00011273727,0.0001715139,0.0024544161,0.000024892588,0.000016989636,0.0025779486],"genre_scores_gemma":[0.9977276,0.0002757458,0.000064802654,0.000026272277,0.00007294234,0.000006113928,0.00014608519,0.000031374544,0.0016490889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965912,0.0004671106,0.00052566314,0.0005651883,0.0013215196,0.0005292792],"domain_scores_gemma":[0.9969626,0.0007206081,0.0007775229,0.000998054,0.00040704204,0.00013418846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075109804,0.0003839761,0.0013804887,0.00033962342,0.00010603391,0.0000068293243,0.0010833057,0.0004082702,0.00004443954],"category_scores_gemma":[0.00032880253,0.00033146408,0.00020869072,0.0005454883,0.00027339158,0.000102146936,0.0001820608,0.0006678414,0.000015108439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03013101,0.012512902,0.40332168,0.08815921,0.010067739,0.033003535,0.029229341,0.023151686,0.012675359,0.003439822,0.31698343,0.03732428],"study_design_scores_gemma":[0.024378913,0.003522871,0.6386325,0.0017553294,0.00085805054,0.00009037827,0.3133594,0.0147432145,0.00067463546,0.000046947316,0.0013521061,0.00058564724],"about_ca_topic_score_codex":0.96458167,"about_ca_topic_score_gemma":0.9991496,"teacher_disagreement_score":0.31563133,"about_ca_system_score_codex":0.07290253,"about_ca_system_score_gemma":0.061547324,"threshold_uncertainty_score":0.99991375},"labels":[],"label_agreement":null},{"id":"W7020437084","doi":"","title":"Le secteur du multimédia a Montréal peut-il être considéré comme un millieu innovateur ?","year":2008,"lang":"fr","type":"report","venue":"Érudit documents and data repository (Érudit Consortium, University of Montreal)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Context (archaeology); Government (linguistics); Subject (documents); Identity (music)","score_opus":0.03590759335135933,"score_gpt":0.2642217766562862,"score_spread":0.22831418330492687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7020437084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6677274,0.13403752,0.00031871966,0.0044648265,0.0071763303,0.006685758,0.015966702,0.00060634053,0.16301636],"genre_scores_gemma":[0.5691389,0.28748143,0.0011120352,0.00029462905,0.0022717076,0.0000129095615,0.010587777,0.00032935783,0.12877128],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9893877,0.0008357046,0.0021164338,0.0030901884,0.0026691314,0.0019008417],"domain_scores_gemma":[0.9881293,0.0013856211,0.0023087717,0.0049128896,0.001799173,0.0014642553],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","sts"],"category_scores_codex":[0.0011216465,0.0015518427,0.0031833535,0.0007876293,0.0021183765,0.00015215616,0.0023240945,0.0014705124,0.00035348453],"category_scores_gemma":[0.0008640331,0.0017607207,0.0005342108,0.00081206055,0.0035046411,0.001129002,0.0043111597,0.0017977561,0.00015907167],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004142608,0.0036833016,0.024118986,0.0047436375,0.010613794,0.15751792,0.0011741794,0.00011933736,0.0015224474,0.0007860453,0.7413086,0.050269105],"study_design_scores_gemma":[0.034155283,0.00070656853,0.0071154316,0.0021313652,0.0029102524,0.023849027,0.0017571542,0.0038227118,0.00052832486,0.000038195343,0.9214204,0.0015652941],"about_ca_topic_score_codex":0.4226873,"about_ca_topic_score_gemma":0.0469821,"teacher_disagreement_score":0.37570518,"about_ca_system_score_codex":0.013182499,"about_ca_system_score_gemma":0.02545981,"threshold_uncertainty_score":0.9998258},"labels":[],"label_agreement":null},{"id":"W7034062508","doi":"","title":"Site selection and foraging behavior of Aleutian Canada geese in a newly colonized spring staging area","year":2011,"lang":"en","type":"article","venue":"CSUN ScholarWorks (California State University, Northridge)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"California Waterfowl Association; Massachusetts Department of Fish and Game; California Department of Fish and Game","keywords":"Foraging; Endangered species; Habitat; Spring (device); Goose; Threatened species; Population; Pasture","score_opus":0.01969363373205639,"score_gpt":0.2232437421939051,"score_spread":0.20355010846184873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7034062508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972668,0.00018459262,0.0009809271,0.000069412505,0.000069211186,0.00065984833,0.00009297233,0.000054349646,0.00062184175],"genre_scores_gemma":[0.9980872,0.00019161066,0.001194005,0.00006303715,0.000019475418,0.0000036582298,0.000035225206,0.000038593455,0.000367187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775296,0.00012637992,0.0003875228,0.00051954685,0.0005285792,0.0006850208],"domain_scores_gemma":[0.9986708,0.00009265504,0.00017767027,0.000343515,0.00028698193,0.0004283721],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005066421,0.00026400315,0.0004858148,0.0006630669,0.00020992116,0.000034253793,0.00020961146,0.00013490167,0.000101188205],"category_scores_gemma":[0.00009463103,0.00029627024,0.00007763733,0.0010783214,0.00015147276,0.0003638744,0.0003375441,0.0007656365,0.0000073364045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010613587,0.00015214922,0.99042857,0.0001759858,0.000072228475,0.0018840315,0.0009785064,0.00029942847,0.0009655063,0.000024522667,0.000060524555,0.003897177],"study_design_scores_gemma":[0.050791856,0.00050349225,0.86325234,0.0012106055,0.00057221856,0.00047175607,0.0034937304,0.06461331,0.00645837,0.000036541547,0.0074265967,0.0011691998],"about_ca_topic_score_codex":0.57410914,"about_ca_topic_score_gemma":0.69540507,"teacher_disagreement_score":0.12717625,"about_ca_system_score_codex":0.0077277534,"about_ca_system_score_gemma":0.005300342,"threshold_uncertainty_score":0.9999489},"labels":[],"label_agreement":null},{"id":"W7036943528","doi":"","title":"Costs of treatment with CHOP, COP/CVP and fludarabine in Canada, Germany and Italy","year":2001,"lang":"en","type":"article","venue":"IRIS UNIMORE (University of Modena and Reggio Emilia)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fludarabine; Disease; MEDLINE; Incidence (geometry); Epidemiology","score_opus":0.011811591514507213,"score_gpt":0.2139779582380445,"score_spread":0.20216636672353727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7036943528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959733,0.0014310252,0.00002702382,0.0009076574,0.000008097495,0.00027230292,0.000019249755,0.0000063694556,0.0013549983],"genre_scores_gemma":[0.9935414,0.004659729,0.00017384235,0.00003018027,0.000008382655,3.6476902e-7,0.000008200141,0.000008933593,0.0015689592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917275,0.000026170948,0.00010661327,0.0002521833,0.00022910628,0.00021318543],"domain_scores_gemma":[0.9993636,0.00008192704,0.00006061423,0.00020887349,0.00008216587,0.00020284325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071996605,0.00012910727,0.00038679037,0.00015155488,0.000055632496,0.0000032438768,0.0000616546,0.00006983219,0.0000189162],"category_scores_gemma":[0.000009341878,0.0001126258,0.00002278309,0.00019159062,0.00037475763,0.0000776073,0.00006862925,0.000089662804,2.946634e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017152278,0.0010461205,0.77242076,0.0022265234,0.0015590513,0.014326396,0.018067414,0.00043809114,0.02168081,0.0007696251,0.007996224,0.14231671],"study_design_scores_gemma":[0.15684289,0.007017018,0.61608595,0.0026739645,0.0010056396,0.0038590499,0.027565645,0.17053263,0.0016601579,0.00014065785,0.011493735,0.0011226782],"about_ca_topic_score_codex":0.74466854,"about_ca_topic_score_gemma":0.65262216,"teacher_disagreement_score":0.17009453,"about_ca_system_score_codex":0.004021904,"about_ca_system_score_gemma":0.003149385,"threshold_uncertainty_score":0.99980146},"labels":[],"label_agreement":null},{"id":"W7093122348","doi":"","title":"DP032 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS PNEUMONIA HAVE AN IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH ACALABRUTINIB AND ZANUBRUTINIB: A MULTICENTRE SEIFEM STUDY.","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina","funders":"","keywords":"COPD; Chronic lymphocytic leukemia; Pneumonia; Mortality rate; Survival rate; Risk factor; Stage (stratigraphy); Retrospective cohort study","score_opus":0.07173892430660646,"score_gpt":0.4826577724479689,"score_spread":0.4109188481413625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093122348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98880905,0.0052567655,0.000008856072,0.000038550537,0.000042724354,0.005013089,0.00008280896,0.00007166332,0.0006765196],"genre_scores_gemma":[0.9978958,0.0013288792,0.000025332749,0.00008713249,0.000050286595,0.00028895983,0.00008683173,0.00009472727,0.00014204987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957988,0.00045802232,0.00087695743,0.0011340335,0.00094034284,0.00079183764],"domain_scores_gemma":[0.9964488,0.0005667171,0.0005712455,0.0010486332,0.00052312686,0.00084146473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000484708,0.00068799127,0.0012387433,0.0012483272,0.0003655356,0.000581079,0.0008291216,0.00013686686,0.00024211533],"category_scores_gemma":[0.0002441576,0.00049268495,0.000097838136,0.0014670443,0.0005214889,0.0011749711,0.00064541213,0.0007066149,0.0000037990203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0075347186,0.0013869454,0.97694176,0.00048967026,0.0007899534,0.00042919134,0.0003234404,0.0020871442,0.00043574016,0.000010003569,0.00007399956,0.009497449],"study_design_scores_gemma":[0.029317712,0.00081478525,0.9545293,0.0021537677,0.0006441571,0.00009577386,0.00016345791,0.011480175,0.00021161814,0.00010161059,0.000027920021,0.00045974046],"about_ca_topic_score_codex":0.008415726,"about_ca_topic_score_gemma":0.0010363501,"teacher_disagreement_score":0.025289547,"about_ca_system_score_codex":0.040568274,"about_ca_system_score_gemma":0.015278727,"threshold_uncertainty_score":0.99975246},"labels":[],"label_agreement":null},{"id":"W7095094585","doi":"","title":"Site Group * of Cancer Care Ontario’s","year":2013,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alemtuzumab; Hematology; Chronic lymphocytic leukemia; Cancer; Guideline; Radiation therapy; Disease; Leukemia","score_opus":0.014994130106706709,"score_gpt":0.30293507378750806,"score_spread":0.28794094368080136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095094585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9386251,0.00060106366,0.000012189256,0.00020543614,0.000058369103,0.0003741414,0.0000021026788,0.000025229516,0.060096394],"genre_scores_gemma":[0.96999216,0.00003019334,0.000529668,0.0002556467,0.00006289638,0.000057547877,0.000012897791,0.0000119886345,0.029047005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999181,0.000008274962,0.00014831257,0.00014588375,0.00030114115,0.0002154238],"domain_scores_gemma":[0.9993446,0.000030039118,0.000024075582,0.00028390516,0.00019300412,0.00012436404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000035735826,0.00007194531,0.00017802721,0.000050483348,0.000016126032,0.000006958296,0.00006552537,0.000057355654,0.017721571],"category_scores_gemma":[0.00001672484,0.000051116516,0.00005805278,0.0000928337,0.000059020098,0.00005383846,0.00005875165,0.00010608916,0.00037859697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042917754,0.00039006156,0.730393,0.002238161,0.0005365563,0.00016125431,0.024066005,0.00003144733,0.071761504,0.0018833481,0.091556065,0.07655345],"study_design_scores_gemma":[0.052598115,0.0012155016,0.7617538,0.0006403113,0.00026347773,0.00012257903,0.0034422216,0.004042913,0.06298025,0.00019203752,0.11217869,0.00057010783],"about_ca_topic_score_codex":0.806522,"about_ca_topic_score_gemma":0.32925105,"teacher_disagreement_score":0.47727096,"about_ca_system_score_codex":0.01128761,"about_ca_system_score_gemma":0.0041652243,"threshold_uncertainty_score":0.9925079},"labels":[],"label_agreement":null},{"id":"W7097846400","doi":"","title":"Obituary","year":2016,"lang":"en","type":"article","venue":"","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Daughter; Obituary; Sister; Power (physics); Bridge (graph theory); Watt","score_opus":0.01882058810300669,"score_gpt":0.30152674633985777,"score_spread":0.2827061582368511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7097846400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5593977,0.00009909777,0.001589787,0.0065518096,0.00007976023,0.00019557934,9.737995e-7,0.00015682362,0.4319285],"genre_scores_gemma":[0.89573824,0.000030626517,0.0005240853,0.000517616,0.000106131374,0.0000054283773,5.044869e-7,0.000007732404,0.10306963],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946135,0.000006697181,0.00006886291,0.00010886724,0.0001838018,0.0001703917],"domain_scores_gemma":[0.99953675,0.00007812278,0.0000058397877,0.00023453067,0.000033818003,0.000110938556],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007514217,0.000039640243,0.00007397674,0.00003466897,0.000012174463,0.0000027412707,0.00004210636,0.00003117536,0.0038828186],"category_scores_gemma":[0.00010033461,0.000018089953,0.0000329467,0.00005982006,0.000053469845,0.000032228363,0.000035290046,0.000026816904,0.0026623711],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060371286,0.00024655383,0.006937929,0.00013781009,0.00015155587,0.0010713008,0.00011790403,1.5952406e-7,0.22778858,0.02766157,0.3727553,0.36252764],"study_design_scores_gemma":[0.090338126,0.0008370163,0.015613622,0.0004184158,0.00005975615,0.0025391094,0.0000982943,0.000910432,0.31069684,0.0027688367,0.5753121,0.00040747735],"about_ca_topic_score_codex":0.0000619266,"about_ca_topic_score_gemma":0.0000040101886,"teacher_disagreement_score":0.36212018,"about_ca_system_score_codex":0.0031522042,"about_ca_system_score_gemma":0.0018777308,"threshold_uncertainty_score":0.99811417},"labels":[],"label_agreement":null},{"id":"W7108443597","doi":"10.1182/blood-2025-4506","title":"Real-world incidence of treatment-emergent cardiovascular events among chronic lymphocytic leukemia/small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Ibrutinib; Propensity score matching; Incidence (geometry); Logistic regression; Cohort; Adverse effect; Retrospective cohort study; Progression-free survival","score_opus":0.02127202425802453,"score_gpt":0.29344711897257236,"score_spread":0.2721750947145478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108443597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98812985,0.0033438194,0.00007139521,0.00002074406,0.00055403804,0.0028173937,0.00003566595,0.00026969257,0.0047573815],"genre_scores_gemma":[0.9800646,0.008468172,0.00062071736,0.0001014464,0.00030175364,0.00045221983,0.00011573102,0.00016719515,0.009708185],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934005,0.00041769107,0.0017076902,0.0015083827,0.0013982006,0.001567531],"domain_scores_gemma":[0.9951613,0.0006049544,0.0004792452,0.0025647453,0.0006442233,0.00054552616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008626288,0.00092059094,0.0019899784,0.0009738784,0.0002820767,0.000049107377,0.00083818496,0.00046941705,0.0001807038],"category_scores_gemma":[0.000720363,0.0007601615,0.0010820992,0.0025918006,0.00041734567,0.00022163897,0.00041003322,0.00023728378,0.000087917266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01316538,0.007982744,0.5053894,0.010426116,0.03729895,0.002646262,0.0031019896,0.0095377965,0.008324735,0.00042644836,0.001472623,0.40022758],"study_design_scores_gemma":[0.47593185,0.0047391984,0.31469363,0.0066231973,0.007302143,0.0002942492,0.0003459433,0.03612402,0.14401275,0.00011116457,0.007840854,0.0019809904],"about_ca_topic_score_codex":0.028207067,"about_ca_topic_score_gemma":0.00196954,"teacher_disagreement_score":0.46276647,"about_ca_system_score_codex":0.22473405,"about_ca_system_score_gemma":0.10273575,"threshold_uncertainty_score":0.99948496},"labels":[],"label_agreement":null},{"id":"W7108456604","doi":"10.1182/blood-2025-4505","title":"Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Chronic lymphocytic leukemia; Cancer; Venetoclax; Proportional hazards model; Prostate cancer; Clinical trial; Leukemia; Population","score_opus":0.06249190916898607,"score_gpt":0.379948571791648,"score_spread":0.3174566626226619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108456604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974624,0.0003641282,0.0000070959327,0.0003341117,0.00004190666,0.00067161996,0.0000142614335,0.000016471262,0.0010880004],"genre_scores_gemma":[0.9978795,0.00061815686,0.00018905058,0.00003902833,0.00006378865,0.000037948208,0.00010664135,0.000011578542,0.0010543235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989401,0.000043937995,0.0003906885,0.00022785198,0.00020689497,0.00019051859],"domain_scores_gemma":[0.9993428,0.00018190691,0.00006843996,0.00027440203,0.00006967527,0.00006278453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011404219,0.00013302121,0.00047208284,0.00023055795,0.000037619982,0.000009985811,0.000056677734,0.00006991186,0.000018311104],"category_scores_gemma":[0.00005211343,0.000098916375,0.000050103503,0.00026048056,0.000051492763,0.000031820502,0.00003753684,0.000077621415,0.0000027218264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081256076,0.0014891812,0.98131835,0.00006457689,0.00018511649,0.000004164048,0.0003713435,0.000011925835,0.00019906693,0.000037715516,0.00014583074,0.01609144],"study_design_scores_gemma":[0.06899457,0.0011459034,0.9039664,0.00010029082,0.0001343432,4.81481e-7,0.000026037309,0.0016132434,0.022902872,0.000037226662,0.0009922864,0.00008631883],"about_ca_topic_score_codex":0.0046507022,"about_ca_topic_score_gemma":0.002743463,"teacher_disagreement_score":0.07735196,"about_ca_system_score_codex":0.0020222059,"about_ca_system_score_gemma":0.00083492335,"threshold_uncertainty_score":0.70305014},"labels":[],"label_agreement":null},{"id":"W7108659049","doi":"10.1182/blood-2025-2118","title":"A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Obinutuzumab; Venetoclax; Fludarabine; Chemoimmunotherapy; Post-hoc analysis; Discontinuation; Adverse effect; Cyclophosphamide; Neutropenia","score_opus":0.018781331082540362,"score_gpt":0.3385754346485994,"score_spread":0.31979410356605903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108659049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911534,0.0004698369,0.00024320038,0.0034725147,0.00013080778,0.0012463438,0.0011471444,0.00005157937,0.002085173],"genre_scores_gemma":[0.99511963,0.00022026012,0.00020439766,0.00051472546,0.00012939642,0.0000619381,0.0024910597,0.000016219388,0.001242379],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99781644,0.00018414519,0.000842296,0.00036477845,0.00053546537,0.00025687434],"domain_scores_gemma":[0.9967685,0.0015841033,0.00023396291,0.0010033537,0.0003425655,0.00006752167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008004306,0.00016419959,0.0005472064,0.00027894,0.00016650859,0.000039740033,0.00030209462,0.00018383174,0.00022708943],"category_scores_gemma":[0.0014895867,0.00011906597,0.00029099933,0.0016888197,0.0001690967,0.00005637696,0.00008492104,0.00028176612,0.000014444859],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76535416,0.022823837,0.00073931646,0.00022247467,0.042950295,0.000109111985,0.008530967,0.0002951128,0.09791398,0.0069000134,0.010039248,0.044121485],"study_design_scores_gemma":[0.94079626,0.0013006284,0.0066985046,0.00015491556,0.0059422,0.0000050148196,0.00033676808,0.013256577,0.020018095,0.00014962305,0.011164392,0.0001770138],"about_ca_topic_score_codex":0.002775362,"about_ca_topic_score_gemma":0.00030166737,"teacher_disagreement_score":0.17544211,"about_ca_system_score_codex":0.0019314983,"about_ca_system_score_gemma":0.005445373,"threshold_uncertainty_score":0.9659858},"labels":[],"label_agreement":null},{"id":"W7108740836","doi":"10.1182/blood-2025-5459","title":"Randomised Phase II study of acalabrutinib in combination with R-CHOP treatment for diffuse large B-cell lymphoma confirms safety and unimpaired treatment delivery","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Clinical endpoint; Diffuse large B-cell lymphoma; Chemotherapy regimen; Progression-free survival; International Prognostic Index; Phases of clinical research; Surrogate endpoint; Chemotherapy; Dasatinib; Clinical trial","score_opus":0.01761737825219514,"score_gpt":0.30622307886079697,"score_spread":0.28860570060860186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108740836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289435,0.00047904806,0.000039925737,0.00009901766,0.00002391197,0.005887488,0.00005278409,0.00003103995,0.00049244304],"genre_scores_gemma":[0.99745303,0.00029538225,0.000079925805,0.000027567507,0.000014360879,0.00047868202,0.00007800551,0.000021621056,0.0015513976],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985147,0.00010503546,0.0004421408,0.00037492265,0.00023345125,0.00032974835],"domain_scores_gemma":[0.9988247,0.00046441186,0.00010260361,0.00037165155,0.00012040912,0.00011620135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024622373,0.00023574162,0.00068243244,0.00023255283,0.00011408272,0.000011844357,0.0000653794,0.00009001965,0.000009166706],"category_scores_gemma":[0.00005535504,0.00016140201,0.0000780747,0.00027689355,0.00006896035,0.000042379503,0.00004603124,0.000037871687,6.7448474e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18588509,0.7434326,0.008165355,0.00052183284,0.002287279,0.00043332897,0.011526967,0.000007881192,0.00410634,0.00019961929,0.00004401385,0.04338972],"study_design_scores_gemma":[0.94475776,0.028706428,0.0028074398,0.00013475183,0.0010064016,0.00001807575,0.0018120756,0.0029229526,0.017207718,0.000007787707,0.0004997255,0.00011886677],"about_ca_topic_score_codex":0.00080295734,"about_ca_topic_score_gemma":0.00043559994,"teacher_disagreement_score":0.7588727,"about_ca_system_score_codex":0.0033713097,"about_ca_system_score_gemma":0.0023845604,"threshold_uncertainty_score":0.8815857},"labels":[],"label_agreement":null},{"id":"W7117357242","doi":"10.1080/13696998.2025.2604971","title":"A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"AstraZeneca United States","keywords":"Ibrutinib; Tolerability; Drug; Health care; Lymphoma; Resource use","score_opus":0.02686499075694019,"score_gpt":0.3300574816797413,"score_spread":0.3031924909228011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117357242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955438,0.00094572763,0.000016645397,0.0010424326,0.00020486649,0.0018189562,0.000010451882,0.00004003508,0.00037710462],"genre_scores_gemma":[0.99662596,0.00060777745,0.0007263326,0.0013348464,0.00025273339,0.00003514266,0.000023319053,0.000087130655,0.0003067839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932063,0.000678387,0.0025099956,0.00090730324,0.0016545024,0.0010434922],"domain_scores_gemma":[0.99458885,0.0015393891,0.0011871078,0.0009819624,0.00053476606,0.0011679298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005589876,0.0005649001,0.0020152694,0.0008890092,0.0002223489,0.00015248354,0.00065833866,0.00026585473,0.000067619345],"category_scores_gemma":[0.0013567222,0.00042304062,0.00016718559,0.0007783621,0.00057257194,0.00036070478,0.00040206962,0.0011107932,0.000005109071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04076124,0.0023539658,0.80810803,0.003483319,0.0016287179,0.0015147504,0.011077648,0.008652201,0.0000022432498,0.00017766145,0.0017892546,0.12045096],"study_design_scores_gemma":[0.34593067,0.017826792,0.5603142,0.007219402,0.0006006701,0.00060334534,0.005939297,0.057751734,0.000035703877,0.00003686194,0.0029480339,0.00079332746],"about_ca_topic_score_codex":0.0072048516,"about_ca_topic_score_gemma":0.009082013,"teacher_disagreement_score":0.3051694,"about_ca_system_score_codex":0.27872804,"about_ca_system_score_gemma":0.22269225,"threshold_uncertainty_score":0.99982214},"labels":[],"label_agreement":null},{"id":"W7117542499","doi":"10.14740/jh2149","title":"Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lymphoma; Clinical trial; Clinical efficacy; Context (archaeology)","score_opus":0.015332011768208965,"score_gpt":0.3273364343177027,"score_spread":0.31200442254949373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117542499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98886913,0.0047629173,0.002689547,0.0018036049,0.0001249027,0.0005524119,0.0000038788535,0.000009014435,0.0011846069],"genre_scores_gemma":[0.99598134,0.0004489101,0.002271548,0.00012904748,0.000056489338,0.0000062680438,0.0000034534637,0.000013904383,0.0010890722],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99853367,0.0000682406,0.0007685503,0.00014266919,0.00020202938,0.00028486992],"domain_scores_gemma":[0.99810165,0.00085846364,0.00032148528,0.0001997204,0.00039087763,0.00012782683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055258407,0.00012064814,0.00083175686,0.00030149822,0.00004083154,0.0000054375982,0.00012335608,0.00015534683,0.000051347353],"category_scores_gemma":[0.0007991639,0.000088793386,0.00013582464,0.00022273761,0.00021752277,0.00003817147,0.000056064826,0.00012967149,0.0000022407414],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28568947,0.007744721,0.07467677,0.02259834,0.011177814,0.008165839,0.0029715432,0.000077498866,0.028767439,0.18810883,0.10520346,0.26481828],"study_design_scores_gemma":[0.6276003,0.011161547,0.045790542,0.006811363,0.0030879877,0.1048768,0.0007378991,0.0061714114,0.10047982,0.0032153537,0.089504555,0.00056243],"about_ca_topic_score_codex":0.000027875454,"about_ca_topic_score_gemma":0.0000054961656,"teacher_disagreement_score":0.3419108,"about_ca_system_score_codex":0.0012276913,"about_ca_system_score_gemma":0.003978876,"threshold_uncertainty_score":0.70583546},"labels":[],"label_agreement":null},{"id":"W7126165233","doi":"10.1016/j.jns.2025.123785","title":"BTKI'S in MS","year":2025,"lang":"en","type":"article","venue":"Journal of the Neurological Sciences","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Multiple sclerosis; Immune system; Haematopoiesis; Intracellular; Central nervous system; Signal transduction; Tyrosine kinase","score_opus":0.038663563151325915,"score_gpt":0.3564105748171007,"score_spread":0.3177470116657748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7126165233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96286297,0.00022717773,0.000007607186,0.026142072,0.00031406977,0.000073834395,7.8466115e-8,0.0000029556868,0.010369244],"genre_scores_gemma":[0.99601763,0.000049838553,0.000108103966,0.003297864,0.00006211755,5.943098e-7,6.361647e-9,9.0458315e-7,0.00046293685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988913,0.00011568797,0.00023823284,0.00009767317,0.0004707966,0.00018631939],"domain_scores_gemma":[0.99940324,0.00031982892,0.000078834164,0.000101931786,0.000044764245,0.00005143182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011093746,0.000044814562,0.00015486024,0.00010877222,0.00006757263,0.000022103673,0.00047834337,0.00004317289,0.00006769456],"category_scores_gemma":[0.0014497648,0.000018290799,0.00009339577,0.0007674846,0.00044221382,0.000050232542,0.00014491736,0.00034786144,0.000004128195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019500932,0.0009816075,0.91637707,0.000095774296,0.000055957225,0.0021770562,0.00022634893,0.0035207386,0.0122820735,0.009494354,0.023275066,0.02956388],"study_design_scores_gemma":[0.0085861655,0.0026897741,0.92927194,0.00022038816,0.000039544255,0.0020532962,0.000059130292,0.013406668,0.0027874617,0.016818257,0.023981268,0.00008612232],"about_ca_topic_score_codex":0.000021974183,"about_ca_topic_score_gemma":0.000008119952,"teacher_disagreement_score":0.033154674,"about_ca_system_score_codex":0.00041583466,"about_ca_system_score_gemma":0.0018484185,"threshold_uncertainty_score":0.3279015},"labels":[],"label_agreement":null},{"id":"W7132933566","doi":"","title":"PRIMA-1met Induces Apoptosis in Waldenström&apos;s Macroglobulinemia Independent of p53, Alone and in Combination with Bortezomib","year":2015,"lang":"","type":"dissertation","venue":"TSpace","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bortezomib; Gene knockdown; Apoptosis; Dexamethasone; Downregulation and upregulation; Multiple myeloma; Macroglobulinemia; Cell culture; Waldenstrom macroglobulinemia","score_opus":0.03407036778253173,"score_gpt":0.3799627529709301,"score_spread":0.3458923851883983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132933566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98972046,0.0037116134,0.000010404804,0.0005182197,0.00030868128,0.0029997353,0.000023454671,0.000031243777,0.0026761722],"genre_scores_gemma":[0.9932359,0.0018837629,0.00048858306,0.000043254313,0.00010370597,0.0001871677,0.00095245347,0.0001442369,0.0029609716],"study_design_codex":"qualitative","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99279535,0.00040358276,0.0016070089,0.0013474626,0.0026910903,0.00115548],"domain_scores_gemma":[0.99602944,0.00041688027,0.001010909,0.00091903267,0.0010708028,0.0005529306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020754826,0.0009116627,0.0021223756,0.0017109779,0.000071715214,0.00008437981,0.0004984515,0.0012902025,0.00019820398],"category_scores_gemma":[0.0008173774,0.0008560789,0.00010826427,0.00196431,0.00044628544,0.00029013073,0.0002358818,0.0018713205,0.0000290802],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.105070144,0.017376162,0.12324281,0.04096056,0.0035952704,0.0052327565,0.3653531,0.001711622,0.19538158,0.0007865995,0.0034808828,0.1378085],"study_design_scores_gemma":[0.31104714,0.007976032,0.14549467,0.021960486,0.0016174724,0.0007547144,0.18165067,0.018359514,0.30673048,0.00066749833,0.00032039278,0.0034209471],"about_ca_topic_score_codex":0.03889697,"about_ca_topic_score_gemma":0.017298466,"teacher_disagreement_score":0.205977,"about_ca_system_score_codex":0.018892618,"about_ca_system_score_gemma":0.02042134,"threshold_uncertainty_score":0.999389},"labels":[],"label_agreement":null},{"id":"W7160232576","doi":"10.1182/bloodadvances.2025018362","title":"Dual action of pimozide through lysosome disruption and inhibition of STATs induces apoptosis in chronic lymphocytic leukemia (CLL)","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Venetoclax; Pimozide; Chronic lymphocytic leukemia; Apoptosis; Lysosome; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Protein kinase B","score_opus":0.02625815589277021,"score_gpt":0.34421720785582954,"score_spread":0.31795905196305935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7160232576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914997,0.006715819,0.00011060123,0.000072380426,0.00010578083,0.00048830936,0.000014528823,0.000032748565,0.00096011406],"genre_scores_gemma":[0.9928954,0.0062572258,0.0004694001,0.00003509791,0.00007665505,0.000049388433,0.000030548297,0.000015716174,0.0001705329],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982707,0.00007226931,0.00057275116,0.00036457714,0.00041306007,0.00030664884],"domain_scores_gemma":[0.99911577,0.00022662427,0.00021084902,0.00027013553,0.0001206217,0.00005597997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023421198,0.00018017764,0.00048866577,0.0003255586,0.00004548176,0.000011028941,0.00006360913,0.00013954414,0.000020962663],"category_scores_gemma":[0.00020178931,0.00016424607,0.00006689913,0.00071676733,0.00030030892,0.0005073959,0.000089284884,0.00016850496,0.0000023986665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010392079,0.0002631633,0.003101348,0.0060436204,0.00023138695,0.000038467824,0.00107806,0.0018627355,0.9514333,0.0019064412,0.00005344882,0.032948792],"study_design_scores_gemma":[0.019583149,0.0005960919,0.0054721064,0.0018731857,0.00020025743,0.000042202148,0.000948303,0.001881695,0.9670588,0.0018825387,0.00030405677,0.00015764115],"about_ca_topic_score_codex":0.0016712652,"about_ca_topic_score_gemma":0.00035772705,"teacher_disagreement_score":0.032791153,"about_ca_system_score_codex":0.015958406,"about_ca_system_score_gemma":0.008982531,"threshold_uncertainty_score":0.9966356},"labels":[],"label_agreement":null},{"id":"W78004312","doi":"10.1096/fasebj.22.2_supplement.214","title":"Pax5 isoform expression and mutation status in B‐cell chronic lymphocytic leukemia","year":2008,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Atlantic Cancer Research Institute; Université de Moncton","funders":"","keywords":"Gene isoform; PAX5; Chronic lymphocytic leukemia; Alternative splicing; RNA splicing; Biology; B cell; Gene; splice; Mutation; Molecular biology; Cancer research; Leukemia; Transcription factor; Genetics; Antibody; RNA","score_opus":0.02091027220049657,"score_gpt":0.2755729636589611,"score_spread":0.25466269145846454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W78004312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993462,0.0039008749,0.00016006797,0.00009275057,0.000115736024,0.00030830535,0.0000023959542,0.000025513064,0.0019323226],"genre_scores_gemma":[0.9937261,0.0041083405,0.00022959204,0.00015547316,0.00033249301,0.00001088817,0.000007739301,0.000029552184,0.0013998396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998015,0.00011836494,0.00039038513,0.00020523323,0.00063422794,0.0006367895],"domain_scores_gemma":[0.9989573,0.00020982727,0.00013315547,0.00029706446,0.00008544835,0.00031725195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000572133,0.00017167453,0.00026080402,0.00020533332,0.0003211147,0.000041123603,0.00014986923,0.00010546864,0.00021838605],"category_scores_gemma":[0.00013666919,0.00010844692,0.00007288394,0.00025889065,0.0002476259,0.00019915642,0.000092711954,0.0005870715,0.0000758452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035866152,0.00018917055,0.0115137,0.0008200645,0.00015345463,0.016333804,0.018861279,0.010170713,0.89785314,0.00007873579,0.009357816,0.031081527],"study_design_scores_gemma":[0.12604125,0.001926618,0.035440147,0.0014069177,0.00015918126,0.087848,0.0028628528,0.21990848,0.52059937,0.0007088881,0.002418305,0.0006799966],"about_ca_topic_score_codex":0.0005892286,"about_ca_topic_score_gemma":0.000041433,"teacher_disagreement_score":0.37725377,"about_ca_system_score_codex":0.07050101,"about_ca_system_score_gemma":0.027505932,"threshold_uncertainty_score":0.9780072},"labels":[],"label_agreement":null}]}